FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Naresh, DN
   Nayak, UY
   Musmade, P
   Mutalik, S
   Nayak, Y
AF Naresh, Dasari Naga
   Nayak, Usha Y.
   Musmade, Prashant
   Mutalik, Srinivas
   Nayak, Yogendra
TI Preparation, Characterization and Pharmacokinetic Study of Nelfinavir
   Nanocrystals for Oral Bioavailability Enhancement
SO CURRENT NANOSCIENCE
LA English
DT Article
DE Combination technique; Homogenizer; Nanocrystals; Nelfinavir;
   Pharmacokinetic; Ultrasonication
ID DRUG NANOCRYSTALS; PRECIPITATION; DISSOLUTION; STABILITY;
   NANOSUSPENSIONS; FORMULATION
AB The study is aimed at development of nanocrystals of Nelfinavir Mesylate, an anti-HIV drug to overcome the drawback associated with drug such as poor solubility and oral bioavailability. Nanocrystals were attempted by combination technique and ultrasonication method using polyvinyl alcohol (PVA) and poloxamer 407 as stabilizers at various concentrations. The solid-state characteristics of optimized nanocrystals were studied by XRD, FTIR, DSC and SEM analysis. The release behavior of the drug was studied by in vitro dissolution. The in vivo pharmacokinetics was assessed in Wister Albino rats by administering nanocrystals orally. Nelfinavir nanocrystals were obtained with the narrow size distribution and mean particle size was ranged from 216 to 360 nm for the nanocrystals obtained from combination technique. At 0.5% w/w of PVA, particle size was 236 +/- 19.23 nm and zeta potential was 18.34 +/- 2.0 mV. Freeze dried Poloxamer 407 and PVA nanocrystals showed very good solubility than the freeze dried powder with cryoprotectant and pure drug. However, nanocrystals with PVA (NC PVA) showed high dissolution velocity as compared to nanocrystals with Poloxamer 407 and were supported by high saturation solubility of NC PVA. SEM and other solid-state studies indicated the crystalline nature of developed nanocrystals. Compared to pure drug, NC PVA formulation had decreased T-max and increased C-max and AUC(0-24). Thus pharmacokinetic study revealed significant increase in oral absorption of the drug with nanocrystals which could be attributed to the increase in dissolution velocity of the Nelfinavir in nanocrystal form.
C1 [Naresh, Dasari Naga; Nayak, Usha Y.; Mutalik, Srinivas] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut, Manipal 576104, Karnataka, India.
   [Musmade, Prashant] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Qual Assurance, Manipal 576104, Karnataka, India.
   [Nayak, Yogendra] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, Karnataka, India.
RP Nayak, UY (reprint author), Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut, Manipal 576104, Karnataka, India.
EM ushaynayak@gmail.com
RI Nayak, Usha Yogendra/L-1936-2015; Mutalik, Srinivas/N-9526-2015
OI Nayak, Usha Yogendra/0000-0002-1995-3114; Mutalik,
   Srinivas/0000-0002-0642-1928
FU Department of Biotechnology, New Delhi, India
   [BT/Bio-CARe/03/9943/2013-14]
FX Authors are thankful to the Department of Biotechnology, New Delhi,
   India for providing financial support under BioCARe scheme
   (BT/Bio-CARe/03/9943/2013-14) and Manipal University for providing
   infrastructure facility to carry out the research work.
CR Baba K., 2011, RECENT PATENTS NANOM, V1, P123
   Du B, 2013, DRUG DELIV, V20, P25, DOI 10.3109/10717544.2012.742939
   Gaur P.K., 2014, BIOMED RES INT, V2014
   Hiremath S.N., 2010, J PHARM RES HLTH CAR, V2, P279
   Ige PP, 2013, COLLOID SURFACE B, V108, P366, DOI 10.1016/j.colsurfb.2013.02.043
   Kakran M, 2012, J PHARM PHARMACOL, V64, P1394, DOI 10.1111/j.2042-7158.2012.01515.x
   Kamboj S, 2014, SCI WORLD J, V2014
   Mauludin R, 2009, INT J PHARMACEUT, V370, P202, DOI 10.1016/j.ijpharm.2008.11.029
   Naresh D.N., 2013, INT J RES PHARM SCI, V4, P586
   Perry CM, 1997, DRUGS, V54, P81, DOI 10.2165/00003495-199754010-00007
   Pu XH, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2043-1
   Pu XH, 2009, INT J PHARMACEUT, V379, P167, DOI 10.1016/j.ijpharm.2009.05.062
   Santos HA, 2013, CURR PHARM BIOTECHNO, V14, P926
   Shono Y, 2011, EUR J PHARM BIOPHARM, V79, P349, DOI 10.1016/j.ejpb.2011.04.005
   Sun W, 2012, NANOMED-NANOTECHNOL, V8, P460, DOI 10.1016/j.nano.2011.07.006
   Torne SJ, 2007, J INCL PHENOM MACRO, V57, P689, DOI 10.1007/s10847-006-9262-3
   Van Eerdenbrugh B, 2008, INT J PHARMACEUT, V364, P64, DOI 10.1016/j.ijpharm.2008.07.023
   Xia DN, 2014, CURR PHARM DESIGN, V20, P408, DOI 10.2174/13816128113199990397                                                    
   Xia DN, 2010, EUR J PHARM SCI, V40, P325, DOI 10.1016/j.ejps.2010.04.006
NR 19
TC 0
Z9 0
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
EI 1875-6786
J9 CURR NANOSCI
JI Curr. Nanosci.
PY 2015
VL 11
IS 3
BP 379
EP 387
DI 10.2174/1573413711666150206234538                                       
          
PG 9
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA CG9JS
UT WOS:000353631800015
DA 2018-01-05
ER

PT J
AU Arenaccio, C
   Manfredi, F
   Anticoli, S
   Chiozzini, C
   Federico, M
AF Arenaccio, Claudia
   Manfredi, Francesco
   Anticoli, Simona
   Chiozzini, Chiara
   Federico, Maurizio
TI Uncovering the role of defective HIV-1 in spreading viral infection
SO FUTURE VIROLOGY
LA English
DT Review
DE ADAM17; cell activation; defective HIV-1; Env gp120; exosomes; Gag p17
   matrix; HAART; Nef; Tat; Vpr
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MATRIX PROTEIN P17;
   ACTIVE-ANTIRETROVIRAL-THERAPY; TREATED AIDS PATIENTS; T-CELL COUNTS;
   HEPARAN-SULFATE PROTEOGLYCANS; CHEMOKINE RECEPTOR CXCR4; TYPE-1 TAT
   PROTEIN; DENDRITIC CELLS; MOLECULAR CHARACTERIZATION
AB Defective HIV-1 genomes populate blood cells of HIV-1 infected patients, especially during HAART treatment. They can express viral proteins which, if released, may induce bystander effects favoring viral spread. Here, we review recent literature regarding the effects of extracellular HIV-1 proteins which can act as effectors of transcriptionally active, defective HIV-1, including Gag p17, Env gp120, Vpr, Tat and Nef. It has been very recently described that, different to the other HIV products, the bystander effects of Nef can be mediated by exosomes, that is, nanovesicles constitutively released by all cell types. Exosomes from Nef-expressing cells induce cell activation and HIV-1 susceptibility in resting CD4(+) T lymphocytes in a TNF alpha-dependent way. This mechanism likely contributes to virus persistence in HAART-treated patients.
C1 [Arenaccio, Claudia; Manfredi, Francesco; Anticoli, Simona; Chiozzini, Chiara; Federico, Maurizio] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
RP Federico, M (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM maurizio.federico@iss.it
RI Arenaccio, Claudia/J-9914-2016; manfredi, francesco/K-3890-2016;
   Anticoli, Simona/M-9940-2017; Federico, Maurizio/J-5867-2016
OI Arenaccio, Claudia/0000-0003-3297-2608; Federico,
   Maurizio/0000-0003-4154-1025; manfredi, francesco/0000-0002-1746-1546
CR AIKEN C, 1995, J VIROL, V69, P5048
   Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153
   Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895
   Alessandrini L, 2000, J GEN VIROL, V81, P2905, DOI 10.1099/0022-1317-81-12-2905                                                    
   Arenaccio C, 2014, J VIROL, V88, P11529, DOI 10.1128/JVI.01712-14
   Arenaccio C, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-46
   Bachis A, 2004, J NEUROSCI RES, V75, P75, DOI 10.1002/jnr.10826
   Barillari G, 1999, BLOOD, V94, P663
   Battistini A, 2013, VIRUSES, V6, P1715
   Bellino S, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-49
   Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Bugatti A, 2013, J BIOL CHEM, V288, P1150, DOI 10.1074/jbc.M112.400077
   Caccuri F, 2012, P NATL ACAD SCI USA, V109, P14580, DOI 10.1073/pnas.1206605109
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Chen AK, 2014, P NATL ACAD SCI USA, V111, pE2676, DOI 10.1073/pnas.1408037111
   Chiozzini C, 2014, AIDS, V28, P2189, DOI 10.1097/QAD.0000000000000389
   Coeytaux E, 2003, J BIOL CHEM, V278, P18110, DOI 10.1074/jbc.M300248200
   Comelli L, 2014, MOL BIOSYST, V10, P1146, DOI 10.1039/c3mb70544g
   D'Aloja P, 1998, J VIROL, V72, P4308
   D'Aversa TG, 2004, J NEUROVIROL, V10, P86, DOI 10.1080/13550280490279807
   DAAR ES, 1995, AIDS RES HUM RETROV, V11, P3, DOI 10.1089/aid.1995.11.3
   De Francesco MA, 2002, P NATL ACAD SCI USA, V99, P9972, DOI 10.1073/pnas.142274699
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Eriksson S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003174
   Eugenin EA, 2003, J NEUROCHEM, V85, P1299, DOI 10.1046/j.1471-4159.2003.01775.x
   Evans JT, 2000, HUM GENE THER, V11, P2331, DOI 10.1089/104303400750038444
   FEDERICO M, 1989, AIDS RES HUM RETROV, V5, P385, DOI 10.1089/aid.1989.5.385
   Ferrucci A, 2013, J NEUROVIROL, V19, P239, DOI 10.1007/s13365-013-0170-1
   Ferrucci A, 2011, ADV VIRUS RES, V81, P165, DOI 10.1016/B978-0-12-385885-6.00010-9
   Fiorentini S, 2006, NEW MICROBIOL, V29, P1
   Fiorentini S, 2008, P NATL ACAD SCI USA, V105, P3867, DOI 10.1073/pnas.0800370105
   Fourati S, 2012, J ANTIMICROB CHEMOTH, V67, P2323, DOI 10.1093/jac/dks219
   Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9                                                    
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gandhi N, 2009, AIDS RES HUM RETROV, V25, P891
   Gemignani A, 2000, EUR J NEUROSCI, V12, P2839, DOI 10.1046/j.1460-9568.2000.00172.x
   Giagulli C, 2012, BLOOD, V119, P2274, DOI 10.1182/blood-2011-06-364083
   Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015
   Guenzel CA, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00127
   Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1
   Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026
   Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020
   Iaria ML, 2014, VACCINE, V32, P1072, DOI 10.1016/j.vaccine.2013.12.051
   Jelicic K, 2013, NAT IMMUNOL, V14, P1256, DOI 10.1038/ni.2746
   Jones MV, 2000, AIDS, V14, P2709, DOI 10.1097/00002030-200012010-00010
   Kanmogne GD, 2002, J NEUROPATH EXP NEUR, V61, P992, DOI 10.1093/jnen/61.11.992                                                          
   Karn J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006916
   Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667
   Kaul M, 2008, FRONT BIOSCI-LANDMRK, V13, P2484, DOI 10.2741/2860
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Kim BO, 2004, J IMMUNOL, V172, P1888, DOI 10.4049/jimmunol.172.3.1888                                                     
   Kim BO, 2003, AM J PATHOL, V162, P1693, DOI 10.1016/S0002-9440(10)64304-0
   Kinter AL, 2003, J IMMUNOL, V170, P2449, DOI 10.4049/jimmunol.170.5.2449                                                     
   Kitayama H, 2008, J VIROL, V82, P2528, DOI 10.1128/JVI.02094-07
   Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004
   Lemke CT, 2012, J VIROL, V86, P6643, DOI 10.1128/JVI.00493-12
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   LI YX, 1991, J VIROL, V65, P3973
   Longordo F, 2006, J PHARMACOL EXP THER, V317, P1097, DOI 10.1124/jpet.105.099630
   Lundquist CA, 2004, J VIROL, V78, P6287, DOI 10.1128/JVI.78.12.6287-6296.2004
   McManus CM, 2000, AM J PATHOL, V156, P1441, DOI 10.1016/S0002-9440(10)65013-4                                                   
   Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1                                                   
   Mishra M, 2008, ANN NEUROL, V63, P366, DOI 10.1002/ana.21292
   Misse D, 2005, AIDS, V19, P897, DOI 10.1097/01.aids.0000171403.07995.92
   Mukerji J, 2012, RETROVIROLOGY, V9
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1
   Nethe M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-52
   OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251
   Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595
   Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005
   Popik W, 1998, J VIROL, V72, P6406
   Popovic M, 2005, P NATL ACAD SCI USA, V102, P14807, DOI 10.1073/pnas.0506857102
   Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302
   Quan YD, 2014, J ANTIMICROB CHEMOTH, V69, P21, DOI 10.1093/jac/dkt326
   Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497
   Rao VR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107074
   Rayne F, 2010, EMBO J, V29, P1348, DOI 10.1038/emboj.2010.32
   Rom I, 2009, BRAIN RES, V1275, P81, DOI 10.1016/j.brainres.2009.03.024
   Romancino DP, 2013, FEBS LETT, V587, P1379, DOI 10.1016/j.febslet.2013.03.012
   Sanchez G, 1997, J VIROL, V71, P2233
   Santa-Marta M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00343
   Santosuosso M, 2009, J INFECT DIS, V200, P1050, DOI 10.1086/605695
   Saurya S, 2005, J CLIN VIROL, V33, P324, DOI 10.1016/j.jcv.2005.05.003
   Saurya S, 2003, J MED VIROL, V71, P167, DOI 10.1002/jmv.10459
   Saurya S, 2003, AIDS RES HUM RETROV, V19, P73, DOI 10.1089/08892220360473998
   Saurya S, 2002, AIDS RES HUM RETROV, V18, P983, DOI 10.1089/088922202760265650                                                      
   Saurya S, 2002, AIDS RES HUM RETROV, V18, P1151, DOI 10.1089/088922202320567905
   Schiavoni I, 2004, J BIOL CHEM, V279, P22996, DOI 10.1074/jbc.M312453200
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1
   Taylor GM, 2001, J VIROL, V75, P11244, DOI 10.1128/JVI.75.22.11244-11248.2001                                              
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Usami Y, 2013, CELL REP, V5, P802, DOI 10.1016/j.celrep.2013.09.028
   VOGT PK, 1965, VIROLOGY, V26, P664, DOI 10.1016/0042-6822(65)90329-6
   Weiss JM, 1999, J IMMUNOL, V163, P2953
   Wilflingseder D, 2004, J IMMUNOL, V173, P7497, DOI 10.4049/jimmunol.173.12.7497                                                    
   Wolf D, 2008, CELL HOST MICROBE, V4, P398, DOI 10.1016/j.chom.2008.08.013
   Wu YT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000520
   Xu Y, 2004, P NATL ACAD SCI USA, V101, P7070, DOI 10.1073/pnas.0304859101
NR 104
TC 1
Z9 1
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PY 2015
VL 10
IS 4
BP 371
EP 381
DI 10.2217/FVL.15.10
PG 11
WC Virology
SC Virology
GA CG8SI
UT WOS:000353581800005
DA 2018-01-05
ER

PT J
AU Aqil, M
   Mallik, S
   Bandyopadhyay, S
   Maulik, U
   Jameel, S
AF Aqil, Madeeha
   Mallik, Saurav
   Bandyopadhyay, Sanghamitra
   Maulik, Ujjwal
   Jameel, Shahid
TI Transcriptomic Analysis of mRNAs in Human Monocytic Cells Expressing the
   HIV-1 Nef Protein and Their Exosomes
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FREE FATTY-ACIDS; DIFFERENTIAL EXPRESSION;
   INFECTED-CELLS; T-CELLS; APOPTOSIS; MICROVESICLES; GENE; SYNTHETASES;
   METABOLISM
AB The Nef protein of human immunodeficiency virus (HIV) promotes viral replication and progression to AIDS. Besides its well-studied effects on intracellular signaling, Nef also functions through its secretion in exosomes, which are nanovesicles containing proteins, microRNAs, and mRNAs and are important for intercellular communication. Nef expression enhances exosome secretion and these exosomes can enter uninfected CD4 T cells leading to apoptotic death. We have recently reported the first miRNome analysis of exosomes secreted from Nef-expressing U937monocytic cells. Here we show genome-wide transcriptome analysis of Nef-expressing U937 cells and their exosomes. We identified four key mRNAs preferentially retained in Nef-expressing cells; these code for MECP2, HMOX1, AARSD1, and ATF2 and are important for chromatin modification and gene expression. Interestingly, their target miRNAs are exported out in exosomes. We also identified three key mRNAs selectively secreted in exosomes from Nef-expressing U937 cells and their corresponding miRNAs being preferentially retained in cells. These are AATK, SLC27A1, and CDKAL and are important in apoptosis and fatty acid transport. Thus, our study identifies selectively expressed mRNAs in Nef-expressing U937 cells and their exosomes and supports a new mode on intercellular regulation by the HIV-1 Nef protein.
C1 [Aqil, Madeeha; Jameel, Shahid] Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India.
   [Aqil, Madeeha] Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, Chicago, IL 60612 USA.
   [Mallik, Saurav; Bandyopadhyay, Sanghamitra] Indian Stat Inst, Machine Intelligence Unit, Kolkata 700108, India.
   [Maulik, Ujjwal] Jadavpur Univ, Dept Comp Sci & Engn, Kolkata 700032, W Bengal, India.
   [Jameel, Shahid] Wellcome Trust DBT India Alliance, Hyderabad 500034, Andhra Pradesh, India.
RP Jameel, S (reprint author), Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India.
EM jameelshahid@gmail.com
OI Maulik, Ujjwal/0000-0003-1167-0774; Mallik, Saurav/0000-0003-4107-6784
FU Department of Biotechnology (DBT), Government of India; Indian Council
   of Medical Research (ICMR); Council for Scientific and Industrial
   Research (CSIR), India
FX This work was funded by grants from the Department of Biotechnology
   (DBT), Government of India, and the Indian Council of Medical Research
   (ICMR). A Senior Research Fellowship from the Council for Scientific and
   Industrial Research (CSIR), India, supported Madeeha Aqil.
CR Acharya Arpan, 2012, Roum Arch Microbiol Immunol, V71, P29
   Naqvi A. R., 2014, J EXTRACELLULAR VESI, V3
   Aqil M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074472
   Arenaccio C, 2014, J VIROL, V88, P11529, DOI 10.1128/JVI.01712-14
   Arenaccio C, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-46
   Bandyopadhyay S, 2002, PATTERN RECOGN, V35, P1197, DOI 10.1016/S0031-3203(01)00108-X                                                   
   Bandyopadhyay S, 2014, IEEE ACM T COMPUT BI, V11, P95, DOI 10.1109/TCBB.2013.147
   Bouchat S, 2012, AIDS, V26, P1473, DOI 10.1097/QAD.0b013e32835535f5
   Brambillasca S, 2012, J BIOL CHEM, V287, P41808, DOI 10.1074/jbc.M112.376558
   Campbell T. D., 2008, ETHNICITY DIS S2, V18
   Chang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105410
   Chaudhry A, 2005, J IMMUNOL, V175, P4566, DOI 10.4049/jimmunol.175.7.4566                                                     
   Das SR, 2005, INDIAN J MED RES, V121, P315
   de Jong OG, 2012, J EXTRACELL VESICLES, V16, P1, DOI [10.3402/jev.v1i0.18396, DOI 10.3402/JEV.V1I0.18396]
   Endo M, 2014, HUM PATHOL, V45, P276, DOI 10.1016/j.humpath.2013.09.003
   Engelman A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000046
   Fackler OT, 2014, NAT REV MICROBIOL, V12, P563, DOI 10.1038/nrmicro3309
   Gobert AP, 2014, J IMMUNOL, V193, P3013, DOI 10.4049/jimmunol.1401075
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hatch GM, 2002, J LIPID RES, V43, P1380, DOI 10.1194/jlr.M200130-JLR200
   Heigele A, 2014, METHODS MOL BIOL, V1087, P115, DOI 10.1007/978-1-62703-670-2_10
   Ivanov KA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P888
   Jablonowska E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095564
   Kadiu I, 2012, J IMMUNOL, V189, P744, DOI 10.4049/jimmunol.1102244
   Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004
   Landi A, 2011, CURR HIV RES, V9, P496, DOI 10.2174/157016211798842116
   Lau E, 2012, J CELL SCI, V125, P2815, DOI 10.1242/jcs.095000
   Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Leoh LS, 2012, MOL CANCER RES, V10, P378, DOI 10.1158/1541-7786.MCR-11-0314
   Lo WS, 2014, SCIENCE, V345, P328, DOI 10.1126/science.1252943
   Ma S, 2014, LAB INVEST, V94, P430, DOI 10.1038/labinvest.2014.13
   Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1
   Martin G, 2000, GENOMICS, V66, P296, DOI 10.1006/geno.2000.6191
   Meininger G, 2002, METABOLISM, V51, P260, DOI 10.1053/meta.2002.29999
   Meng G, 2014, TUMOR BIOL, V35, P11819, DOI 10.1007/s13277-014-2336-8
   Mulcahy L.A., 2014, J EXTRACELLULAR VESI, V3
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Rasheed S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003003
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Schmidt WN, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00129
   Shalit P, 2014, REV CARDIOVASC MED, V15, pS38
   Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211
   Takano T, 2012, J NEUROSCI, V32, P6587, DOI 10.1523/JNEUROSCI.5317-11.2012
   Tomomura M, 2003, MOL BRAIN RES, V112, P103, DOI 10.1016/S0169-328X(03)00054-8
   Tsutsumi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010260
   Walluscheck D, 2013, J CELL MOL MED, V17, P976, DOI 10.1111/jcmm.12071
   Wang F, 2013, J BIOL CHEM, V288, P29223, DOI 10.1074/jbc.C113.490599
NR 48
TC 6
Z9 7
U1 0
U2 1
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 492395
DI 10.1155/2015/492395
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CG7JJ
UT WOS:000353478900001
OA gold
DA 2018-01-05
ER

PT J
AU Sepulveda-Crespo, D
   Sanchez-Rodriguez, J
   Serramia, MJ
   Gomez, R
   De La Mata, FJ
   Jimenez, JL
   Munoz-Fernandez, MA
AF Sepulveda-Crespo, Daniel
   Sanchez-Rodriguez, Javier
   Jesus Serramia, Maria
   Gomez, Rafael
   Javier De La Mata, Francisco
   Luis Jimenez, Jose
   Angeles Munoz-Fernandez, Ma
TI Triple combination of carbosilane dendrimers, tenofovir and maraviroc as
   potential microbicide to prevent HIV-1 sexual transmission
SO NANOMEDICINE
LA English
DT Article
DE carbosilane dendrimer; HIV-1; maraviroc; microbicide; nanomedicine;
   synergy; tenofovir; triple combination; vaginal irritation
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITOR;
   RANDOMIZED CONTROLLED-TRIAL; INFECTIOUS MOLECULAR CLONE; TOPICAL
   MICROBICIDES; IN-VITRO; SEMINAL PLASMA; SYNERGISTIC ACTIVITY; VAGINAL
   MICROBICIDE; CANDIDATE MICROBICIDES
AB Aim: To research the synergistic activity by triple combinations of carbosilane dendrimers with tenofovir and maraviroc as topical microbicide. Methods: Cytotoxicity, anti-HIV-1 activity, vaginal irritation and histological analysis of triple combinations were determined. Analysis of combined effects and the median effective concentration were performed using CalcuSyn software. Results: Combinations showed a greater broad-spectrum anti-HIV-1 activity than the single-drug, and preserved this activity in acid environment or seminal fluid. The strongest combinations were G2-STE16/G2S24P/tenofovir, G2-STE16/G2-S16/maraviroc and G2-STE16/tenofovir/maraviroc at 2:2:1, 10:10:1 10:5:1 ratios, respectively. They demonstrated strong synergistic activity profile due to the weighted average combination indices varied between 0.06 and 0.38. No irritation was detected in female BALB/c mice. Conclusion: The three-drug combination increases their antiviral potency and act synergistically as potential microbicide.
C1 [Sepulveda-Crespo, Daniel; Sanchez-Rodriguez, Javier; Jesus Serramia, Maria; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Lab InmunoBiol Mol,Spanish HIV HGM Biobank, Madrid, Spain.
   [Sepulveda-Crespo, Daniel; Sanchez-Rodriguez, Javier; Jesus Serramia, Maria; Luis Jimenez, Jose; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Plataforma Lab, Madrid, Spain.
   [Gomez, Rafael; Javier De La Mata, Francisco] Univ Alcala De Henares, Dept Quim Inorgan, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Lab InmunoBiol Mol,Spanish HIV HGM Biobank, Madrid, Spain.
EM joseluis.jimenez@salud.madrid.org; mmunoz.hgugm@gmail.com
OI Munoz-Fernandez/0000-0002-0813-4500
FU ISC III [RD09/0076/00103]; FIPSE [CA10/01274]
FX We thank the Centers of Transfusion of Madrid for the buffy coats and
   Spanish HIV HGM BioBank supported by ISC III (grant number
   RD09/0076/00103) and FIPSE. Also, we thank Maribel Clemente Mayoral for
   her technical assistance and advice as cell culture technician
   (CA10/01274).
CR ADACHI A, 1986, J VIROL, V59, P284
   Adams JL, 2012, BEST PRACT RES CL OB, V26, P451, DOI 10.1016/j.bpobgyn.2012.01.004
   ALLEN RD, 1987, AM J REPROD IMMUNOL, V13, P4
   Balandya E, 2010, J IMMUNOL, V185, P7596, DOI 10.4049/jimmunol.1002846
   Barnabas RV, 2012, CURR HIV RES, V10, P228
   Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002
   Belec L, 2011, FUTURE MICROBIOL, V6, P731, DOI [10.2217/fmb.11.64, 10.2217/FMB.11.64]
   BELENKII MS, 1994, ANTIVIR RES, V25, P1, DOI 10.1016/0166-3542(94)90089-2                                                    
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7
   COLLMAN R, 1992, J VIROL, V66, P7517
   Auli NC, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003345
   Cooper DA, 2010, J INFECT DIS, V201, P803, DOI 10.1086/650697
   Corey L, 2007, NEW ENGL J MED, V356, P854, DOI 10.1056/NEJMe068302
   Costin GE, 2011, ATLA-ALTERN LAB ANIM, V39, P317
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Dezzutti CS, 2012, ANTIVIR RES, V96, P221, DOI 10.1016/j.antiviral.2012.08.004
   Doncel GF, 2010, ANTIVIR RES, V88, pS10, DOI 10.1016/j.antiviral.2010.09.018
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Dumond JB, 2009, JAIDS-J ACQ IMM DEF, V51, P546, DOI 10.1097/QAI.0b013e3181ae69c5
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Emau P, 2007, J MED PRIMATOL, V36, P244, DOI 10.1111/j.1600-0684.2007.00242.x
   Ferir G, 2011, VIROLOGY, V417, P253, DOI 10.1016/j.virol.2011.07.004
   Fletcher PS, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-46
   FREED EO, 1995, J VIROL, V69, P3949
   Galan M, 2012, CURR MED CHEM, V19, P4984
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Garcia-Gallego S, 2013, DALTON T, V42, P5874, DOI 10.1039/c3dt32870h
   Garcia-Gallego S, 2012, DALTON T, V41, P6488, DOI 10.1039/c2dt11793b
   Garcia-Merino I, 2010, AIDS RES HUM RETROV, V26, P241, DOI 10.1089/aid.2009.0122
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Grivel JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S6
   Gupta GR, 2002, BRIT MED J, V324, P183, DOI 10.1136/bmj.324.7331.183                                                        
   Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08
   Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924
   Iser DM, 2010, J VIROL, V84, P5860, DOI 10.1128/JVI.02594-09
   Jenabian MA, 2009, J ANTIMICROB CHEMOTH, V64, P1192, DOI 10.1093/jac/dkp380
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2012, BEST PRACT RES CL OB, V26, P427, DOI 10.1016/j.bpobgyn.2012.01.010
   Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9
   Keller MJ, 2003, J ANTIMICROB CHEMOTH, V51, P1099, DOI 10.1093/jac/dkg214
   Koff WC, 2012, VACCINE, V30, P4310, DOI 10.1016/j.vaccine.2011.11.014
   Kumar V, 2009, J BIOSCIENCES, V34, P899, DOI 10.1007/s12038-009-0104-5
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Lee JJ, 2009, STAT BIOPHARM RES, V1, P4, DOI 10.1198/sbr.2009.0001
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   Li L, 2011, JAIDS-J ACQ IMM DEF, V56, P384, DOI 10.1097/QAI.0b013e31820a4a8d
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGowan I, 2006, BIOLOGICALS, V34, P241, DOI 10.1016/j.biologicals.2006.08.002
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Murphy EM, 2006, PLOS MED, V3, P1443, DOI 10.1371/journal.pmed.0030379
   Nagashima KA, 2001, J INFECT DIS, V183, P1121, DOI 10.1086/319284                                                                  
   Nel AM, 2010, JAIDS-J ACQ IMM DEF, V55, P161, DOI 10.1097/QAI.0b013e3181e3293a
   Neurath AR, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-150
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Peters B S, 2011, Adv Dent Res, V23, P23, DOI 10.1177/0022034511399082
   Peterson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001312
   Pirrone V, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-33
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Pruss-Ustun A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063476
   Randolph ME, 2007, ARCH SEX BEHAV, V36, P844, DOI 10.1007/s10508-007-9213-0
   RASHEED S, 1995, J REPROD MED, V40, P747
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Richardson BA, 2001, SEX TRANSM DIS, V28, P394, DOI 10.1097/00007435-200107000-00006
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Sanchez MS, 2006, EMERG INFECT DIS, V12, P191
   Schwartz JL, 2008, SEX TRANSM DIS, V35, P414, DOI 10.1097/OLQ.0b013e318162c4d8
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Sepulveda-Crespo D, 2013, NANOMEDICINE, V10, P609
   Shattock RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007385
   Singer R, 2011, J VIROL, V85, P5504, DOI 10.1128/JVI.02422-10
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Sokal DC, 2013, ANTIVIR THER, V18, P301, DOI 10.3851/IMP2311
   Swanson MD, 2010, J BIOL CHEM, V285, P8646, DOI 10.1074/jbc.M109.034926
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tremblay CL, 2002, ANTIMICROB AGENTS CH, V46, P1336, DOI 10.1128/AAC.46.5.1336-1339.2002
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   Underhill K, 2007, BMJ-BRIT MED J, V335, P248, DOI 10.1136/bmj.39245.446586.BE
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Wawer MJ, 2009, LANCET, V374, P229, DOI 10.1016/S0140-6736(09)60998-3
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weller S. C., 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]
   Zhong MH, 2012, ANTIMICROB AGENTS CH, V56, P3121, DOI 10.1128/AAC.05950-11
NR 101
TC 13
Z9 13
U1 0
U2 14
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2015
VL 10
IS 6
BP 899
EP 914
DI 10.2217/NNM.14.79
PG 16
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA CF8JV
UT WOS:000352806000003
PM 25867856
DA 2018-01-05
ER

PT J
AU Huang, YW
   Lee, HJ
   Tolliver, LM
   Aronstam, RS
AF Huang, Yue-Wern
   Lee, Han-Jung
   Tolliver, Larry M.
   Aronstam, Robert S.
TI Delivery of Nucleic Acids and Nanomaterials by Cell-Penetrating
   Peptides: Opportunities and Challenges
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID ARGININE-RICH PEPTIDES; PROTEIN TRANSDUCTION DOMAIN; INFLUENZA-VIRUS
   HEMAGGLUTININ; HUMAN IMMUNODEFICIENCY VIRUS; EFFICIENT SIRNA DELIVERY;
   SMALL INTERFERING RNA; QUANTUM DOTS; GENE DELIVERY; INTRACELLULAR
   DELIVERY; LIVING CELLS
AB Many viral and nonviral systems have been developed to aid delivery of biologically active molecules into cells. Among these, cell-penetrating peptides (CPPs) have received increasing attention in the past two decades for biomedical applications. In this review, we focus on opportunities and challenges associated with CPP delivery of nucleic acids and nanomaterials. We first describe the nature of versatile CPPs and their interactions with various types of cargoes. We then discuss in vivo and in vitro delivery of nucleic acids and nanomaterials by CPPs. Studies on the mechanisms of cellular entry and limitations in the methods used are detailed.
C1 [Huang, Yue-Wern; Tolliver, Larry M.; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
   [Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
RP Huang, YW (reprint author), Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
EM huangy@mst.edu
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249
   BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982
   Bremner KH, 2004, BIOCONJUGATE CHEM, V15, P152, DOI 10.1021/bc034140k
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chang M, 2014, CURR PHARM BIOTECHNO, V15, P267, DOI 10.2174/1389201015666140617095415                                               
   Chang YR, 2008, NAT NANOTECHNOL, V3, P284, DOI 10.1038/nnano.2008.99
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Jefferies R., 2008, EXPT PARASITOLOGY, V118, P303
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   DING Q, 2010, VIROL SIN, V25, P79, DOI 10.1007/s12250-010-3099-z
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Eguchi A, 2010, CELL CYCLE, V9, P424, DOI 10.4161/cc.9.3.10693                                                            
   Eguchi A, 2009, TRENDS PHARMACOL SCI, V30, P341, DOI 10.1016/j.tips.2009.04.009
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   EPA Office of Research and Development, 2009, NAN RES STRAT
   Erbacher P, 1996, EXP CELL RES, V225, P186, DOI 10.1006/excr.1996.0169
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Godbey WT, 2001, BIOMATERIALS, V22, P471, DOI 10.1016/S0142-9612(00)00203-9
   Godbey WT, 1999, J BIOMED MATER RES, V45, P268, DOI 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q                 
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839                                                            
   GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695                                                           
   Graslund A., 2011, J BIOPHYSICS, V2011, DOI 10.1155/2011/414729
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7
   Hallbrink M, 2005, INT J PEPT RES THER, V11, P249, DOI 10.1007/s10989-005-9393-1
   Hammond TG, 1998, J MEMBRANE BIOL, V162, P157, DOI 10.1007/s002329900353                                                           
   HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Hou W., 2007, EXPT DERMATOLOGY, V16, P999
   Huang Yue-Wern, 2013, Methods Mol Biol, V991, P249, DOI 10.1007/978-1-62703-336-7_23
   JACKMAN MR, 1994, J CELL SCI, V107, P2547
   Jafari M, 2013, BIOCHEMISTRY-US, V52, P3428, DOI 10.1021/bi4001326
   JOHANSSON F, 1993, PLANT CELL, V5, P321
   Johnson LN, 2010, VISION RES, V50, P686, DOI 10.1016/j.visres.2009.08.028
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Karagiannis ED, 2013, ACS NANO, V7, P8616, DOI 10.1021/nn4027382
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Kobayashi S, 2009, BIOCONJUGATE CHEM, V20, P953, DOI 10.1021/bc800530v
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7                                                   
   Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2013, COLLOID SURFACE B, V111, P162, DOI 10.1016/j.colsurfb.2013.05.038
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067100
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205
   Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2013, MAR BIOTECHNOL, V15, P584, DOI 10.1007/s10126-013-9509-0
   Liu B. R., 2013, CELL MEMBRANE, P43
   Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lomize MA, 2006, BIOINFORMATICS, V22, P623, DOI 10.1093/bioinformatics/btk023
   Lou D., 2000, NAT BIOTECHNOL, V18, P33
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.bi.55.070186.003311
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Michiue H, 2009, CANCER BIOL THER, V8, P2306
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487
   Nan XL, 2005, J PHYS CHEM B, V109, P24220, DOI 10.1021/jp056360w
   Navarro-Quiroga I, 2002, MOL BRAIN RES, V105, P86, DOI 10.1016/S0169-328X(02)00396-0
   Neundorf Ines, 2009, Pharmaceuticals (Basel), V2, P49
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Nitin N, 2009, ANN BIOMED ENG, V37, P2018, DOI 10.1007/s10439-009-9768-0
   Scheller A., 1998, BIOCHIM BIOPHYS ACTA, V1414, P127
   Oliveira S, 2007, INT J PHARM, V331, P211, DOI 10.1016/j.ijpharm.2006.11.050
   Peters L, 2007, MOL CELL, V26, P611, DOI 10.1016/j.molcel.2007.05.001
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   REED MA, 1988, PHYS REV LETT, V60, P535, DOI 10.1103/PhysRevLett.60.535                                                      
   Regberg J, 2014, INT J PHARMACEUT, V464, P111, DOI 10.1016/j.ijpharm.2014.01.018
   Regberg Jakob, 2012, Pharmaceuticals (Basel), V5, P991, DOI 10.3390/ph5090991
   Reuter M, 2009, BIOPHYS CHEM, V144, P27, DOI 10.1016/j.bpc.2009.06.002
   Richards DA, 2004, J PHYSIOL-LONDON, V557, P77, DOI 10.1113/jphysiol.2004.062158
   RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Schnitzer E., 1995, J BIOL CHEM, V270, P14399
   SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48
   SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217                                                          
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302                                                          
   Shin MC, 2014, J BIOMED MATER RES A, V102, P575, DOI 10.1002/jbm.a.34859
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Sirsi SR, 2008, HUM GENE THER, V19, P795, DOI 10.1089/hum.2007.129
   SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325                                                            
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775
   Sugita T, 2007, BIOCHEM BIOPH RES CO, V363, P1027, DOI 10.1016/j.bbrc.2007.09.077
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Takayama K, 2009, J CONTROL RELEASE, V138, P128, DOI 10.1016/j.jconrel.2009.05.019
   Takayama K, 2009, BIOCONJUGATE CHEM, V20, P249, DOI 10.1021/bc800327f
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509                                                
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Tusnady GE, 2004, BIOINFORMATICS, V20, P2964, DOI 10.1093/bioinformatics/bth340
   Unnamalai N, 2004, FEBS LETT, V566, P307, DOI 10.1016/j.febslet.2004.04.018
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   von Maltzahn G, 2007, ADV MATER, V19, P3579, DOI 10.1002/adma.200701183
   Voura EB, 2004, NAT MED, V10, P993, DOI 10.1038/nm1096
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wang HY, 2011, J CONTROL RELEASE, V155, P26, DOI 10.1016/j.jconrel.2010.12.009
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wee TL, 2009, DIAM RELAT MATER, V18, P567, DOI 10.1016/j.diamond.2008.08.012
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847
   Wolfert MA, 1998, GENE THER, V5, P409, DOI 10.1038/sj.gt.3300606                                                           
   Wostenberg C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051829
   Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085
   Xu Y, 2010, J BIOMED BIOTECHNOL, V2010
   Yang S, 2009, J CONTROL RELEASE, V135, P159, DOI 10.1016/j.jconrel.2008.12.015
   Yoshikawa T, 2008, J MOL BIOL, V380, P777, DOI 10.1016/j.jmb.2008.05.047
   Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013
NR 142
TC 15
Z9 15
U1 3
U2 33
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 834079
DI 10.1155/2015/834079
PG 16
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CF3LR
UT WOS:000352450700001
OA gold
DA 2018-01-05
ER

PT J
AU Gong, QJ
   Yang, HY
   Dong, YY
   Zhang, WC
AF Gong, Qiaojuan
   Yang, Haiying
   Dong, Yanyun
   Zhang, Wenchan
TI A sensitive impedimetric DNA biosensor for the determination of the HIV
   gene based on electrochemically reduced graphene oxide
SO ANALYTICAL METHODS
LA English
DT Article
ID PYROLYTIC-GRAPHITE ELECTRODE; QUARTZ-CRYSTAL MICROBALANCE; LABEL-FREE;
   CARBON NANOTUBES; POTENTIOMETRIC SENSOR; HYBRIDIZATION; ASSAY;
   CHEMILUMINESCENCE; PLATFORM; PHARMACEUTICALS
AB A sensitive impedimetric DNA biosensor for the determination of the HIV-1 gene was developed by employing electrochemically reduced graphene oxide (ERGO) as a sensing platform. The DNA biosensor was fabricated by drop-coating graphene oxide (GO) on a glassy carbon (GC) electrode and covalently immobilizing the designed single-stranded DNA (ssDNA) probe onto the GO using carbodiimide chemistry. The GO was later electrochemically reduced to obtain ERGO and applied to genosensing. Upon the occurrence of hybridisation events between the surface-confined ssDNA probe with the target DNA in solution to form double-stranded DNA (dsDNA) at the electrode surface, the negative charge in the electrode/electrolyte interface, and as such, the electron transfer resistance of the electrodes toward the [Fe(CN)(6)](3-/4-) redox couple were changed. This change was used for impedimetric DNA biosensing. It was found that the employment of ERGO as an immobilization platform efficiently accelerated the electron transfer and enhanced the EIS response of the DNA biosensor. Under the conditions employed in this study, the change in the electron transfer resistance was linear with the logarithm of the concentration of target DNA within a concentration range of 1.0 x 10(-12) to 1.0 x 10(-9) M, with a detection limit of 3.0 x 10(-1)3 M (S/N = 3). This strategy eliminated the requirement for DNA labelling, greatly simplifying the procedure. This work demonstrates that the employment of GO as an immobilization platform and ERGO as a biosensing platform is a promising approach to designing impedimetric aptasensors with high sensitivity and selectivity.
C1 [Gong, Qiaojuan; Yang, Haiying; Dong, Yanyun; Zhang, Wenchan] Yuncheng Univ, Dept Appl Chem, Yuncheng 044000, Peoples R China.
RP Gong, QJ (reprint author), Yuncheng Univ, Dept Appl Chem, Yuncheng 044000, Peoples R China.
EM gqjuan@163.com; hyyang@ycu.edu.cn
FU Science Foundation of Shanxi [2012011007-1]; Technology Innovation
   Program of the Department of Education of Shanxi [2013151]; Science
   Foundation of Bureau of Science and Technology of Yuncheng [2060499];
   Scientific Research Foundation of Yuncheng University [YKU2014015,
   CY-2014006]
FX Financial support from the Science Foundation of Shanxi (no.
   2012011007-1), the Technology Innovation Program of the Department of
   Education of Shanxi (no. 2013151), the Science Foundation of Bureau of
   Science and Technology of Yuncheng (no. 2060499) and the Scientific
   Research Foundation of Yuncheng University (no. YKU2014015, CY-2014006)
   are gratefully acknowledged.
CR Ahn S, 2005, ANAL CHEM, V77, P5041, DOI 10.1021/ac0505270
   Benoit V, 2001, ANAL CHEM, V73, P2412, DOI 10.1021/ac000946r
   Bonanni A, 2012, CHEM-EUR J, V18, P1668, DOI 10.1002/chem.201102850
   Chang HX, 2007, ANAL CHEM, V79, P5111, DOI 10.1021/ac070639m
   Chen CP, 2009, ANAL CHEM, V81, P36, DOI 10.1021/ac800986q
   Chen X, 2012, ANAL CHEM, V84, P8277, DOI 10.1021/ac3017828
   Claussen JC, 2009, ACS NANO, V3, P37, DOI 10.1021/nn800682m
   CURRIE LA, 1995, PURE APPL CHEM, V67, P1699, DOI 10.1351/pac199567101699                                                         
   Dharmadi Y, 2004, BIOTECHNOL PROGR, V20, P1309, DOI 10.1021/bp0400240
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Farjami E, 2010, ANALYST, V135, P1443, DOI 10.1039/c0an00049c
   Gao L, 2014, BIOSENS BIOELECTRON, V60, P22, DOI 10.1016/j.bios.2014.03.039
   Gasparac R, 2004, J AM CHEM SOC, V126, P12270, DOI 10.1021/ja0458221
   Goyal RN, 2008, TALANTA, V76, P662, DOI 10.1016/j.talanta.2008.04.011
   Goyal RN, 2008, ELECTROCHIM ACTA, V53, P5354, DOI 10.1016/j.electacta.2008.02.059
   Goyal RN, 2007, ANAL CHIM ACTA, V597, P82, DOI 10.1016/j.aca.2007.06.017
   Gupta VK, 2007, ANAL CHIM ACTA, V590, P81, DOI 10.1016/j.aca.2007.03.014
   Gupta VK, 2011, CRIT REV ANAL CHEM, V41, P282, DOI 10.1080/10408347.2011.589773
   Gupta VK, 2011, COMB CHEM HIGH T SCR, V14, P284, DOI 1386-2073/11 $58.00+.00
   Gupta VK, 2011, ANAL BIOCHEM, V408, P179, DOI 10.1016/j.ab.2010.09.027
   Gupta VK, 1999, ELECTROANAL, V11, P573, DOI 10.1002/(SICI)1521-4109(199906)11:8<573::AID-ELAN573>3.3.CO;2-Q
   Gupta VK, 1997, ELECTROANAL, V9, P478, DOI 10.1002/elan.1140090609                                                         
   Gupta VK, 2000, ANAL CHIM ACTA, V420, P19, DOI 10.1016/S0003-2670(00)01013-8
   Han XW, 2013, ANAL BIOCHEM, V443, P117, DOI 10.1016/j.ab.2013.08.027
   Haque AMJ, 2012, ANAL CHEM, V84, P1871, DOI 10.1021/ac202562v
   He Y, 2013, ACS APPL MATER INTER, V5, P11336, DOI 10.1021/am404138x
   He Y, 2011, BIOSENS BIOELECTRON, V29, P76, DOI 10.1016/j.bios.2011.07.069
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Hu YW, 2012, ANAL CHIM ACTA, V753, P82, DOI 10.1016/j.aca.2012.09.038
   Hvastkovs EG, 2007, ANAL CHEM, V79, P6922, DOI 10.1021/ac070358e
   Jain R, 2010, ANAL BIOCHEM, V407, P79, DOI 10.1016/j.ab.2010.07.027
   Kim BC, 2009, ANAL CHEM, V81, P2388, DOI 10.1021/ac802267u
   Li YG, 2009, J AM CHEM SOC, V131, P5851, DOI 10.1021/ja9000882
   Liu BW, 2013, ANAL CHEM, V85, P7987, DOI 10.1021/ac401845p
   McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605
   Norouzi P, 2015, TALANTA, V131, P577, DOI 10.1016/j.talanta.2014.07.033
   Norouzi P, 2011, ANAL CHEM, V83, P1564, DOI 10.1021/ac102270w
   Patolsky F, 1999, ANAL CHEM, V71, P3171, DOI 10.1021/ac9901541                                                               
   Prasad R, 2004, ANAL CHIM ACTA, V508, P61, DOI 10.1016/j.aca.2003.11.056
   Prashanth SN, 2014, J ELECTROCHEM SOC, V161, pB117, DOI 10.1149/2.010406jes
   Radi AE, 2009, BIOSENS BIOELECTRON, V24, P1888, DOI 10.1016/j.bios.2008.09.021
   Ratinac K. R., 2014, ELECTROANAL, V26, P139
   Ruan SP, 2014, MICROCHIM ACTA, V181, P1293, DOI 10.1007/s00604-014-1252-3
   Shiddiky MJA, 2012, BIOSENS BIOELECTRON, V35, P251, DOI 10.1016/j.bios.2012.02.057
   Su XD, 2004, ANAL CHEM, V76, P489, DOI 10.1021/ac035175g
   Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639
   Vamvakaki V, 2008, ANAL CHEM, V80, P5970, DOI 10.1021/ac800614j
   Wang CP, 2013, ANAL CHIM ACTA, V799, P36, DOI 10.1016/j.aca.2013.09.024
   Wang H, 2006, ANAL CHIM ACTA, V575, P205, DOI 10.1016/j.aca.2006.05.080
   Wang J, 2002, ANAL CHIM ACTA, V469, P63, DOI 10.1016/S0003-2670(01)01399-X
   Wang J, 2003, J AM CHEM SOC, V125, P2408, DOI 10.1021/ja028951v
   Wang W, 2013, ELECTROCHEM COMMUN, V34, P18, DOI 10.1016/j.elecom.2013.05.015
   Xing XJ, 2013, BIOMACROMOLECULES, V14, P117, DOI 10.1021/bm301469q
   XU XH, 1994, J AM CHEM SOC, V116, P8386, DOI 10.1021/ja00097a064
   Yan YM, 2005, CHEM MATER, V17, P3457, DOI 10.1021/cm0504182
   Yin HS, 2012, BIOSENS BIOELECTRON, V33, P247, DOI 10.1016/j.bios.2012.01.014
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhao XJ, 2003, J AM CHEM SOC, V125, P11474, DOI 10.1021/ja0358854
   Zhou LY, 2012, ANALYST, V137, P5071, DOI 10.1039/c2an35905g
   Zhou M, 2009, ANAL CHEM, V81, P5603, DOI 10.1021/ac900136z
NR 60
TC 15
Z9 15
U1 6
U2 43
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9660
EI 1759-9679
J9 ANAL METHODS-UK
JI Anal. Methods
PY 2015
VL 7
IS 6
BP 2554
EP 2562
DI 10.1039/c5ay00111k
PG 9
WC Chemistry, Analytical; Food Science & Technology; Spectroscopy
SC Chemistry; Food Science & Technology; Spectroscopy
GA CD9BS
UT WOS:000351391800044
DA 2018-01-05
ER

PT J
AU Ramana, LN
   Sharma, S
   Sethuraman, S
   Ranga, U
   Krishnan, UM
AF Ramana, Lakshmi Narashimhan
   Sharma, Shilpee
   Sethuraman, Swaminathan
   Ranga, Udaykumar
   Krishnan, Uma Maheswari
TI Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral
   drugs - Modern Trojan horses to combat HIV
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Dual drug loaded anti-CD4 conjugated; anti-CD4 conjugated
   immunoliposomes; Anti-CD4; Nevirapine; Saquinavir; HIV; Targeting; Viral
   load
ID IMMUNODEFICIENCY-VIRUS HIV; HUMAN GLIAL-CELLS; IN-VITRO; MOLECULAR
   CLONES; INFECTION; NANOPARTICLES; LIPOSOMES; DELIVERY; ANTIBODY; RELEASE
AB Highly active antiretroviral therapy (HAART) is the currently employed therapeutic intervention against AIDS where a drug combination is used to reduce the viral load. The present work envisages the development of a stealth anti-CD4 conjugated immunoliposomes containing two anti-retroviral drugs (nevirapine and saquinavir) that can selectively home into HIV infected cells through the CD4 receptor. The nanocarrier was characterized using transmission electron microscopy, FTIR, differential scanning calorimetry, particle size and zeta potential. The cell uptake was also evaluated qualitatively using confocal microscopy and quantitatively by flow cytometry. The drug to lipid composition was optimized for maximum encapsulation of the two drugs. Both drugs were found to localize in different regions of the liposome. The release of the reverse transcriptase inhibitor was dominant during the early phases of the release while in the later phases, the protease inhibitor is the major constituent released. The drugs delivered via anti-CD4 conjugated immunoliposomes inhibited viral proliferation at a significantly lower concentration as compared to free drugs. In vitro studies of nevirapine to saquinavir combination at a ratio of 6.2:5 and a concentration as low as 5 ng/mL efficiently blocked viral proliferation suggesting that codelivery of anti-retroviral drugs holds a greater promise for efficient management of HIV-1 infection. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ramana, Lakshmi Narashimhan; Sethuraman, Swaminathan; Krishnan, Uma Maheswari] SASTRA Univ, CeNTAB, Thanjavur 613401, Tamil Nadu, India.
   [Sharma, Shilpee; Ranga, Udaykumar] Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, HIV AIDS Lab, Mol Biol & Genet Unit, Bangalore 560012, Karnataka, India.
RP Krishnan, UM (reprint author), SASTRA Univ, Sch Chem & Biotechnol, CeNTAB, Dept Chem,Dept Bioengn, Thanjavur 613401, Tamil Nadu, India.
EM umakrishnan@sastra.edu
OI sharma, shilpee/0000-0003-4645-9442
FU ICMR [35/9/2009-BMS]; FIST [SR/FST/LSI-453/2010]; SASTRA University
FX The authors acknowledge financial support from ICMR (35/9/2009-BMS),
   FIST (SR/FST/LSI-453/2010), SASTRA University and JNCASR for
   infrastructural support.
CR Alexandre KB, 2010, VIROLOGY, V402, P187, DOI 10.1016/j.virol.2010.03.021
   ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H
   Bangsberg DR, 2004, J ANTIMICROB CHEMOTH, V53, P696, DOI 10.1093/jac/dkh162
   Bilge D, 2013, J MOL STRUCT, V1040, P75, DOI 10.1016/j.molstruc.2013.02.031
   Campbell EM, 2008, TRENDS MICROBIOL, V16, P580, DOI 10.1016/j.tim.2008.09.006
   Canovi M, 2011, BIOMATERIALS, V32, P5489, DOI 10.1016/j.biomaterials.2011.04.020
   Carrion C, 2001, CHEM PHYS LIPIDS, V113, P97, DOI 10.1016/S0009-3084(01)00178-5
   CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0
   Chen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058275
   Dash PK, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-25
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Destache C., 2009, BMC INFECT DIS, V9, P1
   DEWHURST S, 1987, FEBS LETT, V213, P138, DOI 10.1016/0014-5793(87)81479-5
   DEWHURST S, 1987, J VIROL, V61, P3774
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   [Anonymous], 1999, BRIT J CLIN PHARMACO, V48, P543
   Ho R. J., 2012, J ACQ IMMUN DEF SYND, V61, P417
   Federico M, 2011, VIROLOGY, V417, P37, DOI 10.1016/j.virol.2011.05.002
   FLASHER D, 1994, BBA-BIOMEMBRANES, V1194, P185, DOI 10.1016/0005-2736(94)90219-4                                                    
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gao J, 2011, BIOMATERIALS, V32, P3459, DOI 10.1016/j.biomaterials.2011.01.034
   Glynn SL, 1998, J PHARM SCI, V87, P306, DOI 10.1021/js970291i
   Gupta PN, 2012, EUR J PHARM SCI, V46, P315, DOI 10.1016/j.ejps.2012.02.003
   Han HD, 2006, EUR J PHARM BIOPHARM, V62, P110, DOI 10.1016/j.ejpb.2005.07.006
   Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724
   Hengge UR, 2001, EUR J CANCER, V37, P878, DOI 10.1016/S0959-8049(01)00053-3                                                   
   Huang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074679
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Jafari MR, 1998, DRUG DELIV, V5, P227, DOI 10.3109/10717549809065752
   Khantasup K, 2014, ANTIMICROB AGENTS CH, V58, P2816, DOI 10.1128/AAC.02768-13
   Kuo A-T, 2013, LANGMUIR, V30, P55, DOI [10.1021/la403676w, DOI 10.1021/LA403676W]
   Kuo YC, 2013, BIOMATERIALS, V34, P4818, DOI 10.1016/j.biomaterials.2013.03.013
   Li YQ, 2006, PHARM RES, V23, P1877, DOI 10.1007/s11095-006-9033-2
   LOOMIS CR, 1979, J LIPID RES, V20, P525
   Markoutsa E, 2011, EUR J PHARM BIOPHARM, V77, P265, DOI 10.1016/j.ejpb.2010.11.015
   MATTHAY KK, 1989, CANCER RES, V49, P4879
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mercadal M, 1999, BBA-BIOMEMBRANES, V1418, P232, DOI 10.1016/S0005-2736(99)00033-4
   NASSANDER UK, 1995, BBA-BIOMEMBRANES, V1235, P126, DOI 10.1016/0005-2736(94)00300-E                                                    
   Nielsen UB, 2002, BBA-MOL CELL RES, V1591, P109, DOI 10.1016/S0167-4889(02)00256-2
   Nishiyama Y, 2007, MOL IMMUNOL, V44, P2707, DOI 10.1016/j.molimm.2006.12.005
   Notari S, 2006, J CHROMATOGR B, V831, P258, DOI 10.1016/j.jchromb.2005.12.016
   Okamoto A., 2014, BIOCH BIOPHYS RES CO
   Park J W, 1997, Adv Pharmacol, V40, P399, DOI 10.1016/S1054-3589(08)60146-5
   Pedziwiatr-Werbicka E, 2011, COLLOID SURFACE B, V83, P360, DOI 10.1016/j.colsurfb.2010.12.008
   PETERS BS, 1994, DRUG SAFETY, V10, P439, DOI 10.2165/00002018-199410060-00003
   Ramana LN, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-57
   Ramana LN, 2014, BBA-GEN SUBJECTS, V1840, P476, DOI 10.1016/j.bbagen.2013.10.002
   Ramana LN, 2012, INT J PHARMACEUT, V431, P120, DOI 10.1016/j.ijpharm.2012.04.054
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Robinson AM, 1998, BBA-BIOMEMBRANES, V1369, P278, DOI 10.1016/S0005-2736(97)00231-9                                                   
   Sioud M., 2005, GENE THER, V13, P194
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Strong B., 2013, MARRIAGE FAMILY EXPE
   Sundaramurthi D, 2013, J BIOMED NANOTECHNOL, V9, P1383, DOI 10.1166/jbn.2013.1618
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang ZL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-300
   Yang HW, 2003, IMMUNOL LETT, V88, P27, DOI 10.1016/S0165-2478(03)00048-8
   Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011
   Zalipsky S, 1996, J CONTROL RELEASE, V39, P153, DOI 10.1016/0168-3659(95)00149-2
   Zelphati O, 1993, Antisense Res Dev, V3, P323
   Zhang F, 2001, BIOMATERIALS, V22, P1541, DOI 10.1016/S0142-9612(00)00310-0
   Zhang L, 2010, CURR MED CHEM, V17, P585, DOI 10.2174/092986710790416290                                                      
   Zhigaltsev IV, 2005, J CONTROL RELEASE, V104, P103, DOI 10.1016/j.jconrel.2005.01.010
NR 65
TC 2
Z9 3
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD JAN
PY 2015
VL 89
BP 300
EP 311
DI 10.1016/j.ejpb.2014.11.021
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CE1FO
UT WOS:000351557700033
PM 25500283
DA 2018-01-05
ER

PT J
AU Hu, J
   Hou, XD
   Wu, P
AF Hu, Jing
   Hou, Xiandeng
   Wu, Peng
TI Ultrasensitive atomic fluorescence spectrometric detection of DNA with
   quantum dot-assemblies as signal amplification labels
SO JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY
LA English
DT Article
ID PLASMA-MASS SPECTROMETRY; CHEMICAL-VAPOR GENERATION; HYDRIDE GENERATION;
   ISOTOPE-DILUTION; CDS NANOCRYSTALS; NANOPARTICLES; CDTE; MICROSPHERES;
   IMMUNOASSAY; MULTIPLEX
AB Hydride generation atomic fluorescence spectrometry (HG-AFS) has been widely used for highly sensitive determination of more than 10 elements that are capable of hydride generation in geological, environmental and biological samples, but its bioanalytical potential has not been well-exploited yet. With CdS quantum dots (QDs) as both the signal labels for DNA sandwiching and analytes for HG-AFS (acid-released Cd2+ from QDs), here we proposed an ultrasensitive indirect method for HIV DNA analysis by HG-AFS. After a conventional sandwich-type hybridization reaction between capture DNA, target DNA and signal DNA labelled with CdS QD assembled silica microspheres, nitric acid was added to dissolve QDs and release Cd2+ from the QD-labels, which were then detected by HG-AFS. This efficient signal amplification strategy, coupled with the highly sensitive HG-AFS detection, gave rise to an impressive limit of detection of 0.8 aM and a wide dynamic concentration range (1 aM to 1 fM). This HG-AFS-based DNA biosensing platform holds great promise in future tumor marker detection and early cancerous diseases diagnosis.
C1 [Hu, Jing; Hou, Xiandeng] Sichuan Univ, Coll Chem, Chengdu 610064, Peoples R China.
   [Hou, Xiandeng; Wu, Peng] Sichuan Univ, Analyt & Testing Ctr, Chengdu 610064, Peoples R China.
RP Hou, XD (reprint author), Sichuan Univ, Coll Chem, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.
EM houxd@scu.edu.cn; wupeng@scu.edu.cn
RI Wu, Peng/B-4987-2010; Hou, Xiandeng/B-4159-2011
OI Wu, Peng/0000-0002-9128-9027; 
FU National Natural Science Foundation of China [21275103]; Ministry of
   Education [2012 0181110046]
FX This work was financially supported by the National Natural Science
   Foundation of China (no. 21275103) and Ministry of Education (2012
   0181110046).
CR Ariga K, 2007, PHYS CHEM CHEM PHYS, V9, P2319, DOI 10.1039/b700410a
   ARIZA JLG, 2000, TALANTA, V51, P257
   Bao HF, 2006, SMALL, V2, P476, DOI 10.1002/smll.200500346
   Chen X, 2012, ANAL CHEM, V84, P8277, DOI 10.1021/ac3017828
   Chen X, 2011, CHEM COMMUN, V47, P12116, DOI 10.1039/c1cc15695k
   Cheng W, 2010, ANAL CHEM, V82, P3337, DOI 10.1021/ac100144g
   Constantine CA, 2003, LANGMUIR, V19, P9863, DOI 10.1021/la035237y
   Devare SG, 2007, J MED VIROL, V79, pS11, DOI 10.1002/jmv.20967
   Du Y, 2008, ANAL CHEM, V80, P5110, DOI 10.1021/ac800303c
   Gerasimova YV, 2014, CHEM SOC REV, V43, P6405, DOI 10.1039/c4cs00083h
   Halford WP, 1999, NAT BIOTECHNOL, V17, P835, DOI 10.1038/12783                                                                   
   He Q, 2014, J ANAL ATOM SPECTROM, V29, P1477, DOI 10.1039/c4ja00026a
   Heilier JF, 2005, INT ARCH OCC ENV HEA, V78, P51, DOI 10.1007/s00420-004-0562-x
   Hu J, 2010, ANALYST, V135, P1084, DOI 10.1039/b920358c
   Konz T, 2013, ANAL CHEM, V85, P8334, DOI 10.1021/ac401692k
   Li G, 2004, J ANAL ATOM SPECTROM, V19, P1010, DOI 10.1039/b402581d
   Li G, 2003, SPECTROSC LETT, V36, P275, DOI 10.1081/SL-120024578
   Li H, 2007, IND ENG CHEM RES, V46, P2013, DOI 10.1021/ie060963s
   Li J, 2009, J MATER CHEM, V19, P6492, DOI 10.1039/b908830j
   Li XY, 2009, LANGMUIR, V25, P6580, DOI 10.1021/la900066z
   Liu R, 2014, MASS SPECTROM REV, V33, P373, DOI 10.1002/mas.21391
   Liu R, 2013, ANAL CHEM, V85, P4087, DOI 10.1021/ac400158u
   Liu X, 2012, ANALYST, V137, P1473, DOI 10.1039/c2an16014e
   Luo M, 2012, CHEM COMMUN, V48, P1126, DOI 10.1039/c2cc16868e
   Luo YC, 2013, ANAL CHEM, V85, P9428, DOI 10.1021/ac402446a
   Lv Y. K., 2002, ANAL CHEM, V74, P1525
   Nie LB, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/30/305501
   Nie ZH, 2010, NAT NANOTECHNOL, V5, P15, DOI [10.1038/NNANO.2009.453, 10.1038/nnano.2009.453]
   Peng ZA, 2001, J AM CHEM SOC, V123, P183, DOI 10.1021/ja003633m
   Roth WK, 1999, LANCET, V353, P359, DOI 10.1016/S0140-6736(98)06318-1                                                   
   Sapsford KE, 2013, CHEM REV, V113, P1904, DOI 10.1021/cr300143v
   Schweitzer B, 2001, CURR OPIN BIOTECH, V12, P21, DOI 10.1016/S0958-1669(00)00172-5                                                   
   Scrimin P, 2011, CHEM SOC REV, V40, P4488, DOI 10.1039/c1cs15024c
   Smrkolj P, 2004, ANAL CHIM ACTA, V512, P11, DOI 10.1016/j.aca.2004.02.033
   Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113                                                          
   Wang DY, 2002, NANO LETT, V2, P857, DOI 10.1021/nl025624c
   Wang GL, 2009, J PHYS CHEM C, V113, P11142, DOI 10.1021/jp902069s
   Wang XY, 2007, LUMINESCENCE, V22, P1, DOI 10.1002/bio.917
   Wang ZJ, 2014, NANOSCALE, V6, P3110, DOI 10.1039/c3nr05625b
   Wu P, 2008, TALANTA, V74, P505, DOI 10.1016/j.talanta.2007.06.013
   Wu P, 2014, NANOSCALE, V6, P43, DOI 10.1039/c3nr04628a
   Wu YF, 2009, ANAL CHEM, V81, P1600, DOI 10.1021/ac802345z
   Xu W, 2009, ANGEW CHEM INT EDIT, V48, P6849, DOI 10.1002/anie.200901772
   Yang HH, 2003, ANALYST, V128, P462, DOI 10.1039/b210192k
   Yu WW, 2003, CHEM MATER, V15, P2854, DOI 10.1021/cm034081k
   Yuan T, 2011, CHEM COMMUN, V47, P11951, DOI 10.1039/c1cc14854k
   Zhang B, 2013, CHEM-EUR J, V19, P2496, DOI 10.1002/chem.201203131
   Zhang SX, 2014, ANAL CHEM, V86, P3541, DOI 10.1021/ac404245z
   Zhao XJ, 2003, J AM CHEM SOC, V125, P11474, DOI 10.1021/ja0358854
   Zheng CB, 2010, MICROCHEM J, V95, P32, DOI 10.1016/j.microc.2009.09.010
NR 50
TC 6
Z9 6
U1 4
U2 47
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0267-9477
EI 1364-5544
J9 J ANAL ATOM SPECTROM
JI J. Anal. At. Spectrom.
PY 2015
VL 30
IS 4
BP 888
EP 894
DI 10.1039/c4ja00285g
PG 7
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA CE3YQ
UT WOS:000351766400006
DA 2018-01-05
ER

PT J
AU Putz, MV
   Tudoran, MA
   Ori, O
AF Putz, Mihai V.
   Tudoran, Marina A.
   Ori, Ottorino
TI Topological Organic Chemistry: From Distance Matrix to Timisoara
   Eccentricity
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Biological systems; PAH (polycyclic aromatic hydrocarbons); Timisoara
   eccentricity; topological invariants; wienerology
ID TERMINAL-WIENER INDEX; CHEMICAL GRAPH-THEORY; ANTI-HIV ACTIVITY;
   INHIBITORY-ACTIVITY; BIOLOGICAL-ACTIVITY; MOLECULAR GRAPHS; PREDICTION;
   DESCRIPTORS; MODELS; HYDROCARBONS
AB This work presents chemical applications of topological methods in various sectors, from small molecule to biological systems, in studying for example enzyme-catalyzed reaction, protein folding kinetics, DNA sequence characterization. Topological descriptors participate to QSAR/QSPR models and, furthermore, are able to individuate the regions which are stabilized (or, vice versa, made reactive) by certain topological interactions. The Wiener indexes, and other distance-based invariants, constrained by the minimum-principle, oppose any unfavorable topological variation in the molecular structure (e.g. chemical transformations). Topological models characterize therefore chemical structures with astonishing details with computational simplicity predicting novel chemical mechanisms to be confirmed by subsequent ab-initio studies. Reported topological methods for simulating complex chemical mechanism and interesting chemical structures preserve the "usual" computational simplicity and still carry a large amount of chemical information stored in topology, an evident alliance between chemistry and mathematics in explaining how the nano-world works.
C1 [Putz, Mihai V.; Tudoran, Marina A.; Ori, Ottorino] West Univ Timisoara, Fac Chem, Lab Computat & Struct Phys Chem Nanosci & QSAR, Dept Biol Chem,Biol,Geog, RO-300115 Timisoara, Romania.
   [Ori, Ottorino] Actinium Chem Res, I-00133 Rome, Italy.
RP Putz, MV (reprint author), West Univ Timisoara, Fac Chem, Lab Computat & Struct Phys Chem Nanosci & QSAR, Dept Biol Chem,Biol,Geog, Pestalozzi Str 16, RO-300115 Timisoara, Romania.
EM mv_putz@yahoo.com; ottorino.ori@gmail.com
FU Project "Doctoral and Postdoctoral programs support for increased
   competitiveness in Exact Sciences research" [POSDRU/159/1.5/S/137750];
   European Social Fund within the Sectoral Operational Programme Human
   Resources Development
FX This work was supported by the strategic grant POSDRU/159/1.5/S/137750
   Project "Doctoral and Postdoctoral programs support for increased
   competitiveness in Exact Sciences research" cofinanced by the European
   Social Fund within the Sectoral Operational Programme Human Resources
   Development 2007-2013. OO kindly thanks Biology-Chemical Department of
   West University of Timisoara for hospitality during his visit on spring
   of 2014 at Laboratory of Computational and Structural Physical-Chemistry
   for Nanosciences and QSAR. All authors are truly indebted to the
   constructive comments and observations of Roger Mallion (University of
   Kent, Canterbury, England-UK).
CR Agrawal VK, 2005, BIOORGAN MED CHEM, V13, P2109, DOI 10.1016/j.bmc.2005.01.003
   Amigo JM, 2009, NATURWISSENSCHAFTEN, V96, P749, DOI 10.1007/s00114-009-0536-7
   Babaev E., 1994, GRAPH THEORETICAL AP, P209
   Bajaj S, 2005, BIOORGAN MED CHEM, V13, P3263, DOI 10.1016/j.bmc.2005.02.033
   Bajaj S, 2005, CROAT CHEM ACTA, V78, P165
   Balaban AT, 2013, HYLE, V19, P107
   BALABAN AT, 1965, REV ROUM CHIM, V10, P1059
   BALABAN AT, 1982, CHEM PHYS LETT, V89, P399, DOI 10.1016/0009-2614(82)80009-2
   BALABAN AT, 1962, TETRAHEDRON, V18, P315, DOI 10.1016/S0040-4020(01)93245-4                                                   
   BALABAN AT, 1959, LIEBIGS ANN CHEM, V625, P74
   Balaban A.T., 1986, MATH CHEM, V21, P115
   Balaban A.T., 1976, CHEM APPL GRAPH THEO
   Balaban A.T., 1987, STUD PHYS THEOR CHEM, V51, P159
   Balaban A. T., 1980, LECT NOTES CHEM, V15
   Balaban T. A., 1975, MATCH COMMUN MATH CO, V1, P33
   BALASUBRAMANIAN K, 1985, CHEM REV, V85, P599, DOI 10.1021/cr00070a005                                                             
   BASAK SC, 1987, MATH MODELLING, V8, P300, DOI 10.1016/0270-0255(87)90594-X                                                    
   Bonchev D., 1979, MATH CHEM, V6, P21
   Bonchev D, 1979, MATCH-COMMUN MATH CO, V7, P65
   Bonchev D., 1983, INFORM THEORETIC IND
   Bruckler FM, 2011, CHEM PHYS LETT, V503, P336, DOI 10.1016/j.cplett.2011.01.033
   Cai XC, 2009, DISCRETE APPL MATH, V157, P3046, DOI 10.1016/j.dam.2009.05.001
   Cataldo F, 2010, MOL SIMULAT, V36, P341, DOI 10.1080/08927020903483262
   Churkin A, 2012, COMPUT BIOL CHEM, V41, P35, DOI 10.1016/j.compbiolchem.2012.10.004
   CLAR E, 1960, TETRAHEDRON, V9, P202, DOI 10.1016/0040-4020(60)80009-9                                                    
   COOK MJ, 1974, ADV HETEROCYCL CHEM, V17, P255
   Coulson CA, 1939, PROC R SOC LON SER-A, V169, P413, DOI 10.1098/rspa.1939.0006
   Cverkovic D., 1974, CROAT CHEM ACTA, V46, P15
   Dai YM, 2013, J MOL GRAPH MODEL, V44, P113, DOI 10.1016/j.jmgm.2013.04.007
   Dalfo C, 2013, DISCRETE APPL MATH, V161, P768, DOI 10.1016/j.dam.2012.10.024
   Dankelmann P, 2009, DISCRETE APPL MATH, V157, P2773, DOI 10.1016/j.dam.2009.04.006
   Davydov SY, 2010, PHYS SOLID STATE+, V52, P1947, DOI 10.1134/S1063783410090271
   Dobrynin AA, 2013, MATCH-COMMUN MATH CO, V70, P565
   Dureja H, 2006, INT J PHARMACEUT, V323, P27, DOI 10.1016/j.ijpharm.2006.05.042
   Dureja H, 2008, J MOL GRAPH MODEL, V26, P1020, DOI 10.1016/j.jmgm.2007.08.008
   Dureja H, 2006, J MOL GRAPH MODEL, V25, P373, DOI 10.1016/j.jmgm.2006.02.004
   Estrada E., 1999, TOPOLOGICAL INDICES, P404
   Estrada E, 2010, CHEM PHYS LETT, V486, P166, DOI 10.1016/j.cplett.2009.12.090
   Evans C. W., 1979, MATCH COMMUN MATH CO, V6, P117
   Fernandez-Blanco E, 2013, J THEOR BIOL, V317, P331, DOI 10.1016/j.jtbi.2012.10.006
   GLUSHKOV V, 1964, CYBERNETICS THINKING, P53
   GOEL A, 1995, J CHEM INF COMP SCI, V35, P510, DOI 10.1021/ci00025a019                                                             
   GORDON M, 1952, J CHEM PHYS, V20, P428, DOI 10.1063/1.1700437
   GUTMAN I, 1972, CHEM PHYS LETT, V17, P535, DOI 10.1016/0009-2614(72)85099-1
   Gutman I, 2001, J CHEM INF COMP SCI, V41, P739, DOI 10.1021/ci000149u
   GUTMAN I, 1983, MOL PHYS, V50, P859, DOI 10.1080/00268978300102731
   GUTMAN I, 1973, TOP CURR CHEM, V42, P49
   Gutman I., 1997, MATCH COMMUN MATH CO, V35, P1
   Gutman I, 2013, CHEM PHYS LETT, V568, P195, DOI 10.1016/j.cplett.2013.03.045
   Gutman I, 2009, J MATH CHEM, V46, P522, DOI 10.1007/s10910-008-9476-2
   Harary F., 1969, GRAPH THEORY
   HOSOYA H, 1971, B CHEM SOC JPN, V44, P2332, DOI 10.1246/bcsj.44.2332                                                            
   HOSOYA H, 1994, J CHEM INF COMP SCI, V34, P428, DOI 10.1021/ci00018a033                                                             
   Hosoya H, 2013, CROAT CHEM ACTA, V86, P443, DOI 10.5562/cca2311
   Hu Q.-N., 2003, J DATA SCI, V1, P361
   Huckel E, 1931, Z PHYS, V70, P204, DOI 10.1007/BF01339530
   Iglesias-Groth S, 2014, FULLER NANOTUB CAR N, V22, P938, DOI 10.1080/1536383X.2013.863765
   Ivanciuc O, 2000, J CHEM INF COMP SCI, V40, P1412, DOI 10.1021/ci000068y
   Ivanciuc O., 1999, TOPOLOGICAL INDICES, P59
   Ivanciuc O., 1999, TOPOLOGICAL INDICES, P60
   Janezic D., 2007, GRAPH THEORETICAL MA
   Kaatz FH, 2014, J MATH CHEM, V52, P1563, DOI 10.1007/s10910-014-0336-y
   Kaatz FH, 2013, J MATH CHEM, V51, P1221, DOI 10.1007/s10910-012-0131-6
   Kaatz FH, 2013, J MATH CHEM, V51, P1211, DOI 10.1007/s10910-012-0128-1
   Karbasioun A, 2011, SCI IRAN, V18, P1623, DOI 10.1016/j.scient.2011.11.027
   KHADIKAR PV, 1995, J CHEM INF COMP SCI, V35, P547, DOI 10.1021/ci00025a024
   Khalifeh MH, 2010, COMPUT MATH APPL, V60, P2460, DOI 10.1016/j.camwa.2010.08.042
   Kier L. B., 1976, MOL CONNECTIVITY CHE
   King R. B., 1983, CHEM APPL TOPOLOGY G
   KLEIN DJ, 1993, J MATH CHEM, V12, P81, DOI 10.1007/BF01164627                                                              
   Kopp H., 1842, JUSTUS LEIBIGS ANN C, V41, P169
   Kumar V, 2006, J MATH CHEM, V39, P511, DOI 10.1007/s10910-005-9036-y
   Laszlo I, 2010, DIAM RELAT MATER, V19, P1153, DOI 10.1016/j.diamond.2010.05.001
   Lather V, 2005, BIOORGAN MED CHEM, V13, P1599, DOI 10.1016/j.bmc.2004.12.014
   Lather V, 2005, J MOL GRAPH MODEL, V23, P339, DOI 10.1016/j.jmgm.2004.11.005
   Moorthy NSHN, 2011, CHEMOMETR INTELL LAB, V109, P101, DOI 10.1016/j.chemolab.2011.02.010
   Mozrzymas A, 2011, COMPUT BIOL CHEM, V35, P347, DOI 10.1016/j.compbiolchem.2011.10.004
   Munteanu CR, 2008, J THEOR BIOL, V254, P775, DOI 10.1016/j.jtbi.2008.07.018
   Munteanu CR, 2008, J THEOR BIOL, V254, P476, DOI 10.1016/j.jtbi.2008.06.003
   NIKOLIC S, 1993, J MATH CHEM, V12, P251, DOI 10.1007/BF01164639                                                              
   Ori O, 2010, CARBON MATER-CHEM PH, V2, P251, DOI 10.1007/978-1-4020-9887-1_12
   Perez-Montoto LG, 2009, EUR J MED CHEM, V44, P4461, DOI 10.1016/j.ejmech.2009.06.011
   POLANSKY OE, 1976, MATCH MULHEIM, V2, P91
   POLANSKY OE, 1976, MATCH INF COMMUN MAT, V2, P63
   POLANSKY OE, 1980, MATCH MULHEIM, V8, P269
   POLANSKY OE, 1977, MATH CHEM, V3, P97
   Posa M, 2014, BIOCHIMIE, V97, P28, DOI 10.1016/j.biochi.2013.09.010
   Putz MV, 2013, CURR ORG CHEM, V17, P2845, DOI 10.2174/13852728113179990130                                                    
   Putz MV, 2013, CURR ORG CHEM, V17, P2816, DOI 10.2174/13852728113179990128                                                    
   Putz MV, 2013, STRUCT CHEM, V24, P1873, DOI 10.1007/s11224-013-0249-6
   Putz MV, 2013, MOLECULES, V18, P9061, DOI 10.3390/molecules18089061
   Putz MV, 2012, CHEM PHYS LETT, V548, P95, DOI 10.1016/j.cplett.2012.08.019
   Putz M.V., 2014, COMMUNICATION
   RANDIC M, 1984, J CHEM INF COMP SCI, V24, P164, DOI 10.1021/ci00043a009                                                             
   RANDIC M, 1976, J CHEM SOC FARAD T 2, V72, P232, DOI 10.1039/f29767200232
   RANDIC M, 1975, J AM CHEM SOC, V97, P6609, DOI 10.1021/ja00856a001                                                             
   RASHEVSKY N., 1955, BULL MATH BIOPHYS, V17, P229, DOI 10.1007/BF02477860
   Read R. C., 1977, J GRAPH THEOR, V1, P339, DOI DOI 10.1002/JGT.3190010410
   Rouvray D. H., 1975, MATCH MATHEMATICAL C, V1, P125
   Sahu PK, 2008, CHEM PHYS LETT, V454, P133, DOI 10.1016/j.cplett.2008.01.055
   Saliner AG, 2005, J MOL STRUC-THEOCHEM, V727, P97, DOI 10.1016/j.theochem.2004.11.062
   Senbagamalar J., 2013, EJBI, V9, P9
   Senior SA, 2011, CHEMOSPHERE, V85, P7, DOI 10.1016/j.chemosphere.2011.06.062
   Shamsipur M, 2008, J MOL GRAPH MODEL, V27, P506, DOI 10.1016/j.jmgm.2008.09.005
   Shannon C.E., 1949, MATH THEORY COMMUNIC
   Shu Q, 2008, FUEL, V87, P3586, DOI 10.1016/j.fuel.2008.07.007
   Speck-Planche A, 2013, BIOORGAN MED CHEM, V21, P2727, DOI 10.1016/j.bmc.2013.03.015
   Suarez D, 2015, WIRES COMPUT MOL SCI, V5, P1, DOI 10.1002/wcms.1195
   Tian DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078448
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   Trinajstic N., 1983, CHEM GRAPH THEORY
   Vukicevic D, 2011, CHEM PHYS LETT, V501, P442, DOI 10.1016/j.cplett.2010.11.055
   WEININGER D, 1990, J CHEM INF COMP SCI, V30, P237, DOI 10.1021/ci00067a005
   WEININGER D, 1989, J CHEM INF COMP SCI, V29, P97, DOI 10.1021/ci00062a008
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005                                                             
   WIENER H, 1947, J AM CHEM SOC, V69, P17, DOI 10.1021/ja01193a005                                                             
   Yan FY, 2013, FLUID PHASE EQUILIBR, V358, P166, DOI 10.1016/j.fluid.2013.08.021
   YEN TF, 1971, THEOR CHIM ACTA, V20, P399, DOI 10.1007/BF00527196                                                              
NR 118
TC 2
Z9 2
U1 1
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1385-2728
EI 1875-5348
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PY 2015
VL 19
IS 3
BP 249
EP 273
PG 25
WC Chemistry, Organic
SC Chemistry
GA CD3UT
UT WOS:000351008500006
DA 2018-01-05
ER

PT J
AU Jeong, MS
   Ahn, DR
AF Jeong, Min-Suk
   Ahn, Dae-Ro
TI A microwell plate-based multiplex immunoassay for simultaneous
   quantitation of antibodies to infectious viruses
SO ANALYST
LA English
DT Article
ID HEPATITIS-C VIRUS; IMMUNOSORBENT-ASSAY; B-VIRUS; AMPLIFICATION;
   QUANTIFICATION; BIOMARKERS; SYSTEM; REGION; RNA
AB Antibodies (Abs) to disease-causing viruses in human blood are important indicators of infection status. While ELISA has been widely used to detect these Abs, a multiplex assay system for simultaneous detection of multiple Abs is still a desirable alternative method for a more efficient screening process because of the lack of multiplexing ability in ELISA. However, as all antibodies are based on immunoglobulin and recognized commonly by the same secondary antibody, it is impossible to multiplex the conventional indirect ELISA in a 96-microwell plate-based platform. To overcome this hurdle, we designed an assay consisting of two steps: capturing target Abs by specific antigens on DNA-encoded gold nanoparticles; and quantifying the target Abs by producing RNase H-mediated detection signals based on the DNA and additional RNA probes. With this newly designed method, we could simultaneously analyze three infectious disease-related Abs, anti-HIV Ab, anti-HCV Ab, and anti-HBV Ab, on the microwell-based platform. The assay performance was evaluated by comparison with ELISA. Furthermore, the accuracy and precision of the assay in a practical application was also estimated by determining the amount of target Abs in human serum solutions.
C1 [Jeong, Min-Suk; Ahn, Dae-Ro] Korea Inst Sci & Technol, Biomed Res Inst, Ctr Theragnosis, Seoul 136791, South Korea.
   [Ahn, Dae-Ro] Korea Univ Sci & Technol, Seoul 136791, South Korea.
RP Ahn, DR (reprint author), Korea Inst Sci & Technol, Biomed Res Inst, Ctr Theragnosis, Hwarangno 14 Gil 5, Seoul 136791, South Korea.
EM drahn@kist.re.kr
FU KIST; Center for Women In Science, Engineering and Technology (WISET)
   under the Program for Returners into RD; National Research Foundation of
   Korea (NRF) - Korea government (MSIP) [2014-R1A2A2A04002526];
   Proteogenomic Research Program through NRF - MSIP [2012M3A9B9036670];
   Korea Healthcare technology RD Project; Ministry of Health & Welfare,
   Republic of Korea [A121191]; Pioneer Research Center Program through NRF
   - Ministry of Science, ICT & Future Planning [2014M3C1A3054141]
FX This study was supported by an intramural research program of KIST, the
   Center for Women In Science, Engineering and Technology (WISET) under
   the Program for Returners into R&D, the National Research Foundation of
   Korea (NRF) grant funded by the Korea government (MSIP)
   (2014-R1A2A2A04002526), a grant of the Proteogenomic Research Program
   through NRF funded by MSIP (2012M3A9B9036670), a grant of the Korea
   Healthcare technology R&D Project, the Ministry of Health & Welfare,
   Republic of Korea (A121191), and a grant by the Pioneer Research Center
   Program through NRF funded by the Ministry of Science, ICT & Future
   Planning (2014M3C1A3054141).
CR Altunay H, 2010, TRANSFUS APHER SCI, V43, P265, DOI 10.1016/j.transci.2010.09.012
   Botelho-Souza LF, 2014, J VIROL METHODS, V197, P19, DOI 10.1016/j.jviromet.2013.11.016
   Duan LL, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-53
   Fabrizi F, 2005, ALIMENT PHARM THERAP, V21, P861, DOI 10.1111/j.1365-2036.2005.02416.x
   Gilburd Boris, 2004, Clin Dev Immunol, V11, P53, DOI 10.1080/10446670410001670490
   Haab B., 2001, GENOME BIOL, V2
   Han KC, 2012, CHEM COMMUN, V48, P5895, DOI 10.1039/c2cc31659e
   Han KC, 2010, BIOCONJUGATE CHEM, V21, P2190, DOI 10.1021/bc100147a
   Inoue T, 2013, INVEST OPHTH VIS SCI, V54, P5353, DOI 10.1167/iovs.13-12245
   Khan IH, 2006, CLIN VACCINE IMMUNOL, V13, P45, DOI 10.1128/CVI.13.1.45-52.2006
   Komatsu N, 2004, SCAND J CLIN LAB INV, V64, P535, DOI 10.1080/00365510410007008
   Le VP, 2010, J MED VIROL, V82, P1065, DOI 10.1002/jmv.21761
   Mine H, 2003, J VIROL METHODS, V112, P145, DOI 10.1016/S0166-0934(03)00215-5
   Munson E, 2013, J CLIN MICROBIOL, V51, P1855, DOI 10.1128/JCM.00455-13
   Nakamoto S, 2009, SCAND J GASTROENTERO, V44, P872, DOI 10.1080/00365520902937362
   Nuriya H, 2010, J CLIN MICROBIOL, V48, P3843, DOI 10.1128/JCM.00415-10
   Pickering JW, 2002, AM J CLIN PATHOL, V117, P589
   Pickering JW, 2002, CLIN DIAGN LAB IMMUN, V9, P872, DOI 10.1128/CDLI.9.4.872-876.2002
   Rao V, 2010, RENAL FAILURE, V32, P721, DOI 10.3109/0886022X.2010.486499
   Roland ME, 2004, J INFECT DIS, V190, P598, DOI 10.1086/421278                                                                  
   Sarrazin C, 2008, J CLIN VIROL, V43, P162, DOI 10.1016/j.jcv.2008.06.013
   Wang ZF, 2014, BIOSENS BIOELECTRON, V53, P324, DOI 10.1016/j.bios.2013.10.009
NR 22
TC 4
Z9 4
U1 1
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2015
VL 140
IS 6
BP 1995
EP 2000
DI 10.1039/c4an02262a
PG 6
WC Chemistry, Analytical
SC Chemistry
GA CC7UH
UT WOS:000350573400034
PM 25673274
DA 2018-01-05
ER

PT J
AU Ordanini, S
   Varga, N
   Porkolab, V
   Thepaut, M
   Belvisi, L
   Bertaglia, A
   Palmioli, A
   Berzi, A
   Trabattoni, D
   Clerici, M
   Fieschi, F
   Bernardi, A
AF Ordanini, Stefania
   Varga, Norbert
   Porkolab, Vanessa
   Thepaut, Michel
   Belvisi, Laura
   Bertaglia, Andrea
   Palmioli, Alessandro
   Berzi, Angela
   Trabattoni, Daria
   Clerici, Mario
   Fieschi, Franck
   Bernardi, Anna
TI Designing nanomolar antagonists of DC-SIGN-mediated HIV infection:
   ligand presentation using molecular rods
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID MULTIVALENT LIGANDS; INHIBITORS; BINDING; DEPENDENCE; MECHANISM
AB DC-SIGN antagonists were designed combining one selective monovalent glycomimetic ligand with trivalent dendrons separated by a rigid core of controlled length. The design combines multiple multivalency effects to achieve inhibitors of HIV infection, which are active in nanomolar concentration.
C1 [Ordanini, Stefania; Varga, Norbert; Belvisi, Laura; Bertaglia, Andrea; Palmioli, Alessandro; Bernardi, Anna] Univ Milano UniMI, Dipartimento Chim, I-20133 Milan, Italy.
   [Porkolab, Vanessa; Thepaut, Michel; Fieschi, Franck] Univ Grenoble Alpes, Inst Biol Struct, Grenoble, France.
   [Porkolab, Vanessa; Thepaut, Michel; Fieschi, Franck] CNRS, IBS, F-38044 Grenoble, France.
   [Porkolab, Vanessa; Thepaut, Michel; Fieschi, Franck] CEA, IBS, F-38044 Grenoble, France.
   [Belvisi, Laura; Bernardi, Anna] CNR, ISTM, Inst Mol Sci & Technol, I-20133 Milan, Italy.
   [Berzi, Angela; Trabattoni, Daria] UniMI, Dipartimento Sci Biomed & Clin L Sacco, Milan, Italy.
   [Clerici, Mario] UniMI, Dipartimento Fisiopatol Med Chirurg & Trapianti, Segrate, Italy.
   [Clerici, Mario] Fdn Don Carlo Gnocchi IRCCS, Milan, Italy.
RP Bernardi, A (reprint author), Univ Milano UniMI, Dipartimento Chim, Via Golgi 19, I-20133 Milan, Italy.
EM anna.bernardi@unimi.it
RI Belvisi, Laura/J-5046-2012; Palmioli, Alessandro/F-4292-2017; Bernardi,
   Anna/A-1167-2012; Palmioli, Alessandro/A-8695-2013
OI Belvisi, Laura/0000-0002-3593-2970; Palmioli,
   Alessandro/0000-0002-5287-1663; Bernardi, Anna/0000-0002-1258-2007;
   Palmioli, Alessandro/0000-0002-5287-1663; Clerici,
   Mario/0000-0001-5920-6191; Trabattoni, Daria/0000-0001-9535-3359;
   porkolab, vanessa/0000-0002-5075-6389
FU ETN-Carmusys [PITN-GA-2008-213592]; COST Action [CM1102]
FX This work was supported with funds from ETN-Carmusys
   (PITN-GA-2008-213592) and CM1102 COST Action.
CR Bavdek A, 2012, FEBS J, V279, P126, DOI 10.1111/j.1742-4658.2011.08405.x
   Becer CR, 2010, J AM CHEM SOC, V132, P15130, DOI 10.1021/ja1056714
   Bernardi A, 2013, CHEM SOC REV, V42, P4709, DOI 10.1039/c2cs35408j
   Garber KCA, 2010, CHEM COMMUN, V46, P6747, DOI 10.1039/c0cc00830c
   Krishnamurthy V. M., 2006, FRAGMENT BASED APPRO, P11, DOI [DOI 10.1002/3527608761.CH2, 10.1002/3527608761]
   Luczkowiak J, 2011, BIOCONJUGATE CHEM, V22, P1354, DOI 10.1021/bc2000403
   Mack ET, 2012, J AM CHEM SOC, V134, P333, DOI 10.1021/ja2073033
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Menon S, 2009, P NATL ACAD SCI USA, V106, P11524, DOI 10.1073/pnas.0901783106
   Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200                                                          
   Pertici F, 2013, BEILSTEIN J ORG CHEM, V9, P215, DOI 10.3762/bjoc.9.25
   Pieters RJ, 2009, ORG BIOMOL CHEM, V7, P2013, DOI 10.1039/b901828j
   Tabarani G, 2009, J BIOL CHEM, V284, P21229, DOI 10.1074/jbc.M109.021204
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Varga N, 2014, BIOMATERIALS, V35, P4175, DOI 10.1016/j.biomaterials.2014.01.014
   Varga N, 2013, CHEM-EUR J, V19, P4786, DOI 10.1002/chem.201202764
NR 17
TC 16
Z9 16
U1 2
U2 30
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2015
VL 51
IS 18
BP 3816
EP 3819
DI 10.1039/c4cc09709b
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA CB9YL
UT WOS:000349990600024
PM 25648900
OA gold
DA 2018-01-05
ER

PT J
AU El-Hammadi, MM
   Arias, JL
AF El-Hammadi, Mazen M.
   Arias, Jose L.
TI Nano-Sized Platforms for Vaginal Drug Delivery
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Carbon-based nanostructure; cyclodextrin; dendrimer; liposome;
   nanoemulsion; nanomedicine; nanoparticle; vaginal drug delivery
ID BIODEGRADABLE POLYMER NANOPARTICLES; CELL-ASSOCIATED HIV-1; IN-VITRO
   EVALUATION; OF-A-FORMULATION; WOMENS PREFERENCES; ANTIMICROBIAL
   CONTRACEPTIVES; SILVER NANOPARTICLES; CYCLODEXTRIN COMPLEX; INTRAVAGINAL
   DELIVERY; THERMOSENSITIVE GEL
AB Nano-sized systems have shown promise for efficient vaginal drug delivery providing sustained drug release and enhanced permeation. In parallel with advancements in drug discovery of new vaginal therapeutic agents, such as peptides, proteins, nucleic material, antigens, hormones, and microbicides, nanoplatforms are gaining momentum as prospective vectors for these agents. Thus far, extensive research in this arena has been focused on local delivery to the mucus vagina. However, an improved understanding of vaginal route, advantages offered by the vaginal route including being non-invasive and bypassing hepatic first-effect metabolism, and recent success achieved by vaginal drug nanocarriers may open the door for extensive nanotechnology-based research to explore the viability of systemic administration via this route. The review analyzes the possibilities given by nanoplatform-based delivery systems in the vaginal delivery of active agents. Special insight is given to the most important aspects to be considered during nanomedicine development and preclinical evaluation, i.e., the anatomy and physiology of the vagina, advantages of vaginal route of drug administration, and barriers to vaginal drug delivery. Finally, an updated analysis of the recent advancements of nanomedicine technologies and their potential progress into the clinic is compiled in this work.
C1 [El-Hammadi, Mazen M.; Arias, Jose L.] Univ Granada, Dept Pharm & Pharmaceut Technol, Fac Pharm, E-18071 Granada, Spain.
   [El-Hammadi, Mazen M.] Damascus Univ, Fac Pharm, Dept Pharmaceut & Pharmaceut Technol, Damascus, Syria.
RP Arias, JL (reprint author), Univ Granada, Dept Pharm & Pharmaceut Technol, Fac Pharm, Campus Univ Cartuja S-N, E-18071 Granada, Spain.
EM mazenhammadi@yahoo.co.uk; jlarias@ugr.es
RI Arias Mediano, Jose Luis/B-8986-2017
OI Arias Mediano, Jose Luis/0000-0002-3437-3791; El-Hammadi,
   Mazen/0000-0002-3563-5159
FU Erasmus Mundus - JOSYLEEM Program
FX The financial support of the Erasmus Mundus - JOSYLEEM Program is
   acknowledged as is the post-doctoral fellowship to M. El- Hammadi.
CR Acarturk Fusun, 2009, Recent Pat Drug Deliv Formul, V3, P193
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Ambrose Z, 2008, J VIROL, V82, P6591, DOI 10.1128/JVI.02730-07
   Aschberger K, 2010, CRIT REV TOXICOL, V40, P759, DOI 10.3109/10408444.2010.506638
   Bachhav YG, 2009, AAPS PHARMSCITECH, V10, P476, DOI 10.1208/s12249-009-9233-2
   Bakry R, 2007, INT J NANOMED, V2, P639
   Ballou B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051995
   Basnet P, 2012, J PHARM SCI-US, V101, P598, DOI 10.1002/jps.22785
   Bilensoy E, 2006, J CONTROL RELEASE, V116, pE107, DOI 10.1016/j.jconrel.2006.09.075
   Bilensoy E, 2007, J INCL PHENOM MACRO, V57, P363, DOI 10.1007/s10847-006-9259-y
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Cevher E, 2008, J PHARM SCI-US, V97, P4319, DOI 10.1002/jps.21312
   Cevher E, 2014, INT J BIOL MACROMOL, V69, P124, DOI 10.1016/j.ijbiomac.2014.05.033
   Chen DQ, 2012, INT J NANOMED, V7, P2621, DOI 10.2147/IJN.S31757
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   D'Cruz OJ, 2001, CONTRACEPTION, V64, P113, DOI 10.1016/S0010-7824(01)00233-5
   D'Cruz OJ, 2006, AAPS PHARMSCITECH, V7
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Dcruz OJ, 2007, TOXICOL PATHOL, V35, P910, DOI 10.1080/01926230701748115
   Degim Z, 2005, J DRUG TARGET, V13, P563, DOI 10.1080/10611860500441933
   Demirel M, 2011, J INCL PHENOM MACRO, V70, P437, DOI 10.1007/s10847-010-9922-1
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Esposito E, 2013, MAT SCI ENG C-MATER, V33, P411, DOI 10.1016/j.msec.2012.09.007
   Francois M, 2003, AAPS PHARMSCI, V5
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gupta PN, 2012, EUR J PHARM SCI, V46, P315, DOI 10.1016/j.ejps.2012.02.003
   Gupta Sonal, 2011, Recent Pat Drug Deliv Formul, V5, P82
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hardy E, 1998, CONTRACEPTION, V58, P251, DOI 10.1016/S0010-7824(98)00106-1
   Hardy E, 2003, CONTRACEPTION, V67, P391, DOI 10.1016/S0010-7824(03)00026-X
   Hardy E, 1998, CONTRACEPTION, V58, P239, DOI 10.1016/S0010-7824(98)00100-0
   Hardy E, 1998, CONTRACEPTION, V58, P245, DOI 10.1016/S0010-7824(98)00104-8
   Kang JW, 2010, J DRUG TARGET, V18, P637, DOI 10.3109/10611861003649712
   Kima YT, 2010, EUR J PHARM SCI, V41, P399
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Li Wei-Ze, 2012, Eur J Pharm Sci, V47, P162, DOI 10.1016/j.ejps.2012.06.001
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Mattsson LA, 2013, MATURITAS, V74, P259, DOI 10.1016/j.maturitas.2012.12.004
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Meher BR, 2012, J MOL GRAPH MODEL, V38, P430, DOI 10.1016/j.jmgm.2012.10.001
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mirza MA, 2013, COLLOID SURFACE B, V103, P275, DOI 10.1016/j.colsurfb.2012.10.038
   Ning MY, 2005, CHEM PHARM BULL, V53, P620, DOI 10.1248/cpb.53.620
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Pavelic Z, 2005, INT J PHARM, V301, P140, DOI 10.1016/j.ijpharm.2005.05.022
   Pavelic Z, 2001, INT J PHARM, V219, P139, DOI 10.1016/S0378-5173(01)00637-8
   Pavelic Z, 1999, EUR J PHARM SCI, V8, P345, DOI 10.1016/S0928-0987(99)00033-0
   Pavelic Zeljka, 2004, Acta Pharmaceutica (Zagreb), V54, P319
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sepulveda-Crespo D, 2013, NANOMEDICINE, V10, P609
   Sharma N, 2014, DRUG DELIV, V22, P1
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Vermani K., 2000, PSTT, V3, P359, DOI [10.1016/S1461-5347(00)00296-0, DOI 10.1016/S1461-5347(00)00296-0]
   Vijayakumar S, 2012, CURR HIV RES, V10, P643, DOI 10.2174/157016212803901383                                                      
   Wang B, 2010, INT J PHARMACEUT, V395, P298, DOI 10.1016/j.ijpharm.2010.05.030
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Xu X, 2012, NUCLEIC ACIDS RES, V40, P7622, DOI 10.1093/nar/gks517
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhou QN, 2013, INT J PHARMACEUT, V454, P125, DOI 10.1016/j.ijpharm.2013.07.006
NR 76
TC 2
Z9 2
U1 1
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 12
BP 1633
EP 1644
DI 10.2174/1381612820666141029150427                                       
          
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CC3WN
UT WOS:000350281800013
PM 25354177
DA 2018-01-05
ER

PT J
AU Afshari, R
   Mazinani, S
   Abdouss, M
AF Afshari, R.
   Mazinani, S.
   Abdouss, M.
TI Nanohybrid Nanoparticles Based on Chitosan/Functionalized Carbon
   Nanotubes as Anti-HIV Nanocarrier
SO NANO
LA English
DT Article
DE Nanohybrid nanoparticles; functionalized multi-walled carbon nanotube;
   chitosan; Drug delivery; Tenofovir
ID DRUG-DELIVERY; TARGETED DELIVERY; IN-VITRO; PROTEIN CARRIERS;
   FOLIC-ACID; CHITOSAN; FUNCTIONALIZATION; CANCER; ELECTRODE; MEDICINE
AB Carbon nanotube-natural biopolymer nanovectors have important potential applications in delivery system for drugs and biomolecules. In this work, the use of multi-walled carbon nanotubes (MWCNT) as nanoreservoirs for drug loading and controlled release is demonstrated. We synthesized different carbon nanotube-based drug delivery systems including acid and amide-functionalized MWCNT; chitosan (CS) covalently grafted to functionalized MWCNT and MWCNT-CS nanoparticles (NPs) using an ionotropic gelation method as a sustained-release systems for delivery of Tenofovir (hydrophilic anti-retroviral drug). The prepared NPs as different drug delivery systems were characterized by Fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA) and scanning electron microscopy (SEM). As it is shown, in vitro drug release studies indicated that the cumulative release rate of Tenofovir from MWCNT-CS NPs shows the best result and it reaches the maximum value (90%) after about 120 h. Moreover, comparing to ungrafted CNTs, MWCNT-CS shows high dispersability and long-term stability in aqueous medium which approves the effective solubilization of MWCNT followed by grafting with CS.
C1 [Afshari, R.; Abdouss, M.] Amirkabir Univ Technol, Dept Chem, Tehran, Iran.
   [Mazinani, S.] Amirkabir Univ Technol, Amirkabir Nanotechnol Res Inst ANTRI, Tehran, Iran.
RP Afshari, R (reprint author), Amirkabir Univ Technol, Dept Chem, Tehran, Iran.
EM s.mazinani@aut.ac.ir
CR Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300
   Azzaoui F.-Z., 2012, BIOL MED, V4, P89
   Baek SH, 2008, COLLOID SURFACE A, V316, P292, DOI 10.1016/j.colsurfa.2007.09.021
   Battigelli A, 2013, ADV DRUG DELIVER REV, V65, P1899, DOI 10.1016/j.addr.2013.07.006
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4                 
   Castillo JJ, 2012, CARBON, V50, P2691, DOI 10.1016/j.carbon.2012.02.010
   Chen AH, 2009, J HAZARD MATER, V163, P1068, DOI 10.1016/j.jhazmat.2008.07.073
   Cheng JP, 2011, TOXICOL APPL PHARM, V250, P184, DOI 10.1016/j.taap.2010.10.012
   Dash M, 2011, PROG POLYM SCI, V36, P981, DOI 10.1016/j.progpolymsci.2011.02.001
   Dev A, 2010, CARBOHYD POLYM, V80, P833, DOI 10.1016/j.carbpol.2009.12.040
   Dumortier H, 2006, NANO LETT, V6, P1522, DOI 10.1021/nl061160x
   Ghalkhani M, 2013, SENSOR ACTUAT B-CHEM, V185, P669, DOI 10.1016/j.snb.2013.05.054
   Gomathi P, 2011, SENSOR ACTUAT B-CHEM, V155, P897, DOI 10.1016/j.snb.2010.12.050
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   Islam A, 2012, CARBOHYD POLYM, V88, P1055, DOI 10.1016/j.carbpol.2012.01.070
   Ji ZF, 2012, J COLLOID INTERF SCI, V365, P143, DOI 10.1016/j.jcis.2011.09.013
   Jiang B, 2013, ACTA BIOMATER, V9, P4976, DOI 10.1016/j.actbio.2012.10.005
   Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v
   Karchemski F, 2012, J CONTROL RELEASE, V160, P339, DOI 10.1016/j.jconrel.2011.12.037
   Kauffman DR, 2008, ANGEW CHEM INT EDIT, V47, P6550, DOI 10.1002/anie.200704488
   Ke G, 2007, BIOMACROMOLECULES, V8, P322, DOI 10.1021/bm0604146
   Ke G, 2010, CARBOHYD POLYM, V79, P775, DOI 10.1016/j.carbpol.2009.10.010
   Kocak N, 2012, INT J BIOL MACROMOL, V51, P1159, DOI 10.1016/j.ijbiomac.2012.09.003
   Lee HJ, 2011, NAT NANOTECHNOL, V6, P120, DOI 10.1038/nnano.2010.281
   Li CY, 2011, ACTA BIOMATER, V7, P3070, DOI 10.1016/j.actbio.2011.05.005
   Liu XH, 2013, COLLOID SURFACE B, V111, P224, DOI 10.1016/j.colsurfb.2013.06.010
   Liu Z, 2009, NANO RES, V2, P85, DOI 10.1007/s12274-009-9009-8
   Luo XL, 2011, BIOMATERIALS, V32, P6316, DOI 10.1016/j.biomaterials.2011.05.020
   Magrez A, 2006, NANO LETT, V6, P1121, DOI 10.1021/nl060162e
   Mundra RV, 2014, CURR OPIN BIOTECH, V28, P25, DOI 10.1016/j.copbio.2013.10.012
   Park JH, 2010, ADV DRUG DELIVER REV, V62, P28, DOI 10.1016/j.addr.2009.10.003
   Peretz S, 2012, CURR OPIN COLLOID IN, V17, P360, DOI 10.1016/j.cocis.2012.09.001
   Prakash S, 2011, ADV DRUG DELIVER REV, V63, P1340, DOI 10.1016/j.addr.2011.06.013
   Ren JF, 2012, BIOMATERIALS, V33, P3324, DOI 10.1016/j.biomaterials.2012.01.025
   Sayes CM, 2006, TOXICOL LETT, V161, P135, DOI 10.1016/j.toxlet.2005.08.011
   Sharma K, 2012, EUR J PHARM BIOPHARM, V81, P74, DOI 10.1016/j.ejpb.2011.12.014
   Shenoy DB, 2005, INT J PHARM, V293, P261, DOI 10.1016/j.ijpharm.2004.12.010
   Tian HY, 2012, PROG POLYM SCI, V37, P237, DOI 10.1016/j.progpolymsci.2011.06.004
   Vashist SK, 2011, CARBON, V49, P4077, DOI 10.1016/j.carbon.2011.05.049
   Wang HS, 2006, BIOSENS BIOELECTRON, V22, P664, DOI 10.1016/j.bios.2006.02.007
   Wei F., 2003, CHINESE PHYS LETT, V20, P753
   Wong BS, 2013, ADV DRUG DELIVER REV, V65, P1964, DOI 10.1016/j.addr.2013.08.005
   Wu ZG, 2007, CARBON, V45, P1212, DOI 10.1016/j.carbon.2007.02.013
   Zu YG, 2011, INT J NANOMED, V6, P3429, DOI 10.2147/IJN.S27157
NR 44
TC 7
Z9 7
U1 3
U2 23
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 1793-2920
EI 1793-7094
J9 NANO
JI Nano
PD JAN
PY 2015
VL 10
IS 1
AR 1550010
DI 10.1142/S1793292015500101
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA CD0LD
UT WOS:000350763300011
DA 2018-01-05
ER

PT J
AU Marson, D
   Laurini, E
   Posocco, P
   Fermeglia, M
   Pricl, S
AF Marson, D.
   Laurini, E.
   Posocco, P.
   Fermeglia, M.
   Pricl, S.
TI Cationic carbosilane dendrimers and oligonucleotide binding: an
   energetic affair
SO NANOSCALE
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATIONS; PAMAM DENDRIMERS; ANTISENSE
   OLIGONUCLEOTIDES; GENERALIZED BORN; DRUG-DELIVERY; HIV-INFECTION;
   FORCE-FIELD; WATER; NANOMEDICINES; NANOCARRIERS
AB Generation 2 cationic carbosilane dendrimers hold great promise as internalizing agents for gene therapy as they present low toxicity and retain and internalize the genetic material as an oligonucleotide or siRNA. In this work we carried out complete in silico structural and energetical characterization of the interactions of a set of G2 carbosilane dendrimers, showing different affinity towards two single strand oligonucleotide (ODN) sequences in vitro. Our simulations predict that these four dendrimers and the relevant ODN complexes are characterized by similar size and shape, and that the molecule-specific ODN binding ability can be rationalized only by considering a critical molecular design parameter: the normalized effective binding energy Delta G(bind,eff)/N-eff, i.e. the performance of each active individual dendrimer branch directly involved in a binding interaction.
C1 [Marson, D.; Laurini, E.; Posocco, P.; Fermeglia, M.; Pricl, S.] Univ Trieste, DEA, Mol Simulat Engn MOSE Lab, I-34127 Trieste, Italy.
   [Posocco, P.; Pricl, S.] Univ Trieste, Natl Interuniv Consortium Mat Sci & Technol INSTM, Res Unit MOSE DEA, I-34127 Trieste, Italy.
RP Pricl, S (reprint author), Univ Trieste, DEA, Mol Simulat Engn MOSE Lab, Piazzale Europa 1, I-34127 Trieste, Italy.
EM sabrina.pricl@di3.units.it
RI Pricl, Sabrina/M-7493-2015; Marson, Domenico/G-7162-2012; Laurini,
   Erik/Q-4173-2016
OI Pricl, Sabrina/0000-0001-8380-4474; Marson,
   Domenico/0000-0003-1839-9868; Laurini, Erik/0000-0001-6092-6532;
   Fermeglia, Maurizio/0000-0001-8810-5082
FU COST Action [TD0802]; DILUSO project; SYMBIOSI project
FX COST Action TD0802 is acknowledged for scientific network support.
   Access to CINECA supercomputers Eurora and Fermi (Bologna, Italy) was
   granted via DILUSO and SYMBIOSI projects (Iscra supercomputing grants to
   DM and SP).
CR BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Case D. A., 2014, AMBER 14
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Chow EKH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005872
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dassie JP, 2013, THER DELIV, V4, P1527, DOI [10.4155/tde.13.118, 10.4155/TDE.13.118]
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Dawidczyk CM, 2014, J CONTROL RELEASE, V187, P133, DOI 10.1016/j.jconrel.2014.05.036
   Deng Y, 2014, GENE, V538, P217, DOI 10.1016/j.gene.2013.12.019
   Dirin M, 2013, EXPERT OPIN BIOL TH, V13, P875, DOI 10.1517/14712598.2013.774366
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Ehterige M. L., 2013, NANOMEDICINE, V9, P1
   Feig M, 2004, J COMPUT CHEM, V25, P265, DOI 10.1002/jcc.10378
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Godin B, 2011, ACCOUNTS CHEM RES, V44, P979, DOI 10.1021/ar200077p
   Gordon MS, 2005, THEORY AND APPLICATIONS OF COMPUTATIONAL CHEMISTRY: THE FIRST FORTY YEARS, P1167, DOI 10.1016/B978-044451719-7/50084-6
   Isralewitz B, 2001, J MOL GRAPH MODEL, V19, P13, DOI 10.1016/S1093-3263(00)00133-9
   Jhaveri AM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00077
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Laurini E, 2013, MOL ONCOL, V7, P968, DOI 10.1016/j.molonc.2013.06.001
   Lehner R, 2013, NANOMED-NANOTECHNOL, V9, P742, DOI 10.1016/j.nano.2013.01.012
   LII JH, 1991, J COMPUT CHEM, V12, P186, DOI 10.1002/jcc.540120208                                                           
   Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1
   Maiti PK, 2005, MACROMOLECULES, V38, P979, DOI 10.1021/ma0491681
   Maiti PK, 2004, MACROMOLECULES, V37, P6236, DOI 10.1021/ma035629b
   Mintzer MA, 2011, CHEM SOC REV, V40, P173, DOI 10.1039/b901839p
   Moros M, 2013, CURR MED CHEM, V20, P2759, DOI 10.2174/0929867311320220003                                                     
   Nicolas J, 2013, CHEM SOC REV, V42, P1147, DOI 10.1039/c2cs35265f
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s                                                               
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Park S, 2004, J CHEM PHYS, V120, P5946, DOI 10.1063/1.1651473
   Park S, 2003, J CHEM PHYS, V119, P3559, DOI 10.1063/1.1590311
   Pavan GM, 2010, CHEM-EUR J, V16, P7781, DOI 10.1002/chem.200903258
   Pedziwiatr E, 2009, J FLUORESC, V19, P267, DOI 10.1007/s10895-008-0412-4
   Pedziwiatr-Werbicka E, 2013, COLLOID SURFACE B, V109, P183, DOI 10.1016/j.colsurfb.2013.03.045
   Pedziwiatr-Werbicka E, 2012, J BIOMED NANOTECHNOL, V8, P57, DOI 10.1166/jbn.2012.1369
   Rudnick G., 1986, J PHYS A, V4, pL191, DOI DOI 10.1088/0305-4470/19/4/004
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Shcharbin D, 2007, BIOMACROMOLECULES, V8, P2059, DOI 10.1021/bm070333p
   Shen H, 2012, CANCER GENE THER, V19, P367, DOI 10.1038/cgt.2012.22
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+                                                               
   Sun QH, 2012, J CONTROL RELEASE, V164, P156, DOI 10.1016/j.jconrel.2012.05.042
   Svenson S, 2013, MOL PHARMACEUT, V10, P848, DOI 10.1021/mp300644n
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381                                                          
   Venditto VJ, 2013, ADV DRUG DELIVER REV, V65, P80, DOI 10.1016/j.addr.2012.09.038
   Viola JR, 2010, EXPERT OPIN DRUG DEL, V7, P721, DOI 10.1517/17425241003716810
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wu JY, 2013, SCI WORLD J, DOI 10.1155/2013/630654
   Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362
   Wu XW, 2003, CHEM PHYS LETT, V381, P512, DOI 10.1016/j.cplett.2003.10.013
   Zhou JH, 2012, BIODRUGS, V26, P393, DOI 10.2165/11635350-000000000-00000
NR 55
TC 3
Z9 3
U1 2
U2 24
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 9
BP 3876
EP 3887
DI 10.1039/c4nr04510f
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CC1ZJ
UT WOS:000350143700008
PM 25340619
DA 2018-01-05
ER

PT J
AU Li, W
   Wang, Q
   Li, Y
   Yu, F
   Liu, Q
   Qin, BJ
   Xie, L
   Lu, L
   Jiang, SB
AF Li, Wen
   Wang, Qian
   Li, Yuan
   Yu, Fei
   Liu, Qi
   Qin, Bingjie
   Xie, Lan
   Lu, Lu
   Jiang, Shibo
TI A Nanoparticle-Encapsulated Non-Nucleoside Reverse-Transcriptase
   Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation
   Time in Plasma
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE HIV-1; antiretroviral therapy; non-nucleoside reverse-transcriptase
   inhibitor; nanoparticles; drug resistance; pharmacokinetics
ID COMBINATION ANTIRETROVIRAL DRUGS; POLYMERIC NANOPARTICLES; HIV-1;
   BIODISTRIBUTION; DELIVERY; PHARMACOKINETICS; PACLITAXEL; DESIGN;
   NANOTECHNOLOGY; CANDIDATES
AB Non-nucleoside reverse-transcriptase inhibitors (NNRTIs), major components of highly active antiretroviral therapy (HAART), are effective in suppressing viral replication and preventing the progress of HIV-1 infection to AIDS. However, rapid blood clearance in vivo could significantly impair the efficiency of the anti-HIV-1 activity and result in multiple daily doses which might lead to poor patient compliance. Here we attempted to employ biodegradable organic nanoparticles (NPs) to encapsulate DAAN15h, a derivative of 4-substituted 1, 5-diarylaniline with potent anti-HIV activities. Nanoparticles encapsulating DAAN15h (NP-DAAN15h) displayed a spherical shape with a size of 97.01 +/- 3.64 nm and zeta potential of -19.1 +/- 3.78 mV, and they exhibited a sustained controlled release behavior in vitro. The cellular uptake of NPs on TZM-b1 cells, MT-2 cells and M7 cells, possibly through lipid raft-mediated and energy-dependent active transport processes, was significantly enhanced. NP-DAAN15h, which possessed no significant in vitro cytotoxicity, showed improved antiviral activity against laboratory-adapted and primary HIV-1 isolates with different subtypes and tropisms, including RT-resistant variants. NP-DAAN15h exhibited a significantly prolonged blood circulation time, decreased plasma elimination rate, and enhanced AUC((0-t)). NP-DAAN15h, a nanoparticle-encapsulated NNRTI, exhibits enhanced cellular uptake, improved anti-HIV-1 efficacy and prolonged in vivo circulation time, suggesting good potential for further development as a new NNRTI formulation for clinical use.
C1 [Li, Wen; Wang, Qian; Li, Yuan; Liu, Qi; Lu, Lu; Jiang, Shibo] Fudan Univ, Shanghai Med Coll, Ministries Educ & Hlth, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
   [Li, Wen; Wang, Qian; Li, Yuan; Liu, Qi; Lu, Lu; Jiang, Shibo] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China.
   [Yu, Fei; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
   [Qin, Bingjie; Xie, Lan] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
RP Jiang, SB (reprint author), Fudan Univ, Shanghai Med Coll, 130 Dong Rd Rm 611, Shanghai 200032, Peoples R China.
EM shibojiang@fudan.edu.cn
RI Lu, Lu/K-7070-2014
FU National Megaprojects of China for Major Infectious Diseases
   [2013ZX10001-006, 2012ZX10001-007-008]; National Science Fund of China
   [81102476, 30930106]; Shanghai Pujiang Programs [13PJD004]
FX This work was supported by grants from the National Megaprojects of
   China for Major Infectious Diseases (2013ZX10001-006 and
   2012ZX10001-007-008) to SJ, National Science Fund of China (81102476 to
   LL and 30930106 to LX), and the Shanghai Pujiang Programs (13PJD004) to
   LL. We are grateful to Dr. Jun Chen, School of Pharmacy, Fudan
   University, for providing help in liquid chromatography-tandem mass
   spectrometry (LC-MS/MS) analysis. We also thank Mr. Quanyin Hu for his
   assistance in preparing NPs and animal experiments.
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Chavanpatil MD, 2006, J NANOSCI NANOTECHNO, V6, P2651, DOI 10.1166/jnn.2006.443
   Chou TC, 1991, CALCUSYN WINDOWS SOF
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Crosasso P, 2000, J CONTROL RELEASE, V63, P19, DOI 10.1016/S0168-3659(99)00166-2
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Faure AC, 2009, SMALL, V5, P2565, DOI 10.1002/smll.200900563
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Gu GZ, 2013, BIOMATERIALS, V34, P196, DOI 10.1016/j.biomaterials.2012.09.044
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hu QY, 2013, BIOMATERIALS, V34, P5640, DOI 10.1016/j.biomaterials.2013.04.025
   Hu QY, 2013, BIOMATERIALS, V34, P1135, DOI 10.1016/j.biomaterials.2012.10.048
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Johnson BC, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-99
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liu MX, 2008, ARCH PHARM RES, V31, P547, DOI 10.1007/s12272-001-1191-8
   Lu L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-104
   Montefiori DC, 2005, CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735.IM1211S64
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Qin BJ, 2010, J MED CHEM, V53, P4906, DOI 10.1021/jm1002952
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Sun LQ, 2012, J MED CHEM, V55, P7219, DOI 10.1021/jm3007678
   Sun LQ, 2012, BIOORG MED CHEM LETT, V22, P2376, DOI 10.1016/j.bmcl.2012.02.055
   Tong P, 2013, J ANTIMICROB CHEMOTH, V68, P2533, DOI 10.1093/jac/dkt230
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Zeng N, 2012, INT J PHARMACEUT, V424, P58, DOI 10.1016/j.ijpharm.2011.12.058
   Zhang Y, 2008, BIOMED MICRODEVICES, V10, P321, DOI 10.1007/s10544-007-9139-2
NR 36
TC 9
Z9 9
U1 0
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 7
BP 925
EP 935
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CB2MW
UT WOS:000349462800011
PM 25312722
DA 2018-01-05
ER

PT J
AU Cortez, JM
   Quintero, R
   Moss, JA
   Beliveau, M
   Smith, TJ
   Baum, MM
AF Cortez, John M., Jr.
   Quintero, Rafaela
   Moss, John A.
   Beliveau, Martin
   Smith, Thomas J.
   Baum, Marc M.
TI Pharmacokinetics of Injectable, Long-Acting Nevirapine for HIV
   Prophylaxis in Breastfeeding Infants
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID TO-CHILD TRANSMISSION; NANOFORMULATED ANTIRETROVIRAL THERAPY; RANDOMIZED
   CLINICAL-TRIAL; IN-VIVO; POLYVINYL-ALCOHOL; DRUG-DELIVERY; PREVENTION;
   TWICE; UGANDA; SAFETY
AB Mother-to-child transmission (MTCT) of HIV-1 remains a global health problem. The World Health Organization (WHO) recommendations advise the administration of a once-daily, oral, prophylactic regimen of the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) from birth until 4 to 6 weeks of age for infants born to HIV-infected mothers in regions without access to safe and nutritionally adequate alternatives to breast milk. A critical factor driving the successful implementation of the WHOguidelines involves sustaining high adherence to the frequent dosing. With these challenges in mind, we have developed the first injectable, sustained-release NVP formulations with the goal of providing, for 6 weeks or longer, preventative plasma drug levels from a single subcutaneous administration at birth. The long-acting NVP consists of large (>50 mu m), monodisperse NVP particles coated with biocompatible polymers that control the drug release kinetics. Two lead formulations exhibiting burst-free, sustained-release kinetics for up to 75 days in vitro were developed. Subsequent in vivo studies in rats demonstrated no toxicity related to the formulations. Rat plasma NVP concentrations were above the analytical assay's limit of quantification for up to 28 days. Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated. These data then were used to simulate infant NVP exposure from a single injected dose (<200 mg) of our long-acting formulations, demonstrating preliminary feasibility of the technology to maintain safe, preventative NVP plasma levels (0.2 to 3.0 mu ml(-1)) for 6 weeks or longer.
C1 [Cortez, John M., Jr.; Quintero, Rafaela; Smith, Thomas J.] Auritec Pharmaceut Inc, Pasadena, CA USA.
   [Moss, John A.; Smith, Thomas J.; Baum, Marc M.] Oak Crest Inst Sci, Dept Chem, Pasadena, CA 91107 USA.
   [Beliveau, Martin] Pharsight Consulting Serv, Montreal, PQ, Canada.
RP Baum, MM (reprint author), Oak Crest Inst Sci, Dept Chem, Pasadena, CA 91107 USA.
EM m.baum@oak-crest.org
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development [R43HD050146, R44HD050146]
FX The project described here was supported by grants R43HD050146 and
   R44HD050146 from the Eunice Kennedy Shriver National Institute of Child
   Health and Human Development.
CR Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Ansel H, 1999, PHARM DOSAGE FORMS D
   Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001
   Benator D, 2002, LANCET, V360, P528
   BYRON PR, 1987, J PHARM SCI, V76, P65, DOI 10.1002/jps.2600760118
   Chen J, 2005, J CONTROL RELEASE, V101, P357
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Frank M, 2011, ANTIMICROB AGENTS CH, V55, P5529, DOI 10.1128/AAC.00741-11
   Frank M, 2013, J CLIN PHARMACOL, V53, P294, DOI 10.1177/0091270012448397
   Gabrielsson J, 2006, PHARMACOKINETIC PHAR
   Gathe J, 2011, ANTIVIR THER, V16, P759, DOI 10.3851/IMP1803
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7
   Harrison TS, 2004, CNS DRUGS, V18, P113
   Hyon SH, 2000, YONSEI MED J, V41, P720, DOI 10.3349/ymj.2000.41.6.720                                                       
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3
   *JOINT UN PROGR HI, 2013, GLOB REP UNAIDS REP
   KRUSE W, 1991, EUR J CLIN PHARMACOL, V41, P589, DOI 10.1007/BF00314990                                                              
   Kutilek Victoria D., 2003, Current Drug Targets - Infectious Disorders, V3, P295, DOI 10.2174/1568005033481079
   McMahon MA, 2009, CURR OPIN INFECT DIS, V22, P574, DOI 10.1097/QCO.0b013e328332c54d
   Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744
   Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006
   Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4
   Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167
   Petrova NV, 2005, RUSS J APPL CHEM+, V78, P1158, DOI 10.1007/s11167-005-0470-1                                                       
   Rankin WW, 2005, PLOS MED, V2, P702, DOI 10.1371/journal.pmed.0020247
   Sartor O, 2003, UROLOGY, V61, P25, DOI 10.1016/S0090-4295(02)02396-8                                                   
   Schieber G, 1999, HEALTH AFFAIR, V18, P193, DOI 10.1377/hlthaff.18.3.193
   Sershen S, 2002, ADV DRUG DELIVER REV, V54, P1225, DOI 10.1016/S0169-409X(02)00090-X                                                   
   Sharma V, 2009, BRIT J PHARMACOL, V157, P907, DOI 10.1111/j.1476-5381.2009.00267.x
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777
   Shetty AK, 2003, JAIDS-J ACQ IMM DEF, V34, P482, DOI 10.1097/00126334-200312150-00006
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Usach I, 2011, INT J PHARMACEUT, V419, P186, DOI 10.1016/j.ijpharm.2011.07.047
   Van Leth F, 2006, AIDS RES HUM RETROV, V22, P232
   West GB, 2005, J EXP BIOL, V208, P1575, DOI 10.1242/jeb.01589
   World Health Organization (WHO), 2010, ANT DRUGS TREAT PREG
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Yeaw J, 2009, J MANAGE CARE PHARM, V15, P728, DOI 10.18553/jmcp.2009.15.9.728                                                     
   Zhou HH, 2003, J CLIN PHARMACOL, V43, P211, DOI 10.1177/0091270002250613
NR 45
TC 5
Z9 5
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2015
VL 59
IS 1
BP 59
EP 66
DI 10.1128/AAC.03906-14
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CA0LO
UT WOS:000348609500007
PM 25313219
OA gold
DA 2018-01-05
ER

PT J
AU Wang, ZW
   Wang, MX
   Wang, L
   Yao, X
   Li, Y
   Tan, J
   Qiao, WT
   Geng, YQ
   Liu, YX
   Wang, QM
AF Wang, Ziwen
   Wang, Mingxiao
   Wang, Lei
   Yao, Xue
   Li, Yue
   Tan, Juan
   Qiao, Wentao
   Geng, Yunqi
   Liu, Yuxiu
   Wang, Qingmin
TI First Discovery of Tylophora Alkaloids as HIV Inhibitors
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE AIDS; anti-HIV activity; HIV inhibitor; natural product;
   structure-activity relationship; tylophora alkaloids
ID PHENANTHROINDOLIZIDINE ALKALOIDS; ANTIVIRAL ACTIVITY; QUINOLIZIDINE
   ALKALOIDS; DESIGN; INDOLIZIDINE; ANALOGS; TYLOCREBRINE; CHEMISTRY;
   AGENTS
AB A series of tylophora alkaloids and their derivatives (1-38) were synthesized and systematically bioassayed for their anti-HIV activity for the first time. The results revealed that most of these alkaloids possess good HIV inhibitory effect. Especially, compounds 1, 4 and 25 displayed low nanomolar levels of anti-HIV activity (inhibitory effect at 50 nM: 1: 71%; 4: 60%; 25: 64%), which is about similar to that of the first HIV inhibitor AZT (inhibitory effect at 50 nM: 70%) and slightly lower than that of the first HIV integrase inhibitor MK-0518 (inhibitory effect at 50 nM: 82%). Present studies provide fundamental support for the development of tylophora alkaloids as novel HIV inhibitors.
C1 [Wang, Ziwen] Tianjin Normal Univ, Tianjin Key Lab Struct & Performance Funct Mol, Key Lab Inorgan Organ Hybrid Funct Mat Chem, Minist Educ,Coll Chem, Tianjin 300387, Peoples R China.
   [Wang, Lei; Liu, Yuxiu; Wang, Qingmin] Nankai Univ, State Key Lab Elementoorgan Chem, Res Inst Elementoorgan Chem, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China.
   [Wang, Mingxiao; Yao, Xue; Li, Yue; Tan, Juan; Qiao, Wentao; Geng, Yunqi] Nankai Univ, Ctr AIDS Res, Dept Microbiol, Tianjin 300071, Peoples R China.
RP Wang, QM (reprint author), Nankai Univ, State Key Lab Elementoorgan Chem, Res Inst Elementoorgan Chem, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China.
EM wangqm@nankai.edu.cn
FU National Natural Science Foundation of China [21132003, 21121002,
   21372131, 21402142]; Open-ended Fund of State Key Laboratory of
   Elemento-Organic Chemistry [201309]; Scientific Research Foundation of
   Tianjin Normal University [5RL125]
FX We gratefully acknowledge assistance from the National Natural Science
   Foundation of China (21132003, 21121002, 21372131, 21402142), the
   Open-ended Fund of State Key Laboratory of Elemento-Organic Chemistry
   (201309) and the Scientific Research Foundation of Tianjin Normal
   University (5RL125).
CR Chajkowski-Scarry S, 2014, FUTURE MED CHEM, V6, P697, DOI [10.4155/FMC.14.23, 10.4155/fmc.14.23]
   Chemler Sherry R, 2009, Curr Bioact Compd, V5, P2
   Choi JY, 2006, ARTHRITIS RHEUM, V54, P3277, DOI 10.1002/art.22119
   Damu AG, 2005, J NAT PROD, V68, P1071, DOI 10.1021/np050095o
   Fu Y, 2007, BIOORG MED CHEM LETT, V17, P97, DOI 10.1016/j.bmcl.2006.09.080
   GELLERT E, 1964, J MED CHEM, V7, P361, DOI 10.1021/jm00333a029
   GELLERT E, 1982, J NAT PROD, V45, P50, DOI 10.1021/np50019a005                                                             
   GUPTA RS, 1977, BIOCHEMISTRY-US, V16, P3209, DOI 10.1021/bi00633a026
   Li ZG, 2001, SYNTHESIS-STUTTGART, P2365
   Michael JP, 2005, NAT PROD REP, V22, P603, DOI 10.1039/b413748p
   Michael JP, 2001, NAT PROD REP, V18, P520, DOI 10.1039/b005384h
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ramsay RR, 2012, CURR TOP MED CHEM, V12, P2189
   Sechi M, 2009, BIOORGAN MED CHEM, V17, P2925, DOI 10.1016/j.bmc.2008.10.088
   [Anonymous], 2013, UNAIDSJC25021E
   Vianello R, 2012, EUR J ORG CHEM, P7057, DOI 10.1002/ejoc.201201122
   Wan ZW, 2012, EUR J MED CHEM, V53, P275, DOI 10.1016/j.ejmech.2012.04.010
   Wang KL, 2008, TETRAHEDRON, V64, P7504, DOI 10.1016/j.tet.2008.06.003
   Wang ZW, 2012, J AGR FOOD CHEM, V60, P10212, DOI 10.1021/jf303550a
   Wang ZW, 2012, EUR J MED CHEM, V54, P33, DOI 10.1016/j.ejmech.2012.04.020
   Wang ZW, 2012, J AGR FOOD CHEM, V60, P5825, DOI 10.1021/jf3013376
   Wang ZW, 2012, EUR J MED CHEM, V50, P361, DOI 10.1016/j.ejmech.2012.02.015
   Wang ZW, 2011, SYNTHESIS-STUTTGART, P979, DOI 10.1055/s-0030-1259487
   Wang ZW, 2010, EUR J ORG CHEM, P292, DOI 10.1002/ejoc.200900920
   Wang ZW, 2009, SCI CHINA SER B, V52, P1288, DOI 10.1007/s11426-009-0183-z
   Wei LY, 2008, STUD NAT PROD CHEM, V34, P3
   Yang CW, 2006, MOL PHARMACOL, V69, P749, DOI 10.1124/mol.105.017764
   Yang XM, 2011, J MED CHEM, V54, P5097, DOI 10.1021/jm200330s
   You X, 2006, ARTHRITIS RHEUM, V54, P877, DOI 10.1002/art.21640
NR 29
TC 2
Z9 2
U1 3
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
EI 1875-628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2015
VL 12
IS 4
BP 277
EP 283
DI 10.2174/1570180811666141009235124                                       
          
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CB2KT
UT WOS:000349456900004
DA 2018-01-05
ER

PT S
AU Shafiee, H
   Wang, SQ
   Inci, F
   Toy, M
   Henrich, TJ
   Kuritzkes, DR
   Demirci, U
AF Shafiee, Hadi
   Wang, ShuQi
   Inci, Fatih
   Toy, Mehlika
   Henrich, Timothy J.
   Kuritzkes, Daniel R.
   Demirci, Utkan
BE Caskey, CT
TI Emerging Technologies for Point-of-Care Management of HIV Infection
SO ANNUAL REVIEW OF MEDICINE, VOL 66
SE Annual Review of Medicine
LA English
DT Review; Book Chapter
DE CD4 cell count; viral load; diagnostics; AIDS; micro- and nanotechnology
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL
   THERAPY; VIRAL LOAD; LOW-COST; ON-CHIP; MICROFLUIDIC DEVICES;
   DRUG-RESISTANCE; POOR SETTINGS; GLOBAL HEALTH
AB The global HIV/AIDS pandemic has resulted in 39 million deaths to date, and there are currently more than 35 million people living with HIV worldwide. Prevention, screening, and treatment strategies have led to major progress in addressing this disease globally. Diagnostics is critical for HIV prevention, screening and disease staging, and monitoring antiretroviral therapy (ART). Currently available diagnostic assays, which include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and western blot (WB), are complex, expensive, and time consuming. These diagnostic technologies are ill suited for use in low- and middle-income countries, where the challenge of the HIV/AIDS pandemic is most severe. Therefore, innovative, inexpensive, disposable, and rapid diagnostic platform technologies are urgently needed. In this review, we discuss challenges associated with HIV management in resource-constrained settings and review the state-of-the-art HIV diagnostic technologies for CD4(+) T lymphocyte count, viral load measurement, and drug resistance testing.
C1 [Shafiee, Hadi; Demirci, Utkan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Biomed Engn,Dept Med, Boston, MA 02115 USA.
   [Wang, ShuQi; Inci, Fatih; Demirci, Utkan] Stanford Univ, Sch Med, Canary Ctr Early Canc Detect, Bioacoust MEMS Med BAMM Lab, Palo Alto, CA 94304 USA.
   [Toy, Mehlika] Harvard Univ, Sch Publ Hlth, Brigham & Womens Hosp, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Henrich, Timothy J.; Kuritzkes, Daniel R.; Demirci, Utkan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
RP Shafiee, H (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Biomed Engn,Dept Med, Boston, MA 02115 USA.
EM utkan@stanford.edu
OI Inci, Fatih/0000-0002-9918-5038
FU NIAID NIH HHS [R01AI093282, R01AI081534, R21 AI110277, R21AI087107,
   R21AI110277, F32AI102590]; NIBIB NIH HHS [U54EB15408]
CR Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Bergeron M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041166
   Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413
   Boyle DS, 2012, TRENDS BIOTECHNOL, V30, P45, DOI 10.1016/j.tibtech.2011.06.015
   Braitstein P, 2006, LANCET, V367, P817
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Breslauer DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006320
   Bulterys M, 2004, JAMA-J AM MED ASSOC, V292, P219, DOI 10.1001/jama.292.2.219                                                          
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Carrilho E, 2009, ANAL CHEM, V81, P5990, DOI 10.1021/ac900847g
   Cheng X, 2007, LAB CHIP, V7, P746, DOI 10.1039/b705082h
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Coskun AF, 2013, LAB CHIP, V13, P636, DOI 10.1039/c2lc41152k
   Creek TL, 2007, AM J OBSTET GYNECOL, V197, pS64, DOI 10.1016/j.ajog.2007.03.002
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Drosten C, 2006, CLIN CHEM, V52, P1258, DOI 10.1373/clinchem.2006.066498
   Dungchai W, 2009, ANAL CHEM, V81, P5821, DOI 10.1021/ac9007573
   Eshleman SH, 2004, J CLIN MICROBIOL, V42, P2711, DOI 10.1128/JCM.42.6.2711-2717.2004
   Franco-Paredes Carlos, 2006, Curr HIV/AIDS Rep, V3, P169, DOI 10.1007/s11904-006-0012-3
   Galiwango RM, 2013, J VIROL METHODS, V192, P25, DOI 10.1016/j.jviromet.2013.04.003
   Gallegos D, 2013, LAB CHIP, V13, P2124, DOI 10.1039/c3lc40991k
   Ge L, 2012, LAB CHIP, V12, P3150, DOI 10.1039/c2lc40325k
   Glencross DK, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-3
   Gray RH, 2007, BRIT MED J, V335, P188, DOI 10.1136/bmj.39210.582801.BE
   Gurkan UA, 2011, BIOTECHNOL J, V6, P138, DOI 10.1002/biot.201000427
   Hoare A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010981
   Holmes D, 2010, ANAL CHEM, V82, P1455, DOI 10.1021/ac902568p
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   Jangam SR, 2013, BIOSENS BIOELECTRON, V42, P69, DOI 10.1016/j.bios.2012.10.024
   Johnston MI, 2008, NEW ENGL J MED, V359, P888, DOI 10.1056/NEJMp0806162
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kuritzkes DR, 2003, J CLIN MICROBIOL, V41, P1594, DOI 10.1128/JCM.41.4.1594-1599.2003
   Labbett W, 2009, J CLIN MICROBIOL, V47, P3266, DOI 10.1128/JCM.00715-09
   Laperche S, 2012, J INFECT DIS, V206, P1946, DOI 10.1093/infdis/jis616
   Larguinho M, 2012, J PROTEOMICS, V75, P2811, DOI 10.1016/j.jprot.2011.11.007
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Lee HH, 2010, J INFECT DIS, V201, pS65, DOI 10.1086/650385
   Linder V, 2005, ANAL CHEM, V77, P64, DOI 10.1021/ac049071x
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Louie RF, 2014, CLIN CHEM LAB MED, V52, P325, DOI 10.1515/cclm-2013-0440
   Martinez AW, 2007, ANGEW CHEM INT EDIT, V46, P1318, DOI 10.1002/anie.200603817
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Mayer KH, 2001, CLIN INFECT DIS, V32, P774
   Medecins Sans Frontieres Access Campaign, 2013, PUTT HIV TREATM TEST
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Mine M, 2009, J VIROL METHODS, V159, P93, DOI 10.1016/j.jviromet.2009.03.008
   Mok J, 2014, P NATL ACAD SCI USA, V111, P2110, DOI 10.1073/pnas.1323998111
   Moon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021409
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Mudanyali O, 2012, LAB CHIP, V12, P2678, DOI [10.1039/c2lc40235a, 10.1039/c21c40235a]
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8
   Prado JG, 2004, J CLIN MICROBIOL, V42, P1620, DOI 10.1128/JCM.42.4.1620-1625.2004
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Rohrman BA, 2012, LAB CHIP, V12, P3082, DOI 10.1039/c2lc40423k
   Rosenberg NE, 2012, J INFECT DIS, V205, P528, DOI 10.1093/infdis/jir789
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Salmanzadeh A, 2012, LAB CHIP, V12, P182, DOI 10.1039/c1lc20701f
   Shafiee H, 2012, AM I CHEM ENG ANN M
   Shafiee H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04116
   Shafiee H, 2013, SMALL, V9, P2553, DOI 10.1002/smll.201202195
   Shafiee H, 2010, JALA-J LAB AUTOM, V15, P224, DOI 10.1016/j.jala.2010.02.003
   Shafiee H, 2010, LAB CHIP, V10, P438, DOI 10.1039/b920590j
   Shamah SM, 2011, ANALYST, V136, P1090, DOI 10.1039/c0an00899k
   Smith ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017150
   Stevens G, 2005, J CLIN MICROBIOL, V43, P857, DOI 10.1128/JCM.43.2.857-861.2005
   Stevens WS, 2010, J INFECT DIS, V201, pS16, DOI 10.1086/650392
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Tang W, 2010, J INFECT DIS, V201, pS46, DOI 10.1086/650388
   Tanriverdi S, 2010, J INFECT DIS, V201, pS52, DOI 10.1086/650387
   Tokel O, 2014, CHEM REV, V114, P5728, DOI 10.1021/cr4000623
   UNAIDS, 2011, GLOB HIV AIDS RESP E
   UNITAID, 2014, HIV AIDS DIAGN TECHN
   Usdin M, 2010, J INFECT DIS, V201, pS73, DOI 10.1086/650384
   van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x
   Vitoria M, 2013, CURR OPIN HIV AIDS, V8, P12, DOI 10.1097/COH.0b013e32835b8123
   Wang SW, 2012, LAB CHIP, V12, P4489, DOI 10.1039/c2lc40707h
   Wang SQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03796
   Wang SQ, 2013, BIOTECHNOL ADV, V31, P438, DOI 10.1016/j.biotechadv.2013.01.006
   Wang SQ, 2012, INT J NANOMED, V7, P2591, DOI 10.2147/IJN.S29629
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang SQ, 2011, LAB CHIP, V11, P3411, DOI 10.1039/c1lc20479c
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wang ZK, 2010, ANAL CHEM, V82, P36, DOI 10.1021/ac902144w
   Watkins NN, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006870
   Watkins NN, 2011, LAB CHIP, V11, P1437, DOI 10.1039/c0lc00556h
   World Health Organization (WHO), 2013, CONS GUID US ANT DRU
   W. H. Organization, 2014, WORLD HLTH STAT
   WHO, 2013, GLOB UPD HIV TREATM
   World Health Organization, 2014, GLOB UPDT HLTH SECT
   Xu F, 2011, BIOFABRICATION, V3, DOI 10.1088/1758-5082/3/3/034101
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yetisen AK, 2013, LAB CHIP, V13, P2210, DOI 10.1039/c3lc50169h
   Zhang CS, 2007, NUCLEIC ACIDS RES, V35, P4223, DOI 10.1093/nar/gkm389
NR 99
TC 41
Z9 43
U1 4
U2 90
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0066-4219
BN 978-0-8243-0566-6
J9 ANNU REV MED
JI Annu. Rev. Med.
PY 2015
VL 66
BP 387
EP 405
DI 10.1146/annurev-med-092112-143017
PG 19
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BB9PT
UT WOS:000348560300026
PM 25423597
DA 2018-01-05
ER

PT J
AU Piantavigna, S
   Abdelhamid, ME
   Zhao, C
   Qu, XH
   McCubbin, GA
   Graham, B
   Spiccia, L
   O'Mullane, AP
   Martin, LL
AF Piantavigna, Stefania
   Abdelhamid, Muhammad E.
   Zhao, Chuan
   Qu, Xiaohu
   McCubbin, George A.
   Graham, Bim
   Spiccia, Leone
   O'Mullane, Anthony P.
   Martin, Lisandra L.
TI Mechanistic Details of the Membrane Perforation and Passive
   Translocation of TAT Peptides
SO CHEMPLUSCHEM
LA English
DT Article
DE biomimetic membranes; biophysical analysis; membranes; peptides; TAT
   peptide translocation
ID CELL-PENETRATING PEPTIDES; SCANNING ELECTROCHEMICAL MICROSCOPY;
   QUARTZ-CRYSTAL MICROBALANCE; SELF-ASSEMBLED MONOLAYERS; HUMAN
   IMMUNODEFICIENCY VIRUS; PLASMA-MEMBRANE; LIPID-MEMBRANES; PROTEIN
   TRANSDUCTION; MODEL MEMBRANES; ADSORPTION
AB The trans-activator of transcription (TAT) peptide is regarded as the "gold standard" for cell-penetrating peptides, capable of traversing a mammalian membrane passively into the cytosolic space. This characteristic has been exploited through conjugation of TAT for applications such as drug delivery. However, the process by which TAT achieves membrane penetration remains ambiguous and unresolved. Mechanistic details of TAT peptide action are revealed herein by using three complementary methods: quartz crystal microbalance with dissipation (QCM-D), scanning electrochemical microscopy (SECM) and atomic force microscopy (AFM). When combined, these three scales of measurement define that the membrane uptake of the TAT peptide is by trans-membrane insertion using a "worm-hole" pore that leads to ion permeability across the membrane layer. AFM data provided nanometre-scale visualisation of TAT punctuation using a mammalian-mimetic membrane bilayer. The TAT peptide does not show the same specificity towards a bacterial mimetic membrane and QCM-D and SECM showed that the TAT peptide demonstrates a disruptive action towards these membranes. This investigation supports the energy-independent uptake of the cationic TAT peptide and provides empirical data that clarify the mechanism by which the TAT peptide achieves its membrane activity. The novel use of these three biophysical techniques provides valuable insight into the mechanism for TAT peptide translocation, which is essential for improvements in the cellular delivery of TAT-conjugated cargoes including therapeutic agents required to target specific intracellular locations.
C1 [Piantavigna, Stefania; Abdelhamid, Muhammad E.; Zhao, Chuan; Qu, Xiaohu; McCubbin, George A.; Spiccia, Leone; Martin, Lisandra L.] Monash Univ, Sch Chem, Clayton, Vic 3800, Australia.
   [O'Mullane, Anthony P.] Queensland Univ Technol, Sch Chem Phys & Mech Engn, Brisbane, Qld 4001, Australia.
   [Abdelhamid, Muhammad E.] RMIT Univ, Sch Appl Sci, Melbourne, Vic 3001, Australia.
   [Zhao, Chuan] Univ New S Wales, Sch Chem, Sydney, NSW 2052, Australia.
   [Graham, Bim] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia.
RP O'Mullane, AP (reprint author), Queensland Univ Technol, Sch Chem Phys & Mech Engn, Brisbane, Qld 4001, Australia.
EM anthony.omullane@qut.edu.au; Lisa.Martin@monash.edu
RI Martin, Lisandra/E-4482-2010; Abdelhamid, Muhammad/A-5137-2015; Spiccia,
   Leone/I-8085-2013; O'Mullane, Anthony/A-1289-2009
OI Abdelhamid, Muhammad/0000-0002-1666-6398; Spiccia,
   Leone/0000-0003-2258-8506; O'Mullane, Anthony/0000-0001-9294-5180;
   Graham, Bim/0000-0002-1160-7751
FU Australian Research Council; Discovery Outstanding Researcher Award;
   Monash Graduate Scholarship (MGS)
FX This study was financially supported by the Australian Research Council
   Discovery Project (B.G., L.S. and L.L.M.) and a Discovery Outstanding
   Researcher Award (L.S.). S.P. was a recipient of a Monash Graduate
   Scholarship (MGS).
CR Bard A. J., 2001, SCANNING ELECTROCHEM
   Boldt FM, 2005, SURF SCI, V597, P51, DOI 10.1016/j.susc.2004.04.062
   Boohaker RJ, 2012, CURR MED CHEM, V19, P3794
   Chen XC, 2013, BBA-BIOMEMBRANES, V1828, P1982, DOI 10.1016/j.bbamem.2013.04.022
   Cho Nam-Joon, 2007, Anal Chem, V79, P7027, DOI 10.1021/ac0709504
   Choi D, 2012, SOFT MATTER, V8, P8294, DOI 10.1039/c2sm25913c
   Ciobanasu C, 2010, BIOPHYS J, V99, P153, DOI 10.1016/j.bpj.2010.03.065
   Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s
   CLAVILIER J, 1982, J ELECTROANAL CHEM, V135, P159, DOI 10.1016/0022-0728(82)90013-4                                                    
   Czihal P, 2012, ACS CHEM BIOL, V7, P1281, DOI 10.1021/cb300063v
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Foged C, 2008, EXPERT OPIN DRUG DEL, V5, P105, DOI 10.1517/17425247.5.1.105
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Green I, 2003, TRENDS PHARMACOL SCI, V24, P213, DOI 10.1016/S0165-6147(03)00076-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Hook F, 1998, LANGMUIR, V14, P729, DOI 10.1021/la970815u
   Hook F, 1998, P NATL ACAD SCI USA, V95, P12271, DOI 10.1073/pnas.95.21.12271                                                        
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Keller CA, 1998, BIOPHYS J, V75, P1397, DOI 10.1016/S0006-3495(98)74057-3                                                   
   Kiani A, 2008, LANGMUIR, V24, P2841, DOI 10.1021/la702811t
   Knappe D, 2010, J MED CHEM, V53, P5240, DOI 10.1021/jm100378b
   Koley D, 2010, P NATL ACAD SCI USA, V107, P16783, DOI 10.1073/pnas.1011614107
   Lattig-Tunnemann G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1459
   McCubbin GA, 2011, EUR BIOPHYS J BIOPHY, V40, P437, DOI 10.1007/s00249-010-0652-5
   Mechler A, 2007, BIOPHYS J, V93, P3907, DOI 10.1529/biophysj.107.116525
   Mechler A, 2009, BIOMATERIALS, V30, P682, DOI 10.1016/j.biomaterials.2008.10.016
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0                                                                
   Piantavigna S, 2011, BBA-BIOMEMBRANES, V1808, P1811, DOI 10.1016/j.bbamem.2011.03.002
   Piantavigna S, 2009, INT J PEPT RES THER, V15, P139, DOI 10.1007/s10989-009-9175-2
   Qu XH, 2009, ELECTROANAL, V21, P681, DOI 10.1002/elan.200804462
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   RODAHL M, 1995, REV SCI INSTRUM, V66, P3924, DOI 10.1063/1.1145396                                                               
   Rodahl M, 1996, SENSOR ACTUAT A-PHYS, V54, P448, DOI 10.1016/S0924-4247(97)80002-7
   Saalik P, 2011, J CONTROL RELEASE, V153, P117, DOI 10.1016/j.jconrel.2011.03.011
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937                                                              
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260
   Shaw JE, 2008, J STRUCT BIOL, V162, P121, DOI 10.1016/j.jsb.2007.11.003
   Sun P, 2007, PHYS CHEM CHEM PHYS, V9, P802, DOI 10.1039/b612259k
   Tanaka G, 2012, CHEM BIOL, V19, P1437, DOI 10.1016/j.chembiol.2012.09.011
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Tsionsky M, 1999, ANAL CHEM, V71, P4300, DOI 10.1021/ac9903858                                                               
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
NR 52
TC 3
Z9 3
U1 1
U2 26
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 2192-6506
J9 CHEMPLUSCHEM
JI ChemPlusChem
PD JAN
PY 2015
VL 80
IS 1
BP 83
EP 90
DI 10.1002/cplu.201402209
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA CA2EO
UT WOS:000348721900012
DA 2018-01-05
ER

PT J
AU Rizzuti, M
   Nizzardo, M
   Zanetta, C
   Ramirez, A
   Corti, S
AF Rizzuti, Mafalda
   Nizzardo, Monica
   Zanetta, Chiara
   Ramirez, Agnese
   Corti, Stefania
TI Therapeutic applications of the cell-penetrating HIV-1 Tat peptide
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN TRANSDUCTION DOMAIN;
   BLOOD-BRAIN-BARRIER; MEDIATED INTRACELLULAR DELIVERY; IN-VIVO DELIVERY;
   POLY-L-ARGININE; DRUG-DELIVERY; PHARMACEUTICAL NANOCARRIERS; MAGNETIC
   NANOPARTICLES; MEMBRANE TRANSLOCATION
AB Over the past decades, many new therapeutic approaches have been developed for several conditions, including neurodegenerative diseases. However, efficient biodistribution and delivery at biological target sites are hampered by the presence of cell and tissue barriers, and a clinical therapy is prevented by the requirement of invasive administration routes. Candidate drug conjugation to cell-penetrating peptides, which are able to cross cellular membranes and reach biological targets even when administered systemically, represents a promising tool to overcome this issue. Here, we review the biology, classification and mechanisms of internalization of cell-penetrating peptides. We focus our attention on the cell-penetrating peptide: HIV-derived Tat peptide, and discuss its efficient but controversial use in basic, preclinical and clinical research from its discovery to the present day.
C1 [Rizzuti, Mafalda; Nizzardo, Monica; Zanetta, Chiara; Ramirez, Agnese; Corti, Stefania] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Neurol Unit, Dino Ferrari Ctr,Neurosci Sect,Dept Pathophysiol, I-20122 Milan, Italy.
RP Nizzardo, M (reprint author), Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Neurol Unit, Dino Ferrari Ctr,Neurosci Sect,Dept Pathophysiol, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM monica.nizzardo1@gmail.com
RI Nizzardo, Monica/J-1817-2015; Corti, Stefania/K-6034-2016
OI Nizzardo, Monica/0000-0001-5447-0882; Corti,
   Stefania/0000-0001-5425-969X
FU Associazione Amid del Centro Dino Ferrari
FX We wish to thank the Associazione Amid del Centro Dino Ferrari for its
   support.
CR Amantana A, 2007, BIOCONJUGATE CHEM, V18, P1325, DOI 10.1021/bc070060v
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Betts C, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.30
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Bondi ML, 2012, METHOD ENZYMOL, V508, P229, DOI 10.1016/B978-0-12-391860-4.00012-4
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Cooper I, 2012, J BIOL CHEM, V287, P44676, DOI 10.1074/jbc.M112.395384
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706                                                      
   Eugenin EA, 2011, J NEUROSCI, V31, P9456, DOI 10.1523/JNEUROSCI.1460-11.2011
   Ezzat K, 2012, FASEB J, V26, P1172, DOI 10.1096/fj.11-191536
   Falnes PO, 2001, BIOCHEMISTRY-US, V40, P4349, DOI 10.1021/bi002443l
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0                                                                
   Foged C, 2008, EXPERT OPIN DRUG DEL, V5, P105, DOI 10.1517/17425247.5.1.105
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Gupta B, 2007, ONCOL RES, V16, P351
   Han L, 2010, HUM GENE THER, V21, P417, DOI 10.1089/hum.2009.087
   Hill MD, 2012, LANCET NEUROL, V11, P942, DOI 10.1016/S1474-4422(12)70225-9
   Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kanazawa T, 2013, BIOMATERIALS, V34, P9220, DOI 10.1016/j.biomaterials.2013.08.036
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Koppelhus U, 2002, ANTISENSE NUCLEIC A, V12, P51, DOI 10.1089/108729002760070795                                                      
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Lalatsa A, 2014, MOL PHARMACEUT, V11, P1081, DOI 10.1021/mp400680d
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Madocsai C, 2005, MOL THER, V12, P1013, DOI 10.1016/j.ymthe.2005.08.022
   Martin Irene, 2010, Pharmaceuticals (Basel), V3, P1456
   Mediouni Sonia, 2012, Infectious Disorders - Drug Targets, V12, P81
   Mie M, 2003, BIOCHEM BIOPH RES CO, V310, P730, DOI 10.1016/j.bbrc.2003.09.071
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Moulton HM, 2003, ANTISENSE NUCLEIC A, V13, P31, DOI 10.1089/108729003764097322
   Moulton HM, 2013, CURR PHARM DESIGN, V19, P2963
   Moulton HM, 2010, BBA-BIOMEMBRANES, V1798, P2296, DOI 10.1016/j.bbamem.2010.02.012
   Muntoni F, 2011, NAT REV DRUG DISCOV, V10, P621, DOI 10.1038/nrd3459
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nakase I, 2013, MOL BIOSYST, V9, P855, DOI 10.1039/c2mb25467k
   Nestor JJ, 2009, CURR MED CHEM, V16, P4399, DOI 10.2174/092986709789712907                                                      
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Ott Melanie, 2004, Novartis Found Symp, V259, P182
   Paolino D, 2011, DRUG DISCOV TODAY, V16, P311, DOI 10.1016/j.drudis.2011.02.006
   Passini MA, 2011, TRENDS MOL MED, V17, P259, DOI 10.1016/j.molmed.2011.01.002
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Qin Y, 2012, J DRUG TARGET, V20, P235, DOI 10.3109/1061186X.2011.639022
   Qin Y, 2011, INT J PHARMACEUT, V420, P304, DOI 10.1016/j.ijpharm.2011.09.008
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   SANTANA A, 1993, AGENTS ACTIONS, V39, P104, DOI 10.1007/BF01998961
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Shahana S, 2002, MEDIAT INFLAMM, V11, P141, DOI 10.1080/09622935020138172
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187
   Tasciotti E, 2003, CANCER GENE THER, V10, P64, DOI 10.1038/sj.cgt.7700526
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2003, CURR PROTEIN PEPT SC, V4, P133, DOI 10.2174/1389203033487298
   Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Williams JH, 2009, J NEUROSCI, V29, P7633, DOI 10.1523/JNEUROSCI.0950-09.2009
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Xu RF, 2012, BRAIN RES, V1436, P13, DOI 10.1016/j.brainres.2011.11.052
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 92
TC 41
Z9 41
U1 18
U2 82
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD JAN
PY 2015
VL 20
IS 1
BP 76
EP 85
DI 10.1016/j.drudis.2014.09.017
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CA8TL
UT WOS:000349193700009
PM 25277319
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Mistry, NF
   Tolani, MP
   Dholakia, YN
AF Mistry, N. F.
   Tolani, M. P.
   Dholakia, Y. N.
TI NEW DRUGS FOR TUBERCULOSIS
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Antibacterial drugs; Antimycobacterial agents; Treatment of
   tuberculosis; Antibacterial activity enhancers
ID MULTIDRUG-RESISTANT TUBERCULOSIS; EARLY BACTERICIDAL ACTIVITY; POSITIVE
   PULMONARY TUBERCULOSIS; MESOPOROUS SILICA NANOPARTICLES; MYCOBACTERIAL
   ATP SYNTHASE; AFRICAN MEDICINAL-PLANTS; VITAMIN-A METABOLISM; IN-VITRO;
   MURINE TUBERCULOSIS; ANTITUBERCULOSIS ACTIVITY
AB The extent and presentation of advanced forms or drug-resistant tuberculosis (TB), as well as unduly extended and toxic defaulter-generating regimens, present great challenges to TB treatment. The pipeline for approval of new anti-TB drugs has yielded only one drug with a novel mode of action since 1974. Besides enhanced efficacy, compatibility with other conventionally used drugs against TB and its common comorbidities such as HIV and type 2 diabetes is an important prerequisite. This review describes new and/or repurposed drugs currently being tested and outlines principles governing their integration into efficacious and safe treatment regimens.
C1 [Mistry, N. F.; Tolani, M. P.; Dholakia, Y. N.] Fdn Med Res, Bombay 400018, Maharashtra, India.
RP Mistry, NF (reprint author), Fdn Med Res, 84A RG Thadani Marg, Bombay 400018, Maharashtra, India.
EM fmr@fmrindia.org
FU Foundation for Medical Research, Mumbai, India
FX The authors of this article are financially supported by The Foundation
   for Medical Research, Mumbai, India.
CR Abbate E, 2012, J ANTIMICROB CHEMOTH, V67, P473, DOI 10.1093/jac/dkr500
   ABUL HT, 1995, MOL CELL BIOCHEM, V146, P139, DOI 10.1007/BF00944606
   ALANGADEN GJ, 1995, ANTIMICROB AGENTS CH, V39, P1700, DOI 10.1128/AAC.39.8.1700                                                           
   Alcala L, 2003, ANTIMICROB AGENTS CH, V47, P416, DOI 10.1128/AAC.47.1.416-417-2003
   Alffenaar JWC, 2011, ANTIMICROB AGENTS CH, V55, P1287, DOI 10.1128/AAC.01297-10
   Alvirez-Freites EJ, 2002, ANTIMICROB AGENTS CH, V46, P1022, DOI 10.1128/AAC.46.4.1022-1025.2002
   Amaral L, 1996, J ANTIMICROB CHEMOTH, V38, P1049, DOI 10.1093/jac/38.6.1049
   Amaral L., 2013, MYCOBACT DIS, V3, P2
   Amaral L, 2012, INT J TUBERC LUNG D, V16, P1706, DOI 10.5588/ijtld.12.0616
   Amaral L, 2010, IN VIVO, V24, P409
   Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753
   Anger HA, 2010, J ANTIMICROB CHEMOTH, V65, P775, DOI 10.1093/jac/dkq017
   Babalik A, 2013, ANTIMICROB AGENTS CH, V57, P5740, DOI 10.1128/AAC.01345-13
   Baghaei P, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-58
   Balasubramanian V, 2014, ANTIMICROB AGENTS CH, V58, P495, DOI 10.1128/AAC.01903-13
   Balganesh M, 2012, ANTIMICROB AGENTS CH, V56, P2643, DOI 10.1128/AAC.06003-11
   Bento J., 2010, BMJ CASE REP
   Birdi T., 2012, European Journal of Medicinal Plants, V2, P308
   Bonnet M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023081
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6
   Brigden G, 2014, B WORLD HEALTH ORGAN, V92, P68, DOI 10.2471/BLT.13.122028
   Brites D, 2012, INFECT GENET EVOL, V12, P678, DOI 10.1016/j.meegid.2011.08.010
   BROWN ED, 1976, J NUTR, V106, P563
   Bryskier A, 2005, ANTIMICROBIAL AGENTS: ANTIBACTERIALS AND ANTIFUNGALS, P906
   Burhan E, 2013, ANTIMICROB AGENTS CH, V57, P3614, DOI 10.1128/AAC.02468-12
   Caminero JA, 2010, LANCET INFECT DIS, V10, P621, DOI 10.1016/S1473-3099(10)70139-0
   Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0
   Campbell GR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002689
   Carpenter CD, 2012, J ETHNOPHARMACOL, V143, P695, DOI 10.1016/j.jep.2012.07.035
   Centers for Disease Control and Prevention, 2013, MMWR RECOMM REP, V62, P1
   Chatterjee A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054717
   Chen P, 2006, J ANTIMICROB CHEMOTH, V58, P332, DOI 10.1093/jac/dkl227
   Chideya S, 2009, CLIN INFECT DIS, V48, P1685, DOI 10.1086/599040
   Clemens DL, 2012, ANTIMICROB AGENTS CH, V56, P2535, DOI 10.1128/AAC.06049-11
   Cohen K, 2010, CURR OPIN HIV AIDS, V5, P61, DOI 10.1097/COH.0b013e3283339309
   Colijn C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018327
   Cox HS, 2008, NEW ENGL J MED, V359, P2398, DOI 10.1056/NEJMc0805644
   CROWLE AJ, 1989, INFECT IMMUN, V57, P840
   Cynamon M, 2007, J ANTIMICROB CHEMOTH, V60, P429, DOI 10.1093/jac/dkm200
   Danilchanka O, 2008, ANTIMICROB AGENTS CH, V52, P2503, DOI 10.1128/AAC.00298-08
   de Jager P, 2002, INT J TUBERC LUNG D, V6, P622
   De Vriese AS, 2006, CLIN INFECT DIS, V42, P1111, DOI 10.1086/501356                                                                  
   Deoghare S, 2013, INDIAN J PHARMACOL, V45, P536, DOI 10.4103/0253-7613.117765
   Dharmadhikari AS, 2013, ANTIMICROB AGENTS CH, V57, P2613, DOI 10.1128/AAC.02346-12
   Diacon AH, 2012, ANTIMICROB AGENTS CH, V56, P3271, DOI 10.1128/AAC.06126-11
   Diacon AH, 2011, INT J TUBERC LUNG D, V15, P949, DOI 10.5588/ijtld.10.0616
   Diacon AH, 2012, LANCET, V380, P986, DOI 10.1016/S0140-6736(12)61080-0
   Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427
   Dinesh N, 2013, ANTIMICROB AGENTS CH, V57, P1941, DOI 10.1128/AAC.01957-12
   Dogra M, 2011, BRIT J PHARMACOL, V162, P226, DOI 10.1111/j.1476-5381.2010.01040.x
   Dooley KE, 2012, JAIDS-J ACQ IMM DEF, V59, P455, DOI 10.1097/QAI.0b013e3182410503
   Dooley KE, 2009, LANCET INFECT DIS, V9, P737, DOI 10.1016/S1473-3099(09)70282-8
   Dorman SE, 2012, J INFECT DIS, V206, P1030, DOI 10.1093/infdis/jis461
   Duggal P, 2007, BMC EAR NOSE THROAT, V7, DOI 10.1186/1472-6815-7-5
   Engel N, 2014, SCI CULT-UK, V23, P201, DOI 10.1080/09505431.2013.837875
   Fabri M., 2011, SCI TRANSL MED, V3, DOI DOI 10.1126/SCITRANSLMED.3003045
   Fortun J, 2005, J ANTIMICROB CHEMOTH, V56, P180, DOI 10.1093/jac/dki148
   Gagneux S, 2006, SCIENCE, V312, P1944, DOI 10.1126/science.1124410
   Garcia-Prats AJ, 2014, PEDIATR INFECT DIS J, V33, P883, DOI 10.1097/INF.0000000000000336
   Gillespie SH, 1998, INT J TUBERC LUNG D, V2, P265
   Gillespie SH, 2005, J ANTIMICROB CHEMOTH, V56, P1169, DOI 10.1093/jac/dki376
   Gler MT, 2012, NEW ENGL J MED, V366, P2151, DOI 10.1056/NEJMoa1112433
   Global Alliance for TB Drug Development, 2013, ANN REPORT
   Goldberg G., 1946, CLIN TUBERCULOSIS
   Green E, 2010, J ETHNOPHARMACOL, V130, P151, DOI 10.1016/j.jep.2010.04.033
   Gupta R, 2010, INDIAN J MED RES, V131, P809
   Gupta S, 2014, ANTIMICROB AGENTS CH, V58, P574, DOI 10.1128/AAC.01462-13
   Gupta S, 2013, AM J RESP CRIT CARE, V188, P600, DOI 10.1164/rccm.201304-0650OC
   Gurumurthy P, 2004, ANTIMICROB AGENTS CH, V48, P4473, DOI 10.1128/AAC.48.11.4473-4475.2004
   Haagsma AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023575
   Haagsma AC, 2009, ANTIMICROB AGENTS CH, V53, P1290, DOI 10.1128/AAC.01393-08
   He QJ, 2011, SMALL, V7, P271, DOI 10.1002/smll.201001459
   HEIFETS LB, 1990, AM REV RESPIR DIS, V141, P626, DOI 10.1164/ajrccm/141.3.626                                                        
   Ho-Pham LT, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-306
   Hong JY, 2014, INT J TUBERC LUNG D, V18, P73, DOI 10.5588/ijtld.13.0536
   Huitric E, 2007, ANTIMICROB AGENTS CH, V51, P4202, DOI 10.1128/AAC.00181-07
   Ibrahim M, 2007, ANTIMICROB AGENTS CH, V51, P1011, DOI 10.1128/AAC.00898-06
   Ibrahim M, 2009, AM J RESP CRIT CARE, V180, P553, DOI [10.1164/rccm.200807-1152OC, 10.1164/rccrn.200807-1152OC]
   Jawahar MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067030
   Jimenez-Arellanes A, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-258
   Karyadi E, 2002, AM J CLIN NUTR, V75, P720
   Klopper M, 2013, EMERG INFECT DIS, V19, P449, DOI [10.3201/eid1903.120246, 10.3201/EID1903.120246, 10.3201//EID1903.120246]
   Koh WJ, 2012, J ANTIMICROB CHEMOTH, V67, P1503, DOI 10.1093/jac/dks078
   Koh WJ, 2009, J ANTIMICROB CHEMOTH, V64, P388, DOI 10.1093/jac/dkp171
   Koo HK, 2012, RESPIROLOGY, V17, P808, DOI 10.1111/j.1440-1843.2012.02172.x
   Koul A, 2007, NAT CHEM BIOL, V3, P323, DOI 10.1038/nchembio884
   Koul A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4369
   Lakshmanan D, 2011, FITOTERAPIA, V82, P757, DOI 10.1016/j.fitote.2011.03.006
   Lechartier B, 2012, ANTIMICROB AGENTS CH, V56, P5790, DOI 10.1128/AAC.01476-12
   Lee JE, 2010, J AM CHEM SOC, V132, P552, DOI 10.1021/ja905793q
   Lee M, 2012, NEW ENGL J MED, V367, P1508, DOI 10.1056/NEJMoa1201964
   Lenaerts AJ, 2005, ANTIMICROB AGENTS CH, V49, P2294, DOI 10.1285/AAC.49.6.294-2301.2005
   Lounis N, 2006, ANTIMICROB AGENTS CH, V50, P3543, DOI 10.1128/AAC.00766-06
   Machado D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034538
   Makarov V, 2009, SCIENCE, V324, P801, DOI 10.1126/science.1171583
   Manjunatha UH, 2006, P NATL ACAD SCI USA, V103, P431, DOI 10.1073/pnas.0508392103                                                         
   Manjunatha Ujjini, 2009, Commun Integr Biol, V2, P215
   Mariam DH, 2004, ANTIMICROB AGENTS CH, V48, P1289, DOI 10.1128/AAC.48.4.1289-1294.2004
   Martineau AR, 2011, LANCET, V377, P242, DOI 10.1016/S0140-6736(10)61889-2
   Martins A, 2009, INT J ANTIMICROB AG, V34, P602, DOI 10.1016/j.ijantimicag.2009.06.029
   Martins D, 2013, BIOMED RES INT, DOI 10.1155/2013/605831
   Martins M, 2007, IN VIVO, V21, P771
   Matsumoto M, 2006, PLOS MED, V3, P2131, DOI 10.1371/journal.pmed.0030466
   Mboussa J, 2003, Rev Pneumol Clin, V59, P39
   Meacci F, 2005, J CLIN MICROBIOL, V43, P3114, DOI 10.1128/JCM.43.7.3114-3120.2005
   Mehta JB, 2001, CHEST, V120, P1520, DOI 10.1378/chest.120.5.1520
   Mehta S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003703
   Merle CSC, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-61
   Morsy A M, 2003, East Mediterr Health J, V9, P689
   Ngo SC, 2007, ANTIMICROB AGENTS CH, V51, P2430, DOI 10.1128/AAC.01458-06
   Nielsen TRH, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-74
   Nikonenko BV, 2007, ANTIMICROB AGENTS CH, V51, P1563, DOI 10.1128/AAC.01326-06
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885SOC
   Nuermberger E, 2008, ANTIMICROB AGENTS CH, V52, P1522, DOI 10.1128/AAC.00074-08
   Nuermberger E, 2006, ANTIMICROB AGENTS CH, V50, P2621, DOI 10.1128/AAC.00451-06
   O'Neill T, 2013, J ETHNOPHARMACOL, V147, P232, DOI 10.1016/j.jep.2013.03.009
   Ordway D, 2003, ANTIMICROB AGENTS CH, V47, P917, DOI 10.1128/AAC.47.3.917-922.2003
   Pandey Rajesh, 2006, Indian Journal of Experimental Biology, V44, P459
   Pasca MR, 2010, ANTIMICROB AGENTS CH, V54, P1616, DOI 10.1128/AAC.01676-09
   Pasca MR, 2004, ANTIMICROB AGENTS CH, V48, P3175, DOI 10.1128/AAC.48.8.3175-3138.2004
   Piccaro G, 2013, ANTIMICROB AGENTS CH, V57, P1428, DOI 10.1128/AAC.02154-12
   Ramos DF, 2008, REV BRAS CIENC FARM, V44, P669, DOI 10.1590/S1516-93322008000400013
   Range N, 2006, BRIT J NUTR, V95, P762, DOI 10.1079/BJN20051684
   Roderick P, 2014, LANCET, V383, P203, DOI 10.1016/S0140-6736(14)60059-3                                                   
   Rose PC, 2012, INT J TUBERC LUNG D, V16, P1588, DOI 10.5588/ijtld.12.0322
   Rosenthal IM, 2007, PLOS MED, V4, P1931, DOI 10.1371/journal.pmed.0040344
   Rosenthal IM, 2006, AM J RESP CRIT CARE, V174, P94, DOI 10.1164/rccm.200602-280OC
   Ruslami R, 2010, ANTIMICROB AGENTS CH, V54, P1068, DOI 10.1128/AAC.00447-09
   Rustomjee R, 2008, ANTIMICROB AGENTS CH, V52, P2831, DOI 10.1128/AAC.01204-07
   Rustomjee R, 2008, INT J TUBERC LUNG D, V12, P128
   Ryan NJ, 2014, DRUGS, V74, P1041, DOI 10.1007/s40265-014-0241-5
   Safi H, 2008, ANTIMICROB AGENTS CH, V52, P2027, DOI 10.1128/AAC.01486-07
   Saikia D, 2012, COMPLEMENT THER MED, V20, P434, DOI 10.1016/j.ctim.2012.07.010
   Salahuddin N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-22
   Saliu OY, 2007, J ANTIMICROB CHEMOTH, V60, P994, DOI 10.1093/jac/dkm291
   Selvaraj P, 2004, J CLIN IMMUNOL, V24, P523, DOI 10.1023/B:JOCI.0000040923.07879.31
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S
   Shi WL, 2011, SCIENCE, V333, P1630, DOI 10.1126/science.1208813
   Shin SS, 2010, AM J RESP CRIT CARE, V182, P426, DOI 10.1164/rccm.200911-1768OC
   Singh M, 2011, INDIAN J MED RES, V133, P535
   Singh R, 2008, SCIENCE, V322, P1392, DOI 10.1126/science.1164571
   Skripconoka V, 2013, EUR RESPIR J, V41, P1393, DOI 10.1183/09031936.00125812
   SMITH JC, 1973, SCIENCE, V181, P954, DOI 10.1126/science.181.4103.954
   Somoskovi A, 2001, RESPIR RES, V2, P164, DOI 10.1186/rr54                                                                    
   Spies FS, 2008, ANTIMICROB AGENTS CH, V52, P2947, DOI 10.1128/AAC.01570-07
   Srivastava S, 2010, J INFECT DIS, V201, P1225, DOI 10.1086/651377
   Sterling TR, 2011, NEW ENGL J MED, V365, P2155, DOI 10.1056/NEJMoa1104875
   Stevenson CR, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-234
   Sung JC, 2009, ANTIMICROB AGENTS CH, V53, P1338, DOI 10.1128/AAC.01389-08
   Tahlan K, 2012, ANTIMICROB AGENTS CH, V56, P1797, DOI 10.1128/AAC.05708-11
   Taneja NK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010860
   Tasneen R, 2008, ANTIMICROB AGENTS CH, V52, P3664, DOI 10.1128/AAC.00686-08
   [Anonymous], 2014, NEW TUB DRUG REG WIL
   Udwadia ZF, 2012, CLIN INFECT DIS, V54, P579, DOI 10.1093/cid/cir889
   van den Boogaard J, 2009, ANTIMICROB AGENTS CH, V53, P849, DOI 10.1128/AAC.00749-08
   Van der Walt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058817
   van Ingen J, 2009, INT J ANTIMICROB AG, V34, P190, DOI 10.1016/j.ijantimicag.2009.02.015
   Hernandez-Pando R., 2010, PLOS ONE, V5
   Vega P, 2004, Int J Tuberc Lung Dis, V8, P749
   Velayati AA, 2009, CHEST, V136, P420, DOI 10.1378/chest.08-2427
   Veziris N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017556
   Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346
   Vilcheze C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2898
   Visser ME, 2011, AM J CLIN NUTR, V93, P93, DOI 10.3945/ajcn.110.001784
   Viveiros M, 2012, EXPERT REV ANTI-INFE, V10, P983, DOI [10.1586/ERI.12.89, 10.1586/eri.12.89]
   Wallis RS, 2011, ANTIMICROB AGENTS CH, V55, P567, DOI 10.1128/AAC.01179-10
   Wallis RS, 2010, J INFECT DIS, V202, P745, DOI 10.1086/655471
   Wang JY, 2010, INT J TUBERC LUNG D, V14, P65
   WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665
   Webster D, 2010, CAN J MICROBIOL, V56, P487, DOI [10.1139/W10-035, 10.1139/w10-035]
   Werngren J, 2014, ANTIMICROB AGENTS CH, V58, P4222, DOI 10.1128/AAC.02718-14
   World Health Organization, 2011, WHOHTMTB20116
   World Health Organization, 2013, WHOHTMTB20136
   World Health Organization (WHO), 2008, WHOHTMTB2008394
   World Health Organization, 2013, WHOHTMTB201311
   World Health Organization, 2000, WHOEDMTRM20001
   Williams KN, 2009, ANTIMICROB AGENTS CH, V53, P1314, DOI 10.1128/AAC.01182-08
   Williams KN, 2009, AM J RESP CRIT CARE, V180, P371, DOI 10.1164/rccm.200904-0611OC
   Xu HB, 2012, INT J TUBERC LUNG D, V16, P358, DOI 10.5588/ijtld.11.0493
   Yamshchikov AV, 2010, AM J CLIN NUTR, V92, P603, DOI 10.3945/ajcn.2010.29411
   Zhang TY, 2009, AM J RESP CRIT CARE, V180, P1151, DOI 10.1164/rccm.200905-0795OC
NR 181
TC 1
Z9 1
U1 1
U2 16
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JAN
PY 2015
VL 40
IS 1
BP 39
EP 56
DI 10.1358/dof.2015.40.1.2236996
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CB0ES
UT WOS:000349298800005
DA 2018-01-05
ER

PT J
AU Zhang, WW
   Ren, BQ
   Jiang, YQ
   Hu, ZG
AF Zhang, Weiwei
   Ren, Baoqi
   Jiang, Yuqin
   Hu, Zhiguo
TI Carboxymethylpullulan promoted Cu2O-catalyzed Huisgen-click reaction
SO RSC ADVANCES
LA English
DT Article
ID AZIDE-ALKYNE CYCLOADDITION; POLYMER-SUPPORTED COPPER(I); TERMINAL
   ALKYNES; 1,3-DIPOLAR CYCLOADDITION; EFFICIENT CATALYSTS; OXIDE
   NANOPARTICLES; REUSABLE CATALYST; HIV-1 PROTEASE; CHEMISTRY; WATER
AB A combination of carboxymethylpullulan (CMP) and Cu2O has been developed as a highly efficient catalytic system for the Huisgen-click reaction. Our results indicate that the acidic CMP could be used for 6 cycles without decreasing the activating efficiency for Cu2O.
C1 [Zhang, Weiwei; Ren, Baoqi; Jiang, Yuqin; Hu, Zhiguo] Henan Normal Univ, Sch Chem & Chem Engn, Collaborat Innovat Ctr Henan Prov Green Mfg Fine, Key Lab Green Chem Media & React,Minist Educ, Xinxiang 453007, Peoples R China.
RP Zhang, WW (reprint author), Henan Normal Univ, Sch Chem & Chem Engn, Collaborat Innovat Ctr Henan Prov Green Mfg Fine, Key Lab Green Chem Media & React,Minist Educ, Xinxiang 453007, Peoples R China.
EM jiangyuqin@htu.cn; zghu@htu.cn
FU Natural Science Foundation of China [21172058]; Scientific Research
   Foundation for Doctors [01036500508]; Youth Foundation of Henan Normal
   University [2012QK11]; Foundation of Henan Educational Committee
   [14A350005]
FX This work was supported financially by the Natural Science Foundation of
   China (no. 21172058), Scientific Research Foundation for Doctors (no.
   01036500508), Youth Foundation (2012QK11) of Henan Normal University,
   Foundation of Henan Educational Committee (no. 14A350005).
CR Ali G, 2013, CARBOHYD POLYM, V93, P109, DOI 10.1016/j.carbpol.2012.07.039
   Alonso F., 2010, EUR J ORG CHEM, V2010, P1875
   Baig RBN, 2013, GREEN CHEM, V15, P1839, DOI 10.1039/c3gc40401c
   Balcioglu N, 1997, POLYHEDRON, V16, P327, DOI 10.1016/0277-5387(96)00215-X                                                    
   Bataille I, 1997, INT J BIOL MACROMOL, V20, P179, DOI 10.1016/S0141-8130(97)01158-6
   Bonami L, 2009, MACROMOL RAPID COMM, V30, P34, DOI 10.1002/marc.200800607
   Chan TR, 2007, QSAR COMB SCI, V26, P1274, DOI 10.1002/qsar.200740131
   Chtchigrovsky M, 2009, ANGEW CHEM INT EDIT, V48, P5916, DOI 10.1002/anie.200901309
   Deraedt C, 2014, J AM CHEM SOC, V136, P12092, DOI 10.1021/ja5061388
   Diez-Gonzalez S, 2008, ANGEW CHEM INT EDIT, V47, P8881, DOI 10.1002/anie.200803289
   Diez-Gonzalez S, 2008, CHEM COMMUN, P4747, DOI 10.1039/b806806b
   Garcia-Alvarez J, 2010, GREEN CHEM, V12, P2127, DOI 10.1039/c0gc00342e
   Giffin MJ, 2008, J MED CHEM, V51, P6263, DOI 10.1021/jm800149m
   Girard C, 2006, ORG LETT, V8, P1689, DOI 10.1021/ol060283l
   Gruijters BWT, 2006, ORG LETT, V8, P3163, DOI 10.1021/ol0607387
   Himo F, 2005, J AM CHEM SOC, V127, P210, DOI 10.1021/ja0471525
   Horie K, 2004, BIOL PHARM BULL, V27, P1275, DOI 10.1248/bpb.27.1275                                                             
   Huang JL, 2014, RSC ADV, V4, P6965, DOI 10.1039/c3ra47041e
   Jiang YQ, 2014, TETRAHEDRON LETT, V55, P2410, DOI 10.1016/j.tetlet.2014.02.108
   Jiang YQ, 2014, RSC ADV, V4, P1010, DOI 10.1039/c3ra45437a
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Lal S, 2011, ORGANOMETALLICS, V30, P6225, DOI 10.1021/om200791u
   Legros M, 2008, POLYM J, V40, P1132, DOI 10.1295/polymj.PJ2008117
   Li L. D., 2012, DALTON T, P5144
   Lopez-Ruiz H, 2013, ARKIVOC, P139
   Mendoza-Espinosa D., 2014, DALTON T, P7069
   Mocanu G, 2012, CARBOHYD POLYM, V89, P578, DOI 10.1016/j.carbpol.2012.03.052
   Molteni G, 2006, NEW J CHEM, V30, P1137, DOI 10.1039/b604297j
   Nandivada H, 2007, ADV MATER, V19, P2197, DOI 10.1002/adma.200602739
   Ozcubukcu S, 2009, ORG LETT, V11, P4680, DOI 10.1021/ol9018776
   Pachon LD, 2005, ADV SYNTH CATAL, V347, P811, DOI 10.1002/adsc.200404383
   Park IS, 2008, ORG LETT, V10, P497, DOI 10.1021/ol702790w
   Rad MNS, 2013, HELV CHIM ACTA, V96, P688, DOI 10.1002/hlca.201200224
   Rajaram H, 2014, BIOORG MED CHEM LETT, V24, P4523, DOI 10.1016/j.bmcl.2014.07.077
   Reddy KR, 2007, CATAL LETT, V114, P36, DOI 10.1007/s10562-007-9032-x
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Roy S, 2013, GREEN CHEM, V15, P2532, DOI 10.1039/c3gc41114a
   Ryu EH, 2005, ORG LETT, V7, P1035, DOI 10.1021/ol047468h
   Sarkar A, 2008, J PHYS CHEM C, V112, P3334, DOI 10.1021/jp077603i
   Schweinfurth D, 2008, CHEM COMMUN, P2203, DOI 10.1039/b800284c
   Shao CW, 2011, TETRAHEDRON LETT, V52, P3782, DOI 10.1016/j.tetlet.2011.05.061
   Shao CW, 2010, J ORG CHEM, V75, P7002, DOI 10.1021/jo101495k
   Shao CW, 2010, ADV SYNTH CATAL, V352, P1587, DOI 10.1002/adsc.200900768
   Sharpless KB, 2002, ANGEW CHEM INT EDIT, V114, P2708
   Sirion U, 2008, SYNLETT, P2326, DOI 10.1055/s-2008-1078245
   Such GK, 2006, J AM CHEM SOC, V128, P9318, DOI 10.1021/ja063043+
   Tahir MN, 2013, TETRAHEDRON LETT, V54, P3268, DOI 10.1016/j.tetlet.2013.04.042
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Wang D, 2010, GREEN CHEM, V12, P2120, DOI 10.1039/c0gc00381f
   Wang K, 2011, GREEN CHEM, V13, P562, DOI 10.1039/c0gc00848f
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
   Wong CH, 2013, CHEM COMMUN, V49, P1679, DOI 10.1039/c2cc37316e
   Wu P, 2004, ANGEW CHEM INT EDIT, V43, P3928, DOI 10.1002/anie.200454078
   Yao XB, 2014, RSC ADV, V4, P30492, DOI 10.1039/c4ra03476g
   Ye CF, 2007, ORG LETT, V9, P3841, DOI 10.1021/ol701602a
   Yoo EJ, 2007, ANGEW CHEM INT EDIT, V46, P1730, DOI 10.1002/anie.200604241
   Zhang ZF, 2010, ADV SYNTH CATAL, V352, P1600, DOI 10.1002/adsc.201000206
   Zheng ZJ, 2012, CHEM-EUR J, V18, P14094, DOI 10.1002/chem.201202472
   Zhu WP, 2011, MACROMOLECULES, V44, P1920, DOI 10.1021/ma102704g
NR 59
TC 6
Z9 7
U1 2
U2 31
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 16
BP 12043
EP 12047
DI 10.1039/c4ra14813d
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA CA5YR
UT WOS:000348985400045
DA 2018-01-05
ER

PT J
AU Al Garalleh, H
   Thamwattana, N
   Cox, BJ
   Hill, JM
AF Al Garalleh, Hakim
   Thamwattana, Ngamta
   Cox, Barry J.
   Hill, James M.
TI Modeling Interactions Between C-60 Antiviral Compounds and HIV Protease
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Fullerene C-60; Human immunodeficiency virus (HIV-1 and HIV-2);
   Lennard-Jones potential; van der Waals interaction;
   O-Carboxymethoxyl-amine; N-Carboxymethoxyl-amine;
   3-Azido-3-deoxythemidine; Tris-hydroxymethyl-amine
ID MOLECULAR-DYNAMICS; FULLERENE DERIVATIVES; INHIBITION; DEFICIENCY;
   MECHANICS; CARBON; VIRUS; C60; NANOTUBES; BINDING
AB Fullerenes have generated a great deal of interest in recent years, due to their properties and potential applications in many fields, including medicine. In this paper, we study an antiviral fullerene compound which may be used to treat the human immunodeficiency virus (HIV). We formulate a mathematical model which can describe the interaction energy between the C antiviral compounds and the HIV. In particular, this paper predicts the energy and force arising from the interaction between HIV active region and the antiviral molecule which is attached to the external surface of a fullerene C. These interactions are calculated based on the structure of the antiviral molecules. Our results show that the binding of fullerene C to the antiviral molecules increases the efficiency of the compound to prohibit the activity of HIV.
C1 [Al Garalleh, Hakim; Thamwattana, Ngamta] Univ Wollongong, Sch Math & Appl Stat, Nanomech Grp, Wollongong, NSW 2522, Australia.
   [Cox, Barry J.; Hill, James M.] Univ Adelaide, Sch Math Sci, Nanomech Grp, Adelaide, SA 5005, Australia.
RP Al Garalleh, H (reprint author), Univ Wollongong, Sch Math & Appl Stat, Nanomech Grp, Wollongong, NSW 2522, Australia.
EM hakimqaralleh@hotmail.com
OI Cox, Barry/0000-0002-0662-7037
FU Australian Research council
FX The authors are grateful to the Australian Research council for support
   through the Discovery Project Scheme. They are also grateful to the
   provision of an UPA for HA.
CR An YZ, 1996, TETRAHEDRON, V52, P5179, DOI 10.1016/0040-4020(96)00123-8
   Azzam Tony, 2004, Current Drug Delivery, V1, P165, DOI 10.2174/1567201043479902
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bedrov D, 2008, J PHYS CHEM B, V112, P2078, DOI 10.1021/jp075149c
   BLAU WJ, 1991, PHYS REV LETT, V67, P1423, DOI 10.1103/PhysRevLett.67.1423
   COFFIN J, 1986, NATURE, V321, P10
   Cottrell LT, 1954, STRENGTHS CHEM BONDS
   Cox BJ, 2008, P ROY SOC A-MATH PHY, V464, P691, DOI 10.1098/rspa.2007.0247
   Cox BJ, 2007, P R SOC A, V463, P461, DOI 10.1098/rspa.2006.1771
   David WIF, 1992, PHYS REV LETT, V69, P1065
   Delmonico FL, 1998, TRANSPLANTATION, V65, P603, DOI 10.1097/00007890-199803150-00001
   Dresselhaus M. S., 1996, SCI FULLERENES CARBO
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Feuerstein I, 2006, J AM SOC MASS SPECTR, V17, P1203, DOI 10.1016/j.jasms.2006.04.032
   FOWLER PW, 1995, J PHYS CHEM-US, V99, P508, DOI 10.1021/j100002a010                                                             
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   GALLO D, 1986, J CLIN MICROBIOL, V23, P1049
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Hirschfelder J. O., 1964, MOL THEORY GASES LIQ
   Jason RR, 1994, AM J RESP CRIT CARE, V150, P176
   Jensen AW, 1996, BIOORGAN MED CHEM, V4, P767, DOI 10.1016/0968-0896(96)00081-8
   JOHNSON RD, 1990, J AM CHEM SOC, V112, P8983, DOI 10.1021/ja00180a055                                                             
   Kotelnikova RA, 2003, J NANOPART RES, V5, P561, DOI 10.1023/B:NAN0.0000006070.61144.93
   KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0
   KRUSIC PJ, 1991, SCIENCE, V254, P1183, DOI 10.1126/science.254.5035.1183                                                   
   Ma HL, 2010, SCI CHINA CHEM, V53, P2233, DOI 10.1007/s11426-010-4118-5
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   Pauling L, 1960, NATURE CHEM BONDS
   Poling B.E., 2001, PROPERTIES GASES LIQ
   Rainer Prato M, 1997, RAPID MAT CHEM, V7, P1097
   Rainer M, 2006, RAPID COMMUN MASS SP, V20, P2954, DOI 10.1002/rcm.2673
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   Schinazi RF, 1994, ELECTROCHEM SOC, V94, P689
   Schuster DI, 1996, BIOORG MED CHEM LETT, V6, P1253, DOI 10.1016/0960-894X(96)00210-7
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   Sutton LE, 1965, TABLE INTERATOMIC DI
   TAYLOR R, 1990, J CHEM SOC CHEM COMM, P1423, DOI 10.1039/c39900001423                                                            
   Tran-duc T, 2011, J PHYS CONDENS MATT, V23
   TYCKO R, 1991, J PHYS CHEM-US, V95, P518, DOI 10.1021/j100155a006                                                             
   Wang W, 2006, CHEM BIOL DRUG DES, V68, P314, DOI 10.1111/j.1747-0285.2006.00454.x
   Xu ZP, 2006, CHEM ENG SCI, V61, P1027, DOI 10.1016/j.ces.2005.06.019
   Yamakoshi Y, 2003, J AM CHEM SOC, V125, P12803, DOI 10.1021/ja0355574
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 45
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD JAN
PY 2015
VL 77
IS 1
BP 184
EP 201
DI 10.1007/s11538-014-0056-2
PG 18
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA AZ7BL
UT WOS:000348373200008
PM 25583353
DA 2018-01-05
ER

PT J
AU Jayant, RD
   Atluri, VSR
   Agudelo, M
   Sagar, V
   Kaushik, A
   Nair, M
AF Jayant, Rahul Dev
   Atluri, Venkata S. R.
   Agudelo, Marisela
   Sagar, Vidya
   Kaushik, Ajeet
   Nair, Madhavan
TI Sustained-release nanoART formulation for the treatment of neuroAIDS
SO International Journal of Nanomedicine
LA English
DT Article
DE layer-by-layer; magnetic nanocarriers; blood-brain barriers; neuroAIDS;
   sustained release; anti-HIV drug; latency
ID BLOOD-BRAIN-BARRIER; ANTI-HIV DRUG; ACTIVE ANTIRETROVIRAL THERAPY;
   NEUROCOGNITIVE DISORDER; DEXAMETHASONE RELEASE; ALGINATE MICROSPHERES;
   DELIVERY; NANOPARTICLES; NANOCARRIERS; PROGRESSION
AB A novel approach was developed for the coencapsulation of an anti-HIV drug (tenofovir) and a latency-breaking agent (vorinostat), using magnetically guided layer-by-layer (LbL) assembled nanocarriers for the treatment of neuroAIDS. Ultrasmall iron oxide (Fe3O4) nanoparticles (10 +/- 3 nm) were synthesized and characterized. The LbL technique was used to achieve a sustained release profile, and application of 2 bilayers ([tenofovir+dextran sulphate](2)+vorinostat) to magnetic nanoparticles resulted in a 2.8 times increase in drug (tenofovir) loading and also resulted in an increase in the drug release period by 30-fold, with 100% drug release in sustained manner over a period of 5 days with the simultaneous stimulation of latent HIV expression. Nanoformulation showed a good blood-brain barrier transmigration ability (37.95%+/- 1.5%) with good in vitro antiviral efficacy (similar to 33% reduction of p24 level) over a period of 5 days after HIV infection in primary human astrocytes, with good cell viability (>90%). Hence, LbL arrangements of drugs on magnetic nanoparticles provides sustained release and, therefore, may improve the patient's adherence to therapy and lead to better compliance.
C1 [Jayant, Rahul Dev; Atluri, Venkata S. R.; Agudelo, Marisela; Sagar, Vidya; Kaushik, Ajeet; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol, Miami, FL 33199 USA.
RP Jayant, RD (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol, 11200 SW 8th St,Univ Pk,AHC-1, Miami, FL 33199 USA.
EM rjayant@fiu.edu; nairm@fiu.edu
RI Atluri, Venkata/G-3277-2014
OI Atluri, Venkata/0000-0002-8070-6745; Jayant, Rahul
   Dev/0000-0002-2584-3878
FU National Institutes of Health [1R01MH085259, R01DA034547-01]; NIH-AIDS
   Research Program
FX We acknowledge receiving financial support from National Institutes of
   Health (grants 1R01MH085259 and R01DA034547-01) and the NIH-AIDS
   Research Program for the antiretroviral drug.
CR Archin NM, 2009, AIDS RES HUM RETROV, V25, P207, DOI 10.1089/aid.2008.0191
   Atluri VSR, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-37
   Atluri VSR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061399
   AYRE SG, 1989, MED HYPOTHESES, V29, P283, DOI 10.1016/0306-9877(89)90113-8
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3
   Boffito M, 2014, DRUGS, V74, P7, DOI 10.1007/s40265-013-0163-7
   Caraglia M, 2012, CURR CANCER DRUG TAR, V12, P186, DOI 10.2174/156800912799277421                                                      
   de Olalla PG, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI 10.1097/00126334-200205010-00014                                                
   De Rosa G, 2012, CURR DRUG METAB, V13, P61, DOI 10.2174/138920012798356943                                                      
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891
   Jayant RD, 2007, J BIOMED NANOTECHNOL, V3, P245, DOI 10.1166/jbn.2007.039
   Jayant RD, 2014, J NEUROIMMUNE PHARM, V9, P25
   Jayant RD, 2009, DRUG DELIV, V16, P331, DOI 10.1080/10717540903031126
   Kargol A, 2006, ADV MAGNETIC MAT, P89
   Kaushik A, 2014, EXPERT OPIN DRUG DEL, V11, P1635, DOI 10.1517/17425247.2014.933803
   Kelly JA, 2002, J CONSULT CLIN PSYCH, V70, P626, DOI 10.1037//0022-006X.70.3.626
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Sun YK, 2004, COLLOID SURFACE A, V245, P15, DOI 10.1016/j.colsurfa.2004.05.009
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Toduka Y, 2012, ENVIRON SCI TECHNOL, V46, P7629, DOI 10.1021/es300433x
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Williams I, 2012, HIV MED, V13, P1, DOI [10.1111/j.1468-1293.2012.01029_1.x, 10.1111/j.1468-1293.2012.01029.x]
   Wohlfart S, 2012, J CONTROL RELEASE, V161, P264, DOI 10.1016/j.jconrel.2011.08.017
   [Anonymous], 2005, ADHERENCE HIV ANTIRE
NR 35
TC 31
Z9 31
U1 1
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 1077
EP 1093
DI 10.2147/IJN.S76517
PG 17
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CA5YL
UT WOS:000348984700001
PM 25709433
OA gold
DA 2018-01-05
ER

PT J
AU Martinez-Martin, N
   Viejo-Borbolla, A
   Martin, R
   Blanco, S
   Benovic, JL
   Thelen, M
   Alcami, A
AF Martinez-Martin, Nadia
   Viejo-Borbolla, Abel
   Martin, Rocio
   Blanco, Soledad
   Benovic, Jeffrey L.
   Thelen, Marcus
   Alcami, Antonio
TI Herpes simplex virus enhances chemokine function through modulation of
   receptor trafficking and oligomerization
SO Nature Communications
LA English
DT Article
ID IN-VIVO ACTIVITY; GLYCOSAMINOGLYCAN BINDING; LIPID RAFTS; HIV-1
   ACQUISITION; T-CELLS; CXCR4; ACTIVATION; PROTEIN; CHOLESTEROL; MIGRATION
AB Glycoprotein G (gG) from herpes simplex virus 1 and 2 (HSV-1 and HSV-2, important human neurotropic pathogens) is the first viral chemokine-binding protein found to potentiate chemokine function. Here we show that gG attaches to cell surface glycosaminoglycans and induces lipid raft clustering, increasing the incorporation of CXCR4 receptors into these microdomains. gG induces conformational rearrangements in CXCR4 homodimers and changes their intracellular partners, leading to sustained, functional chemokine/receptor complexes at the surface. This results in increased chemotaxis dependent on the cholesterol content of the plasma membrane and receptor association to Src-kinases and phosphatidy-linositol-3-kinase signalling pathways, but independent of clathrin-mediated endocytosis. Furthermore, using electron microscopy, we show that such enhanced functionality is associated with the accumulation of low-order CXCR4 nanoclusters. Our results provide insights into basic mechanisms of chemokine receptor function and into a viral strategy of immune modulation.
C1 [Martinez-Martin, Nadia; Viejo-Borbolla, Abel; Martin, Rocio; Blanco, Soledad; Alcami, Antonio] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.
   [Benovic, Jeffrey L.] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [Thelen, Marcus] Inst Res Biomed, CH-6500 Bellinzona, Switzerland.
   [Alcami, Antonio] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.
RP Alcami, A (reprint author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.
EM aalcami@cbm.csic.es
RI Alcami, Antonio/F-8512-2015
OI Alcami, Antonio/0000-0002-3333-6016
FU Spanish Ministry of Science and Innovation [SAF2009-07857,
   SAF2012-38957]; Red Espanola de Esclerosis Multiple (Instituto de Salud
   Carlos III) [RD07/0060/0014]; Consejo Superior de Investigaciones
   Cientificas; Fundacion Severo Ochoa
FX We thank Elena-Fernandez Arenas and Balbino Alarcon (CBMSO, Madrid,
   Spain) for providing the chemical inhibitors and the beta-arrestin-2
   constructs, Helena Browne and Anthony Minson (Cambridge University, UK)
   for the anti-gG1 antibody (LP-10) and HSV-2 isolate and Mario Mellado
   and Yolanda Carrasco (CNB, Madrid, Spain) for helpful discussions. We
   are also thankful to Maria Teresa Rejas and the Confocal Microscopy Unit
   at CBMSO for their help with electron and confocal microscopy studies,
   respectively. We also thank Santos Manes (CNB, Spain) for providing the
   lipid raft isolation protocol. This work was funded by the Spanish
   Ministry of Science and Innovation (SAF2009-07857 and SAF2012-38957) and
   Red Espanola de Esclerosis Multiple (Instituto de Salud Carlos III,
   RD07/0060/0014). N.M.-M. was funded by a studentship from Consejo
   Superior de Investigaciones Cientificas and by Fundacion Severo Ochoa.
   A.V.-B. was supported by a postdoctoral fellowship from Consejo Superior
   de Investigaciones Cientificas.
CR Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980
   Alcami A, 2009, ADV EXP MED BIOL, V666, P167
   Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916                                                        
   Anton OM, 2011, J IMMUNOL, V186, P6345, DOI 10.4049/jimmunol.1003771
   Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   BALAN P, 1994, J GEN VIROL, V75, P1245, DOI 10.1099/0022-1317-75-6-1245
   Berchiche YA, 2007, J BIOL CHEM, V282, P5111, DOI 10.1074/jbc.C600270200
   Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643
   Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002
   Busillo JM, 2010, J BIOL CHEM, V285, P7805, DOI 10.1074/jbc.M109.091173
   Cabrera J. R., PLOS PATHOG IN PRESS
   Campanella GSV, 2006, J IMMUNOL, V177, P6991, DOI 10.4049/jimmunol.177.10.6991                                                    
   Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   DASILVA PP, 1984, J CELL BIOL, V99, P1156
   Ding ZQ, 2003, BLOOD, V101, P4245, DOI 10.1182/blood-2002-06-1782
   Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009
   Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298
   Gomez-Mouton C, 2007, CELL ADHES MIGR, V1, DOI 10.4161/cam.1.2.4547
   Gurevich VV, 2008, TRENDS NEUROSCI, V31, P74, DOI 10.1016/j.tins.2007.11.007
   Hamatake M, 2009, CANCER SCI, V100, P95, DOI 10.1111/j.1349-7006.2008.00997.x
   Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x
   Huang WJ, 2012, J IMMUNOL, V188, P6247, DOI 10.4049/jimmunol.1103706
   Humpert M. L., 2013, PROTEOMICS, V12, P1938
   Karin N, 2010, J LEUKOCYTE BIOL, V88, P463, DOI 10.1189/jlb.0909602
   Kumar R, 2011, IMMUNITY, V35, P375, DOI 10.1016/j.immuni.2011.08.010
   Li MZ, 2008, PROG NEUROBIOL, V84, P116, DOI 10.1016/j.pneurobio.2007.11.003
   Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004
   Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211                                                        
   McLean TI, 1999, J VIROL, V73, P8415
   MEIGNIER B, 1988, VIROLOGY, V162, P251, DOI 10.1016/0042-6822(88)90417-5
   Molon B, 2005, NAT IMMUNOL, V6, P465, DOI 10.1038/ni1191
   Montanuy I, 2011, FASEB J, V25, P1960, DOI 10.1096/fj.10-177188
   Mythreye K, 2009, CELL SIGNAL, V21, P1548, DOI 10.1016/j.cellsig.2009.05.001
   Nguyen DH, 2002, BLOOD, V99, P4298, DOI 10.1182/blood-2001-11-0087
   Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121                                                     
   Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840
   Palmesino E, 2006, IMMUNOBIOLOGY, V211, P377, DOI 10.1016/j.imbio.2005.12.003
   Paz-Bailey G, 2007, SEX TRANSM INFECT, V83, P16, DOI 10.1136/sti.2006.020966
   Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Pucadyil TJ, 2006, PROG LIPID RES, V45, P295, DOI 10.1016/j.plipres.2006.02.002
   ROIZMAN B, 1984, VIROLOGY, V133, P242, DOI 10.1016/0042-6822(84)90447-1
   Ruiz-Arguello MB, 2008, J VIROL, V82, P917, DOI 10.1128/JVI.02111-07
   Seet BT, 2001, J BIOL CHEM, V276, P30504, DOI 10.1074/jbc.M011401200
   Tabe Y, 2012, LEUKEMIA, V26, P883, DOI 10.1038/leu.2011.291
   Thelen M, 2008, NAT IMMUNOL, V9, P953, DOI 10.1038/ni.f.207
   Tkachenko E, 2004, J CELL SCI, V117, P3189, DOI 10.1242/jcs.01190
   Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.E02-11-0714
   Viejo-Borbolla A, 2010, J GEN VIROL, V91, P23, DOI 10.1099/vir.0.011940-0
   Viejo-Borbolla A., 2012, PLOS PATHOG, V8
   Volpe S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010159
   WEBER PC, 1987, SCIENCE, V236, P576, DOI 10.1126/science.3033824
   Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600                                                                  
   Wysoczynski M, 2005, BLOOD, V105, P40, DOI 10.1128/blood-2004-04-1430
   Zhu J, 2009, NAT MED, V15, P886, DOI 10.1038/nm.2006
NR 58
TC 11
Z9 11
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 6163
DI 10.1038/ncomms7163
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA3UQ
UT WOS:000348832700007
PM 25625471
OA gold
DA 2018-01-05
ER

PT J
AU Li, HJ
   Wen, J
   Yu, RJ
   Meng, J
   Wang, C
   Wang, CX
   Sun, SG
AF Li, Hongjuan
   Wen, Jia
   Yu, Ruijin
   Meng, Jia
   Wang, Cong
   Wang, Chaoxia
   Sun, Shiguo
TI Facile synthesis of a nanocomposite based on graphene and ZnAl layered
   double hydroxides as a portable shelf of a luminescent sensor for DNA
   detection
SO RSC ADVANCES
LA English
DT Article
ID SWITCH RU COMPLEX; LABEL-FREE; ELECTRODE MATERIAL; GRAPHITE OXIDE;
   QUANTUM DOTS; SUPERCAPACITOR; PERFORMANCE; COMPOSITE; FILMS; IONS
AB Recently, nanocomposites based on graphene and layered double hydroxides (LDH) have been developed and used in many fields. However, to the best of our knowledge, there is no report on the luminescence sensor applications of graphene/LDH composites. Herein, a hybrid graphene-ZnAl-LDH nanocomposite has been developed using a facile one-step process and the presence of LDH in the composite can effectively prevent the restacking of graphene and improve both its luminescence properties and thermal stability. Furthermore, the composite can be used as a portable shelf of the Ru(phen)(3)Cl-2 (tris(1,10-phenanthroline) ruthenium(II) dichloride) sensor to selectively discriminate DNA. It was found that the graphene-ZnAl-LDH composite can effectively quench the emission of the Ru(phen)(3)Cl-2 sensor. After the addition of a certain amount of DNA into the system, Ru(phen)(3)Cl-2 was released from the graphene-ZnAl-LDH composite and it interacted with DNA immediately, leading to the luminescence recovery of the sensor. The results indicate that the RGO-ZnAl-LDH composite displayed an excellent luminescence response and good linear correlation to DNA. Therefore, the composite can be employed as a portable shelf of Ru(phen)(3)Cl-2 to discriminate DNA. Moreover, both the shelf and the sensor can be easily collected and made ready for the next sample if there is no DNA in the solution. The proposed method was further applied to detect the immunodeficiency virus gene (HIV), thus providing a new field of application for hybrid graphene/LDH composites.
C1 [Li, Hongjuan; Wen, Jia; Yu, Ruijin; Meng, Jia; Wang, Cong; Sun, Shiguo] Northwest A&F Univ, Coll Sci, Yangling 712100, Shaanxi, Peoples R China.
   [Wang, Chaoxia] Jiangnan Univ, Sch Text & Clothing, Key Lab Ecotext, Minist Educ, Wuxi 214122, Peoples R China.
RP Sun, SG (reprint author), Northwest A&F Univ, Coll Sci, Yangling 712100, Shaanxi, Peoples R China.
EM hongjuanli@nwsuaf.edu.cn; sunsg@nwsuaf.edu.cn
FU National Natural Science Foundation of China [201205095]; Scientific
   Research Foundation of Northwest AF University [Z109021115, Z111021103,
   Z111021107]; Fundamental Research Funds for the Central Universities
   [Z109021204]; Shaanxi Province Science and Technology [2013K12-03-23];
   State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan
   University [2013005]
FX This work was supported by the National Natural Science Foundation of
   China (no. 201205095), the Scientific Research Foundation of Northwest
   A&F University (Z109021115, Z111021103 and Z111021107), the Fundamental
   Research Funds for the Central Universities (Z109021204), the Shaanxi
   Province Science and Technology (no. 2013K12-03-23), and the State Key
   Laboratory of Chemo/Biosensing and Chemometrics, Hunan University (no.
   2013005).
CR An Z, 2011, LANGMUIR, V27, P12745, DOI 10.1021/la2024956
   Baliarsingh N, 2013, RSC ADV, V3, P23865, DOI 10.1039/c3ra42857e
   Bhunia SK, 2011, ACS APPL MATER INTER, V3, P3335, DOI 10.1021/am2004416
   Chen D, 2010, CHEM SOC REV, V39, P3157, DOI 10.1039/b923596e
   Chen ML, 2013, BIOCONJUGATE CHEM, V24, P387, DOI 10.1021/bc3004809
   Climent M.J., 2010, CHEM REV, V111, P1072, DOI DOI 10.1021/CR1002084
   Coggan DZM, 1999, INORG CHEM, V38, P4486, DOI 10.1021/ic990654c                                                               
   Dong XY, 2012, LANGMUIR, V28, P293, DOI 10.1021/la2038685
   Fan XB, 2008, ADV MATER, V20, P4490, DOI 10.1002/adma.200801306
   Gao Z, 2011, CHEM MATER, V23, P3509, DOI 10.1021/cm200975x
   Gunjakar JL, 2013, ENERG ENVIRON SCI, V6, P1008, DOI 10.1039/c3ee23989f
   He HM, 2010, J COLLOID INTERF SCI, V343, P225, DOI 10.1016/j.jcis.2009.11.004
   He S, 2013, CHEM COMMUN, V49, P5912, DOI 10.1039/c3cc42137f
   Hu B, 2008, CHEM-EUR J, V14, P8928, DOI 10.1002/chem.200800458
   Hu H, 2013, BIOCONJUGATE CHEM, V24, P968, DOI 10.1021/bc300683y
   Huang S, 2012, ACS APPL MATER INTER, V4, P2242, DOI 10.1021/am300247x
   Huang ZJ, 2014, J MATER CHEM A, V2, P5534, DOI 10.1039/c3ta15350a
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Kovanda F, 2003, SOLID STATE SCI, V5, P1019, DOI 10.1016/S1293-2558(03)00129-8
   Latorre-Sanchez M, 2012, CARBON, V50, P518, DOI 10.1016/j.carbon.2011.09.007
   Lay PA, 1986, INORG SYNTH, V24, P291
   Lee JH, 2013, ACS NANO, V7, P9366, DOI 10.1021/nn4040734
   Lei ZB, 2012, ENERG ENVIRON SCI, V5, P6391, DOI 10.1039/c1ee02478g
   Li LH, 2013, ACS SUSTAIN CHEM ENG, V1, P144, DOI 10.1021/sc3000724
   Liu YX, 2012, CHEM SOC REV, V41, P2283, DOI 10.1039/c1cs15270j
   Liu ZH, 2002, LANGMUIR, V18, P4926, DOI 10.1021/la011677i
   Liu ZP, 2006, J AM CHEM SOC, V128, P4872, DOI 10.1021/ja0584471
   Memon J, 2014, J MATER CHEM A, V2, P5060, DOI 10.1039/c3ta14613h
   Quintana M, 2013, ACCOUNTS CHEM RES, V46, P138, DOI 10.1021/ar300138e
   Rao CNR, 2009, ANGEW CHEM INT EDIT, V48, P7752, DOI 10.1002/anie.200901678
   Rao CNR, 2009, J MATER CHEM, V19, P2457, DOI 10.1039/b815239j
   Stankovich S, 2006, CARBON, V44, P3342, DOI 10.1016/j.carbon.2006.06.004
   Sun WL, 2013, ANALYST, V138, P421, DOI 10.1039/c2an36142f
   Sun WL, 2012, ANALYST, V137, P1550, DOI 10.1039/c2an16181h
   Sun WL, 2011, ANAL METHODS-UK, V3, P2472, DOI 10.1039/c1ay05521f
   TOSSI AB, 1989, PHOTOCHEM PHOTOBIOL, V49, P545, DOI 10.1111/j.1751-1097.1989.tb08423.x                                              
   Wang L, 2011, CHEM COMMUN, V47, P3556, DOI 10.1039/c0cc05420h
   Wang Y, 2011, J PHYS CHEM C, V115, P23192, DOI 10.1021/jp206444e
   Wang Y, 2014, J MATER CHEM B, V2, P1024, DOI 10.1039/c3tb21608j
   Xu C, 2008, J PHYS CHEM C, V112, P19841, DOI 10.1021/jp807989b
   Xu J, 2014, J MATER CHEM A, V2, P1022, DOI 10.1039/c3ta14048b
   Xu YX, 2008, J AM CHEM SOC, V130, P5856, DOI 10.1021/ja800745y
   Yan L, 2013, ELECTROCHIM ACTA, V95, P146, DOI 10.1016/j.electacta.2013.02.060
   Ye YX, 2014, PHYS CHEM CHEM PHYS, V16, P8801, DOI 10.1039/c4cp00554f
   Yu C, 2014, NANOSCALE, V6, P3097, DOI 10.1039/c3nr05477b
   Yuan XY, 2013, CHEM ENG J, V221, P204, DOI 10.1016/j.cej.2013.01.090
   Zhang LJ, 2012, J POWER SOURCES, V199, P395, DOI 10.1016/j.jpowsour.2011.10.056
   Zhang XB, 2010, ANAL CHEM, V82, P5005, DOI 10.1021/ac1009047
NR 48
TC 9
Z9 9
U1 4
U2 61
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 13
BP 9341
EP 9347
DI 10.1039/c4ra15395b
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA AZ1BY
UT WOS:000347976500004
DA 2018-01-05
ER

PT J
AU Freeling, JP
   Koehn, J
   Shu, C
   Sun, JG
   Ho, RJY
AF Freeling, Jennifer P.
   Koehn, Josefin
   Shu, Cuiling
   Sun, Jianguo
   Ho, Rodney J. Y.
TI Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure
   Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph
   Nodes and Blood in Primates
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; LIPID NANOPARTICLES; VIRAL LOAD; INDINAVIR;
   TISSUES; RITONAVIR; INFECTION; LOCALIZATION; REDUCTION; LIPOSOMES
AB HIV patients on combination oral drug therapy experience insufficient drug levels in lymph nodes, which is linked to viral persistence. Following success in enhancing lymph node drug levels and extending plasma residence time of indinavir formulated in lipid nanoparticles, we developed multidrug anti-HIV lipid nanoparticles (anti-HIV LNPs) containing lopinavir (LPV), ritonavir (RTV), and tenofovir (PMPA). These anti-HIV LNPs were prepared, characterized, scaled up, and evaluated in primates with a focus on plasma time course and intracellular drug exposure in blood and lymph nodes. Four macaques were subcutaneously administered anti-HIV LNPs and free drug suspension in a crossover study. The time course of the plasma drug concentration as well as intracellular drug concentrations in blood and inguinal lymph nodes were analyzed to compare the effects of LNP formulation. Anti-HIV LNPs incorporated LPV and RTV with high efficiency and entrapped a reproducible fraction of hydrophilic PMPA. In primates, anti-HIV LNPs produced over 50-fold higher intracellular concentrations of LPV and RTV in lymph nodes compared to free drug. Plasma and intracellular drug levels in blood were enhanced and sustained up to 7 days, beyond that achievable by their free drug counterpart. Thus, multiple antiretroviral agents can be simultaneously incorporated into anti-HIV lipid nanoparticles to enhance intracellular drug concentrations in blood and lymph nodes, where viral replication persists. As these anti-HIV lipid nanoparticles also prolonged plasma drug exposure, they hold promise as a long-acting dosage form for HIV patients in addressing residual virus in cells and tissue.
C1 [Freeling, Jennifer P.; Koehn, Josefin; Shu, Cuiling; Sun, Jianguo; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
   [Sun, Jianguo] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing, Jiangsu, Peoples R China.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.
EM rodneyho@uw.edu
FU NIH [AI 077390, RR00166, RR025014, UL1TR000423]; Milo Gibaldi endowment
FX We thank the staff of the WaNPRC for animal care and observation, as
   well as Michael Gough, Jason Ogle, and Chris English of the WaNPRC
   Research Support Group for their contributions in conducting the primate
   study. We thank Jake Kraft and Jenny Zhang for critical review of the
   manuscript. This work was supported by NIH grants AI 077390 (S1, S2,
   S3), RR00166, RR025014, and UL1TR000423. R.J.Y.H. is also supported by
   the Milo Gibaldi endowment.
CR ALBERTS B, 2002, MOL BIOL CELL
   Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77
   Bui T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013082
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755                                                                   
   Cicconi P, 2010, HIV MED, V11, P104, DOI 10.1111/j.1468-1293.2009.00750.x
   Endsley AN, 2012, JAIDS-J ACQ IMM DEF, V61, P417, DOI 10.1097/QAI.0b013e3182653c1f
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Horiike M, 2011, VIROLOGY, V423, P107
   Hsu A, 1998, CLIN PHARMACOKINET, V35, P275, DOI 10.2165/00003088-199835040-00002
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Koehn J, 2014, ANTIMICROB AGENTS CH, V58, P2675, DOI 10.1128/AAC.02748-13
   Kuo YC, 2011, COLLOID SURFACE B, V88, P682, DOI 10.1016/j.colsurfb.2011.07.060
   Lafeuillade A, 1998, J INFECT DIS, V177, P235, DOI 10.1086/517362                                                                  
   Martinez E, 2001, AIDS, V15, P1477, DOI 10.1097/00002030-200108170-00004                                                
   Notermans DW, 1998, AIDS, V12, P167, DOI 10.1097/00002030-199802000-00006
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Piliero PJ, 2004, JAIDS-J ACQ IMM DEF, V37, pS2, DOI 10.1097/01.qai.0000137001.40505.56
   Robison LS, 2008, AIDS RES HUM RETROV, V24, P1347, DOI 10.1089/aid.2008.0083
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Storch CH, 2007, BIOCHEM PHARMACOL, V73, P1573, DOI 10.1016/j.bcp.2007.01.027
   STRAUBINGER RM, 1985, FEBS LETT, V179, P148, DOI 10.1016/0014-5793(85)80210-6                                                    
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
NR 31
TC 18
Z9 18
U1 1
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JAN 1
PY 2015
VL 31
IS 1
SI SI
BP 107
EP 114
DI 10.1089/aid.2014.0210
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AY8DO
UT WOS:000347784900016
PM 25402233
OA green_published
DA 2018-01-05
ER

PT J
AU Sanchez-Rodriguez, J
   Vacas-Cordoba, E
   Gomez, R
   De La Mata, FJ
   Munoz-Fernandez, MA
AF Sanchez-Rodriguez, Javier
   Vacas-Cordoba, Enrique
   Gomez, Rafael
   Javier De La Mata, F.
   Angeles Munoz-Fernandez, Ma
TI Nanotech-derived topical microbicides for HIV prevention: The road to
   clinical development
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Microbicides; HIV; Nanotechnology; Nanomedicine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; HUMANIZED BLT MICE;
   LOADED POLYMERIC NANOPARTICLES; ANIONIC CARBOSILANE DENDRIMERS;
   RANDOMIZED CONTROLLED-TRIAL; VAGINAL DRUG-DELIVERY; SODIUM LAURYL
   SULFATE; CELL-ASSOCIATED HIV-1; FEMALE GENITAL-TRACT
AB More than three decades since its discovery, HIV infection remains one of the most aggressive epidemics worldwide, with more than 35 million people infected. In sub-Saharan Africa, heterosexual transmissions represent nearly 80% of new infections, with 50% of these occurring in women. In an effort to stop the dramatic spread of the HIV epidemic, new preventive treatments, such as microbicides, have been developed. Nanotechnology has revolutionized this field by designing and engineering novel highly effective nano-sized materials as microbicide candidates. This review illustrates the most recent advances in nano-tech-derived HIV prevention strategies, as well as the main steps required to translate promising in vitro results into clinical trials. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Sanchez-Rodriguez, Javier; Vacas-Cordoba, Enrique; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
   [Sanchez-Rodriguez, Javier; Vacas-Cordoba, Enrique; Gomez, Rafael; Javier De La Mata, F.; Angeles Munoz-Fernandez, Ma] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Gomez, Rafael; Javier De La Mata, F.] Univ Alcala De Henares, Dendrimers Biomed Applicat Grp BioInDen, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, CIBER BBN, Lab InmunoBiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
OI Munoz-Fernandez/0000-0002-0813-4500
FU Fondo de Investigacion Sanitaria (FIS) [PI13/02016]; Red Espanola de
   Investigacion en SIDA (RIS) [RD12-0017-0037, PT13/0010/0028,
   RD12/0017/0029]; CYTED [214RT0482]; "Fundacion para la Investigacion y
   la Prevencion del Sida en Espana" (FIPSE); Comunidad de Madrid
   [S-2010/BMD-2351, S-2010/BMD-2332]; MEC [CTQ2011-23245]; VI National RDi
   Plan; Iniciativa Ingenio; Consolider Program; CIBER Actions; Instituto
   de Salud Carlos III
FX This work was supported by grants provided through Fondo de
   Investigacion Sanitaria (FIS) [grant number PI13/02016], Red Espanola de
   Investigacion en SIDA (RIS) [grant numbers RD12-0017-0037,
   PT13/0010/0028 and RD12/0017/0029], CYTED 214RT0482, "Fundacion para la
   Investigacion y la Prevencion del Sida en Espana" (FIPSE), Comunidad de
   Madrid [grant numbers, S-2010/BMD-2351 and S-2010/BMD-2332], ME&C (Ref.
   CTQ2011-23245). CIBER-BBN is an initiative funded by the VI National
   R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER
   Actions and financed by the Instituto de Salud Carlos III with
   assistance from the European Regional Development Fund.
CR Administration U.S.D.o.H.a.H.S.F.a.D, 2012, CLIN ANTIMICROB
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Anton PA, 2012, CURR HIV RES, V10, P113, DOI 10.2174/157016212799304634
   Asaftei S, 2012, J MED CHEM, V55, P10405, DOI 10.1021/jm301337y
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Ballagh SA, 2002, CONTRACEPTION, V66, P369, DOI 10.1016/S0010-7824(02)00433-X                                                   
   Balzarini J, 2005, CAN MED ASSOC J, V172, P461, DOI 10.1503/cmaj.1041462
   Balzarini J, 2012, CURR HIV RES, V10, P53, DOI 10.2174/157016212799304652
   Baranova E O, 2011, Bioorg Khim, V37, P592
   Bax R, 2002, CONTRACEPTION, V66, P365, DOI 10.1016/S0010-7824(02)00389-X                                                   
   Belletti D, 2012, INT J PHARMACEUT, V436, P753, DOI 10.1016/j.ijpharm.2012.07.070
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Bestman-Smith J, 2001, ANTIMICROB AGENTS CH, V45, P2229, DOI 10.1128/AAC.45.8.2229-2237.2001
   Blaho J. A., 2005, CURR PROTOC MICROBIO, DOI [10.1002/9780471729259.mc14e01s00, DOI 10.1002/9780471729259.MC14E01S00]
   Borges AR, 2010, VIROLOGY, V408, P80, DOI 10.1016/j.virol.2010.09.004
   Bourinbaiar AS, 1996, AIDS, V10, P558, DOI 10.1097/00002030-199605000-00024
   Brehm MA, 2010, CURR OPIN ENDOCRINOL, V17, P120, DOI 10.1097/MED.0b013e328337282f
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Buckheit RW, 2009, INFECT DIS, P1135, DOI 10.1007/978-1-60327-595-8_79
   Buckheit RW, 2012, CURR HIV RES, V10, P97
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Burello E, 2011, WIRES NANOMED NANOBI, V3, P298, DOI 10.1002/wnan.137
   Carlson C, 2008, J PHYS CHEM B, V112, P13608, DOI 10.1021/jp712087m
   Carter AJ, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.17433
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chateau ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060024
   Chen B.A., 2014, 21 C RETR OPP INF CR
   Chirenje ZM, 2010, EXPERT REV ANTI-INFE, V8, P1177, DOI 10.1586/ERI.10.79
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Cordoba EV, 2013, NANOMED-NANOTECHNOL, V9, P972, DOI 10.1016/j.nano.2013.03.004
   Cordoba E.V., 2013, CURR MED CHEM
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   De Clercq E, 2012, BIOCHEM PHARMACOL, V84, P241, DOI 10.1016/j.bcp.2012.03.024
   de las Cuevas N, 2012, CURR MED CHEM, V19, P5052
   Denton PW, 2011, AIDS REV, V13, P135
   Denton PW, 2011, J VIROL, V85, P7582, DOI 10.1128/JVI.00537-11
   Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829
   Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016
   Dezzutti CS, 2001, J INFECT DIS, V183, P1204, DOI 10.1086/319676
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   EDWARDS JNT, 1985, BRIT J OBSTET GYNAEC, V92, P974, DOI 10.1111/j.1471-0528.1985.tb03080.x
   Emau P, 2007, J MED PRIMATOL, V36, P244, DOI 10.1111/j.1600-0684.2007.00242.x
   Ensign LM, 2014, J CONTROL RELEASE, V190, P500, DOI 10.1016/j.jconrel.2014.04.033
   Fackler OT, 2014, NAT REV MICROBIOL, V12, P563, DOI 10.1038/nrmicro3309
   Fahmy TM, 2008, NANOMEDICINE-UK, V3, P343, DOI 10.2217/17435889.3.3.343
   Farokhzad OC, 2008, EXPERT OPIN DRUG DEL, V5, P927, DOI [10.1517/17425240802370043, 10.1517/17425247.5.9.927 ]
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Fetherston SM, 2012, EUR J PHARM SCI, V48, P406, DOI DOI 10.1016/J.EJPS.2012.12.002
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   Friend DR, 2013, ANTIVIR RES, V99, P391, DOI 10.1016/j.antiviral.2013.06.021
   Galan M, 2014, ORG BIOMOL CHEM, V12, P3222, DOI 10.1039/c4ob00162a
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Gall Y., 2010, J VIROL METHODS, V165, P186
   Garcia-Gallego S, 2012, DALTON T, V41, P6488, DOI 10.1039/c2dt11793b
   Garcia-Vallejo JJ, 2013, INT IMMUNOL, V25, P221, DOI 10.1093/intimm/dxs115
   Gengiah TN, 2012, EXPERT OPIN INV DRUG, V21, P695, DOI 10.1517/13543784.2012.667072
   Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Granich R, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-1
   Grivel JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S6
   Gunn J, 2010, TRENDS BIOTECHNOL, V28, P189, DOI 10.1016/j.tibtech.2009.12.006
   Gupta P, 2013, AIDS RES HUM RETROV, V29, P391, DOI [10.1089/aid.2012.0135, 10.1089/AID.2012.0135]
   Gupta SK, 2013, HIV AIDS-RES PALLIAT, V5, P295, DOI 10.2147/HIV.S39164
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Herrera C, 2012, CURR HIV RES, V10, P42, DOI 10.2174/157016212799304607
   Hillier S., 2013, M FUT PREP MICR WASH
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2014, CURR TOP MICROBIOL, V383, P97, DOI 10.1007/82_2013_330
   Keller MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008781
   Kenney J, 2013, ANTIMICROB AGENTS CH, V57, P4001, DOI 10.1128/AAC.00796-13
   Kenney J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015835
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Krebs FC, 1999, ANTIVIR RES, V43, P157, DOI 10.1016/S0166-3542(99)00044-3
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lazniewska J, 2012, WIRES NANOMED NANOBI, V4, P469, DOI 10.1002/wnan.1181
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Luganini A, 2011, ANTIMICROB AGENTS CH, V55, P3231, DOI 10.1128/AAC.00149-11
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Maeda K, 2012, EXPERT OPIN EMERG DR, V17, P135, DOI 10.1517/14728214.2012.673584
   Mahajan SD, 2012, METHOD ENZYMOL, V509, P41, DOI 10.1016/B978-0-12-391858-1.00003-4
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Martin DH, 2012, AM J MED SCI, V343, P2, DOI 10.1097/MAJ.0b013e31823ea228
   Mauck CK, 2004, CONTRACEPTION, V70, P233, DOI 10.1016/j.contraception.2004.04.010
   Mbopi-Keou FX, 2010, CONTRACEPTION, V81, P79, DOI 10.1016/j.contraception.2009.07.002
   McElrath MJ, 2010, ANTIMICROB AGENTS CH, V54, P763, DOI 10.1128/AAC.00891-09
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mertenskoetter T, 2011, EUR J MED RES, V16, P1
   Microbicides I.P.F., 2012, THE RING STUD
   Morrow K.M., 2010, ANTIVIR RES S1, V88, P40
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Navath RS, 2011, MOL PHARMACEUT, V8, P1209, DOI 10.1021/mp200027z
   Neff CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020209
   Network M.T., 2010, UND RES CAPRISA 004
   Network M.T., 2013, PHAS 2 RAND SEQ OP L
   Network M.T., 2012, PHAS 3 TRIAL DAP RIN
   Network M.T., 2013, PHAS 1 EV COIT PHARM
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Omar R.F., 2011, INT J INFECT DIS, V15, P656
   Padian NS, 2008, LANCET, V372, P585, DOI 10.1016/S0140-6736(08)60885-5
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Piret J, 2002, CURR DRUG TARGETS, V3, P17, DOI 10.2174/1389450023348037
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Quinn TC, 2007, CURR OPIN INFECT DIS, V20, P33, DOI 10.1097/QCO.0b013e328012c5bc
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rebbapragada A, 2007, AIDS, V21, P589, DOI 10.1097/QAD.0b013e328012b896                                                    
   Reina JJ, 2010, FUTURE MED CHEM, V2, P1141, DOI 10.4155/FMC.10.203
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Rohan L.C., 2013, ANTIVIRAL RES S, V100, P17
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Sanchez-Nieves J, 2014, EUR J MED CHEM, V76, P43, DOI 10.1016/j.ejmech.2014.01.061
   Sartori E, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-166
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Shattock RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007385
   Siccardi M, 2013, THER DELIV, V4, P153, DOI [10.4155/TDE.12.156, 10.4155/tde.12.156]
   Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003
   Stefanidou M, 2012, ANTIMICROB AGENTS CH, V56, P4381, DOI 10.1128/AAC.00399-12
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Stephenson J, 2011, JAMA-J AM MED ASSOC, V305, P1397, DOI 10.1001/jama.2011.433
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tao W, 2008, AIDS RES HUM RETROV, V24, P925, DOI 10.1089/aid.2008.0043
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Thiagarajan G, 2013, EUR J PHARM BIOPHARM, V84, P330, DOI 10.1016/j.ejpb.2013.01.019
   Thompson KA, 1996, CONTRACEPTION, V53, P313
   Thurman AR, 2012, INT J STD AIDS, V23, P613, DOI 10.1258/ijsa.2012.011356
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   Turpin JA, 2011, DRUG DELIV TRANSL RE, V1, P194, DOI 10.1007/s13346-011-0034-2
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Vacas-Cordoba E, 2014, INT J NANOMED, V9, P3591, DOI 10.2147/IJN.S62673
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   van Marle G, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-87
   Veazey RS, 2012, CURR HIV RES, V10, P79, DOI 10.2174/157016212799304715
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Veselinovic M, 2012, VIROLOGY, V432, P505, DOI 10.1016/j.virol.2012.06.025
   Vijayakumar S, 2012, CURR HIV RES, V10, P643, DOI 10.2174/157016212803901383                                                      
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Wong TW, 2014, EXPERT OPIN DRUG DEL, V11, P1419, DOI 10.1517/17425247.2014.924499
   Woodsong C, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18505
   Xiong SJ, 2013, ARCH TOXICOL, V87, P1075, DOI 10.1007/s00204-012-0938-8
   Xue WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090799
   Zhang LB, 1998, J SOC GYNECOL INVEST, V5, P72, DOI 10.1016/S1071-5576(97)00107-X                                                   
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
NR 173
TC 10
Z9 10
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JAN
PY 2015
VL 113
BP 33
EP 48
DI 10.1016/j.antiviral.2014.10.014
PG 16
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA AY9JL
UT WOS:000347866200006
PM 25446339
DA 2018-01-05
ER

PT J
AU Raveendran, S
   Chauhan, N
   Palaninathan, V
   Nagaoka, Y
   Yoshida, Y
   Maekawa, T
   Kumar, DS
AF Raveendran, Sreejith
   Chauhan, Neha
   Palaninathan, Vivekanandan
   Nagaoka, Yutaka
   Yoshida, Yasuhiko
   Maekawa, Toru
   Kumar, D. Sakthi
TI Extremophilic Polysaccharide for Biosynthesis and Passivation of Gold
   Nanoparticles and Photothermal Ablation of Cancer Cells
SO PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; SULFATED
   POLYSACCHARIDES; HALOMONAS-MAURA; SILVER NANOPARTICLES; ENVELOPED
   VIRUSES; INHIBITORS; BACTERIUM; THERAPY; BROWN
AB Extremophiles are the group of organisms that are far overlooked for exploring novel biomaterials in the field of material science and bionanotechnology. Extremophilic bacterial-sulfated exopolysaccharide, mauran (MR), is employed for the bioreduction and passivation of gold nanoparticles (AuNps) to enhance the biocompatibility of AuNps and used for photothermal ablation of cancer cells. Here, various concentrations of MR solution are tested for the reduction of HAuCl4 solution in the presence as well as in the absence of an external reducing agent, to produce mauran-gold nanoparticles (MRAu Nps). These biocompatible nanocomposites are treated with cancer cell lines under in vitro conditions and NIR irradiated for complete ablation. MRAu Nps-treated cancer cells on immediate exposure to infrared radiation from a femtosecond pulse laser of operating wavelength 800 nm are subjected to hyperthermia causing cell death. Biocompatible MR stabilization could fairly reduce the cytotoxicity caused by bare AuNps during biomedical applications. Application of a biocompatible polysaccharide from extremophilic bacterial origin for reduction and passivation of AuNps and used for a biomedical purpose is known to be first of its kind in bionanofusion studies.
C1 [Raveendran, Sreejith; Chauhan, Neha; Palaninathan, Vivekanandan; Nagaoka, Yutaka; Yoshida, Yasuhiko; Maekawa, Toru; Kumar, D. Sakthi] Toyo Univ, Grad Sch Interdisciplinary New Sci, Bionano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan.
RP Raveendran, S (reprint author), Toyo Univ, Grad Sch Interdisciplinary New Sci, Bionano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan.
EM sakthi@toyo.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan under the Monbukagakusho fellowship; programme of the the
   strategic research foundation at private universities [S1101017]
FX S.R., N.C., and V.P. acknowledge the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT), Japan for the financial support
   under the Monbukagakusho fellowship. Also, part of this study has been
   supported by a grant for the programme of the the strategic research
   foundation at private universities S1101017, organized by the MEXT,
   Japan since April 2012.
CR Arias S, 2003, EXTREMOPHILES, V7, P319, DOI 10.1007/s00792-003-0325-8
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   Chauhan N, 2011, J COLLOID INTERF SCI, V363, P42, DOI 10.1016/j.jcis.2011.07.018
   Chen J, 2005, NANO LETT, V5, P473, DOI 10.1021/nl047950t
   Costa LS, 2010, BIOMED PHARMACOTHER, V64, P21, DOI 10.1016/j.biopha.2009.03.005
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Gustafson S, 1997, GLYCOBIOLOGY, V7, P1209, DOI 10.1093/glycob/7.8.1209
   HASUI M, 1995, INT J BIOL MACROMOL, V17, P293, DOI 10.1016/0141-8130(95)98157-T                                                    
   Kemp MM, 2009, BIOMACROMOLECULES, V10, P589, DOI 10.1021/bm801266t
   Kirui DK, 2013, NANOMED-NANOTECHNOL, V9, P702, DOI 10.1016/j.nano.2012.11.009
   Li JL, 2010, IEEE J SEL TOP QUANT, V16, P989, DOI 10.1109/JSTQE.2009.2030340
   Llamas I, 2006, ANTON LEEUW INT J G, V89, P395, DOI 10.1007/s10482-005-9043-9
   Lu QH, 2007, J MATER SCI TECHNOL, V23, P189
   Malvern instruments Ltd, 2004, ZET NAN SER US MAN, V16.2
   Meatechkina N. M., 2010, APPL BIOCHEM MICROB, V46, P267
   Parish CR, 1999, CANCER RES, V59, P3433
   Park Y, 2011, IET NANOBIOTECHNOL, V5, P69, DOI 10.1049/iet-nbt.2010.0033
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Pomin VH, 2009, BIOPOLYMERS, V91, P601, DOI 10.1002/bip.21200
   Premkumar T, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-547
   Raveendran S, 2013, CARBOHYD POLYM, V92, P1225, DOI 10.1016/j.carbpol.2012.10.033
   Raveendran S, 2013, CARBOHYD POLYM, V91, P22, DOI 10.1016/j.carbpol.2012.07.079
   de Souza MCR, 2007, J APPL PHYCOL, V19, P153, DOI 10.1007/s10811-006-9121-z
   Soisuwan Suwicha, 2010, American Journal of Applied Sciences, V7, P1038, DOI 10.3844/ajassp.2010.1038.1042
   Tong L, 2007, ADV MATER, V19, P3136, DOI 10.1002/adma.200701974
   Toshihiko T., 2003, TRENDS GLYCOSCI GLYC, V15, P29
   Tsai H., 2003, SURF SCI, V537, P1
   Vigderman L, 2012, ADV MATER, V24, P4811, DOI 10.1002/adma.201201690
   Wijesekara I., 2012, CARBOHYD POLYM, V84, P14
   Wu XZ, 2006, W INDIAN MED J, V55, P270
   Zhang HL, 2003, J PHYS CHEM B, V107, P6087, DOI 10.1021/jp030297y
   Zhu W, 2006, PHYTOMEDICINE, V13, P695, DOI 10.1016/j.phymed.2005.11.003
NR 32
TC 5
Z9 5
U1 3
U2 16
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0934-0866
EI 1521-4117
J9 PART PART SYST CHAR
JI Part. Part. Syst. Charact.
PD JAN
PY 2015
VL 32
IS 1
BP 54
EP 64
DI 10.1002/ppsc.201400081
PG 11
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AY7FW
UT WOS:000347727600007
DA 2018-01-05
ER

PT J
AU Jimenez-Sanchez, G
   Pavot, V
   Chane-Haong, C
   Handke, N
   Terrat, C
   Gigmes, D
   Trimaille, T
   Verrier, B
AF Jimenez-Sanchez, Gloria
   Pavot, Vincent
   Chane-Haong, Christelle
   Handke, Nadege
   Terrat, Celine
   Gigmes, Didier
   Trimaille, Thomas
   Verrier, Bernard
TI Preparation and In Vitro Evaluation of Imiquimod Loaded
   Polylactide-based Micelles as Potential Vaccine Adjuvants
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE dendritic cell maturation; imiquimod; immunostimulation;
   polylactide-based micelles; vaccine
ID DENDRITIC CELL MATURATION; IMMUNE-RESPONSE MODIFIER; ANTIBODY-RESPONSES;
   PLA NANOPARTICLES; RECEPTOR LIGANDS; INNATE IMMUNITY; TLR LIGANDS;
   DELIVERY; MICROPARTICLES; PLATFORM
AB Activation of immune cells through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) or NOD-like receptors (NLRs), has been identified as a key issue in the development of new efficient vaccine adjuvants. We report here on the elaboration and immunostimulatory potential of polylactide (PLA)-based micelles core-loaded with imiquimod TLR7 ligand and able to be further surface-functionalized with antigenic protein (HIV-1 Gag p24) for antigen delivery purpose.
   Micelles prepared from poly(D,L-lactide)-b-poly(N-acryloxysuccinimide-co-N-vinylpyrrolidone) amphiphilic copolymer were incubated in the presence of imiquimod, leading to 1.2 wt% loading, and further conjugated to p24 antigen through reaction of p24 lysines and N-terminal amine with the N-succinimidyl pendant groups of the micelle corona. The impact of imiquimod encapsulation in the micelles on its immunostimulatory properties was investigated in vitro, by monitoring: (i) the NF-kappa B and mitogen-activated protein kinases (MAPK) pathways through experiments with RAW-Blue (TM) cells, a mouse macrophage cell line encoding an NF-kappa B/AP-1-inducible reporter construct; (ii) human dendritic cells (DCs) maturation markers by flow cytometry.
   RAW-Blue (TM) cells based experiments showed that imiquimod encapsulated in the micelles was much more efficient to activate the NF-kappa B and MAPK pathways than free imiquimod. Furthermore, encapsulated imiquimod was found to induce much higher maturation of DCs than the free analog. Finally, these immunostimulatory properties of the loaded imiquimod were shown to be conserved when the p24 antigen was coupled at the micelle surface.
   Taken together, these data regarding improved immunostimulatory efficiency suggest the strong potential of our micelle-based nano-system for vaccine delivery.
C1 [Jimenez-Sanchez, Gloria; Pavot, Vincent; Chane-Haong, Christelle; Terrat, Celine; Verrier, Bernard] Univ Lyon 1, CNRS, UMR Biol Tissulaire & Ingn Therapeut 5305, IBCP, F-69367 Lyon 07, France.
   [Handke, Nadege; Gigmes, Didier; Trimaille, Thomas] Aix Marseille Univ, CNRS, UMR 7273, Inst Chim Radicalaire, F-13397 Marseille 20, France.
RP Pavot, V (reprint author), Univ Lyon 1, CNRS, UMR Biol Tissulaire & Ingn Therapeut 5305, IBCP, 7 Passage Vercors, F-69367 Lyon 07, France.
EM vincent.pavot@gmail.com; thomas.trimaille@univ-amu.fr
FU ANR (French National Research Agency) through Euronanomed grant
   (iNanoDCs); ANR (French National Research Agency) through ANabio
   research projects; Fondation Recherche Medicale (FRM); FP7 European
   grant CUTHIVAC [241904]; FP7 European grant ADITEC [280873]
FX This work was funded by the ANR (French National Research Agency)
   through Euronanomed grant (iNanoDCs) and ANabio research projects, and
   Fondation Recherche Medicale (FRM) to Vincent Pavot. This work was also
   partially supported by grants from the two FP7 European grants CUTHIVAC
   (no 241904) and ADITEC (no 280873). The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alving CR, 2012, CURR OPIN IMMUNOL, V24, P310, DOI 10.1016/j.coi.2012.03.008
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bachelder EM, 2010, MOL PHARMACEUT, V7, P826, DOI 10.1021/mp900311x
   Beutner KR, 1998, J AM ACAD DERMATOL, V38, P230, DOI 10.1016/S0190-9622(98)70243-9
   Burns RP, 2000, CLIN IMMUNOL, V94, P13, DOI 10.1006/clim.1999.4804
   Eby JK, 2012, ACTA BIOMATER, V8, P3210, DOI 10.1016/j.actbio.2012.06.007
   Fievez V, 2009, EUR J PHARM BIOPHARM, V73, P16, DOI 10.1016/j.ejpb.2009.04.009
   Fox CB, 2013, EXPERT REV VACCINES, V12, P747, DOI 10.1586/14760584.2013.811188
   Gaucher G, 2009, BIOMACROMOLECULES, V10, P408, DOI 10.1021/bm801178f
   Geddes K, 2009, NAT REV DRUG DISCOV, V8, P465, DOI 10.1038/nrd2783
   Gregoriadis G, 1999, METHODS, V19, P156, DOI 10.1006/meth.1999.0841
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Hafner AM, 2013, ADV DRUG DELIVER REV, V65, P1386, DOI 10.1016/j.addr.2013.05.013
   Handke N, 2013, MACROMOL BIOSCI, V13, P1213, DOI 10.1002/mabi.201300102
   Handke N, 2013, COLLOID SURFACE B, V103, P298, DOI 10.1016/j.colsurfb.2012.10.032
   Heffernan MJ, 2009, ANN BIOMED ENG, V37, P1993, DOI 10.1007/s10439-009-9734-x
   Hong L, 2009, J POLYM SCI POL PHYS, V47, P207, DOI 10.1002/polb.21634
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010
   Kool M, 2012, J MED MICROBIOL, V61, P927, DOI 10.1099/jmm.0.038943-0
   Larange A, 2009, J LEUKOCYTE BIOL, V85, P673, DOI 10.1189/jlb.0808504
   Le Garrec D, 2004, J CONTROL RELEASE, V99, P83, DOI 10.1016/j.jconrel.2004.06.018
   Miller RL, 1999, INT J IMMUNOPHARMACO, V21, P1, DOI 10.1016/S0192-0561(98)00068-X
   Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Rice-Ficht AC, 2010, CURR OPIN MICROBIOL, V13, P106, DOI 10.1016/j.mib.2009.12.001
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Schon MP, 2007, BRIT J DERMATOL, V157, P8, DOI 10.1111/j.1365-2133.2007.08265.x
   Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615
   Tong J, 2010, MOL PHARMACEUT, V7, P984, DOI 10.1021/mp100102p
   Wischke C, 2012, J CONTROL RELEASE, V164, P299, DOI 10.1016/j.jconrel.2012.06.034
   Wischke C, 2009, INT J PHARMACEUT, V365, P61, DOI 10.1016/j.ijpharm.2008.08.039
   Zhu KJ, 2009, INT IMMUNOPHARMACOL, V9, P412, DOI 10.1016/j.intimp.2008.12.017
NR 36
TC 12
Z9 12
U1 3
U2 29
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JAN
PY 2015
VL 32
IS 1
BP 311
EP 320
DI 10.1007/s11095-014-1465-5
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AY2HF
UT WOS:000347408800023
PM 25248333
DA 2018-01-05
ER

PT J
AU Imperiale, JC
   Nejamkin, P
   del Sole, MJ
   Lanusse, CE
   Sosnik, A
AF Imperiale, Julieta C.
   Nejamkin, Pablo
   del Sole, Maria J.
   Lanusse, Carlos E.
   Sosnik, Alejandro
TI Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery
   System leads to a dramatic improvement of the oral pharmacokinetics in
   dogs
SO BIOMATERIALS
LA English
DT Article
DE HIV infection; Protease inhibitors; Indinavir free base; Pure drug
   Nanoparticle-in-Microparticle; Delivery System (NiMDS); Mucoadhesion;
   Oral bioavailability
ID HIV-1 PROTEASE; P-GLYCOPROTEIN; DRUG-DELIVERY; PHYSICOCHEMICAL
   CHARACTERIZATION; INTRACELLULAR DELIVERY; MULTIDRUG TRANSPORTER;
   INDINAVIR; RELEASE; ALGINATE; BEADS
AB With the advent of the Highly Active Antiretroviral Therapy, the morbidity and the mortality associated to HIV have been considerably reduced. However, 35-40 million people bear the infection worldwide. One of the main causes of therapeutic failure is the frequent administration of several antiretrovirals that results in low patient compliance and treatment cessation. In this work, we have developed an innovative Nanoparticle-in-Microparticle Delivery System (NiMDS) comprised of pure drug nanocrystals of the potent protease inhibitor indinavir free base (used as poorly water-soluble model protease inhibitor) produced by nanoprecipitation that were encapsulated within mucoadhesive polymeric microparticles. Pure drug nanoparticles and microparticles were thoroughly characterized by diverse complementary techniques. NiMDSs displayed an encapsulation efficiency of approximately 100% and a drug loading capacity of up to 43% w/w. In addition, mucoadhesiveness assays ex vivo conducted with bovine gut showed that film-coated microparticles were retained for more than 6 h. Finally, pharmacokinetics studies in mongrel dogs showed a dramatic 47- and 95-fold increase of the drug oral bioavailability and half-life, respectively, with respect to the free unprocessed drug. These results support the outstanding performance of this platform to reduce the dose and the frequency of administration of protease inhibitors, a crucial step to overcome the current patient-incompliant therapy. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Imperiale, Julieta C.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Buenos Aires, DF, Argentina.
   [Nejamkin, Pablo; del Sole, Maria J.; Lanusse, Carlos E.] Natl Univ Cent Buenos Aires, Fac Vet Sci, Small Anim Teaching Hosp, Tandil, Argentina.
   [Lanusse, Carlos E.] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, Grp Pharmaceut Nanomat Sci, Haifa, Israel.
RP Sosnik, A (reprint author), Technion Israel Inst Technol, Dept Mat Sci & Engn, Grp Pharmaceut Nanomat Sci, Haifa, Israel.
EM alesosnik@gmail.com
FU National Agency for the promotion of Science and Technology (ANPCyT,
   Argentina); Marie Curie Reintegration Grant "NANOTAR" (European
   Commission) [PCIG13-GA-2013-612765]
FX J.C.I. thanks a doctoral scholarship of the National Agency for the
   promotion of Science and Technology (ANPCyT, Argentina). AS thanks the
   support of the Marie Curie Reintegration Grant "NANOTAR"
   (PCIG13-GA-2013-612765, European Commission). Authors thank Prof. Paulo
   Rosa (University of Campinas, Brazil) for SEM analysis of unprocessed
   IDV free base, Dr. Daniel Vega (CNEA, Argentina) for TGA and powder XRD
   analysis and Dr. Cristian Hocht for technical support in the
   pharmacokinetics analysis. The authors report no declarations of
   interest.
CR Andrade F, 2011, INT J CARBOHYDR CHEM, V2011
   Andrews L, 2000, INFECT DIS CLIN N AM, V14, P901, DOI 10.1016/S0891-5520(05)70139-2
   Bajpai SK, 2004, REACT FUNCT POLYM, V59, P129, DOI 10.1016/j.reactfunctpolym.2004.01.002
   Bastakoti BP, 2011, COLLOID SURFACE B, V88, P734, DOI 10.1016/j.colsurfb.2011.08.009
   Boyd M, 2007, EXPERT OPIN PHARMACO, V8, P957, DOI 10.1514/14656566.8.7.957
   Bramuglia GF, 2009, J PHARM SCI-US, V98, P327, DOI 10.1002/jps.21411
   Burger D, 2003, J ANTIMICROB CHEMOTH, V51, P1231, DOI 10.1093/jac/dkg198
   Cahn P, 2013, 14 EUR AIDS C EUR AI
   Chiappetta DA, 2009, AAPS PHARMSCITECH, V10, P1, DOI 10.1208/s12249-008-9168-z
   das Neves J, 2011, EXPERT OPIN DRUG DEL, V8, P1085, DOI 10.1517/17425247.2011.586334
   Davidovich-Pinhas M, 2010, EXPERT OPIN DRUG DEL, V7, P259, DOI 10.1517/17425240903473134
   ICH Topic Q3C (R4), IMP GUID RES SOLV EU
   da Silva RMF, 2009, J THERM ANAL CALORIM, V95, P965, DOI 10.1007/s10973-008-8912-7
   Ford J, 2004, J ANTIMICROB CHEMOTH, V54, P982, DOI 10.1093/jac/dkh487
   Glisoni RJ, 2014, MACROMOL BI IN PRESS
   Glisoni RJ, 2013, CARBOHYD POLYM, V93, P449, DOI 10.1016/j.carbpol.2012.12.033
   Glisoni RJ, 2010, NEW J CHEM, V34, P2047, DOI 10.1039/c0nj00061b
   Hochman JH, 2000, J PHARMACOL EXP THER, V292, P310
   Hung SF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100321
   Imperiale JC, 2013, DRUG DEV IND PHARM
   Imperiale JC, 2013, J BIOMATER TISS ENG, V3, P22, DOI 10.1166/jbt.2013.1064
   Kathleen D, 2006, INT J PHARM, V314, P72, DOI 10.1016/j.ijpharm.2006.01.041
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423
   Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x                                                               
   LIN JH, 1995, DRUG METAB DISPOS, V23, P730
   McMillan CJ, 2008, CAN J VET RES, V72, P325
   Muller RH, 2011, EUR J PHARM BIOPHARM, V78, P1, DOI 10.1016/j.ejpb.2011.01.007
   NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274
   Nithitanakool S, 2013, MOLECULES, V18, P6504, DOI 10.3390/molecules18066504
   Pasparakis G, 2006, INT J PHARM, V323, P34, DOI 10.1016/j.ijpharm.2006.05.054
   Phillips DJ, 2012, J PHARM PHARMACOL, V64, P1549, DOI 10.1111/j.2042-7158.2012.01523.x
   Profit L, 1999, AIDS, V13, P1623, DOI 10.1097/00002030-199909100-00004                                                
   Puga AM, 2012, ACTA BIOMATER, V8, P1507, DOI 10.1016/j.actbio.2011.12.020
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rittweger M, 2007, CLIN PHARMACOKINET, V46, P739, DOI 10.2165/00003088-200746090-00002                                                
   Sankalia MG, 2007, EUR J PHARM BIOPHARM, V65, P215, DOI 10.1016/j.ejpb.2006.07.014
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sosnik A., PROG POLYM IN PRESS
   Sosnik A, 2014, ISRN PHARM, V2014, DOI DOI 10.1155/2014/926157
   Sosnik A, 2014, ADV DRUG DELIVER REV, V73, P140, DOI 10.1016/j.addr.2014.05.004
   Sosnik A, 2012, EXPERT OPIN DRUG DEL, V9, P303, DOI 10.1517/17425247.2012.655268
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P3157
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Toteva MM, 2008, J PHARM SCI-US, V97, P3810, DOI 10.1002/jps.21259
   Global, 2014, AIDS RESP PROGR REP
   US Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection, ANT DRUGS US TREATM
   The United States Pharmacopeia Convention, 2008, 33701 USP
   Wu CY, 2005, PHARM RES, V22, P11, DOI 10.1007/s11095-004-9004-4
NR 51
TC 9
Z9 10
U1 3
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2015
VL 37
BP 383
EP 394
DI 10.1016/j.biomaterials.2014.10.026
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AW8WW
UT WOS:000346541100036
PM 25453966
DA 2018-01-05
ER

PT J
AU Alam, MA
   Al-Jenoobi, FI
   Al-Mohizea, AM
   Ali, R
AF Alam, Mohd A.
   Al-Jenoobi, Fahad I.
   Al-Mohizea, Abdullah M.
   Ali, Raisuddin
TI Understanding and Managing Oral Bioavailability: Physiological Concepts
   and Patents
SO RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
LA English
DT Review
DE Bioavailability; cytochrome P-450; gastrointestinal tract;
   P-glycoprotein; multidrug resistance; prodrug
ID MESOPOROUS SILICA NANOPARTICLES; OVERCOME MULTIDRUG-RESISTANCE;
   GLYCOPROTEIN-MEDIATED EFFLUX; SOLID LIPID NANOPARTICLES; HIV PROTEASE
   INHIBITOR; BREAST-CANCER CELLS; P-GLYCOPROTEIN; IN-VITRO; DISINTEGRATING
   TABLETS; DRUG-INTERACTIONS
AB Oral delivery of poorly bioavailable therapeuticals is challenging. The challenges are more serious when physiological factors of gut such as cytochrome P450, P-glycoprotein, permeability, pH triggered precipitation and degradation are responsible for poor bioavailability. P-Glycoprotein mediated multidrug resistance is on high agenda for anti-cancer drugs. The present article compiled different methodologies used to curb these challenges of bioavailability. The concepts of poor bioavailability are illustrated along with possible management. Numerous relevant patents for bioavailability enhancement are also highlighted. Though, there is no universal approach for bioavailability enhancement, the drug related challenges are managed by altering its physicochemical characteristics or employing formulation technology, while the effects of physiological factors are minimized by using efflux transport inhibitor or cytochrome P-450 inhibitor or prodrug or through formulation technologies (enteric coating or microenvironment of pH etc.).
C1 [Alam, Mohd A.; Al-Jenoobi, Fahad I.; Al-Mohizea, Abdullah M.] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia.
   [Ali, Raisuddin] King Saud Univ, Coll Pharm, Res Ctr, Riyadh 11451, Saudi Arabia.
RP Alam, MA (reprint author), King Saud Univ, Coll Pharm, Dept Pharmaceut, POB 2457, Riyadh 11451, Saudi Arabia.
EM afealam@rediffmail.com
FU College of Pharmacy Research Center; King Saud University
FX The authors acknowledge the College of Pharmacy Research Center and the
   Deanship of Scientific Research in King Saud University for financial
   and logistic support.
CR Agarwal S, 2008, INT J PHARMACEUT, V359, P7, DOI 10.1016/j.ijpharm.2008.03.031
   Alam MA, 2013, DRUG DISCOV TODAY, V18, P936, DOI 10.1016/j.drudis.2013.05.007
   Alam MA, 2012, EXPERT OPIN DRUG DEL, V9, P1419, DOI 10.1517/17425247.2012.732064
   Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Alhnan MA, 2011, INT J PHARMACEUT, V416, P55, DOI 10.1016/j.ijpharm.2011.05.079
   Anand BS, 2004, J PHARMACOL EXP THER, V311, P659, DOI 10.1124/jpet.104.069997
   Babusis D, 2013, MOL PHARMACEUT, V10, P459, DOI 10.1021/mp3002045
   Bibi Z, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-27
   Albert KS, 2006, Chronotherapeutic diltiazem formulations and the administration thereof, Patent No. [US 7,108,866, 7108866]
   Bromberg L, 2008, J CONTROL RELEASE, V128, P99, DOI 10.1016/j.jconrel.2008.01.018
   Charman WN, 1997, J PHARM SCI-US, V86, P269, DOI 10.1021/js960085v
   Chen L, 2012, DRUG DISCOV TODAY, V17, P343, DOI 10.1016/j.drudis.2011.11.003
   Clarke A, 2003, J NEURAL TRANSM, V110, P1241, DOI 10.1007/s00702-003-0036-4
   CLAYTON JP, 1974, ANTIMICROB AGENTS CH, V5, P670, DOI 10.1128/AAC.5.6.670                                                             
   Dahmani FZ, 2012, EUR J PHARM SCI, V47, P179, DOI 10.1016/j.ejps.2012.05.015
   Dantzig AH, 2003, ADV DRUG DELIVER REV, V55, P133, DOI 10.1016/S0169-409X(02)00175-8
   Desai P. P., 2012, DRUG DISCOV TODAY TE, V9, pe71
   Dong XW, 2010, NANOMEDICINE-UK, V5, P597, DOI [10.2217/nnm.10.35, 10.2217/NNM.10.35]
   Dresser GK, 2003, EUR J CLIN INVEST, V33, P10, DOI 10.1046/j.1365-2362.33.s2.2.x                                                   
   EHRNEBO M, 1979, J PHARMACOKINET BIOP, V7, P429, DOI 10.1007/BF01062386
   Evans AM, 2000, THER DRUG MONIT, V22, P131, DOI 10.1097/00007691-200002000-00028
   Fenner KS, 2009, CLIN PHARMACOL THER, V85, P173, DOI 10.1038/clpt.2008.195
   Fernandez HH, 2007, PHARMACOTHERAPY, V27, p174S, DOI 10.1592/phco.27.12part2.174S
   Fernandez HH, 2007, CLIN NEUROPHARMACOL, V30, P150, DOI 10.1097/01.WNF.0000240956.49315.BE
   Fu YR, 2004, CRIT REV THER DRUG, V21, P433, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i6.10
   GAFITANU E, 1991, Revista Medico-Chirurgicala Societatii di Medici si Naturalisti din Iasi, V95, P127
   GARCEAU Y, 1978, J PHARM SCI, V67, P1360, DOI 10.1002/jps.2600671007
   He K, 2003, Compositions containing Bergamottin for increasing the oral bioavailability of pharmaceutical agents, Patent No. [6509371, US6509371]
   Hendrikx JJMA, 2013, INT J CANCER, V132, P2439, DOI 10.1002/ijc.27912
   Horn JR, 2005, ALIMENT PHARM THERAP, V22, P20, DOI 10.1111/j.1365-2036.2005.02714.x
   Huang IP, 2011, MOL CANCER THER, V10, P761, DOI 10.1158/1535-7163.MCT-10-0884
   Kin-Kai DH, 2002, Patent No. [US6451815, 6451815]
   Jabr-Milane LS, 2008, CANCER TREAT REV, V34, P592, DOI 10.1016/j.ctrv.2008.04.003
   Jibodh RA, 2013, EUR J PHARMACOL, V717, P40, DOI 10.1016/j.ejphar.2013.02.058
   KAO CH, 2008, NUCL MED BIOL, V35, P35
   Katragadda S, 2006, J OCUL PHARMACOL TH, V22, P110, DOI 10.1089/jop.2006.22.110
   Kostewicz ES, 2004, J PHARM PHARMACOL, V56, P43, DOI 10.1211/0022357022511
   Li B, 2012, INT J NANOMED, V7, P187, DOI 10.2147/IJN.S27864
   Li LY, 2003, J PHARM PHARMACOL, V55, P707, DOI 10.1211/0022357021125
   Li PY, 2010, BIOMACROMOLECULES, V11, P2576, DOI 10.1021/bm1005195
   Liang L, 2006, United States patent, Patent No. [US 7022337, 7022337]
   Lin JH, 2003, ADV DRUG DELIVER REV, V55, P53, DOI 10.1016/S0169-409X(02)00171-0                                                   
   LIN JH, 1995, DRUG METAB DISPOS, V23, P730
   Lu CT, 2012, CLIN DRUG INVEST, V32, P333, DOI 10.2165/11599910-000000000-00000
   Ma P, 2009, J BIOMED NANOTECHNOL, V5, P151, DOI 10.1166/jbn.2009.1021
   Mazzaferro S, 2013, DRUG DISCOV TODAY, V18, P99, DOI 10.1016/j.drudis.2012.08.007
   MELANDER A, 1983, CLIN PHARMACOKINET, V8, P286, DOI 10.2165/00003088-198308040-00002                                                
   Menning MM, 2013, MOL PHARMACEUT, V10, P4005, DOI 10.1021/mp400286s
   Mo R, 2011, BIOMATERIALS, V32, P4609, DOI 10.1016/j.biomaterials.2011.03.005
   NIELSEN LS, 1992, ACTA PHARM NORDICA, V4, P43
   nigene Laboratories Inc, 2012, [No title captured], Patent No. [US8093207, 8093207]
   Ninomiya M, 2011, J MED CHEM, V54, P1529, DOI 10.1021/jm1015457
   Norbeck D, 2000, Method for improving pharmacokinetics, Patent No. [US6037157, 6037157]
   Poston KL, 2007, EXPERT OPIN PHARMACO, V8, P2615, DOI 10.1517/14656566.8.15.2615
   Roger E, 2010, EUR J PHARM SCI, V40, P422, DOI 10.1016/j.ejps.2010.04.015
   Sano S, 2011, INT J PHARMACEUT, V416, P252, DOI 10.1016/j.ijpharm.2011.07.001
   Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2
   Seager H, 1998, J PHARM PHARMACOL, V50, P375, DOI 10.1111/j.2042-7158.1998.tb06876.x                                              
   Sheha M, 2012, ARCH PHARM RES, V35, P523, DOI 10.1007/s12272-012-0316-3
   Shen JN, 2011, NANOSCALE, V3, P4314, DOI 10.1039/c1nr10580a
   Stella VJ, 2007, ADV DRUG DELIVER REV, V59, P677, DOI 10.1016/j.addr.2007.05.013
   Sugimoto M, 2006, CHEM PHARM BULL, V54, P175, DOI 10.1248/cpb.54.175
   Sugimoto M, 2001, PHARM DEV TECHNOL, V6, P487, DOI 10.1081/PDT-120000287                                                           
   Unigene Laboratories Inc, 1999, [No title captured], Patent No. [5,912,014, 5912014, US5912014]
   VADLAPUDI AD, 2010, INT J PHARMACEUT, V434, P315
   Varma MVS, 2003, PHARMACOL RES, V48, P347, DOI 10.1016/S1043-6618(03)00158-0
   Wacher VJ, 1998, J PHARM SCI, V87, P1322, DOI 10.1021/js980082d
   Wang D, 2013, MOL PHARMACEUT, V10, P1465, DOI 10.1021/mp400022h
   Wang JL, 2012, BIOMATERIALS, V33, P6877, DOI 10.1016/j.biomaterials.2012.06.019
   WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319
   Xu Y, 2013, CURR MED CHEM, V20, P2118, DOI 10.2174/0929867311320160005                                                     
   Yan YD, 2010, MOL PHARMACEUT, V7, P2132, DOI 10.1021/mp100166c
   Zhang P, 2011, BIOMATERIALS, V32, P5524, DOI 10.1016/j.biomaterials.2011.04.022
   Zhang Q, 2013, CURR PHARM DESIGN, V19, P6655
   Zhao YX, 2011, PHARMAZIE, V66, P130, DOI 10.1691/ph.2011.0251
   ANTTILA M, 2012, Patent No. 8236861
   HILL WW, 1977, Patent No. 4058621
   ANTONY B, 2013, Patent No. 8329233
   WACHER VJ, 1999, Patent No. 5962522
   MAILLAND F, 2010, Patent No. 7771746
   EDGAR BE, 1993, Patent No. 5229116
   Gullapalli R.P., 2001, US Patent, Patent No. [6,251,426 B1, 6251426]
   JOHNSON L, 2009, Patent No. 7452872
   DAOUD AH, 1999, Patent No. 6001393
   ERION M D, 2014, Patent No. 8664195
   PAUL S M, 2002, Patent No. 6488968
   DONG LC, 2013, Patent No. 8343978
   Wacher VJ, 2001, Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds. US Pat, Patent No. [6180666B1, 6180666]
   VANBUREN CT, 2004, Patent No. 6706691
   CHENG YC, 2011, Patent No. 7875650
   AMORY JK, 2006, Patent No. 7138389
   KRAMER K, 2005, Patent No. 6887894
   PAUL S M, 2002, Patent No. 6375994
   SCAIFE MC, 2010, Patent No. 7714006
   ROBERTS A, 2006, Patent No. 7091236
   KROIN JS, 2000, Patent No. 6130219
   ROSER BJ, 2003, Patent No. 6517860
   Antony B, 2014, Composition to enhance the bioavailability of curcumin, Patent No. [US20140093594, 20140093594]
   ERION M D, 2011, Patent No. 8080536
   HUMPHREY MJ, 2003, Patent No. 6579898
   BREUER E, 2003, Patent No. 6541454
   TZANNIS S, 2012, Patent No. 8252328
   URATA Y, 2007, Patent No. 7276536
   PATEL RB, 1997, Patent No. 5616593
   LIAO TP, 2008, Patent No. 7314641
   ULLAH I, 1999, Patent No. 5880106
   MEHANSHO H, 1992, Patent No. 5118513
   BURNSIDE B, 2005, Patent No. 6890918
   BORTLIK K, 2009, Patent No. 7588781
   LEE FYF, 2005, Patent No. 6936628
   New R.R.C., 1998, [No title captured], Patent No. [US5853748, 5853748]
   BENET LZ, 2000, Patent No. 6028054
   BANDYOPADHYAY R, 2008, Patent No. 40387
   JOHNSON L, 2008, Patent No. 7625884
   CAMENISCH GP, 2010, Patent No. 7709532
   SMITH CD, 2001, Patent No. 6248752
   BRODER S, 2006, Patent No. 7041640
   KOZAK A, 2003, Patent No. 6605638
   WATKINS PB, 1999, Patent No. 5856189
   SNOECK HJM, 2003, Patent No. 6544979
   EEK AT, 1997, Patent No. 5599794
   ZHANG J, 2012, Patent No. 8119602
   NAICKER S A, 2008, Patent No. 7429562
   Benet L.Z., 2000, US Patent, Patent No. [6,121,234, 6121234]
   JONCKERS THM, 2013, Patent No. 8350048
   MOSKOWITZ MA, 2004, Patent No. 6818669
   SNUTCH TP, 2013, Patent No. 8362021
   PERSSON L, 1998, Patent No. 5760022
   BENET L, 1996, Patent No. 5567592
   NAICKER S A, 2006, Patent No. 7060672
NR 130
TC 2
Z9 2
U1 2
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-8928
EI 2212-3970
J9 RECENT PAT ANTI-CANC
JI Recent Patents Anti-Canc. Drug Discov.
PY 2015
VL 10
IS 1
BP 87
EP 96
PG 10
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA AW7BN
UT WOS:000346419500005
PM 25230073
DA 2018-01-05
ER

PT J
AU Patel, KP
   Pathak, CJ
   Patel, RP
AF Patel, Kaushal P.
   Pathak, Chirayu J.
   Patel, Rakesh P.
TI FORMULATION, DEVELOPMENT AND IN-VITRO EVALUATION OF LOPINAVIR LOADED
   SOLID LIPID NANOPARTICLES
SO INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH
LA English
DT Article
DE Lopinavir (LPV); Solid Lipid Nanoparticles (SLNs); Encapsulated;
   Homogeneous Dispersion; Crystalline Behaviour
AB Lopinavir (LPV) is potent and poorly bioavailable molecule which is frequently administered protease inhibitors in the treatment of the HIV. Solid Lipid Nanoparticles (SLNs) of LPV were prepared using High Speed Homogenization. LPV were successfully encapsulated in the mixture of Glyceryl Behenate and Glyceryl monostearate. Poloxamer 188 was used as a surfactant for the preparation of the SLNs. Formulation composition and process parameter were optimized to get the desired quality of the SLNs. Formulation PF5 have mean particle size 185 +/- 5 nm with Polydispersity index 0.11 +/- 0.01 which indicates very narrow particle size distribution. % Entrapment efficiency was 86.2 +/- 1.5. Slow drug release profile indicates the homogeneous dispersion of LPV in lipid matrix. SLNs have spherical shape and smooth surface which has been confirmed using SEM analysis. XRPD spectra show the reduction in crystalline behaviour of the drug and the lipid after formation of the SLNs. There was no significant change in the mean particle size and Polydispersity index after 6 month storage at 25 degrees C/60% RH.
C1 [Patel, Kaushal P.; Pathak, Chirayu J.; Patel, Rakesh P.] Ganpat Univ, Dept Pharmaceut & Pharmaceut Technol, SK Patel Coll Pharmaceut Educ & Res, Mehsana 384012, Gujarat, India.
RP Patel, KP (reprint author), Ganpat Univ, Dept Pharmaceut & Pharmaceut Technol, SK Patel Coll Pharmaceut Educ & Res, Mehsana 384012, Gujarat, India.
EM kaushalpatel_11@yahoo.co.in
CR Agarwal S, 2007, INT J PHARM, V339, P139, DOI 10.1016/j.ijpharm.2007.02.036
   Alex A, 2011, THER DELIV, V2, P25, DOI 10.4155/TDE.10.96
   Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Araujo J, 2010, INT J PHARMACEUT, V393, P167, DOI 10.1016/j.ijpharm.2010.03.034
   Cai S, 2011, ADV DRUG DELIVER REV, V63, P901, DOI 10.1016/j.addr.2011.05.017
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004                                                
   Das S, 2011, AAPS PHARMSCITECH, V12, P62, DOI 10.1208/s12249-010-9563-0
   Flexner C, 2010, CLIN INFECT DIS, V50, P1041, DOI 10.1086/651118
   Holm R, 2004, INT J PHARMACEUT, V272, P189, DOI 10.1016/j.ijpharm.2003.12.017
   Hsu A, 2003, ANTIMICROB AGENTS CH, V47, P350, DOI 10.1128/AAC.47.1.350-359.2003
   Hu LD, 2004, J PHARM PHARMACOL, V56, P1527, DOI 10.1211/0022357044959
   Kumar GN, 2004, PHARM RES, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d                                              
   Maartens G, 2009, ANTIVIR THER, V14, P1039, DOI 10.3851/IMP1455
   Mascolini Z, 2010, 11 INT WORKSH CLIN P
   Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 
   Muller RH, 2006, INT J PHARM, V317, P82, DOI 10.1016/j.ijpharm.2006.02.045
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Paliwal R, 2009, NANOMED-NANOTECHNOL, V5, P184, DOI 10.1016/j.nano.2008.08.003
   Patravale B, 2012, DRUG DISCOV TODAY, V9, P87
   Pranjali G, 2012, INT J PHARM INVENTIO, V2, P27
   Prot M, 2006, ANTIMICROB AGENTS CH, V50, P3998, DOI 10.1128/ACC.00625-06
   Radtke M., 2005, PHARM TECHNOLOGY EUR, V17, P45
   Shafran SD, 2005, HIV MED, V6, P421, DOI 10.1111/j.1468-1293.2005.00328.x                                                
   Tippabhotla SK, 2008, INT J CLIN PHARM TH, V46, P204
   Youm I, 2012, COLLOID SURFACE B, V94, P133, DOI 10.1016/j.colsurfb.2012.01.027
NR 25
TC 0
Z9 0
U1 0
U2 0
PU INT JOURNAL PHARMACEUTICAL SCIENCES & RESEARCH
PI HARYANA
PA 1117, SECTOR 12 A, PANCHKULA, HARYANA, 00000, INDIA
SN 0975-8232
J9 INT J PHARM SCI RES
JI Int. J. Pharm.l Sci. Res.
PD JAN
PY 2015
VL 6
IS 1
BP 442
EP 452
DI 10.13040/IJPSR.0975-8232.6(1).442-52
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V29KI
UT WOS:000215493500056
DA 2018-01-05
ER

PT J
AU Roma, MI
   Hocht, C
   Chiappetta, DA
   Di Gennaro, SS
   Minoia, JM
   Bramuglia, GF
   Rubio, MC
   Sosnik, A
   Peroni, RN
AF Roma, Martin I.
   Hocht, Christian
   Chiappetta, Diego A.
   Di Gennaro, Stefania S.
   Minoia, Juan M.
   Bramuglia, Guillermo F.
   Rubio, Modesto C.
   Sosnik, Alejandro
   Peroni, Roxana N.
TI Tetronic (R) 904-containing polymeric micelles overcome the
   overexpression of ABCG2 in the blood-brain barrier of rats and boost the
   penetration of the antiretroviral efavirenz into the CNS
SO NANOMEDICINE
LA English
DT Article
DE ABCG2 pump inhibition; CNS; drug-loaded poly(ethylene oxide)-b-poly(
   propylene oxide) polymeric micelles; efavirenz; HIV
ID IMMUNODEFICIENCY-VIRUS-INFECTION; P-GLYCOPROTEIN; PREGNANT-WOMEN; DRUG
   EFFLUX; FOLLOW-UP; HIV; PHARMACOKINETICS; HIV/AIDS; CHILDREN; THERAPY
AB To assess the involvement of ABCG2 in the pharmacokinetics of efavirenz in the blood-brain barrier (BBB) and investigate a nanotechnology strategy to overcome its overexpression under a model of chronic oral administration. Materials & methods: A model of chronic efavirenz (EFV) administration was established in male Sprague-Dawley rats treated with a daily oral dose over 5 days. Then, different treatments were conducted and drug concentrations in plasma and brain measured. Results: Chronic treatment with oral EFV led to the overexpression of ABCG2 in the BBB that was reverted after a brief washout period. Moreover, gefitinib and the polymeric amphiphile Tetronic (R) 904 significantly inhibited the activity of the pump and potentiated the accumulation of EFV in CNS. The same effect was observed when the drug was administered within mixed micelles containing Tetronic T904 as the main component. Conclusion: Tetronic 904-containing polymeric micelles overcame the overexpression of ABCG2 in the BBB caused by chronic administration of EFV then boosting its penetration into the CNS.
C1 [Roma, Martin I.; Di Gennaro, Stefania S.; Minoia, Juan M.; Rubio, Modesto C.; Peroni, Roxana N.] Univ Buenos Aires, Pharmacol Res Inst, Buenos Aires, DF, Argentina.
   [Hocht, Christian; Chiappetta, Diego A.; Di Gennaro, Stefania S.; Minoia, Juan M.; Bramuglia, Guillermo F.; Rubio, Modesto C.; Peroni, Roxana N.] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
   [Hocht, Christian; Di Gennaro, Stefania S.; Minoia, Juan M.; Bramuglia, Guillermo F.; Rubio, Modesto C.; Peroni, Roxana N.] Univ Buenos Aires, Dept Pharmacol, Fac Pharm & Biochem, Buenos Aires, DF, Argentina.
   [Chiappetta, Diego A.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Lab Pharmaceut Nanomat Sci, Dept Mat Sci & Engn, Haifa, Israel.
RP Sosnik, A (reprint author), Technion Israel Inst Technol, Lab Pharmaceut Nanomat Sci, Dept Mat Sci & Engn, Haifa, Israel.
EM sosnik@tx.technion.ac.il; rperoni@ffyb.uba.ar
OI Minoia, Juan Mauricio/0000-0002-1675-2675
FU CONICET [PIP0220, PIP0499]
FX This work was supported by CONICET (grant PIP0220 and PIP0499). The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   Alvarez-Lorenzo C, 2010, NANOMEDICINE-UK, V5, P1371, DOI [10.2217/nnm.10.53, 10.2217/NNM.10.53]
   Balani SK, 1999, DRUG METAB DISPOS, V27, P41
   Barrueco N, 2005, Farm Hosp, V29, P367
   BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x                                              
   Caswell RJ, 2011, INT J STD AIDS, V22, P11, DOI 10.1258/ijsa.2009.009184
   Cespedes MS, 2006, DRUG SAFETY, V29, P865, DOI 10.2165/00002018-200629100-00004
   Chan GNY, 2013, ANTIMICROB AGENTS CH, V57, P4481, DOI 10.1128/AAC.00486-13
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, CURR HIV RES, V8, P223, DOI 10.2174/157016210791111142
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   Cuestas ML, 2011, MOL PHARMACEUT, V8, P1152, DOI 10.1021/mp2000132
   Cysique LA, 2009, NEUROPSYCHOL REV, V19, P169, DOI 10.1007/s11065-009-9092-3
   Ene L, 2011, J Med Life, V4, P432
   Fraaij PLA, 2004, THER DRUG MONIT, V26, P122, DOI 10.1097/00007691-200404000-00006
   Gao JZ, 2007, J PHARM SCI-US, V96, P2970, DOI 10.1002/jps.20962
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Lee CA, 2015, DRUG METAB DISPOS, V43, P490, DOI 10.1124/dmd.114.062174
   Legido-Quigley H, 2013, TROP MED INT HEALTH, V18, P199, DOI 10.1111/tmi.12029
   Letendre Scott, 2011, Top Antivir Med, V19, P137
   Lopez-Cortes LF, 2007, THER DRUG MONIT, V29, P171, DOI 10.1097/FTD.0b013e31803bb54e                                                    
   Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006
   Mallapragada SK, 2015, NANOMED-NANOTECHNOL, V11, P715, DOI 10.1016/j.nano.2014.12.013
   Miller DS, 2000, MOL PHARMACOL, V58, P1357
   Nicastri E, 2012, CURR HIV RES, V10, P606, DOI 10.2174/157016212803306014                                                      
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Watson C, 2007, RAT BRAIN STEREOTAXI
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Rabel SR, 2001, AAPS PHARMSCI, V3
   Rahman AF, 2014, GEFITINIB, V39, P239, DOI [10.1016/B978-0-12-800173-8.00005-2, DOI 10.1016/B978-0-12-800173-8.00005-2]
   Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868
   Scherpbier HJ, 2007, PEDIATRICS, V119, pE705, DOI 10.1542/peds.2006-1367
   Shen SS, 2010, REV NEUROSCIENCE, V21, P29
   Sosnik A, 2013, ADV DRUG DELIVER REV, V65, P1828, DOI 10.1016/j.addr.2013.09.002
   Srivalli KMR, 2012, BRAZ J PHARM SCI, V48, P353, DOI 10.1590/S1984-82502012000300002
   Tweedie D, 2013, CLIN PHARMACOL THER, V94, P113, DOI 10.1038/clpt.2013.77
   van Rooy I, 2011, PHARM RES-DORDR, V28, P456, DOI 10.1007/s11095-010-0291-7
   Vivithanaporn P, 2010, NEUROLOGY, V75, P1150, DOI 10.1212/WNL.0b013e3181f4d5bb
   von Hentig N, 2006, EUR J MED RES, V11, P377
   Ward BA, 2003, J PHARMACOL EXP THER, V306, P287, DOI 10.1124/jpet.103.049601
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
NR 46
TC 3
Z9 3
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2015
VL 10
IS 15
BP 2325
EP 2337
DI 10.2217/NNM.15.77
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA CP9NZ
UT WOS:000360222600004
PM 26252052
DA 2018-01-05
ER

PT S
AU Jallouk, AP
   Palekar, RU
   Pan, H
   Schlesinger, PH
   Wickline, SA
AF Jallouk, Andrew P.
   Palekar, Rohun U.
   Pan, Hua
   Schlesinger, Paul H.
   Wickline, Samuel A.
BE Donev, R
TI Modifications of Natural Peptides for Nanoparticle and Drug Design
SO PROTEIN AND PEPTIDE NANOPARTICLES FOR DRUG DELIVERY
SE Advances in Protein Chemistry and Structural Biology
LA English
DT Review; Book Chapter
ID CELL-PENETRATING PEPTIDES; NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS;
   MELITTIN-DERIVED PEPTIDES; C-TYPE LECTIN; TAT PEPTIDE; IN-VIVO;
   ANTIMICROBIAL PEPTIDES; GENE DELIVERY; CANCER-CELLS
AB Natural products serve as an important source of novel compounds for drug development. Recently, peptides have emerged as a new class of therapeutic agents due to their versatility and specificity for biological targets. Yet, their effective application often requires use of a nanoparticle delivery system. In this chapter, we review the role of natural peptides in the design and creation of nanomedicines, with a particular focus on cell- penetrating peptides, antimicrobial peptides, and peptide toxins. The use of natural peptides in conjunction with nanoparticle delivery systems holds great promise for the development of new therapeutic formulations as well as novel platforms for the delivery of various cargoes.
C1 [Jallouk, Andrew P.; Palekar, Rohun U.; Pan, Hua; Wickline, Samuel A.] Washington Univ St Louis, Dept Med, Div Cardiol, Consortium Translat Res Adv Imaging & Nanomed, St Louis, MO 63130 USA.
   [Schlesinger, Paul H.; Wickline, Samuel A.] Washington Univ St Louis, Dept Cell Biol & Physiol, St Louis, MO 63130 USA.
RP Wickline, SA (reprint author), Washington Univ St Louis, Dept Med, Div Cardiol, Consortium Translat Res Adv Imaging & Nanomed, St Louis, MO 63130 USA.; Wickline, SA (reprint author), Washington Univ St Louis, Dept Cell Biol & Physiol, St Louis, MO 63130 USA.
EM wicklines@aol.com
RI Pan, Hua/C-7662-2011
FU NHLBI NIH HHS [R01 HL073646, U54 HL112303]; NIAMS NIH HHS [R01 AR067491,
   R01 AR056223]; NIDDK NIH HHS [R21 DK095555, R01 DK102691]
CR Ahn EH, 2014, BBA-GEN SUBJECTS, V1840, P1686, DOI 10.1016/j.bbagen.2014.01.004
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Andersson DI, 2011, FEMS MICROBIOL REV, V35, P901, DOI 10.1111/j.1574-6976.2011.00289.x
   Aoshiba K, 2003, AM J RESP CELL MOL, V28, P555, DOI 10.1165/rcmb.2002.0090OC
   Apte A, 2014, CANCER BIOL THER, V15, P69, DOI 10.4161/cbt.26609
   Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109
   Badr G, 2013, APOPTOSIS, V18, P300, DOI 10.1007/s10495-012-0787-1
   Badr G, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-27
   Bailey P, 2001, Emerg Med (Fremantle), V13, P28, DOI 10.1046/j.1442-2026.2001.00174.x
   Balayssac S, 2006, BIOCHEMISTRY-US, V45, P1408, DOI 10.1021/bi0518390
   Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200
   Bardag-Gorce F, 2003, EXP MOL PATHOL, V74, P160, DOI 10.1016/S0014-4800(03)00024-2
   Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201
   BESSALLE R, 1992, ANTIMICROB AGENTS CH, V36, P313, DOI 10.1128/AAC.36.2.313                                                            
   Bradshaw JP, 2003, BIODRUGS, V17, P233, DOI 10.2165/00063030-200317040-00002                                                
   Bush K, 2011, NAT REV MICROBIOL, V9, P894, DOI 10.1038/nrmicro2693
   Calderon LD, 2011, AMINO ACIDS, V40, P29, DOI 10.1007/s00726-010-0622-3
   Carredano E, 1998, TOXICON, V36, P75, DOI 10.1016/S0041-0101(97)00051-2
   Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006
   Chereddy KK, 2014, J CONTROL RELEASE, V194, P138, DOI 10.1016/j.jconrel.2014.08.016
   Chu Q., 2014, MED CHEM COMMUNICATI
   Conlon JM, 2004, BBA-PROTEINS PROTEOM, V1696, P1, DOI 10.1016/j.bbapap.2003.09.004
   Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Danhier F, 2012, METHOD ENZYMOL, V508, P157, DOI 10.1016/B978-0-12-391860-4.00008-2
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203
   Desgranges S, 2011, ANTIMICROB AGENTS CH, V55, P2487, DOI 10.1128/AAC.01384-10
   Deshane J, 2003, J BIOL CHEM, V278, P4135, DOI 10.1074/jbc.M205662200
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Ding J, 2014, EXP BIOL MED, V239, P387, DOI 10.1177/1535370213513991
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Dutertre S, 2010, J BIOL CHEM, V285, P13315, DOI 10.1074/jbc.R109.076596
   Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   ESMON C T, 1973, Thrombosis Research, V2, P509, DOI 10.1016/0049-3848(73)90004-2
   Findlay B, 2010, ANTIMICROB AGENTS CH, V54, P4049, DOI 10.1128/AAC.00530-10
   Forde E, 2014, ANTIMICROB AGENTS CH, V58, P978, DOI 10.1128/AAC.01167-13
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gajski G, 2013, ENVIRON TOXICOL PHAR, V36, P697, DOI 10.1016/j.etap.2013.06.009
   Gallo G, 2003, METHOD CELL BIOL, V71, P325, DOI 10.1016/S0091-679X(03)01015-X
   Gao S, 2011, ACS CHEM BIOL, V6, P484, DOI 10.1021/cb100423u
   Garnon J, 2005, J BIOL CHEM, V280, P5750, DOI 10.1074/jbc.M401988200
   Grdisa M, 2011, CURR MED CHEM, V18, P1373, DOI 10.2174/092986711795029591                                                      
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Gullotti E, 2013, PHARM RES-DORDR, V30, P1956, DOI 10.1007/s11095-013-1039-y
   Gupta B, 2007, ONCOL RES, V16, P351
   Hamley IW, 2011, SOFT MATTER, V7, P4122, DOI 10.1039/c0sm01218a
   Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267
   He XH, 2013, J CARDIOVASC PHARM, V62, P436, DOI 10.1097/FJC.0b013e3182a0b638
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Hou KK, 2013, ACS NANO, V7, P8605, DOI 10.1021/nn403311c
   Hou KK, 2013, BIOMATERIALS, V34, P3110, DOI 10.1016/j.biomaterials.2013.01.037
   Hu Q, 2014, INT J NANOMED, V9, P4035, DOI 10.2147/IJN.S64708
   Huang C, 2013, ACS NANO, V7, P5791, DOI 10.1021/nn400683s
   Huang RQ, 2011, BIOMATERIALS, V32, P5177, DOI 10.1016/j.biomaterials.2011.03.075
   Jallouk AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095411
   JIANG Z, 2008, PEPT SCI, V90, P369
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kang MJ, 2013, INT J NANOMED, V8, P1155, DOI 10.2147/IJN.S39491
   Kini RM, 2006, BIOCHEM J, V397, P377, DOI 10.1042/BJ20060302
   KINI RM, 1988, BIOCHEM BIOPH RES CO, V150, P1012, DOI 10.1016/0006-291X(88)90729-2
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Ko YT, 2009, GENE THER, V16, P52, DOI 10.1038/gt.2008.135
   Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657
   Koh CY, 2012, TOXICON, V59, P497, DOI 10.1016/j.toxicon.2011.03.017
   Koren E, 2012, J CONTROL RELEASE, V160, P264, DOI 10.1016/j.jconrel.2011.12.002
   Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197
   Li F, 2008, INT J PHARM, V349, P291, DOI 10.1016/j.ijpharm.2007.08.011
   Li F, 2009, DRUG DEV IND PHARM, V35, P1048, DOI 10.1080/03639040902762987
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Liu LH, 2009, NAT NANOTECHNOL, V4, P457, DOI [10.1038/nnano.2009.153, 10.1038/NNANO.2009.153]
   Liu Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5280
   Lyons SA, 2002, GLIA, V39, P162, DOI 10.1002/glia.10083
   Malhotra M, 2013, BIOMATERIALS, V34, P1270, DOI 10.1016/j.biomaterials.2012.10.013
   Manzoor AA, 2012, CANCER RES, V72, P5566, DOI 10.1158/0008-5472.CAN-12-1683
   Marks JR, 2011, J AM CHEM SOC, V133, P8995, DOI 10.1021/ja2017416
   Marr AK, 2006, CURR OPIN PHARMACOL, V6, P468, DOI 10.1016/j.coph.2006.04.006
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   McCleary RJR, 2013, THROMB RES, V132, P642, DOI 10.1016/j.thromres.2013.09.031
   Meng H, 2007, J AM CHEM SOC, V129, P15615, DOI 10.1021/ja075373f
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Munoz-Morris MA, 2007, BIOCHEM BIOPH RES CO, V355, P877, DOI 10.1016/j.bbrc.2007.02.046
   Myerson J, 2011, J THROMB HAEMOST, V9, P1292, DOI 10.1111/j.1538-7836.2011.04339.x
   Nakase I, 2012, ACCOUNTS CHEM RES, V45, P1132, DOI 10.1021/ar200256e
   Nakayama F, 2011, J BIOL CHEM, V286, P25823, DOI 10.1074/jbc.M110.198267
   Nguyen LT, 2011, TRENDS BIOTECHNOL, V29, P464, DOI 10.1016/j.tibtech.2011.05.001
   Nowak G, 2003, PATHOPHYSIOL HAEMO T, V33, P173, DOI 10.1159/000081505
   Ochocki JD, 2011, BIOORG MED CHEM LETT, V21, P4998, DOI 10.1016/j.bmcl.2011.04.138
   Omata D, 2011, MOL PHARMACEUT, V8, P2416, DOI 10.1021/mp200353m
   Palekar RU, 2013, MOL PHARMACEUT, V10, P4168, DOI 10.1021/mp400210q
   Pan H, 2013, FASEB J, V27, P255, DOI 10.1096/fj.12-218081
   Pan H, 2011, BIOMATERIALS, V32, P231, DOI 10.1016/j.biomaterials.2010.08.080
   Pan H, 2010, FASEB J, V24, P2928, DOI 10.1096/fj.09-153130
   Pooga M, 1998, FASEB J, V12, P67
   Presente A., 2013, PTD CPP PEPTIDE MEDI
   Qin Y, 2011, INT J PHARMACEUT, V420, P304, DOI 10.1016/j.ijpharm.2011.09.008
   Rhee M, 2006, J BIOL CHEM, V281, P1233, DOI 10.1074/jbc.M509813200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Sajevic T, 2011, TOXICON, V57, P627, DOI 10.1016/j.toxicon.2011.01.006
   Sawant RR, 2009, INT J PHARMACEUT, V374, P114, DOI 10.1016/j.ijpharm.2009.02.022
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shai Y., 1999, BIOCHIM BIOPHYS ACTA, V1462, P55
   Sharma G, 2014, PHARM RES-DORDR, V31, P1194, DOI 10.1007/s11095-013-1242-x
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Smith RET, 2007, NAT REV DRUG DISCOV, V6, P597, DOI 10.1038/nrd2354
   Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Soroceanu L, 1999, J NEUROSCI, V19, P5942
   Splith K, 2011, EUR BIOPHYS J BIOPHY, V40, P387, DOI 10.1007/s00249-011-0682-7
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   TAKEYA H, 1992, J BIOL CHEM, V267, P14109
   Taylor BN, 2009, CANCER RES, V69, P537, DOI 10.1158/0008-5472.CAN-08-2932
   THIAGARAJAN P, 1986, BLOOD, V68, P869
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4                                                   
   Tran TD, 2007, INT J NANOMED, V2, P515
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Veiseh O, 2010, BIOMATERIALS, V31, P8032, DOI [10.1016/j.biomaterials.2010.07.016, 10.1016/j.biomaterials.2010.07.0126]
   Veiseh O, 2009, SMALL, V5, P256, DOI 10.1002/smll.200800646
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544
   Wang BY, 2014, BIOMATERIALS, V35, P5897, DOI 10.1016/j.biomaterials.2014.03.068
   Wang GS, 2009, NUCLEIC ACIDS RES, V37, pD933, DOI 10.1093/nar/gkn823
   Wang H, 2014, INT J NANOMED, V9, P1433, DOI 10.2147/IJN.S58783
   Wang HY, 2010, BIOMATERIALS, V31, P2874, DOI 10.1016/j.biomaterials.2009.12.042
   Xia HM, 2012, INT J PHARMACEUT, V436, P840, DOI 10.1016/j.ijpharm.2012.07.029
   Yin PH, 2012, INT J NANOMED, V7, P3961, DOI 10.2147/IJN.S32063
   Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106                                                             
   Zhang Y, 2012, TOXICON, V59, P718, DOI 10.1016/j.toxicon.2012.03.006
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Zhao PQ, 2010, PHARM RES-DORDR, V27, P1914, DOI 10.1007/s11095-010-0196-5
   Zhao XB, 2010, CHEM SOC REV, V39, P3480, DOI 10.1039/b915923c
   Zhou HF, 2014, J CLIN INVEST, V124, P4363, DOI 10.1172/JCI75673
NR 157
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1876-1623
BN 978-0-12-802828-5
J9 ADV PROTEIN CHEM STR
JI Adv. Protein Chem. Struct. Biol.
PY 2015
VL 98
BP 57
EP 91
DI 10.1016/bs.apcsb.2014.12.001
PG 35
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA BI0SS
UT WOS:000405133700003
PM 25819276
OA green_accepted
DA 2018-01-05
ER

PT S
AU Koseva, NS
   Rydz, J
   Stoyanova, EV
   Mitova, VA
AF Koseva, Neli S.
   Rydz, Joanna
   Stoyanova, Ekaterina V.
   Mitova, Violeta A.
BE Donev, R
TI Hybrid Protein-Synthetic Polymer Nanoparticles for Drug Delivery
SO PROTEIN AND PEPTIDE NANOPARTICLES FOR DRUG DELIVERY
SE Advances in Protein Chemistry and Structural Biology
LA English
DT Review; Book Chapter
ID CELL-PENETRATING PEPTIDE; PEG-PLA NANOPARTICLES; PACLITAXEL-LOADED
   NANOPARTICLES; HUMAN IMMUNODEFICIENCY VIRUS; CENTRAL-NERVOUS-SYSTEM;
   IN-VIVO EVALUATIONS; BRAIN DELIVERY; PLGA NANOPARTICLES; TARGETED
   DELIVERY; CANCER-CELLS
AB Among the most common nanoparticulate systems, the polymeric nanocarriers have a number of key benefits, which give a great choice of delivery platforms. Nevertheless, polymeric nanoparticles possess some limitations that include use of toxic solvents in the production process, polymer degradation, drug leakage outside the diseased tissue, and polymer cytotoxicity. The combination of polymers of biological and synthetic origin is an appealing modern strategy for the production of novel nanocarriers with unprecedented properties. Proteins' interface can play an important role in determining bioactivity and toxicity and gives perspective for future development of the polymerbased nanoparticles. The design of hybrid constructs composed of synthetic polymer and biological molecules such as proteins can be considered as a straightforward tool to integrate a broad spectrum of properties and biofunctions into a single device. This review discusses hybrid protein-synthetic polymer nanoparticles with different structures and levels in complexity and functionality, in view of their applications as drug delivery systems.
C1 [Koseva, Neli S.; Rydz, Joanna; Stoyanova, Ekaterina V.; Mitova, Violeta A.] Bulgarian Acad Sci, Inst Polymers, Sofia, Bulgaria.
   [Rydz, Joanna] Polish Acad Sci, Ctr Polymer & Carbon Mat, Zabrze, Poland.
RP Koseva, NS (reprint author), Bulgarian Acad Sci, Inst Polymers, Sofia, Bulgaria.
EM koseva@polymer.bas.bg
RI Mitova, Violeta/K-4522-2016
CR Agrawal D, 2013, INDIAN J CHEM A, V52, P973
   Aubin-Tam ME, 2013, METHODS MOL BIOL, V1025, P19, DOI 10.1007/978-1-62703-462-3_3
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Basle E, 2010, CHEM BIOL, V17, P213, DOI 10.1016/j.chembiol.2010.02.008
   Batist G, 2009, CLIN CANCER RES, V15, P692, DOI 10.1158/1078-0432.CCR-08-0515
   Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011
   Bies C, 2004, ADV DRUG DELIVER REV, V56, P425, DOI 10.1016/j.addr.2003.10.030
   Borner H., 2012, POLYM SCI COMPREHENS, P543
   BOUREL D, 1988, J IMMUNOL METHODS, V106, P161, DOI 10.1016/0022-1759(88)90192-5
   Boyer C, 2011, SOFT MATTER, V7, P1599, DOI 10.1039/c0sm00412j
   Byrne JD, 2008, ADV DRUG DELIVER REV, V60, P1615, DOI 10.1016/j.addr.2008.08.005
   Caruso G, 2011, NANOMED-NANOTECHNOL, V7, P744, DOI 10.1016/j.nano.2011.02.008
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Choi CHJ, 2010, P NATL ACAD SCI USA, V107, P1235, DOI 10.1073/pnas.0914140107
   Coue G, 2011, J CONTROL RELEASE, V152, P90, DOI 10.1016/j.jconrel.2011.01.023
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
   Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016
   Desale SS, 2013, J CONTROL RELEASE, V171, P339, DOI 10.1016/j.jconrel.2013.04.026
   Dinarvand R, 2011, INT J NANOMED, V6, P877, DOI 10.2147/IJN.S18905
   Donev R, 2011, WORLD J BIOL PSYCHIA, V12, P44, DOI 10.3109/15622975.2011.599209
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gan CW, 2010, BIOMATERIALS, V31, P7748, DOI 10.1016/j.biomaterials.2010.06.053
   Gao HL, 2010, ACTA PHARMACOL SIN, V31, P237, DOI 10.1038/aps.2009.199
   Gao W, 2013, BIOMATERIALS, V34, P4137, DOI 10.1016/j.biomaterials.2013.02.014
   Gao XL, 2007, J CONTROL RELEASE, V121, P156, DOI 10.1016/j.jconrel.2007.05.026
   Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038
   Garanger E, 2012, ANGEW CHEM INT EDIT, V51, P3060, DOI 10.1002/anie.201107734
   Ge J, 2012, SMALL, V8, P3573, DOI 10.1002/smll.201200889
   Ge J, 2011, NANO LETT, V11, P2551, DOI 10.1021/nl201303q
   Graff CL, 2005, J PHARM SCI-US, V94, P1187, DOI 10.1002/jps.20318
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grunwald J, 2009, BIOCONJUGATE CHEM, V20, P1531, DOI 10.1021/bc900081e
   Gu GZ, 2013, BIOMATERIALS, V34, P196, DOI 10.1016/j.biomaterials.2012.09.044
   Hadinoto K, 2013, EUR J PHARM BIOPHARM, V85, P427, DOI 10.1016/j.ejpb.2013.07.002
   Hamidi M, 2006, DRUG DELIV, V13, P399, DOI 10.1080/10717540600814402
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hong MH, 2010, J CONTROL RELEASE, V141, P22, DOI 10.1016/j.jconrel.2009.08.024
   Hu CMJ, 2010, MOL PHARMACEUT, V7, P914, DOI 10.1021/mp900316a
   Hu KL, 2011, INT J PHARMACEUT, V415, P273, DOI 10.1016/j.ijpharm.2011.05.062
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   Hua MF, 2014, NANO-MICRO LETT, V6, P20, DOI 10.5101/nml.v6i1.p20-23
   Huang YZ, 2013, ADV DRUG DELIVER REV, V65, P1299, DOI 10.1016/j.addr.2012.11.007
   Huile Gao, 2011, Biomaterials, V32, P8669, DOI 10.1016/j.biomaterials.2011.07.069
   Jain NJ, 1998, J PHYS CHEM B, V102, P8452, DOI 10.1021/jp982568o                                                               
   Jiang YY, 2014, CHEM COMMUN, V50, P6394, DOI 10.1039/c4cc00616j
   Johnson LN, 2010, VISION RES, V50, P686, DOI 10.1016/j.visres.2009.08.028
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Keller M W, 1989, J Am Soc Echocardiogr, V2, P48
   Kolishetti N, 2010, P NATL ACAD SCI USA, V107, P17939, DOI 10.1073/pnas.1011368107
   Koren E, 2011, DRUG DELIV, V18, P377, DOI 10.3109/10717544.2011.567310
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Krpetic Z, 2011, ACS NANO, V5, P5195, DOI 10.1021/nn201369k
   Kuai R, 2011, MOL PHARMACEUT, V8, P2151, DOI 10.1021/mp200100f
   Kundu B, 2014, PROG POLYM SCI, V39, P251, DOI 10.1016/j.progpolymsci.2013.09.002
   Kurinomaru T, 2012, LANGMUIR, V28, P4334, DOI 10.1021/la2043312
   Langel K, 2010, INT J PEPT RES THER, V16, P247, DOI 10.1007/s10989-010-9224-x
   Lee J, 2011, BIOORG MED CHEM LETT, V21, P2941, DOI 10.1016/j.bmcl.2011.03.058
   Lee SY, 1996, BIOTECHNOL BIOENG, V49, P1
   Lee WK, 2003, SURF SCI, V542, P235, DOI 10.1016/S0039-6028(03)00981-6
   Li Y, 2012, CHEM SOC REV, V41, P5998, DOI 10.1039/c2cs35107b
   Lin JP, 2009, BIOMATERIALS, V30, P108, DOI 10.1016/j.biomaterials.2008.09.010
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Lohcharoenkal W, 2014, BIOMED RES INT, DOI 10.1155/2014/180549
   Loyer P, 2013, INT J PHARMACEUT, V454, P727, DOI 10.1016/j.ijpharm.2013.05.060
   Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027
   Lutz JF, 2008, PROG POLYM SCI, V33, P1, DOI 10.1016/j.progpolymsci.2007.07.005
   Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21
   Maeda H, 2012, J CONTROL RELEASE, V164, P138, DOI 10.1016/j.jconrel.2012.04.038
   Mahmoudi M, 2011, CHEM REV, V111, P5610, DOI 10.1021/cr100440g
   Mansour HM, 2010, INT J MOL SCI, V11, P3298, DOI 10.3390/ijms11093298
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mei H, 2010, BIOMATERIALS, V31, P5619, DOI 10.1016/j.biomaterials.2010.03.055
   Messerschmidt SKE, 2009, J CONTROL RELEASE, V137, P69, DOI 10.1016/j.jconrel.2009.03.010
   Misra A, 2003, J PHARM PHARM SCI, V6, P252
   Montero Alberto J, 2011, Expert Rev Clin Pharmacol, V4, P329, DOI 10.1586/ecp.11.7
   Naahidi S, 2013, J CONTROL RELEASE, V166, P182, DOI 10.1016/j.jconrel.2012.12.013
   Nichols JW, 2012, NANO TODAY, V7, P606, DOI 10.1016/j.nantod.2012.10.010
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Olivier Jean-Christophe, 2005, NeuroRx, V2, P108, DOI 10.1007/BF03206647
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pan J, 2008, BIOMATERIALS, V29, P2663, DOI 10.1016/j.biomaterials.2008.02.020
   Pan LM, 2013, BIOMATERIALS, V34, P2719, DOI 10.1016/j.biomaterials.2012.12.040
   Pang ZQ, 2008, J CONTROL RELEASE, V128, P120, DOI 10.1016/j.jconrel.2008.03.007
   Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P5, DOI 10.1016/S1359-6446(01)02082-7                                                   
   Park K, 2013, ACS NANO, V7, P7442, DOI 10.1021/nn404501g
   PATEL HM, 1992, CRIT REV THER DRUG, V9, P39
   Pitek AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040685
   Pulkkinen M, 2008, EUR J PHARM BIOPHARM, V70, P66, DOI 10.1016/j.ejpb.2008.04.018
   Qiu LY, 2006, PHARM RES, V23, P1, DOI 10.1007/s11095-005-9046-2
   Rihova B, 2010, ADV DRUG DELIVER REV, V62, P184, DOI 10.1016/j.addr.2009.10.005
   Rydz J., 2015, ENCY BIOMEDICAL POLY
   Sahoo SK, 2005, MOL PHARMACEUT, V2, P373, DOI 10.1021/mp050032z
   Sahoo SK, 2004, INT J CANCER, V112, P335, DOI 10.1002/ijc.20405
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shah N, 2009, J DRUG TARGET, V17, P533, DOI 10.1080/10611860903046628
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Shi W, 2012, BIOMATERIALS, V33, P7643, DOI 10.1016/j.biomaterials.2012.06.094
   Shin HC, 2011, MOL PHARMACEUT, V8, P1257, DOI 10.1021/mp2000549
   Silva JM, 2013, J CONTROL RELEASE, V168, P179, DOI 10.1016/j.jconrel.2013.03.010
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Stoyanova E, 2013, J INORG BIOCHEM, V120, P54, DOI 10.1016/j.jinorgbio.2012.12.005
   Su YL, 2002, LANGMUIR, V18, P5370, DOI 10.1021/la020007p
   Swaminathan SK, 2013, J CONTROL RELEASE, V171, P280, DOI 10.1016/j.jconrel.2013.07.014
   Tikhonov I, 2004, FEBS LETT, V565, P89, DOI 10.1016/j.febslet.2004.03.079
   Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015
   Tzeng SY, 2013, THER DELIV, V4, P687, DOI [10.4155/TDE.13.38, 10.4155/tde.13.38]
   van Rijn P, 2013, POLYMERS-BASEL, V5, P576, DOI 10.3390/polym5020576
   Vassileva ED, 2010, ADV PROTEIN CHEM STR, V80, P205, DOI [10.1016/S1876-1623(10)80006-9, 10.1016/B978-0-12-381264-3.00006-0]
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9
   Wang AZ, 2008, EXPERT OPIN BIOL TH, V8, P1063, DOI [10.1517/14712590802181330, 10.1517/14712598.8.8.1063 ]
   Wang FL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003031
   Wang QM, 2014, BIOMATERIALS, V35, P7008, DOI 10.1016/j.biomaterials.2014.04.117
   Wang R, 2013, WIRES NANOMED NANOBI, V5, P320, DOI 10.1002/wnan.1210
   Wen ZY, 2011, DRUG DELIV, V18, P555, DOI 10.3109/10717544.2011.596583
   Wen ZY, 2011, J CONTROL RELEASE, V151, P131, DOI 10.1016/j.jconrel.2011.02.022
   Wodzinska J, 1996, J AM CHEM SOC, V118, P6319, DOI 10.1021/ja961108a                                                               
   Xin HL, 2012, BIOMATERIALS, V33, P8167, DOI 10.1016/j.biomaterials.2012.07.046
   Xin HL, 2011, BIOMATERIALS, V32, P4293, DOI 10.1016/j.biomaterials.2011.02.044
   Xu ZH, 2005, INT J PHARM, V288, P361, DOI 10.1016/j.ijpharm.2004.10.009
   Yan L, 2013, MACROMOL RES, V21, P435, DOI 10.1007/s13233-013-1029-2
   Yan Y, 2012, ACS NANO, V6, P3663, DOI 10.1021/nn3016162
   Yang FF, 2013, BIOMATERIALS, V34, P5689, DOI 10.1016/j.biomaterials.2013.03.047
   Yang XZ, 2012, ACS NANO, V6, P771, DOI 10.1021/nn204240b
   Zhang B, 2014, BIOMATERIALS, V35, P4133, DOI 10.1016/j.biomaterials.2014.01.071
   Zhang B, 2013, BIOMATERIALS, V34, P9171, DOI 10.1016/j.biomaterials.2013.08.039
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhang L, 2010, NANO LIFE, V1, P163, DOI 10.1142/S179398441000016X
   Zhang Z, 2013, WIRES NANOMED NANOBI, V5, P205, DOI 10.1002/wnan.1211
   Zheng Y, 2010, INT J PHARMACEUT, V390, P234, DOI 10.1016/j.ijpharm.2010.02.008
NR 134
TC 1
Z9 1
U1 4
U2 9
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1876-1623
BN 978-0-12-802828-5
J9 ADV PROTEIN CHEM STR
JI Adv. Protein Chem. Struct. Biol.
PY 2015
VL 98
BP 93
EP 119
DI 10.1016/bs.apcsb.2014.12.003
PG 27
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA BI0SS
UT WOS:000405133700004
PM 25819277
DA 2018-01-05
ER

PT J
AU Zhu, XL
   Feng, C
   Zhang, B
   Tong, H
   Gao, T
   Li, GX
AF Zhu, Xiaoli
   Feng, Chang
   Zhang, Bin
   Tong, Hui
   Gao, Tao
   Li, Genxi
TI A netlike rolling circle nucleic acid amplification technique
SO ANALYST
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; CREATE NANOSCALE SHAPES; ATOMIC-FORCE
   MICROSCOPY; ISOTHERMAL AMPLIFICATION; NICKING ENDONUCLEASE; SENSITIVE
   DETECTION; PADLOCK PROBES; DNA-POLYMERASE; OLIGONUCLEOTIDES; NANOTUBES
AB A nucleic acid amplification technique termed as netlike rolling circle amplification is proposed by introducing a nicking enzyme into the existing hyperbranched rolling circle amplification system. Surprisingly dense and uniform network morphology is observed; and cubic amplification is achieved for the sensitive detection of a sequence from HIV.
C1 [Zhu, Xiaoli; Feng, Chang; Zhang, Bin; Tong, Hui; Li, Genxi] Shanghai Univ, Sch Life Sci, Lab Biosensing Technol, Shanghai 200444, Peoples R China.
   [Gao, Tao; Li, Genxi] Nanjing Univ, Dept Biochem, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China.
RP Li, GX (reprint author), Shanghai Univ, Sch Life Sci, Lab Biosensing Technol, Shanghai 200444, Peoples R China.
EM genxili@nju.edu.cn
RI Li, Genxi/H-1952-2013
OI Li, Genxi/0000-0001-9663-9914
FU National Science Fund for Distinguished Young Scholars [20925520];
   National Natural Science Foundation of China [61001035, 21235003];
   Innovation Program of Shanghai Municipal Education Commission [12YZ004];
   Natural Science Foundation of Shanghai [14ZR1416500]
FX This work is supported by the National Science Fund for Distinguished
   Young Scholars (Grant no. 20925520), the National Natural Science
   Foundation of China (Grant nos 61001035, 21235003), the Innovation
   Program of Shanghai Municipal Education Commission (no. 12YZ004), and
   the Natural Science Foundation of Shanghai (14ZR1416500). Thanks to the
   Experimental Centre of Life Sciences of Shanghai University for
   providing AFM and real-time PCR apparatus.
CR Beyer S, 2005, NANO LETT, V5, P719, DOI 10.1021/nl050155a
   Bichenkova EV, 2011, BBA-GENE REGUL MECH, V1809, P1, DOI 10.1016/j.bbagrm.2010.11.002
   Cheng W, 2010, ANAL CHEM, V82, P3337, DOI 10.1021/ac100144g
   Cheng YQ, 2009, ANGEW CHEM INT EDIT, V48, P3268, DOI 10.1002/anie.200805665
   Cho EJ, 2005, J AM CHEM SOC, V127, P2022, DOI 10.1021/ja043490u
   Dahl F, 2004, P NATL ACAD SCI USA, V101, P4548, DOI 10.1073/pnas.0400834101
   Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501                                                               
   Ermini ML, 2014, BIOSENS BIOELECTRON, V61, P28, DOI 10.1016/j.bios.2014.04.052
   FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641
   Geng Y, 2014, BIOSENS BIOELECTRON, V61, P593, DOI 10.1016/j.bios.2014.06.010
   Hamblin GD, 2012, J AM CHEM SOC, V134, P2888, DOI 10.1021/ja2107492
   Han DR, 2010, NAT NANOTECHNOL, V5, P712, DOI 10.1038/nnano.2010.193
   Hansma HG, 1996, NUCLEIC ACIDS RES, V24, P713, DOI 10.1093/nar/24.4.713
   Harcourt EM, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1313
   Ji HX, 2012, ANAL CHEM, V84, P7166, DOI 10.1021/ac3015356
   Kaocharoen S, 2008, ELECTROPHORESIS, V29, P3183, DOI 10.1002/elps.200700903
   Liu DY, 1996, J AM CHEM SOC, V118, P1587, DOI 10.1021/ja952786k                                                               
   Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898
   Ma YZ, 2013, J AM CHEM SOC, V135, P2959, DOI 10.1021/ja400102s
   MOU JX, 1995, FEBS LETT, V371, P279, DOI 10.1016/0014-5793(95)00906-P
   Murakami T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1014
   NILSSON M, 1994, SCIENCE, V265, P2085, DOI 10.1126/science.7522346
   Park J., 2012, BIOSENS BIOELECTRON, V43, P419
   Qi XQ, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.22.e116                                                          
   Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586
   Selck DA, 2013, ANAL CHEM, V85, P11129, DOI 10.1021/ac4030413
   Thomas DC, 1999, ARCH PATHOL LAB MED, V123, P1170
   Tomita N, 2008, NAT PROTOC, V3, P877, DOI 10.1038/nprot.2008.57
   Wang LD, 2014, CHEM-EUR J, V20, P2420, DOI 10.1002/chem.201304292
   Wang XY, 2013, BIOSENS BIOELECTRON, V41, P569, DOI 10.1016/j.bios.2012.09.023
   Wilner OI, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1535
   Xu W, 2012, SMALL, V8, P1846, DOI 10.1002/smll.201200263
   Yin BC, 2013, ANAL CHEM, V85, P11487, DOI 10.1021/ac403302a
   Zeng YP, 2013, ANAL CHEM, V85, P6143, DOI 10.1021/ac4011292
   Zhang DY, 1998, GENE, V211, P277
   Zhang DY, 2001, MOL DIAGN, V6, P141, DOI 10.1054/modi.2001.25323
   Zhao WA, 2008, ANGEW CHEM INT EDIT, V47, P6330, DOI 10.1002/anie.200705982
NR 37
TC 10
Z9 10
U1 9
U2 39
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2015
VL 140
IS 1
BP 74
EP 78
DI 10.1039/c4an01711k
PG 5
WC Chemistry, Analytical
SC Chemistry
GA AU8CR
UT WOS:000345824700007
PM 25407326
DA 2018-01-05
ER

PT J
AU Sen, S
   Voorheis, HP
AF Sen, Siddhartha
   Voorheis, H. Paul
TI Protein folding: Understanding the role of water and the low Reynolds
   number environment as the peptide chain emerges from the ribosome and
   folds
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Protein biosynthesis; Water sheath; Quantum field theory; Role of
   hydophobic amino acids; Coherent domains
ID INTRINSICALLY DISORDERED PROTEINS; HIV-1 PROTEASE; CREATE RESISTANCE;
   EXIT TUNNEL; HYDRATION; DYNAMICS; SIMULATIONS; NELFINAVIR; GEOMETRY;
   COLLAPSE
AB The mechanism of protein folding during early stages of the process has three determinants. First, moving water molecules obey the rules of low Reynolds number physics without an inertial component. Molecular movement is instantaneous and size insensitive. Proteins emerging from the ribosome move and rotate without an external force if they change shape, forming and propagating helical structures that increases translocational efficiency. Forward motion ceases when the shape change or propelling force ceases. Second, application of quantum field theory to water structure predicts the spontaneous formation of low density coherent units of fixed size that expel dissolved atmospheric gases. Structured water layers with both coherent and non-coherent domains, form a sheath around the new protein. The surface of exposed hydrophobic amino acids is protected from water contact by small nanobubbles of dissolved atmospheric gases, 5 or 6 molecules on average, that vibrate, attracting even widely separated resonating nanobubbles. This force results from quantum effects, appearing only when the system is within and interacts with an oscillating electromagnetic field. The newly recognized quantum force sharply bends the peptide and is part of a dynamic field determining the pathway of protein folding. Third, the force initiating the tertiary folding of proteins arises from twists at the position of each hydrophobic amino acid, that minimizes surface exposure of the hydrophobic amino acids and propagates along the protein. When the total bend reaches 360, the leading segment of water sheath intersects the trailing segment. This steric self-intersection expels water from overlapping segments of the sheath and by Newton's second law moves the polypeptide chain in an opposite direction. Consequently, with very few exceptions that we enumerate and discuss, tertiary structures are absent from proteins without hydrophobic amino acids, which control the early stages of protein folding and the overall shape of protein. Consequently, proteins only adopt a limited number of forms. The formation of quaternary structures is not necessarily prevented by the absence of hydrophobic amino acids. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Sen, Siddhartha] Univ Dublin Trinity Coll, CRANN, Dublin 2, Ireland.
   [Voorheis, H. Paul] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland.
RP Voorheis, HP (reprint author), Univ Dublin Trinity Coll, Sch Biochem & Immunol, Dublin 2, Ireland.
CR ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223
   ARANI R, 1995, INT J MOD PHYS B, V9, P1813, DOI 10.1142/S0217979295000744
   Attard P, 1996, LANGMUIR, V12, P1693, DOI 10.1021/la950866w                                                               
   Attard P, 2002, PHYSICA A, V314, P696, DOI 10.1016/S0378-4371(02)01191-3
   Babu M.M., 2010, SCIENCE, V337, P1460
   Bernal JD, 1933, J CHEM PHYS, V1, P515, DOI 10.1063/1.1749327
   Bhushan S, 2010, NAT STRUCT MOL BIOL, V17, P313, DOI 10.1038/nsmb.1756
   Broglia RA, 2008, CURR OPIN STRUC BIOL, V18, P60, DOI 10.1016/j.sbi.2007.10.004
   Broglia RA, 2005, PROTEIN SCI, V14, P2668, DOI 10.1110/ps.051670905
   Buchner G.S., 2011, BIOCHIM BIOPHYS ACTA, V184, P1001
   Calugareanu G., 1961, CZECH MATH J, V11, P588
   Chaplin M, 2006, NAT REV MOL CELL BIO, V7, P861, DOI 10.1038/nrm2021
   [Anonymous], 1010, MOL OP ENV MOE 2012
   CHERN SS, 1974, ANN MATH, V99, P48, DOI 10.2307/1971013                                                                 
   Cheung MS, 2002, P NATL ACAD SCI USA, V99, P685, DOI 10.1073/pnas.022387699
   Creighton T. E., 1993, PROTEINS
   Del Giudice E, 2013, J PHYS CONF SER, V442, DOI 10.1088/1742-6596/442/1/012028
   Del Giudice E, 2010, WATER-SUI, V2, P566, DOI 10.3390/w2030566
   Del Guidice E, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.022105
   DELGIUDICE E, 1988, PHYS REV LETT, V61, P1085, DOI 10.1103/PhysRevLett.61.1085
   DESIMONE JA, 1973, SCIENCE, V180, P946, DOI 10.1126/science.180.4089.946                                                    
   DOBSON CM, 2000, MECH PROTEIN FOLDING, P1
   Dosztanyi Z, 2010, BRIEF BIOINFORM, V11, P225, DOI 10.1093/bib/bbp061
   Eyges L, 1972, CLASSICAL ELECTROMAG, P82
   Frank H.S., 1957, DISCUSS FARADAY SOC, V24, P133, DOI DOI 10.1039/DF9572400133
   FRANKS F, 1975, Critical Reviews in Biochemistry, V3, P165, DOI 10.3109/10409237509102556
   Glaser R., 2013, BIOPHYSICS-USSR, P60
   GOMATAM J, 1982, J PHYS A-MATH GEN, V15, P1463, DOI 10.1088/0305-4470/15/5/009
   Huang C, 2009, P NATL ACAD SCI USA, V106, P15214, DOI 10.1073/pnas.0904743106
   Jackson J. D., 1998, CLASSICAL ELECTRODYN
   Kibble T.W.B., 2005, CLASSICAL MECH
   KLOTZ IM, 1958, SCIENCE, V128, P815, DOI 10.1126/science.128.3328.815
   KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036                                                             
   Levinthal C., 1969, MOSSBAUER SPECTROSCO, P22
   Levy Y, 2004, J MOL BIOL, V340, P67, DOI 10.1016/j.jmb.2004.04.028
   Liu XQ, 2011, J MOL STRUCT, V986, P30, DOI 10.1016/j.molstruc.2010.11.027
   Mao AH, 2010, P NATL ACAD SCI USA, V107, P8183, DOI 10.1073/pnas.0911107107
   Mattos C, 2002, TRENDS BIOCHEM SCI, V27, P203, DOI 10.1016/S0968-0004(02)02067-4
   MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6
   Montagnier I., 2011, J PHYS C SER, V306
   Moseby S., 2008, J VIROL, V82, P11464
   Muller-Spath S., 2010, P NATL ACAD SCI USA, V107, P14613
   Ode H, 2005, J PHYS CHEM B, V109, P565, DOI 10.1021/jp046860+
   Ode H, 2007, J MOL BIOL, V370, P598, DOI 10.1016/j.jmb.2007.04.081
   OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083
   Peng J, 2011, PROTEINS, V79, P1930, DOI 10.1002/prot.23016
   Preparata G., 1995, QED COHERENCE MATTER
   PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903                                                                 
   Rontgen W. K., 1892, ANN PHYS, V45, P91
   Shandilya BK, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4813127
   SHAPERE A, 1989, J FLUID MECH, V198, P557, DOI 10.1017/S002211208900025X                                                       
   Soares RO, 2010, J MOL GRAPH MODEL, V29, P137, DOI 10.1016/j.jmgm.2010.05.007
   Theillet F.-X., 2013, INTRIN DISORD PROTEI, V1
   Tompa P, 2012, TRENDS BIOCHEM SCI, V37, P509, DOI 10.1016/j.tibs.2012.08.004
   Udgaonkar JB, 2013, ARCH BIOCHEM BIOPHYS, V531, P24, DOI 10.1016/j.abb.2012.10.003
   Ulversky V.N., 2013, INTRIN DISORD PROTEI, V1
   Voss NR, 2006, J MOL BIOL, V360, P893, DOI 10.1016/j.jmb.2006.05.023
   Xu Y, 2006, J AM CHEM SOC, V128, P15836, DOI 10.1021/ja064865+
NR 58
TC 3
Z9 3
U1 1
U2 24
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD DEC 21
PY 2014
VL 363
BP 169
EP 187
DI 10.1016/j.jtbi.2014.07.025
PG 19
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA AY2SE
UT WOS:000347438600019
PM 25152217
DA 2018-01-05
ER

PT J
AU Csavas, M
   Demeter, T
   Herczeg, M
   Timari, I
   Kover, KE
   Herczegh, P
   Borbas, A
AF Csavas, Magdolna
   Demeter, Tamas
   Herczeg, Mihaly
   Timari, Istvan
   Koever, Katalin E.
   Herczegh, Pal
   Borbas, Aniko
TI Rapid synthesis of self-assembling 1,2-thiomannobioside glycoconjugates
   as potential multivalent ligands of mannose-binding lectins
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Ferrier glycoside; Photoinduced thiol-addition; Amphiphilic;
   Glycomimetic; Multivalent
ID HIV-1 TRANS-INFECTION; DC-SIGN; ANTIBACTERIAL ACTIVITY; FULLERENE
   DERIVATIVES; VIRAL-INFECTION; INHIBITION; CHEMISTRY; POLYMERS; CELLS
AB Among the pathogen-associated carbohydrate patterns, the Man(alpha 1 -> 2)Man alpha disaccharide motif is of particular interest because its multivalent derivatives are considered as potential antiviral or antibacterial agents through interaction with mannose-binding lectins. We present a straightforward synthesis of amphiphilic compounds containing a hydrolytically stable S-linked 1,2-mannobioside residue, a tetraethylene glycol linker to ensure water solubility and various lipophilic carriers such as a hexadecyl chain and two pyrrolidinofullerene derivatives. According to a dynamic light scattering study, the obtained amphiphiles form nanoscale aggregates in water producing multivalent presentation of the thiomannobioside residue. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Csavas, Magdolna; Demeter, Tamas; Herczeg, Mihaly; Herczegh, Pal; Borbas, Aniko] Univ Debrecen, Dept Pharmaceut Chem, H-410 Debrecen, Hungary.
   [Timari, Istvan; Koever, Katalin E.] Univ Debrecen, Dept Inorgan & Analyt Chem, H-410 Debrecen, Hungary.
RP Csavas, M (reprint author), Univ Debrecen, Dept Pharmaceut Chem, POB 70, H-410 Debrecen, Hungary.
EM csavas.magdolna@science.unideb.hu; borbas.aniko@pharm.unideb.hu
OI Herczeg, Mihaly/0000-0002-7938-9789; Borbas, Aniko/0000-0001-8462-4547;
   Herczegh, Pal/0000-0003-4265-5518
FU National Excellence Program [TAMOP 4.2.4.A/2-11-1-2012-0001]; European
   Union; European Social Fund; Hungarian Research Fund (OTKA) [K 109208, K
   105459]
FX This study was supported by the TAMOP 4.2.4.A/2-11-1-2012-0001 Project
   (National Excellence Program). The project is co-financed by the
   European Union and the European Social Fund. Financial support from the
   Hungarian Research Fund (OTKA K 109208 and K 105459) is also
   acknowledged. The authors wish to thank Erzsebet Roth for her dedicated
   technical assistance and Dr. Sandor Keki for the dynamic light
   scattering measurements.
CR Becer CR, 2010, J AM CHEM SOC, V132, P15130, DOI 10.1021/ja1056714
   Berzi A, 2012, AIDS, V26, P127, DOI 10.1097/QAD.0b013e32834e1567
   Dehuyser L, 2012, BIOCONJUGATE CHEM, V23, P1731, DOI 10.1021/bc200644d
   Ferrier RJ, 2001, TOP CURR CHEM, V215, P153
   FERRIER RJ, 1969, J CHEM SOC C, P570, DOI 10.1039/j39690000570
   Hoyle CE, 2004, J POLYM SCI POL CHEM, V42, P5301, DOI 10.1002/pola.20366
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Lasala F, 2003, ANTIMICROB AGENTS CH, V47, P3970, DOI 10.1128/AAC.47.12.3970-3972.2003
   Lazar L, 2013, ORG BIOMOL CHEM, V11, P5339, DOI 10.1039/c3ob40547h
   Lazar L, 2012, ORG LETT, V14, P4650, DOI 10.1021/ol302098u
   Lepenies B, 2013, ADV DRUG DELIVER REV, V65, P1271, DOI 10.1016/j.addr.2013.05.007
   Luczkowiak J, 2013, BIOMACROMOLECULES, V14, P431, DOI 10.1021/bm3016658
   Luczkowiak J, 2011, BIOCONJUGATE CHEM, V22, P1354, DOI 10.1021/bc2000403
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   MATTA KL, 1975, CARBOHYD RES, V43, P101, DOI 10.1016/S0008-6215(00)83976-2
   Nierengarten I, 2014, CHEM-ASIAN J, V9, P1436, DOI 10.1002/asia.201400133
   Pinter G, 2011, MED CHEM, V7, P45, DOI 10.2174/157340611794072670
   Prato M, 1998, ACCOUNTS CHEM RES, V31, P519, DOI 10.1021/ar970210p                                                               
   Reina JJ, 2007, CHEMMEDCHEM, V2, P1030, DOI 10.1002/cmdc.200700047
   Ribeiro-Viana R, 2012, BIOMACROMOLECULES, V13, P3209, DOI 10.1021/bm300998c
   Rojo J, 2004, J ANTIMICROB CHEMOTH, V54, P579, DOI 10.1093/jac/dkh399
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Schaeffer E, 2013, BIOCONJUGATE CHEM, V24, P1813, DOI 10.1021/bc4000806
   Schierholt A, 2010, EUR J ORG CHEM, P3120, DOI 10.1002/ejoc.201000185
   Shirude PS, 2005, EUR J ORG CHEM, P5207, DOI 10.1002/ejoc.200500544
   Sutkeviciute I, 2014, ACS CHEM BIOL, V9, P1377, DOI 10.1021/cb500054h
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   Tollas S, 2014, BIOORG MED CHEM LETT, V24, P2420, DOI 10.1016/j.bmcl.2014.04.032
   Tollas S, 2012, EUR J MED CHEM, V54, P943, DOI 10.1016/j.ejmech.2012.06.054
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Varga N, 2013, CHEM-EUR J, V19, P4786, DOI 10.1002/chem.201202764
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Zhang EY, 2009, CURR OPIN COLLOID IN, V14, P148, DOI 10.1016/j.cocis.2007.10.002
NR 34
TC 5
Z9 5
U1 4
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD DEC 17
PY 2014
VL 55
IS 51
BP 6983
EP 6986
DI 10.1016/j.tetlet.2014.10.104
PG 4
WC Chemistry, Organic
SC Chemistry
GA AX6GC
UT WOS:000347020100007
DA 2018-01-05
ER

PT J
AU Wang, L
   Han, YJ
   Zhou, S
   Guan, XY
AF Wang, Liang
   Han, Yujing
   Zhou, Shuo
   Guan, Xiyun
TI Real-time label-free measurement of HIV-1 protease activity by nanopore
   analysis
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE HIV-1 protease; Proteolysis; Peptide; Biosensors; Nanopore
ID ALPHA-HEMOLYSIN; STOCHASTIC DETECTION; STRANDED-DNA; PORES;
   TRANSLOCATION; SENSITIVITY; PEPTIDES; PROBE; IONS
AB A label-free method for the measurement of the activity of HIV-1 protease is developed by real-time monitoring of the cleavage of a peptide substrate by HIV-1 protease in a nanopore. The method is rapid and sensitive: picomolar concentrations of HIV-1 protease could be detected in similar to 10 min. Simulated clinical samples are analyzed, and the activity of HIV-1 protease could be accurately detected. Our developed nanopore sensor design strategy should find useful applications in the development of stochastic sensors for other proteases of medical, pharmaceutical, and biological importance. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Wang, Liang; Han, Yujing; Zhou, Shuo; Guan, Xiyun] IIT, Dept Biol & Chem Sci, Chicago, IL 60616 USA.
RP Guan, XY (reprint author), IIT, Dept Biol & Chem Sci, Chicago, IL 60616 USA.
EM xguan5@iit.edu
FU National Institutes of Health [1R15GM110632]; Department of Homeland
   Security [HSHQDC-09-C-00091]
FX This work was financially supported by the National Institutes of Health
   (1R15GM110632), and Department of Homeland Security (HSHQDC-09-C-00091).
CR Astier Y, 2006, J AM CHEM SOC, V128, P1705, DOI 10.1021/ja057123+
   Bhimji A., 2013, ANAL CHEM, V14, P6813
   Biswas P, 2011, CHEM COMMUN, V47, P5259, DOI 10.1039/c1cc10648a
   Davis DA, 2009, BIOCHEM J, V419, P497, DOI 10.1042/BJ20082068
   De Cock KM, 2011, EMERG INFECT DIS, V17, P1044, DOI [10.3201/eid1706.100184, 10.3201/eid/1706.100184]
   Esseghaier C, 2013, BIOSENS BIOELECTRON, V41, P335, DOI 10.1016/j.bios.2012.08.049
   Frutos S, 2007, BIOPOLYMERS, V88, P164, DOI 10.1002/bip.20685
   Garaj S, 2013, P NATL ACAD SCI USA, V110, P12192, DOI 10.1073/pnas.1220012110
   Kang XF, 2006, J AM CHEM SOC, V128, P10684, DOI 10.1021/ja063485l
   Laird GM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003398
   Liu AH, 2011, J PHYS CHEM LETT, V2, P1372, DOI 10.1021/jz200525v
   Luchian T, 2003, ANGEW CHEM INT EDIT, V42, P3766, DOI 10.1002/anie.200351313
   Macrae M.X., 2009, ACS NANO, V11, P3567
   Majd S, 2009, J AM CHEM SOC, V131, P16119, DOI 10.1021/ja904072s
   MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561
   Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003
   Perez MAS, 2010, J PHYS CHEM B, V114, P2525, DOI 10.1021/jp910958u
   Schibel AEP, 2010, J AM CHEM SOC, V132, P17992, DOI 10.1021/ja109501x
   Siwy Z, 2005, J AM CHEM SOC, V127, P5000, DOI 10.1021/ja043910f
   Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859
   Squires A, 2013, BIOPHYS J, V105, P543, DOI 10.1016/j.bpj.2013.06.008
   Stefureac RI, 2010, BIOCHEM CELL BIOL, V88, P347, DOI [10.1139/O09-176, 10.1139/o09-176]
   Stoloff DH, 2013, CURR OPIN BIOTECH, V24, P699, DOI 10.1016/j.copbio.2012.11.008
   Talaga DS, 2009, J AM CHEM SOC, V131, P9287, DOI 10.1021/ja901088b
   Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696
   Wang GH, 2013, ACCOUNTS CHEM RES, V46, P2867, DOI 10.1021/ar400031x
   Wang GH, 2014, BIOSENS BIOELECTRON, V53, P453, DOI 10.1016/j.bios.2013.10.013
   Wang GH, 2013, J PHYS CHEM B, V117, P4763, DOI 10.1021/jp309541h
   Yan N, 2011, P NATL ACAD SCI USA, V108, P9244, DOI 10.1073/pnas.1102943108
   Ying YL, 2012, CHEM COMMUN, V48, P8784, DOI 10.1039/c2cc32636a
   Ying YL, 2011, SMALL, V7, P87, DOI 10.1002/smll.201001428
   Zhang DW, 2013, ANAL BIOCHEM, V440, P120, DOI 10.1016/j.ab.2013.05.032
   Zhao Q, 2008, BIOPHYS J, V94, P1267, DOI 10.1529/biophysj.107.117598
   Zhao QT, 2009, J AM CHEM SOC, V131, P6324, DOI 10.1021/ja9004893
NR 34
TC 11
Z9 11
U1 8
U2 187
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 15
PY 2014
VL 62
BP 158
EP 162
DI 10.1016/j.bios.2014.06.041
PG 5
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AN1IB
UT WOS:000340334800026
PM 24997370
OA green_accepted
DA 2018-01-05
ER

PT J
AU Sanpui, P
   Zheng, X
   Loeb, JC
   Bisesi, JH
   Khan, IA
   Afrooz, ARMN
   Liu, K
   Badireddy, AR
   Wiesner, MR
   Ferguson, PL
   Saleh, NB
   Lednicky, JA
   Sabo-Attwood, T
AF Sanpui, Pallab
   Zheng, Xiao
   Loeb, Julia C.
   Bisesi, Joseph H., Jr.
   Khan, Iftheker A.
   Afrooz, A. R. M. Nabiul
   Liu, Keira
   Badireddy, Appala Raju
   Wiesner, Mark R.
   Ferguson, P. Lee
   Saleh, Navid B.
   Lednicky, John A.
   Sabo-Attwood, Tara
TI Single-walled carbon nanotubes increase pandemic influenza A H1N1 virus
   infectivity of lung epithelial cells
SO PARTICLE AND FIBRE TOXICOLOGY
LA English
DT Article
DE Single-walled carbon nanotubes; Influenza virus; H1N1; Lung epithelial
   cells; Infectivity; Cytokines; Interferon Induced Proteins with
   Tetratricopeptide repeats (IFIT)
ID NEAR-INFRARED FLUORESCENCE; PULMONARY TOXICITY; IMMUNE-RESPONSE;
   NANOPARTICLES; EXPRESSION; EXPOSURE; HIV-1; NANOTECHNOLOGY;
   INFLAMMATION; AGGREGATION
AB Background: Airborne exposure to nanomaterials from unintended occupational or environmental exposures or as a consequence of product use may lead to adverse health effects. Numerous studies have focused on single-walled carbon nanotubes (SWCNTs) and their ability to cause pulmonary injury related to fibrosis, and cancer; however few studies have addressed their impact on infectious agents, particularly viruses that are known for causing severe disease. Here we have demonstrated the ability of pristine SWCNTs of diverse electronic structure to increase the susceptibility of small airway epithelial cells (SAEC) to pandemic influenza A H1N1 infection and discerned potential mechanisms of action driving this response.
   Methods: Small airway epithelial cells (SAEC) were exposed to three types of SWCNTs with varying electronic structure (SG65, SG76, CG200) followed by infection with A/Mexico/4108/2009 (pH1N1). Cells were then assayed for viral infectivity by immunofluorescence and viral titers. We quantified mRNA and protein levels of targets involved in inflammation and anti-viral activity (INF beta 1, IL-8, RANTES/CCL5, IFIT2, IFIT3, ST3GAL4, ST6GAL1, IL-10), localized sialic acid receptors, and assessed mitochondrial function. Hyperspectral imaging analysis was performed to map the SWCNTs and virus particles in fixed SAEC preparations. We additionally performed characterization analysis to monitor SWCNT aggregate size and structure under biological conditions using dynamic light scattering (DLS), static light scattering (SLS).
   Results: Based on data from viral titer and immunofluorescence assays, we report that pre-treatment of SAEC with SWCNTs significantly enhances viral infectivity that is not dependent on SWCNT electronic structure and aggregate size within the range of 106 nm - 243 nm. We further provide evidence to support that this noted effect on infectivity is not likely due to direct interaction of the virus and nanoparticles, but rather a combination of suppression of pro-inflammatory (RANTES) and anti-viral (IFIT2, IFIT3) gene/protein expression, impaired mitochondrial function and modulation of viral receptors by SWCNTs.
   Conclusions: Results of this work reveal the potential for SWCNTs to increase susceptibility to viral infections as a mechanism of adverse effect. These data highlight the importance of investigating the ability of carbon-nanomaterials to modulate the immune system, including impacts on anti-viral mechanisms in lung cells, thereby increasing susceptibility to infectious agents.
C1 [Sanpui, Pallab; Zheng, Xiao; Loeb, Julia C.; Bisesi, Joseph H., Jr.; Lednicky, John A.; Sabo-Attwood, Tara] Univ Florida, Dept Environm & Global Hlth, Ctr Environm & Human Toxicol, Gainesville, FL 32611 USA.
   [Sanpui, Pallab; Zheng, Xiao; Loeb, Julia C.; Bisesi, Joseph H., Jr.; Lednicky, John A.; Sabo-Attwood, Tara] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32611 USA.
   [Khan, Iftheker A.; Afrooz, A. R. M. Nabiul; Saleh, Navid B.] Univ Texas Austin, Dept Civil Architectural & Environm Engn, Austin, TX 78712 USA.
   [Liu, Keira; Badireddy, Appala Raju; Wiesner, Mark R.; Ferguson, P. Lee] Duke Univ, Nicholas Sch Environm, Dept Civil & Environm Engn, Durham, NC 27708 USA.
   [Liu, Keira; Badireddy, Appala Raju; Wiesner, Mark R.; Ferguson, P. Lee] Duke Univ, Ctr Environm Implicat NanoTechnol, Durham, NC 27708 USA.
RP Sabo-Attwood, T (reprint author), Univ Florida, Dept Environm & Global Hlth, Ctr Environm & Human Toxicol, 2187 Mowry Rd,Box 110885, Gainesville, FL 32611 USA.
EM sabo@phhp.ufl.edu
RI Ferguson, Lee/A-5501-2013
OI Sanpui, Pallab/0000-0002-2785-0115; Afrooz, ARM/0000-0002-9141-9426
FU National Institute of Health [R01HL114907]; University of Florida
   Research Foundation
FX The authors would like to thanks Drs. Gregory Gray and Gary Heil for the
   influenza virus stocks. This work was supported by the National
   Institute of Health (R01HL114907 to TSA) and the University of Florida
   Research Foundation (to TSA) for funding. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Afrooz ARMN, 2013, ENVIRON SCI TECHNOL, V47, P1853, DOI 10.1021/es3032709
   Arimoto T, 2005, AM J RESP CRIT CARE, V171, P379, DOI 10.1164/rccm.200402-248OC
   Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727
   Badireddy AR, 2012, ENVIRON SCI TECHNOL, V46, P10081, DOI 10.1021/es204140s
   Badireddy AR, 2012, ENVIRON SCI TECHNOL, V46, P5963, DOI 10.1021/es300340u
   Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k
   Bisesi JH, 2014, ENVIRON SCI TECHNOL, V48, P1973, DOI 10.1021/es4046023
   Castranova V, 2013, ACCOUNTS CHEM RES, V46, P642, DOI 10.1021/ar300004a
   Cesta MF, 2009, AM J RESP CELL MOL B, V43, P142
   Chen PH, 2013, BIOMATERIALS, V34, P5661, DOI 10.1016/j.biomaterials.2013.03.093
   Cristaudo A, 2006, Med Lav, V97, P475
   Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344
   Gerlach RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078912
   Guzman KAD, 2006, ENVIRON SCI TECHNOL, V40, P1401, DOI 10.1021/es0515708
   HATCH GE, 1985, ENVIRON RES, V36, P67, DOI 10.1016/0013-9351(85)90008-8
   Inoue K, 2010, FREE RADICAL BIO MED, V48, P924, DOI 10.1016/j.freeradbiomed.2010.01.013
   Inoue K, 2009, TOXICOL APPL PHARM, V237, P306, DOI 10.1016/j.taap.2009.04.003
   Ioannidis I, 2012, J VIROL, V86, P5422, DOI 10.1128/JVI.06757-11
   Irurzun VM, 2009, CHEM MATER, V21, P2238, DOI 10.1021/cm900250k
   Jackson P, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-154
   Kannangai R, 2010, INDIAN J MED MICROBI, V28, P95, DOI 10.4103/0255-0857.62482
   Khan IA, 2013, CHEMOSPHERE, V93, P1997, DOI 10.1016/j.chemosphere.2013.07.019
   Khan IA, 2013, ENVIRON SCI TECHNOL, V47, P8425, DOI 10.1021/es401748f
   Khan IA, 2013, ENVIRON SCI TECHNOL, V47, P1844, DOI 10.1021/es3030337
   Khan IA, 2010, ABSTR PAP AM CHEM S, V240
   Khan IA, 2011, ABSTR PAP AM CHEM S, V241
   Kogure T, 2006, GLYCOCONJUGATE J, V23, P101, DOI 10.1007/s10719-006-5442-z
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Li JJ, 2010, EXP BIOL MED, V235, P1025, DOI 10.1258/ebm.2010.010021
   Liu Y, 2013, ACCOUNTS CHEM RES, V46, P702, DOI 10.1021/ar300028m
   Ma XW, 2012, ACS NANO, V6, P10486, DOI 10.1021/nn302457v
   Mangum James B, 2006, Part Fibre Toxicol, V3, P15, DOI 10.1186/1743-8977-3-15
   Manke A, 2013, TOXICOL MECH METHOD, V23, P196, DOI 10.3109/15376516.2012.753967
   Matsukura S, 1998, AM J RESP CELL MOL, V18, P255, DOI 10.1165/ajrcmb.18.2.2822                                                        
   Matthaei M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056659
   Mizutani N, 2012, BIOL PHARM BULL, V35, P2133, DOI 10.1248/bpb.b12-00357                                                           
   Monteerarat Y, 2010, ARCH VIROL, V155, P889, DOI 10.1007/s00705-010-0658-4
   Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008
   Nowack B, 2013, ENVIRON INT, V59, P1, DOI 10.1016/j.envint.2013.04.003
   Nygaard UC, 2009, TOXICOL SCI, V109, P113, DOI 10.1093/toxsci/kfp057
   Piao CQ, 2005, CARCINOGENESIS, V26, P725, DOI 10.1093/carcin/bgi016
   Reddy ARN, 2012, ENVIRON TOXICOL, V27, P211, DOI 10.1002/tox.20632
   Rivera Z, 2008, CURR OPIN PULM MED, V14, P316, DOI 10.1097/MCP.0b013e3283018220
   Rodriguez-Yanez Y, 2013, TOXICOL MECH METHOD, V23, P178, DOI 10.3109/15376516.2012.754534
   Saber AT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069020
   Sabo-Attwood T, 2005, AM J PATHOL, V167, P1243, DOI 10.1016/S0002-9440(10)61212-6                                                   
   Sayers BC, 2013, AM J RESP CELL MOL, V49, P525, DOI 10.1165/rcmb.2013-0019OC
   Schierz A, 2012, ENVIRON SCI TECHNOL, V46, P12262, DOI 10.1021/es301856a
   Shannahan JH, 2013, SMALL, V9, P2171, DOI 10.1002/smll.201202243
   Shvedova AA, 2009, PHARMACOL THERAPEUT, V121, P192, DOI 10.1016/j.pharmthera.2008.10.009
   Shvedova AA, 2009, J INTERN MED, V267, P106
   Shvedova AA, 2008, AM J RESP CELL MOL, V38, P579, DOI 10.1165/rcmb.2007-0255OC
   Swedin L, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-16
   Teeguarden JG, 2010, TOXICOL SCI ADV ACCE, V120, P123, DOI [10.1093/toxsci/kfq363, DOI 10.1093/TOXSCI/KFQ363]
   Thorley AJ, 2013, PHARMACOL THERAPEUT, V140, P176, DOI 10.1016/j.pharmthera.2013.06.008
   Viswanathan K, 2010, GLYCOCONJUGATE J, V27, P561, DOI 10.1007/s10719-010-9303-4
   Wang J, 2013, CURR DRUG METAB, V14, P891, DOI 10.2174/138920021131400111                                                      
   Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228
   Wu D, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-78
   Wu SH, 2011, CURR OPIN INFECT DIS, V24, P235, DOI 10.1097/QCO.0b013e328344c0e3
   Yang Z, 2010, NANOMED-NANOTECHNOL, V6, P427, DOI 10.1016/j.nano.2009.11.007
   Zhang M, 2013, BIOMATERIALS, V34, P1383, DOI 10.1016/j.biomaterials.2012.10.067
   Zhang ZS, 2013, BIOCHEM BIOPH RES CO, V436, P650, DOI 10.1016/j.bbrc.2013.06.009
   Zhou X, 2013, INT J BIOL SCI, V9, P200, DOI 10.7150/ijbs.5613
   Zuniga J, 2011, AUTOIMMUNITY, V44, P562, DOI 10.3109/08916934.2011.592885
NR 65
TC 5
Z9 5
U1 4
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-8977
J9 PART FIBRE TOXICOL
JI Part. Fibre Toxicol.
PD DEC 14
PY 2014
VL 11
DI 10.1186/s12989-014-0066-0
PG 15
WC Toxicology
SC Toxicology
GA CC5NS
UT WOS:000350405900001
PM 25497303
OA gold
DA 2018-01-05
ER

PT J
AU Gunzenhauser, J
   Wyss, R
   Manley, S
AF Gunzenhaeuser, Julia
   Wyss, Romain
   Manley, Suliana
TI A Quantitative Approach to Evaluate the Impact of Fluorescent Labeling
   on Membrane-Bound HIV-Gag Assembly by Titration of Unlabeled Proteins
SO PLOS ONE
LA English
DT Article
ID CORRELATION SPECTROSCOPY; LOCALIZATION MICROSCOPY; CELL; STOICHIOMETRY;
   VISUALIZATION; PARTICLES; VIRIONS
AB The assembly process of the human immunodeficiency virus 1 (HIV-1) is driven by the viral polyprotein Gag. Fluorescence imaging of Gag protein fusions is widely performed and has revealed important information on viral assembly. Gag fusion proteins are commonly co-transfected with an unlabeled form of Gag to prevent labeling artifacts such as morphological defects and decreased infectivity. Although viral assembly is widely studied on individual cells, the efficiency of the co-transfection rescue has never been tested at the single cell level. Here, we first develop a methodology to quantify levels of unlabeled to labeled Gag in single cells using a fluorescent reporter protein for unlabeled Gag and fluorescence correlation spectroscopy. Using super-resolution imaging based on photoactivated localization microscopy (PALM) combined with molecular counting we then study the nanoscale morphology of Gag clusters as a function of unlabeled to labeled Gag ratios in single cells. We show that for a given co-transfection ratio, individual cells express a wide range of protein ratios, necessitating a quantitative read-out for the expression of unlabeled Gag. Further, we show that monomerically labeled Gag assembles into membrane-bound clusters that are morphologically indistinguishable from mixtures of unlabeled and labeled Gag.
C1 [Gunzenhaeuser, Julia; Manley, Suliana] Ecole Polytech Fed Lausanne, Lab Expt Biophys, Lausanne, Switzerland.
   [Wyss, Romain] Ecole Polytech Fed Lausanne, Lab Phys Chem Polymers & Membranes, Lausanne, Switzerland.
RP Manley, S (reprint author), Ecole Polytech Fed Lausanne, Lab Expt Biophys, Lausanne, Switzerland.
EM suliana.manley@epfl.ch
RI Manley, Suliana/D-3818-2012; EPFL, Physics/O-6514-2016
OI Manley, Suliana/0000-0002-4755-4778; 
FU European Community [243016-PALMassembly]
FX European Community's Seventh Framework Programme 243016-PALMassembly, SM
   JG. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Baumgartel V, 2011, NAT CELL BIOL, V13, P469, DOI 10.1038/ncb2215
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Charette SJ, 2010, J IMMUNOL METHODS, V353, P148, DOI 10.1016/j.jim.2009.12.007
   Chen RH, 1999, AM J PHYSIOL-RENAL, V276, pF777
   Chen Y, 2009, BIOPHYS J, V96, P1961, DOI 10.1016/j.bpj.2008.10.067
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Goedhart J, 2011, PLOS ONE, V6
   Gonzalez G, 2011, PLOS ONE, V6
   Gunzenhauser J, 2012, NANO LETT, V12, P4705, DOI 10.1021/nl3021076
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116
   Ivanchenko S, 2009, PLOS PATHOGENS, V5
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Landgraf D, 2012, NAT METHODS, V9, P480, DOI [10.1038/NMETH.1955, 10.1038/nmeth.1955]
   Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102
   Lehmann M, 2011, PLOS PATHOGENS, V7
   MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705
   Malkusch S, 2012, HISTOCHEM CELL BIOL, P1
   Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176
   Materna SC, 2005, FEMS MICROBIOL LETT, V243, P29, DOI 10.1016/j.femsle.2004.11.035
   McKinney SA, 2009, NAT METHODS, V6, P131, DOI [10.1038/NMETH.1296, 10.1038/nmeth.1296]
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Starr TE, 2002, J PHYS CHEM B, V106, P2365, DOI 10.1021/jp012689f
   Stirnnagel K, 2010, RETROVIROLOGY, V7
   Voelkel C, 2010, P NATL ACAD SCI USA, V107, P7805, DOI 10.1073/pnas.0914517107
   Wang L, 2004, P NATL ACAD SCI USA, V101, P16745, DOI 10.1073/pnas.0407752101
NR 29
TC 2
Z9 2
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2014
VL 9
IS 12
AR e115095
DI 10.1371/journal.pone.0115095
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW9YP
UT WOS:000346611400094
PM 25493438
OA gold
DA 2018-01-05
ER

PT J
AU Guo, QQ
   Chen, Y
   Song, ZP
   Guo, LQ
   Fu, FF
   Chen, GN
AF Guo, Qingquan
   Chen, Ying
   Song, Zhiping
   Guo, Liangqia
   Fu, Fengfu
   Chen, Guonan
TI Label-free and enzyme-free sensitive fluorescent detection of human
   immunodeficiency virus deoxyribonucleic acid based on hybridization
   chain reaction
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE Hybridization chain reaction; Human immunodeficiency virus;
   G-quadruplexes; N-methyl mesoporphyrin IX
ID QUADRUPLEX DNAZYME NANOWIRES; DNA DETECTION; NUCLEIC-ACIDS;
   ULTRASENSITIVE DETECTION; REACTION AMPLIFICATION; COLORIMETRIC
   DETECTION; AMPLIFIED DETECTION; ASSAY; POLYMERASE; UNIVERSAL
AB A label-free and enzyme-free sensitive fluorescent detection of human immunodeficiency virus (HIV) deoxyribonucleic acid (DNA) based on isothermal hybridization chain reaction (HCR) was developed. A G-quadruplex sequence which was incorporated into one of the two hairpin probes was inactive in the absence of target DNA. However, at the presence of target DNA numerous G-quadruplexes along DNA nanowires were self-assembled through HCR. Using N-methyl mesoporphyrin IX (NMM) as the fluorophore, a "turn-on" fluorescent response would be achieved and detected as low as 0.5 nmol L (1) of HIV DNA. This proposed method was applied to detect HIV DNA in biologic samples with satisfactory results. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Guo, Qingquan; Chen, Ying; Song, Zhiping; Guo, Liangqia; Fu, Fengfu; Chen, Guonan] Fuzhou Univ, Coll Chem, Fujian Prov Key Lab Anal & Detect Technol Food Sa, Minist Educ,Key Lab Anal & Detect Food Safety, Fuzhou 350116, Peoples R China.
RP Guo, LQ (reprint author), Fuzhou Univ, Coll Chem, Fujian Prov Key Lab Anal & Detect Technol Food Sa, Minist Educ,Key Lab Anal & Detect Food Safety, Fuzhou 350116, Peoples R China.
EM lqguo@fzu.edu.cn
RI Guo, Liangqia/M-6895-2017
OI Guo, Liangqia/0000-0003-0605-7473
FU NSFC [21177023]; Science Foundation of Fujian Province of China
   [2013J01044]
FX The authors gratefully acknowledge NSFC (21177023) and Science
   Foundation of Fujian Province of China (2013J01044) for financial
   support.
CR Chen X, 2013, P NATL ACAD SCI USA, V110, P5386, DOI 10.1073/pnas.1222807110
   Chen Y, 2012, ANAL CHEM, V84, P7750, DOI 10.1021/ac3012285
   Dirks RM, 2004, P NATL ACAD SCI USA, V101, P15275, DOI 10.1073/pnas.0407024101
   Dong J, 2012, BIOSENS BIOELECTRON, V38, P258, DOI 10.1016/j.bios.2012.05.042
   FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641
   Gao FL, 2013, ANAL CHEM, V85, P11788, DOI 10.1021/ac4032109
   Guo LQ, 2012, BIOSENS BIOELECTRON, V35, P123, DOI 10.1016/j.bios.2012.02.031
   Hao YL, 2014, BIOSENS BIOELECTRON, V52, P261, DOI 10.1016/j.bios.2013.08.034
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Hu D, 2010, CHEM-EUR J, V16, P2605, DOI 10.1002/chem.200902166
   Huang J, 2011, ANGEW CHEM INT EDIT, V50, P401, DOI 10.1002/anie.201005375
   Li D, 2010, ACCOUNTS CHEM RES, V43, P631, DOI 10.1021/ar900245u
   Liu P, 2013, ANAL CHEM, V85, P7689, DOI 10.1021/ac4001157
   Liu SF, 2013, BIOSENS BIOELECTRON, V49, P472, DOI 10.1016/j.bios.2013.05.037
   Liu YF, 2013, CHEM COMMUN, V49, P7424, DOI 10.1039/c3cc42639d
   Orbach R, 2013, LANGMUIR, V29, P13066, DOI 10.1021/la402888b
   Qin HX, 2010, CHEM COMMUN, V46, P7385, DOI 10.1039/c0cc01695k
   Ren W, 2013, BIOSENS BIOELECTRON, V49, P380, DOI 10.1016/j.bios.2013.05.055
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0
   Shen W, 2012, J AM CHEM SOC, V134, P14678, DOI 10.1021/ja306265n
   Shimron S, 2012, ANAL CHEM, V84, P1042, DOI 10.1021/ac202643y
   Tang W, 2012, CHEM COMMUN, V48, P6678, DOI 10.1039/c2cc32747c
   Wang C, 2013, BIOSENS BIOELECTRON, V47, P324, DOI 10.1016/j.bios.2013.03.020
   Wang F, 2011, J AM CHEM SOC, V133, P17149, DOI 10.1021/ja2076789
   Xuan F, 2014, J AM CHEM SOC, V136, P9810, DOI 10.1021/ja502904s
   Yang XJ, 2014, ACS NANO, V8, P4902, DOI 10.1021/nn5008786
   Zheng J, 2014, ANAL CHEM, V86, P2205, DOI 10.1021/ac404004m
NR 28
TC 12
Z9 13
U1 6
U2 84
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD DEC 10
PY 2014
VL 852
BP 244
EP 249
DI 10.1016/j.aca.2014.09.032
PG 6
WC Chemistry, Analytical
SC Chemistry
GA AS4HW
UT WOS:000344235900033
PM 25441904
DA 2018-01-05
ER

PT J
AU Spreen, W
   Ford, SL
   Chen, SG
   Wilfret, D
   Margolis, D
   Gould, E
   Piscitelli, S
AF Spreen, William
   Ford, Susan L.
   Chen, Shuguang
   Wilfret, David
   Margolis, David
   Gould, Elizabeth
   Piscitelli, Stephen
TI GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose
   Long-Acting Injectable Administration in Healthy Subjects
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE GSK1265744; pharmacokinetics; tissue penetration; single dose
ID GENITAL-TRACT; HIV; DOLUTEGRAVIR; INHIBITOR
AB Background: GSK1265744 (744) is an HIV-1 integrase inhibitor in clinical development as a long-acting (LA) injectable formulation. This study evaluated plasma and tissue pharmacokinetics after single-dose administration of 744 LA administered by intramuscular (IM) or subcutaneous injections.
   Methods: This was a phase I, open-label, 9-cohort, parallel study of 744 in healthy subjects. 744 was administered as a 200 mg/mL nanosuspension at doses of 100-800 mg IM and 100-400 mg subcutaneous.
   Results: Eight (6 active and 2 placebo) male and female subjects participated in each of the first 7 cohorts. All 8 subjects, 4 males and 4 females, received active 744 LA in cohorts 8 and 9 and underwent rectal and cervicovaginal tissue sampling, respectively. Plasma pharmacokinetic sampling was performed for a minimum of 12 weeks or until 744 concentrations were <= 0.1 mu g/mL. Rectal and cervicovaginal tissue biopsies were performed at weeks 2 and 8 (cohort 8) and weeks 4 and 12 (cohort 9). 744 LA was generally safe and well tolerated after single injections. A majority of subjects reported injection site reactions, all graded as mild in intensity. Plasma concentration-time profiles were prolonged with measureable concentrations up to 52 weeks after dosing. 744 LA 800 mg IM achieved mean concentrations above protein adjusted-IC90 for approximately 16 weeks. Rectal and cervicovaginal tissue concentrations ranged from <8% to 28% of corresponding plasma concentrations.
   Conclusions: These data suggest 744 LA injection has potential application as a monthly or less frequent HIV treatment or prevention agent.
C1 [Spreen, William; Ford, Susan L.; Chen, Shuguang; Wilfret, David; Margolis, David; Gould, Elizabeth; Piscitelli, Stephen] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
RP Piscitelli, S (reprint author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM stephen.c.piscitelli@gsk.com
FU ViiV Healthcare
FX Supported by ViiV Healthcare.
CR Adams JL, 2013, ANTIVIR THER, V18, P1005, DOI 10.3851/IMP2665
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Chan VO, 2006, EUR J RADIOL, V58, P480, DOI 10.1016/j.ejrad.2006.01.008
   Greener BN, 2013, JAIDS-J ACQ IMM DEF, V64, P39, DOI 10.1097/QAI.0b013e31829ed7a4
   Margolis DA, 2014, 21 C RETR OPP INF BO
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
NR 7
TC 34
Z9 34
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 5
PY 2014
VL 67
IS 5
BP 481
EP 486
DI 10.1097/QAI.0000000000000301                                            
          
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT2NW
UT WOS:000344772300008
PM 25140909
DA 2018-01-05
ER

PT J
AU Spreen, W
   Williams, P
   Margolis, D
   Ford, SL
   Crauwels, H
   Lou, Y
   Gould, E
   Stevens, M
   Piscitelli, S
AF Spreen, William
   Williams, Peter
   Margolis, David
   Ford, Susan L.
   Crauwels, Herta
   Lou, Yu
   Gould, Elizabeth
   Stevens, Marita
   Piscitelli, Stephen
TI Pharmacokinetics, Safety, and Tolerability With Repeat Doses of
   GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in
   Healthy Adults
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE long-acting; GSK1265744; rilpivirine; TMC278; injections;
   pharmacokinetics; nanosuspension
AB Objective: Pharmacokinetics, safety, and tolerability of GSK1265744 (744) and rilpivirine (RPV) (TMC278) were assessed after repeat dosing of long-acting (LA) injectable formulations in healthy subjects.
   Methods: Subjects received a 14-day lead-in of oral 744 (30 mg/d) to assess safety and tolerability before injectable administration. Subjects were randomized into 4 cohorts: 800 mg of 744 LA intramuscularly (IM) followed by 3 monthly doses of (1) 200 mg subcutaneously, (2) 200 mg IM, (3) 400 mg IM, or (4) a second injection of 800 mg IM after 12 weeks. Cohorts 2 and 3 also received IM doses of RPV LA at months 3 (1200 mg) and 4 (900 or 600 mg). Pharmacokinetics and safety were assessed throughout the trial.
   Results: Forty-seven subjects enrolled; 40 received >= 1 LA injection with 37 completing all planned injections. Seven subjects discontinued 744 oral (non-drug-related, n = 6; dizziness, n = 1). The 744 LA and RPV LA injections were generally well tolerated, with grade 1 injection site reactions most commonly reported. Three subjects discontinued during injection phase (consent withdrawn, n = 2; self-limited rash, n = 1). There were no grade 3 or 4 adverse events and no clinically significant trends in laboratory abnormalities, electrocardiograms, or vital signs. All dose cohorts achieved therapeutically relevant plasma concentrations of each drug within 3 days with prolonged exposure over the dosing interval. Plasma concentrations of 744 exceeded the protein-adjusted IC90 and RPV plasma concentrations and were comparable to steady-state oral RPV 25 mg/d.
   Conclusions: These data support the potential application of dual-therapy 744 LA and RPV LA for treatment of HIV-1 infection.
C1 [Spreen, William; Margolis, David; Ford, Susan L.; Lou, Yu; Gould, Elizabeth; Piscitelli, Stephen] GlaxoSmithKline, Infect Dis Res & Dev, Res Triangle Pk, NC 27709 USA.
   [Williams, Peter; Crauwels, Herta; Stevens, Marita] Janssen Infect Dis BVBA, Beerse, Belgium.
RP Piscitelli, S (reprint author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM stephen.c.piscitelli@gsk.com
FU ViiV Healthcare; Janssen Research Development
FX Supported by ViiV Healthcare and Janssen Research & Development.
CR Ammassari A, 2012, ANTIVIR THER, V17, P785, DOI 10.3851/IMP2084
   Arribas JR, 2013, CURR OPIN HIV AIDS, V8, P341, DOI 10.1097/COH.0b013e328361fabd
   Crauwels HM, 2013, J CLIN PHARMACOL, V53, P834, DOI 10.1002/jcph.107
   Crauwels HM, 2010, 10 INT C DRUG THER H
   Llibre JM, 2012, AIDS REV, V14, P168
   Margolis D, 2014, 21 C RETR OPP INF MA
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen W, 2014, J ACQUIR IMMUNE DEFI
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
NR 9
TC 34
Z9 34
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 5
PY 2014
VL 67
IS 5
BP 487
EP 492
DI 10.1097/QAI.0000000000000365                                            
          
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AT2NW
UT WOS:000344772300009
PM 25473882
OA gold
DA 2018-01-05
ER

PT J
AU Wang, WZ
   Wei, ZW
   Zhang, D
   Ma, HL
   Wang, ZH
   Bu, XL
   Li, ML
   Geng, LL
   Lausted, C
   Hood, L
   Fang, QJ
   Wang, H
   Hu, ZY
AF Wang, Weizhi
   Wei, Zewen
   Zhang, Di
   Ma, Huailei
   Wang, Zihua
   Bu, Xiangli
   Li, Menglin
   Geng, Lingling
   Lausted, Christopher
   Hood, Leroy
   Fang, Qiaojun
   Wang, Hao
   Hu, Zhiyuan
TI Rapid Screening of Peptide Probes through In Situ Single-Bead Sequencing
   Microarray
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID AMINOPEPTIDASE N; GOLD NANOPARTICLES; DRUG-DELIVERY; HIV-1; INHIBITOR;
   RECEPTOR; DESIGN; CANCER; CONFORMATION; ENFUVIRTIDE
AB Peptide ligands as targeting probes for in vivo imaging and drug delivery have attracted great interest in the biomedical community. However, high affinity and specificity screening of large peptide libraries remains a tedious process. Here, we report a continuous-flow microfluidic method for one-bead-one-compound (OBOC) combinatorial peptide library screening. We screened a library with 2 x 10(5) peptide beads within 4 h and discovered 140 noncanonical peptide hits targeting the tumor marker, aminopeptidase N (APN). Using the Clustal algorithm, we identified the conserved sequence Tyr-XX-Tyr in the N terminal. We demonstrated that the novel sequence YVEYHLC peptides have both nanomolar affinity and high specificity for APN in ex vivo and in vivo models. We envision that the successful demonstration of this integrated novel nanotechnology for peptide screening and identification open a new avenue for rapid discovery of new peptide-based reagents for disease diagnostics and therapeutics.
C1 [Wang, Weizhi; Wei, Zewen; Zhang, Di; Ma, Huailei; Wang, Zihua; Bu, Xiangli; Li, Menglin; Geng, Lingling; Fang, Qiaojun; Wang, Hao; Hu, Zhiyuan] Chinese Acad Sci, Key Lab Biomed Effects Nanomat & Nanosafety, Natl Ctr Nanosci & Technol China, Beijing 100190, Peoples R China.
   [Wang, Weizhi; Wei, Zewen; Zhang, Di; Hu, Zhiyuan] Beijing Proteome Res Ctr, Beijing Inst Radiat Med, Beijing 102206, Peoples R China.
   [Lausted, Christopher; Hood, Leroy; Hu, Zhiyuan] Inst Syst Biol, Seattle, WA 98109 USA.
RP Wang, H (reprint author), Chinese Acad Sci, Key Lab Biomed Effects Nanomat & Nanosafety, Natl Ctr Nanosci & Technol China, Beijing 100190, Peoples R China.
EM wanghao@nanoctr.cn; huzy@nanoctr.cn
FU National Natural Science Foundation of China [21305023, 31270875,
   31470049]; Beijing Natural Science Foundation [2144058]; Chinese Academy
   of Science [YZ201217]
FX We acknowledge funding from the National Natural Science Foundation of
   China (No. 21305023), Beijing Natural Science Foundation (No. 2144058),
   National Natural Science Foundation of China (Nos. 31270875, 31470049)
   and Project of Chinese Academy of Science (No. YZ201217). We express our
   gratitude to Dr. Yu Gao (Scripps Research Institute), Dr. Zongxiu Nie
   and Dr. Rui Zhao (Institute of Chemistry, Chinese Academy of Science),
   and Dr. Zhihong Li (Peking University) for their valuable help.
CR Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108
   Alberici L, 2013, CANCER RES, V73, P804, DOI 10.1158/0008-5472.CAN-12-1668
   Brown SD, 2010, J AM CHEM SOC, V132, P4678, DOI 10.1021/ja908117a
   Chanda N, 2010, P NATL ACAD SCI USA, V107, P8760, DOI 10.1073/pnas.1002143107
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0                                                                
   Delehanty JB, 2011, J AM CHEM SOC, V133, P10482, DOI 10.1021/ja200555z
   Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960                                                   
   Englund EA, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1629
   Fang XH, 2010, ACCOUNTS CHEM RES, V43, P48, DOI 10.1021/ar900101s
   Fellet MS, 2012, J AM CHEM SOC, V134, P16891, DOI 10.1021/ja308121d
   FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Geng LL, 2012, J COMPUT AID MOL DES, V26, P1327, DOI 10.1007/s10822-012-9617-3
   Gerber EE, 2013, NATURE, V503, P126, DOI 10.1038/nature12614
   Han LA, 2011, BIOMATERIALS, V32, P1242, DOI 10.1016/j.biomaterials.2010.09.070
   Harbut MB, 2011, P NATL ACAD SCI USA, V108, pE526, DOI 10.1073/pnas.1105601108
   Isidro-Llobet A, 2009, CHEM REV, V109, P2455, DOI 10.1021/cr800323s
   Itoh Y, 2010, J AM CHEM SOC, V132, P5820, DOI 10.1021/ja100691p
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Kim YW, 2011, NAT PROTOC, V6, P761, DOI 10.1038/nprot.2011.324
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lazarus MB, 2011, NATURE, V469, P564, DOI 10.1038/nature09638
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Lee S, 2010, CHEM REV, V110, P3087, DOI 10.1021/cr900361p
   Liu CX, 2011, J CONTROL RELEASE, V151, P162, DOI 10.1016/j.jconrel.2011.02.027
   Luo LM, 2013, BIOMATERIALS, V34, P1102, DOI 10.1016/j.biomaterials.2012.10.029
   Maerkle F, 2014, ADV MATER, V26, P3730, DOI 10.1002/adma.201305759
   Moulin E, 2012, CHEM SOC REV, V41, P1031, DOI 10.1039/c1cs15185a
   Oi N, 2010, CANCER RES, V70, P9755, DOI 10.1158/0008-5472.CAN-10-2858
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Pandey AK, 2013, J AM CHEM SOC, V135, P4333, DOI 10.1021/ja3109664
   Pasqualini R, 2000, CANCER RES, V60, P722
   Prasuhn DE, 2010, ACS NANO, V4, P7726, DOI 10.1021/nn102986a
   Schirwitz C, 2013, ADV MATER, V25, P1598, DOI 10.1002/adma.201203853
   Su L, 2011, BIOORGAN MED CHEM, V19, P900, DOI 10.1016/j.bmc.2010.11.066
   Wang HB, 2011, ANGEW CHEM INT EDIT, V50, P7065, DOI 10.1002/anie.201101351
   Wang WZ, 2014, ANAL CHEM, V86, P3703, DOI 10.1021/ac500465e
   Wang WZ, 2011, LAB CHIP, V11, P929, DOI [10.1039/c0lc00542h, 10.1039/c01c00542h]
   Wong AHM, 2012, J BIOL CHEM, V287, P36804, DOI 10.1074/jbc.M112.398842
   Xiong LQ, 2010, BIOMATERIALS, V31, P7078, DOI 10.1016/j.biomaterials.2010.05.065
   Zhang CJ, 2013, ANGEW CHEM INT EDIT, V52, P14060, DOI 10.1002/anie.201307803
   Zhang X, 2011, CURR MED CHEM, V18, P5011, DOI 10.2174/092986711797535155                                                      
   Zheng H, 2013, LAB CHIP, V13, P3347, DOI 10.1039/c3lc50632k
   Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968
NR 46
TC 14
Z9 14
U1 6
U2 64
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 2
PY 2014
VL 86
IS 23
BP 11854
EP 11859
DI 10.1021/ac503454z
PG 6
WC Chemistry, Analytical
SC Chemistry
GA AU7TK
UT WOS:000345803300056
PM 25370073
DA 2018-01-05
ER

PT J
AU Mishra, V
   Kesharwani, P
   Jain, NK
AF Mishra, Vijay
   Kesharwani, Prashant
   Jain, Narendra K.
TI siRNA nanotherapeutics: a Trojan horse approach against HIV
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID SMALL INTERFERING RNA; POLY(PROPYLENE IMINE) DENDRIMERS; SOLUBLE
   CARBOSILANE DENDRIMERS; VIRUS TYPE-1 REPLICATION; GENE DELIVERY;
   HUMAN-CELLS; IN-VITRO; INHIBITION; INFECTION; THERAPY
AB The concept of RNA interference (RNAi) is gaining popularity for the better management of various diseases, including HIV. Currently, the successful biomedical utilization of siRNA therapeutics is hampered, both in vivo and in vitro, mainly by the inherent inability of naked siRNA to cross the cell membrane. RNAi can potentially improve the weakness of current highly active antiretroviral therapy (HAART) by diminishing the chances of the appearance of antiHIV-resistant strains. Here, we discuss the nanocarrier-mediated delivery of siRNA delivery as well as highlighted the scope of siRNA-mediated gene-silencing technology for improved HIV treatment.
C1 [Mishra, Vijay; Kesharwani, Prashant; Jain, Narendra K.] Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar, MP, India.
RP Jain, NK (reprint author), Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar, MP, India.
EM jnarendr@yahoo.co.in
FU University Grant Commission (UGC), New Delhi, India [F7-57/2007/BSR];
   Indian Council of Medical Research (ICMR), New Delhi, India
   [45/03/2011/PHA-BMS]
FX University Grant Commission (UGC) (F7-57/2007/BSR), New Delhi, India and
   Indian Council of Medical Research (ICMR) (45/03/2011/PHA-BMS), New
   Delhi, India, are the only grant sponsors to the authors Vijay Mishra
   and Prashant Kesharwani, respectively in terms of providing the Senior
   Research Fellowships.
CR Behr JP, 1997, CHIMIA, V51, P34
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196                                                     
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004
   Dominska M, 2010, J CELL SCI, V123, P1183, DOI 10.1242/jcs.066399
   Dove A, 2010, NAT MED, V16, P258, DOI 10.1038/nm0310-258
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Eszterhas Susan K, 2011, Infect Dis Rep, V3, pe11, DOI 10.4081/idr.2011.e11
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Han WL, 2004, VIROLOGY, V330, P221, DOI 10.1016/j.virol.2004.09.027
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Hu WY, 2002, CURR BIOL, V12, P1301, DOI 10.1016/S0960-9822(02)00975-2
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Kesharwani P, 2014, PROG POLYM SCI, V39, P268, DOI 10.1016/j.progpolymsci.2013.07.005
   Kesharwani P, 2012, BIOMATERIALS, V33, P7138, DOI 10.1016/j.biomaterials.2012.06.068
   Kesharwani P, 2011, CURR DRUG TARGETS, V12, P1478, DOI 10.2174/138945011796818135                                                      
   Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940
   Kim HJ, 2006, BIOMATERIALS, V27, P2292, DOI 10.1016/j.biomaterials.2005.10.023
   Kim SH, 2008, BIOMATERIALS, V29, P4439, DOI 10.1016/j.biomaterials.2008.07.047
   Kolber MA, 2007, AIDS REV, V9, P68
   Kuiken C, 2010, HIV SEQUENCE COMPEND
   Lares MR, 2010, TRENDS BIOTECHNOL, V28, P570, DOI 10.1016/j.tibtech.2010.07.009
   Lavigne C, 2013, EXPERT OPIN BIOL TH, V13, P973, DOI 10.1517/14712598.2013.743526
   Lee NS, 2004, VIRUS RES, V102, P53, DOI 10.1016/j.virusres.2004.01.015
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Martinez MA, 2002, AIDS, V16, P2385, DOI 10.1097/00002030-200212060-00002
   Martinez Miguel Angel, 2009, V487, P343, DOI [10.1007/978-1-60327-547-7_17, 10.1007/978-1-60327-547_17]
   Mishra V, 2010, PHARMAZIE, V65, P891, DOI 10.1691/ph.2010.9385
   Mishra V, 2014, INT J PHARMACEUT, V461, P380, DOI 10.1016/j.ijpharm.2013.11.043
   Mishra V, 2009, J BIOMAT SCI-POLYM E, V20, P141, DOI 10.1163/156856208X386246
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Park WS, 2002, NUCLEIC ACIDS RES, V30, P4830, DOI 10.1093/nar/gkf627
   Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505
   Pedziwiatr-Werbicka E, 2011, COLLOID SURFACE B, V83, P360, DOI 10.1016/j.colsurfb.2010.12.008
   Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085
   Reynolds JL, 2012, J NEUROIMMUNE PHARM, V7, P673, DOI 10.1007/s11481-012-9379-7
   Sioud M, 2003, BIOCHEM BIOPH RES CO, V312, P1220, DOI 10.1016/j.bbrc.2003.11.057
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Strayer DS, 2005, MOL THER, V11, P823, DOI 10.1016/j.ymthe.2005.01.020
   Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   Tziveleka LA, 2007, J CONTROL RELEASE, V117, P137, DOI 10.1016/j.jconrel.2006.10.019
   Vandekercichove L., 2006, DRUG DISCOV TODAY TH, V3, P227
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071
   Zhao H, 2004, FEBS LETT, V563, P241, DOI 10.1016/S0014-5793(04)00284-4
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
NR 57
TC 11
Z9 11
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD DEC
PY 2014
VL 19
IS 12
BP 1913
EP 1920
DI 10.1016/j.drudis.2014.09.019
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AY7XM
UT WOS:000347769200009
PM 25281591
DA 2018-01-05
ER

PT J
AU Boons, E
   Li, GD
   Vanstreels, E
   Vercruysse, T
   Pannecouque, C
   Vandamme, AM
   Daelemans, D
AF Boons, Eline
   Li, Guangdi
   Vanstreels, Els
   Vercruysse, Thomas
   Pannecouque, Christophe
   Vandamme, Anne-Mieke
   Daelemans, Dirk
TI A stably expressed llama single-domain intrabody targeting Rev displays
   broad-spectrum anti-HIV activity
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE HIV-1; Single-domain antibody; Intrabody; Rev
ID THROMBOTIC THROMBOCYTOPENIC PURPURA; RESONANCE ENERGY-TRANSFER; PFIZER
   MONKEY VIRUS; NUCLEAR EXPORT; IN-VIVO; COLORIMETRIC ASSAY; RESPONSE
   ELEMENT; BINDING; PROTEIN; RNA
AB The HIV Rev protein mediates the transport of partially and unspliced HIV mRNA from the nucleus to the cytoplasm. Rev multimerizes on a secondary stem-loop structure present in the viral intron-containing mRNA species and recruits the cellular karyopherin CRM1 to export viral mRNAs from the nucleus to the cytoplasm. Previously we have identified a single-domain intrabody (Nb-190), derived from a llama heavy-chain antibody, which efficiently inhibits Rev multimerization and suppresses the production of infectious virus. We recently mapped the epitope of this nanobody and demonstrated that Rev residues 1(20 and Y23 are crucial for interaction while residues V16, H53 and L60 are important to a lesser extent.
   Here, we generated cell lines stably expressing Nb-190 and assessed the capacity of these cell lines to suppress the replication of different HIV-1 subtypes. These cells stably expressing the single-domain antibody are protected from virus-induced cytopathogenic effect even in the context of high multiplicity of infection. In addition, the replication of different subtypes of group M and one strain of group 0 is significantly suppressed in these cell lines. Next, we analysed the natural variations of Rev amino acids in sequence samples from HIV-1 infected patients worldwide and assessed the effect of Nb-190 on the most prevalent polymorphisms occurring at the key epitope positions (K20 and Y23) in Rev. We found that Nb-190 was able to suppress the function of these Rev variants except for the K20N mutant, which was present in only 0.7% of HIV-1 sequence populations (n = 4632).
   Cells stably expressing the single-domain intrabody Nb-190 are protected against virus-induced cytopathogenic effect and display a selective survival advantage upon infection. In addition, Nb-190 suppresses the replication of a wide range of different HIV-1 subtypes. Large-scale sequence analysis reveals that the Nb-190 epitope positions in Rev are well conserved across major HIV-1 subtypes and groups. Altogether, our results indicate that Nb-190 may have broad potential as a gene therapeutic agent against HIV-1. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Boons, Eline; Vanstreels, Els; Vercruysse, Thomas; Pannecouque, Christophe; Daelemans, Dirk] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Virol & Chemotherapy, Rega Inst Med Res, B-3000 Leuven, Belgium.
   [Li, Guangdi; Vandamme, Anne-Mieke] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Clin & Epidemiol Virol, Rega Inst Med Res, B-3000 Leuven, Belgium.
   [Vandamme, Anne-Mieke] Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, P-1349008 Lisbon, Portugal.
   [Vandamme, Anne-Mieke] Univ Nova Lisboa, Inst Higiene & Med Trop, Unidade Microbiol, P-1349008 Lisbon, Portugal.
RP Daelemans, D (reprint author), Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Virol & Chemotherapy, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Leuven, Belgium.
EM Eline.boons@rega.kuleuven.be; Guangdi.Li@rega.kuleuven.be;
   Els.vanstreels@rega.kuleuven.be; Thomas.vercruysse@rega.kuleuven.be;
   Christophe.pannecouque@rega.kuleuven.be; Annemie.vandamme@uzleuven.be;
   Dirk.daelemans@rega.kuleuven.be
RI Vandamme, Anne Mieke/I-4127-2012; Daelemans, Dirk/P-7923-2017
OI Vandamme, Anne Mieke/0000-0002-6594-2766; Daelemans,
   Dirk/0000-0001-7092-1153
FU IWT (agency for innovation through science and technology) Grant; Fonds
   voor Wetenschappelijk Onderzoek - Flanders (FWO) [G069214N]
FX We thank L. Bral for help in the construction of the plasmids required
   to establish the stable cell lines, Y. Schrooten for handling of the
   sequencing and K. Erven and C. Heens for MOI determination of the
   different HIV-strains. E.B. is supported by an IWT (agency for
   innovation through science and technology) Grant. A.V. received funding
   from the Fonds voor Wetenschappelijk Onderzoek - Flanders (FWO), Grant
   G069214N.
CR Abecasis AB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-7
   Anderson J, 2008, HUM GENE THER, V19, P217, DOI 10.1089/hum.2007.108
   Barre-Sinoussi F., 2013, PRESENT FUTURE 30 YE
   BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256
   Callewaert F, 2012, BLOOD, V120, P3603, DOI 10.1182/blood-2012-04-420943
   Daelemans D, 2005, MOL CELL BIOL, V25, P728, DOI 10.1128/MCB.25.2.728-739.2005
   Daelemans D, 2004, J BIOL CHEM, V279, P50167, DOI 10.1074/jbc.M407713200
   DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0
   Daugherty MD, 2008, MOL CELL, V31, P824, DOI 10.1016/j.molcel.2008.07.016
   Daugherty MD, 2010, NAT STRUCT MOL BIOL, V17, P1337, DOI 10.1038/nsmb.1902
   DiMattia MA, 2010, P NATL ACAD SCI USA, V107, P5810, DOI 10.1073/pnas.0914946107
   Fischer U, 1999, NUCLEIC ACIDS RES, V27, P4128, DOI 10.1093/nar/27.21.4128
   FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Holz JB, 2012, TRANSFUS APHER SCI, V46, P343, DOI 10.1016/j.transci.2012.03.027
   Jain C, 2001, MOL CELL, V7, P603, DOI 10.1016/S1097-2765(01)00207-6
   Kalland N.H., 1994, MOL CELL BIOL, V14, P7436
   Li GD, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-126
   MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U                                                    
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   McNally JG, 2008, METHOD CELL BIOL, V85, P329, DOI 10.1016/S0091-679X(08)85014-5
   MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538
   Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X
   Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6
   Oliveira S, 2013, J CONTROL RELEASE, V172, P607, DOI 10.1016/j.jconrel.2013.08.298
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Pardon E, 2014, NAT PROTOC, V9, P674, DOI 10.1038/nprot.2014.039
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pineda-Pena AC, 2013, INFECT GENET EVOL, V19, P337, DOI 10.1016/j.meegid.2013.04.032
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Siontorou CG, 2013, INT J NANOMED, V8, P4215, DOI 10.2147/IJN.S39428
   SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0
   SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5
   Stahl SJ, 2010, J MOL BIOL, V397, P697, DOI 10.1016/j.jmb.2010.01.061
   Thomas SL, 1998, J VIROL, V72, P2935
   Ulm JW, 2007, VIROLOGY, V363, P245, DOI 10.1016/j.virol.2006.09.048
   Venken T, 2012, PROTEINS, V80, P1633, DOI 10.1002/prot.24057
   Vercruysse T., 2014, CURR HIV RES
   Vercruysse T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060259
   Vercruysse T, 2011, RNA BIOL, V8, P316, DOI 10.4161/rna.8.2.13782
   Vercruysse T, 2010, J BIOL CHEM, V285, P21768, DOI 10.1074/jbc.M110.112490
   ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734
   Zhen AJ, 2014, VIRUSES-BASEL, V6, P1, DOI 10.3390/v6010001
   ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944
NR 47
TC 8
Z9 8
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD DEC
PY 2014
VL 112
BP 91
EP 102
DI 10.1016/j.antiviral.2014.10.007
PG 12
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA AX5CE
UT WOS:000346943900009
PM 25453342
DA 2018-01-05
ER

PT J
AU Cavazos-Garduno, A
   Flores, AAO
   Serrano-Nino, JC
   Beristain, CI
   Garcia, HS
AF Cavazos-Garduno, A.
   Flores, A. A. Ochoa
   Serrano-Nino, J. C.
   Beristain, C. I.
   Garcia, H. S.
TI OPERATING AND COMPOSITIONAL VARIABLES FOR PREPARATION OF BETULINIC ACID
   NANOEMULSIONS
SO REVISTA MEXICANA DE INGENIERIA QUIMICA
LA English
DT Article
DE betulinic acid; nanoemulsion; ultrasonication; globule size; delivery
   system
ID RESPONSE-SURFACE METHODOLOGY; NANO-EMULSIONS; DELIVERY; DRUG;
   OPTIMIZATION; STABILITY; OIL; FORMULATIONS; MELANOMA; CELLS
AB Betulinic acid is a triterpene with remarkable biological activities, including anticancer and highlights the anti -HIV activity. In recent years, nanoemulsions have been used, as delivery systems to improve the bioavailability of lipophilic bioactive compounds. In this work response surface methodology (RSM) by a central composite design was employed to evaluate the effects of emulsification power, ultrasonication time, emulsifier concentration in the characteristics of betulinic acid nanoemulsions. Optimal conditions for nanoemulsions formation were obtained and different emulsifiers and oils as the dispersed phase were studied. The effect of pH on globule size and zeta potential of betulinic acid nanoemulsions was studied. The statistical model used for globule size effectively fitted the experimental data with a R-2 of 0.94. Operating conditions (power and emulsification time) and the quadratic terms, had significant effects on globule size. The optimal conditions to prepare nanoemulsions with an mean diameter of 64 nm were using 15% emulsifier (tween 60), and an ultrasonication power of 20 W during 220 s. Nanoemulsions prepared with medium chain oil as the dispersed phase had the lowest mean globule size; however, after storage time, nanoemulsions with the mixture medium chain oil:olive oil, the globule size remained unaltered. The pH variation changed the globule surface charge, values from -30 mV were obtained, and after storage time there was no significant change in the zeta potential.
C1 [Cavazos-Garduno, A.; Flores, A. A. Ochoa; Serrano-Nino, J. C.; Garcia, H. S.] UNIDA Inst Tecnol Veracruz, Mexico City 91897, Veracruz, Mexico.
   [Beristain, C. I.] Univ Veracruzana, Inst Ciencias Basicas, Xalapa 91000, Veracruz, Mexico.
RP Garcia, HS (reprint author), UNIDA Inst Tecnol Veracruz, MA Quevedo 2779, Mexico City 91897, Veracruz, Mexico.
EM hugosgg@gmail.com
FU National Council for Science and Technology of Mexico (CONACyT) [129334]
FX The authors gratefully acknowledge the financial support of the National
   Council for Science and Technology of Mexico (CONACyT) through the grant
   129334.
CR Ahmed K, 2012, FOOD CHEM, V132, P799, DOI 10.1016/j.foodchem.2011.11.039
   Aiken C, 2005, TRENDS MOL MED, V11, P31, DOI 10.1016/j.molmed.2004.11.001
   Akowuah GA, 2008, PHARMAZIE, V63, P788, DOI 10.1691/ph.2008.8596
   Alakurtti S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/j.ejps.2006.04.006
   Araujo S.C.A., 2007, INT J PHARMACEUT, V337, P307
   Chaparro-Mercado MC, 2012, REV MEX ING QUIM, V11, P11
   Chau CF, 2007, TRENDS FOOD SCI TECH, V18, P269, DOI 10.1016/j.tifs.2007.01.007
   Chen HD, 2006, FOOD TECHNOL-CHICAGO, V60, P30
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371
   Ciurlea S.A., 2010, J AGROALIMENT PROCES, V16, P420
   Clark RM, 2000, LIPIDS, V35, P803, DOI 10.1007/s11745-000-0589-8
   Constantinides PP, 2004, ADV DRUG DELIVER REV, V56, P1243, DOI 10.1016/j.addr.2003.12.005
   de Melo CL, 2009, J AGR FOOD CHEM, V57, P8776, DOI 10.1021/jf900768w
   Dehelean CA, 2011, J BIOMED NANOTECHNOL, V7, P317, DOI 10.1166/jbn.2011.1297
   Donsi F, 2012, IND ENG CHEM RES, V51, P7606, DOI 10.1021/ie2017898
   Dowling AP, 2004, MATER TODAY, V7, P30, DOI 10.1016/S1369-7021(04)00628-5                                                   
   El Kinawy OS, 2012, CHEM ENG TECHNOL, V35, P937, DOI 10.1002/ceat.201100608
   Fulda S, 2005, NEOPLASIA, V7, P162, DOI 10.1593/neo.04442
   Fulda S, 2008, INT J MOL SCI, V9, P1096, DOI 10.3390/ijms9061096
   Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j
   Gutierrez JM, 2008, CURR OPIN COLLOID IN, V13, P245, DOI 10.1016/j.cocis.2008.01.005
   Hsu JP, 2003, J COLLOID INTERF SCI, V259, P374, DOI 10.1016/S0021-9797(02)00207-2
   Jager S, 2008, MOLECULES, V13, P3224, DOI 10.3390/molecules13123224
   Jafari SM, 2007, J FOOD ENG, V82, P478, DOI 10.1016/j.foodeng.2007.03.007
   Jafari SM, 2006, INT J FOOD PROP, V9, P475, DOI 10.1080/10942910600596464
   Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3                                                   
   Kelmann RG, 2007, INT J PHARM, V342, P231, DOI 10.1016/j.ijpharm.2007.05.004
   Kentish S, 2008, INNOV FOOD SCI EMERG, V9, P170, DOI 10.1016/j.ifset.2007.07.005
   Klang V, 2011, J DRUG DELIV SCI TEC, V21, P55, DOI 10.1016/S1773-2247(11)50006-1                                                   
   Lee SJ, 2011, J AGR FOOD CHEM, V59, P415, DOI 10.1021/jf103511v
   Li PH, 2012, ULTRASON SONOCHEM, V19, P192, DOI 10.1016/j.ultsonch.2011.05.017
   Maali A, 2013, J DISPER SCI TECHNOL, V34, P92, DOI 10.1080/01932691.2011.648498
   PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046                                                             
   Qian C, 2012, FOOD CHEM, V132, P1221, DOI 10.1016/j.foodchem.2011.11.091
   Sadurni N, 2005, EUR J PHARM SCI, V26, P438, DOI 10.1016/j.ejps.2005.08.001
   Santos-Magalhaes NS, 2010, ADV DRUG DELIVER REV, V62, P560, DOI 10.1016/j.addr.2009.11.024
   Sawada N, 2004, BRIT J CANCER, V90, P1672, DOI 10.1038/sj.bjc.6601746
   Shafik A, 2007, MED SCI MONITOR, V13, pCR24
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma N., 2010, CHRONICLES YOUNG SCI, V1, P2
   Silva HD, 2012, FOOD BIOPROCESS TECH, V5, P854, DOI 10.1007/s11947-011-0683-7
   Singh KK, 2008, INT J PHARM, V347, P136, DOI 10.1016/j.ijpharm.2007.06.035
   Solans C, 2005, CURR OPIN COLLOID IN, V10, P102, DOI 10.1016/j.cocis.2005.06.004
   Solans C, 2012, CURR OPIN COLLOID IN, V17, P246, DOI 10.1016/j.cocis.2012.07.003
   Sozer N, 2009, TRENDS BIOTECHNOL, V27, P82, DOI 10.1016/j.tibtech.2008.10.010
   STALIDIS G, 1990, J COLLOID INTERF SCI, V135, P313, DOI 10.1016/0021-9797(90)90002-6                                                    
   Subramanian B, 2008, INT IMMUNOPHARMACOL, V8, P1533, DOI 10.1016/j.intimp.2008.06.009
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023
   Tagne JB, 2008, MOL PHARMACEUT, V5, P1055, DOI 10.1021/mp8000556
   Tang SY, 2013, ULTRASON SONOCHEM, V20, P485, DOI 10.1016/j.ultsonch.2012.04.005
   Tiwari SB, 2006, J NANOSCI NANOTECHNO, V6, P3215, DOI 10.1166/jnn.2006.440
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wang LJ, 2009, J COLLOID INTERF SCI, V330, P443, DOI 10.1016/j.jcis.2008.10.077
   Yogeeswari P, 2005, CURR MED CHEM, V12, P657, DOI 10.2174/0929867053202214                                                        
   Yuan Y, 2008, FOOD CHEM, V107, P1300, DOI 10.1016/j.foodchem.2007.09.015
   Zhao Y, 2010, INT J PHARMACEUT, V383, P170, DOI 10.1016/j.ijpharm.2009.08.035
   Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2
NR 57
TC 6
Z9 6
U1 1
U2 7
PU UNIV AUTONOMA METROPOLITANA-IZTAPALAPA
PI MEXICO
PA C/O DR JAIME VERNON-CARTER, SAN RAFAEL ATLIXCO NO 186, COL VICENTINA,
   DELEGACION IZTAPALAPA, MEXICO, 09340, MEXICO
SN 1665-2738
J9 REV MEX ING QUIM
JI Rev. Mex. Ing. Quim.
PD DEC
PY 2014
VL 13
IS 3
BP 689
EP 703
PG 15
WC Chemistry, Applied; Engineering, Chemical
SC Chemistry; Engineering
GA AW6QY
UT WOS:000346394800004
DA 2018-01-05
ER

PT J
AU Edagwa, BJ
   Guo, DW
   Puligujja, P
   Chen, H
   McMillan, J
   Liu, XM
   Gendelman, HE
   Narayanasamy, P
AF Edagwa, Benson J.
   Guo, Dongwei
   Puligujja, Pavan
   Chen, Han
   McMillan, JoEllyn
   Liu, Xinming
   Gendelman, Howard E.
   Narayanasamy, Prabagaran
TI Long-acting antituberculous therapeutic nanoparticles target macrophage
   endosomes
SO FASEB JOURNAL
LA English
DT Article
DE Mycobacterium tuberculosis; Mycobacterium smegmatis; immunoisolation;
   MDM; subcellular trafficking
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; DRUG-DELIVERY;
   HIV INFECTION; PATHOGENESIS; PHAGOSOME; NANOTECHNOLOGY; NANOMEDICINE;
   EPIDEMIOLOGY; PHAGOCYTOSIS
AB Eradication of Mycobacterium tuberculosis (MTB) infection requires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies. To facilitate and optimize MTB therapeutic selections, a mononuclear phagocyte (MP; monocyte, macrophage, and dendritic cell)-targeted drug delivery strategy was developed. Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were prepared, and their physicochemical properties were evaluated. This included the evaluation of MP particle uptake and retention, cell viability, and antimicrobial efficacy. Drug levels reached 6 mu g/10(6) cells in human monocyte-derived macrophages (MDMs) for nanoparticle treatments compared with 0.1 mu g/10(6) cells for native drugs. High RIF and INHP levels were retained in MDM for > 15 d following nanoparticle loading. Rapid loss of native drugs was observed in cells and culture fluids within 24 h. Antimicrobial activities were determined against Mycobacterium smegmatis (M. smegmatis). Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic efficacy compared with equivalent concentrations of native drugs. Notably, nanoformulated RIF and INHP were found to be localized in recycling and late MDM endosomal compartments. These were the same compartments that contained the pathogen. Our results demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.
C1 [Edagwa, Benson J.; Puligujja, Pavan; McMillan, JoEllyn; Liu, Xinming; Gendelman, Howard E.; Narayanasamy, Prabagaran] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
   [Guo, Dongwei] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA.
   [Chen, Han] Univ Nebraska, Ctr Biotechnol, Lincoln, NE USA.
RP Gendelman, HE (reprint author), Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Narayanasamy, Prabagaran/0000-0002-9617-5555
FU U.S. National Institutes of Health [P01-DA-028555, R01-NS-36126,
   P01-NS-31492, 2R01-NS-034239, P01-MH-64570, P01-NS-43985,
   R01-A-1097550]; Nebraska Research Initiative
FX The authors are grateful to Janice Taylor and James R. Talaska (Confocal
   Laser Scanning Core facility, University of Nebraska Medical Center) for
   assistance with confocal microscopy. This work was supported by U.S.
   National Institutes of Health grants P01-DA-028555, R01-NS-36126,
   P01-NS-31492, 2R01-NS-034239, P01-MH-64570, and P01-NS-43985 (to H.E.G.)
   and R01-A-1097550 (to P.N.) and by the Nebraska Research Initiative (to
   H.E.G. and P.N.).
CR ARMSTRON.JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Banyal S, 2013, CURR OPIN PULM MED, V19, P289, DOI 10.1097/MCP.0b013e32835eff08
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Bhandari R., 2012, J CHROMATOGR SEP TEC, V3, P128, DOI DOI 10.4172/2157-7064.1000128
   Calleja I, 2004, J CHROMATOGR A, V1031, P289, DOI 10.1016/j.chroma.2003.12.041
   CLARK SC, 1989, ANN NY ACAD SCI, V557, P438
   CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257
   Clift MJD, 2008, TOXICOL APPL PHARM, V232, P418, DOI 10.1016/j.taap.2008.06.009
   Cooper AM, 2011, MUCOSAL IMMUNOL, V4, P252, DOI 10.1038/mi.2011.13
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   CROWLE AJ, 1991, INFECT IMMUN, V59, P1823
   de Faria TJ, 2012, ANTIMICROB AGENTS CH, V56, P2259, DOI 10.1128/AAC.05993-11
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dube D, 2012, DRUG DISCOV TODAY, V17, P760, DOI 10.1016/j.drudis.2012.03.012
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   Edagwa B, 2013, BIOORG MED CHEM LETT, V23, P6138, DOI 10.1016/j.bmcl.2013.09.011
   Ehlers S, 2009, INFECTION, V37, P87, DOI 10.1007/s15010-009-8450-7
   El-Sadr WM, 2001, CLIN INFECT DIS, V32, P623, DOI 10.1086/318706
   Eoh H, 2009, CHEM BIOL, V16, P1230, DOI 10.1016/j.chembiol.2009.10.014
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Getahun H, 2010, CLIN INFECT DIS, V50, pS201, DOI 10.1086/651492
   Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861
   HART PD, 1987, J EXP MED, V166, P933, DOI 10.1084/jem.166.4.933
   Hearn MJ, 2009, EUR J MED CHEM, V44, P4169, DOI 10.1016/j.ejmech.2009.05.009
   HONEYBOURNE D, 1994, THORAX, V49, P104, DOI 10.1136/thx.49.2.104
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kang PB, 2005, J EXP MED, V202, P987, DOI 10.1084/jem.20051239
   KUMAR BD, 1992, J TROP MED HYG, V95, P424
   Kurosu M, 2007, J MED CHEM, V50, P3973, DOI 10.1021/jm070638m
   Lawn SD, 2011, LANCET, V378, P57, DOI 10.1016/S0140-6736(10)62173-3
   Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520
   Lenaerts AJ, 2007, ANTIMICROB AGENTS CH, V51, P3338, DOI 10.1128/AAC.00276-07
   Lienhardt C, 2012, NAT REV MICROBIOL, V10, P407, DOI 10.1038/nrmicro2797
   Lillebaek T, 2003, J INFECT DIS, V188, P1032, DOI 10.1086/378240
   MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063                                                         
   Morgan J R, 1993, Respir Med, V87, P320, DOI 10.1016/0954-6111(93)90040-7
   Narayanasamy P, 2010, CHEM BIOL, V17, P117, DOI 10.1016/j.chembiol.2010.01.013
   Nowacek Ari, 2013, Methods Mol Biol, V991, P41, DOI 10.1007/978-1-62703-336-7_5
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Olakanmi O, 2000, INFECT IMMUN, V68, P5619, DOI 10.1128/IAI.68.10.5619-5627.2000                                                
   Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001
   Pandey R, 2011, NANOMED-NANOTECHNOL, V7, P259, DOI 10.1016/j.nano.2011.01.009
   Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464
   Philips JA, 2008, CELL MICROBIOL, V10, P2408, DOI 10.1111/j.1462-5822.2008.01239.x
   Russell DG, 2010, SCIENCE, V328, P852, DOI 10.1126/science.1184784
   Schaible UE, 2007, PLOS MED, V4, P806, DOI 10.1371/journal.pmed.0040115
   SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920
   SHIVE MS, 1997, ADV DRUG DELIV REV, V28, P5
   SMALL PLC, 1994, SCIENCE, V263, P637, DOI 10.1126/science.8303269                                                         
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003
   Smith SJ, 1999, ANN PHARMACOTHER, V33, P27, DOI 10.1345/aph.18116
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277
   Venugopal J, 2008, CURR PHARM DESIGN, V14, P2184, DOI 10.2174/138161208785740180                                                      
   Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346
   Xu PS, 2009, MOL PHARMACEUT, V6, P190, DOI 10.1021/mp800137z
   XU SM, 1994, J IMMUNOL, V153, P2568
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yu SS, 2012, INT J NANOMED, V7, P799, DOI 10.2147/IJN.S28531
NR 61
TC 12
Z9 12
U1 0
U2 12
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2014
VL 28
IS 12
BP 5071
EP 5082
DI 10.1096/fj.14-255786
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AU9EN
UT WOS:000345894500005
PM 25122556
OA gold
DA 2018-01-05
ER

PT J
AU Brito, LA
   Chan, M
   Shaw, CA
   Hekele, A
   Carsillo, T
   Schaefer, M
   Archer, J
   Seubert, A
   Otten, GR
   Beard, CW
   Dey, AK
   Lilja, A
   Valiante, NM
   Mason, PW
   Mandl, CW
   Barnett, SW
   Dormitzer, PR
   Ulmer, JB
   Singh, M
   O'Hagan, DT
   Geall, AJ
AF Brito, Luis A.
   Chan, Michelle
   Shaw, Christine A.
   Hekele, Armin
   Carsillo, Thomas
   Schaefer, Mary
   Archer, Jacob
   Seubert, Anja
   Otten, Gillis R.
   Beard, Clayton W.
   Dey, Antu K.
   Lilja, Anders
   Valiante, Nicholas M.
   Mason, Peter W.
   Mandl, Christian W.
   Barnett, Susan W.
   Dormitzer, Philip R.
   Ulmer, Jeffrey B.
   Singh, Manmohan
   O'Hagan, Derek T.
   Geall, Andrew J.
TI A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
SO MOLECULAR THERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA; DNA VACCINES; NEUTRALIZING
   ANTIBODIES; GENE-TRANSFER; ENVELOPE GLYCOPROTEIN; ALPHAVIRUS VECTORS;
   IMMUNE-RESPONSES; CLINICAL-TRIALS; VACCINATION
AB Nucleic acid-based vaccines such as viral vectors, plasmid DNA, and mRNA are being developed as a means to address a number of unmet medical needs that current vaccine technologies have been unable to address. Here, we describe a cationic nanoemulsion (CNE) delivery system developed to deliver a self-amplifying mRNA vaccine. This nonviral delivery system is based on Novartis's proprietary adjuvant MF59, which has an established clinical safety profile and is well tolerated in children, adults, and the elderly. We show that nonviral delivery of a 9 kb self-amplifying mRNA elicits potent immune responses in mice, rats, rabbits, and nonhuman primates comparable to a viral delivery technology, and demonstrate that, relatively low doses (75 mu g) induce antibody and T-cell responses in primates. We also show the CNE-delivered self-amplifying mRNA enhances the local immune environment through recruitment of immune cells similar to an MF59 adjuvanted subunit vaccine. Lastly, we show that the site of protein expression within the muscle and magnitude of protein expression is similar to a viral vector. Given the demonstration that self-amplifying mRNA delivered using a CNE is well tolerated and immunogenic in a variety of animal models, we are optimistic about the prospects for this technology.
C1 [Brito, Luis A.; Chan, Michelle; Shaw, Christine A.; Carsillo, Thomas; Schaefer, Mary; Archer, Jacob; Otten, Gillis R.; Lilja, Anders; Valiante, Nicholas M.; Mason, Peter W.; Mandl, Christian W.; Barnett, Susan W.; Dormitzer, Philip R.; Ulmer, Jeffrey B.; O'Hagan, Derek T.; Geall, Andrew J.] Novartis Vaccines, Cambridge, MA 02139 USA.
   [Hekele, Armin; Beard, Clayton W.; Dey, Antu K.; Singh, Manmohan] Novartis Vaccines, Holly Springs, NC USA.
   [Seubert, Anja] Novartis Vaccines, Siena, Italy.
RP Geall, AJ (reprint author), Novartis Vaccines, 350 Massachusetts Ave, Cambridge, MA 02139 USA.
EM Andrew.Geall@novartis.com
OI Seubert, Anja/0000-0003-3321-9140
FU HIV Vaccine Research and Design Grant [5P01AI066287]; Defense Advanced
   Research Project Agency [HR0011-12-3-001]
FX We thank the RNA Vaccine Platform Team at Novartis Vaccines and
   Diagnostics and, in particular, Nisha Chander, Mildred Ugozzoli, Madhura
   Shidhore, and Simona Mangiavacchi for coordinating the delivery of
   formulations for the animal studies; Vania Kenanova, Alicia Carlson, and
   Farid SaniSarraf for conducting the bioluminescence studies in mice;
   James Monroe for serology support; Marianna Taccone for cell
   infiltration work; May Liu and Keith Mansfield at NIBR for assisting
   with pathology; LAS in Cambridge for conducing mouse studies; Rino
   Rappouli and Dong Yu for the helpful discussions; Peter Barry at
   University of California Davis for conducing SEAP experiments in NHP;
   Anthony Cristillo, Sharon Orndorff, and Ranajit Pal at Advanced
   Biosciences Laboratories for conducting CMV experiments in NHP; and Joe
   Beirao at Josman LLC for conducting the HIV experiments in rabbits.
   Funding for the HIV studies was provided by HIV Vaccine Research and
   Design Grant 5P01AI066287. Additional funding was provided in part from
   the Defense Advanced Research Project Agency under agreement
   HR0011-12-3-001. The authors are Novartis shareholders and employees of
   Novartis Vaccines and Diagnostics.
CR Abel K, 2011, J VIROL, V85, P2878, DOI 10.1128/JVI.00883-10
   Atkins Gregory J., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000859
   Barnett SW, 2010, J VIROL, V84, P5975, DOI 10.1128/JVI.02533-09
   Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Choi WJ, 2004, BIOMATERIALS, V25, P5893, DOI 10.1016/j.biomaterials.2004.01.031
   Doria-Rose NA, 2005, J VIROL, V79, P11214, DOI 10.1128/JVI.79.17.11214-11224.2005
   Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8
   Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Griffiths PD, 2011, LANCET, V377, P1256, DOI 10.1016/S0140-6736(11)60136-0
   Hippalgaonkar K, 2010, AAPS PHARMSCITECH, V11, P1526, DOI 10.1208/s12249-010-9526-5
   Hoerr I, 2000, EUR J IMMUNOL, V30, P1
   Johansson DX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029732
   Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181
   Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x
   Loomis RJ, 2013, VACCINE, V31, P919, DOI 10.1016/j.vaccine.2012.12.009
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Mooij P, 2000, J VIROL, V74, P4017, DOI 10.1128/JVI.74.9.4017-4027.2000                                                 
   O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061
   O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]
   Ott G, 2002, J CONTROL RELEASE, V79, P1, DOI 10.1016/S0168-3659(01)00545-4
   Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202
   Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085
   Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360
   Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010
   Roman VRG, 2013, AIDS RES HUM RETROV, V29, P1504, DOI [10.1089/AID.2013.0076, 10.1089/aid.2013.0076]
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Scheel B, 2005, EUR J IMMUNOL, V35, P1557, DOI 10.1002/eji.200425656
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402                                                     
   Smerdou C, 1999, CURR OPIN MOL THER, V1, P244
   Smith LR, 2010, VACCINE, V28, P2565, DOI 10.1016/j.vaccine.2010.01.029
   Spearman P, 2011, J INFECT DIS, V203, P1165, DOI 10.1093/infdis/jiq175
   Srivastava IK, 2002, J VIROL, V76, P2835, DOI 10.1128/JVI.76.6.2835-2847.2002
   Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108
   Tritto E, 2009, VACCINE, V27, P3331, DOI 10.1016/j.vaccine.2009.01.084
   Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Xu L, 2011, J PHARM SCI-US, V100, P38, DOI 10.1002/jps.22243
   Zimmer G, 2010, VIRUSES-BASEL, V2, P413, DOI 10.3390/v2020413
NR 46
TC 42
Z9 45
U1 2
U2 19
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD DEC
PY 2014
VL 22
IS 12
BP 2118
EP 2129
DI 10.1038/mt.2014.133
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA AU8BW
UT WOS:000345822600011
PM 25027661
OA gold
DA 2018-01-05
ER

PT J
AU Tsai, N
   Lee, B
   Kim, A
   Yang, R
   Pan, R
   Lee, DK
   Chow, EK
   Ho, D
AF Tsai, Nathaniel
   Lee, Bryan
   Kim, Austin
   Yang, Richard
   Pan, Ricky
   Lee, Dong-Keun
   Chow, Edward K.
   Ho, Dean
TI Nanomedicine for Global Health
SO JALA
LA English
DT Review
DE global health; nanomedicine; drug delivery; HIV; AIDS; cancer
ID CANCER-THERAPY; BREAST-CANCER; DRUG-RELEASE; NANOPARTICLES;
   NANOTECHNOLOGY; RESISTANCE; MEDICINE; DELIVERY; IMPACT; SIZE
AB Despite modern advances, a broad range of disorders such as cancer and infectious diseases continually afflict the global population. Novel therapeutics are continuously being explored to address these challenges. Therefore, scalable, effective, and safe therapies that are readily accessible to third-world countries are of major interest. In this article, we discuss the potential advantages that the nanomedicine field may harness toward successful implementation against some of the major diseases of our generation.
C1 [Tsai, Nathaniel; Kim, Austin; Yang, Richard; Pan, Ricky; Lee, Dong-Keun; Ho, Dean] UCLA Sch Dent, Div Oral Biol & Med, Los Angeles, CA USA.
   [Lee, Bryan; Ho, Dean] UCLA Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA USA.
   [Chow, Edward K.] Natl Univ Singapore, Canc Sci Inst Singapore, Yong Loo Lin Sch Med, Singapore 117599, Singapore.
   [Chow, Edward K.] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Singapore 117599, Singapore.
   [Ho, Dean] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA.
   [Ho, Dean] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA.
RP Chow, EK (reprint author), Natl Univ Singapore, Canc Sci Inst Singapore, Yong Loo Lin Sch Med, Singapore 117599, Singapore.
EM csikce@nus.edu.sg; dean.ho@ucla.edu
RI Chow, Edward/C-4697-2015
OI Chow, Edward/0000-0002-3075-1898
FU National Research Foundation Cancer Science Institute of Singapore RCE
   Main Grant; National Medical Research Council [NMRC CBRG-NIG
   BNIG12nov017]; Ministry of Education Academic Research Fund [MOE AcRF
   Tier 1 T1-2012 Oct-11]; National Science Foundation CAREER Award
   [CMMI-0846323]; Center for Scalable and Integrated NanoManufacturing
   [DMI-0327077, CMMI-0856492, DMR-1105060]; V Foundation for Cancer
   Research Scholars Award; Wallace H. Coulter Foundation Translational
   Research Award; Society for Laboratory Automation and Screening (SLAS)
   Endowed Fellowship; Beckman Coulter Life Sciences; National Cancer
   Institute [U54CA151880]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: National
   Research Foundation Cancer Science Institute of Singapore RCE Main
   Grant, National Medical Research Council (NMRC CBRG-NIG BNIG12nov017)
   and Ministry of Education Academic Research Fund (MOE AcRF Tier 1
   T1-2012 Oct-11) to E. K. C, and National Science Foundation CAREER Award
   (CMMI-0846323), Center for Scalable and Integrated NanoManufacturing
   (DMI-0327077), CMMI-0856492, DMR-1105060, V Foundation for Cancer
   Research Scholars Award, Wallace H. Coulter Foundation Translational
   Research Award, Society for Laboratory Automation and Screening (SLAS)
   Endowed Fellowship, Beckman Coulter Life Sciences, and National Cancer
   Institute grant U54CA151880 to D. H. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health.
CR Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3
   Adiseshaiah P, 2009, WILEY INTERDISCIP RE, V2, P99
   American Cancer Society, 2014, CANC FACTS FIG 2014
   Boisseau P, 2011, CR PHYS, V12, P620, DOI 10.1016/j.crhy.2011.06.001
   Hay Burgess D. C., 2006, NATURE S1, V444, P1, DOI DOI 10.1038/NATURE05440
   Charrois GJR, 2004, BBA-BIOMEMBRANES, V1663, P167, DOI 10.1016/j.bbamem.2004.03.006
   Chow EK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001713
   Chow EK-H, 2013, SCI TRANSL MED, V5, P216
   Creixell M, 2012, NANO TODAY, V7, P367, DOI 10.1016/j.nantod.2012.06.013
   Desimone J. M., 2011, 3 DIMENSIONAL NANOAR, P90
   Dickerson EB, 2008, CANCER LETT, V269, P57, DOI 10.1016/j.canlet.2008.04.026
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Galloway AL, 2013, NANOMED-NANOTECHNOL, V9, P523, DOI 10.1016/j.nano.2012.11.001
   Gao Z, 2008, ULTRASONICS, V48, P260, DOI 10.1016/j.ultras.2007.11.002
   Grand Challenges in Global Health, 2013, CHALL 1 CREAT EFF SI
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   He QJ, 2011, J MATER CHEM, V21, P15190, DOI 10.1039/c1jm13598h
   Hrkach J. H., 2012, SCI TRANSL MED, V4, P1
   Jensen SA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006839
   Kaplan LD, 2012, BEST PRACT RES CL HA, V25, P101, DOI 10.1016/j.beha.2012.01.001
   Kawasaki ES, 2005, NANOMED-NANOTECHNOL, V1, P101, DOI 10.1016/j.nano.2005.03.002
   Khademhosseini A, 2013, ADV HEALTHC MATER, V2, P10, DOI 10.1002/adhm.201200444
   Lal S, 2008, ACCOUNTS CHEM RES, V41, P1842, DOI 10.1021/ar800150g
   Man H. B., 2012, ULTRANANOCRYSTALLINE, P493
   Miele E, 2009, INT J NANOMED, V4, P99
   Mirkin CA, 2011, SCI POL REP, V1, P305, DOI 10.1007/978-94-007-1168-6_8
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Moore L, 2013, ADV MATER, V25, P3532, DOI 10.1002/adma.201300343
   Morton SW, 2013, ADV MATER, V25, P4707, DOI 10.1002/adma.201302025
   Park JH, 2008, PROG POLYM SCI, V33, P113, DOI 10.1016/j.progpolymsci.2007.09.003
   Partridge A H, 2001, J Natl Cancer Inst Monogr, P135
   Shapira A, 2011, DRUG RESIST UPDATE, V14, P150, DOI 10.1016/j.drup.2011.01.003
   Siepmann J, 2004, J CONTROL RELEASE, V96, P123, DOI 10.1016/j.jconrel.2004.01.011
   Singer PA, 2007, PLOS MED, V4, P1440, DOI 10.1371/journal.pmed.0040265
   Valencia PM, 2012, NAT NANOTECHNOL, V7, P623, DOI 10.1038/nnano.2012.168
   Webster TJ, 2006, INT J NANOMED, V1, P1, DOI 10.2147/nano.2006.1.1.1                                                         
   Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872
   World Health Organization, 2013, WORLD HLTH STAT 2013
   World Health Organization (WHO), 2013, NONC DIS FACT SHEET
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   [Anonymous], 2005, NANOMEDICINE
NR 45
TC 8
Z9 8
U1 2
U2 45
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2211-0682
EI 1540-2452
J9 JALA-J LAB AUTOM
JI JALA
PD DEC
PY 2014
VL 19
IS 6
BP 511
EP 516
DI 10.1177/2211068214538263
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA AU2SN
UT WOS:000345468000001
PM 24902713
OA gold
DA 2018-01-05
ER

PT J
AU Zong, TL
   Mei, L
   Gao, HL
   Shi, KR
   Chen, JT
   Wang, Y
   Zhang, QY
   Yang, YT
   He, Q
AF Zong, Taili
   Mei, Ling
   Gao, Huile
   Shi, Kairong
   Chen, Jiantao
   Wang, Yang
   Zhang, Qianyu
   Yang, Yuting
   He, Qin
TI Enhanced Glioma Targeting and Penetration by Dual-Targeting Liposome
   Co-modified with T7 and TAT
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE dual targeting; pharmacokinetics; distribution; stability; blood-brain
   barrier
ID BLOOD-BRAIN-BARRIER; EFFICIENT GENE DELIVERY; IN-VIVO; DRUG-DELIVERY;
   INTRACELLULAR DELIVERY; TUMOR MICROENVIRONMENT; HIV-1 TAT;
   NANOPARTICLES; PEPTIDE; DOXORUBICIN
AB The development of a drug delivery strategy that can not only cross the blood-brain barrier (BBB) rapidly, but also target the glioma and reach the core of glioma is essential and important for glioma treatment. To achieve this goal, we established a dual-targeting liposomal system modified with TAT (AYGRKKRRQRRR) and T7 (HAIYPRH), in which the specific ligand T7 could target BBB and brain glioma tumor and the nonspecific ligand TAT could enhance the effect of passing through BBB, and elevate the penetration into the tumor. The dual-targeting effects were evaluated by both in vitro and in vivo experiments. To identify the targeting effect, in vitro cellular uptake and BBB model were performed. Tumor spheroid penetration was performed to evaluate the penetration characteristics of the dual-targeting liposomes. In vivo pharmacokinetic studies were utilized to evaluate the influence of T7 and TAT peptides on the behavior of nanoparticle drug delivery system, and tissue distribution was further utilized to evaluate the glioma-targeting efficiency of the dual-targeting liposomes. 103:3891-3901, 2014
C1 [Zong, Taili; Mei, Ling; Gao, Huile; Shi, Kairong; Chen, Jiantao; Wang, Yang; Zhang, Qianyu; Yang, Yuting; He, Qin] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu 610041, Peoples R China.
   [Zong, Taili] Chongqing Pharmaceut Res Inst Co Ltd, Chongqing 400061, Peoples R China.
RP He, Q (reprint author), Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Tel 86-28-85502532,Fax 86-28-85502532, Chengdu 610041, Peoples R China.
EM qinhe@scu.edu.cn
RI gao, huile/G-8290-2012
OI gao, huile/0000-0002-5355-7238
FU National Natural Science Foundation of China [81373337]; National Basic
   Research Program of China (973 Program) [2013CB932504]; State Key
   Program of National Natural Science of China [81130060]
FX The work was funded by the National Natural Science Foundation of China
   (81373337) and the National Basic Research Program of China (973
   Program, 2013CB932504) and the State Key Program of National Natural
   Science of China (81130060).
CR Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019
   Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011
   Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8
   Bidros DS, 2009, NEUROTHERAPEUTICS, V6, P539, DOI 10.1016/j.nurt.2009.04.004
   Brightman M W, 1992, NIDA Res Monogr, V120, P87
   Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002
   Chekhonin VP, 2007, B EXP BIOL MED+, V143, P501, DOI 10.1007/s10517-007-0167-y
   Cole AJ, 2011, BIOMATERIALS, V32, P6291, DOI 10.1016/j.biomaterials.2011.05.024
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Du J, 2009, MOL PHARMACEUT, V6, P905, DOI 10.1021/mp800218q
   Du WW, 2013, BIOMATERIALS, V34, P794, DOI 10.1016/j.biomaterials.2012.10.003
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Gao H, 2014, EXPERT OPIN DRUG DEL, P1
   Gao HL, 2014, ACTA BIOMATER, V10, P858, DOI 10.1016/j.actbio.2013.11.003
   Gao HL, 2013, J CONTROL RELEASE, V172, P921, DOI 10.1016/j.jconrel.2013.10.002
   Gao HL, 2013, PHARM RES-DORDR, V30, P2485, DOI 10.1007/s11095-013-1122-4
   Gao HL, 2012, BIOMATERIALS, V33, P6264, DOI 10.1016/j.biomaterials.2012.05.020
   Gao HL, 2012, BIOMATERIALS, V33, P5115, DOI 10.1016/j.biomaterials.2012.03.058
   Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109
   Han HD, 2006, INT J PHARM, V313, P181, DOI 10.1016/j.ijpharm.2006.02.007
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
   Jain RK, 2012, ADV DRUG DELIVER REV, V64, P353, DOI 10.1016/j.addr.2012.09.011
   Jiang XY, 2013, BIOMATERIALS, V34, P1739, DOI 10.1016/j.biomaterials.2012.11.016
   Jiang XY, 2011, BIOMATERIALS, V32, P9457, DOI 10.1016/j.biomaterials.2011.08.055
   Kibria G, 2011, J CONTROL RELEASE, V153, P141, DOI 10.1016/j.jconrel.2011.03.012
   Lee DW, 2004, CARBOHYD POLYM, V58, P371, DOI 10.1016/j.carbpol.2004.06.033
   LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H                                                    
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   Liu SH, 2012, BIOMATERIALS, V33, P4907, DOI 10.1016/j.biomaterials.2012.03.031
   Liu Y., 2013, BIOMED RES INT, V2013
   Liu Y, 2014, MOL THER METHODS CLI, V1
   LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027
   Maeda N, 2004, J CONTROL RELEASE, V100, P41, DOI 10.1016/j.jconrel.2004.07.033
   Oh S, 2009, CANCER LETT, V274, P33, DOI 10.1016/j.canlet.2008.08.03l
   Pang ZQ, 2011, BIOCONJUGATE CHEM, V22, P1171, DOI 10.1021/bc200062q
   Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3
   Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4
   Ren JF, 2012, BIOMATERIALS, V33, P3324, DOI 10.1016/j.biomaterials.2012.01.025
   Roger M, 2011, BIOMATERIALS, V32, P2106, DOI 10.1016/j.biomaterials.2010.11.056
   Sharma G, 2013, J CONTROL RELEASE, V167, P1, DOI 10.1016/j.jconrel.2013.01.016
   Sharma G, 2012, J PHARM SCI-US, V101, P2468, DOI 10.1002/jps.23152
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8                                                   
   Xin HL, 2012, BIOMATERIALS, V33, P8167, DOI 10.1016/j.biomaterials.2012.07.046
   Zong TL, 2014, MOL PHARMACEUT, V11, P2346, DOI 10.1021/mp500057n
NR 48
TC 23
Z9 23
U1 5
U2 48
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD DEC
PY 2014
VL 103
IS 12
BP 3891
EP 3901
DI 10.1002/jps.24186
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA AU0UO
UT WOS:000345340500009
PM 25339554
DA 2018-01-05
ER

PT J
AU Gautam, N
   Puligujja, P
   Balkundi, S
   Thakare, R
   Liu, XM
   Fox, HS
   McMillan, J
   Gendelman, HE
   Alnouti, Y
AF Gautam, Nagsen
   Puligujja, Pavan
   Balkundi, Shantanu
   Thakare, Rhishikesh
   Liu, Xin-Ming
   Fox, Howard S.
   McMillan, JoEllyn
   Gendelman, Howard E.
   Alnouti, Yazen
TI Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated
   Antiretroviral Nanoformulations
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CNS DRUG-DELIVERY; HIV TREATMENT; THERAPY;
   RITONAVIR; MICE; NEUROAIDS; RESPONSES; HIV/AIDS; NANOART
AB The drug delivery platform for folic acid (FA)-coated nanoformulated ritonavir (RTV)-boosted atazanavir (FA-nanoATV/r) using poloxamer 407 was developed to enhance cell and tissue targeting for a range of antiretroviral drugs. Such formulations would serve to extend the drug half-life while improving the pharmacokinetic profile and biodistribution to reservoirs of human immunodeficiency virus (HIV) infection. To this end, we now report enhanced pharmacokinetics and drug biodistribution with limited local and systemic toxicities of this novel nanoformulation. The use of FA as a targeting ligand for nanoATV/r resulted in plasma and tissue drug concentrations up to 200-fold higher compared to equimolar doses of native drug. In addition, ATV and RTV concentrations in plasma from mice on a folate-deficient diet were up to 23-fold higher for mice administered FA-nanoATV/r than for mice on a normal diet. Compared to earlier nanoATV/r formulations, FA-nanoATV/r resulted in enhanced and sustained plasma and tissue ATV concentrations. In a drug interaction study, ATV plasma and tissue concentrations were up to 5-fold higher in mice treated with FA-nanoATV/r than in mice treated with FA-nanoATV alone. As observed in mice, enhanced and sustained plasma concentrations of ATV were observed in monkeys. NanoATV/r was associated with transient local inflammation at the site of injection. There were no systemic adverse reactions associated with up to 10 weeks of chronic exposure of mice or monkeys to FA-nanoATV/r.
C1 [Gautam, Nagsen; Thakare, Rhishikesh; Alnouti, Yazen] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Puligujja, Pavan; Balkundi, Shantanu; Liu, Xin-Ming; Fox, Howard S.; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
RP Alnouti, Y (reprint author), Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
EM yalnouti@unmc.edu
OI Fox, Howard/0000-0003-2032-374X
FU National Institutes of Health [PO1 DA028555-01]
FX This work was supported by the National Institutes of Health (PO1
   DA028555-01).
CR Abrass CK, 2012, J AM GERIATR SOC, V60, P974, DOI 10.1111/j.1532-5415.2012.03948.x
   Anabwani G, 2005, NUTRITION, V21, P96, DOI 10.1016/j.nut.2004.09.013
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
   Cory TJ, 2013, CURR OPIN HIV AIDS, V8, P190, DOI 10.1097/COH.0b013e32835fc68a
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Dandekar Satya, 2007, Curr HIV/AIDS Rep, V4, P10, DOI 10.1007/s11904-007-0002-0
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gendelman HE, 2008, J NEUROIMMUNE PHARM, V3, P58, DOI 10.1007/s11481-008-9103-9
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Leamon CP, 2008, J PHARMACOL EXP THER, V327, P918, DOI 10.1124/jpet.108.143206
   Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w
   Mathias CJ, 1996, J NUCL MED, V37, P1003
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Rathbun RC, 2006, CURR PHARM DESIGN, V12, P1045, DOI 10.2174/138161206776055840
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Tomaru A, 2013, DRUG METAB PHARMACOK, V28, P144, DOI 10.2133/dmpk.DMPK-12-RG-057
   Xia W, 2009, BLOOD, V113, P438, DOI 10.1182/blood-2008-04-150789
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
NR 30
TC 10
Z9 10
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 2014
VL 58
IS 12
BP 7510
EP 7519
DI 10.1128/AAC.04108-14
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AT9AW
UT WOS:000345221000056
PM 25288084
OA gold
DA 2018-01-05
ER

PT J
AU Imperiale, JC
   Bevilacqua, G
   Rosa, PDVE
   Sosnik, A
AF Imperiale, Julieta C.
   Bevilacqua, Gabriela
   Vieira e Rosa, Paulo de Tarso
   Sosnik, Alejandro
TI Production of pure indinavir free base nanoparticles by a supercritical
   anti-solvent (SAS) method
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Drug dissolution; drug solubility; HIV; indinavir free base; pure drug
   nanoparticles; supercritical anti-solvent method
ID DYNAMIC LIGHT-SCATTERING; DRUG-DELIVERY; PROTEASE INHIBITOR; FLUID
   TECHNOLOGY; HIV; SULFATE; PHARMACOKINETICS; CHALLENGE; INFECTION;
   DISCOVERY
AB Context: This work investigated the production of pure indinavir free base nanoparticles by a supercritical anti-solvent method to improve the drug dissolution in intestine-like medium.
   Objective: To increase the dissolution of the drug by means of a supercritical fluid processing method.
   Materials and methods: Acetone was used as solvent and supercritical CO2 as antisolvent. Products were characterized by dynamic light scattering (size, size distribution), scanning electron microscopy (morphology), differential scanning calorimetry (thermal behaviour) and X-rays diffraction (crystallinity). Results and discussion: Processed indinavir resulted in particles of significantly smaller size than the original drug. Particles showed at least one dimension at the nanometer scale with needle or rod-like morphology.
   Results of X-rays powder diffraction suggested the formation of a mixture of polymorphs. Differential scanning calorimetry analysis showed a main melting endotherm at 152 degrees C. Less prominent transitions due to the presence of small amounts of bound water (in the raw drug) or an unstable polymorph (in processed IDV) were also visible. Finally, drug particle size reduction significantly increased the dissolution rate with respect to the raw drug. Conversely, the slight increase of the intrinsic solubility of the nanoparticles was not significant.
   Conclusions: A supercritical anti-solvent method enabled the nanonization of indinavir free base in one single step with high yield. The processing led to faster dissolution that would improve the oral bioavailability of the drug.
C1 [Imperiale, Julieta C.; Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1113 Buenos Aires, DF, Argentina.
   [Bevilacqua, Gabriela; Vieira e Rosa, Paulo de Tarso] Univ Estadual Campinas, Inst Chem, Dept Phys Chem, Campinas, SP, Brazil.
   [Sosnik, Alejandro] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, 956 Junin St,6th Floor, RA-1113 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
RI Vieira e Rosa, Paulo/B-6358-2008; Sosnik, Alejandro/O-7059-2014; Rosa,
   Paulo/I-6668-2016
OI Vieira e Rosa, Paulo/0000-0003-0405-3516; Sosnik,
   Alejandro/0000-0003-4704-4599; Rosa, Paulo/0000-0002-9667-184X
CR Andujar P, 2011, Rev Mal Respir, V28, pe66, DOI 10.1016/j.rmr.2011.09.008
   Arribas JR, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-3
   Boyd M, 2007, EXPERT OPIN PHARMACO, V8, P957, DOI 10.1514/14656566.8.7.957
   Braeuer A, 2011, CHEM ENG J, V173, P258, DOI 10.1016/j.cej.2011.07.064
   Charbit G, 2004, DRUGS PHARM SCI, V138, P159
   Chiappetta DA, 2006, AAPS PHARMSCITECH, V10, P1
   Sacchetin PSC, 2013, J SUPERCRIT FLUID, V77, P52, DOI 10.1016/j.supflu.2013.02.029
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   De Marco I, 2011, J SUPERCRIT FLUID, V58, P295, DOI 10.1016/j.supflu.2011.06.005
   Delaney M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-S1-S6                                                       
   Dowy S, 2010, J SUPERCRIT FLUID, V55, P282, DOI 10.1016/j.supflu.2010.07.007
   Fages J, 2004, POWDER TECHNOL, V141, P219, DOI 10.1016/j.powtec.2004.02.007
   da Silva RMF, 2009, J THERM ANAL CALORIM, V95, P965, DOI 10.1007/s10973-008-8912-7
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Hochman JH, 2000, J PHARMACOL EXP THER, V292, P310
   Imperiale JC, 2013, THESIS U BUENOS AIRE
   Imperiale JC, 2011, OBI 2011 2 WORKSH BI
   Imperiale JC, 2013, J BIOMATER TISS ENG, V3, P22, DOI 10.1166/jbt.2013.1064
   Johnson BD, 1999, ANAL PROF DRUG SUBST, V26, P319, DOI 10.1016/S0099-5428(08)60626-7
   Joint United Nation Programme on HIV/AIDS, UNAIDS REP GLOB AIDS
   Kalani M, 2011, INT J NANOMED, V6, P1429, DOI 10.2147/IJN.S19021
   Kesisoglou F, 2007, ADV DRUG DELIVER REV, V59, P631, DOI 10.1016/j.addr.2007.05.003
   Lehner D, 2000, LANGMUIR, V16, P1689, DOI 10.1021/la9910273                                                               
   Lin JH, 1997, PHARMACOL REV, V49, P403
   Lin JH, 1999, ADV DRUG DELIVER REV, V39, P33, DOI 10.1016/S0169-409X(99)00018-6                                                   
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu HL, 2012, GOLD BULL, V45, P187, DOI 10.1007/s13404-012-0067-4
   Merisko-Liversidge EM, 2008, TOXICOL PATHOL, V36, P43, DOI 10.1177/0192623307310946
   Muller RH, 2011, EUR J PHARM BIOPHARM, V78, P1, DOI 10.1016/j.ejpb.2011.01.007
   Naylor A, 2011, THER DELIV, V2, P1551, DOI 10.4155/TDE.11.125
   Pasquali I, 2006, EUR J PHARM SCI, V27, P299, DOI 10.1016/j.ejps.2005.11.007
   Phillips DJ, 2012, J PHARM PHARMACOL, V64, P1549, DOI 10.1111/j.2042-7158.2012.01523.x
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rehman M, 2001, J PHARM SCI-US, V90, P1570, DOI 10.1002/jps.1107
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868
   Correa JCR, 2012, PHARMACOLOGY, V90, P102, DOI 10.1159/000339862
   Salahuddin S, 2007, J ANTIMICROB CHEMOTH, V59, P114, DOI 10.1093/jac/dkl436
   Silva BDE, 2005, QUIM NOVA, V28, P54, DOI 10.1590/S0100-40422005000100011
   Singh P, 2008, J PHARMACEUT BIOMED, V47, P248, DOI 10.1016/j.jpba.2008.01.001
   Sosnik A, 2012, EXPERT OPIN DRUG DEL, V9, P303, DOI 10.1517/17425247.2012.655268
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Sui XY, 2012, INT J PHARMACEUT, V423, P471, DOI 10.1016/j.ijpharm.2011.12.007
   Toteva MM, 2008, J PHARM SCI-US, V97, P3810, DOI 10.1002/jps.21259
   van der Zande BMI, 2000, LANGMUIR, V16, P459, DOI 10.1021/la990043x                                                               
   Willart JF, 2008, MOL PHARMACEUT, V5, P905, DOI 10.1021/mp800092t
   Wu CY, 2005, PHARM RES, V22, P11, DOI 10.1007/s11095-004-9004-4
   Yang L, 2012, FOOD CHEM, V132, P319, DOI 10.1016/j.foodchem.2011.10.083
   Yeh KC, 1998, ANTIMICROB AGENTS CH, V42, P332
   Yeo SD, 2003, J SUPERCRIT FLUID, V25, P143, DOI 10.1016/S0896-8446(02)00094-3                                                   
   Yu LX, 1999, INT J PHARM, V186, P119, DOI 10.1016/S0378-5173(99)00147-7                                                   
   Yu LX, 1996, INT J PHARM, V140, P111, DOI 10.1016/0378-5173(96)04592-9
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
NR 57
TC 3
Z9 3
U1 1
U2 24
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD DEC
PY 2014
VL 40
IS 12
BP 1607
EP 1615
DI 10.3109/03639045.2013.838581
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AT8WB
UT WOS:000345208700005
PM 24050705
DA 2018-01-05
ER

PT J
AU Shi, NQ
   Qi, XR
   Xiang, B
   Zhang, Y
AF Shi, Nian-Qiu
   Qi, Xian-Rong
   Xiang, Bai
   Zhang, Yong
TI A survey on "Trojan Horse" peptides: Opportunities, issues and
   controlled entry to "Troy"
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Cell-penetrating peptides; Clinical development; Non-specificity;
   Organelle-specific delivery; Controlled delivery strategies
ID CELL-PENETRATING PEPTIDES; HUMAN-IMMUNODEFICIENCY-VIRUS; IRON-OXIDE
   NANOPARTICLES; ARGININE-RICH PEPTIDES; CENTRAL-NERVOUS-SYSTEM;
   MESOPOROUS SILICA NANOPARTICLES; PROTEIN TRANSDUCTION DOMAIN;
   SOYBEAN-DERIVED STEROLS; SMALL INTERFERING RNA; TAT-FUSION PROTEINS
AB Cell-penetrating peptides (CPPs), often vividly termed as the "Trojan Horse" peptides, have attracted considerable interest for the intracellular delivery of a wide range of cargoes, such as small molecules, peptides, proteins, nucleic acids, contrast agents, nanocarriers and so on. Some preclinical and clinical developments of CPP conjugates demonstrate their promise as therapeutic agents for drug discovery. There is increasing evidence to suggest that CPPs have the potential to cross several bio-barriers (e. g., blood-brain barriers, intestinal mucosa, nasal mucosa and skin barriers). Despite revolutionary process in many aspects, there are a lot of basic issues unclear for these entities, such as internalization mechanisms, translocation efficiency, translocation kinetics, metabolic degradation, toxicity, side effect, distribution and non-specificity. Among them, non-specificity remains a major drawback for the in vivo application of CPPs in the targeted delivery of cargoes. So far, diverse organelle-specific CPPs or controlled delivery strategies have emerged and improved their specificity. In this review, we will look at the opportunities of CPPs in clinical development, bio-barriers penetration and nanocarriers delivery. Then, a series of basic problems of CPPs will be discussed. Finally, this paper will highlight the use of various controlled strategies in the organelle-specific delivery and targeted delivery of CPPs. The purpose of this review will be to emphasize most influential advance in this field and present a fundamental understanding for challenges and utilizations of CPPs. This will accelerate their translation as efficient vectors from the in vitro setting into the clinic arena, and retrieve the entry art to "Troy". (C) 2014 Elsevier B.V. All rights reserved.
C1 [Shi, Nian-Qiu] Jilin Med Coll, Sch Pharm, Dept Pharmaceut, Fengman Dist 132013, Jilin, Peoples R China.
   [Shi, Nian-Qiu; Qi, Xian-Rong; Xiang, Bai] Peking Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Beijing 100191, Peoples R China.
   [Xiang, Bai] Hebei Med Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Shijiazhuang 050017, Peoples R China.
   [Zhang, Yong] Jilin Univ, Coll Life Sci, Changchun 130012, Peoples R China.
   [Zhang, Yong] China Shijiazhuang Pharmaceut Grp Co Inc, State Key Lab New Pharmaceut Preparat & Excipient, Shijiazhuang 050017, Peoples R China.
RP Shi, NQ (reprint author), Jilin Med Coll, Sch Pharm, Dept Pharmaceut, 5 Jilin St, Fengman Dist 132013, Jilin, Peoples R China.
EM shinianqiu2009@163.com; qixr@bjmu.edu.cn
RI zhang, yong/H-2552-2013
OI zhang, yong/0000-0001-6577-5235; Qi, Xianrong/0000-0002-8264-0794
FU NSFC [30970785, 81273454, 81302725]; Beijing NSF [7132113]; National
   Basic Research Program [2013CB932501, 2009CB930303]; Doctoral Foundation
   of the Ministry of Education [20100001110056]; Innovation Team of
   Ministry of Education [BMU20110263]; Hebei NSF [C2011206073]; Hebei
   Provincial Natural Science Foundation of China-Shijiazhuang
   Pharmaceutical Group (CSPC) Foundation [C2011319001]
FX This work was supported by the grants from the NSFC (No. 30970785 and
   No. 81273454), Beijing NSF (No. 7132113), National Basic Research
   Program (No. 2013CB932501 and No. 2009CB930303), Doctoral Foundation of
   the Ministry of Education (No. 20100001110056), and Innovation Team of
   Ministry of Education (No. BMU20110263). This work was also supported by
   the grants by the NSFC (No. 81302725), Hebei NSF (No. C2011206073) and
   Hebei Provincial Natural Science Foundation of China-Shijiazhuang
   Pharmaceutical Group (CSPC) Foundation (No. C2011319001).
CR Abes S, 2007, BIOCHEM SOC T, V35, P53, DOI 10.1042/BST0350053                                                              
   Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Alberici L, 2013, CANCER RES, V73, P804, DOI 10.1158/0008-5472.CAN-12-1668
   Allen TD, 2000, J CELL SCI, V113, P1651
   Aroui S, 2010, BIOCHEM BIOPH RES CO, V391, P419, DOI 10.1016/j.bbrc.2009.11.073
   Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867                                                                   
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Bolton SJ, 2000, EUR J NEUROSCI, V12, P2847, DOI 10.1046/j.1460-9568.2000.00171.x                                                
   Brandt F, 2010, DERMATOL SURG, V36, P2111, DOI 10.1111/j.1524-4725.2010.01711.x
   Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003
   Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180
   Christiaens B, 2004, EUR J BIOCHEM, V271, P1187, DOI 10.1111/j.1432-1033.2004.04022.x
   Chugh A, 2007, BBA-BIOMEMBRANES, V1768, P419, DOI 10.1016/j.bbamem.2006.11.012
   Ciftci K, 2001, INT J PHARM, V218, P81, DOI 10.1016/S0378-5173(01)00623-8
   Cousins MJ, 2013, PAIN MED, V14, P533, DOI 10.1111/pme.12058
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203
   Dong DW, 2013, BIOMATERIALS, V34, P4849, DOI 10.1016/j.biomaterials.2013.03.018
   Dong DW, 2013, J BIOMED MATER RES A, V101, P1336, DOI 10.1002/jbm.a.34450
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   El-Andaloussi S, 2007, BIOCHEM J, V407, P285, DOI 10.1042/BJ20070507
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Ernsting MJ, 2012, J CONTROL RELEASE, V162, P575, DOI 10.1016/j.jconrel.2012.07.043
   Feng L, 2006, J CONTROL RELEASE, V112, P35, DOI 10.1016/j.jconrel.2006.01.012
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Foerg C, 2008, J PHARM SCI-US, V97, P144, DOI 10.1002/jps.21117
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fu AL, 2012, PHARM RES-DORDR, V29, P1562, DOI 10.1007/s11095-012-0667-y
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2006, BIOPOLYMERS, V84, P241, DOI 10.1002/hip.20421
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0                                                   
   Gao W, 2013, BIOMATERIALS, V34, P4137, DOI 10.1016/j.biomaterials.2013.02.014
   GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016
   Gerweck LE, 1996, CANCER RES, V56, P1194
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Harris TJ, 2008, SMALL, V4, P1307, DOI 10.1002/smll.200701319
   Hogset A, 2004, ADV DRUG DELIVER REV, V56, P95, DOI 10.1016/j.addr.2003.08.016
   Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015
   Hosseini A, 2012, J OCUL PHARMACOL TH, V28, P194, DOI 10.1089/jop.2011.0135
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191                                                        
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   Johnson RM, 2011, METHODS MOL BIOL, V683, P535, DOI 10.1007/978-1-60761-919-2_38
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kamei N, 2010, J CONTROL RELEASE, V146, P16, DOI 10.1016/j.jconrel.2010.05.004
   Kamei N, 2009, J CONTROL RELEASE, V136, P179, DOI 10.1016/j.jconrel.2009.02.015
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Ke WL, 2009, BIOMATERIALS, V30, P6976, DOI 10.1016/j.biomaterials.2009.08.049
   Kersemans V, 2008, CURR PHARM DESIGN, V14, P2415, DOI 10.2174/138161208785777432                                                      
   Khafagy ES, 2012, ADV DRUG DELIVER REV, V64, P531, DOI 10.1016/j.addr.2011.12.014
   Khafagy ES, 2009, J CONTROL RELEASE, V133, P103, DOI 10.1016/j.jconrel.2008.09.076
   Kim C, 2010, LANGMUIR, V26, P14965, DOI 10.1021/la102632m
   Kogure K, 2008, ADV DRUG DELIVER REV, V60, P559, DOI 10.1016/j.addr.2007.10.007
   Koppelhus U, 2002, ANTISENSE NUCLEIC A, V12, P51, DOI 10.1089/108729002760070795                                                      
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Lee ES, 2008, J CONTROL RELEASE, V129, P228, DOI 10.1016/j.jconrel.2008.04.024
   Lee MS, 2010, BIOCHEM BIOPH RES CO, V394, P348, DOI 10.1016/j.bbrc.2010.03.009
   Lelle M, 2014, J PEPT SCI, V20, P323, DOI 10.1002/psc.2617
   Li Y, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/5/055106
   Liang JF, 2003, BIOCHEMISTRY-MOSCOW+, V68, P116, DOI 10.1023/A:1022109905487
   Liang JF, 2002, J CONTROL RELEASE, V78, P67, DOI 10.1016/S0168-3659(01)00484-9
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Lopes LB, 2009, J INVEST DERMATOL, V129, P590, DOI 10.1038/jid.2008.264
   Low W, 2007, J BIOTECHNOL, V129, P555, DOI 10.1016/j.jbiotec.2007.01.019
   Lu ZX, 2011, INT J NANOMED, V6, P1661, DOI 10.2147/IJN.S22293
   Ma DX, 2011, INT J PHARMACEUT, V419, P200, DOI 10.1016/j.ijpharm.2011.08.001
   Ma HL, 2008, INT J PHARM, V354, P217, DOI 10.1016/j.ijpharm.2007.11.036
   Ma HL, 2008, J BIOMED MATER RES A, V84A, P598, DOI 10.1002/jbm.a.31346
   Ma HL, 2007, INT J PHARM, V333, P177, DOI 10.1016/j.ijpharm.2006.10.006
   MacEwan SR, 2012, NANO LETT, V12, P3322, DOI 10.1021/nl301529p
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Malhotra M, 2013, BIOMATERIALS, V34, P1270, DOI 10.1016/j.biomaterials.2012.10.013
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   Massodi I, 2010, INT J CANCER, V126, P533, DOI 10.1002/ijc.24725
   Meyer-Losic F, 2008, CLIN CANCER RES, V14, P2145, DOI 10.1158/1078-0432.CCR-07-4580
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Miyaji Y, 2011, DRUG METAB DISPOS, V39, P1946, DOI 10.1124/dmd.111.040725
   Moktan S, 2012, MOL CANCER THER, V11, P1547, DOI 10.1158/1535-7163.MCT-11-0998
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Moulton H. M., 2011, SKELET MUSCLE, V1, P8
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Nath A, 1996, J VIROL, V70, P1475
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Omotehara Y, 2011, OTOL NEUROTOL, V32, P1422, DOI 10.1097/MAO.0b013e3182355658
   Padari K, 2011, METHODS MOL BIOL, V683, P181, DOI 10.1007/978-1-60761-919-2_13
   Pan LM, 2013, BIOMATERIALS, V34, P2719, DOI 10.1016/j.biomaterials.2012.12.040
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Park YJ, 2003, ADV DRUG DELIVER REV, V55, P251, DOI 10.1016/S0169-409X(02)00181-3                                                   
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Peng LH, 2014, BIOMATERIALS, V35, P5605, DOI 10.1016/j.biomaterials.2014.03.062
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   QI XR, 1995, CHEM PHARM BULL, V43, P295
   QI XR, 1995, PHARMACEUT RES, V12, P49, DOI 10.1023/A:1016230518884
   QI XR, 1995, INT J PHARM, V114, P33, DOI 10.1016/0378-5173(94)00210-V
   Qi X. R., 1997, INT J PHARMACEUT, V124, P33
   Rajendran L, 2010, NAT REV DRUG DISCOV, V9, P29, DOI 10.1038/nrd2897
   Razakandrainibe R, 2013, INT J BIOCHEM CELL B, V45, P1165, DOI 10.1016/j.biocel.2013.03.010
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sakhrani NM, 2013, DRUG DES DEV THER, V7, P585, DOI 10.2147/DDDT.S45614
   Sarko D, 2010, MOL PHARMACEUT, V7, P2224, DOI 10.1021/mp100223d
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Sawant RR, 2009, INT J PHARMACEUT, V374, P114, DOI 10.1016/j.ijpharm.2009.02.022
   Scheller A, 1999, J PEPT SCI, V5, P185, DOI 10.1002/(SICI)1099-1387(199904)5:4<185::AID-PSC184>3.0.CO;2-9
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sethuraman VA, 2008, PHARM RES, V25, P657, DOI 10.1007/s11095-007-9480-4
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shah PP, 2012, J CONTROL RELEASE, V161, P735, DOI 10.1016/j.jconrel.2012.05.011
   Shamay Y, 2011, BIOMATERIALS, V32, P1377, DOI 10.1016/j.biomaterials.2010.10.029
   Shi NQ, 2012, INT J NANOMED, V7, P1613, DOI 10.2147/IJN.S30104
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P488, DOI 10.1021/mp3004034
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013
   Tian L, 2012, COLLOID SURFACE B, V99, P116, DOI 10.1016/j.colsurfb.2011.10.039
   Tong SW, 2012, INT J PHARMACEUT, V434, P413, DOI 10.1016/j.ijpharm.2012.06.014
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tugyi R, 2005, P NATL ACAD SCI USA, V102, P413, DOI 10.1073/pnas.0407677102
   Tunnemann Gisela, 2008, J Pept Sci, V14, P469, DOI 10.1002/psc.968
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Walker L, 2012, INT J PHARMACEUT, V436, P825, DOI 10.1016/j.ijpharm.2012.07.043
   Wang J, 2003, J NEUROSCI, V23, P8596
   Warso MA, 2013, BRIT J CANCER, V108, P1061, DOI 10.1038/bjc.2013.74
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Xiang B, 2013, BIOMATERIALS, V34, P6976, DOI 10.1016/j.biomaterials.2013.05.055
   Xiang LX, 2011, J DRUG TARGET, V19, P632, DOI 10.3109/1061186X.2010.523788
   Yamada Y, 2008, BBA-BIOMEMBRANES, V1778, P423, DOI 10.1016/j.bbamem.2007.11.002
   Yang ZZ, 2014, BIOMATERIALS, V35, P5226, DOI 10.1016/j.biomaterials.2014.03.017
   Yang ZZ, 2013, INT J PHARMACEUT, V452, P344, DOI 10.1016/j.ijpharm.2013.05.009
   Yang ZZ, 2012, CURR ALZHEIMER RES, V9, P315, DOI 10.2174/156720512800107528                                                      
   Zaro JL, 2012, J CONTROL RELEASE, V158, P357, DOI 10.1016/j.jconrel.2012.01.039
   Zhang PC, 2013, ACS NANO, V7, P5965, DOI 10.1021/nn401667z
   Zhang QY, 2013, BIOMATERIALS, V34, P7980, DOI 10.1016/j.biomaterials.2013.07.014
   Zhang W, 2011, BIOCONJUGATE CHEM, V22, P1410, DOI 10.1021/bc200138d
   Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y
   Zhang YL, 2013, PHARMAZIE, V68, P47, DOI 10.1691/ph.2013.2071
   Zhang Y, 2007, J CONTROL RELEASE, V117, P281, DOI 10.1016/j.jconrel.2006.11.006
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Zhao W, 2011, INT J NANOMED, V6, P3087, DOI 10.2147/IJN.S25399
   Zhu L, 2013, P NATL ACAD SCI USA, V110, P17047, DOI 10.1073/pnas.1304987110
   Zhu L, 2012, ACS NANO, V6, P3491, DOI 10.1021/nn300524f
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
   Zou LL, 2013, CURR NEUROPHARMACOL, V11, P197, DOI 10.2174/1570159X11311020006
NR 177
TC 44
Z9 45
U1 4
U2 110
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2014
VL 194
BP 53
EP 70
DI 10.1016/j.jconrel.2014.08.014
PG 18
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AS4FU
UT WOS:000344229800006
PM 25151981
DA 2018-01-05
ER

PT J
AU Singh, G
   Pai, RS
AF Singh, Gurinder
   Pai, Roopa S.
TI Recent advances of resveratrol in nanostructured based delivery systems
   and in the management of HIV/AIDS
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Anti-retroviral drugs; Bioavailability; Enterohepatic recirculation;
   HIV/AIDS; Nanostructured delivery; Trans-resveratrol
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TARGETED DRUG-DELIVERY;
   TRANS-RESVERATROL; LIPID NANOPARTICLES; POLYMERIC NANOPARTICLES;
   SYNERGISTIC INHIBITION; ORAL BIOAVAILABILITY; NATURAL-PRODUCT;
   LIFE-SPAN; RED WINE
AB Resveratrol, a natural polyphenolic compound present in trees, in peanuts, in grapevines and exhibited multiple pharmacological activities. Extensive research in last two decades suggested that resveratrol possesses anti-inflammatory, anti-cancer, anti-viral, anti-amyloid, anti-arthritic and antioxidant properties. Some clinical reports have proposed that resveratrol might be a potential candidate for the prevention and/or treatment of HIV/AIDS and synergistically enhances the anti-HIV-1 activity. Resveratrol is not toxic to cells, and by itself reduces viral replication by 20% to 30%. With almost 12% of the world population suffering from HIV/AIDS including its resurgence in the developed world, better management of this global threat is highly desired. Further, various studies demonstrated several issues associated with resveratrol which account for its poor systemic bioavailability (almost zero) due to rapid and extensive first pass metabolism and existence of enterohepatic recirculation. In order to improve bioavailability and cellular uptake of resveratrol, various strategies have been adopted to date which includes resveratrol prodrug and the development of nanostructured delivery systems. Besides, nanostructured delivery systems are also known to inhibit the P-glycoprotein (P-gp) efflux, reduced metabolism by gut cytochrome P-450 enzymes, and circumnavigate the hepatic first-pass effect, facilitating absorption of drugs via intestinal lymphatic pathways. This review paper provides an updated bird's-eye view account on the publications and patents study on the recent novel approaches to deliver resveratrol in order to enhance oral bioavailability, overcome first pass metabolism and trounce enterohepatic recirculation to make resveratrol a therapeutically potent drug. Providing a relatively pithy overview, this paper thus presents recent advances of resveratrol for the treatment and prevention of HIV/AIDS. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Singh, Gurinder; Pai, Roopa S.] Al Ameen Coll Pharm, Dept Pharmaceut, Fac Pharm, Bangalore 560027, Karnataka, India.
RP Pai, RS (reprint author), Al Ameen Coll Pharm, Dept Pharmaceut, Fac Pharm, Hosur Rd, Bangalore 560027, Karnataka, India.
EM gurindersingh181@gmail.com; roopaspai@yahoo.com
OI Singh, Gurinder/0000-0003-1525-3898
FU ICMR (Indian Council of Medical Research, Government of India, New
   Delhi) [45/38/2011/Nan-BMS]
FX We are grateful to Prof. B. G. Shivananda, then Principal of Al-Ameen
   College of Pharmacy, Bangalore, India, for his valuable advice and
   support in the preparation and editing of this review. The authors also
   gratefully acknowledge the financial support and research fellowship
   grant (45/38/2011/Nan-BMS) from ICMR (Indian Council of Medical
   Research, Government of India, New Delhi) to carry out the research work
   reported from our lab.
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Amri A, 2012, J CONTROL RELEASE, V158, P182, DOI 10.1016/j.jconrel.2011.09.083
   Amri A, 2014, EUR J PHARM BIOPHARM, V86, P418, DOI 10.1016/j.ejpb.2013.10.015
   Ansari KA, 2011, AAPS PHARMSCITECH, V12, P279, DOI 10.1208/s12249-011-9584-3
   Basavaraj S, 2014, EXPERT OPIN DRUG DEL, V11, P493, DOI 10.1517/17425247.2014.878701
   Baur A. J., 2006, NAT REV, V500, P493
   Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567                                                      
   Bolko K, 2014, DRUG DEV IND PHARM, V40, P102, DOI 10.3109/03639045.2012.749888
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Bradamante S, 2004, CARDIOVASC DRUG REV, V22, P169
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Buryanovskyy L, 2004, BIOCHEMISTRY-US, V43, P11417, DOI 10.1021/bi049162o
   Chang JS, 1999, VACCINE, V17, P1540, DOI 10.1016/S0264-410X(98)00353-3
   Clouser CL, 2012, BIOORG MED CHEM LETT, V22, P6642, DOI 10.1016/j.bmcl.2012.08.108
   Coimbra M, 2011, INT J PHARMACEUT, V416, P433, DOI 10.1016/j.ijpharm.2011.01.056
   Cottart CH, 2010, MOL NUTR FOOD RES, V54, P7, DOI 10.1002/mnfr.200900437
   Das S, 2011, J LIQ CHROMATOGR R T, V34, P1399, DOI 10.1080/10826076.2011.572215
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Villegas I., 2005, MOL NUTR FOOD RES, V49, P405
   De Jong WH, 2008, INT J NANOMED, V3, P133
   des Rieux A, 2006, J CONTROL RELEASE, V116, P1, DOI 10.1016/j.jconrel.2006.08.013
   Fang JY, 2007, EUR J PHARM BIOPHARM, V67, P67, DOI 10.1016/j.ejpb.2007.01.008
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fraser SP, 2014, NUTR CANCER, V66, P1047, DOI 10.1080/01635581.2014.939291
   Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5
   Frozza RL, 2010, J BIOMED NANOTECHNOL, V6, P694, DOI 10.1166/jbn.2010.1161
   Fulda S, 2010, DRUG DISCOV TODAY, V15, P757, DOI 10.1016/j.drudis.2010.07.005
   Gambini Juan, 2013, Rev Esp Geriatr Gerontol, V48, P79, DOI 10.1016/j.regg.2012.04.007
   Hall JB, 2007, NANOMEDICINE-UK, V2, P789, DOI 10.2217/17435889.2.6.789
   Hankins CA, 2013, CURR OPIN HIV AIDS, V8, P50, DOI 10.1097/COH.0b013e32835b809d
   Heredia A, 2000, J ACQ IMMUN DEF SYND, V25, P246, DOI 10.1097/00126334-200011010-00006
   Heredia A, 2014, AIDS, V28, P317, DOI 10.1097/QAD.0000000000000168
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hung CF, 2007, INT J PHARM, V335, P193, DOI 10.1016/j.ijpharm.2006.11.016
   Hung CF, 2006, J NANOSCI NANOTECHNO, V6, P2950, DOI 10.1166/jnn.2006.420
   Jain NK, 2013, EXPERT OPIN DRUG DEL, V10, P353, DOI 10.1517/17425247.2013.751370
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Kim S, 2012, J FOOD ENG, V108, P37, DOI 10.1016/j.jfoodeng.2011.07.034
   Kohli K, 2010, DRUG DISCOV TODAY, V15, P958, DOI 10.1016/j.drudis.2010.08.007
   Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619
   Krishnan V, 2004, J VIROL, V78, P9458, DOI 10.1128/JVI.78.17.9458-9473.2004
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kundu JK, 2008, CANCER LETT, V269, P243, DOI 10.1016/j.canlet.2008.03.057
   LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1
   Langer R, 1998, NATURE, V392, P5
   Le Corre L, 2004, CLIN CHIM ACTA, V344, P115, DOI 10.1016/j.cccn.2004.02.024
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Lin Z., 2014, JSM MICROBIOL, V2, P1, DOI DOI 10.1128/JVI.01867-14
   Lindner G. da Rocha, 2013, SCI WORLD J, V2013
   Lu XW, 2009, INT J PHARMACEUT, V375, P89, DOI 10.1016/j.ijpharm.2009.03.021
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Majid A., HIV AIDS RES PALLIAT, V42012, P17
   Marier JF, 2002, J PHARMACOL EXP THER, V302, P369, DOI 10.1124/jpet.102.033340
   Muller Rainer H, 2011, Curr Drug Discov Technol, V8, P207
   Musazzi U. M., 2014, COLLOIDS SURF B
   Narayanan NK, 2009, INT J CANCER, V125, P1, DOI 10.1002/ijc.24336
   Ndiaye M, 2011, ANN NY ACAD SCI, V1215, P144, DOI 10.1111/j.1749-6632.2010.05851.x
   Neves AR, 2013, INT J NANOMED, V8, P177, DOI 10.2147/IJN.S37840
   NONOMURA S, 1963, Yakugaku Zasshi, V83, P988
   Oganesyan EA, 2010, PHARM CHEM J+, V44, P74, DOI 10.1007/s11094-010-0401-1                                                       
   Pandita D., 2014, FOOD RES INT
   Pando D, 2013, J PHARM PHARMACOL, V65, P1158, DOI 10.1111/jphp.12093
   PIAO ZS, 2010, ACTA PHARM SIN, V45, P1509
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Plapied L, 2011, CURR OPIN COLLOID IN, V16, P228, DOI 10.1016/j.cocis.2010.12.005
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   POUTON CW, 1985, INT J PHARM, V27, P335, DOI 10.1016/0378-5173(85)90081-X
   Qin Y., 2014, MOL MED REP
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P53, DOI 10.1016/j.nano.2006.04.009
   SEGAL AW, 1975, CLIN SCI MOL MED, V49, P99, DOI 10.1042/cs0490099                                                               
   Shao JF, 2009, COLLOID SURFACE B, V72, P40, DOI 10.1016/j.colsurfb.2009.03.010
   SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49
   Singh B., 2014, CRIT REV THER DRUG, V31, P89
   Singh G, 2014, DRUG DELIV
   Singh G, 2014, J PHARM PHARMACOL, V66, P1062, DOI 10.1111/jphp.12232
   Pai Roopa S., 2014, Journal of Pharmaceutical Investigation, V44, P69, DOI 10.1007/s40005-013-0105-0
   Singh G, 2014, EXPERT OPIN DRUG DEL, V11, P647, DOI 10.1517/17425247.2014.890588
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0
   Szebeni J, 1998, CRIT REV THER DRUG, V15, P57
   Takaoka MJ, 1940, J FS HOKKAIDO IMPERI, V3, P1, DOI DOI 10.1246/NIKKASHI1921.60.1261
   Teskac K, 2010, INT J PHARMACEUT, V390, P61, DOI 10.1016/j.ijpharm.2009.10.011
   Touzet O, 2010, AIDS, V24, P1437, DOI 10.1097/QAD.0b013e32833a6114
   UNAIDS, 2008, REP GLOB AIDS EP
   Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038
   Vang O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019881
   Vian MA, 2005, J CHROMATOGR A, V1085, P224, DOI 10.1016/j.chroma.2005.05.083
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6                                                   
   Zhang HS, 2010, J CELL BIOCHEM, V110, P1464, DOI 10.1002/jcb.22704
   Zhang HS, 2009, VIRUS RES, V146, P51, DOI 10.1016/j.virusres.2009.08.005
   Zhang HS, 2009, LIFE SCI, V85, P484, DOI 10.1016/j.lfs.2009.07.014
   Zhang JB, 2014, AAPS PHARMSCITECH, V15, P731, DOI 10.1208/s12249-014-0096-9
   Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x                                              
   Zu Y., 2014, DRUG DELIV
   Oganesjan E. A., 2009, Compositions containing resveratrol particles; and method for making thereof, Patent No. [RU02373926 C1, 02373926]
   Polans S., 2010, Water-soluble formulations of resveratrol and uses thereof, Patent No. [WO2010059628, 20100059628]
   Pillai S., 2002, Patent No. [US6358517 B1, 6358517]
   Giosan CC, 2013, World Patent, Patent No. [US20130023590, 20130023590]
   Arigony S. A., 2010, Process for the preparation of a water-soluble complex having resveratrol compounds; products comprising said complex; and uses thereof, Patent No. [US20100204179, 201000204179]
   Shi Q., 2010, Resveratrol flexible liposome and preparation method thereof, Patent No. [CN101874763 A, 101874763]
   Carson R.G., 2001, U.S. Patent, Patent No. [US6270780, 6270780, 6,270,780]
   Derosa M., 2004, US Patent, Patent No. [US20040009197 A1, 20040009197]
   Souto AA, 2013, World Patent, Patent No. [US20130040920, 20130040920]
   Grant R. S., 2012, Pharmaceutical compositions of resveratrol, Patent No. [WO2013056298, 2013056298]
   Ouyang W. Q., 2008, Resveratrol nano emulsion anti-cancer medicine, Patent No. [CN101214225 A, 101214225]
   Yang W., 2011, Self-emulsified resveratrol soft capsules, Patent No. [CN101961323 A, 101961323]
   Pezzuto J., 2002, Pharmaceutical formulations of resveratrol, Patent No. [US20020173472 A1, 200220173472]
   Pillai S., 2000, Cosmetic compositions containing resveratrol, Patent No. [ZA1998/06039, 199806039]
   Berl V., 2012, Formulations of ubiquinol and resveratrol esters, Patent No. [US20120088829 A1, 2012008829]
   Wei H., 2010, Resveratrol pellet and preparation method thereof, Patent No. [CN101703479 A, 101703479]
   Shen H., 2010, Method for preparing resveratrol sustained-release capsule capable of preventing rheumatoid arthritis, Patent No. [CN101693022 B, 101693022]
   Chen J., 2011, Resveratrol injection solution and intravenous injection, Patent No. [CN102188370 B, 102188370]
   Duan M., 2009, Resveratrol phospholipid composite nano-emulsion and preparation method and application thereof, Patent No. [CN101579291 B, 101579291]
   Kuhrts E., 2010, Enhanced bioactive formulations of resveratrol, Patent No. [WO2010062824, 2010062824]
   Saxena A., 2010, Solid dispersion comprising resveratrol, Patent No. [WO2010102245, 2010102245]
   Arigony S. A., 2009, Resveratrol complex and process for the preparation, Patent No. [CA2694343 A1, 2694343]
   Agostini A., 2014, Patent No. [US 2014/0079835 A1, 20140079835]
   Yu H., 2013, Method for preparing hydrophilic resveratrol by use of PEG (polyethylene glycol) modification technology, Patent No. [CN102887994 A, 10288994]
   Dugas T. R., 2013, Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity, Patent No. [US 2013/0030518 A1, 20130030518]
   Finley J. W., 2010, Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest, Patent No. [US2010/0197801 A1, 20100197801]
   Maes D. H., 2009, [No title captured], Patent No. [US20090035237 A1, 20090035237]
   Tian T., 2013, Method for improving bioavailability of resveratrol, Patent No. [CN102885780 A, 102885780]
   Speck U., 2013, Coated formulation for scoring or cutting balloon catheters, Patent No. [US 2013/0046231 A1, 20130046231]
   Pifferi G., 2004, Patent No. [US 2004/0116386 A1, 20040116386]
   Suo R., 2010, Method for improving stability and water solubility of resveratrol and application thereof, Patent No. [CN101927148 A, 101927148]
   Cappello J. V., 2013, Anti-aging formulations, Patent No. [US 2013/0115195A1, 20130115195]
   Shi Q., 2010, Flexible liposome of resveratrol and preparation method thereof, Patent No. [WO2010124540, 2010124540]
   Pifferi G., 2002, Resveratrol-phospholipids complexes, Patent No. [WO2002072591, 2002072591]
   Chen J., 2012, Resveratrol nanoscale dispersoid and preparation method thereof, Patent No. [CN102614127 A, 102614127]
   Marder G., 2014, Patent No. [US 2014/0073616 A1, 20140073616]
   Bu H., 2010, PEG (Polyethylene Glycol), mPEG (Methoxy Polyethylene glycol) chemical modifier and method thereof for preparing water-soluble resveratrol prodrug, Patent No. [CN101870769 B, 101870769]
   Moretti G., 2013, Patent No. [EP2674155 A1, 2674155]
   Zheng H., 2010, Preparation technology forwater-soluble resveratrol particle, and product and application thereof, Patent No. [CN101759531 B, 101759531]
   Miquel G., 2007, Microemulsion of polar antioxidants in edible oils, Patent No. [EP 1 829 452 A1, 1829452]
   Duan M., 2010, Patent No. [US 2010/0297199 A1, 20100297199]
   Sardi W. F., 2013, Compositions containing resveratrol and nucleotides, Patent No. [WO2013074948 A1, 2013074948]
   Kim C. T., 2009, Nanoemulsion employing resveratrol and middle-chain fatty acid triglyceride, nanoparticle, and manufacturing method thereof, Patent No. [KR1020090132357, 1020090132357]
   Chen C-C., 2011, Compositions containing resveratrol and pectin, Patent No. [US20110039945 B2, 20110039945]
   Liu K., 2012, Resveratrol hydrophilic conjugate, its preparation method and application, Patent No. [CN102766258 A, 102766258]
   Dong Y., 2008, Solid dispersion of resveratrol and glycosides and preparation method thereof, Patent No. [CN101292966 A, 101292966]
   Lunsmann W. J., 2011, Resveratrol formulations, Patent No. [US 2011/0009496 A1, 20110009496]
   Li W., 2012, Preparation method and application of resveratrol freeze-dried polymer micelle, Patent No. [CN102755298 A, 102755298]
   Clement P., 2009, Novel resveratrol compositions, Patent No. [CA2629979 A1, 2629979]
   Xia Q., 2012, Resveratrol nanostructured lipid carrier and preparation method thereof, Patent No. [CN102614091 A, 102614091]
   Yang J., 2011, Resveratrol nanometer preparation and preparation method thereof, Patent No. [CN102106816 A, 102106816]
   Shi Q., 2012, Flexible liposome of resveratrol and preparation method thereof, Patent No. [EP2431023 A4, 2431023]
   Zhou Y., 2008, Oral administration nano-drug administration system of resveratrol, Patent No. [CN101317832 B, 101317832]
   Eric K., 2010, Enhanced bioactive formulations of resveratrol, Patent No. [CA2748344 A1, 2748344]
   Duan M., 2010, Nanoemulsion of resveratrol-phospholipid complex and method for preparing the sameand applications thereof, Patent No. [US20100297199 B2, 201000297199]
   Yao J., 2010, Preparation method of freeze-dried resveratrol albumin powder, Patent No. [CN101658499 A, 101658499]
NR 152
TC 23
Z9 24
U1 4
U2 62
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2014
VL 194
BP 178
EP 188
DI 10.1016/j.jconrel.2014.09.002
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AS4FU
UT WOS:000344229800018
PM 25217813
DA 2018-01-05
ER

PT J
AU Rajan, SS
   Turovskiy, Y
   Singh, Y
   Chikindas, ML
   Sinko, PJ
AF Rajan, Sujata Sundara
   Turovskiy, Yevgeniy
   Singh, Yashveer
   Chikindas, Michael L.
   Sinko, Patrick J.
TI Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable
   hydrogels for restoring the vaginal microenvironment
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Controlled release; Hydrogel; Poly(ethylene glycol); Bacterial
   vaginosis; Lactic acid
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HERPES-SIMPLEX-VIRUS; BACTERIAL
   VAGINOSIS; LACTIC-ACID; IN-VITRO; GAMMA-SCINTIGRAPHY; CONTROLLED-TRIAL;
   HIV MICROBICIDE; PREVENTION; INFECTION
AB Women with bacterial vaginosis (BV) display reduced vaginal acidity, which make them susceptible to associated infections such as HIV. In the current study, poly(ethylene glycol) (PEG) nanocarrier-based degradable hydrogels were developed for the controlled release of lactic acid in the vagina of BV-infected women. PEG-lactic acid (PEG-LA) nanocarriers were prepared by covalently attaching lactic acid to 8-arm PEG-SH via cleavable thioester bonds. PEG-LA nanocarriers with 4 copies of lactic acid per molecule provided controlled release of lactic acid with a maximum release of 23% and 47% bound lactic acid in phosphate buffered saline (PBS, pH 7.4) and acetate buffer (AB, pH 4.3), respectively. The PEG nanocarrier-based hydrogels were formed by cross-linking the PEG-LA nanocarriers with 4-arm PEG-NHS via degradable thioester bonds. The nanocarrier-based hydrogels formed within 20 min under ambient conditions and exhibited an elastic modulus that was 100-fold higher than the viscous modulus. The nanocarrier-based degradable hydrogels provided controlled release of lactic acid for several hours; however, a maximum release of only 10%-14% bound lactic acid was observed possibly due to steric hindrance of the polymer chains in the cross-linked hydrogel. In contrast, hydrogels with passively entrapped lactic acid showed burst release with complete release within 30 min. Lactic acid showed antimicrobial activity against the primary BV pathogen Gardnerella vaginalis with a minimum inhibitory concentration (MIC) of 3.6 mg/ml. In addition, the hydrogels with passively entrapped lactic acid showed retained antimicrobial activity with complete inhibition G. vaginalis growth within 48 h. The results of the current study collectively demonstrate the potential of PEG nanocarrier-based hydrogels for vaginal administration of lactic acid for preventing and treating BV. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Rajan, Sujata Sundara; Singh, Yashveer; Sinko, Patrick J.] Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, New Brunswick, NJ 08903 USA.
   [Turovskiy, Yevgeniy; Chikindas, Michael L.] Rutgers State Univ, Sch Environm & Biol Sci, New Brunswick, NJ 08903 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM sinko@rci.rutgers.edu
RI Chikindas, Michael/G-6323-2016
OI Chikindas, Michael/0000-0001-7265-4562; Sinko,
   Patrick/0000-0003-0157-1895
FU National Institutes of Health [R01AI084137]
FX This work was funded by a grant from the National Institutes of Health
   HIT-IT program (R01AI084137).
CR ANDERSCH B, 1990, GYNECOL OBSTET INVES, V30, P114, DOI 10.1159/000293230                                                               
   Anumolu SS, 2011, BIOMATERIALS, V32, P1204, DOI 10.1016/j.biomaterials.2010.08.117
   Anumolu SS, 2010, BIOMATERIALS, V31, P964, DOI 10.1016/j.biomaterials.2009.10.010
   Anumolu SS, 2009, J CONTROL RELEASE, V137, P152, DOI 10.1016/j.jconrel.2009.03.016
   Atashili J, 2008, AIDS, V22, P1493, DOI 10.1097/QAD.0b013e3283021a37
   Atassi F, 2010, FEMS MICROBIOL LETT, V304, P29, DOI 10.1111/j.1574-6968.2009.01887.x
   Ayehunie S, 2011, TOXICOLOGY, V279, P130, DOI 10.1016/j.tox.2010.10.001
   Baldwin AD, 2012, J BIOMED MATER RES A, V100A, P2106, DOI 10.1002/jbm.a.34050
   Barnhart KT, 2004, CONTRACEPTION, V70, P498, DOI 10.1016/j.contraception.2004.06.013
   Barnhart KT, 2007, OBSTET GYNECOL, V110, P577, DOI 10.1097/01.AOG.0000278078.45640.13
   Boskey ER, 1999, INFECT IMMUN, V67, P5170
   Boskey ER, 2001, HUM REPROD, V16, P1809, DOI 10.1093/humrep/16.9.1809
   Brown J, 1997, PHARMACEUT RES, V14, P1073, DOI 10.1023/A:1012113714552
   COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   Conti C, 2009, J PHYSIOL PHARMACOL, V60, P19
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   das Neves Jose, 2009, Current Drug Delivery, V6, P83
   das Neves J., 2008, AIDS, V22, P2
   Delia A, 2006, Minerva Ginecol, V58, P227
   Falagas ME, 2007, CLIN MICROBIOL INFEC, V13, P657, DOI 10.1111/j.1469-0691.2007.01688.x
   Garg S, 2001, CONTRACEPTION, V64, P67, DOI 10.1016/S0010-7824(01)00217-7
   Gupta KM, 2007, J PHARM SCI-US, V96, P670, DOI 10.1002/jps.20752
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O                                                    
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim S.S. Abdool, 2011, AIDS, V25
   Keller MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046901
   Krebs FC, 2002, ANTIMICROB AGENTS CH, V46, P2292, DOI 10.1128/AAC.46.7.2292-2298.2002
   Kurtoglu YE, 2010, INT J PHARMACEUT, V384, P189, DOI 10.1016/j.ijpharm.2009.10.017
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   LANG W R, 1955, Obstet Gynecol Surv, V10, P546
   Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102
   Linhares IM, 2011, AM J OBSTET GYNECOL, V204
   Maeda H, 2006, ADV POLYM SCI, V193, P103, DOI 10.1007/12_026
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326
   Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127
   Mayer KH, 2001, CLIN INFECT DIS, V32, P476, DOI 10.1086/318496
   Mehta S, 2012, INT J PHARMACEUT, V426, P44, DOI 10.1016/j.ijpharm.2012.01.006
   Moodley P, 2002, J INFECT DIS, V185, P69, DOI 10.1086/338027
   Mourtas S, 2007, COLLOID SURFACE B, V55, P212, DOI 10.1016/j.colsurfb.2006.12.005
   Mumper RJ, 2009, DRUG DEV IND PHARM, V35, P515, DOI 10.1080/03639040802488097
   Najlah M, 2006, INT J PHARM, V308, P175, DOI 10.1016/ijpharm.2005.10.033
   Nuttall J, 2010, DRUGS, V70, P1231, DOI 10.2165/10898650-000000000-00000
   O'Hanlon DE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-200
   Owen DH, 2007, J PHARM SCI-US, V96, P661, DOI 10.1002/jps.20736
   Ramjee G, 2010, AIDS, V24, pS40, DOI 10.1097/01.aids.0000390706.81383.f3
   Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5
   Singh Y, 2012, PHARM RES-DORDR, V29, P2377, DOI 10.1007/s11095-012-0763-z
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Sobel JD, 2000, ANNU REV MED, V51, P349, DOI 10.1146/annurev.med.51.1.349
   Stafford MK, 1998, J ACQ IMMUN DEF SYND, V17, P327, DOI 10.1097/00042560-199804010-00006                                                
   Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019                                                
   Tasdemir M, 1996, Arch AIDS Res, V10, P239
   Tomas MSJ, 2003, J MED MICROBIOL, V52, P1117, DOI 10.1099/jmm.0.05155-0
   Turovskiy Y, 2011, J APPL MICROBIOL, V110, P1105, DOI 10.1111/j.1365-2672.2011.04977.x
   Tuyama ACG, 2006, J INFECT DIS, V194, P795, DOI 10.1086/506948
   UNAIDS, 2012, 2012 UNAIDS REP GLOB
   Valore EV, 2002, AM J OBSTET GYNECOL, V187, P561, DOI 10.1067/mob.2002.125280
   von Mollendorf CE, 2010, CONTRACEPTION, V81, P232, DOI 10.1016/j.contraception.2009.10.011
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
NR 63
TC 4
Z9 4
U1 2
U2 66
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2014
VL 194
BP 301
EP 309
DI 10.1016/j.jconrel.2014.08.031
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AS4FU
UT WOS:000344229800029
PM 25223229
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chen, PM
   Zhang, XP
   Jia, L
   Prud'homme, RK
   Szekely, Z
   Sinko, PJ
AF Chen, Peiming
   Zhang, Xiaoping
   Jia, Lee
   Prud'homme, Robert K.
   Szekely, Zoltan
   Sinko, Patrick J.
TI Optimal structural design of mannosylated nanocarriers for macrophage
   targeting
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Mannose receptor; Nanocarrier; HIV-1; Drug delivery; Ligand design
ID C-TYPE LECTIN; MANNOSE RECEPTOR; DRUG-DELIVERY;
   CARBOHYDRATE-RECOGNITION; HIV-1 INFECTION; MURINE MODEL; POLARIZATION;
   INFLAMMATION; ACTIVATION; PEGYLATION
AB Macrophages are involved in a number of diseases, such as HIV infection/AIDS, tuberculosis, tumor development and atherosclerosis. Macrophages possess several cell surface receptors (e.g., the mannose receptor, MR) that may serve as drug delivery cellular portals for nanocarriers (NCs). In this study, the optimal structural configuration for cell uptake of mannosylated poly(ethylene glycol)-conjugate type NCs was determined. A series of NCs were synthesized to systematically evaluate the effects of the number of mannose units (Man), the PEG carrier size and the mPEG spacer length between adjacent mannose units on NC uptake into MR-expressing J774.E murine macrophage-like cells. Among NCs with 0, 1, 2 or 4 units of mannose, the uptake of (Man)(2)-NC was the highest, suggesting a trade-off between avidity and NC-MR clustering on the cell surface that sterically hinders endocytosis. This optimal (Man) 2-NC configuration was built into subsequent NCs to optimize the other two parameters, PEG carrier size and spacer length. NCs with 0, 5, 12, 20, 30 or 40 kDa linear PEG carriers showed an inverse relationship between PEG size and uptake. The 12 kDa PEG carrier was chosen for investigating the third parameter, the Man-Man distance, since it may represent the best trade off (i.e., tissue penetration vs. systemic clearance) for in vivo macrophage targeting. Three (Man)(2)-PEG(12kDa) NCs with different Man-Man distances (39, 56 or 89 angstrom) were synthesized. The uptake of the NC with the 56 angstrom distance between mannoses was four-and two-fold higher than NCs with 39 angstrom and 89 angstrom distances, respectively. Confocal microscopy confirmed that the optimized (Man)(2)-PEG(12kDa) NC with the 56 angstrom Man-Man distance was internalized via endocytosis consistent with temperature-dependent active uptake. In conclusion, the optimal NC structural parameters for targeting the MR on macrophage-like J774.E cells are (i) a small PEG polymer carrier, (ii) two mannose units per NC and (iii) a 56 angstrom distance between adjacent mannose units. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Chen, Peiming; Zhang, Xiaoping; Szekely, Zoltan; Sinko, Patrick J.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA.
   [Jia, Lee] Fuzhou Univ, Coll Chem & Chem Engn, Canc Metastasis Alert & Prevent Ctr, Fuzhou 350002, Peoples R China.
   [Prud'homme, Robert K.] Princeton Univ, Princeton, NJ 08544 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM pmchenru@gmail.com; xzhang@rci.rutgers.edu; pharmlink@gmail.com;
   prudhomm@princeton.edu; zoltan@rci.rutgers.edu; sinko@rutgers.edu
FU National Institute of Allergy and Infectious Diseases [AI051214];
   National Institutes of Health through the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [U54AR055073]
FX This research is supported by the National Institute of Allergy and
   Infectious Diseases (Award AI051214) and the National Institutes of
   Health CounterACT Program through the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (Award U54AR055073).
CR Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593                                                
   Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774
   Barber B.J., 1990, AM J PHYSIOL, V258, P714
   Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1093/toxsci/42.2.152
   Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733                                                     
   BOURGUIGNON LYW, 1977, P NATL ACAD SCI USA, V74, P5031, DOI 10.1073/pnas.74.11.5031
   Box G.E.P., 1960, TECHNOMETRICS, V2, P455, DOI DOI 10.1080/00401706.1960.10489912
   Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI 10.2217/NNM.10.7
   Cambi A, 2008, J BIOL CHEM, V283, P20590, DOI 10.1074/jbc.M709334200
   Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673
   Cassol E, 2006, J LEUKOCYTE BIOL, V80, P1018, DOI 10.1189/jlb.0306150
   Cho WS, 2009, TOXICOL APPL PHARM, V236, P16, DOI 10.1016/j.taap.2008.12.023
   D'Addio SM, 2013, J CONTROL RELEASE, V168, P41, DOI 10.1016/j.jconrel.2013.02.004
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duncan R, 2012, MOL PHARMACEUT, V9, P2380, DOI 10.1021/mp300293n
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200
   Feriotti C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054845
   Gannu R, 2010, AAPS PHARMSCITECH, V11, P976, DOI 10.1208/s12249-010-9451-7
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gunaseelan S, 2009, BIOMATERIALS, V30, P5649, DOI 10.1016/j.biomaterials.2009.05.068
   Hamidi M, 2006, DRUG DELIV, V13, P399, DOI 10.1080/10717540600814402
   Heilbronn LK, 2008, CURR PHARM DESIGN, V14, P1225, DOI 10.2174/138161208784246153
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33
   HEROLD DA, 1989, BIOCHEM PHARMACOL, V38, P73, DOI 10.1016/0006-2952(89)90151-2
   Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Itano MS, 2012, BIOPHYS J, V102, P1534, DOI 10.1016/j.bpj.2012.02.022
   Kerrigan AM, 2009, IMMUNOBIOLOGY, V214, P562, DOI 10.1016/j.imbio.2008.11.003
   Kragol G, 2001, TETRAHEDRON, V57, P957, DOI 10.1016/S0040-4020(00)01087-5
   Laskin DL, 2011, ANNU REV PHARMACOL, V51, P267, DOI 10.1146/annurev.pharmtox.013909.105812
   Le Cabec V, 2005, J LEUKOCYTE BIOL, V77, P934, DOI 10.1189/jlb.1204705
   Lee RT, 2011, GLYCOBIOLOGY, V21, P512, DOI 10.1093/glycob/cwq193
   Llorca O, 2008, CELL MOL LIFE SCI, V65, P1302, DOI 10.1007/s00018-007-7497-9
   MAGNANI M, 1994, AIDS RES HUM RETROV, V10, P1179, DOI 10.1089/aid.1994.10.1179
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mufamadi MS, 2011, J DRUG DELIV, V2011, DOI DOI 10.1155/2011/939851
   Pasquetto MV, 2011, J IMMUNOTHER, V34, P611, DOI 10.1097/CJI.0b013e318234ecf5
   Pasut G, 2012, J CONTROL RELEASE, V161, P461, DOI 10.1016/j.jconrel.2011.10.037
   Pedrinelli R, 2000, AM J HYPERTENS, V13, P256, DOI 10.1016/S0895-7061(00)00250-8                                                   
   Pierige F, 2008, ADV DRUG DELIVER REV, V60, P286, DOI 10.1016/j.addr.2007.08.029
   Rawat M, 2006, BIOL PHARM BULL, V29, P1790, DOI 10.1248/bpb.29.1790
   Rossi Luiga, 2005, Expert Opin Drug Deliv, V2, P311, DOI 10.1517/17425247.2.2.311
   RUTILI G, 1977, ACTA PHYSIOL SCAND, V99, P1, DOI 10.1111/j.1748-1716.1977.tb10345.x
   Sansone F, 2013, CHEM SOC REV, V42, P4623, DOI 10.1039/c2cs35437c
   Shimada K, 2009, CIRC J, V73, P994, DOI 10.1253/circj.CJ-09-0277                                                        
   Shukla RK, 2011, CRIT REV THER DRUG, V28, P255
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Su YP, 2005, J BIOL CHEM, V280, P32811, DOI 10.1074/jbc.M503457200
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   Thepen T, 2009, CURR PHARM DESIGN, V15, P2712, DOI 10.2174/138161209788923967                                                      
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004
   Vielhauer V, 2010, SEMIN NEPHROL, V30, P318, DOI 10.1016/j.semnephrol.2010.03.006
   Vigerust DJ, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-51
   VISTICA DT, 1991, CANCER RES, V51, P2515
   Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301                                             
   Wilson HM, 2009, CURR VASC PHARMACOL, V7, P234, DOI 10.2174/157016109787455635                                                      
   Zeng XQ, 2012, ANAL BIOANAL CHEM, V402, P3161, DOI 10.1007/s00216-011-5594-y
NR 63
TC 7
Z9 7
U1 8
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2014
VL 194
BP 341
EP 349
DI 10.1016/j.jconrel.2014.09.006
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AS4FU
UT WOS:000344229800034
PM 25220160
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hosny, KM
   Hassan, AH
AF Hosny, Khaled Mohamed
   Hassan, Ali Habiballah
TI Intranasal in situ gel loaded with saquinavir mesylate nanosized
   microemulsion: Preparation, characterization, and in vivo evaluation
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Saquinavir mesylate; Nanosized microemulsion; Intranasal; Human
   immunodeficiency virus (HIV-1); In situ gel
ID DELIVERY-SYSTEMS; ABSORPTION; FORMULATION
AB Saquinavir mesylate (SM) is a protease inhibitor with activity against human immunodeficiency virus type 1 (HIV-1) and is available in tablet form, which has three major problems. First, the drug undergoes extensive first pass metabolism. Second, the drug has a poor aqueous solubility. And third, it has low GIT permeability and absorption. These constrains lead to decrease oral bioavailability (4% only) and administration of large doses which increase the incidence of occurrence of the side effects. The aim of this research was to utilize nanotechnology to formulate (SM) into a nasal in situ nanosized microemulsion gel (NEG) to provide a solution for the previously mentioned problems. The solubility of (SM) in various oils, surfactants, and cosurfactants was estimated. Pseudo-ternary phase diagrams were developed and various nanosized microemulsion (NE) were prepared, and subjected to characterization, stability study, and droplet size measurements. Gellan gum was used as an in situ gelling agent. The gel strength, critical ionic concentration, gelation characteristics, in vitro release, and ex vivo nasal permeation were determined. The pharmacokinetic study was carried out in rabbits. Stable NEs were successfully developed with a droplet size range of 25-61 nm. A NEG composed of 17.5% Labrafac PG, 33% Labrasol, and 11% Transcutol HP successfully provided the maximum in vitro and ex vivo permeation, and enhanced the bioavailability in the rabbits by 12-fold when compared with the marketed tablets. It can be concluded that the nasal NEG is a promising novel formula for (SM) that has higher nasal tissue permeability and enhanced systemic bioavailability. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Hosny, Khaled Mohamed] Beni Suef Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Bani Suwayf, Egypt.
   [Hosny, Khaled Mohamed] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21413, Saudi Arabia.
   [Hassan, Ali Habiballah] King Abdulaziz Univ, Fac Dent, Dept Orthodont, Jeddah 21413, Saudi Arabia.
RP Hosny, KM (reprint author), King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21413, Saudi Arabia.
EM Elswaify2000@yahoo.com
RI Hosny, Khaled/H-9793-2012
CR Campanero M.A., 2001, BIOMED CHROM, V16, P7
   Cao L., 2009, INT J PHARMACEUT, V365, P109
   Djekic L, 2008, INT J PHARM, V352, P231, DOI 10.1016/j.ijpharm.2007.10.041
   Elshafeey AH, 2009, PHARM RES-DORD, V26, P2446, DOI 10.1007/s11095-009-9956-5
   Forestier F, 2001, AM J OBSTET GYNECOL, V185, P178, DOI 10.1067/mob.2001.113319
   Hosny KM, 2009, AAPS PHARMSCITECH, V10, P1336, DOI 10.1208/s12249-009-9335-x
   Jansson B, 2005, EUR J PHARM BIOPHARM, V59, P557, DOI 10.1016/j.ejpb.2004.10.001
   Kawakami K, 2002, J CONTROL RELEASE, V81, P65, DOI 10.1016/S0168-3659(02)00049-4
   Khaled H., 2013, EXPERT OPIN DRUG DEL, V10, P1033
   Kublik H, 1998, ADV DRUG DELIVER REV, V29, P157, DOI 10.1016/S0169-409X(97)00067-7                                                   
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Mahajan HS, 2014, DRUG DELIV, V21, P148, DOI 10.3109/10717544.2013.838014
   Monteiro LM, 2012, INT J NANOMED, V7, P5175, DOI 10.2147/IJN.S36479
   Narayana RC, 2009, YAKUGAKU ZASSHI, V129, P569, DOI 10.1248/yakushi.129.569                                                         
   Richard B.K., 1998, J CLIN INVEST, V101, P289
   Sanjula B., 2007, ACTA PHARM, V57, P315
   Tanaji N., 2008, INT J PHARM SCI NANO, V12, P177
   THACHARODI D, 1994, INT J PHARM, V111, P235, DOI 10.1016/0378-5173(94)90346-8
   Yuan JS, 2008, INT J PHARM, V349, P130, DOI 10.1016/j.ijpharm.2007.07.047
   Zheng C., 2011, AAPS PHARMSCITECH, V12, P1102
NR 21
TC 12
Z9 12
U1 1
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 20
PY 2014
VL 475
IS 1-2
BP 191
EP 197
DI 10.1016/j.ijpharm.2014.08.064
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AU0FR
UT WOS:000345299500020
PM 25178831
DA 2018-01-05
ER

PT J
AU Krogstad, EA
   Woodrow, KA
AF Krogstad, Emily A.
   Woodrow, Kim A.
TI Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers
   containing tenofovir for vaginal drug delivery
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Electrospinning; Scale-up; Microbicides; Tenofovir; Solid dispersions;
   Fibers
ID HIV; NANOFIBERS; WOMEN; DISPERSIONS; PROPHYLAXIS; PREVENTION; FILM; MEN
AB Electrospun fibers containing antiretroviral drugs have recently been investigated as a new dosage form for topical microbicides against HIV-1. However, little work has been done to evaluate the scalability of the fiber platform for pharmaceutical production of medical fabrics. Scalability and cost-effectiveness are essential criteria in developing fibers as a practical platform for use as a microbicide and for translation to clinical use. To address this critical gap in the development of fiber-based vaginal dosage forms, we assessed the scale-up potential of drug-eluting fibers delivering tenofovir (TFV), a nucleotide reverse transcriptase inhibitor and lead compound for topical HIV-1 chemoprophylaxis. Here we describe the process of free-surface electrospinning to scale up production of TFV fibers, and evaluate key attributes of the finished products such as fiber morphology, drug crystallinity, and drug loading and release kinetics. Poly(vinyl alcohol) (PVA) containing up to 60 wt% TFV was successfully electrospun into fibers using a nozzle-free production-scale electrospinning instrument. Actual TFV loading in fibers increased with increasing weight percent TFV in solution, and encapsulation efficiency was improved by maintaining TFV solubility and preventing drug sedimentation during batch processing. These results define important solution and processing parameters for scale-up production of TFV drug-eluting fibers by wire electrospinning, which may have significant implications for pharmaceutical manufacturing of fiber-based medical fabrics for clinical use. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Krogstad, Emily A.; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, WH Foege N410D,3720 15th Ave NE,UW Mailbox 355061, Seattle, WA 98195 USA.
EM emkrog@u.washington.edu; woodrow@uw.edu
FU Bill and Melinda Gates Foundation [OPP1067729]; National Institutes of
   Health [AI09864801]; NSF graduate research fellowship
FX The research was supported by a grant from the Bill and Melinda Gates
   Foundation (OPP1067729) and the National Institutes of Health
   (AI09864801) to KAW. EK was supported by a NSF graduate research
   fellowship. Assistance with solution property characterization and XRD
   was provided by R. Edmark, and assistance with stability studies was
   provided by C. Nhan. We thank R. Edmark and S.F. Chou for critical
   discussions and review of the manuscript.
CR Ago M, 2012, BIOMACROMOLECULES, V13, P918, DOI 10.1021/bm201828g
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022
   Costabeber A, 2013, P 15 EUR C POW EL AP, P1
   Craig D.Q., 2002, INT J PHARMACEUT, V144, P891
   Dobaria NB, 2009, AAPS PHARMSCITECH, V10, P951, DOI 10.1208/s12249-009-9288-0
   Forward KM, 2012, CHEM ENG J, V183, P492, DOI 10.1016/j.cej.2011.12.045
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Gengiah TN, 2012, BEST PRACT RES CL OB, V26, P495, DOI 10.1016/j.bpobgyn.2012.02.004
   Glynn JR, 2001, AIDS, V15, pS51, DOI 10.1097/00002030-200108004-00006
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Greenspan L., 1977, J RES NAT BUR STAND, V81, P81
   Guirguis OW, 2012, NAT SCI, V4, P57, DOI DOI 10.4236/NS.2012.41009
   Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   JEFFREY DJ, 1976, AICHE J, V22, P417, DOI 10.1002/aic.690220303                                                           
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Luo CJ, 2012, CHEM SOC REV, V41, P4708, DOI 10.1039/c2cs35083a
   Microbicide Trials Network, 2013, DAIL HIV PREV APPR D
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   PEPPAS NA, 1976, J APPL POLYM SCI, V20, P1457, DOI 10.1002/app.1976.070200604                                                      
   Persano L, 2013, MACROMOL MATER ENG, V298, P504, DOI 10.1002/mame.201200290
   Sassi AB, 2011, ANTIMICROB AGENTS CH, V55, P2282, DOI 10.1128/AAC.01190-10
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Verreck G, 2003, PHARMACEUT RES, V20, P810, DOI 10.1023/A:1023450006281
   Yu DG, 2010, AAPS PHARMSCITECH, V11, P809, DOI 10.1208/s12249-010-9438-4
   [Anonymous], 2011, CAMI MULT PREV TECHN, P1
NR 30
TC 18
Z9 19
U1 2
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 20
PY 2014
VL 475
IS 1-2
BP 282
EP 291
DI 10.1016/j.ijpharm.2014.08.039
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AU0FR
UT WOS:000345299500029
PM 25169075
OA green_accepted
DA 2018-01-05
ER

PT J
AU Madison, MN
   Roller, RJ
   Okeoma, CM
AF Madison, Marisa N.
   Roller, Richard J.
   Okeoma, Chioma M.
TI Human semen contains exosomes with potent anti-HIV-1 activity
SO RETROVIROLOGY
LA English
DT Article
DE Exosome; Semen; HIV-1; mAIDS; HSV
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 REVERSE-TRANSCRIPTASE; REPLICATION
   IN-VIVO; T-CELLS; SEXUAL TRANSMISSION; BREAST-MILK; INFECTION; APOBEC3G;
   RNA; PLASMA
AB Background: Exosomes are membranous nanovesicles secreted into the extracellular milieu by diverse cell types. Exosomes facilitate intercellular communication, modulate cellular pheno/genotype, and regulate microbial pathogenesis. Although human semen contains exosomes, their role in regulating infection with viruses that are sexually transmitted remains unknown. In this study, we used semen exosomes purified from healthy human donors to evaluate the role of exosomes on the infectivity of different strains of HIV-1 in a variety of cell lines.
   Results: We show that human semen contains a heterologous population of exosomes, enriched in mRNA encoding tetraspanin exosomal markers and various antiviral factors. Semen exosomes are internalized by recipient cells and upon internalization, inhibit replication of a broad array of HIV-1 strains. Remarkably, the anti-HIV-1 activity of semen exosomes is specific to retroviruses because semen exosomes blocked replication of the murine AIDS (mAIDS) virus complex (LP-BM5). However, exosomes from blood had no effect on HIV-1 or LP-BM5 replication. Additionally, semen and blood exosomes had no effect on replication of herpes simplex virus; types 1 and 2 (HSV1 and HSV2). Mechanistic studies indicate that semen exosomes exert a post-entry block on HIV-1 replication by orchestrating deleterious effects on particle-associated reverse transcriptase activity and infectivity.
   Conclusions: These illuminating findings i) improve our knowledge of the cargo of semen exosomes, ii) reveal that semen exosomes possess anti-retroviral activity, and iii) suggest that semen exosome-mediated inhibition of HIV-1 replication may provide novel opportunities for the development of new therapeutics for HIV-1.
C1 [Madison, Marisa N.; Roller, Richard J.; Okeoma, Chioma M.] Univ Iowa, Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA.
   [Okeoma, Chioma M.] Univ Iowa, Interdisciplinary Program Mol & Cellular Biol, Iowa City, IA 52242 USA.
RP Okeoma, CM (reprint author), Univ Iowa, Carver Coll Med, Dept Microbiol, 51 Newton Rd, Iowa City, IA 52242 USA.
EM chioma-okeoma@uiowa.edu
OI Okeoma, Chioma/0000-0001-7737-6493
FU University of Iowa; Infectious Diseases T32
FX The authors acknowledge the support of University of Iowa core
   facilities, including Central Microscopy and DNA core. MNM was supported
   by Infectious Diseases T32. The authors are thankful to Dr. James
   Hildreth of UCLA for providing p24 ELISA reagents. The authors
   gratefully acknowledge comments by Bryson Okeoma of the University of
   Iowa.
CR Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703
   Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969                                                     
   Ajamian L, 2008, RNA, V14, P914, DOI 10.1261/rna.829208
   Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Butsch M, 2000, J VIROL, V74, P11531, DOI 10.1128/JVI.74.24.11531-11537.2000
   Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267
   Conde-Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887
   Cook WJ, 2003, J VIROL METHODS, V108, P49, DOI 10.1016/S0166-0934(02)00256-2
   de Hoog Vince C, 2013, Eur Heart J Acute Cardiovasc Care, V2, P53, DOI 10.1177/2048872612471212
   EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357
   Iwatani Y, 2007, NUCLEIC ACIDS RES, V35, P7096, DOI 10.1093/nar/gkm750
   Jones PH, 2013, CELL SIGNAL, V25, P2752, DOI 10.1016/j.cellsig.2013.08.042
   Jones PH, 2013, VIROLOGY, V444, P124, DOI 10.1016/j.virol.2013.05.042
   Jones PH, 2013, VIROLOGY, V438, P37, DOI 10.1016/j.virol.2013.01.010
   Jones PH, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-50
   Jones PH, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-10
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   Keller S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-86
   Kelly RW, 1997, HUM REPROD, V12, P2200
   Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131
   Khatua AK, 2009, J VIROL, V83, P512, DOI 10.1128/JVI.01658-08
   Kogure T, 2011, HEPATOLOGY, V54, P1237, DOI 10.1002/hep.24504
   Li J, 2013, NAT IMMUNOL, V14, P793
   Li XY, 2007, J BIOL CHEM, V282, P32065, DOI 10.1074/jbc.M703423200
   Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900
   Low A, 2009, VIROLOGY, V385, P455, DOI 10.1016/j.virol.2008.11.051
   Marozsan AJ, 2004, J VIROL, V78, P11130, DOI 10.1128/JVI.78.20.11130-11141.2004                                              
   Martellini JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016285
   Martellini JA, 2009, FASEB J, V23, P3609, DOI 10.1096/fj.09-131961
   MASUDA T, 1995, J VIROL, V69, P6687
   MAURY W, 1994, J VIROL, V68, P6270
   Mbisa JL, 2007, J VIROL, V81, P7099, DOI 10.1128/JVI.00272-07
   Mehta HV, 2012, J IMMUNOL, V189, P4088, DOI 10.4049/jimmunol.1200777
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Naslund TI, 2014, AIDS, V28, P171, DOI 10.1097/QAD.0000000000000159
   OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705
   Ochsenbauer C, 2012, J VIROL, V86, P2715, DOI 10.1128/JVI.06157-11
   Okeoma CM, 2008, J VIROL, V82, P1314, DOI 10.1128/JVI.01848-07
   Okeoma CM, 2007, NATURE, V445, P927, DOI 10.1038/nature05540
   Okeoma CM, 2010, CELL HOST MICROBE, V8, P534, DOI 10.1016/j.chom.2010.11.003
   Okeoma CM, 2009, J VIROL, V83, P3029, DOI 10.1128/JVI.02536-08
   Okeoma CM, 2009, J VIROL, V83, P3486, DOI 10.1128/JVI.02347-08
   Palanisamy V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008577
   Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101
   Poliakov A, 2009, PROSTATE, V69, P159, DOI 10.1002/pros.20860
   Quackenbush JF, 2014, METHODS MOL BIOL, V1102, P641, DOI 10.1007/978-1-62703-727-3_34
   Rekker K, 2013, CLIN BIOCHEM, V47, P135
   Roan NR, 2014, J VIROL, V88, P7221, DOI 10.1128/JVI.00269-14
   Roller RJ, 2014, J VIROL, V88, P4058, DOI 10.1128/JVI.03707-13
   RONQUIST G, 1985, BIOCHIM BIOPHYS ACTA, V822, P203, DOI 10.1016/0304-4157(85)90008-5
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657
   Sun DM, 2010, MOL THER, V18, P1606, DOI 10.1038/mt.2010.105
   Tachedjian G, 2005, PROTEINS, V60, P5, DOI 10.1002/prot.20480
   Tachedjian G, 2003, J MOL BIOL, V326, P381, DOI 10.1016/S0022-2836(02)01433-X
   TANG SB, 1991, J VIROL METHODS, V33, P39, DOI 10.1016/0166-0934(91)90005-K
   Varghese B, 2002, SEX TRANSM DIS, V29, P38, DOI 10.1097/00007435-200201000-00007
   Vojtech L, 2014, NUCLEIC ACIDS RES, V42, P7290, DOI 10.1093/nar/gku347
   Wang XX, 2012, J VIROL, V86, P3777, DOI 10.1128/JVI.06594-11
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
   Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339
NR 66
TC 30
Z9 31
U1 1
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD NOV 19
PY 2014
VL 11
AR 102
DI 10.1186/s12977-014-0102-z
PG 15
WC Virology
SC Virology
GA AU6IH
UT WOS:000345706500001
PM 25407601
OA gold
DA 2018-01-05
ER

PT J
AU Liu, JK
   Du, BC
   Zhang, PH
   Haleyurgirisetty, M
   Zhao, J
   Ragupathy, V
   Lee, S
   Devoe, DL
   Hewlett, IK
AF Liu, Jikun
   Du, Bingchen
   Zhang, Panhe
   Haleyurgirisetty, Mohan
   Zhao, Jiangqin
   Ragupathy, Viswanath
   Lee, Sherwin
   DeVoe, Don L.
   Hewlett, Indira K.
TI Development of a microchip Europium nanoparticle immunoassay for
   sensitive point-of-care HIV detection
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Europium nanoparticles; Microchip; Point-of-care diagnostics; HIV;
   Resource-limited settings
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-RESPONSES; DEVELOPING-WORLD;
   ANALYSIS SYSTEMS; ASSAY; DIAGNOSTICS; AMPLIFICATION; TESTS;
   OPPORTUNITIES; PERFORMANCE
AB Rapid, sensitive and specific diagnostic assays play an indispensable role in determination of HIV infection stages and evaluation of efficacy of antiretroviral therapy. Recently, our laboratory developed a sensitive Europium nanoparticle-based microtiter-plate immunoassay capable of detecting target analytes at subpicogram per milliliter levels without the use of catalytic enzymes and signal amplification processes. Encouraged by its sensitivity and simplicity, we continued to miniaturize this assay to a microchip platform for the purpose of converting the benchtop assay technique to a point-of-care test. It was found that detection capability of the microchip platform could be readily improved using Europium nanoparticle probes. We were able to routinely detect 5 pg/mL (4.6 attomoles) of HIV-1 p24 antigen at a signal-to-blank ratio of 1.5, a sensitivity level reasonably close to that of microtiter-plate Europium nanoparticle assay. Meanwhile, use of the microchip platform effectively reduced sample/reagent consumption 4.5 fold and shortened total assay time 2 fold in comparison with microtiter plate assays. Complex matrix substance in plasma negatively affected the microchip assays and the effects could be minimized by diluting the samples before loading. With further improvements in sensitivity, reproducibility, usability, assay process simplification, and incorporation of portable time-resolved fluorescence reader, Europium nanoparticle immunoassay technology could be adapted to meet the challenges of point-of-care diagnosis of HIV or other health-threatening pathogens at bedside or in resource-limited settings. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Liu, Jikun; Du, Bingchen; Zhang, Panhe; Haleyurgirisetty, Mohan; Zhao, Jiangqin; Ragupathy, Viswanath; Lee, Sherwin; Hewlett, Indira K.] US FDA, CBER, Mol Virol Lab, Bethesda, MD 20892 USA.
   [DeVoe, Don L.] Univ Maryland, Dept Mech Engn, College Pk, MD 20842 USA.
RP Liu, JK (reprint author), US FDA, CBER, Mol Virol Lab, Bldg 29B Room 4NN16 8800 Rockville Pike, Bethesda, MD 20892 USA.
EM jikunliu@fda.hhs.gov; Indira.Hewlett@fda.hhs.gov
RI DeVoe, Don/A-2891-2011
OI DeVoe, Don/0000-0002-7740-9993
FU National Heart, Lung and Blood Institute (NHLBI) [Nano
   IAA-Y1-HB-8027-01]; Oak Ridge Institute for Science and Education
   (ORISE)
FX This work was supported financially by the National Heart, Lung and
   Blood Institute (NHLBI, Nano IAA-Y1-HB-8027-01) and Oak Ridge Institute
   for Science and Education (ORISE). We would like to thank Drs. Xue Wang
   and Krishnakumar Devadas for review of the manuscript. The findings and
   conclusions in this article have not been formally disseminated by the
   Food and Drug Administration and should not be construed to represent
   any Agency determination or policy.
CR Allain JP, 2005, EXPERT REV MOL DIAGN, V5, P31, DOI 10.1586/14737159.5.1.31
   Busch MP, 2005, TRANSFUSION, V45, P1853, DOI 10.1111/j.1537-2995.2005.00649.x
   Cesaro-Tadic S, 2004, LAB CHIP, V4, P563, DOI 10.1039/b408964b
   Cheng XH, 2009, LAB CHIP, V9, P1357, DOI 10.1039/b818813k
   Chin CD, 2012, LAB CHIP, V12, P2118, DOI 10.1039/c2lc21204h
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Colvin CJ, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-31
   Corstjens PLAM, 2007, ANN NY ACAD SCI, V1098, P437, DOI 10.1196/annals.1384.016
   Desai D, 2011, LAB CHIP, V11, P194, DOI 10.1039/c0lc00340a
   Emaminejad S, 2012, LAB CHIP, V12, P4499, DOI 10.1039/c2lc40759k
   Ferguson BS, 2011, J AM CHEM SOC, V133, P9129, DOI 10.1021/ja203981w
   Gordon J, 2008, CLIN CHEM, V54, P1250, DOI 10.1373/clinchem.2007.102491
   Harma H, 2001, CLIN CHEM, V47, P561
   Harma H, 2010, NANOSCALE, V2, P69, DOI 10.1039/b9nr00172g
   Harma H, 2008, ANAL CHEM, V80, P9781, DOI 10.1021/ac801960c
   Iweala OI, 2004, CONTRACEPTION, V70, P141, DOI 10.1016/j.contraception.2004.03.012
   Juntunen E, 2012, ANAL BIOCHEM, V428, P31, DOI 10.1016/j.ab.2012.06.005
   Kim D, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4816934
   Kim JH, 2012, LAB CHIP, V12, P1437, DOI [10.1039/c2lc21131a, 10.1039/c2lc21131]
   Lin XX, 2014, BIOSENS BIOELECTRON, V56, P71, DOI 10.1016/j.bios.2013.12.061
   Liu W, 2011, BIOSENS BIOELECTRON, V28, P438, DOI 10.1016/j.bios.2011.07.067
   Lutz S, 2010, LAB CHIP, V10, P887, DOI 10.1039/b921140c
   Mantymaa A, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3668261
   MANZ A, 1990, SENSOR ACTUAT B-CHEM, V1, P244, DOI 10.1016/0925-4005(90)80209-I                                                    
   Pihlasalo S, 2012, ANAL CHEM, V84, P1386, DOI 10.1021/ac202417j
   Pihlasalo S, 2011, ANAL CHEM, V83, P1163, DOI 10.1021/ac1026385
   Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2
   Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435
   SCHRAMM W, 1993, IMMUNOMETHODS, V3, P93
   Speers D, 2005, J CLIN MICROBIOL, V43, P5397, DOI 10.1128/JCM.43.10.5397-5399.2005
   Stern E, 2010, NAT NANOTECHNOL, V5, P138, DOI [10.1038/nnano.2009.353, 10.1038/NNANO.2009.353]
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2010, CLIN VACCINE IMMUNOL, V17, P1244, DOI 10.1128/CVI.00066-10
   Tang SX, 2009, CLIN VACCINE IMMUNOL, V16, P408, DOI 10.1128/CVI.00412-08
   Thaxton CS, 2005, ANAL CHEM, V77, P8174, DOI 10.1021/ac0514265
   Ukonaho T, 2007, ANAL CHIM ACTA, V596, P106, DOI 10.1016/j.aca.2007.05.060
   Vasan Arvind Sai Sarathi, 2013, Front Biosci (Schol Ed), V5, P39
   Wainberg MA, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-31
   Wong Eric Y., 2010, HIV Therapy, V4, P399, DOI 10.2217/HIV.10.29
   Xia XH, 2009, CLIN CHEM, V55, P179, DOI 10.1373/clinchem.2008.114561
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yoon JY, 2012, SENSORS-BASEL, V12, P10713, DOI 10.3390/s120810713
   Zhou JW, 2010, ELECTROPHORESIS, V31, P2, DOI 10.1002/elps.200900475
NR 43
TC 17
Z9 17
U1 3
U2 100
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD NOV 15
PY 2014
VL 61
BP 177
EP 183
DI 10.1016/j.bios.2014.04.057
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AM2PE
UT WOS:000339692500026
PM 24880655
DA 2018-01-05
ER

PT J
AU Cheng, SF
   Sung, TC
   Chang, CC
   Chou, MJ
   Chiang, YW
   Chang, DK
AF Cheng, Shu-Fang
   Sung, Tai-Ching
   Chang, Chung-Chieh
   Chou, Mei-Ju
   Chiang, Yun-Wei
   Chang, Ding-Kwo
TI Kinetics Study on the HIV-1 Ectodomain Protein Quaternary Structure
   Formation Reveals Coupling of Chain Folding and Self-Assembly in the
   Refolding Cascade
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID MOLTEN GLOBULE STATE; COILED-COIL; ENVELOPE GLYCOPROTEIN; DISORDERED
   PROTEINS; GP41; CONFORMATION; STABILITY; MECHANISM; FUSION; CORE
AB Entry of HIV-1 into the target cell is mediated by the envelope glycoprotein consisting of noncovalently associated surface subunit gp120 and transmembrane subunit gp41. To form a functional gp41 complex, the protein undergoes hairpin formation and self-assembly. The fusion event can be inhibited by gp41-derived peptides at nanomolar concentration and is highly dependent on the time of addition, implying a role of folding kinetics on the inhibitory action. Oligomerization of the gp41 ectodomain was demonstrated by light scattering measurements. Kinetic study by stopped-flow fluorescence and absorption measurements (i) revealed a multistate folding pathway and stable intermediates; (ii) showed a dissection of fast and slow components for early and late stages of folding, respectively, with 3 orders of magnitude difference in the time scale; (iii) showed the slow process was attributed to misfolding and unzipping of the hairpin; and (iv) showed retardation of the native hairpin formation is assumed to lead to coupling of the correctly registered hairpin and self-assembly. This coupling allows the deduction on the time scale of intrachain folding (0.11 s) for the protein. The folding reaction was illustrated by a free energy profile to explain the temporal dichotomy of fast and slow steps of folding as well as effective inhibition by gp41-derived peptide.
C1 [Cheng, Shu-Fang; Chang, Chung-Chieh; Chou, Mei-Ju; Chang, Ding-Kwo] Acad Sinica, Inst Chem, Taipei 11529, Taiwan.
   [Sung, Tai-Ching; Chiang, Yun-Wei] Natl Tsing Hua Univ, Dept Chem, Hsinchu 30013, Taiwan.
   [Sung, Tai-Ching; Chiang, Yun-Wei] Natl Tsing Hua Univ, Frontier Res Ctr Fundamental & Appl Sci Matters, Hsinchu 30013, Taiwan.
RP Chang, DK (reprint author), Acad Sinica, Inst Chem, Taipei 11529, Taiwan.
EM dkc@chem.sinica.edu.tw
RI Chang, Ding-Kwo/E-7079-2015
OI Chiang, Yun-Wei/0000-0002-2101-8918
FU Academia Sinica Research Program on Nano-Sciences and Nanotechnology and
   National Science Council [NSC99-2113-M-001-024-MY3]; National Science
   Council [NSC100-2113-M-007-013-MY2]
FX Financial support from Academia Sinica Research Program on Nano-Sciences
   and Nanotechnology and National Science Council
   (NSC99-2113-M-001-024-MY3 to D.-K.C.) and National Science Council
   (NSC100-2113-M-007-013-MY2 to Y.W.C.) is greatly acknowledged. Technical
   assistance from Dr. Po-Huang Liang, Institute of Biological Sciences,
   Academia Sinica, is appreciated.
CR Arai M, 2000, ADV PROTEIN CHEM, V53, P209
   ARBELOA IL, 1982, CHEM PHYS LETT, V87, P556, DOI 10.1016/0009-2614(82)83177-1
   Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428.12437.2004
   Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X
   BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chang CC, 2011, J STRUCT BIOL, V175, P406, DOI 10.1016/j.jsb.2011.06.007
   Chang DK, 1999, J STRUCT BIOL, V128, P270, DOI 10.1006/jsbi.1999.4182
   Chien MP, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-20
   COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179
   Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10
   Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k
   Du DG, 2006, BIOCHEMISTRY-US, V45, P13131, DOI 10.1021/bi0615745
   Durr E, 1999, BIOCHEMISTRY-US, V38, P870, DOI 10.1021/bi981891e
   Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Hamman BD, 1996, J BIOL CHEM, V271, P7568, DOI 10.1074/jbc.271.13.7568                                                         
   Hoffmann-Thoms S, 2012, BIOCHEMISTRY-US, V51, P3948, DOI 10.1021/bi300154z
   Huang YW, 2011, P NATL ACAD SCI USA, V108, P14145, DOI 10.1073/pnas.1102395108
   Huang YQ, 2009, J MOL BIOL, V393, P1143, DOI 10.1016/j.jmb.2009.09.010
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247
   Lin CH, 2008, ELECTROPHORESIS, V29, P3175, DOI 10.1002/elps.200700863
   Liu J, 2001, BIOCHEMISTRY-US, V40, P2797, DOI 10.1021/bi0024759
   Liu XY, 1996, BIOCHEMISTRY-US, V35, P4306, DOI 10.1021/bi952270d
   Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9
   Neuweiler H, 2010, P NATL ACAD SCI USA, V107, P22106, DOI 10.1073/pnas.1011666107
   Neuweiler H, 2009, J MOL BIOL, V387, P975, DOI 10.1016/j.jmb.2008.12.056
   OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P1989, DOI 10.1021/bi047993o
   Otteken A, 1996, J VIROL, V70, P3407
   PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593
   PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273
   RISCHEL C, 1995, FEBS LETT, V374, P105, DOI 10.1016/0014-5793(95)01087-U
   Rose GD, 2006, P NATL ACAD SCI USA, V103, P16623, DOI 10.1073/pnas.0606843103
   Schindler T, 1996, BIOCHEMISTRY-US, V35, P16833, DOI 10.1021/bi962090j
   Scott KA, 2006, J MOL BIOL, V359, P159, DOI 10.1016/j.jmb.2006.03.011
   SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149
   Sosnick TR, 1996, PROTEINS, V24, P413
   Walters BT, 2013, P NATL ACAD SCI USA, V110, P18898, DOI 10.1073/pnas.1319482110
   Wang T, 2005, BIOPHYS J, V89, P4180, DOI 10.1529/biophysj.105.068809
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110                                                          
   Xu Y, 2006, J AM CHEM SOC, V128, P15836, DOI 10.1021/ja064865+
   Zhu Y, 2003, P NATL ACAD SCI USA, V100, P15486, DOI 10.1073/pnas.2136623100
NR 48
TC 0
Z9 0
U1 3
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD NOV 13
PY 2014
VL 118
IS 45
BP 12827
EP 12836
DI 10.1021/jp508360k
PG 10
WC Chemistry, Physical
SC Chemistry
GA AT5IH
UT WOS:000344976600003
PM 25333416
DA 2018-01-05
ER

PT J
AU Freeling, JP
   Koehn, J
   Shu, CL
   Sun, JG
   Ho, RJY
AF Freeling, Jennifer P.
   Koehn, Josefin
   Shu, Cuiling
   Sun, Jianguo
   Ho, Rodney J. Y.
TI Long-acting three-drug combination anti-HIV nanoparticles enhance drug
   exposure in primate plasma and cells within lymph nodes and blood
SO AIDS
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; VIRAL LOAD; INDINAVIR; TISSUES; LOCALIZATION;
   REDUCTION; RITONAVIR; INFECTION; MACAQUES
AB Insufficient HIV drug levels in lymph nodes have been linked to viral persistence. To overcome lymphatic drug insufficiency, we developed and evaluated in primates a lipid-drug nanoparticle containing lopinavir, ritonavir, and tenofovir. These nanoparticles produced over 50-fold higher intracellular lopinavir, ritonavir and tenofovir concentrations in lymph nodes compared to free drug. Plasma and intracellular drug levels in blood were enhanced and sustained for 7 days after a single subcutaneous dose, exceeding that achievable with current oral therapy.
C1 [Freeling, Jennifer P.; Koehn, Josefin; Shu, Cuiling; Sun, Jianguo; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.
EM rodneyho@uw.edu
FU NIH [AI-077390, RR00166, RR025014, UL1-TR000423]; Milo Gibaldi endowment
FX Supported by NIH grants, AI-077390 (S1, S2, S3), RR00166, RR025014, and
   UL1-TR000423. RJYH is also supported by the Milo Gibaldi endowment.
CR Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Endsley AN, 2012, JAIDS-J ACQ IMM DEF, V61, P417, DOI 10.1097/QAI.0b013e3182653c1f
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   Freeling JP, 2014, P NATL ACAD SCI USA, V111, pE2512, DOI 10.1073/pnas.1406554111
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Hsu A, 1998, CLIN PHARMACOKINET, V35, P275, DOI 10.2165/00003088-199835040-00002
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Koehn J, 2014, ANTIMICROB AGENTS CH, V58, P2675, DOI 10.1128/AAC.02748-13
   Lafeuillade A, 1998, J INFECT DIS, V177, P235, DOI 10.1086/517362                                                                  
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Piliero PJ, 2004, JAIDS-J ACQ IMM DEF, V37, pS2, DOI 10.1097/01.qai.0000137001.40505.56
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Storch CH, 2007, BIOCHEM PHARMACOL, V73, P1573, DOI 10.1016/j.bcp.2007.01.027
   STRAUBINGER RM, 1985, FEBS LETT, V179, P148, DOI 10.1016/0014-5793(85)80210-6                                                    
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
NR 19
TC 18
Z9 18
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 13
PY 2014
VL 28
IS 17
BP 2625
EP 2627
DI 10.1097/QAD.0000000000000421
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2CQ
UT WOS:000344739300017
PM 25102089
OA gold
DA 2018-01-05
ER

PT J
AU He, HN
   Ye, JX
   Liu, EG
   Liang, QL
   Liu, Q
   Yang, VC
AF He, Huining
   Ye, Junxiao
   Liu, Ergang
   Liang, Qiuling
   Liu, Quan
   Yang, Victor C.
TI Low molecular weight protamine (LMWP): A nontoxic protamine substitute
   and an effective cell-penetrating peptide
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Low molecular weight protamine; Protein transduction domain (PTD);
   Cell-penetrating peptide (CPP); Heparin antagonist; Protamine
ID CATASTROPHIC PULMONARY VASOCONSTRICTION; INTRACELLULAR DELIVERY
   PEPTIDES; HUMAN IMMUNODEFICIENCY VIRUS; VIVO PROTEIN TRANSDUCTION;
   RED-BLOOD-CELLS; IN-VIVO; CARDIOPULMONARY BYPASS; TAT-PEPTIDE; GENE
   DELIVERY; MAGNETIC NANOPARTICLES
AB Low molecular weight protamine (LMWP) is a peptide fragment produced in our laboratory from enzymatic digestion of native protamine. More than 30 papers studying the properties and applications of LMWP have been published by our group in various journals since its initial discovery in 1999. Results have shown that LMWP could completely neutralize the anticoagulant functions of both heparin and low molecular weight heparin (LMWH), with reduced antigenicity and cross-reactivity toward the mice-derived anti-protamine antibodies. Aside from its potential as a heparin/LMWH antagonist, LMWP also shows the ability to retard insulin adsorption by the formation of an insoluble complex, making it a less toxic long-lasting insulin product than the conventional neutral protamine Hagedorn (NPH) insulin for diabetic control. Importantly, LMWP (Sequence: VSRRRRRRGGRRRR), with 10 arginine residues in its structure, could function as a cell-penetrating peptide (CPP), also termed protein transduction domain (PTD), to achieve effective intracellular protein or gene delivery in clinical practice. In this paper, we present a thorough review of our work related to LMWP, with the aim of providing readers an insight into its potential to be a clinical protamine substitute as well as a non-toxic cell penetrating peptide applicable to achieve intracellular protein and gene delivery. (C) 2014 Elsevier B.V. All rights reserved.
C1 [He, Huining; Liang, Qiuling; Yang, Victor C.] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300072, Peoples R China.
   [He, Huining; Ye, Junxiao; Liu, Ergang; Liu, Quan; Yang, Victor C.] Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
   [Yang, Victor C.] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.
   [Yang, Victor C.] Seoul Natl Univ, Coll Med, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.
   [Yang, Victor C.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
RP Yang, VC (reprint author), Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.
EM vcyang@med.umich.edu
FU National Natural Science Foundation of China (NSFC) [81361140344];
   Tianjin Municipal Science and Technology Commission [12JCZDJC34000];
   School of Pharmacy; Fudan University & the Open Project Program of Key
   Lab of Smart Drug Delivery (Fudan University); Ministry of Education,
   China [SDD2013-04]; National Key Basic Research Program of China
   [2013CB932502]
FX This work was supported in part by the National Natural Science
   Foundation of China (NSFC, 81361140344) and Tianjin Municipal Science
   and Technology Commission (12JCZDJC34000). This research was also
   partially sponsored by the School of Pharmacy, Fudan University & the
   Open Project Program of Key Lab of Smart Drug Delivery (Fudan
   University), Ministry of Education, China (SDD2013-04) and National Key
   Basic Research Program of China (2013CB932502).
CR ADKINS JR, 1967, ARCH SURG-CHICAGO, V94, P175
   [Anonymous], 1989, PROT SULF, P1725
   Ando T., 1973, MOL BIOL BIOCH BIOPH, P1
   Atkinson SF, 2001, J BIOL CHEM, V276, P27930, DOI 10.1074/jbc.M102825200                                                          
   Balhorn R, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-227
   Barnett EM, 2006, INVEST OPHTH VIS SCI, V47, P2589, DOI 10.1167/iovs.05-1470
   Blaise G, 1998, CAN J ANAESTH, V45, P1144, DOI 10.1007/BF03012453                                                              
   Blanco C, 1996, ALLERGY, V51, P421, DOI 10.1111/j.1398-9995.1996.tb04641.x
   Bollinger ME, 1999, J ALLERGY CLIN IMMUN, V104, P462, DOI 10.1016/S0091-6749(99)70394-5
   Brasseur R, 2010, BBA-BIOMEMBRANES, V1798, P2177, DOI 10.1016/j.bbamem.2010.09.001
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Byun Y, 2000, ASAIO J, V46, P435, DOI 10.1097/00002480-200007000-00013                                                
   Byun Y, 1999, THROMB RES, V94, P53, DOI 10.1016/S0049-3848(98)00201-1                                                   
   Carr JA, 1999, J CARDIOVASC SURG, V40, P659
   Chang LC, 2001, AAPS PHARMSCI, V3, part. no.
   Chang LC, 2001, AAPS PHARMSCI, V3, part. no.
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chargaff E, 1938, J BIOL CHEM, V125, P671
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Choi YS, 2010, BIOMATERIALS, V31, P1429, DOI 10.1016/j.biomaterials.2009.11.001
   Chugh A, 2008, J PEPT SCI, V14, P477, DOI 10.1002/psc.937
   COBB CA, 1982, SURG NEUROL, V17, P245, DOI 10.1016/0090-3019(82)90112-4
   COBELGEARD RJ, 1983, AM J HEMATOL, V14, P227, DOI 10.1002/ajh.2830140304
   Cooper H.N., 1991, CURRENT PROTOCOLS IM
   CORMACK JG, 1993, CORONARY ARTERY DIS, V4, P420, DOI 10.1097/00019501-199305000-00005
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Dietz GPH, 2005, BRAIN RES BULL, V68, P103, DOI 10.1016/j.brainresbull.2005.08.015
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165
   Dietz Gunnar P. H., 2007, V399, P181, DOI 10.1007/978-1-59745-504-6_13
   Do N, 2014, EXP DERMATOL, V23, P326, DOI 10.1111/exd.12384
   Dohmen C, 2011, METHODS MOL BIOL, V683, P453, DOI 10.1007/978-1-60761-919-2_32
   ELLISON N, 1973, TRANSFUSION, V13, P364
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gait MJ, 2003, CELL MOL LIFE SCI, V60, P844, DOI 10.1007/s00018-003-3044-5
   Garin MI, 1996, PHARMACEUT RES, V13, P869, DOI 10.1023/A:1016049027661
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hamidi M, 2007, DRUG DELIV, V14, P295, DOI 10.1080/1071754070120300
   He HN, 2014, J CONTROL RELEASE, V176, P123, DOI 10.1016/j.jconrel.2013.12.019
   He HN, 2013, PHARM RES-DORDR, V30, P2445, DOI 10.1007/s11095-013-0982-y
   He HN, 2013, BIOMATERIALS, V34, P7733, DOI 10.1016/j.biomaterials.2013.06.047
   He HN, 2011, MACROMOL RES, V19, P1224, DOI 10.1007/s13233-011-1214-0
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henriques ST, 2005, BIOCHEMISTRY-US, V44, P10189, DOI 10.1021/bi0502644
   HIRD RB, 1995, CIRCULATION, V92, P433
   Horrow J C, 1988, J Cardiothorac Anesth, V2, P225, DOI 10.1016/0888-6296(88)90277-3
   HORROW JC, 1985, ANESTH ANALG, V64, P348
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Howell W.H., 1922, AM J PHYSIOL, V63, P434
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Huang YS, 2013, TECHNOL REV, V116, P10
   Huang YZ, 2010, CURR PHARM DESIGN, V16, P2369, DOI 10.2174/138161210791920441                                                      
   Huang YZ, 2010, ANGEW CHEM INT EDIT, V49, P2724, DOI 10.1002/anie.200906153
   Hurby M., 1995, ROZHL CHIR, V74, P282
   IHLER GM, 1973, P NATL ACAD SCI USA, V70, P2663, DOI 10.1073/pnas.70.9.2663
   JAQUES LB, 1973, CAN MED ASSOC J, V108, P1291
   Jarvert P, 2007, BIOCHEM SOC T, V35, P770
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   JUSTVIERA JO, 1984, AM SURGEON, V50, P52
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kamei N, 2009, J CONTROL RELEASE, V136, P179, DOI 10.1016/j.jconrel.2009.02.015
   KATZ NM, 1987, J THORAC CARDIOV SUR, V94, P881
   Kim R, 1993, Del Med J, V65, P17
   Kindler C, 1996, EUR J CARDIO-THORAC, V10, P463, DOI 10.1016/S1010-7940(96)80117-5                                                   
   KIRKLIN JK, 1986, ANN THORAC SURG, V41, P193, DOI 10.1016/S0003-4975(10)62668-9                                                   
   Kuitunen A H, 1991, J Cardiothorac Vasc Anesth, V5, P221, DOI 10.1016/1053-0770(91)90278-2
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Kwon YM, 2009, J CONTROL RELEASE, V139, P182, DOI 10.1016/j.jconrel.2009.06.027
   Lee JH, 2013, J PHARM SCI-US, V102, P4109, DOI 10.1002/jps.23725
   Lee LM, 2001, AAPS PHARMSCI, V3, part. no.
   Lee TY, 2012, MOL PHARMACEUT, V9, P1361, DOI 10.1021/mp200623w
   Lehto T, 2012, EXPERT OPIN DRUG DEL, V9, P823, DOI 10.1517/17425247.2012.689285
   Levinson M.M., 1995, PATHOPHYSIOLOGY TREA
   Liang JF, 2003, BIOCHEMISTRY-MOSCOW+, V68, P116, DOI 10.1023/A:1022109905487
   Lindblad B, 1989, Eur J Vasc Surg, V3, P195, DOI 10.1016/S0950-821X(89)80082-9
   Lizano C, 1998, BBA-GEN SUBJECTS, V1425, P328, DOI 10.1016/S0304-4165(98)00085-3
   Lopes LB, 2005, PHARM RES, V22, P750, DOI 10.1007/s11095-005-2591-x
   LOWENSTEIN E, 1983, ANESTHESIOLOGY, V59, P470, DOI 10.1097/00000542-198311000-00022                                                
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   MATOVCIK LM, 1985, BLOOD, V65, P1056
   McDonald SB, 2005, J CARDIOTHOR VASC AN, V19, P4, DOI 10.1053/j.jvca.2004.11.002
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Metz S., 1994, PHARM PHYSL ANESTHET
   NEIDHART PP, 1992, EUR HEART J, V13, P856, DOI 10.1093/oxfordjournals.eurheartj.a060271                                        
   OLINGER GN, 1980, ANN THORAC SURG, V29, P20, DOI 10.1016/S0003-4975(10)61620-7                                                   
   OVRUM E, 1992, SCAND J THORAC CARD, V26, P113, DOI 10.3109/14017439209099064                                                       
   PARK WK, 1994, CARDIOVASC RES, V28, P505, DOI 10.1093/cvr/28.4.505
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04-2322fje
   Park YJ, 2003, J GENE MED, V5, P700, DOI 10.1002/jgm.402
   Park YS, 2012, J CONTROL RELEASE, V161, P1, DOI 10.1016/j.jconrel.2012.04.026
   Park Y.S., 2012, J CONTROL RELEASE, V144, P82
   Porsche R, 1999, HEART LUNG, V28, P418, DOI 10.1016/S0147-9563(99)70031-2                                                   
   Ralley FE, 1999, ANESTH ANALG, V88, P505
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   SHARATH MD, 1985, J THORAC CARDIOV SUR, V90, P86
   Shin MC, 2014, J BIOMED MATER RES A, V102, P575, DOI 10.1002/jbm.a.34859
   Shin MC, 2013, J CONTROL RELEASE, V172, P169, DOI 10.1016/j.jconrel.2013.08.016
   Snyder EL, 2001, CURR OPIN MOL THER, V3, P147
   Splith K, 2011, EUR BIOPHYS J BIOPHY, V40, P387, DOI 10.1007/s00249-011-0682-7
   STIRPE F, 1980, J BIOL CHEM, V255, P6947
   Suh JS, 2014, INT J NANOMED, V9, P1153, DOI 10.2147/IJN.S55433
   Suh JS, 2009, BIOCHEM BIOPH RES CO, V379, P669, DOI 10.1016/j.bbrc.2008.12.041
   Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4                                                   
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Tsui B, 2001, THROMB RES, V101, P417, DOI 10.1016/S0049-3848(00)00427-8
   UPDIKE SJ, 1976, SCIENCE, V193, P681, DOI 10.1126/science.821145
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   WAKEFIELD TW, 1992, J VASC SURG, V16, P47, DOI 10.1016/0741-5214(92)90416-6                                                    
   Walther C, 2008, BIOCONJUGATE CHEM, V19, P2346, DOI 10.1021/bc800172q
   Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020
   WEILER JM, 1990, J ALLERGY CLIN IMMUN, V85, P713, DOI 10.1016/0091-6749(90)90189-B
   WEILER JM, 1985, J ALLERGY CLIN IMMUN, V75, P297, DOI 10.1016/0091-6749(85)90061-2
   WEISS ME, 1991, CLIN REV ALLERG, V9, P339
   Welsby I. J., 2005, ANESTHESIOLOGY, V102, P308
   Xia HM, 2013, BIOCONJUGATE CHEM, V24, P419, DOI 10.1021/bc300520t
   YANG VC, 1991, ANESTHESIOLOGY, V75, P288, DOI 10.1097/00000542-199108000-00017
   Yu FQ, 2010, BIOMATERIALS, V31, P5842, DOI 10.1016/j.biomaterials.2010.03.072
   Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91                                                            
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
   Zhang J., 2013, PHARM RES, V31, P579
   Zhang J, 2013, MOL PHARMACEUT, V10, P3892, DOI 10.1021/mp400360q
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Zhou J., 2013, NANOTECHNOLOGY, V24
NR 134
TC 21
Z9 22
U1 6
U2 104
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 10
PY 2014
VL 193
BP 63
EP 73
DI 10.1016/j.jconrel.2014.05.056
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AS4FO
UT WOS:000344229000008
PM 24943246
DA 2018-01-05
ER

PT J
AU Dietrich, U
   Koch, K
   Wernery, U
   Khazanehdari, K
   Danquah, W
   Koch-Nolte, F
AF Dietrich, Ursula
   Koch, Kathrin
   Wernery, Ulrich
   Khazanehdari, Kamal
   Danquah, Welbeck
   Koch-Nolte, Freidrich
TI Selection of single domain antibody fragments (nanobodies) from
   dromedaries immunized with HIV-1 subtype C gp140 SOSIPs
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 16th Annual International Meeting of the Institute-of-Human-Virology
   (IHV)
CY SEP 14-14, 2014
CL Univ Maryland Sch Med, Baltimore, MD
SP Inst Human Virol
HO Univ Maryland Sch Med
C1 [Dietrich, Ursula; Koch, Kathrin] Georg Speyer Haus, Frankfurt, Germany.
   [Wernery, Ulrich] Cent Vet Res Lab, Hamburg, Germany.
   [Khazanehdari, Kamal] CVRL, Mol Biol & Genet, Dubai, U Arab Emirates.
   [Danquah, Welbeck; Koch-Nolte, Freidrich] Uniklin Eppendorf, Hamburg, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD NOV
PY 2014
VL 67
SU 3
MA P-E2
BP 94
EP 94
DI 10.1097/01.qai.0000456205.71303.ea                                      
          
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CH6BF
UT WOS:000354119800109
OA gold
DA 2018-01-05
ER

PT J
AU Moretton, MA
   Taira, C
   Flor, S
   Bernabeu, E
   Lucangioli, S
   Hocht, C
   Chiappetta, DA
AF Moretton, Marcela A.
   Taira, Carlos
   Flor, Sabrina
   Bernabeu, Ezequiel
   Lucangioli, Silvia
   Hoecht, Christian
   Chiappetta, Diego A.
TI Novel nelfinavir mesylate loaded D-alpha-tocopheryl polyethylene glycol
   1000 succinate micelles for enhanced pediatric anti HIV therapy: In
   vitro characterization and in vivo evaluation
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Nelfinavir mesylate encapsulation; TPGS micelles; Oral bioavailability;
   Pediatric HIV/AIDS pharmacotherapy
ID VITAMIN-E-TPGS; DRUG-DELIVERY; POLYMERIC MICELLES; PROTEASE INHIBITORS;
   BLOCK-COPOLYMERS; ORAL ABSORPTION; P-GLYCOPROTEIN; PHARMACOKINETICS;
   PHARMACOTHERAPY; BIOAVAILABILITY
AB Worldwide more than 35 million people are living with Human Immunodeficiency Virus (HIV) where 3.3 million are children. This translates in approximately 700 new daily infections in children only in 2012. Prolonged High Activity Antiretroviral Therapy (HAART) regimes could present low-patient compliance, especially in children, affecting therapeutic success. Nelfinavir mesylate (NFV) is a non-peptidic HIV-1 protease inhibitor (IP) which was the first IP recommended for pediatric use (>2 years-old). It exhibits pH-dependant aqueous solubility which results highly restricted at physiological pH values. The former represents a main clinical limitation due to the reduction on drug absorption along the small intestine after an oral administration, leading to unpredictable drug bioavailability. Moreover a liquid formulation of NFV is not available worldwide, preventing appropriate dose adjustment and more convenient administration. In this framework, the present investigation reports the development of a NFV highly concentrated aqueous formulation for a more appropriate management of pediatric anti-HIV therapy. The aim was to encapsulate NFV within D-alpha-tocopheryl polyethylene glycol 1000 succinate micelles to improve its aqueous solubility and its oral pharmacokinetic parameters. Results show that NFV aqueous solubility was increased up to 80.3 mg/mL. NFV-loaded micelles exhibited a hydrodynamic diameter of 5.6 nm and a spherical morphology as determined by dynamic light scattering and transmission electronic microscopy, respectively. In vitro NFV release profile demonstrated a cumulative drug release of 56% at 6 h. Finally, in vivo data showed a significant (p < 0.01) increase of Area-Under-the-Curve between 0 and 24h for NFV encapsulated in micelles in comparison with a NFV suspension prepared with glycerin 20% v/v and carboxymethylcellulose sodium 0.5% w/v, representing an increment on drug oral relative bioavailability of 1.71-fold. Thereby, this formulation represents an innovative nanotechnological platform to improve pediatric HIV pharmacotherapy. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Moretton, Marcela A.; Bernabeu, Ezequiel; Lucangioli, Silvia; Chiappetta, Diego A.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, RA-1113 Buenos Aires, DF, Argentina.
   [Taira, Carlos; Hoecht, Christian] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmacol, RA-1113 Buenos Aires, DF, Argentina.
   [Flor, Sabrina] Univ Buenos Aires, Fac Pharm & Biochem, Dept Analyt Chem, RA-1113 Buenos Aires, DF, Argentina.
   [Moretton, Marcela A.; Taira, Carlos; Flor, Sabrina; Lucangioli, Silvia; Chiappetta, Diego A.] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
RP Chiappetta, DA (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, 956 Junin St,6th Floor, RA-1113 Buenos Aires, DF, Argentina.
EM diegochiappetta@yahoo.com.ar
FU University of Buenos Aires [UBACyT 20020100300088, 20020120200058];
   CONICET, Argentina
FX Authors thank the University of Buenos Aires (Grant UBACyT
   20020100300088 and 20020120200058). M.A.M. and S.F. are supported by
   postdoctoral scholarship of CONICET, Argentina. C.T., S.L. and D.A.C.
   are partially supported by CONICET, Argentina.
CR ARGAO EA, 1992, PEDIATR RES, V31, P146, DOI 10.1203/00006450-199202000-00011                                                
   Bergshoeff AS, 2003, ANTIVIR THER, V8, P215
   Bernabeu E, 2013, J BIOMATER TISS ENG, V3, P122, DOI 10.1166/jbt.2013.1076
   Bogman K, 2005, CLIN PHARMACOL THER, V77, P24, DOI 10.1016/j.clpt.2004.09.001
   Bowen A, 2008, DRUG DISCOV TODAY, V13, P530, DOI 10.1016/j.drudis.2008.03.018
   Chandrasekharan P, 2011, BIOMATERIALS, V32, P5663, DOI 10.1016/j.biomaterials.2011.04.037
   Chang T, 1996, CLIN PHARMACOL THER, V59, P297, DOI 10.1016/S0009-9236(96)80007-5
   Chiappetta DA, 2008, EUR J PHARM BIOPHARM, V69, P535, DOI 10.1016/j.ejpb.2007.11.021
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Cho HK, 2010, KOREAN J CHEM ENG, V27, P731, DOI 10.1007/s11814-010-0216-5
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Dou JF, 2014, COLLOID SURFACE B, V114, P20, DOI 10.1016/j.colsurfb.2013.09.010
   Guo YY, 2013, EUR J PHARM SCI, V49, P175, DOI 10.1016/j.ejps.2013.02.006
   Kadam Y, 2011, COLLOID SURFACE B, V83, P49, DOI 10.1016/j.colsurfb.2010.10.041
   Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   LONGER M, 1995, J PHARM SCI, V84, P1090, DOI 10.1002/jps.2600840911
   Lu Y, 2013, INT J PHARMACEUT, V453, P198, DOI 10.1016/j.ijpharm.2012.08.042
   Moretton M.A., 2014, NANOMEDICINE LONDON
   Moretton MA, 2014, COLLOID SURFACE B, V122, P56, DOI 10.1016/j.colsurfb.2014.06.046
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   Nacro B, 2011, B WORLD HEALTH ORGAN, V89, P451, DOI 10.2471/BLT.10.081646
   Nahata MC, 2008, CLIN THER, V30, P2112, DOI 10.1016/j.clinthera.2008.11.020
   Owen SC, 2012, NANO TODAY, V7, P53, DOI 10.1016/j.nantod.2012.01.002
   Pepic I, 2009, COLLOID SURFACE A, V336, P135, DOI 10.1016/j.colsurfa.2008.11.034
   Primard C, 2010, BIOMATERIALS, V31, P6060, DOI 10.1016/j.biomaterials.2010.04.021
   Schuval Susan J, 2009, Ther Clin Risk Manag, V5, P469
   Shono Y, 2011, EUR J PHARM BIOPHARM, V79, P349, DOI 10.1016/j.ejpb.2011.04.005
   Sosnik A, 2012, EXPERT OPIN DRUG DEL, V9, P303, DOI 10.1517/17425247.2012.655268
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Taketomo C. K., 2010, PEDIAT DOSAGE HDB
   Williams GC, 1999, ADV DRUG DELIVER REV, V39, P211, DOI 10.1016/S0169-409X(99)00027-7                                                   
   Xiong XB, 2012, ACTA BIOMATER, V8, P2017, DOI 10.1016/j.actbio.2012.03.006
   Yu L, 1999, PHARMACEUT RES, V16, P1812, DOI 10.1023/A:1018939006780                                                         
   Zhai XR, 2013, COLLOID POLYM SCI, V291, P2825, DOI 10.1007/s00396-013-3013-y
NR 37
TC 11
Z9 11
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD NOV 1
PY 2014
VL 123
BP 302
EP 310
DI 10.1016/j.colsurfb.2014.09.031
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA AY4YI
UT WOS:000347580500039
PM 25270729
DA 2018-01-05
ER

PT J
AU Seremeta, KP
   Tur, MIR
   Perez, SM
   Hocht, C
   Taira, C
   Hernandez, ODL
   Sosnik, A
AF Seremeta, Katia P.
   Reyes Tur, Maria I.
   Martinez Perez, Sandra
   Hoecht, Christian
   Taira, Carlos
   Lopez Hernandez, Orestes D.
   Sosnik, Alejandro
TI Spray-dried didanosine-loaded polymeric particles for enhanced oral
   bioavailability
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE HIV therapy; Didanosine (ddl); Poly(epsilon-caprolactone)
   microparticles; Spray-drying; Enhanced oral bioavailability
ID DRUG-DELIVERY SYSTEMS; SOLID LIPID NANOPARTICLES; IN-VITRO; GELATIN
   NANOPARTICLES; TARGETED DELIVERY; PROCESS VARIABLES; FORMULATION; HIV;
   POLY(EPSILON-CAPROLACTONE); THERAPY
AB Didanosine (ddl) is a water-soluble antiretroviral used in the treatment of HIV that undergoes fast gastric degradation to an inactive hypoxanthine. Therefore, its oral bioavailability is relatively low (20-40%). In this work, we investigated for the first time a scalable open-loop spray-drying method with co-current flow for the encapsulation of ddl (model drug) within particles of the biocompatible polyester poly(epsilon-caprolactone). The average diameter of the particles was 36-118 mu m and the morphology spherical. The encapsulation efficiency ranged from 60% to 100% with yields of up to 65%. ATR/FT-IR analysis indicated that most of the drug was encapsulated within the particles. In vitro release assays showed that the particles released the drug within 120 min. Finally, oral administration to rats led to a statistically significant 2.5-fold increase of the bioavailability with respect to a ddl aqueous solution, highlighting the potential of this technology to encapsulate efficiently other hydrophilic antiretrovirals and, by doing so, to overcome different biopharmaceutical drawbacks associated with the oral administration. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Seremeta, Katia P.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Buenos Aires, DF, Argentina.
   [Seremeta, Katia P.; Taira, Carlos] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
   [Reyes Tur, Maria I.] BioCubaFarma, AICA Labs, Havana, Cuba.
   [Martinez Perez, Sandra] LIORAD Labs, Havana, Cuba.
   [Hoecht, Christian; Taira, Carlos] Univ Buenos Aires, Dept Pharmacol, Fac Pharm & Biochem, Buenos Aires, DF, Argentina.
   [Lopez Hernandez, Orestes D.] Ambato Tech Univ, Fac Food Sci & Engn, Tungurahua, Ecuador.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, Haifa, Israel.
RP Sosnik, A (reprint author), Technion Israel Inst Technol, Dept Mat Sci & Engn, DeJur Bldg Off 607, IL-3200003 Technion, Haifa, Israel.
EM alesosnik@gmail.com
OI Seremeta, Katia/0000-0001-6302-7073
FU CONICET [PIP0220]; UBA [20020090200189]; bilateral exchange program
   between Argentina and Cuba [CU/10/03]
FX KPS thanks a Ph.D. scholarship of CONICET. The work was supported by
   grants 20020090200189 (UBA) and PIP0220 (CONICET). Authors thank Dr.
   Daniel Vega for technical assistance in XRD analysis. The authors thank
   the bilateral exchange program between Argentina and Cuba (Grant
   CU/10/03).
CR Baras B, 2000, INT J PHARM, V200, P133, DOI 10.1016/S0378-5173(00)00363-X
   Bettini R, 2010, J PHARM SCI-US, V99, P1855, DOI 10.1002/jps.21962
   Bittner B, 1998, EUR J PHARM BIOPHARM, V45, P295, DOI 10.1016/S0939-6411(98)00012-5
   Bock N, 2012, PROG POLYM SCI, V37, P1510, DOI 10.1016/j.progpolymsci.2012.03.002
   Boettiger DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106525
   Chaubal MV, 2008, PHARM RES-DORDR, V25, P2302, DOI 10.1007/s11095-008-9625-0
   Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0                                                   
   Cheow WS, 2010, CHEM ENG RES DES, V88, P673, DOI 10.1016/j.cherd.2009.11.012
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Cohn D, 2006, BIOMATERIALS, V27, P1718, DOI 10.1016/j.biomaterials.2005.10.035
   Damle BD, 2002, ANTIMICROB AGENTS CH, V46, P385, DOI 10.1128/AAC.46.2.385-391.2002
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Elversson J, 2003, J PHARM SCI, V92, P900, DOI 10.1002/jps.10352
   ENCK P, 1989, GUT, V30, P455, DOI 10.1136/gut.30.4.455
   Ferguson LM, 2011, THER DELIV, V2, P1535, DOI [10.4155/tde.11.126, 10.4155/TDE.11.126]
   Freitas C, 1998, EUR J PHARM BIOPHARM, V46, P145, DOI 10.1016/S0939-6411(97)00172-0                                                   
   Gharsallaoui A, 2007, FOOD RES INT, V40, P1107, DOI 10.1016/j.foodres.2007.07.004
   Gotelli GA, 2011, J APPL POLYM SCI, V121, P1321, DOI 10.1002/app.33664
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   Jones E, 2014, DRUG DEV IND PHARM, V40, P669, DOI 10.3109/03639045.2014.892957
   Kasongo KW, 2011, DRUG DEV IND PHARM, V37, P396, DOI 10.3109/03639045.2010.516264
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Krishnaiah D, 2012, CHEM ENG RES DES, V90, P622, DOI 10.1016/j.cherd.2011.09.003
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   Lebhardt T, 2011, EUR J PHARM BIOPHARM, V78, P90, DOI 10.1016/j.ejpb.2010.12.002
   Lee SH, 2011, INT J PHARMACEUT, V403, P192, DOI 10.1016/j.ijpharm.2010.10.012
   Li XA, 2010, J CONTROL RELEASE, V147, P304, DOI 10.1016/j.jconrel.2010.07.113
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Maury M, 2005, EUR J PHARM BIOPHARM, V59, P565, DOI 10.1016/j.ejpb.2004.10.002
   Maury M, 2005, EUR J PHARM BIOPHARM, V59, P251, DOI 10.1016/j.ejpb.2004.07.010
   Mishra B, 2010, NANOMED-NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   Nandiyanto ABD, 2011, ADV POWDER TECHNOL, V22, P1, DOI 10.1016/j.apt.2010.09.011
   Nassar M. N., 1993, ANAL PROFILES DRUG S, V22, P185
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Ojewole E, 2014, DRUG DEV IND PHARM, V40, P657, DOI 10.3109/03639045.2014.892958
   Okuyama K, 2006, ADV POWDER TECHNOL, V17, P587, DOI 10.1163/156855206778917733
   Palombo MS, 2009, J DRUG DELIV SCI TEC, V19, P3, DOI 10.1016/S1773-2247(09)50001-9                                                   
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Peltonen L, 2010, EXPERT OPIN DRUG DEL, V7, P705, DOI 10.1517/17425241003716802
   Rabbani NR, 2005, J CONTROL RELEASE, V110, P130, DOI 10.1016/j.jconrel.2005.09.004
   Rao DVNS, 2007, J PHARMACEUT BIOMED, V45, P516, DOI 10.1016/j.jpba.2007.05.034
   Re MI, 2006, DRY TECHNOL, V24, P433, DOI 10.1080/07373930600611877
   Rattes ALR, 2007, POWDER TECHNOL, V171, P7, DOI 10.1016/j.powtec.2006.09.007
   Sastre RL, 2004, DRUG DEVELOP RES, V63, P41, DOI 10.1002/ddr.10396
   Schafroth N, 2012, COLLOID SURFACE B, V90, P8, DOI 10.1016/j.colsurfb.2011.09.038
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Severino P, 2012, J PHARM ANA, V2, P188, DOI 10.1016/j.jpha.2012.02.005
   Sham JOH, 2004, INT J PHARM, V269, P457, DOI 10.1016/j.ijpharm.2003.09.041
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Sosnik A, 2003, POLYMER, V44, P7033, DOI 10.1016/j.polymer.2003.09.012
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Stahl K, 2002, INT J PHARM, V233, P227, DOI 10.1016/S0378-5173(01)00945-0
   Sun HF, 2006, BIOMATERIALS, V27, P1735, DOI 10.1016/j.biomaterials.2005.09.019
   Tewa-Tayne P, 2007, EUR J PHARM SCI, V30, P124, DOI 10.1016/j.ejps.2006.10.006
   Tshweu L., 2014, NANOMEDICIN IN PRESS
   [Anonymous], 2013, HIV 2013 GLOB FACT S
   Vehring R, 2007, J AEROSOL SCI, V38, P728, DOI 10.1016/j.jaerosci.2007.04.005
   World Health Organization, 2014, 2013 CONS GUID US S
   World Health Organization, 2013, HIV AIDS FACT SHEETS
   WHO, HIV AIDS
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Worsoe J, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-145
   Yan ZT, 2011, MOL PHARMACEUT, V8, P319, DOI 10.1021/mp100376q
NR 68
TC 9
Z9 9
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD NOV 1
PY 2014
VL 123
BP 515
EP 523
DI 10.1016/j.colsurfb.2014.09.055
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA AY4YI
UT WOS:000347580500063
PM 25444665
DA 2018-01-05
ER

PT J
AU Enkin, N
   Wang, F
   Sharon, E
   Albada, HB
   Willner, I
AF Enkin, Natalie
   Wang, Fuan
   Sharon, Etery
   Albada, H. Bauke
   Willner, Itamar
TI Multiplexed Analysis of Genes Using Nucleic Acid-Stabilized
   Silver-Nanocluster Quantum Dots
SO ACS NANO
LA English
DT Article
DE sensor; luminescence; optical gene; nanobiotechnology; nanomaterial
ID SYNDROME PROTEIN; DNA; FLUORESCENCE; IONS; FLUOROPHORES; EXONUCLEASE;
   TEMPLATE; SEQUENCE; CLUSTER; BRIGHT
AB Luminescent nucleic acid-stabilized Ag nanoclusters (Ag NCs) are applied for the optical detection of DNA and for the multiplexed analysis of genes. Two different sensing modules including Ag NCs as luminescence labels are described. One sensing module involves the assembly of a three-component sensing module composed of a nucleic acid-stabilized Ag NC and a quencher-modified nucleic acid hybridized with a nucleic acid scaffold that is complementary to the target DNA. The luminescence of the Ag NCs is quenched in the sensing module nanostructure. The strand displacement of the scaffold by the target DNA separates the nucleic acid-functionalized Ag NCs, leading to the turned-on luminescence of the NCs and to the optical readout of the sensing process. By implementing two different-sized Ag NC-modified sensing modules, the parallel multiplexed analysis of two genes (the Werner Syndrome gene and the HIV, human immunodeficiency, gene), using 615 and 560 nm luminescent Ag NCs, is demonstrated. The second sensing module includes the nucleic acid functionalized Ag NCs and the quencher-modified nucleic acid hybridized with a hairpin DNA scaffold. The luminescence of the Ag NCs is quenched in the sensing module. Opening of the hairpin by the target DNA triggers the luminescence of the Ag NCs, due to the spatial separation of the Ag NCs/quencher units. The system is applied for the optical detection of the BRAC1 gene. In addition, by implementing two-sized Ag NCs, the multiplexed analysis of two genes by the hairpin sensing module approach is demonstrated.
C1 [Enkin, Natalie; Wang, Fuan; Sharon, Etery; Albada, H. Bauke; Willner, Itamar] Hebrew Univ Jerusalem, Ctr Nanosci & Nanotechnol, Inst Chem, IL-91904 Jerusalem, Israel.
RP Willner, I (reprint author), Hebrew Univ Jerusalem, Ctr Nanosci & Nanotechnol, Inst Chem, IL-91904 Jerusalem, Israel.
EM willnea@vms.huji.ac.il
RI Wang, Fuan/C-2980-2008; Albada, Bauke/M-5149-2015
OI Wang, Fuan/0000-0002-3063-2485; Albada, Bauke/0000-0003-3659-2434
FU Israel Science Foundation [1083/12]
FX This research is supported by the Israel Science Foundation (Grant No.
   1083/12). We thank Mr. A. Cecconello for helpful discussions.
CR Chen Lishan, 2002, Journal of Biomedicine & Biotechnology, V2, P46, DOI 10.1155/S1110724302201011
   Chen WY, 2011, ANAL CHEM, V83, P9450, DOI 10.1021/ac202162u
   Choi S, 2012, CHEM SOC REV, V41, P1867, DOI 10.1039/c1cs15226b
   Freeman R, 2011, NANO LETT, V11, P4456, DOI 10.1021/nl202761g
   Freeman R, 2011, J AM CHEM SOC, V133, P11597, DOI 10.1021/ja202639m
   Goldman ER, 2004, ANAL CHEM, V76, P684, DOI 10.1021/ac035083r
   Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100
   Gwinn EG, 2008, ADV MATER, V20, P279, DOI 10.1002/adma.200702380
   Han BY, 2012, ANAL BIOANAL CHEM, V402, P129, DOI 10.1007/s00216-011-5307-6
   Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410
   Lan GY, 2011, RSC ADV, V1, P802, DOI 10.1039/c1ra00181g
   Latorre A, 2012, CHEMBIOCHEM, V13, P951, DOI 10.1002/cbic.201200053
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Liu XQ, 2013, J AM CHEM SOC, V135, P11832, DOI 10.1021/ja403485r
   Liu XQ, 2013, NANO LETT, V13, P309, DOI 10.1021/nl304283c
   Liu XQ, 2012, ACS NANO, V6, P3553, DOI 10.1021/nn300598q
   O'Neill PR, 2009, J PHYS CHEM C, V113, P4229, DOI 10.1021/jp809274m
   Patolsky F, 2003, J AM CHEM SOC, V125, P13918, DOI 10.1021/ja035848c
   Petty JT, 2011, J PHYS CHEM B, V115, P7996, DOI 10.1021/jp202024x
   Petty JT, 2010, J PHYS CHEM LETT, V1, P2524, DOI 10.1021/jz100817z
   Petty JT, 2004, J AM CHEM SOC, V126, P5207, DOI 10.1021/ja031931o
   Richards CI, 2008, J AM CHEM SOC, V130, P5038, DOI 10.1021/ja8005644
   Ritchie CM, 2007, J PHYS CHEM C, V111, P175, DOI 10.1021/jp0648487
   Shah P, 2012, ACS NANO, V6, P8803, DOI 10.1021/nn302633q
   Sharma J, 2012, NANOSCALE, V4, P4107, DOI 10.1039/c2nr30662j
   Sharma J, 2011, CHEM COMMUN, V47, P2294, DOI 10.1039/c0cc03711g
   Su YT, 2010, ANAL CHEM, V82, P8566, DOI 10.1021/ac101659d
   Vosch T, 2007, P NATL ACAD SCI USA, V104, P12616, DOI 10.1073/pnas.0610677104
   Yeh HC, 2012, J AM CHEM SOC, V134, P11550, DOI 10.1021/ja3024737
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258
   Zhang LB, 2013, J AM CHEM SOC, V135, P2403, DOI 10.1021/ja3089857
NR 32
TC 46
Z9 46
U1 14
U2 227
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD NOV
PY 2014
VL 8
IS 11
BP 11666
EP 11673
DI 10.1021/nn504983j
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AU4BC
UT WOS:000345553000072
PM 25327411
DA 2018-01-05
ER

PT J
AU Shojaei, TR
   Salleh, MAM
   Tabatabaei, M
   Ekrami, A
   Motallebi, R
   Rahmani-Cherati, T
   Hajalilou, A
   Jorfi, R
AF Shojaei, Taha Roodbar
   Salleh, Mohamad Amran Mohd
   Tabatabaei, Meisam
   Ekrami, Alireza
   Motallebi, Roya
   Rahmani-Cherati, Tauoos
   Hajalilou, Abdollah
   Jorfi, Raheleh
TI Development of sandwich-form biosensor to detect Mycobacterium
   tuberculosis complex in clinical sputum specimens
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Mycobacterium tuberculosis complex (MTBC); Cadmium-telluride quantum
   dots (CdTe-QDs); Gold nanoparticles (AuNPs); Fluorescence resonance
   energy transfer (FRET); Sandwich-form FRET-based biosensor
ID POLYMERASE-CHAIN-REACTION; RESONANCE ENERGY-TRANSFER; SEMICONDUCTOR
   QUANTUM DOTS; NANOPARTICLE PROBES; GOLD NANOPARTICLES; DIAGNOSIS; DNA;
   IDENTIFICATION; ASSAY; AMPLIFICATION
AB Mycobacterium tuberculosis, the causing agent of tuberculosis, comes second only after HIV on the list of infectious agents slaughtering many worldwide. Due to the limitations behind the conventional detection methods, it is therefore critical to develop new sensitive sensing systems capable of quick detection of the infectious agent. In the present study, the surface modified cadmium-telluride quantum dots and gold nanoparticles conjunct with two specific oligonucleotides against early secretory antigenic target 6 were used to develop a sandwich-form fluorescence resonance energy transfer-based biosensor to detect M. tuberculosis complex and differentiate M. tuberculosis and M. bovis Bacille Calmette-Guerin simultaneously. The sensitivity and specificity of the newly developed biosensor were 94.2% and 86.6%, respectively, while the sensitivity and specificity of polymerase chain reaction and nested polymerase chain reaction were considerably lower, 74.2%, 73.3% and 82.8%, 80%, respectively. The detection limits of the sandwich-form fluorescence resonance energy transfer-based biosensor were far lower (10 fg) than those of the polymerase chain reaction and nested polymerase chain reaction (100 fg). Although the cost of the developed nanobiosensor was slightly higher than those of the polymerase chain reaction-based techniques, its unique advantages in terms of turnaround time, higher sensitivity and specificity, as well as a 10-fold lower detection limit would clearly recommend this test as a more appropriate and cost-effective tool for large scale operations. (C) 2014 Elsevier Editora Ltda. All rights reserved.
C1 [Shojaei, Taha Roodbar; Salleh, Mohamad Amran Mohd; Hajalilou, Abdollah; Jorfi, Raheleh] Univ Putra Malaysia, Inst Adv Technol ITMA, Serdang 43400, Selangor, Malaysia.
   [Tabatabaei, Meisam] Agr Biotechnol Res Inst Iran ABRII, Microbial Biotechnol & Biosafety Dept, Nanosyst Res Team NRTeam, Karaj, Iran.
   [Ekrami, Alireza] Ahvaz Jundishapur Univ Med Sci, Infect & Trop Dis Res Ctr, Ahwaz, Iran.
   [Motallebi, Roya] Shahrekord Univ, Dept Plant Breeding & Biotechnol, Coll Agr, Shahrekord, Iran.
   [Rahmani-Cherati, Tauoos] Nanozino, Dept Res & Dev, Tehran 1653643181, Iran.
RP Salleh, MAM (reprint author), Univ Putra Malaysia, Inst Adv Technol ITMA, Serdang 43400, Selangor, Malaysia.
EM asalleh@upm.edu.my
RI Tabatabaei, Meisam/E-7235-2013
OI Tabatabaei, Meisam/0000-0001-8067-1944; Mohd Salleh, Mohamad
   Amran/0000-0002-4976-2132; Ekrami, Alireza/0000-0001-6138-8203
CR Algar WR, 2008, ANAL BIOANAL CHEM, V391, P1609, DOI 10.1007/s00216-007-1703-3
   Algar WR, 2010, ANAL CHIM ACTA, V673, P1, DOI 10.1016/j.aca.2010.05.026
   Amita Jain, 2002, Molecular Biology Today, V3, P43
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211
   Baptista P, 2008, ANAL BIOANAL CHEM, V391, P943
   Bardarov S, 2003, DIAGN MICR INFEC DIS, V45, P53, DOI 10.1016/S0732-8893(02)00478-9
   Caviedes L, 2000, J CLIN MICROBIOL, V38, P1203
   Chan ED, 2000, AM J RESP CRIT CARE, V161, P1713, DOI 10.1164/ajrccm.161.5.9908125                                                    
   Chan ED, 2000, TUBERCLE LUNG DIS, V80, P131, DOI 10.1054/tuld.2000.0243
   Chawla K, 2009, J INFECT DEV COUNTR, V3, P83
   Currie CSM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-130
   Dai Z, 2007, CHINESE J CHEM ENG, V15, P791, DOI 10.1016/S1004-9541(08)60004-X                                                   
   EISENACH KD, 1990, J INFECT DIS, V161, P977, DOI 10.1093/infdis/161.5.977                                                        
   Ekrami A, 2011, INT J NANOMED, V6, P2729, DOI 10.2147/IJN.S23239
   Frasco MF, 2009, SENSORS-BASEL, V9, P7266, DOI 10.3390/s90907266
   Gazouli M, 2010, J CLIN MICROBIOL, V48, P2830, DOI 10.1128/JCM.00185-10
   Gengvinij Nipa, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P114
   Gill P, 2008, NANOBIOTECHNOLOGY, V4, P28, DOI DOI 10.1007/S12030-009-9021-9
   Gueroui Z, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166108
   Hanif SNM, 2011, MYCOBACT DIS, V1, P2
   Hsieh SC, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-180
   Kamelipour N, 2014, MICROCHIM ACTA, V181, P239, DOI 10.1007/s00604-013-1103-7
   Li HJ, 2009, J CLIN MICROBIOL, V47, P3814, DOI 10.1128/JCM.01534-09
   Liandris E, 2009, J MICROBIOL METH, V78, P260, DOI 10.1016/j.mimet.2009.06.009
   Liz-Marzan LM, 2006, LANGMUIR, V22, P32, DOI 10.1021/la0513353
   Maurya AK, 2012, INDIAN J MED MICROBI, V30, P182, DOI 10.4103/0255-0857.96688
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   Mdivani N, 2009, CLIN CHEM, V55, P1694, DOI 10.1373/clinchem.2009.124396
   Oh E, 2005, J AM CHEM SOC, V127, P3270, DOI 10.1021/ja0433323
   PAO CC, 1990, J CLIN MICROBIOL, V28, P1877
   Safarpour H, 2012, CAN J PLANT PATHOL, P34
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shin AR, 2008, CLIN VACCINE IMMUNOL, V15, P1788, DOI 10.1128/CVI.00231-08
   Soo PC, 2009, MOL CELL PROBE, V23, P240, DOI 10.1016/j.mcp.2009.04.006
   Van Deun A, 1998, INT J TUBERC LUNG D, V2, P756
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000
   Vassall A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001120
   Wargnier R, 2004, NANO LETT, V4, P451, DOI 10.1021/nl0350938
   WHO, 2012, WHO GLOB TUB REP 201
   WILSON SM, 1993, J CLIN MICROBIOL, V31, P776
   WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134
   Yeo WH, 2009, ANAL BIOANAL CHEM, V393, P1593, DOI 10.1007/s00216-008-2591-x
   Zekavati R, 2013, MICROCHIM ACTA, V180, P1217, DOI 10.1007/s00604-013-1047-y
NR 43
TC 7
Z9 8
U1 1
U2 26
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD NOV-DEC
PY 2014
VL 18
IS 6
BP 600
EP 608
DI 10.1016/j.bjid.2014.05.015
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA AW1TI
UT WOS:000346072500003
PM 25181404
OA gold
DA 2018-01-05
ER

PT J
AU Rozzi, SJ
   Borelli, G
   Ryan, K
   Steiner, JP
   Reglodi, D
   Mocchetti, I
   Avdoshina, V
AF Rozzi, Summer J.
   Borelli, Giulia
   Ryan, Kerry
   Steiner, Joseph P.
   Reglodi, Dora
   Mocchetti, Italo
   Avdoshina, Valeriya
TI PACAP27 is Protective Against Tat-Induced Neurotoxicity
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE DNA damage; Oxidative stress; Mitochondria; CCL5; HIV; gp120
ID CYCLASE-ACTIVATING POLYPEPTIDE; HIV-1 TAT; OXIDATIVE STRESS; CELL-DEATH;
   MITOCHONDRIAL HYPERPOLARIZATION; NEURODEGENERATIVE DISEASES;
   NEUROCOGNITIVE DISORDERS; RECEPTOR ACTIVATION; SIGNALING PATHWAYS;
   CORTICAL-NEURONS
AB Human immunodeficiency virus type-1 (HIV) infection of the central nervous system promotes neuronal injury and apoptosis that culminate in HIV-associated neurocognitive disorders (HAND). Viral proteins, such as transactivator of transcription (Tat), have emerged as leading candidates to explain HIV-mediated neurotoxicity, though the mechanism remains unclear. To determine the effects of Tat, rat cortical neurons were exposed to nanomolar concentrations of Tat for various time points. Within a few hours, Tat induced the production of reactive oxygen species (ROS), and other indices of mitochondrial destabilization. In addition, we observed a significant induction of DNA double-strand breaks (DSBs) by Tat. We next investigated the neuroprotective activity of the pituitary adenylate cyclase-activating polypeptide 27 (PACAP27) against these cardinal features of Tat-induced neurodegeneration. PACAP27 (100 nM) inhibited all Tat-mediated toxic effects including DNA DSBs. Importantly, PACAP27 prevented the induction of neuronal loss induced by Tat. The neuroprotective effect of PACAP27 is correlated with its ability to release the anti-apoptotic chemokine CCL5. Our data support a mechanism of Tat neurotoxicity in which Tat induces mitochondrial destabilization, thus increasing the release of ROS, which causes DNA DSBs leading to cell death. PACAP27, through CCL5, mitigates the effects of Tat-induced neuronal dysfunction, suggesting that PACAP27 could be a new strategy for an adjunct therapy against HIV-associated neurocognitive disorders.
C1 [Rozzi, Summer J.; Mocchetti, Italo] Georgetown Univ, Interdisciplinary Program Neurosci, Washington, DC USA.
   [Rozzi, Summer J.; Borelli, Giulia; Mocchetti, Italo; Avdoshina, Valeriya] Georgetown Univ, Lab Preclin Neurobiol, Dept Neurosci, Washington, DC 20057 USA.
   [Ryan, Kerry] Georgetown Univ, Dept Biol, Washington, DC 20057 USA.
   [Steiner, Joseph P.] NINDS, NIH, Bethesda, MD 20892 USA.
   [Reglodi, Dora] Univ Pecs, Dept Anat, PTE MTA Lendulet PACAP Res Team, Pecs, Hungary.
RP Mocchetti, I (reprint author), Georgetown Univ, Lab Preclin Neurobiol, Dept Neurosci, Washington, DC 20057 USA.
EM moccheti@georgetown.edu
FU HHS [T32 NS041218, NS079172, NS074916]; Arimura Foundation, PTE-MTA
   "Lendulet" Program [OTKAK104984 NAP, TAMOP4.2.2.A-11/1/KONV-2012-0024]
FX This work was partly supported in part by HHS grant T32 NS041218 to SR
   and NS079172 and NS074916 to IM. PACAP synthesis was supported by
   OTKAK104984 NAP, TAMOP4.2.2.A-11/1/KONV-2012-0024, Arimura Foundation,
   PTE-MTA "Lendulet" Program.
CR Ances BM, 2007, SEMIN NEUROL, V27, P86, DOI 10.1055/s-2006-956759
   Avdoshina V, 2010, GLIA, V58, P1630, DOI 10.1002/glia.21035
   Bachis A, 2003, J NEUROSCI, V23, P5715
   Baxter PS, 2011, J NEUROCHEM, V118, P365, DOI 10.1111/j.1471-4159.2011.07330.x
   Bellizzi MJ, 2006, J NEUROIMMUNE PHARM, V1, P20, DOI 10.1007/s11481-005-9006-y
   Brasnjevic I, 2008, DNA REPAIR, V7, P1087, DOI 10.1016/j.dnarep.2008.03.010
   BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0
   Brenneman DE, 2002, NEUROPEPTIDES, V36, P271, DOI 10.1016/S0143-4179(02)00045-8
   Bruce-Keller AJ, 2003, J NEUROSCI, V23, P8417
   Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683                                                            
   Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385
   Crews L, 2009, INT J MOL SCI, V10, P1045, DOI 10.3390/ijms10031045
   Eckmann J, 2013, INT J BIOCHEM CELL B, V45, P76, DOI 10.1016/j.biocel.2012.06.009
   Eugenin EA, 2007, P NATL ACAD SCI USA, V104, P3438, DOI 10.1073/pnas.0611699104
   Fabian E, 2012, J MOL NEUROSCI, V48, P493, DOI 10.1007/s12031-012-9812-7
   Fishel ML, 2007, MUTAT RES-FUND MOL M, V614, P24, DOI 10.1016/j.mrfmmm.2006.06.007
   Garden GA, 2002, J NEUROSCI, V22, P4015
   Haughey NJ, 2001, J NEUROCHEM, V78, P457, DOI 10.1046/j.1471-4159.2001.00396.x
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   Hui L, 2012, J NEUROCHEM, V122, P382, DOI 10.1111/j.1471-4159.2012.07764.x
   Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006
   James HJ, 1999, NEUROPATH APPL NEURO, V25, P380
   Jeppesen DK, 2011, PROG NEUROBIOL, V94, P166, DOI 10.1016/j.pneurobio.2011.04.013
   Jozsa R, 2005, PEPTIDES, V26, P2344, DOI 10.1016/j.peptides.2005.03.054
   Kantor O, 2000, PEPTIDES, V21, P817, DOI 10.1016/S0196-9781(00)00214-X
   Kaul M, 2007, CELL DEATH DIFFER, V14, P296, DOI 10.1038/sj.cdd.4402006
   Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667
   Kim HJ, 2008, J NEUROSCI, V28, P12604, DOI 10.1523/JNEUROSCI.2958-08.2008
   Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958
   Lee FS, 2002, J BIOL CHEM, V277, P9096, DOI 10.1074/jbc.M107421200
   Li WX, 2009, NEUROTOX RES, V16, P205, DOI 10.1007/s12640-009-9047-8
   Li WX, 2008, J NEUROSCI, V28, P12190, DOI 10.1523/JNEUROSCI.3019-08.2008
   Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.3.CO;2-N
   Liu Y, 2000, NAT MED, V6, P1380
   Ma MH, 1997, J VIROL, V71, P2495
   Mattson MP, 2005, CELL DEATH DIFFER, V12, P893, DOI 10.1038/sj.cdd.4401577
   May V, 2010, J BIOL CHEM, V285, P9749, DOI 10.1074/jbc.M109.043117
   Nath S, 2012, J NEUROVIROL, V18, P445, DOI 10.1007/s13365-012-0122-1
   Doan ND, 2012, BBA-MOL CELL RES, V1823, P940, DOI 10.1016/j.bbamcr.2012.02.001
   Norman JP, 2007, J IMMUNOL, V178, P869, DOI 10.4049/jimmunol.178.2.869                                                      
   Norman JP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003731
   Ohtaki H, 2010, J MOL NEUROSCI, V42, P397, DOI 10.1007/s12031-010-9350-0
   Pocernich CB, 2005, BRAIN RES REV, V50, P14, DOI 10.1016/j.brainresrev.2005.04.002
   Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x                                                
   Reglodi D, 2011, CURR PHARM DESIGN, V17, P962, DOI 10.2174/138161211795589355                                                      
   Sanchez A, 2009, NEUROPEPTIDES, V43, P315, DOI 10.1016/j.npep.2009.05.002
   Sanchez A, 2009, REGUL PEPTIDES, V152, P33, DOI 10.1016/j.regpep.2008.07.004
   Sun T, 2013, CELL REP, V4, P413, DOI 10.1016/j.celrep.2013.06.040
   Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x
   Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370
   Zhang YL, 2012, BRAIN RES, V1458, P1, DOI 10.1016/j.brainres.2012.04.001
NR 51
TC 5
Z9 5
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD NOV
PY 2014
VL 54
IS 3
BP 485
EP 493
DI 10.1007/s12031-014-0273-z
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA AT3ZN
UT WOS:000344875700022
PM 24696163
OA green_accepted
DA 2018-01-05
ER

PT J
AU Knuschke, T
   Bayer, W
   Rotan, O
   Sokolova, V
   Wadwa, M
   Kirschning, CJ
   Hansen, W
   Dittmer, U
   Epple, M
   Buer, J
   Westendorf, AM
AF Knuschke, Torben
   Bayer, Wibke
   Rotan, Olga
   Sokolova, Viktoriya
   Wadwa, Munisch
   Kirschning, Carsten J.
   Hansen, Wiebke
   Dittmer, Ulf
   Epple, Matthias
   Buer, Jan
   Westendorf, Astrid M.
TI Prophylactic and therapeutic vaccination with a nanoparticle-based
   peptide vaccine induces efficient protective immunity during acute and
   chronic retroviral infection
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Retrovirus; Vaccination; Nanoparticle; Delivery system; T cell immunity
ID REGULATORY T-CELLS; DENDRITIC CELLS; CELLULAR-IMMUNITY; VIRAL-INFECTION;
   VIRUS; FRIEND; LEUKEMIA; DELIVERY; MICE; DRUG
AB Retroviral infections e. g. HIV still represent a unique burden in the field of vaccine research. A common challenge in vaccine design is to find formulations that create appropriate immune responses to protect against and/or control the given pathogen. Nanoparticles have been considered to be ideal vaccination vehicles that mimic invading pathogens. In this study, we present biodegradable calcium phosphate (CaP) nanoparticles, functionalized with CpG and retroviral T cell epitopes of Friend virus (FV) as excellent vaccine delivery system. CaP nanoparticles strongly increased antigen delivery to antigen-presenting cells to elicit a highly efficient T cell-mediated immune response against retroviral FV infection. Moreover, single-shot immunization of chronically FV-infected mice with functionalized CaP nanoparticles efficiently reactivated effector T cells which led to a significant decrease in viral loads. Thus, our findings clearly indicate that a nanoparticle-based peptide immunization is a promising approach to improve antiretroviral vaccination.
   From the Clinical Editor: In this study, biodegradable calcium phosphate nanoparticles were used as a vaccine delivery system after functionalization with CpG and Friend virus-derived T-cell epitopes. This vaccination strategy resulted in increased T-cell mediated immune response even in chronically infected mice, providing a promising approach to the development of clinically useful antiretroviral vaccination strategies. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Knuschke, Torben; Wadwa, Munisch; Kirschning, Carsten J.; Hansen, Wiebke; Buer, Jan; Westendorf, Astrid M.] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Microbiol, Essen, Germany.
   [Bayer, Wibke; Dittmer, Ulf] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.
   [Rotan, Olga; Sokolova, Viktoriya; Epple, Matthias] Univ Duisburg Essen, Essen, Germany.
   [Rotan, Olga; Sokolova, Viktoriya; Epple, Matthias] Univ Duisburg Essen, Ctr Nanointegrat Duisburg Essen CeNIDE, Essen, Germany.
RP Westendorf, AM (reprint author), Univ Hosp Essen, Inst Med Microbiol, Hufelandstr 55, D-45122 Essen, Germany.
EM astrid.westendorf@uk-essen.de
FU Deutsche Forschungsgemeinschaft [SFB/Transregio 60]
FX Funding Sources: This work was supported by the Deutsche
   Forschungsgemeinschaft (SFB/Transregio 60 to WB, CJK, UD, ME, JB, and
   AMW).
CR Altfeld M, 2006, TRENDS IMMUNOL, V27, P504, DOI 10.1016/j.it.2006.09.007
   Antunes I, 2008, IMMUNITY, V29, P782, DOI 10.1016/j.immuni.2008.09.016
   Armstead AL, 2011, INT J NANOMED, V6, P3281, DOI 10.2147/IJN.S27285
   Bayer W, 2008, VACCINE, V26, P716, DOI 10.1016/j.vaccine.2007.11.050
   Bayer W, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-75
   Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b
   Cervantes-Barragan L, 2012, P NATL ACAD SCI USA, V109, P3012, DOI 10.1073/pnas.1117359109
   Chen W, 1996, J VIROL, V70, P7773
   CHESEBRO B, 1974, J EXP MED, V140, P1457, DOI 10.1084/jem.140.6.1457
   Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290
   Correia-Pinto JF, 2013, INT J PHARMACEUT, V440, P27, DOI 10.1016/j.ijpharm.2012.04.047
   Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4
   Dane KY, 2011, J CONTROL RELEASE, V156, P154, DOI 10.1016/j.jconrel.2011.08.009
   de Titta A, 2013, P NATL ACAD SCI USA, V110, P19902, DOI 10.1073/pnas.1313152110
   Dietze KK, 2011, P NATL ACAD SCI USA, V108, P2420, DOI 10.1073/pnas.1015148108
   Dittmer U, 1999, J VIROL, V73, P3753
   Dorozhkin SV, 2002, ANGEW CHEM INT EDIT, V41, P3130, DOI 10.1002/1521-3773(20020902)41:17<3130::AID-ANIE3130>3.0.CO;2-1
   Fuse S, 2008, CRIT REV IMMUNOL, V28, P159, DOI 10.1615/CritRevImmunol.v28.i2.40                                                
   Gandhi RT, 2002, CURR OPIN IMMUNOL, V14, P487, DOI 10.1016/S0952-7915(02)00359-X
   Gibbert K, 2010, J IMMUNOL, V185, P6179, DOI 10.4049/jimmunol.1000858
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hart DNJ, 1997, BLOOD, V90, P3245
   Hasenkrug KJ, 2007, FRONT BIOSCI, V12, P1544, DOI 10.2741/2167                                                                    
   Hasenkrug KJ, 1998, J VIROL, V72, P6559
   Klinman DM, 2009, ADV DRUG DELIVER REV, V61, P248, DOI 10.1016/j.addr.2008.12.012
   Knuschke T, 2013, HUM VACC IMMUNOTHER, V10, P1
   Knuschke T, 2013, J IMMUNOL, V190, P6221, DOI 10.4049/jimmunol.1202654
   Krieg AM, 2012, NUCLEIC ACID THER, V22, P77, DOI 10.1089/nat.2012.0340
   Krishnamachari Y, 2009, ADV DRUG DELIVER REV, V61, P205, DOI 10.1016/j.addr.2008.12.013
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Nair S, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-76
   Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   ROBERTSON MN, 1992, J VIROL, V66, P3271
   ROBERTSON MN, 1991, J VIROL METHODS, V34, P255, DOI 10.1016/0166-0934(91)90105-9
   Sheng KC, 2008, EUR J IMMUNOL, V38, P424, DOI 10.1002/eji.200737578
   Sokolova V, 2011, ACTA BIOMATER, V7, P4029, DOI 10.1016/j.actbio.2011.07.010
   Sokolova V, 2010, BIOMATERIALS, V31, P5627, DOI 10.1016/j.biomaterials.2010.03.067
   Sokolova VV, 2006, BIOMATERIALS, V27, P3147, DOI 10.1016/j.biomaterials.2005.12.030
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   von Herrath MG, 2000, VIROLOGY, V268, P411, DOI 10.1006/viro.1999.0130                                                          
   Wherry EJ, 2005, J VIROL, V79, P8960, DOI 10.1128/JVI.79.14.8960-8968.2005
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
   Zelinskyy G, 2006, EUR J IMMUNOL, V36, P2658, DOI 10.1002/eji.200636059
   Zelinskyy G, 2009, BLOOD, V114, P3199, DOI 10.1182/blood-2009-03-208736
   Zhao Z, 1996, J PHARM SCI-US, V85, P1261, DOI 10.1021/js9602812
   Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082
   Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806
NR 49
TC 16
Z9 16
U1 0
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD NOV
PY 2014
VL 10
IS 8
BP 1787
EP 1798
DI 10.1016/j.nano.2014.06.014
PG 12
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA AT4UT
UT WOS:000344939700021
PM 25014891
DA 2018-01-05
ER

PT J
AU Chung, JE
   Tan, S
   Gao, SJ
   Yongvongsoontorn, N
   Kim, SH
   Lee, JH
   Choi, HS
   Yano, H
   Zhuo, L
   Kurisawa, M
   Ying, JY
AF Chung, Joo Eun
   Tan, Susi
   Gao, Shu Jun
   Yongvongsoontorn, Nunnarpas
   Kim, Soon Hee
   Lee, Jeong Heon
   Choi, Hak Soo
   Yano, Hirohisa
   Zhuo, Lang
   Kurisawa, Motoichi
   Ying, Jackie Y.
TI Self-assembled micellar nanocomplexes comprising green tea catechin
   derivatives and protein drugs for cancer therapy
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID IN-VIVO; POLYMERIC MICELLES; LIVER-CANCER; POLYPHENOL; GALLATE;
   CISPLATIN; DELIVERY; MODEL; TAXOL; EGCG
AB When designing drug carriers, the drug-to-carrier ratio is an important consideration, because the use of high quantities of carriers can result in toxicity as a consequence of poor metabolism and elimination of the carriers(1). However, these issues would be of less concern if both the drug and carrier had therapeutic effects. (-)-Epigallocatechin-3-O-gallate (EGCG), a major ingredient of green tea, has been shown, for example, to possess anticancer effects(2-7), anti-HIV effects(8), neuroprotective effects(9) and DNA-protective effects(10). Here, we show that sequential self-assembly of the EGCG derivative with anticancer proteins leads to the formation of stable micellar nanocomplexes, which have greater anticancer effects in vitro and in vivo than the free protein. The micellar nanocomplex is obtained by complexation of oligomerized EGCG with the anticancer protein Herceptin to form the core, followed by complexation of poly(ethylene glycol)-EGCG to form the shell. When injected into mice, the Herceptin-loaded micellar nanocomplex demonstrates better tumour selectivity and growth reduction, as well as longer blood half-life, than free Herceptin.
C1 [Chung, Joo Eun; Tan, Susi; Gao, Shu Jun; Yongvongsoontorn, Nunnarpas; Yano, Hirohisa; Zhuo, Lang; Kurisawa, Motoichi; Ying, Jackie Y.] Inst Bioengn & Nanotechnol, Nanos 138669, Singapore.
   [Kim, Soon Hee; Lee, Jeong Heon; Choi, Hak Soo] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
   [Kim, Soon Hee; Lee, Jeong Heon; Choi, Hak Soo] Harvard Univ, Sch Med, Boston, MA 02215 USA.
   [Yano, Hirohisa] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan.
RP Chung, JE (reprint author), Inst Bioengn & Nanotechnol, 31 Biopolis Way, Nanos 138669, Singapore.
EM jechung@ibn.a-star.edu.sg; mkurisawa@ibn.a-star.edu.sg
RI Choi, Hak Soo/C-9954-2011; KURISAWA, MOTOICHI/C-1325-2014
OI KURISAWA, MOTOICHI/0000-0003-2413-6933; Choi, Hak
   Soo/0000-0002-7982-6483
FU Institute of Bioengineering and Nanotechnology (Biomedical Research
   Council, Agency for Science, Technology and Research, Singapore);
   National Institutes of Health (NIBIB) [R01-EB-011523]
FX This research was funded by the Institute of Bioengineering and
   Nanotechnology (Biomedical Research Council, Agency for Science,
   Technology and Research, Singapore) and the National Institutes of
   Health (NIBIB grant no. R01-EB-011523, to H.S.C.). The authors thank A.
   Yamashita and J.P.K. Tan for their assistance with cell culture and TEM
   experiments, respectively.
CR Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Cabral H, 2013, P NATL ACAD SCI USA, V110, P11397, DOI 10.1073/pnas.1301348110
   Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793                                                                   
   Choi HS, 2011, ANGEW CHEM INT EDIT, V50, P6258, DOI 10.1002/anie.201102459
   CHOU TC, 1994, J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517
   Chung JE, 2004, BIOMACROMOLECULES, V5, P113, DOI 10.1021/bm0342436
   Du GJ, 2012, NUTRIENTS, V4, P1679, DOI 10.3390/nu4111679
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550                                                   
   Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145                                                                   
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hisaka T, 2004, J HEPATOL, V41, P782, DOI 10.1016/j.jhep.2004.07.012
   Hubbell JA, 2003, SCIENCE, V300, P595, DOI 10.1126/science.1083625
   Ishii T, 2013, FASEB J, V27, P1362, DOI 10.1096/fj.12-221325
   Jankun J, 1997, NATURE, V387, P561, DOI 10.1038/42381
   Jobstl E, 2004, BIOMACROMOLECULES, V5, P942, DOI 10.1021/bm0345110
   Kim D, 2009, MOL PHARMACEUT, V6, P1353, DOI 10.1021/mp900021q
   Kopecek J, 2010, ADV DRUG DELIVER REV, V62, P122, DOI 10.1016/j.addr.2009.10.004
   Kuzuhara T, 2006, J BIOL CHEM, V281, P17446, DOI 10.1074/jbc.M601196200
   Li Shenwei, 2011, Antiviral Chemistry & Chemotherapy, V21, P239, DOI 10.3851/IMP1774
   Liang G, 2010, INT J ONCOL, V37, P111, DOI 10.3892/ijo_00000659
   Miura Y, 2013, ACS NANO, V7, P8583, DOI 10.1021/nn402662d
   Miyata K, 2011, REACT FUNCT POLYM, V71, P227, DOI 10.1016/j.reactfunctpolym.2010.10.009
   Morley N, 2005, PHOTODERMATOL PHOTO, V21, P15, DOI 10.1111/j.1600-0781.2005.00119.x
   Musacchio T, 2011, FRONT BIOSCI-LANDMRK, V16, P1388, DOI 10.2741/3795
   Saucier C, 1997, PHYTOCHEMISTRY, V46, P229, DOI 10.1016/S0031-9422(97)00268-9
   Sun JZ, 1999, CANCER RES, V59, P4919
   Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743
   Villalba JJ, 2001, J ANIM SCI, V79, P2066
   Wang FH, 2013, INT J PHARMACEUT, V456, P101, DOI 10.1016/j.ijpharm.2013.08.008
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038
   Yu JX, 2010, FEBS LETT, V584, P2921, DOI 10.1016/j.febslet.2010.05.011
NR 33
TC 74
Z9 78
U1 22
U2 189
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD NOV
PY 2014
VL 9
IS 11
BP 907
EP 912
DI 10.1038/NNANO.2014.208
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA AT4YY
UT WOS:000344951100017
PM 25282044
OA green_accepted
DA 2018-01-05
ER

PT J
AU Lachambre, S
   Chopard, C
   Beaumelle, B
AF Lachambre, Simon
   Chopard, Christophe
   Beaumelle, Bruno
TI Preliminary characterisation of nanotubes connecting T-cells and their
   use by HIV-1
SO BIOLOGY OF THE CELL
LA English
DT Article
DE Ezrin; Gag; HIV-1; Nanotubes; T-cell
ID MEMBRANE NANOTUBES; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL
   4,5-BISPHOSPHATE; TETRASPANIN WEB; CUTTING EDGE; ERM PROTEINS; IN-VIVO;
   CYTOSKELETON; TRANSMISSION; DIFFUSION
AB Background InformationCells, especially those of the immune system, can form long and thin connections termed tunnelling nanotubes (TNTs). These structures can reach >100 mu m in length and, in T-cells, contain actin but no tubulin and are not open ended. T-cell TNTs were found to form following cell contact and to enable the transfer of HIV-1 from an infected- to a connected-T-cell. TNTs are poorly characterised at molecular level.
   ResultsWe found Rab11 and tetraspanins, especially CD81, all along T-cells TNTs, whereas Rab4 and Rab35 were absent from these structures. Regarding actin cytoskeleton regulators, Exo70, N-WASP and especially ezrin accumulated at the level of the TNT tip that contacts the connected cell. Phosphoinositides such as PI(4,5)P-2 were also concentrated at this level together with HIV-1 Gag. Gag spots on cells and TNTs were essentially immobile, and likely correspond to area of Gag multimerisation for budding to form virus-like particles. Mobility of PHPLC, a specific probe for PI(4,5)P-2, was reduced > threefold at the level of TNT basis or tip compared with the cell body.
   ConclusionOur study identified the TNT tip as an active zone of actin cytoskeleton reorganisation with the presence of ezrin, Exo70, N-WASP and PI(4,5)P-2. The latter is also known to enable HIV-1 Gag recruitment for viral budding, and the presence of Gag at this level, contacting the connected cell, indicates that the TNT tip is also a favourite place for HIV-1 assembly and budding.
C1 [Lachambre, Simon; Chopard, Christophe; Beaumelle, Bruno] Univ Montpellier, CNRS, UMR 5236, CPBS, F-34293 Montpellier, France.
RP Beaumelle, B (reprint author), Univ Montpellier, CNRS, UMR 5236, CPBS, F-34293 Montpellier, France.
EM bruno.beaumelle@cpbs.cnrs.fr
FU Sidaction; CNRS through the PEPS program
FX This work was funded by Sidaction and the CNRS through the PEPS program.
CR Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279
   AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218
   Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1
   Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854
   Bell NM, 2013, TRENDS MICROBIOL, V21, P136, DOI 10.1016/j.tim.2012.11.006
   Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595                                                          
   Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   de Joussineau C, 2003, NATURE, V426, P555, DOI 10.1038/nature02157
   Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185
   Espenel C, 2008, J CELL BIOL, V182, P765, DOI 10.1083/jcb.200803010
   Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039
   Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866
   Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9
   Golebiewska U, 2008, MOL BIOL CELL, V19, P1663, DOI 10.1091/mbc.E07-12-1208
   Golebiewska U, 2011, MOL BIOL CELL, V22, P3498, DOI 10.1091/mbc.E11-02-0114
   Hammond GRV, 2009, J CELL BIOL, V184, P297, DOI 10.1083/jcb.200809073
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476
   Helma J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050026
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Kang M, 2012, TRAFFIC, V13, P1589, DOI 10.1111/tra.12008
   Krementsov DN, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-64
   Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Liu JL, 2007, MOL BIOL CELL, V18, P4483, DOI 10.1091/mbc.E07-05-0461
   Liu JL, 2012, CURR BIOL, V22, P1510, DOI 10.1016/j.cub.2012.05.055
   Martin-Serrano J, 2011, NAT REV MICROBIOL, V9, P519, DOI 10.1038/nrmicro2596
   Mitra S, 2011, SEMIN CELL DEV BIOL, V22, P57, DOI 10.1016/j.semcdb.2010.12.005
   Murooka TT, 2012, NATURE, V490, P283, DOI 10.1038/nature11398
   Nobile C, 2010, J VIROL, V84, P2282, DOI 10.1128/JVI.02230-09
   Ohno Hiroshi, 2010, Commun Integr Biol, V3, P231
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Ono A, 2010, BIOL CELL, V102, P335, DOI 10.1042/BC20090165
   Ott DE, 1996, J VIROL, V70, P7734
   Rayne F, 2010, EMBO J, V29, P1348, DOI 10.1038/emboj.2010.32
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sala-Valdes M, 2006, J BIOL CHEM, V281, P19665, DOI 10.1074/jbc.M602116200
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Sowinski S, 2011, METHODS, V53, P27, DOI 10.1016/j.ymeth.2010.04.002
   Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069
   Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724
   Toomre D, 2010, ANNU REV CELL DEV BI, V26, P285, DOI 10.1146/annurev-cellbio-100109-104048
   van den Bogaart G, 2011, NATURE, V479, P552, DOI 10.1038/nature10545
   Van Engelenburg SB, 2014, SCIENCE, V343, P653, DOI 10.1126/science.1247786
   Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501                                                           
   Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921
   Zhao HX, 2011, CURR OPIN CELL BIOL, V23, P14, DOI 10.1016/j.ceb.2010.10.005
   Zhao YT, 2013, DEV CELL, V26, P266, DOI 10.1016/j.devcel.2013.07.007
NR 54
TC 11
Z9 11
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0248-4900
EI 1768-322X
J9 BIOL CELL
JI Biol. Cell
PD NOV
PY 2014
VL 106
IS 11
BP 394
EP 404
DI 10.1111/boc.201400037
PG 11
WC Cell Biology
SC Cell Biology
GA AT0SW
UT WOS:000344646100002
PM 25130443
DA 2018-01-05
ER

PT J
AU Alcazar, W
   Lopez, AS
   Alakurtti, S
   Tuononen, ML
   Yli-Kauhaluoma, J
   Ponte-Sucre, A
AF Alcazar, Wilmer
   Silva Lopez, Adrian
   Alakurtti, Sami
   Tuononen, Maija-Liisa
   Yli-Kauhaluoma, Jari
   Ponte-Sucre, Alicia
TI Betulin derivatives impair Leishmania braziliensis viability and
   host-parasite interaction
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Leishmania; Betulin derivatives; Host-parasite interaction;
   Susceptibility
ID NATURAL-PRODUCT BETULIN; IN-VITRO; ANTILEISHMANIAL ACTIVITY; EUKARYOTIC
   CHEMOTAXIS; DRUG-RESISTANCE; ACID; DONOVANI; AMASTIGOTES; ALLOBETULIN;
   MOTILITY
AB Leishmaniasis is a public health problem in tropical and subtropical areas of the world, including Venezuela. The incidence of treatment failure and the number of cases with Leishmania-HIV co-infection underscore the importance of developing alternative, economical and effective therapies against this disease. The work presented here analyzed whether terpenoids derived from betulin are active against New World Leishmania parasites. Initially we determined the concentration that inhibits the growth of these parasites by 50% or IC50, and subsequently evaluated the chemotactic effect of four compounds with leishmanicidal activity in the sub-micromolar and micromolar range. That is, we measured the migratory capacity of Leishmania (V.) braziliensis in the presence of increasing concentrations of compounds. Finally, we evaluated their cytotoxicity against the host cell and their effect on the infectivity of L. (V.) braziliensis. The results suggest that (1) compounds 14, 17, 18, 25 and 27 are active at concentrations lower than 10 mu M; (2) compound 26 inhibits parasite growth with an IC50 lower than 1 mu M; (3) compounds 18, 26 and 27 inhibit parasite migration at pico-to nanomolar concentrations, suggesting that they impair host-parasite interaction. None of the tested compounds was cytotoxic against J774.A1 macrophages thus indicating their potential as starting points to develop compounds that might affect parasite-host cell interaction, as well as being leishmanicidal. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Alcazar, Wilmer; Silva Lopez, Adrian; Ponte-Sucre, Alicia] Cent Univ Venezuela, IME, Lab Fisiol Mol, Caracas, Venezuela.
   [Alakurtti, Sami; Tuononen, Maija-Liisa; Yli-Kauhaluoma, Jari] Univ Helsinki, Fac Pharm, Div Pharmaceut Chem & Technol, FIN-00014 Helsinki, Finland.
   [Alakurtti, Sami; Tuononen, Maija-Liisa] VTT Tech Res Ctr Finland, Espoo, Finland.
RP Ponte-Sucre, A (reprint author), Cent Univ Venezuela, Fac Med, Inst Expt Med, Lab Mol Physiol, Caracas, Venezuela.
EM aiponte@gmail.com
RI Ponte-Sucre, Alicia/A-7142-2015
OI Ponte-Sucre, Alicia/0000-0001-8135-0763; Yli-Kauhaluoma,
   Jari/0000-0003-0370-7653
FU Finnish Funding Agency for Technology and Innovation (Tekes); Foundation
   for Research of Natural Resources in Finland; Marjatta ja Eino Kollin
   Saatio; European Commission [EU-KBBE-227239-Forest-SpeCs]; Academy of
   Finland [252308, 264020, 265481]; COST Action [CM-0801]; Universidad
   Central de Venezuela Council for Research [CDCH-UCV PI-09-8717-2013/1,
   PG-09-8646-2013/1]; Alexander von Humboldt Foundation, Germany
FX This study was supported by the Finnish Funding Agency for Technology
   and Innovation (Tekes), the Foundation for Research of Natural Resources
   in Finland, Marjatta ja Eino Kollin Saatio, the European Commission
   (Contract No. EU-KBBE-227239-Forest-SpeCs), the Academy of Finland
   (Projects 252308, 264020 and 265481) and the COST Action CM-0801 (New
   drugs for neglected diseases) and by the Universidad Central de
   Venezuela Council for Research (Grants CDCH-UCV PI-09-8717-2013/1 and
   PG-09-8646-2013/1). The authors are grateful to Anja Salakari, Irene
   Kylanlahti and Pilar Rodriguez Lopez for their excellent technical
   assistance as well as Minni Pirttimaa and Dr. Salme Koskimies for
   valuable discussion. A. P. S. had the support of the Alexander von
   Humboldt Foundation, Germany.
CR Alakurtti S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/j.ejps.2006.04.006
   Alakurtti S, 2010, J ANTIBIOT, V63, P123, DOI 10.1038/ja.2010.2
   Alakurtti S, 2010, BIOORGAN MED CHEM, V18, P1573, DOI 10.1016/j.bmc.2010.01.003
   Bagorda A, 2008, J CELL SCI, V121, P2621, DOI 10.1242/jcs.018077
   Chattopadhyay A, 2011, BIOCHEM BIOPH RES CO, V416, P7, DOI 10.1016/j.bbrc.2011.11.023
   Chowdhury S, 2014, ANTIMICROB AGENTS CH, V58, P2186, DOI 10.1128/AAC.02193-13
   Chowdhury S, 2011, MOL PHARMACOL, V80, P694, DOI 10.1124/mol.111.072785
   de Sa MS, 2009, PARASITOL RES, V105, P275, DOI 10.1007/s00436-009-1394-0
   Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200
   Diaz E., 2011, REV FAC FARM UCV, V74, P31
   Dominguez-Carmona DB, 2010, PHYTOMEDICINE, V17, P379, DOI 10.1016/j.phymed.2009.08.002
   Finney D. J., 1971, PROBIT ANAL
   Forestier CL, 2011, CELL HOST MICROBE, V9, P319, DOI 10.1016/j.chom.2011.03.011
   Fulda S, 2009, DRUG DISCOV TODAY, V14, P885, DOI 10.1016/j.drudis.2009.05.015
   Gadelha C, 2007, CELL MOTIL CYTOSKEL, V64, P629, DOI 10.1002/cm.20210
   Green B, 2007, J CHEM EDUC, V84, P1985, DOI 10.1021/ed084p1985                                                              
   Haavikko R, 2014, MEDCHEMCOMM, V5, P445, DOI 10.1039/c3md00282a
   HUBER W, 1993, ACTA TROP, V55, P257, DOI 10.1016/0001-706X(93)90083-N
   KOHIDAI L, 1995, ACTA PROTOZOOL, V34, P181
   Li TS, 1998, J CHEM SOC PERK T 1, P3957, DOI 10.1039/a806735j                                                                
   Pohjala L, 2009, J NAT PROD, V72, P1917, DOI 10.1021/np9003245
   Ponte-Sucre A, 1998, EXP PARASITOL, V88, P11, DOI 10.1006/expr.1998.4200                                                          
   PonteSucre A, 1997, MEM I OSWALDO CRUZ, V92, P601, DOI 10.1590/S0074-02761997000500007
   Pozzo LY, 2009, MICRON, V40, P617, DOI 10.1016/j.micron.2009.02.008
   Rotureau B, 2009, CELL MICROBIOL, V11, P710, DOI 10.1111/j.1462-5822.2009.01295.x
   Salin O, 2010, BIOCHEM PHARMACOL, V80, P1141, DOI 10.1016/j.bcp.2010.06.051
   Saudagar P, 2014, AM J TROP MED HYG, V90, P354, DOI 10.4269/ajtmh.13-0320
   Suresh C, 2012, BIOORG MED CHEM LETT, V22, P1734, DOI 10.1016/j.bmcl.2011.12.102
   Wert L, 2011, J ANTIBIOT, V64, P475, DOI 10.1038/ja.2011.34
   Yoon JJ, 2010, J CELL BIOCHEM, V111, P1501, DOI 10.1002/jcb.22880
NR 30
TC 2
Z9 2
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD NOV 1
PY 2014
VL 22
IS 21
BP 6220
EP 6226
DI 10.1016/j.bmc.2014.08.023
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA AS8AB
UT WOS:000344471800051
PM 25240731
DA 2018-01-05
ER

PT J
AU Yaciuk, JC
   Skaley, M
   Bardet, W
   Schafer, F
   Mojsilovic, D
   Cate, S
   Stewart, CJ
   McMurtrey, C
   Jackson, KW
   Buchli, R
   Olvera, A
   Cedeno, S
   Plana, M
   Mothe, B
   Brander, C
   West, JT
   Hildebrand, WH
AF Yaciuk, Jane C.
   Skaley, Matthew
   Bardet, Wilfried
   Schafer, Fredda
   Mojsilovic, Danijela
   Cate, Steven
   Stewart, Christopher J.
   McMurtrey, Curtis
   Jackson, Kenneth W.
   Buchli, Rico
   Olvera, Alex
   Cedeno, Samandhy
   Plana, Montserrat
   Mothe, Beatriz
   Brander, Christian
   West, John T.
   Hildebrand, William H.
TI Direct Interrogation of Viral Peptides Presented by the Class I HLA of
   HIV-Infected T Cells
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIGHLY PATHOGENIC SIV; FLUORESCENCE
   POLARIZATION; SOLUBLE HLA-A-ASTERISK-0201; ANTIGEN PRESENTATION;
   EPITOPES; BINDING; IMMUNODOMINANCE; REPLICATION; LYMPHOCYTES
AB Identification of CD8(+) cytotoxic T lymphocyte (CTL) epitopes has traditionally relied upon testing of overlapping peptide libraries for their reactivity with T cells in vitro. Here, we pursued deep ligand sequencing (DLS) as an alternative method of directly identifying those ligands that are epitopes presented to CTLs by the class I human leukocyte antigens (HLA) of infected cells. Soluble class I HLA-A*11:01 (sHLA) was gathered from HIV-1 NL4-3-infected human CD4(+) SUP-T1 cells. HLA-A*11:01 harvested from infected cells was immunoaffinity purified and acid boiled to release heavy and light chains from peptide ligands that were then recovered by size-exclusion filtration. The ligands were first fractionated by high-pH high-pressure liquid chromatography and then subjected to separation by nano-liquid chromatography (nano-LC)-mass spectrometry (MS) at low pH. Approximately 10 million ions were selected for sequencing by tandem mass spectrometry (MS/MS). HLA-A*11:01 ligand sequences were determined with PEAKS software and confirmed by comparison to spectra generated from synthetic peptides. DLS identified 42 viral ligands presented by HLA-A*11:01, and 37 of these were previously undetected. These data demonstrate that (i) HIV-1 Gag and Nef are extensively sampled, (ii) ligand length variants are prevalent, particularly within Gag and Nef hot spots where ligand sequences overlap, (iii) noncanonical ligands are T cell reactive, and (iv) HIV-1 ligands are derived from de novo synthesis rather than endocytic sampling. Next-generation immunotherapies must factor these nascent HIV-1 ligand length variants and the finding that CTL-reactive epitopes may be absent during infection of CD4(+) T cells into strategies designed to enhance T cell immunity.
   IMPORTANCE
   HIV-1 epitopes catalogued by the Los Alamos National Laboratory (LANL) have yielded limited success in vaccine trials. Because the HLA of infected cells have not previously been assessed for HIV-1 ligands, the objective here was to directly characterize the viral ligands that mark infected cells. Recovery of HLA-presented peptides from HIV-1-infected CD4(+) T cells and interrogation of the peptide cargo by mass spectrometric DLS show that typical and atypical viral ligands are efficiently presented by HLA and targeted by human CTLs. Nef and Gag ligands dominate the infected cell's antigenic profile, largely due to extensive ligand sampling from select hot spots within these viral proteins. Also, HIV-1 ligands are often longer than expected, and these length variants are quite antigenic. These findings emphasize that an HLA-based view of HIV-1 ligand presentation to CTLs provides previously unrealized information that may enhance the development of immune therapies and vaccines.
C1 [Yaciuk, Jane C.; Skaley, Matthew; Bardet, Wilfried; Schafer, Fredda; Mojsilovic, Danijela; Cate, Steven; Stewart, Christopher J.; McMurtrey, Curtis; Jackson, Kenneth W.; West, John T.; Hildebrand, William H.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.
   [Buchli, Rico] Pure Prot LLC, Oklahoma City, OK USA.
   [Olvera, Alex; Cedeno, Samandhy; Mothe, Beatriz; Brander, Christian] Autonomous Univ Barcelona, Hosp Univ Germans Trias & Pujol, Fundacio irsiCaixa, Lab Retrovirol, Badalona, Spain.
   [Plana, Montserrat] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain.
   [Mothe, Beatriz; Brander, Christian] Univ Vic & Cent Catalonia, Vic, Spain.
   [Brander, Christian] ICREA, Barcelona, Spain.
RP Hildebrand, WH (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA.
EM William-Hildebrand@ouhsc.edu
OI Brander, Christian/0000-0002-0548-5778
FU NIAID HIV HIT-IT [5R01AI090672]; ICREA
FX This work was supported by funds from NIAID HIV HIT-IT 5R01AI090672 to
   W.H.H. and by postdoctoral travel support from the University of
   Oklahoma Health Sciences Center College of Medicine to J.C.Y.
CR Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005
   Buchli R, 2005, BIOCHEMISTRY-US, V44, P12491, DOI 10.1021/bi050255v
   Buchli R, 2004, BIOCHEMISTRY-US, V43, P14852, DOI 10.1021/bi048580q
   Buchli R, 2006, J IMMUNOL METHODS, V314, P38, DOI 10.1016/j.jim.2006.05.010
   Bunnik EM, 2010, VIROLOGY, V397, P224, DOI 10.1016/j.virol.2009.11.009
   Burrows SR, 2006, TRENDS IMMUNOL, V27, P11, DOI 10.1016/j.it.2005.11.001
   Chen HB, 2012, NAT IMMUNOL, V13, P691, DOI 10.1038/ni.2342
   Cohen Yehuda Z, 2013, Ther Adv Vaccines, V1, P99, DOI 10.1177/2051013613494535
   Crowe SR, 2003, J EXP MED, V198, P399, DOI 10.1084/jem.20022151
   Euler Z, 2010, J INFECT DIS, V201, P1045, DOI 10.1086/651144
   Frahm N, 2006, NAT IMMUNOL, V7, P173, DOI 10.1038/ni1281
   Fukazawa Y, 2012, NAT MED, V18, P1673, DOI 10.1038/nm.2934
   Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005
   Goulder PJR, 2000, J VIROL, V74, P5291, DOI 10.1128/JVI.74.11.5291-5299.2000
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   KAPLAN C, 1990, HUM HERED, V40, P290, DOI 10.1159/000153947
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746
   Kim S, 2014, EUR J IMMUNOL, V44, P1936, DOI 10.1002/eji.201444450
   KIMPTON J, 1992, J VIROL, V66, P2232
   Kloverpris HN, 2013, J VIROL, V87, P2628, DOI 10.1128/JVI.02131-12
   Koizumi H, 2010, J VIROL, V84, P5508, DOI 10.1128/JVI.02483-09
   Koning FA, 2004, AIDS, V18, P1117, DOI 10.1097/01.aids.0000125961.78387.f8
   Kulpa DA, 2013, J VIROL, V87, P8085, DOI 10.1128/JVI.00701-13
   Ladell K, 2013, IMMUNITY, V38, P425, DOI 10.1016/j.immuni.2012.11.021
   Li LN, 2005, IMMUNOGENETICS, V57, P315, DOI 10.1007/s00251-005-0801-7
   Liu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094240
   Llano A., 2013, HIV MOL IMMUNOLOGY 2, P3
   Mothe B, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-208
   Nguyen THO, 2008, PROTEIN EXPRES PURIF, V61, P22, DOI 10.1016/j.pep.2008.05.001
   Okoye AA, 2013, IMMUNOL REV, V254, P54, DOI 10.1111/imr.12066
   Raghavan S, 2009, AIDS RES HUM RETROV, V25, P1023, DOI 10.1089/aid.2009.0022
   Schiffner T, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-72
   Sriwanthana B, 2001, AIDS RES HUM RETROV, V17, P719, DOI 10.1089/088922201750236997                                                      
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   Wahl A, 2006, EXPERT REV PROTEOMIC, V3, P641, DOI 10.1586/14789450.3.6.641
NR 37
TC 13
Z9 13
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2014
VL 88
IS 22
BP 12992
EP 13004
DI 10.1128/JVI.01914-14
PG 13
WC Virology
SC Virology
GA AT3CG
UT WOS:000344812500006
PM 25165114
OA gold
DA 2018-01-05
ER

PT J
AU Glisoni, RJ
   Sosnik, A
AF Glisoni, Romina J.
   Sosnik, Alejandro
TI Novel Poly(Ethylene Oxide)-b-Poly(Propylene Oxide) Copolymer-Glucose
   Conjugate by the Microwave-Assisted Ring Opening of a Sugar Lactone
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE darunavir free base; gluconolactone; Glucosylated poly(ethylene
   oxide)-b-poly(propylene oxide) block copolymers; microwave-assisted ring
   opening conjugation; polymeric micelles
ID DRUG-DELIVERY SYSTEMS; TRACKING ANALYSIS NTA; POLYMERIC MICELLES;
   BLOCK-COPOLYMERS; MANNOSE RECEPTOR; MULTIDRUG-RESISTANCE; HIV
   PHARMACOTHERAPY; POLOXAMINE MICELLES; MACROPHAGES; NANOPARTICLES
AB In this work, we investigated for the first time the conjugation of gluconolactone to a poly(ethylene oxide)-poly(propylene oxide) block copolymer by a microwave-assisted ring opening reaction. The glucosylated copolymer was obtained with high yield (90%). A conjugation extent of approximately 100% was achieved within 15 min. The modification reduced the critical micellar concentration and increased the size of the micelles. The agglutination of the modified polymeric micelles by a soluble lectin that binds glucose confirmed the recognizability of the modified nanocarrier. Finally, the solubilization of darunavir, an anti-HIV protease inhibitor, showed a sharp increase of the aqueous solubility from 91 microgram/mL to 14.2 and 18.9 mg/mL for 10% w/v pristine and glucosylated polymeric micelles, respectively.
C1 [Glisoni, Romina J.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1113 Buenos Aires, DF, Argentina.
   [Glisoni, Romina J.] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, Grp Pharmaceut Nanomat Sci, IL-32000 Haifa, Israel.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, IL-32000 Haifa, Israel.
RP Sosnik, A (reprint author), Technion Israel Inst Technol, Dept Mat Sci & Engn, Grp Pharmaceut Nanomat Sci, IL-32000 Haifa, Israel.
EM alesosnik@gmail.com
RI Sosnik, Alejandro/O-7059-2014
OI Sosnik, Alejandro/0000-0003-4704-4599
FU CONICET [PIP0220]; European Union [612675-MC-NANOTAR]
FX RJG is staff member of CONICET. The work was supported by grant of
   CONICET (PIP0220). The authors are very thankful to Dr. Omar Sued
   (Fundacion Huesped, Buenos Aires, Argentina) for valuable discussions
   and inputs on the clinical challenges faced in HIV. We also thank Prof.
   Dr. Carmen Alvarez-Lorenzo (Department of Pharmacy and Pharmaceutical
   Technology, Universidad de Santiago de Compostela, Spain), Prof. Dr.
   Viviana Campo Campo Dall'Orto (Department of Analytical Chemistry,
   Faculty of Pharmacy and Biochemistry, University of Buenos Aires,
   Argentina) and Dr. Ellie Lanning and Joanna Sullivan (NanoSight (R)
   Ltd.) for DSC and MALDI-TOF, ATR/FT-IR and NTA analyses, respectively.
   AS thanks the European Union's - Seventh Framework Programme under grant
   agreement #612675-MC-NANOTAR.
CR Ahire JH, 2013, ACS APPL MATER INTER, V5, P7384, DOI 10.1021/am4017126
   Alvarez-Lorenzo C, 2011, CURR DRUG TARGETS, V12, P1112, DOI 10.2174/138945011795906615                                                      
   Alvarez-Lorenzo C, 2010, NANOMEDICINE-UK, V5, P1371, DOI [10.2217/nnm.10.53, 10.2217/NNM.10.53]
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Becer CR, 2012, MACROMOL RAPID COMM, V33, P742, DOI 10.1002/marc.201200055
   Bierenstiel M, 2004, EUR J ORG CHEM, P1474, DOI 10.1002/ejoc.200300761
   Bordege V, 2011, J POLYM SCI POL CHEM, V49, P526, DOI 10.1002/pola.24467
   Bromberg L, 2008, J CONTROL RELEASE, V128, P99, DOI 10.1016/j.jconrel.2008.01.018
   Burgdorf S, 2006, J IMMUNOL, V176, P6770, DOI 10.4049/jimmunol.176.11.6770                                                    
   Carvalho KC, 2011, CLINICS, V66, P965, DOI 10.1590/S1807-59322011000600008
   Chappuis F., 2007, NAT REV MICROBIOL, pS7, DOI DOI 10.1038/NRMICRO1748
   Chiappetta DA, 2008, EUR J PHARM BIOPHARM, V69, P535, DOI 10.1016/j.ejpb.2007.11.021
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Cohn D, 2006, BIOMATERIALS, V27, P1718, DOI 10.1016/j.biomaterials.2005.10.035
   Cohn D, 2003, J MATER SCI-MATER M, V14, P175, DOI 10.1023/A:1022080115804
   Cuestas ML, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-012-1389-0
   Cuestas ML, 2012, BIOORG MED CHEM LETT, V22, P6577, DOI 10.1016/j.bmcl.2012.09.012
   Cuestas ML, 2011, MOL PHARMACEUT, V8, P1152, DOI 10.1021/mp2000132
   Cuestas ML, 2010, PHARM RES-DORDR, V27, P1184, DOI 10.1007/s11095-010-0112-z
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Fan H, 2012, J MEMBRANE SCI, V415, P161, DOI 10.1016/j.memsci.2012.04.047
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001
   Vior MCG, 2013, PHOTOCHEM PHOTOBIOL, V89, P492, DOI 10.1111/j.1751-1097.2012.01229.x
   Gaucher G, 2010, EUR J PHARM BIOPHARM, V76, P147, DOI 10.1016/j.ejpb.2010.06.007
   Glisoni RJ, 2014, J NANOSCI NANOTECHNO, V14, P4670, DOI 10.1166/jnn.2014.8647
   Glisoni RJ, 2012, PHARM RES-DORDR, V29, P739, DOI 10.1007/s11095-011-0599-y
   GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   Gotelli GA, 2011, J APPL POLYM SCI, V121, P1321, DOI 10.1002/app.33664
   Han YP, 2005, INT IMMUNOPHARMACOL, V5, P1533, DOI 10.1016/j.intimp.2005.04.015
   Hole P, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2101-8
   Hu MX, 2011, COLLOID SURFACE B, V85, P19, DOI [10.1016/j.colsurfb.2010.10.030, 10.1016/j.colsurfb2010.10.030]
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Jain NK, 2013, EXPERT OPIN DRUG DEL, V10, P353, DOI 10.1517/17425247.2013.751370
   Janeway CA, 2001, IMMUNOBIOLOGY IMMUNE
   Jiang HL, 2008, BIOMATERIALS, V29, P1931, DOI 10.1016/j.biomaterials.2007.12.025
   Kakuda TN, 2014, CLIN PHARM DRUG DEV, V3, P346, DOI 10.1002/cpdd.88
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1                                                   
   Kerrigan AM, 2009, IMMUNOBIOLOGY, V214, P562, DOI 10.1016/j.imbio.2008.11.003
   Kim SH, 2001, J BIOL CHEM, V276, P35312, DOI 10.1074/jbc.M009749200                                                          
   KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903
   Lee RT, 2011, GLYCOBIOLOGY, V21, P512, DOI 10.1093/glycob/cwq193
   Li XR, 2009, J DRUG TARGET, V17, P739, DOI 10.3109/10611860903062062
   Lu CH, 2006, BIOMACROMOLECULES, V7, P1806, DOI 10.1021/bm0601225
   Mahida YR, 2000, INFLAMM BOWEL DIS, V6, P21, DOI 10.1097/00054725-200002000-00004                                                
   Moretton MA, 2013, J BIOMED NANOTECHNOL, V9, P1076, DOI 10.1166/jbn.2013.1600
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Raith K, 2006, INT J PHARM, V319, P1, DOI 10.1016/j.ijpharm.2006.03.030
   Ribeiro A, 2012, J R SOC INTERFACE, V9, P2059, DOI 10.1098/rsif.2012.0102
   Sheikh H, 2000, J CELL SCI, V113, P1021
   Sosnik A, 2003, J BIOMAT SCI-POLYM E, V14, P227, DOI 10.1163/156856203763572680
   Sosnik A., 2008, BIOMED ENG, V1, P43
   Sosnik A, 2014, ADV DRUG DELIVER REV, V73, P140, DOI 10.1016/j.addr.2014.05.004
   Sosnik A, 2013, RSC SMART MATER, P115, DOI 10.1039/9781849736800-00115
   Sosnik A, 2013, ADV DRUG DELIVER REV, V65, P1828, DOI 10.1016/j.addr.2013.09.002
   Sosnik A, 2011, PROG POLYM SCI, V36, P1050, DOI 10.1016/j.progpolymsci.2010.12.001
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Takats Z, 2001, RAPID COMMUN MASS SP, V15, P805, DOI 10.1002/rcm.295                                                                 
   Tang M, 2009, CHEM COMMUN, P941, DOI 10.1039/b817658b
   Wang X, 2009, J MATER CHEM, V19, P8944, DOI 10.1039/b917900c
   Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301                                             
   Xiong XB, 2012, ACTA BIOMATER, V8, P2017, DOI 10.1016/j.actbio.2012.03.006
   Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x
   Zhang C, 2005, J APPL POLYM SCI, V97, P2161, DOI 10.1002/app.21975
   [Anonymous], 2013, CONSOLIDATED GUIDELI
NR 74
TC 8
Z9 8
U1 0
U2 19
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-5187
EI 1616-5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD NOV
PY 2014
VL 14
IS 11
BP 1639
EP 1651
DI 10.1002/mabi.201400235
PG 13
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA AT2FT
UT WOS:000344749200014
PM 25159124
DA 2018-01-05
ER

PT J
AU Lee, JH
   El-Said, WA
   Oh, BK
   Choi, JW
AF Lee, Jin-Ho
   El-Said, Waleed Ahmed
   Oh, Byung-Keun
   Choi, Jeong-Woo
TI Enzyme-Free Glucose Sensor Based on Au Nanobouquet Fabricated Indium Tin
   Oxide Electrode
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Enzyme Free; Glucose; Nano-Pattern; Electrochemical Sensor; Nanobouquet
ID CARBON NANOTUBES; GOLD NANOPARTICLES; SINGLE-CRYSTAL; FILM ELECTRODE;
   BIOSENSORS; PLATINUM; OXIDATION; TEMPLATE; HIV-1
AB In this study, we demonstrated a simple, rapid and inexpensive fabrication method to develop a novel gold nanobouquet structure fabricated indium tin oxide (GNB/ITO) electrode based on electrochemical deposition of gold ions onto ITO substrate. The morphology of the fabricated electrode surface was characterized by scanning electron microscopy (SEM) to confirm the GNB formation. Enzyme-free detection of glucose using a GNB/ITO electrode was described with high sensitivity and selectivity based on cyclic voltammetry assay. The results demonstrate a linear relation within wide concentration range (500 nM to 10 mM) of glucose, with a correlation coefficient of 0.988. The interference effect of uric acid was effectively avoided for the detection of glucose (1 mu M to 10 mM). Moreover, the developed sensor was applied to determine the concentration of glucose in the presence of human serum to indicate the ability of GNB/ITO electrodes in real samples. Hence, newly developed GNB/ITO electrode has potential application in enzyme-free glucose sensor with highly sensitivity and selectivity.
C1 [Lee, Jin-Ho; Oh, Byung-Keun; Choi, Jeong-Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
   [Lee, Jin-Ho] Sogang Univ, Res Inst Basic Sci, Seoul 121742, South Korea.
   [El-Said, Waleed Ahmed; Oh, Byung-Keun; Choi, Jeong-Woo] Sogang Univ, Interdisciplinary Program Integrated Biotechnol, Seoul 121742, South Korea.
RP Choi, JW (reprint author), Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeom Ro, Seoul 121742, South Korea.
RI El-Said, Waleed/A-5749-2013
OI El-Said, Waleed/0000-0002-7052-7612
FU Leading Foreign Research Institute Recruitment Program through the
   National Research Foundation of Korea(NRF) - Ministry of Science, ICT
   and Future Planning(MSIP) [2013K1A4A3055268]; National Research
   Foundation of Korea (NRF) - Korea government (MEST) [2009-0080860];
   Sogang University [SRF-201314003.01]
FX This work was supported by the Leading Foreign Research Institute
   Recruitment Program through the National Research Foundation of
   Korea(NRF) funded by the Ministry of Science, ICT and Future
   Planning(MSIP) (2013K1A4A3055268), by a National Research Foundation of
   Korea (NRF) grant funded by the Korea government (MEST) (2009-0080860)
   and by the Sogang University Research Grant of 2013 (SRF-201314003.01).
CR Bai Y, 2008, SENSOR ACTUAT B-CHEM, V134, P471, DOI 10.1016/j.snb.2008.05.028
   Bai Y, 2008, BIOSENS BIOELECTRON, V24, P579, DOI 10.1016/j.bios.2008.06.003
   Chae EJ, 2013, J BIOMED NANOTECHNOL, V9, P659, DOI 10.1166/jbn.2013.1540
   Chen J, 2008, ELECTROCHEM COMMUN, V10, P1268, DOI 10.1016/j.elecom.2008.06.022
   Cui HF, 2007, ANAL CHIM ACTA, V594, P175, DOI 10.1016/j.aca.2007.05.047
   Das J, 2009, J PHYS CHEM C, V113, P6093, DOI 10.1021/jp809850f
   Deng CY, 2008, BIOSENS BIOELECTRON, V23, P1272, DOI 10.1016/j.bios.2007.11.009
   HSIAO MW, 1992, ELECTROCHIM ACTA, V37, P357, DOI 10.1016/0013-4686(92)85024-F                                                    
   Hsiao MW, 1996, J ELECTROCHEM SOC, V143, P759, DOI 10.1149/1.1836536                                                               
   Jena BK, 2006, CHEM-EUR J, V12, P2702, DOI 10.1002/chem.200501051
   Jia Z, 2007, ELECTROCHEM COMMUN, V9, P2739, DOI 10.1016/j.elecom.2007.09.008
   Juaristi E., 1995, ANOMERIC EFFECT
   Kang XH, 2007, ANAL BIOCHEM, V363, P143, DOI 10.1016/j.ab.2007.01.003
   KATAKIS I, 1995, TRAC-TREND ANAL CHEM, V14, P310, DOI 10.1016/0165-9936(95)97058-9                                                    
   Lee JH, 2013, NANOMED-NANOTECHNOL, V9, P1018, DOI 10.1016/j.nano.2013.03.005
   Lee JH, 2013, BIOSENS BIOELECTRON, V49, P531, DOI 10.1016/j.bios.2013.06.010
   Li LH, 2008, ELECTROANAL, V20, P2212, DOI 10.1002/elan.200804312
   Newman JD, 2005, BIOSENS BIOELECTRON, V20, P2435, DOI 10.1016/j.bios.2004.11.012
   Park S, 2006, ANAL CHIM ACTA, V556, P46, DOI 10.1016/j.aca.2005.05.080
   Park S, 2003, ANAL CHEM, V75, P3046, DOI 10.1021/ac0263465
   Rong LQ, 2007, TALANTA, V72, P819, DOI 10.1016/j.talanta.2006.12.037
   Shoji E, 2001, J AM CHEM SOC, V123, P3383, DOI 10.1021/ja005906j
   Soleymani L, 2009, NAT NANOTECHNOL, V4, P844, DOI [10.1038/nnano.2009.276, 10.1038/NNANO.2009.276]
   Song YY, 2005, CHEM-EUR J, V11, P2177, DOI 10.1002/chem.200400981
   Sun YP, 2001, ANAL CHEM, V73, P1599, DOI 10.1021/ac0015117
   Tan CK, 2008, ANALYST, V133, P448, DOI 10.1039/b719914g
   Wang J, 2008, CHEM REV, V108, P814, DOI 10.1021/cr068123a
   Wilson GS, 2005, BIOSENS BIOELECTRON, V20, P2388, DOI 10.1016/j.bios.2004.12.003
   WILSON R, 1992, BIOSENS BIOELECTRON, V7, P165, DOI 10.1016/0956-5663(92)87013-F
   Xu Q, 2006, SENSOR ACTUAT B-CHEM, V114, P379, DOI 10.1016/j.snb.2005.06.005
   Ye JS, 2004, ELECTROCHEM COMMUN, V6, P66, DOI 10.1016/j.elecom.2003.10.013
   You TY, 2003, ANAL CHEM, V75, P5191, DOI 10.1021/ac034204k
   Yuan JH, 2005, ADV FUNCT MATER, V15, P803, DOI 10.1002/adfm.200400321
NR 33
TC 3
Z9 3
U1 0
U2 15
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD NOV
PY 2014
VL 14
IS 11
BP 8432
EP 8438
DI 10.1166/jnn.2014.9921
PG 7
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AS2RE
UT WOS:000344126500057
PM 25958541
DA 2018-01-05
ER

PT J
AU Gendelman, HE
   Gelbard, HA
AF Gendelman, Howard E.
   Gelbard, Harris A.
TI Adjunctive and long-acting nanoformulated antiretroviral therapies for
   HIV-associated neurocognitive disorders
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE HIV-associated neurocognitive disorders; mixed lineage kinase;
   nanoformulated antiretroviral therapy; neuroinflammation
ID MIXED-LINEAGE KINASE; ISCHEMIC BRAIN-INJURY; HAIR CELL-DEATH; INHIBITOR
   CEP-1347; CEREBRAL-ISCHEMIA; NEURONAL APOPTOSIS; PARKINSONS-DISEASE;
   THERAPEUTIC TARGET; SIGNALING CASCADES; RAT HIPPOCAMPUS
AB Purpose of review
   We are pleased to review current and future strategies being developed to modulate neuroinflammation while reducing residual viral burden in the central nervous system. This has been realized by targeted long-acting antiretroviral nano and adjunctive therapies being developed for HIV-infected people. Our ultimate goal is to eliminate virus from its central nervous system reservoirs and, in so doing, reverse the cognitive and motor dysfunctions.
   Recent findings
   Herein, we highlight our laboratories' development of adjunctive and nanomedicine therapies for HIV-associated neurocognitive disorders. An emphasis is placed on drug-drug interactions that target both the viral life cycle and secretory proinflammatory neurotoxic factors and signaling pathways.
   Summary
   Antiretroviral therapy has improved the quality and duration of life for people living with HIV-1. A significant long-term comorbid illness is HIV-associated neurocognitive disorders. Symptoms, although reduced in severity, are common. Disease occurs, in part, through continued low-level viral replication, inducing secondary glial neuroinflammatory activities. Our recent works and those of others have seen disease attenuated in animal models through the use of adjunctive and long-acting reservoir-targeted nanoformulated antiretroviral therapy. The translation of these inventions from animals to humans is the focus of this review.
C1 [Gendelman, Howard E.] Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
   [Gelbard, Harris A.] Univ Rochester Med Ctr, Sch Med & Dent, Ctr Neural Dev & Dis, Dept Neurol, Rochester, NY USA.
RP Gendelman, HE (reprint author), Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU University of Nebraska Foundation; Vice Chancellor's office of the
   University of Nebraska Medical Center; ViiV Healthcare; National
   Institutes of Health [P01 MH64570, RO1 MH104147, P01 DA028555, R01
   NS36126, P01 NS31492, 2R01 NS034239, P01 NS43985, P30 MH062261, R01
   AG043540]
FX The authors thank Robin Taylor and JoEllyn McMillan for critical reading
   of the manuscript and helpful suggestions provided. This work was
   supported by the University of Nebraska Foundation, which includes
   individual donations from Dr Carol Swarts and Frances and Louie Blumkin;
   the Vice Chancellor's office of the University of Nebraska Medical
   Center; ViiV Healthcare; and National Institutes of Health grants P01
   MH64570 and RO1 MH104147 (HAG) and P01 DA028555, R01 NS36126, P01
   NS31492, 2R01 NS034239, P01 NS43985, P30 MH062261, and R01 AG043540
   (HEG).
CR Barber SA, 2004, AM J PATHOL, V164, P355, DOI 10.1016/S0002-9440(10)63125-2
   Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281                                                      
   Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200
   Blackstone K, 2012, J INT NEUROPSYCH SOC, V18, P79, DOI 10.1017/S135561771100141X
   Bodner A, 2004, EXP NEUROL, V188, P246, DOI 10.1016/j.expneurol.2004.04.009
   Bodner A, 2002, J NEUROCHEM, V82, P1424, DOI 10.1046/j.1471-4159.2002.01088.x
   Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005
   Caniglia EC, 2014, NEUROLOGY, V83, P134, DOI 10.1212/WNL.0000000000000564
   Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103
   Dewhurst S, 2007, J NEUROIMMUNE PHARM, V2, P93, DOI 10.1007/s11481-006-9051-1
   Dou HY, 2005, J NEUROSCI, V25, P8375, DOI 10.1523/JNEUROSCI.2164-05.2005
   Eggert D, 2010, J IMMUNOL, V184, P746, DOI 10.4049/jimmunol.0902962
   Ellis RJ, 2014, CLIN INFECT DIS, V58, P1015, DOI 10.1093/cid/cit921
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Falsig J, 2004, J IMMUNOL, V173, P2762, DOI 10.4049/jimmunol.173.4.2762                                                     
   Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906
   Gelbard HA, 2010, NEUROTHERAPEUTICS, V7, P392, DOI 10.1016/j.nurt.2010.08.001
   Goodfellow VS, 2013, J MED CHEM, V56, P8032, DOI 10.1021/jm401094t
   Handley ME, 2007, INT IMMUNOL, V19, P923, DOI 10.1093/intimm/dxm050
   Handley ME, 2007, INT J EXP PATHOL, V88, P111, DOI 10.1111/j.1365-2613.2007.00531.x
   Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727
   Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000
   Hu WW, 2008, HIPPOCAMPUS, V18, P386, DOI 10.1002/hipo.20402
   Jaeschke A, 2007, MOL CELL, V27, P498, DOI 10.1016/j.molcel.2007.07.008
   Johnson GVW, 2003, EXP NEUROL, V183, P263, DOI 10.1016/S0014-4886(03)00268-1
   Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408                                                        
   Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200
   Liao SY, 2007, J MOL CELL CARDIOL, V42, P106, DOI 10.1016/j.yjmcc.2006.10.005
   Lotharius J, 2005, J NEUROSCI, V25, P6329, DOI 10.1523/JNEUROSCI.1746-05.2005
   Lund S, 2005, J NEUROCHEM, V92, P1439, DOI 10.1111/j.1471-4159.2005.03014.x
   Marker DF, 2013, J NEUROSCI, V33, P9998, DOI 10.1523/JNEUROSCI.0598-13.2013
   Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200
   Mathiasen JR, 2004, BRAIN RES, V1003, P86, DOI 10.1016/j.brainres.2003.11.073
   Mishra R, 2007, J BIOL CHEM, V282, P30393, DOI 10.1074/jbc.M705895200
   Morley D, 2013, HIV MED, V14, P497, DOI 10.1111/hiv.12036
   Mota M, 2001, J NEUROSCI, V21, P4949
   New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852                                                        
   Pirvola U, 2000, J NEUROSCI, V20, P43
   Roux PP, 2002, J BIOL CHEM, V277, P49473, DOI 10.1074/jbc.M203428200
   Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421
   Saporito MS, 2002, PROGR MED CHEM, V40, P23, DOI 10.1016/S0079-6468(08)70081-X
   Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7
   Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200
   Schwid S, 2004, NEUROLOGY, V62, P330
   Shoulson I, 2007, NEUROLOGY, V69, P1480
   Silva RM, 2005, MOVEMENT DISORD, V20, P653, DOI 10.1002/mds.20390
   Sugahara K, 2006, HEARING RES, V221, P128, DOI 10.1016/j.heares.2006.08.009
   Sui Z, 2006, J IMMUNOL, V177, P702, DOI 10.4049/jimmunol.177.1.702                                                      
   Tan IL, 2012, CNS DRUGS, V26, P123, DOI 10.2165/11597770-000000000-00000
   Tian H, 2005, BRAIN RES, V1061, P57, DOI 10.1016/j.brainres.2005.09.001
   Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x
   Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840                                       
   Wu SS, 2005, CNS DRUGS, V19, P723, DOI 10.2165/00023210-200519090-00001
   Yin XH, 2005, J NEUROCHEM, V93, P1021, DOI 10.1111/j.1471-4159.2005.03096.x
   Ylikoski J, 2002, HEARING RES, V166, P33, DOI 10.1016/S0378-5955(01)00388-4
   Zhang G, 2014, C RETR OPP INF 3 6 M
   Zhang QG, 2005, J NEUROCHEM, V95, P784, DOI 10.1111/j.1471-4159.2005.03435.x
   Zhang QX, 2007, BIOCHEMISTRY-US, V46, P4006, DOI 10.1021/bi0615386
   Zhang QG, 2006, J NEUROCHEM, V98, P1886, DOI 10.1111/j.1471-4159.2006.04020.x
NR 59
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD NOV
PY 2014
VL 9
IS 6
BP 585
EP 590
DI 10.1097/COH.0000000000000111
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AR0XR
UT WOS:000343298800013
PM 25226025
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hassounah, IA
   Shehata, NA
   Kimsawatde, GC
   Hudson, AG
   Sriranganathan, N
   Joseph, EG
   Mahajan, RL
AF Hassounah, Ibrahim Anwar
   Shehata, Nader Abdelmonem
   Kimsawatde, Gade Carolyn
   Hudson, Amanda Gayle
   Sriranganathan, Nammalwar
   Joseph, Eugene Gregory
   Mahajan, Roop L.
TI Studying the activity of antitubercluosis drugs inside electrospun
   polyvinyl alcohol, polyethylene oxide, and polycaprolacton nanofibers
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE drug delivery; tuberculosis; nanofibers; electrospinning
ID TUBERCULOSIS; DEGRADATION; HYDROGELS
AB The activity of antituberculosis drugs (streptomycin sulfate, isoniazid, pyrazinamid, and clarithromycin) embedded in biodegradable nanofibers against Mycobacterium avium has been studied by broth dilution assay and by agar plate assay. These drugs have also been embedded in electrospun polyvinyl alcohol (PVA), polyethylene oxide (PEO), and polycaprolacton (PCL) nanofibers to design a new single tablet containing first-line antituberculosis drugs. Our results show that antituberculosis drugs are active at tiny amounts (up to 300 mg mL(-1) of solvent). However, within polymer matrices, high amounts of drugs are required to avoid unwanted weak interactions within PEO and PCL matrices. The successful design of a single tablet containing required amounts of antituberculosis drugs is essential for the full treatment of tuberculosis in patients with HIV. (C) 2014 Wiley Periodicals, Inc.
C1 [Hassounah, Ibrahim Anwar; Joseph, Eugene Gregory; Mahajan, Roop L.] Virginia Polytech Inst & State Univ, Inst Crit Technol & Appl Sci ICTAS, Blacksburg, VA 24061 USA.
   [Shehata, Nader Abdelmonem] Virginia Polytech Inst & State Univ, Bradley Dept Elect & Comp Engn ECE, Blacksburg, VA 24061 USA.
   [Shehata, Nader Abdelmonem] Univ Alexandria, Fac Engn, Dept Engn Math & Phys, Alexandria 21526, Egypt.
   [Kimsawatde, Gade Carolyn; Sriranganathan, Nammalwar] Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol DBSP, Blacksburg, VA 24061 USA.
   [Hudson, Amanda Gayle] Virginia Polytech Inst & State Univ, Dept Chem, Blacksburg, VA 24061 USA.
   [Sriranganathan, Nammalwar] Virginia Polytech Inst & State Univ, Ctr Mol Med & Infect Dis CMMID, Blacksburg, VA 24061 USA.
   [Joseph, Eugene Gregory] Virginia Polytech Inst & State Univ, Nanoscale Characterizat & Fabricat Lab NCFL, Blacksburg, VA 24061 USA.
RP Hassounah, IA (reprint author), Virginia Polytech Inst & State Univ, Inst Crit Technol & Appl Sci ICTAS, Blacksburg, VA 24061 USA.
EM Ibrahim.hassounah@usu.edu
OI Shehata, Nader/0000-0002-2913-4825
FU ICTAS; CMMID; Bradley Department of Electrical and Computer Engineering
   at Virginia Tech; Virginia Tech Middle East and North Africa (VT-MENA)
   program in Egypt
FX Contract grant sponsors: ICTAS, CMMID, Bradley Department of Electrical
   and Computer Engineering at Virginia Tech, and The Virginia Tech Middle
   East and North Africa (VT-MENA) program in Egypt
CR Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5                                                        
   Beggs CB, 2003, INT J TUBERC LUNG D, V7, P1015
   Brighenti S, 2012, MYCOBACTERIUM TUBERC, P208
   Dartois V, 2010, CURR CLIN PHARMACOL, V5, P96, DOI 10.2174/157488410791110797
   Dias HM, 2012, GLOBAL TUBERCULOSIS
   Dlamini BS, 2012, SWAZILAND COUNTRY RE
   Dye C, 2007, WHO REPORT 2007 GLOB
   Elisseeff JH, 2003, INJECTABLE HYDROGELS, P1
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Gibas I, 2010, CHEM CHEM TECHOL, V4, P297
   HEIFETS L, 1988, ANTIMICROB AGENTS CH, V32, P1131, DOI 10.1128/AAC.32.8.1131                                                           
   Hodge JG, 2009, TUBERCULOSIS CONTROL
   Kaufmann SHE, 2008, CELL HOST MICROBE, V4, P219, DOI 10.1016/j.chom.2008.08.002
   Koul A, 2007, NAT CHEM BIOL, V3, P323, DOI 10.1038/nchembio884
   Levison ME, 2004, INFECT DIS CLIN N AM, V18, P451, DOI 10.1016/j.idc.2004.04.012
   Martens PJ, 2003, BIOMACROMOLECULES, V4, P283, DOI 10.1021/bm025666v
   Merrett K, 2002, J BIOMAT SCI-POLYM E, V13, P593, DOI 10.1163/156856202320269111                                                      
   Motiwalla MJ, 2012, J ENVIRON BIOL, V34, P43
   Noeske J., 2012, TUBERCULOSIS CONTROL, P433
   Rawat BS, 2013, MED RES REV, V33, P693
   Reed CR, 2009, ANN PLAS SURG, V62, P505, DOI 10.1097/SAP.0b013e31818e48bf
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Strekowski L, 1991, J MED CHEM, V34, P1740
   Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066
   Swendiman KS, 2007, EXTENSIVELY DRUG RES
   Umesiri FE, 2010, MED RES REV, V30, P290, DOI 10.1002/med.20190
   Varaine F, 2013, TUBERCULSOSIS PRACTI
   Wei AF, 2010, J APPL POLYM SCI, V118, P346, DOI 10.1002/app.32363
   Whiteside A, 2003, WHAT IS DRIVING HIV
   Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521
   Bang JJ, 2011, US Patent, Patent No. [8,083,347 B2, 8083347]
NR 31
TC 2
Z9 2
U1 4
U2 29
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2014
VL 102
IS 11
BP 4009
EP 4016
DI 10.1002/jbm.a.35070
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AQ7PC
UT WOS:000343010100024
PM 24376010
DA 2018-01-05
ER

PT J
AU Al Ahmad, M
   Mustafa, F
   Ali, LM
   Rizvi, TA
AF Al Ahmad, Mahmoud
   Mustafa, Farah
   Ali, Lizna M.
   Rizvi, Tahir A.
TI Virus detection and quantification using electrical parameters
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ASSAY; VIROLOGY; PCR
AB Here we identify and quantitate two similar viruses, human and feline immunodeficiency viruses (HIV and FIV), suspended in a liquid medium without labeling, using a semiconductor technique. The virus count was estimated by calculating the impurities inside a defined volume by observing the change in electrical parameters. Empirically, the virus count was similar to the absolute value of the ratio of the change of the virus suspension dopant concentration relative to the mock dopant over the change in virus suspension Debye volume relative to mock Debye volume. The virus type was identified by constructing a concentration-mobility relationship which is unique for each kind of virus, allowing for a fast (within minutes) and label-free virus quantification and identification. For validation, the HIV and FIV virus preparations were further quantified by a biochemical technique and the results obtained by both approaches corroborated well. We further demonstrate that the electrical technique could be applied to accurately measure and characterize silica nanoparticles that resemble the virus particles in size. Based on these results, we anticipate our present approach to be a starting point towards establishing the foundation for label-free electrical-based identification and quantification of an unlimited number of viruses and other nano-sized particles.
C1 [Al Ahmad, Mahmoud] United Arab Emirates Univ, Coll Engn, Dept Elect Engn, Al Ain, U Arab Emirates.
   [Mustafa, Farah] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates.
   [Ali, Lizna M.; Rizvi, Tahir A.] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Microbiol & Immunol, Al Ain, U Arab Emirates.
RP Al Ahmad, M (reprint author), United Arab Emirates Univ, Coll Engn, Dept Elect Engn, Al Ain, U Arab Emirates.
EM m.alahmad@uaeu.ac.ae; fmustafa@uaeu.ac.ae
FU UAE National Research Foundation; Ministry of Higher Education and
   Research
FX This work was supported by funds from the UAE National Research
   Foundation and the Ministry of Higher Education and Research.
CR Baas C, 2013, EUROSURVEILLANCE, V18, P19
   Browning MT, 2001, J VIROL, V75, P5129, DOI 10.1128/JVI.75.11.5129-5140.2001
   COFFIN JM, 1997, RETROVIRUSES
   Cotton MH, 2014, TROP DOCT, V44, P1, DOI 10.1177/0049475513514926
   Dobrovolskaia E, 2006, CLIN EXP ALLERGY, V36, P525, DOI 10.1111/j.1365-2222.2006.02466.x
   Dong H., 2012, J VIROL, V9, P1, DOI DOI 10.1186/1743-422X-9-180
   Elnifro EM, 2000, CLIN MICROBIOL REV, V13, P559, DOI 10.1128/CMR.13.4.559-570.2000
   Faye O., 2013, VIROL J, V10, P1
   Fukushima K, 2011, BIOL PHARM BULL, V34, P996, DOI 10.1248/bpb.34.996                                                              
   Gan S., 2013, J INVEST DERMATOL, V133, P1
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Lodish H., 2000, MOL CELL BIOL
   Mackay IM, 2002, NUCLEIC ACIDS RES, V30, P1292, DOI 10.1093/nar/30.6.1292                                                           
   Mariani M, 1998, CLIN DIAGN LAB IMMUN, V5, P667
   Michen B, 2010, J APPL MICROBIOL, V109, P388, DOI 10.1111/j.1365-2672.2010.04663.x
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Pereira Carla, 2007, V407, P177, DOI 10.1007/978-1-59745-536-7_14
   Rizvi TA, 2010, J MOL BIOL, V403, P103, DOI 10.1016/j.jmb.2010.08.019
   Roingeard P, 2008, BIOL CELL, V100, P491, DOI 10.1042/BC20070173
   Sze S.M., 2007, PHYS SEMICONDUCTOR D
   Uetrecht C, 2011, NAT CHEM, V3, P126, DOI 10.1038/NCHEM.947
   Vermeire J., 2012, PLOS ONE, V7, P1
NR 23
TC 1
Z9 1
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 30
PY 2014
VL 4
AR 6831
DI 10.1038/srep06831
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0RW
UT WOS:000343986400002
PM 25355078
OA gold
DA 2018-01-05
ER

PT J
AU Blum, AP
   Kammeyer, JK
   Yin, J
   Crystal, DT
   Rush, AM
   Gilson, MK
   Gianneschi, NC
AF Blum, Angela P.
   Kammeyer, Jacquelin K.
   Yin, Jian
   Crystal, Dustin T.
   Rush, Anthony M.
   Gilson, Michael K.
   Gianneschi, Nathan C.
TI Peptides Displayed as High Density Brush Polymers Resist Proteolysis and
   Retain Bioactivity
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID CELL-PENETRATING PEPTIDES; OLEFIN METATHESIS CATALYSTS;
   NUCLEAR-LOCALIZATION SIGNALS; HUMAN IMMUNODEFICIENCY VIRUS;
   EPIDERMAL-GROWTH-FACTOR; ARGININE-RICH PEPTIDES; MICELLAR NANOPARTICLES;
   GENE DELIVERY; AMINO-ACIDS; SOMATOSTATIN ANALOGS
AB We describe a strategy for rendering peptides resistant to proteolysis by formulating them as high-density brush polymers. The utility of this approach is demonstrated by polymerizing well-established cell-penetrating peptides (CPPs) and showing that the resulting polymers are not only resistant to proteolysis but also maintain their ability to enter cells. The scope of this design concept is explored by studying the proteolytic resistance of brush polymers composed of peptides that are substrates for either thrombin or a metalloprotease. Finally, we demonstrate that the proteolytic susceptibility of peptide brush polymers can be tuned by adjusting the density of the polymer brush and offer in silico models to rationalize this finding. We contend that this strategy offers a plausible method of preparing peptides for in vivo use, where rapid digestion by proteases has traditionally restricted their utility.
C1 [Blum, Angela P.; Kammeyer, Jacquelin K.; Crystal, Dustin T.; Rush, Anthony M.; Gianneschi, Nathan C.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Yin, Jian; Gilson, Michael K.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
RP Gianneschi, NC (reprint author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
EM ngianneschi@ucsd.edu
RI Gianneschi, Nathan/P-6048-2017
FU AFOSR through PECASE [FA9550-11-1-0105]; BRI grant [FA99550-12-1-0414];
   NIH [1DP2OD008724]; NIH through NIBIB [1R01EB011633]; ARO
   [W911NF-14-1-0169]; American Cancer Society - North Texans Creating
   Tomorrow's Miracles Postdoctoral Fellowship; CRIN program, UCSD; UCSD
   Light Microscopy Facility (P30 Grant) [NS047101];  [NHLBI R01HL117326]
FX We acknowledge generous support for this research from the AFOSR through
   PECASE (FA9550-11-1-0105) to N.C.G. and from a BRI grant
   (FA99550-12-1-0414) in support of collaborative work between the groups
   of M.K.G and N.C.G. In addition, we acknowledge support from the NIH
   through a Director's New Innovator Award (1DP2OD008724), through the
   NIBIB (1R01EB011633) and for a Transformative Award (NHLBI R01HL117326).
   Additional support comes from ARO (W911NF-14-1-0169) including a DURIP
   for instrumentation (W911NF-13-1-0321). A.P.B. was generously supported
   by the American Cancer Society - North Texans Creating Tomorrow's
   Miracles Postdoctoral Fellowship. Cassandra Callmann is thanked for
   assistance with TEM and is supported by the CRIN program, UCSD. We
   acknowledge the UCSD Light Microscopy Facility (P30 Grant NS047101) and
   the UCSD Cryo-Electron Microscopy facility (NIH R37GM-033050, and the
   Agouron Institute support to T. Baker).
CR Barbieri F., 2013, INT J PEPT, V2013, P20
   Belitsky JM, 2002, BIOORGAN MED CHEM, V10, P3313, DOI 10.1016/S0968-0896(02)00204-3
   Bertin PA, 2005, CHEM COMMUN, P3793, DOI 10.1039/b504643b
   Biron E, 2008, ANGEW CHEM INT EDIT, V47, P2595, DOI 10.1002/anie.200705797
   Blackwell HE, 1998, ANGEW CHEM INT EDIT, V37, P3281, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.3.CO;2-M
   Brinckerhoff LH, 1999, INT J CANCER, V83, P326, DOI 10.1002/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X
   Burke RS, 2010, BIOCONJUGATE CHEM, V21, P140, DOI 10.1021/bc9003662
   Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635
   Chatterjee J, 2008, ACCOUNTS CHEM RES, V41, P1331, DOI 10.1021/ar8000603
   Chien MP, 2013, J AM CHEM SOC, V135, P18710, DOI 10.1021/ja408182p
   Chien MP, 2013, ADV MATER, V25, P3599, DOI 10.1002/adma.201300823
   Chien MP, 2012, CHEM SCI, V3, P2690, DOI 10.1039/c2sc20165h
   Chu DSH, 2012, J CONTROL RELEASE, V157, P445, DOI 10.1016/j.jconrel.2011.10.016
   Conrad RM, 2009, ANGEW CHEM INT EDIT, V48, P8328, DOI 10.1002/anie.200903888
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Escriou V, 2003, ADV DRUG DELIVER REV, V55, P295, DOI 10.1016/S0169-409X(02)00184-9
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Falciani C, 2007, CHEM BIOL DRUG DES, V69, P216, DOI 10.1111/j.1747-0285.2007.00487.x
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hahn ME, 2013, CHEM COMMUN, V49, P2873, DOI 10.1039/c3cc40472b
   Hamamoto K, 2002, MICROBIOL IMMUNOL, V46, P741, DOI 10.1111/j.1348-0421.2002.tb02759.x                                              
   HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   James CR, 2014, J AM CHEM SOC, V136, P11216, DOI 10.1021/ja503142s
   Johnson J. A., 2010, J AM CHEM SOC, V133, P559, DOI DOI 10.1021/JA108441D
   Johnson JA, 2010, MACROMOLECULES, V43, P10326, DOI 10.1021/ma1021506
   Johnson RN, 2010, BIOMACROMOLECULES, V11, P3007, DOI 10.1021/bm100806h
   Kammeyer JK, 2013, POLYM CHEM-UK, V4, P3929, DOI 10.1039/c3py00526g
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kaspar AA, 2013, DRUG DISCOV TODAY, V18, P807, DOI 10.1016/j.drudis.2013.05.011
   Kim YW, 2011, NAT PROTOC, V6, P761, DOI 10.1038/nprot.2011.324
   Kolonko EM, 2008, J AM CHEM SOC, V130, P5626, DOI 10.1021/ja8001716
   Kolonko EM, 2009, J AM CHEM SOC, V131, P7327, DOI 10.1021/ja809284s
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Ku TH, 2011, J AM CHEM SOC, V133, P8392, DOI 10.1021/ja2004736
   Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200
   Lee H, 2003, PHARMACEUT RES, V20, P818, DOI 10.1023/A:1023402123119                                                         
   Li WJ, 2002, J BIOTECHNOL, V92, P251, DOI 10.1016/S0168-1656(01)00371-6                                                   
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lopez CA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002020
   Maynard HD, 2001, J AM CHEM SOC, V123, P1275, DOI 10.1021/ja003305m
   McGregor DP, 2008, CURR OPIN PHARMACOL, V8, P616, DOI 10.1016/j.coph.2008.06.002
   MILLER SM, 1994, BIOORG MED CHEM LETT, V4, P2657, DOI 10.1016/S0960-894X(01)80691-0
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   Murata H, 1997, MACROMOLECULES, V30, P2902, DOI 10.1021/ma970131t                                                               
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nischan N, 2013, ANGEW CHEM INT EDIT, V52, P11920, DOI 10.1002/anie.201303467
   OBrienSimpson NM, 1997, J AM CHEM SOC, V119, P1183, DOI 10.1021/ja962707k                                                               
   Osapay G, 1997, J MED CHEM, V40, P2241, DOI 10.1021/jm960850i
   Ouyang MX, 2010, CANCER RES, V70, P2204, DOI 10.1158/0008-5472.CAN-09-3698
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Patel PR, 2012, BIOMACROMOLECULES, V13, P2546, DOI 10.1021/bm300795y
   Pazos E, 2009, CHEM SOC REV, V38, P3348, DOI 10.1039/b908546g
   Pini A, 2008, CURR PROTEIN PEPT SC, V9, P468, DOI 10.2174/138920308785915227
   POWELL MF, 1993, PHARMACEUT RES, V10, P1268, DOI 10.1023/A:1018953309913
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   Ramon J, 2005, PHARM RES, V22, P1374, DOI 10.1007/s11095-005-5278-4
   Rao NV, 2012, BIOMACROMOLECULES, V13, P221, DOI 10.1021/bm201478k
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961                                                            
   Rozek A, 2003, BIOCHEMISTRY-US, V42, P14130, DOI 10.1021/bi035643g
   Ruijtenbeek R, 2001, CHEMBIOCHEM, V2, P171, DOI 10.1002/1439-7633(20010302)2:3<171::AID-CBIC171>3.3.CO;2-2
   Ruttekolk IR, 2011, MOL PHARMACOL, V79, P692, DOI 10.1124/mol.110.068296
   Samarajeewa S, 2014, CHEM COMMUN, V50, P968, DOI 10.1039/c3cc46013d
   Sanford MS, 2001, ORGANOMETALLICS, V20, P5314, DOI 10.1021/om010599r
   Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a
   Schellinger JG, 2013, ACS MACRO LETT, V2, P725, DOI 10.1021/mz400331w
   Scholl M, 1999, ORG LETT, V1, P953, DOI 10.1021/ol990909q                                                               
   Schuster MC, 1997, J MOL CATAL A-CHEM, V116, P209, DOI 10.1016/S1381-1169(96)00194-X                                                   
   Shi J, 2013, J BIOL ENG, V7, DOI 10.1186/1754-1611-7-25
   Som A, 2011, ANGEW CHEM INT EDIT, V50, P6147, DOI 10.1002/anie.201101535
   Steer DL, 2002, CURR MED CHEM, V9, P811, DOI 10.2174/0929867024606759                                                        
   STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W                                                    
   SU CM, 1991, HORM METAB RES, V23, P15, DOI 10.1055/s-2007-1003601
   Thompson MP, 2014, POLYM CHEM-UK, V5, P1954, DOI 10.1039/c3py01338c
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Trnka TM, 2001, ACCOUNTS CHEM RES, V34, P18, DOI 10.1021/ar000114f
   Verdine GL, 2012, METHOD ENZYMOL, V503, P3, DOI 10.1016/B978-0-12-396962-0.00001-X
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233
   Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Weinstock MT, 2012, BIOPOLYMERS, V98, P431, DOI 10.1002/bip.22073
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WOODLEY JF, 1994, CRIT REV THER DRUG, V11, P61
   Yamaguchi H, 2003, BIOSCI BIOTECH BIOCH, V67, P2269, DOI 10.1271/bbb.67.2269
   Zhao YN, 2013, J AM CHEM SOC, V135, P13414, DOI 10.1021/ja404714a
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamen.2007.03.026
NR 97
TC 21
Z9 21
U1 1
U2 73
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 29
PY 2014
VL 136
IS 43
BP 15422
EP 15437
DI 10.1021/ja5088216
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA AS1LP
UT WOS:000344042900043
PM 25314576
OA gold
DA 2018-01-05
ER

PT J
AU Climent, N
   Munier, S
   Pique, N
   Garcia, F
   Pavot, V
   Primard, C
   Casanova, V
   Gatell, JM
   Verrier, B
   Gallart, T
AF Climent, Nuria
   Munier, Severine
   Pique, Nuria
   Garcia, Felipe
   Pavot, Vincent
   Primard, Charlotte
   Casanova, Victor
   Maria Gatell, Jose
   Verrier, Bernard
   Gallart, Teresa
TI Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV
   genes induces HIV-1-specific T cell responses
SO VACCINE
LA English
DT Article
DE HIV immunogens; Polylactic acid (PLA) particles; MVA; Human monocytes
   derived-dendritic cells; Human CD4(+) T and CD8(+) T-cells;
   Proliferation; Cytokines; HIV core protein p24
ID VACCINIA VIRUS ANKARA; ANTIGEN-PRESENTING CELLS; IMMUNE-RESPONSES; PLA
   NANOPARTICLES; IN-VIVO; THERAPEUTIC IMMUNIZATION; ANTIBODY-RESPONSES;
   CANDIDATE VACCINE; DELIVERY-SYSTEMS; POXVIRUS VECTORS
AB Since recent data suggest that nanoparticles and modified vaccinia ankara (MVA) vectors could play a pivotal role in HIV-1 therapeutics and vaccine design, in an ex vivo model of human monocyte-derived dendritic cells (MDDCs), we compared two different loading strategies with HIV-1 vaccine vehicles, either viral or synthetic derived. We used polylactic acid (PLA) colloidal biodegradable particles, coated with HIV Gag antigens (p24), and MVA expressing Gag (rMVA-gag and rMVA-gag/trans membrane) or Tat, Nef and Rev genes (rMVA tat + rev and rMVA net).
   PLA-p24 captured by MDDCs from HIV-1 individuals induced a slight degree of MDDC maturation, cytokine and chemokine secretion and migration towards a gradient of CCL19 chemokine and highly increased HIV-specific CD8(+) T-cell proliferation compared with p24 alone. After complete maturation induction of PLA-p24-pulsed MDDCs, maximal migration towards a gradient of CCL19 chemokine and induction of HIV-specific T-cell proliferation (two-fold higher for CD4(+) than CD8(+)) and cytokine secretion (IFN-gamma and IL-2) in the co-culture were observed.
   Upon exposure to MVA-gag, MDDCs produced cytokines and chemokines and maintained their capacity to migrate to a gradient of CCL19. MDDCs infected with MVA-gag and MVA-gag trans-membrane were able to induce HIV-specific CD8(+) proliferation and secretion of IFN-gamma, IL-2, IL-6 and TNF-alpha.
   We conclude that both HIV antigens loading strategies (PLA-p24 nanoparticles or MVA expressing HIV genes) induce HIV-1-specific T-cell responses, which are able to kill autologous gag-expressing cells. Thus, they are plausible candidates for the development of anti-HIV vaccines. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Climent, Nuria; Gallart, Teresa] Hosp Clin Barcelona, Serv Immunol, Barcelona, Spain.
   [Climent, Nuria; Garcia, Felipe; Maria Gatell, Jose; Gallart, Teresa] AIDS Res Grp, Barcelona, Spain.
   [Climent, Nuria; Garcia, Felipe; Maria Gatell, Jose; Gallart, Teresa] Catalonian Ctr HIV Vaccines HIVACAT, Barcelona, Spain.
   [Munier, Severine; Pavot, Vincent; Primard, Charlotte; Verrier, Bernard] UCBL, Inst Biol & Chim Prot, UMR5305, F-69367 Lyon 07, France.
   [Pique, Nuria] Univ Barcelona, Fac Pharm, Dept Microbiol & Parasitol, Barcelona, Spain.
   [Garcia, Felipe; Maria Gatell, Jose] Hosp Clin Barcelona, Infect Dis & AIDS Unit, Barcelona, Spain.
   [Casanova, Victor] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Barcelona, Spain.
RP Climent, N (reprint author), CELLEX IDIBAPS, Lab Retrovirol & Viral Immunopathol, Med Fac UB, Casanova 140, Barcelona 08036, Spain.
EM ncliment@clinic.ub.es
RI Garcia, Felipe/F-4242-2014
OI Garcia, Felipe/0000-0001-7658-5832; Pique, Nuria/0000-0002-7308-030X;
   Climent, Nuria/0000-0002-0791-656X
FU Spanish Ministry of Health [FIS2006-1259, FIS 2009-80145, FIS
   2010-02984, FIS 2012-01247, FIS 2009-11078]; Spanish Ministry of Health
   (RIS-Spanish Cooperative Network on AIDS Research); Spanish Foundation
   for AIDS Research [FIPSE 36344/02, 36536-05, 36551/06]; Fundacion Botin;
   EU [EuroVac QLRT-PL-1999-01321, QLK2-CT-2002-01867]; ANR (French
   National Research Agency); PESCDELLI; ANABIO; Fondation Recherche
   Medicale (FRM); Pierre Berge funding (Sidaction); FP7 European grant
   CUT'HIVAC [241904]; FP7 European grant [280873]; 
   [MuNanoVac-EU-STREP-037200];  [108821-55-RGRL]
FX This work was supported by grants from the Spanish Ministry of Health
   (FIS2006-1259, RIS-Spanish Cooperative Network on AIDS Research, FIS
   2009-80145, FIS 2010-02984, FIS 2012-01247 and FIS 2009-11078), the
   Spanish Ministry of Education and Science (BIO2004-03954, SAF2005-05566,
   SAF2008-02036, SAF2012-39075 and SAF2008-04395), the Spanish Foundation
   for AIDS Research (FIPSE 36344/02, 36536-05, and 36551/06), Fundacion
   Botin, the EU (EuroVac QLRT-PL-1999-01321 and QLK2-CT-2002-01867),
   MuNanoVac-EU-STREP-037200 and Grant # 108821-55-RGRL. This work was also
   funded by the ANR (French National Research Agency) through Euronanomed
   grant (iNanoDCs), PESCDELLI and ANABIO research projects, Fondation
   Recherche Medicale (FRM) to Vincent Pavot, and Pierre Berge funding
   (Sidaction) to Bernard Verrier. This work was also partially supported
   by grants from the two FP7 European grants CUT'HIVAC (no 241904) and
   ADITEC (no 280873).
CR Aboud S, 2010, CLIN VACCINE IMMUNOL, V17, P1124, DOI 10.1128/CVI.00008-10
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Belisle SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019681
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Brandler S, 2010, J VIROL, V84, P5314, DOI 10.1128/JVI.02329-09
   Brown SA, 2010, VIRUSES-BASEL, V2, P435, DOI 10.3390/v2020435
   Casanova V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051287
   Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039
   Climent N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019644
   Combadiere B, 2008, COMP IMMUNOL MICROB, V31, P293, DOI 10.1016/j.cimid.2007.07.015
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Drexler I, 1999, CANCER RES, V59, P4955
   Gomez CE, 2011, J VIROL, V85, P11468, DOI 10.1128/JVI.05165-11
   Flynn BJ, 2011, P NATL ACAD SCI USA, V108, P7131, DOI 10.1073/pnas.1103869108
   Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340                                                                  
   Garcia F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004682
   Garcia F, 2011, VACCINE, V29, P8309, DOI 10.1016/j.vaccine.2011.08.098
   Garcia F, 2011, VACCINE, V29, P6454, DOI 10.1016/j.vaccine.2011.07.043
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Gomez CE, 2007, VACCINE, V25, P2863, DOI 10.1016/j.vaccine.2006.09.090
   Guerra S, 2007, J VIROL, V81, P8707, DOI 10.1128/JVI.00444-07
   Guerra S, 2010, J VIROL, V84, P8141, DOI 10.1128/JVI.00749-10
   Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Hanke T, 2007, J GEN VIROL, V88, P1, DOI 10.1099/vir.0.82493-0
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hashida S, 1997, J CLIN LAB ANAL, V11, P267, DOI 10.1002/(SICI)1098-2825(1997)11:5<267::AID-JCLA5>3.3.CO;2-T
   Hernandez JC, 2012, AIDS RES HUM RETROV, V28, P1313, DOI 10.1089/aid.2011.0297
   Huang XL, 2003, J INFECT DIS, V187, P315, DOI 10.1086/346054
   Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209                                                          
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kim GG, 2007, J IMMUNOL METHODS, V325, P51, DOI 10.1016/j.jim.2007.05.013
   Kim HJ, 2010, VACCINE, V28, P2877, DOI 10.1016/j.vaccine.2010.01.061
   Kreijtz JHCM, 2013, VACCINE, V31, P4217, DOI 10.1016/j.vaccine.2013.06.073
   Lai LL, 2012, VACCINE, V30, P1737, DOI 10.1016/j.vaccine.2011.12.026
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Locher CP, 2003, IMMUNOL LETT, V90, P67, DOI 10.1016/j.imlet.2003.02.001
   Najera JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011406
   Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008                                                        
   Mahe B, 2009, J INVEST DERMATOL, V129, P1156, DOI 10.1038/jid.2008.356
   Mangino G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022982
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172                                                     
   Mooij P, 2008, J VIROL, V82, P2975, DOI 10.1128/JVI.02216-07
   Mothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029717
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Pillai VKB, 2011, VACCINE, V29, P5399, DOI 10.1016/j.vaccine.2011.05.083
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Promadej-Lanier N, 2010, JAIDS-J ACQ IMM DEF, V53, P574, DOI 10.1097/QAI.0b013e3181d3521f
   Qiao Y, 2010, BIOMATERIALS, V31, P115, DOI 10.1016/j.biomaterials.2009.09.032
   Ramirez JC, 2000, J VIROL, V74, P923, DOI 10.1128/JVI.74.2.923-933.2000
   Rancan F, 2014, J CONTROL RELEASE, V176, P115, DOI 10.1016/j.jconrel.2013.12.022
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Rodriguez-Garcia M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009436
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Sarkar R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059073
   Shegokar R, 2011, PHARMAZIE, V66, P264, DOI 10.1691/ph.2011.0149
   Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839
   Trucco M, 2007, EXPERT OPIN BIOL TH, V7, P951, DOI 10.1517/14712598.7.7.951                                                        
   Vendrame D, 2009, J VIROL, V83, P10527, DOI 10.1128/JVI.01235-09
   Weber C, 2010, J BIOMED MATER RES A, V93A, P1322, DOI 10.1002/jbm.a.32605
   Zhang WF, 2014, PHARM RES-DORDR, V31, P1015, DOI 10.1007/s11095-013-1224-z
   Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006
NR 69
TC 8
Z9 9
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 29
PY 2014
VL 32
IS 47
BP 6266
EP 6276
DI 10.1016/j.vaccine.2014.09.010
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AS3YQ
UT WOS:000344211400013
PM 25240755
DA 2018-01-05
ER

PT J
AU Wan, ZT
   Chen, XL
AF Wan, Zhitao
   Chen, Xulin
TI Triptolide inhibits human immunodeficiency virus type 1 replication by
   promoting proteasomal degradation of Tat protein
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; Triptolide; Antiviral; Tat; Proteasomal degradation
ID HIV-1 GENE-EXPRESSION; ANTIRETROVIRAL THERAPY; KAPPA-B; P-TEFB;
   CELL-DEATH; RNA; TRANSCRIPTION; PATHWAY; CHEMOTHERAPY; ELONGATION
AB Background: Plants remain an important source of new drugs, new leads and new chemical entities. Triptolide is a diterpenoid epoxide isolated from Tripterygium wilfordii Hook F that possesses a broad range of bioactivities, including anti-inflammatory, immunosuppressive and anti-tumor properties. The antiviral activity of triptolide against human immunodeficiency virus type 1 (HIV-1) has not been reported.
   Results: In this study, nanomolar concentrations of triptolide were shown to potently inhibit HIV-1 replication in vitro. To identify the step(s) of the HIV-1 replication cycle affected by triptolide, time-of-addition studies, PCR analysis and direct transfection of viral genomic DNA were performed. The results of these experiments indicated that triptolide acts at the stage of viral gene transcription. In addition, a luciferase-based reporter assay that allows quantitative analysis of long terminal repeat (LTR)-driven transcription showed that Tat-induced LTR activation was impaired in the presence of triptolide. Moreover, Western blot analysis of exogenous gene expression (driven by the human elongation factor 1 a subunit promoter) in transiently transfected cells revealed that triptolide specifically reduces the steady-state level of Tat protein, without suppressing global gene expression. Further studies showed that triptolide accelerates Tat protein degradation, which can be rescued by administration of the proteasome inhibitor MG132. Mutation analysis revealed that N-terminal domains of Tat protein and nuclear localization are required for triptolide to reduce steady-state level of Tat.
   Conclusion: This study suggests for the first time that triptolide exerts its anti-HIV-1 activity by specifically prompting the degradation of the virally encoded Tat protein, which is a novel mechanism of action for an anti-HIV-1 compound. This compound may serve as a starting point for developing a novel HIV-1 therapeutic approach or as a basic research tool for interrogating events during viral replication.
C1 [Wan, Zhitao; Chen, Xulin] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China.
RP Chen, XL (reprint author), Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China.
EM chenxl@wh.iov.cn
FU Important National Science & Technology Specific Projects
   [2009ZX09301-014]; Knowledge Innovation Program of the Chinese Academy
   of Sciences [KSCX1-YW-10-03]
FX This work was jointly funded by the Important National Science &
   Technology Specific Projects (2009ZX09301-014), and the Knowledge
   Innovation Program of the Chinese Academy of Sciences (KSCX1-YW-10-03).
CR Baba M, 2006, ANTIVIR RES, V71, P301, DOI 10.1016/j.antiviral.2006.01.002
   Barboric M, 2005, PLOS BIOL, V3, P200, DOI 10.1371/journal.pbio.0030076
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Carter BZ, 2006, BLOOD, V108, P630, DOI 10.1182/blood-2005-09-3898
   Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200                                                          
   Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200                                                          
   Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   CULLEN BR, 1991, FASEB J, V5, P2361
   Davidson A, 2009, P NATL ACAD SCI USA, V106, P11931, DOI 10.1073/pnas.0900629106
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   FAVRE D, 1994, ARCH VIROL, V137, P149, DOI 10.1007/BF01311181
   Guendel I, 2014, J VIROL, V88, P1189, DOI 10.1128/JVI.01940-13
   Hamasaki T, 2013, ANTIMICROB AGENTS CH, V57, P1323, DOI 10.1128/AAC.01711-12
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Imai K, 2009, FEBS J, V276, P7124, DOI 10.1111/j.1742-4658.2009.07424.x
   Jadlowsky JK, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-63
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Lalonde MS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002038
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012
   Massari S, 2013, CURR PHARM DESIGN, V19, P1860, DOI 10.2174/1381612811319100010                                                     
   Miyake A, 2010, MICROBES INFECT, V12, P400, DOI 10.1016/j.micinf.2010.02.004
   Montessori V, 2004, CAN MED ASSOC J, V170, P229
   Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmn.2003.12.028
   Pande V, 2003, CURR MED CHEM, V10, P1603, DOI 10.2174/0929867033457250
   Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663                                                            
   Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665                                                
   Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000
   Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443
   Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180
   SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x
   Sivakumaran H, 2009, J VIROL, V83, P11694, DOI 10.1128/JVI.00499-09
   Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400                                                          
   Stevens M, 2006, MED RES REV, V26, P595, DOI 10.1002/med.20081
   Titov DV, 2011, NAT CHEM BIOL, V7, P182, DOI [10.1038/nchembio.522, 10.1038/NCHEMBIO.522]
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Wan H, 2010, J CLIN MICROBIOL, V48, P2186, DOI 10.1128/JCM.02034-09
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023993
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200
   Zhang XC, 2003, BIOORG MED CHEM LETT, V13, P1215, DOI 10.1016/S0960-894X(03)00059-3
   Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622
NR 43
TC 15
Z9 16
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD OCT 17
PY 2014
VL 11
AR 88
DI 10.1186/s12977-014-0088-6
PG 13
WC Virology
SC Virology
GA AS9NS
UT WOS:000344569900001
PM 25323821
OA gold
DA 2018-01-05
ER

PT J
AU Chen, YP
   Zhang, LR
   Estaras, C
   Choi, SH
   Moreno, L
   Karn, J
   Moresco, JJ
   Yates, JR
   Jones, KA
AF Chen, Yupeng
   Zhang, Lirong
   Estaras, Conchi
   Choi, Seung H.
   Moreno, Luis, Jr.
   Karn, Jonathan
   Moresco, James J.
   Yates, John R., III
   Jones, Katherine A.
TI A gene-specific role for the Ssu72 RNAPII CTD phosphatase in HIV-1 Tat
   transactivation
SO GENES & DEVELOPMENT
LA English
DT Article
DE HIV-1 Tat; Ssu72; CTD phosphatase; elongation
ID POLYMERASE-II TRANSCRIPTION; C-TERMINAL DOMAIN; MESSENGER-RNA; P-TEFB;
   ELONGATION COMPLEX; 7SK SNRNP; INTERACTS; YEAST; DIRECTIONALITY; PATHWAY
AB HIV-1 Tat stimulates transcription elongation by recruiting the P-TEFb (positive transcription elongation factor-b) (CycT1:CDK9) C-terminal domain (CTD) kinase to the HIV-1 promoter. Here we show that Tat transactivation also requires the Ssu72 CTD Ser5P (S5P)-specific phosphatase, which mediates transcription termination and intragenic looping at eukaryotic genes. Importantly, HIV-1 Tat interacts directly with Ssu72 and strongly stimulates its CTD phosphatase activity. We found that Ssu72 is essential for Tat:P-TEFb-mediated phosphorylation of the S5P-CTD in vitro. Interestingly, Ssu72 also stimulates nascent HIV-1 transcription in a phosphatase-dependent manner in vivo. Chromatin immunoprecipitation (ChIP) experiments reveal that Ssu72, like P-TEFb and AFF4, is recruited by Tat to the integrated HIV-1 proviral promoter in TNF-alpha signaling 2D10 T cells and leaves the elongation complex prior to the termination site. ChIP-seq (ChIP combined with deep sequencing) and GRO-seq (genome-wide nuclear run-on [GRO] combined with deep sequencing) analysis further reveals that Ssu72 predominantly colocalizes with S5P-RNAPII (RNA polymerase II) at promoters in human embryonic stem cells, with a minor peak in the terminator region. A few genes, like NANOG, also have high Ssu72 at the terminator. Ssu72 is not required for transcription at most cellular genes but has a modest effect on cotranscriptional termination. We conclude that Tat alters the cellular function of Ssu72 to stimulate viral gene expression and facilitate the early S5P-S2P transition at the integrated HIV-1 promoter.
C1 [Chen, Yupeng; Zhang, Lirong; Estaras, Conchi; Choi, Seung H.; Moreno, Luis, Jr.; Jones, Katherine A.] Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA.
   [Karn, Jonathan] Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
   [Moresco, James J.; Yates, John R., III] Scripps Res Inst, Dept Chem Physiol & Cell Biol, La Jolla, CA 92037 USA.
RP Jones, KA (reprint author), Salk Inst Biol Studies, Regulatory Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM jones@salk.edu
OI Estaras, Conchi/0000-0002-2600-5841; Moresco, James/0000-0003-1178-1642
FU Blasker-Rose-Miah Fund; Margaret T. Morris Foundation; National Center
   for Research Resources [5P41RR011823]; National Institutes of Health
   (NIH) [GM103533]; NIH [DP1-DA028869, U19-AI096113, AI044615]
FX We thank Chris Benner (Razavi Newman Integrative Genomics and
   Bioinformatics Core, The Salk Institute), Sven Heinz, and Manching Ku
   (Next-Generation Sequencing Core, The Salk Institute) for critical
   bioinformatics analysis and support for the ChIP-seq and GRO-seq
   studies, and W. Travis Beggren in the Salk Stem Cell Core Facility for
   assistance with hESC cultures. Y. C. gratefully acknowledges
   post-doctoral fellowship support from the Blasker-Rose-Miah Fund and the
   Margaret T. Morris Foundation. Proteomics analysis was carried out by
   Patricia G. Tu and J.J.M. and was supported by grants from the National
   Center for Research Resources (5P41RR011823) and the National Institutes
   of Health (NIH) (GM103533) to J.R.Y. III. This study was funded by NIH
   grants to J.K. (DP1-DA028869 and U19-AI096113) and K.A.J. (AI044615).
CR Bartkowiak B, 2010, GENE DEV, V24, P2303, DOI 10.1101/gad.1968210
   Bres V, 2009, MOL CELL, V36, P75, DOI 10.1016/j.molcel.2009.08.015
   Buratowski S., 2009, MOL CELL, V36, P531
   Chiu YL, 2002, MOL CELL, V10, P585, DOI 10.1016/S1097-2765(02)00630-5
   Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200
   Choi SH, 2013, GENE DEV, V27, P2473, DOI 10.1101/gad.229062.113
   Chou S, 2013, P NATL ACAD SCI USA, V110, pE123, DOI 10.1073/pnas.1216971110
   Contreras X, 2012, TRANSCRIPTION, V4, P72
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Czudnochowski N, 2012, NAT COMMUN, V3, P824
   Darby MM, 2012, MOL CELL BIOL, V32, P1762, DOI 10.1128/MCB.00050-12
   Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4
   Eick D, 2013, CHEM REV, V113, P8456, DOI 10.1021/cr400071f
   Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141                                                            
   Gelev V, 2014, SCI REP-UK, V4, DOI 10.1038/srep03664
   Grzechnik P, 2014, TRENDS BIOCHEM SCI, V39, P319, DOI 10.1016/j.tibs.2014.05.001
   Hampsey M, 2011, ADV ENZYME REGUL, V51, P118, DOI 10.1016/j.advenzreg.2010.10.001
   Hanes SD, 2014, BBA-GENE REGUL MECH, V1839, P316, DOI 10.1016/j.bbagrm.2014.02.001
   Hazelbaker DZ, 2013, MOL CELL, V49, P55, DOI 10.1016/j.molcel.2012.10.014
   He NH, 2010, MOL CELL, V38, P428, DOI 10.1016/j.molcel.2010.04.013
   He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203
   Hsu PL, 2014, J MOL BIOL, V426, P2970, DOI 10.1016/j.jmb.2014.06.010
   Jadlowsky JK, 2014, MOL CELL BIOL, V34, P1911, DOI [10.1128/MCB.1013-13, 10.1128/MCB.01013-13]
   Jenks MH, 2008, MOL CELL BIOL, V28, P3883, DOI 10.1128/MCB.00380-08
   Kim KY, 2011, CELL, V144, P745, DOI 10.1016/j.cell.2011.01.034
   Kim YK, 2011, J MOL BIOL, V410, P896, DOI 10.1016/j.jmb.2011.03.054
   Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7                                                   
   Kuehner JN, 2011, NAT REV MOL CELL BIO, V12, P283, DOI 10.1038/nrm3098
   Kwak H, 2013, ANNU REV GENET, V47, P483, DOI 10.1146/annurev-genet-110711-155440
   Luo ZJ, 2012, NAT REV MOL CELL BIO, V13, P543, DOI 10.1038/nrm3417
   Mbonye U, 2012, VIROLOGY, V454-455, P328
   Mbonye UR, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003338
   McNamara RP, 2013, CELL REP, V5, P1256, DOI 10.1016/j.celrep.2013.11.003
   Mosley AL, 2009, MOL CELL, V34, P168, DOI 10.1016/j.molcel.2009.02.025
   Perkins KJ, 2008, MOL CELL, V29, P56, DOI 10.1016/j.molcel.2007.11.030
   Ramakrishnan Rajesh, 2012, Biology (Basel), V1, P94, DOI 10.3390/biology1010094
   Reyes-Reyes M, 2007, MOL CELL BIOL, V27, P926, DOI 10.1128/MCB.01361-06
   Schulze-Gahmen U, 2014, ELIFE, V3, DOI 10.7554/eLife.02375
   Singh BN, 2007, MOL CELL, V27, P806, DOI 10.1016/j.molcel.2007.07.013
   Sobhian B, 2010, MOL CELL, V38, P439, DOI 10.1016/j.molcel.2010.04.012
   St-Pierre B, 2005, NUCLEIC ACIDS RES, V33, P464, DOI 10.1093/nar/gki171
   Steinmetz EJ, 2003, MOL CELL BIOL, V23, P6339, DOI 10.1128/MCB.23.18.6339-6349.2003
   Tan-Wong SM, 2012, SCIENCE, V338, P671, DOI 10.1126/science.1224350
   Tan-Wong SM, 2009, GENE DEV, V23, P2610, DOI 10.1101/gad.1823209
   Wagschal A, 2012, CELL, V150, P1147, DOI 10.1016/j.cell.2012.08.004
   Werner-Allen JW, 2011, J BIOL CHEM, V286, P5717, DOI 10.1074/jbc.M110.197129
   Xiang KH, 2012, GENE DEV, V26, P2265, DOI 10.1101/gad.198853.112
   Xiang KH, 2010, NATURE, V467, P729, DOI 10.1038/nature09391
   Yoh SM, 2007, GENE DEV, V21, P160, DOI 10.1101/gad.1503107
   Zhang DW, 2012, J BIOL CHEM, V287, P8541, DOI 10.1074/jbc.M111.335687
   Zhou Q, 2012, ANNU REV BIOCHEM, V81, P119, DOI 10.1146/annurev-biochem-052610-095910
NR 51
TC 7
Z9 7
U1 0
U2 13
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD OCT 15
PY 2014
VL 28
IS 20
BP 2261
EP 2275
DI 10.1101/gad.250449.114
PG 15
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA AR5RA
UT WOS:000343640000006
PM 25319827
OA gold
DA 2018-01-05
ER

PT J
AU Chuang, KH
   Kao, CH
   Roffler, SR
   Lu, SJ
   Cheng, TC
   Wang, YM
   Chuang, CH
   Hsieh, YC
   Wang, YT
   Wang, JY
   Weng, KY
   Cheng, TL
AF Chuang, Kuo-Hsiang
   Kao, Chien-Han
   Roffler, Steve R.
   Lu, Ssu-Jung
   Cheng, Ta-Chun
   Wang, Yun-Ming
   Chuang, Chih-Hung
   Hsieh, Yuan-Chin
   Wang, Yeng-Tseng
   Wang, Jaw-Yuan
   Weng, Kuo-Yi
   Cheng, Tian-Lu
TI Development of an Anti-Methoxy Poly(ethylene glycol) (alpha-mPEG)
   Cell-Based Capture System to Measure mPEG and mPEGylated Molecules
SO MACROMOLECULES
LA English
DT Article
ID PEGYLATED LIPOSOMAL DOXORUBICIN; IN-VIVO; METHOXYPOLY(ETHYLENE GLYCOL);
   SUSTAINED-RELEASE; HIV ACTIVITY; NANOPARTICLES; ANTIBODIES; EFFICIENT;
   CANCER; SERUM
AB Quantitative pharmacokinetic analysis of methoxy-poly(ethylene glycol) (mPEG) and mPEGylated molecules is important for clinical drug development. Here we developed sensitive sandwich and competitive ELISAs by expressing an anti-mPEG antibody on the surface of fibroblasts for effective capture of mPEG molecules in biological samples. alpha-mPEG sandwich ELISA could quantify the higher-molecular-weight of mPEG (2, 5, and 20 kDa) and mPEGylated molecules. alpha-mPEG cell-based competitive ELISA was developed to measure the lower-molecular-weight of mPEG molecules (559, 750, and 1000 Da) at nanomolar levels. In addition, alpha-mPEG cell-based ELISA was unaffected by the presence of 10% human serum or murine serum. We further demonstrate that the alpha-mPEG cell-based ELISA determined similar pharmacokinetics of mPEG(5K) as traditional gamma counting of I-131-mPEG(5K). The alpha-mPEG cell-based ELISA may provide an accurate, high sensitivity and easy-to-use tool for directly measuring mPEG and mPEGylated molecules in complex biological samples to accelerate the clinical development of mPEG drugs.
C1 [Chuang, Kuo-Hsiang; Cheng, Ta-Chun] Taipei Med Univ, Grad Inst Pharmacognosy, Taipei 11031, Taiwan.
   [Chuang, Kuo-Hsiang] Taipei Med Univ, PhD Program Clin Drug Discovery Bot Herbs, Taipei 11031, Taiwan.
   [Kao, Chien-Han; Hsieh, Yuan-Chin; Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80708, Taiwan.
   [Roffler, Steve R.] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.
   [Lu, Ssu-Jung; Chuang, Chih-Hung; Cheng, Tian-Lu] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung 80708, Taiwan.
   [Wang, Yun-Ming] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 30010, Taiwan.
   [Wang, Yeng-Tseng] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Dept Surg, Coll Med, Fac Med, Kaohsiung 80708, Taiwan.
   [Weng, Kuo-Yi] Ten Chan Gen Hosp, Div Rheumatol, Taoyuan 32043, Taiwan.
   [Cheng, Tian-Lu] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Cheng, Tian-Lu] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung 80708, Taiwan.
RP Weng, KY (reprint author), Ten Chan Gen Hosp, Div Rheumatol, 155 Yanping Rd, Taoyuan 32043, Taiwan.
EM kuoyiweng@gmail.com; tlcheng@kmu.edu.tw
FU National Research Program for Biopharmaceuticals, Ministry of Science
   and Technology, Taipei, Taiwan [MOST 103-2325-B-037-007,
   NSC102-2321-B-037-001, NSC 102-2320-B-038-043-MY2]; Ministry of Health
   and Welfare, Taiwan [MOHW103-TD-B-111-05]; National Health Research
   Institutes, Taiwan [NHRI-EX103-10238SC]; 103NSYSU-KMU Joint Research
   Project [NSYSUKMU103 I-003]; Academia Sinica, Taiwan; Comprehensive
   Cancer Center of Taipei Medical University/Health and welfare surcharge
   of tobacco products [MOHW103-TD-B-111-01];  [KMU-DT103005]; 
   [KMU-TP103C00]
FX This work was supported by grants from the National Research Program for
   Biopharmaceuticals, Ministry of Science and Technology, Taipei, Taiwan
   (MOST 103-2325-B-037-007, NSC102-2321-B-037-001, and NSC
   102-2320-B-038-043-MY2), the Ministry of Health and Welfare, Taiwan
   (MOHW103-TD-B-111-05), the National Health Research Institutes, Taiwan
   (NHRI-EX103-10238SC), 103NSYSU-KMU Joint Research Project (NSYSUKMU103
   I-003), KMU-DT103005, KMU-TP103C00, the Grant of Biosignature in
   Colorectal Cancers, Academia Sinica, Taiwan, and Comprehensive Cancer
   Center of Taipei Medical University/Health and welfare surcharge of
   tobacco products (MOHW103-TD-B-111-01).
CR Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y
   Barani L, 2010, BIOTECHNOL APPL BIOC, V57, P25, DOI 10.1042/BA20100145
   Borden MA, 2008, BIOMATERIALS, V29, P597, DOI 10.1016/j.biomaterials.2007.10.011
   Chao TC, 2003, CANCER INVEST, V21, P837, DOI 10.1081/CNV-120025086
   Cheng TC, 2013, BIOCONJUGATE CHEM, V24, P1408, DOI 10.1021/bc3006144
   Cheng TL, 2012, BIOCONJUGATE CHEM, V23, P881, DOI 10.1021/bc200478w
   Cheng TL, 2005, BIOCONJUGATE CHEM, V16, P1225, DOI 10.1021/bc050133f
   Chuang KH, 2010, J NUCL MED, V51, P933, DOI 10.2967/jnumed.109.071977
   DeForge LE, 2007, J IMMUNOL METHODS, V320, P58, DOI 10.1016/j.jim.2006.12.001
   Dong Y, 2007, BIOMATERIALS, V28, P4154, DOI 10.1016/j.biomaterials.2007.05.026
   Fang JM, 2005, NAT BIOTECHNOL, V23, P584, DOI 10.1038/nbt1087
   Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002                                                
   Guiotto A, 2004, BIOORG MED CHEM LETT, V14, P1803, DOI 10.1016/j.bmcl.2003.12.098
   He XX, 2008, ANAL CHEM, V80, P9597, DOI 10.1021/ac801882g
   Hsiao SM, 2009, GYNECOL ONCOL, V112, P35, DOI 10.1016/j.ygyno.2008.09.033
   Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/nnm.11.19, 10.2217/NNM.11.19]
   Kaminskas LM, 2012, NANOMED-NANOTECHNOL, V8, P103, DOI 10.1016/j.nano.2011.05.013
   Kumada Y, 2009, J BIOTECHNOL, V142, P135, DOI 10.1016/j.jbiotec.2009.03.011
   Kyluik-Price DL, 2014, BIOMATERIALS, V35, P412, DOI 10.1016/j.biomaterials.2013.09.016
   Li WJ, 2012, INT J BIOL MACROMOL, V50, P974, DOI 10.1016/j.ijbiomac.2012.02.019
   Li WJ, 2010, CHEMMEDCHEM, V5, P1893, DOI 10.1002/cmdc.201000352
   Liu HY, 2013, BIOMATERIALS, V34, P6967, DOI 10.1016/j.biomaterials.2013.05.059
   Liu YL, 2007, ANAL CHEM, V79, P2221, DOI 10.1021/ac061578f
   Madan J, 2013, NANOMED-NANOTECHNOL, V9, P492, DOI 10.1016/j.nano.2012.10.003
   Mc Ardle J, 1998, ANI WELF INFORM CENT, V8, P3
   NIELSEN K, 1994, VET RES COMMUN, V18, P433, DOI 10.1007/BF01839419
   Novikova L., 2009, ANAL CHIM ACTA, V656, P8
   Park JW, 2003, SENSOR ACTUAT B-CHEM, V91, P158, DOI 10.1016/S0925-4005(03)00082-0
   Pelham RW, 2008, ALIMENT PHARM THER, V28, P256, DOI 10.1111/j.1365-2036.2008.03727.x
   Ramon J., 2005, PHARM RES, V22, P1375
   Rapoport Natalya Y, 2009, Bubble Sci Eng Technol, V1, P31, DOI 10.1179/175889709X446516
   Roffler SR, 2006, GENE THER, V13, P412, DOI 10.1038/sj.gt.3302671
   Sedlak M, 2001, BIOORG MED CHEM LETT, V11, P2833, DOI 10.1016/S0960-894X(01)00532-7
   Su YC, 2010, BIOCONJUGATE CHEM, V21, P1264, DOI 10.1021/bc100067t
   Tyrrell ZL, 2012, MACROMOLECULES, V45, P4809, DOI 10.1021/ma300271k
   Urbonaviciute V, 2007, J LEUKOCYTE BIOL, V81, P67, DOI 10.1189/jlb.0306196
   Veronese FM, 1996, J CONTROL RELEASE, V40, P199, DOI 10.1016/0168-3659(95)00185-9
   Vyas SP, 2006, DRUG DEV IND PHARM, V32, P699, DOI 10.1080/03639040500528954
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544
   Yang MH, 2009, INT J FOOD MICROBIOL, V133, P265, DOI 10.1016/j.ijfoodmicro.2009.05.029
   Yowell SL, 2002, CANCER TREAT REV, V28, P3, DOI 10.1016/S0305-7372(02)80002-0                                                   
   Yu Y, 2011, MACROMOLECULES, V44, P4793, DOI 10.1021/ma2005102
   Zhang P, 2008, J APPL POLYM SCI, V107, P3230, DOI 10.1002/app.27450
   Zhang Y, 2004, BIOMED MICRODEVICES, V6, P33, DOI 10.1023/B:BMMD.0000013363.77466.63                                              
NR 44
TC 3
Z9 3
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
EI 1520-5835
J9 MACROMOLECULES
JI Macromolecules
PD OCT 14
PY 2014
VL 47
IS 19
BP 6880
EP 6888
DI 10.1021/ma501156r
PG 9
WC Polymer Science
SC Polymer Science
GA AQ9SN
UT WOS:000343196200039
DA 2018-01-05
ER

PT J
AU Liang, GD
   Wang, C
   Shi, WG
   Wang, K
   Jiang, XF
   Xu, XY
   Liu, KL
AF Liang Guodong
   Wang Chao
   Shi Weiguo
   Wang Kun
   Jiang Xifeng
   Xu Xiaoyu
   Liu Keliang
TI Design, Synthesis and Activity Prescreening of Small Molecule-Peptide
   Conjugates as HIV-1 Fusion Inhibitors Targeting gp41
SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
LA Chinese
DT Article
DE HIV-1; Fusion inhibitor; Conjugate
ID MULTIFUNCTIONAL DOMAINS; ENVELOPE GLYCOPROTEIN; MECHANISMS; CONTAINS;
   REGION; ENTRY; CORE
AB HIV-1 fusion inhibitors target the transmembrane subunit( gp41) of HIV-1 envelopeglycoproteins. Previous studies had shown that the small molecule pyrrole derivatives, Noc or Npc, can act as a substitute for the pocket binding domain of the C34 peptide, and the small molecule-peptide conjugates exhibit low nanomolar IC50 value in the cell-cell fusion assay. In this paper, pocket-specific small molecule and P27 peptide were covalently linked together through specified linkers with different lengths and flexibilities Small molecule-peptide conjugates exhibited significant inhibitory activity on HIV-1 Env-mediated cell-cell fusion assay.
C1 [Liang Guodong; Liu Keliang] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
   [Wang Chao; Shi Weiguo; Wang Kun; Jiang Xifeng; Xu Xiaoyu; Liu Keliang] Acad Mil Med Sci, Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
RP Liu, KL (reprint author), Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
EM keliangliu55@126.com
RI Wang, Chao/J-3250-2015
OI Wang, Chao/0000-0002-7673-0638
FU National Natural Science Foundation of China [81373266]; "Creation of
   Major New Drugs" Science and Technology Major Projects of China
   [2012ZX09301003]
FX Supported by the National Natural Science Foundation of China(No.
   81373266) and the "Creation of Major New Drugs" Science and Technology
   Major Projects of China(No. 2012ZX09301003).
CR Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289
   Carmona R, 2005, J CLIN VIROL, V32, P248, DOI 10.1016/j.jcv.2004.11.009
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chen CH, 2000, AIDS RES HUM RETROV, V16, P2037, DOI 10.1089/088922200750054765                                                      
   Cleveland SM, 2003, J GEN VIROL, V84, P591, DOI 10.1099/vir.0.18630-0
   Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w
   Otaka A., 2002, ANGEW CHEM INT EDIT, V41, P2937
   [贾启燕 Jia Qiyan], 2013, [中国科学. 化学, Scientia Sinica Chimica], V43, P984
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Ling YB, 2013, CHEM J CHINESE U, V34, P2102, DOI 10.7503/cjcu20130391
   Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200
   Qi Z, 2008, J BIOL CHEM, V283, P30376, DOI 10.1074/jbc.M804672200
   SHI WG, 2010, ACTA PHARM SIN, V45, P184
   Shi WG, 2012, CHEM COMMUN, V48, P11579, DOI 10.1039/c2cc35973a
   Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   Wang C, 2013, J MED CHEM, V56, P2527, DOI 10.1021/jm3018964
   Zhou JM, 2012, BIOCHEMISTRY-US, V51, P1288, DOI 10.1021/bi2015986
NR 20
TC 3
Z9 3
U1 0
U2 6
PU HIGHER EDUCATION PRESS
PI BEIJING
PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA
SN 0251-0790
J9 CHEM J CHINESE U
JI Chem. J. Chin. Univ.-Chin.
PD OCT 10
PY 2014
VL 35
IS 10
BP 2100
EP 2103
DI 10.7503/cjcu20140495
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA AT3KF
UT WOS:000344833200008
DA 2018-01-05
ER

PT J
AU Wu, HQ
   Yao, J
   He, QQ
   Chen, FE
AF Wu, Hai-Qiu
   Yao, Jin
   He, Qiu-Qin
   Chen, Fen-Er
TI Docking-based CoMFA and CoMSIA studies on naphthyl-substituted
   diarylpyrimidines as NNRTIs
SO SAR AND QSAR IN ENVIRONMENTAL RESEARCH
LA English
DT Article
DE NNRTIs; 3D-QSAR; CoMSIA; CoMFA; molecular docking; DAPYs
ID REVERSE-TRANSCRIPTASE INHIBITORS; MOLECULAR SIMILARITY INDEXES;
   PYRIDINONE DERIVATIVE-TYPE; NONNUCLEOSIDE INHIBITORS; FIELD ANALYSIS;
   ETRAVIRINE TMC125; DAPY ANALOGS; DRUG DESIGN; MTD METHOD; BINDING
AB Non-nucleoside reverse transcriptase inhibitors (NNRTIs) play a significant role in anti-HIV drug development. A series of naphthyl-substituted diarylpyrimidines with most EC50 values in the nanomolar range was reported as potent NNRTIs by our lab. In order to obtain the quantitative structure-activity relationship (QSAR) that can guide rational lead optimization, CoMFA and CoMSIA studies were carried out. Docking study based on the co-crystallized complex (PDB ID: 3MEC) was utilized as an approach to obtain reliable conformations for molecular alignment. Two different molecular alignments were performed, resulting in two CoMFA models and 34 CoMSIA models. The CoMSIA models correspond to all the possible combinations among five fields: steric, electrostatic, hydrophobic, hydrogen bond donor, and hydrogen bond acceptor. Highly predictive models were achieved, in which the statistically reliable CoMFA model had a q(2) of 0.743 and an r(2) of 0.980, whereas the best CoMSIA model had a q(2) of 0.713 and an r(2) of 0.969. The best models were rigorously validated with an external test set, which gave satisfactory predictive r(2) values for CoMFA and CoMSIA models: 0.85 and 0.83, respectively. Contour maps obtained from selected models revealed important structural features and some rational guidance for further optimization.
C1 [Wu, Hai-Qiu; Yao, Jin; He, Qiu-Qin; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
RP Chen, FE (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM rfchen@fudan.edu.cn
FU National Natural Science Foundation of China [81172918]; Shanghai
   Municipal Natural Science Foundation [13ZR1402200]; Chinese National
   Science and Technology Major Project [2012ZX09103101-068]
FX This research was financially supported by National Natural Science
   Foundation of China under Grant No. 81172918; Shanghai Municipal Natural
   Science Foundation under Grant No. 13ZR1402200; and Chinese National
   Science and Technology Major Project by Grant No. 2012ZX09103101-068.
CR Bohm M, 1999, J MED CHEM, V42, P458, DOI 10.1021/jm981062r
   Bringmann G, 2003, J CHEM INF COMP SCI, V43, P304, DOI 10.1021/ci025570s
   Chen HF, 2004, QSAR COMB SCI, V23, P36, DOI 10.1002/qsar.200330844
   CHO SJ, 1995, J MED CHEM, V38, P1060, DOI 10.1021/jm00007a003
   Cichero E, 2009, EUR J MED CHEM, V44, P2059, DOI 10.1016/j.ejmech.2008.10.014
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   De Corte BL, 2005, J MED CHEM, V48, P1689, DOI 10.1021/jm040127p
   Duda-Seiman C, 2006, INT J MOL SCI, V7, P537, DOI 10.3390/i7110537                                                                
   Feng XQ, 2009, CHEMMEDCHEM, V4, P219, DOI 10.1002/cmdc.200800334
   Friedman-Kien AE, 1981, MMWR-MORBID MORTAL W, V30, P305
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Kellenberger E, 2004, PROTEINS, V57, P225, DOI 10.1002/prot.20149
   Klebe G, 1999, J COMPUT AID MOL DES, V13, P1, DOI 10.1023/A:1008047919606                                                         
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   Lansdon EB, 2010, J MED CHEM, V53, P4295, DOI 10.1021/jm1002233
   Liang YH, 2010, BIOORGAN MED CHEM, V18, P4601, DOI 10.1016/j.bmc.2010.05.036
   Liang YH, 2009, CHEMMEDCHEM, V4, P1537, DOI 10.1002/cmdc.200900212
   Medina-Franco JL, 2004, J COMPUT AID MOL DES, V18, P345, DOI 10.1023/B:JCAM.0000047816.15514.ab
   Oprea TI, 2001, SAR QSAR ENVIRON RES, V12, P75, DOI 10.1080/10629360108035372                                                       
   Papandreou I, 2005, MUTAT RES-FUND MOL M, V569, P87, DOI 10.1016/j.mrfmmm.2004.06.054
   Putz MV, 2011, INT J MOL SCI, V12, P9533, DOI 10.3390/ijms12129533
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   Sharma M, 2013, J ANTIMICROB CHEMOTH, V68, P250, DOI 10.1093/jac/dks404
   Sousa SF, 2006, PROTEINS, V65, P15, DOI 10.1002/prot.21082
   Stahle L, 1988, Prog Med Chem, V25, P291, DOI 10.1016/S0079-6468(08)70281-9
   Tronchet JMJ, 2003, CURR TOP MED CHEM, V3, P1496, DOI 10.2174/1568026033451754                                                        
   Secretary-General U. N., 2011, UN UN ACC ZER NEW HI
   Yang GF, 2006, CURR PHARM DESIGN, V12, P4601, DOI 10.2174/138161206779010431
NR 29
TC 3
Z9 4
U1 3
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1062-936X
EI 1029-046X
J9 SAR QSAR ENVIRON RES
JI SAR QSAR Environ. Res.
PD OCT 3
PY 2014
VL 25
IS 10
BP 761
EP 775
DI 10.1080/1062936X.2014.955054
PG 15
WC Chemistry, Multidisciplinary; Computer Science, Interdisciplinary
   Applications; Environmental Sciences; Mathematical & Computational
   Biology; Toxicology
SC Chemistry; Computer Science; Environmental Sciences & Ecology;
   Mathematical & Computational Biology; Toxicology
GA AQ5EN
UT WOS:000342829100001
PM 25242254
DA 2018-01-05
ER

PT J
AU Mccoy, LE
   Groppelli, E
   Blanchetot, C
   de Haard, H
   Verrips, T
   Rutten, L
   Weiss, RA
   Jolly, C
AF Mccoy, Laura E.
   Groppelli, Elisabetta
   Blanchetot, Christophe
   de Haard, Hans
   Verrips, Theo
   Rutten, Lucy
   Weiss, Robin A.
   Jolly, Clare
TI Neutralisation of HIV-1 cell-cell spread by human and llama antibodies
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; Antibody; Virological synapse; Cell-cell; Neutralisation; CD4;
   VHH
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODY; FUSION
   INHIBITOR T-20; T-CELLS; VIROLOGICAL SYNAPSES; SHIV CHALLENGE; ENV
   CLONES; TYPE-1; TRANSMISSION; INFECTION
AB Background: Direct cell-cell spread of HIV-1 is a very efficient mode of viral dissemination, with increasing evidence suggesting that it may pose a considerable challenge to controlling viral replication in vivo. Much current vaccine research involves the study of broadly neutralising antibodies (bNabs) that arise during natural infection with the aims of eliciting such antibodies by vaccination or incorporating them into novel therapeutics. However, whether cell-cell spread of HIV-1 can be effectively targeted by bNabs remains unclear, and there is much interest in identifying antibodies capable of efficiently neutralising virus transmitted by cell-cell contact.
   Results: In this study we have tested a panel of bNAbs for inhibition of cell-cell spread, including some not previously evaluated for inhibition of this mode of HIV-1 transmission. We found that three CD4 binding site antibodies, one from an immunised llama (J3) and two isolated from HIV-1-positive patients (VRC01 and HJ16) neutralised cell-cell spread between T cells, while antibodies specific for glycan moieties (2G12, PG9, PG16) and the MPER (2F5) displayed variable efficacy. Notably, while J3 displayed a high level of potency during cell-cell spread we found that the small size of the llama heavy chain-only variable region (VHH) J3 is not required for efficient neutralisation since recombinant J3 containing a full-length human heavy chain Fc domain was significantly more potent. J3 and J3-Fc also neutralised cell-cell spread of HIV-1 from primary macrophages to CD4+ T cells.
   Conclusions: In conclusion, while bNabs display variable efficacy at preventing cell-cell spread of HIV-1, we find that some CD4 binding site antibodies can inhibit this mode of HIV-1 dissemination and identify the recently described llama antibody J3 as a particularly potent inhibitor. Effective neutralisation of cell-cell spread between physiologically relevant cell types by J3 and J3-Fc supports the development of VHH J3 nanobodies for therapeutic or prophylactic applications.
C1 [Mccoy, Laura E.; Groppelli, Elisabetta; Weiss, Robin A.; Jolly, Clare] UCL, Div Infect & Immun, London WC1E 6BT, England.
   [Blanchetot, Christophe; de Haard, Hans] ArGEN X BVBA, Ghent, Belgium.
   [Verrips, Theo; Rutten, Lucy] QVQ Bv, NL-3584 CH Utrecht, Netherlands.
RP Jolly, C (reprint author), UCL, Div Infect & Immun, London WC1E 6BT, England.
EM c.jolly@ucl.ac.uk
OI Jolly, Clare/0000-0002-4603-2281
FU European Commission sixth Frame Work Programme as part of the European
   Vaccines and Microbicides Enterprise (EUROPRISE); European Commission
   seventh Frame Work Programme as part of the Combined Highly Active
   Anti-retroviral Microbicides project (CHAARM); Bill and Melinda Gates
   Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD
   grant) [38637]; UK Medical Research Council Career Development
   Fellowship [G0800312]; MRC [MR/J008184/1]
FX This work was supported by the European Commission sixth Frame Work
   Programme as part of the European Vaccines and Microbicides Enterprise
   (EUROPRISE); the European Commission seventh Frame Work Programme as
   part of the Combined Highly Active Anti-retroviral Microbicides project
   (CHAARM); the Bill and Melinda Gates Foundation as part of the
   Collaboration for AIDS Vaccine Discovery (CAVD grant 38637) awards to
   RW; a UK Medical Research Council Career Development Fellowship
   (G0800312) and MRC project grant (MR/J008184/1) to CJ.
CR Abela IA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002634
   Amanna IJ, 2008, HUM VACCINES, V4, P316, DOI 10.4161/hv.4.4.5751                                                             
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348                                                          
   Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805
   De Haard HJW, 2005, J BACTERIOL, V187, P4531, DOI 10.1128/JB.187.13.4531-4541.2005
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Duenas-Decamp MJ, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-9
   Duncan CJA, 2013, AIDS, V27, P2201, DOI 10.1097/QAD.0b013e3283632ec4
   Gorlani A, 2011, AIDS RES HUM RETROV, V28, P198
   Gousset K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000015
   Groot F, 2008, BLOOD, V111, P4660, DOI 10.1182/blood-2007-12-130070
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974
   Hulsik DL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003202
   Hultberg A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017665
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jolly C, 2007, J VIROL, V81, P13916, DOI 10.1128/JVI.01585-07
   Jolly C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002226
   Jolly C, 2010, J VIROL, V84, P12185, DOI 10.1128/JVI.01447-10
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Koff WC, 2013, SCIENCE, V340, DOI 10.1126/science.1232910
   Kwong PD, 2012, COLD SPRING HARB PER, V1
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06
   Malbec M, 2013, J EXP MED, V210, P2813, DOI 10.1084/jem.20131244
   Martin N, 2010, J VIROL, V84, P3516, DOI 10.1128/JVI.02651-09
   Massanella M, 2009, AIDS, V23, P183, DOI 10.1097/QAD.0b013e32831ef1a3
   Mazurov D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000788
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   McCoy LE, 2012, J EXP MED, V209, P1091, DOI 10.1084/jem.20112655
   Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599
   Murooka TT, 2012, NATURE, V490, P283, DOI 10.1038/nature11398
   Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003
   Pejchal R, 2010, P NATL ACAD SCI USA, V107, P11483, DOI 10.1073/pnas.1004600107
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Scanlan CN, 2003, ADV EXP MED BIOL, V535, P205
   Sewald X, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2338
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Titanji BK, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-161
   Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0
   Trkola A, 1996, J VIROL, V70, P1100
   Ugolini S, 1997, J EXP MED, V186, P1287, DOI 10.1084/jem.186.8.1287
   Vanlandschoot P, 2011, ANTIVIR RES, V92, P389, DOI 10.1016/j.antiviral.2011.09.002
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weng J, 2009, J VIROL, V83, P7467, DOI 10.1128/JVI.00163-09
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
NR 59
TC 13
Z9 13
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD OCT 2
PY 2014
VL 11
AR 83
DI 10.1186/s12977-014-0083-y
PG 15
WC Virology
SC Virology
GA AS8OX
UT WOS:000344508900001
PM 25700025
OA gold
DA 2018-01-05
ER

PT J
AU Morrison, TG
AF Morrison, Trudy G.
TI Meeting Report VLPNPV: Session 3: Immune Responses
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE adjuvants; anti-glycan immunity; human humoral immune responses; mucosal
   immunity; memory responses; T cell responses; Virus-like particles;
   VLPs; virus-like particles; NP; nanoparticles or nucleocapsid protein;
   MHC; major histocompatibility complex; HIV; human immunodeficiency
   virus; RSV; respiratory syncytial virus; NDV; Newcastle disease virus;
   M; membrane; F; fusion; G; glycoprotein; HN;
   hemagglutinin-neuraminidase; LLPC; long-lived plasma cells; TrV;
   triatoma virus; TMV; tobacco mosaic virus; TLR; toll-like receptor; NOD;
   nucleotide-binding oligomerization domains; RHDV; rabbit hemorrhagic
   disease virus; PBL; peripheral blood lymphocytes; BLys; B lymphocyte
   stimulator; ELISpot; enzyme-linked immunoSpot
ID VIRUS-LIKE PARTICLES; VACCINES; DISEASE; INFECTIONS
AB Virus-like particles (VLPs) and nano-particles (NP) are increasingly considered for both prophylactic and therapeutic vaccines for a wide variety of human and animal diseases. Indeed, 2 VLPs have already been licensed for use in humans, the human papilloma virus vaccine and the hepatitis B virus vaccine.(1) Reflecting this increased interest, a second international conference with a specific focus on VLPs and NP was held at the Salk Institute for Biological Studies in La Jolla, California, in June 2014. Approximately 100 attendees, hailing from many nations, came from academic institutions, research institutes, and biotech companies. A wide variety of topics were discussed, ranging from development and characterization of specific VLP and NP vaccine candidates to methods of production of these particles. Session three was focused on the general question of immune responses to VLPs.
C1 Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01610 USA.
RP Morrison, TG (reprint author), Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01610 USA.
EM trudy.morrison@umassmed.edu
CR Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Hjelm BE, 2014, HUM VACC IMMUNOTHER, V10, P410, DOI 10.4161/hv.27147
   Jackson EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041529
   Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Mathew LG, 2014, BIOMED RES INT, V2014, P9
   McGinnes LW, 2011, J VIROL, V85, P366, DOI 10.1128/JVI.01861-10
   Morrison TG, 2010, FUTURE VIROL, V5, P545, DOI 10.2217/FVL.10.50
   Querido JFB, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-66
   Raboni SM, 2003, TRANSPLANTATION, V76, P142, DOI 10.1097/01.TP.0000072012.26176.68
   Schmidt MR, 2014, J VIROL, V88, P10165, DOI 10.1128/JVI.01250-14
   Schmidt MR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003192
   Walsh EE, 1999, AM J RESP CRIT CARE, V160, P791, DOI 10.1164/ajrccm.160.3.9901004                                                    
   Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161
   Woodland RT, 2006, SEMIN IMMUNOL, V18, P318, DOI 10.1016/j.smim.2006.06.001
   Yin ZJ, 2013, ACS CHEM BIOL, V8, P1253, DOI 10.1021/cb400060x
NR 18
TC 0
Z9 0
U1 0
U2 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD OCT
PY 2014
VL 10
IS 10
BP 3064
EP 3067
DI 10.4161/21645515.2014.979643
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA AZ6FX
UT WOS:000348315500047
PM 25529229
OA gold
DA 2018-01-05
ER

PT J
AU Meador, LR
   Mor, TS
AF Meador, Lydia R.
   Mor, Tsafrir S.
TI Meeting Report VLPNPV: Session 5: Plant based technology
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE bluetongue virus; c-Erbb-2 (human epidermal growth factor receptor 2);
   cowpea mosaic virus; HIV-1; Hepatitis B core antigen; live viral
   vectors; potato virus X; tobacco mosaic virus; virus-like particles;
   viral nanoparticles; Ab; antibody; BPV; bovine papillomavirus; BTV;
   Bluetongue virus; CPMV; cowpea mosaic virus; ELISA; enzyme-linked
   immunosorbent assay; HBV; Hepatitis B virus; HER2; human epidermal
   growth factor receptor 2 (also called c-ErbB-2); HIV; human
   immunodeficiency virus; HT; HyperTrans; Ig; immunoglobulin; i; p;
   intraperitoneal; NPV; nano-particle vaccine; MPR; membrane proximal
   region; PEG; polyethylene glycol; PVX; potato virus X; SNP; spherical
   nanoparticle; TMV; tobacco mosaic virus; UTR; untranslated region; VLP;
   virus-like particle; VNP; viral nanoparticle
ID VIRUS-LIKE PARTICLES; MEMBRANE PROXIMAL REGION; BLUETONGUE VIRUS;
   IN-VIVO; VIRAL NANOPARTICLES; DRUG-DELIVERY; PROTEINS; HIV-1; VACCINES;
   EXPRESSION
AB The VLPNPV 2014 Conference that was convened at the Salk institute was the second conference of its kind to focus on advances in production, purification, and delivery of virus-like particles (VLPs) and nanoparticles. Many exciting developments were reported and discussed in this interdisciplinary arena, but here we report specifically on the contributions of plant-based platforms to VLP vaccine technology as reported in the section of the conference devoted to the topic as well in additional presentations throughout the meeting. The increasing popularity of plant production platforms is due to their lower cost, scalability, and lack of contaminating animal pathogens seen with other systems. Reports include production of complex VLPs consisting of 4 proteins expressed at finely-tuned expression levels, a prime-boost strategy for HIV vaccination using plant-made VLPs and a live viral vector, and the characterization and development of plant viral nanoparticles for use in cancer vaccines, drug delivery, and bioimaging.
C1 [Meador, Lydia R.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85745 USA.
   Arizona State Univ, Biodesign Inst, Tempe, AZ USA.
RP Meador, LR (reprint author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85745 USA.
EM lrmeador@asu.edu; tsafrir.mor@asu.edu
CR Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev.bioeng-071811-150124, 10.1146/annurev-bioeng-071811-150124]
   Batten CA, 2008, VIRUS RES, V137, P56, DOI 10.1016/j.virusres.2008.05.016
   Bessa J, 2012, P NATL ACAD SCI USA, V109, P20566, DOI 10.1073/pnas.1206970109
   Bruckman MA, 2014, VIROLOGY, V449, P163, DOI 10.1016/j.virol.2013.10.035
   Butler JG, 1984, J GEN VIROL, V65, P253
   Caldorera-Moore M, 2010, EXPERT OPIN DRUG DEL, V7, P479, DOI 10.1517/17425240903579971
   Carpenter S, 2009, TRENDS MICROBIOL, V17, P172, DOI 10.1016/j.tim.2009.01.001
   Chung AW, 2014, SCI TRANSL MED, V6, P228, DOI DOI 10.1126/SCITRANSLMED.3007736
   de Diego ACP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026666
   D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x
   Daum N, 2012, WIRES NANOMED NANOBI, V4, P52, DOI 10.1002/wnan.165
   Elbers ARW, 2008, PREV VET MED, V87, P31, DOI 10.1016/j.prevetmed.2008.06.003
   Gomez CE, 2012, HUM VACC IMMUNOTHER, V8, P1192, DOI 10.4161/hv.20778
   FRENCH TJ, 1990, J VIROL, V64, P5695
   FRENCH TJ, 1990, J VIROL, V64, P1530
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874
   Hartemink NA, 2009, EPIDEMICS-NETH, V1, P153, DOI 10.1016/j.epidem.2009.05.004
   Hayden EC, NATURE NEWS
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Hjelm BE, 2014, HUM VACC IMMUNOTHER, V10, P410, DOI 10.4161/hv.27147
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299
   Kaiser CR, 2007, INT J NANOMED, V2, P715
   Kessans SA, 2013, PLANT BIOTECHNOL J, V11, P681, DOI 10.1111/pbi.12058
   Kibler KV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025674
   Langreth R, EBOLA DRUG MADE TOBA
   Link A, 2012, J IMMUNOL, V188, P3724, DOI 10.4049/jimmunol.1103312
   Love AJ, 2012, PLANTA, V236, P1305, DOI 10.1007/s00425-012-1692-0
   Maan NS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032601
   Marillonnet S, 2004, P NATL ACAD SCI USA, V101, P6852, DOI 10.1073/pnas.0400149101
   Matoba N, 2009, PLANT BIOTECHNOL J, V7, P129, DOI 10.1111/j.1467-7652.2008.00381.x
   Matoba N, 2008, CURR HIV RES, V6, P218, DOI 10.2174/157016208784324994                                                      
   Milani A, 2013, ANN ONCOL, V24, P1740, DOI 10.1093/annonc/mdt133
   Montague NP, 2011, HUM VACCINES, V7, P383, DOI 10.4161/hv.7.3.14989
   Mor TS, 2003, BIOTECHNOL BIOENG, V81, P430, DOI 10.1002/bit.10483
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   Peyret H, 2013, PLANT MOL BIOL, V83, P51, DOI 10.1007/s11103-013-0036-1
   PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651
   Quakkelaar ED, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016819
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2210
   Rubin I, 2001, ANN ONCOL         S1, V12, pS3
   Rybicki EP, 2010, PLANT BIOTECHNOL J, V8, P620, DOI 10.1111/j.1467-7652.2010.00507.x
   Sainsbury F, 2008, PLANT BIOTECHNOL J, V6, P82, DOI 10.1111/j.1467-7652.2007.00303.x
   Sainsbury F, 2011, CHEMBIOCHEM, V12, P2435, DOI 10.1002/cbic.201100482
   Sainsbury F, 2009, PLANT BIOTECHNOL J, V7, P682, DOI 10.1111/j.1467-7652.2009.00434.x
   Saunders K, 2009, VIROLOGY, V393, P329, DOI 10.1016/j.virol.2009.08.023
   Savini G, 2008, COMP IMMUNOL MICROB, V31, P101, DOI 10.1016/j.cimid.2007.07.006
   Scotti N, 2013, EXPERT REV VACCINES, V12, P211, DOI [10.1586/erv.12.147, 10.1586/ERV.12.147]
   Shen XY, 2010, P NATL ACAD SCI USA, V107, P5972, DOI 10.1073/pnas.0912381107
   Shukla S, 2013, MOL PHARMACEUT, V10, P33, DOI 10.1021/mp300240m
   Singh P, 2007, J CONTROL RELEASE, V120, P41, DOI 10.1016/j.jconrel.2007.04.003
   Steinmetz NF, 2010, NANOMED-NANOTECHNOL, V6, P634, DOI 10.1016/j.nano.2010.04.005
   Stephenson KE, 2012, J VIROL, V86, P9583, DOI 10.1128/JVI.00996-12
   Stewart M, 2012, VACCINE, V30, P2131, DOI 10.1016/j.vaccine.2012.01.042
   TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B
   Thuenemann EC, 2013, PLANT BIOTECHNOL J, V11, P839, DOI 10.1111/pbi.12076
   Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107
   Wen AM, 2014, ADV HEALTHC MATER, V3, P1739, DOI 10.1002/adhm.201400141
   Wen AM, 2013, J BIOL PHYS, V39, P301, DOI 10.1007/s10867-013-9314-z
   Wilson C, 2014, NEW SCI, V223, P7, DOI 10.1016/S0262-4079(14)61512-8                                                   
   Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730
   Yildiz I, 2011, CURR OPIN BIOTECH, V22, P901, DOI 10.1016/j.copbio.2011.04.020
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 64
TC 3
Z9 3
U1 3
U2 13
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD OCT
PY 2014
VL 10
IS 10
BP 3068
EP 3073
DI 10.4161/21645515.2014.979693
PG 6
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA AZ6FX
UT WOS:000348315500048
PM 25581535
OA gold
DA 2018-01-05
ER

PT J
AU Thiriot, DS
AF Thiriot, David S.
TI Meeting report VLPNPV: Session 8: Vaccines I
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE Bacteriophage display; dengue; E2 display; HIV (human immunodeficiency
   virus); HPV (human papillomavirus); malaria; RSV (respiratory syncytial
   virus); vaccine development; VLP (virus-like particle)
AB In Session 8 of the recent conference Virus-Like Particle and Nano-Particle Vaccines held at the Salk Institute in La Jolla, California (05 June 2014), four scientists described new virus-like particle (VLP) approaches, progress, and early-stage plans for vaccines against significant human pathogens including HPV, malaria, HIV, Dengue, and RSV. A unifying theme was that displaying epitopes in an array on a virus-like particle can be a powerful approach for achieving a strong immune response. VLP approaches described included display of epitopes on bacteriophage, display of epitopes as fusions with other protein multimerization domains, and self-assembly of recombinantly-expressed virus coat proteins. Another theme in some of the presentations was the targeting of neutralizing epitopes that are masked or only transiently accessible during natural infection.
C1 Merck Res Labs, Vaccine Drug Prod Dev, Biol & Vaccine Formulat, West Point, PA 19486 USA.
RP Thiriot, DS (reprint author), Merck Res Labs, Vaccine Drug Prod Dev, Biol & Vaccine Formulat, West Point, PA 19486 USA.
EM david_thiriot@merck.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD OCT
PY 2014
VL 10
IS 10
BP 3078
EP 3079
DI 10.4161/21645515.2014.972841
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA AZ6FX
UT WOS:000348315500051
PM 25483643
OA gold
DA 2018-01-05
ER

PT J
AU Baleux, F
   Arien, K
   Desjardins, D
   Michiels, J
   Coic, YM
   Connell, BJ
   Bonnaffe, D
   Bouchemal, K
   Le Grand, R
   Vanham, G
   Dereuddre-Bosquet, N
   Lortat-Jacob, H
AF Baleux, Francoise
   Arien, Kevin
   Desjardins, Delphine
   Michiels, Jo
   Coic, Yves-Marie
   Connell, Bridgette J.
   Bonnaffe, David
   Bouchemal, Kawthar
   Le Grand, Roger
   Vanham, Guido
   Dereuddre-Bosquet, Nathalie
   Lortat-Jacob, Hugues
TI Mini CD4-heparan Sulfate Mimetic Conjugates Display Sub Nanomolar
   Anti-HIV-1 Activity and Protect Macaques against a SHIV162P3 Vaginal
   Route Challenge
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Symposium on HIV Research for Prevention (HIV R4P)
CY OCT 28-31, 2014
CL Cape Town, SOUTH AFRICA
C1 [Baleux, Francoise; Coic, Yves-Marie] Inst Pasteur, Unite Chim Biomol, URA 2128, CNRS, Paris, France.
   [Arien, Kevin; Michiels, Jo; Vanham, Guido] Inst Trop Med, Virol Unit, B-2000 Antwerp, Belgium.
   [Desjardins, Delphine; Dereuddre-Bosquet, Nathalie] CEA, Serv Immunovirol IDMIT, Fontenay Aux Roses, France.
   [Connell, Bridgette J.; Lortat-Jacob, Hugues] Univ Grenoble Alpes, CNRS, CEA, Inst Biol Struct,UMR 5075, Grenoble, France.
   [Bonnaffe, David] Univ Paris 11, Inst Chim Mol & Mat Orsay, Orsay, France.
   [Bouchemal, Kawthar] Univ Paris 11, Fac Pharm, F-92290 Chatenay Malabry, France.
NR 0
TC 0
Z9 0
U1 1
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2014
VL 30
SU 1
MA P44.05
BP A262
EP A262
DI 10.1089/aid.2014.5588.abstract                                          
          
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2OO
UT WOS:000344774403130
DA 2018-01-05
ER

PT J
AU Climent, N
   Pavot, V
   Garcia, F
   Lioux, T
   Perouzel, E
   Primard, C
   Paul, S
   Gatell, JM
   Plana, M
   Verrier, B
   Gallart, T
AF Climent, Nuria
   Pavot, Vincent
   Garcia, Felipe
   Lioux, Thierry
   Perouzel, Eric
   Primard, Charlotte
   Paul, Stephane
   Maria Gatell, Jose
   Plana, Montserrat
   Verrier, Bernard
   Gallart, Teresa
TI Co-delivery of Antigen p24 and NOD-ligands by PLA Nanoparticles to Human
   Dendritic Cells Promote Highly Functional HIV-1-Specific T-cell
   Responses
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on HIV Research for Prevention (HIV R4P)
CY OCT 28-31, 2014
CL Cape Town, SOUTH AFRICA
C1 [Climent, Nuria; Garcia, Felipe; Maria Gatell, Jose; Plana, Montserrat; Gallart, Teresa] CELLEX IDIBAPS HIVACAT, Barcelona, Spain.
   [Pavot, Vincent; Primard, Charlotte; Verrier, Bernard] UCBL, CNRS, UMR 5305, Inst Biol & Chim Prot, Lyon 07, France.
   [Lioux, Thierry; Perouzel, Eric] InvivoGen, CAYLA, Toulouse, France.
   [Paul, Stephane] Fac Med, CIE Vaccinol 3, INSERM, Grp Immunite Muqueuses & Agents Pathogenes, St Etienne, France.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2014
VL 30
SU 1
MA P41.03
BP A240
EP A241
DI 10.1089/aid.2014.5532.abstract                                          
          
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2OO
UT WOS:000344774403072
DA 2018-01-05
ER

PT J
AU Jiang, YH
   Cao, SJ
   Bright, D
   Sudyam, IT
   Woodrow, KA
AF Jiang, Yonghou
   Cao, Shijie
   Bright, Danielle
   Sudyam, Ian T.
   Woodrow, Kim A.
TI Testing of Nanoparticle-based ARV Drug Combinations for Inhibiting
   Cell-free and Cell-cell HIV Transmission
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Symposium on HIV Research for Prevention (HIV R4P)
CY OCT 28-31, 2014
CL Cape Town, SOUTH AFRICA
C1 [Jiang, Yonghou; Cao, Shijie; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Bright, Danielle; Sudyam, Ian T.] Seattle Univ, Dept Chem, Seattle, WA 98122 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2014
VL 30
SU 1
MA P15.18
BP A147
EP A148
DI 10.1089/aid.2014.5300.abstract                                          
          
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2OO
UT WOS:000344774402008
DA 2018-01-05
ER

PT J
AU Spreen, B
   Rinehart, A
   Smith, K
   Margolis, D
   Ford, S
   Piscitelli, S
AF Spreen, Bill
   Rinehart, Alex
   Smith, Kimberly
   Margolis, David
   Ford, Susan
   Piscitelli, Steve
TI HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting
   Injectable Nanosuspension
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Symposium on HIV Research for Prevention (HIV R4P)
CY OCT 28-31, 2014
CL Cape Town, SOUTH AFRICA
C1 [Spreen, Bill; Margolis, David; Piscitelli, Steve] GlaxoSmithKline R&D, Infect Dis, Res Triangle Pk, NC USA.
   [Rinehart, Alex; Smith, Kimberly] ViiV Healthcare, R&D, Res Triangle Pk, NC USA.
   [Ford, Susan] GlaxoSmithKline R&D, Clin Pharmacol Modeling & Simulat, Res Triangle Pk, NC USA.
NR 0
TC 2
Z9 2
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2014
VL 30
SU 1
MA OA03.02 LB
BP A12
EP A12
DI 10.1089/aid.2014.5010a.abstract                                         
          
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2OO
UT WOS:000344774400015
DA 2018-01-05
ER

PT J
AU Yang, HT
   Li, J
   Dezzutti, CS
   Palmer, K
   Rohan, LC
AF Yang, Haitao
   Li, Jing
   Dezzutti, Charlene S.
   Palmer, Kenneth
   Rohan, Lisa C.
TI Design of Biodegradable Nanoparticles for Vaginal Delivery of the
   anti-HIV Protein Griffithsin
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Symposium on HIV Research for Prevention (HIV R4P)
CY OCT 28-31, 2014
CL Cape Town, SOUTH AFRICA
C1 [Yang, Haitao; Li, Jing; Rohan, Lisa C.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
   [Yang, Haitao; Dezzutti, Charlene S.; Rohan, Lisa C.] Magee Women Res Inst, Pittsburgh, PA USA.
   [Palmer, Kenneth] Univ Louisville, Sch Med, Louisville, KY 40292 USA.
   [Rohan, Lisa C.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT 1
PY 2014
VL 30
SU 1
MA P15.05
BP A142
EP A143
DI 10.1089/aid.2014.5287.abstract                                          
          
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AT2OO
UT WOS:000344774401166
DA 2018-01-05
ER

PT J
AU John, SV
   Rotherham, LS
   Khati, M
   Mamba, BB
   Arotiba, OA
AF John, Suru V.
   Rotherham, Lia S.
   Khati, Makobetsa
   Mamba, Bhekie B.
   Arotiba, Omotayo A.
TI Towards HIV Detection: Novel Poly(propylene imine)
   Dendrimer-Streptavidin Platform for Electrochemical DNA and gp120
   Aptamer Biosensors
SO INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE
LA English
DT Article
DE Biosensor; Aptamer; HIV; gp120; poly (propylene imine) dendrimer;
   streptavidin
ID TAT PROTEIN; IN-VIVO; NANOBIOSENSOR
AB The detection of sequence - specific DNA and HIV glycoprotein 120 (gp120) based on novel generation 4 poly(propylene imine) dendrimer/streptavidin platform is reported. The platform was prepared by the electrodeposition of the dendrimer on a carbon electrode followed by drop coating with streptavidin. The generation 4 poly(propylene imine) dendrimer/streptavidin platform was characterised using scanning electron microscopy, voltammetry and electrochemical impedance spectroscopy (EIS). Electrochemical measurements indicated that the platform was stable, conducting and exhibited reversible electrochemistry at a former potential of 140 mV in pH 7.5 phosphate buffer saline solution (PBS), while EIS interrogation using [Fe(CN)(6)(3-/4-)] redox probe showed a marked reduction in charge transfer resistance (R-ct) after modification. The biosensor was prepared by the immobilisation of single stranded 5'- biotynilated probe DNA and B40 aptamer on the modified electrode and then used to detect complementary DNA and gp120 respectively. The biosensor responses were evaluated with square wave voltammetry (SWV) and EIS in the presence of PBS and Fe(CN)(6)(3-/4-) redox probe. A detection limit of 3.44 x 10(-12) M (S/N = 3) and linearity r(2) = 0.9985 were obtained for the DNA biosensor while the aptamer biosensor detected gp120 in the nanomolar concentration range. The DNA biosensor also showed excellent selectivity in the presence of non complementary and mismatch DNA strands.
C1 [John, Suru V.; Mamba, Bhekie B.; Arotiba, Omotayo A.] Univ Johannesburg, Dept Appl Chem, ZA-2028 Johannesburg, South Africa.
   [Rotherham, Lia S.; Khati, Makobetsa] CSIR, ZA-0001 Pretoria, South Africa.
RP John, SV (reprint author), Univ Johannesburg, Dept Appl Chem, ZA-2028 Johannesburg, South Africa.
EM oarotiba@uj.ac.za
RI Mamba, Bhekie/P-4940-2014; Arotiba, Omotayo/B-4946-2011
OI Mamba, Bhekie/0000-0003-2534-2579; Arotiba, Omotayo/0000-0002-8227-8684
FU Centre for Nanomaterial Science Research (CNSR); National Research
   Foundation of South Africa; Faculty of Science, UJ; Department of
   Applied Chemistry, University of Johannesburg (UJ)
FX The authors acknowledge the Centre for Nanomaterial Science Research
   (CNSR), Department of Applied Chemistry, University of Johannesburg
   (UJ); Faculty of Science, UJ and the National Research Foundation of
   South Africa for financial support. SV John wishes to thank Mr Anton of
   the Laser Research Laboratory, University of Johannesburg for laboratory
   assistance.
CR Alonso-Lomillo MA, 2010, TALANTA, V82, P1629, DOI 10.1016/j.talanta.2010.08.033
   Arotiba O, 2008, SENSORS-BASEL, V8, P6791, DOI 10.3390/s8116791
   Arotiba OA, 2011, INT J ELECTROCHEM SC, V6, P673
   Arotiba OA, 2010, J ELECTROANAL CHEM, V638, P287, DOI 10.1016/j.jelechem.2009.10.032
   Arotiba OA, 2009, CHIM OGGI, V27, P55
   Bonanni A, 2009, BIOSENS BIOELECTRON, V24, P2885, DOI 10.1016/j.bios.2009.02.023
   Cheng AKH, 2009, BIOELECTROCHEMISTRY, V77, P1, DOI 10.1016/j.bioelechem.2009.04.007
   D'Orazio P, 2011, CLIN CHIM ACTA, V412, P1749, DOI 10.1016/j.cca.2011.06.025
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Gosser D.K., 1993, CYCLIC VOLTAMMETRY S
   Kowalczyk A, 2011, BIOSENS BIOELECTRON, V26, P2506, DOI 10.1016/j.bios.2010.10.046
   Li GJ, 2009, BIOSENS BIOELECTRON, V24, P3281, DOI 10.1016/j.bios.2009.04.022
   Liu X., 2012, BIOSENS BIOELECTRON, V26, P2154
   Marisa J. K., 2010, BIOCHEMISTRY-US, V49, P5880
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Mufhandu H. T., 2012, J VIROL, V86, P1
   Orava EW, 2013, MOL ONCOL, V7, P799, DOI 10.1016/j.molonc.2013.03.005
   Radom F, 2013, BIOTECHNOL ADV, V31, P1260, DOI 10.1016/j.biotechadv.2013.04.007
   Ruslinda AR, 2013, BIOSENS BIOELECTRON, V40, P277, DOI 10.1016/j.bios.2012.07.048
   Shamsipur M, 2012, BIOELECTROCHEMISTRY, V83, P31, DOI 10.1016/j.bioelechem.2011.08.003
   Shukla SK, 2013, INT J ELECTROCHEM SC, V8, P11711
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Zhu NN, 2010, BIOSENS BIOELECTRON, V25, P1498, DOI 10.1016/j.bios.2009.11.006
   Ziolkowski R, 2012, BIOELECTROCHEMISTRY, V87, P78, DOI 10.1016/j.bioelechem.2011.10.005
NR 26
TC 3
Z9 3
U1 3
U2 25
PU ESG
PI BELGRADE
PA BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA
SN 1452-3981
J9 INT J ELECTROCHEM SC
JI Int. J. Electrochem. Sci.
PD OCT
PY 2014
VL 9
IS 10
BP 5425
EP 5437
PG 13
WC Electrochemistry
SC Electrochemistry
GA AT9QP
UT WOS:000345261700006
DA 2018-01-05
ER

PT J
AU Zhao, C
   Hoppe, T
   Setty, MKHG
   Murray, D
   Chun, TW
   Hewlett, I
   Appella, DH
AF Zhao, Chao
   Hoppe, Travis
   Setty, Mohan Kumar Haleyur Giri
   Murray, Danielle
   Chun, Tae-Wook
   Hewlett, Indira
   Appella, Daniel H.
TI Quantification of plasma HIV RNA using chemically engineered peptide
   nucleic acids
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; SANDWICH-HYBRIDIZATION; DNA DETECTION; POINT;
   ASSAY; CARE; NANOPARTICLES; ACCURACY; COMPLEX; BLOOD
AB The remarkable stability of peptide nucleic acids (PNAs) towards enzymatic degradation makes this class of molecules ideal to develop as part of a diagnostic device. Here we report the development of chemically engineered PNAs for the quantitative detection of HIV RNA at clinically relevant levels that are competitive with current PCR-based assays. Using a sandwich hybridization approach, chemical groups were systematically introduced into a surface PNA probe and a reporter PNA probe to achieve quantitative detection for HIV RNA as low as 20 copies per millilitre of plasma. For the surface PNA probe, four cyclopentane groups were incorporated to promote stronger binding to the target HIV RNA compared with PNA without the cyclopentanes. For the reporter PNA probe, 25 biotin groups were attached to promote strong signal amplification after binding to the target HIV RNA. These general approaches to engineer PNA probes may be used to detect other RNA target sequences.
C1 [Zhao, Chao; Appella, Daniel H.] NIDDK, Bioorgan Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA.
   [Hoppe, Travis] NIDDK, Lab Biochem & Genet, NIH, DHHS, Bethesda, MD 20892 USA.
   [Setty, Mohan Kumar Haleyur Giri; Hewlett, Indira] FDA, Mol Virol Lab, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.
   [Murray, Danielle; Chun, Tae-Wook] NIDDK, Immunoregulat Lab, NIH, DHHS, Bethesda, MD 20892 USA.
RP Appella, DH (reprint author), NIDDK, Bioorgan Chem Lab, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM appellad@niddk.nih.gov
OI Hoppe, Travis/0000-0002-4694-3050
FU Intramural AIDS Targeted Antiviral Programme of NIH; Intramural Research
   Programme of NIDDK, NIH
FX This research was supported by the Intramural Research Programme of
   NIDDK, NIH and the Intramural AIDS Targeted Antiviral Programme of NIH.
   We would like to thank Dr Frank Maldarelli for assistance in processing
   the patient samples.
CR Alemnji G, 2011, INDIAN J MED RES, V134, P779, DOI 10.4103/0971-5916.92625
   Branson BM, 2010, JAIDS-J ACQ IMM DEF, V55, pS102, DOI 10.1097/QAI.0b013e3181fbca44
   Buraruk T. A., 2012, MODERN CLIN MOL TECH, P123
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Castel AD, 2014, AIDS CARE, V26, P785, DOI 10.1080/09540121.2013.855296
   Chen L, 2008, BIOSENS BIOELECTRON, V23, P1878, DOI 10.1016/j.bios.2008.02.013
   Chin CD, 2012, LAB CHIP, V12, P2118, DOI 10.1039/c2lc21204h
   DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6
   Dequaire M, 2002, ANAL CHEM, V74, P4370, DOI 10.1021/ac025541g
   Dineva MA, 2007, ANALYST, V132, P1193, DOI 10.1039/b705672a
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   Englund EA, 2014, METHODS MOL BIOL, V1050, P13, DOI 10.1007/978-1-62703-553-8_2
   Faraoni S, 2013, J CLIN VIROL, V57, P84, DOI 10.1016/j.jcv.2013.01.007
   Ferapontova EE, 2010, CHEM COMMUN, V46, P1836, DOI 10.1039/b924627d
   Franzini RM, 2011, CHEM-EUR J, V17, P2168, DOI 10.1002/chem.201002426
   Galli RA, 2013, J CLIN VIROL, V58, pE65, DOI 10.1016/j.jcv.2013.08.024
   Gaydos C, 2014, EXPERT REV ANTI-INFE, V12, P657, DOI 10.1586/14787210.2014.880651
   HIV Diagnostics Survey, 2012, PUBL HLTH LAB ISS BR
   Jangam SR, 2013, BIOSENS BIOELECTRON, V42, P69, DOI 10.1016/j.bios.2012.10.024
   Jolliffe I. T., 2002, NAT METHODS
   JOSEPHY PD, 1982, J BIOL CHEM, V257, P3669
   Klein DJ, 2014, AIDS, V28, pS47, DOI 10.1097/QAD.0000000000000081
   Kleinbaum DJ, 2010, CHEM COMMUN, V46, P8154, DOI 10.1039/c0cc01968b
   Li S, 2010, ANAL BIOCHEM, V405, P141, DOI 10.1016/j.ab.2010.05.016
   Marquette CA, 2006, SENSOR ACTUAT B-CHEM, V113, P664, DOI 10.1016/j.snb.2005.07.015
   McNairy ML, 2014, CLIN INFECT DIS, V58, P1003, DOI 10.1093/cid/ciu018
   Micklitsch CM, 2013, ANAL CHEM, V85, P251, DOI 10.1021/ac3026459
   Nasrullah M., 2012, AIDS, V27, P731
   NICHOLLS PJ, 1989, J CLIN LAB ANAL, V3, P122, DOI 10.1002/jcla.1860030210                                                         
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   Nielsen P. E., 2014, PEPTIDE NUCL ACIDS M
   Ouma KN, 2013, J CLIN MICROBIOL, V51, P1208, DOI 10.1128/JCM.03048-12
   Pilcher CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080629
   Pokorski JK, 2004, J AM CHEM SOC, V126, P15067, DOI 10.1021/ja046280q
   Shan L, 2013, J VIROL, V87, P6521, DOI 10.1128/JVI.00006-13
   Stekler JD, 2013, J CLIN VIROL, V58, pE119, DOI 10.1016/j.jcv.2013.09.018
   van Deursen P, 2010, J CLIN VIROL, V47, P120, DOI 10.1016/j.jcv.2009.11.021
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wild D., 2005, IMMUNOASSAY HDB
   Wilson E., 2012, ORAL DIS, V19, P431
   Zhang CY, 2010, ANAL CHEM, V82, P1921, DOI 10.1021/ac9026675
   Zhang N, 2007, J AM CHEM SOC, V129, P8424, DOI 10.1021/ja072744j
   Zhao XJ, 2003, J AM CHEM SOC, V125, P11474, DOI 10.1021/ja0358854
NR 44
TC 4
Z9 4
U1 2
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2014
VL 5
AR 5079
DI 10.1038/ncomms6079
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0OR
UT WOS:000343977900003
PM 25283173
OA gold
DA 2018-01-05
ER

PT J
AU Moretton, MA
   Cohen, L
   Lepera, L
   Bernabeu, E
   Taira, C
   Hocht, C
   Chiappetta, DA
AF Moretton, Marcela A.
   Cohen, Laura
   Lepera, Leandro
   Bernabeu, Ezequiel
   Taira, Carlos
   Hoecht, Christian
   Chiappetta, Diego A.
TI Enhanced oral bioavailability of nevirapine within micellar nanocarriers
   compared with Viramune (R)
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Polymeric micelles; PEO-PPO-PEO block copolymers; Nevirapine; In vivo
   oral pharmacokinetic studies; Viramune (R)
ID BLOCK-COPOLYMER MICELLES; WATER-SOLUBLE POLYMERS; DRUG-DELIVERY;
   POLYETHYLENE-GLYCOL; HIV TRANSMISSION; VIVO EVALUATION; SOLUBILIZATION;
   MIXTURES; STABILITY; EFAVIRENZ
AB In this work, Nevirapine (NVP) was encapsulated within three derivatives of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) block copolymers (Tetronic (R) 904, 1107 and Pluronic (R) F127) with and without the addition of three pharmaceutical cosolvents (glycerin, propylene glycol and polyethylene glycol 400) over a wider range of concentrations (0-40% v/v). Also, we evaluated the effect of addition of the cosolvents on the micellar size as determined by dynamic light scattering (DLS) measurements and transmission electron microscopy (TEM). The solubilization capacity of the systems was investigated by UV-spectrophotometry (282 nm) and the systems stability was evaluated for I month at 25 degrees C. Finally, oral bioavailability of the NVP-loaded micellar systems (2 mg/mL) was assessed in male Wistar rats (8 mg/kg) and compared with a pediatric commercially available formulation (Viramune (R)). The present study demonstrates that PEO-PPO-PEO polymeric micelles were able to enhance apparent aqueous solubility of NVP with the addition of cosolvents. Moreover, micellar nanocarriers significantly (p<0.05) improved the oral bioavailability of the drug versus Viramune (R).
   Overall results support the suitability of the strategy toward the development of an optimized NVP aqueous formulation to prevent HIV/AIDS mother-to-child transmission. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Moretton, Marcela A.; Lepera, Leandro; Bernabeu, Ezequiel; Chiappetta, Diego A.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, RA-1053 Buenos Aires, DF, Argentina.
   [Cohen, Laura; Taira, Carlos; Hoecht, Christian] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmacol, RA-1053 Buenos Aires, DF, Argentina.
   [Taira, Carlos; Chiappetta, Diego A.] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
RP Chiappetta, DA (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, 956 Junin St,6th Floor,Buenos Aires CP1113, RA-1053 Buenos Aires, DF, Argentina.
EM diegochiappetta@yahoo.com.ar
FU University of Buenos Aires [UBACyT 20020100300088, 20020120200058];
   CONICET; PFDT fellowship of the ANPCyT, Argentina [FONARSEC PICT-PRH
   2008-00315]; CONICET, Argentina
FX Authors thank the University of Buenos Aires (Grant UBACyT
   20020100300088 and 20020120200058). MAM is supported by postdoctoral
   scholarship of CONICET and EB by the PFDT fellowship of the ANPCyT
   (FONARSEC PICT-PRH 2008-00315), Argentina. CT and DAC are partially
   supported by CONICET, Argentina.
CR Aimone L.D., 2005, CURR PROTOCOLS PHA S, V30, P1
   Babu PRS, 2008, DHAKA U J PHARM SCI, V7, P119
   Bedri A, 2008, LANCET, V372, P300
   Bowles A, 2010, INT J PHARMACEUT, V395, P37, DOI 10.1016/j.ijpharm.2010.04.048
   Bromberg LE, 1998, ADV DRUG DELIVER REV, V31, P197, DOI 10.1016/S0169-409X(97)00121-X
   Buontempo F, 2010, Farm Hosp, V34, P293, DOI 10.1016/j.farma.2010.01.002
   Chadha R, 2011, J THERM ANAL CALORIM, V105, P1049, DOI 10.1007/s10973-011-1406-z
   Chadha R, 2010, AAPS PHARMSCITECH, V11, P1328, DOI 10.1208/s12249-010-9511-z
   Chen LC, 2013, INT J NANOMED, V8, P73, DOI 10.2147/IJN.S38221
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, CURR HIV RES, V8, P223, DOI 10.2174/157016210791111142
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Arpan C, 2011, INT J PHARMTECH RES, V3, P1159
   Crothers M, 2008, INT J PHARM, V358, P303, DOI 10.1016/j.ijpharm.2008.03.004
   Dong JF, 2003, COLLOID SURFACE A, V212, P9, DOI 10.1016/S0927-7757(02)00295-9                                                   
   Gaucher G, 2010, EUR J PHARM BIOPHARM, V76, P147, DOI 10.1016/j.ejpb.2010.06.007
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   He W, 2009, CHEM PHARM BULL, V57, P122, DOI 10.1248/cpb.57.122                                                              
   Jain P, 2007, INT J PHARM, V342, P1, DOI 10.1016/j.ijpharm.2007.03.056
   Kadam Y, 2011, COLLOID SURFACE B, V83, P49, DOI 10.1016/j.colsurfb.2010.10.041
   Kulthe SS, 2011, COLLOID SURFACE B, V88, P691, DOI 10.1016/j.colsurfb.2011.08.002
   L'homme R, 2007, CURR OPIN HIV AIDS, V2, P405, DOI 10.1097/COH.0b013e3282ced13f
   Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001
   Liu T, 2011, LANGMUIR, V27, P9253, DOI 10.1021/la201676u
   Lokamatha K.M., 2010, INT J PHARM PHARM SC, V2, P169
   Moretton M.A., 2014, NANOMEDICINE LOND
   Morfaw Frederick L I, 2012, Syst Rev, V1, P13, DOI 10.1186/2046-4053-1-13
   Nayak A, 2012, ISRN PHYS CHEM, V2012, P1
   Nesheim S, 2013, CURR OPIN HIV AIDS, V8, P447, DOI 10.1097/COH.0b013e3283636ccb
   NIVAGGIOLI T, 1995, LANGMUIR, V11, P119, DOI 10.1021/la00001a023                                                             
   Oliveira CP, 2011, INT J PHARMACEUT, V421, P252, DOI 10.1016/j.ijpharm.2011.10.010
   Plotkin M, 2014, BIOMATERIALS, V35, P1429, DOI 10.1016/j.biomaterials.2013.10.058
   Qian S., 2014, INT J PHARM
   Rexroad VE, 2006, JAIDS-J ACQ IMM DEF, V43, P373, DOI 10.1097/01.qai.0000242458.51015.25
   Ricardo NMPS, 2012, J COLLOID INTERF SCI, V368, P336, DOI 10.1016/j.jcis.2011.10.062
   Rowe R. C., 2009, HDB PHARM EXCIPIENTS
   Sanan R, 2013, COLLOID SURFACE A, V433, P145, DOI 10.1016/j.colsurfa.2013.05.003
   Sarkar B, 2013, J COLLOID INTERF SCI, V390, P137, DOI 10.1016/j.jcis.2012.09.028
   Sharma M.C., 2011, INT J PHARMTECH RES, V3, P144
   Stieger N, 2010, CRYST GROWTH DES, V10, P3859, DOI 10.1021/cg901501d
   Weinberg GA, 2000, BIRTH-ISS PERINAT C, V27, P199, DOI 10.1046/j.1523-536x.2000.00199.x                                                
   Yu HZ, 2013, EUR J PHARM BIOPHARM, V85, P1325, DOI 10.1016/j.ejpb.2013.08.003
   Zhang W, 2011, BIOMATERIALS, V32, P5934, DOI 10.1016/j.biomaterials.2011.04.075
NR 45
TC 9
Z9 9
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD OCT 1
PY 2014
VL 122
BP 56
EP 65
DI 10.1016/j.colsurfb.2014.06.046
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA AR5GK
UT WOS:000343612900008
PM 25016545
DA 2018-01-05
ER

PT J
AU Yang, HT
   Li, J
   Dezzutti, CS
   Palmer, K
   Rohan, LC
AF Yang, Haitao
   Li, Jing
   Dezzutti, Charlene S.
   Palmer, Kenneth
   Rohan, Lisa C.
TI Design of Biodegradable Poly Lactic-Co-Glycolic Acid (PLGA)
   Nanoparticles for Co-Delivery of Anti-HIV Protein Griffithsin and
   Dapivirine in the Vagina
SO JOURNAL OF WOMENS HEALTH
LA English
DT Meeting Abstract
C1 [Yang, Haitao; Li, Jing; Rohan, Lisa C.] Univ Pittsburgh, Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15260 USA.
   [Yang, Haitao; Dezzutti, Charlene S.; Rohan, Lisa C.] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15260 USA.
   [Dezzutti, Charlene S.; Rohan, Lisa C.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15260 USA.
   [Palmer, Kenneth] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD OCT 1
PY 2014
VL 23
IS 10
MA P-78
BP 873
EP 873
PG 1
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA AR0DT
UT WOS:000343237900092
DA 2018-01-05
ER

PT J
AU Jiang, YH
   Li, M
   Zhang, ZR
   Gong, T
   Sun, X
AF Jiang, Yuhong
   Li, Man
   Zhang, Zhirong
   Gong, Tao
   Sun, Xun
TI Enhancement of Nasal HIV Vaccination with Adenoviral Vector-Based
   Nanocomplexes Using Mucoadhesive and DC-Targeting Adjuvants
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE adenovirus; chitooligosaccharides; human immunodeficiency virus;
   intranasal vaccine; mannosylated polyethyleneimine
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; GENE DELIVERY VECTORS;
   CHITOSAN OLIGOMERS; DNA VACCINE; IN-VIVO; IMMUNE-RESPONSES; MUCOSAL
   VACCINES; DENDRITIC CELLS; DRUG-DELIVERY
AB Purpose To investigate the vaccine effect of a replication-defective recombinant adenovirus 5 (rAd5)-based nanocomplex with chitooligosaccharides (Oligo) and mannosylated polyethyleneimine-triethyleneglycol (mPEI) as adjuvants for human immunodeficiency virus (HIV) infection.
   Methods Physical characteristics were determined through detecting the size, zeta potential and morphology of Oligo-mPEI-rAd5 nanocomplex, and in vitro vaccine uptake and transduction efficiency were estimated. Nanocomplexes were then administered intranasally to Balb/c mice to evaluate in vivo rAd5 residence in nasal cavity and HIVgag-specific immune responses using cytotoxic T lymphocyte (CTL), intracellular cytokine staining (ICS) and ELISA assay.
   Results The mucoadhesivity of Oligo prolonged nasal residence time, while the dendritic cell (DC) specificity of mPEI improved vaccine uptake. These two adjuvants jointly enhanced transduction efficiency of rAd5. Oligo-mPEI-rAd5 nanocomplex elicited potent HIVgag-specific CTL response and increased IFN-gamma positive CD8(+) T and IL-4 positive CD4(+) T cells, indicating high cellular immune responses. This vaccine candidate also led to strong humoral immune responses (IgG/IgG1/IgG2a) with balanced Th1/Th2 CD4(+) T cell activity. Moreover, mice nasally immunized with Oligo-mPEI-rAd5 showed higher levels of SIgA in nasal washes than did mice immunized with rAd5.
   Conclusions Intranasal delivery of Oligo-mPEI-rAd5 with a prime-boost regimen is a potential immunization for HIV infection, inducing HIVgag-specific cellular, humoral and mucosal immune responses.
C1 [Jiang, Yuhong; Li, Man; Zhang, Zhirong; Gong, Tao; Sun, Xun] Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu 610041, Sichuan, Peoples R China.
RP Sun, X (reprint author), Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting & Drug Delivery Syst, 17,Sect 3,Southern Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
EM xunsun22@gmail.com
RI JIANG, YUHONG/D-2099-2017
OI JIANG, YUHONG/0000-0002-5120-9475; Sun, Xun/0000-0002-0218-1664
FU National Natural Science Foundation of China [81173011]; National Basic
   Research Program of China (973 Program) [2013CB932504]; Science
   Foundation for Youths of Sichuan Province [2012JQ0024]
FX We are grateful for financial support from the National Natural Science
   Foundation of China (No. 81173011), the National Basic Research Program
   of China (973 Program, No. 2013CB932504) and Science Foundation for
   Youths of Sichuan Province (No. 2012JQ0024). We also thank Prof.
   Hildegund C.J. Ertl from the Wistar Institute of Anatomy and Biology for
   kindly providing the replication-defective adenovirus 5 HIVgag vector.
CR Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149
   Becker PD, 2001, VACCINE, V19, P4603, DOI 10.1016/S0264-410X(01)00259-6
   Bergquist C, 1997, INFECT IMMUN, V65, P2676
   Byers AM, 2003, J IMMUNOL, V171, P17, DOI 10.4049/jimmunol.171.1.17                                                       
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003
   Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258                                                                  
   Chen J, 2006, MOL THER, V13, P260, DOI 10.1016/j.ymthe.2005.10.006
   Croyle MA, 2008, PLOS ONE, V10, pe3548
   Doria-Rose NA, 2003, METHODS, V31, P207, DOI 10.1016/S1046-2023(03)00135-X
   Fitzgerald JC, 2003, J IMMUNOL, V170, P1416, DOI 10.4049/jimmunol.170.3.1416                                                     
   Foster KA, 2000, INT J PHARM, V208, P1, DOI 10.1016/S0378-5173(00)00452-X                                                   
   Gao Y, 2008, INT J PHARM, V359, P70, DOI 10.1016/j.ijpharm.2008.03.016
   Gebril A, 2012, EXPERT REV VACCINES, V11, P1139, DOI [10.1586/erv.12.81, 10.1586/ERV.12.81]
   Girard MP, 2011, VACCINE, V29, P6191, DOI 10.1016/j.vaccine.2011.06.085
   Gwinn WM, 2010, VACCINE, V28, P6901, DOI 10.1016/j.vaccine.2010.08.006
   Hagenaars N, 2009, J CONTROL RELEASE, V140, P126, DOI 10.1016/j.jconrel.2009.08.018
   Han JF, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/10/105106
   Hogan CM, 2001, ANN INTERN MED, V134, P761, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00013
   Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Irina L, 2011, J MOL MED, V89, P331
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kalams SA, 1999, J VIROL, V73, P6715
   Kean T, 2005, J CONTROL RELEASE, V103, P643, DOI 10.1016/j.jconrel.2004.01.001
   Kirschner M, 2006, PROTEIN EXPRES PURIF, V48, P61, DOI 10.1016/j.pep.2006.02.017
   Koping-Hoggard M, 2004, GENE THER, V11, P1441, DOI 10.1038/sj.gt.3302312
   Kunisawa J, 2012, ADV DRUG DELIVER REV, V64, P523, DOI 10.1016/j.addr.2011.07.003
   Lu W, 2004, NAT MED, V10, P135
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Nochi T, 2010, NAT MATER, V9, P574
   Pinto AR, 2004, VACCINE, V22, P697, DOI 10.1016/j.vaccine.2003.08.029
   Regnstrom K, 2003, GENE THER, V10, P1575, DOI 10.1038/sj.gt.3302054
   Sandra S, 1999, HUM GENE THER, V10, P775
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Shoji M, 2012, BIOCHEM BIOPH RES CO, V425, P89, DOI 10.1016/j.bbrc.2012.07.056
   Slutter B, 2008, J DRUG TARGET, V16, P1, DOI [10.1080/10611860701637966, 10.1080/10611860701637966 ]
   Smit-McBride Z, 1998, J VIROL, V72, P6646
   Sun X, 2012, INT J NANOMED, V7, P2929, DOI 10.2147/IJN.S31760
   Sun X, 2010, J CONTROL RELEASE, V148, P219, DOI 10.1016/j.jconrel.2010.06.017
   Tatsis N, 2007, BLOOD, V110, P1916, DOI 10.1182/blood-2007-02-062117
   Thanou M, 2002, BIOMATERIALS, V23, P153, DOI 10.1016/S0142-9612(01)00090-4
   Ugwoke MI, 2005, ADV DRUG DELIVER REV, V57, P1640, DOI 10.1016/j.addr.2005.07.009
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
   Witschi C, 1999, PHARMACEUT RES, V16, P382, DOI 10.1023/A:1018869601502
   Xiang ZQ, 1999, VACCINE, V17, P2003, DOI 10.1016/S0264-410X(98)00449-6                                                   
   Xiang ZQ, 2003, J VIROL, V77, P10780, DOI 10.1128/JVI.77.20.10780-10789.2003
   Yang KJ, 2008, J IMMUNOL, V180, P6159, DOI 10.4049/jimmunol.180.9.6159                                                     
   Yuanhui F, 2009, BIOCHEM BIOPH RES CO, V381, P528
   Zaman M, 2013, DRUG DELIV TRANSL RE, V3, P100, DOI 10.1007/s13346-012-0085-z
NR 49
TC 5
Z9 5
U1 0
U2 14
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2014
VL 31
IS 10
BP 2748
EP 2761
DI 10.1007/s11095-014-1372-9
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AR9JF
UT WOS:000343889300017
PM 24792827
DA 2018-01-05
ER

PT J
AU Shi, JF
   Du, XW
   Yuan, D
   Zhou, J
   Zhou, N
   Huang, YB
   Xu, B
AF Shi, Junfeng
   Du, Xuewen
   Yuan, Dan
   Zhou, Jie
   Zhou, Ning
   Huang, Yibing
   Xu, Bing
TI D-Amino Acids Modulate the Cellular Response of Enzymatic-Instructed
   Supramolecular Nanofibers of Small Peptides
SO BIOMACROMOLECULES
LA English
DT Article
ID ANTIINFLAMMATORY DRUG NSAID; SMALL MOLECULES; ALKALINE-PHOSPHATASE;
   INTRACELLULAR HYDROGELATION; COMPUTATIONAL DESIGN; SELF-ORGANIZATION;
   HIV-1 ENTRY; IN-VIVO; INHIBITORS; TRIPEPTIDE
AB Peptides made of d-amino acids, as the enantiomer of corresponding l-peptides, are able to resist proteolysis. It is, however, unclear or much less explored whether or how d-amino acids affect the cellular response of supramolecular nanofibers formed by enzyme-triggered self-assembly of d-peptides. In this work, we choose a cell compatible molecule, Nap-l-Phe-l-Phe-l-pTyr (LLL-1P), and systematically replace the l-amino acids in this tripeptidic precursor or its hydrogelator by the corresponding d-amino acid(s). The replacement of even one d-amino acid in this tripeptidic precursor increases its proteolytic resistance. The results of static light scattering and TEM images show the formation of nanostructures upon the addition of alkaline phosphatase, even at concentrations below the minimum gelation concentration (mgc). All these isomers are able to form ordered nanostructures and exhibit different morphologies. According to the cell viability assay on these stereochemical isomers, cells exhibit drastically different responses to the enantiomeric precursors, but almost same responses to the enantiomeric hydrogelators. Furthermore, the different cellular responses of LLL-1P and DDD-1P largely originate from the ecto-phosphatases catalyzed self-assembly of DDD-1 on the surface of cells. Therefore, this report not only illustrates a new way for tailoring the properties of supramolecular assemblies, but also provides new insights to answering the fundamental question of how mammalian cells respond to enzymatic formation of nanoscale supramolecular assemblies (e.g., nanofibers) of d-peptides.
C1 [Shi, Junfeng; Du, Xuewen; Yuan, Dan; Zhou, Jie; Zhou, Ning; Huang, Yibing; Xu, Bing] Brandeis Univ, Dept Chem, Waltham, MA 02453 USA.
RP Xu, B (reprint author), Brandeis Univ, Dept Chem, 415 South St,MS 015, Waltham, MA 02453 USA.
EM bxu@brandeis.edu
RI XU, Bing/A-7828-2008
OI XU, Bing/0000-0002-4639-387X
FU NIH [R01CA142746]; Chinese scholar council [2008638092, 2010638002]
FX This work was partially supported by NIH (R01CA142746) and Fellowship
   from Chinese scholar council (2008638092 for J.F.S. and 2010638002 for
   D.Y.). J.F.S. thanks Mr. R. Haburcak for comments on the manuscript.
CR ALEWOOD PF, 1983, SYNTHESIS-STUTTGART, P30
   Ariga K, 2006, J NANOSCI NANOTECHNO, V6, P1718, DOI 10.1166/jnn.2006.230
   Babu SS, 2014, CHEM REV, V114, P1973, DOI 10.1021/cr400195e
   BACH AC, 1994, J AM CHEM SOC, V116, P3207, DOI 10.1021/ja00087a006
   Baral A, 2014, LANGMUIR, V30, P929, DOI 10.1021/la4043638
   Bong DT, 2001, ANGEW CHEM INT EDIT, V40, P988, DOI 10.1002/1521-3773(20010316)40:6<988::AID-ANIE9880>3.3.CO;2-E
   Bremmer SC, 2014, CHEM COMMUN, V50, P1691, DOI 10.1039/c3cc48132h
   Chalifour RJ, 2003, J BIOL CHEM, V278, P34874, DOI 10.1074/jbc.M212694200
   Chan W. C., 2000, FMOC SOLID PHASE PEP
   Cheetham AG, 2013, J AM CHEM SOC, V135, P2907, DOI 10.1021/ja3115983
   CHOU JY, 1987, BIOCHEMISTRY-US, V26, P3596, DOI 10.1021/bi00386a052                                                             
   Cormier AR, 2013, ACS NANO, V7, P7562, DOI 10.1021/nn401562f
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   FERNLEY HN, 1970, BIOCHEM J, V116, P543, DOI 10.1042/bj1160543                                                               
   FISHMAN WH, 1968, NATURE, V219, P697, DOI 10.1038/219697a0
   Fujino T, 2013, J AM CHEM SOC, V135, P1830, DOI 10.1021/ja309570x
   Gao Y, 2013, ACS NANO, V7, P9055, DOI 10.1021/nn403664n
   Gao Y, 2010, BIOPOLYMERS, V94, P19, DOI 10.1002/bip.21321
   Giano MC, 2011, BIOMATERIALS, V32, P6471, DOI 10.1016/j.biomaterials.2011.05.052
   Goto Y, 2009, J AM CHEM SOC, V131, P5040, DOI 10.1021/ja900597d
   Griffin JP, 2006, TXB PHARM MED, V5th
   Hafezi N, 2012, J AM CHEM SOC, V134, P12861, DOI 10.1021/ja305379c
   Hirsch AKH, 2012, J AM CHEM SOC, V134, P4177, DOI 10.1021/ja2099134
   Hyland L. L., 2012, BIOMACROMOLECULES, V14, P406
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Krause E, 2000, J AM CHEM SOC, V122, P4865, DOI 10.1021/ja9940524                                                               
   Kuang Y, 2014, J BIOL CHEM, V289, P29208, DOI 10.1074/jbc.M114.600288
   Kuang Y, 2014, ANGEW CHEM INT EDIT, V53, P8104, DOI 10.1002/anie.201402216
   Kuang Y, 2013, ANGEW CHEM INT EDIT, V52, P6944, DOI 10.1002/anie.201302658
   Kuang Y, 2013, RSC ADV, V3, P7704, DOI 10.1039/c3ra41523f
   Laromaine A, 2007, J AM CHEM SOC, V129, P4156, DOI 10.1021/ja0706504
   Lee DL, 2003, BIOPOLYMERS, V71, P28, DOI 10.1002/bip.10374
   Lehn JM, 2002, SCIENCE, V295, P2400, DOI 10.1126/science.1071063
   Li JY, 2013, J AM CHEM SOC, V135, P9907, DOI 10.1021/ja404215g
   Li JY, 2013, BEILSTEIN J ORG CHEM, V9, P908, DOI 10.3762/bjoc.9.104
   Li JY, 2013, J AM CHEM SOC, V135, P542, DOI 10.1021/ja310019x
   Li XM, 2012, LANGMUIR, V28, P13512, DOI 10.1021/la302583a
   Li Y, 2013, LANGMUIR, V29, P9721, DOI 10.1021/la402174w
   Liang GL, 2007, CHEM COMMUN, P4096, DOI 10.1039/b712971h
   Liang GL, 2009, LANGMUIR, V25, P8419, DOI 10.1021/la804271d
   Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107
   Lock LL, 2013, ACS NANO, V7, P4924, DOI 10.1021/nn400218a
   Luo JN, 2011, ACS NANO, V5, P7739, DOI 10.1021/nn202822f
   Lupoli TJ, 2011, J AM CHEM SOC, V133, P10748, DOI 10.1021/ja2040656
   Majumder J, 2013, LANGMUIR, V29, P10254, DOI 10.1021/la401929v
   Marchesan S, 2014, NANOSCALE, V6, P5172, DOI 10.1039/c3nr06752a
   Marchesan S, 2013, BIONANOSCIENCE, V3, P21, DOI 10.1007/s12668-012-0074-1
   Marchesan S, 2013, BIOMATERIALS, V34, P3678, DOI 10.1016/j.biomaterials.2013.01.096
   Marchesan S, 2012, NANOSCALE, V4, P6752, DOI 10.1039/c2nr32006a
   Marchesan S, 2012, CHEM COMMUN, V48, P2195, DOI 10.1039/c2cc16609g
   MASON A, 1982, NATURE, V296, P655, DOI 10.1038/296655a0
   McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419                                                             
   MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449
   Morii T, 2002, J AM CHEM SOC, V124, P180, DOI 10.1021/ja017078f
   Nagy KJ, 2011, J AM CHEM SOC, V133, P14975, DOI 10.1021/ja206742m
   Nanda V, 2006, J AM CHEM SOC, V128, P809, DOI 10.1021/ja054452t
   OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027                                                             
   Pentelute BL, 2008, J AM CHEM SOC, V130, P9702, DOI 10.1021/ja801352j
   Pochan DJ, 2003, J AM CHEM SOC, V125, P11802, DOI 10.1021/ja0353154
   Qiu Z., 2009, CHEM COMMUN, V23, P3342
   Rodriguez-Granillo A, 2011, J AM CHEM SOC, V133, P18750, DOI 10.1021/ja205609c
   Rudra JS, 2012, ACS NANO, V6, P1557, DOI 10.1021/nn204530r
   Rughani RV, 2009, BIOMACROMOLECULES, V10, P1295, DOI 10.1021/bm900113z
   Ryadnov MG, 2002, PEPTIDES, V23, P1869, DOI 10.1016/S0196-9781(02)00146-8                                                   
   Sadeghi-Aliabadi H, 2010, RES PHARM SCI, V5, P127
   Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817
   Schneider JP, 2002, J AM CHEM SOC, V124, P15030, DOI 10.1021/ja027993g
   Shi J., 2012, MRS P, V1418
   Shi JF, 2011, BEILSTEIN J ORG CHEM, V7, P167, DOI 10.3762/bjoc.7.23
   Shiraki T, 2008, ANGEW CHEM INT EDIT, V47, P106, DOI 10.1002/anie.200702793
   Sinthuvanich C, 2012, J AM CHEM SOC, V134, P6210, DOI 10.1021/ja210569f
   Song BB, 2010, J AM CHEM SOC, V132, P4508, DOI 10.1021/ja905341p
   Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743
   Sun ZF, 2013, J AM CHEM SOC, V135, P13379, DOI 10.1021/ja403345p
   Swanekamp RJ, 2012, J AM CHEM SOC, V134, P5556, DOI 10.1021/ja301642c
   Toft DJ, 2012, ACS NANO, V6, P7956, DOI 10.1021/nn302503s
   Toledano S, 2006, J AM CHEM SOC, V128, P1070, DOI 10.1021/ja056549l
   Ulijn RV, 2008, CHEM SOC REV, V37, P664, DOI 10.1039/b609047h
   Wakimoto T, 2011, J AM CHEM SOC, V133, P4746, DOI 10.1021/ja2006737
   Wang HM, 2014, ACS APPL MATER INTER, V6, P9815, DOI 10.1021/am502250r
   Wei GX, 2005, ANTIMICROB AGENTS CH, V49, P2336, DOI 10.1128/AAC.49.6.2336-2342.2005
   WEISBLAT DA, 1980, SCIENCE, V209, P1538, DOI 10.1126/science.6159680
   Welch BD, 2007, P NATL ACAD SCI USA, V104, P16828, DOI 10.1073/pnas.0708109104
   Williams RJ, 2009, NAT NANOTECHNOL, V4, P19, DOI [10.1038/NNANO.2008.378, 10.1038/nnano.2008.378]
   Yamamichi S, 2011, CHEM COMMUN, V47, P10344, DOI 10.1039/c1cc13826j
   Yang YL, 2011, CHEM BIOL DRUG DES, V78, P923, DOI 10.1111/j.1747-0285.2011.01238.x
   Yang Z, 2008, ACCOUNTS CHEM RES, V41, P315, DOI 10.1021/ar7001914
   Yang Z, 2007, J MATER CHEM, V17, P2385, DOI 10.1039/b702493b
   Yang Z, 2007, ANGEW CHEM INT EDIT, V46, P8216, DOI 10.1002/anie.200701697
   Yang ZM, 2007, SMALL, V3, P558, DOI 10.1002/smll.200700015
   Yang ZM, 2007, CHEM COMMUN, P843, DOI 10.1039/b616563
   Yang ZM, 2006, J AM CHEM SOC, V128, P3038, DOI 10.1021/ja057412y
   Yuan D, 2014, RSC ADV, V4, P26487, DOI 10.1039/c4ra04765f
   Zhang Y., 2010, LANGMUIR, V27, P529
   Zheng W, 2012, J AM CHEM SOC, V135, P266
NR 95
TC 39
Z9 40
U1 3
U2 89
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD OCT
PY 2014
VL 15
IS 10
BP 3559
EP 3568
DI 10.1021/bm5010355
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AQ7VF
UT WOS:000343026600010
PM 25230147
OA gold
DA 2018-01-05
ER

PT J
AU Lan, J
   Yang, K
   Byrd, D
   Hu, NJ
   Amet, T
   Shepherd, N
   Desai, M
   Gao, JM
   Gupta, S
   Sun, YT
   Yu, QG
AF Lan, Jie
   Yang, Kai
   Byrd, Daniel
   Hu, Ningjie
   Amet, Tohti
   Shepherd, Nicole
   Desai, Mona
   Gao, Jimin
   Gupta, Samir
   Sun, Yongtao
   Yu, Qigui
TI Provirus Activation Plus CD59 Blockage Triggers Antibody-Dependent
   Complement-Mediated Lysis of Latently HIV-1-Infected Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA;
   DECAY-ACCELERATING FACTOR; SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE
   DEACETYLASE INHIBITOR; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS;
   HIV-1 INFECTION; NEUTRALIZING ANTIBODIES; IN-VIVO
AB Latently HIV-1-infected cells are recognized as the last barrier toward viral eradication and cure. To purge these cells, we combined a provirus stimulant with a blocker of human CD59, a key member of the regulators of complement activation, to trigger Ab-dependent complement-mediated lysis. Provirus stimulants including prostratin and histone deacetylase inhibitors such as romidepsin and suberoylanilide hydroxamic acid activated proviruses in the latently HIV-1-infected T cell line ACH-2 as virion production and viral protein expression on the cell surface were induced. Romidepsin was the most attractive provirus stimulant as it effectively activated proviruses at nanomolar concentrations that can be achieved clinically. Antiretroviral drugs including two protease inhibitors (atazanavir and darunavir) and an RT inhibitor (emtricitabine) did not affect the activity of provirus stimulants in the activation of proviruses. However, saquinavir (a protease inhibitor) markedly suppressed virus production, although it did not affect the percentage of cells expressing viral Env on the cell surface. Provirus-activated ACH-2 cells expressed HIV-1 Env that colocalized with CD59 in lipid rafts on the cell surface, facilitating direct interaction between them. Blockage of CD59 rendered provirus-activated ACH-2 cells and primary human CD4(+) T cells that were latently infected with HIV-1 sensitive to Ab-dependent complement-mediated lysis by anti-HIV-1 polyclonal Abs or plasma from HIV-1-infected patients. Therefore, a combination of provirus stimulants with regulators of complement activation blockers represents a novel approach to eliminate HIV-1.
C1 [Lan, Jie; Yang, Kai; Byrd, Daniel; Amet, Tohti; Shepherd, Nicole; Yu, Qigui] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Lan, Jie; Yang, Kai; Byrd, Daniel; Amet, Tohti; Shepherd, Nicole; Yu, Qigui] Indiana Univ Sch Med, Ctr AIDS Res, Indianapolis, IN 46202 USA.
   [Yang, Kai; Hu, Ningjie; Gao, Jimin] Wenzhou Med Coll, Zhejiang Prov Key Lab Technol & Applicat Model Or, Wenzhou 325035, Peoples R China.
   [Desai, Mona; Gupta, Samir; Yu, Qigui] Indiana Univ Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN 46202 USA.
   [Sun, Yongtao] Fourth Mil Med Univ, Dept Infect Dis, Tangdu Hosp, Xian 710038, Peoples R China.
RP Yu, QG (reprint author), Indiana Univ Sch Med, Med Sci Bldg,MS457, Indianapolis, IN 46202 USA.
EM andyu@iupui.edu
FU Grand Challenges Explorations Phase II grant through the Bill & Melinda
   Gates Foundation [OPP1035237]; National Institutes of Health (NIH)
   [1R21AI104268]; Showalter Research Trust Fund; NIH [T32 AI060519];
   Natural Science Foundation [81101247, Y2110608]; National Science and
   Technology Major Project [2014ZX10001002]; Research Facilities
   Improvement Program Grant from the National Center for Research
   Resources, NIH [C06 RR015481-01]
FX This work was supported in part by a Grand Challenges Explorations Phase
   II grant through the Bill & Melinda Gates Foundation (OPP1035237 to
   Q.Y.), National Institutes of Health (NIH) Grant 1R21AI104268 (to Q.Y.),
   the Showalter Research Trust Fund (to Q.Y.), NIH Grant T32 AI060519 (to
   D.B.), the Natural Science Foundation (81101247 and Y2110608 to N.H.),
   the National Science and Technology Major Project (2014ZX10001002 to
   Y.S.), and Research Facilities Improvement Program Grant C06 RR015481-01
   from the National Center for Research Resources, NIH, to Indiana
   University School of Medicine.
CR Aasa-Chapman MMI, 2004, AIDS, V18, P371, DOI 10.1097/01.aids.0000111403.02002.00
   Amet T, 2012, HEPATOLOGY, V55, P354, DOI 10.1002/hep.24686
   Amiri-Kordestani L, 2013, CLIN CANCER RES, V19, P4499, DOI 10.1158/1078-0432.CCR-13-0095
   Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Archin NM, 2009, AIDS RES HUM RETROV, V25, P207, DOI 10.1089/aid.2008.0191
   Azenishi Y, 1999, BRIT J HAEMATOL, V104, P523, DOI 10.1046/j.1365-2141.1999.01214.x                                                
   BELEC L, 1995, J INFECT DIS, V172, P691, DOI 10.1093/infdis/172.3.691                                                        
   Biancotto A, 2004, J VIROL, V78, P10507, DOI 10.1128/JVI.78.19.10507-10515.2004
   Binley JM, 1997, J VIROL, V71, P2799
   Bonsignori M, 2009, J IMMUNOL, V183, P2708, DOI 10.4049/jimmunol.0901068
   Brodbeck WG, 2000, J IMMUNOL, V165, P3999, DOI 10.4049/jimmunol.165.7.3999                                                     
   Brodsky R. A, 2006, HEMATOLOGY AM SOC HE, V24- 28, P516
   Brodsky R. A, 2006, HEMATOL-AM SOC HEMAT, V24- 28, P24
   Brodsky RA, 2006, LEUKEMIA LYMPHOMA, V47, P1215, DOI 10.1080/10428190600555520
   Byrd D, 2013, J VIROL, V87, P9301, DOI 10.1128/JVI.01545-13
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   Contreras X, 2009, J BIOL CHEM, V284, P6782, DOI 10.1074/jbc.M807898200
   Dahl V, 2009, J INFECT DIS, V199, P1258, DOI 10.1086/597760
   DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150
   Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a
   Dierich MP, 1996, NAT MED, V2, P153, DOI 10.1038/nm0296-153
   FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365
   Fondere JM, 2004, J VIROL, V78, P10536, DOI 10.1128/JVI.78.19.10536-10542.2004
   Funk GA, 2006, J MED VIROL, V78, P1141, DOI 10.1002/jmv.20674
   Geddes L., 2010, NEW SCI, V2761, P1
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gulakowski RJ, 1997, ANTIVIR RES, V33, P87, DOI 10.1016/S0166-3542(96)01004-2
   Hall C, 2003, BLOOD, V102, P3587, DOI 10.1182/blood-2003-01-0009
   Han YF, 2007, NAT REV MICROBIOL, V5, P95, DOI 10.1038/nrmicro1580
   Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917
   Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442
   Hu WG, 2010, J IMMUNOL, V184, P359, DOI [10.4049/jimmunol.0902278, 10.4049/jimmunol.0902279]
   Huber M, 2007, J INTERN MED, V262, P5, DOI 10.1111/j.1365-2796.2007.01819.x
   Huber M, 2006, PLOS MED, V3, P2078, DOI 10.1371/journal.pmed.0030441
   Humbert M, 2006, AIDS REV, V8, P51
   Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188
   Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726
   Kalams SA, 1999, J VIROL, V73, P6721
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006
   Lassen KG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030176
   Levy Y, 2009, J CLIN INVEST, V119, P997, DOI 10.1172/JCI38052
   Lewin SR, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-4
   Macor P, 2007, CANCER RES, V67, P10556, DOI 10.1158/0008-5472.CAN-07-1811
   Malkusch S, 2013, HISTOCHEM CELL BIOL, V139, P173, DOI 10.1007/s00418-012-1014-4
   Marsden MD, 2008, AIDS RES HUM RETROV, V24, P1399, DOI 10.1089/aid.2008.0082
   Matalon S, 2010, JAIDS-J ACQ IMM DEF, V54, P1, DOI 10.1097/QAI.0b013e3181d3dca3
   MATSUO S, 1994, J EXP MED, V180, P1619, DOI 10.1084/jem.180.5.1619
   MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007
   Migueles SA, 2009, J VIROL, V83, P11876, DOI 10.1128/JVI.01153-09
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   NICHOLSONWELLER A, 1985, NEW ENGL J MED, V312, P1091, DOI 10.1056/NEJM198504253121704
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   O'Doherty U, 2002, J VIROL, V76, P10942, DOI 10.1128/JVI.76.21.10942-10950.2002
   Ono A, 2010, BIOL CELL, V102, P335, DOI 10.1042/BC20090165
   ORENSTEIN JM, 1988, J VIROL, V62, P2578
   Pace MJ, 2011, VIROLOGY, V411, P344, DOI 10.1016/j.virol.2010.12.041
   Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717                                                      
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614
   Pellegrin I, 1996, J ACQ IMMUN DEF SYND, V11, P438, DOI 10.1097/00042560-199604150-00003                                                
   PINCUS SH, 1994, J CLIN INVEST, V93, P2505, DOI 10.1172/JCI117260
   Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577                                                                   
   Richards SJ, 2007, CYTOM PART B-CLIN CY, V72B, P291, DOI 10.1002/cyto.b.20358
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Rong LB, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000533
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501
   Saifuddin M, 1997, J GEN VIROL, V78, P1907, DOI 10.1099/0022-1317-78-8-1907                                                     
   SCHMITZ J, 1995, J CLIN INVEST, V96, P1520, DOI 10.1172/JCI118190                                                               
   Sedaghat AR, 2008, BMC INFECT DIS, V8, P1
   Sereti I, 2009, BLOOD, V113, P6304, DOI 10.1182/blood-2008-10-186601
   Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014
   Shen L, 2008, J ALLERGY CLIN IMMUN, V122, P22, DOI 10.1016/j.jaci.2008.05.033
   Smith MZ, 2012, CURR HIV-AIDS REP, V9, P5, DOI 10.1007/s11904-011-0108-2
   Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Swiggard WJ, 2005, J VIROL, V79, P14179, DOI 10.1128/JVI.79.22.14179-14188.2005
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Yang HC, 2009, J CLIN INVEST, V119, P3473, DOI 10.1172/JCI39199
NR 81
TC 8
Z9 8
U1 1
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2014
VL 193
IS 7
BP 3577
EP 3589
DI 10.4049/jimmunol.1303030
PG 13
WC Immunology
SC Immunology
GA AR0XQ
UT WOS:000343298700038
PM 25149467
OA gold
DA 2018-01-05
ER

PT J
AU Afonin, KA
   Viard, M
   Koyfman, AY
   Martins, AN
   Kasprzak, WK
   Panigaj, M
   Desai, R
   Santhanam, A
   Grabow, WW
   Jaeger, L
   Heldman, E
   Reiser, J
   Chiu, W
   Freed, EO
   Shapiro, BA
AF Afonin, Kirill A.
   Viard, Mathias
   Koyfman, Alexey Y.
   Martins, Angelica N.
   Kasprzak, Wojciech K.
   Panigaj, Martin
   Desai, Ravi
   Santhanam, Arti
   Grabow, Wade W.
   Jaeger, Luc
   Heldman, Eliahu
   Reiser, Jakob
   Chiu, Wah
   Freed, Eric O.
   Shapiro, Bruce A.
TI Multifunctional RNA Nanoparticles
SO NANO LETTERS
LA English
DT Article
DE RNA nanotechnology; RNA nanoparticles; RNA interference; aptamers;
   RNA-DNA hybrid reassociation
ID MALACHITE GREEN APTAMER; IN-SILICO; THERAPEUTIC APPLICATIONS; SPLIT
   FUNCTIONALITIES; EMERGING FIELD; DNA HYBRIDS; DESIGN; NANOTECHNOLOGY;
   DELIVERY; INTERFERENCE
AB Our recent advancements in RNA nanotechnology introduced novel nanoscaffolds (nanorings); however, the potential of their use for biomedical applications was never fully revealed. As presented here, besides functionalization with multiple different short interfering RNAs for combinatorial RNA interference (e.g., against multiple HIV-1 genes), nanorings also allow simultaneous embedment of assorted RNA aptamers, fluorescent dyes, proteins, as well as recently developed RNADNA hybrids aimed to conditionally activate multiple split functionalities inside cells.
C1 [Afonin, Kirill A.; Viard, Mathias; Desai, Ravi; Santhanam, Arti; Shapiro, Bruce A.] NCI, Basic Res Lab, Ctr Canc Res, Frederick, MD 21702 USA.
   [Viard, Mathias; Kasprzak, Wojciech K.; Heldman, Eliahu] NCI, Basic Sci Program, Leidos Biomed Res Inc, Ctr Canc Res,Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
   [Koyfman, Alexey Y.; Chiu, Wah] Baylor Coll Med, Natl Ctr Macromol Imaging, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Martins, Angelica N.; Freed, Eric O.] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
   [Panigaj, Martin; Reiser, Jakob] US FDA, Ctr Biol Evaluat & Res, Off Cellular Tissue & Gene Therapies, Silver Spring, MD 20993 USA.
   [Grabow, Wade W.] Seattle Pacific Univ, Dept Chem, Seattle, WA 98119 USA.
   [Jaeger, Luc] Univ Calif Santa Barbara, Dept Chem & Biochem, Biomol Sci & Engn Program, Santa Barbara, CA 93106 USA.
RP Shapiro, BA (reprint author), NCI, Basic Res Lab, Ctr Canc Res, Frederick, MD 21702 USA.
EM shapirbr@mail.nih.gov
RI Panigaj, Martin/G-6492-2013
FU NIH, Center for Cancer Research, NCI-Frederick; Frederick National
   Laboratory for Cancer Research, National Institutes of Health
   [HHSN261200800001E]; National Institutes of Health [P41GM103832, P50
   GM1003297]; Postdoctoral Training Fellowship from the Keck Center
   Computational Cancer Biology Training Program of the Gulf Coast
   Consortia (CPRIT) [RP101489]; NIH [R01GM-079604]; U.S. Department of
   Energy; U.S. Food and Drug Administration
FX We thank Faye M. Walker for her assistance at early stages of this
   project. We thank the Pathology Histology Lab of Leidos Biomedical
   Research, Inc. at the Frederick National Laboratory for Cancer Research
   for help with ex vivo imaging. We thank Patricia S. Steeg at the
   National Cancer Institute for providing GFP expressing cells for the in
   vivo experiments. We thank Andrew Anderson for technical assistance
   during electron microscopy reconstruction. This research was supported
   [in part] by the Intramural Research Program of the NIH, Center for
   Cancer Research, NCI-Frederick. This work has been funded in whole or in
   part with Federal funds from the Frederick National Laboratory for
   Cancer Research, National Institutes of Health, under contract no.
   HHSN261200800001E. The content of this publication does not necessarily
   reflect the views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the U.S. Government. This research
   was supported in part by the National Institutes of Health P41GM103832
   and P50 GM1003297 (to W.C.) and the Postdoctoral Training Fellowship
   from the Keck Center Computational Cancer Biology Training Program of
   the Gulf Coast Consortia to A.Y.K. (CPRIT grant no. RP101489). This
   research was also supported by NIH grant no. R01GM-079604 (to L.J.).
   M.P. is supported in part by an appointment to the Research
   Participation Program at the Center for Biologics Evaluation and
   Research administered by the Oak Ridge Institute for Science and
   Education through an inter agency agreement between the U.S. Department
   of Energy and the U.S. Food and Drug Administration.
CR Afonin Kirill A., 2013, RNA Nanotechnology, V1, P1
   Afonin KA, 2006, J AM CHEM SOC, V128, P16131, DOI 10.1021/ja064289h
   Afonin KA, 2008, CHEMBIOCHEM, V9, P1902, DOI 10.1002/cbic.200800183
   Afonin KA, 2008, J AM CHEM SOC, V130, P93, DOI 10.1021/ja071516m
   Afonin KA, 2014, ACCOUNTS CHEM RES, V47, P1731, DOI 10.1021/ar400329z
   Afonin KA, 2014, NUCLEIC ACIDS RES, V42, P2085, DOI 10.1093/nar/gkt1001
   Afonin KA, 2013, NAT NANOTECHNOL, V8, P296, DOI [10.1038/nnano.2013.44, 10.1038/NNANO.2013.44]
   Afonin KA, 2012, NANO LETT, V12, P5192, DOI 10.1021/nl302302e
   Afonin KA, 2011, NAT PROTOC, V6, P2022, DOI 10.1038/nprot.2011.418
   Afonin KA, 2010, NAT NANOTECHNOL, V5, P676, DOI [10.1038/NNANO.2010.160, 10.1038/nnano.2010.160]
   Baugh C, 2000, J MOL BIOL, V301, P117, DOI 10.1006/jmbi.2000.3951
   Bindewald E, 2008, J MOL GRAPH MODEL, V27, P299, DOI 10.1016/j.jmgm.2008.05.004
   Bramsen Jesper B., 2012, Frontiers in Genetics, V3, DOI 10.3389/fgene.2012.00154
   Case D. A., 2012, AMBER12
   Chang CI, 2012, J GENE MED, V14, P138, DOI 10.1002/jgm.1653
   Chen J, 2012, INT J NANOMED, V7, P3971, DOI 10.2147/IJN.S31897
   Chworos A, 2004, SCIENCE, V306, P2068, DOI 10.1126/science.1104686
   Crist RM, 2013, INTEGR BIOL-UK, V5, P66, DOI 10.1039/c2ib20117h
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Farokhzad O. C., 2009, ACS NANO, V3, P16, DOI DOI 10.1021/NN900002M
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FREED EO, 1994, J VIROL, V68, P2503
   Grabow WW, 2014, ACCOUNTS CHEM RES, V47, P1871, DOI 10.1021/ar500076k
   Grabow WW, 2011, NANO LETT, V11, P878, DOI 10.1021/nl104271s
   Grate D, 1999, P NATL ACAD SCI USA, V96, P6131, DOI 10.1073/pnas.96.11.6131
   Grimm D, 2007, MOL THER, V15, P878, DOI 10.1038/mt.sj.6300116
   Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI [10.1038/nnano.2010.231, 10.1038/NNANO.2010.231]
   Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0
   Hao CH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4890
   Haque F, 2012, NANO TODAY, V7, P245, DOI 10.1016/j.nantod.2012.06.010
   Khisamutdinov EF, 2014, ACS NANO, V8, P4771, DOI 10.1021/nn5006254
   Kim T, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.5
   Kolpashchikov DM, 2005, J AM CHEM SOC, V127, P12442, DOI 10.1021/ja0529788
   Koyfman AY, 2009, J AM CHEM SOC, V131, P14237, DOI 10.1021/ja9015638
   Koyfman AY, 2009, LANGMUIR, V25, P1091, DOI 10.1021/la801306j
   Koyfman AY, 2005, J AM CHEM SOC, V127, P11886, DOI 10.1021/ja051144m
   Lee YS, 2009, NAT CELL BIOL, V11, P1150, DOI 10.1038/ncb1930
   Li N, 2010, CHEM COMMUN, V46, P392, DOI 10.1039/b920865h
   Li N, 2009, J PROTEOME RES, V8, P2438, DOI 10.1021/pr801048z
   Low JT, 2012, MOL THER, V20, P820, DOI 10.1038/mt.2011.299
   Martinez HM, 2008, J BIOMOL STRUCT DYN, V25, P669, DOI 10.1080/07391102.2008.10531240                                                  
   Moghimi SM, 2012, ANNU REV PHARMACOL, V52, P481, DOI 10.1146/annurev-pharmtox-010611-134623
   Nakashima Y, 2011, CHEM COMMUN, V47, P8367, DOI 10.1039/c1cc11780g
   Ohno H, 2011, NAT NANOTECHNOL, V6, P115, DOI 10.1038/nnano.2010.268
   Osada E, 2014, ACS NANO, V8, P8130, DOI 10.1021/nn502253c
   Parisien M, 2008, NATURE, V452, P51, DOI 10.1038/nature06684
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Popenda M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks339
   Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265
   Severcan I, 2010, NAT CHEM, V2, P772, DOI [10.1038/nchem.733, 10.1038/NCHEM.733]
   Shu D, 2011, NAT NANOTECHNOL, V6, P658, DOI [10.1038/NNANO.2011.105, 10.1038/nnano.2011.105]
   Shu Y, 2014, ADV DRUG DELIVER REV, V66, P74, DOI 10.1016/j.addr.2013.11.006
   Shu Y, 2013, RNA, V19, P767, DOI 10.1261/rna.037002.112
   Shukla GC, 2011, ACS NANO, V5, P3405, DOI 10.1021/nn200989r
   Stojanovic MN, 2004, J AM CHEM SOC, V126, P9266, DOI 10.1021/ja032013t
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   Tarapore P, 2011, MOL THER, V19, P386, DOI 10.1038/mt.2010.243
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Yingling YG, 2007, NANO LETT, V7, P2328, DOI 10.1021/nl070984r
   Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582                                                            
   Zhou Jiehua, 2013, Pharmaceuticals (Basel), V6, P85, DOI 10.3390/ph6010085
NR 64
TC 41
Z9 41
U1 3
U2 57
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
EI 1530-6992
J9 NANO LETT
JI Nano Lett.
PD OCT
PY 2014
VL 14
IS 10
BP 5662
EP 5671
DI 10.1021/nl502385k
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AQ7RH
UT WOS:000343016400029
PM 25267559
OA gold
DA 2018-01-05
ER

PT J
AU Destache, C
   Date, A
   Yuan, Z
   Kang, GB
   Lu, WX
   Tso, FY
   Wood, C
   Li, QS
AF Destache, Christopher
   Date, Abhijit
   Yuan, Zhe
   Kang, Guobin
   Lu, Wuxun
   Tso, For Yue
   Wood, Charles
   Li, Qingsheng
TI Topical application of tenofovir DF nanoparticles prevents HIV-1 vaginal
   transmission in humanized-BLT mice.
SO PHARMACOTHERAPY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP)
CY OCT 12-15, 2014
CL Austin, TX
SP Amer Coll Clin Pharm
C1 [Destache, Christopher; Date, Abhijit] Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
   [Yuan, Zhe; Kang, Guobin; Lu, Wuxun; Tso, For Yue; Wood, Charles; Li, Qingsheng] Univ Nebraska, Ctr Virol, Lincoln, NE USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD OCT
PY 2014
VL 34
IS 10
MA 109
BP E206
EP E206
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AQ6JF
UT WOS:000342916800081
DA 2018-01-05
ER

PT J
AU Britton, LMP
   Sova, P
   Belisle, S
   Liu, SC
   Chan, EY
   Katze, MG
   Garcia, BA
AF Britton, Laura-Mae P.
   Sova, Pavel
   Belisle, Sarah
   Liu, Shichong
   Chan, Eric Y.
   Katze, Michael G.
   Garcia, Benjamin A.
TI A proteomic glimpse into the initial global epigenetic changes during
   HIV infection
SO PROTEOMICS
LA English
DT Article
DE Acetyltransferases; Deacetylases; Demethylases; HIV; Methyltransferases;
   Systems biology
ID HISTONE ACETYLATION; GENE-EXPRESSION; LATENCY; CHROMATIN; PROMOTER;
   LINES; TAT
AB HIV-1 replication requires the insertion of viral DNA into the host genome, which is catalyzed by HIV-1 integrase. This integration event can lead to vast changes in the chromatin landscape and gene transcription. In this study, we sought to correlate the extensive changes of histone PTM abundances with the equally dynamic shifts in host transcriptional activity. To fully capture the changes that were occurring during the course of HIV-infection, we performed time-courses in which we extracted both histones and mRNA from HIV-infected, UV-inactivated HIV-infected and mock-infected SUP-T1 cells. We then analyzed the alterations to histone PTM profiles using nano-LC-MS/MS, as well as the expression of chromatin-associated enzymes, such as histone deacetylases, acetyltransferases, demethylases, methyltransferases, and histone chaperone proteins. As expected, we observed major changes in histone PTM abundances, which we linked to massive fluctuations in mRNA expression of associated chromatin enzymes. However, we find few differences between HIV and HIVUV (UV-inactivated) infection, which suggests that initial histone PTM changes during HIV infection are from the host in response to the infection, and not due to the HIV virus manipulating the transcriptional machinery. We believe that these preliminary experiments can provide a basis for future forays into targeted manipulations of histone PTM-regulated aspects of HIV progression through its replication cycle.
C1 [Britton, Laura-Mae P.; Chan, Eric Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
   [Sova, Pavel; Belisle, Sarah; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   [Sova, Pavel; Belisle, Sarah; Katze, Michael G.] Washington Natl Primate Res Ctr, Seattle, WA USA.
   [Liu, Shichong; Garcia, Benjamin A.] Univ Penn, Dept Biochem & Biophys, Smilow Ctr Translat Res, Epigenet Program,Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Garcia, BA (reprint author), Univ Penn, Dept Biochem & Biophys, Smilow Ctr Translat Res, Epigenet Program,Perelman Sch Med, 3400 Civic Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA.
EM honey@u.washington.edu; bgarci@mail.med.upenn.edu
FU Public Health Service grants from the National Institutes of Health
   [P30DA015625, DP2OD007447, P51OD010425]
FX This work was funded by Public Health Service grants P30DA015625,
   DP2OD007447, and P51OD010425 from the National Institutes of Health.
CR Chang ST, 2013, MBIO, V4, DOI 10.1128/mBio.00549-12
   Chang ST, 2011, MBIO, V2, DOI 10.1128/mBio.00134-11
   Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200
   Colin L, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-111
   Friedman J, 2011, J VIROL, V85, P9078, DOI 10.1128/JVI.00836-11
   Gatignol A, 2007, ADV PHARMACOL, V55, P137, DOI 10.1016/S1054-3589(07)55004-0
   Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631
   Mbonye U, 2014, VIROLOGY, V454, P328, DOI 10.1016/j.virol.2014.02.008
   Plazas-Mayorca MD, 2009, J PROTEOME RES, V8, P5367, DOI 10.1021/pr900777e
   Ruelas DS, 2013, CELL, V155, P519, DOI 10.1016/j.cell.2013.09.044
   Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4
   Siliciano RF, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007096
   van't Wout AB, 2003, J VIROL, V77, P1392, DOI 10.1128/JVI.77.2.1392-1402.2003
   VanLint C, 1996, EMBO J, V15, P1112
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   Wightman F, 2012, IMMUNOL CELL BIOL, V90, P47, DOI 10.1038/icb.2011.95
   Zee BM, 2012, MOL CELL BIOL, V32, P2503, DOI 10.1128/MCB.06673-11
NR 17
TC 9
Z9 9
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD OCT
PY 2014
VL 14
IS 19
SI SI
BP 2226
EP 2230
DI 10.1002/pmic.201400116
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AQ6IE
UT WOS:000342913200012
PM 25116026
OA green_accepted
DA 2018-01-05
ER

PT J
AU Schwarzer, R
   Levental, I
   Gramatica, A
   Scolari, S
   Buschmann, V
   Veit, M
   Herrmann, A
AF Schwarzer, Roland
   Levental, Ilya
   Gramatica, Andrea
   Scolari, Silvia
   Buschmann, Volker
   Veit, Michael
   Herrmann, Andreas
TI The cholesterol-binding motif of the HIV-1 glycoprotein gp41 regulates
   lateral sorting and oligomerization
SO CELLULAR MICROBIOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 ENVELOPE GLYCOPROTEIN;
   VIRION-ASSOCIATED CHOLESTEROL; DETERGENT-RESISTANT MEMBRANES;
   TRANSMEMBRANE PROTEIN GP41; GPI-ANCHORED PROTEINS; LIPID RAFTS;
   CYTOPLASMIC DOMAIN; NANOSCALE ORGANIZATION; VIRAL INFECTIVITY
AB Enveloped viruses often use membrane lipid rafts to assemble and bud, augment infection and spread efficiently. However, the molecular bases and functional consequences of the partitioning of viral glycoproteins into microdomains remain intriguing questions in virus biology. Here, we measured Foerster resonance energy transfer by fluorescence lifetime imaging microscopy (FLIM-FRET) to study the role of distinct membrane proximal regions of the human immunodeficiency virus glycoprotein gp41 for lipid raft partitioning in living Chinese hamster ovary cells (CHO-K1). Gp41 was labelled with a fluorescent protein at the exoplasmic face of the membrane, preventing any interference of the fluorophore with the proposed role of the transmembrane and cytoplasmic domains in lateral organization of gp41. Raft localization was deduced from interaction with an established raft marker, a fluorescently tagged glycophosphatidylinositol anchor and the cholesterol recognition amino acid consensus (CRAC) was identified as the crucial lateral sorting determinant in CHO-K1 cells. Interestingly, the raft association of gp41 indicates a substantial cell-to-cell heterogeneity of the plasma membrane microdomains. In complementary fluorescence polarization microscopy, a distinct CRAC requirement was found for the oligomerization of the gp41 variants. Our data provide further insight into the molecular basis and biological implications of the cholesterol dependent lateral sorting of viral glycoproteins for virus assembly at cellular membranes.
C1 [Schwarzer, Roland; Gramatica, Andrea; Scolari, Silvia; Herrmann, Andreas] Humboldt Univ, Dept Biol Mol Biophys, D-10115 Berlin, Germany.
   [Levental, Ilya] Univ Texas Houston, Dept Integrat Biol & Pharmacol, Lab Membrane Biol, Houston, TX 77030 USA.
   [Buschmann, Volker] PicoQuant GmbH, D-12489 Berlin, Germany.
   [Veit, Michael] Free Univ Berlin, Dept Immunol & Mol Biol, D-14163 Berlin, Germany.
RP Herrmann, A (reprint author), Humboldt Univ, Dept Biol Mol Biophys, D-10115 Berlin, Germany.
EM andreas.herrmann@rz.hu-berlin.de
RI Gramatica, Andrea/A-2936-2015
OI Gramatica, Andrea/0000-0002-7131-933X
FU Deutsche Forschungsgemeinschaft [SFB 740]
FX The project was supported by grants of the Deutsche
   Forschungsgemeinschaft (to M. V. and A. H., SFB 740).
CR Abad C, 2009, BBA-BIOMEMBRANES, V1788, P2132, DOI 10.1016/j.bbamem.2009.07.008
   ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181
   Bae JH, 2003, J MOL BIOL, V328, P1071, DOI 10.1016/S0022-2836(03)00364-4
   Berlioz-Torrent C, 1999, J VIROL, V73, P1350
   BERNSTEIN HB, 1995, J VIROL, V69, P2745
   Bhattacharya J, 2006, J VIROL, V80, P5292, DOI 10.1128/JVI.01469-05
   Bhattacharya J, 2004, J VIROL, V78, P5500, DOI 10.1128/.78.10.5500-5506.2004
   Borst JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013862
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Buschmann V., POLARIZATION EXTENSI
   Byland R, 2007, MOL BIOL CELL, V18, P414, DOI 10.1091/mbc.E06-06-0535
   Campbell S, 2004, J VIROL, V78, P10556, DOI 10.1128/JVI.78.10556-10565.2004
   Campbell S, 2002, J VIROL, V76, P10050, DOI 10.1128/JVI.76.19.10050-10055.2002
   Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004
   Center RJ, 1997, J VIROL, V71, P5706
   Chan WE, 2005, J VIROL, V79, P8374, DOI 10.1128/JVI.79.13.8374-8387.2005
   Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042
   Chen SW, 2009, J ELECTRON MATER, V38, P1, DOI 10.1007/s11664-008-0572-7
   Chen SSL, 2001, J VIROL, V75, P9925, DOI 10.1128/JVI.75.20.9925-9938.2001
   Day JR, 2006, VIROLOGY, V354, P316, DOI 10.1016/j.virol.2006.06.023
   DUBAY JW, 1992, J VIROL, V66, P6616
   EARL PL, 1991, J VIROL, V65, P31
   EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648
   Engel S, 2010, BIOCHEM J, V425, P567, DOI 10.1042/BJ20091388
   Epand RF, 2006, BIOCHEMISTRY-US, V45, P6105, DOI 10.1021/bi060245+
   Epand RM, 2008, BBA-BIOMEMBRANES, V1778, P1576, DOI 10.1016/j.bbamem.2008.03.016
   Gao F, 1996, J VIROL, V70, P1651
   Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003
   Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002
   Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042
   Kellner RR, 2007, NEUROSCIENCE, V144, P135, DOI 10.1016/j.neuroscience.2006.08.071
   Kim JH, 2009, BBA-BIOMEMBRANES, V1788, P1804, DOI 10.1016/j.bbamem.2009.06.011
   KOGA Y, 1991, J VIROL, V65, P5609
   Lenz O, 2005, J BIOL CHEM, V280, P4095, DOI 10.1074/jbc.M411088200
   Levental I, 2010, P NATL ACAD SCI USA, V107, P22050, DOI 10.1073/pnas.1016184107
   Levental I, 2010, BIOCHEMISTRY-US, V49, P6305, DOI 10.1021/bi100882y
   Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900
   Lichtenberg D, 2005, TRENDS BIOCHEM SCI, V30, P430, DOI 10.1016/j.tibs.2005.06.004
   LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463
   LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102
   Liu J., 2010, STRUCTURE, V48, P2915
   Liu J, 2010, J VIROL, V84, P201, DOI 10.1128/JVI.01558-09
   Lopez-Verges S, 2006, P NATL ACAD SCI USA, V103, P14947, DOI 10.1073/pnas.0602941103
   Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025
   McInerney TL, 1998, J VIROL, V72, P1523
   Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5                                                   
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839
   Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009                                                        
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Owen DM, 2012, BIOESSAYS, V34, P739, DOI 10.1002/bies.201200044
   Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002
   POUMBOURIOS P, 1995, J VIROL, V69, P1209
   Resh Marilyn D, 2006, Sci STKE, V2006, pre14, DOI 10.1126/stke.3592006re14
   Resh MD, 2004, SUB CELL BIOCHEM, V37, P217
   Rivinoja A, 2009, J CELL PHYSIOL, V220, P144, DOI 10.1002/jcp.21744
   Rousso I, 2000, P NATL ACAD SCI USA, V97, P13523, DOI 10.1073/pnas.240459697                                                          
   ROWELL JF, 1995, J IMMUNOL, V155, P473
   Roy NH, 2013, J VIROL, V87, P7516, DOI 10.1128/JVI.00790-13
   Salzwedel K, 1999, J VIROL, V73, P2469
   Sanchez SA, 2012, P NATL ACAD SCI USA, V109, P7314, DOI 10.1073/pnas.1118288109
   SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643
   Scolari S, 2009, J BIOL CHEM, V284, P15708, DOI 10.1074/jbc.M900437200
   Seifert MH, 2002, J AM CHEM SOC, V124, P7932, DOI 10.1021/ja0257725
   Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9                                                   
   Silvius JR, 2005, BBA-MOL CELL RES, V1746, P193, DOI 10.1016/j.bbamcr.2005.09.003
   Silvius JR, 2006, MOL MEMBR BIOL, V23, P5, DOI 10.1080/09687860500473002
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Simons K, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004697
   Snijder B, 2009, NATURE, V461, P520, DOI 10.1038/nature08282
   SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0
   SOMASUNDARAN M, 1987, J VIROL, V61, P3114
   Sugimoto Y, 2001, P NATL ACAD SCI USA, V98, P12391, DOI 10.1073/pnas.221181998
   Surma MA, 2012, BBA-MOL CELL BIOL L, V1821, P1059, DOI 10.1016/j.bbalip.2011.12.008
   Thompson RJ, 2006, AM J PHYSIOL-CELL PH, V290, pC499, DOI 10.1152/ajpcell.00585.2004
   Varma R, 1998, NATURE, V394, P798
   Veillette M, 2014, J VIROL, V88, P2633, DOI 10.1128/JVI.03230-13
   Veit M, 2012, BIOL CELL, V104, P493, DOI 10.1111/boc.201200006
   Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200
   Villoing A, 2008, BIOCHEMISTRY-US, V47, P12483, DOI 10.1021/bi801400d
   Vincent N, 2002, BBA-BIOMEMBRANES, V1567, P157, DOI 10.1016/S0005-2736(02)00611-9
   Wan J, 2007, NAT PROTOC, V2, P1573, DOI 10.1038/nprot.2007.225
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Wyss S, 2001, J VIROL, V75, P2982, DOI 10.1128/JVI.75.6.2982-2992.2001
   YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871                                                         
   Yang PL, 2010, J VIROL, V84, P59, DOI 10.1128/JVI.00899-09
   Yu X., 1993, J VIROL, V19, P505
   Yuste E, 2005, J VIROL, V79, P12455, DOI 10.1128/JVI.79.19.12455-12463.2005
   Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539                                                         
   Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8                                                   
   Zheng YH, 2003, P NATL ACAD SCI USA, V100, P8460, DOI 10.1073/pnas.1437453100
NR 93
TC 11
Z9 11
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-5814
EI 1462-5822
J9 CELL MICROBIOL
JI Cell Microbiol.
PD OCT
PY 2014
VL 16
IS 10
BP 1565
EP 1581
DI 10.1111/cmi.12314
PG 17
WC Cell Biology; Microbiology
SC Cell Biology; Microbiology
GA AQ3VB
UT WOS:000342720500009
PM 24844300
OA gold
DA 2018-01-05
ER

PT J
AU Ambrose, Z
   Kline, C
   Polacino, P
   Hu, SL
AF Ambrose, Zandrea
   Kline, Christopher
   Polacino, Patricia
   Hu, Shiu-Lok
TI Dysregulation of multiple inflammatory molecules in lymph node and ileum
   of macaques during RT-SHIV infection with or without antiretroviral
   therapy
SO JOURNAL OF MEDICAL PRIMATOLOGY
LA English
DT Article
DE HIV; inflammation; persistence reservoirs
ID LASER CAPTURE MICRODISSECTION; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   GRANULOMAS; STRESS-RESPONSE; GUINEA-PIGS; PATHOLOGY; EXPRESSION
AB Background Pathogenic infection with human immunodeficiency virus type 1 (HIV-1) or simian immunodeficiency virus (SIV) is characterized by a loss of CD4+ T cells and chronic lymphocyte activation even during suppressive antiretroviral therapy (ART). Methods Using NanoString, expression of >100 molecules associated with inflammation or immune activation was evaluated in mesenteric lymph nodes and ileum of macaques infected with a pathogenic SIV/HIV virus, RT-SHIV, during viremia or during suppressive ART and compared to uninfected controls. Results Of the 105 RNA species quantified in the tissues, expression of 33 genes was altered significantly in one or both tissues during viremia but returned to normal levels during ART. However, 29 additional genes were altered in expression levels in the tissues of both viremic and ART-suppressed macaques. Conclusions Identification of the mechanisms of chronic inflammation in specific cells and in different tissues may help determine whether early ART initiation or novel therapies can prevent it.
C1 [Ambrose, Zandrea; Kline, Christopher] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA.
   [Polacino, Patricia; Hu, Shiu-Lok] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA.
   [Hu, Shiu-Lok] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Ambrose, Z (reprint author), Univ Pittsburgh, Sch Med, 3550 Terrace St,830 Scaife Hall, Pittsburgh, PA 15261 USA.
EM zaa4@pitt.edu
FU NIH HHS [P51 OD010425]; NIAID NIH HHS [R01 AI080290]
CR Adey N, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-29
   Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481                                                   
   Cambier CJ, 2014, NATURE, V505, P218, DOI 10.1038/nature12799
   Day TA, 2010, EUR J IMMUNOL, V40, P1663, DOI 10.1002/eji.201040299
   Dutta NK, 2010, J INFECT DIS, V201, P1743, DOI 10.1086/652497
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Fend F, 2000, J CLIN PATHOL, V53, P666, DOI 10.1136/jcp.53.9.666
   Frost AR, 2001, CURR PROTOC MOL BIOL, V25, p25A
   Getahun H, 2012, J INFECT DIS, V205, pS216, DOI 10.1093/infdis/jis009
   Gopal R, 2013, AM J RESP CRIT CARE, V188, P1137, DOI 10.1164/rccm.201304-0803OC
   Grant SS, 2013, VIRULENCE, V4, P273, DOI 10.4161/viru.23987
   Hunt JL, 2004, ARCH PATHOL LAB MED, V128, P1372
   Kaufmann SHE, 2005, J EXP MED, V201, P1693, DOI 10.1084/jem.20050842
   Kaushal D, 2012, J MED PRIMATOL, V41, P191, DOI 10.1111/j.1600-0684.2012.00536.x
   Lin PL, 2006, INFECT IMMUN, V74, P3790, DOI 10.1128/IAI.00064-06
   Ly LH, 2008, AM J RESP CELL MOL, V38, P455, DOI 10.1165/rcmb.2007-0326OC
   Ly LH, 2007, CELL MICROBIOL, V9, P1127, DOI 10.1111/j.1462-5822.2006.00854.x
   Mattila JT, 2013, J IMMUNOL, V191, P773, DOI 10.4049/jimmunol.1300113
   Mehra S, 2013, J INFECT DIS, V207, P1115, DOI 10.1093/infdis/jis778
   Mehra S, 2012, J INFECT DIS, V205, P1203, DOI 10.1093/infdis/jis102
   Mehra S, 2011, J MED PRIMATOL, V40, P233, DOI 10.1111/j.1600-0684.2011.00485.x
   Mehra S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012266
   Russell DG, 2013, CURR OPIN MICROBIOL, V16, P78, DOI 10.1016/j.mib.2012.11.007
   Selva E, 2004, PATHOLOGY, V36, P77, DOI 10.1080/00313020310001644516
   Slight SR, 2013, J CLIN INVEST, V123, P712, DOI 10.1172/JCI65728
   Zhu GF, 2003, CELL MICROBIOL, V5, P445, DOI 10.1046/j.1462-5822.2003.00288.x                                                
NR 26
TC 4
Z9 4
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0047-2565
EI 1600-0684
J9 J MED PRIMATOL
JI J. Med. Primatol.
PD OCT
PY 2014
VL 43
IS 5
BP 298
EP 309
DI 10.1111/jmp.12126
PG 12
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA AQ3EZ
UT WOS:000342673700003
PM 24784552
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mohammed, AUR
   Kovalenkov, Y
   Silveira, ELV
   Kasturi, SP
   Legere, TH
   Jinnah, ZS
   Villinger, F
   Pulendran, B
   Ahmed, R
   Wrammert, J
AF Mohammed, Ata Ur Rasheed
   Kovalenkov, Yevgeniy
   Silveira, Eduardo L. V.
   Kasturi, Sudhir P.
   Legere, Traci H.
   Jinnah, Zarpheen S.
   Villinger, Francois
   Pulendran, Bali
   Ahmed, Rafi
   Wrammert, Jens
TI DETERMINING THE MAGNITUDE, QUALITY, PERSISTENCE, AND BREADTH OF HIV
   ENV-SPECIFIC HUMORAL IMMUNE RESPONSE IN RHESUS MACAQUES AFTER GP140
   IMMUNIZATION WITH NANOPARTICLES FORMULATED TLR LIGANDS
SO JOURNAL OF MEDICAL PRIMATOLOGY
LA English
DT Meeting Abstract
C1 [Mohammed, Ata Ur Rasheed; Ahmed, Rafi] Yerkes Natl Primate Res, Dept Microbiol & Immunol, Atlanta, GA USA.
   [Mohammed, Ata Ur Rasheed; Kovalenkov, Yevgeniy; Silveira, Eduardo L. V.; Wrammert, Jens] Yerkes Natl Primate Res, Childrens Ctr Immunol & Vaccines, Atlanta, GA USA.
   [Silveira, Eduardo L. V.; Legere, Traci H.; Jinnah, Zarpheen S.; Villinger, Francois] Yerkes Natl Primate Res, Pathol Res, Atlanta, GA USA.
   [Kasturi, Sudhir P.; Pulendran, Bali] Emory Univ, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0047-2565
EI 1600-0684
J9 J MED PRIMATOL
JI J. Med. Primatol.
PD OCT
PY 2014
VL 43
IS 5
MA 87
BP 414
EP 415
PG 2
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA AQ3EZ
UT WOS:000342673700100
DA 2018-01-05
ER

PT J
AU Reissmann, S
AF Reissmann, Siegmund
TI Cell penetration: scope and limitations by the application of
   cell-penetrating peptides
SO JOURNAL OF PEPTIDE SCIENCE
LA English
DT Review
DE cell-penetrating peptides; amino acid sequences; conformations; cellular
   uptake process; intracellular trafficking; activatable CPPs; pH;
   pO(2)-sensitive CPPs; cell- and tissue selectivity; maurocalcine;
   azurin; oncogenase; uptake efficiency; intracellular concentrations;
   cargos proteins; enzymes; antibodies; siRNA; RNA mimics; coupling to
   dendrimers; multifunctional nanoparticles; preclinical and clinical
   studies
ID ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN; IN-VIVO DELIVERY; NF-KAPPA-B;
   SPLICE-CORRECTING OLIGONUCLEOTIDES; INFLUENZA-VIRUS HEMAGGLUTININ;
   NUCLEAR-LOCALIZATION SIGNALS; DUCHENNE MUSCULAR-DYSTROPHY; UNPROCESSED
   PRION PROTEINS; MEDIATED GENE-TRANSFER
AB The penetration of polar or badly soluble compounds through a cell membrane into live cells requires mechanical support or chemical helpers. Cell-penetrating peptides (CPPs) are very promising chemical helpers. Because of their low cytotoxicity and final degradation to amino acids, they are particularly favored in in vivo studies and for clinical applications. Clearly, the future of CPP research is bright; however, the required optimization studies for each drug require considerable individualized attention. Thus, CPPs are not the philosopher's stone. As of today, a large number of such transporter peptides with very different sequences have been identified. These have different uptake mechanisms and can transport different cargos. Intracellular concentrations of cargos can reach a low micromole range and are able to influence intracellular reactions. Internalized ribonucleic acids such as small interfering RNA (siRNA) and mimics of RNA such as peptide nucleic acids, morpholino nucleic acids, and triesters of oligonucleotides can influence transcription and translation. Despite the highly efficient internalization of antibodies, enzymes, and other protein factors, as well as siRNA and RNA mimics, the uptake and stabile insertion of DNA into the genome of the host cells remain substantially challenging. This review describes a wide array of differing CPPs, cargos, cell lines, and tissues. The application of CPPs is compared with electroporation, magnetofection, lipofection, viral vectors, dendrimers, and nanoparticles, including commercially available products. The limitations of CPPs include low cell and tissue selectivity of the first generation and the necessity for formation of fusion proteins, conjugates, or noncovalent complexes to different cargos and of cargo release from intracellular vesicles. Furthermore, the noncovalent complexes require a strong molar excess of CPPs, and extensive experimentation is required to determine the most optimal CPP for any given cargo and cell type. Yet to predict which CPP is optimal for any given target remains a complex question. More recently, there have been promising developments: the enhancement of cell specificity using activatable CPPs, specific transport into cell organelles by insertion of corresponding localization sequences, and the transport of drugs through blood-brain barriers, through the conjunctiva of eyes, skin, and into nerve cells. Proteins, siRNA, and mimics of oligonucleotides can be efficiently transported into cells and have been tested for treatment of certain diseases. The recent state of the art in CPP research is discussed together with the overall scope, limitations, and some recommendations for future research directions. Copyright (c) 2014 European Peptide Society and John Wiley & Sons, Ltd.
C1 [Reissmann, Siegmund] Univ Jena, Biol & Pharmaceut Fac, Inst Biochem & Biophys, D-07743 Jena, Germany.
   [Reissmann, Siegmund] Jena Biosci GmbH, D-07749 Jena, Germany.
RP Reissmann, S (reprint author), Univ Jena, Biol & Pharmaceut Fac, Inst Biochem & Biophys, Dornburger Stasse 25, D-07743 Jena, Germany.
EM siegmund.reissmann@uni-jena.de
CR Abbate V, 2013, J CONTROL RELEASE, V172, P929, DOI 10.1016/j.jconrel.2013.09.033
   Abes S, 2006, J CONTROL RELEASE, V110, P595, DOI 10.1016/j.jconrel.2005.10.026
   Afonin S, 2006, CHEMPHYSCHEM, V7, P2134, DOI 10.1002/cphc.200600306
   Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Akdag IO, 2013, J CHEM-NY, DOI 10.1155/2013/851915
   Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299
   Andaloussi SEL, 2011, METHODS MOL BIOL, V683, P361, DOI 10.1007/978-1-60761-919-2_26
   Andreev OA, 2010, MOL MEMBR BIOL, V27, P341, DOI 10.3109/09687688.2010.509285
   Andreev OA, 2010, P NATL ACAD SCI USA, V107, P4081, DOI 10.1073/pnas.0914330107
   Anko M, 2012, BBA-BIOMEMBRANES, V1818, P915, DOI 10.1016/j.bbamem.2011.12.028
   Aoyagi H, 1999, PEPTIDES: FRONTIERS OF PEPTIDES SCIENCE, P627
   Arbel M, 2007, TRENDS IMMUNOL, V28, P511, DOI 10.1016/j.it.2007.09.005
   Aroui S, 2009, PHARM RES-DORD, V26, P836, DOI 10.1007/s11095-008-9782-1
   Arsov Z, 2008, J PEPT SCI, V14, P1303, DOI 10.1002/psc.1062
   Arukuusk P, 2013, BBA-BIOMEMBRANES, V1828, P1365, DOI 10.1016/j.bbamem.2013.01.011
   Aussedat B, 2006, BBA-BIOMEMBRANES, V1758, P375, DOI 10.1016/j.bbamem.2006.01.012
   Barany-Wallje E, 2005, BIOPHYS J, V89, P2513, DOI 10.1529/biophysj.105.067694
   Biswas Swati, 2013, Pharmaceuticals (Basel), V6, P161, DOI 10.3390/ph6020161
   Biswas S, 2013, CANCER LETT, V335, P191, DOI 10.1016/j.canlet.2013.02.020
   Bleifuss E, 2006, CELL MOL LIFE SCI, V63, P627, DOI 10.1007/s00018-005-5548-7
   Boisguerin P, 2011, J CONTROL RELEASE, V156, P146, DOI 10.1016/j.jconrel.2011.07.037
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Bolhassani A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-3
   Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911
   Borysowski J, 2010, MED HYPOTHESES, V74, P164, DOI 10.1016/j.mehy.2009.07.006
   Brasseur R, 2010, BBA-BIOMEMBRANES, V1798, P2177, DOI 10.1016/j.bbamem.2010.09.001
   BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Cao MX, 2006, MOL BIOTECHNOL, V32, P55, DOI 10.1385/MB:32:1:055
   Cardoso AMS, 2012, BBA-BIOMEMBRANES, V1818, P877, DOI 10.1016/j.bbamem.2011.12.022
   Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003
   Chaloin L, 1997, BIOCHEMISTRY-US, V36, P11179, DOI 10.1021/bi9708491
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   CHEN CP, 1995, FEBS LETT, V370, P46, DOI 10.1016/0014-5793(95)00792-8
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547                                                    
   Cohen RN, 2009, J CONTROL RELEASE, V135, P166, DOI 10.1016/j.jconrel.2008.12.016
   Constantini DL, 2008, CANCER BIOTHER RADI, V23, P3
   Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899
   Crombez L, 2007, BIOCHEM SOC T, V35, P44, DOI 10.1042/BST0350044                                                              
   Crombez L, 2011, METHODS MOL BIOL, V683, P349, DOI [10.1007/978-1-60751-919-2_25, 10.1007/978-1-60761-919-2_25]
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Crombez L, 2008, CURR PHARM DESIGN, V14, P3656, DOI 10.2174/138161208786898842
   D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Dan Lewis H, 2010, BMC BIOTECHNOL, V10, P79, DOI 1472-6750/10/79
   Dekiwadia CD, 2012, J PEPT SCI, V18, P527, DOI 10.1002/psc.2430
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005
   Diao YW, 2012, J PEPT SCI, V18, P476, DOI 10.1002/psc.2420
   Dietz GPH, 2005, BRAIN RES BULL, V68, P103, DOI 10.1016/j.brainresbull.2005.08.015
   Dietz GPH, 2010, CURR PHARM BIOTECHNO, V11, P167, DOI 10.2174/138920110790909731                                                      
   Duchardt F, 2009, J BIOL CHEM, V284, P36099, DOI 10.1074/jbc.M109.036426
   Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0
   DUVERGER E, 1995, J CELL SCI, V108, P1325
   Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911                                                           
   Eldar-Boock A, 2011, BIOMATERIALS, V32, P3862, DOI 10.1016/j.biomaterials.2011.01.073
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2006, BBA-BIOMEMBRANES, V1758, P721, DOI 10.1016/j.bbamem.2006.05.013
   Erazo-Oliveras Alfredo, 2012, Pharmaceuticals (Basel), V5, P1177, DOI 10.3390/ph5111177
   Ezzat K, 2012, FASEB J, V26, P1172, DOI 10.1096/fj.11-191536
   Ezzat K, 2011, NUCLEIC ACIDS RES, V39, P5284, DOI 10.1093/nar/gkr072
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   Fagerlund R, 2008, CELL SIGNAL, V20, P1442, DOI 10.1016/j.cellsig.2008.03.012
   Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4
   Farrera-Sinfreu Josep, 2007, V386, P241, DOI 10.1007/978-1-59745-430-8_9
   Faustin K, 2011, CHEM BIODIVERS, V8, P1
   Fernandez-Llamazares AI, 2014, BIOCONJUGATE CHEM, V25, P11, DOI 10.1021/bc4003844
   Fischer D, 2002, BIOCONJUGATE CHEM, V13, P1124, DOI 10.1021/bc025550w
   Fischer D, 2004, DRUG METAB DISPOS, V32, P983
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   Foerg C, 2008, AAPS J, V10, P349, DOI 10.1208/s12248-008-9029-4
   Fominaya J, 1996, J BIOL CHEM, V271, P10560, DOI 10.1074/jbc.271.18.10560                                                        
   Fotin-Mleczek M, 2005, J CELL SCI, V118, P3339, DOI 10.1242/jcs.02460
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fridkin G, 2001, PEPTIDES WAVE FUTURE, P230
   Friedler A, 2000, J BIOL CHEM, V275, P23783, DOI 10.1074/jbc.M002200200                                                          
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki Shiroh, 2003, CURR PROTEIN PEPT SC, V4
   Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123
   Ghibaudi E, 2005, J PEPT SCI, V11, P401, DOI 10.1002/psc.633
   Gitton Y, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-40
   GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0
   Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797                                                              
   Gomez Jose A, 2010, Pharmaceuticals (Basel), V3, P3594, DOI 10.3390/ph3123594
   Graslund A, 2011, METHODS MOL BIOL, V683, P33, DOI 10.1007/978-1-60761-919-2_3
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hansen M, 2008, ADV DRUG DELIVER REV, V60, P572, DOI 10.1016/j.addr.2007.09.003
   Hariton-Gazal E, 2003, J CELL SCI, V116, P4577, DOI 10.1242/jcs.00757
   Hariton-Gazal E, 2001, PEPTIDES WAVE FUTURE, P959
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henriques ST, 2010, BIOTECHNOLOGY MEMBRA, V9, P377
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015
   Howl J, 2008, INT J PEPT RES THER, V14, P359, DOI 10.1007/s10989-008-9135-2
   Hoyer J, 2012, BEILSTEIN J ORG CHEM, V8, P1788, DOI 10.3762/bjoc.8.204
   Hoyer J, 2012, J CONTROL RELEASE, V161, P826, DOI 10.1016/j.jconrel.2012.05.017
   Hu WN, 2012, J BIOL INORG CHEM, V17, P175, DOI 10.1007/s00775-011-0840-5
   Hu Yi, 2012, BMC Res Notes, V5, P336, DOI 10.1186/1756-0500-5-336
   Hussain R, 2006, INT J PEPT RES THER, V12, P311, DOI 10.1007/s10989-006-9028-1
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73
   Inoue M, 2004, INT J ONCOL, V25, P713
   Jean-Alphonse F, 2011, MOL CELL ENDOCRINOL, V331, P205, DOI 10.1016/j.mce.2010.07.010
   Jezek J, 2013, EXPERT OPIN DRUG DEL, V10, P811, DOI 10.1517/17425247.2013.780023
   Jin EL, 2013, J AM CHEM SOC, V135, P933, DOI 10.1021/ja311180x
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones S, 2013, HUM REPROD, V28, P1874, DOI 10.1093/humrep/det064
   Kaasch AJ, 2000, CURR OPIN MICROBIOL, V3, P422, DOI 10.1016/S1369-5274(00)00115-6
   Kalafut D, 2012, BIOORG MED CHEM LETT, V22, P561, DOI 10.1016/j.bmcl.2011.10.077
   KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0
   Kallweit E, J CELL BIOCH UNPUB
   Kamei N, 2013, THER DELIV, V4, P315, DOI [10.4155/TDE.12.164, 10.4155/tde.12.164]
   Kamei N, 2013, J PHARM SCI-US, V102, P469, DOI 10.1002/jps.23364
   Kamena F, 2011, CHEM BIODIVERS, V8, P1, DOI 10.1002/cbdv.201000318
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Keller AA, 2014, J CELL BIOCHEM, V115, P243, DOI 10.1002/jcb.24654
   Keller Andrea-Anneliese, 2013, Pharmaceuticals (Basel), V6, P184, DOI 10.3390/ph6020184
   KEMPF C, 1982, J BIOL CHEM, V257, P2469
   Kichler A, 2006, BBA-BIOMEMBRANES, V1758, P301, DOI 10.1016/j.bbamem.2006.02.005
   Kim BK, 2012, BIOORG MED CHEM LETT, V22, P5415, DOI 10.1016/j.bmcl.2012.07.051
   Kim ES, 2010, BIOCHEM BIOPH RES CO, V392, P9, DOI 10.1016/j.bbrc.2009.12.135
   Koczan G, 2002, BIOCONJUGATE CHEM, V13, P518, DOI 10.1021/bc015530e
   Koppelhus U, 2008, BIOCONJUGATE CHEM, V19, P1526, DOI 10.1021/bc800068h
   Krauss U, 2001, PEPT 2000 P EUR PEPT, P131
   Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951
   Kuriyama S, 2006, J PEPT SCI, V12, P626, DOI 10.1002/psc.768
   Kurzawa L, 2010, BBA-BIOMEMBRANES, V1798, P2274, DOI 10.1016/j.bbamem.2010.02.027
   Laakkonen P, 2008, ANN NY ACAD SCI, V1131, P37, DOI 10.1196/annals.1413.003
   Lamaziere A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000201
   Langel U., 2007, HDB CELL PENETRATING
   Lee RW, 2003, CURRENT PROT PEPT SC, V4, P105
   Lentacker I, 2008, J CONTROL RELEASE, V132, P279, DOI 10.1016/j.jconrel.2008.06.023
   Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022
   Levchenko T, 2012, ANTIBODY MEDIATED DR, P13
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindberg S, 2013, INT J PHARMACEUT, V441, P242, DOI 10.1016/j.ijpharm.2012.11.037
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu XL, 2013, INT J PHARMACEUT, V448, P159, DOI 10.1016/j.ijpharm.2013.03.033
   Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819
   Liu Y, 2012, INT J PHARMACEUT, V434, P209
   Lofgren K, 2008, FASEB J, V22, P2177, DOI 10.1096/fj.07-099549
   Lorents A, 2012, J BIOL CHEM, V287, P16880, DOI 10.1074/jbc.M111.318063
   Lukanowska M, 2013, BIOTECHNOL J, V8, P918, DOI 10.1002/biot.201200335
   Ma Y, 2012, J CONTROL RELEASE, V162, P286, DOI 10.1016/j.jconrel.2012.07.022
   Madani F, 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mae M, 2012, INT J PEPT RES THER, V18, P361, DOI 10.1007/s10989-012-9312-1
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Magzoub M., 2006, Biochemistry and biophysics of lipids, P175
   Magzoub M, 2005, BBA-BIOMEMBRANES, V1716, P126, DOI 10.1016/j.bbamem.2005.09.009
   Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065
   Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6
   Mannisto M, 2007, J GENE MED, V9, P479, DOI 10.1002/jgm.1035
   Mano M, 2007, J PEPT SCI, V13, P301, DOI 10.1002/psc.842
   Manoeur AP, 2009, METHODS MOL BIOL STE, V482, P43
   Martin I, 2012, ORG BIOMOL CHEM, V10, P3258, DOI 10.1039/c2ob06907e
   Martin Irene, 2010, Pharmaceuticals (Basel), V3, P1456
   Martin I, 2011, CHEMBIOCHEM, V12, P896, DOI 10.1002/cbic.201000679
   Matschke J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024615
   Matsumoto T, 1999, BIOPHYS CHEM, V79, P153, DOI 10.1016/S0301-4622(99)00051-4
   McGeary RP, 2002, INNOVATION PERSPECTI, P169
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Mellert K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052473
   Mizuno T, 2009, J PEPT SCI, V15, P259, DOI 10.1002/psc.1079
   Mokhtarieh AA, 2013, BIOCHEM BIOPH RES CO, V432, P359, DOI 10.1016/j.bbrc.2013.01.096
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Moulton HM, 2013, CURR PHARM DESIGN, V19, P2963
   Moulton HM, 2012, METHODS MOL BIOL, V867, P407, DOI 10.1007/978-1-61779-767-5_26
   Moulton HM, 2010, BBA-BIOMEMBRANES, V1798, P2296, DOI 10.1016/j.bbamem.2010.02.012
   Moulton HM, 2009, ANN NY ACAD SCI, V1175, P55, DOI 10.1111/j.1749-6632.2009.04976.x
   Muller J, 2012, J PEPT SCI, V18, P293, DOI 10.1002/psc.2396
   Mueller NH, 2013, INVEST OPHTH VIS SCI, V54, P2, DOI 10.1167/iovs.12-10947
   MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137                                           
   Musial-Siwek M, 2010, BBA-BIOMEMBRANES, V1798, P1041, DOI 10.1016/j.bbamem.2009.08.023
   Mussbach F, 2011, J CELL BIOCHEM, V112, P3824, DOI 10.1002/jcb.23313
   Mussbach F, 2011, METHODS MOL BIOL, V683, P375, DOI 10.1007/978-1-60761-919-2_27
   Myrberg H, 2007, BIOCONJUGATE CHEM, V18, P170, DOI 10.1021/bc060266g
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2011, METHODS MOL BIOL, V683, P525, DOI 10.1007/978-1-60761-919-2_37
   Nascimento FD, 2007, J BIOL CHEM, V282, P21349, DOI 10.1074/jbc.M604876200
   Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje
   Neundorf Ines, 2009, Pharmaceuticals (Basel), V2, P49
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Niederhafner P, 2005, J PEPT SCI, V11, P757, DOI 10.1002/psc.721
   Niederhafner P, 2008, J PEPT SCI, V14, P556, DOI 10.1002/psc.1011
   Nielsen PE, 2010, CHEM BIODIVERS, V7, P786, DOI 10.1002/cbdv.201000005
   Niles AL, 2007, ANAL BIOCHEM, V366, P197, DOI 10.1016/j.ab.2007.04.007
   O'Callaghan K, 2012, BLOOD, V119, P1717, DOI 10.1182/blood-2011-04-347518
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oehlke J, 2005, J MOL RECOGNIT, V18, P50, DOI 10.1002/jmr.691
   Oehlke J, 2007, HDB CELL PENETRATING, P43
   Olson ES, 2012, INTEGR BIOL-UK, V4, P595, DOI 10.1039/c2ib00161f
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Orange JS, 2008, CELL MOL LIFE SCI, V65, P3564, DOI 10.1007/s00018-008-8222-z
   Oskolkov N, 2011, INT J PEPT RES THER, V17, P147, DOI 10.1007/s10989-011-9252-1
   Padari K, 2011, METHODS MOL BIOL, V683, P181, DOI 10.1007/978-1-60761-919-2_13
   Palm C, 2006, PEPTIDES, V27, P1710, DOI 10.1016/j.peptides.2006.01.006
   Palm-Apergi C, 2009, FASEB J, V23, P214, DOI 10.1096/fj.08-110254
   Paul RW, 1997, HUM GENE THER, V8, P1253, DOI 10.1089/hum.1997.8.10-1253
   Perche F, 2013, J DRUG DELIV, DOI 10.1155/2013/705265
   Poillot C, 2012, J BIOL CHEM, V287, P17331, DOI 10.1074/jbc.M112.360628
   Polster BM, 2006, J PEPT RES THERAP, V13, P83
   Prud'homme GJ, 2012, ONCOTARGET, V3, P921
   Pujals S, 2008, ADV DRUG DELIVER REV, V60, P473, DOI 10.1016/j.addr.2007.09.012
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Pujals S, 2009, CHEMBIOCHEM, V10, P1025, DOI 10.1002/cbic.200800843
   Qu XL, 2010, J DRUG TARGET, V18, P351, DOI 10.3109/10611860903450049
   Radis-Baptista G, 2008, J MED CHEM, V51, P7041, DOI 10.1021/jm8009475
   Radis-Baptista G, 2011, CURR PHARM DESIGN, V17, P4351, DOI 10.2174/138161211798999429                                                      
   Raagel H, 2013, CELL MOL LIFE SCI, V70, P4825, DOI 10.1007/s00018-013-1416-z
   Rahmat D, 2012, BIOMATERIALS, V33, P2321, DOI 10.1016/j.biomaterials.2011.11.046
   Rechenmacher F, 2013, ANGEW CHEM INT EDIT, V52, P1572, DOI 10.1002/anie.201206370
   Rennert R, 2006, BBA-BIOMEMBRANES, V1758, P347, DOI 10.1016/j.bbamem.2005.10.006
   Rennert R, 2008, CHEMMEDCHEM, V3, P241, DOI 10.1002/cmdc.200700216
   REPKE H, 1987, FEBS LETT, V221, P236, DOI 10.1016/0014-5793(87)80932-8
   Reshetnyak YK, 2008, P NATL ACAD SCI USA, V105, P15340, DOI 10.1073/pnas.0804746105
   Ribeiro S, 2012, CELL REPROGRAM, V14, P130, DOI 10.1089/cell.2011.0093
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rodrigues M, 2013, BBA-GEN SUBJECTS, V1830, P4554, DOI 10.1016/j.bbagen.2013.05.020
   Rodrigues M, 2011, BIOCONJUGATE CHEM, V22, P2339, DOI 10.1021/bc200421z
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Rondanino C, 2003, GLYCOBIOLOGY, V13, P509, DOI 10.1093/glycob/cwg064
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rothbard JB, 2011, METHODS MOL BIOL, V683, P487, DOI 10.1007/978-1-60761-919-2_35
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Rubio I, 2004, J BIOCHEM BIOPH METH, V58, P111, DOI 10.1016/j.jbbm.2003.07.001
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Ruzza P, 2001, BIOPOLYMERS, V60, P290, DOI 10.1002/1097-0282(2001)60:4<290::AID-BIP9991>3.0.CO;2-M                         
   Ryves WJ, 2006, MOL BIOTECHNOL, V33, P123, DOI 10.1385/MB:33:2:123                                                             
   Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033
   Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l
   Sanclimens G, 2005, BIOPOLYMERS, V80, P800, DOI 10.1002/bip.20301
   Sanders WS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002101
   Sarojini HII, 2007, BIOTECHNIQUES, V43, P213, DOI 10.2144/000112493
   Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Schlenk F, 2013, THER DELIV, V4, P95, DOI [10.4155/tde.12.128, 10.4155/TDE.12.128]
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   Scocchi M, 2011, CELL MOL LIFE SCI, V68, P2317, DOI 10.1007/s00018-011-0721-7
   Sebestik J, 2011, AMINO ACIDS, V40, P301, DOI 10.1007/s00726-010-0707-z
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Singh RK, 2010, CELL CYCLE, V9, P4236, DOI 10.4161/cc.9.20.13636
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Snyder EL, 2005, CANCER RES, V65, P10646, DOI 10.1158/0008-5472.CAN-05-0118
   Soomets U, 1997, CURR TOP PEPT PROTEI, V2, P83
   Splith K, 2012, CHEMMEDCHEM, V7, P57, DOI 10.1002/cmdc.201100401
   Splith K, 2011, EUR BIOPHYS J BIOPHY, V40, P387, DOI 10.1007/s00249-011-0682-7
   Splith K, 2010, BIOCONJUGATE CHEM, V21, P1288, DOI 10.1021/bc100089z
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Suresh A, 2013, BIOTECHNOL BIOENG, V110, P2795, DOI 10.1002/bit.24935
   Svensen N, 2012, TRENDS PHARMACOL SCI, V33, P186, DOI 10.1016/j.tips.2012.02.002
   Svensen N, 2011, ANGEW CHEM INT EDIT, V50, P6133, DOI 10.1002/anie.201101804
   Szeto HH, 2004, FASEB J, V18, P118, DOI 10.1096/fj.04-1982fje
   Tanaka G, 2012, CHEM BIOL, V19, P1437, DOI 10.1016/j.chembiol.2012.09.011
   Taylor BN, 2009, CANCER RES, V69, P537, DOI 10.1158/0008-5472.CAN-08-2932
   Tekewe A, 2013, INT J PHARM SCI RES, V4, P1, DOI 10.13040/IJPSR.0975-8232.(1).1-8
   Tisseyre Celine, 2013, Pharmaceuticals (Basel), V6, P320, DOI 10.3390/ph6030320
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin Vladimir P., 2010, CELL PENETRATING PEP
   Toriyabe N, 2013, BIOMATERIALS, V34, P1337, DOI 10.1016/j.biomaterials.2012.10.043
   Trabulo S, 2008, J GENE MED, V10, P1210, DOI 10.1002/jgm.1247
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Trentin D, 2006, P NATL ACAD SCI USA, V103, P2506, DOI 10.1073/pnas.0505964102
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P6837, DOI 10.1093/nar/gki991
   van Duijnhoven SMJ, 2011, J NUCL MED, V52, P279, DOI 10.2967/jnumed.110.082503
   Verdurmen WPR, 2011, CHEM BIOL, V18, P1000, DOI 10.1016/j.chembiol.2011.06.006
   Verdurmen WPR, 2011, TRENDS PHARMACOL SCI, V32, P116, DOI 10.1016/j.tips.2010.11.005
   Verdurmen WPR, 2010, J CONTROL RELEASE, V147, P171, DOI 10.1016/j.jconrel.2010.06.030
   Vesylevsky S, 2009, BIOPHYS J, V97, P40
   Vidal P, 1996, J PEPT SCI, V2, P125, DOI 10.1002/psc.58
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadhwani P, 2012, EUR BIOPHYS J BIOPHY, V41, P177, DOI 10.1007/s00249-011-0771-7
   Walker Johm M., 2011, METHODS MOL BIOL, V683
   Wang CF, 2012, ACTA BIOMATER, V8, P3014, DOI 10.1016/j.actbio.2012.04.034
   Wang HY, 2012, ADV IMMUNOL, V114, P151, DOI 10.1016/B978-0-12-396548-6.00006-8
   Wang H, 2010, J CONTROL RELEASE, V143, P64, DOI 10.1016/j.jconrel.2009.12.003
   Wang HY, 2011, J CONTROL RELEASE, V155, P26, DOI 10.1016/j.jconrel.2010.12.009
   Ward CM, 2000, J DRUG TARGET, V8, P119, DOI 10.3109/10611860008996857                                                       
   Weisbart RH, 2004, INT J ONCOL, V25, P1113
   Weisbart RH, 2012, MOL CANCER THER, V11, P2169, DOI 10.1158/1535-7163.MCT-12-0476-T
   Whitney M, 2013, ANGEW CHEM INT EDIT, V52, P325, DOI 10.1002/anie.201205721
   Whitney M, 2010, J BIOL CHEM, V285, P22532, DOI 10.1074/jbc.M110.138297
   Wolf Y, 2006, BIOCHEMISTRY-US, V45, P14944, DOI 10.1021/bi0606896
   Wu RP, 2007, NUCLEIC ACIDS RES, V35, P5182, DOI 10.1093/nar/gkm478
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Ye YP, 2011, THERANOSTICS, V1, P102, DOI 10.7150/thno/v01p0102
   Yesylevskyy S, 2009, BIOPHYS J, V97, P40, DOI 10.1016/j.bpj.2009.03.059
   Yin HF, 2010, MOL THER, V18, P1822, DOI 10.1038/mt.2010.151
   Yousif LF, 2009, CHEMBIOCHEM, V10, P2081, DOI 10.1002/cbic.200900017
   Yu J, 2010, CHEM BIOL DRUG DES, V76, P70, DOI 10.1111/j.1747-0285.2010.00985.x
   Zelman-Femiak M, 2010, BIOTECHNIQUES, V49, P574, DOI 10.2144/000113466
   Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184                                                         
   Zhao B, 2013, VACCINE, V31, P545, DOI 10.1016/j.vaccine.2012.11.011
   Zhou M, 2007, BIOPOLYMERS, V88, P325, DOI 10.1002/bip.20655
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
   Ziegler A, 2008, BIOPHYS J, V94, P2142, DOI 10.1529/biophysj.107.113472
   Ziegler A, 2011, BIOCHEMISTRY-US, V50, P4650, DOI 10.1021/bi1019429
   Zoda MS, 2010, PEPT 2010 P 31 EUR P, P210
   [Anonymous], 2010, BIOCH BIOPHYSICA ACT, V1798, P2177
NR 312
TC 55
Z9 58
U1 13
U2 219
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1075-2617
EI 1099-1387
J9 J PEPT SCI
JI J. Pept. Sci.
PD OCT
PY 2014
VL 20
IS 10
BP 760
EP 784
DI 10.1002/psc.2672
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA AQ4HI
UT WOS:000342754000002
PM 25112216
DA 2018-01-05
ER

PT J
AU Tsvetkov, NV
   Lebedeva, EV
   Lezov, AA
   Podseval'nikova, AN
   Akhmadeeva, LI
   Mikhailova, ME
   Zorin, IM
   Makarov, IA
   Bilibin, AY
AF Tsvetkov, N. V.
   Lebedeva, E. V.
   Lezov, A. A.
   Podseval'nikova, A. N.
   Akhmadeeva, L. I.
   Mikhailova, M. E.
   Zorin, I. M.
   Makarov, I. A.
   Bilibin, A. Yu.
TI Conformational, optical, electro-optical, and dynamic characteristics of
   cross-linked poly(N-acryloyl-11-aminoundecanoic acid)
SO COLLOID AND POLYMER SCIENCE
LA English
DT Article
DE Comb-like polymer; Cross-linked polymer; Macromolecule conformation;
   Optical anisotropy; Dynamic light scattering
ID ELECTROKINETIC CAPILLARY CHROMATOGRAPHY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   POLYMERIZED MICELLES; LIGHT-SCATTERING; POLYANION INHIBITORS; ANIONIC
   SURFACTANTS; AQUEOUS-SOLUTIONS; DRUG-DELIVERY; MACROMOLECULES;
   NANOPARTICLES
AB Polymerizable surfactants now attract a great interest due to high potential of their practical application as components of pseudostationary phase in micellar chromatography, drug carriers, and "building blocks" for molecular design of nanoparticles and nanostructured polymer materials, for encapsulation of various biological preparations. In the present work, we have studied poly(N-acryloyl-11-aminoundecanoic acid) (cross-linked comb-like polymer). Cross-linked polymers were obtained via copolymerization of the surfactant bearing double bond in hydrophobic tail with hydrophobic bifunctional cross-linker in micellar solution. Of special interest was the comparison between cross-linked and non-cross-linked polymers and influence of alkaline medium on characteristics of these samples. Non-cross-linked polymers were obtained by hydrolysis of the cross-linked product (treating with NaOH). The mixture of cyclohexanol and dioxane (1:1 volume ratio) was used as a solvent. Detailed studies of the obtained polymers by viscometry, dynamic light scattering, flow birefringence, and equilibrium and non-equilibrium electric birefringence were performed. It was established that during cross-linking process, two types of bonds are formed (the ones inside individual molecules and between several polymer chains). It was shown that cross-linked macromolecular nanoparticles can be transformed into comb-like polymers.
C1 [Tsvetkov, N. V.; Lebedeva, E. V.; Lezov, A. A.; Podseval'nikova, A. N.; Akhmadeeva, L. I.; Mikhailova, M. E.] St Petersburg State Univ, Dept Phys, St Petersburg 198504, Russia.
   [Zorin, I. M.; Makarov, I. A.; Bilibin, A. Yu.] St Petersburg State Univ, Dept Chem, St Petersburg 198504, Russia.
RP Tsvetkov, NV (reprint author), St Petersburg State Univ, Dept Phys, Uljanovskaja St 1, St Petersburg 198504, Russia.
EM N.Tsvetkov@mail.ru
RI Lebedeva, Elena/G-5356-2011; Mikhailova, Mariya/J-8575-2013; Lezov,
   Alexey/J-6738-2013; Akhmadeeva, Liliia/O-9335-2014; Zorin,
   Ivan/H-1263-2013; Tsvetkov, Nikolai/J-7975-2013
OI Lebedeva, Elena/0000-0002-3363-7740; Mikhailova,
   Mariya/0000-0001-5019-2248; Lezov, Alexey/0000-0001-7960-6889;
   Akhmadeeva, Liliia/0000-0002-4049-2172; Zorin, Ivan/0000-0001-8133-0615;
   Tsvetkov, Nikolai/0000-0003-2666-6073
FU Russian Foundation for Basic Research [12-03-00687-a, 12-03-00746-a,
   13-03-00474-a]; St. Petersburg State University research grant
   [11.38.267.2014]
FX This work was supported by the Russian Foundation for Basic Research
   (12-03-00687-a, 12-03-00746-a, 13-03-00474-a) and St. Petersburg State
   University research grant (11.38.267.2014).
CR Alvarez-Lorenzo C, 2013, ADV DRUG DELIVER REV, V65, P1148, DOI 10.1016/j.addr.2013.04.016
   Crassous JJ, 2008, COLLOID POLYM SCI, V286, P805, DOI 10.1007/s00396-008-1873-3
   Dodziuk H, 2002, INTRO SUPRAMOLECULAR, VXII, P115, DOI [10.1007/0-306-47587-1_6, DOI 10.1007/0-306-47587-1_6]
   Fu GD, 2011, PROG POLYM SCI, V36, P127, DOI 10.1016/j.progpolymsci.2010.07.011
   Fujimoto C, 2000, J CHROMATOGR A, V871, P415, DOI 10.1016/S0021-9673(99)00848-1                                                   
   Gerber MJ, 2006, LANGMUIR, V22, P941, DOI 10.1021/la052297q
   Hartenstine JR, 2007, IPACK 2007: PROCEEDINGS OF THE ASME INTERPACK CONFERENCE 2007, VOL 1, P715, DOI 10.1007/978-0-387-69002-5_45
   Hentze HP, 2003, CURR OPIN COLLOID IN, V8, P164, DOI 10.1016/S1359-0294(03)00018-9
   Klenin K, 2000, MACROMOLECULES, V33, P1459, DOI 10.1021/ma9914467                                                               
   Leydet A, 1997, J MED CHEM, V40, P342, DOI 10.1021/jm960493b                                                               
   LEYDET A, 1995, J MED CHEM, V38, P2433, DOI 10.1021/jm00013a019                                                             
   LEZOV AV, 1990, VYSOKOMOL SOEDIN A+, V32, P162
   Lin HL, 2000, COLLOID POLYM SCI, V278, P187, DOI 10.1007/s003960050031
   Lu H, 2014, CHEM COMMUN, V50, P139, DOI 10.1039/c3cc46317f
   Lysenko EA, 1998, MACROMOLECULES, V31, P4516, DOI 10.1021/ma980367c                                                               
   Mel'nikov AB, 2010, COLLOID J+, V72, P512, DOI 10.1134/S1061933X10040113
   Miller SA, 1999, CURR OPIN COLLOID IN, V4, P338, DOI 10.1016/S1359-0294(99)90018-3                                                   
   Nagai K, 1996, TRENDS POLYM SCI, V4, P122
   NEWMAN J, 1994, MACROMOLECULES, V27, P6808, DOI 10.1021/ma00101a020                                                             
   Palmer CP, 2004, J CHROMATOGR A, V1044, P159, DOI 10.1016/j.chroma.2004.04.068
   Pamies R, 2008, COLLOID POLYM SCI, V286, P1223, DOI 10.1007/s00396-008-1902-2
   Rambidi NG, 2009, PHYS CHEM BASES NANO
   Summers M, 2003, ADV COLLOID INTERFAC, V100, P137, DOI 10.1016/S0001-8686(02)00058-1                                                   
   Tian L, 2004, J MATER CHEM, V14, P2317, DOI 10.1039/b401398k
   Tsvetkov NV, 2014, POLYMER, V55, P1716, DOI 10.1016/j.polymer.2014.02.019
   Tsvetkov NV, 2011, POLYM SCI SER A+, V53, P666, DOI 10.1134/S0965545X11080104
   TSVETKOV VN, 1981, ADV POLYM SCI, V39, P95
   Tsvetkov V. N., 1964, NEWER METHODS POLYM, P563
   Tsvetkov V. N., 1989, RIGID CHAIN POLYM
   Tsvetkov VN, 1975, POLYM HDB, P377
   WANG JA, 1994, ANAL CHEM, V66, P3773, DOI 10.1021/ac00093a037
   WU C, 1995, MACROMOLECULES, V28, P4914, DOI 10.1021/ma00118a019                                                             
   Yan F, 2006, SOFT MATTER, V2, P109, DOI 10.1039/b513914g
   Yoshida E, 2013, COLLOID POLYM SCI, V291, P993, DOI 10.1007/s00396-012-2821-9
   Zakharova JA, 2007, POLYMER, V48, P220, DOI 10.1016/j.polymer.2006.11.011
   Zhang Y, 2013, ADV DRUG DELIVER REV, V65, P104, DOI 10.1016/j.addr.2012.10.003
   Zorin IM, 2006, POLYM BULL, V57, P57, DOI 10.1007/s00289-006-0539-x
   Zorin IM, 2010, MACROMOL SYMP, V296, P407, DOI 10.1002/masy.201051056
   Dutta PK, 2013, ADV POLYM SCI, V254, P1, DOI 10.1007/978-3-642-40123-7
NR 39
TC 3
Z9 3
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0303-402X
EI 1435-1536
J9 COLLOID POLYM SCI
JI Colloid Polym. Sci.
PD OCT
PY 2014
VL 292
IS 10
BP 2727
EP 2733
DI 10.1007/s00396-014-3346-1
PG 7
WC Chemistry, Physical; Polymer Science
SC Chemistry; Polymer Science
GA AP6FF
UT WOS:000342172300031
DA 2018-01-05
ER

PT J
AU Herberg, S
   Kondrikova, G
   Periyasamy-Thandavan, S
   Howie, RN
   Elsalanty, ME
   Weiss, L
   Campbell, P
   Hill, WD
   Cray, JJ
AF Herberg, Samuel
   Kondrikova, Galina
   Periyasamy-Thandavan, Sudharsan
   Howie, R. Nicole
   Elsalanty, Mohammed E.
   Weiss, Lee
   Campbell, Phil
   Hill, William D.
   Cray, James J.
TI Inkjet-based biopatterning of SDF-1 beta augments BMP-2-induced repair
   of critical size calvarial bone defects in mice
SO BONE
LA English
DT Article
DE Bone; Healing; Biopatterning; BMP-2; SDF-1 beta; TGF-beta 1
ID MESENCHYMAL STEM-CELLS; GROWTH-FACTOR BETA-1; OPEN TIBIAL FRACTURES;
   MORPHOGENETIC PROTEIN-2; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; EXPERIMENTAL-MODEL; COLLAGEN SPONGES; GENE-EXPRESSION;
   HIV-1 ENTRY
AB Background: A major problem in craniofacial surgery is non-healing bone defects. Autologous reconstruction remains the standard of care for these cases. Bone morphogenetic protein-2 (BMP-2) therapy has proven its clinical utility, although non-targeted adverse events occur due to the high milligram-level doses used. Ongoing efforts explore the use of different growth factors, cytokines, or chemokines, as well as co-therapy to augment healing.
   Methods: Here we utilize inkjet-based biopatterning to load acellular DermaMatrix delivery matrices with nanogram-level doses of BMP-2, stromal cell-derived factor-1 beta (SDF-1 beta), transforming growth factor-beta 1 (TGF-beta 1), or co-therapies thereof. We tested the hypothesis that bioprinted SDF-1 beta co-delivery enhances BMP-2 and TGF-beta 1-driven osteogenesis both in-vitro and in-vivo using a mouse calvarial critical size defect (CSD) model.
   Results: Our data showed that BMP-2 bioprinted in low-doses induced significant new bone formation by four weeks post-operation. TGF-beta 1 was less effective compared to BMP-2, and SDF-1 beta therapy did not enhance osteogenesis above control levels. However, co-delivery of BMP-2 + SDF-1 beta was shown to augment BMP-2-induced bone formation compared to BMP-2 alone. In contrast, co-delivery of TGF-beta 1 + SDF-1 beta decreased bone healing compared to TGF-1 beta alone. This was further confirmed in vitro by osteogenic differentiation studies using MC3T3-E1 pre-osteoblasts.
   Conclusions: Our data indicates that sustained release delivery of a low-dose growth factor therapy using biopatterning technology can aid in healing CSD injuries. SDF-1 beta augments the ability for BMP-2 to drive healing, a result confirmed in vivo and in vitro; however, because SDF-1 beta is detrimental to TGF-1 beta-driven osteogenesis, its effect on osteogenesis is not universal. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Herberg, Samuel; Kondrikova, Galina; Periyasamy-Thandavan, Sudharsan; Hill, William D.; Cray, James J.] Georgia Regents Univ, Dept Cellular Biol & Anat, Augusta, GA USA.
   [Howie, R. Nicole; Elsalanty, Mohammed E.; Cray, James J.] Georgia Regents Univ, Dept Oral Biol, Augusta, GA USA.
   [Hill, William D.; Cray, James J.] Georgia Regents Univ, Dept Orthopaed Surg, Augusta, GA USA.
   [Cray, James J.] Georgia Regents Univ, Div Plast Surg, Dept Orthodont & Surg, Augusta, GA USA.
   [Elsalanty, Mohammed E.; Hill, William D.; Cray, James J.] Georgia Regents Univ, Inst Regenerat & Reparat Med, Augusta, GA USA.
   [Weiss, Lee] Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.
   [Campbell, Phil] Carnegie Mellon Univ, Inst Complex Engn Syst, Pittsburgh, PA 15213 USA.
   [Weiss, Lee; Campbell, Phil] McGowan Inst Regenerat Med, Pittsburgh, PA USA.
   [Hill, William D.] Charlie Norwood VA Med Ctr, Augusta, GA USA.
RP Cray, JJ (reprint author), Med Univ S Carolina, Dept Oral Hlth Sci, BSB 2308,173 Ashley Ave, Charleston, SC 29425 USA.
EM crayj@musc.edu
FU Musculoskeletal Transplant Foundation; Institute for Regenerative and
   Reparative Medicine at Georgia Regents University; U.S. Department of
   Veterans Affairs [VA104462]; National Institute on Aging [NIH-NIA
   PO1-AG036675]
FX This study was supported by a grant from the Musculoskeletal Transplant
   Foundation (JC), the Institute for Regenerative and Reparative Medicine
   at Georgia Regents University (JC), the U.S. Department of Veterans
   Affairs VA104462 (WDH), and the National Institute on Aging NIH-NIA
   PO1-AG036675 (WDH). The authors would like to thank Mr. Kameron
   Khaksarfard for his help with this study. The contents of this
   publication do not represent the views of the Department of Veterans
   Affairs, or the United States Government.
CR Bess S, 2012, NEUROSURGERY, V71, pE556, DOI 10.1227/01.neu.0000417730.19602.c4                                              
   Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390
   Burt CW, 1998, VITAL HLTH STAT, V131, P1
   Campbell PG, 2005, BIOMATERIALS, V26, P6762, DOI 10.1016/j.biomaterials.2005.04.032
   Campbell PG, 2007, EXPERT OPIN BIOL TH, V7, P1123, DOI 10.1517/14712598.7.8.1123
   Capron C, 2010, BLOOD, V116, P1244, DOI 10.1182/blood-2009-05-221093
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27
   Chim H, 2012, CELL TISSUE RES, V350, P89, DOI 10.1007/s00441-012-1449-x
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   Cooper GM, 2010, TISSUE ENG PT A, V16, P1749, DOI [10.1089/ten.tea.2009.0650, 10.1089/ten.TEA.2009.0650]
   Cowan CM, 2005, TISSUE ENG, V11, P645, DOI 10.1089/ten.2005.11.645
   Crawford Charles H 3rd, 2009, Am J Orthop (Belle Mead NJ), V38, P567
   Cray JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069067
   David L, 2005, J CRANIOFAC SURG, V16, P129, DOI 10.1097/00001665-200501000-00026                                                
   Davis DA, 2005, BLOOD, V105, P4561, DOI 10.1182/blood-2004-12-4618
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   DeCesare GE, 2011, PLAST RECONSTR SURG, V127, P588, DOI 10.1097/PRS.0b013e3181fed5c5
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Friess W, 1999, INT J PHARM, V187, P91, DOI 10.1016/S0378-5173(99)00174-X                                                   
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623-200212000-00001                                                
   Granero-Molto F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Hasegawa T, 2012, INT J MOL MED, V30, P35, DOI 10.3892/ijmm.2012.957
   He DM, 2010, J NEUROSURG, V112, P319, DOI 10.3171/2009.1.JNS08976
   Heesen M, 1996, J IMMUNOL, V157, P5455
   Herberg S, 2014, TISSUE ENG PT A, V20, P1444, DOI [10.1089/ten.tea.2013.0442, 10.1089/ten.TEA.2013.0442]
   Herberg S, 2013, TISSUE ENG PT A, V19, P1, DOI [10.1089/ten.tea.2012.0085, 10.1089/ten.TEA.2012.0085]
   Higashino K, 2011, TISSUE ENG PT A, V17, P523, DOI 10.1089/ten.tea.2010.0168
   Hodges SD, 2012, ORTHOPEDICS, V35, pE895, DOI 10.3928/01477447-20120525-30
   Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665-199001000-00011
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Johnson EE, 2000, CLIN ORTHOP RELAT R, P61
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kinsella CR, 2011, PLAST RECONSTR SURG, V127, P1865, DOI 10.1097/PRS.0b013e31820cf2c9
   Kitaori T, 2009, ARTHRITIS RHEUM-US, V60, P813, DOI 10.1002/art.24330
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000                                                
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.0.CO;2-M
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Marquez-Curtis L, 2008, STEM CELLS, V26, P1211, DOI 10.1634/stemcells.2007-0725
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264-007-0418-6
   Miller ED, 2006, BIOMATERIALS, V27, P2213, DOI 10.1016/j.biomaterials.2005.10.021
   Miller ED, 2009, COMB CHEM HIGH T SCR, V12, P604, DOI 10.2174/138620709788681907                                                      
   Miraoui H, 2010, GENE, V468, P1, DOI 10.1016/j.gene.2010.07.013
   Mitchener TA, 2010, AM J PREV MED, V38, pS86, DOI 10.1016/j.amepre.2009.10.016
   Morey JS, 2006, BIOL PROCED ONLINE, V8, P175, DOI 10.1251/bpo126
   Otsuru S, 2008, STEM CELLS, V26, P223, DOI 10.1634/stemcells.2007-0515
   Ratanavaraporn J, 2011, BIOMATERIALS, V32, P2797, DOI 10.1016/j.biomaterials.2010.12.052
   Ripoll CB, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-3
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   SCHMITZ JP, 1986, CLIN ORTHOPAEDICS, V205, P299
   Sen MK, 2007, INJURY, V38, pS75, DOI 10.1016/j.injury.2007.02.012
   Sierra MD, 2004, BLOOD, V103, P2452
   Smith DM, 2008, J CRANIOFAC SURG, V19, P1315, DOI 10.1097/SCS.0b013e3181843369
   Smith DM, 2008, J CRANIOFAC SURG, V19, P1244, DOI 10.1097/SCS.0b013e3181843312
   Smith DM, 2012, ANN PLAS SURG, V69, P485, DOI 10.1097/SAP.0b013e31824cfe64
   Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4
   Swiontkowski MF, 2006, J BONE JOINT SURG AM, V88A, P1258, DOI 10.2106/JBJS.E.00499
   Tzakas P, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-29
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264-007-0422-x
   Wise JK, 2012, TISSUE ENG PT A, V18, P861, DOI [10.1089/ten.tea.2011.0187, 10.1089/ten.TEA.2011.0187]
   Yang HS, 2012, EXP MOL MED, V44, P350, DOI 10.3858/emm.2012.44.5.039
   Zhu W, 2007, J BIOL CHEM, V282, P18676, DOI 10.1074/jbc.M610232200
   Zhu W, 2011, J BIOL CHEM, V286, P26794, DOI 10.1074/jbc.M111.250985
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X                                                   
NR 71
TC 12
Z9 13
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD OCT
PY 2014
VL 67
BP 95
EP 103
DI 10.1016/j.bone.2014.07.007
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AO3KJ
UT WOS:000341227800012
PM 25016095
OA green_accepted
DA 2018-01-05
ER

PT J
AU Xi, ZJ
   Huang, RR
   Deng, Y
   He, NY
AF Xi, Zhijiang
   Huang, Rongrong
   Deng, Yan
   He, Nongyue
TI Progress in Selection and Biomedical Applications of Aptamers
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Aptamer; SELEX; Selection; Aptasensor; Application; Nanomaterial
ID IN-VITRO SELECTION; AFFINITY RNA LIGANDS; STRANDED-DNA APTAMERS;
   NUCLEIC-ACID APTAMERS; HEPATITIS-C VIRUS; FACILITATED BIOMARKER
   DISCOVERY; HIV-1 REVERSE-TRANSCRIPTASE; SURFACE-PLASMON RESONANCE;
   COLLOIDAL CRYSTAL BEADS; AVIAN INFLUENZA-VIRUS
AB Aptamers are short single-stranded DNA or RNA, which can be selected from random combinatorial library by SELEX in vitro. The SELEX technology has been modified over the years in different ways to become more efficient and less time-consuming, to reach higher affinities of the aptamers and for automation of the process. The multitude of different targets used in SELEX implicates aptamers are possible to be selected using any target theoretically. This paper presents the SELEX technology screening aptamers and its latest progress including modified selection methods (negative SELEX, counter SELEX and substractive SELEX) and efficient selection methods (CE-SELEX, non-SELEX, automated-SELEX and microfluidic SELEX). Additionally, cell SELEX using whole cells as targets is introduced. Varieties of live pathogenic organisms and many cancer cells have been used as targets for cell SELEX. Finally, an overview of biomedical applications of aptamers is given. Aptamers as a class of biorecognition elements that possess many advantages such as high specificity and binding affinity, easy synthesis, easy modification, small size, non-toxicity and good stability, have been increasingly applied in biomedical field. Especially, the combination of aptamers with nanomaterials will continuously play more and more important roles in many applications such as detection of targets, diagnosis and treatment of diseases, bioimaging, and drugs delivery.
C1 [Xi, Zhijiang; Huang, Rongrong; Deng, Yan; He, Nongyue] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
   [Xi, Zhijiang] Yangtze Univ, Sch Life & Sci, Jinzhou 434025, Peoples R China.
   [Deng, Yan] Hunan Univ Technol, Hunan Key Lab Green Packaging & Biol Nanotechnol, Zhuzhou 412007, Peoples R China.
RP He, NY (reprint author), Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
EM nyhe1958@163.com
FU National Key Program for Developing Basic Research of China
   [2010CB933903, 2014CB744501]; National Key Special Program of Science
   and Technology Infrastructure Program [2013ZX10004103-002,
   2009ZX10004-311]; NSFC [61271056, 61201033, 21205013]; Open Research
   Fund by State Key Laboratory of Bioelectronics, Southeast University,
   China [2013G10]; Jiangsu Postdoctoral Science Foundation, China
   [1301093C]; College Postgraduate Research and Innovation Project in
   Jiangsu province, China [CXLX0146]
FX This research was financially supported by the National Key Program for
   Developing Basic Research of China (2010CB933903 and 2014CB744501), the
   National Key Special Program of Science and Technology Infrastructure
   Program (2013ZX10004103-002, 2009ZX10004-311), NSFC (61271056, 61201033
   and 21205013), Open Research Fund by State Key Laboratory of
   Bioelectronics, Southeast University, China (2013G10), the Jiangsu
   Postdoctoral Science Foundation, China (1301093C) and College
   Postgraduate Research and Innovation Project in Jiangsu province, China
   (CXLX0146).
CR Ahmadi M., 2013, J BIONANOSCI, V7, P503
   Ahn DG, 2009, ANALYST, V134, P1896, DOI 10.1039/b906788d
   Ali ZS, 2013, J NANOSCI NANOTECHNO, V13, P40, DOI 10.1166/jnn.2013.6705
   ALLEN P, 1995, VIROLOGY, V209, P327, DOI 10.1006/viro.1995.1264
   Arnold S, 2012, BIOL CHEM, V393, P343, DOI 10.1515/hsz-2011-0253
   Asai R, 2004, ANAL LETT, V37, P645, DOI 10.1081/AL-120029741
   Ashley J, 2012, ELECTROPHORESIS, V33, P2783, DOI 10.1002/elps.201200032
   Ashmi Mewada, 2013, Journal of Bionanoscience, V7, P296, DOI 10.1166/jbns.2013.1130
   Balamohan P., 2013, J BIONANOSCI, V7, P323
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Becker RC, 2009, CURR OPIN MOL THER, V11, P707
   Berens C, 2001, BIOORGAN MED CHEM, V9, P2549, DOI 10.1016/S0968-0896(01)00063-3                                                   
   Berezovski M, 2006, J AM CHEM SOC, V128, P1410, DOI 10.1021/ja056943j
   Berezovski M, 2005, J AM CHEM SOC, V127, P3165, DOI 10.1021/ja042394q
   Berezovski MV, 2008, J AM CHEM SOC, V130, P9137, DOI 10.1021/ja801951p
   Berezovski MV, 2006, NAT PROTOC, V1, P1359, DOI 10.1038/nprot.2006.200
   BEUTEL BA, 1992, J MOL BIOL, V228, P803, DOI 10.1016/0022-2836(92)90865-H                                                    
   Bianchini M, 2001, J IMMUNOL METHODS, V252, P191, DOI 10.1016/S0022-1759(01)00350-7
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Boote BW, 2014, J NANOSCI NANOTECHNO, V14, P1563, DOI 10.1166/jnn.2014.9077
   Bora T, 2014, J NANOSCI NANOTECHNO, V14, P613, DOI 10.1166/jnn.2014.8898
   Brockstedt U, 2004, BIOCHEM BIOPH RES CO, V313, P1004, DOI 10.1016/j.bbrc.2003.12.030
   Bruno JG, 2002, BIOTECHNIQUES, V32, P178
   Bruno JG, 1997, BIOCHEM BIOPH RES CO, V234, P117, DOI 10.1006/bbrc.1997.6517
   Burgstaller P, 2002, DRUG DISCOV TODAY, V7, P1221, DOI 10.1016/S1359-6446(02)02522-9
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   Burke DH, 1997, CHEM BIOL, V4, P833, DOI 10.1016/S1074-5521(97)90116-2
   Burke DH, 1998, RNA, V4, P1165, DOI 10.1017/S1355838298980542                                                       
   Cao XX, 2009, NUCLEIC ACIDS RES, V37, P4621, DOI 10.1093/nar/gkp489
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100
   Chen CL, 2011, LAB CHIP, V11, P474, DOI 10.1039/c0lc00332h
   Chen CK, 2007, COMPUT BIOL MED, V37, P750, DOI 10.1016/j.compbiomed.2006.06.015
   Chen F, 2007, BIOCHEM BIOPH RES CO, V357, P743, DOI 10.1016/j.bbrc.2007.04.007
   CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016                                                             
   Chen HW, 2008, CHEMMEDCHEM, V3, P991, DOI 10.1002/cmdc.200800030
   Chen LQ, 2010, J PHYS CHEM B, V114, P3655, DOI 10.1021/jp9104618
   Chen XL, 2008, J BIOMED NANOTECHNOL, V4, P400, DOI 10.1166/jbn.2008.002
   Chen YH, 2012, MICROFLUID NANOFLUID, V13, P929, DOI 10.1007/s10404-012-1013-8
   Cherney LT, 2013, ANAL CHEM, V85, P4157, DOI 10.1021/ac400385v
   Cho M, 2010, P NATL ACAD SCI USA, V107, P15373, DOI 10.1073/pnas.1009331107
   Chu T. C., 2006, NUCLEIC ACIDS RES, V34, P1388
   CIESIOLKA J, 1995, RNA, V1, P538
   Ciesiolka J, 1996, METHOD ENZYMOL, V267, P315
   Conrad RC, 1996, METHOD ENZYMOL, V267, P336
   Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143                                                           
   Cox JC, 1998, BIOTECHNOL PROGR, V14, P845, DOI 10.1021/bp980097h
   Cox JC, 2001, BIOORGAN MED CHEM, V9, P2525, DOI 10.1016/S0968-0896(01)00028-1                                                   
   Cox JC, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf107
   Cox JC, 2002, COMB CHEM HIGH T SCR, V5, P289
   Dang C, 1996, J MOL BIOL, V264, P268, DOI 10.1006/jmbi.1996.0640
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Deng Y, 2013, J BIOMED NANOTECHNOL, V9, P1378, DOI 10.1166/jbn.2013.1633
   Deng Y, 2013, J BIOMED NANOTECHNOL, V9, P1123, DOI 10.1166/jbn.2013.1599
   Deng Y, 2013, J BIOMED NANOTECHNOL, V9, P318, DOI 10.1166/jbn.2013.1487
   Djordjevic M, 2007, BIOMOL ENG, V24, P179, DOI 10.1016/j.bioeng.2007.03.001
   DOBBELSTEIN M, 1995, J VIROL, V69, P8027
   Dollins CM, 2008, HUM GENE THER, V19, P443, DOI 10.1089/hum.2008.045
   Drabovich AP, 2006, ANAL CHEM, V78, P3171, DOI 10.1021/ac060144h
   Drolet DW, 1999, COMB CHEM HIGH T SCR, V2, P271
   Duan N, 2013, J MICROBIOL METH, V94, P170, DOI 10.1016/j.mimet.2013.06.016
   Duan N, 2012, J AGR FOOD CHEM, V60, P4034, DOI 10.1021/jf300395z
   Dwivedi HP, 2010, APPL MICROBIOL BIOT, V87, P2323, DOI 10.1007/s00253-010-2728-7
   Elingarami S, 2014, J NANOSCI NANOTECHNO, V14, P932, DOI 10.1166/jnn.2014.9008
   Elingarami S, 2013, J NANOSCI NANOTECHNO, V13, P3204, DOI 10.1166/jnn.2013.7148
   Elingarami S, 2013, J NANOSCI NANOTECHNO, V13, P4539, DOI 10.1166/jnn.2013.7522
   ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0                                                                
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071
   Eulberg D, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni044
   FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065
   Farokhzad OC, 2006, EXPERT OPIN DRUG DEL, V3, P311, DOI 10.1517/17425247.3.3.311
   Feng J., 2013, J GREEN SCI TECHNOLO, V1, P54
   Feng KJ, 2008, ELECTROCHEM COMMUN, V10, P531, DOI 10.1016/j.elecom.2008.01.024
   Feng ZQ, 2009, BIOMATERIALS, V30, P2753, DOI 10.1016/j.biomaterials.2009.01.053
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Ferreira CSM, 2007, BRAZ ARCH BIOL TECHN, V50, P63, DOI 10.1590/S1516-89132007000600008
   Fukusaki E, 2000, BIOORG MED CHEM LETT, V10, P423, DOI 10.1016/S0960-894X(00)00013-5
   Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029
   Ghosh V., 2013, J BIONANOSCI, V7, P581
   Goringer HU, 2003, INT J PARASITOL, V33, P1309, DOI 10.1016/S0020-7519(03)00197-8
   Grate D, 2001, BIOORGAN MED CHEM, V9, P2565, DOI 10.1016/S0968-0896(01)00031-1                                                   
   Green JV, 2009, LAB CHIP, V9, P2245, DOI 10.1039/b906768j
   Guo JW, 2011, BIOMATERIALS, V32, P8010, DOI 10.1016/j.biomaterials.2011.07.004
   Gupta P., 2013, ADV SCI ENG MED, V5, P1279, DOI DOI 10.1166/ASEM.2013.1427
   Haller AA, 1997, P NATL ACAD SCI USA, V94, P8521, DOI 10.1073/pnas.94.16.8521
   Hamula CLA, 2008, ANAL CHEM, V80, P7812, DOI 10.1021/ac801272s
   Hamula CLA, 2011, ANAL CHEM, V83, P3640, DOI 10.1021/ac200575e
   Han D, 2013, J NANOSCI NANOTECHNO, V13, P7259, DOI 10.1166/jnn.2013.8083
   Han SR, 2013, J MICROBIOL BIOTECHN, V23, P878, DOI 10.4014/jmb.1212.12033
   HARADA K, 1995, EMBO J, V14, P5798
   He NY, 2013, J BIOMED NANOTECHNOL, V9, P267, DOI 10.1166/jbn.2013.1478
   He NY, 2012, J NANOSCI NANOTECHNO, V12, P3862, DOI 10.1166/jnn.2012.5868
   He NY, 2012, J NANOSCI NANOTECHNO, V12, P2858, DOI 10.1166/jnn.2012.5756
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Hianik T, 2005, BIOORG MED CHEM LETT, V15, P291, DOI 10.1016/j.bmcl.2004.10.083
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Hirao I, 2004, BIOCHEMISTRY-US, V43, P3214, DOI 10.1021/bi0356146
   Hofmann HP, 1997, RNA, V3, P1289
   Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006
   Huang CJ, 2010, BIOSENS BIOELECTRON, V25, P1761, DOI 10.1016/j.bios.2009.12.029
   Huang JZ, 2001, J PEDIATR SURG, V36, P357, DOI 10.1053/jpsu.2001.20716
   Hwang B, 2004, RNA, V10, P1277, DOI 10.1261/rna.7100904
   Hwang KS, 2007, BIOSENS BIOELECTRON, V23, P459, DOI 10.1016/j.bios.2007.05.006
   Hybarger G, 2006, ANAL BIOANAL CHEM, V384, P191, DOI 10.1007/s00216-005-0089-3
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5
   Ito Y, 2000, METHODS, V22, P107, DOI 10.1006/meth.2000.1041
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   Jeong S, 2001, BIOCHEM BIOPH RES CO, V281, P237, DOI 10.1006/bbrc.2001.4327
   Jhaveri S, 2000, NAT BIOTECHNOL, V18, P1293, DOI 10.1038/82414
   Ji KL, 2013, ANAL BIOANAL CHEM, V405, P6853, DOI 10.1007/s00216-013-7155-z
   Ji XY, 2013, J BIOMED NANOTECHNOL, V9, P1672, DOI 10.1166/jbn.2013.1665
   Ji XY, 2013, J BIOMED NANOTECHNOL, V9, P417, DOI 10.1166/jbn.2013.1556
   Jiang HR, 2013, J NANOSCI NANOTECHNO, V13, P1617, DOI 10.1166/jnn.2013.7103
   Jiang HR, 2013, J BIOMED NANOTECHNOL, V9, P674, DOI 10.1166/jbn.2013.1575
   Jin L, 2013, SCI ADV MATER, V5, P2053, DOI 10.1166/sam.2013.1747
   Jolma A, 2010, GENOME RES, V20, P861, DOI 10.1101/gr.100552.109
   Joshi R, 2009, MOL CELL PROBE, V23, P20, DOI 10.1016/j.mcp.2008.10.006
   Kakati J., 2013, ADV SCI ENG MED, V5, P1267
   Kang HS, 2009, B KOREAN CHEM SOC, V30, P1827
   Kato T, 2000, BBA-GENE STRUCT EXPR, V1493, P12, DOI 10.1016/S0167-4781(00)00080-4                                                   
   Kawakami J, 2000, J INORG BIOCHEM, V82, P197, DOI 10.1016/S0162-0134(00)00158-6
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kerman K, 2008, J BIOMED NANOTECHNOL, V4, P159, DOI 10.1166/jbn.2008.013
   Kim D, 2010, ACS NANO, V4, P3689, DOI 10.1021/nn901877h
   Kim SJ, 2002, BIOCHEM BIOPH RES CO, V291, P925, DOI 10.1006/bbrc.2002.6521
   Kim YJ, 2010, BIOPROC BIOSYST ENG, V33, P31, DOI 10.1007/s00449-009-0371-4
   Ko JH, 1999, B KOREAN CHEM SOC, V20, P1335
   Kong RM, 2011, SCI CHINA CHEM, V54, P1218, DOI 10.1007/s11426-011-4336-5
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Krishnamurthy G., 2013, ADV SCI ENG MED, V5, P726
   Kubik MF, 1997, J IMMUNOL, V159, P259
   Kulbachinskiy AV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1505, DOI 10.1134/S000629790713007X
   Kulveit J., 2013, ADV SCI ENG MED, V5, P561
   Kumar PKR, 1997, VIROLOGY, V237, P270, DOI 10.1006/viro.1997.8773                                                          
   Kunii T, 2011, ANALYST, V136, P1310, DOI 10.1039/c0an00962h
   Kwon M, 2001, MOL CELLS, V11, P303
   Lai YT, 2011, ANAL BIOCHEM, V414, P246, DOI 10.1016/j.ab.2011.03.018
   LATO SM, 1995, CHEM BIOL, V2, P291, DOI 10.1016/1074-5521(95)90048-9                                                    
   Lato SM, 1996, MOL DIVERS, V2, P103, DOI 10.1007/BF01718707
   LAUHON CT, 1995, J AM CHEM SOC, V117, P1246, DOI 10.1021/ja00109a008
   Lee JH, 2008, FEBS LETT, V582, P1835, DOI 10.1016/j.febslet.2008.05.003
   Lee YJ, 2006, J MICROBIOL BIOTECHN, V16, P1149
   Lee YJ, 2012, GASTROENTEROLOGY, V143, P155, DOI 10.1053/j.gastro.2012.03.039
   Lee YJ, 2012, BIOCHEM BIOPH RES CO, V417, P414, DOI 10.1016/j.bbrc.2011.11.130
   Li CY, 2012, J NANOSCI NANOTECHNO, V12, P2964, DOI 10.1166/jnn.2012.6428
   Li H, 2011, CAN J MICROBIOL, V57, P453, DOI [10.1139/W11-030, 10.1139/w11-030]
   Li J, 2009, CHEM COMMUN, P2329, DOI 10.1039/b823173g
   Li S, 2012, THERANOSTICS, V2, P967, DOI 10.7150/thno.5032
   Li W, 2009, TALANTA, V78, P954, DOI 10.1016/j.talanta.2009.01.009
   Li XL, 2014, SCI ADV MATER, V6, P822, DOI 10.1166/sam.2014.1782
   Li XL, 2013, J NANOSCI NANOTECHNO, V13, P5859, DOI 10.1166/jnn.2013.7540
   Li XX, 2008, ELECTROANAL, V20, P1475, DOI 10.1002/elan.200704193
   Li ZY, 2013, J BIOMED NANOTECHNOL, V9, P1945, DOI 10.1166/jbn.2013.1694
   Lian SH, 2012, J NANOSCI NANOTECHNO, V12, P7703, DOI 10.1166/jnn.2012.6622
   Liao LM, 2014, J NANOSCI NANOTECHNO, V14, P958, DOI 10.1166/jnn.2014.9113
   Lin HS, 2014, J NANOSCI NANOTECHNO, V14, P363, DOI 10.1166/jnn.2014.9109
   Liu B, 2013, J BIOMED NANOTECHNOL, V9, P247, DOI 10.1166/jbn.2013.1483
   Liu B, 2012, J BIOMED NANOTECHNOL, V8, P938, DOI 10.1166/jbn.2012.1453
   Liu XM, 2003, J MOL RECOGNIT, V16, P23, DOI 10.1002/jmr.604
   Liu ZC, 2009, COLLOID SURFACE B, V71, P238, DOI 10.1016/j.colsurfb.2009.02.013
   Lorger M, 2003, EUKARYOT CELL, V2, P84, DOI 10.1128/EC.2.1.84-94.2003
   LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016
   Lozupone C, 2003, RNA, V9, P1315, DOI 10.1261/rna.5114503                                                             
   Lunacek J., 2013, ADV SCI ENG MED, V5, P577
   Lupold SE, 2002, CANCER RES, V62, P4029
   Luzi E, 2003, TRAC-TREND ANAL CHEM, V22, P810, DOI 10.1016/S0165-9936(03)01208-1
   Ma C, 2013, J BIOMED NANOTECHNOL, V9, P703, DOI 10.1166/jbn.2013.1566
   Ma C, 2012, J BIOMED NANOTECHNOL, V8, P1000, DOI 10.1166/jbn.2012.1454
   Ma NN, 2014, J NANOSCI NANOTECHNO, V14, P3348, DOI 10.1166/jnn.2014.8236
   Mabrouk M., 2013, J BIOINFORMATICS INT, V2, P265
   Maeng JS, 2012, J NANOSCI NANOTECHNO, V12, P5138, DOI 10.1166/jnn.2012.6369
   Majerfeld I, 2005, J MOL EVOL, V61, P226, DOI 10.1007/s00239-004-0360-9
   MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287
   Majerfeld I, 1998, RNA, V4, P471
   Mallick S, 2014, J NANOSCI NANOTECHNO, V14, P755, DOI 10.1166/jnn.2014.9080
   Mallikaratchy P, 2006, CHEM COMMUN, P3229, DOI 10.1039/b604778e
   Mann AP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013050
   Mann D, 2005, BIOCHEM BIOPH RES CO, V338, P1928, DOI 10.1016/j.bbrc.2005.10.172
   Mannironi C, 1997, BIOCHEMISTRY-US, V36, P9726, DOI 10.1021/bi9700633
   Marshall KA, 2000, METHOD ENZYMOL, V318, P193
   Martell RE, 2002, MOL THER, V6, P30, DOI 10.1006/mthe.2002.0624
   Masud MM, 2004, BIOORGAN MED CHEM, V12, P1111, DOI 10.1016/j.bmc.2003.12.009
   Mendonsa SD, 2004, ANAL CHEM, V76, P5387, DOI 10.1021/ac049857v
   Mendonsa SD, 2005, J AM CHEM SOC, V127, P9382, DOI 10.1021/ja052405n
   Mendonsa SD, 2004, J AM CHEM SOC, V126, P20, DOI 10.1021/ja037832s
   Min K, 2011, BIOMATERIALS, V32, P2124, DOI 10.1016/j.biomaterials.2010.11.035
   Mir M, 2006, ELECTROCHEM COMMUN, V8, P505, DOI 10.1016/j.elecom.2005.12.022
   Misono TS, 2005, ANAL BIOCHEM, V342, P312, DOI 10.1016/j.ab.2005.04.013
   Mithila B. S., 2013, J BIONANOSCI, V7, P403
   Moreno M, 2003, BIOCHEM BIOPH RES CO, V308, P214, DOI 10.1016/S0006-291X(03)01352-4
   Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902                                                          
   Mosing Renee K., 2009, V535, P33, DOI 10.1007/978-1-59745-557-2_3
   Mosing RK, 2005, ANAL CHEM, V77, P6107, DOI 10.1021/ac050836q
   Mukhopadhyay S. S., 2013, J BIONANOSCI, V7, P497
   Nakamura C, 2001, MOL CRYST LIQ CRYST, V371, P369, DOI 10.1080/10587250108024762                                                       
   Nam Y, 2012, J NANOSCI NANOTECHNO, V12, P5547, DOI 10.1166/jnn.2012.6377
   Nie LB, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/30/305501
   Nie LB, 2009, ANAL SCI, V25, P1327, DOI 10.2116/analsci.25.1327                                                         
   Nie LB, 2013, J NANOSCI NANOTECHNO, V13, P2077, DOI 10.1166/jnn.2013.6894
   Ninomiya K, 2013, BIOORG MED CHEM LETT, V23, P1797, DOI 10.1016/j.bmcl.2013.01.040
   Nirnjee SM, 2005, TRENDS CARDIOVAS MED, V15, P41
   Ohk SH, 2010, J APPL MICROBIOL, V109, P808, DOI 10.1111/j.1365-2672.2010.04709.x
   Ohuchi SP, 2006, BIOCHIMIE, V88, P897, DOI 10.1016/j.biochi.2006.02.004
   Okazawa A, 2000, BIOORG MED CHEM LETT, V10, P2653, DOI 10.1016/S0960-894X(00)00540-0
   PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509
   Park SM, 2009, LAB CHIP, V9, P1206, DOI 10.1039/b814993c
   Park SY, 2011, NUCLEIC ACID THER, V21, P395, DOI 10.1089/nat.2011.0321
   Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281
   Patel DJ, 1997, CURR OPIN CHEM BIOL, V1, P32, DOI 10.1016/S1367-5931(97)80106-8                                                   
   Potocky S., 2013, ADV SCI ENG MED, V5, P519
   Qian JR, 2009, ANAL CHEM, V81, P5490, DOI 10.1021/ac900759k
   Qiu YY, 2013, J NANOSCI NANOTECHNO, V13, P5935, DOI 10.1166/jnn.2013.7537
   Raliya R., 2013, J BIONANOSCI, V7, P591
   Ray P, 2012, J CLIN INVEST, V122, P1734, DOI 10.1172/JCI62385
   Ray P, 2011, NUCLEIC ACID THER, V21, pA40
   Rodriguez MC, 2009, TALANTA, V78, P212, DOI 10.1016/j.talanta.2008.11.002
   Roth F, 2012, CANCER RES, V72, P1373, DOI 10.1158/0008-5472.CAN-11-2772
   Sathasivam M., 2013, J BIONANOSCI, V7, P569
   Savran CA, 2004, ANAL CHEM, V76, P3194, DOI 10.1021/ac049859f
   Scarabino D, 1999, EMBO J, V18, P4571, DOI 10.1093/emboj/18.16.4571
   Schlensog MD, 2004, SENSOR ACTUAT B-CHEM, V101, P308, DOI 10.1016/j.snb.2004.03.015
   SCHNEIDER D, 1993, FASEB J, V7, P201
   Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541
   Sefah K, 2009, LEUKEMIA, V23, P235, DOI 10.1038/leu.2008.335
   Shah MAA, 2014, J NANOSCI NANOTECHNO, V14, P881, DOI 10.1166/jnn.2014.9139
   Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Shimada T, 2005, GENES CELLS, V10, P907, DOI 10.1111/j.1365-2443.2005.00868.x
   SMITH D, 1995, CHEM BIOL, V2, P741, DOI 10.1016/1074-5521(95)90102-7                                                    
   Song KM, 2011, ANAL BIOCHEM, V415, P175, DOI 10.1016/j.ab.2011.04.007
   Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b
   Srisawat C, 2001, RNA, V7, P632, DOI 10.1017/S135583820100245X                                                       
   Stoltenburg R, 2005, ANAL BIOANAL CHEM, V383, P83, DOI 10.1007/s00216-005-3388-9
   Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001
   Sveshnikov A., 2013, ADV SCI ENG MED, V5, P569
   Tang JJ, 2006, ELECTROPHORESIS, V27, P1303, DOI 10.1002/elps.200500489
   Tang YJ, 2014, J NANOSCI NANOTECHNO, V14, P4886, DOI 10.1166/jnn.2014.8707
   Tang YJ, 2013, THERANOSTICS, V3, P85, DOI 10.7150/thno.5588
   Tang YJ, 2013, J BIOMED NANOTECHNOL, V9, P312, DOI 10.1166/jbn.2013.1493
   Tang ZW, 2007, ANAL CHEM, V79, P4900, DOI 10.1021/ac070189y
   Tang ZW, 2009, CLIN CHEM, V55, P813, DOI 10.1373/clinchem.2008.113514
   Teng Y, 2007, CANCER RES, V67, P10491, DOI 10.1158/0008-5472.CAN-06-4206
   TIAN Y, 1995, RNA, V1, P317
   Tok JBH, 2008, CHEM COMMUN, P1883, DOI 10.1039/b717936g
   Tok J, 2010, ELECTROPHORESIS, V31, P2055, DOI 10.1002/elps.200900543
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Uddin I., 2013, J GREEN SCI TECHNOL, V1, P48
   Ulrich H, 1998, P NATL ACAD SCI USA, V95, P14051, DOI 10.1073/pnas.95.24.14051                                                        
   Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200
   Vant-Hull B, 1998, J MOL BIOL, V278, P579, DOI 10.1006/jmbi.1998.1727                                                          
   Varma M. Mohan, 2013, J BIONANOSCI, V7, P561
   Vater A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng130
   Vianini E, 2001, BIOORGAN MED CHEM, V9, P2543, DOI 10.1016/S0968-0896(01)00054-2                                                   
   Wahid F, 2014, J NANOSCI NANOTECHNO, V14, P744, DOI 10.1166/jnn.2014.9016
   Wallace ST, 1998, RNA, V4, P112
   Wang C, 2014, J NANOSCI NANOTECHNO, V14, P501, DOI 10.1166/jnn.2014.8746
   Wang CL, 2003, J BIOTECHNOL, V102, P15, DOI 10.1016/S0168-1656(02)00360-7
   Wang F, 2012, J BIOMED NANOTECHNOL, V8, P786, DOI 10.1166/jbn.2012.1446
   Wang J, 2009, BIOSENS BIOELECTRON, V24, P1598, DOI 10.1016/j.bios.2008.08.030
   Wang RH, 2013, J VIROL METHODS, V189, P362, DOI 10.1016/j.jviromet.2013.03.006
   Wang XY, 2007, ANAL CHIM ACTA, V598, P242, DOI 10.1016/j.aca.2007.07.050
   WANG Y, 1995, CHEM BIOL, V2, P281, DOI 10.1016/1074-5521(95)90047-0
   Wang ZF, 2013, ANAL CHEM, V85, P11602, DOI 10.1021/ac403001y
   Wen JD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh179
   White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495
   Wiegand TW, 1996, J IMMUNOL, V157, P221
   Williams KP, 1997, P NATL ACAD SCI USA, V94, P11285, DOI 10.1073/pnas.94.21.11285
   Wilson C, 1998, CHEM BIOL, V5, P609, DOI 10.1016/S1074-5521(98)90289-7
   Wochner A, 2007, BIOTECHNIQUES, V43, P344, DOI 10.2144/000112532
   Xu F, 2013, J NANOSCI NANOTECHNO, V13, P558, DOI 10.1166/jnn.2013.6915
   Yagati AK, 2014, J NANOSCI NANOTECHNO, V14, P433, DOI 10.1166/jnn.2014.9006
   Yan S., 2013, J GREEN SCI TECHNOL, V1, P61
   Yang HW, 2014, J NANOSCI NANOTECHNO, V14, P3337, DOI 10.1166/jnn.2014.8254
   Yang Q, 1998, P NATL ACAD SCI USA, V95, P5462, DOI 10.1073/pnas.95.10.5462
   Yang XB, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gkg054
   Yang XB, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf132                                                              
   Zelada-Guillen GA, 2009, ANGEW CHEM INT EDIT, V48, P7334, DOI 10.1002/anie.200902090
   Zhan LS, 2005, PROG BIOCHEM BIOPHYS, V32, P245
   Zhang LM, 2014, J NANOSCI NANOTECHNO, V14, P6458, DOI 10.1166/jnn.2014.8831
   Zhang LM, 2014, CHEM MATER, V26, P1794, DOI 10.1021/cm403109k
   Zhang LM, 2014, J NANOSCI NANOTECHNO, V14, P4710, DOI 10.1166/jnn.2014.8641
   Zhao JJ, 2012, BIOSENS BIOELECTRON, V36, P129, DOI 10.1016/j.bios.2012.04.013
   Zhao LX, 2009, TRAC-TREND ANAL CHEM, V28, P404, DOI 10.1016/j.trac.2008.12.006
   Zhao XW, 2006, ANGEW CHEM INT EDIT, V45, P6835, DOI 10.1002/anie.200601302
   Zhao YJ, 2009, ANGEW CHEM INT EDIT, V48, P7350, DOI 10.1002/anie.200903472
   Zhao YJ, 2008, ANAL CHEM, V80, P1598, DOI 10.1021/ac702249a
   Zhao YJ, 2011, J AM CHEM SOC, V133, P8790, DOI 10.1021/ja200729w
   Zhao YJ, 2010, ADV FUNCT MATER, V20, P2970, DOI 10.1002/adfm.201000098
   Zhao YJ, 2009, ADV MATER, V21, P569, DOI 10.1002/adma.200802339
   Zhao ZL, 2009, ANALYST, V134, P1808, DOI 10.1039/b904476k
   Zhu SY, 2011, NANOSCALE, V3, P4589, DOI 10.1039/c1nr10774g
NR 300
TC 61
Z9 61
U1 13
U2 145
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD OCT
PY 2014
VL 10
IS 10
SI SI
BP 3043
EP 3062
DI 10.1166/jbn.2014.1979
PG 20
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA AL9QR
UT WOS:000339476300025
PM 25992428
DA 2018-01-05
ER

PT J
AU Ensign, LM
   Cone, R
   Hanes, J
AF Ensign, Laura M.
   Cone, Richard
   Hanes, Justin
TI Nanoparticle-based drug delivery to the vagina: A review
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Microbicides; HIV PrEP; Cervical cancer; Sexually transmitted
   infections; Mucosal vaccines
ID SEXUALLY-TRANSMITTED INFECTIONS; BIODEGRADABLE POLYMER NANOPARTICLES;
   IMMUNODEFICIENCY-VIRUS TYPE-1; FEMALE REPRODUCTIVE-TRACT; HERPES-SIMPLEX
   VIRUS-2; CELL-ASSOCIATED HIV-1; IN-VIVO DISTRIBUTION; HUMAN
   CERVICAL-MUCUS; BACTERIAL VAGINOSIS; DC-SIGN
AB Vaginal drug administration can improve prophylaxis and treatment of many conditions affecting the female reproductive tract, including sexually transmitted diseases, fungal and bacterial infections, and cancer. However, achieving sustained local drug concentrations in the vagina can be challenging, due to the high permeability of the vaginal epithelium and expulsion of conventional soluble drug dosage forms. Nanoparticle-based drug delivery platforms have received considerable attention for vaginal drug delivery, as nanoparticles can provide sustained release, cellular targeting, and even intrinsic antimicrobial or adjuvant properties that can improve the potency and/or efficacy of prophylactic and therapeutic modalities. Here, we review the use of polymeric nanoparticles, liposomes, dendrimers, and inorganic nanoparticles for vaginal drug delivery. Although most of the work toward nanoparticle-based drug delivery in the vagina has been focused on HIV prevention, strategies for treatment and prevention of other sexually transmitted infections, treatment for reproductive tract cancer, and treatment of fungal and bacterial infections are also highlighted. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ensign, Laura M.; Cone, Richard; Hanes, Justin] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Baltimore, MD 21231 USA.
   [Ensign, Laura M.; Hanes, Justin] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21231 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Hanes, Justin] Johns Hopkins Univ, Inst NanoBioTechnol, Ctr Canc Nanotechnol Excellence, Baltimore, MD 21218 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21287 USA.
   [Cone, Richard] Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA.
RP Ensign, LM (reprint author), 400 N Broadway,Smith Bldg 6015, Baltimore, MD 21231 USA.
EM lensign@jhmi.edu
FU National Institute of Health [R01HD062844, R33AI079740, R01EB015031];
   Johns Hopkins University Center for AIDS Research [1P30AI094189]
FX This work was supported by National Institute of Health grants
   R01HD062844 (J.H., R.C., L.M.E.), R33AI079740 (J.H. and R.C.),
   R01EB015031 (J.H.), and the Johns Hopkins University Center for AIDS
   Research 1P30AI094189 (L.M.E.). The mucus penetrating particle
   technology is being developed by Kala Pharmaceuticals. Dr. Hanes is a
   co-founder of Kala. Drs. Hanes and Cone own company stock, which is
   subject to certain restrictions under University policy. The terms of
   this arrangement are being managed by the Johns Hopkins University in
   accordance with its conflict of interest policies.
CR Acarturk Fusun, 2009, Recent Pat Drug Deliv Formul, V3, P193
   Achilles SL, 2002, SEX TRANSM DIS, V29, P655, DOI 10.1097/00007435-200211000-00007
   Alexander NJ, 2004, FERTIL STERIL, V82, P1, DOI 10.1016/j.fertnstert.2004.01.025
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]
   Arias MA, 2011, VACCINE, V29, P1258, DOI 10.1016/j.vaccine.2010.11.084
   Ashok V., 2012, CRIT REV SCI RES, V1, P1
   ASSCHER AW, 1956, J ANAT, V90, P547
   Ballou B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051995
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6                                                   
   Barnhart KT, 2004, CONTRACEPTION, V70, P498, DOI 10.1016/j.contraception.2004.06.013
   Basnet P, 2012, J PHARM SCI-US, V101, P598, DOI 10.1002/jps.22785
   Belletti D, 2012, INT J PHARMACEUT, V436, P753, DOI 10.1016/j.ijpharm.2012.07.070
   Blum JS, 2011, DRUG DELIV TRANSL RE, V1, P383, DOI 10.1007/s13346-011-0038-y
   Borges AR, 2010, VIROLOGY, V408, P80, DOI 10.1016/j.virol.2010.09.004
   Boskey ER, 1999, INFECT IMMUN, V67, P5170
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   BRISELDEN AM, 1992, J CLIN MICROBIOL, V30, P663
   Brotman RM, 2008, AM J EPIDEMIOL, V168, P188, DOI 10.1093/aje/kwn103
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Cauci S, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.05.035
   Chandra N, 2013, AIDS RES HUM RETROV, V29, P592, DOI 10.1089/aid.2012.0271
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Cherpes TL, 2007, SEX TRANSM INFECT, V84, P57, DOI 10.1136/sti.2007.026625
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Ciobanu M, 2011, CHEM COMMUN, V47, P9321, DOI 10.1039/c1cc13213j
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Culhane JF, 2006, AM J OBSTET GYNECOL, V195, P516, DOI 10.1016/j.ajog.2006.02.036
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Dawson M, 2004, BIOTECHNOL PROGR, V20, P851, DOI 10.1021/bp0342553
   Dezzutti CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048328
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   DURRANI MJ, 1985, INT J PHARM, V24, P209, DOI 10.1016/0378-5173(85)90021-3
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dzmitruk V., 2011, DENDRIMERS ANTIHIV T
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Ensign LM, 2013, BIOMATERIALS, V34, P6922, DOI 10.1016/j.biomaterials.2013.05.039
   Ensign LM, 2013, MOL PHARMACEUT, V10, P2176, DOI 10.1021/mp400087y
   Ensign LM, 2012, SCI TRANSL MED, V4
   EVANS GS, 1990, CELL TISSUE KINET, V23, P619, DOI 10.1111/j.1365-2184.1990.tb01350.x                                              
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   FOX CA, 1973, J REPROD FERTIL, V33, P69
   Garg S., 1998, PHARM SCI TECHNOL TO, V1, P369
   Gillgrass AE, 2005, J VIROL, V79, P3107, DOI 10.1128/JVI.79.5.3107-3116.2005
   Gorbach PM, 2012, SEX TRANSM DIS, V39, P59, DOI 10.1097/OLQ.0b013e318235502b
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Han SQ, 2012, CARBOHYD POLYM, V90, P1061, DOI 10.1016/j.carbpol.2012.06.044
   HAROUSE JM, 1995, J VIROL, V69, P7383
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000                                                   
   Hel Z, 2010, ENDOCR REV, V31, P79, DOI 10.1210/er.2009-0018
   Hemmerling A, 2009, SEX TRANSM DIS, V36, P564, DOI 10.1097/OLQ.0b013e3181a74924
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Hubscher CH, 2005, BIOTECH HISTOCHEM, V80, P79, DOI 10.1080/10520290500138422
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Jeong B, 2002, ADV DRUG DELIVER REV, V54, P37, DOI 10.1016/S0169-409X(01)00242-3                                                   
   Kanazawa T, 2008, INT J PHARM, V360, P164, DOI 10.1016/j.ijpharm.2008.04.038
   Kang JW, 2010, J DRUG TARGET, V18, P637, DOI 10.3109/10611861003649712
   Karimunnisa S, 2013, DRUG DEV IND PHARM, V39, P1328, DOI 10.3109/03639045.2012.707204
   KATZ DF, 1993, ADV DRUG DELIVER REV, V11, P385, DOI 10.1016/0169-409X(93)90017-X                                                    
   Kaushic C, 2003, J VIROL, V77, P4558, DOI 10.1128/JVI.77.8.4558-4565.2003
   Kensinger RD, 2004, BIOCONJUGATE CHEM, V15, P349, DOI 10.1021/bc034156a
   Khanna KV, 2002, J CLIN INVEST, V109, P205
   KONOPKA K, 1990, J GEN VIROL, V71, P2899, DOI 10.1099/0022-1317-71-12-2899
   Kumamoto Y, 2012, CURR OPIN IMMUNOL, V24, P411, DOI 10.1016/j.coi.2012.05.006
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lemire JA, 2013, NAT REV MICROBIOL, V11, P371, DOI 10.1038/nrmicro3028
   Ma XW, 2011, ACS NANO, V5, P8629, DOI 10.1021/nn202155y
   Maher S, 2008, BIOCHEM PHARMACOL, V75, P1104, DOI 10.1016/j.bcp.2007.10.029
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Menjoge AR, 2010, BIOMATERIALS, V31, P5007, DOI 10.1016/j.biomaterials.2010.02.075
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Mirmonsef P, 2012, AIDS RES HUM RETROV, V28, P76, DOI [10.1089/aid.2011.0071, 10.1089/AID.2011.0071]
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Navath RS, 2011, MOL PHARMACEUT, V8, P1209, DOI 10.1021/mp200027z
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Nuttall J, 2012, ANTIMICROB AGENTS CH, V56, P103, DOI 10.1128/AAC.00597-11
   O'Hanlon DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080074
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   ODEBLAD E, 1968, ACTA OBSTET GYN SCAN, VS 47, P57, DOI 10.3109/00016346809156845                                                       
   ODEBLAD E, 1965, ACTA OBSTET GYN SCAN, V43, P360
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Patel D. B., 2009, INT J PHARM SCI NANO, V2, P421
   Pattani A, 2012, J CONTROL RELEASE, V162, P529, DOI 10.1016/j.jconrel.2012.07.039
   Patton DL, 2000, AM J OBSTET GYNECOL, V183, P967, DOI 10.1067/mob.2000.108857
   Pavelic Z, 2005, J CONTROL RELEASE, V106, P34, DOI 10.1016/j.jconrel.2005.03.032
   Pavelic Z, 2001, INT J PHARM, V219, P139, DOI 10.1016/S0378-5173(01)00637-8
   Pavelic Z, 1999, EUR J PHARM SCI, V8, P345, DOI 10.1016/S0928-0987(99)00033-0
   Pendergrass PB, 2003, GYNECOL OBSTET INVES, V55, P110, DOI 10.1159/000070184
   Peng JQ, 2013, MOLECULES, V18, P7912, DOI 10.3390/molecules18077912
   Peng WD, 2013, GYNECOL ONCOL, V128, P101, DOI 10.1016/j.ygyno.2012.10.018
   Ramjee G, 2010, AIDS, V24, pS40, DOI 10.1097/01.aids.0000390706.81383.f3
   Rojo J, 2004, J ANTIMICROB CHEMOTH, V54, P579, DOI 10.1093/jac/dkh399
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sande M.A., 1999, HDB ANIMAL MODELS IN
   Smith BG, 1934, AM J ANAT, V54, P27, DOI 10.1002/aja.1000540103                                                          
   Smith SM, 2000, J INFECT DIS, V182, P708, DOI 10.1086/315776
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Vanic Z, 2014, J LIPOSOME RES, V24, P27, DOI 10.3109/08982104.2013.826242
   Vanic Z, 2013, DRUG DEV IND PHARM, V39, P481, DOI 10.3109/03639045.2012.670247
   Verstraelen H, 2013, CURR OPIN INFECT DIS, V26, P86, DOI 10.1097/QCO.0b013e32835c20cd
   Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731                                                      
   Wang B, 2010, INT J PHARMACEUT, V395, P298, DOI 10.1016/j.ijpharm.2010.05.030
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Wang YY, 2014, MUCOSAL IMMUNOL, V7, P1036, DOI 10.1038/mi.2013.120
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Wilson SS, 2009, ANTIVIR THER, V14, P1113, DOI 10.3851/IMP1463
   Wira CR, 2011, AM J REPROD IMMUNOL, V65, P196, DOI 10.1111/j.1600-0897.2011.00970.x
   Wira CR, 2010, AM J REPROD IMMUNOL, V63, P544, DOI 10.1111/j.1600-0897.2010.00842.x
   Wira CR, 2005, IMMUNOL REV, V206, P306, DOI 10.1111/j.0105-2896.2005.00287.x
   Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   YAHI N, 1992, J VIROL, V66, P4848
   Yang M., 2013, VAGINAL DELIVERY PAC
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Zeitlin L, 1997, CONTRACEPTION, V56, P329, DOI 10.1016/S0010-7824(97)00154-6                                                   
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhao XY, 2003, J EXP MED, V197, P153, DOI 10.1084/jem.20021109
NR 152
TC 31
Z9 31
U1 3
U2 83
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 28
PY 2014
VL 190
SI SI
BP 500
EP 514
DI 10.1016/j.jconrel.2014.04.033
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AU9KH
UT WOS:000345910900031
PM 24830303
OA green_accepted
DA 2018-01-05
ER

PT J
AU Khandelwal, N
   Kaur, G
   Chaubey, KK
   Singh, P
   Sharma, S
   Tiwari, A
   Singh, SV
   Kumar, N
AF Khandelwal, Nitin
   Kaur, Gurpreet
   Chaubey, Kundan Kumar
   Singh, Pushpendra
   Sharma, Shalini
   Tiwari, Archana
   Singh, Shoor Vir
   Kumar, Naveen
TI Silver nanoparticles impair Peste des petits ruminants virus replication
SO VIRUS RESEARCH
LA English
DT Article
DE Silver nanoparticles; SNPs; Peste des petits ruminants; PPR virus;
   Antiviral activity
ID CELL-ASSOCIATED HIV-1; HERPES-SIMPLEX-VIRUS; IN-VITRO; GREEN SYNTHESIS;
   LEAF EXTRACT; INFLUENZA-A; INHIBITION; INFECTION; CYTOTOXICITY;
   TRANSMISSION
AB In the present study, we evaluated the antiviral efficacy of the silver nanoparticles (SNPs) against Peste des petits ruminants virus (PPRV), a prototype Morbillivirus. The leaf extract of the Argemone maxicana was used as a reducing agent for biological synthesis of the SNPs from silver nitrate. The SNPs were characterized using UV-vis absorption spectroscopy, X-ray diffraction (XRD) and transmission electron microscopy (TEM). The TEM analysis revealed particle size of 5-30 nm and the XRD analysis revealed their characteristic silver structure. The treatment of Vero cells with the SNPs at a noncytotoxic concentration significantly inhibited PPRV replication in vitro. The time-course and virus step-specific assays showed that the SNPs impair PPRV replication at the level of virus entry. The TEM analysis showed that the SNPs interact with the virion surface as well with the virion core. However, this interaction has no direct virucidal effect, instead exerts a blocking effect on viral entry into the target cells. This is the first documented evidence indicating that the SNPs are capable of inhibiting a Morbillivirus replication in vitro. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Khandelwal, Nitin; Kaur, Gurpreet; Singh, Pushpendra; Tiwari, Archana] Rajiv Gandhi Tech Univ, Sch Biotechnol, Bhopal 462036, Madhya Pradesh, India.
   [Chaubey, Kundan Kumar; Singh, Shoor Vir; Kumar, Naveen] Indian Council Agr Res, Cent Inst Res Goats, Div Anim Hlth, Virol Lab, Mathura 281122, Uttar Pradesh, India.
   [Sharma, Shalini] Lala Lajpat Rai Univ Vet & Anim Sci, Dept Vet Physiol & Biochem, Hisar 125004, Haryana, India.
RP Kumar, N (reprint author), Indian Council Agr Res, Cent Inst Res Goats, Div Anim Hlth, Virol Lab, Mathura 281122, Uttar Pradesh, India.
EM naveenkumar.icar@gmail.com
RI Singh, Pushpendra/A-5632-2017
CR AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Baron MD, 2011, VET REC, V169, P16, DOI 10.1136/vr.d3947
   Boudin P., 1967, REV ELEV MED VET PAY, V20, P383
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   Chan P, 2010, AUST VET J, V88, pN20
   Charleston B, 2011, SCIENCE, V332, P726, DOI 10.1126/science.1199884
   Chen NN, 2013, J VIROL METHODS, V193, P470, DOI 10.1016/j.jviromet.2013.07.020
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   GIBBS EPJ, 1979, INTERVIROLOGY, V11, P268
   Goris N, 2008, ANTIVIR RES, V78, P170, DOI 10.1016/j.antiviral.2007.10.003
   Jahn W, 1999, J STRUCT BIOL, V127, P106, DOI 10.1006/jsbi.1999.4123
   Jones JC, 2006, J VIROL, V80, P11960, DOI [10.1128/JVI.01678-06, 10.1128/JVI.01678.06]
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Kim YS, 2008, INHAL TOXICOL, V20, P575, DOI 10.1080/08958370701874663 
   Kumar N., 2014, ADV ANIM VET SCI S, V1S, P37
   Kumar N, 2008, J VIROL, V82, P9880, DOI 10.1128/JVI.00909-08
   Kumar N, 2013, J VIROL METHODS, V189, P388, DOI 10.1016/j.jviromet.2013.03.002
   Kumar N, 2011, ANTIMICROB AGENTS CH, V55, P5553, DOI 10.1128/AAC.00725-11
   Kumar N, 2011, J VIROL, V85, P2818, DOI 10.1128/JVI.01969-10
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Li SK, 2007, GREEN CHEM, V9, P852, DOI 10.1039/b615357g
   Lu L, 2008, ANTIVIR THER, V13, P253
   Mori Y, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-93
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Parashar V, 2009, DIG J NANOMATER BIOS, V4, P45
   Pareek N, 2012, NATL ACAD SCI LETT, V35, P383, DOI 10.1007/s40009-012-0067-1
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Singh A, 2010, DIG J NANOMATER BIOS, V5, P483
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Trefry JC, 2013, J BIOMED NANOTECHNOL, V9, P1624, DOI 10.1166/jbn.2013.1659
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Xiang DX, 2013, INT J NANOMED, V8, P4103, DOI 10.2147/IJN.S53622
NR 39
TC 7
Z9 7
U1 2
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD SEP 22
PY 2014
VL 190
BP 1
EP 7
DI 10.1016/j.virusres.2014.06.011
PG 7
WC Virology
SC Virology
GA AO7SB
UT WOS:000341551800001
PM 24979044
DA 2018-01-05
ER

PT J
AU Ravi, PR
   Vats, R
   Balija, J
   Adapa, SPN
   Aditya, N
AF Ravi, Punna Rao
   Vats, Rahul
   Balija, Jagadeesh
   Adapa, Sathya Prabhu Naidu
   Aditya, N.
TI Modified pullulan nanoparticles for oral delivery of lopinavir:
   Formulation and pharmacokinetic evaluation
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Pullulan acetate; Lopinavir; Nanoparticles; Physical characterization;
   Pharmacokinetic studies; Tissue distribution
ID INCORPORATED NANOPARTICLES; ANTIRETROVIRAL THERAPY; DRUG-DELIVERY;
   IN-VITRO; RITONAVIR; RELEASE; CHEMOTHERAPY; COMBINATION; RESERVOIRS;
   SYSTEMS
AB In this investigation, we report the use of the pullulan acetate, a hydrophobic derivative of pullulan in the formulation of Lopinavir loaded nanoparticles meant for oral delivery. Pullulan was modified to pullulan acetate by acetylation process in the presence of pyridine; acetylation was confirmed by FT-IR and NMR spectra. Lopinavir, an HIV-protease inhibitor was formulated into nanoparticles of pullulan acetate by the well-known emulsion-solvent-evaporation method. The nanoparticles were tested for particle size, entrapment efficiency, in-vitro drug release and stability. Further, extensive pharmacokinetic and tissue distribution studies were performed in Wistar rats. The results showed that, with our method, we could obtain nanoparticles of similar to 197 nm, high entrapment efficiency (similar to 75%) and monodisperse nature (PDI < 0.2). Stability data showed that the nanoparticles were stable over a period of 3 months. From the pharmacokinetic study data, we found that the relative bioavailability of Lopinavir from nanoparticles was similar to 2 folds higher than the free drug. Moreover, the tissue distribution study showed a higher distribution of Lopinavir loaded nanoparticles to lymphoid organs (liver, spleen and lymph nodes that are also important viral reservoirs in HIV infection). Thus, we conclude that Lopinavir loaded nanoparticle could be a superior alternative approach to free Lopinavir in treating HIV infection. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Ravi, Punna Rao; Vats, Rahul; Balija, Jagadeesh; Adapa, Sathya Prabhu Naidu; Aditya, N.] BITS Pilani, Dept Pharm, Hyderabad, Andhra Pradesh, India.
RP Ravi, PR (reprint author), BITS Pilani, Dept Pharm, Hyderabad Campus, Hyderabad, Andhra Pradesh, India.
EM rpunnarao@hyderabad.bits-pilani.ac.in;
   rahulvats@hyderabad.bits-pilani.ac.in; jagadeesh20191@gmail.com;
   sathya.bitshyd@gmail.com; aditya@hyderabad.bits-pilani.ac.in
FU Department of Science and Technology (DST), Science and Engineering
   Research Council (SERC), New Delhi, India
FX The authors are grateful to Department of Science and Technology (DST),
   Science and Engineering Research Council (SERC), New Delhi, India for
   funding the research under 'Fast Track Scheme for Young Scientists'.
CR AKIYOSHI K, 1993, MACROMOLECULES, V26, P3062, DOI 10.1021/ma00064a011                                                             
   Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev.bioeng-071811-150124, 10.1146/annurev-bioeng-071811-150124]
   Barzegar-Jalali M, 2008, J PHARM PHARM SCI, V11, P167, DOI 10.18433/J3D59T                                                                 
   Byun Y, 2011, LWT-FOOD SCI TECHNOL, V44, P24, DOI 10.1016/j.lwt.2010.06.032
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   du Plooy M, 2011, BIOL PHARM BULL, V34, P66
   Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145
   Feng SS, 2004, EXPERT REV MED DEVIC, V1, P115, DOI 10.1586/17434440.1.1.115                                                        
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Gajendiran M, 2013, COLLOID SURFACE B, V104, P107, DOI 10.1016/j.colsurfb.2012.12.008
   Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625
   Hong GY, 2011, ARCH PHARM RES, V34, P407, DOI 10.1007/s12272-011-0308-8
   Hunter AC, 2012, MATURITAS, V73, P5, DOI 10.1016/j.maturitas.2012.05.014
   [Anonymous], Q1AR2 ICH
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Leathers TD, 2003, APPL MICROBIOL BIOT, V62, P468, DOI 10.1007/s00253-003-1386-4
   Lee A, 2010, LANGMUIR, V26, P18055, DOI 10.1021/la1039128
   Lee SJ, 2012, INT J PHARMACEUT, V433, P121, DOI 10.1016/j.ijpharm.2012.04.048
   Levy JA, 2007, HIV AND THE PATHOGENESIS OF AIDS, 3RD EDITION, P1
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   MOTOZATO Y, 1986, J CHROMATOGR, V355, P434, DOI 10.1016/S0021-9673(01)97349-2
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Ravi PR, 2012, PHYTOTHER RES, V26, P1490, DOI 10.1002/ptr.4593
   Ravi P. R., 2013, EUROPEAN J PHARM BIO
   Ravi P. R., 2013, DRUG DEV IND PHARM
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shafran SD, 2005, HIV MED, V6, P421, DOI 10.1111/j.1468-1293.2005.00328.x                                                
   Shah M, 2010, AAPS PHARMSCITECH, V11, P489, DOI 10.1208/s12249-010-9414-z
   Sundar S, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468-6996/11/1/014104
   Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541
   Trevaskis NL, 2008, ADV DRUG DELIVER REV, V60, P702, DOI 10.1016/j.addr.2007.09.007
   Vats Rahul, 2011, Sci Pharm, V79, P849, DOI 10.3797/scipharm.1107-24
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Yue PF, 2009, AAPS PHARMSCITECH, V10, P376, DOI 10.1208/s12249-009-9216-3
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhang HZ, 2009, COLLOID SURFACE B, V71, P19, DOI 10.1016/j.colsurfb.2008.12.039
NR 38
TC 10
Z9 10
U1 3
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD SEP 22
PY 2014
VL 110
BP 320
EP 328
DI 10.1016/j.carbpol.2014.03.099
PG 9
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA AJ9CS
UT WOS:000338005000042
PM 24906762
DA 2018-01-05
ER

PT J
AU Liang, RP
   Tian, XC
   Qiu, P
   Qin, JD
AF Liang, Ru-Ping
   Tian, Xiao-Cui
   Qiu, Ping
   Qin, Jian-Ding
TI Multiplexed Electrochemical Detection of Trypsin and Chymotrypsin Based
   on Distinguishable Signal Nanoprobes
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID COLOR QUANTUM DOTS; HIV-1 PROTEASE; LABEL-FREE; MASS-SPECTROMETRY;
   SENSING PLATFORM; CYTOCHROME-C; GOLD; ASSAY; NANOPARTICLES; IMMUNOASSAY
AB In this work, we developed a novel multisignal output for simultaneous detection of multiple proteases by using nanoprobes labeled with distinguishable electrochemical probes. First, biotinylated peptide1 (S1) and biotinylated peptide2 (S2) were associated with biotinylated DNA1 and DNA2 via biotinstreptavidin interaction, forming DNA1S1 and DNA2S2, respectively. Two distinguishable signal nanoprobes (DNA1'Au NPsThi and DNA2'Au NPsFc) were prepared by initial assembling DNA1' and DNA2' on the Au NPs surface, respectively, and then carrying corresponding thionine (Thi) and 6-(Ferrocenyl)hexanethiol (Fc). Then, the peptide substrates (DNA1'-S1 and DNA2'-S2) were immobilized on gold electrode surface through AuS bonds, and the DNA1'-Au NPs-Thi and DNA2'Au NPsFc were assembled to the peptideDNA-modified electrode surface via DNA hybridization. The targets of trypsin and chymotrypsin can specifically recognize and cleave peptides with different sequences, releasing DNA1'-Au NPs-Thi and DNA2'-Au NPs-Fc from the electrode surface into solution, thus decreasing the current of Thi and Fc. The decrease in the electrochemical currents of the two signal nanoprobes enables us to simultaneously and quantitatively determine the targets trypsin and chymotrypsin. More importantly, this strategy can be extended easily by designing various proteases-specific peptide substrates and utilizing corresponding electrochemical detectable elements for simultaneous multiplex protease assay in various biosystems.
C1 [Liang, Ru-Ping; Tian, Xiao-Cui; Qiu, Ping; Qin, Jian-Ding] Nanchang Univ, Dept Chem, Nanchang 330031, Peoples R China.
RP Qin, JD (reprint author), Nanchang Univ, Dept Chem, Nanchang 330031, Peoples R China.
EM jdqiu@ncu.edu.cn
OI Qiu, Jian-Ding/0000-0002-6793-9499
FU National Natural Science Foundation of China [21265012, 21265017];
   Program for New Century Excellent Talents in University [NCET-11-1002,
   NCET-13-0848]
FX We greatly appreciate the supports of the National Natural Science
   Foundation of China (21265012 and 21265017) and the Program for New
   Century Excellent Talents in University (NCET-11-1002 and NCET-13-0848).
CR Beckett RP, 1996, DRUG DISCOV TODAY, V1, P16, DOI 10.1016/1359-6446(96)89115-X                                                    
   Chen LX, 2013, NANOSCALE, V5, P5905, DOI 10.1039/c3nr00637a
   Chen L, 2012, ANAL CHEM, V84, P3200, DOI 10.1021/ac203172x
   Chen X, 2013, BIOSENS BIOELECTRON, V50, P356, DOI 10.1016/j.bios.2013.06.054
   Deng DH, 2013, INT J ELECTROCHEM SC, V8, P6933
   Ding YH, 2006, LANGMUIR, V22, P2292, DOI 10.1021/la052897p
   Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784
   Guarise C, 2006, P NATL ACAD SCI USA, V103, P3978, DOI 10.1073/pnas.0509372103
   Han SW, 2000, LANGMUIR, V16, P9493, DOI 10.1021/la000025b
   Jing XY, 2014, BIOSENS BIOELECTRON, V58, P40, DOI 10.1016/j.bios.2014.02.035
   Kong FY, 2013, CHEM COMMUN, V49, P1052, DOI 10.1039/c2cc37675j
   Lathia US, 2010, ANAL BIOCHEM, V398, P93, DOI 10.1016/j.ab.2009.11.010
   Lefkowitz RB, 2010, ELECTROPHORESIS, V31, P2442, DOI 10.1002/elps.201000011
   Li X, 2013, NANOSCALE, V5, P7776, DOI 10.1039/c3nr00006k
   Li Y, 2012, CHEM COMMUN, V48, P537, DOI 10.1039/c1cc14886a
   Liang RP, 2014, ANAL CHIM ACTA, V812, P33, DOI 10.1016/j.aca.2013.12.037
   Liao DL, 2013, ANAL CHIM ACTA, V784, P72, DOI 10.1016/j.aca.2013.04.066
   Liu L, 2013, BIOSENS BIOELECTRON, V41, P730, DOI 10.1016/j.bios.2012.09.061
   Liu RX, 2013, J MATER CHEM B, V1, P1402, DOI 10.1039/c3tb00020f
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Morrison CJ, 2009, CURR OPIN CELL BIOL, V21, P645, DOI 10.1016/j.ceb.2009.06.006
   Park S. M., 2003, ANAL CHEM, V75, P455, DOI DOI 10.1021/AC0313973
   Qiu JD, 2008, ELECTROANAL, V20, P1819, DOI 10.1002/elan.200804252
   Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, P160
   TAILLANDIER E, 1989, J MOL STRUCT, V214, P185, DOI 10.1016/0022-2860(89)80014-6
   Tang J, 2011, ANAL CHEM, V83, P5407, DOI 10.1021/ac200969w
   THOMBERRY NA, 1998, SCIENCE, V281, P1312
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735                                                    
   Wang XH, 2010, BIOSENS BIOELECTRON, V26, P743, DOI 10.1016/j.bios.2010.06.046
   WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   Xia ZY, 2008, ANAL CHEM, V80, P8649, DOI 10.1021/ac801562f
   Xu KH, 2011, ANALYST, V136, P1199, DOI 10.1039/c0an00576b
   Yan SQ, 1998, BIOL CHEM, V379, P113
   Yan XW, 2011, ANGEW CHEM INT EDIT, V50, P5130, DOI 10.1002/anie.201101087
   Ye M, 2009, BIOSENS BIOELECTRON, V24, P2339, DOI 10.1016/j.bios.2008.12.002
   Zaccheo BA, 2011, ANAL CHEM, V83, P1185, DOI 10.1021/ac103115z
   Zhang H, 2013, ANAL CHEM, V85, P10969, DOI 10.1021/ac402496e
   Zhang X, 2010, ANAL CHIM ACTA, V664, P101, DOI 10.1016/j.aca.2010.02.001
   Zhang Z, 2013, ANALYST, V138, P5365, DOI 10.1039/c3an01006f
   Zhao J, 2011, BIOSENS BIOELECTRON, V26, P2297, DOI 10.1016/j.bios.2010.09.056
NR 42
TC 22
Z9 22
U1 8
U2 88
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD SEP 16
PY 2014
VL 86
IS 18
BP 9256
EP 9263
DI 10.1021/ac502318x
PG 8
WC Chemistry, Analytical
SC Chemistry
GA AP1BK
UT WOS:000341801200050
PM 25145572
DA 2018-01-05
ER

PT J
AU Jang, S
   Hyun, S
   Kim, S
   Lee, S
   Lee, IS
   Baba, M
   Lee, Y
   Yu, J
AF Jang, Sangmok
   Hyun, Soonsil
   Kim, Seoyeon
   Lee, Seonju
   Lee, Im-Soon
   Baba, Masanori
   Lee, Yan
   Yu, Jaehoon
TI Cell-Penetrating, Dimeric alpha-Helical Peptides: Nanomolar Inhibitors
   of HIV-1 Transcription
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE antiviral agents; drug design; HIV-1; peptides; transcriptional
   inhibition
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TAT-MEDIATED TRANSCRIPTION; LONG TERMINAL
   REPEAT; PLASMA-MEMBRANE; GENE DELIVERY; RNA; PROTEIN; REPLICATION;
   RECOGNITION; DERIVATIVES
AB We constructed dimeric alpha-helical peptide bundles based on leucine (L) and lysine (K) residues for both efficient cell penetration and inhibition of the Tat-TAR interaction. The LK dimers can penetrate nearly quantitatively into eukaryotic cells and effectively inhibit the elongation of the TAR transcript at low nanomolar concentrations. The effective inhibition of HIV-1 replication strongly suggests that the LK dimer has strong potential as an anti-HIV-1 drug.
C1 [Jang, Sangmok; Lee, Seonju; Lee, Yan] Seoul Natl Univ, Dept Chem, Seoul 151742, South Korea.
   [Hyun, Soonsil; Kim, Seoyeon; Yu, Jaehoon] Seoul Natl Univ, Dept Chem & Educ, Seoul 151742, South Korea.
   [Lee, Im-Soon] Konkuk Univ, Dept Biol Sci, Seoul 143701, South Korea.
   [Baba, Masanori] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima 8908580, Japan.
RP Lee, Y (reprint author), Seoul Natl Univ, Dept Chem, Seoul 151742, South Korea.
EM gacn@snu.ac.kr; jhoonyu@snu.ac.kr
RI Baba, Masanori/G-3867-2011
OI KIM, SEOYEON/0000-0001-7752-2147
FU Mid-career Researcher Program - Ministry of Science, ICT, and Future
   Planning, Korea [2011-0013569, 2013064805]
FX This work was supported by the Mid-career Researcher Program
   (2011-0013569 and 2013064805) funded by the Ministry of Science, ICT,
   and Future Planning, Korea.
CR Baba M, 2000, AIDS RES HUM RETROV, V16, P935, DOI 10.1089/08892220050058344                                                       
   Bannwarth S, 2005, CURR HIV RES, V3, P61, DOI 10.2174/1570162052772924                                                        
   BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4
   Darfeuille F, 2002, P NATL ACAD SCI USA, V99, P9709, DOI 10.1073/pnas.122247199
   Davidson A, 2009, P NATL ACAD SCI USA, V106, P11931, DOI 10.1073/pnas.0900629106
   El-Sayed A, 2013, MOL THER, V21, P1118, DOI 10.1038/mt.2013.54
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Friedler A, 2000, J BIOL CHEM, V275, P23783, DOI 10.1074/jbc.M002200200                                                          
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h
   Hyun S, 2010, CHEMBIOCHEM, V11, P767, DOI 10.1002/cbic.201000072
   KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0
   Lee Y, 2005, BIOMACROMOLECULES, V6, P24, DOI 10.1021/bm0496581
   Lee Y, 2007, BIOCONJUGATE CHEM, V18, P13, DOI 10.1021/bc060113t
   Lee Y, 2008, ANGEW CHEM INT EDIT, V47, P134, DOI 10.1002/anie.200703090
   Lu HS, 2013, CHEM REV, V113, P8567, DOI 10.1021/cr400120z
   Manfroni G, 2009, BIOORG MED CHEM LETT, V19, P714, DOI 10.1016/j.bmcl.2008.12.034
   Massari S, 2010, J MED CHEM, V53, P641, DOI 10.1021/jm901211d
   Pai J, 2012, J AM CHEM SOC, V134, P19287, DOI 10.1021/ja309760g
   ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3
   Svoboda P, 2006, CELL MOL LIFE SCI, V63, P901, DOI 10.1007/s00018-005-5558-5
   Tabarrini O, 2010, CHEMMEDCHEM, V5, P1880, DOI 10.1002/cmdc.201000267
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wang DY, 2009, BIOORG MED CHEM LETT, V19, P6893, DOI 10.1016/j.bmcl.2009.10.078
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
NR 30
TC 15
Z9 15
U1 1
U2 48
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD SEP 15
PY 2014
VL 53
IS 38
BP 10086
EP 10089
DI 10.1002/anie.201404684
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA AQ4JI
UT WOS:000342761700014
PM 25056130
DA 2018-01-05
ER

PT J
AU Lakomek, NA
   Kaufman, JD
   Stah, SJ
   Wingfield, PT
AF Lakomek, Nils-Alexander
   Kaufman, Joshua D.
   Stah, Stephen J.
   Wingfield, Paul T.
TI HIV-1 Envelope Protein gp41: An NMR Study of Dodecyl Phosphocholine
   Embedded gp41 Reveals a Dynamic Prefusion Intermediate Conformation
SO STRUCTURE
LA English
DT Article
ID MEMBRANE-FUSION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CRYOELECTRON
   MICROSCOPY; GLYCOPROTEIN TRIMER; CHEMICAL-SHIFTS; VIRAL MEMBRANE;
   DOMAIN; SPECTROSCOPY; ECTODOMAIN
AB Human immunodeficiency viral (HIV-1) fusion is mediated by the viral envelope gp120/gp41 complex (ENVelope glycoprotein). After gp120 shedding, gp41 is exposed and elicits membrane fusion via a cascade of conformational changes. In contrast to prefusion and postfusion conformation, little is known about any intermediate conformation. We report on a solution NMR investigation of homotrimeric HIV-1 gp41(27-194), comprising the transmembrane region and reconstituted in dodecyl phosphocholine (DPC) micelles. The protein is mainly a-helical, but experiences internal dynamics on the nanosecond and micro to millisecond time scale and transient a-helical behavior for certain residues in the N-terminal heptad repeat (NHR). Strong lipid interactions are observed, in particular for C-terminal residues of the NHR and imunodominant loop region connecting NHR and C-terminal heptad repeat (CHR). Our data indicate an extended conformation with features anticipated for a prefusion intermediate, presumably in exchange with a lowly populated postfusion six-helical bundle conformation.
C1 [Lakomek, Nils-Alexander] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
   [Kaufman, Joshua D.; Stah, Stephen J.; Wingfield, Paul T.] NIAMS, Prot Express Lab, NIH, Bethesda, MD 20892 USA.
RP Lakomek, NA (reprint author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany.
EM nall@nmr.mpibpc.mpc.de; wingfiep@mail.nih.gov
RI Kaufman, Joel/B-5761-2008; Lakomek, Nils/K-6568-2016
OI Kaufman, Joel/0000-0003-4174-9037; Lakomek, Nils/0000-0002-4285-6339
FU National Institute of Diabetes and Digestive and Kidney Diseases, NIH;
   Office of the Director, NIH; DFG/NIH [LA 2724/1-1]
FX This research was funded by the Intramural Research Program of the
   National Institute of Diabetes and Digestive and Kidney Diseases, NIH,
   and the Intramural AIDS-Targeted Antiviral Program of the Office of the
   Director, NIH, as well as the DFG/NIH Research Career Transition Award
   Program (to N.L., LA 2724/1-1). None of the authors have any competing
   financial interests related to this work. N.L. thanks Dr. Ad Bax and
   Prof. Dr. Christian Griesinger for allowing him to use their NMR
   facilities at NIH, Bethesda, MD, USA and the Max-Planck Institute for
   Biophysical Chemistry, Gottingen, Germany. N.L. is very grateful to Dr.
   Ad Bax for his continuous support, for receiving an excellent training
   in NMR spectroscopy, and for allowing him to continue independent
   research on this research project.
CR Bartesaghi A, 2013, NAT STRUCT MOL BIOL, V20, P1352, DOI 10.1038/nsmb.2711
   Blumenthal R, 2012, J BIOL CHEM, V287, P40841, DOI 10.1074/jbc.R112.406272
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Caffrey M, 2011, TRENDS MICROBIOL, V19, P191, DOI 10.1016/j.tim.2011.02.001
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   DIMITROV DS, 1994, J VIROL, V68, P1956
   Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Harrison SC, 2005, ADV VIRUS RES, V64, P231, DOI 10.1016/S0065-3527(05)64007-9
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Henderson R, 2013, P NATL ACAD SCI USA, V110, P18037, DOI 10.1073/pnas.1314449110
   Henzler-Wildman KA, 2007, NATURE, V450, P913, DOI 10.1038/nature06407
   Hilty C, 2004, CHEMBIOCHEM, V5, P467, DOI 10.1002/cbic.200300815
   Jaroniec CP, 2005, BIOCHEMISTRY-US, V44, P16167, DOI 10.1021/bi051672a
   Korzhnev DM, 1997, J MAGN RESON, V127, P184, DOI 10.1006/jmre.1997.1190
   Lai AL, 2012, J MOL BIOL, V418, P3, DOI 10.1016/j.jmb.2012.02.010
   Lakomek NA, 2013, ANGEW CHEM INT EDIT, V52, P3911, DOI 10.1002/anie.201207266
   Lakomek NA, 2012, J BIOMOL NMR, V53, P209, DOI 10.1007/s10858-012-9626-5
   Li YL, 2007, BIOPHYS J, V93, P876, DOI 10.1529/biophysj.106.102335
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Maltsev AS, 2012, J BIOMOL NMR, V54, P181, DOI 10.1007/s10858-012-9666-x
   Mao YD, 2013, P NATL ACAD SCI USA, V110, pE4178, DOI 10.1073/pnas.1316666110
   Mao YD, 2013, P NATL ACAD SCI USA, V110, P12438, DOI 10.1073/pnas.1307382110
   Mao YD, 2012, NAT STRUCT MOL BIOL, V19, P893, DOI 10.1038/nsmb.2351
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Noy D, 2003, ANAL BIOCHEM, V320, P185, DOI 10.1016/S0003-2697(03)00347-6
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006
   Qiang W, 2009, P NATL ACAD SCI USA, V106, P15314, DOI 10.1073/pnas.0907360106
   Roche J, 2014, P NATL ACAD SCI USA, V111, P3425, DOI 10.1073/pnas.1401397111
   Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322
   Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z
   SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079
   Subramaniam S, 2013, P NATL ACAD SCI USA, V110, pE4172, DOI 10.1073/pnas.1313802110
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797
   van Heel M, 2013, P NATL ACAD SCI USA, V110, pE4175, DOI 10.1073/pnas.1314353110
   Wang YJ, 2002, J AM CHEM SOC, V124, P14075, DOI 10.1021/ja026811f
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Wingfield PT, 1997, PROTEIN SCI, V6, P1653, DOI 10.1002/pro.5560060806                                                          
   Yamazaki T, 1996, PROTEIN SCI, V5, P495
   Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   [Anonymous], NAT STRUCT MOL BIOL, V18, P1235
NR 49
TC 7
Z9 7
U1 8
U2 50
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD SEP 2
PY 2014
VL 22
IS 9
BP 1311
EP 1321
DI 10.1016/j.str.2014.06.016
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AO5NW
UT WOS:000341392800012
PM 25132083
OA gold
DA 2018-01-05
ER

PT J
AU Lee, HH
   Cherni, I
   Yu, HQ
   Fromme, R
   Doran, JD
   Grotjohan, I
   Mittman, M
   Basu, S
   Deb, A
   Dorner, K
   Aquila, A
   Barty, A
   Boutet, S
   Chapman, HN
   Doak, RB
   Hunter, MS
   James, D
   Kirian, RA
   Kupitz, C
   Lawrence, RM
   Liu, HG
   Nass, K
   Schlichting, I
   Schmidt, KE
   Seibert, MM
   Shoeman, RL
   Spence, JCH
   Stellato, F
   Weierstall, U
   Williams, GJ
   Yoon, C
   Wang, DJ
   Zatsepin, NA
   Hogue, BG
   Matoba, N
   Fromme, P
   Mor, TS
AF Lee, Ho-Hsien
   Cherni, Irene
   Yu, HongQi
   Fromme, Raimund
   Doran, Jeffrey D.
   Grotjohan, Ingo
   Mittman, Michele
   Basu, Shibom
   Deb, Arpan
   Doerner, Katerina
   Aquila, Andrew
   Barty, Anton
   Boutet, Sebastien
   Chapman, Henry N.
   Doak, R. Bruce
   Hunter, Mark S.
   James, Daniel
   Kirian, Richard A.
   Kupitz, Christopher
   Lawrence, Robert M.
   Liu, Haiguang
   Nass, Karol
   Schlichting, Ilme
   Schmidt, Kevin E.
   Seibert, M. Marvin
   Shoeman, Robert L.
   Spence, John C. H.
   Stellato, Francesco
   Weierstall, Uwe
   Williams, Garth J.
   Yoon, Chunhong
   Wang, Dingjie
   Zatsepin, Nadia A.
   Hogue, Brenda G.
   Matoba, Nobuyuki
   Fromme, Petra
   Mor, Tsafrir S.
TI Expression, purification and crystallization of CTB-MPR, a candidate
   mucosal vaccine component against HIV-1
SO IUCRJ
LA English
DT Article
DE X-ray crystallography; femtosecond nanocrystallography; HIV-1; gp41;
   membrane-proximal region; cholera toxin B subunit; crystallization;
   free-electron lasers
ID PROXIMAL EXTERNAL REGION; SERIAL FEMTOSECOND CRYSTALLOGRAPHY; BROADLY
   NEUTRALIZING ANTIBODIES; TRANSCYTOSIS-BLOCKING ABS;
   SESBANIA-MOSAIC-VIRUS; CHOLERA-TOXIN; EPITHELIAL TRANSCYTOSIS;
   GALACTOSYL CERAMIDE; GP41; MEMBRANE
AB CTB-MPR is a fusion protein between the B subunit of cholera toxin (CTB) and the membrane-proximal region of gp41 (MPR), the transmembrane envelope protein of Human immunodeficiency virus 1 (HIV-1), and has previously been shown to induce the production of anti-HIV-1 antibodies with antiviral functions. To further improve the design of this candidate vaccine, X-ray crystallography experiments were performed to obtain structural information about this fusion protein. Several variants of CTB-MPR were designed, constructed and recombinantly expressed in Escherichia coli. The first variant contained a flexible GPGP linker between CTB and MPR, and yielded crystals that diffracted to a resolution of 2.3 angstrom, but only the CTB region was detected in the electron-density map. A second variant, in which the CTB was directly attached to MPR, was shown to destabilize pentamer formation. A third construct containing a polyalanine linker between CTB and MPR proved to stabilize the pentameric form of the protein during purification. The purification procedure was shown to produce a homogeneously pure and monodisperse sample for crystallization. Initial crystallization experiments led to pseudo-crystals which were ordered in only two dimensions and were disordered in the third dimension. Nanocrystals obtained using the same precipitant showed promising X-ray diffraction to 5 angstrom resolution in femtosecond nanocrystallography experiments at the Linac Coherent Light Source at the SLAC National Accelerator Laboratory. The results demonstrate the utility of femtosecond X-ray crystallography to enable structural analysis based on nano/microcrystals of a protein for which no macroscopic crystals ordered in three dimensions have been observed before.
C1 [Lee, Ho-Hsien; Yu, HongQi; Fromme, Raimund; Grotjohan, Ingo; Basu, Shibom; Doerner, Katerina; Doak, R. Bruce; Hunter, Mark S.; Kupitz, Christopher; Lawrence, Robert M.; Fromme, Petra] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.
   [Cherni, Irene; Doran, Jeffrey D.; Mittman, Michele; Deb, Arpan; Hogue, Brenda G.; Matoba, Nobuyuki; Mor, Tsafrir S.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
   [Cherni, Irene; Doran, Jeffrey D.; Mittman, Michele; Deb, Arpan; Hunter, Mark S.; Lawrence, Robert M.; Hogue, Brenda G.; Matoba, Nobuyuki; Mor, Tsafrir S.] Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, Tempe, AZ 85287 USA.
   [Aquila, Andrew; Barty, Anton; Chapman, Henry N.; Kirian, Richard A.; Nass, Karol; Stellato, Francesco; Yoon, Chunhong] DESY, Ctr Free Electron Laser Sci, D-22607 Hamburg, Germany.
   [Boutet, Sebastien; Williams, Garth J.] SLAC Natl Accelerator Lab, Linac Coherent Light Source, Menlo Pk, CA 94025 USA.
   [Chapman, Henry N.; Nass, Karol] Univ Hamburg, D-22761 Hamburg, Germany.
   [James, Daniel; Kirian, Richard A.; Liu, Haiguang; Schmidt, Kevin E.; Spence, John C. H.; Weierstall, Uwe; Wang, Dingjie; Zatsepin, Nadia A.] Arizona State Univ, Dept Phys, Tempe, AZ 85287 USA.
   [Schlichting, Ilme; Shoeman, Robert L.] Max Planck Inst Med Res, D-69120 Heidelberg, Germany.
   [Yoon, Chunhong] European XFEL GmbH, D-22761 Hamburg, Germany.
RP Fromme, P (reprint author), Arizona State Univ, Dept Chem & Biochem, POB 871604, Tempe, AZ 85287 USA.
EM petra.fromme@asu.edu; tsafrir.mor@asu.edu
RI Schlichting, Ilme/I-1339-2013; Deb, Arpan/C-2898-2017; Fromme,
   Raimund/C-8885-2012; Chapman, Henry/G-2153-2010
OI Deb, Arpan/0000-0002-2989-3661; Fromme, Raimund/0000-0003-4835-1080;
   Chapman, Henry/0000-0002-4655-1743; Seibert, Mark
   Marvin/0000-0003-0251-0744; James, Daniel/0000-0002-8348-6661
FU National Institutes of Health [U19 AI062150, U54 GM094599, 1R01GM095583,
   R03 AI073157]; US National Science Foundation (NSF) [MCB 1120997]; NSF
   [MCB-1021557]; DOE through PULSE Institute at SLAC National Accelerator
   Laboratory; Lawrence Livermore National Laboratory [DE-AC52-07NA27344];
   Human Frontiers Science Project [024940]; Helmholtz Association; Max
   Planck Society
FX We would like to thank Eric Davies (Arizona State University) for
   technical assistance with the cloning. This work was supported in part
   by the National Institutes of Health (awards U19 AI062150 to TM; U54
   GM094599 to PF, BH and TM; 1R01GM095583 to PF; and R03 AI073157 to NM).
   We also gratefully acknowledge support by the US National Science
   Foundation (NSF; award MCB 1120997). Conventional and serial femtosecond
   crystallography experiments were carried out at the Advanced Light
   Source (ALS) and the Linac Coherent Light Source (LCLS), respectively,
   which are national user facilities operated by the University of
   California and Stanford University, respectively, on behalf of the US
   Department of Energy (DOE), Office of Basic Energy Sciences. We are
   grateful for an NSF award (MCB-1021557) to JCHS. We acknowledge support
   from DOE through the PULSE Institute at the SLAC National Accelerator
   Laboratory and by Lawrence Livermore National Laboratory under Contract
   DE-AC52-07NA27344. HL's work was partially supported by Human Frontiers
   Science Project award No. 024940. We also acknowledge the support of the
   Helmholtz Association and the Max Planck Society.
CR Aiyar A, 1996, Methods Mol Biol, V57, P177
   Alfsen A, 2002, J BIOL CHEM, V277, P25649, DOI 10.1074/jbc.M200554200
   Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257                                                    
   Atilgan C, 2010, BIOPHYS J, V99, P933, DOI 10.1016/j.bpj.2010.05.020
   Barty A, 2014, J APPL CRYSTALLOGR, V47, P1118, DOI 10.1107/S1600576714007626
   Barty A, 2012, NAT PHOTONICS, V6, P35, DOI [10.1038/nphoton.2011.297, 10.1038/NPHOTON.2011.297]
   BHUVANESHWARI M, 1995, STRUCTURE, V3, P1021, DOI 10.1016/S0969-2126(01)00238-6
   Biron Z, 2005, BIOCHEMISTRY-US, V44, P13602, DOI 10.1021/bi0509254
   Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Boutet S, 2012, SCIENCE, V337, P362, DOI 10.1126/science.1217737
   Boutet S, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/3/035024
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Chapman HN, 2011, NATURE, V470, P73, DOI 10.1038/nature09750
   Denner J, 2011, HUM VACCINES, V7, P4, DOI 10.4161/hv.7.0.14555
   DePonte DP, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/19/195505
   Dertzbaugh MT, 1998, PROTEIN ENG, V11, P577, DOI 10.1093/protein/11.7.577
   Gach JS, 2011, CURR TOP MED CHEM, V11, P2997
   Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959
   Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Kirian RA, 2011, ACTA CRYSTALLOGR A, V67, P131, DOI 10.1107/S0108767310050981
   Krishna S, 1999, J MOL BIOL, V289, P919, DOI 10.1006/jmbi.1999.2787
   Kupitz C, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0316
   Lawrence RM, 2011, PROTEIN EXPRES PURIF, V76, P15, DOI 10.1016/j.pep.2010.10.009
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Lomb L, 2012, J APPL CRYSTALLOGR, V45, P674, DOI 10.1107/S0021889812024557
   Magerus-Chatinet A, 2007, VIROLOGY, V362, P67, DOI 10.1016/j.virol.2006.11.035
   Matoba N, 2006, VACCINE, V24, P5047, DOI 10.1016/j.vaccine.2006.03.045
   Matoba N, 2004, P NATL ACAD SCI USA, V101, P13584, DOI 10.1073/pnas.0405297101
   Matoba N, 2009, PLANT BIOTECHNOL J, V7, P129, DOI 10.1111/j.1467-7652.2008.00381.x
   Matoba N, 2008, CURR HIV RES, V6, P218, DOI 10.2174/157016208784324994                                                      
   Matoba N, 2011, VACCINE, V29, P5584, DOI 10.1016/j.vaccine.2011.06.007
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Meng G, 2002, NAT MED, V8, P150, DOI 10.1038/nm0202-150
   MERRITT EA, 1994, PROTEIN SCI, V3, P166
   Montero M, 2012, J VIROL, V86, P2930, DOI 10.1128/JVI.06349-11
   Ni D, 2011, PROTEIN EXPRES PURIF, V80, P157, DOI 10.1016/j.pep.2011.08.004
   ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415
   Pejchal R, 2009, J VIROL, V83, P8451, DOI 10.1128/JVI.00685-09
   Pickens JC, 2002, CHEM BIOL, V9, P215, DOI 10.1016/S1074-5521(02)00097-2                                                   
   Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847
   Proteau A., 2010, CURR PROTOC PROTEIN
   Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003
   Reshetnyak YK, 2001, BIOPHYS J, V81, P1735, DOI 10.1016/S0006-3495(01)75825-0                                                   
   Sangita V, 2005, ACTA CRYSTALLOGR D, V61, P1402, DOI 10.1107/S090744905024029
   Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4
   Shen RZ, 2010, J IMMUNOL, V184, P3648, DOI 10.4049/jimmunol.0903346
   Shi WX, 2010, J BIOL CHEM, V285, P24290, DOI 10.1074/jbc.M110.111351
   Song LK, 2009, P NATL ACAD SCI USA, V106, P9057, DOI 10.1073/pnas.0901474106
   Spence JCH, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/10/102601
   Teixeira C, 2011, EUR J MED CHEM, V46, P979, DOI 10.1016/j.ejmech.2011.01.046
   Tudor D, 2009, MUCOSAL IMMUNOL, V2, P412, DOI 10.1038/mi.2009.89
   Valdiserri RO, 2003, NAT MED, V9, P881, DOI 10.1038/nm0703-881
   Weierstall U, 2008, EXP FLUIDS, V44, P675, DOI 10.1007/s00348-007-0426-8
   Weierstall U, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3693040
   White TA, 2012, J APPL CRYSTALLOGR, V45, P335, DOI 10.1107/S0021889812002312
   Yasuda Y, 1998, FEMS IMMUNOL MED MIC, V20, P311, DOI 10.1111/j.1574-695X.1998.tb01141.x
   Zrimi J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015347
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
   Zwick MB, 2005, AIDS, V19, P1725, DOI 10.1097/01.aids.0000189850.83322.41
NR 61
TC 3
Z9 3
U1 0
U2 8
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
SN 2052-2525
J9 IUCRJ
JI IUCrJ
PD SEP
PY 2014
VL 1
BP 305
EP 317
DI 10.1107/S2052252514014900
PN 5
PG 13
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA CL3QI
UT WOS:000356864900007
PM 25295172
OA gold
DA 2018-01-05
ER

PT J
AU Shirazi, AN
   Paquin, KL
   Howlett, NG
   Mandal, D
   Parang, K
AF Shirazi, Amir Nasrolahi
   Paquin, Karissa L.
   Howlett, Niall G.
   Mandal, Dindyal
   Parang, Keykavous
TI Cyclic Peptide-Capped Gold Nanoparticles for Enhanced siRNA Delivery
SO MOLECULES
LA English
DT Article
DE small interfering RNA (siRNA) delivery; gold nanoparticles; cyclic
   peptides; siRNA delivery systems (DDS)
ID SMALL INTERFERING RNA; IN-VIVO; TAT PEPTIDE; CELLULAR UPTAKE; GENE;
   EFFICIENCY; CELLS; MICE; NEURONS; AFFORDS
AB Previously, we have reported the synthesis of a homochiral L-cyclic peptide [WR](5) and its use for delivery of anti-HIV drugs and biomolecules. A physical mixture of HAuCl4 and the peptide generated peptide-capped gold nanoparticles. Here, [WR](5) and [WR](5)-AuNPs were tested for their efficiency to deliver a small interfering RNA molecule (siRNA) in human cervix adenocarcinoma (HeLa) cells. Flow cytometry investigation revealed that the intracellular uptake of a fluorescence-labeled non-targeting siRNA (200 nM) was enhanced in the presence of [WR](5) and [WR](5)-AuNPs by 2- and 3.8-fold when compared with that of siRNA alone after 24 h incubation. Comparative toxicity results showed that [WR](5) and [WR](5)-AuNPs were less toxic in cells compared to other available carrier systems, such as Lipofectamine.
C1 [Shirazi, Amir Nasrolahi; Mandal, Dindyal; Parang, Keykavous] Chapman Univ, Sch Pharm, Irvine, CA 92618 USA.
   [Paquin, Karissa L.; Howlett, Niall G.] Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA.
RP Parang, K (reprint author), Chapman Univ, Sch Pharm, Irvine, CA 92618 USA.
EM parang@chapman.edu
FU National Center for Research Resources, NIH [8 P20 GM103430-12]
FX We thank National Center for Research Resources, NIH, and Grant Number 8
   P20 GM103430-12 for sponsoring the core facility.
CR Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8                                                   
   Duncan B, 2010, J CONTROL RELEASE, V148, P122, DOI 10.1016/j.jconrel.2010.06.004
   Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606
   Jantsch J, 2008, J IMMUNOL METHODS, V337, P71, DOI 10.1016/j.jim.2008.04.004
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2005, BIOORG MED CHEM LETT, V15, P5071, DOI 10.1016/j.bmcl.2005.07.087
   Ma H, 2002, NEUROSCIENCE, V112, P1
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   McCarroll J, 2010, BIOCONJUGATE CHEM, V21, P56, DOI 10.1021/bc900296z
   McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754                                                    
   Morgan MT, 2006, CANCER RES, V66, P11913, DOI 10.1158/0008-5472.CAN-06-2066
   Oh D, 2014, MOL PHARMACEUT, V11, P2845, DOI 10.1021/mp500203e
   Ohki EC, 2001, J NEUROSCI METH, V112, P95, DOI 10.1016/S0165-0270(01)00441-1
   Pushparaj PN, 2006, CLIN EXP PHARMACOL P, V33, P504, DOI 10.1111/j.1440-1681.2006.04399.x
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356
   Shirazi N.A., 2013, MOL PHARM, V10, P3137
   Shirazi N.A., 2013, MOL PHARM, V10, P488
   Shirazi N.A., 2013, MOL PHARM, V10, P2008
   Shirazi N.A., 2013, MOL PHARM, V10, P500
   Sioud M, 2003, BIOCHEM BIOPH RES CO, V312, P1220, DOI 10.1016/j.bbrc.2003.11.057
   Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828
   Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   Strait K.A., 2007, AM J PHYSIOL, V293, P601
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   Wang S, 2000, NEUROCHEM INT, V37, P1, DOI 10.1016/S0197-0186(00)00007-3
NR 35
TC 10
Z9 11
U1 0
U2 16
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2014
VL 19
IS 9
BP 13319
EP 13331
DI 10.3390/molecules190913319
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA AQ8QE
UT WOS:000343093100027
PM 25170952
OA gold
DA 2018-01-05
ER

PT J
AU Jorba, N
   Shitanishi, KT
   Winkler, CJ
   Herring, SW
AF Jorba, Nuria
   Shitanishi, Kenneth T.
   Winkler, Clint J.
   Herring, Steven W.
TI Virus removal capacity at varying ionic strength during nanofiltration
   of AlphaNine (R) SD
SO BIOLOGICALS
LA English
DT Article
DE Viral safety; Nanofiltration; Factor IX; AlphaNine (R) SD; Ion strength;
   Virus removal
ID COAGULATION-FACTOR-IX; VIRAL SAFETY; PLASMA; INACTIVATION; PRODUCTS
AB Nanofiltration is incorporated into the manufacturing processes of many protein biopharmaceuticals to enhance safety by providing the capacity to retain pathogens while allowing protein drugs to pass through the filter. Retention is mainly a function of size; however, the shape of the pathogen may also influence retention. The ability of the Viresolve (R) Pro nanofilter to remove different sized viruses during the manufacture of a Coagulation Factor IX (Alphanine (R) SD) was studied at varying ionic strength, a process condition with the potential to affect virus shape and, hence, virus retention. Eight viruses were tested in a scale-down of the nanofiltration process. Five of the viruses (EMCV, Reo, BVDV, HIV, PRV) were nanofiltered at normal sodium processing conditions and three (PPV, HAV and WNV) were nanofiltered at higher and lower sodium. Representative Reduction Factors for all viruses were >= 4.50 logs and removal was consistent over a wide range of ionic strength. (C) 2014 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
C1 [Jorba, Nuria; Shitanishi, Kenneth T.; Winkler, Clint J.; Herring, Steven W.] Grifols Biol Inc, Dept Res & Dev, Los Angeles, CA 90032 USA.
RP Herring, SW (reprint author), Grifols Biol Inc, Dept Res & Dev, 5555 Valley Blvd, Los Angeles, CA 90032 USA.
EM nuria.jorba@grifols.com; ken.shitanishi@grifols.com;
   clint.winkler@grifols.com; steven.herring@grifols.com
CR Burnouf T, 1996, VOX SANG, V70, P235, DOI 10.1111/j.1423-0410.1996.tb01334.x                                              
   Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   Caballero S, 2010, BIOLOGICALS, V38, P486, DOI 10.1016/j.biologicals.2010.02.008
   Cai K, 2013, TRANSFUSION, V53, P1894, DOI 10.1111/trf.12050
   CPMP EMEA, 2001, CPMPBWP26995 EMEA
   CPMP, 1996, CPMPBWP26895 EMEA
   EMEA, 1997, CPMPICH29595 EMEA
   Gajardo R, 2013, TRANSFUSION, V53, P1141, DOI 10.1111/trf.12140
   GOLDSMITH JC, 1992, AM J HEMATOL, V40, P210, DOI 10.1002/ajh.2830400310
   Herring S, 2010, HAEMOPHILIA, V16, P3, DOI 10.1111/j.1365-2516.2010.02299.x
   Johnston A, 2000, BIOLOGICALS, V28, P129, DOI 10.1006/biol.1999.0242
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Terpstra FG, 2007, BIOLOGICALS, V35, P173, DOI 10.1016/j.biologicals.2006.08.005
   Terpstra FG, 2006, VOX SANG, V90, P21, DOI 10.1111/j.1423-0410.2005.00710.x
   World Health Organization, 2004, WHO TECHN REP SER, V924
   Winkler CJ, 2013, BIOLOGICALS, V41, P176, DOI 10.1016/j.biologicals.2013.01.001
NR 17
TC 1
Z9 1
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
EI 1095-8320
J9 BIOLOGICALS
JI Biologicals
PD SEP
PY 2014
VL 42
IS 5
BP 290
EP 293
DI 10.1016/j.biologicals.2014.06.002
PG 4
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA AQ5YS
UT WOS:000342885100007
PM 24999080
DA 2018-01-05
ER

PT J
AU Timmins, P
   Brown, J
   Meanwell, NA
   Hanna, GJ
   Zhu, L
   Kadow, JF
AF Timmins, Peter
   Brown, Jonathan
   Meanwell, Nicholas A.
   Hanna, George J.
   Zhu, Li
   Kadow, John F.
TI Enabled clinical use of an HIV-1 attachment inhibitor through drug
   delivery
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID PHOSPHATE PRODRUGS; PHARMACOKINETICS; FORMULATION; BMS-663068;
   BMS-488043; BMS-378806; ABSORPTION
AB The clinical advancement of HIV-1 attachment inhibitors was hindered initially by poor bioavailability. Attempts to identify improved candidates revealed that solubility and dissolution-rate-limited absorption are barriers to achieving adequate antiviral plasma levels. This was mitigated by forming nanosized drugs or by creating stabilised amorphous drug-polymer composites. In further improving drug potency and mitigating solubility-limited bioavailability, a candidate based on a phosphate ester prodrug was identified that, although having excellent bioavailability, exhibited unacceptable pharmacokinetics. Based on in silico modelling and a site of absorption study it was confirmed that creating an extended release formulation could provide the desired pharmacokinetic profile. The optimised formulation showed good antiviral activity when dosed employing a once or twice a day regimen.
C1 [Timmins, Peter; Brown, Jonathan] Bristol Myers Squibb Co, Drug Prod Sci & Technol, Moreton CH46 1QW, Merseyside, England.
   [Meanwell, Nicholas A.; Hanna, George J.] Bristol Myers Squibb Co, Global Clin Res, Princeton, NJ 08540 USA.
   [Zhu, Li] Bristol Myers Squibb Co, Exploratory Clin & Translat Res, Hopewell, NJ 08534 USA.
   [Kadow, John F.] Bristol Myers Squibb Co, Discovery Chem, Wallingford, CT 06492 USA.
RP Timmins, P (reprint author), Bristol Myers Squibb Co, Drug Prod Sci & Technol, Reeds Lane, Moreton CH46 1QW, Merseyside, England.
EM peter.timmins@bms.com
CR Brown J, 2013, J PHARM SCI-US, V102, P1742, DOI 10.1002/jps.23476
   Dau B, 2009, DRUGS, V69, P31, DOI 10.2165/00003495-200969010-00003
   Fakes MG, 2009, INT J PHARMACEUT, V370, P167, DOI 10.1016/j.ijpharm.2008.11.018
   Hanna G., 2004, 11 C RETR OPP INF SA, P535
   Hanna GJ, 2011, ANTIMICROB AGENTS CH, V55, P722, DOI 10.1128/AAC.00759-10
   Heimbach T, 2003, INT J PHARM, V261, P81, DOI 10.1016/S0378-5173(03)00287-4
   Heimbach T, 2003, PHARMACEUT RES, V20, P848, DOI 10.1023/A:1023827017224
   Jambhekar SS, 2013, DRUG DISCOV TODAY, V18, P1173, DOI 10.1016/j.drudis.2013.08.013
   Kadow J.F., 2011, 24 ACS NAT M EXP
   Kadow JF, 2011, ANTIVIRAL DRUGS: FROM BASIC DISCOVERY THROUGH CLINICAL TRIALS, P149
   Kadow JF, 2012, J MED CHEM, V55, P2048, DOI 10.1021/jm201218m
   Nettles R., 2011, 12 INT WORKSH CLIN P
   Nettles RE, 2012, J INFECT DIS, V206, P1002, DOI 10.1093/infdis/jis432
   Nowicka-Sans B, 2012, ANTIMICROB AGENTS CH, V56, P3498, DOI 10.1128/AAC.00426-12
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Stella VJ, 2007, ADV DRUG DELIVER REV, V59, P677, DOI 10.1016/j.addr.2007.05.013
   Teixeira C, 2011, EUR J MED CHEM, V46, P979, DOI 10.1016/j.ejmech.2011.01.046
   Timmins P., 2013, IND PHARM, V40, P12
   Tobyn M, 2009, J PHARM SCI-US, V98, P3456, DOI 10.1002/jps.21738
   Weber J, 2006, AIDS REV, V8, P60
   Xue YJ, 2007, J SEP SCI, V30, P1267, DOI 10.1002/jssc.200600499
   Yang Z, 2005, BIOPHARM DRUG DISPOS, V26, P387, DOI 10.1002/bdd.471
   Yang Z, 2010, J PHARM SCI-US, V99, P2135, DOI 10.1002/jps.21948
   Zhou NN, 2011, ANTIMICROB AGENTS CH, V55, P729, DOI 10.1128/AAC.01173-10
   [Anonymous], 2010, U.S. Patent, Patent No. [7,745,625 B2, 7745625, US7745625]
NR 25
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD SEP
PY 2014
VL 19
IS 9
BP 1288
EP 1293
DI 10.1016/j.drudis.2014.03.025
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AQ2GP
UT WOS:000342604100003
PM 24727410
DA 2018-01-05
ER

PT J
AU Ramirez, JEV
   Roychoudhury, R
   Habte, HH
   Cho, MW
   Pohl, NLB
   Narasimhan, B
AF Ramirez, J. E. Vela
   Roychoudhury, R.
   Habte, H. H.
   Cho, M. W.
   Pohl, N. L. B.
   Narasimhan, B.
TI Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen
   stability and activate antigen presenting cells
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE dendritic cells; carbohydrates; nanoparticles; polyanhydrides;
   targeting; HIV antigen; nanovaccines
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PROXIMAL EXTERNAL REGION; AMPHIPHILIC
   POLYANHYDRIDE NANOPARTICLES; HUMAN MONOCLONAL-ANTIBODY; SOLID-PHASE
   EXTRACTION; MURINE DENDRITIC CELLS; LECTIN-LIKE RECEPTORS; DC-SIGN;
   MANNOSE RECEPTOR; POLYMER CHEMISTRY
AB The functionalization of polymeric nanoparticles with ligands that target specific receptors on immune cells offers the opportunity to tailor adjuvant properties by conferring pathogen mimicking attributes to the particles. Polyanhydride nanoparticles are promising vaccine adjuvants with desirable characteristics such as immuno-modulation, sustained antigen release, activation of antigen presenting cells (APCs), and stabilization of protein antigens. These capabilities can be exploited to design nanovaccines against viral pathogens, such as HIV-1, due to the important role of dendritic cells (DCs) and macrophages in viral spread. In this work, an optimized process was developed for carbohydrate functionalization of HIV-1 antigen-loaded polyanhydride nanoparticles. The carbohydrate-functionalized nanoparticles preserved antigenic properties upon release and also enabled sustained antigen release kinetics. Particle internalization was observed to be chemistry-dependent with positively charged nanoparticles being taken up more efficiently by DCs. Up-regulation of the activation makers CD40 and CD206 was demonstrated with carboxymethyl-alpha-D-mannopyranosyl-(1,2)-D-mannopyranoside functionalized nanoparticles. The secretion of the cytokines IL-6 and TNF-alpha was shown to be chemistry-dependent upon stimulation with carbohydrate-functionalized nanoparticles. These results offer important new insights upon the interactions between carbohydrate-functionalized nanoparticles and APCs and provide foundational information for the rational design of targeted nanovaccines against HIV-1.
C1 [Ramirez, J. E. Vela; Narasimhan, B.] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
   [Roychoudhury, R.; Pohl, N. L. B.] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
   [Habte, H. H.; Cho, M. W.] Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA.
   [Habte, H. H.; Cho, M. W.] Iowa State Univ, Ctr Adv Host Def Immunobiot & Translat Comparat M, Ames, IA 50011 USA.
RP Narasimhan, B (reprint author), Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
EM nbalaji@iastate.edu
RI Narasimhan, Balaji/A-5487-2008
OI Narasimhan, Balaji/0000-0002-7955-5353
FU NIH-NIAID [U19 AI-091031]
FX The authors acknowledge financial support from NIH-NIAID (U19
   AI-091031). The authors acknowledge useful discussions with Dr Michael
   J. Wannemuehler on the DC activation data and thank Shawn Rigby of the
   Iowa State University Flow Cytometry facility for his assistance with
   the flow cytometry experiments. MWC has an equity interest in NeoVaxSyn
   Incorporated, and serves as CEO/President. NeoVaxSyn Inc. did not
   contribute to this work or to the interpretation of the data. The
   following reagents were obtained through the NIH AIDS Reagent Program,
   Division of AIDS, NIAID, NIH: HIV-1 gp41 mAb 2F5, 4E10, and Z13e1.
CR Adams EW, 2008, CHEMBIOCHEM, V9, P294, DOI 10.1002/cbic.200700310
   Berzi A, 2014, VIRUSES-BASEL, V6, P391, DOI 10.3390/v6020391
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004
   Carrillo-Conde B, 2011, MOL PHARMACEUT, V8, P1877, DOI 10.1021/mp200213r
   Carrillo-Conde B, 2010, ACTA BIOMATER, V6, P3110, DOI 10.1016/j.actbio.2010.01.040
   Carrillo-Conde BR, 2012, ACTA BIOMATER, V8, P3618, DOI 10.1016/j.actbio.2012.06.001
   Carrillo-Conde BR, 2012, J VIS EXP, V64, pe3884, DOI [10.3791/3884, DOI 10.3791/3884]
   Catalfamo M, 2008, P NATL ACAD SCI USA, V105, P19851, DOI 10.1073/pnas.0810032105
   Chavez-Santoscoy AV, 2012, BIOMATERIALS, V33, P4762, DOI 10.1016/j.biomaterials.2012.03.027
   Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231
   Chung NPY, 2012, J IMMUNOL, V189, P5257, DOI 10.4049/jimmunol.1201905
   Conix A., 1966, MACROMOL SYNTHESES, V2, P95
   Cunningham AL, 2007, NAT IMMUNOL, V8, P556, DOI 10.1038/nio607-556
   Curran DP, 1999, J AM CHEM SOC, V121, P9069, DOI 10.1021/ja991496r                                                               
   Deng ZC, 2009, MACROMOLECULES, V42, P6393, DOI 10.1021/ma9010457
   Determan AS, 2006, J MICROENCAPSUL, V23, P832, DOI 10.1080/02652040601033841
   Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x
   Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941
   Fantuzzi L, 2001, J IMMUNOL, V166, P5381, DOI 10.4049/jimmunol.166.9.5381                                                     
   Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723
   Gaiha GD, 2008, J IMMUNOL, V181, P601, DOI 10.4049/jimmunol.181.1.601                                                      
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569
   Gringhuis SI, 2010, NAT IMMUNOL, V11, P419, DOI 10.1038/ni.1858
   Hedestam GBK, 2008, NAT REV MICROBIOL, V6, P143, DOI 10.1038/nrmicro1819
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-34
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Jaipuri FA, 2008, ORG BIOMOL CHEM, V6, P2686, DOI 10.1039/b803451f
   Jameson B, 2002, J VIROL, V76, P1866, DOI 10.1128/JVI.76.4.1866-1875.2002
   Jiang HL, 2008, BIOMATERIALS, V29, P1931, DOI 10.1016/j.biomaterials.2007.12.025
   Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953
   Kipper MJ, 2006, J BIOMED MATER RES A, V76A, P798, DOI 10.1002/jbm.a.30545
   Kipper MJ, 2002, BIOMATERIALS, V23, P4405, DOI 10.1016/S0142-9612(02)00181-3
   Kumar N, 2002, ADV DRUG DELIVER REV, V54, P889, DOI 10.1016/S0169-409X(02)00050-9                                                   
   Lewis JS, 2012, BIOMATERIALS, V33, P7221, DOI 10.1016/j.biomaterials.2012.06.049
   Lopac SK, 2009, J BIOMED MATER RES B, V91B, P938, DOI 10.1002/jbm.b.31478
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   Masuko T, 2005, ANAL BIOCHEM, V339, P69, DOI 10.1016/j.ab.2004.12.001
   McKenzie EJ, 2007, J IMMUNOL, V178, P4975, DOI 10.4049/jimmunol.178.8.4975                                                     
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06
   Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024                                                          
   Ohtani M, 2012, CELL MICROBIOL, V14, P40, DOI 10.1111/j.1462-5822.2011.01695.x
   Penn-Nicholson A, 2008, VIROLOGY, V372, P442, DOI 10.1016/j.virol.2007.11.009
   Petersen LK, 2012, MOL PHARMACEUT, V9, P874, DOI 10.1021/mp2004059
   Petersen LK, 2010, ACTA BIOMATER, V6, P3873, DOI 10.1016/j.actbio.2010.04.004
   Petersen LK, 2011, BIOMATERIALS, V32, P6815, DOI 10.1016/j.biomaterials.2011.05.063
   Petersen LK, 2009, BIOMATERIALS, V30, P5131, DOI 10.1016/j.biomaterials.2009.05.069
   Phanse Y, 2013, ACTA BIOMATER, V9, P8902, DOI 10.1016/j.actbio.2013.06.024
   PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651
   Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003
   Pyz E, 2006, ANN MED, V38, P242, DOI 10.1080/07853890600608985
   Saunders SP, 2010, J IMMUNOL, V184, P2627, DOI 10.4049/jimmunol.0901970
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Shan MM, 2007, PLOS PATHOG, V3, P1637, DOI 10.1371/journal.ppat.0030169
   Shen E, 2001, BIOMATERIALS, V22, P201, DOI 10.1016/S0142-9612(00)00175-7
   Shi WX, 2010, J BIOL CHEM, V285, P24290, DOI 10.1074/jbc.M110.111351
   Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1
   Song EH, 2010, J AM CHEM SOC, V132, P11428, DOI 10.1021/ja103351m
   STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Torres MP, 2007, BIOMATERIALS, V28, P108, DOI 10.1016/j.biomaterials.2006.08.047
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   Torres MP, 2006, J BIOMED MATER RES A, V76A, P102, DOI 10.1002/jbm.a.30510
   Turville S, 2003, J LEUKOCYTE BIOL, V74, P710, DOI 10.1189/jlb.0503208
   Ulery BD, 2011, SCI REP-UK, V1, DOI 10.1038/srep00198
   Ulery BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017642
   Ulery BD, 2009, PHARM RES-DORD, V26, P683, DOI 10.1007/s11095-008-9760-7
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Upham JP, 2010, J VIROL, V84, P3730, DOI 10.1128/JVI.02148-09
   Zhang W, 2006, TETRAHEDRON, V62, P11837, DOI 10.1016/j.tet.2006.08.051
   Zhang W, 2009, CHEM REV, V109, P749, DOI 10.1021/cr800412s
   Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 76
TC 11
Z9 11
U1 0
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PD SEP
PY 2014
VL 25
IS 13
BP 1387
EP 1406
DI 10.1080/09205063.2014.940243
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA AN6QC
UT WOS:000340719600005
OA green_accepted
DA 2018-01-05
ER

PT J
AU Guo, DW
   Zhang, G
   Wysocki, TA
   Wysocki, BJ
   Gelbard, HA
   Liu, XM
   McMillan, JM
   Gendelman, HE
AF Guo, Dongwei
   Zhang, Gang
   Wysocki, Tadeusz A.
   Wysocki, Beata J.
   Gelbard, Harris A.
   Liu, Xin-Ming
   McMillan, JoEllyn M.
   Gendelman, Howard E.
TI Endosomal Trafficking of Nanoformulated Antiretroviral Therapy
   Facilitates Drug Particle Carriage and HIV Clearance
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; COLONY-STIMULATING FACTOR; TISSUE
   DISTRIBUTION; RAB PROTEINS; DELIVERY; MACROPHAGES; NANOPARTICLES;
   ENDOCYTOSIS; INFECTION; RELEASE
AB Limitations of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, and failure to penetrate viral reservoirs. Recent developments in nanoformulated ART (nanoART) could overcome such limitations. To this end, we now report a novel effect of nanoART that facilitates drug depots within intracellular compartments at or adjacent to the sites of the viral replication cycle. Poloxamer 407-coated nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization. These drug particles readily accumulated in human monocyte-derived macrophages (MDM). NanoATV concentrations were similar to 1,000 times higher in cells than those that could be achieved by the native drug. ATV particles in late and recycling endosome compartments were seen following pulldown by immunoaffinity chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal microscopy provided cross validation by immunofluorescent staining of the compartments. Mathematical modeling validated drug-endosomal interactions. Measures of reverse transcriptase activity and HIV-1 p24 levels in culture media and cells showed that such endosomal drug concentrations enhanced antiviral responses up to 1,000-fold. We conclude that late and recycling endosomes can serve as depots for nanoATV. The colocalization of nanoATV at endosomal sites of viral assembly and its slow release sped antiretroviral activities. Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments and, as such, can facilitate viral clearance.
   IMPORTANCE The need for long-acting ART is significant and highlighted by limitations in drug access, toxicity, adherence, and reservoir penetrance. We propose that targeting nanoformulated drugs to infected tissues, cells, and subcellular sites of viral replication may improve clinical outcomes. Endosomes are sites for human immunodeficiency virus assembly, and increasing ART concentrations in such sites enhances viral clearance. The current work uncovers a new mechanism by which nanoART can enhance viral clearance over native drug formulations.
C1 [Guo, Dongwei; Liu, Xin-Ming; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68182 USA.
   [Guo, Dongwei; Zhang, Gang; Liu, Xin-Ming; McMillan, JoEllyn M.; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
   [Wysocki, Tadeusz A.; Wysocki, Beata J.] Univ Nebraska, Dept Comp & Elect Engn, Omaha, NE 68182 USA.
   [Gelbard, Harris A.] Univ Rochester, Med Ctr, Ctr Neural Dev & Dis, Dept Neurol, Rochester, NY 14642 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68182 USA.
EM hegendel@unmc.edu
OI Zhang, Gang/0000-0002-3109-915X
FU University of Nebraska Foundation; Carol Swarts and Frances and Louie
   Blumkin; University of Nebraska Medical Center; ViiV Healthcare;
   National Institutes of Health [P01 DA028555, R01 NS36126, P01 NS31492,
   2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]
FX This work was supported by the University of Nebraska Foundation, which
   includes individual donations from Carol Swarts and Frances and Louie
   Blumkin; the Vice Chancellor's office of the University of Nebraska
   Medical Center; ViiV Healthcare; and National Institutes of Health
   grants P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01
   MH64570, P01 NS43985, P30 MH062261, and R01 AG043540.
CR Arribas JR, 2013, CURR OPIN HIV AIDS, V8, P341, DOI 10.1097/COH.0b013e328361fabd
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   Bell NM, 2013, BIOCHEMISTRY-US, V52, P9269, DOI 10.1021/bi401270d
   Bell NM, 2013, TRENDS MICROBIOL, V21, P136, DOI 10.1016/j.tim.2012.11.006
   Benaroch P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-29
   Beyrer C, 2010, LANCET, V376, P551, DOI 10.1016/S0140-6736(10)60928-2
   CLARK SC, 1989, ANN NY ACAD SCI, V557, P438
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gollapudi K, 2013, AM J CANCER RES, V3, P523
   Goncalves E, 2013, MOL BIOSYST, V9, P1576, DOI 10.1039/c3mb25489e
   Goshima F, 2014, INT J CANCER, V134, P2865, DOI 10.1002/ijc.28631
   Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009
   Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   KALTER DC, 1991, J IMMUNOL, V146, P298
   Karr JR, 2012, CELL, V150, P389, DOI 10.1016/j.cell.2012.05.044
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kumar L, 2014, ARTIF CELLS NAN 0225
   Kumar R, 2002, J VIROL METHODS, V105, P233, DOI 10.1016/S0166-0934(02)00105-2                                                   
   Kumari S, 2010, CELL RES, V20, P256, DOI 10.1038/cr.2010.19
   Liszewski MK, 2009, METHODS, V47, P254, DOI 10.1016/j.ymeth.2009.01.002
   Martin TM, BIOTECHNOL IN PRESS
   McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151
   Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239
   MELTZER MS, 1990, AIDS RES HUM RETROV, V6, P967
   Meng B, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-5
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Parent A, 2009, BIOCHEM J, V418, P163, DOI 10.1042/BJ20080867
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   Pretorius E, 2011, THER DRUG MONIT, V33, P265, DOI 10.1097/FTD.0b013e31821b42d1
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Ramana LN, 2014, BBA-GEN SUBJECTS, V1840, P476, DOI 10.1016/j.bbagen.2013.10.002
   Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x                                                
   ROWELL JF, 1995, J IMMUNOL, V155, P473
   Schonteich E, 2008, J CELL SCI, V121, P3824, DOI 10.1242/jcs.032441
   Schulz R, 2014, CURR OPIN ONCOL, V26, P108, DOI 10.1097/CCO.0000000000000036
   Schwarcz SK, 2000, AM J EPIDEMIOL, V152, P178, DOI 10.1093/aje/152.2.178                                                           
   Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901
   Varthakavi V, 2006, TRAFFIC, V7, P298, DOI 10.1111/j.1600-0854.2005.00380.x
   Wainberg MA, 2011, NATURE, V469, P306, DOI 10.1038/469306a
   Wang X, 2009, ACS NANO, V3, P3165, DOI 10.1021/nn900649v
   Wood R, 2008, EXPERT REV ANTI-INFE, V6, P785, DOI 10.1586/14787210.6.6.785
   Yamamoto H, 2010, MOL BIOL CELL, V21, P2746, DOI 10.1091/mbc.E10-01-0074
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055                                                                
NR 54
TC 14
Z9 14
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2014
VL 88
IS 17
BP 9504
EP 9513
DI 10.1128/JVI.01557-14
PG 10
WC Virology
SC Virology
GA AO3LW
UT WOS:000341232300003
PM 24920821
OA gold
DA 2018-01-05
ER

PT J
AU Meier, C
   Weil, T
   Kirchhoff, F
   Munch, J
AF Meier, Christoph
   Weil, Tanja
   Kirchhoff, Frank
   Muench, Jan
TI Peptide nanofibrils as enhancers of retroviral gene transfer
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT FIBRONECTIN FRAGMENTS;
   POLYMERIZED ANIONIC SURFACTANTS; SEMEN-MEDIATED ENHANCEMENT; AVIAN
   SARCOMA VIRUSES; POLYANION INHIBITORS; LENTIVIRAL VECTOR; HIV-INFECTION;
   HEMATOPOIETIC STEM; AMYLOID FIBRILS
AB Amyloid fibrils are polypeptide-based polymers that are typically associated with neurodegenerative disorders such as Alzheimer's disease. More recently, it has become clear that amyloid fibrils also fulfill functional roles in hormone storage and biosynthesis. Furthermore, it has been demonstrated that semen contains abundant levels of polycationic amyloid fibrils. The natural role of these seminal amyloids remains elusive. Strikingly, however, they drastically enhance HIV-1 infection and may be exploited by the virus to increase its sexual transmission rate. Their strong activity in enhancing HIV-1 infection suggests that seminal amyloid might also promote transduction by retroviral vectors. Indeed, SEVI (semen-derived enhancer of virus infection), the best characterized seminal amyloid, boosts retroviral gene transfer more efficiently than conventional additives. However, the use of SEVI as laboratory tool for efficient retroviral gene transfer is limited because the polypeptide monomers are relatively expensive to produce. Furthermore, standardized production of SEVI fibrils with similar high activities is difficult to achieve because of the stochastic nature of the amyloid assembly process. These obstacles can be overcome by recently identified smaller peptides that spontaneously self-assemble into nanofibrils. These nanofibrils increase retroviral gene transfer even more efficiently than SEVI, are easy to produce and to handle, and seem to be safe as assessed in an ex vivo gene transfer study. Furthermore, peptide-based nanofibrils allow to concentrate viral particles by low-speed centrifugation. Specific adaption and customization of self-assembling peptides might lead to novel nanofibrils with versatile biological functions, e. g., targeted retroviral gene transfer or drug delivery. (C) 2014 Wiley Periodicals, Inc.
C1 [Meier, Christoph; Weil, Tanja] Univ Ulm, Dept Organ Chem 3, D-89069 Ulm, Germany.
   [Kirchhoff, Frank; Muench, Jan] Univ Ulm, Med Ctr, Inst Mol Virol, D-89069 Ulm, Germany.
RP Munch, J (reprint author), Univ Ulm, Med Ctr, Inst Mol Virol, D-89069 Ulm, Germany.
EM jan.muench@uni-ulm.de
RI Meier, Christoph/G-2779-2012
OI Meier, Christoph/0000-0002-2974-1422
FU Volkswagen Foundation [Akz 86 366]; DFG
FX The authors acknowledge funding from the Volkswagen Foundation, grant
   number Akz 86 366, and the DFG to J.M.
CR Arnold F, 2012, J VIROL, V86, P1244, DOI 10.1128/JVI.06121-11
   Barquinero J, 2004, GENE THER, V11, pS3, DOI 10.1038/sj.gt.3302363
   Bechinger B, 2011, J PEPT SCI, V17, P88, DOI 10.1002/psc.1318
   Bhattacharya M, 2011, J PHYS CHEM B, V115, P4195, DOI 10.1021/jp111528c
   Biancalana M, 2009, J MOL BIOL, V385, P1052, DOI 10.1016/j.jmb.2008.11.006
   Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158
   Bromfield SM, 2013, CHEM SOC REV, V42, P9184, DOI 10.1039/c3cs60278h
   Capule CC, 2012, J AM CHEM SOC, V134, P905, DOI 10.1021/ja210931b
   Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242
   Castellano Laura M, 2012, Biology (Basel), V1, P58, DOI 10.3390/biology1010058
   Castelletto V, 2010, J PHYS CHEM B, V114, P8002, DOI 10.1021/jp102744g
   Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901
   Coffin JM, 1997, RETROVIRUSES INTERAC
   CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8
   Coroadinha AS, 2010, CURR GENE THER, V10, P456
   Davis HE, 2002, BIOPHYS CHEM, V97, P159, DOI 10.1016/S0301-4622(02)00057-1                                                   
   Davis HE, 2004, BIOPHYS J, V86, P1234, DOI 10.1016/S0006-3495(04)74197-1                                                   
   Dong H, 2007, J AM CHEM SOC, V129, P12468, DOI 10.1021/ja072536r
   Easterhoff D, 2011, BIOPHYS J, V100, P1325, DOI 10.1016/j.bpj.2011.01.037
   ELGHETANY MT, 1988, STAIN TECHNOL, V63, P201, DOI 10.3109/10520298809107185                                                       
   FALLER DV, 1984, J VIROL, V49, P269
   Fenard D, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.17
   Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003
   Ghatak P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016019
   Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876
   Hanenberg H, 1997, HUM GENE THER, V8, P2193, DOI 10.1089/hum.1997.8.18-2193                                                      
   Hartman K, 2013, PEERJ, V1, DOI 10.7717/peerj.5
   Hauber I, 2009, P NATL ACAD SCI USA, V106, P9033, DOI 10.1073/pnas.0811827106
   Hauser CAE, 2010, CHEM SOC REV, V39, P2780, DOI 10.1039/b921448h
   Heemskerk B, 2010, HUM GENE THER, V21, P1335, DOI 10.1089/hum.2009.208
   Hodgson CP, 1996, NAT BIOTECHNOL, V14, P339, DOI 10.1038/nbt0396-339
   INNES CL, 1990, J VIROL, V64, P957
   Kim KA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-55
   KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572                                           
   KONOPKA K, 1990, J GEN VIROL, V71, P2899, DOI 10.1099/0022-1317-71-12-2899
   Leydet A, 1996, J MED CHEM, V39, P1626, DOI 10.1021/jm950358j
   Leydet A, 1997, J MED CHEM, V40, P350, DOI 10.1021/jm960348y
   Leydet A, 1998, J MED CHEM, V41, P4927, DOI 10.1021/jm970661f
   Leydet A, 1997, J MED CHEM, V40, P342, DOI 10.1021/jm960493b                                                               
   LEYDET A, 1995, J MED CHEM, V38, P2433, DOI 10.1021/jm00013a019                                                             
   Leyva FJ, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-13
   Lin P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023891
   Maji SK, 2009, SCIENCE, V325, P328, DOI 10.1126/science.1173155
   Makin OS, 2005, FEBS J, V272, P5950, DOI 10.1111/j.1742-4658.2005.05025.x
   Malisauskas M, 2010, J MOL BIOL, V396, P60, DOI 10.1016/j.jmb.2009.11.012
   Segura MM, 2013, EXPERT OPIN BIOL TH, V13, P987, DOI 10.1517/14712598.2013.779249
   Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt.1216
   MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122                                                               
   Moritz T, 1996, BLOOD, V88, P855
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Munch J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-148
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Olsen JS, 2010, J BIOL CHEM, V285, P35488, DOI 10.1074/jbc.M110.163659
   PERKINS AS, 1983, MOL CELL BIOL, V3, P1123, DOI 10.1128/MCB.3.6.1123                                                            
   Pollok KE, 1999, CURR OPIN MOL THER, V1, P595
   Pollok KE, 1998, J VIROL, V72, P4882
   Quintas-Cardama A, 2007, HUM GENE THER, V18, P1253, DOI 10.1089/hum.2007.088
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2010, J BIOL CHEM, V285, P1861, DOI 10.1074/jbc.M109.066167
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   Schambach A, 2013, HUM GENE THER, V24, P132, DOI 10.1089/hum.2012.229
   Smith JF, 2006, P NATL ACAD SCI USA, V103, P15806, DOI 10.1073/pnas.0604035103
   TOYOSHIMA K, 1969, VIROLOGY, V38, P414, DOI 10.1016/0042-6822(69)90154-8                                                    
   VOGT PK, 1967, VIROLOGY, V33, P175, DOI 10.1016/0042-6822(67)90109-2
   Wurm M, 2011, BIOL CHEM, V392, P887, DOI 10.1515/BC.2011.085
   Wurm M, 2010, J GENE MED, V12, P137, DOI 10.1002/jgm.1429
   Yolamanova M, 2013, NAT NANOTECHNOL, V8, P130, DOI [10.1038/NNANO.2012.248, 10.1038/nnano.2012.248]
   Zhang LS, 2014, J PEPT SCI, V20, P46, DOI 10.1002/psc.2587
   Zhang XJ, 2006, ADV DRUG DELIVER REV, V58, P515, DOI 10.1016/j.addr.2006.03.006
   Zhou P, 2001, HUM GENE THER, V12, P1843, DOI 10.1089/104303401753153901
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 71
TC 10
Z9 10
U1 2
U2 36
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5116
EI 1939-0041
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD SEP-OCT
PY 2014
VL 6
IS 5
BP 438
EP 451
DI 10.1002/wnan.1275
PG 14
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA AN2CI
UT WOS:000340390600003
PM 24865496
DA 2018-01-05
ER

PT J
AU Dyawanapelly, S
   Ghodke, SB
   Vishwanathan, R
   Dandekar, P
   Jain, R
AF Dyawanapelly, Sathish
   Ghodke, Sharwari Bhagwat
   Vishwanathan, Ramya
   Dandekar, Prajakta
   Jain, Ratnesh
TI RNA Interference-Based Therapeutics: Molecular Platforms for Infectious
   Diseases
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Review
DE RNA Interference (RNAi); Nanoparticles; siRNA Delivery; Intracellular
   Infections; Gene Silencing; Viral Infections
ID RESPIRATORY SYNCYTIAL VIRUS; HEPATITIS-B-VIRUS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; LATENT TUBERCULOSIS INFECTION;
   INTRACELLULAR BACTERIAL PATHOGENS; PARASITE BRUGIA-MALAYI;
   QUANTIFERON-TB GOLD; MULTIDRUG-RESISTANT TUBERCULOSIS; FUNGUS
   CRYPTOCOCCUS-NEOFORMANS; EQUINE ENCEPHALITIS-VIRUS
AB The potential uses and therapeutic benefits of RNA interference (RNAi) are enormous. Recent insights into RNAi technologies have highlighted their role in analyzing the functions and regulation of gene expression in eukaryotes and further utilizing this information for identification and amelioration of many diseases. These studies have also established the role of RNAi mediated post-transcriptional gene silencing (PTGS) mechanism in mammals by several endogenous, gene regulation systems including small interfering RNAs (siRNA), micro RNA (miRNA) and small hairpin RNAs (shRNA). Moreover, these RNAi-based therapeutics have demonstrated the capability to silence therapeutically relevant genes in various in vivo models of cancer, infections autoimmune diseases and other genetic disorders. Over the past few decades, infectious diseases have been one of the leading causes of death around the world. Ubiquitously, intracellular obligate or facultative microorganisms cause serious or fatal infections and associated diseases in humans. Currently available literature suggests that infections caused by intracellular pathogens present an intriguing area, wherein RNAi technology may be effectively employed to neutralize the harmful effects of various intracellular pathogens. In this manuscript, we have emphasized on the challenges and opportunities involved in the therapy of such intracellular infections, especially employing RNAi-based interventions. We have focused our discussion on the current state-of-the-art RNAi-based therapies, which have been explored for various intracellular infections mediated by bacteria, fungi, viruses and protozoa. Nanocarrier mediated delivery of siRNA and shRNA molecules have also been found to overcome the various delivery challenges of these biotherapeutics; these have also been briefly summarized here. Furthermore, the outcomes and progresses that have been made in pre-clinical models and clinical trials have also been presented to review the numerous challenges encountered so far. Finally, we have also addressed the various future perspectives that could overcome these challenges and accelerate the progress and commercial success of these systems.
C1 [Dyawanapelly, Sathish; Dandekar, Prajakta] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay 400019, Maharashtra, India.
   [Ghodke, Sharwari Bhagwat; Vishwanathan, Ramya; Jain, Ratnesh] Inst Chem Technol, Dept Chem Engn, Bombay 400019, Maharashtra, India.
RP Dandekar, P (reprint author), Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay 400019, Maharashtra, India.
EM pd.jain@ictmumbai.edu.in; rd.jain@ictmumbai.edu.in
FU UGC; Ramalingaswami Grant,Department of Biotechnology; Ramanujan
   Fellowship; SERB; Department of Biotechnology
FX Mr. Sathish Dyawanapelly and Dr. Prajakta Dandekar would like to thank
   Department of Biotechnology for research grant and fellowship. Ms.
   Sharwari Ghodke is thankful to UGC for fellowship. Dr. Ratnesh Jain is
   thankful to Ramalingaswami Grant, Department of Biotechnology for
   fellowship and grant for the financial assistance. Dr. Prajakta Dandekar
   is thankful to Ramanujan Fellowship, SERB for the financial assistance.
   Authors acknowledge Kanumuri S. R. Raju for assistance in figure
   depiction.
CR Aboobaker AA, 2003, MOL BIOCHEM PARASIT, V129, P41, DOI 10.1016/S0166-6851(03)0092-6
   Agaisse H, 2005, SCIENCE, V309, P1248, DOI 10.1126/science.1116008
   Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494
   Akolo C, 2010, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000171.PUB3)
   Al-Attar S, 2011, BIOL CHEM, V392, P277, DOI 10.1515/BC.2011.042
   Alvar J., 2013, PLOS ONE, V7
   Anthony KG, 2009, ANTIVIR RES, V82, P166, DOI 10.1016/j.antiviral.2008.12.007
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   Atayde VD, 2013, MOL MICROBIOL, V87, P580, DOI 10.1111/mmi.12117
   Bai FW, 2005, J INFECT DIS, V191, P1148, DOI 10.1086/428507
   Baldwin TK, 2006, MOL PLANT MICROBE IN, V19, P1451, DOI 10.1094/MPMI-19-1451
   Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236
   Baum J, 2009, NUCLEIC ACIDS RES, V37, P3788, DOI 10.1093/nar/gkp239
   Bennasser Y, 2007, BIODRUGS, V21, P17, DOI 10.2165/00063030-200721010-00003
   Bermudez LE, 1996, INFECT IMMUN, V64, P1400
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110                                                                
   Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2
   Bhattacharyya S, 2008, SCAND J IMMUNOL, V67, P345, DOI 10.1111/j.1365-3083.2008.02076.x
   Bhavsar AP, 2007, NATURE, V449, P827, DOI 10.1038/nature06247
   Bhomia M, 2013, ANTIVIR RES, V100, P429, DOI 10.1016/j.antiviral.2013.08.010
   Billmyre RB, 2013, CHROMOSOME RES, V21, P561, DOI 10.1007/s10577-013-9388-2
   Biswas Swati, 2013, Pharmaceuticals (Basel), V6, P161, DOI 10.3390/ph6020161
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Blagbrough IS, 2009, PHARM RES-DORD, V26, P1, DOI 10.1007/s11095-008-9646-8
   Bliska JB, 2009, NAT REV MICROBIOL, V7, P165, DOI 10.1038/nrmicro2049
   Bohse ML, 2007, INFECT IMMUN, V75, P2811, DOI 10.1128/IAI.00304-07
   Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0
   Bonecini-Almeida MG, 2004, INFECT IMMUN, V72, P2628, DOI 10.1128/IAI.72.5.2628-2634.2004
   Braasch DA, 2004, BIOORG MED CHEM LETT, V14, P1139, DOI 10.1016/j.bmcl.2003.12.074
   Brackney DE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000502
   Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999                                                         
   Bua A, 2007, NEW MICROBIOL, V30, P477
   Bunnell BA, 1998, CLIN MICROBIOL REV, V11, P42
   Burnett JC, 2011, BIOTECHNOL J, V6, P1130, DOI 10.1002/biot.201100054
   Caplen NJ, 2004, GENE THER, V11, P1241, DOI 10.1038/sj.gt.3302324
   Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196                                                     
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Celum C, 2004, B WORLD HEALTH ORGAN, V82, P447
   Chandra PK, 2012, MOL THER, V20, P1724, DOI 10.1038/mt.2012.107
   Chang JH, 2008, J VIROL, V82, P8215, DOI 10.1128/JVI.02575-07
   Chang LJ, 2005, GENE THER, V12, P1133, DOI 10.1038/sj.gt.3302509
   Chang SS, 2012, ANNU REV MICROBIOL, V66, P305, DOI 10.1146/annurev-micro-092611-150138
   Chen Y, 2008, PHARM RES, V25, P72, DOI 10.1007/s11095-007-9504-0
   Cherry S, 2009, CURR OPIN MICROBIOL, V12, P446, DOI 10.1016/j.mib.2009.06.002
   Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193
   Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002
   Horsburgh C. R., 2000, MMWR-MORBID MORTAL W, V49, P1
   Connell TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002624
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124                                                         
   COUVREUR P, 1991, PHARMACEUT RES, V8, P1079, DOI 10.1023/A:1015885814417
   Kadri D., 2012, AM J BIOMED SCI, V4, P1
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Dang YK, 2011, EUKARYOT CELL, V10, P1148, DOI 10.1128/EC.05109-11
   Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677
   Dave RS, 2003, REV MED VIROL, V13, P373, DOI 10.1002/rmv.407
   David S, 2010, PHARMACOL RES, V62, P100, DOI 10.1016/j.phrs.2009.11.013
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Deas TS, 2005, J VIROL, V79, P4599, DOI 10.1128/JVI.79.8.4599-4609.2005
   Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984
   Demento SL, 2010, J IMMUNOL, V185, P2989, DOI 10.4049/jimmunol.1000768
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   DeVincenzo J, 2008, ANTIVIR RES, V77, P225, DOI 10.1016/j.antiviral.2007.11.009
   DeVincenzo J, 2010, P NATL ACAD SCI USA, V107, P8800, DOI 10.1073/pnas.0912186107
   Dhiman R, 2007, BBA-GEN SUBJECTS, V1770, P649, DOI 10.1016/j.bbagen.2006.11.016
   Diamond Michael S, 2005, Expert Rev Anti Infect Ther, V3, P931, DOI 10.1586/14787210.3.6.931
   Dimitrova M, 2008, P NATL ACAD SCI USA, V105, P16320, DOI 10.1073/pnas.0800156105
   DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257
   Dresselhaus M. S., 1996, SCI FULLERENES CARBO
   Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606
   Eisenreich W, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00024
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301                                                              
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elmen J, 2005, NUCLEIC ACIDS RES, V33, P439, DOI 10.1093/nar/gki193
   Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000                                                   
   Feldmesser M, 2000, INFECT IMMUN, V68, P4225, DOI 10.1128/IAI.68.7.4225-4237.2000
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fridkin SK, 1996, CLIN MICROBIOL REV, V9, P499
   Fumoto S, 2003, PHARMACEUT RES, V20, P1452, DOI 10.1023/A:1025766429175
   GAILLARD JL, 1987, INFECT IMMUN, V55, P2822
   Gao K, 2009, MOL PHARMACEUT, V6, P651, DOI 10.1021/mp800134q
   Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021
   Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101
   Ge Q, 2003, P NATL ACAD SCI USA, V100, P2718, DOI 10.1073/pnas.0437841100
   George N. B. R., 2012, J BIOTECHNOL BIOMATE, V2, P1
   Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241
   Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2
   Ginn SL, 2013, J GENE MED, V15, P65, DOI 10.1002/jgm.2698
   Gish RG, 2011, ANTIVIR THER, V16, P547, DOI 10.3851/IMP1798
   Gitlin L, 2005, J VIROL, V79, P1027, DOI 10.1128/JVI.79.2.1027-1035.2005
   Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026                                            
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Greub G, 2012, FEMS IMMUNOL MED MIC, V64, P1, DOI 10.1111/j.1574-695X.2011.00915.x
   Guo PX, 2005, J NANOSCI NANOTECHNO, V5, P1964, DOI 10.1166/jnn.2005.446
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Ha Tai-You, 2011, Immune Netw, V11, P135, DOI 10.4110/in.2011.11.3.135
   Haasnoot J, 2011, METHODS MOL BIOL, V721, P23, DOI 10.1007/978-1-61779-037-9_2
   Hadinoto K, 2013, EUR J PHARM BIOPHARM, V85, P427, DOI 10.1016/j.ejpb.2013.07.002
   Haile Y, 2002, FEMS IMMUNOL MED MIC, V33, P125, DOI 10.1016/S0928-8244(02)00302-4
   Haller AA, 2003, J GEN VIROL, V84, P2153, DOI 10.1099/vir.0.19079-0
   Hamasaki K, 2003, FEBS LETT, V543, P51, DOI 10.1016/S0014-5793(03)00400-9
   Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Harapan H, 2013, TUBERCULOSIS, V93, P596, DOI 10.1016/j.tube.2013.08.004
   Hatsukami DK, 2008, LANCET, V372, P1217, DOI 10.1016/S0140-6736(08)61510-X                                                   
   Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324                                                       
   Horsburgh CR, 2011, NEW ENGL J MED, V364, P1441, DOI 10.1056/NEJMcp1005750
   Hossain MJ, 2010, GENE, V468, P48, DOI 10.1016/j.gene.2010.08.004
   Hu J, 2012, PROTEIN CELL, V3, P364, DOI 10.1007/s13238-012-2036-3
   Hydbring Per, 2013, F1000Res, V2, P136, DOI 10.12688/f1000research.2-136.v2
   Idnurm A, 2005, NAT REV MICROBIOL, V3, P753, DOI 10.1038/nrmicro1245
   Islam MA, 2014, J BIOMED NANOTECHNOL, V10, P67, DOI 10.1166/jbn.2014.1682
   Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706
   Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Janbon G, 2010, FUNGAL GENET BIOL, V47, P1070, DOI 10.1016/j.fgb.2010.10.005
   Jenner RG, 2005, NAT REV MICROBIOL, V3, P281, DOI 10.1038/nrmicro1126
   Jones JL, 2001, AM J EPIDEMIOL, V154, P357, DOI 10.1093/aje/154.4.357
   Jopling CL, 2010, VIRUSES-BASEL, V2, P1382, DOI 10.3390/v2071382
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Kapadia SB, 2003, P NATL ACAD SCI USA, V100, P2014, DOI 10.1073/pnas.252783999
   KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021
   Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324                                                                   
   Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Khatri NI, 2012, CRIT REV THER DRUG, V29, P487, DOI 10.1615/CritRevTherDrugCarrierSyst.v29.i6.20                                    
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955                                              
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Kitabwalla M, 2002, NEW ENGL J MED, V347, P1364, DOI 10.1056/NEJMcibr022294
   Klein C, 2003, GASTROENTEROLOGY, V125, P9, DOI 10.1016/S0016-5085(03)00720-0
   Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8
   Kolev NG, 2011, EUKARYOT CELL, V10, P1156, DOI 10.1128/EC.05114-11
   Korrapati AB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001735
   Kozak K, 2013, NUCLEIC ACID THER, V23, P71, DOI 10.1089/nat.2012.0387
   Krishnan MN, 2008, NATURE, V455, P242, DOI 10.1038/nature07207
   Kuck U, 2010, APPL MICROBIOL BIOT, V86, P51, DOI 10.1007/s00253-009-2416-7
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kundu AK, 2012, EUR J PHARM BIOPHARM, V80, P257, DOI 10.1016/j.ejpb.2011.10.023
   Lai Ching-Juh, 2003, Adv Virus Res, V61, P469, DOI 10.1016/S0065-3527(03)61013-4
   Lam JKW, 2012, ADV DRUG DELIVER REV, V64, P1, DOI 10.1016/j.addr.2011.02.006
   Lamkanfi M, 2010, CELL HOST MICROBE, V8, P44, DOI 10.1016/j.chom.2010.06.007
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784
   Lee JM, 2013, BIOMED RES INT, DOI 10.1155/2013/782041
   Lee SK, 2005, BLOOD, V106, P818, DOI 10.1182/blood-2004-10-3959
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Leonard JN, 2005, J VIROL, V79, P1645, DOI 10.1128/JVI.79.3.1645-1654.2005
   Li CX, 2006, CELL CYCLE, V5, P2103, DOI 10.4161/cc.5.18.3192
   Lighter J, 2009, PEDIATRICS, V123, P30, DOI 10.1542/peds.2007-3618
   Liu H, 2002, GENETICS, V160, P463
   Liu YY, 2008, ACTA PHARMACOL SIN, V29, P975, DOI 10.1111/j.1745-7254.2008.00828.x
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Lopez-Fraga M., 2008, Infectious Disorders - Drug Targets, V8, P262
   Ludwig LB, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-80
   Mahato RI, 1997, PHARMACEUT RES, V14, P853, DOI 10.1023/A:1012187414126                                                         
   Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x
   Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1
   Marion CL, 2006, MOL MICROBIOL, V62, P970, DOI 10.1111/j.1365-2958.2006.05436.x
   Markoff L, 2003, ADV VIRUS RES, V59, P177, DOI 10.1016/S0065-3527(03)59006-6
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824
   McKerrow JH, 2008, CURR OPIN INFECT DIS, V21, P668, DOI 10.1097/QCO.0b013e328315cca9
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   McMillan N. A. I., 2013, NANOTECHNOLOGY DELIV, V4, P193
   McRobert L, 2002, MOL BIOCHEM PARASIT, V119, P273, DOI 10.1016/S0166-6851(01)00429-7
   MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125
   Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006
   Militello KT, 2008, MOL BIOCHEM PARASIT, V157, P117, DOI 10.1016/j.molbiopara.2007.10.004
   Mohmmed A, 2003, BIOCHEM BIOPH RES CO, V309, P506, DOI 10.1016/j.bbrc.2003.08.027
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Moser LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068129
   Mouyna I, 2004, FEMS MICROBIOL LETT, V237, P317, DOI 10.1016/j.femsle.2004.06.048
   Murakami Y, 2009, J HEPATOL, V50, P453, DOI 10.1016/j.jhep.2008.06.010
   Muttil P, 2009, PHARM RES-DORD, V26, P2401, DOI 10.1007/s11095-009-9957-4
   Nakase I, 2013, MOL BIOSYST, V9, P855, DOI 10.1039/c2mb25467k
   Nakayashiki H, 2005, FUNGAL GENET BIOL, V42, P275, DOI 10.1016/j.fgb.2005.01.002
   Nakayashiki H, 2008, CURR OPIN MICROBIOL, V11, P494, DOI 10.1016/j.mib.2008.10.001
   Nalwa H. S., 2004, ENCY NANOSCIENCE NAN, V1-10
   Nalwa H. S., 2001, NANOSTRUCTURED MAT N, V1-5
   Nelson CE, 2013, ADV WOUND CARE, V2, P93, DOI 10.1089/wound.2011.0327
   Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687                                                        
   Nicolas FE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003089
   Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   O'Brien L, 2007, ANTIVIR RES, V75, P20, DOI 10.1016/j.antiviral.2006.11.007
   OH YK, 1995, ANTIMICROB AGENTS CH, V39, P2104, DOI 10.1128/AAC.39.9.2104                                                           
   Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018
   Ohashi N., 2013, Medical Entomology and Zoology, V64, P9
   Olobo JO, 2001, SCAND J IMMUNOL, V53, P85, DOI 10.1046/j.1365-3083.2001.00844.x
   Omsland A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003540
   Ong SP, 2008, VIRUS RES, V135, P292, DOI 10.1016/j.virusres.2008.04.014
   Ong SP, 2006, ANTIVIR RES, V72, P216, DOI 10.1016/j.antiviral.2006.06.005
   OTTENHOFF THM, 1995, EUR J CLIN INVEST, V25, P371, DOI 10.1111/j.1365-2362.1995.tb01716.x
   Pai M, 2008, ANN INTERN MED, V149, P177, DOI 10.7326/0003-4819-149-3-200808050-00241
   Pai SI, 2006, GENE THER, V13, P464, DOI 10.1038/sj.gt.3302694
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Park WS, 2003, GENE THER, V10, P2046, DOI 10.1038/sj.gt.3302099
   Park WS, 2002, NUCLEIC ACIDS RES, V30, P4830, DOI 10.1093/nar/gkf627
   Peer D, 2011, GENE THER, V18, P1127, DOI 10.1038/gt.2011.56
   Peng JL, 2005, J GEN VIROL, V86, P3227, DOI 10.1099/vir.0.81171-0
   Perrimon N, 2007, GENETICS, V175, P7, DOI 10.1534/genetics.106.069963
   Pittella F., 2013, RNA INTERFERENCE BIO, P161
   Pushparaj PN, 2008, J DENT RES, V87, P992, DOI 10.1177/154405910808701109                                                      
   Qin QM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002078
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Rappleye CA, 2004, MOL MICROBIOL, V53, P153, DOI 10.1111/j.1365-2958.2004.04131.x
   Remington JS, 2004, J CLIN MICROBIOL, V42, P941, DOI 10.1125/JCM.42.3.941-945.2004
   Richman DD, 2011, CURR OPIN HIV AIDS, V6, P1, DOI 10.1097/COH.0b013e328340ffa6
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11
   Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3
   Rohan D., 2008, BIOCH BIOPHYS ACTA G, V1780, P733
   Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255
   ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x
   Rosas-Taraco AG, 2011, TUBERCULOSIS, V91, P98, DOI 10.1016/j.tube.2010.11.004
   Rosas-Taraco AG, 2009, AM J RESP CELL MOL, V41, P136, DOI 10.1165/rcmb.2008-0363OC
   Rous P, 1916, J EXP MED, V23, P601, DOI 10.1084/jem.23.5.601
   Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356
   SABIN AB, 1960, JAMA-J AM MED ASSOC, V173, P1521, DOI 10.1001/jama.1960.03020320001001                                                
   Saini NK, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-200
   Salame TM, 2011, APPL MICROBIOL BIOT, V89, P501, DOI 10.1007/s00253-010-2928-1
   Saleh MC, 2004, VIRUS RES, V102, P11, DOI 10.1016/j.virusres.2004.01.010
   Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68
   Semenova E, 2011, P NATL ACAD SCI USA, V108, P10098, DOI 10.1073/pnas.1104144108
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Senaratne RH, 2008, J MED MICROBIOL, V57, P164, DOI 10.1099/jmm.0.47454-0
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   Nochur S., 2013, RNA INTERFERENCE BIO, P315
   Badea I., 2014, REV NANOSCI NANOTECH, V2, P275
   Singh M, 2012, J BIOTECHNOL, V157, P351, DOI 10.1016/j.jbiotec.2011.12.003
   Singh M, 2009, PARASITOL RES, V104, P753, DOI 10.1007/s00436-008-1251-6
   Singh P. K., 2013, GENE, V6, P7
   Singh PK, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-14
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   Song CZ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001239
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Sriwilaijaroen N, 2009, BIOCHEM BIOPH RES CO, V381, P144, DOI 10.1016/j.bbrc.2009.01.165
   Stein DA, 2011, J VIROL, V85, P10154, DOI 10.1128/JVI.05298-11
   Stevenson M, 2004, NEW ENGL J MED, V351, P1772, DOI 10.1056/NEJMra045004
   Subramanya S, 2010, J VIROL, V84, P2490, DOI 10.1128/JVI.02105-08
   Sudhakar N. R., 2013, Advances in Animal and Veterinary Sciences, V1, P1
   Suhy DA, 2012, MOL THER, V20, P1737, DOI 10.1038/mt.2012.119
   Sultana H, 2009, J IMMUNOL, V183, P650, DOI 10.4049/jimmunol.0900093
   Sun Y, 2007, INT J MOL MED, V19, P705
   Sunil S, 2008, BIOCHEM BIOPH RES CO, V372, P373, DOI 10.1016/j.bbrc.2008.05.033
   Sweeney KR, 2010, EUKARYOT CELL, V9, P1680, DOI 10.1128/EC.00079-10
   ter Brake Olivier, 2005, J RNAi Gene Silencing, V1, P56
   ter Brake O, 2006, MOL THER, V14, P883, DOI 10.1016/j.ymthe.2006.07.007
   Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Thomas M, 2007, ADV DRUG DELIVER REV, V59, P124, DOI 10.1016/j.addr.2007.03.003
   Thompson J. D., 2013, DRUG DISCOV IN PRESS
   Tiemann K, 2009, EMBO MOL MED, V1, P142, DOI 10.1002/emmm.200900023
   TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597
   Tiram G, 2014, J BIOMED NANOTECHNOL, V10, P50, DOI 10.1166/jbn.2014.1715
   Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101
   Tuteja Renu, 2010, Commun Integr Biol, V3, P611, DOI 10.4161/cib.3.6.13396
   Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x
   Unwalla HJ, 2006, J VIROL, V80, P1863, DOI 10.1128/JVI.80.4.1863-1873.2006
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Wang XY, 2010, GENE DEV, V24, P2566, DOI 10.1101/gad.1970910
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wong JP, 2003, J CONTROL RELEASE, V92, P265, DOI 10.1016/S0168-3659(03)00358-4
   Wooddell CI, 2013, MOL THER, V21, P973, DOI 10.1038/mt.2013.31
   Wu H, 2003, CANCER RES, V63, P1515
   Xie FY, 2006, DRUG DISCOV TODAY, V11, P67, DOI 10.1016/S1359-6446(05)03668-8
   Xu GX, 2013, TUBERCULOSIS, V93, P606, DOI 10.1016/j.tube.2013.08.006
   Xue XY, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-47
   Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599
   Yang XA, 2010, HEPATOLOGY, V52, P1877, DOI 10.1002/hep.23908
   Yezhelyev MV, 2008, J AM CHEM SOC, V130, P9006, DOI 10.1021/ja800086u
   Ying RS, 2007, ANTIVIR RES, V73, P24, DOI 10.1016/j.antiviral.2006.05.022
   Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840
   Young DD, 2010, J AM CHEM SOC, V132, P7976, DOI 10.1021/ja910275u
   Yowe D, 2001, MICROBES INFECT, V3, P813, DOI 10.1016/S1286-4579(01)01439-3
   Yu L, 2009, PARASITOL RES, V104, P377, DOI 10.1007/s00436-008-1208-9
   YUE JY, 2010, CHINESE J VIROL, V26, P373
   Zager EM, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-10
   Zamora MR, 2011, AM J RESP CRIT CARE, V183, P531, DOI 10.1164/rccm.201003-0422OC
   Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746
   Zangger H, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002006
   Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654.5666.2002
   Zhang MZ, 2012, J NANOSCI NANOTECHNO, V12, P9029, DOI 10.1166/jnn.2012.6783
   Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016
   ZHANG W, 2004, GENET VACCINES THER, V2, P8
   Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174
   Zhe C., 2005, J ZHEJIANG U SC B, V6, P236
   Zucca Mario, 2011, Open Med Chem J, V5, P4, DOI 10.2174/1874104501105010004
   Raker J., 2006, U.S. Patent, Patent No. [7,078,399 B2, 7078399]
   Michaelis A. F., 2002, U.S. Patent, Patent No. [2004/14750 A1, 200414750]
NR 304
TC 10
Z9 12
U1 6
U2 58
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD SEP
PY 2014
VL 10
IS 9
SI SI
BP 1998
EP 2037
DI 10.1166/jbn.2014.1929
PG 40
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA AL9AC
UT WOS:000339430600015
PM 25992447
DA 2018-01-05
ER

PT J
AU Nishimura, Y
   Ishii, J
   Ogino, C
   Kondo, A
AF Nishimura, Yuya
   Ishii, Jun
   Ogino, Chiaki
   Kondo, Akihiko
TI Genetic Engineering of Bio-Nanoparticles for Drug Delivery: A Review
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Review
DE Genetic Engineering; Nanoparticles; Drug Delivery; Virus-Like Particles;
   Inorganic Nanoparticles
ID SACCHAROMYCES-CEREVISIAE; SIRNA DELIVERY; LIPOSOMES; CELLS
AB Techniques using nanotechnology in the detection and treatment of cancers have made great progress in multidisciplinary fields. The advances in drug delivery systems (DDSs) have been supported mainly by the development of varied nanoparticles (NPs). Although the NPs based on organic and inorganic materials are integral parts in DDSs, bio-nanoparticles containing biopolymer and virus-like particles (VLPs) are attractive biomaterials for DDSs because of their unique features originating in bio-based materials, such as biocompatibility, biodegradability and low immunogenicity. It is notable that these NPs additionally have a great advantage to enable the easy and flexible alteration of their features by genetic engineering approaches. Controlling the sequence and oligomeric process of polypeptide genes permits a variety of choices in type or size of biopolymeric NPs (e.g., elastin-like polypeptide NPs). In contrast, the functional genes are often inserted into the coding sequences for self-assembled proteins to give the VLPs (e.g., hemagglutinating virus of Japan, adeno-associated virus, human immunodeficiency virus-1, simian virus 40 and hepatitis B virus) additional functions. Thus, genetic engineering readily allow alterations of the properties of NPs (e.g., particle shape, size and stability) and grant of new abilities (e.g., cell-specificity and drug loading and release). In this review, we introduce recent advances in bio-nanoparticles from the standpoint of engineering.
C1 [Nishimura, Yuya; Ishii, Jun] Kobe Univ, Org Adv Sci & Technol, Nada Ku, Kobe, Hyogo 6578501, Japan.
   [Ogino, Chiaki; Kondo, Akihiko] Kobe Univ, Grad Sch Engn, Dept Chem Sci & Engn, Nada Ku, Kobe, Hyogo 6578501, Japan.
RP Kondo, A (reprint author), Kobe Univ, Grad Sch Engn, Dept Chem Sci & Engn, Nada Ku, 1-1 Rokkodai, Kobe, Hyogo 6578501, Japan.
EM akondo@kobe-u.ac.jp
RI Kondo, Akihiko/A-2130-2015; Totsukawa, Nobuhisa/D-2028-2017; Ishii,
   Jun/D-7670-2016; Ogino, Chiaki/G-9932-2014
OI Ishii, Jun/0000-0003-2568-515X; Ogino, Chiaki/0000-0002-8906-7724
FU Ministry of Education, Culture, Sports and Technology (MEXT); Ministry
   of Health, Labor and Welfare, Japan
FX The writing of this review was supported in part by a Special
   Coordination Fund for Promoting Science and Technology, Creation of
   Innovative Centers for Advanced Interdisciplinary Research Areas
   (Innovative Bioproduction Kobe) from the Ministry of Education, Culture,
   Sports and Technology (MEXT), and Science Research Grants from the
   Ministry of Health, Labor and Welfare, Japan.
CR Mcleland C. B., 2009, ADV DRUG DELIV REV, V61, P6
   Alexis F., 2008, MOL PHARM, V5, P4
   Alkhatib G., 1996, SCIENCE, V272, P5270
   Allen T. M., 2004, SCIENCE, V303, P5665
   Allen T. M., 1991, BIOCHIM BIOPHYS ACTA, V1068, P2
   Al-Taei S., 2006, BIOCONJUGATE CHEM, V17, P1
   Stoddart J. F., 2011, ACCOUNTS CHEM RES, V44, P10
   Apostolov K., 1972, J GEN VIROL, V15, P3
   Liao J. C., 2008, METAB ENG, V10, P6
   Barreto J. A., 2011, ADV MATER, V23, P12
   Beckett D., 1999, PROTEIN SCI, V8, P4
   Berns K. I., 1996, CURR TOP MICROBIOL I, V218
   Berns K. I., 1988, BIOCHIM BIOPHYS ACTA, V951, P2
   Nassal M., 2000, FEBS LETT, V481, P2
   Bikard David, 2013, F1000Prime Rep, V5, P47, DOI 10.12703/P5-47
   Birnbaum F., 1990, J VIROL, V64, P7
   Haggerty S., 1992, P NATL ACAD SCI USA, V89, P14
   Haggerty S., 1993, NATURE, V365, P6447
   Shuin T., 1992, CANCER RES, V52, P8
   Cai W, 2008, NANOTECHNOL SCI APPL, V1, P11
   Callahan D. J., 2012, NANO LETT, V12, P4
   Ferrari F., 1990, BIOTECHNOL PROGR, V6, P3
   Al-Rubeai M., 2004, EXPERT OPIN BIOL TH, V4, P11
   Champion J. A., 2009, PHARM RES, V26, P1
   Chang D., 1997, J GEN VIROL, V78, P6
   Cronan Jr J. E., 1999, J NUTR, V129, P2
   Console S., 2003, J BIOL CHEM, V278, P37
   Conway J. F., 1998, J MOL BIOL, V279, P5
   Cooper A., 2005, BIOCHEM BIOPH RES CO, V327, P4
   Cooper A., 2006, J BIOL CHEM, V281, P24
   Creel H. S., 1991, MACROMOLECULES, V24, P5
   Weiss R. A., 1984, NATURE, V312, P5996
   Hearn M. T., 2005, J MOL RECOGNIT, V18, P2
   Davis M. E., 2008, NAT REV DRUG DISCOV, V7, P9
   Dear J. W., 2005, KIDNEY INT, V67, P6
   Pasqualini R., 2009, PHARM RES, V26, P1
   De Meyer S., 1997, J VIRAL HEPATITUS, V4, P3
   Derossi D., 1994, J BIOL CHEM, V269, P14
   Feng L., 2012, APPL MICROBIOL BIOT, V94, P4
   Duchardt F., 2007, TRAFFIC, V8, P7
   Dudu V, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-9
   Khlebtsov N., 2012, CHEM SOC REV, V41, P6
   Hasegawa M., 2001, J BIOL CHEM, V276, P28
   Escors D., 2010, ARCH IMMUNOL THER EX, V58, P2
   Frye C. C., 2013, J BIOTECHNOL, V168, P4, DOI DOI 10.1016/J.JBI0TEC.2013.08.021
   Fang J., 2011, ADV DRUG DELIV REV, V63, P3
   Farokhzad O. C., 2009, ACS NANO, V3, P1
   Stevens R. C., 2014, NATURE, V506, P7487
   Kennedy P. E., 1996, SCIENCE, V272, P5263
   Parkin D. M., 2010, INT J CANCER, V127, P12, DOI DOI 10.1002/IJC.25516
   Zeitlin P. L., 1994, AM J RESP CELL MOL B, V11, P5
   Flotte T. R., 1995, GENE THER, V2, P6
   Forstova J., 1993, J VIROL, V67, P3
   Storm G., 2007, BIOCHEM J, V403, P2
   Froelich S., 2009, BIOTECHNOL BIOENG, V104, P1
   Fujishima A., 1972, NATURE, V238, P5358
   Eguchi A., 2006, BIOL PHARM BULL, V29, P8
   Fukushima Y., 1998, BIOPOLYMERS, V45, P4
   Futaki S., 2007, BIOCHEM SOC T, V35, P4
   Nakamura T., 2005, J GENE MED, V7, P11
   Futaki S., 2001, J BIOL CHEM, V276, P8
   Gaj T., 2013, TRENDS BIOTECHNOL, V31, P7
   Discher D. E., 2007, NAT NANOTECHNOL, V2, P4
   Giraud C., 1995, J VIROL, V69, P11
   Goncalves C., 2010, COLLOID SURFACE B, V75, P2
   De Meutter J., 1991, EUR J BIOCHEM, V195, P2
   Madden V. J., 2008, P NATL ACAD SCI USA, V105, P33
   Gratz S. J., 2013, FLY AUSTIN, V7, P4
   Flannery J. G., 2007, INVEST OPHTH VIS SCI, V48, P4
   Hagihara Y., 2000, GENE THER, V7, P9
   Kinnaird A. I., 2010, CELL BIOL TOXICOL, V26, P1
   Hasunuma T., 2013, BIORESOURCE TECHNOL, V135
   Hasunuma T, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-2
   Hatakeyama H., 2007, GENE THER, V14, P1
   Hauswirth W. W., 1977, VIROLOGY, V78, P2
   Sakai N., 2001, GENE THER, V8, P15
   He Q., 2011, J MATER CHEM, V21, P16
   Heermann K. H., 1984, J VIROL, V52, P2
   Tawashi R., 1996, PHARM RES, V13, P9
   Heldin C. H., 2004, NAT REV CANCER, V4, P10
   Heo D. N., 2012, BIOMATERIALS, V33, P3
   Hobbs S. K., 1998, P NATL ACAD SCI USA, V95, P8
   Hoff C. M., 2006, PERITON DIALYSIS INT, V26, P5
   Hu K. W., 2009, J AM CHEM SOC, V131, P40
   Lin J., 2011, BIOMATERIALS, V32, P36
   Kim D. S., 2010, J CELL BIOCHEM, V109, P2
   Imai T., 2008, J BIOTECHNOL, V134, P1
   Tanino T., 2009, J BIOCH, V145, P6
   Kondo A., 2012, PLOS ONE, V7, P5
   Kondo A., 2010, FEBS J, V277, P9
   Kondo A., 2013, APPL MICROBIOL BIOT, V97, P6
   Kondo A., 2014, FEMS YEAST IN PRESS, P10
   Ishizu K. I., 2001, J VIROL, V75, P1
   Jabir N. R., 2012, INT J NANOMED, V2012, P7
   Jabr-Milane L. S., 2008, CANC TREAT REV, V34, P7
   Jeffries T. W., 2006, CURR OPIN BIOTECH, V17, P3
   Jendeberg L., 1995, J MOL RECOGNIT, V8, P4
   Jones I. M., 1998, REV MED VIROL, V8, P2
   Josef E., 2013, ACTA BIOMATER, V9, P11
   Govindwar S. P., 2013, APPL BIOCHEM BIOTECH, V169, P5
   Stamp D., 1975, BIOCHEM BIOPH RES CO, V63, P3
   Jung J., 2008, J CONTROL RELEASE, V126, P3
   Kaneda Y., 2002, MOL THER, V6, P2
   Kaneda Y., 1999, MOL MED TODAY, V5, P7
   Kaneda Y., 1987, EXP CELL RES, V173, P1
   Banzai T., 2008, COLLOID SURFACE B, V64, P1
   Yoshimoto N., 2009, METHOD ENZYMOL, V464
   Nagasaki Y., 2001, ADV DRUG DELIV REV, V47, P1
   Okada Y., 1991, J BIOL CHEM, V266, P6
   Kievit F. M., 2011, ADV MATER, V23, P36
   Tullman-Ercek D., 2013, CURR OPIN BIOTECH, V24, P4
   Kim J., 2008, ANGEW CHEM INT EDIT, V47, P44
   Gottesman M. M., 2002, HUM GENE THER, V13, P2
   Sandalon Z., 2003, HUM GENE THER, V14, P2
   Kimchi-Sarfaty C., 2004, CURR PHARM BIOTECHNO, V5, P5
   Drummond D. C., 2006, CANCER RES, V66, P13
   Kittleson J. T., 2012, CURR OPIN CHEM BIOL, V16, P3
   Klibanov A. L., 1990, FEBS LETT, V268, P1
   Kondo A., 2013, J BIOTECHNOL, V163, P2
   Ishii J., 2012, J BIOTECHNOL, V159, P1
   Naylor S., 2008, GENE THER, V15, P19
   Nassal M., 1999, P NATL ACAD SCI USA, V96, P5
   Kubota Y., 1994, BRIT J CANCER, V70, P6
   Akashi M., 2005, J CONTROL RELEASE, V105, P3
   Kurata N., 2008, J BIOCH, V144, P6
   Kuroda S., 1992, J BIOL CHEM, V267, P3
   Kuroyanagi M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-786
   Lucas R. W., 2001, J GEN VIROL, V82, P9
   Ryadnov M. G., 2011, MACROMOL BIOSCI, V11, P4
   Lamb RA, 2001, FUNDAMENTAL VIROLOGY
   Littman D. R., 1988, NATURE, V334, P6178
   Schuler D., 2007, MACROMOL BIOSCI, V7, P2
   DeGrado W. F., 1987, J BIOL CHEM, V262, P14
   Lee Y, 2011, J CONTROL RELEASE, V155, P3, DOI 10.1016/j.jconrel.2010.09.009
   Tana W. S., 2008, J VIROL METHODS, V151, P2
   Carlesso N., 2000, NAT BIOTECHNOL, V18, P4
   Li T. C., 2003, VIROLOGY, V311, P1
   Liddington R. C., 1991, NATURE, V354, P6351
   Stewart Jr C. N., 2013, NAT REV GENET, P14
   Liu Y., 2012, THER DELIV, V3, P2
   Longmire M., 2008, NANOMEDICINE-UK, V3
   Lusby E., 1980, J VIROL, V34, P2
   Chilkoti A., 2012, NANO LETT, V12, P6
   Madani S. Y., 2011, INT J NANOMED, V2011, P6
   Mahapatro A, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-55
   Tanaka Y., 2003, NATURE, V421, P6921
   Malam Y., 2009, TRENDS PHARMACOL SCI, V30, P11
   Pachecka J., 2010, ONCOL LETT, V1, P1
   Matsuda F, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-119
   Matsui K, 2010, MEDCHEMCOMM, V1, P209, DOI 10.1039/c0md00027b
   McMillan R. A., 1999, MACROMOLECULES, V32, P26
   Urry D. W., 1996, PROTEIN EXPRES PURIF, V7, P1
   Nel A. E., 2010, ACS NANO, V4, P8
   Meyer D. E., 2002, BIOMACROMOLECULES, V3, P2
   Bushman F. D., 1997, J VIROL, V71, P7
   O'Connor K. E., 2013, BIOTECHNOL BIOENG, V110, P7
   Montross L., 1991, J VIROL, V65, P9
   Muzyczka N., 1992, CURR TOP MICROBIOL I, V158
   Nakamura T., 2012, ACCOUNTS CHEM RES, V45, P7
   Nakamura Y., 2013, PLOS ONE, V8, P6
   Nakanishi M., 2012, CURR GENE THER, V12, P5
   Negishi M., 2007, BIOCHEMISTRY-US, V46, P2
   Naldini L., 1996, SCIENCE, V272, P5259
   Neurath A. R., 1988, ADV VIRUS RES, P34
   Parker K., 1986, CELL, V46, P3
   Nilsson B., 1987, PROTEIN ENG, V1, P2
   Shimizu N., 2012, ULTRASON SONOCHEM, V19, P3
   Ninomiya K., 2014, ULTRASON SONOCHEM, V21, P1
   Nishimura Y., 2014, J NANOBIOTECHNOLOGY
   Kondo A., 2012, J DRUG TARGET, V20, P10
   Mohamed Suffian I. F., 2013, J BIOCH, V153, P3
   Nishimura Y, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-19
   Numata K., 2013, INT J MOL SCI, V14, P1
   Nygren P. A., 2008, FEBS J, V275, P11
   Shimizu N., 2008, J HAZARD MATER, V153, P1
   Ogino C., 2007, J BIOENG BIOSCI, V104, P4
   Ogino C., 2010, BIOORG MED CHEM LETT, V20, P17
   Okada Y., 1993, METHOD ENZYMOL, P221
   Oliveira H., 2013, J CONTROL RELEASE, V169, P3
   Orlova A., 2007, CANCER RES, V67, P5
   Osborne J. L., 2008, ACTA BIOMATER, V4
   Chao P. C., 1999, J GEN VIROL, V80, P1
   Labhasetwar V., 2003, ADV DRUG DELIV REV, V55, P3
   Chang M. S., 2012, PLOS ONE, V7, P4
   Pedroso S., 2006, COMB CHEM HIGH T SCR, V9, P5
   Peer D., 2007, NAT NANOTECHNOL, V2, P12
   Pluta K., 2009, ACTA BIOCHIM POL, V56, P4
   Podsakoff G., 1994, J VIROL, V68, P9
   Pontisso P., 1989, VIROLOGY, V173, P2
   Poon G. M., 2007, BIOCHEM SOC T, V35, P4
   Qin S., 2012, BIOTECHNOL ADV, V30, P6
   Quesenberry P. J., 2002, STEM CELL BIOL GENE
   Huang L., 2012, THER DELIV, V3, P12
   Naismith J. H., 2013, BIOCHEM J, V453, P2
   Romano G., 2003, EUR J DERMATOL, V13, P5
   Romberg B., 2008, PHARM RES, V25, P1
   Rossmann M. G., 2004, CURR OPIN STRUC BIOL, V14, P2
   Ruoslahti E., 1987, SCIENCE, V238, P4826
   Saga K., 2008, J BIOTECHNOL, V133, P3
   Saha K., 2012, CHEM REV, V112, P5
   Salzmann J. A., 1972, AM J ORTHOD, V61, P5
   Muzyczka N., 1983, CELL, V33, P1
   Chang L. S., 1987, J VIROL, V61, P10
   Samulski R. J., 1989, J VIROL, V63, P9
   Samulski R. J., 1982, P NATL ACAD SCI USA, V79, P6
   Sandalon Z., 1997, HUM GENE THER, V8, P7
   SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407
   Chen X., 2009, SMALL, V5, P1
   Seow Y., 2009, MOL THER, V17, P5
   Ferrari M., 2011, BIOCHIM BIOPHYS ACTA, V1810, P3
   Shah K. V., 2001, DIS MARKERS, V17, P3
   Shamji M. F., 2008, SPINE, V33, P7
   Chatterjee S., 1996, SEMIN ONCOL, V23, P1
   Sheng Y., 2009, J MATER SCI-MATER M, V20, P9
   Oshima K., 2003, BIOCHEM BIOPH RES CO, V300, P2
   Shimbo T., 2007, BIOCHEM BIOPH RES CO, V364, P3
   Murata T., 2007, ULTRASON SONOCHEM, V14, P2
   Shishido T., 2009, J BIOCH, V146, P6
   Shishido T., 2009, BIOORG MED CHEM LETT, V19, P5
   Shishido T., 2010, BIOORG MED CHEM LETT, V20, P19
   Siddiqui I. A., 2012, INT J NANOMED, V2012, P7
   Lillard Jr J. W., 2009, EXP MOL PATHOL, V86, P3
   Sinha R., 2006, MOL CANCER THER, V5, P8
   Smith B. R., 2012, NANO LETTS, V12, P7
   Spencer J. F., 1988, J BASIC MICROB, V28, P5
   Srivastava A., 1987, INTERVIROLOGY, V27, P3
   Berns K. I., 1983, J VIROL, V45, P2
   Harrison S. C., 1996, STRUCTURE, V4, P2
   Sun G., 2011, J CONTROL RELEASE, V155, P2
   Takahashi R. U., 2008, J BIOTECHNOL, V135, P4
   Cheon J., 2010, J AM CHEM SOC, V132, P31
   Tiollais P., 1985, NATURE, V317, P6037
   Tiwari M., 2012, J CANCER RES THER, V8, P1
   Kondo A., 2010, J BIOCH, V147, P6
   Torney F., 2007, NAT NANO, V2, P5
   Touze A., 2001, J GEN VIROL, V82, P12
   Selvamurugan N., 2012, INT J BIOL MACROMOL, V50, P1
   Tsutsui Y., 2007, J CONTROL RELEASE, V122, P2
   Vives E., 1997, J BIOL CHEM, V272, P25
   Vogt V. M., 1999, J VIROL, V73, P8
   Wadia J. S., 2002, CURR OPIN BIOTECH, V13, P1
   Torchilin V. P., 2012, INT J CANCER, V427, P1
   Wang X. S., 1995, J MOL BIOL, V250, P5
   Williams D. F., 2009, BIOMATERIALS, V30, P30
   von Brunn A., 1999, J VIROL METHODS, V77, P2
   Wrobel B., 2000, J BIOTECHNOL, V84, P3
   Wang P., 2010, ACS NANO, V4, P1
   Yallapu M. M., 2011, BIOMATERIALS, V32, P7
   Yamada T., 2001, VACCINE, V19, P23
   Yamazaki K, 1996, ARCH VIROL, P271
   Wang P., 2009, PHARM RES, V26, P6
   Yang L., 2006, P NATL ACAD SCI USA, V103, P31
   Yang Y. Y., 2006, CLIN EXP PHARM PHYSL, V33, P5
   Yih T. C., 2006, J CELL BIOCHEM, V97, P6
   Yokoyama N., 2007, J BIOCH, V141, P2
   Yu D. G., 2007, BIOCONJUG CHEM, V18, P5
   Jain R. K., 1994, CANCER RES, V54, P13
   Zeltins A., 2013, MOL BIOTECHNOL, V53, P1
   Zheng C., 2011, TOXICOL SCI, V123
   Zhu Y., 2005, ANGEW CHEM INT EDIT, V44, P32
NR 260
TC 5
Z9 5
U1 1
U2 62
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD SEP
PY 2014
VL 10
IS 9
SI SI
BP 2063
EP 2085
DI 10.1166/jbn.2014.1951
PG 23
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA AL9AC
UT WOS:000339430600017
PM 25992449
DA 2018-01-05
ER

PT J
AU Xie, ZL
   Ji, ZH
   Zhang, ZR
   Gong, T
   Sun, X
AF Xie, Zhaolu
   Ji, Zhonghua
   Zhang, Zhirong
   Gong, Tao
   Sun, Xun
TI Adenoviral vectors coated with cationic PEG derivatives for intravaginal
   vaccination against HIV-1
SO BIOMATERIALS
LA English
DT Article
DE Adenovirus; Cationic PEG derivative; Intravaginal immunization; Mucus;
   Immune response
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; BIODEGRADABLE POLYMER
   NANOPARTICLES; HUMAN CERVICAL-MUCUS; IMMUNE-RESPONSES; IN-VIVO; BOOST
   VACCINATION; VACCINES; MICE; GENE
AB Mucus layer coating the vaginal epithelium represents a barrier for intravaginally delivered recombined adenoviral (rAd) vectors, but it could be overcome by proper polyethylene glycol (PEG) modification. Here we synthesized two cationic PEG derivatives, amino-(EO)(n)/(AGE)(m)-Cyss (APCs). The polymers contained neutral linear PEG (2-5 kDa) to provide a hydrophilic surface and amine pendants to provide positive charge for coating negatively charged rAd by physical adsorption. Given proper molecular composition, the polymer (5k-APC) could coat rAd without causing aggregation, facilitating its mucus penetrating ability and enhancing gene expression both in vitro and in vivo. With HIVgag as the model antigen, the polymer-rAd complexes were administered intravaginally to elicit both systemic and mucosal immune responses. 5k-APC-rAd immunization elicited robust HIVgag-specific cellular responses and also induced higher antigen-specific serum IgG. More importantly, mice immunized with 5k-APC-rAd showed higher level of IgA in vaginal lavage fluid. These findings suggest that 5k-APC-rAd is a promising system for intravaginal immunization against infectious diseases such as HIV within the vaginal tract. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Xie, Zhaolu; Ji, Zhonghua; Zhang, Zhirong; Gong, Tao; Sun, Xun] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
RP Sun, X (reprint author), Sichuan Univ, West China Sch Pharm, 17,Sect 3,Southern Renmin Rd, Chengdu 610041, Peoples R China.
EM xunsun22@gmail.com
OI Sun, Xun/0000-0002-0218-1664
FU National Natural Science Foundation of China [81173011]; National Basic
   Research Program of China (973 program) [2013CB932504]; Science
   Foundation for Youths of Sichuan Province [2012JQ0024]
FX We are grateful for financial support from the National Natural Science
   Foundation of China (No. 81173011), the National Basic Research Program
   of China (973 Program, No. 2013CB932504) and Science Foundation for
   Youths of Sichuan Province (No. 2012JQ0024). We also thank Prof.
   Hildegund C.J.. Ertl from the Wistar Institute of Anatomy and Biology
   for kindly providing the replication-defective adenovirus 5 HIVgag
   vector.
CR Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149
   Barouch DH, 2003, J VIROL, V77, P8729, DOI 10.1128/JVI.77.16.8729-8735.2003
   Belyakov IM, 2009, J IMMUNOL, V183, P6883, DOI 10.4049/jimmunol.0901466
   Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Borges O, 2013, NOVEL IMMUNE POTENTI, P65
   Byers AM, 2003, J IMMUNOL, V171, P17, DOI 10.4049/jimmunol.171.1.17                                                       
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003
   Chen J, 2006, MOL THER, V13, P260, DOI 10.1016/j.ymthe.2005.10.006
   Cohen Yehuda Z, 2013, Ther Adv Vaccines, V1, P99, DOI 10.1177/2051013613494535
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Dai BB, 2009, P NATL ACAD SCI USA, V106, P20382, DOI 10.1073/pnas.0911742106
   de Souza APD, 2007, VACCINE, V25, P109, DOI 10.1016/j.vaccine.2006.07.011
   Ensign LM, 2012, ADV MATER, V24, P3887, DOI 10.1002/adma.201201800
   Ensign LM, 2012, SCI TRANSL MED, V4
   Fichorova RN, 1997, BIOL REPROD, V57, P847, DOI 10.1095/biolreprod57.4.847
   Hutchings AB, 2004, J VIROL, V78, P947, DOI 10.1128/JVI.78.2.947-957.2004
   Janes H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043396
   Johnston MI, 2008, NEW ENGL J MED, V359, P888, DOI 10.1056/NEJMp0806162
   Kim HD, 2007, IMMUNOL LETT, V112, P30, DOI 10.1016/j.imlet.2007.06.006
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lautenschlager C, 2013, EUR J PHARM BIOPHARM, V85, P578, DOI 10.1016/j.ejpb.2013.09.016
   Lemiale F, 2003, J VIROL, V77, P10078, DOI 10.1128/JVI.77.18.10078-10087.2003
   Li M, 2013, INT J NANOMED, V8, P1843, DOI 10.2147/IJN.S43827
   Lin SW, 2007, J CLIN INVEST, V117, P3958, DOI 10.1172/JCI33138
   Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Norris DA, 1997, J APPL POLYM SCI, V63, P1481, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5               
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Pinto AR, 2004, VACCINE, V22, P697, DOI 10.1016/j.vaccine.2003.08.029
   SALTZMAN WM, 1994, BIOPHYS J, V66, P508, DOI 10.1016/S0006-3495(94)80802-1                                                   
   Shen H, 2003, J CONTROL RELEASE, V86, P339, DOI 10.1016/S0168-3659(02)00354-1
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tatsis N, 2007, BLOOD, V110, P1916, DOI 10.1182/blood-2007-02-062117
   Tritel M, 2003, J IMMUNOL, V171, P2538, DOI 10.4049/jimmunol.171.5.2538                                                     
   Tutykhina IL, 2011, J MOL MED, V89, P331, DOI 10.1007/s00109-010-0696-0
   UNAIDS, 2013, GLOBAL FACT SHEET
   Vajdy M, 2001, J INFECT DIS, V184, P1613, DOI 10.1086/324581
   Vajdy Michael, 2006, Drugs R D, V7, P267, DOI 10.2165/00126839-200607050-00001
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wortmann A, 2008, MOL THER, V16, P154, DOI 10.1038/sj.mt.6300306
   Xiang ZQ, 1999, VACCINE, V17, P2003, DOI 10.1016/S0264-410X(98)00449-6                                                   
   Xiang ZQ, 2003, J VIROL, V77, P10780, DOI 10.1128/JVI.77.20.10780-10789.2003
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
   Yang ZY, 2003, J VIROL, V77, P799, DOI 10.1128/JVI.77.1.799-803.2003
   Yu MK, 2010, EXPERT OPIN BIOL TH, V10, P1181, DOI 10.1517/14712598.2010.496776
   Zaman M, 2013, DRUG DELIV TRANSL RE, V3, P100, DOI 10.1007/s13346-012-0085-z
   Zeng Q, 2012, INT J NANOMED, V7, P985, DOI 10.2147/IJN.S27526
   Zhu Q, 2008, MUCOSAL IMMUNOL, V1, P78, DOI 10.1038/mi.2007.3
NR 54
TC 9
Z9 9
U1 3
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2014
VL 35
IS 27
BP 7896
EP 7908
DI 10.1016/j.biomaterials.2014.05.056
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AL2TF
UT WOS:000338977600021
PM 24929620
DA 2018-01-05
ER

PT J
AU Moraes, ML
   Rodrigues, VC
   Soares, JC
   Ferreira, M
   de Souza, NC
   Oliveira, ON
AF Moraes, Marli L.
   Rodrigues, Valquiria C.
   Soares, Juliana C.
   Ferreira, Marystela
   de Souza, Nara C.
   Oliveira, Osvaldo N., Jr.
TI Immunosensor for HIV-1 Diagnostics Based on Immobilization of the
   Antigenic Peptide p24-3 Into Liposomes
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE HIV Immunosensor; Layer by Layer Films; Antigenic Peptide; Liposome
ID BY-LAYER FILMS; MODIFIED ELECTRODE; IMPEDANCE SPECTROSCOPY; PROTEIN;
   ANTIBODY; SERUM; NANOPARTICLE; COMBINATION; MICROSCOPY; SURFACES
AB In this work we developed an immunosensor for HIV-1 diagnostics that exploits the biorecognition between the antibody anti-p24 and the antigenic peptide p24-3 (AMATLRAEQASQEVKNWMTETL-LVQNA) derived from the HIV-1 p24 protein. p24-3 was encapsulated in phospholipid liposomes and immobilized in layer-by-layer (LbL) films produced with polyethyleneimine (PEI). The incorporation of p24-3 into liposomes was investigated using circular dichroism (CD) spectroscopy, from which an increase in the alpha helix conformation could be noted. The maximum fluorescence emission for p24-3 occurred at 340 nm in solution, compatible with the tryptophan residue being exposed to the solvent, and at 335 and 322 nm when in liposomes and PEI/p24-3-liposome LbL films, respectively. This blue shift is consistent with the tryptophan being in a partially buried environment. With the preserved structure in the LbL films, p24-3 could recognize the anti-p24 antibody in impedance spectroscopy measurements. Therefore, LbL films containing p24-3 may be suitable for detecting HIV-1 in a low-cost, easy-to-use immunosensing assay.
C1 [Moraes, Marli L.] Univ Fed Sao Paulo, Inst Ciencia & Tecnol, BR-12231280 Sao Jose Dos Campos, SP, Brazil.
   [Moraes, Marli L.; Rodrigues, Valquiria C.; Soares, Juliana C.; Oliveira, Osvaldo N., Jr.] Univ Sao Paulo, Inst Fis Sao Carlos, BR-13566590 Sao Carlos, SP, Brazil.
   [Ferreira, Marystela] Univ Fed Sao Carlos, BR-13565905 Sorocaba, SP, Brazil.
   [de Souza, Nara C.] Univ Fed Mato Grosso, BR-78600000 Barra Do Garcas, MT, Brazil.
RP Moraes, ML (reprint author), Univ Fed Sao Paulo, Inst Ciencia & Tecnol, BR-12231280 Sao Jose Dos Campos, SP, Brazil.
RI Sao Carlos Institute of Physics, IFSC/USP/M-2664-2016; Oliveira,
   Osvaldo/A-1714-2008; Ferreira, Marystela/B-8941-2013; de Souza,
   Nara/H-6845-2012
OI Oliveira, Osvaldo/0000-0002-5399-5860; Ferreira,
   Marystela/0000-0002-9459-8167; de Souza, Nara/0000-0001-8554-1663
FU FAPESP; CNPq; CAPES; rede nBioNet (Brazil); microfabrication laboratory
   (LMF/LNNano) (Brazil) [LMF 12298]
FX This work was supported by FAPESP, CNPq, CAPES and rede nBioNet
   (Brazil). The authors are also grateful to Mr. Tacito Neves, Dr.
   Fernando V. Paulovich and Professor Maria Cristina F. de Oliveira
   (ICMC-USP) for the use of the PEx-Sensors tool. We also thank
   microfabrication laboratory (LMF/LNNano) (Brazil) for providing
   interdigitated electrodes (project LMF 12298).
CR Castilho PV, 2005, PEPTIDES, V26, P243, DOI 10.1016/j.peptides.2004.09.014
   Choi JH, 2013, J BIOMED NANOTECHNOL, V9, P291, DOI 10.1166/jbn.2013.1542
   de Oliveira RF, 2011, J PHYS CHEM C, V115, P19136, DOI 10.1021/jp207610w
   de Souza NC, 2009, CHEM PHYS LETT, V484, P33, DOI 10.1016/j.cplett.2009.10.065
   de Souza NC, 2006, J COLLOID INTERF SCI, V297, P546, DOI 10.1016/j.jcis.2005.10.060
   Ferraz RM, 2006, MOL IMMUNOL, V43, P2119, DOI 10.1016/j.molimm.2005.12.012
   FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102                                                          
   Gan N, 2010, MOLECULES, V15, P5053, DOI 10.3390/molecules15075053
   Hickman DT, 2011, J BIOL CHEM, V286, P13966, DOI 10.1074/jbc.M110.186338
   Hudecz F, 2001, BIOLOGICALS, V29, P197, DOI 10.1006/biol.2001.0305
   Iweala OI, 2004, CONTRACEPTION, V70, P141, DOI 10.1016/j.contraception.2004.03.012
   Johnson A, 2012, ANAL CHEM, V84, P6553, DOI 10.1021/ac300835b
   Keblinski P, 1996, PHYS REV E, V53, P759, DOI 10.1103/PhysRevE.53.759                                                         
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Lakowicz JR, 2006, PRINCIPLES FLUORESCE
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Minghim R., 2006, P VIS DAT AN IS T SP, V6060, pS1
   Monaco-Malbet S, 2000, STRUCTURE, V8, P1069, DOI 10.1016/S0969-2126(00)00507-4
   Monsellier E, 2006, J MOL BIOL, V362, P580, DOI 10.1016/j.jmb.2006.07.044
   Moraes ML, 2012, SENSOR ACTUAT B-CHEM, V166, P231, DOI 10.1016/j.snb.2012.02.046
   Moraes ML, 2010, ANAL CHEM, V82, P3239, DOI 10.1021/ac902949h
   Novotna P, 2012, ANAL BIOCHEM, V427, P211, DOI 10.1016/j.ab.2012.03.023
   Oliveira Jr O. N., 2012, BIOINTERPHASES, V7, P1
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815                                                      
   Paulovich FV, 2011, ANALYST, V136, P1344, DOI 10.1039/c0an00822b
   Petri L, 2011, J NANOSCI NANOTECHNO, V11, P6705, DOI 10.1166/jnn.2011.4216
   Prabhakar D, 2012, SCI ADV MATER, V4, P121, DOI 10.1166/sam.2012.1260
   SALVAREZZA RC, 1992, EUROPHYS LETT, V20, P727, DOI 10.1209/0295-5075/20/8/011                                                      
   Sheikh S, 2011, TALANTA, V85, P816, DOI 10.1016/j.talanta.2011.04.008
   Sin EJ, 2012, NANOSCI NANOTECH LET, V4, P821, DOI 10.1166/nnl.2012.1400
   Tan P.-N., 2005, INTRO DATA MINING
   TAYLOR DM, 1987, J PHYS D APPL PHYS, V20, P1277, DOI 10.1088/0022-3727/20/10/010
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Tejada E., 2003, Information Visualization, V2, P218, DOI 10.1057/palgrave.ivs.9500054
   Xiaoqin K. R, 2011, SCI ADV MATER, V3, P763
   Xu LJ, 2012, J BIOMED NANOTECHNOL, V8, P1006, DOI 10.1166/jbn.2012.1456
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
NR 37
TC 9
Z9 9
U1 2
U2 40
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD SEP
PY 2014
VL 14
IS 9
BP 6638
EP 6645
DI 10.1166/jnn.2014.9361
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AH1IN
UT WOS:000335873900019
PM 25924310
DA 2018-01-05
ER

PT J
AU Wang, RR
   Yang, QH
   Luo, RH
   Peng, YM
   Dai, SX
   Zhang, XJ
   Chen, H
   Cui, XQ
   Liu, YJ
   Huang, JF
   Chang, JB
   Zheng, YT
AF Wang, Rui-Rui
   Yang, Qing-Hua
   Luo, Rong-Hua
   Peng, You-Mei
   Dai, Shao-Xing
   Zhang, Xing-Jie
   Chen, Huan
   Cui, Xue-Qing
   Liu, Ya-Juan
   Huang, Jing-Fei
   Chang, Jun-Biao
   Zheng, Yong-Tang
TI Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good
   Drug Combination Features and Better Inhibition on Drug-Resistant
   Strains than Lamivudine In Vitro
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; QUANTITATIVE-ANALYSIS; ANTIVIRAL
   ACTIVITY; 3TC RESISTANCE; HIV TYPE-1; ANALOGS; REPLICATION; COMPLEX;
   PROTEIN; DESIGN
AB Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or in combination with other antiretroviral drugs and its drug resistance features. Azvudine exerted highly potent inhibition on HIV-1 (EC(50)s ranging from 0.03 to 6.92 nM) and HIV-2 (EC(50)s ranging from 0.018 to 0.025 nM). It also showed synergism in combination with six approved anti-HIV drugs on both C8166 and PBMC. In combination assay, the concentrations of azvudine used were 1000 or 500 fold lower than other drugs. Azvudine also showed potent inhibition on NRTI-resistant strains (L74V and T69N). Although M184V caused 250 fold reduction in susceptibility, azvudine remained active at nanomolar range. In in vitro induced resistant assay, the frequency of M184I mutation increased with induction time which suggests M184I as the key mutation in azvudine treatment. As control, lamivudine treatment resulted in a higher frequency of M184I/V given the same induction time and higher occurrence of M184V was found. Molecular modeling analysis suggests that steric hindrance is more pronounced in mutant M184I than M184V due to the azido group of azvudine. The present data demonstrates the potential of azvudine as a complementary drug to current anti-HIV drugs. M184I should be the key mutation, however, azvudine still remains active on HIV-1(LAI-M184V) at nanomolar range.
C1 [Wang, Rui-Rui; Luo, Rong-Hua; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Zheng, Yong-Tang] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China.
   [Wang, Rui-Rui; Luo, Rong-Hua; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Zheng, Yong-Tang] Chinese Acad Sci, Kunming Inst Zool, Kunming, Yunnan, Peoples R China.
   [Yang, Qing-Hua; Peng, You-Mei; Chang, Jun-Biao] Zhengzhou Univ, Coll Chem & Mol Engn, Zhengzhou 450052, Henan, Peoples R China.
   [Zhang, Xing-Jie; Chen, Huan; Liu, Ya-Juan] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Yunnan, Peoples R China.
   [Dai, Shao-Xing; Huang, Jing-Fei] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China.
   [Cui, Xue-Qing] Dali Univ, Coll Pharm & Chem, Dali, Yunnan, Peoples R China.
RP Chang, JB (reprint author), Zhengzhou Univ, Coll Chem & Mol Engn, Zhengzhou 450052, Henan, Peoples R China.
EM changjunbiao@zzu.edu.cn; zhengyt@mail.kiz.ac.cn
OI Dai, Shao-Xing/0000-0002-6919-2034
FU Twelfth Five-Year Key Scientific and Technological Program of China
   [2012ZX10001-006, 2012ZX10001-007, 2012ZX09103-101-022]; National
   Natural Science Foundation of China [21172202, 81001462, 81102483];
   Yunnan Province [2010GA001, Y103951111]
FX This work was supported in part by grants from the Twelfth Five-Year Key
   Scientific and Technological Program of China (2012ZX10001-006,
   2012ZX10001-007, 2012ZX09103-101-022), the National Natural Science
   Foundation of China (21172202, 81001462, 81102483), Yunnan Province
   (2010GA001, Y103951111). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderson Peter L, 2010, Clin Med Rev Ther, V2, pa2004
   Barnas D, 2010, ANTIVIR THER, V15, P437, DOI 10.3851/IMP1539
   Boyer PL, 2012, J VIROL, V86, P5885, DOI 10.1128/JVI.06597-11
   Chesney MA, 2006, JAIDS-J ACQ IMM DEF, V43, pS149, DOI 10.1097/01.qai.0000243112.91293.26                                              
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Cihlar T, 2008, ANTIMICROB AGENTS CH, V52, P655, DOI 10.1128/AAC.01215-07
   Das K, 2012, NAT STRUCT MOL BIOL, V19, P253, DOI 10.1038/nsmb.2223
   GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760
   He X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047289
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Kodama EI, 2001, ANTIMICROB AGENTS CH, V45, P1539, DOI 10.1128/AAC.45.5.1539-1546.2001
   Lacombe K, 2010, J ANTIMICROB CHEMOTH, V65, P10, DOI 10.1093/jac/dkp414
   Li L, 2010, AIDS RES HUM RETROV, V26, P711, DOI 10.1089/aid.2010.0001
   Liu GJ, 2007, CELL MOL IMMUNOL, V4, P203
   Lu XF, 2012, ANTIMICROB AGENTS CH, V56, P341, DOI 10.1128/AAC.05537-11
   Murphy R L, 1999, AIDS Clin Care, V11, P47
   Murphy RL, 1999, AIDS CLIN CARE, V11, P51
   Murphy RL, 1999, AIDS CLIN CARE, V11, P53
   Ntemgwa M, 2007, ANTIMICROB AGENTS CH, V51, P3861, DOI 10.1128/AAC.00646-07
   Ohrui H, 2000, J MED CHEM, V43, P4516, DOI 10.1021/jm000209n
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0
   Rando RF, 2000, DRUG DISCOV TODAY, V5, P465, DOI 10.1016/S1359-6446(00)01558-0                                                   
   Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066                                                          
   Richman DD, 2001, ANTIVIR THER, V6, P83
   SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1                                                    
   Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027
   Scaglione F, 2012, INT J ANTIMICROB AG, V39, P458, DOI 10.1016/j.ijantimicag.2011.11.013
   SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2423, DOI 10.1128/AAC.36.11.2423                                                          
   [Anonymous], 2010, PYMOL MOL GRAPHICS S
   SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411                                                       
   Smith DB, 2009, J MED CHEM, V52, P2971, DOI 10.1021/jm801595c
   Suzuki Y, 2003, VIRUS GENES, V27, P177, DOI 10.1023/A:1025732728195
   Tuccinardi T, 2010, J CHEM INF MODEL, V50, P1432, DOI 10.1021/ci100161z
   Varghese V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010992
   WAINBERG MA, 1995, AIDS, V9, P351
   Wang Q, 2011, EUR J MED CHEM, V46, P4178, DOI 10.1016/j.ejmech.2011.06.020
   Wang QA, 2011, BIOCHEM PHARMACOL, V81, P848, DOI 10.1016/j.bcp.2011.01.001
   Wang RR, 2009, BIOCHEM BIOPH RES CO, V382, P540, DOI 10.1016/j.bbrc.2009.03.057
   Wang YL, 2010, NUCLEIC ACIDS RES, V38, pD255, DOI 10.1093/nar/gkp965
   Wu J, 2013, EUR J MED CHEM, V63, P739, DOI 10.1016/j.ejmech.2013.02.042
   Yoder KE, 2008, J VIROL METHODS, V153, P253, DOI 10.1016/j.jviromet.2008.07.032
   Zhang XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081489
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zheng LY, 2012, ANTIVIR THER, V17, P679, DOI 10.3851/IMP2094
   Zhou YB, 2012, ANTIVIR THER, V17, P1593, DOI 10.3851/IMP2292
NR 46
TC 8
Z9 11
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2014
VL 9
IS 8
AR e105617
DI 10.1371/journal.pone.0105617
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO1WL
UT WOS:000341106100097
PM 25144636
OA gold
DA 2018-01-05
ER

PT J
AU Cecchin, D
   de la Rica, R
   Bain, RES
   Finnis, MW
   Stevens, MM
   Battaglia, G
AF Cecchin, D.
   de la Rica, R.
   Bain, R. E. S.
   Finnis, M. W.
   Stevens, M. M.
   Battaglia, G.
TI Plasmonic ELISA for the detection of gp120 at ultralow concentrations
   with the naked eye
SO NANOSCALE
LA English
DT Article
ID ULTRASENSITIVE DETECTION; GOLD NANOPARTICLES; MEDIATED SYNTHESIS; GROWTH
AB The technique of plasmonic ELISA is utilised here to detect the HIV-1 protein gp120 with the ultralow limit of detection of 8 x 10(-20) M (10(-17) g mL(-1)) in an independent laboratory. It was corroborated that changes in the concentration of hydrogen peroxide as small as 0.05 could lead to nanoparticle solutions of completely different tonality.
C1 [Cecchin, D.; Battaglia, G.] UCL, MRC UCL Ctr Med Mol Virol, Dept Chem, London WC1H 0AJ, England.
   [de la Rica, R.; Bain, R. E. S.; Stevens, M. M.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, Dept Mat, London SW7 2AZ, England.
   [de la Rica, R.; Bain, R. E. S.; Stevens, M. M.] Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 2AZ, England.
   [Finnis, M. W.] Univ London Imperial Coll Sci Technol & Med, Dept Mat, Thomas Young Ctr, London SW7 2AZ, England.
   [Finnis, M. W.] Univ London Imperial Coll Sci Technol & Med, Dept Phys, London SW7 2AZ, England.
RP Battaglia, G (reprint author), UCL, MRC UCL Ctr Med Mol Virol, Dept Chem, 20 Gordon St, London WC1H 0AJ, England.
EM battaglia@ucl.ac.uk
RI Battaglia, Giuseppe/I-2142-2013; de la Rica, Roberto/F-9430-2014
OI Battaglia, Giuseppe/0000-0003-3349-6770; de la Rica,
   Roberto/0000-0002-5750-1469; Bain, Robert/0000-0001-6577-2923
CR Bastus NG, 2011, LANGMUIR, V27, P11098, DOI 10.1021/la201938u
   Cao LY, 2004, CHEM MATER, V16, P3239, DOI 10.1021/cm0348491
   Cho ES, 2012, NAT MATER, V11, P978, DOI [10.1038/NMAT3406, 10.1038/nmat3406]
   COCHRAN WG, 1950, BIOMETRICS, V6, P105, DOI 10.2307/3001491
   de la Rica R, 2013, NAT PROTOC, V8, P1759, DOI 10.1038/nprot.2013.085
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   de la Rica R, 2009, ANAL CHEM, V81, P7732, DOI 10.1021/ac901210f
   Gobbo P, 2013, J MATER CHEM B, V1, P4048, DOI 10.1039/c3tb20913j
   LaGrow AP, 2013, ADV MATER, V25, P1552, DOI 10.1002/adma.201204366
   Rayavarapu RG, 2010, LANGMUIR, V26, P5050, DOI 10.1021/la100166f
   Rodriguez-Lorenzo L, 2012, NAT MATER, V11, P604, DOI [10.1038/NMAT3337, 10.1038/nmat3337]
   Smith DK, 2008, LANGMUIR, V24, P644, DOI 10.1021/la703625a
   Thaxton CS, 2009, P NATL ACAD SCI USA, V106, P18437, DOI 10.1073/pnas.0904719106
NR 13
TC 21
Z9 21
U1 3
U2 74
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PD AUG 21
PY 2014
VL 6
IS 16
BP 9559
EP 9562
DI 10.1039/c3nr06167a
PG 4
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AM9RE
UT WOS:000340217900023
PM 24995368
DA 2018-01-05
ER

PT J
AU Bleck, M
   Itano, MS
   Johnson, DS
   Thomas, VK
   North, AJ
   Bieniasz, PD
   Simon, SM
AF Bleck, Marina
   Itano, Michelle S.
   Johnson, Daniel S.
   Thomas, V. Kaye
   North, Alison J.
   Bieniasz, Paul D.
   Simon, Sanford M.
TI Temporal and spatial organization of ESCRT protein recruitment during
   HIV-1 budding
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE viral assembly; nanobody; TIR-FM; single molecule localization
   microscopy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LIVE CELLS; MICROSCOPY; DYNAMICS; GAG;
   STOICHIOMETRY; MACHINERY; VIRIONS; DOMAINS; PATHWAY
AB HIV-1 virions assemble at the plasma membrane of mammalian cells and recruit the endosomal sorting complex required for transport (ESCRT) machinery to enable particle release. However, little is known about the temporal and spatial organization of ESCRT protein recruitment. Using multiple-color live-cell total internal reflection fluorescence microscopy, we observed that the ESCRT-I protein Tsg101 is recruited together with Gag to the sites of HIV-1 assembly, whereas later-acting ESCRT proteins (Chmp4b and Vps4A) are recruited sequentially, once Gag assembly is completed. Chmp4b, a protein that is required to mediate particle scission, is recruited to HIV-1 assembly sites similar to 10 s before the ATPase Vps4A. Using two-color superresolution imaging, we observed that the ESCRT machinery (Tsg101, Alix, and Chmp4b/c proteins) is positioned at the periphery of the nascent virions, with the Tsg101 assemblages positioned closer to the Gag assemblages than Alix, Chmp4b, or Chmp4c. These results are consistent with the notion that the ESCRT machinery is recruited transiently to the neck of the assembling particle and is thus present at the appropriate time and place to mediate fission between the nascent virus and the plasma membrane.
C1 [Bleck, Marina; Itano, Michelle S.; Johnson, Daniel S.; Simon, Sanford M.] Rockefeller Univ, Lab Cellular Biophys, New York, NY 10065 USA.
   [Thomas, V. Kaye; North, Alison J.] Rockefeller Univ, Bioimaging Resource Ctr, New York, NY 10065 USA.
   [Bieniasz, Paul D.] Rockefeller Univ, Lab Retrovirol, Aaron Diamond AIDS Res Ctr, Howard Hughes Med Inst, New York, NY 10016 USA.
RP Simon, SM (reprint author), Rockefeller Univ, Lab Cellular Biophys, New York, NY 10065 USA.
EM simon@rockefeller.edu
OI Simon, Sanford/0000-0002-8615-4224
FU National Institutes of Health [P50GM103297, 5R01AI089844, R01AI50111]
FX We thank C. Takacs from the S.M.S. laboratory for critical reading of
   our manuscript. The superresolution images were acquired on the Nikon
   STORM microscope system at the Bio-Imaging Resource Center at The
   Rockefeller University. This work was supported by National Institutes
   of Health Grants P50GM103297 (to M. B., D.S.J., and S. M. S.),
   5R01AI089844 (to M. S. I. and S. M. S.), and R01AI50111 (to P.D.B.).
CR Baumgartel V, 2011, NAT CELL BIOL, V13, P469, DOI 10.1038/ncb2215
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Dempsey GT, 2011, NAT METHODS, V8, P1027, DOI [10.1038/NMETH.1768, 10.1038/nmeth.1768]
   Elia N, 2011, P NATL ACAD SCI USA, V108, P4846, DOI 10.1073/pnas.1102714108
   Filonov GS, 2011, NAT BIOTECHNOL, V29, P757, DOI 10.1038/nbt.1918
   Fisher RD, 2007, CELL, V128, P841, DOI 10.1016/j.cell.2007.01.035
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2                                                   
   Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103
   Guizetti J, 2012, TRENDS CELL BIOL, V22, P133, DOI 10.1016/j.tcb.2011.11.007
   Gunzenhauser J, 2012, NANO LETT, V12, P4705, DOI 10.1021/nl3021076
   Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376
   Henne WM, 2011, DEV CELL, V21, P77, DOI 10.1016/j.devcel.2011.05.015
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Johnson DS, 2012, CURR PROTOC CYTOM, DOI [10.1002/0471142956.cy1229s61, DOI 10.1002/0471142956.CY1229S61]
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2011, J MOL BIOL, V410, P501, DOI 10.1016/j.jmb.2011.04.062
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100
   Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313                                                             
   Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350
   Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004
   Muller B, 2013, TRENDS MICROBIOL, V21, P522, DOI 10.1016/j.tim.2013.06.010
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6
   Subach FV, 2009, NAT METHODS, V6, P153, DOI [10.1038/NMETH.1298, 10.1038/nmeth.1298]
   Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924
   Van Engelenburg SB, 2014, SCIENCE, V343, P653, DOI 10.1126/science.1247786
   von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1                                                   
   Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539                                                         
   Zhang J, 2006, MICRON, V37, P14, DOI 10.1016/j.micron.2005.03.014
NR 34
TC 24
Z9 24
U1 0
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 19
PY 2014
VL 111
IS 33
BP 12211
EP 12216
DI 10.1073/pnas.1321655111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AN2TS
UT WOS:000340438800072
PM 25099357
OA gold
DA 2018-01-05
ER

PT J
AU Carcelli, M
   Rogolino, D
   Sechi, M
   Rispoli, G
   Fisicaro, E
   Compari, C
   Grandi, N
   Corona, A
   Tramontano, E
   Pannecouque, C
   Naesens, L
AF Carcelli, Mauro
   Rogolino, Dominga
   Sechi, Mario
   Rispoli, Gabriele
   Fisicaro, Emilia
   Compari, Carlotta
   Grandi, Nicole
   Corona, Angela
   Tramontano, Enzo
   Pannecouque, Christophe
   Naesens, Lieve
TI Antiretroviral activity of metal-chelating HIV-1 integrase inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Antiviral agents; HIV-1 integrase inhibitors; HIV-1 RNase H inhibitors;
   Metal complexes; Dual inhibitors
ID STRAND TRANSFER INHIBITORS; VIRUS TYPE-1 INTEGRASE; RIBONUCLEASE-H; DUAL
   INHIBITORS; DRUG DESIGN; COMPLEXES; RALTEGRAVIR; BINDING; REPLICATION;
   MECHANISM
AB Data regarding the activity of metal complexes against HIV virus in cell are surprisingly scarce. In this study, we present the antiviral activity against HIV-infected cells of different types of chelating ligands and of their metal complexes. In particular, the carboxamide chelating scaffold and the corresponding coordination compounds demonstrated an interesting antiviral profile in the nanomolar range. These molecules inhibit not only HIV integrase catalytic activity, but they also interfere with the function of the RNase H component of the HIV reverse transcriptase. Here we also discuss the thermodynamic characterization in solution of the metal complexes of the most active ligands, affording to the best of our knowledge for the first time this type of data for complexes with anti-HIV activity. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Carcelli, Mauro; Rogolino, Dominga; Rispoli, Gabriele] Univ Parma, Dipartimento Chim, I-43124 Parma, Italy.
   [Sechi, Mario] Univ Sassari, Dipartimento Chim & Farm, I-07100 Sassari, Italy.
   [Fisicaro, Emilia; Compari, Carlotta] Univ Parma, Dipartimento Farm, I-43124 Parma, Italy.
   [Grandi, Nicole; Corona, Angela; Tramontano, Enzo] Univ Cagliari, Dipartimento Sci Vita & Ambiente, Sez Biomed, I-09042 Monserrato, CA, Italy.
   [Pannecouque, Christophe; Naesens, Lieve] Rega Inst, B-3000 Louvain, Belgium.
RP Carcelli, M (reprint author), Univ Parma, Dipartimento Chim, Parco Area Sci 17-A, I-43124 Parma, Italy.
EM mauro.carcelli@unipr.it
RI Rogolino, Dominga/L-6145-2015; Carcelli, Mauro/I-1616-2015; Corona,
   Angela/G-7327-2014; Tramontano, Enzo/B-4919-2012
OI Rogolino, Dominga/0000-0003-2295-5783; Carcelli,
   Mauro/0000-0001-5888-4556; Corona, Angela/0000-0002-6630-8636;
   Tramontano, Enzo/0000-0002-4849-0980; Sechi, Mario/0000-0003-2983-6090;
   Grandi, Nicole/0000-0003-0666-4361
FU Italian Minister dell'Istruzione, dell'Universita e della Ricerca
   [2010W2KM5L_003]
FX The authors thank the "Centro Interfacolta Misure Giuseppe Casnati" of
   the University of Parma for facilities. M.C., D.R, M.S., G.R. and E.T.
   thank Italian Minister dell'Istruzione, dell'Universita e della Ricerca
   for financial support (PRIN 2010, 2010W2KM5L_003).
CR Agrawal A, 2012, P NATL ACAD SCI USA, V109, P2251, DOI 10.1073/pnas.1112389109
   Bacchi A, 2008, J MED CHEM, V51, P7253, DOI 10.1021/jm800893q
   Bacchi A, 2011, J MED CHEM, V54, P8407, DOI 10.1021/jm200851g
   Bacchi A, 2011, MOL PHARMACEUT, V8, P507, DOI 10.1021/mp100343x
   Barry NPE, 2013, CHEM COMMUN, V49, P5106, DOI 10.1039/c3cc41143e
   Beare KD, 2012, CURR MED CHEM, V19, P1177
   Carcelli M, 2013, J INORG BIOCHEM, V118, P74, DOI 10.1016/j.jinorgbio.2012.09.021
   Costi R, 2013, J MED CHEM, V56, P8588, DOI 10.1021/jm401040b
   Dayam R, 2008, MED RES REV, V28, P118, DOI 10.1002/med.20116
   Esposito Francesca, 2014, Antiviral Chemistry & Chemotherapy, V23, P129, DOI 10.3851/IMP2690
   Esposito F, 2013, PATHOG DIS, V68, P116, DOI 10.1111/2049-632X.12051
   Fisicaro E, 2014, THERMOCHIM ACTA, V586, P40, DOI 10.1016/j.tca.2014.04.003
   Fonteh PN, 2011, J INORG BIOCHEM, V105, P1173, DOI 10.1016/j.jinorgbio.2011.05.011
   Gallego S. G., 2011, EUROPEAN J INORGANIC, P1657
   Gans P, 2008, J SOLUTION CHEM, V37, P467, DOI 10.1007/s10953-008-9246-6
   Hare S., 2010, NATURE, P1
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hicks C, 2009, CLIN INFECT DIS, V48, P931, DOI 10.1086/597290
   Hocharoen L, 2009, CHEM-EUR J, V15, P8670, DOI 10.1002/chem.200900821
   Johns BA, 2008, EXPERT OPIN THER PAT, V18, P1225, DOI 10.1517/13543770802500450
   Johns BA, 2013, J MED CHEM, V56, P5901, DOI 10.1021/jm400645w
   Johnson AA, 2007, MOL PHARMACOL, V71, P893, DOI 10.1124/mol.106.030817
   Karmon SL, 2013, DRUGS, V73, P213, DOI 10.1007/s40265-013-0015-5
   Kawasuji T, 2013, J MED CHEM, V56, P1124, DOI 10.1021/jm301550c
   Kawasuji T, 2012, J MED CHEM, V55, P8735, DOI 10.1021/jm3010459
   KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851
   Ladbury JE, 2010, NAT REV DRUG DISCOV, V9, P23, DOI 10.1038/nrd3054
   Loginova NV, 2008, EUR J MED CHEM, V43, P1536, DOI 10.1016/j.ejmech.2007.09.024
   Maertens GN, 2010, NATURE, V468, P326, DOI 10.1038/nature09517
   Nakamoto K., 1986, INFRARED RAMAN SPECT
   Neamati N, 2011, HIV 1 INTEGRASE MECH
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Pelosi G, 2010, J MED CHEM, V53, P8765, DOI 10.1021/jm1007616
   Rogolino D, 2014, EUR J MED CHEM, V78, P425, DOI 10.1016/j.ejmech.2014.03.070
   Rogolino D, 2012, COORDIN CHEM REV, V256, P3063, DOI 10.1016/j.ccr.2012.07.006
   Ronconi L, 2007, COORDIN CHEM REV, V251, P1633, DOI 10.1016/j.ccr.2006.11.017
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   Sechi M, 2006, J MED CHEM, V49, P4248, DOI 10.1021/jm060193m
   Semenova EA, 2008, ADV PHARMACOL, V56, P199, DOI 10.1016/S1054-3589(07)56007-2
   STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498
   Suchaud V, 2012, BIOORG MED CHEM LETT, V22, P3988, DOI 10.1016/j.bmcl.2012.04.096
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Tramontano E, 2005, ANTIVIR RES, V65, P117, DOI 10.1016/j.antiviral.2004.11.002
   Zeinalipour-Loizidou E, 2007, CURR HIV RES, V5, P365
NR 44
TC 7
Z9 7
U1 0
U2 20
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD AUG 18
PY 2014
VL 83
BP 594
EP 600
DI 10.1016/j.ejmech.2014.06.055
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AN6FF
UT WOS:000340689600052
PM 24996145
DA 2018-01-05
ER

PT J
AU Giavazzi, F
   Salina, M
   Ceccarello, E
   Ilacqua, A
   Damin, F
   Sola, L
   Chiari, M
   Chini, B
   Cerbino, R
   Bellini, T
   Buscaglia, M
AF Giavazzi, Fabio
   Salina, Matteo
   Ceccarello, Erica
   Ilacqua, Andrea
   Damin, Francesco
   Sola, Laura
   Chiari, Marcella
   Chini, Bice
   Cerbino, Roberto
   Bellini, Tommaso
   Buscaglia, Marco
TI A fast and simple label-free immunoassay based on a smartphone
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Optical biosensor; Protein microarray; Immunoassay; Biomolecular
   detection; Reflective phantom interface; Point-of-care
ID FREE BIODETECTION; CARE DIAGNOSTICS; CELL-PHONE; POINT; NANOPARTICLES;
   TECHNOLOGIES; DNA
AB Despite the continuous advancements in bio-molecular detection and fluidic systems integration, the realization of portable and high performance devices for diagnostic applications still presents major difficulties, mostly because of the need to combine adequate sensitivity with low cost of production and operational simplicity and speed. In this context, we propose a compact device composed of a smartphone and a custom-designed cradle, containing only a disposable sensing cartridge, a tiny magnetic stirrer and a few passive optical components. The detection principle is the previously proposed Reflective Phantom Interface that is based on measuring the intensity of light reflected by the surface of an amorphous fluoropolymer substrate, which has a refractive index very close to that of the aqueous sample solution and hosts various antibodies immobilized within spots. The reflectivity of dozens of spots is monitored in real time by the phone's camera using the embedded flash LED as the illumination source. We test the performance of the combined device targeting heterologous immunoglobulins and antigens commonly used as markers for diagnoses of hepatitis B and HIV. Target concentrations as low as a few ng/ml can be rapidly and robustly determined by comparing the rate of increase of the signal after the addition of the sample with that measured after the subsequent addition of a standard solution with known concentration. The features of the proposed system enable the realization of novel handheld biosensing devices suitable for those applications where multiple targets have to be rapidly detected even without the presence of trained personnel. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Giavazzi, Fabio; Salina, Matteo; Ceccarello, Erica; Ilacqua, Andrea; Cerbino, Roberto; Bellini, Tommaso; Buscaglia, Marco] Univ Milan, Dipartimento Biotecnol Med & Med Traslaz, I-20090 Segrate, Italy.
   [Giavazzi, Fabio; Salina, Matteo; Ceccarello, Erica] Proxentia Srl, I-20135 Milan, Italy.
   [Damin, Francesco; Sola, Laura; Chiari, Marcella] CNR, Ist Chim Riconoscimento Mol, I-20131 Milan, Italy.
   [Chini, Bice] CNR, Ist Neurosci, I-20129 Milan, Italy.
RP Buscaglia, M (reprint author), Univ Milan, Dipartimento Biotecnol Med & Med Traslaz, I-20090 Segrate, Italy.
EM tommaso.bellini@unimi.it; marco.buscaglia@unimi.it
RI Cerbino, Roberto/A-2286-2008; Giavazzi, Fabio/C-3054-2017; Bellini,
   Tommaso/M-5510-2014
OI Cerbino, Roberto/0000-0003-0434-7741; Giavazzi,
   Fabio/0000-0003-4930-0592; Bellini, Tommaso/0000-0003-4898-4400; Chiari,
   Marcella/0000-0002-4670-1430; Sola, Laura/0000-0002-2603-0318; Chini,
   Bice/0000-0002-1686-284X; Damin, Francesco/0000-0003-1780-7823
FU Cariplo Foundation, Italy [20069869]; EU [NMP-2013-SMALL-7, 604241]
FX We thank Solvay Specialty Polymers R&D Center (Bollate, Italy) for
   providing the perfluorinated material and Dia.Pro Diagnostic Bioprobes
   (Milan, Italy) for providing the antibodies and antigens. This work was
   supported by the Cariplo Foundation (Grant 20069869), Italy and in part
   by EU (NAPES Project - NMP-2013-SMALL-7, project no. 604241).
CR Cretich M, 2004, ANAL BIOCHEM, V332, P67, DOI 10.1016/j.ab.2004.05.041
   Gallegos D, 2013, LAB CHIP, V13, P2124, DOI 10.1039/c3lc40991k
   Ghetta A, 2005, P NATL ACAD SCI USA, V102, P15866, DOI 10.1073/pnas.0505877102
   Giavazzi F, 2013, P NATL ACAD SCI USA, V110, P9350, DOI 10.1073/pnas.1214589110
   Gubala V, 2012, ANAL CHEM, V84, P487, DOI 10.1021/ac2030199
   Holford TRJ, 2012, BIOSENS BIOELECTRON, V34, P12, DOI 10.1016/j.bios.2011.10.023
   Huang YW, 2013, ANALYST, V138, P2522, DOI 10.1039/c3an36875k
   Kozma P, 2013, BIOSENS BIOELECTRON, V47, P415, DOI 10.1016/j.bios.2013.03.043
   Lee DS, 2011, BIOSENS BIOELECTRON, V26, P4349, DOI 10.1016/j.bios.2011.04.036
   Morasso C, 2010, ADV FUNCT MATER, V20, P3932, DOI 10.1002/adfm.201001274
   Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h
   Pedrotti F. L., 2006, INTRO OPTICS
   Prosperi D, 2006, SMALL, V2, P1060, DOI 10.1002/smll.200600106
   Qavi AJ, 2009, ANAL BIOANAL CHEM, V394, P121, DOI 10.1007/s00216-009-2637-8
   Tsai WB, 1999, J BIOMED MATER RES, V44, P130, DOI 10.1002/(SICI)1097-4636(199902)44:2<130::AID-JBM2>3.0.CO;2-9                    
   Tseng D, 2010, LAB CHIP, V10, P1787, DOI 10.1039/c003477k
   You DJ, 2013, BIOSENS BIOELECTRON, V40, P180, DOI 10.1016/j.bios.2012.07.014
   Zhu HY, 2011, ANAL CHEM, V83, P6641, DOI 10.1021/ac201587a
   Zhu HY, 2011, LAB CHIP, V11, P315, DOI [10.1039/c0lc00358a, 10.1039/c01c00358a]
NR 19
TC 35
Z9 35
U1 5
U2 128
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD AUG 15
PY 2014
VL 58
BP 395
EP 402
DI 10.1016/j.bios.2014.02.077
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AH4PG
UT WOS:000336109900058
PM 24721381
DA 2018-01-05
ER

PT J
AU Orlowski, P
   Tomaszewska, E
   Gniadek, M
   Baska, P
   Nowakowska, J
   Sokolowska, J
   Nowak, Z
   Donten, M
   Celichowski, G
   Grobelny, J
   Krzyzowska, M
AF Orlowski, Piotr
   Tomaszewska, Emilia
   Gniadek, Marianna
   Baska, Piotr
   Nowakowska, Julita
   Sokolowska, Justyna
   Nowak, Zuzanna
   Donten, Mikolaj
   Celichowski, Grzegorz
   Grobelny, Jaroslaw
   Krzyzowska, Malgorzata
TI Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in
   Herpes Simplex Virus Type 2 Infection
SO PLOS ONE
LA English
DT Article
ID IN-VITRO; GENITAL HERPES; VIRAL ENTRY; CELLS; INHIBITION; TRANSMISSION;
   IMMUNITY; MICE; HIV; CYTOTOXICITY
AB The interaction between silver nanoparticles and herpesviruses is attracting great interest due to their antiviral activity and possibility to use as microbicides for oral and anogenital herpes. In this work, we demonstrate that tannic acid modified silver nanoparticles sized 13 nm, 33 nm and 46 nm are capable of reducing HSV-2 infectivity both in vitro and in vivo. The antiviral activity of tannic acid modified silver nanoparticles was size-related, required direct interaction and blocked virus attachment, penetration and further spread. All tested tannic acid modified silver nanoparticles reduced both infection and inflammatory reaction in the mouse model of HSV-2 infection when used at infection or for a post-infection treatment. Smaller-sized nanoparticles induced production of cytokines and chemokines important for anti-viral response. The corresponding control buffers with tannic acid showed inferior antiviral effects in vitro and were ineffective in blocking in vivo infection. Our results show that tannic acid modified silver nanoparticles are good candidates for microbicides used in treatment of herpesvirus infections.
C1 [Orlowski, Piotr; Krzyzowska, Malgorzata] Mil Inst Hyg & Epidemiol, Dept Regenerat Med, Warsaw, Poland.
   [Tomaszewska, Emilia; Celichowski, Grzegorz; Grobelny, Jaroslaw] Univ Lodz, Fac Chem, Dept Mat Technol & Chem, PL-90131 Lodz, Poland.
   [Gniadek, Marianna; Donten, Mikolaj] Univ Warsaw, Fac Chem, Warsaw, Poland.
   [Baska, Piotr] Warsaw Univ Life Sci, Fac Vet Med, Dept Preclin Sci, Warsaw, Poland.
   [Nowakowska, Julita] Univ Warsaw, Fac Biol, Lab Elect & Confocal Microscopy, Warsaw, Poland.
   [Sokolowska, Justyna] Warsaw Univ Life Sci, Fac Vet Med, Dept Morphol Sci, Warsaw, Poland.
   [Nowak, Zuzanna] Warsaw Univ Life Sci, Fac Anim Sci, Dept Genet & Anim Breeding, Warsaw, Poland.
RP Krzyzowska, M (reprint author), Mil Inst Hyg & Epidemiol, Dept Regenerat Med, Warsaw, Poland.
EM krzyzowskam@yahoo.com
OI Celichowski, Grzegorz/0000-0002-1624-3088; Grobelny,
   Jaroslaw/0000-0003-2648-2186
FU Polish National Science Centre [2011/03/B/NZ6/04878]; Centre for
   Preclinical Research and Technology (CePT) [POIG.02.02.00-14-024/08-0]
FX This work was supported by the Polish National Science Centre grant No.
   2011/03/B/NZ6/04878 (for MK) and Centre for Preclinical Research and
   Technology (CePT) Project No. POIG.02.02.00-14-024/08-0 (for MG and MD).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akhtar J, 2009, FEBS J, V276, P7228, DOI 10.1111/j.1742-4658.2009.07402.x
   Akiyama H, 2001, J ANTIMICROB CHEMOTH, V48, P487, DOI 10.1093/jac/48.4.487
   Aoki R, 2013, J INVEST DERMATOL, V133, P2170, DOI 10.1038/jid.2013.150
   ATHAR M, 1989, CANCER RES, V49, P5784
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6                                                   
   CHUNG KT, 1993, LETT APPL MICROBIOL, V17, P29, DOI 10.1111/j.1472-765X.1993.tb01428.x
   Cumberbatch M, 1997, ADV EXP MED BIOL, V417, P125
   de Lima R, 2012, J APPL TOXICOL, V32, P867, DOI 10.1002/jat.2780
   DUFF R, 1971, NATURE-NEW BIOL, V233, P48
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   FUKUCHI K, 1989, ANTIVIR RES, V11, P285, DOI 10.1016/0166-3542(89)90038-7                                                    
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Garner JA, 2003, ADV DRUG DELIVER REV, V55, P1497, DOI 10.1016/j.addr.2003.07.006
   Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284
   Gunalp A, 1965, P SOC EXP BIOL MED, V118, P185
   Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4
   Halioua B, 1999, EUR J DERMATOL, V9, P177
   Haslam E, 2007, PHYTOCHEMISTRY, V68, P2713, DOI 10.1016/j.phytochem.2007.09.009
   HORIKAWA K, 1994, MUTAGENESIS, V9, P523, DOI 10.1093/mutage/9.6.523
   Iijima N, 2011, P NATL ACAD SCI USA, V108, P284, DOI 10.1073/pnas.1005201108
   Johnston HJ, 2010, CRIT REV TOXICOL, V40, P328, DOI 10.3109/10408440903453074
   Khan NS, 2000, CHEM-BIOL INTERACT, V125, P177, DOI 10.1016/S0009-2797(00)00143-5                                                   
   Khanbabaee K, 2001, NAT PROD REP, V18, P641, DOI 10.1039/b101061l
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Kim KJ, 2008, J MICROBIOL BIOTECHN, V18, P1482
   Kleymann G, 2005, EXPERT OPIN INV DRUG, V14, P135, DOI 10.1517/13543781.14.2.135
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Krzyzowska M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.14
   Krzyzowska M, 2014, IMMUNOBIOLOGY, V219, P64, DOI 10.1016/j.imbio.2013.08.002
   KULESZMARTIN M, 1985, CARCINOGENESIS, V6, P1245, DOI 10.1093/carcin/6.9.1245
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Levin MJ, 2004, CLIN INFECT DIS, V39, pS248, DOI 10.1086/422364                                                                  
   Lin LT, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-187
   Lin LT, 2011, J VIROL, V85, P4386, DOI 10.1128/JVI.01492-10
   Liu HL, 2013, J HAZARD MATER, V248, P478, DOI 10.1016/j.jhazmat.2013.01.046
   Liu W, 2010, NANOTOXICOLOGY, V4, P319, DOI 10.3109/17435390.2010.483745
   Lu L, 2008, ANTIVIR THER, V13, P253
   Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209
   Mahad D, 2006, BRAIN, V129, P212, DOI 10.1093/brain/awh655
   Milligan GN, 1999, J VIROL, V73, P6380
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   Namvar L, 2005, J CLIN MICROBIOL, V43, P2058, DOI 10.1128/JCM.43.5.2058-2064.2005
   Orlowski P, 2013, TOXICOL IN VITRO, V27, P1798, DOI 10.1016/j.tiv.2013.05.010
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Paludan SR, 2001, J VIROL, V75, P8008, DOI 10.1128/JVI.75.17.8008-8015.2001                                                
   PARR MB, 1994, LAB INVEST, V70, P369
   Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10
   Samberg ME, 2010, ENVIRON HEALTH PERSP, V118, P407, DOI 10.1289/ehp.0901398
   SCALBERT A, 1991, PHYTOCHEMISTRY, V30, P3875, DOI 10.1016/0031-9422(91)83426-L
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI200113799
   Thapa M, 2008, Open Immunol J, V1, P33, DOI 10.2174/1874226200801010033
   Tobian AAR, 2009, CURR OPIN HIV AIDS, V4, P294, DOI 10.1097/COH.0b013e32832c1881
   Trefry JC, 2013, J BIOMED NANOTECHNOL, V9, P1624, DOI 10.1166/jbn.2013.1659
   Varghese 1 M, 2012, INT J CELL BIOL, V2012
   Wade James C, 2006, Hematology Am Soc Hematol Educ Program, P368
   Wong KKY, 2009, CHEMMEDCHEM, V4, P1129, DOI 10.1002/cmdc.200900049
   Xiang DX, 2013, INT J NANOMED, V8, P4103, DOI 10.2147/IJN.S53622
   Yen HJ, 2009, SMALL, V5, P1553, DOI 10.1002/smll.200900126
   Yilma AN, 2013, INT J NANOMED, V8, P2421, DOI 10.2147/IJN.S44090
NR 64
TC 21
Z9 22
U1 1
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 12
PY 2014
VL 9
IS 8
AR e104113
DI 10.1371/journal.pone.0104113
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3LJ
UT WOS:000341230400032
PM 25117537
OA gold
DA 2018-01-05
ER

PT J
AU Wang, L
   Han, YJ
   Zhou, S
   Guan, XY
AF Wang, Liang
   Han, Yujing
   Zhou, Shuo
   Guan, Xiyun
TI Real-time label-free measurement of HIV-1 protease activity by nanopore
   analysis
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 248th National Meeting of the American-Chemical-Society (ACS)
CY AUG 10-14, 2014
CL San Francisco, CA
SP Amer Chem Soc
C1 [Wang, Liang; Han, Yujing; Zhou, Shuo; Guan, Xiyun] IIT, Chicago, IL 60616 USA.
EM lwang118@iit.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 10
PY 2014
VL 248
MA 19-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA CA8JN
UT WOS:000349165101476
DA 2018-01-05
ER

PT J
AU Klein, PM
   Wagner, E
AF Klein, Philipp M.
   Wagner, Ernst
TI Bioreducible Polycations as Shuttles for Therapeutic Nucleic Acid and
   Protein Transfection
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID MOLECULAR-WEIGHT POLYETHYLENIMINE; HUMAN IMMUNODEFICIENCY VIRUS;
   MEDIATED SIRNA DELIVERY; EFFICIENT GENE DELIVERY; IN-VIVO; PLASMID DNA;
   ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; DRUG-DELIVERY; LINEAR
   POLYETHYLENIMINE
AB Significance: Nucleic acids such as gene-encoding DNAs, gene-silencing small interfering RNAs, or recombinant proteins addressing intracellular molecular targets present a major new therapeutic modality, provided efficient solutions for intracellular delivery can be found. The different physiological redox environments inside and outside the cell can be utilized for optimizing the involved transport processes. Recent Advances: Intracellular delivery of nucleic acids or proteins requires dynamic carriers that discriminate between different cellular locations. Bioreducible cationic polymers can package their therapeutic cargo stably in the extracellular environment, but sense the reducing intracellular cytosolic environment. Based on disulfide cleavage, carriers are degraded into biocompatible fragments and release the cargo in functional form. Disulfide linkages between oligocations, between the carrier and the cargo, or spatial caging of complexed cargo by disulfides have been pursued, with polymers or precise sequence-defined peptides and oligomers. Critical Issues: A quantitative knowledge of the bioreductive capacities within different biological compartments and the involved cellular reduction processes would be greatly helpful for improved carriers with disulfides cleaved within the right compartment at the right time. Future Directions: Novel designs of multifunctional nanocarriers will incorporate macromolecular disulfide entry mechanisms previously optimized by natural evolution of toxins and viruses. In addition to extracellular stabilization and intracellular disassembly, tuned disulfides will contribute to deshielding at the cell surface, or translocation from intracellular compartments to the cytosol.
C1 [Klein, Philipp M.; Wagner, Ernst] Univ Munich, Ctr Syst Based Drug Res, D-81377 Munich, Germany.
   [Klein, Philipp M.; Wagner, Ernst] Univ Munich, Ctr Nanosci CeNS, D-81377 Munich, Germany.
RP Wagner, E (reprint author), Univ Munich, Ctr Syst Based Drug Res, Butenandtstr 5-13, D-81377 Munich, Germany.
EM ernst.wagner@cup.uni-muenchen.de
RI Wagner, Ernst/A-7435-2012
OI Wagner, Ernst/0000-0001-8413-0934
FU German Research Foundation (DFG) [SFB1032 B4]; Cluster of Excellence
   Nanosystems Initiative Munich (NIM)
FX The authors thank Olga Bruck (LMU) for skillful assistance in preparing
   this article. This work was supported by the German Research Foundation
   (DFG) special research focus project grant SFB1032 B4 and the Cluster of
   Excellence Nanosystems Initiative Munich (NIM).
CR Behr JP, 1997, CHIMIA, V51, P34
   Benjaminsen RV, 2013, MOL THER, V21, P149, DOI 10.1038/mt.2012.185
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Breunig M, 2007, P NATL ACAD SCI USA, V104, P14454, DOI 10.1073/pnas.0703882104
   Brulisauer L, 2012, ANGEW CHEM INT EDIT, V51, P12454, DOI 10.1002/anie.201207070
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Burke RS, 2008, BIOCONJUGATE CHEM, V19, P693, DOI 10.1021/bc700388u
   Cerritelli S, 2007, BIOMACROMOLECULES, V8, P1966, DOI 10.1021/bm070085x
   Chen XY, 2010, BIOTECHNIQUES, V49, P513, DOI 10.2144/000113450
   Chen XL, 2005, DRUG DISCOV TODAY, V10, P587, DOI 10.1016/S1359-6446(05)03426-4
   Choi S, 2008, J CONTROL RELEASE, V131, P70, DOI 10.1016/j.jconrel.2008.07.007
   Christensen LV, 2006, BIOCONJUGATE CHEM, V17, P1233, DOI 10.1021/bc0602026
   Dalkara D, 2006, J CONTROL RELEASE, V116, P353, DOI 10.1016/j.jconrel.2006.10.005
   DEBS RJ, 1990, J BIOL CHEM, V265, P10189
   DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L
   DeRouchey J, 2008, BIOMACROMOLECULES, V9, P724, DOI 10.1021/bm7011482
   Didenko VV, 2005, ANAL BIOCHEM, V344, P168, DOI 10.1016/j.ab.2005.06.011
   Dohmen C, 2012, ACS NANO, V6, P5198, DOI 10.1021/nn300960m
   Dohmen C, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.10
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Fass D, 2012, ANNU REV BIOPHYS, V41, P63, DOI 10.1146/annurev-biophys-050511-102321
   FEENER EP, 1990, J BIOL CHEM, V265, P18780
   Felgner PL, 1997, HUM GENE THER, V8, P511, DOI 10.1089/hum.1997.8.5-511
   Fidias P, 2002, CLIN LUNG CANCER, V3, P219, DOI 10.3816/CLC.2002.n.006
   Filpula D, 2007, BIOCONJUGATE CHEM, V18, P773, DOI 10.1021/bc060314x
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Frohlich T, 2012, EUR J PHARM SCI, V47, P914, DOI 10.1016/j.ejps.2012.09.006
   Frohlich T, 2012, J CONTROL RELEASE, V160, P532, DOI 10.1016/j.jconrel.2012.03.018
   Futami J, 2005, J BIOSCI BIOENG, V99, P95, DOI 10.1263/jbb.99.095
   Gosselin MA, 2001, BIOCONJUGATE CHEM, V12, P989, DOI 10.1021/bc0100455
   Grandinetti G, 2011, MOL PHARMACEUT, V8, P1709, DOI 10.1021/mp200078n
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Han S, 2000, MOL THER, V2, P302, DOI 10.1006/mthe.2000.0142
   Hartmann L, 2006, BIOMACROMOLECULES, V7, P1239, DOI 10.1021/bm050884k
   Hartmann L, 2008, CHEM-EUR J, V14, P2025, DOI 10.1002/chem.200701223
   Hartmann L, 2007, MACROMOLECULES, V40, P7771, DOI 10.1021/ma071427u
   Hartmann L, 2011, MACROMOL CHEM PHYS, V212, P8, DOI 10.1002/macp.201000479
   HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199
   Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645
   Itaka K, 2004, J GENE MED, V6, P76, DOI 10.1002/jbm.470
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8                                                   
   Joshua-Tor L, 2004, STRUCTURE, V12, P1120, DOI 10.1016/j.str.2004.03.007
   June RK, 2010, J AM CHEM SOC, V132, P10680, DOI 10.1021/ja1040418
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kellogg BA, 2011, BIOCONJUGATE CHEM, V22, P717, DOI 10.1021/bc100480a
   Kim TI, 2011, REACT FUNCT POLYM, V71, P344, DOI 10.1016/j.reactfunctpolym.2010.11.016
   Kloeckner J, 2006, BIOCONJUGATE CHEM, V17, P1339, DOI 10.1021/bc060133v
   Knorr V, 2007, BIOCONJUGATE CHEM, V18, P1218, DOI 10.1021/bc060327a
   Knorr V, 2008, PHARM RES-DORDR, V25, P2937, DOI 10.1007/s11095-008-9700-6
   Koo H, 2010, BIOMATERIALS, V31, P988, DOI 10.1016/j.biomaterials.2009.10.004
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Kuai R, 2010, MOL PHARMACEUT, V7, P1816, DOI 10.1021/mp100171c
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897                                                         
   Kursa M, 2003, BIOCONJUGATE CHEM, V14, P222, DOI 10.1021/bc0256087
   Kwok A, 2011, NANOMED-NANOTECHNOL, V7, P210, DOI 10.1016/j.nano.2010.07.005
   Lee SY, 2010, J CONTROL RELEASE, V141, P339, DOI 10.1016/j.jconrel.2009.10.007
   Lee Y, 2010, ANGEW CHEM INT EDIT, V49, P2552, DOI 10.1002/anie.200905264
   LETVIN NL, 1986, J CLIN INVEST, V77, P977, DOI 10.1172/JCI112399                                                               
   LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553
   Liguori L, 2008, J CONTROL RELEASE, V126, P217, DOI 10.1016/j.jconrel.2007.12.004
   Lin C, 2008, J CONTROL RELEASE, V126, P166, DOI 10.1016/j.jconrel.2007.11.012
   Lin C, 2007, BIOCONJUGATE CHEM, V18, P138, DOI 10.1021/bc060200l
   Maier K, 2012, MOL PHARMACEUT, V9, P3560, DOI 10.1021/mp300404d
   Maier K, 2012, J AM CHEM SOC, V134, P10169, DOI 10.1021/ja302705v
   Matsumoto S, 2009, BIOMACROMOLECULES, V10, P119, DOI 10.1021/bm800985e
   McKenzie DL, 2000, J BIOL CHEM, V275, P9970, DOI 10.1074/jbc.275.14.9970
   Mercer J, 2010, ANNU REV BIOCHEM, V79, P803, DOI 10.1146/annurev-biochem-060208-104626
   Meyer M, 2008, J AM CHEM SOC, V130, P3272, DOI 10.1021/ja710344v
   Meyer Martin, 2006, Expert Opin Drug Deliv, V3, P563, DOI 10.1517/17425247.3.5.563
   Meyer M, 2009, MOL PHARMACEUT, V6, P752, DOI 10.1021/mp9000124
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.mythe.2005.02.010
   Mok H, 2010, NAT MATER, V9, P272, DOI [10.1038/NMAT2626, 10.1038/nmat2626]
   Nie Y, 2011, BIOMATERIALS, V32, P858, DOI 10.1016/j.biomaterials.2010.09.032
   Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319                                                          
   Oh KJ, 1999, P NATL ACAD SCI USA, V96, P8467, DOI 10.1073/pnas.96.15.8467                                                         
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Parmar RG, 2013, BIOCONJUGATE CHEM, V24, P640, DOI 10.1021/bc300600a
   Pichon C, 2000, NUCLEIC ACIDS RES, V28, P504, DOI 10.1093/nar/28.2.504                                                            
   Ping Y, 2013, BIOMATERIALS, V34, P6482, DOI 10.1016/j.biomaterials.2013.03.071
   Pirazzini M, 2013, FEBS LETT, V587, P150, DOI 10.1016/j.febslet.2012.11.007
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437                                                      
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028
   Read ML, 2003, J GENE MED, V5, P232, DOI 10.1002/jgm.331
   Read ML, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni085
   Russ V, 2008, GENE THER, V15, P18, DOI 10.1038/sj.gt.3303046
   Saito G, 2003, GENE THER, V10, P72, DOI 10.1038/sj.gt.3301859
   Saito G, 2003, ADV DRUG DELIVER REV, V55, P199, DOI 10.1016/S0169-409X(02)00179-5                                                   
   Salcher EE, 2012, J CONTROL RELEASE, V164, P380, DOI 10.1016/j.jconrel.2012.06.023
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Schaffert D, 2012, BIOCONJUGATE CHEM, V23, P1157, DOI 10.1021/bc200614x
   Schaffert D, 2011, ANGEW CHEM INT EDIT, V50, P8986, DOI 10.1002/anie.201102165
   Schaffert D, 2011, ORG LETT, V13, P1586, DOI 10.1021/ol200381z
   Schelhaas M, 2007, CELL, V131, P516, DOI 10.1016/j.cell.2007.09.038
   Schlossbauer A, 2011, ANGEW CHEM INT EDIT, V50, P6828, DOI 10.1002/anie.201005120
   Schnell R, 2003, ANN ONCOL, V14, P729, DOI 10.1093/annonc/mdg209
   Scholz C, 2012, J CONTROL RELEASE, V161, P554, DOI 10.1016/j.jconrel.2011.11.014
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Son S, 2012, ACCOUNTS CHEM RES, V45, P1100, DOI 10.1021/ar200248u
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Stolnik S, 2009, BIOTECHNOL LETT, V31, P1, DOI 10.1007/s10529-008-9834-y
   Sun HL, 2009, BIOMATERIALS, V30, P6358, DOI 10.1016/j.biomaterials.2009.07.051
   Tanna AP, 2012, OPHTHALMOLOGY, V119, P468, DOI 10.1016/j.ophtha.2011.08.041
   Thomas M, 2005, PHARM RES, V22, P373, DOI 10.1007/s11095-004-1874-y
   THORPE PE, 1987, CANCER RES, V47, P5924
   Radler J, 2012, EUR J PHARM BIOPHARM, V84, P255
   Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6
   Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.3.CO;2-I
   Vincenzi B, 2010, CURR CANCER DRUG TAR, V10, P80, DOI 10.2174/156800910790980241                                                      
   von Harpe A, 2000, J CONTROL RELEASE, V69, P309, DOI 10.1016/S0168-3659(00)00317-5
   Wagner E, 2006, ADV POLYM SCI, V192, P135, DOI 10.1007/12_023
   Wagner E, 2007, EXPERT OPIN BIOL TH, V7, P587, DOI 10.1517/14712598.7.5.587
   Wagner E, 2013, BIOMATER SCI-UK, V1, P804, DOI 10.1039/c3bm60071h
   Wagner E, 2012, ACCOUNTS CHEM RES, V45, P1005, DOI 10.1021/ar2002232
   Walczak CP, 2012, ANTIOXID REDOX SIGN, V16, P809, DOI 10.1089/ars.2011.4425
   Walker GF, 2005, MOL THER, V11, P418, DOI 10.1016/j.ymthe.2004.11.006
   Wang XL, 2009, J CONTROL RELEASE, V134, P207, DOI 10.1016/j.jconrel.2008.11.010
   Wernick NLB, 2010, TOXINS, V2, P310, DOI 10.3390/toxins2030310
   Wolfert MA, 1996, GENE THER, V3, P269
   Wu CL, 2012, NAT CHEM, V4, P1045, DOI [10.1038/NCHEM.1487, 10.1038/nchem.1487]
   Wu CL, 2011, CHEM-EUR J, V17, P10064, DOI 10.1002/chem.201101024
   Xia CQ, 2000, J PHARMACOL EXP THER, V295, P594
   Zhang GY, 2012, BIOCONJUGATE CHEM, V23, P1290, DOI 10.1021/bc300133r
   Ziady AG, 1999, J BIOL CHEM, V274, P4908, DOI 10.1074/jbc.274.8.4908
   Zinselmeyer BH, 2002, PHARMACEUT RES, V19, P960, DOI 10.1023/A:1016458104359
   Zou SM, 2000, J GENE MED, V2, P128, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W                 
NR 131
TC 22
Z9 23
U1 2
U2 35
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD AUG 10
PY 2014
VL 21
IS 5
BP 804
EP 817
DI 10.1089/ars.2013.5714
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AM2DT
UT WOS:000339660000011
PM 24219092
OA green_published
DA 2018-01-05
ER

PT J
AU Yang, YL
   Zhang, QH
   Gao, M
   Yang, XH
   Huang, ZW
   An, J
AF Yang, Yilei
   Zhang, Qinghao
   Gao, Mei
   Yang, Xiaohong
   Huang, Ziwei
   An, Jing
TI A Novel CXCR4-Selective High-Affinity Fluorescent Probe and Its
   Application in Competitive Binding Assays
SO BIOCHEMISTRY
LA English
DT Article
ID CHEMOKINE VMIP-II; CRYSTAL-STRUCTURE; HIV-1 ENTRY; CXCR4; DISSOCIATION;
   RECEPTORS; PEPTIDES; LIGAND; GPCR
AB We recently developed a new, rapid, and specific bioassay system that employs a fluorescent probe fabricated from our discovered CXCR4-specific ligand DV1. This new probe sensitively and selectively blocks the binding of native and synthetic ligands to CXCR4 at nanomolar levels, with a capability comparable to that seen with a conventional CXCR4 antibody. This nonradioactive, direct, and CXCR4-specific high-affinity screening system provides a new platform for CXCR4-targeted drug screening, as well as for the development of new probes for other GPCRs.
C1 [Yang, Yilei; Zhang, Qinghao; Gao, Mei; Huang, Ziwei; An, Jing] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.
   [Yang, Yilei; Yang, Xiaohong] Jilin Univ, Sch Pharmaceut Sci, Changchun 130021, Jilin, Peoples R China.
RP An, J (reprint author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.
EM anji@upstate.edu
FU National Institutes of Health; Carol M. Baldwin Breast Cancer Research
   Fund; Chinese Scholarship Council
FX This work was supported by grants from the National Institutes of Health
   and the Carol M. Baldwin Breast Cancer Research Fund. Y.Y. was supported
   in part by the Chinese Scholarship Council.
CR Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290
   Brelot A, 1997, J VIROL, V71, P4744
   Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002
   Choi WT, 2012, BIOCHEMISTRY-US, V51, P7078, DOI 10.1021/bi2016712
   Choi WT, 2012, J MED CHEM, V55, P977, DOI 10.1021/jm200568c
   Congreve M, 2011, J MED CHEM, V54, P4283, DOI 10.1021/jm200371q
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8
   Grunbeck A, 2011, BIOCHEMISTRY-US, V50, P3411, DOI 10.1021/bi200214r
   Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1
   Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656
   Li Y, 2007, PROTEINS, V67, P243, DOI 10.1002/prot.21172
   Liwang AC, 1999, PROTEIN SCI, V8, P2270
   Luo ZW, 2000, BIOCHEMISTRY-US, V39, P13545, DOI 10.1021/bi000633q
   Michael NL, 1998, J VIROL, V72, P6040
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390
   Piehler J, 2011, NAT CHEM BIOL, V7, P578, DOI 10.1038/nchembio.641
   Saini V, 2011, J BIOL CHEM, V286, P33466, DOI 10.1074/jbc.M111.233742
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X                                                   
NR 23
TC 0
Z9 0
U1 0
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD AUG 5
PY 2014
VL 53
IS 30
BP 4881
EP 4883
DI 10.1021/bi500500h
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AM7WH
UT WOS:000340078900001
PM 25058910
OA gold
DA 2018-01-05
ER

PT J
AU Maroto, EE
   Izquierdo, M
   Reboredo, S
   Marco-Martinez, J
   Filippone, S
   Martin, N
AF Maroto, Enrique E.
   Izquierdo, Marta
   Reboredo, Silvia
   Marco-Martinez, Juan
   Filippone, Salvatore
   Martin, Nazario
TI Chiral Fullerenes from Asymmetric Catalysis
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID 1,3-DIPOLAR CYCLOADDITION REACTIONS; AZOMETHINE YLIDES; CHIROPTICAL
   PROPERTIES; ADDITION PATTERN; HIV-1 PROTEASE; ORGANOCATALYSIS;
   DERIVATIVES; C-60; CHEMISTRY; FULLEROPYRROLIDINES
AB CONSPECTUS: Fullerenes are among the most studied molecules during the last three decades, and therefore, a huge number of chemical reactions have been tested on these new carbon allotropes. However, the aim of most of the reactions carried out on fullerenes has been to afford chemically modified fullerenes that are soluble in organic solvents or even water in the search for different mechanical, optical, or electronic properties. Therefore, although a lot of effort has been devoted to the chemical functionalization of these molecular allotropes of carbon, important aspects in the chemistry of fullerenes have not been properly addressed. In particular, the synthesis of chiral fullerenes at will in an efficient manner using asymmetric catalysis has not been previously addressed in fullerene science. Thus, despite the fact that the chirality of fullerenes has always been considered a fundamental issue, the lack of a general stereoselective synthetic methodology has restricted the use of enantiopure fullerene derivatives, which have usually been obtained only after highly expensive HPLC isolation on specific chiral columns or prepared from a pool of chiral starting materials. In this Account, we describe the first stereodivergent catalytic enantioselective syntheses in fullerene science, which have allowed the highly efficient synthesis of enantiomerically pure derivatives with total control of the stereochemical result using metallic catalysts and/or organocatalysts under very mild conditions. Density functional theory calculations strongly support the experimental findings for the assignment of the absolute configuration of the new stereocenters, which has also been ascertained by application of the sector rule and single-crystal X-ray diffraction. The use of the curved double bond of fullerene cages as a two-pi-electron component in a variety of stereoselective cycloaddition reactions represents a challenging goal considering that, in contrast to most of the substituted olefins used in these reactions, pristine fullerene is a noncoordinating dipolarophile. The aforementioned features make the study of stereoselective 1,3-dipolar cycloadditions onto fullerenes a unique scenario to shed light onto important mechanistic aspects. On the other hand, the availability of achiral starting materials as well as the use of nonexpensive asymmetric catalysts should provide access to chiral fullerenes and their further application in a variety of different fields. In this regard, in addition to biomedical applications, chiral fullerenes are of interest in less-studied areas such as materials science, organic electronics, and nanoscience, where control of the order and morphology at the nanometer scale are critical issues for achieving better device efficiencies.
C1 [Maroto, Enrique E.; Izquierdo, Marta; Reboredo, Silvia; Marco-Martinez, Juan; Filippone, Salvatore; Martin, Nazario] Univ Complutense Madrid, Fac Quim, Dept Quim Organ 1, E-28040 Madrid, Spain.
   [Martin, Nazario] IMDEA Nanosci, E-28049 Madrid, Spain.
RP Martin, N (reprint author), Univ Complutense Madrid, Fac Quim, Dept Quim Organ 1, Avda Complutense S-N, E-28040 Madrid, Spain.
EM nazmar@ucm.es
RI Izquierdo Barroso, Marta/K-2716-2014; Filippone, Salvatore/K-2360-2014;
   Marco-Martinez, Juan/K-1320-2014; Reboredo, Silvia/K-1285-2014; Martin,
   Nazario/B-4329-2008
OI Izquierdo Barroso, Marta/0000-0003-2696-4230; Filippone,
   Salvatore/0000-0002-2860-8566; Marco-Martinez, Juan/0000-0001-7266-7339;
   Reboredo, Silvia/0000-0002-8831-1828; Martin,
   Nazario/0000-0002-5355-1477
FU European Research Council [ERC-2012-ADG_20120216]; Ministerio de
   Economia y Competitividad (MINECO) of Spain [CTQ2011-24652]; CAM
   (MADRISOLAR-2 Project) [S2009/PPQ-1533]
FX This work was supported by the European Research Council
   ERC-2012-ADG_20120216 (Chirallcarbon), the Ministerio de Economia y
   Competitividad (MINECO) of Spain (Project CTQ2011-24652), and the CAM
   (MADRISOLAR-2 Project S2009/PPQ-1533). N.M. thanks the Alexander von
   Humboldt Foundation.
CR Adrio J, 2011, CHEM COMMUN, V47, P6784, DOI 10.1039/c1cc10779h
   Aleman J, 2011, CHEM-EUR J, V17, P6890, DOI 10.1002/chem.201003694
   Bianco A, 1996, J AM CHEM SOC, V118, P4072, DOI 10.1021/ja9539249                                                               
   CHAI Y, 1991, J PHYS CHEM-US, V95, P7564, DOI 10.1021/j100173a002                                                             
   Connon SJ, 2008, CHEM COMMUN, P2499, DOI 10.1039/b719249e
   Cozzi F, 2005, PURE APPL CHEM, V77, P843, DOI 10.1351/pac200577050843
   Djojo F, 1998, CHEM-EUR J, V4, P344, DOI 10.1002/(SICI)1521-3765(19980210)4:2<344::AID-CHEM344>3.3.CO;2-P
   Donovan B. F. O., 1997, CHEM COMMUN, P81
   Enders D, 2007, CHEM REV, V107, P5606, DOI 10.1021/cr068372z
   ETTL R, 1991, NATURE, V353, P149, DOI 10.1038/353149a0
   Filippone S, 2009, NAT CHEM, V1, P578, DOI 10.1038/NCHEM.361
   Fisk JS, 2007, CHEM SOC REV, V36, P1432, DOI 10.1039/b511113g
   Fleming I., 2010, MOL ORBITALS ORGANIC
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   Gothelf AS, 2002, ANGEW CHEM INT EDIT, V41, P4236, DOI 10.1002/1521-3773(20021115)41:22<4236::AID-ANIE4236>3.0.CO;2-W                  
   Gothelf KV, 1998, CHEM REV, V98, P863, DOI 10.1021/cr970324e                                                               
   Guerra S, 2013, CHEM COMMUN, V49, P4752, DOI 10.1039/c3cc41409d
   Guldi D. M., 2002, FULLERENES SYNTHESIS
   Illescas BM, 2005, J ORG CHEM, V70, P6929, DOI 10.1021/jo0509197
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Lu X, 2011, CHEM COMMUN, V47, P5942, DOI 10.1039/c1cc10123d
   MAGGINI M, 1993, J AM CHEM SOC, V115, P9798, DOI 10.1021/ja00074a056                                                             
   Marco-Martinez J, 2014, J AM CHEM SOC, V136, P2897, DOI 10.1021/ja500071k
   Marco-Martinez J, 2013, ANGEW CHEM INT EDIT, V52, P5115, DOI 10.1002/anie.201301292
   Maroto EE, 2014, J AM CHEM SOC, V136, P705, DOI 10.1021/ja410408c
   Maroto EE, 2014, CHEM COMMUN, V50, P740, DOI 10.1039/c3cc46999a
   Maroto EE, 2012, J AM CHEM SOC, V134, P12936, DOI 10.1021/ja306105b
   Maroto EE, 2011, ANGEW CHEM INT EDIT, V50, P6060, DOI 10.1002/anie.201101246
   Meier MS, 1998, J AM CHEM SOC, V120, P2337, DOI 10.1021/ja973957j                                                               
   Melhado AD, 2007, J AM CHEM SOC, V129, P12638, DOI 10.1021/ja074824t
   Nierengarten JF, 1996, ANGEW CHEM INT EDIT, V35, P2101, DOI 10.1002/anie.199621011                                                          
   Nishimura T, 2004, J AM CHEM SOC, V126, P11711, DOI 10.1021/ja0466331
   Pantarotto D, 2002, J AM CHEM SOC, V124, P12543, DOI 10.1021/ja027603q
   Peddibhotla S, 2004, J AM CHEM SOC, V126, P12776, DOI 10.1021/ja046149i
   Prato M, 1998, ACCOUNTS CHEM RES, V31, P519, DOI 10.1021/ar970210p                                                               
   Sawai K, 2011, J AM CHEM SOC, V133, P17746, DOI 10.1021/ja2062727
   Tan XF, 1998, TETRAHEDRON LETT, V39, P4187, DOI 10.1016/S0040-4039(98)00781-3                                                   
   Thilgen C, 2003, TOP STEREOCHEM, V23, P1
   Thilgen C, 2006, CHEM REV, V106, P5049, DOI 10.1021/cr0505371
   Wakahara T, 2006, J AM CHEM SOC, V128, P14228, DOI 10.1021/ja064751y
   WILSON SR, 1995, J ORG CHEM, V60, P6496, DOI 10.1021/jo00125a040                                                             
   Wu SH, 1998, J CHEM SOC PERK T 1, P1733, DOI 10.1039/a705962k                                                                
   Xi YM, 2013, CHEM COMMUN, V49, P8583, DOI 10.1039/c3cc40825f
   ZHANG CM, 1995, J ORG CHEM, V60, P2906, DOI 10.1021/jo00114a048                                                             
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   [Anonymous], 2007, CHEM REV, V107, P5413
NR 46
TC 52
Z9 53
U1 5
U2 92
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
EI 1520-4898
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD AUG
PY 2014
VL 47
IS 8
BP 2660
EP 2670
DI 10.1021/ar500201b
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA AN6JY
UT WOS:000340702000042
PM 25080165
DA 2018-01-05
ER

PT J
AU Buehler, DC
   Marsden, MD
   Shen, S
   Toso, DB
   Wu, XM
   Loo, JA
   Zhou, ZH
   Kickhoefer, VA
   Wender, PA
   Zack, JA
   Rome, LH
AF Buehler, Daniel C.
   Marsden, Matthew D.
   Shen, Sean
   Toso, Daniel B.
   Wu, Xiaomeng
   Loo, Joseph A.
   Zhou, Z. Hong
   Kickhoefer, Valerie A.
   Wender, Paul A.
   Zack, Jerome A.
   Rome, Leonard H.
TI Bioengineered Vaults: Self-Assembling Protein Shell-Lipophilic Core
   Nanoparticles for Drug Delivery
SO ACS NANO
LA English
DT Article
DE vaults; nanoparticles; drug delivery systems; bryostatin 1; HIV latency
ID HEPATITIS-C VIRUS; LATENT HIV; RIBONUCLEOPROTEIN-PARTICLES; BRYOSTATIN
   ANALOGS; IN-VITRO; SYSTEMS; 5A; THERAPEUTICS; PROSTRATIN; COMPONENT
AB We report a novel approach to a new class of bioengineered, monodispersecl, self-assembling vault nanoparticles consisting of a protein shell exterior with a lipophilic core interior designed for drug and probe delivery. Recombinant vaults were engineered to contain a small amphipathic alpha-helix derived from the nonstructural protein SA of hepatitis C virus, thereby creating within the vault lumen a lipophilic microenvironment into which lipophilic compounds could be reversibly encapsulated. Multiple types of electron microscopy showed that attachment of this peptide resulted in larger than expected additional mass internalized within the vault lumen attributable to incorporation of host lipid membrane constituents spanning the vault waist (>35 nm). These bioengineered lipophilic vaults reversibly associate with a sample set of therapeutic compounds, including all trans retinoic acid, amphotericin B, and bryostatin 1, incorporating hundreds to thousands of drug molecules per vault nanoparticle. Bryostatin 1 is of particular therapeutic interest because of its ability to potently induce expression of latent HIV, thus representing a preclinical lead in efforts to eradicate HIV/AIDS. Vaults loaded with bryostatin 1 released free drug, resulting in activation of HIV from provirus latency in vitro and induction of CD69 biomarker expression following intravenous injection into mice. The ability to preferentially and reversibly encapsulate lipophilic compounds into these novel bioengineered vault nanoparticles greatly advances their potential use as drug delivery systems.
C1 [Buehler, Daniel C.; Loo, Joseph A.; Kickhoefer, Valerie A.; Rome, Leonard H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Marsden, Matthew D.] Univ Calif Los Angeles, Div Hematol & Oncol, Dept Med, Los Angeles, CA 90095 USA.
   [Shen, Sean; Loo, Joseph A.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.
   [Toso, Daniel B.; Wu, Xiaomeng; Zhou, Z. Hong; Zack, Jerome A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Loo, Joseph A.] Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90095 USA.
   [Zhou, Z. Hong; Zack, Jerome A.; Rome, Leonard H.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA.
   [Buehler, Daniel C.; Wender, Paul A.] Stanford Univ, Dept Chem & Syst Biol, Dept Chem, Stanford, CA 94305 USA.
RP Zack, JA (reprint author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
EM jzack@ucla.edu; lrome@mednet.ucla.edu
RI Rome, Leonard/E-8786-2016
OI Rome, Leonard/0000-0002-1236-2063; Kickhoefer,
   Valerie/0000-0002-0048-0580
FU National Institutes of Health [AI70010, U19AI096113, 3.4, GM071940,
   AI094386, S10RR024605, R01GM103479, R01 CA031841, R01 CA031845]; UCLA
   CFAR [AI28697]; Bill and Melinda Gates Foundation [OPP1032668]
FX The authors gratefully acknowledge support from the National Institutes
   of Health (AI70010 to J.Z., U19AI096113, Project 3.4 to J.Z., GM071940
   and AI094386 to Z. H.Z., S10RR024605 and R01GM103479 to J.A.L., and R01
   CA031841 and R01 CA031845 to P.A.W.); the UCLA CFAR (AI28697) for core
   support and a UCLA CFAR Seed Grant to L H.R.; and a Grand Challenges
   Explorations Grant (OPP1032668 to J.Z.) from the Bill and Melinda Gates
   Foundation.
CR Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Bayburt TH, 2010, FEBS LETT, V584, P1721, DOI 10.1016/j.febslet.2009.10.024
   Beans EJ, 2013, P NATL ACAD SCI USA, V110, P11698, DOI 10.1073/pnas.1302634110
   Bear HD, 1996, ANTI-CANCER DRUG, V7, P299, DOI 10.1097/00001813-199605000-00010                                                
   Bignami GS, 1996, BBA-MOL CELL RES, V1312, P197, DOI 10.1016/0167-4889(96)00018-3
   Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200
   Buehler DC, 2011, SMALL, V7, P1432, DOI 10.1002/smll.201002274
   Civjan NR, 2003, BIOTECHNIQUES, V35, P556
   DeChristopher BA, 2012, NAT CHEM, V4, P705, DOI [10.1038/NCHEM.1395, 10.1038/nchem.1395]
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0
   Fauman EB, 2011, CURR OPIN CHEM BIOL, V15, P463, DOI 10.1016/j.cbpa.2011.05.020
   Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005
   Hamill R, 2013, DRUGS, V73, P919, DOI 10.1007/s40265-013-0069-4
   Hu H, 2004, LANGMUIR, V20, P7436, DOI 10.1021/la049423v
   KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225
   KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699
   Khabar KSA, 2002, J INTERF CYTOK RES, V22, P1005, DOI 10.1089/107999002760624224
   Kickhoefer VA, 2005, P NATL ACAD SCI USA, V102, P4348, DOI 10.1073/pnas.0500929102
   Kickhoefer VA, 2009, ACS NANO, V3, P27, DOI 10.1021/nn800638x
   Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Ma YJ, 2012, ADV DRUG DELIVER REV, V64, P811, DOI 10.1016/j.addr.2012.01.005
   Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0
   Marsden MD, 2013, BIOORG MED CHEM LETT, V23, P4003, DOI 10.1016/j.bmcl.2013.05.032
   Marsden MD, 2010, FUTURE VIROL, V5, P97, DOI 10.2217/FVL.09.70
   McLauchlan J, 2009, BIOCHEM SOC T, V37, P986, DOI 10.1042/BST0370986
   Mehla R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011160
   Mikyas Y, 2004, J MOL BIOL, V344, P91, DOI 10.1016/j.jmb.2004.09.021
   Moradpour Darius, 2005, Hepatology, V42, P732, DOI 10.1002/hep.20851
   Nelson T. J., 2013, J CHROMATOGR B, V944C, P55
   Pawlotsky JM, 1999, J VIRAL HEPATITIS, V6, P343, DOI 10.1046/j.1365-2893.1999.00185.x                                                
   Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200
   Poderycki MJ, 2006, BIOCHEMISTRY-US, V45, P12184, DOI 10.1021/bi0610552
   Rome LH, 2013, ACS NANO, V7, P889, DOI 10.1021/nn3052082
   Ryan RO, 2008, EXPERT OPIN DRUG DEL, V5, P343, DOI 10.1517/17425247.5.3.343 
   Stephen AG, 2001, J BIOL CHEM, V276, P23217, DOI 10.1074/jbc.C100226200                                                          
   Suprenant KA, 2002, BIOCHEMISTRY-US, V41, P14447, DOI 10.1021/bi026747e
   Tanaka H, 2009, SCIENCE, V323, P384, DOI 10.1126/science.1164975
   Tellinghuisen TL, 2005, NATURE, V435, P374, DOI 10.1038/nature03580
   Tufteland M, 2008, J PHARM SCI-US, V97, P4425, DOI 10.1002/jps.21325
   Uskokovic V, 2013, J BIOMED NANOTECHNOL, V9, P1441, DOI 10.1166/jbn.2013.1642
   van Zon A, 2003, CELL MOL LIFE SCI, V60, P1828, DOI 10.1007/s00018-003-3030-y
   Wender PA, 2008, SCIENCE, V320, P649, DOI 10.1126/science.1154690
   Wender PA, 2011, P NATL ACAD SCI USA, V108, P6721, DOI 10.1073/pnas.1015270108
   Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561
NR 46
TC 13
Z9 13
U1 0
U2 45
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD AUG
PY 2014
VL 8
IS 8
BP 7723
EP 7732
DI 10.1021/nn5002694
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AO0IM
UT WOS:000340992300017
PM 25061969
OA gold
DA 2018-01-05
ER

PT J
AU Pejawar-Gaddy, S
   Kovacs, JM
   Barouch, DH
   Chen, B
   Irvine, DJ
AF Pejawar-Gaddy, Sharmila
   Kovacs, James M.
   Barouch, Dan H.
   Chen, Bing
   Irvine, Darrell J.
TI Design of Lipid Nanocapsule Delivery Vehicles for Multivalent Display of
   Recombinant Env Trimers in HIV Vaccination
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID BROADLY NEUTRALIZING ANTIBODIES; IMMUNODEFICIENCY-VIRUS TYPE-1;
   NANOPARTICLE VACCINES; SYNTHETIC VACCINES; MONOMERIC GP120; RESPONSES;
   IMMUNOGENICITY; ADJUVANT; ANTIGEN; GP140
AB Immunization strategies that elicit antibodies capable of neutralizing diverse virus strains will likely be an important part of a successful vaccine against HIV. However, strategies to promote robust humoral responses against the native intact HIV envelope trimer structure are lacking. We recently developed chemically crosslinked lipid nanocapsules as carriers of molecular adjuvants and encapsulated or surface-displayed antigens, which promoted follicular helper T-cell responses and elicited high-avidity, durable antibody responses to a candidate malaria antigen. To apply this system to the delivery of HIV antigens, Env gp140 trimers with terminal histags (gp140T-his) were anchored to the surface of lipid nanocapsules via Ni-NTA-functionalized lipids. Initial experiments revealed that the large (409 kDa), heavily glycosylated trimers were capable of extracting fluid phase lipids from the membranes of nanocapsules. Thus, liquid-ordered and/or gel-phase lipid compositions were required to stably anchor trimers to the particle membranes. Trimer-loaded nanocapsules combined with the clinically relevant adjuvant monophosphoryl lipid A primed high-titer antibody responses in mice at antigen doses ranging from 5 mu g to as low as 100 ng, whereas titers dropped more than 50-fold over the same dose range when soluble trimer was mixed with a strong oil-in-water adjuvant comparator. Nanocapsule immunization also broadened the number of distinct epitopes on the HIV trimer recognized by the antibody response. These results suggest that nanocapsules displaying HIV trimers in an oriented, multivalent presentation can promote key aspects of the humoral response against Env immunogens.
C1 [Pejawar-Gaddy, Sharmila; Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Irvine, Darrell J.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Irvine, Darrell J.] MIT, Dept Mat Sci, Cambridge, MA 02139 USA.
   [Kovacs, James M.; Chen, Bing] Boston Childrens Hosp, Boston, MA 02115 USA.
   [Pejawar-Gaddy, Sharmila; Barouch, Dan H.; Irvine, Darrell J.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
   [Barouch, Dan H.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Virol, Boston, MA 02115 USA.
   [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Irvine, DJ (reprint author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM djirvine@mit.edu
FU NIH [AI095109, AI104715]; Ragon Institute of MGH, MIT, and Harvard
FX This work was funded by the NIH (AI095109 and AI104715) and the Ragon
   Institute of MGH, MIT, and Harvard. D.J.I. is an investigator of the
   Howard Hughes Medical Institute.
CR Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bal SM, 2011, VACCINE, V29, P1045, DOI 10.1016/j.vaccine.2010.11.061
   Beddows S, 2005, J VIROL, V79, P8812, DOI 10.1128/JVI.79.14.8812-8827.2005
   Beddows S, 2007, VIROLOGY, V360, P329, DOI 10.1016/j.virol.2006.10.032
   Bershteyn A, 2012, J CONTROL RELEASE, V157, P354, DOI 10.1016/j.jconrel.2011.07.029
   Blumenthal R, 2012, J BIOL CHEM, V287, P40841, DOI 10.1074/jbc.R112.406272
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Chikh GG, 2002, BBA-BIOMEMBRANES, V1567, P204, DOI 10.1016/S0005-2736(02)00618-1                                                   
   Clapham PR, 2011, NATURE, V477, P416, DOI 10.1038/477416a
   Demberg T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00250
   Earl PL, 2001, J VIROL, V75, P645, DOI 10.1128/JVI.75.2.645-653.2001
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Gilbert P, 2010, J INFECT DIS, V202, P595, DOI 10.1086/654816
   Gonzalez N, 2010, CURR HIV RES, V8, P602, DOI 10.2174/157016210794088236
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Henriksen-Lacey M, 2011, MOL PHARMACEUT, V8, P153, DOI 10.1021/mp100208f
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Kang Y, 2009, VACCINE, V27, P5120, DOI 10.1016/j.vaccine.2009.06.037
   Kim M, 2005, AIDS RES HUM RETROV, V21, P58, DOI 10.1089/aid.2005.21.58
   Kovacs JM, 2012, P NATL ACAD SCI USA, V109, P12111, DOI 10.1073/pnas.1204533109
   Kwong PD, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007278
   Li AV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006516
   Masek J, 2011, J CONTROL RELEASE, V151, P193, DOI 10.1016/j.jconrel.2011.01.016
   Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963
   Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109
   Moon JJ, 2011, NAT MATER, V10, P243, DOI [10.1038/nmat2960, 10.1038/NMAT2960]
   Nkolola JP, 2010, J VIROL, V84, P3270, DOI 10.1128/JVI.02252-09
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   Pihlgren M, 2013, BLOOD, V121, P85, DOI 10.1182/blood-2012-02-413831
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Scott EA, 2012, BIOMATERIALS, V33, P6211, DOI 10.1016/j.biomaterials.2012.04.060
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   van Broekhoven CL, 2005, BBA-BIOMEMBRANES, V1716, P104, DOI 10.1016/j.bbamem.2005.09.003
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Watson DS, 2011, CLIN VACCINE IMMUNOL, V18, P289, DOI 10.1128/CVI.00425-10
   Yang XZ, 2001, J VIROL, V75, P1165, DOI 10.1128/JVI.75.3.1165-1171.2001
NR 40
TC 9
Z9 9
U1 1
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD AUG
PY 2014
VL 25
IS 8
BP 1470
EP 1478
DI 10.1021/bc5002246
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA AN6VG
UT WOS:000340735900014
PM 25020048
OA gold
DA 2018-01-05
ER

PT J
AU Manosroi, J
   Lohcharoenkal, W
   Gotz, F
   Werner, RG
   Manosroi, W
   Manosroi, A
AF Manosroi, Jiradej
   Lohcharoenkal, Warangkana
   Goetz, Friedrich
   Werner, Rolf G.
   Manosroi, Worapaka
   Manosroi, Aranya
TI Novel application of polioviral capsid: development of a potent and
   prolonged oral calcitonin using polioviral binding ligand and Tat
   peptide
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Calcitonin; cell penetrating peptide; oral administration; peptide
   delivery; viral ligand
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SALMON-CALCITONIN; IN-VIVO; PROTEIN
   TRANSDUCTION; THERAPEUTIC USE; DELIVERY; RECEPTOR; ABSORPTION; DRUGS;
   NANOPARTICLES
AB Context: Poor absorption and proteolytic degradation are major obstacles of orally administered peptide drugs including calcitonin. Cell penetrating peptides (CPPs) and receptor binding ligands are interesting tools for the application in the delivery of these drugs.
   Objective: To investigate the enhancements of in vitro and in vivo salmon calcitonin (sCT) activity by Tat, a trans-activating transcriptional peptide and VP1 peptide (V) from polioviral capsid.
   Materials and methods: Tat/sCT, V/sCT and V/Tat/sCT mixtures at various molar ratios were prepared and investigated for in vitro and in vivo activities of sCT.
   Results: Tat could increase in vitro sCT activity both in colon adenocarcinoma (HT-29) and mouth epidermal carcinoma (KB) cells. V/sCT (6:1) showed significant increase of intracellular calcium in HT-29 cells. V/Tat/sCT (6:1:1) gave highest increase of intracellular calcium in both cells. Oral administered Tat/sCT (1:1) showed comparable hypocalcemic effect to sCT injection with prolonged action. V/Tat/sCT (6:1:1) demonstrated hypocalcemic effect at 12 h after administration but no hypocalcemic effect was observed from V/sCT.
   Discussion: Positive charge from Tat might facilitate sCT uptake and absorption. Increasing of intracellular calcium in HT-29 cells by V but lacking of hypocalcemic effect from V/sCT in mice indicated the ligand-receptor mediated delivery of sCT by the interaction between V and PVR.
   Conclusion: Potential application of V and Tat in oral calcitonin delivery system was demonstrated. Further study in a proper PVR bearing host is still needed to provide more useful information for the application of V in the development of drug delivery systems.
C1 [Manosroi, Jiradej; Lohcharoenkal, Warangkana; Manosroi, Aranya] Chiang Mai Univ, Fac Pharm, Chiang Mai 50200, Thailand.
   [Manosroi, Jiradej; Manosroi, Aranya] Chiang Mai Univ, Sci & Technol Res Inst, Nat Prod Res & Dev Ctr, Chiang Mai 50200, Thailand.
   [Goetz, Friedrich] Univ Tubingen, Fac Biol, Dept Microbial Genet, Tubingen, Germany.
   [Werner, Rolf G.] Boehringer Ingelheim Co, Ingelheim, Germany.
   [Manosroi, Worapaka] Chiang Mai Univ, Fac Med, Dept Med, Chiang Mai 50200, Thailand.
RP Manosroi, J (reprint author), Chiang Mai Univ, Fac Pharm, Chiang Mai 50200, Thailand.
EM jiradej.manosroi8@gmail.com
FU Thailand Research Fund (TRF) under the RGJ-PhD program; Nanoscience and
   Nanotechnology Research Center Project; Faculty of Sciences, Chiang Mai
   University, Thailand; Natural Product Research and Development Center
   (NPRDC), Science and Technology Research Institute (STRI), Chiang Mai
   University, Thailand
FX This work was supported by the Thailand Research Fund (TRF) under the
   RGJ-PhD program, Nanoscience and Nanotechnology Research Center Project,
   Faculty of Sciences, Chiang Mai University, Thailand and Natural Product
   Research and Development Center (NPRDC), Science and Technology Research
   Institute (STRI), Chiang Mai University, Thailand.
CR AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321
   Azria M, 1989, CALCITONINS PHYSL PH
   Bais MV, 2008, BIOCHEM BIOPH RES CO, V370, P27, DOI 10.1016/j.bbrc.2008.03.023
   BERKHOUT B, 1989, J VIROL, V63, P5501
   Brown ME, 1999, J THERM ANAL CALORIM, V56, P1317, DOI 10.1023/A:1010150305542                                                         
   Cao GD, 2002, J NEUROSCI, V22, P5423
   CHEN T, 1995, THERMOCHIM ACTA, V248, P229, DOI 10.1016/0040-6031(94)01892-K                                                    
   Cheng WP, 2010, J CONTROL RELEASE, V147, P289, DOI 10.1016/j.jconrel.2010.07.128
   [Anonymous], 2007, EUR PHARM 6 0, P1372
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRUCHT H, 1992, CANCER RES, V52, P1114
   GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422
   GRANT RA, 1994, CURR BIOL, V4, P784, DOI 10.1016/S0960-9822(00)00176-7                                                   
   Harell A, 1975, CALCIFIED TISSUE INT, V21, P332
   HAUBER J, 1989, J VIROL, V63, P1181
   He YN, 2000, P NATL ACAD SCI USA, V97, P79, DOI 10.1073/pnas.97.1.79                                                            
   Ida-Hosonuma S, 2003, ARCH VIROL, V148, P29
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   KOIKE S, 1990, EMBO J, V9, P3217
   Lagguth P, 1997, J CONTROL RELEASE, V46, P39
   Lee HE, 2010, J CONTROL RELEASE, V143, P251, DOI 10.1016/j.jconrel.2009.12.011
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li YS, 2008, PHARM RES-DORD, V25, P259, DOI 10.1007/s11095-007-9365-6
   Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6                                                   
   MANN DA, 1991, EMBO J, V10, P1733
   Manosroi A, 2011, J PHARM SCI, V100, P1525
   Manosroi J, 2013, DRUG DEV IND PHARM, V39, P520, DOI 10.3109/03639045.2012.684388
   Manosroi J, 2012, DRUG DELIV, V19, P21, DOI 10.3109/10717544.2011.621991
   Marechal Y, 2007, HYDROGEN BOND FORMAT
   Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236                                                            
   MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv-8-4-377                                                            
   Mosharraf M, 2004, DRUG DEV IND PHARM, V30, P461, DOI 10.1081/DDC-120037472
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Mukesh Kumar, 2008, Scientia Pharmaceutica, V76, P761, DOI 10.3797/scipharm.0808-09
   Myrberg H, 2007, BIOCONJUGATE CHEM, V18, P170, DOI 10.1021/bc060266g
   PATEL S, 1993, DRUGS, V46, P594, DOI 10.2165/00003495-199346040-00003
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Sakuma S, 2002, INT J PHARM, V239, P185, DOI 10.1016/S0378-5173(02)00113-8
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Sarmento B, 2006, CARBOHYD POLYM, V66, P1, DOI 10.1016/j.carbpol.2006.02.008
   Schneyer CR, 1991, MD MED J, V40, P469
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L
   Sinko P. J., 1993, Pharmaceutical Research (New York), V10, pS293
   STEVENSON JC, 1981, DRUGS, V21, P257, DOI 10.2165/00003495-198121040-00002
   STROOP SD, 1995, J BONE MINER RES, V10, P524
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Vyas SP, 2001, CRIT REV THER DRUG, V18, P1
   Wimalawansa SJ, 1997, J BONE MINER METAB, V15, P160
   Wu L, 2010, DRUG DEV IND PHARM, V36, P362, DOI [10.3109/03639040903173580, 10.1080/03639040903173580]
   Yang M, 2007, INT J PHARM, V331, P176, DOI 10.1016/j.ijpharm.2006.10.030
   Yang T, 2006, J CONTROL RELEASE, V115, P289, DOI 10.1016/j.jconrel.2006.08.015
   Yu H., 1994, Pharmaceutical Research (New York), V11, pS254
   ZHOU XH, 1994, J CONTROL RELEASE, V29, P239
NR 54
TC 3
Z9 3
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD AUG
PY 2014
VL 40
IS 8
BP 1092
EP 1100
DI 10.3109/03639045.2013.809533
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AN2ZW
UT WOS:000340455600013
PM 23802147
DA 2018-01-05
ER

PT J
AU Kolonics, A
   Csiszovszki, Z
   Toke, ER
   Lorincz, O
   Haluszka, D
   Szipocs, R
AF Kolonics, Attila
   Csiszovszki, Zsolt
   Toke, Eniko R.
   Lorincz, Orsolya
   Haluszka, Dora
   Szipocs, Robert
TI In vivo study of targeted nanomedicine delivery into Langerhans cells by
   multiphoton laser scanning microscopy
SO EXPERIMENTAL DERMATOLOGY
LA English
DT Article
DE eGFP-Langerin knock-in mice; in vivo; Langerhans cells; multiphoton
   laser microscopy; nanomedicine formulation
AB Epidermal Langerhans cells (LCs) function as professional antigen-presenting cells of the skin. We investigated the LC-targeting properties of a special mannose-moiety-coated pathogen-like synthetic nanomedicine DermaVir (DV), which is capable to express antigens to induce immune responses and kill HIV-infected cells. Our aim was to use multiphoton laser microscopy (MLM) in vivo in order to visualize the uptake of Alexa-labelled DV (AF546-DV) by LCs. Knock-in mice expressing enhanced green fluorescent protein (eGFP) under the control of the langerin gene (CD207) were used to visualize LCs. After 1 h, AF546-DV penetrated the epidermis and entered the eGFP-LCs. The AF546-DV signal was equally distributed inside the LCs. After 9 h, we observed AF546-DV signal accumulation that occurred mainly at the cell body. We demonstrated in live animals that LCs picked up and accumulated the nanoparticles in the cell body.
C1 [Kolonics, Attila; Haluszka, Dora; Szipocs, Robert] Inst Solid State Phys & Opt Wigner RCP, H-1525 Budapest, Hungary.
   [Kolonics, Attila; Szipocs, Robert] R&D Ultrafast Lasers Ltd, Budapest, Hungary.
   [Csiszovszki, Zsolt; Toke, Eniko R.; Lorincz, Orsolya] Genet Immun Kft, Budapest, Hungary.
   [Haluszka, Dora] Semmelweis Univ Hungary, Dept Dermatol Venereol & Dermatooncol, Budapest, Hungary.
RP Szipocs, R (reprint author), Inst Solid State Phys & Opt Wigner RCP, POB 49, H-1525 Budapest, Hungary.
EM szipocs.robert@wigner.mta.hu
FU Hungarian Development Agency (NFU) [TECH-09-A2-2009-0134]
FX The authors wish to thank Drs B. Malissen (Centre d'Immunologie de
   Marseille-Luminy), N. Romani and P. Stoitzner (Department of Dermatology
   & Venereology, Innsbruck Medical University) and Julia Lisziewicz
   (Genetic Immunity) for their support. This research was supported by the
   Hungarian Development Agency (NFU) under contract no.
   TECH-09-A2-2009-0134.
CR Breunig HG, 2010, OPT EXPRESS, V18, P7857, DOI 10.1364/OE.18.007857
   Fichter KM, 2013, ACS NANO, V7, P347, DOI 10.1021/nn304218q
   Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004
   Kolonics A, 2013, OPTICS LIFE SCI
   Kubo Akiharu, 2013, Methods Mol Biol, V961, P119, DOI 10.1007/978-1-62703-227-8_5
   Lee MY, 2013, BMB REP, V46, P17, DOI 10.5483/BMBRep.2013.46.1.001
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Lisziewicz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035416
   Lorincz O, 2012, NANOMED-NANOTECHNOL, V8, P497, DOI 10.1016/j.nano.2011.07.013
   Tirlapur UK, 2006, MICROSC RES TECHNIQ, V69, P767, DOI 10.1002/jemt.20331
   Toke ER, 2010, INT J PHARMACEUT, V392, P261, DOI 10.1016/j.ijpharm.2010.03.048
NR 12
TC 5
Z9 5
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6705
EI 1600-0625
J9 EXP DERMATOL
JI Exp. Dermatol.
PD AUG
PY 2014
VL 23
IS 8
BP 603
EP 605
DI 10.1111/exd.12464
PG 3
WC Dermatology
SC Dermatology
GA AN4CV
UT WOS:000340536100016
PM 24903756
OA gold
DA 2018-01-05
ER

PT J
AU Winnall, WR
   Beasley, MD
   Center, RJ
   Parsons, MS
   Kiefel, BR
   Kent, SJ
AF Winnall, Wendy R.
   Beasley, Matthew D.
   Center, Rob J.
   Parsons, Matthew S.
   Kiefel, Ben R.
   Kent, Stephen J.
TI The maturation of antibody technology for the HIV epidemic
SO IMMUNOLOGY AND CELL BIOLOGY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BROADLY NEUTRALIZING ANTIBODIES; HUMAN
   MONOCLONAL-ANTIBODIES; HIV-1/SIV CHIMERIC VIRUS; SINGLE-DOMAIN
   ANTIBODIES; BISPECIFIC ANTIBODIES; SYNERGISTIC NEUTRALIZATION;
   ESCHERICHIA-COLI; ANTIRETROVIRAL THERAPY; EFFECTOR FUNCTIONS
AB Antibodies are one of our most useful biological tools. Indeed, improvements in antibody-based technologies have ushered in a new era of antibody-based therapeutics, research and diagnostic tools. Although improved technologies have led to the development of therapeutic antibodies for treatment of malignancies and inflammatory conditions, the use of advanced antibody technology in the therapy of viral infections is in its infancy. Non-human primate studies have demonstrated that antibodies against the HIV envelope can both prevent viral infection and control viremia. Despite the obvious potential of antibody therapies against HIV, there remain limitations in production and purification capacity that require further research. Recent advances in recombinant antibody technology have led to the development of a range of novel antibody fragments, such as single-domain nanobodies and bispecific antibodies, that are capable of targeting cancer cells to cytotoxic T cells. Novel antibody production techniques have also been designed, allowing antibodies to be obtained from non-mammalian cells, bovine colostrum and the periplasm and cytoplasm of bacteria. These advances may allow large-scale production of HIV antibodies that are capable of protecting against HIV infection or serving as therapeutics that reduce the need for life-long antiretroviral treatment. This review summarises recent advances in antibody-based technologies and discusses the possibilities and challenges of using these advances to design prophylactics and therapeutics against HIV.
C1 [Winnall, Wendy R.; Center, Rob J.; Parsons, Matthew S.; Kent, Stephen J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.
   [Beasley, Matthew D.; Kiefel, Ben R.] Affin BIO, Small Technol Cluster, Scoresby, Vic, Australia.
   [Center, Rob J.] Burnet Inst Med Res & Publ Hlth, Melbourne, Vic, Australia.
RP Winnall, WR (reprint author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.
EM wwinnall@unimelb.edu.au
OI Kent, Stephen/0000-0002-8539-4891
FU NHMRC fellowships [1013221, 1041832]
FX This work was supported by NHMRC fellowships (1013221 to WRW and 1041832
   to SJK).
CR Abdel-Motal UM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026473
   Acharya P, 2013, J VIROL, V87, P10173, DOI 10.1128/JVI.01332-13
   Aggarwal SR, 2014, NAT BIOTECHNOL, V32, P32, DOI 10.1038/nbt.2794
   Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012
   Baba TW, 2000, NAT MED, V6, P200
   Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660
   Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744
   Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766
   Baudino L, 2008, J IMMUNOL, V181, P6664, DOI 10.4049/jimmunol.181.9.6664                                                     
   BERG J, 1991, P NATL ACAD SCI USA, V88, P4723, DOI 10.1073/pnas.88.11.4723
   BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471
   BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379
   Bonsignori M, 2011, J VIROL, V85, P9998, DOI 10.1128/JVI.05045-11
   Bregenholt S, 2006, CURR PHARM DESIGN, V12, P2007, DOI 10.2174/138161206777442173
   Bruhl H, 2001, J IMMUNOL, V166, P2420, DOI 10.4049/jimmunol.166.4.2420                                                     
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Byrne H, 2013, TRENDS BIOTECHNOL, V31, P621, DOI 10.1016/j.tibtech.2013.08.007
   Callon G, 2012, BRIT J PHARMACOL, V165, P2341
   CHAMOW SM, 1994, J IMMUNOL, V153, P4268
   Chancey CJ, 2006, J IMMUNOL, V176, P5627, DOI 10.4049/jimmunol.176.9.5627                                                     
   Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100
   Correia IR, 2010, MABS-AUSTIN, V2, P221, DOI 10.4161/mabs.2.3.11788                                                          
   Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036
   Dorosko SM, 2008, VACCINE, V26, P5416, DOI 10.1016/j.vaccine.2008.07.079
   Drucker A, 2008, CURR ONCOL, V15, P136
   Duval M, 2008, J VIROL, V82, P4671, DOI 10.1128/JVI.02499-07
   Eroshkin AM, 2014, NUCLEIC ACIDS RES, V42, pD1133, DOI 10.1093/nar/gkt1083
   Ferrantelli F, 2003, AIDS, V17, P301, DOI [10.1097/00002030-200302140-00003, 10.1097/01.aids.0000050803.28043.96]
   Finton KAK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003639
   Forsman A, 2008, J VIROL, V82, P12069, DOI 10.1128/JVI.01379-08
   Frankel SR, 2013, CURR OPIN CHEM BIOL, V17, P385, DOI 10.1016/j.cbpa.2013.03.029
   Frenzel A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00217
   Frey G, 2010, NAT STRUCT MOL BIOL, V17, P1486, DOI 10.1038/nsmb.1950
   Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0
   Gorlani A, 2012, AIDS RES HUM RETROV, V28, P198, DOI 10.1089/aid.2011.0133
   GREENWOOD J, 1993, EUR J IMMUNOL, V23, P1098, DOI 10.1002/eji.1830230518
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09
   Horwitz JA, 2013, P NATL ACAD SCI USA, V110, P16538, DOI 10.1073/pnas.1315295110
   HOWELL AL, 1994, J LEUKOCYTE BIOL, V55, P385
   Hulsik DL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003202
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879                                                         
   Inbar NH, 2012, ARCH BIOCHEM BIOPHYS, V526, P87, DOI 10.1016/j.abb.2011.12.028
   Jacobson JM, 2010, ANTIMICROB AGENTS CH, V54, P4137, DOI 10.1128/AAC.00086-10
   Jia LL, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-142
   Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967
   Kessler JA, 1997, AIDS RES HUM RETROV, V13, P575, DOI 10.1089/aid.1997.13.575                                                         
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   Klein K, 2013, J VIROL, V87, P11604, DOI 10.1128/JVI.01361-13
   Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012
   Kramski M, 2012, ANTIMICROB AGENTS CH, V56, P4310, DOI 10.1128/AAC.00453-12
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   LaFleur DW, 2013, MABS-AUSTIN, V5, P208, DOI 10.4161/mabs.23043
   Lagenaur LA, 2011, MUCOSAL IMMUNOL, V4, P648, DOI 10.1038/mi.2011.30
   Li A, 1997, AIDS RES HUM RETROV, V13, P647, DOI 10.1089/aid.1997.13.647
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Liu YY, 2011, BIOCHEM BIOPH RES CO, V413, P611, DOI 10.1016/j.bbrc.2011.09.012
   Lloyd SB, 2014, AIDS RES HUM RETROV, V30, P8, DOI [10.1089/AID.2013.0153, 10.1089/aid.2013.0153]
   Lotter-Stark HCT, 2012, BIOTECHNOL ADV, V30, P1614, DOI 10.1016/j.biotechadv.2012.06.002
   MABONDZO A, 1994, J GEN VIROL, V75, P1451, DOI 10.1099/0022-1317-75-6-1451                                                     
   Mader A, 2013, APPL MICROBIOL BIOT, V97, P4049, DOI 10.1007/s00253-012-4498-x
   Malbec M, 2013, J EXP MED, V210, P2813, DOI 10.1084/jem.20131244
   Marichal-Gallardo PA, 2012, BIOTECHNOL PROGR, V28, P899, DOI 10.1002/btpr.1567
   Mascola JR, 1997, J VIROL, V71, P7198
   Mascola JR, 1999, J VIROL, V73, P4009
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Matz J, 2013, J VIROL, V87, P1137, DOI 10.1128/JVI.00461-12
   McCoy LE, 2012, J EXP MED, V209, P1091, DOI 10.1084/jem.20112655
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   Mukhtar M, 2000, CURR OPIN MOL THER, V2, P697
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   Nadkarni A, 2007, PROTEIN EXPRES PURIF, V52, P219, DOI 10.1016/j.pep.2006.10.011
   Pace CS, 2013, P NATL ACAD SCI USA, V110, P13540, DOI 10.1073/pnas.1304985110
   Palmberger D, 2011, J BIOTECHNOL, V153, P160, DOI 10.1016/j.jbiotec.2011.02.009
   Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001                                                
   Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457                                                          
   Rau R, 2002, ANN RHEUM DIS, V61, P70
   Reichert JM, 2013, MABS-AUSTIN, V5, P513, DOI 10.4161/mabs.24990
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0                                                                
   Rivkin A, 2009, CLIN THER, V31, P1158, DOI 10.1016/j.clinthera.2009.06.015
   ROBEN P, 1994, J VIROL, V68, P4821
   Schanzer J, 2011, ANTIMICROB AGENTS CH, V55, P2369, DOI 10.1128/AAC.00215-10
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568
   Shingai M, 2013, NATURE, V503, P277, DOI 10.1038/nature12746
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Sigal LH, 2012, JCR-J CLIN RHEUMATOL, V18, P316, DOI 10.1097/RHU.0b013e318269446b
   Spiess C, 2013, NAT BIOTECHNOL, V31, P753, DOI 10.1038/nbt.2621
   Tramontano Anna, 1994, Journal of Molecular Recognition, V7, P9, DOI 10.1002/jmr.300070103
   TRAUNECKER A, 1991, EMBO J, V10, P3655
   Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107
   VijhWarrier S, 1996, J VIROL, V70, P4466
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wibmer CK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003738
   Wolf E, 2005, DRUG DISCOV TODAY, V10, P1237, DOI 10.1016/S1359-6446(05)03554-3                                                   
   Wu CB, 2007, NAT BIOTECHNOL, V25, P1290, DOI 10.1038/nbt1345
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012
NR 104
TC 5
Z9 5
U1 1
U2 21
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0818-9641
EI 1440-1711
J9 IMMUNOL CELL BIOL
JI Immunol. Cell Biol.
PD AUG
PY 2014
VL 92
IS 7
BP 570
EP 577
DI 10.1038/icb.2014.35
PG 8
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA AN3UA
UT WOS:000340513000003
PM 24797582
DA 2018-01-05
ER

PT J
AU Kellish, PC
   Kumar, S
   Mack, TS
   Spano, MN
   Hennig, M
   Arya, DP
AF Kellish, Patrick C.
   Kumar, Sunil
   Mack, Todd S.
   Spano, Meredith Newby
   Hennig, Mirko
   Arya, Dev P.
TI Multivalent amino sugars to recognize different TAR RNA conformations
SO MEDCHEMCOMM
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEIC ACID INTERACTIONS; 30S
   RIBOSOMAL-SUBUNIT; LONG TERMINAL REPEAT; DNA TRIPLE-HELIX; B-DNA;
   NEOMYCIN CONJUGATE; MAJOR GROOVE; AMINOGLYCOSIDE ANTIBIOTICS; TARGETING
   RNA
AB Neomycin dimers synthesized using "click chemistry" with varying functionality and length in the linker region have been shown to be effective in targeting the HIV-1 transactivation response element (TAR) RNA region of the HIV virus. TAR, a 59 base pair stem loop structure located at the 5'-end of all nascent viral transcripts interacts with its target, a key regulatory protein, Tat, and necessitates the replication of HIV-1 virus. Ethidium bromide displacement and FRET competition assays have revealed nanomolar binding affinity between neomycin dimers and wildtype TAR RNA while in case of neomycin, only a weak binding was detected. Here, NMR and FID-based comparisons reveal an extended binding interface for neomycin dimers involving the upper stem of the TAR RNA thereby offering an explanation for increased affinities. To further explore the potential of these modified aminosugars we have extended binding studies to include four TAR RNA mutants that display conformational differences with minimal sequence variation. The differences in binding between neomycin and neomycin dimers is characterized with TAR RNA mutants that include mutations to the bulge region, hairpin region, and both the bulge and hairpin regions. Our results demonstrate the effect of these mutations on neomycin binding and our results show that linker functionalities between dimeric units of neomycin can distinguish between the conformational differences of mutant TAR RNA structures,
C1 [Kellish, Patrick C.; Kumar, Sunil; Arya, Dev P.] Clemson Univ, Dept Chem, Med Chem Lab, HL Hunter Chem Labs 461, Clemson, SC 29634 USA.
   [Spano, Meredith Newby; Arya, Dev P.] NUBAD LLC, Greenville, SC 29605 USA.
   [Mack, Todd S.; Hennig, Mirko] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
RP Arya, DP (reprint author), Clemson Univ, Dept Chem, Med Chem Lab, HL Hunter Chem Labs 461, Clemson, SC 29634 USA.
EM dpoya@clemson.edu
FU National Institutes of Health [R15CAl25724, 1R41GM100607]; National
   Science Foundation [0845512]
FX Financial support for this work was provided by National Institutes of
   Health (grants R15CAl25724 and 1R41GM100607 to DPA) and by the National
   Science Foundation (MCB 0845512 to MH). We thank Dr Nihar Ranjan
   (Clemson University) for his help with CD studies of TAR mutants with
   DPA 51.
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Aiya D. P., 2003, J AM CHEM SOC, V125, P3733
   Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   Arya DP, 2011, ACCOUNTS CHEM RES, V44, P134, DOI 10.1021/ar100113q
   Arya DP, 2005, TOP CURR CHEM, V253, P149, DOI 10.1007/b100446
   Arya DP, 2003, J AM CHEM SOC, V125, P10148, DOI 10.1021/ja035117c
   Arya DP, 2003, J AM CHEM SOC, V125, P8070, DOI 10.1021/ja034241t
   Arya DP, 2003, J AM CHEM SOC, V125, P12398, DOI 10.1021/ja036742k
   Arya DP, 2001, J AM CHEM SOC, V123, P5385, DOI 10.1021/ja003052x
   Arya DP, 2001, J AM CHEM SOC, V123, P11093, DOI 10.1021/ja016481j
   Arya DP, 2000, BIOORG MED CHEM LETT, V10, P1897, DOI 10.1016/S0960-894X(00)00372-3                                                   
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   BERKHOUT B, 1989, J VIROL, V63, P5501
   Boger DL, 2001, J AM CHEM SOC, V123, P5878, DOI 10.1021/ja010041a
   Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6
   Bryson D. I., 2011, ACS CHEM BIOL, V7, P210
   Carter AP, 2000, NATURE, V407, P340
   Charles I, 2007, BIOCONJUGATE CHEM, V18, P160, DOI 10.1021/bc060249r
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dethoff EA, 2008, BIOPHYS J, V95, P3906, DOI 10.1529/biophysj.108.140285
   DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113                                             
   Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200                                                          
   FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0                                                                
   Goddard T. D., SPARKY, V3
   Hamilton PL, 2012, NAT PROD REP, V29, P134, DOI 10.1039/c1np00054c
   HAUBER J, 1988, J VIROL, V62, P673
   Hermann T, 2005, CURR OPIN STRUC BIOL, V15, P355, DOI 10.1016/j.sbi.2005.05.001
   Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   Kumar S, 2012, BIOCHEMISTRY-US, V51, P2331, DOI 10.1021/bi201657k
   Leach KL, 2007, MOL CELL, V26, P393, DOI 10.1016/j.molcel.2007.04.005
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762
   Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3                                                   
   MEI HY, 1995, BIOORG MED CHEM LETT, V5, P2755, DOI 10.1016/0960-894X(95)00467-8
   MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9                                                    
   Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmn.2003.12.028
   Pang RF, 2008, BIOORGAN MED CHEM, V16, P8178, DOI 10.1016/j.bmc.2008.07.043
   PRICE SR, 1995, J MOL BIOL, V249, P398, DOI 10.1006/jmbi.1995.0305
   Raghunathan D, 2006, NUCLEIC ACIDS RES, V34, P3599, DOI 10.1093/nar/gkl494
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Ranjan N, 2013, BIOORG MED CHEM LETT, V20, P5689
   Ranjan N, 2010, BIOCHEMISTRY-US, V49, P9891, DOI 10.1021/bi101517e
   ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3
   Roth BM, 2011, ADV BIOMED SPECTROSC, V3, P205, DOI 10.3233/978-1-60750-695-9-205
   ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365
   Scott Lincoln G., 2008, V452, P29, DOI 10.1007/978-1-60327-159-2_2
   Shaw NN, 2008, BIOORG MED CHEM LETT, V18, P4142, DOI 10.1016/j.bmcl.2008.05.090
   Shaw NN, 2008, BIOCHIMIE, V90, P1026, DOI 10.1016/j.biochi.2008.04.011
   SKLENAR V, 1987, FEBS LETT, V216, P249, DOI 10.1016/0014-5793(87)80699-3
   Suryawanshi H, 2010, J PHYS CHEM B, V114, P11155, DOI 10.1021/jp1000545
   TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723
   Thomas JR, 2008, CHEM REV, V108, P1171, DOI 10.1021/cr0681546
   Tor Y, 2006, BIOCHIMIE, V88, P1045, DOI 10.1016/j.biochi.2006.03.005
   Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a
   Willis B, 2006, CURR ORG CHEM, V10, P663, DOI 10.2174/138527206776359739                                                      
   Willis B, 2006, BIOCHEMISTRY-US, V45, P10217, DOI 10.1021/bi0609265
   Willis B, 2006, ADV CARBOHYD CHEM BI, V60, P251, DOI 10.1016/S0065-2318(06)60006-1
   Willis B, 2010, BIOCHEMISTRY-US, V49, P452, DOI 10.1021/bi9016796
   Willis B, 2009, BIOORG MED CHEM LETT, V19, P4974, DOI 10.1016/j.bmcl.2009.07.079
   Wilson DN, 2005, BIOL CHEM, V386, P1239, DOI 10.1515/BC.2005.141
   Wyszko E, 1999, J BIOCHEM-TOKYO, V126, P326, DOI 10.1093/oxfordjournals.jbchem.a022453                                           
   Xi H., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P327, DOI 10.2174/1568011054222328
   Xi HJ, 2011, BIOCHEMISTRY-US, V50, P9088, DOI 10.1021/bi201077h
   Xi HJ, 2010, BIOCHIMIE, V92, P514, DOI 10.1016/j.biochi.2010.02.004
   Xi HJ, 2009, FEBS LETT, V583, P2269, DOI 10.1016/j.febslet.2009.06.007
   Xue L, 2002, CHEM COMMUN, P70, DOI 10.1039/b108171c
   Xue LA, 2011, BIOCHEMISTRY-US, V50, P2838, DOI 10.1021/bi1017304
   Xue LA, 2010, BIOCHEMISTRY-US, V49, P5540, DOI 10.1021/bi100071j
   Zaman GJR, 2003, DRUG DISCOV TODAY, V8, P297, DOI 10.1016/S1359-6446(03)02624-2
NR 73
TC 2
Z9 2
U1 2
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PD AUG
PY 2014
VL 5
IS 8
BP 1235
EP 1246
DI 10.1039/c4md00165f
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AN1OP
UT WOS:000340353500027
PM 27076899
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ruan, SP
   Li, ZJ
   Qi, HL
   Gao, Q
   Zhang, CX
AF Ruan, Sanpeng
   Li, Zhejian
   Qi, Honglan
   Gao, Qiang
   Zhang, Chengxiao
TI Label-free supersandwich electrogenerated chemiluminescence biosensor
   for the determination of the HIV gene
SO MICROCHIMICA ACTA
LA English
DT Article
DE DNA hybridization; Electrogenerated chemiluminescence; Human
   immunodeficiency virus-1 gene; Supersandwich model
ID GOLD NANOPARTICLES; DNA HYBRIDIZATION; ELECTROCHEMICAL DETECTION;
   CARBON-NANOTUBES; RUTHENIUM COMPLEX; MICROARRAYS; PROBES;
   OLIGONUCLEOTIDE; AMPLIFICATION; APTASENSOR
AB We describe a highly sensitive electrochemiluminescence (ECL) based method for the determination of the human immunodeficiency virus-1 (HIV-1) gene. A long-range self-assembled double strand DNA (ds-DNA) is used as a carrier, and the ruthenium complex Ru(phen)(3) (2+) as an ECL indicator for signal amplification. The thiolated ss-DNA serving as a capture probe is firstly self-assembled on the surface of a gold electrode. After the target HIV-1 gene is completely hybridized with the capture probe, two previously hybridized auxiliary probes are hybridized with the target HIV-1 gene to form long-range supersandwich ds-DNA polymers on the surface of the electrode. Finally, the ECL indicator is intercalated into the supersandwich ds-DNA grooves. This results in a strongly increased ECL in tripropylamine solution because a large fraction of the intercalator is intercalated into supersandwich ds-DNA. The results showed that the increased ECL intensity is directly related to the logarithm of the concentration of the HIV-1 gene in the range from 0.1 pM to 0.1 nM, with a detection limit of 0.022 pM and using only 10 mu L of analyte samples. The method can effectively discriminate target HIV-1 gene (a perfectly matched ss-DNA) from a 2-base mismatched ss-DNA. This work demonstrates that the high sensitivity and selectivity of an ECL DNA biosensor can be largely improved by using supersandwich ds-DNA along with ECL indicators.
C1 [Ruan, Sanpeng; Li, Zhejian; Qi, Honglan; Gao, Qiang; Zhang, Chengxiao] Shaanxi Normal Univ, Sch Chem & Chem Engn, Key Lab Analyt Chem Life Sci Shaanxi Prov, Xian 710062, Peoples R China.
RP Zhang, CX (reprint author), Shaanxi Normal Univ, Sch Chem & Chem Engn, Key Lab Analyt Chem Life Sci Shaanxi Prov, Xian 710062, Peoples R China.
EM cxzhang@snnu.edu.cn
FU National Science Foundations of China [21027007, 21275095]
FX Financial supports from the National Science Foundations of China (No.
   21027007, 21275095) are gratefully acknowledged.
CR Ahn S, 2005, ANAL CHEM, V77, P5041, DOI 10.1021/ac0505270
   Benoit V, 2001, ANAL CHEM, V73, P2412, DOI 10.1021/ac000946r
   Bi S, 2010, ANAL CHEM, V82, P9447, DOI 10.1021/ac1021198
   Chen X, 2012, ANAL CHEM, V84, P8277, DOI 10.1021/ac3017828
   Chen Y, 2012, ANAL CHEM, V84, P7750, DOI 10.1021/ac3012285
   Dharmadi Y, 2004, BIOTECHNOL PROGR, V20, P1309, DOI 10.1021/bp0400240
   Fu YZ, 2005, BIOCHEM ENG J, V23, P37, DOI 10.1016/j.bej.2004.10.008
   Gao M, 2008, ELECTROANAL, V20, P123, DOI 10.1002/clan.200703998
   Gasparac R, 2004, J AM CHEM SOC, V126, P12270, DOI 10.1021/ja0458221
   Gui GF, 2013, BIOSENS BIOELECTRON, V47, P524, DOI 10.1016/j.bios.2013.03.075
   Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586                                                               
   Huo ZH, 2011, MICROCHIM ACTA, V173, P119, DOI 10.1007/s00604-010-0530-y
   Hvastkovs EG, 2007, ANAL CHEM, V79, P6922, DOI 10.1021/ac070358e
   Ito M, 2007, J PHYS CHEM C, V111, P11653, DOI 10.1021/jp070524m
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Li Y, 2007, TALANTA, V72, P1704, DOI 10.1016/j.talanta.2007.01.062
   Li Y, 2011, BIOSENS BIOELECTRON, V26, P2733, DOI 10.1016/j.bios.2010.09.048
   Li Y, 2009, MICROCHIM ACTA, V164, P69, DOI 10.1007/s00604-008-0034-1
   Ma F, 2012, BIOSENS BIOELECTRON, V32, P37, DOI 10.1016/j.bios.2011.11.011
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700                                                          
   Miao WJ, 2003, ANAL CHEM, V75, P5825, DOI 10.1021/ac034596v
   Qi HL, 2008, TALANTA, V75, P684, DOI 10.1016/j.talanta.2007.12.002
   Su XD, 2004, ANAL CHEM, V76, P489, DOI 10.1021/ac035175g
   Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639
   Wang H, 2006, ANAL CHIM ACTA, V575, P205, DOI 10.1016/j.aca.2006.05.080
   Wang J, 2002, ANAL CHIM ACTA, V469, P63, DOI 10.1016/S0003-2670(01)01399-X
   Wang J, 2003, J AM CHEM SOC, V125, P2408, DOI 10.1021/ja028951v
   Xia F, 2010, J AM CHEM SOC, V132, P14346, DOI 10.1021/ja104998m
   XU XH, 1994, J AM CHEM SOC, V116, P8386, DOI 10.1021/ja00097a064
   Yin BC, 2010, ANAL CHEM, V82, P8272, DOI 10.1021/ac101761q
   Yin XB, 2009, ANAL CHEM, V81, P9299, DOI 10.1021/ac901609g
   Yuan T, 2011, CHEM COMMUN, V47, P11951, DOI 10.1039/c1cc14854k
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang J, 2008, ANAL CHEM, V80, P2888, DOI 10.1021/ac701995g
   Zhao XJ, 2003, J AM CHEM SOC, V125, P11474, DOI 10.1021/ja0358854
   Zhou LY, 2012, ANALYST, V137, P5071, DOI 10.1039/c2an35905g
NR 36
TC 7
Z9 7
U1 1
U2 42
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-3672
EI 1436-5073
J9 MICROCHIM ACTA
JI Microchim. Acta
PD AUG
PY 2014
VL 181
IS 11-12
BP 1293
EP 1300
DI 10.1007/s00604-014-1252-3
PG 8
WC Chemistry, Analytical
SC Chemistry
GA AN1RI
UT WOS:000340360900015
DA 2018-01-05
ER

PT J
AU Duan, JH
   Freeling, JP
   Koehn, J
   Shu, CL
   Ho, RJY
AF Duan, Jinghua
   Freeling, Jennifer P.
   Koehn, Josefin
   Shu, Cuiling
   Ho, Rodney J. Y.
TI Evaluation of Atazanavir and Darunavir Interactions with Lipids for
   Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE HIV; lipid-drug interactions; nanotechnology; targeted drug delivery;
   physical characterization; stabilization; pharmacokinetics; primate;
   long acting
ID IMMUNODEFICIENCY-VIRUS-INFECTION; ANTIRETROVIRAL THERAPY;
   PHASE-TRANSITIONS; LYMPHOID-TISSUES; PHOSPHATIDYLCHOLINE LIPOSOMES;
   FLUORESCENCE DEPOLARIZATION; HIV-1-INFECTED PATIENTS; PHOSPHOLIPID
   BILAYERS; INDINAVIR; LOPINAVIR/RITONAVIR
AB We evaluated two human immunodeficiency virus (HIV) protease inhibitors, atazanavir (ATV) and darunavir (DRV), for pH-dependent solubility, lipid binding, and drug release from lipid nanoparticles (LNPs). Both ATV and DRV incorporated into LNPs composed of pegylated and non-pegylated phospholipids with nearly 100% efficiency, but only ATV-LNPs formed stable lipid-drug particles and exhibited pH-dependent drug release. DRV-LNPs were unstable and formed mixed micelles at low drug-lipid concentrations, and thus are not suitable for lipid-drug particle development. When ATV-LNPs were prepared with ritonavir (RTV), a metabolic and cellular membrane exporter inhibitor, and tenofovir (TFV), an HIV reverse-transcriptase inhibitor, stable, scalable, and reproducible anti-HIV drug combination LNPs were produced. Drug incorporation efficiencies of 85.5 +/- 8.2, 85.1 +/- 7.1, and 6.1 +/- 0.8% for ATV, RTV, and TFV, respectively, were achieved. Preliminary primate pharmacokinetic studies with these pH-responsive anti-HIV drug combination LNPs administered subcutaneously produced detectable plasma concentrations that lasted for 7 days for all three drugs. These anti-HIV LNPs could be developed as a long-acting targeted antiretroviral therapy. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2520-2529, 2014
C1 [Duan, Jinghua; Freeling, Jennifer P.; Koehn, Josefin; Shu, Cuiling; Ho, Rodney J. Y.] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA.
EM rodneyho@u.washington.edu
FU NIH [AI077390S3, AI077390S2, AI077390S1, AI077390, P51OD010425,
   UL1-TR000423]
FX This work was supported by NIH grants AI077390S3, AI077390S2,
   AI077390S1, AI077390, P51OD010425, and UL1-TR000423. We acknowledge John
   C. Kraft who helped with critical reading of this manuscript.
CR Antoniou T, 2003, PHARMACOTHERAPY, V23, P29, DOI 10.1592/phco.23.1.29.31915
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Cohen C, 2005, CURR MED RES OPIN, V21, P1683, DOI 10.1185/030079905X65439
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   DITTERT LW, 1964, J PHARM SCI, V53, P1325, DOI 10.1002/jps.2600531108
   Endsley AN, 2012, AAPS J, V14, P225, DOI 10.1208/s12248-012-9329-6
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   Gallicano K, 2000, ANTIMICROB AGENTS CH, V44, P1117, DOI 10.1128/AAC.44.4.1117-1118.2000                                                 
   Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Ho RJ, 2014, BIOTECHNOLOGY BIOPHA, P427
   JACOBSON K, 1975, BIOCHEMISTRY-US, V14, P152, DOI 10.1021/bi00672a026
   Kashuba ADM, 1999, ANTIMICROB AGENTS CH, V43, P1817
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kinman L, 2012, GUIDELINES USE ANTIR
   Koehn J, 2014, ANTIMICROB AGENTS CH, V58, P2675, DOI 10.1128/AAC.02748-13
   LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030                                                             
   LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029                                                             
   LENTZ BR, 1993, CHEM PHYS LIPIDS, V64, P99, DOI 10.1016/0009-3084(93)90060-G                                                    
   MABREY S, 1976, P NATL ACAD SCI USA, V73, P3862, DOI 10.1073/pnas.73.11.3862
   Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6
   Mills AM, 2009, AIDS, V23, P1679, DOI 10.1097/QAD.0b013e32832d7350
   Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Perez-Elias MJ, 2007, EXPERT OPIN PHARMACO, V8, P689, DOI 10.1517/14656566.8.5.689
   Pomerantz RJ, 2001, AIDS, V15, P1201, DOI 10.1097/00002030-200107060-00002
   Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178
   Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623
   Wang RX, 2000, PERSPECT DRUG DISCOV, V19, P47, DOI 10.1023/A:1008763405023
NR 32
TC 6
Z9 6
U1 1
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD AUG
PY 2014
VL 103
IS 8
BP 2520
EP 2529
DI 10.1002/jps.24046
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA AN0MC
UT WOS:000340277700032
PM 24948204
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dennison, SM
   Anasti, KM
   Jaeger, FH
   Stewart, SM
   Pollara, J
   Liu, PH
   Kunz, EL
   Zhang, RJ
   Vandergrift, N
   Permar, S
   Ferrari, G
   Tomaras, GD
   Bonsignori, M
   Michael, NL
   Kim, JH
   Kaewkungwal, J
   Nitayaphan, S
   Pitisuttithum, P
   Rerks-Ngarm, S
   Liao, HX
   Haynes, BF
   Alam, SM
AF Dennison, S. Moses
   Anasti, Kara M.
   Jaeger, Frederick H.
   Stewart, Shelley M.
   Pollara, Justin
   Liu, Pinghuang
   Kunz, Erika L.
   Zhang, Ruijun
   Vandergrift, Nathan
   Permar, Sallie
   Ferrari, Guido
   Tomaras, Georgia D.
   Bonsignori, Mattia
   Michael, Nelson L.
   Kim, Jerome H.
   Kaewkungwal, Jaranit
   Nitayaphan, Sorachai
   Pitisuttithum, Punnee
   Rerks-Ngarm, Supachai
   Liao, Hua-Xin
   Haynes, Barton F.
   Alam, S. Munir
TI Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific
   Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of
   HIV-1 gp140 with Galactosylceramide
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT GLYCOPROTEIN-120 VACCINE;
   NEUTRALIZING HUMAN-ANTIBODY; EFFICACY TRIAL; MONOCLONAL-ANTIBODY;
   EPITHELIAL-CELLS; DOUBLE-BLIND; T-CELLS; QUANTITATIVE MEASUREMENTS;
   VIROLOGICAL SYNAPSES
AB Mucosal epithelial cell surface galactosylceramide (Galcer) has been postulated to be a receptor for HIV-1 envelope (Env) interactions with mucosal epithelial cells. Disruption of the HIV-1 Env interaction with such alternate receptors could be one strategy to prevent HIV-1 entry through the mucosal barrier. To study antibody modulation of HIV-1 Env-Galcer interactions, we used Galcer-containing liposomes to assess whether natural-and vaccine-induced monoclonal antibodies can block HIV-1 Env binding to Galcer. HIV-1 Env gp140 proteins bound to Galcer liposomes with K(d)s (dissociation constants) in the nanomolar range. Several HIV-1 ALVAC/AIDSVAX vaccinee-derived monoclonal antibodies (MAbs) specific for the gp120 first constant (C1) region blocked Galcer binding of a transmitted/founder HIV-1 Env gp140. Among the C1-specific MAbs that showed Galcer blocking, the antibody-dependent cellular cytotoxicity-mediating CH38 IgG and its natural IgA isotype were the most potent blocking antibodies. C1-specific IgG monoclonal antibodies that blocked Env binding to Galcer induced upregulation of the gp120 CD4-inducible (CD4i) epitope bound by MAb 17B, demonstrating that a conformational change in gp120 may be required for Galcer blocking. However, the MAb 17B itself did not block Env-Galcer binding, suggesting that the C1 antibody-induced gp120 conformational changes resulted in alteration in a Galcer binding site distant from the CD4i 17B MAb binding site.
C1 [Dennison, S. Moses; Anasti, Kara M.; Jaeger, Frederick H.; Stewart, Shelley M.; Liu, Pinghuang; Kunz, Erika L.; Zhang, Ruijun; Vandergrift, Nathan; Permar, Sallie; Ferrari, Guido; Tomaras, Georgia D.; Bonsignori, Mattia; Liao, Hua-Xin; Haynes, Barton F.; Alam, S. Munir] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27708 USA.
   [Bonsignori, Mattia; Liao, Hua-Xin; Haynes, Barton F.; Alam, S. Munir] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
   [Permar, Sallie; Tomaras, Georgia D.; Haynes, Barton F.] Duke Univ, Sch Med, Dept Immunol, Durham, NC USA.
   [Ferrari, Guido; Tomaras, Georgia D.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA.
   [Alam, S. Munir] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
   [Permar, Sallie] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA.
   [Permar, Sallie; Tomaras, Georgia D.] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC USA.
   [Michael, Nelson L.; Kim, Jerome H.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA.
   [Kaewkungwal, Jaranit; Pitisuttithum, Punnee] Mahidol Univ, Bangkok 10700, Thailand.
   [Nitayaphan, Sorachai] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand.
   [Rerks-Ngarm, Supachai] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand.
RP Alam, SM (reprint author), Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27708 USA.
EM hayne002@mc.duke.edu; alam0004@mc.duke.edu
RI Tomaras, Georgia/J-5041-2016; Ferrari, Guido/A-6088-2015
OI Kaewkungwal, Jaranit/0000-0001-7916-8460
FU Bill & Melinda Gates Foundation [OPP1033098, OPP1040758]; Center for
   HIV/AIDS Vaccine Immunology (CHAVI) [AI067854]; Center for HIV/AIDS
   Vaccine Immunogen Discovery (CHAVI- ID) from the NIH, NIAID
   [UM1AI100645- 01]
FX This research was conducted as part of the Collaboration for AIDS
   Vaccine Discovery (CAVD) with support from the Bill & Melinda Gates
   Foundation to B.F.H. (OPP1033098 and OPP1040758) and from the Center for
   HIV/AIDS Vaccine Immunology (CHAVI; AI067854) and the Center for
   HIV/AIDS Vaccine Immunogen Discovery (CHAVI- ID; UM1AI100645- 01) from
   the NIH, NIAID.
CR Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07
   Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257                                                    
   BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131
   Bobardt MD, 2007, J VIROL, V81, P395, DOI 10.1128/JVI.01303-06
   Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X
   Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108
   Carias AM, 2013, J VIROL, V87, P11388, DOI 10.1128/JVI.01377-13
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Conboy JC, 2002, J AM CHEM SOC, V124, P968, DOI 10.1021/ja011225s
   Conboy JC, 2000, ANGEW CHEM INT EDIT, V39, P2882, DOI 10.1002/1521-3773(20000818)39:16<2882::AID-ANIE2882>3.0.CO;2-M                  
   COOK DG, 1994, VIROLOGY, V201, P206, DOI 10.1006/viro.1994.1287
   Dale BM, 2013, IMMUNOL REV, V251, P113, DOI 10.1111/imr.12022
   Dorosko SM, 2010, J VIROL, V84, P10533, DOI 10.1128/JVI.01263-10
   Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
   Edmonds TG, 2010, VIROLOGY, V408, P1, DOI [10.1016/j.viro1.2010.08.028, 10.1016/j.virol.2010.08.028]
   FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700
   Ferrari G, 2011, J VIROL, V85, P7029, DOI 10.1128/JVI.00171-11
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Garg H, 2008, ANTIVIR RES, V80, P54, DOI 10.1016/j.antiviral.2008.04.004
   Gilbert PB, 2005, J INFECT DIS, V192, P974, DOI 10.1086/432734
   Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   HAROUSE JM, 1989, J VIROL, V63, P2527
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   Haynes BF, 2008, J ALLERGY CLIN IMMUN, V122, P3, DOI 10.1016/j.jaci.2008.03.036
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   HOLGERSSON J, 1991, J BIOCHEM-TOKYO, V110, P120, DOI 10.1093/oxfordjournals.jbchem.a123530                                           
   Hope TJ, 2011, NAT MED, V17, P1195, DOI 10.1038/nm.2528
   Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115                                                                  
   Kaizu M, 2006, J INFECT DIS, V194, P912, DOI 10.1086/507308                                                                  
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Liao HX, 2013, J VIROL, V87, P4185, DOI 10.1128/JVI.02297-12
   Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011
   Liu PH, 2013, J VIROL, V87, P7828, DOI 10.1128/JVI.02737-12
   LONG D, 1994, J VIROL, V68, P5890
   Magerus-Chatinet A, 2007, VIROLOGY, V362, P67, DOI 10.1016/j.virol.2006.11.035
   Martin N, 2010, J VIROL, V84, P3516, DOI 10.1128/JVI.02651-09
   MCALARNEY T, 1994, J NEUROSCI RES, V37, P453, DOI 10.1002/jnr.490370404
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   Moore JP, 1996, J VIROL, V70, P1863
   Moreno MR, 2006, BBA-BIOMEMBRANES, V1758, P111, DOI 10.1016/j.bbamem.2006.01.007
   Moreno MR, 2004, BBA-BIOMEMBRANES, V1661, P97, DOI 10.1016/j.bbamem.2003.12.003
   Nawaz F, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001301
   Nehete PN, 2002, ANTIVIR RES, V56, P233, DOI 10.1016/S0166-3542(02)00130-4
   Nicely NI, 2010, NAT STRUCT MOL BIOL, V17, P1492, DOI 10.1038/nsmb.1944
   Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110
   Parrish NF, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002686
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14
   RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0                                                                
   RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709                                                          
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Salle B, 2010, J INFECT DIS, V202, P337, DOI 10.1086/653619
   Schust DJ, 2012, CURR HIV RES, V10, P218
   Shukair SA, 2013, MUCOSAL IMMUNOL, V6, P427, DOI 10.1038/mi.2012.87
   SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001
   Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110
   Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108
   WYATT R, 1995, J VIROL, V69, P5723
   YAHI N, 1992, J VIROL, V66, P4848
   Yeaman GR, 2004, IMMUNOLOGY, V113, P524, DOI 10.1111/j.1365-2567.2004.01990.x
   Yu HF, 2008, CELL CALCIUM, V43, P73, DOI 10.1016/j.ceca.2007.04.011
NR 66
TC 3
Z9 3
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2014
VL 88
IS 16
BP 9406
EP 9417
DI 10.1128/JVI.01031-14
PG 12
WC Virology
SC Virology
GA AM7HP
UT WOS:000340036800056
PM 24920809
OA gold
DA 2018-01-05
ER

PT J
AU Pang, YJ
   Song, HN
   Kim, JH
   Hout, XM
   Cheng, W
AF Pang, Yuanjie
   Song, Hanna
   Kim, Jin H.
   Hout, Ximiao
   Cheng, Wei
TI Optical trapping of individual human immunodeficiency viruses in culture
   fluid reveals heterogeneity with single-molecule resolution
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID ENVELOPE GLYCOPROTEIN; 2-PHOTON FLUORESCENCE; MANIPULATION; HIV-1;
   NANOPARTICLES; TWEEZERS; TYPE-1; VISUALIZATION; PROTEINS; ANTIBODY
AB Optical tweezers use the momentum of photons to trap and manipulate microscopic objects, contact-free, in three dimensions. Although this technique has been widely used in biology and nanotechnology to study molecular motors, biopolymers and nanostructures, its application to study viruses has been very limited, largely due to their small size. Here, using optical tweezers that can simultaneously resolve two-photon fluorescence at the single-molecule level, we show that individual HIV-1 viruses can be optically trapped and manipulated, allowing multi-parameter analysis of single virions in culture fluid under native conditions. We show that individual HIV-1 differs in the numbers of envelope glycoproteins by more than one order of magnitude, which implies substantial heterogeneity of these virions in transmission and infection at the single-particle level. Analogous to flow cytometry for cells, this fluid-based technique may allow ultrasensitive detection, multi-parameter analysis and sorting of viruses and other nanoparticles in biological fluid with single-molecule resolution.
C1 [Pang, Yuanjie; Song, Hanna; Kim, Jin H.; Hout, Ximiao; Cheng, Wei] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.
RP Pang, YJ (reprint author), Univ Michigan, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.
EM chengwe@umich.edu
FU National Institutes of Health (NIH) Director's New Innovator Award
   [1DP2OD008693-01]; National Science Foundation CAREER Award
   [CHE1149670]; March of Dimes Foundation [5-FY10-490]
FX This work was supported by a National Institutes of Health (NIH)
   Director's New Innovator Award (1DP2OD008693-01, to W.C.), a National
   Science Foundation CAREER Award (CHE1149670, to W.C.) and also in part
   by a research grant from the March of Dimes Foundation (5-FY10-490, to
   W.C.). The authors thank A. Ono and A. Telesnitsky for discussions and
   Cheng Lab members, especially M. DeSantis, for critical reading of the
   manuscript. The MATLAB code for analysis of transmission electron
   microscopy images of polystyrene beads was provided by M. DeSantis. The
   following reagents were obtained through the AIDS Research and Reference
   Reagent Program, Division of AIDS, National Institute of Allergy and
   Infectious Diseases (NIAID), NIH: pNL4-3 from M. Martin; pNL4-3.Luc.R-E-
   from N. Landau; pEGFP-Vpr from W. C. Greene; TZM-bl cells from J. C.
   Kappes, X. Wu and Tranzyme Inc; b12 antibody from D. Burton and C.
   Barbas.
CR Accola MA, 2000, J VIROL, V74, P6198, DOI 10.1128/JVI.74.13.6198-6202.2000
   Arunajadai SG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059279
   ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288
   ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653
   Aubin-Tam ME, 2011, CELL, V145, P257, DOI 10.1016/j.cell.2011.03.036
   Bendix PM, 2011, NANO LETT, V11, P5431, DOI 10.1021/nl203200g
   Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571
   Bormuth V, 2009, SCIENCE, V325, P870, DOI 10.1126/science.1174923
   Bosanac L, 2008, NANO LETT, V8, P1486, DOI 10.1021/nl080490+
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042
   Chen YF, 2012, NANO LETT, V12, P1633, DOI 10.1021/nl204561r
   Cheng W, 2011, SCIENCE, V333, P1746, DOI 10.1126/science.1206023
   Cheng W, 2010, OPT LETT, V35, P2988, DOI 10.1364/OL.35.002988
   Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002
   Geiselmann M, 2013, NAT NANOTECHNOL, V8, P175, DOI [10.1038/nnano.2012.259, 10.1038/NNANO.2012.259]
   Gittes F, 1998, OPT LETT, V23, P7, DOI 10.1364/OL.23.000007                                                            
   Grier DG, 2003, NATURE, V424, P810, DOI 10.1038/nature01935
   Gross SP, 2003, METHOD ENZYMOL, V361, P162
   Heller I, 2013, NAT METHODS, V10, P910, DOI [10.1038/NMETH.2599, 10.1038/nmeth.2599]
   Hou XM, 2012, BIOMED OPT EXPRESS, V3, P340, DOI 10.1364/BOE.3.000340
   Hou XM, 2011, OPT LETT, V36, P3185, DOI 10.1364/OL.36.003185
   Johnson MC, 2011, AIDS RES HUM RETROV, V27, P239, DOI [10.1089/aid.2010.0350, 10.1089/AID.2010.0350]
   Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067170
   Klasse PJ, 2012, CELL MICROBIOL, V14, P1183, DOI 10.1111/j.1462-5822.2012.01812.x
   Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908
   Knipe DM, 2007, FIELDS VIROLOGY
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lauffer M A, 1968, Adv Virus Res, V13, P1, DOI 10.1016/S0065-3527(08)60250-X
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Marago OM, 2013, NAT NANOTECHNOL, V8, P807, DOI [10.1038/nnano.2013.208, 10.1038/NNANO.2013.208]
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Neuman KC, 2004, REV SCI INSTRUM, V75, P2787, DOI 10.1063/1.1785844
   NEWMAN J, 1976, BIOPOLYMERS, V15, P301, DOI 10.1002/bip.1976.360150208                                                      
   Parrish NF, 2013, P NATL ACAD SCI USA, V110, P6626, DOI 10.1073/pnas.1304288110
   Pauzauskie PJ, 2006, NAT MATER, V5, P97, DOI 10.1038/nmat1563
   PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336                                                         
   Ploschner M, 2012, NANO LETT, V12, P1923, DOI 10.1021/nl204378r
   Qian B, 2013, CHEM SCI, V4, P1420, DOI 10.1039/c2sc21263c
   Reece PJ, 2011, NANO LETT, V11, P2375, DOI 10.1021/nl200720m
   Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001
   Stigler J, 2011, SCIENCE, V334, P512, DOI 10.1126/science.1207598
   Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924
   Tinoco I, 2004, ANNU REV BIOPH BIOM, V33, P363, DOI 10.1146/annurev.biophys.33.110502.140418
   Tolic-Norrelykke SF, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2356852
   Tong LM, 2010, NANO LETT, V10, P268, DOI 10.1021/nl9034434
   Vale RD, 2008, CELL, V135, P779, DOI 10.1016/j.cell.2008.11.009
   Wang MD, 1999, CURR OPIN BIOTECH, V10, P81, DOI 10.1016/S0958-1669(99)80015-9                                                   
   Yanagida T, 2008, PHILOS T R SOC B, V363, P2123, DOI 10.1098/rstb.2008.2265
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 52
TC 32
Z9 33
U1 5
U2 53
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD AUG
PY 2014
VL 9
IS 8
BP 624
EP 630
DI 10.1038/NNANO.2014.140
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA AM8PS
UT WOS:000340140100016
PM 25038779
OA green_accepted
DA 2018-01-05
ER

PT J
AU Huang, CB
   Soenen, SJ
   van Gulck, E
   Rejman, J
   Vanham, G
   Lucas, B
   Geers, B
   Braeckmans, K
   Shahin, V
   Spanoghe, P
   Demeester, J
   De Smedt, SC
AF Huang, Chaobo
   Soenen, Stefaan J.
   van Gulck, Ellen
   Rejman, Joanna
   Vanham, Guido
   Lucas, Bart
   Geers, Bart
   Braeckmans, Kevin
   Shahin, Victor
   Spanoghe, Pieter
   Demeester, Jo
   De Smedt, Stefaan C.
TI Electrospun polystyrene fibers for HIV entrapment
SO POLYMERS FOR ADVANCED TECHNOLOGIES
LA English
DT Article
DE electrospinning; HIV entrapment; polymer fiber
ID CONTROLLED-RELEASE; STEM-CELLS; NANOFIBERS; MICROBICIDES;
   DIFFERENTIATION; TRANSMISSION; REGENERATION; PREVENTION; POLYMERS;
   DELIVERY
AB The high versatility and ease of electrospinning of polymer solutions have recently resulted in electrospun fibers, which are of interest for a wide variety of chemical and biomedical applications. This is partially due to the high surface area of the fibers, which is attractive for the detection and capture of (bio)chemicals. In the present work, polystyrene (PS) fibers were electrospun and coated with cationic poly(allylamine hydrochloride) (PAH) or anionic dextran sulfate sodium (DSS). The fibers were physicochemically characterized. Upon incubation in a dispersion of inactivated HIV-1, avid binding of HIV to all types of fibers occurred. By atomic force microscopy and spatial selective photobleaching, the binding of the inactivated HIV-1 particles to the fibers could be confirmed. Interestingly, all fibers, especially the DSS-coated and PAH-coated ones, resulted in a significant reduction of infection of CD4(+) TZMbl cells by replication-competent HIV-1. On top, DSS-coated PS fibers were not toxic for vaginal epithelial cells, which may make these fibers of potential interest to inhibit HIV infection in the context of topical prevention. Copyright (C) 2014 John Wiley & Sons, Ltd.
C1 [Huang, Chaobo] Nanjing Forestry Univ, Coll Chem Engn, Nanjing 210037, Jiangsu, Peoples R China.
   [Soenen, Stefaan J.; Rejman, Joanna; Lucas, Bart; Geers, Bart; Braeckmans, Kevin; Demeester, Jo; De Smedt, Stefaan C.] Univ Ghent, Fac Pharmaceut Sci, Lab Gen Biochem & Phys Pharm, B-9000 Ghent, Belgium.
   [van Gulck, Ellen; Vanham, Guido] Inst Trop Med, Dept Microbiol, Virol Unit, B-2000 Antwerp, Belgium.
   [Vanham, Guido] Univ Antwerp, Fac Pharmacol Biomed & Vet Sci, Dept Biomed Sci, Antwerp, Belgium.
   [Shahin, Victor] Univ Munster, Inst Physiol 2, D-48149 Munster, Germany.
   [Spanoghe, Pieter] Univ Ghent, Dept Crop Protect Chem, B-9000 Ghent, Belgium.
RP De Smedt, SC (reprint author), Univ Ghent, Fac Pharmaceut Sci, Lab Gen Biochem & Phys Pharm, Harelbekestr 72, B-9000 Ghent, Belgium.
EM Stefaan.DeSmedt@UGent.be
RI Soenen, Stefaan/D-7370-2014; HUANG, Chaobo/E-7686-2011; Spanoghe,
   Pieter/B-9440-2015
OI Soenen, Stefaan/0000-0003-2390-3133; Spanoghe,
   Pieter/0000-0002-8158-4401
FU Ghent University
FX We thank Prof. Martin Moller (DWI an der RWTH, Aachen, Germany) for his
   kind donation of electrospun PP fibers. S.J.S. is a post-doctoral fellow
   from the FWO-Vlaanderen. Financial support from Ghent University is
   greatly acknowledged.
CR Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Arien KK, 2011, REV MED VIROL, V21, P110, DOI 10.1002/rmv.684
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Chew SY, 2007, ADV FUNCT MATER, V17, P1288, DOI 10.1002/adfm.200600441
   Choi SH, 2011, CHEM COMMUN, V47, P9315, DOI 10.1039/c1cc10707k
   Chunder A, 2007, COLLOID SURFACE B, V58, P172, DOI 10.1016/j.colsurfb.2007.03.004
   Clapham PR, 2001, BRIT MED BULL, V58, P43, DOI 10.1093/bmb/58.1.43
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Ding B., 2010, NANOTECHNOLOGY, V21, DOI [10.1088/0957-4484/21/5/055502, DOI 10.1088/0957-4484/21/5/055502]
   Gillette BM, 2011, BIOMATERIALS, V32, P8067, DOI 10.1016/j.biomaterials.2011.05.043
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Hategan A, 2003, BIOPHYS J, V85, P2746, DOI 10.1016/S0006-3495(03)74697-9                                                   
   Huang C, 2011, CHEM SOC REV, V40, P2417, DOI 10.1039/c0cs00181c
   Huang CB, 2010, ADV MATER, V22, P2657, DOI 10.1002/adma.201000130
   Jay JI, 2010, MOL PHARMACEUT, V7, P116, DOI 10.1021/mp900159n
   Ji W, 2011, PHARM RES-DORDR, V28, P1259, DOI 10.1007/s11095-010-0320-6
   Kumbar SG, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/3/034002
   Kurpinski K, 2011, NANOMEDICINE-UK, V6, P325, DOI [10.2217/nnm.10.132, 10.2217/NNM.10.132]
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Li D, 2004, ADV MATER, V16, P361, DOI 10.1002/adma.200306226
   Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719
   Liu Y, 2009, P NATL ACAD SCI USA, V106, P14201, DOI 10.1073/pnas.0903238106
   McGowan I, 2010, CURR OPIN INFECT DIS, V23, P26, DOI 10.1097/QCO.0b013e328334fe70
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Neurath AR, 2001, BMC INFECT DIS, V1, part. no., DOI 10.1186/1471-2334-1-17                                                          
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Pauwels R, 1996, J ACQ IMMUN DEF SYND, V11, P211, DOI 10.1097/00042560-199603010-00001                                                
   Rossio JL, 1998, J VIROL, V72, P7992
   Saraf A, 2010, J CONTROL RELEASE, V143, P95, DOI 10.1016/j.jconrel.2009.12.009
   Sefcik LS, 2008, J TISSUE ENG REGEN M, V2, P210, DOI 10.1002/term.85
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Szentivanyi A, 2011, ADV DRUG DELIVER REV, V63, P209, DOI 10.1016/j.addr.2010.12.002
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Varshosaz J., 2011, INT J NANOMED, P6, DOI [10.2147/IJN.S17595, DOI 10.2147/IJN.S17595]
   Xie JW, 2009, ADV FUNCT MATER, V19, P2312, DOI 10.1002/adfm.200801904
   Xie JW, 2009, BIOMATERIALS, V30, P354, DOI 10.1016/j.biomaterials.2008.09.046
NR 37
TC 10
Z9 10
U1 3
U2 42
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-7147
EI 1099-1581
J9 POLYM ADVAN TECHNOL
JI Polym. Adv. Technol.
PD AUG
PY 2014
VL 25
IS 8
BP 827
EP 834
DI 10.1002/pat.3310
PG 8
WC Polymer Science
SC Polymer Science
GA AM7ZO
UT WOS:000340087800009
DA 2018-01-05
ER

PT J
AU Heider, S
   Metzner, C
AF Heider, Susanne
   Metzner, Christoph
TI Quantitative real-time single particle analysis of virions
SO VIROLOGY
LA English
DT Review
DE Nanoparticle tracking analysis; NanoSight; Tunable resitive pulse
   sensing; VirusCounter; Flow-field-fractionation; Multiple-angle laser
   light scanning; Virus titer; Single particle analysis
ID FIELD-FLOW FRACTIONATION; NANOPARTICLE TRACKING ANALYSIS; VIRUS-LIKE
   PARTICLES; EPITHELIAL-CELLS; LIGHT-SCATTERING; HIV-1; INFECTION;
   VESICLES; EXOSOMES; PROTEIN
AB Providing information about single virus particles has for a long time been mainly the domain of electron microscopy. More recently, technologies have been developed-or adapted from other fields, such as nanotechnology-to allow for the real-time quantification of physical virion particles, while supplying additional information such as particle diameter concomitantly. These technologies have progressed to the stage of commercialization increasing the speed of viral titer measurements from hours to minutes, thus providing a significant advantage for many aspects of virology research and biotechnology applications. Additional advantages lie in the broad spectrum of virus species that may be measured and the possibility to determine the ratio of infectious to total particles. A series of disadvantages remain associated with these technologies, such as a low specificity for viral particles. In this review we will discuss these technologies by comparing four systems for real-time single virus particle analysis and quantification. (C) 2014 The Authors. Published by Elsevier Inc.
C1 [Heider, Susanne; Metzner, Christoph] Univ Vet Med Vienna, Inst Virol, A-1210 Vienna, Austria.
RP Metzner, C (reprint author), Univ Vet Med Vienna, Inst Virol, Bldg AC,3rd Floor,Vet Pl 1, A-1210 Vienna, Austria.
EM christoph.metzner@vetmeduni.ac.at
OI Metzner, Christoph/0000-0001-6036-4138
FU Austrian Science Fund (FWF) [P25297]
FX The authors like to thank Dimitri Aubert (Izon Scientific Ltd, UK),
   Robert Vogel (University of Queensland, Australia) and Sandra Balkow
   (IUL Instrumentation, Germany) for information and/or technical support;
   John A. Dangerfield (Anovasia Pte Ltd, Singapore) and Constantine
   Konstantoulas (University of Veterinary Medicine Vienna, Austria) for
   critically reviewing the manuscript. This work was supported by the
   Austrian Science Fund (FWF) Grant no. P25297.
CR Anderson B., 2011, Bacteriophage, V1, P86
   Arjmandi N, 2012, ANAL CHEM, V84, P8490, DOI 10.1021/ac300705z
   Bousse T, 2013, J VIROL METHODS, V193, P589, DOI 10.1016/j.jviromet.2013.07.026
   Brussaard CPD, 2000, J VIROL METHODS, V85, P175, DOI 10.1016/S0166-0934(99)00167-6
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   Cayatte C, 2013, J VIROL, V87, P11107, DOI 10.1128/JVI.01554-13
   Cervera L, 2013, J BIOTECHNOL, V166, P152, DOI 10.1016/j.jbiotec.2013.05.001
   Chuan YP, 2008, BIOTECHNOL BIOENG, V99, P1425, DOI 10.1002/bit.21710
   de Vrij J, 2013, NANOMEDICINE-UK, V8, P1443, DOI [10.2217/nnm.12.173, 10.2217/NNM.12.173]
   Du SF, 2010, J CHEM TECHNOL BIOT, V85, P1223, DOI 10.1002/jctb.2421
   El-Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Farkas K, 2013, FOOD ENVIRON VIROL, V5, P231, DOI 10.1007/s12560-013-9122-4
   Ferris MM, 2011, J VIROL METHODS, V171, P111, DOI 10.1016/j.jviromet.2010.10.010
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Gutierrez-Granados S, 2013, J VIROL METHODS, V193, P85, DOI 10.1016/j.jviromet.2013.05.010
   Ibiricu I, 2013, CELL MICROBIOL, V15, P285, DOI 10.1111/cmi.12093
   Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815
   Kemp C.W., 2012, BIOPROCESS J, V11, P4
   Kozak D, 2012, ACS NANO, V6, P6990, DOI 10.1021/nn3020322
   Kramberger P, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-265
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Metzner C, 2008, FASEB J, V22, P2734, DOI 10.1096/fj.08-108217
   Metzner C, 2013, MOL BIOTECHNOL, V53, P9, DOI 10.1007/s12033-012-9616-6
   Mironov GG, 2011, ANAL CHEM, V83, P5431, DOI 10.1021/ac201006u
   Ng YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058502
   Ohnesorge FM, 1997, BIOPHYS J, V73, P2183, DOI 10.1016/S0006-3495(97)78250-X                                                   
   Papanikolaou E, 2013, VIRUS RES, V175, P1, DOI 10.1016/j.virusres.2013.03.015
   Pease LF, 2009, BIOTECHNOL BIOENG, V102, P845, DOI 10.1002/bit.22085
   Properzi F, 2013, BIOMARK MED, V7, P769, DOI 10.2217/bmm.13.63
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Rybakova D, 2013, MOL MICROBIOL, V89, P702, DOI 10.1111/mmi.12305
   Schulze-Horsel J, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-45
   Stepp PC, 2010, GENET ENG BIOTECHN N, V30, P24
   Stepp P.C., 2011, BIOPROCESS INT, V9, P50
   Twu O, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003482
   Vogel R, 2011, ANAL CHEM, V83, P3499, DOI 10.1021/ac200195n
   Wei Z, 2007, J VIROL METHODS, V144, P122, DOI 10.1016/j.jviromet.2007.04.008
   Wurdinger Thomas, 2012, Adv Virol, V2012, P767694, DOI 10.1155/2012/767694
   Yang L, 2012, PHARM RES
   Zhang Y, 2008, BIOMED MICRODEVICES, V10, P321, DOI 10.1007/s10544-007-9139-2
NR 40
TC 23
Z9 23
U1 3
U2 51
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD AUG
PY 2014
VL 462
BP 199
EP 206
DI 10.1016/j.virol.2014.06.005
PG 8
WC Virology
SC Virology
GA AM9TY
UT WOS:000340225100021
PM 24999044
OA gold
DA 2018-01-05
ER

PT J
AU Moscatiello, R
   Sello, S
   Novero, M
   Negro, A
   Bonfante, P
   Navazio, L
AF Moscatiello, Roberto
   Sello, Simone
   Novero, Mara
   Negro, Alessandro
   Bonfante, Paola
   Navazio, Lorella
TI The intracellular delivery of TAT-aequorin reveals calcium-mediated
   sensing of environmental and symbiotic signals by the arbuscular
   mycorrhizal fungus Gigaspora margarita
SO NEW PHYTOLOGIST
LA English
DT Article
DE arbuscular mycorrhizal (AM) fungi; calcium; cell-penetrating peptides;
   Gigaspora margarita; strigolactones; TAT-aequorin; TAT-GFP
ID LIVING CELLS; CA2+ SPIKING; PROTEIN TRANSDUCTION; MEDICAGO-TRUNCATULA;
   PLANT-CELLS; EXPRESSION; STRIGOLACTONES; SIGNATURES; DIVERSITY; BIOLOGY
AB Arbuscular mycorrhiza (AM) is an ecologically relevant symbiosis between most land plants and Glomeromycota fungi. The peculiar traits of AM fungi have so far limited traditional approaches such as genetic transformation. The aim of this work was to investigate whether the protein transduction domain of the HIV-1 transactivator of transcription (TAT) protein, previously shown to act as a potent nanocarrier for macromolecule delivery in both animal and plant cells, may translocate protein cargoes into AM fungi.
   We evaluated the internalization into germinated spores of Gigaspora margarita of two recombinant TAT fusion proteins consisting of either a fluorescent (GFP) or a luminescent (aequorin) reporter linked to the TAT peptide.
   Both TAT-fused proteins were found to enter AM fungal mycelia after a short incubation period (5-10 min). Ca2+ measurements in G. margarita mycelia pre-incubated with TAT-aequorin demonstrated the occurrence of changes in the intracellular free Ca2+ concentration in response to relevant stimuli, such as touch, cold, salinity, and strigolactones, symbiosis-related plant signals.
   These data indicate that the cell-penetrating properties of the TAT peptide can be used as an effective strategy for intracellularly delivering proteins of interest and shed new light on Ca2+ homeostasis and signalling in AM fungi.
C1 [Moscatiello, Roberto; Sello, Simone; Navazio, Lorella] Univ Padua, Dept Biol, I-35131 Padua, Italy.
   [Novero, Mara; Bonfante, Paola] Univ Turin, Dept Life Sci & Syst Biol, I-10125 Turin, Italy.
   [Novero, Mara; Bonfante, Paola] IPP CNR, I-10125 Turin, Italy.
   [Negro, Alessandro] Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy.
RP Navazio, L (reprint author), Univ Padua, Dept Biol, Via U Bassi 58-B, I-35131 Padua, Italy.
EM lorella.navazio@unipd.it
OI Bonfante, Paola/0000-0003-3576-8530
FU PRIN [prot. 2010CSJX4F]; Progetti di Ricerca di Ateneo [prot.
   CPDA127210]; University of Padua
FX This work was supported by PRIN 2010-2011 (prot. 2010CSJX4F) and
   Progetti di Ricerca di Ateneo 2012 (prot. CPDA127210) to L.N. R. M. is a
   post-doctoral fellowship holder of the University of Padua. We thank C.
   Prandi (Turin, Italy) for kindly providing the synthetic strigolactone
   analogue EGO5 and C. Rampazzo (Padua, Italy) for useful advice on gentle
   trypsinization.
CR Akiyama K, 2005, NATURE, V435, P824, DOI 10.1038/nature03608
   Arrigoni G, 2013, J PROTEOME RES, V12, P5323, DOI 10.1021/pr400656g
   Battistutta R, 2000, PROTEINS, V41, P429, DOI 10.1002/1097-0134(20001201)41:4<429::AID-PROT10>3.0.CO;2-D                      
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Bencina M, 2005, MOL MICROBIOL, V56, P268, DOI 10.1111/j.1365-2958.2005.04541.x
   Besserer A, 2006, PLOS BIOL, V4, P1239, DOI 10.1371/journal.pbio.0040226
   Bonfante P, 2011, CURR OPIN PLANT BIOL, V14, P1
   Bonfante P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1046
   Breuninger M, 2004, FUNGAL GENET BIOL, V41, P794, DOI 10.1016/j.fgb.2004.04.002
   BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896                                                         
   Cai XJ, 2012, MOL BIOL EVOL, V29, P91, DOI 10.1093/molbev/msr149
   Cardarelli F, 2008, TRAFFIC, V9, P528, DOI 10.1111/j.1600-0854.2007.00696.x
   Cereghetti GM, 2004, J BIOL CHEM, V279, P36497, DOI 10.1074/jbc.M404341200
   Chabaud M, 2011, NEW PHYTOL, V189, P347, DOI 10.1111/j.1469-8137.2010.03464.x
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Dodd AN, 2010, ANNU REV PLANT BIOL, V61, P593, DOI 10.1146/annurev-arplant-070109-104628
   Dominguez DC, 2004, MOL MICROBIOL, V54, P291, DOI 10.1111/j.1365-2958.2004.04276.x
   Frangini M, 2013, J BIOL CHEM, V288, P5624, DOI 10.1074/jbc.M112.441147
   Genre A, 2013, NEW PHYTOL, V198, P179, DOI 10.1111/nph.12146
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gutjahr C, 2013, ANNU REV CELL DEV BI, V29, P593, DOI 10.1146/annurev-cellbio-101512-122413
   Harrier LA, 2001, MOL BIOTECHNOL, V18, P25, DOI 10.1385/MB:18:1:25
   Helber N, 2008, NEW PHYTOL, V177, P537, DOI 10.1111/j.1469-8137.2007.02257.x
   Kim HS, 2012, FUNGAL GENET BIOL, V49, P589, DOI 10.1016/j.fgb.2012.05.011
   Kosuta S, 2008, P NATL ACAD SCI USA, V105, P9823, DOI 10.1073/pnas.0803499105
   Lanfranco L, 2012, CURR OPIN PLANT BIOL, V15, P454, DOI 10.1016/j.pbi.2012.04.003
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu Y, 2013, FUNGAL BIOL-UK, V117, P22, DOI 10.1016/j.funbio.2012.11.002
   Logi C, 1998, APPL ENVIRON MICROB, V64, P3473
   Maillet F, 2011, NATURE, V469, P58, DOI 10.1038/nature09622
   Mithofer Axel, 2002, Biological Procedures Online, V4, P105, DOI 10.1251/bpo40
   Moscatiello R, 2010, NEW PHYTOL, V188, P814, DOI 10.1111/j.1469-8137.2010.03411.x
   Navazio L, 2007, PLANT PHYSIOL, V144, P673, DOI 10.1104/pp.106.086959
   Nelson G, 2004, MOL MICROBIOL, V52, P1437, DOI 10.1111/j.1365-2958.2004.04066.x
   Oldroyd GED, 2013, NAT REV MICROBIOL, V11, P252, DOI 10.1038/nrmicro2990
   Peroni D, 2007, NEUROSCI LETT, V421, P110, DOI 10.1016/j.neulet.2007.05.046
   Prandi C, 2011, EUR J ORG CHEM, P3781, DOI 10.1002/ejoc.201100616
   Requena N, 2007, PHYTOCHEMISTRY, V68, P33, DOI 10.1016/j.phytochem.2006.09.036
   Ruyter-Spira C, 2013, TRENDS PLANT SCI, V18, P72, DOI 10.1016/j.tplants.2012.10.003
   Sanders IR, 2010, ANNU REV GENET, V44, P271, DOI 10.1146/annurev-genet-102108-134239
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Shaw BD, 2001, FUNGAL GENET BIOL, V34, P207, DOI 10.1006/fgbi.2001.1302
   Sieberer BJ, 2012, PLANT J, V69, P822, DOI 10.1111/j.1365-313X.2011.04834.x
   SWARD RJ, 1981, NEW PHYTOL, V87, P761, DOI 10.1111/j.1469-8137.1981.tb01712.x
   Tisserant E, 2013, P NATL ACAD SCI USA, V110, P20117, DOI 10.1073/pnas.1313452110
   Venkateshwaran M, 2013, CURR OPIN PLANT BIOL, V16, P118, DOI 10.1016/j.pbi.2012.11.007
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Xie XN, 2010, ANNU REV PHYTOPATHOL, V48, P93, DOI 10.1146/annurev-phyto-073009-114453
   Zonin E, 2011, PLANT CELL PHYSIOL, V52, P2225, DOI 10.1093/pcp/pcr145
   Zwanenburg B, 2013, MOL PLANT, V6, P38, DOI 10.1093/mp/sss141
NR 51
TC 7
Z9 7
U1 1
U2 31
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0028-646X
EI 1469-8137
J9 NEW PHYTOL
JI New Phytol.
PD AUG
PY 2014
VL 203
IS 3
BP 1012
EP 1020
DI 10.1111/nph.12849
PG 9
WC Plant Sciences
SC Plant Sciences
GA AM0SF
UT WOS:000339556300028
PM 24845011
OA gold
DA 2018-01-05
ER

PT J
AU He, Q
   Zhu, ZL
   Jin, LL
   Peng, L
   Guo, W
   Hu, SH
AF He, Qian
   Zhu, Zhenli
   Jin, Lanlan
   Peng, Lu
   Guo, Wei
   Hu, Shenghong
TI Detection of HIV-1 p24 antigen using streptavidin-biotin and gold
   nanoparticles based immunoassay by inductively coupled plasma mass
   spectrometry
SO JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY
LA English
DT Article
ID ELEMENT-TAGGED IMMUNOASSAY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   LINKED-IMMUNOSORBENT-ASSAY; ICP-MS DETECTION; HUMAN SERUM;
   ULTRASENSITIVE DETECTION; ABSOLUTE QUANTIFICATION; BOOSTED ELISA;
   PROTEINS; IMMUNOSENSOR
AB A sensitive assay for detection of HIV-1 p24 antigen by inductively coupled plasma mass spectrometry (ICP-MS) was developed using a biotin-streptavidin (BA) system and gold nanoparticles (Au NPs) based immunoassay. In this immunoassay, the p24 antigen was firstly captured by an immobilized anti-HIV-1 p24 monoclonal antibody. After immunoreactions with the biotinylated anti-p24 polyclonal antibody and Au NPs-labeled streptavidin, diluted HNO3 (5%, v/v) was used to dissociate Au NPs, which were then introduced to the ICP-MS for measurements. Under the optimized conditions, the calibration graph for the p24 antigen was linear in the range of 7.5-75 pg mL(-1) with a detection limit of 1.49 pg mL(-1) (3 sigma, n = 5). The relative standard deviation (RSD) for three replicate measurements of 37.5 pg mL(-1) of the p24 antigen was 3.7%. Other proteins, such as human IgG, human HSA, human CEA and human AFP, did not obviously interfere with the assay for p24 antigen. This method was also applied to measure p24 concentrations in artificially positive human serum samples. Compared with the biotin-streptavidin enzyme-linked immunosorbent assay (BA-ELISA) method for p24 antigen detection, the ICP-MS linked immunoassay process deals with Au NPs - tagged instead of enzyme-conjugated antibodies, making it free of toxic enzyme substrate reagents. In addition, it also simplifies the experimental process and saves the experimental time, since the color rendering steps are omitted. The proposed approach provides a sensitive method for HIV-1 p24 antigen determination.
C1 [He, Qian; Zhu, Zhenli; Jin, Lanlan; Guo, Wei; Hu, Shenghong] China Univ Geosci, State Key Lab Biogeol & Environm Geol, Wuhan 430074, Peoples R China.
   [He, Qian; Hu, Shenghong] China Univ Geosci, Fac Earth Sci, Wuhan 430074, Peoples R China.
   [Peng, Lu] Chinese Acad Sci, Wuhan Inst Virol, Wuhan 430071, Peoples R China.
RP Zhu, ZL (reprint author), China Univ Geosci, State Key Lab Biogeol & Environm Geol, Wuhan 430074, Peoples R China.
EM zlzhu@cug.edu.cn
FU National Nature Science Foundation of China [21375120, 21175120,
   41173018]; R&D Special Fund for Public Welfare Industry of Hubei
   province [2012DCA19001]; Fundamental Research Funds for the Central
   Universities, China University of Geosciences [CUG120117, CUG120502]
FX We gratefully acknowledge the financial support from the National Nature
   Science Foundation of China (no. 21375120, 21175120 and 41173018), the
   R&D Special Fund for Public Welfare Industry of Hubei province
   (2012DCA19001), and the Fundamental Research Funds for the Central
   Universities (CUG120117 and CUG120502), China University of Geosciences
   (Wuhan).
CR Baranov VI, 2002, ANAL CHEM, V74, P1629, DOI 10.1021/ac0110350
   Barletta JM, 2004, AM J CLIN PATHOL, V122, P20, DOI 10.1309/529T2WDNEB6X8VUN
   Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Careri M, 2007, ANAL BIOANAL CHEM, V387, P1851, DOI 10.1007/s00216-006-1091-0
   Chen BB, 2011, ANALYST, V136, P3934, DOI 10.1039/c1an15387k
   Cho HK, 2013, J ANAL ATOM SPECTROM, V28, P468, DOI 10.1039/c3ja30299g
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   DIAMANDIS EP, 1991, CLIN CHEM, V37, P625
   Dong HH, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-180
   Gan N, 2010, MOLECULES, V15, P5053, DOI 10.3390/molecules15075053
   Giesen C, 2012, SPECTROCHIM ACTA B, V76, P27, DOI 10.1016/j.sab.2012.06.009
   Ginel PJ, 1996, RES VET SCI, V60, P107, DOI 10.1016/S0034-5288(96)90002-8
   GU J, 1989, AM J ANAT, V185, P264, DOI 10.1002/aja.1001850219                                                          
   Hu SH, 2007, ANAL CHEM, V79, P923, DOI 10.1021/ac061269p
   Hu SH, 2009, J AM SOC MASS SPECTR, V20, P1096, DOI 10.1016/j.jasms.2009.02.005
   Jarujamrus P, 2012, J ANAL ATOM SPECTROM, V27, P884, DOI 10.1039/c2ja10319b
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Ledergerber B, 2000, J INFECT DIS, V181, P1280, DOI 10.1086/315366
   Li F, 2010, ANAL CHEM, V82, P3399, DOI 10.1021/ac100325f
   Liu JM, 2011, J ANAL ATOM SPECTROM, V26, P1191, DOI 10.1039/c0ja00232a
   Liu R, 2013, ANAL CHEM, V85, P4087, DOI 10.1021/ac400158u
   Liu R, 2012, ANAL CHEM, V84, P2769, DOI 10.1021/ac203141d
   Liu R, 2011, ANAL CHEM, V83, P2330, DOI 10.1021/ac103265z
   Liu R, 2010, TALANTA, V83, P48, DOI 10.1016/j.talanta.2010.08.037
   Lu YY, 2009, TALANTA, V78, P869, DOI 10.1016/j.talanta.2008.12.065
   Nadal D, 1999, J INFECT DIS, V180, P1089, DOI 10.1086/315012
   Quinn ZA, 2002, J ANAL ATOM SPECTROM, V17, P892, DOI 10.1039/b202306g
   Razumienko E, 2008, J IMMUNOL METHODS, V336, P56, DOI 10.1016/j.jim.2008.03.011
   ROSSMANN MG, 1988, P NATL ACAD SCI USA, V85, P4625, DOI 10.1073/pnas.85.13.4625
   Schupbach Jorg, 2002, AIDS Reviews, V4, P83
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Tehe A, 2006, J CLIN VIROL, V37, P199, DOI 10.1016/j.jcv.2006.08.005
   Terenghi M, 2009, ANAL CHEM, V81, P9440, DOI 10.1021/ac901853g
   Waentig L, 2012, J ANAL ATOM SPECTROM, V27, P1311, DOI 10.1039/c2ja30068k
   Workman S, 2009, J VIROL METHODS, V160, P14, DOI 10.1016/j.jviromet.2009.04.003
   Yan XW, 2010, ANAL CHEM, V82, P1261, DOI 10.1021/ac902163x
   Yang MW, 2012, J ANAL ATOM SPECTROM, V27, P946, DOI 10.1039/c2ja30065f
   Zhang C, 2002, J ANAL ATOM SPECTROM, V17, P1304, DOI 10.1039/b205623b
   Zhang C, 2001, J ANAL ATOM SPECTROM, V16, P1393, DOI 10.1039/b106387c
   Zhang C, 2002, ANAL CHEM, V74, P96, DOI 10.1021/ac.0103468
   Zhang SC, 2004, CLIN CHEM, V50, P1214, DOI 10.1373/clinchem.2003.029850
   Zhang Y, 2012, FOOD ANAL METHOD, V5, P1214, DOI 10.1007/s12161-012-9363-0
NR 44
TC 12
Z9 12
U1 2
U2 82
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0267-9477
EI 1364-5544
J9 J ANAL ATOM SPECTROM
JI J. Anal. At. Spectrom.
PD AUG
PY 2014
VL 29
IS 8
BP 1477
EP 1482
DI 10.1039/c4ja00026a
PG 6
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA AM0LH
UT WOS:000339536600018
DA 2018-01-05
ER

PT J
AU Ball, C
   Woodrow, KA
AF Ball, Cameron
   Woodrow, Kim A.
TI Electrospun Solid Dispersions of Maraviroc for Rapid Intravaginal
   Preexposure Prophylaxis of HIV
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR T-20; RHESUS MACAQUES;
   DRUG-DELIVERY; AFRICAN WOMEN; VAGINAL FILM; CCR5; GEL; INFECTION;
   TRANSMISSION
AB The development of topical anti-human immunodeficiency virus (HIV) microbicides may provide women with strategies to protect themselves against sexual HIV transmission. Pericoital drug delivery systems intended for use immediately before sex, such as microbicide gels, must deliver high drug doses for maximal effectiveness. The goal of achieving a high antiretroviral dose is complicated by the need to simultaneously retain the dose and quickly release drug compounds into the tissue. For drugs with limited solubility in vaginal gels, increasing the gel volume to increase the dose can result in leakage. While solid dosage forms like films and tablets increase retention, they often require more than 15 min to fully dissolve, potentially increasing the risk of inducing epithelial abrasions during sex. Here, we demonstrate that water-soluble electrospun fibers, with their high surface area-to-volume ratio and ability to disperse antiretrovirals, can serve as an alternative solid dosage form for microbicides requiring both high drug loading and rapid hydration. We formulated maraviroc at up to 28 wt% into electrospun solid dispersions made from either polyvinylpyrrolidone or poly(ethylene oxide) nanofibers or microfibers and investigated the role of drug loading, distribution, and crystallinity in determining drug release rates into aqueous media. We show here that water-soluble electrospun materials can rapidly release maraviroc upon contact with moisture and that drug delivery is faster (less than 6 min under sink conditions) when maraviroc is electrospun in polyvinylpyrrolidone fibers containing an excipient wetting agent. These materials offer an alternative dosage form to current pericoital microbicides.
C1 [Ball, Cameron; Woodrow, Kim A.] Univ Washington, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM woodrow@u.washington.edu
FU National Science Foundation; NIH [AI098648]
FX C.B. was supported by a National Science Foundation Graduate Research
   Fellowship, and the research was funded by NIH grant AI098648 awarded to
   K. A. W.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Barnhart KT, 2004, CONTRACEPTION, V70, P498, DOI 10.1016/j.contraception.2004.06.013
   BLAINE RL, 2002, TN048 TA INSTR
   Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   D'Cruz Osmond J, 2005, AAPS PharmSciTech, V6, pE56, DOI 10.1208/pt060111
   Dahlberg C, 2011, MOL PHARMACEUT, V8, P1247, DOI 10.1021/mp200051e
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Fetherston SM, 2012, EUR J PHARM SCI, V48, P406, DOI DOI 10.1016/J.EJPS.2012.12.002
   Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006
   Frank KJ, 2012, INT J NANOMED, V7, P5757, DOI 10.2147/IJN.S36571
   Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Malcolm RK, 2013, J ANTIMICROB CHEMOTH, V68, P678, DOI 10.1093/jac/dks422
   Malcolm RK, 2012, ANTIMICROB AGENTS CH, V56, P2251, DOI 10.1128/AAC.05810-11
   Massud I, 2013, J VIROL, V87, P8952, DOI 10.1128/JVI.01204-13
   *MICR TRIALS NETW, 2013, VOICE FACT SHEET UND
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Nagy ZK, 2014, EXPRESS POLYM LETT, V8, P352, DOI 10.3144/expresspolymlett.2014.39
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   Notari S, 2009, IUBMB LIFE, V61, P470, DOI 10.1002/iub.181
   Platt EJ, 1998, J VIROL, V72, P2855
   Roche M, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-89
   Schlievert PM, 2008, ANTIMICROB AGENTS CH, V52, P4448, DOI 10.1128/AAC.00989-08
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wypych G, 2013, HDB PLASTICIZERS
   Yalkowsky S.H., 1981, TECHNIQUES SOLUBILIZ
   Yu DG, 2011, INT J NANOMED, V6, P3271, DOI 10.2147/IJN.S27468
NR 40
TC 19
Z9 19
U1 0
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2014
VL 58
IS 8
BP 4855
EP 4865
DI 10.1128/AAC.02564-14
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AL6RA
UT WOS:000339259200071
PM 24913168
OA gold
DA 2018-01-05
ER

PT J
AU Ju, RJ
   Li, XT
   Shi, JF
   Li, XY
   Sun, MG
   Zeng, F
   Zhou, J
   Liu, L
   Zhang, CX
   Zhao, WY
   Lu, WL
AF Ju, Rui-Jun
   Li, Xue-Tao
   Shi, Ji-Feng
   Li, Xiu-Ying
   Sun, Meng-Ge
   Zeng, Fan
   Zhou, Jia
   Liu, Lei
   Zhang, Cheng-Xiang
   Zhao, Wei-Yu
   Lu, Wan-Liang
TI Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and
   celecoxib, to target vasculogenic mimicry channels in invasive breast
   cancer
SO BIOMATERIALS
LA English
DT Article
DE Targeting epirubicin plus celecoxib liposomes; PTDHIV-1 peptide;
   Vasculogenic mimicry channels; Invasive breast cancer; Anticancer
   efficacy
ID RESISTANT LUNG-CANCER; TAT PEPTIDE; CELLS; TUMOR; CHEMOTHERAPY;
   CONJUGATE; MECHANISM; SURVIVAL; LEUKEMIA; THERAPY
AB Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies. In the present study, the nanostructured targeting epirubicin plus celecoxib liposomes were developed by modifying a human immunodeficiency virus peptide lipid-derivative conjugate (DSPE-PEGz000-PTDHIv-i) for elimination of invasive breast cancer cells along with their VM channels. The studies were undertaken on invasive human breast cancer MDA-MB-435S cells and MDA-MB-435S xenografts in nude mice. The constructed targeting epirubicin plus celecoxib liposomes were approximately 100 nm in size. In vitro results showed that the targeting liposomes exhibited strong transport ability across cell and nuclei membranes of invasive breast cancer, were able to penetrate and destruct the invasive breast cancer spheroids, initiated apoptosis via activating apoptotic enzymes (caspase 8, 3), and destroyed the VM channels via downregulating the protein indicators (MMP-9, VE-Cad, FAK, EphA2 and HIF-1 a) in invasive breast cancer cells. In vivo results demonstrated that the targeting liposomes displayed a prolonged circulation time in blood system, accumulated more in tumor location, were able to eliminate the VM channels and angiogenesis in tumor tissues, and resulted in a robust overall anticancer efficacy in invasive breast cancer MDA-MB-435S xenografts in nude mice. In conclusion, the nanostructured targeting epirubicin plus celecoxib liposomes could eliminate invasive breast cancer along with the VM channels, hence providing a promising strategy for treatment of invasive breast cancer. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Ju, Rui-Jun; Li, Xue-Tao; Shi, Ji-Feng; Li, Xiu-Ying; Sun, Meng-Ge; Zeng, Fan; Zhou, Jia; Liu, Lei; Zhang, Cheng-Xiang; Zhao, Wei-Yu; Lu, Wan-Liang] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
RP Lu, WL (reprint author), Peking Univ, Sch Pharmaceut Sci, Xueyuan Rd 38, Beijing 100191, Peoples R China.
EM luwl@bjmu.edu.cn
OI Zhou, Jia/0000-0001-7168-5690
FU Beijing Natural Science Foundation [7131009]; National Basic Research
   Program of China (973 program) [2013CB932501]; National Natural Science
   Foundation of China [81172991, 81373343]
FX This work was supported by grants from the Beijing Natural Science
   Foundation (No. 7131009), the National Basic Research Program of China
   (973 program, 2013CB932501), and the National Natural Science Foundation
   of China (No. 81172991 & 81373343).
CR Chow LWC, 2013, EXPERT OPIN INV DRUG, V22, P299, DOI 10.1517/13543784.2013.766715
   Clemente M, 2010, VET PATHOL, V47, P265, DOI 10.1177/0300985809353167
   Cowell IG, 2012, INT J ENV RES PUB HE, V9, P2075, DOI 10.3390/ijerph9062075
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   De Lange Davies Catharina, 1997, Anticancer Research, V17, P4317
   Fan Yue-Zu, 2010, World J Gastrointest Surg, V2, P117, DOI 10.4240/wjgs.v2.i4.117
   Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6
   Glynn SA, 2010, BMC CANCER, V10, P1
   Hess AR, 2006, CANCER BIOL THER, V5, P228, DOI 10.4161/cbt.5.2.2510                                                            
   Hess AR, 2001, CANCER RES, V61, P3250
   Hidema S, 2012, J BIOSCI BIOENG, V113, P5, DOI 10.1016/j.jbiosc.2011.08.025
   Hu Min, 2009, Proc Natl Acad Sci U S A, V106, P3372, DOI 10.1073/pnas.0813306106
   Kariya Shinji, 2005, Radiat Med, V23, P189
   Kersemans Veerle, 2010, Pharmaceuticals (Basel), V3, P600
   Kirschmann DA, 2012, CLIN CANCER RES, V18, P2726, DOI 10.1158/1078-0432.CCR-11-3237
   Kostarelos K, 2004, INT J CANCER, V112, P713, DOI 10.1002/ijc.20457
   Lee SL, 2014, CANCER RES TREAT, V46, P98, DOI 10.4143/crt.2014.46.1.98
   Li X, 2006, J CONTROL RELEASE, V112, P186, DOI 10.1016/j.jconrel.2006.01.007
   Liu TJ, 2013, J CELL MOL MED, V17, P116, DOI 10.1111/j.1582-4934.2012.01653.x
   Liu XM, 2011, J NEURO-ONCOL, V105, P173, DOI 10.1007/s11060-011-0578-5
   Liu Y, 2008, J CONTROL RELEASE, V129, P18, DOI 10.1016/j.jconrel.2008.03.022
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mulligan JM, 2014, JNCI-J NATL CANCER I, V106, P1
   PLOSKER GL, 1993, DRUGS, V45, P788, DOI 10.2165/00003495-199345050-00011                                                
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Shirakawa K, 2003, BREAST CANCER RES, V5, P136, DOI 10.1186/bcr585
   Spizzo G, 2003, BRIT J CANCER, V88, P574, DOI 10.1038/sj.bjc.6600741
   Sun BC, 2004, INT J ONCOL, V25, P1609
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wang XX, 2011, BIOMATERIALS, V32, P5673, DOI 10.1016/j.biomaterials.2011.04.029
   Wang ZH, 2012, MOL PHARMACEUT, V9, P2646, DOI 10.1021/mp3002107
   Zhao N, 2012, MED ONCOL, V29, P3599, DOI 10.1007/s12032-012-0245-5
   Zhou J, 2013, BIOMATERIALS, V34, P3626, DOI 10.1016/j.biomaterials.2013.01.078
NR 33
TC 31
Z9 37
U1 1
U2 44
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2014
VL 35
IS 26
BP 7610
EP 7621
DI 10.1016/j.biomaterials.2014.05.040
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AL3NI
UT WOS:000339035000034
PM 24912818
DA 2018-01-05
ER

PT J
AU Zhou, TQ
   Zhu, J
   Yang, YP
   Gorman, J
   Ofek, G
   Srivatsan, S
   Druz, A
   Lees, CR
   Lu, G
   Soto, C
   Stuckey, J
   Burton, DR
   Koff, WC
   Connors, M
   Kwon, PD
AF Zhou, Tongqing
   Zhu, Jiang
   Yang, Yongping
   Gorman, Jason
   Ofek, Gilad
   Srivatsan, Sanjay
   Druz, Aliaksandr
   Lees, Christopher R.
   Lu, Gabriel
   Soto, Cinque
   Stuckey, Jonathan
   Burton, Dennis R.
   Koff, Wayne C.
   Connors, Mark
   Kwon, Peter D.
TI Transplanting Supersites of HIV-1 Vulnerability
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BROADLY NEUTRALIZING ANTIBODIES;
   RESPIRATORY SYNCYTIAL VIRUS; HUMAN MONOCLONAL-ANTIBODY; STRUCTURE-BASED
   DESIGN; N-GLYCAN RECOGNITION; ENVELOPE GLYCOPROTEIN; COMPUTATIONAL
   DESIGN; VACCINE DEVELOPMENT; EPITOPE-SCAFFOLDS
AB One strategy for isolating or eliciting antibodies against a specific target region on the envelope glycoprotein trimer (Env) of the human immunodeficiency virus type 1 (HIV-1) involves the creation of site transplants, which present the target region on a heterologous protein scaffold with preserved antibody-binding properties. If the target region is a supersite of HIV-1 vulnerability, recognized by a collection of broadly neutralizing antibodies, this strategy affords the creation of "supersite transplants", capable of binding (and potentially eliciting) antibodies similar to the template collection of effective antibodies. Here we transplant three supersites of HIV-1 vulnerability, each targeted by effective neutralizing antibodies from multiple donors. To implement our strategy, we chose a single representative antibody against each of the target supersites: antibody 10E8, which recognizes the membrane-proximal external region (MPER) on the HIV-1 gp41 glycoprotein; antibody PG9, which recognizes variable regions one and two (V1V2) on the HIV-1 gp120 glycoprotein; and antibody PGT128 which recognizes a glycopeptide supersite in variable region 3 (glycan V3) on gp120. We used a structural alignment algorithm to identify suitable acceptor proteins, and then designed, expressed, and tested antigenically over 100-supersite transplants in a 96-well microtiter-plate format. The majority of the supersite transplants failed to maintain the antigenic properties of their respective template supersite. However, seven of the glycan V3-supersite transplants exhibited nanomolar affinity to effective neutralizing antibodies from at least three donors and recapitulated the mannose(9)-N-linked glycan requirement of the template supersite. The binding of these transplants could be further enhanced by placement into self-assembling nanoparticles. Essential elements of the glycan V3 supersite, embodied by as few as 3 N-linked glycans and similar to 25 Env residues, can be segregated into acceptor scaffolds away from the immune-evading capabilities of the rest of HIV-1 Env, thereby providing a means to focus the immune response on the scaffolded supersite.
C1 [Zhou, Tongqing; Zhu, Jiang; Yang, Yongping; Gorman, Jason; Ofek, Gilad; Srivatsan, Sanjay; Druz, Aliaksandr; Lees, Christopher R.; Lu, Gabriel; Soto, Cinque; Stuckey, Jonathan; Kwon, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Design, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
   [Koff, Wayne C.] IAVI, New York, NY USA.
   [Connors, Mark] NIAID, HIV Specif Immun Sect, NIH, Bethesda, MD 20892 USA.
RP Kwon, PD (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM pdkwong@nih.gov
RI Zhou, Tongqing/A-6880-2010; Cheng, Yushao/E-6256-2011
OI Zhou, Tongqing/0000-0002-3935-4637; Gorman, Jason/0000-0002-3775-6560
FU Intramural Research Program of the Vaccine Research Center; National
   Institute of Allergy and Infectious Diseases; National Institutes of
   Health; International AIDS Vaccine Initiative's Neutralizing Antibody
   Consortium; Bill & Melinda Gates Foundation; Ministry of Foreign Affairs
   of Denmark; Irish Aid; Ministry of Finance of Japan; Ministry of Foreign
   Affairs of the Netherlands; Norwegian Agency for Development Cooperation
   (NORAD); United Kingdom Department for International Development (DFID);
   United States Agency for International Development (USAID)
FX Support for this work was provided by the Intramural Research Program of
   the Vaccine Research Center, National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, and by grants from
   the International AIDS Vaccine Initiative's Neutralizing Antibody
   Consortium. IAVI's work is made possible by generous support from many
   donors including: the Bill & Melinda Gates Foundation; the Ministry of
   Foreign Affairs of Denmark; Irish Aid; the Ministry of Finance of Japan;
   the Ministry of Foreign Affairs of the Netherlands; the Norwegian Agency
   for Development Cooperation (NORAD); the United Kingdom Department for
   International Development (DFID), and the United States Agency for
   International Development (USAID). The full list of IAVI donors is
   available at www. iavi. org. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Azoitei ML, 2012, J MOL BIOL, V415, P175, DOI 10.1016/j.jmb.2011.10.003
   Azoitei ML, 2011, SCIENCE, V334, P373, DOI 10.1126/science.1209368
   Badger J, 2005, PROTEINS, V60, P787, DOI 10.1002/prot.20541
   Bhattacharyya S, 2013, J BIOL CHEM, V288, P9815, DOI 10.1074/jbc.M112.425959
   Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08
   Bonsignori M, 2011, J VIROL, V85, P9998, DOI 10.1128/JVI.05045-11
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Chakraborty K, 2006, BIOCHEM J, V399, P483, DOI 10.1042/BJ20060588
   Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   Correia BE, 2010, STRUCTURE, V18, P1116, DOI 10.1016/j.str.2010.06.010
   Lano De, 2002, PYMOL MOL GRAPHICS S
   Desmet J, 2002, PROTEINS, V48, P31, DOI 10.1002/prot.10131
   Georgiev IS, 2013, SCIENCE, V340, P751, DOI 10.1126/science.1233989
   Gerhardt S, 2009, J MOL BIOL, V394, P905, DOI 10.1016/j.jmb.2009.10.008
   Gray ES, 2011, J VIROL, V85, P7719, DOI 10.1128/JVI.00563-11
   Harms JM, 2008, MOL CELL, V30, P26, DOI 10.1016/j.molcel.2008.01.009
   Hasegawa H, 2009, CURR OPIN STRUC BIOL, V19, P341, DOI 10.1016/j.sbi.2009.04.003
   Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Jakuschev S, 2009, ALGORITHMS, V2, P498, DOI 10.3390/a2010498
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Julien JP, 2013, P NATL ACAD SCI USA, V110, P4351, DOI 10.1073/pnas.1217537110
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Kobayashi K, 2010, P NATL ACAD SCI USA, V107, P17575, DOI 10.1073/pnas.1009598107
   Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   McLellan JS, 2011, J MOL BIOL, V409, P853, DOI 10.1016/j.jmb.2011.04.044
   Mikell I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001251
   Morris L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023532
   Moseri A, 2010, VIROLOGY, V401, P293, DOI 10.1016/j.virol.2010.03.007
   Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109
   MUSTER T, 1994, J VIROL, V68, P4031
   MUSTER T, 1993, J VIROL, V67, P6642
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Pejchal R, 2009, J VIROL, V83, P8451, DOI 10.1128/JVI.00685-09
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Saikrishnan K, 2005, ACTA CRYSTALLOGR D, V61, P1140, DOI 10.1107/S0907444905016896
   Samara NL, 2010, SCIENCE, V328, P1025, DOI 10.1126/science.1190049
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Simek MD, 2009, J VIROL, V83, P7337, DOI 10.1128/JVI.00110-09
   Stamatatos L, 2009, NAT MED, V15, P866, DOI 10.1038/nm.1949
   Stanfield RL, 2011, J MOL BIOL, V414, P460, DOI 10.1016/j.jmb.2011.10.014
   STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Stieglitz B, 2008, EMBO J, V27, P1995, DOI 10.1038/emboj.2008.125
   Totrov M, 2010, VIROLOGY, V405, P513, DOI 10.1016/j.virol.2010.06.027
   Trkola A, 1996, J VIROL, V70, P1100
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wang GL, 2003, BIOINFORMATICS, V19, P1589, DOI 10.1093/bioinformatics/btg224
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Xiang ZX, 2001, J MOL BIOL, V311, P421, DOI 10.1006/jmbi.2001.4865
   Xu JR, 2010, BIOINFORMATICS, V26, P889, DOI 10.1093/bioinformatics/btq066
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zhou HY, 2002, PROTEIN SCI, V11, P2714, DOI 10.1110/ps.0217002
   Zhu J, 2008, PROTEINS, V72, P1171, DOI 10.1002/prot.22005
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 71
TC 24
Z9 24
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 3
PY 2014
VL 9
IS 7
AR e99881
DI 10.1371/journal.pone.0099881
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3RT
UT WOS:000341253400014
PM 24992528
OA gold
DA 2018-01-05
ER

PT J
AU Quevedo, MA
   Ribone, SR
   Brinon, MC
   Dehaen, W
AF Quevedo, Mario A.
   Ribone, Sergio R.
   Brinon, Margarita C.
   Dehaen, Wim
TI Development of a receptor model for efficient in silico screening of
   HIV-1 integrase inhibitors
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Integrase inhibitors; Anti-HIV agents; Molecular docking; Molecular
   dynamics
ID FULL-LENGTH INTEGRASE; AMBER FORCE-FIELD; MOLECULAR-DYNAMICS;
   REVERSE-TRANSCRIPTASE; STRAND TRANSFER; PROTEASE INHIBITORS; DRUG
   DISCOVERY; DNA COMPLEX; MM-PBSA; RALTEGRAVIR
AB Integrase (IN) is a key viral enzyme for the replication of the type-1 human immunodeficiency virus (HIV-1), and as such constitutes a relevant therapeutic target for the development of anti-HIV agents. However, the lack of crystallographic data of HIV IN complexed with the corresponding viral DNA has historically hindered the application of modern structure-based drug design techniques to the discovery of new potent IN inhibitors (INIs). Consequently, the development and validation of reliable HIV IN structural models that may be useful for the screening of large databases of chemical compounds is of particular interest. In this study, four HIV-1 IN homology models were evaluated respect to their capability to predict the inhibition potency of a training set comprising 36 previously reported INIs with IC50 values in the low nanomolar to the high micromolar range. Also, 9 inactive structurally related compounds were included in this training set. In addition, a crystallographic structure of the IN-DNA complex corresponding to the prototype foamy virus (PFV) was also evaluated as structural model for the screening of inhibitors. The applicability of high throughput screening techniques, such as blind and ligand-guided exhaustive rigid docking was assessed. The receptor models were also refined by molecular dynamics and clustering techniques to assess protein sidechain flexibility and solvent effect on inhibitor binding. Among the studied models, we conclude that the one derived from the X-ray structure of the PFV integrase exhibited the best performance to rank the potencies of the compounds in the training set, with the predictive power being further improved by explicitly modeling five water molecules within the catalytic side of IN. Also, accounting for protein sidechain flexibility enhanced the prediction of inhibition potencies among the studied compounds. Finally, an interaction fingerprint pattern was established for the fast identification of potent IN inhibitors. In conclusion, we report an exhaustively validated receptor model if IN that is useful for the efficient screening of large chemical compounds databases in the search of potent HIV-1 IN inhibitors. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Quevedo, Mario A.; Ribone, Sergio R.; Brinon, Margarita C.] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Farm, RA-5000 Cordoba, Argentina.
   [Dehaen, Wim] Katholieke Univ Leuven, Dept Chem, B-3001 Louvain, Belgium.
RP Quevedo, MA (reprint author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Farm, Ciudad Univ, RA-5000 Cordoba, Argentina.
EM alfredon@feq.unc.edu.ar
FU Secretaria de Ciencia y Tecnica of the Universidad Nacional de Cordoba
   (SECYT-UNC); Ministerio de Ciencia y Tecnologia of Cordoba (MINCyT
   Cordoba); Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); International Research Offices of KU Leuven; Universidad
   Nacional de Cordoba
FX The authors gratefully acknowledge financial support from Secretaria de
   Ciencia y Tecnica of the Universidad Nacional de Cordoba (SECYT-UNC),
   the Ministerio de Ciencia y Tecnologia of Cordoba (MINCyT Cordoba) and
   the Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET). Mario A. Quevedo acknowledges the GPGPU Computing Group and
   Dr. Nicolas Wolovick from the Facultad de Matematica, Astronomia y
   Fisica (FAMAF), Universidad Nacional de Cordoba, Argentina, for
   providing access to computing resources. The authors would also like to
   acknowledge the International Research Offices of KU Leuven and
   Universidad Nacional de Cordoba for financial support.
CR Bacchi A, 2011, MOL PHARMACEUT, V8, P507, DOI 10.1021/mp100343x
   Balaraju T, 2013, STRUCT CHEM, V24, P1499, DOI 10.1007/s11224-012-0181-1
   Barreca ML, 2007, J CHEM INF MODEL, V47, P557, DOI 10.1021/ci600320q
   Barreiro G, 2007, J CHEM INF MODEL, V47, P2416, DOI 10.1021/ci700271z
   Beare KD, 2012, CURR MED CHEM, V19, P1177
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1007/978-3-540-78246-9_38
   Blanco Arevalo Jose Luis, 2014, Expert Opin Pharmacother, V15, P573, DOI 10.1517/14656566.2014.868883
   Boyd MA, 2013, LANCET, V382, P664, DOI 10.1016/S0140-6736(13)61456-7
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Castro HC, 2006, CURR MED CHEM, V13, P313, DOI 10.2174/092986706775476089                                                      
   Charpentier C, 2008, HIV MED, V9, P765, DOI 10.1111/j.1468-1293.2008.00628.x
   Chen AP, 2006, J BIOL CHEM, V281, P4173, DOI 10.1074/jbc.M510628200
   Cherepanov P, 2010, EMBO REP, V11, P328, DOI 10.1038/embor.2010.58
   Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329
   Dayam R, 2007, BIOORG MED CHEM LETT, V17, P6155, DOI 10.1016/j.bmc1.2007.09.061
   De Luca L, 2005, BIOCHEM BIOPH RES CO, V336, P1010, DOI 10.1016/j.bbrc.2005.08.211
   De Luca L, 2003, BIOCHEM BIOPH RES CO, V310, P1083, DOI 10.1016/j.bbrc.2003.09.120
   Demeulemeester J, 2012, J BIOMOL SCREEN, V17, P618, DOI 10.1177/1087057111436343
   Di Santo R, 2006, J MED CHEM, V49, P1939, DOI 10.1021/jm0511583
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7
   FARNET CM, 1991, J VIROL, V65, P1910
   Gardelli C, 2007, J MED CHEM, V50, P4953, DOI 10.1021/jm0704705
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hare S, 2010, P NATL ACAD SCI USA, V107, P20057, DOI 10.1073/pnas.1010246107
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   Jaskolski M., 2011, HIV 1 INTEGRASE MECH, P35
   Johnson BC, 2013, J MOL BIOL, V425, P2133, DOI 10.1016/j.jmb.2013.03.027
   Johnson BC, 2012, ANTIMICROB AGENTS CH, V56, P411, DOI 10.1128/AAC.05292-11
   Kuhn B, 2005, J MED CHEM, V48, P4040, DOI 10.1021/jm049081q
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee MC, 2004, PROTEINS, V55, P620, DOI 10.1002/prot.10470
   Liao C, 2011, HIV 1 INTEGRASE MECH, P429
   Liao CZ, 2007, BIOORG MED CHEM LETT, V17, P5361, DOI 10.1016/j.bmcl.2007.08.011
   Liao CZ, 2010, FUTURE MED CHEM, V2, P1123, DOI 10.4155/FMC.10.193
   Louis JM, 2007, ADV PHARMACOL, V55, P261, DOI 10.1016/S1054-3589(07)55008-8
   Ma KQ, 2011, BIOORG MED CHEM LETT, V21, P6724, DOI 10.1016/j.bmcl.2011.09.054
   Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600
   McCammon JA, 2005, BBA-PROTEINS PROTEOM, V1754, P221, DOI 10.1016/j.bbapap.2005.07.041
   McGann M, 2012, J COMPUT AID MOL DES, V8, P1
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   Metifiot M, 2013, ACS CHEM BIOL, V8, P209, DOI 10.1021/cb300471n
   Milletti F, 2007, J CHEM INF MODEL, V47, P2172, DOI 10.1021/ci700018y                                                               
   Milletti F, 2009, J CHEM INF MODEL, V49, P68, DOI 10.1021/ci800340j
   Neamati N., 2011, HIV 1 INTEGRASE MECH, P65
   Nichols SE, 2011, J CHEM INF MODEL, V51, P1439, DOI 10.1021/ci200117n
   Pace P, 2008, BIOORG MED CHEM LETT, V18, P3865, DOI 10.1016/j.bmcl.2008.06.056
   Pace P, 2007, J MED CHEM, V50, P2225, DOI 10.1021/jm070027u
   Pandit D, 2006, J CHEM INF MODEL, V46, P1236, DOI 10.1021/ci050511a
   Petrocchi A, 2007, BIOORG MED CHEM LETT, V17, P350, DOI 10.1016/j.bmcl.2006.10.054
   Sichtig N, 2009, J ANTIMICROB CHEMOTH, V64, P25, DOI 10.1093/jac/dkp153
   Srivastava HK, 2012, J CHEM INF MODEL, V52, P3088, DOI 10.1021/ci300385h
   Summa V, 2004, J MED CHEM, V47, P5336, DOI 10.1021/jm0494669
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Valkov E, 2009, NUCLEIC ACIDS RES, V37, P243, DOI 10.1093/nar/gkn938
   Wai JS, 2000, J MED CHEM, V43, P4923, DOI 10.1021/jm000176b
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wielens J, 2005, J COMPUT AID MOL DES, V19, P301, DOI 10.1007/s10822-005-5256-2
   Wills T, 2012, EXPERT OPIN INV DRUG, V21, P395, DOI 10.1517/13543784.2012.658914
   Xue WW, 2013, J CHEM INF MODEL, V53, P210, DOI 10.1021/ci300541c
   Xue WW, 2012, MOL BIOSYST, V8, P2135, DOI 10.1039/c2mb25114k
NR 67
TC 4
Z9 4
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
EI 1873-4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD JUL
PY 2014
VL 52
BP 82
EP 90
DI 10.1016/j.jmgm.2014.06.007
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA CA9XN
UT WOS:000349278200009
PM 25023663
DA 2018-01-05
ER

PT J
AU Sleiman, D
   Bernacchi, S
   Guerrero, SX
   Brachet, F
   Larue, V
   Paillart, JC
   Tisne, C
AF Sleiman, Dona
   Bernacchi, Serena
   Guerrero, Santiago Xavier
   Brachet, Franck
   Larue, Valery
   Paillart, Jean-Christophe
   Tisne, Carine
TI Characterization of RNA binding and chaperoning activities of HIV-1 Vif
   protein Importance of the C-terminal unstructured tail
SO RNA BIOLOGY
LA English
DT Article
DE HIV; Vif; RNA chaperone; nucleocapsid; unstructured domain
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 VIF; REVERSE TRANSCRIPTION;
   NUCLEOCAPSID PROTEIN; GENOMIC RNA; CBF-BETA; INFECTIVITY FACTOR;
   SOCS-BOX; IN-VITRO; FUNCTIONAL INTERACTION
AB The viral infectivity factor (Vif) is essential for the productive infection and dissemination of HIV-1 in non-permissive cells, containing the cellular anti-HIV defense cytosine deaminases APOBEC3 (A3G and A3F). Vif neutralizes the antiviral activities of the APOBEC3G/F by diverse mechanisms including their degradation through the ubiquitin/proteasome pathway and their translational inhibition. In addition, Vif appears to be an active partner of the late steps of viral replication by interacting with Pr55(Gag), reverse transcriptase and genomic RNA. Here, we expressed and purified full-length and truncated Vif proteins, and analyzed their RNA binding and chaperone properties. First, we showed by CD and NMR spectroscopies that the N-terminal domain of Vif is highly structured in solution, whereas the C-terminal domain remains mainly unfolded. Both domains exhibited substantial RNA binding capacities with dissociation constants in the nanomolar range, whereas the basic unfolded C-terminal domain of Vif was responsible in part for its RNA chaperone activity. Second, we showed by NMR chemical shift mapping that Vif and NCp7 share the same binding sites on tRNA(3)(Lys), the primer of HIV-1 reverse transcriptase. Finally, our results indicate that Vif has potent RNA chaperone activity and provide direct evidence for an important role of the unstructured C-terminal domain of Vif in this capacity.
C1 [Sleiman, Dona; Brachet, Franck; Larue, Valery; Tisne, Carine] Univ Paris 05, CNRS, Lab Cristallog & RMN Biol, Sorbonne Paris Cite, Paris, France.
   [Bernacchi, Serena; Guerrero, Santiago Xavier; Paillart, Jean-Christophe] Univ Strasbourg, CNRS, Inst Biol Mol & Cellulaire, Architecture & Reactivite ARN, Strasbourg, France.
RP Tisne, C (reprint author), Univ Strasbourg, CNRS, Inst Biol Mol & Cellulaire, Architecture & Reactivite ARN, Strasbourg, France.
EM jc.paillart@ibmc-cnrs.unistra.fr; carine.tisne@parisdescartes.fr
RI Guerrero, Santiago/H-7382-2015
OI Guerrero, Santiago/0000-0003-3473-7214; Paillart,
   jean-christophe/0000-0003-1647-8917
FU French National Agency for Research on AIDS and Viral Hepatitis (ANRS);
   ANRS
FX We are grateful to Drs. Roland Marquet and Redmond Smyth for critical
   reading of the manuscript. We thank Dr. Jean-Luc Darlix (UMR 7213 CNRS,
   Universite de Strasbourg) for the gift of TAR(+)/TAR(-) system. This
   work was supported by grants from the French National Agency for
   Research on AIDS and Viral Hepatitis (ANRS) to C. T., J.C.P. and S. B.,
   and by doctoral fellowships from ANRS to S.X.G.
CR ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383
   Auclair JR, 2007, PROTEINS, V69, P270, DOI 10.1002/prot.21471
   Bampi C, 2006, J BIOL CHEM, V281, P11736, DOI 10.1074/jbc.M600290200
   Barraud P, 2008, CURR HIV RES, V6, P91, DOI 10.2174/157016208783885056                                                      
   Batisse J, 2013, J VIROL, V87, P6492, DOI 10.1128/JVI.03494-12
   Batisse J, 2012, VIRUS RES, V169, P361, DOI 10.1016/j.virusres.2012.06.018
   Bernacchi S, 2007, J BIOL CHEM, V282, P26361, DOI 10.1074/jbc.M703122200
   Bernacchi S, 2011, NUCLEIC ACIDS RES, V39, P2404, DOI 10.1093/nar/gkq979
   Binka M, 2012, J VIROL, V86, P49, DOI 10.1128/JVI.06082-11
   Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06
   Bouyac M, 1997, J VIROL, V71, P9358
   Camaur D, 1996, J VIROL, V70, P6106
   Cruceanu M, 2006, J MOL BIOL, V363, P867, DOI 10.1016/j.jmb.2006.08.070
   Dang Y, 2010, J VIROL, V84, P8561, DOI 10.1128/JVI.00960-10
   DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000
   Douaisi M, 2005, BIOCHEM BIOPH RES CO, V329, P917, DOI 10.1016/j.bbrc.2005.02.057
   Etienne L, 2013, CELL HOST MICROBE, V14, P85, DOI 10.1016/j.chom.2013.06.002
   Fouchier RAM, 1996, J VIROL, V70, P8263
   Freisz S, 2012, RNA BIOL, V9, P966, DOI 10.4161/rna.20483
   Gabus C, 2004, NUCLEIC ACIDS RES, V32, P2129, DOI 10.1093/nar/gkh535
   Gallerano D, 2011, AMINO ACIDS, V40, P981, DOI 10.1007/s00726-010-0725-x
   Goila-Gaur R, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-51
   GONCALVES J, 1995, J VIROL, V69, P7196
   Guo YY, 2014, NATURE, V505, P229, DOI 10.1038/nature12884
   Harris RS, 2012, J BIOL CHEM, V287, P40875, DOI 10.1074/jbc.R112.416925
   Henriet S, 2007, NUCLEIC ACIDS RES, V35, P5141, DOI 10.1093/nar/gkm542
   Henriet S, 2005, J MOL BIOL, V354, P55, DOI 10.1016/j.jmb.2005.09.025
   Houzet L, 2008, NUCLEIC ACIDS RES, V36, P2311, DOI 10.1093/nar/gkn069
   Hultquist JF, 2012, J VIROL, V86, P2874, DOI 10.1128/JVI.06950-11
   Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069                                                     
   Ivanyi-Nagy R, 2008, NUCLEIC ACIDS RES, V36, P712, DOI 10.1093/nar/gkm1051
   Jager S, 2012, NATURE, V481, P371, DOI 10.1038/nature10693
   Janes RW, 2005, BIOINFORMATICS, V21, P4230, DOI 10.1093/bioinformatics/bti690
   Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003
   Kataropoulou A, 2009, NUCLEIC ACIDS RES, V37, P3660, DOI 10.1093/nar/gkp226
   Khan MA, 2002, J VIROL, V76, P9112, DOI 10.1128/JVI.76.18.9112-9123.2002
   Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001
   Kovacs D, 2012, BIOCHEM SOC T, V40, P963, DOI 10.1042/BST20120108
   Kuciak M, 2008, NUCLEIC ACIDS RES, V36, P3389, DOI 10.1093/nar/gkn177
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Marcsisin SR, 2011, J MOL BIOL, V410, P1008, DOI 10.1016/j.jmb.2011.04.053
   Marcsisin SR, 2010, J MOL BIOL, V402, P892, DOI 10.1016/j.jmb.2010.08.026
   Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4                                                   
   Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946
   MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349
   Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200
   Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904
   MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650                                                          
   Mercenne G, 2010, NUCLEIC ACIDS RES, V38, P633, DOI 10.1093/nar/gkp1009
   Opi S, 2007, J VIROL, V81, P8236, DOI 10.1128/JVI.02694-06
   Paillart JC, 2004, J BIOL CHEM, V279, P48397, DOI 10.1074/jbc.M408294200
   Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200
   PAILLART JC, 1994, J BIOL CHEM, V269, P27486
   Paul I, 2006, P NATL ACAD SCI USA, V103, P18475, DOI 10.1073/pnas.0604150103
   Pery E, 2009, J VIROL, V83, P2374, DOI 10.1128/JVI.01898-08
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Reingewertz TH, 2010, PROTEIN PEPTIDE LETT, V17, P988
   Reingewertz TH, 2009, PROTEIN ENG DES SEL, V22, P281, DOI 10.1093/protein/gzp004
   Russell RA, 2007, J VIROL, V81, P8201, DOI 10.1128/JVI.00395-07
   Schrofelbauer B, 2006, J VIROL, V80, P5984, DOI 10.1128/JVI.00388-06
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
   Simon JHM, 1999, J VIROL, V73, P2667
   SIMON JHM, 1995, J VIROL, V69, P4166
   Stanley BJ, 2008, J VIROL, V82, P8656, DOI 10.1128/JVI.00767-08
   Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8
   Techtmann SM, 2012, BIOCHEMISTRY-US, V51, P2078, DOI 10.1021/bi201738a
   Thomas JA, 2008, J VIROL, V82, P9318, DOI 10.1128/JVI.00583-08
   Tian CJ, 2006, J VIROL, V80, P3112, DOI 10.1128/JVI.80.6.3112-3115.2006
   Tisne C, 2000, RNA, V6, P1403, DOI 10.1017/S1355838200000947
   Tisne C, 2005, CURR HIV RES, V3, P147, DOI 10.2174/1570162053506919
   Tisne C, 2004, J BIOL CHEM, V279, P3588, DOI 10.1074/jbc.M310368200
   Tisne C, 2001, J MOL BIOL, V306, P443, DOI 10.1006/jmbi.2000.4391
   Tompa P, 2012, TRENDS BIOCHEM SCI, V37, P509, DOI 10.1016/j.tibs.2012.08.004
   Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y                                                               
   Xiao ZX, 2007, FASEB J, V21, P217, DOI 10.1096/fj.06-6773com
   Xue B, 2012, CELL MOL LIFE SCI, V69, P1211, DOI 10.1007/s00018-011-0859-3
   Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200                                                          
   Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121                                                        
   Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591
   Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204
   Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000                                                
   Zhang WY, 2012, NATURE, V481, P376, DOI 10.1038/nature10718
   Zhang WY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003963
NR 85
TC 8
Z9 8
U1 1
U2 14
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD JUL
PY 2014
VL 11
IS 7
BP 906
EP 920
DI 10.4161/rna.29546
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AQ6EF
UT WOS:000342901600016
PM 25144404
OA gold
DA 2018-01-05
ER

PT J
AU Shing, CY
   Whiteley, CG
   Lee, DJ
AF Shing, C. -Y.
   Whiteley, C. G.
   Lee, Duu-Jong
TI HIV protease: Multiple fold inhibition by silver
   nanoparticles-Spectrofluorimetric, thermodynamic and kinetic analysis
SO JOURNAL OF THE TAIWAN INSTITUTE OF CHEMICAL ENGINEERS
LA English
DT Article
DE HIV protease; Silver nanoparticles; Inhibition; FRET; Fluorescence
   quenching
ID MOLECULAR DIAGNOSTICS; ARGININE KINASE; DRUG DISCOVERY; SERUM-ALBUMIN;
   PARTICLE-SIZE; LIVING CELLS; WILD-TYPE; NANOTECHNOLOGY; PROTEINS; DESIGN
AB HIV protease, with one binding site, was inhibited by silver nanoparticles (1-2 nm) and the inhibition constants (K-i), dissociation constants (1(K-d) and Stern-Volmer (K-sv) constants were 97 nM, 0.294 mu M and 0.0043 nM(-1), respectively, at 298 degrees K. K-d decreased with increasing temperature but K-sv remained the same supporting a static quenching mechanism. Without silver nanoparticles V-max was 0.22 mu mol/(ml min) while in their presence V-max decreased to 0.0018 mu mol/(min ml). Thermodynamic analysis under different temperatures gave Delta H and Delta S values for the binding reaction of -96.9 kJ/mol and -170 J/mol/K, respectively. The complex produces negative Delta G values and implied that not only were van de Waals and/or hydrogen bonding operative during the binding but also the interaction was exothermic and spontaneous. Based on FRET analysis only one tryptophan residue (Trp(6)) within HIVPR was quenched and the distance between this tryptophan and the silver nanoparticle binding site is 1.03 nm. Nanoparticles interact with Cys(95) that is juxtapositioned 1.05 nm from the reactive COO- of active site Asp(25) and 1.07 nm from the Trp(6), disrupting, not only its electronegativity but also decreasing the nucleophilic potential of the COO- towards water and/or substrate thereby inhibiting the mechanism of reaction. (C) 2014 Taiwan Institute of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
C1 [Whiteley, C. G.] Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, Taipei 106, Taiwan.
   [Lee, Duu-Jong] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei 106, Taiwan.
   [Shing, C. -Y.; Lee, Duu-Jong] Natl Taiwan Univ, Dept Chem Engn, Taipei 10764, Taiwan.
RP Whiteley, CG (reprint author), Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, Taipei 106, Taiwan.
EM c.whiteley@mail.ntust.edu.tw
OI Whiteley, Chris/0000-0001-8956-1338
FU National Science Council (Taiwan) [101-2811-E-011-004]
FX The authors wish to express gratitude towards the National Science
   Council (Taiwan) [Grant No: 101-2811-E-011-004] for financial support to
   undertake this work.
CR Adeyemi OS, 2014, BBA-GEN SUBJECTS, V1840, P701, DOI 10.1016/j.bbagen.2013.10.038
   Banerjee V, 2013, COLLOID SURFACE B, V111, P71, DOI 10.1016/j.colsurfb.2013.04.052
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Brown KR, 2000, CHEM MATER, V12, P306, DOI 10.1021/cm980065p                                                               
   Calzolai L, 2010, NANO LETT, V10, P3101, DOI 10.1021/nl101746v
   Campbell CT, 2011, FARADAY DISCUSS, V152, P227, DOI 10.1039/c1fd00033k
   Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1
   Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104
   Chen Y, 2003, DIFFERENTIATION, V71, P528, DOI 10.1111/j.1432-0436.2003.07109007.x                                             
   Cheng P. C., 2006, HDB BIOL CONFOCAL MI, P162
   de Kozak Y, 2004, EUR J IMMUNOL, V34, P3702, DOI 10.1002/eji.200425022
   Deng QY, 2009, BIOTECHNOL LETT, V31, P1505, DOI 10.1007/s10529-009-0040-3
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Elzey S, 2010, J NANOPART RES, V12, P1945, DOI 10.1007/s11051-009-9783-y
   Fan J, 2011, BIOMATERIALS, V32, P1611, DOI 10.1016/j.biomaterials.2010.11.004
   Feng SS, 2004, CURR MED CHEM, V11, P413, DOI 10.2174/0929867043455909
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Garcia-Garcia E, 2005, CELL MOL LIFE SCI, V62, P1400, DOI 10.1007/s00018-005-5094-3
   Hoshino K, 2007, PROG CARDIOVASC DIS, V49, P414, DOI 10.1016/j.pcad.2007.02.005
   Huang LY, 2001, DRUG METAB DISPOS, V29, P754
   Huang T, 2007, ANAL CHEM, V79, P7708, DOI 10.1021/ac0709706
   Jain KK, 2005, DRUG DISCOV TODAY, V10, P1435, DOI 10.1016/S1359-6446(05)03573-7                                                   
   Jain KK, 2003, EXPERT REV MOL DIAGN, V3, P153, DOI 10.1586/14737159.3.2.153                                                        
   Johnson CJ, 2008, PROTEOMICS, V8, P715, DOI 10.1002/pmic.200700665
   Li LW, 2010, ANALYST, V135, P1519, DOI 10.1039/c0an00075b
   Li W, 2012, INT J SPECTROSC, V2012, P1, DOI DOI 10.1155/2012/638692
   Lin H, 2006, NATL MED J INDIA, V19, P27
   Lindman S, 2007, NANO LETT, V7, P914, DOI [10.1021/nl062743+, 10.1021/nI062743+]
   Lynch I, 2008, NANO TODAY, V3, P40, DOI 10.1016/S1748-0132(08)70014-8                                                   
   Lynch I, 2007, PHYSICA A, V373, P511, DOI 10.1016/j.physa.2006.06.008
   Mager PP, 2001, MED RES REV, V21, P348, DOI 10.1002/med.1012.abs
   Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/nnano.2012.207, 10.1038/NNANO.2012.207]
   Padayachee ER, 2013, NEUROPEPTIDES, V47, P171, DOI 10.1016/j.npep.2012.12.006
   Padayachee E.R., 2013, NEUROCHEM RES
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Perryman AL, 2004, PROTEIN SCI, V13, P1108, DOI 10.1110/ps.03468904
   Prabha S, 2004, MOL PHARMACEUT, V1, P211, DOI 10.1021/mp049970+
   Quintana A, 2002, PHARMACEUT RES, V19, P1310, DOI 10.1023/A:1020398624602
   Rivera-Gil P, 2013, ACCOUNTS CHEM RES, V46, P743, DOI 10.1021/ar300039j
   ROSE JR, 1993, J BIOL CHEM, V268, P11939
   ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017
   Sahoo SK, 2007, NANOMED-NANOTECHNOL, V3, P20, DOI 10.1016/j.nano.2006.11.008
   Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]
   Saptarshi SR, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-26
   Sennuga A, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0824-6
   Sennuga A, 2012, NANOTECHNOLOGY
   Sennuga A, 2012, NANOMED NANOTECHNOL
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Solomon SD, 2007, J CHEM EDUC, V84, P322
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Velazquez-Campoy A, 2001, ARCH BIOCHEM BIOPHYS, V390, P169, DOI 10.1006/abbi.2001.2333
   Wang HR, 2011, INT J BIOL MACROMOL, V49, P985, DOI 10.1016/j.ijbiomac.2011.08.017
   Wang Y, 2014, ANALYST, V139, P416, DOI 10.1039/c3an01818k
   Wickline SA, 2006, ARTERIOSCL THROM VAS, V26, P435, DOI 10.1161/01.ATV.0000201069.47550.8b
   Xu TW, 2003, J COLLOID INTERF SCI, V262, P342, DOI 10.1016/S0021-9797(03)00208-X
NR 56
TC 4
Z9 4
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1876-1070
EI 1876-1089
J9 J TAIWAN INST CHEM E
JI J. Taiwan Inst. Chem. Eng.
PD JUL
PY 2014
VL 45
IS 4
BP 1140
EP 1148
DI 10.1016/j.jtice.2014.01.008
PG 9
WC Engineering, Chemical
SC Engineering
GA AN1OA
UT WOS:000340352000006
DA 2018-01-05
ER

PT J
AU Han, SH
   Kim, HW
   Jeong, WJ
   Lim, YB
AF Han, So-hee
   Kim, Hee-won
   Jeong, Woo-jin
   Lim, Yong-beom
TI Macromolecular Sensing of RNAs by Exploiting Conformational Changes in
   Supramolecular Nanostructures
SO BIOMACROMOLECULES
LA English
DT Article
ID REV RESPONSE ELEMENT; HIV-1 REV; PROTEIN-DETECTION; STRUCTURAL MODEL;
   ALPHA-HELICES; BINDING; RRE; RECOGNITION; PEPTIDES; DYNAMICS
AB Here, we report on a ratiometric fluorescence biosensor based on self-assembled peptide nanostructures (SPN), which can respond to conformational changes induced by RNA ligand binding. The design of the SPN biosensor was inspired by the conformational stabilization and multimerization behaviors of the HIV-1 Rev protein induced by cooperative protein protein and protein RNA interactions. Because conformation-sensitive SPN biosensors can orchestrate binding and signal transduction events, they can be developed as highly sophisticated and smart nanomaterials for biosensing.
C1 [Lim, Yong-beom] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
   Yonsei Univ, Dept Mat Sci & Engn, Seoul 120749, South Korea.
RP Lim, YB (reprint author), Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
EM yblim@yonsei.ac.kr
RI Lim, Yong-beom/D-3603-2011
FU National Research Foundation (NRF) of Korea [2012R1A1A2006453,
   2009-0083522, 2013M2B2A4041202, 2009-0066736]
FX This work was supported by grants from the National Research Foundation
   (NRF) of Korea (2012R1A1A2006453, 2009-0083522, 2013M2B2A4041202,
   2009-0066736).
CR Apostolovic B, 2010, CHEM SOC REV, V39, P3541, DOI 10.1039/b914339b
   Bains GK, 2012, BIOCHEMISTRY-US, V51, P6207, DOI 10.1021/bi3005285
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Capito RM, 2008, SCIENCE, V319, P1812, DOI 10.1126/science.1154586
   Casu F, 2013, BIOPHYS J, V105, P1004, DOI 10.1016/j.bpj.2013.07.022
   DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005
   Daugherty MD, 2010, NAT STRUCT MOL BIOL, V17, P1337, DOI 10.1038/nsmb.1902
   Daugherty MD, 2010, P NATL ACAD SCI USA, V107, P12481, DOI 10.1073/pnas.1007022107
   DiMattia MA, 2010, P NATL ACAD SCI USA, V107, P5810, DOI 10.1073/pnas.0914946107
   Dyson HJ, 2004, CHEM REV, V104, P3607, DOI 10.1021/cr030403s
   Esser B, 2012, ANGEW CHEM INT EDIT, V51, P5752, DOI 10.1002/anie.201201042
   Fang XY, 2013, CELL, V155, P594, DOI 10.1016/j.cell.2013.10.008
   Fletcher JM, 2013, SCIENCE, V340, P595, DOI 10.1126/science.1233936
   Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809
   Gonzalez DC, 2009, J AM CHEM SOC, V131, P7708, DOI 10.1021/ja900579g
   Gradisar H, 2013, NAT CHEM BIOL, V9, P362, DOI 10.1038/nchembio.1248
   Han S, 2012, J AM CHEM SOC, V134, P16047, DOI 10.1021/ja307493t
   Han SH, 2013, BIOMACROMOLECULES, V14, P1594, DOI 10.1021/bm400233x
   He HZ, 2014, CHEM COMMUN, V50, P5313, DOI 10.1039/c3cc47444e
   Huang YJ, 2013, J AM CHEM SOC, V135, P1700, DOI 10.1021/ja311442x
   Jain C, 1996, CELL, V87, P115, DOI 10.1016/S0092-8674(00)81328-8
   Jain C, 2001, MOL CELL, V7, P603, DOI 10.1016/S1097-2765(01)00207-6
   Jeong WJ, 2013, ACS NANO, V7, P6850, DOI 10.1021/nn402025r
   Lim YB, 2007, ANGEW CHEM INT EDIT, V46, P3475, DOI 10.1002/anie.200604576
   Lim YB, 2009, CHEM SOC REV, V38, P925, DOI 10.1039/b809741k
   Lowik DWPM, 2010, CHEM SOC REV, V39, P3394, DOI 10.1039/b914342b
   Ma DL, 2011, CHEM-ASIAN J, V6, P986, DOI 10.1002/asia.201000870
   Micklitsch CM, 2011, ANGEW CHEM INT EDIT, V50, P1577, DOI 10.1002/anie.201006652
   Miranda OR, 2011, J AM CHEM SOC, V133, P9650, DOI 10.1021/ja2021729
   Munoz V, 2007, ANNU REV BIOPH BIOM, V36, P395, DOI 10.1146/annurev.biophys.36.040306.132608
   Nakano S, 2013, J AM CHEM SOC, V135, P3465, DOI 10.1021/ja3097652
   Oh KJ, 2006, J AM CHEM SOC, V128, P14018, DOI 10.1021/ja0651310
   Pless SA, 2013, ANNU REV PHARMACOL, V53, P211, DOI 10.1146/annurev-pharmtox-011112-140343
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387                                                         
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   Thurley S, 2007, J AM CHEM SOC, V129, P12693, DOI 10.1021/ja075487r
   TURRO NJ, 1986, LANGMUIR, V2, P438, DOI 10.1021/la00070a011                                                             
   Wang D, 2006, J AM CHEM SOC, V128, P9248, DOI 10.1021/ja062710w
   Yang YJ, 2010, J AM CHEM SOC, V132, P13114, DOI 10.1021/ja1040013
   Zhuang YD, 2013, ANGEW CHEM INT EDIT, V52, P8124, DOI 10.1002/anie.201302884
NR 41
TC 0
Z9 0
U1 2
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JUL
PY 2014
VL 15
IS 7
BP 2642
EP 2647
DI 10.1021/bm500480y
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AL4GI
UT WOS:000339090500032
PM 24855025
DA 2018-01-05
ER

PT J
AU Wu, ZY
   Liu, N
   Qin, BJ
   Huang, L
   Yu, F
   Qian, KD
   Morris-Natschke, SL
   Jiang, SB
   Chen, CH
   Lee, KH
   Xie, L
AF Wu, Zhi-Yuan
   Liu, Na
   Qin, Bingjie
   Huang, Li
   Yu, Fei
   Qian, Keduo
   Morris-Natschke, Susan L.
   Jiang, Shibo
   Chen, Chin Ho
   Lee, Kuo-Hsiung
   Xie, Lan
TI Optimization of the Antiviral Potency and Lipophilicity of Halogenated
   2,6-Diarylpyridinamines as a Novel Class of HIV-1 NNRTIS
SO CHEMMEDCHEM
LA English
DT Article
DE anti-HIV activity; antiviral agents; diarylpyridinamines; drug-like
   properties; lipophilicity
ID REVERSE-TRANSCRIPTASE INHIBITORS; DRUG CANDIDATES; ANTIRETROVIRAL
   THERAPY; DERIVATIVES; DESIGN; FLEXIBILITY; STRATEGIES; RESISTANCE;
   EFFICIENCY; DISCOVERY
AB Nineteen new halogenated diarylpyridinamine (DAPA) analogues modified at the phenoxy C-ring were synthesized and evaluated for anti-HIV activity and certain drug-like properties. Ten compounds showed high anti-HIV activity (EC50<10 nm). In particular, (E)-6-(2 ''-bromo-4 ''-cyanovinyl-6 ''-methoxy) phenoxy-N-2-(4'-cyanophenyl) pyridin-2,3-diamine (8c) displayed low-nanomolar antiviral potency (3-7 nm) against wild-type and drug-resistant viral strains bearing the E138K or K101E mutations, which are associated with resistance to rilvipirine (1b). Compound 8c exhibited much lower resistance fold changes (RFC: 1.1-2.1) than 1b (RFC: 11.8-13.0). Compound 8c also exhibited better metabolic stability (in vitro half-life) than 1b in human liver microsomes, possessed low lipophilicity (clogD: 3.29; measured logP: 3.31), and had desirable lipophilic efficiency indices (LE>0.3, LLE>5, LELP<10). With balanced potency and drug-like properties, 8c merits further development as an anti-HIV drug candidate.
C1 [Wu, Zhi-Yuan; Liu, Na; Qin, Bingjie; Xie, Lan] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Huang, Li; Chen, Chin Ho] Duke Univ, Med Ctr, Surg Oncol Res Facil, Durham, NC 27710 USA.
   [Yu, Fei; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
   [Qian, Keduo; Morris-Natschke, Susan L.; Lee, Kuo-Hsiung] Univ N Carolina, Nat Prod Res Labs, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Jiang, Shibo] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, Minist Educ, Shanghai 200032, Peoples R China.
   [Jiang, Shibo] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, Minist Hlth, Shanghai 200032, Peoples R China.
   [Lee, Kuo-Hsiung] China Med Univ & Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan.
RP Lee, KH (reprint author), Univ N Carolina, Nat Prod Res Labs, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
EM khlee@unc.edu; lanxieshi@yahoo.com
RI Jiang, Shibo/L-4500-2014
OI Huang, Li/0000-0001-5659-4053
FU National Natural Science Fund of China (NSFC) [30930106, 81120108022];
   US NIH [AI65310, AI33066]
FX This investigation was supported by grants 30930106 and 81120108022 from
   the National Natural Science Fund of China (NSFC) awarded to L. X., and
   US NIH grants awarded to C. H. C. (AI65310) and K. H. L. (AI33066).
CR Anta L, 2013, AIDS, V27, P81, DOI 10.1097/QAD.0b013e3283584500
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Christiansen E, 2012, J MED CHEM, V55, P6624, DOI 10.1021/jm3002026
   Dang Z, 2009, J MED CHEM, V52, P7887, DOI 10.1021/jm9004253
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   Jabeen I, 2012, J MED CHEM, V55, P3261, DOI 10.1021/jm201705f
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Kaufmann GR, 2000, CURR OPIN MICROBIOL, V3, P508, DOI 10.1016/S1369-5274(00)00131-4
   Keseru GM, 2009, NAT REV DRUG DISCOV, V8, P203, DOI 10.1038/nrd2796
   Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445
   Diaz JL, 2013, J MED CHEM, V56, P3656, DOI 10.1021/jm400181k
   Qin BJ, 2010, J MED CHEM, V53, P4906, DOI 10.1021/jm1002952
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Sun LQ, 2012, J MED CHEM, V55, P7219, DOI 10.1021/jm3007678
   Sun LQ, 2012, BIOORG MED CHEM LETT, V22, P2376, DOI 10.1016/j.bmcl.2012.02.055
   Tarcsay A, 2012, J MED CHEM, V55, P1252, DOI 10.1021/jm201388p
   Tian XT, 2010, J MED CHEM, V53, P8287, DOI 10.1021/jm100738d
   Tian XT, 2009, BIOORG MED CHEM LETT, V19, P5482, DOI 10.1016/j.bmcl.2009.07.080
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Wainberg MA, 2013, HIV AIDS-RES PALLIAT, V5, P41, DOI 10.2147/HIV.S32377
   Yanakakis LJ, 2012, DRUG METAB DISPOS, V40, P803, DOI 10.1124/dmd.111.044404
NR 24
TC 5
Z9 5
U1 0
U2 9
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD JUL
PY 2014
VL 9
IS 7
BP 1546
EP 1555
DI 10.1002/cmdc.201400075
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AL2YH
UT WOS:000338991100023
PM 24895029
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chen, HJ
   Zhu, KD
AF Chen, Hua-Jun
   Zhu, Ka-Di
TI Coherent optical responses and their application in biomolecule mass
   sensing based on a monolayer MoS2 nanoresonator
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA B-OPTICAL PHYSICS
LA English
DT Article
ID SINGLE-LAYER MOS2; NANOMECHANICAL RESONATORS; MECHANICAL RESONATORS;
   ELASTIC PROPERTIES; GRAPHENE; TRANSISTORS; SYSTEMS
AB Graphene-like nanomaterials such as monolayer MoS2 have attracted considerable attention recently. In this article, we propose a nano-optomechanical system based on a suspended monolayer MoS2. The coherent linear and non-linear optical properties of this system have been investigated theoretically. A scheme for measuring the coupling strength of exciton-nanoresonator and the frequency of the nanoresonator is also demonstrated by the optical pump-probe method. Based on the coherent optical spectrum, we further propose a nonlinear optical scheme to determine the mass of the biomolecules (such as single influenza virus and HIV virus). This scheme proposed here may have potential applications in quantum sensing and all-optical MoS2-based devices. (C) 2014 Optical Society of America
C1 [Chen, Hua-Jun; Zhu, Ka-Di] Shanghai Jiao Tong Univ, Dept Phys & Astron, Key Lab Artificial Struct & Quantum Control, Minist Educ, Shanghai 200240, Peoples R China.
RP Zhu, KD (reprint author), Shanghai Jiao Tong Univ, Dept Phys & Astron, Key Lab Artificial Struct & Quantum Control, Minist Educ, Shanghai 200240, Peoples R China.
EM zhukadi@sjtu.edu.cn
FU National Natural Science Foundation of China [10974133, 11274230];
   National Basic Research Program of the Ministry of Science and
   Technology of China
FX The authors gratefully acknowledge support from the National Natural
   Science Foundation of China (Nos. 10974133 and 11274230) and the
   National Basic Research Program of the Ministry of Science and
   Technology of China.
CR Ataca C, 2011, J PHYS CHEM C, V115, P16354, DOI 10.1021/jp205116x
   Bertolazzi S, 2011, ACS NANO, V5, P9703, DOI 10.1021/nn203879f
   Boisen A, 2009, NAT NANOTECHNOL, V4, P404, DOI 10.1038/nnano.2009.169
   Boyd R W, 1992, NONLINEAR OPTICS, P225
   Buscema M, 2013, NANO LETT, V13, P358, DOI 10.1021/nl303321g
   Castellanos-Gomez A, 2013, ADV MATER, V25, P6719, DOI 10.1002/adma.201303569
   Castellanos-Gomez A, 2012, ADV MATER, V24, P772, DOI 10.1002/adma.201103965
   Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109
   Chaste J, 2012, NAT NANOTECHNOL, V7, P300, DOI [10.1038/nnano.2012.42, 10.1038/NNANO.2012.42]
   Chen CY, 2009, NAT NANOTECHNOL, V4, P861, DOI [10.1038/NNANO.2009.267, 10.1038/nnano.2009.267]
   Dai MD, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3265731
   Eda G, 2011, NANO LETT, V11, P5111, DOI 10.1021/nl201874w
   Eichler A, 2011, NAT NANOTECHNOL, V6, P339, DOI [10.1038/nnano.2011.71, 10.1038/NNANO.2011.71]
   Ekinci KL, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1927327
   Ekinci KL, 2004, J APPL PHYS, V95, P2682, DOI 10.1063/1.1642738
   Fontana M, 2013, SCI REP-UK, V3, DOI 10.1038/srep01634
   Ge YZ, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.241408
   Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877
   He K, 2013, NANO LETT, V13, P2931, DOI 10.1021/nl4013166
   Kaasbjerg K, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.115317
   Kioseoglou G, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4768299
   Late DJ, 2013, ACS NANO, V7, P4879, DOI 10.1021/nn400026u
   Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996
   Lee C, 2010, ACS NANO, V4, P2695, DOI 10.1021/nn1003937
   Lee HS, 2012, NANO LETT, V12, P3695, DOI 10.1021/nl301485q
   Lee J, 2013, ACS NANO, V7, P6086, DOI 10.1021/nn4018872
   Li H, 2012, SMALL, V8, P63, DOI 10.1002/smll.201101016
   Li JJ, 2013, PHYS REP, V525, P223, DOI 10.1016/j.physrep.2012.11.003
   Li JJ, 2012, J OPT SOC AM B, V29, P965, DOI 10.1364/JOSAB.29.000965
   Li M, 2007, NAT NANOTECHNOL, V2, P114, DOI 10.1038/nnano.2006.208
   Li TS, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.235407
   Li X, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.066803
   Loh KP, 2010, NAT CHEM, V2, P1015, DOI 10.1038/NCHEM.907
   Lopez-Sanchez O, 2013, NAT NANOTECHNOL, V8, P497, DOI [10.1038/NNANO.2013.100, 10.1038/nnano.2013.100]
   Lu HZ, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.016806
   Mahan G. D., 1981, MANY PARTICLE PHYS
   Mak KF, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.136805
   Molina-Sanchez A, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.155413
   Naik AK, 2009, NAT NANOTECHNOL, V4, P445, DOI [10.1038/NNANO.2009.152, 10.1038/nnano.2009.152]
   Perkins FK, 2013, NANO LETT, V13, P668, DOI 10.1021/nl3043079
   Qiu H, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3696045
   Radisavljevic B, 2011, NAT NANOTECHNOL, V6, P147, DOI [10.1038/nnano.2010.279, 10.1038/NNANO.2010.279]
   Ramos D, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2917718
   Rice C, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.081307
   Schwab KC, 2005, PHYS TODAY, V58, P36, DOI 10.1063/1.2012461                                                               
   Song Y, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.026601
   Strait J., 2013, C LAS EL CLEO 2013 L
   Suzuki Hideo, 2009, Acoustical Science and Technology, V30, P348, DOI 10.1250/ast.30.348
   Turner Kimberly L, 2011, AIP Conference Proceedings, V1339, P111, DOI 10.1063/1.3586208
   Wang ZH, 2014, SCI REP-UK, V4, DOI 10.1038/srep03919
   Wehling TO, 2008, NANO LETT, V8, P173, DOI 10.1021/nL072364w
   Weis S, 2010, SCIENCE, V330, P1520, DOI 10.1126/science.1195596
   Xu XD, 2007, SCIENCE, V317, P929, DOI 10.1126/science.1142979
   Yang Y T, 2006, Nano Lett, V6, P583
   Yang YT, 2011, NANO LETT, V11, P1753, DOI 10.1021/nl2003158
   Yie Z, 2011, J MICROMECH MICROENG, V21, DOI 10.1088/0960-1317/21/2/025027
   Zeng HL, 2012, NAT NANOTECHNOL, V7, P490, DOI [10.1038/NNANO.2012.95, 10.1038/nnano.2012.95]
NR 57
TC 5
Z9 6
U1 2
U2 52
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0740-3224
EI 1520-8540
J9 J OPT SOC AM B
JI J. Opt. Soc. Am. B-Opt. Phys.
PD JUL
PY 2014
VL 31
IS 7
BP 1684
EP 1690
DI 10.1364/JOSAB.31.001684
PG 7
WC Optics
SC Optics
GA AL2BU
UT WOS:000338931700038
DA 2018-01-05
ER

PT J
AU Gramatica, A
   Petazzi, RA
   Lehmann, MJ
   Ziomkowska, J
   Herrmann, A
   Chiantia, S
AF Gramatica, Andrea
   Petazzi, Roberto A.
   Lehmann, Maik J.
   Ziomkowska, Joanna
   Herrmann, Andreas
   Chiantia, Salvatore
TI alpha Env-decorated phosphatidylserine liposomes trigger phagocytosis of
   HIV-virus-like particles in macrophages
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE HIV-1; Fluorescence microscopy; Immunoliposomes
ID MONOCYTE-DERIVED MACROPHAGES; FC-GAMMA-R; APOPTOTIC CELLS;
   IMMUNE-RESPONSES; DENDRITIC CELLS; IN-VITRO; RECEPTOR; INFECTION;
   ANTIBODIES; INHIBITION
AB Macrophages represent an important cellular target of HIV-1. Interestingly, they are also believed to play a potential role counteracting its infection. However, HIV-1 is known to impair macrophage immune functions such as antibody-mediated phagocytosis. Here, we present immunoliposomes that can bind HIV-1 virus-like particles (HIV-VLPs) while being specifically phagocytosed by macrophages, thus allowing the co-internalization of HIV-VLPs. These liposomes are decorated with anti-Env antibodies and contain phosphatidylserine (PS). PS mediates liposome internalization by macrophages via a mechanism not affected by HIV-1. Hence, PS-liposomes mimic apoptotic cells and are internalized into the macrophages due to specific recognition, carrying the previously bound HIV-VLPs. With a combination of flow cytometry, confocal live-cell imaging and electron microscopy we demonstrate that the PS-immunoliposomes presented here are able to elicit efficient HIV-VLPs phagocytosis by macrophages and might represent a new nanotechnological approach to enhance HIV-1 antigen presentation and reduce the ongoing inflammation processes.
   From the Clinical Editor: This team of authors demonstrate that specific phosphatidylserin immunoliposomes are able to elicit efficient phagocytosis of HIV-virus-like particle by macrophages and might represent a new nanomedicine approach to enhance HIV-1 antigen presentation and reduce ongoing inflammation processes. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Gramatica, Andrea; Ziomkowska, Joanna; Herrmann, Andreas; Chiantia, Salvatore] Humboldt Univ, Dept Biol Mol Biophys, D-10115 Berlin, Germany.
   [Petazzi, Roberto A.] Free Univ Berlin, Dept Phys, Berlin, Germany.
   [Lehmann, Maik J.] Humboldt Univ, Dept Biol Mol Parasitol, D-10115 Berlin, Germany.
RP Chiantia, S (reprint author), Humboldt Univ, Dept Biol Mol Biophys, Invalidenstr 42, D-10115 Berlin, Germany.
EM chiantis@cms.hu-berlin.de
RI Gramatica, Andrea/A-2936-2015
OI Gramatica, Andrea/0000-0002-7131-933X
FU European Union; Sonderforschungsbereich, Collaborative Research Center
   [SFB 740, 765]
FX This study was supported by the European Union (Marie Curie 7th
   Framework Program Initial Training Network) and by the SFB 740 and 765
   (Sonderforschungsbereich, Collaborative Research Center).
CR Ackerman ME, 2013, J VIROL, V87, P5468, DOI 10.1128/JVI.03403-12
   Ahmad R, 2001, J CLIN IMMUNOL, V21, P227, DOI 10.1023/A:1011087132180
   Armstrong A, 2011, EMBO REP, V12, P287, DOI 10.1038/embor.2011.41
   Benaroch P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-29
   BIGGS BA, 1995, J IMMUNOL, V154, P6132
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042
   Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028
   Etzerodt A, 2012, J CONTROL RELEASE, P1
   Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084
   FIDLER IJ, 1980, CANCER RES, V40, P4460
   Gao F, 2003, AIDS RES HUM RETROV, V19, P817, DOI 10.1089/088922203769232610
   Geelen T, 2012, J NANOBIOTECHNOL, V10, P1
   Goldenbogen B, 2011, LANGMUIR, V27, P10820, DOI 10.1021/la201160y
   Ha S., 2011, ANTENNAS WIRELESS PR, VPP, P1
   Harel-Adar T, 2011, P NATL ACAD SCI USA, V108, P1827, DOI 10.1073/pnas.1015623108
   Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094
   Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080
   Holl V, 2004, J IMMUNOL, V173, P6274, DOI 10.4049/jimmunol.173.10.6274                                                    
   Holl V, 2009, VIRUSES-BASEL, V1, P1265, DOI 10.3390/v1031265
   Ipp H, 2013, CLIN CHIM ACTA, V416, P96, DOI 10.1016/j.cca.2012.11.025
   Jouve M, 2007, CELL HOST MICROBE, V2, P85, DOI 10.1016/j.chom.2007.06.011
   Kedzierska K, 2000, J INFECT DIS, V181, P390, DOI 10.1086/315191
   Kedzierska K, 2002, J IMMUNOL, V168, P2895, DOI 10.4049/jimmunol.168.6.2895                                                     
   Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0
   Lee C, 2005, J LEUKOCYTE BIOL, V78, P1016, DOI 10.1189/jlb.0105056
   Leeansyah E, 2007, J IMMUNOL, V178, P1096, DOI 10.4049/jimmunol.178.2.1096                                                     
   Lima RG, 2002, J INFECT DIS, V185, P1561, DOI 10.1086/340412
   Lindwasser OW, 2004, J VIROL, V78, P6013, DOI 10.1128/JVI.78.11.6013-6023.2004
   Lodge R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032761
   Ma HM, 2011, LAB INVEST, V91, P921, DOI 10.1038/labinvest.2011.54
   Mayne M, 2000, J IMMUNOL, V164, P6538, DOI 10.4049/jimmunol.164.12.6538                                                    
   Michailidis C, 2012, CLIN EXP IMMUNOL, V167, P499, DOI 10.1111/j.1365-2249.2011.04526.x
   Perlman M, 2006, TRAFFIC, V7, P731, DOI 10.1111/j.1600-0854.2006.00428.x
   Perno CF, 2006, ANTIVIR RES, V71, P293, DOI 10.1016/j.antiviral.2006.05.015
   Poggi A, 2002, J LEUKOCYTE BIOL, V71, P531
   Ribes S, 2010, INFECT IMMUN, V78, P865, DOI 10.1128/IAI.01110-09
   Smith-Franklin BA, 2002, J IMMUNOL, V168, P2408, DOI 10.4049/jimmunol.168.5.2408                                                     
   Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002
   Tan J, 2013, TRENDS MICROBIOL, V21, P405, DOI 10.1016/j.tim.2013.05.001
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torre D, 2002, CLIN DIAGN LAB IMMUN, V9, P983, DOI 10.1128/CDLI.9.5.983-986.2002
   Underhill DM, 2012, NAT REV IMMUNOL, V12, P492, DOI 10.1038/nri3244
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   Viegas MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048391
   von Delwig A, 2002, EUR J IMMUNOL, V32, P3714, DOI 10.1002/1521-4141(200212)32:12<3714::AID-IMMU3714>3.0.CO;2-Y
NR 48
TC 6
Z9 7
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JUL
PY 2014
VL 10
IS 5
BP 981
EP 989
DI 10.1016/j.nano.2014.02.008
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA AK9GS
UT WOS:000338736200011
PM 24589930
DA 2018-01-05
ER

PT J
AU Liu, XX
   Liu, C
   Catapano, CV
   Peng, L
   Zhou, JH
   Rocchi, P
AF Liu, Xiaoxuan
   Liu, Cheng
   Catapano, Carlo V.
   Peng, Ling
   Zhou, Jiehua
   Rocchi, Palma
TI Structurally flexible triethanolamine-core poly(amidoamine) dendrimers
   as effective nanovectors to deliver RNAi-based therapeutics
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review
DE Dendrimer; Nanovector; RNAi therapeutics; RNA interference; Gene
   silencing
ID REFRACTORY PROSTATE-CANCER; HEAT-SHOCK PROTEINS; SIRNA DELIVERY;
   IN-VITRO; PAMAM DENDRIMERS; HIV-1 INFECTION; DENDRITIC VECTORS; ANDROGEN
   ABLATION; GENE-EXPRESSION; MICRORNAS
AB RNAi-based nucleic acid molecules have attracted considerable attention as compelling therapeutics providing safe and competent delivery systems are available. Dendrimers are emerging as appealing nanocarriers for nucleic acid delivery thanks to their unique well-defined architecture and the resulting cooperativity and multivalency confined within a nanostructure. The present review offers a brief overview of the structurally flexible triethanolamine-core poly(amidoamine) (PAMAM) dendrimers developed in our group as nanovectors for the delivery of RNAi therapeutics. Their excellent activity for delivering different RNAi therapeutics in various disease models in vitro and in vivo will be highlighted here. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Liu, Xiaoxuan; Rocchi, Palma] INSERM, Ctr Rech Cancerol Marseille, UMR1068, F-13009 Marseille, France.
   [Liu, Xiaoxuan; Rocchi, Palma] Inst Paoli Calmettes, F-13009 Marseille, France.
   [Liu, Xiaoxuan; Rocchi, Palma] Aix Marseille Univ, F-13284 Marseille, France.
   [Liu, Xiaoxuan; Rocchi, Palma] CNRS, UMR7258, F-13009 Marseille, France.
   [Liu, Cheng; Peng, Ling] Aix Marseille Univ, Ctr Interdisciplinaire Nanosci Marseille, F-13288 Marseille 09, France.
   [Liu, Cheng] Wuhan Univ, Coll Chem & Mol Sci, Wuhan 430072, Peoples R China.
   [Catapano, Carlo V.] Inst Southern Switzerland IOSI, IOR, CH-6500 Bellinzona, Switzerland.
   [Zhou, Jiehua] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA USA.
RP Peng, L (reprint author), Aix Marseille Univ, CNRS CINaM UMR 7325, F-13288 Marseille 09, France.
EM ling.peng@univ-amu.fr; palma.rocchi@inserm.fr
RI Rocchi, Palma/P-5455-2014
OI Rocchi, Palma/0000-0002-4383-4684
FU international ERA-Net EURONANOMED European Research project DENANORNA,
   Ministry of Science and Technology of China [2012AA022501]; PACA
   Canceropole; INCa; Wuhan University; Aix-Marseille University; CNRS;
   INSERM; Association pour la Recherche sur les Tumeurs de la Prostate;
   China Scholarship Council; European COST Action [TD0802]
FX This work was supported by the international ERA-Net EURONANOMED
   European Research project DENANORNA, Ministry of Science and Technology
   of China (No. 2012AA022501), PACA Canceropole, INCa, Wuhan University,
   Aix-Marseille University, CNRS, INSERM, Association pour la Recherche
   sur les Tumeurs de la Prostate (LX), China Scholarship Council (LC) and
   under the auspice of European COST Action TD0802 "Dendrimers in
   Biomedical Applications".
CR Acunzo J, 2012, INT J BIOCHEM CELL B, V44, P1622, DOI 10.1016/j.biocel.2012.04.002
   Alabi C, 2012, CURR OPIN PHARMACOL, V12, P427, DOI 10.1016/j.coph.2012.05.004
   Amarzguioui M, 2006, NAT PROTOC, V1, P508, DOI 10.1038/nprot.2006.72
   Amarzguioui Mohammed, 2008, V442, P3, DOI 10.1007/978-1-59745-191-8_1
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Anderson J, 2003, OLIGONUCLEOTIDES, V13, P303, DOI 10.1089/154545703322616989
   Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5                                                   
   Behr JP, 1997, CHIMIA, V51, P34
   Berkhout B, 2009, EXPERT OPIN BIOL TH, V9, P161, DOI [10.1517/14712590802653619, 10.1517/14712590802653619 ]
   Bolcato-Bellemin AL, 2007, P NATL ACAD SCI USA, V104, P16050, DOI 10.1073/pnas.0707831104
   Bouillon C, 2010, J ORG CHEM, V75, P8685, DOI 10.1021/jo101739x
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Brault L, 2010, HAEMATOL-HEMATOL J, V95, P1004, DOI 10.3324/haematol.2009.017079
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Christ F, 2008, CURR BIOL, V18, P1192, DOI 10.1016/j.cub.2008.07.079
   Cornford PA, 2000, CANCER RES, V60, P7099
   Couto LB, 2010, CURR OPIN PHARMACOL, V10, P534, DOI 10.1016/j.coph.2010.06.007
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fusi A, 2004, TUMORI, V90, P535
   Gallagher Eva, 2006, Clin J Oncol Nurs, V10, P233, DOI 10.1188/06.CJON.233-240
   Godlewski J, 2010, CELL DEATH DIFFER, V17, P221, DOI 10.1038/cdd.2009.71
   Guillot-Nieckowski M, 2007, NEW J CHEM, V31, P1111, DOI 10.1039/b614877h
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   HE L, 2004, NAT REV GENET, V5, P522
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208
   Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294
   Kiessling MK, 2011, BLOOD, V117, P2433, DOI 10.1182/blood-2010-09-305128
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Lang MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036248
   Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2                                                   
   Liu X, 2013, DENDRIMERS IN BIOMEDICAL APPLICATIONS, P73, DOI 10.1039/9781849737296-00073
   Liu XX, 2009, CHEMMEDCHEM, V4, P1302, DOI 10.1002/cmdc.200900076
   Liu XX, 2012, MOL PHARMACEUT, V9, P470, DOI 10.1021/mp2006104
   Liu XX, 2012, NEW J CHEM, V36, P256, DOI 10.1039/c1nj20408d
   Liu XX, 2011, BIOCONJUGATE CHEM, V22, P2461, DOI 10.1021/bc200275g
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Martinez Miguel Angel, 2009, V487, P343, DOI [10.1007/978-1-60327-547-7_17, 10.1007/978-1-60327-547_17]
   Mignani S, 2013, ADV DRUG DELIVER REV, V65, P1316, DOI 10.1016/j.addr.2013.01.001
   Nekhai S, 2006, FUTURE MICROBIOL, V1, P417, DOI 10.2217/17460913.1.4.417
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162
   Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2                                                   
   Posocco P, 2013, MOL PHARMACEUT, V10, P3262, DOI 10.1021/mp400329g
   Quelever G, 2013, DENDRIMERS IN BIOMEDICAL APPLICATIONS, P167, DOI 10.1039/9781849737296-00167
   Ravina M, 2010, MINI-REV MED CHEM, V10, P73, DOI 10.2174/138955710791112569                                                      
   Reebye V, 2013, HEPATOLOGY IN PRESS
   Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840
   Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998
   Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x
   Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732
   Rossi JJ, 2006, BIOTECHNIQUES, V40, P25, DOI 10.2144/000112167
   Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367
   Scherer L, 2007, GENE THER, V14, P1057, DOI 10.1038/sj.gt.3302977
   Schroeder A, 2010, J INTERN MED, V267, P9, DOI 10.1111/j.1365-2796.2009.02189.x
   Shen H, 2012, CANCER GENE THER, V19, P367, DOI 10.1038/cgt.2012.22
   Shen XC, 2007, ORG BIOMOL CHEM, V5, P3674, DOI 10.1039/b711242d
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stavridi F, 2010, CANCER TREAT REV, V36, P122, DOI 10.1016/j.ctrv.2009.06.001
   Tan SJ, 2011, SMALL, V7, P841, DOI 10.1002/smll.201001389
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630                                                               
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381                                                          
   Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755
   Tseng YC, 2009, ADV DRUG DELIVER REV, V61, P721, DOI 10.1016/j.addr.2009.03.003
   Vogtle F., 2009, DENDRIMER CHEM CONCE
   Wagner E, 2012, ACCOUNTS CHEM RES, V45, P1005, DOI 10.1021/ar2002232
   Wang Y, 2012, CURR MED CHEM, V19, P5011
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wu JY, 2005, CHEM COMMUN, P313, DOI 10.1039/b414241a
   Wu Y, 2010, ONCOGENE, V29, P2228, DOI 10.1038/onc.2009.504
   Zhou JH, 2006, CHEM COMMUN, P2362, DOI 10.1039/b601381c
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
   Zoubeidi A, 2012, INT J BIOCHEM CELL B, V44, P1646, DOI 10.1016/j.biocel.2012.04.010
NR 87
TC 24
Z9 24
U1 3
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD JUL-AUG
PY 2014
VL 32
IS 4
SI SI
BP 844
EP 852
DI 10.1016/j.biotechadv.2013.08.001
PG 9
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA AL0LL
UT WOS:000338818300014
PM 23938269
DA 2018-01-05
ER

PT J
AU Salomone, F
   Breton, M
   Leray, I
   Cardarelli, F
   Boccardi, C
   Bonhenry, D
   Tarek, M
   Mir, LM
   Beltram, F
AF Salomone, Fabrizio
   Breton, Marie
   Leray, Isabelle
   Cardarelli, Francesco
   Boccardi, Claudia
   Bonhenry, Daniel
   Tarek, Mounir
   Mir, Lluis M.
   Beltram, Fabio
TI High-Yield Nontoxic Gene Transfer through Conjugation of the
   CM18-Tat(11) Chimeric Peptide with Nanosecond Electric Pulses
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE gene delivery; nanopulses; cell-penetrating peptides; antimicrobial
   peptides; electropermeabilization; electroporation; nanoporation
ID PLASMA-MEMBRANE PERMEABILIZATION; MOLECULAR-DYNAMICS SIMULATIONS;
   SINGLE-CELL LEVEL; DIRECT VISUALIZATION; LIPID-MEMBRANES;
   ELECTROPERMEABILIZATION; ELECTROPORATION; ELECTROTRANSFER;
   TRANSLOCATION; DELIVERY
AB We report a novel nontoxic, high-yield, gene delivery system based on the synergistic use of nanosecond electric pulses (NPs) and nanomolar doses of the recently introduced CM18-Tat(11) chimeric peptide (sequence of KWKLFKKIGA-VLKVLTTGYGRKKRRQRRR, residues 1-7 of cecropin-A, 2-12 of melittin, and 47-57 of HIV-1 Tat protein). This combined use makes it possible to drastically reduce the required CM18-Tat(11) concentration and confines stable nanopore formation to vesicle membranes followed by DNA release, while no detectable perturbation of the plasma membrane is observed. Two different experimental assays are exploited to quantitatively evaluate the details of NPs and CM18-Tat(11) cooperation: (i) cytofluorimetric analysis of the integrity of synthetic 1,2-dioleoyl-sn-glycero-3-phosphocholine giant unilamellar vesicles exposed to CM18-Tat(11) and NPs and (ii) the in vitro transfection efficiency of a green fluorescent protein-encoding plasmid conjugated to CM18-Tat(11) in the presence of NPs. Data support a model in which NPs induce membrane perturbation in the form of transient pores on all cellular membranes, while the peptide stabilizes membrane defects selectively within endosomes. Interestingly, atomistic molecular dynamics simulations show that the latter activity can be specifically attributed to the CM18 module, while Tat(11) remains essential for cargo binding and vector subcellular localization. We argue that this result represents a paradigmatic example that can open the way to other targeted delivery protocols.
C1 [Salomone, Fabrizio; Beltram, Fabio] Scuola Normale Super Pisa, NEST, I-56127 Pisa, Italy.
   [Salomone, Fabrizio; Beltram, Fabio] CNR, Ist Nanosci, I-56127 Pisa, Italy.
   [Salomone, Fabrizio; Cardarelli, Francesco; Boccardi, Claudia; Beltram, Fabio] Ist Italian Tecnol, NEST, Ctr Nanotechnol Innovat, I-56127 Pisa, Italy.
   [Breton, Marie; Leray, Isabelle; Mir, Lluis M.] CNRS, Lab Vectorol & Therapeut Anticanc, UMR 8203, F-91405 Orsay, France.
   [Leray, Isabelle; Mir, Lluis M.] Univ Paris 11, Lab Vectorol & Therapeut Anticanc, UMR 8203, F-91405 Orsay, France.
   [Leray, Isabelle; Mir, Lluis M.] Inst Gustave Roussy, Lab Vectorol & Therapeut Anticanc, UMR 8203, F-94805 Villejuif, France.
   [Bonhenry, Daniel; Tarek, Mounir] Univ Lorraine, CNRS, UMR Struct & Reactivite Syst Mol Complexes 7565, F-54003 Nancy, France.
RP Salomone, F (reprint author), Piazza San Silvestro 12, I-56127 Pisa, Italy.
EM fabrizio.salomone@sns.it
RI Beltram, Fabio/F-2920-2013; Bonhenry, Daniel/K-6336-2017
OI Beltram, Fabio/0000-0002-6081-436X; salomone,
   fabrizio/0000-0002-9083-3932
FU CNRS [TD1104]; University of Paris-Sud, Gustave Roussy; Fondation EDF;
   French National Agency for Research (ANR) [Intcell ANR-10-BLAN-916,
   IPSIOAT ANR-11-BS09-0031, Memove ANR-11-BS01-006]
FX This research was performed in the scope of the EBAM European Associated
   Laboratory and of COST Action TD1104 and is partly funded by the CNRS,
   the University of Paris-Sud, Gustave Roussy, the Fondation EDF, and the
   French National Agency for Research (ANR) through the Intcell
   ANR-10-BLAN-916, IPSIOAT ANR-11-BS09-0031, and Memove ANR-11-BS01-006
   grants.
CR Angelova I. A., 1986, FARADAY DISCUSS, V1986, P303
   Bhargava K, 2004, BIOPHYS J, V86, P329, DOI 10.1016/S0006-3495(04)74108-9                                                   
   Breton M, 2012, J AM CHEM SOC, V134, P13938, DOI 10.1021/ja3052365
   Breton M, 2012, BIOELECTROMAGNETICS, V33, P106, DOI 10.1002/bem.20692
   Chen NY, 2004, BIOCHEM BIOPH RES CO, V317, P421, DOI 10.1016/j.bbrc.2004.03.063
   Delemotte L, 2012, J MEMBRANE BIOL, V245, P531, DOI 10.1007/s00232-012-9434-6
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Escoffre JM, 2010, J MEMBRANE BIOL, V236, P61, DOI 10.1007/s00232-010-9275-0
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Gehl J, 1999, BIOCHEM BIOPH RES CO, V261, P377, DOI 10.1006/bbrc.1999.1014                                                          
   Golzio M, 2002, P NATL ACAD SCI USA, V99, P1292, DOI 10.1073/pnas.022646499                                                          
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Ibey BL, 2009, BIOELECTROMAGNETICS, V30, P92, DOI 10.1002/bem.20451
   Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Kolb JF, 2006, BIOELECTROMAGNETICS, V27, P172, DOI 10.1002/bem.20185
   Levine ZA, 2010, J MEMBRANE BIOL, V236, P27, DOI 10.1007/s00232-010-9277-y
   Medina-Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592
   Mir LM, 2009, MOL BIOTECHNOL, V43, P167, DOI 10.1007/s12033-009-9192-6
   Napotnik TB, 2010, MED BIOL ENG COMPUT, V48, P407, DOI 10.1007/s11517-010-0599-9
   NEUMANN E, 1972, J MEMBRANE BIOL, V10, P279, DOI 10.1007/BF01867861
   Paganin-Gioanni A, 2011, P NATL ACAD SCI USA, V108, P10443, DOI 10.1073/pnas.1103519108
   Pakhomov AG, 2007, BIOELECTROMAGNETICS, V28, P655, DOI 10.1002/bem.20354
   Salomone F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070108
   Salomone F, 2012, J CONTROL RELEASE, V163, P293, DOI 10.1016/j.jconrel.2012.09.019
   Satkauskas S, 2002, MOL THER, V5, P133, DOI 10.1006/mthe.2002.0526
   Schoenbach KH, 2004, P ANN INT IEEE EMBS, V26, P5447
   Schoenbach KH, 2001, BIOELECTROMAGNETICS, V22, P440, DOI 10.1002/bem.71
   Silve A, 2011, BIOELECTROCHEMISTRY, V87, P260
   Sundararajan R, 2009, MOL BIOTECHNOL, V41, P69, DOI 10.1007/s12033-008-9107-y
   Teissie J, 1999, ADV DRUG DELIVER REV, V35, P3, DOI 10.1016/S0169-409X(98)00060-X
   Tieleman D. Peter, 2004, BMC Biochemistry, V5, P10, DOI 10.1186/1471-2091-5-10
   Vernier PT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-37
   Vernier PT, 2003, IEEE T DIELECT EL IN, V10, P795, DOI 10.1109/TDEI.2003.1237329
   Vernier PT, 2003, BIOCHEM BIOPH RES CO, V310, P286, DOI 10.1016/j.bbrc.2003.08.140
NR 35
TC 9
Z9 9
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL
PY 2014
VL 11
IS 7
BP 2466
EP 2474
DI 10.1021/mp500223t
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AK9LI
UT WOS:000338748200053
PM 24865174
DA 2018-01-05
ER

PT J
AU Sluis-Cremer, N
   Jordan, MR
   Huber, K
   Wallis, CL
   Bertagnolio, S
   Mellors, JW
   Parkin, NT
   Harrigan, PR
AF Sluis-Cremer, Nicolas
   Jordan, Michael R.
   Huber, Kelly
   Wallis, Carole L.
   Bertagnolio, Silvia
   Mellors, John W.
   Parkin, Neil T.
   Harrigan, P. Richard
TI E138A in HIV-1 reverse transcriptase is more common in subtype C than B:
   Implications for rilpivirine use in resource-limited settings
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE HIV-1; Reverse transcriptase; NNRTI; Rilpivirine; E138A; Resistance
ID SUSCEPTIBILITY; RESISTANCE; INHIBITORS; MUTATION
AB The nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV) has been co-formulated with emtricitabine and tenofovir disoproxil fumarate for initial therapy of HIV-1-infected individual's. RPV, formulated as a long-acting nanosuspension, will also be assessed for its ability to prevent HIV-1 infection in resource limited settings. In this study, we determined whether any pre-existing genetic differences occurred among different HIV-1 subtypes at residues in RT associated with decreased virologic response to RPV. We found that the E138A substitution occurs more frequently in subtype C (range: 5.9-7.5%) than B (range: 0-2.3%) sequences from both treatment-naive and -experienced individuals (p < 0.01) in 4 independent genotype databases. In one of the databases (Stanford University), E138K and E138Q were also more common in RTI-experienced subtype C sequences (1.0% and 1.1%, respectively) than in subtype B sequences (0.3% and 0.6%, respectively). E138A/K/Q in subtype C decreased RPV susceptibility 2.9-, 5.8-, and 5.4-fold, respectively. Taken together, these data suggest that E138A could impact treatment or prevention strategies that include RPV in geographic areas where subtype C infection is prevalent. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Sluis-Cremer, Nicolas; Huber, Kelly; Mellors, John W.] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA.
   [Jordan, Michael R.] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA.
   [Jordan, Michael R.] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA.
   [Wallis, Carole L.] Lancet Labs, Johannesburg, South Africa.
   [Bertagnolio, Silvia] World Hlth Org, HIV Dept, Geneva, Switzerland.
   [Parkin, Neil T.] Data First Consulting, Belmont, CA USA.
   [Harrigan, P. Richard] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
RP Sluis-Cremer, N (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, S817 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM nps2@pitt.edu
FU National Institutes of Health [GM068406, AI081571, AI074423-05]; Bell &
   Melinda Gates Foundation [1019228, 38180]; CIHR/GSK Chair in Clinical
   Virology by the Government of Canada through Genome Canada; Genome
   British Columbia; Tufts-Brown CFAR [P30AI42853]; Driscoll-O'Neil
   Charitable Foundation; CIHR/GSK Chair in Clinical Virology by the
   Government of Canada through Canadian Institutes of Health Research
   (CIHR)
FX This study was supported by the National Institutes of Health grants
   GM068406 (to N.S.-C), AI081571 (to N.S.-C) and AI074423-05 (to M.R.J),
   and by the Bell & Melinda Gates Foundation grants 1019228 (to J.W.M.,
   C.L.W. and N.S.C) and 38180 (to the WHO). R.H. is supported by a
   CIHR/GSK Chair in Clinical Virology by the Government of Canada through
   Genome Canada and Canadian Institutes of Health Research (CIHR) and by
   Genome British Columbia. MRJ is also supported by the Tufts-Brown CFAR
   P30AI42853 and the Christine E. Driscoll O'Neill and James M. Driscoll,
   Driscoll-O'Neil Charitable Foundation. The authors would also like to
   acknowledge intellectual input from Drs Shafer and Rhee.
CR Anta L, 2013, AIDS, V27, P81, DOI 10.1097/QAD.0b013e3283584500
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Brehm JH, 2012, CLIN INFECT DIS, V55, P737, DOI 10.1093/cid/cis501
   Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/01.aids.0000042957.95433.6c
   Gill VS, 2010, CLIN INFECT DIS, V50, P98, DOI 10.1086/648729
   Gupta RK, 2012, LANCET, V380, P1250, DOI 10.1016/S0140-6736(12)61038-1
   Lihana RW, 2012, AIDS REV, V14, P83
   Price MA, 2011, AIDS RES HUM RETROV, V27, P5, DOI 10.1089/aid.2010.0030
   Rhee SY, 2006, AIDS, V20, P643, DOI 10.1097/01.aids.0000216363.36786.2b                                             
   Tambuyzer L, 2011, JAIDS-J ACQ IMM DEF, V58, P18, DOI 10.1097/QAI.0b013e3182237f74
NR 11
TC 21
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUL
PY 2014
VL 107
BP 31
EP 34
DI 10.1016/j.antiviral.2014.04.001
PG 4
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA AK4RT
UT WOS:000338412500005
PM 24746459
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mislak, AC
   Frey, KM
   Bollini, M
   Jorgensen, WL
   Anderson, KS
AF Mislak, Andrea C.
   Frey, Kathleen M.
   Bollini, Mariela
   Jorgensen, William L.
   Anderson, Karen S.
TI A mechanistic and structural investigation of modified derivatives of
   the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE HIV-1; Reverse transcriptase; NNRTI; Crystallography; Transient kinetics
ID NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES;
   DRUG-RESISTANCE; POSITIONAL ADAPTABILITY; CONFORMATIONAL-CHANGES;
   ENHANCED SOLUBILITY; ENTRANCE CHANNEL; WILD-TYPE; DESIGN
AB Background: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are vital in treating HIV-1 infection by inhibiting reverse transcriptase (RT). Drug toxicity and resistance drive the need for effective new inhibitors with improved physiochemical properties and potent antiviral activity. Computer-aided and structure-based drug design have guided the addition of solubilizing substituents to the diaryltriazine scaffold. These derivatives have markedly improved solubility and maintain low nanomolar antiviral activity against RT. The molecular and structural basis of inhibition for this series was determined to facilitate future inhibitor development with improved pharmacological profiles.
   Methods: The molecular mechanism of inhibition was investigated using transient-state kinetic analysis. Crystal structures of RT in complex with each inhibitor were obtained to investigate the structural basis of inhibition.
   Results: The diaryltriazine and its morpholine derivative have RT inhibition constants of 9 +/- 2 nM and 14 +/- 4 nM, respectively. They adopt differential binding modes within the non-nucleoside inhibitor binding pocket to distort the catalytic site geometry and primer grip regions. The novel morpholinopropoxy substituent extends into the RT/solvent interface of the NNIBP.
   Conclusions: Kinetic and structural analyses show that these inhibitors behave as conventional NNRTIs and inhibit the polymerization step. This study confirms that appending solubilizing substituents on the azine ring of diaryltriazine class of NNRTIs that extend into the RT/solvent interface effectively maintains low nanomolar potency and improves physiochemical properties.
   General significance: The modification of NNRTI scaffolds with solubilizing substituents, which extend into the RT/solvent interface, yields potent antivirals and is an effective strategy for developing novel inhibitors with improved pharmacological properties. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Mislak, Andrea C.; Frey, Kathleen M.; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
   [Bollini, Mariela; Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHMB 350,POB 208066, New Haven, CT 06520 USA.
EM Karen.Anderson@yale.edu
FU National Institutes of Health [GM49551, AI44616, GM32136]; ACM
   [GM007324]; KMF [AI104334]
FX Gratitude is expressed to the National Institutes of Health (GM49551,
   AI44616, GM32136) for research support, (GM007324) for training support
   of ACM, and (AI104334) for fellowship support of KMF. We also thank the
   National Synchrotron Light Source at Brookhaven National Laboratory for
   beam time on X29A and training in their RapiData 2013 course.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Arts EJ, 2012, COLD SPRING HARB PER, V2
   Bailey CM, 2013, J MED CHEM, V56, P3959, DOI 10.1021/jm400160s
   BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456                                                       
   Bollini M, 2013, BIOORG MED CHEM LETT, V23, P5213, DOI 10.1016/j.bmcl.2013.06.091
   Bollini M, 2013, BIOORG MED CHEM LETT, V23, P5209, DOI 10.1016/j.bmcl.2013.06.093
   Chen XW, 2012, BIOORGAN MED CHEM, V20, P3856, DOI 10.1016/j.bmc.2012.04.030
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   Das K, 2012, NAT STRUCT MOL BIOL, V19, P253, DOI 10.1038/nsmb.2223
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   Ekkati AR, 2012, BIOORG MED CHEM LETT, V22, P1565, DOI 10.1016/j.bmcl.2011.12.132
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Frey KM, 2012, J AM CHEM SOC, V134, P19501, DOI 10.1021/ja3092642
   Himmel DM, 2005, J MED CHEM, V48, P7582, DOI 10.1021/jm0500323
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Johnson Victoria A, 2011, Top Antivir Med, V19, P156
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862                                                               
   Kertesz DJ, 2010, BIOORG MED CHEM LETT, V20, P4215, DOI 10.1016/j.bmcl.2010.05.040
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Lansdon EB, 2010, J MED CHEM, V53, P4295, DOI 10.1021/jm1002233
   Lansdon EB, 2010, J MOL BIOL, V397, P967, DOI 10.1016/j.jmb.2010.02.019
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975
   Mitchell ML, 2010, BIOORG MED CHEM LETT, V20, P1589, DOI 10.1016/j.bmcl.2010.01.085
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l
   Ren J, 2008, J MED CHEM, V51, P5000, DOI 10.1021/jm8004493
   Ren JS, 2006, FEBS J, V273, P3850, DOI 10.1111/j.1742-4658.2006.05392.x
   ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925
   [Anonymous], PYM MOL GRAPH SYST V
   Singh K, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.398180
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   Sun LQ, 2012, BIOORG MED CHEM LETT, V22, P2376, DOI 10.1016/j.bmcl.2012.02.055
   Tambuyzer L, 2010, AIDS RES HUM RETROV, V26, P1197, DOI 10.1089/aid.2009.0302
   Weuts I, 2011, J PHARM SCI-US, V100, P260, DOI 10.1002/jps.22242
NR 45
TC 4
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD JUL
PY 2014
VL 1840
IS 7
BP 2203
EP 2211
DI 10.1016/j.bbagen.2014.04.001
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AK4NW
UT WOS:000338402400011
PM 24726448
OA green_accepted
DA 2018-01-05
ER

PT J
AU das Neves, J
   Araujo, F
   Andrade, F
   Amiji, M
   Bahia, MF
   Sarmento, B
AF das Neves, Jose
   Araujo, Francisca
   Andrade, Fernanda
   Amiji, Mansoor
   Bahia, Maria Fernanda
   Sarmento, Bruno
TI Biodistribution and Pharmacokinetics of Dapivirine-Loaded Nanoparticles
   after Vaginal Delivery in Mice
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE HIV/AIDS; microbicides; poly(epsilon-caprolactone); pre-exposure
   prophylaxis; vaginal drug delivery
ID REVERSE-TRANSCRIPTASE INHIBITOR; HUMAN-IMMUNODEFICIENCY-VIRUS;
   ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS; HIV-NEGATIVE WOMEN; POLYMERIC
   NANOPARTICLES; BIODEGRADABLE NANOPARTICLES; INTRACELLULAR DELIVERY; GEL
   FORMULATION; DRUG-DELIVERY; TENOFOVIR GEL
AB To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery.
   Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages.
   PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days.
   Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.
C1 [das Neves, Jose; Araujo, Francisca; Sarmento, Bruno] CESPU, Inst Super Ciencias Saude Norte, IINFACTS Inst Invest & Formacao Avancada Ciencias, P-4585116 Gandra, Portugal.
   [das Neves, Jose; Andrade, Fernanda; Bahia, Maria Fernanda] Univ Porto, Fac Pharm, Lab Pharmaceut Technol, P-4100 Oporto, Portugal.
   [Araujo, Francisca; Sarmento, Bruno] INEB Inst Engn Biomed, Oporto, Portugal.
   [Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP das Neves, J (reprint author), CESPU, Inst Super Ciencias Saude Norte, IINFACTS Inst Invest & Formacao Avancada Ciencias, Rua Cent Gandra 1317, P-4585116 Gandra, Portugal.
EM j.dasneves@gmail.com
RI Araujo, Francisca/J-8543-2013; das Neves, Jose/J-8369-2013; Andrade,
   Fernanda/F-3272-2010; Sarmento, Bruno/J-6265-2013
OI Araujo, Francisca/0000-0001-9087-9941; das Neves,
   Jose/0000-0002-2317-2759; Andrade, Fernanda/0000-0002-4947-2346;
   Sarmento, Bruno/0000-0001-5763-7553
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BD/43393/2008]; FCT [VIH/SAU/0021/2011]
FX Jose das Neves gratefully acknowledges Fundacao para a Ciencia e a
   Tecnologia (FCT), Portugal for financial support (grant
   SFRH/BD/43393/2008). This work was supported by a grant from FCT
   (VIH/SAU/0021/2011). The authors would like to express their gratitude
   to Catarina Ferreira (University of Beira Interior, Covilha, Portugal)
   for histology slides preparation. Dapivirine was kindly provided by IPM.
   Dapivirine was originally developed by Tibotec Pharmaceuticals and
   licensed to IPM.
CR Adams JL, 2012, BEST PRACT RES CL OB, V26, P451, DOI 10.1016/j.bpobgyn.2012.01.004
   Baeten J, 2013, ANNU REV MED, V64, P219, DOI 10.1146/annurev-med-050911-163701
   Bulletti C, 1997, HUM REPROD, V12, P1073
   Catalone BJ, 2004, ANTIMICROB AGENTS CH, V48, P1837, DOI 10.1128/AAC.48.5.1837-1847.2004
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2012, J CHROMATOGR B, V911, P76, DOI 10.1016/j.jchromb.2012.10.034
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J, 2010, J PHARMACEUT BIOMED, V52, P167, DOI 10.1016/j.jpba.2010.01.007
   DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Dobard C, 2012, J VIROL, V86, P718, DOI 10.1128/JVI.05842-11
   Duwal S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040382
   Ensign LM, 2013, MOL PHARMACEUT, V10, P2176, DOI 10.1021/mp400087y
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hardy E, 2007, CONTRACEPTION, V76, P126, DOI 10.1016/j.contraception.2007.04.013
   Hendrix CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055013
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hurt CB, 2011, CLIN INFECT DIS, V53, P1265, DOI 10.1093/cid/cir684
   Kanazawa T, 2008, INT J PHARM, V360, P164, DOI 10.1016/j.ijpharm.2008.04.038
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2012, BEST PRACT RES CL OB, V26, P427, DOI 10.1016/j.bpobgyn.2012.01.010
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Keller MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016475
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Liu Y, 2009, EUR J PHARM SCI, V37, P306, DOI 10.1016/j.ejps.2009.02.022
   Malik R, 2011, J BIOMED NANOTECHNOL, V7, P45, DOI 10.1166/jbn.2011.1194
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Nel AM, 2010, AIDS RES HUM RETROV, V26, P1181, DOI 10.1089/aid.2009.0227
   Nel AM, 2010, JAIDS-J ACQ IMM DEF, V55, P161, DOI 10.1097/QAI.0b013e3181e3293a
   Nuttall J, 2011, ANTIMICROB AGENTS CH, V56, P103
   Nuttall J, 2012, ANTIMICROB AGENTS CH, V56, P103, DOI 10.1128/AAC.00597-11
   Nuttall JP, 2008, ANTIMICROB AGENTS CH, V52, P909, DOI 10.1128/AAC.00330-07
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Romano J, 2013, AIDS RES HUM RETROV, V29, P1418, DOI [10.1089/aid.2013.0122, 10.1089/AID.2013.0122]
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264
   Veazey RS, 2012, CURR HIV RES, V10, P79, DOI 10.2174/157016212799304715
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
NR 49
TC 25
Z9 25
U1 1
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUL
PY 2014
VL 31
IS 7
BP 1834
EP 1845
DI 10.1007/s11095-013-1287-x
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AK2UN
UT WOS:000338275100019
PM 24449442
DA 2018-01-05
ER

PT J
AU Singh, G
   Pai, RS
AF Singh, Gurinder
   Pai, Roopa S.
TI Optimized self-nanoemulsifying drug delivery system of atazanavir with
   enhanced oral bioavailability: in vitro/in vivo characterization
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Article
DE bioavailability; central composite design; in vitro/in vivo correlation;
   pharmacokinetic study; self-nanoemulsifying drug-delivery system
ID DESIGN; FORMULATIONS; ABSORPTION; TRANSPORT; SNEDDS
AB Background: Atazanavir (ATV) is a HIV protease inhibitor. Due to its intense lipophilicity, the oral delivery of ATV encounters several problems such as poor aqueous solubility, pH-dependent dissolution and rapid first-pass metabolism in liver by CYP3A5, which result in low and erratic bioavailability.
   Objective: The current study aimed to develop self-nanoemulsifying drug delivery systems (SNEDDS) using long-chain triglycerides of ATV in an attempt to circumvent such obstacles.
   Methods: Equilibrium solubility studies indicated the choice of Maisine 35-1 as lipid, and of Transcutol P and Span 20 as surfactants, for formulating the SNEDDS. Ternary phase diagrams were constructed to select the areas of nanoemulsions, and the amounts of lipid (X-1) and surfactant (X-2) as the critical factor variables. The SNEDDS were optimized (OPT) using 3 2 central composite design and the OPT formulation located using overlay plot. The pharmacokinetics and in situ single-pass intestinal perfusion studies of OPT formulation were investigated in Wistar rats.
   Results: OPT formulation indicated marked improvement in drug release profile vis-A-vis pure drug. Cloud point determination and accelerated stability studies ascertained the stability of OPT formulation. Augmentation in the values of Ka (1.96-fold) and AUC (2.57-fold) indicated significant enhancement in the rate and extent of bioavailability by the OPT formulation compared to pure drug. Successful establishment of in vitro/in vivo correlation Level A substantiated the judicious choice of the in vitro dissolution milieu for simulating the in vivo conditions.
   Conclusion: The studies, therefore, indicate the successful formulation development of SNEDDS with distinctly improved bioavailability of ATV.
C1 [Singh, Gurinder; Pai, Roopa S.] Al Ameen Coll Pharm, Dept Pharmaceut, Bangalore, Karnataka, India.
RP Pai, RS (reprint author), Al Ameen Coll Pharm, Dept Pharmaceut, Bangalore, Karnataka, India.
EM roopaspai@yahoo.com
OI Singh, Gurinder/0000-0003-1525-3898
FU ICMR ( Indian Council of Medical Research, Govt of India, New Delhi)
   [45/38/2011/Nan-BMS]
FX The authors gratefully acknowledge financial support and granting
   research fellowship (45/38/2011/Nan-BMS) from ICMR ( Indian Council of
   Medical Research, Govt of India, New Delhi). Authors are also grateful
   to M/s Hetero Labs, Hyderabad, India for providing the gift sample of
   ATV.
CR Balakrishnan P, 2009, EUR J PHARM BIOPHARM, V72, P539, DOI 10.1016/j.ejpb.2009.03.001
   Balakumar K, 2013, COLLOID SURFACE B, V112, P337, DOI 10.1016/j.colsurfb.2013.08.025
   Balkundi S, 2011, INT J NANOMED, V6, P3393
   Bandyopadhyay S, 2012, COLLOID SURFACE B, V100, P50, DOI 10.1016/j.colsurfb.2012.05.019
   Basalious EB, 2010, INT J PHARMACEUT, V391, P203, DOI 10.1016/j.ijpharm.2010.03.008
   Benet LZ, 2011, AAPS J, V13, P519, DOI 10.1208/s12248-011-9290-9
   Chen FL, 2000, COLLOID SURFACE A, V175, P257, DOI 10.1016/S0927-7757(00)00505-7                                                   
   Date AA, 2010, NANOMEDICINE-UK, V5, P1595, DOI 10.2217/NNM.10.126
   Elnaggar YSR, 2009, INT J PHARMACEUT, V380, P133, DOI 10.1016/j.ijpharm.2009.07.015
   Elsheikh MA, 2012, INT J NANOMED, V7, P3787, DOI 10.2147/IJN.S33186
   Fukushima K, 2007, BIOL PHARM BULL, V30, P733, DOI 10.1248/bpb.30.733
   Gupta S, 2011, COLLOID SURFACE A, V392, P145, DOI 10.1016/j.colsurfa.2011.09.048
   Jyothi BJ, 2011, J YOUNG PHARM, V3, P4, DOI 10.4103/0975-1483.76413
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Nielsen FS, 2008, EUR J PHARM BIOPHARM, V69, P553, DOI 10.1016/j.ejpb.2007.12.020
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P1
   Simpson KN, 2007, CLIN DRUG INVEST, V27, P807, DOI 10.2165/00044011-200727120-00002                                                
   Singh G, 2014, DRUG DELIV, V2014, DOI [10.3109/10717544.2014.885616, DOI 10.3109/10717544.2014.885616]
   Singh G, 2014, DRUG DELIV, V21, P627, DOI 10.3109/10717544.2013.867382
   Singh G, 2014, EXPERT OPIN DRUG DEL, V11, P647, DOI 10.1517/17425247.2014.890588
   Singh G, 2012, J YOUNG PHARM, V4, P146, DOI 10.4103/0975-1483.100020
   Singh G, 2012, J ADV PHARM TECHNOL, V3, P30, DOI 10.4103/2231-4040.93565
   SWENSON ES, 1994, PHARMACEUT RES, V11, P1132, DOI 10.1023/A:1018984731584
NR 25
TC 11
Z9 12
U1 1
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUL
PY 2014
VL 11
IS 7
BP 1023
EP 1032
DI 10.1517/17425247.2014.913566
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AJ7QZ
UT WOS:000337892800005
PM 24820316
DA 2018-01-05
ER

PT J
AU Diez, LT
   Bonsch, C
   Malkusch, S
   Truan, Z
   Munteanu, M
   Heilemann, M
   Hartley, O
   Endesfelder, U
   Furstenberg, A
AF Diez, Laura Tarancon
   Boensch, Claudia
   Malkusch, Sebastian
   Truan, Zinnia
   Munteanu, Mihaela
   Heilemann, Mike
   Hartley, Oliver
   Endesfelder, Ulrike
   Fuerstenberg, Alexandre
TI Coordinate-based co-localization-mediated analysis of arrestin
   clustering upon stimulation of the C-C chemokine receptor 5 with
   RANTES/CCL5 analogues
SO HISTOCHEMISTRY AND CELL BIOLOGY
LA English
DT Article
DE Clustering; Super-resolution microscopy; Single-molecule localization
   microscopy; G protein-coupled receptors; Arrestin; CCR5
ID PROTEIN-COUPLED RECEPTORS; SINGLE-MOLECULE LOCALIZATION; SUPERRESOLUTION
   MICROSCOPY; HIGHLY POTENT; FUNCTIONAL SELECTIVITY; OPTICAL NANOSCOPY;
   BETA-ARRESTIN; RESOLUTION; HIV; FLUOROPHORES
AB G protein-coupled receptor activation and desensitization leads to recruitment of arrestin proteins from cytosolic pools to the cell membrane where they form clusters difficult to characterize due to their small size and further mediate receptor internalization. We quantitatively investigated clustering of arrestin 3 induced by potent anti-HIV analogues of the chemokine RANTES after stimulation of the C-C chemokine receptor 5 using single-molecule localization-based super-resolution microscopy. We determined arrestin 3 cluster sizes and relative fractions of arrestin 3 molecules in each cluster through image-based analysis of the localization data by adapting a method originally developed for co-localization analysis from molecular coordinates. We found that only classical agonists in the set of tested ligands were able to efficiently recruit arrestin 3 to clusters mostly larger than 150 nm in size and compare our results with existing data on arrestin 2 clustering induced by the same chemokine analogues.
C1 [Diez, Laura Tarancon; Truan, Zinnia; Fuerstenberg, Alexandre] Univ Geneva, Dept Human Prot Sci, CMU, CH-1211 Geneva 4, Switzerland.
   [Boensch, Claudia; Munteanu, Mihaela; Hartley, Oliver] Univ Geneva, Dept Pathol & Immunol, CMU, CH-1211 Geneva 4, Switzerland.
   [Malkusch, Sebastian; Heilemann, Mike; Endesfelder, Ulrike] Goethe Univ Frankfurt, Inst Phys & Theoret Chem, D-60438 Frankfurt, Germany.
RP Furstenberg, A (reprint author), Univ Geneva, Dept Human Prot Sci, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.
EM alexandre.fuerstenberg@unige.ch
RI TARANCON DIEZ, LAURA/E-9702-2015; Furstenberg, Alexandre/A-4245-2010;
   Fachbereich14, Dekanat/C-8553-2015
OI Furstenberg, Alexandre/0000-0002-6227-3122; Endesfelder,
   Ulrike/0000-0002-7801-6278; Heilemann, Mike/0000-0002-9821-3578
FU Swiss National Science Foundation through Ambizione fellowship
   [PZ00P3_131935, 310030_143789]; Fondation Dormeur; Bundesministerium fur
   Bildung und Forschung [0315262]; German Science Foundation [EXC 115]
FX We thank Jeffrey Benovic (Thomas Jefferson University) for the arrestin
   3-GFP plasmid. This work was supported by the Swiss National Science
   Foundation through Ambizione fellowship PZ00P3_131935 (A. F.) and
   project number 310030_143789 (O.H.), as well as by Fondation Dormeur
   (O.H. and A. F.). M. H. acknowledges funding by the Bundesministerium
   fur Bildung und Forschung (Grant Number 0315262) and the German Science
   Foundation (EXC 115).
CR Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606
   Banterle N, 2013, J STRUCT BIOL, V183, P363, DOI 10.1016/j.jsb.2013.05.004
   Bertrand L, 2002, J RECEPT SIGNAL TR R, V22, P533, DOI 10.1081/RRS-120014619
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Bockenhauer S, 2011, J PHYS CHEM B, V115, P13328, DOI 10.1021/jp204843r
   Cordes T, 2010, NANO LETT, V10, P645, DOI 10.1021/nl903730r
   Endesfelder U, 2013, BIOPHYS J, V105, P172, DOI 10.1016/j.bpj.2013.05.048
   Escola JM, 2010, J BIOL CHEM, V285, P41772, DOI 10.1074/jbc.M110.153460
   Furstenberg A, 2013, PHYS CHEM CHEM PHYS, V15, P14919, DOI 10.1039/c3cp52289j
   Gaertner H, 2008, PROTEIN ENG DES SEL, V21, P65, DOI 10.1093/protein/gzm079
   Gaertner H, 2008, P NATL ACAD SCI USA, V105, P17706, DOI 10.1073/pnas.0805098105
   Gesty-Palmer D, 2011, ADV PHARMACOL, V62, P79, DOI 10.1016/B978-0-12-385952-5.00009-9
   Hartley O, 2004, P NATL ACAD SCI USA, V101, P16460, DOI 10.1073/pnas.0404802101
   Heilemann M, 2009, ANGEW CHEM INT EDIT, V48, P6903, DOI 10.1002/anie.200902073
   Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395
   Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kenakin T, 2013, NAT REV DRUG DISCOV, V12, P205, DOI 10.1038/nrd3954
   Kenakin T, 2012, ACS CHEM NEUROSCI, V3, P193, DOI 10.1021/cn200111m
   Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003
   Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198
   Kuhmann SE, 2008, ANNU REV PHARMACOL, V48, P425, DOI 10.1146/annurev.pharmtox.48.113006.094847
   Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200                                                          
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Lee SF, 2013, ANGEW CHEM INT EDIT, V52, P8948, DOI 10.1002/anie.201302341
   Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237
   Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655
   Malkusch S, 2013, HISTOCHEM CELL BIOL, V139, P173, DOI 10.1007/s00418-012-1014-4
   Malkusch S, 2012, HISTOCHEM CELL BIOL, V137, P1, DOI 10.1007/s00418-011-0880-5
   Moerner WE, 2012, J MICROSC-OXFORD, V246, P213, DOI 10.1111/j.1365-2818.2012.03600.x
   Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712
   Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828
   Nieuwenhuizen RPJ, 2013, NAT METHODS, V10, P557, DOI [10.1038/NMETH.2448, 10.1038/nmeth.2448]
   Owen DM, 2013, BIOPHYS J, V105, pL05, DOI 10.1016/j.bpj.2013.05.063
   Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577
   Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478
   Ries J, 2012, NAT METHODS, V9, P582, DOI [10.1038/NMETH.1991, 10.1038/nmeth.1991]
   RIPLEY BD, 1977, J ROY STAT SOC B MET, V39, P172
   Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132
   Sengupta P, 2011, NAT METHODS, V8, P969, DOI [10.1038/NMETH.1704, 10.1038/nmeth.1704]
   Smith CS, 2010, NAT METHODS, V7, P373, DOI [10.1038/NMETH.1449, 10.1038/nmeth.1449]
   Specht CG, 2013, NEURON, V79, P308, DOI 10.1016/j.neuron.2013.05.013
   Truan Z, 2013, J STRUCT BIOL, V184, P329, DOI 10.1016/j.jsb.2013.09.019
   Wolter S, 2010, J MICROSC-OXFORD, V237, P12, DOI 10.1111/j.1365-2818.2009.03287.x
   Zidar David A., 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P120
NR 47
TC 11
Z9 11
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0948-6143
EI 1432-119X
J9 HISTOCHEM CELL BIOL
JI Histochem. Cell Biol.
PD JUL
PY 2014
VL 142
IS 1
BP 69
EP 77
DI 10.1007/s00418-014-1206-1
PG 9
WC Cell Biology; Microscopy
SC Cell Biology; Microscopy
GA AK5WY
UT WOS:000338498700007
PM 24623038
DA 2018-01-05
ER

PT J
AU Ravi, PR
   Vats, R
   Dalal, V
   Murthy, AN
AF Ravi, Punna Rao
   Vats, Rahul
   Dalal, Vikas
   Murthy, Aditya Narasimha
TI A hybrid design to optimize preparation of lopinavir loaded solid lipid
   nanoparticles and comparative pharmacokinetic evaluation with marketed
   lopinavir/ritonavir coformulation
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE design of experiments; lopinavir; solid lipid nanoparticles; stearic
   acid; wistar rats
ID ANTIRETROVIRAL THERAPY; RESERVOIRS; DELIVERY; HIV-1; LIPOSOMES;
   RITONAVIR; EMULSION; RELEASE; PLASMA; RATS
AB Objectives To prepare stearic acid-based lopinavir (LPV) loaded solid lipid nanoparticles (SLNs) using a hybrid design and compare in-vivo performance of optimized formulation with marketed LPV/ritonavir (RTV) coformulation. Methods LPV SLNs were prepared by hot melt emulsion technique and optimized using Plackett-Burman design and Box-Behnken design. Physical characterization studies were conducted for the optimized SLNs. Comparative oral pharmacokinetic studies and tissue distribution studies of optimized SLNs and LPV/RTV coformulation were done in Wistar rats. In-vitro metabolic stability and intestinal permeability studies for LPV SLNs were undertaken to elucidate the mechanism involved in the pharmacokinetic improvement of LPV. Key findings Optimized SLNs exhibited nanometeric size (223nm) with high entrapment efficiency (83%). In-vitro drug release study of SLNs showed biphasic sustained release behaviour. Significant increase in oral bioavailability of LPV from LPV SLNs (5 folds) and LPV/RTV coformulation (3.7 folds) was observed as compared with free LPV. LPV SLNs showed better tissue distribution of LPV in HIV reservoirs than LPV/RTV coformulation. In-vitro studies demonstrated that SLNs provided metabolic protection of LPV and were endocytosized during absorption. Conclusions SLNs enhanced oral bioavailability and improved distribution profile of LPV to HIV reservoirs and hence could be better alternative to LPV/RTV coformulation.
C1 [Ravi, Punna Rao; Vats, Rahul; Dalal, Vikas; Murthy, Aditya Narasimha] BITS Pilani Hyderabad Campus, Dept Pharm, Hyderabad 500078, Andhra Pradesh, India.
RP Ravi, PR (reprint author), BITS Pilani Hyderabad Campus, Dept Pharm, Hyderabad 500078, Andhra Pradesh, India.
EM rpunnarao@gmail.com
FU Department of Science and Technology (DST), Science and Engineering
   Research Council (SERC), New Delhi, India
FX The authors are grateful to Department of Science and Technology (DST),
   Science and Engineering Research Council (SERC), New Delhi, India for
   funding the research under 'Fast Track Scheme for Young Scientists'.
CR Aji AMR, 2011, EUR J PHARM SCI, V42, P11, DOI DOI 10.1016/J.EJPS.2010.10.002
   Cai S, 2011, ADV DRUG DELIVER REV, V63, P901, DOI 10.1016/j.addr.2011.05.017
   Castelli F, 2005, INT J PHARM, V304, P231, DOI 10.1016/j.ijpharm.2005.08.011
   D'Souza Susan S, 2005, AAPS PharmSciTech, V6, pE323, DOI 10.1208/pt060242
   du Plooy M, 2011, BIOL PHARM BULL, V34, P66
   Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145
   Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287
   Hao Jifu, 2011, Int J Nanomedicine, V6, P683, DOI 10.2147/IJN.S17386
   Kadajji VG, 2011, AM PHARM REV
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Leroux J., 1994, EUR J PHARM BIOPHARM, V41, P14
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Piacenti FJ, 2006, PHARMACOTHERAPY, V26, P1111, DOI 10.1592/phco.26.8.1111
   Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665                                                
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Ravi PR, 2013, J PHARM PHARMACOL, V65, P337, DOI 10.1111/j.2042-7158.2012.01604.x
   Roger E, 2009, J CONTROL RELEASE, V140, P174, DOI 10.1016/j.jconrel.2009.08.010
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shafran SD, 2005, HIV MED, V6, P421, DOI 10.1111/j.1468-1293.2005.00328.x                                                
   Shah M, 2010, AAPS PHARMSCITECH, V11, P489, DOI 10.1208/s12249-010-9414-z
   Sharma A., 2010, RES J PHARM BIO CHEM, V1, P78
   Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541
   Vats Rahul, 2011, Sci Pharm, V79, P849, DOI 10.3797/scipharm.1107-24
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xu XM, 2011, INT J PHARMACEUT, V419, P52, DOI 10.1016/j.ijpharm.2011.07.012
   Yang YY, 2000, CHEM ENG SCI, V55, P2223, DOI 10.1016/S0009-2509(99)00503-5                                                   
   Yue PF, 2009, AAPS PHARMSCITECH, V10, P376, DOI 10.1208/s12249-009-9216-3
   Zhang QN, 2000, INT J PHARM, V200, P153, DOI 10.1016/S0378-5173(00)00361-6                                                   
   [Anonymous], 2003, Q1AR2 ICH
NR 30
TC 11
Z9 11
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JUL
PY 2014
VL 66
IS 7
BP 912
EP 926
DI 10.1111/jphp.12217
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AJ3WI
UT WOS:000337598200003
PM 24697749
DA 2018-01-05
ER

PT J
AU Kalombo, L
   Tshweu, L
   Hayeshi, R
   Katata, L
   Sosnik, A
   Swai, H
AF Kalombo, L.
   Tshweu, L.
   Hayeshi, R.
   Katata, L.
   Sosnik, A.
   Swai, H.
TI NANOMEDICINE FOR IMPROVED PHARMACOKINETICS OF TB AND HIV DRUGS
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-7835
EI 1742-7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD JUL
PY 2014
VL 115
SU 1
SI SI
MA 1040
BP 322
EP 323
PG 2
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA CK5XJ
UT WOS:000356300903230
DA 2018-01-05
ER

PT J
AU Sosnik, A
   Carcaboso, AM
AF Sosnik, Alejandro
   Carcaboso, Angel M.
TI Nanomedicines in the future of pediatric therapy
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Pediatric nanomedicine; HIV/AIDS; Tuberculosis; Malaria; Cancer
ID FIXED-DOSE COMBINATION; INTRATHECAL LIPOSOMAL CYTARABINE; UNCOMPLICATED
   FALCIPARUM-MALARIA; MICELLAR-ENCAPSULATED DRUG; POLYMERIC MICELLES;
   CANCER-THERAPY; NEUROBLASTOMA-CELLS; LUNG METASTASES; HIV-INFECTION;
   IN-VITRO
AB Nanotechnology has become a key tool to overcome the main (bio)pharmaceutical drawbacks of drugs and to enable their passive or active targeting to specific cells and tissues. Pediatric therapies usually rely on the previous clinical experience in adults. However, there exists scientific evidence that drug pharmacokinetics and pharmacodynamics in children differ from those in adults. For example, the interaction of specific drugs with their target receptors undergoes changes over the maturation of the different organs and systems. A similar phenomenon is observed for toxicity and adverse effects. Thus, it is clear that the treatment of disease in children cannot be simplified to the direct adjustment of the dose to the body weight/surface. In this context, the implementation of innovative technologies (e.g., nanotechnology) in the pediatric population becomes extremely challenging. The present article overviews the different attempts to use nanotechnology to treat diseases in the pediatric population. Due to the relevance, though limited available literature on the matter, we initially describe from preliminary in vitro studies to preclinical and clinical trials aiming to treat pediatric infectious diseases and pediatric solid tumors by means of nanotechnology. Then, the perspectives of pediatric nanomedicine are discussed. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, IL-32000 Haifa, Israel.
   [Carcaboso, Angel M.] Hosp St Joan Deu Barcelona, Dept Oncol, Preclin Therapeut & Drug Delivery Res Program, Barcelona 08950, Spain.
RP Sosnik, A (reprint author), Technion Israel Inst Technol, Dept Mat Sci & Engn, Grp Pharmaceut Nanomat Sci, IL-32000 Haifa, Israel.
EM alesosnik@gmail.com
RI Sosnik, Alejandro/O-7059-2014
OI Sosnik, Alejandro/0000-0003-4704-4599; Carcaboso,
   Angel/0000-0002-8485-426X
FU Marie Curie Reintegration Grant "NANOTAR" (European Commission)
   [PCIG13-GA-2013-612765]; AECC Scientific Foundation; Marie Curie
   Reintegration Grant "NEUROBLASTOMA CHEMO" (European Commission)
   [PIRG-08-GA-2010-276998]; MINECO [SAF2011-22660]; ISCiii (Miguel Servet
   program) [CP13/00189]
FX AS thanks the support of the Marie Curie Reintegration Grant "NANOTAR"
   (PCIG13-GA-2013-612765, European Commission). AMC acknowledges support
   from the AECC Scientific Foundation, Marie Curie Reintegration Grant
   "NEUROBLASTOMA CHEMO" (PIRG-08-GA-2010-276998, European Commission),
   MINECO (Grant SAF2011-22660) and ISCiii (Miguel Servet program, contract
   CP13/00189).
CR Abdulla S, 2008, LANCET, V372, P1819, DOI 10.1016/S0140-6736(08)61492-0
   Abramson DH, 2004, RETINA-J RET VIT DIS, V24, P828, DOI 10.1097/00006982-200412000-00002
   Alhaddad A, 2011, SMALL, V7, P3087, DOI 10.1002/smll.201101193
   Alvarez-Lorenzo C, 2011, CURR DRUG TARGETS, V12, P1112, DOI 10.2174/138945011795906615                                                      
   [Anonymous], NUEV FORM PED EF
   Amankwah Ernest K, 2013, Clin Epidemiol, V5, P147, DOI 10.2147/CLEP.S28390
   Anada T, 2009, BIOORG MED CHEM LETT, V19, P4148, DOI 10.1016/j.bmcl.2009.05.117
   Andrade F, 2013, ADV DRUG DELIVER REV, V65, P1816, DOI 10.1016/j.addr.2013.07.020
   Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507                                                     
   Baker DL, 2010, NEW ENGL J MED, V363, P1313, DOI 10.1056/NEJMoa1001527
   Bardi G, 2010, BIOMATERIALS, V31, P6555, DOI 10.1016/j.biomaterials.2010.04.063
   Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   BENEDETTI MS, 2005, EXPERT OPIN DRUG MET, V1, P447
   Bethune CR, 2001, CANCER RES, V61, P3669
   Boiardi A, 1999, CANCER CHEMOTH PHARM, V43, P178, DOI 10.1007/s002800050881
   Bomgaars L, 2004, J CLIN ONCOL, V22, P3916, DOI 10.1200/JCO.2004.01.046
   Boots I, 2007, EUR J PEDIATR, V166, P849, DOI 10.1007/s00431-006-0381-z
   Booysen LLIJ, 2013, INT J PHARMACEUT, V444, P10, DOI 10.1016/j.ijpharm.2013.01.038
   Bouyou-Akotet MK, 2010, WIEN KLIN WOCHENSCHR, V122, P173, DOI 10.1007/s00508-010-1317-1
   Bowles A, 2010, INT J PHARMACEUT, V395, P37, DOI 10.1016/j.ijpharm.2010.04.048
   Breitkreutz J, 2007, EXPERT OPIN DRUG DEL, V4, P37, DOI 10.1517/17425247.4.1.37
   Brewster ME, 2007, ADV DRUG DELIVER REV, V59, P645, DOI 10.1016/j.addr.2007.05.012
   Bridge JA, 2007, JAMA-J AM MED ASSOC, V297, P1683, DOI 10.1001/jama.297.15.1683
   Brignole C, 2004, J NATL CANCER I, V96, P1171, DOI 10.1093/jnci/djh221
   Bromberg L, 2008, J CONTROL RELEASE, V128, P99, DOI 10.1016/j.jconrel.2008.01.018
   Buchanan CM, 2008, BIOMACROMOLECULES, V9, P305, DOI 10.1021/bm700827h
   Calzolari A, 2007, BLOOD CELL MOL DIS, V39, P82, DOI 10.1016/j.bcmd.2007.02.003
   Carcaboso AM, 2010, INVEST OPHTH VIS SCI, V51, P2126, DOI 10.1167/iovs.09-4050
   Davies Cde L, 2004, CANCER RES, V64, P547
   Center for Pediatric Medicine, 2009, [No title captured], Patent No. [AR 072715,, 072715]
   Chan HK, 2011, ADV DRUG DELIVER REV, V63, P406, DOI 10.1016/j.addr.2011.03.011
   Chang R., 2000, PHARM TECH, V12, P52
   Chappuy H, 2006, ARCH DIS CHILD, V91, P112, DOI 10.1136/adc.2005.076141
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, CURR HIV RES, V8, P223, DOI 10.2174/157016210791111142
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chintagumpala M, 2007, ONCOLOGIST, V12, P1237, DOI 10.1634/theoncologist.12-10-1237
   Chokephaibulkit K, 2011, ANTIVIR THER, V16, P1287, DOI 10.3851/IMP1931
   Chowdhury N, 2010, NANOMEDICINE-UK, V5, P135, DOI 10.2217/NNM.09.91
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159                                                                   
   Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103
   Cram A, 2009, INT J PHARM, V365, P1, DOI 10.1016/j.ijpharm.2008.09.015
   van Dalen E.C., 2006, COCHRANE DB SYST REV
   Das M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032920
   Dass CR, 2008, CANCER BIOL THER, V7, P1033, DOI 10.4161/cbt.7.7.6037
   Dass CR, 2007, BIOMATERIALS, V28, P3026, DOI 10.1016/j.biomaterials.2007.03.016
   Deol G.K., 1997, BIOCHIM BIOPHYS ACTA, V1334, P161
   Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
   Dhule SS, 2012, NANOMED-NANOTECHNOL, V8, P440, DOI 10.1016/j.nano.2011.07.011
   Di Paolo D, 2011, MOL THER, V19, P1131, DOI 10.1038/mt.2011.54
   Dickinson PJ, 2010, NEURO-ONCOLOGY, V12, P928, DOI 10.1093/neuonc/noq046
   Drago-Ferrante R, 2008, INT J ONCOL, V33, P677, DOI 10.3892/ijo_00000053
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Dutour A, 2005, MOL THER, V11, P311, DOI 10.1016/j.ymthe.2004.10.008
   Edelhauser HF, 2008, INVEST OPHTH VIS SCI, V49, P4712, DOI 10.1167/iovs.08-1904
   Eikenes L, 2005, BRIT J CANCER, V93, P81, DOI 10.1038/sj.bjc.6602626
   Elder N C, 1992, Arch Fam Med, V1, P91, DOI 10.1001/archfami.1.1.91
   [Anonymous], 2005, EMEACHMPPEG194810200
   Anon na-b, EMACHMPQWP1801572011
   Emami J, 2009, J MICROENCAPSUL, V26, P1, DOI 10.1080/02652040802083900
   Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013
   Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2003, FED REG
   Fabel K, 2001, CANCER, V92, P1936, DOI 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO;2-H                   
   Fabiano V, 2011, PHARMACOL RES, V63, P362, DOI 10.1016/j.phrs.2011.01.006
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   Federman N, 2010, PEDIATR RES, V67, P514, DOI 10.1203/PDR.0b013e3181d601c5
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Gajjar A, 2013, CLIN CANCER RES, V19, P6305, DOI 10.1158/1078-0432.CCR-13-1425
   Gans-Brangs KR, 2006, ADV DRUG DELIVER REV, V58, P106, DOI 10.1016/j.addr.2005.12.005
   Gao ZG, 2005, J CONTROL RELEASE, V102, P203, DOI 10.1016/j.jconrel.2004.09.021
   Gary-Bobo M, 2012, INT J PHARMACEUT, V432, P99, DOI 10.1016/j.ijpharm.2012.04.056
   Gaucher G, 2010, EUR J PHARM BIOPHARM, V76, P147, DOI 10.1016/j.ejpb.2010.06.007
   Giacoia GP, 2008, CLIN THER, V30, P2097, DOI 10.1016/j.clinthera.2008.11.017
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Glisoni RJ, 2012, EUR J PHARM SCI, V47, P596, DOI 10.1016/j.ejps.2012.07.018
   Glisoni RJ, 2012, PHARM RES-DORDR, V29, P739, DOI 10.1007/s11095-011-0599-y
   Gorlick R, 1999, J CLIN ONCOL, V17, P2781, DOI 10.1200/JCO.1999.17.9.2781                                                      
   Grovit-Ferbas K, 2010, IMMUNOL RES, V48, P40, DOI 10.1007/s12026-010-8166-x
   Gupta B, 2007, CANCER IMMUNOL IMMUN, V56, P1215, DOI 10.1007/s00262-006-0273-0
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Hazra R, 2010, ANNU REV MED, V61, P169, DOI 10.1146/annurev.med.050108.151127
   Hirani JJ, 2009, TROP J PHARM RES, V8, P161
   Hong Y, 2006, ANTIMICROB AGENTS CH, V50, P935, DOI 10.1128/AAC.50.3.935-842.2006
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165
   Husseini GA, 2002, J CONTROL RELEASE, V83, P303, DOI 10.1016/S0168-3659(02)00203-1
   Husseini GA, 2000, CANCER LETT, V154, P211, DOI 10.1016/S0304-3835(00)00399-2
   Iwamoto Y, 2007, JPN J CLIN ONCOL, V37, P79, DOI 10.1093/jjco/hyl142
   Jacqz-Aigrain E, 2011, EARLY HUM DEV, V87, pS27, DOI 10.1016/j.earlhumdev.2011.01.007
   Jain R, 2010, NANOMEDICINE-UK, V5, P575, DOI [10.2217/nnm.10.28, 10.2217/NNM.10.28]
   Jain S, 2013, J BIOMED NANOTECHNOL, V9, P1862, DOI 10.1166/jbn.2013.1683
   James LP, 1998, J CLIN PHARMACOL, V38, P1089
   Jiao PF, 2011, J AM CHEM SOC, V133, P13918, DOI 10.1021/ja206118a
   Juma EA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-262
   Kager L, 2010, THER CLIN RISK MANAG, V6, P279
   Kang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1043, DOI 10.1001/archophthalmol.2009.185
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221
   Kayitare E, 2009, INT J PHARMACEUT, V370, P41, DOI 10.1016/j.ijpharm.2008.11.005
   Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092                                                            
   Killion JJ, 1998, PHARMACOL THERAPEUT, V78, P141, DOI 10.1016/S0163-7258(98)00004-7
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Klassen TP, 2008, PLOS MED, V5, P1180, DOI 10.1371/journal.pmed.0050172
   Knight V, 2000, ANN NY ACAD SCI, V922, P151
   Koshkina NV, 2000, CLIN CANCER RES, V6, P2876
   Kubo T, 2001, INT J ONCOL, V18, P121
   Kurth F, 2010, LANCET INFECT DIS, V10, P125, DOI 10.1016/S1473-3099(09)70327-5
   Kwon GS, 2003, CRIT REV THER DRUG, V20, P357, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20                                    
   Lam CW, 2006, CRIT REV TOXICOL, V36, P189, DOI 10.1080/10408440600570233
   Lee JH, 2006, ANGEW CHEM INT EDIT, V45, P8160, DOI 10.1002/anie.200603052
   Lee P, 2012, INT J NANOMED, V7, P731, DOI 10.2147/IJN.S28783
   Lee Puiyan, 2010, Nanotechnol Sci Appl, V3, P23
   Lim KJ, 2011, CANCER BIOL THER, V11, P464, DOI 10.4161/cbt.11.5.14410
   Lima FRS, 2012, BBA-REV CANCER, V1826, P338, DOI 10.1016/j.bbcan.2012.05.004
   Lohmann D, 2010, ADV EXP MED BIOL, V685, P220
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Loukas YL, 1998, INT J PHARM, V162, P137, DOI 10.1016/S0378-5173(97)00421-3
   Lubrich B, 2000, EUR J BIOCHEM, V267, P2432, DOI 10.1046/j.1432-1327.2000.01255.x
   Lum CT, 2006, INT J CANCER, V118, P1527, DOI 10.1002/ijc.21484
   Lupu M, 2009, PHOTODIAGN PHOTODYN, V6, P214, DOI 10.1016/j.pdpdt.2009.10.009
   Madhankumar AB, 2009, MOL CANCER THER, V8, P648, DOI 10.1158/1535-7163.MCT-08-0853
   Makky A, 2011, BBA-BIOMEMBRANES, V1808, P656, DOI 10.1016/j.bbamem.2010.11.028
   Makky A, 2010, LANGMUIR, V26, P11145, DOI 10.1021/la101040q
   Makky A, 2012, BBA-BIOMEMBRANES, V1818, P2831, DOI 10.1016/j.bbamem.2012.07.003
   Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118
   Marina NM, 2002, CLIN CANCER RES, V8, P413
   Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0                                                   
   Marotta DE, 2011, NANOMEDICINE-UK, V6, P475, DOI [10.2217/nnm.11.8, 10.2217/NNM.11.8]
   Marshall JD, 1999, CLIN PHARMACOL THER, V66, P66, DOI 10.1016/S0009-9236(99)70055-X
   Matsuoka F., 2004, BIOMAGN RES TECHNOL, V2, P3
   McCabe ERB, 2010, PEDIATR RES, V67, P453, DOI 10.1203/PDR.0b013e3181d61ed2
   Melancon MP, 2012, J CONTROL RELEASE, V164, P177, DOI 10.1016/j.jconrel.2012.07.045
   Meng W, 2007, EXP BIOL MED, V232, P1100, DOI 10.3181/0612-RM-301
   Meng W, 2006, J CONTROL RELEASE, V116, P314, DOI 10.1016/j.jconrel.2006.09.014
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Miele E, 2012, INT J NANOMED, V7, P3637, DOI 10.2147/IJN.S23696
   Milne CP, 2008, CLIN THER, V30, P2133, DOI 10.1016/j.clinthera.2008.11.019
   Mizoe T, 2008, AAPS PHARMSCITECH, V9, P755, DOI 10.1208/s12249-008-9109-x
   Modak S, 2007, CANCER INVEST, V25, P67, DOI 10.1080/07357900601130763
   Moore P, 1998, LANCET, V352, P630, DOI 10.1016/S0140-6736(05)79591-X                                                   
   Mora J, 2012, CLIN ONCOL ADOLESC Y, V2, P7, DOI 10.2147/COAYA.S29791
   Moretton M. A., 2013, THESIS U BUENOS AIRE
   Moretton M.A., 2014, NANOMEDICINE, P1
   Moretton M.A., 2009, 1 WORKSH ART ORG BIO
   Moretton MA, 2013, J BIOMED NANOTECHNOL, V9, P1076, DOI 10.1166/jbn.2013.1600
   Moretton MA, 2012, J R SOC INTERFACE, V9, P487, DOI 10.1098/rsif.2011.0414
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   Morita K., 2008, ONCOL REP, V20, P365
   Muller RH, 2011, EUR J PHARM BIOPHARM, V78, P1, DOI 10.1016/j.ejpb.2011.01.007
   Munshi N, 1997, CANCER LETT, V118, P13, DOI 10.1016/S0304-3835(97)00218-8
   Muttil P, 2007, EUR J PHARM SCI, V32, P140, DOI 10.1016/j.ejps.2007.06.006
   Nahata MC, 2008, CLIN THER, V30, P2112, DOI 10.1016/j.clinthera.2008.11.020
   Nakase M, 2005, MOL CANCER THER, V4, P625, DOI 10.1158/1535-7163.MCT-04-0196                                                   
   Nobuto H, 2004, INT J CANCER, V109, P627, DOI 10.1002/ijc.20035
   Northcott PA, 2011, ACTA NEUROPATHOL, V122, P231, DOI 10.1007/s00401-011-0846-7
   Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324
   Novack GD, 2013, J OCUL PHARMACOL TH, V29, P90, DOI 10.1089/jop.2013.1503
   Ohashi K, 2009, J CONTROL RELEASE, V135, P19, DOI 10.1016/j.jconrel.2008.11.027
   Okusanya OO, 2009, ANTIMICROB AGENTS CH, V53, P3847, DOI 10.1128/AAC.00872-08
   Onyebujoh P, 2005, B WORLD HEALTH ORGAN, V83, P857
   Orentas RJ, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00003
   Osuntokun B, 2006, ADV DRUG DELIVER REV, V58, P90, DOI 10.1016/j.addr.2005.12.004
   Padmavathi Y., 2011, INT J PHARM TECHNOL, V3, P2343
   Pagnan G, 2000, J NATL CANCER I, V92, P253, DOI 10.1093/jnci/92.3.253
   Pandey R, 2005, TUBERCULOSIS, V85, P415, DOI 10.1016/j.tube.2005.08.009
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001
   Parareda A, 2014, ACTA OPHTHALMOL, V92, P209, DOI 10.1111/aos.12295
   Pastorino F, 2006, CANCER RES, V66, P10073, DOI 10.1158/0008-5472.CAN-06-2117
   Pastorino F, 2010, CLIN CANCER RES, V16, P4809, DOI 10.1158/1078-0432.CCR-10-1354
   Pensi T, 2007, INDIAN PEDIATR, V44, P519
   Pepic I, 2012, CHEM BIOCHEM ENG Q, V26, P365
   Piccaluga PP, 2002, LEUKEMIA, V16, P1880, DOI 10.1038/sj.leu.2402617
   Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004
   Pui CH, 2011, NAT REV CLIN ONCOL, V8, P540, DOI 10.1038/nrclinonc.2011.95
   Qian LP, 2011, J NANOPART RES, V13, P499, DOI 10.1007/s11051-010-0080-6
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Ramharter M, 2008, J INFECT DIS, V198, P911, DOI 10.1086/591096
   Rapoport N, 2004, INT J PHARMACEUT, V277, P155, DOI 10.1016/j.ijpharm.2003.09.048
   Rapoport NY, 1999, J CONTROL RELEASE, V58, P153, DOI 10.1016/S0168-3659(98)00149-7
   Ribeiro A, 2012, J R SOC INTERFACE, V9, P2059, DOI 10.1098/rsif.2012.0102
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Rodriguez FJ, 2013, ANNU REV PATHOL-MECH, V8, P361, DOI 10.1146/annurev-pathol-020712-164009
   Rodriguez-Galindo C, 2008, PEDIATRICS, V122, pE763, DOI 10.1542/peds.2008-0518
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Ryman-Rasmussen JP, 2009, NAT NANOTECHNOL, V4, P747, DOI [10.1038/nnano.2009.305, 10.1038/NNANO.2009.305]
   Salah M. T., 2006, Tropical Journal of Pharmaceutical Research, V5, P551
   Sankar R, 2003, DRUG DEV IND PHARM, V29, P733, DOI 10.1081/DDC-120021772
   Santos-Magalhaes NS, 2010, ADV DRUG DELIVER REV, V62, P560, DOI 10.1016/j.addr.2009.11.024
   Sathigari S, 2009, AAPS PHARMSCITECH, V10, P81, DOI 10.1208/s12249-008-9180-3
   Schaiquevich P, 2013, PEDIATR BLOOD CANCER, V60, P766, DOI 10.1002/pbc.24356
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Seif AE, 2010, J PEDIAT HEMATOL ONC, V32, pE349, DOI 10.1097/MPH.0b013e3181ec0c25
   Sellers RS, 2005, DRUG CHEM TOXICOL, V28, P423, DOI 10.1080/01480540500262839
   Semmler-Behnke M, 2012, P NATL ACAD SCI USA, V109, P5092, DOI 10.1073/pnas.1119339109
   Shabir A., 2010, BRIT J CLIN PHARMACO, V2, P275
   Shah PP, 2008, AAPS PHARMSCITECH, V9, P1025, DOI 10.1208/s12249-008-9137-6
   Shah PP, 2010, PHARM DEV TECHNOL, V15, P276, DOI 10.3109/10837450903188485
   Shan LQ, 2008, CANCER BIOL THER, V7, P1717, DOI 10.4161/cbt.7.11.6727
   Sharma A, 2004, J ANTIMICROB CHEMOTH, V54, P761, DOI 10.1093/jac/dkh411
   Sharma R, 2001, PHARMACEUT RES, V18, P1405, DOI 10.1023/A:1012296604685                                                         
   Shimose S, 2001, INT J ONCOL, V19, P585
   Shishoo CJ, 1999, INT J PHARM, V190, P109, DOI 10.1016/S0378-5173(99)00286-0
   Shishoo CJ, 2001, INT J PHARM, V228, P53, DOI 10.1016/S0378-5173(01)00831-6
   Siddiqui N., 2010, INT J PHARM SCI REV, V4, P87
   Singh S, 2001, INT J PHARMACEUT, V228, P5, DOI 10.1016/S0378-5173(01)00754-2
   Singh Saranjit, 2000, Pharmacy and Pharmacology Communications, V6, P405
   Sly PD, 2012, PAEDIATR RESPIR REV, V13, P71, DOI 10.1016/j.prrv.2011.07.005
   Smoll NR, 2012, CANCER-AM CANCER SOC, V118, P1313, DOI 10.1002/cncr.26387
   Sosnik A., 2010, RECENT PAT BIOMED EN, V1, P43, DOI DOI 10.2174/1874764710801010043
   Sosnik A, 2013, RSC SMART MATER, P115, DOI 10.1039/9781849736800-00115
   Sosnik A, 2012, EXPERT OPIN DRUG DEL, V9, P303, DOI 10.1517/17425247.2012.655268
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Standing JF, 2005, INT J PHARM, V300, P56, DOI 10.1016/j.ijpharm.2005.05.006
   Steichen S.D., 2012, EUR J PHARM SCI, V48, P416, DOI DOI 10.1016/J.EJPS.2012.12.006
   Stella VJ, 2008, TOXICOL PATHOL, V36, P30, DOI 10.1177/0192623307310945
   Stephan H, 2008, INVEST OPHTH VIS SCI, V49, P3158, DOI 10.1167/iovs.07-1016
   Stevenson-Abouelnasr D, 2007, COLLOID SURFACE B, V55, P59, DOI 10.1016/j.colsurfb.2006.11.006
   Stoltenberg I., 2011, EUR IND PHARM, V8, P4
   Stoyanova-Beninska VV, 2011, EUR NEUROPSYCHOPHARM, V21, P565, DOI 10.1016/j.euroneuro.2010.06.011
   Sun C, 2008, NANOMEDICINE-UK, V3, P495, DOI 10.2217/17435889.3.4.495
   Sun K, 2011, INT J BIOL MACROMOL, V49, P173, DOI 10.1016/j.ijbiomac.2011.04.007
   Svenson S, 2013, MOL PHARMACEUT, V10, P848, DOI 10.1021/mp300644n
   Swai H, 2008, J CONTROL RELEASE, V132, pE48, DOI 10.1016/j.jconrel.2008.09.032
   Swaminathan S, 2010, CLIN INFECT DIS, V50, pS184, DOI 10.1086/651490
   Ta HT, 2009, BIOMATERIALS, V30, P3605, DOI 10.1016/j.biomaterials.2009.03.022
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x
   Takahashi H, 2000, CLIN PHARMACOL THER, V68, P541, DOI 10.1067/mcp.2000.110977
   Tan ML, 2010, BIOMATERIALS, V31, P541, DOI 10.1016/j.biomaterials.2009.09.069
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tivnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038129
   To YF, 2009, INT J CANCER, V124, P1971, DOI 10.1002/ijc.24130
   Toub N, 2006, PHARM RES, V23, P892, DOI 10.1007/s11095-006-9901-9
   Tran PA, 2010, INT J NANOMED, V5, P351
   Tran PA, 2010, J BIOMED MATER RES A, V93A, P1417, DOI 10.1002/jbm.a.32631
   Tsifansky MD, 2008, AAPS J, V10, P254, DOI 10.1208/s12248-008-9033-8
   Ueno Y, 2011, CANCER BIOL THER, V12, P270, DOI 10.4161/cbt.12.4.16259
   Vail DM, 2002, CANCER CHEMOTH PHARM, V50, P131, DOI 10.1007/s00280-002-0469-8
   Van Gyseghem E, 2008, EUR J PHARM BIOPHARM, V70, P853, DOI 10.1016/j.ejpb.2008.06.030
   Van Rie A, 2008, PEDIATRICS, V122, pE123, DOI 10.1542/peds.2007-2558
   vanBree C, 1996, CANCER RES, V56, P563
   Vassal G, 2013, LANCET ONCOL, V14, pE117, DOI 10.1016/S1470-2045(13)70013-5
   Veiseh O, 2009, BIOMATERIALS, V30, P649, DOI 10.1016/j.biomaterials.2008.10.003
   Verschraegen CF, 2004, CLIN CANCER RES, V10, P2319, DOI 10.1158/1078-0432.CCR-0929-3
   Vivithanaporn P, 2011, EXPERT REV ANTI-INFE, V9, P371, DOI [10.1586/eri.10.179, 10.1586/ERI.10.179]
   Wadhwa S, 2009, CURR PHARM DESIGN, V15, P2724, DOI 10.2174/138161209788923886                                                      
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Wang CH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/31/315101
   Wang ST, 2012, EXP EYE RES, V100, P17, DOI 10.1016/j.exer.2012.04.009
   Waning B, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-74
   WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1
   WHO, MAL FACT SHEET
   World Health Organization, 2011, GLOB TUB REP
   WHO, LIST PREQ MED PROD
   WHO (World Health Organization), 2011, TOP 10 CAUS DEATH
   World Health Organization, WORLD MALARIA REPORT
   Wu DC, 2012, BIOMED MICRODEVICES, V14, P497, DOI 10.1007/s10544-011-9626-3
   Wunder JS, 2007, LANCET ONCOL, V8, P513, DOI 10.1016/S1470-2045(07)70169-9
   Zage PE, 2012, PEDIATR BLOOD CANCER, V58, P1099, DOI 10.1002/pbc.24116
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
   Zhang LB, 2013, CLIN CANCER RES, V19, P5972, DOI 10.1158/1078-0432.CCR-13-1485
   Zhi F, 2013, TUMOR BIOL, V34, P9, DOI 10.1007/s13277-012-0579-9
   Zhou Q, 2011, J PHYS CHEM B, V115, P12662, DOI 10.1021/jp207951e
   Zisowsky Jochen, 2010, Pharmaceutics, V2, P364, DOI 10.3390/pharmaceutics2040364
   Zucker D, 2010, J CONTROL RELEASE, V146, P326, DOI 10.1016/j.jconrel.2010.05.024
   Zwaan CM, 2010, CANCER TREAT REV, V36, P328, DOI 10.1016/j.ctrv.2010.02.008
   [Anonymous], 2012, GLOB REP UNAIDS REP
NR 278
TC 18
Z9 19
U1 2
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD JUN 30
PY 2014
VL 73
BP 140
EP 161
DI 10.1016/j.addr.2014.05.004
PG 22
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AL0IY
UT WOS:000338811800011
PM 24819219
DA 2018-01-05
ER

PT J
AU Perise-Barrios, AJ
   Jimenez, JL
   Dominguez-Soto, A
   de la Mata, FJ
   Corbi, AL
   Gomez, R
   Munoz-Fernandez, MA
AF Judith Perise-Barrios, Ana
   Luis Jimenez, Jose
   Dominguez-Soto, Angeles
   Javier de la Mata, F.
   Corbi, Angel L.
   Gomez, Rafael
   Angeles Munoz-Fernandez, Maria
TI Carbosilane dendrimers as gene delivery agents for the treatment of HIV
   infection
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Gene therapy; Carbosilane dendrimers; siRNA delivery; HIV infection; CD4
   lymphocytes and macrophages
ID SMALL INTERFERING RNA; HUMAN T-CELLS; POLY(ETHYLENE CARBONATE); PAMAM
   DENDRIMERS; IN-VITRO; SIRNA; THERAPY; OLIGONUCLEOTIDES;
   BIOCOMPATIBILITY; INTENSIFICATION
AB Despite the use of siRNA in the downregulation of HIV-1 replication which has been reported, CD4 T lymphocytes are difficult to transfect with non-viral vectors. We determined whether second generation carbosilane dendrimers (2G-NN16 and 2G-03NN24) may be efficient transfectants in CD4 T lymphocytes. Dendrimers were also tested on macrophages to determine whether they can modify macrophage phenotype and induce an inflammatory response. The nanoconjugate formed by 2G-03NN24/siRNA-Nef presents the highest inhibition of HIV-1 replication. Dendrimers presented safety properties because they did not induce proliferation on CD4 T lymphocytes and decrease the release of TNF alpha and IL-12p40 by macrophages. Both dendrimers also decrease the phagocytosis activity. Additionally, 2G-03NN24 dendrimer decreases the CCL2 and CCR2 expression in macrophages. Carbosilane dendrimers 2G-NN16 and 2G-03NN24 can be used as efficient non-viral vectors for gene therapy applications, mainly in the treatment of HIV infection. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Judith Perise-Barrios, Ana; Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain.
   [Judith Perise-Barrios, Ana; Angeles Munoz-Fernandez, Maria] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Luis Jimenez, Jose] Hosp Gen Univ Gregorio Maranon, Plataforma Lab, Madrid 28007, Spain.
   [Javier de la Mata, F.; Gomez, Rafael] Univ Alcala De Henares, Dpto Quim Organ & Quim Inorgan, E-28871 Madrid, Spain.
   [Judith Perise-Barrios, Ana; Luis Jimenez, Jose; Javier de la Mata, F.; Gomez, Rafael; Angeles Munoz-Fernandez, Maria] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Dominguez-Soto, Angeles; Corbi, Angel L.] CSIC, Ctr Invest Biol, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Doctor Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
RI Corbi, Angel/B-7194-2011; DOMINGUEZ-SOTO, ANGELES/K-5937-2014; Gomez
   Ramirez, Rafael/K-1216-2014; De la Mata, F. Javier/K-1649-2014
OI Corbi, Angel/0000-0003-1980-5733; Gomez Ramirez,
   Rafael/0000-0001-6448-2414; De la Mata, F. Javier/0000-0003-0418-3935;
   Munoz-Fernandez/0000-0002-0813-4500
FU ISC III [RD09/0076/00103]; Flow Cytometry Unit [CA11/00290]; Maria
   Isabel Clemente Mayoral [CA10/01274]
FX We thank the Center of Transfusion of Madrid for the buffy coats and the
   Spanish HIV HGM BioBank supported by ISC III (Grant no.
   RD09/0076/00103). Additionally, we thank Dr. Laura Diaz of the Flow
   Cytometry Unit (CA11/00290) for her technical assistance and Dr. Maria
   Isabel Clemente Mayoral for her technical assistance and advice
   regarding cell culture (CA10/01274).
CR Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111
   Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673
   Chirila TV, 2002, BIOMATERIALS, V23, P321, DOI 10.1016/S0142-9612(01)00125-9                                                   
   Chu DF, 2013, EUR J PHARM BIOPHARM, V85, P1245, DOI 10.1016/j.ejpb.2013.05.020
   Chu DF, 2013, EUR J PHARM BIOPHARM, V85, P1232, DOI 10.1016/j.ejpb.2013.04.011
   Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106
   Douglas KL, 2008, BIOTECHNOL PROGR, V24, P871, DOI 10.1021/bp070319o
   Duncan CJA, 2013, AIDS, V27, P2201, DOI 10.1097/QAD.0b013e3283632ec4
   Elzoghby AO, 2013, INT J NANOMED, V8, P1721, DOI 10.2147/IJN.S40674
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Jimenez Fuentes J.L., 2013, ADV DELIVERY THERAPE
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Guaraldi G, 2013, HIV CLIN TRIALS, V14, P140, DOI 10.1310/hct1404-140
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   Johnston KM, 2010, AIDS, V24, P1929, DOI 10.1097/QAD.0b013e32833af85d
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   McLachlan G, 2000, GENE THER, V7, P384, DOI 10.1038/sj.gt.3301097
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Pavan GM, 2010, J PHYS CHEM B, V114, P2667, DOI 10.1021/jp100271w
   Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104
   Pushker R, 2010, J VIROL, V84, P3644, DOI 10.1128/JVI.01959-09
   Rockstroh JK, 2004, J ANTIMICROB CHEMOTH, V53, P700, DOI 10.1093/jac/dkh161
   Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367
   Sanchez-Nieves J, 2013, RSC ADV, V3, P23445, DOI 10.1039/c3ra43338b
   Shamay Y., 2013, PHARM RES, V31, P768
   Turner JJ, 2006, BBA-BIOMEMBRANES, V1758, P290, DOI 10.1016/j.bbamem.2005.10.013
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Yin JY, 2006, J IMMUNOL METHODS, V312, P1, DOI 10.1016/j.jim.2006.01.023
NR 35
TC 26
Z9 26
U1 4
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 28
PY 2014
VL 184
BP 51
EP 57
DI 10.1016/j.jconrel.2014.03.048
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AI0XK
UT WOS:000336573800008
PM 24721235
DA 2018-01-05
ER

PT J
AU Zhao, XZ
   Smith, SJ
   Metifiot, M
   Marchand, C
   Boyer, PL
   Pommier, Y
   Hughes, SH
   Burke, TR
AF Zhao, Xue Zhi
   Smith, Steven J.
   Metifiot, Mathieu
   Marchand, Christophe
   Boyer, Paul L.
   Pommier, Yves
   Hughes, Stephen H.
   Burke, Terrence R., Jr.
TI 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having
   High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PHARMACOKINETIC PROFILES; REVERSE-TRANSCRIPTASE; RIBONUCLEASE H;
   INHIBITORS; 4,5-DIHYDROXYPYRIMIDINE; DOLUTEGRAVIR; DERIVATIVES;
   POLYMERASE; DESIGN; ACIDS
AB There are currently three HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) approved by the FDA for the treatment of AIDS. However, the emergence of drug-resistant mutants emphasizes the need to develop additional agents that have improved efficacies against the existent resistant mutants. As reported herein, we modified our recently disclosed 1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides IN inhibitors to develop compounds that have improved efficacies against recombinant IN in biochemical assays. These new compounds show single-digit nanomolar antiviral potencies against HIV vectors that carry wild-type (WT) IN in a single round replication assay and have improved potency against vectors harboring the major forms of drug resistant IN mutants. These compounds also have low toxicity for cultured cells, which in several cases, results in selectivity indices (CC50/EC50) of greater than 10000. The compounds have the potential, with additional structural modifications, to yield clinical agents that are effective against the known strains of resistant viruses.
C1 [Zhao, Xue Zhi; Burke, Terrence R., Jr.] NCI, Biol Chem Lab, NIH, Frederick, MD 21702 USA.
   [Smith, Steven J.; Boyer, Paul L.; Hughes, Stephen H.] NCI, HIV Drug Resistance Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
   [Metifiot, Mathieu; Marchand, Christophe; Pommier, Yves] NCI, Mol Pharmacol Lab, Dev Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
RP Burke, TR (reprint author), NCI, Biol Chem Lab, NIH, Bldg 376,Boyles St,POB B, Frederick, MD 21702 USA.
EM burkete@helix.nih.gov
RI Zhao, Xue Zhi/N-9594-2014; Burke, Terrence/N-2601-2014
OI Zhao, Xue Zhi/0000-0003-1006-6364; 
FU NIH, Center for Cancer Research, National Institutes of Health, NCI at
   Frederick; Joint Science and Technology Office of the Department of
   Defense; Intramural AIDS Targeted Antiviral Program
FX This work was supported in part by the Intramural Research Program of
   the NIH, Center for Cancer Research, National Institutes of Health, NCI
   at Frederick, and the Joint Science and Technology Office of the
   Department of Defense and funds from the Intramural AIDS Targeted
   Antiviral Program. The content of this publication does not necessarily
   reflect the views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the U.S. Government.
CR Ballantyne AD, 2013, DRUGS, V73, P1627, DOI 10.1007/s40265-013-0121-4
   Brachmann A, 2004, MOL GENET GENOMICS, V272, P216, DOI 10.1007/s00438-004-1047-z
   Cherepanov P, 2011, CURR OPIN STRUC BIOL, V21, P249, DOI 10.1016/j.sbi.2010.12.005
   Costi R, 2013, J MED CHEM, V56, P8588, DOI 10.1021/jm401040b
   Croxtall JD, 2010, DRUGS, V70, P631, DOI 10.2165/11204590-000000000-00000
   Delelis O., 2009, ANTIMICROB AGENTS CH, V54, P491
   Esposito F., 2013, ANTIVIR CHEM CHEMOTH, V23, P129, DOI DOI 10.3851/IMP2690
   Geretti AM, 2012, CURR OPIN INFECT DIS, V25, P677, DOI 10.1097/QCO.0b013e32835a1de7
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   Johns BA, 2013, J MED CHEM, V56, P5901, DOI 10.1021/jm400645w
   Katlama C, 2012, EXPERT OPIN INV DRUG, V21, P523, DOI 10.1517/13543784.2012.661713
   Kawasuji T, 2013, J MED CHEM, V56, P1124, DOI 10.1021/jm301550c
   Kawasuji T, 2012, J MED CHEM, V55, P8735, DOI 10.1021/jm3010459
   lvetac A., 2014, CHEM BIOL DRUG DES, V83, P521
   Malet I, 2008, ANTIMICROB AGENTS CH, V52, P1351, DOI 10.1128/AAC.01228-07
   Marchand C, 2009, CURR TOP MED CHEM, V9, P1016, DOI 10.2174/156802609789630910                                                      
   Mesplede T, 2012, CURR OPIN HIV AIDS, V7, P401, DOI 10.1097/COH.0b013e328356db89
   Metifiot M, 2013, ACS CHEM BIOL, V8, P209, DOI 10.1021/cb300471n
   Metifiot M, 2010, BIOCHEMISTRY-US, V49, P3715, DOI 10.1021/bi100130f
   Pratt JK, 2005, BIOORG MED CHEM LETT, V15, P1577, DOI 10.1016/j.bmcl.2005.01.071
   Su HP, 2010, J VIROL, V84, P7625, DOI 10.1128/JVI.00353-10
   Summa V, 2004, J MED CHEM, V47, P5336, DOI 10.1021/jm0494669
   Summa V, 2006, J MED CHEM, V49, P6646, DOI 10.1021/jm060854f
   Williams PD, 2010, BIOORG MED CHEM LETT, V20, P6754, DOI 10.1016/j.bmcl.2010.08.135
   Wills T, 2012, EXPERT OPIN INV DRUG, V21, P395, DOI 10.1517/13543784.2012.658914
   Zhao XZ, 2008, J MED CHEM, V51, P251, DOI 10.1021/jm070715d
   Zhao XZ, 2014, J MED CHEM, V57, P1573, DOI 10.1021/jm401902n
   Zhao XZ, 2012, CHEM BIOL DRUG DES, V79, P157, DOI 10.1111/j.1747-0285.2011.01270.x
   Zhao XZ, 2009, BIOORG MED CHEM LETT, V19, P2714, DOI 10.1016/j.bmcl.2009.03.122
   WILLIAMS PD, 2008, Patent No. 2008010964
NR 30
TC 8
Z9 8
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 26
PY 2014
VL 57
IS 12
BP 5190
EP 5202
DI 10.1021/jm5001908
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AK1OJ
UT WOS:000338184100016
PM 24901667
OA gold
DA 2018-01-05
ER

PT J
AU Mariani, C
   Desdouits, M
   Favard, C
   Benaroch, P
   Muriaux, DM
AF Mariani, Charlotte
   Desdouits, Marion
   Favard, Cyril
   Benaroch, Philippe
   Muriaux, Delphine M.
TI Role of Gag and lipids during HIV-1 assembly in CD4(+) T cells and
   macrophages
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Review
DE HIV-1; lipids; assembly; Gag; CD4(+) T cells; macrophages
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TETRASPANIN-ENRICHED MICRODOMAINS;
   PLASMA-MEMBRANE ASSOCIATION; HIGHLY BASIC REGION; MATRIX PROTEIN;
   INTRACELLULAR TRAFFICKING; CHOLESTEROL EFFLUX; INFECTIOUS HIV-1; BINDING
   DOMAIN; PRODUCER CELL
AB HIV-1 is an RNA enveloped virus that preferentially infects CD4(+) T lymphocytes and also macrophages. In CD4(+) T cells, HIV-1 mainly buds from the host cell plasma membrane. The viral Gag polyprotein targets the plasma membrane and is the orchestrator of the HIV assembly as its expression is sufficient to promote the formation of virus-like particles carrying a lipidic envelope derived from the host cell membrane. Certain lipids are enriched in the viral membrane and are thought to play a key role in the assembly process and the envelop composition. A large body of work performed on infected CD4(+) T cells has provided important knowledge about the assembly process and the membrane virus lipid composition. While HIV assembly and budding in macrophages is thought to follow the same general Gag-driven mechanism as in T-lymphocytes, the HIV cycle in macrophage exhibits specific features. In these cells, new virions bud from the limiting membrane of seemingly intracellular compartments, where they accumulate while remaining infectious. These structures are now often referred to as Virus Containing Compartments (VCCs). Recent studies suggest that VCCs represent intracellularly sequestered regions of the plasma membrane, but their precise nature remains elusive. The proteomic and lipidomic characterization of virions produced by T cells or macrophages has highlighted the similarity between their composition and that of the plasma membrane of producer cells, as well as their enrichment in acidic lipids, some components of raft lipids and in tetraspanin-enriched microdomains. It is likely that Gag promotes the coalescence of these components into an assembly platform from which viral budding takes place. How Gag exactly interacts with membrane lipids and what are the mechanisms involved in the interaction between the different membrane nanodomains within the assembly platform remains unclear. Here we review recent literature regarding the role of Gag and lipids on HIV-1 assembly in CD4(+) T cells and macrophages.
C1 [Mariani, Charlotte; Favard, Cyril; Muriaux, Delphine M.] Ctr Etude Agents Pathogenes & Biotechnol Sante, CNRS, UMR 5236, F-34293 Montpellier, France.
   [Desdouits, Marion; Benaroch, Philippe] Inst Curie Inserm U932, Paris, France.
RP Muriaux, DM (reprint author), Ctr Etude Agents Pathogenes & Biotechnol Sante, CNRS, UMR 5236, 1919 Route Mende, F-34293 Montpellier, France.
EM delphine.muriaux@cpbs.cnrs.fr
RI Favard, Cyril/P-6392-2016
OI Favard, Cyril/0000-0002-8304-2980; Desdouits, Marion/0000-0002-2625-1575
CR ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181
   Asztalos BF, 2010, J INFECT DIS, V202, P614, DOI 10.1086/654817
   Benaroch P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-29
   Bennett AE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000591
   Berre S, 2013, J EXP MED, V210, P2523, DOI 10.1084/jem.20130566
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Brugger B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-70
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523
   Chan J, 2011, J VIROL, V85, P10851, DOI 10.1128/JVI.00760-11
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Charlier L, 2014, BIOPHYS J, V106, P577, DOI 10.1016/j.bpj.2013.12.019
   Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042
   Chen K, 2008, BIOCHEMISTRY-US, V47, P1928, DOI 10.1021/bi701984h
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Chow JYH, 2010, J MOL BIOL, V400, P702, DOI 10.1016/j.jmb.2010.05.022
   Chukkapalli V, 2008, J VIROL, V82, P2405, DOI 10.1128/JVI.01614-07
   Chukkapalli V, 2011, J MOL BIOL, V410, P512, DOI 10.1016/j.jmb.2011.04.015
   Chukkapalli V, 2010, P NATL ACAD SCI USA, V107, P1600, DOI 10.1073/pnas.0908661107
   Cimarelli A, 2002, CELL MOL LIFE SCI, V59, P1166, DOI 10.1007/s00018-002-8495-6
   Coren LV, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-64
   Cui HL, 2012, J LIPID RES, V53, P696, DOI 10.1194/jlr.M023119
   Datta SAK, 2007, J MOL BIOL, V365, P812, DOI 10.1016/j.jmb.2006.10.073
   de Breyne S, 2013, VIRUS RES, V171, P366, DOI 10.1016/j.virusres.2012.10.006
   Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050
   Dick RA, 2012, P NATL ACAD SCI USA, V109, P18761, DOI 10.1073/pnas.1209408109
   Ehrlich LS, 2011, J MOL BIOL, V410, P716, DOI 10.1016/j.jmb.2011.04.069
   Ehrlich LS, 2010, J VIROL, V84, P6438, DOI 10.1128/JVI.01588-09
   Ehrlich L. S., 2012, MOL BIOL INT, V2012, DOI DOI 10.1155/2012/851670
   Fernandes F, 2011, TRAFFIC, V12, P438, DOI 10.1111/j.1600-0854.2010.01153.x
   Freed E. O., 2001, FIELDS VIROLOGY, P1971
   GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365
   Gaudin R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069450
   Ghanam RH, 2010, J BIOL CHEM, V285, P41911, DOI 10.1074/jbc.M110.179093
   Gousset K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000015
   Grigorov B, 2006, J MOL BIOL, V359, P848, DOI 10.1016/j.jmb.2006.04.017
   Grigorov B, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-28
   Hamard-Peron E, 2010, J VIROL, V84, P503, DOI 10.1128/JVI.01134-09
   Hatch SC, 2013, J VIROL, V87, P11912, DOI 10.1128/JVI.01680-13
   Hogue IB, 2011, J VIROL, V85, P9749, DOI 10.1128/JVI.00743-11
   Inlora J, 2011, J VIROL, V85, P3802, DOI 10.1128/JVI.02383-10
   Iordanskiy S, 2013, VIROLOGY, V443, P208, DOI 10.1016/j.virol.2013.05.023
   Jambo KC, 2014, MUCOSAL IMMUNOL, V7, P1116, DOI 10.1038/mi.2013.127
   Jolly C, 2007, J VIROL, V81, P5547, DOI 10.1128/JVI.01469-06
   Jouve M, 2007, CELL HOST MICROBE, V2, P85, DOI 10.1016/j.chom.2007.06.011
   Kerviel A, 2013, VIRUS RES, V171, P332, DOI 10.1016/j.virusres.2012.08.014
   Koppensteiner H, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-82
   Krementsov DN, 2010, TRAFFIC, V11, P1401, DOI 10.1111/j.1600-0854.2010.01111.x
   KURITZKES D.R., 2007, FIELDS VIROLOGY, P2187
   Kutluay SB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001200
   Lindwasser OW, 2004, J VIROL, V78, P6013, DOI 10.1128/JVI.78.11.6013-6023.2004
   Llewellyn GN, 2013, J VIROL, V87, P6441, DOI 10.1128/JVI.00040-13
   Llewellyn GN, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001167
   Lorizate M, 2013, CELL MICROBIOL, V15, P292, DOI 10.1111/cmi.12101
   Lu K, 2011, J MOL BIOL, V410, P609, DOI 10.1016/j.jmb.2011.04.029
   McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398
   Mlcochova P, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-89
   Monde K, 2011, J VIROL, V85, P3584, DOI 10.1128/JVI.02266-10
   Morrow MP, 2010, MOL PHARMACOL, V78, P215, DOI 10.1124/mol.110.065029
   Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365
   Munro JB, 2014, J VIROL, V88, P3577, DOI 10.1128/JVI.03353-13
   Muriaux D, 2010, RNA BIOL, V7, P744, DOI 10.4161/rna.7.6.14065
   Murray PS, 2005, STRUCTURE, V13, P1521, DOI 10.1016/j.str.2005.07.010
   Nadaraia-Hoke S, 2013, J VIROL, V87, P3609, DOI 10.1128/JVI.03059-12
   Nydegger S, 2006, J CELL BIOL, V173, P795, DOI 10.1083/jcb.200508165
   O'Carroll IP, 2013, VIRUS RES, V171, P341, DOI 10.1016/j.virusres.2012.10.016
   Ono A, 2004, P NATL ACAD SCI USA, V101, P14889, DOI 10.1073/pnas.0405596101
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Ono A, 2009, FUTURE VIROL, V4, P241, DOI 10.2217/FVL.09.4
   Orenstein JM, 1998, ULTRASTRUCT PATHOL, V22, P293, DOI 10.3109/01913129809103350                                                       
   ORENSTEIN JM, 1988, J VIROL, V62, P2578
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   Perlman M, 2006, TRAFFIC, V7, P731, DOI 10.1111/j.1600-0854.2006.00428.x
   Prchal J, 2012, J MOL BIOL, V423, P427, DOI 10.1016/j.jmb.2012.07.021
   Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x                                                
   Resh MD, 2005, AIDS REV, V7, P84
   Saad JS, 2008, J MOL BIOL, V382, P434, DOI 10.1016/j.jmb.2008.07.027
   Saad JS, 2006, P NATL ACAD SCI USA, V103, P11364, DOI 10.1073/pnas.0602818103
   Samal AB, 2011, J BIOL CHEM, V286, P33533, DOI 10.1074/jbc.M111.273623
   Schroeder C, 2010, SUBCELL BIOCHEM, V51, P77, DOI 10.1007/978-90-481-8622-8_3
   Sharova N, 2005, EMBO J, V24, P2481, DOI 10.1038/sj.emboj.7600707
   Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08
   Suh BC, 2005, CURR OPIN NEUROBIOL, V15, P370, DOI 10.1016/j.conb.2005.05.005
   Tan J, 2013, TRENDS MICROBIOL, V21, P405, DOI 10.1016/j.tim.2013.05.001
   Taylor JE, 2012, BIOPHYS J, V103, P541, DOI 10.1016/j.bpj.2012.06.042
   Thali M, 2009, CURR TOP MICROBIOL, V339, P85, DOI 10.1007/978-3-642-02175-6_5
   van den Bogaart G, 2011, NATURE, V479, P552, DOI 10.1038/nature10545
   Vlach J, 2014, J BIOL CHEM, V289, P8697, DOI 10.1074/jbc.M113.543694
   Welsch S, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030036
   Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004
NR 90
TC 9
Z9 10
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUN 25
PY 2014
VL 5
AR 312
DI 10.3389/fmicb.2014.00312
PG 9
WC Microbiology
SC Microbiology
GA AK9FT
UT WOS:000338733700002
PM 25009540
OA gold
DA 2018-01-05
ER

PT J
AU Wang, J
   Liu, Y
   Xu, K
   Qi, YF
   Zhong, J
   Zhang, K
   Li, J
   Wang, EB
   Wu, ZY
   Kang, ZH
AF Wang, Juan
   Liu, Yang
   Xu, Kun
   Qi, Yanfei
   Zhong, Jun
   Zhang, Kai
   Li, Juan
   Wang, Enbo
   Wu, Ziyu
   Kang, Zhenhui
TI Broad-Spectrum Antiviral Property of Polyoxometalate Localized on a Cell
   Surface
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE polyoxometalate; antiviral activity; X-ray nanotomography; HepG2 cell;
   nanotomography technique
ID HERPES-SIMPLEX-VIRUS; X-RAY TOMOGRAPHY; HETEROPOLYOXOTUNGSTATE;
   NANOTOMOGRAPHY; MICROSCOPY; MECHANISM; INFECTION; CLUSTERS; TYPE-2;
   PM-19
AB Cs2K4Na[SiW9Nb3O40] has broad antiviral ability including anti-Influenza A, -Influenza B, -HSV-1, -HSV-2, -HIV-1, and -HBV. A series of antivirus and/or biochemical experiments and X-ray nanotomography analysis confirm that this kind of broad-spectrum antiviral property is mainly due to its localization on the cell surface.
C1 [Wang, Juan; Xu, Kun; Qi, Yanfei; Li, Juan] Jilin Univ, Sch Publ Hlth, Changchun 130021, Jilin, Peoples R China.
   [Liu, Yang; Zhong, Jun; Kang, Zhenhui] Soochow Univ, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Inst Funct Nano & Soft Mat, Suzhou 215123, Jiangsu, Peoples R China.
   [Liu, Yang; Zhong, Jun; Kang, Zhenhui] Soochow Univ, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Jiangsu, Peoples R China.
   [Zhang, Kai] Chinese Acad Sci, Inst High Energy Phys, Beijing 100049, Peoples R China.
   [Wang, Enbo] NE Normal Univ, Fac Chem, Changchun 130024, Jilin, Peoples R China.
   [Wu, Ziyu] Univ Sci & Technol China, Natl Synchrotron Radiat Lab, Hefei 230026, Peoples R China.
RP Li, J (reprint author), Jilin Univ, Sch Publ Hlth, Changchun 130021, Jilin, Peoples R China.
EM li_juan@jlu.edu.cn; zhkang@suda.edu.cn
FU National Basic Research Program of China (973 Program) [2012CB825800,
   2013CB932702]; National Natural Science Foundation of China [51132006];
   Specialized Research Fund for the Doctoral Program of Higher Education
   [20123201110018]; Priority Academic Program Development of Jiangsu
   Higher Education Institutions; Talents Ph.D. Project of Bethune College
   of Medicine in Jilin University
FX We are thankful for the support of the National Basic Research Program
   of China (973 Program; Grants 2012CB825800 and 2013CB932702), National
   Natural Science Foundation of China (Grant 51132006), Specialized
   Research Fund for the Doctoral Program of Higher Education (Grant
   20123201110018), a project funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions, and the Talents
   Ph.D. Project of Bethune College of Medicine in Jilin University. Here,
   we also celebrate over 50 years of contributions of Prof. Enbo Wang to
   education at Northeast Normal University.
CR Aitken JB, 2011, CURR TOP MED CHEM, V11, P553, DOI 10.2174/156802611794785217
   Attwood D, 2006, NATURE, V442, P642, DOI 10.1038/442642b
   BERRY JP, 1990, EXP MOL PATHOL, V53, P255, DOI 10.1016/0014-4800(90)90048-I
   Dan K, 2003, PHARMACOLOGY, V67, P83, DOI 10.1159/000067738
   Dan K, 2002, PHARMACOL RES, V46, P357, DOI 10.1016/S1043-6618(02)00170-6
   ELION GB, 1983, J ANTIMICROB CHEMOTH, V12, P9, DOI 10.1093/jac/12.suppl_B.9                                                        
   Fernandez JA, 2007, J AM CHEM SOC, V129, P12244, DOI 10.1021/ja0737321
   IKEDA S, 1993, ANTIVIR CHEM CHEMOTH, V4, P253, DOI 10.1177/095632029300400501                                                      
   IKEDA S, 1993, J MED VIROL, V41, P191, DOI 10.1002/jmv.1890410304
   Judd DA, 2001, J AM CHEM SOC, V123, P886, DOI 10.1021/ja001809e
   Kak AC, 1988, PRINCIPLES COMPUTERI
   Kong XJ, 2010, ACCOUNTS CHEM RES, V43, P201, DOI 10.1021/ar900089k
   Larabell CA, 2004, MOL BIOL CELL, V15, P957, DOI 10.1091/mbc.E03-07-0522
   Long DL, 2007, CHEM SOC REV, V36, P105, DOI 10.1039/b502666k
   Lunkenbein T, 2012, J AM CHEM SOC, V134, P12685, DOI 10.1021/ja304073t
   Ni L, 1996, ANTIVIR RES, V32, P141, DOI 10.1016/S0166-3542(95)00988-4
   NI L, 1994, ANTIMICROB AGENTS CH, V38, P504, DOI 10.1128/AAC.38.3.504                                                            
   Pesola JM, 2007, J GEN VIROL, V88, P1410, DOI 10.1099/vir.0.82787-0
   POPE MT, 1991, ANGEW CHEM INT EDIT, V30, P34, DOI 10.1002/anie.199100341
   Pope M. T., 1994, POLYOXOMETALATES PLA
   Rhule JT, 1998, CHEM REV, V98, P327, DOI 10.1021/cr960396q                                                               
   Schmitz KS, 2009, J PHYS CHEM B, V113, P2624, DOI 10.1021/jp805648a
   Schneider G, 2010, NAT METHODS, V7, P985, DOI 10.1038/NMETH.1533
   Shigeta S, 2003, ANTIVIR RES, V58, P265, DOI 10.1016/S0166-3542(03)00009-3
   Uchida M, 2009, P NATL ACAD SCI USA, V106, P19375, DOI 10.1073/pnas.0906145106
   WEEKS MS, 1992, J MED CHEM, V35, P1216, DOI 10.1021/jm00085a008
   Withers PJ, 2007, MATER TODAY, V10, P26, DOI 10.1016/S1369-7021(07)70305-X
   Yamase T, 2005, J MATER CHEM, V15, P4773, DOI 10.1039/b504585a
   Yang Y, 2010, J MICROSC-OXFORD, V240, P14, DOI 10.1111/j.1365-2818.2010.03379.x
   Zhang H, 2012, BIOORG MED CHEM LETT, V22, P1664, DOI 10.1016/j.bmcl.2011.12.115
   Zhang J, 2008, J AM CHEM SOC, V130, P14408, DOI 10.1021/ja805644a
NR 31
TC 12
Z9 14
U1 4
U2 42
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUN 25
PY 2014
VL 6
IS 12
BP 9785
EP 9789
DI 10.1021/am502193f
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA AK1ON
UT WOS:000338184500106
PM 24878685
DA 2018-01-05
ER

PT J
AU Yan, ZH
   Wua, HQ
   Chen, WX
   Wu, Y
   Piao, HR
   He, QQ
   Chen, FE
   De Clercq, E
   Pannecouque, C
AF Yan, Zi-Hong
   Wua, Hai-Qiu
   Chen, Wen-Xue
   Wu, Yan
   Piao, Hu-Ri
   He, Qiu-Qin
   Chen, Fen-Er
   De Clercq, Erik
   Pannecouque, Christophe
TI Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside
   reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1; NNRTIs; Diarylpyrimidine; SAR; Antiviral activity
ID COLORIMETRIC ASSAY; NNRTIS; DESIGN; DERIVATIVES; DISCOVERY
AB A series of new diarylpyrimidines (DAPYs) characterized by a halogen atom on the methylene linker between wing I and the central pyrimidine ring was synthesized and evaluated for their anti-HIV activity in MT-4 cell cultures. The two most promising compounds 7f and 7g showed excellent activity against wild-type HIV-1 with low nanomolar EC50 values of 0.005 and 0.009 mu M, respectively, which were comparable to or more potent than all the reference drugs zidovudine (AZT), lamivudine (3TC), nevirapine (NEV), efavirenz (EFV), delaviridine (DLV) and etravirine (ETV). In particular, 7g also displayed strong activity against the double mutant strain 103N + 181C with an EC50 value of 8.2 mu M. The preliminary structure-activity relationship (SAR) and molecular docking analysis of this new series of CHX-DAPYs were also investigated. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Yan, Zi-Hong; Wua, Hai-Qiu; Chen, Wen-Xue; He, Qiu-Qin; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Wu, Yan; Piao, Hu-Ri] Yanbian Univ, Coll Pharm, Yanji 133000, Peoples R China.
   [Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [De Clercq, Erik; Pannecouque, Christophe] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP He, QQ (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM qqhe@fudan.edu.cn; rfchen@fudan.edu.cn
FU Chinese National Science and Technology Major Project
   [2012ZX09103101-068]; National Natural Science Foundation of China
   [81172918]; Shanghai Municipal Natural Science Foundation [13ZR1402200];
   KU Leuven [GOA 10/014]
FX This research was financially supported by Grants from Chinese National
   Science and Technology Major Project (No. 2012ZX09103101-068), National
   Natural Science Foundation of China (No. 81172918), Shanghai Municipal
   Natural Science Foundation (No. 13ZR1402200) and KU Leuven (GOA 10/014).
CR Bailey C. M., 2013, J MED CHEM, V10, P3889
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001                                                             
   Chen X., 2013, CHEMMEDCHEM, V7, P1117
   Chen X., 2013, BIOORG MED CHEM LETT, V24, P6593
   Chen XW, 2011, CURR MED CHEM, V18, P359, DOI 10.2174/092986711794839142                                                      
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Erdelyi M, 2012, CHEM SOC REV, V41, P3547, DOI 10.1039/c2cs15292d
   Gu SX, 2011, BIOORGAN MED CHEM, V19, P5117, DOI 10.1016/j.bmc.2011.07.023
   Li DY, 2012, J MED CHEM, V55, P3595, DOI 10.1021/jm200990c
   LU YH, 2009, ACTA ENTOMOL SINICA, V52, P52
   Lu YX, 2010, PHYS CHEM CHEM PHYS, V12, P4543, DOI 10.1039/b926326h
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Metrangolo P, 2008, ANGEW CHEM INT EDIT, V47, P6114, DOI 10.1002/anie.200800128
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Xu Z., 2014, J CHEM INF MODEL
   Yang SQ, 2013, EUR J MED CHEM, V65, P134, DOI 10.1016/j.ejmech.2013.04.052
   Zhang LZ, 2014, BIOORGAN MED CHEM, V22, P633, DOI 10.1016/j.bmc.2013.10.033
NR 18
TC 4
Z9 7
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 15
PY 2014
VL 22
IS 12
BP 3220
EP 3226
DI 10.1016/j.bmc.2014.03.020
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA AH1WL
UT WOS:000335912300016
PM 24794751
DA 2018-01-05
ER

PT J
AU Asquith, CRM
   Meli, ML
   Konstantinova, LS
   Laitinen, T
   Perakyla, M
   Poso, A
   Rakitin, OA
   Allenspach, K
   Hofmann-Lehmann, R
   Hilton, ST
AF Asquith, Christopher R. M.
   Meli, Marina L.
   Konstantinova, Lidia S.
   Laitinen, Tuomo
   Perakyla, Mikael
   Poso, Antti
   Rakitin, Oleg A.
   Allenspach, Karin
   Hofmann-Lehmann, Regina
   Hilton, Stephen T.
TI Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines
   and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein
   of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE FIV; HIV-1; Scorpionine; Nucleocapsid protein; NCp7
ID NUCLEOCAPSID PROTEIN; SULFUR MONOCHLORIDE; ZINC EJECTION; HUNIGS BASE;
   IN-VITRO; ANTI-HIV; ONE-POT; INHIBITORS; BENZISOTHIAZOLONES;
   IDENTIFICATION
AB A diverse library of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives were prepared for evaluation of activity against the nucleocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV, using an in vitro cell culture approach, yielding nanomolar active compounds with low toxicity. Crown Copyright (C) 2014 Published by Elsevier Ltd. All rights reserved.
C1 [Asquith, Christopher R. M.; Hilton, Stephen T.] UCL, Fac Life Sci, Sch Pharm, London WC1N 1AX, England.
   [Meli, Marina L.; Hofmann-Lehmann, Regina] Univ Zurich, Vetsuisse Fac, Clin Lab, CH-8057 Zurich, Switzerland.
   [Meli, Marina L.; Hofmann-Lehmann, Regina] Univ Zurich, Vetsuisse Fac, Ctr Clin Studies, CH-8057 Zurich, Switzerland.
   [Konstantinova, Lidia S.; Rakitin, Oleg A.] Russian Acad Sci, Zelinsky Inst Organ Chem, Moscow 119991, Russia.
   [Laitinen, Tuomo; Perakyla, Mikael; Poso, Antti] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
   [Allenspach, Karin] Royal Vet Coll, Hatfield AL9 7TA, Herts, England.
RP Hilton, ST (reprint author), UCL, Fac Life Sci, Sch Pharm, London WC1N 1AX, England.
EM s.hilton@ucl.ac.uk
RI Rakitin, Oleg/D-7530-2014; Hofmann-Lehmann, Regina/C-6528-2009
OI Rakitin, Oleg/0000-0001-6609-4087; Hofmann-Lehmann,
   Regina/0000-0001-9750-4296; Poso, Antti/0000-0003-4196-4204
FU Bloomsbury Colleges, University of London; Pet Plan Charitable Trust;
   University College London; University of Zurich & Biocenter Finland/DDCB
FX The authors are grateful to the Bloomsbury Colleges, University of
   London; Pet Plan Charitable Trust; University College London; University
   of Zurich & Biocenter Finland/DDCB for financial support towards the
   goals of our work. Also the authors would like to express their thanks
   to the University of Zurich for use of the facilities at the Center for
   Clinical Studies at the Vetsuisse Faculty and to CSC-IT Center for
   Science Ltd, for the allocation of computational resources.
CR Bisset LR, 2002, ANTIVIR RES, V53, P35, DOI 10.1016/S0166-3542(01)00190-5                                                   
   Breuer S, 2012, J MED CHEM, V55, P4968, DOI 10.1021/jm201442t
   Dietz J, 2008, CHEMMEDCHEM, V3, P749, DOI 10.1002/cmdc.200700194
   Elder JH, 2010, CURR HIV RES, V8, P73, DOI 10.2174/157016210790416389                                                      
   Frisch M. J., 2004, GAUSSIAN 03 REVISION
   Goldschmidt Valerie, 2010, HIV Therapy, V4, P179, DOI 10.2217/HIV.10.3
   Greene WC, 2008, ANTIVIR RES, V80, P251, DOI 10.1016/j.antiviral.2008.08.003
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Houzet L, 2008, NUCLEIC ACIDS RES, V36, P2311, DOI 10.1093/nar/gkn069
   Klein D, 2001, J ACQ IMMUN DEF SYND, V26, P8
   Konstantinova LS, 2009, MENDELEEV COMMUN, V19, P55, DOI 10.1016/j.mencom.2009.03.001
   Konstantinova LS, 2000, J CHEM SOC PERK T 1, P3421, DOI 10.1039/b005068g
   LETVIN NL, 1983, P NATL ACAD SCI-BIOL, V80, P2718, DOI 10.1073/pnas.80.9.2718
   Loo JA, 1996, J MED CHEM, V39, P4313, DOI 10.1021/jm960253w
   Manrique ML, 2004, VIROLOGY, V327, P83, DOI 10.1016/j.virol.2004.06.019
   Marcos CF, 1997, CHEM COMMUN, P879, DOI 10.1039/a701340j                                                                
   Marcos CF, 1997, ANGEW CHEM INT EDIT, V36, P281
   Mayasundari A, 2003, BIOORGAN MED CHEM, V11, P3215, DOI 10.1016/S0968-0896(03)00269-4
   Maynard AT, 1998, P NATL ACAD SCI USA, V95, P11578, DOI 10.1073/pnas.95.20.11578
   Rakitin OA, 2008, ADV HETEROCYCL CHEM, V96, P175, DOI 10.1016/S0065-2725(07)00004-9
   Ramboarina S, 1999, BIOCHEMISTRY-US, V38, P9600, DOI 10.1021/bi9905258
   Rees CW, 1998, J ORG CHEM, V63, P2189, DOI 10.1021/jo971864e                                                               
   RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194
   Richards JR, 2005, BIOLOGICALS, V33, P215, DOI 10.1016/j.biologicals.2005.08.004
   Schmalzbauer E, 1996, J VIROL, V70, P771
   Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978-1-61779-012-6_9
   Tummino PJ, 1997, ANTIMICROB AGENTS CH, V41, P394
   Turpin JA, 1999, J MED CHEM, V42, P67, DOI 10.1021/jm9802517                                                               
   *UNAIDS, 2009, AIDS EP UPD
   Vahlenkamp T. W., 1995, ANTIMICROB AGENTS CH, P39
   Vallee H., 1904, HEBD ACAD SCI, V139, P331
   von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555
   Wapling J, 2007, DRUG TARGET INSIGHT, V2, P159
   Warui DM, 2012, J MED CHEM, V55, P4132, DOI 10.1021/jm2007694
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
NR 35
TC 4
Z9 4
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 15
PY 2014
VL 24
IS 12
BP 2640
EP 2644
DI 10.1016/j.bmcl.2014.04.073
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA AH1ZT
UT WOS:000335921200008
PM 24813732
DA 2018-01-05
ER

PT J
AU Arenaccio, C
   Chiozzini, C
   Columba-Cabezas, S
   Manfredi, F
   Federico, M
AF Arenaccio, Claudia
   Chiozzini, Chiara
   Columba-Cabezas, Sandra
   Manfredi, Francesco
   Federico, Maurizio
TI Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes
   ingesting exosomes from cells expressing defective HIV-1
SO RETROVIROLOGY
LA English
DT Article
DE Defective HIV-1; Exosomes; ADAM17; CD4(+) T lymphocytes; Nef
ID TREATED AIDS PATIENTS; BLOOD MONONUCLEAR-CELLS; VIRUS TYPE-1 INFECTION;
   HIGH VIRAL LOAD; COMBINATION THERAPY; PLASMA-MEMBRANE; NEF GENE; GAG;
   COUNTS; SECRETION
AB Background: A relevant burden of defective HIV-1 genomes populates PBMCs from HIV-1 infected patients, especially during HAART treatment. These viral genomes, although unable to codify for infectious viral particles, can express viral proteins which may affect functions of host cells as well as bystander ones. Cells expressing defective HIV-1 have a lifespan longer than that of cells producing infectious particles. Hence, their interaction with other cell types, including resting lymphocytes, is expected to occur frequently in tissues where HIV actively replicates. We investigated the effects of the expression of a prototype of functionally defective HIV-1 on bystander, unstimulated CD4(+) T lymphocytes.
   Results: We observed that unstimulated human primary CD4(+) T lymphocytes were activated and became permissive for HIV-1 replication when co-cultivated with cells expressing a functionally defective HIV-1 (F12/Hut-78 cells). This effect depended on the presence in F12/Hut-78 supernatants of nanovesicles we identified as exosomes. By inspecting the underlying mechanism, we found that ADAM17, i.e., a disintegrin and metalloprotease converting pro-TNF-alpha in its mature form, associated with exosomes from F12/Hut-78 cells, and played a key role in the HIV-1 replication in unstimulated CD4(+) T lymphocytes. In fact, the treatment with an inhibitor of ADAM17 abolished both activation and HIV-1 replication in unstimulated CD4(+) T lymphocytes. TNF-alpha appeared to be the downstream effector of ADAM17 since the treatment of unstimulated lymphocytes with antibodies against TNF-alpha or its receptors blocked the HIV-1 replication. Finally, we found that the expression of Nef(F12) in exosome-producing cells was sufficient to induce the susceptibility to HIV-1 infection in unstimulated CD4(+) T lymphocytes.
   Conclusions: Exosomes from cells expressing a functionally defective mutant can induce cell activation and HIV-1 susceptibility in unstimulated CD4(+) T lymphocytes. This evidence highlights the relevance for AIDS pathogenesis of the expression of viral products from defective HIV-1 genomes.
C1 [Arenaccio, Claudia; Chiozzini, Chiara; Manfredi, Francesco; Federico, Maurizio] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
   [Arenaccio, Claudia] Univ Roma Tre, Dept Sci, Rome, Italy.
   [Columba-Cabezas, Sandra] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy.
RP Federico, M (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM Maurizio.federico@iss.it
RI Columba Cabezas, Sandra/A-6015-2013; Federico, Maurizio/J-5867-2016;
   manfredi, francesco/K-3890-2016; Arenaccio, Claudia/J-9914-2016
OI Columba Cabezas, Sandra/0000-0001-7727-6636; Federico,
   Maurizio/0000-0003-4154-1025; Arenaccio, Claudia/0000-0003-3297-2608
FU AIDS National from the Ministry of Health, Italy; "Ricerca Finalizzata"
   projects, from the Ministry of Health, Italy
FX This work was supported by grants from AIDS National and "Ricerca
   Finalizzata" projects, both from the Ministry of Health, Italy. Rev-CEM
   cells, rabbit anti-HIV-1 CAp24 polyclonal antibodies #4250, and AZT were
   obtained from NIH AIDS Research and Reference Reagent Program. We thank
   Andreas Baur for helpful comments. We are indebted to Pietro Arciero for
   excellent technical support and Stefania De Menna for both secretarial
   and administrative supports.
CR Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Cabezas SC, 2013, CELL MICROBIOL, V15, P412, DOI 10.1111/cmi.12046
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Carlini F, 1996, J GEN VIROL, V77, P2009, DOI 10.1099/0022-1317-77-9-2009
   Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049
   CHOWERS MY, 1994, J VIROL, V68, P2906
   D'Aloja P, 1998, J VIROL, V72, P4308
   D'Aloja P, 2001, J GEN VIROL, V82, P2735, DOI 10.1099/0022-1317-82-11-2735                                                    
   DAAR ES, 1995, AIDS RES HUM RETROV, V11, P3, DOI 10.1089/aid.1995.11.3
   Dettenhofer M, 1999, J VIROL, V73, P1460
   Fackler OT, 2001, J VIROL, V75, P6601, DOI 10.1128/JVI.75.14.6601-6608.2001                                                
   Fang Y, 2007, PLOS BIOL, V5, P1267, DOI 10.1371/journal.pbio.0050158
   FEDERICO M, 1989, AIDS RES HUM RETROV, V5, P385, DOI 10.1089/aid.1989.5.385
   Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752
   Fourati S, 2014, AIDS, V28, P487, DOI 10.1097/QAD.0000000000000182
   Fourati S, 2012, J ANTIMICROB CHEMOTH, V67, P2323, DOI 10.1093/jac/dks219
   Ghose R, 2001, J VIROL, V75, P11336, DOI 10.1128/JVI.75.23.11336-11343.2001
   Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015
   Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3
   Herbein G, 2008, TRENDS IMMUNOL, V29, P61, DOI 10.1016/j.it.2007.10.008
   Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020
   Janini M, 2001, J VIROL, V75, P7973, DOI 10.1128/JVI.75.17.7973-7986.2001
   Kogure T, 2011, HEPATOLOGY, V54, P1237, DOI 10.1002/hep.24504
   Kosaka N, 2012, J BIOL CHEM, V287, P1397, DOI 10.1074/jbc.M111.288662
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Lattanzi L, 2012, VACCINE, V30, P7229, DOI 10.1016/j.vaccine.2012.10.010
   Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   McNamara LA, 2012, J VIROL, V86, P9337, DOI 10.1128/JVI.00895-12
   Moss ML, 2007, ANAL BIOCHEM, V366, P144, DOI 10.1016/j.ab.2007.04.043
   Muratori C, 2007, J VIROL, V81, P9078, DOI 10.1128/JVI.00675-07
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Olivetta E, 2000, J VIROL, V74, P483, DOI 10.1128/JVI.74.1.483-492.2000                                                   
   Park IW, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-234
   Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x                                                
   Sanchez G, 1997, J VIROL, V71, P2233
   Saurya S, 2005, J CLIN VIROL, V33, P324, DOI 10.1016/j.jcv.2005.05.003
   Saurya S, 2003, J MED VIROL, V71, P167, DOI 10.1002/jmv.10459
   Saurya S, 2003, AIDS RES HUM RETROV, V19, P73, DOI 10.1089/08892220360473998
   Saurya S, 2002, AIDS RES HUM RETROV, V18, P983, DOI 10.1089/088922202760265650                                                      
   Saurya S, 2002, AIDS RES HUM RETROV, V18, P1151, DOI 10.1089/088922202320567905
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Vallanti G, 2005, MOL THER, V12, P697, DOI 10.1016/j.mythe.2005.05.014
   Vatakis DN, 2007, J VIROL, V81, P3574, DOI 10.1128/JVI.02569-06
   Wolf D, 2008, CELL HOST MICROBE, V4, P398, DOI 10.1016/j.chom.2008.08.013
   Wu Y, 2007, CURR HIV RES, V5, P394
   Yuyama K, 2012, J BIOL CHEM, V287, P10977, DOI 10.1074/jbc.M111.324616
   ZACK JA, 1992, J VIROL, V66, P1717
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
NR 52
TC 23
Z9 23
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JUN 12
PY 2014
VL 11
AR 46
DI 10.1186/1742-4690-11-46
PG 16
WC Virology
SC Virology
GA AL7DH
UT WOS:000339292800001
PM 24924541
OA gold
DA 2018-01-05
ER

PT J
AU Chiodo, F
   Marradi, M
   Calvo, J
   Yuste, E
   Penades, S
AF Chiodo, Fabrizio
   Marradi, Marco
   Calvo, Javier
   Yuste, Eloisa
   Penades, Soledad
TI Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for
   anti-HIV prodrugs
SO BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
DE drug-delivery system; gold glyconanoparticles; HAART; HIV; multivalent
   glycosystems; reverse transcriptase inhibitors
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR T-20;
   MANNO-GLYCONANOPARTICLES; CELLULAR UPTAKE; DC-SIGN; NANOPARTICLES;
   GP120; SYSTEMS; OLIGOMANNOSIDES; INFECTION
AB The therapeutic approach for the treatment of HIV infection is based on the highly active antiretroviral therapy (HAART), a cocktail of antiretroviral drugs. Notwithstanding HAART has shown different drawbacks like toxic side effects and the emergence of viral multidrug resistance. Nanotechnology offers new tools to improve HIV drug treatment and prevention. In this scenario, gold nanoparticles are an interesting chemical tool to design and prepare smart and efficient drug-delivery systems. Here we describe the preparation and antiviral activity of carbohydrate-coated gold nanoparticles loaded with anti-HIV prodrug candidates. The nucleoside reverse transcriptase inhibitors abacavir and lamivudine have been converted to the corresponding thiol-ending ester derivatives and then conjugated to similar to 3 nm glucose-coated gold nanoparticles by means of "thiol-for-thiol" ligand place exchange reactions. The drugs-containing glyconanoparticles were characterized and the pH-mediated release of the drug from the nanoparticle has been determined. The antiviral activity was tested by evaluating the replication of NL4-3 HIV in TZM-bl infected cells. The proof-of- principle presented in this work aims to introduce gold glyconanoparticles as a new multifunctional drug-delivery system in the therapy against HIV.
C1 [Chiodo, Fabrizio; Marradi, Marco; Penades, Soledad] CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, San Sebastian 20009, Spain.
   [Marradi, Marco; Penades, Soledad] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, San Sebastian 20009, Spain.
   [Calvo, Javier] CIC BiomaGUNE, Technol Platform Mass Spectrometry, San Sebastian 20009, Spain.
   [Yuste, Eloisa] Inst Invest Biomed August Pi i Sunyer, AIDS Res Unit, Barcelona, Spain.
   [Yuste, Eloisa] HIVACAT, Barcelona, Spain.
RP Chiodo, F (reprint author), Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands.
EM chiodo.fabrizio@gmail.com; spenades@cicbiomagune.es
RI CALVO, JOSE JAVIER/K-7661-2014; biomaGUNE, CIC/J-9136-2014; Chiodo,
   Fabrizio/R-1121-2017
OI CALVO, JOSE JAVIER/0000-0001-9513-0518; biomaGUNE,
   CIC/0000-0001-7690-0660; Chiodo, Fabrizio/0000-0003-3619-9982
FU EU (CHAARM); MINECO [CTQ2011-27268]; Department of Industry of the
   Basque Country [ETORTEK2011]; Spanish Ministry of Science and
   Innovation; MICINN [CTQ2008-04638]; EU COST Action [CM1102]
FX We thank Dr. Miguel Angel von Wichmann from Hospital Donostia (San
   Sebastian) for his suggestions and scientific support. Financial support
   from the EU (grant CHAARM), the MINECO (grant No. CTQ2011-27268) and the
   Department of Industry of the Basque Country (Grant No. ETORTEK2011) is
   acknowledged. F.C. was supported by the Spanish Ministry of Science and
   Innovation, MICINN (Grant No. CTQ2008-04638). M.M. and S.P. acknowledge
   EU COST Action CM1102.
CR Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Arnaiz B, 2012, BIOCONJUGATE CHEM, V23, P814, DOI 10.1021/bc200663r
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Bibby DC, 1996, INT J PHARM, V144, P61, DOI 10.1016/S0378-5173(96)04720-5                                                   
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Chiodo F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073027
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   De Clercq E, 2010, CURR OPIN PHARMACOL, V10, P507, DOI 10.1016/j.coph.2010.04.011
   de la Fuente JM, 2007, IEEE T NANOBIOSCI, V6, P275, DOI 10.1109/TNB.2007.908981
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Di Gianvincenzo P, 2012, METHOD ENZYMOL, V509, P21, DOI 10.1016/B978-0-12-391858-1.00002-2
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Duncan B, 2010, J CONTROL RELEASE, V148, P122, DOI 10.1016/j.jconrel.2010.06.004
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194
   Hostetler MJ, 1999, LANGMUIR, V15, P3782, DOI 10.1021/la981598f                                                               
   Irure A, 2013, BIOMATER SCI-UK, V1, P658, DOI 10.1039/c3bm60032g
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Marradi M, 2010, ADV CARBOHYD CHEM BI, V64, P211, DOI 10.1016/S0065-2318(10)64005-X
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Moros M, 2012, ACS NANO, V6, P1565, DOI 10.1021/nn204543c
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Murray RA, 2014, SMALL, V10, P2602, DOI 10.1002/smll.201303604
   Pelgrift RY, 2013, ADV DRUG DELIVER REV, V65, P1803, DOI 10.1016/j.addr.2013.07.011
   Platt EJ, 1998, J VIROL, V72, P2855
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   Shiang YC, 2013, NANOSCALE, V5, P2756, DOI 10.1039/c3nr33403a
   Tahir MN, 2004, CHEM COMMUN, P2848, DOI 10.1039/b410283e
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   Tichy T, 2011, BIOORGAN MED CHEM, V19, P3527, DOI 10.1016/j.bmc.2011.04.016
   Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
NR 39
TC 22
Z9 24
U1 3
U2 45
PU BEILSTEIN-INSTITUT
PI FRANKFURT AM MAIN
PA TRAKEHNER STRASSE 7-9, FRANKFURT AM MAIN, 60487, GERMANY
SN 1860-5397
J9 BEILSTEIN J ORG CHEM
JI Beilstein J. Org. Chem.
PD JUN 12
PY 2014
VL 10
BP 1339
EP 1346
DI 10.3762/bjoc.10.136
PG 8
WC Chemistry, Organic
SC Chemistry
GA AK6WH
UT WOS:000338567500001
PM 24991287
OA gold
DA 2018-01-05
ER

PT J
AU Suchaud, V
   Bailly, F
   Lion, C
   Calmels, C
   Andreola, ML
   Christ, F
   Debyser, Z
   Cotelle, P
AF Suchaud, Virginie
   Bailly, Fabrice
   Lion, Cedric
   Calmels, Christina
   Andreola, Marie-Line
   Christ, Frauke
   Debyser, Zeger
   Cotelle, Philippe
TI Investigation of a Novel Series of
   2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Human Immunodeficiency Virus
   Type 1 Integrase Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SMALL-MOLECULE INHIBITORS; STRAND TRANSFER; DOLUTEGRAVIR S/GSK1349572;
   RESISTANCE PROFILE; HIV-1 REPLICATION; DRUG-RESISTANCE; RNASE-H;
   RALTEGRAVIR; DISCOVERY; DOCKING
AB We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.
C1 [Suchaud, Virginie; Bailly, Fabrice; Lion, Cedric; Cotelle, Philippe] Univ Lille Nord France, F-59000 Lille, France.
   [Suchaud, Virginie; Bailly, Fabrice; Lion, Cedric; Cotelle, Philippe] Univ Lille 1, Equipe Accueil Chim Mol & Formulat, F-59655 Villeneuve Dascq, France.
   [Christ, Frauke; Debyser, Zeger] Katholieke Univ Leuven, Interdisciplinary Res Ctr KULAK, B-3000 Louvain, Flanders, Belgium.
   [Christ, Frauke; Debyser, Zeger] Katholieke Univ Leuven, Ctr Mol Med, B-3000 Louvain, Flanders, Belgium.
   [Calmels, Christina; Andreola, Marie-Line] Univ Bordeaux Segalen, CNRS, Lab Microbiol Fondamentale & Pathogenicite, UMR 5234, F-33076 Bordeaux, France.
RP Bailly, F (reprint author), Univ Lille Nord France, F-59000 Lille, France.
EM fabrice.bailly@univ-lille1.fr
OI debyser, zeger/0000-0002-3982-1565
FU le Ministere de l'Enseignement Superieur et de la Recherche Francaise;
   l'Agence Nationale de la Recherche contre le Sida (ANRS); FP7 project
   CHAARM; IWT
FX This work was financially supported by grants from le Ministere de
   l'Enseignement Superieur et de la Recherche Francaise and l'Agence
   Nationale de la Recherche contre le Sida (ANRS). Experiments at KU
   Leuven were funded by the FP7 project CHAARM and the IWT.
CR [Anonymous], 2012, VISUALIZER DS RELEAS
   ADACHI A, 1986, J VIROL, V59, P284
   Allen FH, 1997, ACTA CRYSTALLOGR B, V53, P1017, DOI 10.1107/S0108768197010239                                                       
   Ballantyne AD, 2013, DRUGS, V73, P1627, DOI 10.1007/s40265-013-0121-4
   Billamboz Muriel, 2013, ACS Med Chem Lett, V4, P606, DOI 10.1021/ml400009t
   Billamboz M, 2011, EUR J MED CHEM, V46, P535, DOI 10.1016/j.ejmech.2010.11.033
   Billamboz M, 2009, J HETEROCYCLIC CHEM, V46, P392, DOI 10.1002/jhet.52
   Billamboz M, 2008, J MED CHEM, V51, P7717, DOI 10.1021/jm8007085
   BRUGGINK A, 1975, TETRAHEDRON, V31, P2607, DOI 10.1016/0040-4020(75)80278-X                                                    
   Canducci F, 2011, J INFECT DIS, V204, P1811, DOI 10.1093/infdis/jir636
   Christ F, 2012, ANTIMICROB AGENTS CH, V56, P4365, DOI 10.1128/AAC.00717-12
   Christ F, 2010, NAT CHEM BIOL, V6, P442, DOI 10.1038/nchembio.370
   Cole J. C., 2005, VIRTUAL SCREENING IN
   Desimmie BA, 2013, ACS CHEM BIOL, V8, P1187, DOI 10.1021/cb4000426
   Dufour E, 1999, J MOL BIOL, V285, P1339, DOI 10.1006/jmbi.1998.2430
   Engelman A, 2013, CURR OPIN CHEM BIOL, V17, P339, DOI 10.1016/j.cbpa.2013.04.010
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Garrido C, 2011, ANTIVIR RES, V90, P164, DOI 10.1016/j.antiviral.2011.03.178
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hilal SH, 1995, QUANT STRUCT-ACT REL, V14, P348, DOI 10.1002/qsar.19950140405
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   MALAMAS MS, 1994, J MED CHEM, V37, P2043, DOI 10.1021/jm00039a017
   Marcelin AG, 2009, CURR OPIN HIV AIDS, V4, P531, DOI 10.1097/COH.0b013e328331d4b1
   Marchand C, 2012, EXPERT OPIN INV DRUG, V21, P901, DOI 10.1517/13543784.2012.685653
   McColl DJ, 2010, ANTIVIR RES, V85, P101, DOI 10.1016/j.antiviral.2009.11.004
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Menendez-Arias L, 2013, ANTIVIR RES, V98, P93, DOI 10.1016/j.antiviral.2013.01.007
   MOELLING K, 1989, J VIROL, V63, P5489
   Parkes KEB, 2003, J MED CHEM, V46, P1153, DOI 10.1021/jm020334u
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Schrijvers R, 2012, EXPERT OPIN PHARMACO, V13, P1969, DOI 10.1517/14656566.2012.712514
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Tintori C, 2012, BIOORG MED CHEM LETT, V22, P3109, DOI 10.1016/j.bmcl.2012.03.064
   Wainberg MA, 2011, NEW ENGL J MED, V365, P637, DOI 10.1056/NEJMra1004180
   World Health Organization, 2011, GLOBAL HIV AIDS RESP
NR 40
TC 11
Z9 12
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 12
PY 2014
VL 57
IS 11
BP 4640
EP 4660
DI 10.1021/jm500109z
PG 21
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AJ0JK
UT WOS:000337336600018
PM 24793360
DA 2018-01-05
ER

PT J
AU Famiglini, V
   La Regina, G
   Coluccia, A
   Pelliccia, S
   Brancale, A
   Maga, G
   Crespan, E
   Badia, R
   Clotet, B
   Este, JA
   Cirilli, R
   Novellino, E
   Silvestri, R
AF Famiglini, Valeria
   La Regina, Giuseppe
   Coluccia, Antonio
   Pelliccia, Sveva
   Brancale, Andrea
   Maga, Giovanni
   Crespan, Emmanuele
   Badia, Roger
   Clotet, Bonaventura
   Este, Jose A.
   Cirilli, Roberto
   Novellino, Ettore
   Silvestri, Romano
TI New indolylarylsulfones as highly potent and broad spectrum HIV-1
   non-nucleoside reverse transcriptase inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE AIDS; HIV-1; Reverse transcriptase; Nonnucleoside inhibitor;
   Indolylarylsulfone
ID INDOLYL ARYL SULFONES; DRUG-RESISTANCE; WILD-TYPE; MUTATIONS; DESIGN;
   DERIVATIVES; VIRUS; DISCOVERY
AB New indolylarylsulfone HIV-1 NNRTIs were synthesized to evaluate unexplored substitutions of the benzyl/phenylethyl group linked at the indole-2-carboxamide. Against the NL4-3 HIV-1 WT strain, 17 out 20 compounds were superior to NVP and EFV. Several compounds inhibited the K103N HIV-1 mutant strain at nanomolar concentration and were superior to EFV. Some derivatives were superior to EFV against the Y181C and L100I HIV-1 mutant strains. Against the NL4-3 HIV-1 strain, the enantiomers 24 and 25 showed small differences of activity. In contrast, 24 turned out significantly more potent than 25 against the whole panel of mutant HIV-1 strains. The docking studies suggested that the difference in the observed inhibitory activities of 24 and 25 against the K03N mutation could be due to a kinetic rather than affinity differences. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Famiglini, Valeria; La Regina, Giuseppe; Coluccia, Antonio; Pelliccia, Sveva; Silvestri, Romano] Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   [Brancale, Andrea] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales.
   [Maga, Giovanni; Crespan, Emmanuele] CNR, IGM, I-27100 Pavia, Italy.
   [Badia, Roger; Clotet, Bonaventura; Este, Jose A.] Univ Autonoma Barcelona, Hosp Germans Trios & Pujol, AIDS Res Inst IrsiCaixa, Badalona 08916, Spain.
   [Cirilli, Roberto] Ist Super Sanita, Dipartimento Farmaco, I-00161 Rome, Italy.
   [Novellino, Ettore] Univ Naples Federico II, Dipartimento Farm, I-80131 Naples, Italy.
RP La Regina, G (reprint author), Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Ist Pasteur, Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM giuseppe.laregina@uniroma1.it; romano.silvestri@icloud.com
RI Brancale, Andrea/N-9445-2014; La Regina, Giuseppe/I-2161-2012
OI Brancale, Andrea/0000-0002-9728-3419; La Regina,
   Giuseppe/0000-0003-3252-1161; Cirilli, Roberto/0000-0001-6346-1953;
   Silvestri, Romano/0000-0003-2489-0178; Badia, Roger/0000-0003-3982-7577;
   Crespan, Emmanuele/0000-0003-0597-6929; Pelliccia,
   Sveva/0000-0002-5526-5554; Este, Jose/0000-0002-1436-5823; Novellino,
   Ettore/0000-0002-2181-2142; /0000-0002-7940-8206
FU Istituto Pasteur-Fondazione Cenci Bolognetti; Spanish MINECO
   [SAF2010-21617-C02, BFU 2012-31569]
FX This research project was supported by grant 2012 of Istituto
   Pasteur-Fondazione Cenci Bolognetti and the Spanish MINECO
   SAF2010-21617-C02 and BFU 2012-31569. Authors thank Prof. Jan Balzarini,
   Rega Institute for Medical Research, Katholieke Universiteit Leuven,
   B-3000 Leuven, Belgium, for the evaluation of some compounds against
   HIV-1 IIIB and HIV-2 ROD strains.
CR [Anonymous], 2014, MOL OP ENV MOE
   Chong P, 2012, J MED CHEM, V55, P10601, DOI 10.1021/jm301294g
   Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   Cortez KJ, 2011, VIRUSES-BASEL, V3, P347, DOI 10.3390/v3040347
   [Anonymous], PYMOL VERS 1 2R1
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Famiglini V, 2013, FUTURE MED CHEM, V5, P2141, DOI 10.4155/fmc.13.174
   FDA, 2012, ANT DRUGS US TREATM
   Geitmann M, 2006, J MED CHEM, V49, P2375, DOI 10.1021/jm0504050
   Gonzalez-Ortega E, 2011, ANTIVIR RES, V92, P479, DOI 10.1016/j.antiviral.2011.10.010
   Grant PM, 2010, CURR OPIN INVEST DR, V11, P901
   Howkins T., 2010, ANTIVIR RES, V85, P201
   Korb O, 2006, LECT NOTES COMPUT SC, V4150, P247
   La Regina G, 2011, J MED CHEM, V54, P1587, DOI 10.1021/jm101614j
   Lafemina R., 2009, ANTIVIRAL RES STRATE
   La G. Regina, 2010, ANTIVIR CHEM CHEMOTH, V20, P231
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Menendez-Arias L, 2013, ANTIVIR RES, V98, P93, DOI 10.1016/j.antiviral.2013.01.007
   Piscitelli F, 2009, J MED CHEM, V52, P1922, DOI 10.1021/jm801470b
   Ragno R, 2005, J MED CHEM, V48, P213, DOI 10.1021/jm040854k
   Ragno R, 2006, J MED CHEM, V49, P3172, DOI 10.1021/jm0512490
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X                                                   
   Silvestri R, 2004, J MED CHEM, V47, P3892, DOI 10.1021/jm031147e
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   Van Nhien AN, 2005, J MED CHEM, V48, P4276, DOI 10.1021/jm050091g
   Virgin H.W., 2011, NATURE, V464, P224
   Zhao ZJ, 2008, BIOORG MED CHEM LETT, V18, P554, DOI 10.1016/j.bmcl.2007.11.085
NR 27
TC 11
Z9 12
U1 0
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN 10
PY 2014
VL 80
BP 101
EP 111
DI 10.1016/j.ejmech.2014.04.027
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AJ8VG
UT WOS:000337985400009
PM 24769348
DA 2018-01-05
ER

PT J
AU Meher, BR
   Kumar, MVS
   Bandyopadhyay, P
AF Meher, Biswa Ranjan
   Kumar, Mattaparthi Venkata Satish
   Bandyopadhyay, Pradipta
TI Interchain hydrophobic clustering promotes rigidity in HIV-1 protease
   flap dynamics: new insights from Molecular Dynamics
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE force field; flap dynamics; Molecular Dynamics simulation; HIV-1
   protease; hydrophobic cluster
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE; FORCE-FIELDS; WILD-TYPE;
   SIMULATIONS; MUTATIONS; MECHANISM; FLEXIBILITY; INHIBITOR; SUBSTRATE
AB The dynamics of HIV-1 protease (HIV-pr), a drug target for HIV infection, has been studied extensively by both computational and experimental methods. The flap dynamics of HIV-pr is considered to be more important for better ligand binding and enzymatic actions. Moreover, it has been demonstrated that the drug-induced mutations can change the flap dynamics of HIV-pr affecting the binding affinity of the ligands. Therefore, detailed understanding of flap dynamics is essential for designing better inhibitors. Previous computational investigations observed significant variation in the flap opening in nanosecond time scale indicating that the dynamics is highly sensitive to the simulation protocols. To understand the sensitivity of the flap dynamics on the force field and simulation protocol, molecular dynamics simulations of HIV-pr have been performed with two different AMBER force fields, ff99 and ff02. Two different trajectories (20 ns each) were obtained using the ff99 and ff02 force field. The results showed polarizable force field (ff02) make the flap tighter than the nonpolarizable force field (ff99). Some polar interactions and hydrogen bonds involving flap residues were found to be stronger with ff02 force field. The formation of interchain hydrophobic cluster (between flap tip of one chain and active site wall of another chain) was found to be dominant in the semi-open structures obtained from the simulations irrespective of the force field. It is proposed that an inhibitor, which will promote this interchain hydrophobic clustering, may make the flaps more rigid, and presumably the effect of mutation would be small on ligand binding.
C1 [Meher, Biswa Ranjan] Indian Inst Technol, Dept Biotechnol, Computat Biol Res Lab, Gauhati 781039, Assam, India.
   [Meher, Biswa Ranjan] Albany State Univ, Dept Nat Sci, Computat Chem Lab, Albany, GA 31705 USA.
   [Kumar, Mattaparthi Venkata Satish] Sastra Univ, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India.
   [Bandyopadhyay, Pradipta] Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, Ctr Computat Biol & Bioinformat, New Delhi 110067, India.
RP Meher, BR (reprint author), Indian Inst Technol, Dept Biotechnol, Computat Biol Res Lab, Gauhati 781039, Assam, India.
EM bmeher@asurams.edu
FU Department of Science and Technology (DST) [SR/FT/L-43/2004]; AICTE,
   Govt. of India
FX The authors thank IIT Guwahati for providing the computational facility.
   This work was funded by a Department of Science and Technology (DST)
   fast-track grant (SR/FT/L-43/2004) awarded to PB.; We deeply acknowledge
   the Pittsburgh Supercomputing Center (PSC), USA as part of this work has
   been performed by utilizing the super-computing facilities therein. BRM
   thanks AICTE, Govt. of India for the financial support in the form of
   National Doctoral Fellowship (NDF). The authors highly appreciate the
   anonymous reviewers for their constructive suggestions for the
   improvement of the article.
CR Ali A, 2010, VIRUSES-BASEL, V2, P2509, DOI 10.3390/v2112509
   Bandyopadhyay P, 2006, CHEM BIOL DRUG DES, V67, P155, DOI 10.1111/1.1747-0285.2006.00348.x
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   CALDWELL JW, 1995, J PHYS CHEM-US, V99, P6208, DOI 10.1021/j100016a067                                                             
   Case D. A., 2006, AMBER, V9
   CHANDRASEKHAR I, 1992, J MOL BIOL, V226, P239, DOI 10.1016/0022-2836(92)90136-8
   Chen JZ, 2010, J MOL MODEL, V16, P459, DOI 10.1007/s00894-009-0553-7
   Chen XF, 2004, J MOL MODEL, V10, P373, DOI 10.1007/s00894-004-0205-x
   Cieplak P, 2001, J COMPUT CHEM, V22, P1048, DOI 10.1002/jcc.1065
   Dirauf P, 2010, J MOL MODEL, V16, P1577, DOI 10.1007/s00894-010-0677-9
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Foulkes JE, 2006, J VIROL, V80, P6906, DOI 10.1128/JVI.01900-05
   Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103
   Hou T, 2008, PROTEINS, V71, P1163, DOI 10.1002/prot.21808
   Hu GD, 2010, EUR J MED CHEM, V45, P227, DOI 10.1016/j.ejmech.2009.09.048
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kar P, 2012, J COMPUT AID MOL DES, V26, P215, DOI 10.1007/s10822-012-9550-5
   LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0                                                                
   Layten M, 2006, J AM CHEM SOC, V128, P13360, DOI 10.1021/ja065133k
   Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x                                                               
   Maschera B, 1996, J BIOL CHEM, V271, P33231, DOI 10.1074/jbc.271.52.33231                                                        
   Meagher KL, 2005, PROTEINS, V58, P119, DOI 10.1002/prot.20274
   Meher BR, 2009, INDIAN J PHYS, V83, P81, DOI 10.1007/s12648-009-0005-3                                                       
   Meher BR, 2012, J BIOINF COMPUT BIOL, V10, DOI 10.1142/S0219720012500187
   Meher BR, 2012, J PHYS CHEM B, V116, P1884, DOI 10.1021/jp2074804
   Mittal S, 2012, J AM CHEM SOC, V134, P4163, DOI 10.1021/ja2095766
   Muzammil S, 2007, J VIROL, V81, P5144, DOI 10.1128/JVI.02706-06
   Muzammil S, 2003, BIOCHEMISTRY-US, V42, P631, DOI 10.1021/bi027019u
   Ode H, 2006, J AM CHEM SOC, V128, P7887, DOI 10.1021/ja060682b
   Perryman AL, 2004, PROTEIN SCI, V13, P1108, DOI 10.1110/ps.03468904
   Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702
   Piana S, 2002, J MOL BIOL, V319, P567, DOI 10.1016/S0022-2836(02)00301-7
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018
   Prabu-Jeyabalan M, 2002, STRUCTURE, V10, P369, DOI 10.1016/S0969-2126(02)00720-7
   Reiling KK, 2002, BIOCHEMISTRY-US, V41, P4582, DOI 10.1021/bi011781z
   Scott WRP, 2000, STRUCTURE, V8, P1259, DOI 10.1016/S0969-2126(00)00537-2                                                   
   Soares RO, 2010, J MOL GRAPH MODEL, V29, P137, DOI 10.1016/j.jmgm.2010.05.007
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   Toth G, 2006, J MOL GRAPH MODEL, V24, P465, DOI 10.1016/j.jmgm.2005.08.008
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   Zhang FL, 2002, J AM CHEM SOC, V124, P12654, DOI 10.1021/ja027847a
NR 44
TC 2
Z9 2
U1 3
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD JUN 3
PY 2014
VL 32
IS 6
BP 899
EP 915
DI 10.1080/07391102.2013.795873
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AB1AU
UT WOS:000331524500005
PM 23782135
DA 2018-01-05
ER

PT J
AU Yu, XW
   Feizpour, A
   Ramirez, NGP
   Wu, LX
   Akiyama, H
   Xu, FD
   Gummuluru, S
   Reinhard, BM
AF Yu, Xinwei
   Feizpour, Amin
   Ramirez, Nora-Guadalupe P.
   Wu, Linxi
   Akiyama, Hisashi
   Xu, Fangda
   Gummuluru, Suryaram
   Reinhard, Bjoern M.
TI Glycosphingolipid-functionalized nanoparticles recapitulate
   CD169-dependent HIV-1 uptake and trafficking in dendritic cells
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-INFECTION; IN-VITRO; GOLD
   NANOPARTICLES; SINGLE-VIRUS; T-CELLS; PARTICLES; PATHWAY; TYPE-1;
   IMMATURE
AB Ganglioside GM3, a host-derived glycosphingolipid incorporated in the membrane of human immunodeficiency virus-1 (HIV-1) viral particles, mediates interactions between HIV-1 and Siglec1/CD169, a protein expressed on dendritic cells (DCs). Such interactions, which seem to be independent of viral envelope glycoprotein gp120, are poorly understood. Here we develop a model system consisting of self-assembled artificial virus nanoparticles (AVNs) that are free of viral glycoproteins or other host-derived glycolipids and glycoproteins. These plasmonic AVNs contain a membrane of defined composition wrapped around a solid metal core. GM3-containing AVNs are captured by CD169-expressing HeLa cells or mature DCs, and are sequestered within non-lysosomal tetraspanin-positive compartments. This distribution is reminiscent of CD169-dependent HIV-1 sequestration in mature DCs. Our results highlight GM3-CD169 binding as a gp120-independent signal for sequestration and preservation of HIV-1 infectivity. They also indicate that plasmonic AVNs offer improved features over liposome-based systems and represent a versatile tool for probing specific virus-cell interactions.
C1 [Yu, Xinwei; Feizpour, Amin; Wu, Linxi; Xu, Fangda; Reinhard, Bjoern M.] Boston Univ, Dept Chem, Boston, MA 02215 USA.
   [Yu, Xinwei; Feizpour, Amin; Wu, Linxi; Xu, Fangda; Reinhard, Bjoern M.] Boston Univ, Photon Ctr, Boston, MA 02215 USA.
   [Ramirez, Nora-Guadalupe P.; Akiyama, Hisashi; Gummuluru, Suryaram] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
RP Gummuluru, S (reprint author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
EM rgummulu@bu.edu; bmr@bu.edu
FU National Institutes of Health [1R56Al104393, AI064099, R01CA138509]
FX This work was supported by the National Institutes of Health through
   grant 1R56Al104393 (B.M.R. and S.G.), AI064099 (S.G.) and R01CA138509
   (B.M.R.). The authors thank Camille Silva for assistance with liposome
   generation, Tian Qin for molecular structure drawings, Ali Khanehzar for
   assistance with the AVN characterization, Alexey Nikiforov for technical
   support of the FIB/SEM, and Anlee Krupp for Zygo measurements.
CR Aniagyei SE, 2008, J MATER CHEM, V18, P3763, DOI 10.1039/b805874c
   Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
   Bakshi MS, 2007, J PHYS CHEM C, V111, P14113, DOI 10.1021/jp072862t
   Bennett AE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000591
   Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   Campbell S, 2001, P NATL ACAD SCI USA, V98, P10875, DOI 10.1073/pnas.191224698
   Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b
   Cavrois M, 2007, PLOS PATHOG, V3, P38, DOI 10.1371/journal.ppat.0090004
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039
   Datta Siddhartha A. K., 2009, V485, P197, DOI 10.1007/978-1-59745-170-3_14
   Dong CS, 2007, J VIROL, V81, P11352, DOI 10.1128/JVI.01081-07
   Felts RL, 2010, P NATL ACAD SCI USA, V107, P13336, DOI 10.1073/pnas.1003040107
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Ganser-Pornillos BK, 2012, ADV EXP MED BIOL, V726, P441, DOI 10.1007/978-1-4614-0980-9_20
   Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   Goicochea NL, 2011, J MOL BIOL, V410, P667, DOI 10.1016/j.jmb.2011.04.012
   Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103
   Gummuluru S, 2003, J VIROL, V77, P12865, DOI 10.1128/JVI.77.23.12865-12874.2003
   Hartnell A, 2001, BLOOD, V97, P288, DOI 10.1182/blood.V97.1.288
   Hatch SC, 2009, J VIROL, V83, P3496, DOI 10.1128/JVI.02249-08
   Huhn D, 2013, ACS NANO, V7, P3253, DOI 10.1021/nn3059295
   Ip S, 2011, LANGMUIR, V27, P7024, DOI 10.1021/la200212c
   Ishitani T, 1997, SCANNING, V19, P489
   Izquierdo-Useros N, 2007, J VIROL, V81, P7559, DOI 10.1128/JVI.02572-06
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001448
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001315
   Izquierdo-Useros N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000740
   Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kreibig U., 1995, OPTICAL PROPERTIES M
   Kukura P, 2009, NAT METHODS, V6, P923, DOI 10.1038/nmeth.1395
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lee SE, 2009, J AM CHEM SOC, V131, P14066, DOI 10.1021/ja904326j
   Liang XM, 2004, J COLLOID INTERF SCI, V278, P53, DOI 10.1016/j.jcis.2004.05.042
   Manchester M, 2006, ADV DRUG DELIVER REV, V58, P1505, DOI 10.1016/j.addr.2006.09.014
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Mittelman D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-111
   Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u
   Nap RJ, 2013, BIOMATER SCI-UK, V1, P814, DOI 10.1039/c3bm00181d
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nycholat CM, 2012, J AM CHEM SOC, V134, P15696, DOI 10.1021/ja307501e
   Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291
   Puryear WB, 2013, ADV EXP MED BIOL, V762, P131, DOI 10.1007/978-1-4614-4433-6_5
   Puryear WB, 2012, P NATL ACAD SCI USA, V109, P7475, DOI 10.1073/pnas.1201104109
   Schultz S, 2000, P NATL ACAD SCI USA, V97, P996, DOI 10.1073/pnas.97.3.996                                                           
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Sharma R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043248
   Thaxton CS, 2009, J AM CHEM SOC, V131, P1384, DOI 10.1021/ja808856z
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   van Schooneveld MM, 2008, NANO LETT, V8, P2517, DOI 10.1021/nl801596a
   Vieweger M, 2011, ACS NANO, V5, P7324, DOI 10.1021/nn202184x
   Waheed AA, 2010, VIRUSES-BASEL, V2, P1146, DOI 10.3390/v2051146
   Wampler HP, 2009, MICRON, V40, P444, DOI 10.1016/j.micron.2009.01.002
   Wang J, 2012, NANO LETT, V12, P3231, DOI 10.1021/nl3012227
   Wang J, 2011, ACS NANO, V5, P6619, DOI 10.1021/nn202055b
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Willis S, 2008, BIOCHEMISTRY-US, V47, P6988, DOI 10.1021/bi800540b
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Wu LX, 2014, CHEM SOC REV, V43, P3884, DOI 10.1039/c3cs60340g
   Yang JA, 2012, LANGMUIR, V28, P5404, DOI 10.1021/la300325p
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760                                                          
   Yu H. J., 2008, PLOS PATHOG, V4
   Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4
NR 70
TC 23
Z9 23
U1 2
U2 46
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 4136
DI 10.1038/ncomms5136
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0SZ
UT WOS:000338838400013
PM 24947940
OA gold
DA 2018-01-05
ER

PT J
AU Zhao, NX
   Pei, SN
   Parekh, P
   Salazar, E
   Zu, YL
AF Zhao, Nianxi
   Pei, Sung-nan
   Parekh, Parag
   Salazar, Eric
   Zu, Youli
TI Blocking interaction of viral gp120 and CD4-expressing T cells by
   single-stranded DNA aptamers
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE ssDNA CD4 aptamer; gp120; HIV infection prevention; Hybrid SELEX;
   Specific blocking
ID NUCLEIC-ACID APTAMERS; DRUG-DELIVERY; ENTRY INHIBITORS; RNA APTAMERS;
   HUMAN CD4; RESISTANCE; NANOPARTICLES; LYMPHOMA; THERAPY; CARRIER
AB To investigate the potential clinical application of aptamers to prevention of HIV infection, single-stranded DNA (ssDNA) aptamers specific for CD4 were developed using the systematic evolution of ligands by exponential enrichment approach and next generation sequencing. In contrast to RNA-based aptamers, the developed ssDNA aptamers were stable in human serum up to 12 h. Cell binding assays revealed that the aptamers specifically targeted CD4-expressing cells with high binding affinity (K-d = 1.59 nM), a concentration within the range required for therapeutic application. Importantly, the aptamers selectively bound CD4 on human cells and disrupted the interaction of viral gp120 to CD4 receptors, which is a prerequisite step of HIV-1 infection. Functional studies showed that the aptamer polymers significantly blocked binding of viral gp120 to CD4-expressing cells by up to 70% inhibition. These findings provide a new approach to prevent HIV-1 transmission using oligonucleotide aptamers. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Zu, Youli] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA.
   Houston Methodist Res Inst, Canc Pathol Lab, Houston, TX 77030 USA.
RP Zu, YL (reprint author), Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA.
EM yzu@houstonmethodist.org
FU NIH [R01CA151955, R33CA173382, 5P50CA126752]
FX This project was supported in part by NIH grants R01CA151955 (Y.Z.),
   R33CA173382 (Y.Z.), 5P50CA126752 (Y.Z.).
CR Andrieux-Meyer I, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17986
   Cabrera C, 2005, MED CLIN-BARCELONA, V124, P618, DOI 10.1157/13074392
   Cahn P, 2010, J ANTIMICROB CHEMOTH, V65, P213, DOI 10.1093/jac/dkp422
   Castro E, 2008, AIDS RES HUM RETROV, V24, P106, DOI 10.1089/aid.2007.0139
   Chang M, 2011, ACS NANO, V5, P6156, DOI 10.1021/nn200693a
   Cheng CS, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2012.59
   Copon DJ, 1991, ANNU REV IMMUNOL, V9, P649
   Davis KA, 1998, NUCLEIC ACIDS RES, V26, P3915, DOI 10.1093/nar/26.17.3915
   Dhalla S, 2013, CURR HIV RES, V11, P238, DOI 10.2174/1570162X11311030009
   Didigu CA, 2012, VIRUSES-BASEL, V4, P309, DOI 10.3390/v4020309
   Fidler Sarah, 2013, Evid Based Med, V18, P184, DOI 10.1136/eb-2012-101034
   Flores A, 2013, CURR MED CHEM, V20, P751
   Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616
   Guo JW, 2011, BIOMATERIALS, V32, P8010, DOI 10.1016/j.biomaterials.2011.07.004
   Hatano H, 2013, CURR OPIN HIV AIDS, V8, P211, DOI 10.1097/COH.0b013e32835f9788
   Hicke BJ, 2001, J BIOL CHEM, V276, P45654
   Holtz CM, 2013, J VIROL, V87, P5296, DOI 10.1128/JVI.03576-12
   Horn WT, 2004, RNA, V10, P1776, DOI 10.1261/rna.7710304
   Hu MD, 2013, FUTURE ONCOL, V9, P369, DOI [10.2217/fon.12.201, 10.2217/FON.12.201]
   Kang KN, 2013, ADV BIOCHEM ENG BIOT, V131, P153, DOI 10.1007/10_2012_136
   Liu J, 2011, CURR MED CHEM, V18, P4117, DOI 10.2174/092986711797189619                                                      
   Mann AP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013050
   Meng L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033434
   Moss JA, 2013, RADIOL TECHNOL, V84, P268
   Moss Joseph Anthony, 2013, Radiol Technol, V84, P247
   Ni X, 2011, CURR MED CHEM, V18, P4206, DOI 10.2174/092986711797189600                                                      
   Pasut G, 2009, DRUG TODAY, V45, P687, DOI [10.1396/674/dot.2009.45.9.1416421, 1396674/dot.2009.45.9.1416421]
   Pasut G, 2009, ADV DRUG DELIVER REV, V61, P1177, DOI 10.1016/j.addr.2009.02.010
   Peeters M, 2010, CLIN MICROBIOL INFEC, V16, P1525, DOI 10.1111/j.1469-0691.2010.03300.x
   Scanlon ML, 2013, HIV AIDS-RES PALLIAT, V5, P1, DOI 10.2147/HIV.S28912
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   Sefah K, 2010, NAT PROTOC, V5, P1169, DOI 10.1038/nprot.2010.66
   Song KM, 2012, SENSORS-BASEL, V12, P612, DOI 10.3390/s120100612
   Stray MM, 2013, J VIROL, V87, P454
   Strehlitz B, 2012, BIOANAL REV, V4, P1, DOI DOI 10.1007/S12566-011-0026-1
   Sundaram P, 2012, NANOMED-NANOTECHNOL, V8, P1143, DOI 10.1016/j.nano.2012.01.010
   Teissier E, 2010, MOLECULES, V16, P221
   Thiel WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043836
   Thiviyanathan V, 2012, PROTEOM CLIN APPL, V6, P563, DOI 10.1002/prca.201200042
   Tombelli S, 2010, COMB CHEM HIGH T SCR, V13, P641, DOI 10.2174/1386207311004070641                                                     
   Ulrich M, 1992, J EXP MED, V176, P507
   Wainberg MA, 2012, CURR OPIN VIROL, V2, P656, DOI 10.1016/j.coviro.2012.08.007
   WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0
   Wang TJ, 2012, PROTEIN CELL, V3, P739, DOI 10.1007/s13238-012-2072-z
   Zhang P, 2010, AM J CLIN PATHOL, V134, P586, DOI 10.1309/AJCP55KQYWSGZRKC
   Zhao N, 2011, GENE THER, V18, P220, DOI 10.1038/gt.2010.123
   Zhao NX, 2013, SMALL, V9, P3477, DOI 10.1002/smll.201202694
   Zhao NX, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-2
NR 48
TC 8
Z9 8
U1 0
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUN
PY 2014
VL 51
BP 10
EP 18
DI 10.1016/j.biocel.2014.03.008
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AJ6BL
UT WOS:000337774600002
PM 24661998
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wang, C
   Shi, WG
   Cai, LF
   Lu, L
   Yu, F
   Wang, Q
   Jiang, XF
   Xu, XY
   Wang, K
   Xu, L
   Jiang, SB
   Liu, KL
AF Wang, Chao
   Shi, Weiguo
   Cai, Lifeng
   Lu, Lu
   Yu, Fei
   Wang, Qian
   Jiang, Xifeng
   Xu, Xiaoyu
   Wang, Kun
   Xu, Liang
   Jiang, Shibo
   Liu, Keliang
TI Artificial peptides conjugated with cholesterol and pocket-specific
   small molecules potently inhibit infection by laboratory-adapted and
   primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE HIV; fusion inhibitors; conjugate
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MEMBRANE-FUSION; 6-HELIX BUNDLE
   FORMATION; TARGETING GP41; MULTIFUNCTIONAL DOMAINS; BIOLOGICAL
   EVALUATION; ANTIVIRAL POTENCY; ENTRY INHIBITORS; MEDIATED FUSION; DESIGN
AB To develop new HIV-1 fusion inhibitors with improved antiviral activities and resistance profiles, we designed two categories of artificial peptides, each containing four heptad repeats (m4HR) conjugated with a pocket-specific small molecule (pssm) or pssm and cholesterol (chol), designated pssm-m4HR or pssm-m4HR-chol, respectively, and tested their anti-HIV-1 activity.
   We synthesized the artificial peptides and conjugated these peptides with pssm and chol using a standard solid-phase Fmoc protocol and a chemoselective thioether conjugation method, respectively. We tested the inhibitory activities of the peptide conjugates against HIV-1 Env-mediated cell-cell fusion and infection by laboratory-adapted and primary HIV-1 isolates, and enfuvirtide-resistant HIV-1 strains using cell-cell fusion and p24 production assays, respectively. We assessed their cytotoxicity towards MT-2 cells using the XTT assay.
   We found that pssm-m4HR conjugates exhibited promising inhibitory activity against HIV-1 Env-mediated cell-cell fusion and laboratory-adapted HIV-1 replication with IC50 values at the low micromolar level, whereas the pssm-m4HR-chol conjugates exhibited dramatically increased anti-HIV-1 activities with IC50 values at the low nanomolar level. Some of the pssm-m4HR-chol conjugates (e.g. 5a and 5b) showed highly potent antiviral activity against infection by primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. All the conjugates displayed no or low cytotoxicity towards MT-2 cells. The result of a prime/wash assay indicated pssm-m4HR-chol conjugates were strongly anchored to the membrane and sustained a potent inhibitory effect after washing.
   These results suggest this scaffold design is a promising strategy for developing novel peptide conjugates with improved antiviral activity against a broad spectrum of HIV-1 strains, including those highly resistant to enfuvirtide.
C1 [Wang, Chao; Shi, Weiguo; Cai, Lifeng; Jiang, Xifeng; Xu, Xiaoyu; Wang, Kun; Xu, Liang; Liu, Keliang] Beijing Inst Pharmacol Toxicol, Beijing 100850, Peoples R China.
   [Lu, Lu; Wang, Qian; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Educ, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Lu, Lu; Wang, Qian; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Hlth, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Lu, Lu; Wang, Qian; Jiang, Shibo] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China.
   [Yu, Fei; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
RP Liu, KL (reprint author), Beijing Inst Pharmacol Toxicol, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
EM keliangliu55@126.com
RI Lu, Lu/K-7070-2014; Wang, Chao/J-3250-2015; Jiang, Shibo/L-4500-2014
OI Wang, Chao/0000-0002-7673-0638; Lu, Lu/0000-0002-2255-0391
FU National Science Foundation of China [81373266, 81273434, 81273560,
   81261120382]; National Science and Technology Major Project of China
   grant [2012ZX09301003]; 973 Programme of China [2012CB519001]
FX This work was supported by grants from the National Science Foundation
   of China (81373266, 81273434, 81273560 and 81261120382), a National
   Science and Technology Major Project of China grant (2012ZX09301003) and
   the 973 Programme of China (2012CB519001).
CR Ashkenazi A, 2012, FASEB J, V26, P4628, DOI 10.1096/fj.12-215111
   Ashkenazi A, 2011, EUR BIOPHYS J BIOPHY, V40, P349, DOI 10.1007/s00249-010-0666-z
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289
   Cai LF, 2009, ANTIMICROB AGENTS CH, V53, P2444, DOI 10.1128/AAC.00150-09
   Case DA, 2004, AMBER
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chou TC, 1991, CALCUSYN WINDOWS SOF
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Francis JN, 2012, BIOCONJUGATE CHEM, V23, P1252, DOI 10.1021/bc300076f
   Frey G, 2006, P NATL ACAD SCI USA, V103, P13938, DOI 10.1073/pnas.0601036103
   Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   He YX, 2008, P NATL ACAD SCI USA, V105, P16332, DOI 10.1073/pnas.0807335105
   Ingallinella P, 2009, P NATL ACAD SCI USA, V106, P5801, DOI 10.1073/pnas.0901007106
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Jiang SB, 2002, CURR PHARM DESIGN, V8, P563
   Joly V, 2010, EXPERT OPIN PHARMACO, V11, P2701, DOI 10.1517/14656566.2010.522178
   Lee KK, 2011, J BIOL CHEM, V286, P42141, DOI 10.1074/jbc.M111.254243
   Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t
   Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200
   Liu SW, 2007, CURR PHARM DESIGN, V13, P143, DOI 10.2174/138161207779313722
   Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013
   Liu SW, 2003, J BIOMOL SCREEN, V8, P685, DOI 10.1177/1087057103259155
   Lu H, 2006, AIDS RES HUM RETROV, V22, P411, DOI 10.1089/aid.2006.22.411
   Lu L, 2012, BBA-BIOMEMBRANES, V1818, P2950, DOI 10.1016/j.bbamem.2012.07.020
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Mink M, 2005, J VIROL, V79, P12447, DOI 10.1128/JVI.79.19.12447-12454.2005
   Naito T, 2009, ANTIMICROB AGENTS CH, V53, P1013, DOI 10.1128/AAC.01211-08
   Porotto M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001168
   Porotto M, 2009, J VIROL, V83, P6947, DOI 10.1128/JVI.00416-09
   Qi Z, 2008, J BIOL CHEM, V283, P30376, DOI 10.1074/jbc.M804672200
   Shi WG, 2012, CHEM COMMUN, V48, P11579, DOI 10.1039/c2cc35973a
   Wang C, 2013, J MED CHEM, V56, P2527, DOI 10.1021/jm3018964
   Wang Y, 2010, BIOORG MED CHEM LETT, V20, P189, DOI 10.1016/j.bmcl.2009.10.139
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]
   Zhou GY, 2011, J MED CHEM, V54, P7220, DOI 10.1021/jm200791z
NR 42
TC 6
Z9 6
U1 1
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUN
PY 2014
VL 69
IS 6
BP 1537
EP 1545
DI 10.1093/jac/dku010
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA AH9ZU
UT WOS:000336506300015
PM 24500189
OA gold
DA 2018-01-05
ER

PT J
AU Qiu, X
   Zhao, GD
   Tang, LQ
   Liu, ZP
AF Qiu, Xin
   Zhao, Guo-Dong
   Tang, Long-Qiang
   Liu, Zhao-Peng
TI Design and synthesis of highly potent HIV-1 protease inhibitors with
   novel isosorbide-derived P2 ligands
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1 protease inhibitors; Isosorbides; P2 ligand; Drug-resistant;
   Design; Synthesis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANCE; BIOLOGICAL EVALUATION;
   DISCOVERY; TMC114; BINDING
AB The design, synthesis, and biological evaluation of a series of six HIV-1 protease inhibitors incorporating isosorbide moiety as novel P2 ligands are described. All the compounds are very potent HIV-1 protease inhibitors with IC50 values in the nanomolar or picomolar ranges (0.05-0.43 nM). Molecular docking studies revealed the formation of an extensive hydrogen-bonding network between the inhibitor and the active site. Particularly, the isosorbide-derived P2 ligand is involved in strong hydrogen bonding interactions with the backbone atoms. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Qiu, Xin; Zhao, Guo-Dong; Tang, Long-Qiang; Liu, Zhao-Peng] Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Inst Med Chem,Key Lab Chem Biol, Jinan 250012, Shandong, Peoples R China.
RP Liu, ZP (reprint author), Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Inst Med Chem,Key Lab Chem Biol, Jinan 250012, Shandong, Peoples R China.
EM liuzhaop@sdu.edu.cn
CR Ali A, 2006, J MED CHEM, V49, P7342, DOI 10.1021/jm060666p
   Ali A, 2010, VIRUSES-BASEL, V2, P2509, DOI 10.3390/v2112509
   Anderson Jeffrey, 2009, V189, P85
   Armbruster Christine, 2008, Anti-Infective Agents in Medicinal Chemistry, V7, P201, DOI 10.2174/187152108784911296
   Brenner BG, 2002, EXPERT OPIN BIOL TH, V2, P751, DOI 10.1517/14712598.2.7.751                                                        
   Carolan CG, 2008, J MED CHEM, V51, P6400, DOI 10.1021/jm800564y
   DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8                                                   
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Gao BL, 2011, BIOORG MED CHEM LETT, V21, P3730, DOI 10.1016/j.bmcl.2011.04.070
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   Ghosh AK, 2004, J ORG CHEM, V69, P7822, DOI 10.1021/jo049156y
   Ghosh AK, 1996, J MED CHEM, V39, P3278, DOI 10.1021/jm960128k
   Ghosh AK, 2008, J MED CHEM, V51, P6021, DOI 10.1021/jm8004543
   Ghosh AK, 2008, ACCOUNTS CHEM RES, V41, P78, DOI 10.1021/ar7001232
   Johnson Victoria A, 2007, Top HIV Med, V15, P119
   Johnson Victoria A, 2011, Top Antivir Med, V19, P156
   King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004
   Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007
   OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153
   Qiu X, 2011, CURR MED CHEM, V18, P4513, DOI 10.2174/092986711797287566                                                      
   Spivak AM, 2010, AIDS, V24, P1603, DOI 10.1097/QAD.0b013e32832f3155
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Tamaki M, 2001, J ORG CHEM, V66, P3593, DOI 10.1021/jo005625u
   Thaisrivongs S, 1999, BIOPOLYMERS, V51, P51
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
   Tsantrizos YS, 2008, ACCOUNTS CHEM RES, V41, P1252, DOI 10.1021/ar8000519
   UNAIDS, 2010, UNAIDS REP GLOB AIDS
   Weber IT, 2009, VIRUSES-BASEL, V1, P1110, DOI 10.3390/v1031110
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
NR 29
TC 5
Z9 5
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 1
PY 2014
VL 24
IS 11
BP 2465
EP 2468
DI 10.1016/j.bmcl.2014.04.008
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA AG6GY
UT WOS:000335518300016
PM 24767846
DA 2018-01-05
ER

PT J
AU Dengler, EC
   Alberti, LA
   Bowman, BN
   Kerwin, AA
   Wilkerson, JL
   Moezzi, DR
   Limanovich, E
   Wallace, JA
   Milligan, ED
AF Dengler, Ellen C.
   Alberti, Lauren A.
   Bowman, Brandi N.
   Kerwin, Audra A.
   Wilkerson, Jenny L.
   Moezzi, Daniel R.
   Limanovich, Eugene
   Wallace, James A.
   Milligan, Erin D.
TI Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a
   transgene adjuvant to control chronic neuropathic pain
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE M2 polarized; Cytokine; Interleukin-1 beta; Sciatic nerve;
   Immunofluorescence microscopy; Intrathecal injection; Dexamethasone;
   Allodynia; Rat
ID PERIPHERAL-NERVE INJURY; DORSAL-ROOT GANGLIA; MESOPOROUS SILICA
   NANOPARTICLES; HIV-1 ENVELOPE GLYCOPROTEIN; ANTIGEN-PRESENTING CELLS;
   ACUTE LUNG INJURY; DENDRITIC CELLS; ALTERNATIVE ACTIVATION; CORD-INJURY;
   INTERLEUKIN-10 RECEPTOR
AB Background: Peri-spinal subarachnoid (intrathecal; i.t.) injection of non-viral naked plasmid DNA encoding the anti-inflammatory cytokine, IL-10 (pDNA-IL-10) suppresses chronic neuropathic pain in animal models. However, two sequential i.t. pDNA injections are required within a discrete 5 to 72-hour period for prolonged efficacy. Previous reports identified phagocytic immune cells present in the peri-spinal milieu surrounding the i.t injection site that may play a role in transgene uptake resulting in subsequent IL-10 transgene expression.
   Methods: In the present study, we aimed to examine whether factors known to induce pro-phagocytic anti-inflammatory properties of immune cells improve i.t. IL-10 transgene uptake using reduced naked pDNA-IL-10 doses previously determined ineffective. Both the synthetic glucocorticoid, dexamethasone, and the hexose sugar, D-mannose, were factors examined that could optimize i.t. pDNA-IL-10 uptake leading to enduring suppression of neuropathic pain as assessed by light touch sensitivity of the rat hindpaw (allodynia).
   Results: Compared to dexamethasone, i.t. mannose pretreatment significantly and dose-dependently prolonged pDNA-IL-10 pain suppressive effects, reduced spinal IL-1 beta and enhanced spinal and dorsal root ganglia IL-10 immunoreactivity. Macrophages exposed to D-mannose revealed reduced proinflammatory TNF-alpha, IL-1 beta, and nitric oxide, and increased IL-10 protein release, while IL-4 revealed no improvement in transgene uptake. Separately, D- mannose dramatically increased pDNA-derived IL-10 protein release in culture supernatants. Lastly, a single i.t. co-injection of mannose with a 25-fold lower pDNA-IL-10 dose produced prolonged pain suppression in neuropathic rats.
   Conclusions: Peri-spinal treatment with D-mannose may optimize naked pDNA-IL-10 transgene uptake for suppression of allodynia, and is a novel approach to tune spinal immune cells toward pro-phagocytic phenotype for improved non-viral gene therapy.
C1 [Dengler, Ellen C.; Alberti, Lauren A.; Bowman, Brandi N.; Kerwin, Audra A.; Wilkerson, Jenny L.; Moezzi, Daniel R.; Wallace, James A.; Milligan, Erin D.] Univ New Mexico, Hlth Sci Ctr, UNM Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA.
   [Limanovich, Eugene] Univ New Mexico, Hlth Sci Ctr, Sch Med, Dept Anesthesiol & Crit Care Med, Albuquerque, NM 87106 USA.
   [Milligan, Erin D.] Univ New Mexico, Hlth Sci Ctr, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA.
RP Milligan, ED (reprint author), Univ New Mexico, Hlth Sci Ctr, UNM Sch Med, Dept Neurosci, 1 Univ New Mexico, Albuquerque, NM 87131 USA.
EM EMilligan@salud.unm.edu
FU National Science Foundation IGERT grant: Integrating Nanotechnology with
   Cell Biology and Neuroscience [DGE 0549500]; National Institute on Drug
   Abuse [RO1 DA018156]; UNM SOM Office of Research, Research Allocations
   Committee Award
FX The authors would to thank Professors Linda C Saland and James Wallace
   (Department of Neurosciences, University of New Mexico, Albuquerque, New
   Mexico) for their expertise in immunohistochemical procedures. This work
   was funded by a National Science Foundation IGERT grant: Integrating
   Nanotechnology with Cell Biology and Neuroscience (DGE 0549500), and a
   grant from the National Institute on Drug Abuse: # RO1 DA018156 and the
   UNM SOM Office of Research, Research Allocations Committee Award.
CR Abraham KE, 2004, NEUROSCIENCE, V124, P945, DOI 10.1016/j.neuroscience.2004.01.004
   Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Bouhassira D, 2008, PAIN, V136, P380, DOI 10.1016/j.pain.2007.08.013
   BRAUN JS, 1993, CELL TISSUE RES, V273, P209, DOI 10.1007/BF00312822
   Burudi EME, 1999, GLIA, V25, P44, DOI 10.1002/(SICI)1098-1136(19990101)25:1<44::AID-GLIA5>3.0.CO;2-C
   Burudi EME, 2001, CELL TISSUE RES, V303, P307, DOI 10.1007/s004410000311
   Cao L, 2008, EUR J IMMUNOL, V38, P448, DOI [10.1002/eji.200737485, 10.1002/eji.2007374851]
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen Y, 2008, P NATL ACAD SCI USA, V105, P16773, DOI 10.1073/pnas.0801793105
   Cheng CF, 2014, PAIN, V155, P906, DOI 10.1016/j.pain.2014.01.010
   Chiang CY, 2011, NEUROSCIENTIST, V17, P303, DOI 10.1177/1073858410386801
   Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552                                                     
   Costigan M, 2009, J NEUROSCI, V29, P14415, DOI 10.1523/JNEUROSCI.4569-09.2009
   Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531
   Czimmerer Z, 2012, IMMUNOBIOLOGY, V217, P1301, DOI 10.1016/j.imbio.2012.08.270
   De Leo J. A., 2007, IMMUNE GLIAL REGULAT
   Dowdall T, 2005, PHARMACOL BIOCHEM BE, V80, P93, DOI 10.1016/j.pbb.2004.10.016
   East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7
   Echeverry S, 2011, J NEUROSCI, V31, P10819, DOI 10.1523/JNEUROSCI.1642-11.2011
   Echeverry S, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-16
   Engering AJ, 1997, ADV EXP MED BIOL, V417, P183
   Filla MS, 2011, INVEST OPHTH VIS SCI, V52, P2952, DOI 10.1167/iovs.10-6618
   Foey AD, 1998, J IMMUNOL, V160, P920
   Ghosh MC, 2009, BLOOD, V113, P575, DOI 10.1182/blood-2008-04-151803
   Ghosh TK, 2006, CELL IMMUNOL, V243, P48, DOI 10.1016/j.cellimm.2006.12.002
   Go A, 2013, BIOMOL THER, V21, P481, DOI 10.4062/biomolther.2013.076
   Gonzalez P, 2009, J NEUROPATH EXP NEUR, V68, P391, DOI 10.1097/NEN.0b013e31819dca30
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Goss James R, 2007, Expert Rev Neurother, V7, P487, DOI 10.1586/14737175.7.5.487
   Grace PM, 2014, NAT REV IMMUNOL, V14, P217, DOI 10.1038/nri3621
   Gratchev A, 2001, SKIN PHARMACOL APPL, V14, P272, DOI 10.1159/000056357
   GRUBBS FE, 1950, ANN MATH STAT, V21, P27, DOI 10.1214/aoms/1177729885                                                         
   HARVEY LO, 1986, BEHAV RES METH INSTR, V18, P623, DOI 10.3758/BF03201438
   Hatashita S, 2008, SPINE, V33, P1344, DOI 10.1097/BRS.0b013e3181733188
   Hirai T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064528
   Hu P, 2007, BRAIN BEHAV IMMUN, V21, P599, DOI 10.1016/j.bbi.2006.10.013
   Huang L, 1999, NONVIRAL VECTORS GEN
   Hughes TS, 2009, J GENE MED, V11, P782, DOI 10.1002/jgm.1364
   Hunt AE, 2002, CYTOKINE, V18, P295, DOI 10.1006/cyto.2002.1043
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kim MH, 2011, ACS NANO, V5, P3568, DOI 10.1021/nn103130q
   Koltzenburg M, 1999, TRENDS NEUROSCI, V22, P122, DOI 10.1016/S0166-2236(98)01302-2
   Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370
   Kossi J, 1999, EUR SURG RES, V31, P74, DOI 10.1159/000008623
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Lan YY, 2006, J IMMUNOL, V177, P5868, DOI 10.4049/jimmunol.177.9.5868                                                     
   Ledeboer A, 2003, J NEUROIMMUNOL, V136, P94, DOI 10.1016/S0165-2728(03)00031-6
   Ledeboer A, 2007, BRAIN BEHAV IMMUN, V21, P686, DOI 10.1016/j.bbi.2006.10.012
   Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540
   Leger T, 2011, J NEUROIMMUNOL, V234, P19, DOI 10.1016/j.jneuroim.2011.01.005
   Lewis CAB, 2009, GLIA, V57, P1410, DOI 10.1002/glia.20859
   Linehan SA, 2000, ADV EXP MED BIOL, V479, P1
   Lingnau M, 2007, HUM IMMUNOL, V68, P730, DOI 10.1016/j.humimm.2007.06.004
   Liu CY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054841
   Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618
   Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200                                                          
   Martinon F, 2009, ANNU REV IMMUNOL, V27, P229, DOI 10.1146/annurev.immunol.021908.132715
   McMaster A, 2008, NAT CLIN PRACT ENDOC, V4, P91, DOI 10.1038/ncpendmet0745
   McMenamin PG, 2003, CELL TISSUE RES, V313, P259, DOI 10.1007/s00441-003-0779-0
   Meinl E, 2008, J NEUROL SCI, V274, P42, DOI 10.1016/j.jns.2008.06.032
   Milligan ED, 2001, J NEUROSCI, V21, P2808
   Milligan ED, 2000, BRAIN RES, V861, P105, DOI 10.1016/S0006-8993(00)02050-3                                                   
   Milligan EM, 2007, IMMUNE GLIAL REGULAT
   Milligan ED, 2006, NEURON GLIA BIOL, V2, P293, DOI 10.1017/S1740925X07000488
   Milligan ED, 2006, PAIN, V126, P294, DOI 10.1016/j.pain.2006.07.009
   Milligan ED, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-9
   Milligan ED, 2012, NEUROMODULATION, V15, P520, DOI 10.1111/j.1525-1403.2012.00462.x
   Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533
   Miraucourt LS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001116
   MIZUNO T, 1994, BIOCHEM BIOPH RES CO, V205, P1907, DOI 10.1006/bbrc.1994.2893                                                          
   Molet J, 2013, EUR J PHARMACOL, V716, P129, DOI 10.1016/j.ejphar.2013.01.073
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Park IY, 2008, INT J PHARM, V359, P280, DOI 10.1016/j.ijpharm.2008.04.010
   Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604
   Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007
   PONTOW SE, 1992, INT REV CYTOL, V137B, P221
   Racz I, 2008, J NEUROSCI, V28, P12136, DOI 10.1523/JNEUROSCI.3402-08.2008
   REST RF, 1988, J LEUKOCYTE BIOL, V43, P158
   Robinson I, 2005, NEUROSCI LETT, V373, P125, DOI 10.1016/j.neulet.2004.09.078
   Ruan GX, 2014, ACTA BIOMATER, V10, P1847, DOI 10.1016/j.actbio.2014.01.012
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Schreiber KL, 2008, NEUROSCI LETT, V440, P63, DOI 10.1016/j.neulet.2008.05.044
   Sloane EM, 2009, GENE THER, V16, P470, DOI 10.1038/gt.2009.21
   Sloane EM, 2009, GENE THER, V1, P1
   Soderquist RG, 2010, J BIOMED MATER RES A, V93A, P1169, DOI 10.1002/jbm.a.32611
   Soderquist RG, 2010, PHARM RES-DORDR, V27, P841, DOI 10.1007/s11095-010-0077-y
   Spataro LE, 2004, J PAIN, V5, P392, DOI 10.1016/j.jpain.2004.06.006
   Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9                                                   
   STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287                                                           
   Sun X, 2012, INT J NANOMED, V7, P2929, DOI 10.2147/IJN.S31760
   Sweitzer SM, 2002, PAIN, V100, P163, DOI 10.1016/S0304-3959(02)00257-9
   Takeda M, 2009, NEUROSCI BIOBEHAV R, V33, P784, DOI 10.1016/j.neubiorev.2008.12.005
   Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942                                                          
   Terayama R, 2007, NEUROSCIENCE, V148, P175, DOI 10.1016/j.neuroscience.2007.05.037
   TIETJEN GL, 1972, TECHNOMETRICS, V14, P583, DOI 10.2307/1267287                                                                 
   Torrance N, 2006, J PAIN, V7, P281, DOI 10.1016/j.jpain.2005.11.008
   Treutwein B, 1999, PERCEPT PSYCHOPHYS, V61, P87, DOI 10.3758/BF03211951                                                              
   Tsuruta T, 2013, MICROBIOLOGYOPEN, V2, P610, DOI 10.1002/mbo3.99
   van Hecke O, 2013, PAIN, V155, P654
   Viguerie N, 2012, PHYSIOL GENOMICS, V44, P141, DOI 10.1152/physiolgenomics.00032.2011
   Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35
   Wallace JA, 1996, CELL MOL NEUROBIOL, V16, P625, DOI 10.1007/BF02151901
   Wang X, 2005, MOL THER, V12, P314, DOI 10.1016/j.ymthe.2005.03.032
   Wang YC, 2005, J VIROL, V79, P14355, DOI 10.1128/JVI.79.22.14355-14370.2005
   White FA, 2007, P NATL ACAD SCI USA, V104, P20151, DOI 10.1073/pnas.0709250104
   Wilkerson JL, 2012, BRAIN BEHAV, V2, P155, DOI 10.1002/brb3.44
   Wilkerson JL, 2012, PAIN, V153, P1091, DOI 10.1016/j.pain.2012.02.015
   WILLENBORG DO, 1992, IMMUNOL CELL BIOL, V70, P369, DOI 10.1038/icb.1992.49
   Wolfe D, 2009, GENE THER, V16, P455, DOI 10.1038/gt.2009.17
   Wu Z, 2005, J NEUROIMMUNOL, V167, P90, DOI 10.1016/j.jneuroim.2005.06.025
   Xu XL, 2008, INFLAMM RES, V57, P104, DOI 10.1007/s00011-007-7037-y
   Xu XL, 2010, EUR J PHARMACOL, V641, P229, DOI 10.1016/j.ejphar.2010.05.021
   Yang H, 2006, J NEUROSCI, V26, P2157, DOI 10.1523/JNEUROSCI.4070-05.2005
   Yew Nelson S, 2004, Expert Opin Drug Deliv, V1, P115, DOI 10.1517/17425247.1.1.115
   Yin LC, 2013, ADV MATER, V25, P3063, DOI 10.1002/adma.201205088
   Zhang J, 2006, J NEUROCHEM, V97, P772, DOI 10.1111/j.1471-4159.2006.03746.x
   Zhang J, 2007, J NEUROSCI, V27, P12396, DOI 10.1523/JNEUROSCI.3016-07.2007
NR 120
TC 10
Z9 10
U1 2
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD MAY 21
PY 2014
VL 11
AR 92
DI 10.1186/1742-2094-11-92
PG 21
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA AI9MM
UT WOS:000337256700001
PM 24884664
OA gold
DA 2018-01-05
ER

PT J
AU Ogunniyi, AO
   Thomas, BA
   Politano, TJ
   Varadarajan, N
   Landais, E
   Poignard, P
   Walker, BD
   Kwon, DS
   Love, JC
AF Ogunniyi, Adebola O.
   Thomas, Brittany A.
   Politano, Timothy J.
   Varadarajan, Navin
   Landais, Elise
   Poignard, Pascal
   Walker, Bruce D.
   Kwon, Douglas S.
   Love, J. Christopher
TI Profiling human antibody responses by integrated single-cell analysis
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 4th Vaccine Technology Conference in the Engineering Conferences
   International (ECI)
CT 4th Vaccine Technology Conference in the Engineering Conferences
   International (ECI)
CY MAY 20-24, 2012
CY MAY 20-24, 2012
CL Albufeira, PORTUGAL
CL Albufeira, PORTUGAL
DE Microengraving; Humoral responses; Immune profiling; Plasma and memory B
   cells analysis; Nanowells
ID HUMAN MONOCLONAL-ANTIBODIES; HUMAN PERIPHERAL-BLOOD; B-CELLS;
   NEUTRALIZING ANTIBODIES; SECRETING CELLS; RT-PCR; ANTIGEN; GENERATION;
   CLONING; VIRUS
AB Comprehensive characterization of the antigen-specific B cells induced during infections or following vaccination would facilitate the discovery of novel antibodies and inform how interventions shape protective humoral responses. The analysis of human B cells and their antibodies has been performed using flow cytometry to evaluate memory B cells and expanded plasmablasts, while microtechnologies have also provided a useful tool to examine plasmablasts/plasma cells after vaccination. Here we present an integrated analytical platform, using arrays of subnanoliter wells (nanowells), for constructing detailed profiles for human B cells comprising the immunophenotypes of these cells, the distribution of isotypes of the secreted antibodies, the specificity and relative affinity for defined antigens, and for a subset of cells, the genes encoding the heavy and light chains. The approach combines on-chip image cytometry, microengraving, and single-cell RT-PCR. Using clinical samples from HIV-infected subjects, we demonstrate that the method can identify antigen-specific neutralizing antibodies, is compatible with both plasmablasts/plasma cells and activated memory B cells, and is well-suited for characterizing the limited numbers of B cells isolated from tissue biopsies (e.g., colon biopsies). The technology should facilitate detailed analyses of human humoral responses for evaluating vaccines and their ability to raise protective antibody responses across multiple anatomical compartments. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Ogunniyi, Adebola O.; Thomas, Brittany A.; Politano, Timothy J.; Love, J. Christopher] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Varadarajan, Navin] Univ Houston, Dept Chem & Biomol Engn, Houston, TX 77204 USA.
   [Landais, Elise; Poignard, Pascal] Scripps Res Inst, Int AIDS Vaccine Initiat, La Jolla, CA 92037 USA.
   [Walker, Bruce D.; Kwon, Douglas S.; Love, J. Christopher] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Walker, Bruce D.; Kwon, Douglas S.; Love, J. Christopher] Harvard Univ, Cambridge, MA 02139 USA.
RP Love, JC (reprint author), MIT, Koch Inst Integrat Canc Res, Dept Chem Engn, 77 Massachusetts Ave,Bldg 76-253, Cambridge, MA 02139 USA.
EM clove@mit.edu
RI poignard, pascal/N-6678-2013
OI Varadarajan, Navin/0000-0001-7524-8228
FU W.M. Keck Foundation; IAVI Innovation award; NIH/NIAID [U19AI090970];
   UNCF/Merck Graduate Research Dissertation Fellowship
FX We thank Dr. Elizabeth Bradshaw, Kenneth M. Law and Tomoyuki Hongo for
   helpful discussions and assistance with optimization of conditions for
   memory B cell activation and single-cell RT-PCR. This research was
   supported by the W.M. Keck Foundation, an IAVI Innovation award, and the
   NIH/NIAID (U19AI090970). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institute of Allergy And Infectious Diseases or the National
   Institutes of Health. A.O.O. was supported by UNCF/Merck Graduate
   Research Dissertation Fellowship. J.C.L. is a Camille Dreyfus
   Teacher-Scholar.
CR Bradshaw EM, 2007, J IMMUNOL, V178, P547, DOI 10.4049/jimmunol.178.1.547                                                      
   Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316
   Bryant VL, 2007, J IMMUNOL, V179, P8180, DOI 10.4049/jimmunol.179.12.8180                                                    
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Choi JH, 2010, BIOTECHNOL PROGR, V26, P888, DOI 10.1002/btpr.374
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   de Tute RM, 2007, LEUKEMIA, V21, P2046, DOI 10.1038/sj.leu.2404815
   Debs B. E., 2012, P NATL ACAD SCI USA, V109, p11 570
   Hendershot LM, 2003, MOL BIOL B CELLS
   International HIV Controllers Study, 2010, SCIENCE, V330, P1551
   Jin A, 2009, NAT MED, V15, P1088, DOI 10.1038/nm.1966
   Kindt TJ, 2007, KUBYS IMMUNOLOGY
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Love JC, 2006, NAT BIOTECHNOL, V24, P703, DOI 10.1038/nbt1210
   Love KR, 2010, BIOTECHNOL BIOENG, V106, P319, DOI 10.1002/bit.22688
   Ogunniyi AO, 2009, NAT PROTOC, V4, P767, DOI 10.1038/nprot.2009.40
   Perez-Andres M, 2010, CYTOM PART B-CLIN CY, V78B, pS47, DOI 10.1002/cyto.b.20547
   Scamurra RW, 2002, J IMMUNOL, V169, P4008, DOI 10.4049/jimmunol.169.7.4008                                                     
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Shacklett Barbara L., 2009, V485, P347, DOI 10.1007/978-1-59745-170-3_23
   Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3
   Story CM, 2008, P NATL ACAD SCI USA, V105, P17902, DOI 10.1073/pnas.0805470105
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Varadarajan N, P NATL ACAD SCI  FEB
   Vollers SS, 2008, IMMUNOLOGY, V123, P305, DOI 10.1111/j.1365-2567.2007.02801.x
   Wang XW, 2000, J IMMUNOL METHODS, V244, P217, DOI 10.1016/S0022-1759(00)00260-X
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
   Zwick MB, 2008, NAT BIOTECHNOL, V26, P886, DOI 10.1038/nbt0808-886
NR 31
TC 9
Z9 9
U1 3
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 19
PY 2014
VL 32
IS 24
SI SI
BP 2866
EP 2873
DI 10.1016/j.vaccine.2014.02.020
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2RD
UT WOS:000336704900018
PM 24602776
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kim, JY
   Ahn, JH
   Moon, DI
   Park, TJ
   Lee, SY
   Choi, YK
AF Kim, Jee-Yeon
   Ahn, Jae-Hyuk
   Moon, Dong-Il
   Park, Tae Jung
   Lee, Sang Yup
   Choi, Yang-Kyu
TI Multiplex electrical detection of avian influenza and human
   immunodeficiency virus with an underlap-embedded silicon nanowire
   field-effect transistor
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Electrical biosensor; Field-effect transistor; Under lap field-effect
   transistor; Avian influenza; Human immunodeficiency virus; Label-free
   detection
ID PROTEIN-DETECTION; BIOSENSORS; DEVICE; SYSTEM
AB The label-free electrical detection of the binding of antibodies and antigens of avian influenza (Al) and human immunodeficiency (HIV) viruses is demonstrated through an underlap-embedded silicon (Si) nanowire field-effect transistor. The proposed sensor was fabricated on a silicon bulk wafer by a topdown process. Specifically, a Si nanowire was fabricated by a combined isotropic and anisotropic patterning technique, which is one route plasma etching process. The sensor was fabricated by a selfaligned process to the gate with tilted implantation, and it allows precise control of the underlap region. This was problematic in earlier underlap field-effect transistors fabricated by a conventional gate-last process. As a sensing metric to detect the binding of a targeted antibody, the transfer characteristic change was traced. Before and after differences between the antibody binding results were caused by changes in the channel potential on the underlap region due to the charge effect arising from the biomolecules; this is also supported by a simulation. Furthermore, the multiplex detection of Al and HIV is demonstrated, showing distinctive selectivity in each case. Thus, the proposed device has inherent benefits for the label-free, electrical, and multiplex detection of biomolecules. Moreover, its processes are compatible with commercialized technology presently used to fabricate semiconductor devices. This advantage is attractive for those involved in the construction of a point-of-care testing (POCT) system on a chip involving simple, low-cost and low-risk fabrication processes of novel structures and materials. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kim, Jee-Yeon; Ahn, Jae-Hyuk; Moon, Dong-Il; Choi, Yang-Kyu] Korea Adv Inst Sci & Technol, Dept Elect Engn, Taejon 305701, South Korea.
   [Park, Tae Jung] Chung Ang Univ, Dept Chem, Seoul 156756, South Korea.
   [Lee, Sang Yup] Korea Adv Inst Sci & Technol, Ctr Syst & Synthet Biotechnol, Bioinformat Res Ctr, Dept Chem & Biomol Engn,Dept Biol Sci,Dept Bio &, Taejon 305701, South Korea.
   [Lee, Sang Yup] Korea Adv Inst Sci & Technol, Inst BioCentury, Taejon 305701, South Korea.
RP Choi, YK (reprint author), Korea Adv Inst Sci & Technol, Dept Elect Engn, 291 Daehak Ro, Taejon 305701, South Korea.
EM ykchoi@ee.kaist.ac.kr
RI Lee, Sang Yup/C-1526-2011
OI Lee, Sang Yup/0000-0003-0599-3091
FU Center for Integrated Smart Sensors; Ministry of Education, Science and
   Technology as Global Frontier Project [CISS-2011-0031848]; National
   Research and Development Program for the development of biomedical
   function monitoring biosensors [2005-2001274]
FX This work was supported by the Center for Integrated Smart Sensors
   funded by the Ministry of Education, Science and Technology as Global
   Frontier Project (CISS-2011-0031848) and the National Research and
   Development Program (2005-2001274) for the development of biomedical
   function monitoring biosensors.
CR Ahn JH, 2012, IEEE T ELECTRON DEV, V59, P2243, DOI 10.1109/TED.2012.2200105
   Baek DJ, 2012, IEEE T ELECTRON DEV, V59, P2507, DOI 10.1109/TED.2012.2201484
   Bausells J, 1999, SENSOR ACTUAT B-CHEM, V57, P56, DOI 10.1016/S0925-4005(99)00135-5
   BERGVELD P, 1991, BIOSENS BIOELECTRON, V6, P55, DOI 10.1016/0956-5663(91)85009-L
   BERGVELD P, 1970, IEEE T BIO-MED ENG, VBM17, P70, DOI 10.1109/TBME.1970.4502688                                                       
   BOUSSE L, 1988, IEEE ELECTR DEVICE L, V9, P44, DOI 10.1109/55.20408
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Gu B, 2009, SMALL, V21, P2407
   Jakobson CG, 2002, IEEE SENS J, V2, P279, DOI 10.1109/JSEN.2002.802237
   Kim CH, 2013, BIOSENS BIOELECTRON, V41, P322, DOI 10.1016/j.bios.2012.08.047
   Lee KW, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3291617
   Moon DI, 2011, IEEE ELECTR DEVICE L, V32, P452, DOI 10.1109/LED.2011.2106758
   SCHASFOORT RBM, 1990, BIOSENS BIOELECTRON, V5, P103, DOI 10.1016/0956-5663(90)80002-U
   SCHASFOORT RBM, 1990, ANAL CHIM ACTA, V238, P323, DOI 10.1016/S0003-2670(00)80554-1
   Singh N, 2006, IEEE ELECTR DEVICE L, V27, P383, DOI 10.1109/LED.2006.873381
   Uslu F, 2004, BIOSENS BIOELECTRON, V19, P1723, DOI 10.1016/j.bios.2004.01.019
   Yuan H, 2011, BIOSENS BIOELECTRON, V28, P434, DOI 10.1016/j.bios.2011.07.062
NR 17
TC 12
Z9 12
U1 2
U2 118
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAY 15
PY 2014
VL 55
BP 162
EP 167
DI 10.1016/j.bios.2013.12.014
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AC3MO
UT WOS:000332426100025
PM 24374298
DA 2018-01-05
ER

PT J
AU Zhou, WJ
   Gong, X
   Xiang, Y
   Yuan, R
   Chai, YQ
AF Zhou, Wenjiao
   Gong, Xue
   Xiang, Yun
   Yuan, Ruo
   Chai, Yaqin
TI Quadratic recycling amplification for label-free and sensitive visual
   detection of HIV DNA
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE HIV DNA; Exonuclease III-assisted amplification; DNAzyme; Visual
   detection
ID SELECTIVE COLORIMETRIC DETECTION; GOLD NANOPARTICLES; NUCLEIC-ACIDS;
   LOGIC GATES; DNAZYME; APTAMERS; ENZYMES; DESIGN; ASSAY
AB Visual detections have attracted great research attentions recently due to their convenient monitoring of the target analytes without using any advanced instruments. However, achieving visual detection of trace amounts of biomolecules with PCR-like sensitivity remains a major challenge. In current work, we describe a new quadratic signal amplification strategy for sensitive visual detection of HIV DNA biomarkers based on exonuclease III (Exo III)-assisted DNA recycling amplification and DNAzymes. The presence of the target HIV DNA leads to two independent and simultaneous DNA recycling processes to achieve quadratic signal amplification with the assistance of Exo III. This quadratic signal amplification results in catalytic cleavage of the G-quadruplex sequence-locked hairpin probes to release numerous active G-quadruplex sequences, which further associate with hemin to form DNAzymes and cause significantly intensified color change for sensitive and visual detection of HIV DNA down to 2.5 pM. The proposed visual detection method employs un-modified hairpin DNA as probes, avoids using any complex and expensive instruments for signal transduction and is essentially simple. This method also shows single-base mismatch discrimination capability as well. All these features make our developed DNA detection method holds great potential for visual monitoring of various DNA biomarkers at ultralow levels with careful and proper probe designs. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Zhou, Wenjiao; Gong, Xue; Xiang, Yun; Yuan, Ruo; Chai, Yaqin] Southwest Univ, Sch Chem & Chem Engn, Minist Educ, Key Lab Luminescence & Real Time Anal, Chongqing 400715, Peoples R China.
RP Xiang, Y (reprint author), Southwest Univ, Sch Chem & Chem Engn, Minist Educ, Key Lab Luminescence & Real Time Anal, Chongqing 400715, Peoples R China.
EM yunatswu@swu.edu.cn
FU NSFC [21275004, 20905062, 21075100, 21275119]; New Century Excellent
   Talent Program of MOE [NCET-12-0932]
FX This work was supported by NSFC (Nos. 21275004, 20905062, 21075100 and
   21275119) and the New Century Excellent Talent Program of MOE
   (NCET-12-0932).
CR Aguilar ZP, 2003, ANAL CHEM, V75, P3890, DOI 10.1021/ac026211z
   Bi S, 2012, CHEM COMMUN, V48, P1018, DOI 10.1039/c1cc16684k
   Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Deng MG, 2008, J AM CHEM SOC, V130, P13095, DOI 10.1021/ja803507d
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Fu RZ, 2011, ANAL CHEM, V83, P494, DOI 10.1021/ac102719x
   Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102
   Ghosh SK, 2007, CHEM REV, V107, P4797, DOI 10.1021/cr0680282
   Laromaine A, 2007, J AM CHEM SOC, V129, P4156, DOI 10.1021/ja0706504
   Lei JP, 2012, CHEM SOC REV, V41, P2122, DOI 10.1039/c1cs15274b
   Li J, 2011, TALANTA, V85, P91, DOI 10.1016/j.talanta.2011.03.042
   Li T, 2007, CHEM COMMUN, P4209, DOI 10.1039/b712165b
   Li T, 2009, CHEM-EUR J, V15, P3347, DOI 10.1002/chem.200900056
   Li T, 2009, CHEM-EUR J, V15, P1036, DOI 10.1002/chem.200801282
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P90, DOI 10.1002/anie.200502589
   Moshe M, 2009, NANO LETT, V9, P1196, DOI 10.1021/nl803887y
   Nam W.M., 2004, J AM CHEM SOC, V126, P5932
   Patolsky F, 1999, LANGMUIR, V15, P3703, DOI 10.1021/la981682v                                                               
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   Sen D, 1998, CURR OPIN CHEM BIOL, V2, P680, DOI 10.1016/S1367-5931(98)80103-8
   Shimron S, 2012, ANAL CHEM, V84, P1042, DOI 10.1021/ac202643y
   Song YL, 2012, CHEM COMMUN, V48, P576, DOI 10.1039/c1cc15777a
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Travascio P, 1998, CHEM BIOL, V5, P505, DOI 10.1016/S1074-5521(98)90006-0
   Wang J, 2005, SMALL, V1, P1036, DOI 10.1002/smll.200500214
   Wang N, 2011, CHEM COMMUN, V47, P1728, DOI 10.1039/c0cc04182c
   Xiao Y, 2004, J AM CHEM SOC, V126, P7430, DOI 10.1021/ja031875r
   Zhang Y, 2012, ANAL CHEM, V84, P9544, DOI 10.1021/ac3024087
   Zhao J, 2011, CHEM COMMUN, V47, P5262, DOI 10.1039/c1cc10186b
   Zhou WH, 2009, CHEM COMMUN, P6845, DOI 10.1039/b916217h
   Zhu JB, 2011, BIOMATERIALS, V32, P7318, DOI 10.1016/j.biomaterials.2011.06.040
NR 33
TC 25
Z9 26
U1 13
U2 157
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAY 15
PY 2014
VL 55
BP 220
EP 224
DI 10.1016/j.bios.2013.12.021
PG 5
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AC3MO
UT WOS:000332426100034
PM 24384263
DA 2018-01-05
ER

PT J
AU Jaworski, E
   Saifuddin, M
   Sampey, G
   Shafagati, N
   Van Duyne, R
   Iordanskiy, S
   Kehn-Hall, K
   Liotta, L
   Petricoin, E
   Young, M
   Lepene, B
   Kashanchi, F
AF Jaworski, Elizabeth
   Saifuddin, Mohammed
   Sampey, Gavin
   Shafagati, Nazly
   Van Duyne, Rachel
   Iordanskiy, Sergey
   Kehn-Hall, Kylene
   Liotta, Lance
   Petricoin, Emanuel, III
   Young, Mary
   Lepene, Benjamin
   Kashanchi, Fatah
TI The Use of Nanotrap Particles Technology in Capturing HIV-1 Virions and
   Viral Proteins from Infected Cells
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; HYDROGEL
   PARTICLES; RESIDUAL HIV-1; P24 ANTIGEN; TAT PROTEIN; PLASMA; BIOMARKER;
   EXOSOMES; RNA
AB HIV-1 infection results in a chronic but incurable illness since long-term HAART can keep the virus to an undetectable level. However, discontinuation of therapy rapidly increases viral burden. Moreover, patients under HAART frequently develop various metabolic disorders and HIV-associated neuronal disease. Today, the main challenge of HIV-1 research is the elimination of the residual virus in infected individuals. The current HIV-1 diagnostics are largely comprised of serological and nucleic acid based technologies. Our goal is to integrate the nanotrap technology into a standard research tool that will allow sensitive detection of HIV-1 infection. This study demonstrates that majority of HIV-1 virions in culture supernatants and Tat/Nef proteins spiked in culture medium can be captured by nanotrap particles. To determine the binding affinities of different baits, we incubated target molecules with nanotrap particles at room temperature. After short sequestration, materials were either eluted or remained attached to nanotrap particles prior to analysis. The unique affinity baits of nanotrap particles preferentially bound HIV-1 materials while excluded albumin. A high level capture of Tat or Tat peptide by NT082 and NT084 particles was measured by western blot (WB). Intracellular Nef protein was captured by NT080, while membrane-associated Nef was captured by NT086 and also detected by WB. Selective capture of HIV-1 particles by NT073 and NT086 was measured by reverse transcriptase assay, while capture of infectious HIV-1 by these nanoparticles was demonstrated by functional transactivation in TZM-bl cells. We also demonstrated specific capture of HIV-1 particles and exosomes-containing TAR-RNA in patients' serum by NT086 and NT082 particles, respectively, using specific qRT-PCR. Collectively, our data indicate that certain types of nanotrap particles selectively capture specific HIV-1 molecules, and we propose to use this technology as a platform to enhance HIV-1 detection by concentrating viral proteins and infectious virions from infected samples.
C1 [Jaworski, Elizabeth; Saifuddin, Mohammed; Sampey, Gavin; Shafagati, Nazly; Van Duyne, Rachel; Iordanskiy, Sergey; Kehn-Hall, Kylene; Kashanchi, Fatah] George Mason Univ, Natl Ctr Biodefense & Infect Dis, Manassas, VA 20110 USA.
   [Van Duyne, Rachel] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
   [Liotta, Lance; Petricoin, Emanuel, III] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA.
   [Young, Mary] Georgetown Univ, Div Infect Dis, Washington, DC USA.
   [Lepene, Benjamin] Ceres Nanosci, Manassas, VA USA.
RP Kashanchi, F (reprint author), George Mason Univ, Natl Ctr Biodefense & Infect Dis, Manassas, VA 20110 USA.
EM fkashanc@gmu.edu
RI Kehn-Hall, Kylene/I-5752-2013
OI Kehn-Hall, Kylene/0000-0001-8036-7213
FU National Institutes of Health [AI070740]; National Institute of Allergy
   and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994,
   UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development [UO1-HD-32632]
FX Funding provided by National Institutes of Health grant AI070740 to FK.
   The WIHS was funded by the National Institute of Allergy and Infectious
   Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
   UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (UO1-HD-32632).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agbottah E, 2006, VIROLOGY, V345, P373, DOI 10.1016/j.virol.2005.09.062
   Deminice R, 2013, NUTRITION, V29, P1326, DOI 10.1016/j.nut.2013.04.017
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106
   DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733
   Dreux M, 2012, CELL HOST MICROBE, V12, P558, DOI 10.1016/j.chom.2012.08.010
   Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
   Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010
   ENSOLI B, 1993, J VIROL, V67, P277
   Feleke Yeweyenhareg, 2012, Ethiop Med J, V50, P221
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Fields BN, 2013, FIELDS VIROLOGY
   Fredolini C, 2010, AAPS J, V12, P504, DOI 10.1208/s12248-010-9211-3
   Fredolini C, 2009, DRUG TEST ANAL, V1, P447, DOI 10.1002/dta.96
   Gaardbo JC, 2012, AIDS RES TREAT, V2012
   GIANAZZA E, 1982, BIOCHEM J, V203, P637, DOI 10.1042/bj2030637                                                               
   HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   The Henry J, 2014, HIV AIDS POL FACT SH
   Hu G, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.114
   Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110
   KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116
   KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673                                                          
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Kiage JN, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-50
   Kilembe W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037154
   Laird GM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003398
   LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0
   Leonard JA, 2011, J VIROL, V85, P6867, DOI 10.1128/JVI.00229-11
   Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014
   Longo C, 2011, EXP DERMATOL, V20, P29, DOI 10.1111/j.1600-0625.2010.01187.x
   Longo C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004763
   Luchini A, 2008, NANO LETT, V8, P350, DOI 10.1021/nl072174l
   Luchini A, 2009, J MATER CHEM, V19, P5071, DOI 10.1039/b822264a
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4                                                   
   Miller WC, 2010, CURR OPIN HIV AIDS, V5, P277, DOI 10.1097/COH.0b013e32833a0d3a
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Ndirangu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051493
   Okulicz JF, 2011, CURR OPIN HIV AIDS, V6, P163, DOI 10.1097/COH.0b013e328344f35e
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI 10.1172/JCI200421540
   Platt EJ, 2009, J VIROL, V83, P8289, DOI 10.1128/JVI.00709-09
   Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502
   Sahu GK, 2010, J VIROL, V84, P8348, DOI 10.1128/JVI.00362-10
   Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Shafagati N, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002296
   Tamburro D, 2011, J AM CHEM SOC, V133, P19178, DOI 10.1021/ja207515j
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   UNAIDS Report on the Global AIDS Epidemic, 2012, UNAIDS REP GLOB AIDS
   van der Sluis RM, 2013, CURR OPIN VIROL
   Varghese B, 2002, SEX TRANSM DIS, V29, P38, DOI 10.1097/00007435-200201000-00007
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Zetola NM, 2008, PUBLIC HEALTH REP, V123, P41, DOI 10.1177/00333549081230S306                                                      
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
NR 60
TC 19
Z9 19
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2014
VL 9
IS 5
AR e96778
DI 10.1371/journal.pone.0096778
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI1ZC
UT WOS:000336653300031
PM 24820173
OA gold
DA 2018-01-05
ER

PT J
AU Osminkina, LA
   Timoshenko, VY
   Shilovsky, IP
   Kornilaeva, GV
   Shevchenko, SN
   Gongalsky, MB
   Tamarov, KP
   Abramchuk, SS
   Nikiforov, VN
   Khaitov, MR
   Karamov, EV
AF Osminkina, L. A.
   Timoshenko, V. Yu
   Shilovsky, I. P.
   Kornilaeva, G. V.
   Shevchenko, S. N.
   Gongalsky, M. B.
   Tamarov, K. P.
   Abramchuk, S. S.
   Nikiforov, V. N.
   Khaitov, M. R.
   Karamov, E. V.
TI Porous silicon nanoparticles as scavengers of hazardous viruses
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Silicon nanoparticles; Human immunodeficiency virus; Respiratory
   syncytial virus; Antiviral treatment; Nanomedicine
ID RESPIRATORY SYNCYTIAL VIRUS; SILVER NANOPARTICLES; BIOMEDICAL
   APPLICATIONS; DRUG-DELIVERY; TOXICITY; MICROPARTICLES; NANOCRYSTALS;
   INFECTION; OXYGEN; PHOTOSENSITIZERS
AB We report that silicon nanoparticles (SiNPs) with typical sizes from 5 to 50 nm prepared by grinding of porous silicon can act as efficient scavengers of human immunodeficiency virus (HIV) and respiratory syncytial virus (RSV). In vitro studies have revealed a strong suppression of the viral activity in the presence of SiNPs with concentration above 0.1 and 0.01 mg/mL for HIV and RSV, respectively. The observed effect is explained by binding of the virions with SiNPs that is supposed to be universal for different enveloped viruses. Because of the cytotoxic concentration of SiNPs is of the order of 1 mg/mL, SiNPs can be proposed for applications in new harmless methods of antiviral treatment.
C1 [Osminkina, L. A.; Timoshenko, V. Yu; Shevchenko, S. N.; Gongalsky, M. B.; Tamarov, K. P.; Abramchuk, S. S.; Nikiforov, V. N.] Moscow MV Lomonosov State Univ, Dept Phys, Moscow 119991, Russia.
   [Shilovsky, I. P.; Khaitov, M. R.] FMBA, NRC Inst Immunol, Lab Nano & Biomed Technol, Moscow 115478, Russia.
   [Kornilaeva, G. V.; Karamov, E. V.] DI Ivanovskii Inst Virol, Moscow 123098, Russia.
RP Osminkina, LA (reprint author), Moscow MV Lomonosov State Univ, Dept Phys, Moscow 119991, Russia.
EM osminkina@vega.phys.msu.ru
RI Timoshenko, Victor/G-9860-2013; Gongalsky, Maxim/G-6493-2014; Nikiforov,
   Vladimir/G-5649-2010; Khaitov, Musa/L-3369-2017; Osminkina,
   Liubov/G-6391-2014
OI Timoshenko, Victor/0000-0001-8498-9853; Gongalsky,
   Maxim/0000-0002-7069-4234; Nikiforov, Vladimir/0000-0002-6153-2188;
   Khaitov, Musa/0000-0003-4961-9640; Osminkina, Liubov/0000-0001-7485-0495
FU RFBR [12-02-31266 mol_a]; Russian Ministry of Education and Science
   [8737]
FX The authors thank Mr. D. Petrov and Dr. A. Gylyazova for their
   assistance in SEM measurements and cell cytotoxicity evaluation,
   respectively. The work was partially supported by RFBR (Project No.
   12-02-31266 mol_a) and the Russian Ministry of Education and Science
   (Project No. 8737).
CR Adair BM, 2009, WIRES NANOMED NANOBI, V1, P405, DOI [10.1002/wnan.45, 10.1002/wnan.045]
   Anglin EJ, 2008, ADV DRUG DELIVER REV, V60, P1266, DOI 10.1016/j.addr.2008.03.017
   Brandenburg AH, 2001, VACCINE, V19, P2769, DOI 10.1016/S0264-410X(00)00536-3
   CANHAM LT, 1990, APPL PHYS LETT, V57, P1046, DOI 10.1063/1.103561
   Canham L.T., 2007, NANOTECHNOLOGY, V18, P1
   Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456                                                        
   Durnev AD, 2010, B EXP BIOL MED+, V149, P445, DOI 10.1007/s10517-010-0967-3                                                       
   Elechiguerra J.L., 2005, J NANOBIOTECHNOL, V29, P3, DOI DOI 10.1186/1477-3155-3-6
   Federici G, 2007, AQUAT TOXICOL, V84, P415, DOI 10.1016/j.aquatox.2007.07.009
   FERIN J, 1985, AM IND HYG ASSOC J, V46, P69, DOI 10.1202/0002-8894(1985)046<0069:BEATAO>2.3.CO;2
   Foll H, 2002, MAT SCI ENG R, V39, P93, DOI 10.1016/S0927-796X(02)00090-6
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Haggstrom J, 2010, NANOSCALE, V2, P234
   Halfpenny KC, 2010, WIRES NANOMED NANOBI, V2, P277, DOI 10.1002/wnan.83
   HAMILTON MA, 1977, ENVIRON SCI TECHNOL, V11, P714, DOI 10.1021/es60130a004                                                             
   Hong C, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-321
   Jafry HR, 2011, ENVIRON SCI TECHNOL, V45, P1563, DOI 10.1021/es102749e
   Kabashin AV, 2010, NANOSCALE RES LETT, V5, P454, DOI 10.1007/s11671-010-9543-z
   Kalem S, 2000, OPT EXPRESS, V6, P7, DOI 10.1364/OE.6.000007                                                             
   Katsuhide F, 2009, TOXICOL LETT, V191, P109
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kovalainen M, 2013, MOL PHARMACEUT, V10, P353, DOI 10.1021/mp300494p
   Kovalev D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137401
   Kaur J., 2011, J FUZZY SET VALUED A, V2011, P1
   Lara H. H., 2011, J NANOBIOTECHNOL, V9, P1, DOI DOI 10.1186/1477-3155-9-30
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Low SP, 2009, BIOMATERIALS, V30, P2873, DOI 10.1016/j.biomaterials.2009.02.008
   Low SP, 2010, J BIOMED MATER RES A, V93A, P1124, DOI 10.1002/jbm.a.32610
   Lozovski V, 2011, J OPT SOC AM B, V28, P365, DOI 10.1364/JOSAB.28.000365                                                         
   Osminkina LA, 2011, APPL PHYS B-LASERS O, V105, P665, DOI 10.1007/s00340-011-4562-8
   Osminkina LA, 2011, B EXP BIOL MED+, V151, P79, DOI 10.1007/s10517-011-1264-5                                                       
   Osminkina LA, 2012, J BIOPHOTONICS, V5, P529, DOI 10.1002/jbio.201100112
   Park JH, 2009, NAT MATER, V8, P331, DOI [10.1038/NMAT2398, 10.1038/nmat2398]
   Porstmann T, 1997, J IMMUNOL METHODS, V150, P5
   Salonen J, 2005, J CONTROL RELEASE, V108, P362, DOI 10.1016/j.jconrel.2005.08.017
   Santos HA, 2010, ACTA BIOMATER, V6, P2721, DOI 10.1016/j.actbio.2009.12.043
   Sekhon BS, 2011, BIOSIMILARS, V1, P1, DOI DOI 10.2147/BS.S16120
   Shen FX, 2012, NANO LETT, V12, P3722, DOI 10.1021/nl301516z
   Smith R, 1991, J APPL PHYS, V71, pR1
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sviridov AP, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4829148
   Theiss W., 1997, Surface Science Reports, V29, P91, DOI 10.1016/S0167-5729(96)00012-X
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Tijssen P, 1985, PRACTICE THEORY ENZY
   Timoshenko VY, 2006, JETP LETT+, V83, P423, DOI 10.1134/S0021364006090128
   UNAIDS (Joint United Nations Programme on HIV/AIDS), 2012, UNAIDS WORLD AIDS DA
   Xiao L, 2011, ACS NANO, V5, P3651, DOI 10.1021/nn1035262
   Yu JC, 2003, ENVIRON SCI TECHNOL, V37, P2296, DOI 10.1021/es0259483
   Zhu RR, 2009, MAT SCI ENG C-BIO S, V29, P691, DOI 10.1016/j.msec.2008.12.023
NR 50
TC 4
Z9 4
U1 3
U2 23
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAY 10
PY 2014
VL 16
IS 6
AR 2430
DI 10.1007/s11051-014-2430-2
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AG8FX
UT WOS:000335655300002
DA 2018-01-05
ER

PT J
AU Gungor, B
   Yagci, FC
   Tincer, G
   Bayyurt, B
   Alpdundar, E
   Yildiz, S
   Ozcan, M
   Gursel, I
   Gursel, M
AF Gungor, Bilgi
   Yagci, Fuat Cem
   Tincer, Gizem
   Bayyurt, Banu
   Alpdundar, Esin
   Yildiz, Soner
   Ozcan, Mine
   Gursel, Ihsan
   Gursel, Mayda
TI CpG ODN Nanorings Induce IFN alpha from Plasmacytoid Dendritic Cells and
   Demonstrate Potent Vaccine Adjuvant Activity
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID T-CELLS; SPATIOTEMPORAL REGULATION; ANTIMICROBIAL PEPTIDE; INNATE
   IMMUNITY; TUMOR-ANTIGEN; MOUTH-DISEASE; I INTERFERONS; SELF-DNA; B-CELL;
   OLIGODEOXYNUCLEOTIDES
AB CpG oligodeoxynucleotides (ODN) are short single-stranded synthetic DNA molecules that activate the immune system and have been found to be effective for preventing and treating infectious diseases, allergies, and cancers. Structurally distinct classes of synthetic ODN expressing CpG motifs differentially activate human immune cells. K-type ODN (K-ODN), which have progressed into human clinical trials as vaccine adjuvants and immunotherapeutic agents, are strong activators of B cells and trigger plasmacytoid dendritic cells (pDCs) to differentiate and produce tumor necrosis factor-alpha (TNF alpha). In contrast, D-type ODN (D-ODN) stimulate large amounts of interferon-alpha (IFN alpha) secretion from pDCs. This activity depends on the ability of D-ODN to adopt nanometer-sized G quadruplex-based structures, complicating their manufacturing and hampering their progress into the clinic. In search of a D-ODN substitute, we attempted to multimerize K-ODN into stable nanostructures using cationic peptides. We show that short ODN with a rigid secondary structure form nuclease-resistant nanorings after condensation with the HIV-derived peptide Tat((47-57)). The nanorings enhanced cellular internalization, targeted the ODN to early endosomes, and induced a robust IFN alpha response from human pDCs. Compared to the conventional K-ODN, nanorings boosted T helper 1-mediated immune responses in mice immunized with the inactivated foot and mouth disease virus vaccine and generated superior antitumor immunity when used as a therapeutic tumor vaccine adjuvant in C57BL/6 mice bearing ovalbumin-expressing EG.7 thymoma tumors. These results suggest that the nanorings can act as D-ODN surrogates and may find a niche for further clinical applications.
C1 [Gungor, Bilgi; Alpdundar, Esin; Yildiz, Soner; Ozcan, Mine; Gursel, Mayda] Middle E Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.
   [Yagci, Fuat Cem; Tincer, Gizem; Bayyurt, Banu; Gursel, Ihsan] Bilkent Univ, Dept Mol Biol & Genet, TR-06800 Ankara, Turkey.
RP Gursel, M (reprint author), Middle E Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.
EM mgursel@metu.edu.tr
OI Gursel, Ihsan/0000-0003-3761-1166
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [111S151]
FX Scientific and Technological Research Council of Turkey (TUBITAK grant
   111S151 to B.G.).
CR Ainalem ML, 2010, LANGMUIR, V26, P8625, DOI 10.1021/la9047177
   Argudo D, 2012, BIOPHYS J, V103, P118, DOI 10.1016/j.bpj.2012.05.033
   Asselin-Paturel C, 2005, J EXP MED, V202, P461, DOI 10.1084/jem.20051395
   Baines J, 2003, CLIN CANCER RES, V9, P2693
   Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878                                                     
   Blackwell SE, 2003, J IMMUNOL, V170, P4061, DOI 10.4049/jimmunol.170.8.4061                                                     
   Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
   Chinnathambi S, 2012, SCI REP-UK, V2, DOI 10.1038/srep00534
   Conwell CC, 2003, P NATL ACAD SCI USA, V100, P9296, DOI 10.1073/pnas.1533135100
   Davis AM, 2008, J IMMUNOL, V181, P8204, DOI 10.4049/jimmunol.181.12.8204                                                    
   Doel TR, 1996, REV SCI TECH OIE, V15, P883, DOI 10.20506/rst.15.3.955                                                           
   Fujita H, 2013, EUR J IMMUNOL, V43, P93, DOI 10.1002/eji.201242699
   Geary SM, 2011, CANCER IMMUNOL IMMUN, V60, P1309, DOI 10.1007/s00262-011-1038-y
   Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401
   Gursel M, 2002, J LEUKOCYTE BIOL, V71, P813
   Gursel M, 2006, J IMMUNOL, V177, P1575, DOI 10.4049/jimmunol.177.3.1575                                                     
   Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944                                                      
   Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813
   Hass T., 2008, IMMUNOLOGY, V126, P290
   Hervas-Stubbs S, 2010, EUR J IMMUNOL, V40, P3389, DOI 10.1002/eji.201040664
   Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547
   Huber JP, 2011, IMMUNOLOGY, V132, P466, DOI 10.1111/j.1365-2567.2011.03412.x
   Hurtado P, 2010, J IMMUNOL, V184, P1425, DOI 10.4049/jimmunol.0902305
   Ishii KJ, 2006, TRENDS IMMUNOL, V27, P525, DOI 10.1016/j.it.2006.09.002
   Kerkmann M, 2005, J BIOL CHEM, V280, P8086, DOI 10.1074/jbc.M410868200
   Kerkmann M, 2006, OLIGONUCLEOTIDES, V16, P313, DOI 10.1089/oli.2006.16.313
   Klinman Dennis M, 2004, Nat Rev Immunol, V4, P249, DOI 10.1038/nri1329
   Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821
   Kong XY, 2004, SCIENCE, V303, P1348, DOI 10.1126/science.1092356
   Krieg AM, 2012, NUCLEIC ACID THER, V22, P77, DOI 10.1089/nat.2012.0340
   Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
   Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116
   Maeda T, 2005, INT J HEMATOL, V81, P148, DOI 10.1532/IJH97.04116
   Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630
   Nakata M, 2007, SCIENCE, V318, P1276, DOI 10.1126/science.1143826
   Okuya K, 2010, J IMMUNOL, V184, P7092, DOI 10.4049/jimmunol.1000490
   Puig M, 2006, NUCLEIC ACIDS RES, V34, P6488, DOI 10.1093/nar/gkl867
   Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]
   Rweyemamu M, 2008, TRANSBOUND EMERG DIS, V55, P57, DOI 10.1111/j.1865-1682.2007.01013.x
   Samulowitz U, 2010, OLIGONUCLEOTIDES, V20, P93, DOI 10.1089/oli.2009.0210
   Sarkar T, 2005, NUCLEIC ACIDS RES, V33, P143, DOI 10.1093/nar/gki156
   Suzuki Y, 2004, CANCER RES, V64, P8754, DOI 10.1158/0008-5472.CAN-04-1691                                                   
   Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372                                                     
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   Wakita D, 2006, INT IMMUNOL, V18, P425, DOI 10.1093/intimm/dxh381
   Wang GS, 2008, J BIOL CHEM, V283, P32637, DOI 10.1074/jbc.M805533200
   Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833
   Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147
   Zwiorek K, 2008, PHARM RES, V25, P551, DOI 10.1007/s11095-007-9410-5
NR 49
TC 27
Z9 28
U1 3
U2 22
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 7
PY 2014
VL 6
IS 235
AR 235ra61
DI 10.1126/scitranslmed.3007909
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA AG6GE
UT WOS:000335516300003
PM 24807558
DA 2018-01-05
ER

PT J
AU Rogolino, D
   Carcelli, M
   Compari, C
   De Luca, L
   Ferro, S
   Fisicaro, E
   Rispoli, G
   Neamati, N
   Debyser, Z
   Christ, F
   Chimirri, A
AF Rogolino, Dominga
   Carcelli, Mauro
   Compari, Carlotta
   De Luca, Laura
   Ferro, Stefania
   Fisicaro, Emilia
   Rispoli, Gabriele
   Neamati, Nouri
   Debyser, Zeger
   Christ, Frauke
   Chimirri, Alba
TI Diketoacid chelating ligands as dual inhibitors of HIV-1 integration
   process
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Antiviral agents; HIV-1 integrase inhibitors; LEDGF/p75 protein-protein
   inhibitors; Magnesium complexes; Dual inhibitors; Diketo acid
ID STRAND-TRANSFER INHIBITORS; HUMAN-IMMUNODEFICIENCY-VIRUS; ACID
   METAL-COMPLEXES; COFACTOR LEDGF/P75; TYPE-1 INTEGRASE; STRUCTURAL BASIS;
   BINDING-SITE; DNA; RALTEGRAVIR; DESIGN
AB HIV-1 Integrase (IN) represents a very attractive pharmacological target for the development of new and more efficient drugs. Recently, an allosteric inhibitory approach also emerged, that targets the interaction between IN and cellular cofactors, such as LEDGF/p75. Small molecules based on the diketoacid pharmachophore were studied for their ability to inhibit at the same time integration and IN-LEDGF/p75 interaction (dual inhibitors): in this study, we evaluated three indole diketoacid derivatives and their magnesium(II) complexes for their ability to act as dual inhibitors.
   Effectively, the metal complexes exhibited IN inhibition potency in low nanomolar/micromolar concentration range; both the complexes and the free ligands are also able to inhibit the IN-LEDGF/p75 interaction at low mu M values. Moreover, these magnesium compounds showed good antiviral activity, suggesting the possibility to exploit metal coordination for the design of new antivirals. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Rogolino, Dominga; Carcelli, Mauro; Rispoli, Gabriele] Univ Parma, Dipartimento Chim, I-43124 Parma, Italy.
   [Compari, Carlotta; Fisicaro, Emilia] Univ Parma, Dipartimento Farm, I-43124 Parma, Italy.
   [De Luca, Laura; Ferro, Stefania; Chimirri, Alba] Univ Messina, Dipartimento Sci Farm & Prod Salute, I-98168 Messina, Italy.
   [Neamati, Nouri] Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA.
   [Debyser, Zeger; Christ, Frauke] Katholieke Univ Leuven, Div Mol Med, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Belgium.
RP Rogolino, D (reprint author), Univ Parma, Dipartimento Chim, Parco Area Sci 17-A, I-43124 Parma, Italy.
EM dominga.rogolino@unipr.it; achimirri@unime.it
RI Carcelli, Mauro/I-1616-2015; Rogolino, Dominga/L-6145-2015
OI Carcelli, Mauro/0000-0001-5888-4556; Rogolino,
   Dominga/0000-0003-2295-5783; De Luca, Laura/0000-0003-0614-5713;
   debyser, zeger/0000-0002-3982-1565
FU Italian Ministero dell'Istruzione, dell'Universita e della Ricerca
   [2010W2KM5L_003]
FX The authors thank the "Centro Interdipartimentale Misure Giuseppe
   Casnati" of the University of Parma for facilities. D.R, M.C. and G.R.
   thank Italian Ministero dell'Istruzione, dell'Universita e della Ricerca
   for financial support (PRIN 2010, 2010W2KM5L_003).
CR Abel S, 2009, ANTIVIR THER, V14, P607
   Agrawa A., 2012, P NATL ACAD SCI USA, P2251
   Bacchi A, 2008, J MED CHEM, V51, P7253, DOI 10.1021/jm800893q
   Bacchi A, 2011, J MED CHEM, V54, P8407, DOI 10.1021/jm200851g
   Bacchi A, 2011, MOL PHARMACEUT, V8, P507, DOI 10.1021/mp100343x
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   BEESE LS, 1991, EMBO J, V10, P25
   Boros EE, 2009, J MED CHEM, V52, P2754, DOI 10.1021/jm801404b
   Busschots K, 2007, J MOL BIOL, V365, P1480, DOI 10.1016/j.jmb.2006.10.094
   Carcelli M, 2013, J INORG BIOCHEM, V118, P74, DOI 10.1016/j.jinorgbio.2012.09.021
   Cherepanov P, 2005, P NATL ACAD SCI USA, V102, P17308, DOI 10.1073/pnas.0506921402
   Christ F, 2013, VIROLOGY, V435, P102, DOI 10.1016/j.virol.2012.09.033
   Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329
   Cocohoba J, 2008, CLIN THER, V30, P1747, DOI 10.1016/j.clinthera.2008.10.012
   Cotelle Philippe, 2006, Recent Pat Antiinfect Drug Discov, V1, P1, DOI 10.2174/157489106775244082
   Dayam R, 2006, MED RES REV, V26, P271, DOI 10.1002/med.20054
   Dayam R, 2008, MED RES REV, V28, P118, DOI 10.1002/med.20116
   Dayam Raveendra, 2007, Drugs R D, V8, P155, DOI 10.2165/00126839-200708030-00003
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Luca L, 2008, BIOORG MED CHEM LETT, V18, P2891, DOI 10.1016/j.bmcl.2008.03.089
   De Luca L, 2012, J CHEM INF MODEL, V52, P3245, DOI 10.1021/ci300361e
   De Luca L, 2011, ANTIVIR RES, V92, P102, DOI 10.1016/j.antiviral.2011.07.005
   De Luca L, 2011, EUR J MED CHEM, V46, P756, DOI 10.1016/j.ejmech.2010.12.012
   De Luca L, 2010, BIOORGAN MED CHEM, V18, P7515, DOI 10.1016/j.bmc.2010.08.051
   De Luca L, 2009, CHEMMEDCHEM, V4, P1311, DOI 10.1002/cmdc.200900070
   Engelman A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000046
   Ferro S, 2010, BIOORGAN MED CHEM, V18, P5510, DOI 10.1016/j.bmc.2010.06.063
   Ferro S, 2009, J MED CHEM, V52, P569, DOI 10.1021/jm8009266
   Fisicaro E., 1988, TALANTA, V10, P769
   Galal SA, 2010, EUR J MED CHEM, V45, P3035, DOI 10.1016/j.ejmech.2010.03.034
   Gallego S. G., 2011, EUROPEAN J INORGANIC, P1657
   de la Mata F. J., 2012, DALTON TRANS, V41, P6488
   Gans P, 1996, TALANTA, V43, P1739, DOI 10.1016/0039-9140(96)01958-3
   Garrido C, 2010, J ANTIMICROB CHEMOTH, V65, P218, DOI 10.1093/jac/dkp447
   GATEHOUSE BM, 1976, ACTA CRYSTALLOGR B, V32, P3145, DOI 10.1107/S0567740876009825                                                       
   GRAN G, 1952, ANALYST, V77, P661, DOI 10.1039/an9527700661                                                            
   Greene WC, 2008, ANTIVIR RES, V80, P251, DOI 10.1016/j.antiviral.2008.08.003
   Hare S., 2010, NATURE, P1
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hare S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000259
   Johns BA, 2008, EXPERT OPIN THER PAT, V18, P1225, DOI 10.1517/13543770802500450
   KAWAI H, 1993, CHEM PHARM BULL, V41, P357
   Kobayashi M, 2011, ANTIMICROB AGENTS CH, V55, P813, DOI 10.1128/AAC.01209-10
   KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331                                                           
   Le GA, 2010, BIOORG MED CHEM LETT, V20, P5909, DOI 10.1016/j.bmcl.2010.07.081
   Loginova NV, 2008, EUR J MED CHEM, V43, P1536, DOI 10.1016/j.ejmech.2007.09.024
   Maurin C, 2004, J MED CHEM, V47, P5583, DOI 10.1021/jm0408464
   Meggers E, 2009, CHEM COMMUN, P1001, DOI 10.1039/b813568a
   Neamati N, 2011, HIV 1 INTEGRASE MECH
   Pais GCG, 2002, DRUG FUTURE, V27, P1101
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pelosi G, 2010, J MED CHEM, V53, P8765, DOI 10.1021/jm1007616
   Plewe MB, 2009, J MED CHEM, V52, P7211, DOI 10.1021/jm900862n
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Rogolino D, 2012, COORDIN CHEM REV, V256, P3063, DOI 10.1016/j.ccr.2012.07.006
   Rowley M, 2008, PROGR MED CHEM, V46, P1, DOI 10.1016/S0079-6468(07)00001-X
   Sax PE, 2012, LANCET, V379, P2439, DOI 10.1016/S0140-6736(12)60917-9
   Sechi M, 2006, J MED CHEM, V49, P4248, DOI 10.1021/jm060193m
   Shimura Kazuya, 2009, Antiviral Chemistry & Chemotherapy, V20, P79, DOI 10.3851/IMP1397
   Tang J, 2011, J MED CHEM, V54, P2282, DOI 10.1021/jm1014378
   Tsutsui KM, 2011, NUCLEIC ACIDS RES, V39, P5067, DOI 10.1093/nar/gkr088
   Vandekerckhove L, 2006, J VIROL, V80, P1886, DOI 10.1128/JVI.80.4.1886-1896.2006
   Vandekerckhove L., 2010, EXPERT OPINION INVES, V11, P203
   Kiyama R., 2001, AIDS EP UPD JOINT UN, Patent No. WO-01/95905
   [Anonymous], 2013, FDA approves new drug to treat HIV infection, Patent No. [01195905, WO-01/95905]
   [Anonymous], 2007, FDA APPROVES NEW DRU
NR 66
TC 9
Z9 10
U1 0
U2 12
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAY 6
PY 2014
VL 78
BP 425
EP 430
DI 10.1016/j.ejmech.2014.03.070
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AH0JO
UT WOS:000335805400040
PM 24704615
DA 2018-01-05
ER

PT J
AU Hansen, EC
   Seamon, KJ
   Cravens, SL
   Stivers, JT
AF Hansen, Erik C.
   Seamon, Kyle J.
   Cravens, Shannen L.
   Stivers, James T.
TI GTP activator and dNTP substrates of HIV-1 restriction factor SAMHD1
   generate a long-lived activated state
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE dNTP induced oligomerization; enzyme catalysis; innate immunity
ID DEOXYNUCLEOSIDE TRIPHOSPHATE TRIPHOSPHOHYDROLASE; MAMMALIAN
   RIBONUCLEOTIDE REDUCTASE; IMMUNODEFICIENCY-VIRUS TYPE-1;
   REVERSE-TRANSCRIPTASE; DNA-REPLICATION; CELLS; MACROPHAGES; INFECTION;
   POOL; DGTP
AB The HIV-1 restriction factor sterile alpha-motif/ histidine-aspartate domain-containing protein 1 (SAMHD1) is a tetrameric protein that catalyzes the hydrolysis of all dNTPs to the deoxynucleoside and tripolyphosphate, which effectively depletes the dNTP substrates of HIV reverse transcriptase. Here, we establish that SAMHD1 is activated by GTP binding to guanine-specific activator sites (A1) as well as coactivation by substrate dNTP binding to a distinct set of nonspecific activator sites (A2). Combined activation by GTP and dNTPs results in a long-lived tetrameric form of SAMHD1 that persists for hours, even after activating nucleotides are withdrawn from the solution. These results reveal an ordered model for assembly of SAMHD1 tetramer from its inactive monomer and dimer forms, where GTP binding to the A1 sites generates dimer and dNTP binding to the A2 and catalytic sites generates active tetramer. Thus, cellular regulation of active SAMHD1 is not determined by GTP alone but instead, the levels of all dNTPs and the generation of a persistent tetramer that is not in equilibrium with free activators. The significance of the long-lived activated state is that SAMHD1 can remain active long after dNTP pools have been reduced to a level that would lead to inactivation. This property would be important in resting CD4(+) T cells, where dNTP pools are reduced to nanomolar levels to restrict infection by HIV-1.
C1 [Hansen, Erik C.; Seamon, Kyle J.; Cravens, Shannen L.; Stivers, James T.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RP Stivers, JT (reprint author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
EM jstivers@jhmi.edu
FU National Institutes of Health [T32GM080189, T32GM008763, T32GM008403,
   GM056834]
FX We thank Dr. Heng Zhu for the cloning vector containing the human SAMHD1
   gene. We thank Dr. Katherine Tripp and the Center for Molecular
   Biophysics at The Johns Hopkins University for assistance with the
   sedimentation velocity experiments. This work was supported by National
   Institutes of Health Grants T32GM080189, T32GM008763, T32GM008403, and
   GM056834 (to J.T.S.).
CR Amie SM, 2013, J BIOL CHEM, V288, P25001, DOI 10.1074/jbc.C113.493619
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964
   BEBENEK K, 1992, J BIOL CHEM, V267, P3589
   Cribier A, 2013, CELL REP, V3, P1036, DOI 10.1016/j.celrep.2013.03.017
   Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200
   ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114
   Franzolin E, 2013, P NATL ACAD SCI USA, V110, P14272, DOI 10.1073/pnas.1312033110
   Gavegnano C, 2012, MOL BIOL INT, V2012, P1, DOI [10.1155/2012/625983, DOI 10.1155/2012/625983]
   Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623
   Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   Ji XY, 2013, NAT STRUCT MOL BIOL, V20, P1304, DOI 10.1038/nsmb.2692
   Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a
   Kennedy EM, 2011, J BIOL CHEM, V286, P25047, DOI 10.1074/jbc.M111.234047
   Kim ET, 2013, J VIROL, V87, P12949, DOI 10.1128/JVI.02291-13
   Kohn G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043879
   KORNBERG SR, 1958, J BIOL CHEM, V233, P159
   Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238
   Lahouassa H, 2012, NAT IMMUNOL, V13, P223, DOI 10.1038/ni.2236
   Laue T. M., 1991, ANAL ULTRACENTRIFUGA, P90
   Li N, 2000, IMMUNOL LETT, V74, P221, DOI 10.1016/S0165-2478(00)00276-5                                                   
   OBRIEN WA, 1994, J VIROL, V68, P1258
   Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628
   Priet S, 2006, CURR HIV RES, V4, P31, DOI 10.2174/157016206775197673
   Rampazzo C, 2010, MUTAT RES-GEN TOX EN, V703, P2, DOI 10.1016/j.mrgentox.2010.06.002
   Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P                       
   SEGEL IH, 1993, ENZYME KINETICS BEHA, P227
   Stafford WF, 2004, BIOPHYS CHEM, V108, P231, DOI 10.1016/j.bpc.2003.10.028
   Vorontsov II, 2011, J BIOL CHEM, V286, P33158, DOI 10.1074/jbc.M111.250456
   Weil AF, 2013, P NATL ACAD SCI USA, V110, pE448, DOI 10.1073/pnas.1219702110
   Yan JP, 2013, J BIOL CHEM, V288, P10406, DOI 10.1074/jbc.M112.443796
   Yao NY, 2013, P NATL ACAD SCI USA, V110, P12942, DOI 10.1073/pnas.1309506110
   Zhu CF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3722
NR 33
TC 38
Z9 38
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 6
PY 2014
VL 111
IS 18
BP E1843
EP E1851
DI 10.1073/pnas.1401706111
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG5RX
UT WOS:000335477300008
PM 24753578
OA gold
DA 2018-01-05
ER

PT J
AU Han, YL
   Hu, J
   Genin, GM
   Lu, TJ
   Xu, F
AF Han, Yu Long
   Hu, Jie
   Genin, Guy M.
   Lu, Tian Jian
   Xu, Feng
TI BioPen: direct writing of functional materials at the point of care
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIP-PEN NANOLITHOGRAPHY; GENE-EXPRESSION
AB Rapid and precise patterning of functional biomaterials is desirable for point-of-care (POC) tissue engineering and diagnostics. However, existing technologies such as dip-pen nanolithography and inkjet printing are currently unsuitable for POC applications due to issues of cost and portability. Here, we report the development of 'BioPen', a portable tool for continuous, defined and scalable deposition of functional materials with micrometer spatial resolution and nanolitre volumetric resolution. BioPen is based upon the ballpoint pen but with multiple "ink sources" (functional material solutions) and with an apparatus that can be optimized for writing living cells, proteins, nucleic acids, etc. We demonstrate POC detection of human immunodeficiency virus type 1 (HIV-1) nucleic acid by writing on paper with BioPen using "ink" consisting of nucleic acid probes and nucleic acid-modified gold nanoparticles. We also demonstrate POC tissue engineering by writing a continuous pattern of living, functional, interconnected cells with a defined extracellular environment. Because it is simple, accurate, inexpensive and portable, BioPen has broad potential for POC detection of diagnostic biomarkers, and for POC engineering of tissues for a range of healing applications.
C1 [Han, Yu Long; Hu, Jie; Xu, Feng] Xi An Jiao Tong Univ, Key Lab Biomed Informat Engn, Minist Educ, Sch Life Sci & Technol, Xian 710049, Peoples R China.
   [Han, Yu Long; Hu, Jie; Lu, Tian Jian; Xu, Feng] Xi An Jiao Tong Univ, BEBC, Xian 710049, Peoples R China.
   [Genin, Guy M.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63130 USA.
   [Genin, Guy M.] Washington Univ, Dept Mech & Mat Sci, St Louis, MO 63130 USA.
RP Lu, TJ (reprint author), Xi An Jiao Tong Univ, BEBC, Xian 710049, Peoples R China.
EM tjlu@mail.xjtu.edu.cn; fengxu@mail.xjtu.edu.cn
RI Lu, Tian Jian/E-6063-2016; Xu, Feng/H-4468-2011; Xu, Feng/C-7430-2011
OI Xu, Feng/0000-0003-4351-0222; 
FU National 111 Project of China [B06024]; Major International Joint
   Research Program of China [11120101002]; National Natural Science
   Foundation of China [11372243]; International Science & Technology
   Cooperation Program of China [2013DFG02930]; Key Project of Chinese
   Ministry of Education [313045]; South Wisdom Valley Innovative Research
   Team Program; Fundamental Research Funds for the Central Universities;
   National Institutes of Health [R01HL109505]; China Young 1000-Talent
   Program; Program for New Century Excellent Talents in University
   [NCET-12-0437]
FX This work was financially supported by the National 111 Project of China
   (B06024), the Major International Joint Research Program of China
   (11120101002), the National Natural Science Foundation of China
   (11372243), the International Science & Technology Cooperation Program
   of China (2013DFG02930), the Key Project of Chinese Ministry of
   Education (313045), South Wisdom Valley Innovative Research Team
   Program, International Science & Technology Cooperation Program of China
   (2013DFG02930), and Fundamental Research Funds for the Central
   Universities. GMG was also partially supported by the National
   Institutes of Health (R01HL109505). FX was also partially supported by
   the China Young 1000-Talent Program and Program for New Century
   Excellent Talents in University (NCET-12-0437).
CR Baumann K, 2011, NAT REV MOL CELL BIO, V12, P770, DOI 10.1038/nrm3235
   Cavallini M, 2012, NAT PROTOC, V7, P1668, DOI 10.1038/nprot.2012.094
   Doyle AD, 2010, NATURE, V466, P192, DOI 10.1038/466192a
   Gu MM, 2009, TALANTA, V80, P246, DOI 10.1016/j.talanta.2009.06.065
   Gubala V., 2011, ANAL CHEM, V84, P487, DOI DOI 10.1021/AC2030199
   Guillotin B, 2011, TRENDS BIOTECHNOL, V29, P183, DOI 10.1016/j.tibtech.2010.12.008
   Han Y. L., 2013, LAB CHIP
   Han YL, 2014, DRUG DISCOV TODAY, V19, P763, DOI 10.1016/j.drudis.2014.01.015
   Han YL, 2013, BIOFABRICATION, V5, DOI 10.1088/1758-5082/5/3/035004
   Hu J, 2014, BIOSENS BIOELECTRON, V54, P585, DOI 10.1016/j.bios.2013.10.075
   Hu J, 2013, LAB CHIP, V13, P4352, DOI 10.1039/c3lc50672j
   Jain N, 2013, P NATL ACAD SCI USA, V110, P11349, DOI 10.1073/pnas.1300801110
   Lee KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/science.1067172
   Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38
   Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701
   MacBeath G, 2000, SCIENCE, V289, P1760
   Mao X, 2009, ANAL CHEM, V81, P1660, DOI 10.1021/ac8024653
   Miller JS, 2012, NAT MATER, V11, P768, DOI [10.1038/nmat3357, 10.1038/NMAT3357]
   Mirica K. A., 2012, ANGEW CHEM INT ED
   Nichol JW, 2009, SOFT MATTER, V5, P1312, DOI 10.1039/b814285h
   Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661
   Russo A, 2011, ADV MATER, V23, P3426, DOI 10.1002/adma.201101328
   Salaita K, 2007, NAT NANOTECHNOL, V2, P145, DOI 10.1038/nnano.2007.39
   Sha BY, 2013, J NANOSCI NANOTECHNO, V13, P1208, DOI 10.1166/jnn.2013.6081
   Skinner M, 2012, NAT REV MOL CELL BIO, V13, P2, DOI 10.1038/nrm3250
   Tomizaki K, 2010, FEBS J, V277, P1996, DOI 10.1111/j.1742-4658.2010.07626.x
   Vega R. A., 2005, ANGEW CHEM, V117, P6167
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Whitesides GM, 2013, LAB CHIP, V13, P11, DOI 10.1039/c2lc90109a
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153                                                 
   Zhang S., NAT MAT, V9, P594
   Zheng Y., 2013, SCI REP, V3
NR 32
TC 13
Z9 13
U1 3
U2 68
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 6
PY 2014
VL 4
AR 4872
DI 10.1038/srep04872
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG4EY
UT WOS:000335373300001
PM 24799039
OA gold
DA 2018-01-05
ER

PT J
AU Magnus, M
   Matelska, D
   Lach, G
   Chojnowski, G
   Boniecki, MJ
   Purta, E
   Dawson, W
   Dunin-Horkawicz, S
   Bujnicki, JM
AF Magnus, Marcin
   Matelska, Dorota
   Lach, Grzegorz
   Chojnowski, Grzegorz
   Boniecki, Michal J.
   Purta, Elzbieta
   Dawson, Wayne
   Dunin-Horkawicz, Stanislaw
   Bujnicki, Janusz M.
TI Computational modeling of RNA 3D structures, with the aid of
   experimental restraints
SO RNA BIOLOGY
LA English
DT Review
DE RNA structure; RNA structure prediction; macromolecular modeling;
   bioinformatics; chemical probing
ID SECONDARY STRUCTURE PREDICTION; NANOMETER DISTANCE MEASUREMENTS; HIV-1
   PACKAGING SIGNAL; SMALL-ANGLE SCATTERING; BIOMOLECULAR SIMULATION;
   NUCLEIC-ACIDS; RIBOSOMAL-RNA; BIOLOGICAL MACROMOLECULES; 3-DIMENSIONAL
   STRUCTURE; STRUCTURE REFINEMENT
AB In addition to mRNAs whose primary function is transmission of genetic information from DNA to proteins, numerous other classes of RNA molecules exist, which are involved in a variety of functions, such as catalyzing biochemical reactions or performing regulatory roles. In analogy to proteins, the function of RNAs depends on their structure and dynamics, which are largely determined by the ribonucleotide sequence. Experimental determination of high-resolution RNA structures is both laborious and difficult, and therefore, the majority of known RNAs remain structurally uncharacterized. To address this problem, computational structure prediction methods were developed that simulate either the physical process of RNA structure formation ("Greek science" approach) or utilize information derived from known structures of other RNA molecules ("Babylonian science" approach). All computational methods suffer from various limitations that make them generally unreliable for structure prediction of long RNA sequences. However, in many cases, the limitations of computational and experimental methods can be overcome by combining these two complementary approaches with each other. In this work, we review computational approaches for RNA structure prediction, with emphasis on implementations (particular programs) that can utilize restraints derived from experimental analyses. We also list experimental approaches, whose results can be relatively easily used by computational methods. Finally, we describe case studies where computational and experimental analyses were successfully combined to determine RNA structures that would remain out of reach for each of these approaches applied separately.
C1 [Magnus, Marcin; Matelska, Dorota; Lach, Grzegorz; Chojnowski, Grzegorz; Boniecki, Michal J.; Purta, Elzbieta; Dawson, Wayne; Dunin-Horkawicz, Stanislaw; Bujnicki, Janusz M.] Int Inst Mol & Cell Biol, Lab Bioinformat & Prot Engn, Warsaw, Poland.
   [Bujnicki, Janusz M.] Adam Mickiewicz Univ, Fac Biol, Inst Mol Biol & Biotechnol, Lab Struct Bioinformat, Poznan, Poland.
RP Bujnicki, JM (reprint author), Int Inst Mol & Cell Biol, Lab Bioinformat & Prot Engn, Warsaw, Poland.
EM iamb@genesilico.pl
OI Dawson, Wayne/0000-0001-7751-7778
FU German Science Foundation (DFG) [SPP 1258, SE 1195/12-2]; Foundation for
   Polish Science (FNP) [TEAM/2009-4/2]; European Research Council (ERC,
   StG grant); European Commission (EC) [316125]; Polish Ministry of
   Science and Higher Education (MNiSW) [POIG.02.03.00-00-003/09]; FNP;
   National Science Centre (NCN) [2011/03/D/NZ8/03011,
   2011/01/D/NZ1/00212]; Polish Ministry of Science and Higher Education
   (MNiSW)
FX The research on the development of methods for RNA 3D structure modeling
   in the Bujnicki laboratory has been funded from several sources.
   Boniecki M and in general the development and application of RNA folding
   methods that use distance restraints from FRET experiments have been
   supported by the German Science Foundation (DFG) within SPP 1258 (grant
   no. SE 1195/12-2 coordinated by Claus Seidel). Chojnowski G, Lach G,
   Magnus M, Matelska D, and Purta E were supported by the Foundation for
   Polish Science (FNP, grant TEAM/2009-4/2 to Bujincki JM). Bujnicki JM
   and Dunin-Horkawicz S were supported by the European Research Council
   (ERC, StG grant RNA<SUP>+</SUP>P = 123D to Bujnicki JM). Dawson W was
   supported by the European Commission (EC; FP7 grant FishMed, 316125).
   The development of our bioinformatics servers was funded mainly by the
   Polish Ministry of Science and Higher Education (MNiSW, grant
   POIG.02.03.00-00-003/09 to Bujnicki JM). Bujnicki JM was additionally
   supported by the "Ideas for Poland" fellowship from the FNP.
   Dunin-Horkawicz S and Chojnowski G were additionally supported by the
   National Science Centre (NCN, grants 2011/03/D/NZ8/03011 to
   Dunin-Horkawicz S and 2011/01/D/NZ1/00212 to Chojnowski G).
   Dunin-Horkawicz S also acknowledges support from the Polish Ministry of
   Science and Higher Education (MNiSW, fellowship for outstanding young
   scientists).
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   BRUNEL C, 1991, J MOL BIOL, V221, P293, DOI 10.1016/0022-2836(91)90820-V
   Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406
   Cai Q, 2007, BIOPHYS J, V93, P2110, DOI 10.1529/biophysj.107.109439
   Cao S, 2009, BIOPHYS J, V96, P4024, DOI 10.1016/j.bpj.2009.02.044
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678
   Chojnowski G, 2014, NUCLEIC ACIDS RES, V42, pD123, DOI 10.1093/nar/gkt1084
   CHOTHIA C, 1986, EMBO J, V5, P823
   Christen M, 2005, J COMPUT CHEM, V26, P1719, DOI 10.1002/jcc.20303
   Cowtan K, 2011, ACTA CRYSTALLOGR D, V67, P233, DOI 10.1107/S0907444911007578
   Cruz JA, 2012, RNA, V18, P610, DOI 10.1261/rna.031054.111
   Das R, 2007, P NATL ACAD SCI USA, V104, P14664, DOI 10.1073/pnas.0703836104
   Das R, 2010, NAT METHODS, V7, P291, DOI [10.1038/NMETH.1433, 10.1038/nmeth.1433]
   Dast R, 2008, P NATL ACAD SCI USA, V105, P4144, DOI 10.1073/pnas.0709032105
   DEVOE H, 1962, J MOL BIOL, V4, P500
   Ding F, 2008, RNA, V14, P1164, DOI 10.1261/rna.894608
   Ding F, 2012, NAT METHODS, V9, P603, DOI [10.1038/NMETH.1976, 10.1038/nmeth.1976]
   Ding Y, 2003, NUCLEIC ACIDS RES, V31, P7280, DOI 10.1093/nar/gkg938
   Doudna JA, 2000, NAT STRUCT BIOL, V7, P954, DOI 10.1038/80729
   Dror O, 2005, BIOINFORMATICS, V21, P47, DOI 10.1093/bioinformatics/bti1108
   Dzananovic E, 2014, J STRUCT BIOL, V185, P48, DOI 10.1016/j.jsb.2013.11.007
   EXPERTBEZANCON A, 1985, J MOL BIOL, V184, P53, DOI 10.1016/0022-2836(85)90043-9
   Flores SC, 2010, BIOCOMPUT-PAC SYM, P216
   FRESCO JR, 1960, NATURE, V188, P98, DOI 10.1038/188098a0
   Gajda MJ, 2010, BIOINFORMATICS, V26, P2986, DOI 10.1093/bioinformatics/btq582
   Gesteland RF, 2005, RNA WORLD, P768
   Gopal A, 2012, RNA, V18, P284, DOI 10.1261/rna.027557.111
   Grigg JC, 2013, P NATL ACAD SCI USA, V110, P7240, DOI 10.1073/pnas.1222214110
   Hajdin CE, 2013, P NATL ACAD SCI USA, V110, P5498, DOI 10.1073/pnas.1219988110
   Hamada M, 2011, NUCLEIC ACIDS RES, V39, P393, DOI 10.1093/nar/gkq792
   Hamada M, 2009, BIOINFORMATICS, V25, P465, DOI 10.1093/bioinformatics/btn601
   Hardin C, 2002, CURR OPIN STRUC BIOL, V12, P176, DOI 10.1016/S0959-440X(02)00306-8                                                   
   Jacques DA, 2012, ACTA CRYSTALLOGR D, V68, P620, DOI 10.1107/S0907444912012073
   Jonikas MA, 2009, RNA, V15, P189, DOI 10.1261/rna.1270809
   Jossinet F, 2005, BIOINFORMATICS, V21, P3320, DOI 10.1093/bioinformatics/bti504
   Kalinin S, 2012, NAT METHODS, V9, P1218, DOI [10.1038/NMETH.2222, 10.1038/nmeth.2222]
   Kladwang W, 2011, NAT CHEM, V3, P954, DOI [10.1038/NCHEM.1176, 10.1038/nchem.1176]
   Klostermeier D, 2001, BIOPOLYMERS, V61, P159
   Knudsen B, 1999, BIOINFORMATICS, V15, P446, DOI 10.1093/bioinformatics/15.6.446                                                 
   Laing C, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/28/283101
   Lavender CA, 2010, BIOCHEMISTRY-US, V49, P4931, DOI 10.1021/bi100142y
   Leontis N, 2012, RNA 3D STRUCTURE ANA
   Leontis NB, 1998, RNA, V4, P1134, DOI 10.1017/S1355838298980566
   LEVITT M, 1969, NATURE, V224, P759, DOI 10.1038/224759a0
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   MALHOTRA A, 1990, P NATL ACAD SCI USA, V87, P1950, DOI 10.1073/pnas.87.5.1950                                                          
   MALHOTRA A, 1994, BIOPHYS J, V66, P1777, DOI 10.1016/S0006-3495(94)80972-5                                                   
   Martinez HM, 2008, J BIOMOL STRUCT DYN, V25, P669, DOI 10.1080/07391102.2008.10531240                                                  
   Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101
   Mathews DH, 2002, J MOL BIOL, V317, P191, DOI 10.1006/jmbi.2001.5351
   MATHEWS DH, 2006, CURR PROTOC BIOINFOR, pCH12, DOI DOI 10.1002/0471250953.BI1206S13
   Merino EJ, 2005, J AM CHEM SOC, V127, P4223, DOI 10.1021/ja043822v
   Mueller F, 2000, J MOL BIOL, V298, P35, DOI 10.1006/jmbi.2000.3635
   Nahvi A, 2013, METHOD ENZYMOL, V530, P381, DOI 10.1016/B978-0-12-420037-1.00022-1
   Parisien M, 2008, NATURE, V452, P51, DOI 10.1038/nature06684
   Popenda M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks339
   Preus S, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks856
   Puton T, 2013, NUCLEIC ACIDS RES, V41, P4307, DOI 10.1093/nar/gkt101
   Qin PZ, 2004, CURR OPIN STRUC BIOL, V14, P350, DOI 10.1016/j.sbi.2004.04.002
   Ramrath DJF, 2012, NATURE, V485, P526, DOI 10.1038/nature11006
   Reuter JS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-129
   Rivas E, 2000, BIOINFORMATICS, V16, P334, DOI 10.1093/bioinformatics/16.4.334                                                 
   Rocca-Serra P, 2011, RNA, V17, P1204, DOI 10.1261/rna.2753211
   Rother K, 2012, RNA 3D STRUCTURE ANA
   Rother K, 2011, J MOL MODEL, V17, P2325, DOI 10.1007/s00894-010-0951-x
   Rother M, 2011, NUCLEIC ACIDS RES, V39, P4007, DOI 10.1093/nar/gkq1320
   Sanbonmatsu KY, 2007, J STRUCT BIOL, V157, P470, DOI 10.1016/j.jsb.2006.10.023
   Sato K, 2011, BIOINFORMATICS, V27, pI85, DOI 10.1093/bioinformatics/btr215
   Scheraga HA, 1996, BIOPHYS CHEM, V59, P329, DOI 10.1016/0301-4622(95)00126-3
   Schiemann O, 2003, J AM CHEM SOC, V125, P3434, DOI 10.1021/ja0274610
   Schneidman-Duhovny D, 2010, NUCLEIC ACIDS RES, V38, pW540, DOI 10.1093/nar/gkq461
   Seemann SE, 2008, NUCLEIC ACIDS RES, V36, P6355, DOI 10.1093/nar/gkn544
   Serganov A, 2012, CURR OPIN STRUC BIOL, V22, P279, DOI 10.1016/j.sbi.2012.04.005
   Shapiro BA, 2007, CURR OPIN STRUC BIOL, V17, P157, DOI 10.1016/j.sbi.2007.03.001
   SIPPL MJ, 1993, J COMPUT AID MOL DES, V7, P473, DOI 10.1007/BF02337562
   Sripakdeevong P., 2012, RNA 3D STRUCTURE ANA
   Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027                                                          
   Stephenson JD, 2013, STRUCTURE, V21, P951, DOI 10.1016/j.str.2013.04.008
   Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047
   Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6                                                   
   Swenson M Shel, 2012, BMC Res Notes, V5, P341, DOI 10.1186/1756-0500-5-341
   Tabei Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-33
   TANAKA S, 1976, MACROMOLECULES, V9, P945, DOI 10.1021/ma60054a013                                                             
   TINOCO I, 1971, NATURE, V230, P362, DOI 10.1038/230362a0
   Tozzini V, 2010, ACCOUNTS CHEM RES, V43, P220, DOI 10.1021/ar9001476
   Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268
   Washietl S, 2012, NUCLEIC ACIDS RES, V40, P4261, DOI 10.1093/nar/gks009
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   Weeks KM, 2010, CURR OPIN STRUC BIOL, V20, P295, DOI 10.1016/j.sbi.2010.04.001
   WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7
   Xin YR, 2008, RNA, V14, P2465, DOI 10.1261/rna.1249208
   Yang SC, 2010, J PHYS CHEM B, V114, P10039, DOI 10.1021/jp1057308
   Yu ET, 2008, P NATL ACAD SCI USA, V105, P12248, DOI 10.1073/pnas.0800509105
   Zarringhalam K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045160
   Zhang QR, 2006, J AM SOC MASS SPECTR, V17, P1570, DOI 10.1016/j.jasms.2006.06.002
   ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133                                                             
   ZWIEB C, 1997, NUCL ACIDS S SER, V36, P69
NR 100
TC 16
Z9 16
U1 2
U2 34
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD MAY
PY 2014
VL 11
IS 5
BP 522
EP 536
DI 10.4161/rna.28826
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AO7FI
UT WOS:000341517200012
PM 24785264
OA gold
DA 2018-01-05
ER

PT J
AU Kanazawa, T
   Morisaki, K
   Suzuki, S
   Takashima, Y
AF Kanazawa, Takanori
   Morisaki, Kazuki
   Suzuki, Shohei
   Takashima, Yuuki
TI Prolongation of Life in Rats with Malignant Glioma by Intranasal
   siRNA/Drug Codelivery to the Brain with Cell-Penetrating
   Peptide-Modified Micelles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE nose-to-brain delivery; malignant glioma; micelles; cell-penetrating
   peptide; siRNA
ID CENTRAL-NERVOUS-SYSTEM; NASAL CAVITY; DELIVERY; THERAPY; COMBINATION;
   TRANSPORT
AB New therapeutic strategies are required to develop candidate drugs and ensure efficient delivery of these drugs to the brain and the central nervous system (CNS). Small interfering RNA (siRNA)-based therapies have been investigated as potential novel approaches for the treatment of brain disorders. Previously, we showed that Tat, a cell-penetrating peptide derived from HIV-Tat, and the modified block copolymers (MPEG-PCL-Tat) can form stable complexes with siRNA or can be loaded with an anticancer drug and efficiently deliver the drugs to the brain tissue via intranasal delivery. In this study, to develop a novel, efficient, and safe therapeutic strategy for managing brain disorders, we used MPEG-PCL-Tat micelles with a nose-to-brain delivery system to investigate its therapeutic effects on a rat model of malignant glioma using siRNA with a Raf-1 (siRaf-1)/camptothecin (CPT) codelivery system. MPEG-PCL-Tat and CPT-loaded MPEG-PCL-Tat can form a stable complex with siRNA with a particle size from 60 to 200 nm and a positive charge at N/P ratios up to 5. Additionally, MPEG-PCL-Tat/siRaf-1 and CPT-loaded MPEG-PCL-Tat/siRaf-1 have fostered cell death in rat glioma cells after the high cellular uptake of siRaf-1/drug by the MPEG-PCL-Tat carrier. Furthermore, compared to the unloaded MPEG-PCL-Tat/siRaf-1 complex, a CPT-loaded MPEG-PCL-Tat/siRaf-1 complex achieved the high therapeutic effect because of the additive effects of CPT and siRaf-1. These results indicate that drug/siRNA codelivery using MPEG-PCL-Tat nanomicelles with nose-to-brain delivery is an excellent therapeutic approach for brain and CNS diseases.
C1 [Kanazawa, Takanori; Morisaki, Kazuki; Suzuki, Shohei; Takashima, Yuuki] Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan.
RP Kanazawa, T (reprint author), Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.
EM kanazawa@toyaku.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [25870767]; Promotion
   and Mutual Aid Corporation for Private Schools of Japan
FX This work was supported in part by a Grant-in-Aid for Young Scientists
   (B) (25870767) from the Japan Society for the Promotion of Science
   (JSPS) and in part by a Grant for Private Universities provided by the
   Promotion and Mutual Aid Corporation for Private Schools of Japan. We
   thank Mr. Fuminari Akiyama, Ms. Shino Kakizaki, and Ms. Mami Kaneko
   (Tokyo University of Pharmacy and Life Sciences) for their technical
   assistance.
CR Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Combs SE, 2008, INT J RADIAT ONCOL, V71, P999, DOI 10.1016/j.ijrobp.2007.11.064
   Dagistan Y, 2012, ACTA CIR BRAS, V27, P383, DOI 10.1590/S0102-86502012000600005
   Frey I.I.W.H., 2002, DRUG DELIV TECHNOL, V2, P46
   Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7
   Kanazawa T, 2013, BIOMATERIALS, V34, P9220, DOI 10.1016/j.biomaterials.2013.08.036
   Kanazawa T, 2012, EUR J PHARM BIOPHARM, V81, P470, DOI 10.1016/j.ejpb.2012.04.021
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Koo YEL, 2006, ADV DRUG DELIVER REV, V58, P1556, DOI 10.1016/j.addr.2006.09.012
   Lee J., 2005, BIOTECHNOL APPL BI 2, V42, P169
   Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Orlacchio A, 2007, MINI-REV MED CHEM, V7, P1166, DOI 10.2174/138955707782331678
   Pappas TC, 2008, EXPERT OPIN THER TAR, V12, P115, DOI 10.1517/14728222.12.1.115
   Pardridge WM, 2001, DRUG DISCOV TODAY, V6, P381, DOI 10.1016/S1359-6446(01)01721-4
   Ross TM, 2004, J NEUROIMMUNOL, V151, P66, DOI 10.1016/j.jneuroim.2004.02.011
   SAKANE T, 1991, J PHARM PHARMACOL, V43, P449, DOI 10.1111/j.2042-7158.1991.tb03510.x                                              
   Taki Hiroyuki, 2012, Pharmaceuticals (Basel), V5, P1092, DOI 10.3390/ph5101092
   Tanaka K, 2010, INT J PHARMACEUT, V396, P229, DOI 10.1016/j.ijpharm.2010.06.028
   Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
NR 21
TC 30
Z9 31
U1 5
U2 52
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY
PY 2014
VL 11
IS 5
BP 1471
EP 1478
DI 10.1021/mp400644e
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AG6SA
UT WOS:000335547500011
PM 24708261
DA 2018-01-05
ER

PT J
AU Dalpiaz, A
   Ferraro, L
   Perrone, D
   Leo, E
   Iannuccelli, V
   Pavan, B
   Paganetto, G
   Beggiato, S
   Scalia, S
AF Dalpiaz, Alessandro
   Ferraro, Luca
   Perrone, Daniela
   Leo, Eliana
   Iannuccelli, Valentina
   Pavan, Barbara
   Paganetto, Guglielmo
   Beggiato, Sarah
   Scalia, Santo
TI Brain Uptake of a Zidovudine Prodrug after Nasal Administration of Solid
   Lipid Microparticles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE solid lipid microparticles; zidovudine; ursodeoxycholic acid; prodrug;
   hydrolysis; liver homogenate; nasal formulation; brain uptake
ID CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; STABILITY ENHANCEMENT;
   INTRANASAL DELIVERY; HIV-1 INFECTION; DRUG-DELIVERY; CHITOSAN;
   TRANSPORT; NANOPARTICLES; RESISTANCE
AB Our previous results demonstrated that a prodrug obtained by the conjugation of the antiretroviral drug zidovudine (AZT) with ursodeoxycholic acid (UDCA) represents a potential carrier for AZT in the central nervous system, thus possibly increasing AZT efficiency as an anti-HIV drug. Based on these results and in order to enhance AZT brain targeting, the present study focuses on solid lipid microparticles (SLMs) as a carrier system for the nasal administration of UDCA-AZT prodrug. SLMs were produced by the hot emulsion technique, using tristearin and stearic acid as lipidic carriers, whose mean diameters were 16 and 7 mu m, respectively. SLMs were of spherical shape, and their prodrug loading was 0.57 +/- 0.03% (w/w, tristearin based) and 1.84 +/- 0.02% (w/w, stearic acid based). The tristearin SLMs were able to control the prodrug release, whereas the stearic acid SLMs induced a significant increase of the dissolution rate of the free prodrug. The free prodrug was rapidly hydrolyzed in rat liver homogenates with a half-life of 2.7 +/- 0.14 min (process completed within 30 mm). The tristearin SLMs markedly enhanced the stability of the prodrug (75% of the prodrug still present after 30 min), whereas the stabilization effect of the stearic acid SLMs was lower (14% of the prodrug still present after 30 mm). No AZT and UDCA-AZT were detected in the rat cerebrospinal fluid (CSF) after an intravenous prodrug administration (200 mu g). Conversely, the nasal administration of stearic acid based SLMs induced the uptake of the prodrug in the CSF, demonstrating the existence of a direct nose-CNS pathway. In the presence of chitosan, the CSF prodrug uptake increased six times, up to 1.5 mu g/mL within 150 mm after nasal administration. The loaded SLMs appear therefore as a promising nasal formulation for selective zidovudine brain uptake.
C1 [Dalpiaz, Alessandro; Perrone, Daniela; Scalia, Santo] Univ Ferrara, Dept Chem & Pharmaceut Sci, I-44121 Ferrara, Italy.
   [Ferraro, Luca; Pavan, Barbara; Paganetto, Guglielmo] Univ Ferrara, Dept Life Sci & Biotechnol, I-44121 Ferrara, Italy.
   [Leo, Eliana; Iannuccelli, Valentina] Univ Modena & Reggio Emilia, Dept Life Sci, Modena, Italy.
   [Beggiato, Sarah] Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy.
RP Dalpiaz, A (reprint author), Univ Ferrara, Dept Chem & Pharmaceut Sci, Via Fossato di Mortara 19, I-44121 Ferrara, Italy.
EM dla@unife.it
RI Iannuccelli, Valentina/C-9810-2015; Leo, Eliana/A-7780-2011; Ferraro,
   Luca/F-9915-2015
OI Iannuccelli, Valentina/0000-0001-6119-5794; Leo,
   Eliana/0000-0003-4721-1676; Ferraro, Luca/0000-0003-2390-6414
FU Ministero dell'Istruzione, dell'Universita e della Ricerca (PRIN)
FX This work was supported by a grant from Ministero dell'Istruzione,
   dell'Universita e della Ricerca (PRIN 2012). The authors thank Andrea
   Margutti (Department of Life Sciences and Biotechnology, University of
   Ferrara, Italy) for technical assistance. Special thanks should be given
   to Roberta Mazzorana Reolon (ECO.RA.V. S.p.A. Longarone, Belluno Italy)
   for her significant support on this project.
CR Barras A, 2009, INT J PHARMACEUT, V379, P270, DOI 10.1016/j.ijpharm.2009.05.054
   Rausch D. M., 2001, PROG NEUROPSYCHOPHAR, V25, P231
   CHAUDHARY PM, 1992, BLOOD, V80, P2735
   Cunningham AL, 1997, J LEUKOCYTE BIOL, V62, P117
   Cunningham PH, 2000, AIDS, V14, P1949, DOI 10.1097/00002030-200009080-00010
   Dalpiaz A, 2008, INT J PHARM, V355, P81, DOI 10.1016/j.ijpharm.2007.11.044
   Dalpiaz A, 2008, J PHARM SCI-US, V97, P4889, DOI 10.1002/jps.21335
   Dalpiaz A, 2012, MOL PHARMACEUT, V9, P957, DOI 10.1021/mp200565g
   Dalpiaz A, 2010, J PHARM SCI-US, V99, P4730, DOI 10.1002/jps.22178
   DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736                                                           
   Davson H., 1987, ANONYMOUS PHYSL PATH, P189
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Dodane V, 1999, INT J PHARM, V182, P21, DOI 10.1016/S0378-5173(99)00030-7                                                   
   FELGENHAUER K, 1974, KLIN WOCHENSCHR, V52, P1158, DOI 10.1007/BF01466734
   Fricker G, 2010, PHARM RES-DORDR, V27, P1469, DOI 10.1007/s11095-010-0130-x
   Gavini E, 2013, EUR J PHARM BIOPHARM, V83, P174, DOI 10.1016/j.ejpb.2012.10.010
   Gavini E, 2011, J PHARM SCI-US, V100, P1488, DOI 10.1002/jps.22382
   GhersiEgea JF, 1996, NEUROSCIENCE, V75, P1271, DOI 10.1016/0306-4522(96)00281-3                                                    
   GILL PS, 1987, ANN INTERN MED, V107, P502, DOI 10.7326/0003-4819-107-4-502
   Gray F, 1996, BRAIN PATHOL, V6, P1, DOI 10.1111/j.1750-3639.1996.tb00775.x                                              
   Horvat S, 2009, EUR J PHARM BIOPHARM, V72, P252, DOI 10.1016/j.ejpb.2008.10.009
   Illum L., 2004, J PHARM PHARMACOL, V56, P3
   Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7
   ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450
   Jaspart Severine, 2005, Expert Opin Drug Deliv, V2, P75, DOI 10.1517/17425247.2.1.75
   Johnson NJ, 2010, MOL PHARMACEUT, V7, P884, DOI 10.1021/mp100029t
   Joshi AS, 2012, J MATER SCI-MATER M, V23, P2163, DOI 10.1007/s10856-012-4702-7
   Kaufmann GR, 2000, CURR OPIN MICROBIOL, V3, P508, DOI 10.1016/S1369-5274(00)00131-4
   Kippax P, 2010, PHARM TECHNOL, V9, P58
   Kolhe Smita, 2012, Int J Bioinform Res Appl, V8, P112, DOI 10.1504/IJBRA.2012.045954
   Kolson DL, 2000, J CLIN INVEST, V106, P11, DOI 10.1172/JCI10553                                                                
   Lee KY, 1998, J CONTROL RELEASE, V51, P213, DOI 10.1016/S0168-3659(97)00173-9
   LEHR CM, 1992, INT J PHARM, V78, P43, DOI 10.1016/0378-5173(92)90353-4                                                    
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MADU A, 1994, ANTIMICROB AGENTS CH, V38, P2111, DOI 10.1128/AAC.38.9.2111                                                           
   MEEK JL, 1973, NEUROPHARMACOLOGY, V12, P497, DOI 10.1016/0028-3908(73)90067-1                                                    
   Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019
   Muller RH, 2002, ADV DRUG DELIVER REV, V54, pS131, DOI 10.1016/S0169-409X(02)00118-7
   Namanja HA, 2012, J AM CHEM SOC, V134, P2976, DOI 10.1021/ja206867t
   NEYFAKH AA, 1989, EXP CELL RES, V185, P496, DOI 10.1016/0014-4827(89)90318-2
   OCKENFELS H, 1977, Arzneimittel-Forschung, V27, P126
   Parhi P, 2012, DRUG DISCOV TODAY, V17, P1044, DOI 10.1016/j.drudis.2012.05.010
   Patel S, 2011, J DRUG TARGET, V19, P468, DOI 10.3109/1061186X.2010.523787
   Pavan B, 2011, CURR PHARM DESIGN, V17, P3560, DOI 10.2174/138161211798194486                                                      
   Renner DB, 2012, J PHARM PHARMACOL, V64, P1709, DOI 10.1111/j.2042-7158.2012.01555.x
   Rohit B, 2013, CURR NANOSCI, V9, P211, DOI 10.2174/1573413711309020008                                                     
   Sacchetti C, 2002, INT J PHARM, V242, P335, DOI 10.1016/S0378-5173(02)00177-1
   SEKI T, 1994, BIOL PHARM BULL, V17, P1135
   SHAH VP, 1995, INT J PHARM, V125, P99, DOI 10.1016/0378-5173(95)00123-Z                                                    
   Shamsipur M, 2013, AAPS PHARMSCITECH, V14, P287, DOI 10.1208/s12249-012-9916-y
   Strazielle N, 2003, AIDS, V17, P1473, DOI 10.1097/01.aids.0000076276.54156.d3
   Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029
   Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003
   van den Berg MP, 2002, J NEUROSCI METH, V116, P99, DOI 10.1016/S0165-0270(02)00033-X
   Vyas Tushar K., 2005, Current Drug Delivery, V2, P165, DOI 10.2174/1567201053586047
   WONG SL, 1993, J PHARMACOL EXP THER, V264, P899
NR 56
TC 13
Z9 13
U1 0
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY
PY 2014
VL 11
IS 5
BP 1550
EP 1561
DI 10.1021/mp400735c
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AG6SA
UT WOS:000335547500019
PM 24717116
DA 2018-01-05
ER

PT J
AU Dalpiaz, A
   Contado, C
   Mari, L
   Perrone, D
   Pavan, B
   Paganetto, G
   Hanuskova, M
   Vighi, E
   Leo, E
AF Dalpiaz, Alessandro
   Contado, Catia
   Mari, Lara
   Perrone, Daniela
   Pavan, Barbara
   Paganetto, Guglielmo
   Hanuskova, Miriam
   Vighi, Eleonora
   Leo, Eliana
TI Development and characterization of PLGA nanoparticles as delivery
   systems of a prodrug of zidovudine obtained by its conjugation with
   ursodeoxycholic acid
SO DRUG DELIVERY
LA English
DT Article
DE Controlled release; PLGA nanoparticles; prodrug; SdFFF; stability;
   zidovudine
ID SOLID LIPID MICROPARTICLES; DRUG-DELIVERY; POLYMERIC NANOPARTICLES;
   STABILITY ENHANCEMENT; POLY(LACTIC ACID); EFFLUX TRANSPORT; HIV-1
   INFECTION; IN-VIVO; RELEASE; FORMULATION
AB Context: Zidovudine (AZT) is employed against AIDS and hepatitis; its use is limited by active efflux transporters (AETs) that induce multidrug resistance for intracellular therapies and hamper AZT to reach the brain. Ursodeoxycholic acid (UDCA) conjugation with AZT (prodrug UDCA-AZT) allows to elude the AET systems.
   Objective: To investigate the effect of the Pluronic F68 coating on the loading, release and stability of poly(D, L lactide-co-glicolide) nanoparticles (NPs) embedded with UDCA-AZT.
   Materials and methods: The mean diameter of the NP prepared by nanoprecipitation or emulsion/solvent evaporation methods was determined using both photon correlation spectroscopy and sedimentation field-flow fractionation; particle morphology was detected by scanning electron microscope. The stability of the free and encapsulated UDCA-AZT was evaluated in rat liver homogenates by high-performance liquid chromatography analysis.
   Results and discussion: The mean diameter of the NPs was found to be similar to 600 nm with a relatively high polydispersity. The NPs obtained by emulsion/solvent evaporation were not able to control the prodrug release, differently from NPs obtained by nanoprecipitation. The presence of the Pluronic coating did not substantially modify the kinetics of the drug release, or the extent of the burst effect that were instead only influenced by the preparation parameters. UDCA-AZT incorporated in the NPs was more stable in the rat liver homogenates than the free prodrug and no influence of the Pluronic coating was observed.
   Conclusions: Considering the different potential applications of nanoparticles coated and uncoated with Pluronic (brain and macrophage targeting, respectively), both of these nanoparticle systems could be useful in the therapies against HIV.
C1 [Dalpiaz, Alessandro; Contado, Catia; Mari, Lara; Perrone, Daniela; Paganetto, Guglielmo] Univ Ferrara, Dept Chem & Pharmaceut Sci, I-44121 Ferrara, Italy.
   [Pavan, Barbara] Univ Ferrara, Dept Life Sci & Technol, I-44121 Ferrara, Italy.
   [Hanuskova, Miriam] Univ Modena & Reggio Emilia, Dept Engn Enzo Ferrari, Modena, Italy.
   [Vighi, Eleonora; Leo, Eliana] Univ Ferrara, Dept Life Sci, I-44121 Ferrara, Italy.
RP Contado, C (reprint author), Univ Ferrara, Dept Chem & Pharmaceut Sci, Via Borsari 46, I-44121 Ferrara, Italy.
EM catia.contado@unife.it
RI Leo, Eliana/A-7780-2011; Contado, Catia/B-6987-2015
OI Leo, Eliana/0000-0003-4721-1676; Contado, Catia/0000-0001-6447-4596
FU Ministero dell'Istruzione, dell'Universita e della Ricerca [PRIN 2012]
FX This work was supported by a grant from Ministero dell'Istruzione,
   dell'Universita e della Ricerca (PRIN 2012).
CR Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Chen J, 2012, J DRUG TARGET, V20, P174, DOI 10.3109/1061186X.2011.622396
   CHILDS CE, 1975, MICROCHEM J, V20, P190, DOI 10.1016/0026-265X(75)90038-7
   Chorny M, 2002, J CONTROL RELEASE, V83, P389, DOI 10.1016/S0168-3659(02)00211-0                                                   
   Contado C, 2013, ANAL BIOANAL CHEM, V405, P703, DOI 10.1007/s00216-012-6113-5
   Contado C, 2011, J CHROMATOGR A, V1218, P4179, DOI 10.1016/j.chroma.2010.11.061
   Contado C, 2009, J CHROMATOGR A, V1216, P9088, DOI 10.1016/j.chroma.2009.08.026
   Dalpiaz A, 2008, INT J PHARM, V355, P81, DOI 10.1016/j.ijpharm.2007.11.044
   Dalpiaz A, 2005, BIOMATERIALS, V26, P1299, DOI 10.1016/j.biomaterials.2004.04.033
   Dalpiaz A, 2002, INT J PHARM, V242, P115, DOI 10.1016/S0378-5173(02)00179-5                                                   
   Dalpiaz A, 2001, PHARMACEUT RES, V18, P531, DOI 10.1023/A:1011018730459                                                         
   Dalpiaz A, 2012, MOL PHARMACEUT, V9, P957, DOI 10.1021/mp200565g
   Dalpiaz A, 2010, J PHARM SCI-US, V99, P4730, DOI 10.1002/jps.22178
   Dalpiaz A, 2009, J PHARM SCI-US, V98, P4272, DOI 10.1002/jps.21710
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736                                                           
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Gelperina S, 2010, EUR J PHARM BIOPHARM, V74, P157, DOI 10.1016/j.ejpb.2009.09.003
   Gray F, 1996, BRAIN PATHOL, V6, P1, DOI 10.1111/j.1750-3639.1996.tb00775.x                                              
   Hunter R. J., 1989, FDN COLLOID SCI, V1
   JALIL RU, 1990, DRUG DEV IND PHARM, V16, P2353, DOI 10.3109/03639049009058535                                                       
   Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5
   Kolson DL, 2000, J CLIN INVEST, V106, P11, DOI 10.1172/JCI10553                                                                
   Leo E, 2006, INT J PHARM, V307, P103, DOI 10.1016/j.ijpharm.2005.09.031
   Leo E, 2006, J NANOSCI NANOTECHNO, V6, P3070, DOI 10.1166/jnn.2006.408
   Liang V., 1987, ANN NY ACAD SCI, V507, P7
   Lobato M, 2012, INT J NANOMED, V7, P5793
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Nafee N, 2009, INT J PHARMACEUT, V381, P130, DOI 10.1016/j.ijpharm.2009.04.049
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90
   Siepmann J, 2004, J CONTROL RELEASE, V96, P123, DOI 10.1016/j.jconrel.2004.01.011
   Takasawa K, 1997, J PHARMACOL EXP THER, V281, P369
   Tomoda K, 2012, COLLOID SURFACE B, V97, P84, DOI 10.1016/j.colsurfb.2012.04.002
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   WONG SL, 1993, J PHARMACOL EXP THER, V264, P899
NR 40
TC 4
Z9 4
U1 0
U2 36
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PD MAY
PY 2014
VL 21
IS 3
BP 221
EP 232
DI 10.3109/10717544.2013.844744
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AG5FF
UT WOS:000335444100008
PM 24134683
OA gold
DA 2018-01-05
ER

PT J
AU D'Cruz, OJ
   Uckun, FM
AF D'Cruz, Osmond J.
   Uckun, Fatih M.
TI Vaginal microbicides and their delivery platforms
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE antiretroviral; heterosexual transmission; human immunodeficiency virus;
   intravaginal ring; live microbicide; nano-microbicides; reverse
   transcriptase; vaginal delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITOR; TENOFOVIR
   DISOPROXIL FUMARATE; LACTIC-ACID BACTERIA; HIV-NEGATIVE WOMEN; IN-VITRO;
   CONTROLLED-TRIAL; RHESUS MACAQUES; NONNUCLEOSIDE INHIBITORS;
   ANTIRETROVIRAL ACTIVITY
AB Introduction: HIV type 1 infection, despite having fallen by one-third over the past decade, remains a global health concern affecting millions of individuals worldwide. A focal point in contemporary research aimed at global HIV prevention has been the development of safe and efficacious coitally dependent and coitally independent anti-HIV microbicides to curb heterosexual HIV transmission. Despite extensive research efforts to develop novel vaginal antiretroviral (ARV) formulations and intravaginal ring delivery systems, the clinical advancement of microbicides with improved safety, efficacy and tolerability has significantly lagged behind.
   Areas covered: This review focuses on the current status of both coitally dependent and coitally independent delivery platforms designed to increase user acceptability and clinical effectiveness of anti-HIV microbicides. The clinical failure of several vaginal microbicide candidates has propelled the field to mechanism-based ARV candidates that act more specifically on viral receptors, viral enzymes and host proteins. Consequently, improved vaginal microbicide delivery strategies that achieve uniform drug distribution with enhanced solubility, sustained drug release, improved product adherence with reduced dosing frequency and lack of effect on the vaginal mucosa and microbiota are being sought.
   Expert opinion: Clinical success with vaginal microbicides may best be achieved through the combined effects of ARV compounds that exhibit different mechanisms of action with potent activity against multidrug-resistant HIV and efficacious delivery systems.
C1 [D'Cruz, Osmond J.; Uckun, Fatih M.] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood, Los Angeles, CA 90027 USA.
   [Uckun, Fatih M.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90027 USA.
RP D'Cruz, OJ (reprint author), Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood, Smith Res Tower Suite 316,4650 Sunset Blvd, Los Angeles, CA 90027 USA.
EM fmuckun@chla.usc.edu
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Acarturk Fusun, 2009, Recent Pat Drug Deliv Formul, V3, P193
   Bastian AR, 2011, CHEMMEDCHEM, V6, P1335, DOI 10.1002/cmdc.201100177
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Cahn P., 2012, Journal of AIDS and Clinical Research, V3, P138
   Calmy A, 2009, J INFECT DIS, V200, P1746, DOI 10.1086/644785
   Carias AM, 2013, J VIROL, V87, P11388, DOI 10.1128/JVI.01377-13
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Chen CL, 2002, DRUG METAB DISPOS, V30, P1523, DOI 10.1124/dmd.30.12.1523
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   D'Cruz O J, 2001, AAPS PharmSciTech, V2, pE5
   D'Cruz O. J., 2012, Journal of AIDS and Clinical Research, V3, P144
   D'Cruz OJ, 2004, BIOL REPROD, V71, P2037, DOI 10.1095/biolreprod.104.032870
   D'Cruz OJ, 2004, FERTIL STERIL, V81, P831, DOI 10.1016/j.fertnstert.2003.08.037
   D'Cruz OJ, 2004, CURR PHARM DESIGN, V10, P315, DOI 10.2174/1381612043386374
   D'Cruz OJ, 2002, J ANTIMICROB CHEMOTH, V50, P793, DOI 10.1093/jac/dkg001
   D'Cruz OJ, 2001, CONTRACEPTION, V64, P113, DOI 10.1016/S0010-7824(01)00233-5
   D'Cruz OJ, 2006, J ENZYM INHIB MED CH, V21, P329, DOI 10.1080/14756360600774413
   D'Cruz Osmond J, 2005, AAPS PharmSciTech, V6, pE56, DOI 10.1208/pt060111
   D'Cruz OJ, 2012, EXPERT OPIN INV DRUG, V21, P265, DOI 10.1517/13543784.2012.655422
   Das K, 2009, J BIOL CHEM, V284, P35092, DOI 10.1074/jbc.M109.022525
   De Rosa G, 2009, MOLECULES, V14, P2801, DOI 10.3390/molecules14082801
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Garcia-Lerma JG, 2012, CURR OPIN HIV AIDS, V7, P505, DOI 10.1097/COH.0b013e328358e484
   Grabovac V, 2005, ADV DRUG DELIVER REV, V57, P1713, DOI 10.1016/j.addr.2005.07.006
   Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959
   Hachiya A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016242
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9
   Kenney J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015835
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   Kohler JJ, 2011, LAB INVEST, V91, P852, DOI 10.1038/labinvest.2011.48
   Kohler JJ, 2009, LAB INVEST, V89, P513, DOI 10.1038/labinvest.2009.14
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Malcolm K, 2003, J CONTROL RELEASE, V90, P217, DOI 10.1016/S0168-3659(03)00178-0
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Masse PJ, 2008, ANNU REV MED, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Neff CP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001581
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Nel AM, 2010, AIDS RES HUM RETROV, V26, P1181, DOI 10.1089/aid.2009.0227
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001                                                
   Peterson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001312
   Pusch O, 2005, JAIDS-J ACQ IMM DEF, V40, P512, DOI 10.1097/01.qai.0000187446.76579.d3
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Schader SM, 2012, ANTIMICROB AGENTS CH, V56, P751, DOI 10.1128/AAC.05821-11
   Singer R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003936
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Smith JM, 2013, P NATL ACAD SCI USA, V110, P16145, DOI 10.1073/pnas.1311355110
   Subbarao S, 2006, J INFECT DIS, V194, P904, DOI 10.1086/507306
   Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019                                                
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Uckun FM, 2007, ARZNEIMITTEL-FORSCH, V57, P278
   Uckun FM, 2007, ARZNEIMITTEL-FORSCH, V57, P112
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P193
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P176
   Uckun FM, 2005, ARZNEIMITTEL-FORSCH, V55, P223
   Uckun FM, 2004, ARZNEIMITTEL-FORSCH, V54, P69
   Uckun FM, 2003, ANTIMICROB AGENTS CH, V47, P1233, DOI 10.1128/AAC.47.4.1233-1240.2003
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3613, DOI 10.1128/AAC.46.11.3613-3616.2002
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   Uckun FM, 2012, J AIDS CLIN RES, P4
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Vangelista L, 2008, VACCINE, V26, P3008, DOI 10.1016/j.vaccine.2007.12.023
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Wells JM, 2008, NAT REV MICROBIOL, V6, P349, DOI 10.1038/nrmicro1840
   White KL, 2004, ANTIMICROB AGENTS CH, V48, P992, DOI 10.1128/AAC.48.3.992-1003.2004
   Ying TL, 2013, J BIOL CHEM, V288, P25154, DOI 10.1074/jbc.M113.484154
   Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
NR 90
TC 12
Z9 12
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD MAY
PY 2014
VL 11
IS 5
BP 723
EP 740
DI 10.1517/17425247.2014.888055
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AF9AT
UT WOS:000335008000008
PM 24506783
DA 2018-01-05
ER

PT J
AU Vacas-Cordoba, E
   Bastida, H
   Pion, M
   Hameau, A
   Ionov, M
   Bryszewska, M
   Caminade, AM
   Majoral, JP
   Munoz-Fernandez, MA
AF Vacas-Cordoba, Enrique
   Bastida, Hugo
   Pion, Marjorie
   Hameau, Aurelien
   Ionov, Maksim
   Bryszewska, Maria
   Caminade, Anne Marie
   Majoral, Jean Pierre
   Munoz-Fernandez, Maria-Angeles
TI HIV-Antigens Charged on Phosphorus Dendrimers as Tools for Tolerogenic
   Dendritic Cells-Based Immunotherapy
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Dendritic cells; phosphorus dendrimers; nanoparticle; HIV; peptide;
   vaccine
ID CARBOSILANE DENDRIMERS; TOLERANCE; VACCINE; INFECTION; PATHWAY; TYPE-1;
   OPTIMIZATION; REPLICATION; LYMPHOCYTES; DELIVERY
AB Aims: The objective was to study if cationic phosphorus dendrimers can be used as DC-based vaccine or adjuvant in anti-HIV-1 vaccine development when associated with HIV-1 derived peptides. Materials & Methods: The HIV-derived peptides uptake in DC and the phenotype of iDC and mDC were studied using Flow Cytometry analysis. Migration of mDC was evaluated by an in vitro chemotaxis assay. Allogenic T-cells proliferative response induced by DC was studied using Flow Cytometry assays. Cytokines production was analysed by Diaclon DIAplex Th1/Th2/Inflammation kit. Results: All phosphorus dendrimers showed the ability to deliver HIV-derived peptides in DC. The phosphorus dendrimers from second and third generations induced important changes in phenotype. Moreover, the treatment of mDC with the second generation dendrimer and derivated dendriplexes modified cellular migratory properties, altered their capacity to stimulate allogenic naive T cells in vitro and impeded the production of pro-inflammatory cytokines. Conclusions: The phosphorus dendrimers cannot be used as vaccines because they would not have the ability to induce an immune response. The cationic phosphorus dendrimers associated with HIV-derived peptides have the ability to deliver peptides as non-viral vectors. However, there are other potential therapeutic applications of these compounds, for instance as topical anti-inflammatory agents, as compounds for allograft rejection or autoimmune diseases and as agents inducing specific tolerance with antigen-loaded DC against allergy reaction. Nevertheless, these applications need to be evaluated.
C1 [Vacas-Cordoba, Enrique; Bastida, Hugo; Pion, Marjorie; Munoz-Fernandez, Maria-Angeles] Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
   [Vacas-Cordoba, Enrique; Bastida, Hugo; Pion, Marjorie; Munoz-Fernandez, Maria-Angeles] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Hameau, Aurelien; Caminade, Anne Marie; Majoral, Jean Pierre] CNRS, Chim Coordinat Lab, F-31077 Toulouse 04, France.
   [Ionov, Maksim; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, PL-90131 Lodz, Poland.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
EM mmunoz.hgugm@gmail.com
RI Pion, Marjorie/D-8139-2012; Caminade, Anne-Marie/E-2819-2015
OI Pion, Marjorie/0000-0002-6406-747X; Caminade,
   Anne-Marie/0000-0001-8487-3578; Pion, Marjorie/0000-0003-1828-4745;
   Bryszewska, Maria/0000-0003-4676-3743;
   Munoz-Fernandez/0000-0002-0813-4500
FU EuroNanoMed DENPEPTHIV [PS09/02669]; COST action [TD0802]; Red Tematica
   de Investigacion Cooperativa Sanitaria ISCIII [RED RIS RD06/0006/0035,
   RD12-0017-0037]; Fondo de Investigacion Sanitaria (INTRASALUD)
   [PS09/02029]; INDISNET [S-2011-BMD2332]; FIPSE by MAMF; Spanish MICINN
   through the Ramon y Cajal [RYC-2009-05486]; Project DENPEPTHIV
   [1/EuroNanoMed/2010]; National Centre of Research and Development of
   Poland
FX This work was supported by grants from EuroNanoMed DENPEPTHIV
   (PS09/02669) and COST action TD0802 by the three groups (MAMF, JPM) and
   Red Tematica de Investigacion Cooperativa Sanitaria ISCIII (RED RIS
   RD06/0006/0035; RD12-0017-0037); Fondo de Investigacion Sanitaria
   (INTRASALUD 2009; PS09/02029); INDISNET S-2011-BMD2332 and FIPSE by
   MAMF. The Spanish MICINN through the Ramon y Cajal (RYC-2009-05486) to
   MP. Project DENPEPTHIV, Grant No. 1/EuroNanoMed/2010 financed by the
   National Centre of Research and Development of Poland to MB.
CR Amico KR, 2012, CURR OPIN HIV AIDS, V7, P542, DOI 10.1097/COH.0b013e3283582d4a
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Caminade AM, 2012, MOLECULES, V17, P13605, DOI 10.3390/molecules171113605
   Caminade AM, 2010, NEW J CHEM, V34, P1512, DOI 10.1039/c0nj00116c
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Ciepluch K, 2012, MOL PHARMACEUT, V9, P448, DOI 10.1021/mp200549c
   Climent N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019644
   de Vries IJM, 2003, CANCER RES, V63, P12
   Gamble LJ, 2010, DRUG DES DEV THER, V5, P9, DOI 10.2147/DDDT.S6959
   Garcia F, 2011, VACCINE, V29, P6454, DOI 10.1016/j.vaccine.2011.07.043
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Giannoukakis N, 2012, CURR OPIN ENDOCRINOL, V19, P279, DOI 10.1097/MED.0b013e328355461b
   Giannoukakis N, 2011, DIABETES CARE, V34, P2026, DOI 10.2337/dc11-0472
   Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616
   Goldmann K, 2012, CLIN VACCINE IMMUNOL, V19, P1758, DOI 10.1128/CVI.00186-12
   Gomulak P, 2012, CURR MED CHEM, V19, P6233
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gras R, 2009, PHARM RES-DORD, V26, P577, DOI 10.1007/s11095-008-9776-z
   Hayder M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002212
   Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Luis Jimenez J, 2012, NEW J CHEM, V36, P299
   Kong Leopold, 2012, J AIDS Clin Res, VS8, P3
   KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629
   Larsson M, 2003, CURR TOP MICROBIOL, V276, P261
   Lewis KL, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007401
   Loup C., 1999, CHEM-EUR J, V5, P36644
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132
   O'Connell RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007351
   Pedziwiatr-Werbicka E, 2012, J BIOMED NANOTECHNOL, V8, P57, DOI 10.1166/jbn.2012.1369
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Qian C, 2013, J BIOL CHEM, V288, P27825, DOI 10.1074/jbc.M112.425751
   Raimondi G, 2005, CONTRIB NEPHROL, V146, P105
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   Rock KL, 1996, J IMMUNOL, V156, P3721
   Rolland O, 2008, CHEM-EUR J, V14, P4836, DOI 10.1002/chem.200701063
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698                                                          
   Stenger EO, 2012, BLOOD, V119, P5088, DOI 10.1182/blood-2011-11-364091
   Wasiak T, 2012, MOL PHARMACEUT, V9, P458, DOI 10.1021/mp2005627
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
NR 48
TC 4
Z9 4
U1 2
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAY
PY 2014
VL 21
IS 16
BP 1898
EP 1909
DI 10.2174/0929867321666131129114022
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AF3CK
UT WOS:000334588900005
PM 24304285
DA 2018-01-05
ER

PT J
AU Jones, E
   Ojewole, E
   Kalhapure, R
   Govender, T
AF Jones, Elsabe
   Ojewole, Elizabeth
   Kalhapure, Rahul
   Govender, Thirumala
TI In vitro comparative evaluation of monolayered multipolymeric films
   embedded with didanosine-loaded solid lipid nanoparticles: a potential
   buccal drug delivery system for ARV therapy
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Antiretrovirals; entrapment efficiency; hydrophilic drug; mucoadhesion;
   permeation; transmucosal
ID ANTIRETROVIRAL THERAPY; POLYMERIC FILMS; OPPOSING SOLUBILITIES; TOPICAL
   DELIVERY; CHITOSAN FILMS; PARTICLE-SIZE; ORAL-MUCOSA; HIV; FORMULATION;
   PERMEABILITY
AB Drug delivery via the buccal route has emerged as a promising alternative to oral drug delivery. Didanosine (DDI) undergoes rapid degradation in the gastrointestinal tract, has a short half-life and low oral bioavailability, making DDI a suitable candidate for buccal delivery. Recent developments in buccal drug delivery show an increased interest toward nano-enabled delivery systems. The advantages of buccal drug delivery can be combined with that of nanoparticulate delivery systems to provide a superior delivery system. The aim of this study was to design and evaluate the preparation of novel nano-enabled films for buccal delivery of DDI. Solid lipid nanoparticles (SLNs) were prepared via hot homogenization followed by ultrasonication and were characterized before being incorporated into nano-enabled monolayered multipolymeric films (MMFs). Glyceryl tripalmitate with Poloxamer 188 was identified as most suitable for the preparation of DDI-loaded SLNs. SLNs with desired particle size (PS) (201 nm), polydispersity index (PDI) (0.168) and zeta potential (-18.8 mV) were incorporated into MMFs and characterized. Conventional and nano-enabled MMFs were prepared via solvent casting/ evaporation using Eudragit RS100 and hydroxypropyl methylcellulose. Drug release from the nano-enabled films was found to be faster (56% versus 20% in first hour). Conventional MMFs exhibited higher mucoadhesion and mechanical strength than nano-enabled MMFs. SLNs did not adversely affect the steady state flux (71.63 +/- 13.54 mu g/cm(2) h versus 74.39 +/- 15.95 mu g/cm(2) h) thereby confirming the potential transbuccal delivery of DDI using nano-enabled MMFs. Nano-enabled buccal films for delivery of DDI can be successfully prepared, and these physico-mechanical studies serve as a platform for future formulation optimization work in this emerging field.
C1 [Jones, Elsabe; Ojewole, Elizabeth; Kalhapure, Rahul; Govender, Thirumala] Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, ZA-4000 Durban, South Africa.
RP Govender, T (reprint author), Univ KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, Private Bag X54001, ZA-4000 Durban, South Africa.
EM govenderth@ukzn.ac.za
OI Kalhapure, Rahul/0000-0003-4627-9628
FU National Research Foundation of South Africa; South African Medical
   Research Council; University of KwaZulu-Natal
FX The authors report no conflicts of interest. The authors are grateful to
   the National Research Foundation of South Africa, the South African
   Medical Research Council and the University of KwaZulu-Natal for
   financial support.
CR Aji Alex M R, 2011, Eur J Pharm Sci, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   ANDERSON BD, 1988, INT J PHARM, V45, P27, DOI 10.1016/0378-5173(88)90031-2
   Andrews GP, 2009, EUR J PHARM BIOPHARM, V71, P505, DOI 10.1016/j.ejpb.2008.09.028
   Avachat AM, 2013, CARBOHYD POLYM, V91, P537, DOI 10.1016/j.carbpol.2012.08.062
   Ayensu I, 2012, COLLOID SURFACE B, V91, P258, DOI 10.1016/j.colsurfb.2011.11.004
   Behrens GMN, 2000, DRUG SAFETY, V23, P57, DOI 10.2165/00002018-200023010-00004
   BEKERS O, 1993, J PHARMACEUT BIOMED, V11, P489, DOI 10.1016/0731-7085(93)80162-T                                                    
   Benghuzzi H, 2000, Biomed Sci Instrum, V36, P343
   Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381                                                          
   Carvalho FC, 2013, EUR J PHARM BIOPHARM, V84, P219, DOI 10.1016/j.ejpb.2012.11.021
   Chandwani S, 2012, J ADOLESCENT HEALTH, V51, P242, DOI 10.1016/j.jadohealth.2011.12.013
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Dodiya SS, 2011, J MICROENCAPSUL, V28, P515, DOI 10.3109/02652048.2011.590612
   Dubey V, 2010, NANOMED-NANOTECHNOL, V6, P590, DOI 10.1016/j.nano.2010.01.002
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Eouani C, 2001, EUR J PHARM BIOPHARM, V52, P45, DOI 10.1016/S0939-6411(01)00146-1
   Gallicano K, 2000, ANTIMICROB AGENTS CH, V44, P1117, DOI 10.1128/AAC.44.4.1117-1118.2000                                                 
   Gerber M, 2008, INT J PHARM, V351, P186, DOI 10.1016/j.ijpharm.2007.09.040
   Ghadiri M, 2012, INT J PHARMACEUT, V424, P128, DOI 10.1016/j.ijpharm.2011.12.037
   Giovino C, 2012, INT J PHARMACEUT, V428, P143, DOI 10.1016/j.ijpharm.2012.02.035
   Hartman T.L., 2012, MOL BIOL INT, V2012, DOI DOI 10.1155/2012/401965
   Heng PWS, 2003, J PHARM PHARM SCI, V6, P334
   Holpuch AS, 2010, PHARM RES-DORDR, V27, P1224, DOI 10.1007/s11095-010-0121-y
   Hoogstraate JAJ, 1998, PHARM SCI TECHNOL TO, V1, P309, DOI 10.1016/S1461-5347(98)00076-5                                                   
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Jones E, 2013, INT J PHARMACEUT, V455, P197, DOI 10.1016/j.ijpharm.2013.07.037
   Kapil R, 2013, DRUG DEV IND PHARM, V39, P466, DOI 10.3109/03639045.2012.665926
   Kasongo KW, 2011, J PHARM SCI-US, V100, P5185, DOI 10.1002/jps.22711
   Kasongo KW, 2011, DRUG DEV IND PHARM, V37, P396, DOI 10.3109/03639045.2010.516264
   Katzung B. G., 2003, BASIC CLIN PHARM
   Khan TA, 2000, J PHARM PHARM SCI, V3, P303
   Koland M, 2010, INDIAN J PHARM EDUC, V44, P315
   Kumar VV, 2007, INT J PHARM, V335, P167, DOI 10.1016/j.ijpharm.2006.11.004
   Kuo YC, 2011, COLLOID SURFACE B, V83, P299, DOI 10.1016/j.colsurfb.2010.11.037
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lv QZ, 2009, INT J PHARMACEUT, V372, P191, DOI 10.1016/j.ijpharm.2009.01.014
   Mehnert W, 2012, ADV DRUG DELIVER REV, V64, P83, DOI 10.1016/j.addr.2012.09.021
   Merson MH, 2008, LANCET, V372, P475, DOI 10.1016/S0140-6736(08)60884-3
   Morales JO, 2013, DRUG DEV IND PHARM, V39, P1793, DOI 10.3109/03639045.2012.737332
   Morales JO, 2013, J PHARM PHARMACOL, V65, P827, DOI 10.1111/jphp.12046
   Morales JO, 2011, EUR J PHARM BIOPHARM, V77, P187, DOI 10.1016/j.ejpb.2010.11.023
   Nair AB, 2013, J CONTROL RELEASE, V166, P10, DOI 10.1016/j.jconrel.2012.11.019
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Ojewole E, 2012, PLANTA MED, V78, P354, DOI 10.1055/s-0031-1280431
   Patel KK, 2012, AAPS PHARMSCITECH, V13, P1502, DOI 10.1208/s12249-012-9871-7
   Patil MN, 2007, ULTRASON SONOCHEM, V14, P519, DOI 10.1016/j.ultsonch.2006.10.007
   Peh KK, 1999, J PHARM PHARM SCI, V2, P53
   Perumal VA, 2008, DRUG DEV IND PHARM, V34, P1036, DOI 10.1080/03639040801928952 
   Perumal VA, 2008, INT J PHARM, V358, P184, DOI 10.1016/j.ijpharm.2008.03.005
   Rambharose S, 2014, DRUG DEV IND PHARM, V40, P639, DOI 10.3109/03639045.2014.884120
   Rambharose S, 2014, PHARM DEV TECHNOL, V19, P82, DOI 10.3109/10837450.2012.752505
   Rana P, 2013, DRUG DELIV, V20, P224, DOI 10.3109/10717544.2013.779331
   Rao SS, 2011, INT J NANOMED, V6, P1245, DOI 10.2147/IJN.S19151
   Reddy R.S., 2012, CONT INVESTIG OBSERV, V1, P44
   Sanchez-Lafuente C, 2002, INT J PHARM, V234, P213, DOI 10.1016/S0378-5173(01)00962-0
   Sanchez-Lafuente C, 2002, FARMACO, V57, P649, DOI 10.1016/S0014-827X(02)01240-5                                                   
   Saravanakumar M, 2010, ASIAN J PHARM, V4, P219, DOI 10.4103/0973-8398.72122
   Shah KA, 2007, INT J PHARM, V345, P163, DOI 10.1016/j.ijpharm.2007.05.061
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shegokar R, 2011, INT J PHARMACEUT, V416, P461, DOI 10.1016/j.ijpharm.2010.08.014
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15
   Shojaei AH, 1999, INT J PHARM, V192, P139, DOI 10.1016/S0378-5173(99)00301-4                                                   
   Sievens-Figueroa L, 2012, INT J PHARMACEUT, V423, P496, DOI 10.1016/j.ijpharm.2011.12.001
   Silva AC, 2012, COLLOID SURFACE B, V93, P241, DOI 10.1016/j.colsurfb.2012.01.014
   Silva AC, 2011, COLLOID SURFACE B, V86, P158, DOI 10.1016/j.colsurfb.2011.03.035
   Singh S, 2010, CHEM PHARM BULL, V58, P650, DOI 10.1248/cpb.58.650                                                              
   Squibb Bristol-Myers, 2013, VID EC PRESCR INF
   SQUIER CA, 1985, J INVEST DERMATOL, V84, P176, DOI 10.1111/1523-1747.ep12264711
   Sudhakar Y, 2006, J CONTROL RELEASE, V114, P15, DOI 10.1016/j.jconrel.2006.04.012
   Teeranachaideekul V, 2007, INT J PHARM, V340, P198, DOI 10.1016/j.ijpharm.2007.03.022
   Ugazio E, 2002, INT J PHARM, V241, P341, DOI 10.1016/S0378-5173(02)00268-5
   Van der Bijl P, 1998, S AFR J SCI, V94, P499
   Vigouroux C, 1999, DIABETES METAB, V25, P225
   Voorspoels J, 1996, PHARMACEUT RES, V13, P1228, DOI 10.1023/A:1016072522151
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   WHO, 2013, WHO TOP 10 CAUS DEAT
   Xiang J, 2002, INT J PHARM, V231, P57, DOI 10.1016/S0378-5173(01)00865-1
   Yedurkar P, 2013, DRUG DEV IND PHARM, V39, P670, DOI 10.3109/03639045.2012.687379
NR 84
TC 9
Z9 9
U1 1
U2 19
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD MAY
PY 2014
VL 40
IS 5
BP 669
EP 679
DI 10.3109/03639045.2014.892957
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AF5FO
UT WOS:000334739600013
PM 24576267
DA 2018-01-05
ER

PT J
AU Jallouk, AP
   Moley, KH
   Omurtag, K
   Hu, G
   Lanza, GM
   Wickline, SA
   Hood, JL
AF Jallouk, Andrew P.
   Moley, Kelle H.
   Omurtag, Kenan
   Hu, Grace
   Lanza, Gregory M.
   Wickline, Samuel A.
   Hood, Joshua L.
TI Nanoparticle Incorporation of Melittin Reduces Sperm and Vaginal
   Epithelium Cytotoxicity
SO PLOS ONE
LA English
DT Article
ID HIV PREVENTION; MICROBICIDES; CELLS
AB Melittin is a cytolytic peptide component of bee venom which rapidly integrates into lipid bilayers and forms pores resulting in osmotic lysis. While the therapeutic utility of free melittin is limited by its cytotoxicity, incorporation of melittin into the lipid shell of a perfluorocarbon nanoparticle has been shown to reduce its toxicity in vivo. Our group has previously demonstrated that perfluorocarbon nanoparticles containing melittin at concentrations,10 mu M inhibit HIV infectivity in vitro. In the current study, we assessed the impact of blank and melittin-containing perfluorocarbon nanoparticles on sperm motility and the viability of both sperm and vaginal epithelial cells. We found that free melittin was toxic to sperm and vaginal epithelium at concentrations greater than 2 mM (p<0.001). However, melittin nanoparticles were not cytotoxic to sperm (p = 0.42) or vaginal epithelium (p = 0.48) at an equivalent melittin concentration of 10 mM. Thus, nanoparticle formulation of melittin reduced melittin cytotoxicity fivefold and prevented melittin toxicity at concentrations previously shown to inhibit HIV infectivity. Melittin nanoparticles were toxic to vaginal epithelium at equivalent melittin concentrations >= 20 mu M (p<0.001) and were toxic to sperm at equivalent melittin concentrations >= 40 mu M (p<0.001). Sperm cytotoxicity was enhanced by targeting of the nanoparticles to the sperm surface antigen sperm adhesion molecule 1. While further testing is needed to determine the extent of cytotoxicity in a more physiologically relevant model system, these results suggest that melittin-containing nanoparticles could form the basis of a virucide that is not toxic to sperm and vaginal epithelium. This virucide would be beneficial for HIV serodiscordant couples seeking to achieve natural pregnancy.
C1 [Jallouk, Andrew P.; Hu, Grace; Lanza, Gregory M.; Wickline, Samuel A.; Hood, Joshua L.] Washington Univ, Sch Med, Dept Med,Div Cardiol, Consortium Translat Res Adv Imaging & Nanomed, St Louis, MO 63110 USA.
   [Moley, Kelle H.; Omurtag, Kenan] Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA.
RP Hood, JL (reprint author), Washington Univ, Sch Med, Dept Med,Div Cardiol, Consortium Translat Res Adv Imaging & Nanomed, St Louis, MO 63110 USA.
EM jhood@dom.wustl.edu
OI Hood, Joshua/0000-0003-3998-4118
FU Bill & Melinda Gates Foundation [OPP1024642]; Campbell Foundation
FX This research was supported by the Bill & Melinda Gates Foundation Grand
   Challenges Explorations Grant Number OPP1024642 (http://www.
   grandchallenges.org/Explorations) and The Campbell Foundation
   (http://www. campbellfoundation.net). The funders had no role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson DJ, 2010, AIDS, V24, P163, DOI 10.1097/QAD.0b013e32833424c8
   Cardona-Maya W, 2011, J REPROD IMMUNOL, V92, P1, DOI 10.1016/j.jri.2011.09.002
   Ceballos A, 2009, J EXP MED, V206, P2717, DOI 10.1084/jem.20091579
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X
   Eke AC, 1996, COCHRANE DATABASE SY
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Hood JL, 2009, LAB INVEST, V89, P1317, DOI 10.1038/labinvest.2009.94
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Klein DH, 2009, PARTICLE SIZE DISTRI
   Kunz G, 1996, HUM REPROD, V11, P627, DOI 10.1093/HUMREP/11.3.627                                                         
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Matthews LT, 2010, AIDS, V24, P1975, DOI 10.1097/QAD.0b013e32833bedeb
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   Palekar RU, 2013, MOL PHARMACEUT, V10, P4168, DOI 10.1021/mp400210q
   Pertoft H, 2000, J BIOCHEM BIOPH METH, V44, P1, DOI 10.1016/S0165-022X(00)00066-X
   Sabeur K, 1997, J ANDROL, V18, P151
   Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959
   Suri A, 2004, REPROD BIOL ENDOCRIN, V2, P1
   Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95
NR 22
TC 13
Z9 13
U1 4
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2014
VL 9
IS 4
AR e95411
DI 10.1371/journal.pone.0095411
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2DP
UT WOS:000335226500098
PM 24748389
OA gold
DA 2018-01-05
ER

PT J
AU Zhou, J
   Gan, N
   Li, TH
   Hu, FT
   Li, X
   Wang, LH
   Zheng, L
AF Zhou, Jing
   Gan, Ning
   Li, Tianhua
   Hu, Futao
   Li, Xing
   Wang, Lihong
   Zheng, Lei
TI A cost-effective sandwich electrochemiluminescence immunosensor for
   ultrasensitive detection of HIV-1 antibody using magnetic molecularly
   imprinted polymers as capture probes
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Sandwich electrochemiluminescence immunosensor; Surface imprinting;
   Epitope imprinting; Human immunodeficiency virus type 1 antibody;
   Horseradish peroxidase; Luminol
ID ENZYME-IMMUNOASSAY; BOVINE HEMOGLOBIN; AIDS VACCINE; 3RD-GENERATION;
   NANOPARTICLES; RECOGNITION; PROTEIN; INFECTION; PERFORMANCE; PREVENTION
AB In this report, a rapid and cost-effective sandwich electrochemiluminescence (ECL) immiinosensor was constructed for the ultrasensitive detection of human immunodeficiency virus type 1 antibody (anti-HIV-1) using magnetic molecularly imprinted polymers (MMIPs) as capture probes by combining surface and epitope imprinting techniques and antigen conjugated with horseradish peroxidase (HRP-HIV-1) as labels. First, 3-aminobenzeneboronic acid (APBA) was used as the functional monomer and cross-linking reagent, which was polymerized on the surface of silicate-coated magnetic iron oxide nanoparticles (Fe3O4@SiO2 NPs) in the presence of human immunoglobulin G (HIgG), as the template exhibiting the same Pc region but different Fab region to anti-HIV-1 after the addition of the initiator, ammonium persulfate. This process resulted in grafting a hydrophilic molecularly imprinted polymer (MIP) film on the Fe3O4@SiO2 NPs. Thus, MMIPs, which could be reused after eluting the template, were used to recognize and enrich ultra-trace levels of anti-HIV-1. Subsequently, a novel sandwich ECL immunosensor was formed through the immunoreaction between MMIPs conjugated with varied concentrations of anti-HIV-1 and HRP-HIV-1. By the catalysis of HRP immobilized onto HRP-HIV-1 on the ECL system of Luminol-H2O2, a linear response range of the anti-HIV-1 dilution ratio (standard positive serum) was achieved from 1:20,000 to 1:50, with a detection limit of 1:60,000 (S/N=3). The developed method provides a low-cost, simple, and sensitive way for the early diagnosis of HIV infected patients. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Zhou, Jing; Gan, Ning; Li, Tianhua; Li, Xing] Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
   [Hu, Futao] Ningbo Univ, Fac Marine, Ningbo 315211, Zhejiang, Peoples R China.
   [Wang, Lihong] Ningbo Univ, Fac Sci, Ningbo 315211, Zhejiang, Peoples R China.
   [Zheng, Lei] Southern Med Univ, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn
FU National Natural Science Foundation of China [30901367]; Natural Science
   Foundation of Zhejiang [LY13C200017, LY12C20004, LY12B01005]; Science
   and Technology Project of Zhejiang [2012C23101, 2011C23126]; Natural
   Science Foundation of Ningbo City [2011B82014, 2013A610241]; K.C. Wong
   Magna Fund in Ningbo University
FX This work was supported by the National Natural Science Foundation of
   China (No. 30901367), the Natural Science Foundation of Zhejiang
   (LY13C200017, LY12C20004, and LY12B01005), the Science and Technology
   Project of Zhejiang (2012C23101 and 2011C23126), the Natural Science
   Foundation of Ningbo City (2011B82014 and 2013A610241, and K.C. Wong
   Magna Fund in Ningbo University.
CR BARBE F, 1994, ANN BIOL CLIN-PARIS, V52, P341
   Carvajal MA, 2012, SENSOR ACTUAT B-CHEM, V169, P46, DOI 10.1016/j.snb.2012.01.072
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Dai H, 2012, CHEM COMMUN, V48, P3055, DOI 10.1039/c1cc16571b
   DODD RY, 1990, ARCH PATHOL LAB MED, V114, P240
   Esseghaier C, 2013, BIOSENS BIOELECTRON, V41, P335, DOI 10.1016/j.bios.2012.08.049
   Galli RA, 1996, J CLIN MICROBIOL, V34, P999
   Garber DA, 2004, LANCET INFECT DIS, V4, P397, DOI 10.1016/S1473-3099(04)01056-4                                                   
   Ge Y, 2008, TRENDS BIOTECHNOL, V26, P218, DOI 10.1016/j.tibtech.2008.01.001
   Haupt K, 2000, CHEM REV, V100, P2495, DOI 10.1021/cr990099w
   Hull DO, 2009, ANAL CHEM, V81, P716, DOI 10.1021/ac802179s
   Jangam SR, 2013, BIOSENS BIOELECTRON, V42, P69, DOI 10.1016/j.bios.2012.10.024
   Jia TT, 2009, BIOSENS BIOELECTRON, V25, P263, DOI 10.1016/j.bios.2009.06.030
   Kan XW, 2010, J PHYS CHEM B, V114, P3999, DOI 10.1021/jp910060c
   Levy JA, 2009, AIDS, V23, P147, DOI 10.1097/QAD.0b013e3283217f9f
   Li L, 2009, CHEM-ASIAN J, V4, P286, DOI 10.1002/asia.200800300
   Louie B, 2006, J CLIN MICROBIOL, V44, P1856, DOI 10.1128/JCM.44.5.1856-1858.2006
   Lu CH, 2012, BIOSENS BIOELECTRON, V31, P439, DOI 10.1016/j.bios.2011.11.008
   Lu FG, 2012, ANAL CHIM ACTA, V718, P84, DOI 10.1016/j.aca.2011.12.054
   Ly TD, 2001, EUR J CLIN MICROBIOL, V20, P104, DOI 10.1007/s10096-001-8057-0
   McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605
   Nematollahzadeh A, 2011, ANGEW CHEM INT EDIT, V50, P495, DOI 10.1002/anie.201004774
   Nishino H, 2006, ANGEW CHEM INT EDIT, V45, P2392, DOI 10.1002/anie.200503760
   Rachkov A, 2000, J CHROMATOGR A, V889, P111, DOI 10.1016/S0021-9673(00)00568-9                                                   
   Richter MM, 2004, CHEM REV, V104, P3003, DOI 10.1021/cr020373d
   Ross AL, 2010, LANCET INFECT DIS, V10, P305, DOI 10.1016/S1473-3099(10)70069-4
   Ruslinda AR, 2013, BIOSENS BIOELECTRON, V40, P277, DOI 10.1016/j.bios.2012.07.048
   Saifuddin M., 1995, J EXP MED, V182, P503
   Shukla J, 2009, DIAGN MICR INFEC DIS, V65, P142, DOI 10.1016/j.diagmicrobio.2009.06.017
   Tai DF, 2010, ANAL CHEM, V82, P2290, DOI 10.1021/ac9024158
   Wang JH, 2013, BIOSENS BIOELECTRON, V41, P484, DOI 10.1016/j.bios.2012.09.011
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Wu YF, 2010, CHEM COMMUN, V46, P7763, DOI 10.1039/c0cc02741c
   Ye L., 2008, CHEM MATER, V20, P959
   Yeom JS, 2006, ANN CLIN LAB SCI, V36, P73
   Zhang J, 2008, ANAL CHEM, V80, P2888, DOI 10.1021/ac701995g
   Zhao Z, 2012, SENSOR ACTUAT B-CHEM, V171, P860, DOI 10.1016/j.snb.2012.05.084
NR 38
TC 36
Z9 38
U1 16
U2 247
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2014
VL 54
BP 199
EP 206
DI 10.1016/j.bios.2013.10.044
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AD2ND
UT WOS:000333071500031
PM 24280050
DA 2018-01-05
ER

PT J
AU Sanchez-Nieves, J
   Fransen, P
   Pulido, D
   Lorente, R
   Munoz-Fernandez, MA
   Albericio, F
   Royo, M
   Gomez, R
   de la Mata, EJ
AF Sanchez-Nieves, Javier
   Fransen, Peter
   Pulido, Daniel
   Lorente, Raquel
   Angeles Munoz-Fernandez, M.
   Albericio, Fernando
   Royo, Miriam
   Gomez, Rafael
   Javier de la Mata, E.
TI Amphiphilic Cationic Carbosilane-PEG Dendrimers: Synthesis and
   Applications in Gene Therapy
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Dendrimers; Click chemistry; Carbosilane; PEG; Gene therapy; HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC POLYMERS; DELIVERY; HIV;
   CARRIERS; VECTORS; OLIGONUCLEOTIDES; BIOCOMPATIBILITY; POLY(AMIDOAMINE);
   NANOCARRIERS
AB Here we synthesized carbosilane, generation 1 to 3, and PEG-based dendrons functionalized at the periphery with NHBoc groups and at the focal point with azide and alkyne moieties, respectively. The coupling of these two types of dendrons via click chemistry led to the formation of new hybrid dendrimers with two distinct moieties, the hydrophobic carbosilane and the hydrophilic PEG-based dendron. The protected dendrimers were transformed into cationic ammonium dendrimers. These unique amphiphilic dendrimers were studied as vectors for gene therapy against HIV in peripheral blood mononuclear cells (PBMC) and their performance was compared with that of a PEG-free carbosilane dendrimer. The presence of the PEG moiety afforded lower toxicities and evidenced a weaker interaction between dendrimers and siRNA when compared to the homodendrimer analogous. Both features, lower toxicity and lower dendriplex strength, are key properties for use of these vectors as carriers of nucleic material. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Sanchez-Nieves, Javier; Gomez, Rafael; Javier de la Mata, E.] Univ Alcala De Henares, Dept Quim Organ & Quim Inorgan, E-28871 Madrid, Spain.
   [Sanchez-Nieves, Javier; Pulido, Daniel; Angeles Munoz-Fernandez, M.; Albericio, Fernando; Royo, Miriam; Gomez, Rafael; Javier de la Mata, E.] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Fransen, Peter; Albericio, Fernando] Inst Res Biomed, Barcelona 08028, Spain.
   [Pulido, Daniel; Royo, Miriam] Combinatorial Chem Unit, Barcelona 08028, Spain.
   [Lorente, Raquel; Angeles Munoz-Fernandez, M.] Hosp Gen Univ Gregorio Maraf, Lab Inmunol Mol, Madrid, Spain.
   [Albericio, Fernando] Univ Barcelona, Dept Organ Chem, E-08028 Barcelona, Spain.
RP Albericio, F (reprint author), Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
EM rafael.gomez@uah.es
RI Sanchez-Nieves, Javier/J-9260-2014; Gomez Ramirez, Rafael/K-1216-2014;
   Pulido, Daniel/K-7739-2014; De la Mata, F. Javier/K-1649-2014; Royo,
   Miriam/B-1665-2013
OI Sanchez-Nieves, Javier/0000-0003-0410-2285; Gomez Ramirez,
   Rafael/0000-0001-6448-2414; Pulido, Daniel/0000-0002-2841-194X; De la
   Mata, F. Javier/0000-0003-0418-3935; Royo, Miriam/0000-0001-5292-0819;
   Lorente Rodriguez, Raquel/0000-0001-7010-644X; Albericio,
   Fernando/0000-0002-8946-0462; Munoz-Fernandez/0000-0002-0813-4500
FU Fondos de Investigacion Sanitaria (FIS) of the Ministerio de Sanidad y
   Consumo [PI061479]; Red RIS [RD06-0006-0035]; FIPSE [24632/07]; MNT-ERA
   NET [NAN2007-31198-E]; Fundacion Caja Navarra; Comunidad de Madrid
   [S-SAL-0159-2006]; Consortium NANODENDMED [S2011/BMD-2351]; MICINN
   [CTQ2009-07758, EUI2008-00174, CTQ2008-00177]; Generalitat de Catalunya
   [2009SGR 1024]; MINECO [SAF2011-30508-C02-01]; CIBER-BBN - VI National R
   D i Plan; Instituto de Salud Carlos III; European Regional Development
   Fund; Iniciativa Ingenio; Consolider Program; CIBER Actions; 
   [CTQ2011-23245]
FX This work has been supported by grants from the Fondos de Investigacion
   Sanitaria (FIS) of the Ministerio de Sanidad y Consumo (PI061479), Red
   RIS RD06-0006-0035, FIPSE (24632/07), MNT-ERA NET 2007
   (NAN2007-31198-E), the Fundacion Caja Navarra and the Comunidad de
   Madrid (S-SAL-0159-2006) to M. A. M.-F.; CTQ2011-23245, Consortium
   NANODENDMED ref S2011/BMD-2351 (CAM) to R. G; MICINN (CTQ2009-07758 and
   EUI2008-00174) and the Generalitat de Catalunya (2009SGR 1024) to F. A.;
   and MICINN (CTQ2008-00177) and MINECO (SAF2011-30508-C02-01) to M. R.
   This study was also supported by CIBER-BBN as an initiative funded by
   the VI National R & D & i Plan 2008-2011, Iniciativa Ingenio 2010,
   Consolider Program, CIBER Actions and financed by the Instituto de Salud
   Carlos III, with assistance from the European Regional Development Fund.
CR Astruc D, 2010, CHEM REV, V110, P1857, DOI 10.1021/cr900327d
   Behr JP, 2012, ACCOUNTS CHEM RES, V45, P980, DOI 10.1021/ar200213g
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Cavazzana-Calvo M, 2007, J CLIN INVEST, V117, P1456, DOI 10.1172/JC130953
   Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004
   Dass CR, 2002, J PHARM PHARMACOL, V54, P3, DOI 10.1211/0022357021771887
   de las Cuevas N, 2012, CURR MED CHEM, V19, P5052
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Elfinger M, 2008, CURR NANOSCI, V4, P322, DOI 10.2174/157341308786306062                                                      
   Fattal E, 2008, INT J PHARMACEUT, V364, P237, DOI 10.1016/j.ijpharm.2008.06.011
   Frechet J. M. J., 2002, DENDRIMERS OTHER DEN
   Gao Y, 2008, MINI-REV MED CHEM, V8, P889, DOI 10.2174/138955708785132729                                                      
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Guillaudeu SJ, 2008, BIOCONJUGATE CHEM, V19, P461, DOI 10.1021/bc700264g
   Guillot-Nieckowski M., 2007, NEW J CHEM, V31, P1111
   Guo X, 2012, ACCOUNTS CHEM RES, V45, P971, DOI 10.1021/ar200151m
   Heegaard PMH, 2010, BIOCONJUGATE CHEM, V21, P405, DOI 10.1021/bc900290d
   Khambete H, 2010, BIOORG MED CHEM LETT, V20, P4279, DOI 10.1016/j.bmcl.2010.03.100
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   Kodama K, 2006, CURR MED CHEM, V13, P2155, DOI 10.2174/092986706777935276
   Kojima C, 2010, INT J PHARMACEUT, V383, P293, DOI 10.1016/j.ijpharm.2009.09.015
   Liu X., 2012, NEW J CHEM, V9, P256
   Lim J, 2008, MOL PHARMACEUT, V5, P540, DOI 10.1021/mp8000292
   Luo D., 2002, MACROMOLECULES, V35, P3456
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Newkome GR, 2008, POLYMER, V49, P1, DOI 10.1016/j.polymer.2007.10.021
   Newkome G. R., 2001, DENDRIMERS DENDRONS
   Newkome G. R., 1996, DENDRITIC MOL CONCEP
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Parekh HS, 2007, CURR PHARM DESIGN, V13, P2837, DOI 10.2174/138161207781757024
   Pietersz GA, 2006, MINI-REV MED CHEM, V6, P1285, DOI 10.2174/138955706778992987                                                      
   Posadas I, 2009, PHARM RES-DORD, V26, P1181, DOI 10.1007/s11095-009-9839-9
   Sanchez-Nieves J., 2010, TETRAHEDRON, P9203
   Shcharbin DG, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1070, DOI 10.1134/S0006297909100022
   Sideratou Z, 2006, GENE THER MOL BIOL, V10A, P71
   Smith DK, 2008, CURR TOP MED CHEM, V8, P1187, DOI 10.2174/156802608785849030
   Sousa-Herves A, 2012, NEW J CHEM, V36, P205, DOI 10.1039/c2nj20849k
   Takahashi T, 2007, BIOCONJUGATE CHEM, V18, P1163, DOI 10.1021/bc070014v
   Tomalia DA, 2002, J POLYM SCI POL CHEM, V40, P2719, DOI 10.1002/pola.10301
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410                                                                   
   Vogtle F., 2003, TOPICS CURRENT CHEM, V228
   Wagner E, 2008, MOL THER, V16, P1, DOI 10.1038/sj.mt.6300378
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Zhong H, 2008, J BIOMATER APPL, V22, P527, DOI 10.1177/0885328207080005
   Denkewalter R G, 1982, Patent No. [4, 360, 646, 4360646, 4,360,646]
   Denkewalter R.G., 1981, U.S. Patent, Patent No. [4,289,872, 4289872]
   Denkewalter R.G., 1983, U.S. Patent, Patent No. [4,410,688, 4410688, 4,410,688 A19831018]
NR 49
TC 19
Z9 20
U1 5
U2 39
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD APR 9
PY 2014
VL 76
BP 43
EP 52
DI 10.1016/j.ejmech.2014.01.061
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AG5VS
UT WOS:000335487400005
PM 24565572
DA 2018-01-05
ER

PT J
AU Horiya, S
   Bailey, JK
   Temme, JS
   Schippe, YVG
   Krauss, IJ
AF Horiya, Satoru
   Bailey, Jennifer K.
   Temme, J. Sebastian
   Schippe, Yollete V. Guillen
   Krauss, Isaac J.
TI Directed Evolution of Multivalent Glycopeptides Tightly Recognized by
   HIV Antibody 2G12
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO SELECTION; MESSENGER-RNA
   DISPLAY; VACCINE DESIGN; DC-SIGN; OLIGOMANNOSE CLUSTERS; CARBOHYDRATE
   EPITOPE; PURIFIED COMPONENTS; RIBOSOMAL SYNTHESIS; UNNATURAL PEPTIDES
AB Herein, we report a method for in vitro selection of multivalent glycopeptides, combining mRNA display with incorporation of unnatural amino acids and "click" chemistry. We have demonstrated the use of this method to design potential glycopeptide vaccines against HIV. From libraries of similar to 10(13) glycopeptides containing multiple Man(9) glycan(s), we selected variants that bind to HIV broadly neutralizing antibody 2G12 with picomolar to low nanomolar affinity. This is comparable to the strength of the natural 2G12-gp120 interaction, and is the strongest affinity achieved to date with constructs containing 3-5 glycans. These glycopeptides are therefore of great interest in HIV vaccine design.
C1 [Horiya, Satoru; Bailey, Jennifer K.; Temme, J. Sebastian; Krauss, Isaac J.] Brandeis Univ, Dept Chem, Waltham, MA 02454 USA.
   [Schippe, Yollete V. Guillen] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   [Schippe, Yollete V. Guillen] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
RP Schippe, YVG (reprint author), 3B Pharmaceut GmbH, Magnusstr 11, D-12489 Berlin, Germany.
EM yolleteg@gmail.com; kraussi@brandeis.edu
FU Brandeis University; NIH [R01 AI090745]
FX I.J.K. gratefully acknowledges Brandeis University and the NIH (R01
   AI090745). We are grateful to Polymun Scientific for a gift of mAb 2G12,
   to Prof. Bradley Pentelute for assistance with rapid flow solid-phase
   peptide synthesis, and to Prof. Jack Szostak for providing S.H. with the
   opportunity to learn mRNA display techniques in his laboratory.
CR Abdiche Y, 2008, ANAL BIOCHEM, V377, P209, DOI 10.1016/j.ab.2008.03.035
   Agrawal-Gamse C, 2011, J VIROL, V85, P470, DOI 10.1128/JVI.01349-10
   Arai K, 2013, BIOORG MED CHEM LETT, V23, P4940, DOI 10.1016/j.bmcl.2013.06.059
   Artner LM, 2012, CHEM COMMUN, V48, P522, DOI 10.1039/c1cc16039g
   Astronomo RD, 2008, J VIROL, V82, P6359, DOI 10.1128/JVI.00293-08
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Chan W. C., 2000, FMOC SOLID PHASE PEP
   Ciobanu M, 2011, CHEM COMMUN, V47, P9321, DOI 10.1039/c1cc13213j
   Clark BE, 2012, CHEM BIOL, V19, P254, DOI 10.1016/j.chembiol.2011.12.019
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P17107, DOI 10.1073/pnas.1002717107
   Gorska K, 2009, ANGEW CHEM INT EDIT, V48, P7695, DOI 10.1002/anie.200903328
   Hartman MCT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000972
   Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974
   Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433
   Hong V, 2009, ANGEW CHEM INT EDIT, V48, P9879, DOI 10.1002/anie.200905087
   Hoorelbeke B, 2013, FEBS LETT, V587, P860, DOI 10.1016/j.febslet.2013.02.037
   Huang W, 2009, CHEMBIOCHEM, V10, P1234, DOI 10.1002/cbic.200800741
   Josephson K, 2005, J AM CHEM SOC, V127, P11727, DOI 10.1021/ja0515809
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Kurz M, 2000, Nucleic Acids Res, V28, pE83, DOI 10.1093/nar/28.18.e83
   Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d
   Li HG, 2003, ORG BIOMOL CHEM, V1, P3507, DOI 10.1039/b307995c
   Lin HN, 2004, J AM CHEM SOC, V126, P13998, DOI 10.1021/ja045147v
   Liu RH, 2000, METHOD ENZYMOL, V318, P268
   Luallen RJ, 2008, J VIROL, V82, P6447, DOI 10.1128/JVI.00412-08
   Luallen RJ, 2009, J VIROL, V83, P4861, DOI 10.1128/JVI.02537-08
   Ma Z, 2012, METHODS MOL BIOL, V805, P367, DOI 10.1007/978-1-61779-379-0_21
   MacPherson IS, 2011, ANGEW CHEM INT EDIT, V50, P11238, DOI 10.1002/anie.201105555
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Mong SK, 2014, CHEMBIOCHEM, V15, P721, DOI 10.1002/cbic.201300797
   Ng S, 2012, ACS CHEM BIOL, V7, P1482, DOI 10.1021/cb300187t
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Ohashi H, 2007, BIOCHEM BIOPH RES CO, V352, P270, DOI 10.1016/j.bbrc.2006.11.017
   Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Schlippe YVG, 2012, J AM CHEM SOC, V134, P10469, DOI 10.1021/ja301017y
   Seelig B, 2011, NAT PROTOC, V6, P540, DOI 10.1038/nprot.2011.312
   Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802
   Shimizu Y, 2005, METHODS, V36, P299, DOI 10.1016/j.ymeth.2005.04.006
   Shimizu Y, 2010, METHODS MOL BIOL, V607, P11, DOI 10.1007/978-1-60327-331-2_2
   Simon MD, 2014, CHEMBIOCHEM, V15, P713, DOI 10.1002/cbic.201300796
   Subtelny AO, 2008, J AM CHEM SOC, V130, P6131, DOI 10.1021/ja710016v
   Tan ZP, 2004, J AM CHEM SOC, V126, P12752, DOI 10.1021/ja0472174
   Temme JS, 2014, J AM CHEM SOC, V136, P1726, DOI 10.1021/ja411212q
   Temme JS, 2013, CHEM-EUR J, V19, P17291, DOI 10.1002/chem.201303848
   Trkola A, 1996, J VIROL, V70, P1100
   van Hest JCM, 2000, J AM CHEM SOC, V122, P1282, DOI 10.1021/ja992749j                                                               
   van Kasteren SI, 2007, NATURE, V446, P1105, DOI 10.1038/nature05757
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
NR 59
TC 31
Z9 31
U1 2
U2 50
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 9
PY 2014
VL 136
IS 14
BP 5407
EP 5415
DI 10.1021/ja500678v
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA AF2WC
UT WOS:000334572200042
PM 24645849
OA gold
DA 2018-01-05
ER

PT J
AU Fogarty, KH
   Berk, S
   Grigsby, IF
   Chen, Y
   Mansky, LM
   Mueller, JD
AF Fogarty, Keir H.
   Berk, Serkan
   Grigsby, Iwen F.
   Chen, Yan
   Mansky, Louis M.
   Mueller, Joachim D.
TI Interrelationship between Cytoplasmic Retroviral Gag Concentration and
   Gag-Membrane Association
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE fluorescence; retrovirus; assembly; oligomerization; membrane
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FLUORESCENCE FLUCTUATION SPECTROSCOPY;
   T-CELL LEUKEMIA; HIV-1 MATRIX PROTEIN; PLASMA-MEMBRANE; LIVING CELLS;
   3-DIMENSIONAL STRUCTURE; BRIGHTNESS ANALYSIS; DRUG-RESISTANCE; VIRAL
   PARTICLES
AB The early events in the retrovirus assembly pathway, particularly the timing and nature of Gag translocation from the site of protein translation to the inner leaflet of the plasma membrane, are poorly understood. We have investigated the interrelationship between cytoplasmic Gag concentration and plasma membrane association using complementary live-cell biophysical fluorescence techniques in real time with both human T-cell leukemia virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1) Gag proteins. In particular, dual-color, z-scan fluorescence fluctuation spectroscopy in conjunction with total internal reflection fluorescence and conventional, epi-illumination imaging were utilized. Our results demonstrate that HTLV-1 Gag is capable of membrane targeting and particle assembly at low (i.e., nanomolar) cytoplasmic concentrations and that there is a critical threshold concentration (approaching micromolar) prior to the observation of HIV-1 Gag associated with the plasma membrane. These observations imply fundamental differences between HIV-1 and HTLV-1 Gag trafficking and membrane association. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Fogarty, Keir H.; Berk, Serkan; Grigsby, Iwen F.; Chen, Yan; Mansky, Louis M.; Mueller, Joachim D.] Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA.
   [Fogarty, Keir H.; Grigsby, Iwen F.; Mansky, Louis M.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA.
   [Fogarty, Keir H.; Chen, Yan; Mueller, Joachim D.] Univ Minnesota, Sch Phys & Astron, Minneapolis, MN 55455 USA.
   [Berk, Serkan; Mueller, Joachim D.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
   [Mansky, Louis M.] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.
RP Mansky, LM (reprint author), Univ Minnesota, Inst Mol Virol, 18-242 Moos Tower,515 Delaware St Southeast, Minneapolis, MN 55455 USA.
EM mansky@umn.edu; mueller@physics.umn.edu
OI Mansky, Louis/0000-0003-2391-1061
FU National Institutes of Health [R01GM098550, R01GM064589]; National
   Science Foundation [PHY-0346782]; American Cancer Society Postdoctoral
   Fellowship
FX This research was supported by National Institutes of Health grants
   R01GM098550 and R01GM064589 and the National Science Foundation
   (PHY-0346782). K.H.F. was supported from an American Cancer Society
   Postdoctoral Fellowship.
CR Ako-Adjei D, 2005, J VIROL, V79, P13463, DOI 10.1128/JVI.79.21.13463-13472.2005
   Alfadhli A, 2011, J MOL BIOL, V410, P653, DOI 10.1016/j.jmb.2011.04.063
   Alfadhli A, 2009, J VIROL, V83, P12196, DOI 10.1128/JVI.01197-09
   Axelrod D, 2008, METHOD CELL BIOL, V89, P169, DOI 10.1016/S0091-679X(08)00607-9
   Baumgartel V, 2011, NAT CELL BIOL, V13, P469, DOI 10.1038/ncb2215
   Baydoun HH, 2008, AIDS REV, V10, P195
   BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4                                                   
   Bouamr F, 2000, VIROLOGY, V278, P597, DOI 10.1006/viro.2000.0663
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523
   Burniston MT, 1999, J VIROL, V73, P8527
   Carlson LA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001173
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Chen RX, 2004, CURR PHARM DESIGN, V10, P4065, DOI 10.2174/1381612043382404
   Chen Y, 2005, BIOPHYS J, V88, P4366, DOI 10.1529/biophysj.105.059170
   Chen Y, 2003, P NATL ACAD SCI USA, V100, P15492, DOI 10.1073/pnas.2533045100
   Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0                                                   
   Christensen AM, 1996, J MOL BIOL, V264, P1117, DOI 10.1006/jmbi.1996.0700
   Chukkapalli V, 2011, J MOL BIOL, V410, P512, DOI 10.1016/j.jmb.2011.04.015
   Chukkapalli V, 2010, P NATL ACAD SCI USA, V107, P1600, DOI 10.1073/pnas.0908661107
   Cimarelli A, 2000, J VIROL, V74, P3046, DOI 10.1128/JVI.74.7.3046-3057.2000
   Dalton AK, 2007, J VIROL, V81, P6434, DOI 10.1128/JVI.02757-06
   Datta SAK, 2007, J MOL BIOL, V365, P799, DOI 10.1016/j.jmb.2006.10.072
   Derdowski A, 2004, J VIROL, V78, P1230, DOI 10.1128/JVI.78.3.1230-1242.2004
   Fogarty KH, 2011, VIRUSES-BASEL, V3, P770, DOI 10.3390/v3060770
   Fogarty KH, 2011, BIOPHYS J, V100, P1587, DOI 10.1016/j.bpj.2011.02.008
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Gao WT, 2004, BIOTECHNOL PROGR, V20, P443, DOI 10.1021/bp0300467
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Giam CZ, 2007, FRONT BIOSCI, V12, P1496, DOI 10.2741/2163                                                                    
   GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781
   Grigsby IF, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-75
   Hamard-Peron E, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-15
   Hubner W, 2007, J VIROL, V81, P12596, DOI 10.1128/JVI.01088-07
   Inlora J, 2011, J VIROL, V85, P3802, DOI 10.1128/JVI.02383-10
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Johnson DC, 2002, J VIROL, V76, P1, DOI 10.1128/JVI.76.1.1-8.2002
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857                                                            
   KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125
   Kutluay SB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001200
   Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102
   Le Blanc I, 2002, J VIROL, V76, P905, DOI 10.1128/JVI.76.2.905-911.2002                                                   
   Lindwasser OW, 2004, J VIROL, V78, P6013, DOI 10.1128/JVI.78.11.6013-6023.2004
   Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001
   Macdonald PJ, 2010, BIOPHYS J, V99, P979, DOI 10.1016/j.bpj.2010.05.017
   Mansky LM, 2002, DRUG RESIST UPDATE, V5, P219, DOI 10.1016/S1368-7646(02)00118-8                                                   
   MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719
   Mazurov D, 2006, VIROLOGY, V346, P194, DOI 10.1016/j.virol.2005.10.033
   Mazurov D, 2007, J BIOL CHEM, V282, P3896, DOI 10.1074/jbc.M607322200
   Mazurov D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000788
   Morikawa Y, 1996, J BIOL CHEM, V271, P2868, DOI 10.1074/jbc.271.5.2868                                                          
   Muriaux D, 2001, P NATL ACAD SCI USA, V98, P5246, DOI 10.1073/pnas.091000398
   Murray PS, 2005, STRUCTURE, V13, P1521, DOI 10.1016/j.str.2005.07.010
   Ono A, 2005, ADV VIRUS RES, V64, P311, DOI 10.1016/S0065-3527(05)64010-9
   Ono A, 2000, J VIROL, V74, P5142, DOI 10.1128/JVI.74.11.5142-5150.2000                                                
   Ono A, 2004, P NATL ACAD SCI USA, V101, P14889, DOI 10.1073/pnas.0405596101
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   PARK J, 1992, J VIROL, V66, P6304
   Perez-Caballero D, 2004, J VIROL, V78, P9560, DOI 10.1128/JVI.78.17.9560-9563.2004
   PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001
   Qualley DF, 2010, J BIOL CHEM, V285, P295, DOI 10.1074/jbc.M109.051334
   Rayne F, 2004, J MOL BIOL, V343, P903, DOI 10.1016/j.jmb.2004.09.013
   Rayne F, 2001, J VIROL, V75, P5277, DOI 10.1128/JVI.75.11.5277-5287.2001
   Resh MD, 2005, AIDS REV, V7, P84
   Saad JS, 2006, P NATL ACAD SCI USA, V103, P11364, DOI 10.1073/pnas.0602818103
   Sandefur S, 1998, J VIROL, V72, P2723
   Swanstrom R., 1997, P263
   Tang C, 2004, P NATL ACAD SCI USA, V101, P517, DOI 10.1073/pnas.0305665101
   Waheed AA, 2009, VIRUS RES, V143, P162, DOI 10.1016/j.virusres.2009.04.007
   WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002
   Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981
NR 75
TC 10
Z9 10
U1 2
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD APR 3
PY 2014
VL 426
IS 7
BP 1611
EP 1624
DI 10.1016/j.jmb.2013.11.025
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AF1MM
UT WOS:000334478000021
PM 24316368
OA green_accepted
DA 2018-01-05
ER

PT J
AU Arcangeli, C
   Circelli, P
   Donini, M
   Aljabali, AAA
   Benvenuto, E
   Lomonossoff, GP
   Marusic, C
AF Arcangeli, Caterina
   Circelli, Patrizia
   Donini, Marcello
   Aljabali, Alaa A. A.
   Benvenuto, Eugenio
   Lomonossoff, George P.
   Marusic, Carla
TI Structure-based design and experimental engineering of a plant virus
   nanoparticle for the presentation of immunogenic epitopes and as a drug
   carrier
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE homology modeling; molecular dynamics; viral nanoparticles;
   nanomedicine; plant-derived vaccine
ID BUSHY STUNT VIRUS; MOLECULAR-DYNAMICS SIMULATIONS; MOSAIC-VIRUS;
   ANTIVIRAL COMPOUND; HUMAN RHINOVIRUS; PARTICLES; ANTIBODY; PLATFORM;
   CAPSIDS; TYPE-1
AB Biomaterials research for the discovery of new generation nanoparticles is one of the most active areas of nanotechnoloy. In the search of nature-made nanometer-sized objects, plant virus particles appear as symmetrically defined entities that can be formed by protein self-assembly. In particular, in the field of plant virology, there is plenty of literature available describing the exploitation of plant viral cages to produce safe vaccine vehicles and nanoparticles for drug delivery. In this context, we have investigated on the use of the artichoke mottled crinkle virus (AMCV) capsid both as a carrier of immunogenic epitopes and for the delivery of anticancer molecules. A dual approach that combines both in silico tools and experimental virology was applied for the rational design of immunologically active chimeric virus-like particles (VLPs) carrying immunogenic peptides. The atomic structures of wild type (wt) and chimeric VLPs were obtained by homology modeling. The effects of insertion of the HIV-1 2F5 neutralizing epitope on the structural stability of chimeric VLPs were predicted and assessed by detailed inspection of the nanoparticle intersubunit interactions at atomic level. Wt and chimeric VLPs, exposing on their surface the 2F5 epitope, were successfully produced in plants. In addition, we demonstrated that AMCV capsids could also function as drug delivery vehicles able to load the chemotherapeutic drug doxorubicin. To our knowledge, this is the first systematic predictive and empirical research addressing the question of how this icosahedral virus can be used for the production of both VLPs and viral nanoparticles for biomedical applications.
C1 [Circelli, Patrizia; Donini, Marcello; Benvenuto, Eugenio; Marusic, Carla] ENEA, Lab Biotecnol, UTBIORAD, CR Casaccia, I-00123 Rome, Italy.
   [Arcangeli, Caterina] ENEA, Lab Diagnost, UTTMAT, CR Casaccia, I-00123 Rome, Italy.
   [Aljabali, Alaa A. A.; Lomonossoff, George P.] John Innes Inst, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.
   [Aljabali, Alaa A. A.] Univ Oxford, Dept Cardiovasc Med, Oxford OX3 9DU, England.
RP Arcangeli, C (reprint author), ENEA, Lab Diagnost, UTTMAT, CR Casaccia, Via Anguillarese 301, I-00123 Rome, Italy.
EM caterina.arcangeli@enea.it; carla.marusic@enea.it
OI Aljabali, Alaa/0000-0002-9519-6338
FU BBSRC [BB/J004561/1]; John Innes Foundation; Italian Ministry of Foreign
   Affairs, Porgetti di Grande Rilevanza, Italia-Giappone; CASPUR; standard
   HPC CASPUR grant [std10-187]; Office of Science of the US Department of
   Energy [DE-AC02-05CH11231]; EC Europrise Network of Excellence [FP6/7];
   NGIN consortia; Bill and Melinda Gates GHRC-CAVD Project
FX This study was supported by BB/J004561/1 from BBSRC and the John Innes
   Foundation; by a grant of the Italian Ministry of Foreign Affairs,
   Porgetti di Grande Rilevanza, Italia-Giappone; by CASPUR; by the
   standard HPC 2010 CASPUR grant (number std10-187).; Part of the
   simulated trajectory was performed using resources of the National
   Energy Research Scientific Computing Center, which is supported by the
   Office of Science of the US Department of Energy under Contract No.
   DE-AC02-05CH11231.The reagent (EVA 3063) was obtained from the Centre
   for AIDS Reagents, NIBSC HPA UK, supported by the EC FP6/7 Europrise
   Network of Excellence, and NGIN consortia and the Bill and Melinda Gates
   GHRC-CAVD Project and was donated by Dr H Katinger.
CR Aramayo R, 2005, BBA-GEN SUBJECTS, V1724, P345, DOI 10.1016/j.bbagen.2005.05.020
   Arcangeli C, 2008, J STRUCT BIOL, V164, P119, DOI 10.1016/j.jsb.2008.06.013
   Arcangeli C, 2008, J BIOMOL STRUCT DYN, V26, P35, DOI 10.1080/07391102.2008.10507221                                                  
   Arkhipov A, 2006, STRUCTURE, V14, P1767, DOI 10.1016/j.str.2006.10.003
   Arkhipov A, 2009, BIOPHYS J, V97, P2061, DOI 10.1016/j.bpj.2009.07.039
   Azuma H, 2009, J MOL GRAPH MODEL, V28, P278, DOI 10.1016/j.jmgm.2009.08.006
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   BERENDSEN HJC, 1981, INTERMOLECULAR FORCE, P331
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Bourzac K., 2012, NATURE, V491, P58
   Buchacher R., 1994, AIDS RES HUM RETROV, V10, P359, DOI [10.1089/aid.1994.10.359, DOI 10.1089/AID.1994.10.359]
   Burgyan J, 1998, METH MOL B, V81, P225
   Carrillo-Tripp M, 2009, NUCLEIC ACIDS RES, V37, pD436, DOI 10.1093/nar/gkn840
   Cieplak M, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3276287
   Circelli Patrizia, 2010, Bioeng Bugs, V1, P221, DOI 10.4161/bbug.1.3.11722
   Daura X., 1999, FUNCTION GENETICS, V34, P269, DOI [10.1002/(SICI)1097-0134(19990215)34:3<269::AID-PROT1>3.0.CO;2-3, DOI 10.1002/(SICI)1097-0134(19990215)34:3<269::AID-PROTI.3.0.CO;2-3]
   Denis J, 2008, VACCINE, V26, P3395, DOI 10.1016/j.vaccine.2008.04.052
   Denis J, 2007, VIROLOGY, V363, P59, DOI 10.1016/j.virol.2007.01.011
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   Freddolino PL, 2006, STRUCTURE, V14, P437, DOI 10.1016/j.str.2005.11.014
   HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hsu C, 2006, VIROLOGY, V349, P222, DOI 10.1016/j.virol.2006.02.038
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Ito T, 2004, LANGMUIR, V20, P6940, DOI 10.1021/la049524t
   Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Kakani K, 2001, J VIROL, V75, P5576, DOI 10.1128/JVI.75.12.5576-5583.2001
   Kumar S, 2009, VIROLOGY, V388, P185, DOI 10.1016/j.virol.2009.02.051
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   Leclerc D, 2007, J VIROL, V81, P1319, DOI 10.1128/JVI.01720-06
   Lico C., 2012, INNOVATION VACCINOLO, P179, DOI [10.1007/978-94-007-4543-8_8, DOI 10.1007/978-94-007-4543-8_8]
   Lico C, 2006, J GEN VIROL, V87, P3103, DOI 10.1099/vir.0.82097-0
   Lockney D, 2011, METHODS MOL BIOL, V726, P207, DOI 10.1007/978-1-61779-052-2_14
   Lomonossoff G. P., 2011, CURRENT TOPICS MICRO
   Marusic C, 2001, J VIROL, V75, P8434, DOI 10.1128/JVI.75.18.8434-8439.2001
   Miao YL, 2010, BIOPOLYMERS, V93, P61, DOI 10.1002/bip.21299
   MUSTER T, 1993, J VIROL, V67, P6642
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   OLSON AJ, 1983, J MOL BIOL, V171, P61, DOI 10.1016/S0022-2836(83)80314-3                                                   
   Phelps DK, 1999, PROTEIN SCI, V8, P2281
   Pokorski JK, 2011, MOL PHARMACEUT, V8, P29, DOI 10.1021/mp100225y
   Porta C, 2003, VIROLOGY, V310, P50, DOI 10.1016/S0042-6822(03)00140-5
   Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003
   Reddy VS, 1998, BIOPHYS J, V74, P546, DOI 10.1016/S0006-3495(98)77813-0                                                   
   Ren Y, 2007, BIOCONJUGATE CHEM, V18, P836, DOI 10.1021/bc060361p
   Saunders K, 2009, VIROLOGY, V393, P329, DOI 10.1016/j.virol.2009.08.023
   SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404
   Soria-Guerra RE, 2011, PLANT CELL REP, V30, P1367, DOI 10.1007/s00299-011-1065-3
   Speelman B, 2001, BIOPHYS J, V80, P121, DOI 10.1016/S0006-3495(01)75999-1                                                   
   Speir JA, 2012, CURR OPIN STRUC BIOL, V22, P65, DOI 10.1016/j.sbi.2011.11.002
   Steinmetz N. F., 2009, VIRUS NANOTECHNOLOGY, V327, P23
   TAVAZZA M, 1994, J GEN VIROL, V75, P1515, DOI 10.1099/0022-1317-75-7-1515
   TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0                                                                
   Terradot L, 2001, VIROLOGY, V286, P72, DOI 10.1006/viro.2001.0900
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Villani ME, 2009, PLANT BIOTECHNOL J, V7, P59, DOI 10.1111/j.1467-7652.2008.00371.x
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Young M, 2008, ANNU REV PHYTOPATHOL, V46, P361, DOI 10.1146/annurev.phyto.032508.131939
   Zhang DQ, 2004, BIOPOLYMERS, V75, P325, DOI 10.1002/bip.20120
   Zink M, 2009, BIOPHYS J, V96, P1350, DOI 10.1016/j.bpj.2008.11.028
NR 62
TC 12
Z9 12
U1 1
U2 85
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD APR 3
PY 2014
VL 32
IS 4
BP 630
EP 647
DI 10.1080/07391102.2013.785920
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 292KB
UT WOS:000329899500011
PM 23672348
DA 2018-01-05
ER

PT J
AU Ciepluch, K
   Ionov, M
   Majoral, JP
   Munoz-Fernandez, MA
   Bryszewska, M
AF Ciepluch, Karol
   Ionov, Maksim
   Majoral, Jean-Pierre
   Angeles Munoz-Fernandez, Maria
   Bryszewska, Maria
TI Interaction of phosphorus dendrimers with HIV peptides-Fluorescence
   studies of nano-complexes formation
SO JOURNAL OF LUMINESCENCE
LA English
DT Article
DE Fluorescence polarization; Nano-complex formation; HIV peptides;
   Phosphorus dendrimers; Biophysical characteristics
ID SOLUBLE CARBOSILANE DENDRIMERS; DENDRITIC CELLS; OLIGONUCLEOTIDES;
   IMMUNOTHERAPY; CULTURE
AB In this study, dendrimers emerge as an alternative approach for delivery of HIV peptides to dendritic cells. Gp 160, NH-EIDNYTNTIYTLLEE-COOH; P24, NH-DTINEEAAEW-COOH and Net NHGMDDPEREVLEWRFDSRLAF-COOH peptides were complexed with two types of positively charged phosphorus containing dendrimers (CPD). Fluorescence polarization, dynamic light scattering, transmission and electron microscopy (TEM) techniques were chosen to evaluate the dendriplexes stability. We were able to show that complexes were stable in time and temperature. This is crucial for using these peptide/dendrimer nano complexes in a new vaccine against HIV-1 infection. (C) 2013 Elsevier B.V. All rights reserved
C1 [Ciepluch, Karol; Ionov, Maksim; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, Fac Biol & Environm Protect, PL-90236 Lodz, Poland.
   [Majoral, Jean-Pierre] CNRS LCC, Lab Chim Coordinat, F-31077 Toulouse 4, France.
   [Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
RP Ciepluch, K (reprint author), Univ Lodz, Dept Gen Biophys, Fac Biol & Environm Protect, Pomorska St 141-143, PL-90236 Lodz, Poland.
EM ciepluch@biol.uni.lodz.pl
OI Bryszewska, Maria/0000-0003-4676-3743;
   Munoz-Fernandez/0000-0002-0813-4500
FU DENPEPTHIV [1/EuroNanoMed/2010]; National Research and Development
   Center, Poland (CIBER-BBN) [PS09102669, FIS (PI08222)]
FX Studies were funded by the Project no. 1/EuroNanoMed/2010, DENPEPTHIV
   financed by National Research and Development Center, Poland
   (PS09102669, FIS (PI08222), CIBER-BBN).
CR Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Baneijee D, 2008, J IMMUNOTHER, V31, P113, DOI 10.1097/CJI.0b013e31815a5892
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51
   Gardikis K, 2011, J NANOSCI NANOTECHNO, V11, P3764, DOI 10.1166/jnn.2011.3847
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hulikova K, 2011, INT IMMUNOPHARMACOL, V11, P955, DOI 10.1016/j.intimp.2011.02.009
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Ionov M, 2012, CHEM PHYS LIPIDS, V165, P408, DOI 10.1016/j.chemphyslip.2011.11.014
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Schuler G, 2010, EUR J IMMUNOL, V40, P2123, DOI 10.1002/eji.201040630
   Shcharbin D, 2009, J CONTROL RELEASE, V135, P186, DOI 10.1016/j.jconrel.2009.01.015
   Smoluchowski M., 1921, HDB ELECT MAGNETISMU, P366
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
NR 23
TC 3
Z9 3
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-2313
EI 1872-7883
J9 J LUMIN
JI J. Lumines.
PD APR
PY 2014
VL 148
BP 364
EP 369
DI 10.1016/j.jlumin.2013.12.052
PG 6
WC Optics
SC Optics
GA AJ2TL
UT WOS:000337516000063
DA 2018-01-05
ER

PT J
AU Borrenberghs, D
   Thys, W
   Rocha, S
   Demeulemeester, J
   Weydert, C
   Dedecker, P
   Hofkens, J
   Debyser, Z
   Hendrix, J
AF Borrenberghs, Doortje
   Thys, Wannes
   Rocha, Susana
   Demeulemeester, Jonas
   Weydert, Caroline
   Dedecker, Peter
   Hofkens, Johan
   Debyser, Zeger
   Hendrix, Jelle
TI HIV Virions as Nanoscopic Test Tubes for Probing Oligomerization of the
   Integrase Enzyme
SO ACS NANO
LA English
DT Article
DE single-molecule fluorescence microscopy; HIV-1 integrase; stoichiometry;
   Forster resonance energy transfer; protein-protein interactions;
   nanoscopy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RED FLUORESCENT PROTEINS; DNA-BINDING
   DOMAIN; TYPE-1 INTEGRASE; SINGLE-MOLECULE; HUMAN-CELLS; IN-VITRO;
   CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; ACTIVE-SITE
AB Employing viruses as nanoscopic lipid-enveloped test tubes allows the miniaturization of protein-protein interaction (PPI) assays while preserving the physiological environment necessary for particular biological processes. Applied to the study of the human immunodeficiency virus type 1 (HIV-1), viral biology and pathology can also be investigated in novel ways, both in vitro as well as in infected cells. In this work we report on an experimental strategy that makes use of engineered HIV-1 viral particles, to allow for probing PPIs of the HIV-1 integrase (IN) inside viruses with single-molecule Forster resonance energy transfer (FRET) using fluorescent proteins (FP). We show that infectious fluorescently labeled viruses can be obtained and that the quantity of labels can be accurately measured and controlled inside individual viral particles. We demonstrate, with proper control experiments, the formation of IN oligomers in single viral particles and inside viral complexes in infected cells. Finally, we show a clear effect on IN oligomerization of small molecule inhibitors of interactions of IN with its natural human cofactor LEDGF/p75, corroborating that IN oligomer enhancing drugs are active already at the level of the virus and strongly suggesting the presence of a dynamic, enhanceable equilibrium between the IN dimer and tetramer in viral particles. Although applied to the HIV-1 IN enzyme, our methodology for utilizing HIV virions as nanoscopic test tubes for probing PPIs is generic, i.e., other PPIs targeted into the HIV-1, or PPIs targeted into other viruses, can potentially be studied with a similar strategy.
C1 [Borrenberghs, Doortje; Rocha, Susana; Dedecker, Peter; Hofkens, Johan; Hendrix, Jelle] Katholieke Univ Leuven, Dept Chem, Lab Photochem & Spect, B-3001 Heverlee, Flanders, Belgium.
   [Thys, Wannes; Demeulemeester, Jonas; Weydert, Caroline; Debyser, Zeger] Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, Dept Pharmaceut & Pharmacol Sci, B-3000 Louvain, Belgium.
   [Hofkens, Johan] Univ Copenhagen, Dept Chem, Nanosci Ctr, DK-2100 Copenhagen, Denmark.
RP Hendrix, J (reprint author), Katholieke Univ Leuven, Dept Chem, Lab Photochem & Spect, Celestijnenlaan 200F, B-3001 Heverlee, Flanders, Belgium.
EM Jelle.Hendrix@chem.kuleuven.be
RI Demeulemeester, Jonas/J-6130-2014; Rocha, Susana/O-7622-2016
OI Demeulemeester, Jonas/0000-0002-2660-2478; Rocha,
   Susana/0000-0003-1258-9396; Dedecker, Peter/0000-0002-1882-2075;
   Hofkens, Johan/0000-0002-9101-0567; debyser, zeger/0000-0002-3982-1565;
   HENDRIX, Jelle/0000-0001-5731-1297
FU Innovation by Science and Technology (IWT Flanders); Research Foundation
   Flanders (FWO); Portuguese Foundation for Science and Technology (FCT)
   [SFR/BD/27265/2006]; FWO; Special Research Fund (BOF); Seventh Framework
   Programme FP7 CHAARM; Interuniversity Attraction Pole BelVir; FWO
   [G0607.09, G0990.11, G0962.13, CASAS METH/08/04]
FX Prof. Richard N. Day (University of Virginia) is acknowledged for
   providing the pmTFP1-5aa- Venus plasmid. The following reagents were
   obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID,
   NIH: pD64E from Dr. Vinay K. Pathak and
   pNL4-3.Luc.R<SUP>-</SUP>.E<SUP>-</SUP> from Dr. Nathaniel Landau. We
   thank Frauke Christ, Rik Gijsbers, and Jan De Rijck for critically
   reading the manuscript D.B. acknowledges the agency for Innovation by
   Science and Technology (IWT Flanders) for a doctoral fellowship. J.
   Hendrix and P.D. are grateful for a postdoctoral fellowship and J.D. is
   grateful for a doctoral fellowship from the Research Foundation Flanders
   (FWO). S.R. acknowledges the Portuguese Foundation for Science and
   Technology (FCT) for a Ph.D. grant (SFR/BD/27265/2006). Z.D.
   acknowledges the FWO, the Special Research Fund (BOF), the Seventh
   Framework Programme FP7 CHAARM and the Interuniversity Attraction Pole
   BelVir. J. Hofkens acknowledges the FWO (Grants G0607.09, G0990.11,
   G0962.13, Methusalem funding CASAS METH/08/04), the KU Leuven Concerted
   Research Action (GOA 2011/03), and the Hercules foundation (HER/08/21).
CR Ai HW, 2006, BIOCHEM J, V400, P531, DOI 10.1042/BJ20060874
   Albanese A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002413
   Arhel N, 2006, NAT METHODS, V3, P817, DOI 10.1038/nmeth931
   Balakrishnan M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074163
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bastiaens PIH, 1996, EMBO J, V15, P4246
   Baumgartel V, 2011, NAT CELL BIOL, V13, P469, DOI 10.1038/ncb2215
   Bojja RS, 2013, J BIOL CHEM, V288, P7373, DOI 10.1074/jbc.M112.434431
   Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615
   Breakefield XO, 2011, MOL THER, V19, P1574, DOI 10.1038/mt.2011.169
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7
   Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200
   Chiu J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh172
   Christ F, 2008, CURR BIOL, V18, P1192, DOI 10.1016/j.cub.2008.07.079
   Christ F, 2010, NAT CHEM BIOL, V6, P442, DOI 10.1038/nchembio.370
   Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329
   CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729                                                          
   Day RN, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2939094
   Dedecker P, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.12.126008
   Demeulemeester J, 2012, J BIOMOL SCREEN, V17, P618, DOI 10.1177/1087057111436343
   Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j
   Desimmie BA, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-57
   Digman MA, 2005, BIOPHYS J, V89, P1317, DOI 10.1529/biophysj.105.062836
   Dupont A, 2013, BIOPHYS J, V104, P2373, DOI 10.1016/j.bpj.2013.04.005
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   Eckhardt M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022007
   EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807                                                             
   Endress T, 2008, EUR BIOPHYS J BIOPHY, V37, P1291, DOI 10.1007/s00249-008-0322-z
   ENGELMAN A, 1993, EMBO J, V12, P3269
   Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150                                                         
   Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990
   Guiot E, 2006, J BIOL CHEM, V281, P22707, DOI 10.1074/jbc.M602198200
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   HE JL, 1995, J VIROL, V69, P6705
   Hendrix J, 2008, BIOPHYS J, V94, P4103, DOI 10.1529/biophysj.107.123596
   Hendrix J, 2013, BIOPHYS J, V105, P848, DOI 10.1016/j.bpj.2013.05.059
   Hendrix J, 2011, NUCLEIC ACIDS RES, V39, P1310, DOI 10.1093/nar/gkq933
   Holmes-Son ML, 2000, J VIROL, V74, P11548, DOI 10.1128/JVI.74.24.11548-11556.2000
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Joo KI, 2008, ACS NANO, V2, P1553, DOI 10.1021/nn8002136
   Kessl JJ, 2012, J BIOL CHEM, V287, P16801, DOI 10.1074/jbc.M112.354373
   Kogan M, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-25
   Kortemme T., 2004, SCI STKE, V2004, pp12, DOI [10.1126/stke.2192004p12, DOI 10.1126/STKE.2192004P12]
   Lam AJ, 2012, NAT METHODS, V9, P1005, DOI [10.1038/NMETH.2171, 10.1038/nmeth.2171]
   Lampe M, 2007, VIROLOGY, V360, P92, DOI 10.1016/j.virol.2006.10.005
   Leavitt AD, 1996, J VIROL, V70, P721
   Lehmann M., 2011, PLOS PATHOG, V7, DOI [10.1371/journal.ppat.1003198, DOI 10.1371/JOURNAL.PPAT.1003198]
   Lelek M, 2012, P NATL ACAD SCI USA, V109, P8564, DOI 10.1073/pnas.1013267109
   Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005
   Llano M, 2004, J BIOL CHEM, V279, P55570, DOI 10.1074/jbc.M408508200
   LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002
   Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200
   Mangeot PE, 2011, MOL THER, V19, P1656, DOI 10.1038/mt.2011.138
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   Mckee CJ, 2008, J BIOL CHEM, V283, P31802, DOI 10.1074/jbc.M805843200
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87
   O'Carroll IP, 2012, J VIROL, V86, P12991, DOI 10.1128/JVI.06287-11
   Pereira CF, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-84
   Petit C, 1999, J VIROL, V73, P5079
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Serrao E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045177
   Shehu-Xhilaga M, 2001, J VIROL, V75, P1834, DOI 10.1128/JVI.75.4.1834-1841.2001
   Smith DE, 2011, CURR OPIN VIROL, V1, P134, DOI 10.1016/j.coviro.2011.05.023
   Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004
   TAKEUCHI Y, 1988, J VIROL, V62, P3900
   Taltynov O., 2012, MOL BIOL INT, DOI [10.1155/2012/863405, DOI 10.1155/2012/863405]
   Thys W., 2009, HIV Therapy, V3, P171, DOI 10.2217/17584310.3.2.171
   Tsiang M, 2012, J BIOL CHEM, V287, P21189, DOI 10.1074/jbc.M112.347534
   Ulbrich MH, 2007, NAT METHODS, V4, P319, DOI 10.1038/NMETH1024
   Van Maele B, 2005, AIDS REV, V7, P26
   Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002
   Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333
   WU XY, 1995, J VIROL, V69, P3389
   ZHANG H, 1994, J VIROL, V68, P7591
NR 81
TC 2
Z9 2
U1 2
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD APR
PY 2014
VL 8
IS 4
BP 3531
EP 3545
DI 10.1021/nn406615v
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AF8UH
UT WOS:000334990600045
PM 24654558
OA gold
DA 2018-01-05
ER

PT J
AU Lalatsa, A
   Schatzlein, AG
   Uchegbu, IF
AF Lalatsa, Aikaterini
   Schatzlein, Andreas G.
   Uchegbu, Ijeoma F.
TI Strategies To Deliver Peptide Drugs to the Brain
SO MOLECULAR PHARMACEUTICS
LA English
DT Review
DE peptides; brain delivery; blood brain barrier; opioid peptides;
   neurodegenerative diseases; intravenous; oral; intranasal;
   receptor-mediated endocytosis; nanoparticles; cell penetrating peptides
ID DENSITY-LIPOPROTEIN RECEPTOR; CELL-PENETRATING PEPTIDES;
   CENTRAL-NERVOUS-SYSTEM; GLYCOL CHITOSAN NANOPARTICLES; CAPILLARY
   ENDOTHELIAL-CELLS; PEG-PLA NANOPARTICLES; HIV-1 TAT PROTEIN;
   TRANSFERRIN-RECEPTOR; INTRANASAL INSULIN; IN-VITRO
AB Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke, and brain cancers would greatly benefit from the use of highly potent and specific peptide pharmaceuticals. Peptides are especially desirable because of their low inherent toxicity. The presence of the blood brain barrier (BBB), their short duration of action, and their need for parenteral administration limits their clinical use. However, over the past decade there have been significant advances in delivering peptides to the central nervous system. Angiopep peptides developed by Angiochem (Montreal, Canada), transferrin antibodies developed by ArmaGen (Santa Monica, USA), and cell penetrating peptides have all shown promise in delivering therapeutic peptides across the BBB after intravenous administration. Noninvasive methods of delivering peptides to the brain include the use of chitosan amphiphile nanoparticles for oral delivery and nose to brain strategies. The uptake of the chitosan amphiphile nanoparticles by the gastrointestinal epithelium is important for oral peptide delivery. Finally protecting peptides from plasma degradation is integral to delivery strategies.
C1 [Lalatsa, Aikaterini] Univ Portsmouth, Sch Pharm & Biomed Sci, Dept Pharmaceut, Portsmouth PO1 2DT, Hants, England.
   [Schatzlein, Andreas G.; Uchegbu, Ijeoma F.] UCL Sch Pharm, London, England.
   [Schatzlein, Andreas G.; Uchegbu, Ijeoma F.] Nanomerics Ltd, St Albans, Herts, England.
RP Uchegbu, IF (reprint author), UCL Sch Pharm, 29-39 Brunswick Sq, London, England.
EM ijeoma.uchegbu@ucl.ac.uk
RI Lalatsa, Aikaterini/I-8546-2016; Schatzlein, Andreas/K-6081-2013
OI Lalatsa, Aikaterini/0000-0003-4791-7468; Schatzlein,
   Andreas/0000-0003-3907-6603; Uchegbu, Ijeoma/0000-0001-9586-6867
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Adenot M, 2007, CHEMOTHERAPY, V53, P73, DOI 10.1159/000098422
   Aktas Y, 2005, BIOCONJUGATE CHEM, V16, P1503, DOI 10.1021/bc050217o
   Aliautdin R N, 1996, Eksp Klin Farmakol, V59, P57
   Allon Therapeutics Inc, 2012, CLINICASPACE
   Banks W A, 2001, Nutrition, V17, P434, DOI 10.1016/S0899-9007(01)00507-X
   Banks WA, 2003, AM J PHYSIOL-ENDOC M, V285, pE10, DOI 10.1152/ajpendo.00468.2002
   BANKS WA, 1994, PEPTIDES, V15, P23, DOI 10.1016/0196-9781(94)90165-1
   Banks WA, 2001, CURR PHARM DESIGN, V7, P125, DOI 10.2174/1381612013398310
   Banks WA, 2001, J PHARMACOL EXP THER, V299, P536
   Batrakova EV, 2005, BIOCONJUGATE CHEM, V16, P793, DOI 10.1021/bc049730c
   Benedict C, 2004, PSYCHONEUROENDOCRINO, V29, P1326, DOI 10.1016/j.psyneuen.2004.04.003
   Benedict C, 2008, J CLIN ENDOCR METAB, V93, P1339, DOI 10.1210/jc.2007-2606
   Benedict C, 2011, DIABETES, V60, P114, DOI 10.2337/db10-0329
   Bertrand Y, 2010, J CELL MOL MED, V14, P2827, DOI 10.1111/j.1582-4934.2009.00930.x
   Bidwell GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055104
   Bilsky EJ, 2000, J MED CHEM, V43, P2586, DOI 10.1021/jm000077y
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Brasnjevic I, 2009, PROG NEUROBIOL, V87, P212, DOI 10.1016/j.pneurobio.2008.12.002
   BROADWELL RD, 1988, P NATL ACAD SCI USA, V85, P632, DOI 10.1073/pnas.85.2.632
   Burguera B, 2001, PHYSIOL BEHAV, V74, P717, DOI 10.1016/S0031-9384(01)00615-1
   Cacciatore I, 2012, OXID MED CELL LONGEV, DOI 10.1155/2012/240146
   Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x
   Chen J, 2000, BIOPOLYMERS, V55, P88, DOI 10.1002/1097-0282(2000)55:1<88::AID-BIP80>3.0.CO;2-K
   Cui HG, 2010, BIOPOLYMERS, V94, P1, DOI 10.1002/bip.21328
   Das D, 2005, J PHARM SCI-US, V94, P1343, DOI 10.1002/jps.20357
   Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x                                                
   Castaigne J. P., 2010, SOC NEUR ANN M NEUR
   Demeule M, 2008, J PHARMACOL EXP THER, V324, P1064, DOI 10.1124/jpet.107.131318
   Demeule M, 2008, J NEUROCHEM, V106, P1534, DOI 10.1111/j.1471-4159.2008.05492.x
   Derad I, 1998, AM J HYPERTENS, V11, P971, DOI 10.1016/S0895-7061(98)00095-8
   Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   DUFFY KR, 1988, METABOLISM, V37, P136, DOI 10.1016/S0026-0495(98)90007-5
   Egleton RD, 2000, BRAIN RES, V881, P37, DOI 10.1016/S0006-8993(00)02794-3
   Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005
   Erazo-Oliveras Alfredo, 2012, Pharmaceuticals (Basel), V5, P1177, DOI 10.3390/ph5111177
   Fehm HL, 2001, J CLIN ENDOCR METAB, V86, P1144, DOI 10.1210/jc.86.3.1144
   FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206
   FRANK HJL, 1981, DIABETES, V30, P757, DOI 10.2337/diabetes.30.9.757
   FRANK HJL, 1986, DIABETES, V35, P654, DOI 10.2337/diabetes.35.6.654
   Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028
   Gaillard PJ, 2006, J CONTROL RELEASE, V116, pE60, DOI 10.1016/j.jconrel.2006.09.050
   Gaillard PJ, 2005, INT CONGR SER, V1277, P185, DOI 10.1016/j.ics.2005.02.002
   Gao XL, 2007, J CONTROL RELEASE, V121, P156, DOI 10.1016/j.jconrel.2007.05.026
   Garrett NL, 2012, J BIOPHOTONICS, V5, P458, DOI 10.1002/jbio.201200006
   Gozes I, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S3
   Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020
   Hallschmid M, 2006, J CLIN ENDOCR METAB, V91, P522, DOI 10.1210/jc.2005-0906
   Harwig SSL, 1996, EUR J BIOCHEM, V240, P352, DOI 10.1111/j.1432-1033.1996.0352h.x                                                
   Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4
   Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7
   IRWIN WJ, 1994, PHARMACEUT RES, V11, P1698, DOI 10.1023/A:1018946829225
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   Ji B, 2006, LIFE SCI, V78, P851, DOI 10.1016/j.lfs.2005.05.085
   Kelder J, 1999, PHARMACEUT RES, V16, P1514, DOI 10.1023/A:1015040217741
   Kern W, 1999, DIABETES, V48, P557, DOI 10.2337/diabetes.48.3.557                                                       
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kubek MJ, 2009, NEUROTHERAPEUTICS, V6, P359, DOI 10.1016/j.nurt.2009.02.001
   Kumar M, 2013, INT J BIOL MACROMOL, V61, P189, DOI 10.1016/j.ijbiomac.2013.06.041
   Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123
   Lalatsa A, 2011, COMPREHENSIVE BIOTECHNOLOGY, VOL 5: MEDICAL BIOTECHNOLOGY AND HEALTHCARE, 2ND EDITION, P657
   Lalatsa A, 2012, MOL PHARMACEUT, V9, P1764, DOI 10.1021/mp300068j
   Lalatsa A, 2012, RSC DRUG DISCOV, P329, DOI 10.1039/9781849735292-00329
   Lalatsa A, 2012, MOL PHARMACEUT, V9, P1665, DOI 10.1021/mp300009u
   Lax R., 2010, PHARMANUF INT PEPT R
   Lennernas Hans, 2004, Drug Discov Today Technol, V1, P417, DOI 10.1016/j.ddtec.2004.11.010
   Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671
   Lindqvist A, 2013, MOL PHARMACEUT, V10, P1533, DOI 10.1021/mp300272a
   Liu LH, 2009, NAT NANOTECHNOL, V4, P457, DOI [10.1038/nnano.2009.153, 10.1038/NNANO.2009.153]
   Liu Y, 2000, NAT MED, V6, P1380
   Liu ZY, 2013, BIOCONJUGATE CHEM, V24, P997, DOI 10.1021/bc400055h
   Liu ZY, 2013, BIOMATERIALS, V34, P3870, DOI 10.1016/j.biomaterials.2013.02.003
   LONNERDAL B, 1995, ANNU REV NUTR, V15, P93, DOI 10.1146/annurev.nutr.15.1.93                                                    
   Malcor JD, 2012, J MED CHEM, V55, P2227, DOI 10.1021/jm2014919
   Mangoni ME, 1996, FEBS LETT, V383, P93, DOI 10.1016/0014-5793(96)00236-0
   Masserini M, 2013, ISRN BIOCH, V2013, DOI DOI 10.1155/2013/238428
   Mazza M, 2013, ACS NANO, V7, P1016, DOI 10.1021/nn305193d
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594
   Nikolich K., 2009, 39 M SOC NEUR CHIC
   Pan W, 2002, EXP NEUROL, V174, P193, DOI 10.1006/exnr.2002.7871
   Pan WH, 1999, PEPTIDES, V20, P1091, DOI 10.1016/S0196-9781(99)00094-7
   Pang ZQ, 2008, J CONTROL RELEASE, V128, P120, DOI 10.1016/j.jconrel.2008.03.007
   Paramonov SE, 2006, J AM CHEM SOC, V128, P7291, DOI 10.1021/ja060573x
   Pardridge WM, 2007, PHARM RES, V24, P1733, DOI 10.1007/s11095-007-9324-2
   Pardridge William M, 2005, NeuroRx, V2, P3
   Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126
   Pardridge WM, 2012, METHOD ENZYMOL, V503, P269, DOI 10.1016/B978-0-12-396962-0.00011-2
   Pauletti GM, 1997, PHARMACEUT RES, V14, P164, DOI 10.1023/A:1012040425146
   Pietrowsky R, 1996, PSYCHONEUROENDOCRINO, V21, P559, DOI 10.1016/S0306-4530(96)00012-1
   Pietrowsky R, 1996, BIOL PSYCHIAT, V39, P332, DOI 10.1016/0006-3223(95)00180-8
   Popov M, 2013, EUR J PHARM BIOPHARM, V85, P381, DOI 10.1016/j.ejpb.2013.06.005
   Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36
   Regina A, 2008, BRIT J PHARMACOL, V155, P185, DOI 10.1038/bjp.2008.260
   Reichert J., 2010, REPORT SUMMARY DEV T
   Reis CP, 2008, J PHARM SCI-US, V97, P5290, DOI 10.1002/jps.21347
   Rousselle C, 2003, J PHARMACOL EXP THER, V306, P371, DOI 10.1124/jpet.102.048520
   Ruan YP, 2012, DRUG DEV IND PHARM, V38, P123, DOI 10.3109/03639045.2011.592533
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Schroeder U, 1998, PEPTIDES, V19, P777, DOI 10.1016/S0196-9781(97)00474-9
   Lopez DRS, 2013, THER DELIV, V4, P479, DOI 10.4155/TDE.13.5
   Siew A, 2012, MOL PHARMACEUT, V9, P14, DOI 10.1021/mp200469a
   Smolnik R, 2000, J CLIN PSYCHOPHARM, V20, P445, DOI 10.1097/00004714-200008000-00009
   Sorensen M, 1997, PHARMACEUT RES, V14, P1341, DOI 10.1023/A:1012104301773                                                         
   Strand FL, 2003, PROG DRUG RES, V61, P1
   Subrizi A, 2012, J CONTROL RELEASE, V158, P277, DOI 10.1016/j.jconrel.2011.11.007
   Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1
   Teixido M, 2005, J PEPT SCI, V11, P789, DOI 10.1002/psc.679
   Thomas FC, 2009, PHARM RES-DORDR, V26, P2486, DOI 10.1007/s11095-009-9964-5
   Tian XH, 2012, INT J NANOMED, V7, P1031, DOI 10.2147/IJN.S26541
   Tosi G, 2012, NANOMEDICINE-UK, V7, P365, DOI [10.2217/NNM.11.98, 10.2217/nnm.11.98]
   Tunnemann G., 2009, MEMBRANE ACTIVE PEPT, P331
   Uchegbu IF, 2013, J PHARM SCI-US, V102, P305, DOI 10.1002/jps.23377
   Ulbrich K, 2009, EUR J PHARM BIOPHARM, V71, P251, DOI 10.1016/j.ejpb.2008.08.021
   Ulijn RV, 2008, CHEM SOC REV, V37, P664, DOI 10.1039/b609047h
   van der Walle C, 2011, PEPTIDE AND PROTEIN DELIVERY, pIX
   van Rooy I, 2011, J CONTROL RELEASE, V150, P30, DOI 10.1016/j.jconrel.2010.11.014
   VANHOUTEN M, 1979, ENDOCRINOLOGY, V105, P666
   Varamini P, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00155
   Veronesi MC, 2009, BRAIN RES, V1303, P151, DOI 10.1016/j.brainres.2009.09.039
   Visser CC, 2004, J DRUG TARGET, V12, P145, DOI 10.1080/10611860410001701706
   Visser CC, 2004, PHARM RES-DORDR, V21, P761, DOI 10.1023/B:PHAM.0000026425.69874.8e                                              
   Vlieghe P, 2010, THER DELIV, V1, P489, DOI 10.4155/TDE.10.44
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175
   Wu HB, 2012, EUR J PHARM BIOPHARM, V80, P368, DOI 10.1016/j.ejpb.2011.10.012
   Xia HM, 2012, INT J PHARMACEUT, V436, P840, DOI 10.1016/j.ijpharm.2012.07.029
   Yang D, 2013, EXP NEUROL, V247, P447, DOI 10.1016/j.expneurol.2013.01.015
   ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334
   Zhang SG, 2002, CURR OPIN CHEM BIOL, V6, P865, DOI 10.1016/S1367-5931(02)00391-5
   Zhou JB, 2013, P NATL ACAD SCI USA, V110, P11751, DOI 10.1073/pnas.1304504110
   ZLOKOVIC BV, 1990, EXP NEUROL, V107, P263, DOI 10.1016/0014-4886(90)90144-H                                                    
   Sabel B. A., 1997, United States Patent Application, Patent No. [US 20020034474 A1. PCT/EP1997/003099, 20020034474]
   Boado R. J., 2008, United States Patent, Patent No. [7,388,079, 7388079]
NR 142
TC 37
Z9 37
U1 10
U2 132
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD APR
PY 2014
VL 11
IS 4
BP 1081
EP 1093
DI 10.1021/mp400680d
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AE6IB
UT WOS:000334092700001
PM 24601686
DA 2018-01-05
ER

PT J
AU Zoppe, JO
   Ruottinen, V
   Ruotsalainen, J
   Ronkko, S
   Johansson, LS
   Hinkkanen, A
   Jarvinen, K
   Seppala, J
AF Zoppe, Justin O.
   Ruottinen, Ville
   Ruotsalainen, Janne
   Ronkko, Seppo
   Johansson, Leena-Sisko
   Hinkkanen, Ari
   Jarvinen, Kristiina
   Seppala, Jukka
TI Synthesis of Cellulose Nanocrystals Carrying Tyrosine Sulfate Mimetic
   Ligands and Inhibition of Alphavirus Infection
SO BIOMACROMOLECULES
LA English
DT Article
ID SEMLIKI-FOREST-VIRUS; MULTIVALENT GOLD NANOPARTICLES; MICROCRYSTALLINE
   CELLULOSE; CHIKUNGUNYA VIRUS; HIV-1 ENTRY; FUSION; NANOWHISKERS;
   ATTACHMENT; BINDING; SYSTEMS
AB We present two facile approaches for introducing multivalent displays of tyrosine sulfate mimetic ligands on the surface of cellulose nanocrystals (CNCs) for application as viral inhibitors. We tested the efficacy of cellulose nanocrystals, prepared either from cotton fibers or Whatman filter paper, to inhibit alphavinis infectivity in Vero (B) cells. Cellulose nanocrystals were produced by sulfuric acid hydrolysis leading to nanocrystal surfaces decorated with anionic sulfate groups. When the fluorescent marker expressing Semliki Forest virus vector, VA7-EGFP, was incubated with CNCs, strong inhibition of virus infectivity was achieved, up to 100 and 88% for cotton and Whatman CNCs, respectively. When surface sulfate groups of CNCs were exchanged for tyrosine sulfate mimetic groups (i.e. phenyl sulfonates), improved viral inhibition was attained. Our observations suggest that the conjugation of target-specific functionafities to CNC surfaces provides a means to control their antiviral activity. Multivalent CNCs did not cause observable in vitro cytotoxicity to Vero (B) cells or human corneal epithelial (HCE-T) cells, even within the 100% virus-inhibitory concentrations. Based on the similar chemistry of known polyanionic inhibitors, our results suggest the potential application of CNCs as inhibitors of other viruses, such as human immunodeficiency virus (HIV) and herpes simplex viruses.
C1 [Zoppe, Justin O.; Seppala, Jukka] Aalto Univ Sch Chem Technol, Dept Biotechnol & Chem Technol, Aalto 00076, Finland.
   [Johansson, Leena-Sisko] Aalto Univ Sch Chem Technol, Dept Forest Prod Technol, Aalto 00076, Finland.
   [Ruottinen, Ville; Ronkko, Seppo; Jarvinen, Kristiina] Univ Eastern Finland, Sch Pharm, Kuopio 70211, Finland.
   [Ruotsalainen, Janne; Hinkkanen, Ari] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Fac Hlth Sci, Kuopio 70211, Finland.
RP Zoppe, JO (reprint author), Aalto Univ Sch Chem Technol, Dept Biotechnol & Chem Technol, POB 16100, Aalto 00076, Finland.
EM jozoppe@gmail.com; jukka.seppala@aalto.fi
RI Zoppe, Justin/G-9021-2012; Seppala, Jukka/G-7698-2012
OI Zoppe, Justin/0000-0002-3599-9227; Johansson,
   Leena-Sisko/0000-0003-0428-8155
FU Aalto University; Cancer Center of Eastern Finland; Foundation for
   Finnish Inventions (Keksintosaatio); Academy of Finland [137759]
FX The authors would like to express their gratitude to Dr. Joseph Campbell
   for conducting XPS measurements. The authors are grateful to Dr.
   Cristina Perez Vera for reviewing the manuscript. Funding support from
   Aalto University, the Cancer Center of Eastern Finland, the Foundation
   for Finnish Inventions (Keksintosaatio), and the Academy of Finland
   (Dec. No. 137759) are greatly appreciated.
CR Acharya P, 2011, ACS CHEM BIOL, V6, P1069, DOI 10.1021/cb200068b
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Araki J, 1998, COLLOID SURFACE A, V142, P75, DOI 10.1016/S0927-7757(98)00404-X                                                   
   ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Beamson G., 1992, HIGH RESOLUTION XPS
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Briolant S, 2004, ANTIVIR RES, V61, P111, DOI 10.1016/j.antiviral.2003.09.005
   Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Dong SP, 2007, J AM CHEM SOC, V129, P13810, DOI 10.1021/ja076196l
   Dong SP, 2012, NANO LIFE, V2, DOI 10.1142/S1793984412410061
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Ferreira LFV, 1998, MACROMOLECULES, V31, P3936
   Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239
   Habibi Y, 2010, CHEM REV, V110, P3479, DOI 10.1021/cr900339w
   Habibi Y, 2010, LANGMUIR, V26, P990, DOI 10.1021/la902444x
   Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978-0-12-370501-3.00001-1
   Jackson JK, 2011, INT J NANOMED, V6, P321, DOI 10.2147/IJN.S16749
   Jiang F, 2010, LANGMUIR, V26, P17919, DOI 10.1021/la1028405
   Johansson LS, 1999, APPL SURF SCI, V144-45, P92, DOI 10.1016/S0169-4332(98)00920-9                                                   
   Johansson LS, 2004, SURF INTERFACE ANAL, V36, P1018, DOI 10.1002/sia.1827
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kloser E, 2010, LANGMUIR, V26, P13450, DOI 10.1021/la101795s
   Lam E, 2012, TRENDS BIOTECHNOL, V30, P283, DOI 10.1016/j.tibtech.2012.02.001
   Leparc-Goffart I, 2014, LANCET, V383, P514, DOI 10.1016/S0140-6736(14)60185-9
   Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8
   Li QQ, 2011, BIOMACROMOLECULES, V12, P650, DOI 10.1021/bm101315y
   Ma HY, 2012, BIOMACROMOLECULES, V13, P180, DOI 10.1021/bm201421g
   Male KB, 2012, NANOSCALE, V4, P1373, DOI 10.1039/c2nr11886f
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Moon RJ, 2011, CHEM SOC REV, V40, P3941, DOI 10.1039/c0cs00108b
   Ni H, 2012, BIO-MED MATER ENG, V22, P121, DOI 10.3233/BME-2012-0697
   Nielsen LJ, 2010, CHEM COMMUN, V46, P8929, DOI 10.1039/c0cc03470c
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6
   Rowe R. C., 2012, HDB PHARM EXCIPIENTS, P1033
   SANTAGATI MG, 1994, J GEN VIROL, V75, P1499, DOI 10.1099/0022-1317-75-6-1499
   Serizawa T, 2013, BIOMACROMOLECULES, V14, P613, DOI 10.1021/bm4000822
   Skoging U, 1996, STRUCTURE, V4, P519, DOI 10.1016/S0969-2126(96)00058-5                                                   
   Smit JM, 2002, J VIROL, V76, P10128, DOI 10.1128/JVI.76.20.10128-10137.2002
   Soumahoro MK, 2009, PLOS ONE, V4, pA221, DOI 10.1371/journal.pone.0007800
   Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011
   Toropainen E, 2003, EUR J PHARM SCI, V20, P99, DOI 10.1016/S0928-0987(03)00173-8
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Yamamoto I, 1991, CARBOHYD POLYM, V14, P53
   ZHAO HX, 1994, EMBO J, V13, P4204
   Zoppe JO, 2013, CELLULOSE, V20, P2569, DOI 10.1007/s10570-013-0008-2
   Burt H. M., 2012, Binding drugs with nanocrystalline cellulose excipient, Patent No. [WO 2012068670, 2012068670]
NR 54
TC 21
Z9 21
U1 2
U2 56
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD APR
PY 2014
VL 15
IS 4
BP 1534
EP 1542
DI 10.1021/bm500229d
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AF2VW
UT WOS:000334571600048
PM 24628489
DA 2018-01-05
ER

PT J
AU Varga, N
   Sutkeviciute, I
   Ribeiro-Viana, R
   Berzi, A
   Ramdasi, R
   Daghetti, A
   Vettoretti, G
   Amara, A
   Clerici, M
   Rojo, J
   Fieschi, F
   Bernardi, A
AF Varga, Norbert
   Sutkeviciute, Ieva
   Ribeiro-Viana, Renato
   Berzi, Angela
   Ramdasi, Rasika
   Daghetti, Anna
   Vettoretti, Gerolamo
   Amara, Ali
   Clerici, Mario
   Rojo, Javier
   Fieschi, Franck
   Bernardi, Anna
TI A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and
   Dengue virus
SO BIOMATERIALS
LA English
DT Article
DE Glycodendrimers; Glycomimetics; HIV; Dengue; DC-SIGN; Nanotechnology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC CELLS; GLYCODENDRITIC
   STRUCTURES; GP120 BINDING; INFECTION; LECTIN; POLYMERS; ORGANIZATION;
   DENDRIMERS; RECEPTOR
AB DC-SIGN is a C-type lectin receptor on antigen presenting cells (dendritic cells) which has an important role in some viral infection, notably by HIV and Dengue virus (DV). Multivalent presentation of carbohydrates on dendrimeric scaffolds has been shown to inhibit DC-SIGN binding to HIV envelope glycoprotein gp120, thus blocking viral entry. This approach has interesting potential applications for infection prophylaxis. In an effort to develop high affinity inhibitors of DC-SIGN mediated viral entry, we have synthesized a group of glycodendrimers of different valency that bear different carbohydrates or glycomimetic DC-SIGN ligands and have studied their DC-SIGN binding activity and antiviral properties both in an HIV and a Dengue infection model. Surface Plasmon Resonance (SPR) competition studies have demonstrated that the materials obtained bind efficiently to DC-SIGN with IC(50)s in the mu M range, which depend on the nature of the ligand and on the valency of the scaffold. In particular, a hexavalent presentation of the DC-SIGN selective antagonist 4 displayed high potency, as well as improved accessibility and chemical stability relative to previously reported dendrimers. At low mu M concentration the material was shown to block both DC-SIGN mediated uptake of DV by Raji cells and HIV trans-infection of T cells. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Varga, Norbert; Daghetti, Anna; Vettoretti, Gerolamo; Bernardi, Anna] Univ Milan, Dipartimento Chim, I-20133 Milan, Italy.
   [Sutkeviciute, Ieva; Fieschi, Franck] Univ Grenoble Alpes, IBS, F-38027 Grenoble, France.
   [Sutkeviciute, Ieva; Fieschi, Franck] CEA Grenoble, IBS, DSV, F-38027 Grenoble, France.
   [Sutkeviciute, Ieva; Fieschi, Franck] CNRS, IBS, F-38027 Grenoble, France.
   [Ribeiro-Viana, Renato; Rojo, Javier] Univ Seville, CSIC, IIQ, Seville 41092, Spain.
   [Berzi, Angela] Univ Milan, Dipartimento Sci Biomed & Clin L Sacco, I-20157 Milan, Italy.
   [Ramdasi, Rasika] Hop St Louis, INSERM, Lab Pathol & Virol Mol, U944, F-75010 Paris, France.
   [Clerici, Mario] Univ Milan, Dipartimento Fisiopatol Med Chirurg & Trapianti, I-20090 Segrate, Italy.
   [Clerici, Mario] Fdn Don Gnocchi IRCCS, I-20148 Milan, Italy.
   [Bernardi, Anna] CNR ISTM, Inst Mol Sci & Technol, Milan, Italy.
RP Bernardi, A (reprint author), Univ Milan, Dipartimento Chim, Via Golgi 19, I-20133 Milan, Italy.
EM anna.bernardi@unimi.it
RI Bernardi, Anna/A-1167-2012; Rojo, Javier/A-2801-2015; Ribeiro-Viana,
   Renato/A-5935-2017
OI Bernardi, Anna/0000-0002-1258-2007; Rojo, Javier/0000-0003-3173-3437;
   Ribeiro-Viana, Renato/0000-0001-6603-4770; Clerici,
   Mario/0000-0001-5920-6191; Sutkeviciute, Ieva/0000-0002-2168-3344
FU EU ITN Marie-Curie program (CARMUSYS) [213592]; Institut Universitaire
   de France; University of Milan; Regione Lombardia (Programma "Dote
   Ricerca-Rafforzare il capitale umano") [POR-Ob.2 Asse IV-FSE 2007-2013]
FX The project was supported under the EU ITN Marie-Curie program
   (CARMUSYS, Grant number 213592). The CM1102 COST Action Multiglyconano
   is also acknowledged. F. Fieschi thanks the Institut Universitaire de
   France for financial support. A. Berzi was supported by a fellowship of
   University of Milan and Regione Lombardia (Programma "Dote
   Ricerca-Rafforzare il capitale umano", POR-Ob.2 Asse IV-FSE 2007-2013).
   This work has been conducted thanks to the access to the SPR and MP3
   platforms of the Partnership for Structural Biology and the Institut de
   Biologie Structurale in Grenoble (PSB/IBS). HRMS analysis was obtained
   at the CIGA center of the University of Milan.
CR Anderluh M, 2012, CURR MED CHEM, V19, P992, DOI 10.2174/092986712799320664                                                      
   Andreini M, 2011, ORG BIOMOL CHEM, V9, P5778, DOI 10.1039/c1ob05573a
   Arce E, 2003, BIOCONJUGATE CHEM, V14, P817, DOI 10.1021/bc034008k
   Becer CR, 2010, J AM CHEM SOC, V132, P15130, DOI 10.1021/ja1056714
   Bernardi A, 2008, CHEM-EUR J, V14, P7434, DOI 10.1002/chem.200800597
   Berzi A, 2012, AIDS, V26, P127, DOI 10.1097/QAD.0b013e32834e1567
   Borrok MJ, 2007, J AM CHEM SOC, V129, P12780, DOI 10.1021/ja072944v
   Cambi A, 2004, J CELL BIOL, V164, P145, DOI 10.1083/jcb.200306112                                                           
   Canalle LA, 2009, ADV FUNCT MATER, V19, P3464, DOI 10.1002/adfm.200900743
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   de Bakker BI, 2007, CHEMPHYSCHEM, V8, P1473, DOI 10.1002/cphc.200700169
   de Witte L, 2007, NAT MED, V13, P367, DOI 10.1038/nm1541
   Garber KCA, 2010, CHEM COMMUN, V46, P6747, DOI 10.1039/c0cc00830c
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Hidari KIPJ, 2013, VIRUSES-BASEL, V5, P605, DOI 10.3390/v5020605
   Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Lambeth RH, 2010, J POLYM SCI POL CHEM, V48, P5752, DOI 10.1002/pola.24380
   Lasala F, 2003, ANTIMICROB AGENTS CH, V47, P3970, DOI 10.1128/AAC.47.12.3970-3972.2003
   Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003
   Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200
   Luczkowiak J, 2011, BIOCONJUGATE CHEM, V22, P1354, DOI 10.1021/bc2000403
   Mangold SL, 2012, CHEM SCI, V3
   Maria S, 2007, CARBOHYD RES, V342, P1859, DOI 10.1016/j.carres.2007.03.019
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Ortega-Munoz M, 2006, ADV SYNTH CATAL, V348, P2410, DOI 10.1002/adsc.200600254
   Pieters RJ, 2009, ORG BIOMOL CHEM, V7, P2013, DOI 10.1039/b901828j
   Reina JJ, 2007, CHEMMEDCHEM, V2, P1030, DOI 10.1002/cmdc.200700047
   Rojo J, 2004, J ANTIMICROB CHEMOTH, V54, P579, DOI 10.1093/jac/dkh399
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   Tabarani G, 2009, J BIOL CHEM, V284, P21229, DOI 10.1074/jbc.M109.021204
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Thepaut M, 2013, J AM CHEM SOC, V135, P2518, DOI 10.1021/ja3053305
   Touaibia M, 2007, CHEMMEDCHEM, V2, P1190, DOI 10.1002/cmdc.200700063
   Tran Thuong H, 2011, J Antivir Antiretrovir, V3, P49
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Varga N, 2013, CHEM-EUR J, V19, P4786, DOI 10.1002/chem.201202764
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Xie JD, 2008, J POLYM SCI POL PHYS, V46, P1140, DOI 10.1002/polb.21447
NR 40
TC 46
Z9 46
U1 2
U2 39
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2014
VL 35
IS 13
BP 4175
EP 4184
DI 10.1016/j.biomaterials.2014.01.014
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AF1NQ
UT WOS:000334481000026
PM 24508075
DA 2018-01-05
ER

PT J
AU Zhang, SX
   Han, GJ
   Xing, Z
   Zhang, SC
   Zhang, XR
AF Zhang, Shixi
   Han, Guojun
   Xing, Zhi
   Zhang, Sichun
   Zhang, Xinrong
TI Multiplex DNA Assay Based on Nanoparticle Probes by Single Particle
   Inductively Coupled Plasma Mass Spectrometry
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID COLLOID ANALYSIS; GOLD NANOPARTICLES; OPTICAL-PROPERTIES; QUANTUM DOTS;
   ICP-MS; QUANTIFICATION; HYBRIDIZATION; COINFECTION; STRATEGY; MODE
AB A, multiplex DNA assay based on nanoparticle (NP) tags detection utilizing single particle mode inductively coupled plasma mass spectrometry (SP-ICP-MS) as ultra-sensitive readout has been demonstrated in the article. Three DNA targets associated with clinical diseases (HIV, HAV, and HBV) down to 1 pM were detected by DNA probes labeled with AuNPs, AgNPs, and PtNPs via DNA sandwich assay. Single nucleotide polymorphisms in genes can also be effectively discriminated. Since our method is unaffected by the sample matrix, it is well-suited for diagnostic applications. Moreover, with the high sensitivity of SP-ICP-MS and the variety of NPs detectable by SP-ICP-MS, high-throughput DNA assay could be achieved without signal amplification or chain reaction amplification.
C1 [Zhang, Shixi; Han, Guojun; Xing, Zhi; Zhang, Sichun; Zhang, Xinrong] Tsinghua Univ, Dept Chem, Beijing Key Lab Microanalyt Methods & Instrumenta, Beijing 100084, Peoples R China.
RP Zhang, SC (reprint author), Tsinghua Univ, Dept Chem, Beijing Key Lab Microanalyt Methods & Instrumenta, Beijing 100084, Peoples R China.
EM sczhang@mail.tsinghua.edu.cn
FU 973 Program [2013CB933800]; National Natural Science Foundation of China
   [21390410, 21125525]; Innovation Method Fund of China [2012IM030400]
FX This research was supported by the 973 Program (2013CB933800), the
   National Natural Science Foundation of China (Grants 21390410 and
   21125525), and Innovation Method Fund of China (No. 2012IM030400).
CR Algar WR, 2010, ANAL CHEM, V82, P400, DOI 10.1021/ac902221d
   Algar WR, 2009, ANAL CHEM, V81, P4113, DOI 10.1021/ac900421p
   Allabashi R, 2009, J NANOPART RES, V11, P2003, DOI 10.1007/s11051-008-9561-2
   Bigall NC, 2008, NANO LETT, V8, P4588, DOI 10.1021/nl802901t
   Brown KR, 2000, CHEM MATER, V12, P306, DOI 10.1021/cm980065p                                                               
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626
   Degueldre C, 2006, TALANTA, V68, P623, DOI 10.1016/j.talanta.2005.05.006
   Degueldre C, 2006, ANAL CHIM ACTA, V555, P263, DOI 10.1016/j.aca.2005.09.021
   Degueldre C, 2004, ANAL CHIM ACTA, V518, P137, DOI 10.1016/j.aca.2004.04.015
   Degueldre C, 2004, TALANTA, V62, P1051, DOI 10.1016/j.talanta.2003.10.016
   Degueldre C, 2003, COLLOID SURFACE A, V217, P137, DOI 10.1016/S0927-7757(02)00568-X
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Gasparac R, 2004, J AM CHEM SOC, V126, P12270, DOI 10.1021/ja0458221
   Han GJ, 2011, ANGEW CHEM INT EDIT, V50, P3462, DOI 10.1002/anie.201006838
   Han GJ, 2013, ANGEW CHEM INT EDIT, V52, P1466, DOI 10.1002/anie.201206903
   He SJ, 2012, ANAL CHEM, V84, P4622, DOI 10.1021/ac300577d
   Hirayama H, 1996, NUCLEIC ACIDS RES, V24, P4098, DOI 10.1093/nar/24.20.4098                                                          
   Hoffmann CJ, 2007, LANCET INFECT DIS, V7, P402, DOI 10.1016/S1473-3099(07)70135-4
   Hu SH, 2009, J AM SOC MASS SPECTR, V20, P1096, DOI 10.1016/j.jasms.2009.02.005
   Keeffe E, 2000, J Viral Hepat, V7 Suppl 1, P15, DOI 10.1046/j.1365-2893.2000.00016.x
   Li YG, 2005, NAT BIOTECHNOL, V23, P885, DOI 10.1038/nbt1106
   Liu XQ, 2013, J AM CHEM SOC, V135, P11832, DOI 10.1021/ja403485r
   Luo YC, 2013, ANAL CHEM, V85, P9428, DOI 10.1021/ac402446a
   Peters PJ, 2012, J INFECT DIS, V205, P166, DOI 10.1093/infdis/jir728
   Sanz-Medel A, 2008, ANAL BIOANAL CHEM, V390, P3, DOI 10.1007/s00216-007-1615-2
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Yan XW, 2013, ANAL BIOANAL CHEM, V405, P5663, DOI 10.1007/s00216-013-6886-1
   Zeng J, 2010, J AM CHEM SOC, V132, P8552, DOI 10.1021/ja103655f
   Zhang CY, 2010, ANAL CHEM, V82, P1921, DOI 10.1021/ac9026675
   Zheng WM, 2009, J AM CHEM SOC, V131, P3432, DOI 10.1021/ja809175q
NR 34
TC 29
Z9 29
U1 11
U2 183
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD APR 1
PY 2014
VL 86
IS 7
BP 3541
EP 3547
DI 10.1021/ac404245z
PG 7
WC Chemistry, Analytical
SC Chemistry
GA AE2AV
UT WOS:000333776600040
PM 24579812
DA 2018-01-05
ER

PT J
AU Dolgin, E
AF Dolgin, Elie
TI Long-acting HIV drugs advanced to overcome adherence challenge
SO NATURE MEDICINE
LA English
DT News Item
ID NANOFORMULATED ANTIRETROVIRAL THERAPY
CR Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
NR 4
TC 22
Z9 22
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD APR
PY 2014
VL 20
IS 4
BP 323
EP 324
DI 10.1038/nm0414-323                                                      
          
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA AE9WF
UT WOS:000334361500005
PM 24710366
DA 2018-01-05
ER

PT J
AU Wu, HQ
   Pannecouque, C
   Yan, ZH
   Chen, WX
   He, QQ
   Chen, FE
   Balzarini, J
   Daelemans, D
   De Clercq, E
AF Wu, Hai-Qiu
   Pannecouque, Christophe
   Yan, Zi-Hong
   Chen, Wen-Xue
   He, Qiu-Qiu
   Chen, Fen-Er
   Balzarini, Jan
   Daelemans, Dirk
   De Clercq, Erik
TI Synthesis and biological evaluation of new conformationally restricted
   S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse
   transcriptase
SO MEDCHEMCOMM
LA English
DT Article
ID ANTI-HIV-1 AGENTS; TIGHT-BINDING; FAMILY; DESIGN; POTENT; MUTANTS;
   2-AMINOPYRIMIDIN-4(3H)-ONES; DERIVATIVES; NNRTIS; ENZYME
AB A series of conformationally restricted dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) hybrids, which combined the structural features of C6-alpha-methylbenzyl-thio-DABOs (a-methyl-S-DABOs) and C6-alpha-cyanobenzyl-thio-DABOs (CN-S-DABOs), has been synthesized and biologically evaluated for their anti-HIV activity against wild-type HIV- 1 strain IIIB, double RT mutant (K103N + Y181C) strain RES056 and HIV- 2 strain ROD in MT-4 cell cultures. Most of these compounds exhibited inhibitory activity (wild-type) within the range of EC50 values from micromolar to nanomolar. Among them, compound 1s displayed the highest anti-HIV-1 activity with an EC50 value of 91 nM and a selectivity index ( SI) of 548, which was more potent than zalcitabine and comparable to nevirapine and delavirdine in the same assay. The HIV- 1 reverse transcriptase inhibitory ( RT) assay confirmed that these conformationally restricted S-DABO hybrids targeted HIV- 1 RT. The preliminary structure-activity relationship (SAR) and molecular docking analysis of this new series of conformationally constrained CN-S-DABO hybrids were also investigated.
C1 [Wu, Hai-Qiu; Yan, Zi-Hong; Chen, Wen-Xue; He, Qiu-Qiu; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Pannecouque, Christophe; Balzarini, Jan; Daelemans, Dirk; De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
   [Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
RP He, QQ (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM qqhe@fudan.edu.cn
RI Daelemans, Dirk/P-7923-2017
OI Daelemans, Dirk/0000-0001-7092-1153
FU National Natural Science Foundation of China [81172918]; Shanghai
   Municipal Natural Science Foundation [13ZR1402200]; Chinese National
   Science and Technology Major Project [2012ZX09103101-068]; KU Leuven
   [GOA 10/014]
FX This research was financially supported by grants from National Natural
   Science Foundation of China (no. 81172918), Shanghai Municipal Natural
   Science Foundation (no. 13ZR1402200), Chinese National Science and
   Technology Major Project (no. 2012ZX09103101-068) and KU Leuven (GOA
   10/014).
CR Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   BOTTA M, 1992, EUR J MED CHEM, V27, P251, DOI 10.1016/0223-5234(92)90009-P
   Cancio R, 2007, CHEMMEDCHEM, V2, P445, DOI 10.1002/cmdc.200600310
   Ji L, 2007, J MED CHEM, V50, P1778, DOI 10.1021/jm061167r
   KORONIAK H, 1993, ORG PREP PROCED INT, V25, P563, DOI 10.1080/00304949309457999                                                       
   Mai A, 2005, BIOORGAN MED CHEM, V13, P2065, DOI 10.1016/j.bmc.2005.01.005
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Mai A, 2007, J MED CHEM, V50, P5412, DOI 10.1021/jm070811e
   Martins S, 2008, CURR MED CHEM, V15, P1083, DOI 10.2174/092986708784221467                                                      
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Nawrozkij MB, 2008, J MED CHEM, V51, P4641, DOI 10.1021/jm800340w
   Radi M, 2009, J MED CHEM, V52, P840, DOI 10.1021/jm801330n
   Ragno R, 2004, J MED CHEM, V47, P928, DOI 10.1021/jm0309856
   Rorig K., 1956, ORG SYNTH, V36, P50
   Rotili D, 2011, J MED CHEM, V54, P3091, DOI 10.1021/jm101626c
   Samuele A, 2008, CHEMMEDCHEM, V3, P1412, DOI 10.1002/cmdc.200800051
   Tronchet JMJ, 2003, CURR TOP MED CHEM, V3, P1496, DOI 10.2174/1568026033451754                                                        
   Yang SQ, 2012, CURR MED CHEM, V19, P152, DOI 10.2174/092986712803414169                                                      
   Yu M, 2011, CURR MED CHEM, V18, P2376, DOI 10.2174/092986711795843209                                                      
   Zhan P, 2009, CURR MED CHEM, V16, P3903, DOI 10.2174/092986709789178019                                                      
NR 21
TC 1
Z9 1
U1 1
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PD APR
PY 2014
VL 5
IS 4
BP 468
EP 473
DI 10.1039/c3md00247k
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AD9JA
UT WOS:000333580000009
DA 2018-01-05
ER

PT J
AU D'Atri, V
   Borbone, N
   Amato, J
   Gabelica, V
   D'Errico, S
   Piccialli, G
   Mayol, L
   Oliviero, G
AF D'Atri, Valentina
   Borbone, Nicola
   Amato, Jussara
   Gabelica, Valerie
   D'Errico, Stefano
   Piccialli, Gennaro
   Mayol, Luciano
   Oliviero, Giorgia
TI DNA-based nanostructures: The effect of the base sequence on octamer
   formation from d(XGGYGGT) tetramolecular G-quadruplexes
SO BIOCHIMIE
LA English
DT Article
DE DNA nanostructures; G-quadruplex multimers; Higher order assemblies;
   NMR; A-tetrads
ID ELECTROSPRAY MASS-SPECTROMETRY; TRIPLET REPEAT DNA; ANTI-HIV ACTIVITY;
   G(-A)-G(-A)-G(-A)-G HEPTAD; PARALLEL QUADRUPLEXES; T-TETRADS; STACKING;
   DYNAMICS; OLIGONUCLEOTIDES; SUPPRESSION
AB In a previous work we have demonstrated that the DNA sequence CGGTGGT folds into a higher order Gquadruplex structure (2Q), obtained by the 5 '-5 ' stacking of two unusual G(:C):G(:C):G(:C):G(:C) planar octads belonging to two identical tetra-stranded parallel quadruplexes, when annealed in the presence of ammonium or potassium ions. In the present paper, we discuss the role played by the title nucleosides X and Y (where X and Y stand for A, C, G, or T) on the formation and stability of 2Q structures formed by the XGGYGGT oligodeoxynucleotides. We found that the above mentioned dimerization pathway is not peculiar to the CGGTGGT sequence, but is possible for all the remaining CGGYGGT sequences (with Y = A, C, or G). Furthermore, we have found that the TGGAGGT sequence, despite the absence of the 5 '-ending C, is also capable of forming a 2Q-like higher order quadruplex by using a slightly different dimerization interface, as characterized by NMR spectroscopy. To the best of our knowledge, this is the first characterization of a quadruplex multimer formed by an oligodeoxynucleotide presenting a thymine at its 5 '-end. Examples of such structures were observed previously only in crystals and in the presence of non-physiological cations. Our results expand the repertoire of DNA quadruplex nanostructures of chosen length and add further complexity to the structural polymorphism of G-rich DNA sequences. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [D'Atri, Valentina; Borbone, Nicola; Amato, Jussara; D'Errico, Stefano; Piccialli, Gennaro; Mayol, Luciano; Oliviero, Giorgia] Univ Naples Federico II, Dipartimento Farm, I-80131 Naples, Italy.
   [Gabelica, Valerie] Univ Bordeaux, IECB, ARNA Lab, F-33600 Pessac, France.
   [Gabelica, Valerie] INSERM, U869, ARNA Lab, F-33000 Bordeaux, France.
RP Borbone, N (reprint author), Univ Naples Federico II, Dipartimento Farm, Via D Montesano 49, I-80131 Naples, Italy.
EM nicola.borbone@unina.it
RI Gabelica, Valerie/E-9417-2011; Oliviero, Giorgia/M-9020-2014; Borbone,
   Nicola/A-6061-2009
OI Gabelica, Valerie/0000-0001-9496-0165; Oliviero,
   Giorgia/0000-0003-0765-2127; Borbone, Nicola/0000-0003-0216-9814;
   D'Atri, Valentina/0000-0002-2601-7092; MAYOL,
   Luciano/0000-0002-9162-5799; d'errico, stefano/0000-0002-8100-3726;
   Amato, Jussara/0000-0001-6096-3544
FU Progetto FARO 2011 (Finanziamento per l'Avvio di Ricerche Originali);
   Italian Ministero dell'Universita e della Ricerca; EU COST action
FX This work was financially supported by "Progetto FARO 2011"
   (Finanziamento per l'Avvio di Ricerche Originali), PRIN grant 2009 from
   the Italian Ministero dell'Universita e della Ricerca, EU COST action
   MP0802 (STSM no 5230 to JA). We are grateful to Prof Concetta Giancola
   for her precious discussions and suggestions, to Dr Luisa Cuorvo for her
   technical assistance and to CSIAS (Centro di Servizio
   Interdipartimentale di Analisi Strutturale) for the NMR facilities.
CR Amato J, 2011, BIOCONJUGATE CHEM, V22, P654, DOI 10.1021/bc100444v
   Bhavesh NS, 2004, BIOCHEM BIOPH RES CO, V317, P625, DOI 10.1016/j.bbrc.2004.03.095
   Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/nchem.1548, 10.1038/NCHEM.1548]
   Borbone N, 2011, NUCLEIC ACIDS RES, V39, P7848, DOI 10.1093/nar/gkr489
   Caceres C, 2004, NUCLEIC ACIDS RES, V32, P1097, DOI 10.1093/nar/gkh269
   Cahoon LA, 2009, SCIENCE, V325, P764, DOI 10.1126/science.1175653
   Choi EW, 2010, NUCLEIC ACIDS RES, V38, P1623, DOI 10.1093/nar/gkp1088
   Collie GW, 2010, J AM CHEM SOC, V132, P9328, DOI 10.1021/ja100345z
   D'Atri V, 2012, CHEM COMMUN, V48, P9516, DOI 10.1039/c2cc34399a
   D'Onofrio J, 2008, BIOCONJUGATE CHEM, V19, P607, DOI 10.1021/bc7003395
   Dalvit C, 1998, J BIOMOL NMR, V11, P437, DOI 10.1023/A:1008272928075
   Haider S, 2008, BIOPHYS J, V95, P296, DOI 10.1529/biophysj.107.120501
   HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047
   Kato Y, 2005, J AM CHEM SOC, V127, P9980, DOI 10.1021/ja050191b
   Kettani A, 2000, J MOL BIOL, V297, P627, DOI 10.1006/jmbi.2000.3524
   Krishnan-Ghosh Y, 2004, J AM CHEM SOC, V126, P11009, DOI 10.1021/ja049259y
   Lena S, 2009, CHEM-EUR J, V15, P7792, DOI 10.1002/chem.200802506
   Lipps HJ, 2009, TRENDS CELL BIOL, V19, P414, DOI 10.1016/j.tcb.2009.05.002
   Maizels N, 2006, NAT STRUCT MOL BIOL, V13, P1055, DOI 10.1038/nsmb1168
   Matsugami A, 2003, J BIOL CHEM, V278, P28147, DOI 10.1074/jbc.M303694200
   Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047
   Musumeci D, 2012, BIOCONJUGATE CHEM, V23, P382, DOI 10.1021/bc200305t
   Do NQ, 2012, CHEM-EUR J, V18, P14752, DOI 10.1002/chem.201103295
   Do NQ, 2011, NUCLEIC ACIDS RES, V39, P9448, DOI 10.1093/nar/gkr539
   Oliviero G, 2006, BIOPOLYMERS, V81, P194, DOI 10.1002/bip.20399
   Oliviero G, 2010, CHEM COMMUN, V46, P8971, DOI 10.1039/c0cc02866e
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Parkinson G. N., 2006, FUNDAMENTALS QUADRUP
   Patel PK, 1999, NUCLEIC ACIDS RES, V27, P2457, DOI 10.1093/nar/27.12.2457
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Phan AT, 2001, METHOD ENZYMOL, V338, P341
   Phan AT, 2009, FEBS J, V277, P1107
   Platt M, 2009, ANAL BIOCHEM, V390, P203, DOI 10.1016/j.ab.2009.04.013
   Randazzo A., 2012, CIRCULAR DICHROISM Q, V330, P67
   Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920
   Richards E. G., 1975, HDB BIOCH MOL BIOL N, P596
   Rosu F, 2002, RAPID COMMUN MASS SP, V16, P1729, DOI 10.1002/rcm.778
   Rusciano G, 2011, ANAL CHEM, V83, P6849, DOI 10.1021/ac201783h
   Russo Krauss I, 2012, NUCLEIC ACIDS RES, V40, P8119, DOI 10.1093/nar/gks512
   Searle MS, 2004, ORG BIOMOL CHEM, V2, P810, DOI 10.1039/b314559j
   SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0                                                                
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Smargiasso N, 2008, J AM CHEM SOC, V130, P10208, DOI 10.1021/ja801535e
   Sotoya H, 2004, NUCLEIC ACIDS RES, V32, P5113, DOI 10.1093/nar/gkh849
   Spindler L, 2010, J NUCL ACIDS, V2010, P1
   Vorlickova M, 2012, METHODS, V57, P64, DOI 10.1016/j.ymeth.2012.03.011
   Xu Y, 2008, J AM CHEM SOC, V130, P11179, DOI 10.1021/ja8031532
   Xu Y, 2009, ANGEW CHEM INT EDIT, V48, P7833, DOI 10.1002/anie.200903858
   Yang H, 2009, ELECTROCHEM COMMUN, V11, P38, DOI 10.1016/j.elecom.2008.10.024
   Zhang N, 2001, J MOL BIOL, V311, P1063, DOI 10.1006/jmbi.2001.4916
NR 50
TC 4
Z9 4
U1 1
U2 29
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD APR
PY 2014
VL 99
BP 119
EP 128
DI 10.1016/j.biochi.2013.11.020
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AC8YX
UT WOS:000332822100014
PM 24316277
DA 2018-01-05
ER

PT J
AU Wang, WX
   Choi, BK
   Li, WY
   Lao, ZG
   Lee, AYH
   Souza, SC
   Yates, NA
   Kowalski, T
   Pocai, A
   Cohen, LH
AF Wang, Weixun
   Choi, Bernard K.
   Li, Wenyu
   Lao, Zhege
   Lee, Anita Y. H.
   Souza, Sandra C.
   Yates, Nathan A.
   Kowalski, Timothy
   Pocai, Alessandro
   Cohen, Lucinda H.
TI Quantification of Intact and Truncated Stromal Cell-Derived Factor-1
   alpha in Circulation by Immunoaffinity Enrichment and Tandem Mass
   Spectrometry
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article
DE SDF-1; DPP-IV; Top-down MS
ID CD26/DIPEPTIDYL PEPTIDASE IV; HUMAN PLASMA; LC-MS/MS; QUANTITATION;
   PROTEINS; IDENTIFICATION; IMMUNOASSAY; ANTI-HIV-1; DIVERSITY; CXCR4
AB Stromal cell-derived factor 1 alpha (SDF-1 alpha) or CXCL12 is a small pro-inflammatory chemoattractant cytokine and a substrate of dipeptidyl peptidase IV (DPP-IV). Proteolytic cleavage by DPP-IV inactivates SDF-1 alpha and attenuates its interaction with CXCR4, its cell surface receptor. To enable investigation of suppression of such inactivation with pharmacologic inhibition of DPP-IV, we developed quantitative mass spectrometric methods that differentiate intact SDF-1 alpha from its inactive form. Using top-down strategy in quantification, we demonstrated the unique advantage of keeping SDF-1 alpha's two disulfide bridges intact in the analysis. To achieve the optimal sensitivity required for quantification of intact and truncated SDF-1 alpha at endogenous levels in blood, we coupled nano-flow tandem mass spectrometry with antibody-based affinity enrichment. The assay has a quantitative range of 20 pmol/L to 20 nmol/L in human plasma as well as in rhesus monkey plasma. With only slight modification, the same assay can be used to quantify SDF-1 alpha in mice. Using two in vivo animal studies as examples, we demonstrated that it was critical to differentiate intact SDF-1 alpha from its truncated form in the analysis of biomarkers for pharmacologic inhibition of DPP-IV activity. These novel methods enable translational research on suppression of SDF-1 inactivation with DPP-IV inhibition and can be applied to relevant clinical samples in the future to yield new insights on change of SDF-1 alpha levels in disease settings and in response to therapeutic interventions.
C1 [Wang, Weixun; Choi, Bernard K.; Lee, Anita Y. H.; Souza, Sandra C.; Yates, Nathan A.; Cohen, Lucinda H.] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Rahway, NJ 07065 USA.
   [Li, Wenyu; Lao, Zhege; Kowalski, Timothy; Pocai, Alessandro] Merck & Co Inc, Diabet & Endocrinol, Rahway, NJ 07065 USA.
RP Wang, WX (reprint author), Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Rahway, NJ 07065 USA.
EM weixun_wang@merck.com
CR Anderson NL, 2004, J PROTEOME RES, V3, P235, DOI 10.1021/pr034086h
   Busso N, 2005, AM J PATHOL, V166, P433, DOI 10.1016/S0002-9440(10)62266-3
   Chappell DL, 2014, BIOANALYSIS, V6, P33, DOI [10.4155/BIO.13.280, 10.4155/bio.13.280]
   Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000                                                    
   CURRIE LA, 1968, ANAL CHEM, V40, P586, DOI 10.1021/ac60259a007                                                             
   De Meester I, 2003, ADV EXP MED BIOL, V524, P3
   Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x                                                
   Huang YY, 2005, ANAL CHEM, V77, P5800, DOI 10.1021/ac0480949
   Huber BC, 2011, CARDIOVASC RES, V90, P529, DOI 10.1093/cvr/cvr014
   Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200
   Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0                                                   
   Murphy AT, 2007, BLOOD, V110, P1048, DOI 10.1182/blood-2006-11-057471
   Nedelkov D, 2005, P NATL ACAD SCI USA, V102, P10852, DOI 10.1073/pnas.0500426102
   Nedelkov D, 2006, EXPERT REV PROTEOMIC, V3, P631, DOI 10.1586/14789450.3.6.631
   Nedelkov D, 2007, MOL CELL PROTEOMICS, V6, P1183, DOI 10.1074/mcp.M700023-MCP200
   NELSON RW, 1995, ANAL CHEM, V67, P1153, DOI 10.1021/ac00103a003
   Nelson RW, 2004, J PROTEOME RES, V3, P851, DOI 10.1021/pr0499388
   Neubert H, 2010, CLIN CHEM, V56, P1413, DOI 10.1373/clinchem.2010.144576
   Niederkofler EE, 2008, CIRC-HEART FAIL, V1, P258, DOI 10.1161/CIRCHEARTFAILURE.108.790774
   Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184
   Rogatsky E, 2006, CLIN CHEM, V52, P872, DOI 10.1373/clinchem.2005.063081
   Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718
   Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331
   Sierra MD, 2004, BLOOD, V103, P2452
   Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200
   Wang WX, 2012, ANAL CHEM, V84, P6891, DOI 10.1021/ac301494d
   Xu H, 2008, J PROTEOME RES, V7, P138, DOI 10.1021/pr070363z
   Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001
NR 32
TC 13
Z9 13
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1044-0305
EI 1879-1123
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD APR
PY 2014
VL 25
IS 4
BP 614
EP 625
DI 10.1007/s13361-013-0822-7
PG 12
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry,
   Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA AD2IL
UT WOS:000333058100013
PM 24500701
DA 2018-01-05
ER

PT J
AU Lenjisa, JL
   Woldu, MA
   Satessa, GD
AF Lenjisa, Jimma Likisa
   Woldu, Minyahil Alebachew
   Satessa, Gizaw Dabessa
TI New hope for eradication of HIV from the body: the role of polymeric
   nanomedicines in HIV/AIDS pharmacotherapy
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Review
DE HIV/AIDS; Antiretrovirals; Nano-polymers; Nanomedicines
ID NANOPARTICLES; RESERVOIRS; INFECTION; MICELLES; CARRIERS
AB Human immunodeficiency virus continued to be the greatest challenge and killer disease of the 21st century despite the advent of potent highly active antiretroviral therapy which are limited by their severe adverse effects, significant drug interactions, frequent dosing, limited bioavailability, and less access to viral reservoir sites like macrophages. Nano-medicines are becoming new hopes in avoiding these shortcomings of conventional antiretroviral drugs. The emphasis of this review is mainly the application of polymers based nanomedicines in pharmacotherapy of HIV/AIDS. Most of the studies to date on this area are in vitro and human clinical trials are totally missed. However, many interesting points are uncovered through this review like the possibility of achieving high intracellular concentration of drugs, very good antiretroviral activity, improved bioavailability, reduced toxicity and release of the drugs from nanocarriers for long time reducing the need for frequent dosing. Indeed, a lot of assignments left behind for researchers to overcome the challenges hindering the wider application of nanomedicines in treatment of HIV/AIDS.
C1 [Lenjisa, Jimma Likisa; Woldu, Minyahil Alebachew] Ambo Univ, Coll Med & Hlth Sci, Dept Clin Pharm, Ambo, Ethiopia.
   [Satessa, Gizaw Dabessa] Ambo Univ, Coll Med & Hlth Sci, Dept Pharmacol, Ambo, Ethiopia.
RP Lenjisa, JL (reprint author), Ambo Univ, Coll Med & Hlth Sci, Dept Clin Pharm, POB 19, Ambo, Ethiopia.
EM jimmapharm@gmail.com
CR Amiji Mansoor M, 2006, Discov Med, V6, P157
   Annemarie S, 2013, AIDS RES HUM RETROV, V29, P746
   Armstead AL, 2011, INT J NANOMED, V6, P3281, DOI 10.2147/IJN.S27285
   Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169-409X(03)00108-X
   Chiappetta DA, 2009, CURR HIV RES, V8, P223
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Christopher JD, 2010, J ANTIMICROB CHEMOTH, V65, P2183
   Crowe SM, 2006, CURR OPIN HIV AIDS, V1, P129, DOI 10.1097/01.COH.0000209583.89952.9d
   Cutlers Gardens, 2007, NAN REV DRUG DEL, P1
   De Jong WH, 2008, INT J NANOMED, V3, P133
   Esmaeil AP, 2013, NANOMED J, V1, P1
   Evrim AT, 2009, AAPS PHARMSCITECH, V10, P88
   Isabella B, 2013, PLOS ONE, V8
   Jianqing P, 2013, MOLECULES, V18, P7912
   Jiehua Z, 2011, MOL THER, V19, P2228
   Jones MC, 1999, EUR J PHARM BIOPHARM, V48, P101, DOI 10.1016/S0939-6411(99)00039-9
   Kay MS, 2003, TRENDS BIOTECHNOL, V21, P420, DOI 10.1016/j.tibtech.2003.08.004
   Nelson AO, 2009, TROP J PHARM RES, V8, P275
   Nilesh J, 2010, ASIA PAC J CLIN RES, V3, P1
   Raveen P, 2012, VIRUSES, V4, P488
   Research Spotlight, 2013, NAN HIV THER 20 C RE
   Sankar V, 2012, INDIAN J PHARM EDUC, V46, P192
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shahriar P, 2007, PHARM RES, V24, P2110
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Simon C, 2013, 1 WORKSH NAN INF DIS
   Sonza S, 2001, AIDS PATIENT CARE ST, V15, P511, DOI 10.1089/108729101753205676                                                      
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Sumit B, 2012, INT J NANOMED, V7, P6049
   Sushama T, 2011, ANTIVIR RES, V90, P195
   Thierry H, LONG LASTING ENFUVIR
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Vinogradov SV, 2011, ANTIVIR CHEM CHEMOTH, V21, P1
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yamamoto T, 2007, J CONTROL RELEASE, V123, P11, DOI 10.1016/j.jconrel.2007.07.008
NR 35
TC 12
Z9 12
U1 1
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD MAR 22
PY 2014
VL 12
AR 9
DI 10.1186/1477-3155-12-9
PG 6
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AG0AF
UT WOS:000335075200001
PM 24655921
OA gold
DA 2018-01-05
ER

PT J
AU Foca, E
   Odolini, S
   Sulis, G
   Calza, S
   Pietra, V
   Rodari, P
   Giorgetti, PF
   Noris, A
   Ouedraogo, P
   Simpore, J
   Pignatelli, S
   Castelli, F
AF Foca, Emanuele
   Odolini, Silvia
   Sulis, Giorgia
   Calza, Stefano
   Pietra, Virginio
   Rodari, Paola
   Giorgetti, Pier Francesco
   Noris, Alice
   Ouedraogo, Paul
   Simpore, Jacques
   Pignatelli, Salvatore
   Castelli, Francesco
TI Clinical and immunological outcomes according to adherence to first-line
   HAART in a urban and rural cohort of HIV-infected patients in Burkina
   Faso, West Africa
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Antiretroviral therapy; Adherence; Death; CD4+; Burkina Faso
ID ACTIVE ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; FOLLOW-UP; 1ST YEAR;
   MORTALITY; MOZAMBIQUE; ADULTS; TRIAL; KENYA
AB Background: Aim of our study is to investigate the clinical and immunological outcomes according to first-line HAART adherence in a large cohort of HIV-infected patients in Burkina Faso.
   Methods: A retrospective study was conducted between 2001 and 2009 among patients from two urban medical centers [St. Camille Medical Center (CMSC) and "Pietro Annigoni" Biomolecular Research Center (CERBA)] and 1 in the rural District of Nanoro (St. Camille District Hospital). Socio-demographical and clinical data were analyzed. Adherence was evaluated through a questionnaire investigating 5 key points related to drugs, consultations and blood exams, by assigning 0 to 2 points each up to 10 points overall. Data were collected at baseline and regularly thereafter. Adherence score was considered as a continuous variable and classified in optimal (8-10 points) and sub-optimal (0-7 points). Immunological outcome was evaluated as modification in CD4+ T-cell count over time, while predictors of death were explored by a univariate and multivariate Cox model considering adherence score as a time-varying covariate.
   Results: A total of 625 patients were included: 455 (72.8%) were females, the median age was 33.3 (IQR 10.2) years, 204 (32.6.%) were illiterates, the median CD4+ T-cell count was 149 (IQR 114) cells/mu l at baseline. At the end of the observation period we recorded 60/625 deaths and 40 lost to follow-up. The analysis of immunological outcomes showed a significant variation in CD4+ T-cell count between M12 and M24 only for patients with optimal adherence (Delta=78.2, p<0.001), with a significant Delta between the two adherence groups at M24 (8-10 vs 0-7, Delta=53.8, p=0.004). Survival multivariate analysis revealed that covariates significantly related to death included being followed at CERBA (urban area) or Nanoro (rural area), and receiving a regimen not including fixed dose combinations, (p=0.024, p=0.001 and p<0.001 respectively); conversely, an increasing adherence score as well as an optimal adherence score were significantly related to survival (p<0.001).
   Conclusions: Adherence to HAART remains pivotal to build up a good therapeutic outcome. Our results confirm that, according to our adherence system evaluation, less adherent patients have a higher risk of death and of inadequate CD4+ count recovery.
C1 [Foca, Emanuele; Odolini, Silvia; Sulis, Giorgia; Rodari, Paola; Giorgetti, Pier Francesco; Noris, Alice; Castelli, Francesco] Univ Brescia, Univ Div Infect & Trop Dis, Brescia, Italy.
   [Calza, Stefano] Univ Brescia, Dept Mol & Translat Med, Unit Biostat & Biomatemath, Brescia, Italy.
   [Pietra, Virginio; Pignatelli, Salvatore; Castelli, Francesco] Medicus Mundi Italy NGO, Brescia, Italy.
   [Pietra, Virginio] St Camille Dist Hosp, Nanoro, Burkina Faso.
   [Ouedraogo, Paul; Pignatelli, Salvatore] CMSC, Ouagadougou, Burkina Faso.
   [Simpore, Jacques] Ctr Rech Biomol Pietro Annigoni, Ouagadougou, Burkina Faso.
   [Foca, Emanuele] Univ Brescia, Sch Med, Univ Div Infect & Trop Dis, I-25123 Brescia, Italy.
RP Foca, E (reprint author), Univ Brescia, Univ Div Infect & Trop Dis, Brescia, Italy.
EM emanuelefoca@gmail.com
RI Calza, Stefano/B-1915-2010
OI Calza, Stefano/0000-0003-4996-7995; SIMPORE,
   Jacques/0000-0002-0415-9161; Sulis, Giorgia/0000-0001-6641-0094; FOCA',
   Emanuele/0000-0003-4395-5379
FU NEAT (Network for Excellence in Antiretroviral Treatment); European
   Commission [LSHP-CT-2006-037570]
FX The Authors would like to thank the ESTHER Project-Italy funded by
   Istituto Superiore di Sanita, Rome, Italy. The Authors thank all
   physicians and medical students who participated to "ESTHER project" -
   Brescia in Burkina Faso. A special thank to the Camillian Vice-Province
   in Burkina Faso and the technical-scientific support assured by the
   University of Brescia, the University of Ouagadougou and the NGO Medicus
   Mundi Italy. This work was partially supported by NEAT (Network for
   Excellence in Antiretroviral Treatment) funded by the European
   Commission (Project number: LSHP-CT-2006-037570).
CR Abrogoua DP, 2012, PATIENT PREFER ADHER, V6, P227, DOI 10.2147/PPA.S26507
   Ammassari A, 2002, JAIDS, V31, pS123, DOI 10.1097/00126334-200212153-00007                                                
   Autino B, 2012, Bull Soc Pathol Exot, V105, P130, DOI 10.1007/s13149-012-0229-x
   Bajunirwe Francis, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P139, DOI 10.1177/1545109709332470
   Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66
   Borrell C, 2006, EUR J PUBLIC HEALTH, V16, P601, DOI 10.1093/eurpub/ckl062
   Castelli Francesco, 2010, Open AIDS J, V4, P28, DOI 10.2174/1874613601004020028
   Etard JF, 2007, TROP MED INT HEALTH, V12, P1191, DOI 10.1111/j.1365-3156.2007.01910.x
   Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002
   Hanif H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-574
   Karcher H, 2007, TROP MED INT HEALTH, V12, P687, DOI 10.1111/j.1365-3156.2007.01830.x
   Kip E, 2009, J NURS SCHOLARSHIP, V41, P149, DOI 10.1111/j.1547-5069.2009.01266.x
   Kiwuwa-Muyingo S, 2012, TROP MED INT HEALTH, V17, P584, DOI 10.1111/j.1365-3156.2012.02974.x
   Kiwuwa-Muyingo S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-395
   Lamb MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038443
   Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011
   Marazzi MC, 2006, HEALTH EDUC RES, V21, P34, DOI 10.1093/her/cyh039
   Mendelsohn Joshua B, 2012, Confl Health, V6, P9, DOI 10.1186/1752-1505-6-9
   Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Pearson CR, 2007, JAIDS-J ACQ IMM DEF, V46, P238, DOI 10.1097/QAI.0b013e318153f7ba
   Peltzer K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-111
   Pignatelli S, 2006, TROP MED INT HEALTH, V11, P350, DOI 10.1111/j.1365-3156.2006.01564.x
   Pinheiro J, 2014, NLME LINEAR NONLINEA
   R Core Team, 2013, R LANG ENV STAT COMP
   Sanjobo N, 2008, SAHARA J-J SOC ASP H, V5, P136, DOI 10.1080/17290376.2008.9724912                                                   
   Simpson SH, 2006, BMJ-BRIT MED J, V333, P15
   Therneau T, 2014, PACKAGE SURVIVAL ANA
   United Nations Development Programme (UNDP), 2011, HUM DEV REP 2011 SUS
   Unge C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013613
   Verbeke G, 2009, LINEAR MIXED MODELS
   World Health Organization, 2003, ADH LONG TERM THER E
   World Health Organization (WHO), 2004, SCAL ANT THER RES LT
   WHO/UNAIDS/UNICEF, 2011, GLOB HIV AIDS RESP E
   WHO, 2006, ANT THER HIV INF AD
   WHO/UNAIDS, 2013, GLOB REP UNAIDS REP
   Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea                                             
NR 38
TC 5
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAR 21
PY 2014
VL 14
AR 153
DI 10.1186/1471-2334-14-153
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA AD9RG
UT WOS:000333601600002
PM 24656065
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, Q
   Su, L
   Collins, J
   Chen, GS
   Wallis, R
   Mitchell, DA
   Haddleton, DM
   Becer, CR
AF Zhang, Qiang
   Su, Lu
   Collins, Jennifer
   Chen, Guosong
   Wallis, Russell
   Mitchell, Daniel A.
   Haddleton, David M.
   Becer, C. Remzi
TI Dendritic Cell Lectin-Targeting Sentinel-like Unimolecular
   Glycoconjugates To Release an Anti-HIV Drug
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID CHAIN-TRANSFER POLYMERIZATION; BETA-CYCLODEXTRIN CORE; DC-SIGN;
   CARBOHYDRATE-RECOGNITION; PROTEIN INTERACTIONS; CLICK CHEMISTRY; STAR
   POLYMERS; BINDING; GLYCOPOLYMERS; OLIGOSACCHARIDE
AB A series of cyclodextrin-based glycoconjugates, including glycoclusters and star glycopolymers, were synthesized via combination of CuAAC Huisgen coupling and copper-mediated living radical polymerization. These glycoconjugates showed high affinity binding to the human transmembrane lectin DC-SIGN and act as inhibitors to prevent the binding of HIV envelope protein gp120 to DC-SIGN at nanomolar concentrations. The star block glycopolymers showed high loading capacity of hydrophobic anticancer and anti-HIV drugs, indicating promising applications in HIV-therapeutic and smart drug delivery.
C1 [Zhang, Qiang; Collins, Jennifer; Haddleton, David M.; Becer, C. Remzi] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
   [Su, Lu; Chen, Guosong] Fudan Univ, Minist Educ, State Key Lab Mol Engn Polymers, Shanghai 200433, Peoples R China.
   [Su, Lu; Chen, Guosong] Fudan Univ, Dept Macromol Sci, Shanghai 200433, Peoples R China.
   [Wallis, Russell] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England.
   [Mitchell, Daniel A.] Univ Warwick, Warwick Med Sch, Clin Sci Res Labs, Coventry CV2 2DX, W Midlands, England.
   [Becer, C. Remzi] Queen Mary Univ London, Sch Engn & Mat Sci, London E1 4NS, England.
RP Haddleton, DM (reprint author), Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
EM D.M.Haddleton@warwick.ac.uk; R.Becer@qmul.ac.uk
RI Mitchell, Daniel/A-6580-2009; Chen, Guosong/A-7007-2012; Zhang,
   Qiang/E-9415-2015
OI Mitchell, Daniel/0000-0003-0936-6212; Chen, Guosong/0000-0001-7089-911X;
   Becer, Remzi/0000-0003-0968-6662; Haddleton, David/0000-0002-4965-0827
FU University of Warwick; China Scholarship Council; Advantage West
   Midlands (AWM); European Regional Development Fund (ERDF)
FX The authors acknowledge the financial support from the University of
   Warwick and China Scholarship Council (Q.Z.). Some of the equipment used
   was supported by the Innovative Uses for Advanced Materials in the Modem
   World (AM2), with support from Advantage West Midlands (AWM) and
   partially funded by the European Regional Development Fund (ERDF).
   D.M.H. is a Royal Society/Wolfson Fellow. Christopher N. Scanlan has
   kindly provided the gp120. Royal Society of Chemistry journal's Grant
   for International Authors Program (G.C.).
CR Andre S, 2004, BIOCONJUGATE CHEM, V15, P87, DOI 10.1021/bc0340666
   Becer CR, 2010, J AM CHEM SOC, V132, P15130, DOI 10.1021/ja1056714
   Boyer C, 2012, POLYM CHEM-UK, V3, P117, DOI 10.1039/c1py00384d
   Buchanan CM, 2008, BIOMACROMOLECULES, V9, P305, DOI 10.1021/bm700827h
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Carpenter C, 2005, EUR J ORG CHEM, P3286, DOI 10.1002/ejoc.200500146
   Chmurski K, 2000, SUPRAMOL CHEM, V12, P221, DOI 10.1080/10610270008027455                                                       
   Fais M, 2011, CHEM SCI, V2, P1952, DOI 10.1039/c1sc00120e
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Fulton DA, 2000, ORG LETT, V2, P1113, DOI 10.1021/ol005668x
   Garcia-Lopez JJ, 1999, CHEM-EUR J, V5, P1775, DOI 10.1002/(SICI)1521-3765(19990604)5:6<1775::AID-CHEM1775>3.3.CO;2-U
   Gomez-Garcia M, 2005, J AM CHEM SOC, V127, P7970, DOI 10.1021/ja050934t
   Gomez-Garcia M, 2012, J ORG CHEM, V77, P1273, DOI 10.1021/jo201797b
   Hoogenboom R, 2006, CHEM COMMUN, P4010, DOI 10.1039/b608313g
   Kakuchi T, 2003, MACROMOLECULES, V36, P3909, DOI 10.1021/ma021295z
   KIMLER BF, 1980, CANCER RES, V40, P42
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Li JS, 2005, TETRAHEDRON LETT, V46, P2227, DOI 10.1016/j.tetlet.2005.02.027
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   Meier MAR, 2004, J AM CHEM SOC, V126, P11517, DOI 10.1021/ja0488481
   Menon S, 2009, P NATL ACAD SCI USA, V106, P11524, DOI 10.1073/pnas.0901783106
   Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200                                                          
   Ohno K, 2001, J POLYM SCI POL CHEM, V39, P2206, DOI 10.1002/pola.1197
   Percec V, 2006, J AM CHEM SOC, V128, P14156, DOI 10.1021/ja065484z
   Percec V, 2013, J AM CHEM SOC, V135, P9055, DOI 10.1021/ja403323y
   Pieters RJ, 2007, MED RES REV, V27, P796, DOI 10.1002/med.20089
   Rosen BM, 2009, CHEM REV, V109, P5069, DOI 10.1021/cr900024j
   Roy B, 2007, TETRAHEDRON LETT, V48, P3783, DOI 10.1016/j.tetlet.2007.03.165
   Schramm OG, 2009, SOFT MATTER, V5, P1662, DOI 10.1039/b816087b
   Slavin S, 2011, EUR POLYM J, V47, P435, DOI 10.1016/j.eurpolymj.2010.09.019
   Smiljanic N, 2006, ANGEW CHEM INT EDIT, V45, P5465, DOI 10.1002/anie.200601123
   Soeriyadi AH, 2011, J AM CHEM SOC, V133, P11128, DOI 10.1021/ja205080u
   Spain SG, 2011, POLYM CHEM-UK, V2, P60, DOI 10.1039/c0py00149j
   Srinivasachari S, 2008, J AM CHEM SOC, V130, P4618, DOI 10.1021/ja074597v
   Stenzel MH, 2002, J POLYM SCI POL CHEM, V40, P4498, DOI 10.1002/pola.10532
   Thiele C, 2011, POLYM CHEM-UK, V2, P209, DOI 10.1039/c0py00241k
   Ting SRS, 2010, POLYM CHEM-UK, V1, P1392, DOI 10.1039/c0py00141d
   WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241
   WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Zhang L, 2009, AUST J CHEM, V62, P813, DOI 10.1071/CH09108
   Zhang Q, 2013, ANGEW CHEM INT EDIT, V52, P4435, DOI 10.1002/anie.201300068
   Zhang Q, 2012, CHEM COMMUN, V48, P8063, DOI 10.1039/c2cc33742h
   Zhang Q, 2012, POLYM CHEM-UK, V3, P1016, DOI 10.1039/c2py20013a
NR 44
TC 58
Z9 58
U1 7
U2 142
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAR 19
PY 2014
VL 136
IS 11
BP 4325
EP 4332
DI 10.1021/ja4131565
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA AD7HV
UT WOS:000333435500035
PM 24568546
DA 2018-01-05
ER

PT J
AU Lulf, S
   Matz, J
   Rouyez, MC
   Jarviluoma, A
   Saksela, K
   Benichou, S
   Geyer, M
AF Luelf, Sebastian
   Matz, Julie
   Rouyez, Marie-Christine
   Jaerviluoma, Annika
   Saksela, Kalle
   Benichou, Serge
   Geyer, Matthias
TI Structural basis for the inhibition of HIV-1 Nef by a high-affinity
   binding single-domain antibody
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1 Nef; Single-domain antibody; Crystal structure; Neffin
ID VIRUS TYPE-1 NEF; VIRAL INFECTIVITY; DOWN-REGULATION; SURFACE; THERAPY
AB Background: The HIV-1 Nef protein is essential for AIDS pathogenesis by its interaction with host cell surface receptors and signaling factors. Despite its critical role as a virulence factor Nef is not targeted by current antiviral strategies.
   Results: We have determined the crystal structure of the complex formed by a camelid single-domain antibody fragment, termed sdAb19, bound to HIV-1 Nef together with a stabilizing SH3 domain. sdAb19 forms a stoichiometric 1: 1 complex with Nef and binds to a conformationally conserved surface at the C-terminus of Nef that overlaps with functionally important interaction sites involved in Nef-induced perturbations of signaling and trafficking pathways. The antibody fragment binds Nef with low nanomolar affinity, which could be attenuated to micromolar affinity range by site-directed mutagenesis of key interaction residues in sdAb19. Fusion of the SH3 domain to sdAb19, termed Neffin, leads to a significantly increased affinity for Nef and formation of a stoichiometric 2: 2 Nef-Neffin complex. The 19 kDa Neffin protein inhibits all functions of Nef as CD4 and MHC-I downregulation, association with Pak2, and the increase in virus infectivity and replication.
   Conclusions: Together, sdAb19 and Neffin thus represent efficient tools for the rational development of antiviral strategies against HIV-1 Nef.
C1 [Luelf, Sebastian; Geyer, Matthias] Ctr Adv European Studies & Res, Grp Phys Biochem, Bonn, Germany.
   [Luelf, Sebastian; Geyer, Matthias] Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44139 Dortmund, Germany.
   [Matz, Julie; Rouyez, Marie-Christine; Benichou, Serge] Inst Cochin, INSERM, U1016, Paris, France.
   [Matz, Julie; Rouyez, Marie-Christine; Benichou, Serge] CNRS, UMR8104, Paris, France.
   [Matz, Julie; Rouyez, Marie-Christine; Benichou, Serge] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Jaerviluoma, Annika; Saksela, Kalle] Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland.
RP Geyer, M (reprint author), Ctr Adv European Studies & Res, Grp Phys Biochem, Bonn, Germany.
EM matthias.geyer@caesar.de
OI Benichou, Serge/0000-0003-3602-3530; Saksela, Kalle/0000-0003-0827-122X
FU Inserm-Transfert; SATTidfInnov
FX We thank Karin Vogel-Bachmayr and Emilie Trinh for expert technical
   assistance and Dr. Ingrid Vetter for help with diffraction data
   analysis. This work was supported by grants from Inserm-Transfert and
   SATTidfInnov to S.B.
CR Agopian K, 2006, J VIROL, V80, P3050, DOI 10.1128/JVI.80.6.3050-3061.2006
   Akgun B, 2013, STRUCTURE, V21, P1822, DOI 10.1016/j.str.2013.08.008
   Bouchet J, 2012, J VIROL, V86, P4856, DOI 10.1128/JVI.06329-11
   Bouchet J, 2011, BLOOD, V117, P3559, DOI 10.1182/blood-2010-07-296749
   Breuer S, 2006, BIOCHEMISTRY-US, V45, P2339, DOI 10.1021/bi052052c
   Breuer S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020033
   CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8
   Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229
   Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fackler OT, 2006, VIROLOGY, V351, P322, DOI 10.1016/j.virol.2006.03.044
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Foster JL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-84
   Gerlach H, 2010, NAT CHEM BIOL, V6, P46, DOI [10.1038/NCHEMBIO.268, 10.1038/nchembio.268]
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Geyer M, 2001, FEBS LETT, V496, P91, DOI 10.1016/S0014-5793(01)02394-8                                                   
   Giese SI, 2006, VIROLOGY, V355, P175, DOI 10.1016/j.virol.2006.07.003
   Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164
   Gupta RK, 2009, LANCET INFECT DIS, V9, P409, DOI 10.1016/S1473-3099(09)70136-7
   Hiipakka M, 1999, J MOL BIOL, V293, P1097, DOI 10.1006/jmbi.1999.3225                                                          
   Hinz A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010482
   Horenkamp FA, 2011, TRAFFIC, V12, P867, DOI 10.1111/j.1600-0854.2011.01205.x
   Hulsik DL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003202
   Hultberg A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017665
   Jarviluoma A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040331
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Khalid M, 2012, J VIROL, V86, P4906, DOI 10.1128/JVI.06856-11
   Kirchhoff F, 2008, CELL MOL LIFE SCI, V65, P2621, DOI 10.1007/s00018-008-8094-2
   Kirchhoff F, 2010, CELL HOST MICROBE, V8, P55, DOI 10.1016/j.chom.2010.06.004
   Lulf S, 2011, CURR HIV RES, V9, P543, DOI 10.2174/157016211798842053
   Malim MH, 2008, CELL HOST MICROBE, V3, P388, DOI 10.1016/j.chom.2008.04.008
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Meuwissen PJ, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-34
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   O'Neill E, 2006, J VIROL, V80, P1311, DOI 10.1128/JVI.80.3.1311-1320.2006
   Roeth JF, 2004, J CELL BIOL, V167, P903, DOI 10.1083/jcb.200407031
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Schmokel J, 2013, CELL REP, V5, P997, DOI 10.1016/j.celrep.2013.10.028
   Sigal A, 2012, CELL HOST MICROBE, V12, P132, DOI 10.1016/j.chom.2012.07.005
   Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752
   Welker R, 1998, J VIROL, V72, P8833
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Witkowski W, 2013, EXPERT OPIN THER TAR, V17, P1345, DOI 10.1517/14728222.2013.830712
   [Anonymous], 2013, UNAIDS REP GLOB AIDS
NR 45
TC 12
Z9 12
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAR 13
PY 2014
VL 11
AR 24
DI 10.1186/1742-4690-11-24
PG 13
WC Virology
SC Virology
GA AD6AG
UT WOS:000333334300001
PM 24620746
OA gold
DA 2018-01-05
ER

PT J
AU Orr, MT
   Kramer, RM
   Barnes, VL
   Dowling, QM
   Desbien, AL
   Beebe, EA
   Laurance, JD
   Fox, CB
   Reed, SG
   Coler, RN
   Vedvick, TS
AF Orr, Mark T.
   Kramer, Ryan M.
   Barnes, Lucien, V
   Dowling, Quinton M.
   Desbien, Anthony L.
   Beebe, Elyse A.
   Laurance, John D.
   Fox, Christopher B.
   Reed, Steven G.
   Coler, Rhea N.
   Vedvick, Thomas S.
TI Elimination of the cold-chain dependence of a nanoemulsion adjuvanted
   vaccine against tuberculosis by lyophilization
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Nanoemulsion; Lyophilization; Vaccine; Adjuvant
ID CHALLENGES; ANTIGENS
AB Next-generation rationally-designed vaccine adjuvants represent a significant breakthrough to enable development of vaccines against challenging diseases including tuberculosis, HIV, and malaria. New vaccine candidates often require maintenance of a cold-chain process to ensure long-term stability and separate vials to enable bedside mixing of antigen and adjuvant. This presents a significant financial and technological barrier to worldwide implementation of such vaccines. Herein we describe the development and characterization of a tuberculosis vaccine comprised of both antigen and adjuvant components that are stable in a single vial at sustained elevated temperatures. Further this vaccine retains the ability to elicit both antibody and T(H)1 responses against the vaccine antigen and protect against experimental challenge with Mycobacterium tuberculosis. These results represent a significant breakthrough in the development of vaccine candidates that can be implemented throughout the world without being hampered by the necessity of a continuous cold chain or separate adjuvant and antigen vials. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Orr, Mark T.; Kramer, Ryan M.; Barnes, Lucien, V; Dowling, Quinton M.; Desbien, Anthony L.; Beebe, Elyse A.; Laurance, John D.; Fox, Christopher B.; Reed, Steven G.; Coler, Rhea N.; Vedvick, Thomas S.] Infect Dis Res Inst, Seattle, WA 98102 USA.
RP Orr, MT (reprint author), 1616 Eastlake Ave E,Suite 400, Seattle, WA 98102 USA.
EM mark.orr@idri.org
OI Fox, Christopher/0000-0002-4644-2619
FU National Institute of Allergy and Infectious Diseases [U01AI078054,
   HHSN272200800045C]; Bill and Melinda Gates Foundation [42387, OP1055855]
FX We thank Valerie Reese, David Argilla, Thomas Hudson, Brian Granger,
   Dean Huang, Ghislain Nana, Susan Lin, Traci Mikasa, and Milllie Fung for
   excellent technical assistance. The project described was supported by
   Grant U01AI078054 and Contract HHSN272200800045C from the National
   Institute of Allergy and Infectious Diseases to RC and grants 42387 and
   OP1055855 from the Bill and Melinda Gates Foundation. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Allergy and
   Infectious Diseases or the National Institutes of Health.
CR Abu-Raddad LJ, 2009, P NATL ACAD SCI USA, V106, P13980, DOI 10.1073/pnas.0901720106
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211
   Anderson RC, 2010, COLLOID SURFACE B, V75, P123, DOI 10.1016/j.colsurfb.2009.08.022
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bertholet S, 2008, J IMMUNOL, V181, P7948, DOI 10.4049/jimmunol.181.11.7948                                                    
   Bertholet S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001094
   Checkley AM, 2011, TRENDS PHARMACOL SCI, V32, P601, DOI 10.1016/j.tips.2011.06.003
   Chen DX, 2013, J PHARM SCI-US, V102, P29, DOI 10.1002/jps.23352
   Ching LK, 2011, J IMMUNOL METHODS, V373, P54, DOI 10.1016/j.jim.2011.07.021
   Clausi AL, 2008, J PHARM SCI, V97, P2049
   Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fox CB, 2008, COLLOID SURFACE B, V65, P98, DOI 10.1016/j.colsurfb.2008.03.003
   Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292
   Ivins B, 1995, VACCINE, V13, P1779, DOI 10.1016/0264-410X(95)00139-R
   Kasper JC, 2013, EUR J PHARM BIOPHARM, V85, P162, DOI 10.1016/j.ejpb.2013.05.019
   Orr MT, 2013, J CONTROL RELEASE, V172, P190, DOI 10.1016/j.jconrel.2013.07.030
   Orr MT, 2013, EUR J IMMUNOL, V43, P2398, DOI 10.1002/eji.201243124
   PATH, 2012, SUMM STAB DAT LIC VA
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Rossi J, 2007, ROLE LIPID EXCIPIENT, P88
   Rowland R, 2011, EXPERT REV VACCINES, V10, P645, DOI [10.1586/erv.11.28, 10.1586/ERV.11.28]
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606
   Thomas T.K.A., 2004, LYOPHILIZATION BIOPH
   US Food and Drug Administration, 2012, VACC REL BIOL PROD A
   Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3
   WHO global tuberculosis control report, 2010, CENT EUR J PUBL HEAL, P237
   Zhang JE, 2012, P NATL ACAD SCI USA, V109, P11981, DOI 10.1073/pnas.1206210109
NR 30
TC 9
Z9 9
U1 1
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 10
PY 2014
VL 177
BP 20
EP 26
DI 10.1016/j.jconrel.2013.12.025
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AC3CQ
UT WOS:000332393000003
PM 24382398
OA green_accepted
DA 2018-01-05
ER

PT J
AU Grove, J
AF Grove, Joe
TI Super-Resolution Microscopy: A Virus' Eye View of the Cell
SO VIRUSES-BASEL
LA English
DT Review
DE microscopy; super-resolution; PALM; STORM; dSTORM; tetraspanin; virus
   assembly; virus entry
ID TETRASPANIN-ENRICHED MICRODOMAINS; PHOTOACTIVATED LOCALIZATION
   MICROSCOPY; PAIR CORRELATION-ANALYSIS; PLASMA-MEMBRANE; ASSEMBLY SITES;
   FLUORESCENCE MICROSCOPY; RESOLUTION LIMIT; CD81; HIV-1; MOLECULES
AB It is difficult to observe the molecular choreography between viruses and host cell components, as they exist on a spatial scale beyond the reach of conventional microscopy. However, novel super-resolution microscopy techniques have cast aside technical limitations to reveal a nanoscale view of virus replication and cell biology. This article provides an introduction to super-resolution imaging; in particular, localisation microscopy, and explores the application of such technologies to the study of viruses and tetraspanins, the topic of this special issue.
C1 UCL, Inst Immun & Transplantat, London NW3 2PF, England.
RP Grove, J (reprint author), UCL, Inst Immun & Transplantat, London NW3 2PF, England.
EM j.grove@ucl.ac.uk
OI Grove, Joe/0000-0001-5390-7579
FU Royal Free Charity; Royal Society
FX Thanks to Alex Knight of the National Physical Laboratory for use of
   their home-built localisation microscope, to Schuyler van Engelenburg
   and Jennifer Lippincott-Schwartz for permission to reproduce the image
   displayed in Figure 3 and to Rachel Colman and Ricardo Henriques for
   critical reading of the manuscript. This work was funded by The Royal
   Free Charity and The Royal Society.
CR Abbe E., 1873, ARCH MIKROSK ANAT, V9, P413, DOI DOI 10.1007/BF02956173
   Allen JR, 2013, PHYS CHEM CHEM PHYS, V15, P18771, DOI 10.1039/c3cp53719f
   Annibale P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022678
   Bari Rafijul, 2011, Biochem Biophys Res Commun, V415, P619, DOI 10.1016/j.bbrc.2011.10.121
   Barreiro O, 2008, J CELL BIOL, V183, P527, DOI 10.1083/jcb.200805076
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422
   Chojnacki J, 2012, SCIENCE, V338, P524, DOI 10.1126/science.1226359
   Curthoys N. M., 2013, J VIS EXP
   Davis C, 2012, CELL MICROBIOL, V14, P1892, DOI 10.1111/cmi.12008
   de Jonge N, 2009, P NATL ACAD SCI USA, V106, P2159, DOI 10.1073/pnas.0809567106
   Espenel C, 2008, J CELL BIOL, V182, P765, DOI 10.1083/jcb.200803010
   Gustafsson MGL, 2000, J MICROSC-OXFORD, V198, P82, DOI 10.1046/j.1365-2818.2000.00710.x                                                
   Harris HJ, 2013, CELL MICROBIOL, V15, P430, DOI 10.1111/cmi.12047
   Harris HJ, 2008, J VIROL, V82, P5007, DOI 10.1128/JVI.02286-07
   Harris HJ, 2010, J BIOL CHEM, V285, P21092, DOI 10.1074/jbc.M110.104836
   He J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003701
   Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376
   HELL SW, 1994, OPT LETT, V19, P780, DOI 10.1364/OL.19.000780                                                            
   Henriques R, 2010, NAT METHODS, V7, P339, DOI 10.1038/nmeth0510-339
   Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116
   Hogue IB, 2011, J VIROL, V85, P9749, DOI 10.1128/JVI.00743-11
   Holden SJ, 2011, NAT METHODS, V8, P279, DOI 10.1038/nmeth0411-279
   Holm T, 2014, CHEMPHYSCHEM, V15, P651, DOI 10.1002/cphc.201300739
   Huang F, 2013, NAT METHODS, V10, P653, DOI [10.1038/NMETH.2488, 10.1038/nmeth.2488]
   Jolly C, 2007, J VIROL, V81, P7873, DOI 10.1128/JVI.01845-06
   Jones SA, 2011, NAT METHODS, V8, P499, DOI [10.1038/nmeth.1605, 10.1038/NMETH.1605]
   Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621
   Kiskowski MA, 2009, BIOPHYS J, V97, P1095, DOI 10.1016/j.bpj.2009.05.039
   Krementsov DN, 2010, TRAFFIC, V11, P1401, DOI 10.1111/j.1600-0854.2010.01111.x
   Lee SH, 2012, P NATL ACAD SCI USA, V109, P17436, DOI 10.1073/pnas.1215175109
   Lehmann M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002456
   Lelek M, 2012, P NATL ACAD SCI USA, V109, P8564, DOI 10.1073/pnas.1013267109
   Malkusch S., 2012, CELL BIOL, V139, P173
   Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176
   Mattila PK, 2013, IMMUNITY, V38, P461, DOI 10.1016/j.immuni.2012.11.019
   Metcalf DJ, 2013, JOVE-J VIS EXP, DOI 10.3791/50579
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Nienhaus K, 2014, CHEM SOC REV, V43, P1088, DOI 10.1039/c3cs60171d
   Nydegger S, 2006, J CELL BIOL, V173, P795, DOI 10.1083/jcb.200508165
   Nyquist H, 2002, P IEEE, V90, P280, DOI 10.1109/5.989875
   Pereira CF, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-84
   Perez-Hernandez D, 2013, J BIOL CHEM, V288, P11649, DOI 10.1074/jbc.M112.445304
   Potel J, 2013, CELL MICROBIOL, V15, P1234, DOI 10.1111/cmi.12112
   Puchner EM, 2013, P NATL ACAD SCI USA, V110, P16015, DOI 10.1073/pnas.1309676110
   Quast T, 2011, BLOOD, V118, P1818, DOI 10.1182/blood-2010-12-326595
   Rees EJ, 2013, J OPTICS-UK, V15, DOI 10.1088/2040-8978/15/9/094012
   Rocha-Perugini V, 2013, MOL CELL BIOL, V33, P3644, DOI 10.1128/MCB.00302-13
   Roy NH, 2013, J VIROL, V87, P7516, DOI 10.1128/JVI.00790-13
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Scheffer KD, 2013, J VIROL, V87, P3435, DOI 10.1128/JVI.02906-12
   Schermelleh L, 2010, J CELL BIOL, V190, P165, DOI 10.1083/jcb.201002018
   Sengupta P, 2014, CHEM REV, V114, P3189, DOI 10.1021/cr400614m
   Sengupta P, 2013, NAT PROTOC, V8, P345, DOI 10.1038/nprot.2013.005
   Sengupta P, 2011, NAT METHODS, V8, P969, DOI [10.1038/NMETH.1704, 10.1038/nmeth.1704]
   Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X                                                   
   van de Linde S, 2014, CHEM SOC REV, V43, P1076, DOI 10.1039/c3cs60195a
   Van Engelenburg SB, 2014, SCIENCE, V343, P653, DOI 10.1126/science.1247786
   Wolter S, 2012, NAT METHODS, V9, P1040, DOI 10.1038/nmeth.2224
   Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398
   Zhang J, 2006, MICRON, V37, P14, DOI 10.1016/j.micron.2005.03.014
NR 61
TC 9
Z9 9
U1 1
U2 29
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAR
PY 2014
VL 6
IS 3
BP 1365
EP 1378
DI 10.3390/v6031365
PG 14
WC Virology
SC Virology
GA AG9RC
UT WOS:000335756100023
PM 24651030
OA gold
DA 2018-01-05
ER

PT J
AU Tian, Y
   Wang, HM
   Liu, Y
   Mao, LN
   Chen, WW
   Zhu, ZN
   Liu, WW
   Zheng, WF
   Zhao, YY
   Kong, DL
   Yang, ZM
   Zhang, W
   Shao, YM
   Jiang, XY
AF Tian, Yue
   Wang, Huaimin
   Liu, Ye
   Mao, Lina
   Chen, Wenwen
   Zhu, Zhening
   Liu, Wenwen
   Zheng, Wenfu
   Zhao, Yuyun
   Kong, Deling
   Yang, Zhimou
   Zhang, Wei
   Shao, Yiming
   Jiang, Xingyu
TI A Peptide-Based Nanofibrous Hydrogel as a Promising DNA Nanovector for
   Optimizing the Efficacy of HIV Vaccine
SO NANO LETTERS
LA English
DT Article
DE Peptide-based nanofibrous hydrogel; HIV DNA vaccine; DNA condensation;
   immune response; safety evaluation
ID POTENT DELIVERY-SYSTEM; T-CELL RESPONSES; IMMUNE-RESPONSES; PLASMID DNA;
   PLGA MICROSPHERES; PEI/DNA COMPLEXES; DENDRITIC CELLS; SMALL MOLECULES;
   VIRUS; ADJUVANT
AB This report shows that a nanovector composed of peptide-based nanofibrous hydrogel can condense DNA to result in strong immune responses against HIV. This nanovector can strongly activate both humoral and cellular immune responses to a balanced level rarely reported in previous studies, which is crucial for HIV prevention and therapy. In addition, this nanovector shows good biosafety in vitro and in vivo. Detailed characterizations show that the nanofibrous structure of the hydrogel is critical for the dramatically improved immune responses compared to existing materials. This peptide-based nanofibrous hydrogel shows great potential for efficacious HIV DNA vaccines and can be potentially used for delivering other vaccines and drugs.
C1 [Tian, Yue; Chen, Wenwen; Zhu, Zhening; Liu, Wenwen; Zheng, Wenfu; Zhao, Yuyun; Zhang, Wei; Jiang, Xingyu] Beijing Engn Res Ctr BioNanotechnol, Beijing 100190, Peoples R China.
   [Tian, Yue; Chen, Wenwen; Zhu, Zhening; Liu, Wenwen; Zheng, Wenfu; Zhao, Yuyun; Zhang, Wei; Jiang, Xingyu] Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Tian, Yue; Chen, Wenwen; Zhu, Zhening; Liu, Wenwen] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Wang, Huaimin; Mao, Lina; Kong, Deling; Yang, Zhimou] Nankai Univ, State Key Lab Med Chem Biol, Key Lab Bioact Mat, Minist Educ, Tianjin 300071, Peoples R China.
   [Wang, Huaimin; Mao, Lina; Kong, Deling; Yang, Zhimou] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China.
   [Wang, Huaimin; Mao, Lina; Kong, Deling; Yang, Zhimou] Nankai Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China.
   [Liu, Ye; Shao, Yiming] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Natl Ctr AIDS STD Control & Prevent, Collaborat Innovat Ctr Diag & Treatment Infect Di, Beijing 102206, Peoples R China.
RP Yang, ZM (reprint author), Nankai Univ, State Key Lab Med Chem Biol, Key Lab Bioact Mat, Minist Educ, Tianjin 300071, Peoples R China.
EM yangzm@nankai.edu.cn; yshao08@gmail.com; xingyujiang@nanoctr.cn
RI Yang, Zhimou/F-1798-2010; wang, huaimin/G-8722-2011
OI wang, huaimin/0000-0002-8796-0367; Jiang, Xingyu/0000-0002-5008-4703
FU Ministry of Science and Technology [2012AA022703]; Ministry of Health P.
   R. China [2012ZX10001-008]; Chinese Academy of Science [NNCAS-2010-5,
   XDA01020304]; National Science Foundation of China [21025520,
   81361140345, 51222303]; Beijing Municipal Science & Technology
   Commission [Z131100002713024]
FX We acknowledge Ministry of Science and Technology (2012AA022703), the
   Ministry of Health P. R. China (2012ZX10001-008), the Chinese Academy of
   Science (NNCAS-2010-5 and XDA01020304), the National Science Foundation
   of China (21025520, 81361140345, and 51222303), and Beijing Municipal
   Science & Technology Commission (Z131100002713024). We thank members of
   Dr. Shao laboratory for helpful discussions and Ms. Qi X. Y. for help
   with TEM.
CR Aida T, 2012, SCIENCE, V335, P813, DOI 10.1126/science.1205962
   Aldinucci A, 2013, NANO LETT, V13, P6098, DOI 10.1021/nl403396e
   Ando S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687
   Baldini L, 2007, CHEM SOC REV, V36, P254, DOI 10.1039/b603082n
   Bellan LM, 2006, NANO LETT, V6, P2526, DOI 10.1021/nl061894+
   Berry LJ, 2004, INFECT IMMUN, V72, P1019, DOI 10.1128/IAI.72.2.1019-1028.2004
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Buckheit RW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1697
   Bulheller BM, 2009, J AM CHEM SOC, V131, P13305, DOI 10.1021/ja902662e
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Catanzaro AT, 2007, VACCINE, V25, P4085, DOI 10.1016/j.vaccine.2007.02.050
   CHEDID L, 1976, P NATL ACAD SCI USA, V73, P2472, DOI 10.1073/pnas.73.7.2472
   Chen L., 2009, LANGMUIR, V26, P5232
   Choosakoonkriang S, 2003, J PHARM SCI, V92, P1710, DOI 10.1002/jps.10437
   DeMuth PC, 2013, NAT MATER, V12, P367, DOI [10.1038/NMAT3550, 10.1038/nmat3550]
   Do TT, 2011, BIOMACROMOLECULES, V12, P1731, DOI 10.1021/bm200127u
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Gao Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2040
   Garzon MR, 2005, VACCINE, V23, P1384, DOI 10.1016/j.vaccine.2004.09.009
   Ghanaati S, 2009, BIOMATERIALS, V30, P6202, DOI 10.1016/j.biomaterials.2009.07.063
   Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999
   Hokey DA, 2006, SPRINGER SEMIN IMMUN, V28, P267, DOI 10.1007/s00281-006-0046-z
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Huang XG, 2007, VACCINE, V25, P2620, DOI 10.1016/j.vaccine.2006.12.020
   Jiang L, 2007, J GENE MED, V9, P253, DOI 10.1002/jgm.1017
   Joint United Nations Programme on HIV/AIDS, 2010, UNAIDS REP GLOB AIDS
   Koutsopoulos S, 2012, J CONTROL RELEASE, V160, P451, DOI 10.1016/j.jconrel.2012.03.014
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   Liang GL, 2010, NAT CHEM, V2, P54, DOI [10.1038/nchem.480, 10.1038/NCHEM.480]
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Liu Y, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-297
   Liu YY, 2012, SMALL, V8, P676, DOI 10.1002/smll.201101199
   Mahdavi Mehdi, 2011, Immunol Lett, V140, P14, DOI 10.1016/j.imlet.2011.05.005
   Malmsten M, 2006, SOFT MATTER, V2, P760, DOI 10.1039/b608348j
   Minigo G, 2007, VACCINE, V25, P1316, DOI 10.1016/j.vaccine.2006.09.086
   Misra SK, 2012, J MATER CHEM, V22, P7985, DOI 10.1039/c2jm15659h
   Mu X, 2013, LAB CHIP, V13, P1612, DOI 10.1039/c3lc41342j
   Nesgaard LW, 2008, BIOPOLYMERS, V89, P779, DOI 10.1002/bip.21011
   OKUDA K, 1995, AIDS RES HUM RETROV, V11, P933, DOI 10.1089/aid.1995.11.933                                                         
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Park S, 2009, NANO LETT, V9, P1325, DOI 10.1021/nl802962t
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Qiao Y, 2010, BIOMATERIALS, V31, P115, DOI 10.1016/j.biomaterials.2009.09.032
   REICH Z, 1990, J BIOL CHEM, V265, P5590
   Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107
   Ryan DM, 2011, LANGMUIR, V27, P4029, DOI 10.1021/la1048375
   Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162
   Smith Clara R, 2007, J Chromatogr B Analyt Technol Biomed Life Sci, V854, P121, DOI 10.1016/j.jchromb.2007.04.005
   Toledano S, 2006, J AM CHEM SOC, V128, P1070, DOI 10.1021/ja056549l
   Um SH, 2006, NAT MATER, V5, P797, DOI 10.1038/nmat1741
   Walter E, 1999, J CONTROL RELEASE, V61, P361, DOI 10.1016/S0168-3659(99)00151-0                                                   
   Wang HM, 2011, SOFT MATTER, V7, P3897, DOI 10.1039/c0sm01405b
   Wang HM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/22/225606
   Wang S, 2008, VACCINE, V26, P1098, DOI 10.1016/j.vaccine.2007.12.024
   Wen J, 2012, VACCINE, V30, P5733, DOI 10.1016/j.vaccine.2012.07.008
   Wijesundara DK, 2011, IMMUNOL CELL BIOL, V89, P367, DOI 10.1038/icb.2010.118
   Williams RJ, 2009, NAT NANOTECHNOL, V4, P19, DOI [10.1038/NNANO.2008.378, 10.1038/nnano.2008.378]
   Xu LG, 2013, ADV MATER, V25, P5928, DOI 10.1002/adma.201300583
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yan X., 2007, ANGEW CHEM, V119, P2483
   Yan Y, 2009, ANGEW CHEM INT EDIT, V48, P2003, DOI 10.1002/anie.200805824
   Yang DY, 2008, ADV MATER, V20, P4770, DOI 10.1002/adma.200801302
   Yang Z, 2008, ACCOUNTS CHEM RES, V41, P315, DOI 10.1021/ar7001914
   Yang ZM, 2006, J AM CHEM SOC, V128, P3038, DOI 10.1021/ja057412y
   Zhang X, 2012, ANGEW CHEM, V124, P4464
   Zheng WF, 2010, ADV ENG MATER, V12, pB451, DOI 10.1002/adem.200980087
   Zhou XF, 2008, EUR J PHARM BIOPHARM, V68, P589, DOI 10.1016/j.ejpb.2007.09.006
   Zuidam NJ, 1999, FEBS LETT, V457, P419, DOI 10.1016/S0014-5793(99)01053-4
NR 71
TC 60
Z9 63
U1 11
U2 158
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
EI 1530-6992
J9 NANO LETT
JI Nano Lett.
PD MAR
PY 2014
VL 14
IS 3
BP 1439
EP 1445
DI 10.1021/nl404560v
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AG9EA
UT WOS:000335720300053
PM 24564254
DA 2018-01-05
ER

PT J
AU Caballero, S
   Diez, JM
   Belda, FJ
   Otegui, M
   Herring, S
   Roth, NJ
   Lee, D
   Gajardo, R
   Jorquera, JI
AF Caballero, Santiago
   Diez, Jose M.
   Belda, Francisco J.
   Otegui, Magdalena
   Herring, Steven
   Roth, Nathan J.
   Lee, Douglas
   Gajardo, Rodrigo
   Jorquera, Juan I.
TI Robustness of nanofiltration for increasing the viral safety margin of
   biological products
SO BIOLOGICALS
LA English
DT Article
DE Viral safety; Nanofiltration; Plasma-derived product
ID VIRUS; FILTRATION; REMOVAL
AB In this study, the virus-removal capacity of nanofiltration was assessed using validated laboratory scale models on a wide range of viruses (pseudorabies virus; human immunodeficiency virus; bovine viral diarrhea virus; West Nile virus; hepatitis A virus; murine encephalomyocarditis virus; and porcine parvovirus) with sizes from 18 nm to 200 nm and applying the different process conditions existing in a number of Grifols' plasma-derived manufacturing processes (thrombin, alpha 1-proteinase inhibitor, Factor IX, antithrombin, plasmin, intravenous immunoglobulin, and fibrinogen). Spiking experiments (n = 133) were performed in process intermediate products, and removal was subsequently determined by infectivity titration. Reduction Factor (RF) was calculated by comparing the virus load before and after nanofiltration under each product purification condition. In all experiments, the RFs were close to or greater than 4 log(10) (>99.99% of virus elimination). RF values were not significantly affected by the process conditions within the limits assayed (pH, ionic strength, temperature, filtration ratio, and protein concentration). The virus-removal capacity of nanofiltration correlated only with the size of the removed agent. In conclusion, nanofiltration, as used in the manufacturing of several Grifols' products, is consistent, robust, and not significantly affected by process conditions. (C) 2013 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
C1 [Caballero, Santiago; Diez, Jose M.; Belda, Francisco J.; Otegui, Magdalena; Gajardo, Rodrigo; Jorquera, Juan I.] Grifols, Biol Ind Grp, Res & Dev Area, Barcelona 08150, Spain.
   [Herring, Steven] Grifols, Biol Ind Grp, Res & Dev Area, Los Angeles, CA USA.
   [Roth, Nathan J.; Lee, Douglas] Grifols, Biol Ind Grp, Res & Dev Area, Res Triangle Pk, NC USA.
RP Caballero, S (reprint author), Grifols, Inst Grifols SA, Biol Ind Grp, Res & Dev Area, Poligono Levante Can Guasch 2, Barcelona 08150, Spain.
EM santiago.caballero@grifols.com
CR Biescas H, 1998, HAEMATOLOGICA, V83, P305
   Burnouf T, 1996, VOX SANG, V70, P235, DOI 10.1111/j.1423-0410.1996.tb01334.x                                              
   Burnouf T, 2003, VOX SANG, V84, P111, DOI 10.1046/j.1423-0410.2003.00265.x
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   Caballero S, 2010, BIOLOGICALS, V38, P486, DOI 10.1016/j.biologicals.2010.02.008
   Dichtelmuller HO, 2009, TRANSFUSION, V49, P1931, DOI 10.1111/j.1537-2995.2009.02222.x
   EMEA, 2001, CPMPBWP26995REV EMEA
   EMEA, 1997, CPMPICH29595 EMEA
   EMEA, 1996, CPMPBWP26895REV EMEA
   Furuya K, 2006, VOX SANG, V91, P119, DOI 10.1111/j.1423-0410.2006.00792.x
   Heimburger N, 1989, Curr Stud Hematol Blood Transfus, P23
   Hongo-Hirasaki T, 2011, BIOTECHNOL PROGR, V27, P162, DOI 10.1002/btpr.533
   Jorquera JI, 2007, HAEMOPHILIA, V13, P41, DOI 10.1111/j.1365-2516.2007.01578.x
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Korneyeva M, 2002, BIOLOGICALS, V30, P153, DOI 10.1006/biol.2002.0334
   Manabe SI, 1996, DEV BIOL STAND, V88, P81
   Menache D, 1985, Prog Clin Biol Res, V182, P407
   Menconi MC, 2009, TRANSFUSION MED, V19, P213, DOI 10.1111/j.1365-3148.2009.00931.x
   OGrady J, 1996, DEV BIOL STAND, V88, P319
   Terpstra FG, 2007, BIOLOGICALS, V35, P173, DOI 10.1016/j.biologicals.2006.08.005
   Terpstra FG, 2006, VOX SANG, V90, P21, DOI 10.1111/j.1423-0410.2005.00710.x
   Zhou JX, 2008, BIOTECHNOL BIOENG, V100, P488, DOI 10.1002/bit.21781
   [Anonymous], 1992, BIOLOGICALS, V20, P159
NR 23
TC 8
Z9 8
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
EI 1095-8320
J9 BIOLOGICALS
JI Biologicals
PD MAR
PY 2014
VL 42
IS 2
BP 79
EP 85
DI 10.1016/j.biologicals.2013.10.003
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA AG1UR
UT WOS:000335202200003
PM 24485384
DA 2018-01-05
ER

PT J
AU Copolovici, DM
   Langel, K
   Eriste, E
   Langel, U
AF Copolovici, Dana Maria
   Langel, Kent
   Eriste, Elo
   Langel, Ulo
TI Cell-Penetrating Peptides: Design, Synthesis, and Applications
SO ACS NANO
LA English
DT Review
DE cell-penetrating peptides; delivery agents; uptake mechanism;
   nanoparticles; gene therapy; nucleic acids
ID ARGININE-RICH PEPTIDES; SARCOMA-ASSOCIATED HERPESVIRUS; HEPARAN-SULFATE
   PROTEOGLYCANS; PROTEIN TRANSDUCTION DOMAINS; CONJUGATED MORPHOLINO
   OLIGOMERS; HUMAN IMMUNODEFICIENCY VIRUS; DUCHENNE MUSCULAR-DYSTROPHY;
   TAT-FUSION PROTEINS; D-ISOMER PEPTIDES; P53 C-TERMINUS
AB The intrinsic property of cell-penetrating peptides (CPPs) to deliver therapeutic molecules (nucleic acids, drugs, imaging agents) to cells and tissues in a nontoxic manner has indicated that they may be potential components of future drugs and disease diagnostic agents. These versatile peptides are simple to synthesize, functionalize, and characterize yet are able to deliver covalently or noncovalently conjugated bioactive cargos (from small chemical drugs to large plasmid DNA) inside cells, primarily via endocytosis, in order to obtain high levels of gene expression, gene silencing, or tumor targeting. Typically, CPPs are often passive and nonselective yet must be functionalized or chemically modified to create effective delivery vectors that succeed in targeting specific cells or tissues. Furthermore, the design of clinically effective systemic delivery systems requires the same amount of attention to detail in both design of the delivered cargo and the cell-penetrating peptide used to deliver it.
C1 [Copolovici, Dana Maria; Langel, Kent; Eriste, Elo; Langel, Ulo] Univ Tartu, Mol Biotechnol Lab, Inst Technol, EE-50411 Tartu, Estonia.
   [Langel, Ulo] Stockholm Univ, Dept Neurochem, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden.
RP Copolovici, DM (reprint author), Univ Tartu, Mol Biotechnol Lab, Inst Technol, EE-50411 Tartu, Estonia.
EM danaban76@gmail.com
RI Copolovici, Dana/C-5207-2012
OI Copolovici, Dana/0000-0002-1491-0473
FU Estonian Ministry of Education and Research [SF0180027s08, IUT20-26];
   Estonian Science Foundation [Mobilitas-MJD64, ETF9438]; DoRa Program of
   The European Social Fund; EU through the European Regional Development
   Fund through the Center of Excellence in Chemical Biology, Estonia;
   Swedish Research Council (VR-NT)
FX Work in the authors' laboratory was supported by the targeted financing
   SF0180027s08 and IUT20-26 from the Estonian Ministry of Education and
   Research; by the Estonian Science Foundation (Mobilitas-MJD64, ETF9438);
   by the DoRa Program of The European Social Fund; by the EU through the
   European Regional Development Fund through the Center of Excellence in
   Chemical Biology, Estonia; and by the Swedish Research Council (VR-NT).
CR Abdul F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048721
   Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593                                                
   Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Ahn DG, 2011, ANTIVIR RES, V91, P1, DOI 10.1016/j.antiviral.2011.04.009
   Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   Almeida PF, 2009, BIOCHEMISTRY-US, V48, P8083, DOI 10.1021/bi900914g
   Alves I. D., 2011, INTRACELLULAR DELIVE
   Alves ID, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024096
   Alves ID, 2010, BBA-BIOMEMBRANES, V1798, P2231, DOI 10.1016/j.bbamem.2010.02.009
   Alves ID, 2009, J PEPT SCI, V15, P200, DOI 10.1002/psc.1070
   Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299
   Angeles-Boza AM, 2010, BIOCONJUGATE CHEM, V21, P2164, DOI 10.1021/bc100130r
   Araki D, 2010, UROLOGY, V75, P813, DOI 10.1016/j.urology.2009.10.002
   Aroui S, 2010, BIOCHEM BIOPH RES CO, V391, P419, DOI 10.1016/j.bbrc.2009.11.073
   Aroui S, 2009, CANCER LETT, V285, P28, DOI 10.1016/j.canlet.2009.04.044
   Arrighi RBG, 2008, ANTIMICROB AGENTS CH, V52, P3414, DOI 10.1128/AAC.01450-07
   Arukuusk P, 2013, BIOCONJUGATE CHEM, V24, P1721, DOI 10.1021/bc4002757
   Barany-Wallje E, 2007, FEBS LETT, V581, P2389, DOI 10.1016/j.febslet.2007.04.046
   Baumgartner P, 2007, J CELL BIOL, V179, P793, DOI 10.1083/jcb.200707165                                                           
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729                                                
   BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053                                             
   Binder H, 2003, BIOPHYS J, V85, P982, DOI 10.1016/S0006-3495(03)74537-8
   Bode SA, 2014, CHEM COMMUN, V50, P415, DOI 10.1039/c3cc46826g
   Bodor N, 2007, J PHARM PHARMACOL, V59, P1065, DOI 10.1211/jpp.59.8.0003
   Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004
   Brown DR, 2000, BIOCHEM J, V352, P511, DOI 10.1042/0264-6021:3520511
   Brugnano JL, 2011, J CONTROL RELEASE, V155, P128, DOI 10.1016/j.jconrel.2011.05.007
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Chaloin L, 1998, BIOCHEM BIOPH RES CO, V243, P601, DOI 10.1006/bbrc.1997.8050
   Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821                                                              
   Christiaens B, 2002, EUR J BIOCHEM, V269, P2918, DOI 10.1046/j.1432-1033.2002.02963.x
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Czihal P, 2009, INT J PEPT RES THER, V15, P157, DOI 10.1007/s10989-009-9178-z
   Dasgupta D, 2002, J BIOCHEM, V132, P23, DOI 10.1093/oxfordjournals.jbchem.a003194                                           
   Delcroix Melaine, 2010, Pharmaceuticals (Basel), V3, P448
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005
   Dobchev DA, 2010, CURR COMPUT-AID DRUG, V6, P79
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Drin G, 2001, BIOCHEMISTRY-US, V40, P1824, DOI 10.1021/bi002019k
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Dunkin CM, 2011, J PHYS CHEM B, V115, P1188, DOI 10.1021/jp107763b
   Eiriksdottir E, 2010, BIOCONJUGATE CHEM, V21, P1662, DOI 10.1021/bc100174y
   Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2006, BBA-BIOMEMBRANES, V1758, P721, DOI 10.1016/j.bbamem.2006.05.013
   Ezzat K, 2012, FASEB J, V26, P1172, DOI 10.1096/fj.11-191536
   Ezzat K, 2011, NUCLEIC ACIDS RES, V39, P5284, DOI 10.1093/nar/gkr072
   Farrera-Sinfreu J, 2005, J AM CHEM SOC, V127, P9459, DOI 10.1021/ja051648k
   Farrera-Sinfreu Josep, 2007, V386, P241, DOI 10.1007/978-1-59745-430-8_9
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Foster K, 2006, GENE THER, V13, P1677, DOI 10.1038/sj.gt.3302877
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i
   Good L, 2001, NAT BIOTECHNOL, V19, P360, DOI 10.1038/86753                                                                   
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Hallbrink M, 2005, INT J PEPT RES THER, V11, P249, DOI 10.1007/s10989-005-9393-1
   Hansen A, 2012, ANTIMICROB AGENTS CH, V56, P5194, DOI 10.1128/AAC.00585-12
   Hansen M, 2008, ADV DRUG DELIVER REV, V60, P572, DOI 10.1016/j.addr.2007.09.003
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henriques ST, 2008, J PEPT SCI, V14, P482, DOI 10.1002/psc.1003
   Henriques ST, 2004, BIOCHEMISTRY-US, V43, P9716, DOI 10.1021/bi036325k
   Herbig ME, 2006, BIOCHEMISTRY-US, V45, P3598, DOI 10.1021/bi050923c
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1
   Holm T, 2005, FEBS LETT, V579, P5217, DOI 10.1016/j.febslet.2005.07.099
   Holm T, 2012, LETT APPL MICROBIOL, V54, P39, DOI 10.1111/j.1472-765X.2011.03168.x
   Howl J, 2012, CELL MOL LIFE SCI, V69, P2951, DOI 10.1007/s00018-012-0979-4
   Hoyer J, 2012, BEILSTEIN J ORG CHEM, V8, P1788, DOI 10.3762/bjoc.8.204
   Hoyer J, 2012, J CONTROL RELEASE, V161, P826, DOI 10.1016/j.jconrel.2012.05.017
   Inomata K, 2009, NATURE, V458, P106, DOI 10.1038/nature07839
   Iversen PL, 2012, VIRUSES-BASEL, V4, P2806, DOI 10.3390/v4112806
   Jearawiriyapaisarn N, 2010, CARDIOVASC RES, V85, P444, DOI 10.1093/cvr/cvp335
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Jones S, 2010, CHEM BIOL, V17, P735, DOI 10.1016/j.chembiol.2010.05.018
   Jung HJ, 2006, BIOCHEM BIOPH RES CO, V345, P222, DOI 10.1016/j.bbrc.2006.04.059
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Khafagy ES, 2013, EUR J PHARM BIOPHARM, V85, P736, DOI 10.1016/j.ejpb.2013.09.014
   Khafagy ES, 2012, ADV DRUG DELIVER REV, V64, P531, DOI 10.1016/j.addr.2011.12.014
   Khafagy ES, 2009, J CONTROL RELEASE, V133, P103, DOI 10.1016/j.jconrel.2008.09.076
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kobayashi N, 2006, ANTIMICROB AGENTS CH, V50, P1118, DOI 10.1128/AAC.50.3.1118-1119.2006
   KOKENYESI R, 1994, J BIOL CHEM, V269, P12304
   Ladokhin AS, 2001, BBA-BIOMEMBRANES, V1514, P253, DOI 10.1016/S0005-2736(01)00382-0
   Lattig-Tunnemann G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1459
   Langel U., 2011, CELL PENETRATING PEP
   Langel U., 2007, HDB CELL PENETRATING
   Lau AL, 2007, P NATL ACAD SCI USA, V104, P11551, DOI 10.1073/pnas.0704260104
   Lehto T, 2012, EXPERT OPIN DRUG DEL, V9, P823, DOI 10.1517/17425247.2012.689285
   Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028
   Lempens EHM, 2011, BIOCONJUGATE CHEM, V22, P397, DOI 10.1021/bc100403e
   Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022
   Ifediba M. A., 2010, BIOCONJUGATE CHEM, V11, P803
   Li Y, 2012, INT J PHARMACEUT, V434, P209, DOI 10.1016/j.ijpharm.2012.06.003
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lofgren K, 2008, FASEB J, V22, P2177, DOI 10.1096/fj.07-099549
   Lu SW, 2006, ANAL BIOCHEM, V353, P7, DOI 10.1016/j.ab.2006.01.044
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Lundin P, 2008, BIOCONJUGATE CHEM, V19, P2535, DOI 10.1021/bc800212j
   Madani F., 2011, J BIOPHYS, V2011
   Mae M, 2005, BBA-BIOMEMBRANES, V1669, P101, DOI 10.1016/j.bbamem.2005.01.006
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Mager I., 2009, BIOCHIM BIOPHYS ACTA, V1798, P338
   Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   Matsumoto K, 2010, BIOCHEM BIOPH RES CO, V395, P7, DOI 10.1016/j.bbrc.2010.03.088
   Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P8450, DOI 10.1021/bi960342a
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   McKeown AN, 2011, BIOCHEMISTRY-US, V50, P654, DOI 10.1021/bi1013358
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Mo RH, 2012, MOL PHARMACEUT, V9, P299, DOI 10.1021/mp200481g
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moulton HM, 2010, BBA-BIOMEMBRANES, V1798, P2296, DOI 10.1016/j.bbamem.2010.02.012
   Moulton JD, 2009, MOLECULES, V14, P1304, DOI 10.3390/molecules14031304
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Naik RJ, 2011, J BIOL CHEM, V286, P18982, DOI 10.1074/jbc.M111.227793
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016
   Nakase I, 2009, MOL THER, V17, P1868, DOI 10.1038/mt.2009.192
   Nan YH, 2011, J PEPT SCI, V17, P812, DOI 10.1002/psc.1408
   Nekhotiaeva N, 2004, MOL THER, V10, P652, DOI 10.1016/j.ymthe.2004.07.006
   Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje
   Nelson AR, 2007, BIOCHEMISTRY-US, V46, P14771, DOI 10.1021/bi701295k
   Doan ND, 2012, J CONTROL RELEASE, V163, P256, DOI 10.1016/j.jconrel.2012.08.021
   Doan ND, 2012, BBA-MOL CELL RES, V1823, P940, DOI 10.1016/j.bbamcr.2012.02.001
   Nicolas P, 2009, FEBS J, V276, P6483, DOI 10.1111/j.1742-4658.2009.07359.x
   Niidome T, 1999, J PEPT RES, V54, P361, DOI 10.1034/j.1399-3011.1999.00122.x
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Oskolkov N, 2011, INT J PEPT RES THER, V17, P147, DOI 10.1007/s10989-011-9252-1
   Ouyang D, 2011, BIOPHYS CHEM, V158, P126, DOI 10.1016/j.bpc.2011.06.003
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Padari K, 2005, BIOCONJUGATE CHEM, V16, P1399, DOI 10.1021/bc050125z
   Palm C, 2006, PEPTIDES, V27, P1710, DOI 10.1016/j.peptides.2006.01.006
   Parseghian MH, 2006, BIOCHEM CELL BIOL, V84, P589, DOI 10.1139/O06-082
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Persson D, 2003, BIOCHEMISTRY-US, V42, P421, DOI 10.1021/bi026453t
   Persson D, 2004, BIOCHEMISTRY-US, V43, P11045, DOI 10.1021/bi036054d
   Pham W, 2005, NEUROIMAGE, V28, P287, DOI 10.1016/j.neuroimage.2005.06.007
   Plenat T, 2004, LANGMUIR, V20, P9255, DOI 10.1021/la048622b
   Pooga M, 1998, FASEB J, V12, P67
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Rangel R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1773
   Repici M., 2006, HYPOXIA EXERCISE, V588
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rullo A, 2011, BIOPOLYMERS, V95, P722, DOI 10.1002/bip.21641
   Rydstrom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025924
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Saalik P, 2009, BIOCONJUGATE CHEM, V20, P877, DOI 10.1021/bc800416f
   Salamon Z, 2004, BIOPHYS J, V86, P2508, DOI 10.1016/S0006-3495(04)74306-4                                                   
   Saleh AF, 2010, BIOCONJUGATE CHEM, V21, P1902, DOI 10.1021/bc100275r
   Saleh AF, 2010, J CONTROL RELEASE, V143, P233, DOI 10.1016/j.jconrel.2009.12.025
   Salomone F, 2012, J CONTROL RELEASE, V163, P293, DOI 10.1016/j.jconrel.2012.09.019
   Sandberg M, 1998, J MED CHEM, V41, P2481, DOI 10.1021/jm9700575                                                               
   Sanders WS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002101
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Schwieger C, 2009, BIOMACROMOLECULES, V10, P2152, DOI 10.1021/bm9003207
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Song JJ, 2011, PEPTIDES, V32, P1934, DOI 10.1016/j.peptides.2011.07.018
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stein DA, 2008, CURR PHARM DESIGN, V14, P2619, DOI 10.2174/138161208786071290
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Suhorutsenko J, 2012, INT J PEPT RES THER, V18, P291, DOI 10.1007/s10989-012-9302-3
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Svensen N, 2012, TRENDS PHARMACOL SCI, V33, P186, DOI 10.1016/j.tips.2012.02.002
   Takechi Y, 2011, LANGMUIR, V27, P7099, DOI 10.1021/la200917y
   Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029
   Thoren PEG, 2005, BIOPHYS CHEM, V114, P169, DOI 10.1016/j.bpc.2004.11.016
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Tiriveedhi V, 2007, BIOCHEMISTRY-US, V46, P3888, DOI 10.1021/bi602527t
   Tobias J., 2010, CANC ITS MANAGEMENT
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Ueda Y, 2012, BIOMATERIALS, V33, P9061, DOI 10.1016/j.biomaterials.2012.09.003
   van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108
   Van Mau N, 1999, J MEMBRANE BIOL, V167, P241
   Vandenbroucke RE, 2007, BBA-BIOMEMBRANES, V1768, P571, DOI 10.1016/j.bbamem.2006.11.006
   Vaslin A, 2011, J NEUROCHEM, V119, P1243, DOI 10.1111/j.1471-4159.2011.07535.x
   Vie V, 2000, BIOPHYS J, V78, P846, DOI 10.1016/S0006-3495(00)76642-2                                                   
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Wadia JS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003314
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Walrant A, 2012, NANOMEDICINE-UK, V7, P133, DOI [10.2217/NNM.11.165, 10.2217/nnm.11.165]
   Wang HY, 2011, J CONTROL RELEASE, V155, P26, DOI 10.1016/j.jconrel.2010.12.009
   Ward B, 2009, J PEPT SCI, V15, P668, DOI 10.1002/psc.1168
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Wender PA, 2012, GYNECOL ONCOL, V126, P118, DOI 10.1016/j.ygyno.2012.03.049
   Wu GQ, 2010, BIOCHEM BIOPH RES CO, V395, P31, DOI 10.1016/j.bbrc.2010.03.107
   Yamada T, 2013, BRIT J CANCER, V108, P2495, DOI 10.1038/bjc.2013.266
   Yandek L. E., 2007, BIOPHYS J A, p68A
   Yandek LE, 2008, BIOCHEMISTRY-US, V47, P3051, DOI 10.1021/bi702205r
   Yandek LE, 2007, BIOPHYS J, V92, P2434, DOI 10.1529/biophysj.106.100198
   Yandek LE, 2009, BIOCHEMISTRY-US, V48, P7342, DOI 10.1021/bi9008243
   Yang B, 2004, BIOORG MED CHEM LETT, V14, P1403, DOI 10.1016/j/bmcl.2003.09.101
   Yang H, 2010, J BIOL CHEM, V285, P25666, DOI 10.1074/jbc.M109.089417
   Yin HF, 2010, MOL THER, V18, P1822, DOI 10.1038/mt.2010.151
   Yoshida T, 2003, APPL MICROBIOL BIOT, V62, P21, DOI 10.1007/s00253-003-1312-9
   Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a
   Zhang YJ, 2008, MOL CANCER THER, V7, P712, DOI 10.1158/1535-7163.MCT-07-2036
   Zhang YJ, 2007, ANTIVIR RES, V73, P12, DOI 10.1016/j.antiviral.2006.05.017
   Zhang YJ, 2011, ANTIVIR THER, V16, P657, DOI 10.3851/IMP1810
   Zhu WL, 2009, J PEPT SCI, V15, P345, DOI 10.1002/psc.1120
   Zhu WL, 2009, CHEM BIOL DRUG DES, V73, P209, DOI 10.1111/j.1747-0285.2008.00769.x
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Ziegler A, 2008, BIOPHYS J, V94, P2142, DOI 10.1529/biophysj.107.113472
NR 234
TC 237
Z9 239
U1 41
U2 420
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2014
VL 8
IS 3
BP 1972
EP 1994
DI 10.1021/nn4057269
PG 23
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AD8TU
UT WOS:000333539400016
PM 24559246
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Ding, H
   Yatfung, C
   Raymond, A
   Atluri, V
   Roy, U
   Yndart-Arias, A
   Kanthikeel, SP
   Sagar, V
   Thangavel, S
   Nair, M
AF Ding Hong
   Yatfung, Chiu
   Raymond, Andrea
   Atluri, Venkata
   Roy, Upal
   Yndart-Arias, Adriana
   Kanthikeel, Pilakka Sudheesh
   Sagar, Vidya
   Thangavel, Samikkannu
   Nair, Madhavan
TI Development of hybrid nanocarrier (Au/Fe3O4) for active drug delivery to
   brain to eliminate HIV-1 persistence
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Ding Hong; Yatfung, Chiu; Raymond, Andrea; Atluri, Venkata; Roy, Upal; Yndart-Arias, Adriana; Kanthikeel, Pilakka Sudheesh; Sagar, Vidya; Thangavel, Samikkannu; Nair, Madhavan] Florida Int Univ, Dept Immunol, Miami, FL 33199 USA.
RI ROY, UPAL/C-6126-2012
NR 0
TC 0
Z9 0
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2014
VL 9
IS 1
BP 14
EP 14
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA AD3ER
UT WOS:000333121600030
DA 2018-01-05
ER

PT J
AU Jayant, RD
AF Jayant, R. D.
TI Layer-by-Layer (LbL) Assembly of Anti HIV Drug for Sustained Release to
   Brain Using Magnetic Nanoparticle
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Jayant, R. D.] Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Inst Neuro Immune Pharmacol, Miami, FL 33199 USA.
OI Jayant, Rahul Dev/0000-0002-2584-3878
NR 0
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2014
VL 9
IS 1
BP 25
EP 25
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA AD3ER
UT WOS:000333121600060
DA 2018-01-05
ER

PT J
AU Raymond, AD
   Hong, D
   Roy, U
   Yndarta-Arias, A
   Agudelo, M
   Munoz, K
   Alturi, VS
   Pilakka-Khantakeel, S
   Thangavel, S
   Rao, K
   Nair, MP
AF Raymond, A. D.
   Hong, D.
   Roy, U.
   Yndarta-Arias, A.
   Agudelo, M.
   Munoz, K.
   Alturi, V. S.
   Pilakka-Khantakeel, S.
   Thangavel, S.
   Rao, K.
   Nair, M. P.
TI Polydrug mediated effects on HIV Nef plus exosome release and
   neuropathogenesis is modulated by Nef peptide magnetic nanocarriers
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Raymond, A. D.; Yndarta-Arias, A.; Agudelo, M.; Munoz, K.; Alturi, V. S.; Thangavel, S.; Rao, K.; Nair, M. P.] Florida Int Univ, Dept Immunol, Miami, FL 33199 USA.
   [Hong, D.; Roy, U.; Pilakka-Khantakeel, S.] Florida Int Univ, Inst NeuroImmune Pharmacol, Miami, FL 33199 USA.
RI ROY, UPAL/C-6126-2012
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2014
VL 9
IS 1
BP 46
EP 47
PG 2
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA AD3ER
UT WOS:000333121600116
DA 2018-01-05
ER

PT J
AU Roy, U
   Ding, H
   Kanthikeel, SP
   Raymond, A
   Atluri, V
   Yndart-Arias, A
   Munoz-Caamano, K
   Sagar, V
   Thangavel, S
   Nair, M
AF Roy, Upal
   Ding, H.
   Kanthikeel, S. P.
   Raymond, A.
   Atluri, V
   Yndart-Arias, A.
   Munoz-Caamano, K.
   Sagar, V
   Thangavel, S.
   Nair, M.
TI MAGNETIC NANOPARTICLE FOR TARGETTED ANTI-HIV DRUG DELIVERY IN IN VIVO
   MODEL
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Roy, Upal; Ding, H.; Kanthikeel, S. P.; Raymond, A.; Atluri, V; Yndart-Arias, A.; Munoz-Caamano, K.; Sagar, V; Thangavel, S.; Nair, M.] Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Miami, FL 33183 USA.
RI ROY, UPAL/C-6126-2012
NR 0
TC 0
Z9 0
U1 2
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2014
VL 9
IS 1
BP 48
EP 49
PG 2
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA AD3ER
UT WOS:000333121600121
DA 2018-01-05
ER

PT J
AU Sagar, V
   Plakka-Kanthikeel, S
   Ding, H
   Atluri, VSR
   Jayant, RD
   Kaushik, A
   Nair, M
AF Sagar, V
   Plakka-Kanthikeel, S.
   Ding, H.
   Atluri, V. S. R.
   Jayant, R. D.
   Kaushik, A.
   Nair, M.
TI Novel magneto-electric nanodelivery of microRNA mimic across blood-brain
   barrier: Implications to cocaine modulation on HIV-associated
   neurocognitive disorders
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Sagar, V; Plakka-Kanthikeel, S.; Ding, H.; Atluri, V. S. R.; Jayant, R. D.; Kaushik, A.; Nair, M.] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Inst NeuroImmune Pharmacol,Dept Immunol, Miami, FL 33199 USA.
OI Jayant, Rahul Dev/0000-0002-2584-3878
NR 0
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2014
VL 9
IS 1
BP 49
EP 49
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA AD3ER
UT WOS:000333121600122
DA 2018-01-05
ER

PT J
AU Uzasci, L
   Bianchet, MA
   Cotter, RJ
   Nath, A
AF Uzasci, Lerna
   Bianchet, Mario A.
   Cotter, Robert J.
   Nath, Avindra
TI Identification of Nitrated Immunoglobulin Variable Regions in the
   HIV-Infected Human Brain: Implications in HIV Infection and Immune
   Response
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE HIV; nitroproteome; HIV-associated neurocognitive disorders; nitration;
   mass spectrometry; antibody; immune response
ID PROTEIN-TYROSINE NITRATION; NEUROCOGNITIVE DISORDERS; STRUCTURAL BASIS;
   PEROXYNITRITE; ANTIBODY; DEMENTIA; NEUTRALIZATION; THERAPEUTICS;
   TRYPTOPHAN; SULFATION
AB HIV can infiltrate the brain and lead to HIV-associated neurocognitive disorders (HAND). The pathophysiology of HAND is poorly understood, and there are no diagnostic biomarkers for it. Previously, an increase in inducible nitric oxide synthase levels and protein tyrosine nitration in the brain were found to correlate with the severity of HAND.(1,2) In this study, we analyzed human brains from individuals who had HIV infection without encephalitis and with encephalitis/HAND and compared them to the brains of healthy individuals. We identified the nitrated proteins and determined the sites of modification using affinity enrichment followed by high-resolution and high-mass-accuracy nanoLC-MS/MS. We found that nitrated proteins were predominantly present in the HIV-infected individuals with encephalitis, and, interestingly, the modifications were predominantly located on immunoglobulin variable regions. Our molecular model indicated potential interactions with HIV envelope proteins and changes on the heavy and light chain interface upon the nitration and nitrohydroicylation of these residues.. Therefore, our findings suggest a role for these modifications in the immune response, which may have implications in disease pathogenesis.
C1 [Uzasci, Lerna; Cotter, Robert J.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   [Bianchet, Mario A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA.
RP Uzasci, L (reprint author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
EM lerna.uzasci@nih.gov
RI Bianchet, Mario/K-2131-2015
OI Bianchet, Mario/0000-0001-9032-7549
FU National Institute of Neurological Disorders and Stroke [R01NS039253];
   intramural NIH funds
FX R.J.C M.A.B., and L.U. were supported by grant R01NS039253 (to R.J.C.)
   from the National Institute of Neurological Disorders and Stroke. A.N.
   is supported by intramural NIH funds. We thank the Johns Hopkins School
   of Medicine Mass Spectrometry and Proteomics Facility for technical
   assistance and Drs. Stefani
CR Adamson DC, 1999, MOL MED, V5, P98
   Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198
   Beasley A., 2010, CLIN PROTEOMICS, V1, P29
   Birtalan S, 2008, J MOL BIOL, V377, P1518, DOI 10.1016/j.jmb.2008.01.093
   Boven LA, 1999, J IMMUNOL, V162, P4319
   Burkala EJ, 2005, AIDS, V19, P675, DOI 10.1097/01.aids.0000166090.31693.aa
   Butterfield D. A, 2011, FREE RADICAL RES, V1, P59
   Castagna A., 1995, NEUROLOGY, V9, P1678
   Chen H. J., 2012, ANAL CHEM, V18, P7881
   Cherner M, 2007, J NEUROVIROL, V13, P23, DOI 10.1080/13550280601089175
   Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693                                                          
   Danielson S. R., 2009, ANAL CHEM, V18, P7823
   Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566                                                          
   Eugenin E. A., 2011, J NEUROSCI, V26, P9456
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Fellouse FA, 2004, P NATL ACAD SCI USA, V101, P12467, DOI 10.1073/pnas.0401789101
   Franco M. C., 2013, P NATL ACAD SCI USA, V12, pE1102
   Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3
   Koide S., 2009, ACS CHEM BIOL, V5, P325
   Kwong J. A., 2011, J VIROL, V15, P7563
   Lee E. Y., 2011, ACTA DIABETOL, V2, P167
   Li W., 2008, NEUROLOGY, V19, P1753
   Liu H., 2008, RAPID COMMUN MASS SP, V1, P1
   Luftig MA, 2006, NAT STRUCT MOL BIOL, V13, P740, DOI 10.1038/nsmb1127
   Masuda K, 2006, FEBS J, V273, P2184, DOI 10.1111/j.1742-4658.2006.05232.x
   Mian I. S., 1991, J MOL BIOL, V1, P133
   Nuriel T., 2011, J PROTEOMICS, V11, P2300
   Ohno S., 1985, P NATL ACAD SCI USA, V9, P2945
   Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200
   Pejchal R., 2010, P NATL ACAD SCI USA, V25, P11483
   Perreau M., 2013, CURR OPIN HIV AIDS, V4, P333
   Petre B. A., 2012, J AM SOC MASS SPECTR, V11, P1831
   Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101
   Rebrin I, 2007, BIOCHEMISTRY-US, V46, P10130, DOI 10.1021/bi7001482
   Scharf L., 2013, P NATL ACAD SCI USA, V15, P6049
   Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957
   Siclunann A., 2002, J CHROMATOGR B, V1-2, P167
   Steiner J, 2006, ANTIOXID REDOX SIGN, V8, P2089, DOI 10.1089/ars.2006.8.2089
   Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222
   Toborek M, 2005, CELL MOL NEUROBIOL, V25, P181, DOI 10.1007/s10571-004-1383-x
   Uzasci L., 2013, J NEUROIMMUNE PHARM, V5, P1167
   Wan J., 2012, PLOS ONE, V4
   Wei Z., 2007, ANAL CHEM, V7, P2797
   Yamakura F, 2006, NITRIC OXIDE-BIOL CH, V14, P152, DOI 10.1016/j.niox.2005.07.009
   Zemlin M, 2003, J MOL BIOL, V334, P733, DOI 10.1016/j/jmb.2003.10.007
NR 49
TC 5
Z9 5
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR
PY 2014
VL 13
IS 3
BP 1614
EP 1623
DI 10.1021/pr401117m
PG 10
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA AC8AV
UT WOS:000332756300040
PM 24479669
OA gold
DA 2018-01-05
ER

PT J
AU Sagar, V
   Pilakka-Kanthikeel, S
   Pottathil, R
   Saxena, SK
   Nair, M
AF Sagar, Vidya
   Pilakka-Kanthikeel, Sudheesh
   Pottathil, Ravi
   Saxena, Shailendra K.
   Nair, Madhavan
TI Towards nanomedicines for neuroAIDS
SO REVIEWS IN MEDICAL VIROLOGY
LA English
DT Review
ID BLOOD-BRAIN-BARRIER; HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE-DERIVED
   MACROPHAGES; SOLID LIPID NANOPARTICLES; CENTRAL-NERVOUS-SYSTEM; ANTI-HIV
   DRUGS; CEREBROSPINAL-FLUID; NEUROCOGNITIVE DISORDERS; ANTIRETROVIRAL
   THERAPY; METHYLMETHACRYLATE-SULFOPROPYLMETHACRYLATE
AB Although highly active antiretroviral therapy (HAART) has resulted in remarkable decline in the morbidity and mortality in AIDS patients, controlling HIV infections still remain a global health priority. HIV access to the CNS serves as the natural viral preserve because most antiretroviral (ARV) drugs possess inadequate or zero delivery across the brain barriers. Thus, development of target-specific, effective, safe, and controllable drug-delivery approach is an important health priority for global elimination of AIDS progression. Emergence of nanotechnology in medicine has shown exciting prospect for development of novel drug delivery systems to administer the desired therapeutic levels of ARV drugs in the CNS. Neuron-resuscitating and/or antidependence agents may also be delivered in the brain through nanocarriers to countercheck the rate of neuronal degradation during HIV infection. Several nanovehicles such as liposomes, dendrimers, polymeric nanoparticles, micelles, and solid lipid nanoparticles have been intensively explored. Recently, magnetic nanoparticles and monocytes/macrophages have also been used as carrier to improve the delivery of nanoformulated ARV drugs across the blood-brain barrier. Nevertheless, more rigorous research homework has to be elucidated to sort out the shortcomings that affect the target specificity, delivery, release, and/or bioavailability of desired amount of drugs for treatment of neuroAIDS. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Sagar, Vidya; Pilakka-Kanthikeel, Sudheesh; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Miami, FL 33199 USA.
   [Sagar, Vidya; Pilakka-Kanthikeel, Sudheesh; Pottathil, Ravi; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Miami, FL 33199 USA.
   [Saxena, Shailendra K.] CSIR, Ctr Cellular & Mol Biol, Hyderabad, Andhra Pradesh, India.
RP Nair, M (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Miami, FL 33199 USA.
EM nairm@fiu.edu
OI Saxena, Shailendra K/0000-0003-2856-4185
FU National Institute on Drug Abuse [R01DA027049, R37DA025576]
FX This work was supported in part by grants R01DA027049 and R37DA025576
   from the National Institute on Drug Abuse.
CR AIDSinfo-NIH, 2012, HIV ITS TREATM FDA A
   Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   An Shu F., 1997, Archives d'Anatomie et de Cytologie Pathologiques, V45, P94
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Apetrei C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002892
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   Boven LA, 2000, J NEUROVIROL, V6, P382, DOI 10.3109/13550280009018302
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI 10.2217/NNM.10.7
   Carvalho FC, 2011, UNDERSTANDING HIV AI, P367
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chaughule RS, 2012, P NATL A SCI INDIA A, V82, P257, DOI 10.1007/s40010-012-0038-4
   Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250
   Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481
   Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0                         
   de Almeida Sergio Monteiro, 2006, Braz J Infect Dis, V10, P41, DOI 10.1590/S1413-86702006000100009
   Deeks SG, 2012, NAT REV IMMUNOL, V12, P607, DOI 10.1038/nri3262
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dzmitruk V., 2011, ADV NANOCOMPOSITE TE
   El-Hage N, 2005, GLIA, V50, P91, DOI 10.1002/glia.20148
   Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005
   Ferris MJ, 2008, NEUROSCI BIOBEHAV R, V32, P883, DOI 10.1016/j.neubiorev.2008.01.004
   Ghafouri M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-28
   Gray F, 1996, BRAIN PATHOL, V6, P1, DOI 10.1111/j.1750-3639.1996.tb00775.x                                              
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Hau VS, 2005, THESIS U ARIZONA
   Hauser KF, 2005, NEUROTOX RES, V8, P63, DOI 10.1007/BF03033820                                                              
   Hauser KF, 2007, J NEUROCHEM, V100, P567, DOI 10.1111/j.1471-4159.2006.04227.x
   Holt JL, 2012, J NEUROVIROL, V18, P291, DOI 10.1007/s13365-012-0114-1
   Ikehara Y, 2006, CANCER RES, V66, P8740, DOI 10.1158/0008-5472.CAN-06-0470
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Jaeger LB, 2012, DIS MODEL MECH, V5, P313, DOI 10.1242/dmm.008763
   Jain S, 2003, INT J PHARM, V261, P43, DOI 10.1016/S0378-5173(03)00269-2
   Jain TK, 2008, MOL PHARM, V5, P316, DOI 10.1021/mp7001285
   Jin SX, 2005, PHARMAZIE, V60, P840
   Johanson CE, 2011, METHODS MOL BIOL, V686, P101, DOI 10.1007/978-1-60761-938-3_4
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   KIM S, 1990, J INFECT DIS, V162, P750, DOI 10.1093/infdis/162.3.750                                                        
   Kozal MJ, 2009, CLIN MICROBIOL INFEC, V15, P69, DOI 10.1111/j.1469-0691.2008.02687.x
   Kramer-Hammerle S, 2005, VIRUS RES, V111, P194, DOI 10.1016/j.virusres.2005.04.009
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Letendre Scott L, 2009, Top HIV Med, V17, P46
   Liu Y, 2010, NATURAL SCI, V2, P41
   Lu J., 2012, J EXP INTEGR MED, V2, P39
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4                                                   
   Mcgee B, 2006, HIV CLIN TRIALS, V7, P142, DOI 10.1310/AW2H-TP5C-NP43-K6BY                                                     
   Naik P, 2012, J PHARM SCI-US, V101, P1337, DOI 10.1002/jps.23022
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Nair MPN, 2011, NEUROLOGY AIDS, P999
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   OMAR RF, 1995, ANTIMICROB AGENTS CH, V39, P1973, DOI 10.1128/AAC.39.9.1973                                                           
   Pan Y, 2012, CHEM SOC REV, V41, P2912, DOI 10.1039/c2cs15315g
   Pardridge WM, 2001, BRAIN DRUG TARGETING
   Pereira de Oliveira M, 2005, PHARM RES-DORDR, V22, P1898, DOI 10.1007/s11095-005-7147-6
   Persidsky Y, 2006, BLOOD, V107, P4770, DOI 10.1182/blood-2005-11-4721
   PETERSON PK, 1993, ADV EXP MED BIOL, V335, P181
   Peterson PK, 1999, NEUROPHARMACOLOGY, V38, P273, DOI 10.1016/S0028-3908(98)00167-1
   Peterson PK, 1998, J NEUROIMMUNOL, V83, P63, DOI 10.1016/S0165-5728(97)00222-1                                                   
   Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Reddy PVB, 2012, AIDS RES TREATMENT, V2011
   Reynolds JL, 2012, J NEUROIMMUNE PHARM, V7, P673, DOI 10.1007/s11481-012-9379-7
   Riddle EL, 2006, AAPS J, V8, pE413
   Rogers TJ, 2011, J NEUROIMMUNE PHARM, V6, P20, DOI 10.1007/s11481-010-9247-2
   Rogers TJ, 2000, ANN NY ACAD SCI, V917, P19
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Semete B, 2010, SMART BIOMOL MED, P15
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Singer EJ, 2010, NEUROL CLIN, V28, P253, DOI 10.1016/j.ncl.2009.09.018
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Sporer B, 1998, J INFECT DIS, V178, P854, DOI 10.1086/515342                                                                  
   Sun JB, 2011, J NANOMATER, DOI 10.1155/2011/469031
   Tombacz E., 2006, ROM REP PHYS, V58, P281
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI 10.2217/NNM.10.10
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vivithanaporn P, 2011, EXPERT REV ANTI-INFE, V9, P371, DOI [10.1586/eri.10.179, 10.1586/ERI.10.179]
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wilhelm I, 2011, ACTA NEUROBIOL EXP, V71, P113
   Williams R, 2008, J NEUROVIROL, V14, P292, DOI 10.1080/13550280802074539
   Wong HL, 2012, ADV DRUG DELIVER REV, V64, P686, DOI 10.1016/j.addr.2011.10.007
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Woods SP, 2009, NEUROPSYCHOL REV, V19, P152, DOI 10.1007/s11065-009-9102-5
   Zhang XB, 2003, J DRUG TARGET, V11, P117, DOI 10.1080/1061186031000115150
   Zhang Z., 2010, THESIS FIU
NR 96
TC 27
Z9 27
U1 1
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1052-9276
EI 1099-1654
J9 REV MED VIROL
JI Rev. Med. Virol.
PD MAR
PY 2014
VL 24
IS 2
BP 103
EP 124
DI 10.1002/rmv.1778
PG 22
WC Virology
SC Virology
GA AD0VI
UT WOS:000332951900004
PM 24395761
OA green_accepted
DA 2018-01-05
ER

PT J
AU Agrahari, V
   Zhang, C
   Zhang, T
   Li, WJ
   Gounev, TK
   Oyler, NA
   Youan, BBC
AF Agrahari, Vivek
   Zhang, Chi
   Zhang, Tao
   Li, Wenjing
   Gounev, Todor K.
   Oyler, Nathan A.
   Youan, Bi-Botti C.
TI Hyaluronidase-Sensitive Nanoparticle Templates for Triggered Release of
   HIV/AIDS Microbicide In Vitro
SO AAPS JOURNAL
LA English
DT Article
DE experimental design; hyaluronic acid; hyaluronidase; microbicide;
   nanoparticles
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV PREVENTION; TESTICULAR HYALURONIDASE;
   AQUEOUS-SOLUTION; DRUG-RELEASE; HUMAN SEMEN; GEL BEADS; TENOFOVIR; ACID;
   PH
AB This study was designed to test the hypothesis that a triggered release of a topical microbicide (tenofovir) from hyaluronic acid nanoparticles (HA-NPs) can be achieved under the influence of hyaluronidase (HAase) enzyme. A fractional factorial experimental design was used to examine the factors [molar concentrations of adipic acid dihydrazide (X-1) and 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (X-2), volume of acetone (X-3) and reaction time (X-4)] influencing the responses, Y-1; particle mean diameter: PMD (nanometers: nm), Y-2; polydispersity index: PDI and Y-3; zeta (zeta) potential: (millivolts). The amide bond formation between HA and ADH after cross-linking was confirmed by FT-IR and C-13-NMR analyses. These NPs were also characterized for cytotoxicity on a human vaginal epithelial cell line and L. crispatus. When formulated with factors X-1; 2.49 mM, X-2; 9.96 mM, X-3; 60 mL, X-4; 6 h, HA-NPs exhibited a spherical shape with PMD, PDI, zeta potential, encapsulation efficiency, and drug loading of 70.6 +/- 4.1 nm, 0.07 +/- 0.02, -38.2 +/- 2.8 mV, 51.8 +/- 2.4% w/w and 26.1 +/- 1.2% w/w, respectively, (n=3). Unlike for HA based gel, HAase significantly triggered the drug release and HA degradation from the NPs after 24 h (similar to 90% w/w and 65% w/w, respectively); whereas, in its absence, these values were similar to 39% w/w and 26% w/w, respectively. The NPs were non-cytotoxic to human vaginal VK2/E6E7, End1/E6E7 cells and Lactobacillus crispatus. These data highlight the potential of HAase-sensitive HA-NPs templates for the controlled and vaginal delivery of anti-HIV/AIDS microbicides.
C1 [Agrahari, Vivek; Zhang, Tao; Youan, Bi-Botti C.] Univ Missouri, Lab Future Nanomed & Theoret Chronopharmaceut, Div Pharmaceut Sci, Sch Pharm, Kansas City, MO 64108 USA.
   [Zhang, Chi; Li, Wenjing; Gounev, Todor K.; Oyler, Nathan A.] Univ Missouri, Dept Chem, Kansas City, MO 64110 USA.
RP Youan, BBC (reprint author), Univ Missouri, Lab Future Nanomed & Theoret Chronopharmaceut, Div Pharmaceut Sci, Sch Pharm, 2464 Charlotte St, Kansas City, MO 64108 USA.
EM youanb@umkc.edu
RI Zhang, Tao/G-1312-2014
FU National Institute of Allergy and Infectious Diseases (Bethesda, MD,
   USA) [R01AI087304]
FX The project was supported by Award Number R01AI087304 from the National
   Institute of Allergy and Infectious Diseases (Bethesda, MD, USA). The
   content is the sole responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Allergy and Infectious Diseases or the National Institutes of Health. We
   gratefully acknowledge Mr. Jack Liu (Zhenjiang Dong Yuan Biotech Co.,
   Ltd., Jiangsu, China) for providing the samples of hyaluronic acid. We
   are thankful to Dr. Vladimir M. Dusevich (School of Dentistry,
   University of Missouri-Kansas City, Kansas City, MO, USA) for his
   valuable help in TEM analysis.
CR Agrahari V, 2012, AAPS PHARMSCITECH, V13, P202, DOI 10.1208/s12249-011-9735-6
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Bajaj G, 2012, J CONTROL RELEASE, V158, P386, DOI 10.1016/j.jconrel.2011.12.001
   BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Chouhan R., 2009, J NANOBIOTECHNOL, V7, P1
   Cooper TG, 2010, HUM REPROD UPDATE, V16, P231, DOI 10.1093/humupd/dmp048
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X
   D'Cruz OJ, 2004, CURR PHARM DESIGN, V10, P315, DOI 10.2174/1381612043386374
   De Iaco PA, 2001, SURGERY, V130, P60, DOI 10.1067/msy.2001.115102
   Deng Y, 2007, POLYM INT, V56, P738, DOI 10.1002/pi.2197
   DESALEGU.M, 1967, ARCH BIOCHEM BIOPHYS, V121, P548, DOI 10.1016/0003-9861(67)90037-9
   Dezzutti CS, 2012, ANTIVIR RES, V96, P221, DOI 10.1016/j.antiviral.2012.08.004
   Ferir G, 2011, ANTIVIR RES, V90, P200, DOI 10.1016/j.antiviral.2011.03.188
   FOX CA, 1973, J REPROD FERTIL, V33, P69
   Galindo-Rodriguez S, 2004, PHARM RES, V21, P1428, DOI 10.1023/B:PHAM.0000036917.75634.be
   Grammen C, 2012, ANTIVIR RES, V96, P226, DOI 10.1016/j.antiviral.2012.09.011
   Gupta KM, 2007, J PHARM SCI-US, V96, P670, DOI 10.1002/jps.20752
   Hackley V. A., 2001, USE NOMENCLATURE DIS
   Haynes BF, 2008, J ALLERGY CLIN IMMUN, V122, P3, DOI 10.1016/j.jaci.2008.03.036
   HIGHSMITH S, 1975, J BIOL CHEM, V250, P7473
   Honda T, 2012, BIOMOLECULES, V2, P549, DOI 10.3390/biom2040549
   Katzel U, 2008, PART PART SYST CHAR, V25, P19, DOI 10.1002/ppsc.200700005
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289                                                           
   Komei M, 1959, Activation of hyaluronidase by spermine and related diamines, V7, P123, Patent No. [2,012,089,537, 2012089537]
   KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153                                                               
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lenormand H, 2011, CARBOHYD POLYM, V85, P303, DOI 10.1016/j.carbpol.2011.02.007
   LOWRY KM, 1994, J BIOMED MATER RES, V28, P1239, DOI 10.1002/jbm.820281014
   Ma Xiaowei, 2010, AAPS J, V12, P272, DOI 10.1208/s12248-010-9187-z
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Minaberry Y, 2013, BIOMACROMOLECULES, V14, P1, DOI 10.1021/bm300814h
   Mizrahy S, 2011, J CONTROL RELEASE, V156, P231, DOI 10.1016/j.jconrel.2011.06.031
   Moebus K, 2009, EUR J PHARM BIOPHARM, V72, P42, DOI 10.1016/j.ejpb.2008.12.004
   Montgomery D. C, 2005, DESIGN ANAL EXPT
   Oh EJ, 2010, J CONTROL RELEASE, V141, P2, DOI 10.1016/j.jconrel.2009.09.010
   Omar RF, 2011, INT J INFECT DIS, V15, pE656, DOI 10.1016/j.ijid.2011.05.001
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Pitarresi G, 2007, BIOMACROMOLECULES, V8, P1890, DOI 10.1021/bm070224a
   Prestwich GD, 2011, J CONTROL RELEASE, V155, P193, DOI 10.1016/j.jconrel.2011.04.007
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Schante CE, 2011, CARBOHYD POLYM, V85, P469, DOI 10.1016/j.carbpol.2011.03.019
   Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850                                                          
   Sriamornsak P, 2010, AAPS PHARMSCITECH, V11, P1315, DOI 10.1208/s12249-010-9513-x
   Sriamornsak P, 2010, CARBOHYD POLYM, V79, P219, DOI 10.1016/j.carbpol.2009.07.059
   Stern R, 2007, BIOTECHNOL ADV, V25, P537, DOI 10.1016/j.biotechadv.2007.07.001
   Su WY, 2010, ACTA BIOMATER, V6, P3044, DOI 10.1016/j.actbio.2010.02.037
   SUGRUE S, 1992, AM LAB, V24, P64
   SWYER GIM, 1947, BIOCHEM J, V41, P409, DOI 10.1042/bj0410409                                                               
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Vernasca C, 2012, WO Patent, Patent No. [7,601,704 B2, 7601704B2, 2,012,089,537]
   WAGNER G, 1982, ANN INTERN MED, V96, P921, DOI 10.7326/0003-4819-96-6-921
   Zhang GZ, 2001, ACCOUNTS CHEM RES, V34, P249, DOI 10.1021/ar000011x
   Zhang T, 2013, ANTIVIR RES, V97, P334, DOI 10.1016/j.antiviral.2012.12.019
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhang T, 2011, J PHARM SCI-US, V100, P1031, DOI 10.1002/jps.22341
   Zhang YZ, 2010, EUR J PHARM BIOPHARM, V76, P17, DOI 10.1016/j.ejpb.2010.05.010
   ZHONG SP, 1994, BIOMATERIALS, V15, P359, DOI 10.1016/0142-9612(94)90248-8
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 65
TC 21
Z9 21
U1 2
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD MAR
PY 2014
VL 16
IS 2
BP 181
EP 193
DI 10.1208/s12248-013-9546-7
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AC1AD
UT WOS:000332225700001
PM 24343770
OA green_published
DA 2018-01-05
ER

PT J
AU McDonald, TO
   Giardiello, M
   Martin, P
   Siccardi, M
   Liptrott, NJ
   Smith, D
   Roberts, P
   Curley, P
   Schipani, A
   Khoo, SH
   Long, J
   Foster, AJ
   Rannard, SP
   Owen, A
AF McDonald, Tom O.
   Giardiello, Marco
   Martin, Philip
   Siccardi, Marco
   Liptrott, Neill J.
   Smith, Darren
   Roberts, Phill
   Curley, Paul
   Schipani, Alessandro
   Khoo, Saye H.
   Long, James
   Foster, Alison J.
   Rannard, Steven P.
   Owen, Andrew
TI Antiretroviral Solid Drug Nanoparticles with Enhanced Oral
   Bioavailability: Production, Characterization, and In Vitro-In Vivo
   Correlation
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bioavailability; drug nanoparticles; HIV; nanodispersions; pharmacology
ID REVERSE-TRANSCRIPTASE INHIBITORS; POLYMERIC MICELLES; PHARMACEUTICAL
   EXCIPIENTS; ORGANIC NANOPARTICLES; CATALYTIC-ACTIVITY; DOSE REDUCTION;
   EFAVIRENZ; HIV; DELIVERY; EXPRESSION
AB Nanomedicine strategies have produced many commercial products. However, no orally dosed HIV nanomedicines are available clinically to patients. Although nanosuspensions of drug particles have demonstrated many benefits, experimentally achieving >25 wt% of drug relative to stabilizers is highly challenging. In this study, the emulsion-templated freeze-drying technique for nanoparticles formation is applied for the first time to optimize a nanodispersion of the leading non-nucleoside reverse transcriptase inhibitor efavirenz, using clinically acceptable polymers and surfactants. Dry monoliths containing solid drug nanoparticles with extremely high drug loading (70 wt% relative to polymer and surfactant stabilizers) are stable for several months and reconstitute in aqueous media to provide nanodispersions with z-average diameters of 300 nm. The solid drug nanoparticles exhibit reduced cytoxicity and increased in vitro transport through model gut epithelium. In vivo studies confirm bioavailability benefits with an approximately four-fold higher pharmacokinetic exposure after oral administration to rodents, and predictive modeling suggests dose reduction with the new formulation may be possible.
C1 [McDonald, Tom O.; Giardiello, Marco; Rannard, Steven P.] Univ Liverpool, Dept Chem, Liverpool L69 3BX, Merseyside, England.
   [Martin, Philip; Siccardi, Marco; Liptrott, Neill J.; Smith, Darren; Roberts, Phill; Curley, Paul; Schipani, Alessandro; Khoo, Saye H.; Owen, Andrew] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GF, Merseyside, England.
   [Long, James; Foster, Alison J.] IOTA NanoSolut Ltd, Liverpool L69 7ZB, Merseyside, England.
RP Rannard, SP (reprint author), Univ Liverpool, Dept Chem, Crown St, Liverpool L69 3BX, Merseyside, England.
EM srannard@liv.ac.uk; aowen@liverpool.ac.uk
RI Giardiello, Marco/K-6703-2016; Owen, Andrew/M-7509-2017; McDonald,
   Tom/H-1294-2011
OI Giardiello, Marco/0000-0003-0560-4711; Owen, Andrew/0000-0002-9819-7651;
   McDonald, Tom/0000-0002-9273-9173; Liptrott, Neill/0000-0002-5980-8966;
   Curley, Paul/0000-0003-4596-2708; Rannard, Steve/0000-0002-6946-1097
FU Research Councils UK [EP/G066272/1]; Engineering and Physical Sciences
   Research Council [EP/K002201/1]; Medical Research Council [G0800247]
FX The authors thank the Centre for Materials Discovery at the University
   of Liverpool for assistance. This work was supported by a Research
   Councils UK Grand Challenge: Nanotechnology for Healthcare grant
   (EP/G066272/1) and an Engineering and Physical Sciences Research Council
   grant (EP/K002201/1). Model systems utilized within the project were
   developed as part of funding from the Medical Research Council
   (G0800247).
CR Apostolova N, 2011, HEPATOLOGY, V54, P1009, DOI 10.1002/hep.24459
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Balani SK, 1999, DRUG METAB DISPOS, V27, P41
   Bawa R., 2008, NANOTECHNOL LAW BUSI, P135
   Borlak J, 2003, XENOBIOTICA, V33, P927, DOI 10.1080/00498250310001614286
   Bosgra S, 2012, CRIT REV TOXICOL, V42, P751, DOI 10.3109/10408444.2012.709225
   Branco MC, 2009, ACTA BIOMATER, V5, P817, DOI 10.1016/j.actbio.2008.09.018
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Bromberg L, 2008, J CONTROL RELEASE, V128, P99, DOI 10.1016/j.jconrel.2008.01.018
   Chadha R, 2012, J PHARM PHARM SCI, V15, P234, DOI 10.18433/J3J30Z                                                                 
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Crewe HK, 2011, BIOPHARM DRUG DISPOS, V32, P303, DOI 10.1002/bdd.760
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   De Jong WH, 2008, INT J NANOMED, V3, P133
   Deschamps B, 2009, INT J NANOMED, V4, P185
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Duncan R, 2011, CURR OPIN BIOTECH, V22, P492, DOI 10.1016/j.copbio.2011.05.507
   Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002
   Gaucher G, 2010, EUR J PHARM BIOPHARM, V76, P147, DOI 10.1016/j.ejpb.2010.06.007
   Gutierrez F, 2005, CLIN INFECT DIS, V41, P1648, DOI 10.1086/497835
   Horn D, 2001, ANGEW CHEM INT EDIT, V40, P4331
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kedar U, 2010, NANOMED-NANOTECHNOL, V6, P714, DOI 10.1016/j.nano.2010.05.005
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Liu P, 2011, INT J PHARMACEUT, V411, P215, DOI 10.1016/j.ijpharm.2011.03.050
   Maggiolo F, 2009, J ANTIMICROB CHEMOTH, V64, P910, DOI 10.1093/jac/dkp334
   Manfredi R, 2005, JAIDS-J ACQ IMM DEF, V38, P236, DOI 10.1097/01.qai.0000143037.70120.fc
   Martin P, 2008, BRIT J PHARMACOL, V153, P805, DOI 10.1038/sj.bjp.0707601
   Martin P, 2013, MOL PHARMACEUT, V10, P2739, DOI 10.1021/mp400175n
   McDonald TO, 2012, ADV FUNCT MATER, V22, P2469, DOI 10.1002/adfm.201103059
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Obach RS, 1999, DRUG METAB DISPOS, V27, P1350
   Ohtsuki S, 2012, DRUG METAB DISPOS, V40, P83, DOI 10.1124/dmd.111.042259
   Peltonen L, 2010, J PHARM PHARMACOL, V62, P1569, DOI 10.1111/j.2042-7158.2010.01022.x
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Poulin P, 2002, J PHARM SCI, V91, P129, DOI 10.1002/jps.10005
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Sax PE, 2009, NEW ENGL J MED, V360, P1897, DOI 10.1056/NEJMe0902713
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Siccardi M, 2012, CLIN PHARMACOL THER, V92, P494, DOI 10.1038/clpt.2012.61
   Siccardi M, 2013, CLIN PHARMACOKINET, V52, P583, DOI 10.1007/s40262-013-0056-7
   Stormer E, 2002, PHARMACEUT RES, V19, P1038, DOI 10.1023/A:1016430825740
   Taipalensuu J, 2001, J PHARMACOL EXP THER, V299, P164
   Tashima KT, 2003, HIV CLIN TRIALS, V4, P29
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vento S, 2013, TROP MED INT HEALTH, V18, P40, DOI 10.1111/tmi.12008
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Wang GD, 2011, CURR OPIN CHEM ENG, V1, P1
   Ward BA, 2003, J PHARMACOL EXP THER, V306, P287, DOI 10.1124/jpet.103.049601
   WHO UNICEF, 2011, PROGRESS REPORT 2011
   Wyen C, 2008, J ANTIMICROB CHEMOTH, V61, P914, DOI 10.1093/jac/dkn029
   Yamagata T, 2007, J CONTROL RELEASE, V124, P1, DOI 10.1016/j.jconrel.2007.08.021
   Yamagata T, 2009, INT J PHARMACEUT, V370, P216, DOI 10.1016/j.ijpharm.2008.12.005
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   Yu LX, 1999, INT J PHARM, V186, P119, DOI 10.1016/S0378-5173(99)00147-7                                                   
   Zhang HF, 2008, NAT NANOTECHNOL, V3, P506, DOI 10.1038/nnano.2008.188
   Zhang HB, 2011, EXPERT OPIN DRUG DEL, V8, P171, DOI 10.1517/17425247.2011.547470
NR 69
TC 23
Z9 23
U1 2
U2 62
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD MAR
PY 2014
VL 3
IS 3
BP 400
EP 411
DI 10.1002/adhm.201300280
PG 12
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA AC2MW
UT WOS:000332336400012
PM 23997027
DA 2018-01-05
ER

PT J
AU Rai, M
   Kon, K
   Ingle, A
   Duran, N
   Galdiero, S
   Galdiero, M
AF Rai, Mahendra
   Kon, Kateryna
   Ingle, Avinash
   Duran, Nelson
   Galdiero, Stefania
   Galdiero, Massimiliano
TI Broad-spectrum bioactivities of silver nanoparticles: the emerging
   trends and future prospects
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review
DE Silver nanoparticles; Bioactivity; Antimicrobial; Antiarthropod;
   Anticancer
ID ANOPHELES-STEPHENSI LISTON; CELL-ASSOCIATED HIV-1; HERPES-SIMPLEX-VIRUS;
   OF-THE-ART; IN-VITRO; ANTIFUNGAL ACTIVITY; ESCHERICHIA-COLI;
   ANTIBACTERIAL PROPERTIES; CUTANEOUS LEISHMANIASIS; ANTIMICROBIAL
   ACTIVITY
AB There are alarming reports of growing microbial resistance to all classes of antimicrobial agents used against different infections. Also the existing classes of anticancer drugs used against different tumours warrant the urgent search for more effective alternative agents for treatment. Broad-spectrum bioactivities of silver nanoparticles indicate their potential to solve many microbial resistance problems up to a certain extent. The antibacterial, antifungal, antiviral, antiprotozoal, acaricidal, larvicidal, lousicidal and anticancer activities of silver nanoparticles have recently attracted the attention of scientists all over the world. The aim of the present review is to discuss broad-spectrum multifunctional activities of silver nanoparticles and stress their therapeutic potential as smart nanomedicine. Much emphasis has been dedicated to the antimicrobial and anticancer potential of silver nanoparticles showing their promising characteristics for treatment, prophylaxis and control of infections, as well as for diagnosis and treatment of different cancer types.
C1 [Rai, Mahendra; Ingle, Avinash] Sant Gadge Baba Amravati Univ, Dept Biotechnol, Amravati 444602, Maharashtra, India.
   [Kon, Kateryna] Kharkiv Natl Med Univ, Dept Microbiol Virol & Immunol, Kharkov, Ukraine.
   [Duran, Nelson] Univ Fed ABC, Ctr Nat & Human Sci, Santo Andre, SP, Brazil.
   [Rai, Mahendra; Duran, Nelson] Univ Estadual Campinas, Inst Quim, Biol Chem Lab, Campinas, SP, Brazil.
   [Galdiero, Stefania] Univ Naples Federico II, Dept Pharm, I-80134 Naples, Italy.
   [Galdiero, Massimiliano] Univ Naples Federico II, Dept Expt Med 2, Div Microbiol, I-80138 Naples, Italy.
   [Galdiero, Stefania; Galdiero, Massimiliano] Univ Naples Federico II, CIRPEB, I-80134 Naples, Italy.
   [Galdiero, Stefania; Galdiero, Massimiliano] Ist Biostrutture & Bioimmagini, CNR, I-80134 Naples, Italy.
RP Rai, M (reprint author), Sant Gadge Baba Amravati Univ, Dept Biotechnol, Amravati 444602, Maharashtra, India.
EM mahendrarai@sgbau.ac.in
OI galdiero, stefania/0000-0002-7849-7024; Rai,
   Mahendra/0000-0003-0291-0422
CR Abebe L, 2012, CGH S 1 OCT 2012
   Abraham I, 2012, MAR DRUGS, V10, P2312, DOI 10.3390/md10102312
   ADHIKARI U, 2013, ASIAN PAC J TROP DIS, V3, P167, DOI DOI 10.1016/S2222-1808(13)60033-X
   Allahverdiyev AM, 2011, INT J NANOMED, V6, P2705, DOI 10.2147/IJN.S23883
   Allahverdiyev AM, 2011, EXPERT REV ANTI-INFE, V9, P1035, DOI [10.1586/eri.11.121, 10.1586/ERI.11.121]
   Allahverdiyev AM, 2011, FUTURE MICROBIOL, V6, P933, DOI [10.2217/FMB.11.78, 10.2217/fmb.11.78]
   Banerjee M, 2010, LANGMUIR, V26, P5901, DOI 10.1021/la9038528
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Bawaskar M, 2010, CURR NANOSCI, V6, P376, DOI 10.2174/157341310791658919                                                      
   Bhattacharyya Soumya Sundar, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P546
   Birla SS, 2009, LETT APPL MICROBIOL, V48, P173, DOI 10.1111/j.1472-765X.2008.02510.x
   Bonde SR, 2012, NANOSCI METH, V1, P25, DOI DOI 10.1080/17458080.2010.529172
   Conde J, 2012, J DRUG DELIV, DOI 10.1155/2012/751075
   Dar MA, 2013, NANOMED-NANOTECHNOL, V9, P105, DOI 10.1016/j.nano.2012.04.007
   De Gusseme B, 2010, APPL ENVIRON MICROB, V76, P1082, DOI 10.1128/AEM.02433-09
   de Lima R, 2012, J APPL TOXICOL, V32, P867, DOI 10.1002/jat.2780
   De-Lima R, 2013, J PHYS C SERIES, V429
   Devi Lamabam Sophiya, 2012, Mycobiology, V40, P27, DOI 10.5941/MYCO.2012.40.1.027
   Duran N, 2013, INT J FOOD SCI TECH, V48, P1127, DOI 10.1111/ijfs.12027
   Duran N, 2010, J BRAZIL CHEM SOC, V21, P949, DOI 10.1590/S0103-50532010000600002
   Duran N, 2009, CURR NANOSCI, V5, P396, DOI 10.2174/157341309789378069                                                      
   Durand R, 2012, CLIN MICROBIOL INFEC, V18, P338, DOI 10.1111/j.1469-0691.2012.03806.x
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Elliott Chris, 2010, Br J Nurs, V19, pS32
   Fall B, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-107
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   Gade A, 2010, CURR NANOSCI, V6, P370, DOI 10.2174/157341310791659026                                                      
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   Gajbhiye M. B., 2009, NANOMED-NANOTECHNOL, V5, P282, DOI DOI 10.1016/J.NANO.2009.01.002
   Galdiero S, 2014, FRONTIERS NANOMEDICA
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Howard CR, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.47
   Ingle A, 2008, CURR NANOSCI, V4, P141, DOI 10.2174/157341308784340804                                                      
   Ingle A, 2009, J NANOPART RES, V11, P2079, DOI 10.1007/s11051-008-9573-y
   Jacob SJP, 2012, COLLOID SURFACE B, V91, P212, DOI 10.1016/j.colsurfb.2011.11.001
   Jaidev LR, 2010, COLLOID SURFACE B, V81, P430, DOI 10.1016/j.colsurfb.2010.07.033
   Jain KK, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-83
   Jayaseelan C, 2012, PARASITOL RES, V111, P1369, DOI 10.1007/s00436-011-2559-1
   Jayaseelan C, 2012, PARASITOL RES, V111, P921, DOI 10.1007/s00436-011-2473-6
   Jeyaraj M, 2013, COLLOID SURFACE B, V102, P708, DOI 10.1016/j.colsurfb.2012.09.042
   Jo YK, 2009, PLANT DIS, V93, P1037, DOI 10.1094/PDIS-93-10-1037
   Johnson AP, 2011, J ANTIMICROB CHEMOTH, V66, pIV43, DOI 10.1093/jac/dkr076
   Johnson Victoria A, 2013, Top Antivir Med, V21, P6
   Kamareddine L, 2012, TOXINS, V4, P748, DOI 10.3390/toxins4090748
   Kandile NG, 2010, B KOREAN CHEM SOC, V31, P3530, DOI 10.5012/bkcs.2010.31.12.3530
   Kaur P, 2012, INT J SCI TECHNOL RE, V1, P83
   Kilpatrick AM, 2012, LANCET, V380, P1946, DOI 10.1016/S0140-6736(12)61151-9
   Kim KJ, 2008, J MICROBIOL BIOTECHN, V18, P1482
   Kim KJ, 2009, BIOMETALS, V22, P235, DOI 10.1007/s10534-008-9159-2
   KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Liu HL, 2010, INT J NANOMED, V5, P1017, DOI 10.2147/IJN.S14572
   Lu L, 2008, ANTIVIR THER, V13, P253
   Marr AK, 2012, FUTURE MICROBIOL, V7, P1047, DOI [10.2217/fmb.12.85, 10.2217/FMB.12.85]
   Marsich E, 2013, ACTA BIOMATER, V9, P5088, DOI 10.1016/j.actbio.2012.10.002
   Mehrbod P, 2009, DARU, V17, P88
   Misra R, 2010, DRUG DISCOV TODAY, V15, P842, DOI 10.1016/j.drudis.2010.08.006
   Mohebali M, 2009, DARU, V17, P285
   MURRAY HW, 1981, J EXP MED, V153, P1302, DOI 10.1084/jem.153.5.1302
   Murugan K, 2013, GREEN SYNTHESIS SILV
   Narasimha G, 2012, J NANOSCI NANOTECHNO, V6, P18
   Nasrollahi A, 2011, INT J NANO DIMENS, V1, P233, DOI 10.7508/ijnd.2010.03.007
   Nilforoushzadeh MA, 2012, J VECTOR DIS, V49, P249
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Panneerselvam C., 2011, Archives of Applied Science Research, V3, P208
   Piao MJ, 2011, TOXICOL LETT, V201, P92, DOI 10.1016/j.toxlet.2010.12.010
   Ponarulselvam S., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P574, DOI 10.1016/S2221-1691(12)60100-2
   Prabhu D, 2013, PROCESS BIOCHEM, V48, P317, DOI 10.1016/j.procbio.2012.12.013
   Qiao WL, 2010, J NANOMATER, DOI 10.1155/2010/796303
   Raghavendra K, 2011, PARASITOL RES, V108, P757, DOI 10.1007/s00436-010-2232-0
   Raheman F, 2011, NANO BIOMED ENG, V3, P174, DOI DOI 10.5101/NBE.V3I3.P174-178
   Rai M, 2012, APPL MICROBIOL BIOT, V94, P287, DOI 10.1007/s00253-012-3969-4
   Rai M, 2012, J BRAZIL CHEM SOC, V23, P14, DOI 10.1590/S0103-50532012000100004
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rigo C, 2013, INT J MOL SCI, V14, P4817, DOI 10.3390/ijms14034817
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Rossi-Bergmann B, 2012, J NANO RES-SW, V20, P89, DOI 10.4028/www.scientific.net/JNanoR.20.89
   Said DE, 2012, PARASITOL RES, V111, P545, DOI 10.1007/s00436-012-2866-1
   Salunkhe RB, 2011, PARASITOL RES, V109, P823, DOI 10.1007/s00436-011-2328-1
   Satyavani Kaliyamurthi, 2012, Avicenna Journal of Medical Biotechnology, V4, P35
   Savithramma N., 2011, International Journal of ChemTech Research, V3, P1394
   Seigneuric R, 2010, CURR MOL MED, V10, P640, DOI 10.2174/156652410792630634                                                      
   Shameli K., 2012, CHEM CENT J, V27, P73
   Shio MT, 2010, J LEUKOCYTE BIOL, V88, P1, DOI 10.1189/jlb.0210088
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Sriram MI, 2010, INT J NANOMED, V5, P753, DOI 10.2147/IJN.S11727
   Su YH, 2012, ANN M AM EL SOC AES
   Subarani S, 2013, PARASITOL RES, V112, P487, DOI 10.1007/s00436-012-3158-5
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tile V. A., 2012, Journal of Environmental Research and Development, V7, P338
   Trefry JC, 2013, J BIOMED NANOTECHNOL, V9, P1624, DOI 10.1166/jbn.2013.1659
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Xu Y, 2013, J OCUL PHARMACOL TH, V29, P270, DOI 10.1089/jop.2012.0155
   Zhang HY, 2012, WATER RES, V46, P691, DOI 10.1016/j.watres.2011.11.037
   Zhang K, 2013, J BIOMED MATER RES B, V101B, P929, DOI 10.1002/jbm.b.32898
NR 99
TC 69
Z9 71
U1 5
U2 76
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD MAR
PY 2014
VL 98
IS 5
BP 1951
EP 1961
DI 10.1007/s00253-013-5473-x
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA AB9JB
UT WOS:000332107700003
PM 24407450
DA 2018-01-05
ER

PT J
AU Kim, MG
   Shon, Y
   Lee, J
   Byun, Y
   Choi, BS
   Kim, YB
   Oh, YK
AF Kim, Mi-Gyeong
   Shon, Yuna
   Lee, Jaiwoo
   Byun, Youngro
   Choi, Byeong-Sun
   Kim, Young Bong
   Oh, Yu-Kyoung
TI Double stranded aptamer-anchored reduced graphene oxide as
   target-specific nano detector
SO BIOMATERIALS
LA English
DT Article
DE Nano detectors; Graphene nanosheets; Aptamers; Rapid detection;
   Target-specificity; Target-sensitivity
ID RESONANCE ENERGY-TRANSFER; CDSE/ZNS QUANTUM DOTS; INTERFERON-GAMMA;
   FLOW-CYTOMETRY; FLUORESCENCE; DNA; BIOSENSOR; DNAZYME; IONS
AB Here, we report a double-stranded, dual-anchored, fluorescent aptamer on reduced graphene oxide (rGO) for the sensitive, selective, and speedy detection of a target protein in biological samples. This nano detector is composed of a target protein-specific fluorescent aptamer with BHQ1 as one anchoring moiety that forms double-stranded sequences with a complementary oligonucleotide sequence with BHQ1 as the other anchoring moiety, anchored to rGO nanosheets. The double-stranded and dual-anchored aptamer on rGO nanosheets (DAGO) exhibited 7.3-fold higher fluorescence intensities compared to a single-stranded, single-anchored fluorescent aptamer on rGO. As a model target protein, interferon-gamma was used. DAGO detected the target protein, with linearity over a five-orders-of-magnitude concentration range (0.1 ng/ml-10 mu g/ml) in buffer and human serum. DAGO was highly specific for the target protein, exhibiting little changes in fluorescence intensity in response to the non-target proteins, interleukin-2 and tumor necrosis factor-alpha. Moreover, DAGO allowed rapid quantification of the target protein in human immunodeficiency virus-positive patient serum samples. DAGO-based detection was complete in less than 10 min. Our results indicate that the DAGO provides new opportunities for the rapid and specific detection of target proteins in biological samples and could be widely applied to quantitate various target proteins by replacing the aptamer sequences. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Kim, Mi-Gyeong; Shon, Yuna; Oh, Yu-Kyoung] Seoul Natl Univ, Coll Pharm & Res, Inst Pharmaceut Sci, Seoul 151742, South Korea.
   [Lee, Jaiwoo; Byun, Youngro] Seoul Natl Univ, Grad Sch Convergence Sci, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea.
   [Choi, Byeong-Sun] Korea Natl Inst Hlth, Ctr Immunol & Pathol, Div Aids, Osong 363951, Chungcheongbuk, South Korea.
   [Kim, Young Bong] Konkuk Univ, Coll Anim Biosci & Technol, Dept Bioind Technol, Seoul 143701, South Korea.
RP Kim, YB (reprint author), Konkuk Univ, Coll Anim Biosci & Technol, Dept Bioind Technol, Seoul 143701, South Korea.
EM kimera@konkuk.ac.kr; ohyk@snu.ac.kr
RI BYUN, YOUNG RO/D-5735-2013; Oh, Yu Kyoung /G-8754-2013
FU Ministry of Science, ICT and Future Planning [2013K000264, 2013035166];
   Korean Health Technology R&D Project, Ministry for Health Welfare
   [A092010]; Bio & Medical Technology Development Program of the National
   Research Foundation; Korean government (MSIP) [2013036131]
FX This work was supported by research grants from the Ministry of Science,
   ICT and Future Planning (2013K000264; 2013035166), from the Korean
   Health Technology R&D Project (No. A092010), Ministry for Health &
   Welfare, and from the Bio & Medical Technology Development Program of
   the National Research Foundation funded by the Korean government (MSIP)
   (No. 2013036131).
CR Babendure JR, 2003, J AM CHEM SOC, V125, P14716, DOI 10.1021/ja037994o
   Balamurugan S, 2008, ANAL BIOANAL CHEM, V390, P1009, DOI 10.1007/s00216-007-1587-2
   Bjork J, 2010, J PHYS CHEM LETT, V1, P3407, DOI 10.1021/jz101360k
   Chang HX, 2010, ANAL CHEM, V82, P2341, DOI 10.1021/ac9025384
   Chen H, 2012, CHEM COMMUN, V48, P269, DOI 10.1039/c1cc16127j
   Dong HF, 2010, ANAL CHEM, V82, P5511, DOI 10.1021/ac100852z
   Freeman R, 2011, J AM CHEM SOC, V133, P11597, DOI 10.1021/ja202639m
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Huang Y, 2012, CHEM COMMUN, V48, P7480, DOI 10.1039/c2cc33021k
   Karlsson AC, 2003, J IMMUNOL METHODS, V283, P141, DOI 10.1016/j.jim.2003.09.001
   Kim J, 2010, J AM CHEM SOC, V132, P260, DOI 10.1021/ja906730d
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Lee PP, 1996, TRANSPLANTATION, V62, P1297, DOI 10.1097/00007890-199611150-00021
   Li M, 2013, BIOSENS BIOELECTRON, V43, P69, DOI 10.1016/j.bios.2012.11.039
   Liu Y, 2010, ANAL CHEM, V82, P8131, DOI 10.1021/ac101409t
   Lu CH, 2012, J AM CHEM SOC, V134, P10651, DOI 10.1021/ja3037838
   Miao W, 2013, BIOMATERIALS, V34, P3402, DOI 10.1016/j.biomaterials.2013.01.010
   Nutiu R, 2005, METHODS, V37, P16, DOI 10.1016/j.ymeth.2005.07.001
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Pelossof G, 2012, ANAL CHEM, V84, P3703, DOI 10.1021/ac3002269
   Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X
   Rao CNR, 2009, ANGEW CHEM INT EDIT, V48, P7752, DOI 10.1002/anie.200901678
   Romagnani S, 1996, CLIN IMMUNOL IMMUNOP, V80, P225, DOI 10.1006/clin.1996.0118
   Rotem D, 2012, J AM CHEM SOC, V134, P2781, DOI 10.1021/ja2105653
   Tuleuova N, 2010, ANAL CHEM, V82, P1851, DOI 10.1021/ac9025237
   Varghese N, 2009, CHEMPHYSCHEM, V10, P206, DOI 10.1002/cphc.200800459
   Zhao HM, 2013, MICROCHIM ACTA, V180, P829, DOI 10.1007/s00604-013-1006-7
NR 27
TC 14
Z9 14
U1 2
U2 100
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2014
VL 35
IS 9
BP 2999
EP 3004
DI 10.1016/j.biomaterials.2013.12.058
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AC0MH
UT WOS:000332188900043
PM 24418663
DA 2018-01-05
ER

PT J
AU Mahajan, HS
   Mahajan, MS
   Nerkar, PP
   Agrawal, A
AF Mahajan, Hitendra S.
   Mahajan, Milind S.
   Nerkar, Pankaj P.
   Agrawal, Anshuman
TI Nanoemulsion-based intranasal drug delivery system of saquinavir
   mesylate for brain targeting
SO DRUG DELIVERY
LA English
DT Article
DE CNS targeting; intranasal delivery; nanoemulsion; neuro-AIDS;
   saquinavir; mesylate
ID DIRECT TRANSPORT; NASAL CAVITY; RATS
AB The central nervous system (CNS) is an immunological privileged sanctuary site-providing reservoir for HIV-1 virus. Current anti-HIV drugs, although effective in reducing plasma viral levels, cannot eradicate the virus completely from the body. The low permeability of anti-HIV drugs across the blood-brain barrier (BBB) leads to insufficient delivery. Therefore, developing a novel approaches enhancing the CNS delivery of anti-HIV drugs are required for the treatment of neuro-AIDS. The aim of this study was to develop intranasal nanoemulsion (NE) for enhanced bioavailability and CNS targeting of saquinavir mesylate (SQVM). SQVM is a protease inhibitor which is a poorly soluble drug widely used as antiretroviral drug, with oral bioavailability is about 4%. The spontaneous emulsification method was used to prepare drug-loaded o/w nanoemulsion, which was characterized by droplet size, zeta potential, pH, drug content. Moreover, ex-vivo permeation studies were performed using sheep nasal mucosa. The optimized NE showed a significant increase in drug permeation rate compared to the plain drug suspension (PDS). Cilia toxicity study on sheep nasal mucosa showed no significant adverse effect of SQVM-loaded NE. Results of in vivo biodistribution studies show higher drug concentration in brain after intranasal administration of NE than intravenous delivered PDS. The higher percentage of drug targeting efficiency (% DTE) and nose-to-brain drug direct transport percentage (% DTP) for optimized NE indicated effective CNS targeting of SQVM via intranasal route. Gamma scintigraphy imaging of the rat brain conclusively demonstrated transport of drug in the CNS at larger extent after intranasal administration as NE.
C1 [Mahajan, Hitendra S.; Mahajan, Milind S.; Nerkar, Pankaj P.] RC Patel Inst Pharmaceut Educ & Res, Shirpur, India.
   [Agrawal, Anshuman] Shri Siddhivinayak Ganapati Canc Hosp, Miraj, India.
RP Mahajan, HS (reprint author), RC Patel Inst Pharmaceut Educ & Res, Dhule 425405, Maharashtra, India.
EM hsmahajan@rediffmail.com
FU AICTE (All India council for technical education, New Delhi, India)
   [8023/BOR/RID/RPS-133]
FX The authors report no conflicts of interest. The authors alone are
   responsible for the contents and writing of the article. Financial
   assistance from AICTE (All India council for technical education, New
   Delhi, India) under RPS research promotion scheme duly acknowledged
   (Grant No 8023/BOR/RID/RPS-133).
CR Bali V, 2010, COLLOID SURFACE B, V76, P410, DOI 10.1016/j.colsurfb.2009.11.021
   Chow HHS, 1999, J PHARM SCI, V88, P754
   Danielyan L, 2011, REJUV RES, V14, P3, DOI 10.1089/rej.2010.1130
   Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001
   Hanson LR, 2007, J NEUROIMMUNE PHARM, V2, P81, DOI 10.1007/s11481-006-9039-x
   Hanson LR, 2009, J PHARMACOL EXP THER, V330, P679, DOI 10.1124/jpet.108.149807
   Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022764
   JIANG XG, 1995, ACTA PHARMACOL SINIC, V30, P848
   Kaul M, 2008, FRONT BIOSCI-LANDMRK, V13, P2484, DOI 10.2741/2860
   Liang WQ, 2003, BIOPHARMACEUTICS PHA, P37
   Mahajan HS, 2010, DRUG DELIV, V17, P19, DOI 10.3109/10717540903447194
   Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019
   Mudigonda K, 2006, BIOMED CHROMATOGR, V20, P1028, DOI 10.1002/bmc.631
   Nicolas A, 2009, INT J PHARMACEUT, V377, P142
   Nottet HSLM, 1996, J IMMUNOL, V156, P1284
   Parveen R, 2011, INT J PHARMACEUT, V413, P245, DOI 10.1016/j.ijpharm.2011.04.041
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   Strazielle N, 2005, REV MED VIROL, V15, P105, DOI 10.1002/rmv.454
   Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003
   Yang JP, 2009, NEUROSCI LETT, V449, P108, DOI 10.1016/j.neulet.2008.10.090
   Zhang HJ, 2003, ARCH PHARM RES, V26, P768, DOI 10.1007/BF02976689
   Zhang QZ, 2004, INT J PHARM, V275, P85, DOI 10.1016/j.ijpharm.2004.01.039
   KIECHEL JR, 1989, Patent No. 4885305
NR 23
TC 31
Z9 31
U1 4
U2 47
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PD MAR
PY 2014
VL 21
IS 2
BP 148
EP 154
DI 10.3109/10717544.2013.838014
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AB8JQ
UT WOS:000332036600008
PM 24128122
OA gold
DA 2018-01-05
ER

PT J
AU Rancan, F
   Amselgruber, S
   Hadama, S
   Munier, S
   Pavot, V
   Verrier, B
   Hackbarth, S
   Combadiere, B
   Blume-Peytavi, U
   Vogt, A
AF Rancan, Fiorenza
   Amselgruber, Sarah
   Hadama, Sabrina
   Munier, Severine
   Pavot, Vincent
   Verrier, Bernard
   Hackbarth, Steffen
   Combadiere, Behazine
   Blume-Peytavi, Ulrike
   Vogt, Annika
TI Particle-based transcutaneous administration of HIV-1 p24 protein to
   human skin explants and targeting of epidermal antigen presenting cells
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Cyanoacrylate stripping; DC activation; Langerhans cells; Poly-lactic
   acid; Transcutaneous vaccination
ID HAIR-FOLLICLES; IMMUNE-RESPONSES; PLA NANOPARTICLES; DRUG-DELIVERY;
   DENDRITIC CELLS; INTRADERMAL VACCINATION; PENETRATION; IMMUNIZATION;
   TRANSPORT; DERMATOTHERAPY
AB Transcutaneous immunization is a promising vaccination strategy for the treatment of infectious diseases and cancer. In this study, we investigate the combination of cyanoacrylate skin surface stripping (CSSS) and particle-based antigen delivery to target the HIV-1 p24 protein to skin antigen presenting cells (APC). The CSSS treatment pre-activates skin APC and opens hair follicles, where protein-loaded particles accumulate and allow for sustained delivery of the loaded antigen to perifollicular APC. We found that poly-lactic acid (PLA) and polystyrene (PS) particles targeted the adsorbed HIV-1 p24 protein to the hair follicles. Small amounts of PS and PLA particles were found to translocate to the epidermis and be internalized by skin cells, where as most of the particles aggregated in the hair follicle canal, where they released the loaded antigen. The p24 protein diffused to the epidermis and dermis and was detected in skin cells, especially in Langerhans cells and dermal dendritic cells. Furthermore, the combination of CSSS and particle-based delivery resulted in activation and maturation of Langerhans cells (HLA-DR, CD80 and CD83). We conclude that particle-based antigen delivery across partially disrupted skin barrier is a feasible and effective approach to needle-free transcutaneous vaccination. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Rancan, Fiorenza; Amselgruber, Sarah; Hadama, Sabrina; Blume-Peytavi, Ulrike; Vogt, Annika] Charite, Dept Dermatol & Allergy, Clin Res Ctr Hair & Skin Sci, D-10117 Berlin, Germany.
   [Munier, Severine; Pavot, Vincent; Verrier, Bernard] Univ Lyon, CNRS, Inst Biol & Chim Prot, UMR 5305, Lyon, France.
   [Hackbarth, Steffen] Humboldt Univ, Dept Phys, Berlin, Germany.
   [Combadiere, Behazine] Univ Paris 06, Lab Immun & Infect, Paris 13, France.
RP Rancan, F (reprint author), Charite, Dept Dermatol & Allergy, Clin Res Ctr Hair & Skin Sci, Charitepl 1, D-10117 Berlin, Germany.
EM fiorenza.rancan@charite.de
RI Combadiere, Behazine/G-3881-2013
FU European funding: FP6 STREP MuNanoVac program; European funding: FP7
   Cut'hivac program
FX This work was supported by European funding: FP6 STREP MuNanoVac and FP7
   Cut'hivac programs.
CR Alvarez-Roman R, 2004, J CONTROL RELEASE, V99, P53, DOI 10.1016/j.jconrel.2004.06.015
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bal SM, 2010, J CONTROL RELEASE, V147, P218, DOI 10.1016/j.jconrel.2010.07.104
   Baleeiro RB, 2013, J INVEST DERMATOL, V133, P1933, DOI 10.1038/jid.2013.79
   Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x
   Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274
   Combadiere B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010818
   Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015
   Eisenberg G, 2010, CELL IMMUNOL, V266, P98, DOI 10.1016/j.cellimm.2010.09.003
   Glenn GM, 2006, CURR TOP MICROBIOL, V304, P247
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527
   Lademann J, 2006, SKIN PHARMACOL PHYS, V19, P232, DOI 10.1159/000093119
   Lademann J, 2007, EUR J PHARM BIOPHARM, V66, P159, DOI 10.1016/j.ejpb.2006.10.019
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lee MY, 2013, BMB REP, V46, P17, DOI 10.5483/BMBRep.2013.46.1.001
   Liard C, 2012, J INVEST DERMATOL, V132, P615, DOI 10.1038/jid.2011.346
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Mahe B, 2009, J INVEST DERMATOL, V129, P1156, DOI 10.1038/jid.2008.356
   Mattheolabakis G, 2010, INT J PHARMACEUT, V385, P187, DOI 10.1016/j.ijpharm.2009.10.033
   MILLS OH, 1983, DERMATOLOGICA, V167, P57
   Mittal A, 2013, VACCINE, V31, P3442, DOI 10.1016/j.vaccine.2012.12.048
   Panyam J, 2003, PHARMACEUT RES, V20, P212, DOI 10.1023/A:1022219003551                                                         
   Partidos CD, 2005, CELL MOL LIFE SCI, V62, P1418, DOI 10.1007/s00018-005-4529-1
   Pearton M, 2013, ADV HEALTHC MATER, V2, P1401, DOI 10.1002/adhm.201300006
   Prow TW, 2011, ADV DRUG DELIVER REV, V63, P470, DOI 10.1016/j.addr.2011.01.012
   Rancan F, 2012, ACS NANO, V6, P6829, DOI 10.1021/nn301622h
   Rancan F, 2012, EUR J PHARM BIOPHARM, V80, P76, DOI 10.1016/j.ejpb.2011.09.004
   Rancan F, 2009, PHARM RES-DORDR, V26, P2027, DOI 10.1007/s11095-009-9919-x
   Romani N, 2010, IMMUNOL CELL BIOL, V88, P424, DOI 10.1038/icb.2010.39
   Schaefer H, 2001, SKIN PHARMACOL APPL, V14, P23, DOI 10.1159/000056386
   Seid RC, 2012, VACCINE, V30, P4349, DOI 10.1016/j.vaccine.2011.09.113
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Teunissen MBM, 2012, CURR TOP MICROBIOL, V351, P25, DOI 10.1007/82_2011_169
   Toll R, 2004, J INVEST DERMATOL, V123, P168, DOI 10.1111/j.0022-202X.2004.22717.x
   Valladeau J, 2005, SEMIN IMMUNOL, V17, P273, DOI 10.1016/j.smim.2005.05.009
   Vogt A, 2005, J INVEST DERM SYMP P, V10, P252, DOI 10.1111/j.1087-0024.2005.10124.x
   Vogt A, 2008, J IMMUNOL, V180, P1482, DOI 10.4049/jimmunol.180.3.1482                                                     
   Vogt A, 2007, EXP DERMATOL, V16, P946, DOI 10.1111/j.1600-0625.2007.00602.x
   Vogt A, 2006, J INVEST DERMATOL, V126, P1316, DOI 10.1038/sj.jid.5700226
   Yan SY, 2013, J COLLOID INTERF SCI, V395, P1, DOI 10.1016/j.jcis.2012.11.061
NR 41
TC 16
Z9 16
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 28
PY 2014
VL 176
BP 115
EP 122
DI 10.1016/j.jconrel.2013.12.022
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AB5FX
UT WOS:000331815400012
PM 24384300
DA 2018-01-05
ER

PT J
AU Shafiee, H
   Lidstone, EA
   Jahangir, M
   Inci, F
   Hanhauser, E
   Henrich, TJ
   Kuritzkes, DR
   Cunningham, BT
   Demirci, U
AF Shafiee, Hadi
   Lidstone, Erich A.
   Jahangir, Muntasir
   Inci, Fatih
   Hanhauser, Emily
   Henrich, Timothy J.
   Kuritzkes, Daniel R.
   Cunningham, Brian T.
   Demirci, Utkan
TI Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load
   Measurement
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL THERAPY; OVARIAN-CANCER;
   PROTEIN MICROARRAYS; PROTEOMIC ANALYSIS; SERUM BIOMARKERS; COLON-CANCER;
   INFECTION; DIAGNOSIS; VIRUS
AB Detecting and quantifying biomarkers and viruses in biological samples have broad applications in early disease diagnosis and treatment monitoring. We have demonstrated a label-free optical sensing mechanism using nanostructured photonic crystals (PC) to capture and quantify intact viruses (HIV-1) from biologically relevant samples. The nanostructured surface of the PC biosensor resonantly reflects a narrow wavelength band during illumination with a broadband light source. Surface-adsorbed biotarget induces a shift in the resonant Peak Wavelength Value (PWV) that is detectable with, 10 pm wavelength resolution, enabling detection of both biomolecular layers and small number of viruses that sparsely populate the transducer surface. We have successfully captured and detected HIV-1 in serum and phosphate buffered saline (PBS) samples with viral loads ranging from 10(4) to 10(8) copies/mL. The surface density of immobilized biomolecular layers used in the sensor functionalization process, including 3-mercaptopropyltrimethoxysilane (3-MPS), N-gamma-Maleimidobutyryl-oxysuccinimide ester (GMBS), NeutrAvidin, anti-gp120, and bovine serum albumin (BSA) were also quantified by the PC biosensor.
C1 [Shafiee, Hadi; Jahangir, Muntasir; Inci, Fatih; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Bioacoust MEMS Med BAMM Lab,Div Biomed Engn,Dept, Boston, MA 02115 USA.
   [Lidstone, Erich A.; Cunningham, Brian T.] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA.
   [Lidstone, Erich A.; Cunningham, Brian T.] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
   [Hanhauser, Emily; Henrich, Timothy J.; Kuritzkes, Daniel R.; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA.
   [Demirci, Utkan] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Cunningham, BT (reprint author), Univ Illinois, Dept Elect & Comp Engn, 1406 W Green St, Urbana, IL 61801 USA.
EM bcunning@illinois.edu; udemirci@rics.bwh.harvard.edu
OI Inci, Fatih/0000-0002-9918-5038
FU National Institute of Health under NIH [R01AI093282, R01AI081534,
   R21AI087107, F32AI102590]
FX This work was supported by the National Institute of Health under NIH
   award numbers R01AI093282, R01AI081534, R21AI087107, and F32AI102590.
CR Amano Y, 2005, ANAL BIOANAL CHEM, V381, P156, DOI 10.1007/s00216-004-2927-0
   Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162
   Arnold S, 2003, OPT LETT, V28, P272, DOI 10.1364/OL.28.000272
   Boltovets P. M., 2004, J VIROL METHODS, V121, P6
   Branson B., 2011, J INFECT DIS, V205, P4
   BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x
   Chan L. L., 2007, APOPTOSIS, V12, P8
   Choi CJ, 2007, LAB CHIP, V7, P550, DOI 10.1039/b618584c
   Cooper MA, 2001, NAT BIOTECHNOL, V19, P833, DOI 10.1038/nbt0901-833
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Cunningham BT, 2004, J BIOMOL SCREEN, V9, P481, DOI 10.1177/1087057104267604
   Diamandis EP, 2003, TUMOR BIOL, V24, P299, DOI 10.1159/000076462
   Diamandis EP, 2003, J CLIN ONCOL, V21, P1035, DOI 10.1200/JCO.2003.02.022
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316                                                    
   Furin JJ, 2008, ANN NY ACAD SCI, V1136, P12, DOI 10.1196/annals.1425.004
   Gale H. B., 2013, HIV AIDS BRIEF REPOR, V56, P4
   Henrich TJ, 2010, JAIDS-J ACQ IMM DEF, V55, P420, DOI 10.1097/QAI.0b013e3181f25574
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kirchherr JL, 2007, J VIROL METHODS, V143, P104, DOI 10.1016/j.jviromet.2007.02.015
   KLEVAN L, 1995, ELECTROPHORESIS, V16, P1553, DOI 10.1002/elps.11501601258
   Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009                                                
   Lal S., 2007, NAT PHOTONICS, V1, P8
   Laperche S., 2012, J INFECT DIS, V206
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Little SJ, 1999, J EXP MED, V190, P841, DOI 10.1084/jem.190.6.841
   Luo LY, 2003, CANCER RES, V63, P807
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Maurya P, 2007, ANTICANCER RES, V27, P1247
   Mee P., 2008, AIDS, V22, P1971
   MH M., 2006, N ENGL J MED, V354
   Moon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021409
   Nam MJ, 2003, PROTEOMICS, V3, P2108, DOI 10.1002/pmic.200300594
   Nowak MA, 1997, J VIROL, V71, P7518
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Patz EF, 2007, J CLIN ONCOL, V25, P5578, DOI 10.1200/JCO.2007.13.5392
   Pineda MF, 2009, IEEE SENS J, V9, P470, DOI 10.1109/JSEN.2009.2014427
   Pineda M. F., 2009, IEEE SENSORS, V9, P8
   Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8
   Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295
   Rosenberg N. E., 2012, J INFECT DIS, V206
   Rosenberg NE, 2012, J INFECT DIS, V205, P528, DOI 10.1093/infdis/jir789
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Salmanzadeh A, 2012, LAB CHIP, V12, P182, DOI 10.1039/c1lc20701f
   Sanders-Buell E., 1995, SEQUENCING PRIMERS H
   Schofield DJ, 1996, J VIROL METHODS, V62, P33, DOI 10.1016/0166-0934(96)02086-1                                                    
   Shafiee H, 2013, SMALL, V9, P2553, DOI 10.1002/smll.201202195
   Shafiee H, 2010, LAB CHIP, V10, P438, DOI 10.1039/b920590j
   Shamah S. M., 2011, ANALYST, V136, P12
   Stevens WS, 2010, J INFECT DIS, V201, pS16, DOI 10.1086/650392
   Stroock AD, 2002, SCIENCE, V295, P647, DOI 10.1126/science.1066238                                                         
   Tannapfel A, 2003, J PATHOL, V201, P238, DOI 10.1002/path.1420
   Tanriverdi S, 2010, J INFECT DIS, V201, pS52, DOI 10.1086/650387
   Tasoglu S, 2013, CHEM SOC REV, V42, P5788, DOI 10.1039/c3cs60042d
   Terrel M, 2009, APPL OPTICS, V48, P4874, DOI 10.1364/AO.48.004874
   Usdin M, 2010, J INFECT DIS, V201, pS73, DOI 10.1086/650384
   van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x
   Vekemans M, 2007, AIDS, V21, P1205, DOI 10.1097/QAD.0b013e3281c617e8
   Wang LX, 2013, NANO TODAY, V8, P374, DOI 10.1016/j.nantod.2013.07.001
   Wang SQ, 2013, BIOTECHNOL ADV, V31, P438, DOI 10.1016/j.biotechadv.2013.01.006
   Wang SQ, 2012, INT J NANOMED, V7, P2591, DOI 10.2147/IJN.S29629
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188
   WHO, 2013, GUIDELINES USE ANTIR
   World Health Organization, 2011, ANT THER LOW MIDDL I
   World Health Organization, 2011, HIV AIDS MAL OTH DIS
   World Health Organization, US ANT DRUGS TREATM
   Wong J, 2009, J IMMUNOL METHODS, V350, P171, DOI 10.1016/j.jim.2009.08.013
   Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746
NR 71
TC 39
Z9 39
U1 4
U2 70
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 28
PY 2014
VL 4
AR 4116
DI 10.1038/srep04116
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB8BC
UT WOS:000332014100001
PM 24576941
OA gold
DA 2018-01-05
ER

PT J
AU Kotta, S
   Khan, AW
   Ansari, SH
   Sharma, RK
   Ali, J
AF Kotta, Sabna
   Khan, Abdul Wadood
   Ansari, Shahid H.
   Sharma, Rakesh Kumar
   Ali, Javed
TI Anti HIV nanoemulsion formulation: Optimization and in vitro-in vivo
   evaluation
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanoemulsion; Efavirenz; Condensation method; Phase inversion
   composition
ID ABSORPTION; MECHANISMS; EFAVIRENZ; DELIVERY
AB The objective of the present work is to develop a dose adjustable nanotechnology based liquid formulation of efavirenz with improved bioavailability for HIV therapy. Nanoemulsion of efavirenz was developed using phase inversion composition method with the help of ternary phase diagram. Globule size of the o/w nanoemulsion was studied with the help of dynamic light scattering and further confirmed with TEM analysis. Optimized formulations were subjected for in vitro dissolution studies and in vivo studies were done in rats to calculate pharmacokinetics parameters and compared with efavirenz suspension. TEM results revealed that the globule size of optimized formulation was less than 30 nm. In vitro release profile showed more than 80% release within 6 h which was highly significant (p > 0.05) and pharmacokinetic studies also proved a promising in vivo absorption profile when compared to the efavirenz suspension. The developed nanoemulsion proved to be an effective dose adjustable formulation of efavirenz for pediatric HIV therapy. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kotta, Sabna; Khan, Abdul Wadood; Ali, Javed] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India.
   [Ansari, Shahid H.] Jamia Hamdard, Fac Pharm, Dept Pharmacognosy & Phytochem, New Delhi 110062, India.
   [Sharma, Rakesh Kumar] Inst Nucl Med & Allied Sci, Div CBRN Def, New Delhi 110054, India.
RP Ali, J (reprint author), Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India.
EM javedaali@yahoo.com
OI Ali, Javed/0000-0001-5308-0655
FU Defense Research Development Organization (DRDO), Government of India
FX The authors are grateful to the Defense Research Development
   Organization (DRDO), Government of India for providing a fellowship as
   financial assistance to Sabna Kotta. A portion of this work has been
   presented as a poster in FIP world Congress-2013, Dublin, Ireland.
CR Ammar HO, 2009, AAPS PHARMSCITECH, V10, P808, DOI 10.1208/s12249-009-9268-4
   Bali V., 2011, INT J PHARMACEUT, V403, P246
   Bali V, 2010, COLLOID SURFACE B, V76, P410, DOI 10.1016/j.colsurfb.2009.11.021
   Ballesteros M. A., 2003, J PHARM SCI, V92, P1428
   Bath A. C., 1996, J LIPID RES, V37, P708
   Brusewitz C, 2007, INT J PHARM, V329, P173, DOI 10.1016/j.ijpharm.2006.08.022
   Chiappetta DA, 2009, CURR HIV RES, V8, P223
   Clarke J.R., 2000, AIDS REV, V2, P15
   CONSTANTINIDES PP, 1995, PHARMACEUT RES, V12, P1561, DOI 10.1023/A:1016268311867
   CRAIG DQM, 1995, INT J PHARM, V114, P103, DOI 10.1016/0378-5173(94)00222-Q
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Vedha Hari B.N., 2012, BMC INFECT DIS, V12, pp7
   Jain S, 2013, J BIOMED NANOTECHNOL, V9, P1862, DOI 10.1166/jbn.2013.1683
   Kim JY, 2000, INT J PHARM, V194, P81, DOI 10.1016/S0378-5173(99)00367-1
   Kulkosky J, 2006, CURR HIV RES, V4, P199, DOI 10.2174/157016206776055084
   MacGregor KJ, 1997, ADV DRUG DELIVER REV, V25, P33, DOI 10.1016/S0169-409X(96)00489-9
   Madhavi BB, 2011, INT J PHARM INVESTIG, V1, P29, DOI 10.4103/2230-973X.76726
   Mason TG, 2006, J PHYS-CONDENS MAT, V18, pR635, DOI 10.1088/0953-8984/18/41/R01
   Mogatle S, 2009, J PHARMACEUT BIOMED, V49, P1308, DOI 10.1016/j.jpba.2009.03.008
   Parveen R, 2011, INT J PHARMACEUT, V413, P245, DOI 10.1016/j.ijpharm.2011.04.041
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sailaja AL, 2007, CHROMATOGRAPHIA, V65, P359, DOI 10.1365/s10337-006-0170-x
   Vyas SP, 2002, TARGETED CONTROLLED
NR 23
TC 13
Z9 13
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD FEB 28
PY 2014
VL 462
IS 1-2
BP 129
EP 134
DI 10.1016/j.ijpharm.2013.12.038
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 296FS
UT WOS:000330171200016
PM 24374067
DA 2018-01-05
ER

PT J
AU Zhao, XZ
   Smith, SJ
   Metifiot, M
   Johnson, BC
   Marchand, C
   Pommier, Y
   Hughes, SH
   Burke, TR
AF Zhao, Xue Zhi
   Smith, Steven J.
   Metifiot, Mathieu
   Johnson, Barry C.
   Marchand, Christophe
   Pommier, Yves
   Hughes, Stephen H.
   Burke, Terrence R., Jr.
TI Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing
   HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells
   Harboring Raltegravir-Resistant Integrase Mutants
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DERIVATIVES; PHARMACOPHORE; DOLUTEGRAVIR; INFECTION; DESIGN
AB Integrase (IN) inhibitors are the newest class of antiretroviral agents developed for the treatment of HIV-1 infections. Merck's Raltegravir (RAL) (October 2007) and Gilead's Elvitegravir (EVG) (August 2012), which act as IN strand transfer inhibitors (INSTIs), were the first anti-IN drugs to be approved by the FDA. However, the virus develops resistance to both RAL and EVG, and there is extensive cross-resistance to these two drugs. New "2nd-generation" INSTIs are needed that will have greater efficacy against RAL- and EVG-resistant strains of IN. The FDA has recently approved the first second generation INSTI, GSK's Dolutegravir (DTG) (August 2013). Our current article describes the design, synthesis, and evaluation of a series of 1,8-dihydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides, 1,4-dihydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides, and 1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides. This resulted in the identification of noncytotoxic inhibitors that exhibited single digit nanomolar EC50 values against HIV-1 vectors harboring wild-type IN in cell-based assays. Importantly, some of these new inhibitors retain greater antiviral efficacy compared to that of RAL when tested against a panel of IN mutants that included Y143R, N155H, G140S/Q148H, G118R, and E138K/Q148K.
C1 [Zhao, Xue Zhi; Burke, Terrence R., Jr.] NCI, Chem Biol Lab, NIH, Frederick, MD 21702 USA.
   [Smith, Steven J.; Johnson, Barry C.; Hughes, Stephen H.] NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA.
   [Metifiot, Mathieu; Marchand, Christophe; Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Burke, TR (reprint author), NCI, Chem Biol Lab, NIH, Frederick, MD 21702 USA.
EM burkete@helix.nih.gov
RI Zhao, Xue Zhi/N-9594-2014; Burke, Terrence/N-2601-2014
OI Zhao, Xue Zhi/0000-0003-1006-6364; 
FU Intramural Research Program of the NIH, Center for Cancer Research,
   Frederick National Laboratory for Cancer Research; National Cancer
   Institute, National Institutes of Health; Joint Science and Technology
   Office of the Department of Defense; Intramural AIDS Targeted Antiviral
   Program
FX This work was supported in part by the Intramural Research Program of
   the NIH, Center for Cancer Research, Frederick National Laboratory for
   Cancer Research and the National Cancer Institute, National Institutes
   of Health and the Joint Science and Technology Office of the Department
   of Defense, and by funds from the Intramural AIDS Targeted Antiviral
   Program.
CR Ballantyne AD, 2013, DRUGS, V73, P1627, DOI 10.1007/s40265-013-0121-4
   Billamboz Muriel, 2013, ACS Med Chem Lett, V4, P606, DOI 10.1021/ml400009t
   Brachmann A, 2004, MOL GENET GENOMICS, V272, P216, DOI 10.1007/s00438-004-1047-z
   Cherepanov P, 2011, CURR OPIN STRUC BIOL, V21, P249, DOI 10.1016/j.sbi.2010.12.005
   Croxtall JD, 2010, DRUGS, V70, P631, DOI 10.2165/11204590-000000000-00000
   Delelis O., 2009, ANTIMICROB AGENTS CH, V54, P491
   Desimmie BA, 2013, ACS CHEM BIOL, V8, P1187, DOI 10.1021/cb4000426
   Di Santo R, 2014, J MED CHEM, V57, P539, DOI 10.1021/jm400674a
   Flipo M, 2007, J MED CHEM, V50, P1322, DOI 10.1021/jm061169b
   Geretti AM, 2012, CURR OPIN INFECT DIS, V25, P677, DOI 10.1097/QCO.0b013e32835a1de7
   Johns BA, 2013, J MED CHEM, V56, P5901, DOI 10.1021/jm400645w
   Johnson TW, 2011, J MED CHEM, V54, P3393, DOI 10.1021/jm200208d
   Katlama C, 2012, EXPERT OPIN INV DRUG, V21, P523, DOI 10.1517/13543784.2012.661713
   Kawasuji T, 2013, J MED CHEM, V56, P1124, DOI 10.1021/jm301550c
   Kawasuji T, 2012, J MED CHEM, V55, P8735, DOI 10.1021/jm3010459
   Malet I, 2008, ANTIMICROB AGENTS CH, V52, P1351, DOI 10.1128/AAC.01228-07
   Marchand C, 2009, CURR TOP MED CHEM, V9, P1016, DOI 10.2174/156802609789630910                                                      
   Mesplede T, 2012, CURR OPIN HIV AIDS, V7, P401, DOI 10.1097/COH.0b013e328356db89
   Metifiot M, 2013, ADV PHARMACOL, V67, P75, DOI 10.1016/B978-0-12-405880-4.00003-2
   Metifiot M, 2013, ACS CHEM BIOL, V8, P209, DOI 10.1021/cb300471n
   Metifiot M, 2010, VIRUSES-BASEL, V2, P1347, DOI 10.3390/v2071347
   Metifiot M, 2010, BIOCHEMISTRY-US, V49, P3715, DOI 10.1021/bi100130f
   Nicolaou KC, 1997, J AM CHEM SOC, V119, P11353, DOI 10.1021/ja973000g                                                               
   Perryman AL, 2010, J MOL BIOL, V397, P600, DOI 10.1016/j.jmb.2010.01.033
   Plewe MB, 2009, J MED CHEM, V52, P7211, DOI 10.1021/jm900862n
   Pryde DC, 2013, MEDCHEMCOMM, V4, P709, DOI 10.1039/c3md00014a
   Quashie PK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-34
   RYLANDER PN, 1970, ANN NY ACAD SCI, V172, P266, DOI 10.1111/j.1749-6632.1970.tb34984.x                                              
   Sangeetha B, 2013, SAR QSAR ENVIRON RES, V24, P753, DOI 10.1080/1062936X.2013.792870
   Takenaka Y, 2009, GREEN CHEM, V11, P1385, DOI 10.1039/b904672k
   Tang J, 2011, J MED CHEM, V54, P2282, DOI 10.1021/jm1014378
   Vandekerckhove L, 2010, CURR OPIN INVEST DR, V11, P203
   Wills T, 2012, EXPERT OPIN INV DRUG, V21, P395, DOI 10.1517/13543784.2012.658914
   Zhao XZ, 2008, J MED CHEM, V51, P251, DOI 10.1021/jm070715d
   Zhao XZ, 2012, BIOORG MED CHEM LETT, V22, P7309, DOI 10.1016/j.bmcl.2012.10.088
   Zhao XZ, 2012, CHEM BIOL DRUG DES, V79, P157, DOI 10.1111/j.1747-0285.2011.01270.x
   Zhao XZ, 2009, BIOORG MED CHEM LETT, V19, P2714, DOI 10.1016/j.bmcl.2009.03.122
   WILLIAMS PD, 2008, Patent No. 2008010964
NR 38
TC 15
Z9 15
U1 0
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 27
PY 2014
VL 57
IS 4
BP 1573
EP 1582
DI 10.1021/jm401902n
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AC0LV
UT WOS:000332187700032
PM 24471816
OA gold
DA 2018-01-05
ER

PT J
AU Liu, R
   Zhang, Y
   Zhang, SY
   Qiu, W
   Gao, Y
AF Liu, Rui
   Zhang, Yue
   Zhang, Shuyue
   Qiu, Wei
   Gao, Ying
TI Silver Enhancement of Gold Nanoparticles for Biosensing: From
   Qualitative to Quantitative
SO APPLIED SPECTROSCOPY REVIEWS
LA English
DT Review
DE Silver enhancement; gold nanoparticles; biosensing; ICP-MS;
   amplification
ID PLASMA-MASS SPECTROMETRY; HUMAN-IMMUNODEFICIENCY-VIRUS; LABELED
   IMMUNOSORBENT-ASSAY; COLLOIDAL GOLD; SIGNAL AMPLIFICATION; ELECTRICAL
   DETECTION; COLORIMETRIC DETECTION; SCANOMETRIC DETECTION; DNA
   HYBRIDIZATION; AU NANOPARTICLES
AB The establishment and rapid progress in sensitive biosensing using immunogold silver enhancement has occurred in the past 30years. Its high sensitivity and simplicity have made immunogold silver enhancement a revolutionary technique for signal amplification in biosensing. This review focuses on the major applications of immunogold silver enhancement, with special emphasis on quantitative biosensing. In this review, the combinations of immunogold silver enhancement with a series of quantitative techniques, such as colorimetry, electrical and electrochemical methods, gravimetry, chemiluminescence, Raman spectroscopy, and inductively coupled plasma-mass spectrometry (ICP-MS), are discussed in detail. Immunogold silver enhancement has become one of the most useful methods in highly sensitive quantitative bioanalysis. The recent development of ICP-MS detection shows great potential in combination with immunogold silver enhancement.
C1 [Liu, Rui; Zhang, Yue; Zhang, Shuyue; Qiu, Wei] Chengdu Univ Technol, Mineral Resources Chem Key Lab, Sichuan Higher Educ Inst, Coll Mat & Chem & Chem Engn, Chengdu 610059, Sichuan, Peoples R China.
   [Gao, Ying] Chengdu Univ Technol, Coll Nucl Technol & Automat Engn, Sichuan Prov Key Lab Nucl Technol Geol, Chengdu 610059, Sichuan, Peoples R China.
RP Gao, Y (reprint author), Chengdu Univ Technol, Coll Nucl Technol & Automat Engn, Sichuan Prov Key Lab Nucl Technol Geol, 1 Erxianqiao,Dongsan Rd, Chengdu 610059, Sichuan, Peoples R China.
EM ying.gaoy@gmail.com
RI liu, tang/M-9444-2013; Gao, Ying/J-5913-2012; Liu, Rui/B-6218-2011
OI Liu, Rui/0000-0001-9928-5373
FU National Natural Science Foundation of China [21205007]; Education
   Department of Sichuan Province [12ZB186]; cultivating program of
   middle-aged backbone teachers of the Chengdu University of Technology
   [KYGG201307]
FX The authors gratefully thank the National Natural Science Foundation of
   China (Grant No. 21205007), the Education Department of Sichuan Province
   (Grant No. 12ZB186), and the cultivating program of middle-aged backbone
   teachers of the Chengdu University of Technology (Grant No. KYGG201307)
   for funding this study.
CR Alexandre I, 2001, ANAL BIOCHEM, V295, P1, DOI 10.1006/abio.2001.5176
   Bai YH, 2010, ANALYST, V135, P1672, DOI 10.1039/b923847f
   Bakalova R, 2005, J AM CHEM SOC, V127, P9328, DOI 10.1021/ja0510055
   Baranov VI, 2002, ANAL CHEM, V74, P1629, DOI 10.1021/ac0110350
   Baschong W, 1998, MICROSC RES TECHNIQ, V42, P66
   Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704
   Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902
   Cai H, 2002, ANAL CHIM ACTA, V469, P165, DOI 10.1016/S0003-2670(02)00670-0
   Cao XD, 2011, ANAL BIOCHEM, V417, P1, DOI 10.1016/j.ab.2011.05.027
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chiao DJ, 2004, J CHROMATOGR B, V809, P37, DOI 10.1016/j.jchromb.2004.05.033
   Chu X, 2005, J IMMUNOL METHODS, V301, P77, DOI 10.1016/j.jim.2005.03.005
   Chu X, 2005, BIOSENS BIOELECTRON, V20, P1805, DOI 10.1016/j.bios.2004.07.012
   DANSCHER G, 1993, J HISTOTECHNOL, V16, P201, DOI 10.1179/his.1993.16.3.201                                                       
   DANSCHER G, 1983, J HISTOCHEM CYTOCHEM, V31, P1394, DOI 10.1177/31.12.6631001                                                           
   DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572                                                              
   Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001
   Ding L, 2010, ANAL CHEM, V82, P5804, DOI 10.1021/ac100866e
   Faulk P. W., 1971, IMMUNOCHEMISTRY, V8, P1081, DOI DOI 10.1016/0019-2791(71)90496-4
   Gonzalez-Garcia MB, 2000, BIOSENS BIOELECTRON, V15, P663, DOI 10.1016/S0956-5663(00)00111-1
   Gupta S, 2007, ANAL CHEM, V79, P3810, DOI 10.1021/ac062341m
   HACKER GW, 1988, J HISTOTECHNOL, V11, P213, DOI 10.1179/his.1988.11.4.213                                                       
   Hainfeld JF, 2000, J HISTOCHEM CYTOCHEM, V48, P471, DOI 10.1177/002215540004800404                                                      
   Han GJ, 2011, ANGEW CHEM INT EDIT, V50, P3462, DOI 10.1002/anie.201006838
   Han GJ, 2013, ANGEW CHEM INT EDIT, V52, P1466, DOI 10.1002/anie.201206903
   HAYAT MA, 1993, J HISTOTECHNOL, V16, P197, DOI 10.1179/his.1993.16.3.197                                                       
   He WL, 2008, PROG BIOCHEM BIOPHYS, V35, P1332
   HOLGATE CS, 1983, J HISTOCHEM CYTOCHEM, V31, P938, DOI 10.1177/31.7.6189883                                                            
   Hou SY, 2007, ANAL CHEM, V79, P980, DOI 10.1021/ac061507g
   Hu SH, 2009, J AM SOC MASS SPECTR, V20, P1096, DOI 10.1016/j.jasms.2009.02.005
   Ji HX, 2011, CHEM-EUR J, V17, P11344, DOI 10.1002/chem.201100563
   Ko YJ, 2008, SENSOR ACTUAT B-CHEM, V132, P327, DOI 10.1016/j.snb.2008.01.061
   Lackie PM, 1996, HISTOCHEM CELL BIOL, V106, P9
   Lai GS, 2012, ANAL CHIM ACTA, V721, P1, DOI 10.1016/j.aca.2012.01.048
   Lee JS, 2008, ANAL CHEM, V80, P6805, DOI 10.1021/ac801046a
   Lei JP, 2012, CHEM SOC REV, V41, P2122, DOI 10.1039/c1cs15274b
   Li BS, 2006, ANAL SCI, V22, P1367, DOI 10.2116/analsci.22.1367                                                         
   Li ZP, 2006, ANAL BIOCHEM, V359, P247, DOI 10.1016/j.ab.2006.09.030
   Liang RQ, 2004, J IMMUNOL METHODS, V285, P157, DOI 10.1016/j.jim.2003.11.008
   Lin DJ, 2012, ANAL CHEM, V84, P3662, DOI 10.1021/ac3001435
   Lin L, 2011, ANALYST, V136, P4732, DOI 10.1039/c1an15610a
   Liu R, 2014, MASS SPECTROM REV, V33, P373, DOI 10.1002/mas.21391
   Liu R, 2013, ANAL CHEM, V85, P4087, DOI 10.1021/ac400158u
   Liu R, 2012, ANAL CHEM, V84, P2769, DOI 10.1021/ac203141d
   Liu R, 2011, ANAL CHEM, V83, P2330, DOI 10.1021/ac103265z
   Liu R, 2010, TALANTA, V83, P48, DOI 10.1016/j.talanta.2010.08.037
   Liu Y, 2010, NANOSCALE RES LETT, V5, P533, DOI 10.1007/s11671-010-9542-0
   Liu Y, 2010, ANAL CHEM, V82, P3679, DOI 10.1021/ac1000114
   Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739
   Maeng JH, 2008, BIOSENS BIOELECTRON, V23, P1319, DOI 10.1016/j.bios.2007.11.019
   Min IH, 2010, BIOSENS BIOELECTRON, V26, P1326, DOI 10.1016/j.bios.2010.07.038
   Moller R, 2001, LANGMUIR, V17, P5426, DOI 10.1021/la0102408
   Newman GR, 1998, J PATHOL, V186, P119
   Pan Q, 2008, ANAL BIOCHEM, V375, P179, DOI 10.1016/j.ab.2007.12.006
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   PATEL N, 1991, J CLIN PATHOL, V44, P334, DOI 10.1136/jcp.44.4.334
   PATEL N, 1993, J HISTOTECHNOL, V16, P259, DOI 10.1179/his.1993.16.3.259                                                       
   Penault-Llorca F, 2009, AM J CLIN PATHOL, V132, P539, DOI 10.1309/AJCPV2I0HGPMGBSQ
   PINNADUWAGE P, 1988, CLIN CHEM, V34, P268
   ROCKS BF, 1991, ANN CLIN BIOCHEM, V28, P155, DOI 10.1177/000456329102800206                                                      
   ROCKS BF, 1990, ANN CLIN BIOCHEM, V27, P114, DOI 10.1177/000456329002700205                                                      
   Saha K, 2012, CHEM REV, V112, P2739, DOI 10.1021/cr2001178
   Seuma J, 2008, PROTEOMICS, V8, P3775, DOI 10.1002/pmic.200800167
   Shim SY, 2008, NANOMEDICINE-UK, V3, P215, DOI 10.2217/17435889.3.2.215
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947
   Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a
   Su XD, 2001, CHEM COMMUN, P755, DOI 10.1039/b009768n                                                                
   Tang JF, 2010, DIAGN MICR INFEC DIS, V67, P122, DOI 10.1016/j.diagmicrobio.2010.01.009
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Wada A, 2011, J VIROL METHODS, V178, P82, DOI 10.1016/j.jviromet.2011.08.017
   Wan Y, 2011, ANAL CHEM, V83, P648, DOI 10.1021/ac103047c
   Wang AW, 1998, SENSOR ACTUAT B-CHEM, V49, P13, DOI 10.1016/S0925-4005(98)00127-0
   Wang J, 2001, LANGMUIR, V17, P5739, DOI 10.1021/la011002f
   Wang YL, 2008, CHEM COMMUN, P2520, DOI 10.1039/b801055b
   Wang ZX, 2005, ANAL CHEM, V77, P5770, DOI 10.1021/ac050679v
   Wilson R, 2008, CHEM SOC REV, V37, P2028, DOI 10.1039/b712179m
   Yang MH, 2009, ANAL BIOCHEM, V385, P128, DOI 10.1016/j.ab.2008.10.019
   Yang W, 2011, BIOSENS BIOELECTRON, V26, P3710, DOI 10.1016/j.bios.2011.02.016
   Yeh CH, 2009, BIOSENS BIOELECTRON, V24, P1661, DOI 10.1016/j.bios.2008.08.039
   Zhang C, 2002, ANAL CHEM, V74, P96, DOI 10.1021/ac.0103468
   Zhang Z, 2009, ELECTROANAL, V21, P1316, DOI 10.1002/elan.200804562
   Zhuang J, 2010, TOXICON, V55, P145, DOI 10.1016/j.toxicon.2009.07.015
NR 83
TC 27
Z9 27
U1 5
U2 437
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0570-4928
EI 1520-569X
J9 APPL SPECTROSC REV
JI Appl. Spectrosc. Rev.
PD FEB 17
PY 2014
VL 49
IS 2
BP 121
EP 138
DI 10.1080/05704928.2013.807817
PG 18
WC Instruments & Instrumentation; Spectroscopy
SC Instruments & Instrumentation; Spectroscopy
GA 198TO
UT WOS:000322945400002
DA 2018-01-05
ER

PT J
AU Monforte, AM
   Ferro, S
   De Luca, L
   Lo Surdo, G
   Morreale, F
   Pannecouque, C
   Balzarini, J
   Chimirri, A
AF Monforte, Anna-Maria
   Ferro, Stefania
   De Luca, Laura
   Lo Surdo, Giuseppa
   Morreale, Francesca
   Pannecouque, Christophe
   Balzarini, Jan
   Chimirri, Alba
TI Design and synthesis of N-1-aryl-benzimidazoles 2-substituted as novel
   HIV-1 non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1 reverse transcriptase; NNRTIs; N-1-Aryl-benzimidazoles
   2-substituted; Synthesis
ID IMMUNODEFICIENCY-VIRUS TYPE-1; WILD-TYPE; POTENT; MUTANT; DISCOVERY;
   STRAINS; ANALOGS; UPDATE; NNRTIS
AB A series of novel N-1-aryl-2-arylthioacetamido-benzimidazoles were synthesized and evaluated as inhibitors of human immunodeficiency virus type-1 (HIV-1). Some of them proved to be effective in inhibiting HIV-1 replication at submicromolar and nanomolar concentration acting as HIV-1 non-nucleoside RT inhibitors (NNRTIs), with low cytotoxicity. The preliminary structure-activity relationship (SAR) of these new derivatives was discussed and rationalized by docking studies. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Monforte, Anna-Maria; Ferro, Stefania; De Luca, Laura; Lo Surdo, Giuseppa; Morreale, Francesca; Chimirri, Alba] Univ Messina, Dipartimento Sci Farmaco & Prod Salute, I-98168 Messina, Italy.
   [Pannecouque, Christophe; Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Monforte, AM (reprint author), Univ Messina, Dipartimento Sci Farmaco & Prod Salute, Viale Annunziata, I-98168 Messina, Italy.
EM ammonforte@unime.it
OI De Luca, Laura/0000-0003-0614-5713
FU Fondo Ateneo di ricerca (Messina, Italy)
FX Financial support for this research by the Fondo Ateneo di ricerca
   (2008, Messina, Italy).
CR Auwerx J, 2002, MOL PHARMACOL, V61, P400, DOI 10.1124/mol.61.2.400                                                            
   BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   Barreca ML, 2007, BIOORG MED CHEM LETT, V17, P1956, DOI 10.1016/j.bmcl.2007.01.025
   Barreca ML, 2007, J CHEM INF MODEL, V47, P557, DOI 10.1021/ci600320q
   Barreca ML, 2005, J MED CHEM, V48, P3433, DOI 10.1021/jm049279a
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De La Rosa M, 2006, BIOORG MED CHEM LETT, V16, P4444, DOI 10.1016/j.bmcl.2006.06.048
   DeLano WL, 2008, PYMOL MOL GRAPHICS S
   Gagnon A, 2007, BIOORG MED CHEM LETT, V17, P4437, DOI 10.1016/j.bmcl.2007.06.012
   La Regina G, 2012, J MED CHEM, V55, P6634, DOI 10.1021/jm300477h
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Minuto Joshua J, 2008, Futur HIV Ther, V2, P525, DOI 10.2217/17469600.2.6.525
   [Anonymous], 2005, ADT TOOLS VERS 1 5 4
   Monforte AM, 2008, BIOORGAN MED CHEM, V16, P7429, DOI 10.1016/j.bmc.2008.06.012
   Monforte AM, 2010, BIOORGAN MED CHEM, V18, P1702, DOI 10.1016/j.bmc.2009.12.059
   Monforte AM, 2009, BIOORGAN MED CHEM, V17, P5962, DOI 10.1016/j.bmc.2009.06.068
   Moyle Graeme, 2010, Antimicrob Agents Chemother, V54, P3170, DOI 10.1128/AAC.00268-10
   Muraglia E, 2006, BIOORG MED CHEM LETT, V16, P2748, DOI 10.1016/j.bmcl.2006.02.024
   O'Meara JA, 2007, BIOORG MED CHEM LETT, V17, P3362, DOI 10.1016/j.bmcl.2007.03.097
   Ren J, 2008, J MED CHEM, V51, P5000, DOI 10.1021/jm8004493
   Samuele A, 2010, ANTIVIR RES, V86, P268, DOI 10.1016/j.antiviral.2010.03.008
   Singer VL, 1997, ANAL BIOCHEM, V249, P228, DOI 10.1006/abio.1997.2177
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang ZW, 2006, BIOORG MED CHEM LETT, V16, P4174, DOI 10.1016/j.bmcl.2006.05.096
   Zaharatos GJ, 2013, ANN MED, V45, P236, DOI 10.3109/07853890.2012.732704
   Zhan P, 2009, MINI-REV MED CHEM, V9, P1014, DOI 10.2174/138955709788681618                                                      
   Zhang ZJ, 2007, ANTIMICROB AGENTS CH, V51, P429, DOI 10.1128/AAC.01032-06
   Yueping W., Application Number CN, Patent No. [2012114145820120509, 20121141458201205]
NR 28
TC 8
Z9 9
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD FEB 15
PY 2014
VL 22
IS 4
BP 1459
EP 1467
DI 10.1016/j.bmc.2013.12.045
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA AA5CI
UT WOS:000331112900025
PM 24457088
DA 2018-01-05
ER

PT J
AU Cho, S
   Park, L
   Chong, R
   Kim, YT
   Lee, JH
AF Cho, Sandy
   Park, Lucienne
   Chong, Richard
   Kim, Young Teck
   Lee, Ji Hoon
TI Rapid and simple G-quadruplex DNA aptasensor with guanine
   chemiluminescence detection
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Guanine chemiluminescence; G-quaduplex DNA Aptasensor; Chemiluminescence
   resonance energy transfer (CRET); Thrombin;
   3,4,5-trimethoxylphenylglyoxal hydrate (TMPG); Magnetic Fe3O4 graphene
   oxide
ID THROMBIN-BINDING APTAMER; PEROXYOXALATE CHEMILUMINESCENCE; LABEL-FREE;
   POTASSIUM-ION; DNAZYME; ADENOSINE; SELECTION; REAGENT; AMPLIFICATION;
   PEROXIDASE
AB Cost-effective and sensitive aptasensor with guanine chemiluminescence detection capable of simply quantifying thrombin in human serum was developed using thrombin aptamer (TBA), one of the G-quadruplex DNA aptamers, without expensive nanoparticles and complicated procedures. Guanines of G-quadruplex TBA-conjugated carboxyfluorescein (6-FAM) bound with thrombin do not react with 3,4,5-trimethoxylphenylglyoxal (TMPG) in the presence of tetra-n-propylammonium hydroxide (TPA), whereas guanines of free TBA- and TBA-conjugated 6-FAM immobilized on the surface of graphene oxide rapidly react with TMPG to emit light. Thus, guanine chemiluminescence in 5% human serum with thrombin was lower than that without thrombin when TBA-conjugated 6-FAM was added in two samples and incubated for 20 min. In other words, the brightness of guanine chemiluminescence was quenched due to the formation of G-quadruplex TBA-conjugated 6-FAM bound with thrombin in a sample. High-energy intermediate, capable of emitting dim light by itself, formed from the reaction between guanines of TBA and TMPG in the presence of TPA, transfers energy to 6-FAM to emit bright light based on the principle of chemiluminescence energy transfer (CRET). G-quadruplex TBA aptasensor devised using the rapid interaction between TBA-conjugated 6-FAM and thrombin quantified trace levels of thrombin without complicated procedures. The limit of detection (LOD=background +3 x standard deviation) of G-quadruplex TBA aptasensor with good linear calibration curve, accuracy, precision, and recovery was as low as 12.3 nM in 5% human serum. Using the technology reported in this research, we expect that various types of G-quadruplex DNA aptasensors capable of specifically sensing a target molecule such as ATP, HIV, ochratoxin, potassium ions, and thrombin can be developed. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Cho, Sandy; Park, Lucienne; Chong, Richard; Lee, Ji Hoon] Luminescent MD LLC, Hagerstown, MD 21742 USA.
   [Park, Lucienne] Univ Maryland, Dept Biol, College Pk, MD 20742 USA.
   [Kim, Young Teck] Virginia Polytech Inst & State Univ, Dept Wood Sci & Forest Prod, Blacksburg, VA 24061 USA.
RP Lee, JH (reprint author), Luminescent MD LLC, 20140 Scholar Dr, Hagerstown, MD 21742 USA.
EM jhlee@luminescentmd.com
FU Luminescent MD, LLC [LMD-2012-6]
FX This research was performed based on the intern program (LMD-2012-6) of
   Luminescent MD, LLC.
CR Bi S, 2010, ANAL CHEM, V82, P9447, DOI 10.1021/ac1021198
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Cruz-Aguado JA, 2008, J AGR FOOD CHEM, V56, P10456, DOI 10.1021/jf801957h
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Freeman R, 2012, ANAL CHEM, V84, P6192, DOI 10.1021/ac3011473
   Freeman R, 2011, J AM CHEM SOC, V133, P11597, DOI 10.1021/ja202639m
   Goda T, 2013, BIOSENS BIOELECTRON, V45, P89, DOI 10.1016/j.bios.2013.01.053
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   Jalit Y, 2013, BIOSENS BIOELECTRON, V41, P424, DOI 10.1016/j.bios.2012.08.061
   Kai M, 1999, ANAL CHIM ACTA, V381, P155, DOI 10.1016/S0003-2670(98)00724-7                                                   
   Kassaee MZ, 2011, CHEM ENG J, V172, P540, DOI 10.1016/j.cej.2011.05.093
   Kelly JA, 1996, J MOL BIOL, V256, P417, DOI 10.1006/jmbi.1996.0097
   Lee JH, 2002, J CHEM SOC PERK T 2, P802, DOI 10.1039/b109210c
   Lee J. H., 2002, J CHEM SOC P2, P1653
   Li F, 2013, BIOSENS BIOELECTRON, V41, P907, DOI 10.1016/j.bios.2012.10.007
   Maruyama T, 2013, J PHOTOCH PHOTOBIO A, V252, P222, DOI 10.1016/j.jphotochem.2012.12.006
   Padmanabhan K., 1993, J BIOL CHEM, P268
   Park PS, 2011, CHEM COMMUN, V47, P5542, DOI 10.1039/c1cc10554j
   Pasternak A, 2011, NUCLEIC ACIDS RES, V39, P1155, DOI 10.1093/nar/gkq823
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Shum KT, 2011, BIOCHEM J, V434, P493, DOI 10.1042/BJ20101096
   Shum KT, 2008, CHEMBIOCHEM, V9, P3037, DOI 10.1002/cbic.200800491
   Travascio P, 1998, CHEM BIOL, V5, P505, DOI 10.1016/S1074-5521(98)90006-0
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ueyama H, 2002, J AM CHEM SOC, V124, P14286, DOI 10.1021/ja026892f
   Xing XJ, 2012, BIOSENS BIOELECTRON, V37, P61, DOI 10.1016/j.bios.2012.04.037
   Yamasuji M, 2011, ANAL BIOCHEM, V413, P50, DOI 10.1016/j.ab.2011.01.047
   Yoshida W, 2009, BIOSENS BIOELECTRON, V24, P1116, DOI 10.1016/j.bios.2008.06.016
   Yuan YL, 2011, BIOSENS BIOELECTRON, V26, P4236, DOI 10.1016/j.bios.2011.03.038
   Yuanboonlim W, 2012, BIOSENS BIOELECTRON, V33, P17, DOI 10.1016/j.bios.2011.11.049
   Zhang J, 2011, BIOSENS BIOELECTRON, V26, P4053, DOI 10.1016/j.bios.2011.03.029
   Zhou MY, 2012, BIOSENS BIOELECTRON, V35, P489, DOI 10.1016/j.bios.2012.03.013
NR 32
TC 21
Z9 21
U1 58
U2 414
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD FEB 15
PY 2014
VL 52
BP 310
EP 316
DI 10.1016/j.bios.2013.09.017
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 267KB
UT WOS:000328095400048
PM 24080210
DA 2018-01-05
ER

PT J
AU Van Engelenburg, SB
   Shtengel, G
   Sengupta, P
   Waki, K
   Jarnik, M
   Ablan, SD
   Freed, EO
   Hess, HF
   Lippincott-Schwartz, J
AF Van Engelenburg, Schuyler B.
   Shtengel, Gleb
   Sengupta, Prabuddha
   Waki, Kayoko
   Jarnik, Michal
   Ablan, Sherimay D.
   Freed, Eric O.
   Hess, Harald F.
   Lippincott-Schwartz, Jennifer
TI Distribution of ESCRT Machinery at HIV Assembly Sites Reveals Virus
   Scaffolding of ESCRT Subunits
SO SCIENCE
LA English
DT Article
ID CYTOKINESIS; DYNAMICS; PROTEIN; COMPLEX; ABSCISSION; FILAMENTS; MIDBODY;
   RELEASE; TSG101; VPS4
AB The human immunodeficiency virus (HIV) hijacks the endosomal sorting complexes required for transport (ESCRT) to mediate virus release from infected cells. The nanoscale organization of ESCRT machinery necessary for mediating viral abscission is unclear. Here, we applied three-dimensional superresolution microscopy and correlative electron microscopy to delineate the organization of ESCRT components at HIV assembly sites. We observed ESCRT subunits localized within the head of budding virions and released particles, with head-localized levels of CHMP2A decreasing relative to Tsg101 and CHMP4B upon virus abscission. Thus, the driving force for HIV release may derive from initial scaffolding of ESCRT subunits within the viral bud interior followed by plasma membrane association and selective remodeling of ESCRT subunits.
C1 [Van Engelenburg, Schuyler B.; Sengupta, Prabuddha; Jarnik, Michal; Lippincott-Schwartz, Jennifer] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, Bethesda, MD 20892 USA.
   [Shtengel, Gleb; Hess, Harald F.] Howard Hughes Med Inst, Ashburn, VA 20147 USA.
   [Waki, Kayoko; Ablan, Sherimay D.; Freed, Eric O.] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, Ctr Canc Res,Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
RP Lippincott-Schwartz, J (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, Bethesda, MD 20892 USA.
EM lippincj@mail.nih.gov
OI Sengupta, Prabuddha/0000-0001-7094-6967
FU Howard Hughes Medical Institute; Intramural NIH HHS [Z99 HD999999]
CR Baumgartel V, 2011, NAT CELL BIOL, V13, P469, DOI 10.1038/ncb2215
   Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422
   Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899                                                          
   Elia N, 2011, P NATL ACAD SCI USA, V108, P4846, DOI 10.1073/pnas.1102714108
   Fabrikant G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000575
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   Guizetti J, 2011, SCIENCE, V331, P1616, DOI 10.1126/science.1201847
   Hanson PI, 2008, J CELL BIOL, V180, P389, DOI 10.1083/jcb.200707031
   HUANG MJ, 1995, J VIROL, V69, P6810
   Im YJ, 2010, STRUCTURE, V18, P1536, DOI 10.1016/j.str.2010.08.010
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Langelier C, 2006, J VIROL, V80, P9465, DOI 10.1128/JVI.01049-06
   Lata S, 2008, SCIENCE, V321, P1354, DOI 10.1126/science.1161070
   Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042
   Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313                                                             
   Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850
   Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004
   Obita T, 2007, NATURE, V449, P735, DOI 10.1038/nature06171
   Shtengel G, 2009, P NATL ACAD SCI USA, V106, P3125, DOI 10.1073/pnas.0813131106
   Wollert T, 2009, NATURE, V458, P172, DOI 10.1038/nature07836
NR 20
TC 67
Z9 67
U1 2
U2 51
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD FEB 7
PY 2014
VL 343
IS 6171
BP 653
EP 656
DI 10.1126/science.1247786
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CB7QC
UT WOS:000349821400001
PM 24436186
OA green_accepted
DA 2018-01-05
ER

PT J
AU Toropova, AP
   Toropov, AA
   Benfenati, E
   Korenstein, R
AF Toropova, Alla P.
   Toropov, Andrey A.
   Benfenati, Emilio
   Korenstein, Rafi
TI QSAR model for cytotoxicity of SiO2 nanoparticles on human lung
   fibroblasts
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE QSAR; SiO2 nanoparticle; Optimal descriptor; CORAL software; Modeling
   and simulation; Health effects
ID LOCAL GRAPH INVARIANTS; HIV-1 PR INHIBITORS; OPTIMAL DESCRIPTORS;
   ORGANOMETALLIC COMPOUNDS; PARTITION-COEFFICIENT; THERMAL-CONDUCTIVITY;
   CORRELATION WEIGHTS; ACUTE TOXICITY; QSPR; BALANCE
AB The possibility of building up predictive model for cytotoxicity of SiO2-nanoparticles (SiO2-NPs) by means of so-called optimal descriptors which are mathematical functions of size and concentration of SiO2-NPs is demonstrated with data on sixteen systems' "size-concentration." The calculation has been carried out by means of the CORAL software (http://www.insilico.eu/coral/). The statistical quality of the best model for the cytotoxic inhibition ratio (%) of human lung fibroblasts cultured in the media containing different concentrations of SiO2-NPs which is measured by MTT assay is the following: n = 10, r(2) = 0.9837, s = 2.53 %, F = 483 (training set) and n = 6, r(2) = 0.9269, s = 7.94 % (test set). The perspectives of this approach are discussed.
C1 [Toropova, Alla P.; Toropov, Andrey A.; Benfenati, Emilio] Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
   [Korenstein, Rafi] Tel Aviv Univ, Dept Physiol & Pharmacol, Fac Med, IL-69978 Tel Aviv, Israel.
RP Toropov, AA (reprint author), Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
EM andrey.toropov@marionegri.it
OI Toropov, Andrey/0000-0001-6864-6340; Toropova, Alla/0000-0002-4194-9963
FU EU FP7 project PreNanoTox [309666]
FX The authors thank EU FP7 project PreNanoTox (contract 309666) for
   financial support.
CR Afantitis A, 2011, EUR J MED CHEM, V46, P497, DOI 10.1016/j.ejmech.2010.11.029
   Afantitis A, 2009, EUR J MED CHEM, V44, P877, DOI 10.1016/j.ejmech.2008.05.028
   Cattaneo AG, 2010, J APPL TOXICOL, V30, P730, DOI 10.1002/jat.1609
   Deng Y, 2008, J AM CHEM SOC, V130, P28, DOI 10.1021/ja0777584
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Furtula B, 2011, J CHEMOMETR, V25, P87, DOI 10.1002/cem.1342
   Gajewicz A, 2012, ADV DRUG DELIVER REV, V64, P1663, DOI 10.1016/j.addr.2012.05.014
   Garcia J, 2011, J MOL GRAPH MODEL, V31, P10, DOI 10.1016/j.jmgm.2011.07.007
   Martinez JCG, 2011, INT J MOL SCI, V12, P9354, DOI 10.3390/ijms12129354
   Gonzalez MP, 2004, MOLECULES, V9, P1019, DOI 10.3390/91201019                                                                
   Hollas B, 2005, CROAT CHEM ACTA, V78, P489
   Ibezim E, 2012, CHEMOMETR INTELL LAB, V110, P81, DOI 10.1016/j.chemolab.2011.10.002
   Ivanciuc T, 2006, MOL DIVERS, V10, P133, DOI 10.1007/s11030-005-9003-3
   Leszczynski J, 2010, NAT NANOTECHNOL, V5, P633, DOI 10.1038/nnano.2010.182
   Li WG, 2013, J NANOSCI NANOTECHNO, V13, P1399, DOI 10.1166/jnn.2013.6084
   Marinescu G, 2006, J NANOPART RES, V8, P1045, DOI 10.1007/s11051-006-9134-1
   Melagraki G, 2011, CURR MED CHEM, V18, P2612, DOI 10.2174/092986711795933759                                                      
   Melagraki G, 2010, CHEM BIOL DRUG DES, V76, P397, DOI 10.1111/j.1747-0285.2010.01029.x
   Mullen LMA, 2011, CHEMOMETR INTELL LAB, V107, P269, DOI 10.1016/j.chemolab.2011.04.011
   Nurgaliev IN, 2006, J STRUCT CHEM+, V47, P362, DOI 10.1007/s10947-006-0307-7                                                       
   Ojha PK, 2011, CHEMOMETR INTELL LAB, V107, P194, DOI 10.1016/j.chemolab.2011.03.011
   Olson MA, 2009, ORG BIOMOL CHEM, V7, P4391, DOI 10.1039/b911874h
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Puzyn T, 2009, SMALL, V5, P2494, DOI 10.1002/smll.200900179
   Roy K, 2005, J MOL MODEL, V11, P89, DOI 10.1007/s00894-004-0224-7
   Sayes C, 2010, RISK ANAL, V30, P1723, DOI 10.1111/j.1539-6924.2010.01438.x
   Thomas DG, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-2
   Toropov AA, 2008, CHEM PHYS LETT, V461, P343, DOI 10.1016/j.cplett.2008.07.027
   Toropov AA, 2008, EUR J MED CHEM, V43, P714, DOI 10.1016/j.ejmech.2007.05.007
   Toropov AA, 2010, MOL DIVERS, V14, P183, DOI 10.1007/s11030-009-9156-6
   Toropov AA, 2009, J MATH CHEM, V46, P1060, DOI 10.1007/s10910-008-9491-3
   Toropov AA, 2009, MOL DIVERS, V13, P367, DOI 10.1007/s11030-009-9113-4
   Toropov AA, 2004, J STRUCT CHEM+, V45, P945, DOI 10.1007/s10947-005-0084-8                                                       
   Toropov AA, 2005, INDIAN J CHEM A, V44, P1545
   Toropov AA, 2001, POLYM SCI SER B+, V43, P116
   TOROPOV AA, 1999, POLYM SCI SER A, V41, P975
   Toropov AA, 2008, BIOORGAN MED CHEM, V16, P5999, DOI 10.1016/j.bmc.2008.04.055
   Toropov Andrey A, 2007, Curr Drug Discov Technol, V4, P77
   Toropov AA, 2007, QSAR COMB SCI, V26, P686, DOI 10.1002/qsar.200610135
   Toropov AA, 2007, MATER LETT, V61, P4777, DOI 10.1016/j.matlet.2007.03.026
   Toropov AA, 2006, CHEM PHYS LETT, V433, P125, DOI 10.1016/j.cplett.2006.11.010
   Toropov AA, 2010, EUR J MED CHEM, V45, P1387, DOI 10.1016/j.ejmech.2009.12.037
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropov AA, 2009, J MATH CHEM, V46, P1232, DOI 10.1007/s10910-008-9514-0
   Toropova AP, 2011, CHEMOMETR INTELL LAB, V105, P215, DOI 10.1016/j.chemolab.2010.12.007
   Toropova AP, 2013, J MATH CHEM, V51, P2230, DOI 10.1007/s10910-013-0211-2
   Toropova AP, 2011, CENT EUR J CHEM, V9, P75, DOI 10.2478/s11532-010-0116-x
   Xu ZL, 2012, J APPL TOXICOL, V32, P358, DOI 10.1002/jat.1710
NR 49
TC 11
Z9 11
U1 1
U2 24
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD FEB 1
PY 2014
VL 16
IS 2
AR 2282
DI 10.1007/s11051-014-2282-9
PG 7
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AA3DY
UT WOS:000330974300002
DA 2018-01-05
ER

PT J
AU Nel, A
   Swindells, S
   Bronich, T
   Gendelman, HE
AF Nel, Andre
   Swindells, Susan
   Bronich, Tatiana
   Gendelman, Howard E.
TI Nanomedicine and the fight against HIV/AIDS
SO NANOMEDICINE
LA English
DT Editorial Material
ID NANOFORMULATED ANTIRETROVIRAL THERAPY; MESOPOROUS SILICA NANOPARTICLES;
   SOCIETY-USA PANEL; HIV-INFECTION; DRUG-RESISTANCE; IN-VITRO; DELIVERY;
   MODEL; PREVENTION; TOXICITY
AB Ahead of the 4th Annual Meeting of the American Society of Nanomedicine, this collection of interviews brings together experts from the fields of nanomedicine and HIV/AIDS treatment. Professor Andre Nel gives us a general introduction and update on the nanomedicine field and how he hopes it will progress. Professor Susan Swindells describes the current challenges faced in the clinic for HIV/AIDS treatment. Professor Tatiana Bronich explains the research efforts being undertaken by the nanomedicine community for the treatment of microbial infections and HIV/AIDS specifically. Finally, Professor Howard Gendelman looks to the future and assesses the potential and challenges of nanomedicine approaches for HIV eradication.
C1 [Nel, Andre] Univ Calif Los Angeles, David Geffen Sch Med, Calif NanoSyst Inst, Ctr Hlth Sci 52 175, Los Angeles, CA 90095 USA.
   [Swindells, Susan] Coll Med, Dept Internal Med, Omaha, NE USA.
   [Bronich, Tatiana] Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Coll Med, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
RI Nel, Andre/J-2808-2012
CR Balkundi S, 2010, J VIS EXP, V46
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bhattacharya S, 2009, J INFECTION, V59, P377, DOI 10.1016/j.jinf.2009.09.014
   Blecher K, 2011, VIRULENCE, V2, P395, DOI 10.4161/viru.2.5.17035
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duncan R, 2013, ADV DRUG DELIVER REV, V65, P60, DOI 10.1016/j.addr.2012.08.012
   Ensign LM, 2012, ADV MATER, V24, P3887, DOI 10.1002/adma.201201800
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gluck R, 2002, VACCINE, V20, pB10, DOI 10.1016/S0264-410X(02)00513-3
   Guo D, 2013, NANOMEDICINE-UK, DOI [10.2217/nnm.13.92, DOI 10.2217/NNM.13.92]
   Hamill R, 2013, DRUGS, V73, P919, DOI 10.1007/s40265-013-0069-4
   Hirsch MS, 2008, CLIN INFECT DIS, V47, P266, DOI 10.1086/589297
   Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kim SS, 2011, METHODS MOL BIOL, V721, P339, DOI 10.1007/978-1-61779-037-9_21
   Klatt NR, 2012, IMMUNOL REV, V254, P326
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Marsden MD, 2010, FUTURE VIROL, V5, P97, DOI 10.2217/FVL.09.70
   Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w
   McDonald TO, 2014, ADV HEALTHC MATER, V3, P400, DOI 10.1002/adhm.201300280
   Meng H, 2013, ACS NANO, V7, P10048, DOI 10.1021/nn404083m
   Meng H, 2013, ACS NANO, V7, P994, DOI 10.1021/nn3044066
   Meng H, 2011, ACS NANO, V5, P4131, DOI 10.1021/nn200809t
   Meng HA, 2010, J AM CHEM SOC, V132, P12690, DOI 10.1021/ja104501a
   Nederberg F, 2011, NAT CHEM, V3, P409, DOI [10.1038/nchem.1012, 10.1038/NCHEM.1012]
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Nel A, 2013, ACCOUNTS CHEM RES, V46, P607, DOI 10.1021/ar300022h
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Recum HA, 2013, EXP BIOL MED MAYWOOD, V238, P442
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Rupp R, 2007, INT J NANOMED, V2, P561
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Van Duyne R, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-76
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Wang X, 2012, NANO LETT, V12, P3050, DOI 10.1021/nl300895y
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
NR 60
TC 2
Z9 2
U1 0
U2 24
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD FEB
PY 2014
VL 9
IS 2
BP 193
EP 206
DI 10.2217/nnm.13.213
PG 14
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AB0YA
UT WOS:000331517000013
PM 24552561
DA 2018-01-05
ER

PT J
AU Toropov, AA
   Toropova, AP
   Raska, I
   Leszczynska, D
   Leszczynski, J
AF Toropov, Andrey A.
   Toropova, Alla P.
   Raska, Ivan, Jr.
   Leszczynska, Danuta
   Leszczynski, Jerzy
TI Comprehension of drug toxicity: Software and databases
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE In silica toxicology; In silica methods; QSAR; Computational toxicology;
   Drug toxicity
ID HIV-1 PR INHIBITORS; METAL-OXIDE NANOPARTICLES; DESCRIPTORS QSAR
   ANALYSIS; PREDICTION; DERIVATIVES; MODELS; VALIDATION; DESIGN; CORAL;
   CYTOTOXICITY
AB Quantitative structure-property/activity relationships (QSPRs/QSARs) are a tool (in silico) to rapidly predict various endpoints in general, and drug toxicity in particular. However, this dynamic evolution of experimental data (expansion of existing experimental data on drugs toxicity) leads to the problem of critical estimation of the data. The carcinogenicity, mutagenicity, liver effects and cardiac toxicity should be evaluated as the most important aspects of the drug toxicity. The toxicity is a multidimensional phenomenon. It is apparent that the main reasons for the increase in applications of in silica prediction of toxicity include the following: (i) the need to reduce animal testing; (ii) computational models provide reliable toxicity prediction; (iii) development of legislation that is related to use of new substances; (iv) filling data gaps; (v) reduction of cost and time; (vi) designing of new compounds; (vii) advancement of understanding of biology and chemistry. This mini-review provides analysis of existing databases and software which are necessary for use of robust computational assessments and robust prediction of potential drug toxicities by means of in silica methods. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Toropov, Andrey A.; Toropova, Alla P.] Ist Ric Farmacol Mario Negri IRCCS, IRCCS, I-20156 Milan, Italy.
   [Raska, Ivan, Jr.] Charles Univ Prague, Dept Endocrinol & Metab, Dept Med 3, Fac Med 1, Prague 12808 2, Czech Republic.
   [Raska, Ivan, Jr.] Gen Univ Hosp Prague, Prague 12808 2, Czech Republic.
   [Leszczynska, Danuta] Jackson State Univ, Dept Civil & Environm Engn, Interdisciplinary Nanotox Ctr, Jackson, MS 39217 USA.
   [Leszczynski, Jerzy] Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Nanotox Ctr, Jackson, MS 39217 USA.
RP Toropov, AA (reprint author), Ist Ric Farmacol Mario Negri IRCCS, IRCCS, Via La Masa 19, I-20156 Milan, Italy.
EM andrey.toropov@marionegri.it
RI Raska, Ivan/E-9179-2017
OI Raska, Ivan/0000-0003-3895-5286; Toropova, Alla/0000-0002-4194-9963;
   Toropov, Andrey/0000-0001-6864-6340
CR Bartels M, 2012, COMPUT METH PROG BIO, V108, P773, DOI 10.1016/j.cmpb.2012.04.014
   Chen A, 2012, CURR DRUG METAB, V13, P863, DOI 10.2174/138920012800840419                                                      
   Dobo KL, 2012, REGUL TOXICOL PHARM, V62, P449, DOI 10.1016/j.yrtph.2012.01.007
   Fernandez M, 2011, MOL DIVERS, V15, P269, DOI 10.1007/s11030-010-9234-9
   Fourches D, 2010, CHEM RES TOXICOL, V23, P171, DOI 10.1021/tx900326k
   Frid AA, 2010, REGUL TOXICOL PHARM, V56, P276, DOI 10.1016/j.yrtph.2009.11.005
   Gajewicz A, 2012, ADV DRUG DELIVER REV, V64, P1663, DOI 10.1016/j.addr.2012.05.014
   Garcia J, 2011, J MOL GRAPH MODEL, V31, P10, DOI 10.1016/j.jmgm.2011.07.007
   Martinez JCG, 2011, INT J MOL SCI, V12, P9354, DOI 10.3390/ijms12129354
   Hamon V, 2012, MOL INFORM, V31, P669, DOI 10.1002/minf.201200004
   Helguera AM, 2008, CURR TOP MED CHEM, V8, P1628, DOI 10.2174/156802608786786598
   Ibezim E, 2012, CHEMOMETR INTELL LAB, V110, P81, DOI 10.1016/j.chemolab.2011.10.002
   Ishikawa T, 2012, MINI-REV MED CHEM, V12, P505, DOI 10.2174/138955712800493825                                                      
   Kar S, 2011, INDIAN J BIOCHEM BIO, V48, P111
   Kar S, 2010, J INDIAN CHEM SOC, V87, P1455
   Kirchmair J, 2012, J CHEM INF MODEL, V52, P617, DOI 10.1021/ci200542m
   Kortagere S, 2010, J PHARMACOL TOX MET, V61, P67, DOI 10.1016/j.vascn.2010.02.005
   Linkov I, 2013, NANO TODAY, V8, P5, DOI 10.1016/j.nantod.2012.10.002
   Makhaeva GF, 2013, CHEM-BIOL INTERACT, V203, P231, DOI 10.1016/j.cbi.2012.10.012
   Mullard A, 2011, NAT REV DRUG DISCOV, V10, P82, DOI 10.1038/nrd3370
   Mullen LMA, 2011, CHEMOMETR INTELL LAB, V107, P269, DOI 10.1016/j.chemolab.2011.04.011
   Myshkin E, 2012, CHEM BIOL DRUG DES, V80, P406, DOI 10.1111/j.1747-0285.2012.01411.x
   Perisic-Janjic N, 2013, J PHARMACEUT BIOMED, V72, P65, DOI 10.1016/j.jpba.2012.09.006
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Rhoades JA, 2012, PHARM RES-DORDR, V29, P972, DOI 10.1007/s11095-011-0637-9
   Roy K, 2012, CURR COMPUT-AID DRUG, V8, P135
   Ruark CD, 2013, ARCH TOXICOL, V87, P281, DOI 10.1007/s00204-012-0934-z
   Segan S, 2013, J PHARMACEUT BIOMED, V72, P231, DOI 10.1016/j.jpba.2012.08.025
   Speck-Planche A, 2013, EUR J PHARM SCI, V48, P812, DOI 10.1016/j.ejps.2013.01.011
   Toropov AA, 2013, CENT EUR J CHEM, V11, P371, DOI 10.2478/s11532-012-0166-3
   Toropov AA, 2012, STRUCT CHEM, V23, P1891, DOI 10.1007/s11224-012-9995-0
   Toropov AA, 2012, CHEMOSPHERE, V89, P1098, DOI 10.1016/j.chemosphere.2012.05.077
   Toropov AA, 2010, EUR J MED CHEM, V45, P1387, DOI 10.1016/j.ejmech.2009.12.037
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2012, STRUCT CHEM, V23, P1873, DOI 10.1007/s11224-012-9996-z
   Toropova AP, 2011, J COMPUT CHEM, V32, P2727, DOI 10.1002/jcc.21848
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Valerio Luis G Jr, 2013, Methods Mol Biol, V930, P341, DOI 10.1007/978-1-62703-059-5_15
   Valerio LG, 2012, TOXICOL APPL PHARM, V260, P209, DOI 10.1016/j.taap.2012.03.001
   Valerio Luis G. Jr., 2011, Human Genomics, V5, P200
   Valerio LG, 2009, TOXICOL APPL PHARM, V241, P356, DOI 10.1016/j.taap.2009.08.022
   Yadav DK, 2013, J CHEMOMETR, V27, P21, DOI 10.1002/cem.2488
   Yadav DK, 2012, J MOL MODEL, V18, P2513, DOI 10.1007/s00894-011-1265-3
NR 44
TC 15
Z9 16
U1 2
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD FEB 1
PY 2014
VL 45
BP 20
EP 25
DI 10.1016/j.compbiomed.2013.11.013
PG 6
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA AC3PJ
UT WOS:000332433400003
PM 24480159
DA 2018-01-05
ER

PT J
AU Chiodo, F
   Marradi, M
   Park, J
   Ram, AFJ
   Penades, S
   van Die, I
   Tefsen, B
AF Chiodo, Fabrizio
   Marradi, Marco
   Park, Joohae
   Ram, Arthur F. J.
   Penades, Soledad
   van Die, Irma
   Tefsen, Boris
TI Galactofuranose-Coated Gold Nanoparticles Elicit a Pro-inflammatory
   Response in Human Monocyte-Derived Dendritic Cells and Are Recognized by
   DC-SIGN
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID UDP-GALACTOPYRANOSE MUTASE; ASPERGILLUS-FUMIGATUS; BINDING; LECTIN;
   GLYCONANOPARTICLES; HIV-1; POLYSACCHARIDES; GLYCOBIOLOGY; BIOSYNTHESIS;
   VIRULENCE
AB Galactofuranose (Galf) is the five-membered ring form of galactose exclusively found in nonmammalian species, among which several are pathogens. To determine the putative role of this carbohydrate in host pathogen interactions, we synthesized multivalent gold nanoparticles carrying Galf (Galf-GNPs) and show that they are recognized by the EB-A2 antibody, which is widely used to detect Galf-containing galactomannan in the serum of Aspergillosis patients. We demonstrated that human monocyte-derived dendritic cells bound Galf-GNPs via interaction with the lectin DC-SIGN. Moreover, interaction of dendritic cells with Galf-GNPs resulted in increased expression of several maturation markers on these cells and induced secretion of the pro-inflammatory cytokines IL-6 and TNF-alpha. These data indicate that Galf is able to modulate the innate immune response via dendritic cells. In conclusion, Galf-GNPs are a versatile tool that can be applied in multiple functional studies to gain a better understanding of the role of Galf in host-pathogen interaction.
C1 [Chiodo, Fabrizio; Marradi, Marco; Penades, Soledad] CIC biomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, San Sebastian 20009, Spain.
   [Marradi, Marco; Penades, Soledad] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, San Sebastian 20009, Spain.
   [Park, Joohae; Ram, Arthur F. J.] Leiden Univ, Inst Biol Leiden, NL-2333 BE Leiden, Netherlands.
   [Ram, Arthur F. J.] Kluyver Ctr Genom Ind Fermentat, NL-2600 GA Delft, Netherlands.
   [Chiodo, Fabrizio; van Die, Irma; Tefsen, Boris] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands.
RP Chiodo, F (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
EM chiodo.fabrizio@gmail.com; b.tefsen@im.ac.cn
RI Tefsen, Boris/J-1503-2012; Chiodo, Fabrizio/R-1121-2017; biomaGUNE,
   CIC/J-9136-2014
OI Tefsen, Boris/0000-0001-6668-217X; Chiodo, Fabrizio/0000-0003-3619-9982;
   biomaGUNE, CIC/0000-0001-7690-0660
FU MINECO [CTQ2011-27268]; Department of Industry of the Basque Country
   [ETOR-TEK2011]; Spanish Ministry of Science and Innovation, MICINN
   [CTQ2008-04638]; Dutch Technology Foundation (STW) [10622]
FX We thank A. Pettersson and D. van het Oever (both from Department of
   Medical Microbiology, VU University Medical Center) for sharing
   materials. Financial support from the MINECO (Grant No. CTQ2011-27268)
   and the Department of Industry of the Basque Country (Grant No.
   ETOR-TEK2011) is acknowledged. F.C. was supported by the Spanish
   Ministry of Science and Innovation, MICINN (Grant No. CTQ2008-04638).
   B.T. and J.H.P. were financially supported by the Dutch Technology
   Foundation (STW, Grant No. 10622). M.M., I.v.D., and S.P. acknowledge
   COST action CM1102.
CR Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Cardoso LS, 2007, MICROB CELL FACT, V6, DOI 10.1186/1475-2859-6-1
   Chiodo F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073027
   Damveld RA, 2008, GENETICS, V178, P873, DOI 10.1534/genctics.107.073148
   Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b                                                               
   El-Ganiny AM, 2008, FUNGAL GENET BIOL, V45, P1533, DOI 10.1016/j.fgb.2008.09.008
   Engel J, 2009, J BIOL CHEM, V284, P33859, DOI 10.1074/jbc.M109.070219
   Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200
   Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778
   Heesemann L, 2011, INT J MED MICROBIOL, V301, P523, DOI [10.1016/j.nmm.2011.02.003, 10.1016/j.ijmm.2011.02.003]
   Ilyas R, 2011, IMMUNOBIOLOGY, V216, P126, DOI 10.1016/j.imbio.2010.06.002
   Irure A, 2013, BIOMATER SCI-UK, V1, P658, DOI 10.1039/c3bm60032g
   Kiessling LL, 2010, ANNU REV BIOCHEM, V79, P619, DOI 10.1146/annurev.biochem.77.070606.100917
   Kleczka B, 2007, J BIOL CHEM, V282, P10498, DOI 10.1074/jbc.M700023200
   LATGE JP, 1994, INFECT IMMUN, V62, P5424
   Lee RT, 2011, GLYCOBIOLOGY, V21, P512, DOI 10.1093/glycob/cwq193
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Marino C, 2012, GLYCANS BIOCH CHARAC, P207
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Marradi M, 2010, ADV CARBOHYD CHEM BI, V64, P211, DOI 10.1016/S0065-2318(10)64005-X
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   NOTERMANS S, 1988, MOL IMMUNOL, V25, P975, DOI 10.1016/0161-5890(88)90003-X
   Richards MR, 2009, CHEMBIOCHEM, V10, P1920, DOI 10.1002/cbic.200900208
   Sainz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032273
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Schmalhorst PS, 2008, EUKARYOT CELL, V7, P1268, DOI 10.1128/EC.00109-08
   Serrano-Gomez D, 2004, J IMMUNOL, V173, P5635, DOI 10.4049/jimmunol.173.9.5635                                                     
   Splain RA, 2010, BIOORGAN MED CHEM, V18, P3753, DOI 10.1016/j.bmc.2010.04.068
   STYNEN D, 1995, J CLIN MICROBIOL, V33, P497
   Tefsen B, 2012, GLYCOBIOLOGY, V22, P456, DOI 10.1093/glycob/cwr144
   Thomann JS, 2012, EUR J MED CHEM, V51, P174, DOI 10.1016/j.ejmech.2012.02.039
   Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200                                                          
   van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009
   van Stijn CMW, 2010, MOL IMMUNOL, V47, P1544, DOI 10.1016/j.molimm.2010.01.014
   van Vliet SJ, 2005, INT IMMUNOL, V17, P661, DOI 10.1093/intimm/dxh246
   Zughaier SM, 2011, J LEUKOCYTE BIOL, V89, P469, DOI 10.1189/jlb.0610369
NR 36
TC 27
Z9 27
U1 3
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD FEB
PY 2014
VL 9
IS 2
BP 383
EP 389
DI 10.1021/cb4008265
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AB6VG
UT WOS:000331927000011
PM 24304188
DA 2018-01-05
ER

PT J
AU Shin, MC
   Zhang, J
   Min, KA
   Lee, K
   Byun, Y
   David, AE
   He, HN
   Yang, VC
AF Shin, Meong Cheol
   Zhang, Jian
   Min, Kyoung Ah
   Lee, Kyuri
   Byun, Youngro
   David, Allan E.
   He, Huining
   Yang, Victor C.
TI Cell-penetrating peptides: Achievements and challenges in application
   for cancer treatment
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Review
DE cell penetrating peptides; cancer; macromolecule; nanoparticle; in vivo
ID INTRACELLULAR PROTEIN DELIVERY; BIOLOGICALLY-ACTIVE PROTEINS;
   MOLECULAR-WEIGHT PROTAMINE; VECTOR-MEDIATED STRATEGY; IN-VITRO
   ASSESSMENT; HIV-TAT PEPTIDE; DRUG-DELIVERY; PHARMACEUTICAL NANOCARRIERS;
   ANTENNAPEDIA HOMEODOMAIN; TRANSDUCTION DOMAINS
AB One of the major hurdles to cure cancer lies in the low potency of currently available drugs, which could eventually be solved by using more potent therapeutic macromolecules, such as proteins or genes. However, although these macromolecules possess greater potency inside the cancer cells, the barely permeable cell membrane remains a formidable barrier to exert their efficacy. A widely used strategy is to use cell penetrating peptides (CPPs) to improve their intracellular uptake. Since the discovery of the first CPP, numerous CPPs have been derived from natural or synthesized products. Both in vitro and in vivo studies have demonstrated that those CPPs are highly efficient in transducing cargoes into almost all cell types. Therefore, to date, CPPs have been widely used for intracellular delivery of various cargoes, including peptides, proteins, genes, and even nanoparticles. In addition, recently, based on the successes of CPPs in cellular studies, their applications in vivo have been actively pursued. This review will focus on the advanced applications of CPP-based in vivo delivery of therapeutics (e.g., small molecule drugs, proteins, and genes). In addition, we will highlight certain updated applications of CPPs for intracellular delivery of nanoparticulate drug carriers, as well as several smart strategies for tumor targeted delivery of CPP-cargoes. (c) 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 575-587, 2014.
C1 [Shin, Meong Cheol; Zhang, Jian; Min, Kyoung Ah; Lee, Kyuri; Yang, Victor C.] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.
   [Byun, Youngro; Yang, Victor C.] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea.
   [David, Allan E.] Auburn Univ, Dept Chem Engn, Auburn, AL 36849 USA.
   [He, Huining; Yang, Victor C.] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
RP Shin, MC (reprint author), Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.
EM vcyang@umich.edu
RI BYUN, YOUNG RO/D-5735-2013
FU NIH [CA114612, NS066945]; National Key Basic Research Program of China
   973 [2013CB932502]; Tianjin Municipal Science and Technology Commission
   [12JCZDJC34000]; World Class University (WCU) project of the MEST; NRF,
   South Korea [R31-2008-000-10103-01]
FX Contract grant sponsor: NIH R01; contract grant numbers: CA114612,
   NS066945; Contract grant sponsor: National Key Basic Research Program of
   China 973; contract grant number: 2013CB932502; Contract grant sponsor:
   Tianjin Municipal Science and Technology Commission; contract grant
   number: 12JCZDJC34000; Contract grant sponsor: World Class University
   (WCU) project of the MEST and NRF, South Korea; contract grant number:
   R31-2008-000-10103-01
CR Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593                                                
   Agarwal R, 2009, CLIN CANCER RES, V15, P3654, DOI 10.1158/1078-0432.CCR-08-3293
   Balzeau J, 2013, BIOMATERIALS, V34, P3381, DOI 10.1016/j.biomaterials.2013.01.068
   BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340                                                          
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   Choi YS, 2010, BIOMATERIALS, V31, P1429, DOI 10.1016/j.biomaterials.2009.11.001
   Chopra S, 2006, J PHARM PHARMACOL, V58, P1021, DOI 10.1211/jpp.58.8.0002
   Christiaens B, 2004, EUR J BIOCHEM, V271, P1187, DOI 10.1111/j.1432-1033.2004.04022.x
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Dupont E, 2011, METHODS MOL BIOL, V683, P21, DOI 10.1007/978-1-60761-919-2_2
   El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Ezzat K, 2010, CURR PHARM DESIGN, V16, P1167, DOI 10.2174/138161210790963832                                                      
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fisher L, 2004, GENE THER, V11, P1264, DOI 10.1038/sj.gt.3302291
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz M, 2006, J CONTROL RELEASE, V116, P247, DOI 10.1016/j.jconrel.2006.07.009
   Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Hajdu Steven I, 2011, Cancer, V117, P1097, DOI 10.1002/cncr.25553
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Han L, 2010, HUM GENE THER, V21, P417, DOI 10.1089/hum.2009.087
   Harris TJ, 2008, SMALL, V4, P1307, DOI 10.1002/smll.200701319
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Hosotani R, 2002, CLIN CANCER RES, V8, P1271
   Hutmacher DW, 2010, NAT MATER, V9, P90, DOI 10.1038/nmat2619
   Inoue M, 2004, INT J ONCOL, V25, P713
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jarver P, 2010, TRENDS PHARMACOL SCI, V31, P528, DOI 10.1016/j.tips.2010.07.006
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jiang TY, 2012, BIOMATERIALS, V33, P9246, DOI 10.1016/j.biomaterials.2012.09.027
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Juliano RL, 2006, ANN NY ACAD SCI, V1082, P18, DOI 10.1196/annals.1348.011
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Kim HY, 2011, BIOMATERIALS, V32, P5262, DOI 10.1016/j.biomaterials.2011.03.074
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Koppelhus U, 2002, ANTISENSE NUCLEIC A, V12, P51, DOI 10.1089/108729002760070795                                                      
   Koren E, 2012, J CONTROL RELEASE, V160, P264, DOI 10.1016/j.jconrel.2011.12.002
   Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083                                                           
   Kushner D M, 2000, Curr Oncol Rep, V2, P23, DOI 10.1007/s11912-000-0007-y
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Kwon YM, 2009, J CONTROL RELEASE, V139, P182, DOI 10.1016/j.jconrel.2009.06.027
   Lee JY, 2011, INT J CANCER, V128, P2470, DOI 10.1002/ijc.25578
   LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120                                                         
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197                                                      
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Los M, 2007, ONCOLOGIST, V12, P443, DOI 10.1634/theoncologist.12-4-443
   Lu PY, 2003, CURR OPIN MOL THER, V5, P225
   Ludtke S, 1995, BIOCHEMISTRY-US, V34, P16764, DOI 10.1021/bi00051a026
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Mei J., 2008, Experimental Oncology, V30, P29
   Michiue H, 2009, CANCER BIOL THER, V8, P2306
   Michl J, 2006, INT J CANCER, V119, P1577, DOI 10.1002/ijc.22029
   Moon C, 2007, J CONTROL RELEASE, V124, P43, DOI 10.1016/j.jconrel.2007.08.029
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mortensen MW, 2006, BIOCONJUGATE CHEM, V17, P284, DOI 10.1021/bc050208v
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nan YH, 2011, J PEPT SCI, V17, P812, DOI 10.1002/psc.1408
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oehlke J, 2004, EUR J BIOCHEM, V271, P3043, DOI 10.1111/j.1432-1033.2004.04236.x
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04-2322fje
   Park YJ, 2003, J GENE MED, V5, P700, DOI 10.1002/jgm.402
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Pridgen EM, 2007, NANOMEDICINE-UK, V2, P669, DOI 10.2217/17435889.2.5.669
   Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X
   Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x                                              
   Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Roach P, 2007, J MATER SCI-MATER M, V18, P1263, DOI 10.1007/s10856-006-0064-3
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Sethuraman VA, 2008, PHARM RES, V25, P657, DOI 10.1007/s11095-007-9480-4
   Shokolenko IN, 2005, DNA REPAIR, V4, P511, DOI 10.1016/j.dnarep.2004.11.009
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   STIRPE F, 1980, J BIOL CHEM, V255, P6947
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Winer I, 2010, CANCER RES, V70, P8674, DOI 10.1158/0008-5472.CAN-10-1917
   Yagi N, 2007, BIOORG MED CHEM LETT, V17, P2590, DOI 10.1016/j.bmcl.2007.02.001
   Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 129
TC 42
Z9 45
U1 5
U2 140
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD FEB
PY 2014
VL 102
IS 2
BP 575
EP 587
DI 10.1002/jbm.a.34859
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 269MT
UT WOS:000328246100028
PM 23852939
OA green_accepted
DA 2018-01-05
ER

PT J
AU Vorontsov, II
   Wu, Y
   DeLucia, M
   Minasov, G
   Mehrens, J
   Shuvalova, L
   Anderson, WF
   Ahn, J
AF Vorontsov, Ivan I.
   Wu, Ying
   DeLucia, Maria
   Minasov, George
   Mehrens, Jennifer
   Shuvalova, Ludmilla
   Anderson, Wayne F.
   Ahn, Jinwoo
TI Mechanisms of Allosteric Activation and Inhibition of the
   Deoxyribonucleoside Triphosphate Triphosphohydrolase from Enterococcus
   faecalis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Allosteric regulation; Enzyme catalysis; Nucleoside nucleotide
   metabolism; Site directed mutagenesis; X-ray crystallography; dNTPase;
   dNTP; HD domain; triphosphohydrolase
ID RESTRICTION FACTOR SAMHD1; CD4(+) T-CELLS; ESCHERICHIA-COLI; HIV-1
   INFECTION; DGTP TRIPHOSPHOHYDROLASE; DNTP TRIPHOSPHOHYDROLASE; POOLS;
   PROTEIN; VPX; VIRULENCE
AB Background: EF1143 from Enterococcus faecalis is a deoxyribonucleoside triphosphate (dNTP) triphosphohydrolase. Results: Enzymatic studies and crystal structure of EF1143 bound to dNTPs show that dNTP binding at two adjacent allosteric sites can differentially modulate enzyme catalysis. Conclusion: EF1143 enzyme catalysis is differentially regulated by four dNTPs. Significance: Learning how the enzyme activity is regulated by substrates is fundamental for understanding enzyme catalysis and allostery.
   EF1143 from Enterococcus faecalis, a life-threatening pathogen that is resistant to common antibiotics, is a homo-tetrameric deoxyribonucleoside triphosphate (dNTP) triphosphohydrolase (dNTPase), converting dNTPs into the deoxyribonucleosides and triphosphate. The dNTPase activity of EF1143 is regulated by canonical dNTPs, which simultaneously act as substrates and activity modulators. Previous crystal structures of apo-EF1143 and the protein bound to both dGTP and dATP suggested allosteric regulation of its enzymatic activity by dGTP binding at four identical allosteric sites. However, whether and how other canonical dNTPs regulate the enzyme activity was not defined. Here, we present the crystal structure of EF1143 in complex with dGTP and dTTP. The new structure reveals that the tetrameric EF1143 contains four additional secondary allosteric sites adjacent to the previously identified dGTP-binding primary regulatory sites. Structural and enzyme kinetic studies indicate that dGTP binding to the first allosteric site, with nanomolar affinity, is a prerequisite for substrate docking and hydrolysis. Then, the presence of a particular dNTP in the second site either enhances or inhibits the dNTPase activity of EF1143. Our results provide the first mechanistic insight into dNTP-mediated regulation of dNTPase activity.
C1 [Vorontsov, Ivan I.; Minasov, George; Shuvalova, Ludmilla; Anderson, Wayne F.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
   [Wu, Ying; DeLucia, Maria; Mehrens, Jennifer; Ahn, Jinwoo] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
RP Anderson, WF (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
EM wf-anderson@northwestern.edu; jahn@structbio.pitt.edu
OI Minasov, George/0000-0001-5460-3462
FU National Institutes of Health [U54 GM094585, P50GM082251]; University of
   Pittsburgh School of Medicine
FX This work was supported in part by National Institutes of Health Grant
   U54 GM094585 for the Midwest Center for Structural Genomics (to W. F.
   A.) and Grant P50GM082251 (to J. A.). This work was also supported by
   funds from the University of Pittsburgh School of Medicine (to J. A.).
CR Ahn J, 2012, J BIOL CHEM, V287, P12550, DOI 10.1074/jbc.M112.340711
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964
   Berger A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002425
   Buckstein MH, 2008, J BACTERIOL, V190, P718, DOI 10.1128/JB.01020-07
   DeLano W.L, 2010, PYMOL MOL GRAPHICS S
   DeLucia M, 2013, J BIOL CHEM, V288, P19116, DOI 10.1074/jbc.M113.469007
   Descours B, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-87
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fisher K, 2009, MICROBIOL-SGM, V155, P1749, DOI 10.1099/mic.0.026385-0
   Franzolin E, 2013, P NATL ACAD SCI USA, V110, P14272, DOI 10.1073/pnas.1312033110
   Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623
   HOPKINS RL, 1985, J BIOL CHEM, V260, P6618
   Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195
   Ji XY, 2013, NAT STRUCT MOL BIOL, V20, P1304, DOI 10.1038/nsmb.2692
   Kondo N, 2004, J BIOCHEM, V136, P221, DOI 10.1093/jb/mvh115
   Kondo N, 2007, ACTA CRYSTALLOGR D, V63, P230, DOI 10.1107/S0907444906049262
   Kumar D, 2011, NUCLEIC ACIDS RES, V39, P1360, DOI 10.1093/nar/gkq829
   KUNKEL TA, 1992, J BIOL CHEM, V267, P18251
   KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X
   Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Li ZP, 2011, APPL MICROBIOL BIOT, V91, P1203, DOI 10.1007/s00253-011-3407-z
   Lopes MD, 2005, INT J FOOD MICROBIOL, V103, P191, DOI 10.1016/j.ijfoodmicro.2004.12.025
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   NAKAI H, 1990, J BIOL CHEM, V265, P4411
   National Nosocomial Infections Surveillance, 2004, AM J INFECT CONTROL, V32, P470, DOI DOI 10.1016/S0196655304005425
   Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443
   Oganesyan V, 2007, ACTA CRYSTALLOGR F, V63, P369, DOI 10.1107/S1744309107018945
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628
   Rosenthal VD, 2012, AM J INFECT CONTROL, V40, P396, DOI 10.1016/j.ajic.2011.05.020
   SARGENT RG, 1987, J BIOL CHEM, V262, P5546
   Sava IG, 2010, CLIN MICROBIOL INFEC, V16, P533, DOI 10.1111/j.1469-0691.2010.03213.x
   St Gelais C, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-105
   Vorontsov II, 2011, J BIOL CHEM, V286, P33158, DOI 10.1074/jbc.M111.250456
   Wisplinghoff H, 2003, CLIN INFECT DIS, V36, P1103, DOI 10.1086/374339                                                                  
   WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740
   Yan JP, 2013, J BIOL CHEM, V288, P10406, DOI 10.1074/jbc.M112.443796
   Zhu CF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3722
NR 41
TC 6
Z9 6
U1 1
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 31
PY 2014
VL 289
IS 5
BP 2815
EP 2824
DI 10.1074/jbc.M113.524207
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AD6WW
UT WOS:000333403000030
PM 24338016
OA gold
DA 2018-01-05
ER

PT J
AU Fleta-Soriano, E
   Martinez, JP
   Hinkelmann, B
   Gerth, K
   Washausen, P
   Diez, J
   Frank, R
   Sasse, F
   Meyerhans, A
AF Fleta-Soriano, Eric
   Martinez, Javier P.
   Hinkelmann, Bettina
   Gerth, Klaus
   Washausen, Peter
   Diez, Juana
   Frank, Ronald
   Sasse, Florenz
   Meyerhans, Andreas
TI The myxobacterial metabolite ratjadone A inhibits HIV infection by
   blocking the Rev/CRM1-mediated nuclear export pathway
SO MICROBIAL CELL FACTORIES
LA English
DT Article
DE Ratjadone; Myxobacteria; HIV; Rev; Host factor; CRM1; Nuclear export
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LEPTOMYCIN-B; HOST FACTORS; STRUCTURAL
   BASIS; IMPORTIN-BETA; RNA TRANSPORT; REV FUNCTION; CRM1; PROTEIN;
   IDENTIFICATION
AB Background: The nuclear export of unspliced and partially spliced HIV-1 mRNA is mediated by the recognition of a leucine-rich nuclear export signal (NES) in the HIV Rev protein by the host protein CRM1/Exportin1. This makes the CRM1-Rev complex an attractive target for the development of new antiviral drugs. Here we tested the anti-HIV efficacy of ratjadone A, a CRM1 inhibitor derived from myxobacteria.
   Results: Ratjadone A inhibits HIV infection in vitro in a dose-dependent manner with EC50 values at the nanomolar range. The inhibitory effect of ratjadone A occurs around 12 hours post-infection and is specific for the Rev/CRM1-mediated nuclear export pathway. By using a drug affinity responsive target stability (DARTS) assay we could demonstrate that ratjadone A interferes with the formation of the CRM1-Rev-NES complex by binding to CRM1 but not to Rev.
   Conclusion: Ratjadone A exhibits strong anti-HIV activity but low selectivity due to toxic effects. Although this limits its potential use as a therapeutic drug, further studies with derivatives of ratjadones might help to overcome these difficulties in the future.
C1 [Fleta-Soriano, Eric; Martinez, Javier P.; Meyerhans, Andreas] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Infect Biol Grp, Barcelona 08003, Spain.
   [Hinkelmann, Bettina; Washausen, Peter; Frank, Ronald; Sasse, Florenz] Helmholtz Ctr Infect Res, Dept Biol Chem, Braunschweig, Germany.
   [Diez, Juana] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Mol Virol Grp, Barcelona 08003, Spain.
   [Gerth, Klaus] Helmholtz Ctr Infect Res, Dept Microbial Drugs, Braunschweig, Germany.
   [Meyerhans, Andreas] ICREA, Barcelona, Spain.
RP Meyerhans, A (reprint author), Univ Pompeu Fabra, Dept Expt & Hlth Sci, Infect Biol Grp, Dr Aiguader 88, Barcelona 08003, Spain.
EM andreas.meyerhans@upf.edu
RI Meyerhans, Andreas/D-3382-2014
OI Meyerhans, Andreas/0000-0003-0620-5317; Martinez Vesga, Javier
   Pablo/0000-0003-3333-5272
FU Bill and Melinda Gates Foundation; Institucio Catalana de Recerca i
   Estudis Avancats (ICREA); Spanish Ministry of Science and Innovation
   [SAF2010-21336, BFU2010-20803]; FPI [BES-2011-048569]; ICREA
FX The research is supported by grants from the Bill and Melinda Gates
   Foundation, Institucio Catalana de Recerca i Estudis Avancats (ICREA),
   the Spanish Ministry of Science and Innovation SAF2010-21336,
   BFU2010-20803 and FPI grant number BES-2011-048569.
CR Ammaranond P, 2012, FUND CLIN PHARMACOL, V26, P146, DOI 10.1111/j.1472-8206.2011.01009.x
   Arhel N, 2010, BBA-MOL BASIS DIS, V1802, P313, DOI 10.1016/j.bbadis.2009.12.003
   Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161
   Bogerd HP, 1998, J VIROL, V72, P8627
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Buckheit RW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1697
   Cerutti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025854
   Cmarko D, 2002, J VIROL, V76, P10473, DOI 10.1128/JVI.76.20.10473-10484.2002
   Colin L, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-111
   CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U
   Daelemans D, 2002, P NATL ACAD SCI USA, V99, P14440, DOI 10.1073/pnas.212285299
   Daelemans D, 2011, NAT PROTOC, V6, P925, DOI 10.1038/nprot.2011.330
   Diez J, 2012, MICROB CELL FACT, V11
   Dong XH, 2009, NAT STRUCT MOL BIOL, V16, P558, DOI 10.1038/nsmb.1586
   Dong XH, 2009, NATURE, V458, P1136, DOI 10.1038/nature07975
   Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231
   Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319
   FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0
   FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0
   Friedrich BM, 2011, VIRUS RES, V161, P101, DOI 10.1016/j.virusres.2011.08.001
   Gegerfelt ASV, 2006, AIDS RES HUM RETROV, V22, P516
   GERTH K, 1995, J ANTIBIOT, V48, P973, DOI 10.7164/antibiotics.48.973                                                      
   Guttler T, 2011, EMBO J, V30, P3457, DOI 10.1038/emboj.2011.287
   Guo J, 2011, J VIROL, V85, P9824, DOI 10.1128/JVI.05170-11
   Hakata Y, 1998, J VIROL, V72, P6602
   HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534                                                           
   HAUBER J, 1988, J VIROL, V62, P4801
   Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420
   Huttel S, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-59
   Khattab MA, 2009, WORLD J GASTROENTERO, V15, P3472, DOI 10.3748/wjg.15.3472
   Kimura T, 2009, MED MOL MORPHOL, V42, P70, DOI 10.1007/s00795-009-0441-3
   Koster M, 2003, EXP CELL RES, V286, P321, DOI 10.1016/S0014-4827(03)00100-9
   Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112
   Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136
   Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742
   Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153
   Lalonde MS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002038
   Lin MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051466
   Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163
   MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U                                                    
   MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9                                                    
   Martinez JP, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-85
   Meissner T, 2004, FEBS LETT, V576, P27, DOI 10.1016/j.febslet.2004.08.056
   Naji S, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.015313
   Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746                                                        
   PACE CN, 1980, J BIOL CHEM, V255, P3862
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   Perez-Vilaro G, 2012, MATH MODEL NAT PHENO, V7, P123, DOI [10.1051/mmnp/201.27509, 10.1051/mmnp/20127509]
   Ratmeyer L, 1996, BIOCHEMISTRY-US, V35, P13689, DOI 10.1021/bi960954v
   Rawlinson SM, 2009, J BIOL CHEM, V284, P15589, DOI 10.1074/jbc.M808271200
   Shida H, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00179
   Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295                                                          
   Sun QX, 2013, P NATL ACAD SCI USA, V110, P1303, DOI 10.1073/pnas.1217203110
   Szilvay AM, 1997, VIROLOGY, V235, P73, DOI 10.1006/viro.1997.8671
   Tamamura H, 2000, BIOORG MED CHEM LETT, V10, P2633, DOI 10.1016/S0960-894X(00)00535-7
   Turner JG, 2009, CANCER RES, V69, P6899, DOI 10.1158/0008-5472.CAN-09-0484
   WEGENER AD, 1984, J BIOL CHEM, V259, P1834
   Weissman KJ, 2010, NAT PROD REP, V27, P1276, DOI 10.1039/c001260m
   Wodrich H, 2000, NUCLEIC ACIDS RES, V28, P901, DOI 10.1093/nar/28.4.901
   Yang XY, 1999, J VIROL, V73, P3460
   Yedavalli VSRK, 2010, P NATL ACAD SCI USA, V107, P14787, DOI 10.1073/pnas.1009490107
   ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B
NR 62
TC 7
Z9 8
U1 4
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2859
J9 MICROB CELL FACT
JI Microb. Cell. Fact.
PD JAN 29
PY 2014
VL 13
AR 17
DI 10.1186/1475-2859-13-17
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA AD3CX
UT WOS:000333116600001
PM 24475978
OA gold
DA 2018-01-05
ER

PT J
AU Lippincott-Schwartz, J
   Sengupta, P
   Chen, A
   van Engelenburg, S
AF Lippincott-Schwartz, Jennifer
   Sengupta, Prabuddha
   Chen, Antony
   van Engelenburg, Schuyler
TI Nanoscale Mechanisms Underlying HIV-1 Viral Particle Assembly and
   Release
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the Biophysical-Society
CY FEB 15-19, 2014
CL San Francisco, CA
SP Biophys Soc
C1 [Lippincott-Schwartz, Jennifer; Sengupta, Prabuddha; Chen, Antony; van Engelenburg, Schuyler] NICHD, NIH, Bethesda, MD USA.
OI Sengupta, Prabuddha/0000-0001-7094-6967
NR 0
TC 0
Z9 0
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD JAN 28
PY 2014
VL 106
IS 2
SU 1
BP 5A
EP 6A
DI 10.1016/j.bpj.2013.11.065                                               
          
PG 2
WC Biophysics
SC Biophysics
GA AI6QE
UT WOS:000337000400028
OA gold
DA 2018-01-05
ER

PT J
AU Reardon, PN
   Sage, H
   Dennison, SM
   Martin, JW
   Donald, BR
   Alam, SM
   Haynes, BF
   Spicer, LD
AF Reardon, Patrick N.
   Sage, Harvey
   Dennison, S. Moses
   Martin, Jeffrey W.
   Donald, Bruce R.
   Alam, S. Munir
   Haynes, Barton F.
   Spicer, Leonard D.
TI Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41
   envelope membrane proximal region trimer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BROADLY NEUTRALIZING ANTIBODIES;
   ENV-MEDIATED FUSION; EXTERNAL REGION; DODECYLPHOSPHOCHOLINE MICELLES;
   CRYOELECTRON MICROSCOPY; ECTODOMAIN REGION; HIV-1 ANTIBODIES; VIRAL
   MEMBRANE; VACCINE DESIGN
AB The membrane proximal external region (MPER) of HIV-1 glycoprotein (gp) 41 is involved in viral-host cell membrane fusion. It contains short amino acid sequences that are binding sites for the HIV-1 broadly neutralizing antibodies 2F5, 4E10, and 10E8, making these binding sites important targets for HIV-1 vaccine development. We report a high-resolution structure of a designed MPER trimer assembled on a detergent micelle. The NMR solution structure of this trimeric domain, designated gp41-M-MAT, shows that the three MPER peptides each adopt symmetric a-helical conformations exposing the amino acid side chains of the antibody binding sites. The helices are closely associated at their N termini, bend between the 2F5 and 4E10 epitopes, and gradually separate toward the C termini, where they associate with the membrane. The mAbs 2F5 and 4E10 bind gp41-M-MAT with nanomolar affinities, consistent with the substantial exposure of their respective epitopes in the trimer structure. The traditional structure determination of gp41-M-MAT using the Xplor-NIH protocol was validated by independently determining the structure using the DISCO sparse-data protocol, which exploits geometric arrangement algorithms that guarantee to compute all structures and assignments that satisfy the data.
C1 [Reardon, Patrick N.; Sage, Harvey; Donald, Bruce R.; Spicer, Leonard D.] Duke Univ, Sch Med, Dept Biochem, Durham, NC 27710 USA.
   [Dennison, S. Moses; Alam, S. Munir; Haynes, Barton F.] Duke Univ, Sch Med, Duke Dept Med, Duke Human Vaccine Inst, Durham, NC 27710 USA.
   [Spicer, Leonard D.] Duke Univ, Sch Med, Dept Radiol, Durham, NC 27710 USA.
   [Martin, Jeffrey W.; Donald, Bruce R.] Duke Univ, Dept Comp Sci, Durham, NC 27708 USA.
RP Spicer, LD (reprint author), Duke Univ, Sch Med, Dept Biochem, Durham, NC 27710 USA.
EM spicer@biochem.duke.edu
OI Reardon, Patrick/0000-0002-6858-0086
FU Bill and Melinda Gates Foundation; National Institutes of Health
   [GM-78031, GM-65982]
FX NMR experiments were conducted at the Duke NMR center and the David H.
   Murdoch Research Institute. We are grateful to Dr. Ron Venters for
   assistance with NMR data collection and interpretation. We thank Dr.
   Steven Harrison for comments during the preparation of this manuscript.
   We also thank Dr. Pei Zhou for helpful discussions about RDC analysis,
   Kara Anasti for assistance in performing the SPR experiments, Dr.
   Hua-Xin Liao for helpful discussions, and Dr. Mark Conners for providing
   10E8 Mab. We gratefully acknowledge Dr. Marian Miller for original
   artistic contributions. This work was funded by a Collaboration for AIDS
   Vaccine Discovery grant from the Bill and Melinda Gates Foundation (to
   B.F.H. and L.D.S.) and by National Institutes of Health Grants GM-78031
   and GM-65982 (to B.R.D.).
CR Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07
   Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Ashkenazi A, 2011, EUR BIOPHYS J BIOPHY, V40, P349, DOI 10.1007/s00249-010-0666-z
   Bartesaghi A, 2013, NAT STRUCT MOL BIOL, V20, P1352, DOI 10.1038/nsmb.2711
   Beel AJ, 2008, BIOCHEMISTRY-US, V47, P9428, DOI 10.1021/bi800993c
   Burton DR, 2010, P NATL ACAD SCI USA, V107, P17859, DOI 10.1073/pnas.1012923107
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Chen Y, 2013, J IMMUNOL, V191, P1260, DOI 10.4049/jimmunol.1300770
   Coutant J, 2008, FASEB J, V22, P4338, DOI 10.1096/fj.08-113142
   Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7                                                   
   Dennison SM, 2009, J VIROL, V83, P10211, DOI 10.1128/JVI.00571-09
   Doyle-Cooper C, 2013, J IMMUNOL, V191, P3186, DOI 10.4049/jimmunol.1301285
   Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5
   Guenaga J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016074
   Guthe S, 2004, J MOL BIOL, V337, P905, DOI 10.1016/j.jmb.2004.02.020
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781
   Hinz A, 2009, VIROLOGY, V390, P221, DOI 10.1016/j.virol.2009.05.015
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Lenz O, 2005, J BIOL CHEM, V280, P4095, DOI 10.1074/jbc.M411088200
   Liu J, 2009, BIOCHEMISTRY-US, V48, P2915, DOI 10.1021/bi802303b
   Mao YD, 2012, NAT STRUCT MOL BIOL, V19, P893, DOI 10.1038/nsmb.2351
   Martin JW, 2011, PROTEIN SCI, V20, P970, DOI 10.1002/pro.620
   Munoz-Barroso I, 1999, J VIROL, V73, P6089
   MUSTER T, 1993, J VIROL, V67, P6642
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Ofek G, 2010, J VIROL, V84, P2955, DOI 10.1128/JVI.02257-09
   Phogat S, 2008, VIROLOGY, V373, P72, DOI 10.1016/j.virol.2007.11.005
   REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467
   Salzwedel K, 1999, J VIROL, V73, P2469
   Scherer EM, 2010, P NATL ACAD SCI USA, V107, P1529, DOI 10.1073/pnas.0909680107
   Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u
   Schwieters CD, 2006, PROG NUCL MAG RES SP, V48, P47, DOI 10.1016/j.pnmrs.2005.10.001
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5
   Verkoczy L, 2013, J IMMUNOL, V191, P2538, DOI 10.4049/jimmunol.1300971
   Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107
   White TA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001249
   Wu SR, 2010, P NATL ACAD SCI USA, V107, P18844, DOI 10.1073/pnas.1007227107
   Yang G, 2013, J EXP MED, V210, P241, DOI 10.1084/jem.20121977
   Zamoon J, 2003, BIOPHYS J, V85, P2589, DOI 10.1016/S0006-3495(03)74681-5
   Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 50
TC 29
Z9 30
U1 1
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 28
PY 2014
VL 111
IS 4
BP 1391
EP 1396
DI 10.1073/pnas.1309842111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297BV
UT WOS:000330231100048
PM 24474763
OA gold
DA 2018-01-05
ER

PT J
AU Jeon, G
   Jee, M
   Yang, SY
   Lee, BY
   Jang, SK
   Kim, JK
AF Jeon, Gumhye
   Jee, Minhyeok
   Yang, Seung Yun
   Lee, Bom-yi
   Jang, Sung Key
   Kim, Jin Kon
TI Hierarchically Self-Organized Monolithic Nanoporous Membrane for
   Excellent Virus Enrichment
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE nanoporous membrane; hierarchical structure; monolithic structure; virus
   enrichment; hepatitis C virus
ID HEPATITIS-C-VIRUS; BLOCK-COPOLYMER; ANODIC ALUMINA; POROUS ALUMINA;
   FILTRATION MEMBRANES; INFECTION; PORES; ARRAYS; FABRICATION; SYSTEM
AB Enrichment of viruses is essential for making high dose viral stocks for vaccines and virus-related research. Since the widely used ultracentrifugation for concentrating viral stock requires ultra-high speed rotation, it easily destroys the activity of some viruses, for instance, hepatitis c virus (HCV), which has a fragile structure and low virus titer. We introduce a novel method to concentrate HCV virus in stock by using a hierarchically self-organized monolithic nanoporous membrane made by stepwise anodization. The pores at the top part of the membrane have very regular sizes that are suitable for the perfect filtration of the virus particles in the stock. On the other hand, the remaining part has large pores that maintain high flux and mechanical strength of the membrane under the high pressure (up to 10 bar). The enrichment efficiency of HCV in crude stocks by using the membrane became over 91%, which is four times higher than that (similar to 22%) obtained by conventionally used centrifugation. A very high efficiency results from the perfect filtration and no damage to the virion particles during the enrichment process, whereas significant damage to the HCV occurs during centrifugation. The hierarchically self-organized monolithic nanoporous membrane could be effectively employed for concentrating various fragile viruses in stocks, for instance, rabies virus and human immunodeficiency virus in addition to HCV virus.
C1 [Jeon, Gumhye; Lee, Bom-yi; Kim, Jin Kon] Pohang Univ Sci & Technol, Natl Creat Res Ctr Smart Block Copolymers, Dept Chem Engn, Pohang 790784, Kyungbuk, South Korea.
   [Jee, Minhyeok; Jang, Sung Key] Pohang Univ Sci & Technol, POSTECH Biotech Ctr, Dept Life Sci, Mol Virol Lab, Pohang 790784, Kyungbuk, South Korea.
   [Yang, Seung Yun] Pusan Natl Univ, Dept Biomat Sci, Miryang 627706, Gyeongnam, South Korea.
RP Jang, SK (reprint author), Pohang Univ Sci & Technol, POSTECH Biotech Ctr, Dept Life Sci, Mol Virol Lab, Pohang 790784, Kyungbuk, South Korea.
EM sungkey@postech.ac.kr; jkkim@postech.ac.kr
RI Yang, Seung Yun/B-5974-2016
OI Yang, Seung Yun/0000-0002-1233-8960
FU Bio RD Program [2012-054974]; BRL through the National Research
   Foundation [2010-0019706]; MEST; National Creative Research Initiative
   Program of the National Research Foundation of Korea of the Ministry of
   Education, Science and Technology, Korea
FX This research was supported by the Bio R&D Program (No. 2012-054974) and
   the BRL (No. 2010-0019706) through the National Research Foundation
   funded by the MEST. This work was also supported by the National
   Creative Research Initiative Program of the National Research Foundation
   of Korea of the Ministry of Education, Science and Technology, Korea.
CR Arifin MA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/586363
   Buijnsters JG, 2013, ACS APPL MATER INTER, V5, P3224, DOI 10.1021/am4001425
   Chen W, 2008, ACS NANO, V2, P959, DOI 10.1021/nn700389j
   Dorner M, 2011, NATURE, V474, P208, DOI 10.1038/nature10168
   Hayama M, 2002, J MEMBRANE SCI, V197, P243, DOI 10.1016/S0376-7388(01)00627-5                                                   
   Jung A, 2012, MACROMOL MATER ENG, V297, P790, DOI 10.1002/mame.201100359
   Kato T, 2006, NAT PROTOC, V1, P2334, DOI 10.1038/nprot.2006.395
   Kato T, 2007, J VIROL, V81, P4405, DOI 10.1128/JVI.02334-06
   Kim CS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022808
   LAWRENCE J E, 2010, MANUAL AQUATIC VIRAL, V17, P166
   Lazzara TD, 2010, ACS NANO, V4, P3909, DOI 10.1021/nn1007594
   Lee DY, 2012, SOFT MATTER, V8, P4905, DOI 10.1039/c2sm07319f
   Li AP, 1999, ADV MATER, V11, P483, DOI 10.1002/(SICI)1521-4095(199904)11:6<483::AID-ADMA483>3.0.CO;2-I
   Losic D, 2005, NANOTECHNOLOGY, V16, P2275, DOI 10.1088/0957-4484/16/10/049
   Madhavan P, 2013, ACS APPL MATER INTER, V5, P7152, DOI 10.1021/am401497m
   Martin CR, 2004, NAT MATER, V3, P284, DOI 10.1038/nmat1124
   Masuda H, 1998, JPN J APPL PHYS 2, V37, pL1340, DOI 10.1143/JJAP.37.L1340                                                           
   MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466
   Montero-Moreno JM, 2009, ELECTROCHIM ACTA, V54, P2529, DOI 10.1016/j.electacta.2008.03.067
   Nielsch K, 2000, ADV MATER, V12, P582, DOI 10.1002/(SICI)1521-4095(200004)12:8<582::AID-ADMA582>3.0.CO;2-3
   Nunes SP, 2011, ACS NANO, V5, P3516, DOI 10.1021/nn200484v
   Nuxoll EE, 2009, ACS APPL MATER INTER, V1, P888, DOI 10.1021/am900013v
   Park JH, 2013, VIROLOGY, V439, P13, DOI 10.1016/j.virol.2013.01.014
   Peinemann KV, 2007, NAT MATER, V6, P992, DOI 10.1038/nmat2038
   Phillip WA, 2011, NANO LETT, V11, P2892, DOI 10.1021/nl2013554
   Phillip WA, 2010, ACS APPL MATER INTER, V2, P847, DOI 10.1021/am900882t
   Ploss A, 2009, NATURE, V457, P882, DOI 10.1038/nature07684
   Querelle SE, 2013, ACS APPL MATER INTER, V5, P5044, DOI 10.1021/am400847m
   Ravaggi A, 1997, J VIROL METHODS, V65, P123, DOI 10.1016/S0166-0934(97)02175-7
   Sanders BP, 2012, VACCINE, V31, P850
   Yamaguchi A, 2004, NAT MATER, V3, P337, DOI 10.1038/nmat1107
   Yang SY, 2008, ADV FUNCT MATER, V18, P1371, DOI 10.1002/adfm.200700832
   Yang SY, 2011, NANO LETT, V11, P1032, DOI 10.1021/nl200357y
   Yang SY, 2010, ACS NANO, V4, P3817, DOI 10.1021/nn100464u
   Yang SY, 2006, ADV MATER, V18, P709, DOI 10.1002/adma.200501500
   Zhao XW, 2007, J ELECTROCHEM SOC, V154, pC553, DOI 10.1149/1.2759780
   Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102
NR 37
TC 4
Z9 4
U1 1
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JAN 22
PY 2014
VL 6
IS 2
BP 1200
EP 1206
DI 10.1021/am4049404
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 296RA
UT WOS:000330201900063
PM 24354273
DA 2018-01-05
ER

PT J
AU Su, ZY
AF Su, Zhi-Yuan
TI Ibalizumab-Human CD4 Receptor Interaction: Computational Alanine
   Scanning Molecular Dynamics Studies
SO CURRENT COMPUTER-AIDED DRUG DESIGN
LA English
DT Article
DE Antibody drugs; drug resistance; human immunodeficiency virus type 1
   (HIV-1); Ibalizumab; molecular dynamics; Robetta alanine-scanning
   mutagenesis method
ID DOCKING SIMULATIONS; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE;
   BINDING-AFFINITY; HIV-1 INFECTION; ENERGY; DOMAIN; GLYCOPROTEIN;
   RECOGNITION; ACTIVATION
AB Antibody drugs are used in the treatment of many chronic diseases. Recently, however, patients and doctors have encountered problems with drug resistance, and improving the affinity of antibody drugs has therefore become a pressing issue. Ibalizumab is a humanized monoclonal antibody that binds human CD4, the primary receptor for human immunodeficiency virus type 1 (HIV-1). In this study, we sought to identify the key residues of the complementarity-determining regions (CDRs) of ibalizumab. Virtual alanine mutations (complementarity-determining regions of ibalizumab) were also studied using solvated interaction energies derived from molecular dynamics and the explicit water model. Using 1,000 nanosecond molecular dynamic simulations, we identified six residues: Tyr50 [HCDR2], Tyr53 [HCDR3], Asp58 [HCDR2], Glu95 [HCDR2], and Arg95 [LCDR3]. The Robetta alanine-scanning mutagenesis method and crystallographic information were used to verify our simulations. Our simulated binding affinity of -17.33 kcal/mol is close to the experimentally determined value of -16.48 kcal/mol. Our findings may be useful for protein engineering the structure of the ibalizumab-human CD4 receptor complex. Moreover, the six residues that we identified may play a significant role in the development of bioactive antibody analogues.
C1 Chia Nan Univ Pharm & Sci, Dept Informat Management, Tainan, Taiwan.
RP Su, ZY (reprint author), Chia Nan Univ Pharm & Sci, Dept Informat Management, 60 Erh Jen RD,Sec 1, Tainan, Taiwan.
EM szj1974@gmail.com
FU National Science Council of the Republic of China, Taiwan [NSC
   102-2221-E-041-011-, NSC 101-2221-E-041-013-]
FX The authors would like to thank the National Science Council of the
   Republic of China, Taiwan, for supporting this research (Contract No.
   NSC 102-2221-E-041-011- and NSC 101-2221-E-041-013-).
CR Allcorn LC, 2002, BIOINFORMATICS, V18, P175, DOI 10.1093/bioinformatics/18.1.175
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385
   Azevedo LS, 2012, CURR BIOINFORM, V7, P352
   Banting FG, 1922, J LAB CLIN MED, V7, P251
   Bhat S, 2006, PROTEINS, V62, P244, DOI 10.1002/prot.20682
   Boon L, 2002, TOXICOLOGY, V172, P191, DOI 10.1016/S0300-483X(02)00002-1
   Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4
   Bren U, 2006, J PHYS CHEM B, V110, P10557, DOI 10.1021/jp060292b
   Bruno CJ, 2010, J ANTIMICROB CHEMOTH, V65, P1839, DOI 10.1093/jac/dkq261
   BURKLY LC, 1992, J IMMUNOL, V149, P1779
   Canduri F, 2008, CURR DRUG TARGETS, V9, P1048, DOI 10.2174/138945008786949423                                                      
   Cohen J, 1996, SCIENCE, V272, P809, DOI 10.1126/science.272.5263.809
   Cui QZ, 2008, J MOL BIOL, V379, P787, DOI 10.1016/j.jmb.2008.04.035
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Azevedo WF, 2011, CURR MED CHEM, V18, P1353
   de Azevedo WF, 2008, CURR DRUG TARGETS, V9, P1031, DOI 10.2174/138945008786949405                                                      
   DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0
   Edelheit O, 2011, AM J PHYSIOL-RENAL, V300, pF887, DOI 10.1152/ajprenal.00648.2010
   Freeman MM, 2010, STRUCTURE, V18, P1632, DOI 10.1016/j.str.2010.09.017
   Heberle G, 2011, CURR MED CHEM, V18, P1339, DOI 10.2174/092986711795029573                                                      
   Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799
   Kortemme T, 2004, SCI STKE, V2004, ppl2
   Kunik V, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002388
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   McFarland BJ, 2003, STRUCTURE, V11, P411, DOI 10.1016/S0969-2126(03)00047-0
   MODROW S, 1987, J VIROL, V61, P570
   Morrison KL, 2001, CURR OPIN CHEM BIOL, V5, P302, DOI 10.1016/S1367-5931(00)00206-4                                                   
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Perdih A, 2009, J MOL MODEL, V15, P983, DOI 10.1007/s00894-009-0455-8
   Purisima EO, 1998, J COMPUT CHEM, V19, P1494, DOI 10.1002/(SICI)1096-987X(199810)19:13<1494::AID-JCC6>3.0.CO;2-L
   Rivera A, 2006, IMMUNITY, V25, P665, DOI 10.1016/j.immuni.2006.08.016
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121
   Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987
   XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N
NR 38
TC 0
Z9 0
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4099
EI 1875-6697
J9 CURR COMPUT-AID DRUG
JI Curr. Comput.-Aided Drug Des.
PY 2014
VL 10
IS 3
BP 217
EP 225
PG 9
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Computer Science
GA CC4QR
UT WOS:000350338600005
PM 25756667
DA 2018-01-05
ER

PT J
AU Vanic, Z
   Skalko-Basnet, N
AF Vanic, Z.
   Skalko-Basnet, N.
TI Mucosal nanosystems for improved topical drug delivery: vaginal route of
   administration
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Mucoadhesion; Nanosystems; (Phosho)lipid; Polymer; Topical therapy;
   Vaginal therapy
ID SOLID-LIPID NANOPARTICLES; IN-VITRO EVALUATION; CHITOSAN-COATED
   LIPOSOMES; BIODEGRADABLE POLYMER NANOPARTICLES; OCULAR DELIVERY; LOADED
   NANOPARTICLES; FUTURE PERSPECTIVES; PULMONARY DELIVERY; HIV PROPHYLAXIS;
   VIVO EVALUATION
AB This review represents an attempt to summarize the current developments in the area of mucosal drug delivery destined for localized effects, address the challenges and comment on the potentials this therapy approach offers. Among different mucosal drug delivery systems currently available in the pipelines of pharmaceutical development, we have focused on the delivery systems in nanosize range, as they offer certain advantages which will be herewith discussed in more details. According to their surface properties, mucosal nanosystems are generally classified as conventional (non-mucoadhesive), mucoadhesive and mucus-penetrating nanosystems, while on the structural basis they are often classified as lipid- and polymer-based nanoparticles. Particular emphasis was put on nanosystems for topical vaginal therapy. Most of the presented nanosysterns are destined for improved treatment of vaginitis and prevention of sexually transmitted viral diseases.
C1 [Vanic, Z.] Univ Zagreb, Fac Pharm & Biochem, Dept Pharmaceut Technol, Zagreb 10000, Croatia.
   [Skalko-Basnet, N.] Arctic Univ Norway, Univ Tromso, Fac Hlth Sci, Drug Transport & Delivery Res Grp,Dept Pharm, N-9037 Tromso, Norway.
RP Skalko-Basnet, N (reprint author), Arctic Univ Norway, Univ Tromso, Fac Hlth Sci, Drug Transport & Delivery Res Grp,Dept Pharm, Univ Veien 57, N-9037 Tromso, Norway.
EM natasa.skalko-basnet@uit.no
RI Skalko-Basnet, Natasa/A-4117-2012
OI Skalko-Basnet, Natasa/0000-0002-4301-2840
CR Abdelbary G, 2008, AAPS PHARMSCITECH, V9, P740, DOI 10.1208/s12249-008-9105-1
   Aggarwal D, 2005, INT J PHARM, V290, P155, DOI 10.1016/j.ijpharm.2004.10.026
   Allaker RP, 2014, INT J ANTIMICROB AG, V43, P95, DOI 10.1016/j.ijantimicag.2013.11.002
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Andersen Toril, 2013, Pharmaceutics, V5, P445, DOI 10.3390/pharmaceutics5030445
   Arangoa MA, 2000, EUR J PHARM SCI, V11, P333, DOI 10.1016/S0928-0987(00)00121-4
   Basnet P, 2012, J PHARM SCI-US, V101, P598, DOI 10.1002/jps.22785
   Bendas ER, 2013, INT J PHARMACEUT, V458, P287, DOI 10.1016/j.ijpharm.2013.10.042
   Berginc Katja, 2014, Eur J Pharm Biopharm, V87, P40, DOI 10.1016/j.ejpb.2014.02.006
   Berginc K, 2012, AAPS PHARMSCITECH, V13, P1045, DOI 10.1208/s12249-012-9837-9
   Bernkop-Schnurch A, 2006, INT J PHARM, V317, P76, DOI 10.1016/j.ijpharm.2006.02.044
   Bernkop-Schnurch A, 2005, ADV DRUG DELIVER REV, V57, P1569, DOI 10.1016/j.addr.2005.07.002
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Berry M, 2014, MUCOADHESIVE MATERIALS AND DRUG DELIVERY SYSTEMS, P135
   Calderon L, 2013, EUR J PHARM SCI, V48, P216, DOI 10.1016/j.ejps.2012.11.002
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Casettari L., 2014, J CONTROL RELEASE
   Cavalli R, 2002, INT J PHARM, V238, P241, DOI 10.1016/S0378-5173(02)00080-7                                                   
   Cheng YY, 2008, J PHARM SCI-US, V97, P123, DOI 10.1002/jps.21079
   Chetoni P, 2004, J OCUL PHARMACOL TH, V20, P169, DOI 10.1089/108076804773710849
   CHICKERING DE, 1999, BIOADHESIVE DRUG DEL, V98, P1
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, EXPERT OPIN DRUG DEL, V8, P1085, DOI 10.1517/17425247.2011.586334
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J., 2014, MOL PHARM, V10, P2793
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Desai N, 2012, AAPS J, V14, P282, DOI 10.1208/s12248-012-9339-4
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Duchene D, 1997, EUR J PHARM BIOPHARM, V44, P15, DOI 10.1016/S0939-6411(97)00097-0                                                   
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Ensign LM, 2012, ADV MATER, V24, P3887, DOI 10.1002/adma.201201800
   Ensign L. M., 2012, SCI TRANS MED, V138
   Erjavec V, 2006, INT J PHARM, V307, P1, DOI 10.1016/j.ijpharm.2005.09.016
   Foldvari M., 1997, Journal of Liposome Research, V7, P115, DOI 10.3109/08982109709035489
   Franz-Montan M, 2012, BRIT J ORAL MAX SURG, V50, P60, DOI 10.1016/j.bjoms.2010.10.018
   Franz-Montan M, 2010, J CLIN ANESTH, V22, P313, DOI 10.1016/j.jclinane.2010.03.001
   Gardiner J, 2008, J ENZYM INHIB MED CH, V23, P623, DOI [10.1080/14756360802205257, 10.1080/14756360802205257 ]
   Gilani K, 2011, J PHARM SCI-US, V100, P252, DOI 10.1002/jps.22274
   Gluck U, 2007, ORL J OTO-RHINO-LARY, V69, P92, DOI 10.1159/000097758
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   GORTNER L, 1992, PEDIATR PULM, V14, P4, DOI 10.1002/ppul.1950140103                                                         
   Guinedi AS, 2005, INT J PHARM, V306, P71, DOI 10.1016/j.ijpharm.2005.09.023
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Harush-Frenkel O, 2010, TOXICOL APPL PHARM, V246, P83, DOI 10.1016/j.taap.2010.04.011
   Holpuch AS, 2010, PHARM RES-DORDR, V27, P1224, DOI 10.1007/s11095-010-0121-y
   Jain K, 2013, CURR DRUG DELIV, V10, P493, DOI 10.2174/1567201811310050001                                                     
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Jonassen H, 2013, BIOMACROMOLECULES, V14, P3523, DOI 10.1021/bm4008474
   Joraholmen MW, 2014, INT J PHARMACEUT, V472, P94, DOI 10.1016/j.ijpharm.2014.06.016
   Jung T, 2000, EUR J PHARM BIOPHARM, V50, P147, DOI 10.1016/S0939-6411(00)00084-9
   Kamel R, 2013, J LIPOSOME RES, V23, P28, DOI 10.3109/08982104.2012.727422
   Karn PR, 2011, DRUG DEV IND PHARM, V37, P482, DOI 10.3109/03639045.2010.523425
   Katz DF, 2011, DRUG DELIV TRANSL RE, V1, P256, DOI 10.1007/s13346-011-0029-z
   Khutoryanskiy VV, 2014, MUCOADHESIVE MATERIALS AND DRUG DELIVERY SYSTEMS, P1, DOI 10.1002/9781118794203
   Kish-Catalone T, 2007, AIDS RES HUM RETROV, V23, P33, DOI 10.1089/aid.2006.0076
   Kish-Catalone TM, 2006, ANTIMICROB AGENTS CH, V50, P1497, DOI 10.1128/AAC.50.4.1497-1509.2006
   Klemetsrud T, 2013, COLLOID SURFACE B, V103, P158, DOI 10.1016/j.colsurfb.2012.10.012
   Laffleur F, 2013, NANOMEDICINE-UK, V8, P2061, DOI 10.2217/nnm.13.178
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lembo David, 2010, Antiviral Chemistry & Chemotherapy, V21, P53, DOI 10.3851/IMP1684
   Lieleg O, 2012, BIOMACROMOLECULES, V13, P1724, DOI 10.1021/bm3001292
   Lieleg O, 2010, BIOPHYS J, V98, P1782, DOI 10.1016/j.bpj.2010.01.012
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Manca ML, 2012, J PHARM SCI-US, V101, P566, DOI 10.1002/jps.22775
   Matsuo Y, 2009, CELL IMMUNOL, V260, P33, DOI 10.1016/j.cellimm.2009.07.004
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Mehanna MM, 2010, DRUG DEV IND PHARM, V36, P108, DOI 10.3109/03639040903099751
   Mendes AI, 2013, COLLOID SURFACE B, V111, P755, DOI 10.1016/j.colsurfb.2013.05.041
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Moazeni E, 2010, J MICROENCAPSUL, V27, P618, DOI 10.3109/02652048.2010.506579
   Mourtas S, 2010, NANO LIFE, V1, P195, DOI 10.1142/S1793984410000225
   Mukhopadhyay P., 2012, PROG POLYM SCI, V37, P1457
   Muller RH, 2002, INT J PHARM, V242, P121, DOI 10.1016/S0378-5173(02)00180-1
   Navath RS, 2011, MOL PHARMACEUT, V8, P1209, DOI 10.1021/mp200027z
   Ning MY, 2005, DRUG DEV IND PHARM, V31, P375, DOI 10.1081/DDC-200054315
   Ning MY, 2005, CHEM PHARM BULL, V53, P620, DOI 10.1248/cpb.53.620
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Paranjpe M, 2013, INHAL TOXICOL, V25, P536, DOI 10.3109/08958378.2013.810315
   Paranjpe M, 2014, INT J MOL SCI, V15, P5852, DOI 10.3390/ijms15045852
   Pavelic Z, 2005, INT J PHARM, V301, P140, DOI 10.1016/j.ijpharm.2005.05.022
   Pavelic Z, 2005, J CONTROL RELEASE, V106, P34, DOI 10.1016/j.jconrel.2005.03.032
   Pavelic Z, 2004, METHOD ENZYMOL, V387, P287
   Pavelic Z, 2001, INT J PHARM, V219, P139, DOI 10.1016/S0378-5173(01)00637-8
   Pavelic Z, 1999, EUR J PHARM SCI, V8, P345, DOI 10.1016/S0928-0987(99)00033-0
   Pavelic Zeljka, 2004, Acta Pharmaceutica (Zagreb), V54, P319
   Pepic I, 2010, J PHARM SCI-US, V99, P4317, DOI 10.1002/jps.22137
   Peppas NA, 1996, BIOMATERIALS, V17, P1553, DOI 10.1016/0142-9612(95)00307-X
   Petelin M, 2000, J CLIN PERIODONTOL, V27, P918, DOI 10.1034/j.1600-051x.2000.027012918.x
   PONCHEL G, 1987, Journal of Controlled Release, V5, P129, DOI 10.1016/0168-3659(87)90004-6
   Ravani L, 2013, INT J PHARMACEUT, V454, P695, DOI 10.1016/j.ijpharm.2013.06.015
   Ryan GM, 2013, MOL PHARMACEUT, V10, P2986, DOI 10.1021/mp400091n
   Sassi AB, 2008, J PHARM SCI-US, V97, P3123, DOI 10.1002/jps.21192
   Seyfoddin A, 2013, DRUG DEV IND PHARM, V39, P508, DOI 10.3109/03639045.2012.665460
   Seyfoddin A, 2010, DRUG DELIV, V17, P467, DOI 10.3109/10717544.2010.483257
   Skalko N, 1998, J LIPOSOME RES, V8, P283, DOI 10.3109/08982109809035532                                                       
   Skalko-Basnet N, 2014, BIOL-TARGETS THER, V8, P107, DOI 10.2147/BTT.S38387
   Smart JD, 2014, MUCOADHESIVE MATERIALS AND DRUG DELIVERY SYSTEMS, P159
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Takeuchi H, 2003, J CONTROL RELEASE, V86, P235, DOI 10.1016/S0168-3659(02)00411-X
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Taratula O, 2013, J CONTROL RELEASE, V171, P349, DOI 10.1016/j.jconrel.2013.04.018
   Tirosh B, 2009, MOL PHARMACEUT, V6, P1083, DOI [10.1021/mpg000926, 10.1021/mp9000926]
   Tiyaboonchai W, 2015, PHARM DEV TECHNOL, V20, P426, DOI 10.3109/10837450.2013.879884
   Tsai SW, 2013, INT J NANOMED, V8, P2399, DOI 10.2147/IJN.S46613
   Ugwoke MI, 2005, ADV DRUG DELIVER REV, V57, P1640, DOI 10.1016/j.addr.2005.07.009
   Uner M, 2007, INT J NANOMED, V2, P289
   Valerii MC, 2013, NANOMED-NANOTECHNOL, V9, P675, DOI 10.1016/j.nano.2012.11.007
   Vandamme TF, 2005, J CONTROL RELEASE, V102, P23, DOI 10.1016/j.jconrel.2004.09.015
   Vanic Z., 2014, EUR J PHARM BIOPHARM
   Vanic Z, 2014, J LIPOSOME RES, V24, P27, DOI 10.3109/08982104.2013.826242
   Vanic Z, 2013, DRUG DEV IND PHARM, V39, P481, DOI 10.3109/03639045.2012.670247
   Vanic Z., 2013, EUR J PHARM SCI, V50, P29
   Varshosaz J, 2013, BIOMED RES INT, DOI 10.1155/2013/136859
   Varshosaz J, 2014, PHARM DEV TECHNOL, V19, P605, DOI 10.3109/10837450.2013.819011
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Wei N-N., 2003, ACTA PHARMACOL SIN, V1, P53
   Wei-Ze L, 2012, EUR J PHARM SCI, V47, P162, DOI 10.1016/j.ejps.2012.06.001
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Yang M, 2014, ADV HEALTHC MATER, V3, P1044, DOI 10.1002/adhm.201300519
   Yassin AEB, 2010, INT J MED SCI, V7, P398
   Yavuz B, 2013, SCI WORLD J, DOI 10.1155/2013/732340
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Yu M, 2012, INT J MOL SCI, V13, P5554, DOI 10.3390/ijms13055554
   Zaru M, 2009, COLLOID SURFACE B, V71, P88, DOI 10.1016/j.colsurfb.2009.01.010
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhou WJ, 2013, INT J NANOMED, V8, P3715, DOI 10.2147/IJN.S51186
NR 134
TC 4
Z9 4
U1 0
U2 13
PU EDITIONS SANTE
PI PARIS
PA 47 RUE GALILEE, 75116 PARIS, FRANCE
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PY 2014
VL 24
IS 5
BP 435
EP 444
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CC2LU
UT WOS:000350177300001
DA 2018-01-05
ER

PT S
AU Rohan, LC
   Devlin, B
   Yang, H
AF Rohan, L. C.
   Devlin, B.
   Yang, H.
BE Nuttall, J
TI Microbicide Dosage Forms
SO MICROBICIDES FOR PREVENTION OF HIV INFECTION
SE Current Topics in Microbiology and Immunology
LA English
DT Review; Book Chapter
ID CONTRACEPTIVE VAGINAL RING; REVERSE-TRANSCRIPTASE INHIBITOR;
   SEXUALLY-TRANSMITTED-DISEASES; IMMUNODEFICIENCY-VIRUS TYPE-1;
   HIV-NEGATIVE WOMEN; POLYURETHANE INTRAVAGINAL RINGS; TISSUE-ENGINEERING
   SCAFFOLDS; DRUG-DELIVERY SYSTEM; IN-VITRO EVALUATION; NANOFIBROUS
   SCAFFOLDS
AB Microbicides are topically applied, user controlled dosage forms that are being developed to prevent the transmission of HIV during coitus. Early candidates focused on coitally dependent dosage forms such as gels and creams. More recent development has focused on broadening the coitally dependent options through the introduction of films and fast dissolving tablets. Additionally, it has become important to have longer acting products to minimize the burden of user compliance and thus vaginal rings have been developed providing sustained delivery of antiretroviral drugs. This chapter discusses the history of microbicides along with a detailed description of coitally dependent products, gels, films, tablets diaphragms, as well as coitally independent dosage forms such as vaginal rings and the introduction of a new technology, electrospun fibers.
C1 [Rohan, L. C.; Yang, H.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Magee Womens Res Inst, Pittsburgh, PA 15261 USA.
   [Devlin, B.] Int Partnership Microbicides, Silver Spring, MD USA.
RP Rohan, LC (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Magee Womens Res Inst, Pittsburgh, PA 15261 USA.
EM rohanlc@upmc.edu; bdevlin@ipmglobal.org
CR Adriaens E, 2008, SEX TRANSM DIS, V35, P512, DOI 10.1097/OLQ.0b013e3181644669
   Agashe H, 2012, CURR HIV RES, V10, P88, DOI 10.2174/157016212799304599
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Alexander NJ, 2004, FERTIL STERIL, V82, P1, DOI 10.1016/j.fertnstert.2004.01.025
   Ayres C, 2006, BIOMATERIALS, V27, P5524, DOI 10.1016/j.biomaterials.2006.06.014
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Baloglu E, 2011, CHEM PHARM BULL, V59, P952, DOI 10.1248/cpb.59.952
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Beigi R, 2011, J INFECT DIS, V204, P1527, DOI 10.1093/infdis/jir562
   Bradshaw CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034540
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Cao HQ, 2010, J CONTROL RELEASE, V144, P203, DOI 10.1016/j.jconrel.2010.02.003
   Chandra Anjani, 2011, Natl Health Stat Report, P1
   Chatterjee A, 2010, INT J PHARM SCI RES, V1, P28, DOI 10.13040/IJPSR.0975-8232.1(3).28-37
   Chen DQ, 2012, INT J NANOMED, V7, P2621, DOI 10.2147/IJN.S31757
   Chiu JB, 2007, J BIOMED MATER RES A, V83A, P1117, DOI 10.1002/jbm.a.31279
   Clark M, 2011, AAPS M WASH DC
   Clark M, 2012, MICR 2012 SYDN AUSTR
   Cole AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015111
   Courtney T, 2006, BIOMATERIALS, V27, P3631, DOI 10.1016/j.biomaterials.2006.02.024
   Creatsas G, 2001, EUR J CONTRACEP REPR, V6, P172, DOI 10.1080/713604234
   Cui WG, 2006, BIOMACROMOLECULES, V7, P1623, DOI 10.1021/bm060057z
   Dobaria N, 2010, PHARM DEV TECHNOL, V15, P405, DOI 10.3109/10837450903262058
   Dobaria NB, 2009, AAPS PHARMSCITECH, V10, P951, DOI 10.1208/s12249-009-9288-0
   Escobar-Chavez JJ, 2006, J PHARM PHARM SCI, V9, P339
   Fan M, 2011, SEX TRANSM INFECT, V87, pA263, DOI 10.1136/sextrans-2011-050108.392
   Fares HM, 1995, PHARM TECHNOL, V19, P52
   FDA-SUPAC-SS. Guidance for Industry, 1997, IN VITR REL TEST IN
   Feng K, 2010, J CONTROL RELEASE, V146, P363, DOI 10.1016/j.jconrel.2010.05.035
   Fetherston SM, 2010, THER DELIV, V1, P785, DOI 10.4155/TDE.10.74
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Foran TM, 2003, MED J AUSTRALIA, V178, P616
   Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006
   Gallagher SJ, 2003, INT J PHARM, V268, P37, DOI 10.1016/j.ijpharm.20003.08.012
   Garg S, 2005, PHARM RES, V22, P584, DOI 10.1007/s11095-005-2494-x
   Garg S, 2001, CONTRACEPTION, V64, P67, DOI 10.1016/S0010-7824(01)00217-7
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Gohel MC, 2005, J PHARM PHARM SCI, V8, P76
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Gupta J, 2011, CURR PHARM ANAL, V7, P21, DOI 10.2174/157341211794708703                                                      
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Gupta P, 2002, DRUG DISCOV TODAY, V7, P569, DOI 10.1016/S1359-6446(02)02255-9
   Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7
   Han YA, 2007, CONTRACEPTION, V76, P132, DOI 10.1016/j.contraception.2007.04.006
   Hariharn M, 2009, DRUG DELIVERY TECH, V9, P24
   Herrera C, 2013, CURR TOP MICROBIOL I
   Holt JDS, 2014, CURR TOP MICROBIOL, V383, P55, DOI 10.1007/82_2013_327
   Huang ZM, 2006, J BIOMED MATER RES A, V77A, P169, DOI 10.1002/jbm.a.30564
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Ionescu LC, 2010, BIOMATERIALS, V31, P4113, DOI 10.1016/j.biomaterials.2010.01.098
   Iyer V, 2008, EUR J CONTRACEP REPR, V13, P339, DOI 10.1080/13625180802263515
   Jespers VA, 2007, JAIDS-J ACQ IMM DEF, V44, P154, DOI 10.1097/QAI.0b013e31802bb35f
   Jiang HL, 2005, J CONTROL RELEASE, V108, P237, DOI 10.1016/j.jconrel.2005.08.006
   Jin QM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001729
   Joglekar NS, 2006, INDIAN J MED RES, V123, P547
   Johansson EDB, 2000, STEROIDS, V65, P709, DOI 10.1016/S0039-128X(00)00126-4                                                   
   Johnson TJ, 2012, ANTIMICROB AGENTS CH, V56, P1291, DOI 10.1128/AAC.05721-11
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Joshi SN, 2005, T ROY SOC TROP MED H, V99, P769, DOI 10.1016/j.trstmh.2005.01.007
   Kalichman SC, 2009, SEX TRANSM INFECT, V85, P411, DOI 10.1136/sti.2008.035287
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9
   Kawarkhe S, 2010, INDIAN J PHARM SCI, V72, P652, DOI 10.4103/0250-474X.78540
   Keller MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016475
   Kidoaki S, 2005, BIOMATERIALS, V26, P37, DOI 10.1016/j.biomaterials.2004.01.063
   Kidoaki S, 2006, J BIOMED MATER RES B, V76B, P219, DOI 10.1002/jbm.b.30336
   Kim HS, 2010, J CONTROL RELEASE, V145, P264, DOI 10.1016/j.jconrel.2010.03.006
   Kiser PF, 2012, AIDS REV, V14, P62
   Kumar P, 1993, DRUG DEV IND PHARM, V19, P1573, DOI DOI 10.3109/03639049309069327
   Lacey CJ, 2010, INT J STD AIDS, V21, P714, DOI 10.1258/ijsa.2010.010215
   Lai BE, 2010, ANTIVIR RES, V88, P143, DOI 10.1016/j.antiviral.2010.08.006
   Liang DH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gnil171
   LICHTMAN AS, 1973, CONTRACEPTION, V8, P291, DOI 10.1016/S0010-7824(73)80001-0
   Loxley A, 2011, DRUG DELIV TRANSL RE, V1, P247, DOI 10.1007/s13346-011-0031-5
   Luong-Van E, 2006, BIOMATERIALS, V27, P2042, DOI 10.1016/j.biomaterials.2005.10.028
   Macht DI, 1918, J PHARMACOL EXP THER, V10, P509
   Mahalingam A, 2011, ANTIMICROB AGENTS CH, V55, P1650, DOI 10.1128/AAC.01368-10
   Mahalingam A, 2010, PHARM RES-DORDR, V27, P2478, DOI 10.1007/s11095-010-0244-1
   Major I, 2012, MICR 2012 SYDN AUSTR
   Major I, 2010, IEEE ENG MED BIO, P1089, DOI 10.1109/IEMBS.2010.5627333
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Maretschek S, 2008, J CONTROL RELEASE, V127, P180, DOI 10.1016/j.jconrel.2008.01.011
   Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127
   Mauck CK, 1997, CONTRACEPTION, V56, P97, DOI 10.1016/S0010-7824(97)00099-1                                                   
   Mauck CK, 1997, CONTRACEPTION, V56, P89, DOI 10.1016/S0010-7824(97)00097-8                                                   
   Mauck CK, 1997, CONTRACEPTION, V56, P103, DOI 10.1016/S0010-7824(97)00100-5
   Mauck RL, 2009, TISSUE ENG PART B-RE, V15, P171, DOI 10.1089/ten.TEB.2008.0652
   Mayer KH, 2006, AIDS, V20, P543, DOI 10.1097/01.aids.0000210608.70762.c3
   Mcgowan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060147
   Minces Lucio R, 2010, Curr Infect Dis Rep, V12, P56, DOI 10.1007/s11908-009-0076-5
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Morrow KM, 2010, ANTIVIR RES, V88, pS40, DOI 10.1016/j.antiviral.2010.09.008
   Moss JA, 2012, ANTIMICROB AGENTS CH, V56, P875, DOI 10.1128/AAC.05662-11
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Nel AA, 2009, AIDS, V23, P1531, DOI 10.1097/QAD.0b013e32832c413d
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   Nel AM, 2010, AIDS RES HUM RETROV, V26, P1181, DOI 10.1089/aid.2009.0227
   Nel AM, 2010, JAIDS-J ACQ IMM DEF, V55, P161, DOI 10.1097/QAI.0b013e3181e3293a
   Nerurkar NL, 2007, J ORTHOP RES, V25, P1018, DOI 10.1002/jor.20384
   Neurath AR, 1999, BIOLOGICALS, V27, P11, DOI 10.1006/biol.1998.0169                                                          
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Neurath AR, 2001, BMC INFECT DIS, V1, part. no., DOI 10.1186/1471-2334-1-17                                                          
   Novak A, 2003, CONTRACEPTION, V67, P187, DOI 10.1016/S0010-7824(02)00514-0
   O'Dowd MJ, 2001, HIST MEDICATIONS WOM
   Okuda T, 2010, J CONTROL RELEASE, V143, P258, DOI 10.1016/j.jconrel.2009.12.029
   Owen DH, 2003, CONTRACEPTION, V67, P57, DOI 10.1016/S0010-7824(02)00430-4                                                   
   Pham QP, 2006, TISSUE ENG, V12, P1197, DOI 10.1089/ten.2006.12.1197
   POLITZ ML, 1994, CARBOHYD POLYM, V24, P91, DOI 10.1016/0144-8617(94)90017-5
   Rad M, 2006, AM J OBSTET GYNECOL, V195, P72, DOI 10.1016/j.ajog.2005.12.007
   Reeves JD, 2005, DRUGS, V65, P1747, DOI 10.2165/00003495-200565130-00002
   Reilly B, 2004, 31 M EXP CONTR REL S
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Roumen FJME, 2001, HUM REPROD, V16, P469, DOI 10.1093/humrep/16.3.469
   Roy S, 2001, ANTIMICROB AGENTS CH, V45, P1671, DOI 10.1128/AAC.45.6.1671-1681.2001
   Sam AP, 1997, PHARM TECH EUR, V9, P58
   Sassi AB, 2011, ANTIMICROB AGENTS CH, V55, P2282, DOI 10.1128/AAC.01190-10
   Sassi AB, 2008, J PHARM SCI-US, V97, P3123, DOI 10.1002/jps.21192
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Schwartz JL, 2008, CONTRACEPTION, V78, P237, DOI 10.1016/j.contraception.2008.04.118
   Schwartz JL, 2008, SEX TRANSM DIS, V35, P414, DOI 10.1097/OLQ.0b013e318162c4d8
   Seager H, 1998, J PHARM PHARMACOL, V50, P375, DOI 10.1111/j.2042-7158.1998.tb06876.x                                              
   Seattle King County Department of Public Health, 2000, WHAT IS STD HIV CONN
   Seeras R. C., 1995, Clinical and Experimental Obstetrics and Gynecology, V22, P105
   SEERAS RC, 1995, INT J GYNECOL OBSTET, V48, P163, DOI 10.1016/0020-7292(94)02260-6
   SHAH VP, 1989, INT J PHARM, V53, P53, DOI 10.1016/0378-5173(89)90361-X
   Siewert Martin, 2003, AAPS PharmSciTech, V4, pE7
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Song Yifan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P195, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.20
   Stitzel J, 2006, BIOMATERIALS, V27, P1088, DOI 10.1016/j.biomaterials.2005.07.048
   Sudeendra BR, 2010, ACTA PHARM SCI, V52, P417
   Szycher M, 1988, J Biomater Appl, V3, P297, DOI 10.1177/088532828800300207
   Taepaiboon P, 2006, NANOTECHNOLOGY, V17, P2317, DOI 10.1088/0957-4484/17/9/041
   Tamburic S, 1996, PHARMACEUT RES, V13, P279, DOI 10.1023/A:1016003400886
   Tan AR, 2008, J BIOMED MATER RES A, V87A, P1034, DOI 10.1002/jbm.a.31853
   Tao W, 2008, AIDS RES HUM RETROV, V24, P925, DOI 10.1089/aid.2008.0043
   Theron A, 2001, NANOTECHNOLOGY, V12, P384, DOI 10.1088/0957-4484/12/3/329
   Thyssen H, 2001, BJU INT, V88, P889, DOI 10.1046/j.1464-4096.2001.01548.x                                                
   Trifonova RT, 2006, ANTIMICROB AGENTS CH, V50, P4005, DOI 10.1128/AAC.00588-06
   Turpin JA, 2011, DRUG DELIV TRANSL RE, V1, P194, DOI 10.1007/s13346-011-0034-2
   van Laarhoven JAH, 2002, INT J PHARM, V232, P163, DOI 10.1016/S0378-5173(01)00900-0
   van Laarhoven JAH, 2002, J CONTROL RELEASE, V82, P309, DOI 10.1016/S0168-3659(02)00139-6
   Ventuneac A, 2010, AIDS BEHAV, V14, P618, DOI 10.1007/s10461-009-9611-5
   Vermani K., 2000, PSTT, V3, P359, DOI [10.1016/S1461-5347(00)00296-0, DOI 10.1016/S1461-5347(00)00296-0]
   VIRLEY P, 1990, MANUF CHEMIST, V61, P36
   Vondrak B, 2008, PHARM TECHNOL
   Wang JW, 2010, J APPL POLYM SCI, V115, P1769, DOI 10.1002/app.31287
   Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142
   Wei GB, 2006, J CONTROL RELEASE, V112, P103, DOI 10.1016/j.jconrel.2006.01.011
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   Woolfson AD, 1999, J CONTROL RELEASE, V61, P319, DOI 10.1016/S0168-3659(99)00148-0                                                   
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yoo JW, 2009, BIOMATERIALS, V30, P3978, DOI 10.1016/j.biomaterials.2009.04.004
   Yoo JW, 2006, INT J PHARM, V309, P139, DOI 10.1016/j.ijpharm.2005.11.020
   Zhang W, 2012, 2012 MICR SYDN AUSTR
   Zhang YZ, 2006, BIOMACROMOLECULES, V7, P1049, DOI 10.1021/bm050743i
   Duncan G, 1970, US Patent Number, Patent No. [3, 439, 3439]
   Austin GD, 1998, US patent Number, Patent No. [5, 900, 5900]
NR 157
TC 14
Z9 14
U1 0
U2 9
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0070-217X
BN 978-3-662-44596-9; 978-3-662-44595-2
J9 CURR TOP MICROBIOL
JI Curr.Top.Microbiol.Immunol.
PY 2014
VL 383
BP 27
EP 54
DI 10.1007/82_2013_357
D2 10.1007/978-3-662-44596-9
PG 28
WC Immunology; Microbiology; Pharmacology & Pharmacy; Virology
SC Immunology; Microbiology; Pharmacology & Pharmacy; Virology
GA BC0DY
UT WOS:000348980600003
PM 24220751
DA 2018-01-05
ER

PT J
AU Vacas-Cordoba, E
   Climent, N
   De La Mata, FJ
   Plana, M
   Gomez, R
   Pion, M
   Garcia, F
   Munoz-Fernandez, MA
AF Vacas-Cordoba, Enrique
   Climent, Nuria
   De La Mata, Francisco J.
   Plana, Montserrat
   Gomez, Rafael
   Pion, Marjorie
   Garcia, Felipe
   Angeles Munoz-Fernandez, Maria
TI Dendrimers as nonviral vectors in dendritic cell-based immunotherapies
   against human immunodeficiency virus: steps toward their clinical
   evaluation
SO NANOMEDICINE
LA English
DT Review
DE dendrimer; dendritic cell; HIV; immunotherapy; nanomedicine; vaccine
ID SOLUBLE CARBOSILANE DENDRIMERS; HIV-DERIVED PEPTIDES; PBL-SCID MICE;
   IN-VITRO; IMMUNE-RESPONSES; BIOLOGICAL-PROPERTIES; PROSTATE-CANCER;
   SIPULEUCEL-T; GENE-THERAPY; DC-SIGN
AB Although the antiretroviral therapy has led to a long-term control of HIV-1, it does not cure the disease. Therefore, several strategies are being explored to develop an effective HIV vaccine, such as the use of dendritic cells (DCs). DC-based immunotherapies bear different limitations, but one of the most critical point is the antigen loading into DCs. Nanotechnology offers new tools to overcome these constraints. Dendrimers have been proposed as carriers for targeted delivery of HIV antigens in DCs. These nanosystems can release the antigens in a controlled manner leading to a more potent specific immune response. This review focuses on the first steps for clinical development of dendrimers to assess their safety and potential use in DC-based immunotherapies against HIV.
C1 [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Secc Inmunol, Lab InmunoBiol Mol, Madrid, Spain.
   [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, Maria] Inst Invest Sanitaria Gregorio Maranon, Madrid 28007, Spain.
   [Vacas-Cordoba, Enrique; De La Mata, Francisco J.; Gomez, Rafael; Pion, Marjorie; Angeles Munoz-Fernandez, Maria] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Climent, Nuria; Plana, Montserrat; Garcia, Felipe] Univ Barcelona, AIDS Res Unit, Hosp Clin HIVACAT, IDIBAPS, E-08007 Barcelona, Spain.
   [De La Mata, Francisco J.; Gomez, Rafael] Univ Alcala De Henares, Dendrimers Biomed Applicat Grp BioInDen, Madrid 28871, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Secc Inmunol, Lab InmunoBiol Mol, Madrid, Spain.
EM mmunoz.hgugm@salud.madrid.org
RI Pion, Marjorie/D-8139-2012; Garcia, Felipe/F-4242-2014
OI Pion, Marjorie/0000-0002-6406-747X; Climent, Nuria/0000-0002-0791-656X;
   Garcia, Felipe/0000-0001-7658-5832; Munoz-Fernandez/0000-0002-0813-4500;
   Pion, Marjorie/0000-0003-1828-4745
FU EuroNanoMed DENPEPTHIV; COST action [TD0802]; Red Tematica de
   Investigacion Cooperativa Sanitaria ISCIII [RED RIS RD06/0006/0035];
   Fondo de Investigacion Sanitaria (INTRASALUD) [PI09/02029, PS09102669];
   INDISNET [S-2011-BMD2332]; FIPSE; Spanish MICINN through the Ramon y
   Cajal Programme [RYC-2009-05486]
FX This work was supported by grants from EuroNanoMed DENPEPTHIV, COST
   action TD0802, Red Tematica de Investigacion Cooperativa Sanitaria
   ISCIII (RED RIS RD06/0006/0035), Fondo de Investigacion Sanitaria
   (INTRASALUD 2009; PI09/02029; PS09102669), INDISNET S-2011-BMD2332 and
   FIPSE to MAMF. In addition, it was supported by grants from the Spanish
   MICINN through the Ramon y Cajal Programme (RYC-2009-05486) to MP. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ahlers JD, 2009, TRENDS MOL MED, V15, P263, DOI 10.1016/j.molmed.2009.04.003
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Allard SD, 2011, CLIN IMMUNOL, V142, P252
   Angel JB, 2011, AIDS, V25, P731, DOI 10.1097/QAD.0b013e328344cea5
   Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061
   Berges BK, 2010, VIROLOGY, V397, P100, DOI 10.1016/j.virol.2009.10.034
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Betts MR, 2002, DNA CELL BIOL, V21, P665, DOI 10.1089/104454902760330200                                                      
   Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Borthwick N, 2014, MOL THER, V22, P464, DOI 10.1038/mt.2013.248
   Boyapalle S, 2012, J GLOB INFECT DIS, V4, P62, DOI 10.4103/0974-777X.93764
   Brehm MA, 2010, CURR OPIN ENDOCRINOL, V17, P120, DOI 10.1097/MED.0b013e328337282f
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Caminade AM, 2012, MOLECULES, V17, P13605, DOI 10.3390/molecules171113605
   Caminade AM, 2010, NEW J CHEM, V34, P1512, DOI 10.1039/c0nj00116c
   Carbonetti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086905
   Carrillo-Conde B, 2011, MOL PHARMACEUT, V8, P1877, DOI 10.1021/mp200213r
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Cheever MA, 2011, CLIN CANCER RES, V17, P3520, DOI 10.1158/1078-0432.CCR-10-3126
   Cho HJ, 2011, BIOMATERIALS, V32, P4621, DOI 10.1016/j.biomaterials.2011.03.004
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Ciepluch K, 2012, MOL PHARMACEUT, V9, P448, DOI 10.1021/mp200549c
   Connolly NC, 2007, CURR OPIN MOL THER, V9, P353
   Cordoba EV, 2013, NANOMED-NANOTECHNOL, V9, P972, DOI 10.1016/j.nano.2013.03.004
   Cordoba EV, 2013, CURR MED CHEM, DOI [10.2174/0929867321666131129114022, DOI 10.2174/0929867321666131129114022]
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Davenport MP, 2008, TRENDS MICROBIOL, V16, P561, DOI 10.1016/j.tim2008.09.001
   de las Cuevas N, 2012, CURR MED CHEM, V19, P5052
   de Vries IJM, 2003, CLIN CANCER RES, V9, P5091
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037                                                    
   Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Fahmy TM, 2008, NANOMEDICINE-UK, V3, P343
   Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723
   Fruchon S, 2013, MOLECULES, V18, P9305, DOI 10.3390/molecules18089305
   Galan M, 2012, CURR MED CHEM, V19, P4984
   GARCIA F, 2013, SCI TRANSL MED, V5, DOI DOI 10.1126/SCITRANSLMED.3004682
   Garcia F, 2012, IMMUNOTHERAPY-UK, V4, P245, DOI [10.2217/IMT.12.2, 10.2217/imt.12.2]
   Garcia F, 2011, VACCINE, V29, P6454, DOI 10.1016/j.vaccine.2011.07.043
   Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
   Garcia-Gallego S, 2012, DALTON T, V41, P6488, DOI 10.1039/c2dt11793b
   Garcia-Vallejo JJ, 2013, INT IMMUNOL, V25, P221, DOI 10.1093/intimm/dxs115
   Gert P, 2010, CLIN IMMUNOL, V135
   Giannoukakis N, 2012, CURR OPIN ENDOCRINOL, V19, P279, DOI 10.1097/MED.0b013e328355461b
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021
   Hanke T, 2014, EXPERT OPIN BIOL TH, V14, P601, DOI 10.1517/14712598.2014.885946
   Hauptmann N, 2013, MACROMOL BIOSCI, V13, P531, DOI 10.1002/mabi.201200449
   Hobel S, 2011, J CONTROL RELEASE, V149, P146, DOI 10.1016/j.jconrel.2010.10.008
   Hori Y, 2008, BIOMATERIALS, V29, P3671, DOI 10.1016/j.biomaterials.2008.05.033
   Ionov M, 2013, CURR MED CHEM, V20, P3935
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Kalantari T, 2011, IMMUNOL RES, V51, P153, DOI 10.1007/s12026-011-8255-5
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953
   Khandare J, 2012, CHEM SOC REV, V41, P2824, DOI 10.1039/c1cs15242d
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Klajnert B, 2008, CHEM-EUR J, V14, P7030, DOI 10.1002/chem.200800342
   Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013
   Klementieva O, 2011, BIOMACROMOLECULES, V12, P3903, DOI 10.1021/bm2008636
   Kwong PD, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17407
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1081/jem.20021924
   Lazniewska J, 2012, WIRES NANOMED NANOBI, V4, P469, DOI 10.1002/wnan.1181
   Lewis JS, 2012, BIOMATERIALS, V33, P7221, DOI 10.1016/j.biomaterials.2012.06.049
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Lipscomb MF, 2002, PHYSIOL REV, V82, P97, DOI 10.1152/physrev.00023.2001                                                      
   Lisziewicz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035416
   Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633
   Lori F, 2011, EXPERT REV VACCINES, V10, P1371, DOI [10.1586/ERV.11.118, 10.1586/erv.11.118]
   Loup C., 1999, CHEM-EUR J, V5, P36644
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673                                                           
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mccullough KC, 2013, NANOMEDICINE LONDON, V8, P871
   Mills R, 2010, VACCINE, V28, P4204, DOI 10.1016/j.vaccine.2010.04.003
   Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132
   Mothe B, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-208
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Nchinda G, 2010, P NATL ACAD SCI USA, V107, P4281, DOI 10.1073/pnas.1000621107
   Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004
   Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007
   Pedziwiatr E, 2009, J FLUORESC, V19, P267, DOI 10.1007/s10895-008-0412-4
   Pedziwiatr-Werbicka E, 2013, COLLOID SURFACE B, V109, P183, DOI 10.1016/j.colsurfb.2013.03.045
   Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Pitisuttithum P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027837
   Platt AM, 2013, ADV IMMUNOL, V120, P51, DOI 10.1016/B978-0-12-417028-5.00002-8
   Pollard RB, 2014, LANCET INFECT DIS, V14, P291, DOI 10.1016/S1473-3099(13)70343-8
   Posadas I, 2009, PHARM RES-DORD, V26, P1181, DOI 10.1007/s11095-009-9839-9
   Ramakrishna V, 2004, J IMMUNOL, V172, P2845, DOI 10.4049/jimmunol.172.5.2845                                                     
   Rasines B, ANIONIC CARBOS UNPUB
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634                                                     
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83                                                            
   Routy JP, 2010, IMMUNOTHERAPY-UK, V2, P467, DOI 10.2217/IMT.10.28
   Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009
   Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403
   Sadler K, 2002, REV MOL BIOTECHNOL, V90, P195, DOI DOI 10.1016/S1389-0352(01)00061-7
   Sanchez-Nieves J, 2014, EUR J MED CHEM, V76, P43, DOI 10.1016/j.ejmech.2014.01.061
   Scherer E, 2008, CLIN EXP IMMUNOL, V154, P6, DOI 10.1111/j.1365-2249.2008.03750.x
   Schiffner T, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-72
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Serda RE, 2013, INT J NANOMED, V8, P1683, DOI 10.2147/IJN.S31756
   SGOURAS D, 1990, J MATER SCI-MATER M, V1, P61, DOI 10.1007/BF00839070                                                              
   Sheng KC, 2008, EUR J IMMUNOL, V38, P424, DOI 10.1002/eji.200737578
   Shimada M, 2009, GENE THER, V16, P218, DOI 10.1038/gt.2008.152
   Siccardi M, 2013, THER DELIV, V4, P153, DOI [10.4155/TDE.12.156, 10.4155/tde.12.156]
   Singh SK, 2006, VACCINE, V24, P4161, DOI 10.1016/j.vaccine.2006.02.047
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839
   Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698                                                          
   Stenger EO, 2012, BLOOD, V119, P5088, DOI 10.1182/blood-2011-11-364091
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Tacken PJ, 2011, SEMIN IMMUNOL, V23, P12, DOI 10.1016/j.smim.2011.01.001
   Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583
   Thara E, 2011, MATURITAS, V69, P296, DOI 10.1016/j.maturitas.2011.04.012
   Trepiakas R, 2010, CYTOTHERAPY, V12, P721, DOI 10.3109/14653241003774045
   Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Vacchelli E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25771
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8
   van Kooyk Y, 2013, MOL IMMUNOL, V55, P143, DOI 10.1016/j.molimm.2012.10.031
   Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49
   Vanham G, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-72
   Wagner A, 2007, J LIPOSOME RES, V17, P139, DOI 10.1080/08982100701530159
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Xin HM, 2009, CAN J MICROBIOL, V55, P859, DOI [10.1139/W09-041, 10.1139/w09-041]
   Xu Jing, 2012, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V29, P1003
   Yoshida A, 2003, J VIROL, V77, P8719, DOI 10.1128/JVI.77.16.8719-8728.2003
   Zhang G, 2013, J BIOMED NANOTECHNOL, V9, P741, DOI 10.1166/jbn.2013.1583
   Zhang JJ, 2013, BIOMATERIALS, V34, P3846, DOI 10.1016/j.biomaterials.2013.01.026
NR 152
TC 3
Z9 3
U1 4
U2 16
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2014
VL 9
IS 17
BP 2683
EP 2702
DI 10.2217/NNM.14.172
PG 20
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AX0TO
UT WOS:000346665400008
PM 25529571
DA 2018-01-05
ER

PT J
AU Saxena, S
   Shrivastava, R
   Satsangee, SP
   Srivastava, S
AF Saxena, Sachin
   Shrivastava, Ratnanjali
   Satsangee, Soami P.
   Srivastava, Shalini
TI TiO2/Graphene/Chitosan-Nanocomposite-Based Electrochemical Sensor for
   the Sensing of Anti-HIV Drug Topotecan
SO JOURNAL OF THE ELECTROCHEMICAL SOCIETY
LA English
DT Article
ID GLASSY-CARBON ELECTRODE; PERFORMANCE LIQUID-CHROMATOGRAPHY; SELECTIVE
   POTENTIOMETRIC SENSOR; STRIPPING VOLTAMMETRIC BEHAVIOR;
   PYROLYTIC-GRAPHITE ELECTRODE; LITHIUM ION BATTERIES; PVC MATRIX;
   SOLUBILIZED SYSTEMS; BIOLOGICAL-FLUIDS; MERCURY-ELECTRODE
AB Ahighly sensitive and stable TiO2/graphene/chitosan (TiO2/GRP/CHIT) modified glassy carbon electrodewas developed. The sensor exhibits excellent electrocatalytic activity with fast response and convenient determination of an anti-HIV drug Topotecan (TPT). Moreover, from the response characteristics of cyclic voltammetry(CV) and square wave voltammetry (SWV), it was observed that TPT could be effectively accumulated at TiO2/GRP/CHIT/GCE and resulted in a sensitive anodic peak current in Britton-Robinson buffer (pH 5.6). Under the optimized experimental conditions, electro-oxidation of TPT demonstrates linearity within a dynamic concentration of 100 to 1200 ng/mL, with a detection limit of 122.07 ng/mL (LOD) and a quantification limit of 369.9 ng/mL (LOQ). On the basis of the electrochemical measurements, electrode dynamics parameters have been evaluated and the sensor has been successfully employed for determination of TPT in pharmaceutical formulation. (C) 2014 The Electrochemical Society. All rights reserved.
C1 [Saxena, Sachin; Shrivastava, Ratnanjali; Satsangee, Soami P.] Dayalbagh Educ Inst, USIC, Agra 282005, Uttar Pradesh, India.
   [Srivastava, Shalini] Dayalbagh Educ Inst, Dept Chem, Agra 282005, Uttar Pradesh, India.
RP Saxena, S (reprint author), Dayalbagh Educ Inst, USIC, Agra 282005, Uttar Pradesh, India.
EM deiusic@gmail.com
FU Ministry of Human Resource and Development, India; UGC-BSR
FX The authors greatly acknowledge the Ministry of Human Resource and
   Development, India, for providing funds for carrying out the research
   work reported. They are also thankful to UGC-BSR for providing
   fellowship to two authors (Sachin Saxena and Ratnanjali Shrivastava) and
   IIT Delhi for carrying out SEM.
CR Arellano C, 2010, J CHROMATOGR B, V878, P645, DOI 10.1016/j.jchromb.2010.01.019
   Arun B, 2001, Expert Opin Pharmacother, V2, P491, DOI 10.1517/14656566.2.3.491
   Asahi R, 2000, PHYS REV B, V61, P7459, DOI 10.1103/PhysRevB.61.7459
   Baczek T, 2012, J PHARMACEUT BIOMED, V70, P330, DOI 10.1016/j.jpba.2012.05.012
   Balandin AA, 2008, NANO LETT, V8, P902, DOI 10.1021/nl0731872
   Bard A. J., 1980, ELECTROCHEMICAL METH
   Chen J, 2005, J CHROMATOGR B, V816, P183, DOI 10.1016/j.jchromb.2004.11.035
   Das M, 2011, BIOMACROMOLECULES, V12, P540, DOI 10.1021/bm1013074
   de Vries NA, 2007, BIOMED CHROMATOGR, V21, P1191, DOI 10.1002/bmc.874
   Dhakane V., 2012, J PHARM SCI INNOVATI, V4, P61
   Erk N, 2004, ANAL BIOANAL CHEM, V378, P1351, DOI 10.1007/s00216-003-2427-7
   Filipiak M, 2001, ANAL SCI, V17, P1667
   Geng DS, 2011, ENERG ENVIRON SCI, V4, P760, DOI 10.1039/c0ee00326c
   Gosser D. K., 1994, CYCLIC VOLTAMMETRY V
   Goyal RN, 2008, TALANTA, V76, P662, DOI 10.1016/j.talanta.2008.04.011
   Goyal RN, 2008, ELECTROCHIM ACTA, V53, P5354, DOI 10.1016/j.electacta.2008.02.059
   Goyal RN, 2007, ANAL CHIM ACTA, V605, P34, DOI 10.1016/j.aca.2007.10.022
   Goyal RN, 2007, ANAL CHIM ACTA, V597, P82, DOI 10.1016/j.aca.2007.06.017
   Goyal RN, 2008, ELECTROANAL, V20, P757, DOI 10.1002/elan.200704073
   Goyal R.N., 2010, OPEN CHEM BIOMED MET, V3, P115
   Gupta K., 2000, ANAL CHIM ACTA, V420, P19
   Gupta VK, 2007, ANAL CHIM ACTA, V590, P81, DOI 10.1016/j.aca.2007.03.014
   Gupta VK, 2006, SENSOR ACTUAT B-CHEM, V120, P259, DOI 10.1016/j.snb.2006.02.019
   Gupta VK, 2006, SENSOR ACTUAT B-CHEM, V117, P99, DOI 10.1016/j.snb.2005.11.003
   Gupta VK, 2011, CRIT REV ANAL CHEM, V41, P282, DOI 10.1080/10408347.2011.589773
   Gupta VK, 2011, COMB CHEM HIGH T SCR, V14, P284, DOI 1386-2073/11 $58.00+.00
   Gupta VK, 2011, ANAL BIOCHEM, V408, P179, DOI 10.1016/j.ab.2010.09.027
   Gupta VK, 2013, ELECTROCHIM ACTA, V105, P149, DOI 10.1016/j.electacta.2013.04.136
   Gupta VK, 2013, J MOL LIQ, V177, P114, DOI 10.1016/j.molliq.2012.10.008
   Gupta VK, 2012, J MOL LIQ, V174, P11, DOI 10.1016/j.molliq.2012.07.016
   Gupta VK, 1999, ELECTROANAL, V11, P573, DOI 10.1002/(SICI)1521-4109(199906)11:8<573::AID-ELAN573>3.3.CO;2-Q
   Gupta VK, 2006, ANAL CHIM ACTA, V566, P5, DOI 10.1016/j.aca.2006.02.038
   Gupta VK, 2006, SENSOR ACTUAT B-CHEM, V113, P182, DOI 10.1016/j.snb.2005.02.046
   Gupta VK, 2005, TALANTA, V66, P575, DOI 10.1016/j.talanta.2004.11.028
   Gupta VK, 2003, ANAL CHIM ACTA, V486, P199, DOI 10.1016/S0003-2670(03)00506-3
   Gupta VK, 2003, TALANTA, V60, P149, DOI 10.1016/S0039-9140(03)00118-8
   Gupta VK, 2002, ELECTROCHIM ACTA, V47, P1579, DOI 10.1016/S0013-4686(01)00895-7                                                   
   Gupta VK, 1997, ELECTROANAL, V9, P478, DOI 10.1002/elan.1140090609                                                         
   Hass J., 2008, J PHYS CONDENS MATT, V20, P3232
   Herben VMM, 1996, CLIN PHARMACOKINET, V31, P85, DOI 10.2165/00003088-199631020-00001                                                
   Jain AK, 1997, ANALYST, V122, P583, DOI 10.1039/a608421d                                                                
   Jain AK, 2006, ELECTROCHIM ACTA, V51, P2547, DOI 10.1016/j.electacta.2005.07.040
   Jain R., 2013, J ELECTROCHEMICAL SO, V160, P179
   Jain R., 2013, J ELECTROCHEM SOC, V160, pH1
   Jain R, 2007, J COLLOID INTERF SCI, V314, P572, DOI 10.1016/j.jcis.2007.06.007
   Jain R, 2013, COLLOID SURFACE B, V105, P278, DOI 10.1016/j.colsurfb.2013.01.015
   Jain R, 2011, DRUG TEST ANAL, V3, P171, DOI 10.1002/dta.200
   Jain R, 2011, COLLOID SURFACE B, V88, P729, DOI 10.1016/j.colsurfb.2011.08.008
   Jain R, 2010, ANAL BIOCHEM, V407, P79, DOI 10.1016/j.ab.2010.07.027
   Jain R, 2009, J SCI IND RES INDIA, V68, P540
   Jain R, 2009, J HAZARD MATER, V169, P667, DOI 10.1016/j.jhazmat.2009.03.138
   Kang XH, 2009, BIOSENS BIOELECTRON, V25, P901, DOI 10.1016/j.bios.2009.09.004
   KULYS J, 2008, OPEN NANOSCI J, V2, P34
   Lee B., 2008, SCIENCE, V321, P385
   LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839
   Li QW, 2001, ELECTROANAL, V13, P359, DOI 10.1002/1521-4109(200104)13:5<359::AID-ELAN359>3.0.CO;2-J
   Li XF, 2011, ELECTROCHEM COMMUN, V13, P822, DOI 10.1016/j.elecom.2011.05.012
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Loos WJ, 2002, J CHROMATOGR B, V766, P99, DOI 10.1016/S0378-4347(01)00432-7
   Macak JM, 2008, J ELECTROANAL CHEM, V621, P254, DOI 10.1016/j.jelechem.2008.01.005
   Muderspach LI, 2001, GYNECOL ONCOL, V81, P213, DOI 10.1006/gyno.2000.6024
   Nolotin KI, 2008, SOLID STATE COMMUN, V146, P351
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Perenlei G, 2011, INT J ELECTROCHEM SC, V6, P520
   Prasad R, 2004, ANAL CHIM ACTA, V508, P61, DOI 10.1016/j.aca.2003.11.056
   ROSING H, 1995, J CHROMATOGR B, V668, P107, DOI 10.1016/0378-4347(95)00054-M
   SABATANI E, 1987, J PHYS CHEM-US, V91, P6663, DOI 10.1021/j100311a021
   Saini PK, 2010, INDIAN J PHARM SCI, V72, P494, DOI 10.4103/0250-474X.73925
   Saravanan G, 2008, CHROMATOGRAPHIA, V67, P179, DOI 10.1365/s10337-007-0468-3
   Saxena S, 2012, MACED J CHEM CHEM EN, V31, P195
   Saxena S, 2012, INT J ELECTROCHEM SC, V7, P4636
   Shankara K. S., 2009, E J ELECTROANAL CHEM, V636, P93
   Singh P, 2008, PHYSICA B, V403, P3769, DOI 10.1016/j.physb.2008.07.021
   Srivastava R., 2012, J ELECTROCHEM SOC, V159, P795
   Srivastava SK, 1996, ANAL CHEM, V68, P1272, DOI 10.1021/ac9507000
   Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y
   Tabeshnia M, 2010, TURK J CHEM, V34, P35, DOI 10.3906/kim-0810-9
   Teradal NL, 2012, J APPL ELECTROCHEM, V42, P917, DOI 10.1007/s10800-012-0473-6
   Thompson J, 1999, CLIN CANCER RES, V5, P3617
   Wang X, 2008, ANGEW CHEM INT EDIT, V47, P2990, DOI 10.1002/anie.200704909
   Wu JB, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2924771
   Yan JL, 2008, COLLOID SURFACE B, V67, P205, DOI 10.1016/j.colsurfb.2008.08.015
   Yang SL, 2010, J CHEM SCI, V122, P919, DOI 10.1007/s12039-010-0080-1
   Yoo E, 2008, NANO LETT, V8, P2277, DOI 10.1021/nl800957b
   Yuan S, 2004, ELECTROCHIM ACTA, V49, P4287, DOI 10.1016/j.electacta.2004.03.037
   Zhang JL, 1997, ANTIMICROB AGENTS CH, V41, P977
   Zhang WY, 2014, ELECTROANAL, V26, P178, DOI 10.1002/elan.201300343
NR 87
TC 2
Z9 2
U1 1
U2 30
PU ELECTROCHEMICAL SOC INC
PI PENNINGTON
PA 65 SOUTH MAIN STREET, PENNINGTON, NJ 08534 USA
SN 0013-4651
EI 1945-7111
J9 J ELECTROCHEM SOC
JI J. Electrochem. Soc.
PY 2014
VL 161
IS 14
BP H934
EP H940
DI 10.1149/2.0891414jes
PG 7
WC Electrochemistry; Materials Science, Coatings & Films
SC Electrochemistry; Materials Science
GA AW0IO
UT WOS:000345975500117
DA 2018-01-05
ER

PT J
AU Campian, M
   Putala, M
   Sebesta, R
AF Campian, Michaela
   Putala, Martin
   Sebesta, Radovan
TI Bioactive Carbocyclic Nucleoside Analogues - Syntheses and Properties of
   Entecavir
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Biological activity; carbocyclic saccharide; entecavir; non-natural
   nucleoside
ID HEPATITIS-B-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; RING-CLOSING
   METATHESIS; DESS-MARTIN PERIODINANE; ANTI-HIV ACTIVITY; ANTIVIRAL
   ACTIVITY; ENANTIOSELECTIVE SYNTHESIS; ANTITUMOR-ACTIVITY;
   ASYMMETRIC-SYNTHESIS; RADICAL CYCLIZATION
AB Carbocyclic nucleoside analogs are highly biologically relevant compounds. A large variety of them already serve as drugs or are investigated with this aim in mind. This review analyses syntheses of major types of carbocyclic nucleoside derivatives including those of pharmacological interest. The emphasis of this review is on entecavir, a derivative exhibiting selective activity at nanomolar level against hepatitis B virus.
   The first subject of this review is the summary of nucleoside analogs, mainly classification and synthetic strategies employed for the preparation of these derivatives. The second part focuses on the recent developments in the field of enanti oselective approaches of synthesis of entecavir and related compounds. This paper covers the literature from 1992 to 2013.
C1 [Campian, Michaela; Putala, Martin; Sebesta, Radovan] Comenius Univ, Fac Nat Sci, Dept Organ Chem, SK-84215 Bratislava, Slovakia.
RP Putala, M (reprint author), Comenius Univ, Fac Nat Sci, Dept Organ Chem, Mlynska Dolina CH-2, SK-84215 Bratislava, Slovakia.
EM putala@fns.uniba.sk; radovan.sebesta@fns.uniba.sk
RI Sebesta, Radovan/F-6129-2010
OI Sebesta, Radovan/0000-0002-7975-3608
FU OPRaD - European Regional Development Fund [ITMS 26240220061]
FX This contribution is the result of the project implementation (ITMS
   26240220061) supported by the OPRaD funded by the European Regional
   Development Fund.
CR AGROFOGLIO L, 1994, TETRAHEDRON, V50, P10611, DOI 10.1016/S0040-4020(01)89258-9
   Agrofoglio LA, 2003, CHEM REV, V103, P1875, DOI 10.1021/cr010374q
   Amblard F, 2005, TETRAHEDRON, V61, P7067, DOI 10.1016/j.tet.2005.04.040
   Arjona O, 2007, CHEM REV, V107, P1919, DOI 10.1021/cr0203701
   BIGGADIKE K, 1988, J CHEM SOC PERK T 1, P549, DOI 10.1039/p19880000549                                                            
   BISACCHI GS, 1995, J ORG CHEM, V60, P2902, DOI 10.1021/jo00114a047                                                             
   Bisacchi GS, 1997, BIOORG MED CHEM LETT, V7, P127, DOI 10.1016/S0960-894X(96)00594-X
   BONNAL C, 1994, J CHEM SOC PERK T 1, P1401, DOI 10.1039/p19940001401
   BORTHWICK AD, 1991, J MED CHEM, V34, P907, DOI 10.1021/jm00107a006
   BORTHWICK AD, 1992, TETRAHEDRON, V48, P571, DOI 10.1016/S0040-4020(01)88122-9                                                   
   Boutureira O, 2013, CHEM SOC REV, V42, P5056, DOI 10.1039/c3cs00003f
   Boyer SJ, 1997, J ORG CHEM, V62, P3976, DOI 10.1021/jo970153d                                                               
   Brown B, 2000, J ORG CHEM, V65, P1865, DOI 10.1021/jo9919759                                                               
   BROWN HC, 1984, J ORG CHEM, V49, P945, DOI 10.1021/jo00179a041                                                             
   CAMPBELL JA, 1995, J ORG CHEM, V60, P4602, DOI 10.1021/jo00119a044                                                             
   Chu C. K, 1993, NUCLEOSIDES AND NUCL
   CLAUSEN FP, 1993, ORG PREP PROCED INT, V25, P373, DOI 10.1080/00304949309457984                                                       
   COREY EJ, 1990, TETRAHEDRON LETT, V31, P3833, DOI 10.1016/S0040-4039(00)97481-1                                                   
   CRAIG GW, 1986, J ORG CHEM, V51, P1258, DOI 10.1021/jo00358a017                                                             
   Crimmins MT, 1996, J ORG CHEM, V61, P4192, DOI 10.1021/jo960708p                                                               
   Crimmins MT, 1998, TETRAHEDRON, V54, P9229, DOI 10.1016/S0040-4020(98)00320-2                                                   
   CURRAN DP, 1982, J AM CHEM SOC, V104, P4024, DOI 10.1021/ja00378a050                                                             
   DECLERCQ E, 1991, BIOCHEM PHARMACOL, V41, P1821, DOI 10.1016/0006-2952(91)90120-T                                                    
   Delaney WE, 2001, ANTIVIR CHEM CHEMOTH, V12, P1
   DESGRANGES C, 1983, BIOCHEM PHARMACOL, V32, P3583, DOI 10.1016/0006-2952(83)90307-6                                                    
   DESS DB, 1991, J AM CHEM SOC, V113, P7277, DOI 10.1021/ja00019a027                                                             
   Dusheiko G, 2005, GUT, V54, P9, DOI 10.1136/gut.2004.047548
   EASTWOOD FW, 1970, TETRAHEDRON LETT, P5223
   EVANS CT, 1992, J CHEM SOC PERK T 1, P589, DOI 10.1039/p19920000589
   Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099
   Ferrero M, 2000, CHEM REV, V100, P4319, DOI 10.1021/cr000446y
   FRANCHETTI P, 1990, J MED CHEM, V33, P2849, DOI 10.1021/jm00172a027                                                             
   FRANCHETTI P, 1995, J MED CHEM, V38, P3829, DOI 10.1021/jm00019a013
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   GAO Y, 1987, J AM CHEM SOC, V109, P5765, DOI 10.1021/ja00253a032                                                             
   Gillaizeau I, 2001, TETRAHEDRON LETT, V42, P8817, DOI 10.1016/S0040-4039(01)01905-0
   GRIFFITH WP, 1987, J CHEM SOC CHEM COMM, P1625, DOI 10.1039/c39870001625                                                            
   GRUBBS RH, 1989, SCIENCE, V243, P907, DOI 10.1126/science.2645643
   Hacksell U, 1985, Prog Med Chem, V22, P1, DOI 10.1016/S0079-6468(08)70228-5
   Herdewijn P, 2001, BIOORG MED CHEM LETT, V11, P1591, DOI 10.1016/S0960-894X(01)00270-0
   HILDBRAND S, 1994, HELV CHIM ACTA, V77, P1236, DOI 10.1002/hlca.19940770506                                                        
   HURYN DM, 1992, CHEM REV, V92, P1745, DOI 10.1021/cr00016a004                                                             
   Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444
   IRELAND RE, 1993, J ORG CHEM, V58, P2899, DOI 10.1021/jo00062a040                                                             
   IRELAND RE, 1985, J ORG CHEM, V50, P2198, DOI 10.1021/jo00212a041
   Ito H, 2005, SYNTHESIS-STUTTGART, P3035, DOI 10.1055/s-2005-916030
   Jeong LS, 1998, BIOORG MED CHEM LETT, V8, P847, DOI 10.1016/S0960-894X(98)00122-X                                                   
   JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163
   KATAGIRI N, 1992, J MED CHEM, V35, P1882, DOI 10.1021/jm00088a026
   KATAGIRI N, 1992, TETRAHEDRON LETT, V33, P3507, DOI 10.1016/S0040-4039(00)92675-3
   KHANAPURE SP, 1995, J ORG CHEM, V60, P7548, DOI 10.1021/jo00128a029                                                             
   KUSAKA T, 1968, J ANTIBIOT, V21, P255, DOI 10.7164/antibiotics.21.255                                                      
   Lai CL, 2002, GASTROENTEROLOGY, V123, P1831, DOI 10.1053/gast.2002.37058
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   Lee JA, 2005, J ORG CHEM, V70, P5006, DOI 10.1021/jo0503207
   Leung LMH, 2008, J ORG CHEM, V73, P9197, DOI 10.1021/jo801848h
   Li GG, 1996, ANGEW CHEM INT EDIT, V35, P2813, DOI 10.1002/anie.199628131                                                          
   Liu XY, 2012, TETRAHEDRON LETT, V53, P3805, DOI 10.1016/j.tetlet.2012.05.058
   Lopez RM, 1997, J AM CHEM SOC, V119, P6949, DOI 10.1021/ja971400y                                                               
   Lui YYN, 2009, EXPERT REV ANTI-INFE, V7, P259, DOI [10.1586/eri.09.6, 10.1586/ERI.09.6]
   Lv ZL, 2010, J MED CHEM, V53, P660, DOI 10.1021/jm901237x
   Ma SM, 2004, CHEM-EUR J, V10, P3286, DOI 10.1002/chem.200305581
   MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021                                                             
   Magnus P, 1999, TETRAHEDRON, V55, P6435, DOI 10.1016/S0040-4020(99)00305-1                                                   
   Malik AH, 2000, ANN INTERN MED, V132, P723, DOI 10.7326/0003-4819-132-9-200005020-00007
   MARQUEZ VE, 1988, J ORG CHEM, V53, P5709, DOI 10.1021/jo00259a019
   MARQUEZ VE, 1986, MED RES REV, V6, P1, DOI 10.1002/med.2610060102                                                          
   Maurinsh Y, 1997, J ORG CHEM, V62, P2861, DOI 10.1021/jo962204x                                                               
   MEVELLEC L, 1995, TETRAHEDRON LETT, V36, P7441, DOI 10.1016/0040-4039(95)01536-1                                                    
   NAKAMURA H, 1986, J ANTIBIOT, V39, P1626, DOI 10.7164/antibiotics.39.1626                                                     
   Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520
   NORBECK DW, 1990, J MED CHEM, V33, P1281, DOI 10.1021/jm00167a002
   Ogan MD, 2005, J LABELLED COMPD RAD, V48, P645, DOI 10.1002/jlcr.955
   OHIRA S, 1995, TETRAHEDRON LETT, V36, P1537, DOI 10.1016/0040-4039(95)00081-M
   OHIRA S, 1989, SYNTHETIC COMMUN, V19, P561, DOI 10.1080/00397918908050700                                                       
   PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503
   Ranu BC, 1997, CHEM COMMUN, P1225, DOI 10.1039/a702241g                                                                
   Rejman D, 2009, TETRAHEDRON, V65, P8513, DOI 10.1016/j.tet.2009.08.019
   Riches AG, 1998, J ORG CHEM, V63, P4691, DOI 10.1021/jo980282+                                                               
   Rife J, 1999, ORG LETT, V1, P1221, DOI 10.1021/ol990203w                                                               
   ROBINS RK, 1982, J MED CHEM, V25, P107, DOI 10.1021/jm00344a002
   ROBINS RK, 1985, ADV ENZYME REGUL, V24, P29, DOI 10.1016/0065-2571(85)90068-8                                                    
   Rokach J, 1998, SYNTHESIS-STUTTGART, P569
   ROY BL, 1985, CAN J CHEM, V63, P651, DOI 10.1139/v85-106
   Roy SC, 2002, J ORG CHEM, V67, P3242, DOI 10.1021/jo010857u
   Santana L, 2001, SYNTHESIS-STUTTGART, P1532
   SATO Y, 1995, CHEM PHARM BULL, V43, P91
   Scott LJ, 2009, DRUGS, V69, P1003, DOI 10.2165/00003495-200969080-00005
   Sekiyama T, 1998, J MED CHEM, V41, P1284, DOI 10.1021/jm9705869                                                               
   SHAW G, 1958, J CHEM SOC, P157, DOI 10.1039/jr9580000157                                                            
   SHEALY YF, 1966, J AM CHEM SOC, V88, P3885, DOI 10.1021/ja00968a055                                                             
   SHIMADA N, 1987, J ANTIBIOT, V40, P1788, DOI 10.7164/antibiotics.40.1788                                                     
   SHIMADA N, 1986, J ANTIBIOT, V39, P1623, DOI 10.7164/antibiotics.39.1623                                                     
   Shing TKM, 2007, ORG LETT, V9, P753, DOI 10.1021/ol062873p
   SLUSARCHYK W A, 1992, Antiviral Research, V17, P98
   SLUSARCHYK WA, 1992, J MED CHEM, V35, P1799, DOI 10.1021/jm00088a015
   SRIVASTAVA PC, 1983, J MED CHEM, V26, P445, DOI 10.1021/jm00357a024
   SWEENEY MJ, 1973, CANCER RES, V33, P2619
   TAKAI K, 1994, J ORG CHEM, V59, P2668, DOI 10.1021/jo00089a002                                                             
   TEBBE FN, 1978, J AM CHEM SOC, V100, P3611, DOI 10.1021/ja00479a061                                                             
   Tenney DJ, 2009, HEPATOLOGY, V49, P1503, DOI 10.1002/hep.22841
   TIDWELL TT, 1990, SYNTHESIS-STUTTGART, P857
   Townsend L. B., 1988, CHEMISTRY OF NUCLEOS
   Tran SB, 2009, J LABELLED COMPD RAD, V52, P485, DOI 10.1002/jlcr.1664
   Velasco J, 2013, J ORG CHEM, V78, P5482, DOI 10.1021/jo400607v
   VERHEGGEN I, 1995, J MED CHEM, V38, P826, DOI 10.1021/jm00005a010
   VINCE R, 1990, J MED CHEM, V33, P17, DOI 10.1021/jm00163a004
   Walker JA, 1998, J MED CHEM, V41, P1236, DOI 10.1021/jm970532z                                                               
   Wang J, 2000, J MED CHEM, V43, P736, DOI 10.1021/jm991171l
   Wang JN, 2011, BIOORG MED CHEM LETT, V21, P6328, DOI 10.1016/j.bmcl.2011.08.113
   Wang PY, 1997, TETRAHEDRON LETT, V38, P4207, DOI 10.1016/S0040-4039(97)00898-8
   Warnecke S, 2009, J ORG CHEM, V74, P3024, DOI 10.1021/jo802348h
   Wu JY, 1997, J MED CHEM, V40, P1401, DOI 10.1021/jm960770e
   Wyatt PG, 1995, NUCLEOS NUCLEOT, V14, P2039, DOI 10.1080/15257779508010722
   YAGINUMA S, 1981, J ANTIBIOT, V34, P359, DOI 10.7164/antibiotics.34.359                                                      
   YOSHIKAWA M, 1994, TETRAHEDRON, V50, P9961, DOI 10.1016/S0040-4020(01)89611-3
   Zhou B, 2012, TETRAHEDRON LETT, V53, P502, DOI 10.1016/j.tetlet.2011.11.073
   Zhu XF, 2000, NUCLEOS NUCLEOT NUCL, V19, P651, DOI 10.1080/15257770008035015                                                       
   Ziegler FE, 2003, TETRAHEDRON, V59, P9013, DOI 10.1016/j.tet.2003.02.001
   Hu T.-C., 2011, Patent US, Patent No. [20110201809 Al, 20110201809]
   Nysted L. N, 1975, [US Patent, Chem. Abstr], Patent No. [3,865,848, 3865848, 3 865 848]
   Lee J., 2012, US Patent Application Publication, Patent No. [US 2012/0202998 A1, 20120202998]
   Chan Y. Y., 2006, US Patent Application Publication, Patent No. [US 2006/0106215 A1, 20060106215]
   Pendri Y. R., 2004, US Patent Application Publication, Patent No. [US 2004/0192912 A1, 20040192912]
   Lee J., 2011, US Patent Application Publication, Patent No. [US 2011/0251387 A1, 20110251387]
   Lee J., 2010, World Intelectual Property Organization Patent, Patent No. [WO 2010/074534 A2, 2010074534]
   Zahler R, 1993, [No title captured], Patent No. [US5206244, 5206244]
   Bisacchi G. S., 1998, [No title captured], Patent No. [WO 9809964, 9809964]
   Liotta D. C., 2010, US Patent Application Publication, Patent No. [US 2010/0204463 A1, 20100204463]
   Zhou MX, 2009, [No title captured], Patent No. [US7511139, 7511139]
   Alberico D., 2013, Patent US, Patent No. [20130066071 Al, 20130066071]
   Alberico D., 2011, Patent WO, Patent No. [2011150512 Al, 2011150512]
   Pendri YR, 2004, World Intelectual Property Organization Patent, Patent No. [WO 2004/052310 A2, 2004052310]
NR 133
TC 5
Z9 5
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1385-2728
EI 1875-5348
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PY 2014
VL 18
IS 22
BP 2808
EP 2832
DI 10.2174/1385272819666140929200719                                       
          
PG 25
WC Chemistry, Organic
SC Chemistry
GA AU5IG
UT WOS:000345639600002
DA 2018-01-05
ER

PT J
AU Ramalingam, S
   Annaluru, N
   Kandavelou, K
   Chandrasegaran, S
AF Ramalingam, Sivaprakash
   Annaluru, Narayana
   Kandavelou, Karthikeyan
   Chandrasegaran, Srinivasan
TI TALEN-Mediated Generation and Genetic Correction of Disease-Specific
   Human Induced Pluripotent Stem Cells
SO CURRENT GENE THERAPY
LA English
DT Article
DE Cystic fibrosis (CF); Gaucher's disease (GD); gene correction; sickle
   cell disease (SCD); transcription activatorlike effector nucleases
   (TALENs); zinc finger nucleases (ZFNs)
ID ZINC-FINGER NUCLEASES; EFFECTOR NUCLEASES; HOMOLOGOUS RECOMBINATION;
   CHIMERIC NUCLEASES; T-CELLS; CCR5; HIV; CRISPR/CAS9; RESISTANCE;
   INTEGRASE
AB Generation and precise genetic correction of patient-derived hiPSCs have great potential in regenerative medicine. Such targeted genetic manipulations can now be achieved using gene-editing nucleases. Here, we report generation of cystic fibrosis (CF) and Gaucher's disease (GD) hiPSCs respectively from CF (homozygous for CFTR Delta F508 mutation) and Type II GD [homozygous for beta-glucocerebrosidase (GBA) 1448T>C mutation] patient fibroblasts, using CCR5-specific TALENs. Site-specific addition of loxP-flanked Oct4/Sox2/Klf4/Lin28/Nanog/eGFP gene cassette at the endogenous CCR5 site of patient-derived disease-specific primary fibroblasts induced reprogramming, giving rise to both monoallele (heterozygous) and biallele CCR5-modified hiPSCs. Subsequent excision of the donor cassette was done by treating CCR5-modified CF and GD hiPSCs with Cre. We also demonstrate site-specific correction of sickle cell disease (SCD) mutations at the endogenous HBB locus of patient-specific hiPSCs [TNC1 line that is homozygous for mutated beta-globin alleles (beta(S)/beta(S))], using HBB-specific TALENs. SCD-corrected hiPSC lines showed gene conversion of the mutated beta(S) to the wild-type beta(A) in one of the HBB alleles, while the other allele remained a mutant phenotype. After excision of the loxP-flanked DNA cassette from the SCD-corrected hiPSC lines using Cre, we obtained secondary heterozygous beta(S)/beta(A) hiPSCs, which express the wild-type (beta(A)) transcript to 30-40% level as compared to uncorrected (beta(S)/beta(S)) SCD hiPSCs when differentiated into erythroid cells. Furthermore, we also show that TALEN-mediated generation and genetic correction of disease-specific hiPSCs did not induce any off-target mutations at closely related sites.
C1 [Ramalingam, Sivaprakash; Annaluru, Narayana; Chandrasegaran, Srinivasan] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   [Kandavelou, Karthikeyan] Pondicherry Biotech Private Ltd, Pondy Technopolis, Pondicherry 605014, India.
RP Ramalingam, S (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St, Baltimore, MD 21205 USA.
EM skullam1@jhu.edu
FU MSCRF Exploratory Research Grant; Bill & Melinda Gates Foundation; PBPL
   institutional funds
FX This work was supported by a MSCRF Exploratory Research Grant to S.R.,
   by a Phase I grant from the Bill & Melinda Gates Foundation and by PBPL
   institutional funds to K.K. We thank Dr. Curt Civin for helpful
   suggestions with the hiPSC experiments. We thank Dr. Linzhao Cheng for
   providing the TNC1 hiPSC line and Dr. Huimin Zhao for providing the
   HBB-specific TALENs. We thank Dr. Margolick lab for assistance with flow
   cytometry and FACS studies.
CR Ashley-Koch A, 2000, AM J EPIDEMIOL, V151, P839
   Bauer DE, 2013, SCIENCE, V342, P253, DOI 10.1126/science.1242088
   Beumer KJ, 2013, G3-GENES GENOM GENET, V3, P1717, DOI 10.1534/g3.113.007260
   Bibikova M, 2001, MOL CELL BIOL, V21, P289, DOI 10.1128/MCB.21.1.289-297.2001                                                   
   Campbell JM, 2013, CIRC RES, V113, P571, DOI 10.1161/CIRCRESAHA.113.301765
   Chang JC, 2006, P NATL ACAD SCI USA, V103, P1036, DOI 10.1073/pnas.0510177103
   Choi SM, 2013, HEPATOLOGY, V57, P2458, DOI 10.1002/hep.26237
   Christian M, 2010, GENETICS, V186, P757, DOI 10.1534/genetics.110.120717
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cradick TJ, 2013, NUCLEIC ACIDS RES, V41, P9584, DOI 10.1093/nar/gkt714
   Ding QR, 2013, CELL STEM CELL, V12, P238, DOI 10.1016/j.stem.2012.11.011
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Gabriel R, 2011, NAT BIOTECHNOL, V29, P816, DOI 10.1038/nbt.1948
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hockemeyer D, 2011, NAT BIOTECHNOL, V29, P731, DOI 10.1038/nbt.1927
   Hockemeyer D, 2009, NAT BIOTECHNOL, V27, P851, DOI 10.1038/nbt.1562
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Kandavelou K, 2010, BIOCHEM BIOPH RES CO, V388, P56
   Karow M, 2011, STEM CELLS, V29, P1696, DOI 10.1002/stem.730
   Kay MA, 2014, NEW ENGL J MED, V370, P968, DOI 10.1056/NEJMe1400593
   Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156                                                          
   Li XH, 2013, P NATL ACAD SCI USA, V110, pE2279, DOI 10.1073/pnas.1305987110
   Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Mali P, 2010, STEM CELLS, V28, P713, DOI 10.1002/stem.402
   Ng ES, 2005, BLOOD, V106, P1601, DOI 10.1182/blood-2005-03-0987
   Panicker LM, 2012, P NATL ACAD SCI USA, V109, P18054, DOI 10.1073/pnas.1207889109
   Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806                                                         
   Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410
   Porteus MH, 2003, SCIENCE, V300, P763, DOI 10.1126/science.1078395
   Ramalingam S, 2013, STEM CELLS DEV, V22, P595, DOI 10.1089/scd.2012.0245
   Ramalingam S, 2011, J MOL BIOL, V405, P630, DOI 10.1016/j.jmb.2010.10.043
   Sabastiano V, 2011, STEM CELLS, V29, P1717
   Schwank G, 2013, CELL STEM CELL, V13, P653, DOI 10.1016/j.stem.2013.11.002
   Sun N, 2014, BIOTECHNOL BIOENG, V111, P1048, DOI 10.1002/bit.25018
   Sun N, 2012, MOL BIOSYST, V8, P1255, DOI 10.1039/c2mb05461b
   Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662
   Urnov FD, 2005, NATURE, V435, P646, DOI 10.1038/nature03556
   Wu LC, 2006, BLOOD, V108, P1183, DOI 10.1182/blood-2006-02-004812
   Yang LH, 2013, NUCLEIC ACIDS RES, V41, P9049, DOI 10.1093/nar/gkt555
   Yanik M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082539
   Ye L, 2010, P NATL ACAD SCI USA, V107, P19467, DOI 10.1073/pnas.1012677107
   Ye L, 2009, P NATL ACAD SCI USA, V106, P9826, DOI 10.1073/pnas.0904689106
   Yusa K, 2011, NATURE, V478, P391, DOI 10.1038/nature10424
   Zou JZ, 2011, BLOOD, V118, P4599, DOI 10.1182/blood-2011-02-335554
   Zou JZ, 2011, BLOOD, V117, P5561, DOI 10.1182/blood-2010-12-328161
   Zou SM, 2013, BLOOD, V122, P3111, DOI 10.1182/blood-2013-07-518316
NR 47
TC 22
Z9 24
U1 3
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5232
EI 1875-5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PY 2014
VL 14
IS 6
BP 461
EP 472
DI 10.2174/1566523214666140918101725                                       
          
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA AT9LD
UT WOS:000345248000006
PM 25245091
DA 2018-01-05
ER

PT J
AU Girish, YR
   Kumar, KSS
   Muddegowda, U
   Lokanath, NK
   Rangappa, KS
   Shashikanth, S
AF Girish, Yarabally R.
   Kumar, Kothanahally S. Sharath
   Muddegowda, Umashankar
   Lokanath, Neartur Krishnappagowda
   Rangappa, Kanchugarakoppal S.
   Shashikanth, Sheena
TI ZrO2-supported Cu(II)-beta-cyclodextrin complex: construction of
   2,4,5-trisubstituted-1,2,3-triazoles via azide-chalcone oxidative
   cycloaddition and post-triazole alkylation
SO RSC ADVANCES
LA English
DT Article
ID ONE-POT SYNTHESIS; CLICK-CHEMISTRY; REGIOSELECTIVE SYNTHESIS; TERMINAL
   ALKYNES; BORONIC ACIDS; SODIUM-AZIDE; 1,4,5-TRISUBSTITUTED
   1,2,3-TRIAZOLES; EFFICIENT SYNTHESIS; HIV-1 PROTEASE; NANOPARTICLES
AB An efficient one-pot three-component stepwise approach for the synthesis of N-2-substituted-1,2,3-triazoles from chalcones, sodium azide and esters has been developed using a recoverable and reusable ZrO2 nanoparticle-supported Cu(II)-beta-cyclodextrin complex as a catalyst. N-2 alkylation of triazoles using different aryl-alkyl esters without any additives has been achieved for the first time. The one-pot operation, atom-economical nature, regioselectivity and good yields are the noteworthy features of this protocol. The reusability of the prepared nanocatalyst was successfully examined four times without any appreciable loss in catalytic activity.
C1 [Girish, Yarabally R.; Kumar, Kothanahally S. Sharath; Rangappa, Kanchugarakoppal S.; Shashikanth, Sheena] Univ Mysore, Dept Studies Chem, Mysore 570006, Karnataka, India.
   [Muddegowda, Umashankar] KSOU, Dept Studies Chem, Mysore 570006, Karnataka, India.
   [Lokanath, Neartur Krishnappagowda] Univ Mysore, Dept Studies Phys, Mysore 570006, Karnataka, India.
RP Shashikanth, S (reprint author), Univ Mysore, Dept Studies Chem, Mysore 570006, Karnataka, India.
EM shashis1956@gmail.com
OI Y R, Girish/0000-0001-6709-7159
FU UGC-BSR, New Delhi, India [DV-5/662/RFSMS/2012-13]
FX YRG and KSS are thankful to UGC-BSR for meritorious fellowship Order no.
   DV-5/662/RFSMS/2012-13, New Delhi, India for financial support and we
   are also thankful to IOE, University of Mysore and NCBS, Bengaluru,
   Karnataka, India for their support in carrying out research work
   regarding the single crystal XRD and TEM analysis.
CR Abdulkin P, 2013, NANOSCALE, V5, P342, DOI 10.1039/c2nr32570e
   Alonso F, 2011, ORG BIOMOL CHEM, V9, P6385, DOI 10.1039/c1ob05735a
   Anastas P, 2010, CHEM SOC REV, V39, P301, DOI 10.1039/b918763b
   Aucagne V, 2006, ORG LETT, V8, P4505, DOI 10.1021/ol061657d
   Bai L, 2013, CRYSTENGCOMM, V15, P2076, DOI 10.1039/c2ce26540k
   BALACHANDRAN KS, 1975, TETRAHEDRON, V31, P1171, DOI 10.1016/0040-4020(75)85053-8                                                    
   Chen YF, 2008, CHEM COMMUN, P3254, DOI 10.1039/b805328f
   Ding Y, 2011, NANOSCALE, V3, P1149, DOI 10.1039/c0nr00773k
   Dubrovina NV, 2013, TETRAHEDRON, V69, P8809, DOI 10.1016/j.tet.2013.07.070
   Fann W.-Q., 1996, COMPREHENSIVE HETERO, V4, P1
   Giffin MJ, 2008, J MED CHEM, V51, P6263, DOI 10.1021/jm800149m
   Huisgen R., 1984, 1 3 DIPOLAR CYCLOADD
   Jariwala D, 2013, CHEM SOC REV, V42, P2824, DOI 10.1039/c2cs35335k
   Kaboudin B, 2013, GREEN CHEM, V15, P2266, DOI 10.1039/c3gc40753e
   Kaboudin B, 2012, ORG BIOMOL CHEM, V10, P4543, DOI 10.1039/c2ob25061f
   Kalisiak J, 2008, ORG LETT, V10, P3171, DOI 10.1021/ol8006748
   Kamal A, 2013, RSC ADV, V3, P7419, DOI 10.1039/c3ra22485f
   Kamijo S, 2003, J AM CHEM SOC, V125, P7786, DOI 10.1021/ja034191a
   Kang HG, 2010, NEW J CHEM, V34, P2166, DOI 10.1039/c0nj00094a
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Koszytkowska-Stawinska M, 2012, TETRAHEDRON, V68, P214, DOI 10.1016/j.tet.2011.10.067
   Li J., 2010, SYNLETT, P1622
   Liao JY, 2013, J MATER CHEM C, V1, P6541, DOI 10.1039/c3tc30895b
   Liu X, 2013, ASIAN J ORG CHEM, V2, P212, DOI 10.1002/ajoc.201300009
   Liu X, 2013, NEW J CHEM, V37, P965, DOI 10.1039/c3nj40912k
   Liu YX, 2008, ORG LETT, V10, P5389, DOI 10.1021/ol802246q
   Majireck MM, 2006, J ORG CHEM, V71, P8680, DOI 10.1021/jo061688m
   Mariola K. S., 2012, TETRAHEDRON, V68, P214
   MATSUI Y, 1972, B CHEM SOC JPN, V45, P3229, DOI 10.1246/bcsj.45.3229                                                            
   Mohammed S, 2012, TETRAHEDRON, V68, P8156, DOI 10.1016/j.tet.2012.07.080
   Mukherjee N, 2013, GREEN CHEM, V15, P389, DOI 10.1039/c2gc36521a
   Murali M. G., 2012, J ORG CHEM, V77, P5063
   Narayanan R, 2005, J PHYS CHEM B, V109, P12663, DOI 10.1021/jp051066p
   Qian WY, 2011, ORG LETT, V13, P1682, DOI 10.1021/ol200183b
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Roy S, 2013, GREEN CHEM, V15, P2532, DOI 10.1039/c3gc41114a
   Sadik OA, 2009, J ENVIRON MONITOR, V11, P1782, DOI 10.1039/b912860c
   Sheldon R. A., 2007, GREEN CHEM CATALYSIS
   Sheldon RA, 2008, CHEM COMMUN, P3352, DOI 10.1039/b803584a
   Shi F, 2008, ORG LETT, V10, P2409, DOI 10.1021/ol800675u
   Shi HY, 2011, J MATER CHEM, V21, P12309, DOI 10.1039/c1jm10809c
   Song PX, 2008, PHYS CHEM CHEM PHYS, V10, P5057, DOI 10.1039/b800672e
   Spiteri C, 2010, ANGEW CHEM INT EDIT, V49, P31, DOI 10.1002/anie.200905322
   Sreedhar B, 2007, TETRAHEDRON LETT, V48, P5831, DOI 10.1016/j.tetlet.2007.06.069
   Tan SW, 2013, NANOSCALE, V5, P860, DOI 10.1039/c2nr32880a
   Tao CZ, 2007, TETRAHEDRON LETT, V48, P3525, DOI 10.1016/j.tetlet.2007.03.107
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Veerakumar P, 2011, CATAL SCI TECHNOL, V1, P1512, DOI 10.1039/c1cy00300c
   Wang XJ, 2010, ORG LETT, V12, P4632, DOI 10.1021/ol101965a
   Wang XJ, 2009, ORG LETT, V11, P5026, DOI 10.1021/ol9019875
   Wang XD, 2013, CHEM SOC REV, V42, P7834, DOI 10.1039/c3cs60102a
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
   Yan WM, 2011, CHEM-ASIAN J, V6, P2720, DOI 10.1002/asia.201100357
   Yang D, 2007, SYNLETT, P278, DOI 10.1055/s-2007-968007
   Yong KT, 2009, J MATER CHEM, V19, P4655, DOI 10.1039/b817667c
   Zhang C, 2013, NEW J CHEM, V37, P2606, DOI 10.1039/c3nj00468f
   Zhang L, 2012, SYNLETT, P1052, DOI 10.1055/s-0031-1290770
   Zhang YQ, 2012, ORG LETT, V14, P26, DOI 10.1021/ol202718d
NR 59
TC 13
Z9 13
U1 1
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 99
BP 55800
EP 55806
DI 10.1039/c4ra09970b
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA AT5QT
UT WOS:000344997800016
DA 2018-01-05
ER

PT J
AU Edagwa, BJ
   Zhou, T
   McMillan, JM
   Liu, XM
   Gendelman, HE
AF Edagwa, Benson J.
   Zhou, Tian
   McMillan, JoEllyn M.
   Liu, Xin-Ming
   Gendelman, Howard E.
TI Development of HIV Reservoir Targeted Long Acting Nanoformulated
   Antiretroviral Therapies
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Dendrimers; drug delivery systems; gut associated lymphoid tissue; HIV;
   HIV reservoir targeted ART; liposomes; lymphoid tissues; micelles;
   nanomedicine; polymeric nanoparticles
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SOLID LIPID NANOPARTICLES;
   BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; POLY PROPYLENEIMINE
   DENDRIMER; IN-VIVO EVALUATION; DRUG-DELIVERY; TISSUE DISTRIBUTION;
   FOLATE-RECEPTOR; METHYLMETHACRYLATE-SULFOPROPYLMETHACRYLATE
AB Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid conditions secondary to immune deficiency. Infection also affects broad organ system function. Although current antiretroviral therapy (ART) reduces disease morbidity and mortality through effective control of peripheral viral load, restricted infection in HIV reservoirs including gut, lymphoid and central nervous system tissues, is not eliminated. What underlies these events is, in part, poor ART penetrance into each organ across tissue barriers, viral mutation and the longevity of infected cells. We posit that one means to improve these disease outcomes is through nanotechnology. To this end, this review discusses a broad range of cutting-edge nanomedicines and nanomedicine platforms that are or can be used to improve ART delivery. Discussion points include how polymer-drug conjugates, dendrimers, micelles, liposomes, solid lipid nanoparticles and polymeric nanoparticles can be harnessed to best yield cell-based delivery systems. When completely developed, such nanomedicine platforms have the potential to clear reservoirs of viral infection.
C1 [Edagwa, Benson J.; McMillan, JoEllyn M.; Liu, Xin-Ming; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Zhou, Tian; Liu, Xin-Ming; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
RP Liu, XM (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM xliu@unmc.edu
FU Carol Swarts MD Neuroscience Research Laboratory; National Institutes of
   Health [1P01 DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR
   15635, P01MH64570, P01 NS43985]
FX This work was supported in part by the Carol Swarts MD Neuroscience
   Research Laboratory and National Institutes of Health grants: 1P01
   DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635,
   P01MH64570, and P01 NS43985 (to H.E.G.).
CR ADACHI A, 1987, J VIROL, V61, P209
   Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Biddlestone-Thorpe L, 2012, ADV DRUG DELIVER REV, V64, P605, DOI 10.1016/j.addr.2011.11.014
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Boisse L, 2008, NEUROL CLIN, V26, P799, DOI 10.1016/j.ncl.2008.04.002
   Brew BJ, 2004, AIDS, V18, pS75
   BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI 10.2217/NNM.10.7
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chen DB, 2001, CHEM PHARM BULL, V49, P1444, DOI 10.1248/cpb.49.1444
   Chen HL, 2011, EUR J PHARM SCI, V44, P164, DOI 10.1016/j.ejps.2011.07.007
   Chiappetta D.A., 2012, NANOMEDICINE, V8, P223
   CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404
   COHEN EA, 1990, J VIROL, V64, P3097
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   Craparo EF, 2011, CNS NEUROSCI THER, V17, P670, DOI 10.1111/j.1755-5949.2010.00199.x
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, PROG BRAIN RES, V180, P225, DOI 10.1016/S0079-6123(08)80012-X
   Dhanya K.P., 2011, PHARM GLOBALE, V2
   Donaldson Y K, 1994, Lancet, V343, P383
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fontaine M, 1996, LIFE SCI, V59, P1521, DOI 10.1016/0024-3205(96)00483-3
   Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287
   Freitas C, 1998, INT J PHARM, V168, P221, DOI 10.1016/S0378-5173(98)00092-1
   Fresta M, 1996, INT J PHARM, V134, P89, DOI 10.1016/0378-5173(95)04448-5
   FRESTA M, 1995, PHARMACEUT RES, V12, P1769, DOI 10.1023/A:1016234226404
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Gomes MJ, 2014, INT J NANOMED, V9, P1757, DOI 10.2147/IJN.S45886
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Grant I, 2008, INT REV PSYCHIATR, V20, P33, DOI 10.1080/09540260701877894
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Haag R, 2006, ANGEW CHEM INT EDIT, V45, P1198, DOI 10.1002/anie.200502113
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5                                                    
   Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
   Ikehara Y, 2006, CANCER RES, V66, P8740, DOI 10.1158/0008-5472.CAN-06-0470
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   JEFFERIES WA, 1985, IMMUNOLOGY, V54, P333
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   Jin SX, 2005, PHARMAZIE, V60, P840
   KALTER DC, 1991, DERMATOL CLIN, V9, P415
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   KIM S, 1990, J INFECT DIS, V162, P750, DOI 10.1093/infdis/162.3.750                                                        
   KIM SY, 1989, J VIROL, V63, P3708
   Kotler DP, 2005, AIDS, V19, P107, DOI 10.1097/00002030-200501280-00002
   Kularatne SA, 2010, METHODS MOL BIOL, V624, P249, DOI 10.1007/978-1-60761-609-2_17
   Kumar PD, 2013, RES PHARM, V3, P08
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2013, BIOMATERIALS, V34, P4818, DOI 10.1016/j.biomaterials.2013.03.013
   Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048
   Letendre Scott, 2008, Top HIV Med, V16, P15
   Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Li WJ, 2012, INT J BIOL MACROMOL, V50, P974, DOI 10.1016/j.ijbiomac.2012.02.019
   Liu XR, 2008, J PHARMACOL EXP THER, V325, P349, DOI 10.1124/jpet.107.130294
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   Lockman PR, 2003, PHARMACEUT RES, V20, P705, DOI 10.1023/A:1023492015851
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   Lu YJ, 2002, CANCER IMMUNOL IMMUN, V51, P153, DOI 10.1007/s00262-002-0266-6
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Majoros IJ, 2005, J MED CHEM, V48, P5892, DOI 10.1021/jm0401863
   Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w
   McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042
   Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239
   Michaels SH, 1998, NEW ENGL J MED, V339, P405, DOI 10.1056/NEJM199808063390612                                                     
   Misra A, 2003, J PHARM PHARM SCI, V6, P252
   MOYER MP, 1991, J LEUKOCYTE BIOL, V49, P499
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Nanjwade BK, 2009, EUR J PHARM SCI, V38, P185, DOI 10.1016/j.ejps.2009.07.008
   Neeraj A, 2011, DRUG DELIV, V18, P272, DOI 10.3109/10717544.2010.536272
   NELSON JA, 1988, LANCET, V1, P259
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Pathan Shadab A, 2009, Recent Pat Drug Deliv Formul, V3, P71
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Podio V, 2000, J PHARM PHARMACOL, V52, P1057, DOI 10.1211/0022357001774976                                                        
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Pyreddy S, 2014, INT J PHARM INVESTIG, V4, P15, DOI 10.4103/2230-973X.127735
   Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   RUBEN S, 1989, J VIROL, V63, P1
   Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Saiyed M.P.N.N.a.Z.M., 2011, NEUROLOGY AIDS, P999
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Saksena Nitin K., 2003, Current Drug Targets - Infectious Disorders, V3, P179, DOI 10.2174/1568005033481187
   Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178
   Schmidt J, 2003, BRAIN, V126, P1895, DOI 10.1093/brain/awg176
   SCHWARTZ S, 1990, J VIROL, V64, P5448
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Soni V, 2008, J DRUG TARGET, V16, P73, DOI [10.1080/10611860701725381, 10.1080/10611860701725381 ]
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI 10.2217/NNM.10.10
   Valcour V., 2011, Current HIV/AIDS Reports, V8, P54, DOI 10.1007/s11904-010-0070-4
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xia HM, 2012, INT J PHARMACEUT, V436, P840, DOI 10.1016/j.ijpharm.2012.07.029
   Xia W, 2009, BLOOD, V113, P438, DOI 10.1182/blood-2008-04-150789
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Yang SC, 1999, PHARMACEUT RES, V16, P751, DOI 10.1023/A:1018888927852
   Yang SC, 1999, J CONTROL RELEASE, V59, P299, DOI 10.1016/S0168-3659(99)00007-3
   Yoo HS, 2004, J CONTROL RELEASE, V100, P247, DOI 10.1016/j.jconrel.2004.08.017
   Yoshizawa T, 2008, EUR J PHARM BIOPHARM, V70, P718, DOI 10.1016/j.ejpb.2008.06.026
   Yusuf M, 2013, J DRUG TARGET, V21, P300, DOI 10.3109/1061186X.2012.747529
   ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0
   Zara GP, 1999, PHARMACOL RES, V40, P281, DOI 10.1006/phrs.1999.0509
   Zhang Y, 2000, BRAIN RES, V876, P148, DOI 10.1016/S0006-8993(00)02628-7                                                   
   Zhao XB, 2008, EXPERT OPIN DRUG DEL, V5, P309, DOI [10.1517/17425247.5.3.309, 10.1517/17425247.5.3.309 ]
NR 143
TC 24
Z9 24
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2014
VL 21
IS 36
BP 4186
EP 4198
DI 10.2174/0929867321666140826114135                                       
          
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AS0SM
UT WOS:000343988700007
PM 25174930
DA 2018-01-05
ER

PT J
AU Meng, JN
   Zhang, T
   Agrahari, V
   Ezoulin, MJ
   Youan, BBC
AF Meng, Jianing
   Zhang, Tao
   Agrahari, Vivek
   Ezoulin, Miezan J.
   Youan, Bi-Botti C.
TI Comparative biophysical properties of tenofovir-loaded, thiolated and
   nonthiolated chitosan nanoparticles intended for HIV prevention
SO NANOMEDICINE
LA English
DT Article
DE HIV prevention; mucoadhesion; nanoparticle; tenofovir; thiolated
   chitosan; vaginal drug delivery
ID IN-VITRO EVALUATION; DRUG-DELIVERY; MUCOADHESIVE PROPERTIES;
   INTRACELLULAR TRAFFICKING; DEPENDENT INTERNALIZATION; MEDIATED
   ENDOCYTOSIS; CELLULAR UPTAKE; NEW-GENERATION; POLYMERS; PERMEABILITY
AB This study is designed to test the hypothesis that tenofovir-loaded (an anti-HIV microbicide) chitosan-thioglycolic acid-conjugated (CS-TGA) nanoparticles (NPs) exhibit superior biophysical properties for mucoadhesion compared with those of native CS NPs. Materials & methods: The NPs are prepared by ionotropic gelation. The particle mean diameter, encapsulation efficiency and release profile are analyzed by dynamic light scattering and UV spectroscopy, respectively. The cytotoxicity, cellular uptake and uptake mechanism are assessed on VK2/E6E7 and End1/E6E7 cell lines by colorimetry/fluorimetry, and percentage mucoadhesion is assessed using porcine vaginal tissue. Results: The mean diameter of the optimal NP formulations ranges from 240 to 252 nm, with a maximal encapsulation efficiency of 22.60%. Tenofovir release from CS and CS-TGA NPs follows first-order and Higuchi models, respectively. Both NPs are noncytotoxic in 48 h. The cellular uptake, which is time dependent, mainly occurs via the caveolin-mediated pathway. The percentage of mucoadhesion of CS-TGA NPs is fivefold higher than that of CS NPs, and reached up to 65% after 2 h. Conclusion: Collectively, CS-TGA NPs exhibit superior biophysical properties and can potentially maximize the retention time of a topical microbicide, such as tenofovir, intended for the prevention of HIV transmission.
C1 [Meng, Jianing; Zhang, Tao; Agrahari, Vivek; Ezoulin, Miezan J.; Youan, Bi-Botti C.] Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmaceut, Kansas City, MO 64108 USA.
RP Youan, BBC (reprint author), Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmaceut, Kansas City, MO 64108 USA.
EM youanb@umkc.edu
RI Meng, Jianing/I-1483-2017
OI Meng, Jianing/0000-0001-6913-0880
FU National Institute of Allergy and Infectious Diseases (MD, USA)
   [R01A1087304]
FX The work presented was supported by Grant Number R01A1087304 from the
   National Institute of Allergy and Infectious Diseases (MD, USA). The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Albrecht K, 2006, DRUG DEV IND PHARM, V32, P1149, DOI 10.1080/03639040600712334
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Askew I, 2003, REPROD HEALTH MATTER, V11, P51, DOI 10.1016/S0968-8080(03)22101-7
   Au C, 2007, BIOL TRACE ELEM RES, V120, P248, DOI 10.1007/s12011-007-0067-z
   Baloglu E, 2009, J PHARM PHARM SCI, V12, P312, DOI 10.18433/J3HP41                                                                 
   Bathori G, 2004, CRIT REV THER DRUG, V21, P67, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i2.10                                    
   Bei D, 2009, AAPS PHARMSCITECH, V10, P1040, DOI 10.1208/s12249-009-9296-0
   Benmerah A, 2007, TRAFFIC, V8, P970, DOI 10.1111/j.1600-0854.2007.00585.x                                                
   Bernkop-Schnurch A, 1999, PHARMACEUT RES, V16, P876, DOI 10.1023/A:1018830204170                                                         
   Bernkop-Schnurch A, 2004, EUR J PHARM BIOPHARM, V57, P9, DOI 10.1016/s0939-6411(03)00147-4
   Bernkop-Schnurch A, 2005, ADV DRUG DELIVER REV, V57, P1569, DOI 10.1016/j.addr.2005.07.002
   CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002                                                             
   Ferreira SLC, 2007, J CHROMATOGR A, V1158, P2, DOI 10.1016/j.chroma.2007.03.051
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7
   Don TM, 2001, J POLYM SCI POL CHEM, V39, P1646, DOI 10.1002/pola.1142                                                               
   Douglas KL, 2008, EUR J PHARM BIOPHARM, V68, P676, DOI 10.1016/j.ejpb.2007.09.002
   Dudhani AR, 2010, CARBOHYD POLYM, V81, P243, DOI 10.1016/j.carbpol.2010.02.026
   Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446                                                         
   Georgieva JV, 2011, MOL THER, V19, P318, DOI 10.1038/mt.2010.236
   Grabovac V, 2005, ADV DRUG DELIVER REV, V57, P1713, DOI 10.1016/j.addr.2005.07.006
   Grim SA, 2003, ANN PHARMACOTHER, V37, P849, DOI 10.1345/aph.1C388
   Hackley V. A., 2001, USE NOMENCLATURE DIS
   Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032
   Hu B, 2008, J AGR FOOD CHEM, V56, P7451, DOI 10.1021/jf801111c
   Jang KI, 2008, J AGR FOOD CHEM, V56, P1936, DOI 10.1021/jf073385e
   Jorgenson JH, 1999, MANUAL CLIN MICROBIO, P1327
   Katzel U, 2008, PART PART SYST CHAR, V25, P19, DOI 10.1002/ppsc.200700005
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Krishnan S, 2008, ANN NY ACAD SCI, V1136, P101, DOI 10.1196/annals.1425.013
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898-1906.2005
   Leitner VM, 2003, EUR J PHARM BIOPHARM, V56, P207, DOI 10.1016/S0939-6411(03)00061-4
   LESCH CA, 1989, J DENT RES, V68, P1345, DOI 10.1177/00220345890680091101
   Lopes LB, 2006, PHARM RES, V23, P1332, DOI 10.1007/s11095-006-0143-7
   LUXFORD KA, 1993, BIOL CELL, V79, P111, DOI 10.1016/0248-4900(93)90246-B
   Ma ZS, 2003, PHARM RES, V20, P1812, DOI 10.1023/B:PHAM.0000003379.76417.3e                                              
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129
   Meng H, 2011, ACS NANO, V5, P4434, DOI 10.1021/nn103344k
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510
   Merchant HA, 2006, AAPS PHARMSCITECH, V7
   Miller J.N., 2010, STAT CHEMOMETRICS AN, P39
   Montgomery D, 1995, DESIGN ANAL EXPT, P405
   Murugeshu A, 2011, NANOMEDICINE-UK, V6, P1513, DOI [10.2217/nnm.11.44, 10.2217/NNM.11.44]
   Nagarwal RC, 2011, CHEM PHARM BULL, V59, P272, DOI 10.1248/cpb.59.272
   Nasti A, 2009, PHARM RES, V26, P1918
   Nayak AK, 2011, ACTA PHARMACEUT, V61, P25, DOI 10.2478/v10007-011-0002-x
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Nicolazzo JA, 2003, J PHARM SCI-US, V92, P2399, DOI 10.1002/jps.10505
   Peng SF, 2011, BIOMATERIALS, V32, P239, DOI 10.1016/j.biomaterials.2010.08.081
   Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038
   Pho MT, 2000, J VIROL, V74, P2288, DOI 10.1128/JVI.74.5.2288-2292.2000                                                 
   Pifer MA, 2012, ORTHOPEDICS, V35, P35, DOI 10.3928/01477447-20111122-19
   Ranga Rao KV, 1989, ENDOCR REV, V52, P265
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Roldo M, 2004, EUR J PHARM BIOPHARM, V57, P115, DOI 10.1016/S0939-6411(03)00157-7
   Rybin VO, 2003, AM J PHYSIOL-HEART C, V285, pH325, DOI 10.1152/ajpheart.00946.2002
   Sassi AB, 2008, J PHARM SCI-US, V97, P3123, DOI 10.1002/jps.21192
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Squier CA, 2008, J PHARM SCI-US, V97, P9, DOI 10.1002/jps.21077
   Thongborisute J, 2006, J LIPOSOME RES, V16, P127, DOI 10.1080/08982100600680816
   Uboldi C, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-18
   UNAIDS, 2013, GLOB REP UNAIDS REP, P4
   UNAIDS, 2013, GLOB REP UNAIDS REP, P78
   Van Gelder J, 1999, INT J PHARMACEUT, V186, P127, DOI 10.1016/S0378-5173(99)00150-7
   Vander Heyden Y, 2001, J PHARMACEUT BIOMED, V24, P723, DOI 10.1016/S0731-7085(00)00529-X                                                   
   Verhelst R, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-61
   Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142
   Wilks M, 2004, J CLIN MICROBIOL, V42, P713, DOI 10.1128/JCM.42.2.713-717.2004
   Xie JW, 2005, PHARM RES, V22, P2079, DOI 10.1007/s11095-005-7782-y
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
NR 75
TC 23
Z9 23
U1 1
U2 12
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2014
VL 9
IS 11
BP 1595
EP 1612
DI 10.2217/NNM.13.136
PG 18
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AR9OC
UT WOS:000343903400002
PM 24405490
OA green_accepted
DA 2018-01-05
ER

PT J
AU Moretton, MA
   Hocht, C
   Taira, C
   Sosnik, A
AF Moretton, Marcela A.
   Hocht, Christian
   Taira, Carlos
   Sosnik, Alejandro
TI Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral
   bioavailability in an extemporaneous liquid fixed-dose combination with
   isoniazid
SO NANOMEDICINE
LA English
DT Article
DE extemporaneous liquid rifampicin/isoniazid fixed-dose combination;
   improved oral pharmacokinetics; pediatric tuberculosis;
   poly(epsilon-caprolactone)-b-PEG-b-poly(epsilon-caprolactone)
   'flower-like' polymeric micelle; rifampicin chemical stabilization
ID ANTITUBERCULOSIS DRUGS; COPOLYMER MICELLES; SUSTAINED-RELEASE;
   TUBERCULOSIS; CYCLODEXTRINS; FORMULATION; STABILITY; EFAVIRENZ; HIV;
   STRATEGIES
AB Background: Coadministration of rifampicin (RIF)/isoniazid (INH) is clinically recommended to improve the treatment of tuberculosis. Under gastric conditions, RIF undergoes fast hydrolysis (a pathway hastened by INH) and oral bioavailability loss. Aim: We aimed to assess the chemical stabilization and the oral pharmacokinetics of RIF nanoencapsulated within poly(epsilon-caprolactone)-b-PEG-b-poly(epsilon-caprolactone) 'flower-like' polymeric micelles. Materials & methods: The chemical stability of RIF was evaluated in vitro under acid conditions with and without INH, and the oral pharmacokinetics of RIF-loaded micelles in rats was compared with those of a suspension coded by the US Pharmacopeia. Results: Nanoencapsulation decreased the degradation rate of RIF with respect to the free drug. Moreover, in vivo data showed a statistically significant increase of RIF oral bioavailability (up to 3.3-times) with respect to the free drug in the presence of INH. Conclusion: Overall results highlight the potential of this nanotechnology platform to develop an extemporaneous liquid RIF/INH fixed-dose combination suitable for pediatric administration.
C1 [Moretton, Marcela A.; Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med, Buenos Aires, DF, Argentina.
   [Moretton, Marcela A.; Taira, Carlos; Sosnik, Alejandro] Natl Sci Res Council, Buenos Aires, DF, Argentina.
   [Hocht, Christian; Taira, Carlos] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmacol, Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, Haifa, Israel.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med, Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
RI Sosnik, Alejandro/O-7059-2014
OI Sosnik, Alejandro/0000-0003-4704-4599
FU Consejo Nacional de Investigaciones Cientificas y Tecnicas [PIP0220];
   University of Buenos Aires [UBA-CyT 20020090200189]
FX MA Moretton thanks PhD scholarships from Consejo Nacional de
   Investigaciones Cientificas y Tecnicas. The work was supported by grants
   from University of Buenos Aires (UBA-CyT 20020090200189) and Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (PIP0220). The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Agrawal SK, 2006, J CONTROL RELEASE, V112, P64, DOI 10.1016/j.jconrel.2005.12.024
   Armijo JA, 1997, FARMACOLOGIA HUMANA
   Bastakoti BP, 2011, COLLOID SURFACE B, V88, P734, DOI 10.1016/j.colsurfb.2011.08.009
   Blomberg B, 2001, B WORLD HEALTH ORGAN, V79, P61
   Brewster ME, 2007, ADV DRUG DELIVER REV, V59, P645, DOI 10.1016/j.addr.2007.05.012
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, CURR HIV RES, V8, P223, DOI 10.2174/157016210791111142
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Choonara YE, 2011, COLLOID SURFACE B, V87, P243, DOI 10.1016/j.colsurfb.2011.05.025
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159                                                                   
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Forrest ML, 2006, J CONTROL RELEASE, V110, P370, DOI 10.1016/j.jconrel.2005.10.008
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Gotelli GA, 2011, J APPL POLYM SCI, V121, P1321, DOI 10.1002/app.33664
   Hu Y, 2006, J NANOSCI NANOTECHNO, V6, P1
   Jansook P, 2009, INT J PHARMACEUT, V379, P32, DOI 10.1016/j.ijpharm.2009.06.005
   Jayaram R, 2003, ANTIMICROB AGENTS CH, V47, P2118, DOI 10.1128/AAC.47.7.2118-2124.2003
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221
   Lin WJ, 2003, PHARMACEUT RES, V20, P668, DOI 10.1023/A:1023215320026                                                         
   Loftsson T, 2012, J PHARM SCI-US, V101, P3019, DOI 10.1002/jps.23077
   Loftsson T, 2011, J PHARM PHARMACOL, V63, P1119, DOI 10.1111/j.2042-7158.2011.01279.x
   Matteelli A, 2010, FUTURE MICROBIOL, V5, P849, DOI 10.2217/FMB.10.50
   McConnell EL, 2008, J PHARM PHARMACOL, V60, P63, DOI 10.1211/jpp.60.1.0008
   Moretton MA, 2009, BIOOMAT 2009 I WORKS
   Moretton MA, 2012, J R SOC INTERFACE, V9, P487, DOI 10.1098/rsif.2011.0414
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Rao BS, 2002, INT J PHARM, V231, P97, DOI 10.1016/S0378-5173(01)00874-2                                                   
   Ribeiro A, 2012, J R SOC INTERFACE, V9, P2059, DOI 10.1098/rsif.2012.0102
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Rivers EC, 2008, DRUG DISCOV TODAY, V13, P1090, DOI 10.1016/j.drudis.2008.09.004
   Sankar R, 2003, DRUG DEV IND PHARM, V29, P733, DOI 10.1081/DDC-120021772
   Sharma S, 2011, BIOMED PHARMACOTHER, V65, P244, DOI 10.1016/j.biopha.2011.04.005
   Shishoo CJ, 1999, INT J PHARM, V190, P109, DOI 10.1016/S0378-5173(99)00286-0
   Shishoo CJ, 2001, INDIAN J PHARM SCI, V63, P443
   Singh S, 2001, INT J PHARMACEUT, V228, P5, DOI 10.1016/S0378-5173(01)00754-2
   Singh Saranjit, 2000, Pharmacy and Pharmacology Communications, V6, P405
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   Sosnik A, 2012, EXPERT OPIN DRUG DEL, V9, P303, DOI 10.1517/17425247.2012.655268
   Sosnik A, 2011, PROG POLYM SCI, V36, P1050, DOI 10.1016/j.progpolymsci.2010.12.001
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   Bertel Squire S, 2009, TUBERCULOSIS COMPREH
   Swaminathan S, 2010, CLIN INFECT DIS, V50, pS184, DOI 10.1086/651490
   Tewes F, 2008, J CONTROL RELEASE, V129, P93, DOI 10.1016/j.jconrel.2008.04.007
   Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7
   Wang Q, 2009, CARBOHYD POLYM, V78, P731, DOI 10.1016/j.carbpol.2009.06.010
   [Anonymous], 1993, SOC PREVENT MED, V38, P251
NR 50
TC 8
Z9 8
U1 1
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2014
VL 9
IS 11
BP 1635
EP 1650
DI 10.2217/NNM.13.154
PG 16
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AR9OC
UT WOS:000343903400005
PM 24410279
DA 2018-01-05
ER

PT J
AU Tshweu, L
   Katata, L
   Kalombo, L
   Chiappetta, DA
   Hocht, C
   Sosnik, A
   Swai, H
AF Tshweu, Lesego
   Katata, Lebogang
   Kalombo, Lonji
   Chiappetta, Diego A.
   Hocht, Christian
   Sosnik, Alejandro
   Swai, Hulda
TI Enhanced oral bioavailability of the antiretroviral efavirenz
   encapsulated in poly(epsilon-caprolactone) nanoparticles by a
   spray-drying method
SO NANOMEDICINE
LA English
DT Article
DE efavirenz; HIV; in vitro drug release; oral bioavailability enhancement;
   poly(epsilon-caprolactone) nanoparticle; spray drying
ID BIODEGRADABLE POLYMERIC NANOPARTICLES; SOLID LIPID NANOPARTICLES;
   DRUG-DELIVERY SYSTEMS; WATER-SOLUBLE DRUGS; HIV PHARMACOTHERAPY;
   DISSOLUTION RATE; PARTICLE-SIZE; FORMULATION; ABSORPTION; MICELLES
AB Aim: To encapsulate efavirenz (EFV) within poly(epsilon-caprolactone) (PCL) nanoparticles (NPs) and compare the oral pharmacokinetics with that of EFV-loaded micelles and pure EFV NPs. Materials & methods: EFV-loaded PCL NPs were produced by a double-emulsion/spray-drying method. Results: NPs displayed a hydrodynamic diameter of 200-250 nm. The encapsulation efficiency was 86-93% and the mass recovery was above 60%. X-ray diffraction indicated that drug and PCL underwent amorphization during the spray-drying process. Encapsulation within NPs significantly increased the maximum concentration in plasma and the bioavailability. Conclusion: EFV-loaded PCL NPs represent a promising platform to develop scalable pharmaceuticals with improved (bio)pharmaceutic performance.
C1 [Tshweu, Lesego; Katata, Lebogang; Kalombo, Lonji; Swai, Hulda] CSIR, Council Sci & Ind Res Mat Sci & Mfg, Pretoria, South Africa.
   [Katata, Lebogang] North West Univ, Chem Dept, Fac Agr Sci & Technol, Pretoria, South Africa.
   [Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Grp Biomat & Nanotechnol Improved Med BIONIMED, Dept Pharmaceut Technol, Fac Pharm & Biochem, RA-1053 Buenos Aires, DF, Argentina.
   [Chiappetta, Diego A.; Sosnik, Alejandro] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
   [Hocht, Christian] Univ Buenos Aires, Dept Pharmacol, Fac Pharm & Biochem, RA-1053 Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, Haifa, Israel.
RP Swai, H (reprint author), CSIR, Council Sci & Ind Res Mat Sci & Mfg, Pretoria, South Africa.
EM hswai@csir.co.za
RI Sosnik, Alejandro/O-7059-2014
OI Sosnik, Alejandro/0000-0003-4704-4599
FU Ministry of Science, Technology and Productive Innovation (Argentina);
   National Research Foundation (South Africa)
FX The authors thank the Ministry of Science, Technology and Productive
   Innovation (Argentina) and the National Research Foundation (South
   Africa) for the bilateral exchange program that supported this work in
   the period 2011-2013. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR AIDSinfo, PAN ANT THER MED MAN
   Aimone LD, 2005, CURR PROTOC PHARM
   Alcaro S, 2011, DRUG RESIST UPDATE, V14, P141, DOI 10.1016/j.drup.2011.01.002
   Andrade F., 2011, INT J CARBOHYDR CHEM, P1, DOI DOI 10.1155/2011/865704
   Balani SK, 1999, DRUG METAB DISPOS, V27, P41
   Bhavsar MD, 2008, AAPS PHARMSCITECH, V9, P288, DOI 10.1208/s12249-007-9021-9
   Chan HK, 2011, ADV DRUG DELIVER REV, V63, P406, DOI 10.1016/j.addr.2011.03.011
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Clercq ED, 2009, INT J ANTIMICROB AG, V33, P307
   Cohn D, 2006, BIOMATERIALS, V27, P1718, DOI 10.1016/j.biomaterials.2005.10.035
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Das S, 2011, COLLOID SURFACE B, V88, P483, DOI 10.1016/j.colsurfb.2011.07.036
   Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064
   Dybul M, 2002, GUIELINES USING ANTI
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   Gomes ECD, 2013, J BRAZIL CHEM SOC, V24, P573, DOI 10.5935/0103-5053.20130071
   Gotelli GA, 2011, J APPL POLYM SCI, V121, P1321, DOI 10.1002/app.33664
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   HINTZ RJ, 1989, INT J PHARM, V51, P9, DOI 10.1016/0378-5173(89)90069-0
   Jyothi NVN, 2010, J MICROENCAPSUL, V27, P187, DOI 10.3109/02652040903131301
   Katata L, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1247-0
   Kesisoglou F, 2007, ADV DRUG DELIVER REV, V59, P631, DOI 10.1016/j.addr.2007.05.003
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Look M, 2010, ADV DRUG DELIVER REV, V62, P378, DOI 10.1016/j.addr.2009.11.011
   Maurin MB, 2002, PHARMACEUT RES, V19, P517, DOI 10.1023/A:1015160132290
   Mishra B, 2010, NANOMED-NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Muller RH, 2006, INT J PHARM, V317, P82, DOI 10.1016/j.ijpharm.2006.02.045
   NIH, 1985, NIH PUBL, V85-3
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   Rabel SR, 2001, AAPS PHARMSCI, V3
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rathbun RC, ANTIRETROVIRAL THERA
   Sachs-Barrable K, 2008, ADV DRUG DELIVER REV, V60, P692, DOI 10.1016/j.addr.2007.08.042
   Sarmento B, 2011, CARBOHYD POLYM, V84, P919, DOI 10.1016/j.carbpol.2010.12.042
   Schmidt M, 1998, NATURE, V393, P238
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Shin ILG, 1998, J CONTROL RELEASE, V51, P1
   Shown I, 2010, MACROMOL SYMP, V287, P51, DOI 10.1002/masy.201050108
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Sosnik A, 2003, POLYMER, V44, P7033, DOI 10.1016/j.polymer.2003.09.012
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Sun W, 2012, NANOMED-NANOTECHNOL, V8, P460, DOI 10.1016/j.nano.2011.07.006
   Thanou M, 2001, ADV DRUG DELIVER REV, V50, pS91, DOI 10.1016/S0169-409X(01)00180-6                                                   
   TOKIWA Y, 1977, NATURE, V270, P76, DOI 10.1038/270076a0                                                                
   Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005
   Verma S, 2009, INT J PHARMACEUT, V377, P185, DOI 10.1016/j.ijpharm.2009.05.006
   Viljoen M, 2010, AIDS RES HUM RETROV, V26, P613, DOI 10.1089/aid.2009.0200
   WORLD HEALTH ORGANIZATION (WHO), 2010, ANT THER HIV INF AD
   Williams I, 2011, HIV MED, V7, P487
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wong SM, 2006, INT J PHARM, V317, P61, DOI 10.1016/j.ijpharm.2006.03.001
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Wu CS, 2005, POLYMER, V46, P147, DOI 10.1016/j.polymer.2004.11.013
NR 63
TC 10
Z9 10
U1 2
U2 14
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2014
VL 9
IS 12
BP 1821
EP 1833
DI 10.2217/NNM.13.167
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AR9OQ
UT WOS:000343904800005
PM 24364871
DA 2018-01-05
ER

PT J
AU Hu, RL
   Li, SR
   Kong, FJ
   Hou, RJ
   Guan, XL
   Guo, F
AF Hu, R. L.
   Li, S. R.
   Kong, F. J.
   Hou, R. J.
   Guan, X. L.
   Guo, F.
TI Inhibition effect of silver nanoparticles on herpes simplex virus 2
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Silver nanoparticles; Herpes simplex virus 2; Antiviral therapy
ID GENITAL HERPES; DOUBLE-BLIND; SUPPRESSION; ACYCLOVIR; INFECTION; TYPE-2;
   WOMEN; VALACYCLOVIR; TRANSMISSION; ACQUISITION
AB The herpes simplex virus 2 (HSV-2) is one of the most important sexually transmitted pathogens, and can facilitate the spread of human immunodeficiency virus. The currently available antiviral drugs have certain limitations. Nanosilver has received increasing attention recently with respect to its antibacterial and antiviral properties. The purpose of this study was to determine the inhibiting effect and mechanism of silver nanoparticles (Ag-NPs) on HSV-2. The cytotoxicity of Vero cells induced by different Ag-NP concentrations was investigated by using the methyl thiazolyl tetrazolium (MTT) assay. The inhibiting effect of Ag-NPs on HSV-2 at various times was also evaluated by using a plaque assay. The toxicity of 100 mu g/mL Ag-NPs on Vero cells was very low. The mixture of Ag-NP suspension and HSV-2 prior to infecting cells could significantly inhibit the production of progeny viruses. Ag-NPs also inhibited the replication of HSV-2 for 24 h before infecting cells with HSV-2. Therefore, 100 mu g/mL Ag-NPs could completely inhibit HSV-2 replication. Ag-NPs at nontoxic concentrations were capable of inhibiting HSV-2 replication when administered prior to viral infection or soon after initial virus exposure. This suggests that the mode of action of Ag-Nps occurs during the early phases of viral replication.
C1 [Hu, R. L.; Li, S. R.; Kong, F. J.; Hou, R. J.; Guan, X. L.; Guo, F.] Xinxiang Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Weihui, Henan Province, Peoples R China.
RP Hu, RL (reprint author), Xinxiang Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Weihui, Henan Province, Peoples R China.
EM ruilihu@126.com
CR Ashammakhi N, 2006, J CRANIOFAC SURG, V17, P3, DOI 10.1097/01.scs.0000201086.73166.f0                                              
   AshaRani PV, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-65
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Celum C, 2010, NEW ENGL J MED, V362, P427, DOI 10.1056/NEJMoa0904849
   Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4
   Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Gupta R, 2004, J INFECT DIS, V190, P1374, DOI 10.1086/424519
   Katakowski JA, 2010, CURR OPIN MOL THER, V12, P192
   Looker KJ, 2008, B WORLD HEALTH ORGAN, V86, P805, DOI 10.2471/BLT.07.046128
   MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201
   Morris SR, 2008, SEX TRANSM DIS, V35, P14, DOI 10.1097/OLQ.0b013e3180f62bc7
   Reitano M, 1998, J INFECT DIS, V178, P603, DOI 10.1086/515385                                                                  
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Schrand AM, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/23/235104
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Sondi I, 2003, J COLLOID INTERF SCI, V260, P75, DOI 10.1016/S0021-9797(02)00205-9
   Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002
   Watson-Jones D, 2008, NEW ENGL J MED, V358, P1560, DOI 10.1056/NEJMoa0800260
   Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964
NR 21
TC 13
Z9 15
U1 4
U2 13
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2014
VL 13
IS 3
BP 7022
EP 7028
DI 10.4238/2014.March.19.2
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AQ8CG
UT WOS:000343049600066
PM 24682984
OA gold
DA 2018-01-05
ER

PT J
AU Ghouse, SM
   Kumar, YS
   Jin, JS
   Kim, JP
   Bae, JS
   Chung, EH
   Kim, DY
   Jang, EK
   Khan, FRN
   Jeong, ED
AF Ghouse, Shaik Mohammed
   Kumar, Yadavalli Suneel
   Jin, Jong Sung
   Kim, Jong-Pil
   Bae, Jong Seong
   Chung, Eun Hyuk
   Kim, Do Yeon
   Jang, Eun Kyung
   Khan, Fazlur-Rahman Nawaz
   Jeong, Euh Duck
TI Green chemical approach: microwave assisted, titanium dioxide
   nanoparticles catalyzed, convenient and efficient C-C bond formation in
   the synthesis of highly functionalized quinolines and quinolinones
SO RSC ADVANCES
LA English
DT Article
ID RING-SUBSTITUTED QUINOLINES; AMINE EXCHANGE-REACTION; ONE-STEP
   SYNTHESIS; ONE-POT SYNTHESIS; 2-SUBSTITUTED QUINOLINES; HIV-1 INTEGRASE;
   ANTIMYCOBACTERIAL ACTIVITIES; REGIOSELECTIVE SYNTHESIS; ANTITUBERCULOSIS
   AGENTS; BIOLOGICAL EVALUATION
AB Highly efficient titanium dioxide nanoparticles (TiO2 Nps) catalyzed, C-C bond formation under microwave irradiation and solventless conditions provided highly functionalized quinolines and quinolinones in excellent yields.
C1 [Ghouse, Shaik Mohammed; Kumar, Yadavalli Suneel; Khan, Fazlur-Rahman Nawaz] VIT Univ, Sch Adv Sci, Div Organ Chem, Organ & Med Chem Res Lab, Vellore 632014, Tamil Nadu, India.
   [Jin, Jong Sung; Kim, Jong-Pil; Bae, Jong Seong; Chung, Eun Hyuk; Kim, Do Yeon; Jang, Eun Kyung; Khan, Fazlur-Rahman Nawaz; Jeong, Euh Duck] Busan Ctr, Korea Basic Sci Inst, Pusan 618230, South Korea.
RP Khan, FRN (reprint author), VIT Univ, Sch Adv Sci, Div Organ Chem, Organ & Med Chem Res Lab, Vellore 632014, Tamil Nadu, India.
EM nawaz_f@yahoo.co.in; edjeong@kbsi.re.kr
FU Ministry of Trade, Industry Energy [R0001026]; Busan Metropolitan City,
   Korea; KBSI [C34920, C34927, P0E013]
FX The authors wish to express their gratitude to the VIT University
   Vellore for Major research initiative support and facilities and SIF-VIT
   for their support of NMR, GCMS and IR facilities, Sathyabama University,
   India for SEM facilities and KBSI, Busan Center, South Korea for Mass,
   TEM and XPS facilities. This work was supported by the grant no.
   R0001026 from the Ministry of Trade, Industry & Energy and Busan
   Metropolitan City, Korea. The authors also acknowledge grants from KBSI,
   no. C34920, C34927, P0E013.
CR AGUI H, 1977, J MED CHEM, V20, P791, DOI 10.1021/jm00216a010
   ALHAIDER AA, 1985, J MED CHEM, V28, P1394, DOI 10.1021/jm00148a004
   Amii H, 2001, ORG LETT, V3, P1109, DOI 10.1021/ol006936u
   Aponte JC, 2008, J MED CHEM, V51, P6230, DOI 10.1021/jm800812k
   Aramoto H, 2009, J ORG CHEM, V74, P628, DOI 10.1021/jo801966u
   Bailly C, 2000, ANTI-CANCER DRUG DES, V15, P191
   Balasubramanian M., 1996, COMPREHENSIVE HETERO, V5, P167
   Benkovic SJ, 2005, J MED CHEM, V48, P7468, DOI 10.1021/jm050676a
   Bilker O., 1998, NATURE, V392, P289, DOI DOI 10.1038/32667
   BLACKBURN TP, 1987, J MED CHEM, V30, P2252, DOI 10.1021/jm00395a013
   Bu XY, 2000, AUST J CHEM, V53, P143, DOI 10.1071/CH99166                                                                 
   BURCKHALTER J, 1961, J ORG CHEM, V26, P4070, DOI 10.1021/jo01068a103                                                             
   Cai XH, 2011, NAT PRODUCT BIOPROSP, V1, P25, DOI 10.1007/s13659-011-0001-0
   Calloway NO, 1937, J AM CHEM SOC, V59, P809, DOI 10.1021/ja01284a011                                                             
   CAMPBELL SF, 1988, J MED CHEM, V31, P1031, DOI 10.1021/jm00400a025
   Chen YL, 2001, J MED CHEM, V44, P2374, DOI 10.1021/jm0100335                                                               
   CHENG CC, 1982, ORG REACTIONS, V28, P37
   Chevalier J, 2001, J MED CHEM, V44, P4023, DOI 10.1021/jm010911z
   Cho CS, 2000, CHEM COMMUN, P1885, DOI 10.1039/b005966h                                                                
   Cho CS, 2003, B KOREAN CHEM SOC, V24, P1026
   Cho CS, 1999, J HETEROCYCLIC CHEM, V36, P1175, DOI 10.1002/jhet.5570360510                                                         
   Croisy-Delcey M, 2000, BIOORGAN MED CHEM, V8, P2629, DOI 10.1016/S0968-0896(00)00194-2                                                   
   Crousse B, 1998, TETRAHEDRON LETT, V39, P5765, DOI 10.1016/S0040-4039(98)01202-7
   Crousse B, 2000, J ORG CHEM, V65, P5009, DOI 10.1021/jo9918807
   Dassonneville L, 1999, BIOCHEMISTRY-US, V38, P7719, DOI 10.1021/bi990094t                                                               
   Dassonneville L, 2000, EUR J PHARMACOL, V409, P9, DOI 10.1016/S0014-2999(00)00805-0
   Dassonneville L., 2002, BIOORGAN MED CHEM, V10, P1337
   De SK, 2005, TETRAHEDRON LETT, V46, P1647, DOI 10.1016/j.tetlet.2005.01.075
   Demaude T, 2004, J COMB CHEM, V6, P768, DOI 10.1021/cc049937c
   Desai PK, 1996, INDIAN J CHEM B, V35, P871
   Elderfield R. C., 1960, HETEROCYCL COMPOUNDS, V4, P6
   Ethiraj KR, 2013, MED CHEM RES, V22, P5408, DOI 10.1007/s00044-013-0520-9
   Ethiraj KR, 2013, CHEM BIOL DRUG DES, V82, P732, DOI 10.1111/cbdd.12184
   Fang KC, 2000, J MED CHEM, V43, P3809, DOI 10.1021/jm000153x
   FARGHALY AM, 1990, ARCH PHARM, V323, P247, DOI 10.1002/ardp.19903230414
   FOURNET A, 1993, J NAT PROD, V56, P1547, DOI 10.1021/np50099a013                                                             
   Gonfa BA, 2014, SOL ENERG MAT SOL C, V124, P67, DOI 10.1016/j.solmat.2014.01.037
   Gopinath VS, 2013, EUR J MED CHEM, V69, P527, DOI 10.1016/j.ejmech.2013.08.028
   Gund M, 2013, EUR J PHARM SCI, V49, P227, DOI 10.1016/j.ejps.2013.02.007
   Iranpoor N, 1998, TETRAHEDRON, V54, P9475, DOI 10.1016/S0040-4020(98)00575-4                                                   
   Isaac-Marquez AP, 2010, NAT PROD COMMUN, V5, P387
   Isogai Y, 2009, TETRAHEDRON, V65, P9575, DOI 10.1016/j.tet.2009.09.061
   Jayashree BS, 2008, ASIAN J CHEM, V20, P1
   Jin F, 2007, ARCH PHARM RES, V30, P1359, DOI 10.1007/BF02977357
   Jones G., 1977, CHEM HETEROCYCL COMP, V32, P93
   Kalluraya B, 1998, FARMACO, V53, P399, DOI 10.1016/S0014-827X(98)00037-8
   Katade S, 2008, INDIAN J CHEM B, V47, P927
   Khatib S, 2005, BIOORGAN MED CHEM, V13, P433, DOI 10.1016/j.bmc.2004.10.010
   Khobragade CN, 2008, J ENZYM INHIB MED CH, V23, P341, DOI [10.1080/14756360701608585, 10.1080/14756360701608585 ]
   Kleeman A., 2001, PHARM SUBSTANCES SYN
   Krishnakumar V, 2014, TETRAHEDRON LETT, V55, P3717, DOI 10.1016/j.tetlet.2014.05.015
   LEATHAM PA, 1983, EUR J RHEUMATOL INFL, V6, P209
   Lee BD, 2004, J MED CHEM, V47, P1413, DOI 10.1021/jm0303204
   Lilienkampf A, 2009, J MED CHEM, V52, P2109, DOI 10.1021/jm900003c
   Loiseau PM, 2011, ANTIMICROB AGENTS CH, V55, P1777, DOI 10.1128/AAC.01299-10
   LUTZ RE, 1946, J AM CHEM SOC, V68, P1813, DOI 10.1021/ja01213a042
   Mahamoud A, 2006, CURR DRUG TARGETS, V7, P843, DOI 10.2174/138945006777709557
   MAKIOKA Y, 1995, SYNTHESIS-STUTTGART, P801
   Mani NS, 1999, J ORG CHEM, V64, P6911, DOI 10.1021/jo990586b                                                               
   Manivel P, 2014, IND ENG CHEM RES, V53, P7866, DOI 10.1021/ie500119p
   Marco-Contelles J, 2009, CHEM REV, V109, P2652, DOI 10.1021/cr800482c
   MARKEES DG, 1970, J MED CHEM, V13, P324, DOI 10.1021/jm00296a048                                                             
   Matsugi M, 2000, TETRAHEDRON LETT, V41, P8523, DOI 10.1016/S0040-4039(00)01542-2                                                   
   MAZZA LJ, 1980, SYNTHESIS-STUTTGART, P41
   McNaughton BR, 2003, ORG LETT, V5, P4257, DOI 10.1021/ol035333q
   Michael JP, 2008, NAT PROD REP, V25, P166, DOI 10.1039/b612168n
   Michael JP, 2007, NAT PROD REP, V24, P223, DOI 10.1039/b509528j
   MINISCI F, 1971, TETRAHEDRON, V27, P3575, DOI 10.1016/S0040-4020(01)97768-3                                                   
   Miranda-Garcia N, 2014, CATAL TODAY, V230, P27, DOI 10.1016/j.cattod.2013.12.048
   Monga V, 2004, BIOORGAN MED CHEM, V12, P6465, DOI 10.1016/j.bmc.2004.09.017
   Mostahar S, 2007, J BIOL SCI, V7, P514
   Mouscadet JF, 2010, MOLECULES, V15, P3048, DOI 10.3390/molecules15053048
   Muruganantham N, 2004, BIOL PHARM BULL, V27, P1683, DOI 10.1248/bpb.27.1683
   Musiol R, 2006, BIOORGAN MED CHEM, V14, P3592, DOI 10.1016/j.bmc.2006.01.016
   Nakayama H, 2005, ANTIMICROB AGENTS CH, V49, P4950, DOI 10.1128/AAC.49.12.4950-4956.2005
   Narender T, 2007, TETRAHEDRON LETT, V48, P3177, DOI 10.1016/j.tetlet.2007.03.054
   Nasveld P, 2005, T ROY SOC TROP MED H, V99, P2, DOI 10.1016/j.trstmh.2004.01.013
   Nayyar A, 2006, BIOORGAN MED CHEM, V14, P847, DOI 10.1016/j.bmc.2005.09.018
   Nayyar A, 2006, BIOORGAN MED CHEM, V14, P7302, DOI 10.1016/j.bmc.2006.06.049
   NEWHOUSE BJ, 1992, J ORG CHEM, V57, P6991, DOI 10.1021/jo00051a061                                                             
   Newton B. M. I., 1999, ANNU REV MED, V50, P179
   Nobuhide M., 1993, TETRAHEDRON LETT, V24, P8263
   Opletalova V, 2000, Ceska Slov Farm, V49, P278
   Patil NT, 2004, TETRAHEDRON LETT, V45, P8497, DOI 10.1016/j.tetlet.2004.099
   Patteux C, 2003, ORG LETT, V5, P3061, DOI 10.1021/ol035049z
   Phan LT, 2004, J MED CHEM, V47, P2965, DOI [10.1021/jm034233n, 10.1021/jm034233m]
   Polanski J, 2007, LETT DRUG DES DISCOV, V4, P99, DOI 10.2174/157018007779422532                                                      
   Polanski J, 2006, LETT DRUG DES DISCOV, V3, P175, DOI 10.2174/157018006776286934                                                      
   Polanski J, 2004, Acta Pol Pharm, V61 Suppl, P3
   Polanski J, 2002, J MED CHEM, V45, P4647, DOI 10.1021/jm020845g
   Prabakaran K, 2011, TETRAHEDRON LETT, V52, P2566, DOI 10.1016/j.tetlet.2011.03.040
   Prabakaran K, 2010, TETRAHEDRON LETT, V51, P4340, DOI 10.1016/j.tetlet.2010.06.045
   Prabakaran K, 2011, CHEM PAP, V65, P883, DOI 10.2478/s11696-011-0074-6
   Roopan SM, 2008, CAN J CHEM, V86, P1019, DOI 10.1139/V08-149
   Roopan SM, 2011, MED CHEM RES, V20, P732, DOI 10.1007/s00044-010-9381-7
   Roopan SM, 2010, TETRAHEDRON LETT, V51, P2309, DOI 10.1016/j.tetlet.2010.02.128
   Russ TH, 2012, NAT PROD COMMUN, V7, P301
   Shah A, 2008, INT J MOL SCI, V9, P1424, DOI 10.3390/ijms9081424
   Shivaraj Y, 2013, J KOREAN CHEM SOC, V57, P241, DOI 10.5012/jkcs.2013.57.2.241
   Singh S, 2012, SENSOR ACTUAT B-CHEM, V171, P899, DOI 10.1016/j.snb.2012.06.002
   STREKOWSKI L, 1991, J MED CHEM, V34, P1739, DOI 10.1021/jm00109a031
   Subashini R, 2012, MONATSH CHEM, V143, P485, DOI 10.1007/s00706-011-0608-1
   SURREY AR, 1950, J AM CHEM SOC, V72, P1814, DOI 10.1021/ja01160a116                                                             
   Tajudeen SS, 2007, SYNTHETIC COMMUN, V37, P3649, DOI 10.1080/00397910701557796
   TORII S, 1992, SYNLETT, P513
   Vaitilingam B, 2004, BIOORGAN MED CHEM, V12, P4179, DOI 10.1016/j.bmc.2004.05.018
   Vaitilingam B., 2004, BIOORGAN MED CHEM, V21, P417
   Vangapandu S, 2004, BIOORGAN MED CHEM, V12, P2501, DOI 10.1016/j.bmc.2004.03.045
   Wang J, 2014, ELECTROCHIM ACTA, V133, P209, DOI 10.1016/j.electacta.2014.03.095
   Wilson W. D., 1992, MED CHEM RES, V1, P102
   Winstanley PA, 2000, PARASITOL TODAY, V16, P146, DOI 10.1016/S0169-4758(99)01622-1
   Yadav JS, 2004, SYNTHESIS-STUTTGART, P2381, DOI 10.1055/s-2004-831185
   Yamashkin S. A., 2006, CHEM HETEROCYCL COMP, V42, P701, DOI DOI 10.1007/S10593-006-0150-Y
   Yauli N., 2005, J PHOTOCH PHOTOBIO A, V169, P229
   Zhang XX, 2005, ORG LETT, V7, P763, DOI 10.1021/ol0476218
   Ziegler J, 2001, CURR MED CHEM, V8, P171, DOI 10.2174/0929867013373840                                                        
   Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o                                                               
   Denny W. A., 2006, U.S Patent, Patent No. [7,064,117, 7064117]
NR 118
TC 2
Z9 2
U1 1
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 84
BP 44408
EP 44417
DI 10.1039/c4ra06772j
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA AQ7KP
UT WOS:000342993800010
DA 2018-01-05
ER

PT J
AU Guo, DW
   Li, TYZ
   McMillan, J
   Sajja, BR
   Puligujja, P
   Boska, MD
   Gendelman, HE
   Liu, XM
AF Guo, Dongwei
   Li, Tianyuzi
   McMillan, JoEllyn
   Sajja, Balasrinivasa R.
   Puligujja, Pavan
   Boska, Michael D.
   Gendelman, Howard E.
   Liu, Xin-Ming
TI Small magnetite antiretroviral therapeutic nanoparticle probes for MRI
   of drug biodistribution
SO NANOMEDICINE
LA English
DT Article
DE HIV; macrophage; monocyte; nanomedicine; nanoparticles; small magnetite
   antiretroviral therapy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CANCER CELLS; DELIVERY; QUANTIFICATION;
   RELEASE; NANOMEDICINE; RELAXOMETRY; LIPOSOMES; INFECTION; TISSUE
AB Aim: Drug toxicities, compliance and penetrance into viral reservoirs have diminished the efficacy of long-term antiretroviral therapy (ART) for treatment of HIV infection. Cell-targeted nanoformulated ART was developed to improve disease outcomes. However, rapid noninvasive determination of drug biodistribution is unrealized. To this end, small magnetite ART (SMART) nanoparticles can provide assessments of ART biodistribution by MRI. Materials & methods: Poly(lactic-co-glycolic acid), 1,2-distearoyl-sn- glycero-3-phosphocholine- and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy-PEG 2000)-encased particles were synthesized with atazanavir (ATV) and magnetite. Uptake and retention of ATV and magnetite administered at 3: 1 ratios (weight/weight) were determined in human monocyte-derived macrophages and mice. Results: SMART particles were taken up and retained in macrophages. In mice, following parenteral SMART injection, magnetite and drug biodistribution paralleled one another with MRI signal intensity greatest in the liver and spleen at 24 h. Significantly, ATV and magnetite levels correlated. Conclusion: SMART can permit rapid assessment of drug tissue concentrations in viral reservoirs.
C1 [Guo, Dongwei; Gendelman, Howard E.; Liu, Xin-Ming] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Li, Tianyuzi; McMillan, JoEllyn; Puligujja, Pavan; Gendelman, Howard E.; Liu, Xin-Ming] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Sajja, Balasrinivasa R.; Boska, Michael D.] Univ Nebraska Med Ctr, Dept Radiol, Omaha, NE 68198 USA.
   [Boska, Michael D.; Gendelman, Howard E.; Liu, Xin-Ming] Univ Nebraska Med Ctr, Ctr Drug Delivery & Nanomed, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU NIH [1P01 DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR
   15635, P01MH64570, P01 NS43985]; Nebraska Research Initiative
FX The work was supported by the NIH grants 1P01 DA028555, 2R01 NS034239,
   2R37 NS36126, P01 NS31492, P20RR 15635, P01MH64570 and P01 NS43985 (to
   HE Gendelman) and support of the Nebraska Research Initiative (to MD
   Boska). The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood-2007-12-077388
   Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Beduneau A, 2009, PLOS ONE, V4, P4343
   Chan JM, 2009, BIOMATERIALS, V30, P1627, DOI 10.1016/j.biomaterials.2008.12.013
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Choi KY, 2012, NANOSCALE, V4, P330, DOI 10.1039/c1nr11277e
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Ganz T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011668
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gendelman HE, 2003, NEUROLOGICAL MANIFES
   Girard OM, 2012, CONTRAST MEDIA MOL I, V7, P411, DOI 10.1002/cmmi.1467
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Guthi JS, 2010, MOL PHARMACEUT, V7, P32, DOI 10.1021/mp9001393
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kibuule D, 2006, 12 ANN M SOC NEUROIM
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Lasic DD, 1996, NATURE, V380, P561, DOI 10.1038/380561a0                                                                
   Lebel RM, 2006, MAGN RESON MED, V55, P583, DOI 10.1002/mrm.20799
   Li B, 2012, INT J NANOMED, V7, P187, DOI 10.2147/IJN.S27864
   Liu W, 2009, MAGN RESON MED, V61, P761, DOI 10.1002/mrm.21923
   Liu YT, 2010, INT J PHARMACEUT, V395, P243, DOI 10.1016/j.ijpharm.2010.05.008
   Mascheri N, 2009, MAGN RESON IMAGING, V27, P961, DOI 10.1016/j.mri.2009.02.008
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Petre CE, 2007, INT J NANOMED, V2, P277
   Pretorius E, 2011, THER DRUG MONIT, V33, P265, DOI 10.1097/FTD.0b013e31821b42d1
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Wainberg MA, 2011, NATURE, V469, P306, DOI 10.1038/469306a
   Wessels E, 2007, SEMIN CELL DEV BIOL, V18, P412, DOI 10.1016/j.semcdb.2007.07.002
NR 39
TC 4
Z9 4
U1 0
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2014
VL 9
IS 9
BP 1341
EP 1352
DI 10.2217/NNM.13.92
PG 12
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA AP4TM
UT WOS:000342071700011
PM 23905578
OA green_accepted
DA 2018-01-05
ER

PT J
AU Choi, J
   Jeong, Y
   Han, HS
   Lee, KH
AF Choi, Jonghoon
   Jeong, Yoon
   Han, Hyung-Seop
   Lee, Kwan Hyi
TI Microdevices for examining immunological responses of single cells to
   HIV
SO BIOSCIENCE REPORTS
LA English
DT Review
DE cellular immune response; HIV; integrative analysis; microfluidics;
   microwells; single-cell analysis; T cells; vaccines
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CD8(+)
   T-CELLS; GP120 ENVELOPE GLYCOPROTEIN; MULTICENTER AIDS COHORT;
   NEUTRALIZING ANTIBODIES; MYOCARDIAL-INFARCTION; DISEASE PROGRESSION;
   IMMUNE-DEFICIENCY; ELITE SUPPRESSORS
AB More than 60 million people in the world have been diagnosed with HIV infections since the virus was recognized as the causative agent of AIDS in the 1980s. Even though more than half of the infected patients have died, effective disease treatment and prevention measures have not been established. ART (antiretroviral therapy) is the only proven HIV treatment that sustains the suppression of patient viraemia. Current routine approaches to treat HIV infections are targeted at developing vaccines that will induce humoral or cell memory immune responses. However, developing an effective vaccine has been challenging because the HIV mutates rapidly, which allows the virus to evade immune surveillances established against the previous strain. In addition, the virus is able to quickly establish a reservoir and treatment is difficult because of the general lack of knowledge about HIV immune response mechanisms. This review introduces common disease symptoms and the progression of HIV infection with a brief summary of the current treatment approaches. Different cellular immune responses against HIV are also discussed, with emphasis on a nanotechnology research that has focused on probing T-cell response to HIV infection. Furthermore, we discuss recent noteworthy nanotechnology updates on T-cell response screening that is focused on HIV infection. Finally, we review potential future treatment strategies based on the correlations between T-cell response and HIV infection.
C1 [Choi, Jonghoon; Jeong, Yoon] Hanyang Univ, Grad Sch, Dept BioNano Technol, Seoul 133791, South Korea.
   [Choi, Jonghoon; Jeong, Yoon] Hanyang Univ, Dept BioNano Engn, Ansan, South Korea.
   [Jeong, Yoon; Han, Hyung-Seop; Lee, Kwan Hyi] Korea Inst Sci & Technol, Biomed Res Inst, Ctr Biomat, Seoul, South Korea.
RP Lee, KH (reprint author), Korea Inst Sci & Technol, Biomed Res Inst, Ctr Biomat, Seoul, South Korea.
EM kwanhyi@kist.re.kr
OI Lee, Kwan Hyi/0000-0002-7891-844X; Han, Hyung-Seop/0000-0001-6870-1485
FU KIST [2Z04150, 2V03320]; National Research Foundation of Korea (NRF)
   grant - Korean government (MEST) [2008-0061856]; Basic Science Research
   Programme through the NRF - MEST [2013R1A1A1012653]
FX This work was supported by the KIST [grant numbers K-GRL #2Z04150, CTP
   #2V03320], the National Research Foundation of Korea (NRF) grant funded
   by the Korean government (MEST) [grant number 2008-0061856] and the
   Basic Science Research Programme through the NRF funded by the MEST
   [grant number 2013R1A1A1012653].
CR Alfano M, 2005, MOL IMMUNOL, V42, P161, DOI 10.1016/j.molimm.2004.06.016
   Allen TM, 2000, NATURE, V407, P386
   Almeida JR, 2009, BLOOD, V113, P6351, DOI 10.1182/blood-2009-02-206557
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Baba TW, 1999, NAT MED, V5, P194
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Blackwell JM, 1996, PARASITOLOGY, V112, pS67
   Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06
   Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376                                                    
   Brouzes E, 2009, P NATL ACAD SCI USA, V106, P14195, DOI 10.1073/pnas.0903542106
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Chong SY, 2007, VACCINE, V25, P4967, DOI 10.1016/j.vaccine.2006.11.070
   Citri A, 2012, NAT PROTOC, V7, P118, DOI 10.1038/nprot.2011.430
   Corti D, 2011, CURR OPIN IMMUNOL, V23, P430, DOI 10.1016/j.coi.2011.04.006
   Fauci AS, 2008, NATURE, V453, P289, DOI 10.1038/453289a
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0
   Finzi D, 1999, NAT MED, V5, P512
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Hinrichs CS, 2011, BLOOD, V117, P808, DOI 10.1182/blood-2010-05-286286
   Itoh Y, 1997, J EXP MED, V186, P757, DOI 10.1084/jem.186.5.757
   Ji JX, 2009, INT IMMUNOL, V21, P283, DOI 10.1093/intimm/dxn146
   Joensson HN, 2012, ANGEW CHEM INT EDIT, V51, P12176, DOI 10.1002/anie.201200460
   Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107
   Kannanganat S, 2007, J VIROL, V81, P8468, DOI 10.1128/JVI.00228-07
   KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474
   Kim JM, 2011, IMMUNOTHERAPY-UK, V3, P247, DOI 10.2217/IMT.10.91
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   Koster S, 2008, LAB CHIP, V8, P1110, DOI 10.1039/b802941e
   Koff WC, 2006, NAT IMMUNOL, V7, P19, DOI 10.1038/ni1296
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong P. D., 2011, COLD SPRING HARB PER, V3
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Leone A, 2009, CURR HIV RES, V7, P83, DOI 10.2174/157016209787048519                                                      
   Levy Y, 2009, J CLIN INVEST, V119, P997, DOI 10.1172/JCI38052
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Liu Y, 2012, BIOMATERIALS, V33, P7347, DOI 10.1016/j.biomaterials.2012.06.089
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003                                                
   Ma C, 2011, NAT MED, V17, P738, DOI 10.1038/nm.2375
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Masopust D, 2009, J INTERN MED, V265, P125, DOI 10.1111/j.1365-2796.2008.02054.x
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   May MT, 2006, LANCET, V368, P451
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   Meddows-Taylor S, 2007, J VIROL METHODS, V144, P115, DOI 10.1016/j.jviromet.2007.04.004
   Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2
   MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923                                                         
   Nitayaphan S, 2004, J INFECT DIS, V190, P702, DOI 10.1086/422258
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0                                                                
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Rosa DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016921
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sereti I, 2009, BLOOD, V113, P6304, DOI 10.1182/blood-2008-10-186601
   Shelburne SA, 2005, AIDS, V19, P399, DOI 10.1097/01.aids.0000161769.06158.8a
   Spolski R, 2012, J IMMUNOL, V188, P1924, DOI 10.4049/jimmunol.1100767
   Stemberger C, 2007, IMMUNITY, V27, P985, DOI 10.1016/j.immuni.2007.10.012
   Story CM, 2008, P NATL ACAD SCI USA, V105, P17902, DOI 10.1073/pnas.0805470105
   Thienemann F, 2013, EUR HEART J, V34, P3538, DOI 10.1093/eurheartj/eht388
   Varadarajan N, 2012, P NATL ACAD SCI USA, V109, P3885, DOI 10.1073/pnas.1111205109
   Varadarajan N, 2011, J CLIN INVEST, V121, P4322, DOI 10.1172/JCI58653
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Weiss RA, 2008, CLIN EXP IMMUNOL, V152, P201, DOI 10.1111/j.1365-2249.2008.03645.x
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Yalcin Ayca, 2012, Methods Mol Biol, V853, P211, DOI 10.1007/978-1-61779-567-1_16
   Yamane H, 2012, NAT IMMUNOL, V13, P1037, DOI 10.1038/ni.2431
   Zygmunt B, 2011, ADV IMMUNOL, V109, P159, DOI 10.1016/B978-0-12-387664-5.00005-4
NR 84
TC 1
Z9 1
U1 0
U2 5
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PY 2014
VL 34
BP 501
EP 511
AR e00134
DI 10.1042/BSR20140097
PN 4
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AP2YW
UT WOS:000341943100018
OA gold
DA 2018-01-05
ER

PT J
AU Heravi, MM
   Hamidi, H
   Zadsirjan, V
AF Heravi, Majid M.
   Hamidi, Hoda
   Zadsirjan, Vahideh
TI Recent Applications of Click Reaction in the Syntheses of
   1,2,3-triazoles
SO CURRENT ORGANIC SYNTHESIS
LA English
DT Article
DE 1,2,3-triazoles; azides; bis-1,2,3-triazoles; click reaction;
   cycloaddition; heterocycles; fused 1,2,3-triazoles
ID AZIDE-ALKYNE CYCLOADDITION; ONE-POT SYNTHESIS; REVERSE-TRANSCRIPTASE
   INHIBITORS; POTENTIAL ANTICANCER AGENTS; COPPER IODIDE NANOPARTICLES;
   CROSS-COUPLING REACTION; ACTION HIV-1 PROTEASE; 1,4-DISUBSTITUTED
   1,2,3-TRIAZOLES; MYCOBACTERIUM-TUBERCULOSIS; 1,3-DIPOLAR CYCLOADDITION
AB Triazoles and their derivatives have been widely utilized as precursors in the syntheses of biologically active systems such as anticancers, antimicrobials, antifungals and other cytotoxic active agents. In this review, we tried to highlight the recent advances (2010-2013) in the syntheses of 1,2,3-triazoles, bis-1,2,3-triazoles and fused triazoles via click reaction. Click reaction provides substances quickly and reliably by combining small units together. Click chemistry can also be applied widely for the syntheses of biologically active compounds. Since the 1,2,3-triazole scaffold is present in many beneficial biologically structures, we hope this review attracts the attentions of synthetic organic chemists to make use of the advantages of click reaction in the total syntheses of natural products containing 1,2,3-triazoles.
C1 [Heravi, Majid M.; Hamidi, Hoda; Zadsirjan, Vahideh] Alzahra Univ, Sch Sci, Dept Chem, Tehran, Iran.
RP Heravi, MM (reprint author), Alzahra Univ, Sch Sci, Dept Chem, Tehran, Iran.
EM mmh1331@yahoo.com
FU Alzahra Research Council
FX MMH is thankful to Alzahra Research Council for partial financial
   supports.
CR Agalave SG, 2011, CHEM-ASIAN J, V6, P2696, DOI 10.1002/asia.201100432
   Albadi J, 2012, CATAL COMMUN, V27, P17, DOI 10.1016/j.catcom.2012.05.023
   Albadi J, 2012, CHINESE CHEM LETT, V23, P797, DOI 10.1016/j.cclet.2012.05.009
   Ankati H, 2008, J ORG CHEM, V73, P6433, DOI 10.1021/jo8009616
   Balogh J, 2011, J ORGANOMET CHEM, V696, P1394, DOI 10.1016/j.jorganchem.2011.01.008
   Banday AH, 2010, STEROIDS, V75, P801, DOI 10.1016/j.steroids.2010.02.015
   Banerjee S., 2013, J ADV PHARM ED RES, V3, P102
   Bock VD, 2005, EUR J ORG CHEM, P51, DOI 10.1002/ejoc.200500483
   Bouhfid R, 2005, HETEROCYCLES, V65, P2949
   Boz E, 2013, J ORGANOMET CHEM, V724, P167, DOI 10.1016/j.jorganchem.2012.11.011
   Breinbauer R, 2003, CHEMBIOCHEM, V4, P1147, DOI 10.1002/cbic.200300705
   Brisbois RG, 2013, TETRAHEDRON LETT, V54, P272, DOI 10.1016/j.tetlet.2012.11.019
   Chen LQ, 2010, J MED CHEM, V53, P4768, DOI 10.1021/jm100424m
   Collins LA, 1998, ANTIMICROB AGENTS CH, V42, P344
   da Silva FD, 2009, EUR J MED CHEM, V44, P373, DOI 10.1016/j.ejmech.2008.02.047
   Diaz L, 2010, J MED CHEM, V53, P5248, DOI 10.1021/jm100198t
   Dou DF, 2011, BIOORGAN MED CHEM, V19, P5782, DOI 10.1016/j.bmc.2011.08.029
   Duan YC, 2013, EUR J MED CHEM, V62, P11, DOI 10.1016/j.ejmech.2012.12.046
   Elamari H, 2013, EUR J MED CHEM, V60, P360, DOI 10.1016/j.ejmech.2012.12.025
   Elayadi H, 2012, CATAL COMMUN, V26, P155, DOI 10.1016/j.catcom.2012.05.016
   Ellison A, 2013, TETRAHEDRON LETT, V54, P6005, DOI 10.1016/j.tetlet.2013.08.065
   Evans RA, 2007, AUST J CHEM, V60, P384, DOI 10.1071/CH06457
   Fazeli A, 2013, LETT ORG CHEM, V10, P738, DOI 10.2174/15701786113109990036                                                    
   Fazeli A, 2013, MONATSH CHEM, V144, P1407, DOI 10.1007/s00706-013-1025-4
   Fazeli A, 2013, Z NATURFORSCH B, V68, P391, DOI 10.5560/ZNB.2013-3043
   Feher K, 2012, STEROIDS, V77, P738, DOI 10.1016/j.steroids.2012.04.005
   Ferreira SB, 2007, EUR J MED CHEM, V42, P1388, DOI 10.1016/j.ejmech.2007.02.020
   Fiandanese V, 2012, TETRAHEDRON, V68, P10310, DOI 10.1016/j.tet.2012.10.005
   Finn MG, 2010, CHEM SOC REV, V39, P1231, DOI 10.1039/c003740k
   Gmieir P., 1994, J ORG CHEM, V59, P6766
   Gothelf KV, 1998, CHEM REV, V98, P863, DOI 10.1021/cr970324e                                                               
   Hans RH, 2010, BIOORG MED CHEM LETT, V20, P942, DOI 10.1016/j.bmcl.2009.12.062
   Heravi MM, 2009, J IRAN CHEM SOC, V6, P1, DOI 10.1007/BF03246501                                                              
   Heravi MM, 2012, SYNLETT, P2927, DOI 10.1055/s-0032-1317671
   Heravi MM, 2012, MONATSH CHEM, V143, P1575, DOI 10.1007/s00706-012-0838-x
   Heravi MM, 2012, TETRAHEDRON, V68, P9145, DOI 10.1016/j.tet.2012.08.058
   Heravi MM, 2012, CURR ORG CHEM, V16, P2097
   Heravi MM, 2012, MONATSH CHEM, V143, P861, DOI 10.1007/s00706-012-0746-0
   Heravi MM, 2010, HETEROCYCLES, V81, P1979, DOI 10.3987/REV-10-675
   Heravi MM, 2009, CURR ORG CHEM, V13, P1002, DOI 10.2174/138527209788680790                                                      
   Heravi MM, 2009, TETRAHEDRON, V65, P7761, DOI 10.1016/j.tet.2009.06.028
   Heravi M. M., 2011, HETEROCYCLES, V85, P545
   Howe JD, 2013, BIOORGAN MED CHEM, V21, P4831, DOI 10.1016/j.bmc.2013.03.014
   Hu J, 2010, BIOORG MED CHEM LETT, V20, P4342, DOI 10.1016/j.bmcl.2010.06.079
   Huang X, 1998, SYNLETT, P1191
   Huang YE, 2010, TETRAHEDRON LETT, V51, P6951, DOI 10.1016/j.tetlet.2010.10.149
   HUISGEN R, 1963, ANGEW CHEM INT EDIT, V75, P604, DOI 10.1002/ange.19630751304                                                        
   Huisgen R, 1963, ANGEW CHEM INT EDIT, V2, P565, DOI DOI 10.1002/ANIE.196305651
   Hwang S, 2012, TETRAHEDRON, V68, P1460, DOI 10.1016/j.tet.2011.12.025
   Ibrahim DA, 2009, EUR J MED CHEM, V44, P2776, DOI 10.1016/j.ejmech.2009.01.003
   IIDA H, 1987, J ORG CHEM, V52, P3337, DOI 10.1021/jo00391a031
   Kallander LS, 2005, J MED CHEM, V48, P5644, DOI 10.1021/jm0504080c
   Kappe CO, 2010, CHEM SOC REV, V39, P1280, DOI 10.1039/b901973c
   Kategaonkar AH, 2010, EUR J MED CHEM, V45, P3142, DOI 10.1016/j.ejmech.2010.04.002
   Keivanloo A, 2013, CR CHIM, V16, P239, DOI 10.1016/j.crci.2012.11.007
   Keshavarz M., 2013, CR CHIM, V16, P1002
   Khan MW, 2005, BIOORGAN MED CHEM, V13, P4796, DOI 10.1016/j.bmc.2005.05.009
   KHOUKHI N, 1987, TETRAHEDRON, V43, P1811, DOI 10.1016/S0040-4020(01)81492-7                                                   
   Kim S, 2012, BIOORG MED CHEM LETT, V22, P6844, DOI 10.1016/j.bmcl.2012.09.041
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Kolb H. C., 2001, ANGEW CHEM, V113, P2056, DOI DOI 10.1002/1521-3757(20010601)113:11<2056::AID-ANGE2056>3.0.CO;2-W
   Kovalovs A, 2013, TETRAHEDRON LETT, V54, P850, DOI 10.1016/j.tetlet2012.11.095
   Kumar BSPA, 2012, TETRAHEDRON LETT, V53, P4595, DOI 10.1016/j.tetlet.2012.06.077
   Kumar I, 2012, TETRAHEDRON-ASYMMETR, V23, P225, DOI 10.1016/j.tetasy.2012.02.011
   Kumar K, 2012, EUR J MED CHEM, V58, P153, DOI 10.1016/j.ejmech.2012.10.008
   Kuriakose J, 2012, BIOORG MED CHEM LETT, V22, P4410, DOI 10.1016/j.bmcl.2012.04.125
   Labadie GR, 2011, MOL DIVERS, V15, P1017, DOI 10.1007/s11030-011-9319-0
   Lee BY, 2006, TETRAHEDRON LETT, V47, P5105, DOI 10.1016/j.tetlet.2006.05.079
   Lee T, 2007, J MED CHEM, V50, P585, DOI 10.1021/jm061243q
   Li LT, 2012, BIOORG MED CHEM LETT, V22, P642, DOI 10.1016/j.bmcl.2011.10.062
   Lowary T, 1998, J ORG CHEM, V63, P9657, DOI 10.1021/jo980517h                                                               
   Majeed R, 2013, EUR J MED CHEM, V63, P782, DOI 10.1016/j.ejmech.2013.03.028
   Mavrova AT, 2009, EUR J MED CHEM, V44, P63, DOI 10.1016/j.ejmech.2008.03.006
   Meldal M, 2008, CHEM REV, V108, P2952, DOI 10.1021/cr0783479
   Mohammed AI, 2012, TETRAHEDRON LETT, V53, P5081, DOI 10.1016/j.tetlet.2012.07.014
   Mohammed S, 2012, TETRAHEDRON, V68, P8156, DOI 10.1016/j.tet.2012.07.080
   Moorhouse D., 2008, CHEMMEDCHEM, V3, P715
   More D. J., 2002, ORG LETT, V4, P3001
   Moro AV, 2013, TETRAHEDRON, V69, P201, DOI 10.1016/j.tet.2012.10.043
   Moses JE, 2007, CHEM SOC REV, V36, P1249, DOI 10.1039/b613014n
   Muller S, 1996, SYNLETT, P521
   Oestreich M, 1998, TETRAHEDRON LETT, V39, P1745, DOI 10.1016/S0040-4039(98)00085-9                                                   
   OHIRA S, 1989, SYNTHETIC COMMUN, V19, P561, DOI 10.1080/00397918908050700                                                       
   Olomola TO, 2013, BIOORGAN MED CHEM, V21, P1964, DOI 10.1016/j.bmc.2013.01.025
   Olomola TO, 2010, TETRAHEDRON LETT, V51, P6325, DOI 10.1016/j.tetlet.2010.09.121
   Pagliai F, 2006, J MED CHEM, V49, P467, DOI 10.1021/jm051118z
   Pericherla K, 2012, TETRAHEDRON LETT, V53, P6761, DOI 10.1016/j.tetlet.2012.09.129
   Pramitha P, 2012, BIOORG MED CHEM LETT, V22, P2598, DOI 10.1016/j.bmcl.2012.01.111
   Qian WY, 2012, TETRAHEDRON LETT, V53, P271, DOI 10.1016/j.tetlet.2011.11.030
   Quan ZJ, 2013, TETRAHEDRON, V69, P881, DOI 10.1016/j.tet.2012.10.097
   Rad MNS, 2012, TETRAHEDRON, V68, P7812, DOI 10.1016/j.tet.2012.07.032
   Raj R, 2013, EUR J MED CHEM, V63, P897, DOI 10.1016/j.ejmech.2013.03.019
   Raj R, 2013, EUR J MED CHEM, V62, P590, DOI 10.1016/j.ejmech.2013.01.032
   Rathinam B, 2013, TETRAHEDRON, V69, P235, DOI 10.1016/j.tet.2012.10.040
   Rathwell K, 2010, TETRAHEDRON, V66, P4002, DOI 10.1016/j.tet.2010.04.048
   Ravichandran S, 2001, SYNTHETIC COMMUN, V31, P1233, DOI 10.1081/SCC-100104009                                                           
   Reddy M. K., 2012, J SAUDI CHE IN PRESS
   Rivara M, 2012, BIOORG MED CHEM LETT, V22, P6401, DOI 10.1016/j.bmcl.2012.08.067
   Rogers SA, 2008, ANGEW CHEM INT EDIT, V47, P5229, DOI 10.1002/anie.200800862
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Sangshetti JN, 2010, BIOORG MED CHEM LETT, V20, P742, DOI 10.1016/j.bmcl.2009.11.048
   Sangshetti JN, 2009, BIOORG MED CHEM LETT, V19, P3564, DOI 10.1016/j.bmcl.2009.04.134
   SCHMID CR, 1991, J ORG CHEM, V56, P4056, DOI 10.1021/jo00012a049                                                             
   SCHONECKER B, 1975, TETRAHEDRON, V31, P1113, DOI 10.1016/0040-4020(75)80134-7
   Schulz M, 2013, TETRAHEDRON, V69, P802, DOI 10.1016/j.tet.2012.10.107
   Schuster EM, 2008, ANGEW CHEM INT EDIT, V47, P4555, DOI 10.1002/anie.200800123
   Seus N, 2012, TETRAHEDRON, V68, P10419, DOI 10.1016/j.tet.2012.07.019
   Shafi S, 2012, EUR J MED CHEM, V49, P324, DOI 10.1016/j.ejmech.2012.01.032
   Shafran EA, 2008, CHEM HETEROCYCL COM+, V44, P1040, DOI 10.1007/s10593-008-0155-9
   Shanmugavelan P, 2011, BIOORG MED CHEM LETT, V21, P7273, DOI 10.1016/j.bmcl.2011.10.048
   Sharghi H, 2009, ADV SYNTH CATAL, V351, P207, DOI 10.1002/adsc.200800612
   Sharpless KB, 2006, EXPERT OPIN DRUG DIS, V1, P525, DOI 10.1517/17460441.1.6.525
   Shen J, 2008, J MED CHEM, V51, P7417, DOI 10.1021/jm8005355
   Siddiqui N., 2011, INT J PHARM SCI REV, V8, P161
   Singh MK, 2013, EUR J MED CHEM, V63, P635, DOI 10.1016/j.ejmech.2013.02.027
   Singh P, 2012, EUR J MED CHEM, V55, P455, DOI 10.1016/j.ejmech.2012.06.057
   Singh P, 2012, EUR J MED CHEM, V47, P594, DOI 10.1016/j.ejmech.2011.10.033
   Singh P, 2011, BIOORG MED CHEM LETT, V21, P4561, DOI 10.1016/j.bmcl.2011.05.119
   Smith G, 2008, J MED CHEM, V51, P8057, DOI 10.1021/jm801107u
   Spiteri C, 2010, ANGEW CHEM INT EDIT, V49, P31, DOI 10.1002/anie.200905322
   Stefani HA, 2012, TETRAHEDRON LETT, V53, P6495, DOI 10.1016/j.tetlet.2012.09.062
   Stefani HA, 2012, TETRAHEDRON LETT, V53, P1742, DOI 10.1016/j.tetlet.2012.01.102
   Stefely JA, 2010, J MED CHEM, V53, P3389, DOI 10.1021/jm1000979
   Sumangala V, 2010, ARCH PHARM RES, V33, P1911, DOI 10.1007/s12272-010-1204-3
   Tan YH, 2012, TETRAHEDRON, V68, P2827, DOI 10.1016/j.tet.2012.01.092
   Thirumurugan P, 2013, CHEM REV, V113, P4905, DOI 10.1021/cr200409f
   Tiew KC, 2012, BIOORGAN MED CHEM, V20, P1213, DOI 10.1016/j.bmc.2011.12.047
   Urankar D, 2008, J COMB CHEM, V10, P981, DOI 10.1021/cc8001475
   Yamakoshi H, 2010, ACS MED CHEM LETT, V1, P273, DOI 10.1021/ml1000454
   Yan SJ, 2010, BIOORG MED CHEM LETT, V20, P5225, DOI 10.1016/j.bmcl.2010.06.141
   Yim CB, 2010, J MED CHEM, V53, P3944, DOI 10.1021/jm100246m
   Zarei A, 2012, TETRAHEDRON LETT, V53, P5176, DOI 10.1016/j.tetlet.2012.07.081
NR 133
TC 26
Z9 26
U1 3
U2 57
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1794
EI 1875-6271
J9 CURR ORG SYNTH
JI Curr. Org. Synth.
PY 2014
VL 11
IS 5
BP 647
EP 675
DI 10.2174/1570179411666140530210314                                       
          
PG 29
WC Chemistry, Organic
SC Chemistry
GA AO8ZM
UT WOS:000341644800002
DA 2018-01-05
ER

PT J
AU Torrecilla, J
   Rodriguez-Gascon, A
   Solinis, MA
   del Pozo-Rodriguez, A
AF Torrecilla, Josune
   Rodriguez-Gascon, Alicia
   Angeles Solinis, Maria
   del Pozo-Rodriguez, Ana
TI Lipid Nanoparticles as Carriers for RNAi against Viral Infections:
   Current Status and Future Perspectives
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID SMALL INTERFERING RNA; HEPATITIS-B-VIRUS; CONJUGATE LDC NANOPARTICLES;
   GENE DELIVERY-SYSTEM; REPLICATION IN-VIVO; APOLIPOPROTEIN-A-I; SHORT
   HAIRPIN RNA; SIRNA DELIVERY; DRUG-CONJUGATE; IMMUNE-RESPONSES
AB The efforts made to develop RNAi-based therapies have led to productive research in the field of infections in humans, such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), herpetic keratitis, human papillomavirus, or influenza virus. Naked RNAi molecules are rapidly digested by nucleases in the serum, and due to their negative surface charge, entry into the cell cytoplasm is also hampered, which makes necessary the use of delivery systems to exploit the full potential of RNAi therapeutics. Lipid nanoparticles (LNP) represent one of the most widely used delivery systems for in vivo application of RNAi due to their relative safety and simplicity of production, joint with the enhanced payload and protection of encapsulated RNAs. Moreover, LNP may be functionalized to reach target cells, and they may be used to combine RNAi molecules with conventional drug substances to reduce resistance or improve efficiency. This review features the current application of LNP in RNAi mediated therapy against viral infections and aims to explore possible future lines of action in this field.
C1 [Torrecilla, Josune; Rodriguez-Gascon, Alicia; Angeles Solinis, Maria; del Pozo-Rodriguez, Ana] Univ Basque Country UPV EHU, Fac Farm, Ctr Invest Lascaray Ikergunea, Pharmacokinet Nanotechnol & Gene Therapy Grp Phar, Vitoria 01006, Spain.
RP del Pozo-Rodriguez, A (reprint author), Univ Basque Country UPV EHU, Fac Farm, Ctr Invest Lascaray Ikergunea, Pharmacokinet Nanotechnol & Gene Therapy Grp Phar, Paseo Univ 7, Vitoria 01006, Spain.
EM ana.delpozo@ehu.es
OI Solinis, Maria Angeles/0000-0001-9127-0775
FU Basque Government's Department of Education, Universities and
   Investigation [IT-341-10]
FX This work was supported by the Basque Government's Department of
   Education, Universities and Investigation (IT-341-10).
CR Aditya NP, 2010, EUR J PHARM SCI, V40, P448, DOI 10.1016/j.ejps.2010.05.007
   Amado RG, 2004, HUM GENE THER, V15, P251, DOI 10.1089/104303404322886101                                                      
   Ambegia E, 2005, BBA-BIOMEMBRANES, V1669, P155, DOI 10.1016/j.bbamem.2005.02.001
   An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104
   Anderson JS, 2009, JAIDS-J ACQ IMM DEF, V52, P152, DOI 10.1097/QAI.0b013e3181b010a0
   Arias MA, 2011, VACCINE, V29, P1258, DOI 10.1016/j.vaccine.2010.11.084
   Arima H, 2012, MOL PHARMACEUT, V9, P2591, DOI 10.1021/mp300188f
   Beloqui A, 2014, INT J PHARMACEUT, V468, P105, DOI 10.1016/j.ijpharm.2014.04.027
   Beloqui A, 2014, J MICROENCAPSUL, V31, P1, DOI 10.3109/02652048.2013.788090
   Beloqui A, 2013, J CONTROL RELEASE, V166, P115, DOI 10.1016/j.jconrel.2012.12.021
   Betakova T, 2013, ACTA VIROL, V57, P97, DOI 10.4149/av_2013_02_97
   Blake SJ, 2012, CURR DRUG TARGETS, V13, P1411
   Boutimah F, 2013, ANTIVIR RES, V98, P121, DOI 10.1016/j.antiviral.2013.02.011
   Carmona S, 2006, MOL THER, V13, P411, DOI 10.1016/j.ymthe.2005.10.013
   Carmona S, 2009, MOL PHARMACEUT, V6, P706, DOI 10.1021/mp800157x
   Committee for Advanced Therapies (CAT), 2012, EMACAT6002802010
   Chandra PK, 2012, MOL THER, V20, P1724, DOI 10.1038/mt.2012.107
   Chen XZ, 2010, CLIN EXP DERMATOL, V35, P509, DOI 10.1111/j.1365-2230.2009.03624.x
   Cortesi R, 2014, NEW BIOTECHNOL, V31, P44, DOI 10.1016/j.nbt.2013.10.001
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Dallas A, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.50
   Das S, 2012, EUR J PHARM SCI, V47, P139, DOI 10.1016/j.ejps.2012.05.010
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   De Francesco R, 2005, NATURE, V436, P953, DOI 10.1038/nature04080
   del Pozo-Rodriguez A, 2009, EUR J PHARM BIOPHARM, V71, P181, DOI 10.1016/j.ejpb.2008.09.015
   del Pozo-Rodriguez A, 2009, J CONTROL RELEASE, V133, P52, DOI 10.1016/j.jconrel.2008.09.004
   del Pozo-Rodriguez A, 2013, J OCUL PHARMACOL TH, V29, P173, DOI 10.1089/jop.2012.0128
   del Pozo-Rodriguez Ana, 2011, Recent Pat Drug Deliv Formul, V5, P214
   del Pozo-Rodriguez A, 2010, INT J PHARMACEUT, V385, P157, DOI 10.1016/j.ijpharm.2009.10.020
   Delgado D, 2013, EUR J PHARM SCI, V50, P484, DOI 10.1016/j.ejps.2013.08.013
   Delgado D, 2012, HUM GENE THER, V23, P345, DOI 10.1089/hum.2011.115
   Delgado D, 2012, INT J PHARMACEUT, V425, P35, DOI 10.1016/j.ijpharm.2011.12.052
   Delgado D, 2011, EUR J PHARM BIOPHARM, V79, P495, DOI 10.1016/j.ejpb.2011.06.005
   Deng L, 2013, INT J NANOMED, V8, P3271, DOI 10.2147/IJN.S47597
   DeVincenzo J, 2010, P NATL ACAD SCI USA, V107, P8800, DOI 10.1073/pnas.0912186107
   DiGiusto DL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000931
   Doroud D, 2010, J CONTROL RELEASE, V148, pE105, DOI 10.1016/j.jconrel.2010.07.079
   Dyer V, 2010, BIOCHEM BIOPH RES CO, V398, P640, DOI 10.1016/j.bbrc.2010.06.122
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301                                                              
   Fang CL, 2013, RECENT PAT NANOTECH, V7, P41, DOI 10.2174/187221013804484827                                                      
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gavrilov Kseniya, 2012, Yale Journal of Biology and Medicine, V85, P187
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Gebert LFR, 2014, NUCLEIC ACIDS RES, V42, P609, DOI 10.1093/nar/gkt852
   Geiben-Lynn R, 2011, CLIN VACCINE IMMUNOL, V18, P533, DOI 10.1128/CVI.00390-10
   Geisbert TW, 2006, J INFECT DIS, V193, P1650, DOI 10.1086/504267
   Geisbert TW, 2010, LANCET, V375, P1896, DOI 10.1016/S0140-6736(10)60357-1
   Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2
   Gomes-da-Silva LC, 2012, ACCOUNTS CHEM RES, V45, P1163, DOI 10.1021/ar300048p
   Greenland JR, 2007, J IMMUNOL, V178, P5652, DOI 10.4049/jimmunol.178.9.5652                                                     
   Guettouche T, 2005, ANTIVIR THER, V10, P593
   Hammond SM, 2005, FEBS LETT, V579, P5822, DOI 10.1016/j.febslet.2005.08.079
   He F, 2012, LIVER INT, V32, P742, DOI 10.1111/j.1478-3231.2011.02748.x
   Hean J., 2010, ARTIFICIAL DNA PNA X, V1, P17, DOI DOI 10.4161/ADNA.1.1.11981
   Henry SD, 2006, MOL THER, V14, P485, DOI 10.1016/j.ymthe.2006.04.012
   Hyvonen Z, 2004, J CONTROL RELEASE, V99, P177, DOI 10.1016/j.jconrel.2004.06.019
   Iqbal MA, 2012, J DRUG TARGET, V20, P813, DOI 10.3109/1061186X.2012.716845
   Ivacik D, 2011, REV MED VIROL, V21, P383, DOI 10.1002/rmv.705
   Janssen H. L., 2011, P LIV M AASLD 62 ANN
   Jiang WZ, 2012, VACCINE, V30, P758, DOI 10.1016/j.vaccine.2011.11.076
   Jin J, 2011, BIOCONJUGATE CHEM, V22, P2568, DOI 10.1021/bc200406n
   Joshi M, 2008, INT J PHARMACEUT, V364, P119, DOI 10.1016/j.ijpharm.2008.07.032
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Kanda T, 2007, J VIROL, V81, P669, DOI 10.1128/JVI.01496-06
   Kaneda MM, 2010, BIOMATERIALS, V31, P3079, DOI 10.1016/j.biomaterials.2010.01.006
   Kasongo KW, 2011, J PHARM SCI-US, V100, P5185, DOI 10.1002/jps.22711
   Keeffe EB, 2008, CLIN GASTROENTEROL H, V6, P268, DOI 10.1016/j.cgh.2007.12.043
   Khantasup K, 2014, ANTIMICROB AGENTS CH, V58, P2816, DOI 10.1128/AAC.02768-13
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim HR, 2008, MOL PHARMACEUT, V5, P622, DOI 10.1021/mp8000233
   Kim M, 2006, VIRUS RES, V122, P1, DOI 10.1016/j.viruses.2006.05.003
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Kim SI, 2007, MOL THER, V15, P1145, DOI 10.1038/sj.mt.6300168
   Kim SI, 2009, J HEPATOL, V50, P479, DOI 10.1016/j.jhep.2008.10.029
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kundu AK, 2012, EUR J PHARM BIOPHARM, V80, P257, DOI 10.1016/j.ejpb.2011.10.023
   Kwon SM, 2008, J CONTROL RELEASE, V128, P89, DOI 10.1016/j.jconrel.2008.02.004
   Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530
   Lares MR, 2010, TRENDS BIOTECHNOL, V28, P570, DOI 10.1016/j.tibtech.2010.07.009
   Lee H, 2009, BIOCHEM BIOPH RES CO, V378, P192, DOI 10.1016/j.bbrc.2008.11.029
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Levine BL, 2006, P NATL ACAD SCI USA, V103, P17372, DOI 10.1073/pnas.0608138103
   Liu D., 2012, J HEMATOLOGY ONCO S1, V5, pA4
   Liu YP, 2008, NUCLEIC ACIDS RES, V36, P2811, DOI 10.1093/nar/gkn109
   Lu XB, 2004, J VIROL, V78, P7079, DOI 10.1128/JVI.78.13.7079-7088.2004
   Luke JM, 2011, J VIROL, V85, P1370, DOI 10.1128/JVI.01250-10
   Machitani M, 2013, VIRUS RES, V178, P357, DOI 10.1016/j.virusres.2013.09.021
   Marimani MD, 2013, BIOORGAN MED CHEM, V21, P6145, DOI 10.1016/j.bmc.2013.04.073
   Mevel M, 2010, J CONTROL RELEASE, V143, P222, DOI 10.1016/j.jconrel.2009.12.001
   Miele E, 2012, INT J NANOMED, V7, P3637, DOI 10.2147/IJN.S23696
   Mishra H, 2010, J PHARM PHARM SCI, V13, P495, DOI 10.18433/J3XK53                                                                 
   Montana G, 2007, BIOCONJUGATE CHEM, V18, P302, DOI 10.1021/bc0601166
   Moore CB, 2010, METHODS MOL BIOL, V629, P139, DOI 10.1007/978-1-60761-657-3_10
   Moore MD, 2005, J GENE MED, V7, P918, DOI 10.1002/jgm.739
   Moreira JN, 2008, J NANOSCI NANOTECHNO, V8, P2187, DOI 10.1166/jnn.2008.319
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Motavaf M, 2012, J VIRAL HEPATITIS, V19, P757, DOI 10.1111/jvh.12006
   Muller RH, 2002, ADV DRUG DELIVER REV, V54, pS131, DOI 10.1016/S0169-409X(02)00118-7
   Naito Y, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-80
   Nayak AP, 2010, COLLOID SURFACE B, V81, P263, DOI 10.1016/j.colsurfb.2010.07.020
   Neupane YR, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/41/415102
   Novobrantseva TI, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.3
   Olbrich C, 2004, J CONTROL RELEASE, V96, P425, DOI 10.1016/j.jconrel.2004.02.024
   Olbrich C, 2002, J DRUG TARGET, V10, P387, DOI 10.1080/1061186021000001832
   Ovcharenko D, 2005, RNA, V11, P985, DOI 10.1261/rna.7288405
   Paliwal R, 2011, J BIOMED NANOTECHNOL, V7, P130, DOI 10.1166/jbn.2011.1235
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Pan QW, 2009, EXPERT OPIN BIOL TH, V9, P713, DOI 10.1517/14712590902989970
   Park C, 2014, J CLIN PHARM THER, V39, P14, DOI 10.1111/jcpt.12106
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Pedersen IM, 2007, NATURE, V449, P919, DOI 10.1038/nature06205
   Pedersen N, 2006, EUR J PHARM BIOPHARM, V62, P155, DOI 10.1016/j.ejpb.2005.09.003
   Prabhu R, 2005, J MED VIROL, V76, P511, DOI 10.1002/jmv.20391
   Prabhu R, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-100
   Priano L, 2007, J NANOSCI NANOTECHNO, V7, P3596, DOI 10.1166/jnn.2007.809
   Puri A, 2009, CRIT REV THER DRUG, V26, P523, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10                                    
   Radtke M., 2005, PHARM TECHNOLOGY EUR, V17, P45
   Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004
   Ray Ratna B., 2009, V510, P251, DOI 10.1007/978-1-59745-394-3_19
   Rodriguez-Gascon A, 2014, INT J NANOMED, V9, P1833, DOI 10.2147/IJN.S39810
   Romano PR, 2006, ONCOGENE, V25, P3857, DOI 10.1038/sj.onc.1209549
   ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904
   Ruiz de Garibay Aritz Perez, 2012, Drug Des Devel Ther, V6, P303, DOI 10.2147/DDDT.S36131
   Schluep T., 2013, GLOBAL ANTIVIRAL S2, V9, P57
   Sharma P, 2012, J BIOMED NANOTECHNOL, V8, P928, DOI 10.1166/jbn.2012.1464
   Sheridan C, 2011, NAT BIOTECHNOL, V29, P121, DOI 10.1038/nbt.1769
   Shlomai A, 2003, HEPATOLOGY, V37, P764, DOI 10.1053/jhep.2003.50146
   Simon A., 2012, EUROPEAN RESP J, V40, p267s
   Singhania Richa, 2012, Open Virol J, V6, P204, DOI 10.2174/1874357901206010204
   Apaolaza PS, 2014, INT J PHARMACEUT, V465, P413, DOI 10.1016/j.ijpharm.2014.02.038
   Sun DX, 2010, J HEPATOL, V52, P817, DOI 10.1016/j.jhep.2009.10.038
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Takigawa Y, 2004, MICROBIOL IMMUNOL, V48, P591, DOI 10.1111/j.1348-0421.2004.tb03556.x                                              
   Tam Yuen Yi C, 2013, Pharmaceutics, V5, P498, DOI 10.3390/pharmaceutics5030498
   Taratula O, 2013, J CONTROL RELEASE, V171, P349, DOI 10.1016/j.jconrel.2013.04.018
   Teeranachaideekul V, 2007, INT J PHARM, V340, P198, DOI 10.1016/j.ijpharm.2007.03.022
   ter Brake O, 2009, GENE THER, V16, P148, DOI 10.1038/gt.2008.124
   ter Brake O, 2006, MOL THER, V14, P883, DOI 10.1016/j.ymthe.2006.07.007
   Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319
   Uprichard SL, 2005, P NATL ACAD SCI USA, V102, P773, DOI 10.1073/pnas.0409028102
   Vaishnaw Akshay K, 2010, Silence, V1, P14, DOI 10.1186/1758-907X-1-14
   Verissimo LM, 2010, J DRUG TARGET, V18, P333, DOI 10.3109/10611860903434019
   Vighi E, 2010, INT J PHARMACEUT, V389, P254, DOI 10.1016/j.ijpharm.2010.01.030
   Vlachakis D, 2013, EVOL BIOINFORM, V9, P203, DOI 10.4137/EBO.S11412
   Wang XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056110
   Watanabe T, 2007, J HEPATOL, V47, P744, DOI 10.1016/j.jhep.2007.06.015
   Weinberg MS, 2010, GENOME MED, V2, DOI 10.1186/gm149
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilkins C, 2005, NATURE, V436, P1044, DOI 10.1038/nature03957
   Wooddell CI, 2013, MOL THER, V21, P973, DOI 10.1038/mt.2013.31
   Wu KL, 2005, VIRUS RES, V112, P100, DOI 10.1016/j.virusres.2005.04.001
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Xiaofei E, 2012, J Virol, V86, P5660, DOI 10.1128/JVI.06338-11
   Yang YJ, 2012, VIRUS RES, V169, P169, DOI 10.1016/j.virusres.2012.07.024
   Yi SW, 2000, PHARMACEUT RES, V17, P314, DOI 10.1023/A:1007553106681
   Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840
   Yoo HS, 2006, J CONTROL RELEASE, V112, P139, DOI 10.1016/j.jconrel.2006.01.019
   Yu WY, 2010, PHARM RES-DORDR, V27, P1584, DOI 10.1007/s11095-010-0149-z
   Yu WY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/21/215102
   Zekri ARN, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-13
   Zeller Skye J., 2011, Yale Journal of Biology and Medicine, V84, P301
   Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100                                                         
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhang Y, 2013, J CONTROL RELEASE, V172, P962, DOI 10.1016/j.jconrel.2013.09.015
   Zoulim F, 2011, LIVER INT, V31, P111, DOI 10.1111/j.1478-3231.2010.02399.x
   Rodriguez-Gascon A., 2012, Lipid nanoparticles for gene therapy, Patent No. [US 20120183589 A1, 20120183589]
   Muller R.H., 2004, US Patent, Patent No. [US 6,770,299 B1, 6770299]
   Rodriguez-Gascon A., 2012, Lipid nanoparticles for treating ocular diseases, Patent No. [WO 2012085318 A1, 2012085318]
NR 169
TC 8
Z9 9
U1 0
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 161794
DI 10.1155/2014/161794
PG 17
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AN7BF
UT WOS:000340752800001
OA gold
DA 2018-01-05
ER

PT J
AU Chang, M
   Huang, YW
   Aronstam, RS
   Lee, HJ
AF Chang, Microsugar
   Huang, Yue-Wern
   Aronstam, Robert S.
   Lee, Han-Jung
TI Cellular Delivery of Noncovalently-Associated Macromolecules by
   Cell-Penetrating Peptides
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Cellular internalization; cell-penetrating peptide; macropinocytosis;
   polyarginine; protein transduction domain; quantum dots
ID RICH INTRACELLULAR DELIVERY; HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN
   TRANSDUCTION; PLANT-CELLS; QUANTUM DOTS; IN-VIVO; MAMMALIAN-CELLS;
   RATIONAL DESIGN; PLASMA-MEMBRANE; FUSION PROTEINS
AB Cellular and nuclear delivery of biomolecules is limited by low membrane permeability. Cell-penetrating peptides (CPPs) can be covalently linked to cargos to improve cellular internalization. Our work indicates that arginine-rich CPPs are also able to interact with a variety of cargos, including DNA, RNA, proteins and nanomaterials, in a noncovalent manner and subsequently effect their delivery into cells. The advantages of noncovalent attachment in CPP-mediated transduction are multiple: ease of use, ease of production, and versatility with respect to both cargo composition and functional delivery (i.e., the cargo is not chemically modified). We have extended this approach to achieve simultaneous transduction of covalently and noncovalently associated complexes, opening a new method for delivering multiple types of cargos, including proteins, fluorescent nanomaterials, nucleic acid and others. These novel variations of CPP-mediated transport should be of broad utility in the transport of genes, small interfering RNAs, proteins and nanoparticles in biomedical research and therapeutic intervention.
C1 [Chang, Microsugar] Hung Kuang Univ, Dept Biotechnol, Taichung 43302, Taiwan.
   [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
   [Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, 1,Sec 2,Da Hsueh Rd, Hualien 97401, Taiwan.
EM hjlee@mail.ndhu.edu.tw
FU Ministry of Science and Technology, Taiwan [NSC101-2320-B-259-002-MY3]
FX This work was supported by the Grant Number NSC101-2320-B-259-002-MY3
   from the Ministry of Science and Technology, Taiwan (to H.-J. Lee).
CR Aubry S, 2010, BBA-BIOMEMBRANES, V1798, P2182, DOI 10.1016/j.bbamem.2009.11.011
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen J, 2006, BIOCHEM BIOPH RES CO, V347, P931, DOI 10.1016/j.bbrc.2006.06.173
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   DOWDY SF, 2005, EXPERT OPIN DRUG DEL, V2, P43
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Schmidt S., 2014, J CONTROL R IN PRESS
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   Gauram A., 2013, J TRANSL MED, V11, P74
   Gautam A., 2012, DATABASE, V2012
   Goda N, 2007, BBA-MOL CELL RES, V1773, P141, DOI 10.1016/j.bbamcr.2006.11.016
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Holton TA, 2013, BIOINFORMATICS, V29, P3094, DOI 10.1093/bioinformatics/btt518
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Huang YZ, 2013, ADV DRUG DELIVER REV, V65, P1299, DOI 10.1016/j.addr.2012.11.007
   Huang Yue-Wern, 2013, Methods Mol Biol, V991, P249, DOI 10.1007/978-1-62703-336-7_23
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Nakakubo H., 2009, INT J MOL MED, V25, P41
   Karagiannis ED, 2013, ACS NANO, V7, P8616, DOI 10.1021/nn4027382
   Kilk K, 2009, TOXICOLOGY, V265, P87, DOI 10.1016/j.tox.2009.09.016
   Kim D, 2006, EXP CELL RES, V312, P1277, DOI 10.1016/j.yexcr.2005.12.029
   Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012
   LI JC, 2010, ACTA BOT BOREALI-OCC, V30, P30
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6                                                   
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2013, COLLOID SURFACE B, V111, P162, DOI 10.1016/j.colsurfb.2013.05.038
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067100
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205
   Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2013, MAR BIOTECHNOL, V15, P584, DOI 10.1007/s10126-013-9509-0
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   Huang Y. W., 2014, J NANOSCI N IN PRESS
   LIU BR, 2013, ADV STUD BIOL, V5, P11
   Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   LIU MJ, 2013, ADV STUD BIOL, V5, P71
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Mae M, 2009, EXPERT OPIN DRUG DEL, V6, P1195, DOI 10.1517/17425240903213688
   Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065
   Margus H, 2012, MOL THER, V20, P525, DOI 10.1038/mt.2011.284
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nath A, 1996, J VIROL, V70, P1475
   Nomura T, 2007, PHARMAZIE, V62, P569, DOI 10.1691/ph.2007.8.6278
   Regberg J, 2014, INT J PHARMACEUT, V464, P111, DOI 10.1016/j.ijpharm.2014.01.018
   Reuter M, 2009, BIOPHYS CHEM, V144, P27, DOI 10.1016/j.bpc.2009.06.002
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Mishra A., 2009, FEBS LETT, V584, P1806
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shin MC, 2014, J BIOMED MATER RES A, V102, P575, DOI 10.1002/jbm.a.34859
   Shokolenko IN, 2005, DNA REPAIR, V4, P511, DOI 10.1016/j.dnarep.2004.11.009
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160                                                         
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   D'Souza G. G., 2003, P NATL ACAD SCI USA, V100, P1972
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Unnamalai N, 2004, FEBS LETT, V566, P307, DOI 10.1016/j.febslet.2004.04.018
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020
   Wang WW, 2013, CURR PHARM BIOTECHNO, V14, P46
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   WU GY, 1987, J BIOL CHEM, V262, P4429
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
NR 89
TC 9
Z9 9
U1 6
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2014
VL 15
IS 3
BP 267
EP 275
DI 10.2174/1389201015666140617095415                                       
          
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AN6OU
UT WOS:000340715300009
PM 24938892
DA 2018-01-05
ER

PT J
AU Wei, L
   Yang, QY
   Xiao, LH
AF Wei, Lin
   Yang, Qiaoyu
   Xiao, Lehui
TI Tempo-spatially resolved cellular dynamics of human immunodeficiency
   virus transacting activator of transcription (Tat) peptide-modified
   nanocargos in living cells
SO NANOSCALE
LA English
DT Article
ID MODIFIED GOLD NANOPARTICLES; PENETRATING PEPTIDES; INTRACELLULAR
   DELIVERY; METAL NANOPARTICLES; MAMMALIAN-CELLS; DRUG-DELIVERY; SIZE;
   INTERNALIZATION; MECHANISM; MEMBRANE
AB Understanding the cellular uptake mechanism and intracellular fate of nanocarriers in living cells is of great importance for the rational design of efficient drug delivery cargos as well as the development of robust biomedical diagnostic probes. In present study, with a dual wavelength view darkfield microscope (DWVD), the tempo-spatially resolved dynamics of Tat peptide-functionalized gold nanoparticles (TGNPs, with size similar to viruses) in living HeLa cells were extensively explored. It was found that energy-dependent endocytosis (both clathrin-and caveolae-mediated processes were involved) was the prevailing pathway for the cellular uptake of TGNPs. The time-correlated dynamic spatial distribution information revealed that TGNPs could not actively target the cell nuclei, which is contrary to previous observations based on fixed cell results. More importantly, the inheritance of TGNPs to the daughter cells through mitosis was found to be the major route to metabolize TGNPs by HeLa cells. These understandings on the cellular uptake mechanism and intracellular fate of nanocargos in living cells would provide deep insight on how to improve and controllably manipulate their translocation efficiency for targeted drug delivery.
C1 [Wei, Lin; Yang, Qiaoyu; Xiao, Lehui] Hunan Normal Univ, Key Lab Phytochem Res & Dev Hunan Prov, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ,Coll Chem & Chem Engn, Changsha 410081, Hunan, Peoples R China.
RP Xiao, LH (reprint author), Hunan Normal Univ, Key Lab Phytochem Res & Dev Hunan Prov, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ,Coll Chem & Chem Engn, Changsha 410081, Hunan, Peoples R China.
EM lehuixiao@gmail.com
FU NSFC [21205037, 20927005, 21275049]; Program for New Century Excellent
   Talents in University (China) [NCET-13-0789]; Hunan Natural Science
   Funds for Distinguished Young Scholar [14JJ1017]; aid program for
   science and technology innovation research team in higher education
   institutions of Hunan Province
FX This work was supported by NSFC (21205037, 20927005, 21275049), Program
   for New Century Excellent Talents in University (China, NCET-13-0789),
   Hunan Natural Science Funds for Distinguished Young Scholar (14JJ1017),
   and the aid program for science and technology innovation research team
   in higher education institutions of Hunan Province.
CR Alvarez YD, 2013, NANO LETT, V13, P6156, DOI 10.1021/nl403490e
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Brandenberger C, 2010, SMALL, V6, P1669, DOI 10.1002/smll.201000528
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cho EC, 2010, SMALL, V6, P517, DOI 10.1002/smll.200901622
   Ciobanasu C, 2010, BIOPHYS J, V99, P153, DOI 10.1016/j.bpj.2010.03.065
   Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Eustis S, 2006, CHEM SOC REV, V35, P209, DOI 10.1039/b514191e
   Faraji AH, 2009, BIOORGAN MED CHEM, V17, P2950, DOI 10.1016/j.bmc.2009.02.043
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Han G, 2006, ANGEW CHEM INT EDIT, V45, P3165, DOI 10.1002/anie.200600214
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Krpetic Z, 2011, ACS NANO, V5, P5195, DOI 10.1021/nn201369k
   Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u
   Nan XL, 2008, CHEMPHYSCHEM, V9, P707, DOI 10.1002/cphc.200700839
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   Oh E, 2011, ACS NANO, V5, P6434, DOI 10.1021/nn201624c
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Rajendran L, 2010, NAT REV DRUG DISCOV, V9, P29, DOI 10.1038/nrd2897
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   van Dijk MA, 2006, PHYS CHEM CHEM PHYS, V8, P3486, DOI 10.1039/b606090k
   Wei L, 2013, ANAL CHEM, V85, P5169, DOI 10.1021/ac400503z
   Wong BS, 2013, ADV DRUG DELIVER REV, V65, P1964, DOI 10.1016/j.addr.2013.08.005
   Xiao LH, 2012, ANGEW CHEM INT EDIT, V51, P4181, DOI 10.1002/anie.201108647
   Xiao LH, 2011, ANAL CHEM, V83, P7340, DOI 10.1021/ac2012366
   Xiao LH, 2010, ANAL CHEM, V82, P6308, DOI 10.1021/ac101018v
   Xiao LH, 2009, J PHYS CHEM C, V113, P1209, DOI 10.1021/jp807776w
   Yuan H, 2012, J AM CHEM SOC, V134, P11358, DOI 10.1021/ja304180y
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 51
TC 6
Z9 6
U1 3
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2014
VL 6
IS 17
BP 10207
EP 10215
DI 10.1039/c4nr02732a
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AN3WX
UT WOS:000340520500041
PM 25051531
DA 2018-01-05
ER

PT J
AU Vacas-Cordoba, E
   Galan, M
   de la Mata, FJ
   Gomez, R
   Pion, M
   Munoz-Fernandez, MA
AF Vacas-Cordoba, Enrique
   Galan, Marta
   de la Mata, Francisco J.
   Gomez, Rafael
   Pion, Marjorie
   Angeles Munoz-Fernandez, M.
TI Enhanced activity of carbosilane dendrimers against HIV when combined
   with reverse transcriptase inhibitor drugs: searching for more potent
   microbicides
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE microbicides; HIV; carbosilane dendrimer; antiretroviral; synergy
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUAL TRANSMISSION; TOPICAL
   MICROBICIDES; SYNERGISTIC ACTIVITY; PROTEASE INHIBITORS; RHESUS
   MACAQUES; EARLY EVENTS; IN-VITRO; COMBINATION; PREVENTION
AB Self-administered topical microbicides or oral preexposure prophylaxis could be very helpful tools for all risk groups to decrease the human immunodeficiency virus (HIV)-1 infection rates. Up until now, antiretrovirals (ARVs) have been the most advanced microbicide candidates. Nevertheless, the majority of clinical trials has failed in HIV-1 patients. Nanotechnology offers suitable approaches to develop novel antiviral agents. Thereby, new nanosystems, such as carbosilane dendrimers, have been shown to be safe and effective compounds against HIV with great potential as topical microbicides. In addition, because most of the attempts to develop effective topical microbicides were unsuccessful, combinatorial strategies could be a valid approach when designing new microbicides. We evaluated various combinations of anionic carbosilane dendrimers with sulfated (G3-S16) and naphthyl sulfonated (G2-NF16) ended groups with different ARVs against HIV-1 infection. The G3-S16 and G2-NF16 dendrimers showed a synergistic or additive activity profile with zidovudine, efavirenz, and tenofovir in the majority of the combinations tested against the X4 and R5 tropic HIV-1 in cell lines, as well as in human primary cells. Therefore, the combination of ARVs and polyanionic carbosilane dendrimers enhances the antiviral potency of the individual compounds, and our findings support further clinical research on combinational approaches as potential microbicides to block the sexual transmission of HIV-1.
C1 [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, M.] Univ Gregorio Maranon, Gen Hosp, Lab InmunoBiol Mol, Madrid 28007, Spain.
   [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, M.] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Vacas-Cordoba, Enrique; Galan, Marta; de la Mata, Francisco J.; Gomez, Rafael; Pion, Marjorie; Angeles Munoz-Fernandez, M.] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Madrid, Spain.
   [Galan, Marta; de la Mata, Francisco J.; Gomez, Rafael] Univ Alcala De Henares, Dendrimers Biomed Applicat Grp BioInDen, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Univ Gregorio Maranon, Gen Hosp, CIBER BBN, Lab InmunoBiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
RI Pion, Marjorie/D-8139-2012; Gomez Ramirez, Rafael/K-1216-2014
OI Pion, Marjorie/0000-0002-6406-747X; Gomez Ramirez,
   Rafael/0000-0001-6448-2414; Pion, Marjorie/0000-0003-1828-4745;
   Munoz-Fernandez/0000-0002-0813-4500
FU Fondos de Investigacion Sanitaria ISCIII [INTRASALUD PI09/02029,
   PI13/02016, PI12_01763]; Red Tematica de Investigacion Cooperativa
   Sanitaria ISCIII [RETIC RD06/0006/0035, RD12-0017-0037, RD09-0076-00103,
   PT13-0010-0028]; Consorcium INDISNET [S-2011-BMD2332]; CYTED
   [P213RT0409]; FIPSE; MEyC [CTQ2011-23245]; Consorcium NANODENDMED
   [S2011/BMD-2351]; CYTED; CIBER-BBN; Spanish Ministerio de Ciencia e
   Innovacion (MICINN) through the Ramon y Cajal [RYC-2009-05486]; Red
   Nacional de Biobancos [RD09/0076/00103]
FX This work was supported by grants from: Fondos de Investigacion
   Sanitaria ISCIII (INTRASALUD PI09/02029, PI13/02016); Red Tematica de
   Investigacion Cooperativa Sanitaria ISCIII (RETIC RD06/0006/0035 and
   RD12-0017-0037, RD09-0076-00103, PT13-0010-0028); Consorcium INDISNET
   S-2011-BMD2332 (Comunidad de Madrid [CM]); CYTED (P213RT0409), and FIPSE
   to MA Munoz-Fernandez and by fellowships from CTQ2011-23245 (MEyC),
   Consorcium NANODENDMED S2011/BMD-2351 (CM), CYTED and CIBER-BBN to the
   University of Alcala. M Pion is supported by Spanish Ministerio de
   Ciencia e Innovacion (MICINN) through the Ramon y Cajal (RYC-2009-05486)
   and by Fondos de Investigacion Sanitaria ISCIII (PI12_01763). We would
   like to acknowledge the Centre of Transfusion of Madrid for the buffy
   coats and the HIV HGM Spanish BioBank (Hospital General Universitario
   Gregorio Maranon, Madrid, Spain) for processing these buffy coats. The
   Spanish HIV HGM Biobank is supported by Red Nacional de Biobancos
   RD09/0076/00103.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Arnaiz E, 2014, J POLYM SCI POL CHEM, V52, P1099, DOI 10.1002/pola.27090
   Barouch DH, 2012, P NATL ACAD SCI USA, V109, P8694, DOI 10.1073/pnas.1203183109
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   De Clercq E, 2012, BIOCHEM PHARMACOL, V84, P241, DOI 10.1016/j.bcp.2012.03.024
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Grivel JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S6
   Ham AS, 2012, J PHARM SCI-US, V101, P1423, DOI 10.1002/jps.23026
   Herrera C, 2012, CURR HIV RES, V10, P42, DOI 10.2174/157016212799304607
   *JOINT UN PROGR HI, 2013, GLOB REP UNAIDS REP
   Karim SSA, 2010, INDIAN J MED RES, V132, P656
   Li LZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037381
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Miller CJ, 1999, J INFECT DIS, V179, pS413, DOI 10.1086/314795
   Neff CP, 2011, PLOS ONE, V6
   Nel AM, 2010, AIDS RES HUM RETROV, V26, P1181, DOI 10.1089/aid.2009.0227
   Patton DL, 2007, ANTIMICROB AGENTS CH, V51, P1608, DOI 10.1128/AAC.00984-06
   Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Pirrone V, 2011, ANTIMICROB AGENTS CH, V55, P1831, DOI 10.1128/AAC.00976-10
   Platt EJ, 1998, J VIROL, V72, P2855
   Saba E, 2010, MUCOSAL IMMUNOL, V3, P280, DOI 10.1038/mi.2010.2
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Shattock RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007385
   Stefanidou M, 2012, ANTIMICROB AGENTS CH, V56, P4381, DOI 10.1128/AAC.00399-12
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Vanpouille C, 2012, TRENDS MICROBIOL, V20, P369, DOI 10.1016/j.tim.2012.05.005
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Vermeire K, 2004, AIDS, V18, P2115, DOI 10.1097/00002030-200411050-00003
NR 34
TC 12
Z9 12
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2014
VL 9
BP 3591
EP 3600
DI 10.2147/IJN.S62673
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA AM4UW
UT WOS:000339852400002
PM 25114528
OA gold
DA 2018-01-05
ER

PT J
AU Okada, H
   Ogawa, T
   Tanaka, K
   Kanazawa, T
   Takashima, Y
AF Okada, H.
   Ogawa, T.
   Tanaka, K.
   Kanazawa, T.
   Takashima, Y.
TI Cytoplasm-responsive delivery systems for siRNA using cell-penetrating
   peptide nanomicelles
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Review
DE DNA vaccine; siRNA therapy; Local and systemic delivery; Polymer
   micelles; Functional cell-penetrating peptide; Cytoplasm-responsive
   nanocarriers
ID ARGININE-RICH PEPTIDES; INTERFERENCE-BASED THERAPEUTICS; POLYMERIC
   MICELLE FORMULATION; HUMAN IMMUNODEFICIENCY VIRUS; LOCAL
   GENE-EXPRESSION; PHASE-II TRIAL; DRUG-DELIVERY; RNA-INTERFERENCE;
   TRANSFECTION EFFICIENCY; INTESTINAL-ABSORPTION
AB Arginine-rich cell-penetrating peptides (CPPs) involved in the uptake of large molecules such as proteins. nucleotides and even nanoparticles are non-viral carriers for nucleotides. The core-shell-type polyion complexes with a disulfide cross-linked siRNA to poly(L-lysine) or poly(aspartic acid) respond to a reducing environment and achieve higher siRNA transfection efficiency. We synthesized a stable analog of transactivator of transcription (Tat) and a cytoplasm-responsive CPP, CH2R4H2C (C. cysteine [Cys]; H. histamine [His]; R. arginine [Arg]). having 2 Cys residues (for physically trapping in micelles by disulfide linkage): we conjugated the CPP with stearic acid for topical administration or with methoxy poly(ethylene glycol)-block-poly(epsilon-caprolactone) for sustained systemic circulation. Nucleotides were rigidly shielded in the surface of nanomicelles, protected against nucleases in the blood, and persistently released into the reductive environment of the cytoplasm (glutathione, 0.5-10 mM). In this review, we describe DNA vaccination and delivery of siRNA into the cytoplasm using these functional CPP-conjugated nanomicelles.
C1 [Okada, H.] Okada DDS Res Inst Inc, Hachioji, Tokyo 1920375, Japan.
   [Ogawa, T.; Tanaka, K.; Kanazawa, T.; Takashima, Y.] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Pharmaceut & Drug Delivery, Hachioji, Tokyo 1920392, Japan.
RP Okada, H (reprint author), Okada DDS Res Inst Inc, 2-83-2-1108 Yarimizu, Hachioji, Tokyo 1920375, Japan.
EM okada@toyaku.ac.jp
CR Amand HL, 2012, BIOCHEM BIOPH RES CO, V418, P469, DOI 10.1016/j.bbrc.2012.01.041
   Aroui S, 2010, BIOCHEM BIOPH RES CO, V391, P419, DOI 10.1016/j.bbrc.2009.11.073
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Biswas S, 2013, EUR J PHARM BIOPHARM, V84, P517, DOI 10.1016/j.ejpb.2012.12.021
   Biswas S, 2013, CANCER LETT, V335, P191, DOI 10.1016/j.canlet.2013.02.020
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Dickerson EB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-10
   Dou S, 2012, J CONTROL RELEASE, V161, P875, DOI 10.1016/j.jconrel.2012.05.015
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Fougerolles AD, 2007, NAT REV DRUG DISCOV, V6, P443
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Furuhata M, 2008, J NANOSCI NANOTECHNO, V8, P2308, DOI 10.1166/jnn.2008.170
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Goun EA, 2006, CHEMBIOCHEM, V7, P1497, DOI 10.1002/cbic.200600171
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0
   Guo PX, 2010, ADV DRUG DELIVER REV, V62, P650, DOI 10.1016/j.addr.2010.03.008
   Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515
   Kanazawa T, 2008, INT J PHARM, V360, P164, DOI 10.1016/j.ijpharm.2008.04.038
   Kanazawa T, 2013, INT J PHARMACEUT, V447, P70, DOI 10.1016/j.ijpharm.2013.02.018
   Kanazawa T, 2012, EUR J PHARM BIOPHARM, V81, P470, DOI 10.1016/j.ejpb.2012.04.021
   Kanazawa T, 2010, INT J PHARMACEUT, V396, P11, DOI 10.1016/j.ijpharm.2010.05.040
   Khalil L. A., 2004, GENE THER, V11, P636
   Kim DW, 2007, ANN ONCOL, V18, P2009, DOI 10.1093/annonc/mdm374
   Kim SH, 2006, J CONTROL RELEASE, V116, P123, DOI 10.1016/j.jconrel.2006.05.023
   Kim TI, 2009, BIOMATERIALS, V30, P658, DOI 10.1016/j.biomaterials.2008.10.009
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Lee KS, 2008, BREAST CANCER RES TR, V108, P241, DOI 10.1007/s10549-007-9591-y
   Liu PF, 2012, BIOMATERIALS, V33, P4403, DOI 10.1016/j.biomaterials.2012.02.041
   Liu XL, 2013, INT J PHARMACEUT, V448, P159, DOI 10.1016/j.ijpharm.2013.03.033
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lopez-Fraga M., 2008, Infectious Disorders - Drug Targets, V8, P262
   Malhotra M, 2013, BIOMATERIALS, V34, P1270, DOI 10.1016/j.biomaterials.2012.10.013
   Mao CQ, 2011, BIOMATERIALS, V32, P3124, DOI 10.1016/j.biomaterials.2011.01.006
   Matsumoto S, 2009, BIOMACROMOLECULES, V10, P119, DOI 10.1021/bm800985e
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Matsumura Y, 2004, BRIT J CANCER, V91, P1775, DOI 10.1038/sj.bjc.6602204
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Mithchel D. J., 2000, J REPT RES, V56, P318
   Morishita M, 2007, J CONTROL RELEASE, V118, P177, DOI 10.1016/j.jconrel.2006.12.022
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Orlacchio A, 2007, MINI-REV MED CHEM, V7, P1166, DOI 10.2174/138955707782331678
   Ponnappa BC, 2009, CURR OPIN INVEST DR, V10, P418
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Saito G, 2003, ADV DRUG DELIVER REV, V55, P199, DOI 10.1016/S0169-409X(02)00179-5                                                   
   Salomone F, 2012, J CONTROL RELEASE, V163, P293, DOI 10.1016/j.jconrel.2012.09.019
   Segura T, 2007, BIOCONJUGATE CHEM, V18, P736, DOI 10.1021/bc060284y
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Song KH, 2008, EUR J PHARM BIOPHARM, V69, P231, DOI 10.1016/j.ejpb.2007.10.011
   Takemoto H, 2010, BIOMATERIALS, V31, P8097, DOI 10.1016/j.biomaterials.2010.07.015
   Tanaka K, 2013, INT J PHARMACEUT, V455, P40, DOI 10.1016/j.ijpharm.2013.07.069
   Tanaka K, 2011, CHEM PHARM BULL, V59, P202, DOI 10.1248/cpb.59.202
   Tanaka K, 2010, INT J PHARMACEUT, V398, P219, DOI 10.1016/j.ijpharm.2010.07.038
   Tanaka K, 2010, INT J PHARMACEUT, V396, P229, DOI 10.1016/j.ijpharm.2010.06.028
   Tonges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Uchida T., 2011, CHEM PHARM BULL, V59, P195
   Uchida T, 2011, J PHARMACOL EXP THER, V338, P443, DOI 10.1124/jpet.111.180042
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Walrant A, 2011, BBA-BIOMEMBRANES, V1808, P382, DOI 10.1016/j.bbamem.2010.09.009
   Wooddell CI, 2013, MOL THER, V21, P973, DOI 10.1038/mt.2013.31
   Xia HM, 2011, BIOMATERIALS, V32, P9888, DOI 10.1016/j.biomaterials.2011.09.004
   Zhang ZH, 2012, INT J NANOMED, V7, P3333, DOI 10.2147/IJN.S31711
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 78
TC 3
Z9 4
U1 4
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PY 2014
VL 24
IS 1
BP 3
EP 11
DI 10.1016/S1773-2247(14)50001-9                                           
          
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AM5VI
UT WOS:000339928700001
DA 2018-01-05
ER

PT J
AU Krishnaraj, RN
   Chandran, S
   Pal, P
   Berchmans, S
AF Krishnaraj, R. Navanietha
   Chandran, Saravanan
   Pal, Parimal
   Berchmans, Sheela
TI Investigations on the Antiretroviral Activity of Carbon Nanotubes Using
   Computational Molecular Approach
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article
DE Binding affinity; Graphene; HIV; immobilization; therapeutic potential
ID BIOMEDICAL APPLICATIONS; IN-VITRO; PROTEIN; NANOPARTICLES; CYTOTOXICITY;
   INHIBITOR; BINDING; HIV
AB Carbon nanotubes are the interesting class of materials with wide range of applications. They have excellent physical, chemical and electrical properties. Numerous reports were made on the antiviral activities of carbon nanotubes. However the mechanism of antiviral action is still in infancy. Herein we report, our recent novel findings on the molecular interactions of carbon nanotubes with the three key target proteins of HIV using computational chemistry approach. Armchair, chiral and zigzag CNTs were modeled and used as ligands for the interaction studies. The structure of the key proteins involved in HIV mediated infection namely HIV- Vpr, Nef and Gag proteins were collected from the PDB database. The docking studies were performed to quantify the interaction of the CNT with the three different disease targets. Results showed that the carbon nanotubes had high binding affinity to these proteins which confirms the antagonistic molecular interaction of carbon nanotubes to the disease targets. The modeled armchair carbon nanotubes had the binding affinities of -12.4 Kcal/mole, -20 Kcal/mole and -11.7 Kcal/mole with the Vpr, Nef and Gag proteins of HIV. Chiral CNTs also had the maximum affinity of -16.4 Kcal/mole to Nef. The binding affinity of chiral CNTs to Vpr and Gag was found to be -10.9 Kcal/mole and -10.3 Kcal/mole respectively. The zigzag CNTs had the binding affinity of -11.1 Kcal/mole with Vpr, -18.3 Kcal/mole with Nef and -10.9 with Gag respectively. The strong molecular interactions suggest the efficacy of CNTs for targeting the HIV mediated retroviral infections.
C1 [Krishnaraj, R. Navanietha; Pal, Parimal] Natl Inst Technol, Dept Chem Engn, Durgapur, W Bengal, India.
   [Chandran, Saravanan] Natl Inst Technol, Ctr Comp, Durgapur, W Bengal, India.
   [Berchmans, Sheela] CSIR, Cent Electrochem Res Inst, Karaikkudi, Tamil Nadu, India.
RP Krishnaraj, RN (reprint author), Natl Inst Technol, Dept Chem Engn, Durgapur, W Bengal, India.
EM biotecnkr@gmail.com
CR Barone Paul W, 2009, J Diabetes Sci Technol, V3, P242
   Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928
   Bukrinsky M., VIRLA PROTEIN R HIV
   Chen BD, 2013, CURR APPL PHYS, V13, P1001, DOI 10.1016/j.cap.2013.02.004
   Cirillo G, 2011, J PHARM PHARMACOL, V63, P179, DOI 10.1111/j.2042-7158.2010.01211.x
   Fan ZJ, 2010, ADV MATER, V22, P3723, DOI 10.1002/adma.201001029
   Fourches D, 2011, COMB CHEM HIGH T SCR, V14, P217, DOI 10.2174/138620711794728743
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108
   Gomez-Gualdron DA, 2011, PROG MOL BIOL TRANSL, V104, P175, DOI 10.1016/B978-0-12-416020-0.00005-X
   Gong KP, 2009, SCIENCE, V323, P760, DOI 10.1126/science.1168049
   Ittisanronnachai S, 2008, CARBON, V46, P1361, DOI 10.1016/j.carbon.2008.05.013
   Ji H, 2008, J HUAZHONG U SCI-MED, V28, P243, DOI 10.1007/s11596-008-0303-6
   Kogan M, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-25
   Krishnaraj RN, 2013, RSC ADV, V3, P8953, DOI 10.1039/c3ra41246f
   Laurie ATR, 2005, BIOINFORMATICS, V21, P1908, DOI 10.1093/bioinformatics/bti315
   Liu K, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/4/045708
   Meng LJ, 2012, BIOMATERIALS, V33, P1689, DOI 10.1016/j.biomaterials.2011.11.004
   Quaranta MG, 2009, BIOFACTORS, V35, P169, DOI 10.1002/biof.28
   Reddy ALM, 2010, ACS NANO, V4, P6337, DOI 10.1021/nn101926g
   Roldo M, 2013, ANNU REP PROG CHEM C, V109, P10, DOI 10.1039/c3pc90010j
   Saikia N, 2013, J COMPUT AID MOL DES, V27, P257, DOI 10.1007/s10822-013-9638-6
   Samori C, 2010, CHEM COMMUN, V46, P1494, DOI 10.1039/b923560d
   Scopelliti PE, 2011, COMB CHEM HIGH T SCR, V14, P206
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vecitis CD, 2010, ACS NANO, V4, P5471, DOI 10.1021/nn101558x
   Zhang ZS, 2013, BIOCHEM BIOPH RES CO, V436, P650, DOI 10.1016/j.bbrc.2013.06.009
NR 27
TC 1
Z9 1
U1 6
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386-2073
EI 1875-5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PY 2014
VL 17
IS 6
BP 531
EP 535
DI 10.2174/1386207317666140116110558
PG 5
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA AL0WU
UT WOS:000338848600006
PM 24433396
DA 2018-01-05
ER

PT J
AU Vistas, CR
   Soares, SS
   Rodrigues, RMM
   Chu, V
   Conde, JP
   Ferreira, GNM
AF Vistas, Claudia R.
   Soares, Sandra S.
   Rodrigues, Rogerio M. M.
   Chu, Virginia
   Conde, Joao P.
   Ferreira, Guilherme N. M.
TI An amorphous silicon photodiode microfluidic chip to detect nanomolar
   quantities of HIV-1 virion infectivity factor
SO ANALYST
LA English
DT Article
ID SURFACE-PLASMON RESONANCE; CHAIN VARIABLE FRAGMENT; VIF PROTEIN;
   ANTIBODIES; BIOSENSORS; SYSTEMS
AB A hydrogenated amorphous silicon (a-Si: H) photosensor was explored for the quantitative detection of a HIV-1 virion infectivity factor (Vif) at a detection limit in the single nanomolar range. The a-Si: H photosensor was coupled with a microfluidic channel that was functionalized with a recombinant single chain variable fragment antibody. The biosensor selectively recognizes HIV-1 Vif from human cell extracts.
C1 [Vistas, Claudia R.; Soares, Sandra S.; Rodrigues, Rogerio M. M.; Ferreira, Guilherme N. M.] Univ Algarve, IBB, Ctr Mol & Struct Biomed CBME, P-8000139 Faro, Portugal.
   [Chu, Virginia; Conde, Joao P.] INESC Microsistemas & Nanotecnol, P-1000029 Lisbon, Portugal.
   [Chu, Virginia; Conde, Joao P.] IN Inst Nanosci & Nanotechnol, P-1000029 Lisbon, Portugal.
   [Conde, Joao P.] Inst Super Tecn, Dept Chem & Biol Engn, P-1049001 Lisbon, Portugal.
RP Ferreira, GNM (reprint author), Univ Algarve, IBB, Ctr Mol & Struct Biomed CBME, Campus Gambelas, P-8000139 Faro, Portugal.
EM gferrei@ualg.pt
RI Chu, Virginia/I-6048-2014; Vistas, Claudia/B-6396-2015
OI Chu, Virginia/0000-0002-5306-4409; Vistas, Claudia/0000-0001-9370-1997;
   Conde, Joao Pedro/0000-0002-5677-3024
FU Fundacao para a Ciencia e a Tecnologia (FCT) [PTDC/EBB-EBI/108517,
   PEst-OE/EQB/LA0023/2011, PEst-OE/CTM/LA0024/2013, SFRH/BD/39278/2007,
   SFRH/BPD/30290/2006, SFRH/BD/38136/2007]
FX This work was supported by Fundacao para a Ciencia e a Tecnologia (FCT)
   through research project PTDC/EBB-EBI/108517, project ref.
   PEst-OE/EQB/LA0023/2011 and PEst-OE/CTM/LA0024/2013, and grants
   SFRH/BD/39278/2007, SFRH/BPD/30290/2006 and SFRH/BD/38136/2007.
CR Chediak JA, 2004, SENSOR ACTUAT A-PHYS, V111, P1, DOI 10.1016/j.sna.2003.10.015
   Chen YT, 2010, CANCER IMMUNOL IMMUN, V59, P933, DOI 10.1007/s00262-010-0819-z
   Encarnacao JM, 2007, J BIOTECHNOL, V132, P142, DOI 10.1016/j.jbiotec.2007.04.010
   Ferreira GNM, 2007, BIOSENS BIOELECTRON, V23, P384, DOI 10.1016/j.bios.2007.04.022
   Ferreira GNM, 2009, TRENDS BIOTECHNOL, V27, P689, DOI 10.1016/j.tibtech.2009.09.003
   Gai HW, 2011, TOP CURR CHEM, V304, P171, DOI 10.1007/128_2011_144
   Gervais T, 2006, CHEM ENG SCI, V61, P1102, DOI 10.1016/j.ces.2005.06.024
   GONCALVES J, 1994, J VIROL, V68, P704
   Goncalves J, 2002, J BIOL CHEM, V277, P32036, DOI 10.1074/jbc.M201906200
   Ha TH, 2007, ANAL CHEM, V79, P546, DOI 10.1021/ac061639+
   Jones DB, 2004, PROTEOMICS, V4, P1007, DOI 10.1002/pmic.200300662
   Novo P, 2011, LAB CHIP, V11, P4063, DOI 10.1039/c1lc20362b
   Pelat T, 2007, ANTIMICROB AGENTS CH, V51, P2758, DOI 10.1128/AAC.01528-06
   Pereira AT, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3553014
   Pimentel AC, 2009, J APPL PHYS, V106, DOI 10.1063/1.3259389
   Pimentel AC, 2008, J APPL PHYS, V104, DOI 10.1063/1.2976343
   Pimentel AC, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3122345
   Smith JL, 2009, TRENDS PHARMACOL SCI, V30, P638, DOI 10.1016/j.tips.2009.09.006
   Squires TM, 2008, NAT BIOTECHNOL, V26, P417, DOI 10.1038/nbt1388
   Vistas CR, 2013, APPL SURF SCI, V286, P314, DOI 10.1016/j.apsusc.2013.09.077
   Yuk JS, 2006, BIOSENS BIOELECTRON, V21, P1521, DOI 10.1016/j.bios.2005.07.009
   Zhuang GQ, 2001, J BIOSCI BIOENG, V92, P330, DOI 10.1263/jbb.92.330                                                              
NR 22
TC 5
Z9 5
U1 1
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2014
VL 139
IS 15
BP 3709
EP 3713
DI 10.1039/c4an00695j
PG 5
WC Chemistry, Analytical
SC Chemistry
GA AK7ZO
UT WOS:000338647100007
PM 24922601
DA 2018-01-05
ER

PT J
AU Frank, LA
   Sandri, G
   D'Autilia, F
   Contri, RV
   Bonferoni, MC
   Caramella, C
   Frank, AG
   Pohlmann, AR
   Guterres, SS
AF Frank, Luiza A.
   Sandri, Giuseppina
   D'Autilia, Francesca
   Contri, Renata V.
   Bonferoni, Maria Cristina
   Caramella, Carla
   Frank, Alejandro G.
   Pohlmann, Adriana R.
   Guterres, Silvia S.
TI Chitosan gel containing polymeric nanocapsules: a new formulation for
   vaginal drug delivery
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE Eudragit (R) RS 100; Eudragit (R) S 100; vaginal route; nanotechnology
ID IN-VITRO EVALUATION; MUCOADHESIVE GELS; HIV PREVENTION; NANOPARTICLES;
   CAPSAICINOIDS; RELEASE; WASHABILITY; INHIBITION; DEPOSITION; HYDROGEL
AB The vaginal route of administration is an alternative for several treatments for either local or systemic pharmacological effects. However, the permanence of a drug in this route represents a challenge for formulation development that can be overcome by using nanoencapsulation and chitosan gel. Thus, this work aimed to evaluate the performance of chitosan hydrogels containing cationic and anionic acrylic-based nanocapsules (Eudragit (R) RS 100 and Eudragit (R) S 100, respectively) with Nile red as a model of lipophilic substance in the vaginal route of administration, as measured by increases in the residence time and the penetration of these formulations. Several formulations were prepared with increasing chitosan concentrations, and were analyzed in terms of pH and rheological behavior so that the most suitable formulation could be selected. The enhancement of the adhesion (tensile stress test and washability profile) and penetration (confocal laser scanning microscopy and extraction followed by quantification) properties of the formulations, when applied to porcine vaginal mucosa, were evaluated. The nanocapsule suspensions produced presented adequate properties: size of approximately 200 nm (polydispersity index of <= 0.2); zeta potential around +10 mV for the cationic formulation and -10 mV for the anionic formulation; and pH values of 6.1 +/- 0.1 (Eudragit RS 100), 5.3 +/- 0.2 (Eudragit S 100), 6.2 +/- 0.1 (Nile red loaded Eudragit RS 100), and 5.1 +/- 0.1 (Nile red loaded Eudragit S 100). The chitosan formulation presented suitable viscosity for vaginal application and acidic pH (approximately 4.5). The tensile stress test showed that both formulations containing polymeric nanocapsules presented higher mucoadhesion when compared with the formulation without nanocapsules. In the washability experiment, no significant differences were found between formulations. Confocal microscopy and fluorescence quantification after extraction from the mucosa showed higher penetration of Nile red when it was nanoencapsulated, particularly in cationic nanocapsules. The formulations developed based on chitosan gel vehicle at 2.5% weight/weight containing polymeric nanocapsules, especially the cationic nanocapsules, demonstrated applicability for the vaginal delivery of hydrophobic substances.
C1 [Frank, Luiza A.; Contri, Renata V.; Pohlmann, Adriana R.; Guterres, Silvia S.] Univ Fed Rio Grande do Sul, Pharmaceut Sci Grad Program, BR-90610000 Porto Alegre, RS, Brazil.
   [Sandri, Giuseppina; D'Autilia, Francesca; Bonferoni, Maria Cristina; Caramella, Carla] Univ Pavia, Dept Drug Sci, I-27100 Pavia, PV, Italy.
   [Frank, Alejandro G.] Univ Fed Rio Grande do Sul, Dept Ind Engn, BR-90610000 Porto Alegre, RS, Brazil.
RP Guterres, SS (reprint author), Univ Fed Rio Grande do Sul, Fac Farm, Av Ipiranga 2752-405, BR-90610000 Porto Alegre, RS, Brazil.
EM silvia.guterres@ufrgs.br
RI Bonferoni, Maria Cristina/G-2760-2017; Guterres, Silvia/B-6420-2015;
   Pohlmann, Adriana/B-9910-2008
OI Guterres, Silvia/0000-0002-6085-6826; Pohlmann,
   Adriana/0000-0001-5222-1807; Frank, Alejandro/0000-0001-5041-6467;
   Bonferoni, Maria Cristina/0000-0002-1194-9372; Sandri,
   Giuseppina/0000-0001-6766-9321; Frank, Luiza/0000-0002-5918-1008
FU Capes; CNPq; FAPERGS
FX The authors thank Capes, CNPq, and FAPERGS for the financial support
   received.
CR Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Bachhav YG, 2009, AAPS PHARMSCITECH, V10, P476, DOI 10.1208/s12249-009-9233-2
   Baloglu E, 2009, J PHARM PHARM SCI, V12, P312, DOI 10.18433/J3HP41                                                                 
   Berger J, 2004, EUR J PHARM BIOPHARM, V57, P19, DOI 10.1016/s0939-6411(03)00161-9
   Bonferoni MC, 2008, EUR J PHARM SCI, V33, P166, DOI 10.1016/j.ejps.2007.11.004
   Bonferoni MC, 1999, PHARM DEV TECHNOL, V4, P45, DOI 10.1081/PDT-100101338
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Contri RV, 2014, INT J NANOMED, V9, P951, DOI 10.2147/IJN.S56579
   Contri RV, 2014, J BIOMED NANOTECHNOL, V10, P820, DOI 10.1166/jbn.2014.1752
   Contri RV, 2011, J NANOSCI NANOTECHNO, V11, P2398, DOI 10.1166/jnn.2011.3521
   Contri RV, 2010, SOFT MATER, V8, P370, DOI 10.1080/1539445X.2010.525161
   Contri RV, 2010, P 12 INT MACR C SEPT
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Haas SE, 2009, INT J ANTIMICROB AG, V34, P156, DOI 10.1016/j.ijantimicag.2009.02.024
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Illum L, 2001, INT J PHARM, V222, P109, DOI 10.1016/S0378-5173(01)00708-6
   Katzer T, 2014, PHARM DEV TECHNOL, V19, P232, DOI 10.3109/10837450.2013.769569
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Patel G.M., 2011, AM J PHARMTECH RES, V1, P366
   Perioli L, 2008, COLLOID SURFACE B, V66, P141, DOI 10.1016/j.colsurfb.2008.06.005
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   Rossi S, 1999, PHARM DEV TECHNOL, V4, P55, DOI 10.1080/10837459908984224
   Sandri S, 2004, EUR J PHARM SCI, V21, P351
   Santos SS, 2013, MAT SCI ENG C-MATER, V33, P1389, DOI 10.1016/j.msec.2012.12.040
   Sayin B, 2009, EUR J PHARM SCI, V38, P362, DOI 10.1016/j.ejps.2009.08.010
   Schaffazick SR, 2005, INT J PHARMACEUT, V289, P209, DOI 10.1016/j.ijpharm.2004.11.003
   Schaffazick SR, 2003, QUIM NOVA, P1
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Valenta C, EUR J PHARM BIOPHARM, V2204, P279
   Wittaya-areekul S, 2006, INT J PHARM, V312, P113, DOI 10.1016/j.ijpharm.2006.01.003
   Zhang SL, 2010, INT J PHARMACEUT, V397, P211, DOI 10.1016/j.ijpharm.2010.07.007
NR 34
TC 19
Z9 19
U1 4
U2 26
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2014
VL 9
BP 3151
EP 3161
DI 10.2147/IJN.S62599
PG 11
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA AK3XD
UT WOS:000338357600001
PM 25061292
OA gold
DA 2018-01-05
ER

PT J
AU Abebe, LS
   Smith, JA
   Narkiewicz, S
   Oyanedel-Craver, V
   Conaway, M
   Singo, A
   Amidou, S
   Mojapelo, P
   Brant, J
   Dillingham, R
AF Abebe, Lydia Shawel
   Smith, James A.
   Narkiewicz, Sophia
   Oyanedel-Craver, Vinka
   Conaway, Mark
   Singo, Alukhethi
   Amidou, Samie
   Mojapelo, Paul
   Brant, Julia
   Dillingham, Rebecca
TI Ceramic water filters impregnated with silver nanoparticles as a
   point-of-use water-treatment intervention for HIV-positive individuals
   in Limpopo Province, South Africa: a pilot study of technological
   performance and human health benefits
SO JOURNAL OF WATER AND HEALTH
LA English
DT Article
DE ceramic water filters; Cryptosporidium parvum; HIV; point-of-use; South
   Africa
ID DIARRHEA; CRYPTOSPORIDIOSIS; MORTALITY; OUTBREAK; VIRUS
AB Waterborne pathogens present a significant threat to people living with the human immunodeficiency virus (PLWH). This study presents a randomized, controlled trial that evaluates whether a household-level ceramic water filter (CWF) intervention can improve drinking water quality and decrease days of diarrhea in PLWH in rural South Africa. Seventy-four participants were randomized in an intervention group with CWFs and a control group without filters. Participants in the CWF arm received CWFs impregnated with silver nanoparticles and associated safe-storage containers. Water and stool samples were collected at baseline and 12 months. Diarrhea incidence was self-reported weekly for 12 months. The average diarrhea rate in the control group was 0.064 days/week compared to 0.015 days/week in the intervention group (p < 0.001, Mann-Whitney). Median reduction of total coliform bacteria was 100% at enrollment and final collection. CWFs are an acceptable technology that can significantly improve the quality of household water and decrease days of diarrhea for PLWH in rural South Africa.
C1 [Abebe, Lydia Shawel; Smith, James A.] Univ Virginia, Dept Civil & Environm Engn, Charlottesville, VA 22908 USA.
   [Narkiewicz, Sophia; Oyanedel-Craver, Vinka] Univ Rhode Isl, Dept Civil Engn, Kingston, RI 02881 USA.
   [Conaway, Mark] Univ Virginia, Dept Publ Hlth Sci, Publ Hlth Sci Hosp West, Charlottesville, VA 22908 USA.
   [Singo, Alukhethi; Amidou, Samie; Mojapelo, Paul] Univ Venda, Dept Chem, Dept Microbiol, ZA-0950 Thohoyandou, Limpopo Provinc, South Africa.
   [Brant, Julia; Dillingham, Rebecca] Univ Virginia, Dept Med, Charlottesville, VA 22908 USA.
RP Dillingham, R (reprint author), Univ Virginia, Dept Med, POB 801379, Charlottesville, VA 22908 USA.
EM rd8v@virginia.edu
RI Oyanedel Craver, Vinka/F-6765-2013
OI Oyanedel Craver, Vinka/0000-0002-7851-2108
FU Pfizer Foundation; National Science Foundation
FX We are grateful to St Joseph's Clinic for welcoming and making
   accommodations for the research team. We would like to acknowledge
   Beauty Mashau, Beauty Selima, and Caroline Dhavhana for their
   contributions. We would also like to thank Professor Paul Mojapelo PhD,
   at the University of Venda for granting team members access to equipment
   to conduct laboratory analysis. The authors would also like to thank
   Jeff Schwarz of the Pot Shop at the Braddock Carnegie Library for
   providing the silverimpregnated ceramic filters used in this study. The
   filter press used to produce these filters was designed by Manny
   Hernandez and Maximus Andreus at Slippery Rock University. Finally, we
   would like to express our gratitude towards the Water and Health in
   Limpopo (WHIL) faculty and administrative staff. This study was
   supported by grants from the Pfizer Foundation to the University of
   Virginia and the National Science Foundation.
CR APHA, 1998, STANDARD METHODS EXA
   Barzilay EJ, 2011, AIDS CARE, V23, P330, DOI 10.1080/09540121.2010.507749
   Bielefeldt AR, 2010, WATER RES, V44, P1482, DOI 10.1016/j.watres.2009.10.043
   Brown J, 2008, AM J TROP MED HYG, V79, P394
   Clasen T, 2007, BMJ-BRIT MED J, V334, P782, DOI 10.1136/bmj.39118.489931.BE
   Clasen T, 2006, TROP MED INT HEALTH, V11, P1399, DOI 10.1111/j.1365-3156.2006.01699.x
   Dillingham RA, 2002, MICROBES INFECT, V4, P1059, DOI 10.1016/S1286-4579(02)01630-1
   Dillingham RA, 2009, AM J TROP MED HYG, V80, P1060
   Dwivedi KK, 2007, JPN J INFECT DIS, V60, P76
   Frisby HR, 1997, J ACQ IMMUN DEF SYND, V16, P367, DOI 10.1097/00042560-199712150-00010                                                
   Hoxie NJ, 1997, AM J PUBLIC HEALTH, V87, P2032, DOI 10.2105/AJPH.87.12.2032
   Kallman EN, 2011, J ENVIRON ENG-ASCE, V137, P407, DOI 10.1061/(ASCE)EE.1943-7870.0000330
   Kulkarni SV, 2009, INDIAN J MED RES, V130, P63
   Lantagne DS., 2001, INVESTIGATION POTTER
   Lule JR, 2005, AM J TROP MED HYG, V73, P926
   Makubalo L., 2003, NATL HIV SYPHILIS AN
   MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Obi C., 2007, WATER SA, V32, P323
   Oyanedel-Craver VA, 2008, ENVIRON SCI TECHNOL, V42, P927, DOI 10.1021/es071268u
   Samie A, 2006, EXP PARASITOL, V114, P314, DOI 10.1016/j.exppara.2006.04.007
   Schmidt WP, 2009, ENVIRON SCI TECHNOL, V43, P986, DOI 10.1021/es802232w
   United Nations Human Settlements Programme, 2003, WAT SAN WORLDS CIT L
   YAMAMURA S, 2000, DRINKING WATER GUIDE
   Zhang HY, 2012, WATER RES, V46, P691, DOI 10.1016/j.watres.2011.11.037
NR 25
TC 19
Z9 19
U1 2
U2 31
PU IWA PUBLISHING
PI LONDON
PA ALLIANCE HOUSE, 12 CAXTON ST, LONDON SW1H0QS, ENGLAND
SN 1477-8920
J9 J WATER HEALTH
JI J. Water Health
PY 2014
VL 12
IS 2
BP 288
EP 300
DI 10.2166/wh.2013.185
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Microbiology; Water Resources
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Microbiology; Water Resources
GA AK6BJ
UT WOS:000338512100009
PM 24937223
DA 2018-01-05
ER

PT J
AU Bhatia, S
   Dimde, M
   Haag, R
AF Bhatia, Sumati
   Dimde, Mathias
   Haag, Rainer
TI Multivalent glycoconjugates as vaccines and potential drug candidates
SO MEDCHEMCOMM
LA English
DT Review
ID INFLUENZA-VIRUS INFECTION; KEYHOLE LIMPET HEMOCYANIN; HEAT-LABILE
   ENTEROTOXIN; OLIGOSACCHARIDE-DERIVATIZED DENDRIMERS; CONJUGATED
   DENDRITIC POLYMERS; MEDIATED HIV-INFECTION; SOLID-PHASE SYNTHESIS;
   SIALIC-ACID; CHOLERA-TOXIN; ESCHERICHIA-COLI
AB Pathogens adhere to the host cells during the first steps of infection through multivalent interactions which involve protein-glycan recognition. Multivalent interactions are also involved at different stages of immune response. Insights into these multivalent interactions generate a way to use suitable carbohydrate ligands that are attached to a basic scaffold consisting of e. g., dendrimer, polymer, nanoparticle, etc., with a suitable linker. Thus a multivalent architecture can be obtained with controllable spatial and topology parameters which can interfere with pathogen adhesion. Multivalent glycoconjugates bearing natural or unnatural carbohydrate antigen epitopes have also been used as carbohydrate based vaccines to stimulate an innate and adaptive immune response. Designing and synthesizing an efficient multivalent architecture with optimal ligand density and a suitable linker is a challenging task. This review presents a concise report on the endeavors to potentially use multi-and polyvalent glycoconjugates as vaccines as well as anti-infectious and anti-inflammatory drug candidates.
C1 [Bhatia, Sumati; Dimde, Mathias; Haag, Rainer] Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany.
RP Haag, R (reprint author), Free Univ Berlin, Inst Chem & Biochem, Takustr 3, D-14195 Berlin, Germany.
EM haag@chemie.fu-berlin.de
CR Andre S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W                     
   Andre S, 2011, CHEM COMMUN, V47, P6126, DOI 10.1039/c1cc11163a
   ARMSTRONG GD, 1991, J INFECT DIS, V164, P1160, DOI 10.1093/infdis/164.6.1160                                                       
   Arosio D, 2005, J AM CHEM SOC, V127, P3660, DOI 10.1021/jp0444029
   Astronomo R. D., 2011, CHEM BIOL, V17, P357
   Astronomo RD, 2008, J VIROL, V82, P6359, DOI 10.1128/JVI.00293-08
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   Astronomo RD, 2010, NAT REV DRUG DISCOV, V9, P308, DOI 10.1038/nrd3012
   Avery O T, 1931, J Exp Med, V54, P437, DOI 10.1084/jem.54.3.437
   Barras A, 2013, NANOSCALE, V5, P2307, DOI 10.1039/c3nr33826f
   Bernardi A, 2013, CHEM SOC REV, V42, P4709, DOI 10.1039/c2cs35408j
   Berzi A, 2012, AIDS, V26, P127, DOI 10.1097/QAD.0b013e32834e1567
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Bondioli L, 2010, BIOMATERIALS, V31, P3395, DOI 10.1016/j.biomaterials.2010.01.049
   Bouckaert J, 2013, CHEM-EUR J, V19, P7847, DOI 10.1002/chem.201204015
   Bovin NV, 2004, GLYCOCONJUGATE J, V21, P471, DOI 10.1007/s10719-004-5537-3
   Branderhorst HM, 2007, CHEM COMMUN, P5043, DOI 10.1039/b711070g
   Buskas T, 2004, CHEM-EUR J, V10, P3517, DOI 10.1002/chem.200400074
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Cecioni S, 2011, CHEM-EUR J, V17, P3252, DOI 10.1002/chem.201003258
   Cecioni S, 2009, CHEM-EUR J, V15, P13232, DOI 10.1002/chem.200901799
   Chefalo P, 2006, BIOCHEMISTRY-US, V45, P3733, DOI 10.1021/bi052161r
   COLEMAN WG, 1979, J BACTERIOL, V139, P899
   Davis BG, 2002, CHEM REV, V102, P579, DOI 10.1021/cr0004310
   DE SN, 1953, J PATHOL BACTERIOL, V66, P559, DOI 10.1002/path.1700660228                                                         
   DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071
   Dernedde J, 2011, J CARBOHYD CHEM, V30, P347, DOI 10.1080/07328303.2011.608227
   Dernedde J, 2010, P NATL ACAD SCI USA, V107, P19679, DOI 10.1073/pnas.1003103107
   Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4
   Dondoni A, 2010, CHEM REV, V110, P4949, DOI 10.1021/cr100027b
   Durka M, 2012, CHEM-EUR J, V18, P641, DOI 10.1002/chem.201102052
   Durka M, 2011, CHEM-EUR J, V17, P11305, DOI 10.1002/chem.201100396
   Durka M, 2011, CHEM COMMUN, V47, P1321, DOI 10.1039/c0cc04468g
   DUTTA NK, 1959, J BACTERIOL, V78, P594
   Enders S, 2007, BBA-GEN SUBJECTS, V1770, P1441, DOI 10.1016/j.bbagen.2007.06.015
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   Feizi T, 2013, ANN NY ACAD SCI, V1292, P33, DOI 10.1111/nyas.12210
   Ferguson MAJ, 1999, J CELL SCI, V112, P2799
   Gabius H J, 1988, Acta Histochem Suppl, V36, P209
   Gan ZH, 2002, CAN J CHEM, V80, P908, DOI 10.1139/V02-053
   GLASS RI, 1980, J INFECT DIS, V142, P939, DOI 10.1093/infdis/142.6.939                                                        
   GLICK GD, 1991, J BIOL CHEM, V266, P23660
   GLICK GD, 1991, J AM CHEM SOC, V113, P4701, DOI 10.1021/ja00012a060
   Grabosch C, 2011, CHEMBIOCHEM, V12, P1066, DOI 10.1002/cbic.201000774
   Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R
   Guo CT, 2002, GLYCOBIOLOGY, V12, P183, DOI 10.1093/glycob/12.3.183
   Heidecke CD, 2007, CHEM-EUR J, V13, P9056, DOI 10.1002/chem.200700787
   HELLING F, 1994, CANCER RES, V54, P197
   HELLING F, 1995, CANCER RES, V55, P2783
   Hewitt MC, 2001, J ORG CHEM, V66, P4233, DOI 10.1021/jo015521z
   HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0
   Horlacher T, 2008, CHEM SOC REV, V37, P1414, DOI 10.1039/b708016f
   Imberty A, 2008, CHEM-EUR J, V14, P7490, DOI 10.1002/chem.200800700
   Ingale S, 2007, NAT CHEM BIOL, V3, P663, DOI 10.1038/nchembio.2007.25
   Jarre G, 2011, CHEM COMMUN, V47, P544, DOI 10.1039/c0cc02931a
   Jones C, 2005, AN ACAD BRAS CIENC, V77, P293, DOI 10.1590/S0001-37652005000200009
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   Kabanova A, 2010, GLYCOCONJUGATE J, V27, P501, DOI 10.1007/s10719-010-9295-0
   Kalovidouris SA, 2003, J ORG CHEM, V68, P8485, DOI 10.1021/jo030203g
   Kamena F, 2008, NAT CHEM BIOL, V4, P238, DOI 10.1038/nchembio.75
   Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971
   KINGERYWOOD JE, 1992, J AM CHEM SOC, V114, P7303, DOI 10.1021/ja00044a057
   Kisiela DI, 2013, P NATL ACAD SCI USA, V110, P19089, DOI 10.1073/pnas.1314395110
   Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095                                                                
   Knight SD, 2009, TOP CURR CHEM, V288, P67, DOI 10.1007/128_2008_13
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Krug LM, 2004, CLIN CANCER RES, V10, P916, DOI 10.1158/1078-0432.CCR-03-0101                                                   
   Landers JJ, 2002, J INFECT DIS, V186, P1222, DOI 10.1086/344316
   Lee CM, 2012, P NATL ACAD SCI USA, V109, P20385, DOI 10.1073/pnas.1219155109
   LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027
   Lemoine D, 1998, J CONTROL RELEASE, V54, P15, DOI 10.1016/S0168-3659(97)00241-1                                                   
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Llinares M, 1997, CHEM COMMUN, P2119, DOI 10.1039/a703679e                                                                
   Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218                                                                    
   Luallen RJ, 2008, J VIROL, V82, P6447, DOI 10.1128/JVI.00412-08
   Luczkowiak J, 2011, BIOCONJUGATE CHEM, V22, P1354, DOI 10.1021/bc2000403
   Makimura Y, 2006, CARBOHYD RES, V341, P1803, DOI 10.1016/j.carres.2006.04.024
   MAMMEN M, 1995, J MED CHEM, V38, P4179, DOI 10.1021/jm00021a007
   Mammen M., 1998, ANGEW CHEM, V110, P2908, DOI DOI 10.1002/(SICI)1521-3757(19981016)110:20<2908::AID-ANGE2908>3.0.CO;2-2
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   MARRA A, 1994, ANGEW CHEM INT EDIT, V33, P2479
   Marra A., 1994, ANGEW CHEM, V106, P2533
   Marra A, 2008, ORG BIOMOL CHEM, V6, P1396, DOI 10.1039/b800598b
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Marradi M, 2010, ADV CARBOHYD CHEM BI, V64, P211, DOI 10.1016/S0065-2318(10)64005-X
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Matsuoka K, 2001, TETRAHEDRON LETT, V42, P3327, DOI 10.1016/S0040-4039(01)00422-1
   MEEZAN E, 1969, BIOCHEMISTRY-US, V8, P2518, DOI 10.1021/bi00834a039                                                             
   *MERCK CO INC, 1986, PNEUM 23 PNEUM VACC
   Merritt EA, 2002, J AM CHEM SOC, V124, P8818, DOI 10.1021/ja0202560
   MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9                                                    
   Meunier SJ, 1996, TETRAHEDRON LETT, V37, P5469, DOI 10.1016/0040-4039(96)01167-7
   Meunier SJ, 1997, CAN J CHEM, V75, P1472, DOI 10.1139/v97-177                                                                 
   MHALU FS, 1979, LANCET, V1, P345
   Mintzer MA, 2012, MOL PHARMACEUT, V9, P342, DOI 10.1021/mp2005033
   MOCHALOVA LV, 1994, ANTIVIR RES, V23, P179, DOI 10.1016/0166-3542(94)90016-7
   MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.immunol.13.1.655
   MOODY SF, 1993, J BIOL CHEM, V268, P18457
   Mowery P, 2004, CHEM BIOL, V11, P725, DOI 10.1016/j.chembiol.2004.03.027
   Mulvey GL, 2003, J INFECT DIS, V187, P640, DOI 10.1086/373996
   Musselli C, 2001, J CANCER RES CLIN, V127, pR20, DOI 10.1007/BF01470995                                                              
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Nierengarten I, 2013, TETRAHEDRON LETT, V54, P2398, DOI 10.1016/j.tetlet.2013.02.100
   Nierengarten JF, 2010, CHEM COMMUN, V46, P3860, DOI 10.1039/c0cc00034e
   Nyame AK, 2004, ARCH BIOCHEM BIOPHYS, V426, P182, DOI 10.1016/j.abb.2004.04.004
   Ohta T, 2003, ANGEW CHEM INT EDIT, V42, P5186, DOI 10.1002/anie.200351640
   Ohta T., 2003, ANGEW CHEM, V115, P5344
   Otsuka I, 2010, CHEMBIOCHEM, V11, P2399, DOI 10.1002/cbic.201000447
   Pan YB, 2005, J MED CHEM, V48, P875, DOI 10.1021/jm0494422
   Papp I, 2008, CHEM COMMUN, P5851, DOI 10.1039/b813414f
   Papp I, 2011, CHEMBIOCHEM, V12, P887, DOI 10.1002/cbic.201000776
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Parry AL, 2013, J AM CHEM SOC, V135, P9362, DOI 10.1021/ja4046857
   Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785
   Payne RJ, 2010, CHEM COMMUN, V46, P21, DOI 10.1039/b913845e
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   Ponader D, 2012, BIOMACROMOLECULES, V13, P1845, DOI 10.1021/bm300331z
   Pozsgay V, 1999, P NATL ACAD SCI USA, V96, P5194, DOI 10.1073/pnas.96.9.5194                                                          
   Pozsgay V, 2007, P NATL ACAD SCI USA, V104, P14478, DOI 10.1073/pnas.0706969104
   Price Virginia L., 2001, Current Drug Targets - Infectious Disorders, V1, P315, DOI 10.2174/1568005014606026
   PRITCHETT TJ, 1989, J BIOL CHEM, V264, P9850
   Pukin AV, 2008, CARBOHYD RES, V343, P636, DOI 10.1016/j.carres.2008.01.007
   Pukin AV, 2007, CHEMBIOCHEM, V8, P1500, DOI 10.1002/cbic.200700266
   Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414
   Ragupathi G, 2006, J AM CHEM SOC, V128, P2715, DOI 10.1021/ja057244+
   Ragupathi G, 2003, CANCER IMMUNOL IMMUN, V52, P608, DOI 10.1007/s00262-003-0399-2
   Ragupathi G, 2002, VACCINE, V20, P1030, DOI 10.1016/S0264-410X(01)00451-0
   Ramanathan T, 2008, NAT NANOTECHNOL, V3, P327, DOI 10.1038/nnano.2008.96
   Ratner DM, 2007, CURR PHARM DESIGN, V13, P173, DOI 10.2174/138161207779313650
   Reichardt NC, 2013, CHEM SOC REV, V42, P4358, DOI 10.1039/c2cs35427f
   REICHERT A, 1995, J AM CHEM SOC, V117, P829, DOI 10.1021/ja00107a032
   Rendle PM, 2004, J AM CHEM SOC, V126, P4750, DOI 10.1021/ja031698u
   Reuter JD, 1999, BIOCONJUGATE CHEM, V10, P271, DOI 10.1021/bc980099n
   Richards S.-J., 2012, ANGEW CHEM, V124, P7932
   Rieger J, 2007, BIOMACROMOLECULES, V8, P2717, DOI 10.1021/bm070342y
   RITTER G, 1990, IMMUNOBIOLOGY, V182, P32, DOI 10.1016/S0171-2985(11)80581-4                                                   
   RITTER G, 1991, INT J CANCER, V48, P379, DOI 10.1002/ijc.2910480312                                                          
   Robins J. B., 1983, J INFECT DIS, V148, P1136
   ROY R, 1993, J CHEM SOC CHEM COMM, P1869, DOI 10.1039/c39930001869                                                            
   SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004
   Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Scanlan C, 2005, ADV EXP MED BIOL, V564, P7
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Schengrund CL, 2003, BIOCHEM PHARMACOL, V65, P699, DOI 10.1016/S0006-2952(02)01553-8                                                   
   Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937
   Seeberger PH, 2007, NATURE, V446, P1046, DOI 10.1038/nature05819
   SELL S, 1990, HUM PATHOL, V21, P1003, DOI 10.1016/0046-8177(90)90250-9
   Sisson AL, 2010, SOFT MATTER, V6, P4968, DOI 10.1039/c0sm00149j
   Slovin SF, 2007, CANCER IMMUNOL IMMUN, V56, P1921, DOI 10.1007/s00262-007-0335-y
   Snapper CM, 1996, J IMMUNOL, V157, P2229
   SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047
   Steinhilber D, 2010, ADV FUNCT MATER, V20, P4133, DOI 10.1002/adfm.201000410
   Takagi A, 2008, J TOXICOL SCI, V33, P105, DOI 10.2131/jts.33.105
   TAYLORPAPADIMITRIOU J, 1994, TRENDS BIOTECHNOL, V12, P227, DOI 10.1016/0167-7799(94)90121-X                                                    
   Thoma G, 2001, J AM CHEM SOC, V123, P10113, DOI 10.1021/ja0164430
   Thompson JP, 1998, BIOCHEM PHARMACOL, V56, P591, DOI 10.1016/S0006-2952(98)00198-1
   Thompson JP, 1997, GLYCOCONJUGATE J, V14, P837, DOI 10.1023/A:1018590021762
   Touaibia M, 2007, MINI-REV MED CHEM, V7, P1270, DOI 10.2174/138955707782795610                                                      
   Touaibia M, 2007, CHEMMEDCHEM, V2, P1190, DOI 10.1002/cmdc.200700063
   TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.micro.46.1.65
   Turnbull W Bruce, 2002, J Biotechnol, V90, P231
   Tuzikov AB, 2003, CHEMBIOCHEM, V4, P147, DOI 10.1002/cbic.200390025                                                          
   Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang QL, 2007, BIOORGAN MED CHEM, V15, P7561, DOI 10.1016/j.bmc.2007.09.005
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wang X, 2011, CHEM COMMUN, V47, P8620, DOI 10.1039/c1cc12981c
   Weight AK, 2011, J PHARM SCI-US, V100, P831, DOI 10.1002/jps.22338
   WEINHOLD EG, 1992, J AM CHEM SOC, V114, P9270, DOI 10.1021/ja00050a004
   WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0
   Werz DB, 2005, CHEM-EUR J, V11, P3194, DOI 10.1002/chem.200500025
   Yu GC, 2013, J AM CHEM SOC, V135, P10310, DOI 10.1021/ja405237q
   Zanini D, 1996, J ORG CHEM, V61, P7348, DOI 10.1021/jo961047z                                                               
   Zanini D, 1997, J AM CHEM SOC, V119, P2088, DOI 10.1021/ja963874n                                                               
   Zhang ZS, 2002, J AM CHEM SOC, V124, P12991, DOI 10.1021/ja027584k
   Zuercher AW, 2006, FEMS IMMUNOL MED MIC, V47, P302, DOI 10.1111/j.1574-695X.2006.00103.x
NR 182
TC 19
Z9 19
U1 4
U2 53
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PY 2014
VL 5
IS 7
BP 862
EP 878
DI 10.1039/c4md00143e
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AK4YW
UT WOS:000338431500003
OA gold
DA 2018-01-05
ER

PT J
AU Blakney, AK
   Krogstad, EA
   Jiang, YHH
   Woodrow, KA
AF Blakney, Anna K.
   Krogstad, Emily A.
   Jiang, Yonghou H.
   Woodrow, Kim A.
TI Delivery of multipurpose prevention drug combinations from electrospun
   nanofibers using composite microarchitectures
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE co-delivery; electrospinning; antiretroviral; contraceptive;
   microbicide; multipurpose prevention technology
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR T-20; HIV; INFECTIONS;
   RELEASE; FIBERS; CONTRACEPTIVES; SYSTEMS
AB Background: Electrospun drug-eluting fabrics have enormous potential for the delivery of physicochemically diverse drugs in combination by controlling the underlying material chemistry and fabric microarchitecture. However, the rationale for formulating drugs at high drug loading in the same or separate fibers is unknown but has important implications for product development and clinical applications.
   Methods: Using a production-scale free-surface electrospinning instrument, we produced electrospun nanofibers with different microscale geometries for the co-delivery of tenofovir (TFV) and levonorgestrel (LNG) - two lead drug candidates for multipurpose prevention of HIV acquisition and unintended pregnancy. We investigated the in vitro drug release of TFV and LNG combinations from composites that deliver the two drugs from the same fiber ( combined fibers) or from separate fibers in a stacked or interwoven architecture. For stacked composites, we also examined the role that fabric thickness has on drug-release - kinetics. We also measured the cytotoxicity and antiviral activity of the drugs delivered alone and in combination.
   Results: Herein, we report on the solution and processing parameters for the free-surface electrospinning of medical fabrics with controlled microarchitecture and high drug loading ( up to 20 wt%). We observed that in vitro release of the highly water-soluble TFV, but not the water-insoluble LNG, was affected by composite microarchitecture, fabric thickness, and drug content. Finally, we showed that the drug-loaded nanofibers are noncytotoxic and that the antiviral activity of TFV is preserved through the electrospinning process and when combined with LNG.
   Conclusion: Electrospun fabrics with high drug loading create multicomponent systems that benefit from the independent control of the nanofibrous microarchitecture. Our findings are significant because they will inform the design and production of composite electrospun fabrics for the co-delivery of physicochemically diverse drugs that may be useful for multipurpose prevention.
C1 [Blakney, Anna K.; Krogstad, Emily A.; Jiang, Yonghou H.; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), William H Foege Bldg N410D,3720 15th Ave NE, Seattle, WA 98195 USA.
EM woodrow@uw.edu
FU Bill and Melinda Gates Foundation [OPP1067729]; NIH/NIAID grant
   [AI098648]; National Science Foundation Graduate Research Fellowships;
   NIH Molecular Medicine Training Fellowship [5T32GM095421-03]
FX The research was supported by funding from the Bill and Melinda Gates
   Foundation (OPP1067729) and a NIH/NIAID grant (AI098648) to KAW. AKB and
   EAK were supported by National Science Foundation Graduate Research
   Fellowships, and AKB was also supported by an NIH Molecular Medicine
   Training Fellowship (5T32GM095421-03). We thank Dr. Shih-Feng Chou for
   assistance with mechanical testing of electrospun fabrics.
CR Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Chen DWC, 2012, INT J NANOMED, V7, P763, DOI 10.2147/IJN.S29119
   Chrisman CE, 2006, CONTRACEPTION, V73, P125, DOI 10.1016/j.contraception.2005.08.004
   Craig DQM, 2002, INT J PHARM, V231, P131, DOI 10.1016/S0378-5173(01)00891-2
   De Clercq E, 2007, BIOCHEM PHARMACOL, V73, P911, DOI 10.1016/j.bcp.2006.09.014
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Dhanaraju MD, 2003, INT J PHARM, V268, P23, DOI 10.1016/j.ijpharm.2003.08.011
   Friend DR, 2010, ANTIVIR RES, V88, pS47, DOI 10.1016/j.antiviral.2010.09.005
   Gallo MF, 2005, CONTRACEPTION, V71, P162, DOI 10.1016/j.contraception.2004.09.005
   Goh YF, 2013, J MATER SCI, V48, P3027, DOI 10.1007/s10853-013-7145-8
   Greco F, 2009, ADV DRUG DELIVER REV, V61, P1203, DOI 10.1016/j.addr.2009.05.006
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Jannesari Marziyeh, 2011, Int J Nanomedicine, V6, P993, DOI 10.2147/IJN.S17595
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Li XQ, 2013, COLLOID SURFACE B, V103, P182, DOI 10.1016/j.colsurfb.2012.10.016
   Mayer LD, 2007, MOL INTERV, V7, P216, DOI 10.1124/mi.7.4.8
   Miao YE, 2012, MATER CHEM PHYS, V134, P623, DOI 10.1016/j.matchemphys.2012.03.041
   Morrow K, 2003, J WOMENS HEALTH, V12, P655, DOI 10.1089/154099903322404302                                                      
   Nicol MR, 2010, CLIN PHARMACOL THER, V88, P598, DOI 10.1038/clpt.2010.189
   Okuda T, 2010, J CONTROL RELEASE, V143, P258, DOI 10.1016/j.jconrel.2009.12.029
   Platt EJ, 1998, J VIROL, V72, P2855
   Prabaharan M, 2012, ADV POLYM SCI, V246, P241, DOI 10.1007/12_2011_125
   Rasband W. S, 1997, IMAGEJ
   Rawlinson CF, 2007, INT J PHARM, V336, P42, DOI 10.1016/j.ijpharm.2006.11.029
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Shao CL, 2003, MATER LETT, V57, P1579, DOI 10.1016/S0167-577X(02)01036-4
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Xu XL, 2009, EUR J PHARM BIOPHARM, V72, P18, DOI 10.1016/j.ejpb.2008.10.015
   Zhang LF, 2007, CHEMMEDCHEM, V2, P1268, DOI 10.1002/cmdc.200700121
   Zhang YZ, 2006, BIOMACROMOLECULES, V7, P1049, DOI 10.1021/bm050743i
NR 33
TC 19
Z9 20
U1 3
U2 20
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2014
VL 9
BP 2967
EP 2978
DI 10.2147/IJN.S61664
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA AJ5EE
UT WOS:000337704100001
PM 24971008
OA gold
DA 2018-01-05
ER

PT J
AU Gaur, PK
   Mishra, S
   Bajpai, M
   Mishra, A
AF Gaur, Praveen Kumar
   Mishra, Shikha
   Bajpai, Meenakshi
   Mishra, Anushika
TI Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles:
   In Vitro Drug Release and Pharmacokinetics Studies
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID TRANSDERMAL DELIVERY; NANOVESICULAR SYSTEM; VIVO EVALUATION; EX-VIVO;
   FORMULATION; DICLOFENAC
AB Solid lipid nanoparticle is an efficient lipid based drug delivery systemwhich can enhance the bioavailability of poorly water soluble drugs. Efavirenz is a highly lipophilic drug from nonnucleoside inhibitor category for treatment of HIV. Present work illustrates development of an SLN formulation for Efavirenz with increased bioavailability. At first, suitable lipid component and surfactant were chosen. SLNs were prepared and analyzed for physical parameters, stability, and pharmacokinetic profile. Efavirenz loaded SLNs were formulated using Glyceryl monostearate as main lipid and Tween 80 as surfactant. ESLN-3 has shown mean particle size of 124.5 +/- 3.2 nm with a PDI value of 0.234, negative zeta potential, and 86% drug entrapment. In vitro drug release study has shown 60.6-98.22% drug release in 24 h by various SLN formulations. Optimized SLNs have shown good stability at 40 degrees C +/- 2 degrees C and 75 +/- 5% relative humidity (RH) for 180 days. ESLN-3 exhibited 5.32-fold increase in peak plasma concentration (C-max) and 10.98-fold increase in AUC in comparison to Efavirenz suspension (ES).
C1 [Gaur, Praveen Kumar; Bajpai, Meenakshi; Mishra, Anushika] ITS Paramed Coll Pharm, Dept Pharmaceut, Muradnagar 201206, Ghaziabad, India.
   [Mishra, Shikha] Jamia Hamdard, Dept Pharmacognosy & Phytochem, New Delhi 110062, India.
RP Gaur, PK (reprint author), ITS Paramed Coll Pharm, Dept Pharmaceut, Muradnagar 201206, Ghaziabad, India.
EM gaurmpharma@rediffmail.com
OI Gaur, Praveen/0000-0002-4221-1485
CR Attama AA, 2008, INT J PHARM, V355, P307, DOI 10.1016/j.ijpharm.2007.12.007
   Baert L, 2008, INT J PHARM, V355, P38, DOI 10.1016/j.ijpharm.2008.01.029
   Bhaskar K, 2009, LIPIDS HEALTH DIS, V8, DOI 10.1186/1476-511X-8-6
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chime SA, 2013, J MICROENCAPSUL, V30, P335, DOI 10.3109/02652048.2012.726284
   Dragicevic-Curic N, 2008, J CONTROL RELEASE, V127, P59, DOI 10.1016/j.jconrel.2007.12.013
   FALZARANO MS, 2013, BIOMED RES INT
   Gaur PK, 2013, BIOMED RES INT, V2013
   Gaur PK, 2014, SCI WORLD J, V2014
   Gaur PK, 2014, DRUG DEV IND PHARM, V40, P568, DOI 10.3109/03639045.2013.782502
   Gaur PK, 2014, PHARM DEV TECHNOL, V19, P48, DOI 10.3109/10837450.2012.751406
   Gaur PK, 2013, J BIOMAT SCI-POLYM E, V24, P2126, DOI 10.1080/09205063.2013.828579
   Helgason T, 2009, J COLLOID INTERF SCI, V334, P75, DOI 10.1016/j.jcis.2009.03.012
   Ishida T, 2002, INT J PHARM, V232, P59, DOI 10.1016/S0378-5173(01)00896-1
   Jukanti R, 2011, J PHARM SCI-US, V100, P3208, DOI 10.1002/jps.22542
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kwon TK, 2011, J IND ENG CHEM, V17, P10, DOI 10.1016/j.jiec.2010.10.001
   Liu DF, 2011, J NANOPART RES, V13, P2375, DOI 10.1007/s11051-010-9998-y
   Morel S, 1996, INT J PHARM, V132, P259, DOI 10.1016/0378-5173(95)04388-8
   Nemmar A, 2013, BIOMED RES INT, DOI 10.1155/2013/279371
   Patel GV, 2014, DRUG DEV IND PHARM, V40, P80, DOI 10.3109/03639045.2012.746362
   Reithmeier H, 2001, INT J PHARM, V218, P133, DOI 10.1016/S0378-5173(01)00620-2
   Sahoo S. K., 2006, NANOPARTICLES INTERF
   SCHWARZ C, 1994, J CONTROL RELEASE, V30, P83, DOI 10.1016/0168-3659(94)90047-7
   Vyas S. P., 2002, NANOPARTICLES TARGET
NR 25
TC 13
Z9 13
U1 4
U2 15
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 363404
DI 10.1155/2014/363404
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AI1BO
UT WOS:000336584800001
OA gold
DA 2018-01-05
ER

PT J
AU Jain, A
   Jain, P
   Kurmi, J
   Jain, D
   Jain, R
   Chandel, S
   Sahu, A
   Mody, N
   Upadhaya, S
   Jain, A
AF Jain, Ankita
   Jain, Priyanka
   Kurmi, Jaya
   Jain, Darshana
   Jain, Roshni
   Chandel, Silky
   Sahu, Anamika
   Mody, Nishi
   Upadhaya, Satish
   Jain, Aviral
TI Novel Strategies for Effective Transdermal Drug Delivery: A Review
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE nanocarriers; liposomes; nanoemulsion; micro needle; vaccines;
   transdermal drug delivery
ID SOLID LIPID NANOPARTICLES; ERBIUM-YAG LASER; HUMAN STRATUM-CORNEUM;
   MEDIATED EPIDERMAL DELIVERY; CYTOTOXIC T-LYMPHOCYTES; VITRO SKIN
   PERMEATION; TUMOR-BEARING MICE; EXCISED HUMAN SKIN; HIV-1 DNA VACCINE;
   IN-VITRO
AB Skin is the largest and easily accessible organ of the body and therefore can be extensively used as a prominent route of delivery for local and systemic effects. Though it presents a multifunctional barrier between body and surrounding particles, there are chances to deliver therapeutic nanocarrier, particularly in diseased skin. Both for dermal and transdermal drug delivery, the horny layer, i.e., the uppermost layer of the skin serve as the most resistant layer to be crossed and for this purpose, different perforation techniques are used that relatively widen the skin opening and allow the passage of drug (<= 10 mg) and micromolecules, but this amateur disruption of the skin can be avoided in order to preserve this barrier against cutaneous microbiota by using deformable nanocarriers. In this review, we discuss the nanosized aggregates and microneedle technology for the advanced delivery of vaccines, protein, peptides, nucleic acid, and hormone across the skin.
C1 [Jain, Ankita; Jain, Priyanka; Kurmi, Jaya; Jain, Darshana; Jain, Roshni; Chandel, Silky; Sahu, Anamika; Mody, Nishi; Upadhaya, Satish; Jain, Aviral] Adina Inst Pharmaceut Sci, Dept Pharmaceut, Pharmaceut Res Lab, Sagar 470002, MP, India.
RP Jain, A (reprint author), Adina Inst Pharmaceut Sci, Dept Pharmaceut, Pharmaceut Res Lab, Sagar 470002, MP, India.
EM draviraljain@gmail.com
OI Jain, Aviral/0000-0001-7808-6180
CR Aboud S, 2010, CLIN VACCINE IMMUNOL, V17, P1124, DOI 10.1128/CVI.00008-10
   ABRAHAM W, 1990, BIOCHIM BIOPHYS ACTA, V1021, P119, DOI 10.1016/0005-2736(90)90023-H                                                    
   Ada G, 2003, METH MOLEC MED, V87, P1
   Alexis F, 2008, UROL ONCOL-SEMIN ORI, V26, P74, DOI 10.1016/j.urolonc.2007.03.017
   Alvarez-Roman R, 2004, J CONTROL RELEASE, V99, P53, DOI 10.1016/j.jconrel.2004.06.015
   Alvarez-Roman R, 2001, EUR J PHARM BIOPHARM, V52, P191, DOI 10.1016/S0939-6411(01)00188-6
   Ambrosio L, 1999, J MACROMOL SCI PURE, VA36, P991, DOI 10.1081/MA-100101578
   Ameri M, 2009, PHARM RES-DORD, V26, P2454, DOI 10.1007/s11095-009-9960-9
   Arangoa MA, 2001, PHARMACEUT RES, V18, P1521, DOI 10.1023/A:1013018111829                                                         
   Archer DF, 2003, MENOPAUSE, V10, P516, DOI 10.1097/01.GME.0000070526.74726.8A
   Arora A, 2007, P NATL ACAD SCI USA, V104, P4255, DOI 10.1073/pnas.0700182104
   Arora A, 2008, INT J PHARMACEUT, V364, P227, DOI 10.1016/j.ijpharm.2008.08.032
   Azarmi S, 2006, J PHARM PHARM SCI, V9, P124
   BacchiModena A, 1997, MATURITAS, V27, P285, DOI 10.1016/S0378-5122(97)00039-X                                                   
   BAKER H, 1967, ARCH DERMATOL, V96, P441, DOI 10.1001/archderm.96.4.441
   Bal SM, 2008, EUR J PHARM SCI, V35, P193, DOI 10.1016/j.ejps.2008.06.016
   Bal SM, 2010, PHARM RES-DORDR, V27, P1837, DOI 10.1007/s11095-010-0182-y
   Banga AK, 2007, PHARM RES, V24, P1357, DOI 10.1007/s11095-007-9323-3
   Baroli B, 2007, J INVEST DERMATOL, V127, P1701, DOI 10.1038/sj.jid.5700733
   Baroli B, 2010, J PHARM SCI-US, V99, P21, DOI 10.1002/jps.21817
   Barry BW, 2001, EUR J PHARM SCI, V14, P101, DOI 10.1016/S0928-0987(01)00167-1                                                   
   Belyakov IM, 2004, J CLIN INVEST, V113, P998, DOI 10.1172/JCI200420261
   Beran J, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-13
   Bergh VD, 1999, J CONTROL RELEASE, V62, P367
   Birchall J, 2006, INT J PHARM, V312, P15, DOI 10.1016/j.ijpharm.2005.12.036
   BLANK IH, 1965, J INVEST DERMATOL, V45, P249, DOI 10.1038/jid.1965.125                                                            
   Blume G., 2003, TRANSFERSOMES BIOCH, V1614, P156
   Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x
   Bouwstra JA, 2003, J INVEST DERMATOL, V120, P750, DOI 10.1046/j.1523-1747.2003.12128.x                                                
   Bouwstra JA, 2002, ADV DRUG DELIVER REV, V54, pS41, DOI 10.1016/S0169-409X(02)00114-X
   Braun RP, 2008, HUM VACCINES, V4, P36, DOI 10.4161/hv.4.1.4876                                                             
   Bremseth D L, 2001, Diabetes Technol Ther, V3, P225
   Caniglia Ronald J, 2004, Facial Plast Surg Clin North Am, V12, P373, DOI 10.1016/j.fsc.2004.03.005
   Cassaday RD, 2007, CLIN CANCER RES, V13, P540, DOI 10.1158/1078-0432.CCR-06-2039
   Celluzzi CM, 1997, J INVEST DERMATOL, V108, P716, DOI 10.1111/1523-1747.ep12292095
   Cevc G, 1996, CRIT REV THER DRUG, V13, P257, DOI 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.30                                  
   Cevc G, 2004, BBA-BIOMEMBRANES, V1663, P61, DOI 10.1016/j.bbamem.2004.01.006
   Cevc G, 2004, ADV DRUG DELIVER REV, V56, P675, DOI 10.1016/j.addr.2003.10.028
   Cevc G, 2002, BBA-BIOMEMBRANES, V1564, P21, DOI 10.1016/S0005-2736(02)00401-7                                                   
   Cevc G, 2001, BBA-BIOMEMBRANES, V1514, P191, DOI 10.1016/S0005-2736(01)00369-8
   Cevc G, 1997, Expert Opin Investig Drugs, V6, P1887, DOI 10.1517/13543784.6.12.1887
   Cevc G, 2007, J CONTROL RELEASE, V118, P18, DOI 10.1016/j.jconrel.2006.10.022
   Chabri F, 2004, BRIT J DERMATOL, V150, P869, DOI 10.1111/j.0007-0963.2004.05921.x
   Chang LC, 2009, INT J PHARMACEUT, V376, P195, DOI 10.1016/j.ijpharm.2009.04.045
   Chen BT, 2008, MICROSYST TECHNOL, V14, P1015, DOI 10.1007/s00542-007-0530-y
   Chen XF, 2009, J CONTROL RELEASE, V139, P212, DOI 10.1016/j.jconrel.2009.06.029
   Chien YW, 1982, NOVEL DRUG DELIVERY, P149
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Choi AHC, 2007, VACCINE, V25, P3215, DOI 10.1016/j.vaccine.2007.01.035
   Choi MJ, 2005, SKIN PHARMACOL PHYSI, V18, P209, DOI 10.1159/000086666
   Cleary GW., 1983, MED APPL CONTROLLED, V1, P203
   Coester C, 2006, EUR J PHARM BIOPHARM, V62, P306, DOI 10.1016/j.ejpb.2005.09.009
   Combadiere B, 2008, COMP IMMUNOL MICROB, V31, P293, DOI 10.1016/j.cimid.2007.07.015
   Combadiere B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010818
   Coulman SA, 2009, INT J PHARM, V366, P190, DOI 10.1016/j.ijpharm.2008.08.040
   Crichton ML, 2010, BIOMATERIALS, V31, P4562, DOI 10.1016/j.biomaterials.2010.02.022
   Cristillo AD, 2008, BIOCHEM BIOPH RES CO, V366, P29, DOI 10.1016/j.bbrc.2007.11.052
   Cui ZR, 2001, J CONTROL RELEASE, V75, P409, DOI 10.1016/S0168-3659(01)00407-2                                                   
   DANIELSSON I, 1981, COLLOID SURFACE, V3, P391, DOI 10.1016/0166-6622(81)80064-9                                                    
   Davis SP, 2005, IEEE T BIO-MED ENG, V52, P909, DOI 10.1109/TBME.2005.845240
   Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203
   Dincer Z, 2006, EXP TOXICOL PATHOL, V57, P351, DOI 10.1016/j.etp.2006.03.014
   Ding Z, 2009, J CONTROL RELEASE, V136, P71, DOI 10.1016/j.jconrel.2009.01.025
   Ding Z, 2009, PHARM RES-DORD, V26, P1635, DOI 10.1007/s11095-009-9874-6
   Drape RJ, 2006, VACCINE, V24, P4475, DOI 10.1016/j.vaccine.2005.08.012
   Dubina M, 2009, AM J DERMATOPATH, V31, P561, DOI 10.1097/DAD.0b013e3181a58234
   EGBARIA K, 1991, SKIN PHARMACOL, V4, P21, DOI 10.1159/000210920                                                               
   Elena P, 2001, INT J PHARMACEUT, V226, P47
   Epstein JE, 2002, HUM GENE THER, V13, P1551, DOI 10.1089/10430340260201644
   Erdogan S, 2009, J BIOMED NANOTECHNOL, V5, P141, DOI 10.1166/jbn.2009.1016
   Ezpeleta I, 1996, INT J PHARMACEUT, V131, P191, DOI 10.1016/0378-5173(95)04338-1                                                    
   Ferreira LS, 2004, DRUG DEV IND PHARM, V30, P289, DOI 10.1081/DDC-120030423
   FLYNN GL, 1974, J PHARM SCI-US, V63, P479, DOI 10.1002/jps.2600630403
   Flynn GL, 1989, PERCUTANEOUS ABSORPT, P27
   FOLDVARI M, 1990, J MICROENCAPSUL, V7, P479, DOI 10.3109/02652049009040470                                                       
   Frech SA, 2005, VACCINE, V23, P946, DOI 10.1016/j.vaccine.2004.06.036
   Fresta M, 1997, J CONTROL RELEASE, V44, P141, DOI 10.1016/S0168-3659(96)01519-2
   Frisken BJ, 2000, LANGMUIR, V16, P928, DOI 10.1021/la9905113                                                               
   Fukushima K, 2011, PHARM RES-DORDR, V28, P7, DOI 10.1007/s11095-010-0097-7
   Gajbhiye V, 2008, INDIAN J PHARM SCI, V70, P431, DOI 10.4103/0250-474X.44589
   GALEY WR, 1976, J INVEST DERMATOL, V67, P713, DOI 10.1111/1523-1747.ep12598596
   Gardeniers HJGE, 2003, J MICROELECTROMECH S, V12, P855, DOI [10.1109/JMEMS.2003.820293, 10.1109/JMEMS.2003.080293]
   Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962
   Garg S, 2007, CLIN VACCINE IMMUNOL, V14, P926, DOI 10.1128/CVI.00450-06
   Gill HS, 2010, GENE THER, V17, P811, DOI 10.1038/gt.2010.22
   Glenn GM, 2007, EXPERT REV VACCINES, V6, P809, DOI 10.1586/14760584.6.5.809
   Goldstein AM, 2001, ARCH DERMATOL, V137, P1493
   Good WR., 1986, MED DEVICE DIAGN IND, V34-42
   Gowrishankar TR, 2009, IEEE ENG MED BIOL, V28, P55, DOI 10.1109/MEMB.2008.931016
   Gowrishankar TR, 1999, J CONTROL RELEASE, V60, P101, DOI 10.1016/S0168-3659(99)00064-4
   Gregor C., 2010, J CONTROL RELEASE, V141, P277
   Gupta J, 2009, DIABETES TECHNOL THE, V11, P329, DOI 10.1089/dia.2008.0103
   Gupta PN, 2005, INT J PHARM, V293, P73, DOI 10.1016/j.ijpharm.2004.12.022
   Harvey AJ, 2011, PHARM RES-DORDR, V28, P107, DOI 10.1007/s11095-010-0123-9
   Henderson DA, 2008, SMALLPOX VACCINIA, V5, P773
   Henry S, 1998, J PHARM SCI, V87, P922, DOI 10.1021/js980042+                                                               
   Herndon TO, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-12
   Honeywell-Nguyen PL, 2003, PHARMACEUT RES, V20, P1619, DOI 10.1023/A:1026191402557                                                         
   Honeywell-Nguyen PL, 2002, PHARMACEUT RES, V19, P991, DOI 10.1023/A:1016466406176                                                         
   Hooper JW, 2007, VACCINE, V25, P1814, DOI 10.1016/j.vaccine.2006.11.017
   Ito Y, 2006, J DRUG TARGET, V14, P255, DOI 10.1080/10611860600785080
   Jahanshahi M, 2008, PHYS STATUS SOLIDI, V10, P1
   Jain N.K., 2011, CONTROLLED NOVEL DRU, P105
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   JAMEELA SR, 1995, BIOMATERIALS, V16, P769, DOI 10.1016/0142-9612(95)99639-4
   Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061
   Joshi A, 2002, J CONTROL RELEASE, V83, P13, DOI 10.1016/S0168-3659(02)00200-6                                                   
   Jung T, 2000, EUR J PHARM BIOPHARM, V50, P147, DOI 10.1016/S0939-6411(00)00084-9
   Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10
   KALE NJ, 1989, INT J PHARM, V57, P87, DOI 10.1016/0378-5173(89)90296-2
   Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026
   Kendall M, 2004, J INVEST DERMATOL, V122, P739, DOI 10.1111/j.0022-202X.2004.22320.x
   Kenry S, 1998, J PHARM SCI, V87, P922
   Kigasawa K, 2010, INT J PHARMACEUT, V383, P157, DOI 10.1016/j.ijpharm.2009.08.036
   Kigasawa K, 2011, J CONTROL RELEASE, V150, P256, DOI 10.1016/j.jconrel.2011.01.018
   Kim A, 2004, BIOMATERIALS, V25, P305, DOI 10.1016/S0142-9612(03)00534-9
   Kirjavainen M, 1996, BBA-LIPID LIPID MET, V1304, P179, DOI 10.1016/S0005-2760(96)00126-9                                                   
   Kitagawa S, 2006, CHEM PHARM BULL, V54, P242, DOI 10.1248/cpb.54.242                                                              
   Klimuk SK, 2004, J INVEST DERMATOL, V122, P1042, DOI 10.1111/j.0022-202X.2004.22411.x
   Knorr F, 2009, EUR J PHARM BIOPHARM, V71, P173, DOI 10.1016/j.ejpb.2008.11.001
   Kogan A, 2006, ADV COLLOID INTERFAC, V123, P369, DOI 10.1016/j.cis.2006.05.014
   Kohli AK, 2004, INT J PHARM, V275, P13, DOI 10.1016/j.ijpharm.2003.10.038
   Kong M, 2011, CARBOHYD POLYM, V83, P1303, DOI 10.1016/j.carbpol.2010.09.041
   Kratz F, 1998, J PHARM SCI, V87, P338, DOI 10.1021/js970246a                                                               
   Kratz F., 1997, EUR J CANCER, V33, pS175
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Kreilgaard M, 2000, J CONTROL RELEASE, V69, P421, DOI 10.1016/S0168-3659(00)00325-4
   KRIWET K, 1995, INT J PHARM, V125, P231, DOI 10.1016/0378-5173(95)00130-B
   Kuhl H, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500148875
   Kumar D, 2009, PHARMAZIE, P6480
   Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310
   Lademann J, 2007, EUR J PHARM BIOPHARM, V66, P159, DOI 10.1016/j.ejpb.2006.10.019
   Larese FF, 2009, TOXICOLOGY, V255, P33, DOI 10.1016/j.tox.2008.09.025
   Lauer AC, 1996, ADV DRUG DELIVER REV, V18, P311, DOI 10.1016/0169-409X(95)00089-P                                                    
   Lee CH, 2001, INT J PHARM, V221, P1, DOI 10.1016/S0378-5173(01)00691-3
   Lee EH, 2005, BIOMATERIALS, V26, P205, DOI 10.1016/j.biomaterials.2004.02.020
   Lee JW, 2008, BIOMATERIALS, V29, P2113, DOI 10.1016/j.biomaterials.2007.12.048
   Lee JW, 2000, J PHARM SCI, V89, P850, DOI 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G
   Lee PW, 2008, BIOMATERIALS, V29, P742, DOI 10.1016/j.biomaterials.2007.10.034
   Lee PW, 2010, BIOMATERIALS, V31, P2425, DOI 10.1016/j.biomaterials.2009.11.100
   Lee RW, 2010, HANDBOOK OF NON-INVASIVE DRUG DELIVERY SYSTEMS: NON-INVASIVE AND MINIMALLY-INVASIVE DRUG DELIVERY SYSTEMS FOR PHARMACEUTICAL AND PERSONAL CARE PRODUCTS, P37, DOI 10.1016/B978-0-8155-2025-2.10002-2
   Lee WR, 2006, J CONTROL RELEASE, V115, P344, DOI 10.1016/j.jconrel.2006.08.012
   Lee WR, 2003, J INVEST DERMATOL, V121, P1118, DOI 10.1046/j.1523-1747.2003.12537.x
   Lee WR, 2002, J PHARM SCI, V91, P1613, DOI 10.1002/jps.10142
   Lee WR, 2001, J CONTROL RELEASE, V75, P155, DOI 10.1016/S0168-3659(01)00391-1
   Liang CH, 2009, CHEM PHYS LIPIDS, V158, P81, DOI 10.1016/j.chemphyslip.2009.01.006
   LIEB LM, 1992, J INVEST DERMATOL, V99, P108, DOI 10.1111/1523-1747.ep12611886
   Lin MTS, 2000, INT J DERMATOL, V39, P161, DOI 10.1046/j.1365-4362.2000.00925.x                                                
   Liu H, 2004, PHARMAZIE, V59, P203
   Lu DM, 2007, EXPERT REV VACCINES, V6, P213, DOI 10.1586/14760584.6.2.213
   Lu Z, 2004, CLIN CANCER RES, V10, P7677, DOI 10.1158/1078-0432.CCR-04-1443
   Maaden K, 2012, J CONTROL RELEASE, V161, P645
   Maghraby El, 1999, J PHARM PHARMACOL, V51, P1123
   Maghraby GMME, 2001, J PHARM PHARMACOL, V53, P1311
   Mahe B, 2009, J INVEST DERMATOL, V129, P1156, DOI 10.1038/jid.2008.356
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   Martanto W, 2004, PHARM RES, V21, P947, DOI 10.1023/B:PHAM.0000029282.44140.2e
   Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040                                                         
   MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0
   McAllister DV, 2003, P NATL ACAD SCI USA, V100, P13755, DOI 10.1073/pnas.2331316100
   MEZEI M, 1980, LIFE SCI, V26, P1473, DOI 10.1016/0024-3205(80)90268-4
   MEZEI M, 1985, TOP PHARM SCI, P345
   Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415
   Mikszta JA, 2008, EXPERT REV VACCINES, V7, P1329, DOI 10.1586/14760584.7.9.1329
   Mikszta JA, 2006, INFECT IMMUN, V74, P6806, DOI 10.1128/IAI.01210-06
   Mirshahi T, 2002, J DRUG TARGET, V10, P625, DOI 10.1080/1061186021000066237
   Mishra D, 2006, VACCINE, V24, P4847, DOI 10.1016/j.vaccine.2006.03.011
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Najar HM, 2008, J INVEST DERMATOL, V128, P2204, DOI 10.1038/jid.2008.59
   Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018
   Nguyen DN, 2009, ADV MATER, V21, P847, DOI 10.1002/adma.200801478
   Norlen L, 1997, ARCH DERMATOL RES, V289, P506, DOI 10.1007/s004030050231
   Olie V, 2011, MENOPAUSE, V18, P488, DOI 10.1097/gme.0b013e3181f9f7c3
   Ossadnik M, 2006, LASER PHYS, V16, P747, DOI 10.1134/S1054660X06050033
   Pan J, 2009, BIOMATERIALS, V30, P1176, DOI 10.1016/j.biomaterials.2008.10.039
   Pardeike J, 2009, INT J PHARM, V366, P170, DOI 10.1016/j.ijpharm.2008.10.003
   Park JH, 2005, J CONTROL RELEASE, V104, P51, DOI 10.1016/j.jconrel.2005.02.002
   Patty PJ, 2003, BIOPHYS J, V85, P996, DOI 10.1016/S0006-3495(03)74538-X
   Patzelt A, 2008, EUR J PHARM BIOPHARM, V70, P234, DOI 10.1016/j.ejpb.2008.02.024
   Paul A, 1995, EUR J IMMUNOL, V25, P3521, DOI 10.1002/eji.1830251248
   Paul A, 1998, VACCINE, V16, P188, DOI 10.1016/S0264-410X(97)00185-0
   Pettis RJ, 2011, DIABETES TECHNOL THE, V13, P435, DOI 10.1089/dia.2010.0184
   PIKAL MJ, 1990, PHARMACEUT RES, V7, P118, DOI 10.1023/A:1015816532532
   PLANAS ME, 1992, ANESTH ANALG, V75, P615
   Ponvert C, 2003, EUR J DERMATOL, V13, P10
   PRAUSNITZ MR, 1995, BIO-TECHNOL, V13, P1205, DOI 10.1038/nbt1195-1205
   Prausnitz MR, 1997, CRIT REV THER DRUG, V14, P455
   Prausnitz MR, 2008, MODIFIED RELEASE DRU, P295
   Premjeet S, 2011, INT J RES PHARM CHEM, V1, P1139
   Ramon E, 2005, DRUG DELIV, V12, P83, DOI 10.1080/10717540490446080
   Raviprakash K, 2003, VIROLOGY, V315, P345, DOI 10.1016/S0042-6822(03)00542-7
   Reddy LH, 2005, J CONTROL RELEASE, V105, P185, DOI 10.1016/j.jconrel.2005.02.028
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P53, DOI 10.1016/j.nano.2006.04.009
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   Renoux C, 2010, BMJ-BRIT MED J, V340, P2519
   Roberts LK, 2005, VACCINE, V23, P4867, DOI 10.1016/j.vaccine.2005.05.026
   Rothman S, 1954, PHYSIOLOGY BIOCHEMIS, P26
   Roxhed N, 2008, IEEE T BIO-MED ENG, V55, P1063, DOI 10.1109/TBME.2007.906492
   Ryman-Rasmussen JP, 2007, NANO LETT, V7, P1344, DOI 10.1021/nl070375j
   Sakamoto T, 2004, GENE THER, V11, P317, DOI 10.1038/sj.gt.3302171
   Saurer EM, 2010, BIOMACROMOLECULES, V11, P3136, DOI 10.1021/bm1009443
   Schafer P, 2002, SKIN PHARMACOL APPL, V15, P7, DOI 10.1159/000049384
   Schaller M, 1996, ADV DRUG DELIVER REV, V18, P303, DOI 10.1016/0169-409X(95)00076-J
   Scharton-Kersten T, 2000, INFECT IMMUN, V68, P5306, DOI 10.1128/IAI.68.9.5306-5313.2000                                                 
   Schatzlein A, 1998, BRIT J DERMATOL, V138, P583
   SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702
   Scheuplein RJ, 1983, BIOCH PHYSL SKIN, V2, P1255
   Schneider M, 2009, DERM-ENDOCRINOL, V1, P197, DOI 10.4161/derm.1.4.9501
   SCHREIER H, 1994, J CONTROL RELEASE, V30, P1, DOI 10.1016/0168-3659(94)90039-6                                                    
   Shen SC, 2006, J PHARM SCI-US, V95, P929, DOI 10.1002/jps.20577
   Shifren JL, 2008, J CLIN ENDOCR METAB, V93, P1702, DOI 10.1210/jc.2007-2193
   Simerska Pavla, 2009, Current Drug Delivery, V6, P347
   Simon JA, 2006, MENOPAUSE, V13, P222, DOI 10.1097/01.gme.0000174096.56652.4f
   Sinha VR, 2001, INT J PHARM, V224, P19, DOI 10.1016/S0378-5173(01)00720-7
   Sivamani RK, 2007, EXPERT OPIN DRUG DEL, V4, P19, DOI 10.1517/17425247.4.1.19
   Sivamani RK, 2005, SKIN RES TECHNOL, V11, P152, DOI 10.1111/j.1600-0846.2005.00107.x                                                
   Slutter B, 2008, J DRUG TARGET, V16, P1, DOI [10.1080/10611860701637966, 10.1080/10611860701637966 ]
   Sonavane G, 2008, COLLOIDS SURF B, P651
   Stoughton RD., 1965, TOXICOL APPL PHARM, V7, P1
   Subedi RK, 2009, EUR J PHARM SCI, V37, P508, DOI 10.1016/j.ejps.2009.04.008
   Sugita K, 2007, CLIN EXP IMMUNOL, V147, P176, DOI 10.1111/j.1365-2249.2006.03258.x
   Sullivan SP, 2010, NAT MED, V16, P915, DOI 10.1038/nm.2182
   Sun MJ, 2012, SOFT MATTER, V8, P4301, DOI 10.1039/c2sm07280g
   Suzanne M, 2010, J CONTROL RELEASE, V148, P266
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   TAKAKURA Y, 1990, PHARMACEUT RES, V7, P339, DOI 10.1023/A:1015807119753
   TAN EL, 1993, DRUG DEV IND PHARM, V19, P685, DOI 10.3109/03639049309062975                                                       
   TINGSTAD JE, 1958, J AM PHARM ASSOC, V47, P192, DOI 10.1002/jps.3030470313                                                          
   Uchida M, 2006, VACCINE, V24, P2120, DOI 10.1016/j.vaccine.2005.11.027
   Uner M, 2005, PHARMAZIE, V60, P751
   Uner M, 2007, INT J NANOMED, V2, P289
   Upadhyay P, 2006, VACCINE, V24, P5593, DOI 10.1016/j.vaccine.2006.04.039
   Valenzuela P, 2012, NANOMED-NANOTECHNOL, V8, pS83, DOI 10.1016/j.nano.2012.05.008
   Van D. P., 2009, VACCINE, V27, P454
   Vandermeulen G, 2009, PHARM RES-DORD, V26, P1745, DOI 10.1007/s11095-009-9885-3
   Vemuri S, 1995, Pharm Acta Helv, V70, P95, DOI 10.1016/0031-6865(95)00010-7
   Venuganti VVK, 2009, J PHARM SCI-US, V98, P2345, DOI 10.1002/jps.21603
   Verbaan FJ, 2007, J CONTROL RELEASE, V117, P238, DOI 10.1016/j.jconrel.2006.11.009
   Verdier-Sevrain S, 2006, EXP DERMATOL, V15, P83, DOI 10.1111/j.1600-0625.2005.00377.x
   Vogt A, 2008, J IMMUNOL, V180, P1482, DOI 10.4049/jimmunol.180.3.1482                                                     
   Vringer TD, 1995, J PHARM SCI, V84, P466
   Wang KH, 2004, DERMATOL SURG, V30, P441, DOI 10.1111/j.1524-4725.2004.30122.x                                                
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Warner RR, 2003, J INVEST DERMATOL, V120, P275, DOI 10.1046/j.1523-1747.2003.12046.x
   WEINER N, 1989, DRUG DEV IND PHARM, V15, P1523, DOI 10.3109/03639048909052502                                                       
   Widera G, 2006, VACCINE, V24, P1653, DOI 10.1016/j.vaccine.2005.09.049
   Wilkes G L, 1973, CRC Crit Rev Bioeng, V1, P453
   Williams J, 2000, VACCINE, V18, P1939, DOI 10.1016/S0264-410X(99)00446-6
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Woodburne RT, 1967, ESSENTIALS HUMAN ANA, P6
   Wu XM, 2006, INT J PHARM, V316, P102, DOI 10.1016/j.ijpharm.2006.02.046
   Xiao CH, 2005, J INVEST DERMATOL, V124, P622, DOI 10.1111/j.0022-202X.2004.23608.x
   Xu ZH, 2009, BIOMATERIALS, V30, P226, DOI 10.1016/j.biomaterials.2008.09.014
   Yagi H, 2006, CANCER RES, V66, P10136, DOI 10.1158/0008-5472.CAN-06-1029
   Yang M, 2004, BIOMED MICRODEVICES, V6, P177, DOI 10.1023/B:BMMD.0000042046.07678.2e
   YOSHIDA NH, 1993, J CONTROL RELEASE, V25, P177, DOI 10.1016/0168-3659(93)90077-I
   Yuqin Q, 2008, J CONTROL RELEASE, V129, P144
   Zhai HB, 2001, SKIN PHARMACOL APPL, V14, P1, DOI 10.1159/000056328                                                               
   Zhao YL, 2006, VACCINE, V24, P1282, DOI 10.1016/j.vaccine.2005.09.035
   Zhu QY, 2009, P NATL ACAD SCI USA, V106, P7968, DOI 10.1073/pnas.0812652106
NR 261
TC 11
Z9 11
U1 9
U2 81
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0743-4863
EI 2162-660X
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2014
VL 31
IS 3
BP 219
EP 272
DI 10.1615/CritRevTherDrugCarrierSyst.2014008126                           
          
PG 54
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AI0QR
UT WOS:000336554300002
PM 24940749
DA 2018-01-05
ER

PT S
AU Tanke, HJ
   Zuiderwijk, M
   Wiesmeijer, KC
   Breedveld, RN
   Abrams, WR
   de Dood, CJ
   Fat, EMTK
   Corstjens, PLAM
AF Tanke, Hans J.
   Zuiderwijk, Michel
   Wiesmeijer, Karien C.
   Breedveld, Robert N.
   Abrams, William R.
   de Dood, Claudia J.
   Fat, Elisa M. Tjon Kon
   Corstjens, Paul L. A. M.
BE Farkas, DL
   Nicolau, DV
   Leif, RC
TI The use of upconverting phosphors in point-of-care (POC) testing
SO IMAGING, MANIPULATION, AND ANALYSIS OF BIOMOLECULES, CELLS, AND TISSUES
   XII
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Imaging, Manipulation, and Analysis of Biomolecules,
   Cells, and Tissues XII
CY FEB 03-06, 2014
CL San Francisco, CA
SP SPIE
DE Point-of-care; upconversion; nanophosphors; luminescence; infectious
   diseases; immunodrug monitoring; lab-on-a-chip; handheld detector;
   melatonin; fruit-ripening marker
ID LATERAL FLOW ASSAY; CIRCULATING ANODIC ANTIGEN; HUMORAL
   IMMUNE-RESPONSES; UP-CONVERSION; BIOANALYTICAL SYSTEMS; RAPID ASSAY;
   VIRAL LOAD; TECHNOLOGY; DETECT; INFECTION
AB Point-of-care (POC) testing is increasingly applied as a cost effective alternative to many diagnostic tests. Key in POC testing is to create sufficient assay sensitivity with relatively low cost reagents and equipment. For this purpose we have employed a unique reporter, upconverting phosphor (UCP) particles, in combination with lateral flow (LF) assays. UCPs, submicron ceramic particles doped with rare earth ions (lanthanides), convert infrared to visible light and do not suffer from autofluorescence which limits conventional fluorescence based assays. Low cost handheld readers and microfluidics were evaluated in various applications. Designed assays are well suited for applications outside diagnostic laboratories, in resource poor settings, and can even be used by patients at home. Using two distinctly different UCP-LF assay formats, we focussed on assays for infectious diseases based on the detection of pathogen-specific antibodies and/or antigens including nucleic acids to demonstrate active infection with HIV. Only minor adaptation of the standard UCP-LF assay format is needed to render the format suitable for applications involving low affinity capture antibodies (e. g. in the detection of neurotoxin, botulism), capture of small molecules (e. g. detection of melatonin, a key hormone in chronopharmacology) or the use of dry UCP reagents (e. g. detection of protein based fruit-ripening markers, of economic interest in agriculture). Finally, we anticipate on developments in healthcare (personalized medicine) by discussing the potential of one of the UCP-LF assay formats to measure serum trough levels of immunodrugs (e. g. infliximab or adalimumab) in patients treated for inflammatory bowel disease and rheumatoid arthritis.
C1 [Tanke, Hans J.; Zuiderwijk, Michel; Wiesmeijer, Karien C.; Breedveld, Robert N.; de Dood, Claudia J.; Fat, Elisa M. Tjon Kon; Corstjens, Paul L. A. M.] Leiden Univ Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands.
   [Abrams, William R.] New York Univ, Coll Dent, New York, NY USA.
RP Tanke, HJ (reprint author), Leiden Univ Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands.
OI Corstjens, Paul/0000-0002-0004-0526
FU NIH [U01- DE- 017855]; Senternovem/ Ministry of Economic Affairs, The
   Netherlands to GT Diagnostics B. V. ( Wageningen; The Netherlands) [FND
   07001]
FX We gratefully thank Dr. Nelson Michael ( Walter Reed Army Institute of
   Research; Silver Spring, MA) for providing the HIV- 1 culture samples,
   Dr. Sam Niedbala ( OraSure Technologies Inc.; Bethlehem, PA) for
   providing clinical HIV samples, Prof. David Kennaway ( University of
   Adelaide; Australia) for supplying the goat polyclonal anti- melatonin
   antibody and the melatonin- BSA conjugate, Dr. Frank Gessler (
   University of Gttingen; Germany) for the BoNT/ D samples and specific
   antibodies. Dr. Shang Li ( OraSure Technologies Inc.; Bethlehem, PA) is
   acknowledged for supplying the 400 nm UCP particles. Part of this work
   was supported by NIH grant U01- DE- 017855 and grant FND 07001 from
   Senternovem/ Ministry of Economic Affairs, The Netherlands to GT
   Diagnostics B. V. ( Wageningen; The Netherlands).
CR Abrams WR, 2007, ANN NY ACAD SCI, V1098, P375, DOI 10.1196/annals.1384.020
   Achatz DE, 2011, TOP CURR CHEM, V300, P29, DOI 10.1007/128_2010_98
   Assadollahi S, 2009, SENSORS-BASEL, V9, P6084, DOI 10.3390/s90806084
   Auzel F, 2004, CHEM REV, V104, P139, DOI 10.1021/cr020357g
   Baraldo M, 2008, EXPERT OPIN DRUG MET, V4, P175, DOI 10.1517/17425255.4.2.175
   BLAIR IA, 1979, AUST J CHEM, V32, P399, DOI 10.1071/CH9790399                                                               
   Burns MA, 2002, SCIENCE, V296, P1818, DOI 10.1126/science.1073562
   CARDINALI DP, 1972, ENDOCRINOLOGY, V91, P1213, DOI 10.1210/endo-91-5-1213                                                          
   Chen Z., 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/543294
   Chen ZY, 2007, ANN NY ACAD SCI, V1098, P429, DOI 10.1196/annals.1384.024
   Ching KH, 2012, J IMMUNOL METHODS, V380, P23, DOI 10.1016/j.jim.2012.03.008
   Corstjens P, 2001, CLIN CHEM, V47, P1885
   Corstjens P. L. A. M., 2005, IEE Proceedings Nanobiotechnology, V152, P64, DOI 10.1049/ip-nbt:20045014
   Corstjens PLAM, 2008, CLIN BIOCHEM, V41, P440, DOI 10.1016/j.clinbiochem.2007.12.015
   Corstjens PLAM, 2008, J CLIN MICROBIOL, V46, P171, DOI 10.1128/JCM.00877-07
   Corstjens PLAM, 2007, ANN NY ACAD SCI, V1098, P437, DOI 10.1196/annals.1384.016
   Corstjens PLAM, 2013, ANAL BIOANAL CHEM, V405, P7367, DOI 10.1007/s00216-013-7154-0
   Corstjens PLAM, 2011, CLIN BIOCHEM, V44, P1241, DOI 10.1016/j.clinbiochem.2011.06.983
   Corstjens PLAM, 2003, ANAL BIOCHEM, V312, P191, DOI 10.1016/S0003-2697(02)00505-5                                                   
   Djomand G, 2006, JAIDS-J ACQ IMM DEF, V43, P401, DOI 10.1097/01.qai.0000243117.21788.90                                              
   Downs JA, 2012, AM J TROP MED HYG, V87, P868, DOI 10.4269/ajtmh.2012.12-0395
   Fat EMTK, 2012, METHOD CELL BIOL, V112, P203, DOI 10.1016/B978-0-12-405914-6.00011-1
   Gessler F, 2007, DIAGN MICR INFEC DIS, V57, P243, DOI 10.1016/j.diagmicrobio.2006.07.017
   Gessler F, 2006, DIAGN MICR INFEC DIS, V56, P225, DOI 10.1016/j.diagmicrobio.2006.04.014
   Gorris HH, 2013, ANGEW CHEM INT EDIT, V52, P3584, DOI 10.1002/anie.201208196
   Haase M, 2011, ANGEW CHEM INT EDIT, V50, P5808, DOI 10.1002/anie.201005159
   Hampl J, 2001, ANAL BIOCHEM, V288, P176, DOI 10.1006/abio.2000.4902
   KENNAWAY DJ, 1983, LIFE SCI, V32, P2461, DOI 10.1016/0024-3205(83)90372-7
   Kennaway DJ, 1998, J CLIN ENDOCR METAB, V83, P1013, DOI 10.1210/jc.83.3.1013                                                            
   Klewitz T, 2006, SENSOR ACTUAT B-CHEM, V113, P582, DOI 10.1016/j.snb.2005.07.007
   Lee SR, 2010, J CLIN VIROL, V48, P15, DOI 10.1016/j.jcv.2010.02.018
   Li JJ, 2008, IEEE T BIO-MED ENG, V55, P1560, DOI 10.1109/TBME.2007.914674
   Liebherr RB, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/48/485103
   Liu CC, 2009, LAB CHIP, V9, P768, DOI 10.1039/b814322f
   Malamud D, 2005, Adv Dent Res, V18, P12
   Meldrum DR, 2002, SCIENCE, V297, P1197, DOI 10.1126/science.297.5584.1197                                                   
   Michael NL, 1999, J CLIN MICROBIOL, V37, P2557
   Mitchell P, 2001, NAT BIOTECHNOL, V19, P717, DOI 10.1038/90754                                                                   
   Mokkapati VK, 2007, ANN NY ACAD SCI, V1098, P476, DOI 10.1196/annals.1384.021
   Musiek ES, 2013, HDB EXP PHARM, P243, DOI DOI 10.1007/978-3-642-25950-0_
   Niedbala RS, 2001, ANAL BIOCHEM, V293, P22, DOI 10.1006/abio.2001.5105
   Ongagna-Yhombi SY, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-74
   Ouellette AL, 2009, ANAL CHEM, V81, P3216, DOI 10.1021/ac900475u
   Qiu XB, 2011, SENSOR ACTUAT B-CHEM, V160, P1529, DOI 10.1016/j.snb.2011.08.012
   Qiu XB, 2009, BIOMED MICRODEVICES, V11, P1175, DOI 10.1007/s10544-009-9334-4
   Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4
   Soukka T, 2005, J FLUORESC, V15, P513, DOI 10.1007/s10895-005-2825-7
   Soukka T, 2008, ANN NY ACAD SCI, V1130, P188, DOI 10.1196/annals.1430.027
   Spizz G, 2012, POINT CARE, V11, P42, DOI 10.1097/POC.0b013e318222e184                                                    
   van Dam GJ, 2013, EXP PARASITOL, V135, P274, DOI 10.1016/j.exppara.2013.06.017
   van de Rijke F, 2001, NAT BIOTECHNOL, V19, P273, DOI 10.1038/85734
   Wang F, 2009, CHEM SOC REV, V38, P976, DOI 10.1039/b809132n
   Wang J, 2006, LAB CHIP, V6, P46, DOI 10.1039/b511494b
   Wright W. H., 1998, FLOW CYTOMETRY UPCON
   Xu CT, 2013, LASER PHOTONICS REV, V7, P663, DOI 10.1002/lpor.201200052
   Yan ZQ, 2006, SENSOR ACTUAT B-CHEM, V119, P656, DOI 10.1016/j.snb.2006.01.029
   Ye XC, 2013, NAT CHEM, V5, P466, DOI [10.1038/NCHEM.1651, 10.1038/nchem.1651]
   Ye XC, 2010, P NATL ACAD SCI USA, V107, P22430, DOI 10.1073/pnas.1008958107
   Zhou P, 2010, BIOMED MICRODEVICES, V12, P821, DOI 10.1007/s10544-010-9436-z
   Zijlmans HJMAA, 1999, ANAL BIOCHEM, V267, P30, DOI 10.1006/abio.1998.2965                                                          
   Zuiderwijk M, 2003, CLIN BIOCHEM, V36, P401, DOI 10.1016/S0009-9120(03)00057-2
   Corstjens Paul LAM, 2010, US Patent, Patent No. [#7,858,396, 7858396]
NR 62
TC 1
Z9 1
U1 1
U2 17
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-9860-1
J9 PROC SPIE
PY 2014
VL 8947
AR UNSP 89470P
DI 10.1117/12.2036906
PG 15
WC Cell & Tissue Engineering; Optics; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cell Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BA4NO
UT WOS:000336037200014
DA 2018-01-05
ER

PT J
AU Jiang, HX
   Zhuang, DM
   Huang, Y
   Cao, XX
   Yao, JH
   Li, JY
   Wang, JY
   Zhang, C
   Jiang, B
AF Jiang, Hai-Xia
   Zhuang, Dao-Min
   Huang, Ying
   Cao, Xing-Xin
   Yao, Jian-Hua
   Li, Jing-Yun
   Wang, Jian-Yong
   Zhang, Chen
   Jiang, Biao
TI Design, synthesis, and biological evaluation of novel trifluoromethyl
   indoles as potent HIV-1 NNRTIs with an improved drug resistance profile
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID NONNUCLEOSIDE REVERSE-TRANSCRIPTASE; ETRAVIRINE-CONTAINING REGIMEN;
   INHIBITORS; MUTATIONS; DISCOVERY; TOXICITY; FAILURE; ANALOGS; TMC125;
   AGENTS
AB novel series of trifluoromethyl indole derivatives have been designed, synthesized and evaluated for anti-HIV-1 activities in MT-2 cells. The hydrophobic constant, acute toxicity, carcinogenicity and mutagenicity were predicted. Trifluoromethyl indoles 10i and 10k showed extremely promising activities against WT HIV-1 with IC50 values at the low nanomolar level, similar to efavirenz, better than nevirapine, and also possessed higher potency towards the drug-resistant mutant strain Y181C than nevirapine. Preliminary SAR and docking studies of detailed binding mode provided some insights for discovery of more potent NNRTIs.
C1 [Jiang, Hai-Xia; Huang, Ying; Cao, Xing-Xin; Yao, Jian-Hua; Zhang, Chen; Jiang, Biao] Chinese Acad Sci, Shanghai Inst Organ Chem, CAS Key Lab Synthet Chem Nat Subst, Shanghai 200032, Peoples R China.
   [Zhuang, Dao-Min; Li, Jing-Yun] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Dept AIDS Res, Beijing, Peoples R China.
   [Wang, Jian-Yong; Jiang, Biao] Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai 201210, Peoples R China.
RP Zhang, C (reprint author), Chinese Acad Sci, Shanghai Inst Organ Chem, CAS Key Lab Synthet Chem Nat Subst, 345 Lingling Rd, Shanghai 200032, Peoples R China.
EM lijy@nic.bmi.ac.cn; zhangchen@mail.sioc.ac.cn; jiangb@mail.sioc.ac.cn
FU Important National Science & Technology Specific Projects
   [2009ZX09501-007]; National Natural Scientific Foundation of China
   [20832007]; National Program on Key Basic Research Project (973 Program)
   [2010CB126103]; National Natural Science Foundation of China [21072216]
FX This work was financially supported by Important National Science &
   Technology Specific Projects (no. 2009ZX09501-007), National Natural
   Scientific Foundation of China (Key Program, no. 20832007), National
   Program on Key Basic Research Project (973 Program, no. 2010CB126103)
   and National Natural Science Foundation of China (General Program, no.
   21072216).
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4680.2004
   Banks RE., 1994, ORGANOFLUORINE CHEM
   Bollini M, 2011, J MED CHEM, V54, P8582, DOI 10.1021/jm201134m
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   De Clercq E, 2004, MED CHEM RES, V13, P439, DOI 10.1007/s00044-004-0047-1                                                       
   Desroses M, 2011, TETRAHEDRON LETT, V52, P4417, DOI 10.1016/j.tetlet.2011.06.053
   Ekkati AR, 2012, BIOORG MED CHEM LETT, V22, P1565, DOI 10.1016/j.bmcl.2011.12.132
   Gomez R, 2011, J MED CHEM, V54, P7920, DOI 10.1021/jm2010173
   Purohit M. G., 1978, INDIAN J CHEM B, V9, P789
   Jones LH, 2007, ORG BIOMOL CHEM, V5, P3431, DOI 10.1039/b714091f
   Jorgensen WL, 2011, J AM CHEM SOC, V133, P15686, DOI 10.1021/ja2058583
   Kukhar V. P., 1995, FLUORINE CONTAINING
   La Regina G, 2009, J MED CHEM, V52, P7512, DOI 10.1021/jm900016t
   Liao Q, 2004, SAR QSAR ENVIRON RES, V15, P217, DOI 10.1080/10629360410001697780
   Liao QL, 2007, MOL DIVERS, V11, P59, DOI 10.1007/s11030-007-9057-5
   Liao Q, 2006, MOL DIVERS, V10, P301, DOI 10.1007/s11030-006-9036-2
   Liebman J.F., 1988, FLUORINE CONTAINING
   Lin P, 2000, TETRAHEDRON, V56, P3635, DOI 10.1016/S0040-4020(00)00158-7
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   List B, 2000, J AM CHEM SOC, V122, P2395, DOI 10.1021/ja994280y                                                               
   Marcelin AG, 2012, ANTIVIR THER, V17, P119, DOI 10.3851/IMP1886
   OJIMA I, 1996, ACS S SERIES
   Petersen L, 2005, J MED CHEM, V48, P1211, DOI 10.1021/jm040845b
   Petersen L, 2003, ORG BIOMOL CHEM, V1, P3541, DOI 10.1039/b307800k
   Piscitelli F, 2009, J MED CHEM, V52, P1922, DOI 10.1021/jm801470b
   Ramachary DB, 2009, CHEM-EUR J, V15, P4516, DOI 10.1002/chem.200900066
   Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477
   Regina G. L., 2012, J MED CHEM, V55, P6634
   Regina GL, 2011, J MED CHEM, V54, P1587
   Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988
   Sax Paul E, 2008, AIDS Clin Care, V20, P17
   Scholler-Gyure M, 2008, BRIT J CLIN PHARMACO, V66, P508, DOI 10.1111/j.1365-2125.2008.03214.x
   SCRIVEN EFV, 1988, CHEM REV, V88, P297, DOI 10.1021/cr00084a001                                                             
   Seminari E, 2008, EXPERT REV ANTI-INFE, V6, P427, DOI 10.1586/14787210.6.4.427
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   Soloshonok V. A., 1999, ENANTIOCONTROLLED SY
   Sudhakara A, 2009, SYNTHETIC COMMUN, V39, P2506, DOI 10.1080/00397910802656059
   Sun LQ, 2012, J MED CHEM, V55, P7219, DOI 10.1021/jm3007678
   Tambuyzer L, 2010, AIDS RES HUM RETROV, V26, P1197, DOI 10.1089/aid.2009.0302
   Therkelsen FD, 2003, ORG BIOMOL CHEM, V1, P2908, DOI 10.1039/b303658h
   Tian XT, 2010, J MED CHEM, V53, P8287, DOI 10.1021/jm100738d
   Wahab B, 2010, TETRAHEDRON, V66, P3861, DOI 10.1016/j.tet.2010.03.005
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   Xu HT, 2012, J VIROL, V86, P12983, DOI 10.1128/JVI.02005-12
   Zhang F, 2011, EUR J MED CHEM, V46, P3149, DOI 10.1016/j.ejmech.2011.03.055
   Williams T. A., 1992, Patent Application, Patent No. [EP 0530907 A1, 1663240]
   Stoffels P., 2006, PREDICTION SYSTEM AC, Patent No. EP1663240A1
   Williams T. A, 1992, Patent Application EP, Patent No. [0 530 907 A1, 0530907]
NR 48
TC 9
Z9 10
U1 1
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2014
VL 12
IS 21
BP 3446
EP 3458
DI 10.1039/c3ob42186d
PG 13
WC Chemistry, Organic
SC Chemistry
GA AH3KY
UT WOS:000336023400019
PM 24752610
DA 2018-01-05
ER

PT J
AU Zhang, W
   Li, FH
   Hu, YW
   Gan, SY
   Han, DX
   Zhang, QX
   Niu, L
AF Zhang, Wei
   Li, Fenghua
   Hu, Yuwei
   Gan, Shiyu
   Han, Dongxue
   Zhang, Qixian
   Niu, Li
TI Perylene derivative-bridged Au-graphene nanohybrid for label-free HpDNA
   biosensor
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID MOLECULAR BEACON BIOSENSORS; DNA HYBRIDIZATION; CARBON NANOTUBES; OXIDE;
   NANOPARTICLES; SHEETS; PROBE; COMPOSITES; SURFACTANT; NANOSHEETS
AB Along with the challenges of wet-chemically preparing graphene-based nanohybrids, for example easy aggregation, low-stability in solution environment and insufficient loading amount, here we report the preparation and application of a type of p-conjugated molecule, perylenetetracarboxylic acid di-imide (PDI)-functionalized graphene material with high density of gold nanoparticles (AuNPs). In this nanohybrid, the PDI molecule comprises five-connected benzene rings and positively charged terminals composed of two symmetrical imidazole rings and amine groups, which offers the intrinsic driving force for p-p interactions with graphene and also serves as the active sites for immobilization of AuNPs. Transmission electron microscopy results demonstrated that AuNPs were uniformly dispersed and densely covered the PDI-functionalized graphene compared to the control experiment without PDI. To prove its biological application, the Au-PDI-graphene nanohybrid was chosen as a sensing material for fabricating a label-free electrochemical impedance hairpin DNA (hpDNA) biosensor for detection of human immunodeficiency virus 1 gene. When hpDNA was hybridized, it exhibited a sensitive electrochemical impedance variation on an Au-PDI-graphene modified electrode. This fabricated hpDNA biosensor reveals a wide linear detection range and a relatively low detection limit. Thanks to its high stability and efficient electrochemical impedance sensitivity, this nanohybrid would offer a broad range of possible DNA sequences for specific applications in biodiagnostics and bionanotechnology.
C1 [Zhang, Wei; Li, Fenghua; Hu, Yuwei; Gan, Shiyu; Han, Dongxue; Zhang, Qixian; Niu, Li] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Engn Lab Modern Analyt Tech, Changchun 130022, Peoples R China.
RP Niu, L (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Engn Lab Modern Analyt Tech, Changchun 130022, Peoples R China.
EM fhli@ciac.ac.cn; lniu@ciac.ac.cn
OI niu, li/0000-0003-3652-2903
FU NSFC [21205112, 21105096, 21175130, 21225524]; Ministry of Science and
   Technology of China [2012YQ170003]; Department of Science and Technology
   of Jilin Province [201215091, 20120308]
FX The authors are most grateful to the NSFC (No. 21205112, 21105096,
   21175130 and 21225524), Ministry of Science and Technology of China
   (2012YQ170003) and Department of Science and Technology of Jilin
   Province (No. 201215091 and 20120308).
CR Backes C, 2010, ADV MATER, V22, P788, DOI 10.1002/adma.200902525
   Backes C, 2009, J AM CHEM SOC, V131, P2172, DOI 10.1021/ja805660b
   Cai B, 2013, NANOSCALE, V5, P1910, DOI 10.1039/c2nr33521b
   Claussen JC, 2012, ADV FUNCT MATER, V22, P3399, DOI 10.1002/adfm.201200551
   Diao P, 2008, J PHYS CHEM C, V112, P7036, DOI 10.1021/jp077653n
   Du H, 2005, J AM CHEM SOC, V127, P7932, DOI 10.1021/ja042482a
   Du H, 2003, J AM CHEM SOC, V125, P4012, DOI 10.1021/ja0290781
   Fang XH, 1999, J AM CHEM SOC, V121, P2921, DOI 10.1021/ja9837809                                                               
   Gao JX, 2003, LANGMUIR, V19, P9065, DOI 10.1021/la034919i
   Hu YW, 2012, ANAL CHIM ACTA, V753, P82, DOI 10.1016/j.aca.2012.09.038
   Hu YW, 2012, BIOMATERIALS, V33, P1097, DOI 10.1016/j.biomaterials.2011.10.045
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Johnston APR, 2006, ANAL CHEM, V78, P5913, DOI 10.1021/ac060765a
   Kjallman THM, 2008, ANAL CHEM, V80, P9460, DOI 10.1021/ac801567d
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u                                                               
   Li ADQ, 2003, CHEM-EUR J, V9, P4594, DOI 10.1002/chem.200305025
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li FH, 2009, J MATER CHEM, V19, P4022, DOI 10.1039/b902791b
   Lin CT, 2013, ADV FUNCT MATER, V23, P2301, DOI 10.1002/adfm.201202672
   Liu XQ, 2012, ACS NANO, V6, P3553, DOI 10.1021/nn300598q
   Muszynski R, 2008, J PHYS CHEM C, V112, P5263, DOI 10.1021/jp800977b
   Park S, 2010, NAT NANOTECHNOL, V5, P309, DOI 10.1038/nnano.2010.69
   Qi XY, 2010, ANGEW CHEM INT EDIT, V49, P9426, DOI 10.1002/anie.201004497
   Sahu A, 2013, BIOMATERIALS, V34, P6239, DOI 10.1016/j.biomaterials.2013.04.066
   Shen JF, 2009, SMALL, V5, P82, DOI 10.1002/smll.200800988
   Sun ST, 2011, PHYS CHEM CHEM PHYS, V13, P21116, DOI 10.1039/c1cp22727k
   Tian JQ, 2012, INORG CHEM, V51, P4742, DOI 10.1021/ic300332x
   Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303
   Wang Y, 2008, ANAL CHEM, V80, P2255, DOI 10.1021/ac7024688
   Wang ZJ, 2008, CARBON, V46, P1687, DOI 10.1016/j.carbon.2008.07.020
   Xu Y, 2006, ELECTROANAL, V18, P873, DOI 10.1002/elan.200503465
   Yang HF, 2009, CHEM COMMUN, P3880, DOI 10.1039/b905085j
   Yue QL, 2010, CHEM COMMUN, V46, P3369, DOI 10.1039/c000084a
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zhang W, 2013, BIOSENS BIOELECTRON, V42, P481, DOI 10.1016/j.bios.2012.10.052
NR 35
TC 13
Z9 13
U1 0
U2 50
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2014
VL 2
IS 20
BP 3142
EP 3148
DI 10.1039/c3tb21817a
PG 7
WC Materials Science, Biomaterials
SC Materials Science
GA AG2DF
UT WOS:000335225400020
DA 2018-01-05
ER

PT S
AU Halasa, S
   Dickinson, E
AF Halasa, Salaheldin
   Dickinson, Eva
BE Hamblin, MR
   Carroll, JD
   Arany, P
TI Combination of nitric oxide therapy, anti-oxidative therapy, low level
   laser therapy, plasma rich platelet therapy and stem cell therapy as a
   novel therapeutic application to manage the pain and treat many clinical
   conditions.
SO MECHANISMS FOR LOW-LIGHT THERAPY IX
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Mechanisms for Low-Light Therapy IX
CY FEB 01-02, 2014
CL San Francisco, CA
SP SPIE
DE Nitric oxide; peroxynitrite; stem cells; platelet rich plasma; low level
   laser; redox phtobiomodulation; gold nanoparticle; antioxidant; reactive
   oxygen species; antioxidants
ID OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE-CELLS;
   RESPIRATORY-DISTRESS-SYNDROME; CALCIUM-PHOSPHATE CERAMICS; KERATINOCYTES
   IN-VITRO; GROWTH-FACTOR RECEPTOR; SPINAL-CORD-INJURY;
   MUSCULAR-DYSTROPHY; LIGHT THERAPY; CYCLIC-GMP
AB From hypertension to diabetes, cancer to HIV, stroke to memory loss and learning disorders to septic shock, male impotence to tuberculosis, there is probably no pathological condition where nitric oxide does not play an important role. Nitric oxide is an analgesic, immune-modulator, vasodilator, anti-apoptotic, growth modulator, angiogenetic, anti-thrombotic, anti-inflammatory and neuro-modulator. Because of the above actions of nitric oxide, many clinical conditions associated with abnormal Nitric oxide (NO) production and bioavailability. Our novel therapeutic approach is to restore the homeostasis of nitric oxide and replace the lost cells by combining nitric oxide therapy, anti-oxidative therapy, low level laser therapy, plasma rich platelet therapy and stem cell therapy.
CR AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103-011-0885-2
   Ali G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-75
   Aliyev A, 2004, NEUROL RES, V26, P547, DOI 10.1179/01610425017613
   Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980                                                         
   Anaya-Prado R, 2004, J TRAUMA, V57, P980, DOI 10.1097/01.TA.0000135354.82494.8D
   Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859                                                           
   Ashutosh K, 2000, THORAX, V55, P109, DOI 10.1136/thorax.55.2.109
   Avci P, 2013, LASERS SURG MED
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Bajt ML, 2003, J PHARMACOL EXP THER, V307, P67, DOI 10.1124/jpet.103.052506
   Barbosa D, 2013, LASER MED SCI, V28, P1489, DOI 10.1007/s10103-012-1241-x
   Basso FG, 2013, LASER MED SCI, V28, P367, DOI 10.1007/s10103-012-1057-8
   Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147
   Bergandi L, 2003, ARTERIOSCL THROM VAS, V23, P2215, DOI 10.1161/01.ATV.0000107028.20478.8e
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907                                                              
   Bonavida B, 2008, NITRIC OXIDE-BIOL CH, V19, P152, DOI 10.1016/j.niox.2008.04.018
   Brown GC, 2007, CARDIOVASC RES, V75, P283, DOI 10.1016/j.cardiores.2007.03.022
   Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104
   Buono R, 2012, STEM CELLS, V30, P197, DOI 10.1002/stem.783
   Burgaud JL, 2002, CURR PHARM DESIGN, V8, P201, DOI 10.2174/1381612023396357                                                        
   Burgaud JL, 2002, ANN NY ACAD SCI, V962, P360, DOI 10.1111/j.1749-6632.2002.tb04080.x                                              
   Cardinale F, 2005, PEDIATR ALLERGY IMMU, V16, P236, DOI 10.1111/j.1399-3038.2005.00265.x
   Carreira B. P., 2012, STEM CELLS INT, V2012
   Carreira BP, 2010, STEM CELLS, V28, P1219, DOI 10.1002/stem.444
   Charriaut-Marlangue C, 2012, STROKE, V43, P3078, DOI 10.1161/STROKEAHA.112.664243
   Chen JL, 2005, J NEUROSCI, V25, P2366, DOI 10.1523/JNEUROSCI.5071-04.2005
   Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080
   Chen W, 2009, BIOCHEM BIOPH RES CO, V390, P142, DOI 10.1016/j.bbrc.2009.09.083
   Cho HH, 2010, LARYNGOSCOPE, V120, P907, DOI 10.1002/lary.20860
   Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116
   Choi K, 2013, J BIOMED MATER RES B, V101B, P919, DOI 10.1002/jbm.b.32897
   Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582                                                     
   Cooke RM, 2013, J NEUROSCI, V33, P5626, DOI 10.1523/JNEUROSCI.3659-12.2013
   Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7
   Corbett SA, 1999, J BONE JOINT SURG BR, V81B, P531, DOI 10.1302/0301-620X.81B3.8852                                                     
   Xu Cui, 2010, J NEUROSCI RES UNPUB
   Cui X, 2009, J NEUROSCI RES, V87, P86, DOI 10.1002/jnr.21836
   Cunha TM, 2010, P NATL ACAD SCI USA, V107, P4442, DOI 10.1073/pnas.0914733107
   D'Angelo MG, 2012, PHARMACOL RES, V65, P472, DOI 10.1016/j.phrs.2012.01.006
   D'Atri LP, 2009, CURR MED CHEM, V16, P417, DOI 10.2174/092986709787315513                                                      
   Da Silva AA, 2013, J COSMET LASER THER, V15, P210, DOI 10.3109/14764172.2012.761345
   Davila Soledad, 2011, Laser Ther, V20, P287
   Day BJ, 2009, BIOCHEM PHARMACOL, V77, P285, DOI 10.1016/j.bcp.2008.09.029
   de Boer J, 2001, BRIT J PHARMACOL, V133, P1235, DOI 10.1038/sj.bjp.0704191                                                          
   de Boer J, 1999, BRIT J PHARMACOL, V128, P1114, DOI 10.1038/sj.bjp.0702882
   Demirakca S, 1996, CRIT CARE MED, V24, P1913, DOI 10.1097/00003246-199611000-00024
   DeSantiago J, 2013, STEM CELLS DEV, V22, P2497, DOI 10.1089/scd.2013.0136
   Deshmukh AS, 2010, DIABETOLOGIA, V53, P1142, DOI 10.1007/s00125-010-1716-x
   Deupree Susan M., 2010, MOL PHARM UNPUB, V7, P2289
   Dhir A, 2011, NITRIC OXIDE-BIOL CH, V24, P125, DOI 10.1016/j.niox.2011.02.002
   Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993
   Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342
   Drowley L, 2010, MOL THER, V18, P1865, DOI 10.1038/mt.2010.160
   Duplain H, 2001, CIRCULATION, V104, P342
   Eduardo FD, 2008, LASER SURG MED, V40, P433, DOI 10.1002/lsm.20646
   Elizalde M, 2000, J LIPID RES, V41, P1244
   El-Remessy A. B., 2010, EXP DIABETES RES, V2010, DOI DOI 10.1155/2010/247861.
   Englander Laura, 2010, J Clin Aesthet Dermatol, V3, P45
   Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829                                                                 
   Ferry-Dumazet H, 2002, LEUKEMIA, V16, P708, DOI 10.1038/sj/leu/2402404
   Fontoura PC, 2012, PSYCHOSOM MED, V74, P873, DOI 10.1097/PSY.0b013e3182689460
   Fraszczak J, 2010, J IMMUNOL, V184, P1876, DOI 10.4049/jimmunol.0900831
   Freitag J, 2012, BMJ CASE REP    1217
   Freitag JB, 2013, BMJ CASE REP    0326
   Friedman AJ, 2011, NITRIC OXIDE-BIOL CH, V25, P381, DOI 10.1016/j.niox.2011.09.001
   Galleano M, 2010, CURR PHARM BIOTECHNO, V11, P837, DOI 10.2174/138920110793262114                                                      
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-4
   Gao Y, 2013, BIOCHIMIE, V95, P2107, DOI 10.1016/j.biochi.2013.08.001
   GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652                                                       
   Geusens P, 2009, EXPERT OPIN BIOL TH, V9, P649, DOI [10.1517/14712590902926071 , 10.1517/14712590902926071]
   Giustizieri ML, 2002, AM J PATHOL, V161, P1409, DOI 10.1016/S0002-9440(10)64416-1                                                   
   Gladwin MT, 2002, BRIT J HAEMATOL, V116, P436, DOI 10.1046/j.1365-2141.2002.03274.x                                                
   Gonzalez-Abraldes J, 2002, METAB BRAIN DIS, V17, P311, DOI 10.1023/A:1021957818240
   Gruber HJ, 2008, INT J OBESITY, V32, P826, DOI 10.1038/sj.ijo.0803795
   Gurusamy N, 2010, J CELL MOL MED, V14, P2235, DOI 10.1111/j.1582-4934.2010.01140.x
   Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469
   Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013
   Hattori MA, 1996, AM J PHYSIOL-CELL PH, V270, pC812
   Hayashi T, 2008, PHARMACOL THERAPEUT, V120, P333, DOI 10.1016/j.pharmthera.2008.09.002
   Hermann Matthias, 2006, J Clin Hypertens (Greenwich), V8, P17, DOI 10.1111/j.1524-6175.2006.06032.x
   Hetrick EM, 2008, ACS NANO, V2, P235, DOI 10.1021/nn700191
   Hink U, 2003, J AM COLL CARDIOL, V42, P1826, DOI 10.1016/j.jacc.2003.07.009
   Hirst D, 2010, CURR PHARM DESIGN, V16, P411, DOI 10.2174/138161210790232185                                                      
   Honing MLH, 1998, DIABETES METAB REV, V14, P241, DOI 10.1002/(SICI)1099-0895(1998090)14:3<241::AID-DMR216>3.0.CO;2-R
   Hoshida S, 1996, J PHARMACOL EXP THER, V278, P741
   Hoskins C, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-27
   Hotkar M. S., 2013, INT WOUND J
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Huang L, 2008, ACTA PHARMACOL SIN, V29, P580, DOI 10.1111/j.1745-7254.2008.00778.x
   Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin
   Jamal SA, 2012, CURR OSTEOPOROS REP, V10, P86, DOI 10.1007/s11914-011-0087-7
   Jayet Pierre-Yves, 2004, Rev Med Suisse Romande, V124, P642
   Jia ZQ, 2009, MOL CELL BIOCHEM, V323, P131, DOI 10.1007/s11010-008-9971-6
   Jimenez ER, 2012, J WOUND OSTOMY CONTI
   Jimenez JL, 2001, J VIROL, V75, P4655, DOI 10.1128/JVI.75.10.4655-4663.2001
   Joyner MJ, 1997, J APPL PHYSIOL, V83, P1785
   Kashfi K, 2002, J PHARMACOL EXP THER, V303, P1273, DOI 10.1124/jpet.102.042754
   Kashyap SR, 2005, J CLIN ENDOCR METAB, V90, P1100, DOI 10.1210/jc.2004-0745
   Kasten P, 2006, CELLS TISSUES ORGANS, V183, P68, DOI 10.1159/000095511
   Kato GJ., 2008, HEMATOL-AM SOC HEMAT, V2008, P186, DOI DOI 10.1182/ASHEDUCATION-2008.1.186
   Kawashima S, 2004, ARTERIOSCL THROM VAS, V24, P998, DOI 10.1161/01.ATV.0000125114.88079.96
   Keeble JE, 2002, BRIT J PHARMACOL, V137, P295, DOI 10.1038/sj.bjp.0704876
   Kharitonov SA, 2003, CURR ALLERGY ASTHM R, V3, P121, DOI 10.1007/s11882-003-0024-7                                                       
   Khosla S, 2011, JAMA-J AM MED ASSOC, V305, P826, DOI 10.1001/jama.2011.191
   Kielbik M, 2013, NITRIC OXIDE-BIOL CH, V35, P93, DOI 10.1016/j.niox.2013.09.001
   Kim JE, 2003, PHYTOTHER RES, V17, P481, DOI 10.1002/ptr.1179
   Kim PJ, 2006, J AM PODIAT MED ASSN, V96, P318, DOI 10.7547/0960318                                                                 
   Kim SJ, 2008, CELL RES, V18, P686, DOI 10.1038/cr.2008.48
   Kim WS, 2009, EXPERT OPIN BIOL TH, V9, P879, DOI 10.1517/14712590903039684
   Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664
   Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199
   Klahr S, 2001, NEPHROL DIAL TRANSPL, V16, P60, DOI 10.1093/ndt/16.suppl_1.60                                                       
   Kolios G, 2004, IMMUNOLOGY, V113, P427, DOI 10.1111/j.1365-2567.2004.01984.x
   Kunieda T, 2008, CIRC RES, V102, P607, DOI 10.1161/CIRCRESAHA.107.162230
   Kushibiki T, 2013, INT J MOL SCI, V14, P13542, DOI 10.3390/ijms140713542
   Kutun S, 2010, S AFR J SURG, V48, P119
   Lagente Vincent, 2004, Curr Opin Investig Drugs, V5, P537
   Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069
   Lee JC, 2013, ARTHROSCOPY, V29, P1034, DOI 10.1016/j.arthro.2013.02.026
   Lee UL, EFFECT PLATELET RICH
   Li YS, 2013, BRAIN RES, V1507, P134, DOI 10.1016/j.brainres.2013.02.031
   Lupp A, 2010, ARZNEIMITTEL-FORSCH, V60, P229
   Maccarrone M, 1996, BIOCHEM BIOPH RES CO, V219, P128, DOI 10.1006/bbrc.1996.0193
   Mack AK, 2006, INT J BIOCHEM CELL B, V38, P1237, DOI 10.1016/j.biocel.2006.01.010
   Mangialardi G, 2011, BRIT J PHARMACOL, V164, P570, DOI 10.1111/j.1476-5381.2011.01423.x
   Mannick JB, 1999, J ACQ IMMUN DEF SYND, V22, P1, DOI 10.1097/00042560-199909010-00001                                                
   Marin E, 2007, CURR OPIN NEPHROL HY, V16, P105, DOI 10.1097/MNH.0b013e328017f893                                                    
   Marino J, 2006, REV NEUROLOGIA, V42, P535
   Martins MAT, 2012, ORAL ONCOL, V48, P79, DOI 10.1016/j.oraloncology.2011.08.010
   Masha A, 2011, CURR PHARM BIOTECHNO, V12, P1354, DOI 10.2174/138920111798281054                                                      
   Mason R Preston, 2006, J Clin Hypertens (Greenwich), V8, P40, DOI 10.1111/j.1524-6175.2006.06041.x
   McLeod T M, 2001, Psychopharmacol Bull, V35, P24
   Michurina T, 2004, MOL THER, V10, P241, DOI 10.1016/j.ymthe.2004.05.030
   Miller MR, 2007, BRIT J PHARMACOL, V151, P305, DOI 10.1038/sj.bjb.0707224
   Millet A, 2002, GASTROENTEROLOGY, V123, P235, DOI 10.1053/gast.2002.34310
   Min Pok Kee, 2013, Laser Ther, V22, P43
   Mishra A, 2009, TISSUE ENG PART C-ME, V15, P431, DOI 10.1089/ten.tec.2008.0534
   Mittermayr R, 2007, MOL MED, V13, P22, DOI 10.2119/2006-00035.Mittermayr
   Mocellin S, 2007, MED RES REV, V27, P317, DOI 10.1002/med.20092
   Mollace V, 2005, PHARMACOL REV, V57, P217, DOI 10.1124/pr.57.2.1
   Mondoro TH, 2001, BRIT J HAEMATOL, V112, P1048, DOI 10.1046/j.1365-2141.2001.02623.x
   Montesanto A, 2013, BIOGERONTOLOGY, V14, P177, DOI 10.1007/s10522-013-9421-z
   Moreno-Lopez B, 2006, REV NEUROSCIENCE, V17, P309
   Morimoto Yusuke, 2013, Laser Ther, V22, P17
   Morlin B, 2005, ACTA OBSTET GYN SCAN, V84, P883, DOI 10.1111/j.0001-6349.2005.00752.x                                                
   Mujoo K, 2012, PROTEIN CELL, V3, P535, DOI 10.1007/s13238-012-2053-2
   Mujoo K, 2011, FREE RADICAL BIO MED, V51, P2150, DOI 10.1016/j.freeradbiomed.2011.09.037
   Mujoo K, 2008, P NATL ACAD SCI USA, V105, P18924, DOI 10.1073/pnas.0810230105
   Muscara Marcelo N., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P155, DOI 10.2174/187152506776369917
   Musicki B, 2009, J SEX MED, V6, P247, DOI 10.1111/j.1743-6109.2008.01122.x
   Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814
   Namazi MR, 2003, INFLAMM RES, V52, P227, DOI 10.1007/s00011-003-1175-7
   Napoli C, 2006, NITRIC OXIDE-BIOL CH, V15, P265, DOI 10.1016/j.niox.2006.03.011
   Napoli C, 2013, J AM COLL CARDIOL, V62, P89, DOI 10.1016/j.jacc.2013.03.070
   Monteiro BS, 2012, CLIN EXP DERMATOL, V37, P544
   Nikonenko I, 2013, P NATL ACAD SCI USA, V110, pE4142, DOI 10.1073/pnas.1311927110
   Oosthuizen Frasia, 2005, Neuropsychiatr Dis Treat, V1, P109, DOI 10.2147/nedt.1.2.109.61049
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Park KY, 2013, J DERMATOL TREAT, V24, P332, DOI 10.3109/09546634.2012.735637
   Paul V, 2011, INDIAN J MED RES, V133, P471
   Payne Donald N R, 2003, Curr Opin Allergy Clin Immunol, V3, P133, DOI 10.1097/00130832-200304000-00007
   Persichini T, 1999, BIOCHEM BIOPH RES CO, V254, P200, DOI 10.1006/bbrc.1998.9880
   Persichini T, 1999, BIOCHEM BIOPH RES CO, V258, P624, DOI 10.1006/bbrc.1999.0581                                                          
   Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998
   Van Pham P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt277
   Pieri F, 2008, J CLIN PERIODONTOL, V35, P539, DOI 10.1111/j.1600-051X.2008.01220.x
   Pinto Vivian Liane M., 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P142, DOI 10.2174/187152508783955060
   Pol O, 2005, BRIT J PHARMACOL, V145, P758, DOI 10.1038/sj.bjp.0706227
   Pol O, 2007, CURR MED CHEM, V14, P1945
   Prast H, 2001, PROG NEUROBIOL, V64, P51, DOI 10.1016/S0301-0082(00)00044-7
   Provost P, 1997, ARTERIOSCL THROM VAS, V17, P1806, DOI 10.1161/01.ATV.17.9.1806                                                        
   Quintanilha LF, 2013, HEPATOL RES
   Rapozzi V, 2013, NITRIC OXIDE-BIOL CH, V30, P26, DOI 10.1016/j.niox.2013.01.002
   Rashid Parveen A, 2003, J Stroke Cerebrovasc Dis, V12, P82, DOI 10.1053/jscd.2003.9
   Reitz A, 2004, EUR UROL, V45, P516, DOI 10.1016/j.eururo.2003.11.006
   Reynaert NL, 2005, ANTIOXID REDOX SIGN, V7, P129, DOI 10.1089/ars.2005.7.129
   Ribas Eduardo Santamaria Carvalhal, 2012, Int J Gen Med, V5, P739, DOI 10.2147/IJGM.S18511
   Ricciardolo FLM, 2006, CURR DRUG TARGETS, V7, P721, DOI 10.2174/138945006777435290                                                      
   Rigas B, 2007, BIOCHEM SOC T, V35, P1364, DOI 10.1042/BST0351364                                                              
   Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139
   Roberts BW, 2013, SHOCK, V39, P229, DOI 10.1097/SHK.0b013e31827f565b
   Salvemini D, 2009, ARCH BIOCHEM BIOPHYS, V484, P238, DOI 10.1016/j.abb.2008.11.005
   Sang Jian-Rong, 2010, Chin J Cancer, V29, P158
   Sansbury BE, 2012, CIRC RES, V111, P1176, DOI 10.1161/CIRCRESAHA.112.266395
   Santoscopy C, 2002, NEUROSCI LETT, V330, P94, DOI 10.1016/S0304-3940(02)00716-4
   Saraiva J, 2011, J DRUG DELIV, V2011, DOI DOI 10.1155/2011/936438
   Saraiva RM, 2006, CURR OPIN CARDIOL, V21, P221, DOI 10.1097/01.hco.0000221584.56372.dc                                              
   Scatena R, 2005, EXPERT OPIN INV DRUG, V14, P835, DOI 10.1517/13543784.14.7.835
   Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154
   Sciorati C, 2006, J CELL SCI, V119, P5114, DOI 10.1242/jcs.03300
   Sciorati C, 2010, BRIT J PHARMACOL, V160, P1550, DOI 10.1111/j.1476-5381.2010.00809.x
   Sehajpal PK, 1999, BIOCHEMISTRY-US, V38, P13407, DOI 10.1021/bi9912995
   Serezhenkov V A, 2011, Biofizika, V56, P1125
   Shami PJ, 2009, LEUKEMIA RES, V33, P1525, DOI 10.1016/j.leukres.2009.01.002
   Shimizu S, 2004, INT J BIOCHEM CELL B, V36, P114, DOI 10.1016/S1357-2725(03)00170-5
   Siemens DR, 2009, UROLOGY, V74, P878, DOI 10.1016/j.urology.2009.03.004
   Singh VK, 2000, IMMUNOL RES, V22, P1, DOI 10.1385/IR:22:1:1
   Spitler R, 2013, CELL SIGNAL, V25, P2374, DOI 10.1016/j.cellsig.2013.07.029
   Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091                                                        
   Sun LY, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-53
   Sun YJ, 2005, J CEREBR BLOOD F MET, V25, P485, DOI 10.1038/sj.jcbfm.9600049
   Sydow K, 2005, VASC MED, V10, pS35, DOI 10.1191/1358863x05vm604oa
   Tadayyon F, 2012, SAUDI J KIDNEY DIS T, V23, P782, DOI 10.4103/1319-2442.98160
   Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184
   Takashima S, 2006, J THORAC CARDIOV SUR, V132, P132, DOI 10.1016/j.jtcvs.2006.02.032
   Tegenge MA, 2011, CELL MOL LIFE SCI, V68, P2089, DOI 10.1007/s00018-010-0554-9
   Terpolilli NA, 2012, J CEREBR BLOOD F MET, V32, P1332, DOI 10.1038/jcbfm.2012.12
   Terpolilli NA, 2012, CIRC RES, V110, P727, DOI 10.1161/CIRCRESAHA.111.253419
   Tilton RG, 2001, EXPERT OPIN INV DRUG, V10, P1291, DOI 10.1517/13543784.10.7.1291                                                      
   Togo T, 2004, NEUROL RES, V26, P563, DOI 10.1179/016164104225016236
   Torre D, 2002, LANCET INFECT DIS, V2, P273, DOI 10.1016/S1473-3099(02)00262-1
   TRAUB O, 1995, WESTERN J MED, V162, P439
   Tuby H, 2006, LASER SURG MED, V38, P682, DOI 10.1002/lsm.20377
   Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063
   Tziros C, 2006, CURR DRUG TARGETS, V7, P1243, DOI 10.2174/138945006778559111
   van Amsterdam JGC, 1999, PSYCHIAT RES, V85, P33, DOI 10.1016/S0165-1781(98)00140-1                                                   
   Van Hove CE, 2009, BRIT J PHARMACOL, V158, P920, DOI 10.1111/j.1476-5381.2009.00396.x
   Verma RK, 2012, MOL PHARMACEUT, V9, P3183, DOI 10.1021/mp300269g
   Verma RK, 2013, TUBERCULOSIS, V93, P412, DOI 10.1016/j.tube.2013.02.012
   Vleeming Wim, 2002, Nicotine Tob Res, V4, P341
   Vogel JP, 2006, PLATELETS, V17, P462, DOI 10.1080/09537100600758867
   Wallace JL, 2009, TRENDS PHARMACOL SCI, V30, P112, DOI 10.1016/j.tips.2009.01.001
   Cao H, 2013, THERIOGENOLOGY
   Wei FL, 2012, J CELL PHYSIOL, V227, P3216, DOI 10.1002/jcp.24012
   Weller R, 2002, SKIN PHARMACOL APPL, V15, P348, DOI 10.1159/000064540                                                               
   Wenk GL, 2004, J NEUROCHEM, V89, P484, DOI 10.1111/j.1471-4159.2004.02359.x
   Willmot M, 2005, NITRIC OXIDE-BIOL CH, V12, P141, DOI 10.1016/j.niox.2005.01.003
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550
   Witte MB, 2002, BRIT J SURG, V89, P1594, DOI 10.1046/j.1365-2168.2002.02263.x
   Wong JC, 2011, J CELL BIOCHEM, V112, P829, DOI 10.1002/jcb.22981
   Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729
   Chen Chia-Hsin, 2013, INT J ORAL SCI, V5, P85
   Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454
   Yamada Y, 2004, TISSUE ENG, V10, P955, DOI 10.1089/1076327041348284                                                        
   Yang C.C., 2013, J TISSUE ENG REGEN M
   Yang ZK, 2011, PHOTOMED LASER SURG, V29, P391, DOI 10.1089/pho.2010.2866
   Yasuda H, 2008, NITRIC OXIDE-BIOL CH, V19, P205, DOI 10.1016/j.niox.2008.04.026
   Yin XK, 2006, PROTEOMICS, V6, P6437, DOI 10.1002/pmic.200600351
   Yoo JW, 2010, J BIOMED MATER RES A, V92A, P1233, DOI 10.1002/jbm.a.32434
   Yoshimi R, 2009, J CRANIOFAC SURG, V20, P1523, DOI 10.1097/SCS.0b013e3181b09b7e
   Yu D, 2009, STEM CELLS, V27, P1212, DOI 10.1002/stem.26
   Zaidi M, 2013, PHOTOCHEM PHOTOBIOL, V89, P709, DOI 10.1111/php.12024
   Zhan Ri-xing, 2012, Zhonghua Shao Shang Za Zhi, V28, P125
   Zhang H, 2006, ARCH PHARM RES, V29, P145, DOI 10.1007/BF02974276                                                              
   Zhang RL, 2003, CIRC RES, V92, P308, DOI 10.1161/01.RES.000056757.93432.8C
   Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249
   Zhu W, 2002, J BONE MINER RES, V17, P1470, DOI 10.1359/jbmr.2002.17.8.1470
   Zhu W, 2001, J BONE MINER RES, V16, P535, DOI 10.1359/jbmr.2001.16.3.535
   Zidek Z, 1998, INT J IMMUNOPHARMACO, V20, P319, DOI 10.1016/S0192-0561(98)00036-8                                                   
   Zordan P, 2013, EUR J PHARMACOL, V715, P296, DOI 10.1016/j.ejphar.2013.05.007
NR 253
TC 0
Z9 0
U1 0
U2 6
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-9845-8
J9 PROC SPIE
PY 2014
VL 8932
AR 893205
DI 10.1117/12.2038329
PG 24
WC Biophysics; Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Biophysics; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BA3KX
UT WOS:000334338800003
DA 2018-01-05
ER

PT J
AU Wang, XG
   Zhang, QF
   Hao, F
   Gao, XNA
   Wu, W
   Liang, MY
   Liao, ZH
   Luo, SH
   Xu, WW
   Li, DX
   Wang, SW
AF Wang, Xianguo
   Zhang, Quanfu
   Hao, Fen
   Gao, Xunian
   Wu, Wei
   Liang, Minyao
   Liao, Zhihua
   Luo, Shuhong
   Xu, Weiwen
   Li, Dexin
   Wang, Shiwen
TI Development of a Colloidal Gold Kit for the Diagnosis of Severe Fever
   with Thrombocytopenia Syndrome Virus Infection
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID IMMUNOCHROMATOGRAPHIC TEST STRIP; LINKED-IMMUNOSORBENT-ASSAY;
   BUNYAVIRUS; CHINA; AFLATOXINS; ANTIBODY
AB It is critical to develop a cost-effective detection kit for rapid diagnosis and on-site detection of severe fever with thrombocytopenia syndrome virus (SFTSV) infection. Here, an immunochromatographic assay (ICA) to detect SFTSV infection is described. The ICA uses gold nanoparticles coated with recombinant SFTSV for the simultaneous detection of IgG and IgM antibodies to SFTSV. The ICA was developed and evaluated by using positive sera samples of SFTSV infection (n=245) collected from the CDC of China. The reference laboratory diagnosis of SFTSV infection was based on the "gold standard". The results demonstrated that the positive coincidence rate and negative coincidence rate were determined to be 98.4% and 100% for IgM and 96.7% and 98.6% for IgG, respectively. The kit showed good selectivity for detection of SFTSV-specific IgG and IgM with no interference from positive sera samples of Japanese encephalitis virus infection, Dengue virus infection, Hantavirus infection, HIV infection, HBV surface antigen, HCV antibody, Mycobacterium tuberculosis antibody, or RF. Based on these results, the ICS test developed may be a suitable tool for rapid on-site testing for SFTSV infections.
C1 [Wang, Xianguo; Hao, Fen; Luo, Shuhong; Xu, Weiwen] Southern Med Univ, Sch Biotechnol, Inst Antibody Engn, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhang, Quanfu; Wu, Wei; Li, Dexin; Wang, Shiwen] China CDC, Natl Inst Viral Dis Control & Prevent, Key Lab Med Virol, Beijing 102206, Peoples R China.
   [Liang, Minyao; Liao, Zhihua] Sun Yat Sen Univ, DaAn Gene Co Ltd, Guangzhou 510515, Guangdong, Peoples R China.
RP Xu, WW (reprint author), Southern Med Univ, Sch Biotechnol, Inst Antibody Engn, 1838 N Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China.
EM xusandy2006@126.com; 379763511@qq.com
FU China Mega-Project for Infectious Diseases [2012ZX10004215]; MOH; Key
   Project, Ministry of Science and Technology [2013ZX10004-803]
FX The authors thank Shandong province CDC, Hubei province CDC, and
   Liaoning province CDC for providing SFTS patients sera. This work was
   supported by the China Mega-Project for Infectious Diseases
   (2012ZX10004215), MOH, and Key Project (2013ZX10004-803), Ministry of
   Science and Technology.
CR Cui LB, 2012, J CLIN MICROBIOL, V50, P3881, DOI 10.1128/JCM.01931-12
   Frens G., NATURE PHYS SCI, V241, P20
   Gai ZT, 2012, J INFECT DIS, V206, P1095, DOI 10.1093/infdis/jis472
   Jiao YJ, 2012, J CLIN MICROBIOL, V50, P372, DOI 10.1128/JCM.01319-11
   Krajaejun T, 2009, CLIN VACCINE IMMUNOL, V16, P506, DOI 10.1128/CVI.00276-08
   李德新, 2011, [中华实验和临床病毒学杂志, Chinese Journal of Experimental and Clinical Virology], V25, P81
   Li ZF, 2013, J MED VIROL, V85, P370, DOI 10.1002/jmv.23415
   Liu BH, 2008, ANAL CHEM, V80, P7029, DOI 10.1021/ac800951p
   LU J, 2011, CHINESE J VIROL, V27, P515
   Sheibani A, 2008, TALANTA, V75, P233, DOI 10.1016/j.talanta.2007.11.006
   Sithigorngul P, 2007, J MICROBIOL METH, V71, P256, DOI 10.1016/j.mimet.2007.09.012
   Sithigorngul W, 2007, J VIROL METHODS, V140, P193, DOI 10.1016/j.jviromet.2006.11.034
   Stone R, 2010, SCIENCE, V330, P20, DOI 10.1126/science.330.6000.20
   Sun YL, 2012, J CLIN VIROL, V53, P48, DOI 10.1016/j.jcv.2011.09.031
   Sundar S, 2006, J CLIN MICROBIOL, V44, P251, DOI 10.1128/JCM.44.1.251-253.2006
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   Xu Y, 2010, FOOD CHEM, V119, P834, DOI 10.1016/j.foodchem.2009.08.049
   Yang GL, 2012, ARCH VIROL, V157, P1779, DOI 10.1007/s00705-012-1348-1
   Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095
   Zhang DH, 2013, SENSOR ACTUAT B-CHEM, V185, P432, DOI 10.1016/j.snb.2013.05.034
   Zhang LJ, 2008, JAMA-J AM MED ASSOC, V300, P2263, DOI 10.1001/jama.2008.626
NR 21
TC 0
Z9 1
U1 1
U2 9
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
AR 530621
DI 10.1155/2014/530621
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AF9KR
UT WOS:000335034300001
OA gold
DA 2018-01-05
ER

PT J
AU Wu, YM
   Cen, Y
   Huang, LJ
   Yu, RQ
   Chu, X
AF Wu, Yan-Mei
   Cen, Yao
   Huang, Li-Jiao
   Yu, Ru-Qin
   Chu, Xia
TI Upconversion fluorescence resonance energy transfer biosensor for
   sensitive detection of human immunodeficiency virus antibodies in human
   serum
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID LUMINESCENT NANOPARTICLES; GRAPHENE OXIDE; COMPLEX; NANOCRYSTALS;
   EMISSION; CELLS
AB A facile one-step approach was proposed to prepare hydrophilic and peptide-functionalized upconversion nanoparticles (UCNPs), which were used in the design of a biosensor for the sensitive and selective determination of human immunodeficiency virus antibodies in human serum based on FRET from the UCNPs to the graphene oxide.
C1 [Wu, Yan-Mei; Cen, Yao; Huang, Li-Jiao; Yu, Ru-Qin; Chu, Xia] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemobio Sensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
RP Chu, X (reprint author), Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemobio Sensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
EM xiachu@hnu.edu.cn
FU National Natural Science Foundation of China [21275045, NCET-11-0121];
   Hunan Provincial Natural Science Foundation of China [12JJ1004]
FX This work was supported by the National Natural Science Foundation of
   China (No. 21275045), NCET-11-0121, and Hunan Provincial Natural Science
   Foundation of China (Grant 12JJ1004).
CR Achatz DE, 2011, ANGEW CHEM INT EDIT, V50, P260, DOI 10.1002/anie.201004902
   Chen D, 2012, CHEM REV, V112, P6027, DOI 10.1021/cr300115g
   Gill R, 2008, ANGEW CHEM INT EDIT, V47, P7602, DOI 10.1002/anie.200800169
   Haase M, 2011, ANGEW CHEM INT EDIT, V50, P5808, DOI 10.1002/anie.201005159
   Li LL, 2012, ANGEW CHEM INT EDIT, V51, P6121, DOI 10.1002/anie.201109156
   Li ZQ, 2008, ADV MATER, V20, P4765, DOI 10.1002/adma.200801056
   Liu CH, 2011, CHEM COMMUN, V47, P4661, DOI 10.1039/c1cc10597c
   Liu JL, 2011, J AM CHEM SOC, V133, P15276, DOI 10.1021/ja205907y
   Liu Q, 2011, ACS NANO, V5, P8040, DOI 10.1021/nn202620u
   Lu CH, 2011, ANAL CHEM, V83, P7276, DOI 10.1021/ac200617k
   Mader HS, 2010, ANAL CHEM, V82, P5002, DOI 10.1021/ac1007283
   Schafer H, 2007, CHEM MATER, V19, P1396, DOI 10.1021/cm062385b
   Wang F, 2008, J AM CHEM SOC, V130, P5642, DOI 10.1021/ja800868a
   Wang F, 2011, NAT MATER, V10, P968, DOI [10.1038/nmat3149, 10.1038/NMAT3149]
   Wang LY, 2006, CHEM COMMUN, P2557, DOI 10.1039/b604871d
   Wang Y, 2011, NEURAL REGEN RES, V6, P6, DOI 10.3969/j.issn.1673-5374.2011.01.001
   Wang Y, 2011, TRENDS BIOTECHNOL, V29, P205, DOI 10.1016/j.tibtech.2011.01.008
   Wang Y, 2010, J AM CHEM SOC, V132, P9274, DOI 10.1021/ja103169v
   Wang YH, 2012, ANAL CHEM, V84, P1466, DOI 10.1021/ac202627b
   Wu BY, 2011, J AM CHEM SOC, V133, P686, DOI 10.1021/ja108788p
   Wu SJ, 2012, ANAL CHEM, V84, P6263, DOI 10.1021/ac301534w
   Wu SJ, 2012, CHEM COMMUN, V48, P4866, DOI 10.1039/c2cc00092j
   Zhang P, 2006, J AM CHEM SOC, V128, P12410, DOI 10.1021/ja0644024
NR 23
TC 31
Z9 31
U1 1
U2 109
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2014
VL 50
IS 36
BP 4759
EP 4762
DI 10.1039/c4cc00569d
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA AF3GY
UT WOS:000334601000026
PM 24686326
DA 2018-01-05
ER

PT J
AU Gomes, MJ
   das Neves, J
   Sarmento, B
AF Gomes, Maria Joao
   das Neves, Jose
   Sarmento, Bruno
TI Nanoparticle-based drug delivery to improve the efficacy of
   antiretroviral therapy in the central nervous system
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE HIV/AIDS; blood-brain barrier; protease inhibitors; efflux transporters;
   drug targeting
ID BLOOD-BRAIN-BARRIER; SOLID LIPID NANOPARTICLES; CEREBROSPINAL-FLUID
   CONCENTRATIONS; MONOCYTE-DERIVED MACROPHAGES; AIDS DEMENTIA COMPLEX;
   IN-VIVO EVALUATION; ANTI-HIV DRUGS; TARGETED DELIVERY; P-GLYCOPROTEIN;
   MULTIDRUG-RESISTANCE
AB Antiretroviral drug therapy plays a cornerstone role in the treatment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome patients. Despite obvious advances over the past 3 decades, new approaches toward improved management of infected individuals are still required. Drug distribution to the central nervous system (CNS) is required in order to limit and control viral infection, but the presence of natural barrier structures, in particular the blood-brain barrier, strongly limits the perfusion of anti-HIV compounds into this anatomical site. Nanotechnology-based approaches may help providing solutions for antiretroviral drug delivery to the CNS by potentially prolonging systemic drug circulation, increasing the crossing and reducing the efflux of active compounds at the blood-brain barrier, and providing cell/tissue-targeting and intracellular drug delivery. After an initial overview on the basic features of HIV infection of the CNS and barriers to active compound delivery to this anatomical site, this review focuses on recent strategies based on antiretroviral drug-loaded solid nanoparticles and drug nanosuspensions for the potential management of HIV infection of the CNS.
C1 [Gomes, Maria Joao; das Neves, Jose; Sarmento, Bruno] Inst Engn Biomed INEB, P-4150180 Oporto, Portugal.
   [das Neves, Jose; Sarmento, Bruno] CESPU, Inst Super Ciencias Saude Norte, Inst Invest & Formacao Avancada Ciencias & Tecnol, Gandra, Portugal.
RP Sarmento, B (reprint author), Inst Engn Biomed INEB, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.
EM bruno.sarmento@ineb.up.pt
RI Sarmento, Bruno/J-6265-2013; das Neves, Jose/J-8369-2013
OI Sarmento, Bruno/0000-0001-5763-7553; das Neves,
   Jose/0000-0002-2317-2759; Gomes, Maria Joao/0000-0002-1732-8913
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BD/90404/2012, SFRH/BPD/92934/2013]; FCT [VIH/SAU/0021/2011];
   European Regional Development Fund (ERDF); Portuguese funds through FCT
   [C/SAU/LA0002/2013]; North Portugal Regional Operational Programme (ON.2
   - O Novo Norte) [SAESCTN-PIICDT/2011]; National Strategic Reference
   Framework (NSRF)
FX Maria Joao Gomes and Jose das Neves gratefully acknowledge Fundacao para
   a Ciencia e a Tecnologia (FCT), Portugal for financial support (grants
   SFRH/BD/90404/2012 and SFRH/BPD/92934/2013, respectively). This work was
   financed by a grant from FCT (reference VIH/SAU/0021/2011) and by the
   European Regional Development Fund (ERDF) through the Programa
   Operacional Factores de Competitividade (COMPETE), by Portuguese funds
   through FCT in the framework of the project PEst-C/SAU/LA0002/2013, and
   cofinanced by North Portugal Regional Operational Programme (ON.2 - O
   Novo Norte) in the framework of project SAESCTN-PIIC&DT/2011, under the
   National Strategic Reference Framework (NSRF).
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Antinori A, 2005, CLIN INFECT DIS, V41, P1787, DOI 10.1086/498310                                                                  
   Aweeka F, 1999, J ACQ IMMUN DEF SYND, V20, P39, DOI 10.1097/00042560-199901010-00006                                                
   Bauer B, 2005, EXP BIOL MED, V230, P118
   Beard J, 2009, AIDS CARE, V21, P1343, DOI 10.1080/09540120902889926
   Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844
   Berger JR, 2004, FRONT BIOSCI, V9, P2680, DOI 10.2741/1427
   Best BM, 2012, JAIDS-J ACQ IMM DEF, V59, P376, DOI 10.1097/QAI.0b013e318247ec54
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   BLUM MR, 1988, AM J MED, V85, P189
   Boisse L, 2008, NEUROL CLIN, V26, P799, DOI 10.1016/j.ncl.2008.04.002
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413
   Borgmann K, 2011, AIDS RES HUM RETROV, V27, P853, DOI [10.1089/aid.2010.0295, 10.1089/AID.2010.0295]
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Brew BJ, 2004, AIDS, V18, pS75
   Calcagno A, 2011, AIDS, V25, P1437, DOI 10.1097/QAD.0b013e3283489cb1
   Cecchelli R, 2007, NAT REV DRUG DISCOV, V6, P650, DOI 10.1038/nrd2368
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Croteau D, 2012, AIDS, V26, P890, DOI 10.1097/QAD.0b013e328351f627
   Croteau D, 2012, ANTIMICROB AGENTS CH, V56, P1985, DOI 10.1128/AAC.05098-11
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dauchy S, 2008, J NEUROCHEM, V107, P1518, DOI 10.1111/j.1471-4159.2008.05720.x
   de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237
   Dean M, 2001, J LIPID RES, V42, P1007
   Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877
   Destache CJ, 2009, PROG BRAIN RES, V180, P225, DOI 10.1016/S0079-6123(08)80012-X
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Foster RH, 1998, DRUGS, V55, P729, DOI 10.2165/00003495-199855050-00018
   Fuest C, 2009, NEUROSCI LETT, V464, P47, DOI 10.1016/j.neulet.2009.08.014
   Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028
   Gaillard PJ, 2012, J CONTROL RELEASE, V164, P364, DOI 10.1016/j.jconrel.2012.06.022
   Gerson T, 2014, NANOMED-NANOTECHNOL, V10, P177, DOI 10.1016/j.nano.2013.06.012
   Gessner A, 2002, EUR J PHARM BIOPHARM, V54, P165, DOI 10.1016/S0939-6411(02)00081-4
   Gimenez F, 2004, JAIDS-J ACQ IMM DEF, V36, P649, DOI 10.1097/00126334-200406010-00001                                                
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Goppert TM, 2005, J DRUG TARGET, V13, P179, DOI 10.1080/10611860500071292
   Hartz AMS, 2010, MOL INTERV, V10, P293, DOI 10.1124/mi.10.5.6
   Haworth SJ, 1998, J ACQ IMMUN DEF SYND, V17, P235, DOI 10.1097/00042560-199803010-00008                                                
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Honjo K, 2010, J GENE MED, V12, P219, DOI 10.1002/jgm.1378
   Hu YL, 2010, INT J PHARMACEUT, V394, P115, DOI 10.1016/j.ijpharm.2010.04.026
   Jain KK, 2006, NANOMEDICINE-UK, V1, P9, DOI 10.2217/17435889.1.1.9
   Jain K. K., 2012, HDB NANOMEDICINE
   Joint United Nations Programme on HIV/AIDS, 2013, 2013 UNAIDS REP GLOB
   Joshy K. S., 2012, ADV SCI LETT, V6, P47
   Juillerat-Jeanneret L, 2008, DRUG DISCOV TODAY, V13, P1099, DOI 10.1016/j.drudis.2008.09.005
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kravcik S, 1999, J ACQ IMMUN DEF SYND, V21, P371
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kumar AM, 2007, J NEUROVIROL, V13, P210, DOI 10.1080/13550280701327038
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048
   Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5
   Letendre S, 2013, 20 C RETR OPP INF MA
   Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31
   Letendre Scott L, 2010, Top HIV Med, V18, P45
   Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1
   Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481                                                           
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mahajan SD, 2012, METHOD ENZYMOL, V509, P41, DOI 10.1016/B978-0-12-391858-1.00003-4
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Markoutsa E, 2011, EUR J PHARM BIOPHARM, V77, P265, DOI 10.1016/j.ejpb.2010.11.015
   Mcgee B, 2006, HIV CLIN TRIALS, V7, P142, DOI 10.1310/AW2H-TP5C-NP43-K6BY                                                     
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674                                                         
   Murthy SK, 2007, INT J NANOMED, V2, P129
   Nagpal K, 2013, EXPERT OPIN DRUG DEL, V10, P927, DOI 10.1517/17425247.2013.762354
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90
   Prabhakar K, 2011, COLLOID SURFACE B, V86, P305, DOI 10.1016/j.colsurfb.2011.04.013
   Price RW, 2008, ANTIVIR THER, V13, P369
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Santaguida S, 2006, BRAIN RES, V1109, P1, DOI 10.1016/j.brainres.2006.06.027
   Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699                                                               
   Shah L, 2013, DRUG DELIV TRANSL RE, V3, P336, DOI 10.1007/s13346-013-0133-3
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Shegokar R, 2011, NANOMED-NANOTECHNOL, V7, P333, DOI 10.1016/j.nano.2010.10.012
   SHELTON MJ, 1992, ANN PHARMACOTHER, V26, P660, DOI 10.1177/106002809202600511                                                      
   Smith PF, 2001, CLIN PHARMACOKINET, V40, P893, DOI 10.2165/00003088-200140120-00002                                                
   Smurzynski M, 2011, AIDS, V25, P357, DOI 10.1097/QAD.0b013e32834171f8
   Tahara K, 2011, EUR J PHARM BIOPHARM, V77, P84, DOI 10.1016/j.ejpb.2010.11.002
   Tiraboschi JM, 2012, J ANTIMICROB CHEMOTH, V67, P1446, DOI 10.1093/jac/dks048
   Valcour V., 2011, Current HIV/AIDS Reports, V8, P54, DOI 10.1007/s11904-010-0070-4
   Vance JE, 2010, BBA-MOL CELL BIOL L, V1801, P806, DOI 10.1016/j.bbalip.2010.02.007
   VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166                                                       
   Vella S, 1998, CLIN PHARMACOKINET, V34, P189, DOI 10.2165/00003088-199834030-00002                                                
   Vilella A, 2013, J CONTROL RELEASE, V174, P195
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wilson B, 2008, EUR J PHARM BIOPHARM, V70, P75, DOI 10.1016/j.ejpb.2008.03.009
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Chen XP, 2006, WORLD J GASTROENTERO, V12, P3332, DOI 10.3748/wjg.v12.i21.3332                                                        
   Xu G, 2008, BIOCONJUGATE CHEM, V19, P1179, DOI 10.1021/bc700477u
   Yilmaz A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006877
   Yilmaz A, 2009, AIDS RES HUM RETROV, V25, P457, DOI 10.1089/aid.2008.0216
NR 112
TC 21
Z9 21
U1 2
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2014
VL 9
BP 1757
EP 1769
DI 10.2147/IJN.S45886
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA AE2PR
UT WOS:000333815900001
PM 24741312
OA gold
DA 2018-01-05
ER

PT S
AU Labib, M
   Berezovski, MV
AF Labib, Mahmoud
   Berezovski, Maxim V.
BE Gu, MB
   Kim, HS
TI Electrochemical Aptasensors for Microbial and Viral Pathogens
SO BIOSENSORS BASED ON APTAMERS AND ENZYMES
SE Advances in Biochemical Engineering-Biotechnology
LA English
DT Article; Book Chapter
DE Affinity; Aptamers; Aptasensor; Bacteria; Electrochemical; Epitope;
   Oncolytic viruses; Pathogen; Viability
ID LABEL-FREE DETECTION; NEUTRALIZING MONOCLONAL-ANTIBODIES; VIABILITY
   IMPEDIMETRIC SENSOR; HIV-1 REVERSE-TRANSCRIPTASE; ION-SELECTIVE
   ELECTRODES; FIELD-EFFECT TRANSISTORS; WALLED CARBON NANOTUBES; VACCINIA
   VIRUS L1R; DNA APTAMER; STAPHYLOCOCCUS-AUREUS
AB Aptamers are DNA and RNA oligonucleotides that can bind to a variety of nonnucleic acid targets with high affinity and specificity. Pathogen detection is a promising area in aptamer research. One of its major advantages is the ability of the aptamers to target and specifically differentiate microbial and viral strains without previous knowledge of the membrane-associated antigenic determinants or molecular biomarkers present in that particular microorganism. Electrochemical sensors emerged as a promising field in the area of aptamer research and pathogen detection. An electrochemical sensor is a device that combines a recognition element and an electrochemical transduction unit, where aptamers represent the latest addition to the large catalog of recognition elements. This chapter summarizes and evaluates recent developments of electrochemical aptamer-based sensors for microbial and viral pathogen detection, viability assessment of microorganisms, bacterial typing, identification of epitope-specific aptamers, affinity measurement between aptamers and their respective targets, and estimation of the degree of aptamer protection of oncolytic viruses for therapeutic purposes.
C1 [Labib, Mahmoud; Berezovski, Maxim V.] Univ Ottawa, Dept Chem, Ottawa, ON K1N 6N5, Canada.
RP Berezovski, MV (reprint author), Univ Ottawa, Dept Chem, 10 Marie Curie, Ottawa, ON K1N 6N5, Canada.
EM Maxim.Berezovski@uottawa.ca
RI Berezovski, Maxim/F-8961-2012; Labib, Mahmoud/P-2267-2014
OI Berezovski, Maxim/0000-0003-0514-599X; Labib,
   Mahmoud/0000-0003-4565-2056
CR Alocilja EC, 2003, BIOSENS BIOELECTRON, V18, P841, DOI 10.1016/S0956-5663(03)00009-5
   Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059
   BCC-Research, 2010, NUCL AC APT DIAGN TH
   Berezovski M, 2006, J AM CHEM SOC, V128, P1410, DOI 10.1021/ja056943j
   Berezovski MV, 2008, J AM CHEM SOC, V130, P9137, DOI 10.1021/ja801951p
   Bogomolova A, 2009, ANAL CHEM, V81, P3944, DOI 10.1021/ac9002358
   Borghesi L, 2006, IMMUNOL RES, V36, P27, DOI 10.1385/IR:36:1:27
   BREITHOLTZ A, 1991, FOOD ADDIT CONTAM, V8, P183, DOI 10.1080/02652039109373968                                                       
   Cao XX, 2009, NUCLEIC ACIDS RES, V37, P4621, DOI 10.1093/nar/gkp489
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   Chiu CH, 2005, NUCLEIC ACIDS RES, V33, P1690, DOI 10.1093/nar/gki297
   Condit RC, 2006, ADV VIRUS RES, V66, P31, DOI 10.1016/S0065-3527(06)66002-8
   Crespo GA, 2008, ANAL CHEM, V80, P1316, DOI 10.1021/ac071156l
   Crespo GA, 2009, ANAL CHEM, V81, P676, DOI 10.1021/ac802078z
   Cruz-Aguado JA, 2008, J AGR FOOD CHEM, V56, P10456, DOI 10.1021/jf801957h
   Czerwinski JD, 2005, ANAL BIOCHEM, V336, P300, DOI 10.1016/j.ab.2004.10.029
   Dai HJ, 2002, ACCOUNTS CHEM RES, V35, P1035, DOI 10.1021/ar0101640
   Damon I, 2007, FIELDS VIROLOGY, P2079
   Davies DH, 2005, J VIROL, V79, P11724, DOI 10.1128/JVI.79.18.11724-11733.2005
   Decludt B, 2000, EPIDEMIOL INFECT, V124, P215, DOI 10.1017/S0950268899003623
   del Toro M, 2008, ANAL BIOCHEM, V379, P8, DOI 10.1016/j.ab.2008.04.044
   Doronin K, 2009, HUM GENE THER, V20, P975, DOI 10.1089/hum.2009.028
   Du XY, 2001, TALANTA, V55, P93, DOI 10.1016/S0039-9140(01)00393-9
   Edwards RA, 2002, TRENDS MICROBIOL, V10, P94, DOI 10.1016/S0966-842X(01)02293-4
   Eyigor A, 2002, LETT APPL MICROBIOL, V34, P37, DOI 10.1046/j.1472-765x.2002.01036.x
   Fabris L, 2007, J AM CHEM SOC, V129, P6086, DOI 10.1021/ja0705184
   Fisher KD, 2001, GENE THER, V8, P341, DOI 10.1038/sj.gt.3301389
   Gerber MA, 2004, CLIN MICROBIOL REV, V17, P571, DOI 10.1128/CMR.17.3.571-580.2004
   GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2
   Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096
   Hsiao JC, 1999, J VIROL, V73, P8750
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   June GA, 1996, J AOAC INT, V79, P1307
   Kim SE, 2012, ANAL BIOCHEM, V424, P12, DOI 10.1016/j.ab.2012.02.016
   Kostrzynska M, 2002, J MICROBIOL METH, V48, P43, DOI 10.1016/S0167-7012(01)00335-9
   Kuang H, 2010, BIOSENS BIOELECTRON, V26, P710, DOI 10.1016/j.bios.2010.06.058
   Kukol A, 2008, ANAL BIOCHEM, V374, P143, DOI 10.1016/j.ab.2007.10.035
   Labib M, 2009, ANAL CHIM ACTA, V634, P255, DOI 10.1016/j.aca.2008.12.035
   Labib M, 2012, ANAL CHEM, V84, P8966, DOI 10.1021/ac302902s
   Labib M, 2012, ANAL CHEM, V84, P8114, DOI 10.1021/ac302217u
   Labib M, 2012, ANAL CHEM, V84, P1813, DOI 10.1021/ac203412m
   Labib M, 2012, ANAL CHEM, V84, P2548, DOI 10.1021/ac300047c
   Labib M, 2012, ANAL CHEM, V84, P1677, DOI 10.1021/ac202978r
   Labib M, 2011, ELECTROCHIM ACTA, V56, P5122, DOI 10.1016/j.electacta.2011.03.063
   Labib M, 2011, TALANTA, V85, P770, DOI 10.1016/j.talanta.2011.04.070
   Labib M, 2011, ANALYST, V136, P708, DOI 10.1039/c0an00741b
   Labib M, 2010, ANAL BIOANAL CHEM, V397, P1217, DOI 10.1007/s00216-010-3641-8
   Labib M, 2010, ANAL CHIM ACTA, V659, P194, DOI 10.1016/j.aca.2009.11.028
   Labib M, 2009, BIOTECHNOL BIOENG, V104, P312, DOI 10.1002/bit.22395
   Labib M, 2009, ANAL BIOANAL CHEM, V393, P1539, DOI 10.1007/s00216-008-2559-x
   Lai WA, 2012, BIOSENS BIOELECTRON, V35, P456, DOI 10.1016/j.bios.2012.02.049
   Lazcka O, 2007, BIOSENS BIOELECTRON, V22, P1205, DOI 10.1016/j.bios.2006.06.036
   Lee JO, 2008, ANAL BIOANAL CHEM, V390, P1023, DOI 10.1007/s00216-007-1643-y
   Liu XG, 2011, ELECTROCHIM ACTA, V56, P6266, DOI 10.1016/j.electacta.2011.05.055
   Martic S, 2011, ELECTROCHIM ACTA, V56, P10676, DOI 10.1016/j.electacta.2011.05.013
   Martic S, 2011, TALANTA, V85, P2430, DOI 10.1016/j.talanta.2011.07.090
   Mead D, 2000, SCIENCE, V287, P486
   Mendonsa SD, 2004, J AM CHEM SOC, V126, P20, DOI 10.1021/ja037832s
   Michaud M, 2003, J AM CHEM SOC, V125, P8672, DOI 10.1021/ja034483t
   Muharemagic D, 2012, J AM CHEM SOC, V134, P17168, DOI 10.1021/ja306856y
   Muller M, 2006, NUCLEIC ACIDS RES, V34, P2607, DOI 10.1093/nar/gkl347
   Nelson GE, 2008, VIROLOGY, V380, P394, DOI 10.1016/j.virol.2008.08.009
   Ng A, 2012, ENVIRON SCI TECHNOL, V46, P10697, DOI 10.1021/es301686k
   Ong HT, 2007, GENE THER, V14, P324, DOI 10.1038/sj.gt.3302880
   Pan Q, 2005, ANTIMICROB AGENTS CH, V49, P4052, DOI 10.1128/AAC.49.10.4052-4060.2005
   Pearson L, 2010, MAR DRUGS, V8, P1650, DOI 10.3390/md8051650
   Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458
   Proske D, 2005, APPL MICROBIOL BIOT, V69, P367, DOI 10.1007/s00253-005-0193-5
   Qi C, 2010, BIOSENS BIOELECTRON, V25, P1530, DOI 10.1016/j.bios.2009.10.030
   Rahal EA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00138
   RODRIGUEZ JF, 1985, J VIROL, V56, P482
   Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2                                                   
   Sakudo A, 2008, BIOCHEM BIOPH RES CO, V377, P85, DOI 10.1016/j.bbrc.2008.09.083
   SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0                                                                
   Shen L, 2008, ANAL CHEM, V80, P6323, DOI 10.1021/ac800601y
   So HM, 2008, SMALL, V4, P197, DOI 10.1002/smll.200700664
   Star A, 2006, P NATL ACAD SCI USA, V103, P921, DOI 10.1073/pnas.0504146103
   Stojdl DF, 2000, NAT MED, V6, P821
   Subrahmanyam S, 2002, ANAL CHEM, V74, P3942, DOI 10.1021/ac025673+
   Tahiri-Alaoui A, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e45                                                           
   Uludag Y, 2007, FEBS J, V274, P5471, DOI 10.1111/j.1742-4658.2007.06079.x
   Wang JL, 2008, ANAL BIOANAL CHEM, V390, P1059, DOI 10.1007/s00216-007-1697-x
   Wei F, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn299
   Wei F, 2009, ANAL BIOANAL CHEM, V393, P1943, DOI 10.1007/s00216-009-2687-y
   White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325
   Whitley RJ, 2003, ANTIVIR RES, V57, P7, DOI 10.1016/S0166-3542(02)00195-X
   WOLFFE EJ, 1995, VIROLOGY, V211, P53, DOI 10.1006/viro.1995.1378
   Wong SS, 1998, NATURE, V394, P52
   Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937
   Zelada-Guillen GA, 2012, BIOSENS BIOELECTRON, V31, P226, DOI 10.1016/j.bios.2011.10.021
   Zelada-Guillen GA, 2010, ANAL CHEM, V82, P9254, DOI 10.1021/ac101739b
   Zelada-Guillen GA, 2009, ANGEW CHEM INT EDIT, V48, P7334, DOI 10.1002/anie.200902090
   Zhang WY, 2012, ANAL CHEM, V84, P350, DOI 10.1021/ac2026942
   Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911
   Zhu XB, 2009, ELECTROCHEM COMMUN, V11, P1543, DOI 10.1016/j.elecom.2009.05.055
NR 95
TC 9
Z9 9
U1 4
U2 54
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0724-6145
BN 978-3-642-54143-8; 978-3-642-54142-1
J9 ADV BIOCHEM ENG BIOT
JI Adv. Biochem. Eng. Biotechnol.
PY 2014
VL 140
BP 155
EP 181
DI 10.1007/10_2013_229
D2 10.1007/978-3-642-54143-8
PG 27
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA BA0KT
UT WOS:000331739700007
PM 23917779
DA 2018-01-05
ER

PT J
AU Yen, PW
   Lu, YP
   Lin, CT
   Hwang, CH
   Yeh, JA
   Lin, MY
   Huang, KS
AF Yen, Pei-Wen
   Lu, Yen-Pei
   Lin, Chih-Ting
   Hwang, Chi-Hung
   Yeh, J. Andrew
   Lin, Ming-Yu
   Huang, Keng-Shiang
TI Emerging Electrical Biosensors for Detecting Pathogens and Antimicrobial
   Susceptibility Tests
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Pathogens; Electrical biosensors; Human immunodeficiency virus (HIV);
   Tuberculosis (TB); group B Streptococcus (GBS); methicillin-resistant
   Staphylococcus aureus (MRSA)
ID QUARTZ-CRYSTAL MICROBALANCE; FIELD-EFFECT TRANSISTOR; ELECTROCHEMICAL
   DNA BIOSENSOR; HIV-1 REVERSE-TRANSCRIPTASE; REAL-TIME DETECTION;
   MYCOBACTERIUM-TUBERCULOSIS; NUCLEIC-ACIDS; LABEL-FREE; APTAMER; SENSORS
AB The past decade has witnessed the development of innovative biosensing technologies for detecting pathogens, and evaluating the anti-microbial susceptibility test in the infectious diseases. Recent advances in the field have been focused on the development of miniaturized biosensors with high sensitivity, specificity and stability. Possibility for commercialization is also a key criterion to develop biosensors in reality. In this article, we introduced several electrical-based biosensors with prospective for commercialization. To have an in-field detection for pathogens, the electrical biosensor is promising because of its ease to be implemented with micro/nano fabrication technologies. Several electrical biosensing techniques, such as ion-sensitive field effect transistor, nanowire, and microcantilever have been introduced. In addition, advantages and achievements of each electrical biosensing technique have also been reviewed.
C1 [Yen, Pei-Wen; Lin, Chih-Ting] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 10764, Taiwan.
   [Lu, Yen-Pei; Hwang, Chi-Hung; Yeh, J. Andrew; Lin, Ming-Yu] Natl Appl Res Labs, Instrument Technol Res Ctr, Hsinchu 30076, Taiwan.
   [Yeh, J. Andrew] Natl Tsing Hua Univ, Inst NanoEngn & Microsyst, Hsinchu, Taiwan.
   [Huang, Keng-Shiang] I Shou Univ, Sch Chinese Med Post Baccalaureate, Kaohsiung, Taiwan.
RP Lin, MY (reprint author), Natl Appl Res Labs, Instrument Technol Res Ctr, 20 R&D Rd VI, Hsinchu 30076, Taiwan.
EM minyulin@narlabs.org.tw
RI Lin, Chih-Ting/J-2580-2014; Hwang, Chi-Hung /N-1601-2013
OI Lin, Chih-Ting/0000-0002-4150-9693; Hwang, Chi-Hung /0000-0003-4492-8647
CR Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0
   Amine A, 2006, BIOSENS BIOELECTRON, V21, P1405, DOI 10.1016/j.bios.2005.07.012
   Banu O., 2012, LETT APPL NANOBIOSCI, V1, P18
   Bard A. J., 2001, ELECTROCHEMICAL METH, P2
   BERGVELD P, 1981, SENSOR ACTUATOR, V1, P1
   Bhatta D, 2010, SENSOR ACTUAT B-CHEM, V149, P233, DOI 10.1016/j.snb.2010.05.040
   Bruno JG, 2002, BIOTECHNIQUES, V32, P178
   Bruno JG, 2009, J FLUORESC, V19, P427, DOI 10.1007/s10895-008-0429-8
   Buchapudi KR, 2011, ANALYST, V136, P1539, DOI 10.1039/c0an01007c
   Campuzano S., 2012, PORTABLE CHEM SENS, P119
   Chang HX, 2011, CURR ORG CHEM, V15, P506, DOI 10.2174/138527211794474500                                                      
   Chang KM, 2010, SENSORS-BASEL, V10, P6115, DOI 10.3390/s100606115
   Chen Y, 2011, CURR ORG CHEM, V15, P518, DOI 10.2174/138527211794474438                                                      
   Chirea M, 2011, BIOINTERFACE RES APP, V1, P151
   CLARK LC, 1962, ANN NY ACAD SCI, V102, P29, DOI 10.1111/j.1749-6632.1962.tb13623.x
   Clerc O, 2010, CLIN MICROBIOL INFEC, V16, P1054, DOI 10.1111/j.1469-0691.2010.03281.x
   Das M, 2010, THIN SOLID FILMS, V519, P1196, DOI 10.1016/j.tsf.2010.08.069
   Dwarakanath S, 2004, BIOCHEM BIOPH RES CO, V325, P739, DOI 10.1016/j.bbrc.2004.10.099
   Encarnacao JM, 2007, J BIOTECHNOL, V132, P142, DOI 10.1016/j.jbiotec.2007.04.010
   Fan C., 2011, CURR ORG CHEM, V15, P445
   Ferapontova EE, 2011, CURR ORG CHEM, V15, P498
   Fischer J, 2011, CURR ORG CHEM, V15, P2923, DOI 10.2174/138527211798357146                                                      
   Fojta M, 2011, CURR ORG CHEM, V15, P2936, DOI 10.2174/138527211798357173                                                      
   Foulds J, 1998, INT J TUBERC LUNG D, V2, P778
   Grieshaber D, 2008, SENSORS-BASEL, V8, P1400, DOI 10.3390/s8031400                                                                
   Grumezescu A. M., 2012, LETT APPL NANOBIOSCI, V1, P77
   Grumezescu A.M., 2011, BIOINTERFACE RES APP, V1, P139
   Halford C, 2013, ANTIMICROB AGENTS CH, V57, P936, DOI 10.1128/AAC.00615-12
   Hamula CLA, 2011, TRAC-TREND ANAL CHEM, V30, P1587, DOI 10.1016/j.trac.2011.08.006
   He FJ, 2002, SENSOR ACTUAT B-CHEM, V85, P284, DOI 10.1016/S0925-4005(02)00144-2                                                   
   Huang CW, 2013, SENSOR ACTUAT B-CHEM, V181, P867, DOI 10.1016/j.snb.2013.02.061
   Huang C.W., 2012, VLSI CIRC VLSIC 2012, P124
   Jimenez-Jorquera C, 2010, SENSORS-BASEL, V10, P61, DOI 10.3390/s100100061
   Joshi PJ, 2005, MOL THER, V11, P677, DOI 10.1016/j.ymthe.2005.01.013
   K'Owino IO, 2005, ELECTROANAL, V17, P2101, DOI 10.1002/elan.200503371
   Kaewphinit T, 2010, SENSORS-BASEL, V10, P1846, DOI 10.3390/s100301846
   Karaseva NA, 2012, TALANTA, V93, P44, DOI 10.1016/j.talanta.2011.12.047
   Kim K. S., 2009, NANOTECHNOLOGY, V20
   Klonoski J, 2010, ANAL BIOCHEM, V396, P284, DOI 10.1016/j.ab.2009.09.035
   Knoll B, 2007, INT J DERMATOL, V46, P1219, DOI 10.1111/j.1365-4632.2007.03520.x
   Lau PS, 2011, CURR ORG CHEM, V15, P557
   Lavrik NV, 2004, REV SCI INSTRUM, V75, P2229, DOI 10.1063/1.1763252
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7
   Lee CS, 2009, SENSORS-BASEL, V9, P7111, DOI 10.3390/s90907111
   Li DC, 2010, IEEE T ELECTRON DEV, V57, P2761, DOI 10.1109/TED.2010.2063330
   Li N, 2008, NUCLEIC ACIDS RES, V36, P6739, DOI 10.1093/nar/gkn775
   Lin CH, 2009, BIOSENS BIOELECTRON, V24, P3019, DOI 10.1016/j.bios.2009.03.014
   Lin MY, 2013, CURR ORG CHEM, V17, P144, DOI 10.2174/1385272811317020010                                                     
   Lin MY, 2013, CURR ORG CHEM, V17, P132, DOI 10.2174/1385272811317020008                                                     
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Liu AL, 2012, TRAC-TREND ANAL CHEM, V37, P101, DOI 10.1016/j.trac.2012.03.008
   Liu DS, 2011, CURR ORG CHEM, V15, P477, DOI 10.2174/138527211794474519                                                      
   Luo CH, 2013, BIOSENS BIOELECTRON, V48, P132, DOI 10.1016/j.bios.2013.03.084
   Ma F., 2013, ELECTROCHIM ACTA, DOI [10.1016/j.bbr.2011.03.031, DOI 10.1016/J.BBR.2011.03.031]
   Mach KE, 2011, J UROLOGY, V185, P148, DOI 10.1016/j.juro.2010.09.022
   Mannelli I, 2003, BIOSENS BIOELECTRON, V18, P129, DOI 10.1016/S0956-5663(02)00166-5
   Mannoor MS, 2010, P NATL ACAD SCI USA, V107, P19207, DOI 10.1073/pnas.1008768107
   Marx KA, 2003, BIOMACROMOLECULES, V4, P1099, DOI 10.1021/bm020116i
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Nomngongo PN, 2012, PHYS CHEM EARTH, V50-52, P252, DOI 10.1016/j.pce.2012.08.001
   O'Sullivan CK, 1999, BIOSENS BIOELECTRON, V14, P663, DOI 10.1016/S0956-5663(99)00040-8
   Ogasawara D, 2009, BIOSENS BIOELECTRON, V24, P1372, DOI 10.1016/j.bios.2008.07.082
   Oliveira DC, 2002, LANCET INFECT DIS, V2, P180, DOI 10.1016/S1473-3099(02)00227-X                                                   
   Pantosti A, 2007, FUTURE MICROBIOL, V2, P323, DOI 10.2217/17460913.2.3.323
   Patolsky F, 2006, NAT PROTOC, V1, P1711, DOI 10.1038/nprot.2006.227
   Pircalabioru G., 2011, BIOINTERFACE RES APP, V1
   Pozniak AL, 1999, AIDS, V13, P435, DOI 10.1097/00002030-199903110-00001
   Ren JL, 2008, BIOSENS BIOELECTRON, V24, P403, DOI 10.1016/j.bios.2008.04.018
   Rocha-Gaso MI, 2009, SENSORS-BASEL, V9, P5740, DOI 10.3390/s90705740
   Ronkainen NJ, 2010, CHEM SOC REV, V39, P1747, DOI 10.1039/b714449k
   Saltini C, 1998, EUR RESPIR J, V11, P1215, DOI 10.1183/09031936.98.11061215                                                    
   Samanich KM, 2000, CLIN DIAGN LAB IMMUN, V7, P662, DOI 10.1128/CDLI.7.4.662-668.2000
   Sapsford KE, 2008, MATER TODAY, V11, P38, DOI 10.1016/S1369-7021(08)70018-X
   Sassolas A, 2012, BIOTECHNOL ADV, V30, P489, DOI 10.1016/j.biotechadv.2011.09.003
   Saviuc C, 2011, BIOINTERFACE RES APP, V1, P31
   Saviuc C., 2012, LETT APPL NANOBIOSCI, V1, P67
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Shekhawat G, 2006, SCIENCE, V311, P1592, DOI 10.1126/science.1122588
   Shinde SB, 2012, J CONTROL RELEASE, V159, P164, DOI 10.1016/j.jconrel.2011.11.033
   Su LA, 2011, BIOSENS BIOELECTRON, V26, P1788, DOI 10.1016/j.bios.2010.09.005
   Torrado E, 2011, TRENDS IMMUNOL, V32, P66, DOI 10.1016/j.it.2010.12.001
   Tran L.D., 2011, MAT SCI ENG C, V31, P477
   Upadhyayula VKK, 2012, ANAL CHIM ACTA, V715, P1, DOI 10.1016/j.aca.2011.12.008
   Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Wang CM, 2011, CURR ORG CHEM, V15, P465, DOI 10.2174/138527211794474465                                                      
   Wang SQ, 2013, BIOTECHNOL ADV, V31, P438, DOI 10.1016/j.biotechadv.2013.01.006
   Wilson GS, 2005, BIOSENS BIOELECTRON, V20, P2388, DOI 10.1016/j.bios.2004.12.003
   Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856
   Xu S, 2012, MICROCHIM ACTA, V178, P245, DOI 10.1007/s00604-012-0831-4
   Yao CY, 2009, BIOSENS BIOELECTRON, V24, P2499, DOI 10.1016/j.bios.2008.12.036
   Zamfir LG, 2013, BIOSENS BIOELECTRON, V46, P61, DOI 10.1016/j.bios.2013.02.018
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang GJ, 2012, ANAL CHIM ACTA, V749, P1, DOI 10.1016/j.aca.2012.08.035
   Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138
   Zhou L, 2011, CHINESE J ANAL CHEM, V39, P432, DOI 10.3724/SP.J.1096.2011.00432
NR 95
TC 4
Z9 4
U1 2
U2 52
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1385-2728
EI 1875-5348
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PD JAN
PY 2014
VL 18
IS 2
BP 165
EP 172
DI 10.2174/13852728113176660140                                            
          
PG 8
WC Chemistry, Organic
SC Chemistry
GA AE2MY
UT WOS:000333808400003
DA 2018-01-05
ER

PT J
AU Singh, KP
   Gupta, S
AF Singh, Kunwar P.
   Gupta, Shikha
TI Nano-QSAR modeling for predicting biological activity of diverse
   nanomaterials
SO RSC ADVANCES
LA English
DT Article
ID HIV-1 PR INHIBITORS; METAL-OXIDE NANOPARTICLES; CONCORDANCE
   CORRELATION-COEFFICIENT; QUANTITATIVE STRUCTURE-PROPERTY; IN-VITRO;
   MOLECULAR-DYNAMICS; CARBON NANOTUBES; VIBRIO-FISCHERI; RISK-ASSESSMENT;
   SURFACE-AREA
AB This study reports robust reliable ensemble learning (EL) approach based nano-QSAR models for predicting the biological effects of diverse nanomaterials (NMs) using simple molecular descriptors. EL based nano-QSAR models implementing stochastic gradient boosting and bagging algorithms were constructed and used to establish statistically significant relationships between measured biological activity profiles of nanoparticles (NPs) and their simple structural properties. To demonstrate the predictive ability of the developed nano-QSAR models, five different representative data sets (case studies) of NMs (NPs with diverse metal cores, NPs with similar core but diverse surface modifiers, metal oxide NPs, surface modified multi-walled carbon nanotubes, and fullerene derivatives) studied recently using in vitro cell based assays were employed. Rigorous validation of the constructed classification and regression nano-QSAR models performed using various statistical parameters suggested robustness of the EL based models for their future use. Proposed nano-QSAR models showed high prediction accuracy (binary classification) of more than 93.18% (case study 1), 97.25% (case study 2), and yielded correlation (R-2) of more than 0.851 between experimental and model predicted values of biological activity in complete data of different diverse sets of NPs. Results for all five case studies demonstrated better predictive performance of the proposed nano-QSAR models compared to the previous studies. The proposed models reliably predicted the biological activity of all considered NPs, and the methodology is expected to provide guidance for the future design and manufacturing of NMs ensuring better and safer products.
C1 [Singh, Kunwar P.; Gupta, Shikha] Acad Sci & Innovat Res, New Delhi 110001, India.
   [Singh, Kunwar P.; Gupta, Shikha] Indian Inst Toxicol Res, CSIR, Div Environm Chem, Lucknow 226001, Uttar Pradesh, India.
RP Singh, KP (reprint author), Acad Sci & Innovat Res, Rafi Marg, New Delhi 110001, India.
EM kpsingh_52@yahoo.com
CR Abu-Awwad F. M., 2010, PHARM CHEMICA, V2, P1
   Auffan M, 2009, ENVIRON POLLUT, V157, P1127, DOI 10.1016/j.envpol.2008.10.002
   Benigni R., 2008, 23241EN EUR EUR COMM
   Benigni R, 2007, J ENVIRON SCI HEAL C, V25, P53, DOI 10.1080/10590500701201828
   Bhaisare M., 2010, SCIFORUM ELECT C SER, P1
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1023/A:1018054314350
   Chau YT, 2012, RSC ADV, V2, P8489, DOI 10.1039/c2ra21489j
   Chen HW, 2006, FASEB J, V20, P2393, DOI 10.1096/fj.06-6485fje
   Chirico N, 2011, J CHEM INF MODEL, V51, P2320, DOI 10.1021/ci200211n
   Consonni V, 2009, J CHEM INF MODEL, V49, P1669, DOI 10.1021/ci900115y
   Dai YZ, 2006, CHEMOSPHERE, V65, P2427, DOI 10.1016/j.chemosphere.206.04.052
   Dietterich TG, 2000, LECT NOTES COMPUT SC, V1857, P1
   Dudek AZ, 2006, COMB CHEM HIGH T SCR, V9, P213, DOI 10.2174/138620706776055539
   Duffin R, 2007, INHAL TOXICOL, V19, P849, DOI 10.1080/08958370701479323
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Epa VC, 2012, NANO LETT, V12, P5808, DOI 10.1021/nl303144k
   Erdal HI, 2013, J HYDROL, V477, P119, DOI 10.1016/j.jhydrol.2012.11.015
   Eriksson L, 2003, ENVIRON HEALTH PERSP, V111, P1361, DOI 10.1289/ehp.5758
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fiorito S., 2007, NANOTOXICOLOGY INTER, P167
   Fourches D, 2011, COMB CHEM HIGH T SCR, V14, P217, DOI 10.2174/138620711794728743
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Friedman JH, 2002, COMPUT STAT DATA AN, V38, P367, DOI 10.1016/S0167-9473(01)00065-2
   Ghorbanzadeh M, 2012, IND ENG CHEM RES, V51, P10712, DOI 10.1021/ie3006947
   Gill S, 2007, J BIOMED NANOTECHNOL, V3, P107, DOI 10.1166/jbn.2007.015
   Gupta L, 2010, J CURRENT PHARM RES, V01, P19
   Hancock T, 2005, CHEMOMETR INTELL LAB, V76, P185, DOI 10.1016/j.chemolab.2004.11.001
   Heinemann M, 2009, HUM EXP TOXICOL, V28, P407, DOI 10.1177/0960327109105149
   Heinlaan M, 2008, CHEMOSPHERE, V71, P1308, DOI 10.1016/j.chemosphere.2007.11.047
   Ishwaran H, 2010, STAT PROBABIL LETT, V80, P1056, DOI 10.1016/j.spl.2010.02.020
   Karakoti AS, 2006, JOM-US, V58, P77, DOI 10.1007/s11837-006-0147-0
   Karelson M, 2009, ARKIVOC, P218
   Karlsson HL, 2008, CHEM RES TOXICOL, V21, P1726, DOI 10.1021/tx800064j
   Katritzky AR, 2001, J CHEM INF COMP SCI, V41, P679, DOI 10.1021/ci000134w
   Kim JS, 2006, TOXICOL SCI, V89, P338, DOI 10.1093/toxsci/kfj027
   Klaine SJ, 2008, ENVIRON TOXICOL CHEM, V27, P1825, DOI 10.1897/08-090.1
   Kovarich S, 2011, J HAZARD MATER, V190, P106, DOI 10.1016/j.jhazmat.2011.03.008
   Kubinyi H., 1993, METHODS PRINCIPLES M, VI
   Labute P, 2000, J MOL GRAPH MODEL, V18, P464, DOI 10.1016/S1093-3263(00)00068-1
   LIN LIK, 1992, BIOMETRICS, V48, P599, DOI 10.2307/2532314                                                                 
   Linkov I, 2009, J NANOPART RES, V11, P513, DOI 10.1007/s11051-008-9514-9
   Mahjoobi J, 2008, APPL OCEAN RES, V30, P172, DOI 10.1016/j.apor.2008.11.001
   Medina C, 2007, BRIT J PHARMACOL, V150, P552, DOI 10.1038/sj.bjp.0707130
   Meng H, 2009, ACS NANO, V3, P1620, DOI 10.1021/nn9005973
   Moore MN, 2006, ENVIRON INT, V32, P967, DOI 10.1016/j.envint.2006.06.014
   Moss OR, 2006, INHAL TOXICOL, V18, P711, DOI 10.1080/08958370600747770
   Neal AL, 2008, ECOTOXICOLOGY, V17, P362, DOI 10.1007/s10646-008-0217-x
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155
   Nikaljea A P. G., 2012, PHARM SINICA, V3, P229
   Niu B, 2009, CHEMOMETR INTELL LAB, V96, P43, DOI 10.1016/j.chemolab.2008.11.003
   Paliwal SK, 2010, INDIAN J CHEM B, V49, P554
   Parvez S, 2008, TOXICOL IN VITRO, V22, P1806, DOI 10.1016/j.tiv.2008.07.011
   Patel D. M., 2009, J SCI RES, V1, P594
   Powers KW, 2007, NANOTOXICOLOGY, V1, P42, DOI 10.1080/17435390701314902
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Schuurmann G, 2008, J CHEM INF MODEL, V48, P2140, DOI 10.1021/ci800253u
   Shao CY, 2013, J CHEM INF MODEL, V53, P142, DOI [10.1021/ci3005308, 10.1021/ci30053081]
   Sharma MC, 2011, WORLD APPL SCI J, V12, P2111
   Shaw SY, 2008, P NATL ACAD SCI USA, V105, P7387, DOI 10.1073/pnas.0802878105
   Shi LM, 2001, J CHEM INF COMP SCI, V41, P186, DOI 10.1021/ci000066d
   Singh KP, 2013, ATMOS ENVIRON, V80, P426, DOI 10.1016/j.atmosenv.2013.08.023
   Singh KP, 2013, TOXICOL APPL PHARM, V272, P465, DOI 10.1016/j.taap.2013.06.029
   Singh KP, 2013, ECOTOX ENVIRON SAFE, V95, P221, DOI 10.1016/j.ecoenv.2013.05.017
   Singh KP, 2011, ANAL CHIM ACTA, V703, P152, DOI 10.1016/j.aca.2011.07.027
   Singh KP, 2010, ANAL CHIM ACTA, V658, P1, DOI 10.1016/j.aca.2009.11.001
   Steinbeck C., 2006, CURR PHARM DESIGN, V12, P2110
   Todeschini R., 1998, 3D QSAR DRUG DESIGN, P355
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropov AA, 2012, CHEMOSPHERE, V89, P1098, DOI 10.1016/j.chemosphere.2012.05.077
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   Tsuji JS, 2006, TOXICOL SCI, V89, P42, DOI 10.1093/toxsci/kfi339
   Varmuza K, 2003, ANAL CHIM ACTA, V490, P313, DOI 10.1016/S0003-2670(03)00668-8
   VISWANADHAN VN, 1989, J CHEM INF COMP SCI, V29, P163, DOI 10.1021/ci00063a006
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Winiwarter S, 2003, J MOL GRAPH MODEL, V21, P273, DOI 10.1016/S1093-3263(02)00163-8
   Worle-Knirsch JM, 2006, NANO LETT, V6, P1261, DOI 10.1021/nl060177c
   Yuan Y., 2012, J BIOPHYS CHEM, V3, P49
   Zhao CY, 2006, TOXICOLOGY, V217, P105, DOI 10.1016/j.tox.2005.08.019
   Zhou HY, 2008, NANO LETT, V8, P859, DOI 10.1021/nl0730155
NR 82
TC 53
Z9 54
U1 5
U2 60
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 26
BP 13215
EP 13230
DI 10.1039/c4ra01274g
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA AD2RL
UT WOS:000333082700003
DA 2018-01-05
ER

PT J
AU Khandelwal, N
   Kaur, G
   Kumar, N
   Tiwari, A
AF Khandelwal, N.
   Kaur, G.
   Kumar, N.
   Tiwari, A.
TI APPLICATION OF SILVER NANOPARTICLES IN VIRAL INHIBITION: A NEW HOPE FOR
   ANTIVIRALS
SO DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES
LA English
DT Article
DE Viral infection; Antiviral drugs; Drug Resistant Viruses; Silver
   Nanoparticles; Antiviral Agent
ID ESCHERICHIA-COLI; VIRUS; TRANSMISSION; INFECTION; AGENTS; HIV-1
AB In modern era, viral infections constitute one of the main health problems. Chemically synthesized antiviral drugs have adverse side effects which are associated with other health complications. The emergence of new infectious diseases and increase in frequency of drug resistant viruses demand the most effective and novel therapeutic agents, one of which are nanoparticles. Nanoparticles excel as therapeutic agents due to their unique physiochemical properties and a universally applicable physical mode of action. Their large surface area to volume ratio offers them an edge as an antiviral agent. The review focuses on the mechanism of action of silver nanoparticles and their novel therapeutic applications against some viruses bearing potentially fatal consequences.
C1 [Khandelwal, N.; Kaur, G.; Tiwari, A.] Rajiv Gandhi Proudyogiki Vishwavidyalaya, Sch Biotechnol, Bhopal 462036, Madhya Pradesh, India.
   [Kumar, N.] Indian Council Agr Res, Cent Inst Res Goats, Div Anim Hlth, Jhansi, Uttar Pradesh, India.
RP Khandelwal, N (reprint author), Rajiv Gandhi Proudyogiki Vishwavidyalaya, Sch Biotechnol, Airport Rd, Bhopal 462036, Madhya Pradesh, India.
EM nitinkhandelwal.29@hotmail.com
CR Reske Adi PG, 2007, UNDERSTANDING REV ME, V17, P205
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Bryaskova R. PD, 2011, J CHEM BIOL, V4, P185
   Carter SV J., 2007, VIROLOGY PRINCIPLES
   Egger S. LRP, 2009, APPL ENVIRON MICROB, V75, P2973
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Feng QL, 2000, J BIOMED MATER RES, V52, P662, DOI 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3
   TT Fleming-Dutra K. E., 2013, J INFECT DIS
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   HD A., 1987, B WORLD HEALTH ORGAN, V65, P535
   HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4
   IAPALUCCI S, 1991, VIROLOGY, V182, P269, DOI 10.1016/0042-6822(91)90670-7
   Jahn W, 1999, J STRUCT BIOL, V127, P106, DOI 10.1006/jsbi.1999.4123
   Kim Juyoung, 2009, J Biol Eng, V3, P20, DOI 10.1186/1754-1611-3-20
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Sun SAK Lova, 2008, J BIOMEDICAL NANOTEC, V4, P149
   Lu L, 2008, ANTIVIR THER, V13, P253
   Mechanisms E. D., 2010, VET RES, V41, P38
   Morens DM, 2011, J INFECT DIS, V204, P502, DOI 10.1093/infdis/jir327
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Naiwa HS, 2000, HDB NANOSTRUCTURAL M, P1
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Reusken CBEM, 2013, J TRAVEL MED, V20, P44, DOI 10.1111/j.1708-8305.2012.00670.x
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Sharma VK, 2009, ADV COLLOID INTERFAC, V145, P83, DOI 10.1016/j.cis.2008.09.002
   Brooker Simon BJ, 2004, ADV PARASIT, P197
   Singh DJ A., 2010, DIG J NANOMATER BIOS, V2, P483
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Stokes KL, 2011, J VIROL, V85, P5782, DOI 10.1128/JVI.01693-10
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tripathi KD., 2008, ESSENTIALS MED PHARM, P62
   Yamanaka M, 2005, APPL ENVIRON MICROB, V71, P7589, DOI 10.1128/AEM.71.11.7589-7593.2005
   [Anonymous], 2007, J ANTIMICROBIAL CHEM, V59, P587
   [Anonymous], 2000, BURNS J INT SOC BURN, V26, P117
NR 41
TC 14
Z9 15
U1 0
U2 14
PU INST MATERIALS PHYSICS
PI BUCHAREST
PA NATL INST R&D MATERIALS PHYSICS, ATOMISTILOR STR, 105 BIS, BUCHAREST,
   077125, ROMANIA
SN 1842-3582
J9 DIG J NANOMATER BIOS
JI Dig. J. Nanomater. Biostruct.
PD JAN-MAR
PY 2014
VL 9
IS 1
BP 175
EP 186
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA AC8CN
UT WOS:000332760700020
DA 2018-01-05
ER

PT J
AU Goyvaerts, C
   Kurt, D
   Van Lint, S
   Heirman, C
   Van Ginderachter, JA
   De Baetselier, P
   Raes, G
   Thielemans, K
   Breckpot, K
AF Goyvaerts, Cleo
   Kurt, De Groeve
   Van Lint, Sandra
   Heirman, Carlo
   Van Ginderachter, Jo A.
   De Baetselier, Patrick
   Raes, Geert
   Thielemans, Kris
   Breckpot, Karine
TI Immunogenicity of targeted lentivectors
SO ONCOTARGET
LA English
DT Article
DE lentivector; targeting; antigen presenting cell; vaccine; antitumor
   immunotherapy
ID T-CELL RESPONSES; CD8-ALPHA(+) DENDRITIC CELLS; ANTIGEN-PRESENTING
   CELLS; LENTIVIRAL VECTORS; IN-VIVO; CANCER-IMMUNOTHERAPY; MESSENGER-RNA;
   VIRAL VECTORS; TUMOR-ANTIGEN; GENE-TRANSFER
AB To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we recently developed the Nanobody (Nb) display technology to target LVs to antigen presenting cells (APCs). In this study, we extend these data with exclusive targeting of LVs to conventional dendritic cells (DCs), which are believed to be the main cross-presenting APCs for the induction of a TH1-conducted antitumor immune response. The immunogenicity of these DC-subtype targeted LVs was compared to that of broad tropism, general APC-targeted and non-infectious LVs. Intranodal immunization with ovalbumin encoding LVs induced proliferation of antigen specific CD4(+) T cells, irrespective of the LVs' targeting ability. However, the cytokine secretion profile of the restimulated CD4(+) T cells demonstrated that general APC targeting induced a similar TH1-profile as the broad tropism LVs while transduction of conventional DCs alone induced a similar and less potent TH1 profile as the non-infectious LVs. This observation contradicts the hypothesis that conventional DCs are the most important APCs and suggests that the activation of other APCs is also meaningful. Despite these differences, all targeted LVs were able to stimulate cytotoxic T lymphocytes, be it to a lesser extent than broad tropism LVs. Furthermore this induction was shown to be dependent on type I interferon for the targeted and non-infectious LVs, but not for broad tropism LVs. Finally we demonstrated that the APC-targeted LVs were as potent in therapy as broad tropism LVs and as such deliver on their promise as safer and efficacious LV-based vaccines.
C1 [Goyvaerts, Cleo; Van Lint, Sandra; Heirman, Carlo; Thielemans, Kris; Breckpot, Karine] Vrije Univ Brussel, Dept Immunol Physiol, Lab Mol & Cellular Therapy, Brussels, Belgium.
   [Kurt, De Groeve; Van Ginderachter, Jo A.; De Baetselier, Patrick; Raes, Geert] Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium.
   [Kurt, De Groeve; Van Ginderachter, Jo A.; De Baetselier, Patrick; Raes, Geert] VIB, Lab Myeloid Cell Immunol, Brussels, Belgium.
RP Breckpot, K (reprint author), Vrije Univ Brussel, Dept Immunol Physiol, Lab Mol & Cellular Therapy, Brussels, Belgium.
EM kbreckpo@vub.ac.be
RI Raes, Geert/H-5185-2013; Breckpot, Karine/A-4298-2008
OI Raes, Geert/0000-0002-9065-1549; Breckpot, Karine/0000-0003-4331-3480
FU Research foundation Flanders (FWO-V); Agency of Innovation by Science
   and Technology (IWT-SBO); Interuniversity Attraction Poles Program
   (IUAP); Belgian State-Belgian Science Policy; research committee of the
   VUB (OZR); FWO-V
FX This research was performed with the financial support of the Research
   foundation Flanders (FWO-V), the Agency of Innovation by Science and
   Technology (IWT-SBO), the Interuniversity Attraction Poles Program
   (IUAP), the Belgian State-Belgian Science Policy and the research
   committee of the VUB (OZR). CG and KB are funded by the FWO-V.
CR Ageichik A, 2011, HUM GENE THER, V22, P1249, DOI 10.1089/hum.2010.184
   Akiyama Y, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-623
   Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183
   Arce F, 2009, MOL THER, V17, P1643, DOI 10.1038/mt.2009.149
   Barry MA, 2012, BIOCHEM J, V443, P603
   Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596
   Bonehill A, 2004, J IMMUNOL, V172, P6649, DOI 10.4049/jimmunol.172.11.6649                                                    
   Breckpot K, 2007, GENE THER, V14, P847, DOI 10.1038/sj.gt.3302947
   Breckpot K, 2003, J GENE MED, V5, P654, DOI 10.1002/jgm.400
   Breckpot K, 2010, J VIROL, V84, P5627, DOI 10.1128/JVI.00014-10
   Breckpot K, 2008, CURR GENE THER, V8, P438, DOI 10.2174/156652308786848058                                                      
   Brown BD, 2007, BLOOD, V109, P2797, DOI 10.1182/blood-2006-10-049312
   Bryson PD, 2013, JOVE-J VIS EXP, DOI 10.3791/50606
   Byrne KT, 2011, ONCOTARGET, V2, P684
   Chapatte L, 2006, CANCER RES, V66, P1155, DOI 10.1158/0008-5472.CAN-05-2597
   Coquerelle C, 2010, IMMUNOL REV, V234, P317, DOI 10.1111/j.0105-2896.2009.00887.x
   Cronin J, 2005, CURR GENE THER, V5, P387, DOI 10.2174/1566523054546224
   Cubillos-Zapata C, 2011, J VIROL, V85, P9385, DOI 10.1128/JVI.05127-11
   De Groeve K, 2010, J NUCL MED, V51, P782, DOI 10.2967/jnumed.109.070078
   den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685
   Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829
   Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080
   Dullaers M, 2006, GENE THER, V13, P630, DOI 10.1038/sj.gt.3302697
   Flacher V, 2012, J IMMUNOL, V188, P2146, DOI 10.4049/jimmunol.1004120
   Fonteneau JF, 2004, J VIROL, V78, P5223, DOI 10.1128/JVI.78.10.5223-5232.2004
   Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618
   Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159
   Gallois A, 2010, NAT MED, V16, DOI 10.1038/nm0810-854
   Garaude J, 2012, ONCOTARGET, V3, P361
   Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921
   Gennari F, 2009, HUM GENE THER, V20, P554, DOI 10.1089/hum.2008.189
   Goold HD, 2011, J IMMUNOL, V186, P4565, DOI 10.4049/jimmunol.1002529
   Gottschalk S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082658
   Goyvaerts C, 2012, GENE THER, P1
   Goyvaerts C, 2013, J VIROL, V87, P11304, DOI 10.1128/JVI.01498-13
   Hamilton DH, 2013, ONCOTARGET, V4, P1777, DOI 10.18632/oncotarget.1295                                                        
   Hickman HD, 2011, J EXP MED, V208, P2511, DOI 10.1084/jem.20102545
   Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161
   Joffre O, 2009, IMMUNOL REV, V227, P234, DOI 10.1111/j.1600-065X.2008.00718.x
   Jonuleit H, 2001, INT J CANCER, V93, P243, DOI 10.1002/ijc.1323                                                                
   Joshi MD, 2012, J CONTROL RELEASE, V161, P25, DOI 10.1016/j.jconrel.2012.05.010
   Keyaerts M, 2008, EUR J NUCL MED MOL I, V35, P999, DOI 10.1007/s00259-007-0664-2
   Kreutz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040208
   Kruit WHJ, 2013, J CLIN ONCOL, V31, P2413, DOI 10.1200/JCO.2012.43.7111
   Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587
   Maurice M, 2002, BLOOD, V99, P2342, DOI 10.1182/blood.V99.7.2342
   Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004
   Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950
   Merten OW, 2011, HUM GENE THER, V22, P343, DOI 10.1089/hum.2010.060
   Nizzoli G, 2013, BLOOD, V122, P932, DOI 10.1182/blood-2013-04-495424
   Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007
   Paulis LE, 2013, CURR OPIN IMMUNOL, V25, P389, DOI 10.1016/j.coi.2013.03.001
   Rossetti M, 2011, HUM GENE THER, V22, P177, DOI 10.1089/hum.2010.085
   Rusakiewicz S, 2010, VACCINE, V28, P6374, DOI 10.1016/j.vaccine.2010.06.071
   Schliehe C, 2011, J IMMUNOL, V187, P2112, DOI 10.4049/jimmunol.1002084
   Sharma MD, 2009, BLOOD, V113, P6102, DOI 10.1182/blood-2008-12-195354
   Suleman M, 2011, VACCINE, V29, P5892, DOI 10.1016/j.vaccine.2011.06.071
   Sun Jun Zhong, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P544
   Thomann-Harwood LJ, 2013, J CONTROL RELEASE, V166, P95, DOI 10.1016/j.jconrel.2012.11.015
   Tuyaerts S, 2007, CANCER IMMUNOL IMMUN, V56, P1513, DOI 10.1007/s00262-007-0334-z
   Van Meirvenne S, 2002, CANCER GENE THER, V9, P787, DOI 10.1038/sj.cgt.7700499
   Van Tendeloo VF, 2010, P NATL ACAD SCI USA, V107, P13824, DOI 10.1073/pnas.1008051107
   Vandendriessche T, 2007, J THROMB HAEMOST, V5, P16, DOI 10.1111/j.1538-7836.2006.02220.x                                                
   Velders MP, 2003, INT REV IMMUNOL, V22, P113, DOI 10.1080/08830180305220                                                          
   Venanzi F, 2013, ONCOTARGET, V4, P1
   Wilgenhof S, 2013, ANN ONCOL, V24, P2686, DOI 10.1093/annonc/mdt245
   Yang L, 2008, NAT BIOTECHNOL, V26, P326, DOI 10.1038/nbt1390
   Zhang XY, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-3
NR 68
TC 12
Z9 12
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PY 2014
VL 5
IS 3
BP 704
EP 715
DI 10.18632/oncotarget.1680                                                
          
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AC7IK
UT WOS:000332701300012
PM 24519916
OA green_published
DA 2018-01-05
ER

PT J
AU Ye, T
   Liu, YF
   Luo, M
   Xiang, X
   Ji, XH
   Zhou, GH
   He, ZK
AF Ye, Tai
   Liu, Yufei
   Luo, Ming
   Xiang, Xia
   Ji, Xinghu
   Zhou, Guohua
   He, Zhike
TI Metal-organic framework-based molecular beacons for multiplexed DNA
   detection by synchronous fluorescence analysis
SO ANALYST
LA English
DT Article
ID COORDINATION POLYMER; CARBON NANOTUBES; GRAPHENE OXIDE; STRANDED-DNA;
   PLATFORM; BIOSENSOR; DITHIOOXAMIDE; SEPARATION; MOF
AB We report a new sensor combined two dimensional metal-organic framework (MOF), N,N-bis(2-hydroxyethyl)dithiooxamidato copper(II) (H2dtoaCu), with the hairpin-structured oligonucleotides and demonstrate its feasibility in detecting multiplexed sequence-specific DNA. The key component of this sensor (MOF-MBs) is the hairpin-structured fluorescent oligonucleotide that allows the MOFs to function as both a "nanoscaffold" for the oligonucleotide and a "nanoquencher" of the fluorophore. An oligonucleotide sequence fragment of wild-type HBV (T-1) and a reverse-transcription oligonucleotide sequence of RNA fragment of HIV (T-2) were used as model systems. While in the presence of the targets, the fluorescence of dyes was recovered by forming a double strand structure. Multiplex DNA detection can be realized by synchronous scanning fluorescence spectrometry, and there was no cross reaction between the two probes. Under the optimum conditions, the fluorescence intensities of two dyes all exhibit good linear dependence on their target DNA concentration in the range of 1-10 nM with the detection limit of 0.87 nM and 0.22 nM for T-1 and T-2, respectively. As a proof of concept, the MOF-MBs have been successfully used as a potential sensing platform for simultaneous detection of multiplexed DNA.
C1 [Ye, Tai; Liu, Yufei; Luo, Ming; Xiang, Xia; Ji, Xinghu; Zhou, Guohua; He, Zhike] Wuhan Univ, Coll Chem & Mol Sci, Minist Educ, Key Lab Analyt Chem Biol & Med, Wuhan 430072, Peoples R China.
RP Ji, XH (reprint author), Wuhan Univ, Coll Chem & Mol Sci, Minist Educ, Key Lab Analyt Chem Biol & Med, Wuhan 430072, Peoples R China.
EM zhkhe@whu.edu.cn
OI Zhou, Guohua/0000-0001-6252-959X
FU National Key Scientific Program-Nanoscience and Nanotechnology
   [2011CB933600]; National Science Foundation of China [21075093,
   21275109, 21205089]
FX This work was financially supported by the National Key Scientific
   Program-Nanoscience and Nanotechnology (2011CB933600) and the National
   Science Foundation of China (21075093, 21275109 and 21205089).
CR Brunner J, 2004, J AM CHEM SOC, V126, P13626, DOI 10.1021/ja047252a
   Chen H, 2012, CHEM COMMUN, V48, P269, DOI 10.1039/c1cc16127j
   Chen LF, 2013, ANALYST, V138, P3490, DOI 10.1039/c3an00426k
   Farha OK, 2010, NAT CHEM, V2, P944, DOI [10.1038/NCHEM.834, 10.1038/nchem.834]
   Fujishima M, 2003, SYNTHETIC MET, V133, P433, DOI 10.1016/S0379-6779(02)00281-3                                                   
   Gu ZY, 2012, ACCOUNTS CHEM RES, V45, P734, DOI 10.1021/ar2002599
   Guo SJ, 2011, CHEM SOC REV, V40, P2644, DOI 10.1039/c0cs00079e
   Jung S, 2011, CHEM COMMUN, V47, P2904, DOI 10.1039/c0cc03288c
   Kitagawa H, 2003, INORG CHEM COMMUN, V6, P346, DOI 10.1016/S1387-7003(02)00749-9                                                   
   Kong RM, 2011, ANAL CHEM, V83, P7603, DOI 10.1021/ac2018926
   Kreno LE, 2012, CHEM REV, V112, P1105, DOI 10.1021/cr200324t
   Lee J, 2009, CHEM SOC REV, V38, P1450, DOI 10.1039/b807080f
   Li F, 2010, NANOSCALE, V2, P1021, DOI 10.1039/b9nr00401g
   Liu WL, 2013, J MATER CHEM B, V1, P928, DOI 10.1039/c3tb00257h
   Loh KP, 2010, NAT CHEM, V2, P1015, DOI 10.1038/NCHEM.907
   Lu CH, 2010, CHEM-EUR J, V16, P4889, DOI 10.1002/chem.200903071
   Nagao Y, 2005, SYNTHETIC MET, V154, P89, DOI 10.1016/j.synthmet.2005.07.006
   Wei WL, 2012, SMALL, V8, P2138, DOI 10.1002/smll.201200104
   Wei XF, 2013, J MATER CHEM B, V1, P1812, DOI 10.1039/c3tb00501a
   Wu WH, 2011, CHEM COMMUN, V47, P1201, DOI 10.1039/c0cc04312e
   Xia F, 2010, P NATL ACAD SCI USA, V107, P10837, DOI 10.1073/pnas.1005632107
   Xiang DS, 2012, ANALYST, V137, P3787, DOI 10.1039/c2an35262a
   Zhang LB, 2013, J AM CHEM SOC, V135, P2403, DOI 10.1021/ja3089857
   Zhen SJ, 2010, ANAL CHEM, V82, P8432, DOI 10.1021/ac100709s
   Zheng M, 2003, NAT MATER, V2, P338, DOI 10.1038/nmat877
   Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911
   Zhu X, 2013, CHEM COMMUN, V49, P1276, DOI 10.1039/c2cc36661d
   Zuo XL, 2010, J AM CHEM SOC, V132, P1816, DOI 10.1021/ja909551b
NR 28
TC 17
Z9 17
U1 19
U2 205
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2014
VL 139
IS 7
BP 1721
EP 1725
DI 10.1039/c3an02077k
PG 5
WC Chemistry, Analytical
SC Chemistry
GA AC3MB
UT WOS:000332422400020
PM 24524118
DA 2018-01-05
ER

PT J
AU Shete, HK
   Prabhu, RH
   Patravale, VB
AF Shete, Harshad K.
   Prabhu, Rashmi H.
   Patravale, Vandana B.
TI Endosomal Escape: A Bottleneck in Intracellular Delivery
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE Endosomal Escape; Intracellular Delivery; Lysosome; Smart Polymeric
   Nanocarriers
ID CELL-PENETRATING PEPTIDES; SOLID-LIPID NANOPARTICLES; STERIC-BLOCK
   OLIGONUCLEOTIDES; SENSITIVE FUSOGENIC PEPTIDE; NONVIRAL GENE DELIVERY;
   AERUGINOSA EXOTOXIN-A; HIV-1 TAT PROTEIN; SPERM-EGG FUSION;
   DRUG-DELIVERY; DIPHTHERIA-TOXIN
AB With advances in therapeutic science, apart from drugs, newer bioactive moieties like oligonucleotides, proteins, peptides, enzymes and antibodies are constantly being introduced for the betterment of therapeutic efficacy. These moieties have intracellular components of the cells like cytoplasm and nucleus as one of their pharmacological sites for exhibiting therapeutic activity. Despite their promising efficacy, their intracellular bioavailability has been critically hampered leading to failure in the treatment of numerous diseases and disorders. The endosomal uptake pathway is known to be a rate-limiting barrier for such systems. Bioactive molecules get trapped in the endosomal vesicles and degraded in the lysosomal compartment, necessitating the need for effective strategies that facilitate the endosomal escape and enhance the cytosolic bioavailability of bioactives. Microbes like viruses and bacteria have developed their innate mechanistic tactics to translocate their genome and toxins by efficiently penetrating the host cell membrane. Understanding this mechanism and exploring it further for intracellular delivery has opened new avenues to surmount the endosomal barrier. These strategies include membrane fusion, pore formation and proton sponge effects. On the other hand, progress in designing a novel smart polymeric carrier system that triggers endosomal escape by undergoing modulations in the intracellular milieu has further led to an improvement in intracellular delivery. These comprise pH, enzyme and temperature-induced modulators, synthetic cationic lipids and photo-induced physical disruption. Each of the aforementioned strategies has its own unique mechanism to escape the endosome. This review recapitulates the numerous strategies designed to surmount the bottleneck of endosomal escape and thereby achieve successful intracellular uptake of bioactives.
C1 [Shete, Harshad K.; Prabhu, Rashmi H.; Patravale, Vandana B.] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay 400019, Maharashtra, India.
RP Patravale, VB (reprint author), Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay 400019, Maharashtra, India.
FU University Grants Commission (UGC); Department of Science and Technology
   (DST) for INSPIRE fellowship
FX The authors wish to thank University Grants Commission (UGC) for
   research fellowship and Department of Science and Technology (DST) for
   INSPIRE fellowship.
CR Abes R, 2008, J PEPT SCI, V14, P455, DOI 10.1002/pse.979
   Abes R, 2008, NUCLEIC ACIDS RES, V36, P6343, DOI 10.1093/nar/gkn541
   ARGIOLAS A, 1984, J BIOL CHEM, V259, P106
   ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437
   ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012
   Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Barati S, 2002, EXP NEUROL, V177, P75, DOI 10.1006/exnr.2002.7999
   Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258
   Behr JP, 1997, CHIMIA, V51, P34
   Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848
   BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912                                                          
   Berg K, 1999, CANCER RES, V59, P1180
   Berg K, 2005, J MICROSC-OXFORD, V218, P133, DOI 10.1111/j.1365-2818.2005.01471.x
   Bettinger T, 2001, NUCLEIC ACIDS RES, V29, P3882, DOI 10.1093/nar/29.18.3882
   BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G
   Bitler BG, 2010, RECENT PAT ANTI-CANC, V5, P99, DOI 10.2174/157489210790936252                                                      
   BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0                                                                
   Boeckle S, 2006, J CONTROL RELEASE, V112, P240, DOI 10.1016/j.jconrel.2006.02.002
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Bondi ML, 2007, J DRUG TARGET, V15, P295, DOI 10.1080/10611860701324698
   Bonsted A, 2004, GENE THER, V11, P152, DOI 10.1038/sj.gt.3302166
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Browne KA, 1999, MOL CELL BIOL, V19, P8604
   Bruell D, 2003, INT J ONCOL, V23, P1179
   Calderon M, 2009, BIOORG MED CHEM LETT, V19, P3725, DOI 10.1016/j.bmcl.2009.05.058
   CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5
   Choi SH, 2006, LANGMUIR, V22, P1758, DOI 10.1021/la052549n
   Choi SH, 2008, EUR J PHARM BIOPHARM, V68, P545, DOI 10.1016/j.ejpb.2007.07.011
   Couffin-Hoarau AC, 2004, BIOMACROMOLECULES, V5, P2082, DOI 10.1021/bm0400527
   Cronin M, 2012, CANCER GENE THER, V19, P731, DOI 10.1038/cgt.2012.59
   Cui JW, 2012, BIOMACROMOLECULES, V13, P2225, DOI 10.1021/bm300835r
   de Bruin KG, 2008, J CONTROL RELEASE, V130, P175, DOI 10.1016/j.jconrel.2008.06.001
   Deda DK, 2013, J BIOMED NANOTECHNOL, V9, P1307, DOI 10.1166/jbn.2013.1614
   del Pozo-Rodriguez A, 2007, INT J PHARM, V339, P261, DOI 10.1016/j.ijpharm.2007.02.015
   del Pozo-Rodriguez A, 2010, INT J PHARMACEUT, V385, P157, DOI 10.1016/j.ijpharm.2009.10.020
   DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X
   Dufresne MH, 2004, INT J PHARM, V277, P81, DOI 10.1016/j.ijpharm.2003.07.014
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Eiriksdottir E., 2004, DRUG DESIGN REV, V1, P161
   Ekokoski E., 2010, EUR J PHARM SCI, V11, P404
   Endoh T, 2009, ADV DRUG DELIVER REV, V61, P704, DOI 10.1016/j.addr.2009.04.005
   ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F                                                    
   ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4                                                    
   Folini M, 2003, CANCER RES, V63, P3490
   Funhoff AM, 2004, BIOCONJUGATE CHEM, V15, P1212, DOI 10.1021/bc049864q
   Funhoff AM, 2004, PHARM RES, V21, P170, DOI 10.1023/B:PHAM.0000012165.68765.e6
   Futaki S, 2005, J GENE MED, V7, P1450, DOI 10.1002/jgm.796
   Gao X, 1995, GENE THER, V2, P710
   Giacca M, 2012, J CONTROL RELEASE, V161, P377, DOI 10.1016/j.jconrel.2012.04.008
   Glomski IJ, 2002, J CELL BIOL, V156, P1029, DOI 10.1083/jcb.200201081
   Gruenberg J, 2006, NAT REV MOL CELL BIO, V7, P495, DOI 10.1038/nrm1959
   Haba K, 2005, ANGEW CHEM INT EDIT, V44, P716, DOI 10.1002/anie.200461657
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Han J, 2000, INT J PHARM, V202, P151, DOI 10.1016/S0378-5173(00)00441-5
   Hardy PA, 2000, INT J MOL MED, V5, P241
   Hayes ME, 2006, BBA-BIOMEMBRANES, V1758, P429, DOI 10.1016/j.bbamem.2006.03.020
   Hellum M, 2003, PHOTOCH PHOTOBIO SCI, V2, P407, DOI 10.1039/b211880g
   HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491
   Hogset A, 2002, CANCER GENE THER, V9, P365, DOI 10.1038/sj/cgt/7700447
   Hruby M, 2005, J CONTROL RELEASE, V103, P137, DOI 10.1016/j.jconrel.2004.11.017
   Huang HW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.198304
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05
   Jia LT, 2003, CANCER RES, V63, P3257
   Jiang X, 2007, BIOCONJUGATE CHEM, V18, P2077, DOI 10.1021/bc0701186
   Jun C., 2013, J BIOMED NANOTECHNOL, V9, P1847
   Kakimoto S, 2009, BIOMATERIALS, V30, P402, DOI 10.1016/j.biomaterials.2008.09.042
   Kakudo T, 2004, BIOCHEMISTRY-US, V43, P5618, DOI 10.1021/bi035802w
   Kamper N, 2006, J VIROL, V80, P759, DOI 10.1128/JVI.80.2.759-768.2006
   Kasuya Y, 2001, J CONTROL RELEASE, V74, P203, DOI 10.1016/S0168-3659(01)00318-2
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Khandare JJ, 2006, BIOCONJUGATE CHEM, V17, P1464, DOI 10.1021/bc060240p
   Kim GM, 2005, MACROMOL BIOSCI, V5, P1118, DOI 10.1002/mabi.200500121                                                          
   Kim HR, 2008, MOL PHARMACEUT, V5, P622, DOI 10.1021/mp8000233
   Kim TH, 2013, J NANOSCI NANOTECHNO, V13, P7325, DOI 10.1166/jnn.2013.8084
   KIMURA T, 1988, J GEN VIROL, V69, P1247, DOI 10.1099/0022-1317-69-6-1247
   Kullberg M, 2010, J DRUG TARGET, V18, P313, DOI 10.3109/10611861003663549
   LEAR JD, 1987, J BIOL CHEM, V262, P6500
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Lee ES, 2005, J CONTROL RELEASE, V103, P405, DOI 10.1016/j.jconrel.2004.12.018
   Lee ES, 2003, J CONTROL RELEASE, V91, P103, DOI 10.1016/S0168-3659(03)00239-6
   Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0
   Lee ES, 2008, ANGEW CHEM INT EDIT, V47, P2418, DOI 10.1002/anie.200704121
   Lee H, 2001, J CONTROL RELEASE, V76, P183, DOI 10.1016/S0168-3659(01)00426-6                                                   
   Lee SH, 2008, J CONTROL RELEASE, V125, P25, DOI 10.1016/j.jconrel.2007.09.011
   LEGENDRE JY, 1993, P NATL ACAD SCI USA, V90, P893, DOI 10.1073/pnas.90.3.893
   Li L, 2013, J CONTROL RELEASE, V168, P142, DOI 10.1016/j.jconrel.2013.03.011
   Lin YL, 2010, BIOMATERIALS, V31, P7150, DOI 10.1016/j.biomaterials.2010.05.048
   LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D
   LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9                                                    
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lorenzi GL, 2005, J GENE MED, V7, P1077, DOI 10.1002/jgm.750
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Maier K, 2012, J AM CHEM SOC, V134, P10169, DOI 10.1021/ja302705v
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.bi.55.070186.003311
   Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8
   Meyer M, 2008, J AM CHEM SOC, V130, P3272, DOI 10.1021/ja710344v
   Midoux Patrick, 2002, Somatic Cell and Molecular Genetics, V27, P27, DOI 10.1023/A:1022931923153
   Min SH, 2006, J GENE MED, V8, P1425, DOI 10.1002/jgm.973
   Montana G, 2007, BIOCONJUGATE CHEM, V18, P302, DOI 10.1021/bc0601166
   MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709
   MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002
   Munyendo WL, 2012, BIOMOLECULES, V2, P187, DOI 10.3390/biom2020187
   Na K, 2004, J CONTROL RELEASE, V97, P513, DOI 10.1016/j.jconrel.2004.04.005
   Nimesh S, 2011, J BIOMED NANOTECHNOL, V7, P504, DOI 10.1166/jbn.2011.1313
   Ogasawara D, 2013, ANGEW CHEM INT EDIT, V52, P8620, DOI 10.1002/anie.201303999
   Ogris M, 2001, J BIOL CHEM, V276, P47550, DOI 10.1074/jbc.M108331200
   Oliveira S, 2007, INT J PHARM, V331, P211, DOI 10.1016/j.ijpharm.2006.11.050
   Oliveira S, 2007, BBA-BIOMEMBRANES, V1768, P1211, DOI 10.1016/j.bbamem.2007.01.013
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   PARENTE RA, 1988, J BIOL CHEM, V263, P4724
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031
   Peisajovich SG, 2002, EUR J BIOCHEM, V269, P4342, DOI 10.1046/j.1432-1033.2002.03132.x
   Pfeifer A, 2001, ANNU REV GENOM HUM G, V2, P177, DOI 10.1146/annurev.genom.2.1.177                                                   
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Prasmickaite L, 2001, PHOTOCHEM PHOTOBIOL, V73, P388, DOI 10.1562/0031-8655(2001)073<0388:EODPFU>2.0.CO;2                                 
   Prasmickaite L, 2000, J GENE MED, V2, P477, DOI 10.1002/1521-2254(200011/12)2:6<477::AID-JGM137>3.0.CO;2-B                      
   PRCHLA E, 1995, J CELL BIOL, V131, P111, DOI 10.1083/jcb.131.1.111
   PRIMOR N, 1985, EXPERIENTIA, V41, P693, DOI 10.1007/BF02007726
   PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001
   Rai P, 2010, ADV DRUG DELIVER REV, V62, P1094, DOI 10.1016/j.addr.2010.09.002
   RASPER DM, 1994, BIOCHEMISTRY-US, V33, P12981, DOI 10.1021/bi00248a006
   Resina S, 2007, INT J PHARM, V344, P96, DOI 10.1016/j.ijpharm.2007.04.039
   Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Saito G, 2003, GENE THER, V10, P72, DOI 10.1038/sj.gt.3301859
   Sandvig K, 2004, INT J MED MICROBIOL, V293, P483, DOI 10.1078/1438-4221-00294                                                         
   Sasaki K, 2008, ANAL BIOANAL CHEM, V391, P2717, DOI 10.1007/s00216-008-2012-1
   SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T
   Selbo PK, 2000, BBA-GEN SUBJECTS, V1475, P307, DOI 10.1016/S0304-4165(00)00082-9
   Serrano D, 2012, ARTERIOSCL THROM VAS, V32, P1178, DOI 10.1161/ATVBAHA.111.244186
   Shim WS, 2007, INT J PHARM, V331, P11, DOI 10.1016/j.ijpharm.2006.09.027
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Siddiqui A, 2010, INT J PHARMACEUT, V400, P251, DOI 10.1016/j.ijpharm.2010.08.044
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Simoes S, 1999, GENE THER, V6, P1798, DOI 10.1038/sj.gt.3301015
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1
   Subramanian A, 2002, J GENE MED, V4, P75, DOI 10.1002/jgm.235
   Tang LY, 2009, BIOCONJUGATE CHEM, V20, P1095, DOI 10.1021/bc900144m
   Tang RP, 2011, J CONTROL RELEASE, V151, P18, DOI 10.1016/j.jconrel.2010.12.005
   Teter K, 2002, INFECT IMMUN, V70, P6172, DOI 10.1128/IAI.70.11.6172-6179.2002
   Tijerina M, 2003, PHARMACEUT RES, V20, P728, DOI 10.1023/A:1023425300829                                                         
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Tu Y, 2008, J GENE MED, V10, P646, DOI 10.1002/jgm.1184
   Tweten RK, 2005, INFECT IMMUN, V73, P6199, DOI 10.1128/IAI.73.10.6199-6209.2005
   Van Dyke R W, 1996, Subcell Biochem, V27, P331
   Walton CM, 1999, WORLD J GASTROENTERO, V5, P465
   Wang C, 2013, J BIOMED NANOTECHNOL, V9, P357, DOI 10.1166/jbn.2013.1440
   Wang Y, 2013, CHEM COMMUN, V49, P7123, DOI 10.1039/c3cc43687j
   Wei C., 2008, J BIOMED NANOTECHNOL, V4, P369
   WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803                                                         
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Xu HF, 2009, J MATER CHEM, V19, P4183, DOI 10.1039/b901141b
   Yang C, 2013, J NANOSCI NANOTECHNO, V13, P6553, DOI 10.1166/jnn.2013.7520
   Yoshikawa T, 2008, BIOCHEM BIOPH RES CO, V366, P408, DOI 10.1016/j.bbre.2007.11.153
   Yu WY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/21/215102
   Zamai M, 2003, MOL CANCER THER, V2, P29
   ZAUNER W, 1995, J VIROL, V69, P1085
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 165
TC 54
Z9 54
U1 12
U2 153
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD JAN
PY 2014
VL 14
IS 1
BP 460
EP 474
DI 10.1166/jnn.2014.9082
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AB5BM
UT WOS:000331803900027
PM 24730275
DA 2018-01-05
ER

PT J
AU Shah, MAA
   Khan, SU
   Ali, Z
   Yang, HW
   Liu, KK
   Mao, LL
AF Shah, Muhammad Ali A.
   Khan, Sajid Umar
   Ali, Zeeshan
   Yang, Haowen
   Liu, Keke
   Mao, Lanlan
TI Applications of Nanoparticles for DNA Based Rabies Vaccine
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE Rabies; DNA Vaccines; Nanoparticles
ID WEST-NILE-VIRUS; MESENCHYMAL STEM-CELLS; HEMATOPOIETIC NECROSIS VIRUS;
   CALCIUM-PHOSPHATE NANOPARTICLES; INDUCED PROTECTIVE IMMUNITY;
   BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; MAGNETIC NANOPARTICLES;
   DRUG-DELIVERY; IN-VITRO
AB Rabies is a fatal encephalomyelitis. Most cases occur in developing countries and are transmitted by dogs. The cell culture vaccines as associated with high cost; therefore, have not replaced the unsafe brain-derived vaccines. In the developing countries these brain-derived rabies vaccines still can be seen in action. Moreover, there will be a need for vaccines against rabies-related viruses against which classical vaccines are not always effective. The worldwide incidence of rabies and the inability of currently used vaccination strategies to provide highly potent and cost-effective therapy indicate the need for alternate control strategies. DNA vaccines have emerged as the safest vaccines and best remedy for complicated diseases like hepatitis, HIV, and rabies. A number of recombinant DNA vaccines are now being developed against several diseases such as AIDS and malaria. Therefore, it can be a valuable alternative for the production of cheaper rabies vaccines against its larger spectrum of viruses. In this review we report published data on DNA-based immunization with sequences encoding rabies with special reference to nanotechnology.
C1 [Shah, Muhammad Ali A.; Ali, Zeeshan; Yang, Haowen] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
   [Shah, Muhammad Ali A.; Khan, Sajid Umar] PMAS Arid Agr Univ, Fac Vet & Anim Sci, Rawalpindi 44000, Pakistan.
   [Liu, Keke; Mao, Lanlan] Hunan Univ Technol, Hunan Key Lab Green Packaging & Biomed Nanotechno, Zhuzhou 412007, Peoples R China.
RP Shah, MAA (reprint author), Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
FU National Key Program for Developing Basic Research of China
   [2010CB933903]; National Key Special Program of Science and Technology
   Infrastructure Program [2013ZX10004103-002]; NSFC [61271056]; Hunan
   Science and Technology Projects [2013TP4062, 2012SK3105, 2010SK2003];
   Natural Science Foundation of Hunan Province, China [12JJ6060]; key
   Research Foundation of Education Bureau of Hunan Province, China
   [11A030]; China Postdoctoral Science Foundation [2013M531253]
FX This research was financially supported by the National Key Program for
   Developing Basic Research of China (2010CB933903), the National Key
   Special Program of Science and Technology Infrastructure Program
   (2013ZX10004103-002), NSFC (61271056), Hunan Science and Technology
   Projects (2013TP4062, 2012SK3105 and 2010SK2003), the Natural Science
   Foundation of Hunan Province, China (No. 12JJ6060), the key Research
   Foundation of Education Bureau of Hunan Province, China (No. 11A030),
   and the China Postdoctoral Science Foundation (No. 2013M531253).
CR Acosta F, 2006, FISH SHELLFISH IMMUN, V21, P272, DOI 10.1016/j.fsi.2005.12.006
   Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134
   Ali ZS, 2013, J NANOSCI NANOTECHNO, V13, P40, DOI 10.1166/jnn.2013.6705
   Ali Z, 2012, J NANOSCI NANOTECHNO, V12, P8241, DOI 10.1166/jnn.2012.6692
   Anderson ED, 1996, MOL MAR BIOL BIOTECH, V5, P114
   Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108
   Bahloul C, 2006, VACCINE, V24, P1063, DOI 10.1016/j.vaccine.2005.09.016
   Beran J, 2005, VACCINE, V23, P3902, DOI 10.1016/j.vaccine.2005.03.007
   Bergman PJ, 2003, CLIN CANCER RES, V9, P1284
   Bertram JP, 2010, PHARM RES-DORD, V27, P82, DOI 10.1007/s11095-009-0009-x
   Biswas S, 2001, HUM GENE THER, V12, P1917, DOI 10.1089/104303401753153965                                                      
   Biswas Subhabrata, 2001, Indian Journal of Experimental Biology, V39, P533
   Bjorklund T, 2010, MOVEMENT DISORD, V25, pS161, DOI 10.1002/mds.22785
   Boyer JD, 1999, CLIN IMMUNOL, V90, P100, DOI 10.1006/clim.1998.4616
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Bu J, 2003, COMP IMMUNOL MICROB, V26, P175, DOI 10.1016/S0147-9571(02)00050-4
   Bua J., 2000, VET RES, V31, P138
   Burki T, 2008, LANCET, V372, P1135, DOI 10.1016/S0140-6736(08)61462-2                                                   
   Chappell KJ, 2008, CURR MED CHEM, V15, P2771, DOI 10.2174/092986708786242804                                                      
   Checa-Casalengua P, 2012, INT J PHARMACEUT, V436, P545, DOI 10.1016/j.ijpharm.2012.07.019
   Chen JP, 2011, J NANOSCI NANOTECHNO, V11, P11089, DOI 10.1166/jnn.2011.3953
   Chen Y., 2004, Current Drug Delivery, V1, P361, DOI 10.2174/1567201043334542
   Chen Y, 2012, ADV DRUG DELIVER REV, V64, P640, DOI 10.1016/j.addr.2011.11.010
   Cherian AK, 2000, DRUG DEV IND PHARM, V26, P459, DOI 10.1081/DDC-100101255
   Chua KY, 2009, CURR OPIN ALLERGY CL, V9, P50, DOI 10.1097/ACI.0b013e3283207ad8
   Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
   Corbeil S, 1999, DIS AQUAT ORGAN, V39, P29, DOI 10.3354/dao039029
   Cui ZR, 2005, MOL PHARMACEUT, V2, P22, DOI 10.1021/mp049907k
   Cupillard L, 2005, VACCINE, V23, P1910, DOI 10.1016/j.vaccine.2004.10.018
   Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001
   Davis HL, 1999, MICROBES INFECT, V1, P7, DOI 10.1016/S1286-4579(99)80009-4
   de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237
   Denduangboripant J, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-52
   Deng Y, 2013, J BIOMED NANOTECHNOL, V9, P1123, DOI 10.1166/jbn.2013.1599
   Deng Y, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-190
   Deng Y, 2013, J BIOMED NANOTECHNOL, V9, P318, DOI 10.1166/jbn.2013.1487
   Deng Y, 2013, NEUROCHEM RES, V38, P504, DOI 10.1007/s11064-012-0942-7
   Dhama K, 2008, VET RES COMMUN, V32, P341, DOI 10.1007/s11259-008-9040-3
   Diogo MM, 2001, J GENE MED, V3, P577, DOI 10.1002/jgm.218
   Dodet Betty, 2007, Vaccine, V25, P8647, DOI 10.1016/j.vaccine.2007.10.004
   Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633                                                      
   Donnelly JJ, 1999, BRAZ J MED BIOL RES, V32, P215, DOI 10.1590/S0100-879X1999000200010                                                 
   Drape RJ, 2006, VACCINE, V24, P4475, DOI 10.1016/j.vaccine.2005.08.012
   Elingarami S, 2013, J NANOSCI NANOTECHNO, V13, P3204, DOI 10.1166/jnn.2013.7148
   Elingarami S, 2013, J NANOSCI NANOTECHNO, V13, P4539, DOI 10.1166/jnn.2013.7522
   FALLOUH NA, 1986, INT J PHARM, V28, P125
   Fan XL, 2009, MICROBIOL RES, V164, P374, DOI 10.1016/j.micres.2007.04.006
   Feltquate DM, 1998, J CELL BIOCHEM, P304
   Fu J, 2012, J BIOMED NANOTECHNOL, V8, P669, DOI 10.1166/jbn.2012.1427
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Garbayo E, 2011, MOVEMENT DISORD, V26, P1943, DOI 10.1002/mds.23793
   Garcia-Garcia E, 2005, INT J PHARM, V298, P274, DOI 10.1016/j.ijpharm.2005.03.031
   GARCIAARENAL F, 1987, VIROLOGY, V158, P339, DOI 10.1016/0042-6822(87)90206-6
   Goren D, 1996, BRIT J CANCER, V74, P1749, DOI 10.1038/bjc.1996.625
   Gu XS, 2011, PROG NEUROBIOL, V93, P204, DOI 10.1016/j.pneurobio.2010.11.002
   Guan J, 2012, BIOMATERIALS, V33, P1386, DOI 10.1016/j.biomaterials.2011.10.073
   Gupta PK, 2006, ACTA VIROL, V50, P87
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Guzman LA, 1996, CIRCULATION, V94, P1441
   Haley B, 2008, UROL ONCOL-SEMIN ORI, V26, P57, DOI 10.1016/j.urolonc.2007.03.015
   Hao YZ, 2012, J NANOSCI NANOTECHNO, V12, P7716, DOI 10.1166/jnn.2012.6647
   He N., 2012, J NANOSCI NANOTECHNO, V12, P3866
   He NY, 2012, J NANOSCI NANOTECHNO, V12, P2858, DOI 10.1166/jnn.2012.5756
   Herrmann JE, 1999, VIROLOGY, V259, P148, DOI 10.1006/viro.1999.9751
   Hiszczynska-Sawicka Elzbieta, 2009, Wiad Parazytol, V55, P125
   Hunsperger E, 2011, CLIN VACCINE IMMUNOL, V18, P978, DOI 10.1128/CVI.00040-11
   Ingolotti M, 2010, EXPERT REV VACCINES, V9, P747, DOI 10.1586/ERV.10.57
   Chadee K., 2004, GENET VACCINES THER, V2, P17, DOI DOI 10.1186/1479-0556-2-17
   Jamilpour N, 2011, J BIOMED NANOTECHNOL, V7, P542, DOI 10.1166/jbn.2011.1319
   Jha A. K., 2013, Journal of Bionanoscience, V7, P245, DOI 10.1166/jbns.2013.1139
   Jiang H., 2012, ADV SCI LETT, V7, P1, DOI [10.1166/asl.2012.3315, DOI 10.1166/ASL.2012.3315]
   Jiang HR, 2013, J NANOSCI NANOTECHNO, V13, P1617, DOI 10.1166/jnn.2013.7103
   Jiang YF, 2011, NEUROL RES, V33, P331, DOI 10.1179/016164110X12816242542571
   John TJ, 2011, LANCET, V377, P252, DOI 10.1016/S0140-6736(10)61265-2
   Kakkar M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001748
   Kalinna BH, 1997, IMMUNOL CELL BIOL, V75, P370, DOI 10.1038/icb.1997.58
   Kamath AT, 1999, INFECT IMMUN, V67, P1702
   Kersten Gideon, 2004, Expert Rev Vaccines, V3, P453, DOI 10.1586/14760584.3.4.453
   Khan AS, 2010, VACCINE, V28, P1905, DOI 10.1016/j.vaccine.2009.10.093
   Kilpatrick AM, 2010, VECTOR-BORNE ZOONOT, V10, P377, DOI 10.1089/vbz.2009.0029
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kulkamp IC, 2011, J BIOMED NANOTECHNOL, V7, P598, DOI 10.1166/jbn.2011.1318
   Kumar R, 2011, J BIOMED NANOTECHNOL, V7, P325, DOI 10.1166/jbn.2011.1290
   Labhasetwar V, 1999, COLLOID SURFACE B, V16, P281, DOI 10.1016/S0927-7765(99)00079-X                                                   
   Lampe KJ, 2011, J BIOMED MATER RES A, V96A, P595, DOI 10.1002/jbm.a.33011
   Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775
   Lasic DD, 1999, CURR OPIN MOL THER, V1, P177
   Le TP, 2000, VACCINE, V18, P1893, DOI 10.1016/S0264-410X(99)00407-7
   Ledgerwood JE, 2011, J INFECT DIS, V203, P1396, DOI 10.1093/infdis/jir054
   Lekshmi UMD, 2011, J BIOMED NANOTECHNOL, V7, P578, DOI 10.1166/jbn.2011.1317
   Li CY, 2012, J NANOSCI NANOTECHNO, V12, P2964, DOI 10.1166/jnn.2012.6428
   Li HY, 2011, J NANOSCI NANOTECHNO, V11, P8547, DOI 10.1166/jnn.2011.4965
   Li L, 2012, J BIOTECHNOL, V162, P171, DOI 10.1016/j.jbiotec.2012.08.012
   Li S, 2013, J BIOMED NANOTECHNOL, V9, P689, DOI 10.1166/jbn.2013.1568
   Li S, 2012, THERANOSTICS, V2, P967, DOI 10.7150/thno.5032
   Li X., 2012, ADV SCI LETT, V10, P284, DOI [10.1166/asl.2012.3723, DOI 10.1166/ASL.2012.3723]
   Li XL, 2013, J NANOSCI NANOTECHNO, V13, P5859, DOI 10.1166/jnn.2013.7540
   Li XL, 2013, NANOSCI NANOTECH LET, V5, P271, DOI 10.1166/nnl.2013.1495
   Li XL, 2012, J NANOSCI NANOTECHNO, V12, P2028, DOI 10.1166/jnn.2012.5177
   Li ZY, 2013, J BIOMED NANOTECHNOL, V9, P1945, DOI 10.1166/jbn.2013.1694
   Liao Jack C F, 2006, Cancer Immun, V6, P8
   Liu HG, 2012, BRAIN RES, V1477, P37, DOI 10.1016/j.brainres.2012.08.007
   Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x
   Liu Q, 2012, J NANOSCI NANOTECHNO, V12, P7709, DOI 10.1166/jnn.2012.6618
   Liu Y, 2009, BIOMATERIALS, V30, P4195, DOI 10.1016/j.biomaterials.2009.02.051
   Liu Z, 2012, J NANOSCI NANOTECHNO, V12, P8448, DOI 10.1166/jnn.2012.6623
   LORENZEN N, 1990, J GEN VIROL, V71, P561, DOI 10.1099/0022-1317-71-3-561                                                      
   Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018
   Lu ZX, 2012, NANOSCALE, V4, P5840, DOI 10.1039/c2nr31497e
   Ma C, 2013, J BIOMED NANOTECHNOL, V9, P703, DOI 10.1166/jbn.2013.1566
   Ma C, 2013, NANOSCI NANOTECH LET, V5, P301, DOI 10.1166/nnl.2013.1497
   Ma C, 2012, J BIOMED NANOTECHNOL, V8, P1000, DOI 10.1166/jbn.2012.1454
   Ma NN, 2013, J NANOSCI NANOTECHNO, V13, P6485, DOI 10.1166/jnn.2013.7525
   Ma NN, 2013, J NANOSCI NANOTECHNO, V13, P33, DOI 10.1166/jnn.2013.6697
   Madduri S, 2010, BIOMATERIALS, V31, P2323, DOI 10.1016/j.biomaterials.2009.11.073
   Maeda A, 2009, VIRUS RES, V144, P35, DOI 10.1016/j.virusres.2009.03.021
   Mahvi DM, 2002, HUM GENE THER, V13, P1711, DOI 10.1089/104303402760293556                                                      
   Malerba F, 2011, EXPERT OPIN DRUG DEL, V8, P1277, DOI 10.1517/17425247.2011.588204
   Manoj S, 2004, CRIT REV CL LAB SCI, V41, P1, DOI 10.1080/10408360490269251
   Martin JE, 2007, J INFECT DIS, V196, P1732, DOI 10.1086/523650
   Mathur A., 2013, J BIONANOSCI, V7, P140
   Medigeshi GR, 2009, J VIROL, V83, P6125, DOI 10.1128/JVI.02617-08
   Moloney TC, 2010, BRAIN RES, V1359, P33, DOI 10.1016/j.brainres.2010.08.040
   Mukherjee P, 2005, J BIOMED NANOTECHNOL, V1, P224, DOI 10.1166/jbn.2005.016
   Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912
   Nandedkar TD, 2009, J BIOSCIENCES, V34, P995, DOI 10.1007/s12038-009-0114-3
   Naresh M, 2011, J BIOMED NANOTECHNOL, V7, P572, DOI 10.1166/jbn.2011.1323
   Navalakhe RM, 2007, INDIAN J EXP BIOL, V45, P160
   Nimesh S, 2011, J BIOMED NANOTECHNOL, V7, P504, DOI 10.1166/jbn.2011.1313
   Nithiyanantham S., 2013, J BIONANOSCI, V7, P292
   O'Hagan DT, 2004, IMMUNOL REV, V199, P191, DOI 10.1111/j.0105-2896.2004.00153.x                                                
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   Osinubi MOV, 2009, VACCINE, V27, P7214, DOI 10.1016/j.vaccine.2009.09.031
   Pachuk CJ, 2000, CURR OPIN MOL THER, V2, P188
   Paitya N., 2013, J BIONANOSCI, V7, P145
   Panyam J, 2002, J DRUG TARGET, V10, P515, DOI 10.1080/1061186021000038391
   Patial S, 2007, VACCINE, V25, P4020, DOI 10.1016/j.vaccine.2007.02.051
   Perrin P, 2000, INTERVIROLOGY, V43, P302, DOI 10.1159/000053998
   Prince HE, 2009, CLIN VACCINE IMMUNOL, V16, P587, DOI 10.1128/CVI.00462-08
   Purcell MK, 2006, MOL IMMUNOL, V43, P2089, DOI 10.1016/j.molimm.2005.12.005
   Qin B., 2012, ADV SCI LETT, V5, P160
   Raghuvanshi RJ, 2001, J MICROENCAPSUL, V18, P723
   Ramaswamy S, 2012, NEUROBIOL DIS, V48, P243, DOI 10.1016/j.nbd.2011.12.030
   Ramshaw IA, 1997, IMMUNOL CELL BIOL, V75, P409, DOI 10.1038/icb.1997.64
   Rao M, 2000, ADV DRUG DELIVER REV, V41, P171, DOI 10.1016/S0169-409X(99)00064-2
   Rath A, 2005, VIRUS RES, V113, P143, DOI 10.1016/j.virusres.2005.05.002
   Redding L, 2009, EXPERT REV VACCINES, V8, P1251, DOI 10.1586/EPV.09.77
   Reece JF, 2007, VET REC, V161, P292, DOI 10.1136/vr.161.9.292                                                            
   Rejinold NS, 2011, J BIOMED NANOTECHNOL, V7, P521, DOI 10.1166/jbn.2011.1320
   Robertson James S., 2006, V127, P363
   Robertson JS, 2000, METH MOLEC MED, V29, P499, DOI 10.1385/1-59259-688-6:499
   Robertson JS, 2001, MOL BIOTECHNOL, V17, P143, DOI 10.1385/MB:17:2:143
   Rottinghaus ST, 2003, VACCINE, V21, P4604, DOI 10.1016/S0264-410X(03)00447-X
   Roy I, 2003, INT J PHARM, V250, P25, DOI 10.1016/S0378-5173(02)00452-0                                                   
   Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9                                                   
   Ruozi B, 2012, INT REV NEUROBIOL, V102, P207, DOI 10.1016/B978-0-12-386986-9.00009-0
   Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/erv.11.188, 10.1586/ERV.11.188]
   Shah MAA, 2010, VET PARASITOL, V169, P185, DOI 10.1016/j.vetpar.2009.12.035
   Shah MAA, 2010, EXP PARASITOL, V124, P330, DOI 10.1016/j.exppara.2009.11.010
   Shah MAA, 2010, PARASITOL RES, V107, P747, DOI 10.1007/s00436-010-1940-9
   Shah MAA, 2011, RES VET SCI, V90, P72, DOI 10.1016/j.rvsc.2010.05.003
   Sheets EE, 2003, AM J OBSTET GYNECOL, V188, P916, DOI 10.1067/mob.2003.256
   Shi J, 2012, INT J MOL SCI, V13, P4714, DOI 10.3390/ijms13044714
   Singh R, 2011, J BIOMED NANOTECHNOL, V7, P489, DOI 10.1166/jbn.2011.1324
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Soman P, 2011, J BIOMED NANOTECHNOL, V7, P334, DOI 10.1166/jbn.2011.1295
   Somoza R, 2010, BIOL BLOOD MARROW TR, V16, P1530, DOI 10.1016/j.bbmt.2010.06.006
   Song HY, 2010, EXP PARASITOL, V126, P224, DOI 10.1016/j.exppara.2010.05.015
   Song XK, 2009, VET PARASITOL, V159, P30, DOI 10.1016/j.vetpar.2008.10.015
   Staecker H, 2010, EXP NEUROL, V226, P1, DOI 10.1016/j.expneurol.2010.07.012
   Stevenson FK, 2004, IMMUNOL REV, V199, P5, DOI 10.1111/j.0105-2896.2004.00146.x
   Strugnell RA, 1997, IMMUNOL CELL BIOL, V75, P364, DOI 10.1038/icb.1997.57
   Sultana N., 2013, J BIONANOSCI, V7, P169
   Sun EC, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-100
   Sun HX, 2012, J NANOSCI NANOTECHNO, V12, P267, DOI 10.1166/jnn.2012.5170
   Tang YJ, 2013, THERANOSTICS, V3, P85, DOI 10.7150/thno.5588
   Tang YJ, 2013, J BIOMED NANOTECHNOL, V9, P312, DOI 10.1166/jbn.2013.1493
   Tang YJ, 2012, J NANOSCI NANOTECHNO, V12, P8081, DOI 10.1166/jnn.2012.6639
   Cruz ET, 2008, VACCINE, V26, P6936, DOI 10.1016/j.vaccine.2008.09.083
   Tesoro-Cruz E, 2008, VET RES, V39, DOI 10.1051/vetres:2007054
   Tuinstra HM, 2012, BIOMATERIALS, V33, P1618, DOI 10.1016/j.biomaterials.2011.11.002
   Ullah S, 2013, WORLD POULTRY SCI J, V69, P125, DOI 10.1017/S0043933913000111
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   Versluis AJ, 1998, PHARMACEUT RES, V15, P531, DOI 10.1023/A:1011917508056
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Wang RB, 2004, J IMMUNOL, V172, P5561, DOI 10.4049/jimmunol.172.9.5561                                                     
   Wang T, 2013, ACS APPL MATER INTER, V5, P3757, DOI 10.1021/am400369c
   Wang T, 2012, INT J PHARMACEUT, V422, P462, DOI 10.1016/j.ijpharm.2011.10.058
   Wang W, 2013, J BIOMED NANOTECHNOL, V9, P736, DOI 10.1166/jbn.2013.1577
   Wang W, 2012, J NANOSCI NANOTECHNO, V12, P7301, DOI 10.1166/jnn.2012.6154
   Wang W, 2012, J NANOSCI NANOTECHNO, V12, P7206, DOI 10.1166/jnn.2012.6504
   Wang YC, 2012, J NANOSCI NANOTECHNO, V12, P6176, DOI 10.1166/jnn.2012.6436
   Wang Y, 2012, J NANOSCI NANOTECHNO, V12, P8266, DOI 10.1166/jnn.2012.6677
   Wang ZF, 2013, J BIOMED NANOTECHNOL, V9, P1050, DOI 10.1166/jbn.2013.1609
   Wang ZF, 2012, NANOSCALE, V4, P3536, DOI 10.1039/c2nr30649b
   Watnasirichaikul S, 2000, PHARMACEUT RES, V17, P684, DOI 10.1023/A:1007574030674                                                         
   Wertheimer AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015514
   WHO Expert Consultation on rabies, 2005, WHO TECH REP SER, V931, P1
   Wilde H, 2005, VACCINE, V23, P2284, DOI 10.1016/j.vaccine.2005.01.030
   Wise AK, 2010, MOL THER, V18, P1111, DOI 10.1038/mt.2010.28
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Wu SQ, 2004, PARASITOL RES, V94, P332, DOI 10.1007/s00436-004-1185-6
   Xu LJ, 2013, J NANOSCI NANOTECHNO, V13, P2302, DOI 10.1166/jnn.2013.6860
   Xu QM, 2008, VET PARASITOL, V156, P319, DOI 10.1016/j.vetpar.2008.05.025
   Yager Eric J, 2013, Methods Mol Biol, V940, P223, DOI 10.1007/978-1-62703-110-3_19
   Yasuike M, 2007, FISH SHELLFISH IMMUN, V23, P531, DOI 10.1016/j.fsi.2006.12.006
   Yih TC, 2006, J CELL BIOCHEM, V97, P1184, DOI 10.1002/jcb.20796
   Youssef S, 1999, J AUTOIMMUN, V13, P21, DOI 10.1006/jaut.1999.0306
   Zeng X., 2012, ADV SCI LETT, V5, P212
   Zhang J, 2012, J NANOSCI NANOTECHNO, V12, P2045, DOI 10.1166/jnn.2012.5179
   Zhang LM, 2012, POLYM CHEM-UK, V3, P1958, DOI 10.1039/c2py20201h
   Zhang LM, 2012, J NANOSCI NANOTECHNO, V12, P2924, DOI 10.1166/jnn.2012.5698
   Zhang L. M., 2013, J NANOSCI N IN PRESS, V13
   Zhang MZ, 2012, J NANOSCI NANOTECHNO, V12, P9029, DOI 10.1166/jnn.2012.6783
   Zhang W, 2010, BRAIN RES, V1359, P256, DOI 10.1016/j.brainres.2010.08.072
   Zuccato C, 2009, NAT REV NEUROL, V5, P311, DOI 10.1038/nrneurol.2009.54
NR 217
TC 34
Z9 34
U1 3
U2 25
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD JAN
PY 2014
VL 14
IS 1
BP 881
EP 891
DI 10.1166/jnn.2014.9139
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AB5BM
UT WOS:000331803900057
PM 24730305
DA 2018-01-05
ER

PT J
AU Hao, R
   Liu, YM
   Zhong, RG
AF Hao, Run
   Liu, Yameng
   Zhong, Rugang
TI Application of electrospray ionization mass spectrometry for the
   evaluation of alkaloids binding to G-quadruplex of HIV-1 integrase
   inhibitors
SO ANALYTICAL METHODS
LA English
DT Article
ID TETRAD-FORMING OLIGONUCLEOTIDES; TELOMERIC DNA; IN-VITRO; RNA;
   THERAPEUTICS; SANGUINARINE; COMPLEXES; CHEMISTRY; SEQUENCE; LIGANDS
AB The G-rich oligonucleotide T30695 and T30177 with the sequence of d(GGGTGGGTGGGTGGGT) and d(GTGGTGGGTGGGTGGGT) can inhibit HIV-1 IN activity at nanomolar concentration levels. The formation of G-quadruplex of T30695 and T30177 as well as the interaction of two natural alkaloids berberine and sanguinarine with G-quadruplex were investigated using circular dichroism spectrometry and electrospray ionization-mass spectrometry. The results indicated that T30695 and T30177 could fold to form intramolecular G-quadruplex at low concentrations of NH4OAc. As the concentration of NH4OAc increased to 40 mM, the intramolecular G-quadruplex could be completely transformed to dimeric G-quadruplex for T30695, however, this concentration needed to be increased to 60 mM for T30177. The inducing study illustrated that berberine and sanguinarine could induce T30695 and T30177 to form intramolecular G-quadruplex but not dimeric G-quadruplex. Berberine and sanguinarine could bind to intramolecular G-quadruplex, and the relative binding affinity of sanguinarine was greater than that of berberine for T30695, but the two alkaloids showed nearly identical relative binding affinities for T30177. Berberine and sanguinarine could also bind to dimeric G-quadruplex, and the relative binding affinity of berberine was greater than that of sanguinarine. Both berberine and sanguinarine exhibited good affinities toward intramolecular and dimeric G-quadruplex, which may be significant in the process of G-quadruplex formation against HIV.
C1 [Hao, Run; Liu, Yameng; Zhong, Rugang] Beijing Univ Technol, Dept Life Sci & Bioengn, Beijing, Peoples R China.
RP Zhong, RG (reprint author), Beijing Univ Technol, Dept Life Sci & Bioengn, Beijing, Peoples R China.
EM life_sci@163.com
CR Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Beck JL, 2001, MASS SPECTROM REV, V20, P61, DOI 10.1002/mas.1003
   Bessi I, 2012, ACS CHEM BIOL, V7, P1109, DOI 10.1021/cb300096g
   Brodbelt JS, 2010, ANNU REV ANAL CHEM, V3, P67, DOI 10.1146/annurev.anchem.111808.073627
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   Cordell GA, 2001, PHYTOTHER RES, V15, P183, DOI 10.1002/ptr.890
   Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200
   Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589                                                          
   De Clercq E, 2009, REV MED VIROL, V19, P287, DOI 10.1002/rmv.624
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   Gornall KC, 2010, CHEM COMMUN, V46, P6602, DOI 10.1039/c0cc01933j
   Guittat L, 2003, BIOCHIMIE, V85, P535, DOI 10.1016/S0300-9084(03)00035-X
   HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0
   Hofstadler SA, 2001, CHEM REV, V101, P377, DOI 10.1021/cr990105o
   Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421
   Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967                                                  
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y
   Kypr J, 2001, EUR BIOPHYS J BIOPHY, V30, P555, DOI 10.1007/s002490100174
   Maizels N, 2006, NAT STRUCT MOL BIOL, V13, P1055, DOI 10.1038/nsmb1168
   Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u
   Mazzitelli CL, 2006, J AM SOC MASS SPECTR, V17, P593, DOI 10.1016/j.jasms.2005.12.011
   Monchaud D, 2008, ORG BIOMOL CHEM, V6, P627, DOI 10.1039/b714772b
   Mukundan VT, 2011, NUCLEIC ACIDS RES, V39, P8984, DOI 10.1093/nar/gkr540
   Neidle S, 2009, CURR OPIN STRUC BIOL, V19, P239, DOI 10.1016/j.sbi.2009.04.001
   Patel DJ, 2007, NUCLEIC ACIDS RES, V35, P7429, DOI 10.1093/nar/gkm711
   Phan AT, 2006, CURR OPIN STRUC BIOL, V16, P288, DOI 10.1016/j.sbi.2006.05.011
   Phan AT, 2010, FEBS J, V277, P1107, DOI 10.1111/j.1742-4658.2009.07464.x
   Raju G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035920
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Reyzer ML, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.21.e103
   Rosu F, 2008, BIOCHIMIE, V90, P1074, DOI 10.1016/j.biochi.2008.01.005
   Rosu F, 2010, NUCLEIC ACIDS RES, V38, P5217, DOI 10.1093/nar/gkq208
   SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0                                                                
   WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
   Yang S, 2010, CHINESE J CHEM, V28, P771, DOI 10.1002/cjoc.201090145
NR 38
TC 1
Z9 1
U1 0
U2 28
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9660
EI 1759-9679
J9 ANAL METHODS-UK
JI Anal. Methods
PY 2014
VL 6
IS 4
BP 1059
EP 1066
DI 10.1039/c3ay41494a
PG 8
WC Chemistry, Analytical; Food Science & Technology; Spectroscopy
SC Chemistry; Food Science & Technology; Spectroscopy
GA AA0OS
UT WOS:000330795200013
DA 2018-01-05
ER

PT J
AU Sachdeva, H
   Saroj, R
   Dwivedi, D
AF Sachdeva, Harshita
   Saroj, Rekha
   Dwivedi, Diksha
TI Nano-ZnO Catalyzed Multicomponent One-Pot Synthesis of Novel
   Spiro(indoline-pyranodioxine) Derivatives
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID ANTI-HIV ACTIVITY; ZINC-OXIDE; ISATIN DERIVATIVES; NANOPARTICLES;
   CONDENSATION; INHIBITORS; DESIGN
AB A simple catalytic protocol for the synthesis of novel spiro[indoline-pyranodioxine] derivatives has been developed using ZnO nanoparticle as an efficient, green, and reusable catalyst. The derivatives are obtained in moderate to excellent yield by one-pot three-component reaction of an isatin, malononitrile/ethylcyanoacetate, and 2,2-dimethyl-1,3-dioxane-4,6-dione in absolute ethanol under conventional heating and microwave irradiation. The catalyst was recovered by filtration from the reaction mixture and reused during five consecutive runs without any apparent loss of activity for the same reaction. The mild reaction conditions and recyclability of the catalyst make it environmentally benign synthetic procedure.
C1 [Sachdeva, Harshita; Saroj, Rekha; Dwivedi, Diksha] Mody Inst Technol & Sci, Fac Engn & Technol, Dept Chem, Sikar 332311, Rajasthan, India.
RP Sachdeva, H (reprint author), Mody Inst Technol & Sci, Fac Engn & Technol, Dept Chem, Sikar 332311, Rajasthan, India.
EM drhmsachdevaster@gmail.com
FU FET, MITS
FX The authors are thankful to the Dean and to the Head of the Department
   (Science and Humanities), FET, MITS, for providing necessary research
   facilities in the department. Financial assistance from FET, MITS, is
   gratefully acknowledged. They are also thankful to SAIF Punjab
   University, Chandigarh, for the spectral and elemental analyses.
CR Alinezhad H., 2013, SCI WORLD J, V2013
   Bal TR, 2005, BIOORG MED CHEM LETT, V15, P4451, DOI 10.1016/j.bmcl.2005.07.046
   Biswal S., 2012, ASIAN J PHARM CLIN R, V5, P1
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Chiyanzu I, 2005, BIOORGAN MED CHEM, V13, P3249, DOI 10.1016/j.bmc.2005.02.037
   Gould S. J., 1982, PROGR CHEM NATURAL P, V41, P77
   Guzel O, 2008, BIOORGAN MED CHEM, V16, P8976, DOI 10.1016/j.bmc.2008.08.050
   HIGASHIYAMA K, 1980, CHEM PHARM BULL, V28, P648
   JOSHI KC, 1985, HETEROCYCLES, V23, P957
   Joshi K.C., 1988, J INDIAN CHEM SOC, V115, P202
   Kraus GA, 2002, J ORG CHEM, V67, P5857, DOI 10.1021/jo020029g
   Kumar BV, 2011, J CHEM SCI, V123, P615
   Mashelkar UC, 2005, INDIAN J CHEM B, V44, P1937
   Moghaddam FM, 2009, J IRAN CHEM SOC, V6, P317, DOI 10.1007/BF03245840                                                              
   Palucki BL, 2001, BIOORG MED CHEM LETT, V11, P1955, DOI 10.1016/S0960-894X(01)00324-9                                                   
   RAJASHEKHAR B, 1986, J BIOL CHEM, V261, P3617
   RICH DH, 1980, J MED CHEM, V23, P27, DOI 10.1021/jm00175a006
   Sachdeva H, 2013, J CHEM-NY, DOI 10.1155/2013/606259
   Safaei-Ghomi J, 2013, J MEX CHEM SOC, V57, P1
   Selvam P, 2001, EUR J PHARM SCI, V14, P313, DOI 10.1016/S0928-0987(01)00197-X
   Shi HY, 2011, J MATER CHEM, V21, P12309, DOI 10.1039/c1jm10809c
   Siddiqui N, 2008, ACTA PHARMACEUT, V58, P445, DOI 10.2478/v10007-008-0025-0
   Sin N, 2009, BIOORG MED CHEM LETT, V19, P4857, DOI 10.1016/j.bmcl.2009.06.030
   Sun ZP, 2006, NANOTECHNOLOGY, V17, P2266, DOI 10.1088/0957-4484/17/9/032
   Tamaddon F, 2005, TETRAHEDRON LETT, V46, P7841, DOI 10.1016/j.tetlet.2005.09.005
   Vassiliou S, 1999, J MED CHEM, V42, P2610, DOI 10.1021/jm9900164
NR 26
TC 1
Z9 1
U1 0
U2 6
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2014
AR 427195
DI 10.1155/2014/427195
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB0HZ
UT WOS:000331473900001
OA gold
DA 2018-01-05
ER

PT J
AU Ramana, LN
   Sharma, S
   Sethuraman, S
   Ranga, U
   Krishnan, UM
AF Ramana, Lakshmi Narashimhan
   Sharma, Shilpee
   Sethuraman, Swaminathan
   Ranga, Udaykumar
   Krishnan, Uma Maheswari
TI Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic
   systems
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE Nanocarrier; Chitosan; Saquinavir; Antiretroviral
ID SOLID LIPID NANOPARTICLES; SAQUINAVIR; RELEASE; TRANSPORT; HIV/AIDS
AB Background: Antiretroviral Therapy (ART) is currently the major therapeutic intervention in the treatment of AIDS. ART, however, is severely limited due to poor availability, high cytotoxicity, and enhanced metabolism and clearance of the drug molecules by the renal system. The use of nanocarriers encapsulating the antiretroviral drugs may provide a solution to the aforementioned problems. Importantly, the application of mildly immunogenic polymeric carrier confers the advantage of making the nanoparticles more visible to the immune system leading to their efficient uptake by the phagocytes.
   Methods: The saquinavir-loaded chitosan nanopartides were characterized by transmission electron microscopy and differential scanning calorimetry and analyzed for the encapsulation efficiency, swelling characteristics, particle size properties, and the zeta potential. Furthermore, cellular uptake of the chitosan nanocarriers was evaluated using confocal microscopy and Flow cytometry. The antiviral efficacy was quantified using viral infection of the target cells.
   Results: Using novel chitosan carriers loaded with saquinavir, a protease inhibitor, we demonstrate a drug encapsulation efficiency of 75% and cell targeting efficiency greater than 92%. As compared to the soluble drug control, the saquinavir-loaded chitosan carriers caused superior control of the viral proliferation as measured by using two different viral strains, NL4-3 and Indie-C1, and two different target T-cells, Jurkat and CEM-CCR5.
   Conclusion: Chitosan nanoparticles loaded with saquinavir were characterized and they demonstrated superior drug loading potential with greater cell targeting efficiency leading to efficient control of the viral proliferation in target T-cells.
   General significance: Our data ascertain the potential of chitosan nanocarriers as novel vehicles for HIV-1 therapeutics. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Ramana, Lakshmi Narashimhan; Sethuraman, Swaminathan; Krishnan, Uma Maheswari] SASTRA Univ, Ctr Nanotechnol & Adv Biomat CeNTAB, Thanjavur 613401, Tamil Nadu, India.
   [Sharma, Shilpee; Ranga, Udaykumar] Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, HIV AIDS Lab, Mol Biol & Genet Unit, Bangalore 560012, Karnataka, India.
RP Krishnan, UM (reprint author), SASTRA Univ, Ctr Nanotechnol & Adv Biomat CeNTAB, Dept Chem, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India.
EM umakrishnan@sastra.edu
OI sharma, shilpee/0000-0003-4645-9442
FU ICMR [35/9/2009-BMS]; SASTRA University; JNCASR
FX The authors acknowledge the financial support from ICMR (No.
   35/9/2009-BMS) and SASTRA University and JNCASR for the infrastructural
   support.
CR Anitha A, 2011, CARBOHYD POLYM, V84, P1158, DOI 10.1016/j.carbpol.2011.01.005
   Annice E.K., 1998, J PHARMACOL EXP THER, V286, P1439
   Boudad H, 2001, INT J PHARM, V218, P113, DOI 10.1016/S0378-5173(01)00622-6
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Gunaseelan S, 2004, BIOCONJUGATE CHEM, V15, P1322, DOI 10.1021/bc0498875
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Jae H.P., 2010, ADV DRUG DELIVERY RE, V62, P28
   Jain A, 2010, NANOMED-NANOTECHNOL, V6, P179, DOI 10.1016/j.nano.2009.03.002
   Jain V, 2009, DRUG DELIV, V16, P37, DOI 10.1080/10717540802481646
   Jardine DK, 2000, ANTIVIR RES, V45, P59, DOI 10.1016/S0166-3542(99)00074-1
   Johan B., 2002, BIOMATERIALS, V23, P2561
   Jonathan S., 1996, ANN INTERN MED, V124, P1039
   Kuo YC, 2013, COLLOID SURFACE B, V101, P101, DOI 10.1016/j.colsurfb.2012.06.002
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Lalita K., 2011, COLLOID SURFACE B, V84, P163
   LI GP, 2009, CELL MOL IMMUNOL, V6, P45
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Li XM, 2012, COLLOID SURFACE B, V92, P136, DOI 10.1016/j.colsurfb.2011.11.030
   Liu J, 2010, CARBOHYD POLYM, V82, P432, DOI 10.1016/j.carbpol.2010.04.084
   MARCHESI VT, 1972, P NATL ACAD SCI USA, V69, P1445, DOI 10.1073/pnas.69.6.1445
   Meringo H., 2012, BIOMATERIALS, V33, P6393
   Merlin R., 2011, INT J PHARMACEUT, V410, P145
   Min L.T., 2011, CARBOHYD POLYM, V84, P756
   Mohammad R.S., 2010, CARBOHYD POLYM, V81, P726
   Mourya, 2009, J MATER SCI, V20, P1057
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   Pretzer E., 1995, ANTIVIR RES, V26, pA358
   Radonna J. T., 1991, J VIROL, V65, P922
   Ramana LN, 2012, INT J PHARMACEUT, V431, P120, DOI 10.1016/j.ijpharm.2012.04.054
   Richard B.K., 1998, J CLIN INVEST, V101, P289
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma P, 2012, J ADV PHARM TECHNOL, V3, P147, DOI 10.4103/2231-4040.101007
   Thummel KE, 1997, ADV DRUG DELIVER REV, V27, P99, DOI 10.1016/S0169-409X(97)00039-2
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xu G, 2008, BIOCONJUGATE CHEM, V19, P1179, DOI 10.1021/bc700477u
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Yang Y, 2007, COMP IMMUNOL MICROB, V30, P19, DOI 10.1016/j.cimid.2006.09.006
   Yuvan Q., 2010, ACTA BIOMATER, V6, P1140
NR 40
TC 17
Z9 17
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD JAN
PY 2014
VL 1840
IS 1
BP 476
EP 484
DI 10.1016/j.bbagen.2013.10.002
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 301TY
UT WOS:000330556200051
PM 24121104
DA 2018-01-05
ER

PT J
AU Vonnemann, J
   Sieben, C
   Wolff, C
   Ludwig, K
   Bottcher, C
   Herrmann, A
   Haag, R
AF Vonnemann, Jonathan
   Sieben, Christian
   Wolff, Christopher
   Ludwig, Kai
   Boettcher, Christoph
   Herrmann, Andreas
   Haag, Rainer
TI Virus inhibition induced by polyvalent nanoparticles of different sizes
SO NANOSCALE
LA English
DT Article
ID DENDRITIC POLYGLYCEROL SULFATES; GOLD NANOPARTICLES; SIALOSIDE GROUPS;
   INFLUENZA-VIRUS; HIV
AB The development of antiviral agents is one of the major challenges in medical science. So far, small monovalent molecular drugs that inhibit the late steps in the viral replication cycle, i.e., virus budding, have not worked well which emphasizes the need for alternative approaches. Polyvalently presented viral receptors, however, show potential as good inhibitors of virus-cell binding, which is the first step in the viral infection cycle. By gradually increasing the size of ligand functionalized gold nanoparticles up to virus-like dimensions, we are now able to quantify the polyvalent enhancement of virus-cell binding inhibition and to identify varying mechanisms of virus inhibition with different efficacies: by employing a new binding assay we found that surface area-normalized polysulfated gold nanoparticles of diameters equal to and larger than the virus diameter (>50 nm) more efficiently inhibit the binding of vesicular stomatitis virus (VSV) to cells than smaller particles. On a per particle basis, larger sized gold nanoparticles were surprisingly shown to inhibit the viral infection up to two orders of magnitude more efficiently than smaller particles, which suggests different mechanisms of virus inhibition. Based on complementary electron microscopic data, we noticed that larger gold nanoparticles act as efficient cross-linkers between virions, whereas smaller gold nanoparticles decorate the surface of individual virus particles. Our systematic study accentuates the need for the design of biodegradable, virus-sized inhibitors capitalizing on polyvalent binding.
C1 [Vonnemann, Jonathan; Haag, Rainer] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany.
   [Sieben, Christian; Wolff, Christopher; Herrmann, Andreas] Humboldt Univ, Inst Biol Mol Biophys, D-10099 Berlin, Germany.
   [Ludwig, Kai; Boettcher, Christoph] Free Univ Berlin, Forschungszentrum Elektronenmikroskopie, Berlin, Germany.
   [Ludwig, Kai; Boettcher, Christoph] Free Univ Berlin, Core Facil Biosupramol, Inst Chem & Biochem, Berlin, Germany.
RP Bottcher, C (reprint author), Free Univ Berlin, Forschungszentrum Elektronenmikroskopie, Berlin, Germany.
EM christoph.boettcher@fzem.fu-berlin.de; andreas.herrmann@rz.hu-berlin.de;
   haag@chemie.fu-berlin.de
OI Sieben, Christian/0000-0002-2836-2623
FU Deutsche Forschungsgemeinschaft [SFB 765]
FX This work was financially supported by the Deutsche
   Forschungsgemeinschaft (SFB 765) and the Core Facility Biosupramol.
CR Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Calderon M, 2010, ADV MATER, V22, P190, DOI 10.1002/adma.200902144
   Choi SK, 1996, CHEM BIOL, V3, P97, DOI 10.1016/S1074-5521(96)90285-9
   Dernedde J, 2010, P NATL ACAD SCI USA, V107, P19679, DOI 10.1073/pnas.1003103107
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   Finkelshtein D, 2013, P NATL ACAD SCI USA, V110, P7306, DOI 10.1073/pnas.1214441110
   Herrmann A., 1990, BIOCHEMISTRY-US, P4054
   Ivanova L, 2008, ANAL BIOCHEM, V379, P16, DOI 10.1016/j.ab.2008.04.035
   Liu W, 2008, J AM CHEM SOC, V130, P1274, DOI 10.1021/ja076069p
   Lou XH, 2007, BIOMACROMOLECULES, V8, P1385, DOI 10.1021/bm061217+
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Mei BC, 2009, LANGMUIR, V25, P10604, DOI 10.1021/la901423z
   Niikura K, 2009, BIOCONJUGATE CHEM, V20, P1848, DOI 10.1021/bc900255x
   Papp I, 2011, CHEMBIOCHEM, V12, P887, DOI 10.1002/cbic.201000776
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Perrault SD, 2009, J AM CHEM SOC, V131, P17042, DOI 10.1021/ja907069u
   Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u                                                               
   Turk H, 2004, BIOCONJUGATE CHEM, V15, P162, DOI 10.1021/bc034044j
   Wyszogrodzka M, 2008, CHEM-EUR J, V14, P9202, DOI 10.1002/chem.200800892
   Ziegler C, 2011, J PHYS CHEM C, V115, P4502, DOI 10.1021/jp1106982
NR 22
TC 25
Z9 25
U1 3
U2 36
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2014
VL 6
IS 4
BP 2353
EP 2360
DI 10.1039/c3nr04449a
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AA0PE
UT WOS:000330796700050
PM 24430614
DA 2018-01-05
ER

PT J
AU Singh, G
   Pai, RS
AF Singh, Gurinder
   Pai, Roopa S.
TI Optimization (Central Composite Design) and Validation of HPLC Method
   for Investigation of Emtricitabine Loaded Poly(lactic-co-glycolic acid)
   Nanoparticles: In Vitro Drug Release and In Vivo Pharmacokinetic Studies
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID HUMAN PLASMA; LIQUID-CHROMATOGRAPHY; HIV-1 INFECTION; TENOFOVIR;
   MICROBICIDES; FORMULATION; INHIBITORS; TABLET
AB The objective of the current study is to develop nanoparticles (NPs) drug delivery system of emtricitabine solely using poly(lactic-co-glycolic acid) (PLGA) and evaluate its in vitro and in vivo release performance by systematically optimized HPLC method using Formulation by Design (FbD). NPs were evaluated for in vitro release and in vivo absorption study. The desired chromatographic separation was achieved on a Phenomenex C-18 (250 mm x 4.6 mm I.D., 5 mu m) column, under isocratic conditions using UV detection at 280 nm. The optimized mobile phase consisted of a mixture of 40 mM phosphate dihydrogen phosphate buffer (pH 6.8), methanol, and 2% acetonitrile in a ratio of (83 : 15 : 2, v/v/v) at a flow rate of 1 mL/min. The linear regression analysis for the calibration curves showed a good linear correlation over the concentration range 0.040-2.0 mu g/mL, with retention time of 4.39 min. An average encapsulation efficiency of 74.34% was obtained for NPs. In vitro studies showed zero-order release and about 95% drug being released within 15 days in PBS (pH 7.4). In conclusion, the proposed optimized method was successfully applied for the determination of in vitro and in vivo release studies of emtricitabine NPs.
C1 [Singh, Gurinder; Pai, Roopa S.] Al Ameen Coll Pharm, Fac Pharm, Dept Pharmaceut, Bangalore 560027, Karnataka, India.
RP Pai, RS (reprint author), Al Ameen Coll Pharm, Fac Pharm, Dept Pharmaceut, Hosur Rd, Bangalore 560027, Karnataka, India.
EM roopaspai@yahoo.com
OI Singh, Gurinder/0000-0003-1525-3898
FU ICMR (Indian Council of Medical Research, Government of India, New
   Delhi) [45/38/2011/Nan-BMS]
FX The authors gratefully acknowledge financial support and granting
   research fellowship (45/38/2011/Nan-BMS) from ICMR (Indian Council of
   Medical Research, Government of India, New Delhi). The authors are also
   grateful to Cipla Laboratories, Mumbai, India, for providing the gift
   samples of emtricitabine and lamivudine.
CR Budawari S., 2001, MERCK INDEX
   Dabrowska MM, 2011, HIV AIDS REV, V10, P38, DOI 10.1016/j.hivar.2011.03.004
   Darque A, 1999, ANTIMICROB AGENTS CH, V43, P2245
   Devrukhakar P. S., 2013, ISRN CHROMATOGRAPHY, V2013
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Droste JAH, 2007, J LIQ CHROMATOGR R T, V30, P2769, DOI 10.1080/10826070701560900
   FDA, 2001, GUID IND BIOAN METH
   Gomes NA, 2008, J PHARMACEUT BIOMED, V48, P918, DOI 10.1016/j.jpba.2008.07.022
   Hamarapurkar PD, 2013, J CHROMATOGR SCI, V51, P419, DOI 10.1093/chromsci/bms157
   [Anonymous], 2005, P INT C HARM TECHN R
   Karunakaran A, 2010, PHARM SINICA, V1, P52
   Kumar P, 2012, FARMACIA, V60, P402
   Lamorde M, 2012, AIDS RES TREAT, V2012
   Mangoankar K, 2008, INDIAN DRUGS, V45, P188
   Mostafavi A, 2009, TALANTA, V77, P1415, DOI 10.1016/j.talanta.2008.09.024
   Nirogi R, 2012, BIOPHARM DRUG DISPOS, V33, P265, DOI 10.1002/bdd.1794
   Notari S, 2006, J CHROMATOGR B, V833, P109, DOI 10.1016/j.jchromb.2006.02.010
   Olin JL, 2012, ANN PHARMACOTHER, V46, P1671, DOI 10.1345/aph.1R468
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Peepliwal A., 2010, J PHARM RES, V3, P1712
   Rezk NL, 2005, J CHROMATOGR B, V822, P201, DOI 10.1016/j.jchromb.2005.06.019
   Sean C. S., 2002, MARTINDALE COMPLETE
   Seshachalam U, 2007, J SEP SCI, V30, P999, DOI 10.1002/jssc.200600429
   Sharma S, 2011, AM EURASIAN J TOXICO, V3, P138
   Singh G, 2012, J YOUNG PHARM, V4, P146, DOI 10.4103/0975-1483.100020
   Singh G, 2012, J ADV PHARM TECHNOL, V3, P30, DOI 10.4103/2231-4040.93565
   Snehal J. M., 2012, ISRN CHROMATOGRAPHY, V2012
   Sparidans RW, 2007, BIOMED CHROMATOGR, V21, P621, DOI 10.1002/bmc.797
   Terrazas-Aranda Katty, 2007, Antiviral Chemistry & Chemotherapy, V18, P141
   [Anonymous], 2007, EMTR MON IND PHARM C
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Wang LH, 2004, ANTIMICROB AGENTS CH, V48, P183, DOI 10.1128/AAC.48.1.183-191.2004
   Xiong Y, 2009, J PHARMACEUT BIOMED, V49, P646, DOI 10.1016/j.jpba.2008.12.023
NR 33
TC 2
Z9 2
U1 0
U2 6
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2014
AR 583090
DI 10.1155/2014/583090
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA1XC
UT WOS:000330888300001
OA gold
DA 2018-01-05
ER

PT J
AU Barton, C
   Kouokam, JC
   Lasnik, AB
   Foreman, O
   Cambon, A
   Brock, G
   Montefiori, DC
   Vojdani, F
   McCormick, AA
   O'Keefe, BR
   Palmer, KE
AF Barton, Christopher
   Kouokam, J. Calvin
   Lasnik, Amanda B.
   Foreman, Oded
   Cambon, Alexander
   Brock, Guy
   Montefiori, David C.
   Vojdani, Fakhrieh
   McCormick, Alison A.
   O'Keefe, Barry R.
   Palmer, Kenneth E.
TI Activity of and Effect of Subcutaneous Treatment with the Broad-Spectrum
   Antiviral Lectin Griffithsin in Two Laboratory Rodent Models
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HEPATITIS-C VIRUS; ENTRY INHIBITOR GRIFFITHSIN; N-LINKED GLYCANS;
   CYANOVIRIN-N; CARBOHYDRATE-BINDING; PROTEIN GRIFFITHSIN; TYPE-1 STRAINS;
   IN-VITRO; GP120; RESISTANCE
AB Griffithsin (GRFT) is a red-alga-derived lectin that binds the terminal mannose residues of N-linked glycans found on the surface of human immunodeficiency virus type 1 (HIV-1), HIV-2, and other enveloped viruses, including hepatitis C virus (HCV), severe acute respiratory syndrome coronavirus (SARS-CoV), and Ebola virus. GRFT displays no human T-cell mitogenic activity and does not induce production of proinflammatory cytokines in treated human cell lines. However, despite the growing evidence showing the broad-spectrum nanomolar or better antiviral activity of GRFT, no study has reported a comprehensive assessment of GRFT safety as a potential systemic antiviral treatment. The results presented in this work show that minimal toxicity was induced by a range of single and repeated daily subcutaneous doses of GRFT in two rodent species, although we noted treatment-associated increases in spleen and liver mass suggestive of an antidrug immune response. The drug is systemically distributed, accumulating to high levels in the serum and plasma after subcutaneous delivery. Further, we showed that serum from GRFT-treated animals retained antiviral activity against HIV-1-enveloped pseudoviruses in a cell-based neutralization assay. Overall, our data presented here show that GRFT accumulates to relevant therapeutic concentrations which are tolerated with minimal toxicity. These studies support further development of GRFT as a systemic antiviral therapeutic agent against enveloped viruses, although deimmunizing the molecule may be necessary if it is to be used in long-term treatment of chronic viral infections.
C1 [Barton, Christopher; Kouokam, J. Calvin; Lasnik, Amanda B.; Palmer, Kenneth E.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
   [Barton, Christopher; Kouokam, J. Calvin; Lasnik, Amanda B.; Palmer, Kenneth E.] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
   [Kouokam, J. Calvin; Palmer, Kenneth E.] Owensboro Canc Res Program, Owensboro, KY USA.
   [Foreman, Oded] Jackson Lab, Bar Harbor, ME 04609 USA.
   [Cambon, Alexander; Brock, Guy] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY 40292 USA.
   [Montefiori, David C.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA.
   [Vojdani, Fakhrieh; Palmer, Kenneth E.] Intrucept Biomed LLC, Owensboro, KY USA.
   [McCormick, Alison A.] Touro Coll Pharm, Vallejo, CA USA.
   [O'Keefe, Barry R.] NCI, Frederick, MD 21701 USA.
RP Palmer, KE (reprint author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
EM kenneth.palmer@louisville.edu
OI Palmer, Kenneth/0000-0002-2811-1111
FU NIH [AI076169, T32-ES011564, HHSN27201100016C]; DOD [USAMRMC
   W81XWH-10-2-CLIN 1]; Intramural Research Program of the NIH, National
   Cancer Institute, Center for Cancer Research
FX This work was supported by NIH grant AI076169 to K.E.P. and NIH grant
   T32-ES011564, DOD grant USAMRMC W81XWH-10-2-CLIN 1, and NIH contract
   HHSN27201100016C. This research was supported by the Intramural Research
   Program of the NIH, National Cancer Institute, Center for Cancer
   Research.
CR Alexandre KB, 2010, VIROLOGY, V402, P187, DOI 10.1016/j.virol.2010.03.021
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Balzarini J, 2006, J VIROL, V80, P8411, DOI 10.1128/JVI.00369-06
   Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521
   BOX GE, 1978, STAT EXPT
   Choi Y, 2013, J COMPUT CHEM, V34, P879, DOI 10.1002/jcc.23213
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107
   Ferir G, 2012, AIDS RES HUM RETROV, V28, P1513, DOI [10.1089/aid.2012.0026, 10.1089/AID.2012.0026]
   Gavrovic-Jankulovic M, 2008, INT J BIOCHEM CELL B, V40, P929, DOI 10.1016/j.biocel.2007.10.033
   Helle F, 2011, VIRUSES-BASEL, V3, P1909, DOI 10.3390/v3101909
   Helle F, 2010, J VIROL, V84, P11905, DOI 10.1128/JVI.01548-10
   Hoorelbeke B, 2010, ANTIMICROB AGENTS CH, V54, P3287, DOI 10.1128/AAC.00254-10
   Huang X, 2011, J GEN VIROL, V92, P2367, DOI 10.1099/vir.0.033092-0
   Huskens D, 2008, INT J BIOCHEM CELL B, V40, P2802, DOI 10.1016/j.biocel.2008.05.023
   Ishag HZA, 2013, ARCH VIROL, V158, P349, DOI 10.1007/s00705-012-1489-2
   Kagiampakis I, 2011, ANTIMICROB AGENTS CH, V55, P264, DOI 10.1128/AAC.00376-10
   KOSHTE VL, 1990, BIOCHEM J, V272, P721, DOI 10.1042/bj2720721                                                               
   Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635
   Liu B, 2008, BMB REP, V41, P369, DOI 10.5483/BMBRep.2008.41.5.369                                                    
   Meuleman P, 2011, ANTIMICROB AGENTS CH, V55, P5159, DOI 10.1128/AAC.00633-11
   Michelow IC, 2011, J INFECT DIS, V203, P175, DOI 10.1093/infdis/jiq025
   Montefiori DC, 2005, CURR PROTOC IMMUNOL, V64
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Moulaei T, 2010, STRUCTURE, V18, P1104, DOI 10.1016/j.str.2010.05.016
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106
   Ooi LSM, 2004, INT J BIOCHEM CELL B, V36, P1440, DOI 10.1016/j.biocel.2004.01.015
   PAINTER RG, 1976, P NATL ACAD SCI USA, V73, P837, DOI 10.1073/pnas.73.3.837
   Parker AS, 2013, J COMPUT BIOL, V20, P152, DOI 10.1089/cmb.2012.0251
   Prettyman J., 2005, MEDSURG NURS, V14, P99
   Prettyman Julie, 2005, Medsurg Nurs, V14, P93
   Shan MM, 2007, PLOS PATHOG, V3, P1637, DOI 10.1371/journal.ppat.0030169
   Smee DF, 2008, ANTIVIR RES, V80, P266, DOI 10.1016/j.antiviral.2008.06.003
   Smee Donald F., 2007, Antiviral Chemistry & Chemotherapy, V18, P317
   Smith CM, 2011, J IMMUNOL, V187, P1201, DOI 10.4049/jimmunol.1002152
   Student B., 1908, BIOMETRIKA, V6, P25
   Takebe Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064449
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.2307/3001968
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Ziolkowska NE, 2007, PROTEINS, V67, P661, DOI 10.1002/prot.21336
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
NR 42
TC 31
Z9 32
U1 0
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2014
VL 58
IS 1
BP 120
EP 127
DI 10.1128/AAC.01407-13
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 287ZL
UT WOS:000329581100015
PM 24145548
OA gold
DA 2018-01-05
ER

PT J
AU Boffito, M
   Jackson, A
   Owen, A
   Becker, S
AF Boffito, Marta
   Jackson, Akil
   Owen, Andrew
   Becker, Stephen
TI New Approaches to Antiretroviral Drug Delivery: Challenges and
   Opportunities Associated with the Use of Long-Acting Injectable Agents
SO DRUGS
LA English
DT Article
ID ANTI-CD4 MONOCLONAL-ANTIBODY; PREEXPOSURE PROPHYLAXIS; PROTEASE
   INHIBITORS; THERAPY; HIV-1; PHARMACOKINETICS; RILPIVIRINE; PREVALENCE;
   PREVENTION; DISEASE
AB Research on improved treatment of HIV infection and pre-exposure prophylaxis continues. Poor adherence to treatment is the critical risk factor for virological failure and resistance development, and long-acting formulations of anti-HIV medications that need only infrequent dosing may facilitate long-term therapeutic responses. Importantly, long-acting formulations of therapeutic agents have been used to avoid missing doses or treatment fatigue to prescribed lifelong medications in a number of different medical fields, with demonstrable success. However, such formulations are associated with challenges, such as the prolongation of adverse events with the persistence of drug concentrations and concerns over the development of resistance as a result of selective pressure as drug concentrations decline. Furthermore, long-acting injectable formulations of antiretroviral (ARV) agents with infrequent dosing may be advantageous over daily oral drug intake to prevent transmission of HIV. However, the knowledge on protective drug concentrations and frequency of dosing is poor to date and implementation globally is challenging. Importantly, if nanoformulations of ARVs requiring lower drug doses become available globally, the potential for treatment cost reductions is high, as, especially in resource-limited settings, the active pharmaceutical ingredient accounts for the greater proportion of the total cost of the medicine. In conclusion, different long-acting ARVs are being studied in phase I/II for both the treatment and prevention of HIV infection, and research on administering these agents in combination has started.
C1 [Boffito, Marta; Jackson, Akil] Chelsea & Westminster Hosp, St Stephens Ctr, London SW10 9NH, England.
   [Owen, Andrew] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   [Becker, Stephen] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Boffito, M (reprint author), Chelsea & Westminster Hosp, St Stephens Ctr, 369 Fulham Rd, London SW10 9NH, England.
EM marta.boffito@chelwest.nhs.uk
RI Owen, Andrew/M-7509-2017
OI Owen, Andrew/0000-0002-9819-7651
FU Bill and Melinda Gates Foundation; Engineering and Physical Sciences
   Research Council towards Nanomedicine Interventions for HIV/AIDS
FX Dr. Marta Boffito was principal investigator on the SSAT040 study aimed
   at investigating the pharmacokinetics of rilpivirine long-acting, funded
   by the Bill and Melinda Gates Foundation. Dr. Marta Boffito and Prof.
   Andrew Owen have received funding from the Engineering and Physical
   Sciences Research Council towards Nanomedicine Interventions for
   HIV/AIDS.
CR Abel S, 2008, BRIT J CLIN PHARMACO, V65, P60, DOI 10.1111/j.1365-2125.2008.03137.x
   Anderson PL, 2012, SCI TRANSL MED, V11, pra125
   Andrew C, 2013, 20 C RETR OPP INF AT
   BACK D J, 1987, Alimentary Pharmacology and Therapeutics, V1, P339
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Barry M, 1997, CLIN PHARMACOKINET, V32, P194, DOI 10.2165/00003088-199732030-00003                                                
   British Pharmacopoeia Commission, 2012, BHIVA GUID TREATM HI, P1
   Cohen MS, 2012, CURR OPIN HIV AIDS, V7, P99, DOI 10.1097/COH.0b013e32834f5cf2
   Coleman CI, 2012, CURR MED RES OPIN, V28, P669, DOI 10.1185/03007995.2012.677419
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dassah ET, 2013, EUR J CONTRACEP REPR, V18, P293, DOI 10.3109/13625187.2013.790951
   Donnell D, 19 C RETR OPP INF SE
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Jackson A, 2004, AIDS REV, V6, P208
   Jackson AG, PHARMACOKIN IN PRESS
   Jackson AGA, PLASMA FEMALE GENITA
   Jacobson JM, 2009, ANTIMICROB AGENTS CH, V53, P450, DOI 10.1128/AAC.00942-08
   Lambert-Niclot S, 2013, J ANTIMICROB CHEMOTH, V68, P1237, DOI 10.1093/jac/dkt003
   Marrazzo J, 2013, 20 C RETR OPP INF CR
   McDonald TO, 2013, ADV HEALTHC IN PRESS
   Min S, 2009, 49 INT C ANT AG CHEM, P1
   Nelson MR, 2013, HIV CLIN TRIALS, V14, P81, DOI 10.1310/hct1403-81
   Nieschlag E, 1999, CLIN ENDOCRINOL, V51, P757, DOI 10.1046/j.1365-2265.1999.00881.x                                                
   Norris D, 2006, AIDS 2006 16 INT AID
   Owens DR, 2013, DIABETES METAB RES R
   Pace CS, 2013, JAIDS-J ACQ IMM DEF, V62, P1, DOI 10.1097/QAI.0b013e3182732746
   Prescott GM, 2013, PHARMACOTHERAPY
   Rimsky L, 2012, JAIDS-J ACQ IMM DEF, V59, P39, DOI 10.1097/QAI.0b013e31823df4da
   Rossi G, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-122
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Spreen W, 2013, 7 IAS C HIV PATH TRE
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Underwood M, 2013, AIDS 2010 18 INT AID
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Verloes R., 2008, 17 INT AIDS C MEX CI
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Wysham C, 2013, DIABETES OBES METAB, V15, P871, DOI 10.1111/dom.12084
   Yoshinaga T, 2012, 52 INT C ANT AG CHEM
   Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301                                                     
NR 42
TC 18
Z9 18
U1 0
U2 9
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD JAN
PY 2014
VL 74
IS 1
BP 7
EP 13
DI 10.1007/s40265-013-0163-7
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 291KK
UT WOS:000329827400002
PM 24327298
DA 2018-01-05
ER

PT J
AU Guendel, I
   Iordanskiy, S
   Van Duyne, R
   Kehn-Hall, K
   Saifuddin, M
   Das, R
   Jaworski, E
   Sampey, GC
   Senina, S
   Shultz, L
   Narayanan, A
   Chen, H
   Lepene, B
   Zeng, C
   Kashanchi, F
AF Guendel, Irene
   Iordanskiy, Sergey
   Van Duyne, Rachel
   Kehn-Hall, Kylene
   Saifuddin, Mohammed
   Das, Ravi
   Jaworski, Elizabeth
   Sampey, Gavin C.
   Senina, Svetlana
   Shultz, Leonard
   Narayanan, Aarthi
   Chen, Hao
   Lepene, Benjamin
   Zeng, Chen
   Kashanchi, Fatah
TI Novel Neuroprotective GSK-3 beta Inhibitor Restricts Tat-Mediated HIV-1
   Replication
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GLYCOGEN-SYNTHASE KINASE-3; CEREBELLAR
   GRANULE NEURONS; SMALL-MOLECULE INHIBITORS; CENTRAL-NERVOUS-SYSTEM;
   HUMAN MICROGLIAL CELLS; AMINO-ACID RECEPTORS; EXPOSURE IN-VITRO; PROTEIN
   TAT; P-TEFB
AB The implementation of new antiretroviral therapies targeting transcription of early viral proteins in postintegrated HIV-1 can aid in overcoming current therapy limitations. Using high-throughput screening assays, we have previously described a novel Tat-dependent HIV-1 transcriptional inhibitor named 6-bromoindirubin-3'-oxime (6BIO). The screening of 6BIO derivatives yielded unique compounds that show potent inhibition of HIV-1 transcription. We have identified a second-generation derivative called 18BIOder as an inhibitor of HIV-1 Tat-dependent transcription in TZM-bl cells and a potent inhibitor of GSK-3 beta kinase in vitro. Structurally, 18BIOder is half the molecular weight and structure of its parental compound, 6BIO. More importantly, we also have found a different GSK-3 beta complex present only in HIV-1-infected cells. 18BIOder preferentially inhibits this novel kinase complex from infected cells at nanomolar concentrations. Finally, we observed that neuronal cultures treated with Tat protein are protected from Tat-mediated cytotoxicity when treated with 18BIOder. Overall, our data suggest that HIV-1 Tatdependent transcription is sensitive to small-molecule inhibition of GSK-3 beta.
C1 [Guendel, Irene; Iordanskiy, Sergey; Van Duyne, Rachel; Kehn-Hall, Kylene; Saifuddin, Mohammed; Das, Ravi; Jaworski, Elizabeth; Sampey, Gavin C.; Senina, Svetlana; Narayanan, Aarthi; Kashanchi, Fatah] George Mason Univ, Natl Ctr Biodef & Infect Dis, Manassas, VA USA.
   [Van Duyne, Rachel] George Washington Univ, Sch Med, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
   [Shultz, Leonard] Jackson Lab, Bar Harbor, ME 04609 USA.
   [Chen, Hao; Zeng, Chen] George Washington Univ, Dept Phys, Washington, DC 20052 USA.
   [Zeng, Chen] Huazhong Univ Sci & Technol, Dept Phys, Wuhan 430074, Peoples R China.
   [Lepene, Benjamin] Ceres Nanosci Inc, Manassas, VA USA.
RP Kashanchi, F (reprint author), George Mason Univ, Natl Ctr Biodef & Infect Dis, Manassas, VA USA.
EM fkashanc@gmu.edu
RI Kehn-Hall, Kylene/I-5752-2013
FU NIH [AI070740]
FX This work was supported by NIH grant AI070740 to F.K.
CR Agbottah E, 2005, J BIOL CHEM, V280, P3029, DOI 10.1074/jbc.M406435200
   Aksenov MY, 2003, BRAIN RES, V987, P1, DOI 10.1016/S0006-8993(03)03194-9
   Aksenov MY, 2001, NEUROSCI LETT, V305, P5, DOI 10.1016/S0304-3940(01)01786-4                                                   
   Ances BM, 2007, SEMIN NEUROL, V27, P86, DOI 10.1055/s-2006-956759
   ATANASSOV CL, 1995, NEUROCHEM INT, V27, P417, DOI 10.1016/0197-0186(95)00023-2
   Baba M, 1998, MOL PHARMACOL, V53, P1097
   Baba M, 1997, ANTIMICROB AGENTS CH, V41, P1250
   Bachis A, 2012, J NEUROSCI, V32, P9477, DOI 10.1523/JNEUROSCI.0865-12.2012
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   Bansal AK, 2000, BRAIN RES, V879, P42, DOI 10.1016/S0006-8993(00)02725-6
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   Bennett BA, 1995, BRAIN RES, V705, P168, DOI 10.1016/0006-8993(95)01166-8
   Berro R, 2006, J VIROL, V80, P3189, DOI 10.1128/JVI.80.7.3.189-3204.2006
   Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200
   Blanpain C, 2002, RECEPTOR CHANNEL, V8, P19, DOI 10.1080/10606820290004967
   Boska MD, 2004, CURR HIV RES, V2, P61, DOI 10.2174/1570162043485095
   Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200
   Cao H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031502
   Carlson B, 1999, CANCER RES, V59, P4634
   Carpio Lawrence, 2010, J RNAi Gene Silencing, V6, P386
   Chao CC, 2000, NEUROPHARMACOLOGY, V39, P150, DOI 10.1016/S0028-3908(99)00063-5                                                   
   Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200                                                          
   Chao SH, 2003, MOL CELL BIOL, V23, P831, DOI 10.1128/MCB.23.3.831-841.2003
   Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200
   Cheng J, 1998, NEUROSCIENCE, V82, P97
   Chihara T, 2012, J IMMUNOL, V188, P3620, DOI 10.4049/jimmunol.1101593
   Chin PC, 2005, MOL BRAIN RES, V137, P193, DOI 10.1016/j.molbrainres.2005.03.004
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9
   Coley W, 2010, J BIOL CHEM, V285, P31930, DOI 10.1074/jbc.M110.101709
   Crews L, 2008, J NEUROVIROL, V14, P327, DOI 10.1080/13550280802132840
   Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.t01-1-00251.x
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   de Gannes FMP, 1998, NEUROCHEM INT, V33, P61, DOI 10.1016/S0197-0186(05)80010-5
   DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0                                                                
   Del Bufalo A, 2011, TOXICOL APPL PHARM, V256, P35, DOI 10.1016/j.taap.2011.06.025
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Deshmane SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016148
   Dou HY, 2005, J NEUROSCI, V25, P8375, DOI 10.1523/JNEUROSCI.2164-05.2005
   Dou HY, 2003, J NEUROSCI, V23, P9162
   Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3
   Edwards TE, 2002, BIOCHEMISTRY-US, V41, P14843, DOI 10.1021/bi026299a
   ENSOLI B, 1993, J VIROL, V67, P277
   Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8
   Everall IP, 2002, MOL CELL NEUROSCI, V21, P493, DOI 10.1006/mcne.2002.1196
   FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729
   Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001                                                       
   Fujinaga K, 1998, J VIROL, V72, P7154
   Galons H, 2010, EXPERT OPIN THER PAT, V20, P377, DOI 10.1517/13543770903524284
   Gavriil ES, 2000, BIOCHEM BIOPH RES CO, V267, P252, DOI 10.1006/bbrc.1999.1894                                                          
   Gentile G, 2012, BIOORG MED CHEM LETT, V22, P1989, DOI 10.1016/j.bmcl.2012.01.034
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
   Guendel I, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-7
   Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s
   HAUBRICH RH, 1995, J INFECT DIS, V172, P1246, DOI 10.1093/infdis/172.5.1246                                                       
   Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x
   Haughey NJ, 2002, JAIDS, V31, pS55, DOI 10.1097/01.QAI.0000028065.79472.50
   Haughey NJ, 2001, J NEUROCHEM, V78, P457, DOI 10.1046/j.1471-4159.2001.00396.x
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   Henderson LJ, 2012, J VIROL, V86, P9495, DOI 10.1128/JVI.00486-12
   HERRMANN CH, 1995, J VIROL, V69, P1612
   Holden CP, 1999, NEUROSCIENCE, V91, P1369, DOI 10.1016/S0306-4522(98)00714-3                                                   
   HSU MC, 1993, P NATL ACAD SCI USA, V90, P6395, DOI 10.1073/pnas.90.14.6395
   Jaeger LB, 2012, DIS MODEL MECH, V5, P313, DOI 10.1242/dmm.008763
   JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0
   Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5
   Ju SM, 2012, MOL CELLS, V33, P335, DOI 10.1007/s10059-012-2287-0
   Jung DJ, 2002, MOL CELL BIOL, V22, P5203, DOI 10.1128/MCB.22.14.5203-5211.2002
   Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4
   KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673                                                          
   Kashanchi F, 2009, CURR PHARM DESIGN, V15, P2520, DOI 10.2174/138161209788682280                                                      
   Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212
   Kehn-Hall K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034761
   Kehn-Hall K, 2011, VIROLOGY, V415, P56, DOI 10.1016/j.virol.2011.03.025
   Khurdayan VK, 2004, EUR J NEUROSCI, V19, P3171, DOI 10.1111/j.1460-9568.2004.03416.x
   Kim SE, 2012, J NEUROSCI RES, V90, P1732, DOI 10.1002/jnr.23051
   Kim YK, 2011, J MOL BIOL, V410, P896, DOI 10.1016/j.jmb.2011.03.054
   King JE, 2006, MICROBES INFECT, V8, P1347, DOI 10.1016/j.micinf.2005.11.014
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Klein RS, 1999, J IMMUNOL, V163, P1636
   Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930
   Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958
   Kumar A, 2008, J VIROL, V82, P2813, DOI 10.1128/JVI.02498-07
   LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0
   Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000
   Li WX, 2009, NEUROTOX RES, V16, P205, DOI 10.1007/s12640-009-9047-8
   Liu Y, 2000, NAT MED, V6, P1380
   Luchini A, 2008, NANO LETT, V8, P350, DOI 10.1021/nl072174l
   Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x                                              
   MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314
   Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012
   Maragos WF, 2003, NEUROSCIENCE, V117, P43, DOI 10.1016/S0306-4522(02)00713-3
   Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4                                                   
   McArthur JC, 2010, AIDS, V24, P1367, DOI 10.1097/QAD.0b013e3283391d56
   Meares GP, 2007, J BIOL CHEM, V282, P16989, DOI 10.1074/jbc.M700610200
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Mestre B, 1999, BBA-GENE STRUCT EXPR, V1445, P86, DOI 10.1016/S0167-4781(99)00019-6
   Muller W E, 1996, Prog Mol Subcell Biol, V16, P44
   Munoz-Montano J.R., 1999, J ALZHEIMERS DIS, V1, P361
   Murrell JR, 1999, J NEUROSCI, V19, P8260
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   Narayanan A, 2012, VIROLOGY, V432, P219, DOI 10.1016/j.virol.2012.06.007
   Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V
   Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1
   Nath A, 1996, J VIROL, V70, P1475
   Nguyen TB, 2009, J NEUROVIROL, V15, P434, DOI [10.3109/13550280903168131, 10.1080/13550280903168131]
   Noonan D, 2000, Adv Pharmacol, V48, P229
   Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755
   PEREZ VL, 1991, J IMMUNOL, V147, P3145
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207
   Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595
   Pocernich CB, 2005, MOL BRAIN RES, V133, P307, DOI 10.1016/j.molbrainres.2004.10.023
   Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005
   Pulliam L, 2001, BRAIN RES, V893, P95, DOI 10.1016/S0006-8993(00)03293-5
   Rayne F, 2010, EMBO J, V29, P1348, DOI 10.1038/emboj.2010.32
   Reddy PVB, 2012, NEUROCHEM INT, V61, P807, DOI 10.1016/j.neuint.2011.06.011
   RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0
   Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180
   Rusnati Marco, 2002, Angiogenesis, V5, P141, DOI 10.1023/A:1023892223074
   SABATIER JM, 1991, J VIROL, V65, P961
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sobhian B, 2010, MOL CELL, V38, P439, DOI 10.1016/j.molcel.2010.04.012
   SPEAR M, 2012, RETROVIROLOGY, V9, P9, DOI DOI 10.1186/1742-4690-9-45
   Spokoini R, 2010, MOL ENDOCRINOL, V24, P1136, DOI 10.1210/me.2009-0466
   Tamburro D, 2011, J AM CHEM SOC, V133, P19178, DOI 10.1021/ja207515j
   Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15
   Thakur BK, 2012, BIOCHEM BIOPH RES CO, V424, P245, DOI 10.1016/j.bbrc.2012.06.084
   Toggas SM, 1996, BRAIN RES, V706, P303, DOI 10.1016/0006-8993(95)01197-8
   Van Duyne R, 2008, VIROLOGY, V376, P308, DOI 10.1016/j.virol.2008.02.036
   Van Duyne R, 2013, J MOL BIOL, V425, P812, DOI 10.1016/j.jmb.2012.12.005
   Van Duyne R, 2011, J MOL BIOL, V411, P581, DOI 10.1016/j.jmb.2011.06.001
   Villalba M, 1997, J NEUROSCI, V17, P83
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wallace DR, 2006, NEUROTOXICOLOGY, V27, P101, DOI 10.1016/j.neuro.2005.07.008
   WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   WOODGETT JR, 1990, EMBO J, V9, P2431
   Wu P, 1996, NEUROREPORT, V7, P1045, DOI 10.1097/00001756-199604100-00018
   Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466
   Yao H, 2009, CELL DEATH DIFFER, V16, P1681, DOI 10.1038/cdd.2009.108
   Zauli G, 2000, J BIOL CHEM, V275, P4159, DOI 10.1074/jbc.275.6.4159
   Zhong J, 2007, INT J DEV NEUROSCI, V25, P359, DOI 10.1016/j.ijdevneu.2007.07.003
   Zou SP, 2011, J NEUROVIROL, V17, P41, DOI 10.1007/s13365-010-0016-z
NR 147
TC 5
Z9 5
U1 1
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2014
VL 88
IS 2
BP 1189
EP 1208
DI 10.1128/JVI.01940-13
PG 20
WC Virology
SC Virology
GA 282SY
UT WOS:000329194900039
PM 24227837
OA gold
DA 2018-01-05
ER

PT J
AU Zhao, L
   Lu, WY
AF Zhao, Le
   Lu, Wuyuan
TI Defensins in innate immunity
SO CURRENT OPINION IN HEMATOLOGY
LA English
DT Article
DE antimicrobial peptides; defensins; innate immunity
ID HUMAN ALPHA-DEFENSIN; RHESUS THETA-DEFENSIN-1 RTD-1; CYCLIC CYSTINE
   LADDER; THETA-DEFENSINS; ANTIVIRAL ACTIVITY; CHEMICAL LIGATION; PANETH
   CELLS; PROTEINS; HIV-1; MICROBICIDE
AB Purpose of reviewDefensins are a major family of antimicrobial peptides expressed predominantly in neutrophils and epithelial cells, and play important roles in innate immune defense against infectious pathogens. Their biological functions in and beyond innate immunity, structure and activity relationships, mechanisms of action, and therapeutic potential continue to be interesting research topics. This review examines recent progress in our understanding of alpha and theta-defensins - the two structural classes composed of members of myeloid origin.Recent findingsA novel mode of antibacterial action is described for human enteric alpha-defensin 6, which forms structured nanonets to entrap bacterial pathogens and protect against bacterial invasion of the intestinal epithelium. The functional multiplicity and mechanistic complexity of defensins under different experimental conditions contribute to a debate over the role of enteric alpha-defensins in mucosal immunity against HIV-1 infection. Contrary to common belief, hydrophobicity rather than cationicity plays a dominant functional role in the action of human alpha-defensins; hydrophobicity-mediated high-order assembly endows human alpha-defensins with an extraordinary ability to acquire structural diversity and functional versatility. Growing evidence suggests that theta-defensins offer the best opportunity for therapeutic development as a novel class of broadly active anti-infective and anti-inflammatory agents.SummaryDefensins are the Swiss army knife' in innate immunity against microbial pathogens. Their modes of action are often reminiscent of the story of The Blind Men and the Elephant'. The functional diversity and mechanistic complexity, as well as therapeutic potential of defensins, will continue to attract attention to this important family of antimicrobial peptides.
C1 [Zhao, Le] Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Xian, Peoples R China.
   [Lu, Wuyuan] Univ Maryland, Inst Human Virol, Sch Med, College Pk, MD 20742 USA.
   [Lu, Wuyuan] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, College Pk, MD 20742 USA.
RP Lu, WY (reprint author), Univ Maryland, Inst Human Virol, Sch Med, College Pk, MD 20742 USA.
EM wlu@ihv.umaryland.edu
RI Zhao, Le/J-8452-2017; Lu, Wuyuan/B-2268-2010
FU NIH; Xi'an Jiaotong University School of Medicine
FX W.L. has been supported by NIH grants for the past 10 years and L.Z. is
   a Guanghua Scholar supported by Xi'an Jiaotong University School of
   Medicine.
CR Aboye TL, 2012, BIOORG MED CHEM LETT, V22, P2823, DOI 10.1016/j.bmcl.2012.02.080
   Buck CB, 2006, P NATL ACAD SCI USA, V103, P1516, DOI 10.1073/pnas.0508033103
   Chu HT, 2012, SCIENCE, V337, P477, DOI 10.1126/science.1218831
   Clevers HC, 2013, ANNU REV PHYSIOL, V75, P289, DOI 10.1146/annurev-physiol-030212-183744
   Conibear AC, 2013, J BIOL CHEM, V288, P10830, DOI 10.1074/jbc.M113.451047
   Conibear AC, 2012, BIOCHEMISTRY-US, V51, P9718, DOI 10.1021/bi301363a
   Craik DJ, 2012, J BIOL CHEM, V287, P26999, DOI 10.1074/jbc.R112.390344
   DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629                                                         
   Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923                                                
   Demirkhanyan L, 2013, PLOS PATHOG, V9
   Demirkhanyan LH, 2012, J BIOL CHEM, V287, P28821, DOI 10.1074/jbc.M112.375949
   Ding J, 2013, PLOS ONE, V8
   Doss M, 2012, J IMMUNOL, V188, P2759, DOI 10.4049/jimmunol.1101335
   Eade CR, 2013, AM J REPROD IMMUNOL, V69, P150, DOI 10.1111/aji.12036
   Eade CR, 2012, CURR HIV RES, V10, P61, DOI 10.2174/157016212799304580
   Eriguchi Y, 2012, BLOOD, V120, P223, DOI 10.1182/blood-2011-12-401166
   Flatt JW, 2013, PLOS ONE, V8
   Furci L., 2012, PLOS ONE, V7
   Gersemann M, 2012, J INTERN MED, V271, P421, DOI 10.1111/j.1365-2796.2012.02515.x
   Glenthoj A, 2013, EUR J CLIN INVEST, V43, P836, DOI 10.1111/eci.12114
   Gould A, 2012, MOL BIOSYST, V8, P1359, DOI 10.1039/c2mb05451e
   Gounder AP, 2012, J BIOL CHEM, V287, P24554, DOI 10.1074/jbc.M112.354068
   Gupta P, 2013, AIDS RES HUM RETROV, V29, P391, DOI [10.1089/aid.2012.0135, 10.1089/AID.2012.0135]
   Jarvis GA, 2012, CURR HIV RES, V10, P211
   Klotman ME, 2008, J IMMUNOL, V180, P6176, DOI 10.4049/jimmunol.180.9.6176                                                     
   Klotman ME, 2006, NAT REV IMMUNOL, V6, P447, DOI 10.1038/nri1860
   Koslowski MJ, 2012, PLOS GENET, V8
   Lehrer RI, 2012, J BIOL CHEM, V287, P27014, DOI 10.1074/jbc.R112.346098
   Lehrer RI, 2012, IMMUNOL REV, V245, P84, DOI 10.1111/j.1600-065X.2011.01082.x
   Liu PT, 2012, NAT MED, V18, P267, DOI 10.1038/nm.2584
   Lu WY, 2013, BIOCHEM BIOPH RES CO, V436, P557, DOI 10.1016/j.bbrc.2013.06.015
   Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900
   Oeemig JS, 2012, J BIOL CHEM, V287, P42361, DOI 10.1074/jbc.M112.382028
   Ouellette AJ, 2011, CELL MOL LIFE SCI, V68, P2215, DOI 10.1007/s00018-011-0714-6
   Pazgier M, 2012, J BIOL CHEM, V287, P8944, DOI 10.1074/jbc.M111.332205
   Raetz M, 2013, NAT IMMUNOL, V14, P136, DOI 10.1038/ni.2508
   Rajabi M, 2012, J BIOL CHEM, V287, P21615, DOI 10.1074/jbc.M112.367995
   Rapireddy S, 2012, J AM CHEM SOC, V134, P4041, DOI 10.1021/ja211867j
   Rapista A, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-45
   Rothan HA, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-314
   Schaal JB, 2012, PLOS ONE, V7
   Schmidt NW, 2012, J BIOL CHEM, V287, P21866, DOI 10.1074/jbc.M112.358721
   Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206
   Semple F, 2012, J INNATE IMMUN, V4, P337, DOI 10.1159/000336619
   Snijder J, 2013, J VIROL, V87, P2756, DOI 10.1128/JVI.02516-12
   Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498
   Teles RMB, 2013, SCIENCE, V339, P1448, DOI 10.1126/science.1233665
   Tollner TL, 2012, NAT REV UROL, V9, P365, DOI [10.1038/nruro1.2012.109, 10.1038/nrurol.2012.109]
   Tongaonkar P, 2012, PLOS ONE, V7
   Vega LA, 2012, MOL MICROBIOL, V85, P1119, DOI 10.1111/j.1365-2958.2012.08163.x
   Venkataraman N, 2009, PLOS BIOL, V7, P720, DOI 10.1371/journal.pbio.1000095
   Wang AP, 2013, J VIROL, V87, P2835, DOI 10.1128/JVI.02209-12
   Wei G, 2010, J BIOL CHEM, V285, P16275, DOI 10.1074/jbc.M110.102749
   Weinberg A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00294
   Wommack AJ, 2012, BIOCHEMISTRY-US, V51, P9624, DOI 10.1021/bi301255u
   Wood MP, 2013, PLOS ONE, V8
   Yount NY, 2013, ANN NY ACAD SCI, V1277, P127, DOI 10.1111/nyas.12005
   Zhao L, 2012, J BIOL CHEM, V287, P18900, DOI 10.1074/jbc.M112.355255
NR 58
TC 29
Z9 30
U1 2
U2 41
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1065-6251
EI 1531-7048
J9 CURR OPIN HEMATOL
JI Curr. Opin. Hematol.
PD JAN
PY 2014
VL 21
IS 1
BP 37
EP 42
DI 10.1097/MOH.0000000000000005
PG 6
WC Hematology
SC Hematology
GA 282PT
UT WOS:000329185200008
PM 24275690
DA 2018-01-05
ER

PT J
AU Grigorenko, E
   Fisher, C
   Patel, S
   Chancey, C
   Rios, M
   Nakhasi, HL
   Duncan, RC
AF Grigorenko, Elena
   Fisher, Carolyn
   Patel, Sunali
   Chancey, Caren
   Rios, Maria
   Nakhasi, Hira L.
   Duncan, Robert C.
TI Multiplex Screening for Blood-Borne Viral, Bacterial, and Protozoan
   Parasites using an Open Array Platform
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID WEST-NILE-VIRUS; REAL-TIME PCR; HEPATITIS-C-VIRUS; INTERNATIONAL
   STANDARD; WORKING REAGENTS; RNA; ASSAY; DNA; LEISHMANIA; HIV-1
AB The use of nucleic acid tests for detection of pathogens has improved the safety of blood products. However, ongoing pathogen emergence demonstrates a need for development of devices testing for multiple pathogens simultaneously. One approach combines two proven technologies: Taqman chemistry for target identification and quantification and the OpenArray nanofluidic real-time PCR platform for spatial multiplexing of assays. A panel of Taqman assays was developed to detect nine blood-borne pathogens (BBPs): four viral, two bacterial, and three protozoan parasites. The custom BBP OpenArray plate with 18 assays was tested for specificity and analytical sensitivity for nucleic acid from each purified pathogen and with pathogen-spiked human blood and plasma samples. For most targets, the Limits of detection (10 to 10,000 copies/mL) were comparable with existing real-time platforms. The testing of the BBP OpenArray with pathogen-spiked coded human plasma or blood samples and negative control specimens demonstrated no false-positive results among the samples tested and correctly identified pathogens with the lowest concentration detected ranging from 10 cells/mL (Trypanosoma cruzi) to 10,000 cells/mL (Escherichia coli). These results represent a proof of concept that indicated the BBP OpenArray platform in combination with Taqman chemistry may provide a multiplex real-time PCR pathogen detection method that pints the way for a next-generation platform for infectious disease testing in blood.
C1 [Grigorenko, Elena; Patel, Sunali] Life Technol Corp, San Francisco, CA USA.
   [Fisher, Carolyn; Chancey, Caren; Rios, Maria; Nakhasi, Hira L.; Duncan, Robert C.] US FDA, Ctr Biol Evaluat & Res, Div Emerging & Transfus Transmitted Dis, Bethesda, MD USA.
RP Duncan, RC (reprint author), 1401 Rockville Pike,HFM310, Rockville, MD 20852 USA.
EM robert.duncan@fda.hhs.gov
OI Duncan, Robert/0000-0001-8409-2501
FU internal FDA grant under the Modernizing Science Program
FX Supported in part by an internal FDA grant under the Modernizing Science
   Program.
CR Araujo F, 2005, TRANSFUS CLIN BIOL, V12, P331, DOI 10.1016/j.tracli.2005.08.004
   Busch MP, 2005, TRANSFUSION, V45, P492, DOI 10.1111/j.0041-1132.2005.04382.x
   Davis C, 2003, J VIROL METHODS, V107, P37, DOI 10.1016/S0166-0934(02)00187-8
   Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011
   Drexler JF, 2009, PLOS MED, V6, P210, DOI 10.1371/journal.pmed.1000031
   Elnifro EM, 2000, CLIN MICROBIOL REV, V13, P559, DOI 10.1128/CMR.13.4.559-570.2000
   Gonzales TK, 2011, MOL CELL PROBE, V25, P222, DOI 10.1016/j.mcp.2011.08.004
   Grinev A, 2008, J VIROL METHODS, V154, P27, DOI 10.1016/j.jviromet.2008.09.015
   Lee S, 2006, J VIROL METHODS, V137, P287, DOI 10.1016/j.jviromet.2006.07.001
   Li JH, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-10
   Li L, 2008, TRANSFUSION, V48, P1198, DOI 10.1111/j.1537-2995.2008.01672.x
   Mahajan B, 2012, TRANSFUSION, V52, P1949, DOI 10.1111/j.1537-2995.2011.03541.x
   Margaritis AR, 2007, TRANSFUSION, V47, P1783, DOI 10.1111/j.1537-2995.2007.01343.x
   Mary C, 2004, J CLIN MICROBIOL, V42, P5249, DOI 10.1128/JCM.42.11.5249-5255.2004
   MCDANIEL JP, 1993, MOL BIOCHEM PARASIT, V57, P213, DOI 10.1016/0166-6851(93)90197-6                                                    
   Morrison T, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl639
   Najdenski H, 2012, VET MICROBIOL, V160, P428, DOI 10.1016/j.vetmic.2012.06.013
   Nicolas L, 2002, J CLIN MICROBIOL, V40, P1666, DOI 10.1128/JCM.40.5.1666-1669.2002
   Noutsias M, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-3
   Patel P, 2012, TRANSFUSION, V52, P1423, DOI 10.1111/j.1537-2995.2011.03484.x
   Pichl L, 2005, TRANSFUSION, V45, P1106, DOI 10.1111/j.1537-2995.2005.04365.x
   Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019
   Pisani G, 2011, BLOOD TRANSFUS-ITALY, V9, P425, DOI 10.2450/2011.0025-11
   Rios M, 2008, J INFECT DIS, V198, P1300, DOI 10.1086/592277
   Rios M, 2006, TRANSFUSION, V46, P659, DOI 10.1111/j.1537-2995.2006.00769.x
   Rios M, 2007, CLIN INFECT DIS, V45, P181, DOI 10.1086/518850
   Saldanha J, 2000, VOX SANG, V78, P217, DOI 10.1159/000031184
   Schachterle SE, 2011, J CLIN MICROBIOL, V49, P3885, DOI 10.1128/JCM.01157-11
   Schijman AG, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000931
   Slinger R, 2012, CLIN MICROBIOL INFEC, V18, pE286, DOI 10.1111/j.1469-0691.2012.03896.x
   Sokal RR, 1981, BIOMETRY PRINCIPLES
   Tomioka K, 2005, J MOL DIAGN, V7, P486, DOI 10.1016/S1525-1578(10)60579-X
   van Doorn R, 2009, APPL ENVIRON MICROB, V75, P7253, DOI 10.1128/AEM.00796-09
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
NR 34
TC 13
Z9 13
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD JAN
PY 2014
VL 16
IS 1
BP 136
EP 144
DI 10.1016/j.jmoldx.2013.08.002
PG 9
WC Pathology
SC Pathology
GA 278YT
UT WOS:000328926500015
PM 24184228
DA 2018-01-05
ER

PT J
AU Gerson, T
   Makarov, E
   Senanayake, TH
   Gorantla, S
   Poluektova, LY
   Vinogradov, SV
AF Gerson, Trevor
   Makarov, Edward
   Senanayake, Thulani H.
   Gorantla, Santhi
   Poluektova, Larisa Y.
   Vinogradov, Serguei V.
TI Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity
   against HIV infection in the brain
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Nanogel; Nucleoside reverse transcriptase inhibitors; HIV-1 infection;
   CNS drug delivery; Neurotoxicity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; COMBINATION ANTIRETROVIRAL THERAPY;
   DRUG-DELIVERY; NUCLEOSIDE ANALOGS; NEUROPROTECTIVE RESPONSES;
   MITOCHONDRIAL TOXICITY; GOLD NANOPARTICLES; NEURONAL INJURY;
   PARTICLE-SIZE; BARRIER
AB Antiviral therapy using nucleoside reverse transcriptase inhibitors (NRTIs) is neurotoxic and has low efficiency in eradication of HIV-1 harbored in central nervous system (CNS). Previously, we reported that active 5'-triphosphates of NRTIs encapsulated in cationic nanogels (nano-NRTIs) suppress HIV-1 activity more efficiently than NRTIs and exhibit reduced mitochondrial toxicity [Vinogradov SV, Poluektova LY, Makarov E, Gerson T, Senanayake MT. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antivir Chem Chemother. 2010; 21:1-14. Makarov E, Gerson T, Senanayake T, Poluektova LY, Vinogradov. Efficient suppression of Human Immunodeficiency Virus in Macrophages by Nano-NRTIs. Antiviral Res. 2010; 86(1):A38-9]. Here, we demonstrated low neurotoxicity and excellent antiviral activity of nano-NRTIs decorated with the peptide (AP) binding brain-specific apolipoprotein E receptor. Nano-NRTIs induced lower levels of apoptosis and formation of reactive oxygen species, a major cause of neuron death, than free NRTIs. Optimization of size, surface decoration with AP significantly increased brain accumulation of nano-NRTIs. The efficient CNS delivery of nano-NRTIs resulted in up to 10-fold suppression of retroviral activity and reduced virus-associated inflammation in humanized mouse model of HIV-1 infection in the brain. Our data provide proof of the advanced efficacy of nano-NRTIs as safer alternative of current antiviral drugs.
   From the Clinical Editor: This team of investigators demonstrated low neurotoxicity and excellent anti-HIV activity of nano-nucleoside reverse transcriptase inhibitors decorated with the peptide (AP) binding brain-specific apolipoprotein E receptor, providing proof of enhanced efficacy and a safer alternative compared with current antiviral drugs. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Gerson, Trevor; Senanayake, Thulani H.; Vinogradov, Serguei V.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA.
   [Makarov, Edward; Gorantla, Santhi; Poluektova, Larisa Y.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
RP Vinogradov, SV (reprint author), Coll Pharm, Dept Pharmaceut Sci, 986025 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM vinograd@unmc.edu
OI Poluektova, Larisa/0000-0001-7339-8732
FU NIH [NS076386]
FX This work was supported by the NIH R01 grant NS076386 to Serguei V.
   Vinogradov.
CR Banks WA, 2006, CURR HIV RES, V4, P259, DOI 10.2174/157016206777709447                                                      
   Calza L, 2012, HIV CLIN TRIALS, V13, P189, DOI 10.1310/hct1304-189
   Charoenphol P, 2010, BIOMATERIALS, V31, P1392, DOI 10.1016/j.biomaterials.2009.11.007
   Clark US, 2010, CURR OPIN INVEST DR, V11, P884
   Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   De Jong WH, 2008, BIOMATERIALS, V29, P1912, DOI 10.1016/j.biomaterials.2007.12.037
   Evliyaoglu F, 2012, MUSCLE NERVE, V46, P681, DOI 10.1002/mus.23414
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Gorantla S, 2007, J IMMUNOL, V179, P4345, DOI 10.4049/jimmunol.179.7.4345                                                     
   Gorantla S, 2012, TRENDS NEUROSCI, V35, P197, DOI 10.1016/j.tins.2011.12.006
   Harrison Taylor B, 2011, J Clin Neuromuscul Dis, V13, P68, DOI 10.1097/CND.0b013e318221256f
   Jones M, 2012, SEMIN LIVER DIS, V32, P167, DOI 10.1055/s-0032-1316472
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Leung GPH, 2012, ADV EXP MED BIOL, V942, P347, DOI 10.1007/978-94-007-2869-1_16
   Limoges J, 2000, NEUROLOGY, V54, P379, DOI 10.1212/WNL.54.2.379                                                            
   Lu W, 2005, INT J PHARM, V295, P247, DOI 10.1016/j.ijpharm.2005.01.043
   Makarov E, 2010, ANTIVIR RES, V86, pA38, DOI 10.1016/j.antivira1.2010.02.388
   Malakoutikhah M, 2011, ANGEW CHEM INT EDIT, V50, P7998, DOI 10.1002/anie.201006565
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nunnari G, 2005, J NEUROVIROL, V11, P319, DOI 10.1080/13550280500187005
   Persidsky Y, 2002, J NEUROVIROL, V8, P49, DOI 10.1080/13550280290167993
   Persidsky Y, 2000, J LEUKOCYTE BIOL, V68, P413
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Sauer I, 2005, BIOCHEMISTRY-US, V44, P2021, DOI 10.1021/bi048080x
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   Taiwo B, 2010, J ANTIMICROB CHEMOTH, V65, P1100, DOI 10.1093/jac/dkq096
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Vinogradov SV, 2010, NANOMEDICINE-UK, V5, P165, DOI 10.2217/NNM.09.103
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r
   Wang CC, 2009, J CELL BIOCHEM, V107, P933, DOI 10.1002/jcb.22196
   WATANABE W, 1994, J VIROL METHODS, V48, P257, DOI 10.1016/0166-0934(94)90124-4
   Wiebe LA, 2011, J PAIN, V12, P619, DOI 10.1016/j.jpain.2011.03.006
   Wu DA, 1998, BRAIN RES, V791, P313, DOI 10.1016/S0006-8993(98)00139-5
NR 43
TC 17
Z9 18
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JAN
PY 2014
VL 10
IS 1
BP 177
EP 185
DI 10.1016/j.nano.2013.06.012
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 281LR
UT WOS:000329103500019
PM 23845925
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jiang, YQ
   Kong, DY
   Zhao, JL
   Qi, QH
   Li, W
   Xu, GQ
AF Jiang, Yuqin
   Kong, Duanyang
   Zhao, Jinglin
   Qi, Qinghua
   Li, Wei
   Xu, Guiqing
TI Cu(OAc)(2) center dot H2O/NH2NH2 center dot H2O: an efficient catalyst
   system that in situ generates Cu2O nanoparticles and HOAc for Huisgen
   click reactions
SO RSC ADVANCES
LA English
DT Article
ID AZIDE-ALKYNE CYCLOADDITION; COPPER NANOPARTICLES; TERMINAL ALKYNES;
   1,3-DIPOLAR CYCLOADDITIONS; OXIDE NANOPARTICLES; HIV-1 PROTEASE;
   CHEMISTRY; WATER; COMPLEXES; DERIVATIVES
AB A combination of Cu(OAc)(2) center dot H2O and NH2NH2 center dot H2O, which in situ generates Cu2O-NPs and HOAc in water at room temperature, has been developed as a highly efficient catalytic system for Huisgen click reactions. Our results indicate that the in situ generated Cu2O-NPs and HOAc play important roles in the Huisgen click reaction.
C1 [Jiang, Yuqin; Kong, Duanyang; Zhao, Jinglin; Qi, Qinghua; Li, Wei; Xu, Guiqing] Henan Normal Univ, Sch Chem & Chem Engn, Xinxiang 453007, Henan, Peoples R China.
RP Jiang, YQ (reprint author), Henan Normal Univ, Sch Chem & Chem Engn, Xinxiang 453007, Henan, Peoples R China.
EM jiangyuqin@htu.cn; guiqingxu@163.com
FU Natural Science Foundation of China [21172058]; Scientific Research
   Foundation for Doctors [01036500508]; Youth Foundation of Henan Normal
   University [2012QK11]
FX This work was supported financially by the Natural Science Foundation of
   China (No. 21172058) and Scientific Research Foundation for Doctors (No.
   01036500508) and the Youth Foundation (2012QK11) of Henan Normal
   University.
CR Alonso F., 2010, EUR J ORG CHEM, V2010, P1875
   Balcioglu N, 1997, POLYHEDRON, V16, P327, DOI 10.1016/0277-5387(96)00215-X                                                    
   Diez-Gonzalez S, 2008, ANGEW CHEM INT EDIT, V47, P8881, DOI 10.1002/anie.200803289
   Diez-Gonzalez S, 2008, CHEM COMMUN, P4747, DOI 10.1039/b806806b
   Gadhe JB, 2007, INT J HYDROGEN ENERG, V32, P2374, DOI 10.1016/j.ijhydene.2006.10.050
   Garcia-Alvarez J, 2010, GREEN CHEM, V12, P2127, DOI 10.1039/c0gc00342e
   Giffin MJ, 2008, J MED CHEM, V51, P6263, DOI 10.1021/jm800149m
   Gruijters BWT, 2006, ORG LETT, V8, P3163, DOI 10.1021/ol0607387
   Himo F, 2005, J AM CHEM SOC, V127, P210, DOI 10.1021/ja0471525
   Huisgen R., 1984, 1 3 DIPOLAR CYCLOADD
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kumar AS, 2013, J NANOSCI NANOTECHNO, V13, P3136, DOI 10.1166/jnn.2013.7343
   Lal S, 2011, ORGANOMETALLICS, V30, P6225, DOI 10.1021/om200791u
   Li LD, 2012, DALTON T, V41, P5144, DOI 10.1039/c2dt11854h
   Lide David R., 2002, HDB CHEM PHYS
   Lopez-Ruiz H, 2013, ARKIVOC, P139
   Molteni G, 2006, NEW J CHEM, V30, P1137, DOI 10.1039/b604297j
   Nandivada H., 2007, ADV MATER, V19, P2197
   Ozcubukcu S, 2009, ORG LETT, V11, P4680, DOI 10.1021/ol9018776
   Pachon LD, 2005, ADV SYNTH CATAL, V347, P811, DOI 10.1002/adsc.200404383
   Park IS, 2008, ORG LETT, V10, P497, DOI 10.1021/ol702790w
   Pathigoolla A, 2013, APPL CATAL A-GEN, V453, P151, DOI 10.1016/j.apcata.2012.12.025
   Rad MNS, 2013, HELV CHIM ACTA, V96, P688, DOI 10.1002/hlca.201200224
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Ryu EH, 2005, ORG LETT, V7, P1035, DOI 10.1021/ol047468h
   Sarkar A, 2008, J PHYS CHEM C, V112, P3334, DOI 10.1021/jp077603i
   Shao CW, 2011, TETRAHEDRON LETT, V52, P3782, DOI 10.1016/j.tetlet.2011.05.061
   Shao CW, 2010, J ORG CHEM, V75, P7002, DOI 10.1021/jo101495k
   Shao CW, 2010, ADV SYNTH CATAL, V352, P1587, DOI 10.1002/adsc.200900768
   Sharpless KB, 2002, ANGEW CHEM INT EDIT, V114, P2708
   Such GK, 2006, J AM CHEM SOC, V128, P9318, DOI 10.1021/ja063043+
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Wang D, 2010, GREEN CHEM, V12, P2120, DOI 10.1039/c0gc00381f
   Wang K, 2011, GREEN CHEM, V13, P562, DOI 10.1039/c0gc00848f
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
   Wu P, 2004, ANGEW CHEM INT EDIT, V43, P3928, DOI 10.1002/anie.200454078
   Ye CF, 2007, ORG LETT, V9, P3841, DOI 10.1021/ol701602a
   Yoo EJ, 2007, ANGEW CHEM INT EDIT, V46, P1730, DOI 10.1002/anie.200604241
   Zhang ZF, 2010, ADV SYNTH CATAL, V352, P1600, DOI 10.1002/adsc.201000206
NR 39
TC 17
Z9 18
U1 0
U2 22
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2014
VL 4
IS 2
BP 1010
EP 1014
DI 10.1039/c3ra45437a
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 264AQ
UT WOS:000327849700067
DA 2018-01-05
ER

PT B
AU Fatin, MF
   Ruslinda, AR
   Arshad, MKM
   Norhafizah, S
   Farehanim, MA
   Ayub, RM
   Hashim, U
AF Fatin, M. F.
   Ruslinda, A. Rahim
   Arshad, M. K. Md
   Norhafizah, S.
   Farehanim, M. A.
   Ayub, R. M.
   Hashim, U.
GP IEEE
TI Aptamer Immobilization on MWCNT-modified SGFET for Detection of HIV-1
   Tat Protein
SO 2014 IEEE CONFERENCE ON BIOMEDICAL ENGINEERING AND SCIENCES (IECBES)
LA English
DT Proceedings Paper
CT IEEE INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND SCIENCES
CY DEC 08-10, 2014
CL MIRI, MALAYSIA
SP IEEE, EMB, Sarawak, MARA, DanMedik, SSILTERRA, Minist Hlth Malaysia, TME, Univ Malaya
ID FIELD-EFFECT TRANSISTORS; CARBON NANOTUBES; BIOSENSORS; DNA
AB A solution gate field effect transistor (SGFET) has been fabricated for the detection of HIV-1 Tat protein. Functionalized carboxylated multiwalled carbon nanotube (COOH-MWCNT) has been deposited on the FET to act as amplification layer and immobilization site for aptamer. Aptamer has been a very reliable probe for detection of protein with high specificity. In this paper, we demonstrated the immobilized aptamer on MWCNT-modified SGFET. The bond formation and surface morphology of MWCNT were examined using FTIR and FESEM, respectively. The fabricated device shows the current decreases due to resistance increased after every immobilization step. The implementation of aptamer as a recognition element is promising for HIV-1 Tat protein detection.
C1 [Fatin, M. F.; Ruslinda, A. Rahim; Arshad, M. K. Md; Norhafizah, S.; Farehanim, M. A.; Ayub, R. M.; Hashim, U.] Univ Malaysia Perlis, Inst Nano Elect Engn, Kangar 01000, Perlis, Malaysia.
RP Fatin, MF (reprint author), Univ Malaysia Perlis, Inst Nano Elect Engn, Kangar 01000, Perlis, Malaysia.
EM nabilah.faudzi@gmail.com
CR Buang NA, 2012, DIG J NANOMATER BIOS, V7, P33
   Edgington R, 2012, BIOSENS BIOELECTRON, V33, P152, DOI 10.1016/j.bios.2011.12.044
   Gopinath S. C. B., NUCL ACID STRUCTURE
   Kara P, 2010, BIOSENS BIOELECTRON, V26, P1715, DOI 10.1016/j.bios.2010.07.090
   Kawarada H, 2011, PHYS STATUS SOLIDI A, V208, P2005, DOI 10.1002/pssa.201100503
   Liu S, 2012, NPG ASIA MATER, V4, P1, DOI 10.1038/am.2012.42
   Maehashi K, 2007, ANAL CHEM, V79, P782, DOI 10.1021/ac060830g
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Pilehvar S, 2014, BIOSENS BIOELECTRON, V54, P78, DOI 10.1016/j.bios.2013.10.018
   Poghossian A, 2005, SENSOR ACTUAT B-CHEM, V111, P470, DOI 10.1016/j.snb.2005.03.083
   Ruslinda AR, 2013, BIOSENS BIOELECTRON, V40, P277, DOI 10.1016/j.bios.2012.07.048
   Skoog D. A., 2007, PRINCIPLES INSTRUMEN
   Spuhler P., 2011, GEN ASS SCI S, V30, P8
   Wepasnick KA, 2010, ANAL BIOANAL CHEM, V396, P1003, DOI 10.1007/s00216-009-3332-5
   Yamamoto R, 2000, GENES CELLS, V5, P371, DOI 10.1046/j.1365-2443.2000.00330.x                                                
NR 15
TC 0
Z9 0
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4799-4084-4
PY 2014
BP 840
EP 844
PG 5
WC Engineering, Biomedical
SC Engineering
GA BF2GY
UT WOS:000380466700171
DA 2018-01-05
ER

PT J
AU Arribat, Y
   Talmat-Amar, Y
   Paucard, A
   Lesport, P
   Bonneaud, N
   Bauer, C
   Bec, N
   Parmentier, ML
   Benigno, L
   Larroque, C
   Maurel, P
   Maschat, F
AF Arribat, Yoan
   Talmat-Amar, Yasmina
   Paucard, Alexia
   Lesport, Pierre
   Bonneaud, Nathalie
   Bauer, Caroline
   Bec, Nicole
   Parmentier, Marie-Laure
   Benigno, Lorraine
   Larroque, Christian
   Maurel, Patrick
   Maschat, Florence
TI Systemic delivery of P42 peptide: a new weapon to fight Huntington's
   disease
SO ACTA NEUROPATHOLOGICA COMMUNICATIONS
LA English
DT Article
DE Huntington's disease; Mouse model; Peptide; Microemulsion
AB Background: In Huntington's disease (HD), the ratio between normal and mutant Huntingtin (polyQ-hHtt) is crucial in the onset and progression of the disease. As a result, addition of normal Htt was shown to improve polyQ-hHtt-induced defects. Therefore, we recently identified, within human Htt, a 23aa peptide (P42) that prevents aggregation and polyQ-hHtt-induced phenotypes in HD Drosophila model. In this report, we evaluated the therapeutic potential of P42 in a mammalian model of the disease, R6/2 mice.
   Results: To this end, we developed an original strategy for P42 delivery, combining the properties of the cell penetrating peptide TAT from HIV with a nanostructure-based drug delivery system (Aonys (R) technology), to form a water-in-oil microemulsion (referred to as NP42T) allowing non-invasive per mucosal buccal/rectal administration of P42. Using MALDI Imaging Mass Spectrometry, we verified the correct targeting of NP42T into the brain, after per mucosal administration. We then evaluated the effects of NP42T in R6/2 mice. We found that P42 (and/or derivatives) are delivered into the brain and target most of the cells, including the neurons of the striatum. Buccal/rectal daily administrations of NP42T microemulsion allowed a clear improvement of behavioural HD-associated defects (foot-clasping, rotarod and body weights), and of several histological markers (aggregation, astrogliosis or ventricular areas) recorded on brain sections.
   Conclusions: These data demonstrate that NP42T presents an unprecedented protective effect, and highlight a new therapeutic strategy for HD, associating an efficient peptide with a powerful delivery technology.
C1 [Arribat, Yoan; Talmat-Amar, Yasmina; Paucard, Alexia; Lesport, Pierre; Bonneaud, Nathalie; Parmentier, Marie-Laure; Maschat, Florence] Univ Montpellier, CNRS UMR, Inserm U661, IGF, F-34006 Montpellier, France.
   [Bauer, Caroline; Benigno, Lorraine; Maurel, Patrick] Medesis Pharma, Baillargues, France.
   [Bec, Nicole; Larroque, Christian] Univ Montpellier I, Inst Reg Canc Montpellier, Inserm U896, IRCM, F-34298 Montpellier, France.
RP Maschat, F (reprint author), Univ Montpellier, CNRS UMR, Inserm U661, IGF, F-34006 Montpellier, France.
EM florence.maschat@igf.cnrs.fr
RI Parmentier, Marie-Laure/N-9915-2017
FU French Ministry of Research and Technology; CNRS; ANR Emergence
   [ANR-12-EMMA-0013]
FX YA was supported by a fellowship from the French Ministry of Research
   and Technology. This work has been supported by the CNRS, "soutien au
   transfert" grant, UM2 contribution, and ANR Emergence
   (ANR-12-EMMA-0013).
CR Adam OR, 2008, NEUROTHERAPEUTICS, V5, P181, DOI 10.1016/j.nurt.2008.01.008
   Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998
   Arribat Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068775
   Bauer PO, 2010, NAT BIOTECHNOL, V28, P256, DOI 10.1038/nbt.1608
   Busch A, 2003, J BIOL CHEM, V278, P41452, DOI 10.1074/jbc.M303354200
   Butler DC, 2012, PROG NEUROBIOL, V97, P190, DOI 10.1016/j.pneurobio.2011.11.004
   Carter RJ, 1999, J NEUROSCI, V19, P3248
   Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806
   Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299
   Chopra V, 2007, P NATL ACAD SCI USA, V104, P16685, DOI 10.1073/pnas.0707842104
   Costanzo M, 2013, J CELL SCI, V126, P3678, DOI 10.1242/jcs.126086
   Dragatsis I, 2000, NAT GENET, V26, P300
   Drexler Dieter M., 2007, Journal of Pharmacological and Toxicological Methods, V55, P279, DOI 10.1016/j.vascn.2006.11.004
   Ferrante RJ, 2002, J NEUROSCI, V22, P1592
   Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018
   Godin JD, 2010, EMBO J, V29, P2433, DOI 10.1038/emboj.2010.117
   Heng MY, 2010, AUTOPHAGY, V6, P1206, DOI 10.1093/hmg/ddq285
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Khafagy ES, 2012, ADV DRUG DELIVER REV, V64, P531, DOI 10.1016/j.addr.2011.12.014
   Kordasiewicz HB, 2012, NEURON, V74, P1031, DOI 10.1016/j.neuron.2012.05.009
   Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207
   Lee WCM, 2004, P NATL ACAD SCI USA, V101, P3224, DOI 10.1073/pnas.0400243101
   Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0
   Mihm MJ, 2007, NEUROBIOL DIS, V25, P297, DOI 10.1016/j.nbd.2006.09.016
   Mitra S, 2008, THESCIENTIFICWORLDJO, V8, P421, DOI 10.1100/tsw.2008.60
   Mouri A, 2014, J COLLOID INTERF SCI, V416, P139, DOI 10.1016/j.jcis.2013.10.058
   Mugat B, 2008, HUM MOL GENET, V17, P3601, DOI 10.1093/hmg/ddn255
   Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437                                                        
   Popiel HA, 2009, NEUROSCI LETT, V449, P87, DOI 10.1016/j.neulet.2008.06.015
   Pouladi MA, 2012, NEUROBIOL DIS, V48, P282, DOI 10.1016/j.nbd.2012.06.026
   Rattray I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060012
   Rockabrand E, 2007, HUM MOL GENET, V16, P61, DOI 10.1093/hmg/ddl440
   Rodriguez-Navarro JA, 2010, NEUROBIOL DIS, V39, P423, DOI 10.1016/j.nbd.2010.05.014
   Sah DWY, 2011, J CLIN INVEST, V121, P500, DOI 10.1172/JCI45130
   Sassone J, 2009, EXP NEUROL, V219, P385, DOI 10.1016/j.expneurol.2009.05.012
   SIEUWERTS AM, 1995, EUR J CLIN CHEM CLIN, V33, P813
   Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2
   Southwell AL, 2008, J NEUROSCI, V28, P9013, DOI 10.1523/JNEUROSCI.2747-08.2008
   Southwell AL, 2009, J NEUROSCI, V29, P13589, DOI 10.1523/JNEUROSCI.4286-09.2009
   Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077
   Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283
   Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7
   Tam S, 2009, NAT STRUCT MOL BIOL, V16, P1279, DOI 10.1038/nsmb.1700
   Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985
   Van Raamsdonk JM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-80
   Wadia AS, 2002, CURR OPIN BIOTECH, V13, P32
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wolfgang WJ, 2005, P NATL ACAD SCI USA, V102, P11563, DOI 10.1073/pnas.0505321102
   Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6
   Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102
   Zuccato C, 2010, PHYSIOL REV, V90, P905, DOI 10.1152/physrev.00041.2009
NR 51
TC 9
Z9 9
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2051-5960
J9 ACTA NEUROPATHOL COM
JI Acta Neuropathol. Commun.
PY 2014
VL 2
AR 86
DI 10.1186/s40478-014-0086-x
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA V9K3A
UT WOS:000422389300086
PM 25091984
OA gold
DA 2018-01-05
ER

PT J
AU Patel, GV
   Patel, VB
   Pathak, A
   Rajput, SJ
AF Patel, Greeshma V.
   Patel, Vaibhav B.
   Pathak, Abhishek
   Rajput, Sadhana J.
TI Nanosuspension of efavirenz for improved oral bioavailability:
   formulation optimization, in vitro, in situ and in vivo evaluation
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Bioavailability; Box-Behnken; efavirenz; media milling; nanosuspension
ID PARTICLE-SIZE REDUCTION; DRUG-DELIVERY SYSTEMS; PHYSICOCHEMICAL
   PROPERTIES; LIPID NANOPARTICLES; EXPERIMENTAL-DESIGN; SOLUBLE DRUGS;
   ABSORPTION; DISSOLUTION; HIV; STABILITY
AB Context: Nanosuspensions (NSs) of poorly water-soluble drugs are known to increase the oral bioavailability.
   Objectives: The purpose of this study was to develop NS of efavirenz (EFV) and to investigate its potential in enhancing the oral bioavailability of EFV.
   Materials and methods: EFV NS was prepared using the media milling technique. The Box-Behnken design was used for optimization of the factors affecting EFV NS. Sodium lauryl sulfate and PVP K30 were used to stabilize the NS. Freeze-dried NS was completely re-dispersed with double-distilled filtered water.
   Results: Mean particle size and zeta potential of the optimized NS were found to be 320.4 +/- 3.62nm and -32.8 +/- 0.4 mV, respectively. X-ray diffraction and differential scanning calorimetric analysis indicated no phase transitions. Rate and extent of drug dissolution in the dissolution medium for NS was significantly higher compared to marketed formulation. The parallel artificial membrane permeability assay revealed that NS successfully enhanced the permeation of EFV. Results of in situ absorption studies showed a significant difference in absorption parameters such as K-a, t(1/2) and uptake percentages between lyophilized NS and marketed formulation of EFV. Oral bioavailability of EFV in rabbits resulting from NS was increased by 2.19-fold compared to the marketed formulation.
   Conclusion: Thus, it can be concluded that NS formulation of EFV can provide improved oral bioavailability due to enhanced solubility, dissolution velocity, permeability and hence absorption.
C1 [Patel, Greeshma V.; Pathak, Abhishek; Rajput, Sadhana J.] Maharaja Sayajirao Univ Baroda, Qual Assurance Lab, Ctr Relevance & Excellence Novel Drug Delivery Sy, Vadodara 390002, Gujarat, India.
   [Patel, Vaibhav B.] Maharaja Sayajirao Univ Baroda, Pharmacol Lab, Dept Pharm, Vadodara 390002, Gujarat, India.
RP Patel, GV (reprint author), Maharaja Sayajirao Univ Baroda, Qual Assurance Lab, GH Patel Pharm Bldg,Donors Plaza, Vadodara 390002, Gujarat, India.
EM grish.vab@gmail.com
RI Patel, Vaibhav/B-4163-2016
OI Patel, Vaibhav/0000-0001-5917-5962
CR Ali HSM, 2009, INT J PHARMACEUT, V375, P107, DOI 10.1016/j.ijpharm.2009.03.029
   Anagha B, 2011, DRUG DEV IND PHARM, V37, P963
   Baert L, 2008, INT J PHARM, V355, P38, DOI 10.1016/j.ijpharm.2008.01.029
   Berglund KD, 2003, LANGMUIR, V19, P2705, DOI 10.1021/la026429g
   Box G.E.P., 1960, TECHNOMETRICS, V2, P455, DOI DOI 10.1080/00401706.1960.10489912
   Cerdeira AM, 2010, INT J PHARMACEUT, V396, P210, DOI 10.1016/j.ijpharm.2010.06.020
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Cui J, 2009, INT J PHARM, V371, P148, DOI 10.1016/j.ijpharm.2008.12.009
   Dodiya S, 2013, DRUG DEV IND PHARM, V39, P733, DOI 10.3109/03639045.2012.694889
   Dressman JB, 1998, PHARMACEUT RES, V15, P11, DOI 10.1023/A:1011984216775
   Gao L, 2008, INT J PHARM, V355, P321, DOI 10.1016/j.ijpharm.2007.12.016
   Gao Y, 2009, COLLOID SURFACE B, V71, P306, DOI 10.1016/j.colsurfb.2009.03.005
   Ghosh I, 2011, INT J PHARMACEUT, V409, P260, DOI 10.1016/j.ijpharm.2011.02.051
   Hanafy A, 2007, ADV DRUG DELIVER REV, V59, P419, DOI 10.1016/j.addr.2007.04.005
   HINTZ RJ, 1989, INT J PHARM, V51, P9, DOI 10.1016/0378-5173(89)90069-0
   Hiremath PS, 2009, INT J PHARMACEUT, V380, P96, DOI 10.1016/j.ijpharm.2009.07.008
   Horter D, 2001, ADV DRUG DELIVER REV, V46, P75, DOI 10.1016/S0169-409X(00)00130-7
   JACKSON CL, 1990, J CHEM PHYS, V93, P9002, DOI 10.1063/1.459240                                                                
   Jinno J, 2006, J CONTROL RELEASE, V111, P56, DOI 10.1016/j.jconrel.2005.11.013
   Kansy M, 1998, J MED CHEM, V41, P1007, DOI 10.1021/jm970530e                                                               
   Karnachi AA, 1996, INT J PHARM, V131, P9, DOI 10.1016/0378-5173(95)04216-4
   Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h
   Kincl M, 2005, INT J PHARM, V291, P39, DOI 10.1016/j.ijpharm.2004.07.041
   Lee J, 2008, INT J PHARM, V355, P328, DOI 10.1016/j.ijpharm.2007.12.032
   Li HL, 2009, J CONTROL RELEASE, V133, P238, DOI 10.1016/j.jconrel.2008.10.002
   LIVERSIDGE GG, 1995, INT J PHARM, V125, P309, DOI 10.1016/0378-5173(95)00148-C
   Madhavi BB, 2011, INT J PHARM INVESTIG, V1, P29, DOI 10.4103/2230-973X.76726
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Muller RH, 2002, INT J PHARM, V237, P151, DOI 10.1016/S0378-5173(02)00040-6
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007
   Muller RH, 2000, NANOSUSPENSIONS FORM
   Niwa T, 2011, PHARM RES-DORDR, V28, P2339, DOI 10.1007/s11095-011-0465-y
   Palla BJ, 2002, J COLLOID INTERF SCI, V256, P143, DOI 10.1006/jcis.2002.8648
   Pardeike J, 2011, INT J PHARMACEUT, V420, P93, DOI 10.1016/j.ijpharm.2011.08.033
   Park CH, 2009, DRUG DEV IND PHARM, V35, P1305, DOI 10.3109/03639040902902385
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   Pongpeerapat A, 2004, J DRUG DELIV SCI TEC, V14, P441, DOI 10.1016/S1773-2247(04)50082-5                                                   
   Puxiu W, 2012, DRUG DEV IND PHARM, V38, P1344
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Ragonese R, 2002, J PHARMACEUT BIOMED, V27, P995, DOI 10.1016/S0731-7085(01)00659-8
   Shah CA, 2007, INDIAN J PEDIATR, V74, P55, DOI 10.1007/s12098-007-0028-8
   Sharma Pradeep, 2005, Farmaco (Lausanne), V60, P874, DOI 10.1016/j.farmac.2005.08.007
   Shegokar R, 2010, INT J PHARMACEUT, V399, P129, DOI 10.1016/j.ijpharm.2010.07.044
   Singare DS, 2010, INT J PHARMACEUT, V402, P213, DOI 10.1016/j.ijpharm.2010.09.041
   Singh SK, 2011, EUR J PHARM BIOPHARM, V78, P441, DOI 10.1016/j.ejpb.2011.03.014
   Singh SP, 2011, FOOD CHEM TOXICOL, V49, P1056, DOI 10.1016/j.fct.2011.01.012
   Smith KA, 2001, CURR OPIN IMMUNOL, V13, P617, DOI 10.1016/S0952-7915(00)00270-3                                                   
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Sun W, 2011, J PHARM SCI-US, V100, P3365, DOI 10.1002/jps.22587
   Takano R, 2006, PHARM RES, V23, P1144, DOI 10.1007/s11095-006-0162-4
   Teeranachaideekul V, 2008, INT J PHARMACEUT, V354, P227, DOI 10.1016/j.ijpharm.2007.11.062
   Trotta M, 2001, J CONTROL RELEASE, V76, P119, DOI 10.1016/S0168-3659(01)00432-1
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   Van Eerdenbrugh B, 2008, EUR J PHARM BIOPHARM, V70, P590, DOI 10.1016/j.ejpb.2008.06.007
   Van Eerdenbrugh B, 2009, J PHARM SCI-US, V98, P2091, DOI 10.1002/jps.21563
   Xia DN, 2010, EUR J PHARM SCI, V40, P325, DOI 10.1016/j.ejps.2010.04.006
NR 57
TC 22
Z9 25
U1 1
U2 24
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD JAN
PY 2014
VL 40
IS 1
BP 80
EP 91
DI 10.3109/03639045.2012.746362
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 268VR
UT WOS:000328199300010
PM 23323843
DA 2018-01-05
ER

PT J
AU Betapudi, V
AF Betapudi, Venkaiah
TI Life without double-headed non-muscle myosin II motor proteins
SO FRONTIERS IN CHEMISTRY
LA English
DT Review
DE myosin II; motor proteins; molecular machines; cell migration;
   cytokinesis; cancer; pathogenesis; microparticles
AB Non-muscle myosin II motor proteins (myosin IIA, myosin IIB, and myosin IIC) belong to a class of molecular motor proteins that are known to transduce cellular free-energy into biological work more efficiently than man-made combustion engines. Nature has given a single myosin II motor protein for lower eukaryotes and multiple for mammals but none for plants in order to provide impetus for their life. These specialized nanomachines drive cellular activities necessary for embryogenesis, organogenesis, and immunity. However, these multifunctional myosin II motor proteins are believed to go awry due to unknown reasons and contribute for the onset and progression of many autosomal-dominant disorders, cataract, deafness, infertility, cancer, kidney, neuronal, and inflammatory diseases. Many pathogens like HIV, Dengue, hepatitis C, and Lymphoma viruses as well as Salmonella and Mycobacteria are now known to take hostage of these dedicated myosin II motor proteins for their efficient pathogenesis. Even after four decades since their discovery, we still have a limited knowledge of how these motor proteins drive cell migration and cytokinesis. We need to enrich our current knowledge on these fundamental cellular processes and develop novel therapeutic strategies to fix mutated myosin II motor proteins in pathological conditions. This is the time to think how to relieve the hijacked myosins from pathogens in order to provide a renewed impetus for patients' life. Understanding how to steer these molecular motors in proliferating and differentiating stem cells will improve stem cell based-therapeutics development. Given the plethora of cellular activities non-muscle myosin motor proteins are involved in, their importance is apparent for human life.
C1 [Betapudi, Venkaiah] Cleveland Clin, Dept Cellular & Mol Med, Lerner Res Inst, Cleveland, OH 44106 USA.
   [Betapudi, Venkaiah] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
RP Betapudi, V (reprint author), Cleveland Clin, Lerner Res Inst, Dept Cellular & Mol Med NC10, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM betapuv@ccf.org
FU U.S. National Institute of Health
FX The present review article was written with a particular theme on
   non-muscle myosin II motor proteins. The author apologizes for the
   omission of any study that has direct relevance with the main theme of
   the present article. The present work would not have been possible
   without the mentorship of author's previous mentors Professors Seyed E.
   Hasnain and Thomas T. Egelhoff, and critical reading by Dr. Saurabh
   Chattopadhyay as well as private and public funding agencies including
   the U.S. National Institute of Health.
CR Althaus K, 2010, TRANSFUS MED HEMOTH, V37, P260, DOI 10.1159/000320335
   Antony-Debre I, 2012, BLOOD, V120, P2719, DOI 10.1182/blood-2012-04-422352
   Arii J, 2010, NATURE, V467, P859, DOI 10.1038/nature09420
   Badyal SK, 2011, J MOL BIOL, V405, P1004, DOI 10.1016/j.jmb.2010.11.036
   Bagshaw C.R., 1993, MUSCLE CONTRACTION
   Balduini CL, 2011, BRIT J HAEMATOL, V154, P161, DOI 10.1111/j.1365-2141.2011.08716.x
   BARYLKO B, 1986, EUR J BIOCHEM, V158, P271, DOI 10.1111/j.1432-1033.1986.tb09747.x                                              
   Beach JR, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-52
   Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780                                                            
   Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236
   Betapudi V, 2005, MOL BIOL CELL, V16, P2248, DOI 10.1091/mbc.E04-07-0639
   Betapudi V, 2011, J MOL BIOL, V407, P673, DOI 10.1016/j.jmb.2011.02.010
   Betapudi V, 2010, EXP CELL RES, V316, P980, DOI 10.1016/j.yexcr.2010.01.024
   Betapudi V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008560
   Betapudi V, 2009, TRAFFIC, V10, P1773, DOI 10.1111/j.1600-0854.2009.00992.x
   Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012                                                       
   Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526
   Brown ME, 2003, J CELL SCI, V116, P1087, DOI 10.1242/jcs.00335
   Bryce NS, 2003, MOL BIOL CELL, V14, P1002, DOI 10.1091/mbc.E02-04-0244
   Burt RA, 2008, THROMB RES, V122, P861, DOI 10.1016/j.thromres.2008.06.011
   Bustamante C, 2004, ANNU REV BIOCHEM, V73, P705, DOI 10.1146/annurev.biochem.72.121801.161542
   CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227
   Chakravorty S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090077
   Chen AKL, 2014, TISSUE ENG PART C-ME, V20, P227, DOI [10.1089/ten.tec.2013.0191, 10.1089/ten.TEC.2013.0191]
   CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933                                                          
   Chen Z, 2007, BLOOD, V110, P171, DOI 10.1182/blood-2007-02-071589
   CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H
   Choi BO, 2011, HUM MUTAT, V32, P669, DOI 10.1002/humu.21488
   Clark K, 2008, FEBS LETT, V582, P2993, DOI 10.1016/j.febslet.2008.07.043
   Clark K, 2008, J MOL BIOL, V378, P790, DOI 10.1016/j.jmb.2008.02.057
   COLLINS JH, 1980, J BIOL CHEM, V255, P8011
   CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012
   Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200
   Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112
   Cotman SL, 2012, CLIN LIPIDOL, V7, P79, DOI 10.2217/CLP.11.70
   CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0
   CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3
   CROSS RA, 1986, EMBO J, V5, P2637
   Dahan I, 2012, MOL BIOL CELL, V23, P591, DOI 10.1091/mbc.E11-01-0015
   De la Roche MA, 2002, J MUSCLE RES CELL M, V23, P703, DOI 10.1023/A:1024467426244                                                         
   De Leersnyder H, 2001, J MED GENET, V38, P586, DOI 10.1136/jmg.38.9.586                                                            
   De Lorenzo C, 1999, CANCER METAST REV, V18, P295, DOI 10.1023/A:1006381526008                                                         
   De Rocco D, 2013, EUR J MED GENET, V56, P7, DOI 10.1016/j.ejmg.2012.10.009
   Derycke L, 2011, INT J DEV BIOL, V55, P835, DOI [10.1387/ijdb.113336ld, 10.1387/ijdb.1133361d]
   Donaudy F, 2004, AM J HUM GENET, V74, P770, DOI 10.1086/383285                                                                  
   Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9
   Du M, 2012, J BIOL CHEM, V287, P15330, DOI 10.1074/jbc.M112.349787
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dulyaninova Natalya G, 2013, Bioarchitecture, V3, P77
   Dulyaninova NG, 2005, BIOCHEMISTRY-US, V44, P6867, DOI 10.1021/bi0500776
   Egelhoff TT, 2005, J BIOL CHEM, V280, P2879, DOI 10.1074/jbc.M410803200
   EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R
   Engelhardt W A, 1994, Mol Biol (Mosk), V28, P1229
   Even-Faitelson L, 2006, MOL BIOL CELL, V17, P2869, DOI 10.1091/mbc.E05-11-1001
   Flores C, 2007, GENET EPIDEMIOL, V31, P296, DOI 10.1002/gepi.20210
   Flynn PG, 2010, J CELL BIOCHEM, V110, P1365, DOI 10.1002/jcb.22653
   Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l
   Foth BJ, 2006, P NATL ACAD SCI USA, V103, P3681, DOI 10.1073/pnas.0506307103
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Gao L, 2007, TRANSL RES, V150, P18, DOI 10.1016/j.trsl.2007.02.007
   Gazda L, 2013, CELL, V152, P183, DOI 10.1016/j.cell.2012.12.025
   Getty AL, 2011, EXP CELL RES, V317, P51, DOI 10.1016/j.yexcr.2010.09.007
   Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309
   Gupton SL, 2006, CELL, V125, P1361, DOI 10.1016/j.cell.2006.05.029
   Haigo SL, 2003, CURR BIOL, V13, P2125, DOI 10.1016/j.cub.2003.11.054
   Hays T, 2012, AIDS, V26, P797, DOI 10.1097/QAD.0b013e328351f6cf
   Heintzelman MB, 1997, J MOL BIOL, V271, P139, DOI 10.1006/jmbi.1997.1167
   Hellerschmied D, 2014, CURR OPIN STRUC BIOL, V25, P9, DOI 10.1016/j.sbi.2013.11.002
   Hildebrand JD, 2005, J CELL SCI, V118, P5191, DOI 10.1242/jcs.02626
   HosonoA Y, 2012, BIOCHEM BIOPH RES CO, V428, P173, DOI 10.1016/j.bbrc.2012.10.036
   Howard Jonathon, 2014, J Cell Biol, V204, P150, DOI 10.1083/jcb.2042pi
   Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923
   Jung HS, 2008, P NATL ACAD SCI USA, V105, P6022, DOI 10.1073/pnas.0707846105
   Kabir AMR, 2011, MACROMOL BIOSCI, V11, P1314, DOI 10.1002/mabi.201100060
   Kalmes A, 1996, J CELL SCI, V109, P1359
   KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101
   KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915                                                           
   Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069
   Kim JH, 2012, J BIOL CHEM, V287, P27345, DOI 10.1074/jbc.M111.304824
   Kim JH, 2011, J CELL PHYSIOL, V226, P2881, DOI 10.1002/jcp.22631
   Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245                                                    
   Kiss B, 2012, P NATL ACAD SCI USA, V109, P6048, DOI 10.1073/pnas.1114732109
   Kolomeisky AB, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/46/463101
   Koyama K, 1996, CYTOGENET CELL GENET, V72, P78, DOI 10.1159/000134167
   KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679
   Krzyzaniak MA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003309
   KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292                                                         
   Kumar A, 2013, GENE, V522, P226, DOI 10.1016/j.gene.2013.03.059
   KUZNICKI J, 1983, J BIOL CHEM, V258, P6011
   Lamant L, 2003, GENE CHROMOSOME CANC, V37, P427, DOI 10.1002/gcc.10232
   Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Leung T, 1996, MOL CELL BIOL, V16, P5313
   Li ZH, 2003, BIOCHEMISTRY-US, V42, P14258, DOI 10.1021/bi0354379
   Liu X, 1998, P NATL ACAD SCI USA, V95, P14124, DOI 10.1073/pnas.95.24.14124                                                        
   LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I
   Ma XF, 2010, MOL BIOL CELL, V21, P3952, DOI 10.1091/mbc.E10-04-0293
   Maravillas-Montero JL, 2012, J LEUKOCYTE BIOL, V91, P35, DOI 10.1189/jlb.0711335
   Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004
   Matsumura F, 2008, BIOCHEM BIOPH RES CO, V369, P149, DOI 10.1016/j.bbrc.2007.12.090
   MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110
   Mene P, 2013, CURR TOP MED CHEM, V13, P386
   Middelbeek J, 2010, CELL MOL LIFE SCI, V67, P875, DOI 10.1007/s00018-009-0215-z
   Min SY, 2014, TRANSPL P, V46, P654, DOI 10.1016/j.transproceed.2013.11.144
   Mitsuhashi M, 2011, J BIOCHEM, V149, P253, DOI 10.1093/jb/mvq134
   Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a
   Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5
   NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808
   Odronitz F, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-103
   ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001                                           
   PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203
   PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811
   Pecci A, 2008, HUM MUTAT, V29, P409, DOI 10.1002/humu.20661
   Pecci A, 2014, HUM MUTAT, V35, P236, DOI 10.1002/humu.22476
   Pecci A, 2010, EUR J HAEMATOL, V84, P291, DOI 10.1111/j.1600-0609.2009.01398.x
   Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948
   POLLARD TD, 1973, J BIOL CHEM, V248, P4691
   Rai V, 2011, EUKARYOT CELL, V10, P604, DOI 10.1128/EC.00296-10
   Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431
   Rey M, 2007, J CELL SCI, V120, P1126, DOI 10.1242/jcs.03415
   Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949
   Rinaldi F, 2012, NEUROBIOL DIS, V45, P264, DOI 10.1016/j.nbd.2011.08.010
   ROCHLIN MW, 1995, J CELL SCI, V108, P3661
   Rodgers BD, 2005, GROWTH HORM IGF RES, V15, P377, DOI 10.1016/j.ghir.2005.08.001
   Ronen D, 2009, J BIOL CHEM, V284, P24948, DOI 10.1074/jbc.M109.023754
   Rosenberg MM, 2013, J BIOL CHEM, V288, P9779, DOI 10.1074/jbc.M112.430173
   Rottbauer W, 2006, CIRC RES, V99, P323, DOI 10.1161/01.RES.0000234807.16034.fe
   Runnels LW, 2011, CURR PHARM BIOTECHNO, V12, P42
   Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2
   Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083                                                   
   Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200
   Scheeff ED, 2005, PLOS COMPUT BIOL, V1, P359, DOI 10.1037/journal.pcbi.0010049
   Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889
   Schramek D, 2014, SCIENCE, V343, P309, DOI 10.1126/science.1248627
   SELLERS JR, 1982, J BIOL CHEM, V257, P3880
   Sharma-Walia N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000777
   Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576
   Shutova M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040814
   SIMONS M, 1991, CIRC RES, V69, P530
   Slonska A, 2012, POSTEP HIG MED DOSW, V66, P810, DOI 10.5604/17322693.1016360
   SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303
   Solinet S, 2008, J CELL SCI, V121, P1681, DOI 10.1242/jcs.022640
   Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003
   Stedman HH, 2004, NATURE, V428, P415, DOI 10.1038/nature02358
   STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361                                                          
   Su LT, 2010, J MOL BIOL, V396, P858, DOI 10.1016/j.jmb.2010.01.014
   Takizawa N, 2007, J CELL SCI, V120, P3792, DOI 10.1242/jcs.008219
   Tan I, 2008, CELL, V135, P123, DOI 10.1016/j.cell.2008.09.018
   TAN JL, 1990, J BIOL CHEM, V265, P13818
   Tang HW, 2011, EMBO J, V30, P636, DOI 10.1038/emboj.2010.338
   TOOTHAKER LE, 1991, BLOOD, V78, P1826
   Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172
   TROTTER JA, 1982, BIOCHEM BIOPH RES CO, V106, P1071, DOI 10.1016/0006-291X(82)91820-4
   TROTTER JA, 1985, J BIOL CHEM, V260, P4374
   TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151
   TRYBUS KM, 1984, J BIOL CHEM, V259, P8564
   Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407
   Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125
   Underwood Julie, 2010, BMC Res Notes, V3, P56, DOI 10.1186/1756-0500-3-56
   Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459
   VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082
   Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9
   van den Heuvel MGL, 2007, NANO LETT, V7, P3138, DOI 10.1021/nl071696y
   van Leeuwen H, 2002, J VIROL, V76, P3471, DOI 10.1128/JVI.76.7.3471-3481.2002
   Varlamova O, 2001, J MUSCLE RES CELL M, V22, P243, DOI 10.1023/A:1012289905754
   Vasioukhin V, 2006, DEV NEUROSCI-BASEL, V28, P13, DOI 10.1159/000090749
   VONMUHLEN CA, 1995, CLIN EXP IMMUNOL, V100, P67
   Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901
   Wang L, 2010, AM J HUM GENET, V87, P701, DOI 10.1016/j.ajhg.2010.10.006
   Wasylnka JA, 2008, INFECT IMMUN, V76, P2722, DOI 10.1128/IAI.00152-08
   Weir L, 1996, GENE EXPRESSION, V6, P45
   Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098
   Xia DL, 2005, EXP CELL RES, V304, P506, DOI 10.1016/j.yexcr.2004.11.025
   Xia ZK, 2012, DIS ESOPHAGUS, V25, P427, DOI 10.1111/j.1442-2050.2011.01261.x
   Xu JS, 2008, NAT IMMUNOL, V9, P880, DOI 10.1038/ni.1628
   Xu XXS, 1996, DEV BIOL, V175, P218, DOI 10.1006/dbio.1996.0109
   Yumura S, 2005, MOL BIOL CELL, V16, P4256, DOI 10.1091/mbc.E05-03-0219
   Zamudio-Meza H, 2009, J GEN VIROL, V90, P2902, DOI 10.1099/vir.0.014159-0
NR 180
TC 5
Z9 5
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PY 2014
VL 2
AR 45
DI 10.3389/fchem.2014.00045
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA V43JV
UT WOS:000209678600048
PM 25072053
OA gold
DA 2018-01-05
ER

PT J
AU Hernandez, JC
   Latz, E
   Urcuqui-Inchima, S
AF Hernandez, Juan C.
   Latz, Eicke
   Urcuqui-Inchima, Silvio
TI HIV-1 Induces the First Signal to Activate the NLRP3 Inflammasome in
   Monocyte-Derived Macrophages
SO INTERVIROLOGY
LA English
DT Article
DE HIV-1; NLRP3 inflammasome; IL-1 beta; Macrophages; Inflammation
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADAPTIVE IMMUNE-RESPONSES; NALP3
   INFLAMMASOME; NANOPARTICLES ACTIVATE; CASPASE-1 ACTIVATION; CHOLESTEROL
   CRYSTALS; CYTOPLASMIC DNA; DENDRITIC CELLS; INFLUENZA-VIRUS; BACTERIAL
   RNA
AB Background/Aims: Inflammasomes are multimolecular complexes that regulate caspase-1. They act as sensors for endogenous and exogenous signals, and mediate the processing of pro-IL-1 beta into its secreted, biologically active form. The NLRP3 inflammasome and IL-1 beta are particularly interesting because they are required for efficient control of viral infections. Indeed, HIV-1 induces expression of NLRP3 and IL-1 beta in healthy controls, but not in HIV-1-infected patients. Here we evaluate whether HIV-1 can induce activation of the NLRP3 inflammasome. Methods: Human primary monocyte-derived macrophages were infected with HIV-1 in the absence or presence of classical NLRP3 inflammasome activators, and IL-1 beta release was assessed by ELISA. Results: HIV-1 initiates the priming signal for NLRP3 inflammasome activation through the NF-kappa B-associated pathway in human primary monocyte-derived macrophages. Furthermore, priming of NLRP3 activation in response to HIV-1 was independent of the viral envelope, since similar results were observed with HIV-1 and pseudotyped HIV-1 lacking the env gene. Conclusion: Our findings suggest that HIV-1 infection promotes IL-1 beta secretion by inducing the first signal for NLRP3 inflammasome activation, a phenomenon that may contribute to AIDS progression. Copyright (C) 2013 S. Karger AG, Basel
C1 [Hernandez, Juan C.] Univ Cooperativa Colombia, Fac Med, Medellin, Colombia.
   [Latz, Eicke] Univ Massachusetts, Sch Med, Dept Immunol & Infect Dis, Worcester, MA USA.
   [Latz, Eicke] Univ Bonn, Univ Hosp, Inst Innate Immun, Bonn, Germany.
   [Urcuqui-Inchima, Silvio] Univ Antioquia, Grp Inmunovirol, Medellin, Colombia.
RP Hernandez, JC (reprint author), Univ Cooperativa Colombia, Fac Med, Medellin, Colombia.
EM juankhernandez@gmail.com
RI Latz, Eicke/H-3951-2014
OI Latz, Eicke/0000-0003-1488-5666; Hernandez, Juan C./0000-0002-9200-5698
FU COLCIENCIAS [111549326099]
FX We acknowledge the help of Gloria Vasquez, Cherilyn Sirois and Anne-Lise
   Haenni for critically reviewing the manuscript. The authors also
   acknowledge the technical assistance of Joana Monteiro and Ann Dauphin
   of the University of Massachusetts Medical School, Worcester, Mass.,
   USA. Finally, the authors acknowledge the contribution of Mario
   Stevenson of the Developmental Center for AIDS Research, University of
   Miami, Miami, Fla., USA, for supplying several reagents. This study was
   supported by COLCIENCIAS, grant No. 111549326099.
CR Aiken C, 1997, J VIROL, V71, P5871
   Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Barlan AU, 2011, J VIROL, V85, P146, DOI 10.1128/JVI.01265-10
   Barlan AU, 2011, VIROLOGY
   Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032
   Brabers NACH, 2006, EUR J CLIN INVEST, V36, P447, DOI 10.1111/j.1365-2362.2006.01657.x
   Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002
   Burdette D, 2012, J GEN VIROL, V93, P235, DOI 10.1099/vir.0.034033-0
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Dinarello CA, 2010, EUR J IMMUNOL, V40, P599, DOI 10.1002/eji.201040319
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Eigenbrod T, 2012, J IMMUNOL, V189, P328, DOI 10.4049/jimmunol.1103258
   ELDIRANIDIAB R, 1992, FEBS LETT, V301, P23
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Grebe A, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-012-0313-z
   Gregory SM, 2011, SCIENCE, V331, P330, DOI 10.1126/science.1199478
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Heggelund L, 2004, CLIN INFECT DIS, V39, P264, DOI 10.1086/421780
   Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918                                                                
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861
   Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851
   Koh KB, 2000, J VIROL METHODS, V90, P99, DOI 10.1016/S0166-0934(00)00224-X
   Kumar H, 2009, J IMMUNOL, V183, P8061, DOI 10.4049/jimmunol.0902477
   Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588
   Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080
   Lunov O, 2011, ACS NANO, V5, P9648, DOI 10.1021/nn203596e
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinon F, 2009, ANNU REV IMMUNOL, V27, P229, DOI 10.1146/annurev.immunol.021908.132715
   McCoy AJ, 2010, J IMMUNOL, V185, P7077, DOI 10.4049/jimmunol.1002165
   Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109
   Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   Nitkiewicz J, 2004, J NEUROVIROL, V10, P400, DOI 10.1080/13550280490890097
   Nour AM, 2011, J BIOL CHEM, V286, P17921, DOI 10.1074/jbc.M110.210575
   Oosting M, 2011, EUR J IMMUNOL, V41, P172, DOI 10.1002/eji.201040385
   Pontillo A, 2011, AIDS, V25, P11
   Pontillo A, 2010, JAIDS-J ACQ IMM DEF, V54, P236, DOI 10.1097/QAI.0b013e3181dd17d4
   Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765
   Rajan JV, 2011, J VIROL, V85, P4167, DOI 10.1128/JVI.01687-10
   Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Tassi S, 2009, J IMMUNOL, V183, P1456, DOI 10.4049/jimmunol.0900578
   Thea DM, 1996, ANN INTERN MED, V124, P757, DOI 10.7326/0003-4819-124-8-199604150-00009
   Willingham SB, 2009, J IMMUNOL, V183, P2008, DOI 10.4049/jimmunol.0900138
   Xing HQ, 2009, NEUROPATHOLOGY, V29, P433, DOI 10.1111/j.1440-1789.2008.00996.x
   Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 57
TC 17
Z9 17
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0300-5526
EI 1423-0100
J9 INTERVIROLOGY
JI Intervirology
PY 2014
VL 57
IS 1
BP 36
EP 42
DI 10.1159/000353902
PG 7
WC Virology
SC Virology
GA 266FN
UT WOS:000328008900006
PM 24008203
DA 2018-01-05
ER

PT J
AU Hu, J
   Wen, CY
   Zhang, ZL
   Xie, M
   Hu, J
   Wu, M
   Pang, DW
AF Hu, Jun
   Wen, Cong-Ying
   Zhang, Zhi-Ling
   Xie, Min
   Hu, Jiao
   Wu, Min
   Pang, Dai-Wen
TI Optically Encoded Multifunctional Nanospheres for One-Pot Separation and
   Detection of Multiplex DNA Sequences
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID C VIRUS COINFECTION; QUANTUM DOTS; HEPATITIS-B; BEADS; CDSE;
   NANOCRYSTALS; RECOGNITION; INHIBITION; MICROBEADS; SILICA
AB In this study, we report a simple method for simultaneous detection of multiplex DNA sequences, including complementary DNA (cDNA) sequences of HIV and HCV, DNA sequence of HBV, with QDs-encoded fluorescent nanospheres and nano-gamma-Fe2O3-coated magnetic nanospheres. Detection was achieved on a fluorescence spectrophotometer without additional auxiliary instruments, and the detection limit was about 100 pM. Here, QDs-encoded fluorescent nanospheres (FNS) with different photoluminescent properties, and magnetic nanospheres (MNS) were separately fabricated by stepwise assembly of hydrophobic QDs or nano-gamma-Fe2O3 on the surface of branched poly(ethylene imine) (PEI)-coated nanospheres in precisely controlled amounts, finally followed by silica encapsulation. FNS-labeled probe DNAs and MNS-labeled capture DNAs were used to hybridize with the corresponding targets at the same time. After magnetic separation, the sandwich-structured adducts were measured by fluorescence spectrophotometry. The results indicated that the targets could be detected with high sensitivity. This method is convenient, fast enough, and capable of high anti-interference. Therefore, it is expected to be used for simultaneous detection and separation of multiple targets at high levels of purity and throughput.
C1 [Hu, Jun; Wen, Cong-Ying; Zhang, Zhi-Ling; Xie, Min; Hu, Jiao; Wu, Min; Pang, Dai-Wen] Wuhan Univ, Key Lab Analyt Chem Biol & Med, Minist Educ, Coll Chem & Mol Sci, Wuhan 430072, Peoples R China.
   [Hu, Jun; Wen, Cong-Ying; Zhang, Zhi-Ling; Xie, Min; Hu, Jiao; Wu, Min; Pang, Dai-Wen] Wuhan Univ, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Hu, Jun] Huazhong Univ Sci & Technol, Natl Engn Res Ctr Nanomed, Coll Life Sci & Technol, Wuhan 430074, Peoples R China.
RP Pang, DW (reprint author), Wuhan Univ, Key Lab Analyt Chem Biol & Med, Minist Educ, Coll Chem & Mol Sci, Wuhan 430072, Peoples R China.
EM dwpang@whu.edu.cn
RI Zhang, Zhi-Ling/B-3135-2010
OI Zhang, Zhi-Ling/0000-0001-7807-2264
FU National Basic Research Program of China (973 Program) [2011CB933600];
   863 program [2013AA032204]; Science Fund for Creative Research Groups of
   NSFC [20921062]; National Natural Science Foundation of China [81201193,
   2117510]; Program for New Century Excellent Talents in University
   [NCET-10-0656]; 111 Project [111-2-10]; "3551 Talent Program" of the
   Administrative Committee of East Lake Hi-Tech Development Zone [[2011]
   137]
FX This work was supported by the National Basic Research Program of China
   (973 Program, No. 2011CB933600), 863 program (2013AA032204), the Science
   Fund for Creative Research Groups of NSFC (No. 20921062), the National
   Natural Science Foundation of China (Grant Nos. 81201193 and 2117510),
   the Program for New Century Excellent Talents in University
   (NCET-10-0656), the 111 Project (111-2-10), and the "3551 Talent
   Program" of the Administrative Committee of East Lake Hi-Tech
   Development Zone ([2011] 137).
CR Anggorowati N, 2012, J MED VIROL, V84, P857, DOI 10.1002/jmv.23293
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Candotti D, 2009, J HEPATOL, V51, P798, DOI 10.1016/j.jhep.2009.05.020
   FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0                                                                
   Gao XH, 2004, ANAL CHEM, V76, P2406, DOI 10.1021/ac0354600
   Gershon D, 2002, NATURE, V416, P885, DOI 10.1038/416885a
   Gomez DE, 2005, SMALL, V1, P238, DOI 10.1002/smll.200400019
   Graf C, 2003, LANGMUIR, V19, P6693, DOI 10.1021/la0347859
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Kagan CR, 1996, PHYS REV LETT, V76, P1517, DOI 10.1103/PhysRevLett.76.1517                                                     
   Li J, 2009, CHEM COMMUN, P2329, DOI 10.1039/b823173g
   Li ZT, 2012, J AM CHEM SOC, V134, P3322, DOI 10.1021/ja209981n
   Li ZT, 2011, J AM CHEM SOC, V133, P15284, DOI 10.1021/ja205712a
   MacBeath G, 2000, SCIENCE, V289, P1760
   Micic OI, 1998, J PHYS CHEM B, V102, P9791, DOI 10.1021/jp981703u
   Nann T, 2005, CHEM COMMUN, P1735, DOI 10.1039/b414807j
   O'Brien P, 2003, CHEM COMMUN, P2532, DOI 10.1039/b307500a
   Piroth L, 1998, AIDS, V12, P381, DOI 10.1097/00002030-199804000-00006
   Rauf S, 2009, ADV MATER, V21, P4020, DOI 10.1002/adma.200900223
   Semaine W, 2006, J MED CHEM, V49, P2049, DOI 10.1021/jm058271d
   Song EQ, 2007, CLIN CHEM, V53, P2177, DOI 10.1373/clinchem.2007.092023
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Sukhanova A, 2007, NANO LETT, V7, P2322, DOI 10.1021/nl070966+
   Trau M, 2001, ADV MATER, V13, P975, DOI 10.1002/1521-4095(200107)13:12/13<975::AID-ADMA975>3.0.CO;2-#                   
   Tzoupis H, 2012, J MED CHEM, V55, P5784, DOI 10.1021/jm300180r
   Wang GP, 2005, CHEM COMMUN, P4276, DOI 10.1039/b508075d
   Wilson R, 2007, ACS NANO, V1, P487, DOI 10.1021/nn700289m
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xie HY, 2007, BIOCONJUGATE CHEM, V18, P1749, DOI 10.1021/bc060387g
   Xie HY, 2005, SMALL, V1, P506, DOI 10.1002/smll.200400136
   Xie M, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/3/035602
   Xie M, 2009, BIOSENS BIOELECTRON, V24, P1311, DOI 10.1016/j.bios.2008.07.058
   Yu WW, 2003, CHEM MATER, V15, P2854, DOI 10.1021/cm034081k
NR 33
TC 29
Z9 31
U1 11
U2 153
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 17
PY 2013
VL 85
IS 24
BP 11929
EP 11935
DI 10.1021/ac4027753
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 277CV
UT WOS:000328797200036
PM 24191690
DA 2018-01-05
ER

PT J
AU Navara, CS
   Hornecker, J
   Grow, D
   Chaudhari, S
   Hornsby, PJ
   Ichida, JK
   Eggan, K
   McCarrey, JR
AF Navara, Christopher S.
   Hornecker, Jacey
   Grow, Douglas
   Chaudhari, Shital
   Hornsby, Peter J.
   Ichida, Justin K.
   Eggan, Kevin
   McCarrey, John R.
TI Derivation of Induced Pluripotent Stem Cells from the Baboon: A Nonhuman
   Primate Model for Preclinical Testing of Stem Cell Therapies
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID MARMOSET CALLITHRIX-JACCHUS; LINES; ESTABLISHMENT; BLASTOCYSTS;
   GENERATION; FIBROBLASTS; MACAQUES; NEURONS; HUMANS; VOLUME
AB Development of effective pluripotent stem cell-based therapies will require safety and efficacy testing in a clinically relevant preclinical model such as nonhuman primates (NHPs). Baboons and macaques are equally similar to humans genetically and both have been extensively used for biomedical research. Macaques are preferred for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) research whereas baboons are preferred for transplantation studies because of the greater similarity of their anatomy and immunogenetic system to those of humans. We generated four induced pluripotent stem cell (iPSC) lines from skin cells of the olive baboon (Papio anubis). Each line shows the distinct morphology of primate pluripotent stem cells, including flat colonies with well-defined borders and a high nuclear/cytoplasm ratio. Each is positive for the pluripotency markers OCT4, SOX2, NANOG, and SSEA4. Pluripotency was confirmed in two lines by teratoma formation with representative tissues from each germ layer, whereas a third produced cells from all three germ layers following embryoid body differentiation. Three lines have a normal male karyotype and the fourth is missing the short arm of one copy of chromosome 18. This may serve as an in vitro model for the human developmental disorder 18p-, which impacts 1 in 50,000 births/year. These iPSC lines represent the first step toward establishing the baboon as a NHP model for developing stem cell-based therapies.
C1 [Navara, Christopher S.; Hornecker, Jacey; Grow, Douglas; Chaudhari, Shital; McCarrey, John R.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA.
   [Hornsby, Peter J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78245 USA.
   [Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78245 USA.
   [Ichida, Justin K.; Eggan, Kevin] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
   [Eggan, Kevin] Howard Hughes Med Inst, Cambridge, MA 02138 USA.
RP Navara, CS (reprint author), Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA.
EM Christopher.Navara@utsa.edu
RI Navara, Christopher/C-2813-2011
FU National Institutes of Health (NIH) [RR022865, HD046732, GM099117]
FX This work was partially supported by National Institutes of Health (NIH)
   grants RR022865 to J.R.M. and HD046732 and GM099117 to K.E.
CR Aurboonyawat T, 2007, INTERV NEURORADIOL, V13, P335, DOI 10.1177/159101990701300404                                                      
   Ben-Nun IF, 2011, NAT METHODS, V8, P829, DOI [10.1038/nmeth.1706, 10.1038/NMETH.1706]
   Boulting GL, 2011, NAT BIOTECHNOL, V29, P279, DOI 10.1038/nbt.1783
   Carpenter MK, 2009, NAT BIOTECHNOL, V27, P606, DOI 10.1038/nbt0709-606
   Chan A.W., 2011, CELL REPROGRAM, V12, P509
   Chang TC, 2011, STEM CELLS DEV, V20, P1053, DOI 10.1089/scd.2010.0372
   D'Ambrosio AL, 2004, METHOD ENZYMOL, V386, P60
   DAMIAN RT, 1972, FOLIA PRIMATOL, V17, P458, DOI 10.1159/000155462
   Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   Duan HL, 2003, CEREB CORTEX, V13, P950, DOI 10.1093/cercor/13.9.950                                                         
   Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199
   Goldring CEP, 2011, CELL STEM CELL, V8, P618, DOI 10.1016/j.stem.2011.05.012
   Gori JL, 2012, BLOOD, V120, pE35, DOI 10.1182/blood-2012-05-433797
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hardman CD, 2002, J COMP NEUROL, V445, P238, DOI 10.1002/cne.10165
   Herculano-Houzel S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017514
   Inder T, 2005, DEV NEUROSCI-BASEL, V27, P100, DOI 10.1159/000085981
   Lindvall O, 2012, CELL STEM CELL, V10, P151, DOI DOI 10.1016/J.STEM.2012.01.009
   Liu HS, 2008, CELL STEM CELL, V3, P587, DOI 10.1016/j.stem.2008.10.014
   Mekhoubad S, 2012, CELL STEM CELL, V10, P595, DOI 10.1016/j.stem.2012.02.014
   Mitalipov S, 2006, STEM CELLS, V24, P2177, DOI 10.1634/stemcells.2006-0125
   Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19
   Muller T, 2009, HUM REPROD, V24, P1359, DOI 10.1093/humrep/dep012
   NAVARA CS, 2007, CURR PROTOC STEM CEL, pCH1
   Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466
   Pandrea I, 2009, CURR HIV RES, V7, P57, DOI 10.2174/157016209787048456                                                      
   Pau K-Y Francis, 2004, Reprod Biol Endocrinol, V2, P41, DOI 10.1186/1477-7827-2-41
   Sasaki E, 2005, STEM CELLS, V23, P1304, DOI 10.1634/stemcells.2004-0366
   Schoenemann PT, 2005, NAT NEUROSCI, V8, P242, DOI 10.1038/nn1394
   Schultz C, 2000, NEUROBIOL AGING, V21, P905, DOI 10.1016/S0197-4580(00)00176-7
   Shedlock DJ, 2009, NAT REV IMMUNOL, V9, P717, DOI 10.1038/nri2636
   Simerly CR, 2009, STEM CELL RES, V2, P178, DOI 10.1016/j.scr.2009.02.004
   Suemori H, 2001, DEV DYNAM, V222, P273, DOI 10.1002/dvdy.1191                                                               
   Suemori Hirofumi, 2006, V329, P81
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024                                                      
   Thomson JA, 1996, BIOL REPROD, V55, P254, DOI 10.1095/biolreprod55.2.254
   THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Turleau C, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-4
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   VandeBerg J.L., 2009, BABOON BIOMEDICAL RE, P391
   Varum S, 2009, STEM CELL RES, V3, P142, DOI 10.1016/j.scr.2009.07.002
   Wu YH, 2010, STEM CELL RES, V4, P180, DOI 10.1016/j.scr.2010.02.003
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971                                                             
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
   Yu JY, 2007, SCIENCE, V318, P1917, DOI [10.1126/science.1151526, 10.1126/science.1172482]
NR 48
TC 3
Z9 3
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
EI 2152-4998
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD DEC
PY 2013
VL 15
IS 6
BP 495
EP 502
DI 10.1089/cell.2012.0093
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA 300HC
UT WOS:000330454000004
PM 24182315
OA green_published
DA 2018-01-05
ER

PT J
AU Rodriguez, B
   Asmuth, DM
   Matining, RM
   Spritzler, J
   Jacobson, JM
   Mailliard, RB
   Li, XD
   Martinez, AI
   Tenorio, AR
   Lori, F
   Lisziewicz, J
   Yesmin, S
   Rinaldo, CR
   Pollard, RB
AF Rodriguez, Benigno
   Asmuth, David M.
   Matining, Roy M.
   Spritzler, John
   Jacobson, Jeffrey M.
   Mailliard, Robbie B.
   Li, Xiao-Dong
   Martinez, Ana I.
   Tenorio, Allan R.
   Lori, Franco
   Lisziewicz, Julianna
   Yesmin, Suria
   Rinaldo, Charles R.
   Pollard, Richard B.
TI Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir,
   a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving
   Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE DermaVir; CTL responses; HIV therapeutic vaccines; HIV-specific immune
   responses
ID T-CELL RESPONSES; SIMIAN IMMUNODEFICIENCY VIRUS; TYPE-1 HIV-1; DENDRITIC
   CELLS; PLASMA VIREMIA; EX-VIVO; IMMUNIZATION; REPLICATION; MACAQUES;
   LYMPHOCYTES
AB Background: HIV-specific cellular immune responses are associated with control of viremia and delayed disease progression. An effective therapeutic vaccine could mimic these effects and reduce the need for continued antiretroviral therapy. DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses.
   Methods: Treated HIV-infected adults (HIV RNA <50 and CD4 >350) were randomized to placebo or escalating DermaVir doses (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13 in the low-and intermediate-dose groups and 0.8 mg at weeks 0, 1, 6, 7, 12, and 13 in the high-dose group), n = 5-6 evaluable subjects per group. Immunogenicity was assessed by a 12-day cultured interferon-g enzyme-linked immunosorbent spot assay at baseline and at weeks 9, 17, and 37 using 1 Tat/Rev and 3 overlapping Gag peptide pools (p17, p24, and p15).
   Results: Groups were comparable at baseline. The study intervention was well tolerated, without dose-limiting toxicities. Most responses were highest at week 17 (4 weeks after last vaccination) when Gag p24 responses were significantly greater among intermediate-dose group compared with control subjects [median (IQR): 67,600 (5633-74,368) versus 1194 (9-1667)] net spot-forming units per million cells, P = 0.032. In the intermediate-dose group, there was also a marginal Gag p15 response increase from baseline to week 17 [2859 (1867-56,933), P = 0.06], and this change was significantly greater than in the placebo group [0 (2713 to 297), P = 0.016].
   Conclusions: DermaVir administration was associated with a trend toward greater HIV-specific, predominantly central memory T-cell responses. The intermediate DermaVir dose tended to show the greatest immunogenicity, consistent with previous studies in different HIV-infected patient populations.
C1 [Rodriguez, Benigno] Case Western Reserve Univ, Univ Hosp Cleveland, Div Infect Dis, Cleveland, OH 44106 USA.
   [Rodriguez, Benigno] Case Western Reserve Univ, Univ Hosp Cleveland, Ctr AIDS Res, Cleveland, OH 44106 USA.
   [Asmuth, David M.; Li, Xiao-Dong; Pollard, Richard B.] Univ Calif Davis, Med Ctr, Div Infect Dis, Sacramento, CA 95817 USA.
   [Matining, Roy M.; Spritzler, John] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA.
   [Jacobson, Jeffrey M.] Drexel Univ, Coll Med, Div Infect Dis & HIV Med, Philadelphia, PA 19104 USA.
   [Mailliard, Robbie B.; Rinaldo, Charles R.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Martinez, Ana I.] NIAID, Div Aids, Bethesda, MD 20892 USA.
   [Tenorio, Allan R.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
   [Lori, Franco] ViroStat Srl, Sassari, Italy.
   [Lisziewicz, Julianna] Genet Immun, Budapest, Hungary.
   [Lisziewicz, Julianna] Genet Immun, Mclean, VA USA.
   [Yesmin, Suria] Social & Sci Syst Inc, Silver Spring, MD USA.
RP Rodriguez, B (reprint author), Case Western Reserve Univ, Univ Hosp Cleveland, Div Infect Dis, 2061 Cornell Rd,Suite 401, Cleveland, OH 44106 USA.
EM rodriguez.benigno@clevelandactu.org
RI Rodriguez, Benigno/C-3365-2009
OI Rodriguez, Benigno/0000-0001-9736-7957; Mailliard,
   Robbie/0000-0001-5501-503X
FU Genetic Immunity; NIAID [AI-36219, AI-069501, AI-68636, AI-68634,
   201IC001]; SSSS, Inc (ACTG Immunol. Support Lab) [U01 AI-069471];
   National Office for Research and Technology (Hungary) [HIKC05, DVCLIN01]
FX F.L. is CEO of Virostatics srl; J.L. is CEO of Genetic Immunity; R. B.
   P. is a consultant and has received financial compensation from Genetic
   Immunity. NIAID: AI-36219 and AI-069501 (B. R.), AI-68636 and AI-68634
   (R. B. M. and J.S.), and 201IC001. SSSS, Inc (ACTG Immunol. Support Lab,
   D. M. A., X-D. L., and R. B. P.), U01 AI-069471 (A. R. T.). National
   Office for Research and Technology (Hungary): HIKC05 and DVCLIN01
   (J.L.).
CR Abdel-Motal UM, 2005, VIROLOGY, V333, P226, DOI 10.1016/j.virol.2004.12.030
   Baker BM, 2009, EXPERT OPIN BIOL TH, V9, P55, DOI [10.1517/14712590802571928, 10.1517/14712590802571928 ]
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907                                                     
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Dinges WL, 2010, J VIROL, V84, P4461, DOI 10.1128/JVI.02438-09
   Ehl S, 2000, EUR J IMMUNOL, V30, P883
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Friedrich D, 2011, JAIDS-J ACQ IMM DEF, V58, P248, DOI 10.1097/QAI.0b013e318228f992
   Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06
   Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
   Gill DK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014330
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   Hel Z, 2002, J IMMUNOL, V169, P4778, DOI 10.4049/jimmunol.169.9.4778                                                     
   Huang XL, 2000, CLIN DIAGN LAB IMMUN, V7, P279, DOI 10.1128/CDLI.7.2.279-287.2000
   Jacobson JM, 2006, J INFECT DIS, V194, P623, DOI 10.1086/506364
   Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675                                                     
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365                                                          
   Kloverpris H, 2009, AIDS, V23, P1329, DOI 10.1097/QAD.0b013e32832d9b00
   Kuller L. H., 2008, PLoS Medicine, V5, pe203, DOI 10.1371/journal.pmed.0050203
   Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lisziewicz Julianna, 2006, Current Drug Delivery, V3, P83, DOI 10.2174/156720106775197574
   Lisziewicz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035416
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Lori F, 2011, EXPERT REV VACCINES, V10, P1371, DOI [10.1586/ERV.11.118, 10.1586/erv.11.118]
   Lorincz O, 2012, NANOMED-NANOTECHNOL, V8, P497, DOI 10.1016/j.nano.2011.07.013
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mudd PA, 2011, CURR OPIN HIV AIDS, V6, P197, DOI 10.1097/COH.0b013e3283453e16
   Ndhlovu ZM, 2012, J VIROL, V86
   Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749
   Nilsson C, 1998, AIDS, V12, P2261, DOI 10.1097/00002030-199817000-00006
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Reynolds MR, 2008, J EXP MED, V205, P2537, DOI 10.1084/jem.20081524
   RINALDO C, 1995, J VIROL, V69, P5838
   Rockstroh JK, 2011, AIDS VACC 2011 SEPT
   Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Schooley RT, 2010, J INFECT DIS, V202, P705, DOI 10.1086/655468
   Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014
   Somogyi E, 2011, VACCINE, V29, P744, DOI 10.1016/j.vaccine.2010.11.019
   Todryk SM, 2009, IMMUNOLOGY, V128, P83, DOI 10.1111/j.1365-2567.2009.03073.x
   Toke ER, 2010, INT J PHARMACEUT, V392, P261, DOI 10.1016/j.ijpharm.2010.03.048
   Turnbull EL, 2006, J IMMUNOL, V176, P6130, DOI 10.4049/jimmunol.176.10.6130                                                    
   UNAIDS, 2011, WORLD AIDS REP 2011
   Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8
   van Lunzen J, 2010, 18 INT AIDS C JUL 18
   Vardas E, 2010, AIDS 2010 JUL 18 23
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Wood E, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1649
   Wyand MS, 1999, J VIROL, V73, P8356
NR 58
TC 21
Z9 22
U1 1
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2013
VL 64
IS 4
BP 351
EP 359
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300HE
UT WOS:000330454200005
PM 24169120
DA 2018-01-05
ER

PT J
AU Lin, JQ
   Alexander-Katz, A
AF Lin, Jiaqi
   Alexander-Katz, Alfredo
TI Cell Membranes Open "Doors" for Cationic Nanoparticles/Biomolecules:
   Insights into Uptake Kinetics
SO ACS NANO
LA English
DT Article
DE cell membranes; nanoscale holes; gold nanoparticles; cell-penetrating
   peptides; direct translocation; transmembrane potential
ID FUNCTIONALIZED GOLD NANOPARTICLES; COARSE-GRAINED MODEL; LIPID-BILAYERS;
   PENETRATING PEPTIDES; TAT PEPTIDE; PORE FORMATION; FORCE-FIELD;
   SIMULATIONS; SURFACE; INTERNALIZATION
AB Cationic nanoparticles (NPs) and cell-penetrating peptides (CPPs) can enter cells in an energy-independent fashion, escaping the traditional endocytosis route, which is known as direct translocation. This unconventional entry, usually complementary to endocytosis, features rapid uptake and thus makes both cationic NPs and CPPs fascinating intracellular delivery agents. However, the mechanisms of the direct translocation of both cationic NPs and CPPs across cell membranes into the cytosol are not understood. Moreover, the relationship between direct translocation and endocytosis is also unclear. Here, using coarse-grained molecular dynamics simulations we show that a model cell membrane generates a nanoscale hole to assist the spontaneous translocation of cationic gold nanoparticles (AuNPs) as well as HIV-1 Tat peptides to the cytoplasm side under a transmembrane (TM) potential. After translocation, the AuNPs/Tat peptides move freely in the "cytoplasm" region and the membrane reseals itself within a microsecond, while the TM potential is strongly diminished. Furthermore, we show that the shape of the cationic object is crucial in determining if it can translocate or not across. The results provide insights into the uptake kinetics of cationic NPs/CPPs, which features the relationship between direction translocation and endocytosis. The mechanism put forward here establishes fundamental principles of the intracellular delivery of cationic nanocarriers.
C1 [Lin, Jiaqi; Alexander-Katz, Alfredo] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
RP Alexander-Katz, A (reprint author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
EM aalexand@mit.edu
FU NSF through the NSF MRSEC program at MIT [DMR-0819762]; MGHPCC
FX This work was supported by the NSF through the NSF MRSEC program at MIT
   under grant no. DMR-0819762. Partial support from the MGHPCC is also
   greatly appreciated.
CR ADAMS JB, 1989, J MATER RES, V4, P102, DOI 10.1557/JMR.1989.0102
   Avrvizo R. R., 2010, NANO LETT, V10, P2543
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Chen JM, 2009, J PHYS CHEM B, V113, P11179, DOI 10.1021/jp9033936
   Chen XM, 2013, SOFT MATTER, V9, P7592, DOI 10.1039/c3sm50931a
   Cho EC, 2009, NANO LETT, V9, P1080, DOI 10.1021/nl803487r
   Chosh P., 2008, ADV DRUG DELIVERY RE, V60, P1307
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Foged C., 2008, EXPERT OPIN DRUG DEL, V5
   GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016
   Ginzburg V., 2009, NANOTECHNOLOGIES LIF, V2
   Ginzburg VV, 2007, NANO LETT, V7, P3716, DOI 10.1021/nl072053l
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Lee H, 2008, J PHYS CHEM B, V112, P12279, DOI 10.1021/jp805026m
   Lee H, 2009, MOLECULES, V14, P423, DOI 10.3390/molecules14010423
   Leroueil PR, 2008, NANO LETT, V8, P420, DOI 10.1021/nl0722929
   Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y
   Lin J. Q., 2010, ACS NANO, V4, P3421
   Luedtke WD, 1998, J PHYS CHEM B, V102, P6566, DOI 10.1021/jp981745i                                                               
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Marks JR, 2011, J AM CHEM SOC, V133, P8995, DOI 10.1021/ja2017416
   Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f
   Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g
   Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Reynwar BJ, 2007, NATURE, V447, P461, DOI 10.1038/nature05840
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Schmid G, 2005, CHEM COMMUN, P697, DOI 10.1039/b411696h
   Tatur S, 2013, LANGMUIR, V29, P6606, DOI 10.1021/la401074y
   Terrill RH, 1995, J AM CHEM SOC, V117, P12537, DOI 10.1021/ja00155a017                                                             
   Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y
   Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419
   Tieleman DP, 2003, J AM CHEM SOC, V125, P6382, DOI 10.1021/ja029504i
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Van Lehn RC, 2013, NANO LETT, V13, P4060, DOI 10.1021/nl401365n
   Van Lehn RC, 2011, SOFT MATTER, V7, P11392, DOI 10.1039/c1sm06405c
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Yesylevskyy SO, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000810
NR 45
TC 72
Z9 72
U1 5
U2 93
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD DEC
PY 2013
VL 7
IS 12
BP 10799
EP 10808
DI 10.1021/nn4040553
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 281YO
UT WOS:000329137100039
PM 24251827
DA 2018-01-05
ER

PT J
AU Yanamala, N
   Kagan, VE
   Shvedova, AA
AF Yanamala, Naveena
   Kagan, Valerian E.
   Shvedova, Anna A.
TI Molecular modeling in structural nano-toxicology: Interactions of
   nano-particles with nano-machinery of cells
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Molecular interactions; Computational predictions; Nano-bio
   interactions; Inhibition of nano-mechanisms; Oxidative damage;
   Comparable sizes of nanoparticles
ID WALLED CARBON NANOTUBES; HIV-1 PR INHIBITORS; GLUTATHIONE-S-TRANSFERASE;
   METALLOFULLERENOL GD-AT-C-82(OH)(22); DYNAMICS SIMULATION; ELECTRON
   TOMOGRAPHY; PROTEIN MACHINES; C-60 FULLERENES; LIPID-BILAYER; KCSA
   CHANNEL
AB Over the past two decades, nanotechnology has emerged as a key player in various disciplines of science and technology. Some of the most exciting applications are in the field of biomedicine - for theranostics (for combined diagnostic and therapeutic purposes) as well as for exploration of biological systems. A detailed understanding of the molecular interactions between nanoparticles and biological nano-machinery - macromolecules, membranes, and intracellular organelles - is crucial for obtaining adequate information on mechanisms of action of nanomaterials as well as a perspective on the long term effects of these materials and their possible toxicological outcomes. This review focuses on the use of structure-based computational molecular modeling as a tool to understand and to predict the interactions between nanomaterials and nano-biosystems. We review major approaches and provide examples of computational analysis of the structural principles behind such interactions. A rationale on how nanopartides of different sizes, shape, structure and chemical properties can affect the organization and functions of nano-machinery of cells is also presented. Published by Elsevier B.V.
C1 [Yanamala, Naveena; Shvedova, Anna A.] NIOSH, Pathol & Physiol Res Branch, CDC, Morgantown, WV 26505 USA.
   [Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA USA.
   [Shvedova, Anna A.] WVU, Dept Physiol & Pharmacol, Morgantown, WV USA.
RP Shvedova, AA (reprint author), NIOSH, Pathol & Physiol Res Branch, CDC, 1095 Willowdale Rd, Morgantown, WV 26505 USA.
EM ats1@cdc.gov
RI Arumugam, Thirumagal/C-3408-2014
FU NIH [HL70755, U19AI068021]; NORA [3927ZKCY/3927ZJQP]; NTRC
   [32927ZJHF/3927ZKNL]; NIOSH [OH008282, 2927ZKCY]
FX This work was supported by NIH (HL70755 and U19AI068021), NORA
   (3927ZKCY/3927ZJQP), NTRC (32927ZJHF/3927ZKNL), and NIOSH (OH008282 and
   2927ZKCY) grants.
CR Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8
   Alberts B, 1998, BIOFUTUR, P42
   Allen BL, 2009, J AM CHEM SOC, V131, P17194, DOI 10.1021/ja9083623
   Asuri P, 2007, LANGMUIR, V23, P12318, DOI 10.1021/la702091c
   Bedrov D, 2008, J PHYS CHEM B, V112, P2078, DOI 10.1021/jp075149c
   Boiteux C, 2007, J MOL MODEL, V13, P699, DOI 10.1007/s00894-007-0202-y
   Calvaresi M, 2011, NANOSCALE, V3, P2873, DOI 10.1039/c1nr10082c
   Cathcart H, 2008, J AM CHEM SOC, V130, P12734, DOI 10.1021/ja803273s
   Chen HHC, 1998, TOXICOL PATHOL, V26, P143, DOI 10.1177/019262339802600117                                                      
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Chiu CC, 2008, J PHYS CHEM B, V112, P16326, DOI 10.1021/jp805313p
   Chiu CC, 2009, BIOPOLYMERS, V92, P156, DOI 10.1002/bip.21159
   Cui DX, 2005, TOXICOL LETT, V155, P73, DOI 10.1016/j.toxlet.2004.08.015
   Dinu CZ, 2009, SMALL, V5, P310, DOI 10.1002/smll.200801434
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Dutta D, 2007, TOXICOL SCI, V100, P303, DOI 10.1093/toxsci/kfm217
   Ehrenberg MS, 2009, BIOMATERIALS, V30, P603, DOI 10.1016/j.biomaterials.2008.09.050
   FEYNMAN RP, 1960, ENG SCI, V23, P15
   FRIEDMAN SH, 1993, FASEB J, V7, pA1184
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gajewicz A, 2012, ADV DRUG DELIVER REV, V64, P1663, DOI 10.1016/j.addr.2012.05.014
   Gao HJ, 2004, ANNU REV MATER RES, V34, P123, DOI 10.1146/annurev.matsci.34.040203.120402
   Gao HJ, 2003, NANO LETT, V3, P471, DOI 10.1021/nl025967a
   Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108
   Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370
   Holt Brian D, 2012, J Funct Biomater, V3, P398, DOI 10.3390/jfb3020398
   Holt BD, 2010, ACS NANO, V4, P4872, DOI 10.1021/nn101151x
   Hubbs AF, 2011, TOXICOL PATHOL, V39, P301, DOI 10.1177/0192623310390705
   Hung A, 2013, CHEM SCI, V4, P928, DOI 10.1039/c2sc21639f
   Iwata N, 1998, FULLERENE SCI TECHN, V6, P213, DOI 10.1080/10641229809350196                                                       
   Johnson RR, 2009, NANO LETT, V9, P537, DOI 10.1021/nl802645d
   Kagan VE, 2010, NAT NANOTECHNOL, V5, P354, DOI [10.1038/NNANO.2010.44, 10.1038/nnano.2010.44]
   Kaiser JP, 2008, J MATER SCI-MATER M, V19, P1523, DOI 10.1007/s10856-007-3296-y
   Kang SG, 2013, NANOSCALE, V5, P2703, DOI 10.1039/c3nr33756a
   Kang SG, 2012, SCI REP-UK, V2, DOI 10.1038/srep00957
   Kang SG, 2012, P NATL ACAD SCI USA, V109, P15431, DOI 10.1073/pnas.1204600109
   Kapralov AA, 2012, ACS NANO, V6, P4147, DOI 10.1021/nn300626q
   Kotchey GP, 2011, ACS NANO, V5, P2098, DOI 10.1021/nn103265h
   Kraszewski S, 2008, PHYS CHEM CHEM PHYS, V10, P2249, DOI 10.1039/b719512e
   Kraszewski S, 2010, ACS NANO, V4, P4158, DOI 10.1021/nn100723r
   Kulkarni SA, 2013, PHARM RES-DORDR, V30, P2512, DOI 10.1007/s11095-012-0958-3
   Kyani A, 2009, J MOL STRUC-THEOCHEM, V913, P63, DOI 10.1016/j.theochem.2009.07.018
   Li LW, 2007, J PHYS CHEM B, V111, P4067, DOI 10.1021/jp064982r
   Lu G, 2005, NANO LETT, V5, P897, DOI 10.1021/nl050354u
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   Mahmoudi M, 2011, CHEM REV, V111, P5610, DOI 10.1021/cr100440g
   Makarucha AJ, 2011, EUR BIOPHYS J BIOPHY, V40, P103, DOI 10.1007/s00249-010-0651-6
   Mangum James B, 2006, Part Fibre Toxicol, V3, P15, DOI 10.1186/1743-8977-3-15
   MARKETS IF, 2002, GLOBAL MARKET NANOMA, P371
   Martin D, 2010, LETT DRUG DES DISCOV, V7, P587, DOI 10.2174/157018010792062759                                                      
   Meher BR, 2012, J MOL GRAPH MODEL, V38, P430, DOI 10.1016/j.jmgm.2012.10.001
   Miyata N, 1998, ABSTR PAP AM CHEM S, V215, pU882
   Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/nnano.2012.207, 10.1038/NNANO.2012.207]
   Mroz P, 2007, FREE RADICAL BIO MED, V43, P711, DOI 10.1016/j.freeradbiomed.2007.05.005
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Noon WH, 2002, P NATL ACAD SCI USA, V99, P6466, DOI 10.1073/pnas.022532599
   Pampaloni F, 2008, TRENDS BIOTECHNOL, V26, P302, DOI 10.1016/j.tibtech.2008.03.002
   Pan H, 2012, LANGMUIR, V28, P12779, DOI 10.1021/la302258k
   Park KH, 2003, J BIOL CHEM, V278, P50212, DOI 10.1074/jbc.M310216200
   Porter AE, 2006, ACTA BIOMATER, V2, P409, DOI 10.1016/j.actbio.2006.02.006
   Porter AE, 2007, NAT NANOTECHNOL, V2, P713, DOI 10.1038/nnano.2007.347
   Porter AE, 2007, ENVIRON SCI TECHNOL, V41, P3012, DOI 10.1021/es062541f
   Porter DW, 2010, TOXICOLOGY, V269, P136, DOI 10.1016/j.tox.2009.10.017
   Qiao R, 2007, NANO LETT, V7, P614, DOI 10.1021/nl062515f
   Railsback JG, 2012, ADV MATER, V24, P4261, DOI 10.1002/adma.201104891
   Sargent LM, 2012, MUTAT RES-GEN TOX EN, V745, P28, DOI 10.1016/j.mrgentox.2011.11.017
   Sargent LM, 2009, ENVIRON MOL MUTAGEN, V50, P708, DOI 10.1002/em.20529
   Sasidharan A, 2011, NANOSCALE, V3, P2461, DOI 10.1039/c1nr10172b
   Shi BY, 2013, J PHYS CHEM B, V117, P3541, DOI 10.1021/jp312423y
   Shim M, 2002, NANO LETT, V2, P285, DOI 10.1021/nl015692j
   Shukla MK, 2009, CHEM PHYS LETT, V480, P269, DOI 10.1016/j.cplett.2009.09.031
   Shukla MK, 2009, CHEM PHYS LETT, V469, P207, DOI 10.1016/j.cplett.2008.12.092
   Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/15287390390231566
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   SIMAKOV O, 2012, LINKING MICRO MACROE, DOI DOI 10.1093/BFGP/ELS049
   Simpson ML, 2009, WIRES NANOMED NANOBI, V1, P214, DOI 10.1002/wnan.022
   Takahashi H, 2006, CHEM PHYS LETT, V418, P535, DOI 10.1016/j.cplett.2005.10.150
   Tkach AV, 2011, ACS NANO, V5, P5755, DOI 10.1021/nn2014479
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Tzoupis H, 2011, J COMPUT AID MOL DES, V25, P959, DOI 10.1007/s10822-011-9475-4
   Winkler DA, 2013, TOXICOLOGY, V313, P15, DOI 10.1016/j.tox.2012.11.005
   Wong-Ekkabut J, 2008, NAT NANOTECHNOL, V3, P363, DOI 10.1038/nnano.2008.130
   Xu X, 2012, NUCLEIC ACIDS RES, V40, P7622, DOI 10.1093/nar/gks517
   Yang ST, 2013, SMALL, V9, P1635, DOI 10.1002/smll.201201492
   Zhao XC, 2005, BIOPHYS J, V89, P3856, DOI 10.1529/biophysj.105.064410
   Zhao Y, 2011, J PHYS CHEM A, V115, P9536, DOI 10.1021/jp112324d
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   Zuo GH, 2013, SMALL, V9, P1546, DOI 10.1002/smll.201201381
   Zuo G, 2011, J PHYS CHEM C, V115, P23323, DOI 10.1021/jp208967t
   Zuo GH, 2010, ACS NANO, V4, P7508, DOI 10.1021/nn101762b
NR 92
TC 21
Z9 23
U1 8
U2 99
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC
PY 2013
VL 65
IS 15
BP 2070
EP 2077
DI 10.1016/j.addr.2013.05.005
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 286OQ
UT WOS:000329479000013
PM 23726945
OA green_accepted
DA 2018-01-05
ER

PT J
AU Blakney, AK
   Ball, C
   Krogstad, EA
   Woodrow, KA
AF Blakney, Anna K.
   Ball, Cameron
   Krogstad, Emily A.
   Woodrow, Kim A.
TI Electrospun fibers for vaginal anti-HIV drug delivery
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Human immunodeficiency virus; Microbicide; Vaginal delivery; Electrospun
   fibers; Antiretroviral
ID CONTROLLED-RELEASE; NANOFIBROUS SCAFFOLDS; GENE DELIVERY; IN-VITRO;
   MICROBICIDE; GLIOMA; PACLITAXEL; NONWOVENS; PROTEINS; SYSTEM
AB Diversity of microbicide delivery systems is essential for future success in the prevention and treatment of HIV in order to account for the varied populations of women all over the world that may benefit from use of these products. Recently, a novel dosage form for intravaginal drug delivery has been developed using drug-eluting fibers fabricated by electrospinning. There is a strong rationale to support the idea that drug-eluting fibers can be designed to realize multiple design constraints in a single product for topical HIV prevention: fibers are able to deliver a wide range of agents, incorporate multiple agents via composites, and facilitate controlled release over relevant time frames for pericoital and sustained (coitally-independent) use. It is also technologically feasible to scale-up production of fiber-based microbicides. Electrospun fibers may allow for prioritization of physical attributes that affect user perceptions without compromising biological efficacy. Challenges with using fibers as a microbicide include issues related to vehicle deployment, spreading and retention in the vaginal vault. In addition, studies will need to address the interaction of the fibers With the mucosal environment, including unknown safety and toxicity. Sustained release fiber microbicides capable of delivering multiple antiretroviral drugs while simultaneously exhibiting tunable degradation or dissolution of the fibers is also a challenge. However, electrospun fibers are a promising new platform for vaginal delivery of anti-HIV agents and future research will inform their place in the field. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies", held in Arlington, Virginia on February 20-21, 2013. It forms part of a special supplement to Antiviral Research. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Blakney, Anna K.; Ball, Cameron; Krogstad, Emily A.; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Box 355061,3720 15th Ave NE, Seattle, WA 98195 USA.
EM woodrow@uw.edu
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Agarwal S, 2008, POLYMER, V49, P5603, DOI 10.1016/j.polymer.2008.09.014
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Ball C., 2012, PLOS ONE, P7
   Beck-Broichsitter M, 2010, MACROMOL BIOSCI, V10, P1527, DOI 10.1002/mabi.201000100
   Cao HQ, 2010, J CONTROL RELEASE, V144, P203, DOI 10.1016/j.jconrel.2010.02.003
   Chew SY, 2005, BIOMACROMOLECULES, V6, P2017, DOI 10.1021/bm0501149
   Chunder A, 2007, COLLOID SURFACE B, V58, P172, DOI 10.1016/j.colsurfb.2007.03.004
   Cui WG, 2006, BIOMACROMOLECULES, V7, P1623, DOI 10.1021/bm060057z
   DONBROW M, 1975, J PHARM SCI, V64, P76, DOI 10.1002/jps.2600640114
   El-Refaie K., 2007, MAT SCI ENG A, V459
   Feng-Lei Z., 2009, POLYM INT, V58
   Forward KM, 2012, CHEM ENG J, V183, P492, DOI 10.1016/j.cej.2011.12.045
   Forward K.M., 2012, CHEM ENG J, V183
   Frenot R., 2003, CURRENT OPINION COLL, V8
   Garg S, 2003, AIDS PATIENT CARE ST, V17, P17, DOI 10.1089/108729103321042881                                                      
   Garg S., 2010, ANTIVIRAL RES S1, V88, P29
   Hong Y, 2008, BIOMACROMOLECULES, V9, P1200, DOI 10.1021/bm701201w
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Jannesari Marziyeh, 2011, Int J Nanomedicine, V6, P993, DOI 10.2147/IJN.S17595
   Jiang HL, 2005, J CONTROL RELEASE, V108, P237, DOI 10.1016/j.jconrel.2005.08.006
   Kim K, 2004, J CONTROL RELEASE, V98, P47, DOI 10.1016/j.jconrel.2004.04.009
   Li J., 2013, J BIOMATERIALS SCI P
   Li XQ, 2013, COLLOID SURFACE B, V103, P182, DOI 10.1016/j.colsurfb.2012.10.016
   Liao IC, 2009, J CONTROL RELEASE, V139, P48, DOI 10.1016/j.jconrel.2009.06.007
   Lopez-Rubio A, 2009, BIOMACROMOLECULES, V10, P2823, DOI 10.1021/bm900660b
   Luo CJ, 2012, CHEM SOC REV, V41, P4708, DOI 10.1039/c2cs35083a
   Luong-Van E, 2006, BIOMATERIALS, V27, P2042, DOI 10.1016/j.biomaterials.2005.10.028
   Macri LK, 2012, J CONTROL RELEASE, V161, P813, DOI 10.1016/j.jconrel.2012.04.035
   Mahalingam A, 2011, ANTIMICROB AGENTS CH, V55, P1650, DOI 10.1128/AAC.01368-10
   Malcolm R., 2010, ANTIVIRAL RES S1, V88, P9
   Maretschek S, 2008, J CONTROL RELEASE, V127, P180, DOI 10.1016/j.jconrel.2008.01.011
   Marrazzo J. M., 2013, 20 C RETR OPP INF AT
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   Patel S, 2007, NANO LETT, V7, P2122, DOI 10.1021/nl071182z
   Persano L, 2013, MACROMOL MATER ENG, V298, P504, DOI 10.1002/mame.201200290
   Prabaharan M, 2012, ADV POLYM SCI, V246, P241, DOI 10.1007/12_2011_125
   Ranganath SH, 2008, BIOMATERIALS, V29, P2996, DOI 10.1016/j.biomaterials.2008.04.002
   Richardson J.L., 1992, ADV DRUG DELIVERY RE, V8
   Roy DS, 2002, EUR J PHARM SCI, V16, P193
   Saraf A, 2010, J CONTROL RELEASE, V143, P95, DOI 10.1016/j.jconrel.2009.12.009
   Sassi AB, 2011, ANTIMICROB AGENTS CH, V55, P2282, DOI 10.1128/AAC.01190-10
   Schiffman J.D., 2008, POLYM REV, V48
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Silva SY, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-26
   Taepaiboon P, 2006, NANOTECHNOLOGY, V17, P2317, DOI 10.1088/0957-4484/17/9/041
   Theron S.A., 2005, POLYMER, V46
   Townsend-Nicholson A, 2006, BIOMACROMOLECULES, V7, P3364, DOI 10.1021/bm060649h
   Varesano A., 2010, POLYM INT, V59
   Vaz CM, 2005, ACTA BIOMATER, V1, P575, DOI 10.1016/j.actbio.2005.06.006
   Verreck G, 2003, PHARMACEUT RES, V20, P810, DOI 10.1023/A:1023450006281
   Volpato Z.F., 2012, ACTA BIOMATER, V8, P1551
   Wang Y, 2008, J MEMBRANE SCI, V309, P73, DOI 10.1016/j.memsci.2007.10.008
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
   Xie JW, 2006, PHARM RES, V23, P1817, DOI 10.1007/s11095-006-9036-z
   Xu X., 2006, MACROMOLECULAR RAPID, V27
   Xu XL, 2006, J CONTROL RELEASE, V114, P307, DOI 10.1016/j.jconrel.2006.05.031
   Yohe ST, 2012, J AM CHEM SOC, V134, P2016, DOI 10.1021/ja211148a
   Yu D.G., 2010, J DISPERSION SCI TEC, V31
   Zeng Jing, 2003, Journal of Controlled Release, V92, P227, DOI 10.1016/S0168-3659(03)00372-9
NR 60
TC 26
Z9 28
U1 4
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD DEC
PY 2013
VL 100
SU 1
BP S9
EP S16
DI 10.1016/j.antiviral.2013.09.022
PG 8
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 278XM
UT WOS:000328923200003
PM 24188701
DA 2018-01-05
ER

PT J
AU Zaware, N
   Sharma, H
   Yang, J
   Devambatla, RKV
   Queener, SF
   Anderson, KS
   Gangjee, A
AF Zaware, Nilesh
   Sharma, Hitesh
   Yang, Jie
   Devambatla, Ravi Kumar Vyas
   Queener, Sherry F.
   Anderson, Karen S.
   Gangjee, Aleem
TI Discovery of Potent and Selective Inhibitors of Toxoplasma gondii
   Thymidylate Synthase for Opportunistic Infections
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Opportunistic infection; Toxoplasma gondii; crystal structure;
   thymidylate-synthase inhibitors; active-site inhibitors
ID AGENTS
AB Infection by the parasite Toxoplasma gondii (tg) can lead to toxoplasmosis in iimnunocompromised patients such as organ transplant, cancer, and HIV/AIDS patients. The bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme is crucial for nucleotide synthesis in T. gondii and represents a potential target to combat T. gondii infection. While species selectivity with drugs has been attained for DHFR, TS is much more conserved across species, and specificity is significantly more challenging. We discovered novel substituted-9H-pyrimido[4,5-b]indoles 1-3 with single-digit nanomolar K-i for tgTS, two of which, 2 and 3, are 28- and 122 fold selective over human TS (hTS). The synthesis of these compounds, and their structures in complex with tgTS-DHFR are presented along with binding measurements and cell culture data These results show, for the very first time, that, in spite of the high degree of conservation of active site residues between hTS and the parasite TS, specificity has been accomplished via novel structures and provides a new target (TS) for selective drug development against parasitic infections.
C1 [Zaware, Nilesh; Yang, Jie; Devambatla, Ravi Kumar Vyas; Gangjee, Aleem] Duquesne Univ, Grad Sch Pharmaceut Sci, Div Med Chem, Pittsburgh, PA 15282 USA.
   [Sharma, Hitesh; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06511 USA.
   [Queener, Sherry F.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06511 USA.
EM karen.anderson@yale.edu; gangjee@duq.edu
FU NIH [CA152316]; Duquesne University Adrian Van Kaam Chair in Scholarly
   Excellence;  [AI083146]
FX This work was supported, in part, by NIH grant CA152316 (to A.G.), the
   Duquesne University Adrian Van Kaam Chair in Scholarly Excellence (to
   A.G.), and AI083146 (to K.S.A.).
CR Aspinall TV, 2002, J INFECT DIS, V185, P1637, DOI 10.1086/340577
   [Anonymous], 2008, MOL OP ENV MOE 2011
   CHULAY JD, 1984, AM J TROP MED HYG, V33, P325, DOI 10.4269/ajtmh.1984.33.325                                                       
   Dudrand C. M., 2013, CLIN PHARMACOL THER, V93, P382
   Ferrari S, 2008, CHEMMEDCHEM, V3, P392, DOI 10.1002/cmdc.200700215
   Fox BA, 2002, NATURE, V415, P926, DOI 10.1038/415926a
   Gangjee A, 2010, J MED CHEM, V53, P1563, DOI 10.1021/jm9011142
   Hyde JE, 2007, CURR DRUG TARGETS, V8, P31, DOI 10.2174/138945007779315524
   Masur H., 2009, CDC MMWR, V58
   Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X
   Pang CKT, 2005, MOL BIOCHEM PARASIT, V143, P121, DOI 10.1016/j.molbiopara.2005.02.016
   Piper JR, 1996, J MED CHEM, V39, P1271, DOI 10.1021/jm950760y
   Sharma H., 2013, BIOCHEMISTRY UNPUB
   Sperotto E, 2008, J ORG CHEM, V73, P5625, DOI 10.1021/jo800491k
   WEBBER SE, 1993, J MED CHEM, V36, P733, DOI 10.1021/jm00058a010
NR 15
TC 6
Z9 6
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD DEC
PY 2013
VL 4
IS 12
BP 1148
EP 1151
DI 10.1021/ml400208v
PG 4
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 273IV
UT WOS:000328529400008
PM 24470841
OA green_published
DA 2018-01-05
ER

PT J
AU Iyidogan, P
   Sullivan, TJ
   Chordia, MD
   Frey, KM
   Anderson, KS
AF Iyidogan, Pinar
   Sullivan, Todd J.
   Chordia, Mahendra D.
   Frey, Kathleen M.
   Anderson, Karen S.
TI Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of
   HIV Reverse Transcriptase
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; reverse transcriptase; nucleoside H-phosphonate; NNRTI; synthesis
ID POTENTIAL MULTIFUNCTIONAL INHIBITORS; DOUBLE-DRUG INHIBITORS;
   DEOXYRIBONUCLEOSIDE KINASES; NONNUCLEOSIDE INHIBITORS; BIFUNCTIONAL
   INHIBITION; SUBSTRATE-SPECIFICITY; DEOXYCYTIDINE KINASE;
   MOLECULAR-MECHANISM; NUCLEOSIDE ANALOGS; HETERODIMERS
AB In a continuing study of potent bifunctional anti-HIV agents, we rationally designed a novel chimeric inhibitor utilizing thymidine (THY) and a TMC derivative (a diarylpyrimidine NNRTI) linked via a polymethylene linker (ALK). The nucleoside, 5'-hydrogen-phosphonate (H-phosphonate), and S'-triphosphate forms of this chimeric inhibitor (THY-ALK-TMC) were synthesized and the antiviral activity profiles were evaluated at the enzyme and cellular level. The nucleoside triphosphate (11) and the H-phosphonate (10) derivatives inhibited RT polymerization with an IC50 value of 6.0 and 4.3 nM, respectively. Additionally, chimeric nucleoside (9) and H-phosphonate (10) derivatives reduced HIV replication in a cell-based assay with low nanomolar antiviral potencies.
C1 [Iyidogan, Pinar; Sullivan, Todd J.; Frey, Kathleen M.; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
   [Chordia, Mahendra D.] Chemin Pharma, New Haven, CT 06511 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.
EM karen.anderson@yale.edu
OI Chordia, Mahendra/0000-0001-9364-4697
FU NIH [GM49551]
FX This study was supported by NIH Grant GM49551 to K.S.A.
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Bailey CM, 2013, J MED CHEM, V56, P3959, DOI 10.1021/jm400160s
   Basavapathruni A, 2006, BIOCHEMISTRY-US, V45, P7334, DOI 10.1021/bi052362v
   Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200
   CHABRIER P, 1957, CR HEBD ACAD SCI, V245, P174
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4
   Gavriliu D, 2002, NUCLEOS NUCLEOT NUCL, V21, P505, DOI 10.1081/NCN-120015066
   Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Ijichi K, 1996, ANTIVIR RES, V31, P115, DOI 10.1016/0166-3542(96)00945-X
   [Иванова Эльвира Сергеевна Ivanova E.S.], 2010, [Вопросы вирусологии, Voprosy virusologii], V55, P31
   Iyidogan P, 2008, BIOCHEMISTRY-US, V47, P4711, DOI 10.1021/bi800157e
   Iyidogan P, 2012, ANTIVIR RES, V95, P93, DOI [10.1016/j.antiviral.2012.05.012, 10.1016/j.antivira1.2012.05.012]
   JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046
   Leabman MK, 2003, P NATL ACAD SCI USA, V100, P5896, DOI 10.1073/pnas.0730857100
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024
   Mahony WB, 2004, BIOCHEM PHARMACOL, V68, P1797, DOI 10.1016/j.bcp.2004.06.025
   MARUGG JE, 1986, TETRAHEDRON LETT, V27, P2661, DOI 10.1016/S0040-4039(00)84611-0
   McGuigan C, 2005, J MED CHEM, V48, P3504, DOI 10.1021/jm0491400
   Muhanji CI, 2007, CURR MED CHEM, V14, P1207, DOI 10.2174/092986707780597952                                                      
   Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Petersen L, 2005, J MED CHEM, V48, P1211, DOI 10.1021/jm040845b
   Piao DY, 2013, BIOORG MED CHEM LETT, V23, P1511, DOI 10.1016/j.bmcl.2012.12.015
   Pontikis R, 2000, J MED CHEM, V43, P1927, DOI 10.1021/jm991125l                                                               
   Renoud-Grappin M, 1998, ANTIVIR CHEM CHEMOTH, V9, P205, DOI 10.1177/095632029800900302                                                      
   RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046
   Skoblov Y, 2004, ANTIVIR RES, V63, P107, DOI 10.1016/j.antiviral.2004.03.001
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   Sugeac E, 2003, J ENZYM INHIB MED CH, V18, P175, DOI 10.1080/1475636032000069846
   Tamamura H, 2001, BIOORGAN MED CHEM, V9, P2179, DOI 10.1016/S0968-0896(01)00128-6                                                   
   Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001
   Velazquez S, 1999, J MED CHEM, V42, P5188, DOI 10.1021/jm991092+
   Velazquez S, 2004, J MED CHEM, V47, P3418, DOI 10.1021/jm031045o
   VELAZQUEZ S, 1995, J MED CHEM, V38, P1641, DOI 10.1021/jm00010a008
   Vlieghe P, 2002, J MED CHEM, V45, P1275, DOI 10.1021/jm010969d
   Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z                          
   Younis Y, 2010, BIOORGAN MED CHEM, V18, P4661, DOI 10.1016/j.bmc.2010.05.025
NR 40
TC 2
Z9 2
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD DEC
PY 2013
VL 4
IS 12
BP 1183
EP 1188
DI 10.1021/ml4002979
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 273IV
UT WOS:000328529400015
PM 24900627
OA green_published
DA 2018-01-05
ER

PT J
AU Li, JY
   Li, XM
   Kuang, Y
   Gao, Y
   Du, XW
   Shi, JF
   Xu, B
AF Li, Jiayang
   Li, Xinming
   Kuang, Yi
   Gao, Yuan
   Du, Xuewen
   Shi, Junfeng
   Xu, Bing
TI Self-Delivery Multifunctional Anti-HIV Hydrogels for Sustained Release
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE anti-HIV hydrogels; nanotechnology; self-delivery; self-assembly;
   supramolecular interaction
ID SUPRAMOLECULAR HYDROGELS; IN-VITRO; MICROBICIDE; NANOFIBERS; VIRUS;
   MOLECULES; SAFETY; VIVO; GELS
AB None of the clinical trials of anti-HIV gels based on conventional polymers or lipid emulsions has been successful, suggesting the need of new molecular design of the anti-HIV gels. This paper reports the conversion of anti-HIV prodrugs into self-delivery supramolecular hydrogels. By covalently conjugating reverse transcriptase inhibitors to a versatile self-assembly motif, the hydrogelators that self-assemble to form supramolecular nanofibers as the matrices of hydrogels in a weak acidic condition are obtained. Upon the treatment of prostate acid phosphatase (PAP), the hydrogels exhibit drastically enhanced elasticity. The hydrogelators are biocompatible and able to release the inhibitors under physiological condition. The use of the self-assembly motif as a self-delivery agent containing non-steroid anti-inflammatory drug (NSAID) renders this hydrogel to be both anti-inflammatory and anti-HIV. This work illustrates an unprecedented approach for designing multifunctional supramolecular hydrogels that may serve as potential anti-HIV hydrogels for sustained drug release.
C1 [Li, Jiayang; Li, Xinming; Kuang, Yi; Gao, Yuan; Du, Xuewen; Shi, Junfeng; Xu, Bing] Brandeis Univ, Dept Chem, Waltham, MA 02454 USA.
RP Xu, B (reprint author), Brandeis Univ, Dept Chem, MS 015, Waltham, MA 02454 USA.
EM bxu@brandeis.edu
RI Gao, Yuan/U-1539-2017; XU, Bing/A-7828-2008
OI Gao, Yuan/0000-0001-9714-4219; XU, Bing/0000-0002-4639-387X
FU NIH [R01CA142746]; HFSP [RGP 0056/2008]; Brandeis University
FX This work was partially supported by NIH (R01CA142746), a HFSP grant
   (RGP 0056/2008), and start-up grant from Brandeis University. The TEM
   images were taken at Brandeis EM facilities.
CR Balzarini J, 1998, AIDS, V12, P1129, DOI 10.1097/00002030-199810000-00004
   BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1
   Boekhoven J, 2012, J AM CHEM SOC, V134, P12908, DOI 10.1021/ja3051876
   Bommel K.J.C.V., 2003, ANGEW CHEM INT EDIT, V42, P980
   Brunton L.L, 2006, GOODMAN GILMANS PHAR
   D'Cruz OJ, 2001, CONTRACEPTION, V64, P113, DOI 10.1016/S0010-7824(01)00233-5
   Estroff LA, 2004, CHEM REV, V104, P1201, DOI 10.1021/cr0302049                                                               
   Gao Y, 2009, J AM CHEM SOC, V131, P13576, DOI 10.1021/ja904411z
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Lai BE, 2010, ANTIVIR RES, V88, P143, DOI 10.1016/j.antiviral.2010.08.006
   Laneuville O., 1994, J PHARMACOL EXP THER, V271, P927
   Langer R., 2004, NATURE, V428, P487
   Li JY, 2013, J AM CHEM SOC, V135, P542, DOI 10.1021/ja310019x
   MALKOVSKY M, 1988, LANCET, V1, P645
   Marques MRC, 2011, DISSOLUT TECHNOL, V18, P15, DOI 10.14227/DT180311P15                                                            
   Mayer KH, 2006, AIDS, V20, P543, DOI 10.1097/01.aids.0000210608.70762.c3
   Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867
   O'Keefe BR, 2011, FUTURE VIROL, V6, P553, DOI 10.2217/fvl.11.38                                                               
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   PODZAMCZER D, 2002, T COMBINE STUDY ANTI, V7, P81
   Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Sangeetha NM, 2005, CHEM SOC REV, V34, P821, DOI 10.1039/b417081b
   Shah RN, 2010, P NATL ACAD SCI USA, V107, P3293, DOI 10.1073/pnas.0906501107
   Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Telisman S, 2000, ENVIRON HEALTH PERSP, V108, P45, DOI 10.2307/3454294                                                                 
   Valery C, 2003, P NATL ACAD SCI USA, V100, P10258, DOI 10.1073/pnas.1730609100
   Yang Z, 2007, J MATER CHEM, V17, P2385, DOI 10.1039/b702493b
   Yang ZM, 2012, CHEM COMMUN, V48, P9257, DOI 10.1039/c2cc34935c
   Yang ZM, 2006, J AM CHEM SOC, V128, P3038, DOI 10.1021/ja057412y
   Yoshimura I., 2004, J AM CHEM SOC, V126, P12204
   Zhao F., 2009, CHEM SOC REV, V38, P883
NR 33
TC 33
Z9 33
U1 7
U2 67
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD DEC
PY 2013
VL 2
IS 12
BP 1586
EP 1590
DI 10.1002/adhm.201300041
PG 5
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 270UI
UT WOS:000328344000006
PM 23616384
OA green_accepted
DA 2018-01-05
ER

PT J
AU Agostoni, V
   Chalati, T
   Horcajada, P
   Willaime, H
   Anand, R
   Semiramoth, N
   Baati, T
   Hall, S
   Maurin, G
   Chacun, H
   Bouchemal, K
   Martineau, C
   Taulelle, F
   Couvreur, P
   Rogez-Kreuz, C
   Clayette, P
   Monti, S
   Serre, C
   Gref, R
AF Agostoni, Valentina
   Chalati, Tamim
   Horcajada, Patricia
   Willaime, Herve
   Anand, Resmi
   Semiramoth, Nicolas
   Baati, Tarek
   Hall, Shaun
   Maurin, Guillaume
   Chacun, Helene
   Bouchemal, Kawthar
   Martineau, Charlotte
   Taulelle, Francis
   Couvreur, Patrick
   Rogez-Kreuz, Christine
   Clayette, Pascal
   Monti, Sandra
   Serre, Christian
   Gref, Ruxandra
TI Towards an Improved anti-HIV Activity of NRTI via Metal-Organic
   Frameworks Nanoparticles
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE metal organic framework; AZT-TP; nanoparticle; drug delivery; NRTI
ID DRUG-DELIVERY; NUCLEOSIDE ANALOGS; AZIDOTHYMIDINE-TRIPHOSPHATE; NANOGEL
   FORMULATIONS; 5'-TRIPHOSPHATE; ENCAPSULATION; NANOCAPSULES; CARRIERS;
   NANOFORMULATION; MACROPHAGES
AB Nanoscale mesoporous iron carboxylates metal-organic frameworks (nanoMOFs) have recently emerged as promising platforms for drug delivery, showing biodegradability, biocompatibility and important loading capability of challenging highly water-soluble drugs such as azidothymidine tryphosphate (AZT-TP). In this study, nanoMOFs made of iron trimesate (MIL-100) were able to act as efficient molecular sponges, quickly adsorbing up to 24 wt% AZT-TP with entrapment efficiencies close to 100%, without perturbation of the supramolecular crystalline organization. These data are in agreement with molecular modelling predictions, indicating maximal loadings of 33 wt% and preferential location of the drug in the large cages. Spectrophotometry, isothermal titration calorimetry, and solid state NMR investigations enable to gain insight on the mechanism of interaction of AZT and AZT-TP with the nanoMOFs, pointing out the crucial role of phosphates strongly coordinating with the unsaturated iron(III) sites. Finally, contrarily to the free AZT-TP, the loaded nanoparticles efficiently penetrate and release their cargo of active triphosphorylated AZT inside major HIV target cells, efficiently protecting against HIV infection.
C1 [Agostoni, Valentina; Chalati, Tamim; Willaime, Herve; Semiramoth, Nicolas; Chacun, Helene; Bouchemal, Kawthar; Couvreur, Patrick; Gref, Ruxandra] Univ Paris 11, CNRS, Inst Galien, UMR 8612, Chatenay Malabry, France.
   [Horcajada, Patricia; Baati, Tarek; Martineau, Charlotte; Taulelle, Francis; Serre, Christian] Univ Versailles, CNRS, UMR 8180, Inst Lavoisier, F-78000 Versailles, France.
   [Anand, Resmi; Monti, Sandra] CNR, Ist Sintesi Organ & Fotoreatt, I-40126 Bologna, Italy.
   [Hall, Shaun; Maurin, Guillaume] UM1, UM2, CNRS, Inst Charles Gerhardt Montpellier,UMR 5253,ENSCM, Montpellier, France.
   [Rogez-Kreuz, Christine; Clayette, Pascal] CEA, Bertin Pharma, Lab Neurovirol, Fontenay Aux Roses, France.
RP Horcajada, P (reprint author), Univ Versailles, CNRS, UMR 8180, Inst Lavoisier, F-78000 Versailles, France.
EM horcajada@chimie.uvsq.fr; ruxandra.gref@u-psud.fr
RI Anand, Resmi/E-6072-2012; MAURIN, Guillaume/G-7435-2015
OI MAURIN, Guillaume/0000-0002-2096-0450; Martineau-Corcos,
   Charlotte/0000-0003-1887-1042; Patrick, COUVREUR/0000-0001-7961-5443
FU European ITN network CYCLON [237962]; French ANR project VIRMIL
   [ANR-2010-RMNP-004-01]; EU [ERC-2007-209241-BioMOFs]; Region Languedoc
   Roussillon
FX Authors thank Karen Storck for her technical assistance, Dr Denis David
   (Department of Neuropharmacology of Paris-Sud University) for
   microscopy, Dr Herve Hillaireau and Dr Davide Brambilla for helpful
   discussions. This work has been carried out in the frame of the European
   ITN network CYCLON (no 237962). It was also supported by the French ANR
   project VIRMIL (ANR-2010-RMNP-004-01) and the EU
   ERC-2007-209241-BioMOFs. G.M. also thanks the Region Languedoc
   Roussillon for its financial support through the award "Chercheur
   d'Avenir" 2009.
CR BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Chalati T, 2011, NANOMEDICINE-UK, V6, P1683, DOI [10.2217/NNM.11.69, 10.2217/nnm.11.69]
   Della Rocca J, 2011, ACCOUNTS CHEM RES, V44, P957, DOI 10.1021/ar200028a
   Duren T, 2007, J PHYS CHEM C, V111, P15350, DOI 10.1021/jp074723h
   Ferey G, 2004, ANGEW CHEM INT EDIT, V43, P6296, DOI 10.1002/anie.200460592
   Ferey G, 2005, SCIENCE, V309, P2040, DOI 10.1126/science.1116275
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   Glebov EM, 2011, PHOTOCH PHOTOBIO SCI, V10, P425, DOI 10.1039/c0pp00151a
   Hillaireau H, 2007, INT J PHARM, V331, P148, DOI 10.1016/j.ijpharm.2006.10.031
   Hillaireau H, 2006, INT J PHARM, V324, P37, DOI 10.1016/j.ijpharm.2006.07.006
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Horcajada P, 2007, CHEM COMMUN, P2820, DOI 10.1039/b704325b
   Horcajada P, 2006, ANGEW CHEM INT EDIT, V45, P5974, DOI 10.1002/anie.200601878
   Horcajada P, 2012, CHEM REV, V112, P1232, DOI 10.1021/cr200256v
   Horcajada P, 2010, NAT MATER, V9, P172, DOI [10.1038/nmat2608, 10.1038/NMAT2608, 10.1038/NMAT260B]
   Huxford RC, 2010, CURR OPIN CHEM BIOL, V14, P262, DOI 10.1016/j.cbpa.2009.12.012
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Kukhanova M, 2000, CURR PHARM DESIGN, V6, P585, DOI 10.2174/1381612003400687                                                        
   Leclerc H, 2011, PHYS CHEM CHEM PHYS, V13, P11748, DOI 10.1039/c1cp20502a
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474
   Rieter WJ, 2008, J AM CHEM SOC, V130, P11584, DOI 10.1021/ja803383k
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Taylor-Pashow KML, 2009, J AM CHEM SOC, V131, P14261, DOI 10.1021/ja906198y
   Vinogradov SV, 2007, EXPERT OPIN DRUG DEL, V4, P5, DOI 10.1517/17425247.4.1.5
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
NR 30
TC 38
Z9 40
U1 9
U2 119
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD DEC
PY 2013
VL 2
IS 12
BP 1630
EP 1637
DI 10.1002/adhm.201200454
PG 8
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 270UI
UT WOS:000328344000012
PM 23776182
DA 2018-01-05
ER

PT J
AU Epstein, AA
   Narayanasamy, P
   Dash, PK
   High, R
   Bathena, SPR
   Gorantla, S
   Poluektova, LY
   Alnouti, Y
   Gendelman, HE
   Boska, MD
AF Epstein, Adrian A.
   Narayanasamy, Prabagaran
   Dash, Prasanta K.
   High, Robin
   Bathena, Sai Praneeth R.
   Gorantla, Santhi
   Poluektova, Larisa Y.
   Alnouti, Yazen
   Gendelman, Howard E.
   Boska, Michael D.
TI Combinatorial assessments of brain tissue metabolomics and
   histopathology in rodent models of human immunodeficiency virus
   infection
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE Focused beam microwave irradiation; Neural antigens; Human
   immunodeficiency virus type one; neuroAIDS; Antigen preservation;
   Magnetic resonance spectroscopy; Metabolomics
ID PROGRESSIVE HIV-1 INFECTION; ANTIRETROVIRAL THERAPY; MICROWAVE
   IRRADIATION; COGNITIVE IMPAIRMENT; MAGNETIC-RESONANCE; MOUSE-BRAIN;
   MICE; DISEASE; MRS; METABOLITES
AB Metabolites are biomarkers for a broad range of central nervous system disorders serving as molecular drivers and byproducts of disease pathobiology. However, despite their importance, routine measures of brain tissue metabolomics are not readily available based on the requirements of rapid tissue preservation. They require preservation by microwave irradiation, rapid freezing or other methods designed to reduce post mortem metabolism. Our research on human immunodeficiency virus type one (HIV-1) infection has highlighted immediate needs to better link histology to neural metabolites. To this end, we investigated such needs in well-studied rodent models. First, the dynamics of brain metabolism during ex vivo tissue preparation was shown by proton magnetic resonance spectroscopy in normal mice. Second, tissue preservation methodologies were assessed using liquid chromatography tandem mass spectrometry and immunohistology to measure metabolites and neural antigens. Third, these methods were applied to two animal models. In the first, immunodeficient mice reconstituted with human peripheral blood lymphocytes then acutely infected with HIV-1. In the second, NOD scid IL2 receptor gamma chain knockout mice were humanized with CD34+ human hematopoietic stem cells and chronically infected with HIV-1. Replicate infected animals were treated with nanoformulated antiretroviral therapy (nanoART). Results from chronic infection showed that microgliosis was associated with increased myoinostitol, choline, phosphocholine concentrations and with decreased creatine concentrations. These changes were partially reversed with nanoART. Metabolite responses were contingent on the animal model. Taken together, these studies integrate brain metabolomics with histopathology towards uncovering putative biomarkers for neuroAIDS.
C1 [Epstein, Adrian A.; Narayanasamy, Prabagaran; Dash, Prasanta K.; Gorantla, Santhi; Poluektova, Larisa Y.; Gendelman, Howard E.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Epstein, Adrian A.; Boska, Michael D.] Univ Nebraska Med Ctr, Coll Med, Dept Radiol, Omaha, NE 68198 USA.
   [Bathena, Sai Praneeth R.; Alnouti, Yazen] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [High, Robin] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Dept Pharmacol & Expt Neurosci, Nebraska Med Ctr 985880, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Narayanasamy, Prabagaran/0000-0002-9617-5555; Poluektova,
   Larisa/0000-0001-7339-8732
FU NIDA NIH HHS [P01 DA026146, P01 DA028555]; NIMH NIH HHS [P01 MH064570,
   P30 MH062261]; NIA NIH HHS [R01 AG043540]; NINDS NIH HHS [R01 NS036126,
   P01 NS031492, R01 NS036127, R01 NS034239, R37 NS036126, P01 NS043985,
   R13 NS083315]
CR Angel Thomas E, 2012, Clin Proteomics, V9, P3, DOI 10.1186/1559-0275-9-3
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bathena SP, 2012, J CHROMATOGR B, V893, P15, DOI 10.1016/j.jchromb.2012.01.035
   Bonneh-Barkay D, 2008, AM J PATHOL, V173, P130, DOI 10.2353/ajpath.2008.080045
   Boska MD, 2004, CURR HIV RES, V2, P61, DOI 10.2174/1570162043485095
   Cho KI, 2012, CELL MOL LIFE SCI, V69, P3511, DOI 10.1007/s00018-012-1071-9
   Choi JK, 2007, NMR BIOMED, V20, P216, DOI 10.1002/nbm.1145
   Cysique LA, 2009, NEUROLOGY, V73, P342, DOI 10.1212/WNL.0b013e3181ab2b3b
   Cysique LA, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-148
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011
   de Graaf RA, 2009, J NEUROCHEM, V109, P494, DOI 10.1111/j.1471-4159.2009.05967.x
   Delaney SM, 1996, J NEUROSCI METH, V64, P151, DOI 10.1016/0165-0270(95)00119-0
   Detour J, 2011, J NEUROSCI METH, V201, P89, DOI 10.1016/j.jneumeth.2011.07.014
   Francis BM, 2012, NEUROPSYCHOPHARMACOL, V37, P1934, DOI 10.1038/npp.2012.40
   Fujieda Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043152
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gendelman HE, 1998, J INFECT DIS, V178, P1000, DOI 10.1086/515693                                                                  
   Gong N, 2011, J NEUROIMMUNOL, V230, P33, DOI 10.1016/j.jneuroim.2010.08.014
   Gorantla S, 2012, TRENDS NEUROSCI, V35, P197, DOI 10.1016/j.tins.2011.12.006
   Gorantla S, 2010, AM J PATHOL, V177, P2938, DOI 10.2353/ajpath.2010.100536
   Gorantla S, 2010, J NEUROIMMUNE PHARM, V5, P456, DOI 10.1007/s11481-010-9225-8
   Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V
   Greco JB, 2004, MAGNET RESON MED, V51, P1108, DOI 10.1002/mrm.20073
   HAMPSON RK, 1982, ANAL BIOCHEM, V123, P49, DOI 10.1016/0003-2697(82)90621-2
   Holt JL, 2012, J NEUROVIROL, V18, P291, DOI 10.1007/s13365-012-0114-1
   King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365-2249.2009.03933.x
   Koyanagi Y, 1997, J VIROL, V71, P2417
   Kraft-Terry SD, 2009, NEURON, V64, P133, DOI 10.1016/j.neuron.2009.09.042
   Laspiur JP, 2007, J NEUROIMMUNOL, V192, P157, DOI 10.1016/j.jneuroim.2007.08.004
   Lentz MR, 2011, J NEUROVIROL, V17, P220, DOI 10.1007/s13365-011-0030-9
   Login GR, 1998, METHODS, V15, P107, DOI 10.1006/meth.1998.0613                                                          
   Lucas EK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042878
   Maher AD, 2011, J PROTEOME RES, V10, P1737, DOI 10.1021/pr1010263
   Mochel F, 2012, J BIOL CHEM, V287, P1361, DOI 10.1074/jbc.M111.309849
   Nischang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038853
   Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200
   Patti GJ, 2012, NAT CHEM BIOL, V8, P232, DOI [10.1038/NCHEMBIO.767, 10.1038/nchembio.767]
   Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895
   Ratai EM, 2011, MAGN RESON MED, V66, P625, DOI 10.1002/mrm.22821
   Ratiney H, 2005, NMR BIOMED, V18, P1, DOI 10.1002/nbm.895
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Rozek W, 2007, J PROTEOME RES, V6, P4189, DOI 10.1021/pr070220c
   Schneider P, 2012, BRAIN BEHAV IMMUN, V26, P277, DOI 10.1016/j.bbi.2011.09.011
   Schwarcz A, 2003, MAGNET RESON MED, V49, P822, DOI 10.1002/mrm.10445
   SMITH SA, 1994, J MAGN RESON SER A, V106, P75, DOI 10.1006/jmra.1994.1008
   Tkac I, 2004, MAGNET RESON MED, V52, P478, DOI 10.1002/mrm.20184
   Valcour V, 2012, J INFECT DIS, V206, P275, DOI 10.1093/infdis/jis326
   Valcour V, 2011, CLIN INFECT DIS, V53, P836, DOI 10.1093/cid/cir524
   Velazquez I, 2009, J NEUROIMMUNOL, V206, P106, DOI 10.1016/j.jneuroim.2008.10.013
   Wikoff WR, 2008, J CLIN INVEST, V118, P2661, DOI 10.1172/JCI34138
   Yadav A, 2009, J NEUROIMMUNE PHARM, V4, P430, DOI 10.1007/s11481-009-9174-2
   Zgoda-Pols JR, 2011, TOXICOL APPL PHARM, V255, P48, DOI 10.1016/j.taap.2011.05.015
NR 54
TC 13
Z9 14
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD DEC
PY 2013
VL 8
IS 5
BP 1224
EP 1238
DI 10.1007/s11481-013-9461-9
PG 15
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 272XI
UT WOS:000328496000019
PM 23702663
OA gold
DA 2018-01-05
ER

PT J
AU Chang, S
   Wu, XM
   Li, YS
   Niu, DC
   Gao, YP
   Ma, Z
   Gu, JL
   Zhao, WR
   Zhu, WH
   Tian, H
   Shi, JL
AF Chang, Shu
   Wu, Xumeng
   Li, Yongsheng
   Niu, Dechao
   Gao, Yongping
   Ma, Zhi
   Gu, Jinlou
   Zhao, Wenru
   Zhu, Weihong
   Tian, He
   Shi, Jianlin
TI A pH-responsive hybrid fluorescent nanoprober for real time cell
   labeling and endocytosis tracking
SO BIOMATERIALS
LA English
DT Article
DE Copolymer; Self assembly; Nanoparticle; Fluorescence; Biosensor; Image
   analysis
ID BIOIMAGING IN-VIVO; LARGE STOKES SHIFT; MAGNETIC NANOPARTICLES;
   INTRACELLULAR PH; BIOMEDICAL APPLICATIONS; GOLD NANOPARTICLES; LIVING
   CELLS; CANCER; DESIGN; SENSOR
AB Hydrophilic, fluorescent hybrid nanoprobes (NDI@HNPs) encapsulated with the hydrophobic pH-responsive fluorophore (N,N'-di-n-dodecy1-2,6-di(4-methyl-piperazin-1-yl)naphthalene-1,4,5,8-tetracarboxylic acid diimide, NDI) for recognizing and mapping the route of cell phagocytosis have been fabricated based on the self-assembly of amphiphilic diblock copolymer PS-b-PAA and the subsequent shell cross-linking with 3-mercaptopropyltrimethoxy silane (MPTMS). The as-synthesized NDI@HNPs has a typical spherical morphology of 46 nm in diameter with excellent monodispersity in aqueous solution. The NDI@HNPs probe exhibits extremely low cytotoxicity, fast real time pH response and enhanced fluorescence intensity under acidic environment with respect to the corresponding free dye in highly polar aqueous system because of the encapsulation of NDI molecules inside nanoparticle cores with weak polarity environment. The fluorescence intensity of NDI@HNPs is enhanced by 55-fold upon changing from neutral (pH = 7.4) or basic (pH = 8.4) to acid (pH = 3.4) in aqueous system, in contrast to the serious fluorescence quenching of free NDI in the same medium, which can exactly meet the physiological pH range in cells. The favorably long emission wavelength is beneficial to the low scattering and minimal interfering requirements to fluorescent bioimaging. Moreover, functionalization with rapid cell-penetrating peptides (HIV-1 TAT) allows them to overcome the physiological and biological barriers during the phagocytosis process. Its characteristic fluorescent response to pH benefits the intracellular labeling and organelle targeting, realizing the real time tracking of the probe entry into cancer cells, the accumulation into the endolysosome and the further escape. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Chang, Shu; Li, Yongsheng; Niu, Dechao; Gao, Yongping; Gu, Jinlou; Zhao, Wenru; Shi, Jianlin] E China Univ Sci & Technol, Sch Mat Sci & Engn, Key Lab Ultrafine Mat, Lab Low Dimens Mat Chem,Minist Educ, Shanghai 200237, Peoples R China.
   [Wu, Xumeng; Zhu, Weihong; Tian, He] E China Univ Sci & Technol, Key Lab Adv Mat, Shanghai Key Lab Funct Mat Chem, Shanghai 200237, Peoples R China.
   [Wu, Xumeng; Zhu, Weihong; Tian, He] E China Univ Sci & Technol, Inst Fine Chem, Shanghai 200237, Peoples R China.
   [Ma, Zhi] Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China.
   [Shi, Jianlin] Chinese Acad Sci, Shanghai Inst Ceram, Shanghai 200050, Peoples R China.
RP Li, YS (reprint author), E China Univ Sci & Technol, Key Lab Adv Mat, Shanghai Key Lab Funct Mat Chem, Shanghai 200237, Peoples R China.
EM ysli@ecust.edu.cn; whzhu@ecust.edu.cn; jlshi@mail.sic.ac.cn
RI Gu, Jinlou/B-2388-2014; ZHU, Weihong/B-7066-2014
OI ZHU, Weihong/0000-0001-9103-166X
FU National 973 Program [2012CB933602, 2013CB733700]; National Natural
   Science Foundation of China [51172070, 51132009, 51202068, 61077085];
   Oriental Scholarship, SRFDP [20120074110002]; Program for New Century
   Excellent Talents in University [NCET-10-0379]; Shuguang Project
   [11SG30]; Scientific Innovation Project of Shanghai Municipal Education
   Commission [11ZZ53]; Fundamental Research Funds for the Central
   Universities [222201313010, WD1114002, WD1124010, WK1013002]
FX This work was financially supported by National 973 Program
   (2012CB933602, 2013CB733700), National Natural Science Foundation of
   China (51172070, 51132009, 51202068 and 61077085), the Oriental
   Scholarship, SRFDP 20120074110002, Program for New Century Excellent
   Talents in University (NCET-10-0379), Shuguang Project (11SG30),
   Scientific Innovation Project of Shanghai Municipal Education Commission
   (11ZZ53), Fundamental Research Funds for the Central Universities
   (222201313010, WD1114002, WD1124010 and WK1013002).
CR Albanese A, 2011, ACS NANO, V5, P5478, DOI 10.1021/nn2007496
   Albertazzi L, 2010, J AM CHEM SOC, V132, P18158, DOI 10.1021/ja105689u
   Almutairi A, 2008, J AM CHEM SOC, V130, P444, DOI 10.1021/ja078147e
   Bardhan R, 2011, ACCOUNTS CHEM RES, V44, P936, DOI 10.1021/ar200023x
   Benjaminsen RV, 2011, ACS NANO, V5, P5864, DOI 10.1021/nn201643f
   Benniston AC, 2004, PHYS CHEM CHEM PHYS, V6, P51, DOI 10.1039/b312286g
   BISSELL RA, 1992, J CHEM SOC PERK T 2, P1559, DOI 10.1039/p29920001559                                                            
   Byrne JD, 2008, ADV DRUG DELIVER REV, V60, P1615, DOI 10.1016/j.addr.2008.08.005
   Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820
   Chang S, 2012, ADV HEALTHC MATER, V1, P475, DOI 10.1002/adhm.201200144
   Dennis AM, 2012, ACS NANO, V6, P2917, DOI 10.1021/nn2038077
   Erathodiyil N, 2011, ACCOUNTS CHEM RES, V44, P925, DOI 10.1021/ar2000327
   Gao JH, 2009, ACCOUNTS CHEM RES, V42, P1097, DOI 10.1021/ar9000026
   Guo Z, 2012, J AM CHEM SOC, V134, P17846, DOI 10.1021/ja306891c
   Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z
   He HR, 2003, ANAL CHEM, V75, P549, DOI 10.1021/ac0205107
   He XX, 2012, ANAL CHEM, V84, P9056, DOI 10.1021/ac301461s
   Hotzer B, 2012, SMALL, V8, P2297, DOI 10.1002/smll.201200109
   Hu JM, 2011, J MATER CHEM, V21, P19030, DOI 10.1039/c1jm13575a
   Huang WC, 2012, ADV FUNCT MATER, V22, P2267, DOI 10.1002/adfm.201103117
   Izumi H, 2003, CANCER TREAT REV, V29, P541, DOI 10.1016/S0305-7372(03)00106-3
   Jin PW, 2013, AICHE J, V59, P2743, DOI 10.1002/aic.14083
   Jun YW, 2008, ACCOUNTS CHEM RES, V41, P179, DOI 10.1021/ar700121f
   Kaneda K, 2003, PHOTOCH PHOTOBIO SCI, V2, P402, DOI 10.1039/b211834n
   Kang YJ, 2005, ANGEW CHEM INT EDIT, V44, P409, DOI 10.1002/anie.200461119
   Kim J, 2008, ADV MATER, V20, P478, DOI 10.1002/adma.200701726
   Kobayashi H, 2010, CHEM REV, V110, P2620, DOI 10.1021/cr900263j
   Lee JE, 2011, ACCOUNTS CHEM RES, V44, P893, DOI 10.1021/ar2000259
   Li C, 2010, ADV FUNCT MATER, V20, P2222, DOI 10.1002/adfm.201000038
   Li L, 2008, CHEM MATER, V20, P6292, DOI 10.1021/cm8012107
   Lin Y, 2005, LANGMUIR, V21, P191, DOI 10.1021/la048000q
   Liu Q, 2013, J AM CHEM SOC, V135, P5029, DOI 10.1021/ja3104268
   Liu Q, 2012, J AM CHEM SOC, V134, P5390, DOI 10.1021/ja3003638
   Liu YD, 2013, CHEM SOC REV, V42, P2610, DOI 10.1039/c2cs35369e
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Lu XY, 2010, CHEM-EUR J, V16, P8355, DOI 10.1002/chem.201000461
   Lu ZD, 2012, CHEM SOC REV, V41, P6874, DOI 10.1039/c2cs35197h
   Lu ZD, 2011, NANO LETT, V11, P3404, DOI 10.1021/nl201820r
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   Myochin T, 2011, J AM CHEM SOC, V133, P3401, DOI 10.1021/ja1063058
   Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729
   Niu DC, 2008, CHEM COMMUN, P4463, DOI 10.1039/b807781a
   Oh E, 2011, ACS NANO, V5, P6434, DOI 10.1021/nn201624c
   Owen SC, 2012, NANO TODAY, V7, P53, DOI 10.1016/j.nantod.2012.01.002
   Stolwijk J. A., 2010, ANGEW CHEM, V122, P4342
   Peng XJ, 2011, J AM CHEM SOC, V133, P6626, DOI 10.1021/ja1104014
   Peng XJ, 2005, J AM CHEM SOC, V127, P4170, DOI 10.1021/ja043413z
   Rivera-Gil P, 2012, SMALL, V8, P943, DOI 10.1002/smll.201101780
   Roger C, 2008, J AM CHEM SOC, V130, P5929, DOI 10.1021/ja710253q
   Sakai N, 2010, CHEM COMMUN, V46, P4225, DOI 10.1039/c0cc00078g
   Shcherbakova DM, 2012, ANGEW CHEM INT EDIT, V51, P10724, DOI 10.1002/anie.201200408
   Shen LJ, 2011, MACROMOLECULES, V44, P5612, DOI 10.1021/ma200736t
   Srikun D, 2011, CHEM SCI, V2, P1156, DOI 10.1039/c1sc00064k
   Suraru SL, 2011, CHEM COMMUN, V47, P11504, DOI 10.1039/c1cc15144d
   Tang R, 2012, J AM CHEM SOC, V134, P4545, DOI 10.1021/ja300276s
   Tantama M, 2011, J AM CHEM SOC, V133, P10034, DOI 10.1021/ja202902d
   Taylor-Pashow KML, 2010, CHEM COMMUN, V46, P5832, DOI 10.1039/c002073g
   Urano Y, 2009, NAT MED, V15, P104, DOI 10.1038/nm.1854
   Vollath D, 2010, ADV MATER, V22, P4410, DOI 10.1002/adma.201001743
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Wen S, 2012, ANGEW CHEM INT EDIT, V26, P6538
   Wu JB, 2013, CHEM COMMUN, V49, P4995, DOI 10.1039/c3cc40936h
   Wu XM, 2013, CHEM SCI, V4, P1221, DOI 10.1039/c2sc22035k
   Yang GJ, 2013, J PHYS CHEM C, V117, P8214, DOI 10.1021/jp312857p
   Yu HB, 2012, J AM CHEM SOC, V134, P17486, DOI 10.1021/ja308967u
   Yuan L, 2013, CHEM SOC REV, V42, P622, DOI 10.1039/c2cs35313j
NR 66
TC 22
Z9 22
U1 10
U2 249
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2013
VL 34
IS 38
BP 10182
EP 10190
DI 10.1016/j.biomaterials.2013.09.044
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 267JT
UT WOS:000328094600043
PM 24095249
DA 2018-01-05
ER

PT J
AU Azari, M
   Iranmanesh, A
AF Azari, Mandieh
   Iranmanesh, Ali
TI Computing the eccentric-distance sum for graph operations
SO DISCRETE APPLIED MATHEMATICS
LA English
DT Article
DE Distance; Eccentricity; Graph operations
ID ANTI-HIV ACTIVITY; TOPOLOGICAL DESCRIPTOR; WIENER INDEX; CONNECTIVITY
   INDEX; TREES; DERIVATIVES
AB In this paper, we present explicit formulas for computing the eccentric-distance sum of the most important graph operations such as the Cartesian product, join, composition, disjunction, symmetric difference, cluster and corona product of graphs. Also, we apply our results to compute this eccentricity-related invariant for some important classes of molecular graphs and nano-structures by specializing components of these graph operations. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Azari, Mandieh; Iranmanesh, Ali] Tarbiat Modares Univ, Fac Math Sci, Dept Pure Math, Tehran, Iran.
RP Iranmanesh, A (reprint author), Tarbiat Modares Univ, Fac Math Sci, Dept Pure Math, POB 14115-137, Tehran, Iran.
EM mandie.azari@gmail.com; iranmanesh@modares.ac.ir
FU Center of Excellence of Algebraic Hyperstructures and its Applications
   of Tarbiat Modares University (CEAHA)
FX The authors would like to thank the referees for their valuable
   comments. This work was partially supported by Center of Excellence of
   Algebraic Hyperstructures and its Applications of Tarbiat Modares
   University (CEAHA).
CR Alizadeh Y, 2013, J COMPUT THEOR NANOS, V10, P1297, DOI 10.1166/jctn.2013.2709
   Azari M, 2012, UTILITAS MATHEMATICA, V87, P151
   Azari M, 2011, ARS COMBINATORIA, V100, P113
   Bajaj S, 2006, QSAR COMB SCI, V25, P813, DOI 10.1002/qsar.200430918
   Dankelmann P, 2004, UTILITAS MATHEMATICA, V65, P41
   DOBRYNIN AA, 1994, J CHEM INF COMP SCI, V34, P1082, DOI 10.1021/ci00021a008
   Doslic T, 2008, ARS MATH CONTEMP, V1, P66
   Dureja H, 2008, J MOL GRAPH MODEL, V26, P1020, DOI 10.1016/j.jmgm.2007.08.008
   GRAOVAC A, 1991, J MATH CHEM, V8, P53, DOI 10.1007/BF01166923                                                              
   Gupta S., 2002, J MATH ANAL APPL, V275, P386
   GUTMAN I, 1994, J CHEM INF COMP SCI, V34, P1087, DOI 10.1021/ci00021a009
   Hua HB, 2012, DISCRETE APPL MATH, V160, P170, DOI 10.1016/j.dam.2011.10.002
   Hua HB, 2011, J MATH ANAL APPL, V382, P364, DOI 10.1016/j.jmaa.2011.04.054
   Ilic A, 2011, MATCH-COMMUN MATH CO, V65, P731
   Ilic A, 2011, J MATH ANAL APPL, V381, P590, DOI 10.1016/j.jmaa.2011.02.086
   Imrich W., 2000, PRODUCT GRAPHS STRUC
   Khalifeh MH, 2008, COMPUT MATH APPL, V56, P1402, DOI 10.1016/j.camwa.2008.03.003
   Li SC, 2012, J MATH ANAL APPL, V390, P99, DOI 10.1016/j.jmaa.2012.01.022
   Milicevic A, 2006, CHEM MODEL APPL THEO, V4, P405
   Sagan BE, 1996, INT J QUANTUM CHEM, V60, P959
   Sardana S, 2003, J MOL STRUC-THEOCHEM, V624, P53, DOI 10.1016/S0166-1280(02)00737-6
   Sardana S, 2002, J MOL MODEL, V8, P258, DOI 10.1007/s00894-002-0093-X
   Sardana S., 2000, MATCH COMMUN MATH CO, V43, P85
   Sharma V, 1997, J CHEM INF COMP SCI, V37, P273, DOI 10.1021/ci960049h                                                               
   Trinajstic N., 1992, CHEM GRAPH THEORY
   WIENER H, 1947, J AM CHEM SOC, V69, P17, DOI 10.1021/ja01193a005                                                             
   Yu GH, 2011, J MATH ANAL APPL, V375, P99, DOI 10.1016/j.jmaa.2010.08.054
NR 27
TC 21
Z9 21
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-218X
EI 1872-6771
J9 DISCRETE APPL MATH
JI Discret Appl. Math.
PD DEC
PY 2013
VL 161
IS 18
BP 2827
EP 2840
DI 10.1016/j.dam.2013.06.003
PG 14
WC Mathematics, Applied
SC Mathematics
GA 269IS
UT WOS:000328235600004
DA 2018-01-05
ER

PT J
AU Shirazi, AN
   Oh, D
   Tiwari, RK
   Sullivan, B
   Gupta, A
   Bothun, GD
   Parang, K
AF Shirazi, Amir Nasrolahi
   Oh, Donghoon
   Tiwari, Rakesh Kumar
   Sullivan, Brian
   Gupta, Anju
   Bothun, Geoffrey D.
   Parang, Keykavous
TI Peptide Amphiphile Containing Arginine and Fatty Acyl Chains as
   Molecular Transporters
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE cellular uptake; drug delivery; nuclear targeting; peptide amphiphiles
ID CYCLIC-PEPTIDES; DELIVERY-SYSTEMS; DRUG-DELIVERY; CELL; RELEASE;
   ENCAPSULATION; NANOFIBERS; TRYPTOPHAN; CARRIERS; DESIGN
AB Peptide amphiphiles (PAs) are promising tools for the intracellular delivery of numerous drugs. PAs are known to be biodegradable systems. Here, four PA derivatives containing arginine and lysine conjugated with fatty acyl groups with different chain lengths, namely, PA1: R-K(C-14)-R, PA2: R-K(C-16)-R, PA3: K(C-14)-R-K(C-14), and PA4: K(C-16)-R-K(C-16), where C-16 = palmitic acid and C-14 = myristic acid, were synthesized through Fmoc chemistry. Flow cytometry studies showed that, among all synthesized PAs, only K(C-16)-R-K(C-16), PA4 was able to enhance the cellular uptake of a fluorescence-labeled anti-HIV drug 2',3'-dideoxy-3'-thiacythidine (F'-3TC, F' = fluorescein) and a biologically important phosphopeptide (F'-PEpYLGLD) in human leukemia cells (CCRF-CEM) after 2 h incubation. For example, the cellular uptake of F'-3TC and F'-PEpYLGLD was enhanced approximately 7.1- and 12.6-fold in the presence of the PA4 compared to those of the drugs alone. Confocal microscopy of F'-3TC and F'-PEpYLGLD loaded PA4 in live cells showed significantly higher intracellular localization than the drug alone in human ovarian cells (SK-OV-3) after 2 h incubation. The high-performance liquid chromatography (HPLC) results showed that loading of Dox by the peptide amphiphile was 56% after 24 h. The loaded Dox was released (34%) within 48 h intracellularly. The circular dichrosim (CD) results exhibited that the secondary structure of the peptide was changed upon interactions with Dox. Mechanistic studies revealed that endocytosis is the major pathway of the internalization. These studies suggest that PM containing the appropriate sequence of amino acids, chain length, charge, and hydrophobicity can be used as cellular delivery tools for transporting drugs and biomolecules.
C1 [Shirazi, Amir Nasrolahi; Oh, Donghoon; Tiwari, Rakesh Kumar; Sullivan, Brian; Parang, Keykavous] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
   [Shirazi, Amir Nasrolahi; Tiwari, Rakesh Kumar; Parang, Keykavous] Chapman Univ, Sch Pharm, Orange, CA 92866 USA.
   [Gupta, Anju] Texas A&M Int Univ, Coll Arts & Sci, Dept Engn, Dept Biol & Chem, Laredo, TX 78041 USA.
   [Bothun, Geoffrey D.] Univ Rhode Isl, Coll Engn, Dept Chem Engn, Kingston, RI 02881 USA.
RP Parang, K (reprint author), Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, 7 Greenhouse Rd, Kingston, RI 02881 USA.
EM kparang@uri.edu
FU American Cancer Society [RSG-07-290-01-CDD]; National Center for
   Research Resources, NIH [1 P20 RR16457]
FX We acknowledge the financial support from the American Cancer Society,
   Grant No. RSG-07-290-01-CDD. We thank the National Center for Research
   Resources, NIH, and Grant No. 1 P20 RR16457 for sponsoring the core
   facility.
CR Accardo A, 2007, BIOPOLYMERS, V88, P115, DOI 10.1002/bip.20648
   Agarwal HK, 2013, MOL PHARMACEUT, V10, P467, DOI 10.1021/mp300361a
   Agarwal HK, 2012, J MED CHEM, V55, P4861, DOI 10.1021/jm300492q
   Bulut S, 2011, BIOMACROMOLECULES, V12, P3007, DOI 10.1021/bm200641e
   Cai HX, 2013, NANOSCALE, V5, P2892, DOI 10.1039/c3nr00178d
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Guler MO, 2005, J MATER CHEM, V15, P4507, DOI 10.1039/b509246a
   Gupta A, 2011, EUR BIOPHYS J BIOPHY, V40, P727, DOI 10.1007/s00249-011-0685-4
   Haines-Butterick L, 2007, P NATL ACAD SCI USA, V104, P7791, DOI 10.1073/pnas.0701980104
   Hess GT, 2007, BBA-MOL CELL RES, V1773, P1583, DOI 10.1016/j.bbamcr.2007.07.009
   Javali NM, 2012, PHARM RES-DORDR, V29, P3347, DOI 10.1007/s11095-012-0830-5
   Kim JK, 2009, MOL PHARMACEUT, V6, P978, DOI 10.1021/mp900009n
   Lundberg P., 2007, FASEB J, V21, P664
   Machida K, 2005, BBA-PROTEINS PROTEOM, V1747, P1, DOI 10.1016/j.bbapap.2004.10.005
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   Massard J, 2008, Gastroenterol Clin Biol, V32, pS20, DOI 10.1016/S0399-8320(08)73261-5
   Matson JB, 2012, SOFT MATTER, V8, P3586, DOI 10.1039/c2sm07420f
   Nelson M, 2004, INT J CLIN PRACT, V58, P504, DOI 10.1111/j.1368-5031.2004.00100.x                                                
   Peterfreund R. A., 2013, EXPERT OPIN DRUG DEL, V10
   Saag Michael S, 2006, Clin Infect Dis, V42, P126
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P3137, DOI 10.1021/mp400199e
   Shirazi AN, 2013, BIOORG MED CHEM LETT, V23, P3230, DOI 10.1016/j.bmcl.2013.03.124
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P2008, DOI 10.1021/mp400046u
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P500, DOI 10.1021/mp300448k
   Soukasene S, 2011, ACS NANO, V5, P9113, DOI 10.1021/nn203343z
   Tan A, 2012, J CONTROL RELEASE, V163, P342, DOI 10.1016/j.jconrel.2012.08.009
   Thornton PD, 2008, SOFT MATTER, V4, P821, DOI 10.1039/b714750c
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   Wiethoff CM, 2004, J PHARM SCI-US, V93, P108, DOI 10.1002/jps.10519
   Wiradharma N, 2010, MACROMOL RAPID COMM, V31, P1212, DOI 10.1002/marc.200900935
   Ye GF, 2010, COLLOID SURFACE B, V76, P76, DOI 10.1016/j.colsurfb.2009.10.016
NR 32
TC 12
Z9 12
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD DEC
PY 2013
VL 10
IS 12
BP 4717
EP 4727
DI 10.1021/mp400539r
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 263TS
UT WOS:000327831500031
OA green_accepted
DA 2018-01-05
ER

PT J
AU Altunbek, M
   Yalvac, ME
   Keseroglu, K
   Palotas, A
   Culha, M
   Rizvanov, AA
AF Altunbek, Mine
   Yalvac, Mehmet E.
   Keseroglu, Kemal
   Palotas, Andras
   Culha, Mustafa
   Rizvanov, Albert A.
TI Gold- and Silver-based Nano-Particles Influence Pseudo-Typed Lenti-viral
   Infection
SO CURRENT NANOSCIENCE
LA English
DT Article
DE Cell culture; infection; lenti-virus; pseudo-typed lenti-viral
   particles; nano-material; nano-particle; transfection
ID TITANIUM-DIOXIDE; WATER-TREATMENT; GENE-THERAPY; IN-VITRO;
   NANOPARTICLES; VIRUS; INHIBITION; CELLS; ANTIBACTERIAL; INACTIVATION
AB The application of bio-active noble-metal-based nano-particles (NPs) with unique physico-chemical properties is multifaceted. Among other roles, they can be used as anti-viral agents, and at the same time might serve as matrix to facilitate the transport of various molecules for therapeutic purposes directly or via genetically modified microbes. For this reason, the influence of nano-materials on viral infection in living cells is described in this study utilizing pseudo-typed lenti-viral particles based on human immuno-deficiency virus 1 (HIV-1). Cells were exposed to various NPs and subsequently infected with lenti-virus. Transfection efficiency was quantified by flow-cytometry analysis. Gold-based NPs increased, silver-containing NPs decreased, while other NPs had little or no effect on viral infection rate. The opposing effect of NPs is determined by the size, chemical nature and surface chemistry of the nano-materials, which govern their interactions with molecular species present in their environment. These characteristics enable the distinct use of different NPs in various fields of bio-medicine.
C1 [Altunbek, Mine; Keseroglu, Kemal; Culha, Mustafa] Yeditepe Univ, Dept Genet & BioEngn, Istanbul, Turkey.
   [Yalvac, Mehmet E.] Ohio State Univ, Ctr Gene Therapy, Columbus, OH 43210 USA.
   [Palotas, Andras] Asklepios Med Private Med Practice & Res Ctr, Szeged, Hungary.
   [Rizvanov, Albert A.] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia.
RP Palotas, A (reprint author), Asklepios Med, Kossuth Lajos Sgt 23, H-6722 Szeged, Hungary.
EM palotas@asklepios-med.eu; mculha@yeditepe.edu.tr
RI Rizvanov, Albert/H-4486-2013
OI Rizvanov, Albert/0000-0002-9427-5739; Yalvac, Mehmet/0000-0001-6262-1476
FU Yeditepe University (Turkey); Scientific and Technological Research
   Council of Turkey (Tubitak) [108T605, 109T941]; Russian Foundation
   [11-04-00612-a]; Russian Federation President [M-433.2013.4];
   Asklepios-Med (Hungary)
FX This study was supported by Yeditepe University (Turkey), the Scientific
   and Technological Research Council of Turkey (Tubitak grants # 108T605
   and # 109T941), the Russian Foundation for Basic Research
   (11-04-00612-a), and Russian Federation President grant for young
   scientists (M-433.2013.4), and by Asklepios-Med (Hungary). Some of the
   experiments were conducted with the support of the Federal Center of
   Collective Use and Pharmaceutical Research and Education Center, Kazan
   (Volga Region) Federal University, Kazan, Russia.
CR Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927
   Annoni A, 2013, TRANSL RES, V161, P230, DOI 10.1016/j.trsl.2012.12.018
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Carrot G, 1998, COLLOID POLYM SCI, V276, P853, DOI 10.1007/s003960050321
   Catauro M, 2004, J MATER SCI-MATER M, V15, P831, DOI 10.1023/B:JMSM.0000032825.51052.00                                              
   Chen JS, 2003, WATER RES, V37, P3815, DOI 10.1016/S0043-1354(03)00332-4
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Diebold U, 2003, SURF SCI REP, V48, P53, DOI 10.1016/S0167-5729(02)00100-0                                                   
   Fujishima A, 2000, ELECTROCHIM ACTA, V45, P4683, DOI 10.1016/S0013-4686(00)00620-4                                                   
   Garcia JM, 2009, ANTIVIR RES, V81, P239, DOI [10.1016/j.antivira1.2008.12.004, 10.1016/j.antiviral.2008.12.004]
   Golovin E. V., 2012, SOVREM TEHNOL MED, V1, P55
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Handy RD, 2007, HEALTH RISK SOC, V9, P125, DOI 10.1080/13698570701306807
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Khosroshahi ME, 2010, LASER MED SCI, V25, P207, DOI 10.1007/s10103-009-0679-y
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Liau SY, 1997, LETT APPL MICROBIOL, V25, P279, DOI 10.1046/j.1472-765X.1997.00219.x                                                
   Liga MV, 2011, WATER RES, V45, P535, DOI 10.1016/j.watres.2010.09.012
   Lu L, 2008, ANTIVIR THER, V13, P253
   Mastro MA, 2010, MED CHEM RES, V19, P1074, DOI 10.1007/s00044-009-9253-1
   MATSUNAGA T, 1985, FEMS MICROBIOL LETT, V29, P211
   Nakano R, 2012, PHOTOCH PHOTOBIO SCI, V11, P1293, DOI 10.1039/c2pp05414k
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895
   Shiang YC, 2013, NANOSCALE, V5, P2756, DOI 10.1039/c3nr33403a
   Singer O, 2006, NAT PROTOC, V1, P286, DOI 10.1038/nprot.2006.44
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Villanueva SF, 2007, SOL ENERG MAT SOL C, V91, P1492, DOI 10.1016/j.solmat.2007.04.020
NR 30
TC 0
Z9 0
U1 1
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
EI 1875-6786
J9 CURR NANOSCI
JI Curr. Nanosci.
PD DEC
PY 2013
VL 9
IS 6
BP 693
EP 697
DI 10.2174/15734137113096660105                                            
          
PG 5
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 252MG
UT WOS:000327008600001
DA 2018-01-05
ER

PT J
AU Zitka, O
   Skalickova, S
   Rodrigo, MAM
   Krejcova, L
   Kopel, P
   Adam, V
   Kizek, R
AF Zitka, Ondrej
   Skalickova, Sylvie
   Rodrigo, Miguel Angel Merlos
   Krejcova, Ludmila
   Kopel, Pavel
   Adam, Vojtech
   Kizek, Rene
TI Sequences of Pandemic-Causing Viruses Isolated and Detected by
   Paramagnetic Particles Coupled with Microfluidic System and
   Electrochemical Detector
SO INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE
LA English
DT Article
DE Paramagnetic Particles Based Isolation; Microfluidics; Glassy Carbon
   Electrode; Copper Nanoparticles Modification; Viral Nucleic Sequences;
   Stopped Flow Injection Analysis; Microwave Hydrolysis
ID GLASSY-CARBON ELECTRODE; STRIPPING VOLTAMMETRY; GOLD NANOPARTICLES;
   MAGNETIC BEADS; DNA; ADENINE; GUANINE; COPPER; ACID; FABRICATION
AB Detection of the specific sequences of pandemic-causing viral nucleic acids is area attracting numerous scientists worldwide. In this study, we focused on the isolation and detection of oligonucleotide specific sequences of life-threatening viruses (HIV (GAGCAGTGGGAATA), Influenza (TAATAACCATTGGA) and Ebola (ACCTCACTAGAAAA)) by flow injection analysis with electrochemical detection coupled with paramagnetic particles based isolation. All of used viral genomic sequences contained A6 adenine repetition on the 5' end. This modification enables us to bind them on paramagnetic particle anchoring T25 (MPs-(dT)(25)). The isolated sequences were subsequently hydrolysed by optimized method using microwaves to obtain single adenines. The obtained samples were detected by microfluidic tool based on stopped flow injection analysis with glassy carbon electrode in the presence of Cu(II)/or CuS nanoparticles to enhance sensitivity and to lower detection limit for adenine. Basic detection parameters as accumulation of CuS nanoparticles, flow influence and accumulation of the adenine deposition influencing the analytical response were also tested. We found that bases gave well developed signals with detection limit down to 30 ng per ml (50 pg per electrochemical cell) under the optimized conditions.
C1 [Zitka, Ondrej; Skalickova, Sylvie; Rodrigo, Miguel Angel Merlos; Krejcova, Ludmila; Kopel, Pavel; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic.
   [Zitka, Ondrej; Rodrigo, Miguel Angel Merlos; Kopel, Pavel; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic.
RP Zitka, O (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.
EM kizek@sci.muni.cz
RI Kizek, Rene/D-7748-2012; Skalickova, Sylvie/E-8430-2012; Kopel,
   Pavel/E-5711-2012; Krejcova, Ludmila/E-8440-2012; Adam,
   Vojtech/D-7686-2012; Merlos, Miguel/H-7196-2012; Zitka,
   Ondrej/E-1107-2012
OI Kopel, Pavel/0000-0003-4216-9544; Krejcova, Ludmila/0000-0002-5199-2949;
   Adam, Vojtech/0000-0002-8527-286X; Merlos, Miguel/0000-0002-1920-0948; 
FU CEITEC [CZ.1.05/1.1.00/02.0068]; NanoBioTECell [GA CR P102/11/1068, IGA
   IP16/2013]
FX Financial support from CEITEC CZ.1.05/1.1.00/02.0068, NanoBioTECell GA
   CR P102/11/1068 and IGA IP16/2013 is highly acknowledged.
CR Adam V, 2010, MICROFLUID NANOFLUID, V8, P329, DOI 10.1007/s10404-009-0464-z
   Aladag N, 2010, ELECTROANAL, V22, P1675, DOI 10.1002/elan.201000031
   Brunklaus S, 2012, ELECTROPHORESIS, V33, P3222, DOI 10.1002/elps.201200259
   Chomoucka J, 2012, INT J NANOTECHNOL, V9, P746, DOI 10.1504/IJNT.2012.046752
   Craighead H, 2006, NATURE, V442, P387, DOI 10.1038/nature05061
   Desmarais SM, 2012, ELECTROPHORESIS, V33, P2639, DOI 10.1002/elps.201200189
   Doyle PS, 2002, SCIENCE, V295, P2237, DOI 10.1126/science.1068420
   Dutse SW, 2011, SENSORS-BASEL, V11, P5754, DOI 10.3390/s110605754
   Fatemi K, 2009, BIOTECHNOL APPL BIOC, V52, P221, DOI 10.1042/BA20070199
   Fojt L, 2006, J ELECTROANAL CHEM, V586, P136, DOI 10.1016/j.jelechem.2005.07.027
   Ganbold EO, 2012, COLLOID SURFACE B, V93, P148, DOI 10.1016/j.colsurfb.2011.12.026
   Gooneratne CP, 2012, SENSOR LETT, V10, P770, DOI 10.1166/sl.2012.2583
   Hubalek J, 2009, PROCEDIA CHEM, V1, P1011, DOI 10.1016/j.proche.2009.07.252
   Huska D, 2010, CHIM OGGI, V28, P18
   Huska D, 2010, CHIM OGGI, V28, P15
   Huska D, 2010, INT J ELECTROCHEM SC, V5, P1535
   Huska D, 2009, TALANTA, V79, P402, DOI 10.1016/j.talanta.2009.04.007
   Hynek D, 2012, INT J ELECTROCHEM SC, V7, P943
   Jelen F, 2002, ANAL CHEM, V74, P4788, DOI 10.1021/ac0200771
   Klosova K, 2011, CURR NANOSCI, V7, P984, DOI 10.2174/157341311798220529                                                      
   Krejcova L., 2013, INT J ELECT IN PRESS
   Krejcova L., 2013, CHROMATOGRA IN PRESS
   Krejcova L, 2012, ELECTROPHORESIS, V33, P3195, DOI 10.1002/elps.201200304
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Lei KF, 2013, RECENT PAT NANOTECH, V7, P81
   Liu HY, 2008, SENSOR ACTUAT B-CHEM, V128, P414, DOI 10.1016/j.snb.2007.06.028
   Liu J, 2011, CURR MED CHEM, V18, P4117, DOI 10.2174/092986711797189619                                                      
   Liu KK, 2010, SENSORS-BASEL, V10, P6623, DOI 10.3390/s100706623
   LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001                                                             
   Majzlik P, 2011, INT J ELECTROCHEM SC, V6, P2171
   Marrubini G, 2012, J CHROMATOGR A, V1249, P8, DOI 10.1016/j.chroma.2012.06.015
   Ng AHC, 2012, ANAL CHEM, V84, P8805, DOI 10.1021/ac3020627
   Oliveira-Brett AM, 2004, ANAL BIOCHEM, V332, P321, DOI 10.1016/j.ab.2004.06.021
   Palchetti I, 2012, ANAL BIOANAL CHEM, V402, P3103, DOI 10.1007/s00216-012-5769-1
   Prasek J., 2011, NANOSCALE RES LETT, V6, P1
   Pumera M, 2007, SENSOR ACTUAT B-CHEM, V123, P1195, DOI 10.1016/j.snb.2006.11.016
   Pumera M, 2007, ELECTROPHORESIS, V28, P1274, DOI 10.1002/elps.200600632
   Ramadan Q, 2012, MICROFLUID NANOFLUID, V13, P529, DOI 10.1007/s10404-012-1041-4
   Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242
   Sakudo A, 2011, NEUROSCI LETT, V494, P237, DOI 10.1016/j.neulet.2011.03.023
   Sambrook J, 1989, MOL CLONING LAB MANU
   Shahrokhian S, 2012, BIOELECTROCHEMISTRY, V86, P78, DOI 10.1016/j.bioelechem.2012.02.004
   Shang FJ, 2012, ELECTROPHORESIS, V33, P105, DOI 10.1002/elps.201100454
   Shim TS, 2013, PART PART SYST CHAR, V30, P9, DOI 10.1002/ppsc.201200044
   SHIRAISHI H, 1993, BIOELECTROCH BIOENER, V31, P203, DOI 10.1016/0302-4598(93)80008-I
   Song KM, 2012, SENSORS-BASEL, V12, P612, DOI 10.3390/s120100612
   Song YP, 2012, PROG CHEM, V24, P1665
   Tang C, 2009, ANAL CHIM ACTA, V636, P19, DOI 10.1016/j.aca.2009.01.055
   Taube R., 2008, PLOS ONE, V3, P1
   Vaculovicova M., 2013, ELECTROPHOR IN PRESS
   Wang HS, 2002, ANAL CHIM ACTA, V461, P243, DOI 10.1016/S0003-2670(02)00297-0                                                   
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang J, 2010, ELECTROCHIM ACTA, V55, P4436, DOI 10.1016/j.electacta.2010.02.078
   Wang ZZ, 2012, MICROCHIM ACTA, V179, P227, DOI 10.1007/s00604-012-0874-6
   Yumak T, 2011, COLLOID SURFACE B, V86, P397, DOI 10.1016/j.colsurfb.2011.04.030
   Zhang XY, 2012, J APPL ELECTROCHEM, V42, P375, DOI 10.1007/s10800-012-0407-3
   Zitka O, 2011, ELECTROPHORESIS, V32, P3207, DOI 10.1002/elps.201100430
NR 57
TC 6
Z9 6
U1 6
U2 45
PU ESG
PI BELGRADE
PA BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA
SN 1452-3981
J9 INT J ELECTROCHEM SC
JI Int. J. Electrochem. Sci.
PD DEC
PY 2013
VL 8
IS 12
BP 12628
EP 12642
PG 15
WC Electrochemistry
SC Electrochemistry
GA 251WA
UT WOS:000326961400020
DA 2018-01-05
ER

PT J
AU Schon, A
   Brown, RK
   Hutchins, BM
   Freire, E
AF Schoen, Arne
   Brown, Richard K.
   Hutchins, Burleigh M.
   Freire, Ernesto
TI Ligand binding analysis and screening by chemical denaturation shift
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Ligand binding analysis; Chemical denaturation
ID GUANIDINE-HYDROCHLORIDE DENATURATION; DIFFERENTIAL SCANNING CALORIMETRY;
   LINEAR EXTRAPOLATION METHOD; HIV-1 PROTEASE INHIBITION;
   CARBONIC-ANHYDRASE; ALPHA-CHYMOTRYPSIN; ENTRY INHIBITORS; DRUG
   DISCOVERY; STABILITY; PROTEINS
AB The identification of small molecule ligands is an important first step in drug development, especially drugs that target proteins with no intrinsic activity. Toward this goal, it is important to have access to technologies that are able to measure binding affinities for a large number of potential ligands in a fast and accurate way. Because ligand binding stabilizes the protein structure in a manner dependent on concentration and binding affinity, the magnitude of the protein stabilization effect elicited by binding can be used to identify and characterize ligands. For example, the shift in protein denaturation temperature (T-m shift) has become a popular approach to identify potential ligands. However, T-m shifts cannot be readily transformed into binding affinities, and the ligand rank order obtained at denaturation temperatures (>= 60 degrees C) does not necessarily coincide with the rank order at physiological temperature. An alternative approach is the use of chemical denaturation, which can be implemented at any temperature. Chemical denaturation shifts allow accurate determination of binding affinities with a surprisingly wide dynamic range (high micromolar to sub nanomolar) and in situations where binding changes the cooperativity of the unfolding transition. In this article, we develop the basic analytical equations and provide several experimental examples. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
   [Brown, Richard K.; Hutchins, Burleigh M.] AVIA Biosyst, East Falmouth, MA 02536 USA.
RP Freire, E (reprint author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
EM ef@jhu.edu
FU National Institutes of Health [GM056550, GM096751]; National Science
   Foundation [MCB-1157506]
FX This work was supported by grants from the National Institutes of Health
   (GM056550 to E.F. and GM096751 to R.K.B.) and from the National Science
   Foundation (MCB-1157506 to E.F.).
CR BHAT TN, 1994, NAT STRUCT BIOL, V1, P552, DOI 10.1038/nsb0894-552
   BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015
   BRANDTS JF, 1970, BIOCHEMISTRY-US, V9, P1038, DOI 10.1021/bi00806a045
   BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024                                                             
   Brower ET, 2010, BIOCHEMISTRY-US, V49, P2359, DOI 10.1021/bi1000933
   Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999
   D'Auria S, 2005, REV FLUORESCENCE, V2, P25
   DELPINO IMP, 1992, BIOCHEMISTRY-US, V31, P11196
   Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027
   Freire E, 2001, Methods Mol Biol, V168, P37
   Freire E, 2013, DRUG DISCOV TODAY, V18, P1007, DOI 10.1016/j.drudis.2013.06.005
   Gaudet M, 2010, PROTEIN SCI, V19, P1544, DOI 10.1002/pro.433
   GREENE RF, 1974, J BIOL CHEM, V249, P5388
   Hawe A, 2008, PHARM RES-DORDR, V25, P1487, DOI 10.1007/s11095-007-9516-9
   Kawasaki Y, 2010, CHEM BIOL DRUG DES, V75, P143, DOI 10.1111/j.1747-0285.2009.00921.x
   Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031
   Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521
   Luque I, 2002, ANNU REV BIOPH BIOM, V31, P235, DOI 10.1146/annurev.biophys.31.082901.134215
   Mahendrarajah K, 2011, ANAL BIOCHEM, V411, P155, DOI 10.1016/j.ab.2010.12.001
   Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v                                                               
   MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020                                                          
   PACE CN, 1980, J BIOL CHEM, V255, P3862
   PACE CN, 1992, BIOCHEMISTRY-US, V31, P2728, DOI 10.1021/bi00125a013
   Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922
   Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X
   SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O
   SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014
   Schon A, 2006, BIOCHEMISTRY-US, V45, P10973, DOI 10.1021/bi061193r
   STRAUME M, 1992, ANAL BIOCHEM, V203, P259, DOI 10.1016/0003-2697(92)90311-T
   Temperini C, 2009, BIOORGAN MED CHEM, V17, P1214, DOI 10.1016/j.bmc.2008.12.023
   Todd MJ, 2000, BIOCHEMISTRY-US, V39, P11876, DOI 10.1021/bi001013s
   WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3
   WYMAN J, 1948, ADV PROTEIN CHEM, V4, P407, DOI 10.1016/S0065-3233(08)60011-X
   Wyman J., 1990, BINDING LINKAGE FUNC
   Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008
NR 35
TC 15
Z9 15
U1 0
U2 26
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD DEC 1
PY 2013
VL 443
IS 1
BP 52
EP 57
DI 10.1016/j.ab.2013.08.015
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 242CB
UT WOS:000326213900009
PM 23994566
OA green_accepted
DA 2018-01-05
ER

PT J
AU Lau, ML
   Lau, KT
   Ku, H
   Cardona, F
   Lee, JH
AF Lau, Mei-ling
   Lau, Kin-tak
   Ku, Harry
   Cardona, Francisco
   Lee, Joong-Hee
TI Analysis of heat-treated bovine cortical bone by thermal gravimetric and
   nanoindentation
SO COMPOSITES PART B-ENGINEERING
LA English
DT Article
DE Bovine cortical bone; Nano-structures; Mechanical properties;
   Non-destructive testing; Thermal analysis
ID MECHANICAL-PROPERTIES; ELASTIC PROPERTIES; I COLLAGEN; FRACTURE;
   TOUGHNESS; BEHAVIOR; HARDNESS; MODULUS; FEMUR
AB Xenograft bone has been widely used as a bone grafting material because it gains advantages in biological and mechanical properties as compare with the use of an allograft bone. Heat-treatment of bone is recognized as one of the simple and practical methods to lower the human immunodeficiency virus (HIV) infection and overcome the risks of rejection and disease transfer during the bone transplantation. Therefore, understanding the change of bone's organic matrix after heat treatment has become a significant topic. In this study, thermal gravimetric analysis (TGA) was used to investigate the condition of organic constituents of a bovine cortical bone. In order to well characterize the microstructural and mechanical property of the bone after heat treatment, nanoindention technique was also employed to measure the localized elastic modulus (E) and hardness (H) of its interstitial lamellae and osteons lamellae at the temperatures of 23 degrees C (RT), 37 degrees C, 90 degrees C, 120 degrees C and 160 degrees C, respectively.
   The TGA results demonstrated that heat-treated bones had three stages of weight loss. The first stage was the loss of water, which started from RT to 160 degrees C. Follow by a weight loss of organic constituents starting from 200 degrees C to 600 degrees C. Upon reaching 600 degrees C, the organic constituents were decomposed and mineral phase loss started taking place until 850 degrees C. From the nanoindentation results, it showed the values of E and H measured for the interstitial lamellae were higher than that of the osteons lamellae. This phenomenon indicates that the interstitial lamellae are stiffer and easy to be mineralized than osteons lamellae. For a specimen heat-treated at 90 degrees C, the values of E and H of interstitial lamellae and osteons lamellae were similar to a non-heat-treated specimen. For a specimen heat-treated at 120 degrees C, its interstitial lamellae had higher E and H values than osteons lamellae. When a specimen was heat-treated at 160 degrees C, both interstitial lamellae and osteons lamellae demonstrated a slight decrease of their E and H values. An ANOVA statistical analysis was used to analyze the difference in elastic properties and hardness in various temperature ranges. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Lau, Mei-ling; Lau, Kin-tak; Ku, Harry; Cardona, Francisco] Univ So Queensland, Ctr Excellence Engn Fibre Composites, Fac Engn & Surveying, Toowoomba, Qld 4350, Australia.
   [Lau, Kin-tak] Hong Kong Polytech Univ, Dept Mech Engn, Kowloon, Hong Kong, Peoples R China.
   [Lee, Joong-Hee] Chonbuk Natl Univ, Dept BIN Fus Technol, Chonju, South Korea.
RP Lau, KT (reprint author), Univ So Queensland, Ctr Excellence Engn Fibre Composites, Fac Engn & Surveying, Toowoomba, Qld 4350, Australia.
EM mmktlau@polyu.edu.hk
RI Lee, Joong Hee/D-1643-2011
OI LAU, Kin Tak/0000-0001-5138-6079
FU Centre of Excellence in Engineered Fibre Composites, The University of
   southern Queensland, Australia; Hong Kong Polytechnic University
FX This project is supported by the Centre of Excellence in Engineered
   Fibre Composites, The University of southern Queensland, Australia and
   The Hong Kong Polytechnic University.
CR Behari J., 2009, BIOPHYSICAL BONE BEH
   Catanese J, 1999, J BIOMED MATER RES, V45, P327, DOI 10.1002/(SICI)1097-4636(19990615)45:4<327::AID-JBM7>3.3.CO;2-C
   CURREY JD, 1995, BIOMATERIALS, V16, P1267, DOI 10.1016/0142-9612(95)98135-2
   Ebenstein DM, 2006, NANO TODAY, V1, P26, DOI 10.1016/S1748-0132(06)70077-9                                                   
   Fan Z, 2002, J ORTHOPAED RES, V20, P806, DOI 10.1016/S0736-0266(01)00186-3                                                   
   Fantner GE, 2004, BONE, V35, P1013, DOI 10.1016/j.bone.2004.05.027
   Hengsberger S, 2002, BONE, V30, P178, DOI 10.1016/S8756-3282(01)00624-X                                                   
   Hoc T, 2006, BONE, V38, P466, DOI 10.1016/j.bone.2005.09.017
   Hoffler CE, 2000, BONE, V26, P603, DOI 10.1016/S8756-3282(00)00268-4
   Jepsen KJ, 1997, J BIOMECH, V30, P1141, DOI 10.1016/S0021-9290(97)00088-2
   Ji BH, 2006, COMPOS SCI TECHNOL, V66, P1212, DOI 10.1016/j.compscitech.2005.10.017
   Khan K, 2001, HUMAN KINET, P200
   Labastida-Polito A, 2009, J APPL BIOMATER BIOM, V7, P200
   Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099
   Lozano LF, 2003, J MATER SCI, V38, P4777, DOI 10.1023/A:1027483220584
   Martin R. B., 1998, SKELETAL TISSUE MECH
   Nalla RK, 2003, NAT MATER, V2, P164, DOI 10.1038/nmat832
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   Ooi CY, 2007, CERAM INT, V33, P1171, DOI 10.1016/j.ceramint.2006.04.001
   Oxlund H., 1995, BONE S, V17, p365S
   Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142-9612(97)00073-2
   Rho JY, 1999, J MATER SCI-MATER M, V10, P485, DOI 10.1023/A:1008901109705
   Rho JY, 1999, BONE, V25, P295, DOI 10.1016/S8756-3282(99)00163-5                                                   
   Rho JY, 1998, MED ENG PHYS, V20, P92, DOI 10.1016/S1350-4533(98)00007-1
   Shin S, 2005, ARCH ORTHOP TRAUM SU, V125, P1, DOI 10.1007/s00402-004-0746-6
   Todoh M, 2008, P ICBME 2008, V23, P2034
   Wang X, 1999, 45 ANN M, P782
   Wang XD, 2000, CLIN ORTHOP RELAT R, P228
   Wang XD, 2001, J ORTHOPAED RES, V19, P1021, DOI 10.1016/S0736-0266(01)00047-X                                                   
   Wang XJ, 2006, T NONFERR METAL SOC, V16, pS744, DOI 10.1016/S1003-6326(06)60293-8                                                   
   Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271                                                 
   Yan JH, 2008, J BIOMECH, V41, P1929, DOI 10.1016/j.jbiomech.2008.03.037
   Zioupos P, 1999, J BIOMED MATER RES, V45, P108, DOI 10.1002/(SICI)1097-4636(199905)45:2<108::AID-JBM5>3.3.CO;2-1
NR 33
TC 5
Z9 5
U1 1
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-8368
J9 COMPOS PART B-ENG
JI Compos. Pt. B-Eng.
PD DEC
PY 2013
VL 55
BP 447
EP 452
DI 10.1016/j.compositesb.2013.06.027
PG 6
WC Engineering, Multidisciplinary; Materials Science, Composites
SC Engineering; Materials Science
GA 229XT
UT WOS:000325301900051
DA 2018-01-05
ER

PT J
AU Andrade, F
   Rafael, D
   Videira, M
   Ferreira, D
   Sosnik, A
   Sarmento, B
AF Andrade, Fernando
   Rafael, Diana
   Videira, Mafalda
   Ferreira, Domingos
   Sosnik, Alejandro
   Sarmento, Bruno
TI Nanotechnology and pulmonary delivery to overcome resistance in
   infectious diseases
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nanoparticles; Inhalation; Drug resistance; Tuberculosis; Respiratory
   infections
ID TUFTSIN-BEARING LIPOSOMES; AEROSOLIZED NANOSTRUCTURED ITRACONAZOLE;
   RESPIRATORY-TRACT INFECTIONS; ANTITUBERCULAR DRUG CARRIERS; ALVEOLAR
   MACROPHAGES; AMPHOTERICIN-B; IN-VITRO; EXPERIMENTAL TUBERCULOSIS;
   THERAPEUTIC EFFECTIVENESS; PSEUDOMONAS-AERUGINOSA
AB Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations.
   Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic.
   Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Andrade, Fernando; Ferreira, Domingos] Univ Porto, Fac Pharm, Lab Pharmaceut Technol, P-4050313 Oporto, Portugal.
   [Rafael, Diana; Videira, Mafalda] Univ Lisbon, Sch Pharm, IMed UL Res Inst Med & Pharmaceut Sci, P-1649003 Lisbon, Portugal.
   [Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1113 Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, IL-32000 Haifa, Israel.
   [Sarmento, Bruno] Inst Super Ciencias Saude Norte, Hlth Sci Res Ctr, CICS, P-4585116 Gandra, Portugal.
   [Sarmento, Bruno] New Therapies Grp, INEB Inst Engn Biomed, P-4150180 Oporto, Portugal.
RP Andrade, F (reprint author), Univ Porto, Fac Pharm, Lab Pharmaceut Technol, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.
EM fersilandrade@gmail.com; bruno.sarmento@ineb.up.pt
RI iMed.ULisboa, iMed.ULisboa/C-6292-2014; Sosnik, Alejandro/O-7059-2014;
   Sarmento, Bruno/J-6265-2013; Andrade, Fernanda/F-3272-2010;
   iMed.ULisboa, PharmRegSci/B-5723-2014; Videira, Mafalda/J-7563-2012;
   iMed.ULisboa, InTraCellADD/B-4826-2014; Ferreira, Domingos/M-7978-2017
OI Sosnik, Alejandro/0000-0003-4704-4599; Sarmento,
   Bruno/0000-0001-5763-7553; Andrade, Fernanda/0000-0002-4947-2346;
   iMed.ULisboa, PharmRegSci/0000-0003-0910-7245; Videira,
   Mafalda/0000-0003-4184-3963; Ferreira, Domingos/0000-0001-6200-7169
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BD/73062/2010]
FX Fernanda Andrade gratefully acknowledges the Fundacao para a Ciencia e a
   Tecnologia (FCT), Portugal, for financial support (SFRH/BD/73062/2010).
   FA, DF, AS and BS thank the FCT (Portugal)/Ministry of Science,
   Technology and Innovation (MINCyT, Argentina) exchange program granted
   for the period 2010-2011. There is no potential conflict of interest to
   be reported.
CR Abdulla JMA, 2010, AAPS PHARMSCITECH, V11, P663, DOI 10.1208/s12249-010-9428-6
   AGARWAL A, 1994, ANTIMICROB AGENTS CH, V38, P588, DOI 10.1128/AAC.38.3.588                                                            
   Agrawal AK, 2002, J DRUG TARGET, V10, P41, DOI 10.1080/10611860290007513
   Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947
   Alexander BD, 2011, PHARM DEV TECHNOL, V16, P577, DOI 10.3109/10837450.2011.591803
   Alipour M, 2008, INT J PHARM, V355, P293, DOI 10.1016/j.ijpharm.2007.11.035
   Alvarez CA, 2007, J INFECTION, V55, P68, DOI 10.1016/j.jinf.2007.01.014
   Anderson Paula J, 2005, Respir Care, V50, P1139
   Andrade F., 2011, DRUG DELIV LETT, V1, P171
   Andrade F, 2011, NANOMEDICINE-UK, V6, P123, DOI 10.2217/NNM.10.143
   Bailey MM, 2008, LANGMUIR, V24, P13614, DOI 10.1021/la802405p
   Bailey MM, 2009, MED RES REV, V29, P196, DOI 10.1002/med.20140
   Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002
   BCC Research, NAN MED APPL GLOB MA
   Beckham JD, 2005, J INFECTION, V50, P322, DOI 10.1016/j.jinf.2004.07.011
   BERNSTEIN DI, 1988, ANTIMICROB AGENTS CH, V32, P761, DOI 10.1128/AAC.32.5.761                                                            
   Bosetti R, 2011, NANOMEDICINE-UK, V6, P747, DOI [10.2217/nnm.11.55, 10.2217/NNM.11.55]
   Carvalho TC, 2011, INT J PHARMACEUT, V406, P1, DOI 10.1016/j.ijpharm.2010.12.040
   Centers for Disease Control and Prevention, ANT ANT RES
   Changsan N, 2009, J PHARM SCI-US, V98, P628, DOI 10.1002/jps.21441
   Chono S, 2008, J CONTROL RELEASE, V127, P50, DOI 10.1016/j.jconrel.2007.12.011
   Crowder Timothy M, 2005, Expert Opin Drug Deliv, V2, P579, DOI 10.1517/17425247.2.3.579
   Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576
   de Galan BE, 2006, NETH J MED, V64, P319
   Desai TR, 2003, EUR J PHARM SCI, V20, P459, DOI 10.1016/j.ejps.2003.09.008
   Dessanges JF, 2001, J AEROSOL MED, V14, P65, DOI 10.1089/08942680152007918                                                       
   Dhillon J, 2001, J ANTIMICROB CHEMOTH, V48, P869, DOI 10.1093/jac/48.6.869
   Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9
   Donovan MJ, 2012, J PHARM SCI-US, V101, P1097, DOI 10.1002/jps.22824
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   GANGADHARAM PRJ, 1995, ANTIMICROB AGENTS CH, V39, P725, DOI 10.1128/AAC.39.3.725                                                            
   Garcia-Contreras L, 2007, ANTIMICROB AGENTS CH, V51, P2830, DOI 10.1128/AAC.01164-06
   Geller DE, 2011, AM J RESP CRIT CARE, V183, P1510, DOI 10.1164/rccm.201008-1293OC
   Gilani K, 2011, J PHARM SCI-US, V100, P252, DOI 10.1002/jps.22274
   Grenha A, 2007, EUR J PHARM SCI, V31, P73, DOI 10.1016/j.ejps.2007.02.008
   Gupta CM, 2005, METHOD ENZYMOL, V391, P291, DOI 10.1016/S0076-6879(05)91016-1                                                   
   Hamburg MA, 2012, SCIENCE, V336, P299, DOI 10.1126/science.1205441
   Heinemann Lutz, 2008, J Diabetes Sci Technol, V2, P518
   Hindi KM, 2009, BIOMATERIALS, V30, P3771, DOI 10.1016/j.biomaterials.2009.03.044
   Hoeben BJ, 2006, ANTIMICROB AGENTS CH, V50, P1552, DOI 10.1128/AAC.50.4.1552-1554.2006
   Hokey DA, 2011, TUBERCULOSIS, V91, P82, DOI 10.1016/j.tube.2010.09.007
   Huland E, 2003, FOLIA BIOL-PRAGUE, V49, P183
   HUMPHREY J H, 1946, Lancet, V2, P221
   HURST A, 1946, Rocky Mt Med J, V43, P219
   Hwang SM, 2008, J CONTROL RELEASE, V129, P100, DOI 10.1016/j.jconrel.2008.04.009
   ICH S3A, 1994, S3A ICH
   [Anonymous], 2009, M3R2 ICH
   Jartti T, 2012, CURR OPIN PULM MED, V18, P271, DOI 10.1097/MCP.0b013e328351f8d4
   Jones LH, 2011, BIOORG MED CHEM LETT, V21, P2759, DOI 10.1016/j.bmcl.2010.10.132
   Justo OR, 2005, J PHARM PHARMACOL, V57, P23, DOI 10.1211/0022357055092
   Justo OR, 2003, DRUG DELIV, V10, P201, DOI 10.1080/10717540390215627
   KNOTT FA, 1946, ARCH DIS CHILD, V21, P16, DOI 10.1136/adc.21.105.16                                                           
   Kriksunov LB., 2008, INHALER
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P600, DOI 10.1046/j.1365-2125.2003.01893.x
   Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x
   Laniado-Laborin R, 2009, REV IBEROAM MICOL, V26, P223, DOI 10.1016/j.riam.2009.06.003
   Leitzke S, 1998, ANTIMICROB AGENTS CH, V42, P459
   Limper AH, 2011, AM J RESP CRIT CARE, V183, P96, DOI 10.1164/rccm.2008-740ST
   Lu DM, 2010, AAPS J, V12, P338, DOI 10.1208/s12248-010-9193-1
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Marier JF, 2003, J ANTIMICROB CHEMOTH, V52, P247, DOI 10.1093/jac/dkg317
   Marier JF, 2002, ANTIMICROB AGENTS CH, V46, P3776, DOI 10.1128/AAC.46.12.3776-3781.2002
   MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171                                                          
   McConville JT, 2006, PHARM RES, V23, P901, DOI 10.1007/s11095-006-9904-6
   Mohammad RA, 2006, ANN PHARMACOTHER, V40, P2148, DOI 10.1345/aph.1G477
   Moretton M.A., 2013, J BIOMED NANOTECHNOL, V9, P1
   Mura S, 2011, INT J NANOMED, V6, P2591, DOI 10.2147/IJN.S24552
   Muttil P, 2009, PHARM RES-DORD, V26, P2401, DOI 10.1007/s11095-009-9957-4
   O'Riordan T G, 2000, Respir Care, V45, P836
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Ohashi K, 2009, J CONTROL RELEASE, V135, P19, DOI 10.1016/j.jconrel.2008.11.027
   Omri A, 2002, BIOCHEM PHARMACOL, V64, P1407, DOI 10.1016/S0006-2952(02)01346-1
   ONYEJI CO, 1994, INFECTION, V22, P338, DOI 10.1007/BF01715542
   OWAIS M, 1993, FEBS LETT, V326, P56, DOI 10.1016/0014-5793(93)81760-W
   Pandey R, 2005, TUBERCULOSIS, V85, P227, DOI 10.1016/j.tube.2004.11.003
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477
   Petersen EA, 1996, J ANTIMICROB CHEMOTH, V38, P819
   Pilcer G, 2010, INT J PHARMACEUT, V392, P1, DOI 10.1016/j.ijpharm.2010.03.017
   Pilcer G, 2009, J PHARM SCI-US, V98, P1463, DOI 10.1002/jps.21545
   Pimentel D., 2009, 1 POSTGR IMED UL STU
   Pinheiro M, 2011, NANOMEDICINE-UK, V6, P1413, DOI [10.2217/NNM.11.122, 10.2217/nnm.11.122]
   Pinto-Alphandary H, 2000, INT J ANTIMICROB AG, V13, P155, DOI 10.1016/S0924-8579(99)00121-1
   Ragle BE, 2010, ANTIMICROB AGENTS CH, V54, P298, DOI 10.1128/AAC.00973-09
   Rastogi Rachna, 2006, Current Drug Delivery, V3, P121, DOI 10.2174/156720106775197448
   Rello J, 2003, CRIT CARE MED, V31, P2544, DOI 10.1097/01.CCM.0000089928.84326.D2
   Rosenthal LA, 2010, J ALLERGY CLIN IMMUN, V125, P1212, DOI 10.1016/j.jaci.2010.04.002
   Roy I, 2010, NANOMED-NANOTECHNOL, V6, P237, DOI 10.1016/j.nano.2009.07.001
   Rytting E, 2008, EXPERT OPIN DRUG DEL, V5, P629, DOI [10.1517/17425247.5.6.629 , 10.1517/17425240802141568]
   Sanders Mark, 2007, Prim Care Respir J, V16, P71, DOI 10.3132/pcrj.2007.00017
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Sharma A, 2004, J ANTIMICROB CHEMOTH, V54, P761, DOI 10.1093/jac/dkh411
   Smola M, 2008, INT J NANOMED, V3, P1
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   SOUTHWELL N, 1946, Lancet, V2, P225
   Suarez S, 2001, J ANTIMICROB CHEMOTH, V48, P431, DOI 10.1093/jac/48.3.431
   Suarez S, 2001, PHARMACEUT RES, V18, P1315, DOI 10.1023/A:1013094112861
   Sweeney LG, 2005, INT J PHARM, V305, P180, DOI 10.1016/j.ijpharm.2005.09.010
   SWENSON CE, 1988, CRIT REV MICROBIOL, V15, pS1, DOI 10.3109/10408418809104463                                                       
   Telko Martin J, 2005, Respir Care, V50, P1209
   Tewes F, 2008, J CONTROL RELEASE, V129, P93, DOI 10.1016/j.jconrel.2008.04.007
   TOMIOKA H, 1991, AM REV RESPIR DIS, V144, P575, DOI 10.1164/ajrccm/144.3_Pt_1.575                                                   
   U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Guidance for Industry: Nonclinical studies for the safety evaluation of pharmaceutical excipients Office of Training and Communication Division of Drug Information, 2005, GUID IND NONCL STUD
   U.S. Department of Health and Human Services Food and Drug Administration, 2011, GUID IND CONS WHETH
   Valle MJDJ, 2008, J BIOMAT SCI-POLYM E, V19, P387, DOI 10.1163/156856208783721038
   Vaughn JM, 2007, INT J PHARM, V338, P219, DOI 10.1016/j.ijpharm.2007.02.014
   Vaughn JM, 2006, EUR J PHARM BIOPHARM, V63, P95, DOI 10.1016/j.ejpb.2006.01.006
   Videira M, 2012, NANOMED-NANOTECHNOL, V8, P1208, DOI 10.1016/j.nano.2011.12.007
   VLADIMIRSKY MA, 1982, BIOMED PHARMACOTHER, V36, P375
   Vyas SP, 2005, INT J PHARM, V296, P12, DOI 10.1016/j.ijpharm.2005.02.003
   Vyas SP, 2004, INT J PHARM, V269, P37, DOI 10.1016/j.ijpharm.2003.08.017
   Vyas SP, 2007, EXPERT OPIN DRUG DEL, V4, P95, DOI 10.1517/17425247.4.2.95
   Wakefield K., 2001, PNEUMATIC BREATH ACT
   World Health Organization and UNICEF, 2009, GLOB ACT PLAN PREV C
   WHO, ANT RES
   World Health Organization Geneva, 2012, GLOB TUB CONTR WHO R
   Organization WH, TOP 10 CAUS DEATH 10
   Williams III R.O., 2009, TREATMENT PULMONARY
   Wong JP, 2003, J CONTROL RELEASE, V92, P265, DOI 10.1016/S0168-3659(03)00358-4
   Yang W, 2008, INT J PHARM, V361, P177, DOI 10.1016/j.ijpharm.2008.05.003
   Young PM, 2002, J PHARM PHARMACOL, V54, P1339, DOI 10.1211/002235702760345400
   Zahoor A, 2005, INT J ANTIMICROB AG, V26, P298, DOI 10.1016/j.ijantimicag.2005.07.012
   Zaru M, 2007, EUR J PHARM BIOPHARM, V67, P655, DOI 10.1016/j.ejpb.2007.04.005
   Zaru M, 2009, J LIPOSOME RES, V19, P68, DOI 10.1080/08982100802610835
   Zaru M, 2009, COLLOID SURFACE B, V71, P88, DOI 10.1016/j.colsurfb.2009.01.010
   Zhang L, 2010, CURR MED CHEM, V17, P585, DOI 10.2174/092986710790416290                                                      
   Zumla A, 2012, CURR OPIN PULM MED, V18, P173, DOI 10.1097/MCP.0b013e328351f7d8
NR 128
TC 56
Z9 56
U1 6
U2 97
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD NOV 30
PY 2013
VL 65
IS 13-14
BP 1816
EP 1827
DI 10.1016/j.addr.2013.07.020
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 270HM
UT WOS:000328309500011
PM 23932923
DA 2018-01-05
ER

PT J
AU Sosnik, A
AF Sosnik, Alejandro
TI Reversal of multidrug resistance by the inhibition of ATP-binding
   cassette pumps employing "Generally Recognized As Safe" (GRAS)
   nanopharmaceuticals: A review
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE ATP-binding casette superfamily pumps (ABCs); Multidrug resistance;
   Cancer; Infectious diseases; "Generally Recognized As Safe" (GRAS);
   pharmaceutical excipients; Nanopharmaceuticals; Polymeric amphiphiles
ID PLURONIC BLOCK-COPOLYMERS; CACO-2 CELL MONOLAYERS; GLYCOPROTEIN-MEDIATED
   EFFLUX; INTESTINAL P-GLYCOPROTEIN; IN-VIVO EVALUATION; AMPHIPHILIC
   DIBLOCK COPOLYMERS; ABC TRANSPORTER SUPERFAMILY; ORAL PACLITAXEL
   ABSORPTION; OXIDE) TRIBLOCK COPOLYMERS; HIV-1 PROTEASE INHIBITORS
AB Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance (MDR) in cancer and infectious diseases (e.g., viral hepatitis and the human immunodeficiency virus) and is associated with therapeutic failure. Since their discovery, ABCs have emerged as attractive therapeutic targets and the search of compounds that inhibit their genetic expression and/or their functional activity has gained growing interest. Different generations of pharmacological ABC inhibitors have been explored over the last four decades to address resistance in cancer, though clinical results have been somehow disappointing. "Generally Recognized As Safe" (GRAS) is a U.S. Food and Drug Administration designation for substances that are accepted as safe for addition in food. Far from being "inert", some amphiphilic excipients used in the production of pharmaceutical products have been shown to inhibit the activity of ABCs in MDR tumors, emerging as a clinically translatable approach to overcome resistance. The present article initially overviews the classification, structure and function of the different ABCs, with emphasis on those pumps related to drug resistance. Then, the different attempts to capitalize on the activity of GRAS nanopharmaceuticals as ABC inhibitors are discussed. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1053 Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Technion Israel Inst Technol, Dept Mat Sci & Engn, IL-32000 Technion, Haifa, Israel.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1053 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
RI Sosnik, Alejandro/O-7059-2014
OI Sosnik, Alejandro/0000-0003-4704-4599
CR Agrawal SK, 2006, J CONTROL RELEASE, V112, P64, DOI 10.1016/j.jconrel.2005.12.024
   Alakhov V, 1999, COLLOID SURFACE B, V16, P113, DOI 10.1016/S0927-7765(99)00064-8                                                   
   Alakhov VY, 1996, BIOCONJUGATE CHEM, V7, P209, DOI 10.1021/bc950093n
   Alakhova DY, 2010, J CONTROL RELEASE, V142, P89, DOI 10.1016/j.jconrel.2009.09.026
   Albrecht C, 2007, PFLUG ARCH EUR J PHY, V453, P581, DOI 10.1007/s00424-006-0047-8
   ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009                                                             
   Allikmets R, 1998, CANCER RES, V58, P5337
   Alvarez-Lorenzo C, 2011, CURR DRUG TARGETS, V12, P1112, DOI 10.2174/138945011795906615                                                      
   Alvarez-Lorenzo C, 2007, EUR J PHARM BIOPHARM, V66, P244, DOI 10.1016/j.ejpb.2006.10.010
   Alvarez-Lorenzo C, 2010, NANOMEDICINE-UK, V5, P1371, DOI [10.2217/nnm.10.53, 10.2217/NNM.10.53]
   Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948
   Andrade F., 2011, INT J CARBOHYDR CHEM
   Arima H, 2004, PHARM RES, V21, P625, DOI 10.1023/B:PHAM.0000022409.27896.d4
   Augsburger L.L., 2006, ENCY PHARM TECHNOLOG
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Bachmeier CJ, 2005, PHARM RES, V22, P1259, DOI 10.1007/s11095-005-5271-y
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Batrakova EV, 2010, J CONTROL RELEASE, V143, P290, DOI 10.1016/j.jconrel.2010.01.004
   Batrakova EV, 2004, PHARM RES, V21, P2226, DOI 10.1007/s11095-004-7675-5
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Batrakova EV, 1996, BRIT J CANCER, V74, P1545, DOI 10.1038/bjc.1996.587                                                            
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Batrakova EV, 2003, PHARMACEUT RES, V20, P1581, DOI 10.1023/A:1026179132599
   Batrakova EV, 1998, PHARMACEUT RES, V15, P850, DOI 10.1023/A:1011964213024
   Batrakova EV, 2001, BRIT J CANCER, V85, P1987, DOI 10.1054/bjoc.2001.2165
   Batrakova EV, 2001, J PHARMACOL EXP THER, V296, P551
   Batrakova EV, 1998, PHARMACEUT RES, V15, P1525, DOI 10.1023/A:1011942814300                                                         
   Berger W, 2005, J CANCER RES CLIN, V131, P355, DOI 10.1007/s00432-004-0653-9
   Booth C, 2000, MACROMOL RAPID COMM, V21, P501, DOI 10.1002/1521-3927(20000601)21:9<501::AID-MARC501>3.0.CO;2-R                     
   Booth C, 2006, PHYS CHEM CHEM PHYS, V8, P3612, DOI 10.1039/b605367j
   Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055
   Brewster ME, 2007, ADV DRUG DELIVER REV, V59, P645, DOI 10.1016/j.addr.2007.05.012
   Bromberg L, 2003, J CONTROL RELEASE, V88, P11, DOI 10.1016/S0168-3659(02)00419-4
   Bromberg LE, 1998, ADV DRUG DELIVER REV, V31, P197, DOI 10.1016/S0169-409X(97)00121-X
   Burt HM, 1999, COLLOID SURFACE B, V16, P161, DOI 10.1016/S0927-7765(99)00067-3                                                   
   Calucci L, 2010, LANGMUIR, V26, P12890, DOI 10.1021/la101613b
   Cambon A, 2013, J CONTROL RELEASE, V167, P68, DOI 10.1016/j.jconrel.2013.01.010
   Candussio L, 2002, LIFE SCI, V71, P3109, DOI 10.1016/S0024-3205(02)02175-6
   Chang D, 2007, PHARM TECH, V31, P56
   Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2                                                   
   Chen ZS, 2011, FEBS J, V278, P3226, DOI 10.1111/j.1742-4658.2011.08235.x
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Choi JS, 2004, INT J PHARM, V280, P221, DOI 10.1016/j.ijpharm.2004.05.014
   Cohn D, 2006, BIOMATERIALS, V27, P1718, DOI 10.1016/j.biomaterials.2005.10.035
   Cohn D, 2005, BIOMACROMOLECULES, V6, P1168, DOI 10.1021/bm0495250
   Cohn D, 2003, J MATER SCI-MATER M, V14, P175, DOI 10.1023/A:1022080115804
   COLE SPC, 1994, CANCER RES, V54, P5902
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704                                                         
   Collnot EM, 2006, J CONTROL RELEASE, V111, P35, DOI 10.1016/j.jconrel.2005.11.005
   Cooray HC, 2002, NEUROREPORT, V13, P2059, DOI 10.1097/00001756-200211150-00014                                                
   Couvreur P, 2006, PHARM RES, V23, P1417, DOI 10.1007/s11095-006-0284-8
   Cuestas ML, 2012, BIOORG MED CHEM LETT, V22, P6577, DOI 10.1016/j.bmcl.2012.09.012
   Cuestas ML, 2011, MOL PHARMACEUT, V8, P1152, DOI 10.1021/mp2000132
   Cuestas ML, 2010, PHARM RES-DORDR, V27, P1184, DOI 10.1007/s11095-010-0112-z
   Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3
   Danson S, 2004, BRIT J CANCER, V90, P2085, DOI 10.1038/sj.bjc.6601856
   Davidson AL, 2007, TRENDS MICROBIOL, V15, P448, DOI 10.1016/j.tim.2007.09.005
   Dean M, 2001, J LIPID RES, V42, P1007
   Dean M, 2005, METHOD ENZYMOL, V400, P409, DOI 10.1016/S0076-6879(05)00024-8
   Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R
   Dietrich CG, 2003, GUT, V52, P1788, DOI 10.1136/gut.52.12.1788
   Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012
   Dong J., 2003, COLLOID SURF A, V212, P91
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Dunnhaupt S, 2012, MOL PHARMACEUT, V9, P1331, DOI 10.1021/mp200598j
   Dumortier G, 2006, PHARM RES, V23, P2709, DOI 10.1007/s11095-006-9104-4
   Eckford PDW, 2008, BIOCHEMISTRY-US, V47, P13686, DOI 10.1021/bi801409r
   EMANUELE AD, 2004, J CONTROL RELEASE, V95, P447, DOI DOI 10.1016/J.JC0NREL.2003.12.006
   Estudante M, 2013, ADV DRUG DELIVER REV, V65, P1340, DOI 10.1016/j.addr.2012.09.042
   Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886
   Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262                                                          
   Fenyvesi F, 2008, EUR J PHARM SCI, V34, P236, DOI 10.1016/j.ejps.2008.04.005
   Fernandez-Tarrio M, 2007, J THERM ANAL CALORIM, V87, P171, DOI 10.1007/s10973-006-7834-5
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Ferry DR, 1996, EUR J CANCER, V32A, P1070, DOI 10.1016/0959-8049(96)00091-3
   Firestone MA, 2003, BIOMACROMOLECULES, V4, P1539, DOI 10.1021/bm034134r
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Foger F, 2008, J DRUG TARGET, V16, P149, DOI [10.1080/10611860701850130, 10.1080/10611860701850130 ]
   Foger F, 2006, BIOMATERIALS, V27, P5855, DOI 10.1016/j.biomaterials.2006.08.004
   Foger F, 2006, BIOMATERIALS, V27, P4250, DOI 10.1016/j.biomaterials.2006.03.033
   FOGER F, 2006, J DRUG TARGET, V15, P132
   Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327
   Franke RM, 2010, CURR PHARM DESIGN, V16, P220, DOI 10.2174/138161210790112683                                                      
   FRICHE E, 1990, CANCER COMMUN, V2, P297
   Garraway LA, 2002, EUR J CANCER, V38, P2337, DOI 10.1016/S0959-8049(02)00490-2                                                   
   Giliyar C., 2006, DRUG DELIV TECHNOL, V6, P57
   Giri N, 2008, DRUG METAB DISPOS, V36, P1476, DOI 10.1124/dmd.108.020974
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Gradauer K, 2013, J CONTROL RELEASE, V165, P207, DOI 10.1016/j.jconrel.2012.12.001
   Greindl M, 2009, EUR J PHARM BIOPHARM, V72, P561, DOI 10.1016/j.ejpb.2009.03.008
   Hara Y, 2011, J CLIN INVEST, V121, P2888, DOI 10.1172/JCI45023
   Harris J, 1997, ACS SYM SER, V680, P1
   Hartz AMS, 2011, CURR PHARM BIOTECHNO, V12, P656
   Haywood A, 2011, AUST PRESCR, V34, P112
   Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630
   Hill A, 2009, AIDS, V23, P2237, DOI 10.1097/QAD.0b013e328332c3a5
   Hochman JH, 2000, J PHARMACOL EXP THER, V292, P310
   Hosoya KI, 2009, PHARM RES-DORD, V26, P2055, DOI 10.1007/s11095-009-9930-2
   Hotta T, 1999, SURG TODAY, V29, P591, DOI 10.1007/BF02482982                                                              
   Hu SY, 2009, CLIN CANCER RES, V15, P6062, DOI 10.1158/1078-0432.CCR-09-0048
   Hugger ED, 2003, J PHARM SCI, V92, P21, DOI 10.1002/jps.10265
   Hugger ED, 2002, J PHARM SCI, V91, P1980, DOI 10.1002/jps.10175
   Hugger ED, 2002, J PHARM SCI, V91, P1991, DOI 10.1002/jps.10176
   HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0                                                                
   Iqbal J, 2010, J CONTROL RELEASE, V147, P62, DOI 10.1016/j.jconrel.2010.06.023
   Izzedine H, 2005, AIDS, V19, P455, DOI 10.1097/01.aids.0000162333.35686.4c
   Janvilisri T, 2005, BIOCHEM J, V385, P419, DOI 10.1042/BJ20040791                                                              
   Jekerle V, 2006, INT J CANCER, V119, P414, DOI 10.1002/ijc.21827
   Johnson BM, 2002, AAPS PHARMSCI, V4
   Jones K, 2001, AIDS, V15, P1353, DOI 10.1097/00002030-200107270-00004                                                
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9
   Kabanov AV, 2003, J CONTROL RELEASE, V91, P75, DOI 10.1016/S0168-3659(03)00211-6
   Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100
   Kaminski WE, 2006, BBA-MOL BASIS DIS, V1762, P510, DOI 10.1016/j.bbadis.2006.01.011
   Kaminski WE, 2001, BIOCHEM BIOPH RES CO, V285, P1295, DOI 10.1006/bbrc.2001.5326
   Kaye SB, 2008, J CLIN ONCOL, V26, P2616, DOI 10.1200/JCO.2008.16.2123
   Kelly RJ, 2011, CLIN CANCER RES, V17, P569, DOI 10.1158/1078-0432.CCR-10-1725
   Kibbe A. H., 2000, HDB PHARM EXCIPIENTS, P386
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kim TY, 2004, CLIN CANCER RES, V10, P3708, DOI 10.1158/1078-0432.CCR-03-0655
   KIRILLOVA GP, 1993, BIOTECHNOL APPL BIOC, V18, P329
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Krol M, 2010, POL J VET SCI, V13, P399
   Krylova OO, 2004, BIOCHEMISTRY-US, V43, P3696, DOI 10.1021/bi0357681
   Kuppens IELM, 2005, CANCER INVEST, V23, P443, DOI 10.1081/CNV-200058823
   Kuppens IELM, 2007, CLIN CANCER RES, V13, P3276, DOI 10.1158/1078-0432.CCR-06-2414
   Kurkalli BGS, 2010, CURR STEM CELL RES T, V5, P49, DOI 10.2174/157488810790442831
   Lee B, 2008, BIOMACROMOLECULES, V9, P1541, DOI 10.1021/bm701348r
   Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411                                                   
   Lhomme C, 2008, J CLIN ONCOL, V26, P2674, DOI 10.1200/JCO.2007.14.9807
   Liggins RT, 2002, ADV DRUG DELIVER REV, V54, P191, DOI 10.1016/S0169-409X(02)00016-9                                                   
   Lin YL, 2007, BIOL PHARM BULL, V30, P1301, DOI 10.1248/bpb.30.1301
   Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001
   Linton KJ, 2007, PHYSIOLOGY, V22, P122, DOI 10.1152/physiol.00046.2006
   Lipinski C. A., 2002, AM PHARM REV, V5, P82
   Lo YI, 2003, J CONTROL RELEASE, V90, P37, DOI 10.1016/S0168-3659(03)00163-9
   Locarnini S, 2006, J HEPATOL, V44, P422, DOI 10.1016/j.jhep.2005.11.036
   Loe DW, 1998, CANCER RES, V58, P5130
   Maliepaard M, 2001, CLIN CANCER RES, V7, P935
   Maliepaard M, 2001, CANCER RES, V61, P3458
   Melchior DL, 2012, J PHARMACOL TOX MET, V65, P64, DOI 10.1016/j.vascn.2012.02.002
   Melik-Nubarov NS, 1999, FEBS LETT, V446, P194, DOI 10.1016/S0014-5793(99)00208-2                                                   
   Miller DW, 1999, PHARMACEUT RES, V16, P396, DOI 10.1023/A:1018873702411                                                         
   Miller DW, 1997, BIOCONJUGATE CHEM, V8, P649, DOI 10.1021/bc970118d
   Mimeault M, 2009, STEM CELL BIOLOGY IN HEALTH AND DISEASE, P385, DOI 10.1007/978-90-481-3040-5_17
   Minko T, 2005, J CONTROL RELEASE, V105, P269, DOI 10.1016/j.jconrel.2005.03.019
   Mizuno N, 2007, DRUG METAB DISPOS, V35, P2045, DOI 10.1124/dmd.107.016352
   Modok S, 2006, CURR OPIN PHARMACOL, V6, P350, DOI 10.0116/j.coph.2006.01.009
   Mruk DD, 2011, TRENDS PHARMACOL SCI, V32, P99, DOI 10.1016/j.tips.2010.11.007
   Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285
   Najlah M, 2007, BIOCONJUGATE CHEM, V18, P937, DOI 10.1021/bc060325q
   Nerurkar MM, 1996, PHARMACEUT RES, V13, P528, DOI 10.1023/A:1016033702220
   Nobili S, 2012, MED RES REV, V32, P1220, DOI 10.1002/med.20239
   OKADA Y, 1988, CHEM PHARM BULL, V36, P2176
   Okada Y, 2012, CARBOHYD RES, V357, P68, DOI 10.1016/j.carres.2012.04.019
   Okada Y, 2011, CARBOHYD RES, V346, P1018, DOI 10.1016/j.carres.2011.02.023
   Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077
   Peroni R. N., 2010, 1 WORLD C NAN DRUG D
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Pluchino KM, 2012, DRUG RESIST UPDATE, V15, P98, DOI 10.1016/j.drup.2012.03.002
   Rahman S.R., 2011, DARU, V19, P83
   Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924                                                         
   Rapoport N, 2000, ARCH BIOCHEM BIOPHYS, V384, P100, DOI 10.1006/abbi.2000.2104
   Rappa G, 1997, CANCER RES, V57, P5232
   Reeve LE, 1997, DRUG TARG D, V7, P231
   Rege BD, 2002, EUR J PHARM SCI, V16, P237, DOI 10.1016/S0928-0987(02)00055-6
   Ribeiro A, 2012, J R SOC INTERFACE, V9, P2059, DOI 10.1098/rsif.2012.0102
   RIEHM H, 1972, CANCER RES, V32, P1195
   Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3                                                   
   Robey RW, 2008, BIOCHEM PHARMACOL, V75, P1302, DOI 10.1016/j.bcp.2007.12.001
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Robey RW, 2011, CURR PHARM BIOTECHNO, V12, P595
   Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003
   Robillard KR, 2012, J PHARMACOL EXP THER, V340, P96, DOI 10.1124/jpet.111.186916
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Ross DD, 2004, BEST PRACT RES CL HA, V17, P641, DOI 10.1016/j.beha.2004.08.014
   ROSS DD, 1994, BLOOD, V83, P1337
   Ruff P, 2009, CANCER CHEMOTH PHARM, V64, P763, DOI 10.1007/s00280-009-0925-9
   Sachs-Barrable K, 2008, ADV DRUG DELIVER REV, V60, P692, DOI 10.1016/j.addr.2007.08.042
   Sachs-Barrable K, 2007, J PHARM PHARM SCI, V10, P319
   Sakloetsakun D, 2011, DRUG DEV IND PHARM, V37, P648, DOI 10.3109/03639045.2010.534484
   Sarmento B., 2011, INT J CARBOHYDR CHEM
   Sarti F, 2010, EUR J PHARM BIOPHARM, V76, P421, DOI 10.1016/j.ejpb.2010.08.008
   Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2
   Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487                                                                   
   SCHUURHUIS GJ, 1990, BRIT J CANCER, V62, P591, DOI 10.1038/bjc.1990.335                                                            
   Shaik N, 2007, DRUG METAB DISPOS, V35, P2076, DOI 10.1124/dmd.107.017723
   Shaik N, 2009, J PHARM SCI-US, V98, P4170, DOI 10.1002/jps.21723
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x
   Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x
   Sharma AK, 2008, J CONTROL RELEASE, V131, P220, DOI 10.1016/j.jconrel.2008.07.031
   Sharom FJ, 2008, PHARMACOGENOMICS, V9, P105, DOI 10.2217/14622416,9.1.105
   Shen F, 2008, J PHARMACOL EXP THER, V324, P95, DOI 10.1124/jpet.107.127704
   Shen Q, 2006, INT J PHARM, V313, P49, DOI 10.1016/j.ijpharm.2006.01.020
   Shen Q, 2008, J PHARM PHARMACOL, V60, P1633, DOI 10.1211/jpp/60.12.0009
   Shono Y, 2004, J PHARM SCI-US, V93, P877, DOI 10.1002/jps.20017
   Singh AB, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.115
   Sosnik A, 2005, TISSUE ENG, V11, P1807, DOI 10.1089/ten.2005.11.1807                                                        
   Sosnik A, 2006, BIOMACROMOLECULES, V7, P331, DOI 10.1021/bm050693h
   Sosnik A, 2005, J BIOMED MATER RES A, V75A, P295, DOI 10.1002/jbm.a.30419
   Sosnik A, 2005, BIOMATERIALS, V26, P7425, DOI 10.1016/j.biomaterials.2005.05.086
   Sosnik A, 2005, BIOMATERIALS, V26, P349, DOI 10.1016/j.biomaterials.2004.02.041
   Sosnik A, 2004, BIOMATERIALS, V25, P2851, DOI 10.1016/j.biomaterials.2003.09.057
   Sosnik A, 2003, J BIOMAT SCI-POLYM E, V14, P227, DOI 10.1163/156856203763572680
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   Sosnik A, 2013, RSC SMART MATER, P115, DOI 10.1039/9781849736800-00115
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Sosnik Alejandro, 2009, P79, DOI 10.1007/978-88-470-1104-5_8
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   SPOELSTRA EC, 1991, BIOCHEM PHARMACOL, V41, P349, DOI 10.1016/0006-2952(91)90531-9                                                    
   Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95
   Steinbach D, 2006, CLIN CANCER RES, V12, P4357, DOI 10.1158/1078-0432.CCR-05-2587
   Sun L, 2010, J POLYM SCI POL CHEM, V48, P4583, DOI 10.1002/pola.24255
   Szaltacs G., 2006, NAT REV DRUG DISCOV, V5, P219
   Tamaki A, 2011, ESSAYS BIOCHEM, V50, P209, DOI [10.1042/bse0500209, 10.1042/BSE0500209]
   Tarasova NI, 2005, J MED CHEM, V48, P3768, DOI 10.1021/jm049065t
   Telbisz A, 2007, BBA-BIOMEMBRANES, V1768, P2698, DOI 10.1016/j.bbamem.2007.06.026
   Teodori E, 2006, CURR DRUG TARGETS, V7, P893, DOI 10.2174/138945006777709520
   Tomi M, 2010, EXPERT OPIN DRUG MET, V6, P1111, DOI 10.1517/17425255.2010.486401
   Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0
   Vahakangas K, 2009, BRIT J PHARMACOL, V158, P665, DOI 10.1111/j.1476-5381.2009.00336.x
   Valle JW, 2011, INVEST NEW DRUG, V29, P1029, DOI 10.1007/s10637-010-9399-1
   van de Ven R, 2008, BLOOD, V112, P2353, DOI 10.1182/blood-2008-03-147850
   Varma MVS, 2005, EUR J PHARM SCI, V25, P445, DOI 10.1016/j.ejps.2005.04.003
   Vasiliou Vasilis, 2009, Human Genomics, V3, P281
   Velamakanni S, 2007, J BIOENERG BIOMEMBR, V39, P465, DOI 10.1007/s10863-007-9122-x
   Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697
   Venne A, 1996, CANCER RES, V56, P3626
   Vigl C, 2009, J DRUG DELIV SCI TEC, V19, P405, DOI 10.1016/S1773-2247(09)50084-6                                                   
   Wang X, 2003, MOL PHARMACOL, V63, P65, DOI 10.1124/mol.63.1.65
   Wang YZ, 2012, BIOMATERIALS, V33, P4741, DOI 10.1016/j.biomaterials.2012.03.013
   Wang Z, 2011, DRUG METAB DISPOS, V39, P2155, DOI 10.1124/dmd.111.041228
   Wei Z, 2013, EUR J PHARM BIOPHARM, V83, P266, DOI 10.1016/j.ejpb.2012.09.014
   Weiss J, 2007, J ANTIMICROB CHEMOTH, V59, P238, DOI 10.1093/jac/dkl474
   Weiss J, 2010, INT REV CEL MOL BIO, V280, P219, DOI 10.1016/S1937-6448(10)80005-X
   Werle M, 2006, J CONTROL RELEASE, V111, P41, DOI 10.1016/j.cornel.2005.11.011
   Werle M, 2008, PHARM RES, V25, P500, DOI 10.1007/s11095-007-9347-8
   Williams GC, 2002, ANTIMICROB AGENTS CH, V46, P3456, DOI 10.1128/AAC.46.11.3456-3462.2002
   Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   WOODCOCK DM, 1992, BRIT J CANCER, V66, P62, DOI 10.1038/bjc.1992.217
   WOODCOCK DM, 1990, CANCER RES, V50, P4199
   Wu CY, 2005, PHARM RES, V22, P11, DOI 10.1007/s11095-004-9004-4
   ZALIPSKY S, 1995, BIOCONJUGATE CHEM, V6, P150, DOI 10.1021/bc00032a002                                                             
   Zastre J, 2004, PHARM RES, V21, P1489, DOI 10.1023/B:PHAM.0000036925.45002.a2
   Zastre J, 2007, J PHARM SCI-US, V96, P864, DOI 10.1002/jps.20785
   Zelcer N, 2003, J BIOL CHEM, V278, P23538, DOI 10.1074/jbc.M303504200
   Zhang HJ, 2003, ARCH PHARM RES, V26, P768, DOI 10.1007/BF02976689
   Zhang XC, 1997, CANCER CHEMOTH PHARM, V40, P81, DOI 10.1007/s002800050630
   Zhang XC, 1996, INT J PHARM, V132, P195, DOI 10.1016/0378-5173(95)04386-1                                                    
   Zhao HZ, 2008, J BIOMED MATER RES A, V84A, P954, DOI 10.1002/jbm.a.31402
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamen.2007.03.026
   Carreno-Gomez B., 2002, Compositions with Enhanced Oral Bioavailability, Patent No. [USP2003/0211072A1, 20030211072]
NR 265
TC 39
Z9 40
U1 9
U2 175
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD NOV 30
PY 2013
VL 65
IS 13-14
BP 1828
EP 1851
DI 10.1016/j.addr.2013.09.002
PG 24
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 270HM
UT WOS:000328309500012
PM 24055628
DA 2018-01-05
ER

PT J
AU Zhang, XJ
   Lu, LH
   Wang, RR
   Wang, YP
   Luo, RH
   Lai, CC
   Yang, LM
   He, YP
   Zheng, YT
AF Zhang, Xing-Jie
   Lu, Li-He
   Wang, Rui-Rui
   Wang, Yue-Ping
   Luo, Rong-Hua
   Lai, Christopher Cong
   Yang, Liu-Meng
   He, Yan-Ping
   Zheng, Yong-Tang
TI DB-02, a C-6-Cyclohexylmethyl Substituted Pyrimidinone HIV-1 Reverse
   Transcriptase Inhibitor with Nanomolar Activity, Displays an Improved
   Sensitivity against K103N or Y181C Than S-DABOs
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BENZYL-OXOPYRIMIDINE DERIVATIVES;
   STRUCTURE-BASED DESIGN; IN-VITRO SELECTION; DRUG-RESISTANCE;
   NONNUCLEOSIDE INHIBITORS; BIOLOGICAL EVALUATION; ANTI-HIV-1 ACTIVITY;
   WILD-TYPE; POTENT
AB 6-(cyclohexylmethyl)-5-ethyl-2-((2-oxo-2-phenylethyl)thio)pyrimidin-4(3H)-one (DB-02) is a member of the newly reported synthetic anti-HIV-1 compounds dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines, S-DACOs. In vitro anti-HIV-1 activity and resistance profile studies have suggested that DB-02 has very low cytotoxicity (CC50>1mM) to cell lines and peripheral blood mononuclear cells (PBMCs). It displays potent anti-HIV-1 activity against laboratory adapted strains and primary isolated strains including different subtypes and tropism strains (EC(50)s range from 2.40 to 41.8 nM). Studies on site-directed mutagenesis, genotypic resistance profiles revealed that V106A was the major resistance contributor for the compound. Molecular docking analysis showed that DB-02 located in the hydrophobic pocket with interactions of Lys101, Val106, Leu234, His235. DB-02 also showed non-antagonistic effects to four approved antiretroviral drugs. All studies indicated that DB-02 would be a potential NNRTI with low cytotoxicity and improved activity.
C1 [Zhang, Xing-Jie; Wang, Rui-Rui; Luo, Rong-Hua; Yang, Liu-Meng; Zheng, Yong-Tang] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.
   [Zhang, Xing-Jie; Wang, Rui-Rui; Luo, Rong-Hua; Yang, Liu-Meng; Zheng, Yong-Tang] Chinese Acad Sci, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.
   [Zhang, Xing-Jie] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Lu, Li-He; Wang, Yue-Ping; He, Yan-Ping] Yunnan Univ, Sch Chem Sci & Technol, Key Lab Med Chem Nat Resource, Minist Educ, Kunming, Yunnan, Peoples R China.
   [Lai, Christopher Cong] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
RP He, YP (reprint author), Yunnan Univ, Sch Chem Sci & Technol, Key Lab Med Chem Nat Resource, Minist Educ, Kunming, Yunnan, Peoples R China.
EM yphe@ynu.edu.cn; zhengyt@mail.kiz.ac.cn
FU 973 Program [2009CB522306]; Key Scientific and Technological Program of
   China Yunnan Province [2012ZX10001-006, 2012ZX10001-007,
   2012ZX09103-101-068, 2009BC018, 2010GA001, Y103951111]; National Science
   Foundation of China [21262044, 30560179, 30960459, 81001462, 81102483];
   Chinese Academy of Sciences [W8090303]
FX This work was supported in part by grants from the 973 Program
   (2009CB522306), the Key Scientific and Technological Program of China
   (2012ZX10001-006; 2012ZX10001-007, 2012ZX09103-101-068) and of Yunnan
   Province (2009BC018, 2010GA001, Y103951111), the National Science
   Foundation of China (21262044, 30560179, 30960459, 81001462, 81102483)
   and the Chinese Academy of Sciences (W8090303). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4680.2004
   Chen WM, 2012, CURR PHARM DESIGN, V18, P4165, DOI 10.2174/138161212802430440                                                      
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Conway B, 2001, AIDS, V15, P1269, DOI 10.1097/00002030-200107060-00008
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Halvas EK, 2010, J INFECT DIS, V201, P672, DOI 10.1086/650542
   He X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047289
   He YP, 2011, BIOORG MED CHEM LETT, V21, P694, DOI 10.1016/j.bmcl.2010.12.003
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Johnson VA, 2011, HIV MED, V18, P156
   Le Grice SFJ, 2012, J BIOL CHEM, V287, P40850, DOI 10.1074/jbc.R112.389056
   Li L, 2010, AIDS RES HUM RETROV, V26, P711, DOI 10.1089/aid.2010.0001
   Liu GJ, 2007, CELL MOL IMMUNOL, V4, P203
   LIU SY, 2010, ACTA PHARM SIN, V45, P241
   LONG J, 2010, ACTA PHARM SIN, V45, P228
   Lu XF, 2012, ANTIMICROB AGENTS CH, V56, P341, DOI 10.1128/AAC.05537-11
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MAI A, 1995, J MED CHEM, V38, P3258, DOI 10.1021/jm00017a010
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   MANSKY LM, 1995, J VIROL, V69, P5087
   Marcellin F, 2013, EXPERT REV ANTI-INFE, V11, P239, DOI [10.1586/eri.13.8, 10.1586/ERI.13.8]
   Menendez-Arias L, 2013, ANTIVIR RES, V98, P93, DOI 10.1016/j.antiviral.2013.01.007
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Nawrozkij MB, 2008, J MED CHEM, V51, P4641, DOI 10.1021/jm800340w
   Ordonez P, 2012, ANTIMICROB AGENTS CH, V56, P2581, DOI 10.1128/AAC.06307-11
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Radi M, 2012, CHEMMEDCHEM, V7, P883, DOI 10.1002/cmdc.201200056
   Radi M, 2009, J MED CHEM, V52, P840, DOI 10.1021/jm801330n
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   UNAIDS, 2012, WORLD AIDS DAY REP R
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Wang RR, 2009, BIOCHEM BIOPH RES CO, V382, P540, DOI 10.1016/j.bbrc.2009.03.057
   Wang YP, 2008, BIOORGAN MED CHEM, V16, P3887, DOI 10.1016/j.bmc.2008.01.039
   Yang SQ, 2012, CURR MED CHEM, V19, P152, DOI 10.2174/092986712803414169                                                      
   Yu MY, 2011, CHEMMEDCHEM, V6, P826, DOI 10.1002/cmdc.201000555
   Yu MY, 2011, CURR MED CHEM, V18, P10
   Zhang J, 2011, BIOORGAN MED CHEM, V19, P4366, DOI 10.1016/j.bmc.2011.05.024
NR 41
TC 8
Z9 8
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 25
PY 2013
VL 8
IS 11
AR e81489
DI 10.1371/journal.pone.0081489
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259RH
UT WOS:000327543500102
PM 24282600
OA gold
DA 2018-01-05
ER

PT J
AU das Neves, J
   Amiji, M
   Bahia, MF
   Sarmento, B
AF das Neves, Jose
   Amiji, Mansoor
   Bahia, Maria Fernanda
   Sarmento, Bruno
TI Assessing the physical-chemical properties and stability of
   dapivirine-loaded polymeric nanoparticles
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE HIV/AIDS; Microbicides; Poly(epsilon-caprolactone); Colloidal stability;
   Drug release
ID DRUG-DELIVERY SYSTEMS; INTRACELLULAR DELIVERY; HIV PREVENTION; VAGINAL
   FLUID; MICROBICIDE; FORMULATION; PHARMACOKINETICS; OPTIMIZATION; GELS
AB Nanocarriers may provide interesting delivery platforms for microbicide drugs and their characterization should be addressed early in development. Differently surface-engineered dapivirine-loaded, poly( epsilon-caprolactone) (PCL)-based nanoparticles (NPs) were obtained by nanoprecipitation using polyethylene oxide (PEO), sodium lauryl sulfate (SLS), or cetyltrimethylammonium bromide (CTAB) as surface modifiers. Physical-chemical properties of NP aqueous dispersions were evaluated upon storage at -20-40 degrees C for one year. NPs presented 170-200 nm in diameter, roundish-shape, low polydispersity index (<= 0.18), and high drug association efficiency (>= 97%) and loading (>= 12.7%). NPs differed in zeta potential, depending on surface modifier (PEO: -27.9 mV; SLS: -54.7 mV; CTAB: +42.4 mV). No interactions among formulation components were detected by differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR), except for SLS-PCL NPs. Colloidal properties of NPs were lost at -20 degrees C storage. Negatively charged NPs were stable up to one year at 5-40 degrees C; as for CTAB-PCL NPs, particle aggregation was observed from 30 to 90 days of storage depending on temperature. Colloidal instability affected the in vitro drug release of CTAB-PCL NPs after 360 days. In any case, no degradation of dapivirine was apparent. Overall, PEO-PCL and SLS-PCL NPs presented suitable properties as nanocarriers for dapivirine. Conversely, CTAB-PCL NPs require additional strategies in order to increase stability. (C) 2013 Elsevier B.V. All rights reserved.
C1 [das Neves, Jose; Sarmento, Bruno] CESPU, Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, CICS, P-4585116 Gandra, Portugal.
   [das Neves, Jose; Bahia, Maria Fernanda] Univ Porto, Lab Pharmaceut Technol, Fac Pharm, P-4050313 Oporto, Portugal.
   [Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   [Sarmento, Bruno] INEB Inst Engn Biomed, P-4150180 Oporto, Portugal.
RP das Neves, J (reprint author), CESPU, Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, CICS, Rua Cent Gandra 1317, P-4585116 Gandra, Portugal.
EM j.dasneves@gmail.com
RI Sarmento, Bruno/J-6265-2013; das Neves, Jose/J-8369-2013; Amiji,
   Mansoor/A-4365-2014
OI Sarmento, Bruno/0000-0001-5763-7553; das Neves,
   Jose/0000-0002-2317-2759; Amiji, Mansoor/0000-0001-6170-881X
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BD/43393/2008]; FCT [VIH/SAU/0021/2011]
FX Jose das Neves gratefully acknowledges Fundacao para a Ciencia e a
   Tecnologia (FCT), Portugal for financial support (grant
   SFRH/BD/43393/2008). This work was partially supported by a grant from
   FCT (VIH/SAU/0021/2011). The authors would like to express their
   gratitude to Jing Xu for SEM imaging at the Nanomaterials
   Characterization Facility, Northeastern University, and Pedro Fonte for
   assistance with FTIR spectra processing at Instituto Superior de
   Ciencias da Saude-Norte, CESPU. Dapivirine was kindly provided by the
   International Partnership for Microbicides (IPM). Dapivirine was
   originally developed by Janssen Pharmaceuticals and licensed to IPM.
CR Abdelwahed W, 2006, INT J PHARM, V309, P178, DOI 10.1016/j.ijpharm.2005.10.003
   Agashe H, 2012, CURR HIV RES, V10, P88, DOI 10.2174/157016212799304599
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Arien KK, 2011, REV MED VIROL, V21, P110, DOI 10.1002/rmv.684
   Chan-Chan LH, 2010, ACTA BIOMATER, V6, P2035, DOI 10.1016/j.actbio.2009.12.010
   Clark MR, 2012, AIDS RES HUM RETROV, V28, P1458, DOI [10.1089/aid.2011.0328, 10.1089/AID.2011.0328]
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J, 2010, J PHARMACEUT BIOMED, V52, P167, DOI 10.1016/j.jpba.2010.01.007
   Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173
   FDA, 2012, GUID IND VA IN PRESS
   Freire FD, 2009, J THERM ANAL CALORIM, V97, P355, DOI 10.1007/s10973-009-0258-2
   Garg S, 2003, AIDS PATIENT CARE ST, V17, P377, DOI 10.1089/108729103322277402
   ICH, 2003, Q1A R2 STAB TEST NEW
   IMMELMAN E, 1992, THERMOCHIM ACTA, V207, P177, DOI 10.1016/0040-6031(92)80133-H                                                    
   Jelvehgari M, 2010, AAPS PHARMSCITECH, V11, P1237, DOI 10.1208/s12249-010-9488-7
   Lever T., 2007, THERMAL ANAL PHARM, P23
   Lewi P, 2012, CURR HIV RES, V10, P27, DOI 10.2174/157016212799304643
   Liu SJ, 2010, ANN BIOMED ENG, V38, P3185, DOI 10.1007/s10439-010-0075-6
   Major I, 2012, CONTRACEPTION, V88, P58
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Moore JW, 1996, PHARM TECH, V20, P64
   Nel AM, 2010, JAIDS-J ACQ IMM DEF, V55, P161, DOI 10.1097/QAI.0b013e3181e3293a
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Purslow C, 2012, EXPERT REV CLIN PHAR, V5, P497, DOI 10.1586/ecp.12.66
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Roohani-Esfahani SI, 2012, ACTA BIOMATER, V8, P302, DOI 10.1016/j.actbio.2011.10.009
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shahin M, 2010, INT J PHARMACEUT, V389, P213, DOI 10.1016/j.ijpharm.2010.01.015
   Turpin JA, 2011, DRUG DELIV TRANSL RE, V1, P194, DOI 10.1007/s13346-011-0034-2
   World Health Organization, 2012, US PROC ADD LUBR MAL
   Woolfson AD, 2010, INT J PHARMACEUT, V388, P136, DOI 10.1016/j.ijpharm.2009.12.042
NR 34
TC 17
Z9 17
U1 0
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 18
PY 2013
VL 456
IS 2
BP 307
EP 314
DI 10.1016/j.ijpharm.2013.08.049
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 234LC
UT WOS:000325644600006
PM 24012910
DA 2018-01-05
ER

PT J
AU Lee, JH
   Oh, BK
   Choi, JW
AF Lee, Jin-Ho
   Oh, Byeung-Keun
   Choi, Jeong-Woo
TI Electrochemical sensor based on direct electron transfer of HIV-1 Virus
   at Au nanoparticle modified ITO electrode
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Electrochemical sensor; Virus; Nanoparticle; HIV-1; Direct electron
   transfer
ID P24 ANTIGEN; GLUCOSE; ENZYME; DNA; IMMUNOSENSOR; BIOSENSORS; INFECTION;
   PROBES
AB In this study, for the first time, an electrochemical detection method was proposed to detect direct electron transfer signal from HIV-1 Virus. Au nanoparticles were fabricated on the Indium Tin Oxide coated glass (ITO) electrode by electrochemical deposition to improve the surface area to provide better electron-transfer kinetics, and higher background charging current. On the Au nanoparticle modified ITO electrode, antibody fragment was immobilized by self-assembly method with gold-thiol interaction and different concentrations of HIV-1 Virus like particles (VLPs) were applied for the direct determination. Due to the advantage of fabricated Au nanoparticle's excellent electrical and mechanical properties, HIV-1 VLPs were successfully detected from 600 fg/mL to 375 pg/mL. Furthermore, since the proposed electrochemical virus sensor is designed for direct determination without any labeling structure, the electrochemical communication between redox target and electrode surface will reduce interference reactions and simplifies the detection system with small amount of reagent and better stability. Therefore, highly sensitive virus sensor was developed to detect HIV-1 Virus in a label free system. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Lee, Jin-Ho; Oh, Byeung-Keun; Choi, Jeong-Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
   [Lee, Jin-Ho] Sogang Univ, Res Inst Basic Sci, Seoul 121742, South Korea.
   [Choi, Jeong-Woo] Sogang Univ, Grad Sch Management Technol, Seoul 121742, South Korea.
RP Choi, JW (reprint author), Sogang Univ, Dept Chem & Biomol Engn, 1 Shinsu Dong, Seoul 121742, South Korea.
EM jwchoi@sogang.ac.kr
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2009-0080860]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (2009-0080860).
CR Albers J, 2003, ANAL BIOANAL CHEM, V377, P521, DOI 10.1007/s00216-003-2192-7
   Arrigan DWM, 2004, ANALYST, V129, P1157, DOI 10.1039/b415395m
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Cui HF, 2007, ANAL CHIM ACTA, V594, P175, DOI 10.1016/j.aca.2007.05.047
   Das J, 2009, J PHYS CHEM C, V113, P6093, DOI 10.1021/jp809850f
   Ding CF, 2008, BIOELECTROCHEMISTRY, V72, P28, DOI 10.1016/j.bioelechem.2007.11.001
   Gan N, 2013, MATERIALS, V6, P1255, DOI 10.3390/ma6041255
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   KOST TA, 1991, J VIROL, V65, P3276
   Lu CH, 2012, BIOSENS BIOELECTRON, V31, P439, DOI 10.1016/j.bios.2011.11.008
   Merkoci A, 2007, FEBS J, V274, P310, DOI 10.1111/j.1742-4658.2006.05603.x
   MODROW S, 1987, J VIROL, V61, P570
   Nair PR, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.256101
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   Patolsky F, 2006, ANAL CHEM, V78, P4260, DOI 10.1021/ac069419j
   Richardson JN, 2003, ELECTROCHIM ACTA, V48, P4291, DOI 10.1016/j.electacta.2003.08.004
   RIKLIN A, 1995, NATURE, V376, P672, DOI 10.1038/376672a0
   RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559
   Stadler B, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/15/155306
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Toghill KE, 2010, INT J ELECTROCHEM SC, V5, P1246
   Wanekaya AK, 2006, ELECTROANAL, V18, P533, DOI 10.1002/elan.200503449
   Wang Y, 2008, SENSORS-BASEL, V8, P2043, DOI 10.3390/s8042043
   Yu JJ, 2008, TALANTA, V74, P1586, DOI 10.1016/j.talanta.2007.10.005
   Zhang X, 2008, ELECTROCHEMICAL SENSORS, BIOSENSORS AND THEIR BIOMEDICAL APPLICATIONS, P1
   Zong WS, 2010, PROTEIN SCI, V19, P263, DOI 10.1002/pro.313
NR 27
TC 14
Z9 15
U1 6
U2 210
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD NOV 15
PY 2013
VL 49
BP 531
EP 535
DI 10.1016/j.bios.2013.06.010
PG 5
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 204UM
UT WOS:000323396700082
PM 23816850
DA 2018-01-05
ER

PT J
AU Bache, M
   Bosco, FG
   Brogger, AL
   Frohling, KB
   Alstrom, TS
   Hwu, ET
   Chen, CH
   Eugen-Olsen, J
   Hwang, IS
   Boisen, A
AF Bache, Michael
   Bosco, Filippo G.
   Brogger, Anna L.
   Frohling, Kasper B.
   Alstrom, Tommy Sonne
   Hwu, En-Te
   Chen, Ching-Hsiu
   Eugen-Olsen, Jesper
   Hwang, Ing-Shouh
   Boisen, Anja
TI Nanomechanical recognition of prognostic biomarker suPAR with DVD-ROM
   optical technology
SO NANOTECHNOLOGY
LA English
DT Article
ID QUARTZ-CRYSTAL MICROBALANCE; UROKINASE RECEPTOR; DNA; DISSIPATION;
   CANTILEVERS; ADSORPTION; EXPRESSION; BIOSENSORS; SENSORS; PROTEIN
AB In this work the use of a high-throughput nanomechanical detection system based on a DVD-ROM optical drive and cantilever sensors is presented for the detection of urokinase plasminogen activator receptor inflammatory biomarker (uPAR). Several large scale studies have linked elevated levels of soluble uPAR (suPAR) to infectious diseases, such as HIV, and certain types of cancer. Using hundreds of cantilevers and a DVD-based platform, cantilever deflection response from antibody-antigen recognition is investigated as a function of suPAR concentration. The goal is to provide a cheap and portable detection platform which can carry valuable prognostic information. In order to optimize the cantilever response the antibody immobilization and unspecific binding are initially characterized using quartz crystal microbalance technology. Also, the choice of antibody is explored in order to generate the largest surface stress on the cantilevers, thus increasing the signal. Using optimized experimental conditions the lowest detectable suPAR concentration is currently around 5 nM. The results reveal promising research strategies for the implementation of specific biochemical assays in a portable and high-throughput microsensor-based detection platform.
C1 [Bache, Michael; Bosco, Filippo G.; Brogger, Anna L.; Frohling, Kasper B.; Boisen, Anja] Tech Univ Denmark, Dept Micro & Nanotechnol, DK-2800 Lyngby, Denmark.
   [Alstrom, Tommy Sonne] Tech Univ Denmark, Dept Appl Math & Comp Sci, DK-2800 Lyngby, Denmark.
   [Hwu, En-Te; Chen, Ching-Hsiu] Acad Sin, Inst Phys, DK-11529 Taipei, Taiwan.
   [Eugen-Olsen, Jesper] Univ Copenhagen, Hvidovre Hosp, Clin Res Ctr, DK-2650 Hvidovre, Denmark.
RP Bache, M (reprint author), Tech Univ Denmark, Dept Micro & Nanotechnol, DK-2800 Lyngby, Denmark.
EM michael.bache@nanotech.dtu.dk
RI Boisen, Anja/F-9442-2011
OI Boisen, Anja/0000-0002-9918-6567; Hwu, En-Te/0000-0002-5971-4978;
   Eugen-Olsen, jesper/0000-0002-4630-4275
FU MUSE project, Danish Council for Strategic Research
FX This work has been funded by the MUSE project, Danish Council for
   Strategic Research.
CR Boisen A, 2011, REP PROG PHYS, V74, DOI 10.1088/0034-4885/74/3/036101
   Bosco FG, 2012, SENSOR ACTUAT B-CHEM, V171, P1054, DOI 10.1016/j.snb.2012.06.033
   Bosco FG, 2011, LAB CHIP, V11, P2411, DOI 10.1039/c1lc20116f
   Braun T, 2009, NAT NANOTECHNOL, V4, P179, DOI [10.1038/NNANO.2008.398, 10.1038/nnano.2008.398]
   Cha BH, 2009, BIOSENS BIOELECTRON, V25, P130, DOI 10.1016/j.bios.2009.06.015
   Datar R, 2009, MRS BULL, V34, P449, DOI 10.1557/mrs2009.121                                                             
   de Bock CE, 2004, MED RES REV, V24, P13, DOI 10.1002/med.10054
   Eugen-Olsen J, 2011, J INTERN MED, V270, P29, DOI 10.1111/j.1365-2796.2011.02372.x
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316                                                    
   Fritz J, 2008, ANALYST, V133, P855, DOI 10.1039/b718174d
   Godin M, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/7/075501
   Gustafsson A, 2011, BIOMARK INSIGHTS, V6, P119, DOI 10.4137/BMI.S8326
   Hook F, 1998, LANGMUIR, V14, P729, DOI 10.1021/la970815u
   Hwu ET, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2817750
   Jing JX, 2012, J CLIN LAB ANAL, V26, P16, DOI 10.1002/jcla.20499
   Johansson A, 2005, SENSOR ACTUAT A-PHYS, V123-24, P111, DOI 10.1016/j.sna.2005.03.025
   Kleo K, 2012, ANAL BIOANAL CHEM, V404, P843, DOI 10.1007/s00216-012-6172-7
   McKendry R, 2002, P NATL ACAD SCI USA, V99, P9783, DOI 10.1073/pnas.152330199
   MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193
   Moulin AM, 2000, ULTRAMICROSCOPY, V82, P23, DOI 10.1016/S0304-3991(99)00145-X
   Mukhopadhyay R, 2005, LANGMUIR, V21, P8400, DOI 10.1021/la0511687
   Nordstrom M, 2008, SENSORS-BASEL, V8, P1595, DOI 10.3390/s8031595
   REUNING U, 1994, BLOOD, V84, P3700
   Thuno M, 2009, DIS MARKERS, V27, P157, DOI 10.3233/DMA-2009-0657
   Watari M, 2007, J AM CHEM SOC, V129, P601, DOI 10.1021/ja065222x
   Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856
   Zhang J, 2006, NAT NANOTECHNOL, V1, P214, DOI 10.1038/nnano.2006.134
   Zhou C, 2004, LANGMUIR, V20, P5870, DOI 10.1021/la036251d
NR 28
TC 4
Z9 4
U1 0
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
EI 1361-6528
J9 NANOTECHNOLOGY
JI Nanotechnology
PD NOV 8
PY 2013
VL 24
IS 44
SI SI
AR 444011
DI 10.1088/0957-4484/24/44/444011
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 239IJ
UT WOS:000326015600014
PM 24113286
DA 2018-01-05
ER

PT J
AU Fan, Z
   Kanchanapally, R
   Ray, PC
AF Fan, Zhen
   Kanchanapally, Rajashekhar
   Ray, Paresh Chandra
TI Hybrid Graphene Oxide Based Ultrasensitive SERS Probe for Label-Free
   Biosensing
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID ENHANCED RAMAN-SPECTROSCOPY; ANCHORING SEMICONDUCTOR; METAL
   NANOPARTICLES; SCATTERING; SUBSTRATE; REDUCTION; APTAMERS; BACTERIA;
   SENSORS
AB A metal nanoparticle attached to graphene oxide has the ability to open a new avenue of research with significant opportunities in the biomedical field. In this Letter, we report graphene oxide attached to a popcorn-shaped gold nanoparticle based hybrid SERS probe with ultrasensitive label-free sensing of HIV DNA and bacteria and provide its chemical fingerprint. Our SERS data with the hybrid material shows that it can be used for label-free detection of HIV DNA on the femto-molar level without any labeling. Experimental data with a novel SERS substrate show excellent reproducibility of the SERS signal. The current Letter demonstrates that the label-free SERS detection limit using a hybrid material can be as low as 10 CFU/mL for MRSA bacteria. The possible mechanism for very high sensitivity has been discussed.
C1 [Fan, Zhen; Kanchanapally, Rajashekhar; Ray, Paresh Chandra] Jackson State Univ, Dept Chem & Biochem, Jackson, MS 39217 USA.
RP Ray, PC (reprint author), Jackson State Univ, Dept Chem & Biochem, Jackson, MS 39217 USA.
EM paresh.c.ray@jsums.edu
RI fan, zhen/M-8774-2014; fan, zhen/N-5244-2014
OI fan, zhen/0000-0001-7937-8441; fan, zhen/0000-0001-7937-8441;
   Kanchanapally, Rajashekhar/0000-0002-9846-2611
FU NSF-PREM [DMR-1205194]
FX Dr. Ray thanks NSF-PREM Grant # DMR-1205194 for their generous funding.
CR Angulo AM, 2011, J PHYS CHEM LETT, V2, P1978, DOI 10.1021/jz200825g
   Bagri A, 2010, NAT CHEM, V2, P581, DOI [10.1038/nchem.686, 10.1038/NCHEM.686]
   Barhoumi A, 2011, J PHYS CHEM LETT, V2, P3118, DOI 10.1021/jz201423b
   Barhoumi A, 2010, J AM CHEM SOC, V132, P12792, DOI 10.1021/ja105678z
   Berkley S, 2010, NAT MED, V16, P981, DOI 10.1038/nm0910-981
   Brown LV, 2013, J AM CHEM SOC, V135, P3688, DOI 10.1021/ja312694g
   Dasary SSR, 2009, J AM CHEM SOC, V131, P13806, DOI 10.1021/ja905134d
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Du Y, 2013, ACCOUNTS CHEM RES, V46, P203, DOI 10.1021/ar300011g
   Dwivedi HP, 2013, APPL MICROBIOL BIOT, V97, P3677, DOI 10.1007/s00253-013-4766-4
   Fang XQ, 2010, J AM CHEM SOC, V132, P2274, DOI 10.1021/ja9082649
   Frontiera RR, 2011, J PHYS CHEM LETT, V2, P1199, DOI 10.1021/jz200498z
   Gao W, 2009, NAT CHEM, V1, P403, DOI [10.1038/NCHEM.281, 10.1038/nchem.281]
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Haran G, 2010, ACCOUNTS CHEM RES, V43, P1135, DOI 10.1021/ar100031v
   Hossain MZ, 2012, NAT CHEM, V4, P305, DOI 10.1038/nchem.1269
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   Ji W, 2012, J PHYS CHEM LETT, V3, P3204, DOI 10.1021/jz301428e
   Joseph V, 2012, ANGEW CHEM INT EDIT, V51, P7592, DOI 10.1002/anie.201203526
   Kamat PV, 2010, J PHYS CHEM LETT, V1, P520, DOI 10.1021/jz900265j
   Kim NH, 2010, NANO LETT, V10, P4181, DOI 10.1021/nl102495j
   Kleinman SL, 2011, J AM CHEM SOC, V133, P4115, DOI 10.1021/ja110964d
   Laurence TA, 2009, J AM CHEM SOC, V131, P162, DOI 10.1021/ja806236k
   Le Ru EC, 2012, ANNU REV PHYS CHEM, V63, P65, DOI 10.1146/annurev-physchem-032511-143757
   Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878
   Lightcap IV, 2013, ACCOUNTS CHEM RES, V46, P2235, DOI 10.1021/ar300248f
   Lightcap IV, 2010, NANO LETT, V10, P577, DOI 10.1021/nl9035109
   Lim DK, 2011, NAT NANOTECHNOL, V6, P452, DOI [10.1038/nnano.2011.79, 10.1038/NNANO.2011.79]
   Ling X, 2010, NANO LETT, V10, P553, DOI 10.1021/nl903414x
   Liu JW, 2009, CHEM REV, V109, P1948, DOI 10.1021/cr030183i
   Lu WT, 2010, J AM CHEM SOC, V132, P18103, DOI 10.1021/ja104924b
   Mei QS, 2010, CHEM COMMUN, V46, P7319, DOI 10.1039/c0cc02374d
   Miranda OR, 2011, J AM CHEM SOC, V133, P9650, DOI 10.1021/ja2021729
   Murphy S, 2013, J PHYS CHEM C, V117, P4740, DOI 10.1021/jp3108528
   Panikkanvalappil SR, 2013, J AM CHEM SOC, V135, P4815, DOI 10.1021/ja400187b
   Premasiri WR, 2005, J PHYS CHEM B, V109, P312, DOI 10.1021/jp040442n
   Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377
   Ray PC, 2012, CHEM SOC REV, V41, P3193, DOI 10.1039/c2cs15340h
   Ren W, 2011, ACS NANO, V5, P6425, DOI 10.1021/nn201606r
   Robinson JT, 2011, J AM CHEM SOC, V133, P6825, DOI 10.1021/ja2010175
   Saha K, 2012, CHEM REV, V112, P2739, DOI 10.1021/cr2001178
   Saikin SK, 2010, J PHYS CHEM LETT, V1, P2740, DOI 10.1021/jz1008714
   Singh AK, 2012, J AM CHEM SOC, V134, P8662, DOI 10.1021/ja301921k
   Sivapalan ST, 2013, ACS NANO, V7, P2099, DOI 10.1021/nn305710k
   Sun YH, 2010, NANO LETT, V10, P1747, DOI 10.1021/nl100170j
   Thrall ES, 2012, NANO LETT, V12, P1571, DOI 10.1021/nl204446h
   van Dijk T, 2013, J PHYS CHEM LETT, V4, P1193, DOI 10.1021/jz4005043
   Wang YL, 2010, J PHYS CHEM C, V114, P16122, DOI 10.1021/jp1015406
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Willets KA, 2012, J PHYS CHEM LETT, V3, P1286, DOI 10.1021/jz300110x
   Yu XX, 2011, ACS NANO, V5, P952, DOI 10.1021/nn102291j
   Zhu Y, 2011, ACS NANO, V5, P6472, DOI 10.1021/nn201696g
NR 53
TC 55
Z9 58
U1 4
U2 109
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD NOV 7
PY 2013
VL 4
IS 21
BP 3813
EP 3818
DI 10.1021/jz4020597
PG 6
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 250IC
UT WOS:000326845200042
DA 2018-01-05
ER

PT J
AU Lee, WG
   Gallardo-Macias, R
   Frey, KM
   Spasov, KA
   Bollini, M
   Anderson, KS
   Jorgensen, WL
AF Lee, Won-Gil
   Gallardo-Macias, Ricardo
   Frey, Kathleen M.
   Spasov, Krasimir A.
   Bollini, Mariela
   Anderson, Karen S.
   Jorgensen, William L.
TI Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic
   Replacement of a Cyanovinylphenyl Group
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID BIOMOLECULAR SYSTEMS; DRUG; OPTIMIZATION; SOLUBILITY; DISCOVERY; AGENTS;
   WATER; RILPIVIRINE; ENERGETICS; INFECTION
AB Members of the catechol diether class are highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). The most active compounds yield EC50 values below 0.5 nM in assays using human T-cells infected by wild-type HIV-1. However, these compounds such as rilpivirine, the most recently FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group. This is an uncommon substructure in drugs that gives reactivity concerns. In the present work, computer simulations were used to design bicyclic replacements for the CVP group. The predicted viability of a 2-cyanoindolizinyl alternative was confirmed experimentally and provided compounds with 0.4 nM activity against the wild-type virus. The compounds also performed well with EC50 values of 10 nM against the challenging HIV-1 variant that contains the Lys103Asn/Tyr181Cys double mutation in the RT enzyme. Indolyl and benzofuranyl analogues were also investigated; the most potent compounds in these cases have EC50 values toward wild-type HIV-1 near 10 nM and high-nanomolar activities toward the double-variant. The structural expectations from the modeling were much enhanced by obtaining an X-ray crystal structure at 2.88 angstrom resolution for the complex of the parent 2-cyanoindolizine 10b and HIV-1 RT. The aqueous solubilities of the most potent indolizine analogues were also measured to be similar to 40 mu g/mL, which is similar to that for the approved drug efavirenz and similar to 1000-fold greater than for rilpivirine.
C1 [Lee, Won-Gil; Gallardo-Macias, Ricardo; Bollini, Mariela; Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [Frey, Kathleen M.; Spasov, Krasimir A.; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.
EM karen.anderson@yale.edu; william.jorgensen@yale.edu
FU National Institutes of Health [AI44616, GM32136, GM49551, AI104334]; NIH
   AIDS Research and Reference Reagent Program, Division of AIDS, NIAID,
   NIH
FX Gratitude is expressed to the National Institutes of Health (AI44616,
   GM32136, GM49551) for research support and for a fellowship to K.M.F.
   (AI104334). Dr. Xiaoling Wu is thanked for assistance with the NMR
   spectroscopy. Receipt of the following reagents through the NIH AIDS
   Research and Reference Reagent Program, Division of AIDS, NIAID, NIH is
   also greatly appreciated: MT-2 cells, catalog #237, and
   nevirapine-resistant HIV-1 (N119), catalog #1392, from Dr. Douglas
   Richman; HTLV-III<INF>B</INF>/H9, #398, from Dr. Robert Gallo; and
   HIV-1<INF>IIIB</INF> (A17 Variant) from Dr. Emilio Emini.
CR Asahchop EL, 2012, ANTIMICROB AGENTS CH, V56, P5000, DOI 10.1128/AAC.00591-12
   ATTANASI O, 1983, SYNTHESIS-STUTTGART, P741
   Baka E, 2008, J PHARMACEUT BIOMED, V46, P335, DOI 10.1016/j.jpba.2007.10.030
   BODE ML, 1993, J CHEM SOC PERK T 1, P1809, DOI 10.1039/p19930001809                                                            
   Bollini M, 2013, BIOORG MED CHEM LETT, V23, P5213, DOI 10.1016/j.bmcl.2013.06.091
   Bollini M, 2011, J MED CHEM, V54, P8582, DOI 10.1021/jm201134m
   ChemDraw; CambridgeSoft Inc, 2013, [No title captured], Patent No. [7,741,326 B2, 7741326]
   Dahlgren MK, 2013, J CHEM INF MODEL, V53, P1191, DOI [10.1021/ci4001597, 10.1021/ci400159711]
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Fleming FF, 2003, CHEM REV, V103, P2035, DOI 10.1021/cr020045d
   Fleming FF, 2010, J MED CHEM, V53, P7902, DOI 10.1021/jm100762r
   Frey KM, 2012, J AM CHEM SOC, V134, P19501, DOI 10.1021/ja3092642
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Heugebaert TSA, 2012, CHEM SOC REV, V41, P5626, DOI 10.1039/c2cs35093a
   James C, 2012, AM J HEALTH-SYST PH, V69, P857, DOI 10.2146/ajhp110395
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Jorgensen WL, 2008, J CHEM THEORY COMPUT, V4, P869, DOI 10.1021/ct800011m
   Jorgensen WL, 2011, J AM CHEM SOC, V133, P15686, DOI 10.1021/ja2058583
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Jorgensen WL, 2005, P NATL ACAD SCI USA, V102, P6665, DOI 10.1073/pnas.0408037102
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kim JT, 2006, J AM CHEM SOC, V128, P15372, DOI 10.1021/ja066472g
   LIN TS, 1994, BIOCHEM PHARMACOL, V47, P171
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   MORELOCK MM, 1994, J PHARM SCI, V83, P948, DOI 10.1002/jps.2600830706
   Newman SG, 2009, CHEM COMMUN, P5236, DOI 10.1039/b912093a
   Permpalung N, 2012, EXPERT OPIN PHARMACO, V13, P2301, DOI 10.1517/14656566.2012.729040
   Ray AS, 2002, ANTIMICROB AGENTS CH, V46, P887, DOI 10.1128/AAC.46.3.887-891.2002
   Ryabova SY, 2006, RUSS CHEM B+, V55, P1248, DOI 10.1007/s11172-006-0407-8                                                       
   Stepan AF, 2011, CHEM RES TOXICOL, V24, P1345, DOI 10.1021/tx200168d
   Sun LQ, 2012, BIOORG MED CHEM LETT, V22, P2376, DOI 10.1016/j.bmcl.2012.02.055
   Weuts I, 2011, J PHARM SCI-US, V100, P260, DOI 10.1002/jps.22242
   Whitlock GA, 2008, BIOORG MED CHEM LETT, V18, P596, DOI 10.1016/j.bmcl.2007.11.080
   Zhan P, 2013, MED RES REV, V33, pE1, DOI 10.1002/med.20241
   Zheng CW, 2010, CHEM-EUR J, V16, P5853, DOI 10.1002/chem.201000130
   Zhou W, 2012, ORG BIOMOL CHEM, V10, P4172, DOI 10.1039/c2ob25356a
NR 39
TC 22
Z9 23
U1 2
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD NOV 6
PY 2013
VL 135
IS 44
BP 16705
EP 16713
DI 10.1021/ja408917n
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 249JU
UT WOS:000326774300071
PM 24151856
OA green_accepted
DA 2018-01-05
ER

PT J
AU Alam, SM
   Dennison, SM
   Aussedat, B
   Vohra, Y
   Park, PK
   Fernandez-Tejada, A
   Stewart, S
   Jaeger, FH
   Anasti, K
   Blinn, JH
   Kepler, TB
   Bonsignori, M
   Liao, HX
   Sodroski, JG
   Danishefsky, SJ
   Haynes, BF
AF Alam, S. Munir
   Dennison, S. Moses
   Aussedat, Baptiste
   Vohra, Yusuf
   Park, Peter K.
   Fernandez-Tejada, Alberto
   Stewart, Shelley
   Jaeger, Frederick H.
   Anasti, Kara
   Blinn, Julie H.
   Kepler, Thomas B.
   Bonsignori, Mattia
   Liao, Hua-Xin
   Sodroski, Joseph G.
   Danishefsky, Samuel J.
   Haynes, Barton F.
TI Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing
   antibodies and their unmutated ancestors
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODIES; ENVELOPE; PROTEIN; DESIGN; PG9; PEPTIDES;
   EPITOPES; BINDING; RV144; IDENTIFICATION
AB Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. Broadly neutralizing antibodies (BnAbs) are not induced by current vaccines, but are found in plasma in similar to 20% of HIV-1-infected individuals after several years of infection. One strategy for induction of unfavored antibody responses is to produce homogeneous immunogens that selectively express BnAb epitopes but minimally express dominant strain-specific epitopes. Here we report that synthetic, homogeneously glycosylated peptides that bind avidly to variable loop 1/2 (V1V2) BnAbs PG9 and CH01 bind minimally to strain-specific neutralizing V2 antibodies that are targeted to the same envelope polypeptide site. Both oligomannose derivatization and conformational stabilization by disulfide-linked dimer formation of synthetic V1V2 peptides were required for strong binding of V1V2 BnAbs. An HIV-1 vaccine should target BnAb unmutated common ancestor (UCA) B-cell receptors of naive B cells, but to date no HIV-1 envelope constructs have been found that bind to the UCA of V1V2 BnAb PG9. We demonstrate herein that V1V2 glycopeptide dimers bearing Man(5)GlcNAc(2) glycan units bind with apparent nanomolar affinities to UCAs of V1V2 BnAbs PG9 and CH01 and with micromolar affinity to the UCA of a V2 strain-specific antibody. The higher-affinity binding of these V1V2 glycopeptides to BnAbs and their UCAs renders these glycopeptide constructs particularly attractive immunogens for targeting subdominant HIV-1 envelope V1V2-neutralizing antibody-producing B cells.
C1 [Alam, S. Munir; Dennison, S. Moses; Stewart, Shelley; Jaeger, Frederick H.; Anasti, Kara; Blinn, Julie H.; Bonsignori, Mattia; Liao, Hua-Xin; Haynes, Barton F.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA.
   [Alam, S. Munir; Bonsignori, Mattia; Liao, Hua-Xin; Haynes, Barton F.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Alam, S. Munir] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
   [Haynes, Barton F.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.
   [Aussedat, Baptiste; Vohra, Yusuf; Park, Peter K.; Fernandez-Tejada, Alberto; Danishefsky, Samuel J.] Sloan Kettering Inst Canc Res, Bioorgan Chem Lab, New York, NY 10065 USA.
   [Kepler, Thomas B.] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
   [Sodroski, Joseph G.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   [Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02215 USA.
   [Sodroski, Joseph G.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Sodroski, Joseph G.] MIT, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA.
   [Sodroski, Joseph G.] Harvard Univ, Cambridge, MA 02139 USA.
   [Danishefsky, Samuel J.] Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Danishefsky, SJ (reprint author), Sloan Kettering Inst Canc Res, Bioorgan Chem Lab, New York, NY 10065 USA.
EM s-danishefsky@ski.mskcc.org; barton.haynes@duke.edu
RI Fernandez-Tejada, Alberto/M-2439-2015
OI Fernandez-Tejada, Alberto/0000-0002-1680-0059; Vohra,
   Yusuf/0000-0003-0385-2965
FU Center for HIV/AIDS Vaccine Immunology (CHAVI) [Division of AIDS
   (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),
   National Institutes of Health (NIH)] [AI0678501]; Duke Center for
   HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID) (DAIDS,
   NIAID, NIH) [UM1-AI100645]; Collaboration for AIDS Vaccine Discovery
   Grant from The Bill and Melinda Gates Foundation [OPP1033098]; American
   Cancer Society [PF-11-014-01-CDD]; European Commission
FX We acknowledge the technical assistance of Hieu Nguyen (Duke Human
   Vaccine Institute) for SDS/PAGE analysis of V1V2 peptides, and Kim
   McClammy for secretarial assistance. This work was funded by Center for
   HIV/AIDS Vaccine Immunology (CHAVI) [Division of AIDS (DAIDS), National
   Institute of Allergy and Infectious Diseases (NIAID), National
   Institutes of Health (NIH)] Grant AI0678501; Duke Center for HIV/AIDS
   Vaccine Immunology-Immunogen Discovery (CHAVI-ID) (DAIDS, NIAID, NIH)
   Grant UM1-AI100645; and a Collaboration for AIDS Vaccine Discovery Grant
   (OPP1033098; to B. F. H.) from The Bill and Melinda Gates Foundation. P.
   K. P. was supported by a postdoctoral fellowship (PF-11-014-01-CDD) from
   the American Cancer Society. A.F.-T. thanks the European Commission
   (Marie Curie International Outgoing Fellowship) for financial support.
CR Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07
   Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424                                                     
   Alam SM, 2013, J VIROL, V87, P1554, DOI 10.1128/JVI.00718-12
   Amin MN, 2013, NAT CHEM BIOL, V9, P521, DOI 10.1038/nchembio.1288
   Aussedat B, 2013, J AM CHEM SOC, V135, P13113, DOI 10.1021/ja405990z
   Bonsignori M, 2011, J VIROL, V85, P9998, DOI 10.1128/JVI.05045-11
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Chen W, 2008, AIDS RES HUM RETROV, V24, P11
   de Souza MS, 2012, J IMMUNOL, V188, P5166, DOI 10.4049/jimmunol.1102756
   Dimitrov DS, 2010, MABS-AUSTIN, V2, P347, DOI 10.4161/mabs.2.3.11779                                                          
   Doores KJ, 2010, J VIROL, V84, P10510, DOI 10.1128/JVI.00552-10
   Dyson HJ, 1991, ANN REV BIOPHYS BIOP, V20, P519
   Finzi A, 2010, J VIROL METHODS, V168, P155, DOI 10.1016/j.jviromet.2010.05.008
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Julien JP, 2013, P NATL ACAD SCI USA, V110, P4351, DOI 10.1073/pnas.1217537110
   Khakshoor O, 2009, ORG LETT, V11, P3000, DOI 10.1021/ol901015a
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011
   Ma BJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002200
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709                                                          
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Montefiori DC, 2012, J INFECT DIS, V206, P431, DOI 10.1093/infdis/jis367
   Munshaw S, 2010, BIOINFORMATICS, V26, P867, DOI 10.1093/bioinformatics/btq056
   Nesloney CL, 1996, BIOORGAN MED CHEM, V4, P739, DOI 10.1016/0968-0896(96)00051-X
   Pancera M, 2010, J VIROL, V84, P8098, DOI 10.1128/JVI.00966-10
   QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747
   Santiveri CM, 2008, CHEM-EUR J, V14, P488, DOI 10.1002/chem.200700845
   Sattentau Quentin J, 2010, F1000 Biol Rep, V2, P60, DOI 10.3410/B2-60
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Steers NJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042579
   TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044                                                             
   Venkatraman J, 2002, J AM CHEM SOC, V124, P4987, DOI 10.1021/ja0174276
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wan Q, 2007, ANGEW CHEM INT EDIT, V46, P9248, DOI 10.1002/anie.200704195
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029
   YAN YB, 1994, PROTEIN SCI, V3, P1069, DOI 10.1002/pro.5560030709                                                          
NR 42
TC 41
Z9 41
U1 1
U2 27
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 5
PY 2013
VL 110
IS 45
BP 18214
EP 18219
DI 10.1073/pnas.1317855110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 246PG
UT WOS:000326550800051
PM 24145434
OA gold
DA 2018-01-05
ER

PT J
AU Schleifman, EB
   McNeer, NA
   Jackson, A
   Yamtich, J
   Brehm, MA
   Shultz, LD
   Greiner, DL
   Kumar, P
   Saltzman, WM
   Glazer, PM
AF Schleifman, Erica B.
   McNeer, Nicole Ali
   Jackson, Andrew
   Yamtich, Jennifer
   Brehm, Michael A.
   Shultz, Leonard D.
   Greiner, Dale L.
   Kumar, Priti
   Saltzman, W. Mark
   Glazer, Peter M.
TI Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered
   PNAs Confers HIV-1 Resistance in Humanized Mice
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; ZINC-FINGER NUCLEASES; PEPTIDE NUCLEIC-ACIDS;
   DNA TRIPLE-HELIX; SIRNA DELIVERY; GENE; RECOMBINATION; INFECTION;
   INDIVIDUALS; DISRUPTION
AB Biodegradable poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating triplex-forming peptide nucleic acids (PNAs) and donor DNAs for recombination-mediated editing of the CCR5 gene were synthesized for delivery into human peripheral blood mononuclear cells (PBMCs). NPs containing the CCR5-targeting molecules efficiently entered PBMCs with low cytotoxicity. Deep sequencing revealed that a single treatment with the formulation resulted in a targeting frequency of 0.97% in the CCR5 gene and a low off-target frequency of 0.004% in the CCR2 gene, a 216-fold difference. NP-treated PBMCs efficiently engrafted immunodeficient NOD-scid IL-2 gamma(-/-) mice, and the targeted CCR5 modification was detected in splenic lymphocytes 4 weeks posttransplantation. After infection with an R5-tropic strain of HIV-1, humanized mice with CCR5-NP-treated PBMCs displayed significantly higher levels of CD4(+) T cells and significantly reduced plasma viral RNA loads compared with control mice engrafted with mock-treated PBMCs. This work demonstrates the feasibility of PLGA-NP-encapsulated PNA-based gene-editing molecules for the targeted modification of CCR5 in human PBMCs as a platform for conferring HIV-1 resistance.
C1 [Schleifman, Erica B.; Yamtich, Jennifer; Glazer, Peter M.] Yale Univ, Sch Med, Dept Therapeut Radiol & Genet, New Haven, CT USA.
   [McNeer, Nicole Ali; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT USA.
   [Jackson, Andrew; Kumar, Priti] Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06510 USA.
   [Brehm, Michael A.; Greiner, Dale L.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA.
   [Shultz, Leonard D.] Jackson Lab, Bar Harbor, ME 04609 USA.
RP Glazer, PM (reprint author), Yale Univ, Sch Med, Deparment Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.
EM priti.kumar@yale.edu; mark.saltzman@yale.edu; peter.glazer@yale.edu
FU Doris Duke Charitable Foundation [2011102]; National Institutes of
   Health [R01HL082655, R01HL085416, AI46629, DK32520]; George R. Pfeiffer
   Fellowship; NIH predoctoral Genetics [T32 GM007499]; Ministry of
   Knowledge Economy under the KORUS Tech Program [KT-2008-NT-APFS0-0001];
   NIGMS Medical Scientist Training Program [T32GM07205]; National Heart,
   Lung, and Blood institute [F30HL110372]
FX We thank Lisa Cabral (Yale University School of Medicine), Barbara
   Johnson (Yale University School of Medicine), Denise Hegan (Yale
   University School of Medicine), and Faye Rogers (Yale University School
   of Medicine) for their help. This work was supported by the Doris Duke
   Charitable Foundation Grant #2011102 (to P.M.G.), National Institutes of
   Health Grants R01HL082655 (to P.M.G.), R01HL085416 (to W.M.S.), AI46629
   (to D.L.G., M.A.B., L.D.S.), DK32520 (to D.L.G., L.D.S.), by the George
   R. Pfeiffer Fellowship and NIH predoctoral Genetics training grant T32
   GM007499 (to E.B.S), Ministry of Knowledge Economy under the KORUS Tech
   Program KT-2008-NT-APFS0-0001 (to P.K.), NIGMS Medical Scientist
   Training Program T32GM07205 (to N.A.M.) and F30HL110372 from the
   National Heart, Lung, and Blood institute (to N.A.M.), and the content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the funding organizations.
CR ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804
   Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Bashir A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000051
   Braasch DA, 2001, METHODS, V23, P97, DOI 10.1006/meth.2000.1111
   Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200                                                          
   Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053
   Fahmy TM, 2005, BIOMATERIALS, V26, P5727, DOI 10.1016/j.biomaterials.2005.02.025
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Ioannidis JP, 2001, ANN INTERN MED, V135, P782
   Jain A, 2010, BIOCHEMISTRY-US, V49, P6992, DOI 10.1021/bi100795m
   Knauert MP, 2005, BIOCHEMISTRY-US, V44, P3856, DOI 10.1021/bi0480140
   Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330
   Koppelhus U, 2003, ADV DRUG DELIVER REV, V55, P267, DOI 10.1016/S0169-409X(02)00182-5                                                   
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Lucotte G, 2002, INFECT GENET EVOL, V1, P201, DOI 10.1016/S1567-1348(02)00027-8
   Lundstrom EA, 2009, CLIN DRUG INVEST, V29, P757, DOI 10.2165/11319690-000000000-00000
   Maurisse R, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-9
   McNeer NA, 2013, GENE THER, V20, P658, DOI 10.1038/gt.2012.82
   McNeer NA, 2011, MOL THER, V19, P172, DOI 10.1038/mt.2010.200
   O'Brien SJ, 2004, NAT GENET, V36, P565, DOI 10.1038/ng1369
   Papapetrou EP, 2005, GENE THER, V12, pS118, DOI 10.1038/sj.gt.3302626
   Park MC, 2009, JOINT BONE SPINE, V76, P170, DOI 10.1016/j.jbspin.2008.04.018
   Pattanayak V, 2011, NAT METHODS, V8, P765, DOI 10.1038/nmeth.1670
   Pearson T, 2008, CURR PROTOC IMMUNOL
   Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410
   Rogers FA, 2002, P NATL ACAD SCI USA, V99, P16695, DOI 10.1073/pnas.262556899
   Rogers FA, 2012, MOL THER, V20, P109, DOI 10.1038/mt.2011.163
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Schleifman EB, 2011, CHEM BIOL, V18, P1189, DOI 10.1016/j.chembiol.2011.07.010
   Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood-2009-04-215855
   Shiraishi T, 2006, NAT PROTOC, V1, P633, DOI 10.1038/nprot.2006.92
   VANAMERSFOORT ES, 1994, CYTOMETRY, V17, P294, DOI 10.1002/cyto.990170404
   VISSCHER GE, 1985, J BIOMED MATER RES, V19, P349, DOI 10.1002/jbm.820190315
   Zhou J, 2012, BIOMATERIALS, V33, P583, DOI 10.1016/j.biomaterials.2011.09.061
NR 35
TC 8
Z9 8
U1 3
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD NOV
PY 2013
VL 2
AR e135
DI 10.1038/mtna.2013.59
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AC4CU
UT WOS:000332469000005
PM 24253260
OA gold
DA 2018-01-05
ER

PT J
AU Garcia, F
   Plana, M
   Climent, N
   Leon, A
   Gatell, JM
   Gallart, T
AF Garcia, Felipe
   Plana, Montserrat
   Climent, Nuria
   Leon, Agathe
   Gatell, Josep M.
   Gallart, Teresa
TI Dendritic cell based vaccines for HIV infection The way ahead
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE therapeutic vaccine; HIV; dendritic cells; functional cure; T cell
   responses
ID CD4(+) T-CELLS; VIRUS TYPE-1 HIV-1; ACTIVE ANTIRETROVIRAL THERAPY;
   PBL-SCID MICE; ADENOSINE-DEAMINASE; HIV-1-INFECTED PATIENTS;
   IMMUNE-RESPONSES; IN-VIVO; TREATMENT INTERRUPTION; PLA NANOPARTICLES
AB Dendritic cells have a central role in HIV infection. On one hand, they are essential to induce strong HIV-specific CD4(+) helper T-cell responses that are crucial to achieve a sustained and effective HIV-specific CD8(+) cytotoxic T-lymphocyte able to control HIV replication. On the other hand, DCs contribute to virus dissemination and HIV itself could avoid a correct antigen presentation. As the efficacy of immune therapy and therapeutic vaccines against HIV infection has been modest in the best of cases, it has been hypothesized that ex vivo generated DC therapeutic vaccines aimed to induce effective specific HIV immune responses might overcome some of these problems. In fact, DC-based vaccine clinical trials have yielded the best results in this field. However, despite these encouraging results, functional cure has not been reached with this strategy in any patient. In this Commentary, we discuss new approaches to improve the efficacy and feasibility of this type of therapeutic vaccine.
C1 [Garcia, Felipe; Plana, Montserrat; Climent, Nuria; Leon, Agathe; Gatell, Josep M.; Gallart, Teresa] Univ Barcelona, Hosp Clin HIVACAT, IDIBAPS, Barcelona, Spain.
RP Garcia, F (reprint author), Univ Barcelona, Hosp Clin HIVACAT, IDIBAPS, Barcelona, Spain.
EM fgarcia@clinic.ub.es
RI Leon, Agathe/K-9851-2015; Garcia, Felipe/F-4242-2014
OI Leon, Agathe/0000-0002-1198-5090; Garcia, Felipe/0000-0001-7658-5832;
   Climent, Nuria/0000-0002-0791-656X
FU RIS; HIVACAT; ORVACS; Red Tematica Cooperativa de Grupos de
   Investigacion en Sida del Fondo de Investigacion Sanitaria (FIS); 
   [FP7-HEALTH-2013-INNOVATION-1];  [602570-2];  [SAF 2012-39075]; 
   [EC10-153];  [PI10/02984];  [TRA-094];  [FIS PS09/01297]; 
   [SAF2008-04395]
FX This study was partially supported by grants:
   FP7-HEALTH-2013-INNOVATION-1 Proposal No: 602570-2, SAF 2012-39075,
   EC10-153, PI10/02984, TRA-094, FIS PS09/01297, SAF2008-04395, RIS*,
   HIVACAT**, ORVACS***. *Red Tematica Cooperativa de Grupos de
   Investigacion en Sida del Fondo de Investigacion Sanitaria (FIS).
   **HIVACAT: HIV development program in Catalonia. ***ORVACS: Objectif
   recherche vaccin sida.
CR Aline F, 2007, MICROBES INFECT, V9, P536, DOI 10.1016/j.micinf.2007.01.021
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010
   Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005
   Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005
   Autran B, 2004, SCIENCE, V305, P205, DOI 10.1126/science.1100600
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Blanco J, 2000, FEBS LETT, V477, P123, DOI 10.1016/S0014-5793(00)01751-8
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930
   Casanova V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051287
   Chehimi J, 2002, J IMMUNOL, V168, P4796, DOI 10.4049/jimmunol.168.9.4796                                                     
   Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493
   Climent N, 2012, AIDS VACC 2012 C BOS
   Climent N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019644
   Climent N, 2009, IMMUNOL CELL BIOL, V87, P634, DOI 10.1038/icb.2009.53
   Cohen J, 2010, SCIENCE, V330, P1301, DOI 10.1126/science.330.6009.1301                                                   
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Day CL, 2003, J EXP MED, V198, P1773, DOI 10.1084/jem.20031947
   Donaghy H, 2003, BLOOD, V101, P4505, DOI 10.1182/blood-2002-10-3189
   Dorrell L, 2005, AIDS, V19, P1321, DOI 10.1097/01.aids.0000180104.65640.16
   Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524                                                    
   Flamar A, 2012, AIDS VACC C BOST US
   Flynn BJ, 2011, P NATL ACAD SCI USA, V108, P7131, DOI 10.1073/pnas.1103869108
   Gandhi RT, 2009, VACCINE, V27, P6088, DOI 10.1016/j.vaccine.2009.05.016
   Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340                                                                  
   Garcia F, 2013, SCI TRANSL MED, V5
   Garcia F, 2012, HUM VACC IMMUNOTHER, V8, P569, DOI 10.4161/hv.19555
   Garcia F, 2011, VACCINE, V29, P6454, DOI 10.1016/j.vaccine.2011.07.043
   Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
   Gorse GJ, 2006, CLIN VACCINE IMMUNOL, V13, P26, DOI 10.1128/CVI.13.1.26-32.2006
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Ide F, 2006, J MED VIROL, V78, P711, DOI 10.1002/jmv.20612
   Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642
   Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5                                                   
   Kaech SM, 2003, SCIENCE, V300, P263, DOI 10.1126/science.1084511
   Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193                                                        
   Kloverpris H, 2009, AIDS, V23, P1329, DOI 10.1097/QAD.0b013e32832d9b00
   Kundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551
   Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1081/jem.20021924
   Larsson M, 2003, CURR TOP MICROBIOL, V276, P261
   Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Martinez-Navio JM, 2011, J LEUKOCYTE BIOL, V89, P127, DOI 10.1189/jlb.1009696
   Martinez-Navio JM, 2009, IMMUNOLOGY, V128, P393, DOI 10.1111/j.1365-2567.2009.03121.x
   Pacheco R, 2005, P NATL ACAD SCI USA, V102, P9583, DOI 10.1073/pnas.0501050102
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Papagno L, 2011, AIDS, V25, P27, DOI 10.1097/QAD.0b013e328340fe55
   Pion M, 2006, J EXP MED, V203, P2887, DOI 10.1081/jem.20061519
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rodriguez-Garcia M, 2007, J LEUKOCYTE BIOL, V82, P1143, DOI 10.1189/jlb.0507295
   Rodriguez-Garcia M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009436
   Rodriguez-Garcia M, 2009, CLIN IMMUNOL, V131, P374, DOI 10.1016/j.clim.2009.01.012
   Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009
   Routy JP, 2009, AIDS VACC 2009 C PAR
   Routy JP, 2011, 18 C RETR OPP INF BO
   Sabado RL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004256
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8
   Van Lint S, 2012, CANCER RES, V72, P1661, DOI 10.1158/0008-5472.CAN-11-2957
   Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Yoshida A, 2003, J VIROL, V77, P8719, DOI 10.1128/JVI.77.16.8719-8728.2003
NR 72
TC 20
Z9 21
U1 1
U2 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD NOV
PY 2013
VL 9
IS 11
BP 2445
EP 2452
DI 10.4161/hv.25876
PG 8
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA 299FW
UT WOS:000330382300029
PM 23912672
OA gold
DA 2018-01-05
ER

PT J
AU Buckheit, RW
   Buckheit, KW
   Sturdevant, CB
   Buckheit, RW
AF Buckheit, Robert W., Jr.
   Buckheit, Karen Watson
   Sturdevant, Christa Buckheit
   Buckheit, Robert W., III
TI Selection and characterization of viruses resistant to the dual acting
   pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor
   IQP-0410
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE HIV; Resistance; Pyrimidinediones; NNRTIs
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIGHLY POTENT; HIV-INFECTION;
   ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; IN-VITRO; TYPE-1; DERIVATIVES;
   NNRTIS; AGENTS
AB The 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT)-like compounds with homocyclic moieties at the N-1 of the pyrimidinedione, including the highly potent lead compound IQP-0410, inhibit HIV-1 at sub-nanomolar concentrations primarily through a typical non-nucleoside mechanism involving allosteric inhibition at the hydrophobic binding pocket of the HIV-1 RT. Like all NNRTIs, the pyrimidinediones have no activity against HIV-2 RT. The pyrimidinediones, however, also possess a second mode of action involving inhibition of virus entry at nanomolar concentrations which extends their range of action to include HIV-2. Entry inhibition occurs through recognition of a complex conformational binding site formed upon interaction of the virus with target cells, but does not involve direct inhibition of gp120-CD4 binding. In order to further explore the means by which the pyrimidinediones act, resistant strains of HIV-1 and HIV-2 were selected in cell culture and molecularly and biologically characterized. With HIV-1, three phases of resistance selection occurred which involve an initial appearance of single amino changes in the NNRTI binding pocket, followed by changes in the envelope glycoproteins gp120 and gp41, and subsequent multiple additional changes in the RT, resulting in high level resistance to IQP-0410. With HIV-2, resistance to entry inhibition was achieved with no resistance-engendering mutations detected in the HIV-2 RT. Detailed molecular and biological characterization of IQP-0410-resistant viruses was performed to define the resistance-engendering mutations present in the RT and envelope and to quantify cross-resistance to other HIV inhibitors. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Buckheit, Robert W., Jr.; Buckheit, Karen Watson] ImQuest BioSci Inc, Frederick, MD 21704 USA.
   [Sturdevant, Christa Buckheit] Univ N Carolina, Lineberger Comprehens Canc Ctr 22 062, Chapel Hill, NC 27599 USA.
   [Buckheit, Robert W., III] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
RP Buckheit, RW (reprint author), ImQuest BioSci Inc, 7340 Execut Way, Frederick, MD 21704 USA.
EM rbuckheit@imquestbio.com; Christa_Buckheit@med.unc.edu;
   rbuckhe2@jhmi.edu
FU NIAID/NIH [R43AI078858]
FX This work was funded in part by a Small Business Innovative Research
   (SBIR) award to ImQuest BioSciences, Inc. from NIAID/NIH (Grant
   R43AI078858).
CR Adams J, 2010, ANN PHARMACOTHER, V44, P157, DOI 10.1345/aph.1M359
   BABA M, 1992, ANTIVIR RES, V17, P245, DOI 10.1016/0166-3542(92)90021-V
   BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688                                                            
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   Blas-Garcia A, 2011, CURR MED CHEM, V18, P2186, DOI 10.2174/092986711795656180                                                      
   BOYER PL, 1993, J VIROL, V67, P2412
   Buckheit KW, 2011, ANTIMICROB AGENTS CH, V55, P5243, DOI 10.1128/AAC.05237-11
   Buckheit Robert W. Jr., 2007, Antiviral Chemistry & Chemotherapy, V18, P259
   Buckheit RW, 2008, ANTIMICROB AGENTS CH, V52, P225, DOI 10.1128/AAC.00972-07
   Buckheit RW, 1999, ANTIMICROB AGENTS CH, V43, P1827
   BUCKHEIT RW, 1995, VIROLOGY, V210, P186, DOI 10.1006/viro.1995.1330
   BUCKHEIT RW, 1995, ANTIVIR RES, V26, P117, DOI 10.1016/0166-3542(94)00069-K
   Buckheit RW, 2001, ANTIMICROB AGENTS CH, V45, P393, DOI 10.1128/AAC.45.2.393-400.2001
   Cane PA, 2009, J ANTIMICROB CHEMOTH, V64, P37, DOI 10.1093/jac/dkp258
   COHEN KA, 1991, J BIOL CHEM, V266, P14670
   CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441                                                           
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Gathe J, 2003, JAIDS-J ACQ IMM DEF, V34, pS118, DOI 10.1097/00126334-200310012-00004
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   Hartman TL, 2011, ANTIVIR RES, V92, P505, DOI 10.1016/j.antiviral.2011.10.013
   KIMPTON J, 1992, J VIROL, V66, P2232
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MCMAHON JB, 1995, ANTIMICROB AGENTS CH, V39, P484, DOI 10.1128/AAC.39.2.484                                                            
   Mellors J., 1995, INT ANTIVIRAL NEWS, V3, P8
   Milinkovic Ana, 2004, Expert Rev Anti Infect Ther, V2, P367, DOI 10.1586/14787210.2.3.367
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283
   Palmisano L, 2011, ANN I SUPER SANITA, V47, P44, DOI 10.4415/ANN_11_01_10
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Portsmouth S, 2003, CURR TOP MED CHEM, V3, P1458, DOI 10.2174/1568026033451808
   Prajapati DG, 2009, BIOORGAN MED CHEM, V17, P5744, DOI 10.1016/j.bmc.2009.06.060
   Romero DL, 1996, J MED CHEM, V39, P3769, DOI 10.1021/jm960158n
   SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   TANAKA H, 1991, J MED CHEM, V34, P1394, DOI 10.1021/jm00108a023
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   Zhan P, 2009, CURR MED CHEM, V16, P3903, DOI 10.2174/092986709789178019                                                      
   Zhan P, 2009, CURR MED CHEM, V16, P2876, DOI 10.2174/092986709788803231                                                      
NR 43
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD NOV
PY 2013
VL 100
IS 2
BP 382
EP 391
DI 10.1016/j.antiviral.2013.09.005
PG 10
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 269ID
UT WOS:000328234100012
PM 24055450
DA 2018-01-05
ER

PT J
AU Xu, LG
   Liu, Y
   Chen, ZY
   Li, W
   Liu, Y
   Wang, LM
   Ma, LY
   Shao, YM
   Zhao, YL
   Chen, CY
AF Xu, Ligeng
   Liu, Ye
   Chen, Zhiyun
   Li, Wei
   Liu, Ying
   Wang, Liming
   Ma, Liying
   Shao, Yiming
   Zhao, Yuliang
   Chen, Chunying
TI Morphologically Virus-Like Fullerenol Nanoparticles Act as the
   Dual-Functional Nanoadjuvant for HIV-1 Vaccine
SO ADVANCED MATERIALS
LA English
DT Article
DE fullerenol; virus-like particle; nano-adjuvant; HIV-1; vaccine
ID YELLOW-FEVER VACCINE; POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES; TOLL-LIKE
   RECEPTORS; T-CELL MEMORY; IMMUNE-RESPONSES; INNATE IMMUNITY; RECOGNITION
   RECEPTORS; DENDRITIC CELLS; DNA; ADJUVANT
C1 [Xu, Ligeng; Liu, Ye; Chen, Zhiyun; Wang, Liming; Chen, Chunying] Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Li, Wei; Wang, Liming; Zhao, Yuliang] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Liu, Ye; Ma, Liying; Shao, Yiming] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Div Res Virol & Immunol, Beijing 102206, Peoples R China.
RP Shao, YM (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Div Res Virol & Immunol, 155 Changbai Rd, Beijing 102206, Peoples R China.
EM yshao08@gmail.com; zhaoyuliang@ihep.ac.cn; chenchy@nanoctr.cn
RI Xu, Ligeng/F-9844-2013; Wang, Liming/A-6924-2012
OI Xu, Ligeng/0000-0003-4946-2567; Wang, Liming/0000-0003-1382-9195
FU Ministry of Science and Technology of China [2011CB933401, 2012CB934003,
   2010CB934004]; National Major ST Program [2012ZX10001-008];
   International Science & Technology Cooperation Program of China
   [2013DFG32340]; National Major Scientific Instruments Development
   Project [2011YQ03013406]; Natural Science Foundation of China [21001034,
   31070854]; German Federal Ministry of Education and Research [BMBF
   0315773A]
FX The authors acknowledge the financial support by the Ministry of Science
   and Technology of China as the National Basic Research Programs
   (2011CB933401, 2012CB934003 and 2010CB934004), National Major S&T
   Program (2012ZX10001-008), International Science & Technology
   Cooperation Program of China (2013DFG32340) and National Major
   Scientific Instruments Development Project (2011YQ03013406), the Natural
   Science Foundation of China (21001034 and 31070854), and German Federal
   Ministry of Education and Research (BMBF 0315773A).
CR Abbas AK, 2010, BASIC IMMUNOLOGY FUN
   Bachmann MF, 1997, P NATL ACAD SCI USA, V94, P640, DOI 10.1073/pnas.94.2.640                                                           
   Brant JA, 2007, J COLLOID INTERF SCI, V314, P281, DOI 10.1016/j.jcis.2007.05.020
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019976
   Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706
   Hamasaki T, 2010, CLIN VACCINE IMMUNOL, V17, P748, DOI 10.1128/CVI.00505-09
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Janeway CA, 1998, SEMIN IMMUNOL, V10, P349, DOI 10.1006/smim.1998.0142                                                          
   Jiao F, 2010, CARBON, V48, P2231, DOI 10.1016/j.carbon.2010.02.032
   Jo JI, 2008, EUR J PHARM BIOPHARM, V68, P90, DOI 10.1016/j.ejpb.2007.04.021
   Joint United Nations Programme on HIV/AIDS, 2010, UNAIDS REP GLOB AIDS
   Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3                                                   
   Kapsenberg M. L., 1998, ENCY IMMUNOLOGY
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Keitel W, 2010, VACCINE, V28, P840, DOI 10.1016/j.vaccine.2009.10.019
   Lao F, 2009, ACS NANO, V3, P3358, DOI 10.1021/nn900912n
   Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378
   Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107
   Liu Y, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/41/415102
   Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001
   Locher CP, 2003, IMMUNOL LETT, V90, P67, DOI 10.1016/j.imlet.2003.02.001
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Mori T, 2006, TOXICOLOGY, V225, P48, DOI 10.1016/j.tox.2006.05.001
   Mumper RJ, 2001, MOL BIOTECHNOL, V19, P79, DOI 10.1385/MB:19:1:079
   Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P9293, DOI 10.1073/pnas.96.16.9293
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   Pulendran B, 2005, J IMMUNOL, V174, P2457, DOI 10.4049/jimmunol.174.5.2457                                                     
   Pulendran B, 2009, NAT REV IMMUNOL, V9, P741, DOI 10.1038/nri2629
   Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   Robinson HL, 2005, NAT MED, V11, pS25, DOI 10.1038/nm1212
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Sharma R, 1999, JMRI-J MAGN RESON IM, V9, P291, DOI 10.1002/(SICI)1522-2586(199902)9:2<291::AID-JMRI21>3.0.CO;2-#                   
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Tamayo I, 2010, CLIN VACCINE IMMUNOL, V17, P1356, DOI 10.1128/CVI.00164-10
   Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038
   Uto T, 2011, BIOMATERIALS, V32, P5206, DOI 10.1016/j.biomaterials.2011.03.052
   Vileno B, 2006, ADV FUNCT MATER, V16, P120, DOI 10.1002/adfm.200500425
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wilsonl KD, 2009, J GENE MED, V11, P14, DOI 10.1002/jgm.1267
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yamashita K, 2009, TOXICOLOGY, V261, P19, DOI 10.1016/j.tox.2009.04.034
   Yang D, 2010, ACS NANO, V4, P1178, DOI 10.1021/nn901478z
NR 55
TC 32
Z9 32
U1 12
U2 94
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD NOV
PY 2013
VL 25
IS 41
BP 5928
EP 5936
DI 10.1002/adma.201300583
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 261VO
UT WOS:000327692900014
PM 23963730
DA 2018-01-05
ER

PT J
AU Jimenez-Mancilla, N
   Ferro-Flores, G
   Santos-Cuevas, C
   Ocampo-Garcia, B
   Luna-Gutierrez, M
   Azorin-Vega, E
   Isaac-Olive, K
   Camacho-Lopez, M
   Torres-Garcia, E
AF Jimenez-Mancilla, Nallely
   Ferro-Flores, Guillermina
   Santos-Cuevas, Clara
   Ocampo-Garcia, Blanca
   Luna-Gutierrez, Myrna
   Azorin-Vega, Erika
   Isaac-Olive, Keila
   Camacho-Lopez, Miguel
   Torres-Garcia, Eugenio
TI Multifunctional targeted therapy system based on Tc-99m/Lu-177-labeled
   gold nanoparticles-Tat(49-57)-Lys(3)-bombesin internalized in nuclei of
   prostate cancer cells
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Article
DE gold nanoparticles; radiolabeled nanoparticles; Lys(3)-bombesin;
   radiolabeled peptides; nanoparticle-peptide; Tat peptide; lutetium-177;
   technetium-99m
ID PEPTIDE-RECEPTOR; IN-VITRO; TAT PEPTIDE; NANOPARTICLES; LOCALIZATION;
   BIOKINETICS; XENOGRAFTS; EXPRESSION; DOSIMETRY; RADIATION
AB Radiolabeled gold nanoparticles may function simultaneously as radiotherapy and thermal ablation systems. The gastrin-releasing peptide receptor (GRP-r) is overexpressed in prostate cancer, and Lys(3)-bombesin is a peptide that binds with high affinity to the GRP-r. HIV Tat(49-57) is a cell-penetrating peptide that reaches the DNA. In cancer cells, Lu-177 shows efficient crossfire effect, whereas Tc-99m that is internalized in the cancer cell nuclei acts as an effective system of targeted radiotherapy because of the biological Auger effect. The aim of this research was to evaluate the in vitro potential of Tc-99m-labeled and Lu-177-labeled gold nanoparticles conjugated to Tat(49-57)-Lys(3)-bombesin peptides (Tc-99m/Lu-177-AuNP-Tat-BN) as a plasmonic photothermal therapy and targeted radiotherapy system in PC3 prostate cancer cells. Peptides were conjugated to AuNPs (5nm) by spontaneous reaction with the thiol group of cysteine (Cys). The effect on PC3 cell viability after laser heating of the AuNP-Tat-BN incubated with the cancer cells was conducted using an Nd:YAG laser pulsed for 5ns at 532nm (0.65W/cm(2)). For the Tc-99m/Lu-177-AuNP-Tat-BN to be obtained, the Lu-177-DOTA-Gly-Gly-Cys and Tc-99m-HYNIC-octreotide radiopeptides were first prepared and added simultaneously to a solution of AuNP-Tat-BN. Tc-99m/Lu-177-AuNP-Tat-BN (20Bq/cell) was incubated with PC3 cells, and the effect on the cell proliferation was evaluated after 3days. Fluorescence images of Tc-99m/Lu-177-AuNP-Tat-BN internalized in nuclei of PC3 were also obtained. After laser irradiation, the presence of AuNP-Tat-BN caused a significant increase in the temperature of the medium (46.4 vs 39.5 degrees C of that without AuNP) resulting in a significant decrease in PC3 cell viability down to 1.3%. After treatment with Tc-99m/Lu-177-AuNP-Tat-BN, the PC3 cell proliferation was inhibited. The nanosystem exhibited properties suitable for plasmonic photothermal therapy and targeted radiotherapy in the treatment of prostate cancer.
C1 [Jimenez-Mancilla, Nallely; Ferro-Flores, Guillermina; Santos-Cuevas, Clara; Ocampo-Garcia, Blanca; Luna-Gutierrez, Myrna; Azorin-Vega, Erika] Inst Nacl Invest Nucl, Dept Mat Radiact, Ocoyoacac 52750, Estado De Mexic, Mexico.
   [Jimenez-Mancilla, Nallely; Luna-Gutierrez, Myrna; Isaac-Olive, Keila; Camacho-Lopez, Miguel; Torres-Garcia, Eugenio] Univ Autonoma Estado De Mexico, Fac Med, Toluca, Estado De Mexic, Mexico.
RP Ferro-Flores, G (reprint author), Inst Nacl Invest Nucl, Dept Mat Radiact, Carretera Mexico Toluca S-N, Ocoyoacac 52750, Estado De Mexic, Mexico.
EM ferro_flores@yahoo.com.mx
RI Torres-Garcia, Eugenio/B-3234-2016
OI Torres-Garcia, Eugenio/0000-0001-8355-3927; Luna-Gutierrez, Myrna
   Alejandra/0000-0002-4082-3816; Jimenez-Mancilla, Nallely
   Patricia/0000-0001-9480-4621; azorin-vega, erika
   patricia/0000-0002-7520-461X; Isaac-Olive, Keila/0000-0003-4388-3811;
   FERRO-FLORES, GUILLERMINA/0000-0003-0296-7605; Santos-Cuevas, Clara
   L./0000-0001-5903-1598; Ocampo-Garcia, Blanca E./0000-0002-5831-8412
FU Mexican National Council of Science and Technology
   [CONACYT-SEP-CB-2010-01-150942]
FX The authors are grateful for the support of the Mexican National Council
   of Science and Technology (CONACYT-SEP-CB-2010-01-150942).
CR Baidoo KE, 1998, BIOCONJUGATE CHEM, V9, P218, DOI 10.1021/bc9701959                                                               
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Bodei L, 2008, EUR J NUCL MED MOL I, V35, P1847, DOI 10.1007/s00259-008-0778-1
   Buchegger F, 2006, EUR J NUCL MED MOL I, V33, P1352, DOI 10.1007/s00259-006-0187-2
   Chanda N, 2010, P NATL ACAD SCI USA, V107, P8760, DOI 10.1073/pnas.1002143107
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cornelissen B, 2008, NUCL MED BIOL, V35, P101, DOI 10.1016/j.nucmedbio.2007.09.007
   Costantini DL, 2008, CANCER BIOTHER RADIO, V23, P3, DOI 10.1089/cbr.2007.0430
   Coulter JA, 2012, INT J NANOMED, V7, P2673, DOI 10.2147/IJN.S31751
   Curley Steven A, 2008, J Exp Ther Oncol, V7, P313
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   de Visser M, 2007, J NUCL MED, V48, P88
   Feinendegen LE, 2012, NUKLEARMED-NUCL MED, V51, P161
   Ferro-Flores G, 2006, NUCL MED COMMUN, V27, P371, DOI 10.1097/01.mnm.0000202863.52046.7f                                              
   Ferro-Flores G, 2006, CURR PHARM ANAL, V2, P339, DOI 10.2174/157341206778699555                                                      
   Franckena M, 2010, CURR OPIN OBSTET GYN, V22, P9, DOI 10.1097/GCO.0b013e328333d1e2
   Franckena M, 2009, EUR J CANCER, V45, P1969, DOI 10.1016/j.ejca.2009.03.009
   Garayoa EG, 2007, NUCL MED BIOL, V34, P17, DOI 10.1016/j.nucmedbio.2006.10.004
   Glazer ES, 2010, CLIN CANCER RES, V16, P5712, DOI 10.1158/1078-0432.CCR-10-2055
   Gonzalez-Vazquez A, 2006, APPL RADIAT ISOTOPES, V64, P792, DOI 10.1016/j.apradiso.2006.01.015
   Huang XH, 2010, ACS NANO, V4, P5887, DOI 10.1021/nn102055s
   Huang XH, 2010, METHODS MOL BIOL, V624, P343, DOI 10.1007/978-1-60761-609-2_23
   Jadzinsky PD, 2007, SCIENCE, V318, P430, DOI 10.1126/science.1148624
   Jimenez-Mancilla N, 2012, CURR NANOSCI, V8, P193, DOI 10.2174/157341312800167678                                                      
   Joseph Y, 2003, J PHYS CHEM B, V107, P7406, DOI 10.1021/jp030439o
   Koumarianou E, 2009, NUCL MED BIOL, V36, P591, DOI 10.1016/j.nucmedbio.2009.03.006
   Letfullin RR, 2011, NANOMED-NANOTECHNOL, V7, P137, DOI 10.1016/j.nano.2010.06.011
   Levy R, 2004, J AM CHEM SOC, V126, P10076, DOI 10.1021/ja0487269
   Linder KE, 2009, BIOCONJUGATE CHEM, V20, P1171, DOI 10.1021/bc9000189
   Luna-Gutierrez M, 2012, J LABELLED COMPD RAD, V55, P140, DOI 10.1002/jlcr.2910
   Lundqvist Hans, 2008, P195, DOI 10.1007/978-1-4020-8696-0_11
   Maeda H, 2012, J CONTROL RELEASE, V164, P138, DOI 10.1016/j.jconrel.2012.04.038
   Mendoza-Sanchez AN, 2010, J BIOMED NANOTECHNOL, V6, P375, DOI 10.1166/jbn.2010.1132
   Montet X, 2006, J MED CHEM, V49, P6087, DOI 10.1021/jm060515m
   Morales-Avila E, 2011, BIOCONJUGATE CHEM, V22, P913, DOI 10.1021/bc100551s
   Ocampo-Garcia B, 2011, NUCL MED COMMUN, V32, P1095, DOI 10.1097/MNM.0b013e32834acf33
   Ocampo-Garcia BE, 2011, NUCL MED BIOL, V38, P1, DOI 10.1016/j.nucmedbio.2010.07.007
   Olmedo I, 2008, BIOCONJUGATE CHEM, V19, P1154, DOI 10.1021/bc800016y
   Petroski J, 2009, J ORGANOMET CHEM, V694, P1138, DOI 10.1016/j.jorganchem.2008.11.057
   Porta F, 2007, MAT SCI ENG B-SOLID, V140, P187, DOI 10.1016/j.mseb.2007.03.019
   Santos-Cuevas CL, 2008, NUCL MED COMMUN, V29, P741, DOI 10.1097/MNM.0b013e3282ffb45c
   Santos-Cuevas CL, 2011, NUCL MED COMMUN, V32, P303, DOI 10.1097/MNM.0b013e328341b27f
   Santos-Cuevas CL, 2009, INT J PHARMACEUT, V375, P75, DOI 10.1016/j.ijpharm.2009.04.018
   Tedesco S, 2010, COMP BIOCHEM PHYS C, V151, P167, DOI 10.1016/j.cbpc.2009.10.002
NR 45
TC 26
Z9 26
U1 6
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
EI 1099-1344
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD NOV
PY 2013
VL 56
IS 13
BP 663
EP 671
DI 10.1002/jlcr.3087
PG 9
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
   Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 256LW
UT WOS:000327312900004
PM 25196028
DA 2018-01-05
ER

PT J
AU Gogtay, JA
   Malhotra, G
AF Gogtay, Jaideep A.
   Malhotra, Geena
TI Reformulation of existing antiretroviral drugs
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE antiretroviral therapy; nanomedicine; reformulation
ID NEVIRAPINE
AB Purpose of reviewIn the last decade, there has been marked progress in the treatment of HIV/AIDS. Today, nearly 10 million people are receiving ART. Yet, there are several opportunities for the enhancement of current antiretroviral (ARV) drugs by developing new formulations, which could increase bioavailability, reduce pharmacokinetic variability, and reduce the total daily dose.Recent findingsSignificant developments are occurring in new formulations of ARV drugs. The introduction of once daily combination pills and combination dispersible pills for children have been important steps. Several researchers and pharmaceutical companies are using nanomedicine for improved formulations and to reduce the dose. Other novel methods include intramuscular depot formulations, vaginal gels for prevention of transmission and sprinkle formulations for children. Regulatory approval, efficacy, safety and cost-effectiveness are factors that will have to be determined for the new formulations. Collaboration between pharmaceutical companies, academic centers, funding agencies and regulatory agencies will be crucial to achieve this goal.SummaryIn this review, we describe the objectives of new formulations, recent advances including combinations, copackaged drugs, nanomedicine, pediatric products and new routes of delivery and the challenges that lie ahead.
C1 [Gogtay, Jaideep A.] Med Serv Dept, Bombay, Maharashtra, India.
   [Malhotra, Geena] Integrated Prod Dev, Bombay, Maharashtra, India.
RP Gogtay, JA (reprint author), Cipla Ltd, Med Serv Dept, Mumbai Cent, Bombay 400008, Maharashtra, India.
EM jgogtay@cipla.com
CR Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Balkundi S, 2011, INT J NANOMED, V5, P592
   Drugs for Neglected Diseases initiative, DNDI CIPL ADV DEV PA
   Ferguson LM, 2011, THER DELIV, V2, P1535, DOI [10.4155/tde.11.126, 10.4155/TDE.11.126]
   Fillekes Q, 2012, AIDS, V26, P1795, DOI 10.1097/QAD.0b013e32835705fd
   Gathe J, 2011, ANTIVIR THER, V16, P759, DOI 10.3851/IMP1803
   Holt BY, 2010, CONTRACEPTION, V81, P177, DOI 10.1016/j.contraception.2009.11.009
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Martin P, 2013, 20 C RETR OPP INF AT
   Nachega JB, 2011, PATIENT PREFER ADHER, V5, P645, DOI 10.2147/PPA.S27558
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Parienti JJ, 2009, CLIN INFECT DIS, V48, P484, DOI 10.1086/596482
   Siccardi M, 2013, THER DELIV, V4, P149
   Spreen W, 2013, 7 INT AIDS SOC C 30
   UNAIDS, REC 10 MILL PEOPL LI
   World Health Organization (WHO), 2013, CONS GUID US ANT DRU
NR 17
TC 2
Z9 3
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD NOV
PY 2013
VL 8
IS 6
BP 550
EP 555
DI 10.1097/COH.0000000000000006
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 248UJ
UT WOS:000326729400005
PM 24100875
DA 2018-01-05
ER

PT J
AU Spreen, WR
   Margolis, DA
   Pottage, JC
AF Spreen, William R.
   Margolis, David A.
   Pottage, John C., Jr.
TI Long-acting injectable antiretrovirals for HIV treatment and prevention
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE GSK1265744; HIV-1; long-acting injectable antiretroviral;
   nanoformulation; rilpivirine; TMC278 LA
ID PREEXPOSURE PROPHYLAXIS; PHARMACOKINETICS; INFECTION; WOMEN
AB Purpose of reviewLong-acting antiretroviral (ARV) drugs may improve adherence to therapy and extend opportunities for therapeutic or prophylactic intervention to underserved patient populations. This review focuses on recent advances in the development of small molecule long-acting injectable ARV agents.Recent findingsThe need for combination ART and physicochemical and dosing limitations of current ARV drugs impede attempts to redevelop them as long-acting injectable formulations. However, the intrinsic properties of rilpivirine, a nonnucleoside reverse transcriptase inhibitor, and GSK1265744, an HIV-1 integrase strand transfer inhibitor, have enabled crystalline nanoparticle formulations to progress to clinical trials.SummaryInvestigational long-acting injectable nanoformulations of rilpivirine and GSK1265744 are clinical-stage development candidates. Complementary pharmacologic properties of both agents - different mechanisms of action, resistance profiles, metabolic pathways, lack of drug interactions and low daily oral doses - offer the potential for combination use. Phase I studies of the pharmacokinetics and safety of each long-acting formulation alone and in combination indicate that a monthly dosing regimen is possible for HIV treatment. An ongoing phase IIb trial of oral GSK1265744 and oral rilpivirine is evaluating this two-drug regimen for maintenance of virologic suppression; results will inform future studies using the injectable formulations. Additional preclinical and clinical studies indicate a potential use of each agent for HIV pre-exposure prophylaxis.
C1 [Spreen, William R.; Margolis, David A.] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
   [Pottage, John C., Jr.] ViiV Healthcare, Philadelphia, PA USA.
RP Spreen, WR (reprint author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM william.r.spreen@gsk.com
FU GlaxoSmithKline
FX W. R. S. is an employee of GlaxoSmithKline, owns stock/ stock options,
   and receives support for travel to meetings for the study or other
   purposes from GlaxoSmithKline. D. A. M. is an employee of
   GlaxoSmithKline and owns stock/ stock options. J. C. P., Jr, is an
   employee of ViiV Healthcare and owns stock/ stock options.
CR Adams CE, 2001, BRIT J PSYCHIAT, V179, P290, DOI 10.1192/bjp.179.4.290                                                           
   Andrews C, 2013, 20 C RETR OPP INF AT
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bruno CJ, 2010, J ANTIMICROB CHEMOTH, V65, P1839, DOI 10.1093/jac/dkq261
   Ford S, 2013, 14 INT WORKSH CLIN P
   Ford SL, 2012, 52 INT C ANT AG CHEM
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Jackson A., 2012, 19 C RETR OPP INF SE
   Marrazzo J. M., 2013, 20 C RETR OPP INF AT
   Min S, 2009, 49 INT C ANT AG CHEM
   ViiV Healthcare, 2012, DOS RANG STUD GSK126
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Puligujja P, 2013, NANOMEDICINE
   Schooler NR, 2003, J CLIN PSYCHIAT, V64, P14
   Spreen W, 2013, 7 INT AIDS SOC C HIV
   Spreen W., 2012, 19 INT AIDS C WASH D
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   UNAIDS, 2012, GLOB REP UNAIDS REP
   Underwood M, 2010, 28 INT AIDS C VIENN
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Verloes R., 2008, 17 INT AIDS C MEX CI
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-8724(03)00136-7
   Yoshinaga T, 2012, 52 INT C ANT AG CHEM
NR 26
TC 96
Z9 97
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD NOV
PY 2013
VL 8
IS 6
BP 565
EP 571
DI 10.1097/COH.0000000000000002
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 248UJ
UT WOS:000326729400007
PM 24100877
OA gold
DA 2018-01-05
ER

PT J
AU Dukhin, SS
   Labib, ME
AF Dukhin, Stanislav S.
   Labib, Mohamed E.
TI Convective diffusion of nanoparticles from the epithelial barrier toward
   regional lymph nodes
SO ADVANCES IN COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE Convective diffusion; Interstitium hydrodynamics; Interstitium channels;
   Effective channels; Foci; Effective foci; Epithelial barrier defects;
   Lymphatic vaccine delivery; Therapeutic nanoparticles; Quantum dots; HIV
   prevention
ID MATHEMATICAL-MODEL; QUANTUM DOTS; TRANSPORT; FLOW; CAPILLARIES; SIZE;
   MACROMOLECULES; PHYSIOLOGY; LIPOSOMES; PATTERNS
AB Drug delivery using nanoparticles as drug carriers has recently attracted the attention of many investigators. Targeted delivery of nanoparticles to the lymph nodes is especially important to prevent cancer metastasis or infection, and to diagnose disease stage. However, systemic injection of nanoparticles often results in organ toxicity because they reach and accumulate in all the lymph nodes in the body. An attractive strategy would be to deliver the drug-loaded nanoparticles to a subset of draining lymph nodes corresponding to a specific site or organ to minimize systemic toxicity. In this respect, mucosal delivery of nanoparticles to regional draining lymph nodes of a selected site creates a new opportunity,to accomplish this task with minimal toxicity. One example is the delivery of nanoparticles from the vaginal lumen to draining lymph nodes to prevent the transmission of HIV in women. Other known examples include mucosal delivery of vaccines to induce immunity. In all cases, molecular and particle transport by means of diffusion and convective diffusion play a major role. The corresponding transport processes have common inherent regularities and are addressed in this review. Here we use nanoparticle delivery from the vaginal lumen to the lymph nodes as an example to address the many aspects of associated transport processes. In this case, nanoparticles penetrate the epithelial barrier and move through the interstitium (tissue) to the initial lymphatics until they finally reach the lymph nodes.
   Since the movement of interstitial liquid near the epithelial barrier is retarded, nanoparticle transport was found to take place through special foci present in the epithelium. Immediately after nanoparticles emerge from the foci, they move through the interstitium due to diffusion affected by convection (convective diffusion). Specifically, the convective transport of nanoparticles occurs due to their convection together with interstitial fluid through the interstitium toward the initial lymph capillaries. Afterwards, nanoparticles move together with the lymph flow along the initial lymph capillaries and then enter the afferent lymphatics and ultimately reach the lymph node. As the liquid moves through the interstitium toward the initial lymph capillaries due to the axial movement of lymph along the lymphatics, the theory for coupling between lymph flow and concomitant flow through the interstitium is developed to describe this general case.
   The developed theory is applied to interpret the large uptake of Qdots by lymph nodes during inflammation, which is induced by pre-treating mouse vagina with the surfactant Nonoxynol-9 prior to instilling the Qdots. Inflammation is viewed here to cause broadening of the pores within the interstitium with the concomitant formation of transport channels which function as conduits to transport the nanoparticles to the initial lymph capillaries. We introduced the term "effective channels" to denote those channels which interconnect with foci present in the epithelial barrier and which function to transport nanoparticles to initial lymph capillaries. The time of transport toward the lymph node, predicated by the theory, increases rapidly with increasing the distance y(0) between the epithelial barrier and the initial lymph capillaries. Transport time is only a few hours, when y(0) is small, about some R (where R is the initial lymph capillary radius), due to the predomination of a rather rapid convection in this case. This transport time to the lymph nodes may be tens of hours (or longer) when y(0) is essentially larger and the slow diffusion controls the transport rate in a zone not far from the epithelial barrier, where convection is weak at large y(0). Accounting for transport by diffusion only, which is mainly considered in many relevant publications, is not sufficient to explain our nanoparticle uptake kinetics because the possibility of fast transport due to convection is overlooked. Our systematic investigations have revealed that the information about the main transport conditions, namely, y(0) and the pore broadening up to the dimension of the interstitial transport channels, is necessary to create the quantitative model of enhanced transport during inflammation with the use of the proposed model as a prerequisite.
   The modeling for convective diffusion of nanoparticles from the epithelial barrier to the lymph node has been mainly accomplished here, while the diffusion only scenario is accounted for in other studies. This first modeling is a semi-quantitative one. A more rigorous mathematical approach is almost impossible at this stage because the transport properties of the model are introduced here for the first time. These properties include: discovery of foci in the epithelium, formation of transport channels, definition of channels interconnecting with foci (effective foci and channels), generation of flow in the interstitium toward the initial lymph capillaries due to axial flow within afferent lymphatics, deformation of this flow due to hydrodynamic impermeability of the squamous layer with the formation of the hydrodynamic stagnation zone near the epithelial barrier, predomination of slow diffusion transport within the above zone, and predomination of fast convection of nanoparticles near the initial lymph capillaries. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Dukhin, Stanislav S.] New Jersey Inst Technol, Dept Civil & Environm Engn, Newark, NJ 07102 USA.
   [Dukhin, Stanislav S.; Labib, Mohamed E.] Novaflux Technol, Princeton, NJ 08540 USA.
RP Labib, ME (reprint author), Novaflux Technol, 1 Wall St, Princeton, NJ 08540 USA.
EM labib@novaflux.com
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health [R21AI082738, R33AI082738]
FX The authors acknowledge funding for this research from the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health (grant numbers R21AI082738 and R33AI082738). The authors
   especially acknowledge the key contributions of Dr. Byron Ballou and Ms.
   Susan Andreko of Carnegie Mellon University for performing the Qdot
   uptake experiments in the mouse model and for providing the data to
   support the development of the models presented in this paper. We would
   like to thank Dr. Thomas Hope and his laboratory staff at Northwestern
   University for the results that elucidated the presence of foci in the
   epithelial barrier. Special thanks are dedicated to Dr. Yacoob Tabani
   for his great effort in preparing this manuscript and the figures, and
   to Ms. Anita Labib for editing and enhancing the final version of this
   review.
CR AUKLAND K, 1993, PHYSIOL REV, V73, P1
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Ballou B, 2012, PLOS ONE, V7
   Ballou B, 2007, BIOCONJUGATE CHEM, V18, P389, DOI 10.1021/bc060261j
   Berk DA, 1996, AM J PHYSIOL-HEART C, V270, pH330
   CASLEYSMITH JR, 1978, TISSUE CELL, V10, P571, DOI 10.1016/S0040-8166(16)30350-0                                                   
   Catalone BJ, 2005, ANTIMICROB AGENTS CH, V49, P1509, DOI 10.1128/AAC.49.4.1509-1520.2005
   Catalone BJ, 2004, ANTIMICROB AGENTS CH, V48, P1837, DOI 10.1128/AAC.48.5.1837-1847.2004
   Cone RA, 2006, BMC INFECT DIS, V6, P1471
   de Witte L, 2008, TRENDS MOL MED, V14, P12, DOI 10.1016/j.molmed.2007.11.001
   Dukhin SS, 2010, J COLLOID INTERF SCI, V350, P1, DOI 10.1016/j.jcis.2010.04.049
   Elimelech M., 1995, PARTICLE DEPOSITION
   Galie P, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3212108
   Gashev A A, 2001, Ross Fiziol Zh Im I M Sechenova, V87, P97
   Gashev AA, 2002, ANN NY ACAD SCI, V979, P178, DOI 10.1111/j.1749-6632.2002.tb04878.x                                              
   Gashev AA, 2002, J PHYSIOL-LONDON, V540, P1023, DOI 10.1113/jphysiol.2002.016642
   Granger HJ, 1975, P WORKSHOP ALBUMIN, P114
   Grinberg GA, 1948, COLLECTION PROBLEMS
   GUYTON AC, 1966, CIRC RES, V19, P412
   Guyton AC, 1978, FED PROC, V35, P1861
   Happel J, 1966, LOW REYNOLDS NUMBER
   HAWLEY AE, 1995, ADV DRUG DELIVER REV, V17, P129, DOI 10.1016/0169-409X(95)00045-9
   Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Lai SK, 2009, ADV DRUG DELIV REV, V27, P86
   Landau L. D., 1959, FLUID MECH
   LANDAU LD, 1960, ELECTRODYNAMICS CONT, pCH1
   LEAK LV, 1971, J CELL BIOL, V50, P300, DOI 10.1083/jcb.50.2.300                                                            
   LEU AJ, 1994, AM J PHYSIOL-HEART C, V267, pH1507
   Levich V.G., 1962, PHYSICOCHEMICAL HYDR
   LEWIS GP, 1970, BRIT J PHARMACOL, V40, P446, DOI 10.1111/j.1476-5381.1970.tb10626.x                                              
   Liu J, 2006, LUNG CANCER, V51, P377, DOI 10.1016/j.lungcan.2005.11.006
   Lyklema J, 2000, FUNDAMENTALS COLLOID, V1
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Margaris KN, 2012, J R SOC INTERFACE, V9, P601, DOI 10.1098/rsif.2011.0751
   Mendoza E, 2003, J BIOMECH, V21, P118
   Olszewski WL, 2002, ANN NY ACAD SCI, V979, P52, DOI 10.1111/j.1749-6632.2002.tb04867.x                                              
   Oussoren C, 2001, ADV DRUG DELIVER REV, V50, P143, DOI 10.1016/S0169-409X(01)00154-5
   Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
   PARKER JC, 1985, J APPL PHYSIOL, V59, P1128
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X
   POWERS MR, 1988, AM J PHYSIOL, V254, pH89
   Probstein R.F., 1989, PHYSICOCHEMICAL HYDR
   REDDY NP, 1995, MED ENG PHYS, V17, P134, DOI 10.1016/1350-4533(95)91885-K
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, J APPL PHYSIOL, V101, P1162, DOI 10.1152/japplphysiol.00389.2006
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Russel WB, 1989, COLLOIDAL DISPERSION
   Saraf S, 2011, RES J NANOSCI NANOTE, V1, P60
   SWABB EA, 1974, CANCER RES, V34, P2814
   Swartz MA, 1996, AM J PHYSIOL-HEART C, V270, pH324
   Swartz MA, 1999, J BIOMECH, V32, P1297, DOI 10.1016/S0021-9290(99)00125-6
   Swartz MA, 2001, ADV DRUG DELIVER REV, V50, P3, DOI 10.1016/S0169-409X(01)00150-8
   TAYLOR DG, 1990, MICROVASC RES, V39, P253, DOI 10.1016/0026-2862(90)90042-P
   TUMER A, 1983, J MUSCLE RES CELL M, V4, P103, DOI 10.1007/BF00711961
   van de Ven T. G. M., 1989, COLLOIDAL HYDRODYNAM
   Veronese F, 2011, AIDS RES HUM RETROV, V27, P81, DOI [10.1089/aid.2010.0226, 10.1089/AID.2010.0226]
   Zawieja DC, 2011, MICROLYMPHATIC BIOL
NR 58
TC 14
Z9 14
U1 1
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-8686
EI 1873-3727
J9 ADV COLLOID INTERFAC
JI Adv. Colloid Interface Sci.
PD NOV
PY 2013
VL 199
BP 23
EP 43
DI 10.1016/j.cis.2013.06.002
PG 21
WC Chemistry, Physical
SC Chemistry
GA 245TM
UT WOS:000326486700003
PM 23859221
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhao, CQ
   Qu, XG
AF Zhao, Chuanqi
   Qu, Xiaogang
TI Recent progress in G-quadruplex DNA in deep eutectic solvent
SO METHODS
LA English
DT Article
DE G-quadruplex; Parallel structure; Deep eutectic solvent; Ultrastability
ID TELOMERIC G-QUADRUPLEX; INTRAMOLECULAR G-QUADRUPLEX; HYDRATED IONIC
   LIQUIDS; K+ SOLUTION; HIV-1 INTEGRASE; NUCLEIC-ACIDS; SEQUENCE;
   STABILITY; FORMS; BINDING
AB Guanine-rich nucleic acids are known to form four-stranded G-quadruplex structures which are attracting increasing attention in diverse areas such as biology, medicinal chemistry, supramolecular chemistry and nanotechnology. To date, the handling media for DNA has largely been limited to an aqueous phase. Since many chemical reactions and devices are required to be performed under strictly anhydrous conditions, even at high temperature, it is meaningful but challenging to conduct G-quadruplex DNA in water-free medium. Recently, deep eutectic solvent (DES), a related material to ionic liquilds (ILs) was considered as a new class of anhydrous media for DNA. This review highlights the stability, structure, folding dynamics and thermodynamics of G-quadruplex in DES. Spectroscopic methodologies, like circular dichroism, UV and fluorescence, are mainly employed in these studies. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Zhao, Chuanqi; Qu, Xiaogang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Rare Earth Resource Utilizat, Lab Chem Biol,Div Biol Inorgan Chem, Changchun 130022, Jilin, Peoples R China.
RP Qu, XG (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Rare Earth Resource Utilizat, Lab Chem Biol,Div Biol Inorgan Chem, Changchun 130022, Jilin, Peoples R China.
EM xqu@ciac.jl.cn
RI Qu, xiaogang/M-9472-2016
OI Zhao, Chuanqi/0000-0003-1211-3873
FU 973 Project [2011CB936004, 2012CB720602]; NSFC [21210002, 91213302,
   21202158]
FX This work was supported by 973 Project (2011CB936004, 2012CB720602), and
   NSFC (21210002, 91213302, 21202158).
CR Abbott AP, 2004, J AM CHEM SOC, V126, P9142, DOI 10.1021/ja048266j
   Abe H, 2012, ANGEW CHEM INT EDIT, V51, P6475, DOI 10.1002/anie.201201111
   Alberti P, 2003, P NATL ACAD SCI USA, V100, P1569, DOI 10.1073/pnas.0335459100
   Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428
   Carriazo D, 2012, CHEM SOC REV, V41, P4996, DOI 10.1039/c2cs15353j
   Chandran A, 2012, J AM CHEM SOC, V134, P20330, DOI [10.1021/0304519d, 10.1021/ja304519d]
   Constantinescu D, 2007, ANGEW CHEM INT EDIT, V46, P8887, DOI 10.1002/anie.200702295
   Dai JX, 2007, NUCLEIC ACIDS RES, V35, P4927, DOI 10.1093/nar/gkm522
   Debeljuh N, 2011, CHEM COMMUN, V47, P6371, DOI 10.1039/c1cc10377f
   Dutta K, 2010, CHEM COMMUN, V46, P7772, DOI 10.1039/c0cc00710b
   Feig M, 1998, BIOPOLYMERS, V48, P199, DOI 10.1002/(SICI)1097-0282(1998)48:4<199::AID-BIP2>3.0.CO;2-5
   Fujita K, 2005, CHEM COMMUN, P4804, DOI 10.1039/b508238b
   Fujita K, 2012, CHEM COMMUN, V48, P5751, DOI 10.1039/c2cc30554b
   Fujita K, 2009, GREEN CHEM, V11, P351, DOI 10.1039/b813529k
   Hassan ERE, 2013, ENVIRON SCI TECHNOL, V47, P2809, DOI 10.1021/es303884n
   Heddi B, 2011, J AM CHEM SOC, V133, P9824, DOI 10.1021/ja200786q
   Huppert JL, 2008, CHEM SOC REV, V37, P1375, DOI 10.1039/b702491f
   Kan ZY, 2006, ANGEW CHEM INT EDIT, V45, P1629, DOI 10.1002/anie.200502960
   Lannan FM, 2012, J AM CHEM SOC, V134, P15324, DOI 10.1021/ja303499m
   Li JWJ, 2002, NANO LETT, V2, P315, DOI [10.1021/nl015713+, 10.1021/n1015713+]
   Li X, 2006, P NATL ACAD SCI USA, V103, P19658, DOI 10.1073/pnas.0607245103
   Lim KW, 2009, J AM CHEM SOC, V131, P4301, DOI 10.1021/ja807503g
   Luo N, 2012, CHEM COMMUN, V48, P6283, DOI 10.1039/c2cc31483e
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Mamajanov I., 2010, ANGEW CHEM, V122, P6454, DOI DOI 10.1002/ANGE.201001561
   Mergny JL, 2003, OLIGONUCLEOTIDES, V13, P515, DOI 10.1089/154545703322860825
   Miller MC, 2010, J AM CHEM SOC, V132, P17105, DOI 10.1021/ja105259m
   Miyoshi D, 2006, J AM CHEM SOC, V128, P7957, DOI 10.1021/ja061267m
   Mukundan VT, 2011, NUCLEIC ACIDS RES, V39, P8984, DOI 10.1093/nar/gkr540
   Murat P, 2011, CHEM SOC REV, V40, P5293, DOI 10.1039/c1cs15117g
   Palumbo SL, 2009, J AM CHEM SOC, V131, P10878, DOI 10.1021/ja902281d
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Pedersen EB, 2011, NUCLEIC ACIDS RES, V39, P2470, DOI 10.1093/nar/gkq1133
   Petraccone L, 2012, J PHYS CHEM B, V116, P2294, DOI 10.1021/jp209170v
   Petraccone L, 2011, J AM CHEM SOC, V133, P20951, DOI 10.1021/ja209192a
   Phan AT, 2007, NUCLEIC ACIDS RES, V35, P6517, DOI 10.1093/nar/gkm706
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Ren JS, 2002, NUCLEIC ACIDS RES, V30, P2307, DOI 10.1093/nar/30.11.2307
   Renciuk D, 2009, NUCLEIC ACIDS RES, V37, P6625, DOI 10.1093/nar/gkp701
   Reshetnikov RV, 2011, NUCLEIC ACIDS RES, V39, P9789, DOI 10.1093/nar/gkr639
   Roe S., 2010, CHEM COMMUN, V46, P4307
   Russo Krauss I, 2011, NUCLEIC ACIDS RES, V39, P7858, DOI 10.1093/nar/gkr522
   Shi YG, 2012, CHEM COMMUN, V48, P5325, DOI 10.1039/c2cc31740k
   Takekiyo T, 2012, J PHYS CHEM B, V116, P11092, DOI 10.1021/jp3057064
   Tateishi-Karimata H, 2012, ANGEW CHEM INT EDIT, V51, P1416, DOI 10.1002/anie.201106423
   van Rantwijk F, 2007, CHEM REV, V107, P2757, DOI 10.1021/cr050946x
   Vijayaraghavan R, 2010, ANGEW CHEM INT EDIT, V49, P1631, DOI 10.1002/anie.200906610
   Wang CY, 2010, ADV MATER, V22, P2792, DOI 10.1002/adma.201000445
   Wang H, 2012, CHEM SOC REV, V41, P1519, DOI 10.1039/c2cs15311d
   WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9
   Xiao Y, 2004, J AM CHEM SOC, V126, P7430, DOI 10.1021/ja031875r
   Xu Y, 2011, CHEM SOC REV, V40, P2719, DOI 10.1039/c0cs00134a
   Xu Y, 2009, ANGEW CHEM INT EDIT, V48, P7833, DOI 10.1002/anie.200903858
   Xue Y, 2007, J AM CHEM SOC, V129, P11185, DOI 10.1021/ja0730462
   Yang Z, 2005, ENZYME MICROB TECH, V37, P19, DOI 10.1016/j.enzmictec.2005.02.014
   Yu HJ, 2008, NUCLEIC ACIDS RES, V36, P5695, DOI 10.1093/nar/gkn569
   Zhang QH, 2012, CHEM SOC REV, V41, P7108, DOI 10.1039/c2cs35178a
   Zhang ZJ, 2010, NUCLEIC ACIDS RES, V38, P1009, DOI 10.1093/nar/gkp1029
   Zhao CQ, 2013, LANGMUIR, V29, P1183, DOI 10.1021/la3043186
   Zhao CQ, 2011, CHEM-EUR J, V17, P8209, DOI 10.1002/chem.201100272
   Zhao CQ, 2011, CHEM COMMUN, V47, P5461, DOI 10.1039/c1cc11396h
NR 62
TC 6
Z9 6
U1 3
U2 74
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD NOV
PY 2013
VL 64
IS 1
BP 52
EP 58
DI 10.1016/j.ymeth.2013.04.017
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 245AA
UT WOS:000326430100008
PM 23628945
DA 2018-01-05
ER

PT J
AU Gioia, CJ
   Stieh, D
   Cianci, G
   Maric, D
   Anderson, M
   Allen, S
   De Leon, O
   Hope, TJ
AF Gioia, C. J.
   Stieh, D.
   Cianci, G.
   Maric, D.
   Anderson, M.
   Allen, S.
   De Leon, O.
   Hope, T. J.
TI Assessing Differences in HIV and Nanoparticle Transport in Mucus over
   the Course of the Female Menstrual Cycle
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY OCT 07-10, 2013
CL Barcelona, SPAIN
C1 [Gioia, C. J.; Stieh, D.; Cianci, G.; Maric, D.; Anderson, M.; Allen, S.; De Leon, O.; Hope, T. J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV 1
PY 2013
VL 29
IS 11
SI SI
BP A107
EP A108
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 239PI
UT WOS:000326037500275
DA 2018-01-05
ER

PT J
AU Scherer, K
   Wiedemann, I
   Ciobanasu, C
   Sahl, HG
   Kubitscheck, U
AF Scherer, Katharina
   Wiedemann, Imke
   Ciobanasu, Corina
   Sahl, Hans-Georg
   Kubitscheck, Ulrich
TI Aggregates of nisin with various bactoprenol-containing cell wall
   precursors differ in size and membrane permeation capacity
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE Nisin; Lipid II; Cell wall precursor; Giant unilamellar vesicles;
   Confocal microscopy; Membrane pore formation
ID PEPTIDE ANTIBIOTIC NISIN; HIV-1 TAT PEPTIDES; LIPID-II; PORE FORMATION;
   STAPHYLOCOCCUS-AUREUS; LANTIBIOTICS; BINDING; BIOSYNTHESIS; VANCOMYCIN;
   MECHANISM
AB Many lantibiotics use the membrane bound cell wall precursor Lipid II as a specific target for killing Gram-positive bacteria. Binding of Lipid II usually impedes cell wall biosynthesis, however, some elongated lantibiotics such as nisin, use Lipid II also as a docking molecule for pore formation in bacterial membranes. Although the unique nisin pore formation can be analyzed in Lipid II-doped vesicles, mechanistic details remain elusive. We used optical sectioning microscopy to directly visualize the interaction of fluorescently labeled nisin with membranes of giant unilamellar vesicles containing Lipid II and its various bactoprenol precursors. We quantitatively analyzed the binding and permeation capacity of nisin when applied at nanomolar concentrations. Specific interactions with Lipid I, Lipid II and bactoprenol-diphosphate (C-55-PP), but not bactoprenol-phosphate (C-55-P), resulted in the formation of large molecular aggregates. For Lipid II, we demonstrated the presence of both nisin and Lipid II in these aggregates. Membrane permeation induced by nisin was observed in the presence of Lipid land Lipid II, but not in the presence of C-55-PP. Notably, the size of the C-55-PP-nisin aggregates was significantly smaller than that of the aggregates formed with Lipid land Lipid II. We conclude that the membrane permeation capacity of nisin is determined by the size of the bactoprenol-containing aggregates in the membrane. Notably, transmitted light images indicated that the formation of large aggregates led to a pinch-off of small vesicles, a mechanism, which probably limits the growth of aggregates and induces membrane leakage. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Scherer, Katharina; Ciobanasu, Corina; Kubitscheck, Ulrich] Univ Bonn, Inst Phys & Theoret Chem, D-53115 Bonn, Germany.
   [Wiedemann, Imke; Sahl, Hans-Georg] Univ Bonn, Inst Med Microbiol Immunol & Parasitol, Pharmaceut Microbiol Unit, D-53115 Bonn, Germany.
RP Scherer, K (reprint author), Univ Bonn, Inst Phys & Theoret Chem, Wegelerstr 12, D-53115 Bonn, Germany.
EM kscherer@uni-bonn.de; iwiedemann@medpharmaservice.de;
   corinaciobanasu@yahoo.com; sahl@mibi03.meb.uni-bonn.de;
   u.kubitscheck@uni-bonn.de
RI Ciobanasu, Corina/O-4117-2014
OI Ciobanasu, Corina/0000-0003-1107-8738; Kubitscheck,
   Ulrich/0000-0003-3750-5355
FU German Research Foundation through the Collaborative Research Centre
   [SFB 624, FOR 854]; Cusanuswerk; European Commission [MCRTN - 33439]
FX We gratefully acknowledge funding by the German Research Foundation
   through the Collaborative Research Centre SFB 624 "Templates -
   Functional Chemical Matrices" and through the FOR 854, project TP4. K.S.
   was supported by the Cusanuswerk. C.C. was supported by the European
   Commission's 6th Framework Program through the Marie-Curie Action
   BIOCONTROL, contract number MCRTN - 33439.
CR Bond PJ, 2008, BIOPHYS J, V95, P3802, DOI 10.1529/biophysj.108.128686
   Bonelli RR, 2006, ANTIMICROB AGENTS CH, V50, P1449, DOI 10.1128/AAC.50.4.1449-1457.2006
   Bonev BB, 2004, FASEB J, V18, P1862, DOI 10.1096/fj.04-2358com
   Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x
   Brumfitt W, 2002, J ANTIMICROB CHEMOTH, V50, P731, DOI 10.1093/jac/dkf190
   Christ K, 2007, BBA-BIOMEMBRANES, V1768, P694, DOI 10.1016/j.bbamem.2006.12.003
   Ciobanasu C, 2010, BIOPHYS J, V99, P153, DOI 10.1016/j.bpj.2010.03.065
   Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s
   DIMITROV DS, 1988, BIOELECTROCH BIOENER, V19, P323, DOI 10.1016/0302-4598(88)80013-8
   GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073                                                             
   Hasper HE, 2004, BIOCHEMISTRY-US, V43, P11567, DOI 10.1021/bi049476b
   Hasper HE, 2006, SCIENCE, V313, P1636, DOI 10.1126/science.1129818
   Hsu STD, 2004, NAT STRUCT MOL BIOL, V11, P963, DOI 10.1038/nsmb830
   Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235                                                          
   Jia ZG, 2011, BIOPHYS J, V101, P2684, DOI 10.1016/j.bpj.2011.10.047
   KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253
   KUIPERS OP, 1992, J BIOL CHEM, V267, P24340
   Lamsa A, 2012, MOL MICROBIOL, V84, P486, DOI 10.1111/j.1365-2958.2012.08038.x
   Lee MT, 2008, P NATL ACAD SCI USA, V105, P5087, DOI 10.1073/pnas.0710625105
   MATTICK ATR, 1947, LANCET, V253, P5
   Menger FM, 1998, ADV MATER, V10, P888, DOI 10.1002/(SICI)1521-4095(199808)10:11<888::AID-ADMA888>3.0.CO;2-U
   Mishra A, 2008, ANGEW CHEM INT EDIT, V47, P2986, DOI 10.1002/anie.200704444
   Mohammadi T, 2011, EMBO J, V30, P1425, DOI 10.1038/emboj.2011.61
   Muller A, 2012, MICROB DRUG RESIST, V18, P261, DOI 10.1089/mdr.2011.0242
   RAYMAN MK, 1981, APPL ENVIRON MICROB, V41, P375
   REISINGER P, 1980, ARCH MICROBIOL, V127, P187, DOI 10.1007/BF00427192
   RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841                                                            
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schneider T, 2004, MOL MICROBIOL, V53, P675, DOI 10.1111/j.1365-2958.2004.04149.x
   Schneider T, 2010, INT J MED MICROBIOL, V300, P161, DOI 10.1016/j.ijmm.2009.10.005
   Schneider T, 2010, CURR OPIN INVEST DR, V11, P157
   Wiedemann I, 2004, J BACTERIOL, V186, P3259, DOI 10.1128/JB.186.10.3259-3261.2004
   Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200                                                          
   Woo HJ, 2011, J PHYS CHEM B, V115, P8122, DOI 10.1021/jp2023023
NR 34
TC 11
Z9 11
U1 0
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
EI 0006-3002
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD NOV
PY 2013
VL 1828
IS 11
BP 2628
EP 2636
DI 10.1016/j.bbamem.2013.07.014
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 241CE
UT WOS:000326143200030
PM 23872123
OA gold
DA 2018-01-05
ER

PT J
AU Hosseini-Sarvari, M
   Tavakolian, M
AF Hosseini-Sarvari, Mona
   Tavakolian, Mina
TI Nano-rod ZnO as a novel and reusable catalyst for C-P bond formation and
   hydrophosphonation of isatin derivatives under solvent-free conditions
SO CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE
LA English
DT Article
DE nano-rod ZnO; hydrophosphonation; C-P bond formation; solvent-free
ID PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-HORMONE SECRETAGOGUES; HIV
   PROTEASE; INHIBITORS; PHOSPHONATES; ANALOGS; ACIDS; 1B
AB A highly efficient method for the synthesis of alpha(1)-oxindole-alpha-hydroxyphosphonates via nano-rod ZnO catalyzed hydrophosphonation of isatin derivatives was developed. The reaction products are in excellent yields using the catalytic system nano-rod ZnO (25 mol%) under solvent-free conditions at room temperature. The catalyst can be reused several times without any significant loss of its activity.
C1 [Hosseini-Sarvari, Mona; Tavakolian, Mina] Shiraz Univ, Dept Chem, Shiraz 71454, Iran.
RP Hosseini-Sarvari, M (reprint author), Shiraz Univ, Dept Chem, Shiraz 71454, Iran.
EM hossaini@shirazu.ac.ir
FU Shiraz University Research Council
FX We gratefully acknowledge the support of this work by the Shiraz
   University Research Council.
CR Anastas PT, 2002, ACCOUNTS CHEM RES, V35, P686, DOI 10.1021/ar010065m
   ASANO M, 1995, CANCER RES, V55, P5296
   Bubenik M, 2002, BIOORG MED CHEM LETT, V12, P3063, DOI 10.1016/S0960-894X(02)00679-0
   DELLARIA JF, 1990, J MED CHEM, V33, P534, DOI 10.1021/jm00164a011                                                             
   FALCK JR, 1990, J CHEM SOC CHEM COMM, P953, DOI 10.1039/c39900000953                                                            
   Frechette RF, 1997, BIOORG MED CHEM LETT, V7, P2169, DOI 10.1016/S0960-894X(97)00390-9
   Gan CY, 2009, TETRAHEDRON LETT, V50, P1059, DOI 10.1016/j.tetlet.2008.12.077
   Ganzhorn AJ, 1998, BIOORGAN MED CHEM, V6, P1865, DOI 10.1016/S0968-0896(98)00148-5                                                   
   Gurevich P. A., 1998, RUSS J GEN CHEM+, V68, P1501
   Hayashi M, 2011, ANGEW CHEM INT EDIT, V50, P2249, DOI 10.1002/anie.201007568
   Hosseini-Sarvari M, 2011, J IRAN CHEM SOC, V8, pS119, DOI 10.1007/BF03254288                                                              
   Hosseini-Sarvari M, 2008, HELV CHIM ACTA, V91, P715, DOI 10.1002/hlca.200890072                                                          
   Hosseini-Sarvari M., 2011, CATAL LETT, V114, P347, DOI [10.1007/s10562-010-0489-7, DOI 10.1007/S10562-010-0489-7]
   Jun S.J., 1998, J KOR CERAM SOC, V35, P209
   KAMANO Y, 1995, TETRAHEDRON LETT, V36, P2783, DOI 10.1016/0040-4039(95)00395-S
   Kim DY, 2003, TETRAHEDRON LETT, V44, P2803, DOI 10.1016/S0040-4039(03)00454-4
   Kohno J, 2000, J ORG CHEM, V65, P990, DOI 10.1021/jo991375+                                                               
   Kolodiazhnyi OI, 2005, TETRAHEDRON-ASYMMETR, V16, P3295, DOI 10.1016/j.tetasy.2005.09.007
   Murano T, 2003, TETRAHEDRON, V59, P10223, DOI 10.1016/j.tet.2003.10.064
   Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525                                                      
   Nouri A, 2011, LETT ORG CHEM, V8, P38, DOI 10.2174/157017811794557859                                                      
   Peng L, 2011, TETRAHEDRON LETT, V52, P1157, DOI 10.1016/j.tetlet.2010.12.101
   PEYMAN A, 1992, TETRAHEDRON LETT, V33, P4549, DOI 10.1016/S0040-4039(00)61309-6                                                   
   Samanta S, 2006, J AM CHEM SOC, V128, P7442, DOI 10.1021/ja062091r
   Shankar J, 2010, TETRAHEDRON LETT, V51, P3938, DOI 10.1016/j.tetlet.2010.05.096
   Sikorski J. A., 1993, PHOSPHORUS SULFUR, V76, P115
   Soeda S, 2002, FEBS LETT, V524, P54, DOI 10.1016/S0014-5793(02)03002-8
   STOWASSER B, 1992, TETRAHEDRON LETT, V33, P6625, DOI 10.1016/S0040-4039(00)61002-X                                                   
   Tang YQ, 2001, EUR J ORG CHEM, P261
   Tao M, 1998, J MED CHEM, V41, P3912, DOI 10.1021/jm980325e                                                               
   Tas AC, 2000, J AM CERAM SOC, V83, P2954, DOI 10.1111/j.1151-2916.2000.tb01666.x                                              
   Taylor SD, 1998, BIOORGAN MED CHEM, V6, P1457, DOI 10.1016/S0968-0896(98)00075-3                                                   
   Tokunaga T, 2005, BIOORG MED CHEM LETT, V15, P1789, DOI 10.1016/j.bmcl.2005.02.042
   Tokunaga T, 2001, J MED CHEM, V44, P4641, DOI 10.1021/jm0103763
   Wang F, 2009, CHEM-EUR J, V15, P589, DOI 10.1002/chem.200802237
   Wiemer DF, 1997, TETRAHEDRON, V53, P16609, DOI 10.1016/S0040-4020(97)10305-2
   Yao ZJ, 1998, BIOORGAN MED CHEM, V6, P1799, DOI 10.1016/S0968-0896(98)00140-0
   Yokemates T., 2001, BIOORG MED CHEM LETT, V11, P1277, DOI [10.1016/S0960-894X(01)00179-2, DOI 10.1016/S0960-894X(01)00179-2]
   Yokomatsu T, 1998, BIOORGAN MED CHEM, V6, P2495, DOI 10.1016/S0968-0896(98)80023-0                                                   
   Yokomatsu T, 1999, BIOORG MED CHEM LETT, V9, P2833, DOI 10.1016/S0960-894X(99)00495-3                                                   
NR 40
TC 4
Z9 4
U1 0
U2 14
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA
SN 0008-4042
EI 1480-3291
J9 CAN J CHEM
JI Can. J. Chem.-Rev. Can. Chim.
PD NOV
PY 2013
VL 91
IS 11
BP 1117
EP 1122
DI 10.1139/cjc-2011-0432
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 236JP
UT WOS:000325792200011
DA 2018-01-05
ER

PT J
AU Gullo, FP
   Rossi, SA
   Sardi, JDO
   Teodoro, VLI
   Mendes-Giannini, MJS
   Fusco-Almeida, AM
AF Gullo, F. P.
   Rossi, S. A.
   Sardi, J. de C. O.
   Teodoro, V. L. I.
   Mendes-Giannini, M. J. S.
   Fusco-Almeida, A. M.
TI Cryptococcosis: epidemiology, fungal resistance, and new alternatives
   for treatment
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Review
ID ANTIFUNGAL DRUG-RESISTANCE; IN-VITRO SUSCEPTIBILITY; AMPHOTERICIN-B;
   MONOCLONAL-ANTIBODIES; CANDIDA-ALBICANS; PHOTODYNAMIC INACTIVATION;
   FLUCONAZOLE RESISTANCE; NEOFORMANS INFECTION; ASPERGILLUS-FUMIGATUS;
   PULMONARY INFECTION
AB Cryptococcosis is an important systemic mycosis and the third most prevalent disease in human immunodeficiency virus (HIV)-positive individuals. The incidence of cryptococcosis is high among the 25 million people with HIV/acquired immunodeficiency syndrome (AIDS), with recent estimates indicating that there are one million cases of cryptococcal meningitis globally per year in AIDS patients. In Cryptococcus neoformans, resistance to azoles may be associated with alterations in the target enzyme encoded by the gene ERG11, lanosterol 14 alpha-demethylase. These alterations are obtained through mutations, or by overexpressing the gene encoding. In addition, C. gattii and C. neoformans present a heteroresistance phenotype, which may be related to increased virulence. Other species beyond C. neoformans and C. gattii, such as C. laurentii, have been diagnosed mainly in patients with immunosuppression. Infections of C. albidus have been isolated in cats and marine mammals. Recent evidence suggests that the majority of infections produced by this pathogen are associated with biofilm growth, which is also related with increased resistance to antifungal agents. Therefore, there is a great need to search for alternative antifungal agents for these fungi. The search for new molecules is currently occurring from nanoparticle drugs of plant peptide origin. This article presents a brief review of the literature regarding the epidemiology of cryptococcosis, as well as fungal resistance and new alternatives for treatment.
C1 [Gullo, F. P.; Rossi, S. A.; Sardi, J. de C. O.; Teodoro, V. L. I.; Mendes-Giannini, M. J. S.; Fusco-Almeida, A. M.] Univ Estadual Paulista UNESP, Fac Pharmaceut Sci Araraquara, Dept Clin Anal, Lab Clin Mycol, BR-14801902 Sao Paulo, Brazil.
RP Fusco-Almeida, AM (reprint author), Univ Estadual Paulista UNESP, Fac Pharmaceut Sci Araraquara, Dept Clin Anal, Lab Clin Mycol, R Expedicionarios Brasil 1621, BR-14801902 Sao Paulo, Brazil.
EM ana.marisa@uol.com.br
RI FUSCO-ALMEIDA, ANA/G-1507-2013; Mendes Giannini, Maria Jose/C-5387-2012
OI FUSCO-ALMEIDA, ANA/0000-0002-5399-8527; Mendes Giannini, Maria
   Jose/0000-0002-8059-0826
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
FX We thank Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES) for the financial support.
CR Abruzzo GK, 1997, ANTIMICROB AGENTS CH, V41, P2333
   Ahmad A, 2013, EUR J PHARM SCI, V48, P80, DOI 10.1016/j.ejps.2012.09.016
   Andrade-Silva L, 2013, MED MYCOL
   Andriole VT, 1998, CURR CLIN TOPICS INF, V18, P19
   Antachopoulos C, 2012, CLIN MICROBIOL INFEC, V18, P126, DOI 10.1111/j.1469-0691.2011.03741.x
   Averbuch D, 2002, MED MYCOL, V40, P479, DOI 10.1080/714031137
   Bach A, 1996, INTENS CARE MED, V22, P613, DOI 10.1007/BF01708112                                                              
   Basso LA, 2005, MEM I OSWALDO CRUZ, V100, P575, DOI 10.1590/S0074-02762005000600001
   Bovers M, 2008, EMERG INFECT DIS, V14, P1105, DOI 10.3201/eid1407.080122
   Bryan RA, 2010, J INFECT DIS, V202, P633, DOI 10.1086/654813
   Byrnes EJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002205
   Byrnes EJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000850
   Byrnes EJ, 2009, J INFECT DIS, V199, P1081, DOI 10.1086/597306
   Cabras T, 2008, J PEPT SCI, V14, P251, DOI 10.1002/psc.914
   Calvo BM, 2001, J CLIN MICROBIOL, V39, P2348, DOI 10.1128/JCM.39.6.2348-2350.2001
   Cannon RD, 2009, CLIN MICROBIOL REV, V22, P291, DOI 10.1128/CMR.00051-08
   Casadevall A, 2006, CLIN INFECT DIS, V42, P1414, DOI 10.1086/503431                                                                  
   Catalan Mercedes, 2006, Revista Iberoamericana de Micologia, V23, P39
   Chen S, 2000, CLIN INFECT DIS, V31, P499, DOI 10.1086/313992
   Cheng MF, 2001, J CLIN MICROBIOL, V39, P1608, DOI 10.1128/JCM.39.4.1608-1611.2001
   Chong HS, 2010, J CLIN MICROBIOL, V48, P4115, DOI 10.1128/JCM.01271-10
   Clancy CJ, 1998, J ANTIMICROB CHEMOTH, V41, P127, DOI 10.1093/jac/41.1.127
   CLEMONS KV, 1994, ANTIMICROB AGENTS CH, V38, P460, DOI 10.1128/AAC.38.3.460                                                            
   Clemons KV, 1998, ANTIMICROB AGENTS CH, V42, P899
   Clemons KV, 2001, ANTIMICROB AGENTS CH, V45, P686, DOI 10.1128/AAC.45.3.686-689.2001
   Colom MF, 2005, J CLIN MICROBIOL, V43, P3548, DOI 10.1128/JCM.43.7.3548-3550.2005
   Cruz MCS, 2007, J ETHNOPHARMACOL, V111, P409, DOI 10.1016/j.jep.2006.12.005
   da Silva PR, 2008, REV SOC BRAS MED TRO, V41, P158, DOI 10.1590/S0037-86822008000200005
   Day JN, 2011, J CLIN MICROBIOL, V49, P658, DOI 10.1128/JCM.01985-10
   Cordeiro RD, 2013, EUR J CLIN MICROBIOL, V32, P557, DOI 10.1007/s10096-012-1774-8
   DeBess E., 2010, Morbidity and Mortality Weekly Report, V59, P865
   Decken K, 1998, INFECT IMMUN, V66, P4994
   Diaz-Guerra TM, 2003, ANTIMICROB AGENTS CH, V47, P1120, DOI 10.1128/AAC.47.3.1120-1124.2003
   Dixit A, 2009, INTERDISCIP PERSPECT, V2009, DOI DOI 10.1155/2009/840452
   Escandon P, 2006, FEMS YEAST RES, V6, P625, DOI 10.1111/j.1567-1364.2006.00055.x
   Espinel-Ingroff A, 2012, ANTIMICROB AGENTS CH, V56, P5898, DOI 10.1128/AAC.01115-12
   Espinel-Ingroff A, 2008, REV IBEROAM MICOL, V25, P101, DOI 10.1016/S1130-1406(08)70027-5                                                   
   Espinel-Ingroff A, 2009, REV IBEROAM MICOL, V26, P15, DOI 10.1016/S1130-1406(09)70004-X
   Faria Renata Osorio de, 2010, Rev Soc Bras Med Trop, V43, P198, DOI 10.1590/S0037-86822010000200018
   Ferreira MJU, 2005, ANTICANCER RES, V25, P4173
   Filiu Wander Fernando de Oliveira, 2002, Rev Soc Bras Med Trop, V35, P591, DOI 10.1590/S0037-86822002000600008
   Firacative C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037566
   Firacative C, 2011, BIOMEDICA, V31, P118, DOI 10.1590/S0120-41572011000100014
   Fuchs BB, 2007, ANTIMICROB AGENTS CH, V51, P2929, DOI 10.1128/AAC.00121-07
   Fukuyama N, 2012, CHEM PHARM BULL, V60, P377, DOI 10.1248/cpb.60.377
   Fukuyama N, 2011, NAT PROD RES, V25, P1295, DOI 10.1080/14786419.2010.502532
   Funari CS, 2012, FOOD CHEM, V135, P2086, DOI 10.1016/j.foodchem.2012.06.077
   Furman-Kuklinska K, 2009, ADV MED SCI-POLAND, V54, P116, DOI 10.2478/v10039-009-0014-7
   Almeida AMF, 2007, FEMS YEAST RES, V7, P152, DOI 10.1111/j.1567-1364.2006.00128.x
   GALLIS HA, 1990, REV INFECT DIS, V12, P308
   Garcia-Effron G, 2008, J CLIN MICROBIOL, V46, P1200, DOI 10.1128/JCM.02330-07
   Georgi A, 2009, INFECTION, V37, P370, DOI 10.1007/s15010-008-8211-z
   Goldman DL, 2000, INFECT IMMUN, V68, P832, DOI 10.1128/IAI.68.2.832-838.2000
   Gonzalez-Hein Gisela, 2010, J Avian Med Surg, V24, P227, DOI 10.1647/2009-003.1
   Grechi J, 2011, J BIOL CHEM, V286, P14820, DOI 10.1074/jbc.M110.177030
   Guerrero A, 2008, INFECT IMMUN, V76, P4322, DOI 10.1128/IAI.00529-08
   Gullo FP, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/340787
   Hagen F, 2012, EMERG INFECT DIS, V18, P1618, DOI 10.3201/eid1810.120068
   Hagen F, 2010, ANTIMICROB AGENTS CH, V54, P5139, DOI 10.1128/AAC.00746-10
   Han Y, 2005, BIOL PHARM BULL, V28, P541, DOI 10.1248/bpb.28.541
   Han Y, 2007, PHYTOMEDICINE, V14, P733, DOI 10.1016/j.phymed.2007.08.004
   Hardison SE, 2012, J IMMUNOL, V189, P4060, DOI 10.4049/jimmunol.1103455
   Illnait-Zaragozi MT, 2008, ANTIMICROB AGENTS CH, V52, P1580, DOI 10.1128/AAC.01384-07
   Jarvis JN, 2012, AIDS, V26, P1105, DOI 10.1097/QAD.0b013e3283536a93
   Jarvis JN, 2008, CURR OPIN INFECT DIS, V21, P596, DOI 10.1097/QCO.0b013e3283177f6c
   Jesus Mariana Santos de, 2012, Mem Inst Oswaldo Cruz, V107, P466
   Jiang ZW, 2012, ANTIMICROB AGENTS CH, V56, P552, DOI 10.1128/AAC.00473-11
   Johnson E, 2008, INT J ANTIMICROB AG, V32, P511, DOI 10.1016/j.ijantimicag.2008.05.023
   Johnson MD, 2004, ANTIMICROB AGENTS CH, V48, P693, DOI 10.1128/AAC.48.3.693-715.2004
   Jong A, 2008, CELL MICROBIOL, V10, P1313, DOI 10.1111/j.1462-5822.2008.01128.x
   Kano R, 2008, MED MYCOL, V46, P75, DOI 10.1080/13693780701541106
   Kantarcioglu AS, 2007, MED MYCOL, V45, P173, DOI 10.1080/13693780601045166
   Kawakami K, 1996, CLIN EXP IMMUNOL, V104, P208, DOI 10.1046/j.1365-2249.1996.14723.x
   Khan AA, 2012, J DRUG TARGET, V20, P453, DOI 10.3109/1061186X.2012.685474
   Khawcharoenporn T, 2007, INFECTION, V35, P51, DOI 10.1007/s15010-007-6142-8
   Kidd SE, 2004, P NATL ACAD SCI USA, V101, P17258, DOI 10.1073/pnas.0402981101
   Kontoyiannis DP, 2002, LANCET, V359, P1135, DOI 10.1016/S0140-6736(02)08162-X
   KWONCHUNG KJ, 1991, ZBL BAKT-INT J MED M, V275, P390, DOI 10.1016/S0934-8840(11)80305-1                                                   
   Lago JHG, 2011, MOLECULES, V16, P9827, DOI 10.3390/molecules16129827
   Lanjewar DN, 2011, PATHOLOG RES INT, V2011
   Larsen RA, 2005, ANTIMICROB AGENTS CH, V49, P952, DOI 10.1128/AAC.49.3.952-958.2005
   Leite DP, 2012, J OCCUP MED TOXICOL, V7, DOI 10.1186/1745-6673-7-11
   Leite FS, 2010, PERFIL FENOTIPICO EX
   Levitz SM, 2006, FEMS YEAST RES, V6, P513, DOI 10.1111/j.1567-1364.2006.00071.x
   Litvintseva AP, 2005, J INFECT DIS, V192, P888, DOI 10.1086/432486
   MacDougall L, 2011, EMERG INFECT DIS, V17, P193, DOI 10.3201/eid1702.101020
   Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2                                                   
   Mann PA, 2003, ANTIMICROB AGENTS CH, V47, P577, DOI 10.1128/AAC.47.2.577-581.2003
   Marichal P, 1995, ACTA BIOCHIM POL, V42, P509
   Marichal P, 1997, ANTIMICROB AGENTS CH, V41, P2229
   Marongiu B, 2012, NAT PROD RES
   Martinez LR, 2005, INFECT IMMUN, V73, P6350, DOI 10.1128/IAI.73.10.6350-6362.2005
   Martinez LR, 2006, INFECT IMMUN, V74, P6118, DOI 10.1128/IAI.00995-06
   Martinez Luis R, 2010, Curr Fungal Infect Rep, V4, P266
   Martinez LR, 2010, BIOMATERIALS, V31, P669, DOI 10.1016/j.biomaterials.2009.09.087
   McCurdy Lewis H., 2003, Comprehensive Therapy, V29, P95, DOI 10.1385/COMP:29:2-3:095
   Mcleland S, 2012, J WILDLIFE DIS, V48, P1030, DOI 10.7589/2011-08-226
   Meyer W, 2003, EMERG INFECT DIS, V9, P189
   Mondon P, 1999, ANTIMICROB AGENTS CH, V43, P1856
   Monk BC, 2005, ANTIMICROB AGENTS CH, V49, P57, DOI 10.1128/AAC.49.1.57-70.2005
   Morschhauser J, 2010, FUNGAL GENET BIOL, V47, P94, DOI 10.1016/j.fgb.2009.08.002
   MUKHERJEE J, 1995, ANTIMICROB AGENTS CH, V39, P1398, DOI 10.1128/AAC.39.7.1398                                                           
   MUKHERJEE J, 1994, ANTIMICROB AGENTS CH, V38, P580, DOI 10.1128/AAC.38.3.580                                                            
   Mukherjee J, 1998, J IMMUNOL, V161, P3557
   MUKHERJEE J, 1992, INFECT IMMUN, V60, P4534
   Mukherjee PK, 2005, MED MYCOL, V43, P191, DOI 10.1080/13693780500107554
   Nascimento GGF, 2000, BRAZ J MICROBIOL, V31, P247
   Nishikawa MM, 2003, J CLIN MICROBIOL, V41, P73, DOI 10.1128/JCM.41.1.73-77.2003
   Nondo RSO, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-33
   Nosanchuk JD, 2003, CELL MICROBIOL, V5, P203, DOI 10.1046/j.1462-5814.2003.00268.x
   Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301
   Pachl J, 2006, CLIN INFECT DIS, V42, P1404, DOI 10.1086/503428
   Passoni LFC, 1998, MED MYCOL, V36, P305, DOI 10.1080/02681219880000481
   Patel KD, 2011, J AGR FOOD CHEM, V59, P12864, DOI 10.1021/jf2035466
   Patterson TF, 2000, MEDICINE, V79, P250, DOI 10.1097/00005792-200007000-00006
   Peman J, 2009, EXPERT REV ANTI-INFE, V7, P453, DOI [10.1586/eri.09.18, 10.1586/ERI.09.18]
   Perea S, 2001, ANTIMICROB AGENTS CH, V45, P2676, DOI 10.1128/AAC.45.10.2676-2684.2001
   Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858
   Pettit RK, 2010, MED MYCOL, V48, P421, DOI [10.3109/13693780903136879, 10.1080/13693780903136879]
   Pfaller MA, 2009, J CLIN MICROBIOL, V47, P117, DOI 10.1128/JCM.01747-08
   POLAK A, 1975, CHEMOTHERAPY, V21, P113, DOI 10.1159/000221854                                                               
   Prado M, 2009, MEM I OSWALDO CRUZ, V104, P513, DOI 10.1590/S0074-02762009000300019
   Prasad R., 2006, Infectious Disorders - Drug Targets, V6, P69, DOI 10.2174/187152606784112164
   Quindos G, 2009, REV IBEROAM MICOL, V26, P49, DOI 10.1016/S1130-1406(09)70008-7
   Quindos Guillermo, 2007, Revista Iberoamericana de Micologia, V24, P179
   Qureshi MH, 1999, EUR J IMMUNOL, V29, P643, DOI 10.1002/(SICI)1521-4141(199902)29:02<643::AID-IMMU643>3.0.CO;2-E
   Ramage G, 2002, J ANTIMICROB CHEMOTH, V49, P973, DOI [10.1093/jac/dkf049, 10.1093/jac.dkf049]
   Randhawa HS, 2008, MED MYCOL, V46, P823, DOI 10.1080/13693780802124026
   Rangkadilok N, 2012, FITOTERAPIA, V83, P545, DOI 10.1016/j.fitote.2011.12.023
   Regasini LO, 2010, REV BRAS FARMACOGN, V20, P706, DOI [10.1590/S0102-695X2010005000017, 10.1590/S0102-695X2010000500009]
   REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1
   Robertson EJ, 2012, APPL ENVIRON MICROB, V78, P7977, DOI 10.1128/AEM.01953-12
   Rodero L, 2003, ANTIMICROB AGENTS CH, V47, P3653, DOI 10.1128/AAC.47.11.3653-3656.2003
   Rodrigues GB, 2012, PHOTOCHEM PHOTOBIOL, V88, P440, DOI 10.1111/j.1751-1097.2011.01055.x
   Rojas Jhon J, 2006, BMC Complement Altern Med, V6, P2, DOI 10.1186/1472-6882-6-2
   Rosas AL, 2001, INFECT IMMUN, V69, P3410, DOI 10.1128/IAI.69.5.3410-3412.2001
   Saag MS, 2000, CLIN INFECT DIS, V30, P710, DOI 10.1086/313757
   SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378                                                          
   Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405                                                      
   Sanglard D, 2009, FEMS YEAST RES, V9, P1029, DOI 10.1111/j.1567-1364.2009.00578.x
   Schwarz P, 2003, ANTIMICROB AGENTS CH, V47, P3361, DOI 10.1128/AAC.47.10.3361-3364.2003
   Serena C, 2005, ANTIMICROB AGENTS CH, V49, P2994, DOI 10.1128/AAC.49.7.2994-2996.2005
   Severo Luiz Carlos, 1999, Revista Iberoamericana de Micologia, V16, P152
   Shankar Esaki Muthu, 2006, Can Respir J, V13, P275
   SHAO LC, 2007, ACTA PHARM SIN, V42, P1129
   Sheng CQ, 2009, ANTIMICROB AGENTS CH, V53, P3487, DOI 10.1128/AAC.01630-08
   Sionov E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000848
   Sionov E, 2009, ANTIMICROB AGENTS CH, V53, P2804, DOI 10.1128/AAC.00295-09
   Sloan D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005647.pub2
   Soares BM, 2011, PHOTOCHEM PHOTOBIOL, V87, P357, DOI 10.1111/j.1751-1097.2010.00868.x
   Martins LMS, 2011, MEM I OSWALDO CRUZ, V106, P725, DOI 10.1590/S0074-02762011000600012
   Sugita T, 2001, MICROBIOL IMMUNOL, V45, P291, DOI 10.1111/j.1348-0421.2001.tb02621.x                                              
   Suzano FR, 2012, ESTUDO ATIVIDADE ANT
   Taborda CP, 2001, J IMMUNOL, V166, P2100, DOI 10.4049/jimmunol.166.3.2100                                                     
   Tavares LD, 2011, EUR J MED CHEM, V46, P4448, DOI 10.1016/j.ejmech.2011.07.019
   Tocci N, 2011, APPL MICROBIOL BIOT, V91, P977, DOI 10.1007/s00253-011-3303-6
   Trosken ER, 2006, TOXICOLOGY, V219, P33, DOI 10.1016/j.tox.2005.10.020
   Tudela JLR, 1997, REV CLIN ESP, V197, P67
   Vandeputte P, 2005, ANTIMICROB AGENTS CH, V49, P4608, DOI 10.1128/AAC.49.11.4608-4615.2005
   Varma A, 2010, ANTIMICROB AGENTS CH, V54, P2303, DOI 10.1128/AAC.00153-10
   Wang HY, 2010, BIOMATERIALS, V31, P2874, DOI 10.1016/j.biomaterials.2009.12.042
   White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2
   Xu Shu-feng, 2011, Zhonghua Jie He He Hu Xi Za Zhi, V34, P816
   Yaguchi Takashi, 2007, Nihon Ishinkin Gakkai Zasshi, V48, P97, DOI 10.3314/jjmm.48.97
   Zhang TT, 1997, INFECT IMMUN, V65, P3594
   Zhu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039782
NR 166
TC 32
Z9 36
U1 3
U2 54
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD NOV
PY 2013
VL 32
IS 11
BP 1377
EP 1391
DI 10.1007/s10096-013-1915-8
PG 15
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 237CQ
UT WOS:000325846200002
PM 24141976
DA 2018-01-05
ER

PT J
AU Williams, J
   Sayles, HR
   Meza, JL
   Sayre, P
   Sandkovsky, U
   Gendelman, HE
   Flexner, C
   Swindells, S
AF Williams, Jennifer
   Sayles, Harlan R.
   Meza, Jane L.
   Sayre, Patrick
   Sandkovsky, Uriel
   Gendelman, Howard E.
   Flexner, Charles
   Swindells, Susan
TI Long-acting parenteral nanoformulated antiretroviral therapy: interest
   and attitudes of HIV-infected patients
SO NANOMEDICINE
LA English
DT Article
DE AIDS; antiretroviral therapy; HIV; intravenous drug abuse;
   nanoformulated antiretroviral therapy; nonadherence; substance abuse
ID DRUG-RESISTANCE; NANOMEDICINE; ADHERENCE; MICE
AB Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. (2) tests were used for comparisons of interest across groups. Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy. Original submitted 24 May 2012; Revised submitted 2 November 2012; Published online 23 April 2013
C1 [Williams, Jennifer; Sandkovsky, Uriel; Gendelman, Howard E.; Swindells, Susan] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   [Sayles, Harlan R.; Meza, Jane L.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA.
   [Sayre, Patrick; Flexner, Charles] Johns Hopkins Univ, Div Clin Pharmacol, Baltimore, MD 21287 USA.
   [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Swindells, S (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, 982055 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM sswindells@unmc.edu
FU GlaxoSmithKline; Pfizer; National Institute of Drug Abuse [P01
   DA028555-01A1]
FX U Sandkovsky and S Swindells report receiving grant support to the
   University of Nebraska Medical Center (USA) from GlaxoSmithKline and
   Pfizer for research unrelated to this study. C Flexner reports receiving
   grant support from GlaxoSmithKline for research unrelated to this study,
   and has served as a consultant to Bristol-Myers Squibb, GlaxoSmithKline,
   Merck, Roche, Vertex and ViiV Healthcare. U Sandkovsky has served as a
   Consultant for Merck. This work was supported by the National Institute
   of Drug Abuse P01 DA028555-01A1 (to S Swindells and HE Gendelman). The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Jackson Akil EL, 2012, 19 C RETR OPP INF SE
   Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Bainbridge WS, 2002, J NANOPART RES, V4, P561
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bottini M, 2011, INT J NANOMED, V6, P3473, DOI 10.2147/IJN.S26340
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891                                                       
   [Anonymous], 2009, 2 COMM COMM COUNC EU
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1
   Hu CMJ, 2012, BIOCHEM PHARMACOL, V83, P1104, DOI 10.1016/j.bcp.2012.01.008
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kozal MJ, 2005, JAIDS-J ACQ IMM DEF, V40, P106, DOI 10.1097/01.qai.0000159666.95455.d2
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Pautler M, 2010, INT J NANOMED, V5, P803, DOI 10.2147/IJN.S13816
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   Tang Mu-Fei, 2010, Chin J Cancer, V29, P775
   Trono D, 2010, SCIENCE, V329, P174, DOI 10.1126/science.1191047
NR 19
TC 21
Z9 21
U1 0
U2 13
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD NOV
PY 2013
VL 8
IS 11
BP 1807
EP 1813
DI 10.2217/nnm.12.214
PG 7
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 239OC
UT WOS:000326034100016
PM 23611617
OA green_accepted
DA 2018-01-05
ER

PT J
AU Puligujja, P
   McMillan, JE
   Kendrick, L
   Li, T
   Balkundi, S
   Smith, N
   Veerubhotla, RS
   Edagwa, BJ
   Kabanov, AV
   Bronich, T
   Gendelman, HE
   Liu, XM
AF Puligujja, Pavan
   McMillan, JoEllyn
   Kendrick, Lindsey
   Li, Tianyuzi
   Balkundi, Shantanu
   Smith, Nathan
   Veerubhotla, Ram S.
   Edagwa, Benson J.
   Kabanov, Alexander V.
   Bronich, Tatiana
   Gendelman, Howard E.
   Liu, Xin-Ming
TI Macrophage folate receptor-targeted antiretroviral therapy facilitates
   drug entry, retention, antiretroviral activities and biodistribution for
   reduction of human immunodeficiency virus infections
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Human immunodeficiency virus; NanoART; ATV/r; Targeted drug delivery;
   Folate; Poloxamer 407; Macrophages
ID CROSS-LINKING; DELIVERY; NANOPARTICLES; MONOCYTES; ADHERENCE; REGIMENS;
   RELEASE; CELLS; MICE
AB Macrophages serve as vehicles for the carriage and delivery of polymer-coated nanoformulated antiretroviral therapy (nanoART). Although superior to native drug, high drug concentrations are required for viral inhibition. Herein, folate-modified ritonavir-boosted atazanavir (ATV/r)-encased polymers facilitated macrophage receptor targeting for optimizing drug dosing. Folate coating of nanoART ATV/r significantly enhanced cell uptake, retention and antiretroviral activities without altering cell viability. Enhanced retentions of folate-coated nanoART within recycling endosomes provided a stable subcellular drug depot. Importantly, up to a five-fold enhanced plasma and tissue drug levels followed folate-coated formulation injection in mice. Folate polymer encased ATV/r improves nanoART pharmacokinetics bringing the technology one step closer to human use.
   From the Clinical Editor: This team of authors describes a novel method for macrophage folate receptor-targeted antiretroviral therapy. Atazanvir entry, retention, and antiretroviral activities were superior using the presented method, and so was its biodistribution, enabling a more efficient way to address human immunodeficiency virus infections, with a hoped for clinical application in the near future. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Puligujja, Pavan; McMillan, JoEllyn; Kendrick, Lindsey; Li, Tianyuzi; Balkundi, Shantanu; Smith, Nathan; Veerubhotla, Ram S.; Edagwa, Benson J.; Gendelman, Howard E.; Liu, Xin-Ming] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
   [Kabanov, Alexander V.; Bronich, Tatiana; Gendelman, Howard E.; Liu, Xin-Ming] Univ Nebraska, Med Ctr, Ctr Drug Delivery & Nanomed, Omaha, NE USA.
   [Kabanov, Alexander V.; Bronich, Tatiana; Liu, Xin-Ming] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE USA.
RP Gendelman, HE (reprint author), Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM pavan.puligujja@unmc.edu; jmmcmillan@unmc.edu;
   lindsey.kendrick@unmc.edu; tianyuzi.li@unmc.edu; sbalkundi@unmc.edu;
   nathana.smith@unmc.edu; ram.veerubhotla@unmc.edu;
   benson.edagwa@unmc.edu; kabanov@email.unc.edu; tbronich@unmc.edu;
   hegendel@unmc.edu; xliu@unmc.edu
FU Carol Swarts Neuroscience Research Laboratory; Frances and Louie Blumkin
   Foundation; National Institutes of Health [P01 DA028555, R01 NS36126,
   P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, 9P20GM103480]
FX This work was supported by the Carol Swarts Neuroscience Research
   Laboratory, the Frances and Louie Blumkin Foundation and National
   Institutes of Health grants P01 DA028555, R01 NS36126, P01 NS31492, 2R01
   NS034239, P01 MH64570, P01 NS43985 (H. E. G.) and 9P20GM103480 (T.B.).
CR Balkundi S, 2010, J VIS EXP, V46
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bartlett JA, 2009, LANCET INFECT DIS, V9, P637, DOI 10.1016/S1473-3099(09)70227-0
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773                                                      
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Feng Y, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3312
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Hattori Y, 2006, BIOL PHARM BULL, V29, P1516, DOI 10.1248/bpb.29.1516
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   KALTER DC, 1991, J IMMUNOL, V146, P298
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kularatne SA, 2010, METHODS MOL BIOL, V624, P249, DOI 10.1007/978-1-60761-609-2_17
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x                                              
   MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582
   McMillan J, 2011, PROG MOL BIOL TRANSL, V104, P563, DOI 10.1016/B978-0-12-416020-0.00014-0
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   TUREK JJ, 1993, J CELL SCI, V106, P423
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Wang X, 2009, ACS NANO, V3, P3165, DOI 10.1021/nn900649v
   Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277
   Xia W, 2009, BLOOD, V113, P438, DOI 10.1182/blood-2008-04-150789
NR 37
TC 31
Z9 32
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD NOV
PY 2013
VL 9
IS 8
BP 1263
EP 1273
DI 10.1016/j.nano.2013.05.003
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 240TA
UT WOS:000326118700014
PM 23680933
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wildum, S
   Paulsen, D
   Thede, K
   Ruebsamen-Schaeff, H
   Zimmermann, H
AF Wildum, Steffen
   Paulsen, Daniela
   Thede, Kai
   Ruebsamen-Schaeff, Helga
   Zimmermann, Holger
TI In Vitro and In Vivo Activities of AIC292, a Novel HIV-1 Nonnucleoside
   Reverse Transcriptase Inhibitor
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ALPHA(1)-ACID GLYCOPROTEIN LEVELS; DRUG-RESISTANCE; RT INHIBITORS;
   VIRUS; ETRAVIRINE; RILPIVIRINE; AIDS; SENSITIVITY; NUCLEOSIDE; EFAVIRENZ
AB Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are important and frequently used elements of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. However, the development of drug resistance, as well as the side effects of existing drugs, defines a medical need for novel NNRTIs with excellent tolerability, improved activity against NNRTI-resistant viruses, and a low barrier to resistance. Within the chemical class of diarylpyrazole-[imidazolidinone]-carboxamides, AIC292 was identified as a promising novel HIV-1 NNRTI and has successfully completed single-dose clinical phase I studies. Here, we report on the antiviral activity of AIC292, evaluated in vitro against wild-type and NNRTI-resistant HIV-1 isolates and in vivo using an engineered mouse xenograft model. AIC292 inhibited wild-type HIV-1 laboratory strains at low nanomolar concentrations, was well tolerated in different cell lines, and showed excellent selectivity in a lead profiling screen. In addition, activity of AIC292 could be demonstrated against a broad panel of wild-type HIV-1 group M and group O clinical isolates. AIC292 also retained activity against viruses harboring NNRTI resistance-associated mutations (RAMs), including the most prevalent variants, K103N, Y181C, and G190A. Interestingly, viruses bearing the L100I RAM were hypersusceptible to AIC292. Two-drug combination assays showed no antagonistic interactions between AIC292 and representative marketed HIV drugs with regard to antiviral activity. Furthermore, AIC292 displayed potent antiviral in vivo efficacy in a mouse xenograft model when applied once daily. Taken together, these data show that AIC292 represents a molecule with the antiviral properties of a novel NNRTI for the treatment of HIV-1 infection.
C1 [Wildum, Steffen; Paulsen, Daniela; Ruebsamen-Schaeff, Helga; Zimmermann, Holger] AiCuris GmbH & Co KG, Wuppertal, Germany.
   [Thede, Kai] Bayer Pharma AG, Berlin, Germany.
RP Wildum, S (reprint author), AiCuris GmbH & Co KG, Wuppertal, Germany.
EM steffen.wildum@aicuris.com
CR Anta L, 2013, AIDS, V27, P81, DOI 10.1097/QAD.0b013e3283584500
   Asahchop EL, 2012, ANTIMICROB AGENTS CH, V56, P5000, DOI 10.1128/AAC.00591-12
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Balamane M, 2012, ANTIMICROB AGENTS CH, V56, P4522, DOI 10.1128/AAC.00648-12
   Barre-Sinoussi F, 2004, REV INVEST CLIN, V56, P126
   Best BM, 2008, EXPERT OPIN DRUG MET, V4, P965, DOI [10.1517/17425255.4.7.965 , 10.1517/17425250802204217]
   Boffito M, 2003, AIDS RES HUM RETROV, V19, P825, DOI 10.1089/088922203769232629
   Boffito M, 2002, DRUG METAB DISPOS, V30, P859, DOI 10.1124/dmd.30.7.859
   BUCKHEIT RW, 1994, AIDS RES HUM RETROV, V10, P1497, DOI 10.1089/aid.1994.10.1497
   BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295
   Buonaguro L, 2007, J VIROL, V81, P10209, DOI 10.1128/JVI.00872-07
   Chilton DN, 2010, ANTIVIR THER, V15, P985, DOI 10.3851/IMP1658
   Ciccozzi M, 2012, NEW MICROBIOL, V35, P377
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Gupta S, 2010, ANTIMICROB AGENTS CH, V54, P1973, DOI 10.1128/AAC.00870-09
   Jayaweera DT, 2008, EXPERT OPIN PHARMACO, V9, P3083, DOI 10.1517/14656560802489569 
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   Lai MT, 2010, ANTIMICROB AGENTS CH, V54, P4812, DOI 10.1128/AAC.00829-10
   Lai MT, 2009, ANTIMICROB AGENTS CH, V53, P2424, DOI 10.1128/AAC.01559-08
   Lischka P, 2010, ANTIMICROB AGENTS CH, V54, P1290, DOI 10.1128/AAC.01596-09
   Margot NA, 2005, ANTIVIR THER, V10, P343
   Markova SV, 2004, J BIOL CHEM, V279, P3212, DOI 10.1074/jbc.M309639200
   McNamara Patrick J, 2002, AAPS PharmSci, V4, pE4
   OIE S, 1993, J ACQ IMMUN DEF SYND, V6, P531
   Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   Ruebsamen-Waigmann H, 1989, LANCET, V334, P1155
   SCHULZ TF, 1990, J VIROL, V64, P5177
   Tambuyzer Lotke, 2009, Antivir Ther, V14, P103
   Tang MW, 2012, DRUGS, V72, pE1, DOI 10.2165/11633630-000000000-00000
   Tebit DM, 2010, J VIROL, V84, P9817, DOI 10.1128/JVI.00991-10
   Fernandez-Montero JV, 2012, EXPERT OPIN PHARMACO, V13, P1007, DOI 10.1517/14656566.2012.667802
   Vingerhoets J, 2010, AIDS, V24, P503, DOI 10.1097/QAD.0b013e32833677ac
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026
   Walter H, 1999, J CLIN VIROL, V13, P71, DOI 10.1016/S1386-6532(99)00010-4
   Waters L, 2007, INT J CLIN PRACT, V61, P105, DOI 10.1111/j.1742-1241.2006.01146.x
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   Zhou Zhigang, 2006, Infectious Disorders - Drug Targets, V6, P391, DOI 10.2174/187152606779025833
   Paulsen D, 2008, Patent, Patent No. [DE102006046423A1, 102006046423]
   Golz S, 2002, Patent, Patent No. [WO/2002/042469, 2002042469]
NR 44
TC 4
Z9 4
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2013
VL 57
IS 11
BP 5320
EP 5329
DI 10.1128/AAC.01377-13
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 235ZY
UT WOS:000325764000018
PM 23959304
OA gold
DA 2018-01-05
ER

PT J
AU Liu, BR
   Winiarz, JG
   Moon, JS
   Lo, SY
   Huang, YW
   Aronstam, RS
   Lee, HJ
AF Liu, Betty R.
   Winiarz, Jeffrey G.
   Moon, Jong-Sik
   Lo, Shih-Yen
   Huang, Yue-Wern
   Aronstam, Robert S.
   Lee, Han-Jung
TI Synthesis, characterization and applications of carboxylated and
   polyethylene-glycolated bifunctionalized InP/ZnS quantum dots in
   cellular internalization mediated by cell-penetrating peptides
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Cell-penetrating peptides (CPPs); Functionalization; Nanoparticles;
   Polyethylene-glycolylated (PEGylated); Quantum dots (QDs)
ID HUMAN IMMUNODEFICIENCY VIRUS; IN-VIVO; PROTEIN TRANSDUCTION;
   INTRACELLULAR DELIVERY; LIVING CELLS; NANOCRYSTALS; DIAGNOSTICS; GENE;
   NANOPARTICLE; TRANSPORT
AB Semiconductor nanoparticles, also known as quantum dots (QDs), are widely used in biomedical imaging studies and pharmaceutical research. Cell-penetrating peptides (CPPs) are a group of small peptides that are able to traverse cell membrane and deliver a variety of cargoes into living cells. CPPs deliver QDs into cells with minimal nonspecific absorption and toxic effect. In this study, water-soluble, monodisperse, carboxyl-functionalized indium phosphide (InP)/zinc sulfide (ZnS) QDs coated with polyethylene glycol lipids (designated QInP) were synthesized for the first time. The physicochemical properties (optical absorption, fluorescence and charging state) and cellular internalization of QInP and CPP/QInP complexes were characterized. CPPs noncovalently interact with QInP in vitro to form stable CPP/QInP complexes, which can then efficiently deliver QInP into human A549 cells. The introduction of 500 nM of CPP/QInP complexes and QInP at concentrations of less than 1 mu M did not reduce cell viability. These results indicate that carboxylated and polyethylene-glycolylated (PEGylated) bifunctionalized QInP are biocompatible nanoparticles with potential for use in biomedical imaging studies and drug delivery applications. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Liu, Betty R.; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Shoufeng 97401, Hualien, Taiwan.
   [Winiarz, Jeffrey G.; Moon, Jong-Sik] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO 65409 USA.
   [Lo, Shih-Yen] Tzu Chi Univ, Dept Lab Med & Biotechnol, Hualien 97004, Taiwan.
   [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, 1,Sec 2,Da Hsueh Rd, Shoufeng 97401, Hualien, Taiwan.
EM huangy@mst.edu; hjlee@mail.ndhu.edu.tw
FU National Science Council of Taiwan [NSC 101-2811-B-259-001, NSC
   101-2320-B-259-002-MY3]
FX We are grateful to Chia-Liang Cheng (Department of Physics, National
   Dong Hwa University, Taiwan) for performing the zeta-potential
   measurements, and Core Instrument Center (National Health Research
   Institutes, Miaoli, Taiwan) for the Typhoon Trio imager and Leica TCS
   SP5 II confocal system. This work was supported by the Postdoctoral
   Fellowship NSC 101-2811-B-259-001 (to B.R. Liu) and the Grant Number NSC
   101-2320-B-259-002-MY3 from the National Science Council of Taiwan (to
   H.-J. Lee).
CR Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933                                                    
   Bharali DJ, 2005, J AM CHEM SOC, V127, P11364, DOI 10.1021/ja051455x
   Bruchez M, 1998, SCIENCE, V281, P2012
   Byun HJ, 2011, J COLLOID INTERF SCI, V355, P35, DOI 10.1016/j.jcis.2010.12.013
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Chibli H, 2011, NANOSCALE, V3, P2552, DOI 10.1039/c1nr10131e
   Clift MJD, 2012, THERANOSTICS, V2, P668, DOI 10.7150/thno.4545
   Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y                                                               
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4
   Depalo N, 2008, J COLLOID INTERF SCI, V325, P558, DOI 10.1016/j.jcis.2008.06.018
   Farias PMA, 2009, METHODS MOL BIOL, V544, P407, DOI 10.1007/978-1-59745-483-4_27
   Fears TM, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2993253
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gao JH, 2012, NANO LETT, V12, P281, DOI 10.1021/nl203526f
   Gao JH, 2010, BIOCONJUGATE CHEM, V21, P604, DOI 10.1021/bc900323v
   Gao JH, 2010, SMALL, V6, P256, DOI 10.1002/smll.200901672
   Gautam A, 2012, DATABASE
   Gerbec JA, 2005, J AM CHEM SOC, V127, P15791, DOI 10.1021/ja052463g
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Hu R, 2012, THERANOSTICS, V2, P723, DOI 10.7150/thno.4275
   Joung S, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-93
   Kilk K, 2009, TOXICOLOGY, V265, P87, DOI 10.1016/j.tox.2009.09.016
   Kim K, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/6/065602
   Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mager I, 2012, BBA-BIOMEMBRANES, V1818, P502, DOI 10.1016/j.bbamem.2011.11.020
   Mattoussi H, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2011.09.011
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Mutlugun E, 2012, NANO LETT, V12, P3986, DOI 10.1021/nl301198k
   Nag A, 2009, J NANOSCI NANOTECHNO, V9, P5633, DOI 10.1166/jnn.2009.1161
   Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016
   Rogach AL, 2007, SMALL, V3, P536, DOI 10.1002/smll.200600625
   Rosenberg JT, 2010, MAGN RESON MED, V64, P871, DOI 10.1002/mrm.22441
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Shao LJ, 2011, SENSORS-BASEL, V11, P11736, DOI 10.3390/s111211736
   Shi YF, 2008, MATER RES BULL, V43, P2626, DOI 10.1016/j.materresbull.2007.10.034
   Stasiuk GJ, 2011, ACS NANO, V5, P8193, DOI 10.1021/nn202839w
   Suhorutsenko J, 2011, BIOCONJUGATE CHEM, V22, P2255, DOI 10.1021/bc200293d
   Tunnemann Gisela, 2008, J Pept Sci, V14, P469, DOI 10.1002/psc.968
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
   Yong KT, 2012, THERANOSTICS, V2, P629, DOI 10.7150/thno.4757
   Young K.T, 2012, THERANOSTICS, V2, P681
   Zhang X, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/27/275103
   Zhang Y, 2012, THERANOSTICS, V2, P631, DOI 10.7150/thno.4308
NR 60
TC 20
Z9 20
U1 6
U2 81
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD NOV 1
PY 2013
VL 111
BP 162
EP 170
DI 10.1016/j.colsurfb.2013.05.038
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 224OM
UT WOS:000324897900021
PM 23792556
DA 2018-01-05
ER

PT J
AU Chen, NN
   Zheng, Y
   Yin, JJ
   Li, XJ
   Zheng, CL
AF Chen, Nana
   Zheng, Yang
   Yin, Jianjian
   Li, Xiujing
   Zheng, Conglong
TI Inhibitory effects of silver nanoparticles against adenovirus type 3 in
   vitro
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Silver nanoparticles; Inhibitory effects; Adenovirus type 3
ID RESPIRATORY SYNCYTIAL VIRUS; REPLICATION; INFECTIONS; RECEPTOR; IMPACT;
   ASSAY; DNA
AB Adenoviruses are associated with respiratory, ocular, or gastrointestinal disease. With various species and high morbidity, adenoviruses are increasingly recognized as significant viral pathogen among pediatric and immunocompromised patients. However, there is almost no specific drug for treatment. Silver nanoparticles are demonstrated to be virucidal against influenza A (H1N1) virus, human immunodeficiency virus and Hepatitis B virus. Currently, there is no data regarding whether the silver nanoparticles inhibit the adenovirus or not. The aim of this study is to investigate the effect of silver nanoparticles on adenovirus type 3 (Ad3). The results revealed that HeLa cells infected with silver nanoparticles treated Ad3 did not show obvious CPE. The viability of HeLa cells infected with silver nanoparticles treated Ad3 was significantly higher than that of cells infected with untreated Ad3. There was a significant difference of fluorescence intensity between the cells infected with silver nanoparticles treated and untreated Ad3. The transmission electron microscopy (TEM) showed that silver nanoparticles could directly damage the structure of Ad3 particle. The PCR amplification products of DNA isolated from silver nanoparticles treated Ad3 was decreased in a dose-dependent manner. The decreased DNA loads were also confirmed by real-time PCR experiment. The present study indicates silver nanoparticles exhibit remarkably inhibitory effects on Ad3 in vitro, which suggests silver nanoparticles could be a potential antiviral agent for inhibiting Ad3 infection. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Chen, Nana; Yin, Jianjian; Li, Xiujing; Zheng, Conglong] Dalian Univ, Coll Med, Dept Pathogeny Biol, Dalian 116622, Liaoning, Peoples R China.
   [Zheng, Yang] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 565, Japan.
RP Zheng, CL (reprint author), Dalian Univ, Coll Med, Dept Pathogeny Biol, 10 Xue Fu St, Dalian 116622, Liaoning, Peoples R China.
EM zcl9812@yahoo.com.cn
FU National Natural Science Foundation of China [30870681]
FX We would like to thank the Professor Xulin Chen who worked in Wuhan
   Institute of Virology, Chinese Academy of Sciences for offering the Ad3
   to this study. Thanks for Chuanzhou Gao in Dalian University for
   assistance with transmission electron microscopy. This study was
   supported by National Natural Science Foundation of China (No.
   30870681).
CR AshaRani P., 2008, ACS NANO, V3, P279, DOI DOI 10.1021/NN800596W
   Bhumbra Nasreen, 2010, Pediatr Rev, V31, P173, DOI 10.1542/pir.31-4-173
   Bruno B, 2003, BIOL BLOOD MARROW TR, V9, P341, DOI 10.1016/S1083-8791(03)00102-3
   Chen X, 2008, TOXICOL LETT, V176, P1, DOI 10.1016/j.toxlet.2007.10.004
   DINGLE JH, 1968, AM REV RESPIR DIS, V97, P1
   Dorjnamjin D, 2008, INT J MOL SCI, V9, P807, DOI 10.3390/ijms9050807
   Echavarria M, 2008, CLIN MICROBIOL REV, V21, P704, DOI 10.1128/CMR.00052-07
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Feng QL, 2000, J BIOMED MATER RES, V52, P662, DOI 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3
   Freimoser FM, 1999, APPL ENVIRON MICROB, V65, P3727
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Garnett CT, 2002, J VIROL, V76, P10608, DOI 10.1128/JVI.76.21.10608-10616.2002
   Gustafsson D., 2012, ADENOVIRUS SPECIES B
   Hussain SM, 2006, TOXICOL SCI, V92, P456, DOI 10.1093/toxsci/kfl020
   KIM HW, 1983, J CLIN MICROBIOL, V18, P1399
   Kinchington PR, 2005, J ANTIMICROB CHEMOTH, V55, P424, DOI 10.1093/jac/dki057
   Kojaoghlanian T, 2003, REV MED VIROL, V13, P155, DOI 10.1002/rmv.386
   La Rosa AM, 2001, CLIN INFECT DIS, V32, P871, DOI 10.1086/319352
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lara HH, 2010, WORLD J MICROB BIOT, V26, P615, DOI 10.1007/s11274-009-0211-3
   Lenaerts L, 2006, ANTIVIR RES, V71, P172, DOI 10.1016/j.antiviral.2006.04.007
   Lu L, 2008, ANTIVIR THER, V13, P253
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Russell WC, 2009, J GEN VIROL, V90, P1, DOI 10.1099/vir.0.003087-0
   Sirena D, 2004, J VIROL, V78, P4454, DOI 10.1128/JVI.78.9.4454-4462.2004
   Sirikanchana K, 2008, APPL ENVIRON MICROB, V74, P3774, DOI 10.1128/AEM.02049-07
   Sivaraman SK, 2009, CURR SCI INDIA, V97, P1055
   Sondi I, 2003, J COLLOID INTERF SCI, V260, P75, DOI 10.1016/S0021-9797(02)00205-9
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Suparno C, 2004, LEUKEMIA LYMPHOMA, V45, P873
   Walls T, 2003, LANCET INFECT DIS, V3, P79, DOI 10.1016/S1473-3099(03)00515-2                                                   
   Wu E, 2003, J VIROL, V77, P7225, DOI 10.1128/JVI.77.13.7225-7235.2003
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Xu WH, 2001, J MED VIROL, V64, P537, DOI 10.1002/jmv.1083
   Yamanaka M., 2005, APPL ENVIRON MICROB, V71, P89
NR 38
TC 17
Z9 18
U1 2
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD NOV
PY 2013
VL 193
IS 2
BP 470
EP 477
DI 10.1016/j.jviromet.2013.07.020
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 228MH
UT WOS:000325190400035
PM 23886562
DA 2018-01-05
ER

PT J
AU Karami, B
   Khodabakhshi, S
   Eskandari, K
AF Karami, Bahador
   Khodabakhshi, Saeed
   Eskandari, Khalil
TI Alternative two-step route to khellactone analogues using silica
   tungstic acid and sodium hydrogen phosphate
SO CHEMICAL PAPERS
LA English
DT Article
DE anti-HIV; khellactone; coumarins; Pechmann condensation; silica tungstic
   acid; sodium hydrogen phosphate
ID ANTI-AIDS AGENTS; ONE-POT; 3-COMPONENT SYNTHESIS; COUMARIN DERIVATIVES;
   PECHMANN REACTION; HIV AGENTS; EFFICIENT; CATALYST; NANOPARTICLES; WATER
AB A series of coumarins was synthesised via the silica tungstic acid-catalysed Pechmann reaction; some of these were employed for known three-component reactions with aromatic aldehydes and malononitrile in the presence of sodium hydrogen phosphate (Na2HPO4) as a basic catalyst, affording a variety of potentially anti-HIV active khellactone analogues.
C1 [Karami, Bahador; Khodabakhshi, Saeed; Eskandari, Khalil] Univ Yasuj, Dept Chem, Yasuj 7591874831, Iran.
RP Karami, B (reprint author), Univ Yasuj, Dept Chem, POB 353, Yasuj 7591874831, Iran.
EM karami@mail.yu.ac.ir
RI Eskandari, Khalil/G-1542-2017
OI Eskandari, Khalil/0000-0002-2919-7324; Khodabakhshi,
   Saeed/0000-0002-8096-6854
FU Yasouj University, Iran
FX The authors are grateful to Mr. Abbas Biglari (Institute for Advanced
   Studies in Basic Sciences, Zanjan, Iran) for his helpful cooperation and
   the support for this work provided by the Yasouj University, Iran.
CR Ballini R, 2001, SYNTHESIS-STUTTGART, P1519
   El-Agrody AM, 2001, MOLECULES, V6, P519, DOI 10.3390/60600519                                                                
   Gladkov E, 2007, CHEM PAP, V61, P146, DOI 10.2478/s11696-007-0012-9
   Gutierrez-Sanchez C, 2009, CATAL LETT, V128, P318, DOI 10.1007/s10562-008-9709-9
   HUANG L, 1994, BIOORG MED CHEM LETT, V4, P593, DOI 10.1016/S0960-894X(01)80161-X
   Junistia L, 2008, STARCH-STARKE, V60, P667, DOI 10.1002/star.200800025
   Karami B, 2012, CHEM PAP, V66, P684, DOI 10.2478/s11696-012-0152-4
   Karami B, 2012, CATAL COMMUN, V20, P71, DOI 10.1016/j.catcom.2012.01.012
   Karami B, 2012, TETRAHEDRON LETT, V53, P1445, DOI 10.1016/j.tetlet.2012.01.024
   Karami B, 2012, CATAL SCI TECHNOL, V2, P331, DOI 10.1039/c1cy00289a
   Karami B, 2011, CATAL COMMUN, V14, P62, DOI 10.1016/j.catcom.2011.07.002
   Karami B, 2011, POLYCYCL AROMAT COMP, V31, P97, DOI 10.1080/10406638.2011.572577
   Kumar V, 2008, SYNTHETIC COMMUN, V38, P2646, DOI 10.1080/00397910802219569
   Mehrabi H, 2010, J IRAN CHEM SOC, V7, P890, DOI 10.1007/BF03246084                                                              
   Meng XY, 2011, SYNTHETIC COMMUN, V41, P3477, DOI 10.1080/00397911.2010.518299
   Opanasenko M, 2013, CHEMCATCHEM, V5, P1024, DOI 10.1002/cctc.201200232
   Oyamada J, 2002, CHEM LETT, P380, DOI 10.1246/cl.2002.380
   da Silva BHST, 2012, SYNLETT, P1973, DOI 10.1055/s-0032-1316587
   Sanki AK, 2008, TETRAHEDRON, V64, P10406, DOI 10.1016/j.tet.2008.08.050
   Shaabani A, 2007, CHEM PAP, V61, P333, DOI 10.2478/s11696-007-0043-2
   Sheng SR, 2006, SYNTHETIC COMMUN, V36, P3175, DOI 10.1080/00397910600908868
   Szakonyi Z, 2010, MOL DIVERS, V14, P59, DOI 10.1007/s11030-009-9143-y
   Von Pechmann H. C., 1884, BER DTSCH CHEM GES, V17, P929, DOI DOI 10.1002/CBER.18840170
   Wu J, 2006, SYNTHETIC COMMUN, V36, P2949, DOI 10.1080/00397910600773692
   Xie L, 1999, J MED CHEM, V42, P2662, DOI 10.1021/jm9900624
   Yavari I, 2011, J IRAN CHEM SOC, V8, P1030, DOI 10.1007/BF03246559                                                              
NR 26
TC 14
Z9 14
U1 0
U2 10
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 0366-6352
J9 CHEM PAP
JI Chem. Pap.
PD NOV
PY 2013
VL 67
IS 11
BP 1474
EP 1478
DI 10.2478/s11696-013-0411-z
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 173WN
UT WOS:000321112800013
DA 2018-01-05
ER

PT J
AU Mulder, KCL
   Lima, LA
   Miranda, VJ
   Dias, SC
   Franco, OL
AF Mulder, Kelly C. L.
   Lima, Loiane A.
   Miranda, Vivian J.
   Dias, Simoni C.
   Franco, Octavio L.
TI Current scenario of peptide-based drugs: the key roles of cationic
   antitumor and antiviral peptides
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Review
DE cationic peptides; antiviral; antitumor; target selectivity; therapeutic
   drugs
ID HERPES-SIMPLEX-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; HOST-DEFENSE
   PEPTIDES; HUMAN ANTIMICROBIAL PEPTIDE; RIBOSOME-INACTIVATING PROTEINS;
   CYTOTOXIC CYCLIC HEPTAPEPTIDE; SOLUBLE FUSION EXPRESSION; HUMAN LUNG
   ADENOCARCINOMA; LIPID-BILAYER DISRUPTION; HIGH-LEVEL EXPRESSION
AB Cationic antimicrobial peptides (AMPs) and host defense peptides (HDPs) show vast potential as peptide-based drugs. Great effort has been made in order to exploit their mechanisms of action, aiming to identify their targets as well as to enhance their activity and bioavailability. In this review, we will focus on both naturally occurring and designed antiviral and antitumor cationic peptides, including those here called promiscuous, in which multiple targets are associated with a single peptide structure. Emphasis will be given to their biochemical features, selectivity against extra targets, and molecular mechanisms. Peptides which possess antitumor activity against different cancer cell lines will be discussed, as well as peptides which inhibit virus replication, focusing on their applications for human health, animal health and agriculture, and their potential as new therapeutic drugs. Moreover, the current scenario for production and the use of nanotechnology as delivery tool for both classes of cationic peptides, as well as the perspectives on improving them is considered.
C1 [Mulder, Kelly C. L.; Lima, Loiane A.; Miranda, Vivian J.; Dias, Simoni C.; Franco, Octavio L.] Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, Programa Posgrad Ciencias Genom & Biotecnol, BR-71837360 Brasilia, DF, Brazil.
RP Franco, OL (reprint author), Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, Programa Posgrad Ciencias Genom & Biotecnol, SGAN 916N,Modulo C,Ave W5, BR-71837360 Brasilia, DF, Brazil.
EM ocfranco@gmail.com
CR Abonyi DO, 2009, AFR J BIOTECHNOL, V8, P3989
   ABOUDY Y, 1994, INT J PEPT PROT RES, V43, P573
   ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957
   Andersen JH, 2003, ANTIVIR RES, V58, P209, DOI [10.1016/S0166-3542(02)00214-0, 10.1016/j.antiviral.2003.07.004]
   Andersen JH, 2001, ANTIVIR RES, V51, P141, DOI 10.1016/S0166-3542(01)00146-2
   Aneiros A, 2004, J CHROMATOGR B, V803, P41, DOI 10.1016/j.jchromb.2003.11.005
   BAI R, 1990, BIOCHEM PHARMACOL, V39, P1941, DOI 10.1016/0006-2952(90)90613-P
   Barlow PG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025333
   BARRA D, 1995, TRENDS BIOTECHNOL, V13, P205, DOI 10.1016/S0167-7799(00)88947-7
   Bastian A, 2001, REGUL PEPTIDES, V101, P157, DOI 10.1016/S0167-0115(01)00282-8
   Belaid A, 2002, J MED VIROL, V66, P229, DOI 10.1002/jmv.2134
   BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.biochem.59.1.395
   Bhargava A, 2007, PLANT SCI, V172, P515, DOI 10.1016/j.plantsci.2006.10.016
   BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61
   Brocal I, 2006, APPL MICROBIOL BIOT, V72, P1217, DOI 10.1007/s00253-006-0393-7
   Burrowes OJ, 2005, J BIOMED BIOTECHNOL, P374, DOI 10.1155/JBB.2005.374
   Cao P, 2010, BIOTECHNOL PROGR, V26, P1240, DOI 10.1002/btpr.433
   Carriel-Gomes MC, 2007, MEM I OSWALDO CRUZ, V102, P469, DOI 10.1590/S0074-02762007005000028
   CARROLL AR, 1994, AUST J CHEM, V47, P61, DOI 10.1071/CH9940061                                                               
   Carroll AR, 1996, J ORG CHEM, V61, P4059, DOI 10.1021/jo951379o                                                               
   Chan SC, 1998, ANTICANCER RES, V18, P4467
   Chan SC, 1998, J PEPT SCI, V4, P413, DOI 10.1002/(SICI)1099-1387(1998110)4:7<413::AID-PSC160>3.3.CO;2-X
   CHAUDHARY J, 1995, CYTOPATHOLOGY, V6, P162, DOI 10.1111/j.1365-2303.1995.tb00469.x
   Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X
   Chen JG, 2005, CANCER RES, V65, P4614, DOI 10.1158/0008-5472.CAN-04-2253                                                   
   Chen YLS, 2012, PEPTIDES, V36, P257, DOI 10.1016/j.peptides.2012.05.011
   CHEN ZC, 1991, PLANT PATHOL, V40, P612, DOI 10.1111/j.1365-3059.1991.tb02426.x
   Cheng LY, 2012, CLIN COLORECTAL CANC, V11, P207, DOI [10.1016/j.clcc.2012.01.002, 10.1016/j.dcc.2012.01.002]
   Chernysh S, 2002, P NATL ACAD SCI USA, V99, P12628, DOI 10.1073/pnas.192301899
   Chernysh S, 2012, INT IMMUNOPHARMACOL, V12, P312, DOI 10.1016/j.intimp.2011.10.016
   Chia TJ, 2010, FISH SHELLFISH IMMUN, V28, P434, DOI 10.1016/j.fsi.2009.11.020
   Chiou PP, 2002, MAR BIOTECHNOL, V4, P294, DOI 10.1007/s10126-002-0021-1
   Chuang CM, 2009, HUM GENE THER, V20, P303, DOI 10.1089/hum.2008.124
   Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399
   Craik DJ, 2013, CURR OPIN CHEM BIOL, V17, P546, DOI 10.1016/j.cbpa.2013.05.033
   Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055
   CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792
   Cruz-Chamorro L, 2006, PEPTIDES, V27, P1201, DOI 10.1016/j.peptides.2005.11.008
   DAHER KA, 1986, J VIROL, V60, P1068
   Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276
   De Clercq E, 2008, FUTURE VIROL, V3, P393, DOI 10.2217/17460794.3.4.393
   Dobrzynska I, 2005, MOL CELL BIOCHEM, V276, P113, DOI 10.1007/s11010-005-3557-3
   Doyle J, 2003, EUR J BIOCHEM, V270, P1141, DOI 10.1046/j.1432-1033.2003.03462.x
   Ebada SS, 2009, MAR DRUGS, V7, P435, DOI 10.3390/md7030435
   Edler MC, 2002, BIOCHEM PHARMACOL, V63, P707, DOI 10.1016/S0006-2952(01)00898-X
   Edwards DJ, 2004, CHEM BIOL, V11, P817, DOI 10.1016/j.chembiol.2004.03.030
   Eliassen LT, 2006, INT J CANCER, V119, P493, DOI 10.1002/ijc.21886
   Escudero E, 2012, MEAT SCI, V91, P306, DOI 10.1016/j.meatsci.2012.02.008
   Faivre S, 2005, J CLIN ONCOL, V23, P7871, DOI 10.1200/JCO.2005.09.357
   Falco A, 2007, ANTIVIR RES, V76, P111, DOI 10.1016/j.antiviral.2007.06.006
   Falco A, 2009, MINI-REV MED CHEM, V9, P1159, DOI 10.2174/138955709789055171                                                      
   Feng XJ, 2012, APPL MICROBIOL BIOT, V95, P1191, DOI 10.1007/s00253-011-3816-z
   Findlay EG, 2013, BIODRUGS, V27, P479, DOI 10.1007/s40259-013-0039-0
   FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0
   Fox JL, 2013, NAT BIOTECHNOL, V31, P379, DOI 10.1038/nbt.2572
   Franco OL, 2006, FEBS J, V273, P3489, DOI 10.1111/j.1742-4658.2006.05349.x
   Franco OL, 2011, FEBS LETT, V585, P995, DOI 10.1016/j.febslet.2011.03.008
   Freitas VM, 2008, J CELL PHYSIOL, V216, P583, DOI 10.1002/jcp.21432
   GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120
   Ghavami S, 2008, J CELL MOL MED, V12, P1005, DOI 10.1111/j.1582-4934.2007.00129.x
   Ghosh AK, 2010, BIOORG MED CHEM LETT, V20, P5104, DOI 10.1016/j.bmcl.2010.07.023
   Gifford JL, 2005, CELL MOL LIFE SCI, V62, P2588, DOI 10.1007/s00018-005-5373-z
   Gordon YJ, 2009, CURR EYE RES, V34, P241, DOI 10.1080/02713680802714066
   Gracia C, 2006, J ORG CHEM, V71, P7196, DOI 10.1021/jo060976f
   GRAVITT KR, 1994, BIOCHEM PHARMACOL, V47, P425, DOI 10.1016/0006-2952(94)90037-X                                                    
   Gropp R, 1999, HUM GENE THER, V10, P957, DOI 10.1089/10430349950018355
   Gu Y, 2013, ONCOL LETT, V5, P483, DOI 10.3892/ol.2012.1049
   Guevara M. G., 2011, ISOLATION NEW ANTIMI
   Hallock KJ, 2002, BIOPHYS J, V83, P1004, DOI 10.1016/S0006-3495(02)75226-0                                                   
   Hamann MT, 1996, J ORG CHEM, V61, P6594, DOI 10.1021/jo960877+                                                               
   HAMBLEY TW, 1992, TETRAHEDRON, V48, P341, DOI 10.1016/S0040-4020(01)88146-1
   Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5
   Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317
   Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267
   HARMSEN MC, 1995, J INFECT DIS, V172, P380, DOI 10.1093/infdis/172.2.380                                                        
   Held-Kuznetsov V, 2009, FASEB J, V23, P4299, DOI 10.1096/fj.09-136358
   Henzler-Wildman KA, 2004, BIOCHEMISTRY-US, V43, P8459, DOI 10.1021/bi036284s
   Hitotsuyanagi Y, 2004, TETRAHEDRON LETT, V45, P935, DOI 10.1016/j.tetlet.2003.11.112
   Hook LM, 2006, J VIROL, V80, P4038, DOI 10.1128/JVI.80.8.4038-4046.2006
   Horgen FD, 2002, J NAT PROD, V65, P487, DOI 10.1021/np010560r
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Hou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053491
   Hsieh CC, 2010, J FOOD SCI, V75, pH311, DOI 10.1111/j.1750-3841.2010.01861.x
   Hsieh PW, 2005, CHEM PHARM BULL, V53, P336, DOI 10.1248/cpb.53.336
   Hsieh PW, 2004, J NAT PROD, V67, P1522, DOI 10.1021/np040036v
   Hsu CH, 2005, NUCLEIC ACIDS RES, V33, P4053, DOI 10.1093/nar/gki725
   Hu J, 2011, BIOMACROMOLECULES, V12, P3839, DOI 10.1021/bm201098j
   Huang L, 2008, PROTEIN EXPRES PURIF, V61, P168, DOI 10.1016/j.pep.2008.05.016
   Huang L, 2009, APPL MICROBIOL BIOT, V84, P301, DOI 10.1007/s00253-009-1982-z
   Huang TC, 2011, MAR DRUGS, V9, P1995, DOI 10.3390/md9101995
   Hull R, 2002, MATHEWS PLANT VIROLO
   Ikeda Masanori, 1998, Biochemical and Biophysical Research Communications, V245, P549, DOI 10.1006/bbrc.1998.8481
   ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524                                                     
   JACOB L, 1994, CIBA F SYMP, V186, P197
   Jan PS, 2010, APPL ENVIRON MICROB, V76, P769, DOI 10.1128/AEM.00698-09
   Jenssen H, 2004, ANTIVIR RES, V61, P101, DOI 10.1016/j.antiviral.2003.09.001
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05
   Jin FL, 2006, PROTEIN EXPRES PURIF, V49, P39, DOI 10.1016/j.pep.2006.03.008
   Kalemkerian GP, 1999, CANCER CHEMOTH PHARM, V43, P507, DOI 10.1007/s002800050931
   Kaur I., 2001, VIROL SIN, V26, P357, DOI 10.1007/s12250-011-3223-8
   Kim HK, 2006, APPL MICROBIOL BIOT, V72, P330, DOI 10.1007/s00253-005-0266-5
   Kinchington D., 1995, DESIGN TESTING ANTIV
   KOBAYASHI M, 1994, CHEM PHARM BULL, V42, P2196
   Koszalka P, 2011, ACTA BIOCHIM POL, V58, P111
   Lax R, 2010, PHARMANUFACTURING IN, P10
   Lee HS, 2008, CANCER LETT, V271, P47, DOI 10.1016/j.canlet.2008.05.041
   Lee SB, 2011, PLANT BIOTECHNOL J, V9, P100, DOI 10.1111/j.1467-7652.2010.00538.x
   Lehmann J, 2006, EUR UROL, V50, P141, DOI 10.1016/j.eururo.2005.12.043
   Leuschner C, 2004, CURR PHARM DESIGN, V10, P2299, DOI 10.2174/1381612043383971
   Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159                                                   
   Li JF, 2010, PROTEIN J, V29, P314, DOI 10.1007/s10930-010-9254-4
   Li WL, 2003, J NAT PROD, V66, P146, DOI 10.1021/np020223y
   Liang YL, 2006, DEV COMP IMMUNOL, V30, P249, DOI 10.1016/j.dci.2005.04.005
   Liu S, 2013, CANCER BIOTHER RADIO, V28, P289, DOI 10.1089/cbr.2012.1328
   Luo HX, 2007, J DAIRY RES, V74, P233, DOI 10.1017/S0022029907002531
   Ma DW, 2006, CHEM-EUR J, V12, P7615, DOI 10.1002/chem.200600599
   Mader JS, 2006, AM J PATHOL, V169, P1753, DOI 10.2353/ajpath.2006.051229
   Mader JS, 2006, EXPERT OPIN INV DRUG, V15, P933, DOI 10.1517/13543784.15.8.933
   Mader JS, 2005, MOL CANCER THER, V4, P612, DOI 10.1158/1535-7163.MCT-04-0077                                                   
   Mai JC, 2001, CANCER RES, V61, P7709
   Malaker A, 2013, INT J ENG APPL SCI, V2, P82
   Mandal SM, 2013, BIOCHIMIE, V95, P1939, DOI 10.1016/j.biochi.2013.06.027
   Mandal SM, 2012, J CELL BIOCHEM, V113, P184, DOI 10.1002/jcb.23343
   Marcos JF, 1995, P NATL ACAD SCI USA, V92, P12466, DOI 10.1073/pnas.92.26.12466
   Martin-Algarra S, 2009, EUR J CANCER, V45, P732, DOI 10.1016/j.ejca.2008.12.005
   Matanic VCA, 2004, INT J ANTIMICROB AG, V23, P382, DOI 10.1016/j.ijantimicag.2003.07.022
   Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v
   McDaniel JR, 2010, ADV DRUG DELIVER REV, V62, P1456, DOI 10.1016/j.addr.2010.05.004
   McKeown STW, 2006, ORAL ONCOL, V42, P685, DOI 10.1016/j.oraloncology.2005.11.005
   Medina RA, 2008, J AM CHEM SOC, V130, P6324, DOI 10.1021/ja801383f
   Mendieta JR, 2010, FITOTERAPIA, V81, P329, DOI 10.1016/j.fitote.2009.10.004
   Mendoza FJ, 2005, ARCH IMMUNOL THER EX, V53, P47
   Migliolo L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047047
   Mistry N, 2007, ANTIVIR RES, V75, P258, DOI 10.1016/j.antiviral.2007.03.012
   Mooberry SL, 2003, INT J CANCER, V104, P512, DOI 10.1002/ijc.10982
   Moon JY, 2006, BBA-BIOMEMBRANES, V1758, P1351, DOI 10.1016/j.bbamem.2006.02.003
   MORIMOTO M, 1991, CHEMOTHERAPY, V37, P206, DOI 10.1159/000238855                                                               
   Morin KM, 2006, APPL MICROBIOL BIOT, V70, P698, DOI 10.1007/s00253-005-0132-5
   Munk C, 2003, AIDS RES HUM RETROV, V19, P875, DOI 10.1089/088922203322493049
   MURAKAMI T, 1991, CHEMOTHERAPY, V37, P327, DOI 10.1159/000238875                                                               
   NAKASHIMA H, 1992, ANTIMICROB AGENTS CH, V36, P1249, DOI 10.1128/AAC.36.6.1249                                                           
   NAKASHIMA H, 1993, AIDS, V7, P1129, DOI 10.1097/00002030-199308000-00019
   Nguyen LT, 2011, TRENDS BIOTECHNOL, V29, P464, DOI 10.1016/j.tibtech.2011.05.001
   OKA M, 1988, J ANTIBIOT, V41, P1906, DOI 10.7164/antibiotics.41.1906                                                     
   Okubo BM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033639
   Onwulata CI, 2012, ANNU REV FOOD SCI T, V3, P183, DOI 10.1146/annurev-food-022811-101140
   Papo N, 2005, CELL MOL LIFE SCI, V62, P784, DOI 10.1007/s00018-005-4560-2
   Parachin NS, 2012, PEPTIDES, V38, P446, DOI 10.1016/j.peptides.2012.09.020
   Paredes-Gamero EJ, 2012, BBA-GEN SUBJECTS, V1820, P1062, DOI 10.1016/j.bbagen.2012.02.015
   Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159
   PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757
   Park JY, 2012, J KOREAN SOC APPL BI, V55, P89, DOI 10.1007/s13765-012-0015-2
   Pepe G, 2013, J AMINO ACIDS, DOI [10.1155/2013/939804, DOI 10.1155/2013/939804]
   Peters BM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001067
   Pichereau C., 2005, EUR BIOPHARM REV, V5, P88
   Power O, 2013, AMINO ACIDS, V44, P797, DOI 10.1007/s00726-012-1393-9
   Puddu P, 1998, INT J BIOCHEM CELL B, V30, P1055, DOI 10.1016/S1357-2725(98)00066-1
   Rashid MA, 2001, J NAT PROD, V64, P117, DOI 10.1021/np0002379
   Reichert J., 2010, P 2010 C USENIX ANN, P1
   RENAN MJ, 1993, MOL CARCINOGEN, V7, P139
   Riedl S, 2011, CHEM PHYS LIPIDS, V164, P766, DOI 10.1016/j.chemphyslip.2011.09.004
   RINEHART KL, 1983, FED PROC, V42, P87
   RINEHART KL, 1981, SCIENCE, V212, P933, DOI 10.1126/science.7233187
   Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002
   Risso A, 1998, CELL IMMUNOL, V189, P107, DOI 10.1006/cimm.1998.1358
   Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94
   Rotem S, 2009, BBA-BIOMEMBRANES, V1788, P1582, DOI 10.1016/j.bbamem.2008.10.020
   Rozek T, 2000, EUR J BIOCHEM, V267, P5330, DOI 10.1046/j.1432-1327.2000.01536.x
   Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200
   Schweizer F, 2009, EUR J PHARMACOL, V625, P190, DOI 10.1016/j.ejphar.2009.08.043
   Sen Z, 2013, ONCOL LETT, V5, P641, DOI 10.3892/ol.2012.1042
   SHARMA SV, 1993, ONCOGENE, V8, P939
   SHARMA SV, 1992, ONCOGENE, V7, P193
   Shimizu K, 1996, ARCH VIROL, V141, P1875, DOI 10.1007/BF01718201
   Silva ON, 2012, BIOPOLYMERS, V98, P322, DOI 10.1002/bip.22071
   Silvestro L, 1999, BIOCHEMISTRY-US, V38, P3850, DOI 10.1021/bi995071t                                                               
   Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721
   Singh R, 2008, ANTI-CANCER AGENT ME, V8, P603, DOI 10.2174/187152008785133074                                                      
   Sinha S, 2003, ANTIMICROB AGENTS CH, V47, P494, DOI 10.1128/AAC.47.2.494-500.2003
   Smith LL, 2000, CRIT REV TOXICOL, V30, P571, DOI 10.1080/10408440008951120
   Sok M, 1999, CANCER LETT, V139, P215, DOI 10.1016/S0304-3835(99)00044-0
   Srisailam S, 2001, EUR J BIOCHEM, V268, P4278, DOI 10.1046/j.1432-1327.2001.02345.x
   STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0
   Steinstraesser L, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-2
   SUI SF, 1994, J BIOCHEM-TOKYO, V116, P482, DOI 10.1093/oxfordjournals.jbchem.a124550                                           
   Suttmann Henrik, 2008, BMC Urol, V8, P5, DOI 10.1186/1471-2490-8-5
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jcb.M208762200
   Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871
   Tamamura H, 1996, BIOCHEM BIOPH RES CO, V219, P555, DOI 10.1006/bbrc.1996.0272
   Tavares LS, 2012, PEPTIDES, V37, P294, DOI 10.1016/j.peptides.2012.07.017
   TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x
   Teixeira LD, 2013, PEPTIDES, V42, P144, DOI 10.1016/j.peptides.2013.02.001
   TERRAS FRG, 1992, J BIOL CHEM, V267, P15301
   Thakur N, 2012, NUCLEIC ACIDS RES, V40, pW199, DOI 10.1093/nar/gks450
   Thundimadathil J, 2012, J AMINO ACIDS, V2012, P13, DOI [10.1155/2012/967347, DOI 10.1155/2012/967347]
   TOSTESON MT, 1985, J MEMBRANE BIOL, V87, P35, DOI 10.1007/BF01870697
   Tripathi GR, 2006, J AGR FOOD CHEM, V54, P8437, DOI 10.1021/jf061794p
   Valenti P, 2005, CELL MOL LIFE SCI, V62, P2576, DOI 10.1007/s00018-005-5372-0
   van der Strate BWA, 2001, ANTIVIR RES, V52, P225, DOI 10.1016/S0166-3542(01)00195-4                                                   
   VanCompernolle SE, 2005, J VIROL, V79, P11598, DOI 10.1128/JVI.79.18.11598-11606.2005
   Vasko RC, 2010, ACS MED CHEM LETT, V1, P4, DOI 10.1021/ml900003f
   Vervoort H, 2000, J ORG CHEM, V65, P782, DOI 10.1021/jo991425a
   Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731                                                      
   Wagner Edward K., 1999, BASIC VIROLOGY
   Wang AP, 2010, APPL MICROBIOL BIOT, V87, P1935, DOI 10.1007/s00253-010-2688-y
   Wang AP, 2009, APPL MICROBIOL BIOT, V84, P877, DOI 10.1007/s00253-009-2020-x
   Wang C, 2009, J BIOL CHEM, V284, P3804, DOI 10.1074/jbc.M807191200
   Wang CC, 2012, EXP BIOL MED, V237, P442, DOI 10.1258/ebm.2012.011337
   Wang Q, 2011, BIOTECHNOL LETT, V33, P2121, DOI 10.1007/s10529-011-0687-4
   Wang XQ, 2013, BIOTECHNOL PROGR, V29, P681, DOI 10.1002/btpr.1725
   Wang YD, 2010, PEPTIDES, V31, P1026, DOI 10.1016/j.peptides.2010.02.025
   WATTERS DJ, 1994, CANCER CHEMOTH PHARM, V33, P399, DOI 10.1007/s002800050072
   Wele A, 2004, J NAT PROD, V67, P1577, DOI 10.1021/np040068i
   Wesson KJ, 1996, J NAT PROD, V59, P629, DOI 10.1021/np960153t
   WESTERHOFF HV, 1989, BIOCHIM BIOPHYS ACTA, V975, P361, DOI 10.1016/S0005-2728(89)80344-5
   Wildman KAH, 2003, BIOCHEMISTRY-US, V42, P6545, DOI 10.1021/bi0273563
   Williams PG, 2003, J NAT PROD, V66, P595, DOI 10.1021/np030011g
   Won HS, 2006, J MED CHEM, V49, P4886, DOI 10.1021/jm050996u
   Xu JX, 1999, CHEM J CHINESE U, V20, P722
   Xu N, 2008, MOL CANCER THER, V7, P1588, DOI 10.1158/1535-7163.MCT-08-0010
   Xu XX, 2007, PROTEIN EXPRES PURIF, V55, P175, DOI 10.1016/j.pep.2007.04.018
   Xu XX, 2007, PROTEIN EXPRES PURIF, V53, P293, DOI 10.1016/j.pep.2006.12.020
   Xu ZN, 2006, BIOTECHNOL PROGR, V22, P382, DOI 10.1021/bp0502680
   Yan R, 2011, PEPTIDES, V32, P11, DOI 10.1016/j.peptides.2010.10.008
   Yang Q. -Z., 2013, ARCH PHARM RES, DOI [10.1007/s12272-013-0112-8, DOI 10.1007/S12272-013-0112-8.[]
   Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004
   Yasin B, 2000, EUR J CLIN MICROBIOL, V19, P187, DOI 10.1007/s100960050457                                                           
   Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2
   Yi MY, 1997, J VIROL, V71, P5997
   Yoo YC, 1997, BIOCHEM BIOPH RES CO, V237, P624, DOI 10.1006/bbrc.1997.7199
   Yu ZG, 2008, J NAT PROD, V71, P1052, DOI 10.1021/np070580e
   Zakharchenko NS, 2013, RUSS J GENET+, V49, P523, DOI 10.1134/S102279541305013X
   Zampella A, 2009, ORG BIOMOL CHEM, V7, P4037, DOI 10.1039/b910015f
   ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449                                                         
   Zhang JJ, 2013, BIOMATERIALS, V34, P3846, DOI 10.1016/j.biomaterials.2013.01.026
   Zhang JF, 2013, MOL IMMUNOL, V55, P264, DOI 10.1016/j.molimm.2013.02.006
   Zhang LH, 1999, LIFE SCI, V64, P1013, DOI 10.1016/S0024-3205(99)00028-4
   Zhang XX, 2012, J CONTROL RELEASE, V159, P2, DOI 10.1016/j.jconrel.2011.10.023
   Zhao YL, 2011, J CELL BIOCHEM, V112, P2424, DOI 10.1002/jcb.23166
   Zheng LH, 2011, MAR DRUGS, V9, P1840, DOI 10.3390/md9101840
   Zhong ZX, 2006, APPL MICROBIOL BIOT, V71, P661, DOI 10.1007/s00253-005-0212-6
NR 242
TC 50
Z9 52
U1 0
U2 55
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD OCT 31
PY 2013
VL 4
AR UNSP 321
DI 10.3389/fmicb.2013.00321
PG 23
WC Microbiology
SC Microbiology
GA AB1DU
UT WOS:000331532500001
PM 24198814
OA gold
DA 2018-01-05
ER

PT J
AU Deshmukh, L
   Schwieters, CD
   Grishaev, A
   Ghirlando, R
   Baber, JL
   Clore, GM
AF Deshmukh, Lalit
   Schwieters, Charles D.
   Grishaev, Alexander
   Ghirlando, Rodolfo
   Baber, James L.
   Clore, G. Marius
TI Structure and Dynamics of Full-Length HIV-1 Capsid Protein in Solution
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID RESIDUAL DIPOLAR COUPLINGS; MOLECULAR-STRUCTURE DETERMINATION;
   N-TERMINAL DOMAIN; ANALYTICAL ULTRACENTRIFUGATION;
   SEDIMENTATION-VELOCITY; PERDEUTERATED PROTEINS; DIMERIZATION DOMAIN;
   INTERDOMAIN MOTION; NMR STRUCTURES; CA PROTEIN
AB The HIV-1 capsid protein plays a crucial role in viral infectivity, assembling into a cone that encloses the viral RNA. In the mature virion, the N-terminal domain of the capsid protein forms hexameric and pentameric rings, while C-terminal domain homodimers connect adjacent N-terminal domain rings to one another. Structures of disulfide-linked hexamer and pentamer assemblies, as well as structures of the isolated domains, have been solved previously. The dimer configuration in C-terminal domain constructs differs in solution (residues 144-231) and crystal (residues 146-231) structures by similar to 30 degrees, and it has been postulated that the former connects the hexamers while the latter links pentamers to hexamers. Here we study the structure and dynamics of full-length capsid protein in solution, comprising a mixture of monomeric and dimeric forms in dynamic equilibrium, using ensemble simulated annealing driven by experimental NMR residual dipolar couplings and X-ray scattering data. The complexity of the system necessitated the development of a novel computational framework that should be generally applicable to many other challenging systems that currently escape structural characterization by standard application of mainstream techniques of structural biology. We show that the orientation of the C-terminal domains in dimeric full-length capsid and isolated C-terminal domain constructs is the same in solution, and we obtain a quantitative description of the conformational space sampled by the N-terminal domain relative to the C-terminal domain on the nano- to millisecond time scale. The positional distribution of the N-terminal domain relative to the C-terminal domain is large and modulated by the oligomerization state of the C-terminal domain. We also show that a model of the hexamer/pentamer assembly can be readily generated with a single configuration of the C-terminal domain dimer, and that capsid assembly likely proceeds via conformational selection of sparsely populated configurations of the N-terminal domain within the capsid protein dimer.
C1 [Deshmukh, Lalit; Grishaev, Alexander; Baber, James L.; Clore, G. Marius] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
   [Ghirlando, Rodolfo] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
   [Schwieters, Charles D.] NIH, Div Computat Biosci, Ctr Informat Technol, Bethesda, MD 20892 USA.
RP Clore, GM (reprint author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
EM mariusc@mail.nih.gov
RI Deshmukh, Lalit/C-5073-2015; Clore, G. Marius/A-3511-2008
OI Clore, G. Marius/0000-0003-3809-1027; Grishaev,
   Alexander/0000-0002-9347-2327
FU NIH, NIDDK; CIT; Office of the Director of the NIH
FX We thank Vincenzo Venditti, Marvin Bayro, and Mengli Cai for useful
   discussions, Rob Tycko for generously giving us the full-length capsid
   DNA, Dan Garrett for technical support, and Mark Yeager (Scripps
   Research Institute) for providing the fullerene cone model coordinates.
   Use of the Advanced Photon Source (DOE W-31-109-ENG-38) and the shared
   scattering beamline resource (PUP-77 agreement between NCI, NIH, and
   Argonne National Laboratory) is acknowledged. This work was supported by
   funds from the Intramural Program of the NIH, NIDDK (G.M.C.), and CIT
   (C.D.S.), and from the Intramural AIDS Targeted Antiviral Program of the
   Office of the Director of the NIH (to G.M.C.).
CR Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000
   Baber JL, 2001, J AM CHEM SOC, V123, P3953, DOI 10.1021/ja0041876
   Bermejo GA, 2012, PROTEIN SCI, V21, P1824, DOI 10.1002/pro.2163
   Bewley CA, 2000, J AM CHEM SOC, V122, P6009, DOI 10.1021/ja000858o
   Borsetti A, 1998, J VIROL, V72, P9313
   Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a
   Braddock DT, 2001, J AM CHEM SOC, V123, P8634, DOI 10.1021/ja016234f
   Brautigam CA, 2011, METHODS, V54, P4, DOI 10.1016/j.ymeth.2010.12.029
   Byeon IJL, 2012, J AM CHEM SOC, V134, P6455, DOI 10.1021/ja300937v
   Byeon IJL, 2009, CELL, V139, P780, DOI 10.1016/j.cell.2009.10.010
   Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k                                                               
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9
   Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f                                                               
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   Dahirel V, 2011, P NATL ACAD SCI USA, V108, P11530, DOI 10.1073/pnas.1105315108
   del Alamo M, 2005, J VIROL, V79, P14271, DOI 10.1128/JVI.79.22.14271-14281.2005
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Douglas CC, 2004, BIOCHEMISTRY-US, V43, P10435, DOI 10.1021/bi049359g
   Du SC, 2011, J MOL BIOL, V406, P371, DOI 10.1016/j.jmb.2010.11.027
   Fitzkee NC, 2010, J BIOMOL NMR, V48, P65, DOI 10.1007/s10858-010-9441-9
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004
   Ghirlando R, 2011, METHODS, V54, P145, DOI 10.1016/j.ymeth.2010.12.005
   Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231
   Hanke T, 2011, EUR J IMMUNOL, V41, P3390, DOI 10.1002/eji.201190072
   Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176                                                                    
   HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252
   Huang JR, 2010, J AM CHEM SOC, V132, P694, DOI 10.1021/ja907974m
   Johnson ML, 1994, MODERN ANAL ULTRACEN, P37
   Kelly BN, 2007, J MOL BIOL, V373, P355, DOI 10.1016/j.jmb.2007.07.070
   King V, 2000, J MAGN RESON, V142, P177, DOI 10.1006/jmre.1999.1928
   Lakomek NA, 2012, J BIOMOL NMR, V53, P209, DOI 10.1007/s10858-012-9626-5
   Lemke CT, 2012, J VIROL, V86, P6643, DOI 10.1128/JVI.00493-12
   Monaco-Malbet S, 2000, STRUCTURE, V8, P1069, DOI 10.1016/S0969-2126(00)00507-4
   NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27
   NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307
   Pornillos O, 2011, NATURE, V469, P424, DOI 10.1038/nature09640
   Pornillos O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656
   Riek R, 2000, TRENDS BIOCHEM SCI, V25, P462, DOI 10.1016/S0968-0004(00)01665-0
   Ryabov Y, 2009, J AM CHEM SOC, V131, P9522, DOI 10.1021/ja902336c
   Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0                                                   
   Schwieters CD, 2006, PROG NUCL MAG RES SP, V48, P47, DOI 10.1016/j.pnmrs.2005.10.001
   Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9
   Schwieters CD, 2010, J AM CHEM SOC, V132, P13026, DOI 10.1021/ja105485b
   Shin R, 2011, BIOCHEMISTRY-US, V50, P9457, DOI 10.1021/bi2011493
   Takayama Y, 2011, J AM CHEM SOC, V133, P424, DOI 10.1021/ja109866w
   Tang C, 2007, NATURE, V449, P1078, DOI 10.1038/nature06232
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   Worthylake DK, 1999, ACTA CRYSTALLOGR D, V55, P85, DOI 10.1107/S0907444998007689
   Yeager M, 2011, J MOL BIOL, V410, P534, DOI 10.1016/j.jmb.2011.04.073
   Zhao GP, 2013, NATURE, V497, P643, DOI 10.1038/nature12162
   Zhao HY, 2013, ANAL BIOCHEM, V437, P104, DOI 10.1016/j.ab.2013.02.011
   Zhao HY, 2011, BIOPHYS J, V100, P2309, DOI 10.1016/j.bpj.2011.03.004
   Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908                                                               
NR 60
TC 50
Z9 53
U1 3
U2 40
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
EI 1520-5126
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 30
PY 2013
VL 135
IS 43
BP 16133
EP 16147
DI 10.1021/ja406246z
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA 245TX
UT WOS:000326487800035
PM 24066695
OA green_accepted
DA 2018-01-05
ER

PT J
AU Tshweu, L
   Katata, L
   Kalombo, L
   Swai, H
AF Tshweu, Lesego
   Katata, Lebogang
   Kalombo, Lonji
   Swai, Hulda
TI Nanoencapsulation of water-soluble drug, lamivudine, using a double
   emulsion spray-drying technique for improving HIV treatment
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Spray-dried; Poly(epsilon-caprolactone); Lamivudine; Nanoparticles;
   Double emulsion; Nanomedicine
ID SOLVENT EVAPORATION; NANOPARTICLES; DELIVERY; TREHALOSE; PARAMETERS;
   SIZE
AB Current treatments available for human immunodeficiency virus, namely antiretrovirals, do not completely eradicate the virus from the body, leading to life-time commitment. Many antiretrovirals suffer drawbacks from toxicity and unpleasant side effects, causing patience non-compliance. To minimize challenges associated with the antiretrovirals, biodegradable nanoparticles used as drug delivery systems hold tremendous potential to enhance patience compliance. The main objective of this work was to load lamivudine (LAM) into poly(epsiloncaprolactone) (PCL) nanoparticles. LAM is a hydrophilic drug with low plasma half-life of 5-7 h and several unpleasant side effects. LAM was nanoencapsulated into PCL polymer via the double emulsion spray-drying method. Formulation parameters such as the effect of solvent, excipient and drug concentration were optimized for the synthesis of the nanoparticles. Spherical nanoparticles with an average size of 215 +/- 3 nm and polydispersity index (PDI) of 0.227 +/- 0.01 were obtained, when ethyl acetate and lactose were used in the preparation. However, dichloromethane presented sizes larger than 454 +/- 11 nm with PDI of more than 0.4 +/- 0.05, irrespective of whether lactose or trehalose was used in the preparation. Some of the nanoparticles prepared with trehalose resulted in crystal formation. UV spectroscopy showed encapsulation efficiency ranging from 68 +/- 4 to 78 +/- 4 % for LAM depending on the starting drug concentration. Fourier transform infrared spectroscopy and X-ray diffraction confirmed the possibility of preparing amorphous PCL nanoparticles containing LAM. Drug release extended for 4 days in pH 1.3, pH 4.5 and pH 6.8. These results indicated that LAM-loaded PCL nanoparticles show promise for controlled delivery.
C1 [Tshweu, Lesego; Kalombo, Lonji; Swai, Hulda] CSIR, ZA-0001 Pretoria, South Africa.
   [Katata, Lebogang] North West Univ, Fac Agr Sci & Technol, Dept Chem, ZA-2735 Mmabatho, South Africa.
RP Tshweu, L (reprint author), CSIR, POB 395,Meiring Naude Rd, ZA-0001 Pretoria, South Africa.
EM tshweull@gmail.com
FU South African National Research Foundation
FX The authors would like to thank South African National Research
   Foundation for providing financial support for the manuscript presented.
   Thomas Malwela is acknowledged for the SEM analysis of the
   nanoparticles.
CR Arpagaus C., 2010, RESP DRUG DELIVERY, P469
   Baras B, 2000, J MICROENCAPSUL, V17, P485
   BROADHEAD J, 1992, DRUG DEV IND PHARM, V18, P1169, DOI 10.3109/03639049209046327                                                       
   Caroline MP, 1997, DRUGS, V53, P7
   Chernysheva YV, 2003, MENDELEEV COMMUN, P65, DOI 10.1070/MC2003v013n02ABEH001690
   Clercq ED, 2009, INT J ANTIMICROB AG, V33, P307
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash S, 2012, COLLOID SURFACE B, V88, P483
   Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064
   Dev A, 2010, CARBOHYD POLYM, V80, P833, DOI 10.1016/j.carbpol.2009.12.040
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Higashiyama T, 2002, PURE APPL CHEM, V74, P1263, DOI 10.1351/pac200274071263                                                         
   Inez MV, 2003, VACCINE, V21, P13
   Jozwiakowski MJ, 1996, J PHARM SCI, V85, P193, DOI 10.1021/js9501728
   Jyothi NVN, 2010, J MICROENCAPSUL, V27, P187, DOI 10.3109/02652040903131301
   Kao JH, 2000, J HEPATOL, V33, P998, DOI 10.1016/S0168-8278(00)80135-X
   Katata L, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1247-0
   Kho K, 2010, POWDER TECHNOL, V203, P432, DOI 10.1016/j.powtec.2010.06.003
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Look M, 2010, ADV DRUG DELIVER REV, V62, P378, DOI 10.1016/j.addr.2009.11.011
   Luong-Van E, 2007, BIOMATERIALS, V28, P2127, DOI 10.1016/j.biomaterials.2007.01.002
   Maia JL, 2004, BRAZ J CHEM ENG, V21, P1, DOI 10.1590/S0104-66322004000100002
   Mishra B, 2010, NANOMED-NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Mourya VK, 2008, REACT FUNCT POLYM, V68, P1013, DOI 10.1016/j.reactfunctpolym.2008.03.002
   Proikakis CS, 2006, EUR POLYM J, V42, P3269, DOI 10.1016/j.eurpolymj.2006.08.023
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Rathbun R C, 2011, ANTIRETROVIRAL THERA
   ROSER B, 1991, BIOPHARM-TECHNOL BUS, V4, P47
   Sahoo S, 2010, CARBOHYD POLYM, V79, P106, DOI 10.1016/j.carbpol.2009.07.042
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Shin ILG, 1998, J CONTROL RELEASE, V51, P1
   Simperler A, 2006, J PHYS CHEM B, V110, P19678, DOI 10.1021/jp063134t
   Song KC, 2006, COLLOID SURFACE A, V276, P162, DOI 10.1016/j.colsurfa.2005.10.064
   Takeuchi H, 1998, INT J PHARM, V174, P91, DOI 10.1016/S0378-5173(98)00248-8
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Wu CS, 2005, POLYMER, V46, P147, DOI 10.1016/j.polymer.2004.11.013
   Young RJ, 1991, INTRO POLYM, P265
   Zhao Y, 2004, MACROMOL BIOSCI, V4, P901, DOI 10.1002/mabi.200400072
NR 39
TC 2
Z9 2
U1 0
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD OCT 22
PY 2013
VL 15
IS 11
AR UNSP 2040
DI 10.1007/s11051-013-2040-4
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 237GO
UT WOS:000325857000001
DA 2018-01-05
ER

PT J
AU Huang, YZ
   Jiang, YF
   Wang, HY
   Wang, JX
   Shin, MC
   Byun, Y
   He, HN
   Liang, YQ
   Yang, VC
AF Huang, Yongzhuo
   Jiang, Yifan
   Wang, Huiyuan
   Wang, Jianxin
   Shin, Meong Cheol
   Byun, Youngro
   He, Huining
   Liang, Yanqin
   Yang, Victor C.
TI Curb challenges of the "Trojan Horse" approach: Smart strategies in
   achieving effective yet safe cell-penetrating peptide-based drug
   delivery
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Cell-penetrating peptide (CPP); Drug delivery system; Prodrug; Targeted
   delivery; In vivo
ID MULTIFUNCTIONAL POLYMERIC MICELLE; HUMAN IMMUNODEFICIENCY VIRUS;
   IN-VIVO; INTRACELLULAR DELIVERY; TAT-PEPTIDE; PROTEIN TRANSDUCTION;
   PEGYLATED LIPOSOMES; GENE DELIVERY; PHARMACEUTICAL NANOCARRIERS; QUANTUM
   DOTS
AB Cell-penetrating peptide (CPP)-mediated intracellular drug delivery system, often specifically termed as "the Trojan horse approach", has become the "holy grail" in achieving effective delivery of macromolecular compounds such as proteins, DNA, siRNAs, and drug carriers. It is characterized by the unique cell(or receptor-), temperature-, and payload-independent mechanisms, therefore offering potent means to improve poor cellular uptake of a variety of macromolecular drugs. Nevertheless, this "Trojan horse" approach also acts like a double-edged sword, causing serious safety and toxicity concerns to normal tissues or organs for in vivo application, due to lack of target selectivity of the powerful cell penetrating activity. To overcome this problem of potent yet non-selective penetration vs. targeting delivery, a number of "smart" strategies have been developed in recent years, including controllable CPP-based drug delivery systems based on various stimuli-responsive mechanisms. This review article provides a fundamental understanding of these smart systems, as well as a discussion of their real-time in vivo applicability. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Huang, Yongzhuo; Jiang, Yifan; Wang, Huiyuan] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Huang, Yongzhuo; Wang, Jianxin] Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China.
   [Huang, Yongzhuo; Wang, Jianxin] MOE PLA, Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China.
   [Shin, Meong Cheol; Yang, Victor C.] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA.
   [Byun, Youngro; Yang, Victor C.] Seoul Natl Univ, Dept Mol Med & Biopharmaceut, Seoul, South Korea.
   [He, Huining; Liang, Yanqin; Yang, Victor C.] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
RP Huang, YZ (reprint author), Chinese Acad Sci, Shanghai Inst Mat Med, 501 Hai Ke Rd, Shanghai 201203, Peoples R China.
EM yzhuang@simm.ac.cn; vcyang@umich.edu
RI BYUN, YOUNG RO/D-5735-2013; Wang, Jianxin/C-9435-2016; Huang,
   Yongzhuo/A-4688-2013
OI Huang, Yongzhuo/0000-0001-7067-8915
FU NSFC, China [91029743, 81172996]; National Basic Research Program of
   China (973 Program) [2013CB932503]; Shanghai Pu-jiang Scholar Program;
   School of Pharmacy, Fudan University; Key Lab of Smart Drug Delivery
   (Fudan University); MOE PLA, China [SDD2011-02]; NIH [CA114612]; World
   Class University (WCU) project of the MEST [R31-2008-000-10103-01]; NRF
   of South Korea
FX We thank the support from NSFC, China (91029743, 81172996), and National
   Basic Research Program of China (973 Program 2013CB932503), and Shanghai
   Pu-jiang Scholar Program, as well as School of Pharmacy, Fudan
   University & The Open Project Program of Key Lab of Smart Drug Delivery
   (Fudan University), and MOE & PLA, China (SDD2011-02). This work was
   also supported in part by NIH R01 Grant CA114612 and by Grant
   R31-2008-000-10103-01 from the World Class University (WCU) project of
   the MEST and NRF of South Korea. Victor C. Yang is currently a
   Participating Faculty in the Department of Molecular Medicine and
   Biopharmaceutical Sciences, College of Medicine & College of Pharmacy,
   Seoul National University, South Korea.
CR Barnett EM, 2006, INVEST OPHTH VIS SCI, V47, P2589, DOI 10.1167/iovs.05-1470
   BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Choi JK, 2012, BIOMATERIALS, V33, P8579, DOI 10.1016/j.biomaterials.2012.07.061
   Chugh A, 2008, J PEPT SCI, V14, P477, DOI 10.1002/psc.937
   Davidson B, 1999, GYNECOL ONCOL, V73, P372, DOI 10.1006/gyno.1999.5381
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Dietz GPH, 2005, BRAIN RES BULL, V68, P103, DOI 10.1016/j.brainresbull.2005.08.015
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165
   Dietz Gunnar P. H., 2007, V399, P181, DOI 10.1007/978-1-59745-504-6_13
   ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699                                                        
   Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gerweck LE, 1996, CANCER RES, V56, P1194
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584
   Gullotti E, 2009, MOL PHARMACEUT, V6, P1041, DOI 10.1021/mp900090z
   Hansen M.B., 2012, J CONTROL RELEASE, DOI DOI 10.1016/JJC0NRE1.2012.10.008
   Harada H, 2007, ONCOGENE, V26, P7508, DOI 10.1038/sj.onc.1210556
   Harada H, 2002, CANCER RES, V62, P2013
   Harris TJ, 2008, SMALL, V4, P1307, DOI 10.1002/smll.200701319
   He HN, 2011, MACROMOL RES, V19, P1224, DOI 10.1007/s13233-011-1214-0
   Henriques ST, 2005, BIOCHEMISTRY-US, V44, P10189, DOI 10.1021/bi0502644
   Hong RL, 1999, CLIN CANCER RES, V5, P3645
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Huang YZ, 2010, CURR PHARM DESIGN, V16, P2369, DOI 10.2174/138161210791920441                                                      
   Huang YZ, 2010, ANGEW CHEM INT EDIT, V49, P2724, DOI 10.1002/anie.200906153
   Inoue M, 2004, INT J ONCOL, V25, P713
   Ishida T, 2003, INT J PHARM, V255, P167, DOI 10.1016/S0378-5173(03)00085-1
   Ishida T, 2006, J CONTROL RELEASE, V115, P251, DOI 10.1016/j.jconret.2006.08.017
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kamei N, 2009, J CONTROL RELEASE, V136, P179, DOI 10.1016/j.jconrel.2009.02.015
   Kang SI, 2002, J CONTROL RELEASE, V80, P145, DOI 10.1016/S0168-3659(02)00021-4
   Kim C, 2010, LANGMUIR, V26, P14965, DOI 10.1021/la102632m
   Kirpotin D, 1996, FEBS LETT, V388, P115, DOI 10.1016/0014-5793(96)00521-2
   Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x
   Kizaka-Kondoh S, 2009, CLIN CANCER RES, V15, P3433, DOI 10.1158/1078-0432.CCR-08-2267
   Koren E, 2012, J CONTROL RELEASE, V160, P264, DOI 10.1016/j.jconrel.2011.12.002
   Kuai R, 2010, MOL PHARMACEUT, V7, P1816, DOI 10.1021/mp100171c
   Kuchimaru T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015736
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee ES, 2008, J CONTROL RELEASE, V129, P228, DOI 10.1016/j.jconrel.2008.04.024
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Lo SL, 2010, MACROMOL RAPID COMM, V31, P1134, DOI 10.1002/marc.200900934
   Lopes LB, 2005, PHARM RES, V22, P750, DOI 10.1007/s11095-005-2591-x
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   MARTIN GR, 1994, CANCER RES, V54, P5670
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Mazza M, 2008, BRIT J PHARMACOL, V155, P149, DOI 10.1038/bjp.2008.274
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Mohajer G, 2007, PHARM RES-DORDR, V24, P1618, DOI 10.1007/s11095-007-9277-5
   Mok H, 2009, LANGMUIR, V25, P1645, DOI 10.1021/la803542v
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   MURRAY JC, 1995, ADV DRUG DELIVER REV, V17, P117, DOI 10.1016/0169-409X(95)00044-8                                                    
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Niedzielski MF, 2007, INT J BIOL SCI, V3, P225
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Park YS, 2010, J CONTROL RELEASE, V144, P82, DOI 10.1016/j.jconrel.2010.01.026
   Prescott DM, 2000, CLIN CANCER RES, V6, P2501
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Romberg B, 2007, BBA-BIOMEMBRANES, V1768, P737, DOI 10.1016/j.bbamem.2006.12.005
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shamay Y, 2011, BIOMATERIALS, V32, P1377, DOI 10.1016/j.biomaterials.2010.10.029
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Splith K, 2011, EUR BIOPHYS J BIOPHY, V40, P387, DOI 10.1007/s00249-011-0682-7
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5
   Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014
   van Duijnhoven SMJ, 2011, J NUCL MED, V52, P279, DOI 10.2967/jnumed.110.082503
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Walther C, 2008, BIOCONJUGATE CHEM, V19, P2346, DOI 10.1021/bc800172q
   Wang XY, 2007, J CONTROL RELEASE, V119, P236, DOI 10.1016/j.jconrel.2007.02.010
   Xia HM, 2011, BIOMATERIALS, V32, P9888, DOI 10.1016/j.biomaterials.2011.09.004
   Yan L, 2013, MACROMOL RES, V21, P435, DOI 10.1007/s13233-013-1029-2
   Yang VC, 2005, J CONTROL RELEASE, V110, P164, DOI 10.1016/j.jconrel.2005.09.027
   Yang YX, 2012, J MATER CHEM, V22, P10029, DOI 10.1039/c2jm00121g
   Yu Zhao, 2009, Cancer Lett, V279, P101, DOI 10.1016/j.canlet.2009.01.030
   Zhang Y, 2006, NANO LETT, V6, P1988, DOI 10.1021/nl0611586
   Zhu L, 2012, ACS NANO, V6, P3491, DOI 10.1021/nn300524f
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 103
TC 87
Z9 90
U1 10
U2 174
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD OCT 15
PY 2013
VL 65
IS 10
BP 1299
EP 1315
DI 10.1016/j.addr.2012.11.007
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 246TB
UT WOS:000326560900003
PM 23369828
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Luo, YC
   Yan, XW
   Huang, YS
   Wen, RB
   Li, ZX
   Yang, LM
   Yang, CJ
   Wang, QQ
AF Luo, Yacui
   Yan, Xiaowen
   Huang, Yishun
   Wen, Ruibin
   Li, Zhaoxin
   Yang, Limin
   Yang, Chaoyong James
   Wang, Qiuquan
TI ICP-MS-Based Multiplex and Ultrasensitive Assay of Viruses with
   Lanthanide-Coded Biospecific Tagging and Amplification Strategies
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID PLASMA-MASS SPECTROMETRY; ROLLING-CIRCLE AMPLIFICATION; ABSOLUTE
   QUANTIFICATION; NUCLEIC-ACIDS; SENSITIVE DETECTION; DNA DETECTION;
   QUANTUM DOTS; PATHOGEN DNA; NANOPARTICLES; PROTEINS
AB Highly sensitive and a multiplex assay of viruses and viral DNAs in complex biological samples is extremely important for clinical diagnosis and prognosis of pathogenic diseases as well as virology studies. We present an effective ICP-MS-based multiplex and ultrasensitive assay of viral DNAs with lanthanide-coded oligonucleotide hybridization and rolling circle amplification (RCA) strategies on biofunctional magnetic nanoparticles (MNPs), in which single-stranded capture DNA (ss-Cap-DNA)-functionalized MNPs (up to 1.65 X 10(4) ss-Cap-DNA per MNP) were used to recognize and enrich target DNAs, and single-stranded report DNA (ss-Rep-DNA-DOTA-Ln) coded by the lanthanide-DOTA complex hybridized with the targeted DNA for highly sensitive readout of HIV (28 amol), HAV (48 amol), and HBV (19 amol). When utilizing the RCA technique in association with the design and synthesis of a "bridge" DNA and a corresponding ss-Rep-DNA-DOTA-Ho, as low as 90 zmol HBV could be detected. Preliminary applications to the determination of the viral DNAs in 4T1 cell lysates and in serum confirmed the feasibility of this ICP-MS-based multiplex DNA assay for clinical use. One can expect that this element-coded ICP-MS-based multiplex and ultrasensitive DNA assay will play an ever more important role in the fields of bioanalysis and virology and in medical studies after further sophisticated modifications.
C1 [Luo, Yacui; Yan, Xiaowen; Huang, Yishun; Wen, Ruibin; Li, Zhaoxin; Yang, Limin; Yang, Chaoyong James; Wang, Qiuquan] Xiamen Univ, Dept Chem, Xiamen 361005, Peoples R China.
   [Wang, Qiuquan] Xiamen Univ, MOE Key Lab Spectrochem Anal & Instrumentat, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China.
   [Wang, Qiuquan] Xiamen Univ, State Key Lab Marine Environm Sci, Xiamen 361005, Peoples R China.
RP Wang, QQ (reprint author), Xiamen Univ, Dept Chem, Xiamen 361005, Peoples R China.
EM qqwang@xmu.edu.cn
RI yang, chaoyong/F-9741-2010
OI yang, chaoyong/0000-0002-2374-5342
FU National Natural Science Foundation of China [21035006, 21275120];
   National Basic Research 973 Project [2014CB932004]
FX This study was financially supported by the National Natural Science
   Foundation of China (Grants 21035006 and 21275120) and the National
   Basic Research 973 Project (Grant 2014CB932004). We thank Prof. John
   Hodgkiss of The University of Hong Kong for helping with the English in
   this article.
CR Algar WR, 2009, ANAL CHEM, V81, P4113, DOI 10.1021/ac900421p
   Bake KD, 2008, ANNU REV ANAL CHEM, V1, P515, DOI 10.1146/annurev.anchem.1.031207.112826
   Baranov VI, 2002, ANAL CHEM, V74, P1629, DOI 10.1021/ac0110350
   Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704
   Bruce IJ, 2005, LANGMUIR, V21, P7029, DOI 10.1021/la050553t
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Deng H, 2005, ANGEW CHEM INT EDIT, V44, P2782, DOI 10.1002/anie.200462551
   FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641
   Giri S, 2011, ACS NANO, V5, P1580, DOI 10.1021/nn102873w
   Han GJ, 2011, ANGEW CHEM INT EDIT, V50, P3462, DOI 10.1002/anie.201006838
   Han GJ, 2013, ANGEW CHEM INT EDIT, V52, P1466, DOI 10.1002/anie.201206903
   Hansen JA, 2006, J AM CHEM SOC, V128, P3860, DOI 10.1021/ja0574116
   He SJ, 2012, ANAL CHEM, V84, P4622, DOI 10.1021/ac300577d
   Hoffmann CJ, 2007, LANCET INFECT DIS, V7, P402, DOI 10.1016/S1473-3099(07)70135-4
   Hu JA, 2010, ANAL CHEM, V82, P8991, DOI 10.1021/ac1019599
   Hu SH, 2007, ANAL CHEM, V79, P923, DOI 10.1021/ac061269p
   Kang T, 2010, NANO LETT, V10, P1189, DOI 10.1021/nl1000086
   Keeffe E, 2000, J Viral Hepat, V7 Suppl 1, P15, DOI 10.1046/j.1365-2893.2000.00016.x
   Kerr SL, 2007, CHEM COMMUN, P4537, DOI 10.1039/b709466c
   Kourtis AP, 2012, NEW ENGL J MED, V366, P1749, DOI 10.1056/NEJMp1201796
   Leipold Michael D, 2009, J Proteome Res, V8, P443, DOI 10.1021/pr800645r
   Li YG, 2005, NAT BIOTECHNOL, V23, P885, DOI 10.1038/nbt1106
   Liu R, 2013, ANAL CHEM, V85, P4087, DOI 10.1021/ac400158u
   Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898
   Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701
   Lou XD, 2007, ANGEW CHEM INT EDIT, V46, P6111, DOI 10.1002/anie.200700796
   Merkoci A, 2005, ANAL CHEM, V77, P6500, DOI 10.1021/ac050539I
   Peters PJ, 2012, J INFECT DIS, V205, P166, DOI 10.1093/infdis/jir728
   Sanz-Medel A, 2012, TRAC-TREND ANAL CHEM, V40, P52, DOI 10.1016/j.trac.2012.07.020
   Schaumloffel D, 2007, ANAL CHEM, V79, P2859, DOI 10.1021/ac061864r
   Song YL, 2011, CHEM-EUR J, V17, P9042, DOI 10.1002/chem.201101353
   Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Wang M, 2010, MASS SPECTROM REV, V29, P326, DOI 10.1002/mas.20241
   Wang ZY, 2012, J AM CHEM SOC, V134, P2993, DOI 10.1021/ja208154m
   Wilson R, 2006, ANGEW CHEM INT EDIT, V45, P6104, DOI 10.1002/anie.200600288
   Xuan SH, 2009, CHEM MATER, V21, P5079, DOI 10.1021/cm901618m
   Yan XW, 2013, ANAL BIOANAL CHEM, V405, P5663, DOI 10.1007/s00216-013-6886-1
   Yan XW, 2012, ANGEW CHEM INT EDIT, V51, P3358, DOI 10.1002/anie.201108277
   Yan XW, 2011, ANGEW CHEM INT EDIT, V50, P5130, DOI 10.1002/anie.201101087
   Yan XW, 2010, ANAL CHEM, V82, P1261, DOI 10.1021/ac902163x
   Zhang C, 2002, ANAL CHEM, V74, P96, DOI 10.1021/ac.0103468
   Zhang ZB, 2012, ANAL CHEM, V84, P8946, DOI 10.1021/ac302029w
   Zhou J, 2013, J AM CHEM SOC, V135, P2056, DOI 10.1021/ja3110329
NR 45
TC 28
Z9 30
U1 5
U2 150
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 15
PY 2013
VL 85
IS 20
BP 9428
EP 9432
DI 10.1021/ac402446a
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 240VU
UT WOS:000326126600003
PM 24069956
DA 2018-01-05
ER

PT J
AU Freeley, M
   Long, A
AF Freeley, Michael
   Long, Aideen
TI Advances in siRNA delivery to T-cells: potential clinical applications
   for inflammatory disease, cancer and infection
SO BIOCHEMICAL JOURNAL
LA English
DT Review
DE gene silencing; knockdown; RNAi; siRNA; T-cell; therapeutic
ID SMALL INTERFERING RNA; VERSUS-HOST-DISEASE; SUPPRESSES HIV-1 INFECTION;
   IN-VIVO DELIVERY; GENE-THERAPY; LENTIVIRAL VECTORS; RETROVIRAL VECTOR;
   HUMANIZED MICE; CD34(+) CELLS; ADOPTIVE IMMUNOTHERAPY
AB The specificity of RNAi and its ability to silence 'undruggable' targets has made inhibition of gene expression in T-cells with siRNAs an attractive potential therapeutic strategy for the treatment of inflammatory disease, cancer and infection. However, delivery of siRNAs into primary T-cells represents a major hurdle to their use as potential therapeutic agents. Recent advances in siRNA delivery through the use of electroporation/nucleofection, viral vectors, peptides/proteins, nanoparticles, aptamers and other agents have now enabled efficient gene silencing in primary T-cells both in vitro and in vivo. Overcoming such barriers in siRNA delivery offers exciting new prospects for directly targeting T-cells systemically with siRNAs, or adoptively transferring T-cells back into patients following ex vivo manipulation with siRNAs. In the present review, we outline the challenges in delivering siRNAs into primary T-cells and discuss the mechanism and therapeutic opportunities of each delivery method. We emphasize studies that have exploited RNAi-mediated gene silencing in T-cells for the treatment of inflammatory disease, cancer and infection using mouse models. We also discuss the potential therapeutic benefits of manipulating T-cells using siRNAs for the treatment of human diseases.
C1 [Freeley, Michael; Long, Aideen] Univ Dublin Trinity Coll, Dept Clin Med, Inst Mol Med, Dublin 2, Ireland.
RP Freeley, M (reprint author), Univ Dublin Trinity Coll, Dept Clin Med, Inst Mol Med, Dublin 2, Ireland.
EM freeleym@tcd.ie
OI Freeley, Michael/0000-0002-5763-6582
FU Programme for Research in Third Level Institutions in Ireland (PRTLI)
FX This work was supported by the Programme for Research in Third Level
   Institutions in Ireland (PRTLI).
CR Agosto LM, 2009, J VIROL, V83, P8153, DOI 10.1128/JVI.00220-09
   Ahlfors H, 2010, BLOOD, V116, P1443, DOI 10.1182/blood-2009-11-252205
   Alon R, 2011, EXP CELL RES, V317, P632, DOI 10.1016/j.yexcr.2010.12.007
   Alvarez RA, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-29
   Amos SM, 2011, BLOOD, V118, P499, DOI 10.1182/blood-2011-01-325266
   An DS, 2006, MOL THER, V14, P494, DOI 10.1016/j.ymthe.2006.05.015
   Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299
   Asai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056820
   Bancos S, 2009, CELL IMMUNOL, V257, P44, DOI 10.1016/j.cellimm.2009.02.006
   Bendle GM, 2010, NAT MED, V16, P565, DOI 10.1038/nm.2128
   Berger JR, 2009, MABS-AUSTIN, V1, P583, DOI 10.4161/mabs.1.6.9884                                                           
   Berkhout B, 2011, ANTIVIR RES, V92, P7, DOI 10.1016/j.antiviral.2011.04.002
   Biasco L, 2011, EMBO MOL MED, V3, P89, DOI 10.1002/emmm.201000108
   Biragyn A, 2013, J IMMUNOTHER, V36, P258, DOI 10.1097/CJI.0b013e318294357c
   Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212
   Bolon B, 2012, TOXICOL PATHOL, V40, P216, DOI 10.1177/0192623311428481
   Boutimah F, 2013, ANTIVIR RES, V98, P121, DOI 10.1016/j.antiviral.2013.02.011
   Brahmamdam P, 2009, SHOCK, V32, P131, DOI 10.1097/SHK.0b013e318194bcee
   Bramsen Jesper B., 2012, Frontiers in Genetics, V3, DOI 10.3389/fgene.2012.00154
   Brown CY, 2010, HUM GENE THER, V21, P1005, DOI 10.1089/hum.2009.107
   Burnett JC, 2012, CURR OPIN IMMUNOL, V24, P625, DOI 10.1016/j.coi.2012.08.013
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Caspi RR, 2008, NAT REV IMMUNOL, V8, P970, DOI 10.1038/nri2438
   Cattoglio C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015688
   Chehtane M, 2010, AM J PHYSIOL-CELL PH, V298, pC1560, DOI 10.1152/ajpcell.00506.2009
   Chen Y, 2010, J SURG RES, V159, P582, DOI 10.1016/j.jss.2008.09.019
   Chen ZB, 2006, P NATL ACAD SCI USA, V103, P16400, DOI 10.1073/pnas.0607854103
   Chiyo M, 2008, AM J TRANSPLANT, V8, P537, DOI 10.1111/j.1600-6143.2007.02116.x
   Chtanova T, 2001, J IMMUNOL, V167, P3057, DOI 10.4049/jimmunol.167.6.3057                                                     
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Chung JS, 2011, EUR J IMMUNOL, V41, P1794, DOI 10.1002/eji.201041233
   Correale J, 2010, ANN NEUROL, V67, P625, DOI 10.1002/ana.21944
   Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3
   Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968
   De Angelis B, 2009, BLOOD, V114, P4784, DOI 10.1182/blood-2009-07-230482
   DiGiusto DL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000931
   Dinesh R, 2011, GENES IMMUN, V12, P360, DOI 10.1038/gene.2011.4
   Doi Y, 2008, P NATL ACAD SCI USA, V105, P8381, DOI 10.1073/pnas.0803454105
   Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006
   Eguchi A, 2009, TRENDS PHARMACOL SCI, V30, P341, DOI 10.1016/j.tips.2009.04.009
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Elahi S, 2011, NAT MED, V17, P989, DOI 10.1038/nm.2422
   Fausther-Bovendo H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000975
   Felber AE, 2011, J CONTROL RELEASE, V152, P159, DOI 10.1016/j.jconrel.2010.12.012
   Frecha C, 2010, MOL THER, V18, P1748, DOI 10.1038/mt.2010.178
   Frecha C, 2008, BLOOD, V112, P4843, DOI 10.1182/blood-2008-05-155945
   Freeley M., 2013, J IMMUNOL M IN PRESS
   Gavrilov Kseniya, 2012, Yale Journal of Biology and Medicine, V85, P187
   Gehl J, 2003, ACTA PHYSIOL SCAND, V177, P437, DOI 10.1046/j.1365-201X.2003.01093.x
   Gerold KD, 2011, DIABETES, V60, P1955, DOI 10.2337/db11-0130
   Getts DR, 2011, IMMUNOTHERAPY-UK, V3, P853, DOI [10.2217/IMT.11.61, 10.2217/imt.11.61]
   Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612
   Gocke AR, 2007, J IMMUNOL, V178, P1341, DOI 10.4049/jimmunol.178.3.1341                                                     
   Goffinet C, 2006, FASEB J, V20, P500, DOI 10.1096/fj.05-4651fje
   Goldsmith M, 2011, NANOMEDICINE-UK, V6, P1771, DOI [10.2217/nnm.11.162, 10.2217/NNM.11.162]
   Gomez-Valades AG, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.37
   Gonzalez S, 2005, MOL THER, V11, P811, DOI 10.1016/j.ymthe.2004.12.023
   Gorska MM, 2010, J IMMUNOL, V184, P4488, DOI 10.4049/jimmunol.0903115
   Gresch O, 2004, METHODS, V33, P151, DOI 10.1016/j.ymeth.2003.11.009
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Guo LY, 2013, P NATL ACAD SCI USA, V110, pE1849, DOI 10.1073/pnas.1305070110
   Gust Tatjana C, 2008, Cell Commun Signal, V6, P3, DOI 10.1186/1478-811X-6-3
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JC135700
   Hinterleitner R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044295
   Hogg N, 2011, NAT REV IMMUNOL, V11, P416, DOI 10.1038/nri2986
   Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798
   Humphries LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045276
   Hurez V, 2002, IMMUNOL RES, V26, P131, DOI 10.1385/IR:26:1-3:131
   Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760
   Iwami K, 2013, NEURO-ONCOLOGY, V15, P747, DOI 10.1093/neuonc/not007
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Jin HS, 2013, P NATL ACAD SCI USA, V110, P624, DOI 10.1073/pnas.1213819110
   June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635
   Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007
   Kanda N, 2011, J LEUKOCYTE BIOL, V89, P935, DOI 10.1189/jlb.0111004
   Kesharwani P, 2012, BIOMATERIALS, V33, P7138, DOI 10.1016/j.biomaterials.2012.06.068
   Ketroussi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022776
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kunii N, 2013, HUM GENE THER, V24, P27, DOI 10.1089/hum.2012.130
   Lai W, 2003, J IMMUNOL METHODS, V282, P93, DOI 10.1016/j.jim.2003.07.015
   Lambeth Luke S, 2013, Methods Mol Biol, V942, P205, DOI 10.1007/978-1-62703-119-6_12
   Lamers CHJ, 2011, BLOOD, V117, P72, DOI 10.1182/blood-2010-07-294520
   LaRosa DF, 2008, J ALLERGY CLIN IMMUN, V121, pS364, DOI 10.1016/j.jaci.2007.06.016
   Lebbink RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026213
   Lee CC, 2008, MOL THER, V16, P60, DOI 10.1038/sj.mt.6300309
   Lee J, 2012, BIOCONJUGATE CHEM, V23, P1174, DOI 10.1021/bc2006219
   Lee YK, 2010, MOL CELLS, V29, P457, DOI 10.1007/s10059-010-0056-5
   Leuci V, 2011, J BIOTECHNOL, V156, P218, DOI 10.1016/j.jbiotec.2011.09.001
   Levy J A, 2011, Adv Dent Res, V23, P13, DOI 10.1177/0022034511398874
   Li CY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-26
   Liu H, 2011, INT J HEMATOL, V94, P118, DOI 10.1007/s12185-011-0899-3
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Lizee G, 2013, ANNU REV MED, V64, P71, DOI 10.1146/annurev-med-112311-083918
   Lovett-Racke AE, 2004, IMMUNITY, V21, P719, DOI 10.1016/j.immuni.2004.09.010
   MacLachlan I, 2008, NAT BIOTECHNOL, V26, P403, DOI 10.1038/nbt0408-403
   Maetzig T, 2011, VIRUSES-BASEL, V3, P677, DOI 10.3390/v3060677
   Manjunath N, 2009, ADV DRUG DELIVER REV, V61, P732, DOI 10.1016/j.addr.2009.03.004
   Mantei A, 2008, EUR J IMMUNOL, V38, P2616, DOI 10.1002/eji.200738075
   McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7
   McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754                                                    
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Milstein O, 2011, BLOOD, V117, P1042, DOI 10.1182/blood-2010-05-283770
   Moriwaki A, 2011, AM J RESP CELL MOL, V44, P448, DOI 10.1165/rcmb.2009-0051OC
   Nasr R, 2011, VIRUSES-BASEL, V3, P750, DOI 10.3390/v3060750
   Neff CP, 2011, SCI TRANSL MED, V3
   Newrzela S, 2008, BLOOD, V112, P2278, DOI 10.1182/blood-2007-12-128751
   Newrzela S, 2011, MOL MED, V17, P1223, DOI 10.2119/molmed.2010.00193
   Oberdoerffer P, 2005, MOL CELL BIOL, V25, P3896, DOI 10.1128/MCB.25.10.3896-3905.2005
   Ochi T, 2011, BLOOD, V118, P1495, DOI 10.1182/blood-2011-02-337089
   Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103
   Okamoto S, 2009, CANCER RES, V69, P9003, DOI 10.1158/0008-5472.CAN-09-1450
   Ovcharenko D, 2005, RNA, V11, P985, DOI 10.1261/rna.7288405
   Pallandre JR, 2007, J IMMUNOL, V179, P7593, DOI 10.4049/jimmunol.179.11.7593                                                    
   Palmer S, 2011, J INTERN MED, V270, P550, DOI 10.1111/j.1365-2796.2011.02457.x
   Park TS, 2011, TRENDS BIOTECHNOL, V29, P550, DOI 10.1016/j.tibtech.2011.04.009
   Peer D, 2011, GENE THER, V18, P1127, DOI 10.1038/gt.2011.56
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104
   Peer D, 2009, CELL CYCLE, V8, P853, DOI 10.4161/cc.8.6.7936
   Perez-Rivero G, 2013, EUR J IMMUNOL, V43, P1745, DOI 10.1002/eji.201243178
   Perro M, 2010, GENE THER, V17, P721, DOI 10.1038/gt.2010.4
   Petterson T, 2011, IMMUNOLOGY, V133, P84, DOI 10.1111/j.1365-2567.2011.03414.x
   Pfoertner S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r54
   Qin HJ, 2011, P NATL ACAD SCI USA, V108, P2016, DOI 10.1073/pnas.1019082108
   Rabinovich PM, 2006, HUM GENE THER, V17, P1027, DOI 10.1089/hum.2006.17.1027
   Rangachari M, 2012, NAT MED, V18, P1394, DOI 10.1038/nm.2871
   Raveney BJE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056595
   Recchia A, 2006, P NATL ACAD SCI USA, V103, P1457, DOI 10.1073/pnas.0507496103
   Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191
   Rosenberg SA, 2010, MOL THER, V18, P1744, DOI 10.1038/mt.2010.195
   Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614
   Sakuma T, 2012, BIOCHEM J, V443, P603, DOI 10.1042/BJ20120146
   Saldanha-Araujo F, 2012, J CELL MOL MED, V16, P1232, DOI 10.1111/j.1582-4934.2011.01391.x
   Samuel-Abraham S, 2010, FEBS J, V277, P4828, DOI 10.1111/j.1742-4658.2010.07905.x
   Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042
   Sang W, 2011, IMMUNOL LETT, V136, P194, DOI 10.1016/j.imlet.2011.01.010
   Saxena A, 2012, J IMMUNOL, V189, P3140, DOI 10.4049/jimmunol.1103111
   Schallon A, 2012, BIOMACROMOLECULES, V13, P3463, DOI 10.1021/bm3012055
   Soholler J, 2012, SCI TRANSL MED, V4
   Shalek AK, 2010, P NATL ACAD SCI USA, V107, P1870, DOI 10.1073/pnas.0909350107
   Sharma S, 2009, NAT IMMUNOL, V10, P799, DOI 10.1038/ni0809-799
   Singh S, 2011, PHARM RES-DORDR, V28, P2996, DOI 10.1007/s11095-011-0608-1
   Singh SK, 2008, EXPERT OPIN BIOL TH, V8, P449, DOI 10.1517/14712598.8.4.449 
   Sioud M, 2005, J MOL BIOL, V348, P1079, DOI 10.1016/j.jmb.2005.03.013
   Sioud M, 2010, NEW BIOTECHNOL, V27, P236, DOI 10.1016/j.nbt.2010.02.015
   Smith LD, 2007, CELL SIGNAL, V19, P2528, DOI 10.1016/j.cellsig.2007.08.006
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Srivastava V, 2011, IMMUNOL CELL BIOL, V89, P786, DOI 10.1038/icb.2011.1
   Steward-Tharp SM, 2010, ANN NY ACAD SCI, V1183, P123, DOI 10.1111/j.1749-6632.2009.05124.x
   Stromnes IM, 2012, J IMMUNOL, V189, P1812, DOI 10.4049/jimmunol.1200552
   Sun L, 2012, TRANSPL IMMUNOL, V26, P71, DOI 10.1016/j.trim.2011.10.005
   Tahvanainen J, 2006, J IMMUNOL METHODS, V310, P30, DOI 10.1016/j.jim.2005.11.024
   Tebas P, 2013, BLOOD, V121, P1524, DOI 10.1182/blood-2012-07-447250
   Tesniere A, 2010, CELL CYCLE, V9, P2830, DOI 10.4161/cc.9.14.12256
   Tezgel AO, 2013, MOL THER, V21, P201, DOI 10.1038/mt.2012.209
   Unwalla HJ, 2004, NAT BIOTECHNOL, V22, P1573, DOI 10.1038/nbt1040
   Van Tendeloo VFI, 2000, GENE THER, V7, P1431, DOI 10.1038/sj.gt.3301252
   Villablanca EJ, 2011, GASTROENTEROLOGY, V140, P1776, DOI 10.1053/j.gastro.2011.02.015
   Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463
   Wakim LM, 2013, NAT IMMUNOL, V14, P238, DOI 10.1038/ni.2525
   Wang C. W., 2013, J ALLERGY CLIN IMMUN, DOI 10.1016/j.jaci.2013.04.036
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Westwood JA, 2008, GENE THER, V15, P1056, DOI 10.1038/gt.2008.47
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Wood KJ, 2012, TRANSPLANTATION, V93, P1, DOI 10.1097/TP.0b013e31823cab44
   Yang HG, 2009, PHARM RES-DORD, V26, P1432, DOI 10.1007/s11095-009-9853-y
   Yang L, 2006, P NATL ACAD SCI USA, V103, P11479, DOI 10.1073/pnas.0604993103
   Yang LL, 2012, J EXP MED, V209, P1655, DOI 10.1084/jem.20112218
   Yang YH, 2009, J EXP MED, V206, P1549, DOI 10.1084/jem.20082584
   Yin JY, 2006, J IMMUNOL METHODS, V312, P1, DOI 10.1016/j.jim.2006.01.023
   Yosef N, 2013, NATURE, V496, P461, DOI 10.1038/nature11981
   Zanin-Zhorov A, 2011, TRENDS IMMUNOL, V32, P358, DOI 10.1016/j.it.2011.04.007
   Zhang JY, 2010, J IMMUNOL, V185, P3554, DOI 10.4049/jimmunol.1000431
   Zhao M, 2010, J AUTOIMMUN, V35, P58, DOI 10.1016/j.jaut.2010.02.002
   Zhao XY, 2007, J IMMUNOL, V179, P8297, DOI 10.4049/jimmunol.179.12.8297                                                    
   Zhou JH, 2013, MOL THER, V21, P192, DOI 10.1038/mt.2012.226
   Zhou Jiehua, 2012, Frontiers in Genetics, V3, P234, DOI 10.3389/fgene.2012.00234
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
   Zhou JH, 2011, METHODS, V54, P284, DOI 10.1016/j.ymeth.2010.12.039
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
   Zhu QC, 2012, EUR J MED CHEM, V56, P396, DOI 10.1016/j.ejmech.2012.07.045
NR 184
TC 19
Z9 19
U1 4
U2 44
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD OCT 15
PY 2013
VL 455
BP 133
EP 147
DI 10.1042/BJ20130950
PN 2
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 243ZV
UT WOS:000326357800001
PM 24070422
OA gold
DA 2018-01-05
ER

PT J
AU Xuan, SY
   Wang, ML
   Kang, H
   Kirchmair, J
   Tan, L
   Yan, AX
AF Xuan, Shouyi
   Wang, Maolin
   Kang, Hang
   Kirchmair, Johannes
   Tan, Lu
   Yan, Aixia
TI Support Vector Machine (SVM) Models for Predicting Inhibitors of the 3 '
   Processing Step of HIV-1 Integrase
SO MOLECULAR INFORMATICS
LA English
DT Article
DE HIV-1 integrase 3 ' P inhibitors (HIV-1 IN3' PIs); Support vector
   machine (SVM); Classification model; Virtual screening
ID VIRUS TYPE-1 INTEGRASE; DIKETO ACID-DERIVATIVES; STRAND TRANSFER STEP;
   CELL-BASED ASSAYS; BIOLOGICAL EVALUATION; ACTIVE-SITE; ORBITAL
   ELECTRONEGATIVITY; ANTI-HIV-1 INTEGRASE; NUCLEOBASE SCAFFOLDS; ATOMIC
   CHARGES
AB Inhibition of the 3' processing step of HIV- 1 integrase by small molecule inhibitors is one of the most promising strategies for the treatment of AIDS. Using a support vector machine (SVM) approach, we developed six classification models for predicting 3' P inhibitors. The models are based on up to 48 selected molecular descriptors and a comprehensive data set of 1253 molecules, with measured activities ranging from nanomolar to micromolar IC50 values. Model B2, the most robust SVM model, obtains a prediction accuracy, sensitivity, specificity and Matthews correlation coefficient (MCC) of 93%, 81%, 94% and 0.67 on the test set, respectively. The presence of hydrogen bonding features and hydrophilicity in general were identified as key determinants of inhibitory activity. Further important properties include molecular refractivity, p atom charge, total charge, lone pair electronegativity, and effective atom polarizability. Comparative fragment- based analysis of the active and inactive molecules corroborated these observations and revealed several characteristic structural elements of 3' P inhibitors. The models built in this study can be obtained from the authors.
C1 [Xuan, Shouyi; Wang, Maolin; Kang, Hang; Yan, Aixia] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
   [Kirchmair, Johannes] Univ Cambridge, Dept Chem, Unilever Ctr Mol Sci Informat, Cambridge CB2 1EW, England.
   [Tan, Lu] Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 0XY, England.
RP Yan, AX (reprint author), Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53,15 BeiSanHuan East Rd, Beijing 100029, Peoples R China.
EM aixia_yan@yahoo.com
RI Kirchmair, Johannes/J-1559-2012
OI Yan, Aixia/0000-0003-4811-8510
FU National Natural Science Foundation of China [20975011]; "Chemical Grid
   Project" of Beijing University of Chemical Technology
FX This work was supported by the National Natural Science Foundation of
   China (20975011) and "Chemical Grid Project" of Beijing University of
   Chemical Technology. We thank Molecular Networks GmbH, Erlangen, Germany
   for ADRIANA.Code, CORINA, and SONNIA.
CR Aiello F, 2004, BIOORGAN MED CHEM, V12, P4459, DOI 10.1016/j.bmc.2004.05.037
   Al-Mawsawi LQ, 2007, FEBS LETT, V581, P1151, DOI 10.1016/j.febslet.2007.02.023
   Artico M, 1998, J MED CHEM, V41, P3948, DOI 10.1021/jm9707232
   Bailly F, 2008, EUR J MED CHEM, V43, P1222, DOI 10.1016/j.ejmech.2007.08.005
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   Bender A, 2009, J CHEM INF MODEL, V49, P108, DOI 10.1021/ci800249s
   Bernard C, 2004, BIOORG MED CHEM LETT, V14, P2473, DOI 10.1016/j.bmcl.2004.03.005
   Boros EE, 2006, BIOORG MED CHEM LETT, V16, P5668, DOI 10.1016/j.bmcl.2006.08.007
   Brzozowski Z, 2004, BIOORGAN MED CHEM, V12, P3663, DOI 10.1016/j.bmc.2004.04.024
   Brzozowski Z, 2008, EUR J MED CHEM, V43, P1188, DOI 10.1016/j.ejmech.2007.08.013
   Buolamwini JK, 2002, J MED CHEM, V45, P841, DOI 10.1021/jm010399h
   BURKE TR, 1995, J MED CHEM, V38, P4171, DOI 10.1021/jm00021a006
   Chang Chih-Chung, LIBSVM LIB SUPPORT V
   Charpentier C, 2008, HIV MED, V9, P765, DOI 10.1111/j.1468-1293.2008.00628.x
   MOE (The Molecular Operating Environment) Version 2009.10 software available from Chemical Computing Group Inc., MOE MOL OP ENV VERS
   Chi GC, 2004, BIOORG MED CHEM LETT, V14, P4815, DOI 10.1016/j.bmcl.2004.07.050
   Chiang CC, 2007, CHEM PHARM BULL, V55, P1740, DOI 10.1248/cpb.55.1740
   Costi R, 2004, BIOORG MED CHEM LETT, V14, P1745, DOI 10.1016/j.bmcl.2004.01.037
   Costi R, 2004, BIOORGAN MED CHEM, V12, P199, DOI 10.1016/j.bmc.2003.10.005
   Crosby DC, 2010, J MED CHEM, V53, P8161, DOI 10.1021/jm1010594
   Dayam R, 2005, J MED CHEM, V48, P8009, DOI 10.1021/jm050837a
   Dayam R, 2007, BIOORG MED CHEM LETT, V17, P6155, DOI 10.1016/j.bmc1.2007.09.061
   Dayam R, 2006, CHEMMEDCHEM, V1, P238, DOI 10.1002/cmdc.200500018
   Deng JX, 2006, J MED CHEM, V49, P1684, DOI 10.1021/jm0510629
   Deng JX, 2005, J MED CHEM, V48, P1496, DOI 10.1021/jm049410e
   Dupont R, 2001, BIOORG MED CHEM LETT, V11, P3175, DOI 10.1016/S0960-894X(01)00658-8                                                   
   Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8
   GASTEIGER J, 1978, TETRAHEDRON LETT, P3181
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2                                                    
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   Hadi V, 2010, BIOORG MED CHEM LETT, V20, P6854, DOI 10.1016/j.bmcl.2010.08.057
   Hemmer MC, 1999, VIB SPECTROSC, V19, P151, DOI 10.1016/S0924-2031(99)00014-4                                                   
   HINZE J, 1962, J AM CHEM SOC, V84, P540, DOI 10.1021/ja00863a008
   Hong HX, 1997, J MED CHEM, V40, P930, DOI 10.1021/jm960754h
   Kim SN, 2000, BIOORG MED CHEM LETT, V10, P1879, DOI 10.1016/S0960-894X(00)00355-3                                                   
   Kleinoeder T., 2005, THESIS U ERLANGEN NU
   KOHONEN T, 1982, BIOL CYBERN, V43, P59, DOI 10.1007/BF00337288                                                              
   Kuo CL, 2004, J MED CHEM, V47, P385, DOI 10.1021/jm030378i
   Lasko TA, 2005, J BIOMED INFORM, V38, P404, DOI 10.1016/j.jbi.2005.02.008
   Le GA, 2010, BIOORG MED CHEM LETT, V20, P5909, DOI 10.1016/j.bmcl.2010.07.081
   Lee JY, 2003, BIOORG MED CHEM LETT, V13, P4331, DOI 10.1016/j.bmcl.2003.09.046
   Lin ZW, 1999, J MED CHEM, V42, P1401, DOI 10.1021/jm980531m
   Long YQ, 2004, J MED CHEM, V47, P2561, DOI 10.1021/jm030559k
   MATTHEWS BW, 1975, BIOCHIM BIOPHYS ACTA, V405, P442, DOI 10.1016/0005-2795(75)90109-9
   Maurin C, 2006, BIOORGAN MED CHEM, V14, P2978, DOI 10.1016/j.bmc.2005.12.039
   Maurin C, 2010, BIOORGAN MED CHEM, V18, P5194, DOI 10.1016/j.bmc.2010.05.059
   Mazumder A, 1996, J MED CHEM, V39, P2472, DOI 10.1021/jm960074e
   Mazumder A, 1997, J MED CHEM, V40, P3057, DOI 10.1021/jm970190x
   Meadows DC, 2007, BIOORGAN MED CHEM, V15, P1127, DOI 10.1016/j.bmc.2006.10.017
   Meadows DC, 2005, J MED CHEM, V48, P4526, DOI 10.1021/jm049171v
   Mekouar K, 1998, J MED CHEM, V41, P2846, DOI 10.1021/jm980043e
   [Anonymous], ADRIANA COD
   [Anonymous], CORINA
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018                                                             
   Nair V, 2006, J MED CHEM, V49, P445, DOI 10.1021/jm0508890
   Nair V, 2006, BIOORG MED CHEM LETT, V16, P1920, DOI 10.1016/j.bmcl.2005.12.093
   Neamati N, 1999, J MED CHEM, V42, P3334, DOI 10.1021/jm990047z
   Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760                                                               
   Neamati N, 2002, J MED CHEM, V45, P5661, DOI 10.1021/jm0201417
   Neamati N, 1997, J MED CHEM, V40, P942, DOI 10.1021/jm960759e
   Nicklaus MC, 1997, J MED CHEM, V40, P920, DOI 10.1021/jm960596u
   Pais GCG, 2002, J MED CHEM, V45, P3184, DOI 10.1021/jm020037p
   Patil S, 2007, BIOORGAN MED CHEM, V15, P1212, DOI 10.1016/j.bmc.2006.11.026
   Peat TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040147
   RAGHAVAN K, 1995, J MED CHEM, V38, P890, DOI 10.1021/jm00006a006
   Ramkumar K, 2010, MOLECULES, V15, P3958, DOI 10.3390/molecules15063958
   Rhodes David I., 2011, Antiviral Chemistry & Chemotherapy, V21, P155, DOI 10.3851/IMP1716
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Santo R. D., 2006, J MED CHEM, V49, P1939
   Sc C. X., 2006, CHEM PHARM BULL, V54, P682
   [Anonymous], PIP PIL 6 1
   Sechi M, 2004, J MED CHEM, V47, P5298, DOI 10.1021/jm049944f
   Sechi M, 2006, J MED CHEM, V49, P4248, DOI 10.1021/jm060193m
   Sechi M, 2009, BIOORGAN MED CHEM, V17, P2925, DOI 10.1016/j.bmc.2008.10.088
   Sharma H, 2011, BIOORGAN MED CHEM, V19, P2030, DOI 10.1016/j.bmc.2011.01.047
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   [Anonymous], 2005, MACCS STRUCT KEYS
   Tang J, 2011, ACS MED CHEM LETT, V2, P63, DOI 10.1021/ml1002162
   Tsiang M, 2012, J BIOL CHEM, V287, P21189, DOI 10.1074/jbc.M112.347534
   Vandurm P, 2011, EUR J MED CHEM, V46, P1749, DOI 10.1016/j.ejmech.2011.02.028
   Vapnik V, 2000, NEURAL COMPUT, V12, P2013, DOI 10.1162/089976600300015042                                                      
   Wielens J, 2011, CHEMMEDCHEM, V6, P258, DOI 10.1002/cmdc.201000483
   Xuan SY, 2013, BIOORG MED CHEM LETT, V23, P1648, DOI 10.1016/j.bmcl.2013.01.081
   Yan AX, 2008, INT J MOL SCI, V9, P1961, DOI 10.3390/ijms9101961
   Yan AX, 2012, COMB CHEM HIGH T SCR, V15, P792, DOI 10.2174/138620712803901108                                                      
   Yan AX, 2003, J CHEM INF COMP SCI, V43, P429, DOI 10.1021/ci025590u
   Yang LF, 2010, BIOORG MED CHEM LETT, V20, P5469, DOI 10.1016/j.bmcl.2010.07.087
   Zeng LF, 2008, BIOORGAN MED CHEM, V16, P7777, DOI 10.1016/j.bmc.2008.07.008
   Zhang XC, 2003, BIOORG MED CHEM LETT, V13, P1215, DOI 10.1016/S0960-894X(03)00059-3
   Zhang XC, 2001, BIOORGAN MED CHEM, V9, P1649, DOI 10.1016/S0968-0896(01)00075-X                                                   
   Zhao H, 1997, J MED CHEM, V40, P1186, DOI 10.1021/jm960449w
   Zhao H, 1997, J MED CHEM, V40, P937, DOI 10.1021/jm960755+                                                               
   Zhao H, 1997, J MED CHEM, V40, P242, DOI 10.1021/jm960450v
   Zhao XZ, 2008, J MED CHEM, V51, P251, DOI 10.1021/jm070715d
   Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o                                                               
NR 95
TC 3
Z9 4
U1 1
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
PD OCT
PY 2013
VL 32
IS 9-10
BP 811
EP 826
DI 10.1002/minf.201300107
PG 16
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA 296IW
UT WOS:000330179500006
PM 27480234
DA 2018-01-05
ER

PT J
AU Hodge, RAV
AF Hodge, R. Anthony Vere
TI Meeting report: 26th International Conference on Antiviral Research
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Human immunodeficiency virus; Hepatitis B; Hepatitis C; Herpesviruses;
   Antiviral therapy
AB The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening symposium on the legacy of the late Antonin Holy included presentations on his pioneering work with nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor cenicriviroc and the reverse transcriptase inhibitor festinavir (R), and also reviewed the evaluation of biodegradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the creation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investigation of cytomegalovirus resistance to CMX001. Two chemistry minisymposia examined strategies and tactics in drug design and the use of in drug discovery. (C) 2013 The Author. Published by Elsevier B.V. All rights reserved.
C1 Vere Hodge Antivirals Ltd, Reigate, Surrey, England.
RP Hodge, RAV (reprint author), Vere Hodge Antivirals Ltd, Reigate, Surrey, England.
EM ISAR@courtesyassoc.com
CR Dhareshwar S.S., 2003, J PHARM SCI, V97, P4184
   Vere Hodge R. A., 2012, ANTIVIR CHEM CHEMOTH, V23, P19
NR 2
TC 4
Z9 4
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD OCT
PY 2013
VL 100
IS 1
BP 276
EP 285
DI 10.1016/j.antivira1.2013.08.006
PG 10
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 268OB
UT WOS:000328179300031
DA 2018-01-05
ER

PT J
AU Zhou, HK
   Chen, S
   Gan, N
   Li, TH
   Cao, YT
   Jiang, QL
AF Zhou, Hankun
   Chen, Si
   Gan, Ning
   Li, Tianhua
   Cao, Yuting
   Jiang, Qianli
TI Design of Sensitive Biocompatible Quantum-Dots Embedded in Mesoporous
   Silica Microspheres for the Quantitative Immunoassay of Human
   Immunodeficiency Virus-1 Antibodies
SO ELECTROANALYSIS
LA English
DT Article
ID ELECTROGENERATED CHEMILUMINESCENCE; SIGNAL AMPLIFICATION; THROMBIN
   DETECTION; DRUG-DELIVERY; NANOPARTICLES; ELECTROCHEMILUMINESCENCE;
   ASSAY; IMMUNOSENSOR; HIV; DNA
C1 [Zhou, Hankun; Gan, Ning; Li, Tianhua; Cao, Yuting] Ningbo Univ, State Key Lab Base Novel Funct Mat & Preparat Sci, Fac Mat Sci & Chem Engn, Ningbo 315211, Zhejiang, Peoples R China.
   [Chen, Si] Ningbo Univ, Fac Marine Sci, Ningbo 315211, Zhejiang, Peoples R China.
   [Jiang, Qianli] Southern Med Univ, Nanfang Hosp, Dept Lab Med, Guangzhou 510515, Guangdong, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, State Key Lab Base Novel Funct Mat & Preparat Sci, Fac Mat Sci & Chem Engn, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn
FU National Natural Science Foundation of China [30901367]; Natural Science
   Foundation of Zhejiang [LY13C200017, LY12B01005, LY12C20004]; Science
   and Technology Project of Zhejiang [2011B82014, 2012C23101]; Natural
   Science Foundation of Ningbo [2013A610241]; KC Wong Magna Fund in Ningbo
   University
FX This work was supported by the National Natural Science Foundation of
   China (No. 30901367), the Natural Science Foundation of Zhejiang
   (LY13C200017, LY12B01005 and LY12C20004), the Science and Technology
   Project of Zhejiang (2011B82014, 2012C23101), the Natural Science
   Foundation of Ningbo (2013A610241), and the KC Wong Magna Fund in Ningbo
   University.
CR Azoulay S, 2004, J IMMUNOL METHODS, V295, P37, DOI 10.1016/j.jim.2004.08.016
   Baniukevic J, 2013, BIOSENS BIOELECTRON, V43, P281, DOI 10.1016/j.bios.2012.12.014
   Bassett I. V., 2012, CLIN INFECT DIS, V50, P77
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Candotti D, 2004, J VIROL METHODS, V118, P39, DOI [10.1016/S0166-0934(04)00019-9, 10.1016/j.jviromet.2004.01.017]
   Chen DH, 2006, J MATER CHEM, V16, P1511, DOI 10.1039/b517975k
   Chen XJ, 2011, SENSOR ACTUAT B-CHEM, V159, P220, DOI 10.1016/j.snb.2011.06.076
   Chen Y, 2011, ADV FUNCT MATER, V21, P270, DOI 10.1002/adfm.201001495
   Cui H, 2003, ANAL CHEM, V75, P324, DOI 10.1021/ac0201631
   Fahnrich KA, 2001, TALANTA, V54, P531, DOI 10.1016/S0039-9140(01)00312-5
   Hassen WM, 2008, SENSOR ACTUAT B-CHEM, V134, P755, DOI 10.1016/j.snb.2008.06.020
   Hu XF, 2010, TALANTA, V80, P1737, DOI 10.1016/j.talanta.2009.10.015
   Iliuk AB, 2011, ANAL CHEM, V83, P4440, DOI 10.1021/ac201057w
   Jie GF, 2008, BIOSENS BIOELECTRON, V23, P1896, DOI 10.1016/j.bios.2008.02.028
   Kannangai R, 2001, J CLIN VIROL, V22, P41, DOI 10.1016/S1386-6532(01)00170-6                                                   
   Kolacyak D, 2011, J COLLOID INTERF SCI, V359, P311, DOI 10.1016/j.jcis.2011.03.069
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0                                                                
   Lad U, 2008, ANAL CHEM, V80, P7910, DOI 10.1021/ac801500t
   Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l
   Li HF, 2012, COLLOID SURFACE B, V89, P175, DOI 10.1016/j.colsurfb.2011.09.010
   Li X, 2011, LANGMUIR, V27, P6099, DOI 10.1021/la104653s
   Ly TD, 2001, EUR J CLIN MICROBIOL, V20, P104, DOI 10.1007/s10096-001-8057-0
   Mei QS, 2012, ANGEW CHEM INT EDIT, V51, P5602, DOI 10.1002/anie.201201389
   Moller K, 2007, ADV FUNCT MATER, V17, P605, DOI [10.1002/adfm.200600578, 10.1002/admf.200600578]
   Myung N, 2002, NANO LETT, V2, P1315, DOI 10.1021/nl0257824
   Niu HA, 2011, BIOSENS BIOELECTRON, V26, P3175, DOI 10.1016/j.bios.2010.12.023
   Privett BJ, 2010, ANAL CHEM, V82, P4723, DOI 10.1021/ac101075n
   Qian J, 2010, ANAL CHEM, V82, P6422, DOI 10.1021/ac100558t
   Qian J, 2010, ANAL CHIM ACTA, V665, P32, DOI 10.1016/j.aca.2010.03.013
   Ramanaviciene A, 2012, BIOSENS BIOELECTRON, V36, P48, DOI 10.1016/j.bios.2012.03.036
   Richter MM, 2004, CHEM REV, V104, P3003, DOI 10.1021/cr020373d
   Sen T, 2006, J AM CHEM SOC, V128, P7130, DOI 10.1021/ja061393q
   Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191
   Son SJ, 2005, J AM CHEM SOC, V127, P7316, DOI 10.1021/ja0517365
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Suzuki K, 2004, J AM CHEM SOC, V126, P462, DOI 10.1021/ja038250d
   Tennico YH, 2010, ANAL CHEM, V82, P5591, DOI 10.1021/ac101269u
   Virginia M. P., 2011, J CLIN MICROBIOL, V49, P1642
   Wang J, 2011, ANAL CHEM, V83, P4004, DOI 10.1021/ac200616g
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Wu J, 2011, SENSOR ACTUAT B-CHEM, V160, P511, DOI 10.1016/j.snb.2011.08.019
   Xie CG, 2010, ANAL CHEM, V82, P241, DOI 10.1021/ac901860t
   Zhang K, 2011, J AM CHEM SOC, V133, P8424, DOI 10.1021/ja2015873
   Zhou HK, 2012, ANAL CHIM ACTA, V746, P107, DOI 10.1016/j.aca.2012.08.036
   Zhou M, 2003, ANAL CHEM, V75, P6708, DOI 10.1021/ac034664d
NR 45
TC 6
Z9 6
U1 1
U2 13
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1040-0397
EI 1521-4109
J9 ELECTROANAL
JI Electroanalysis
PD OCT
PY 2013
VL 25
IS 10
BP 2384
EP 2393
PG 10
WC Chemistry, Analytical; Electrochemistry
SC Chemistry; Electrochemistry
GA 261MG
UT WOS:000327668500019
DA 2018-01-05
ER

PT J
AU Mathew, S
   Murakami, T
   Nakatsuji, H
   Okamoto, H
   Morone, N
   Heuser, JE
   Hashida, M
   Imahori, H
AF Mathew, Simon
   Murakami, Tatsuya
   Nakatsuji, Hirotaka
   Okamoto, Haruki
   Morone, Nobuhiro
   Heuser, John E.
   Hashida, Mitsuru
   Imahori, Hiroshi
TI Exclusive Photothermal Heat Generation by a Gadolinium
   Bis(naphthalocyanine) Complex and Inclusion into Modified High-Density
   Lipoprotein Nanocarriers for Therapeutic Applications
SO ACS NANO
LA English
DT Article
DE photothermal; hyperthermia; naphthalocyanine; high-density lipoprotein;
   drug delivery; phototherapy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNO GOLD NANOCAGES; INDOCYANINE GREEN;
   CANCER-THERAPY; TAT PROTEIN; PHOTODYNAMIC ACTIVITIES; NANOPARTICLES;
   CELLS; MEMBRANE; DELIVERY
AB A hydrophobic gadolinium bis(naphthalocyanine) sandwich complex (GdSand) possessing several absorbances across visible and infrared wavelengths (up to 2500 nm) was solubilized in aqueous solution by uptake into a nascent mutant high-density lipoprotein (HDL) nanocarrier. The HDL nanocarrier was additionally functionalized with a trans-activator of transcription peptide sequence to promote efficient cell penetration of the drug delivery system (cpHDL). The dye-loaded nanocarrier (GdSand@cpHDL) exhibited photothermal heat generation properties upon irradiation with near-infrared (NIR) laser light, with controllable heat generation abilities as a function of the incident laser light power. Comparison of the photothermal behavior of the dyes GdSand and the well-explored molecular photothermal agent indocyanine green (ICG) in the cpHDL nanocarrier (i.e., ICG@cpHDL) revealed two significant advantages of GdSand@cpHDL: (1) the ability to maintain elevated temperatures upon light absorption for extended periods of time, with a reduced degree of self-destruction of the dye, and (2) exclusive photothermal heat generation with no detectable singlet oxygen production leading to improved integrity of the cpHDL nanocarrier after irradiation. Finally, GdSand@cpHDL was successfully subjected to an in vitro study against NCI-H460 human lung cancer cells, demonstrating the proof-of-principle utility of lanthanide sandwich complexes in photothermal therapeutic applications.
C1 [Mathew, Simon; Murakami, Tatsuya; Morone, Nobuhiro; Heuser, John E.; Hashida, Mitsuru; Imahori, Hiroshi] Kyoto Univ, Inst Integrated Cell Mat Sci WPI ICeMS, Sakyo Ku, Kyoto 6068501, Japan.
   [Nakatsuji, Hirotaka; Okamoto, Haruki; Imahori, Hiroshi] Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Nishikyo Ku, Kyoto 6158510, Japan.
   [Hashida, Mitsuru] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Drug Delivery Res, Sakyo Ku, Kyoto 6068501, Japan.
RP Murakami, T (reprint author), Kyoto Univ, Inst Integrated Cell Mat Sci WPI ICeMS, Sakyo Ku, Kyoto 6068501, Japan.
EM murakami@icems.kyoto-u.ac.jp; imahori@scl.kyoto-u.ac.jp
RI Imahori, Hiroshi/B-5574-2013; Mathew, Simon/E-9732-2014
OI Imahori, Hiroshi/0000-0003-3506-5608; Mathew, Simon/0000-0003-2480-3222;
   Nakatsuji, Hirotaka/0000-0002-0716-7976
FU Japanese Society for the Promotion of Science (JSPS)
FX S.M. gratefully acknowledges the Japanese Society for the Promotion of
   Science (JSPS) for the award of a JSPS Postdoctoral Fellowship for
   Foreign Researchers.
CR Abramoff MD, 2004, J BIOPHOTONICS INT, V11, P36
   ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297
   Au L, 2008, ACS NANO, V2, P1645, DOI 10.1021/nn800370j
   BJORNSSON OG, 1983, J CLIN CHEM CLIN BIO, V21, P453
   Blanco E, 2011, CANCER SCI, V102, P1247, DOI 10.1111/j.1349-7006.2011.01941.x
   BORRELLI MJ, 1986, J CELL PHYSIOL, V126, P181, DOI 10.1002/jcp.1041260206                                                          
   BRASSEUR N, 1994, J MED CHEM, V37, P415, DOI 10.1021/jm00029a014
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   BRUNETAUD JM, 1995, LASER MED SCI, V10, P3, DOI 10.1007/BF02133156
   Campbell RB, 2002, CANCER RES, V62, P6831
   Chen JY, 2007, NANO LETT, V7, P1318, DOI 10.1021/nl070345g
   Chen JY, 2010, SMALL, V6, P811, DOI 10.1002/smll.200902216
   CHEN WR, 1995, CANCER LETT, V94, P125, DOI 10.1016/0304-3835(95)03837-M
   Cheng L, 2012, ACS NANO, V6, P5605, DOI 10.1021/nn301539m
   Cobley CM, 2011, CHEM SOC REV, V40, P44, DOI 10.1039/b821763g
   COLLINS GCS, 1982, J ELECTROANAL CHEM, V139, P335, DOI 10.1016/0022-0728(82)85133-4                                                    
   DECIAN A, 1985, INORG CHEM, V24, P3162, DOI 10.1021/ic00214a016                                                             
   DEWEY WC, 1994, INT J HYPERTHER, V10, P457, DOI 10.3109/02656739409009351
   Dzurinko Victoria L, 2004, Optometry, V75, P743, DOI 10.1016/S1529-1839(04)70234-1
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GATHJE J, 1970, J APPL PHYSIOL, V29, P181
   HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310                                                         
   Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h                                                                
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x
   HUANG XX, 2010, STUD FUZZ SOFT COMP, V250, P1
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   Jelveh Salomeh, 2011, Cancers (Basel), V3, P1081, DOI 10.3390/cancers3011081
   Jiang JZ, 2009, ACCOUNTS CHEM RES, V42, P79, DOI 10.1021/ar800097s
   Jiang JZ, 2000, EUR J INORG CHEM, P205
   Jin CS, 2013, ACS NANO, V7, P2541, DOI 10.1021/nn3058642
   Jin YD, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1042
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kim J, 2006, ANGEW CHEM INT EDIT, V45, P7754, DOI 10.1002/anie.200602471
   Kirin I.S., 1965, RUSS J INORG CHEM, V10, P1065
   KOMATSU T, 1994, J MATER CHEM, V4, P533, DOI 10.1039/jm9940400533
   Kowal-Vern A, 2000, BURNS, V26, P97, DOI 10.1016/S0305-4179(99)00099-6                                                   
   Krawczyk PM, 2011, P NATL ACAD SCI USA, V108, P9851, DOI 10.1073/pnas.1101053108
   Krishna V, 2010, NAT NANOTECHNOL, V5, P330, DOI [10.1038/NNANO.2010.35, 10.1038/nnano.2010.35]
   Lal S, 2008, ACCOUNTS CHEM RES, V41, P1842, DOI 10.1021/ar800150g
   LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575
   Lanigan S, 2003, HDB LASER TECHNOLOGY, P2045
   Lovell JF, 2011, NAT MATER, V10, P324, DOI [10.1038/NMAT2986, 10.1038/nmat2986]
   Luan LQ, 2013, BIOORG MED CHEM LETT, V23, P3775, DOI 10.1016/j.bmcl.2013.04.093
   MARKOVITSI D, 1987, CHEM PHYS LETT, V137, P107, DOI 10.1016/0009-2614(87)80313-5                                                    
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Murakami T, 2010, NANOMEDICINE-UK, V5, P867, DOI [10.2217/nnm.10.66, 10.2217/NNM.10.66]
   Murakami T, 2010, MOL BIOSYST, V6, P789, DOI 10.1039/c001442g
   Nam J, 2009, J AM CHEM SOC, V131, P13639, DOI 10.1021/ja902062j
   Ng KK, 2013, ACS NANO, V7, P3484, DOI 10.1021/nn400418y
   Numata T, 2012, J AM CHEM SOC, V134, P6092, DOI 10.1021/ja3007275
   PARRISH JA, 1981, J INVEST DERMATOL, V77, P45, DOI 10.1111/1523-1747.ep12479235
   Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e
   RUBEN S, 1989, J VIROL, V63, P1
   Sakka SG, 2007, CURR OPIN CRIT CARE, V13, P207, DOI 10.1097/MCC.0b013e328012b268                                                    
   Schmitt-Sody M, 2003, CLIN CANCER RES, V9, P2335
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shopova M, 1999, J BIOMED OPT, V4, P276, DOI 10.1117/1.429930
   Song LP, 2007, INT J NANOMED, V2, P767
   SVAASAND L O, 1990, Lasers in Medical Science, V5, P121, DOI 10.1007/BF02031373
   Tang Y, 2009, J PHOTOCH PHOTOBIO B, V97, P138, DOI 10.1016/j.jphotobiol.2009.09.001
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vollano JF, 1997, J PHOTOCH PHOTOBIO B, V37, P230, DOI 10.1016/S1011-1344(96)07403-9
   Wu MC, 2013, ACS NANO, V7, P1281, DOI 10.1021/nn304782d
   Yu J, 2010, J AM CHEM SOC, V132, P1929, DOI 10.1021/ja908139y
   Zheng MB, 2013, ACS NANO, V7, P2056, DOI 10.1021/nn400334y
   Zheng XH, 2012, MOL PHARMACEUT, V9, P514, DOI 10.1021/mp200526m
   Zheng XH, 2011, MOL PHARMACEUT, V8, P447, DOI 10.1021/mp100301t
   Zhou FF, 2011, SMALL, V7, P2727, DOI 10.1002/smll.201100669
   ZHOU JF, 1994, P SOC PHOTO-OPT INS, V2128, P495, DOI 10.1117/12.184936
NR 71
TC 18
Z9 18
U1 2
U2 45
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD OCT
PY 2013
VL 7
IS 10
BP 8908
EP 8916
DI 10.1021/nn403384k
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 242AF
UT WOS:000326209100062
PM 24053139
DA 2018-01-05
ER

PT J
AU Quan, ZF
   Ye, N
   Chen, SJ
   Cao, SJ
   He, M
   Yan, QG
AF Quan, Zifang
   Ye, Ni
   Chen, Shijie
   Cao, Sanjie
   He, Min
   Yan, Qigui
TI High-throughput digital PCR in a low-cost and practical format
   introduction: the application progress in copy number variation,
   low-level detection and absolute quantification
SO REVIEWS IN MEDICAL MICROBIOLOGY
LA English
DT Article
DE absolute quantification; copy number variation; droplet digital PCR;
   low-level detection
ID POLYMERASE-CHAIN-REACTION; REAL-TIME; BRAF-V600E MUTATION; PICOLITER
   DROPLETS; MATERNAL BLOOD; HIV-1 DNA; ON-CHIP; QUANTITATION; DIAGNOSIS;
   RESISTANCE
AB Currently, there are two means used in commercially available digital PCR systems. The first one uses microfluidic chambers or microwells to split the sample into hundreds of nanolitre volumes. Microfluidic chips simplify reaction setup; nevertheless, it is challenging to scale to achieve high-throughput. The second one is based on emulsion PCR, called BEAMing. BEAMing requires specialized heterogeneous assay schemes that add complexity to the workflow, thereby limiting its adoption to a few applications including DNA methylation and rare allele detection. All in all, limited throughput, high costs and complicated workflows have hampered the adoption of digital PCR. It is important to develop a method that uses water-in-oil droplets as the enabling technology to realize high-throughput digital PCR in a practical and low-cost format. In this review, we discuss the application areas of droplet digital PCR in low-level detection, determination of copy number variation and the absolute quantitation of circulating DNA in cell-free plasma.
C1 [Quan, Zifang; Ye, Ni; Cao, Sanjie; He, Min; Yan, Qigui] Sichuan Agr Univ, Coll Vet Med, Yaan 625014, Peoples R China.
   [Chen, Shijie] Entry Exit Inspect & Quarantine Sichuan Prov, Chengdu, Peoples R China.
   [Yan, Qigui] Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Yaan 625014, Peoples R China.
RP Yan, QG (reprint author), Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Yaan 625014, Peoples R China.
EM yanqigui@126.com
CR Aldhous MC, 2010, HUM MOL GENET, V19, P4930, DOI 10.1093/hmg/ddq411
   Alkan C, 2009, NAT GENET, V41, P1061, DOI 10.1038/ng.437
   Beer NR, 2008, ANAL CHEM, V80, P1854, DOI 10.1021/ac800048k
   Beer NR, 2007, ANAL CHEM, V79, P8471, DOI 10.1021/ac701809w
   Bhat S, 2009, ANAL BIOANAL CHEM, V394, P457, DOI 10.1007/s00216-009-2729-5
   Bustin A., 2009, CLIN CHEM, V55, P611
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen CY, 2013, J CLIN MICROBIOL, V51, P908, DOI 10.1128/JCM.02770-12
   Diehl F, 2006, NAT METHODS, V3, P551, DOI 10.1038/NMETH898
   Dressman D, 2003, P NATL ACAD SCI USA, V100, P8817, DOI 10.1073/pnas.1133470100
   Fan HC, 2008, P NATL ACAD SCI USA, V105, P16266, DOI 10.1073/pnas.0808319105
   Fan HC, 2007, ANAL CHEM, V79, P7576, DOI 10.1021/ac0709394
   GibellIn ID, 2004, J VIROL METHODS, V115, P183
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Groves KC, 2012, JAIDS-J ACQ IMM DEF, V61, P407, DOI 10.1097/QAI.0b013e318269c414
   He XY, 2012, NEOPLASMA, V59, P693, DOI 10.4149/neo_2012_088
   He YJ, 2012, PHARMACOGENET GENOM, V22, P322, DOI 10.1097/FPC.0b013e3283510a51
   Henrich TJ, 2012, J VIROL METHODS, V186, P68, DOI 10.1016/j.jviromet.2012.08.019
   Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g
   Metz CHD, 2013, CANCER MED-US, V2, P208, DOI 10.1002/cam4.61
   Morrison T, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl639
   Ottesen EA, 2006, SCIENCE, V314, P1464, DOI 10.1126/science.1131370
   Pathak AK, 2006, CLIN CHEM, V52, P1833, DOI 10.1373/clinchem.2005.062893
   Peng NC, 2007, PROG CHINESE BIOMED, V2, P989
   Pinheiro L. B., 2011, ANAL CHEM, V84, P1003, DOI DOI 10.1021/AC202578X
   Ropers HH, 2007, AM J HUM GENET, V81, P199, DOI 10.1086/520679
   Shahabi V, 2012, CANCER IMMUNOL IMMUN, V61, P733, DOI 10.1007/s00262-012-1227-3
   Springer NM, 2009, PLOS GENET, V5
   SYKES PJ, 1992, BIOTECHNIQUES, V13, P444
   Taiwo B, 2011, J INFECT DIS, V204, P515, DOI 10.1093/infdis/jir353
   Mathew AG, 2012, HDB FOOD SAFETY ENG, P217
   Tiacci E, 2012, BLOOD, V119, P192, DOI 10.1182/blood-2011-08-371179
   Tong YK, 2010, CLIN CHEM, V56, P90, DOI 10.1373/clinchem.2009.134114
   van der Sluis RM, 2013, J VIROL METHODS, V187, P94, DOI 10.1016/j.jviromet.2012.09.019
   Vogelstein B, 1999, P NATL ACAD SCI USA, V96, P9236, DOI 10.1073/pnas.96.16.9236
   Warren L, 2006, P NATL ACAD SCI USA, V103, P17807, DOI 10.1073/pnas.0608512103
   Wen B, 2012, 2 MILITARY MED U PRE, V33, P5
   Whan RM, 2009, DALTON T, P932, DOI 10.1039/b814604g
   Wright CF, 2009, HUM REPROD UPDATE, V15, P139, DOI 10.1093/humupd/dmn047
   Yukl SA, 2010, J INFECT DIS, V202, P1553, DOI 10.1086/656722
   Zhang XQ, 2006, RADIO DETECTION 22QL
NR 41
TC 3
Z9 3
U1 2
U2 39
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0954-139X
EI 1473-5601
J9 REV MED MICROBIOL
JI Rev. Med. Microbiol.
PD OCT
PY 2013
VL 24
IS 4
BP 89
EP 93
DI 10.1097/MRM.0b013e328364ff68
PG 5
WC Microbiology
SC Microbiology
GA 247UN
UT WOS:000326647900002
DA 2018-01-05
ER

PT J
AU Nair, M
   Guduru, R
   Liang, P
   Hong, J
   Sagar, V
   Khizroev, S
AF Nair, Madhavan
   Guduru, Rakesh
   Liang, Ping
   Hong, Jeongmin
   Sagar, Vidya
   Khizroev, Sakhrat
TI Externally controlled on-demand release of anti-HIV drug using
   magneto-electric nanoparticles as carriers (vol 4, pg 1707, 2013)
SO NATURE COMMUNICATIONS
LA English
DT Correction
CR NAIR M, 2013, NATURE COMMUNICATION, V14, P1707, DOI DOI 10.1038/NC0MMS2717
NR 1
TC 6
Z9 6
U1 3
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2013
VL 4
AR 2729
DI 10.1038/ncomms3729
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 245VT
UT WOS:000326492600001
OA gold
DA 2018-01-05
ER

PT J
AU Eugenin, E
AF Eugenin, Eliseo
TI Tunneling nanotubes (TNT) a pathway for HIV trafficking and
   communication: role in HIV spread and reactivation
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on NeuroVirology
CY OCT 29-NOV 02, 2013
CL Washington, DC
C1 [Eugenin, Eliseo] Rutgers State Univ, Publ Hlth Res Inst Anf, Piscataway, NJ 08855 USA.
EM eugeniea@umdnj.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD OCT
PY 2013
VL 19
SU 1
MA P56
BP S27
EP S27
PG 1
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 236EM
UT WOS:000325777200057
DA 2018-01-05
ER

PT J
AU Jaworski, E
   Shafagati, N
   Van Duyne, R
   Saifuddin, M
   Iordanskiy, S
   Kehn-Hall, K
   Lepene, B
   Kashanchi, F
AF Jaworski, Elizabeth
   Shafagati, Nazly
   Van Duyne, Rachel
   Saifuddin, Mohammed
   Iordanskiy, Sergey
   Kehn-Hall, Kylene
   Lepene, Benjamin
   Kashanchi, Fatah
TI The use of nanoparticle technology in capturing HIV-1 virions and viral
   proteins
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
CT 12th International Symposium on NeuroVirology
CY OCT 29-NOV 02, 2013
CL Washington, DC
C1 [Jaworski, Elizabeth; Shafagati, Nazly; Van Duyne, Rachel; Saifuddin, Mohammed; Iordanskiy, Sergey; Kehn-Hall, Kylene; Kashanchi, Fatah] George Mason Univ, Natl Ctr Biodef & Infect Dis, Dept Mol & Microbiol, Fairfax, VA 22030 USA.
   [Van Duyne, Rachel] George Washington Univ, Med Ctr, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
EM fkashanc@gmu.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD OCT
PY 2013
VL 19
SU 1
MA P83
BP S40
EP S40
PG 1
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 236EM
UT WOS:000325777200084
DA 2018-01-05
ER

PT J
AU Lian, W
   Wu, MY
   Huang, N
   Gao, N
   Xiao, C
   Li, Z
   Zhang, ZG
   Zheng, YT
   Peng, WL
   Zhao, JH
AF Lian, Wu
   Wu, Mingyi
   Huang, Ning
   Gao, Na
   Xiao, Chuang
   Li, Zi
   Zhang, Zhigang
   Zheng, Yongtang
   Peng, Wenlie
   Zhao, Jinhua
TI Anti-HIV-1 activity and structure-activity-relationship study of a
   fucosylated glycosaminoglycan from an echinoderm by targeting the
   conserved CD4 induced epitope
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE Glycosaminoglycan; Anti-human immunodeficiency virus activity; Envelope
   glycoprotein 120; Cluster of Differentiation 4 induced epitope; Biolayer
   interferometry; Structure-activity relationship
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FREE-RADICAL DEPOLYMERIZATION; CUCUMBER
   THELENATA-ANANAS; CORECEPTOR BINDING-SITE; ANTI-HIV ACTIVITY;
   CHONDROITIN SULFATE; SEA-CUCUMBER; ENVELOPE GLYCOPROTEIN; ANTIRETROVIRAL
   THERAPY; DEXTRAN SULFATE
AB Background: Fucosylated glycosaminoglycan (FG) is a novel glycosaminoglycan with a chondroitin sulfate-like backbone and fucose sulfate branches. The aim of this study is to investigate the mechanism and structure-activity relationships (SAR) of FG for combating HIV-1 infection.
   Methods: Anti-HIV activities of FGs were assessed by a cytopathic effect assay and an HIV-1 p24 detection assay. The biomolecule interactions were explored via biolayer interferometry technology. The SAR was established by comparing its anti-HIV-1 activities, conserved CD4 induced (CD4i) epitope-dependent interactions and anticoagulant activities.
   Results: FG efficiently and selectively inhibited the X4- and R5X4-tropic HIV-1 infections in C8166 cells with little cytotoxicity against C8166 cells and PBMCs. Our data indicated that FG bound to gp120 with nanomolar affinity and may interact with CD4i of gp120. Additionally, the CD4i binding affinity of FG was higher than that of dextran sulfate. SAR studies suggested that the unique sulfated fucose branches account for the anti-HIV-1 activity. The molecular size and present carboxyl groups of FG may also play important roles in various activities. Notably, several FG derivatives showed higher anti-HIV-1 activities and much lower anticoagulant activities than those of heparin.
   Conclusions: FG exhibits strong activity against X4- and R5X4-tropic HIV-1 infections. The mechanism may be related to targeting CD4i of gp120, which results in inhibition of HIV-1 entry. The carboxyl group substituted derivatives of FG (8.5-12.8 kDa), might display high anti-HIV-1 activity and low anticoagulant activity.
   General significance: Our data supports further the investigation of FG derivatives as novel HIV-1 entry inhibitors targeting CD4i. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Lian, Wu; Wu, Mingyi; Gao, Na; Xiao, Chuang; Li, Zi; Zhang, Zhigang; Zhao, Jinhua] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Yunnan, Peoples R China.
   [Lian, Wu; Xiao, Chuang; Peng, Wenlie] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China.
   [Huang, Ning; Zheng, Yongtang] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.
   [Huang, Ning; Zheng, Yongtang] Chinese Acad Sci, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.
RP Zheng, YT (reprint author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.
EM zhengyt@mail.kiz.ac.cn; pengwenlie@21cn.com; zhaojinhua@yahoo.com
FU Yunnan Provincial Science and Technology Department in China [2010CI116,
   2012BC011, 2012FB177]; National Natural Science Foundation of China
   [81102372]; Outstanding Technical Talent Foundation of the Chinese
   Academy of Sciences; West Light Foundation of the Chinese Academy of
   Sciences
FX This work was funded in part by the Yunnan Provincial Science and
   Technology Department in China (Nos. 2010CI116, 2012BC011 and
   2012FB177), National Natural Science Foundation of China (No. 81102372),
   Outstanding Technical Talent Foundation of the Chinese Academy of
   Sciences and West Light Foundation of the Chinese Academy of Sciences.
CR Baranova E O, 2011, Bioorg Khim, V37, P592
   BARZU T, 1993, J MED CHEM, V36, P3546, DOI 10.1021/jm00075a009
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Chen SG, 2013, BBA-GEN SUBJECTS, V1830, P3054, DOI 10.1016/j.bbagen.2013.01.001
   Crublet E, 2008, J BIOL CHEM, V283, P15193, DOI 10.1074/jbc.M800066200
   Damonte EB, 2004, CURR MED CHEM, V11, P2399, DOI 10.2174/0929867043364504                                                        
   Gao N, 2012, MAR DRUGS, V10, P1647, DOI 10.3390/md10081647
   Gulick RM, 2003, AIDS, V17, P2345, DOI 10.1097/01.aids.0000076346.42412.97
   ITO M, 1987, ANTIVIR RES, V7, P361, DOI 10.1016/0166-3542(87)90018-0
   Jagodzinski PP, 1996, VIROLOGY, V226, P217, DOI 10.1006/viro.1996.0649
   Jeon K.J., 2000, J AM CHEM SOC, V122
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Kensinger RD, 2004, ANTIMICROB AGENTS CH, V48, P1614, DOI 10.1128/AAC.48.5.1614-1623.2004
   Li BZ, 2009, BIOCHEM PHARMACOL, V78, P292, DOI 10.1016/j.bcp.2009.04.012
   Liu HY, 2005, GLYCOBIOLOGY, V15, P501, DOI 10.1093/glycob/cwi031
   Miao BC, 2004, BIOCHEM PHARMACOL, V68, P641, DOI 10.1016/j.bcp.2004.04.009
   MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Nakamura K, 2012, ANTIVIR RES, V94, P89, DOI [10.1016/j.antivira1.2012.02.011, 10.1016/j.antiviral.2012.02.011]
   NAKASHIMA H, 1987, ANTIMICROB AGENTS CH, V31, P1524, DOI 10.1128/AAC.31.10.1524                                                          
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187                                                               
   Sheehan JP, 2003, BIOCHEMISTRY-US, V42, P11316, DOI 10.1021/bi0342923
   THALI M, 1993, J VIROL, V67, P3978
   URYU T, 1992, BIOCHEM PHARMACOL, V43, P2385, DOI 10.1016/0006-2952(92)90317-C
   Vermeire K, 2006, CURR MED CHEM, V13, P731, DOI 10.2174/092986706776055599                                                      
   VIEIRA RP, 1988, J BIOL CHEM, V263, P18176
   Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Wang JH, 2003, BIOCHEM BIOPH RES CO, V302, P89, DOI 10.1016/S0006-291X(03)00119-0
   Wang Q, 2004, ANTIVIR RES, V64, P189, DOI 10.1016/j.antiviral.2004.08.005
   Wilkin T.J., 2012, ANNU REV MED, V76, P6332
   Wu MY, 2012, CARBOHYD POLYM, V87, P862, DOI 10.1016/j.carbpol.2011.08.082
   Wu MY, 2010, FOOD CHEM, V122, P716, DOI 10.1016/j.foodchem.2010.03.042
   Wu MY, 2010, CARBOHYD POLYM, V80, P1116, DOI 10.1016/j.carbpol.2010.01.032
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yamada T, 2000, CARBOHYD POLYM, V41, P115, DOI 10.1016/S0144-8617(99)00083-1                                                   
   ZHENG YT, 1995, IMMUNOPHARM IMMUNOT, V17, P69, DOI 10.3109/08923979509052721                                                       
   Zhao J. H., 2011, CN, Patent No. [201110114860. 4, 201110114860]
NR 41
TC 20
Z9 24
U1 3
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD OCT
PY 2013
VL 1830
IS 10
BP 4681
EP 4691
DI 10.1016/j.bbagen.2013.06.003
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 210SN
UT WOS:000323854900031
PM 23769857
DA 2018-01-05
ER

PT J
AU Contarino, M
   Bastian, AR
   Sundaram, RVK
   McFadden, K
   Duffy, C
   Gangupomu, V
   Baker, M
   Abrams, C
   Chaiken, I
AF Contarino, Mark
   Bastian, Arangassery R.
   Sundaram, Ramalingam Venkat Kalyana
   McFadden, Karyn
   Duffy, Caitlin
   Gangupomu, Vamshi
   Baker, Michelle
   Abrams, Cameron
   Chaiken, Irwin
TI Chimeric Cyanovirin-MPER Recombinantly Engineered Proteins Cause
   Cell-Free Virolysis of HIV-1
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MICROBICIDE DEVELOPMENT; INACTIVATING
   PROTEIN; GP120; ENTRY; FUSION; GP41; INHIBITION; MEMBRANE; RECEPTOR
AB Human immunodeficiency virus (HIV) is the primary etiologic agent responsible for the AIDS pandemic. In this work, we used a chimeric recombinant protein strategy to test the possibility of irreversibly destroying the HIV-1 virion using an agent that simultaneously binds the Env protein and viral membrane. We constructed a fusion of the lectin cyanovirin-N (CVN) and the gp41 membrane-proximal external region (MPER) peptide with a variable-length (Gly(4)Ser)(x) linker (where x is 4 or 8) between the C terminus of the former and N terminus of the latter. The His-tagged recombinant proteins, expressed in BL21(DE3)pLysS cells and purified by immobilized metal affinity chromatography followed by gel filtration, were found to display a nanomolar efficacy in blocking BaL-pseudotyped HIV-1 infection of HOS.T4.R5 cells. This antiviral activity was HIV-1 specific, since it did not inhibit cell infection by vesicular stomatitis virus (VSV) or amphotropic-murine leukemia virus. Importantly, the chimeric proteins were found to release intraviral p24 protein from both BaL-pseudotyped HIV-1 and fully infectious BaL HIV-1 in a dose-dependent manner in the absence of host cells. The addition of either MPER or CVN was found to outcompete this virolytic effect, indicating that both components of the chimera are required for virolysis. The finding that engaging the Env protein spike and membrane using a chimeric ligand can destabilize the virus and lead to inactivation opens up a means to investigate virus particle metastability and to evaluate this approach for inactivation at the earliest stages of exposure to virus and before host cell encounter.
C1 [Contarino, Mark; Bastian, Arangassery R.; Sundaram, Ramalingam Venkat Kalyana; Duffy, Caitlin; Abrams, Cameron; Chaiken, Irwin] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA.
   [Bastian, Arangassery R.; Sundaram, Ramalingam Venkat Kalyana] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
   [McFadden, Karyn] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA.
   [Gangupomu, Vamshi; Baker, Michelle; Abrams, Cameron] Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA.
RP Abrams, C (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA.
EM cfa22@drexel.edu; ichaiken@drexelmed.edu
FU National Institutes of Health [R01AI048117, P01GM56550]; National
   Science Foundation [CBET-0853680]; Schlumberger Foundation Faculty of
   the Future award
FX We gratefully acknowledge support from the National Institutes of Health
   grants R01AI048117 and P01GM56550, from the National Science Foundation
   grant CBET-0853680, and from the Schlumberger Foundation Faculty of the
   Future award to A.R.B.
CR Arthos J, 2002, J BIOL CHEM, V277, P11456, DOI 10.1074/jbc.M111191200
   Bastian AR, 2011, CHEMMEDCHEM, V6, P1335, DOI 10.1002/cmdc.201100177
   Bennett A, 2007, J BIOL CHEM, V282, P27754, DOI 10.1074/jbc.M702025200
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Cocklin S, 2007, J VIROL, V81, P3645, DOI 10.1128/JVI.01778-06
   Colleluori DM, 2005, PROTEIN EXPRES PURIF, V39, P229, DOI 10.1016/j.pep.2004.10.009
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   Coutant J, 2008, FASEB J, V22, P4338, DOI 10.1096/fj.08-113142
   Dimitrov AS, 2001, J BIOL CHEM, V276, P30335, DOI 10.1074/jbc.M103788200                                                          
   Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Esser MT, 1999, J VIROL, V73, P4360
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Kagiampakis I, 2011, ANTIMICROB AGENTS CH, V55, P264, DOI 10.1128/AAC.00376-10
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Keeffe JR, 2011, P NATL ACAD SCI USA, V108, P14079, DOI 10.1073/pnas.1108777108
   McFadden K, 2007, PROTEINS, V67, P617, DOI 10.1002/prot.21295
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Montefiori DC, 2005, CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735.IM1211S64
   Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Vanpouille C, 2012, TRENDS MICROBIOL, V20, P369, DOI 10.1016/j.tim.2012.05.005
   Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866
   Xiong S, 2010, APPL MICROBIOL BIOT, V86, P805, DOI 10.1007/s00253-010-2470-1
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
NR 28
TC 5
Z9 5
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD OCT
PY 2013
VL 57
IS 10
BP 4743
EP 4750
DI 10.1128/AAC.00309-13
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 219BU
UT WOS:000324480300019
PM 23856780
OA gold
DA 2018-01-05
ER

PT J
AU Cordoba, EV
   Pion, M
   Rasines, B
   Filippini, D
   Komber, H
   Ionov, M
   Bryszewska, M
   Appelhans, D
   Munoz-Fernandez, MA
AF Cordoba, E. Vacas
   Pion, M.
   Rasines, B.
   Filippini, D.
   Komber, H.
   Ionov, M.
   Bryszewska, M.
   Appelhans, D.
   Munoz-Fernandez, M. A.
TI Glycodendrimers as new tools in the search for effective anti-HIV
   DC-based immunotherapies
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Dendritic cells; HIV; Vaccine; Dendrimer; Maltose
ID POLY(PROPYLENE IMINE) DENDRIMERS; DENDRITIC CELLS;
   BIOLOGICAL-PROPERTIES; CELLULAR UPTAKE; VACCINE; NANOPARTICLES;
   DELIVERY; MALTOSE; ACTIVATION; TOXICITY
AB Dendritic cells (DC), which play a major role in development of cell-mediated immunity, represent opportunities to develop novel anti-HIV vaccines. Dendrimers have been proposed as new carriers to ameliorate DC antigen loading and in this way, we have determined the potential use of maltose decorated neutrally and positively charged G4 glycodendrimers. Thus, immunostimulatory properties of these glycodendrimers on human DC were evaluated in the context of HIV infection. We have demonstrated that DC treated with glycodendrimers were fully functional with respect to viability, maturation and HIV-derived antigens uptake. Nevertheless, iDC and mDC phenotypes as well as mDC functions such as migration ability and cytokines profile production were changed. Our results showed the potential carrier properties of glycodendrimers to activate the immune system by the way of DC stimulation. This is the first study for exploring the use of maltose-functionalized dendrimers-peptides complexes as a potential DC-based vaccine candidate. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Cordoba, E. Vacas; Pion, M.; Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
   [Cordoba, E. Vacas; Pion, M.; Munoz-Fernandez, M. A.] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Rasines, B.; Filippini, D.; Komber, H.; Appelhans, D.] Leibniz Inst Poymerforch Dersden eV, Dresden, Germany.
   [Ionov, M.; Bryszewska, M.] Univ Lodz, Dept Gen Biophys, PL-90131 Lodz, Poland.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
EM mmunoz.hgugm@gmail.com
RI Umlauf, Ursula/D-3356-2014; Rasines, Beatriz/H-4309-2015; Komber,
   Hartmut/K-8758-2016; Pion, Marjorie/D-8139-2012
OI Pion, Marjorie/0000-0002-6406-747X; Munoz-Fernandez/0000-0002-0813-4500;
   Pion, Marjorie/0000-0003-1828-4745; Bryszewska,
   Maria/0000-0003-4676-3743
FU EuroNanoMed (DEN-PEPTHIV), COST action [TD0802]; Fondos de Investigacion
   Sanitaria (INTRASALUD) [PI09/02029, PS09/02669]; Red Tematica de
   Investigacion Cooperativa Sanitaria ISCIII [RED RIS RD06/0006/0035,
   RD12-0017-0037]; INDISNET [S-2011-BMD2332]; FIPSE; Saxon Ministry for
   Science and Art; German Ministry for Education and Science; Ramon y
   Cajal [RYC-2009-05486]
FX This work was supported by grants from EuroNanoMed (DEN-PEPTHIV), COST
   action TD0802 ("Dendrimers in Biomedical Applications"), Fondos de
   Investigacion Sanitaria (INTRASALUD PI09/02029, PS09/02669), Red
   Tematica de Investigacion Cooperativa Sanitaria ISCIII (RED RIS
   RD06/0006/0035; RD12-0017-0037), INDISNET S-2011-BMD2332 and FIPSE. This
   work was also funded by the Saxon Ministry for Science and Art, the
   German Ministry for Education and Science. M.P. is supported by Ramon y
   Cajal (RYC-2009-05486).
CR Akagawa KS, 1996, BLOOD, V88, P4029
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Appelhans D, 2009, BIOMACROMOLECULES, V10, P1114, DOI 10.1021/bm801310d
   Carrillo-Conde B, 2011, MOL PHARMACEUT, V8, P1877, DOI 10.1021/mp200213r
   Chatwell L, 2008, MOL IMMUNOL, V45, P1981, DOI 10.1016/j.molimm.2007.10.030
   Cho HJ, 2011, BIOMATERIALS, V32, P4621, DOI 10.1016/j.biomaterials.2011.03.004
   Cho NH, 2011, NAT NANOTECHNOL, V6, P675, DOI [10.1038/NNANO.2011.149, 10.1038/nnano.2011.149]
   Ciolkowski M, 2012, COLLOID SURFACE B, V95, P103, DOI 10.1016/j.colsurfb.2012.02.021
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Cruz LJ, 2011, MOL PHARMACEUT, V8, P104, DOI 10.1021/mp100178k
   Fischer W, 2010, J CONTROL RELEASE, V148, pE89, DOI 10.1016/j.jconrel.2010.07.064
   Gamble LJ, 2010, DRUG DES DEV THER, V5, P9, DOI 10.2147/DDDT.S6959
   Garcia F, 2011, VACCINE, V29, P6454, DOI 10.1016/j.vaccine.2011.07.043
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Hobel S, 2011, J CONTROL RELEASE, V149, P146, DOI 10.1016/j.jconrel.2010.10.008
   Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Jefford M, 2001, Lancet Oncol, V2, P343, DOI 10.1016/S1470-2045(00)00389-2
   Kameyama S, 2007, BIOPOLYMERS, V88, P98, DOI 10.1002/bip.20689
   Klajnert B, 2008, CHEM-EUR J, V14, P7030, DOI 10.1002/chem.200800342
   Klementieva O, 2011, BIOMACROMOLECULES, V12, P3903, DOI 10.1021/bm2008636
   Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/nnano.2011.153, 10.1038/NNANO.2011.153]
   Mkandawire M, 2009, J BIOPHOTONICS, V2, P596, DOI 10.1002/jbio.200910002
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007
   Park IY, 2008, INT J PHARM, V359, P280, DOI 10.1016/j.ijpharm.2008.04.010
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Scherer E, 2008, CLIN EXP IMMUNOL, V154, P6, DOI 10.1111/j.1365-2249.2008.03750.x
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Sokolova V, 2011, ACTA BIOMATER, V7, P4029, DOI 10.1016/j.actbio.2011.07.010
   Song CK, 2009, INT J PHARMACEUT, V380, P161, DOI 10.1016/j.ijpharm.2009.07.014
   Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698                                                          
   Tacken PJ, 2011, BLOOD
   Thara E, 2011, MATURITAS, V69, P296, DOI 10.1016/j.maturitas.2011.04.012
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   Trepiakas R, 2010, CYTOTHERAPY, V12, P721, DOI 10.3109/14653241003774045
   Vu-Quang Hieu, 2011, Acta Biomater, V7, P3935, DOI 10.1016/j.actbio.2011.06.044
   Weber C, 2010, J BIOMED MATER RES A, V93A, P1322, DOI 10.1002/jbm.a.32605
   Zhu AP, 2011, AM J REPROD IMMUNOL, V65, P54, DOI 10.1111/j.1600-0897.2010.00851.x
   Ziemba B, 2011, J BIOMED MATER RES A, V99A, P261, DOI 10.1002/jbm.a.33196
NR 40
TC 19
Z9 19
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD OCT
PY 2013
VL 9
IS 7
BP 972
EP 984
DI 10.1016/j.nano.2013.03.004
PG 13
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 219PU
UT WOS:000324520900015
PM 23506949
DA 2018-01-05
ER

PT J
AU Lee, JH
   Kim, BC
   Oh, BK
   Choi, JW
AF Lee, Jin-Ho
   Kim, Byung-Chan
   Oh, Byung-Keun
   Choi, Jeong-Woo
TI Highly sensitive localized surface plasmon resonance immunosensor for
   label-free detection of HIV-1
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE AIDS; HIV-1 virus; Localized surface plasmon resonance; Biosensor;
   Immunosensor
ID HEPATITIS-B-VIRUS; INFLUENZA-VIRUS; GOLD NANOPARTICLES;
   OPTICAL-PROPERTIES; BIOSENSOR; ASSAY; RECOGNITION; ANTIBODY; DNA
AB A highly sensitive label-free immunosensor for the detection of HIV-1 is newly developed based on localized surface plasmon resonance (LSPR) method. Uniform nanopattern of circular Au-dots (10-20 nm) was fabricated on indium tin oxide (ITO) coated glass substrate by simple electrochemical deposition method. The surface of Au nanopattern was modified with HIV-1 neutralizing gp120 monoclonal antibody fragments. The modified substrate was employed to measure various concentrations of HIV-1 particles quantitatively based on the shift of longitudinal wavelength in the UV-Vis spectrum which results from the changes of local refractive index induced by specific antigen-antibody recognition events. The detection limit of the HIV-1 particles was estimated to be 200 fg/mL, which is 10 fold higher than that of previously reported virus detection method based on LSPR. Since fabricated LSPR immunosensor has high sensitivity and selectivity, it is a promising approach for biological/medical sample analysis and various kinds of virus detection. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Lee, Jin-Ho; Oh, Byung-Keun; Choi, Jeong-Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
   [Lee, Jin-Ho] Sogang Univ, Res Inst Basic Sci, Seoul 121742, South Korea.
   [Kim, Byung-Chan] Korea Inst Sci & Technol, Environm Div, Seoul 136791, South Korea.
   [Choi, Jeong-Woo] Sogang Univ, Grad Sch Management Technol, Seoul 121742, South Korea.
RP Choi, JW (reprint author), Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
EM jwchoi@sogang.ac.kr
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2009-0080860]; Nano/Bio Science & Technology Program of the Ministry of
   Education, Science, and Technology (MEST) [M10536090001-05N3609-00110];
   Ministry of Education, Science and Technology [2012-0006592]; Original
   Technology Research Program for Brain Science through the National
   Research Foundation of Korea (NRF)
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korea government (MEST) (2009-0080860), by the
   Nano/Bio Science & Technology Program (M10536090001-05N3609-00110) of
   the Ministry of Education, Science, and Technology (MEST), and by the
   Original Technology Research Program for Brain Science through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology (2012-0006592).
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Armani AM, 2007, SCIENCE, V317, P783, DOI 10.1126/science.1145002
   Bartlett PN, 2004, FARADAY DISCUSS, V125, P117, DOI 10.1039/b304116f
   Bozhevolnyi SI, 2006, NATURE, V440, P508, DOI 10.1038/nature04594
   Chang YF, 2010, BIOSENS BIOELECTRON, V26, P1068, DOI 10.1016/j.bios.2010.08.060
   Cho HS, 2006, J VET MED SCI, V68, P1327, DOI 10.1292/jvms.68.1327
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Ding CF, 2008, BIOELECTROCHEMISTRY, V72, P28, DOI 10.1016/j.bioelechem.2007.11.001
   Geng HF, 2006, J VIROL METHODS, V132, P25, DOI 10.1016/j.jviromet.2005.08.018
   Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541
   Griffin J, 2009, SMALL, V5, P839, DOI 10.1002/smll.200801334
   Gupta AK, 2006, P NATL ACAD SCI USA, V103, P13362, DOI 10.1073/pnas.0602022103
   Gupta G, 2008, SENSOR ACTUAT B-CHEM, V130, P689, DOI 10.1016/j.snb.2007.10.029
   Hnaien M, 2008, BIOCHEM ENG J, V39, P443, DOI 10.1016/j.bej.2007.09.018
   Karst SM, 2010, VIRUSES-BASEL, V2, P748, DOI 10.3390/v2030748
   Kleo K, 2011, ANAL BIOCHEM, V418, P260, DOI 10.1016/j.ab.2011.07.016
   KOST TA, 1991, J VIROL, V65, P3276
   Kosuda K. M., 2011, COMPREHENSIVE NANOSC, V3, P263
   Lee JH, 2010, BIOCHIP J, V4, P1, DOI 10.1007/s13206-010-4101-4
   Lee JH, 2009, J NANOSCI NANOTECHNO, V9, P7155, DOI 10.1166/jnn.2009.1613
   Munoz-Berbel X, 2008, IMPEDANCE BASED BIOS
   Nguyen Binh Thi Thanh, 2012, Bioelectrochemistry, V88, P15, DOI 10.1016/j.bioelechem.2012.04.006
   Nilsson CE, 2010, VACCINE, V28, P759, DOI 10.1016/j.vaccine.2009.10.070
   Park TJ, 2012, TALANTA, V89, P246, DOI 10.1016/j.talanta.2011.12.021
   Pepin KM, 2008, INFECT GENET EVOL, V8, P825, DOI 10.1016/j.meegid.2008.08.008
   Pineda MF, 2009, IEEE SENS J, V9, P470, DOI 10.1109/JSEN.2009.2014427
   Platt EJ, 2012, P NATL ACAD SCI USA, V109, P7829, DOI 10.1073/pnas.1109728109
   Rodriguez-Lazaro D, 2012, FEMS MICROBIOL REV, V36, P786, DOI 10.1111/j.1574-6976.2011.00306.x
   Tam P. D., 2010, MAT SCI ENG C, V30, P1145
   Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212
   Tseng AA, 2005, SMALL, V1, P594, DOI 10.1002/smll.200500050
   Wang CG, 2006, ADV FUNCT MATER, V16, P1673, DOI 10.1002/adfm.200500898
   Wang RH, 2013, BIOSENS BIOELECTRON, V42, P148, DOI 10.1016/j.bios.2012.10.038
   Wang XH, 2010, BIOSENS BIOELECTRON, V26, P404, DOI 10.1016/j.bios.2010.07.121
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   Yao CY, 2008, BIOSENS BIOELECTRON, V23, P879, DOI 10.1016/j.bios.2007.09.003
NR 36
TC 24
Z9 25
U1 2
U2 67
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD OCT
PY 2013
VL 9
IS 7
BP 1018
EP 1026
DI 10.1016/j.nano.2013.03.005
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 219PU
UT WOS:000324520900019
PM 23506952
DA 2018-01-05
ER

PT J
AU Ionov, M
   Ciepluch, K
   Moreno, BR
   Appelhans, D
   Sanchez-Nieves, J
   Gomez, R
   de la Mata, FJ
   Munoz-Fernandez, MA
   Bryszewska, M
AF Ionov, M.
   Ciepluch, K.
   Moreno, B. R.
   Appelhans, D.
   Sanchez-Nieves, J.
   Gomez, R.
   de la Mata, F. J.
   Munoz-Fernandez, M. A.
   Bryszewska, M.
TI Biophysical Characterization of Glycodendrimers As Nano-carriers for HIV
   Peptides
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE PPI-glycodendrimer; HIV-peptide carrier; complex formation; stability of
   dendriplexes
ID POLY(PROPYLENE IMINE) DENDRIMERS; CARBOSILANE DENDRIMERS; PHOSPHORUS
   DENDRIMERS; BIOLOGICAL-PROPERTIES; CIRCULAR-DICHROISM; IN-VIVO;
   TOXICITY; VACCINE; OLIGONUCLEOTIDES; DENDRIPLEXES
AB This paper examines the formation and stability of nano-complexes that could provide a new therapeutic approach against HIV-1 infection. Poly(propylene imine) glycodendrimers decorated with 2nd generation cationic carbosilane dendrons were generated and their use in polyplex formation checked. Owing to their positively-charged terminal amino groups the hybrid glycodendrimers can bind anionic peptides. It was shown that they form nano-complexes with the HIV-derived peptides P24, Gp160 and Nef. Complexes 130-190 nm in size were formed in molar ratios (dendrimer/peptide) of (3-4):1. These were sufficiently stable over time and at different pHs. The results obtained suggest that the hybrid dendrimers studied can be considered as alternative carriers for delivering HIV peptides to dendritic cells.
C1 [Ionov, M.; Ciepluch, K.; Bryszewska, M.] Univ Lodz, Dept Gen Biophys, Fac Biol & Environm Protect, PL-90236 Lodz, Poland.
   [Moreno, B. R.; Appelhans, D.] Leibniz Inst Polymer Res Dresden, D-01069 Dresden, Germany.
   [Sanchez-Nieves, J.; Gomez, R.; de la Mata, F. J.] Univ Alcala de Henares, Dpto Quim Organ & Quim Inorgan, E-28871 Alcala De Henares, Madrid, Spain.
   [Sanchez-Nieves, J.; Gomez, R.; de la Mata, F. J.; Munoz-Fernandez, M. A.] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
RP Ionov, M (reprint author), Univ Lodz, Dept Gen Biophys, Pomorska St 141-143, PL-90236 Lodz, Poland.
EM maksion@biol.uni.lodz.pl
RI Umlauf, Ursula/D-3356-2014; Rasines, Beatriz/H-4309-2015;
   Sanchez-Nieves, Javier/J-9260-2014; De la Mata, F. Javier/K-1649-2014;
   Gomez Ramirez, Rafael/K-1216-2014
OI Sanchez-Nieves, Javier/0000-0003-0410-2285; De la Mata, F.
   Javier/0000-0003-0418-3935; Gomez Ramirez, Rafael/0000-0001-6448-2414;
   Bryszewska, Maria/0000-0003-4676-3743;
   Munoz-Fernandez/0000-0002-0813-4500
FU DENPEPTHIV [PS09102669]; MINECO [CTQ 2011-23245]; NANODENDMED Consortium
   [S2011/BMD-2351]; CIBER-BBN; Instituto de Salud Carlos III; 
   [1/EuroNanoMed]
FX These study were funded by project No. 1/EuroNanoMed/2010, DENPEPTHIV
   PS09102669 and grants from CTQ 2011-23245 (MINECO) and NANODENDMED
   Consortium ref S2011/BMD-2351 (CAM) awarded to UAH (University of
   Alcala). This study was also supported by CIBER-BBN financed by the
   Instituto de Salud Carlos III, with assistance from the European
   Regional Development Fund, the Saxon Ministry for Science and Art, and
   the German Ministry for Education and Science.
CR Ahmed Z, 2013, ADV EXP MED BIOL, V762, P201, DOI 10.1007/978-1-4614-4433-6_8
   Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s
   BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Vacas Cordoba E., 2013, NANOMED-NANOTECHNOL, DOI [10.1016/j.nano.2013.03.004, DOI 10.1016/J.NAN0.2013.03.004]
   Cunningham AL, 2013, ADV EXP MED BIOL, V762, P1, DOI 10.1007/978-1-4614-4433-6_1
   Dehuyser L, 2012, BIOCONJUGATE CHEM, V23, P1731, DOI 10.1021/bc200644d
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Fischer M, 2010, BIOMACROMOLECULES, V11, P1314, DOI 10.1021/bm100101s
   Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
   Gulck E., 2010, CURR HIV RES, V8, P310
   Hauptmann N., 2013, MACROMOL BIOSCI, DOI 10.1002/mabi201200
   Hobel S, 2011, J CONTROL RELEASE, V149, P146, DOI 10.1016/j.jconrel.2010.10.008
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Ionov M, 2012, CHEM PHYS LIPIDS, V165, P408, DOI 10.1016/j.chemphyslip.2011.11.014
   Klajnert B, 2008, CHEM-EUR J, V14, P7030, DOI 10.1002/chem.200800342
   Klajnert B, 2012, NANOMED-NANOTECHNOL, V8, P1372, DOI 10.1016/j.nano.2012.03.005
   Lesniak W, 2005, NANO LETT, V5, P2123, DOI 10.1021/nl051077u
   Lori F, 2007, CURR MED CHEM, V14, P1911
   Maly J, 2012, CURR MED CHEM, V19, P4708, DOI 10.2174/092986712803306457                                                      
   Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177
   Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007
   Paroo Z, 2004, TRENDS BIOTECHNOL, V22, P390, DOI 10.1016/j.tibtech.2004.06.004
   Patham B, 2011, CURR MED CHEM, V18, P3987, DOI 10.2174/092986711796957194                                                      
   Pedziwiatr-Werbicka E, 2012, J BIOMED NANOTECHNOL, V8, P57, DOI 10.1166/jbn.2012.1369
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   Shcharbin DG, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1070, DOI 10.1134/S0006297909100022
   Smoluchowski M., 1921, HDB ELEKT MAGNETISMU, P366
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Thara E, 2011, MATURITAS, V69, P296, DOI 10.1016/j.maturitas.2011.04.012
   Trepiakas R, 2010, CYTOTHERAPY, V12, P721, DOI 10.3109/14653241003774045
   Wasiak T, 2012, MOL PHARMACEUT, V9, P458, DOI 10.1021/mp2005627
   Woody RW, 1985, CONFORMATION BIOL DR, P15
   YANG JT, 1986, METHOD ENZYMOL, V130, P208
   Ziemba B, 2012, BIOPOLYMERS, V97, P642, DOI 10.1002/bip.22056
   Ziemba B, 2011, J BIOMED MATER RES A, V99A, P261, DOI 10.1002/jbm.a.33196
NR 37
TC 8
Z9 8
U1 0
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD OCT
PY 2013
VL 20
IS 31
BP 3935
EP 3943
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 214WO
UT WOS:000324168400008
PM 23895684
DA 2018-01-05
ER

PT J
AU Chopra, S
   Venkatesan, N
   Betageri, GV
AF Chopra, Shruti
   Venkatesan, Natarajan
   Betageri, Guru V.
TI Liposomes as nanocarriers for anti-HIV therapy
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Review
DE Liposomes; Nanocarrier; Patents; Drug delivery; HIV; Antiretroviral
   drugs
AB Globally, in the last three decades of medical research, the use of liposomes as carrier for anti-HIV/AIDS drugs is gaining prominence. These potential anti-HIV nanocarriers are concentric lipid bilayers which can be fabricated to protect molecules and to target the drugs to specific sites, which is the reason behind their popularity in the antiretroviral drug delivery. The development of an effective drug delivery system such as liposomes presents an opportunity to circumvent the many challenges associated with antiretroviral drug therapy. The physiochemical properties of liposomes such as size, charge, and lipid composition significantly affect the liposomal efficiency. These nanocarriers offer advantages such as drug loading both in aqueous region and within the bilayer of the vesicles, act as solubilizing agents, protect drug from degradation in the body, allow modification of the pharmacokinetic and tissue distribution patterns of the drug, provide drug targeting, and have low immunogenicity, biocompatibility, and cell specificity. Different types of liposome-based delivery systems, such as cationic, anionic, sterically stabilized, and immunoliposomes, have been studied for the anti-HIV/AIDS drug delivery. Liposomes, however, face challenges with regard to their use in antiretroviral drug delivery such as limited hydrophilic drug-loading capacity, issues related to physical and biologic stability, poor scale-up, cost, short shelf life, and toxicity. Numerous patented strategies have been granted in the USA and around the world related to these anti-HIV nanocarriers. In the present article, we have discussed the general physiological aspects of the HIV infection, relevance of the nanocarrier, liposomes, in the treatment of this disease and some recently awarded US patents and patent applications of these liposomal delivery systems for anti-HIV drugs.
C1 [Chopra, Shruti; Betageri, Guru V.] Western Univ Hlth Sci, Grad Coll Biomed Sci, Pomona, CA 91766 USA.
   [Venkatesan, Natarajan] Midwestern Univ, Chicago Coll Pharm, Downers Grove, IL 60515 USA.
RP Betageri, GV (reprint author), Western Univ Hlth Sci, Grad Coll Biomed Sci, Pomona, CA 91766 USA.
EM gbetageri@westernu.edu
CR Ahmad N, 2005, CRIT REV CL LAB SCI, V42, P1, DOI 10.1080/10408360490512520
   ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X
   Alving CR, 2012, EXPERT REV VACCINES, V11, P733, DOI [10.1586/erv.12.35, 10.1586/ERV.12.35]
   Beck Z, 2008, J DRUG TARGET, V16, P535, DOI 10.1080/10611860802228517
   BETAGERI GV, 1993, INT J PHARM, V98, P149, DOI 10.1016/0378-5173(93)90051-G                                                    
   Bhambere DS, 2010, INT J DRUG DEV RES, V2, P8
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Bronshtein T, 2011, J CONTROL RELEASE, V151, P139, DOI 10.1016/j.jconrel.2011.02.023
   Burnett JC, 2012, CURR OPIN IMMUNOL, V24, P625, DOI 10.1016/j.coi.2012.08.013
   Chamoun AM, 2012, ANTIMICROB AGENTS CH, V56, P672, DOI 10.1128/AAC.05722-11
   CHONN A, 1995, CURR OPIN BIOTECH, V6, P698, DOI 10.1016/0958-1669(95)80115-4
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   DeJesus E, 2012, LANCET, V379, P2429, DOI 10.1016/S0140-6736(12)60918-0
   Department of Sustainability and Environment, 2011, GUID US ANT AG HIV 1, P1
   Dipali SR, 1996, DRUG DELIV, V3, P279
   Dubey V, 2011, J DRUG TARGET, V19, P258, DOI 10.3109/1061186X.2010.499460
   Espert L, 2008, AUTOPHAGY, V4, P272
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Franquelim HG, 2011, SOFT MATTER, V7, P11089, DOI 10.1039/c1sm06553j
   Garg BR, 2011, INT J PHARM SCI RES, V2, P620, DOI 10.13040/IJPSR.0975-8232.2(3).620-36
   Gupta PN, 2012, EUR J PHARM SCI, V46, P315, DOI 10.1016/j.ejps.2012.02.003
   Gupta PN, 2010, J CONTROL RELEASE, V148, pE108, DOI 10.1016/j.jconrel.2010.07.081
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   HARVIE P, 1995, AIDS, V9, P701, DOI 10.1097/00002030-199507000-00006
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0
   Lasic D. D., 1997, LIPOSOMES GENE DELIV, P67
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Pai RS, 2009, INT J PHARM SCI NANO, V1, P317
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Pollock S, 2010, P NATL ACAD SCI USA, V107, P17176, DOI 10.1073/pnas.1009445107
   Pollock S, 2010, FASEB J, V24, P1866, DOI 10.1096/fj.09-145755
   Ramana LN, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-57
   Ramana LN, 2012, INT J PHARMACEUT, V431, P120, DOI 10.1016/j.ijpharm.2012.04.054
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Satyanarayana K, 2009, INDIAN J MED RES, V130, P671
   Semete B, 2010, SMART BIOMOL MED, P15
   Skanji R, 2011, INT J PHARMACEUT, V414, P285, DOI 10.1016/j.ijpharm.2011.05.005
   Steers NJ, 2009, VACCINE, V27, P6939, DOI 10.1016/j.vaccine.2009.08.105
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   SZEBENI J, 1990, AIDS RES HUM RETROV, V6, P691, DOI 10.1089/aid.1990.6.691
   Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   TORCHILIN VP, 1992, FASEB J, V6, P2716
   Tyagi M, 2012, MOL MED, V18, P1096, DOI 10.2119/molmed.2012.00194
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Yan N, 2011, CURR OPIN IMMUNOL, V23, P21, DOI 10.1016/j.coi.2010.11.004
NR 52
TC 3
Z9 3
U1 1
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD OCT
PY 2013
VL 3
IS 5
BP 471
EP 478
DI 10.1007/s13346-013-0134-2
PG 8
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA V39QE
UT WOS:000209424700012
PM 25788354
DA 2018-01-05
ER

PT J
AU Gutierrez-Granados, S
   Cervera, L
   Godia, F
   Carrillo, J
   Segura, MM
AF Gutierrez-Granados, Sonia
   Cervera, Laura
   Godia, Francesc
   Carrillo, Jorge
   Mercedes Segura, Maria
TI Development and validation of a quantitation assay for fluorescently
   tagged HIV-1 virus-like particles
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Virus-like particles (VLPs); Fluorescently tagged virus; Gag-GFP; HIV-1
   VLPs; Quantitation assays; Fluorometry
ID SIZE-EXCLUSION CHROMATOGRAPHY; TYPE-1 GAG; CELLULAR PROTEINS; VECTOR
   PARTICLES; GENE-THERAPY; INSECT CELLS; QUANTIFICATION; PURIFICATION;
   ADENOVIRUS; GLYCOPROTEIN
AB Upon expression, the Gag polyprotein of HIV-1 assembles spontaneously in the vicinity of the plasma membrane giving rise to enveloped virus-like particles (VLPs). These particulate immunogens offer great promise as HIV-1 vaccines. Robust VLP production and purification processes are required to generate VLPs of sufficient quality and quantity for both pre-clinical and clinical evaluation. The availability of simple, fast and reliable quantitation tools is critical to develop, optimize and monitor such processes. Traditionally, enzyme-linked immunosorbent assays (ELISA) are used to quantify p24 antigen concentrations, which reflect tightly virus particle concentrations. However, this quantitation technique is not only time-consuming, laborious and costly but it is also prone to methodological variability. As an alternative, the development and validation of a fluorescence-based quantitation assay for Gag VLPs is presented here. A Gag polyprotein fused to the enhanced green fluorescent protein was used for generation of fluorescent VLPs. A purified standard reference Gag-GFP VLP material was prepared and characterized in house. The method was validated according to ICH guidelines. The validation characteristics evaluated included accuracy, precision, specificity, linearity, range and limit of detection. The method showed to be specific for Gag-GFP. The fluorescence signal correlated well with p24 concentrations measured using a reference p24 ELISA assay. The method showed little variability compared to ELISA and was linear over a 3-log range. The limit of detection was similar to 10 ng of p24/mL. Finally, fluorescence-based titers were in good agreement with those obtained using transmission electron microscopy and nanoparticle tracking analysis. This simple, rapid and cost-effective quantitation assay should facilitate development and optimization of bioprocessing strategies for Gag-based VLPs. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Gutierrez-Granados, Sonia; Cervera, Laura; Godia, Francesc; Mercedes Segura, Maria] Univ Autonoma Barcelona, Dept Engn Quim, E-08193 Barcelona, Spain.
   [Carrillo, Jorge] Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst HIVACAT, Badalona, Spain.
RP Segura, MM (reprint author), Univ Autonoma Barcelona, Dept Engn Quim, Campus Bellaterra, E-08193 Barcelona, Spain.
EM mersegura@gmail.com
RI Godia, Francesc/H-9962-2015
OI Godia, Francesc/0000-0002-4060-9887; Carrillo, Jorge/0000-0003-0221-5948
FU Plan Nacional de Investigacion, Ministry of Science and Innovation of
   Spain [MICINN BIO2011-2330]
FX The authors would like to thank Dr. Amine Kamen at National Research
   Council of Canada (NRC, Montreal, Canada) for kindly providing the HEK
   293 cell line. The following reagent was obtained through the NIH AIDS
   Reagent Program, Division of AIDS, NIAID, NIH: pGag-EGFP (Cat#11468)
   from Dr. Marilyn Resh. We would also like to thank Dr. Julia Blanco and
   Silvia Marfil at Fundacio IrsiCaixa, Hospital Germans Trias i Pujol
   (Badalona, Spain) for support and discussions. The help of Anna
   Tarruella from Servei de Microscopia located at the UAB campus is
   greatly appreciated. The valuable comments of Gavin Whissell are
   appreciated. We thank Dr. Miguel Chillon at Centre de Biotecnologia
   Animal i Terapia Genica (CBATEG, UAB, Spain) for generously making his
   laboratory space and equipment available. Dr. Salvador Bartolome from
   Departament de Bioquimica i de Biologia Molecular (UAB, Spain) was very
   helpful in the development of this work which is greatly appreciated.
   This work was supported by the Plan Nacional de Investigacion, Ministry
   of Science and Innovation of Spain (MICINN BIO2011-2330).
CR Adamson CS, 2003, VIROLOGY, V308, P157, DOI 10.1016/S0042-6822(02)00141-1
   Alain R., 1997, MICROSC TODAY, V97, P20
   Altaras NE, 2005, ADV BIOCHEM ENG BIOT, V99, P193, DOI 10.1007/10_008
   Aucoin MG, 2008, BIOTECHNOL ADV, V26, P73, DOI 10.1016/j.biotechadv.2007.09.001
   BLAND JM, 1995, INT J EPIDEMIOL, V24, pS7, DOI 10.1093/ije/24.Supplement_1.S7                                                  
   Block O, 2012, J VIROL METHODS, V182, P70, DOI 10.1016/j.jviromet.2012.03.012
   Caygill RL, 2010, ANAL CHIM ACTA, V681, P8, DOI 10.1016/j.aca.2010.09.038
   Chang Lung-Ji, 2002, Methods Mol Med, V69, P303
   Chen Y, 2009, BIOPHYS J, V96, P1961, DOI 10.1016/j.bpj.2008.10.067
   Clark KR, 1996, GENE THER, V3, P1124
   Cox MMJ, 2012, VACCINE, V30, P1759, DOI 10.1016/j.vaccine.2012.01.016
   Dale BM, 2011, METHODS, V53, P20, DOI 10.1016/j.ymeth.2010.06.018
   Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028
   DePhillips P, 2000, J CHROMATOGR A, V883, P39, DOI 10.1016/S0021-9673(00)00420-9
   FDA, 2001, GUID IND BIOAN METH
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   GARNIER L, 1995, J VIROL, V69, P4060
   Graham F.L., 1973, VIROLOGY, V52, P12
   Hammonds J, 2007, VACCINE, V25, P8036, DOI 10.1016/j.vaccine.2007.09.016
   Haynes JR, 2009, VACCINE, V27, P530, DOI 10.1016/j.vaccine.2008.11.011
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Hermle J, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-32
   ICH Harmonised Tripartite Guideline, 2005, VAL AN PROC TEXT MET
   Joshi S, 1996, TRANSFUS SCI, V17, P351
   Lindwasser OW, 2002, P NATL ACAD SCI USA, V99, P13037, DOI 10.1073/pnas.212409999
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Lynch AG, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-30
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9                                                    
   MCGRATH M, 1978, J VIROL, V25, P923
   Segura MM, 2010, J VIROL METHODS, V163, P129, DOI 10.1016/j.jviromet.2009.09.010
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   OSTERRIEDER N, 1995, VIROLOGY, V208, P500, DOI 10.1006/viro.1995.1181                                                          
   Ott DE, 2002, REV MED VIROL, V12, P359, DOI 10.1002/rmv.367
   Ott DE, 1997, REV MED VIROL, V7, P167, DOI 10.1002/(SICI)1099-1654(199709)7:3<167::AID-RMV199>3.3.CO;2-B
   Pease 3rd L.F., 2009, BIOTECHNOL BIOENG, V102, P11
   Pecora A, 2009, J VIROL METHODS, V162, P170, DOI 10.1016/j.jviromet.2009.07.031
   Perlman M, 2006, TRAFFIC, V7, P731, DOI 10.1111/j.1600-0854.2006.00428.x
   Phogat S, 2007, J INTERN MED, V262, P26, DOI 10.1111/j.1365-2796.2007.01820.x
   Pillay S, 2009, BIOTECHNOL PROGR, V25, P1153, DOI 10.1002/btpr.187
   Roberts GS, 2012, BIOSENS BIOELECTRON, V31, P17, DOI 10.1016/j.bios.2011.09.040
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Sakuragi S, 2006, MICROBES INFECT, V8, P1875, DOI 10.1016/j.micinf.2006.02.027
   Schroder M, 2006, J PHYS CHEM B, V110, P1429, DOI 10.1021/jp0542726
   SCHWARTZ S, 1992, J VIROL, V66, P7176
   Segura MDM, 2006, J VIROL METHODS, V133, P82, DOI 10.1016/j.jviromet.2005.10.030
   Segura MM, 2008, J VIROL, V82, P1107, DOI 10.1128/JVI.01909-07
   Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x                                                
   Sutjipto S, 2005, HUM GENE THER, V16, P109, DOI 10.1089/hum.2005.16.109
   Tagliamonte M, 2011, VACCINE, V29, P4913, DOI 10.1016/j.vaccine.2011.05.004
   Transfiguracion J, 2003, HUM GENE THER, V14, P1139, DOI 10.1089/104303403322167984
   Transfiguracion J, 2011, J CHROMATOGR B, V879, P61, DOI 10.1016/j.jchromb.2010.11.011
   Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9
   Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261
   Valley-Omar Z, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-462
   Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001
   Yao QZ, 2003, VACCINE, V21, P638, DOI 10.1016/S0264-410X(02)00572-8
NR 59
TC 11
Z9 11
U1 0
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD OCT
PY 2013
VL 193
IS 1
BP 85
EP 95
DI 10.1016/j.jviromet.2013.05.010
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 204JR
UT WOS:000323362100013
PM 23707924
DA 2018-01-05
ER

PT J
AU Liu, BR
   Liou, JS
   Chen, YJ
   Huang, YW
   Lee, HJ
AF Liu, Betty Revon
   Liou, Ji-Sing
   Chen, Yung-Jen
   Huang, Yue-Wern
   Lee, Han-Jung
TI Delivery of Nucleic Acids, Proteins, and Nanoparticles by Arginine-Rich
   Cell-Penetrating Peptides in Rotifers
SO MARINE BIOTECHNOLOGY
LA English
DT Article
DE Cell-penetrating peptides (CPPs); Green fluorescent protein (GFP); MTT
   assay; Quantum dots (QDs); Red fluorescent protein (RFP); Transgenesis
ID HUMAN IMMUNODEFICIENCY VIRUS; INTRACELLULAR DELIVERY; PLANT-CELLS;
   QUANTUM DOTS; FLUORESCENT PROTEINS; RNA INTERFERENCE; GENE-TRANSFER;
   LIVING CELLS; TRANSDUCTION; EXPRESSION
AB Cell-penetrating peptides (CPPs) are a group of short, membrane-permeable cationic peptides that represent a nonviral technology for delivering nanomaterials and macromolecules into live cells. In this study, two arginine-rich CPPs, HR9 and IR9, were found to be capable of entering rotifers. CPPs were able to efficiently deliver noncovalently associated with cargoes, including plasmid DNAs, red fluorescent proteins (RFPs), and semiconductor quantum dots, into rotifers. The functional reporter gene assay demonstrated that HR9-delivered plasmid DNAs containing the enhanced green fluorescent protein and RFP coding sequences could be actively expressed in rotifers. The 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan assay further confirmed that CPP-mediated cargo delivery was not toxic to rotifers. Thus, these two CPPs hold a great potential for the delivery of exogenous genes, proteins, and nanoparticles in rotifers.
C1 [Liu, Betty Revon; Liou, Ji-Sing; Chen, Yung-Jen; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Shoufeng 97401, Hualien, Taiwan.
   [Huang, Yue-Wern] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, 1,Sec 2,Da Hsueh Rd, Shoufeng 97401, Hualien, Taiwan.
EM hjlee@mail.ndhu.edu.tw
FU National Science Council of Taiwan [NSC 101-2811-B-259-001,
   NSC101-2311-B-259-003-MY3]
FX We thank Roger Y. Tsien (University of California, San Diego, CA, USA)
   for provision of the mCherry plasmid, Goo-Young Kim and Hyangshuk Rhim
   (The Catholic University of Korea, Seoul, Korea) for the pCS2+ EGFP
   plasmid, Daniel Goldman (University of Michigan, Ann Arbor, MI, USA) for
   the pCS2+ DsRed plasmid, Chia-Wei Huang for the construction of the
   pCS2+ mCherry plasmid, Tze-Bin Chou (National Taiwan University, Taipei,
   Taiwan) and Core Instrument Center (National Health Research Institutes,
   Miaoli, Taiwan) for the Leica confocal systems, Institute of Cellular
   and Systems Medicine (National Health Research Institutes, Miaoli,
   Taiwan) for the Olympus microscope, and Robert S. Aronstam (Missouri
   University of Science and Technology, USA) for technical editing. This
   work was supported by Postdoctoral Fellowship NSC 101-2811-B-259-001 (to
   B. R. L.) and Grant Number NSC101-2311-B-259-003-MY3 (to H-J.L.) from
   the National Science Council of Taiwan.
CR Bolhassani A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-3
   Chang M, 2005, ELECTROPHORESIS, V26, P3062, DOI 10.1002/elps.200500041
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Dahms HU, 2011, AQUAT TOXICOL, V101, P1, DOI 10.1016/j.aquatox.2010.09.006
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005
   Feder D, 2009, PARASITOL RES, V106, P85, DOI 10.1007/s00436-009-1631-6
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Holbrook RD, 2008, NAT NANOTECHNOL, V3, P352, DOI 10.1038/nnano.2008.110
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Jo JI, 2008, EUR J PHARM BIOPHARM, V68, P90, DOI 10.1016/j.ejpb.2007.04.021
   Kim GY, 2011, BIOTECHNOL LETT, V33, P1319, DOI 10.1007/s10529-011-0589-5
   Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012
   Li JF, 2010, ANTICANCER RES, V30, P2193
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   LIU BR, 2013, ADV STUD BIOL, V5, P11
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   LIU MJ, 2013, ADV STUD BIOL, V5, P71
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mager I, 2012, BBA-BIOMEMBRANES, V1818, P502, DOI 10.1016/j.bbamem.2011.11.020
   May RC, 2005, METHOD ENZYMOL, V392, P308, DOI 10.1016/S0076-6879(04)92018-6                                                   
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487
   Oo AKS, 2010, J COMP PHYSIOL B, V180, P105, DOI 10.1007/s00360-009-0389-6
   Pfannkuchen M, 2009, INT J DEV BIOL, V53, P1113, DOI 10.1387/ijdb.072526mp
   Piedrahita JA, 2011, REPROD FERT DEVELOP, V23, P56, DOI 10.1071/RD10246
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037
   Shearer TL, 2007, HYDROBIOLOGIA, V593, P141, DOI 10.1007/s10750-007-9067-4
   Snell TW, 2011, MAR BIOTECHNOL, V13, P264, DOI 10.1007/s10126-010-9295-x
   Snell TW, 2011, ENVIRON TOXICOL, V26, P146, DOI 10.1002/tox.20538
   Snell TW, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-60
   Son SW, 2009, SKIN RES TECHNOL, V15, P157, DOI 10.1111/j.1600-0846.2008.00341.x
   Sosa MAG, 2010, BRAIN STRUCT FUNCT, V214, P91, DOI 10.1007/s00429-009-0230-8
   Stylianou P, 2009, MECH DEVELOP, V126, P828, DOI 10.1016/j.mod.2009.07.008
   Suhr ST, 2009, GENE EXPR PATTERNS, V9, P54, DOI 10.1016/j.gep.2008.07.002
   Swanson KS, 2004, EXP BIOL MED, V229, P866
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Yu WW, 2003, CHEM MATER, V15, P2854, DOI 10.1021/cm034081k
   Zhang Y, 2012, THERANOSTICS, V2, P631, DOI 10.7150/thno.4308
NR 58
TC 12
Z9 13
U1 3
U2 78
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1436-2228
EI 1436-2236
J9 MAR BIOTECHNOL
JI Mar. Biotechnol.
PD OCT
PY 2013
VL 15
IS 5
BP 584
EP 595
DI 10.1007/s10126-013-9509-0
PG 12
WC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
SC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
GA 200YN
UT WOS:000323107800008
PM 23715807
DA 2018-01-05
ER

PT J
AU Guo, YH
   Xu, P
   Hu, H
   Zhou, XD
   Hu, JM
AF Guo, Yahui
   Xu, Pei
   Hu, Hui
   Zhou, Xiaodong
   Hu, Jiming
TI A label-free biosensor for DNA detection based on ligand-responsive
   G-quadruplex formation
SO TALANTA
LA English
DT Article
DE Label-free; NMM; G-quadruplex; DNA detection
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; MOLECULAR BEACONS; COLORIMETRIC
   DETECTION; GOLD NANOPARTICLES; GRAPHENE OXIDE; HYBRIDIZATION; PROBES;
   OLIGONUCLEOTIDES; FLUORESCE; SEQUENCE
AB A facile and label-free assay with label-free molecular beacons (MBs) and fluorescent dye N-methyl mesoporphyrin IX (NMM) was developed for the detection of specific single-stranded DNA sequences. It was demonstrated by a reverse transcription oligonucleotide sequence (target DNA, 20 bases) of RNA fragment of human immunodeficiency virus (HIV) as model systems. In the absence of target DNA, the MBs were in the stem-closed form, the G-quadruplex structure could not form and the fluorescence signal of NMM was very low. In the presence of target DNA the MBs turned "Off" to "On", thus promoting the formation of G-quadruplex which could greatly enhance the fluorescence of NMM. This biosensor was simple in design, fast in operation, and more convenient and promising than other methods. It took less than 30 min to finish and its detection limit was 1.4 nM. No sophisticated experimental techniques or chemical modification for DNA sequences were required. This new approach could be widely applied to sensitive and selective nucleic acids detection. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Guo, Yahui; Xu, Pei; Hu, Hui; Zhou, Xiaodong; Hu, Jiming] Wuhan Univ, Coll Chem & Mol Sci, Minist Educ, Key Lab Analyt Chem Biol & Med, Wuhan 430072, Peoples R China.
RP Zhou, XD (reprint author), Wuhan Univ, Coll Chem & Mol Sci, Minist Educ, Key Lab Analyt Chem Biol & Med, Wuhan 430072, Peoples R China.
EM zhouxd@whu.edu.cn; jmhu@whu.edu.cn
RI zhou, xiaodong/J-6139-2016
FU National Natural Science Foundation of China [20805034, 30772058,
   20927003, 90913013]; State Key Laboratory of Electroanalytical Chemistry
FX The work was supported by the National Natural Science Foundation of
   China (Nos. 20805034, 30772058, 20927003, and 90913013) and the State
   Key Laboratory of Electroanalytical Chemistry.
CR Arthanari H, 1998, NUCLEIC ACIDS RES, V26, P3724, DOI 10.1093/nar/26.16.3724
   Bonnet G, 1998, P NATL ACAD SCI USA, V95, P8602, DOI 10.1073/pnas.95.15.8602                                                         
   Broude NE, 2002, TRENDS BIOTECHNOL, V20, P249, DOI 10.1016/S0167-7799(02)01942-X
   Eun AJC, 2000, PHYTOPATHOLOGY, V90, P269, DOI 10.1094/PHYTO.2000.90.3.269
   Fan JB, 2006, NAT REV GENET, V7, P632, DOI 10.1038/nrg1901
   Fang XH, 1999, J AM CHEM SOC, V121, P2921, DOI 10.1021/ja9837809                                                               
   Guo LQ, 2012, BIOSENS BIOELECTRON, V35, P123, DOI 10.1016/j.bios.2012.02.031
   Hacia JG, 1999, NAT GENET, V22, P164
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Hu D, 2011, CHEM-EUR J, V17, P1635, DOI 10.1002/chem.201001331
   Li HL, 2013, BIOSENS BIOELECTRON, V41, P563, DOI 10.1016/j.bios.2012.09.024
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li W, 2002, FEBS LETT, V526, P77, DOI 10.1016/S0014-5793(02)03118-6
   Liu YZ, 2012, CHEM COMMUN, V48, P3164, DOI 10.1039/c2cc16741g
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Luo M, 2012, CHEM COMMUN, V48, P1126, DOI 10.1039/c2cc16868e
   Ren JT, 2011, ANAL BIOANAL CHEM, V399, P2763, DOI 10.1007/s00216-011-4669-0
   Ren JS, 1999, BIOCHEMISTRY-US, V38, P16067, DOI 10.1021/bi992070s
   Sokol DL, 1998, P NATL ACAD SCI USA, V95, P11538, DOI 10.1073/pnas.95.20.11538                                                        
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Turner EH, 2009, ANNU REV GENOM HUM G, V10, P263, DOI 10.1146/annurev-genom-082908-150112
   Tyagi S, 2000, NAT BIOTECHNOL, V18, P1191, DOI 10.1038/81192
   Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303
   Vallee-Belisle A, 2009, P NATL ACAD SCI USA, V106, P13802, DOI 10.1073/pnas.0904005106
   WILLIAMSON JR, 1993, CURR OPIN STRUC BIOL, V3, P357, DOI 10.1016/S0959-440X(05)80106-X
   Xiang DS, 2011, BIOSENS BIOELECTRON, V26, P4405, DOI 10.1016/j.bios.2011.04.051
   Xiao Y, 2009, ANGEW CHEM INT EDIT, V48, P4354, DOI 10.1002/anie.200900369
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   Zhang J, 2010, SMALL, V6, P201, DOI 10.1002/smll.200901012
   Zhang ZX, 2012, ANAL CHEM, V84, P4789, DOI 10.1021/ac300348v
   Zhao CQ, 2011, CHEM COMMUN, V47, P5461, DOI 10.1039/c1cc11396h
   Zhou J, 2012, TALANTA, V99, P625, DOI 10.1016/j.talanta.2012.06.049
   Zhou ZX, 2012, BIOSENS BIOELECTRON, V34, P100, DOI 10.1016/j.bios.2012.01.024
NR 34
TC 17
Z9 18
U1 5
U2 119
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD SEP 30
PY 2013
VL 114
BP 138
EP 142
DI 10.1016/j.talanta.2013.04.003
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 212WJ
UT WOS:000324013200022
PM 23953453
DA 2018-01-05
ER

PT J
AU Vanic, Z
   Skalko-Basnet, N
AF Vanic, Zeljka
   Skalko-Basnet, Natasa
TI Nanopharmaceuticals for improved topical vaginal therapy: Can they
   deliver?
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Review
DE Vagina; Mucosa; Topical therapy; Nanomedicine; Drug delivery
ID IN-VITRO EVALUATION; SOLID LIPID NANOPARTICLES; DRUG-DELIVERY; SPL7013
   GEL; HIV PREVENTION; POLYMERIC NANOPARTICLES; RHEOLOGICAL PROPERTIES;
   INTRAVAGINAL DELIVERY; SILVER NANOPARTICLES; PAMAM DENDRIMERS
AB Nanopharmaceuticals have the potential to revolutionise medical treatment by permitting the design of more potent, less toxic "smart" therapeutics, ultimately leading to personalised medicine. This review summarises the challenges and potential uses of nanodelivery system for the topical drug therapy of vaginal diseases. The vaginal route of drug administration remains a challenge in the development of novel drug therapies, including nanomedicines. We attempted to provide an unbiased overview of currently investigated nanodelivery systems, some of which remain to be extensively studied under laboratory conditions, and some of which are already in clinical trials. Most nanodelivery systems are aimed at improving the treatment of vaginal infections, including HIV prevention. Promising new approaches in nanopharmaceutical design are discussed in this review, as well as the controversies related to mucoadhesiveness of nanopharmaceuticals. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Vanic, Zeljka] Univ Zagreb, Fac Pharm & Biochem, Dept Pharmaceut, Zagreb 10000, Croatia.
   [Skalko-Basnet, Natasa] Univ Tromso, Fac Hlth Sci, Dept Pharm, Drug Transport & Delivery Res Grp, N-9037 Tromso, Norway.
RP Skalko-Basnet, N (reprint author), Univ Tromso, Fac Hlth Sci, Dept Pharm, Drug Transport & Delivery Res Grp, Univ Veien 57, N-9037 Tromso, Norway.
EM zeljka.vanic@pharma.hr; natasa.skalko-basnet@uit.no
RI Skalko-Basnet, Natasa/A-4117-2012
OI Skalko-Basnet, Natasa/0000-0002-4301-2840
FU Ministry of Science, Education and Sports of the Republic of Croatia
   [006-0061117-1244]; Phospholipid Research Center, Heidelberg, Germany;
   Norwegian Women's Public Health Association
FX The authors would like to thank all of their co-authors for contributing
   to the authors' publications related to vaginal drug therapy. The
   continuing support by Lipoid (Ludwigshafen, Germany) in providing free
   lipids is greatly appreciated. Z. Vanic acknowledges Grant
   006-0061117-1244 from the Ministry of Science, Education and Sports of
   the Republic of Croatia, and N. Skalko-Basnet Phospholipid Research
   Center, Heidelberg, Germany and the Norwegian Women's Public Health
   Association for supporting her research on vaginal drug therapy.
CR Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Andrews GP, 2009, BIOMACROMOLECULES, V10, P2427, DOI 10.1021/bm9003332
   Bachhav YG, 2009, AAPS PHARMSCITECH, V10, P476, DOI 10.1208/s12249-009-9233-2
   Basnet P, 2012, J PHARM SCI-US, V101, P598, DOI 10.1002/jps.22785
   Berginc K, 2012, AAPS PHARMSCITECH, V13, P1045, DOI 10.1208/s12249-012-9837-9
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Bilensoy E, 2006, AAPS PHARMSCITECH, V7
   Borges A. Rosa, 2005, Current Drug Targets - Infectious Disorders, V5, P247, DOI 10.2174/1568005054880127
   Boulmedarat L, 2003, INT J PHARM, V254, P59, DOI 10.1016/S0378-5173(02)00683-X
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Calabretta MK, 2007, BIOMACROMOLECULES, V8, P1807, DOI 10.1021/bm0701088
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Chen DQ, 2012, INT J NANOMED, V7, P2621, DOI 10.2147/IJN.S31757
   Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6
   Cheng YY, 2007, EUR J MED CHEM, V42, P1032, DOI 10.1016/j.ejmech.2006.12.035
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Cristofaro P, 2006, NAT BIOTECHNOL, V24, P48, DOI 10.1038/nbt0106-48                                                              
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   D'Cruz OJ, 2005, AAPS PHARMSCITECH, V6
   D'Cruz OJ, 2001, CONTRACEPTION, V64, P113, DOI 10.1016/S0010-7824(01)00233-5
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, EXPERT OPIN DRUG DEL, V8, P1085, DOI 10.1517/17425247.2011.586334
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Desai N, 2012, AAPS J, V14, P282, DOI 10.1208/s12248-012-9339-4
   Dittgen M, 1997, STP PHARMA SCI, V7, P403
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Elsaesser A, 2012, ADV DRUG DELIVER REV, V64, P129, DOI 10.1016/j.addr.2011.09.001
   Elsayed MMA, 2007, INT J PHARM, V332, P1, DOI 10.1016/j.ijpharm.2006.12.005
   Ensign LM, 2012, ADV MATER, V24, P3887, DOI 10.1002/adma.201201800
   Ensign U.M., 2012, SCI TRANSL MED, V138
   Ferguson LM, 2011, THER DELIV, V2, P1535, DOI [10.4155/tde.11.126, 10.4155/TDE.11.126]
   Foldvari M., 1997, Journal of Liposome Research, V7, P115, DOI 10.3109/08982109709035489
   Foldvari M, 1996, J MICROENCAPSUL, V13, P589, DOI 10.3109/02652049609026043                                                       
   Francois M, 2003, AAPS PHARMSCI, V5
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gupta PN, 2012, EUR J PHARM SCI, V46, P315, DOI 10.1016/j.ejps.2012.02.003
   Gupta Sonal, 2011, Recent Pat Drug Deliv Formul, V5, P82
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hubert P, 2004, ANTIMICROB AGENTS CH, V48, P4342, DOI 10.1128/AAC-48.11.4342-4348.2004
   Jain SK, 1997, DRUG DEV IND PHARM, V23, P827, DOI 10.3109/03639049709150553                                                       
   Janiszewska J, 2012, BIOORG MED CHEM LETT, V22, P1388, DOI 10.1016/j.bmcl.2011.12.051
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Kang JW, 2010, J DRUG TARGET, V18, P637, DOI 10.3109/10611861003649712
   Kim YT, 2010, EUR J PHARM SCI, V41, P399, DOI 10.1016/j.ejps.2010.07.009
   Kish-Catalone T, 2007, AIDS RES HUM RETROV, V23, P33, DOI 10.1089/aid.2006.0076
   Kish-Catalone TM, 2006, ANTIMICROB AGENTS CH, V50, P1497, DOI 10.1128/AAC.50.4.1497-1509.2006
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lembo David, 2010, Antiviral Chemistry & Chemotherapy, V21, P53, DOI 10.3851/IMP1684
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Luganini A, 2011, ANTIMICROB AGENTS CH, V55, P3231, DOI 10.1128/AAC.00149-11
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGill SL, 2010, MOL PHARMACEUT, V7, P2280, DOI 10.1021/mp100242r
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Menjoge AR, 2011, J CONTROL RELEASE, V150, P326, DOI 10.1016/j.jconrel.2010.11.023
   Menjoge AR, 2010, BIOMATERIALS, V31, P5007, DOI 10.1016/j.biomaterials.2010.02.075
   Mohanraj VJ, 2007, TROP J PHARM RES, V5, P561, DOI DOI 10.4314/TJPR.V5I1.14634
   Mourtas S, 2008, J COLLOID INTERF SCI, V317, P611, DOI 10.1016/j.jcis.2007.09.070
   Mourtas S, 2010, NANO LIFE, V1, P195, DOI 10.1142/S1793984410000225
   Mumper RJ, 2009, DRUG DEV IND PHARM, V35, P515, DOI 10.1080/03639040802488097
   Navath RS, 2011, MOL PHARMACEUT, V8, P1209, DOI 10.1021/mp200027z
   Ning MY, 2005, DRUG DEV IND PHARM, V31, P375, DOI 10.1081/DDC-200054315
   Ning MY, 2005, CHEM PHARM BULL, V53, P620, DOI 10.1248/cpb.53.620
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Omar R.F., 2011, J INFECT DIS, V15, P3656
   Patel G.M., 2011, AM J PHARMTECH RES, V1, P366
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Pavelic Z, 2005, INT J PHARM, V301, P140, DOI 10.1016/j.ijpharm.2005.05.022
   Pavelic Z, 2005, J CONTROL RELEASE, V106, P34, DOI 10.1016/j.jconrel.2005.03.032
   Pavelic Z, 2004, METHOD ENZYMOL, V387, P287
   Pavelic Z, 2001, INT J PHARM, V219, P139, DOI 10.1016/S0378-5173(01)00637-8
   Pavelic Z, 1999, EUR J PHARM SCI, V8, P345, DOI 10.1016/S0928-0987(99)00033-0
   Pavelic Zeljka, 2004, Acta Pharmaceutica (Zagreb), V54, P319
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1675, DOI 10.1016/j.addr.2004.03.001
   Peschka R, 1998, J CONTROL RELEASE, V56, P41, DOI 10.1016/S0168-3659(98)00067-4                                                   
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Robinson J.R., 1994, J CONTROL RELEASE, V42, P133
   Rojo J., 2007, Anti-Infective Agents in Medicinal Chemistry, V6, P151
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sankhyan A., 2012, J APPL PHARM SCI, V2, P20
   Sassi AB, 2008, J PHARM SCI-US, V97, P3123, DOI 10.1002/jps.21192
   Singh A., 2011, ADV BIOL RES, V5, P184
   Skalko N, 1998, J LIPOSOME RES, V8, P283, DOI 10.3109/08982109809035532                                                       
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tulu M, 2009, EUR J MED CHEM, V44, P1093, DOI 10.1016/j.ejmech.2009.06.016
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Vanic Z, 2013, DRUG DEV IND PHARM, V39, P481, DOI 10.3109/03639045.2012.670247
   Wang B, 2010, INT J PHARMACEUT, V395, P298, DOI 10.1016/j.ijpharm.2010.05.030
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Wang YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021547
   Wei-Ze L, 2012, EUR J PHARM SCI, V47, P162, DOI 10.1016/j.ejps.2012.06.001
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yu T, 2012, DRUG DELIV TRANSL RE, V2, P124, DOI 10.1007/s13346-011-0048-9
   Yu T, 2011, EXPERT OPIN DRUG DEL, V8, P1309, DOI 10.1517/17425247.2011.600119
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
NR 118
TC 29
Z9 29
U1 5
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD SEP 27
PY 2013
VL 50
IS 1
SI SI
BP 29
EP 41
DI 10.1016/j.ejps.2013.04.035
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 204VU
UT WOS:000323400200005
PM 23684936
DA 2018-01-05
ER

PT J
AU Ahmed, L
   Rasulev, B
   Turabekova, M
   Leszczynska, D
   Leszczynski, J
AF Ahmed, Lucky
   Rasulev, Bakhtiyor
   Turabekova, Malakhat
   Leszczynska, Danuta
   Leszczynski, Jerzy
TI Receptor- and ligand-based study of fullerene analogues: comprehensive
   computational approach including quantum-chemical, QSAR and molecular
   docking simulations
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID HIV-1 PR INHIBITORS; ELECTROTOPOLOGICAL STATE INDEXES; OPTIMAL
   DESCRIPTORS; STRUCTURE/RESPONSE CORRELATIONS; SIMILARITY/DIVERSITY
   ANALYSIS; GETAWAY DESCRIPTORS; ORGANIC-COMPOUNDS; OXIDATIVE STRESS; C-60
   SOLUBILITY; CARBON NANOTUBE
AB Fullerene and its derivatives have potential antiviral activity due to their specific binding interactions with biological molecules. In this study fullerene derivatives were investigated by the synergic combination of three approaches: quantum-mechanical calculations, protein-ligand docking and quantitative structure-activity relationship methods. The protein-ligand docking studies and improved structure-activity models have been able both to predict binding affinities for the set of fullerene-C-60 derivatives and to help in finding mechanisms of fullerene derivative interactions with human immunodeficiency virus type 1 aspartic protease, HIV-1 PR. Protein-ligand docking revealed several important molecular fragments that are responsible for the interaction with HIV-1 PR. In addition, a density functional theory method has been utilized to identify the optimal geometries and predict physico-chemical parameters of the studied compounds. The 5-variable GA-MLRA based model showed the best predictive ability (r(training)(2) = 0.882 and r(test)(2) = 0.738), with high internal and external correlation coefficients.
C1 [Ahmed, Lucky; Rasulev, Bakhtiyor; Turabekova, Malakhat; Leszczynski, Jerzy] Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Ctr Nanotox, Jackson, MS 39217 USA.
   [Turabekova, Malakhat; Leszczynska, Danuta] Jackson State Univ, Dept Civil & Environm Engn, Jackson, MS 39217 USA.
RP Rasulev, B (reprint author), Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Ctr Nanotox, 1400 JR Lynch St,POB 17910, Jackson, MS 39217 USA.
EM rasulev@icnanotox.org
RI Rasulev, Bakhtiyor/A-3030-2008
OI Rasulev, Bakhtiyor/0000-0002-7845-4884
FU National Science Foundation [OCI-1053575]; NSF CREST Interdisciplinary
   Nanotoxicity Center [HRD-0833178]; NSF-EPSCoR
   [362492-190200-01\NSFEPS-0903787]; NSF RISE program [HRD-1137763];
   Extreme Science and Engineering Discovery Environment (XSEDE) award
   [DMR110088]
FX The authors thank the National Science Foundation for support from the
   NSF CREST Interdisciplinary Nanotoxicity Center - grant #HRD-0833178;
   NSF-EPSCoR Award #362492-190200-01\NSFEPS-0903787; and the NSF RISE
   program NSF-RISE #HRD-1137763. This research was also supported in part
   by the National Science Foundation grant number OCI-1053575 and by the
   Extreme Science and Engineering Discovery Environment (XSEDE) award
   allocation number DMR110088. The authors are grateful to the Mississippi
   Center for Supercomputing Research (MCSR) for providing state-of-the-art
   high performance computing facilities and excellent services for
   supporting this research.
CR Babakhani A, 2009, COMPUT BIOL CHEM, V33, P160, DOI 10.1016/j.compbiolchem.2008.12.002
   Balamurugan K, 2010, J PHYS CHEM B, V114, P14048, DOI 10.1021/jp106177n
   Banerjee S., 2013, J CHEM PHYS, V138
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Benyamini H, 2006, BIOCONJUGATE CHEM, V17, P378, DOI 10.1021/bc050299g
   BINGEL C, 1993, CHEM BER-RECL, V126, P1957, DOI 10.1002/cber.19931260829                                                        
   Bortolus M, 2011, LANGMUIR, V27, P12560, DOI 10.1021/la202524r
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Cao HY, 2009, J LOSS PREVENT PROC, V22, P222, DOI 10.1016/j.jlp.2009.01.002
   Cao Z., 2008, J PHYS CHEM C, V113, P3096
   Chen T, 2011, J APPL TOXICOL, V31, P255, DOI 10.1002/jat.1588
   Chen YW, 2004, AM J PHYSIOL-REG I, V287, pR21, DOI 10.1152/ajpregu.00310.2003
   Consonni V, 2002, J CHEM INF COMP SCI, V42, P693, DOI 10.1021/ci0155053
   Consonni V, 2002, J CHEM INF COMP SCI, V42, P682, DOI 10.1021/ci015504a
   Cook SM, 2010, J HAZARD MATER, V176, P367, DOI 10.1016/j.jhazmat.2009.11.039
   Davis L., 1991, HDB GENETIC ALGORITH
   Gaudio C., 2000, QUANT STRUCT-ACT REL, V19, P599, DOI DOI 10.1002/1521-3838(200012)19:6<599::AID-QSAR599>3.0.C0;2-B
   Devillers J, 1996, GENETIC ALGORITHMS M
   Dinadayalane T.C., 2012, HDB COMPUTATIONAL CH, P793
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Echegoyen L, 1998, ACCOUNTS CHEM RES, V31, P593, DOI 10.1021/ar970138v                                                               
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   GANAPATHI PS, 1995, J ORG CHEM, V60, P2954, DOI 10.1021/jo00115a002                                                             
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Gianese G, 2009, J PHYS CHEM B, V113, P12105, DOI 10.1021/jp903652v
   Giust D, 2011, CHEM COMMUN, V47, P10617, DOI 10.1039/c1cc13971a
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1                                                   
   Guldi DM, 2000, ACCOUNTS CHEM RES, V33, P695, DOI 10.1021/ar990144m
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hemmer MC, 1999, VIB SPECTROSC, V19, P151, DOI 10.1016/S0924-2031(99)00014-4                                                   
   Higashi N, 1997, CHEM COMMUN, P1507, DOI 10.1039/a701265i                                                                
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   Huuskonen J, 2003, CHEMOSPHERE, V50, P949, DOI 10.1016/S0045-6535(02)00172-8                                                   
   Huuskonen J, 2000, J CHEM INF COMP SCI, V40, P773, DOI 10.1021/ci9901338                                                               
   Huuskonen JJ, 2000, J CHEM INF COMP SCI, V40, P947, DOI 10.1021/ci9904261
   [Anonymous], HYPERCHEM TM, P32601
   Isayev O, 2006, MOL DIVERS, V10, P233, DOI 10.1007/s11030-005-9002-4
   Isobe H, 2006, CHEM-ASIAN J, V1, P167, DOI 10.1002/asia.200600051
   Klein CT, 2004, J CHEM INF COMP SCI, V44, P200, DOI 10.1021/ci0256236
   Kotelnikova RA, 2003, J NANOPART RES, V5, P561, DOI 10.1023/B:NAN0.0000006070.61144.93
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Labute P, 2000, J MOL GRAPH MODEL, V18, P464, DOI 10.1016/S1093-3263(00)00068-1
   Lin AMY, 1999, J NEUROCHEM, V72, P1634, DOI 10.1046/j.1471-4159.1999.721634.x
   Lin AMY, 2002, NEUROSCI RES, V43, P317, DOI 10.1016/S0168-0102(02)00056-1
   Liu FP, 2011, INT J MOL SCI, V12, P2448, DOI 10.3390/ijms12042448
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Mercader AG, 2010, EUR J MED CHEM, V45, P1724, DOI 10.1016/j.ejmech.2010.01.005
   Michielan L, 2008, BIOORGAN MED CHEM, V16, P5733, DOI 10.1016/j.bmc.2008.03.064
   Mitra I, 2010, MOL SIMULAT, V36, P1067, DOI 10.1080/08927022.2010.503326
   Park KH, 2003, J BIOL CHEM, V278, P50212, DOI 10.1074/jbc.M310216200
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   Puzyn T., 2010, RECENT ADV QSAR STUD
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Puzyn T, 2009, SMALL, V5, P2494, DOI 10.1002/smll.200900179
   Rassolov VA, 2001, J COMPUT CHEM, V22, P976, DOI 10.1002/jcc.1058.abs
   Rasulev BF, 2005, QSAR COMB SCI, V24, P1056, DOI 10.1002/qsar.200430013
   Roy K, 2013, J COMPUT CHEM, V34, P1071, DOI 10.1002/jcc.23231
   Roy PP, 2008, QSAR COMB SCI, V27, P302, DOI 10.1002/qsar.200710043
   Rupp M, 2009, J COMPUT CHEM, V30, P2285, DOI 10.1002/jcc.21218
   Ryman-Rasmussen JP, 2006, TOXICOL SCI, V91, P159, DOI 10.1093/toxsci/kfj122
   Saiz-Urra L, 2007, BIOORGAN MED CHEM, V15, P3565, DOI 10.1016/j.bmc.2007.02.032
   Schneider G, 1999, ANGEW CHEM INT EDIT, V38, P2894, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2894::AID-ANIE2894>3.3.CO;2-6
   [Anonymous], 2012, MAESTR VERS 9 3
   Schuster DI, 1996, BIOORG MED CHEM LETT, V6, P1253, DOI 10.1016/0960-894X(96)00210-7
   Service RF, 2004, SCIENCE, V304, P1732, DOI 10.1126/science.304.5678.1732                                                   
   Sharma SK, 2011, NANOMEDICINE-UK, V6, P1813, DOI [10.2217/NNM.11.144, 10.2217/nnm.11.144]
   Shenderova OA, 2002, CRIT REV SOLID STATE, V27, P227, DOI 10.1080/10408430208500497                                                       
   Shi BY, 2013, J PHYS CHEM B, V117, P3541, DOI 10.1021/jp312423y
   Shukla MK, 2009, CHEM PHYS LETT, V469, P207, DOI 10.1016/j.cplett.2008.12.092
   Shukla MK, 2010, CHEM PHYS LETT, V493, P130, DOI 10.1016/j.cplett.2010.05.032
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   Sitharaman B, 2008, MOL PHARMACEUT, V5, P567, DOI 10.1021/mp700106w
   Tkach AV, 2013, SMALL, V9, P1686, DOI 10.1002/smll.201201546
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   Tong J, 2011, BIOMATERIALS, V32, P3654, DOI 10.1016/j.biomaterials.2011.01.068
   Toropov AA, 2008, CHEM PHYS LETT, V457, P332, DOI 10.1016/j.cplett.2008.04.013
   Toropov AA, 2007, CHEM PHYS LETT, V444, P209, DOI 10.1016/j.cplett.2007.07.024
   Toropov AA, 2010, EUR J MED CHEM, V45, P1387, DOI 10.1016/j.ejmech.2009.12.037
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turabekova MA, 2010, EUR J MED CHEM, V45, P3885, DOI 10.1016/j.ejmech.2010.05.042
   Wolff DJ, 2002, ARCH BIOCHEM BIOPHYS, V399, P130, DOI 10.1006/abbi.2002.2766
   Xiao L, 2006, BIOORG MED CHEM LETT, V16, P1590, DOI 10.1016/j.bmcl.2005.12.011
   Xu X, 2012, SOFT MATTER, V8, P2915, DOI 10.1039/c2sm06811g
   Yang Z., 2012, J CHEM PHYS, V136, P025103
   Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
   Zuo GH, 2010, ACS NANO, V4, P7508, DOI 10.1021/nn101762b
   [Anonymous], 2011, DRAGON SOFTWARE MOL
NR 97
TC 21
Z9 21
U1 0
U2 42
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PD SEP 21
PY 2013
VL 11
IS 35
BP 5798
EP 5808
DI 10.1039/c3ob40878g
PG 11
WC Chemistry, Organic
SC Chemistry
GA 210WS
UT WOS:000323866400006
PM 23900343
DA 2018-01-05
ER

PT J
AU Ham, AS
   Lustig, W
   Yang, L
   Boczar, A
   Buckheit, KW
   Buckheit, RW
AF Ham, Anthony S.
   Lustig, William
   Yang, Lu
   Boczar, Ashlee
   Buckheit, Karen W.
   Buckheit, Robert W., Jr.
TI In Vitro and Ex Vivo Evaluations on Transdermal Delivery of the HIV
   Inhibitor IQP-0410
SO PLOS ONE
LA English
DT Article
ID CONTROLLED DRUG-DELIVERY; SOCIETY-USA PANEL; PLGA NANOPARTICLES; RELEASE
   PROFILES; SKIN PERMEATION; AIDS; RECOMMENDATIONS; MODULATION;
   ZIDOVUDINE; DIFFUSION
AB The aim of this study was to investigate the physicochemical and in vitro/ex vivo characteristics of the pyrmidinedione IQP-0410 formulated into transdermal films. IQP-0410 is a potent therapeutic anti-HIV nonnucleoside reverse transcriptase inhibitor that would be subjected to extensive first pass metabolism, through conventional oral administration. Therefore, IQP-0410 was formulated into ethyl cellulose/HPMC-based transdermal films via solvent casting. In mano evaluations were performed to evaluate gross physical characteristics. In vitro release studies were performed in both Franz cells and USP-4 dissolution vessels. Ex vivo release and permeability assays were performed on human epidermal tissue models, and the permeated IQP-0410 was collected for in vitro HIV-1 efficacy assays in CEM-SS cells and PBMCs. Film formulation D3 resulted in pliable, strong transdermal films that were loaded with 2% (w/w) IQP-0410. Composed of 60% (w/w) ethyl cellulose and 20% (w/w) HPMC, the films contained < 1.2% (w/w) of water and were hygroscopic resulting in significant swelling under humid conditions. The water permeable nature of the film resulted in complete in vitro dissolution and drug release in 26 hours. When applied to ex vivo epidermal tissues, the films were non-toxic to the tissue and also were non-toxic to HIV target cells used in the in vitro efficacy assays. Over a 3 day application, the films delivered IQP-0410 through the skin tissue at a zero-order rate of 0.94 +/- 0.06 mu g/cm(2)/hr with 134 +/- 14.7 mu M collected in the basal media. The delivered IQP-0410 resulted in in vitro EC50 values against HIV-1 of 2.56 +/- 0.40 nM (CEM-SS) and 0.58 +/- 0.03 nM (PBMC). The film formulation demonstrated no significant deviation from target values when packaged in foil pouches under standard and accelerated environmental conditions. It was concluded that the transdermal film formulation was a potentially viable method of administering IQP-0410 that warrants further development.
C1 [Ham, Anthony S.; Lustig, William; Yang, Lu; Boczar, Ashlee; Buckheit, Karen W.; Buckheit, Robert W., Jr.] ImQuest BioSci Inc, Frederick, MD USA.
RP Ham, AS (reprint author), ImQuest BioSci Inc, Frederick, MD USA.
EM aham@imquestbio.com
FU National Institutes of Health [NIH R43AI089331]
FX This research was supported by the National Institutes of Health (NIH
   R43AI089331). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BABAR A, 1992, DRUG DEV IND PHARM, V18, P1823, DOI 10.3109/03639049209040905                                                       
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   Buckheit RW, 2001, ANTIMICROB AGENTS CH, V45, P393, DOI 10.1128/AAC.45.2.393-400.2001
   Budhian A, 2008, INT J PHARM, V346, P151, DOI 10.1016/j.ijpharm.2007.06.01
   CANNON CL, 1994, TOXICOL IN VITRO, V8, P889, DOI 10.1016/0887-2333(94)90095-7
   Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381                                                          
   Chien Y. W., 1987, CONTROLLED DRUG DELI, P524
   Cleary GW, 1984, TRANSDERMAL CONTROLL, V1, P203
   Cleary G.W., 1984, MED APPLICATIONS CON, V1, P203
   Costa P, 2003, DRUG DEV IND PHARM, V29, P89, DOI 10.1081/DDC-120016687
   Feng SS, 2008, BIOMATERIALS, V29, P4146
   KEITH AD, 1983, DRUG DEV IND PHARM, V9, P605, DOI 10.3109/03639048309044695                                                       
   Kim DD, 1996, J PHARM SCI, V85, P214, DOI 10.1021/js950141c
   Kuksal A, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070101                                                                
   Kydonieus A., 1987, CONTROLLED RELEASE T
   Lewi Paul, 2004, Drugs R D, V5, P245, DOI 10.2165/00126839-200405050-00001
   Li YP, 2001, J CONTROL RELEASE, V71, P203, DOI 10.1016/S0168-3659(01)00218-8
   Mahalingam A, 2011, ANTIMICROB AGENTS CH, V55, P1650, DOI 10.1128/AAC.01368-10
   Mirsa A, 1997, TRANSDERMAL DRUG DEL, P100
   Mukherjee B, 2005, EUR J PHARM BIOPHARM, V59, P475, DOI 10.1016/j.ejpb.2004.09.009
   NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283
   Oh SY, 1998, J CONTROL RELEASE, V51, P161, DOI 10.1016/S0168-3659(97)00162-4                                                   
   Padula C, 2007, EUR J PHARM BIOPHARM, V66, P422, DOI 10.1016/j.ejpb.2006.11.014
   Paudel KS, 2010, THER DELIV, V1, P109, DOI 10.4155/TDE.10.16
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Richman DD, 1996, SCIENCE, V272, P1886, DOI 10.1126/science.272.5270.1886
   Sassi AB, 2004, J PHARM SCI-US, V93, P2009, DOI 10.1002/jps.20107
   Scheindlin S, 2004, MOL INTERV, V4, P308, DOI 10.1124/mi.4.6.1
   Siepmann J, 1999, PHARMACEUT RES, V16, P1748, DOI 10.1023/A:1018914301328
   Siepmann J, 1999, J CONTROL RELEASE, V60, P379, DOI 10.1016/S0168-3659(99)00093-0
   Singh A, 2006, J IRAN CHEM SOC, V3, P220
   Trabattoni D, 2002, CLIN DIAGN LAB IMMUN, V9, P1114, DOI 10.1128/CDLI.9.5.1114-1118.2002
   UNAIDS/WHO, 2007, IDS EP
   Watson Buckheit Karen, 2011, Antimicrob Agents Chemother, V55, P5243, DOI 10.1128/AAC.05237-11
   Watson KM, 2008, ANTIMICROB AGENTS CH, V52, P2787, DOI 10.1128/AAC.01657-07
   Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251
   Zorbist R, 2003, PHARM RES, V20, P103, DOI [10.1023/A:1022259011052, DOI 10.1023/A:1022259011052.PUBMED:12608543]
NR 37
TC 5
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2013
VL 8
IS 9
AR e75306
DI 10.1371/journal.pone.0075306
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 221YD
UT WOS:000324695900105
PM 24058672
OA gold
DA 2018-01-05
ER

PT J
AU Bollini, M
   Cisneros, JA
   Spasov, KA
   Anderson, KS
   Jorgensen, WL
AF Bollini, Mariela
   Cisneros, Jose A.
   Spasov, Krasimir A.
   Anderson, Karen S.
   Jorgensen, William L.
TI Optimization of diarylazines as anti-HIV agents with dramatically
   enhanced solubility
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Anti-HIV agent; NNRTI; Drug solubility
ID REVERSE-TRANSCRIPTASE INHIBITORS; BIOMOLECULAR SYSTEMS; DRUG; DISCOVERY;
   INFECTION; POTENT; RILPIVIRINE; ETRAVIRINE; ANALOGS; SEARCH
AB Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity. The solubility enhancements come from strategic placement of a morpholinylalkoxy substituent in the entrance channel of the NNRTI binding site. Compound 4d shows low-nanomolar activity similar to etravirine towards wild-type HIV-1 and key viral variants. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Bollini, Mariela; Cisneros, Jose A.; Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [Spasov, Krasimir A.; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.
EM karen.anderson@yale.edu; william.jorgensen@yale.edu
FU National Institutes of Health [AI44616, GM32136, GM49551]
FX Gratitude is expressed to the National Institutes of Health (AI44616,
   GM32136, GM49551) for research support. Receipt of reagents through the
   NIH AIDS Research and Reference Reagent Program, Division of AIDS,
   NIAID, NIH is also greatly appreciated.
CR Baka E, 2008, J PHARMACEUT BIOMED, V46, P335, DOI 10.1016/j.jpba.2007.10.030
   Bollini M., 2013, BIOORG MED CHEM LETT, V23
   Bollini M, 2011, J MED CHEM, V54, P8582, DOI 10.1021/jm201134m
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Ekkati AR, 2012, BIOORG MED CHEM LETT, V22, P1565, DOI 10.1016/j.bmcl.2011.12.132
   Frenkel YV, 2005, J MED CHEM, V48, P1974, DOI 10.1021/jm049439i
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Jorgensen WL, 2005, P NATL ACAD SCI USA, V102, P6665, DOI 10.1073/pnas.0408037102
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Lyseng-Williamson KA, 2012, CLIN DRUG INVEST, V32, P715, DOI 10.2165/11209870-000000000-00000
   Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7
   MORELOCK MM, 1994, J PHARM SCI, V83, P948, DOI 10.1002/jps.2600830706
   Permpalung N, 2012, EXPERT OPIN PHARMACO, V13, P2301, DOI 10.1517/14656566.2012.729040
   Prajapati DG, 2009, BIOORGAN MED CHEM, V17, P5744, DOI 10.1016/j.bmc.2009.06.060
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Sun LQ, 2012, BIOORG MED CHEM LETT, V22, P2376, DOI 10.1016/j.bmcl.2012.02.055
   Weuts I, 2011, J PHARM SCI-US, V100, P260, DOI 10.1002/jps.22242
   Yang Y., 2008, AAPS J, V10, P606
NR 24
TC 15
Z9 16
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 15
PY 2013
VL 23
IS 18
BP 5213
EP 5216
DI 10.1016/j.bmcl.2013.06.091
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 210AN
UT WOS:000323801800036
PM 23937980
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dordovic, V
   Uchman, M
   Prochazka, K
   Zhigunov, A
   Plestil, J
   Nykanen, A
   Ruokolainen, J
   Matejicek, P
AF Dordovic, Vladimir
   Uchman, Mariusz
   Prochazka, Karel
   Zhigunov, Alexander
   Plestil, Josef
   Nykanen, Antti
   Ruokolainen, Janne
   Matejicek, Pavel
TI Hybrid Nanospheres Formed by Intermixed Double-Hydrophilic Block
   Copolymer Poly(ethylene oxide)-block-poly(2-ethyloxazoline) with High
   Content of Metallacarboranes
SO MACROMOLECULES
LA English
DT Article
ID NEUTRON-CAPTURE THERAPY; AQUEOUS-SOLUTIONS; LIGHT-SCATTERING; HIV
   PROTEASE; TITRATION CALORIMETRY; COORDINATING ANIONS; BORON CLUSTERS;
   ACID) MICELLES; OXIDE); PHARMACOPHORES
AB In search for biocompatible hydrophilic polymers suitable for preparation of delivery systems of boron cluster compounds with high loading capacity, we studied the interaction of metallacarborane sodium [3-cobalt(III) bis(1,2-dicarbollide)] with poly(2-ethyloxazoline) (PEOX) and with a double-hydrophilic block copolymer poly(ethylene oxide)-block-poly(2-ethyloxazoline) (PEO-PEOX) in aqueous solutions by a combination of scattering, microscopy, spectroscopy, and thermochemistry techniques. The paper is a contribution to our long-time study of novel hybrid nanostructures based on hydrophilic polymer-metallacarborane complexes. PEOX homopolymer interacts with metallacarborane, resulting in a water-soluble, negatively charged complex. In the case of diblock copolymer PEO-PEOX, both blocks interact with metallacarborane via dihydrogen bonds and participate in the formation of hybrid gel-like nanostructures in 0.1 M NaCl aqueous solutions, which are unique as compared to other boron cluster-containing polymeric systems. The stable spherical nanoparticles with high metallacarborane content do not adopt core/shell structure, which has been observed for other PEO-containing double hydrophilic block copolymers [Macromolecules 2009, 42, 4829], but the nanospheres are homogeneous. They contain intermixed PEO and PEOX blocks, which are cross-linked by metallacarborane molecules. The size of the nanospheres depends on a preparation protocol, while their inner structure does not. Besides the detailed study on PEO-PEOX/metallacarborane system, a high application potential of PEO-PEOX complexes with several metallacarborane-based drugs is also shown. The study clearly demonstrates that PEOX is suitable polymer for designing novel hybrid nanostructures.
C1 [Dordovic, Vladimir; Uchman, Mariusz; Prochazka, Karel; Matejicek, Pavel] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12840 2, Czech Republic.
   [Zhigunov, Alexander; Plestil, Josef] Acad Sci Czech Republic, Inst Macromol Chem, Vvi, CR-16206 Prague 6, Czech Republic.
   [Nykanen, Antti; Ruokolainen, Janne] Aalto Univ, Dept Appl Phys Nanotalo, FI-02150 Espoo, Finland.
RP Matejicek, P (reprint author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Hlavova 2030, Prague 12840 2, Czech Republic.
EM pavel.matejicek@natur.cuni.cz
RI Matejicek, Pavel/M-6582-2017; Ruokolainen, Janne/F-6369-2010; Plestil,
   Josef/H-6807-2014; Dordovic, Vladimir/G-2385-2017; Nykanen,
   Antti/F-6941-2010; Mo, Xiulei/A-1616-2017; Zhigunov,
   Alexander/C-3924-2012; Prochazka, Karel/C-3012-2014
OI Matejicek, Pavel/0000-0001-5482-3465; Dordovic,
   Vladimir/0000-0002-1794-4185; Nykanen, Antti/0000-0003-4989-2911;
   Prochazka, Karel/0000-0003-2144-5378
FU Grant Agency of the Academy of Sciences of the Czech Republic
   [IAAX00320901]; Grant Agency of the Czech Republic [P106/12/0143,
   P208/12/P236]; long term Research Plans of the Ministry of Education of
   the Czech Republic [MSM 0021620857]
FX The authors acknowledge financial support of the Grant Agency of the
   Academy of Sciences of the Czech Republic IAAX00320901, the Grant Agency
   of the Czech Republic P106/12/0143 and P208/12/P236, and long term
   Research Plans of the Ministry of Education of the Czech Republic MSM
   0021620857. The authors thank Bohumir Gruner from IIC Prague for
   providing of metallacarborane samples and Jiri Zednik for assistance
   with NMR measurements.
CR Barth RF, 1999, NEUROSURGERY, V44, P433, DOI 10.1097/00006123-199903000-00001
   Bregadze V. I., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P75, DOI 10.2174/187152006776119180
   Bregadze VI, 2012, BORON SCIENCE: NEW TECHNOLOGIES AND APPLICATIONS, P181
   Bronich TK, 2005, J AM CHEM SOC, V127, P8236, DOI 10.1021/ja043042m
   Brown A, 2009, INT J MOL SCI, V10, P3457, DOI 10.3390/ijms10083457
   Casse O, 2012, MACROMOLECULES, V45, P4772, DOI 10.1021/ma300621g
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   Crespo E, 2007, J PHYS CHEM C, V111, P18381, DOI 10.1021/jp0755443
   Crossley EL, 2007, MINI-REV MED CHEM, V7, P303, DOI 10.2174/138955707780059808                                                      
   Farras P, 2012, CHEM SOC REV, V41, P3445, DOI 10.1039/c2cs15338f
   Freiburger LA, 2009, CHEMBIOCHEM, V10, P2871, DOI 10.1002/cbic.200900614
   Gentil S, 2005, POLYMER, V46, P12218, DOI 10.1016/j.polymer.2005.10.092
   Gil ES, 2004, PROG POLYM SCI, V29, P1173, DOI 10.1016/j.progpolymsci.2004.08.003
   Grimes RN, 2011, CARBORANES, 2ND EDITION, P1053, DOI 10.1016/B978-0-12-374170-7.00002-1
   Harada A, 2006, PROG POLYM SCI, V31, P949, DOI 10.1016/j.progpolymsci.2006.09.004
   Hawthorne MF, 1999, CHEM REV, V99, P3421, DOI 10.1021/cr980442h                                                               
   Hawthorne MF, 2003, J NEURO-ONCOL, V62, P33, DOI 10.1007/BF02699932
   Hawthorne MF, 1998, MOL MED TODAY, V4, P174, DOI 10.1016/S1357-4310(98)01226-X
   HAWTHORNE MF, 1993, ANGEW CHEM INT EDIT, V32, P950, DOI 10.1002/anie.199309501                                                          
   Humpolickova J, 2005, J PHYS CHEM A, V109, P10803, DOI 10.1021/jp053348v
   Issa F, 2011, CHEM REV, V111, P5701, DOI 10.1021/cr2000866
   Ke FY, 2009, MACROMOLECULES, V42, P5339, DOI 10.1021/ma900740b
   Kjellander R., 1981, SOFT MATTER, V77, P2053
   Kozisek M, 2008, J MED CHEM, V51, P4839, DOI 10.1021/jm8002334
   Kubat P, 2007, J PHYS CHEM B, V111, P4539, DOI 10.1021/jp066494p
   Lad MD, 2003, LANGMUIR, V19, P5098, DOI 10.1021/la0269560
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Lesnikowski ZJ, 2007, COLLECT CZECH CHEM C, V72, P1646, DOI 10.1135/cccc20071646
   Lesnikowski ZJ, 2012, BORON SCIENCE: NEW TECHNOLOGIES AND APPLICATIONS, P3
   Llop J, 2003, DALTON T, P556, DOI 10.1039/b211860m
   Luxenhofer R, 2012, MACROMOL RAPID COMM, V33, P1613, DOI 10.1002/marc.201200354
   Masalles C, 2000, ADV MATER, V12, P1199, DOI 10.1002/1521-4095(200008)12:16<1199::AID-ADMA1199>3.0.CO;2-W
   Masalles C, 2002, ADV MATER, V14, P826, DOI 10.1002/1521-4095(20020605)14:11<826::AID-ADMA826>3.0.CO;2-C                    
   Matejicek P, 2006, LANGMUIR, V22, P575, DOI 10.1021/la052201s
   Matejicek P, 2008, LANGMUIR, V24, P2625, DOI 10.1021/la702852e
   Matejicek P, 2007, J PHYS CHEM B, V111, P8394, DOI 10.1021/jp0685075
   Matejicek P, 2013, CHEMPLUSCHEM, V78, P528, DOI 10.1002/cplu.201300046
   Matejicek P, 2011, MACROMOLECULES, V44, P3847, DOI 10.1021/ma200502t
   Matejicek P, 2009, MACROMOLECULES, V42, P4829, DOI 10.1021/ma900484y
   Okur HI, 2013, J AM CHEM SOC, V135, P5062, DOI 10.1021/ja3119256
   Olofsson G, 2009, J BRAZIL CHEM SOC, V20, P577, DOI 10.1590/S0103-50532009000400002
   PLESEK J, 1992, CHEM REV, V92, P269, DOI 10.1021/cr00010a005                                                             
   Prochazka K, 2010, PROC SPIE, V7571, DOI 10.1117/12.842172
   Rak J, 2013, MOL PHARMACEUT, V10, P1751, DOI 10.1021/mp300565z
   Rak J, 2011, EUR J MED CHEM, V46, P1140, DOI 10.1016/j.ejmech.2011.01.032
   Rezacova P, 2012, BORON SCIENCE: NEW TECHNOLOGIES AND APPLICATIONS, P41
   Rezacova P, 2009, J MED CHEM, V52, P7132, DOI 10.1021/jm9011388
   Rodriguez-Hernandez J, 2005, PROG POLYM SCI, V30, P691, DOI 10.1016/j.progpolymsci.2005.04.002
   Sachl R, 2008, LANGMUIR, V24, P288, DOI 10.1021/la702277t
   Satapathy R, 2010, COLLECT CZECH CHEM C, V75, P995, DOI 10.1135/cccc2010050
   Scholz M, 2011, CHEM REV, V111, P7035, DOI 10.1021/cr200038x
   Sedlacek O, 2012, MACROMOL RAPID COMM, V33, P1648, DOI 10.1002/marc.201200453
   Sibrian-Vazquez M, 2012, BORON SCIENCE: NEW TECHNOLOGIES AND APPLICATIONS, P209
   Smart TP, 2009, SOFT MATTER, V5, P3607, DOI 10.1039/b908731a
   Soloway AH, 1998, CHEM REV, V98, P1515, DOI 10.1021/cr941195u                                                               
   Stepanek M, 2005, LANGMUIR, V21, P10783, DOI 10.1021/la0516680
   Stepanek M, 2003, COLLECT CZECH CHEM C, V68, P2120, DOI 10.1135/cccc20032120
   Stepanek M, 2009, POLYMER, V50, P3638, DOI 10.1016/j.polymer.2009.05.024
   Stuart MAC, 2005, CURR OPIN COLLOID IN, V10, P30, DOI 10.1016/j.cocis.2005.04.004
   Tjarks W, 2000, J ORGANOMET CHEM, V614, P37, DOI 10.1016/S0022-328X(00)00574-X                                                   
   Tsitsilianis C, 2000, LANGMUIR, V16, P6868, DOI 10.1021/la000176e
   Tsuji M, 2000, BIOL PHARM BULL, V23, P513
   Uchman M, 2013, MACROMOLECULES, V46, P2172, DOI 10.1021/ma302503w
   Uchman M, 2012, MACROMOLECULES, V45, P6471, DOI 10.1021/ma301510j
   Uchman M, 2011, COLLOID POLYM SCI, V289, P1045, DOI 10.1007/s00396-011-2433-9
   Uchman M, 2010, J COLLOID INTERF SCI, V348, P129, DOI 10.1016/j.jcis.2010.04.037
   Uchman M, 2010, LANGMUIR, V26, P6268, DOI 10.1021/la904047k
   Uchman M, 2009, MACROMOLECULES, V42, P5605, DOI 10.1021/ma9008115
   Vinas C, 2012, BORON SCIENCE: NEW TECHNOLOGIES AND APPLICATIONS, P701
   Xu SQ, 1998, ACTA CHIM SINICA, V56, P445
   Zhao Q, 2006, PROG CHEM, V18, P768
NR 71
TC 13
Z9 14
U1 4
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
EI 1520-5835
J9 MACROMOLECULES
JI Macromolecules
PD SEP 10
PY 2013
VL 46
IS 17
BP 6881
EP 6890
DI 10.1021/ma4013626
PG 10
WC Polymer Science
SC Polymer Science
GA 295WA
UT WOS:000330145900021
DA 2018-01-05
ER

PT J
AU Abia, I
   Peng, TY
   Mains, S
   Pohl, N
AF Abia, Irene
   Peng, Tianyuan
   Mains, Sasha
   Pohl, Nicola
TI Design and synthesis of thiol-terminated oligosaccharides for attachment
   on gold nanoparticles: Toward the development of an HIV vaccine
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 246th National Meeting of the American-Chemical-Society (ACS)
CY SEP 08-12, 2013
CL Indianapolis, IN
SP Amer Chem Soc
C1 [Abia, Irene; Peng, Tianyuan; Mains, Sasha; Pohl, Nicola] Indiana Univ, Bloomington, IN 47403 USA.
EM iabia@indiana.edu
NR 0
TC 1
Z9 1
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 8
PY 2013
VL 246
MA 27-CARB
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 288NJ
UT WOS:000329618401110
DA 2018-01-05
ER

PT J
AU Suaifan, GARY
   Shehadeh, M
   Al-Ijel, H
   Ng, A
   Zourob, M
AF Suaifan, Ghadeer A. R. Y.
   Shehadeh, Mayadah
   Al-Ijel, Hebah
   Ng, Andy
   Zourob, Mohammed
TI Recent progress in prostate-specific antigen and HIV proteases detection
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE acquired immune deficiency syndrome; biosensors; human immunodeficiency
   virus; nanotechnology; prostate cancer; point of care; protease
   detection; prostate-specific antigen
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RESOLVED IMMUNOFLUOROMETRIC ASSAY; CANCER
   BIOMARKER DETECTION; CARBON NANOTUBES; P24 ANTIGEN; ELECTROCHEMICAL
   IMMUNOSENSOR; AMPEROMETRIC IMMUNOSENSOR; PROTEOLYTIC-ENZYMES; MODIFIED
   ELECTRODE; CHEMILUMINESCENCE IMMUNOSENSOR
AB Proteases mediate a wide variety of biological events and have a critical role in the development of many diseases. Protease detection methods can be hindered by the limitation of assay safety, sensitivity, specificity, time constraints and ease of on-site analysis. Notably, the implementation of various detection methods on biosensing platforms translates them into practical biosensing applications. Currently, the detection of prostate cancer and AIDS at the earliest occasion is one of the major research obstacles. Therefore, recent advances focus on the development of portable detection systems toward point-of-care testing. These detection systems should be highly sensitive and specific for the detection of their prognostic biomarkers, such as the prostate-specific antigen and HIV load assay for prostate cancer and AIDS, respectively. These methods will also facilitate decision-making on a treatment regimen.
C1 [Suaifan, Ghadeer A. R. Y.; Shehadeh, Mayadah; Al-Ijel, Hebah] Univ Jordan, Fac Pharm, Dept Pharmaceut Sci, Amman 11942, Jordan.
   [Ng, Andy; Zourob, Mohammed] Cranfield Univ, Cranfield Hlth, Cranfield MK43 0AL, Beds, England.
RP Suaifan, GARY (reprint author), Univ Jordan, Fac Pharm, Dept Pharmaceut Sci, Amman 11942, Jordan.
EM gh.suaifan@ju.edu.jo
RI Ng, Andy/I-3060-2016
OI Ng, Andy/0000-0003-3257-0801
CR Acevedo B, 2002, CLIN CHIM ACTA, V317, P55, DOI 10.1016/S0009-8981(01)00749-5                                                   
   Baeyens WRG, 1998, J PHARMACEUT BIOMED, V17, P941, DOI 10.1016/S0731-7085(98)00062-4                                                   
   Bi S, 2009, BIOSENS BIOELECTRON, V24, P2961, DOI 10.1016/j.bios.2009.03.002
   Braun K, 2011, TUMOUR MARKERS, P14
   Armas Cayarga A., 2011, BIOTECHNOLOGY RES IN, V2011
   Chen ZG, 2012, BIOSENS BIOELECTRON, V36, P35, DOI 10.1016/j.bios.2012.03.041
   Chikae M, 2010, ELECTROCHEMISTRY, V78, P748, DOI 10.5796/electrochemistry.78.748                                                 
   Chikkaveeraiah BV, 2011, BIOSENS BIOELECTRON, V26, P4477, DOI 10.1016/j.bios.2011.05.005
   Choi JW, 2008, APPL PHYS LETT, V93
   Chuah K, 2012, CHEM COMMUN, V48, P3503, DOI 10.1039/c2cc30512g
   Dey A, 2012, J MATER CHEM, V22, P14763, DOI 10.1039/c2jm31663c
   Dong HH, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-180
   Drosten C, 2006, CLIN CHEM, V52, P1258, DOI 10.1373/clinchem.2006.066498
   Dultsev FN, 2011, ANAL CHIM ACTA, V687, P75, DOI 10.1016/j.aca.2010.11.055
   Eriksson S, 2000, CLIN CHEM, V46, P658
   Esseghaier C, 2013, BIOSENS BIOELECTRON, V41, P335, DOI 10.1016/j.bios.2012.08.049
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Gan N, 2010, CHINESE J ANAL CHEM, V38, P1556, DOI 10.3724/SP.J.1096.2010.01556
   Gleaves CA, 2002, J CLIN VIROL, V25, P205, DOI 10.1016/S1386-6532(02)00011-2
   Grant SA, 2002, IEEE SENS J, V2, P409, DOI 10.1109/JSEN.2002.804575
   He JK, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-26
   Herszenyi Laszlo, 1999, Orvosi Hetilap, V140, P1833
   Hildebrandt N, 2006, P SOC PHOTOOPT INS, pW1910
   Hou YX, 2006, BIOSENS BIOELECTRON, V21, P1393, DOI 10.1016/j.bios.2005.06.002
   Hsia CC, 2007, BIOCHEM BIOPH RES CO, V356, P1017, DOI 10.1016/j.bbrc.2007.03.087
   Huang Y, 2009, CLIN CHEM, V55, P964, DOI 10.1373/clinchem.2008.116582
   Jain A, 2003, J MICROBIOL METH, V53, P107, DOI 10.1016/S0167-7012(02)00233-6
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Kim DJ, 2010, BIOSENS BIOELECTRON, V25, P2477, DOI 10.1016/j.bios.2010.04.013
   Kim M, 2006, ANAL BIOCHEM, V351, P298, DOI 10.1016/j.ab.2006.01.042
   Labbett W, 2009, J CLIN MICROBIOL, V47, P3266, DOI 10.1128/JCM.00715-09
   Labib M, 2011, TALANTA, V85, P770, DOI 10.1016/j.talanta.2011.04.070
   Labib M, 2011, ANALYST, V136, P708, DOI 10.1039/c0an00741b
   Lee J, 2011, BIOCHIP J, V5, P158, DOI 10.1007/s13206-011-5209-x
   Li CC, 2005, J CLIN MICROBIOL, V43, P3901, DOI 10.1128/JCM.43.8.3901-3905.2005
   Li H, 2011, BIOSENS BIOELECTRON, V26, P3590, DOI 10.1016/j.bios.2011.02.006
   Li H, 2011, BIOSENS BIOELECTRON, V26, P3044, DOI 10.1016/j.bios.2010.12.011
   Li T, 2011, J ELECTROANAL CHEM, V655, P50, DOI 10.1016/j.jelechem.2011.02.009
   Lin YY, 2008, BIOSENS BIOELECTRON, V23, P1659, DOI 10.1016/j.bios.2008.01.037
   Liu B, 2012, MICROCHIM ACTA, V178, P163, DOI 10.1007/s00604-012-0822-5
   Liu J, 2011, 15 INT C MIN SYST CH, P1197
   Lu CH, 2012, BIOSENS BIOELECTRON, V31, P439, DOI 10.1016/j.bios.2011.11.008
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Mahmoud KA, 2010, ANAL LETT, V43, P1680, DOI 10.1080/00032711003653924
   Mao KX, 2012, ANAL BIOCHEM, V422, P22, DOI 10.1016/j.ab.2011.12.047
   McCormick MK, 2006, J CLIN VIROL, V36, P166, DOI 10.1016/j.jcv.2005.12.003
   Miedouge M, 2011, J CLIN VIROL, V50, P57, DOI 10.1016/j.jcv.2010.09.003
   Mittl PRE, 2006, CURR OPIN STRUC BIOL, V16, P769, DOI 10.1016/j.sbi.2006.10.014
   Nakajima H, 2011, J SEP SCI, V34, P2906, DOI 10.1002/jssc.201100429
   NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825
   Niemela P, 2002, CLIN CHEM, V48, P1257
   Okada H, 2011, ANAL SCI, V27, P237, DOI 10.2116/analsci.27.237                                                          
   Okuno J, 2007, BIOSENS BIOELECTRON, V22, P2377, DOI 10.1016/j.bios.2006.09.038
   Panini NV, 2008, BIOSENS BIOELECTRON, V23, P1145, DOI 10.1016/j.bios.2007.11.003
   Patrick GL, 2005, 4 INTR MED CHEM, P483
   Qi XH, 2005, ELECTROCHEM COMMUN, V7, P227, DOI 10.1016/j.elecom.2005.01.001
   Rawlings ND, 2012, NUCLEIC ACIDS RES, V40, pD343, DOI 10.1093/nar/gkr987
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Rouet F, 2001, AIDS, V15, P1849, DOI 10.1097/00002030-200109280-00015
   Rupert K, 1999, METHODS DETECTION HI
   Sardesai NP, 2011, ANAL CHEM, V83, P6698, DOI 10.1021/ac201292q
   Sarkar P, 2002, INT J PHARMACEUT, V238, P1, DOI 10.1016/S0378-5173(02)00015-7
   Schumacher W, 2007, J CLIN VIROL, V38, P304, DOI 10.1016/j.jcv.2006.12.022
   Seto Y, 2001, LUMINESCENCE, V16, P285, DOI 10.1002/bio.654.abs
   Shulga OV, 2008, ANALYST, V133, P319, DOI 10.1039/b712760j
   Sokoll LJ, 2012, CLIN CHIM ACTA, V413, P1279, DOI 10.1016/j.cca.2012.04.015
   Soukka T, 2001, CLIN CHEM, V47, P1269
   STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501
   Stangelberger A, 2007, JMHG, V4, P233
   Suaifan GARY, 2013, ANALYST, V138, P3735, DOI 10.1039/c3an36881e
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Taylor JA, 2006, BJU INT, V98, P540, DOI 10.1111/j.1464-410X.2006.06294.x
   Thaxton CS, 2009, P NATL ACAD SCI USA, V106, P18437, DOI 10.1073/pnas.0904719106
   Tian CY, 2012, ANALYST, V137, P3070, DOI 10.1039/c2an35493d
   Tian JN, 2012, MICROCHIM ACTA, V178, P81, DOI 10.1007/s00604-012-0816-3
   Triroj N, 2011, BIOSENS BIOELECTRON, V26, P2927, DOI 10.1016/j.bios.2010.11.039
   Tshishi TA, 2007, IMMUNO-ANAL BIOL SPE, V22, P190, DOI 10.1016/j.immbio.2007.02.005
   Wang RB, 2011, MICROCHIM ACTA, V172, P291, DOI 10.1007/s00604-010-0490-2
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wei Q, 2011, BIOSENS BIOELECTRON, V26, P3714, DOI 10.1016/j.bios.2011.02.024
   Wians FH, 2002, CLIN CHIM ACTA, V326, P81, DOI 10.1016/S0009-8981(02)00250-4                                                   
   Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024
   Workman S, 2009, J VIROL METHODS, V160, P14, DOI 10.1016/j.jviromet.2009.04.003
   Wu CC, 2012, INT J ELECTROCHEM SC, V7, P4432
   Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856
   Wu P, 2004, CLIN CHEM, V50, P125, DOI 10.1373/clinchem.2003.026146
   Xia ZY, 2008, ANAL CHEM, V80, P8649, DOI 10.1021/ac801562f
   Xu SJ, 2011, ANAL CHEM, V83, P3817, DOI 10.1021/ac200237j
   Yan M, 2012, BIOSENS BIOELECTRON, V38, P355, DOI 10.1016/j.bios.2012.06.019
   Yang J, 2011, ASIAN J CHEM, V23, P5373
   Yang MH, 2011, SENSOR ACTUAT B-CHEM, V155, P357, DOI 10.1016/j.snb.2010.11.055
   Yeh CH, 2012, SENSOR ACTUAT B-CHEM, V161, P1168, DOI 10.1016/j..snb.2011.10.016
   Zhang M, 2012, ANALYST, V137, P2112, DOI 10.1039/c2an35186b
   Zhang TH, 2012, BIOSENS BIOELECTRON, V38, P382, DOI 10.1016/j.bios.2012.06.029
   Zhao N, 2010, ELECTROCHEM COMMUN, V12, P471, DOI 10.1016/j.elecom.2010.01.022
   Zhao XH, 2012, INDIAN J MED MICROBI, V30, P391, DOI 10.4103/0255-0857.103757
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
   Zheng Y, 2008, TALANTA, V77, P809, DOI 10.1016/j.talanta.2008.07.038
   Zhu L, 2009, CLIN CHEM, V55, P1665, DOI 10.1373/clinchem.2009.127779
NR 99
TC 5
Z9 5
U1 0
U2 33
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD SEP
PY 2013
VL 13
IS 7
BP 707
EP 718
DI 10.1586/14737159.2013.835576
PG 12
WC Pathology
SC Pathology
GA AA7PH
UT WOS:000331288900013
PM 24063398
DA 2018-01-05
ER

PT J
AU Kozielski, KL
   Tzeng, SY
   Green, JJ
AF Kozielski, Kristen L.
   Tzeng, Stephany Y.
   Green, Jordan J.
TI Bioengineered nanoparticles for siRNA delivery
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID SMALL-INTERFERING RNA; SEMICONDUCTOR QUANTUM DOTS; DNA/TRANSFERRIN-PEI
   COMPLEXES; HUMAN IMMUNODEFICIENCY VIRUS; BLOCK-COPOLYMER MICELLES;
   EFFICIENT GENE DELIVERY; LIPID-LIKE MATERIALS; DOUBLE-STRANDED-RNA;
   IN-VIVO DELIVERY; INTRACELLULAR DELIVERY
AB Short interfering RNA (siRNA) has been an important laboratory tool in the last two decades and has allowed researchers to better understand the functions of nonprotein-coding genes through RNA interference (RNAi). Although RNAi holds great promise for this purpose as well as for treatment of many diseases, efforts at using siRNA have been hampered by the difficulty of safely and effectively introducing it into cells of interest, both in vitro and in vivo. To overcome this challenge, many biomaterials and nanoparticles (NPs) have been developed and optimized for siRNA delivery, often taking cues from the DNA delivery field, although different barriers exist for these two types of molecules. In this review, we discuss general properties of biomaterials and nanoparticles that are necessary for effective nucleic acid delivery. We also discuss specific examples of bioengineered materials, including lipid-based NPs, polymeric NPs, inorganic NPs, and RNA-based NPs, which clearly illustrate the problems and successes in siRNA delivery. WIREs Nanomed Nanobiotechnol 2013. doi: 10.1002/wnan.1233 Conflict of interest: The authors have declared no conflicts of interest for this article. For further resources related to this article, please visit the WIREs website.
C1 [Kozielski, Kristen L.; Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Univ, Dept Biomed Engn, Inst Nanobiotechnol, Baltimore, MD 21218 USA.
   [Kozielski, Kristen L.; Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Univ, Translat Tissue Engn Ctr, Baltimore, MD USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
RP Green, JJ (reprint author), Johns Hopkins Univ, Dept Biomed Engn, Inst Nanobiotechnol, Baltimore, MD 21218 USA.
EM green@jhu.edu
FU NIH [1R01EB016721]; NIH Cancer Nanotechnology Training Center at the JHU
   Institute for Nanobiotechnology [R25CA153952]; National Science
   Foundation
FX This work was supported in part by the NIH (1R01EB016721). K.L.K. thanks
   the NIH Cancer Nanotechnology Training Center (R25CA153952) at the JHU
   Institute for Nanobiotechnology for fellowship support and S.Y.T. thanks
   the National Science Foundation for fellowship support.
CR Adair JH, 2010, ACS NANO, V4, P4967, DOI 10.1021/nn102324e
   Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Akinc A, 2009, MOL THER, V17, P872, DOI 10.1038/mt.2009.36
   ALVING CR, 1978, P NATL ACAD SCI USA, V75, P2959, DOI 10.1073/pnas.75.6.2959
   Ameres SL, 2007, CELL, V130, P101, DOI 10.1016/j.cell.2007.04.037
   Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874
   Benjaminsen RV, 2013, MOL THER, V21, P149, DOI 10.1038/mt.2012.185
   Benns JM, 2000, BIOCONJUGATE CHEM, V11, P637, DOI 10.1021/bc0000177
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110                                                                
   Bertram JP, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000397
   Bolcato-Bellemin AL, 2007, P NATL ACAD SCI USA, V104, P16050, DOI 10.1073/pnas.0707831104
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Boxem M, 1999, DEVELOPMENT, V126, P2227
   Breunig M, 2008, J CONTROL RELEASE, V130, P57, DOI 10.1016/j.jconrel.2008.05.016
   Chen AA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni188
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745                                                            
   Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053
   Chono S, 2008, J CONTROL RELEASE, V131, P64, DOI 10.1016/j.jconrel.2008.07.006
   Christensen LV, 2006, BIOCONJUGATE CHEM, V17, P1233, DOI 10.1021/bc0602026
   Christie RJ, 2012, ACS NANO, V6, P5174, DOI 10.1021/nn300942b
   Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597                                                          
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850
   Cutler JI, 2011, J AM CHEM SOC, V133, P9254, DOI 10.1021/ja203375n
   Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Decher G., 1991, MAKROMOLEKULARE CHEM
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   Diegelman AM, 1998, NUCLEIC ACIDS RES, V26, P3235, DOI 10.1093/nar/26.13.3235                                                          
   Drummond DC, 2000, PROG LIPID RES, V39, P409, DOI 10.1016/S0163-7827(00)00011-4
   Elbakry A, 2009, NANO LETT, V9, P2059, DOI 10.1021/nl9003865
   ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Forbes DC, 2012, J CONTROL RELEASE, V162, P435
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021
   Ghosh PS, 2008, ACS NANO, V2, P2213, DOI 10.1021/nn800507t
   Giljohann DA, 2009, J AM CHEM SOC, V131, P2072, DOI 10.1021/ja808719p
   Grayson ACR, 2006, PHARM RES, V23, P1868, DOI 10.1007/s11095-006-9009-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hafez IM, 2001, ADV DRUG DELIVER REV, V47, P139, DOI 10.1016/S0169-409X(01)00103-X
   Hafez IM, 2001, GENE THER, V8, P1188, DOI 10.1038/sj.gt.3301506
   Hagerman PJ, 1997, ANNU REV BIOPH BIOM, V26, P139, DOI 10.1146/annurev.biophys.26.1.139                                                
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Harris TJ, 2010, BIOMATERIALS, V31, P998, DOI 10.1016/j.biomaterials.2009.10.012
   Hatakeyama H, 2007, GENE THER, V14, P68, DOI 10.1038/sj.gt.3302843
   Heyes J, 2005, J CONTROL RELEASE, V107, P276, DOI 10.1016/j.jconrel.2005.06.014
   Hill IRC, 1999, BBA-GEN SUBJECTS, V1427, P161, DOI 10.1016/S0304-4165(99)00021-5
   Jeong JH, 2007, BIOMATERIALS, V28, P1912, DOI 10.1016/j.biomaterials.2006.12.019
   Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596                                                            
   Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002
   Kakizawa Y, 1999, J AM CHEM SOC, V121, P11247, DOI 10.1021/ja993057y                                                               
   Kakizawa Y, 2006, J CONTROL RELEASE, V111, P368, DOI 10.1016/j.jconrel.2006.01.004
   Kakizawa Y, 2002, LANGMUIR, V18, P4539, DOI 10.1021/la011736s
   Kakizawa Y, 2001, BIOMACROMOLECULES, V2, P491, DOI 10.1021/bm000142I
   Kaul G, 2005, PHARM RES, V22, P951, DOI 10.1007/s11095-005-4590-3
   Kawano T, 2006, J CONTROL RELEASE, V111, P382, DOI 10.1016/j.jconrel.2005.12.022
   Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg/158
   KEBBEKUS P, 1995, BIOCHEMISTRY-US, V34, P4354, DOI 10.1021/bi00013a026
   Kim SH, 2008, J CONTROL RELEASE, V129, P107, DOI 10.1016/j.jconrel.2008.03.008
   Kim SH, 2006, J CONTROL RELEASE, V116, P123, DOI 10.1016/j.jconrel.2006.05.023
   Kozielski KL, 2013, CHEM COMMUN, V49, P5319, DOI 10.1039/c3cc40718g
   Kuwabara PE, 2000, PARASITOL TODAY, V16, P347, DOI 10.1016/S0169-4758(00)01677-X
   Leconet W, 2012, MOL THER, V20, P2315, DOI 10.1038/mt.2012.190
   Lee JS, 2009, NANO LETT, V9, P2402, DOI 10.1021/nl9009793
   Lee JB, 2012, NAT MATER, V11, P316, DOI [10.1038/NMAT3253, 10.1038/nmat3253]
   LI HJ, 1973, BIOCHEMISTRY-US, V12, P1763, DOI 10.1021/bi00733a016                                                             
   Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323
   Lim YB, 2000, PHARMACEUT RES, V17, P811, DOI 10.1023/A:1007552007765
   LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D
   Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936
   Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Love KT, 2010, P NATL ACAD SCI USA, V107, P1864, DOI 10.1073/pnas.0910603106
   Lu JJ, 2009, MOL PHARMACEUT, V6, P763, DOI 10.1021/mp900023v
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Ma Z, 2005, BIOCHEM BIOPH RES CO, V330, P755, DOI 10.1016/j.bbrc.2005.03.041
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Matsumoto S, 2009, BIOMACROMOLECULES, V10, P119, DOI 10.1021/bm800985e
   Mattheakis LC, 2004, ANAL BIOCHEM, V327, P200, DOI 10.1016/j.ab.2004.01.031
   Medarova Z, 2007, NAT MED, V13, P372, DOI 10.1038/nm1486
   Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m
   Meyer M, 2008, J AM CHEM SOC, V130, P3272, DOI 10.1021/ja710344v
   Meyer Martin, 2006, Expert Opin Drug Deliv, V3, P563, DOI 10.1517/17425247.3.5.563
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Miyata K, 2004, J AM CHEM SOC, V126, P2355, DOI 10.1021/ja0379666
   Mok H, 2008, BIOPOLYMERS, V89, P881, DOI 10.1002/bip.21032
   Mok H, 2010, NAT MATER, V9, P272, DOI [10.1038/NMAT2626, 10.1038/nmat2626]
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Okuda T, 2004, BIOMATERIALS, V25, P537, DOI 10.1016/S0142-9612(03)00542-8
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Sanchez-Vargas I, 2004, VIRUS RES, V102, P65, DOI 10.1016/j.virusres.2004.01.017
   SCHERPHOF GL, 1985, ANN NY ACAD SCI, V446, P368, DOI 10.1111/j.1749-6632.1985.tb18414.x                                              
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Shmueli RB, 2010, EXPERT OPIN DRUG DEL, V7, P535, DOI 10.1517/17425241003603653
   Singh N, 2010, J AM CHEM SOC, V132, P8241, DOI 10.1021/ja102132e
   Son S, 2012, ACCOUNTS CHEM RES, V45, P1100, DOI 10.1021/ar200248u
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Spagnou S, 2004, BIOCHEMISTRY-US, V43, P13348, DOI 10.1021/bi048950a
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Sutton D, 2006, INT J NANOMED, V1, P155, DOI 10.2147/nano.2006.1.2.155                                                       
   Svoboda P, 2000, DEVELOPMENT, V127, P4147
   Tanaka T, 2010, CANCER RES, V70, P3687, DOI 10.1158/0008-5472.CAN-09-3931
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   TOLOU H, 1993, ANAL BIOCHEM, V215, P156, DOI 10.1006/abio.1993.1568
   Tzeng SY, 2013, ADV HEALTHC MATER, V2, P468, DOI 10.1002/adhm.201200257
   Tzeng SY, 2012, BIOMATERIALS, V33, P8142, DOI 10.1016/j.biomaterials.2012.07.036
   Tzeng SY, 2010, SOFT MATTER, V6, P2208, DOI 10.1039/b923544b
   Tzeng SY, 2012, INT J NANOMED, V6, P3309
   UMEDA M, 1985, J BIOCHEM-TOKYO, V97, P1301, DOI 10.1093/oxfordjournals.jbchem.a135181                                           
   Vader P, 2012, PHARM RES-DORDR, V29, P352, DOI 10.1007/s11095-011-0545-z
   Vader P, 2011, PHARM RES-DORDR, V28, P1013, DOI 10.1007/s11095-010-0344-y
   VADIEI K, 1989, INT J PHARM, V57, P133, DOI 10.1016/0378-5173(89)90301-3
   van der Aa LJ, 2011, J CONTROL RELEASE, V150, P177, DOI 10.1016/j.jconrel.2010.11.030
   Vandenbroucke RE, 2008, J GENE MED, V10, P783, DOI 10.1002/jgm.1202
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   Ward CM, 2001, BLOOD, V97, P2221, DOI 10.1182/blood.V97.8.2221
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187                                                                 
   Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   WU GY, 1987, J BIOL CHEM, V262, P4429
   Wu W, 2007, INT J CANCER, V120, P953, DOI 10.1002/ijc.22454
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019
   Yadav S, 2009, CANCER CHEMOTH PHARM, V63, P711, DOI 10.1007/s00280-008-0790-y
   Yuan XD, 2010, PHARM RES-DORDR, V27, P1285, DOI 10.1007/s11095-010-0103-0
   Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493
   Zhang MZ, 2009, ADV MATER, V21, P3520, DOI 10.1002/adma.200800448
   Zheng D, 2012, P NATL ACAD SCI USA, V109, P11975, DOI 10.1073/pnas.1118425109
   Zhou J, 2012, BIOMATERIALS, V33, P583, DOI 10.1016/j.biomaterials.2011.09.061
   Zhou JH, 2013, MOL THER, V21, P192, DOI 10.1038/mt.2012.226
NR 152
TC 10
Z9 10
U1 0
U2 50
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5116
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD SEP
PY 2013
VL 5
IS 5
BP 449
EP 468
DI 10.1002/wnan.1233
PG 20
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 227IX
UT WOS:000325107300004
PM 23821336
OA green_accepted
DA 2018-01-05
ER

PT J
AU Devadhasan, JP
   Kim, S
AF Devadhasan, Jasmine Pramila
   Kim, Sanghyo
TI CMOS image sensor based HIV diagnosis: a smart system for point-of-care
   approach
SO BIOCHIP JOURNAL
LA English
DT Article
DE Antigen-Antibody interactions; Complementary metal oxide semiconductor;
   Human immuno deficiency virus; Indium nanoparticle substrate; Photon
   detection technique; Point-of-care diagnosis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DNA; NANOPARTICLES; PARTICLES; PROTEIN;
   ARRAYS
AB We report on the use of a complementary metal oxide semiconductor (CMOS) image sensor in an immunodiagnostic system for detecting the human immunodeficiency virus (HIV). It is based on photon counting and the interaction of the HIV antigen (Ag) with respective antibodies, which are deposited in various thicknesses on indium nanoparticles (InNPs) substrate. The sensor measures the number of photons that depends on the concentration of HIV Ag and converts them into digital numbers. Photons are refracted on the protein adsorbed InNP substrate and hit the CMOS image sensor surface based on the Ag concentration. Topographical studies such as field emission scanning electron microscopy (FE-SEM) and fluorescence microscopy images are demonstrated the reliability of this scheme. Also, the UV-spectral studies proved the efficiency of the analysis with InNP substrate. The sensor is simple, compact, highly specific and accurate. Also, it can detect HIV at levels as low as 10 fg mL(-1). Therefore, the sophisticated system of the CMOS image sensor based immunodetection now requires point-of-care (POC) diagnosis.
C1 [Devadhasan, Jasmine Pramila; Kim, Sanghyo] Gachon Univ, Dept Bionanotechnol, Songnam 461701, Gyeonggi Do, South Korea.
   [Kim, Sanghyo] Gil Med Ctr, Gachon Med Res Inst, Inchon 405760, South Korea.
RP Kim, S (reprint author), Gachon Univ, Dept Bionanotechnol, San 65, Songnam 461701, Gyeonggi Do, South Korea.
EM samkim@gachon.ac.kr
FU IT R&D program of MOTIE/KEIT [10035197]; Korea-New Zealand Joint
   Research Program; Ministry of Education, Science and Technology
   [2011K000700]
FX This research was supported by the IT R&D program of MOTIE/KEIT
   (10035197) and the Korea-New Zealand Joint Research Program funded by
   the Ministry of Education, Science and Technology (2011K000700).
CR Block O, 2012, J VIROL METHODS, V182, P70, DOI 10.1016/j.jviromet.2012.03.012
   Chen X, 2012, ANAL CHEM, V84, P8277, DOI 10.1021/ac3017828
   Constantine Niel T., 2002, International Journal of Infectious Diseases, V6, P170, DOI 10.1016/S1201-9712(02)90106-2
   Constantine NT, 2005, CELL RES, V15, P870, DOI 10.1038/sj.cr.7290361
   Devadhasan JP, 2012, ANAL SCI, V28, P875
   Devadhasan JP, 2012, ANALYST, V137, P3917, DOI 10.1039/c2an35458f
   Devadhasan J. P., 2011, ANAL BIOANAL CHEM, V402, P813
   Fu YZ, 2006, ANAL LETT, V39, P467, DOI 10.1080/00032710500536102
   GIAEVER I, 1974, P NATL ACAD SCI USA, V71, P4533, DOI 10.1073/pnas.71.11.4533                                                         
   Heer F., 2008, IEEE INT SOL STAT CI
   Kandasamy K, 2010, ANAL SCI, V26, P1215, DOI 10.2116/analsci.26.1215
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Liu ZM, 2009, ANAL LETT, V42, P3046, DOI 10.1080/00032710903276638
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Marimuthu M, 2011, ANAL BIOANAL CHEM, V401, P1641, DOI 10.1007/s00216-011-5231-9
   Minamisawa RA, 2008, INSTRUM SCI TECHNOL, V36, P97, DOI 10.1080/10739140701750086
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Perrin A, 2003, ANAL BIOCHEM, V322, P148, DOI 10.1016/j.ab.2003.08.002
   Rodrigues ERGO, 2010, ANAL BIOANAL CHEM, V397, P381, DOI 10.1007/s00216-010-3518-x
   Sheikh A., 2011, TALANTA, V85, P816
   Stadler V, 2007, J PROTEOME RES, V6, P3197, DOI 10.1021/pr0701310
   UNAIDS, 2011, UNAIDS WORLD AIDS DA
   Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448
   Wang YJ, 2005, SOLID STATE ELECTRON, V49, P1933, DOI 10.1016/j.sse.2005.09.015
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yu XX, 2012, J PHOTOCH PHOTOBIO A, V241, P45, DOI 10.1016/j.jphotochem.2012.04.023
NR 26
TC 4
Z9 4
U1 0
U2 15
PU KOREAN BIOCHIP SOCIETY-KBCS
PI SEOUL
PA KOREA SCI & TECHNOL CENT, #310, 635-4, YEOGSAM-DONG, KANGNAM-GU, SEOUL,
   135-703, SOUTH KOREA
SN 1976-0280
J9 BIOCHIP J
JI BioChip J.
PD SEP
PY 2013
VL 7
IS 3
BP 258
EP 266
DI 10.1007/s13206-013-7309-2
PG 9
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 221BF
UT WOS:000324631500009
DA 2018-01-05
ER

PT J
AU Arakelyan, A
   Fitzgerald, W
   Margolis, L
   Grivel, JC
AF Arakelyan, Anush
   Fitzgerald, Wendy
   Margolis, Leonid
   Grivel, Jean-Charles
TI Nanoparticle-based flow virometry for the analysis of individual virions
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-MEMBRANE-PROTEINS; CUCUMBER
   MOSAIC-VIRUS; HOST HLA-DR; OPPORTUNISTIC INFECTION; HIV-1 INFECTION;
   IN-VIVO; CYTOMETRY; PARTICLES; ANTIBODY
AB While flow cytometry has been used to analyze the antigenic composition of individual cells, the antigenic makeup of viral particles is still characterized predominantly in bulk. Here, we describe a technology, "flow virometry," that can be used for antigen detection on individual virions. The technology is based on binding magnetic nanoparticles to virions, staining the virions with monoclonal antibodies, separating the formed complexes with magnetic columns, and characterizing them with flow cytometers. We used this technology to study the distribution of two antigens (HLA-DR and LFA-1) that HIV-1 acquires from infected cells among individual HIV-1 virions. Flow virometry revealed that the antigenic makeup of virions from a single preparation is heterogeneous. This heterogeneity could not be detected with bulk analysis of viruses. Moreover, in two preparations of the same HIV-1 produced by different cells, the distribution of antigens among virions was different. In contrast, HIV-1 of two different HIV-1 genotypes replicating in the same cells became somewhat antigenically similar. This nanotechnology allows the study of virions in bodily fluids without virus propagation and in principle is not restricted to the analysis of HIV, but can be applied to the analysis of the individual surface antigenic makeup of any virus.
C1 [Arakelyan, Anush; Fitzgerald, Wendy; Margolis, Leonid; Grivel, Jean-Charles] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD USA.
RP Margolis, L (reprint author), NIH, 10 Ctr Dr,Bldg 10,Rm 9D58, Bethesda, MD 20892 USA.
EM margolis@helix.nih.gov; grivelj@mail.nih.gov
FU NCI, NIH [HHSN261200800001E]; intramural program of the Eunice
   Kennedy-Shriver National Institute of Child Health and Human Development
FX The authors would like to thank John Mascola for providing VRC01, Tome
   Hope for providing GFP-expressing HIV-1, Mimi Gosh for providing samples
   of CVL, and Michael Lederman for providing plasma samples obtained from
   HIV-1-infected patients. These experiments used reagents provided by the
   AIDS and Cancer Virus Program, SAIC Frederick, Inc./National Cancer
   Institute (NCI), Frederick, supported with Federal funds from the NCI,
   NIH, under contract HHSN261200800001E. We are grateful to Elena Zaitseva
   for her excellent guidance in staining virions with lipophilic dyes and
   to Sonia Zicari for her generous help with dengue viruses. We are
   thankful to Jeremy Swan and Yumiko Shepherd for the preparation of
   Figure 1. This work was supported by the intramural program of the
   Eunice Kennedy-Shriver National Institute of Child Health and Human
   Development.
CR ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916                                                         
   Biancotto A, 2008, BLOOD, V111, P699, DOI 10.1182/blood-2007-05-088435
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   BONNER WA, 1972, REV SCI INSTRUM, V43, P404, DOI 10.1063/1.1685647
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Brussaard CPD, 2000, J VIROL METHODS, V85, P175, DOI 10.1016/S0166-0934(99)00167-6
   Cantin R, 1996, VIROLOGY, V218, P372, DOI 10.1006/viro.1996.0206                                                          
   Cantin R, 2001, J GEN VIROL, V82, P2979, DOI 10.1099/0022-1317-82-12-2979                                                    
   CAPOBIANCHI MR, 1994, J INFECT DIS, V169, P886, DOI 10.1093/infdis/169.4.886                                                        
   Ferris MM, 2002, ANAL CHEM, V74, P1849, DOI 10.1021/ac011183q
   GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548                                                       
   GOMEZ MB, 1995, J VIROL, V69, P4628
   HERCHER M, 1979, J HISTOCHEM CYTOCHEM, V27, P350, DOI 10.1177/27.1.374599                                                             
   Hulme AE, 2011, P NATL ACAD SCI USA, V108, P9975, DOI 10.1073/pnas.1014522108
   Iannelli D, 1996, PHYTOPATHOLOGY, V86, P959, DOI 10.1094/Phyto-86-959
   Iannelli D, 1997, J VIROL METHODS, V69, P137, DOI 10.1016/S0166-0934(97)00149-3
   Jouvenet N, 2011, J MOL BIOL, V410, P501, DOI 10.1016/j.jmb.2011.04.062
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Kim BC, 2009, ANAL CHEM, V81, P2388, DOI 10.1021/ac802267u
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lawn SD, 2000, J VIROL, V74, P139, DOI 10.1128/JVI.74.21.10256-10259.2000
   Lawn SD, 2000, J VIROL, V74, P10256, DOI 10.1128/JVI.74.21.10256-10259.2000
   Leaman DP, 2010, J VIROL, V84, P3382, DOI 10.1128/JVI.02363-09
   Lehmann M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002456
   Lien KY, 2011, BIOSENS BIOELECTRON, V26, P3900, DOI 10.1016/j.bios.2011.03.006
   Mao YD, 2012, NAT STRUCT MOL BIOL, V19, P893, DOI 10.1038/nsmb.2351
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   MEERLOO T, 1993, J GEN VIROL, V74, P129, DOI 10.1099/0022-1317-74-1-129
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Nolan JP, 2013, CYTOM PART A, V83A, P301, DOI 10.1002/cyto.a.22255
   Nyambi PN, 2001, J IMMUNOL METHODS, V253, P253, DOI 10.1016/S0022-1759(01)00384-2                                                   
   Ott DE, 2008, REV MED VIROL, V18, P159
   Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416
   ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774                                                         
   Steen HB, 2004, CYTOM PART A, V57A, P94, DOI 10.1002/cyto.a.10115
   Stoffel CL, 2005, CYTOM PART A, V65A, P140, DOI 10.1002/ctyo.a.20145
   Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9
   Trkola A, 1996, J VIROL, V70, P1100
   Trubey CM, 2003, J VIROL, V77, P12699, DOI 10.1128/JVI.77.23.12699-12709.2003
   Van der Pol E, 2012, J THROMB HAEMOST, V10, P919, DOI 10.1111/j.1538-7836.2012.04683.x
   Yan XM, 2005, ANAL CHEM, V77, P7673, DOI 10.1021/ac0508797
   Yan XM, 2004, J IMMUNOL METHODS, V284, P27, DOI 10.1016/j.jim.2003.09.016
   Yang Sung-Yi, 2008, Biosens Bioelectron, V24, P861, DOI 10.1016/j.bios.2008.07.019
   Zhang XK, 2013, NAT STRUCT MOL BIOL, V20, P105, DOI 10.1038/nsmb.2463
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 47
TC 22
Z9 23
U1 0
U2 21
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP
PY 2013
VL 123
IS 9
BP 3716
EP 3727
DI 10.1172/JCI67042
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 220DQ
UT WOS:000324562600017
PM 23925291
OA gold
DA 2018-01-05
ER

PT J
AU Hu, Y
   Cheng, XH
   Ou-Yang, HD
AF Hu, Yi
   Cheng, Xuanhong
   Ou-Yang, H. Daniel
TI Enumerating virus-like particles in an optically concentrated suspension
   by fluorescence correlation spectroscopy
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID MICROSCOPY; DIFFUSION
AB Fluorescence correlation spectroscopy (FCS) is one of the most sensitive methods for enumerating low concentration nanoparticles in a suspension. However, biological nanoparticles such as viruses often exist at a concentration much lower than the FCS detection limit. While optically generated trapping potentials are shown to effectively enhance the concentration of nanoparticles, feasibility of FCS for enumerating field-enriched nanoparticles requires understanding of the nanoparticle behavior in the external field. This paper reports an experimental study that combines optical trapping and FCS to examine existing theoretical predictions of particle concentration. Colloidal suspensions of polystyrene (PS) nanospheres and HIV-1 virus-like particles are used as model systems. Optical trapping energies and statistical analysis are used to discuss the applicability of FCS for enumerating nanoparticles in a potential well produced by a force field. (C) 2013 Optical Society of America
C1 [Hu, Yi; Ou-Yang, H. Daniel] Lehigh Univ, Dept Phys, Bethlehem, PA 18015 USA.
   [Cheng, Xuanhong] Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.
   [Cheng, Xuanhong; Ou-Yang, H. Daniel] Lehigh Univ, Inst Emuls Polymers, Bethlehem, PA 18015 USA.
RP Hu, Y (reprint author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
EM hdo0@lehigh.edu
FU PA Department of Health CURE Formula Funds; NSF [DMR 0923299]; Lehigh
   University Center for Optical Technologies; Emulsion Polymers Institute;
    [NIAID-IR21AI081638]
FX The authors wish to thank Ming-Tzo Wei, Drs. Denis Pristinski, Ya Liu
   and Professor Dimitrios Vavylonis for their helpful suggestions during
   the course of this study, and Professor Olga Latinovic for her training
   on virus production. This project is supported in part by funds from
   NIAID-IR21AI081638, PA Department of Health CURE Formula Funds, NSF DMR
   0923299, Lehigh University Center for Optical Technologies and Emulsion
   Polymers Institute.
CR Chen Y, 2009, BIOPHYS J, V96, P1961, DOI 10.1016/j.bpj.2008.10.067
   ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102                                                      
   Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9
   Grom F, 2006, ELECTROPHORESIS, V27, P1386, DOI 10.1002/elps.200500416
   Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512
   Hosokawa C, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.061410
   Hosokawa C, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021408
   Ito S, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.061402
   Junio J, 2011, OPT LETT, V36, P1497, DOI 10.1364/OL.36.001497
   Junio J, 2010, SOLID STATE COMMUN, V150, P1003, DOI 10.1016/j.ssc.2010.01.018
   Liao KT, 2012, J AM CHEM SOC, V134, P8742, DOI 10.1021/ja3016523
   Ling L., 2010, J APPL PHYS, V108
   MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705
   Meng FB, 2005, J PHYS CHEM B, V109, P5580, DOI 10.1021/jp044898g
   Osborne MA, 1998, J PHYS CHEM B, V102, P3160, DOI 10.1021/jp9715078
   Shevchuk AI, 2008, BIOPHYS J, V94, P4089, DOI 10.1529/biophysj.107.112524
   Wang J, 2011, LASER PHYS, V21, P130, DOI 10.1134/S1054660X1101021X
   Wu B, 2008, BIOPHYS J, V94, P2800, DOI 10.1529/biophysj.107.112789
NR 18
TC 6
Z9 6
U1 1
U2 22
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD SEP 1
PY 2013
VL 4
IS 9
BP 1646
EP 1653
DI 10.1364/BOE.4.001646
PG 8
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 211FD
UT WOS:000323889800015
PM 24049685
OA green_published
DA 2018-01-05
ER

PT J
AU Petrova, MI
   Mathys, L
   Lebeer, S
   Noppen, S
   Van Damme, EJM
   Tanaka, H
   Igarashi, Y
   Vaneechoutte, M
   Vanderleyden, J
   Balzarini, J
AF Petrova, Mariya I.
   Mathys, Leen
   Lebeer, Sarah
   Noppen, Sam
   Van Damme, Els J. M.
   Tanaka, Haruo
   Igarashi, Yasuhiro
   Vaneechoutte, Mario
   Vanderleyden, Jos
   Balzarini, Jan
TI Inhibition of infection and transmission of HIV-1 and lack of
   significant impact on the vaginal commensal lactobacilli by
   carbohydrate-binding agents
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE adhesion; HIV; AIDS; antimicrobial agents; antiretroviral therapy;
   bacterial biofilms; lactic acid bacteria; microbicides
ID HUMAN-IMMUNODEFICIENCY-VIRUS; URTICA-DIOICA AGGLUTININ; COMPLETE GENOME
   SEQUENCE; PRADIMICIN-S; RHAMNOSUS GG; BIOLOGICAL-ACTIVITIES;
   ESCHERICHIA-COLI; PLANT-LECTINS; ANTIBODY 2G12; DC-SIGN
AB A selection of carbohydrate-binding agents (CBAs) with different glycan specificities were evaluated for their inhibitory effect against HIV infection and transmission, and their interaction with vaginal commensal bacteria.
   Several assays were used for the antiviral evaluation: (i) cell-free virus infection of human CD4 T lymphocyte C8166 cells; (ii) syncytium formation in co-cultures of persistently HIV-1-infected HUT-78/HIV-1 and non-infected CD4 SupT1 cells; (iii) DC-SIGN-directed capture of HIV-1 particles; and (iv) transmission of DC-SIGN-captured HIV-1 particles to uninfected CD4 C8166 cells. CBAs were also examined for their interaction with vaginal commensal lactobacilli using several viability, proliferation and adhesion assays.
   The CBAs showed efficient inhibitory activity in the nanomolar to low-micromolar range against four events that play a crucial role in HIV-1 infection and transmission: cell-free virus infection, fusion between HIV-1-infected and non-infected cells, HIV-1 capture by DC-SIGN and transmission of DC-SIGN-captured virus to T cells. As candidate microbicides should not interfere with the normal human microbiota, we examined the effect of CBAs against Lactobacillus strains, including a variety of vaginal strains, a gastrointestinal strain and several non-human isolates. None of the CBAs included in our studies inhibited the growth of these bacteria in several media, affected their viability or had any significant impact on their adhesion to HeLa cell monolayers.
   The CBAs in this study were inhibitory to HIV-1 in several in vitro infection and transmission models, and may therefore qualify as potential microbicide candidates. The lack of significant impact on commensal vaginal lactobacilli is an important property of these CBAs in view of their potential microbicidal use.
C1 [Petrova, Mariya I.; Lebeer, Sarah; Vanderleyden, Jos] Katholieke Univ Leuven, Ctr Microbial & Plant Genet, B-3001 Louvain, Belgium.
   [Petrova, Mariya I.; Lebeer, Sarah] Univ Antwerp, Dept Biosci Engn, B-2020 Antwerp, Belgium.
   [Mathys, Leen; Noppen, Sam; Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
   [Van Damme, Els J. M.] Univ Ghent, Dept Mol Biotechnol, Lab Biochem & Glycobiol, B-9000 Ghent, Belgium.
   [Tanaka, Haruo] Iwaki Meisei Univ, Fac Pharm, Iwaki, Fukushima 9708551, Japan.
   [Tanaka, Haruo] Iwaki Meisei Univ, Coll Sci & Engn, Iwaki, Fukushima 9708551, Japan.
   [Igarashi, Yasuhiro] Toyama Prefectural Univ, Biotechnol Res Ctr, Toyama 9390398, Japan.
   [Vaneechoutte, Mario] Univ Ghent, Lab Bacteriol Res, B-9000 Ghent, Belgium.
RP Balzarini, J (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.
EM jan.balzarini@rega.kuleuven.be
RI Van Damme, Els/B-4410-2015
OI Van Damme, Els/0000-0001-9848-766X
FU KU Leuven [PF 10/018, GOA 10/14]; Fonds voor Wetenschappelijk Onderzoek
   (FWO) [G.0528.12N]; European Community (CHAARM); L'Oreal-UNESCO; Belgian
   FWO
FX This work was supported by the KU Leuven (PF 10/018, GOA 10/14), the
   Fonds voor Wetenschappelijk Onderzoek (FWO; G.0528.12N) and the European
   Community (CHAARM). L. M. is supported by a fellowship from
   L'Oreal-UNESCO, in collaboration with the Belgian FWO.
CR Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Balzarini J, 2007, J VIROL, V81, P362, DOI 10.1128/JVI.01404-06
   Balzarini J, 2010, ANTIMICROB AGENTS CH, V54, P1425, DOI 10.1128/AAC.01347-09
   Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453
   Bolton M, 2008, SEX TRANSM DIS, V35, P214, DOI 10.1097/OLQ.0b013e31815b017a
   CHAN RCY, 1985, INFECT IMMUN, V47, P84
   Chiba H, 2001, BIOCHEM BIOPH RES CO, V282, P595, DOI 10.1006/bbrc.2001.4495
   Covens K, 2009, J CLIN MICROBIOL, V47, P2232, DOI 10.1128/JCM.01739-08
   Cribby S, 2008, INTERDISCIP PERSPECT, V29
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Francius G, 2008, ACS NANO, V2, P1921, DOI 10.1021/nn800341b
   Francois KO, 2012, MED RES REV, V32, P349, DOI 10.1002/med.20216
   Fujikawa K, 1998, GLYCOBIOLOGY, V8, P407, DOI 10.1093/glycob/8.4.407                                                          
   GASSER F, 1970, J GEN MICROBIOL, V62, P219, DOI 10.1099/00221287-62-2-219                                                       
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Giomarelli B, 2002, AIDS, V16, P1351, DOI 10.1097/00002030-200207050-00006
   HANSEN PA, 1968, TYPE STRAINS LACTOBA
   Hoorelbeke B, 2010, ANTIMICROB AGENTS CH, V54, P3287, DOI 10.1128/AAC.00254-10
   Huskens D, 2007, VIROLOGY, V360, P294, DOI 10.1016/j.virol.2006.10.027
   Inokoshi J, 2001, BIOCHEM BIOPH RES CO, V281, P1261, DOI 10.1006/bbrc.2001.4496
   KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K                                                    
   Kankainen M, 2009, P NATL ACAD SCI USA, V106, P17193, DOI 10.1073/pnas.0908876106
   KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289                                                           
   Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100
   Lebeer S, 2008, MICROBIOL MOL BIOL R, V72, P728, DOI 10.1128/MMBR.00017-08
   Lebeer S, 2011, MICROB BIOTECHNOL, V4, P368, DOI 10.1111/j.1751-7915.2010.00199.x
   Lebeer S, 2009, APPL ENVIRON MICROB, V75, P3554, DOI 10.1128/AEM.02919-08
   Lee RT, 1998, GLYCOCONJUGATE J, V15, P649, DOI 10.1023/A:1006976129458                                                         
   Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127
   MOORE WEC, 1980, APPL ENVIRON MICROB, V39, P900
   OKI T, 1988, J ANTIBIOT, V41, P1701, DOI 10.7164/antibiotics.41.1701                                                     
   Princen Katrien, 2004, Retrovirology, V1, P2, DOI 10.1186/1742-4690-1-2
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   Reid G, 1999, APPL ENVIRON MICROB, V65, P3763
   Reid G, 2001, FEMS IMMUNOL MED MIC, V30, P49, DOI 10.1016/S0928-8244(00)00233-9
   Reid G, 2008, J CLIN GASTROENTEROL, V42, pS234, DOI 10.1097/MCG.0b013e31817f1298
   ROGOSA M, 1953, J BACTERIOL, V65, P681
   SAITOH K, 1993, J ANTIBIOT, V46, P580, DOI 10.7164/antibiotics.46.580                                                      
   SAITOH K, 1995, J ANTIBIOT, V48, P162, DOI 10.7164/antibiotics.48.162                                                      
   SAWADA Y, 1990, J ANTIBIOT, V43, P715, DOI 10.7164/antibiotics.43.715                                                      
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   SHIBUYA N, 1988, J BIOL CHEM, V263, P728
   Tanaka H, 2009, P NATL ACAD SCI USA, V106, P15633, DOI 10.1073/pnas.0907572106
   VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52
   VANDAMME EJM, 1988, PLANT PHYSIOL, V86, P598, DOI 10.1104/pp.86.2.598
   VIDWANS SJ, 1995, J BACTERIOL, V177, P3308, DOI 10.1128/jb.177.11.3308-3311.1995                                                
   Weber J, 2006, J VIROL METHODS, V136, P102, DOI 10.1016/j.jviromet.2006.04.004
NR 51
TC 5
Z9 5
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD SEP
PY 2013
VL 68
IS 9
BP 2026
EP 2037
DI 10.1093/jac/dkt152
PG 12
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 205EF
UT WOS:000323424100013
PM 23640125
OA gold
DA 2018-01-05
ER

PT J
AU Graham, BS
AF Graham, Barney S.
TI Advances in antiviral vaccine development
SO IMMUNOLOGICAL REVIEWS
LA English
DT Review
DE viral immunity; vaccine development; monoclonal antibodies; neutralizing
   antibody; structure-based vaccine design; vaccines
ID RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA-A VIRUSES; MEMORY B-CELLS; GP120
   ENVELOPE GLYCOPROTEIN; HUMAN MONOCLONAL-ANTIBODIES; X-RAY-DIFFRACTION;
   NEUTRALIZING ANTIBODY; HIV-1 VACCINE; HUMAN-IMMUNOGLOBULIN; POTENT
   NEUTRALIZATION
AB Antiviral vaccines have been the most successful biomedical intervention for preventing epidemic viral disease. Vaccination for smallpox in humans and rinderpest in cattle was the basis for disease eradication, and recent progress in polio eradication is promising. Although early vaccines were developed empirically by passage in live animals or eggs, more recent vaccines have been developed because of the advent of new technologies, particularly cell culture and molecular biology. Recent technological advances in gene delivery and expression, nanoparticles, protein manufacturing, and adjuvants have created the potential for new vaccine platforms that may provide solutions for vaccines against viral pathogens for which no interventions currently exist. In addition, the technological convergence of human monoclonal antibody isolation, structural biology, and high-throughput sequencing is providing new opportunities for atomic-level immunogen design. Selection of human monoclonal antibodies can identify immunodominant antigenic sites associated with neutralization and provide reagents for stabilizing and solving the structure of viral surface proteins. Understanding the structural basis for neutralization can guide selection of vaccine targets. Deep sequencing of the antibody repertoire and defining the ontogeny of the desired antibody responses can reveal the junctional recombination and somatic mutation requirements for B-cell recognition and affinity maturation. Collectively, this information will provide new strategic approaches for selecting vaccine antigens, formulations, and regimens. Moreover, it creates the potential for rational vaccine design and establishing a catalogue of vaccine technology platforms that would be effective against any given family or class of viral pathogens and improve our readiness to address new emerging viral threats.
C1 NIAID, NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA.
RP Graham, BS (reprint author), NIAID, NIH, Vaccine Res Ctr, 40 Convent Dr Bldg 40,Rm 2502, Bethesda, MD 20892 USA.
EM bgraham@nih.gov
FU National Institute of Allergy and Infectious Diseases
FX I thank Dr. Julie E. Ledgerwood and Dr. Kayvon Modjarrad for thoughtful
   advice and suggestions. This study was supported by the intramural
   funding from the National Institute of Allergy and Infectious Diseases.
   The author has no conflicts of interest to declare.
CR Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
   Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071                                                         
   BIZEBARD T, 1990, J MOL BIOL, V216, P513, DOI 10.1016/0022-2836(90)90378-Y
   BORROW P, 1994, J VIROL, V68, P6103
   Boyd SD, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000540
   Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620                                                         
   Centers for Disease Control and Prevention (CDC), 2013, MMWR-MORBID MORTAL W, V62, P335
   Chung A, 2012, HIV VACC KEYST S KEY
   COONEY EL, 1993, P NATL ACAD SCI USA, V90, P1882, DOI 10.1073/pnas.90.5.1882
   Correia BE, 2010, STRUCTURE, V18, P1116, DOI 10.1016/j.str.2010.06.010
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   de Swart RL, 2012, CURR OPIN VIROL, V2, P330, DOI 10.1016/j.coviro.2012.02.010
   DeKosky BJ, 2013, NAT BIOTECHNOL, V31, P166, DOI 10.1038/nbt.2492
   Ekiert DC, 2012, NATURE, V489, P526, DOI 10.1038/nature11414
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Glanville J, 2009, P NATL ACAD SCI USA, V106, P20216, DOI 10.1073/pnas.0909775106
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026                                            
   Graham BS, 2009, CLIN PHARMACOL THER, V86, P234, DOI 10.1038/clpt.2009.128
   Graham BS, 2011, IMMUNE RESPONSE TO INFECTION, P559
   GRAHAM BS, 1994, J INFECT DIS, V170, P782, DOI 10.1093/infdis/170.4.782                                                        
   GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533                                                        
   GREEN LL, 1994, NAT GENET, V7, P13, DOI 10.1038/ng0594-13
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   HENDERSON DA, 1980, PUBLIC HEALTH REP, V95, P422
   HERTZ MI, 1989, MEDICINE, V68, P269, DOI 10.1097/00005792-198909000-00002                                                
   Hope TJ, 2011, NAT MED, V17, P1195, DOI 10.1038/nm.2528
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Janes H, 2012, PLOS ONE, V7
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Keele BF, 2009, J EXP MED, V206, P1117, DOI 10.1084/jem.20082831
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KOUP RA, 1994, J VIROL, V68, P4650
   Kwakkenbos MJ, 2010, NAT MED, V16, P123, DOI 10.1038/nm.2071
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2009, NAT IMMUNOL, V10, P573, DOI 10.1038/ni.1746
   Ledgerwood JE, 2011, LANCET INFECT DIS, V11, P916, DOI 10.1016/S1473-3099(11)70240-7
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Letvin NL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002351
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011
   Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371
   LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340                                                        
   MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11
   McLellan JS, 2011, J MOL BIOL, V409, P853, DOI 10.1016/j.jmb.2011.04.044
   Morse SS, 2012, LANCET, V380, P1956, DOI 10.1016/S0140-6736(12)61684-5
   Null D, 1998, PEDIATRICS, V102, P531
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   OKUNO Y, 1993, J VIROL, V67, P2552
   OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Perry RT, 2013, MMWR-MORBID MORTAL W, V62, P27
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Roeder PL, 2011, PREV VET MED, V102, P98, DOI 10.1016/j.prevetmed.2011.04.004
   Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W
   Rolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519
   Russell ND, 2007, JAIDS-J ACQ IMM DEF, V44, P203, DOI 10.1097/01.qai.0000248356.48501.ff
   STEINITZ M, 1977, NATURE, V269, P420, DOI 10.1038/269420a0
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108
   TERRY WD, 1968, NATURE, V220, P239, DOI 10.1038/220239a0
   Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Turchaninova MA, 2013, EUR J IMMUNOL, DOI 10.1002/eji.201343453
   Victoria JG, 2010, J VIROL, V84, P6033, DOI 10.1128/JVI.02690-09
   Villa LL, 2007, NEW ENGL J MED, V356, P1915
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wei CJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004273
   Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517
   WILEY DC, 1977, J MOL BIOL, V112, P343, DOI 10.1016/S0022-2836(77)80149-6
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Yin HS, 2006, NATURE, V439, P38, DOI 10.1038/nature04322
   Yin HS, 2005, P NATL ACAD SCI USA, V102, P9288, DOI 10.1073/pnas.0503989102
   Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 89
TC 11
Z9 12
U1 0
U2 91
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-2896
J9 IMMUNOL REV
JI Immunol. Rev.
PD SEP
PY 2013
VL 255
IS 1
SI SI
BP 230
EP 242
DI 10.1111/imr.12098
PG 13
WC Immunology
SC Immunology
GA 201OM
UT WOS:000323150900017
PM 23947359
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chang, JJ
   Woods, M
   Lindsay, RJ
   Doyle, EH
   Griesbeck, M
   Chan, ES
   Robbins, GK
   Bosch, RJ
   Altfeld, M
AF Chang, J. Judy
   Woods, Matt
   Lindsay, Robert J.
   Doyle, Erin H.
   Griesbeck, Morgane
   Chan, Ellen S.
   Robbins, Gregory K.
   Bosch, Ronald J.
   Altfeld, Marcus
TI Higher Expression of Several Interferon-Stimulated Genes in
   HIV-1-Infected Females After Adjusting for the Level of Viral
   Replication
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; innate immunity; type I Interferon; Toll-like receptors; T cells;
   sex differences; immune activation; dendritic cells; pathogenesis
ID PLASMACYTOID DENDRITIC CELLS; HIV-1 INFECTION; SEX-DIFFERENCES; IMMUNE
   ACTIVATION; VIRUS BURDEN; RNA LEVELS; T-CELLS; RESPONSES; AIDS;
   PROGRESSION
AB Background. Clinical studies have shown faster disease progression and stronger immune activation in human immunodeficiency virus (HIV)-1-infected females when compared with males for the same level of HIV-1 replication. Here we determine whether the elevated levels of HIV-1-induced interferon-alpha (IFN-alpha) production observed in females are associated with higher interferon-stimulated gene (ISG) expression levels in T cells, hence suggesting type-I IFN as a mechanism for the higher HIV-1-associated immune activation observed.
   Methods. T-cell and dendritic cell populations were isolated from treatment-naive chronically HIV-1-infected individuals enrolled in the Adult Clinical Trials Group 384 by fluorescence-activated cell sorting. The expression of 98 genes involved in Toll-like receptor and type I IFN signaling pathways were quantified using Nanostring technology.
   Results. Several ISGs were significantly correlated with HIV-1 viral load and/or CD4(+) T-cell count. Higher expression levels of a subset of these ISGs were observed in cells derived from females as compared to males after adjusting for viral load and were correlated to higher levels of T-cell activation.
   Conclusion. These data show that higher IFN-alpha production is associated with higher ex vivo expression of several ISGs in females. This might contribute to higher levels of immune activation and the observed faster HIV-1 disease progression in females for a given level of viral replication.
C1 [Chang, J. Judy; Woods, Matt; Lindsay, Robert J.; Doyle, Erin H.; Griesbeck, Morgane; Altfeld, Marcus] Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA.
   [Chang, J. Judy; Woods, Matt; Lindsay, Robert J.; Doyle, Erin H.; Griesbeck, Morgane; Altfeld, Marcus] MIT, Cambridge, MA 02139 USA.
   [Chang, J. Judy; Woods, Matt; Lindsay, Robert J.; Doyle, Erin H.; Griesbeck, Morgane; Altfeld, Marcus] Harvard Univ, Sch Med, Boston, MA USA.
   [Chan, Ellen S.; Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
   [Robbins, Gregory K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
RP Altfeld, M (reprint author), Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, 9th Floor,400 Technol Sq, Cambridge, MA 02139 USA.
EM maltfeld@partners.org
OI Doyle, Erin/0000-0001-9380-2819
FU National Institutes of Health/National Institute of Allergy and
   Infectious Diseases (NIAID) [R01 AI078784]; National Health and Medical
   Research Council of Australia [519578]; Phillip T. and Susan M. Ragon
   Foundation; NIAID [AI38855, AI27659, AI38858, AI25879, AI27666, AI68634,
   AI68636]; Agouron/Pfizer; Bristol Myers Squibb; GlaxoSmithKline
FX These studies were supported by the National Institutes of
   Health/National Institute of Allergy and Infectious Diseases (NIAID; R01
   AI078784) and fellowships awarded to J. J. C. from the National Health
   and Medical Research Council of Australia (519578) and the Phillip T.
   and Susan M. Ragon Foundation. ACTG 384 was supported in part by NIAID
   (grants AI38855, AI27659, AI38858, AI25879, AI27666, AI68634, AI68636)
   and by Agouron/Pfizer, Bristol Myers Squibb, and GlaxoSmithKline.
CR Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050
   Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088                                                     
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Evans JS, 1997, J INFECT DIS, V175, P795, DOI 10.1086/513973
   Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1                                                   
   Foster GR, 1998, J VIRAL HEPATITIS, V5, P143, DOI 10.1046/j.1365-2893.1998.00103.x                                                
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660                                                                  
   Giri MS, 2006, J LEUKOCYTE BIOL, V80, P1031, DOI 10.1189/jlb.0306157
   Hilkens CMU, 2003, J IMMUNOL, V171, P5255, DOI 10.4049/jimmunol.171.10.5255                                                    
   Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547
   Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Komatsuda A, 2008, CLIN EXP IMMUNOL, V152, P482, DOI 10.1111/j.1365-2249.2008.03646.x
   Li QS, 2009, J IMMUNOL, V183, P1975, DOI 10.4049/jimmunol.0803222
   Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815
   Mandl JN, 2008, NAT MED, V14, P1077, DOI 10.1038/nm.1871
   Meditz AL, 2011, J INFECT DIS, V203, P442, DOI 10.1093/infdis/jiq085
   Mehla R, 2012, CURR HIV-AIDS REP, V9, P34, DOI 10.1007/s11904-011-0100-x
   Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07
   Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004
   Mitchell LA, 1999, J MED MICROBIOL, V48, P1075, DOI 10.1099/00222615-48-12-1075                                                     
   Nascimbeni M, 2009, BLOOD, V113, P6112, DOI 10.1182/blood-2008-07-170803
   O'Brien M, 2011, J CLIN INVEST, V121, P1088, DOI 10.1172/JCI44960
   Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103
   Pincetic A, 2010, J VIROL, V84, P4725, DOI 10.1128/JVI.02478-09
   Rotger M, 2011, J CLIN INVEST, V121, P2391, DOI 10.1172/JCI45235
   Sabado RL, 2010, BLOOD, V116, P3839, DOI 10.1182/blood-2010-03-273763
   Sandberg JK, 2003, EUR J IMMUNOL, V33, P588, DOI 10.1002/eji.200323707
   Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003
   Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967                                                                  
   Thibault S, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-42
NR 34
TC 28
Z9 28
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2013
VL 208
IS 5
BP 830
EP 838
DI 10.1093/infdis/jit262
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 198YB
UT WOS:000322958900015
PM 23757341
OA gold
DA 2018-01-05
ER

PT J
AU Lazniewska, J
   Milowska, K
   Katir, N
   El Kadib, A
   Bryszewska, M
   Majoral, JP
   Gabryelak, T
AF Lazniewska, Joanna
   Milowska, Katarzyna
   Katir, Nadia
   El Kadib, Abdelkim
   Bryszewska, Maria
   Majoral, Jean-Pierre
   Gabryelak, Teresa
TI Viologen-phosphorus dendrimers exhibit minor toxicity against a murine
   neuroblastoma cell line
SO CELLULAR & MOLECULAR BIOLOGY LETTERS
LA English
DT Article
DE Apoptosis; Cytotoxicity; N2a cell line; ROS; Viologen-phosphorus
   dendrimers
ID SUPPORTED LIPID-BILAYERS; ALPHA-SYNUCLEIN; INTRACELLULAR TRAFFICKING;
   PAMAM DENDRIMERS; LIVING CELLS; MITOCHONDRIAL; APOPTOSIS;
   INTERNALIZATION; POLYMERS; EXPOSURE
AB Dendrimers containing viologen (derivatives of 4,4'-bipyridyl) units in their structure have been demonstrated to exhibit antiviral activity against human immunodeficiency virus (HIV-1). It has also recently been revealed that novel dendrimers with both viologen units and phosphorus groups in their structure show different antimicrobial, cytotoxic and hemotoxic properties, and have the ability to influence the activity of cholinesterases and to inhibit alpha-synuclein fibrillation. Since the influence of viologen-phosphorus structures on basic cellular processes had not been investigated, we examined the impact of such macromolecules on the murine neuroblastoma cell line (N2a). We selected three water-soluble viologen-phosphorus (VPD) dendrimers, which differ in their core structure, number of viologen units and number and type of surface groups, and analyzed several aspects of the cellular response. These included cell viability, generation of reactive oxygen species (ROS), alterations in mitochondrial activity, morphological modifications, and the induction of apoptosis and necrosis. The MTT assay results suggest that all of the tested dendrimers are only slightly cytotoxic. Although some changes in ROS formation and mitochondrial function were detected, the three compounds did not induce apoptosis or necrosis. In light of these results, we can assume that the tested VPD are relatively safe for mouse neuroblastoma cells. Although more research on their safety is needed, VPD seem to be promising nanoparticles for further biomedical investigation.
C1 [Lazniewska, Joanna; Milowska, Katarzyna; Bryszewska, Maria; Gabryelak, Teresa] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, PL-90236 Lodz, Poland.
   [Katir, Nadia; Majoral, Jean-Pierre] CNRS, Chim Coordinat Lab, F-31077 Toulouse, France.
   [El Kadib, Abdelkim] ENSET, Inst Nanomat & Nanotechnol & Moroccan Fdn Adv Sci, Rabat 10100, Morocco.
RP Lazniewska, J (reprint author), Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, Pomorska 141-143, PL-90236 Lodz, Poland.
EM jolazn@biol.uni.lodz.pl
RI Lazniewska, Joanna/H-6666-2014
OI Lazniewska, Joanna/0000-0001-5729-4773; Bryszewska,
   Maria/0000-0003-4676-3743; Milowska, Katarzyna/0000-0002-4050-2756
FU COST program [TD0802]
FX This study was supported by the COST TD0802 program. The authors would
   like to acknowledge the access granted to a fluorescence/phase contrast
   microscope from the laboratory of Professor Janusz Maszewski of the
   Department of Cytophysiology at the University of Lodz.
CR Agnello M, 2008, CYTOTECHNOLOGY, V56, P145, DOI 10.1007/s10616-008-9143-2
   Albertazzi L, 2013, MOL PHARMACEUT, V10, P249, DOI 10.1021/mp300391v
   Albertazzi L, 2012, BIOCONJUGATE CHEM, V23, P1059, DOI 10.1021/bc300079h
   Albertazzi L, 2010, MOL PHARMACEUT, V7, P680, DOI 10.1021/mp9002464
   Asaftei S, 2010, J MED CHEM, V53, P3480, DOI 10.1021/jm100093p
   BABBS CF, 1989, PLANT PHYSIOL, V90, P1267, DOI 10.1104/pp.90.4.1267
   Baker Jr J. R., 2009, HEMATOLOGY, V1, P708
   Bartosz G, 2006, CLIN CHIM ACTA, V368, P53, DOI 10.1016/j.cca.2005.12.039
   Bernas T, 2002, CYTOMETRY, V47, P236, DOI 10.1002/cyto.10080
   Bielefeld EC, 2005, HEARING RES, V207, P35, DOI 10.1016/j.heares.2005.03.025
   Caminade AM, 2010, NEW J CHEM, V34, P1512, DOI 10.1039/c0nj00116c
   Ciepluch K, 2013, INT J BIOL MACROMOL, V54, P119, DOI 10.1016/j.ijbiomac.2012.12.002
   Ciepluch K, 2012, MOL PHARMACEUT, V9, P448, DOI 10.1021/mp200549c
   Dai H., 2010, NANOMEDICINE, V5, P317
   Freire C, 2012, NEUROTOXICOLOGY, V33, P947, DOI 10.1016/j.neuro.2012.05.011
   Fukushima Tetsuhito, 2002, Environ Health Prev Med, V7, P89, DOI 10.1265/ehpm.2002.89
   Galliot C, 1997, SCIENCE, V277, P1981, DOI 10.1126/science.277.5334.1981
   Gollamudi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036191
   Guo R, 2012, CURR DRUG METAB, V13, P1097, DOI 10.2174/138920012802850010                                                      
   Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x
   Hong SP, 2006, BIOCONJUGATE CHEM, V17, P728, DOI 10.1021/bc060077y
   Huang C., 2012, TOXICOL IND HEALTH, DOI [10.1177/0748233712442712, DOI 10.1177/0748233712442712]
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Ionov M, 2012, CHEM PHYS LIPIDS, V165, P408, DOI 10.1016/j.chemphyslip.2011.11.014
   Janaszewska A., 2013, NANOMEDICINE, DOI [10.1016/j.nano.2013.01.010, DOI 10.1016/J.NAN0.2013.01.010]
   Janiszewska J, 2012, BIOORG MED CHEM LETT, V22, P1388, DOI 10.1016/j.bmcl.2011.12.051
   Kannan S., 2012, SCI TRANSL MED, V4
   Kitchens KM, 2008, MOL PHARM, V5, P364, DOI 10.1021/mp700089s
   Kitchens KM, 2007, PHARM RES, V24, P2138, DOI 10.1007/s11095-007-9415-0
   Klajnert B, 2001, ACTA BIOCHIM POL, V48, P199
   Kuo JHS, 2007, J CONTROL RELEASE, V120, P51, DOI 10.1016/j.jconrel.2007.03.019
   LAUNAY N, 1994, ANGEW CHEM INT EDIT, V33, P1589, DOI 10.1002/anie.199415891                                                          
   Lee JH, 2009, TOXICOL LETT, V190, P202, DOI 10.1016/j.toxlet.2009.07.018
   Leroueil PR, 2008, NANO LETT, V8, P420, DOI 10.1021/nl0722929
   Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y
   Luganini A, 2011, ANTIMICROB AGENTS CH, V55, P3231, DOI 10.1128/AAC.00149-11
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Merino S, 2001, CHEM-EUR J, V7, P3095, DOI 10.1002/1521-3765(20010716)7:14<3095::AID-CHEM3095>3.0.CO;2-S                   
   Michalowicz J, 2009, TOXICOL LETT, V191, P246, DOI 10.1016/j.toxlet.2009.09.010
   Milowska K, 2013, MOL PHARMACEUT, V10, P1131, DOI 10.1021/mp300636h
   Milowska K, 2013, J LUMIN, V134, P132, DOI 10.1016/j.jlumin.2012.08.060
   Milowska K, 2012, INT J BIOL MACROMOL, V50, P1138, DOI 10.1016/j.ijbiomac.2012.02.003
   Mukherjee SP, 2010, TOXICOL APPL PHARM, V248, P259, DOI 10.1016/j.taap.2010.08.016
   Mukherjee S. P., 2012, NANOMEDICINE, V9, P202
   Naha PC, 2010, TOXICOL APPL PHARM, V246, P91, DOI 10.1016/j.taap.2010.04.014
   Ottaviani MF, 2010, BIOMACROMOLECULES, V11, P3014, DOI 10.1021/bm100824z
   Patel D, 2006, BBA-GEN SUBJECTS, V1760, P1802, DOI 10.1016/j.bbagen.2006.08.008
   Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038
   Ribble D, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-12
   Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8
   Spivey A, 2011, ENVIRON HEALTH PERSP, V119, pA259, DOI 10.1289/ehp.119-a259a
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Wang B, 2010, INT J PHARMACEUT, V395, P298, DOI 10.1016/j.ijpharm.2010.05.030
   Wang W, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/10/105103
   Wasiak T, 2012, MOL PHARMACEUT, V9, P458, DOI 10.1021/mp2005627
NR 55
TC 6
Z9 6
U1 3
U2 26
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 1425-8153
J9 CELL MOL BIOL LETT
JI Cell. Mol. Biol. Lett.
PD SEP
PY 2013
VL 18
IS 3
BP 459
EP 478
DI 10.2478/s11658-013-0100-5
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 191AZ
UT WOS:000322386300010
PM 23893290
OA gold
DA 2018-01-05
ER

PT J
AU Pedziwiatr-Werbicka, E
   Fuentes, E
   Dzmitruk, V
   Sanchez-Nieves, J
   Sudas, M
   Drozd, E
   Shakhbazau, A
   Shcharbin, D
   de la Mata, FJ
   Gomez-Ramirez, R
   Munoz-Fernandez, MA
   Bryszewska, M
AF Pedziwiatr-Werbicka, Elzbieta
   Fuentes, Elena
   Dzmitruk, Volha
   Sanchez-Nieves, Javier
   Sudas, Marharyta
   Drozd, Elizaveta
   Shakhbazau, Antos
   Shcharbin, Dzmitry
   Javier de la Mata, Francisco
   Gomez-Ramirez, Rafael
   Angeles Munoz-Fernandez, Maria
   Bryszewska, Maria
TI Novel 'Si-C' carbosilane dendrimers as carriers for anti-HIV nucleic
   acids: Studies on complexation and interaction with blood cells
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Cationic carbosilane dendrimer; Anti-HIV nucleic acids; Dendriplex;
   Synthesis; Stability; Cytotoxicity
ID POLYAMIDOAMINE DENDRIMERS; PAMAM DENDRIMERS; GENE DELIVERY; SURFACE
   MODIFICATION; IN-VITRO; OLIGONUCLEOTIDES; CYTOTOXICITY; DENDRIPLEXES;
   TRANSFECTION; SIRNA
AB Treatment of HIV infection by gene therapy is a promising tool for combating AIDS. One of the primary limitations of gene therapy is the effective delivery of nucleic acids to the target cells. Dendrimers are nanoparticles that are increasingly being used as nucleic acid vehicles. We have synthesized "Si-C" amino-terminated carbosilane dendrimers [G(n)O(3)(NMe3)(m)](m+) functionalized with quaternary ammonium (NMe3+) terminal groups via hydrosilylation of allyl dimethylamine with the corresponding G(n)O(3)(SiH)(m) dendrimers and further addition of MeI. These dendrimers are soluble in water. Initially, complexation between these "Si-C" dendrimers and anti-HIV nucleic acids (oligodeoxynucleotides ANTITAR and GEM91, siRNA siP24) was studied and molar ratios for complete complexation were determined. Then the charge and size of the dendriplexes (complexes of "Si-C" dendrimers with nucleic acids) were analyzed and it was found that they possessed charges of +5 to +40 mV and sizes of 60-600 nm (zeta-size) or 50-100 nm (atomic force microscopy) suitable for cell transfection. Stability studies showed that the dendriplexes were stable over time and were resistant to degradation by serum albumin. The effects of dendrimers and their dendriplexes on erythrocytes (isolated and in whole blood) revealed that the dendriplexes were significantly less cytotoxic than the pure dendrimers. The effects of dendrimers and their dendriplexes on peripheral blood mononuclear cells (the main target of HIV) were analyzed and it was found that the dendriplexes were 10 times less cytotoxic than the pure dendrimers. Finally, transfection experiments revealed that "Si-C"-carbosilane dendrimers had a restricted ability to deliver long-chain double-stranded nucleic acids. The results indicate that these cationic carbosilane dendrimers are good candidates for delivering short-chain siRNA and oligodeoxynucleotide to HIV-infected peripheral blood mononuclear cells or lymphocytes. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Pedziwiatr-Werbicka, Elzbieta; Bryszewska, Maria] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, PL-90236 Lodz, Poland.
   [Fuentes, Elena; Sanchez-Nieves, Javier; Javier de la Mata, Francisco; Gomez-Ramirez, Rafael] Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, Alcala De Henares, Spain.
   [Dzmitruk, Volha; Shcharbin, Dzmitry] NASB, Inst Biophys & Cell Engn, Minsk 220072, Byelarus.
   [Sudas, Marharyta; Drozd, Elizaveta] NASB, AV Luikov Heat & Mass Transfer Inst, Minsk 220072, Byelarus.
   [Shakhbazau, Antos] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada.
   [Shakhbazau, Antos] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
   [Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid, Spain.
RP Pedziwiatr-Werbicka, E (reprint author), Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, 141-143 Pomorska St, PL-90236 Lodz, Poland.
EM epedz@biol.uni.lodz.pl; d.shcharbin@mail.ru
RI Shcharbin, Dzmitry/G-2046-2011; Sanchez-Nieves, Javier/J-9260-2014;
   Gomez Ramirez, Rafael/K-1216-2014; De la Mata, F. Javier/K-1649-2014
OI Shcharbin, Dzmitry/0000-0002-1414-4465; Sanchez-Nieves,
   Javier/0000-0003-0410-2285; Gomez Ramirez, Rafael/0000-0001-6448-2414;
   De la Mata, F. Javier/0000-0003-0418-3935; Pedziwiatr-Werbicka,
   Elzbieta/0000-0001-7943-2612; Munoz-Fernandez/0000-0002-0813-4500;
   Bryszewska, Maria/0000-0003-4676-3743
FU Iuventus Plus [IP2011 041071]; MEC (Spain) [CTQ2011-23245]; Consortium
   NANODENDMED (CAM, Spain) [S2011/BMD-2351]; Project UAH
   [UAH2011/EXP-037]; Belarusian Republican Foundation for Fundamental
   Research; Consejeria de Educacion de la Comunidad de Madrid; VI National
   RDi Plan; Iniciativa Ingenio; Consolider Program; CIBER Actions;
   Instituto de Salud Carlos III; Fondo Social Europeo
FX This work was supported by the project Iuventus Plus (nr IP2011 041071),
   grants from ME&C (Spain) (Ref. CTQ2011-23245), Consortium NANODENDMED
   ref S2011/BMD-2351 (CAM, Spain) and Project UAH 2011 (Ref.
   UAH2011/EXP-037) to University of Alcala, grant from the Belarusian
   Republican Foundation for Fundamental Research,. This work was also
   supported by grants from the Consejeria de Educacion de la Comunidad de
   Madrid and Fondo Social Europeo (F.S.E.) for S.G.G. CIBER-BBN is an
   initiative funded by the VI National R&D&i Plan 2008-2011, Iniciativa
   Ingenio 2010, Consolider Program, CIBER Actions and financed by the
   Instituto de Salud Carlos III with assistance from the European Regional
   Development Fund.
CR BAASE WA, 1979, NUCLEIC ACIDS RES, V6, P797, DOI 10.1093/nar/6.2.797                                                             
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   BRIAND P, 1993, PATHOL BIOL, V41, P663
   Choi JS, 2006, INT J PHARM, V320, P171, DOI 10.1016/j.ijpharm.2006.05.002
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Dobrovolskaia M.A., 2005, ITA6 NCL NCI
   Dobrovolskaia MA, 2012, MOL PHARMACEUT, V9, P382, DOI 10.1021/mp200463e
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Dutta T, 2010, NANOMED-NANOTECHNOL, V6, P25, DOI 10.1016/j.nano.2009.05.005
   Dzmitruk V., 2011, ADV NANOCOMPOSITE TE
   Fant K, 2008, BIOCHEMISTRY-US, V47, P1732, DOI 10.1021/bi7017199
   Gebhart CL, 2001, J CONTROL RELEASE, V73, P401, DOI 10.1016/S0168-3659(01)00357-1
   Glantz SA, 1994, PRIMER BIOSTATISTICS
   Jevprasesphant R, 2003, PHARMACEUT RES, V20, P1543, DOI 10.1023/A:1026166729873                                                         
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   Jones CF, 2012, ACS NANO, V6, P9900, DOI 10.1021/nn303472r
   Jones CF, 2012, MOL PHARMACEUT, V9, P1599, DOI 10.1021/mp2006054
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   Klajnert B, 2006, INT J PHARM, V309, P208, DOI 10.1016/j.ijpharm.2005.10.039
   Kono K, 2005, BIOCONJUGATE CHEM, V16, P208, DOI 10.1021/bc049785e
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Mintzer MA, 2011, CHEM SOC REV, V40, P173, DOI 10.1039/b901839p
   MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530
   Ortega P, 2011, ORG BIOMOL CHEM, V9, P5238, DOI 10.1039/c1ob05321c
   Ortega P, 2010, TETRAHEDRON, V66, P3326, DOI 10.1016/j.tet.2010.02.097
   Parodi C, 2007, CURR HIV RES, V5, P55, DOI 10.2174/157016207779316341
   Pearson AS, 1999, CLIN CANCER RES, V5, P4208
   Pearson S, 2004, NAT BIOTECHNOL, V22, P3, DOI 10.1038/nbt0104-3
   Pedziwiatr-Werbicka E, 2012, J BIOMED NANOTECHNOL, V8, P57, DOI 10.1166/jbn.2012.1369
   Ritort F, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.118301
   Sanchez-Nieves J, 2010, TETRAHEDRON, V66, P9203, DOI 10.1016/j.tet.2010.09.063
   Shakhbazau A, 2010, MOL BIOL REP, V37, P2003, DOI 10.1007/s11033-009-9651-y
   Shakhbazau A, 2010, INT J PHARMACEUT, V383, P228, DOI 10.1016/j.ijpharm.2009.09.020
   Shcharbin D, 2009, J CONTROL RELEASE, V135, P186, DOI 10.1016/j.jconrel.2009.01.015
   Shcharbin D, 2007, BIOMACROMOLECULES, V8, P2059, DOI 10.1021/bm070333p
   Shcharbin D, 2011, COLLOID SURFACE B, V83, P388, DOI 10.1016/j.colsurfb.2010.11.009
   Shcharbin D, 2010, J CONTROL RELEASE, V141, P110, DOI 10.1016/j.jconrel.2009.09.030
   Shieh MJ, 2008, J CONTROL RELEASE, V129, P200, DOI 10.1016/j.jconrel.2008.03.024
   Snyder-Cappione JE, 2006, J IMMUNOL, V176, P2662, DOI 10.4049/jimmunol.176.4.2662                                                     
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630                                                               
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381                                                          
   Tsutsumi T, 2007, J CONTROL RELEASE, V119, P349, DOI 10.1016/j.jconrel.2007.03.013
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Zhang XQ, 2007, BIOCONJUGATE CHEM, V18, P2068, DOI 10.1021/bc070116l
NR 46
TC 22
Z9 22
U1 2
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD SEP 1
PY 2013
VL 109
BP 183
EP 189
DI 10.1016/j.colsurfb.2013.03.045
PG 7
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 164MD
UT WOS:000320413300027
PM 23643914
DA 2018-01-05
ER

PT J
AU Ying, TL
   Chen, WZ
   Feng, Y
   Wang, YP
   Gong, R
   Dimitrov, DS
AF Ying, Tianlei
   Chen, Weizao
   Feng, Yang
   Wang, Yanping
   Gong, Rui
   Dimitrov, Dimiter S.
TI Engineered Soluble Monomeric IgG1 CH3 Domain GENERATION, MECHANISMS OF
   FUNCTION, AND IMPLICATIONS FOR DESIGN OF BIOLOGICAL THERAPEUTICS
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NEONATAL-FC-RECEPTOR; ANTIBODY DOMAIN; INCREASED-STABILITY;
   CRYSTAL-STRUCTURE; BINDING-SITE; GAMMA-RIII; HALF-LIFE; GLYCOPROTEIN;
   FRAGMENTS; PROTEINS
AB Most of the therapeutic antibodies approved for clinical use are full-size IgG1 molecules. The interaction of the IgG1 Fc with the neonatal Fc receptor (FcRn) plays a critical role in maintaining their long half-life. We have hypothesized that isolated Fc domains could be engineered to functionally mimic full-size IgG1 (nanoantibodies) but with decreased (10-fold) size. Here, we report for the first time the successful generation of a soluble, monomeric CH3 domain (mCH3). In contrast to the wild-type dimeric CH3, the mCH3 exhibited pH-dependent binding to FcRn similar to that of Fc. The binding free energy of mCH3 to FcRn was higher than that of isolated CH2 but lower than that of Fc. Therefore, CH3 may contribute a larger portion of the free energy of binding to FcRn than CH2. A fusion protein of mCH3 with an engineered antibody domain (m36.4) also bound to FcRn in a pH-dependent fashion and exhibited significantly higher neutralizing activity against HIV-1 than m36.4-Fc fusion proteins. The m36.4-mCH3 fusion protein was monomeric, stable, soluble, and expressed at a high level in Escherichia coli. We also found that engineering an additional disulfide bond in mCH3 remarkably increased its thermal stability, whereas the FcRn binding was not affected. These data suggest that mCH3 could not only help in the exploration of the dual mechanisms of the CH3 contribution to Fc functions (dimerization and FcRn interactions) but could also be used for the development of candidate therapeutics with optimized half-life, enhanced tissue penetration, access to sterically restricted binding sites, and increased therapeutic efficacy.
C1 [Ying, Tianlei; Chen, Weizao; Feng, Yang; Wang, Yanping; Gong, Rui; Dimitrov, Dimiter S.] NCI, Prot Interact Grp, Canc & Inflammat Program, Ctr Canc Res,NIH, Frederick, MD 21702 USA.
   [Wang, Yanping] SAIC Frederick Inc, Frederick, MD 21702 USA.
RP Ying, TL (reprint author), NCI, Prot Interact Grp, NIH, Bldg 469,Rm 150B, Frederick, MD 21702 USA.
EM yingt@mail.nih.gov
FU Intramural Research Program of the National Institutes of Health, NCI,
   Center for Cancer Research; National Institutes of Health, NCI
   [N01-CO-12400]
FX This work was supported, in whole or in part, by the Intramural Research
   Program of the National Institutes of Health, NCI, Center for Cancer
   Research and by federal funds from the National Institutes of Health,
   NCI, under Contract N01-CO-12400.
CR BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582                                                          
   Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen WZ, 2008, P NATL ACAD SCI USA, V105, P17121, DOI 10.1073/pnas.0805297105
   DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279
   Dimitrov Dimiter S, 2012, Methods Mol Biol, V899, P1, DOI 10.1007/978-1-61779-921-1_1
   Dimitrov Dimiter S., 2009, V525, P1, DOI 10.1007/978-1-59745-554-1_1
   Dimitrov DS, 2009, MABS, V1, P26, DOI 10.4161/mabs.1.1.7480                                                           
   Feige MJ, 2004, J MOL BIOL, V344, P107, DOI 10.1016/j.jmb.2004.09.033
   Feng Y, 2011, PROTEIN EXPRES PURIF, V79, P66, DOI 10.1016/j.pep.2011.03.012
   Flanagan Meg L, 2007, Methods Mol Biol, V378, P33, DOI 10.1007/978-1-59745-323-3_3
   Gong R, 2011, J BIOL CHEM, V286, P27288, DOI 10.1074/jbc.M111.254219
   Gong R, 2009, J BIOL CHEM, V284, P14203, DOI 10.1074/jbc.M900769200
   Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007
   Jazayeri JA, 2008, BIODRUGS, V22, P11, DOI 10.2165/00063030-200822010-00002                                                
   Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x
   Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003
   Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1
   Nelson AL, 2009, NAT BIOTECHNOL, V27, P331, DOI 10.1038/nbt0409-331
   Ober RJ, 2004, J IMMUNOL, V172, P2021, DOI 10.4049/jimmunol.172.4.2021                                                     
   Prabakaran P, 2008, ACTA CRYSTALLOGR D, V64, P1062, DOI 10.1107/S0907444908025274
   Reichert JM, 2011, MABS-AUSTIN, V3, P76, DOI 10.4161/mabs.3.1.13895
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Saerens D, 2008, CURR OPIN PHARMACOL, V8, P600, DOI 10.1016/j.coph.2008.07.006
   Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200
   SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0
   Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508                                                                
   Suzuki T, 2010, J IMMUNOL, V184, P1968, DOI 10.4049/jimmunol.0903296
   Thies MJW, 1999, J MOL BIOL, V293, P67, DOI 10.1006/jmbi.1999.3128                                                          
   Thies MJW, 2002, J MOL BIOL, V319, P1267, DOI 10.1016/S0022-2836(02)00375-3
   Vaccaro C, 2005, NAT BIOTECHNOL, V23, P1283, DOI 10.1038/nbt1143
   Vaughn DE, 1997, J MOL BIOL, V274, P597, DOI 10.1006/jmbi.1997.1388
   Wozniak-Knopp G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030083
   Ying TL, 2012, J BIOL CHEM, V287, P19399, DOI 10.1074/jbc.M112.368647
   Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601
NR 37
TC 26
Z9 26
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 30
PY 2013
VL 288
IS 35
BP 25154
EP 25164
DI 10.1074/jbc.M113.484154
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 302QC
UT WOS:000330619000015
PM 23867459
OA gold
DA 2018-01-05
ER

PT J
AU Vervaeke, P
   Alen, M
   Noppen, S
   Schols, D
   Oreste, P
   Liekens, S
AF Vervaeke, Peter
   Alen, Marijke
   Noppen, Sam
   Schols, Dominique
   Oreste, Pasqua
   Liekens, Sandra
TI Sulfated Escherichia coli K5 Polysaccharide Derivatives Inhibit Dengue
   Virus Infection of Human Microvascular Endothelial Cells by Interacting
   with the Viral Envelope Protein E Domain III
SO PLOS ONE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; HEPARAN-SULFATE; CAPSULAR POLYSACCHARIDE; HIV-1
   INFECTION; DENDRITIC CELLS; BINDING; HYBRIDIZATION; ENHANCEMENT;
   NONINTEGRIN; ACTIVATION
AB Dengue virus (DENV) is an emerging mosquito-borne pathogen that causes cytokine-mediated alterations in the barrier function of the microvascular endothelium, leading to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). We observed that DENV (serotype 2) productively infects primary (HMVEC-d) and immortalized (HMEC-1) human dermal microvascular endothelial cells, despite the absence of well-described DENV receptors, such as dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) or the mannose receptor on the cell surface. However, heparan sulfate proteoglycans (HSPGs) were highly expressed on these cells and pre-treatment of HMEC-1 cells with heparinase II or with glycosaminoglycans reduced DENV infectivity up to 90%, suggesting that DENV uses HSPGs as attachment receptor on microvascular endothelial cells. Sulfated Escherichia coli K5 derivatives, which are structurally similar to heparin/heparan sulfate but lack anticoagulant activity, were able to block DENV infection of HMEC-1 and HMVEC-d cells in the nanomolar range. The highly sulfated K5-OS(H) and K5-N, OS(H) inhibited virus attachment and subsequent entry into microvascular endothelial cells by interacting with the viral envelope (E) protein, as shown by surface plasmon resonance (SPR) analysis using the receptor-binding domain III of the E protein.
C1 [Vervaeke, Peter; Alen, Marijke; Noppen, Sam; Schols, Dominique; Oreste, Pasqua; Liekens, Sandra] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Louvain, Belgium.
   [Oreste, Pasqua] Glycores 2000 Srl, Milan, Italy.
RP Liekens, S (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Louvain, Belgium.
EM sandra.liekens@rega.kuleuven.be
RI Schols, Dominique/S-9057-2017
OI Schols, Dominique/0000-0003-3256-5850
FU KU Leuven (GOA) [10/014, 10/18]
FX This work was supported by the KU Leuven (GOA no. 10/014 and PF no.
   10/18). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748
   Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Alen MMF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021658
   Arevalo MT, 2009, J MED VIROL, V81, P519, DOI 10.1002/jmv.21408
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Avirutnan P, 2007, PLOS PATHOG, V3, P183
   Balsitis SJ, 2009, AM J TROP MED HYG, V80, P416
   Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Bonner SM, 1998, J VIROL METHODS, V71, P159, DOI 10.1016/S0166-0934(97)00211-5
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Cabello-Guterrez C, 2009, THROMB HAEMOSTASIS, V101, P916, DOI 10.1160/TH08-04-0271
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Chen HC, 2007, J VIROL, V81, P5518, DOI 10.1128/JVI.02575-06
   Chen LC, 2009, J INFECTION, V58, P368, DOI 10.1016/j.jinf.2009.02.018
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Dalrymple N. A., 2012, ADV VIROL, V2012, DOI DOI 10.1155/2012/840654
   Dalrymple N, 2011, J VIROL, V85, P9478, DOI 10.1128/JVI.05008-11
   Dalrymple NA, 2012, J VIROL, V86, P6408, DOI 10.1128/JVI.00213-12
   de Jong MAWP, 2008, J GEN VIROL, V89, P2398, DOI 10.1099/vir.0.2008/003129-0
   de Witte L, 2007, P NATL ACAD SCI USA, V104, P19464, DOI 10.1073/pnas.0703747104
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Fang SY, 2013, SCI WORLD J, DOI 10.1155/2013/684690
   Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232
   Guzman MG, 2010, NATURE REV MICROBIOL, V8, P7, DOI DOI 10.1038/NRMICR02460
   Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713
   Huang YH, 2003, J MED VIROL, V70, P610, DOI 10.1002/jmv.10438
   Huang YH, 2000, AM J TROP MED HYG, V63, P71, DOI 10.4269/ajtmh.2000.63.71                                                        
   Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633                                                          
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Jiang Z, 2007, J INFECTION, V55, P23
   Kanlaya R, 2009, J PROTEOME RES, V8, P2551, DOI 10.1021/pr900060g
   Kato D, 2010, ANTIVIR RES, V88, P236, DOI 10.1016/j.antiviral.2010.09.002
   KILLEN H, 1993, J VIROL METHODS, V41, P135, DOI 10.1016/0166-0934(93)90121-7                                                    
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435                                                       
   Leali D, 2001, J BIOL CHEM, V276, P37900
   Lembo D, 2008, ANTIMICROB AGENTS CH, V52, P1374, DOI 10.1128/AAC.01467-07
   Lin YL, 2002, ANTIVIR RES, V56, P93, DOI 10.1016/S0166-3542(02)00095-5
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   Mas-Moruno C, 2010, ANTI-CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639                                                      
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63
   Mercorelli B, 2010, ANTIMICROB AGENTS CH, V54, P4561, DOI 10.1128/AAC.00721-10
   Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017
   Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866
   Oreste P, 2012, HDB EXP PHARM, V207, P403
   Peyrefitte CN, 2006, J MED VIROL, V78, P229, DOI 10.1002/jmv.20532
   Pinna D, 2008, ANTIMICROB AGENTS CH, V52, P3078, DOI 10.1128/AAC.00359-08
   Rusnati M, 2009, PHARMACOL THERAPEUT, V123, P310, DOI 10.1016/j.pharmthera.2009.05.001
   Srikiatkhachorn A, 2007, J VIROL, V81, P1592, DOI 10.1128/JVI.01642-06
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   Tripathi CKM, 2012, APPL MICROBIOL BIOT, V94, P307, DOI 10.1007/s00253-012-3967-6
   VANDAMME EJM, 1991, EUR J BIOCHEM, V202, P23
   VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x
   Vicenzi E, 2003, AIDS, V17, P177, DOI 10.1097/01.aids.0000042949.95433.74
   Warke RV, 2008, J VIROL, V82, P555, DOI 10.1128/JVI.01694-06
   Warke RV, 2003, J VIROL, V77, P11822, DOI 10.1128/JVI.21.11822-11832.2003
   Watterson D, 2012, J GEN VIROL, V93, P72, DOI 10.1099/vir.0.037317-0
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   World Health Organization, 2012, DENG SEV DENG FACT S
   Yeh TM, 2013, PLOS ONE, V8, P55018
   Yen YT, 2008, J VIROL, V82, P12312, DOI 10.1128/JVI.00968-08
   Zamudio-Meza H, 2009, J GEN VIROL, V90, P2902, DOI 10.1099/vir.0.014159-0
   Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004
   Zhang JL, 2007, BIOCHEM BIOPH RES CO, V356, P763, DOI 10.1016/j.bbrc.2007.03.051
   Zhu WY, 2011, BIOMED ENVIRON SCI, V24, P81, DOI 10.3967/0895-3988.2011.01.011
NR 67
TC 16
Z9 16
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 28
PY 2013
VL 8
IS 8
AR e74035
DI 10.1371/journal.pone.0074035
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 209DG
UT WOS:000323733800109
PM 24015314
OA gold
DA 2018-01-05
ER

PT J
AU Chiodo, F
   Marradi, M
   Tefsen, B
   Snippe, H
   van Die, I
   Penades, S
AF Chiodo, Fabrizio
   Marradi, Marco
   Tefsen, Boris
   Snippe, Harm
   van Die, Irma
   Penades, Soledad
TI High Sensitive Detection of Carbohydrate Binding Proteins in an
   ELISA-Solid Phase Assay Based on Multivalent Glyconanoparticles
SO PLOS ONE
LA English
DT Article
ID DC-SIGN; MYCOBACTERIUM-LEPRAE; ANTIBODY 2G12; GOLD NANOPARTICLES; GLYCAN
   MICROARRAYS; DENDRITIC CELLS; GP120; ANTIGENS; HIV-1; IDENTIFICATION
AB Improved detection of anti-carbohydrate antibodies is a need in clinical identification of biomarkers for cancer cells or pathogens. Here, we report a new ELISA approach for the detection of specific immunoglobulins (IgGs) against carbohydrates. Two nanometer gold glyconanoparticles bearing oligosaccharide epitopes of HIV or Streptococcus pneumoniae were used as antigens to coat ELISA-plates. A similar to 3,000-fold improved detection of specific IgGs in mice immunized against S. pneumoniae respect to the well known BSA-glycoconjugate ELISA was achieved. Moreover, these multivalent glyconanoparticles have been employed in solid phase assays to detect the carbohydrate-dependent binding of human dendritic cells and the lectin DC-SIGN. Multivalent glyconanoparticles in ELISA provide a versatile, easy and highly sensitive method to detect and quantify the binding of glycan to proteins and to facilitate the identification of biomarkers.
C1 [Chiodo, Fabrizio; Marradi, Marco; Penades, Soledad] CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, San Sebastian, Spain.
   [Marradi, Marco; Penades, Soledad] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, San Sebastian, Spain.
   [Tefsen, Boris; van Die, Irma] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.
   [Snippe, Harm] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
RP Chiodo, F (reprint author), CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, San Sebastian, Spain.
EM fchiodo@cicbiomagune.es; spenades@cicbiomagune.es
RI Chiodo, Fabrizio/R-1121-2017; Tefsen, Boris/J-1503-2012; biomaGUNE,
   CIC/J-9136-2014
OI Chiodo, Fabrizio/0000-0003-3619-9982; Tefsen, Boris/0000-0001-6668-217X;
   biomaGUNE, CIC/0000-0001-7690-0660
FU Spanish Ministry of Economy and Competitiveness [CTQ2011-04638];
   Department of Industry of the Basque Country [ETORTEK biomaGUNE 2011];
   COST action [CM1102]; Ministerio de Ciencia e Innovacion; Dutch
   Technology Foundation (STW) [10622]
FX This research was supported by the Spanish Ministry of Economy and
   Competitiveness, (grant CTQ2011-04638), and the Department of Industry
   of the Basque Country (grant ETORTEK biomaGUNE 2011). The authors thank
   the COST action CM1102 for support. FC thanks Ministerio de Ciencia e
   Innovacion for a predoctoral grant. BT was financially supported by the
   Dutch Technology Foundation (STW, grant 10622). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ARNAIZ B, 2011, BIOCONJUG CHEM, V23, P814
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   de la Escosura-Muniz Alfredo, 2010, Materials Today, V13, P24, DOI 10.1016/S1369-7021(10)70125-5
   de la Fuente J.M., 2001, ANGEW CHEM INT EDIT, V40, P2257, DOI DOI 10.1002/1521-3773(20010618)40:12
   Di Gianvincenzo P, 2012, METHOD ENZYMOL, V509, P21, DOI 10.1016/B978-0-12-391858-1.00002-2
   Disney MD, 2004, CHEM BIOL, V11, P1701, DOI 10.1016/j.chembiol.2004.10.011
   FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0
   Fei YY, 2011, ANAL CHEM, V83, P6336, DOI 10.1021/ac201260c
   Galanina OE, 2003, LAB CHIP, V3, P260, DOI 10.1039/b305963e
   Garcia-Vallejo JJ, 2009, IMMUNOL REV, V230, P22, DOI 10.1111/j.1600-065X.2009.00786.x
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Gervay J, 1999, CURR MED CHEM, V6, P129
   GRAY BM, 1979, J IMMUNOL METHODS, V28, P187, DOI 10.1016/0022-1759(79)90340-5
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433
   Ilyas R, 2011, IMMUNOBIOLOGY, V216, P126, DOI 10.1016/j.imbio.2010.06.002
   MARINOALBERNAS J, 1988, CARBOHYD RES, V183, P175, DOI 10.1016/0008-6215(88)84072-2                                                    
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Marradi M, 2010, ADV CARBOHYD CHEM BI, V64, P211, DOI 10.1016/S0065-2318(10)64005-X
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Nimrichter L, 2004, GLYCOBIOLOGY, V14, P197, DOI 10.1093/glycob/cwh022
   Ojeda R, 2007, CARBOHYD RES, V342, P448, DOI 10.1016/j.carres.2006.11.018
   Oyelaran O, 2009, J PROTEOME RES, V8, P4301, DOI 10.1021/pr900515y
   Park S, 2013, CHEM SOC REV, V42, P4310, DOI 10.1039/c2cs35401b
   Park S, 2009, BIOCONJUGATE CHEM, V20, P155, DOI 10.1021/bc800442z
   Pochechueva T, 2011, GLYCOCONJUGATE J, V28, P507, DOI 10.1007/s10719-011-9349-y
   REGGIARDO Z, 1980, J IMMUNOL METHODS, V34, P55, DOI 10.1016/0022-1759(80)90224-0
   Rillahan CD, 2011, ANNU REV BIOCHEM, V80, P797, DOI 10.1146/annurev-biochem-061809-152236
   Safari D, 2008, INFECT IMMUN, V76, P4615, DOI 10.1128/IAI.00472-08
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Spencer JS, 2011, LEPROSY REV, V82, P344
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50, DOI DOI 10.1016/0076-6879(90)82008-P.PUBMED:2314256
   Tong Q, 2012, ANAL CHEM, V84, P3049, DOI 10.1021/ac203455b
   van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009
   van Vliet SJ, 2005, INT IMMUNOL, V17, P661, DOI 10.1093/intimm/dxh246
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   WILLATS WG, 2000, PROTEOMICS, V2, P1879
   YOUNG DB, 1983, SCIENCE, V221, P1057, DOI 10.1126/science.6348948
NR 42
TC 15
Z9 15
U1 5
U2 35
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 27
PY 2013
VL 8
IS 8
AR UNSP e73027
DI 10.1371/journal.pone.0073027
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 210FR
UT WOS:000323815200063
PM 24014084
OA gold
DA 2018-01-05
ER

PT J
AU Meng, XM
   Wang, JL
   Zhang, SL
   Zhang, QG
AF Meng Xianmei
   Wang Jialei
   Zhang Shaolong
   Zhang Qinggang
TI Molecular Dynamics Study on Function of 2-ylacetic acid-Benzothiophene
   in Binding of HIV-1 Protease and Inhibitor
SO ACTA CHIMICA SINICA
LA Chinese
DT Article
DE HIV-1 protease; inhibitor; molecular dynamics simulation; MM-PB/GBSA
   method; allosteric inhibitor
ID FREE-ENERGY CALCULATION; DRUG-RESISTANCE; SIMULATIONS; INSIGHTS; AMBER;
   SAQUINAVIR; MECHANISM; ANALOGS; COMPLEX; MUTANT
AB In order to study the role of allosteric fragment 2-ylacetic acid-benzothiophene (2FX) in the binding of HIV-1 protease (PR) and inhibitor, the molecular dynamics simulations of 100 nanoseconds have been successfully performed on two systems of HIV-1 protease and inhibitor, respectively, one of which 2FX is attached to and another is not. Both types of new force fields, ff99SBildn and ffl2SB, and GPU parallel computing technology have been used for each of the two systems in the simulations. By investigating the influence of 2FX on the protease, it is found that the binding of 2FX induces a conformational change of the protease. The dynamics behaviors of the two systems under the two force fields are compared with the VMD visualization software and it is found that, to a certain extent, there exist differences between those from the different forces. The root-mean-square deviations (RMSD), the B-factors of the two systems, and structure superposition between the calculated and X-ray crystal structures, which display that the system with 2FX has a more stable dynamics process and the vibration extent of the residues decreases, indicate that the 2FX bound in the protease can stabilize the system. The binding free energies have been calculated using the two force fields and using two methods, MM-PB/GBSA, respectively. The resulting free energy values, ff99SBildn: -70.52 and -68.42 kcal/mol (PB), -86.72 and -89.40 kcal/mol (GB); ffl2SB: -75.40 and -77.68 kcal/mol (PB), -87.01 and -93.75 kcal/mol (GB), 2FX-system being generally of greater magnitudes, also suggest the allosteric fragment stabilizes the binding of inhibitor and PR. The present results, despite the discrepancies between those from the two different force fields, demonstrate that the allosteric fragment 2FX unambiguously gives rise to subtle changes of structure of the PR and make the inhibitor and PR combine more firmly. In particular, it is clear that the fragment acts to weaken the flexibility of the flap, strengthening the combination of the inhibitor and PR. In addition, it is also found that, with ffl2SB force field, the dynamics processes are more stable, the calculated binding free energies are more favorable, and the results are better consistent with the experiments than with ff99SBildn. It is expected that this work could be helpful to design new allosteric inhibitors in the future.
C1 [Meng Xianmei; Wang Jialei; Zhang Shaolong; Zhang Qinggang] Shandong Normal Univ, Coll Phys & Elect, Jinan 250014, Peoples R China.
RP Meng, XM (reprint author), Shandong Normal Univ, Coll Phys & Elect, Jinan 250014, Peoples R China.
EM zhangqg@sdnu.edu.cn
FU Natural Science Foundation of Shandong Province [ZR2011HM048]; National
   Natural Science Foundation of China [11274206]
FX Project supported by the Natural Science Foundation of Shandong Province
   (No. ZR2011HM048) and the National Natural Science Foundation of China
   (No. 11274206).
CR Adcock SA, 2006, CHEM REV, V106, P1589, DOI 10.1021/cr040426m
   Cai WS, 2013, ACTA CHIM SINICA, V71, P159, DOI 10.6023/A12110930
   Case D. A., 2012, AMBER 12
   Chen JZ, 2009, J MOL MODEL, V15, P1245, DOI 10.1007/s00894-009-0452-y
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   Fogolari F, 2002, J MOL RECOGNIT, V15, P377, DOI 10.1002/jmr.577
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Hong L, 2000, PROTEIN SCI, V9, P1898, DOI 10.1110/ps.9.10.1898                                                            
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hou TJ, 2009, PROTEINS, V74, P837, DOI 10.1002/prot.22192
   Hu GD, 2010, EUR J MED CHEM, V45, P227, DOI 10.1016/j.ejmech.2009.09.048
   Hu GD, 2010, ACTA CHIM SINICA, V68, P603
   Hu JP, 2006, ACTA CHIM SINICA, V64, P2079
   Klepeis JL, 2009, CURR OPIN STRUC BIOL, V19, P120, DOI 10.1016/j.sbi.2009.03.004
   Leach A. R., 2003, MOL MODELLING PRINCI
   Lindorff L. K., 2010, PROTEIN FORCE FIELD, V78, P1950
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Perryman AL, 2010, CHEM BIOL DRUG DES, V75, P257, DOI 10.1111/j.1747-0285.2009.00943.x
   Sa DJ, 2003, J CLIN VIROL, V28, P186, DOI 10.1016/S1386-6532(03)00007-6
   Stoica I, 2008, J AM CHEM SOC, V130, P2639, DOI 10.1021/ja0779250
   Sun D. F., 2012, SHANDONG SCI, V25, P20
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wu EL, 2008, CHEM-EUR J, V14, P8704, DOI 10.1002/chem.200800277
   Wu EL, 2009, J PHYS CHEM B, V113, P2477, DOI 10.1021/jp808182y
   Yao XX, 2011, ACTA CHIM SINICA, V69, P405
   Zhuang SL, 2006, J MOL STRUC-THEOCHEM, V763, P97, DOI 10.1016/j.theochem.2006.01.031
   Zhuang SL, 2005, J MED CHEM, V48, P7208, DOI 10.1021/jm050562z
NR 28
TC 3
Z9 3
U1 0
U2 16
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 0567-7351
J9 ACTA CHIM SINICA
JI Acta Chim. Sin.
PD AUG 15
PY 2013
VL 71
IS 8
BP 1167
EP 1174
DI 10.6023/A13030327
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 217LW
UT WOS:000324362000013
OA gold
DA 2018-01-05
ER

PT J
AU Kwon, OS
   Lee, SH
   Park, SJ
   An, JH
   Song, HS
   Kim, T
   Oh, JH
   Bae, J
   Yoon, H
   Park, TH
   Jang, J
AF Kwon, Oh Seok
   Lee, Seung Hwan
   Park, Seon Joo
   An, Ji Hyun
   Song, Hyun Seok
   Kim, Taejoon
   Oh, Joon Hak
   Bae, Joonwon
   Yoon, Hyeonseok
   Park, Tai Hyun
   Jang, Jyongsik
TI Large-Scale Graphene Micropattern Nano-biohybrids: High-Performance
   Transducers for FET-Type Flexible Fluidic HIV Immunoassays
SO ADVANCED MATERIALS
LA English
DT Article
DE graphene; immunoassay; nano-biohybrids; flexible electronics;
   microfluidics
ID CONDUCTING-POLYMER NANOMATERIALS; OPTICAL MODULATOR; NANOPARTICLES;
   TRANSISTORS; NANOTUBES; HYBRID; SENSOR; SYSTEMS; ARRAYS; FILM
C1 [Kwon, Oh Seok; Park, Seon Joo; An, Ji Hyun; Jang, Jyongsik] Seoul Natl Univ, World Class Univ Program Chem Convergence Energy, Sch Chem & Biol Engn, Seoul 151742, South Korea.
   [Lee, Seung Hwan; Song, Hyun Seok; Park, Tai Hyun] Seoul Natl Univ, Sch Chem & Biol Engn, BioMAX Inst, Seoul 151744, South Korea.
   [Kim, Taejoon; Yoon, Hyeonseok] Chonnam Natl Univ, Alan G MacDiarmid Energy Res Inst, Dept Polymer & Fiber Syst Engn, Kwangju 500757, South Korea.
   [Oh, Joon Hak] Ulsan Natl Inst Sci & Technol, KIER UNIST Adv Ctr Energy, Low Dimens Carbon Mat Ctr, Sch Nanobiosci & Chem Engn, Ulsan 689798, South Korea.
   [Bae, Joonwon] Dongduk Womens Univ, Dept Appl Chem, Seoul 136714, South Korea.
RP Park, TH (reprint author), Seoul Natl Univ, Sch Chem & Biol Engn, BioMAX Inst, Seoul 151744, South Korea.
EM thpark@snu.ac.kr; jsjang@plaza.snu.ac.kr
RI Park, Tai Hyun/C-6529-2013; Yoon, Hyeonseok/B-2855-2015; kwon, ohseok
   /N-5440-2014; Oh, Joon Hak/F-1454-2010
OI Yoon, Hyeonseok/0000-0002-5403-1617; Oh, Joon Hak/0000-0003-0481-6069
FU National Research Foundation of Korea (NRF) [2011-0017125, 2012-0000144,
   2012-050100]; World Class University (WCU) program through the NRF;
   Ministry of Education, Science and Technology (MEST) [R31-10013]
FX This research was supported by the National Research Foundation of Korea
   (NRF) grant (No. 2011-0017125, 2012-0000144, 2012-050100), World Class
   University (WCU) program through the NRF funded by the Ministry of
   Education, Science and Technology (MEST) (R31-10013).
CR Al-Mashat L, 2010, J PHYS CHEM C, V114, P16168, DOI 10.1021/jp103134u
   Alam MM, 2005, J PHYS CHEM B, V109, P12777, DOI 10.1021/jp050903k
   Ang PK, 2011, NANO LETT, V11, P5240, DOI 10.1021/nl202579k
   Arsat R, 2009, CHEM PHYS LETT, V467, P344, DOI 10.1016/j.cplett.2008.11.039
   Bange A, 2005, BIOSENS BIOELECTRON, V20, P2488, DOI 10.1016/j.bios.2004.10.016
   BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307
   Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109
   Choi BG, 2010, ACS NANO, V4, P2910, DOI 10.1021/nn100145x
   DECOCK KM, 1991, AIDS, V5, pS21
   Ding MN, 2013, J PHYS CHEM LETT, V4, P147, DOI 10.1021/jz301711a
   Dong XC, 2010, ADV MATER, V22, P1649, DOI 10.1002/adma.200903645
   Dresselhaus MS, 2010, NANO LETT, V10, P751, DOI 10.1021/nl904286r
   Du V, 2010, ANGEW CHEM INT EDIT, V49, P2154
   Gerasimov JY, 2010, CHEM COMMUN, V46, P395, DOI 10.1039/b919070h
   Had T., 1995, BIOSENS BIOELECTRON, V10, P477
   Heeger AJ, 2001, ANGEW CHEM INT EDIT, V40, P2591, DOI 10.1002/1521-3773(20010716)40:14<2591::AID-ANIE2591>3.0.CO;2-0                  
   Huang YX, 2011, J MATER CHEM, V21, P12358, DOI 10.1039/c1jm11436k
   Huang YX, 2010, NANOSCALE, V2, P1485, DOI 10.1039/c0nr00142b
   Jang J, 2005, LANGMUIR, V21, P11484, DOI 10.1021/la051447u
   Jang J, 2006, ADV POLYM SCI, V199, P189, DOI 10.1007/12_075
   Jang MS, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3454909
   Jiang HJ, 2011, SMALL, V7, P2413, DOI 10.1002/smll.201002352
   Kalantar-Zadeh K, 2003, SENSOR ACTUAT B-CHEM, V91, P143, DOI 10.1016/S0925-4005(03)00079-0
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kim T, 2012, NANO LETT, V12, P743, DOI 10.1021/nl203691d
   Koppens FHL, 2011, NANO LETT, V11, P3370, DOI 10.1021/nl201771h
   Kwon OS, 2012, ACS NANO, V6, P5549, DOI 10.1021/nn301482x
   Kwon OS, 2012, NANO LETT, V12, P2797, DOI 10.1021/nl204587t
   Kwon OS, 2012, ACS NANO, V6, P1486, DOI 10.1021/nn204395n
   Kwon OS, 2010, J PHYS CHEM C, V114, P18874, DOI 10.1021/jp1083086
   Kwon OS, 2010, BIOMATERIALS, V31, P4740, DOI 10.1016/j.biomaterials.2010.02.040
   Lee SK, 2012, NANO LETT, V12, P3472, DOI 10.1021/nl300948c
   Lee SK, 2011, NANO LETT, V11, P4642, DOI 10.1021/nl202134z
   Lee SH, 2012, NAT MATER, V11, P936, DOI [10.1038/NMAT3433, 10.1038/nmat3433]
   Lee SH, 2012, LAB CHIP, V12, P1841, DOI 10.1039/c2lc20677c
   Lee SH, 2009, LAB CHIP, V9, P479, DOI 10.1039/b814371d
   Li WW, 2011, ACS NANO, V5, P6955, DOI 10.1021/nn201433r
   Liu M, 2012, NANO LETT, V12, P1482, DOI 10.1021/nl204202k
   Liu M, 2011, NATURE, V474, P64, DOI 10.1038/nature10067
   Liu S, 2012, BIOSENS BIOELECTRON, V36, P186, DOI 10.1016/j.bios.2012.04.011
   Lu CH, 2012, BIOSENS BIOELECTRON, V31, P439, DOI 10.1016/j.bios.2011.11.008
   Mei YF, 2010, MAT SCI ENG R, V70, P209, DOI 10.1016/j.mser.2010.06.009
   Mohanty N, 2008, NANO LETT, V8, P4469, DOI 10.1021/nl802412n
   Moon JJ, 2012, ADV MATER, V24, P3724, DOI 10.1002/adma.201200446
   Myung S, 2012, ADV MATER, V24, P6081, DOI 10.1002/adma.201202961
   Nair RR, 2008, SCIENCE, V320, P1308, DOI 10.1126/science.1156965
   Nakada K, 1996, PHYS REV B, V54, P17954, DOI 10.1103/PhysRevB.54.17954
   Nakayama K, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2988288
   Newaz AKM, 2012, NANO LETT, V12, P2931, DOI 10.1021/nl300603v
   Nourbakhsh A, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/43/435203
   Park SJ, 2012, NANO LETT, V12, P5082, DOI 10.1021/nl301714x
   REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6
   Roberts ME, 2008, P NATL ACAD SCI USA, V105, P12134, DOI 10.1073/pnas.0802105105
   Rogers JA, 2012, SCIENCE, V337, P1459, DOI 10.1126/science.1228493
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   Sakhaee-Pour A, 2008, SOLID STATE COMMUN, V147, P336, DOI 10.1016/j.ssc.2008.04.016
   Sills J., 2012, SCIENCE, V337, P798
   Song L, 2009, ACS NANO, V3, P1353, DOI 10.1021/nn9003082
   Taguchi T, 2012, ADV MATER, V24, P6462, DOI 10.1002/adma.201202979
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   THORSTENSSON R, 1991, J ACQ IMMUN DEF SYND, V4, P374
   Vaddiraju S, 2008, ADV FUNCT MATER, V18, P1929, DOI 10.1002/adfm.200800196
   Wang HL, 2010, J AM CHEM SOC, V132, P13978, DOI 10.1021/ja105296a
   Wei DC, 2010, ADV MATER, V22, P3225, DOI 10.1002/adma.200904144
   Willner I, 2010, NANO LETT, V10, P3805, DOI 10.1021/nl102083j
   Wong Eric Y., 2010, HIV Therapy, V4, P399, DOI 10.2217/HIV.10.29
   Xiang R., 2012, NANO LETT, V12, P1404
   Yang D., 2008, ADV MATER, V20, P4775
   Yang WR, 2010, ANGEW CHEM INT EDIT, V49, P2114, DOI 10.1002/anie.200903463
   Yoon H, 2007, SMALL, V3, P1774, DOI 10.1002/smll.200700245
   Yoon H, 2009, ADV FUNCT MATER, V19, P1567, DOI 10.1002/adfm.200801141
   You SA, 2012, J MATER CHEM, V22, P17805, DOI 10.1039/c2jm33589a
   Zheng GF, 2008, J AM CHEM SOC, V130, P9644, DOI 10.1021/ja803035p
   Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138
   Zhou Y, 2010, ADV MATER, V22, P3615, DOI 10.1002/adma.201000436
   Zhu MS, 2011, ACS NANO, V5, P4529, DOI 10.1021/nn200088x
   Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068
NR 77
TC 36
Z9 37
U1 4
U2 103
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD AUG 14
PY 2013
VL 25
IS 30
BP 4177
EP 4185
DI 10.1002/adma.201301523
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 261QY
UT WOS:000327680900017
PM 23744620
DA 2018-01-05
ER

PT J
AU Liu, XQ
   Wang, F
   Aizen, R
   Yehezkeli, O
   Willner, I
AF Liu, Xiaoqing
   Wang, Fuan
   Aizen, Ruth
   Yehezkeli, Omer
   Willner, Itamar
TI Graphene Oxide/Nucleic-Acid-Stabilized Silver Nanoclusters: Functional
   Hybrid Materials for Optical Aptamer Sensing and Multiplexed Analysis of
   Pathogenic DNAs
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID LOGIC-GATE OPERATIONS; EXONUCLEASE III; QUANTUM DOTS; OXIDE;
   FLUORESCENCE; PLATFORM; PROBES; AMPLIFICATION; REGENERATION; CLUSTER
AB Hybrid systems consisting of nucleic-acid-functionalized silver nanoclusters (AgNCs) and graphene oxide (GO) are used for the development of fluorescent DNA sensors and aptasensors, and for the multiplexed analysis of a series of genes of infectious pathogens. Two types of nucleic-acid-stabilized AgNCs are used: one type includes the red-emitting AgNCs (616 nm) and the second type is near-infrared-emitting AgNCs (775 nm). Whereas the nucleic-acid-stabilized AgNCs do not bind to GO, the conjugation of single-stranded nucleic acid to the DNA-stabilized AgNCs leads to the adsorption of the hybrid nanostructures to GO and to the fluorescence quenching of the AgNCs. By the conjugation of oligonucleotide sequences acting as probes for target genes, or as aptamer sequences, to the nucleic-acid-protected AgNCs, the desorption of the probe/nucleic-acid-stabilized AgNCs from GO through the formation of duplex DNA structures or aptamer-substrate complexes leads to the generation of fluorescence as a readout signal for the sensing events. The hybrid nanostructures are implemented for the analysis of hepatitis B virus gene (HBV), the immunodeficiency virus gene (HIV), and the syphilis (Treponema pallidum) gene. Multiplexed analysis of the genes is demonstrated. The nucleic-acid-AgNCs-modified GO is also applied to detect ATP or thrombin through the release of the respective AgNCs-labeled aptamer-substrate complexes from GO.
C1 [Liu, Xiaoqing; Wang, Fuan; Aizen, Ruth; Yehezkeli, Omer; Willner, Itamar] Hebrew Univ Jerusalem, Inst Chem, Ctr Nanosci & Nanotechnol, IL-91904 Jerusalem, Israel.
RP Willner, I (reprint author), Hebrew Univ Jerusalem, Inst Chem, Ctr Nanosci & Nanotechnol, IL-91904 Jerusalem, Israel.
EM willnea@vms.huji.ac.il
RI Liu, Xiaoqing/A-3080-2015; Liu, Xiaoqing/C-5752-2009; Wang,
   Fuan/C-2980-2008
OI Liu, Xiaoqing/0000-0002-1309-5454; Wang, Fuan/0000-0002-3063-2485
FU NanoSensoMach ERC [267574]; Israel National Nanotechnology Initiative
   (INNI), Focal Technology Areas program
FX Parts of this research are supported by the NanoSensoMach ERC Grant No.
   267574 under the EU FP7/2007-2013 program and by the Israel National
   Nanotechnology Initiative (INNI), Focal Technology Areas program.
CR Algar WR, 2010, ANAL BIOANAL CHEM, V398, P2439, DOI 10.1007/s00216-010-3837-y
   Chen WY, 2011, ANAL CHEM, V83, P9450, DOI 10.1021/ac202162u
   Cho EJ, 2005, J AM CHEM SOC, V127, P2022, DOI 10.1021/ja043490u
   Choi HMT, 2010, NAT BIOTECHNOL, V28, P1208, DOI 10.1038/nbt.1692
   Choi S, 2012, CHEM SOC REV, V41, P1867, DOI 10.1039/c1cs15226b
   Erickson K, 2010, ADV MATER, V22, P4467, DOI 10.1002/adma.201000732
   Freeman R, 2011, NANO LETT, V11, P4456, DOI 10.1021/nl202761g
   Geissler D, 2013, J AM CHEM SOC, V135, P1102, DOI 10.1021/ja310317n
   Gwinn EG, 2008, ADV MATER, V20, P279, DOI 10.1002/adma.200702380
   Han BY, 2012, ANAL BIOANAL CHEM, V402, P129, DOI 10.1007/s00216-011-5307-6
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Jang H, 2013, ANGEW CHEM INT EDIT, V52, P2340, DOI 10.1002/anie.201209222
   Latorre A, 2012, CHEMBIOCHEM, V13, P951, DOI 10.1002/cbic.201200053
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Li JL, 2012, ANAL CHEM, V84, P4140, DOI 10.1021/ac3003402
   Li T, 2008, CHEM COMMUN, P3654, DOI 10.1039/b805565c
   Li YG, 2005, NAT BIOTECHNOL, V23, P885, DOI 10.1038/nbt1106
   Liu XQ, 2013, NANO LETT, V13, P309, DOI 10.1021/nl304283c
   Liu XQ, 2012, ACS NANO, V6, P3553, DOI 10.1021/nn300598q
   Liu XQ, 2012, CHEM-EUR J, V18, P2207, DOI 10.1002/chem.201103342
   Liu XQ, 2011, ACS NANO, V5, P7648, DOI 10.1021/nn202799d
   Loh KP, 2010, NAT CHEM, V2, P1015, DOI 10.1038/NCHEM.907
   Lu CH, 2010, CHEM-EUR J, V16, P4889, DOI 10.1002/chem.200903071
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368
   Morales-Narvaez E, 2012, ADV MATER, V24, P3298, DOI 10.1002/adma.201200373
   Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137                                                    
   O'Neill PR, 2009, J PHYS CHEM C, V113, P4229, DOI 10.1021/jp809274m
   Orbach R, 2012, CHEM-EUR J, V18, P14689, DOI 10.1002/chem.201201995
   Petty JT, 2011, J PHYS CHEM B, V115, P7996, DOI 10.1021/jp202024x
   Petty JT, 2010, J PHYS CHEM LETT, V1, P2524, DOI 10.1021/jz100817z
   Pu WD, 2012, ANAL METHODS-UK, V4, P1662, DOI 10.1039/c2ay25166c
   Richards CI, 2008, J AM CHEM SOC, V130, P5038, DOI 10.1021/ja8005644
   Shah P, 2012, ACS NANO, V6, P8803, DOI 10.1021/nn302633q
   Sharma J, 2012, NANOSCALE, V4, P4107, DOI 10.1039/c2nr30662j
   Sharma J, 2011, CHEM COMMUN, V47, P2294, DOI 10.1039/c0cc03711g
   Shi Y, 2011, CHEM COMMUN, V47, P4676, DOI 10.1039/c0cc05518b
   Song FY, 2012, ANGEW CHEM INT EDIT, V51, P8773, DOI 10.1002/anie.201201872
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Su YT, 2010, ANAL CHEM, V82, P8566, DOI 10.1021/ac101659d
   Wang FA, 2012, J AM CHEM SOC, V134, P5504, DOI 10.1021/ja300616w
   Yeh HC, 2012, J AM CHEM SOC, V134, P11550, DOI 10.1021/ja3024737
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   Zhang LB, 2013, J AM CHEM SOC, V135, P2403, DOI 10.1021/ja3089857
   Zhu CF, 2009, CHEM-EUR J, V15, P11898, DOI 10.1002/chem.200901275
NR 45
TC 175
Z9 177
U1 52
U2 704
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD AUG 14
PY 2013
VL 135
IS 32
BP 11832
EP 11839
DI 10.1021/ja403485r
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 202SZ
UT WOS:000323241200035
PM 23841845
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Shafiee, H
   Jahangir, M
   Inci, F
   Wang, SQ
   Willenbrecht, RBM
   Giguel, FF
   Tsibris, AMN
   Kuritzkes, DR
   Demirci, U
AF Shafiee, Hadi
   Jahangir, Muntasir
   Inci, Fatih
   Wang, ShuQi
   Willenbrecht, Remington B. M.
   Giguel, Francoise F.
   Tsibris, Athe M. N.
   Kuritzkes, Daniel R.
   Demirci, Utkan
TI Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of
   Viral Nano-Lysate
SO SMALL
LA English
DT Article
DE pathogen detection; impedance spectroscopy; point-of-care diagnosis;
   virus lysis; lab-on-chip
ID VIRUS TYPE-1 INFECTION; IMPEDANCE SPECTROSCOPY; INTERDIGITATED
   ELECTRODES; REVERSE TRANSCRIPTION; CELLS; SEPARATION; DIELECTROPHORESIS;
   MICROFLUIDICS; DIAGNOSTICS; CYTOMETRY
AB Development of portable biosensors has broad applications in environmental monitoring, clinical diagnosis, public health, and homeland security. There is an unmet need for pathogen detection at the point-of-care (POC) using a fast, sensitive, inexpensive, and easy-to-use method that does not require complex infrastructure and well-trained technicians. For instance, detection of Human Immunodeficiency Virus (HIV-1) at acute infection stage has been challenging, since current antibody-based POC technologies are not effective due to low concentration of antibodies. In this study, we demonstrated for the first time a label-free electrical sensing method that can detect lysed viruses, i.e. viral nano-lysate, through impedance analysis, offering an alternative technology to the antibody-based methods such as dipsticks and Enzyme-linked Immunosorbent Assay (ELISA). The presented method is a broadly applicable platform technology that can potentially be adapted to detect multiple pathogens utilizing impedance spectroscopy for other infectious diseases including herpes, influenza, hepatitis, pox, malaria, and tuberculosis. The presented method offers a rapid and portable tool that can be used as a detection technology at the POC in resource-constrained settings, as well as hospital and primary care settings.
C1 [Shafiee, Hadi; Jahangir, Muntasir; Inci, Fatih; Wang, ShuQi; Willenbrecht, Remington B. M.; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Dept Med,Sch Med, Bioacoust MEMS Med BAMM Lab,Div Biomed Engn, Boston, MA 02115 USA.
   [Giguel, Francoise F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
   [Tsibris, Athe M. N.; Kuritzkes, Daniel R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA.
   [Demirci, Utkan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Biomed Engn,Div Infect Dis,Dept Med, Cambridge, MA 02138 USA.
RP Demirci, U (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Med,Sch Med, Bioacoust MEMS Med BAMM Lab,Div Biomed Engn, Boston, MA 02115 USA.
EM udemirci@rics.bwh.harvard.edu
RI Shafiee, Hadi/C-8646-2014; Arumugam, Thirumagal/C-3408-2014
OI Inci, Fatih/0000-0002-9918-5038
FU National Institute of Health [RO1AI093282, RO1AI081534, R21AI087107,
   1F32AI102590]; US Army Medical Research and Materiel Command;
   Telemedicine and Advanced Technology Research Center (TATRC), at Fort
   Detrick, MD; NIH [U54EB15408]
FX The authors would like to thank Dr. Zixin Hu at the Division of
   Infectious Diseases, Brigham and Women's Hospital for his generous help
   on providing GFP tagged HIV-1 samples. The devices were fabricated using
   facilities at the Center for Nanoscale Systems (CNS), a member of the
   National Nanotechnology Infrastructure Network (NNIN). This work was
   supported by the National Institute of Health under NIH award numbers
   RO1AI093282, RO1AI081534, R21AI087107, 1F32AI102590 and NIH U54EB15408.
   This work was also supported by a research grant that was awarded and
   administered by the US Army Medical Research and Materiel Command and
   the Telemedicine and Advanced Technology Research Center (TATRC), at
   Fort Detrick, MD.
CR Aldaeus F, 2005, ELECTROPHORESIS, V26, P4252, DOI 10.1002/elps.200500068
   Asami K, 2002, PROG POLYM SCI, V27, P1617, DOI 10.1016/S0079-6700(02)00015-1                                                   
   Brown BK, 2005, J VIROL, V79, P6089, DOI 10.1128/JVI.79.10.6089-6101.2005
   Hay Burgess D. C., 2006, NATURE S1, V444, P1, DOI DOI 10.1038/NATURE05440
   BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x
   Chang BY, 2010, ANNU REV ANAL CHEM, V3, P207, DOI 10.1146/annurev.anchem.012809.102211
   Chen GD, 2010, ANAL CHEM, V82, P723, DOI 10.1021/ac9024522
   Cheng X, 2007, LAB CHIP, V7, P746, DOI 10.1039/b705082h
   Cheung K, 2005, CYTOM PART A, V65A, P124, DOI 10.1002/cyto.a.20141
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Cohen J, 2012, SCIENCE, V337, P168, DOI 10.1126/science.337.6091.168
   Coulter W.H, 1956, P NATIONAL ELECTRONI, V12, P1034
   DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Fricke H, 1935, NATURE, V135, P436, DOI 10.1038/135436a0                                                                
   Girosi Federico, 2006, Nature, V444 Suppl 1, P3, DOI 10.1038/nature05441
   Kim SK, 2004, BIOSENS BIOELECTRON, V20, P887, DOI 10.1016/j.bios.2004.04.004
   Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009                                                
   Li HB, 2002, SENSOR ACTUAT B-CHEM, V86, P215, DOI 10.1016/S0925-4005(02)00172-7                                                   
   Madhukar Varshney Y. L., 2007, SENSOR ACTUAT B-CHEM, V128, P99
   Moon S., PLOS ONE, V6, P21406
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Morgan H, 1999, BIOPHYS J, V77, P516, DOI 10.1016/S0006-3495(99)76908-0
   Patel P, 2006, JAIDS-J ACQ IMM DEF, V42, P75, DOI 10.1097/01.qai.0000218363.21088.ad
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Powers KA, 2011, LANCET, V378, P256, DOI 10.1016/S0140-6736(11)60842-8
   Rosenberg NE, 2012, J INFECT DIS, V205, P528, DOI 10.1093/infdis/jir789
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Salmanzadeh A, 2012, LAB CHIP, V12, P182, DOI 10.1039/c1lc20701f
   Shafiee H, 2010, LAB CHIP, V10, P438, DOI 10.1039/b920590j
   Sohn LL, 2000, P NATL ACAD SCI USA, V97, P10687, DOI 10.1073/pnas.200361297                                                          
   Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448
   Varshney M, 2009, BIOSENS BIOELECTRON, V24, P2951, DOI 10.1016/j.bios.2008.10.001
   Wang S., 2013, J BIOTECHADV, DOI [10.1016/j.biotechadv.2013.01.006, DOI 10.1016/J.BI0TECHADV.2013.01.006]
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Warrilow D, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-77
   Warrilow D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013229
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yang L, 2008, BIOTECHNOL ADV, V26, P135, DOI 10.1016/j.biotechadv.2007.10.003
   Yang LJ, 2004, ANAL CHEM, V76, P1107, DOI 10.1021/ac0352575
   [Anonymous], 2011, UNAIDS REPORT GLOABL
NR 42
TC 40
Z9 40
U1 6
U2 70
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD AUG 12
PY 2013
VL 9
IS 15
BP 2553
EP 2563
DI 10.1002/smll.201202195
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 263FO
UT WOS:000327792600013
PM 23447456
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bertok, T
   Klukova, L
   Sediva, A
   Kasak, P
   Semak, V
   Micusik, M
   Omastova, M
   Chovanova, L
   Vlcek, M
   Imrich, R
   Vikartovska, A
   Tkac, J
AF Bertok, Tomas
   Klukova, Ludmila
   Sediva, Alena
   Kasak, Peter
   Semak, Vladislav
   Micusik, Matej
   Omastova, Maria
   Chovanova, Lucia
   Vlcek, Miroslav
   Imrich, Richard
   Vikartovska, Alica
   Tkac, Jan
TI Ultrasensitive lmpedimetric Lectin Biosensors with Efficient Antifouling
   Properties Applied in Glycoprofiling of Human Serum Samples
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; BROADLY NEUTRALIZING ANTIBODIES;
   SURFACE-PLASMON RESONANCE; FREE PROTEIN-DETECTION; HIV GLYCAN SHIELD;
   CONCANAVALIN-A; FUNCTIONAL GLYCOMICS; EXPRESSION PATTERNS; GOLD
   NANOPARTICLES; PEPTIDE APTAMERS
AB Ultrasensitive impedimetric lectin biosensors recognizing different glycan entities on serum glycoproteins were constructed. Lectins were immobilized on a novel mixed self-assembled monolayer containing 11-mercaptoundecanoic acid for covalent immobilization of lectins and betaine terminated thiol to resist nonspecific interactions. Construction of biosensors based on Concanavalin A (Con A), Sambucus nigra agglutinin type I (SNA), and Ricinus communis agglutinin (RCA) on polycrystalline gold electrodes was optimized and characterized with a battery of tools including electrochemical impedance spectroscopy, various electrochemical techniques, quartz crystal microbalance (QCM), Fourier transform infrared (FT-IR) spectroscopy, atomic force microscopy (AFM), and X-ray photoelectron spectroscopy (XPS) and compared with a protein/lectin microarray. The lectin biosensors were able to detect glycoproteins from 1 fM (Con A), 10 fM (Ricinus communis agglutinin (RCA), or 100 fM (SNA) with a linear range spanning 6 (SNA), 7 (RCA), or 8 (Con A) orders of magnitude. Furthermore, a detection limit for the Con A biosensor down to 1 aM was achieved in a sandwich configuration. A nonspecific binding of proteins for the Con A biosensor was only 6.1% (probed with an oxidized invertase) of the signal toward its analyte invertase and a negligible nonspecific interaction of the Con A biosensor was observed in diluted human sera (1000X), as well. The performance of the lectin biosensors was finally tested by glycoprofiling of human serum samples from healthy individuals and those having rheumatoid arthritis, which resulted in a distinct glycan pattern between these two groups.
C1 [Bertok, Tomas; Klukova, Ludmila; Sediva, Alena; Vikartovska, Alica; Tkac, Jan] Slovak Acad Sci, Inst Chem, Dept Glycobiotechnol, Bratislava 84538, Slovakia.
   [Kasak, Peter] Qatar Univ, Ctr Adv Mat, Doha, Qatar.
   [Semak, Vladislav; Micusik, Matej; Omastova, Maria] Slovak Acad Sci, Inst Polymer, Dept Composite Mat, Bratislava 84541, Slovakia.
   [Chovanova, Lucia; Vlcek, Miroslav; Imrich, Richard] Slovak Acad Sci, Inst Expt Endocrinol, Lab Human Endocrinol, Bratislava 83306, Slovakia.
RP Tkac, J (reprint author), Slovak Acad Sci, Inst Chem, Dept Glycobiotechnol, Dubravska Cesta 9, Bratislava 84538, Slovakia.
EM Jan.Tkac@savba.sk
RI Bertok, Tomas/I-4034-2015; Vernerova, Lucia/G-4735-2015; Tkac,
   Jan/B-4313-2008; Tkac, Jan/D-6962-2015
OI Vernerova, Lucia/0000-0001-6087-2175; Tkac, Jan/0000-0002-0765-7262;
   Kasak, Peter/0000-0003-4557-1408; Bertok, Tomas/0000-0001-7075-2687
FU Slovak scientific grant agency VEGA [2/0127/10]; Slovak research and
   development agency APVV [0282-11]; European Research Council under the
   European Union's Seventh Framework Programme [311532]
FX The financial support from the Slovak scientific grant agency VEGA
   2/0127/10 and from the Slovak research and development agency APVV
   0282-11 is acknowledged. The research leading to these results has
   received funding from the European Research Council under the European
   Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement
   No. 311532.
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315
   Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134
   Arnaud J, 2013, CHEM SOC REV, V42, P4798, DOI 10.1039/c2cs35435g
   Beck A, 2012, MABS-AUSTIN, V4, P419, DOI 10.4161/mabs.20996
   Beck A, 2012, ANAL CHEM, V84, P4637, DOI 10.1021/ac3002885
   BECKER JW, 1975, J BIOL CHEM, V250, P1513
   Bertok T, 2013, TALANTA, V108, P11, DOI 10.1016/j.talanta.2013.02.052
   Bertok T, 2013, MICROCHIM ACTA, V180, P151, DOI 10.1007/s00604-012-0902-6
   Bertok T, 2013, MICROCHIM ACTA, V180, P1, DOI 10.1007/s00604-012-0876-4
   Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820
   Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144                                                        
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Cairo CW, 2002, J AM CHEM SOC, V124, P1615, DOI 10.1021/ja016727k
   Castner DG, 1996, LANGMUIR, V12, P5083, DOI 10.1021/la960465w                                                               
   Chandler K, 2013, MOL CELL PROTEOMICS, V12, P836, DOI 10.1074/mcp.R112.026930
   Chen SF, 2006, LANGMUIR, V22, P2418, DOI 10.1021/la052851w
   Cohen M, 2010, OMICS, V14, P455, DOI 10.1089/omi.2009.0148
   Cummings RD, 2009, MOL BIOSYST, V5, P1087, DOI 10.1039/b907931a
   Cunningham S, 2010, ANALYST, V135, P2471, DOI 10.1039/c0an00276c
   Davis JJ, 2007, ANAL CHEM, V79, P1089, DOI 10.1021/ac061863z
   Davis JJ, 2009, ANAL CHEM, V81, P3314, DOI 10.1021/ac802513n
   Dong YZ, 2003, LANGMUIR, V19, P8922, DOI 10.1021/la0261141
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P17107, DOI 10.1073/pnas.1002717107
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863                                                        
   Ferens-Sieczkowska M, 2013, BIOMARKERS, V18, P10, DOI 10.3109/1354750X.2012.719035
   Furukawa JI, 2013, BIOMOLECULES, V3, P198, DOI 10.3390/biom3010198
   Gabius HJ, 2011, TRENDS BIOCHEM SCI, V36, P298, DOI 10.1016/j.tibs.2011.01.005
   Gemeiner P, 2009, BIOTECHNOL ADV, V27, P1, DOI 10.1016/j.biotechadv.2008.07.003
   Gerlach JQ, 2010, BIOCHEM SOC T, V38, P1333, DOI 10.1042/BST0381333
   Gilgunn S, 2013, NAT REV UROL, V10, P99, DOI [10.1038/nruro1.2012.258, 10.1038/nrurol.2012.258]
   Gry M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-365
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720
   Hirabayashi J, 2013, CHEM SOC REV, V42, P4443, DOI 10.1039/c3cs35419a
   Hirabayashi J, 2011, ELECTROPHORESIS, V32, P1118, DOI 10.1002/elps.201000650
   Hirabayashi J, 2009, NAT CHEM BIOL, V5, P198, DOI 10.1038/nchembio0409-198
   JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127                                                         
   Katrlik J, 2010, MED RES REV, V30, P394, DOI 10.1002/med.20195
   Kim D, 2012, LANGMUIR, V28, P9634, DOI 10.1021/la300043m
   Kim EH, 2011, INT J PROTEOMICS, V2011, DOI DOI 10.1155/2011/610937
   Kim G, 2012, BIOCONJUGATE CHEM, V23, P2114, DOI 10.1021/bc300339b
   Kim JH, 2013, SCIENCE, V340, P71, DOI 10.1126/science.1232552
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   Krishnamoorthy L, 2009, ACS CHEM BIOL, V4, P715, DOI 10.1021/cb900103n
   Krishnamoorthy L, 2009, NAT CHEM BIOL, V5, P244, DOI 10.1038/nchembio.151
   La Belle JT, 2007, ANAL CHEM, V79, P6959, DOI 10.1021/ac070651e
   Lahiri J, 1999, ANAL CHEM, V71, P777, DOI 10.1021/ac980959t                                                               
   Lee JR, 2013, EXPERT REV PROTEOMIC, V10, P65, DOI [10.1586/EPR.12.67, 10.1586/epr.12.67]
   Li FB, 2011, SCIENCE, V333, P1030, DOI 10.1126/science.1206954
   MacBeath G, 2000, SCIENCE, V289, P1760
   Mislovicova D, 2012, COLLOID SURFACE B, V94, P163, DOI 10.1016/j.colsurfb.2012.01.036
   Mislovicova D, 2009, BIOLOGIA, V64, P1, DOI 10.2478/s11756-009-0029-3
   Murphy PV, 2013, MOLECULES, V18, P4026, DOI 10.3390/molecules18044026
   Nagaraj VJ, 2010, NANOMEDICINE-UK, V5, P369, DOI 10.2217/NNM.10.11
   Oliveira C, 2013, CRIT REV BIOTECHNOL, V33, P66, DOI 10.3109/07388551.2012.670614
   Ooi Y, 2005, LANGMUIR, V21, P11185, DOI 10.1021/la051160x
   Ostuni E, 2001, LANGMUIR, V17, P6336, DOI 10.1021/la010552a
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Rakus JF, 2011, ANNU REV ANAL CHEM, V4, P367, DOI 10.1146/annurev-anchem-061010-113951
   Raman R, 2005, NAT METHODS, V2, P817, DOI 10.1038/NMETH807
   Reuel NF, 2012, CHEM SOC REV, V41, P5744, DOI 10.1039/c2cs35142k
   Reuel NF, 2011, J AM CHEM SOC, V133, P17923, DOI 10.1021/ja2074938
   Rusmini F, 2007, BIOMACROMOLECULES, V8, P1775, DOI 10.1021/bm061197b
   Sanchez-Pomales G., 2011, INT J ELECTROCHEM, V2011
   Schauer R, 2011, CHEMBIOCHEM, V12, P2246, DOI 10.1002/cbic.201100421
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Schmaltz RM, 2011, CHEM REV, V111, P4259, DOI 10.1021/cr200113w
   Shen C. H., 2009, 13 INT C BIOM ENG, V23
   Shen CH, 2013, COLLOID SURFACE B, V101, P376, DOI 10.1016/j.colsurfb.2012.07.035
   Shen CH, 2011, LANGMUIR, V27, P7091, DOI 10.1021/la200906b
   Smith DF, 2013, MOL CELL PROTEOMICS, V12, P902, DOI 10.1074/mcp.R112.027110
   Song XZ, 2011, NAT METHODS, V8, P85, DOI 10.1038/NMETH.1540
   Tkac J, 2008, J ELECTROANAL CHEM, V621, P117, DOI 10.1016/j.jelechem.2008.04.010
   Tkac J, 2009, ENGINEERING THE BIOELECTRONIC INTERFACE: APPLICATIONS TO ANALYTE BIOSENSING AND PROTEIN DETECTION, P193, DOI 10.1039/9781847559777-00193
   Vaishnava S, 2011, SCIENCE, V334, P255, DOI 10.1126/science.1209791
   van Bueren JJL, 2011, NAT BIOTECHNOL, V29, P574, DOI 10.1038/nbt.1912
   Varki A., 2009, ESSENTIALS GLYCOBIOL
   Volkert AA, 2011, ACS NANO, V5, P4570, DOI 10.1021/nn200276a
   Yonzon CR, 2004, J AM CHEM SOC, V126, P12669, DOI 10.1021/ja047118q
   Yu L, 2007, ANAL CHEM, V79, P8979, DOI 10.1021/ac071453q
   Zhang Y, 2006, ANAL CHEM, V78, P2001, DOI 10.1021/ac051919+
   Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4
NR 83
TC 48
Z9 48
U1 10
U2 108
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD AUG 6
PY 2013
VL 85
IS 15
BP 7324
EP 7332
DI 10.1021/ac401281t
PG 9
WC Chemistry, Analytical
SC Chemistry
GA 199RW
UT WOS:000323014000049
PM 23808876
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhao, YX
   Sun, HX
   Li, XY
   Mo, XM
   Zhang, GZ
AF Zhao, Yingxia
   Sun, Hanxiao
   Li, Xiuying
   Mo, Xuemei
   Zhang, Guang
TI Anti-HIV Effect of Liposomes Bearing CXCR4 Receptor Antagonist N15P
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Antagonist; CXCR4; Liposomes; Receptor; Inflammation; HIV
ID SURVIVAL; BINDING
AB Purpose: To evaluate lymphatic system targeting and inhibitory ability of N15P nano-liposomal preparation (naLipo-N15P) of CXCR4 receptor antagonist in HIV infection.
   Methods: Chemotactic and chemotaxic inhibition activity assays were used to analyze the biological activity of naLipo-N15P. The anti-HIV potential of NaLipo-N15P in vitro was evaluated when NaLipo-N15P combined with the peripheral blood mononuclear cells of Macaca fascicularis which carry the Simian immunodeficiency virus. Furthermore, the anti-HIV potential in vivo of NaLipo-N15P was evaluated by the plasma concentration and tissue distribution (Ki)
   Results: The half-maximal inhibitory concentration of naLipo-N15P binding to CXCR4 as an antagonist in competition with SDF-1 alpha was 1.89 pM while Ki was 2.4 pM. Viral load was 289 +/- 45. NaLipo-N15P majorly accumulated in liver and spleen.
   Conclusion: When N15P is encapsulated into nano-liposomes, it not only retains specific binding to CXCR4 and facilitates cell-type-specific targeting of nano-liposomes to PBMCs with high CXCR4 expression, but also shows enhanced anti-HIV effect. Therefore, we propose that naLipo-N15P as a CXCR4 antagonist will play an important role in inflammation and blocking of HIV infection.
C1 [Zhao, Yingxia; Sun, Hanxiao; Li, Xiuying; Mo, Xuemei; Zhang, Guang] Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China.
RP Sun, HX (reprint author), Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China.
EM fangcaobi860317@163.com
FU Guangzhou Major Science and Technology Projects [2005Z1-E4081]; Nanyang
   Qi Wei Microecological Gene Science and Technology Development Co, Ltd.
FX This study was supported by grants from Guangzhou Major Science and
   Technology Projects (2005Z1-E4081) and Nanyang Qi Wei Microecological
   Gene Science and Technology Development Co, Ltd. The authors also thank
   the staff of the Radiological Department of Nan Yang Central Hospital
   for assistance and suggestions.
CR Bailey G. S., 1990, IN VITRO LABELING PR, P191
   de Jong LAA, 2005, J CHROMATOGR B, V829, P1, DOI 10.1016/j.jchromb.2005.10.002
   JinNan University Ethical Committee, 1985, NIH PUBLICATION, V85-23
   Kijowski J, 2001, STEM CELLS, V19, P453, DOI 10.1634/stemcells.19-5-453                                                      
   Majka M, 2000, EUR J HAEMATOL, V64, P164, DOI 10.1034/j.1600-0609.2000.90112.x
   Huang Ziwei, 2005, BIOCH BIOPHYSICAL RE, V335, P651
   Rawat SS, 2005, BIOSCIENCE REP, V25, P329, DOI 10.1007/s10540-005-2894-5
   Sun H, 2010, CHIN PHARM J, V11, P814
   van der Meer P, 2000, EXP MOL PATHOL, V69, P192, DOI 10.1006/exmp.2000.2336
   Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546                                                    
   Zhou NM, 2000, BIOCHEMISTRY-US, V39, P3782, DOI 10.1021/bi992750v
NR 11
TC 1
Z9 1
U1 1
U2 5
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596-5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD AUG
PY 2013
VL 12
IS 4
BP 503
EP 509
DI 10.4314/tjpr.v12i4.9
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 211BM
UT WOS:000323879100009
OA gold
DA 2018-01-05
ER

PT J
AU Devappa, RK
   Malakar, CC
   Makkar, HPS
   Becker, K
AF Devappa, Rakshit K.
   Malakar, Chandi C.
   Makkar, Harinder P. S.
   Becker, Klaus
TI Pharmaceutical potential of phorbol esters from Jatropha curcas oil
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE by-product; Jatropha; phorbol esters; prostratin; toxicity
ID CD-1 MOUSE SKIN; NONPROMOTING 12-DEOXYPHORBOL 13-ESTERS; SAMOAN
   MEDICINAL-PLANT; 12-MYRISTATE 13-ACETATE; HOMALANTHUS-NUTANS; SEED OIL;
   PROSTRATIN; 12-DEOXY-16-HYDROXYPHORBOL; EXPRESSION; HIV-1
AB Phorbol esters (PEs) are diterpenes present in Jatropha curcas L. seeds and have a myriad of biological activities. Since PEs are toxic, they are considered to be futile in Jatropha-based biodiesel production chain. In the present study, the extracted PEs from Jatropha oil were used as a starting material to synthesise pharmacologically important compound, prostratin. The prostratin synthesised from Jatropha showed identical mass with that of the reference standard prostratin, as determined by Nano-LC-ESI-MS/MS. Considering the rapid growth in Jatropha biodiesel industry, potential exists to harness large amount of PEs which can be further utilised to synthesise prostratin as a value added product.
C1 [Devappa, Rakshit K.; Makkar, Harinder P. S.] Univ Hohenheim, Inst Anim Prod Trop & Subtrop, D-70599 Stuttgart, Germany.
   [Malakar, Chandi C.; Becker, Klaus] Univ Hohenheim, Inst Chem, D-70599 Stuttgart, Germany.
RP Makkar, HPS (reprint author), Univ Hohenheim, Inst Anim Prod Trop & Subtrop, 480B, D-70599 Stuttgart, Germany.
EM Harinder.Makkar@fao.org
OI Malakar, Chandi/0000-0002-9478-017X
FU Bundesministerium fur Bildung und Forschung (BMBF), Berlin, Germany
FX The authors are grateful to the Bundesministerium fur Bildung und
   Forschung (BMBF), Berlin, Germany, for financial assistance. The
   technical assistance of Mr Hermann Baumgartner is acknowledged.
CR CAIRNES DA, 1981, CANCER LETT, V14, P85, DOI 10.1016/0304-3835(81)90013-6
   Cox PA, 2001, PHARM BIOL, V39, P33, DOI 10.1076/phbi.39.s1.33.0001
   GEXSI, 2008, GLOB MARK STUD JATR
   Goel G, 2007, INT J TOXICOL, V26, P279, DOI 10.1080/10915810701464641
   GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006
   Haas W, 2002, J NAT PROD, V65, P1434, DOI 10.1021/np020060d
   HIROTA M, 1988, CANCER RES, V48, P5800
   Johnson HE, 2008, J NAT PROD, V71, P2041, DOI 10.1021/np800295m
   Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006
   Makkar HRS, 2009, EUR J LIPID SCI TECH, V111, P773, DOI 10.1002/ejlt.200800244
   Makkar HPS, 1997, J AGR FOOD CHEM, V45, P3152, DOI 10.1021/jf970036j
   MIANA GA, 1985, PLANTA MED, V51, P353, DOI 10.1055/s-2007-969515                                                           
   SZALLASI Z, 1991, CANCER RES, V51, P5355
   SZALLASI Z, 1993, CANCER RES, V53, P2507
   SZALLASI Z, 1992, CARCINOGENESIS, V13, P2161, DOI 10.1093/carcin/13.11.2161
   Ventura C, 2001, CRIT REV EUKAR GENE, V11, P243
   Wender PA, 2008, SCIENCE, V320, P649, DOI 10.1126/science.1154690
   Wender P.A, 2009, United States patent publication number, Patent No. [2009/0187046, 20090187046]
NR 18
TC 5
Z9 5
U1 0
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1478-6419
J9 NAT PROD RES
JI Nat. Prod. Res.
PD AUG 1
PY 2013
VL 27
IS 16
BP 1459
EP 1462
DI 10.1080/14786419.2012.716057
PG 4
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 210EO
UT WOS:000323812300006
PM 22913490
DA 2018-01-05
ER

PT J
AU Shirazi, AN
   Tiwari, RK
   Oh, D
   Sullivan, B
   McCaffrey, K
   Mandal, D
   Parang, K
AF Shirazi, Amir Nasrolahi
   Tiwari, Rakesh Kumar
   Oh, Donghoon
   Sullivan, Brian
   McCaffrey, Kellen
   Mandal, Dindyal
   Parang, Keykavous
TI Surface Decorated Gold Nanoparticles by Linear and Cyclic Peptides as
   Molecular Transporters
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE cellular uptake; cyclic peptide; drug delivery; gold nanoparticles;
   lysine; nuclear targeting; tryptophan
ID NUCLEAR-PORE COMPLEX; DRUG-DELIVERY SYSTEMS; TARGETED DELIVERY; CELLULAR
   UPTAKE; INTRACELLULAR DELIVERY; CANCER-CELLS; TAT PEPTIDE;
   CAMPTOTHECINS; TRYPTOPHAN; INHIBITORS
AB Gold nanoparticles (AuNPs) were synthesized in situ in a green and rapid method from the reaction of reducing linear and cyclic peptides containing tryptophan and lysine residues, (KW)(5) and cyclic [KW](5), with an aqueous solution of HAuCl4 and were evaluated as cellular nanodrug delivery systems. The cyclic or linear nature of the peptide was found to determine the morphology and size of the formed peptide-AuNPs and their in vitro molecular transporting efficiency. While cyclic [KW](5)-AuNPs formed sponge like agglomerates, linear (KW)(5)-AuNPs demonstrated ball-shaped structures. A comparative flow cytometry study showed that the cellular uptake of fluorescence labeled anti-HIV drugs (emtricitabine (FTC) and lamivudine (3TC)) in human leukemia (CCRF-CEM) cells, and a negatively charged cell impermeable phosphopeptide (GpYEEI) in human ovarian adecarcinoma (SK-OV-3) cells was significantly higher in the presence of cyclic [KW](5)-AuNPs than that of linear (KW)(5)-AuNPs, parent cyclic [KW](5), and linear (KW)(5) peptides. For example, the cellular uptake of F'-GpYEEI was enhanced 12.8-fold by c[KW](5)-AuNPs. Confocal microscopy revealed the localization of fluorescence-labeled-3TC in the presence of c[KW](5)-AuNPs mostly in nucleus in SK-OV-3 cells after 1 h. On the other hand, 1(KW)(5)-AuNPs delivered fluorescence-labeled-3TC in cytoplasm. These data suggest that noncell penetrating peptides can be converted to efficient molecular transporters through peptide-capped AuNPs formation.
C1 [Shirazi, Amir Nasrolahi; Tiwari, Rakesh Kumar; Oh, Donghoon; Sullivan, Brian; McCaffrey, Kellen; Mandal, Dindyal; Parang, Keykavous] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
   [Tiwari, Rakesh Kumar; Parang, Keykavous] Chapman Univ, Coll Pharm, Orange, CA 92866 USA.
RP Parang, K (reprint author), Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, 7 Greenhouse Rd, Kingston, RI 02881 USA.
EM kparang@uri.edu
FU American Cancer Society [RSG-07-290-01-CDD]; US National Science
   Foundation [CHE 0748555]; National Center for Research Resources, NIH; 
   [8 P20 GM103430-12]
FX We acknowledge the financial support from the American Cancer Society,
   Grant No. RSG-07-290-01-CDD, and from the US National Science
   Foundation, Grant No. CHE 0748555. We thank National Center for Research
   Resources, NIH, and Grant Number 8 P20 GM103430-12 for sponsoring the
   core facility.
CR Agarwal HK, 2013, MOL PHARMACEUT, V10, P467, DOI 10.1021/mp300361a
   Agarwal HK, 2012, J MED CHEM, V55, P4861, DOI 10.1021/jm300492q
   Alkilany AM, 2010, J NANOPART RES, V12, P2313, DOI 10.1007/s11051-010-9911-8
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Cai HX, 2013, NANOSCALE, V5, P2892, DOI 10.1039/c3nr00178d
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   De M, 2008, ADV MATER, V20, P4225, DOI 10.1002/adma.200703183
   Dekiwadia CD, 2012, J PEPT SCI, V18, P527, DOI 10.1002/psc.2430
   Duncan B, 2010, J CONTROL RELEASE, V148, P122, DOI 10.1016/j.jconrel.2010.06.004
   Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641
   Hodoniczky J, 2008, BIOPOLYMERS, V90, P595, DOI 10.1002/bip.20986
   Iosin M, 2010, J NANOPART RES, V12, P2843, DOI 10.1007/s11051-010-9869-6
   Kailasan A., 2009, ACTA BIOMATER, V6, P1131
   Kang B, 2010, J AM CHEM SOC, V132, P1517, DOI 10.1021/ja9102698
   Kim CK, 2009, J AM CHEM SOC, V131, P1360, DOI 10.1021/ja808137c
   Kubitscheck U, 2005, J CELL BIOL, V168, P233, DOI 10.1083/jcb.200411005
   Langel U., 2002, CELL PENETRATING PEP
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Liu JN, 2012, BIOMATERIALS, V33, P7282, DOI 10.1016/j.biomaterials.2012.06.035
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   Massard J, 2008, Gastroenterol Clin Biol, V32, pS20, DOI 10.1016/S0399-8320(08)73261-5
   Meinema AC, 2011, SCIENCE, V333, P90, DOI 10.1126/science.1205741
   Morgan MT, 2006, CANCER RES, V66, P11913, DOI 10.1158/0008-5472.CAN-06-2066
   Nelson M, 2004, INT J CLIN PRACT, V58, P504, DOI 10.1111/j.1368-5031.2004.00100.x                                                
   Rana S, 2012, ADV DRUG DELIVER REV, V64, P200, DOI 10.1016/j.addr.2011.08.006
   Raurio J., 2008, NAT REV, V7, P255
   Saag Michael S, 2006, Clin Infect Dis, V42, P126
   Saha K, 2011, SMALL, V7, P1903, DOI 10.1002/smll.201100478
   Shiraishi T, 2005, BIOCONJUGATE CHEM, V16, P1112, DOI 10.1021/bc050093f
   Shirazi AN, 2013, BIOORG MED CHEM LETT, V23, P3230, DOI 10.1016/j.bmcl.2013.03.124
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P2008, DOI 10.1021/mp400046u
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P500, DOI 10.1021/mp300448k
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Songyang Z, 1993, Cell, V72, P767
   Subramani C, 2011, J MATER CHEM, V21, P14156, DOI 10.1039/c1jm11035g
   Tan YN, 2010, J AM CHEM SOC, V132, P5677, DOI 10.1021/ja907454f
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   van der Aa MAEM, 2006, PHARM RES, V23, P447, DOI 10.1007/s11095-005-9445-4
   WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0                                                                
   Yuan H, 2012, J AM CHEM SOC, V134, P11358, DOI 10.1021/ja304180y
NR 42
TC 12
Z9 12
U1 2
U2 40
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD AUG
PY 2013
VL 10
IS 8
BP 3137
EP 3151
DI 10.1021/mp400199e
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 197PN
UT WOS:000322863200030
PM 23834324
OA green_accepted
DA 2018-01-05
ER

PT J
AU Schellinger, JG
   Pahang, JA
   Shi, JL
   Pun, SH
AF Schellinger, Joan G.
   Pahang, Joshuel A.
   Shi, Julie
   Pun, Suzie H.
TI Block Copolymers Containing a Hydrophobic Domain of Membrane-Lytic
   Peptides Form Micellar Structures and Are Effective Gene Delivery Agents
SO ACS MACRO LETTERS
LA English
DT Article
ID IN-VITRO; VECTORS; NANOPARTICLES
AB Endosomal release peptides have been incorporated in synthetic gene delivery formulations to increase transfection efficiencies. In this work, cationic copolymers containing sHGP, a membrane-lytic peptide derived from HIV gp41, were synthesized and evaluated. Diblock, with sHGP displayed on one block, and statistical, with sHGP randomly displayed, copolymers were prepared via reversible addition-fragmentation chain transfer (RAFT) polymerization. While the statistical copolymers existed as unimers in solution, amphiphilic diblock copolymers self-assembled into cationic micelles in aqueous solution as evidenced by transmission electron microscopy (TEM) and dynamic light scattering analyses. This self-assembly sequestered the lytic domain and significantly reduced the cytotoxicity of the materials. However, when complexed with plasmid DNA, both the diblock and statistical copolymers of sHGP showed higher gene delivery efficacy compared to the copolymers without the membrane lytic motif. The ability of amphiphilic, diblock copolymers containing endosomal release motifs to self-assemble and sequester lytic domains is a promising feature for the nucleic acid delivery.
C1 [Pun, Suzie H.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   Univ Washington, Mol Engn & Sci Inst, Seattle, WA 98195 USA.
RP Pun, SH (reprint author), Univ Washington, Dept Bioengn, 3720 15th Ave NE,Box 355061, Seattle, WA 98195 USA.
EM spun@u.washington.edu
FU NIH/NINDS [1R01NS064404]; NSF DMR [1206426]; NSF [DGE-0718124]
FX This work was funded by NIH/NINDS 1R01NS064404 and NSF DMR 1206426. JAP
   was supported by a Mary Gates Undergraduate Research Fellowship, and JS
   was supported by an NSF graduate research fellowship under grant
   DGE-0718124. The authors would like to acknowledge Dr. Russell Johnson
   and David Chu for their insights and helpful discussions and Profs.
   Anthony Convertine and Patrick Stayton for generously providing the ECT
   chain transfer agent and macroCTA.
CR Ahmed M, 2013, PROG POLYM SCI, V38, P767, DOI 10.1016/j.progpolymsci.2012.09.008
   Behr JP, 1997, CHIMIA, V51, P34
   Branco MC, 2009, ACTA BIOMATER, V5, P817, DOI 10.1016/j.actbio.2008.09.018
   Chen S, 2011, MACROMOL BIOSCI, V11, P576, DOI 10.1002/mabi.201000427
   Chu DSH, 2012, ACCOUNTS CHEM RES, V45, P1089, DOI 10.1021/ar200242z
   Convertine AJ, 2010, BIOMACROMOLECULES, V11, P2904, DOI 10.1021/bm100652w
   Costin JM, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-123
   Guo XD, 2008, BIOMATERIALS, V29, P4838, DOI 10.1016/j.biomaterials.2008.07.053
   Harada-Shiba M, 2002, GENE THER, V9, P407, DOI 10.1038/sj.gt/3301665
   Hoo CM, 2008, J NANOPART RES, V10, P89, DOI 10.1007/s11051-008-9435-7
   Hoyer J, 2012, ACCOUNTS CHEM RES, V45, P1048, DOI 10.1021/ar2002304
   Johnson RN, 2011, J CONTROL RELEASE, V155, P303, DOI 10.1016/j.jconrel.2011.07.009
   Kwon EJ, 2008, BIOCONJUGATE CHEM, V19, P920, DOI 10.1021/bc700448h
   Kwon EJ, 2010, MOL PHARMACEUT, V7, P1260, DOI 10.1021/mp1000668
   Merkel OM, 2011, BIOMATERIALS, V32, P4936, DOI 10.1016/j.biomaterials.2011.03.035
   Miyata K, 2007, J CONTROL RELEASE, V122, P252, DOI 10.1016/j.jconrel.2007.06.020
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Schellinger JG, 2013, BIOMATERIALS, V34, P2318, DOI 10.1016/j.biomaterials.2012.09.072
   Seow WY, 2009, J CONTROL RELEASE, V139, P40, DOI 10.1016/j.jconrel.2009.05.028
   Shi JL, 2013, BIOMACROMOLECULES, V14, P1961, DOI 10.1021/bm400342f
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2                                                   
   Wei H, 2013, ANGEW CHEM INT EDIT, V52, P5377, DOI 10.1002/anie.201301896
   Wei H, 2012, J AM CHEM SOC, V134, P16554, DOI 10.1021/ja3085803
   Wiradharma N, 2008, ADV FUNCT MATER, V18, P943, DOI 10.1002/adfm.200700884
   Wolfert MA, 1998, GENE THER, V5, P409, DOI 10.1038/sj.gt.3300606                                                           
NR 27
TC 8
Z9 8
U1 0
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2161-1653
J9 ACS MACRO LETT
JI ACS Macro Lett.
PD AUG
PY 2013
VL 2
IS 8
BP 725
EP 730
DI 10.1021/mz400331w
PG 6
WC Polymer Science
SC Polymer Science
GA 205VE
UT WOS:000323472100018
PM 24044103
OA green_accepted
DA 2018-01-05
ER

PT J
AU Shekhar, H
   Kant, V
AF Shekhar, H.
   Kant, Vishnu
TI Thermodynamic Studies on Solid Dispersions of Nicotinamide - Khellin
   Drug System
SO MOLECULAR CRYSTALS AND LIQUID CRYSTALS
LA English
DT Article
DE Critical radius; interfacial energy; roughness parameter; solid-liquid
   equilibrium data; thermodynamic excess and mixing functions
ID ORGANIC ALLOYS; BINARY; DISSOLUTION; SOLUBILITY; COCRYSTALS; ENERGY;
   ACID
AB Biomolecules, nicotinamide (NA), and khellin (KH) have been used orally for a number of diseases for the last few decades. NA is shown as an HIV, Mycobaterium tuberculosis, and pellagra preventive agent, whereas KH is used in renal colic, diuretic, kidney stone, coronary, bronchial asthma, angina, vitiligo, and psoriasis. In recent years, research on solid dispersions of binary drug products is playing a significant role in the drug delivery process of the pharmaceutical industries. The present study highlights the thermodynamic characteristics of solid dispersions binary products of active pharmaceutical ingredient KH with pharmaceutical excipient NA. These products have been prepared through melting/fusion method. The solid-liquid equilibrium (SLE) data of NA-KH system favors the formation of an eutectic (E) at 0.135 mole fraction of KH and melting temperature 120.6 degrees C and noneutectic solid dispersions (A1-A8) at their defined compositions and temperatures. To illustrate the molecular interaction, the activity coefficient model based on enthalpy of fusion is employed to calculate the excess partial and integral thermodynamic functions such as g(E), h(E), and s(E). The positive value of excess Gibbs free energy predicts the stronger molecular interaction between the like molecules as compared to unlike molecules. The spontaneity of mixing of eutectic and noneutectic alloys was discussed by the integral mixing quantities G(M), H-M, and S-M. The value of critical radius (r*) of solid dispersions is found in nanometer (nm) scale, which suggests the process of solidification for nanosolid dispersions, and it is very surprising for the pharma world. The binary interface structure of alloys has been discussed in light of the Jackson model of interface structure.
C1 [Shekhar, H.; Kant, Vishnu] VKS Univ, Dept Chem, Ara 802301, Bihar, India.
RP Shekhar, H (reprint author), VKS Univ, Dept Chem, Ara 802301, Bihar, India.
EM hshe2503@reiffmail.com
CR Aggarwal AK, 2011, CHEM PHARM BULL, V59, P629, DOI 10.1248/cpb.59.629
   Agrwal T., 2010, J CHEM ENG DATA, V55, P4206
   Akbulut S, 2009, APPL SURF SCI, V255, P3594, DOI 10.1016/j.apsusc.2008.10.003
   Ansari MT, 2012, PAK J PHARM SCI, V25, P447
   Bryn S., 2001, ADV DRUG DELIV REV, V48, P115
   Chadwick G A., 1972, METALLOGRAPHY PHASE, P61
   Charles P. H., 1951, CHEM REV, V48, P543
   Del S. R., 2010, DRUG DELIV, V17, P130
   Girgis AS, 2006, BIOORGAN MED CHEM, V14, P4466, DOI 10.1016/j.bmc.2006.02.031
   Good DJ, 2009, CRYST GROWTH DES, V9, P2252, DOI 10.1021/cg801039j
   GUNDUZ M, 1989, ACTA METALL MATER, V37, P1839, DOI 10.1016/0001-6160(89)90068-0                                                    
   HUNT JD, 1966, T METALL SOC AIME, V236, P843
   Hunt J. D., 1994, HDB CRYSTAL GROWTH, P112
   Klaus F., 1980, ANAL PROFILES DRUG S, V9
   de Leeuw J., 2010, J EUR ACAD DERMATOL, V10, P1468
   MALAVIOLLE R, 1988, THERMOCHIM ACTA, V121, P283
   Murray F. M., 1995, BIOCHEM BIOPH RES CO, V210, P954
   Murray F. M., 2003, CLIN INFECT DIS, V36, P453
   Nieto R, 1999, AM J PHYS, V67, P1096, DOI 10.1119/1.19089
   Niren Neil M, 2006, Cutis, V77, P11
   Remenar JF, 2003, J AM CHEM SOC, V125, P8456, DOI 10.1021/ja035776p
   Sangster J, 1999, J PHYS CHEM REF DATA, V28, P889, DOI 10.1063/1.556040
   Shamsuddin M, 1998, THERMOCHIM ACTA, V316, P11, DOI 10.1016/S0040-6031(98)00291-3                                                   
   Sharma BL, 2009, CRYST RES TECHNOL, V44, P258, DOI 10.1002/crat.200800034
   Shekhar H, 2011, J INDIAN CHEM SOC, V88, P947
   Shekhar H, 2011, NATL ACAD SCI LETT, V34, P117
   Shiraki K, 2008, PHARM RES-DORDR, V25, P2581, DOI 10.1007/s11095-008-9676-2
   SINGH NB, 1989, J CRYST GROWTH, V98, P573, DOI 10.1016/0022-0248(89)90293-5                                                    
   TRABALZINI L, 1990, J PHOTOCH PHOTOBIO B, V7, P317, DOI 10.1016/1011-1344(90)85165-S
   TURNBULL D, 1950, J CHEM PHYS, V18, P768, DOI 10.1063/1.1747765                                                               
   WILCOX WR, 1974, J CRYST GROWTH, V26, P153, DOI 10.1016/0022-0248(74)90218-8
NR 31
TC 0
Z9 0
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1542-1406
J9 MOL CRYST LIQ CRYST
JI Mol. Cryst. Liquid Cryst.
PD AUG 1
PY 2013
VL 577
IS 1
BP 103
EP 115
DI 10.1080/15421406.2013.782207
PG 13
WC Crystallography
SC Crystallography
GA 184KB
UT WOS:000321887400011
DA 2018-01-05
ER

PT J
AU Date, AA
   Destache, CJ
AF Date, Abhijit A.
   Destache, Christopher J.
TI A review of nanotechnological approaches for the prophylaxis of HIV/AIDS
SO BIOMATERIALS
LA English
DT Review
DE HIV; Nanotechnology; Polymeric nanoparticles; Dendrimers; Prophylaxis;
   Vaginal delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MEDIATED IMMUNE-RESPONSES; TENOFOVIR
   DISOPROXIL FUMARATE; ANTI-HIV ACTIVITY; INACTIVATED HIV-1-CAPTURING
   NANOSPHERES; BIODEGRADABLE POLYMER NANOPARTICLES; VACCINE
   DELIVERY-SYSTEMS; CORE-SHELL NANOPARTICLES; PH-SENSITIVE LIPOSOMES;
   VAGINAL DRUG-DELIVERY
AB Successful treatment and control of HIV/AIDS is one of the biggest challenges of 21st century. More than 33 million individuals are infected with HIV worldwide and more than 2 million new cases of HIV infection have been reported. The situation demands development of effective prevention strategies to control the pandemic of AIDS. Due to lack of availability of an effective HIV vaccine, antiretroviral drugs and nucleic acid therapeutics like siRNA have been explored for HIV prophylaxis. Clinical trials shave shown that antiretroviral drugs, tenofovir and emtricitabine can offer some degree of HIV prevention. However, complete prevention of HIV infection has not been achieved yet. Nanotechnology has brought a paradigm shift in the diagnosis, treatment and prevention of many diseases. The current review discusses potential of various nanocarriers such as dendrimers, polymeric nanoparticles, liposomes, lipid nanocarriers, drug nanocrystals, inorganic nanocarriers and nanofibers in improving efficacy of various modalities available for HIV prophylaxis. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Date, Abhijit A.; Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
EM destache@creighton.edu
OI Date, Abhijit/0000-0001-6617-882X; Destache,
   Christopher/0000-0001-7923-3939
FU National Institute of Health [1R56AI095115-01]
FX This work was supported by National Institute of Health grants
   1R56AI095115-01 (to CJ.D.). The authors have no conflict of interest.
CR Adams JL, 2012, BEST PRACT RES CL OB, V26, P451, DOI 10.1016/j.bpobgyn.2012.01.004
   Agrawal L, 2003, J IMMUNE BASED THER, V1, DOI [10.1186/1476-8518-1-5, DOI 10.1186/1476-8518-1-5]
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev.bioeng-071811-150124, 10.1146/annurev-bioeng-071811-150124]
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Allen TM, 1998, DRUGS, V56, P747, DOI 10.2165/00003495-199856050-00001                                                
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]
   Arab-Alameddine M, 2012, ANTIMICROB AGENTS CH, V56, P2959, DOI 10.1128/AAC.05424-11
   Arias MA, 2011, VACCINE, V29, P1258, DOI 10.1016/j.vaccine.2010.11.084
   Arnida, 2011, EUR J PHARM BIOPHARM, V77, P417, DOI 10.1016/j.ejpb.2010.11.010
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Ballard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037410
   Baribaud Frederic, 2002, Expert Opin Ther Targets, V6, P423, DOI 10.1517/14728222.6.4.423
   Belletti D, 2012, INT J PHARMACEUT, V436, P753, DOI 10.1016/j.ijpharm.2012.07.070
   Ben Haij N, 2012, INT J PHARMACEUT, V423, P116, DOI 10.1016/j.ijpharm.2011.06.049
   Berzi A, 2012, AIDS, V26, P127, DOI 10.1097/QAD.0b013e32834e1567
   Bitar A, 2012, DRUG DISCOV TODAY, V17, P1147, DOI 10.1016/j.drudis.2012.06.014
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Borges AR, 2010, VIROLOGY, V408, P80, DOI 10.1016/j.virol.2010.09.004
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Buchbinder SP, 2011, AIDS BEHAV, V15, pS72, DOI 10.1007/s10461-011-9894-1
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   BUI T, 1994, J ACQ IMMUN DEF SYND, V7, P799
   Caputo A, 2009, VACCINE, V27, P3605, DOI 10.1016/j.vaccine.2009.03.047
   Carlson C, 2008, J PHYS CHEM B, V112, P13608, DOI 10.1021/jp712087m
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef
   Champion JA, 2007, J CONTROL RELEASE, V121, P3, DOI 10.1016/j.jconrel.2007.03.022
   Champion JA, 2009, PHARM RES-DORD, V26, P244, DOI 10.1007/s11095-008-9626-z
   Chang JS, 1999, VACCINE, V17, P1540, DOI 10.1016/S0264-410X(98)00353-3
   Chavanpatil MD, 2007, J BIOMED NANOTECHNOL, V3, P291, DOI 10.1166/jbn.2007.040
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Clavel C, 2011, ANTIMICROB AGENTS CH, V55, P3018, DOI 10.1128/AAC.01460-10
   Clayton R, 2011, BIOCONJUGATE CHEM, V22, P2186, DOI 10.1021/bc200331v
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   Cohen JA, 2009, BIOCONJUGATE CHEM, V20, P111, DOI 10.1021/bc800338n
   Cohen MS, 2012, AIDS, V26, P1585, DOI 10.1097/QAD.0b013e3283543e83
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cu Y, 2010, NANOMED-NANOTECHNOL, V6, P334, DOI 10.1016/j.nano.2009.09.001
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Dahlin RL, 2011, TISSUE ENG PART B-RE, V17, P349, DOI [10.1089/ten.teb.2011.0238, 10.1089/ten.TEB.2011.0238]
   Damian F, 2010, INT J PHARMACEUT, V396, P1, DOI 10.1016/j.ijpharm.2010.05.024
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Daum N, 2012, WIRES NANOMED NANOBI, V4, P52, DOI 10.1002/wnan.165
   Dawson M, 2004, BIOTECHNOL PROGR, V20, P851, DOI 10.1021/bp0342553
   De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006
   Decuzzi P, 2010, J CONTROL RELEASE, V141, P320, DOI 10.1016/j.jconrel.2009.10.014
   Decuzzi P, 2009, PHARM RES-DORD, V26, P235, DOI 10.1007/s11095-008-9697-x
   Demberg T, 2009, INT REV IMMUNOL, V28, P20, DOI 10.1080/08830180802684331
   Desai PP, 2012, DRUG DISCOV TODAY, V9, pe87
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Devarajan PV, 2010, J PHARM SCI-US, V99, P2576, DOI 10.1002/jps.22052
   Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Domenech R, 2010, BIOMACROMOLECULES, V11, P2069, DOI 10.1021/bm100432x
   Drogoz A, 2008, BIOMACROMOLECULES, V9, P583, DOI 10.1021/bm701154h
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Duerr A, 2010, CURR OPIN HIV AIDS, V5, P397, DOI 10.1097/COH.0b013e32833d2e39
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Eichhorn ME, 2010, INT J CANCER, V126, P1235, DOI 10.1002/ijc.24846
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Elizondo E, 2011, PROG MOL BIOL TRANSL, V104, P1, DOI 10.1016/B978-0-12-416020-0.00001-2
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   Ensign LM, 2012, SCI TRANSL MED, V4
   Fairman J, 2009, HUM VACCINES, V5, P141, DOI 10.4161/hv.5.3.6589                                                             
   Fanibunda SE, 2008, JAIDS-J ACQ IMM DEF, V48, P389, DOI 10.1097/QAI.0b013e318179a0fb
   Fanibunda SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028014
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148                                                     
   Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006
   Ford N, 2011, AIDS, V25, P2301, DOI 10.1097/QAD.0b013e32834cdb71
   Frenkel YV, 2005, J MED CHEM, V48, P1974, DOI 10.1021/jm049439i
   Friend DR, 2010, PHARM DEV TECHNOL, V15, P562, DOI 10.3109/10837450903369879
   Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI [10.2217/nnm.10.114, 10.2217/NNM.10.114]
   Fukasawa M, 1998, FEBS LETT, V441, P353, DOI 10.1016/S0014-5793(98)01577-4
   Gan Q, 2012, BIOMED MICRODEVICES, V14, P259, DOI 10.1007/s10544-011-9604-9
   Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028
   Garzon MR, 2005, VACCINE, V23, P1384, DOI 10.1016/j.vaccine.2004.09.009
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Ghosn J, 2009, AIDS REV, V11, P165
   Grammen C, 2012, ANTIVIR RES, V96, P226, DOI 10.1016/j.antiviral.2012.09.011
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Gunn J, 2010, TRENDS BIOTECHNOL, V28, P189, DOI 10.1016/j.tibtech.2009.12.006
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Guzman-Villanueva D, 2012, J PHARM SCI-US, V101, P4046, DOI 10.1002/jps.23300
   Haaland RE, 2012, ANTIMICROB AGENTS CH, V56, P3592, DOI 10.1128/AAC.00452-12
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021
   Han SQ, 2012, CARBOHYD POLYM, V90, P1061, DOI 10.1016/j.carbpol.2012.06.044
   Han SQ, 2010, CARBOHYD POLYM, V80, P1111, DOI 10.1016/j.carbpol.2010.01.031
   Hankins CA, 2013, CURR OPIN HIV AIDS, V8, P50, DOI 10.1097/COH.0b013e32835b809d
   Hao YZ, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/4/045103
   HARDING CV, 1991, J IMMUNOL, V147, P2860
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   Himeno A, 2010, VACCINE, V28, P5377, DOI 10.1016/j.vaccine.2010.04.110
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Huang J, 2010, ACS NANO, V4, P7151, DOI 10.1021/nn101643u
   Huang XL, 2010, BIOMATERIALS, V31, P438, DOI 10.1016/j.biomaterials.2009.09.060
   Jain A, 2010, INT J PHARMACEUT, V401, P87, DOI 10.1016/j.ijpharm.2010.09.003
   Jazayeri M, 2009, COMP IMMUNOL MICROB, V32, P453, DOI 10.1016/j.cimid.2008.05.002
   Kaminskas LM, 2008, MOL PHARMACEUT, V5, P449, DOI 10.1021/mp7001208
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   Karim SSA, 2012, BEST PRACT RES CL OB, V26, P427, DOI 10.1016/j.bpobgyn.2012.01.010
   Katakowski JA, 2010, CURR OPIN MOL THER, V12, P192
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Kensinger RD, 2004, ANTIMICROB AGENTS CH, V48, P1614, DOI 10.1128/AAC.48.5.1614-1623.2004
   Kensinger RD, 2004, BIOCONJUGATE CHEM, V15, P349, DOI 10.1021/bc034156a
   Khalil NM, 2011, EXPERT OPIN DRUG DEL, V8, P95, DOI 10.1517/17425247.2011.543673
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Koblin BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024517
   Koff WC, 2012, VACCINE, V30, P4310, DOI 10.1016/j.vaccine.2011.11.014
   Koh Y, 2011, ANTIMICROB AGENTS CH, V55, P42, DOI 10.1128/AAC.01064-10
   Lacey CJ, 2010, INT J STD AIDS, V21, P714, DOI 10.1258/ijsa.2010.010215
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lee JE, 2011, ACCOUNTS CHEM RES, V44, P893, DOI 10.1021/ar2000259
   Lee SY, 2009, J BIOMECH, V42, P1885, DOI 10.1016/j.jbiomech.2009.05.012
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Lian TS, 1999, VACCINE, V18, P604, DOI 10.1016/S0264-410X(99)00315-1
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Lim SH, 2009, ADV DRUG DELIVER REV, V61, P1084, DOI 10.1016/j.addr.2009.07.011
   Lin SY, 2011, J CONTROL RELEASE, V154, P84, DOI 10.1016/j.jconrel.2011.04.023
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Maitani Y, 2013, J CONTROL RELEASE, V166, P139, DOI 10.1016/j.jconrel.2012.12.027
   Majid A, 2012, HIV AIDS-RES PALLIAT, V4, P17, DOI 10.2147/HIV.S25082
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Mathias A, 2012, J BIOEQUIV AVAILAB, V4, P100
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   McKinnon LR, 2010, AIDS REV, V12, P209
   McNeil SE, 2011, J PHARM SCI-US, V100, P1856, DOI 10.1002/jps.22427
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Mert O, 2012, J CONTROL RELEASE, V157, P455, DOI 10.1016/j.jconrel.2011.08.032
   Mesquita PMM, 2012, J ANTIMICROB CHEMOTH, V67, P1730, DOI 10.1093/jac/dks097
   Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moghimi SM, 2012, ANNU REV PHARMACOL, V52, P481, DOI 10.1146/annurev-pharmtox-010611-134623
   Moghimi SM, 2011, ADV DRUG DELIVER REV, V63, P1000, DOI 10.1016/j.addr.2011.06.002
   Moghimi SM, 2006, BIOMATERIALS, V27, P136, DOI 10.1016/j.biomaterials.2005.05.082
   Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012
   Morimoto K, 2003, MOL THER, V7, P254, DOI 10.1016/S1525-0016(02)00053-9
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Moss DM, 2012, ANTIMICROB AGENTS CH, V56, P3020, DOI 10.1128/AAC.06407-11
   Muller Rainer H, 2011, Curr Drug Discov Technol, V8, P207
   Naesens L, 1998, ANTIMICROB AGENTS CH, V42, P1568
   Navath RS, 2011, MOL PHARMACEUT, V8, P1209, DOI 10.1021/mp200027z
   Neff CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015257
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nuttall J, 2012, ANTIMICROB AGENTS CH, V56, P103, DOI 10.1128/AAC.00597-11
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Okada E, 1997, J IMMUNOL, V159, P3638
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Owais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Pardeike J, 2009, INT J PHARM, V366, P170, DOI 10.1016/j.ijpharm.2008.10.003
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Patel JD, 2007, PHARM RES, V24, P343, DOI 10.1007/s11095-006-9154-7
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   Pattani A, 2012, J CONTROL RELEASE, V162, P529, DOI 10.1016/j.jconrel.2012.07.039
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Pearson RM, 2013, ACS MACRO LETT, V2, P77, DOI 10.1021/mz300533w
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Perez-Anes A, 2010, BIOORGAN MED CHEM, V18, P242, DOI 10.1016/j.bmc.2009.10.058
   Perez-Anes A, 2009, ORG BIOMOL CHEM, V7, P3491, DOI 10.1039/b908352a
   Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038
   Phillips NC, 1996, VACCINE, V14, P898, DOI 10.1016/0264-410X(96)82949-5
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Qiao Y, 2010, BIOMATERIALS, V31, P115, DOI 10.1016/j.biomaterials.2009.09.032
   Ramjee G, 2010, AIDS, V24, pS40, DOI 10.1097/01.aids.0000390706.81383.f3
   Ramjee G, 2010, CURR OPIN HIV AIDS, V5, P316, DOI 10.1097/COH.0b013e32833a9f66
   Rao M, 2004, IMMUNOL CELL BIOL, V82, P523, DOI 10.1111/j.1440-1711.2004.01283.x
   REDDY R, 1991, J IMMUNOL METHODS, V141, P157, DOI 10.1016/0022-1759(91)90142-3                                                    
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P53, DOI 10.1016/j.nano.2006.04.009
   Pinto Reis C, 2006, NANOMEDICINE, V2, P8
   Rosenberg ZF, 2012, BEST PRACT RES CL OB, V26, P503, DOI 10.1016/j.bpobgyn.2012.02.001
   Roy S, 2001, ANTIMICROB AGENTS CH, V45, P1671, DOI 10.1128/AAC.45.6.1671-1681.2001
   Ruel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   Rupp R, 2007, INT J NANOMED, V2, P561
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Scholler-Gyure M, 2008, BRIT J CLIN PHARMACO, V66, P508, DOI 10.1111/j.1365-2125.2008.03214.x
   Shah KA, 2007, INT J PHARM, V345, P163, DOI 10.1016/j.ijpharm.2007.05.061
   Sharma G, 2010, J CONTROL RELEASE, V147, P408, DOI 10.1016/j.jconrel.2010.07.116
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shiang YC, 2013, NANOSCALE, V5, P2756, DOI 10.1039/c3nr33403a
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   Singh SK, 2006, VACCINE, V24, P4161, DOI 10.1016/j.vaccine.2006.02.047
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Suffa V, 2012, PLOS ONE, V7
   Sunshine JC, 2012, MOL PHARMACEUT, V9, P3375, DOI 10.1021/mp3004176
   Symonds GP, 2010, IMMUNOL RES, V48, P84, DOI 10.1007/s12026-010-8169-7
   Szebeni J, 1998, CRIT REV THER DRUG, V15, P57
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   Tabatt K, 2004, EUR J PHARM BIOPHARM, V57, P155, DOI 10.1016/j.ejpb.2003.10.015
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Thiagarajan G, 2013, EUR J PHARM IN PRESS
   Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tsai YM, 2012, INT J NANOMED, V7, P2957, DOI 10.2147/IJN.S32630
   Turpin JA, 2011, DRUG DELIV TRANSL RE, V1, P194, DOI 10.1007/s13346-011-0034-2
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Uto T, 2011, IMMUNOL LETT, V140, P36, DOI 10.1016/j.imlet.2011.06.002
   van Gelder J, 2002, DRUG METAB DISPOS, V30, P924, DOI 10.1124/dmd.30.8.924
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vasilyeva SV, 2013, BIOORGAN MED CHEM, V21, P703, DOI 10.1016/j.bmc.2012.11.057
   Venkataraman S, 2011, ADV DRUG DELIVER REV, V63, P1228, DOI 10.1016/j.addr.2011.06.016
   Vijayakumar S, 2012, CURR HIV RES, V10, P643, DOI 10.2174/157016212803901383                                                      
   Voltan R, 2007, PHARM RES-DORDR, V24, P1870, DOI 10.1007/s11095-007-9310-8
   Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338
   Wang TY, 2012, INT J PHARMACEUT, V436, P351, DOI 10.1016/j.ijpharm.2012.06.028
   Wang W, 2010, J BIOMED MATER RES B, V93B, P59, DOI 10.1002/jbm.b.31558
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Watson DS, 2011, CLIN VACCINE IMMUNOL, V18, P289, DOI 10.1128/CVI.00425-10
   Watson DS, 2009, VACCINE, V27, P4672, DOI 10.1016/j.vaccine.2009.05.059
   Weatherley B, 2009, BRIT J CLIN PHARMACO, V68, P355, DOI 10.1111/j.1365-2125.2009.03455.x
   Weber C, 2010, J BIOMED MATER RES A, V93A, P1322, DOI 10.1002/jbm.a.32605
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weuts I, 2011, J PHARM SCI-US, V100, P260, DOI 10.1002/jps.22242
   Win KY, 2005, BIOMATERIALS, V26, P2713, DOI 10.1016/j.biomaterials.2004.07.050
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wren L, 2011, HUM VACCINES, V7, P467, DOI 10.4161/hv.7.4.14123
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Xiong S, 2013, ARCH TOXICOL
   Xu AR, 2012, INT J NANOMED, V7, P3547, DOI 10.2147/IJN.S32188
   Yan WL, 2009, HIV AIDS-RES PALLIAT, V1, P1
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Yu MK, 2010, EXPERT OPIN BIOL TH, V10, P1181, DOI 10.1517/14712598.2010.496776
   Yu SS, 2012, INT J NANOMED, V7, P799, DOI 10.2147/IJN.S28531
   Zanini D, 1996, J ORG CHEM, V61, P7348, DOI 10.1021/jo961047z                                                               
   Zeller Skye J., 2011, Yale Journal of Biology and Medicine, V84, P301
   Zembruski NCL, 2011, J ANTIMICROB CHEMOTH, V66, P802, DOI 10.1093/jac/dkq501
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhu Q, 2012, NAT MED, V18, P1291, DOI 10.1038/nm.2866
NR 272
TC 41
Z9 41
U1 7
U2 101
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2013
VL 34
IS 26
BP 6202
EP 6228
DI 10.1016/j.biomaterials.2013.05.012
PG 27
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 173KY
UT WOS:000321079600013
PM 23726227
OA green_accepted
DA 2018-01-05
ER

PT J
AU Suzuki, Y
   Roy, CN
   Promjunyakul, W
   Hatakeyama, H
   Gonda, K
   Imamura, J
   Vasudevanpillai, B
   Ohuchi, N
   Kanzaki, M
   Higuchi, H
   Kaku, M
AF Suzuki, Yasuhiro
   Roy, Chandra Nath
   Promjunyakul, Warunya
   Hatakeyama, Hiroyasu
   Gonda, Kohsuke
   Imamura, Junji
   Vasudevanpillai, Biju
   Ohuchi, Noriaki
   Kanzaki, Makoto
   Higuchi, Hideo
   Kaku, Mitsuo
TI Single Quantum Dot Tracking Reveals that an Individual Multivalent HIV-1
   Tat Protein Transduction Domain Can Activate Machinery for Lateral
   Transport and Endocytosis
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID CELL-PENETRATING PEPTIDES; HUMAN IMMUNODEFICIENCY VIRUS; LIVING CELLS;
   GLUT4 TRAFFICKING; MEMBRANE DYNAMICS; VESICLE TRANSPORT; BINDING
   MECHANISM; MOLECULE TRACKING; HEPARAN-SULFATE; PLASMA-MEMBRANE
AB The mechanisms underlying the cellular entry of the HIV-1 Tat protein transduction domain (TatP) and the molecular information necessary to improve the transduction efficiency of TatP remain unclear due to the technical limitations for direct visualization of TatP's behavior in cells. Using confocal microscopy, total internal reflection fluorescence microscopy, and four-dimensional microscopy, we developed a single-molecule tracking assay for TatP labeled with quantum dots (QDs) to examine the kinetics of TatP initially and immediately before, at the beginning of, and immediately after entry into living cells. We report that even when the number of multivalent TatP (mTatP)-QDs bound to a cell was low, each single mTatP-QD first locally induced the cell's lateral transport machinery to move the mTatP-QD toward the center of the cell body upon cross-linking of heparan sulfate proteoglycans. The centripetal and lateral movements were linked to the integrity and flow of actomyosin and microtubules. Individual mTatP underwent lipid raft-mediated temporal confinement, followed by complete immobilization, which ultimately led to endocytotic internalization. However, bivalent TatP did not sufficiently promote either cell surface movement or internalization. Together, these findings provide clues regarding the mechanisms of TatP cell entry and indicate that increasing the valence of TatP on nanoparticles allows them to behave as cargo delivery nanomachines.
C1 [Suzuki, Yasuhiro; Roy, Chandra Nath; Promjunyakul, Warunya; Imamura, Junji] Tohoku Univ, Grad Sch Med, Dept Emerging Infect Dis, Sendai, Miyagi 980, Japan.
   [Suzuki, Yasuhiro; Kaku, Mitsuo] Tohoku Univ, Grad Sch Med, Dept Infect Dis, Sendai, Miyagi 980, Japan.
   [Gonda, Kohsuke; Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Dept Nanomed Sci, Sendai, Miyagi 980, Japan.
   [Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Dept Surg Oncol, Sendai, Miyagi 980, Japan.
   [Hatakeyama, Hiroyasu; Kanzaki, Makoto] Tohoku Univ, Grad Sch Biomed Engn, Sendai, Miyagi 980, Japan.
   [Vasudevanpillai, Biju] Natl Inst Adv Ind Sci & Technol, Nanobioanal Grp, Hlth Res Inst, Takamatsu, Kagawa, Japan.
   [Higuchi, Hideo] Univ Tokyo, Grad Sch Sci, Dept Phys, Tokyo 113, Japan.
RP Suzuki, Y (reprint author), Tohoku Univ, Grad Sch Med, Dept Emerging Infect Dis, Sendai, Miyagi 980, Japan.
EM suzukiy39@med.tohoku.ac.jp
RI Kanzaki, Makoto/H-6680-2017; Kaku, Mitsuo/E-5811-2017; Vasudevan,
   Biju/K-6879-2015
OI Kanzaki, Makoto/0000-0002-6884-2955; Roy, Chandra
   Nath/0000-0001-6667-1550
FU Ministry of Health, Labor, and Welfare of Japan; Japanese Foundation for
   AIDS Prevention; Ministry of Education, Culture, Sports, Science and
   Technology
FX Y.S. acknowledges the financial support from the Ministry of Health,
   Labor, and Welfare of Japan in the form of a grant-in-aid for AIDS
   research, from the Japanese Foundation for AIDS Prevention, and from the
   Ministry of Education, Culture, Sports, Science and Technology in the
   form of a Grant-in-Aid for Challenging Exploratory Research.
CR Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059
   Axelrod D, 2003, METHOD ENZYMOL, V361, P1
   Biju V, 2010, CHEM SOC REV, V39, P3031, DOI 10.1039/b926512k
   BUBB MR, 1994, J BIOL CHEM, V269, P14869
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473
   Duan HW, 2007, J AM CHEM SOC, V129, P3333, DOI 10.1021/ja068158s
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fujita H, 2010, MOL BIOL CELL, V21, P2721, DOI 10.1091/mbc.E10-01-0029
   Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101
   Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i
   Gonda K, 2010, J BIOL CHEM, V285, P2750, DOI 10.1074/jbc.M109.075374
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hatakeyama H, 2013, MOL BIOL CELL, V24, P809, DOI 10.1091/mbc.E12-10-0725
   Hatakeyama H, 2011, TRAFFIC, V12, P1805, DOI 10.1111/j.1600-0854.2011.01279.x
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6
   Imamura J, 2011, J BIOL CHEM, V286, P10581, DOI 10.1074/jbc.M110.187450
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   JORDAN MA, 1985, CANCER RES, V45, P2741
   Kang J, 2001, AM J PHYSIOL-ENDOC M, V280, pE428
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097
   Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Mishra A, 2008, ANGEW CHEM INT EDIT, V47, P2986, DOI 10.1002/anie.200704444
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957
   Pinaud F, 2010, NAT METHODS, V7, P275, DOI [10.1038/NMETH.1444, 10.1038/nmeth.1444]
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373                                                
   Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412                                                         
   Sung M, 2006, BBA-BIOMEMBRANES, V1758, P355, DOI 10.1016/j.bbamem.2005.11.016
   Suzuki KGN, 2007, J CELL BIOL, V177, P717, DOI 10.1083/jcb.200609174
   Suzuki Y, 2012, SENSORS-BASEL, V12, P549, DOI 10.3390/s120100549
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Watanabe TM, 2007, BIOPHYS J, V92, P4109, DOI 10.1529/biophysj.106.094649
   Watanabe TM, 2010, J BIOL CHEM, V285, P19605, DOI 10.1074/jbc.M109.093864
   Watanabe TM, 2007, BIOCHEM BIOPH RES CO, V359, P1, DOI 10.1016/j.bbrc.2007.04.168
   Yoo Jungwoo, 2008, Exp Cell Res, V314, P3563, DOI 10.1016/j.yexcr.2008.09.014
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
   Ziegler A, 2007, BIOCHEMISTRY-US, V46, P8138, DOI 10.1021/bi700416h
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 55
TC 11
Z9 11
U1 4
U2 29
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2013
VL 33
IS 15
BP 3036
EP 3049
DI 10.1128/MCB.01717-12
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 180SD
UT WOS:000321615500019
PM 23732912
OA gold
DA 2018-01-05
ER

PT J
AU Park, EJ
   Roh, J
   Kim, SN
   Kim, Y
   Han, SB
   Hong, JT
AF Park, Eun-Jung
   Roh, Jinkyu
   Kim, Soo Nam
   Kim, Younghun
   Han, Sang-Bae
   Hong, Jin Tae
TI CCR5 plays an important role in resolving an inflammatory response to
   single-walled carbon nanotubes
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Article
DE CCR5; SWCNTs; chemokine; inflammation; cytokine
ID OBSTRUCTIVE PULMONARY-DISEASE; CHEMOKINE RECEPTORS; OXIDATIVE STRESS;
   C57BL/6 MICE; HIV-1 INFECTION; CELLS; NANOPARTICLES; TRAFFICKING;
   NEUTROPHILS; MIGRATION
AB Owing to the development of new materials and technology, the pollutants in the environment are becoming more varied and complex over time. In our previous study using ICR mice, we suggested that a single intratracheal instillation of single-walled carbon nanotubes (SWCNTs) induced early lung fibrosis and subchronic tissue damage. In the present study, to investigate the role of CCR5 in inflammatory responses to the uptake of SWCNTs, we compared BAL (Bronchoalveolar lavage) cell composition, cell cycles, cytokines, cell phenotypes, inflammatory response-related proteins, cell surface receptors and histopathology using CCR5 knockout (KO) and wild-type mice. Results showed that the distribution of neutrophils in BAL fluid significantly decreased in KO mice. The expression of apoptosis-related proteins including caspase-3, p53, phospho-p53, p21 and cleaved PARP, TGF l and mesothelin markedly increased in KO mice compared with wild-type mice. Histopathological lesions were also more frequently noted in KO mice. Moreover, the secretion of IL-13 and IL-17 with IL-6 significantly increased in KO mice compared with wild-type mice, whereas that of IL-12 significantly decreased in comparison to wild-type mice. The distribution of B cells and CD8+ T cells was predominant in the inflammatory responses in KO mice, whereas that of T cells and CD4+ T cells was predominant in the inflammatory responses in wild-type mice. Furthermore, the expression of CCR4 and CCR7 significantly increased in KO mice. Based on these results, we suggest that the absence of CCR5 delays the resolution of inflammatory responses triggered by SWCNTs inflowing into the lungs and shifts inflammatory response for SWCNTs clearance from Th1-type to Th2-type. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Park, Eun-Jung] Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, Gyeonggi Do, South Korea.
   [Roh, Jinkyu; Kim, Younghun] Kwangwoon Univ, Dept Chem Engn, Seoul 139701, South Korea.
   [Kim, Soo Nam] Inhalat Toxicol Ctr, Shinjeong Dong, Jeongeup, South Korea.
   [Han, Sang-Bae; Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Cheongju, Chungbuk, South Korea.
   [Han, Sang-Bae; Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Cheongju, Chungbuk, South Korea.
RP Park, EJ (reprint author), Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, Gyeonggi Do, South Korea.
EM world1@ajou.ac.kr; jthong@chungbuk.ac.kr
FU National Research Foundation of Korea; Ministry of Education, Science
   and Technology (MRC) [2010-0029480, 2011-35B-E00011]
FX This work was supported by the National Research Foundation of Korea
   funded by the Ministry of Education, Science and Technology (MRC,
   2010-0029480; 2011-35B-E00011).
CR Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1
   Annunziato F, 1998, EUR CYTOKINE NETW, V9, P12
   Balistreri CR, 2007, ANN NY ACAD SCI, V1100, P162, DOI 10.1196/annals.1395.014
   Borrelli I, 2007, G Ital Med Lav Ergon, V29, P851
   Bracke Ken R., 2007, Inflammation & Allergy Drug Targets, V6, P75
   Bujak-Pietrek S, 2010, MED PR, V61, P183
   Campbell J. Darren, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P451
   Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053
   Chou CC, 2008, NANO LETT, V8, P437, DOI 10.1021/nl0723634
   Donnelly LE, 2006, TRENDS PHARMACOL SCI, V27, P546, DOI 10.1016/j.tips.2006.08.001
   Doodes PD, 2009, ARTHRITIS RHEUM, V60, P2945, DOI 10.1002/art.24842
   Egido J, 1999, KIDNEY INT, V56, P347, DOI 10.1046/j.1523-1755.1999.00551.x                                                
   Galanaud Pierre, 2001, Journal de la Societe de Biologie, V195, P9
   Gani Federica, 1998, Recenti Progressi in Medicina, V89, P520
   GRAVES DT, 1995, CRIT REV ORAL BIOL M, V6, P109, DOI 10.1177/10454411950060020101                                                    
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Hagens WI, 2007, REGUL TOXICOL PHARM, V49, P217, DOI 10.1016/j.yrtph.2007.07.006
   Inoue K, 2010, FREE RADICAL BIO MED, V48, P924, DOI 10.1016/j.freeradbiomed.2010.01.013
   Kaempgen M, 2009, NANO LETT, V9, P1872, DOI 10.1021/nl8038579
   Kagan VE, 2010, NAT NANOTECHNOL, V5, P354, DOI [10.1038/NNANO.2010.44, 10.1038/nnano.2010.44]
   Kim Chang H., 2009, Inflammation & Allergy Drug Targets, V8, P221
   Komatsu K, 2008, CURR EYE RES, V33, P736, DOI 10.1080/02713680802344716
   Lademann J, 2009, HAUTARZT, V60, P305, DOI 10.1007/s00105-008-1627-7
   Liebig T. M., 2009, JOVE-J VIS EXP, V32, P1373
   Madl AK, 2009, CRIT REV TOXICOL, V39, P629, DOI 10.1080/10408440903133788
   Misu Tatsuro, 2003, Nihon Rinsho, V61, P1422
   Morris MA, 2004, CURR MOL MED, V4, P431, DOI 10.2174/1566524043360609                                                        
   Nardelli B, 1999, J LEUKOCYTE BIOL, V65, P822
   Nygaard UC, 2009, TOXICOL SCI, V109, P113, DOI 10.1093/toxsci/kfp057
   Oberdorster G, 2010, J INTERN MED, V267, P89, DOI 10.1111/j.1365-2796.2009.02187.x
   Owen C, 2001, PULM PHARMACOL THER, V14, P193, DOI 10.1006/pupt.2001.0281
   Pacurari M, 2008, ENVIRON HEALTH PERSP, V116, P1211, DOI 10.1289/ehp.10924
   Park E, 2011, PLOS ONE, V6
   Park EJ, 2011, ARCH TOXICOL, V85, P1121, DOI 10.1007/s00204-011-0655-8
   Perry CM, 2010, DRUGS, V70, P1189, DOI 10.2165/11203940-000000000-00000
   Pliyev BK, 2008, BIOCHEMISTRY-MOSCOW+, V73, P970, DOI 10.1134/S0006297908090034
   Prato M, 2008, ACCOUNTS CHEM RES, V41, P60, DOI 10.1021/ar700089b
   Reichel CA, 2006, J LEUKOCYTE BIOL, V79, P114, DOI 10.1189/jlb.0605337
   Sakamoto Y, 2009, J TOXICOL SCI, V34, P65, DOI 10.2131/jts.34.65                                                               
   Seaton A, 2010, J R SOC INTERFACE, V7, pS119, DOI 10.1098/rsif.2009.0252.focus
   Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008
   Shvedova AA, 2008, TOXICOL APPL PHARM, V231, P235, DOI 10.1016/j.taap.2008.04.018
   Shvedova AA, 2010, J INTERN MED, V267, P106, DOI 10.1111/j.1365-2796.2009.02188.x
   Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005
   Shvedova AA, 2007, TOXICOL APPL PHARM, V221, P339, DOI 10.1016/j.taap.2007.03.018
   Snopczynski Tomasz, 2009, Rocz Panstw Zakl Hig, V60, P101
   Su DS, 2010, CHEMSUSCHEM, V3, P136, DOI 10.1002/cssc.200900182
   Syrbe U, 1999, SPRINGER SEMIN IMMUN, V21, P263, DOI 10.1007/BF00812257
   Tsuda H, 2008, YAKUGAKU ZASSHI, V128, P1727, DOI 10.1248/yakushi.128.1727
   Wahl SM, 2000, J LEUKOCYTE BIOL, V68, P303
   Wei G, 2005, J PHYS CHEM B, V109, P8738, DOI 10.1021/jp044314a
   Witasp Erika, 2009, Inhal Toxicol, V21 Suppl 1, P131, DOI 10.1080/08958370902942574
   Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9                                                   
   Yang CM, 2005, J PHYS CHEM B, V109, P19242, DOI 10.1021/jp053245c
   Yu XC, 2010, NANO LETT, V10, P3343, DOI 10.1021/nl1010178
   Zernecke A, 2008, ARTERIOSCL THROM VAS, V28, P1897, DOI 10.1161/ATVBAHA.107.161174
   Zhao QH, 2010, J LEUKOCYTE BIOL, V88, P41, DOI 10.1189/jlb.1009671
NR 57
TC 3
Z9 4
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0260-437X
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD AUG
PY 2013
VL 33
IS 8
BP 845
EP 853
DI 10.1002/jat.2744
PG 9
WC Toxicology
SC Toxicology
GA 169KH
UT WOS:000320778400015
PM 22438032
DA 2018-01-05
ER

PT J
AU Rezvani, M
   Ganji, MD
   Faghihnasiri, M
AF Rezvani, Mahyar
   Ganji, Masoud Darvish
   Faghihnasiri, M.
TI Encapsulation of lamivudine into single walled carbon nanotubes: A
   vdW-DF study
SO PHYSICA E-LOW-DIMENSIONAL SYSTEMS & NANOSTRUCTURES
LA English
DT Article
DE SWCNTs; HIV; Drug delivery; ab initio calculations; Vdw-DF
ID DRUG-DELIVERY; AMINO-ACIDS; HEPATITIS-B; SYSTEMS; ADSORPTION; DESIGN
AB To explore a suitable carrier for lamivudine drug, the incorporation of lamivudine inside the single walled carbon nanotubes (SWCNTs) has been investigated by using first-principles van der Waals density functional (vdW-DF) calculations. The obtained binding energies reveal that lamivudine prefers to be encapsulated into the metallic nanotubes with diameter of about 13 A. Semiconducting SWCNTs exhibit slightly weaker interaction strength with the lamivudine in comparison with the metallic counterparts. However, the calculated binding energies for both considered nanotubes are typical for the physisorption. The influence of nanotube length on the lamivudine incorporation inside the various considered nanotubes has also been investigated and the results show that it plays an important role in the encapsulation process. The electronic structures analysis for the energetically most favorable complexes reveal that incorporated lamivudine changes slightly the electronic properties of SWCNTs. This indicates that there is no considerable hybridization between the corresponding orbitals and the weak interaction obtained quantitatively in terms of binding energies. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Rezvani, Mahyar] Islamic Azad Univ, Dept Chem, Cent Tehran Branch, Young Res Club & Elite, Tehran, Iran.
   [Ganji, Masoud Darvish] Islamic Azad Univ, Dept Chem, Qaernshahr Branch, Qaemshahr, Iran.
   [Faghihnasiri, M.] Univ Guilan, Dept Phys, Rasht, Iran.
RP Ganji, MD (reprint author), Islamic Azad Univ, Dept Chem, Qaernshahr Branch, Qaemshahr, Iran.
EM ganji_md@yahoo.com
CR Ajima K, 2006, J PHYS CHEM B, V110, P5773, DOI 10.1021/jp056813x
   Asselah T, 2006, PRESSE MED, V35, P327, DOI 10.1016/S0755-4982(06)74578-X                                                   
   Bhirde AA, 2009, ACS NANO, V3, P307, DOI 10.1021/nn800551s
   Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.006
   Blankenburg S, 2009, J PHYS CHEM C, V113, P12653, DOI 10.1021/jp902337p
   Blankenburg S, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/18/185001
   Dhar S, 2008, J AM CHEM SOC, V130, P11467, DOI 10.1021/ja803036e
   Feazell RP, 2007, J AM CHEM SOC, V129, P8438, DOI 10.1021/ja073231f
   Gallo M, 2007, CHEM PHYS LETT, V447, P105, DOI 10.1016/j.cplett.2007.08.098
   Ganji MD, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/02/025709
   Ganji MD, 2008, PHYS LETT A, V372, P3277, DOI 10.1016/j.physleta.2008.01.032
   Ganji MD, 2011, FULLER NANOTUB CAR N, V19, P421, DOI 10.1080/1536383X.2010.481059
   Ganji MD, 2010, FULLER NANOTUB CAR N, V18, P24, DOI 10.1080/15363830903293594
   Ganji MD, 2009, J MOL STRUC-THEOCHEM, V913, P54, DOI 10.1016/j.theochem.2009.07.015
   Ganji MD, 2009, DIAM RELAT MATER, V18, P662, DOI 10.1016/j.diamond.2008.11.021
   Ganji MD, 2009, PHYSICA E, V41, P1406, DOI 10.1016/j.physe.2009.04.006
   Ganji MD, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468-6996/11/4/045001
   Harrell CC, 2004, J AM CHEM SOC, V126, P15646, DOI 10.1021/ja044948v
   Kostarelos K, 2003, ADV COLLOID INTERFAC, V106, P147, DOI 10.1016/S0001-8686(03)00109-X
   Maynard JE, 1990, VACCINE S, V8, P18
   Ordejon P, 1996, PHYS REV B, V53, P10441, DOI 10.1103/PhysRevB.53.R10441                                                      
   Pakarinen OH, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.085401
   Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865                                                     
   Shi Kam N W, 2004, J AM CHEM SOC, V126, P6850, DOI DOI 10.1021/JA0486059
   Siegfried N.L., 2006, COCHRANE DB SYST REV, V12
   Soler JM, 2002, J PHYS-CONDENS MAT, V14, P2745, DOI 10.1088/0953-8984/14/11/302
   Striolo A, 2006, NANO LETT, V6, P633, DOI 10.1021/nl052254u
   Tang ZR, 2010, PHYSICA B, V405, P770, DOI 10.1016/j.physb.2009.09.103
   Thierfelder C, 2011, SURF SCI, V605, P746, DOI 10.1016/j.susc.2011.01.012
   Torii N, 2002, HEPATOL RES, V24, P34, DOI 10.1016/S1386-6346(02)00009-8
   TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993
   Ttrzaskowski B., 2006, CHEM PHYS LETT, V430, P97
   Usui Y, 2008, SMALL, V4, P240, DOI 10.1002/smll.200700670
   Wang W, 2007, J BIOMED MATER RES B, V82B, P223, DOI 10.1002/jbm.b.30724
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xu X., 1999, THEOR CHEM ACC, V172, P170
   Xu YJ, 2004, CHEM PHYS LETT, V400, P406, DOI 10.1016/j.cplett.2004.11.010
NR 39
TC 16
Z9 16
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-9477
J9 PHYSICA E
JI Physica E
PD AUG
PY 2013
VL 52
BP 27
EP 33
DI 10.1016/j.physe.2013.03.024
PG 7
WC Nanoscience & Nanotechnology; Physics, Condensed Matter
SC Science & Technology - Other Topics; Physics
GA 164SN
UT WOS:000320429900005
DA 2018-01-05
ER

PT J
AU Chen, BD
   Yang, CL
   Yang, JS
   Wang, MS
   Ma, XG
AF Chen, Bao-Dong
   Yang, Chuan-Lu
   Yang, Jun-Sheng
   Wang, Mei-Shan
   Ma, Xiao-Guang
TI Dynamic mechanism of HIV replication inhibitor peptide encapsulated into
   carbon nanotubes
SO CURRENT APPLIED PHYSICS
LA English
DT Article
DE Molecular dynamics simulation; Drug delivery; Peptide-CNT interaction;
   Spontaneous encapsulation; Conformational change
ID HYDROPHOBIC GRAPHITE SURFACE; MOLECULAR-DYNAMICS; PROTEIN ADSORPTION;
   SINGLE; TRANSPORTERS; SIMULATION; FUNCTIONALIZATION; HYDROGEN; VIRUS;
   CELLS
AB Biomolecules encapsulated in carbon nanotubes (CNTs) have attracted much interest and facilitated exciting opportunities for biological and biomedical applications of CNTs. Understanding the fundamental interaction and change in biomolecules during encapsulation is indispensable but remains a challenge for both theoretical and experimental investigations. This paper focuses on the interaction between HIV replication inhibitor peptide (HRIP) and CNTs in a neutral solution with molecular dynamics simulation. We observed that HRIP spontaneously inserts into the CNTs and oscillates around the center of the tube, where the non-covalent interaction is minimum. The effects of the diameters of the CNTs on HRIP were investigated. The optimal diameter of the CNT that can provide the most effective encapsulation and causes minimum conformational change in HRIP was found. The present results provide valuable insights in the understanding of nanoscale drug delivery using CNT-based devices. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Chen, Bao-Dong; Yang, Chuan-Lu; Yang, Jun-Sheng; Wang, Mei-Shan; Ma, Xiao-Guang] Ludong Univ, Sch Phys & Optoelect Engn, Yantai 264025, Peoples R China.
RP Yang, CL (reprint author), Ludong Univ, Sch Phys & Optoelect Engn, Yantai 264025, Peoples R China.
EM scuycl@gmail.com
RI Yang, Chuan-Lu/K-3052-2013; Ma, Xiao Guang/A-8683-2012
OI Yang, Chuan-Lu/0000-0001-9138-3075; Ma, Xiao Guang/0000-0002-7935-499X
FU National Science Foundation of China [NSFC-11174117, NSFC-10974078];
   Shandong Province Natural Science Foundation of China [ZR2011AL010]
FX This work was supported in part by the National Science Foundation of
   China under Grant Nos. NSFC-11174117 and NSFC-10974078 and in part by
   the Shandong Province Natural Science Foundation of China (ZR2011AL010).
CR Agbottah E, 2006, VIROLOGY, V345, P373, DOI 10.1016/j.virol.2005.09.062
   Ajima K, 2008, ACS NANO, V2, P2057, DOI 10.1021/nn800395t
   Azamian BR, 2002, J AM CHEM SOC, V124, P12664, DOI 10.1021/ja0272989
   Chen Q, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3148025
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   Cherukuri P, 2004, J AM CHEM SOC, V126, P15638, DOI 10.1021/ja0466311
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0
   Duyne R. V., 2008, VIROLOGY, V376, P308
   EVANS DJ, 1985, J CHEM PHYS, V83, P4069, DOI 10.1063/1.449071
   FRECHET D, 1994, BIOCHEMISTRY-US, V33, P42, DOI 10.1021/bi00167a006
   Fu ZM, 2009, BIOPHYS J, V97, P1795, DOI 10.1016/j.bpj.2009.07.014
   Gao HJ, 2003, NANO LETT, V3, P471, DOI 10.1021/nl025967a
   Hilder TA, 2008, MICRO NANO LETT, V3, P41, DOI 10.1049/mnl:20080008
   Hirsch A, 2002, ANGEW CHEM INT EDIT, V41, P1853, DOI 10.1002/1521-3773(20020603)41:11<1853::AID-ANIE1853>3.0.CO;2-N                  
   Hirschfelder J. O., 1964, MOL THEORY GASES LIQ
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Jana AK, 2012, BIOPHYS J, V102, P1889, DOI 10.1016/j.bpj.2012.03.036
   Johnson RR, 2009, J PHYS CHEM B, V113, P11589, DOI 10.1021/jp901999a
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   Kang Y, 2008, J PHYS CHEM B, V112, P4801, DOI 10.1021/jp711392g
   Kang Y, 2010, J PHYS CHEM B, V114, P2869, DOI 10.1021/jp905995s
   Kang Y, 2009, BIOMATERIALS, V30, P2807, DOI 10.1016/j.biomaterials.2009.01.024
   Karajanagi SS, 2004, LANGMUIR, V20, P11594, DOI 10.1021/la047994h
   Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015
   Lin Y, 2004, J MATER CHEM, V14, P527, DOI 10.1039/b314481j
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Mitchell DT, 2002, J AM CHEM SOC, V124, P11864, DOI 10.1021/ja027247b
   Mucksch C, 2011, CHEM PHYS LETT, V510, P252, DOI 10.1016/j.cplett.2011.05.036
   Park KA, 2005, J PHYS CHEM B, V109, P8967, DOI 10.1021/jp0500743
   Pei QX, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2981798
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Raffaini G, 2010, LANGMUIR, V26, P5679, DOI 10.1021/la903769c
   Shen JW, 2008, BIOMATERIALS, V29, P513, DOI 10.1016/j.biomaterials.2007.10.016
   Sheng YB, 2010, PROTEIN SCI, V19, P1639, DOI 10.1002/pro.444
   TSANG SC, 1995, CHEM COMMUN, V17, P1803
   Veetil JV, 2007, BIOTECHNOL PROGR, V23, P517, DOI 10.1021/bp0602395
   Walther JH, 2001, J PHYS CHEM B, V105, P9980, DOI 10.1021/jp011344u
   Xie YH, 2005, MATER LETT, V59, P971, DOI 10.1016/j.matlet.2004.10.079
   Zhou L, 2006, NANOTECHNOLOGY, V17, P1891, DOI 10.1088/0957-4484/17/8/014
NR 44
TC 7
Z9 7
U1 0
U2 67
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1739
J9 CURR APPL PHYS
JI Curr. Appl. Phys.
PD AUG
PY 2013
VL 13
IS 6
BP 1001
EP 1007
DI 10.1016/j.cap.2013.02.004
PG 7
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 139GA
UT WOS:000318568800010
DA 2018-01-05
ER

PT J
AU Guo, Y
   Chen, JH
   Chen, GN
AF Guo, Yang
   Chen, JingHua
   Chen Guonan
TI A label-free electrochemical biosensor for detection of HIV related gene
   based on interaction between DNA and protein
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE Electrochemical DNA biosensor; HIV related gene diagnosis; Interaction
   between DNA and protein
ID SEQUENCE-SPECIFIC DETECTION; GOLD; HYBRIDIZATION; ELECTRODES; SENSORS;
   INTERROGATION; NANOPARTICLES; BINDING; LEVEL; ACID
AB Non-invasive early diagnosis of HIV is an important and effective means to reduce death from this disease. In this manuscript, we describe a method using a novel label-free electrochemical DNA biosensor for HIV related gene diagnosis with ultrahigh sensitivity and selectivity. The DNA biosensor was based on the interaction of hybrid double-stranded DNA and protein. In the presence of target DNA, the target/probe hybridization encountered the NF-kB protein. Upon addition of HRP, they formed the sandwich-like DNA sensor. The formed sandwich-like ds/NF-kappa B/HRP complex effectively catalyzed the H2O2-mediated oxidation of TMB, accompanied by a changed color of the reaction solution and an increased electrochemical current signal. However, in the absence of target DNA, no duplex DNA could bind NF-kB protein or HRP to form the DNA sensor. By employing the above strategy, the DNA biosensor was able to gain an amplified electrochemical signal and thus detected as low as 7.05 pM target DNA. Due to the high selectivity of the method, the developed biosensor also exhibited high discrimination ability even against single-base mismatch. Combined with the advantages of electrochemical detection and its ready integration with microelectronics, the proposed electrochemical DNA biosensor might represent a promising path toward direct HIV detection at the point of care. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Guo, Yang; Chen, JingHua; Chen Guonan] Fuzhou Univ, Fujian Prov Key Lab Anal & Detect Food Safety, Key Lab Anal & Detect Technol Food Safety, Minist Educ,Dept Chem, Fuzhou 350002, Peoples R China.
   [Chen, JingHua] Fujian Med Univ, Fac Pharm, Dept Pharmaceut Anal, Foochow 350004, Peoples R China.
   [Guo, Yang; Chen, JingHua; Chen Guonan] Hong Kong Baptist Univ, Dept Chem, Kowloon, Hong Kong, Peoples R China.
RP Chen, GN (reprint author), Fuzhou Univ, Fujian Prov Key Lab Anal & Detect Food Safety, Key Lab Anal & Detect Technol Food Safety, Minist Educ,Dept Chem, Fuzhou 350002, Peoples R China.
EM gnchen@fzu.edu.cn
FU National Science Foundation of China [41076059, 20928005, 21105012];
   Nature Sciences Funding of Fujian Province [2011J01028]; Outstanding
   Youth Research Training Program of University of Fujian Province
   [JA11105, JA10295]; Fujian Medical Innovation Fund [2011-CX-22]; Program
   for Changjiang Scholars and Innovative Research Team in University
   [IRT1116]
FX The authors gratefully acknowledge the financial support from the
   National Science Foundation of China (41076059, 20928005 and 21105012),
   Nature Sciences Funding of Fujian Province (2011J01028), Outstanding
   Youth Research Training Program of University of Fujian Province
   (JA11105 and JA10295), Fujian Medical Innovation Fund (2011-CX-22) and
   the Program for Changjiang Scholars and Innovative Research Team in
   University (No. IRT1116).
CR Boon EM, 2000, NAT BIOTECHNOL, V18, P1096, DOI 10.1038/80301
   Chen JH, 2011, CHEM COMMUN, V47, P8004, DOI 10.1039/c1cc11929j
   Fan CH, 2005, TRENDS BIOTECHNOL, V23, P186, DOI 10.1016/j.tibtech.2005.02.005
   Fan CH, 2003, P NATL ACAD SCI USA, V100, P9134, DOI 10.1073/pnas.1633515100
   Hassen WM, 2008, SENSOR ACTUAT B-CHEM, V134, P755, DOI 10.1016/j.snb.2008.06.020
   Huang Y, 2009, J AM CHEM SOC, V131, P2478, DOI 10.1021/ja808700d
   Kuralay F, 2011, TALANTA, V85, P1330, DOI 10.1016/j.talanta.2011.06.012
   Lao RJ, 2005, ANAL CHEM, V77, P6475, DOI 10.1021/ac050911x
   Lee J.M., 2010, ANGEW CHEM, V122, P8844
   Li D, 2007, CHEM COMMUN, P3544, DOI 10.1039/b704731b
   Li YT, 2009, ANAL CHEM, V81, P4076, DOI 10.1021/ac900295j
   Liu G, 2008, J AM CHEM SOC, V130, P6820, DOI 10.1021/ja800554t
   Loaiza OA, 2008, ANAL CHEM, V80, P8239, DOI 10.1021/ac801319b
   Lucarelli F, 2004, BIOSENS BIOELECTRON, V19, P515, DOI 10.1016/S0956-5663(03)00256-2
   Lundgren JS, 2000, BIOSENS BIOELECTRON, V15, P417, DOI 10.1016/S0956-5663(00)00098-1
   Moreno-Hagelsieb L, 2004, SENSOR ACTUAT B-CHEM, V98, P269, DOI 10.1016/j.snb.2003.10.036
   Napier ME, 1997, BIOCONJUGATE CHEM, V8, P906, DOI 10.1021/bc9701149                                                               
   Odenthal KJ, 2007, ANALYST, V132, P603, DOI 10.1039/b701816a
   Peng ZY, 2010, ANAL CHEM, V82, P9727, DOI 10.1021/ac101843n
   Petrovykh DY, 2003, J AM CHEM SOC, V125, P5219, DOI 10.1021/ja029450c
   Shiddiky MJA, 2010, J AM CHEM SOC, V132, P10053, DOI 10.1021/ja1021365
   Sipova H, 2010, ANAL CHEM, V82, P10110, DOI 10.1021/ac102131s
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Van Ert MN, 2007, J CLIN MICROBIOL, V45, P47, DOI 10.1128/JCM.01233-06
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang ZX, 2010, ANAL CHEM, V82, P9901, DOI 10.1021/ac102416f
   Wu CK, 2011, ANALYST, V136, P2106, DOI 10.1039/c1an15061h
   Xiao Y, 2007, NAT PROTOC, V2, P2875, DOI 10.1038/nprot.2007.413
   Xiao Y, 2007, J AM CHEM SOC, V129, P11896, DOI 10.1021/ja074218y
   Xiao Y, 2009, J AM CHEM SOC, V131, P15311, DOI 10.1021/ja905068s
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang J, 2013, CHEM COMMUN, V49, P996, DOI 10.1039/c2cc37783g
   Zhang J, 2010, CHEM COMMUN, V46, P6986, DOI 10.1039/c0cc02080j
NR 33
TC 30
Z9 30
U1 5
U2 104
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD JUL 31
PY 2013
VL 184
BP 113
EP 117
DI 10.1016/j.snb.2013.04.046
PG 5
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 157BG
UT WOS:000319869700017
DA 2018-01-05
ER

PT J
AU Zhang, B
   Jarrell, JA
   Price, JV
   Tabakman, SM
   Li, YG
   Gong, M
   Hong, GS
   Feng, J
   Utz, PJ
   Dai, HJ
AF Zhang, Bo
   Jarrell, Justin A.
   Price, Jordan V.
   Tabakman, Scott M.
   Li, Yanguang
   Gong, Ming
   Hong, Guosong
   Feng, Ju
   Utz, Paul J.
   Dai, Hongjie
TI An Integrated Peptide-Antigen Microarray on Plasmonic Gold Films for
   Sensitive Human Antibody Profiling
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   NEAR-INFRARED-FLUORESCENCE; SMALL-MOLECULE MICROARRAY; PROTEIN
   MICROARRAYS; SUBSTRATE-SPECIFICITY; SPOT SYNTHESIS; ARRAYS; BINDING;
   EPITOPE
AB High-throughput screening for interactions of peptides with a variety of antibody targets could greatly facilitate proteomic analysis for epitope mapping, enzyme profiling, drug discovery and biomarker identification. Peptide microarrays are suited for such undertaking because of their high-throughput capability. However, existing peptide microarrays lack the sensitivity needed for detecting low abundance proteins or low affinity peptide-protein interactions. This work presents a new peptide microarray platform constructed on nanostructured plasmonic gold substrates capable of metal enhanced NIR fluorescence enhancement (NIR-FE) by hundreds of folds for screening peptide-antibody interactions with ultrahigh sensitivity. Further, an integrated histone peptide and whole antigen array is developed on the same plasmonic gold chip for profiling human antibodies in the sera of systemic lupus erythematosus (SLE) patients, revealing that collectively a panel of biomarkers against unmodified and post-translationally modified histone peptides and several whole antigens allow more accurate differentiation of SLE patients from healthy individuals than profiling biomarkers against peptides or whole antigens alone.
C1 [Zhang, Bo; Tabakman, Scott M.; Li, Yanguang; Gong, Ming; Hong, Guosong; Feng, Ju; Dai, Hongjie] Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
   [Jarrell, Justin A.; Price, Jordan V.; Utz, Paul J.] Stanford Univ, Sch Med, Div Rheumatol & Immunol, Dept Med, Stanford, CA 94305 USA.
   [Utz, Paul J.] Stanford Univ, Sch Med, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA.
RP Dai, HJ (reprint author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
EM hdai@stanford.edu
RI Li, Yanguang/A-2319-2014
OI Li, Yanguang/0000-0003-0506-0451; Hong, Guosong/0000-0002-8858-4471
FU NIH-NCI [5R01CA135109-02]; Stanford SPARK program; Stanford BioX-SIGF
   fellowship; Donald E. and Delia B. Baxter Foundation; National Heart,
   Lung, and Blood Institute (NHLBI) [HHSN288201000034C]; NIH [5
   U19-AI082719, 5 U19-AI050864, 5 U19-AI056363, 1 U19 AI090019, 4 U19
   AI090019]; Canadian Institutes of Health Research [2 OR-92141]; Alliance
   for Lupus Research [21858]; European Union [261382]
FX This work is supported by NIH-NCI 5R01CA135109-02 and the Stanford SPARK
   program. B.Z. is the recipient of Stanford BioX-SIGF fellowship. P.J.U.
   is the recipient of a Donald E. and Delia B. Baxter Foundation Career
   Development Award and is supported by National Heart, Lung, and Blood
   Institute (NHLBI) Proteomics contract HHSN288201000034C, Proteomics of
   Inflammatory Immunity and Pulmonary Arterial Hypertension; grants from
   the NIH (5 U19-AI082719, 5 U19-AI050864, 5 U19-AI056363, 1 U19 AI090019
   and 4 U19 AI090019); Canadian Institutes of Health Research (2
   OR-92141); Alliance for Lupus Research (grant number 21858); a gift from
   the Ben May Trust and a gift from the Floren Family Trust. The research
   leading to these results has received funding from the European Union
   Seventh Framework Programme (FP7/2007-2013) under grant agreement number
   261382. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anger P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.113002
   Blasco H, 2007, J IMMUNOL METHODS, V325, P127, DOI 10.1016/j.jim.2007.06.011
   Bua DJ, 2009, PLOS ONE, V4, P6789
   Carlsson A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005033
   Crow MK, 2003, AUTOIMMUNITY, V36, P481, DOI 10.1080/08916930310001625952
   DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126
   Dieker JW, 2007, ARTHRITIS RHEUM-US, V56, P1921, DOI 10.1002/art.22646
   Duburcq X, 2004, BIOCONJUGATE CHEM, V15, P307, DOI 10.1021/bc034226d
   Dulkeith E, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.203002
   Falsey JR, 2001, BIOCONJUGATE CHEM, V12, P346, DOI 10.1021/bc000141q
   Fattal I, 2010, IMMUNOLOGY, V130, P337, DOI 10.1111/j.1365-2567.2010.03245.x
   Foong YM, 2012, CURR OPIN CHEM BIOL, V16, P234, DOI 10.1016/j.cbpa.2011.12.007
   Fort E, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/1/013001
   Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0
   GEOKAS MC, 1982, ANN INTERN MED, V97, P389, DOI 10.7326/0003-4819-97-3-389
   GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998
   Gill JM, 2003, AM FAM PHYSICIAN, V68, P2179
   GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261                                                        
   HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847
   Hong GS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1698
   Hong GS, 2011, ANGEW CHEM INT EDIT, V50, P4644, DOI 10.1002/anie.201100934
   Hong GS, 2010, J AM CHEM SOC, V132, P15920, DOI 10.1021/ja1087997
   Houseman BT, 2002, NAT BIOTECHNOL, V20, P270, DOI 10.1038/nbt0302-270
   Kannangai R, 2001, J CLIN VIROL, V22, P41, DOI 10.1016/S1386-6532(01)00170-6                                                   
   Kattah MG, 2006, NAT METHODS, V3, P745, DOI 10.1038/nmeth910
   KENNEDY RC, 1986, SCIENCE, V231, P1556, DOI 10.1126/science.3006246
   KITAMURA K, 1994, FEBS LETT, V351, P35, DOI 10.1016/0014-5793(94)00810-8
   Kochinyan S, 2007, BIOTECHNIQUES, V42, P63, DOI 10.2144/000112311
   Lesaicherre ML, 2002, BIOORG MED CHEM LETT, V12, P2079, DOI 10.1016/S0960-894X(02)00379-7
   Liu CC, 2009, BEST PRACT RES CL RH, V23, P507, DOI 10.1016/j.berh.2009.01.008
   Liu CL, 2012, ARTHRITIS RES THER, V14, P25
   Lu ZQJ, 2007, J ROY STAT SOC A STA, V170, P1178
   MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q                                                               
   MacBeath G, 2000, SCIENCE, V289, P1760
   Mertens H, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.115123
   Min DH, 2004, CURR OPIN CHEM BIOL, V8, P554, DOI 10.1016/j.cbpa.2004.08.007
   Mok CC, 2003, J CLIN PATHOL, V56, P481, DOI 10.1136/jcp.56.7.481                                                            
   Panicker RC, 2004, COMB CHEM HIGH T SCR, V7, P547
   Papp K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044824
   Parra MA, 2006, MOL CELL BIOL, V26, P3842, DOI 10.1128/MCB.26.10.3842-3852.2006
   Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473
   Petricoin EF, 2003, J NUTR, V133, p2476S
   Price JV, 2012, NAT MED, V18, P1434, DOI 10.1038/nm.2913
   Reimer U, 2002, CURR OPIN BIOTECH, V13, P315, DOI 10.1016/S0958-1669(02)00339-7
   Salisbury CM, 2002, J AM CHEM SOC, V124, P14868, DOI 10.1021/ja027477q
   Saxon E, 2000, ORG LETT, V2, P2141, DOI 10.1021/ol006054v
   Schellekens GA, 2000, ARTHRITIS RHEUM, V43, P155, DOI 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
   Schneider G, 2006, NANO LETT, V6, P530, DOI 10.1021/nl052441s
   SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1
   Sun L, 2004, BIOTECHNIQUES, V37, P430
   Tabakman SM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1477
   Tabakman SM, 2011, SMALL, V7, P499, DOI 10.1002/smll.201001836
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van Bavel CC, 2009, MOL IMMUNOL, V47, P511, DOI 10.1016/j.molimm.2009.08.009
   Waddell E, 2000, ANAL CHEM, V72, P5907, DOI 10.1021/ac0009705
   Wegner GJ, 2002, ANAL CHEM, V74, P5161, DOI 10.1021/ac025922u
   Weiser AA, 2005, ANAL BIOCHEM, V342, P300, DOI 10.1016/j.ab.2005.04.033
   Zhang B, 2013, NANO RES, V6, P113, DOI 10.1007/s12274-012-0286-2
NR 58
TC 20
Z9 20
U1 3
U2 61
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2013
VL 8
IS 7
AR e71043
DI 10.1371/journal.pone.0071043
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 204MP
UT WOS:000323369700222
PM 23923050
OA gold
DA 2018-01-05
ER

PT J
AU Nishiyama, K
AF Nishiyama, Katsuhiko
TI Enzymatic activity induced by interactions with a nanofabricated
   hydrophobic Si surface
SO APPLIED PHYSICS LETTERS
LA English
DT Article
ID MOLECULAR-DYNAMICS; DRUG-RESISTANCE; HIV-1 PROTEASES; CHAIN-LENGTH;
   INHIBITORS; FABRICATION; PROTEINS; SIMULATIONS; COMPLEXES; BINDING
AB The binding of peptides of 2-10 glycine residues (2-10Gly) to papain on nanofabricated hydrophobic Si surfaces was investigated by molecular dynamics and docking simulations. 5Gly, 7Gly, 9Gly, and 10Gly were distributed on sites near the active center of papain on the Si surface, while 6-10Gly were distributed on sites near the active center of free papain. The Si surface changed the substrate specificity of papain, and modification of this surface should allow full control of substrate specificity. Molecular surgery of proteins in cells may be realized using papain on specially designed surfaces. (C) 2013 AIP Publishing LLC.
C1 Tsuruoka Natl Coll Technol, Tsuruoka, Yamagata 9978511, Japan.
RP Nishiyama, K (reprint author), Tsuruoka Natl Coll Technol, 104 Sawada, Tsuruoka, Yamagata 9978511, Japan.
EM nisiyama@asagi.waseda.jp
FU Institute of National Colleges of Technology
FX This study is supported by Institute of National Colleges of Technology.
CR Ahmed M., 2013, J BIOMATER NANOBIOTE, V4, P194
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Bien DCS, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-288
   Brandes N, 2006, J COLLOID INTERF SCI, V299, P56, DOI 10.1016/j.jcis.2006.01.065
   Buijs J, 1996, LANGMUIR, V12, P1605, DOI 10.1021/la950665s                                                               
   Case D. A., 2006, AMBER, V9
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dong AC, 2006, ANAL BIOCHEM, V351, P282, DOI 10.1016/j.ab.2006.01.008
   HALL A, 1992, J ENZYM INHIB, V6, P113, DOI 10.3109/14756369209040742                                                       
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212
   KoH M, 2000, JPN J APPL PHYS 1, V39, P2186, DOI 10.1143/JJAP.39.2186                                                            
   Koh M, 2000, JPN J APPL PHYS 1, V39, P5352, DOI 10.1143/JJAP.39.5352                                                            
   LaLonde JM, 1998, J MED CHEM, V41, P4567, DOI 10.1021/jm980249f
   Li DW, 2009, J AM CHEM SOC, V131, P14610, DOI 10.1021/ja905340s
   Matsuyama S, 2010, J PHYS CHEM B, V114, P521, DOI 10.1021/jp908314f
   MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Nishiyama K, 2005, JPN J APPL PHYS 1, V44, P8210, DOI 10.1143/JJAP.44.8210
   Nishiyama K, 2011, CHEM PHYS LETT, V510, P143, DOI 10.1016/j.cplett.2011.05.022
   Ode H, 2006, J AM CHEM SOC, V128, P7887, DOI 10.1021/ja060682b
   Polaina J, 2007, IND ENZYMES STRUCTUR
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Schirmeister T, 1999, J MED CHEM, V42, P560, DOI 10.1021/jm981061z
   Tanii T, 2001, JPN J APPL PHYS 2, V40, pL1135, DOI 10.1143/JJAP.40.L1135                                                           
   Walsh G., 2002, PROTEINS BIOCH BIOTE
   Yanagita H, 2012, ACS CHEM BIOL, V7, P552, DOI 10.1021/cb200332k
   YGUERABIDE J, 1970, J MOL BIOL, V51, P573, DOI 10.1016/0022-2836(70)90009-4
   Yuki H, 2012, BIOORGAN MED CHEM, V20, P775, DOI 10.1016/j.bmc.2011.12.004
NR 30
TC 0
Z9 0
U1 1
U2 6
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD JUL 22
PY 2013
VL 103
IS 4
AR 043705
DI 10.1063/1.4816442
PG 4
WC Physics, Applied
SC Physics
GA 191IM
UT WOS:000322406600128
DA 2018-01-05
ER

PT J
AU Cervera, L
   Gutierrez-Granados, S
   Martinez, M
   Blanco, J
   Godia, F
   Segura, MM
AF Cervera, Laura
   Gutierrez-Granados, Sonia
   Martinez, Marta
   Blanco, Julia
   Godia, Francesc
   Mercedes Segura, Maria
TI Generation of HIV-1 Gag VLPs by transient transfection of HEK 293
   suspension cell cultures using an optimized animal-derived component
   free medium
SO JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Animal cell culture; Media supplementation; Design of experiments (DoE);
   Virus-like particles (VLP); HIV-1 vaccine; Transient gene expression
   (TGE)
ID VIRUS-LIKE PARTICLES; RECOMBINANT PROTEIN-PRODUCTION; SERUM-FREE MEDIA;
   MAMMALIAN-CELLS; GENE-EXPRESSION; CHROMATOGRAPHY PURIFICATION; EFFICIENT
   PRODUCTION; VECTOR PRODUCTION; EBNA1 CELLS; TYPE-1 GAG
AB Virus-like particles (VLPs) offer great promise as candidates for new vaccine strategies. Large-scale approaches for the manufacturing of HIV-1 Gag VLPs have mainly focused on the use of the baculovirus expression system. In this work, the development and optimization of an HIV-1 Gag VLP production protocol by transient gene expression in mammalian cell suspension cultures is reported. To facilitate process optimization, a Gag-GFP fusion construct enabling the generation of fluorescent VLPs was used. The great majority of Gag-GFP present in cell culture supernatants was shown to be correctly assembled into virus-like particles of the expected size and morphology consistent with immature HIV-1 particles. Medium optimization was performed using design of experiments (DoE). Culture medium supplementation with non-animal derived components including recombinant proteins and lipids of synthetic or non-animal-derived origin resulted in improved HEK 293 cell growth and VLP production. The maximum cell density attained using the optimized Freestyle culture medium was 5.4 x 10(6) cells/mL in batch mode, almost double of that observed using the unsupplemented medium (2.9 x 10(6) cells/mL). Best production performance was attained when cells were transfected at mid-log phase (2-3 x 10(6) cells/mL) with medium exchange at the time of transfection using standard amounts of plasmid DNA and polyethylenimine. By using an optimized production protocol, VLP titers were increased 2.4-fold obtaining 2.8 mu g of Gag-GFP/mL or 2.7 x 10(9) VLPs/mL according to ELISA and nanoparticle tracking quantification analyses, respectively. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Cervera, Laura; Gutierrez-Granados, Sonia; Martinez, Marta; Godia, Francesc; Mercedes Segura, Maria] Univ Autonoma Barcelona, Dept Engn Quim, E-08193 Barcelona, Spain.
   [Blanco, Julia] Hosp Univ Germans Trias i Pujol, IrsiCaixa AIDS Res Inst HIVACAT, Badalona, Spain.
RP Segura, MM (reprint author), Univ Autonoma Barcelona, Dept Engn Quim, Campus Bellaterra, E-08193 Barcelona, Spain.
EM mersegura@gmail.com
RI Martinez Calle, Marta/H-1451-2015; Godia, Francesc/H-9962-2015; Blanco,
   Julia/A-5347-2008
OI Godia, Francesc/0000-0002-4060-9887; Blanco, Julia/0000-0002-2225-0217;
   Martinez-Calle, Marta/0000-0003-1198-2532
FU Ministerio de Innovacion y Ciencia of Spain [MICIN BIO2011-2330]; UAB
FX The authors wish to thank Dr. Amine Kamen (NRC, Montreal, Canada) for
   valuable discussions and for providing the HEK 293 cell line used in
   this study. The following reagent was obtained through the NIH AIDS
   Reagent Program, Division of AIDS, NIAID, NIH: pGag-EGFP (Cat#11468)
   from Dr. Marilyn Resh. We would also like to thank Dr. Jorge Carrillo at
   IrsiCaixa (Badalona, Spain) and Gavin Whissell for helpful advice and
   comments. The help of Manuela Costa from Institut de Biotecnologia i
   Biomedicina with FACS analyses and Dr. Salvador Bartolome from
   Departament de Bioquimica i de Biologia Molecular is appreciated. The
   recombinant albumin was a generous gift from Merck Millipore. This work
   is supported by a grant of Ministerio de Innovacion y Ciencia of Spain
   (MICIN BIO2011-2330). Laura Cervera is a recipient of a PIF scholarship
   from UAB.
CR Altaras NE, 2005, ADV BIOCHEM ENG BIOT, V99, P193, DOI 10.1007/10_008
   Ansorge S, 2009, J GENE MED, V11, P868, DOI 10.1002/jgm.1370
   Aravindan L, 2009, INT J PHARMACEUT, V378, P201, DOI 10.1016/j.ijpharm.2009.05.052
   Backliwal G, 2008, BIOTECHNOL BIOENG, V99, P721, DOI 10.1002/bit.21596
   Backliwal G, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn423
   Baldi L, 2007, BIOTECHNOL LETT, V29, P677, DOI 10.1007/s10529-006-9297-y
   Box G.E.P., 1960, TECHNOMETRICS, V2, P455, DOI DOI 10.1080/00401706.1960.10489912
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Brunner D, 2010, ALTEX-ALTERN ANIM EX, V27, P53
   Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102
   Buonaguro L, 2001, ANTIVIR RES, V49, P35, DOI 10.1016/S0166-3542(00)00136-4
   Butler M, 2005, APPL MICROBIOL BIOT, V68, P283, DOI 10.1007/s00253-005-1980-8
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Carpentier E, 2007, J BIOTECHNOL, V128, P268, DOI 10.1016/j.jbiotec.2006.10.014
   Chen Y, 2009, BIOPHYS J, V96, P1961, DOI 10.1016/j.bpj.2008.10.067
   Cruz PE, 1998, BIOTECHNOL BIOENG, V60, P408, DOI 10.1002/(SICI)1097-0290(19981120)60:4<408::AID-BIT2>3.3.CO;2-C
   Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028
   Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9                                                             
   Durocher Y, 2007, J VIROL METHODS, V144, P32, DOI 10.1016/j.jviromet.2007.03.014
   Gebhart CL, 2001, J CONTROL RELEASE, V73, P401, DOI 10.1016/S0168-3659(01)00357-1
   Geisse Sabine, 2005, V308, P87
   Geisse Sabine, 2005, Journal of Structural and Functional Genomics, V6, P165, DOI 10.1007/s10969-005-2826-4
   Geisse S, 2009, PROTEIN EXPRES PURIF, V64, P99, DOI 10.1016/j.pep.2008.10.017
   Geng ZH, 2007, CELL TECHNOLOGY FOR CELL PRODUCTS, P53, DOI 10.1007/978-1-4020-5476-1_7
   Ghani K, 2006, BIOTECHNOL BIOENG, V95, P653, DOI 10.1002/bit.20947
   Grigorov B, 2006, J MOL BIOL, V359, P848, DOI 10.1016/j.jmb.2006.04.017
   Gutierrez-Granados S., 2013, J VIROL METHODS
   Hammonds J, 2007, VACCINE, V25, P8036, DOI 10.1016/j.vaccine.2007.09.016
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Jalaguier P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028314
   Kamen A, 2004, J GENE MED, V6, pS184, DOI 10.1002/jgm.503
   Keenan J, 2006, CYTOTECHNOLOGY, V50, P49, DOI 10.1007/s10616-006-9002-y
   Le Ru Audrey, 2010, Vaccine, V28, P3661, DOI 10.1016/j.vaccine.2010.03.029
   Pham PL, 2006, MOL BIOTECHNOL, V34, P225, DOI 10.1385/MB:34:2:225
   Pham PL, 2003, BIOTECHNOL BIOENG, V84, P332, DOI 10.1002/bit.10774
   Pillay S, 2009, BIOTECHNOL PROGR, V25, P1153, DOI 10.1002/btpr.187
   PLACKETT RL, 1946, BIOMETRIKA, V34, P255
   Rajendra Y, 2011, J BIOTECHNOL, V153, P22, DOI 10.1016/j.jbiotec.2011.03.001
   ROVINSKI B, 1995, AIDS RES HUM RETROV, V11, P1187, DOI 10.1089/aid.1995.11.1187
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Schlaeger EJ, 1999, CYTOTECHNOLOGY, V30, P71, DOI 10.1023/A:1008000327766
   SCHWARTZ S, 1992, J VIROL, V66, P7176
   Segura MM, 2007, BIOTECHNOL BIOENG, V98, P789, DOI 10.1002/bit.21467
   Sun XM, 2008, BIOTECHNOL BIOENG, V99, P108, DOI 10.1002/bit.21537
   Swiech K, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-114
   Tait AS, 2004, BIOTECHNOL BIOENG, V88, P707, DOI 10.1002/bit.20265
   Tom R, 2008, CSH PROTOCOLS
   Transfiguracion J, 2003, HUM GENE THER, V14, P1139, DOI 10.1089/104303403322167984
   Tuvesson O, 2008, CYTOTECHNOLOGY, V56, P123, DOI 10.1007/s10616-008-9135-2
   Valley-Omar Z, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-462
   Visciano ML, 2011, VACCINE, V29, P4903, DOI 10.1016/j.vaccine.2011.05.005
NR 51
TC 25
Z9 26
U1 3
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1656
J9 J BIOTECHNOL
JI J. Biotechnol.
PD JUL 20
PY 2013
VL 166
IS 4
BP 152
EP 165
DI 10.1016/j.jbiotec.2013.05.001
PG 14
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 182NF
UT WOS:000321749500002
PM 23688724
DA 2018-01-05
ER

PT J
AU Hilder, TA
   Chung, SH
AF Hilder, Tamsyn A.
   Chung, Shin-Ho
TI Designing a C-84 fullerene as a specific voltage-gated sodium channel
   blocker
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
DE C-84 fullerene derivative; Bacterial voltage gated sodium channel
   Na(v)Ab; Voltage-gated potassium channel Kv1.3; Binding; Molecular
   dynamics
ID WALLED CARBON NANOTUBES; POTASSIUM CHANNEL; MOLECULAR-DYNAMICS;
   MU-CONOTOXIN; BINDING; CONDUCTION; ENERGETICS; ISOMERS; TOXINS; POTENT
AB Fullerene derivatives demonstrate considerable potential for numerous biological applications, such as the effective inhibition of HIV protease. Recently, they were identified for their ability to indiscriminately block biological ion channels. A fullerene derivative which specifically blocks a particular ion channel could lead to a new set of drug leads for the treatment of various ion channel-related diseases. Here, we demonstrate their extraordinary potential by designing a fullerene which mimics some of the functions of mu-conotoxin, a peptide derived from cone snail venom which potently binds to the bacterial voltage-gated sodium channel (Na(v)Ab). We show, using molecular dynamics simulations, that the C-84 fullerene with six lysine derivatives uniformly attached to its surface is selective to Na(v)Ab over a voltage-gated potassium channel (Kv1.3). The side chain of one of the lysine residues protrudes into the selectivity filter of the channel, while the methionine residues located just outside of the channel form hydrophobic contacts with the carbon atoms of the fullerene. The modified C-84 fullerene strongly binds to the Na(v)Ab channel with an affinity of 46 nM but binds weakly to Kv1.3 with an affinity of 3 mM. This potent blocker of Na(v)Ab may serve as a structural template from which potent compounds can be designed for the targeting of mammalian Nav channels. There is a genuine need to target mammalian Nav channels as a form of treatment of various diseases which have been linked to their malfunction, such as epilepsy and chronic pain.
C1 [Hilder, Tamsyn A.; Chung, Shin-Ho] Australian Natl Univ, Res Sch Biol, Computat Biophys Grp, Canberra, ACT 0200, Australia.
RP Hilder, TA (reprint author), Australian Natl Univ, Res Sch Biol, Computat Biophys Grp, GPO Box 4, Canberra, ACT 0200, Australia.
EM tamsyn.hilder@anu.edu.au
RI Chung, Shin-Ho/A-5057-2010
OI Hilder, Tamsyn/0000-0002-0267-2754
FU NCI National Facility at the Australian National University; Australian
   Research Council through a Discovery Early Career Researcher Award;
   National Health and Medical Council
FX We thank A. Robinson and R. Chen for their scientific advice. This work
   was supported by the NCI National Facility at the Australian National
   University. We gratefully acknowledge the support from the Australian
   Research Council through a Discovery Early Career Researcher Award and
   the National Health and Medical Council.
CR Allen TW, 2004, P NATL ACAD SCI USA, V101, P117, DOI 10.1073/pnas.2635314100
   BAKOWIES D, 1992, CHEM PHYS LETT, V200, P411, DOI 10.1016/0009-2614(92)87013-F                                                    
   Bakry R, 2007, INT J NANOMED, V2, P639
   BALCH AL, 1994, J AM CHEM SOC, V116, P2227, DOI 10.1021/ja00084a106                                                             
   Chen R, 2012, BIOCHEMISTRY-US, V51, P1976, DOI 10.1021/bi201811j
   Chen R, 2012, BIOPHYS J, V102, P483, DOI 10.1016/j.bpj.2011.12.041
   Chen R, 2011, BIOPHYS J, V101, P2652, DOI 10.1016/j.bpj.2011.10.029
   Chen XR, 2010, P NATL ACAD SCI USA, V107, P11352, DOI 10.1073/pnas.1000142107
   Chhowalla M, 2005, NANOTECHNOLOGY, V16, P2982, DOI 10.1088/0957-4484/16/12/042
   Clark RJ, 2012, TOXICON, V59, P446, DOI 10.1016/j.toxicon.2010.12.003
   Da Ros T, 2008, CARBON MATER-CHEM PH, V1, P1
   de Leon A, 2008, CHEM PHYS LETT, V452, P306, DOI 10.1016/j.cplett.2007.12.065
   Dekan Z, 2011, J AM CHEM SOC, V133, P15866, DOI 10.1021/ja206408q
   DIEDERICH F, 1992, ACCOUNTS CHEM RES, V25, P119, DOI 10.1021/ar00015a004                                                             
   DIEDERICH F, 1991, SCIENCE, V252, P548, DOI 10.1126/science.252.5005.548                                                    
   Eijkelkamp N, 2012, BRAIN, V135, P2585, DOI 10.1093/brain/aws225
   Ekberg J, 2006, P NATL ACAD SCI USA, V103, P17030, DOI 10.1073/pnas.0601819103
   EMBL-EBI, 2013, MUSCLE MULT SEQ COMP
   Faber CG, 2012, P NATL ACAD SCI USA, V109, P19444, DOI 10.1073/pnas.1216080109
   Finol-Urdaneta RK, 2013, BIOPHYS J, V104, p136A, DOI 10.1016/j.bpj.2012.11.778                                                       
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gordon D, 2013, PHYSIOL REV, V93, P767, DOI 10.1152/physrev.00035.2012
   Heister E, 2013, ACS APPL MATER INTER, V5, P1870, DOI 10.1021/am302902d
   Hilder TA, 2013, BIOCHEMISTRY-US, V52, P967, DOI 10.1021/bi301498x
   Hu Z, 2007, CHEM-BIOL INTERACT, V167, P135, DOI 10.1016/j.cbi.2007.02.009
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   JCrystalSoft, 2005, NAN MOD VERS 1 7 3 C
   Khoo KK, 2011, J MED CHEM, V54, P7558, DOI 10.1021/jm200839a
   Koishi R, 2004, J BIOL CHEM, V279, P9532, DOI 10.1074/jbc.M313100200
   Kraszewski S, 2010, ACS NANO, V4, P4158, DOI 10.1021/nn100723r
   KUMAR S, 1995, J COMPUT CHEM, V16, P1339, DOI 10.1002/jcc.540161104
   LIU X, 1992, CHEM PHYS LETT, V188, P550, DOI 10.1016/0009-2614(92)80864-8                                                    
   Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Macnab RM, 1999, J BACTERIOL, V181, P7149
   Monticelli L, 2012, PHYS CHEM CHEM PHYS, V14, P12526, DOI 10.1039/c2cp41117b
   Norton RS, 2010, MOLECULES, V15, P2825, DOI 10.3390/molecules15042825
   Park KH, 2003, J BIOL CHEM, V278, P50212, DOI 10.1074/jbc.M310216200
   Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Prinzbach H, 2000, NATURE, V407, P60, DOI 10.1038/35024037                                                                
   Safo P, 2000, J NEUROSCI, V20, P76
   SHINOHARA H, 1991, J PHYS CHEM-US, V95, P8449, DOI 10.1021/j100175a010                                                             
   Stevens M, 2011, FRONT PHARMACOL, V2, P1, DOI DOI 10.3389/FPHAR.2011.00071
   Strom TA, 2010, CHEM COMMUN, V46, P4764, DOI 10.1039/c003019h
   Taylor R., 1999, LECT NOTES FULLERENE
   Wadhams GH, 2004, NAT REV MOL CELL BIO, V5, P1024, DOI 10.1038/nrm1524
   Wong-Ekkabut J, 2008, NAT NANOTECHNOL, V3, P363, DOI 10.1038/nnano.2008.130
   Xu HF, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/28/285102
   Yang JZ, 2007, CHEM-EUR J, V13, P2530, DOI 10.1002/chem.200601186
   Zhang Min-Min, 2013, Br J Pharmacol, V169, P102, DOI 10.1111/bph.12119
NR 51
TC 2
Z9 2
U1 1
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1931-7573
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD JUL 16
PY 2013
VL 8
AR 323
DI 10.1186/1556-276X-8-323
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 195AZ
UT WOS:000322675100001
PM 23855749
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, ZS
   Wang, BQ
   Wan, B
   Yu, L
   Huang, Q
AF Zhang, Zhishun
   Wang, Bingqiang
   Wan, Bo
   Yu, Long
   Huang, Qiang
TI Molecular dynamics study of carbon nanotube as a potential
   dual-functional inhibitor of HIV-1 integrase
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE HIV-1 integrase; Integrase inhibitor; Carbon nanotube; Drug delivery;
   Molecular dynamics simulation
ID BINDING; SIMULATION; FULLERENE; VIRUS; WATER; RALTEGRAVIR; DISCOVERY;
   INFECTION; PROTEINS
AB HIV-1 integrase (IN) plays an important role in integrating viral DNA into human genome, which has been considered as the drug target for anti-AIDS therapy. The appearance of drug-resistance mutants urgently requires novel inhibitors that act on non-active site of HIV-1 IN. Nanoparticles have such unique geometrical and chemical properties, which inspires us that nanoparticles like nanotubes may serve as better HIV-1 IN inhibitors than the conventional inhibitors. To test this hypothesis, we performed molecular dynamics (MD) simulation to study the binding of a carbon nanotube (CNT) to a full-length HIV-1 IN. The results showed that the CNT could stably bind to the C-terminal domain (CTD) of HIV-1 IN. The CNT also induced a domain-shift which disrupted the binding channel for viral DNA. Further MD simulation showed that a HIV-1 IN inhibitor, 5CITEP was successfully sealed inside the uncapped CNT. These results indicate that the CNT may serve as a potential dual-functional HIV-1 IN inhibitor, not only inducing conformation change as an allosteric inhibitor but also carrying small-molecular inhibitors as a drug delivery system. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Zhang, Zhishun; Wan, Bo; Yu, Long; Huang, Qiang] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Wang, Bingqiang] BGI Shenzhen, Bioinformat Ctr, Shenzhen 518083, Peoples R China.
RP Huang, Q (reprint author), Fudan Univ, Sch Life Sci, 220 Handan Rd, Shanghai 200433, Peoples R China.
EM huangqiang@fudan.edu.cn
FU HI-tech Research and Development Program of China [2008AA02Z311];
   Shanghai Leading Academic Discipline [B111]; Shanghai Supercomputer
   Center (SSC)
FX This study was supported in part by the HI-tech Research and Development
   Program of China (Grant No. 2008AA02Z311), the Shanghai Leading Academic
   Discipline (B111), and Shanghai Supercomputer Center (SSC).
CR Alexiadis A, 2008, CHEM REV, V108, P5014, DOI 10.1021/cr078140f
   Alian A, 2009, P NATL ACAD SCI USA, V106, P8192, DOI 10.1073/pnas.0811919106
   Benyamini H, 2006, BIOCONJUGATE CHEM, V17, P378, DOI 10.1021/bc050299g
   Bomboi F, 2011, J COLLOID INTERF SCI, V355, P342, DOI 10.1016/j.jcis.2010.12.026
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   Chaban VV, 2011, ACS NANO, V5, P5647, DOI 10.1021/nn201277a
   Chen AP, 2006, J BIOL CHEM, V281, P4173, DOI 10.1074/jbc.M510628200
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Eswar N, 2006, CURR PROTOC BIOINFOR, V15, P561
   Feller SE, 1997, BIOPHYS J, V73, P2269, DOI 10.1016/S0006-3495(97)78259-6                                                   
   Fitzkee NC, 2011, PROTEIN SCI, V20, P500, DOI 10.1002/pro.582
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Gupta SK, 2011, J BIOMED NANOTECHNOL, V7, P179, DOI 10.1166/jbn.2011.1258
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Huang M, 2011, J MOL GRAPH MODEL, V29, P956, DOI 10.1016/j.jmgm.2011.04.002
   HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5
   Madani SY, 2011, INT J NANOMED, V6, P2963, DOI 10.2147/IJN.S16923
   Perez A, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3672063
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7
   Reinke RA, 2004, VIROLOGY, V326, P203, DOI 10.1016/J.VIROL.2004.06.005
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   Schames JR, 2004, J MED CHEM, V47, P1879, DOI 10.1021/jm0341913
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Xie H, 2008, J PEPT SCI, V14, P139, DOI 10.1002/psc.978
   Ye HF, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-87
   Zhao H, 1997, J MED CHEM, V40, P242, DOI 10.1021/jm960450v
NR 34
TC 5
Z9 5
U1 0
U2 37
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 12
PY 2013
VL 436
IS 4
BP 650
EP 654
DI 10.1016/j.bbrc.2013.06.009
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 191LV
UT WOS:000322415400015
PM 23769827
DA 2018-01-05
ER

PT J
AU Long, YQ
   Huang, SX
   Zawahir, Z
   Xu, ZL
   Li, HY
   Sanchez, TW
   Zhi, Y
   De Houwer, S
   Christ, F
   Debyser, Z
   Neamati, N
AF Long, Ya-Qiu
   Huang, Shao-Xu
   Zawahir, Zahrah
   Xu, Zhong-Liang
   Li, Huiyuan
   Sanchez, Tino W.
   Zhi, Ying
   De Houwer, Stephanie
   Christ, Frauke
   Debyser, Zeger
   Neamati, Noun
TI Design of Cell-Permeable Stapled Peptides as HIV-1 Integrase Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ALPHA-AMINO-ACIDS; LEDGF/P75 PROTEIN; P53 PEPTIDE; SIDE-CHAIN; BH3
   HELIX; IN-VIVO; DOLUTEGRAVIR; REPLICATION; DISCOVERY; INFECTION
AB HIV-1 integrase (IN) catalyzes the integration of viral DNA into the host genome involving several interactions with the viral and cellular proteins. We have previously identified peptide IN inhibitors derived from the a-helical regions along the dimeric interface of HIV-1 IN. Herein, we show that appropriate hydrocarbon stapling of these peptides to stabilize their., helical structure remarkably improves the cell permeability, thus allowing inhibition of the HIV-1 replication in cell culture. Furthermore, the stabilized peptides inhibit the interaction of IN with the cellular cofactor LEDGF/p75. Cellular uptake of the stapled peptide was confirmed in four different cell lines using a fluorescein-labeled analogue. Given their enhanced potency and cell permeability, these stapled peptides can serve as not only lead IN inhibitors but also prototypical biochemical probes or "nanoneedles" for the elucidation of HIV-1 IN dimerization and host cofactor interactions within their native cellular environment.
C1 [Long, Ya-Qiu; Huang, Shao-Xu; Xu, Zhong-Liang; Li, Huiyuan; Zhi, Ying] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.
   [Zawahir, Zahrah; Sanchez, Tino W.; Neamati, Noun] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90033 USA.
   [De Houwer, Stephanie; Christ, Frauke; Debyser, Zeger] Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Belgium.
   [De Houwer, Stephanie; Christ, Frauke; Debyser, Zeger] IRC KUIAK, B-3000 Louvain, Belgium.
RP Long, YQ (reprint author), Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.
EM yqlong@mail.shcnc.ac.cn; neamati@usc.edu
FU National Natural Science Foundation of China [81021062, 81072527,
   81123004]; Science and Technology Commission of Shanghai Municipality
   [08JC1422200]; NIH/NIAID [R21AI081610]
FX The work in Long's laboratory was supported by funds from the National
   Natural Science Foundation of China (Grants 81021062, 81072527, and
   81123004), and Science and Technology Commission of Shanghai
   Municipality (Grant 08JC1422200). The work in the Neamati and Debyser
   laboratories were supported by NIH/NIAID (Grant R21AI081610). We thank
   N. J. Van Der Veken, B. Van Remoortel, and M. Michiels and Multiphoton
   Unit at KU Leuven for excellent technical assistance.
CR [Anonymous], 1985, HELV CHIM ACTA, V68,, P1243
   Al-Mawsawi LQ, 2008, FEBS LETT, V582, P1425, DOI 10.1016/j.febslet.2008.02.076
   Al-Mawsawi LQ, 2007, TRENDS PHARMACOL SCI, V28, P526, DOI 10.1016/j.tips.2007.09.005
   Al-Mawsawi LQ, 2006, P NATL ACAD SCI USA, V103, P10080, DOI 10.1073/pnas.0511254103
   ALTMANN E, 1991, HELV CHIM ACTA, V74, P800, DOI 10.1002/hlca.19910740414                                                        
   Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1
   Baek S, 2012, J AM CHEM SOC, V134, P103, DOI 10.1021/ja2090367
   Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Brown P. O., 1997, INTEGRATION RETROVIR, P161
   Chen HM, 2000, J VIROL, V74, P8188, DOI 10.1128/JVI.74.17.8188-8193.2000
   Cherepanov P, 2005, P NATL ACAD SCI USA, V102, P17308, DOI 10.1073/pnas.0506921402
   Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200
   Christ F, 2008, CURR BIOL, V18, P1192, DOI 10.1016/j.cub.2008.07.079
   Craigie R., 2011, HIV 1 INTEGRASE MECH
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   Desimmie BA, 2012, MOL THER, V20, P2064, DOI 10.1038/mt.2012.132
   DeVreese K, 1996, J VIROL, V70, P689
   Dooley KE, 2013, JAIDS-J ACQ IMM DEF, V62, P21, DOI 10.1097/QAI.0b013e318276cda9
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   Engelman A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000046
   Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Foged C, 2008, BBA-BIOMEMBRANES, V1778, P2487, DOI 10.1016/j.bbamem.2008.06.020
   FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838
   Guiot E, 2006, J BIOL CHEM, V281, P22707, DOI 10.1074/jbc.M602198200
   Hamamoto S, 2006, J VIROL, V80, P5670, DOI 10.1128/JVI.02471-05
   Hayouka Z, 2012, BIOORGAN MED CHEM, V20, P3317, DOI 10.1016/j.bmc.2012.03.039
   Hayouka Z, 2010, BIOORGAN MED CHEM, V18, P8388, DOI 10.1016/j.bmc.2010.09.046
   Henchey LK, 2008, CURR OPIN CHEM BIOL, V12, P692, DOI 10.1016/j.cbpa.2008.08.019
   Hwang DJ, 2001, BIOORGAN MED CHEM, V9, P1429, DOI 10.1016/S0968-0896(01)00013-X                                                   
   de Vega MJP, 2011, MED RES REV, V31, P677, DOI 10.1002/med.20199
   Kapadia SR, 2001, J ORG CHEM, V66, P1903, DOI 10.1021/jo0013913
   KARADY S, 1984, TETRAHEDRON LETT, V25, P4337, DOI 10.1016/S0040-4039(01)81432-5                                                   
   Krishnan L, 2010, J VIROL, V84, P397, DOI 10.1128/JVI.01899-09
   Kritzer JA, 2010, NAT CHEM BIOL, V6, P566, DOI 10.1038/nchembio.407
   Li HY, 2006, J MED CHEM, V49, P4477, DOI 10.1021/jm060307u
   Li P, 2002, CURR ORG CHEM, V6, P411, DOI 10.2174/1385272024604970                                                        
   Li Peng, 2002, Current Topics in Medicinal Chemistry, V2, P325, DOI 10.2174/1568026023394209
   Long YQ, 2008, J MED CHEM, V51, P6371, DOI 10.1021/jm800487r
   Okamoto T, 2013, ACS CHEM BIOL, V8, P297, DOI 10.1021/cb3005403
   Permpalung N, 2012, EXPERT OPIN PHARMACO, V13, P2301, DOI 10.1517/14656566.2012.729040
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a
   Thys W., 2011, HIV 1 INTEGRASE MECH
   Underwood MR, 2012, JAIDS-J ACQ IMM DEF, V61, P297, DOI 10.1097/QAI.0b013e31826bfd02
   van Lunzen J, 2012, LANCET INFECT DIS, V12, P111, DOI 10.1016/S1473-3099(11)70290-0
   Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184
   Verdine GL, 2012, METHOD ENZYMOL, V503, P3, DOI 10.1016/B978-0-12-396962-0.00001-X
   Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191
   Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020
   Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333
   Whelan J, 2004, DRUG DISCOV TODAY, V9, P907, DOI 10.1016/S1359-6446(04)03268-4
   Zawahir Z, 2006, BIOORG MED CHEM LETT, V16, P5199, DOI 10.1016/j.bmcl.2006.07.022
   ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395                                                          
   Zhang H, 2008, J MOL BIOL, V378, P565, DOI 10.1016/j.jmb.2008.02.066
   Zhang JL, 2007, J CLIN INVEST, V117, P473, DOI 10.1172/JCI28971
NR 57
TC 27
Z9 28
U1 5
U2 42
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 11
PY 2013
VL 56
IS 13
BP 5601
EP 5612
DI 10.1021/jm4006516
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 184IV
UT WOS:000321884200028
PM 23758584
DA 2018-01-05
ER

PT J
AU Sarkar, R
   Mukhopadhyay, C
AF Sarkar, Rajib
   Mukhopadhyay, Chhanda
TI Admicellar catalysis in multicomponent synthesis of polysubstituted
   pyrrolidinones
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Pyrrolidinones; TiO2 nano-particle; Admicellar catalysis; Multicomponent
   reaction; Green methodology
ID ANIONIC SURFACTANTS; HIV-1 INTEGRASE; WATER; ADSOLUBILIZATION;
   POLYMERIZATION; ALUMINA; SILICA; NANOPARTICLES; DISELENIDES; DERIVATIVES
AB A multicomponent green methodology was developed to synthesize 3-hydroxy-2-pyrrolidinones under admicellar catalysis by TiO2 nano-particles at room temperature (30 degrees C). TiO2 nano-particles in aqueous CTAB solution promote the formation of admicelles and the reaction occurs in admicellar environment. The methodology was successfully applied to synthesize a variety of 3-hydroxy-2-pyrrolidinones and 3'-hydroxyspiro-2'-pyrrolidinone derivatives. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Sarkar, Rajib; Mukhopadhyay, Chhanda] Univ Calcutta, Dept Chem, Kolkata 700009, India.
RP Mukhopadhyay, C (reprint author), Univ Calcutta, Dept Chem, 92 APC Rd, Kolkata 700009, India.
EM cmukhop@yahoo.co.in
FU Council of Scientific and Industrial Research, New Delhi; UGC
   [37-398/2009]
FX One of the authors (R.S.) thanks the Council of Scientific and
   Industrial Research, New Delhi, for his fellowship (J.R.F.). We
   acknowledge Grant received from UGC funded Major project, F. No.
   37-398/2009 (R.S.) dated 11-01-2010.
CR Alberto EE, 2012, TETRAHEDRON, V68, P10476, DOI 10.1016/j.tet.2012.08.004
   Barbaro P, 2012, GREEN CHEM, V14, P3211, DOI 10.1039/c2gc36144b
   Bardajee GR, 2012, J INORG BIOCHEM, V117, P367, DOI 10.1016/j.jinorgbio.2012.06.012
   Dickson J, 2002, LANGMUIR, V18, P9171, DOI 10.1021/la020324w
   Favoriti P, 1998, LANGMUIR, V14, P7493, DOI 10.1021/la980890k                                                               
   Gangula S, 2010, MICROCHEM J, V95, P2, DOI 10.1016/j.microc.2009.10.005
   Gein VL, 2011, PHARM CHEM J+, V45, P162, DOI 10.1007/s11094-011-0584-0                                                       
   Gein VL, 2005, PHARM CHEM J+, V39, P484, DOI 10.1007/s11094-006-0006-x
   Gein V. L., 2007, PHARM CHEM J, V41, P208
   GLATZHOFER DT, 1993, LANGMUIR, V9, P2949, DOI 10.1021/la00035a036                                                             
   Godoi M, 2012, TETRAHEDRON, V68, P10426, DOI 10.1016/j.tet.2012.08.086
   Han Y, 2012, TETRAHEDRON, V68, P8539, DOI 10.1016/j.tet.2012.08.030
   Khamarui S, 2011, CHEM COMMUN, V47, P12667, DOI 10.1039/c1cc16126a
   Kozminykh V. O., 2002, PHARM CHEM J, V36, P188, DOI DOI 10.1023/A:1019832621371
   Lai CL, 1997, LANGMUIR, V13, P4267, DOI 10.1021/la960366i                                                               
   Li HY, 2004, LANGMUIR, V20, P10526, DOI 10.1021/la048898j
   Ma KQ, 2011, BIOORG MED CHEM LETT, V21, P6724, DOI 10.1016/j.bmcl.2011.09.054
   Maria P. D., 2005, TETRAHEDRON, V61, P7176
   Marquez M, 2007, LANGMUIR, V23, P10008, DOI 10.1021/la7011809
   Metten B, 2006, TETRAHEDRON, V62, P6018, DOI 10.1016/j.tet.2006.04.05
   Monticone V., 1996, LANGMUIR, V11, P1753
   NAYYAR SP, 1994, ENVIRON SCI TECHNOL, V28, P1874, DOI 10.1021/es00060a018
   Ninness BJ, 2002, COLLOID SURFACE A, V203, P21, DOI 10.1016/S0927-7757(01)01088-3                                                   
   Pandit P, 2011, CHEM COMMUN, V47, P6933, DOI 10.1039/c1cc11685a
   Pendri A, 2010, J COMB CHEM, V12, P84, DOI 10.1021/cc9001026
   Price BK, 2006, J AM CHEM SOC, V128, P12899, DOI 10.1021/ja063609u
   Ryabukhin SV, 2012, ACS COMB SCI, V14, P631, DOI 10.1021/co300082t
   Sedghi A, 2011, DIG J NANOMATER BIOS, V6, P1457
   Sen IK, 2013, CARBOHYD POLYM, V91, P518, DOI 10.1016/j.carbpol.2012.08.058
   Srivastava M, 2012, GREEN CHEM, V14, P901, DOI 10.1039/c2gc16425f
   Sun J., 2011, EUR J ORG CHEM, V17, P2981
   Tyrode E, 2008, J AM CHEM SOC, V130, P17434, DOI 10.1021/ja805169z
   Wang W, 2004, J PHYS CHEM B, V108, P17477, DOI 10.1021/jp048325f
   Xu ZH, 1996, LANGMUIR, V12, P2263, DOI 10.1021/la950939b                                                               
   YESKIE MA, 1988, J PHYS CHEM-US, V92, P2346, DOI 10.1021/j100319a048                                                             
   Yuan WL, 2002, LANGMUIR, V18, P3343, DOI 10.1021/la011349i
   Zhang Y, 2008, WATER RES, V42, P2204, DOI 10.1016/j.watres.2007.11.036
   Zhao Q, 2005, ANALYST, V130, P750, DOI 10.1039/b417785a
   Zhu C, 2012, J AM CHEM SOC, V134, P20234, DOI 10.1021/ja3091214
   Michael T., 2008, Patent WO, Patent No. [2008055945 A1, 2008055945, WO 2,008,055,945 (A1)]
NR 40
TC 21
Z9 21
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD JUL 10
PY 2013
VL 54
IS 28
BP 3706
EP 3711
DI 10.1016/j.tetlet.2013.05.017
PG 6
WC Chemistry, Organic
SC Chemistry
GA 168ER
UT WOS:000320689000032
DA 2018-01-05
ER

PT J
AU Narayanan, A
   Iordanskiy, S
   Das, R
   Van Duyne, R
   Santos, S
   Jaworski, E
   Guendel, I
   Sampey, G
   Dalby, E
   Iglesias-Ussel, M
   Popratiloff, A
   Hakami, R
   Kehn-Hall, K
   Young, M
   Subra, C
   Gilbert, C
   Bailey, C
   Romerio, F
   Kashanchi, F
AF Narayanan, Aarthi
   Iordanskiy, Sergey
   Das, Ravi
   Van Duyne, Rachel
   Santos, Steven
   Jaworski, Elizabeth
   Guendel, Irene
   Sampey, Gavin
   Dalby, Elizabeth
   Iglesias-Ussel, Maria
   Popratiloff, Anastas
   Hakami, Ramin
   Kehn-Hall, Kylene
   Young, Mary
   Subra, Caroline
   Gilbert, Caroline
   Bailey, Charles
   Romerio, Fabio
   Kashanchi, Fatah
TI Exosomes Derived from HIV-1-infected Cells Contain Trans-activation
   Response Element RNA
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HIV-1 TAR ELEMENT; VIRAL MIRNAS; MICRORNA BIOGENESIS; VIRUS-PARTICLES;
   GENE-EXPRESSION; INFECTED-CELLS; INTERFERENCE; MEMBRANE; NEF; VESICLES
AB Exosomes are nano-sized vesicles produced by healthy and virus-infected cells. Exosomes derived from infected cells have been shown to contain viral microRNAs (miRNAs). HIV-1 encodes its own miRNAs that regulate viral and host gene expression. The most abundant HIV-1-derived miRNA, first reported by us and later by others using deep sequencing, is the trans-activation response element (TAR) miRNA. In this study, we demonstrate the presence of TAR RNA in exosomes from cell culture supernatants of HIV-1-infected cells and patient sera. TAR miRNA was not in Ago2 complexes outside the exosomes but enclosed within the exosomes. We detected the host miRNA machinery proteins Dicer and Drosha in exosomes from infected cells. We report that transport of TAR RNA from the nucleus into exosomes is a CRM1 (chromosome region maintenance 1)-dependent active process. Prior exposure of naive cells to exosomes from infected cells increased susceptibility of the recipient cells to HIV-1 infection. Exosomal TAR RNA down-regulated apoptosis by lowering Bim and Cdk9 proteins in recipient cells. We found 10(4)-10(6) copies/ml TAR RNA in exosomes derived from infected culture supernatants and 10(3) copies/ml TAR RNA in the serum exosomes of highly active antiretroviral therapy-treated patients or long term nonprogressors. Taken together, our experiments demonstrated that HIV-1-infected cells produced exosomes that are uniquely characterized by their proteomic and RNA profiles that may contribute to disease pathology in AIDS.
C1 [Narayanan, Aarthi; Iordanskiy, Sergey; Das, Ravi; Van Duyne, Rachel; Jaworski, Elizabeth; Guendel, Irene; Sampey, Gavin; Dalby, Elizabeth; Hakami, Ramin; Kehn-Hall, Kylene; Bailey, Charles; Kashanchi, Fatah] George Mason Univ, Natl Ctr Biodef & Infect Dis, Manassas, VA 20110 USA.
   [Iordanskiy, Sergey; Van Duyne, Rachel; Santos, Steven; Popratiloff, Anastas] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
   [Iglesias-Ussel, Maria; Romerio, Fabio] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Young, Mary] Georgetown Univ, Med Ctr, Washington Metropolitan Womens Interagency HIV St, Div Infect Dis, Washington, DC 20007 USA.
   [Subra, Caroline; Gilbert, Caroline] Univ Laval, Ctr Hosp Univ Quebec, Res Ctr, Dept Microbiol Infectiol & Immunol,Med Fac, Quebec City, PQ G1R 2J6, Canada.
RP Kashanchi, F (reprint author), George Mason Univ, Natl Ctr Biodef & Infect Dis, Discovery Hall,Rm 182,10900 Univ Blvd,MS 1H8, Manassas, VA 20110 USA.
EM fkashanc@gmu.edu
RI Kehn-Hall, Kylene/I-5752-2013
OI Kehn-Hall, Kylene/0000-0001-8036-7213
FU National Institutes of Health [AI078859, AI074410, AI043894]; NCI; NIDA;
   NIDCD; NCRR UCSF-CTSI [UL1 RR024131]; District of Columbia Developmental
   Center for AIDS Research Grant [5P30AI087714-02]; United States
   Department of Energy [DE-SC0001599]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants AI078859, AI074410, and AI043894 (to F. K.), NCI, NIDA,
   NIDCD, and NCRR UCSF-CTSI Grant UL1 RR024131, and District of Columbia
   Developmental Center for AIDS Research Grant 5P30AI087714-02 (to S. I.).
   This work was also supported by United States Department of Energy Grant
   DE-SC0001599 (to F. K. and C. B.).
CR Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003
   Ali SA, 2010, AIDS RES HUM RETROV, V26, P173, DOI 10.1089/aid.2009.0068
   Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Anand Paras K, 2010, Commun Integr Biol, V3, P405, DOI 10.4161/cib.3.5.12474
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5                                                   
   Barth S, 2011, BBA-GENE REGUL MECH, V1809, P631, DOI 10.1016/j.bbagrm.2011.05.010
   Bentham M, 2006, J GEN VIROL, V87, P563, DOI 10.1099/vir.0.81200-0
   Bivalkar-Mehla S, 2011, VIRUS RES, V155, P1, DOI 10.1016/j.virusres.2010.10.003
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Boss IW, 2009, TRENDS MICROBIOL, V17, P544, DOI 10.1016/j.tim.2009.09.002
   Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933                                                              
   Brandano L, 2012, J VIROL, V86, P2347, DOI 10.1128/JVI.06047-11
   Brocker C, 2010, CURR BIOL, V20, pR943, DOI 10.1016/j.cub.2010.09.015
   Campbell TD, 2008, ETHN DIS, V18
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   Carpio Lawrence, 2010, J RNAi Gene Silencing, V6, pE386
   Carpio Lawrence, 2010, J RNAi Gene Silencing, V6, P386
   Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422
   Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868
   Coley W, 2010, J BIOL CHEM, V285, P31930, DOI 10.1074/jbc.M110.101709
   de Vries W, 2008, INT J BIOCHEM CELL B, V40, P2007, DOI 10.1016/j.biocel.2008.04.015
   Denzer K, 2000, J CELL SCI, V113, P3365
   Dimov I, 2009, THESCIENTIFICWORLDJO, V9, P1107, DOI 10.1100/tsw.2009.128
   Dolken L, 2009, VIRUS GENES, V38, P355, DOI 10.1007/s11262-009-0347-0
   Duijvesz D, 2011, EUR UROL, V59, P823, DOI 10.1016/j.eururo.2010.12.031
   Easley R, 2010, VIROLOGY, V405, P322, DOI 10.1016/j.virol.2010.06.009
   Eldh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015353
   Fang Y, 2007, PLOS BIOL, V5, P1267, DOI 10.1371/journal.pbio.0050158
   Furnes C, 2008, ARCH VIROL, V153, P357, DOI 10.1007/s00705-007-1095-x
   Gan X, 2011, MOL BIOL CELL, V22, P817, DOI 10.1091/mbc.E10-07-0625
   Geanacopoulos Mark, 2005, Science Progress, V88, P49, DOI 10.3184/003685005783238444
   Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504
   Gourzones C, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-271
   Grishok A, 2005, FEBS LETT, V579, P5932, DOI 10.1016/j.febslet.2005.08.001
   Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/2326106
   Haasnoot J, 2011, METHODS MOL BIOL, V721, P23, DOI 10.1007/978-1-61779-037-9_2
   Klase Z, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-63
   Klase Z, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-38
   Klase Z, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-18
   Lamers SL, 2010, BIOSYSTEMS, V101, P88, DOI 10.1016/j.biosystems.2010.05.001
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lejeune E, 2011, CURR OPIN CELL BIOL, V23, P258, DOI 10.1016/j.ceb.2011.03.005
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Lin J, 2007, J VIROL, V81, P12218, DOI 10.1128/JVI.01390-07
   Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005
   Marini A, 2008, J IMMUNOL, V181, P7713, DOI 10.4049/jimmunol.181.11.7713                                                    
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Mohammed KD, 2011, J VIROL, V85, P4654, DOI 10.1128/JVI.02374-10
   Montgomery Mary K, 2004, Methods Mol Biol, V265, P3
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Nair V, 2006, TRENDS MICROBIOL, V14, P169, DOI 10.1016/j.tim.2006.02.007
   Naqvi AR, 2009, INT J BIOL SCI, V5, P97
   Narayanan A, 2011, EXPERT OPIN BIOL TH, V11, P17, DOI 10.1517/14712598.2011.540564
   Omoto Shinya, 2004, Retrovirology, V1, P44, DOI 10.1186/1742-4690-1-44
   Ouellet DL, 2008, NUCLEIC ACIDS RES, V36, P2353, DOI 10.1093/nar/gkn076
   Paolucci S, 2011, CURR HIV RES, V9, P17, DOI 10.2174/157016211794582641
   Pegtel DM, 2011, BBA-GENE REGUL MECH, V1809, P715, DOI 10.1016/j.bbagrm.2011.08.002
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Perron MP, 2008, FRONT BIOSCI-LANDMRK, V13, P2537, DOI 10.2741/2865
   Perron Marjorie P., 2009, V487, P369, DOI 10.1007/978-1-60327-547-7_18
   Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746
   Plaisance-Bonstaff K, 2011, METHODS MOL BIOL, V721, P43, DOI 10.1007/978-1-61779-037-9_3
   Poe JA, 2009, J MOL BIOL, V394, P329, DOI 10.1016/j.jmb.2009.09.047
   Pols MS, 2009, EXP CELL RES, V315, P1584, DOI 10.1016/j.yexcr.2008.09.020
   Rana S, 2011, BIOCHEM SOC T, V39, P559, DOI 10.1042/BST0390559
   Record M, 2011, BIOCHEM PHARMACOL, V81, P1171, DOI 10.1016/j.bcp.2011.02.011
   Sandonis V, 2009, VIROLOGY, V391, P73, DOI 10.1016/j.virol.2009.05.022
   Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68
   Schopman NCT, 2012, NUCLEIC ACIDS RES, V40, P414, DOI 10.1093/nar/gkr719
   Schuetz S, 2006, VIROLOGY, V344, P151, DOI 10.1016/j.virol.2005.09.034
   Shelton MN, 2012, J VIROL, V86, P406, DOI 10.1128/JVI.05720-11
   Shen BY, 2011, J BIOL CHEM, V286, P14383, DOI 10.1074/jbc.M110.208660
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17
   Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Van Duyne R, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-21
   Van Rij RP, 2006, TRENDS BIOTECHNOL, V24, P186, DOI 10.1016/j.tibtech.2006.02.006
   Venkatachari NJ, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-119
   Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686
   Wang SH, 2008, BIOMED ENVIRON SCI, V21, P485, DOI 10.1016/S0895-3988(09)60007-6
   Wang Z, 2012, PROTEOMICS, V12, P329, DOI 10.1002/pmic.201100477
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Yeung ML, 2009, NUCLEIC ACIDS RES, V37, P6575, DOI 10.1093/nar/gkp707
   Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X
   Zhu JY, 2009, J VIROL, V83, P3333, DOI 10.1128/JVI.01689-08
   Zofall M, 2006, COLD SPRING HARB SYM, V71, P487, DOI 10.1101/sqb.2006.71.059                                                         
   Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339
   Zou SP, 2011, J NEUROVIROL, V17, P41, DOI 10.1007/s13365-010-0016-z
NR 93
TC 79
Z9 80
U1 2
U2 31
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 5
PY 2013
VL 288
IS 27
BP 20014
EP 20033
DI 10.1074/jbc.M112.438895
PG 20
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 179JG
UT WOS:000321515800065
PM 23661700
OA gold
DA 2018-01-05
ER

PT J
AU Wojta-Stremayr, D
   Pickl, WF
AF Wojta-Stremayr, Daniela
   Pickl, Winfried F.
TI Fluorosomes: Fluorescent Virus-Like Nanoparticles that Represent a
   Convenient Tool to Visualize Receptor-Ligand Interactions
SO SENSORS
LA English
DT Review
DE virus-like nanoparticles; fluorosomes; fluorescent dyes; receptor-ligand
   interactions
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VESICULAR STOMATITIS-VIRUS;
   HERPES-SIMPLEX-VIRUS; EPSTEIN-BARR VIRUS; TYPE-1 MATRIX PROTEIN; HUMAN
   LYMPHOCYTES-B; SEMICONDUCTOR QUANTUM DOTS; MURINE LEUKEMIA-VIRUS;
   LABELED RABIES-VIRUS; PARTICLES IN-VITRO
AB Viruses are the smallest life forms and parasitize on many eukaryotic organisms, including humans. Consequently, the study of viruses and viral diseases has had an enormous impact on diverse fields of biology and medicine. Due to their often pathogenic properties, viruses have not only had a strong impact on the development of immune cells but also on shaping entire immune mechanisms in their hosts. In order to better characterize virus-specific surface receptors, pathways of virus entry and the mechanisms of virus assembly, diverse methods to visualize virus particles themselves have been developed in the past decades. Apart from characterization of virus-specific mechanisms, fluorescent virus particles also serve as valuable platforms to study receptor-ligand interactions. Along those lines the authors have developed non-infectious virus-like nanoparticles (VNP), which can be decorated with immune receptors of choice and used for probing receptor-ligand interactions, an especially interesting application in the field of basic but also applied immunology research. To be able to better trace receptor-decorated VNP the authors have developed technology to introduce fluorescent proteins into such particles and henceforth termed them fluorosomes (FS). Since VNP are assembled in a simple expression system relying on HEK-293 cells, gene-products of interest can be assembled in a simple and straightforward fashionone of the reasons why the authors like to call fluorosomes the poor-man's staining tool'. Within this review article an overview on virus particle assembly, chemical and recombinant methods of virus particle labeling and examples on how FS can be applied as sensors to monitor receptor-ligand interactions on leukocytes are given.
C1 [Wojta-Stremayr, Daniela; Pickl, Winfried F.] Christian Doppler Lab Immunomodulat, A-1090 Vienna, Austria.
   [Wojta-Stremayr, Daniela; Pickl, Winfried F.] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Inst Immunol, A-1090 Vienna, Austria.
RP Pickl, WF (reprint author), Christian Doppler Lab Immunomodulat, A-1090 Vienna, Austria.
EM winfried.pickl@meduniwien.ac.at
FU Austrian Science Fund (FWF) [SFB-F4609]; Christian Doppler Society;
   Biomay AG
FX The authors thank Alina Neunkirchner and Peter Steinberger for
   critically reading the manuscript and for helpful discussions and
   suggestions. This work was supported by the Austrian Science Fund (FWF)
   grant SFB-F4609, the Christian Doppler Society and Biomay AG.
CR Adams S, 2002, FORBES, V169, P124
   Ali MM, 2012, WIRES NANOMED NANOBI, V4, P547, DOI 10.1002/wnan.1179
   ALTSTIEL LD, 1981, J VIROL, V39, P82
   Ball JM, 1999, GASTROENTEROLOGY, V117, P40, DOI 10.1016/S0016-5085(99)70548-2
   Balogh A, 2011, ENZYME MICROB TECH, V49, P255, DOI 10.1016/j.enzmictec.2011.06.005
   Bartlett JS, 1998, HUM GENE THER, V9, P1181, DOI 10.1089/hum.1998.9.8-1181
   Bearer EL, 2000, P NATL ACAD SCI USA, V97, P8146, DOI 10.1073/pnas.97.14.8146
   BERGER J, 1988, J BIOL CHEM, V263, P10016
   BLUMENTHAL R, 1987, J BIOL CHEM, V262, P13614
   Bosio CM, 2004, VIROLOGY, V326, P280, DOI 10.1016/j.virol.2004.05.025
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Campbell EM, 2007, VIROLOGY, V360, P286, DOI 10.1016/j.virol.2006.10.025
   Charpilienne A, 2001, J BIOL CHEM, V276, P29361, DOI 10.1074/jbc.M101935200
   CHOPPIN PW, 1970, J VIROL, V5, P609
   Chukkapalli V, 2011, J MOL BIOL, V410, P512, DOI 10.1016/j.jmb.2011.04.015
   Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200
   Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4
   DALES S, 1962, J CELL BIOL, V13, P303, DOI 10.1083/jcb.13.2.303
   Dalton KP, 2001, VIROLOGY, V279, P414, DOI 10.1006/viro.2000.0736
   DaPoian AT, 1996, P NATL ACAD SCI USA, V93, P8268, DOI 10.1073/pnas.93.16.8268
   Das SC, 2009, J VIROL, V83, P2611, DOI 10.1128/JVI.01668-08
   Decker T, 2010, ANN HEMATOL, V89, P1125, DOI 10.1007/s00277-010-0994-1
   del Rio T, 2005, J VIROL, V79, P3903, DOI 10.1128/JVI.79.7.3903-3919.2005
   DELCHAMBRE M, 1989, EMBO J, V8, P2653
   De Lima P. M. C., 1992, EUR J BIOCHEM, V205, P181
   Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103
   Desai P, 1998, J VIROL, V72, P7563
   Dolnik O, 2008, CELL MOL LIFE SCI, V65, P756, DOI 10.1007/s00018-007-7406-2
   Donnelly M, 2001, J VIROL, V75, P2575, DOI 10.1128/JVI.75.6.2575-2583.2001                                                 
   Duprex WP, 2002, J VIROL, V76, P7322, DOI 10.1128/JVI.76.14.7322-7328.2002
   Elliott G, 1999, J VIROL, V73, P4110
   Everett RD, 2003, J VIROL, V77, P3680, DOI 10.1128/JVI.77.6.3680-3689.2003
   FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510
   Finke S, 2004, J VIROL, V78, P12333, DOI 10.1128/JVI.78.22.12333-12343.2004
   Fisher RD, 2007, CELL, V128, P841, DOI 10.1016/j.cell.2007.01.035
   FRADE R, 1985, P NATL ACAD SCI USA, V82, P1490, DOI 10.1073/pnas.82.5.1490
   Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793
   Galla M, 2004, MOL CELL, V16, P309, DOI 10.1016/j.molcel.2004.09.023                                                    
   GEORGI A, 1990, P NATL ACAD SCI USA, V87, P6579, DOI 10.1073/pnas.87.17.6579
   Ghosh D, 2012, NAT NANOTECHNOL, V7, P677, DOI [10.1038/NNANO.2012.146, 10.1038/nnano.2012.146]
   Glotzer JB, 2001, J VIROL, V75, P2421, DOI 10.1128/JVI.75.5.2421-2434.2001
   Goldman ER, 2002, ANAL CHEM, V74, P841, DOI 10.1021/ac010662m
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   Gousset K., 2008, PLOS PATHOG, V4
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269                                                    
   Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7
   HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339                                                           
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Hernaez B, 2006, VIROLOGY, V350, P1, DOI 10.1016/j.virol.2006.01.021
   HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665
   Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099
   HOEKSTRA D, 1985, BIOCHEMISTRY-US, V24, P4739, DOI 10.1021/bi00339a005
   HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002
   Horan P K, 1990, Methods Cell Biol, V33, P469
   HUANG AS, 1973, J VIROL, V12, P659
   HUANG AS, 1974, NATURE, V252, P743, DOI 10.1038/252743a0
   Hutchinson I, 2002, J VIROL, V76, P10365, DOI 10.1128/JVI.76.20.10365-10373.2002
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Jalaguier P., 2011, PLOS ONE, V6
   Jansen KU, 1999, Recombinant papillomavirus vaccines, Patent No. [US5888516A, 5888516]
   JOLING P, 1993, J IMMUNOL, V150, P1065
   Jons A, 1997, J VIROL METHODS, V66, P283, DOI 10.1016/S0166-0934(97)00065-7
   Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122
   Kampani K, 2007, J VIROL METHODS, V141, P125, DOI 10.1016/j.jviromet.2006.11.043
   KHELIFA R, 1982, J VIROL, V41, P649
   KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9                                                   
   KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180                                                        
   Kizhatil K, 2001, J VIROL, V75, P11881, DOI 10.1128/JVI.75.23.11881-11885.2001                                              
   Klingen Y, 2008, J VIROL, V82, P237, DOI 10.1128/JVI.04342-07
   Kueng HJ, 2010, FASEB J, V24, P1572, DOI 10.1096/fj.09-137281
   Kumari K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-42
   La Boissiere S, 2004, J VIROL, V78, P8002, DOI 10.1128/JVI.78.15.8002-8014.2004
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Lampe M, 2007, VIROLOGY, V360, P92, DOI 10.1016/j.virol.2006.10.005
   Lanman J, 2008, J STRUCT BIOL, V161, P439, DOI 10.1016/j.jsb.2007.09.009
   Le Blanc I, 2005, NAT CELL BIOL, V7, P653, DOI 10.1038/ncb1269
   Lechner F, 2002, INTERVIROLOGY, V45, P212, DOI 10.1159/000067912
   Lee S, 2007, NAT STRUCT MOL BIOL, V14, P194, DOI 10.1038/nsmb1203
   Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367
   Lidke DS, 2004, PHYSIOLOGY, V19, P322, DOI 10.1152/physiol.00030.2004
   Liu HB, 2011, J VIROL, V85, P6252, DOI 10.1128/JVI.00109-11
   Liu SL, 2012, BIOMATERIALS, V33, P7828, DOI 10.1016/j.biomaterials.2012.07.026
   Lux K, 2005, J VIROL, V79, P11776, DOI 10.1128/JVI.79.18.11776-11787.2005
   Maetzig T, 2012, CURR GENE THER, V12, P389, DOI 10.2174/156652312802762581                                                      
   Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335                                                         
   MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719
   Mattheakis LC, 2004, ANAL BIOCHEM, V327, P200, DOI 10.1016/j.ab.2004.01.031
   MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0
   Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   Metzner C, 2008, FASEB J, V22, P2734, DOI 10.1096/fj.08-108217
   Metzner C, 2013, MOL BIOTECHNOL, V53, P9, DOI 10.1007/s12033-012-9616-6
   MILLER AD, 1991, J VIROL, V65, P2220
   Mire C. E., 2010, PLOS PATHOG, V6
   Mire CE, 2009, J VIROL, V83, P12139, DOI 10.1128/JVI.00955-09
   MIYANOHARA A, 1986, J VIROL, V59, P176
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025                                                             
   Nabiev I, 2008, FLUORESCENT COLLOIDA, P133
   NEMEROW GR, 1985, J VIROL, V55, P347
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   Nutiu R, 2005, METHODS, V37, P16, DOI 10.1016/j.ymeth.2005.07.001
   Ono A, 1999, J VIROL, V73, P4136
   Ono A, 2000, J VIROL, V74, P2855, DOI 10.1128/JVI.74.6.2855-2866.2000
   Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400
   Pan Y, 2012, FEBS J, V279, P1198, DOI 10.1111/j.1742-4658.2012.08512.x
   Panchal RG, 2003, P NATL ACAD SCI USA, V100, P15936, DOI 10.1073/pnas.2533915100
   Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536
   Pattenden LK, 2005, TRENDS BIOTECHNOL, V23, P523, DOI 10.1016/j.tibtech.2005.07.011
   PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020                                                             
   Pereira C.S., 2011, PLOS ONE, V6
   PERSSON R, 1983, J VIROL, V46, P956
   Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001
   Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856
   Potel C, 2002, J VIROL METHODS, V105, P13, DOI 10.1016/S0166-0934(02)00027-7                                                   
   PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H                                                    
   RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0
   Rawsthorne H, 2009, APPL ENVIRON MICROB, V75, P7822, DOI 10.1128/AEM.01986-09
   Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992
   Rivera-Hernandez T, 2013, VACCINE, V31, P1950, DOI 10.1016/j.vaccine.2013.02.013
   ROSE RC, 1993, J VIROL, V67, P1936
   Rudner L, 2005, J VIROL, V79, P4055, DOI 10.1128/JVI.79.7.4055-4065.2005
   Sampaio KL, 2005, J VIROL, V79, P2754, DOI 10.1128/JVI/79.5.2754-2767.2005
   San R. K., 1999, VIROLOGY, V260, P329
   Sanchez-Rodriguez SP, 2012, BIOCHIMIE, V94, P870, DOI 10.1016/j.biochi.2011.12.006
   Schnierle BS, 1997, P NATL ACAD SCI USA, V94, P8640, DOI 10.1073/pnas.94.16.8640
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022
   SINANGIL F, 1988, FEBS LETT, V239, P88, DOI 10.1016/0014-5793(88)80551-9
   Smith GA, 2004, P NATL ACAD SCI USA, V101, P16034, DOI 10.1073/pnas.0404686101
   Smith GA, 2001, P NATL ACAD SCI USA, V98, P3466, DOI 10.1073/pnas.061029798
   Soliman TM, 2000, J VIROL, V74, P7600, DOI 10.1128/JVI.74.16.7600-7609.2000
   Sourvinos G, 2002, EMBO J, V21, P4989, DOI 10.1093/emboj/cdf458
   SRINIVASAKUMAR N, 1991, J VIROL, V65, P4063
   Steckel JS, 2004, ANGEW CHEM INT EDIT, V43, P2154, DOI 10.1002/anie.200453728
   STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021
   Stroffekova K, 2001, PFLUG ARCH EUR J PHY, V442, P859, DOI 10.1007/s004240100619                                                           
   Sugimoto K, 2008, J VIROL, V82, P5198, DOI 10.1128/JVI.02681-07
   Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657                                                           
   Swanstrom R., 1990, VIROLOGY, V1, P175
   van der Schaar HM, 2007, J VIROL, V81, P12019, DOI 10.1128/JVI.00300-07
   Wahl-Jensen V, 2005, J VIROL, V79, P2413, DOI 10.1128/JVI79.4.2413-2419.2005
   Ward BM, 2001, J VIROL, V75, P4802, DOI 10.1128/JVI.75.10.4802-4813.2001                                                
   Warrington KH, 2004, J VIROL, V78, P6595, DOI 10.1128/JVI.78.12.6595-6609.2004
   Wei B, 2009, BIOMED PHARMACOTHER, V63, P313, DOI 10.1016/j.biopha.2008.07.086
   Wei HJ, 2011, VACCINE, V29, P7163, DOI 10.1016/j.vaccine.2011.05.077
   WELDON RA, 1993, J VIROL, V67, P5550
   Welsch S, 2007, FEBS LETT, V581, P2089, DOI 10.1016/j.febslet.2007.03.060
   Whitt MA, 2011, METHODS, V55, P127, DOI 10.1016/j.ymeth.2011.09.002
   Willard M, 2002, J VIROL, V76, P5220, DOI 10.1128/JVI.76.10.5220.5232.2002
   WILLS JW, 1994, J VIROL, V68, P6605
   Wu M, 2005, NANOMED-NANOTECHNOL, V1, P67, DOI 10.1016/j.nano.2004.11.011
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xiao W, 2002, J VIROL, V76, P11505, DOI 10.1128/JVI.76.22.11505-11517.2002
   Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251                                                     
   Yin SH, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-166
   Yoo L, 2012, BIOMATERIALS, V33, P6194, DOI 10.1016/j.biomaterials.2012.05.028
   YOSHIMURA A, 1984, J VIROL, V51, P497
   You JO, 2006, INT J NANOMED, V1, P59, DOI 10.2147/nano.2006.1.1.59
   YUAN X, 1993, J VIROL, V67, P6387
   ZAVADA J, 1972, J GEN VIROL, V15, P183, DOI 10.1099/0022-1317-15-3-183
   Zhang SLX, 2010, J VIROL METHODS, V167, P172, DOI 10.1016/j.jviromet.2010.04.001
   Zhang W, 1998, VIROLOGY, V243, P423, DOI 10.1006/viro.1998.9050                                                          
   Zhang Y, 2007, CELL IMMUNOL, V247, P18, DOI 10.1016/j.cellimm.2007.07.003
   Zhao QH, 2011, BIOCONJUGATE CHEM, V22, P346, DOI 10.1021/bc1002532
   ZHOU J, 1991, VIROLOGY, V185, P251, DOI 10.1016/0042-6822(91)90772-4
   Zhou P, 2012, ANGEW CHEM INT EDIT, V51, P670, DOI 10.1002/anie.201105701
   ZHOU WJ, 1994, J VIROL, V68, P2556
   Zola H., 2007, LEUCOCYTE SROMAL CEL
   Volkin D. B., 2001, U. S. Patent, Patent No. [6245568, 6,245,568]
NR 174
TC 4
Z9 4
U1 1
U2 32
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1424-8220
J9 SENSORS-BASEL
JI Sensors
PD JUL
PY 2013
VL 13
IS 7
BP 8722
EP 8749
DI 10.3390/s130708722
PG 28
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 274NI
UT WOS:000328612800037
PM 23881135
OA gold
DA 2018-01-05
ER

PT J
AU Shafagati, N
   Narayanan, A
   Baer, A
   Fite, K
   Pinkham, C
   Bailey, C
   Kashanchi, F
   Lepene, B
   Kehn-Hall, K
AF Shafagati, Nazly
   Narayanan, Aarthi
   Baer, Alan
   Fite, Katherine
   Pinkham, Chelsea
   Bailey, Charles
   Kashanchi, Fatah
   Lepene, Benjamin
   Kehn-Hall, Kylene
TI The Use of NanoTrap Particles as a Sample Enrichment Method to Enhance
   the Detection of Rift Valley Fever Virus
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID HYDROGEL PARTICLES; PATHOGENESIS; CONCENTRATE; ATTENUATION; BIOMARKERS;
   VECTORS; STRAIN
AB Background: Rift Valley Fever Virus (RVFV) is a zoonotic virus that is not only an emerging pathogen but is also considered a biodefense pathogen due to the threat it may cause to public health and national security. The current state of diagnosis has led to misdiagnosis early on in infection. Here we describe the use of a novel sample preparation technology, NanoTrap particles, to enhance the detection of RVFV. Previous studies demonstrated that NanoTrap particles lead to both 100 percent capture of protein analytes as well as an improvement of more than 100-fold in sensitivity compared to existing methods. Here we extend these findings by demonstrating the capture and enrichment of viruses.
   Results: Screening of NanoTrap particles indicated that one particle, NT53, was the most efficient at RVFV capture as demonstrated by both qRT-PCR and plaque assays. Importantly, NT53 capture of RVFV resulted in greater than 100-fold enrichment from low viral titers when other diagnostics assays may produce false negatives. NT53 was also capable of capturing and enhancing RVFV detection from serum samples. RVFV that was inactivated through either detergent or heat treatment was still found bound to NT53, indicating the ability to use NanoTrap particles for viral capture prior to transport to a BSL-2 environment. Furthermore, both NP-40-lysed virus and purified RVFV RNA were bound by NT53. Importantly, NT53 protected viral RNA from RNase A degradation, which was not observed with other commercially available beads. Incubation of RVFV samples with NT53 also resulted in increased viral stability as demonstrated through preservation of infectivity at elevated temperatures. Finally, NanoTrap particles were capable of capturing VEEV and HIV, demonstrating the broad applicability of NanoTrap particles for viral diagnostics.
   Conclusion: This study demonstrates NanoTrap particles are capable of capturing, enriching, and protecting RVFV virions. Furthermore, the use of NanoTrap particles can be extended to a variety of viruses, including VEEV and HIV.
C1 [Shafagati, Nazly; Narayanan, Aarthi; Baer, Alan; Fite, Katherine; Pinkham, Chelsea; Bailey, Charles; Kashanchi, Fatah; Kehn-Hall, Kylene] George Mason Univ, Natl Ctr Biodef & Infect Dis, Manassas, VA USA.
   [Lepene, Benjamin] Ceres Nanosci, Manassas, VA USA.
RP Shafagati, N (reprint author), George Mason Univ, Natl Ctr Biodef & Infect Dis, Manassas, VA USA.
EM kkehnhal@gmu.edu
RI Kehn-Hall, Kylene/I-5752-2013
OI Kehn-Hall, Kylene/0000-0001-8036-7213
FU National Center for Foreign Animal and Zoonotic Diseases Defense (FAZD
   Center), Texas AM/DHS; FAZD Center, HS-STEM Career Development Program;
   U.S. Department of Homeland Security [20011-ST-104-000002]
FX This work was supported by a grant from The National Center for Foreign
   Animal and Zoonotic Diseases Defense (FAZD Center), Texas A&M/DHS to BL
   and KKH. NS was supported through a graduate student fellowship provided
   through the FAZD Center, HS-STEM Career Development Program. This
   material is based upon work supported by the U.S. Department of Homeland
   Security under Grant Award Number 20011-ST-104-000002. The views and
   conclusions contained in this document are those of the authors and
   should not be interpreted as necessarily representing the official
   policies, either expressed or implied, of the U.S. Department of
   Homeland Security. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bouloy Michele, 2010, Open Virol J, V4, P8, DOI 10.2174/1874357901004020008
   Darsie R. F., 2005, IDENTIFICATION GEOGR
   Douglas TA, 2011, BIOMATERIALS, V32, P1157, DOI 10.1016/j.biomaterials.2010.10.004
   Ikegami T, 2011, VIRUSES-BASEL, V3, P493, DOI 10.3390/v3050493
   Kassab A, 2000, J CHROMATOGR B, V746, P123, DOI 10.1016/S0378-4347(00)00311-X                                                   
   KINNEY RM, 1993, J VIROL, V67, P1269
   LaBeaud AD, 2011, AM J TROP MED HYG, V84, P641, DOI 10.4269/ajtmh.2011.10-0187
   Longo C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004763
   Luchini A, 2008, NANO LETT, V8, P350, DOI 10.1021/nl072174l
   Luchini A, 2009, J MATER CHEM, V19, P5071, DOI 10.1039/b822264a
   Mansuroglu Z, 2010, J VIROL, V84, P928, DOI 10.1128/JVI.01165-09
   Paweska JT, 2005, J VIROL METHODS, V127, P10, DOI 10.1016/j.jviromet.2005.02.008
   Pepin M, 2010, VET RES, V41, DOI 10.1051/vetres/2010033
   PEREZ VL, 1991, J IMMUNOL, V147, P3145
   Tamburro D, 2011, J AM CHEM SOC, V133, P19178, DOI 10.1021/ja207515j
   Vialat P, 1997, VIRUS RES, V52, P43, DOI 10.1016/S0168-1702(97)00097-X
   WILSON ML, 1994, AM J TROP MED HYG, V50, P663, DOI 10.4269/ajtmh.1994.50.663                                                       
NR 17
TC 8
Z9 8
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2013
VL 7
IS 7
AR e2296
DI 10.1371/journal.pntd.0002296
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 190EJ
UT WOS:000322321500013
PM 23861988
OA gold
DA 2018-01-05
ER

PT J
AU Kim, JM
   Shin, E
   Ryou, SM
   Yeom, JH
   Lee, K
AF Kim, Jong-Myung
   Shin, Eunkyoung
   Ryou, Sang-Mi
   Yeom, Ji-Hyun
   Lee, Kangseok
TI Gene delivery platforms
SO BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
LA English
DT Review
DE gene delivery system; GDS; nanoparticle; viral GDS; non-viral GDS
ID RECOMBINANT ADENOASSOCIATED VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   MODIFIED GOLD NANOPARTICLES; SMALL INTERFERING RNA;
   LOW-MOLECULAR-WEIGHT; HEPATOCYTES IN-VIVO; CATIONIC LIPOSOMES; SIRNA
   DELIVERY; DNA DELIVERY; TRANSFECTION EFFICIENCY
AB One of the key challenges in the experimental and therapeutic use of gene delivery agents is the development of methods that can efficiently deliver nucleic acids into living systems. During the past decade, the development of effective and safe gene delivery systems has been intensively investigated. This review summarizes the current state of gene delivery methods based on viral and non-viral agents.
C1 [Kim, Jong-Myung] JM ENB, Life & Environm Res Ctr, Gwangmyung 423795, South Korea.
   [Kim, Jong-Myung; Shin, Eunkyoung; Ryou, Sang-Mi; Yeom, Ji-Hyun; Lee, Kangseok] Chung Ang Univ, Dept Life Sci, Seoul 156756, South Korea.
RP Kim, JM (reprint author), JM ENB, Life & Environm Res Ctr, Gwangmyung 423795, South Korea.
EM jihyun82@cau.ac.kr; kangseok@cau.ac.kr
FU Chung-Ang University
FX This study was supported by funding from the Young Investigator Research
   Program of Chung-Ang University in 2010.
CR Belting M, 1999, BIOCHEM J, V342, P281, DOI 10.1042/0264-6021:3420281                                                       
   BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802
   Blau S, 2000, CRIT REV THER DRUG, V17, P425
   Blessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488
   Bottini M, 2011, BIOMACROMOLECULES, V12, P3381, DOI 10.1021/bm201020h
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Carpenter DE, 1996, HUM GENE THER, V7, P1447, DOI 10.1089/hum.1996.7.12-1447
   Chen GH, 2009, BIOMATERIALS, V30, P1962, DOI 10.1016/j.biomaterials.2008.12.043
   Chia MC, 2004, MOL THER, V9, P804, DOI 10.1016/j.ymthe.2004.03.016
   Dobson J, 2006, GENE THER, V13, P283, DOI 10.1038/sj.gt.3302720
   Dokka S, 2000, PHARMACEUT RES, V17, P521, DOI 10.1023/A:1007504613351
   ElOuahabi A, 1997, FEBS LETT, V414, P187, DOI 10.1016/S0014-5793(97)00973-3
   Filion MC, 1998, INT J PHARM, V162, P159, DOI 10.1016/S0378-5173(97)00423-7                                                   
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Follenzi A, 2002, HUM GENE THER, V13, P243, DOI 10.1089/10430340252769770
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7
   Gao X., 2007, AAPS J, V9, P92
   Giljohann DA, 2007, NANO LETT, V7, P3818, DOI [10.1021/nl072471q, 10.1021/nl07247lq]
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Guissouma H, 2006, NEUROSCI LETT, V406, P240, DOI 10.1016/j.neulet.2006.07.041
   Guo QF, 2011, INT J NANOMED, V6, P1641, DOI 10.2147/IJN.S21141
   Guo ST, 2010, ACS NANO, V4, P5505, DOI 10.1021/nn101638u
   Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616                                                            
   HART SL, 1995, GENE THER, V2, P552
   Hashida M, 1998, J CONTROL RELEASE, V53, P301, DOI 10.1016/S0168-3659(97)00263-0
   Heller L.C., 2005, AAPS J, V2, P255
   Huh MS, 2010, J CONTROL RELEASE, V144, P134, DOI 10.1016/j.jconrel.2010.02.023
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Ji AM, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/40/405103
   Kim JH, 2010, CHEM COMMUN, V46, P4151, DOI 10.1039/c0cc00103a
   Kim YJ, 2012, J MATER CHEM, V22, P25036, DOI 10.1039/c2jm34047j
   Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
   Kong WH, 2012, PHARM RES-DORDR, V29, P362, DOI 10.1007/s11095-011-0554-y
   Kumar S, 2008, NAT PROTOC, V3, P314, DOI 10.1038/nprot.2008.1
   Lee H, 2011, ANAL BIOANAL CHEM, V400, P535, DOI 10.1007/s00216-011-4770-4
   Li J, 2010, J CONTROL RELEASE, V142, P416, DOI 10.1016/j.jconrel.2009.11.008
   Li S., 1999, AM J PHYSIOL, V276, P796
   Loisel S, 2001, HUM GENE THER, V12, P685, DOI 10.1089/104303401300057405                                                      
   Lu ZX, 2011, INT J NANOMED, V6, P1661, DOI 10.2147/IJN.S22293
   Lundstrom K, 2003, TECHNOL CANCER RES T, V2, P471, DOI 10.1177/153303460300200513                                                      
   Manservigi Roberto, 2010, Open Virol J, V4, P123, DOI 10.2174/1874357901004030123
   Meir Yaa-Jyuhn James, 2011, Chang Gung Med J, V34, P565
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921
   Namiki Y, 2009, NAT NANOTECHNOL, V4, P598, DOI [10.1038/nnano.2009.202, 10.1038/NNANO.2009.202]
   O'Brien J, 2002, BRAIN RES PROTOC, V10, P12
   Ofek P, 2010, FASEB J, V24, P3122, DOI 10.1096/fj.09-149641
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Podesta JE, 2009, SMALL, V5, P1176, DOI 10.1002/smll.200801572
   Prasad TK, 2005, CELL MOL BIOL LETT, V10, P203
   Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m
   Rainov NG, 2003, J NEURO-ONCOL, V65, P227, DOI 10.1023/B:NEON.0000003652.71665.f2
   ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Ryou SM, 2010, BIOCHEM BIOPH RES CO, V398, P542, DOI 10.1016/j.bbrc.2010.06.115
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj/gt/3301624
   SCHMID G, 1992, CHEM REV, V92, P1709, DOI 10.1021/cr00016a002                                                             
   Taetz S, 2009, OLIGONUCLEOTIDES, V19, P103, DOI 10.1089/oli.2008.0168
   Talaei F, 2011, INT J NANOMED, V6, P1963, DOI 10.2147/IJN.S22731
   WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477                                                          
   Wendtner CM, 2002, BLOOD, V100, P1655
   Wright JF, 2003, CURR OPIN DRUG DI DE, V6, P174
   Yang J, 2008, LANGMUIR, V24, P3417, DOI 10.1021/la701688t
   YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568
   Yang Y, 1996, GENE THER, V3, P137
   Yao H, 2009, BIOMATERIALS, V30, P5793, DOI 10.1016/j.biomaterials.2009.06.051
   YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194                                                         
   Zhu SG, 2004, BIOTECHNOL APPL BIOC, V39, P179, DOI 10.1042/BA20030077                                                              
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
   Zong CH, 2011, ANAL CHEM, V83, P3126, DOI 10.1021/ac2001324
NR 77
TC 5
Z9 5
U1 0
U2 56
PU KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
PI SEOUL
PA KOREAN SCIENCE TECHNOLOGY CENTER, #704 YEOGSAM-DONG, KANGNAM-KU, SEOUL
   135-703, SOUTH KOREA
SN 1226-8372
J9 BIOTECHNOL BIOPROC E
JI Biotechnol. Bioprocess Eng.
PD JUL
PY 2013
VL 18
IS 4
BP 637
EP 647
DI 10.1007/s12257-012-0546-8
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 202UH
UT WOS:000323244600002
DA 2018-01-05
ER

PT J
AU Yang, SQ
   Pannecouque, C
   Daelemans, D
   Ma, XD
   Liu, Y
   Chen, FE
   De Clercq, E
AF Yang, Shiqiong
   Pannecouque, Christophe
   Daelemans, Dirk
   Ma, Xiao-Dong
   Liu, Yang
   Chen, Fen-Er
   De Clercq, Erik
TI Molecular design, synthesis and biological evaluation of BP-O-DAPY and
   O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase
   inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1; NNRTIs; Diarylpyrimidine; Benzophenone; Molecular hybridization;
   Antiviral activity
ID COLORIMETRIC ASSAY; CRYSTAL-STRUCTURES; POTENT; NNRTIS; GENERATION;
   DISCOVERY; ANALOGS; SEARCH; HYBRIDIZATION; FLEXIBILITY
AB This paper reports the synthesis and antiviral evaluation of a series of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that combine the peculiar structural features of diarylpyrimidine derivatives (DAPYs) and benzophenone derivatives (BPs). The DAPY derivatives bearing benzoyl or alkoxyl substitutes on the A-ring showed the inhibitory activity against wild-type HIV-1 at the cellular level within the range of EC50 values from micromolar to nanomolar. Among these compounds, 1u exhibited the most potent anti-HIV-1 activity (EC50 = 0.06 +/- 0.01 mu M, SI > 6260), which were about 1.8-fold more active than nevirapine (NVP) and delavirdine (DLV). In addition, the binding modes with HIV-1 RI and the preliminary SAR studies of these derivatives were also considered for further investigation. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Yang, Shiqiong; Ma, Xiao-Dong; Liu, Yang; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Pannecouque, Christophe; Daelemans, Dirk; De Clercq, Erik] Rega Inst Med Res KU Leuven, B-3000 Louvain, Belgium.
RP Chen, FE (reprint author), Fudan Univ, Dept Chem, 220 Handan Rd, Shanghai 200433, Peoples R China.
EM rfchen@fudan.edu.cn
RI Daelemans, Dirk/P-7923-2017
OI Daelemans, Dirk/0000-0001-7092-1153
FU China Postdoctoral Science Foundation [2012M511046]; National Natural
   Science Foundation of China [20872018, 81172918]
FX This work was supported in part by grants from the General Financial
   Grant from the China Postdoctoral Science Foundation (No. 2012M511046)
   and the National Natural Science Foundation of China (No. 20872018 and
   No. 81172918). We would like to thank Jun Wang for MS and Dr. Wen-Xue
   Chen for running the NMR spectra. We are indebted to Kristien Erven,
   Cindy Heens and Kris Uyttersprot for evaluating the compounds for their
   antiviral activity.
CR Auwerx J, 2002, MOL PHARMACOL, V61, P400, DOI 10.1124/mol.61.2.400                                                            
   Chen JZ, 2007, J CHEM INF MODEL, V47, P1626, DOI 10.1021/ci7000814
   Chen XW, 2012, EUR J MED CHEM, V51, P60, DOI 10.1016/j.ejmech.2012.02.019
   Chen XW, 2011, CURR MED CHEM, V18, P359, DOI 10.2174/092986711794839142                                                      
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   Feng XQ, 2009, CHEMMEDCHEM, V4, P219, DOI 10.1002/cmdc.200800334
   Jain AN, 2007, J COMPUT AID MOL DES, V21, P281, DOI 10.1007/s10822-007-9114-2
   Lansdon EB, 2010, J MED CHEM, V53, P4295, DOI 10.1021/jm1002233
   Liu Q, 2007, J MED CHEM, V50, P5392, DOI 10.1021/jm070750k
   Ma XD, 2011, BIOORGAN MED CHEM, V19, P4704, DOI 10.1016/j.bmc.2011.07.003
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Park J, 2011, B KOREAN CHEM SOC, V32, P1241, DOI 10.5012/bkcs.2011.32.4.1241
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Ren J, 2008, J MED CHEM, V51, P5000, DOI 10.1021/jm8004493
   Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m                                                               
   Reynolds C, 2012, CHEM SOC REV, V41, P4657, DOI 10.1039/c2cs35058k
   Ribone SR, 2012, EUR J MED CHEM, V58, P485, DOI 10.1016/j.ejmech.2012.10.036
   Ribone SR, 2011, J CHEM INF MODEL, V51, P130, DOI 10.1021/ci1001636
   Romines KR, 2006, J MED CHEM, V49, P727, DOI 10.1021/jm0506701
   Ruppert J, 1997, PROTEIN SCI, V6, P524
   Sahlberg Christer, 2008, Anti-Infective Agents in Medicinal Chemistry, V7, P101, DOI 10.2174/187152108783954597
   Singer VL, 1997, ANAL BIOCHEM, V249, P228, DOI 10.1006/abio.1997.2177
   Terasaka T, 2004, J AM CHEM SOC, V126, P34, DOI 10.1021/ja0386061
   Viegas-Junior C, 2007, CURR MED CHEM, V14, P1829
   Zhan P., 2011, MED RES REV, DOI [10.1002/med.20241, DOI 10.1002/MED.20241]
   Zhang Zhijun, 2004, Antiviral Chemistry & Chemotherapy, V15, P121
NR 28
TC 11
Z9 12
U1 2
U2 18
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUL
PY 2013
VL 65
BP 134
EP 143
DI 10.1016/j.ejmech.2013.04.052
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 197KM
UT WOS:000322850100014
PM 23707918
DA 2018-01-05
ER

PT J
AU Darini, CY
   Martin, P
   Azoulay, S
   Drici, MD
   Hofman, P
   Obba, S
   Dani, C
   Ladoux, A
AF Darini, C. Y.
   Martin, P.
   Azoulay, S.
   Drici, M-D
   Hofman, P.
   Obba, S.
   Dani, C.
   Ladoux, A.
TI Targeting cancer stem cells expressing an embryonic signature with
   anti-proteases to decrease their tumor potential
SO CELL DEATH & DISEASE
LA English
DT Article
DE cancer stem cells; HIV-protease inhibitors; stemness signature;
   apoptosis; Oct-4
ID ENDOPLASMIC-RETICULUM STRESS; IMMUNODEFICIENCY-VIRUS PROTEASE;
   ANTIRETROVIRAL THERAPY; IN-VITRO; INHIBITOR INDINAVIR; INITIATING CELLS;
   HUMAN ADIPOCYTES; ADIPOSE-TISSUE; GROWTH ARREST; SELF-RENEWAL
AB Cancer stem cells (CSCs) are a specific subset of cancer cells that sustain tumor growth and dissemination. They might represent a significant treatment target to reduce malignant progression and prevent tumor recurrence. In solid tumors, several hierarchically organized CSC clones coexist, even within a single tumor. Among them, CSCs displaying an embryonic stem cell 'stemness' signature, based on the expression of Oct-4, Nanog and Sox2, are present in distinct high-grade tumor types associated with poor prognosis. We previously designed a model to isolate pure populations of these CSCs from distinct solid tumors and used it to screen for molecules showing selective toxicity for this type of CSC. Here we show that human immunodeficiency virus (HIV)-protease inhibitors (HIV-PIs) specifically target CSCs expressing an embryonic signature derived from tumors with distinct origins. They reduced proliferation in a dose-dependent manner with a higher specificity as compared with the total population of cancer cells and/or healthy stem cells, and they were efficient in inducing cell death. Lopinavir was the most effective HIV-PI among those tested. It reduced self-renewal and induced apoptosis of CSCs, subsequently impairing in vivo CSC-induced allograft formation. Two key pharmacophores in the LPV structure were also identified. They are responsible for the specificity of CSC targeting and also for the overall antitumoral activity. These results contribute to the identification of molecules presenting selective toxicity for CSCs expressing an embryonic stemness signature. This paves the way to promising therapeutic opportunities for patients suffering from solid cancer tumors of poor prognosis.
C1 [Darini, C. Y.; Martin, P.; Obba, S.; Dani, C.; Ladoux, A.] CNRS, iBV, F-06107 Nice, France.
   [Darini, C. Y.; Martin, P.; Obba, S.; Dani, C.; Ladoux, A.] Univ Nice Sophia Antipolis, iBV, F-06107 Nice 2, France.
   [Azoulay, S.] Univ Nice Sophia Antipolis, UMR 7272, Inst Chim Nice, F-06108 Nice, France.
   [Drici, M-D] Univ Nice, Med Ctr Hosp, Dept Pharmacol, F-06002 Nice, France.
   [Hofman, P.] Univ Nice Sophia Antipolis, INSERM ERI 21, EA 4319, F-06107 Nice 2, France.
   [Hofman, P.] Univ Nice Sophia Antipolis, Fac Med, Human Biobank, F-06107 Nice 2, France.
   [Hofman, P.] Univ Nice Sophia Antipolis, CHU Nice, Pasteur Hosp, F-06107 Nice 2, France.
RP Ladoux, A (reprint author), Univ Nice Sophia Antipolis, Inst Biol Valrose, CNRS, 28 Ave Valombrose, F-06107 Nice 2, France.
EM ladoux@unice.fr
RI LADOUX, ANNIE/O-4267-2016; DANI, Christian/G-3639-2014
OI Hofman, Paul/0000-0003-0431-9353; Dani, Christian/0000-0003-3228-0230
FU Institut National du Cancer (INCa) [CT 30008187]; Agence Nationale de
   Recherche sur le SIDA (ANRS) [AO-2013-1]; La Ligue Contre le Cancer
FX We thank our colleagues, for helpful suggestions and discussions. We are
   indebted to, Drs. Pascal Peraldi and Didier Pisani, for a careful
   reading of the manuscript. We acknowledge the expert technical
   assistance of Agnes Loubat with flow cytometry; Franck Paput and
   Cendrine Dubaud with animal care. Our lab receives financial support
   from Institut National du Cancer (INCa; grant number: CT 30008187) and
   from Agence Nationale de Recherche sur le SIDA (ANRS; grant number:
   AO-2013-1). Pauline Martin is recipient of a predoctoral fellowship from
   La Ligue Contre le Cancer.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X
   Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008
   Caron M, 2004, AIDS, V18, P2127, DOI 10.1097/00002030-200411050-00004                                                
   Caron-Debarle M, 2010, CURR PHARM DESIGN, V16, P3352, DOI 10.2174/138161210793563446
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033
   Darini CY, 2012, ONCOGENE, V31, P2438, DOI 10.1038/onc.2011.421
   Dash C, 2003, CRIT REV BIOCHEM MOL, V38, P89, DOI 10.1080/713609213                                                               
   Dean Michael, 2005, Discov Med, V5, P278
   Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505
   Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002
   Djedaini M, 2009, BIOCHEM BIOPH RES CO, V386, P96, DOI 10.1016/j.bbrc.2009.05.148
   Esposito V, 2006, CLIN CANCER RES, V12, P2634, DOI 10.1158/1078-0432.CCR-05-2188
   Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829
   Gavrilov Kseniya, 2012, Yale Journal of Biology and Medicine, V85, P187
   Gill J, 2002, JAIDS-J ACQ IMM DEF, V31, P384, DOI 10.1097/00126334-200212010-00003                                                
   Gills J, 2007, CLIN CANCER RES, V13, P5183, DOI 10.1158/1078-0432.CCR-07-0161
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Ikezoe T, 2004, MOL CANCER THER, V3, P473
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Johnson MD, 2011, J NEURO-ONCOL, V101, P441, DOI 10.1007/s11060-010-0281-y
   Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Marangoni E, 2009, BRIT J CANCER, V100, P918, DOI 10.1038/sj.bjc.6604953
   McLean K, 2009, GYNECOL ONCOL, V112, P623, DOI 10.1016/j.ygyno.2008.11.028
   Monini P, 2004, NAT REV CANCER, V4, P861, DOI 10.1038/nrc1479
   Monini P, 2009, AIDS, V23, P534, DOI 10.1097/QAD.0b013e3283262a8d
   Prot M, 2006, ANTIMICROB AGENTS CH, V50, P3998, DOI 10.1128/ACC.00625-06
   Pyrko P, 2007, CANCER RES, V67, P10920, DOI 10.1158/0008-5471CAN-07-0796
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rodriguez AM, 2005, J EXP MED, V201, P1397, DOI 10.1084/jem.20042224
   Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   Sham HL, 2002, BIOORG MED CHEM LETT, V12, P3101, DOI 10.1016/S0960-894X(02)00643-1                                                   
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039
   Stoner EJ, 2000, ORG PROCESS RES DEV, V4, P264, DOI 10.1021/op990202j
   Sugihara E, 2012, INT J CANCER, V132, P1249
   Thuerauf DJ, 2006, CIRC RES, V99, P275, DOI 10.1161/01.RES.0000233317.70421.03
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
   Vernochet C, 2005, J BIOL CHEM, V280, P2238, DOI 10.1074/jbc.M408687200
   Wdziekonski B, 2003, METHOD ENZYMOL, V365, P268
   Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104
   Yang Y, 2005, CANCER SCI, V96, P425, DOI 10.1111/j.1349-7006.2005.00063.x
   Zhang S, 2009, AM J PHYSIOL-ENDOC M, V296, pE925, DOI 10.1152/ajpendo.90445.2008
NR 56
TC 6
Z9 7
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2013
VL 4
AR e706
DI 10.1038/cddis.2013.206
PG 10
WC Cell Biology
SC Cell Biology
GA 192US
UT WOS:000322512100007
PM 23828569
OA gold
DA 2018-01-05
ER

PT J
AU Billamboz, M
   Suchaud, V
   Bailly, F
   Lion, C
   Demeulemeester, J
   Calmels, C
   Andreola, ML
   Christ, F
   Debyser, Z
   Cotelle, P
AF Billamboz, Muriel
   Suchaud, Virginie
   Bailly, Fabrice
   Lion, Cedric
   Demeulemeester, Jonas
   Calmels, Christina
   Andreola, Marie-Line
   Christ, Frauke
   Debyser, Zeger
   Cotelle, Philippe
TI 4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class
   of HIV-1 Integrase Inhibitors
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; antiretroviral; integrase; 3 ' processing;
   2-hydroxy-1,3-dioxoisoquinoline-4-carboxamide
ID STRAND TRANSFER; STYRYLQUINOLINE DERIVATIVES; REVERSE-TRANSCRIPTASE;
   RESISTANCE PROFILE; DUAL INHIBITORS; IN-VITRO; RALTEGRAVIR;
   S/GSK1349572; DISCOVERY; DESIGN
AB A series of 2-hydroxy-1,3-dioxoisoquinoline-4-carboxamides featuring an N-hydroxyimide chelating functionality was evaluated for their inhibitory properties against human immunodeficiency virus type 1 integrase (HIV-1 IN). Several derivatives displayed low nanomolar IC50 values comparable to that of the clinically used raltegravir. A marked effect of one compound on both primary IN-catalyzed reactions, strand transfer (ST), and 3' processing (3'-P), emphasizes a novel IN inhibition mechanism establishing it as a potential new generation IN inhibitor. Substitution of the 2-hydroxyisoquinoline-1,3-dione scaffold at position 4 by carboxamido, chains was beneficial for antiviral activity since reproducible low micromolar anti-HIV activities were obtained for the first time within this scaffold.
C1 [Billamboz, Muriel; Suchaud, Virginie; Bailly, Fabrice; Lion, Cedric; Cotelle, Philippe] Univ Lille Nord France, F-59000 Lille, France.
   [Billamboz, Muriel; Suchaud, Virginie; Bailly, Fabrice; Lion, Cedric; Cotelle, Philippe] Univ Lille 1 Sci & Technol, EA Chim Mol & Formulat 4478, F-5965S Villeneuve Dascq, France.
   [Demeulemeester, Jonas; Christ, Frauke; Debyser, Zeger] Katholieke Univ Leuven, Mol Virol & Gene Therapy VCTB 5, B-3000 Louvain, Flanders, Belgium.
   [Calmels, Christina; Andreola, Marie-Line] Univ Bordeaux Segalen, CNRS, UMR 5234, F-33076 Bordeaux, France.
RP Bailly, F (reprint author), Univ Lille Nord France, F-59000 Lille, France.
EM fabrice.bailly@univ-lille1.fr
RI Demeulemeester, Jonas/J-6130-2014
OI Demeulemeester, Jonas/0000-0002-2660-2478; BILLAMBOZ,
   Muriel/0000-0003-1486-7206; debyser, zeger/0000-0002-3982-1565
FU le Ministere de l'Enseignement Superieur et de la Recherche Francaise;
   le Centre National de la Recherche Scientifique (CNRS); l'Agence
   Nationale de la Recherche contre le Sida (ANRS); FP7 project CHAARM; IWT
FX This work was financially supported by grants from le Ministere de
   l'Enseignement Superieur et de la Recherche Francaise, le Centre
   National de la Recherche Scientifique (CNRS), and l'Agence Nationale de
   la Recherche contre le Sida (ANRS). Experiments at KU Leuven were funded
   by the FP7 project CHAARM and the IWT.
CR Agapkina J, 2011, ACS MED CHEM LETT, V2, P532, DOI 10.1021/ml200066k
   Al-Mawsawi LQ, 2007, BIOORG MED CHEM LETT, V17, P6472, DOI 10.1016/j.bmcl.2007.09.102
   Billamboz M, 2011, J MED CHEM, V54, P1812, DOI 10.1021/jm1014692
   Billamboz M, 2011, EUR J MED CHEM, V46, P535, DOI 10.1016/j.ejmech.2010.11.033
   Billamboz M, 2009, J HETEROCYCLIC CHEM, V46, P392, DOI 10.1002/jhet.52
   Billamboz M, 2008, J MED CHEM, V51, P7717, DOI 10.1021/jm8007085
   Canducci F, 2011, J INFECT DIS, V204, P1811, DOI 10.1093/infdis/jir636
   Christ F, 2010, NAT CHEM BIOL, V6, P442, DOI 10.1038/nchembio.370
   Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85                                                             
   Desimmie BA, 2013, ACS CHEM BIOL, V8, P1187, DOI 10.1021/cb4000426
   Hare S, 2012, EMBO J, V31, P3020, DOI 10.1038/emboj.2012.118
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Lenz JCC, 2011, EXPERT OPIN INV DRUG, V20, P537, DOI 10.1517/13543784.2011.562189
   Marchand C, 2012, EXPERT OPIN INV DRUG, V21, P901, DOI 10.1517/13543784.2012.685653
   McColl DJ, 2010, ANTIVIR RES, V85, P101, DOI 10.1016/j.antiviral.2009.11.004
   Metifiot M, 2011, ANTIMICROB AGENTS CH, V55, P5127, DOI 10.1128/AAC.05288-11
   Mousnier A, 2004, MOL PHARMACOL, V66, P783, DOI 10.1124/mol.104.001735
   Ramkumar K, 2010, MED RES REV, V30, P890, DOI 10.1002/med.20194
   Serrao E., 2009, RETROVIROLOGY, V6, P1
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Tang J, 2011, ACS MED CHEM LETT, V2, P63, DOI 10.1021/ml1002162
   Witvrouw M, 2004, CURR DRUG METAB, V5, P291, DOI 10.2174/1389200043335487
NR 24
TC 11
Z9 11
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JUL
PY 2013
VL 4
IS 7
BP 41
EP 46
DI 10.1021/ml400009t
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 184IR
UT WOS:000321883800010
OA green_published
DA 2018-01-05
ER

PT J
AU Gemmill, KB
   Muttenthaler, M
   Delehanty, JB
   Stewart, MH
   Susumu, K
   Dawson, PE
   Medintz, IL
AF Gemmill, Kelly Boeneman
   Muttenthaler, Markus
   Delehanty, James B.
   Stewart, Michael H.
   Susumu, Kimihiro
   Dawson, Philip E.
   Medintz, Igor L.
TI Evaluation of diverse peptidyl motifs for cellular delivery of
   semiconductor quantum dots
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Cell-penetrating peptide; Quantum dot; Nanoparticle; Cell; Delivery;
   Endocytosis; Labeling; Nanotechnology; Sweet arrow peptide; Quantum dot;
   Metal affinity
ID BIOCOMPATIBLE SEMICONDUCTOR; INTRACELLULAR DELIVERY; PENETRATING
   PEPTIDES; GOLD NANOPARTICLES; DRUG-DELIVERY; RICH PEPTIDES; HISTIDINE;
   PH; CARRIERS; LIGANDS
AB Cell-penetrating peptides (CPPs) have rapidly become a mainstay technology for facilitating the delivery of a wide variety of nanomaterials to cells and tissues. Currently, the library of CPPs to choose from is still limited, with the HIV TAT-derived motif still being the most used. Among the many materials routinely delivered by CPPs, nanoparticles are of particular interest for a plethora of labeling, imaging, sensing, diagnostic, and therapeutic applications. The development of nanoparticle-based technologies for many of these uses will require access to a much larger number of functional peptide motifs that can both facilitate cellular delivery of different types of nanoparticles to cells and be used interchangeably in the presence of other peptides and proteins on the same surface. Here, we evaluate the utility of four peptidyl motifs for their ability to facilitate delivery of luminescent semiconductor quantum dots (QDs) in a model cell culture system. We find that an LAH4 motif, derived from a membrane-inserting antimicrobial peptide, and a chimeric sequence that combines a sweet arrow peptide with a portion originating from the superoxide dismutase enzyme provide effective cellular delivery of QDs. Interestingly, a derivative of the latter sequence lacking just a methyl group was found to be quite inefficient, suggesting that even small changes can have significant functional outcomes. Delivery was effected using 1 h incubation with cells, and fluorescent counterstaining strongly suggests an endosomal uptake process that requires a critical minimum number or ratio of peptides to be displayed on the QD surface. Concomitant cytoviability testing showed that the QD-peptide conjugates are minimally cytotoxic in the model COS-1 cell line tested. Potential applications of these peptides in the context of cellular delivery of nanoparticles and a variety of other (bio)molecules are discussed.
C1 [Gemmill, Kelly Boeneman; Delehanty, James B.; Medintz, Igor L.] US Naval Res Lab, Ctr Bio Mol Sci & Engn Code 6900, Washington, DC 20375 USA.
   [Stewart, Michael H.; Susumu, Kimihiro] US Naval Res Lab, Div Opt Sci Code 5600, Washington, DC 20375 USA.
   [Muttenthaler, Markus; Dawson, Philip E.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Muttenthaler, Markus; Dawson, Philip E.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
   [Susumu, Kimihiro] Sotera Def Solut, Annapolis Jct, MD 20701 USA.
RP Medintz, IL (reprint author), US Naval Res Lab, Ctr Bio Mol Sci & Engn Code 6900, Washington, DC 20375 USA.
EM igor.medintz@nrl.navy.mil
RI Muttenthaler, Markus/B-4944-2017
OI Muttenthaler, Markus/0000-0003-1996-4646
FU NRL NSI; DTRA JSTO MIPR [B112582M]; European Union [254897]
FX The authors acknowledge NRL NSI and DTRA JSTO MIPR # B112582M for
   financial support. M.M. acknowledges funding from the European Union
   Seventh Framework Programme (FP7/2007-2013) under grant agreement number
   254897.
CR Algar WR, 2011, ANAL CHEM, V83, P8826, DOI 10.1021/ac201331r
   Algar WR, 2009, BIOCONJUGATE CHEM, V22, P825
   Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614
   Blanco-Canosa JB, 2010, J AM CHEM SOC, V132, P10027, DOI 10.1021/ja910988d
   Boeneman K, 2010, J AM CHEM SOC, V132, P18177, DOI 10.1021/ja106465x
   Boeneman K, 2010, ACS NANO, V4, P7253, DOI 10.1021/nn1021346
   Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8
   Crespo L, 2002, J AM CHEM SOC, V124, P8876, DOI 10.1021/ja020364m
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Delehanty JB, 2010, THER DELIV, V1, P411, DOI 10.4155/TDE.10.27
   Delehanty JB, 2010, INTEGR BIOL-UK, V2, P265, DOI 10.1039/c0ib00002g
   Delehanty JB, 2009, EXPERT OPIN DRUG DEL, V6, P1091, DOI 10.1517/17425240903167934
   Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4
   Dennis AM, 2010, BIOCONJUGATE CHEM, V21, P1160, DOI 10.1021/bc900500m
   Duncan R, 2012, MOL PHARMACEUT, V9, P2380, DOI 10.1021/mp300293n
   Fernandez-Carneado J, 2004, BIOPOLYMERS, V76, P196, DOI 10.1002/bip.10585
   Fernandez-Carneado J, 2004, ANGEW CHEM INT EDIT, V43, P1811, DOI 10.1002/anie.200352540
   Boeneman Gemmill K, 2013, ACS NANO IN PRESS
   Gemmill KB, 2013, BIOCONJUGATE CHEM, V24, P269, DOI 10.1021/bc300644p
   Ho YP, 2010, NANOSCALE, V2, P60, DOI 10.1039/b9nr00178f
   Janib SM, 2010, ADV DRUG DELIVER REV, V62, P1052, DOI 10.1016/j.addr.2010.08.004
   Leng QX, 2005, J GENE MED, V7, P977, DOI 10.1002/jgm.748
   Licht SS, 2003, BIOCHEMISTRY-US, V42, P2916, DOI 10.1021/bi026059v
   Liu W, 2008, J AM CHEM SOC, V130, P1274, DOI 10.1021/ja076069p
   Lo SL, 2008, BIOMATERIALS, V29
   Mason AJ, 2006, ANTIMICROB AGENTS CH, V50, P3305, DOI 10.1128/AAC.00490-06
   Medintz IL, 2008, BIOCONJUGATE CHEM, V19, P1785, DOI 10.1021/bc800089r
   Mei BC, 2008, J MATER CHEM, V18, P4949, DOI 10.1039/b810488c
   Mei BC, 2009, NAT PROTOC, V4, P412, DOI 10.1038/nprot.2008.243
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Midoux P, 2009, BRIT J PHARMACOL, V157, P166, DOI 10.1111/j.1476-5381.2009.00288.x
   Oh E, 2011, ACS NANO, V5, P6434, DOI 10.1021/nn201624c
   Prasuhn DE, 2010, SMALL, V6, P555, DOI 10.1002/smll.200901845
   Sapsford KE, 2007, J PHYS CHEM C, V111, P11528, DOI 10.1021/jp073550t
   Sapsford KE, 2013, CHEM REV, V113, P1904, DOI 10.1021/cr300143v
   Sapsford KE, 2011, ACS NANO, V5, P2687, DOI 10.1021/nn102997b
   Sapsford KE, 2009, SENSOR ACTUAT B-CHEM, V139, P13, DOI 10.1016/j.snb.2008.07.026
   Susumu K, 2011, J AM CHEM SOC, V133, P9480, DOI 10.1021/ja201919s
   Vogt TCB, 1999, J BIOL CHEM, V274, P29115, DOI 10.1074/jbc.274.41.29115
   Walters R, 2012, ASN NEURO, V4, DOI 10.1042/AN20120042
NR 41
TC 13
Z9 13
U1 2
U2 61
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD JUL
PY 2013
VL 405
IS 19
BP 6145
EP 6154
DI 10.1007/s00216-013-6982-2
PG 10
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 177OM
UT WOS:000321384700002
PM 23732866
DA 2018-01-05
ER

PT J
AU das Neves, J
   Araujo, F
   Andrade, F
   Michiels, J
   Arien, KK
   Vanham, G
   Amiji, M
   Bahia, MF
   Sarmento, B
AF das Neves, Jose
   Araujo, Francisca
   Andrade, Fernanda
   Michiels, Johan
   Arien, Kevin K.
   Vanham, Guido
   Amiji, Mansoor
   Bahia, Maria Fernanda
   Sarmento, Bruno
TI In Vitro and Ex Vivo Evaluation of Polymeric Nanoparticles for Vaginal
   and Rectal Delivery of the Anti-HIV Drug Dapivirine
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE poly(epsilon-caprolactone); surface modifiers; nanomedicine; HIV/AIDS;
   antiretroviral; microbicides
ID REVERSE-TRANSCRIPTASE INHIBITORS; ANTIRETROVIRAL PREEXPOSURE
   PROPHYLAXIS; FEMALE REPRODUCTIVE-TRACT; INTRACELLULAR DELIVERY;
   MICROBICIDE GEL; NEGATIVE WOMEN; HPLC METHOD; PERMEABILITY; PREVENTION;
   MUCOSA
AB Prevention strategies such as the development of microbicides are thought to be valuable in the fight against HIV/AIDS. Despite recent achievements, there is still a long road ahead in the field, particularly at the level of drug formulation. Drug nanocarriers based on polymers may be useful in enhancing local drug delivery while limiting systemic exposure. We prepared differently surface-engineered poly(epsilon-caprolactone) (PCL) nanoparticles (NPs) and tested their ability to modulate the permeability and retention of dapivirine in cell monolayers and pig vaginal and rectal mucosa. NPs coated with poly(ethylene oxide) (PEO) were shown able to reduce permeability across monolayers/tissues, while modification of nanosystems with cetyl trimethylammonium bromide (CTAB) enhanced transport. In the case of coating NPs with sodium lauryl sulfate (SI,S), dapivirine permeability was unchanged. All NPs increased monolayer/tissue drug retention as compared to unformulated dapivirine. This fact was associated, at least partially, to the ability of NPs to be taken up by cells or penetrate mucosal tissue. Cell and tissue toxicity was also affected differently by NPs: PEO modification decreased the in vitro (but not ex vivo) toxicity of dapivirine, while higher toxicity was generally observed for NPs coated with SLS or CTAB. Overall, presented results support that PCL nanoparticles are capable of modulating drug permeability and retention in cell monolayers and mucosal tissues relevant for vaginal and rectal delivery of microbicides. In particular, PEO-modified dapivirine-loaded PCL NPs may be advantageous in increasing drug residence at epithelial cell lines/mucosal tissues, which may potentially increase the efficacy of microbicide drugs.
C1 [das Neves, Jose; Andrade, Fernanda; Bahia, Maria Fernanda; Sarmento, Bruno] Univ Porto, Lab Pharmaceut Technol, Fac Pharm, P-4050313 Oporto, Portugal.
   [das Neves, Jose; Araujo, Francisca; Sarmento, Bruno] Inst Super Ciencias Saude Norte, CICS Ctr Invest Ciencias Saude, Dept Pharmaceut Sci, P-4585116 Gandra, Portugal.
   [Araujo, Francisca; Sarmento, Bruno] INEB Inst Engn Biomed, P-4150180 Oporto, Portugal.
   [Michiels, Johan; Arien, Kevin K.; Vanham, Guido] Inst Trop Med, Dept Microbiol, Virol Unit, B-2000 Antwerp, Belgium.
   [Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP das Neves, J (reprint author), Univ Porto, Lab Pharmaceut Technol, Fac Pharm, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.
EM j.dasneves@gmail.com
RI Sarmento, Bruno/J-6265-2013; Amiji, Mansoor/A-4365-2014; Araujo,
   Francisca/J-8543-2013; das Neves, Jose/J-8369-2013; Andrade,
   Fernanda/F-3272-2010
OI Sarmento, Bruno/0000-0001-5763-7553; Amiji, Mansoor/0000-0001-6170-881X;
   Araujo, Francisca/0000-0001-9087-9941; das Neves,
   Jose/0000-0002-2317-2759; Andrade, Fernanda/0000-0002-4947-2346
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BD/43393/2008]; FCT [VIH/SAU/0021/2011]
FX J.d.N. acknowledges Fundacao para a Ciencia e a Tecnologia (FCT),
   Portugal for financial support (grant SFRH/BD/43393/2008). This work was
   supported by a grant from FCT (VIH/SAU/0021/2011). The authors would
   like to express their gratitude to the following people: W. Fowle at the
   Electron Microscopy Center, Northeastern University, for assistance with
   SEM imaging; C. Ferreira at the University of Beira Interior, Covilha,
   Portugal for histology slides preparation; and M. Salgueirinho at
   Carneiro & Salgueirinho, Lda, Trofa, Portugal, for providing pig mucosa
   samples. Dapivirine was kindly provided by the International Partnership
   for Microbicides (IPM). Dapivirine was originally developed by Tibotec
   Pharmaceuticals and licensed to IPM.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Akil A., 2012, 2012 INT MICR C SYDN
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]
   Antunes F, 2013, EUR J PHARM BIOPHARM, V83, P427, DOI 10.1016/j.ejpb.2012.10.003
   Arien KK, 2011, REV MED VIROL, V21, P110, DOI 10.1002/rmv.684
   Arien K. K., 2011, CURR PROTOCOLS CELL, V26, P26131
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Beer BE, 2006, ANTIMICROB AGENTS CH, V50, P713, DOI 10.1128/AAC.50.2.713-723.2006
   Blaskewicz CD, 2011, BIOL REPROD, V85, P97, DOI 10.1095/biolreprod.110.090423
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   D'Cruz OJ, 2008, J APPL TOXICOL, V28, P303, DOI 10.1002/jat.1280
   Da Violante G, 2002, BIOL PHARM BULL, V25, P1600, DOI 10.1248/bpb.25.1600
   das Neves J, 2012, J CHROMATOGR B, V911, P76, DOI 10.1016/j.jchromb.2012.10.034
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J, 2010, J PHARMACEUT BIOMED, V52, P167, DOI 10.1016/j.jpba.2010.01.007
   Dcruz OJ, 2007, TOXICOL PATHOL, V35, P910, DOI 10.1080/01926230701748115
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Fuchs EJ, 2013, J INFECT DIS, V207, P1389, DOI 10.1093/infdis/jit030
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Gorodeski GI, 1998, AM J PHYSIOL-CELL PH, V275, pC888
   Grammen C, 2012, ANTIVIR RES, V96, P226, DOI 10.1016/j.antiviral.2012.09.011
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Harush-Frenkel O, 2008, BIOMACROMOLECULES, V9, P435, DOI 10.1021/bm700535p
   Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08
   Hjelm BE, 2010, BIOL REPROD, V82, P617, DOI 10.1095/biolreprod.109.080408
   Holpuch AS, 2010, PHARM RES-DORDR, V27, P1224, DOI 10.1007/s11095-010-0121-y
   Hurt CB, 2011, CLIN INFECT DIS, V53, P1265, DOI 10.1093/cid/cir684
   International Partnership for Microbicides, 1 EFF TRIAL MICR RIN
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Keller MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016475
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lewi Paul, 2004, Drugs R D, V5, P245, DOI 10.2165/00126839-200405050-00001
   Lewi P, 2012, CURR HIV RES, V10, P27, DOI 10.2174/157016212799304643
   Microbicides Trials Network, 1 EFF TRIAL MICR RIN
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Nel AA, 2009, AIDS, V23, P1531, DOI 10.1097/QAD.0b013e32832c413d
   Nel AM, 2010, AIDS RES HUM RETROV, V26, P1181, DOI 10.1089/aid.2009.0227
   Nel AM, 2010, JAIDS-J ACQ IMM DEF, V55, P161, DOI 10.1097/QAI.0b013e3181e3293a
   Nicolazzo JA, 2004, J PHARM SCI-US, V93, P431, DOI 10.1002/jps.10559
   Nuttall J., 2012, 2012 INT MICR C SYDN
   Nuttall JP, 2008, ANTIMICROB AGENTS CH, V52, P909, DOI 10.1128/AAC.00330-07
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Richardson-Harman N, 2012, AIDS RES HUM RETROV, V28, P1422, DOI [10.1089/aid.2012.0073, 10.1089/AID.2012.0073]
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Sakloetsakun D, 2010, AAPS PHARMSCITECH, V11, P1185, DOI 10.1208/s12249-010-9479-8
   Sarmento B, 2012, THER DELIV, V3, P1, DOI 10.4155/TDE.11.139
   Sarmento B, 2012, EXPERT OPIN DRUG MET, V8, P607, DOI 10.1517/17425255.2012.673586
   Schmidt C, 1999, J CONTROL RELEASE, V57, P115, DOI 10.1016/S0168-3659(98)00108-4
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Squier CA, 2008, J PHARM SCI-US, V97, P9, DOI 10.1002/jps.21077
   SWENSON ES, 1994, PHARMACEUT RES, V11, P1132, DOI 10.1023/A:1018984731584
   Swindle MM, 1998, SCAND J LAB ANIM S1, V25, P1
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Thompson IOC, 2001, ARCH ORAL BIOL, V46, P1091, DOI 10.1016/S0003-9969(01)00082-6
   van Eyk AD, 2005, INT J PHARM, V305, P105, DOI 10.1016/j.ijpharm.2005.09.002
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Van Herrewege Y, 2007, ANTIVIR RES, V74, P111, DOI 10.1016/j.antiviral.2006.10.010
   World Health Organization/United Nations Population Fund/Family Health International, 2012, US PROC ADD LUBR MAL
   Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
NR 65
TC 28
Z9 28
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL
PY 2013
VL 10
IS 7
BP 2793
EP 2807
DI 10.1021/mp4002365
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 178UD
UT WOS:000321472000028
PM 23738946
DA 2018-01-05
ER

PT J
AU Dellinger, A
   Zhou, ZG
   Connor, J
   Madhankumar, AB
   Pamujula, S
   Sayes, CM
   Kepley, CL
AF Dellinger, Anthony
   Zhou, Zhiguo
   Connor, James
   Madhankumar, A. B.
   Pamujula, Sarala
   Sayes, Christie M.
   Kepley, Christopher L.
TI Application of fullerenes in nanomedicine: an update
SO NANOMEDICINE
LA English
DT Review
DE arthritis; asthma; atherosclerosis; diagnostic; fullerene; glioblastoma;
   multiple sclerosis; theranostic; therapeutic
ID NEPHROGENIC SYSTEMIC FIBROSIS; ANTI-HIV PROPERTIES; MAST-CELLS;
   IN-VITRO; INFLAMMATORY ARTHRITIS; MULTIPLE-SCLEROSIS; OXIDATIVE STRESS;
   TNF-ALPHA; EPOXYEICOSATRIENOIC ACIDS; GLIOBLASTOMA-MULTIFORME
AB Fullerenes are carbon spheres presently being pursued globally for a wide range of applications in nanomedicine. These molecules have unique electronic properties that make them attractive candidates for diagnostic, therapeutic and theranostic applications. Herein, the latest research is discussed on developing fullerene-based therapeutics as antioxidants for inflammatory diseases, their potential as antiviral/bacterial agents, utility as a drug delivery device and the promise of endohedral fullerenes as new MRI contrast agents. The recent discovery that certain fullerene derivatives can stabilize immune effector cells to prevent or inhibit the release of proinflammatory mediators makes them potential candidates for several diseases such as asthma, arthritis and multiple sclerosis. Gadolinium-containing endohedral fullerenes are being pursued as diagnostic MRI contrast agents for several diseases. Finally, a new class of fullerene-based theranostics has been developed, which combine therapeutic and diagnostic capabilities to specifically detect and kill cancer cells.
C1 [Dellinger, Anthony; Pamujula, Sarala; Sayes, Christie M.; Kepley, Christopher L.] Joint Sch Nanosci & Nanoengn, Greensboro, NC 27401 USA.
   [Zhou, Zhiguo] Luna Innovat Inc, NanoWorks Div, Danville, VA 24541 USA.
   [Connor, James; Madhankumar, A. B.] Penn State Univ, Dept Neurosurg, Hershey Med Ctr, Hershey, PA 17033 USA.
   [Sayes, Christie M.] RTI Int, Ctr Aerosol & Nanomat Engn, Res Triangle Pk, NC 27709 USA.
RP Kepley, CL (reprint author), Joint Sch Nanosci & Nanoengn, 2907 East Lee St, Greensboro, NC 27401 USA.
EM clkepley@uncg.edu
RI Sayes, Christie/C-1333-2016
OI Sayes, Christie/0000-0002-5529-4101
FU  [1R01GM083274-01C];  [R21 ESO15696-01A1]
FX CL Kepley has received the following grants: 1R01GM083274-01C and R21
   ESO15696-01A1. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002
   Baati T, 2012, BIOMATERIALS, V33, P4936, DOI 10.1016/j.biomaterials.2012.03.036
   Bakry R, 2007, INT J NANOMED, V2, P639
   Barnaby JF, 2004, NY TIMES
   Basso AS, 2008, J CLIN INVEST, V118, P1532, DOI 10.1172/JCI33464
   Berger CS, 2011, TRANSL ONCOL, V4, P350, DOI 10.1593/tlo.11157
   Bolskar RD, 2008, NANOMEDICINE-UK, V3, P201, DOI 10.2217/17435889.3.2.201
   Borland MK, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-21
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   BRIDGES AJ, 1991, ARTHRITIS RHEUM, V34, P1116, DOI 10.1002/art.1780340907
   Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028
   Brown MA, 2002, MOL IMMUNOL, V38, P1373, DOI 10.1016/S0161-5890(02)00091-3
   Chen HHC, 1998, TOXICOL PATHOL, V26, P143, DOI 10.1177/019262339802600117                                                      
   Chewning RH, 2007, J VASC INTERV RADIOL, V18, P331, DOI 10.1016/j.jvir.2007.01.025
   Chirico F, 2007, EXP DERMATOL, V16, P429, DOI 10.1111/j.1600-0625.2007.00545.x
   Collot-Teixeira S, 2007, CARDIOVASC RES, V75, P468, DOI 10.1016/j.cardiores.2007.03.010
   Cowper Shawn E, 2007, Adv Dermatol, V23, P131, DOI 10.1016/j.yadr.2007.07.002
   Daroczi B, 2006, CLIN CANCER RES, V12, P7086, DOI 10.1158/1078-0432.CCR-06-0514
   Dellinger A, 2010, NANOMED-NANOTECHNOL, V6, P575, DOI 10.1016/j.nano.2010.01.008
   Dellinger A, 2009, EXP DERMATOL, V18, P1079, DOI 10.1111/j.1600-0625.2009.00904.x
   Dinser R, 2008, BEST PRACT RES CL RH, V22, P253, DOI 10.1016/j.berh.2008.01.007
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Dugan LL, 1996, NEUROBIOL DIS, V3, P129, DOI 10.1006/nbdi.1996.0013
   Ehrich M, 2011, TOXICOL IN VITRO, V25, P301, DOI 10.1016/j.tiv.2010.09.010
   Feng LZ, 2011, NANOSCALE, V3, P1252, DOI 10.1039/c0nr00680g
   Fumelli C, 2000, J INVEST DERMATOL, V115, P835, DOI 10.1046/j.1523-1747.2000.00140.x
   Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204
   Ge Yimin, 2005, Lab Hematol, V11, P31, DOI 10.1532/LH96.04056
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Gilgun-Sherki Y, 2004, J NEUROL, V251, P261, DOI 10.1007/s00415-004-0348-9
   Gonzalez KA, 2002, BIOORGAN MED CHEM, V10, P1991, DOI 10.1016/S0968-0896(02)00049-4                                                   
   GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0
   Gotis-Graham I, 1998, ANN RHEUM DIS, V57, P664, DOI 10.1136/ard.57.11.664
   [Anonymous], 2005, NOVART FDN SYMP
   Gregory Greg D, 2005, Novartis Found Symp, V271, P215
   Henry TB, 2011, CURR OPIN BIOTECH, V22, P533, DOI 10.1016/j.copbio.2011.05.511
   Ibrahim M, 2012, MINI-REV MED CHEM, V12, P447, DOI 10.2174/138955712800493762                                                      
   Irani AA, 1987, ARTHRITIS RHEUM, V30, P66
   Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024
   Jaffer FA, 2006, J AM COLL CARDIOL, V47, P1328, DOI 10.1016/j.jacc.2006.01.029
   Jaffer FA, 2006, MOL IMAGING, V5, P85, DOI 10.2310/7290.2006.00009
   KEPLEY CL, 1995, J IMMUNOL, V154, P6548
   Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025                                                    
   Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855                                                     
   Kolovou G, 2008, CURR PHARM DESIGN, V14, P338, DOI 10.2174/138161208783497769
   Kornev AB, 2011, CHEM COMMUN, V47, P8298, DOI 10.1039/c1cc12209f
   Lai YL, 2003, LIFE SCI, V72, P1271, DOI 10.1016/S0024-3205(02)02374-3
   LAVERY JP, 1994, ANN ALLERGY, V72, P425
   Ledneva E, 2009, RADIOLOGY, V250, P618, DOI 10.1148/radiol.2503080253
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Li CB, 2002, PROTEIN ENG, V15, P419, DOI 10.1093/protein/15.5.419
   Li LB, 1999, J NEUROCHEM, V72, P1095, DOI 10.1046/j.1471-4159.1999.0721095.x
   Liu YF, 2007, NAT NANOTECHNOL, V2, P20, DOI 10.1038/nnano.2006.188
   Liu Z, 2011, MATER TODAY, V14, P316, DOI 10.1016/S1369-7021(11)70161-4
   Lu FS, 2009, ADV MATER, V21, P139, DOI 10.1002/adma.200801491
   Luo ZG, 2013, MINI-REV MED CHEM, V13, P1160, DOI 10.2174/1389557511313080004                                                     
   MacFarland DK, 2008, J MED CHEM, V51, P3681, DOI 10.1021/jm800521j
   Madhankumar AB, 2006, MOL CANCER THER, V5, P3162, DOI 10.1158/1535-7163.MCT-06-0480
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Marcorin GL, 2000, ORG LETT, V2, P3955, DOI 10.1021/ol000217y
   McCarthy JR, 2006, SMALL, V2, P983, DOI 10.1002/smll.200600139
   Mody VV, 2009, ADV DRUG DELIVER REV, V61, P795, DOI 10.1016/j.addr.2009.04.020
   Mori T, 2006, TOXICOLOGY, V225, P48, DOI 10.1016/j.tox.2006.05.001
   Morin C, 2008, AM J RESP CELL MOL, V38, P192, DOI 10.1165/rcmb.2007-0232OC
   Morin C, 2007, PROSTAG OTH LIPID M, V82, P30, DOI 10.1016/j.prostaglandins.2006.05.012
   Nergiz-Unal R., 2011, Cardiovascular & Hematological Agents in Medicinal Chemistry, V9, P42, DOI 10.2174/187152511794182855
   Nigrovic P A, 2005, Novartis Found Symp, V271, P200
   Nigrovic PA, 2007, IMMUNOL REV, V217, P19, DOI 10.1111/j.1600-065X.2007.00506.x
   Nitta N, 2008, CARDIOVASC INTER RAD, V31, P359, DOI 10.1007/s00270-007-9238-8
   Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276
   Norton SK, 2012, J ALLERGY CLIN IMMUN, V130, P761, DOI 10.1016/j.jaci.2012.04.023
   Norton SK, 2010, CTS-CLIN TRANSL SCI, V3, P158, DOI 10.1111/j.1752-8062.2010.00212.x
   Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021
   Ouimet T, 2012, MOL PHARMACEUT, V9, P850, DOI 10.1021/mp2003863
   Park JH, 2008, ANGEW CHEM INT EDIT, V47, P7284, DOI 10.1002/anie.200801810
   Park JH, 2008, ADV MATER, V20, P1630, DOI 10.1002/adma.200800004
   Patra CR, 2010, NANOTECHNOLOGY, V1, P13
   Pfister SL, 2010, ADV PHARMACOL, V60, P27, DOI [10.1016/S1054-3589(10)60008-7, 10.1016/B978-0-12-385061-4.00002-7]
   Pitman N, 2011, ANN RHEUM DIS, V70, P1170, DOI 10.1136/ard.2010.134528
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014
   Rancan F, 2002, J PHOTOCH PHOTOBIO B, V67, P157, DOI 10.1016/S1011-1344(02)00320-2                                                   
   Rao CNR, 2001, J MATER CHEM, V11, P2887, DOI 10.1039/b105058n                                                                
   Runge VM, 2009, AM J ROENTGENOL, V192, pW195, DOI 10.2214/AJR.08.1949
   Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665                                                      
   Saathoff JG, 2011, TOXICOL IN VITRO, V25, P2105, DOI 10.1016/j.tiv.2011.09.013
   Sadeghi MM, 2010, J NUCL MED, V51, p51S, DOI [10.2967/numed.109.068163, 10.2967/jnumed.109.068163]
   Schroeder JT, 2009, ADV IMMUNOL, V101, P123, DOI 10.1016/S0065-2776(08)01004-3
   Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813
   Shen H, 2012, THERANOSTICS, V2, P283, DOI 10.7150/thno.3642
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Sudhahar V, 2010, CURR MED CHEM, V17, P1181, DOI 10.2174/092986710790827843                                                      
   Sun Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021073
   Todhunter DA, 2004, PROTEIN ENG DES SEL, V17, P157, DOI 10.1093/protein/gzh023                                                          
   Tsao N, 2002, J ANTIMICROB CHEMOTH, V49, P641, DOI 10.1093/jac/49.4.641
   Uno K, 2010, BIOMARK MED, V4, P361, DOI [10.2217/bmm.10.57, 10.2217/BMM.10.57]
   von Maltzahn G, 2008, BIOCONJUGATE CHEM, V19, P1570, DOI 10.1021/bc800077y
   Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455
   Winyard PG, 2011, BIOCHEM SOC T, V39, P1226, DOI 10.1042/BST0391226
   Woolley DE, 2003, NEW ENGL J MED, V348, P1709, DOI 10.1056/NEJMcibr023206
   YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8                                                    
   Yigit MV, 2011, ACS NANO, V5, P1056, DOI 10.1021/nn102587h
   Zhao W, 2011, J CLIN IMMUNOL, V32, P150
   Zhou ZG, 2010, BIOCONJUGATE CHEM, V21, P1656, DOI 10.1021/bc1001664
   Zhu SQ, 2006, MAR ENVIRON RES, V62, pS5, DOI 10.1016/j.marenvres.2006.04.059
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 106
TC 32
Z9 33
U1 9
U2 111
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUL
PY 2013
VL 8
IS 7
BP 1191
EP 1208
DI 10.2217/NNM.13.99
PG 18
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 170LX
UT WOS:000320853500020
PM 23837857
DA 2018-01-05
ER

PT J
AU Shaterian, HR
   Farbodeh, J
   Mohammadnia, M
AF Shaterian, Hamid Reza
   Farbodeh, Javad
   Mohammadnia, Majid
TI Nano-TiO2: An Eco-Friendly and Clean Reusable Heterogeneous Catalyst for
   Preparation of alpha-Aminophosphonates Under Ambient and Solvent-Free
   Conditions
SO PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS
LA English
DT Article
DE Nano-TiO2; three-component reaction; alpha-aminophosphonates; catalyst;
   solvent-free; ambient conditions
ID STATE ANALOG INHIBITORS; ONE-POT; 3-COMPONENT SYNTHESIS; RENIN
   INHIBITORS; HIV PROTEASE; ACID; PHOSPHONATES
AB A one-pot catalytic three-component synthesis of -aminophosphonates from arylaldehydes, anilines, and triethylphosphite by employing TiO2 nanoparticles as a catalyst is described. Nano-TiO2 has been found to be an excellent catalyst for the green synthesis of -aminophosphonates under ambient and solvent-free conditions. This green and mild nano catalytic procedure showed good recyclability and provides cleaner conversion in a short reaction time. These advantages make the protocol feasible and economically attractive for researchers.
C1 [Shaterian, Hamid Reza; Farbodeh, Javad; Mohammadnia, Majid] Univ Sistan & Baluchestan, Fac Sci, Dept Chem, Zahedan, Iran.
RP Shaterian, HR (reprint author), Univ Sistan & Baluchestan, Fac Sci, Dept Chem, POB 98135-674, Zahedan, Iran.
EM hrshaterian@chem.usb.ac.ir
FU University of Sistan; Baluchestan Research Council
FX We are thankful to the University of Sistan and Baluchestan Research
   Council for the partial support of this research.
CR Agawane SM, 2011, TETRAHEDRON LETT, V52, P3499, DOI 10.1016/j.tetlet.2011.04.112
   ALLEN MC, 1989, J MED CHEM, V32, P1652, DOI 10.1021/jm00127a041
   ATHERTON FR, 1986, J MED CHEM, V29, P29, DOI 10.1021/jm00151a005
   Baylis E. K., 1984, J CHEM SOC P1, V1, P2845, DOI 10.1039/P19840002845
   Bruke Jr T. R, 1995, J MED CHEM, V38, P1386
   Dake SA, 2011, BIOORG MED CHEM LETT, V21, P2527, DOI 10.1016/j.bmcl.2011.02.039
   Dindulkar SD, 2012, CATAL COMMUN, V17, P114, DOI 10.1016/j.catcom.2011.10.025
   Disale ST, 2012, TETRAHEDRON LETT, V53, P2277, DOI 10.1016/j.tetlet.2012.02.054
   Fang D, 2010, PHOSPHORUS SULFUR, V185, P2520, DOI 10.1080/10426501003724905
   FIELDS EK, 1952, J AM CHEM SOC, V74, P1528, DOI 10.1021/ja01126a054                                                             
   GIANNOUSIS PP, 1987, J MED CHEM, V30, P1603, DOI 10.1021/jm00392a014
   Hosseini-Sarvari M, 2008, TETRAHEDRON, V64, P5459, DOI 10.1016/j.tet.2008.04.016
   Jafari AA, 2010, HETEROATOM CHEM, V21, P397, DOI 10.1002/hc.20635
   Kabachnik M. I., 1952, DOKL AKAD NAUK SSSR, V83, P689
   Mandhane PG, 2011, CHINESE CHEM LETT, V22, P563, DOI 10.1016/j.cclet.2010.11.021
   Moonen K, 2004, CHEM REV, V104, P6177, DOI 10.1021/cr030451c
   Niralwad KS, 2010, ULTRASON SONOCHEM, V17, P760, DOI 10.1016/j.ultsonch.2010.02.002
   PATEL DV, 1990, TETRAHEDRON LETT, V31, P5587, DOI 10.1016/S0040-4039(00)97903-6
   PEYMAN A, 1992, TETRAHEDRON LETT, V33, P4549, DOI 10.1016/S0040-4039(00)61309-6                                                   
   Ray PC, 2010, CHEM REV, V110, P5332, DOI 10.1021/cr900335q
   Reddy BVS, 2011, TETRAHEDRON LETT, V52, P1359, DOI 10.1016/j.tetlet.2011.01.074
   Reddy MV, 2011, TETRAHEDRON LETT, V52, P4764, DOI 10.1016/j.tetlet.2011.07.027
   Schmid G., 2004, NANOPARTICLES THEORY
   SIKORSKI JA, 1993, PHOSPHORUS SULFUR, V76, P375
   Sobhani S, 2008, J ORGANOMET CHEM, V693, P3313, DOI 10.1016/j.jorganchem.2008.07.037
   STOWASSER B, 1992, TETRAHEDRON LETT, V33, P6625, DOI 10.1016/S0040-4039(00)61002-X                                                   
NR 26
TC 3
Z9 3
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1042-6507
J9 PHOSPHORUS SULFUR
JI Phosphorus Sulfur Silicon Relat. Elem.
PD JUL 1
PY 2013
VL 188
IS 7
BP 850
EP 854
DI 10.1080/10426507.2012.717135
PG 5
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
SC Chemistry
GA 181TL
UT WOS:000321691300005
DA 2018-01-05
ER

PT J
AU Dresselhaus, MS
   Terrones, M
AF Dresselhaus, Mildred S.
   Terrones, Mauricio
TI Carbon-Based Nanomaterials From a Historical Perspective
SO PROCEEDINGS OF THE IEEE
LA English
DT Article
DE Carbon; fullerenes; graphene; graphite; history; nanocarbons; nanotubes
ID ENERGY ELECTRON-DIFFRACTION; RESONANT RAMAN-SCATTERING;
   SCIENCE-AND-TECHNOLOGY; ALKALI-METAL-COMPOUNDS; MOS2 ATOMIC LAYERS;
   GRAPHENE TRANSISTORS; EPITAXIAL GRAPHENE; KOHLENSTOFF-FOLIEN; HIV-1
   PROTEASE; SOLAR-ENERGY
AB Carbon, an ancient element, is still fascinating us with its flexibility to be transformed into different materials via its different degrees of hybridization (sp, sp(2), and sp(3)). After the structural identification in the beginning of the 20th century by John D. Bernal, graphite became a material of intense study. In the 1950s and 1960s, the physics and chemistry of graphite started to be developed from both theoretical and experimental perspectives. Soon after, graphite intercalation compounds and the synthesis of carbon microfibers became popular, and then in 1985, the era of nanocarbons started with the discovery of fullerenes (carbon cage molecules), followed by the structural identification of nanotubes and the isolation of graphene. Today, these three novel nanocarbons are being intensively studied and the physico-chemical properties are different among the three. This review intends to provide a historical perspective of these novel forms of carbon and their impact on electronics and other fields. We believe that, within a short time, commercial products based on any of these materials will be a reality but further experimental and theoretical research is still needed in some areas, as well as the development of low-cost production processes for commercial materials, devices, and products.
C1 [Dresselhaus, Mildred S.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Dresselhaus, Mildred S.] MIT, Dept Phys, Cambridge, MA 02139 USA.
   [Terrones, Mauricio] Penn State Univ, Dept Phys, Dept Mat Sci & Engn, University Pk, PA 16802 USA.
   [Terrones, Mauricio] Penn State Univ, Ctr Two Dimens & Layered Mat, University Pk, PA 16802 USA.
   [Terrones, Mauricio] Shinshu Univ, Res Ctr Exot Nanocarbons JST, Nagano 3808553, Japan.
RP Dresselhaus, MS (reprint author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
EM millie@mgm.mit.edu
RI Terrones, Mauricio/B-3829-2014
FU Research Center for Exotic Nanocarbons, Japan regional Innovation
   Strategy Program by the Excellence, JST; Multidisciplinary University
   Research Initiative (MURI) of the U.S. Office of Naval Research (ONR)
   [N00014-09-1-1063]; U.S. Air Force Office of Scientific Research under
   MURI [FA9550-12-1-0035]; Center for Nanoscale Science under a seed grant
   entitled "Defect Engineering of 2-D Sheets of Layered Materials''
   [DMR-0820404]
FX This work was supported by the Research Center for Exotic Nanocarbons,
   Japan regional Innovation Strategy Program by the Excellence, JST (MT).
   The work of M. S. Dresselhaus was supported by the Multidisciplinary
   University Research Initiative (MURI) of the U.S. Office of Naval
   Research (ONR) under Contract N00014-09-1-1063. The work of M. Terrones
   was supported by the U.S. Air Force Office of Scientific Research under
   MURI Grant FA9550-12-1-0035 and the Center for Nanoscale Science under a
   seed grant entitled "Defect Engineering of 2-D Sheets of Layered
   Materials'' (DMR-0820404).
CR Arnold MS, 2006, NAT NANOTECHNOL, V1, P60, DOI 10.1038/nnano.2006.52
   Balandin A. A., NATURE MAT, V10
   Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f
   BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0
   Blake P, 2008, NANO LETT, V8, P1704, DOI 10.1021/nl080649i
   BOEHM HP, 1962, Z ANORG ALLG CHEM, V316, P119, DOI 10.1002/zaac.19623160303                                                        
   BOEHM HP, 1962, Z NATURFORSCH PT B, VB 17, P150
   Carrero-Sanchez JC, 2006, NANO LETT, V6, P1609, DOI 10.1021/nl060548p
   Checkelsky JG, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.196801
   Chen SS, 2012, NAT MATER, V11, P203, DOI [10.1038/NMAT3207, 10.1038/nmat3207]
   Dal HJ, 1996, CHEM PHYS LETT, V260, P471, DOI 10.1016/0009-2614(96)00862-7
   DAVID WIF, 1991, NATURE, V353, P147, DOI 10.1038/353147a0
   de Heer WA, 2007, SOLID STATE COMMUN, V143, P92, DOI 10.1016/j.ssc.2007.04.023
   DRESSELHAUS G, 1953, PHYS REV, V92, P827, DOI 10.1103/PhysRev.92.827
   DRESSELHAUS G, 1977, MATER SCI ENG, V31, P235, DOI 10.1016/0025-5416(77)90039-8
   DRESSELHAUS G, 1965, PHYS REV, V140, pA401, DOI 10.1103/PhysRev.140.A401                                                        
   DRESSELHAUS MS, 1981, ADV PHYS, V30, P139, DOI 10.1080/00018738100101367
   DRESSELHAUS MS, 1964, CARBON, V1, P263, DOI 10.1016/0008-6223(64)90280-5                                                    
   DRESSELHAUS MS, 1964, IBM J RES DEV, V8, P262, DOI 10.1147/rd.83.0262                                                              
   DRESSELHAUS MS, 1980, SYNTHETIC MET, V2, P121, DOI 10.1016/0379-6779(80)90037-5                                                    
   DRESSELHAUS MS, 1995, ANNU REV MATER SCI, V25, P487, DOI 10.1146/annurev.ms.25.080195.002415                                             
   Dresselhaus M. S., 1988, GRAPHITE FIBERS FILA, V5
   Dresselhaus M. S., 1996, SCI FULLERENES CARBO
   EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0                                                                
   EKLUND PC, 1977, PHYS REV B, V16, P3330, DOI 10.1103/PhysRevB.16.3330
   Elias AL, 2007, SMALL, V3, P1723, DOI 10.1002/smll.200700331
   Endo M, 2008, TOP APPL PHYS, V111, P13, DOI 10.1007/978-3-540-72865-8_2
   Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Ghosh S, 2010, NAT MATER, V9, P555, DOI [10.1038/NMAT2753, 10.1038/nmat2753]
   Granqvist CG, 2007, SOL ENERG MAT SOL C, V91, P1529, DOI 10.1016/j.solmat.2007.04.031
   Gutierrez H. R., 2012, NANO LETT, DOI [DOI: 10.1021/ nl3026357., DOI 10.1021/NL3026357, 10.1021/nl3026357]
   Hirschmann TC, 2013, ACS NANO, V7, P2381, DOI 10.1021/nn3055708
   HOLDEN JM, 1994, CHEM PHYS LETT, V220, P186, DOI 10.1016/0009-2614(94)00154-5                                                    
   Howard J. N. Smith, 1967, FUNDAMENTALS GAS SUR, P102
   Hu YH, 2010, CHEMSUSCHEM, V3, P782, DOI 10.1002/cssc.201000061
   IIJIMA S, 1992, PHYS REV LETT, V69, P3100, DOI 10.1103/PhysRevLett.69.3100                                                     
   IIJIMA S, 1993, NATURE, V364, P737
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Jorio A, 2000, PHYS REV LETT, V85, P2617, DOI 10.1103/PhysRevLett.85.2617
   Jorio A, 2001, PHYS REV LETT, V86, P1118, DOI 10.1103/PhysRevLett.86.1118
   Jorio A., 2011, RAMAN SPECTROSCOPY G
   Katsnelson MI, 2006, NAT PHYS, V2, P620, DOI 10.1038/nphys384
   Kim G, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2828976
   Kneipp K, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.081401
   KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0
   KROTO HW, 1992, ANGEW CHEM INT EDIT, V31, P111, DOI 10.1002/anie.199201113                                                          
   Lee YH, 2012, ADV MATER, V24, P2320, DOI 10.1002/adma.201104798
   Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245
   Liao L, 2010, NATURE, V467, P305, DOI 10.1038/nature09405
   Lin YM, 2010, SCIENCE, V327, P662, DOI 10.1126/science.1184289
   Lin YM, 2009, NANO LETT, V9, P422, DOI 10.1021/nl803316h
   Liu H., 2011, NATURE COMMUN, V2
   Lu XK, 1999, NANOTECHNOLOGY, V10, P269, DOI 10.1088/0957-4484/10/3/308
   Lu X. K., APPL PHYS LETT, V75
   LYON HB, 1967, J CHEM PHYS, V46, P2539, DOI 10.1063/1.1841082
   Mak KF, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.136805
   Maltz M, 1970, PHYS REV B-SOLID ST, V2, P2877, DOI 10.1103/PhysRevB.2.2877                                                         
   MAVROIDE.JG, 1966, J PHYS SOC JPN, VS 21, P184
   MAY JW, 1969, SURF SCI, V17, P267, DOI 10.1016/0039-6028(69)90227-1                                                    
   MCCLURE JW, 1964, IBM J RES DEV, V8, P255, DOI 10.1147/rd.83.0255                                                              
   Miller JR, 2010, SCIENCE, V329, P1637, DOI 10.1126/science.1194372
   MORGAN AE, 1968, SURF SCI, V12, P405, DOI 10.1016/0039-6028(68)90089-7                                                    
   Muramatsu H, 2011, ADV MATER, V23, P1761, DOI 10.1002/adma.201004709
   Myung S, 2011, ADV MATER, V23, P2221, DOI 10.1002/adma.201100014
   Nardes AM, 2012, ADV FUNCT MATER, V22, P4115, DOI 10.1002/adfm.201200336
   Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102
   Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   OBERLIN A, 1976, J CRYST GROWTH, V32, P335, DOI 10.1016/0022-0248(76)90115-9                                                    
   Odom TW, 1998, NATURE, V391, P62
   Palnitkar UA, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3464168
   Pimenta MA, 1998, J MATER RES, V13, P2396
   Pimenta MA, 1998, PHYS REV B, V58, P16016, DOI 10.1103/PhysRevB.58.R16016                                                      
   Radushkevich L. V., 1952, ZH FIZ KHIM, V26, P88
   Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187
   Reina A, 2009, NANO LETT, V9, P3087, DOI 10.1021/nl901829a
   ROHLFING EA, 1984, J CHEM PHYS, V81, P3322, DOI 10.1063/1.447994                                                                
   SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080                                                                
   Scheuermann GM, 2009, J AM CHEM SOC, V131, P8262, DOI 10.1021/ja901105a
   SCHROEDER PR, 1968, PHYS REV LETT, V20, P1292, DOI 10.1103/PhysRevLett.20.1292                                                     
   STEPHENS PW, 1991, NATURE, V351, P632, DOI 10.1038/351632a0
   TAYLOR R, 1990, J CHEM SOC CHEM COMM, P1423, DOI 10.1039/c39900001423                                                            
   Terrones M, 2003, ANNU REV MATER RES, V33, P419, DOI 10.1146/annurev.matsci.33.012802.100255
   Teweldebrhan D, 2010, NANO LETT, V10, P1209, DOI 10.1021/nl903590b
   Thomsen C, 2000, PHYS REV LETT, V85, P5214, DOI 10.1103/PhysRevLett.85.5214                                                     
   Tomanek D, 2008, TOP APPL PHYS, V111, P1, DOI 10.1007/978-3-540-72865-8_1
   TOY WW, 1977, PHYS REV B, V15, P4077, DOI 10.1103/PhysRevB.15.4077                                                        
   UBBELOHDE AR, 1962, NATURE, V193, P571, DOI 10.1038/193571a0
   VECCHI MP, 1974, PHYS REV B, V9, P3257, DOI 10.1103/PhysRevB.9.3257                                                         
   Villalpando-Paez F, 2008, NANO LETT, V8, P3879, DOI 10.1021/nl802306t
   Wang QH, 2012, NAT NANOTECHNOL, V7, P699, DOI [10.1038/nnano.2012.193, 10.1038/NNANO.2012.193]
   Wang XL, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3259650
   Wang X, 2008, NANO LETT, V8, P323, DOI 10.1021/nl072838r
   Wang Y, 2010, ACS NANO, V4, P1790, DOI 10.1021/nn100315s
   Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139                                                                   
   WILLIAMSON SJ, 1966, CARBON, V4, P29, DOI 10.1016/0008-6223(66)90006-6                                                    
   Yin SY, 2011, ACS NANO, V5, P3831, DOI 10.1021/nn2001728
   Yoo E, 2008, NANO LETT, V8, P2277, DOI 10.1021/nl800957b
   YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789                                                   
   Yu XX, 2011, ACS NANO, V5, P952, DOI 10.1021/nn102291j
   Zhan YJ, 2012, SMALL, V8, P966, DOI 10.1002/smll.201102654
   Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235
   ZHAO YX, 1988, CARBON, V26, P291, DOI 10.1016/0008-6223(88)90218-7                                                    
   Zhu HW, 2009, SOL ENERG MAT SOL C, V93, P1461, DOI 10.1016/j.solmat.2009.04.006
   Zhu YW, 2011, SCIENCE, V332, P1537, DOI 10.1126/science.1200770
NR 108
TC 20
Z9 20
U1 4
U2 138
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9219
EI 1558-2256
J9 P IEEE
JI Proc. IEEE
PD JUL
PY 2013
VL 101
IS 7
SI SI
BP 1522
EP 1535
DI 10.1109/JPROC.2013.2261271
PG 14
WC Engineering, Electrical & Electronic
SC Engineering
GA 167WW
UT WOS:000320667200002
DA 2018-01-05
ER

PT J
AU Shibata
   McMullen
   Pharm
   Belshan
   Sanford
   Abhijit
AF Shibata
   McMullen
   Pharm
   Belshan
   Sanford
   Abhijit
TI Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for
   HIV Type 1 Treatment (vol 29, 746, 2013)
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Correction
C1 [Shibata; McMullen; Pharm] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
   [Belshan; Sanford] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE USA.
RP Shibata (reprint author), Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
CR Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
NR 1
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUL
PY 2013
VL 29
IS 7
BP 1095
EP 1095
DI 10.1089/aid.2012.0301.cnx
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 163ZP
UT WOS:000320378300018
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gautam, N
   Roy, U
   Balkundi, S
   Puligujja, P
   Guo, DW
   Smith, N
   Liu, XM
   Lamberty, B
   Morsey, B
   Fox, HS
   McMillan, J
   Gendelman, HE
   Alnouti, Y
AF Gautam, Nagsen
   Roy, Upal
   Balkundi, Shantanu
   Puligujja, Pavan
   Guo, Dongwei
   Smith, Nathan
   Liu, Xin-Ming
   Lamberty, Benjamin
   Morsey, Brenda
   Fox, Howard S.
   McMillan, JoEllyn
   Gendelman, Howard E.
   Alnouti, Yazen
TI Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting
   Nanoformulated Antiretroviral Therapy
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CNS DRUG-DELIVERY; HIV-INFECTION;
   ATAZANAVIR; HIV/AIDS; BRAIN; BLOOD; TRAFFICKING; COMBINATION; INHIBITOR
AB Long-acting injectable nanoformulated antiretroviral therapy (nanoART) was developed with the explicit goal of improving medicine compliance and for drug targeting of viral tissue reservoirs. Prior nanoART studies completed in humanized virus-infected mice demonstrated sustained antiretroviral responses. However, the pharmacokinetics (PK) and tissue distribution of nanoART were not characterized. To this end, the PK and tissue distribution of nanoformulated atazanavir (ATV) and ritonavir (RTV) injected subcutaneously or intramuscularly in mice and monkeys were evaluated. Fourteen days after injection, ATV and RTV levels were up to 13-, 41-, and 4,500-fold higher than those resulting from native-drug administration in plasma, tissues, and at the site of injection, respectively. At nanoART doses of 10, 50, 100, and 250 mg/kg of body weight, relationships of more- and less-than-proportional increases in plasma and tissue levels with dose increases were demonstrated with ATV and RTV. Multiple-dose regimens showed serum and tissue concentrations up to 270-fold higher than native-drug concentrations throughout 8 weeks of study. Importantly, nanoART was localized in nonlysosomal compartments in tissue macrophages, creating intracellular depot sites. Reflective data were obtained in representative rhesus macaque studies. We conclude that nanoART demonstrates blood and tissue antiretroviral drug levels that are enhanced compared to those of native drugs. The sustained and enhanced PK profile of nanoART is, at least in part, the result of the sustained release of ATV and RTV from tissue macrophases and at the site of injection.
C1 [Gautam, Nagsen; Guo, Dongwei; Alnouti, Yazen] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Roy, Upal; Balkundi, Shantanu; Puligujja, Pavan; Smith, Nathan; Liu, Xin-Ming; Lamberty, Benjamin; Morsey, Brenda; Fox, Howard S.; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
RP Alnouti, Y (reprint author), Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
EM yalnouti@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Fox, Howard/0000-0003-2032-374X; Roy, Upal/0000-0002-0325-567X
FU Carol Swarts Neuroscience Research Laboratory Fund; National Institutes
   of Health [DA028555-01, P20 DA026146, R01 NS36126, P01 NS31492, 2R01
   NS034239, P20 RR15635, P01 MH64570, P01 NS43985, R01 NS070190]
FX This work was supported by the Carol Swarts Neuroscience Research
   Laboratory Fund and the National Institutes of Health (grants
   DA028555-01, P20 DA026146, R01 NS36126, P01 NS31492, 2R01 NS034239, P20
   RR15635, P01 MH64570, P01 NS43985, and R01 NS070190).
CR Abrass CK, 2012, J AM GERIATR SOC, V60, P974, DOI 10.1111/j.1532-5415.2012.03948.x
   Anabwani G, 2005, NUTRITION, V21, P96, DOI 10.1016/j.nut.2004.09.013
   ARNAOUT MA, 1990, BLOOD, V75, P1037
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bansal T, 2009, DRUG DISCOV TODAY, V14, P1067, DOI 10.1016/j.drudis.2009.07.010
   Barrail-Tran A, 2010, ANTIMICROB AGENTS CH, V54, P614, DOI 10.1128/AAC.00797-09
   CASEY CA, 1987, J BIOL CHEM, V262, P2704
   Cohen J, 2011, SCIENCE, V334, P1614, DOI 10.1126/science.334.6063.1614
   Coiras M, 2010, DISCOV MED, V9, P185
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   Foisy MM, 2008, ANN PHARMACOTHER, V42, P1048, DOI 10.1345/aph.1K615
   Gendelman HE, 2008, J NEUROIMMUNE PHARM, V3, P58, DOI 10.1007/s11481-008-9103-9
   Havlir DV, 2004, CLIN INFECT DIS, V38, P1599, DOI 10.1086/420932                                                                  
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   Liu W, 2011, PROTEOMICS, V11, P3556, DOI 10.1002/pmic.201100157
   Novitsky V, 2012, CURR OPIN HIV AIDS, V7, P117, DOI 10.1097/COH.0b013e32834fe8ff
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Pasternak AO, 2012, J INFECT DIS, V206, P1443, DOI 10.1093/infdis/jis502
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Rathbun RC, 2006, CURR PHARM DESIGN, V12, P1045, DOI 10.2174/138161206776055840
   Rathbun RC, 2005, CLIN THER, V27, P199, DOI 10.1016/j.clinthera.2005.02.010
   Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000                                                 
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Schmidt S, 2010, J PHARM SCI-US, V99, P1107, DOI 10.1002/jps.21916
   Schroeder U, 1998, J PHARM SCI, V87, P1305, DOI 10.1021/js980084y
   Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663
   Sterling TR, 2010, CLIN INFECT DIS, V50, pS223, DOI 10.1086/651495
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   Thaker HK, 2003, POSTGRAD MED J, V79, P36, DOI 10.1136/pmj.79.927.36
NR 43
TC 28
Z9 28
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUL
PY 2013
VL 57
IS 7
BP 3110
EP 3120
DI 10.1128/AAC.00267-13
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 161YG
UT WOS:000320229600027
PM 23612193
OA gold
DA 2018-01-05
ER

PT J
AU Sturino, CF
   Bousquet, Y
   James, CA
   DeRoy, P
   Duplessis, M
   Edwards, PJ
   Halmos, T
   Minville, J
   Morency, L
   Morin, S
   Thavonekham, B
   Tremblay, M
   Duan, JM
   Ribadeneira, M
   Garneau, M
   Pelletier, A
   Tremblay, S
   Lamorte, L
   Bethell, R
   Cordingley, MG
   Rajotte, D
   Simoneau, B
AF Sturino, Claudio F.
   Bousquet, Yves
   James, Clint A.
   DeRoy, Patrick
   Duplessis, Martin
   Edwards, Paul J.
   Halmos, Ted
   Minville, Joannie
   Morency, Louis
   Morin, Sebastien
   Thavonekham, Bounkham
   Tremblay, Martin
   Duan, Jianmin
   Ribadeneira, Maria
   Garneau, Michel
   Pelletier, Alex
   Tremblay, Sonia
   Lamorte, Louie
   Bethell, Richard
   Cordingley, Michael G.
   Rajotte, Daniel
   Simoneau, Bruno
TI Identification of potent and orally bioavailable nucleotide competing
   reverse transcriptase inhibitors: In vitro and in vivo optimization of a
   series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Reverse transcriptase; NcRTI; HIV-1; Benzofuranopyrimidone; Nucleotide
   competing
ID HIV-PROTEASE INHIBITORS; FUSION INHIBITORS; ENTRY INHIBITORS; INTEGRASE;
   DISCOVERY; PERMEABILITY; NUCLEOSIDE; RESISTANCE; MUTATIONS; MECHANISM
AB Recently, a new class of HIV reverse transcriptase (HIV-RT) inhibitors has been reported. The novel mechanism of inhibition by this class involves competitive binding to the active site of the RT enzyme and has been termed Nucleotide-Competing Reverse Transcriptase Inhibitors (NcRTIs). In this publication we describe the optimization of a novel benzofurano[3,2-d]pyrimidin-2-one series of NcRTIs. The starting point for the current study was inhibitor 2, which had high biochemical and antiviral potency but only moderate permeability in a Caco-2 assay and high B-to-A efflux, resulting in moderate rat bioavailability and low C-max. We present herein the results and strategies we employed to optimize both the potency as well as the permeability, metabolic stability and pharmacokinetic profile of this series. One of the key observations of the present study was the importance of shielding polar functionality, at least in the context of the current chemotype, to enhance permeability. These studies led to the identification of inhibitors 39 and 45, which display sub-nanomolar antiviral potency in a p24 ELISA assay with significantly reduced efflux ratios (ratios <1.5). These inhibitors also display excellent rat pharmacokinetic profiles with high bioavailabilities and low clearance. (c) 2013 Elsevier Ltd. All rights reserved.
C1 [Sturino, Claudio F.; Bousquet, Yves; James, Clint A.; DeRoy, Patrick; Duplessis, Martin; Edwards, Paul J.; Halmos, Ted; Minville, Joannie; Morency, Louis; Morin, Sebastien; Thavonekham, Bounkham; Tremblay, Martin; Simoneau, Bruno] Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Chem, Laval, PQ H7S 2G5, Canada.
   [Duan, Jianmin; Ribadeneira, Maria; Garneau, Michel; Pelletier, Alex; Tremblay, Sonia; Lamorte, Louie; Bethell, Richard; Cordingley, Michael G.; Rajotte, Daniel] Boehringer Ingelheim Canada Ltd, Res & Dev, Dept Biol Sci, Laval, PQ H7S 2G5, Canada.
RP Sturino, CF (reprint author), Vertex Pharmaceut Canada Inc, Laval, PQ, Canada.
EM daniel.rajotte@boehringer-ingelheim.com
CR Alex A, 2011, MEDCHEMCOMM, V2, P669, DOI 10.1039/c1md00093d
   Berkhout B, 2012, CURR OPIN VIROL, V2, P50, DOI 10.1016/j.coviro.2012.01.002
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De Clercq E, 2011, MED RES REV, V31, P118, DOI 10.1002/med.20179
   Dhami H, 2009, J CLIN PHARM THER, V34, P147, DOI 10.1111/j.1365-2710.2008.00978.x
   Didigu CA, 2012, VIRUSES-BASEL, V4, P309, DOI 10.3390/v4020309
   Eggink D, 2010, CURR PHARM DESIGN, V16, P3716, DOI 10.2174/138161210794079218
   Ehteshami M, 2008, J BIOL CHEM, V283, P29904, DOI 10.1074/jbc.M804882200
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   Ghosh AK, 2012, ANGEW CHEM INT EDIT, V51, P1778, DOI 10.1002/anie.201102762
   Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616
   Hitchcock SA, 2012, J MED CHEM, V55, P4877, DOI 10.1021/jm201136z
   Huang LY, 2010, DRUG METAB DISPOS, V38, P223, DOI 10.1124/dmd.109.029066
   James CA, 2013, BIOORG MED CHEM LETT, V23, P2781, DOI 10.1016/j.bmcl.2013.02.021
   Jochmans D, 2008, VIRUS RES, V134, P171, DOI 10.1016/j.virusres.2008.01.003
   Jochmans D, 2006, J VIROL, V80, P12283, DOI 10.1128/JVI.00889-06
   Maga G, 2010, VIRUSES-BASEL, V2, P880, DOI 10.3390/v2040880
   NORBECK DW, 1991, ANNU REP MED CHEM, V26, P141
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Quashie PK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-34
   Schols D, 2004, CURR TOP MED CHEM, V4, P883, DOI 10.2174/1568026043388501
   Singh IP, 2011, EXPERT OPIN THER PAT, V21, P399, DOI 10.1517/13543776.2011.550876
   Singh IP, 2011, EXPERT OPIN THER PAT, V21, P227, DOI 10.1517/13543776.2011.542412
   Steen A, 2009, MINI-REV MED CHEM, V9, P1605, DOI 10.2174/138955709791012265                                                      
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Thomas VH, 2006, EXPERT OPIN DRUG MET, V2, P591, DOI 10.1517/17425255.2.4.591
   Tremblay M, 2013, BIOORG MED CHEM LETT, V23, P2775, DOI 10.1016/j.bmcl.2013.02.042
   Tressler R, 2012, DRUGS, V72, P2051, DOI 10.2165/11640830-000000000-00000
   UNAIDS, 2012, UNAIDS REP GLOB AIDS
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
   Zhang ZJ, 2006, ANTIMICROB AGENTS CH, V50, P2772, DOI 10.1128/AAC.00127-06
   Sturino C., 2010, PCT Int. Appl., Patent No. [WO 2010/115264, 2010115264]
NR 34
TC 3
Z9 3
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUL 1
PY 2013
VL 23
IS 13
BP 3967
EP 3975
DI 10.1016/j.bmcl.2013.04.043
PG 9
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 168JX
UT WOS:000320702900055
PM 23673016
DA 2018-01-05
ER

PT J
AU Lavigne, C
   Slater, K
   Gajanayaka, N
   Duguay, C
   Peyrotte, EA
   Fortier, G
   Simard, M
   Kell, AJ
   Barnes, ML
   Thierry, AR
AF Lavigne, Carole
   Slater, Kathryn
   Gajanayaka, Niranjala
   Duguay, Christian
   Peyrotte, Erika Arnau
   Fortier, Germaine
   Simard, Martin
   Kell, Arnold J.
   Barnes, Michael L.
   Thierry, Alain R.
TI Influence of lipoplex surface charge on siRNA delivery: application to
   the in vitro downregulation of CXCR4 HIV-1 co-receptor
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE anti-HIV therapy; CXCR4; lipoplex charge; nanodelivery system;
   Neutraplex; siRNA delivery
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL INTERFERING RNA; GENE DELIVERY;
   ANTISENSE OLIGONUCLEOTIDES; TRANSFECTION EFFICIENCY; LIPID COMPLEXES;
   CELLULAR UPTAKE; DNA; INHIBITION; EXPRESSION
AB Objective: Cationic lipidic formulations have been successfully used to deliver small interfering RNA (siRNA) into cells but they show limitations for in vivo application due to their cytotoxicity and instability in the presence of serum. To overcome these limitations, the authors developed an anionic lipid-based carrier named Neutraplex (Nx). Here, they wanted to investigate the influence of the lipoplex (Lx) surface charge on cytotoxicity, delivery and silencing activity of siRNAs.
   Methods: The efficiency of three Nx formulations (cationic, close to neutrality and anionic) to deliver anti-CXCR4 siRNAs in MAGI cells was investigated and compared with the cationic commercial transfection reagent Lipofectamine RNAiMAX. Cellular uptake and intracellular localization of a fluorescent siRNA was monitored in live cells using fluorescence microscopy and silencing activity was measured by flow cytometry and RT-PCR analysis.
   Results: The authors found that the Lx surface charge influenced cellular uptake and silencing activity of siRNA in cell cultures. Although cationic Lx formulations were the most efficient carriers to deliver active silencing siRNAs, negatively charged lipoplexes were taken up by cells, delivered active siRNAs and presented low cytotoxicity.
   Conclusions: Altogether, the findings support further investigation for in vivo delivery of therapeutic siRNAs using Nx. Furthermore, this study indicates that anionic delivery systems may have potential for in vivo RNAi therapeutics.
C1 [Lavigne, Carole; Slater, Kathryn; Gajanayaka, Niranjala; Duguay, Christian; Peyrotte, Erika Arnau; Fortier, Germaine; Simard, Martin] Publ Hlth Agcy Canada, Natl Microbiol Lab, Natl HIV & Retrovirol Labs, Ottawa, ON K1A 0K9, Canada.
   [Kell, Arnold J.; Barnes, Michael L.] Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada.
   [Thierry, Alain R.] CRLC Val dAurelle Paul Lamarque, Inst Rech Cancerol Montpellier, U896, F-34298 Montpellier, France.
RP Lavigne, C (reprint author), Publ Hlth Agcy Canada, Natl Microbiol Lab, Natl HIV & Retrovirol Labs, 200 Tunneys Pasture Driveway, Ottawa, ON K1A 0K9, Canada.
EM carole.lavigne@phac-aspc.gc.ca
RI thierry, alain/F-9492-2014
FU Public Health Agency of Canada; INSERM, Paris, France
FX This work was supported by the Public Health Agency of Canada. AR
   Thierry is supported by the INSERM, Paris, France. The authors are
   grateful to M Bergeron and T Ding for their technical help with the flow
   cytometry analysis.
CR Akhtar S, 2007, ADV DRUG DELIVER REV, V59, P164, DOI 10.1016/j.addr.2007.03.010
   Aleman LM, 2007, RNA, V13, P385, DOI 10.1261/rna.352507
   Almsherqi Z, 2008, J R SOC INTERFACE, V5, P1023, DOI 10.1098/rsif.2007.1351
   Anderson J, 2003, OLIGONUCLEOTIDES, V13, P303, DOI 10.1089/154545703322616989
   Anderson Joseph, 2005, AIDS Res Ther, V2, P1, DOI 10.1186/1742-6405-2-1
   Barteau B, 2008, CURR GENE THER, V8, P313, DOI 10.2174/156652308786070961                                                      
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Chackerian B, 1997, J VIROL, V71, P3932
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703
   Dritschilo A, 2006, CLIN CANCER RES, V12, P1251, DOI 10.1158/1078-0432.CCR-05-1260
   Felgner PL, 1997, HUM GENE THER, V8, P511, DOI 10.1089/hum.1997.8.5-511
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Hassan A, 2005, PHYSIOL GENOMICS, V21, P382, DOI 10.1152/physiolgenomics.00147.2004
   Hassani Z, 2005, J GENE MED, V7, P198, DOI 10.1002/jgm.659
   Hofland HEJ, 1996, P NATL ACAD SCI USA, V93, P7305, DOI 10.1073/pnas.93.14.7305
   Lavigne C, 1997, BIOCHEM BIOPH RES CO, V237, P566, DOI 10.1006/bbrc.1997.7191
   Lavigne C, 2001, AAPS PHARMSCI, V3
   Lavigne C, SUPRAMOLECULAR UNPUB
   Lavigne C, 2007, BIOCHIMIE, V89, P1245, DOI 10.1016/j.biochi.2007.05.002
   Li MJ, 2006, ANN NY ACAD SCI, V1082, P172, DOI 10.1196/annals.1348.006
   LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Marchini C, 2009, LANGMUIR, V25, P3013, DOI 10.1021/la8033726
   Masotti A, 2009, COLLOID SURFACE B, V68, P136, DOI 10.1016/j.colsurfb.2008.09.017
   Meryet-Figuieres M, 2007, BIOCHIMIE, V89, P1228, DOI 10.1016/j.biochi.2007.03.017
   Mescalchin A, 2007, EXPERT OPIN BIOL TH, V7, P1531, DOI 10.1517/14712598.7.10.1531                                                      
   Midoux P, 2008, CURR GENE THER, V8, P335, DOI 10.2174/156652308786071014                                                      
   Ortiz A, 1999, BIOPHYS J, V77, P2003, DOI 10.1016/S0006-3495(99)77041-4                                                   
   Pirollo KF, 2007, CANCER RES, V67, P2938, DOI 10.1158/0008-5472.CAN-06-4535
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437                                                      
   Pozharski EV, 2007, MOL PHARM, V4, P962, DOI 10.1021/mp700080m
   Resina S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006058
   Schmutz M, 1999, P NATL ACAD SCI USA, V96, P12293, DOI 10.1073/pnas.96.22.12293
   Shim MS, 2010, FEBS J, V277, P4814, DOI 10.1111/j.1742-4658.2010.07904.x
   Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102
   Tamhane Mayur, 2008, AIDS Res Ther, V5, P16, DOI 10.1186/1742-6405-5-16
   Tarahovsky Y, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1293, DOI 10.1134/S0006297909120013
   Tavitian B, 2002, PHARM RES-DORDR, V19, P367, DOI 10.1023/A:1015133205457
   Thierry AR, 2006, BBA-BIOMEMBRANES, V1758, P364, DOI 10.1016/j.bbamem.2005.10.010
   Thierry AR, 2003, CURR OPIN MOL THER, V5, P133
   THIERRY AR, 1992, NUCLEIC ACIDS RES, V20, P5691, DOI 10.1093/nar/20.21.5691
   THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742
   White PJ, 2008, CLIN EXP PHARMACOL P, V35, P1371, DOI 10.1111/j.1440-1681.2008.04992.x
   Yano J, 2004, CLIN CANCER RES, V10, P7721, DOI 10.1158/1078-0432.CCR-04-1049                                                   
   Zaghloul EM, 2010, MOL PHARMACEUT, V7, P652, DOI 10.1021/mp900220p
   Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493
   Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004
   Zhou N, 2004, GENE THER, V11, P1703, DOI 10.1038/sj.gt.3302339
   ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 52
TC 9
Z9 9
U1 0
U2 26
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JUL
PY 2013
VL 13
IS 7
BP 973
EP 985
DI 10.1517/14712598.2013.743526
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 159RY
UT WOS:000320064800004
PM 23289797
DA 2018-01-05
ER

PT J
AU Al-Ghananeem, AM
   Smith, M
   Coronel, ML
   Tran, H
AF Al-Ghananeem, Abeer M.
   Smith, Michael
   Coronel, Maria L.
   Tran, Hieu
TI Advances in brain targeting and drug delivery of anti-HIV therapeutic
   agents
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE AID; BBB; brain targeting; CNS; dementia; HIV; nanotechnology; nasal
   delivery; prodrug
ID CENTRAL-NERVOUS-SYSTEM; HUMAN-IMMUNODEFICIENCY-VIRUS;
   PLATELET-ACTIVATING-FACTOR; MICROVESSEL ENDOTHELIAL-CELLS; PLURONIC
   BLOCK-COPOLYMERS; BLOOD-BRAIN; CEREBROSPINAL-FLUID; BIOLOGICAL
   EVALUATION; ANTI-HIV-1 ACTIVITY; PROTEASE INHIBITOR
AB Introduction: Human immunodeficiency virus (HIV) is a neurotropic virus that enters the central nervous system (CNS) early in the course of infection. Although antiretroviral drugs are able to eliminate the majority of the HIV virus in the bloodstream, however, no specific treatment currently exist for CNS infections related to HIV. This is mainly attributed to the poor penetrability of antiretroviral therapy across the blood-brain barrier (BBB), and the protective nature of the BBB. Therefore, in order to increase the efficacy of anti-HIV drugs, novel drug delivery methodologies that can exhibit activity in the CNS are most needed and warranted.
   Areas covered: In this review article, the authors discussed the challenges with delivering drugs to the brain especially under HIV infection pathophysiology status. Also, they discussed the approaches currently being investigated to enhance brain targeting of anti-HIV drugs. A literature search was performed to cover advances in major approaches used to enhance drug delivery to the brain.
   Expert opinion: If drugs could reach the CNS in sufficient quantity by the methodologies discussed, mainly through intranasal administration and the utilization of nanotechnology, this could generate interest in previously abandoned therapeutic agents and enable an entirely novel approach to CNS drug delivery.
C1 [Al-Ghananeem, Abeer M.; Smith, Michael; Coronel, Maria L.; Tran, Hieu] Sullivan Univ, Coll Pharm, Dept Pharmaceut Sci, Louisville, KY 40205 USA.
RP Al-Ghananeem, AM (reprint author), Sullivan Univ, Coll Pharm, Dept Pharmaceut Sci, 2100 Gardiner Lane West Campus, Louisville, KY 40205 USA.
EM aalghananeem@sullivan.edu
CR AGGARWAL SK, 1990, J MED CHEM, V33, P1505, DOI 10.1021/jm00167a034
   Al-Ghananeem AM, 2011, DRUG DEV IND PHARM, V37, P329, DOI 10.3109/03639045.2010.513009
   Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   ALGHANANEEM AM, 2002, AAPS PHARMSCITECH, V3, P1, DOI DOI 10.1208/PT030105
   ANDERSON BD, 1990, J PHARMACOL EXP THER, V253, P113
   Andras IE, 2003, J NEUROSCI RES, V74, P255, DOI 10.1002/jnr.10762
   Baratchi S, 2009, CURR NANOSCI, V5, P15, DOI 10.2174/157341309787314665                                                      
   Begley DJ, 1996, J PHARM PHARMACOL, V48, P136, DOI 10.1111/j.2042-7158.1996.tb07112.x                                              
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Berezovskaya YV, 2005, RUSS J BIOORG CHEM+, V31, P303, DOI 10.1007/s11171-005-0043-3
   BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C                                                    
   BLASBERG RG, 1975, J PHARMACOL EXP THER, V195, P73
   Brem H, 2001, J CONTROL RELEASE, V74, P63, DOI 10.1016/S0168-3659(01)00311-X
   Brem H, 1996, SCI MED, V3, P1
   CARNE CA, 1987, BRIT MED J, V294, P1399, DOI 10.1136/bmj.294.6584.1399                                                       
   Charlton ST, 2007, J DRUG TARGET, V15, P370, DOI 10.1080/10611860701393370
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   CHIEN YW, 1987, CRC CR REV THER DRUG, V4, P67
   CHU CK, 1990, J MED CHEM, V33, P2188, DOI 10.1021/jm00170a023
   Dandagi PM, 2012, ASIAN J PHARM, V6, P116, DOI 10.4103/0973-8398.102934
   Ding D, 2010, J NEURO-ONCOL, V98, P1, DOI 10.1007/s11060-009-0046-7
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Drewe J, 1999, BIOCHEM PHARMACOL, V57, P1147, DOI 10.1016/S0006-2952(99)00026-X
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   DYKSTRA KH, 1993, J PHARMACOL EXP THER, V267, P1227
   Engelman A, 2003, CURR TOP MICROBIOL, V281, P209
   Eval S, 2009, PHARMACOL THERAPEUT, V123, P80
   Farese-Di Giorgio A, 2000, ANTIVIR CHEM CHEMOTH, V11, P97
   FISHMAN RA, 1966, ARCH NEUROL-CHICAGO, V15, P113, DOI 10.1001/archneur.1966.00470140003001                                            
   Frey I.I.W.H., 2002, DRUG DELIV TECHNOL, V2, P46
   Fung LK, 1998, CANCER RES, V58, P672
   GALINSKY RE, 1991, J PHARMACOL EXP THER, V257, P972
   GELBARD HA, 1994, J VIROL, V68, P4628
   Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125                                                               
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125                                             
   Gray F, 2001, CLIN NEUROPATHOL, V20, P146
   HARBAUGH RE, 1988, NEUROSURGERY, V23, P693, DOI 10.1227/00006123-198812000-00001                                                
   HEDAYA MA, 1989, J PHARM SCI, V78, P716, DOI 10.1002/jps.2600780903
   HEDAYA MA, 1990, PHARMACEUT RES, V7, P411, DOI 10.1023/A:1015835826114
   HOSTETLER KY, 1990, J BIOL CHEM, V265, P6112
   Huang TY, 1999, J NEURO-ONCOL, V45, P9, DOI 10.1023/A:1006377312403                                                         
   Hussain AA, 1998, ADV DRUG DELIVER REV, V29, P39, DOI 10.1016/S0169-409X(97)00060-4
   Illum L, 2003, J PHARM PHARM J PHAR, V56, P3
   Im J, 2009, CHEM COMMUN, P4669, DOI 10.1039/b909541a
   Johnson MD, 1996, PHARM RES-DORDR, V13, P1881, DOI 10.1023/A:1016001712524
   Johnson MD, 2002, DRUG METAB DISPOS, V30, P191, DOI 10.1124/dmd.30.2.191
   Joshi S, 2011, J NEURO-ONCOL, V104, P11, DOI 10.1007/s11060-010-0466-4
   KAWAGUCHI T, 1990, J PHARM SCI, V79, P531, DOI 10.1002/jps.2600790616
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   KOPPEL BS, 1985, ACTA NEUROL SCAND, V71, P337
   Kramer-Hammerle S, 2005, VIRUS RES, V111, P194, DOI 10.1016/j.virusres.2005.04.009
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   KUMAR R, 1994, J MED CHEM, V37, P4297, DOI 10.1021/jm00051a006
   Lesniak MS, 2004, NAT REV DRUG DISCOV, V3, P499, DOI 10.1038/nrd1414
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Li W, 2005, NEUROTOX RES, V8, P119, DOI 10.1007/BF03033824                                                              
   Lindl KA, 2010, J NEUROIMMUNE PHARM, V5, P294, DOI 10.1007/s11481-010-9205-z
   LIPTON SA, 1994, ANN NY ACAD SCI, V747, P205
   LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407                                                     
   Lipton SA, 1991, BRAIN PATHOL, V1, P193, DOI 10.1111/j.1750-3639.1991.tb00659.x
   Maiti KK, 2006, ANGEW CHEM INT EDIT, V45, P2907, DOI 10.1002/anie.200600312
   MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015                                                             
   Martin M, 2000, ANTIMICROB AGENTS CH, V44, P3150, DOI 10.1128/AAC.44.11.3150-3154.2000
   MASEREEUW R, 1994, PHARMACEUT RES, V11, P324, DOI 10.1023/A:1018932213953
   MASOOD R, 1990, MOL PHARMACOL, V37, P590
   McArthur JC, 1999, SEMIN NEUROL, V19, P129, DOI 10.1055/s-2008-1040831
   MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013
   Miller DW, 1997, BIOCONJUGATE CHEM, V8, P649, DOI 10.1021/bc970118d
   Minagar A, 2008, MOL DIAGN THER, V12, P25, DOI 10.1007/BF03256266                                                              
   Misra A, 2003, J PHARM PHARM SCI, V6, P252
   NAMANE A, 1992, J MED CHEM, V35, P3039, DOI 10.1021/jm00094a018
   Namanja HA, 2012, J AM CHEM SOC, V134, P2976, DOI 10.1021/ja206867t
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Palmer A., 2010, NEUROBIOL DIS, V37, P13
   PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0
   PARDRIDGE WM, 1988, ANNU REV PHARMACOL, V28, P25
   Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660                                                        
   PIANTADOSI C, 1991, J MED CHEM, V34, P1408, DOI 10.1021/jm00108a025
   Polli JW, 1999, PHARMACEUT RES, V16, P1206, DOI 10.1023/A:1018941328702
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Reger M, 2002, J INT NEUROPSYCH SOC, V8, P410, DOI 10.1017/S1355617701020215
   ROMEO VD, 1998, ADV DRUG DELIV REV, V29, P89
   Rouquayrol M, 2002, PHARMACEUT RES, V19, P1704, DOI 10.1023/A:1020913631309
   Rouquayrol M, 2001, CARBOHYD RES, V336, P161, DOI 10.1016/S0008-6215(01)00260-9
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Sallem W, 2006, BIOORGAN MED CHEM, V14, P7999, DOI 10.1016/j.bmc.2006.07.043
   SEKI T, 1994, BIOL PHARM BULL, V17, P1135
   Serradji N, 2004, J MED CHEM, V47, P6410, DOI 10.1021/jm040860g
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Skalka AM, 2005, CELL DEATH DIFFER, V12, P971, DOI 10.1038/sj.cdd.4401573
   Song L, 2003, J NEUROVIROL, V9, P399, DOI 10.1080/13550280390201704
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   SPECTOR R, 1986, AM J PHYSIOL, V250, pR292
   SPECTOR R, 1986, J NEUROCHEM, V46, P1308, DOI 10.1111/j.1471-4159.1986.tb00655.x
   SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Takasawa K, 1997, J PHARMACOL EXP THER, V281, P369
   Tamai I, 2000, J PHARM SCI, V89, P1371, DOI 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D
   Tamai I, 1997, J PHARMACOL EXP THER, V280, P410
   Taylor EM, 2002, CLIN PHARMACOKINET, V41, P81, DOI 10.2165/00003088-200241020-00001                                                
   Thomas SA, 1997, J PHARMACOL EXP THER, V281, P1211
   Varatharajan L, 2009, ANTIVIR RES, V84, P203, DOI 10.1016/j.antiviral.2009.07.015
   Ved PM, 2011, INT J PHARMACEUT, V411, P1, DOI 10.1016/j.ijpharm.2011.02.040
   Visalli V, 2007, NEUROSCIENCES, V8, P106
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang LL, 1996, J MED CHEM, V39, P826, DOI 10.1021/jm9408326
   Williams Sarah A. Thomas, 1996, Brain Research, V741, P230
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wu DA, 1998, BRAIN RES, V791, P313, DOI 10.1016/S0006-8993(98)00139-5
   Yang Z, 2005, J PHARM SCI-US, V94, P1577, DOI 10.1002/jps.20334
NR 112
TC 6
Z9 6
U1 1
U2 27
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUL
PY 2013
VL 10
IS 7
BP 973
EP 985
DI 10.1517/17425247.2013.781999
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 168LM
UT WOS:000320707300007
PM 23510097
DA 2018-01-05
ER

PT J
AU Roy, NH
   Chan, J
   Lambele, M
   Thali, M
AF Roy, Nathan H.
   Chan, Jany
   Lambele, Marie
   Thali, Markus
TI Clustering and Mobility of HIV-1 Env at Viral Assembly Sites Predict Its
   Propensity To Induce Cell-Cell Fusion
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GP41 CYTOPLASMIC TAIL; ENVELOPE
   GLYCOPROTEIN INCORPORATION; SUPERRESOLUTION IMAGING REVEALS; MATRIX
   PROTEIN; TYPE-1 MATRIX; PLASMA-MEMBRANE; VIROLOGICAL SYNAPSES; CLATHRIN
   ADAPTER; LIPID RAFTS
AB HIV-1 Env mediates virus attachment to and fusion with target cell membranes, and yet, while Env is still situated at the plasma membrane of the producer cell and before its incorporation into newly formed particles, Env already interacts with the viral receptor CD4 on target cells, thus enabling the formation of transient cell contacts that facilitate the transmission of viral particles. During this first encounter with the receptor, Env must not induce membrane fusion, as this would prevent the producer cell and the target cell from separating upon virus transmission, but how Env's fusion activity is controlled remains unclear. To gain a better understanding of the Env regulation that precedes viral transmission, we examined the nanoscale organization of Env at the surface of producer cells. Utilizing superresolution microscopy (stochastic optical reconstruction microscopy [STORM]) and fluorescence recovery after photobleaching (FRAP), we quantitatively assessed the clustering and dynamics of Env upon its arrival at the plasma membrane. We found that Gag assembly induced the aggregation of small Env clusters into larger domains and that these domains were completely immobile. Truncation of the cytoplasmic tail (CT) of Env abrogated Gag's ability to induce Env clustering and restored Env mobility at assembly sites, both of which correlated with increased Env-induced fusion of infected and uninfected cells. Hence, while Env trapping by Gag secures Env incorporation into viral particles, Env clustering and its sequestration at assembly sites likely also leads to the repression of its fusion function, and thus, by preventing the formation of syncytia, Gag helps to secure efficient transfer of viral particles to target cells.
C1 [Roy, Nathan H.; Thali, Markus] Univ Vermont, Grad Program Cell & Mol Biol, Burlington, VT 05405 USA.
   [Chan, Jany; Lambele, Marie; Thali, Markus] Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.
   [Thali, Markus] Univ Vermont, Coll Med, Burlington, VT USA.
   [Thali, Markus] Univ Vermont, CALS, Burlington, VT USA.
RP Thali, M (reprint author), Univ Vermont, Grad Program Cell & Mol Biol, Burlington, VT 05405 USA.
EM markus.thali@uvm.edu
RI sourisseau, marion/M-7542-2014
OI Thali, Markus/0000-0001-8621-2095
FU NIH grant [R01 AI080302, T32 AI055402-06A1]
FX Support for this work was provided by NIH grant R01 AI080302 to M.T. and
   training grant T32 AI055402-06A1 to N.H.R.
CR Akari H, 2000, J VIROL, V74, P4891, DOI 10.1128/JVI.74.10.4891-4893.2000
   AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4                                                   
   Bar-On D, 2012, J BIOL CHEM, V287, P27158, DOI 10.1074/jbc.M112.353250
   Baumgartel V, 2011, NAT CELL BIOL, V13, P469, DOI 10.1038/ncb2215
   Berlioz-Torrent C, 1999, J VIROL, V73, P1350
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773
   Brandano L, 2012, J VIROL, V86, P2347, DOI 10.1128/JVI.06047-11
   Byland R, 2007, MOL BIOL CELL, V18, P414, DOI 10.1091/mbc.E06-06-0535
   Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002
   CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0
   Chojnacki J, 2012, SCIENCE, V338, P524, DOI 10.1126/science.1226359
   DIMITROV DS, 1993, J VIROL, V67, P2182
   DORFMAN T, 1994, J VIROL, V68, P1689
   Dou J, 2009, VIROLOGY, V387, P341, DOI 10.1016/j.virol.2009.02.037
   Eckhardt M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022007
   Edwards TG, 2002, J VIROL, V76, P2683, DOI 10.1128/JVI.76.6.2683-2691.2002
   Egan MA, 1996, J VIROL, V70, P6547
   Eggeling C, 2009, NATURE, V457, P1159, DOI 10.1038/nature07596
   FREED EO, 1995, J VIROL, V69, P1984
   FREED EO, 1994, J VIROL, V68, P5311
   Freed EO, 1996, J VIROL, V70, P341
   Gaudin R, 2012, J CELL BIOL, V199, P467, DOI 10.1083/jcb.201201144
   Gomez CY, 2006, J VIROL, V80, P8796, DOI 10.1128/JVI.02159-05
   Grove J, 2011, J CELL BIOL, V195, P1071, DOI 10.1083/jcb.201108131
   Gunzenhauser J, 2012, NANO LETT, V12, P4705, DOI 10.1021/nl3021076
   Hess ST, 2007, P NATL ACAD SCI USA, V104, P17370, DOI 10.1073/pnas.0708066104
   Hogue IB, 2011, J VIROL, V85, P9749, DOI 10.1128/JVI.00743-11
   Huang B, 2008, SCIENCE, V319, P810, DOI 10.1126/science.1153529
   Hubner W, 2007, J VIROL, V81, P12596, DOI 10.1128/JVI.01088-07
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Itano MS, 2012, BIOPHYS J, V102, P1534, DOI 10.1016/j.bpj.2012.02.022
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Jiang JY, 2007, J VIROL, V81, P9999, DOI 10.1128/JVI.00592-07
   Johnson MC, 2011, AIDS RES HUM RETROV, V27, P239, DOI [10.1089/aid.2010.0350, 10.1089/AID.2010.0350]
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jorgenson RL, 2009, J VIROL, V83, P4060, DOI 10.1128/JVI.02425-08
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   Joyner AS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002234
   Kalia V, 2005, J VIROL, V79, P2097, DOI 10.1128/JVI.79.4.2097-2107.2005
   Kellner RR, 2007, NEUROSCIENCE, V144, P135, DOI 10.1016/j.neuroscience.2006.08.071
   Kemler I, 2010, J VIROL, V84, P6352, DOI 10.1128/JVI.00363-10
   Kiskowski MA, 2009, BIOPHYS J, V97, P1095, DOI 10.1016/j.bpj.2009.05.039
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Krementsov DN, 2010, TRAFFIC, V11, P1401, DOI 10.1111/j.1600-0854.2010.01111.x
   Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102
   Lehmann M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002456
   Lelek M, 2012, P NATL ACAD SCI USA, V109, P8564, DOI 10.1073/pnas.1013267109
   Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Lucas TM, 2010, VIROLOGY, V405, P548, DOI 10.1016/j.virol.2010.06.017
   Malkusch S, 2013, HISTOCHEM CELL BIOL, V139, P173, DOI 10.1007/s00418-012-1014-4
   MAMMANO F, 1995, J VIROL, V69, P3824
   Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004
   Murakami T, 2000, J VIROL, V74, P3548, DOI 10.1128/JVI.74.8.3548-3554.2000
   Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Murooka TT, 2012, NATURE, V490, P283, DOI 10.1038/nature11398
   Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839
   Ono A, 2010, BIOL CELL, V102, P335, DOI 10.1042/BC20090165
   Owen DM, 2010, J BIOPHOTONICS, V3, P446, DOI 10.1002/jbio.200900089
   Pereira CF, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-84
   Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699
   RIPLEY BD, 1977, J ROY STAT SOC B MET, V39, P172
   RIPLEY BD, 1979, J ROY STAT SOC B MET, V41, P368
   Rossy J, 2013, NAT IMMUNOL, V14, P82, DOI 10.1038/ni.2488
   ROWELL JF, 1995, J IMMUNOL, V155, P473
   SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q                                                    
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Sengupta P, 2011, NAT METHODS, V8, P969, DOI [10.1038/NMETH.1704, 10.1038/nmeth.1704]
   Shutt DC, 1998, J CELL SCI, V111, P99
   Sieber JJ, 2007, SCIENCE, V317, P1072, DOI 10.1126/science.1141727
   Snapp EL, 2003, CURR PROTOC CELL BIO, V21
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   SOUMPASIS DM, 1983, BIOPHYS J, V41, P95, DOI 10.1016/S0006-3495(83)84410-5                                                   
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924
   Sylwester A, 1997, J IMMUNOL, V158, P3996
   TAN X, 1993, J VIROL, V67, P6447
   van den Bogaart G, 2011, NATURE, V479, P552, DOI 10.1038/nature10545
   Veatch SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031457
   Waheed AA, 2009, VIRUS RES, V143, P162, DOI 10.1016/j.virusres.2009.04.007
   Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004
   Wyss S, 2005, J VIROL, V79, P12231, DOI 10.1128/JVI.79.19.12231-12241.2005
   YU XF, 1992, J VIROL, V66, P4966
   Zhong P, 2013, CURR OPIN VIROL, V3, P44, DOI 10.1016/j.coviro.2012.11.004
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 93
TC 42
Z9 42
U1 1
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUL
PY 2013
VL 87
IS 13
BP 7516
EP 7525
DI 10.1128/JVI.00790-13
PG 10
WC Virology
SC Virology
GA 160JT
UT WOS:000320116500027
PM 23637402
OA gold
DA 2018-01-05
ER

PT J
AU Raveendran, S
   Yoshida, Y
   Maekawa, T
   Kumar, S
AF Raveendran, Sreejith
   Yoshida, Yasuhiko
   Maekawa, Toru
   Kumar, Sakthi
TI Pharmaceutically versatile sulfated polysaccharide based bionano
   platforms
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Review
DE Sulfated polysaccharides; Nanoparticles; Drug-delivery; Bio-nanoscience;
   Polysaccharides; Nanotechnology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS;
   EXOPOLYSACCHARIDE-PRODUCING BACTERIUM; DRUG-DELIVERY SYSTEMS; IN-VITRO;
   CHONDROITIN SULFATE; DERMATAN SULFATE; HALOMONAS-MAURA; DEXTRAN SULFATE;
   BIOLOGICAL-ACTIVITIES
AB Sulfated polysaccharides are complex polysaccharide molecules with excellent physico-chemical properties and bioactivities. On the basis of origin, they are classified as plant, animal, microbial and chemically synthesized sulfated polysaccharides. They have been widely applied in the fields of material and biological sciences. Biocompatibility and biodegradability of these molecules facilitate their increased use in the nanoparticle synthesis and tissue engineering applications. This review focuses on the structure, function and applications of important types of natural and chemically derived sulfated polysaccharides in the fields of nanotechnology and biomedical sciences. In the first part, we discuss the classification and role of sulfated polysaccharides in various fields. Later, we elaborate the specific bionano applications of commercially important sulfated polysaccharides in ionic gelation, stabilizing, cross-linking, capping and encapsulation of drugs. Finally, we conclude with the future scope and advanced applications of sulfated polysaccharides in various fields of interdisciplinary science. From the Clinical Editor: This comprehensive review focuses on the structure, function, and applications of natural and chemically derived sulfated polysaccharides in the fields of nanotechnology and biomedical sciences. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Raveendran, Sreejith; Yoshida, Yasuhiko; Maekawa, Toru; Kumar, Sakthi] Toyo Univ, Bionano Elect Res Ctr, Grad Sch Interdisciplinary New Sci, Kawagoe, Saitama, Japan.
RP Kumar, S (reprint author), Toyo Univ, Bionano Elect Res Ctr, Grad Sch Interdisciplinary New Sci, Kawagoe, Saitama, Japan.
EM sakthi@toyo.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan; grant for the programme of the the strategic research foundation
   at private universities [S1101017]
FX Sreejith Raveendran would like to acknowledge the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT), Japan for the financial
   support under the Monbukagakusho fellowship. Also, part of this study
   has been supported by a grant for the programme of the the strategic
   research foundation at private universities S1101017, organized by the
   MEXT, Japan since April 2012.
CR Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   Alban S, 2002, CARBOHYD POLYM, V47, P267, DOI 10.1016/S0144-8617(01)00178-3
   Mata JA, 2006, RES MICROBIOL, V157, P827, DOI 10.1016/j.resmic.2006.06.004
   Aquino RS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018862
   Aquino RS, 2005, GLYCOBIOLOGY, V15, P11, DOI 10.1093/glycob/cwh138
   Arad M. S., 2010, CURR OPIN BIOTECH, V21, P358
   Arco Y, 2005, MICROBIOL-SGM, V151, P2841, DOI 10.1099/mic.0.27981-0
   Argandona M, 2005, FEMS MICROBIOL LETT, V244, P69, DOI 10.1016/j.femsle.2005.01.019
   Arias S, 2003, EXTREMOPHILES, V7, P319, DOI 10.1007/s00792-003-0325-8
   Ayala G. G., 2008, MOLECULES, V13, P2069
   BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132                                                         
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   Becker CF, 2007, J MOL GRAPH MODEL, V26, P391, DOI 10.1016/j.jmgm.2006.01.008
   Bejar V, 1998, J BIOTECHNOL, V61, P135, DOI 10.1016/S0168-1656(98)00024-8
   Bender FC, 2005, J VIROL, V79, P11588, DOI 10.1128/JVI.79.18.11588-11597.2005
   BEUTLER JA, 1993, ANTIVIR CHEM CHEMOTH, V4, P167, DOI 10.1177/095632029300400306                                                      
   Bouchotroch S, 2000, J IND MICROBIOL BIOT, V24, P374, DOI 10.1038/sj.jim.7000002
   Bouchotroch S, 2001, INT J SYST EVOL MICR, V51, P1625, DOI 10.1099/00207713-51-5-1625                                                      
   Calvo C, 1998, J IND MICROBIOL BIOT, V20, P205, DOI 10.1038/sj.jim.2900513
   CARRE V, 1995, BBA-GEN SUBJECTS, V1243, P175, DOI 10.1016/0304-4165(94)00144-M                                                    
   Chen Y, 2003, LETT PEPT SCI, V10, P621, DOI 10.1007/BF02442596                                                              
   Chen Y, 2007, AAPS PHARMSCITECH, V8
   Chen YL, 2008, BIOTECHNOL BIOENG, V101, P821, DOI 10.1002/bit.21953
   Chen YL, 2007, BIOMATERIALS, V28, P2294, DOI 10.1016/j.biomaterials.2007.01.027
   Cheng JJ, 2009, PROCESS BIOCHEM, V44, P453, DOI 10.1016/j.procbio.2008.12.012
   Costa LS, 2010, BIOMED PHARMACOTHER, V64, P21, DOI 10.1016/j.biopha.2009.03.005
   Coviello T, 2007, J CONTROL RELEASE, V119, P5, DOI 10.1016/j.jconrel.2007.01.004
   Crouzier T, 2010, CURR OPIN COLLOID IN, V15, P417, DOI 10.1016/j.cocis.2010.05.007
   Cumashi A, 2007, GLYCOBIOLOGY, V17, P541, DOI 10.1093/glycob/cwm014
   Daniel-da-Silva AL, 2007, BIOMACROMOLECULES, V8, P2350, DOI 10.1021/bm070096q
   Dhahri M, 2011, J BIOMED MATER RES A, V98A, P114, DOI 10.1002/jbm.a.33077
   Dietrich U, 2001, AIDS REV, V3, P89
   Eidi H, 2010, INT J PHARMACEUT, V396, P156, DOI 10.1016/j.ijpharm.2010.06.006
   FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544                                                          
   Gandhi NS, 2008, CHEM BIOL DRUG DES, V72, P455, DOI 10.1111/j.1747-0285.2008.00741.x
   Ghosh T, 2009, GLYCOBIOLOGY, V19, P2, DOI 10.1093/glycob/cwn092
   Ginzberg A, 2008, BIOTECHNOL BIOENG, V99, P411, DOI 10.1002/bit.21573
   Girod S, POLYELECTROLYTE COMP, P37
   Grassauer A, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-107
   Grenha A, 2010, J BIOMED MATER RES A, V92A, P1265, DOI 10.1002/jbm.a.32466
   Guangli Y, 2007, J OCEAN U CHINA, V6, P16
   Guezennec J, 1998, CARBOHYD POLYM, V37, P19, DOI 10.1016/S0144-8617(98)00006-X                                                   
   Guilherme MR, 2010, J COLLOID INTERF SCI, V352, P107, DOI 10.1016/j.jcis.2010.08.051
   Gustafson S, 1997, GLYCOBIOLOGY, V7, P1209, DOI 10.1093/glycob/7.8.1209
   HASUI M, 1995, INT J BIOL MACROMOL, V17, P293, DOI 10.1016/0141-8130(95)98157-T                                                    
   Hayashi K, 2008, INT IMMUNOPHARMACOL, V8, P109, DOI 10.1016/j.intimp.2007.10.017
   Ho YC, 2010, BIOCONJUGATE CHEM, V21, P28, DOI 10.1021/bc900208t
   Hoffart V, 2006, J CONTROL RELEASE, V113, P38, DOI 10.1016/j.jconrel.2006.03.020
   HOSOYA M, 1991, ANTIMICROB AGENTS CH, V35, P2515, DOI 10.1128/AAC.35.12.2515                                                          
   Levov AN, 2009, NANOTECHNOLOGY RUSSI, V4, P244
   Jain R, 2005, MAR BIOTECHNOL, V7, P184, DOI 10.1007/s10126-004-4025-x
   Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X                                                   
   Jaulneau V., 2010, J BIOMED BIOTECHNOL, V525291, P1
   Jayakumar R, 2007, INT J BIOL MACROMOL, V40, P175, DOI 10.1016/j.ijbiomac.2006.06.021
   Jiao YY, 2002, CIRCULATION, V105, P230, DOI 10.1161/hc0202.101988                                                           
   Kemp MM, 2010, WIRES NANOMED NANOBI, V2, P77, DOI 10.1002/wnan.68
   Kemp MM, 2009, BIOMACROMOLECULES, V10, P589, DOI 10.1021/bm801266t
   Keppeler S, 2009, CARBOHYD POLYM, V78, P973, DOI 10.1016/j.carbpol.2009.07.029
   Kumar AS, 2007, J BASIC MICROB, V47, P103, DOI 10.1002/jobm.200610203
   Laurienzo P, 2010, MAR DRUGS, V8, P2435, DOI 10.3390/md8092435
   Lee CT, 2006, BIOMACROMOLECULES, V7, P1179, DOI 10.1021/bm050995j
   Lee ES, 2007, BIOMATERIALS, V28, P2754, DOI 10.1016/j.biomaterials.2007.01.049
   Li W, 2011, MATER CHEM PHYS, V125, P518, DOI 10.1016/j.matchemphys.2010.10.023
   Lin YH, 2009, BIOMATERIALS, V30, P3332, DOI 10.1016/j.biomaterials.2009.02.036
   LINHARDT RJ, 1995, GEN PHARMACOL-VASC S, V26, P443, DOI 10.1016/0306-3623(94)00231-B
   Lira MCB, 2011, EUR J PHARM BIOPHARM, V79, P162, DOI 10.1016/j.ejpb.2011.02.013
   Liu Y, 2009, EUR J PHARM SCI, V37, P306, DOI 10.1016/j.ejps.2009.02.022
   Liu ZG, 2007, J BIOMED MATER RES A, V83A, P806, DOI 10.1002/jbm.a.31407
   Llamas I, 2006, ANTON LEEUW INT J G, V89, P395, DOI 10.1007/s10482-005-9043-9
   Llamas I, 2010, MAR DRUGS, V8, P2240, DOI 10.3390/md8082240
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   Martinez-Canovas MJ, 2004, INT J SYST EVOL MICR, V54, P1329, DOI 10.1099/ijs.0.63108-0
   Martinez-Canovas MJ, 2004, INT J SYST EVOL MICR, V54, P733, DOI 10.1099/ijs.0.02942-0
   Martinez-Checa F, 2002, APPL MICROBIOL BIOT, V58, P358, DOI 10.1007/s00253-001-0903-6
   Matsui MS, 2003, APPL BIOCHEM BIOTECH, V104, P13, DOI 10.1385/ABAB:104:1:13                                                           
   McGowan I, 2006, BIOLOGICALS, V34, P241, DOI 10.1016/j.biologicals.2006.08.002
   Mestechkina NM, 2010, APPL BIOCHEM MICRO+, V46, P267, DOI 10.1134/S000368381003004X
   Mori Y, 2010, INT J NANOMED, V5, P147
   Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973                                                        
   Murugesan S, 2006, LANGMUIR, V22, P3461, DOI 10.1021/la0534468
   Na K, 2007, J AM CHEM SOC, V129, P5788, DOI 10.1021/ja067707r
   Naim S, 2004, AAPS PHARMSCITECH, V5
   Nair R., 2009, J PHARM SCI RES, V1, P1
   Nicholas CAM, 2003, J APPL MICROBIOL, V96, P1057
   Nichols CAM, 2005, MAR BIOTECHNOL, V7, P253, DOI 10.1007/s10126-004-5118-2
   Nichols CM, 2005, MICROB ECOL, V49, P578, DOI 10.1007/s00248-004-0093-8
   Nie XH, 2006, INT J BIOL MACROMOL, V39, P228, DOI 10.1016/j.ijbiomac.2006.03.030
   O'Donnell Christopher D, 2008, Virol Sin, V23, P383, DOI 10.1007/s12250-008-2992-1
   Okajima-Kaneko M, 2007, PURE APPL CHEM, V79, P2039, DOI 10.1351/pac200779112039
   Pariah R. C., 1999, CANCER RES, V59, P3433
   Park K, 2004, LANGMUIR, V20, P11726, DOI 10.1021/la048646i
   Park W, 2009, BIOTECHNOL BIOPROC E, V14, P668, DOI 10.1007/s12257-009-0058-3
   Passirani C, 1998, PHARM RES-DORDR, V15, P1046, DOI 10.1023/A:1011930127562                                                         
   Paulert R, 2009, J PLANT DIS PROTECT, V116, P263, DOI 10.1007/BF03356321                                                              
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Pereira L, 2007, INT J BIOL BIOMEDICA, V1, P1
   Petit E, 2004, BIOMACROMOLECULES, V5, P445, DOI 10.1021/bm034257b
   Piyakulawat P, 2007, AAPS PHARMSCITECH, V8
   Poli A, 2010, MAR DRUGS, V8, P1779, DOI 10.3390/md8061779
   Pomin VH, 2009, BIOPOLYMERS, V91, P601, DOI 10.1002/bip.21200
   Pomin VH, 2008, GLYCOBIOLOGY, V18, P1016, DOI 10.1093/glycob/cwn085
   Pourjavadi A, 2007, REACT FUNCT POLYM, V67, P644, DOI 10.1016/j.reactfunctpolym.2007.04.007
   QUESADA E, 1990, INT J SYST BACTERIOL, V40, P261, DOI 10.1099/00207713-40-3-261                                                       
   Ramachandran R, 2010, INDIAN J BIOCHEM BIO, V47, P56
   Ranney D, 2005, J CONTROL RELEASE, V109, P222, DOI 10.1016/j.jconrel.2005.09.022
   Richert L, 2005, CURR MICROBIOL, V51, P379, DOI 10.1007/s00284-005-0069-z
   Roberts MA, 1999, TRENDS FOOD SCI TECH, V10, P169, DOI 10.1016/S0924-2244(99)00043-6
   de Souza MCR, 2007, J APPL PHYCOL, V19, P153, DOI 10.1007/s10811-006-9121-z
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   RUÍZ Gloria, 2006, Vitae, V13, P31
   Rusnati M, 2009, PHARMACOL THERAPEUT, V123, P310, DOI 10.1016/j.pharmthera.2009.05.001
   Santo VE, 2010, J SUPERCRIT FLUID, V54, P320, DOI 10.1016/j.supflu.2010.05.021
   Schiraldi C, 2010, APPL MICROBIOL BIOT, V87, P1209, DOI 10.1007/s00253-010-2677-1
   Sezer AD, 2008, EUR J PHARM BIOPHARM, V69, P189, DOI 10.1016/j.ejpb.2007.09.004
   Shi JB, 2007, CARBOHYD POLYM, V68, P687
   Sinha VR, 2001, INT J PHARM, V224, P19, DOI 10.1016/S0378-5173(01)00720-7
   SINTOV A, 1995, BIOMATERIALS, V16, P473, DOI 10.1016/0142-9612(95)98820-5
   Slepmann F, 2007, BIOMACROMOLECULES, V8, P3984
   Soisuwan Suwicha, 2010, American Journal of Applied Sciences, V7, P1038, DOI 10.3844/ajassp.2010.1038.1042
   Spanguolo P. A., 2005, FOOD HYDROCOLLOIDS, V19, P371
   Stiles J, 2008, INVEST OPHTH VIS SCI, V49, P1496, DOI 10.1167/iovs.07-1245
   Sundar S, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468-6996/11/1/014104
   Tan Q, 2011, INT J NANOMED, V6, P929, DOI 10.2147/IJN.S18753
   Tang XL, 2006, CANCER BIOL THER, V5, P1474, DOI 10.4161/cbt.5.11.3278                                                           
   Tiyaboonchai W, 2003, INT J PHARM, V255, P139, DOI 10.1016/S0378-5173(03)00055-3
   Toshihiko T., 2003, TRENDS GLYCOSCI GLYC, V15, P29
   Toskas G, 2011, CARBOHYD POLYM, V84, P1093, DOI 10.1016/j.carbpol.2010.12.075
   Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066                                                           
   Vicente CP, 2004, BLOOD, V104, P3965, DOI 10.1182/blood-2004-02-0598
   Vlierberghe S. V., 2011, BIOMACROMOLECULES, V12, P1387
   Vu B, 2009, MOLECULES, V14, P2535, DOI 10.3390/molecules14072535
   Wang J, 2008, INT J BIOL MACROMOL, V42, P127, DOI 10.1016/j.ijbiomac.2007.10.003
   Wijesekara I, 2011, CARBOHYD POLYM, V84, P14, DOI 10.1016/j.carbpol.2010.10.062
   Witvrouw M, 1997, GEN PHARMACOL-VASC S, V29, P497, DOI 10.1016/S0306-3623(96)00563-0
   WORAWATTANAMATEEKUL W, 1992, NIPPON SUISAN GAKK, V58, P1729
   Wu XZ, 2006, W INDIAN MED J, V55, P270
   Yu Guangli, 2010, Journal of Ocean University of China, V9, P193, DOI 10.1007/s11802-010-0193-7
   Yuk SH, 2011, BIOMACROMOLECULES, V12, P2335, DOI 10.1021/bm200413a
   Zhu W, 2006, PHYTOMEDICINE, V13, P695, DOI 10.1016/j.phymed.2005.11.003
NR 139
TC 22
Z9 22
U1 2
U2 45
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JUL
PY 2013
VL 9
IS 5
BP 605
EP 626
DI 10.1016/j.nano.2012.12.006
PG 22
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 166XO
UT WOS:000320593600004
PM 23347895
DA 2018-01-05
ER

PT J
AU Novikov, VV
   Varzatskii, OA
   Negrutska, VV
   Bubnov, YN
   Palchykovska, LG
   Dubey, IY
   Voloshin, YZ
AF Novikov, Valentin V.
   Varzatskii, Oleg A.
   Negrutska, Valentina V.
   Bubnov, Yurii N.
   Palchykovska, Larisa G.
   Dubey, Igor Y.
   Voloshin, Yan Z.
TI Size matters, so does shape: Inhibition of transcription of T7 RNA
   polymerase by iron(II) clathrochelates
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Drug design; Inhibitors; Clathrochelates; RNA polymerase; Macromolecular
   interfaces
ID PROTEIN-PROTEIN INTERACTIONS; IN-VITRO TRANSCRIPTION; STRUCTURAL BASIS;
   DIRHODIUM(II,II) COMPLEXES; ANCILLARY LIGANDS; DRUG DISCOVERY; CAGE
   COMPLEXES; HIV-1 PROTEASE; RUTHENIUM(II); MECHANISM
AB Coordination and organoelement compounds are rarely proposed as the drug candidates despite their vast potential in the area owing to their strictly controlled geometry and rather extensive surface. This is the first example of the inhibition of transcription in the system of T7 RNA polymerase by cage metal complexes. Their IC50 values reach as low as the nanomolar range, placing them among the most potent metal-based transcription inhibitors. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Novikov, Valentin V.; Bubnov, Yurii N.; Voloshin, Yan Z.] Nesmeyanov Inst Organoelement Cpds RAS, Moscow, Russia.
   [Varzatskii, Oleg A.] Vernadskii Inst Gen & Inorgan Chem NASU, Kiev, Ukraine.
   [Negrutska, Valentina V.; Palchykovska, Larisa G.; Dubey, Igor Y.] Inst Mol Biol & Genet NASU, Kiev, Ukraine.
RP Voloshin, YZ (reprint author), Nesmeyanov Inst Organoelement Cpds RAS, Moscow, Russia.
EM voloshin@ineos.ac.ru
RI Dubey, Igor/M-3629-2013; Novikov, Valentin/R-2946-2016; Negrutska,
   Valentyna/K-5967-2016
OI Dubey, Igor/0000-0003-4023-4293; Novikov, Valentin/0000-0002-0225-0594;
   Negrutska, Valentyna/0000-0003-1742-9797; Voloshin,
   Yan/0000-0003-2823-6560; Palchykovska, Larysa/0000-0002-9524-7414
FU Marie Curie IIF Scheme of the 7th EU Framework Program [295160]; RFBR
   [11-03-12117, 11-03-12181, 11-03-90458, 12-03-33107, 12-03-90431]; SFFR
   of Ukraine [F40.4/078, 0112U004235]; RAS
FX This research was supported by the Marie Curie IIF Scheme of the 7th EU
   Framework Program (grant 295160), the RFBR (grants 11-03-12117,
   11-03-12181, 11-03-90458, 12-03-33107 and 12-03-90431), SFFR of Ukraine
   (grants F40.4/078 and 0112U004235), and RAS (program 6). We thank Dr. A
   Belov for technical assistance.
CR Aguirre JD, 2009, INORG CHEM, V48, P4435, DOI 10.1021/ic900164j
   Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343
   Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305
   Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999                                                                   
   Chen X, 2010, J INORG BIOCHEM, V104, P576, DOI 10.1016/j.jinorgbio.2010.01.010
   Chifotides HT, 2004, INORG CHEM, V43, P1175, DOI 10.1021/ic034438m
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   Davies CL, 2009, DALTON T, P10141, DOI 10.1039/b915776j
   Fricker SP, 2007, DALTON T, P4903, DOI 10.1039/b705551j
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   Fu PKL, 2003, INORG CHEM, V42, P878, DOI 10.1021/ic020338p
   Gao F, 2009, INORG CHEM, V48, P5599, DOI 10.1021/ic900902f
   Gunasekaran K, 2004, PROTEINS, V57, P433, DOI 10.1002/prot.20232
   Judd DA, 2001, J AM CHEM SOC, V123, P886, DOI 10.1021/ja001809e
   Kennedy WP, 2007, J MOL BIOL, V370, P256, DOI 10.1016/j.jmb.2007.03.041
   Lee GM, 2009, SCIENCE, V324, P213, DOI 10.1126/science.1169378
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Meggers E, 2011, ANGEW CHEM INT EDIT, V50, P2442, DOI 10.1002/anie.201005673
   Meggers E, 2009, CHEM COMMUN, P1001, DOI 10.1039/b813568a
   Oleksi A, 2006, ANGEW CHEM INT EDIT, V45, P1227, DOI 10.1002/anie.200503822
   Ozbabacan SEA, 2010, CURR OPIN DRUG DISC, V13, P527
   Piestrzeniewicz M, 1998, ACTA BIOCHIM POL, V45, P127
   Puvvada MS, 1997, BIOCHEMISTRY-US, V36, P2478, DOI 10.1021/bi952490r
   Sargeson AM, 1996, COORDIN CHEM REV, V151, P89, DOI 10.1016/S0010-8545(96)90197-6
   Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vassylyev DG, 2007, NATURE, V448, P163, DOI 10.1038/nature05931
   Voloshin YZ, 2007, RUSS CHEM B+, V56, P577, DOI 10.1007/s11172-007-0100-6
   Voloshin YZ, 2005, ANGEW CHEM INT EDIT, V44, P3400, DOI 10.1002/anie.200463070
   Voloshin Y.Z., 2002, CLATHROCHELATES SYNT
   Wagner CE, 2003, J MED CHEM, V46, P2823, DOI 10.1021/jm020326d
   Wilson AJ, 2009, CHEM SOC REV, V38, P3289, DOI 10.1039/b807197g
   Yin H, 2005, ANGEW CHEM INT EDIT, V44, P4130, DOI 10.1002/anie.200461786
   Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5
NR 34
TC 30
Z9 30
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0162-0134
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD JUL
PY 2013
VL 124
BP 42
EP 45
DI 10.1016/j.jinorgbio.2013.03.005
PG 4
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
SC Biochemistry & Molecular Biology; Chemistry
GA 159ZZ
UT WOS:000320087100006
PM 23598064
DA 2018-01-05
ER

PT J
AU Habib, I
   Smolarek, D
   Hattab, C
   Grodecka, M
   Hassanzadeh-Ghassabeh, G
   Muyldermans, S
   Sagan, S
   Gutierrez, C
   Laperche, S
   Le-Van-Kim, C
   Colin Aronovicz, Y
   Wasniowska, K
   Gangnard, S
   Bertrand, O
AF Habib, Ibrahim
   Smolarek, Dorota
   Hattab, Claude
   Grodecka, Magdalena
   Hassanzadeh-Ghassabeh, Gholamreza
   Muyldermans, Serge
   Sagan, Sandrine
   Gutierrez, Carlos
   Laperche, Syria
   Le-Van-Kim, Caroline
   Colin Aronovicz, Yves
   Wasniowska, Kazimiera
   Gangnard, Stephane
   Bertrand, Olivier
TI VHH (nanobody) directed against human glycophorin A: A tool for
   autologous red cell agglutination assays
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE VHH; Nanobody; Glycophorin A; Autologous erythrocyte agglutination
   assay; HIV
ID HIV-1 INFECTION; CHAGAS-DISEASE; WHOLE-BLOOD; ANTIBODIES; DIAGNOSIS;
   PROTEINS; NEUROCYSTICERCOSIS; ELIMINATION; PERFORMANCE; ANTIGENS
AB The preparation of a VHH (nanobody) named IH4 that recognizes human glycophorin A (GPA) is described. IH4 was isolated by screening a library prepared from the lymphocytes of a dromedary immunized by human blood transfusion. Phage display and panning against GPA as the immobilized antigen allowed isolating this VHH. IH4, representing 67% of the retrieved VHH sequences, was expressed as a soluble correctly folded protein in SHuffle Escherichia coli cells, routinely yielding approximately 100 mg/L fermentation medium. Because IH4 recognizes GPA independently of the blood group antigens, it recognizes red cells of all humans with the possible exception of those with some extremely rare genetic background. The targeted linear epitope comprises the GPA Y52PPE55 sequence. Based on surface plasmon resonance results, the dissociation constant of the IH4-GPA equilibrium is 33 nM. IH4 is a stable protein with a transition melting temperature of 75.8 degrees C (measured by differential scanning calorimetry). As proof of concept, we fused HIV p24 to IH4 and used the purified construct expressed in E. coli to show that IH4 was amenable to the preparation of autologous erythrocyte agglutination reagents: reconstituted blood prepared with serum from an HIV-positive patient was readily agglutinated by the addition of the bifunctional reagent. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Habib, Ibrahim; Smolarek, Dorota; Hattab, Claude; Le-Van-Kim, Caroline; Colin Aronovicz, Yves; Gangnard, Stephane; Bertrand, Olivier] INSERM, Inst Natl Transfus Sanguine, Lab Excellence GR Ex, UMR S 665, 6 Rue Alexandre Cabanel, F-75015 Paris, France.
   [Habib, Ibrahim; Hattab, Claude; Le-Van-Kim, Caroline; Colin Aronovicz, Yves; Gangnard, Stephane; Bertrand, Olivier] Univ Paris 07, F-75013 Paris, France.
   [Smolarek, Dorota; Grodecka, Magdalena; Wasniowska, Kazimiera] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland.
   [Hassanzadeh-Ghassabeh, Gholamreza; Muyldermans, Serge] Vrije Univ Brussel, Lab Cellular & Mol Immunol, B-1050 Brussels, Belgium.
   [Hassanzadeh-Ghassabeh, Gholamreza; Muyldermans, Serge] VIB, Dept Biol Struct, B-1050 Brussels, Belgium.
   [Sagan, Sandrine] UPMC Univ Paris 6, CNRS, ENS, LBM,UMR 7203, F-75005 Paris, France.
   [Gutierrez, Carlos] Univ Las Palmas, Fac Vet, Dept Anim Med & Surg, Las Palmas Gran Canaria 35416, Spain.
   [Laperche, Syria] Inst Natl Transfus Sanguine, Natl Reference HIV Transfus, Virol Unit, F-75015 Paris, France.
RP Bertrand, O (reprint author), INSERM, Inst Natl Transfus Sanguine, Lab Excellence GR Ex, UMR S 665, 6 Rue Alexandre Cabanel, F-75015 Paris, France.
EM olivier-s.bertrand@inserm.fr
RI SAGAN, Sandrine/I-8132-2013; Muyldermans, Serge/C-6418-2016; colin,
   yves/O-1910-2017; Gutierrez, Carlos/E-2989-2012
OI SAGAN, Sandrine/0000-0003-0083-4411; Muyldermans,
   Serge/0000-0002-3678-3575; colin, yves/0000-0001-5196-4254; Gutierrez,
   Carlos/0000-0003-0764-7408; le van kim, caroline/0000-0002-3251-1310
FU Association pour la Recherche en Transfusion [62-2012]; PHC Polonium
   [27691NH]; Region Ile de France (DIM Malinf)
FX This work was supported by the Association pour la Recherche en
   Transfusion (contract 62-2012) and by PHC Polonium (contract 27691NH).
   The Laboratory of Excellence GR-Ex is funded by the program
   "Investissements d'avenir." S.G. is supported by a grant from the Region
   Ile de France (DIM Malinf). We thank Julien Picot and Sylvain Bigot for
   help with cytometry experiments, and we thank Philippe Buscher for
   helpful discussions and for introducing us to autologous RBC
   agglutination assays.
CR Barfield CA, 2011, IEEE T BIO-MED ENG, V58, P814, DOI 10.1109/TBME.2010.2087334
   Blumenfeld OO, 1997, TRANSFUS CLIN BIOL, V4, P357, DOI 10.1016/S1246-7820(97)80041-9                                                   
   Branson D. M., 2000, AIDS REV, V2, P76
   Carod JF, 2012, DIAGN MICR INFEC DIS, V72, P85, DOI 10.1016/j.diagmicrobio.2011.09.014
   CARTRON JP, 1995, TRANSFUS CLIN BIOL, V2, P251, DOI 10.1016/S1246-7820(05)80091-6                                                   
   Centers for Disease Control and Prevention, FDA APPR RAP HIV ANT
   Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005
   Chappuis F, 2006, BRIT MED J, V333, P723, DOI 10.1136/bmj.38917.503056.7C
   Cochet S, 2001, J CHROMATOGR B, V750, P109, DOI 10.1016/S0378-4347(00)00434-5                                                   
   Cohen MS, 2011, NEW ENGL J MED, V364, P1943, DOI 10.1056/NEJMra1011874
   Daar ES, 2008, CURR OPIN HIV AIDS, V3, P10, DOI 10.1097/COH.0b013e3282f2e295
   De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103
   Downes K. A., 2008, TECHNICAL MANUAL, P437
   Duk M, 1997, ANAL BIOCHEM, V253, P98, DOI 10.1006/abio.1997.9994
   Ferreira AW, 2001, J CLIN MICROBIOL, V39, P4390, DOI 10.1128/JCM.39.12.4390-4395.2001
   GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8                                                    
   Goto Y, 2006, INFECT IMMUN, V74, P3939, DOI 10.1128/IAI.00101-06
   Gupta A, 2003, J CLIN MICROBIOL, V41, P2814, DOI 10.1128/JCM.41.7.2814-2821.2003
   Gupta A, 2001, J IMMUNOL METHODS, V256, P121, DOI 10.1016/S0022-1759(01)00435-5
   Habib I., 2011, 19 BIENN M INT SOC M
   Hassanzadeh-Ghassabeh G, 2011, METHODS MOL BIOL, V790, P239, DOI 10.1007/978-1-61779-319-6_19
   Kane B, 1999, ANN INTERN MED, V131, P481, DOI 10.7326/0003-4819-131-6-199909210-00101
   KEMP BE, 1988, SCIENCE, V241, P1352, DOI 10.1126/science.3413497
   Lobstein J, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-56
   Mabry R, 2010, PROTEIN ENG DES SEL, V23, P115, DOI 10.1093/protein/gzp073
   McCarthy JS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001601
   MISSELWITZ R, 1995, BBA-PROTEIN STRUCT M, V1250, P9, DOI 10.1016/0167-4838(95)00041-R
   Mohamad S, 2009, J CLIN MICROBIOL, V47, P1712, DOI 10.1128/JCM.00001-09
   Murphy G., 2008, Eurosurveillance, V13, P18966
   Muyldermans S, 2001, J Biotechnol, V74, P277
   RAHUEL C, 1988, EUR J BIOCHEM, V177, P605, DOI 10.1111/j.1432-1033.1988.tb14413.x
   RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x
   Reid ME, 1997, TRANSFUS CLIN BIOL, V4, P57, DOI 10.1016/S1246-7820(97)80011-0                                                   
   Reid ME, 2007, BLOOD GROUP ANTIGEN
   SIRIVICHAYAKUL S, 1993, J CLIN MICROBIOL, V31, P1373
   Smolarek D, 2010, CELL MOL LIFE SCI, V67, P3371, DOI 10.1007/s00018-010-0387-6
   Srivastava A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020270
   Van Nieuwenhove L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001682
   Veggiani G, 2011, PROTEIN EXPRES PURIF, V79, P111, DOI 10.1016/j.pep.2011.03.005
   Vincke Cecile, 2012, Methods Mol Biol, V907, P145, DOI 10.1007/978-1-61779-974-7_8
   Wesolowski J, 2009, MED MICROBIOL IMMUN, V198, P157, DOI 10.1007/s00430-009-0116-7
   White AC, 1997, CLIN INFECT DIS, V24, P101, DOI 10.1093/clinids/24.2.101                                                        
   Pardon E., 2011, WIPO patent application, Patent No. [W0/2011/147890 VIB VZW, 2011147890]
NR 43
TC 10
Z9 12
U1 3
U2 30
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JUL 1
PY 2013
VL 438
IS 1
BP 82
EP 89
DI 10.1016/j.ab.2013.03.020
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 156SW
UT WOS:000319845200014
PM 23541519
DA 2018-01-05
ER

PT J
AU Hillaireau, H
   Dereuddre-Bosquet, N
   Skanji, R
   Bekkara-Aounallah, F
   Caron, J
   Lepetre, S
   Argote, S
   Bauduin, L
   Yousfi, R
   Rogez-Kreuz, C
   Desmaele, D
   Rousseau, B
   Gref, R
   Andrieux, K
   Clayette, P
   Couvreur, P
AF Hillaireau, Herve
   Dereuddre-Bosquet, Nathalie
   Skanji, Rym
   Bekkara-Aounallah, Fawzia
   Caron, Joachim
   Lepetre, Sinda
   Argote, Sebastien
   Bauduin, Laurent
   Yousfi, Rahima
   Rogez-Kreuz, Christine
   Desmaele, Didier
   Rousseau, Bernard
   Gref, Ruxandra
   Andrieux, Karine
   Clayette, Pascal
   Couvreur, Patrick
TI Anti-HIV efficacy and biodistribution of nucleoside reverse
   transcriptase inhibitors delivered as squalenoylated prodrug
   nanoassemblies
SO BIOMATERIALS
LA English
DT Article
DE Squalenoylation; Nanoassemblies; Prodrug; Didanosine; Zalcitabine
ID DRUG; ANALOGS; NANOMEDICINE; GEMCITABINE; INFECTION; SYSTEMS
AB Due to their hydrophilic nature, most nucleoside reverse transcriptase inhibitors (NRTIs) display a variable bioavailability after oral administration and a poor control over their biodistribution, thus hampering their access to HIV sanctuaries. The limited cellular uptake and activation in the triphosphate form of NRTIs further restrict their efficacy and favour the emergence of viral resistance. We have shown that the conjugation of squalene (sq) to the nucleoside analogues dideoxycytidine (ddC) and didanosine (ddI) leads to amphiphilic prodrugs (ddC-sq and ddI-sq) that spontaneously self-organize in water as stable nanoassemblies of 100-300 nm. These nanoassemblies can also be formulated with polyethylene glycol coupled to either cholesterol (Chol-PEG) or squalene (sq-PEG). When incubated with peripheral blood mononuclear cells (PBMCs) in vitro infected with HIV, the NRTI-sq prodrugs enhanced the antiviral efficacy of the parent NRTIs, with a 2- to 3-fold decrease of the 50% effective doses and a nearly 2-fold increase of the selectivity index. This was also the case with HIV-1 strains resistant to ddC and/or ddI. The enhanced antiviral activity of ddI-sq was correlated with an up to 5-fold increase in the intracellular concentration of the corresponding pharmacologically active metabolite ddA-TP. The ddI-sq prodrug was further investigated in vivo by the oral route, the preferred route of administration of NRTIs. Pharmacokinetics studies performed on rats showed that the prodrug maintained low amounts of free ddI in the plasma. Administration of H-3-ddI-sq led to radioactivity levels higher in the plasma and relevant organs in HIV infection as compared to administration of free H-3-ddI. Taken together, these results show the potential of the squalenoylated prodrugs of NRTIs to enhance their absorption and improve their biodistribution, but also to enhance their intracellular delivery and antiviral efficacy towards HIV-infected cells. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Hillaireau, Herve; Skanji, Rym; Bekkara-Aounallah, Fawzia; Caron, Joachim; Lepetre, Sinda; Desmaele, Didier; Gref, Ruxandra; Andrieux, Karine; Couvreur, Patrick] Univ Paris 11, Inst Galien Paris Sud, UMR 8612, F-92290 Chatenay Malabry, France.
   [Hillaireau, Herve; Skanji, Rym; Bekkara-Aounallah, Fawzia; Caron, Joachim; Lepetre, Sinda; Desmaele, Didier; Gref, Ruxandra; Andrieux, Karine; Couvreur, Patrick] CNRS, F-92290 Chatenay Malabry, France.
   [Dereuddre-Bosquet, Nathalie; Yousfi, Rahima; Rogez-Kreuz, Christine; Clayette, Pascal] CEA, Bertin Pharma, Neurovirol Dept, F-92265 Fontenay Aux Roses, France.
   [Bekkara-Aounallah, Fawzia] Univ Djillali Liabes Sidi Bel Abbes, LCOPM, Sidi Bel Abbes 22000, Algeria.
   [Argote, Sebastien; Rousseau, Bernard] CEA Saclay, Dept Radiolabeled Mol, F-91191 Gif Sur Yvette, France.
   [Bauduin, Laurent] CEA, Bertin Pharma, Bioanal Dept, F-91191 Gif Sur Yvette, France.
RP Couvreur, P (reprint author), Univ Paris 11, Inst Galien Paris Sud, UMR 8612, 5 Rue JB Clement, F-92290 Chatenay Malabry, France.
EM patrick.couvreur@u-psud.fr
RI Hillaireau, Herve/U-7781-2017; Lepetre-Mouelhi, Sinda/J-7176-2012;
   Andrieux, Karine/P-3010-2017
OI Hillaireau, Herve/0000-0002-0628-7618; Andrieux,
   Karine/0000-0002-2002-7556; Patrick, COUVREUR/0000-0001-7961-5443
FU European Research Council under the European Community's Seventh
   Framework Programme [249835]; PRES Universud Paris (Institut du
   medicament, appel d'offre)
FX The research leading to these results has received funding from the
   European Research Council under the European Community's Seventh
   Framework Programme FP7/2007-2013 (grant agreement no 249835). The
   financial support of the PRES Universud Paris (Institut du medicament,
   appel d'offre 2008) is acknowledged. The authors wish to thank Julie
   Mouguin (UMR CNRS 8612) and Danielle Jaillard (CCME, Univ. Paris-Sud,
   Orsay) for TEM experiments, Thierry Pouget (LVMH, France) for FF-TEM
   experiments, Helene Chacun (UMR CNRS 8612) for radioactivity
   experiments, Karen Storck (Bertin Pharma) for PBMC experiments, Celine
   Declein and Emeline Chu-van (Bertin Pharma) for the LC-MS/MS bioanalysis
   experiments, Valerie Domergue-Dupont (IFR IPSIT, Chatenay-Malabry,
   France) for animal experiments, Angelo Paci (UMR 8203, Institut Gustave
   Roussy, Univ. Paris-Sud) for pharmacokinetics calculations and Sylvie
   Demignot (UMRS 872, Ecole Pratique des Hautes Etudes, France) for
   helpful comments.
CR BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Becher F, 2003, J MASS SPECTROM, V38, P879, DOI 10.1002/jms.500
   Bekkara-Aounallah F, 2008, ADV FUNCT MATER, V18, P3715, DOI 10.1002/adfm.200800705
   Bildstein L, 2010, J CONTROL RELEASE, V147, P163, DOI 10.1016/j.jconrel.2010.07.120
   Calogeropoulou T, 2003, CURR TOP MED CHEM, V3, P1467, DOI 10.2174/1568026033451763
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Gallois-Montbrun S, 2004, MINI-REV MED CHEM, V4, P361
   Hillaireau H, 2006, J NANOSCI NANOTECHNO, V6, P2608, DOI 10.1166/jnn.2006.453
   Lyseng-Williamson KA, 2005, DRUGS, V65, P413, DOI 10.2165/00003495-200565030-00006
   MABONDZO A, 1991, RES VIROLOGY, V142, P205, DOI 10.1016/0923-2516(91)90058-B
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Reddy LH, 2008, J PHARMACOL EXP THER, V325, P484, DOI 10.1124/jpet.107.133751
   Rejiba S, NANOMEDICINE, V201, P841
   Roisin A, 2004, J BIOL CHEM, V279, P9208, DOI 10.1074/jbc.M311594200
   Skanji R, 2011, INT J PHARMACEUT, V414, P285, DOI 10.1016/j.ijpharm.2011.05.005
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
NR 17
TC 14
Z9 14
U1 1
U2 86
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2013
VL 34
IS 20
BP 4831
EP 4838
DI 10.1016/j.biomaterials.2013.03.022
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 137UR
UT WOS:000318464200014
PM 23562054
DA 2018-01-05
ER

PT J
AU DeLucia, M
   Mehrens, J
   Wu, Y
   Ahn, J
AF DeLucia, Maria
   Mehrens, Jennifer
   Wu, Ying
   Ahn, Jinwoo
TI HIV-2 and SIVmac Accessory Virulence Factor Vpx Down-regulates SAMHD1
   Enzyme Catalysis Prior to Proteasome-dependent Degradation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RESTRICTION FACTOR SAMHD1; AICARDI-GOUTIERES SYNDROME; CD4(+) T-CELLS;
   IMMUNODEFICIENCY-VIRUS VPX; DENDRITIC CELLS; TRIPHOSPHATE
   TRIPHOSPHOHYDROLASE; UBIQUITIN LIGASE; PROTEIN; INFECTION; REPLICATION
AB SAMHD1, a dGTP-regulated deoxyribonucleoside triphosphate (dNTP) triphosphohydrolase, down-regulates dNTP pools in terminally differentiated and quiescent cells, thereby inhibiting HIV-1 infection at the reverse transcription step. HIV-2 and simian immunodeficiency virus (SIV) counteract this restriction via a virion-associated virulence accessory factor, Vpx (Vpr in some SIVs), which loads SAMHD1 onto CRL4-DCAF1 E3 ubiquitin ligase for polyubiquitination, programming it for proteasome-dependent degradation. However, the detailed molecular mechanisms of SAMHD1 recruitment to the E3 ligase have not been defined. Further, whether divergent, orthologous Vpx proteins, encoded by distinct HIV/SIV strains, bind SAMHD1 in a similar manner, at a molecular level, is not known. We applied surface plasmon resonance analysis to assess the requirements for and kinetics of binding between various primate SAMHD1 proteins and Vpx proteins from SIV or HIV-2 strains. Our data indicate that Vpx proteins, bound to DCAF1, interface with the C terminus of primate SAMHD1 proteins with nanomolar affinity, manifested by rapid association and slow dissociation. Further, we provide evidence that Vpx binding to SAMHD1 inhibits its catalytic activity and induces disassembly of a dGTP-dependent oligomer. Our studies reveal a previously unrecognized biochemical mechanism of Vpx-mediated SAMHD1 inhibition: direct down-modulation of its catalytic activity, mediated by the same binding event that leads to SAMHD1 recruitment to the E3 ubiquitin ligase for proteasome-dependent degradation.
C1 [DeLucia, Maria; Mehrens, Jennifer; Wu, Ying; Ahn, Jinwoo] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
   [DeLucia, Maria; Mehrens, Jennifer; Wu, Ying; Ahn, Jinwoo] Univ Pittsburgh, Sch Med, Pittsburgh Ctr HIV Prot Interact, Pittsburgh, PA 15260 USA.
RP Ahn, J (reprint author), Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
EM jahn@structbio.pitt.edu
FU National Institutes of Health [P50GM082251]; University of Pittsburgh
   School of Medicine
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant P50GM082251. This work was also supported by funds from the
   University of Pittsburgh School of Medicine.
CR Ahn J, 2012, J BIOL CHEM, V287, P12550, DOI 10.1074/jbc.M112.340711
   Ahn J, 2010, J BIOL CHEM, V285, P37333, DOI 10.1074/jbc.M110.133181
   Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964
   Beloglazova N, 2013, J BIOL CHEM, V288, P8101, DOI 10.1074/jbc.M112.431148
   Bergamaschi A, 2009, J VIROL, V83, P4854, DOI 10.1128/JVI.00187-09
   Berger A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002425
   Brandariz-Nunez A, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-49
   Britan-Rosich E, 2011, J MOL BIOL, V410, P1065, DOI 10.1016/j.jmb.2011.03.058
   Chen RX, 2004, J BIOL CHEM, V279, P28419, DOI 10.1074/jbc.M403875200
   Descours B, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-87
   Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623
   Goncalves A, 2012, HUM MUTAT, V33, P1116, DOI 10.1002/humu.22087
   Goujon C, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-2
   Gramberg T, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-26
   Gramberg T, 2010, J VIROL, V84, P1387, DOI 10.1128/JVI.01437-09
   Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992                                                                    
   Hofmann H, 2012, J VIROL, V86, P12552, DOI 10.1128/JVI.01657-12
   Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195
   KAWAMURA M, 1994, MICROBIOL IMMUNOL, V38, P871, DOI 10.1111/j.1348-0421.1994.tb02140.x                                              
   Kim B, 2012, J BIOL CHEM, V287, P21570, DOI 10.1074/jbc.C112.374843
   Laguette N, 2012, CELL HOST MICROBE, V11, P205, DOI 10.1016/j.chom.2012.01.007
   Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117
   Lahouassa H, 2012, NAT IMMUNOL, V13, P223, DOI 10.1038/ni.2236
   Lim ES, 2012, CELL HOST MICROBE, V11, P194, DOI 10.1016/j.chom.2012.01.004
   Luban J, 2012, CELL HOST MICROBE, V12, P408, DOI 10.1016/j.chom.2012.10.002
   Pierce NW, 2009, NATURE, V462, P615, DOI 10.1038/nature08595
   Planelles V, 2012, CELL HOST MICROBE, V11, P103, DOI 10.1016/j.chom.2012.02.001
   Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628
   Puigdomenech I, 2013, J VIROL, V87, P2846, DOI 10.1128/JVI.02514-12
   Santa-Marta M, 2005, J BIOL CHEM, V280, P8765, DOI 10.1074/jbc.M409309200
   Santa-Marta M, 2007, MOL IMMUNOL, V44, P583, DOI 10.1016/j.molimm.2006.02.005
   Schaller T, 2012, SCIENCE, V335, P1313, DOI 10.1126/science.1221057
   Sharova N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000057
   Srivastava S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000059
   St Gelais C, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-105
   Vorontsov II, 2011, J BIOL CHEM, V286, P33158, DOI 10.1074/jbc.M111.250456
   Wei W, 2012, CELL MICROBIOL, V14, P1745, DOI 10.1111/j.1462-5822.2012.01835.x
   White TE, 2013, VIROLOGY, V436, P81, DOI 10.1016/j.virol.2012.10.029
   Wu L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-88
   Yan JP, 2013, J BIOL CHEM, V288, P10406, DOI 10.1074/jbc.M112.443796
   Yan N, 2012, NAT MED, V18, P1611, DOI 10.1038/nm.2980
   Yu HX, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-27
   YU XF, 1991, J VIROL, V65, P5088
   Zhang CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037477
NR 44
TC 20
Z9 21
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 28
PY 2013
VL 288
IS 26
BP 19116
EP 19126
DI 10.1074/jbc.M113.469007
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 176WB
UT WOS:000321335800046
PM 23677995
OA gold
DA 2018-01-05
ER

PT J
AU Dengler, EC
   Liu, JW
   Kerwin, A
   Torres, S
   Olcott, CM
   Bowman, BN
   Armijo, L
   Gentry, K
   Wilkerson, J
   Wallace, J
   Jiang, XM
   Carnes, EC
   Brinker, CJ
   Milligan, ED
AF Dengler, Ellen C.
   Liu, Juewen
   Kerwin, Audra
   Torres, Sergio
   Olcott, Clara M.
   Bowman, Brandi N.
   Armijo, Leisha
   Gentry, Katherine
   Wilkerson, Jenny
   Wallace, James
   Jiang, Xingmao
   Carnes, Eric C.
   Brinker, C. Jeffrey
   Milligan, Erin D.
TI Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo
   delivery to the spinal cord
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Interleukin-10 cytokine; Gene delivery; Biocompatibility; Neuropathic
   pain; Cell and tissue viability; Non-viral vector
ID HIV-1 ENVELOPE GLYCOPROTEIN; CLINICAL-TRIALS WORLDWIDE; NONVIRAL
   GENE-THERAPY; NEUROPATHIC PAIN; IN-VITRO; CONTROLLED-RELEASE;
   DRUG-DELIVERY; ANTIINFLAMMATORY CYTOKINE; ADENOASSOCIATED VIRUS;
   PATHOLOGICAL PAIN
AB Amorphous mesoporous silica nanoparticles ('protocells') that support surface lipid bilayers recently characterized in vitro as carrier constructs for small drug and DNA delivery are reported here as highly biocompatible both in vitro and in vivo, involving the brain and spinal cord following spinal delivery into the lumbosacral subarachnoid space (intrathecal; i.t.). Specifically, positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP)-cholesterol (DOTAP:Chol) liposome-formulated protocells revealed stable in vitro cargo release kinetics and cellular interleukin-10 (IL-10) transgene transfection. Recent approaches using synthetic non-viral vector platforms to deliver the pain-suppressive therapeutic transgene, IL-10, to the spinal subarachnoid space have yielded promising results in animal models of peripheral neuropathy, a condition involving aberrant neuronal communication within sensory pathways in the nervous system.
   Non-viral drug and gene delivery protocell platforms offer potential flexibility because cargo release-rates can be pH-dependent. We report here that i.t. delivery of protocells, with modified chemistry supporting a surface coating of DOTAP: Chol liposomes and containing the IL-10 transgene, results in functional suppression of pain-related behavior in rats for extended periods. This study is the first demonstration that protocell vectors offer amenable and enduring in vivo biological characteristics that can be applied to spinal gene delivery. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Dengler, Ellen C.; Kerwin, Audra; Torres, Sergio; Olcott, Clara M.; Bowman, Brandi N.; Armijo, Leisha; Wilkerson, Jenny; Wallace, James] Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA.
   [Liu, Juewen; Jiang, Xingmao; Carnes, Eric C.; Brinker, C. Jeffrey] Univ New Mexico, Dept Chem & Nucl Engn, Albuquerque, NM 87131 USA.
   [Gentry, Katherine] Univ New Mexico, Dept Anesthesiol & Crit Care Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
   [Milligan, Erin D.] Univ New Mexico, Sch Med, Dept Neurosci, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
RP Milligan, ED (reprint author), Univ New Mexico, Sch Med, Dept Neurosci, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
EM edengler@salud.unm.edu; liujuewen@gmail.com; akerwin@salud.unm.edu;
   sertorres@salud.unm.edu; colcott@salud.unm.edu; bbowman@salud.unm.edu;
   liesha.armijo@gmail.com; k8gentry@gmail.com; jlwilkerson@salud.unm.edu;
   jwallace@salud.unm.edu; jiangxm@unm.edu; eric.carnes@gmail.com;
   cjbrink@sandia.gov; EMilligan@salud.unm.edu
RI Liu, Juewen/A-2701-2014; jiang, xingmao /H-3554-2013
OI Gentry, Katherine/0000-0002-3978-6659
FU National Science Foundation [DGE 0549500]; National Institute on Drug
   Abuse [2RO1 0181549500]; NCI Cancer Nanotechnology Platform Partnership
   grant [1U01CA151792-01]; U.S. Department of Energy, Office of Basic
   Energy Sciences, Division of Materials Sciences and Engineering; Sandia
   National Laboratories' Laboratory Directed Research and Development
   (LDRD) program; US Department of Energy's National Nuclear Security
   Administration [DE-AC04-94AL85000]
FX The authors would like to thank Linda C. Saland (Department of
   Neurosciences, University of New Mexico, Albuquerque, New Mexico) for
   her kind advice regarding tissue immunohistochemistry studies, Becky Lee
   and Genevieve Phillips (Fluorescence Microscopy Shared Resource,
   University of New Mexico, Albuquerque, New Mexico) for their assistance
   in spectral imaging and Tamara Roitbak (Department of Neurosurgery,
   Health Sciences Center, University of New Mexico) for assisting with
   confocal imaging. This work was funded by a National Science Foundation
   IGERT grant: Integrating Nanotechnology with Cell Biology and
   Neuroscience (DGE 0549500), and a grant from the National Institute on
   Drug Abuse: #2RO1 0181549500.; CJB received support from the NCI Cancer
   Nanotechnology Platform Partnership grant 1U01CA151792-01; the U.S.
   Department of Energy, Office of Basic Energy Sciences, Division of
   Materials Sciences and Engineering; and the Sandia National
   Laboratories' Laboratory Directed Research and Development (LDRD)
   program. Sandia is a multiprogram laboratory operated by Sandia
   Corporation, a wholly owned subsidiary of Lockheed Martin Company, for
   the US Department of Energy's National Nuclear Security Administration
   under contract DE-AC04-94AL85000. The authors report no conflict of
   interest.
CR Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126                                                             
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Beutler AS, 2005, CURR OPIN MOL THER, V7, P431
   Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102
   Bimbo LM, 2012, CURR DRUG METAB, V13, P1068
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Crook K, 1998, GENE THER, V5, P137, DOI 10.1038/sj.gt.3300554                                                           
   Davis RW, 2007, LANGMUIR, V23, P3864, DOI 10.1021/la062576t
   Edelstein ML, 2007, J GENE MED, V9, P833, DOI 10.1002/jgm.1100
   Gao F, 2009, J PHYS CHEM B, V113, P1796, DOI 10.1021/jp807956r
   Ginn SL, 2013, J GENE MED, V15, P65, DOI 10.1002/jgm.2698
   Goss James R, 2007, Expert Rev Neurother, V7, P487, DOI 10.1586/14737175.7.5.487
   HARVEY LO, 1986, BEHAV RES METH INSTR, V18, P623, DOI 10.3758/BF03201438
   Hudson SP, 2008, BIOMATERIALS, V29, P4045, DOI 10.1016/j.biomaterials.2008.07.007
   Jiang XM, 2006, J AM CHEM SOC, V128, P4512, DOI 10.1021/ja058260+
   KAISER J, 2011, SCIENCE, V333, P29
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Khan A, 2004, J DRUG TARGET, V12, P393, DOI 10.1080/10611860400003858
   Kim MH, 2011, ACS NANO, V5, P3568, DOI 10.1021/nn103130q
   Langer R, 1998, NATURE, V392, P5
   Ledeboer A., 2006, P 11 WORLD C PAIN IN
   Lee JK, 2011, ARCH PHARM RES, V34, P671, DOI 10.1007/s12272-011-0418-3
   Liu JW, 2009, J AM CHEM SOC, V131, P7567, DOI 10.1021/ja902039y
   Liu JW, 2009, J AM CHEM SOC, V131, P1354, DOI 10.1021/ja808018y
   Milligan ED, 2005, EUR J NEUROSCI, V21, P2136, DOI 10.1111/j.1460-9568.2005.04057.x
   Milligan ED, 2001, J NEUROSCI, V21, P2808
   Milligan ED, 2000, BRAIN RES, V861, P105, DOI 10.1016/S0006-8993(00)02050-3                                                   
   Milligan ED, 2006, NEURON GLIA BIOL, V2, P293, DOI 10.1017/S1740925X07000488
   Milligan ED, 2006, PAIN, V126, P294, DOI 10.1016/j.pain.2006.07.009
   Milligan ED, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-9
   Milligan ED, 2012, NEUROMODULATION, V15, P520, DOI 10.1111/j.1525-1403.2012.00462.x
   Miraucourt LS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001116
   Morille M, 2008, BIOMATERIALS, V29, P3477, DOI 10.1016/j.biomaterials.2008.04.036
   Murphy S, 1996, NEUROSCIENTIST, V2, P90, DOI 10.1177/107385849600200210                                                      
   Park EJ, 2009, TOXICOL LETT, V184, P18, DOI 10.1016/j.toxlet.2008.10.012
   Perez-Martinez FC, 2011, PHARM RES-DORDR, V28, P1843, DOI 10.1007/s11095-010-0364-7
   Qureshi AA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-177
   Rogers ML, 2012, J CONTROL RELEASE, V157, P183, DOI 10.1016/j.jconrel.2011.08.026
   Roy I, 2005, P NATL ACAD SCI USA, V102, P279, DOI 10.1073/pnas.0408039101
   Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   Samad T.A., 2004, P SOC NEUR
   Singh KP, 2011, J BIOMED NANOTECHNOL, V7, P60, DOI 10.1166/jbn.2011.1201
   Sloane EM, 2009, GENE THER, V16, P470, DOI 10.1038/gt.2009.21
   Sloane EM, 2009, GENE THER, V1, P1
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F
   Soderquist RG, 2010, PHARM RES-DORDR, V27, P841, DOI 10.1007/s11095-010-0077-y
   Sons Y, 2011, J SIGNAL TRANSDUCT, V2011
   Tarn D, 2013, ACCOUNTS CHEM RES, V46, P792, DOI 10.1021/ar3000986
   Trewyn BG, 2007, CHEM COMMUN, P3236, DOI 10.1039/b701744h
   Troutier AL, 2007, ADV COLLOID INTERFAC, V133, P1, DOI 10.1016/j.cis.2007.02.003
   Wang X, 2005, MOL THER, V12, P314, DOI 10.1016/j.ymthe.2005.03.032
   Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002
   Wilkerson JL, 2012, BRAIN BEHAV, V2, P155, DOI 10.1002/brb3.44
   Yang TH, 2007, NANO LETT, V7, P2446, DOI 10.1021/nl071184j
   Zha LY, 2011, BIOORG MED CHEM LETT, V21, P2415, DOI 10.1016/j.bmcl.2011.02.071
NR 60
TC 35
Z9 36
U1 6
U2 132
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 10
PY 2013
VL 168
IS 2
BP 209
EP 224
DI 10.1016/j.jconrel.2013.03.009
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 151ZP
UT WOS:000319499200010
PM 23517784
OA gold
DA 2018-01-05
ER

PT J
AU Hoppe, AD
   Scott, BL
   Welliver, TP
   Straight, SW
   Swanson, JA
AF Hoppe, Adam D.
   Scott, Brandon L.
   Welliver, Timothy P.
   Straight, Samuel W.
   Swanson, Joel A.
TI N-Way FRET Microscopy of Multiple Protein-Protein Interactions in Live
   Cells
SO PLOS ONE
LA English
DT Article
ID RECEPTOR-MEDIATED PHAGOCYTOSIS; LIVING CELLS; FLUORESCENT PROTEIN;
   STOICHIOMETRY; ACTIVATION; CDC42
AB Fluorescence Resonance Energy Transfer (FRET) microscopy has emerged as a powerful tool to visualize nanoscale protein-protein interactions while capturing their microscale organization and millisecond dynamics. Recently, FRET microscopy was extended to imaging of multiple donor-acceptor pairs, thereby enabling visualization of multiple biochemical events within a single living cell. These methods require numerous equations that must be defined on a case-by-case basis. Here, we present a universal multispectral microscopy method (N-Way FRET) to enable quantitative imaging for any number of interacting and non-interacting FRET pairs. This approach redefines linear unmixing to incorporate the excitation and emission couplings created by FRET, which cannot be accounted for in conventional linear unmixing. Experiments on a three-fluorophore system using blue, yellow and red fluorescent proteins validate the method in living cells. In addition, we propose a simple linear algebra scheme for error propagation from input data to estimate the uncertainty in the computed FRET images. We demonstrate the strength of this approach by monitoring the oligomerization of three FP-tagged HIV Gag proteins whose tight association in the viral capsid is readily observed. Replacement of one FP-Gag molecule with a lipid raft-targeted FP allowed direct observation of Gag oligomerization with no association between FP-Gag and raft-targeted FP. The N-Way FRET method provides a new toolbox for capturing multiple molecular processes with high spatial and temporal resolution in living cells.
C1 [Hoppe, Adam D.; Scott, Brandon L.] S Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA.
   [Welliver, Timothy P.; Swanson, Joel A.] Univ Michigan, Sch Med, Program Immunol, Ann Arbor, MI USA.
   [Straight, Samuel W.; Swanson, Joel A.] Univ Michigan, Sch Med, Ctr Live Cell Imaging, Ann Arbor, MI USA.
   [Swanson, Joel A.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
RP Hoppe, AD (reprint author), S Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA.
EM adam.hoppe@sdstate.edu
RI Swanson, Joel/P-4362-2014
OI Swanson, Joel/0000-0003-0900-8212
FU National Science Foundation [0953561]; South Dakota Governor's 2010
   center for the Biological Control and Analysis by Applied Photonics
   (BCAAP); South Dakota State University Chemistry and Biochemistry
   startup funds; Department of Education GAANN Fellowship [P200A100103];
   University of Michigan Basic Biomedical Sciences
FX This material is based on work supported by the National Science
   Foundation under Grant No. 0953561, the South Dakota Governor's 2010
   center for the Biological Control and Analysis by Applied Photonics
   (BCAAP), and South Dakota State University Chemistry and Biochemistry
   startup funds to ADH. A Department of Education GAANN Fellowship No.
   P200A100103 supported BLS. Construction of one of the microscopes was
   supported by funds from the University of Michigan Basic Biomedical
   Sciences. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andersson CA, 2000, CHEMOMETR INTELL LAB, V52, P1, DOI 10.1016/S0169-7439(00)00071-X
   Becker PL, 1996, FLUORESCENCE IMAGING, P1
   Beemiller P, 2006, PLOS BIOL, V4, P987, DOI 10.1137/journal.pbio.0040162
   Beemiller P, 2010, MOL BIOL CELL, V21, P470, DOI 10.1091/mbc.E08-05-0494
   Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1                                                   
   Bro R., 1998, MULTIWAY ANAL FOOD I
   Bro R, 2009, J CHEMOMETR, V23, P324, DOI 10.1002/cem.1206
   Cai DW, 2007, J CELL BIOL, V176, P51, DOI 10.1083/jcb.200605097
   Chen YC, 2011, J MICROSC-OXFORD, V244, P21, DOI 10.1111/j.1365-2818.2011.03488.x
   CLEGG RM, 1996, FLUORESCENCE IMAGING, P179
   Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X
   Galperin E, 2004, NAT METHODS, V1, P209, DOI 10.1038/NMETH720
   Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7                                                   
   Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200
   Hammond JW, 2009, PLOS BIOL, V7, P650, DOI 10.1371/journal.pbio.1000072
   Hogue IB, 2009, J VIROL
   Hohng S, 2004, BIOPHYS J, V87, P1328, DOI 10.1529/biophysj.104.043935
   Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4                                                   
   Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847
   Hoppe AD, 2008, 3D FRET RECONSTRUCTI
   Hoppe Adam D., 2007, P157, DOI 10.1007/978-3-540-71331-9_6
   Hoppe AD, 2009, CELL MICROBIOL, V11, P540, DOI 10.1111/j.1462-5822.2009.01283.x
   Kawata S, 1996, FLUORESCENCE IMAGING, P55
   Kim J, 2012, CYTOM PART A, V81A, P112, DOI 10.1002/cyto.a.21150
   Koushik SV, 2006, BIOPHYS J, V91, pL99, DOI 10.1529/biophysj.106.096206
   Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, pxxiii
   Lee J, 2010, ANGEW CHEM INT EDIT, V49, P9922, DOI 10.1002/anie.201005402
   Lichten CA, 2011, BMC BIOPHYS, V4, DOI 10.1186/2046-1682-4-10
   Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186
   Meyer S. L., 1992, DATA ANAL SCI ENG
   Nadrigny F, 2006, EUR BIOPHYS J BIOPHY, V35, P533, DOI 10.1007/s00249-005-0040-8
   Neher R, 2004, J MICROSC-OXFORD, V213, P46, DOI 10.1111/j.1365-2818.2004.01262.x
   Neher RA, 2004, MICROSC RES TECHNIQ, V64, P185, DOI 10.1002/jemt.20078
   Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945
   Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037
   Shirakawa H, 2004, BIOPHYS J, V86, P1739, DOI 10.1016/S0006-3495(04)74242-3                                                   
   Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5
   Sun YS, 2010, BIOPHYS J, V99, P1274, DOI 10.1016/j.bpj.2010.06.004
   Wlodarczyk J, 2008, BIOPHYS J, V94, P986, DOI 10.1529/biophysj.107.111773
   Woehler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061096
   Woehler A, 2010, BIOPHYS J, V99, P2344, DOI 10.1016/j.bpj.2010.07.053
   Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9                                                   
   Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049
   Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539                                                         
   Zal T, 2002, IMMUNITY, V16, P521, DOI 10.1016/S1074-7613(02)00301-1
NR 45
TC 25
Z9 25
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2013
VL 8
IS 6
AR e64760
DI 10.1371/journal.pone.0064760
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173SK
UT WOS:000321099000019
PM 23762252
OA gold
DA 2018-01-05
ER

PT J
AU Giavazzi, F
   Salina, M
   Cerbino, R
   Bassi, M
   Prosperi, D
   Ceccarello, E
   Damin, F
   Sola, L
   Rusnati, M
   Chiari, M
   Chini, B
   Bellini, T
   Buscaglia, M
AF Giavazzi, Fabio
   Salina, Matteo
   Cerbino, Roberto
   Bassi, Mattia
   Prosperi, Davide
   Ceccarello, Erica
   Damin, Francesco
   Sola, Laura
   Rusnati, Marco
   Chiari, Marcella
   Chini, Bice
   Bellini, Tommaso
   Buscaglia, Marco
TI Multispot, label-free biodetection at a phantom plastic-water interface
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE immunoassay; optical biosensor; protein microarray; biomolecular
   detection; reflective phantom interface
ID SURFACE-PLASMON RESONANCE; MONOCLONAL-ANTIBODY; BIOMOLECULAR
   INTERACTIONS; MICROARRAY APPLICATIONS; PROTEIN MICROARRAYS;
   KINETIC-ANALYSIS; BIOSENSORS; TECHNOLOGIES; THROUGHPUT;
   FUNCTIONALIZATION
AB Recognizing and quantifying specific biomolecules in aqueous samples are constantly needed in research and diagnostic laboratories. As the typical detection procedures are rather lengthy and involve the use of labeled secondary antibodies or other agents to provide a signal, efforts have been made over the last 10 y to develop alternative label-free methods that enable direct detection. We propose and demonstrate an extremely simple, low-cost, label-free biodetector based on measuring the intensity of light reflected by the interface between a fluid sample and an amorphous fluoropolymer substrate having a refractive index very close to that of water and hosting various antibodies immobilized in spots. Under these index-matching conditions, the amount of light reflected by the interface allows straightforward quantification of the amount of antigen binding to each spot. Using antibodies targeting heterologous immunoglobulins and antigens commonly used as markers for diagnoses of hepatitis B and HIV, we demonstrate the limit of detection of a few picograms per square millimeter of surface-bound molecules. We also show that direct and real-time access to the amount of binding molecules allows the precise extrapolation of adhesion rates, from which the concentrations of antigens in solution can be estimated down to fractions of nanograms per milliliter.
C1 [Giavazzi, Fabio; Salina, Matteo; Cerbino, Roberto; Ceccarello, Erica; Bellini, Tommaso; Buscaglia, Marco] Univ Milan, Dipartimento Biotecnol Med & Med Traslaz, I-20090 Segrate, Italy.
   [Giavazzi, Fabio; Salina, Matteo; Ceccarello, Erica] Proxentia Srl, I-20135 Milan, Italy.
   [Bassi, Mattia] Solvay Specialty Polymers Res & Dev Ctr, Dept Mat Sci, I-20021 Bollate, Italy.
   [Prosperi, Davide] Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy.
   [Damin, Francesco; Sola, Laura; Chiari, Marcella] CNR, Ist Chim Riconoscimento Mol, I-20131 Milan, Italy.
   [Rusnati, Marco] Univ Brescia, Dipartimento Med Mol & Traslaz, I-25123 Brescia, Italy.
   [Chini, Bice] CNR, Ist Neurosci, I-20129 Milan, Italy.
RP Bellini, T (reprint author), Univ Milan, Dipartimento Biotecnol Med & Med Traslaz, I-20090 Segrate, Italy.
EM tommaso.bellini@unimi.it; marco.buscaglia@unimi.it
RI Buscaglia, Marco/C-2435-2008; Cerbino, Roberto/A-2286-2008; Bellini,
   Tommaso/M-5510-2014; Giavazzi, Fabio/C-3054-2017; Prosperi,
   Davide/A-4379-2008
OI Buscaglia, Marco/0000-0001-5010-0278; Cerbino,
   Roberto/0000-0003-0434-7741; Bellini, Tommaso/0000-0003-4898-4400;
   Giavazzi, Fabio/0000-0003-4930-0592; Prosperi,
   Davide/0000-0003-4577-9575; Chiari, Marcella/0000-0002-4670-1430; Damin,
   Francesco/0000-0003-1780-7823; RUSNATI, Marco/0000-0001-9968-5908;
   Chini, Bice/0000-0002-1686-284X; Sola, Laura/0000-0002-2603-0318
FU Cariplo Foundation, Italy [2006-9869]
FX We thank Antonella Bugatti for performing SPR analyses and Dia.Pro
   Diagnostic Bioprobes for providing the antibodies and antigens. This
   work was supported by the Cariplo Foundation (Grant 2006-9869), Italy.
CR Boozer C, 2006, CURR OPIN BIOTECH, V17, P400, DOI 10.1016/j.copbio.2006.06.012
   Brash JL, 1996, CURR OPIN COLLOID IN, V1, P682, DOI 10.1016/S1359-0294(96)80109-9                                                   
   Cretich M, 2004, ANAL BIOCHEM, V332, P67, DOI 10.1016/j.ab.2004.05.041
   Cretich M, 2008, SENSOR ACTUAT B-CHEM, V132, P258, DOI 10.1016/j.snb.2008.01.033
   Drake AW, 2004, ANAL BIOCHEM, V328, P35, DOI 10.1016/j.ab.2003.12.025
   ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X
   Fan XD, 2008, ANAL CHIM ACTA, V620, P8, DOI 10.1016/j.aca.2008.05.022
   Gauglitz G, 2010, ANAL BIOANAL CHEM, V398, P2363, DOI 10.1007/s00216-010-3904-4
   Ghetta A, 2005, P NATL ACAD SCI USA, V102, P15866, DOI 10.1073/pnas.0505877102
   GROH W, 1991, MACROMOLECULES, V24, P6660, DOI 10.1021/ma00025a016                                                             
   Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+
   Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9
   Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034
   KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9                                                    
   LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7
   Luppa PB, 2011, TRAC-TREND ANAL CHEM, V30, P887, DOI 10.1016/j.trac.2011.01.019
   Martinez AW, 2008, P NATL ACAD SCI USA, V105, P19606, DOI 10.1073/pnas.0810903105
   Michaud GA, 2003, NAT BIOTECHNOL, V21, P1509, DOI 10.1038/nbt910
   Morasso C, 2010, ADV FUNCT MATER, V20, P3932, DOI 10.1002/adfm.201001274
   Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h
   Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7                                                   
   Ngom B, 2010, ANAL BIOANAL CHEM, V397, P1113, DOI 10.1007/s00216-010-3661-4
   NICKERSON DA, 1990, P NATL ACAD SCI USA, V87, P8923, DOI 10.1073/pnas.87.22.8923
   Ozkumur E, 2008, P NATL ACAD SCI USA, V105, P7988, DOI 10.1073/pnas.0711421105
   Pedrotti F. L., 1993, INTRO OPTICS, p[392, 402]
   Pirri G, 2004, ANAL CHEM, V76, P1352, DOI 10.1021/ac0352629
   Pizarro JC, 2001, FEBS LETT, V509, P463, DOI 10.1016/S0014-5793(01)03190-8                                                   
   Prosperi D, 2006, SMALL, V2, P1060, DOI 10.1002/smll.200600106
   Qavi AJ, 2009, ANAL BIOANAL CHEM, V394, P121, DOI 10.1007/s00216-009-2637-8
   Ramachandran N, 2005, FEBS J, V272, P5412, DOI 10.1111/j.1742-4685.2005.04971.x
   Rapp BE, 2010, ANAL BIOANAL CHEM, V398, P2403, DOI 10.1007/s00216-010-3906-2
   Rich RL, 2007, ANAL BIOCHEM, V361, P1, DOI 10.1016/j.ab.2006.10.040
   Rushi L, 2009, APPL BIOCHEM BIOTECH, V158, P432
   Walker J.M., 2009, BIOSENSORS BIODETECT
   Warsinke A, 2009, ANAL BIOANAL CHEM, V393, P1393, DOI 10.1007/s00216-008-2572-0
   Yalcin A, 2009, ANAL CHEM, V81, P625, DOI [10.1021/ac801954x, 10.1021/ac80101954x]
   Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4
   Zolg JW, 2004, MOL CELL PROTEOMICS, V3, P345, DOI 10.1074/mcp.M400007-MCP200
NR 38
TC 17
Z9 17
U1 1
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 4
PY 2013
VL 110
IS 23
BP 9350
EP 9355
DI 10.1073/pnas.1214589110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 165SD
UT WOS:000320503000043
PM 23696673
OA gold
DA 2018-01-05
ER

PT J
AU Dietrich, U
   Durr, R
   Koch, J
AF Dietrich, Ursula
   Duerr, Ralf
   Koch, Joachim
TI Peptides as Drugs: From Screening to Application
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Peptide inhibitors; Peptidomimetics; Protein-protein interactions;
   Binding hot spots; Peptide display; Peptide delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-PROTEIN INTERACTIONS; RANDOM
   SYSTEMATIC MUTAGENESIS; PACKAGING SIGNAL-PSI; IN-VIVO; INTERACTION
   SITES; MONOCLONAL-ANTIBODIES; HETEROLOGOUS PROTEINS; INHIBITORY PEPTIDE;
   BIOACTIVE PEPTIDES
AB Peptides are ideally suited to mimic natural ligands and thereby function in an antagonistic or agonistic way. Furthermore they are able to physiologically disrupt functional complexes due to their small size and specific binding properties. Proteins form homo-or heteromeric (macro) molecular complexes and intricate networks by interacting with small molecules, peptides, nucleic acids or other proteins. On average, five interaction partners have been estimated for any given cellular protein, illustrating the complexity of the formed 'interactomes' and the impact of their investigation. Many protein-protein interactions are mediated by hot-spots, which comprise only a small part of the large binding interface but account for 80% of the binding energy. Thus, these hot spots provide an 'Achilles heel' for pharmaceutical interventions aiming at the disruption of functional protein-protein complexes. Methods to select peptides for defined target structures include display technologies on phages, ribosomes or yeast, and the yeast-two-hybrid system. Once selected, these peptides can be optimized for their binding affinity using peptide arrays. Stabilization of biologically unstable peptides is achieved by the introduction of non-natural amino acids to form so-called peptidomimetics that are resistant to cellular proteases. Moreover, lipocalins and peptide aptamers represent scaffolded binding structures with unique binding characteristics and enhanced stability. In case of extracellular targets, like cell surface receptors or pathogens in patients' plasma, peptide inhibitors have direct access. Addressing intracellular targets with peptides is more difficult since short hydrophilic peptides generally do not cross plasma membranes on their own. However, intracellular uptake of peptides can be achieved by coupling to carrier systems like liposomes or nanoparticles or upon fusion to a protein transduction domain. Alternatively, peptides may be expressed within cells after transduction with viral vectors in a gene therapy setting. This review will summarize the broad potential of peptides as drugs, with special emphasis on peptides which inhibit protein-protein interactions.
C1 [Dietrich, Ursula; Duerr, Ralf; Koch, Joachim] Georg Speyer Haus, Inst Biomed Res, D-60596 Frankfurt, Germany.
RP Dietrich, U (reprint author), Georg Speyer Haus, Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.
EM ursula.dietrich@gsh.uni-frankfurt.de
FU Bundesministerium fur Gesundheit; Hessisches Ministerium fur
   Wissenschaft und Kunst
FX The Georg-Speyer-Haus is supported by the Bundesministerium fur
   Gesundheit and the Hessisches Ministerium fur Wissenschaft und Kunst.
CR Abed N, 2007, MOL CELL PROTEOMICS, V6, P2110, DOI 10.1074/mcp.M700105-MCP200
   ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533
   Benhar I, 2000, J MOL BIOL, V301, P893, DOI 10.1006/jmbi.2000.4021
   Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553
   Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1                                                   
   Buchholz CJ, 1998, NAT BIOTECHNOL, V16, P951, DOI 10.1038/nbt1098-951                                                             
   Burgoyne NJ, 2006, BIOINFORMATICS, V22, P1335, DOI 10.1093/bioinformatics/bt/079
   Caffrey DR, 2004, PROTEIN SCI, V13, P190, DOI 10.1110/ps.03323604
   Cervia JS, 2003, CLIN INFECT DIS, V37, P1102, DOI 10.1086/378302
   Chatterjee J, 2008, ACCOUNTS CHEM RES, V41, P1331, DOI 10.1021/ar8000603
   CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940
   Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272                                                        
   Colas Pierre, 2008, Curr Drug Discov Technol, V5, P190, DOI 10.2174/157016308785739875
   DeLano D. W., 2002, PYMOL MOL GRAPHICS S
   DeNardo SJ, 2003, CLIN CANCER RES, V9, p3854S
   DERVILLEZ X, 2010, J VIROL
   Dervillez X, 2006, CHEMMEDCHEM, V1, P330, DOI 10.1002/cmdc.200500062
   Dietz GPH, 2010, CURR PHARM BIOTECHNO, V11, P167, DOI 10.2174/138920110790909731                                                      
   Dietz J, 2008, CHEMMEDCHEM, V3, P749, DOI 10.1002/cmdc.200700194
   Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083                                                                 
   Durani S, 2008, ACCOUNTS CHEM RES, V41, P1301, DOI 10.1021/ar700265t
   Egelhofer M, 2004, J VIROL, V78, P568, DOI 10.1128/JVI.78.2.568-575.2004
   Evans TG, 2008, J EXP BIOL, V211, P3636, DOI 10.1242/jeb.022160
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0
   Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0
   Gebauer M, 2009, CURR OPIN CHEM BIOL, V13, P245, DOI 10.1016/j.cbpa.2009.04.627
   Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29
   Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567                                                         
   Groner B, 2009, PEPTIDES DRUGS DISCO
   Groves MR, 2001, J BIOL CHEM, V276, P27778, DOI 10.1074/jbc.M103470200
   Hanessian S, 2008, ACCOUNTS CHEM RES, V41, P1241, DOI 10.1021/ar8000052
   Harris KS, 2005, INFECT IMMUN, V73, P6981, DOI 10.1128/IAI.73.10.6981-6989.2005
   Hermann FG, 2009, HUM GENE THER, V20, P325, DOI 10.1089/hum.2006.158
   Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001                                                 
   Hilpert K, 2007, NAT PROTOC, V2, P1333, DOI 10.1038/nprot.2007.160
   Hohlbaum Andreas M, 2007, Expert Rev Clin Immunol, V3, P491, DOI 10.1586/1744666X.3.4.491
   JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340
   Jones S, 1997, J MOL BIOL, V272, P121, DOI 10.1006/jmbi.1997.1234
   Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13
   Kagan L, 2007, EUR J PHARM BIOPHARM, V67, P759, DOI 10.1016/j.ejpb.2007.04.002
   Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111
   Kehoe JW, 2005, CHEM REV, V105, P4056, DOI 10.1021/cr000261r
   Koch J., 2002, PEPTIDE ARRAYS MEMBR
   Krumpe LRH, 2006, INT J PEPT RES THER, V12, P79, DOI 10.1007/s10989-005-9002-3
   Li PW, 2001, NAT IMMUNOL, V2, P443
   Li X, 2004, J MOL BIOL, V344, P781, DOI 10.1016/j.jmb.2004.09.051
   Libyh MT, 1997, BLOOD, V90, P3978
   Lin JH, 2009, CURR DRUG METAB, V10, P661, DOI 10.2174/138920009789895499                                                      
   Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107
   Lo Conte L, 1999, J MOL BIOL, V285, P2177
   MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022                                                         
   Meloen R, 2004, MOL DIVERS, V8, P57, DOI 10.1023/B:MODI.0000025698.16766.11
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025                                                             
   Mersich C, 2008, J CHROMATOGR B, V861, P160, DOI 10.1016/j.jchromb.2007.06.031
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Newton Jessica, 2008, V185, P145
   Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0
   Pegram M D, 2000, Cancer Treat Res, V103, P57
   PEREZ F, 1992, J CELL SCI, V102, P717
   Plewnia G, 2007, J MOL BIOL, V369, P95, DOI 10.1016/j.jmb.2007.02.102
   Porter CJH, 2000, J PHARM SCI, V89, P297, DOI 10.1002/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P
   Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006
   Pustowka A, 2003, CHEMBIOCHEM, V4, P1093, DOI 10.1002/cbic.200300681
   Reimer U, 2002, CURR OPIN BIOTECH, V13, P315, DOI 10.1016/S0958-1669(02)00339-7
   RESNICK DA, 1994, AIDS RES HUM RETROV, V10, pS47
   Robertson D, 2003, NAT BIOTECHNOL, V21, P470, DOI 10.1038/nbt0503-470                                                             
   Rondot S, 2001, NAT BIOTECHNOL, V19, P75
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Schafmeister CE, 2008, ACCOUNTS CHEM RES, V41, P1387, DOI 10.1021/ar700283y
   Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shibasaki S, 2009, ANAL SCI, V25, P41, DOI 10.2116/analsci.25.41                                                           
   Shinya E, 1999, BIOMED PHARMACOTHER, V53, P471, DOI 10.1016/S0753-3322(00)88106-8
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Skerra A, 2008, FEBS J, V275, P2677, DOI 10.1111/j.1742-4658.2008.06439.x
   Skerra A, 2007, CURR OPIN BIOTECH, V18, P295, DOI 10.1016/j.copbio.2007.04.010
   SMITH AD, 1994, J VIROL, V68, P575
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187                                                          
   Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964
   Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057
   Ternois F, 2005, NAT STRUCT MOL BIOL, V12, P678, DOI 10.1038/nsmb967
   Toby GG, 2001, METHODS, V24, P201, DOI 10.1006/meth.2001.1182
   TRKOLA A, 1995, J VIROL, V69, P6609
   Tsantrizos YS, 2008, ACCOUNTS CHEM RES, V41, P1252, DOI 10.1021/ar8000519
   Urban JH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni033
   Vagner J, 2008, CURR OPIN CHEM BIOL, V12, P292, DOI 10.1016/j.cbpa.2008.03.009
   van der Slurs EO, 2006, J MOL BIOL, V361, P839, DOI 10.1016/j.jmb.2006.07.017
   van Lunzen J, 2007, MOL THER, V15, P1024, DOI 10.1038/mt.sj.6300124
   Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Wodak Shoshana J, 2002, Adv Protein Chem, V61, P9
   Wolkowicz R, 2005, J BIOL CHEM, V280, P15195, DOI 10.1074/jbc.M500254200
   Wu YD, 2008, ACCOUNTS CHEM RES, V41, P1231, DOI 10.1021/ar800216e
   Xu CW, 2002, ONCOGENE, V21, P5753, DOI 10.1038/sj.onc.1205680
   Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999                                                        
   Zahnd C, 2007, NAT METHODS, V4, P269, DOI 10.1038/NMETH1003
   Zhang H, 2008, J MOL BIOL, V378, P565, DOI 10.1016/j.jmb.2008.02.066
NR 99
TC 9
Z9 9
U1 1
U2 37
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD JUN
PY 2013
VL 14
IS 5
BP 501
EP 512
DI 10.2174/13892010113149990205                                            
          
PG 12
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 252DW
UT WOS:000326986200004
PM 22429133
DA 2018-01-05
ER

PT J
AU Aghasadeghi, MR
   Heidari, H
   Sadat, SM
   Irani, S
   Amini, S
   Siadat, SD
   Fazlhashemy, ME
   Zabihollahi, R
   Atyabi, SM
   Momen, SB
   Khosraavy, MS
   Davari, M
   Darvishmohammadi, T
   Doroudian, M
   Ardestani, MS
AF Aghasadeghi, Mohammad R.
   Heidari, Hossein
   Sadat, Seyed M.
   Irani, Shiva
   Amini, Safieh
   Siadat, Seyed D.
   Fazlhashemy, Mohammad E.
   Zabihollahi, Rezvan
   Atyabi, Seyed M.
   Momen, Seyed B.
   Khosraavy, Mohammad S.
   Davari, Mehdi
   Darvishmohammadi, Tahmineh
   Doroudian, Mohammad
   Ardestani, Mehdi S.
TI Lamivudine-PEGylated Chitosan: A Novel Effective Nanosized
   Antiretroviral Agent
SO CURRENT HIV RESEARCH
LA English
DT Article
DE HIV; AIDS; lamivudine; antiretroviral drugs; chitosan nanoparticle
ID DRUG-RESISTANCE; HIV-INFECTION; MANAGEMENT
AB Due to the fact that a definite treatment for AIDS disease has not been discovered so far, antiretroviral drugs are relatively significant in controlling the disease. In this study, Lamivudine-which is an old and effective anti-AIDS drug-was connected to PEGylated chitosan nanoparticle in order to produce a new and greater version of Lamivudine. First, physicochemical studies such as HNMR, FTIR spectroscopy and CHN analysis were performed to ensure the proper synthesis. Following that, Lamivudine-PEGylated Chitosan (LPC) drug was evaluated in terms of its inhibitory capability in producing HIV virions and its cytotoxicity in different doses. HIV virions were created by transfection of psPAX2, PmzNL4-3 and pMD2. G plasmids into HEK293T cell line. Also, assessment of the P24 amounts of cell supernatant was performed using ELISA method. Among the different doses of LPC drug (0.1, 1, 10 and 100 mu M), it was found that 0.1 mu M was the most effective and least toxic dose compared to Lamivudine in the same dose. Results of this study indicate that LPC drug has the ability to inhibit HIV virus replication in a more significant way in comparison to the old drug. Besides, the drug has a low cytotoxicity and is effective with a lower dose.
C1 [Aghasadeghi, Mohammad R.; Sadat, Seyed M.; Amini, Safieh; Fazlhashemy, Mohammad E.; Zabihollahi, Rezvan; Davari, Mehdi] Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran.
   [Heidari, Hossein; Irani, Shiva; Darvishmohammadi, Tahmineh] Islamic Azad Univ, Sci & Res Branch, Dept Biol, Tehran, Iran.
   [Siadat, Seyed D.] Pasteur Inst Iran, Dept Microbiol, Tehran, Iran.
   [Atyabi, Seyed M.; Momen, Seyed B.] Pasteur Inst Iran, Dept Pilot Biotechnol, Tehran, Iran.
   [Khosraavy, Mohammad S.] Pasteur Inst Iran, Dept Rabies, Tehran, Iran.
   [Ardestani, Mehdi S.] Tehran Med Sci Univ, Dept Radiopharm, Tehran, Iran.
   [Doroudian, Mohammad] Islamic Azad Univ, Cent Tehran Branch, Young Researchers & Elite Club, Tehran, Iran.
RP Ardestani, MS (reprint author), Tehran Med Sci Univ, Dept Radiopharm, Tehran, Iran.
EM shafieeardestani@gmail.com
RI aghasadeghi, mohammad reza/K-9497-2017; Sadat, Seyed Mehdi/L-8867-2017
OI aghasadeghi, mohammad reza/0000-0003-2186-0774; Sadat,
   Mehdi/0000-0001-7739-179X
FU Pasteur Institute of Iran [648]
FX This research is partially supported by Pasteur Institute of Iran (Grant
   No. 648). The authors have declared their deep gratitude to all
   technicians who supported the project.
CR Abbas AK, 2007, CELLULAR MOL IMMUNOL, P445
   Bishai D, 2010, VACCINE, V52631, P20
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   Flint SJ, 2000, MULTIPLE FACETS HUMA
   Hammer SM, 2005, NEW ENGL J MED, V353, P1702, DOI 10.1056/NEJMcp051203
   Jain NK, 2010, METHODS MOL BIOL, V624, P221, DOI 10.1007/978-1-60761-609-2_15
   Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1
   Marcus U, 2002, INTERVIROLOGY, V45, P260, DOI 10.1159/000067917
   Perry CM, 1997, DRUGS, V53, P657, DOI 10.2165/00003495-199753040-00008                                                
   Shafer RW, 2008, AIDS REV, V10, P67
   UNAIDS, 2010, UNAIDS REP GLOB AIDS
   Vergis EN, 2000, INFECT DIS CLIN N AM, V14, P809, DOI 10.1016/S0891-5520(05)70135-5
   Zabihollahi R, 2012, ACTA VIROL, V56, P11, DOI 10.4149/av_2012_01_11
   Zabihollahi R, 2012, INDIAN J PHARMACOL, V44, P448, DOI 10.4103/0253-7613.99301
NR 14
TC 3
Z9 3
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
EI 1873-4251
J9 CURR HIV RES
JI Curr. HIV Res.
PD JUN
PY 2013
VL 11
IS 4
BP 309
EP 320
DI 10.2174/1570162X113119990043                                            
          
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 224FS
UT WOS:000324868700008
PM 23808639
DA 2018-01-05
ER

PT J
AU Inci, F
   Tokel, O
   Wang, SQ
   Gurkan, UA
   Tasoglu, S
   Kuritzkes, DR
   Demirci, U
AF Inci, Fatih
   Tokel, Onur
   Wang, ShuQi
   Gurkan, Umut Atakan
   Tasoglu, Saves
   Kuritzkes, Daniel R.
   Demirci, Utkan
TI Nanoplasmonic Quantitative Detection of Intact Viruses from Unprocessed
   Whole Blood
SO ACS NANO
LA English
DT Article
DE nanoplasmonic; HIV; AIDS; viral load; point-of-care; Nanotechnology
ID SURFACE-PLASMON RESONANCE; ACUTE RESPIRATORY SYNDROME; SILVER
   NANOPARTICLES; OPTICAL BIOSENSOR; HIV VACCINE; ON-CHIP; THERAPY; GOLD;
   RNA; SPECTROSCOPY
AB Infectious diseases such as HIV and hepatitis B pose an omnipresent threat to global health. Reliable, fast, accurate, and sensitive platforms that can be deployed at the point-of-care (POC) in multiple settings, such as airports and offices, for detection of Infectious pathogens are essential for the management of epidemics and possible biological attacks. To the best of our knowledge, no viral load technology adaptable to the POC settings exists today due to critical technical and biological challenges. Here, we present for the first time a broadly applicable technology for quantitative, nanoplasmonic-based intact virus detection at clinically relevant concentrations. The sensing platform is based on unique nanoplasmonic properties of nanoparticles utilizing immobilized antibodies to selectively capture rapidly evolving viral subtypes. We demonstrate the capture, detection, and quantification of multiple HIV subtypes (A, B, C, D, E, G, and subtype panel) with high repeatability, sensitivity, and specificity down to 98 +/- 39 copies/mL (i.e., HIV subtype D) using spiked whole blood samples and clinical discarded HIV-infected patient whole blood samples validated by the gold standard, Le., RT-qPCR. This platform technology offers an assay time of 1 hand 10 mm (1 h for capture, 10 mm for detection and data analysis). The presented platform is also able to capture intact viruses at high efficiency using immuno-surface chemistry approaches directly from whole blood samples without any sample preprocessing steps such as spin-down or sorting. Evidence is presented showing the system to be accurate, repeatable, and reliable. Additionally, the presented platform technology can be broadly adapted to detect other pathogens having reasonably well-described biomarkers by adapting the surface chemistry. Thus, this broadly applicable detection platform holds great promise to be implemented at POC settings, hospitals, and primary care settings.
C1 [Inci, Fatih; Tokel, Onur; Wang, ShuQi; Gurkan, Umut Atakan; Tasoglu, Saves; Demirci, Utkan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Biomed Engn,Dept Med,Demirei Bio Acoust MEMS, Cambridge, MA 02139 USA.
   [Kuritzkes, Daniel R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
   [Demirci, Utkan] Harvard MIT Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Demirci, U (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Biomed Engn,Dept Med,Demirei Bio Acoust MEMS, Cambridge, MA 02139 USA.
EM udemirci@rics.bwh.harvard.edu
OI Inci, Fatih/0000-0002-9918-5038; Gurkan, Umut/0000-0002-0331-9960
FU U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine &
   Advanced Technology Research Center (TATRC) at Fort Detrick, MD
FX We thank Drs. John Carney and Paul Nisson for discussions and feedback.
   We would like to acknowledge NIH RO1AI093282, NIH RO1AI081534, NIH
   U54EB15408, NIH R21AI087107, and BRI Translatable Technologies and Care
   Innovation Grant. This work was made possible by a research grant that
   was awarded and administered by the U.S. Army Medical Research &
   Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology
   Research Center (TATRC) at Fort Detrick, MD.
CR Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162
   Barletta JM, 2004, AM J CLIN PATHOL, V122, P20, DOI 10.1309/529T2WDNEB6X8VUN
   Barone Paul W, 2009, J Diabetes Sci Technol, V3, P242
   Berkley S, 2010, NAT MED, V16, P981, DOI 10.1038/nm0910-981
   Busch Michael P., 1997, American Journal of Medicine, V102, P117, DOI 10.1016/S0002-9343(97)00077-6
   Castelnuovo B, 2011, AIDS RES TREAT, DOI 10.1155/2011/736938
   Chau LK, 2006, SENSOR ACTUAT B-CHEM, V113, P100, DOI 10.1016/j.snb.2005.02.034
   Day ES, 2010, INT J NANOMED, V5, P445
   Endo T, 2005, ANAL CHEM, V77, P6976, DOI 10.1021/ac0513459
   FAUNT LM, 1992, METHOD ENZYMOL, V210, P340
   Ginocchio CC, 2011, J CLIN MICROBIOL, V49, P44
   Gurkan UA, 2011, BIOTECHNOL J, V6, P138, DOI 10.1002/biot.201000427
   Haes AJ, 2004, J PHYS CHEM B, V108, P6961, DOI 10.1021/jp036261n                                                               
   Haes AJ, 2002, J AM CHEM SOC, V124, P10596, DOI 10.1021/ja020393x
   Haynes CL, 2001, J PHYS CHEM B, V105, P5599, DOI 10.1021/jp010657m
   Irvine DJ, 2011, NAT MATER, V10, P342, DOI 10.1038/nmat3014
   Johnston MI, 2008, NEW ENGL J MED, V359, P888, DOI 10.1056/NEJMp0806162
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   Karst SM, 2010, VIRUSES-BASEL, V2, P748, DOI 10.3390/v2030748
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kulinski MD, 2009, BIOMED MICRODEVICES, V11, P671, DOI 10.1007/s10544-008-9277-1
   Kuzmych O., 2007, NANOTECHNOLOGY, P18
   Larguinho M, 2012, J PROTEOMICS, V75, P2811, DOI 10.1016/j.jprot.2011.11.007
   Law WC, 2011, ACS NANO, V5, P4858, DOI 10.1021/nn2009485
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   Lujan-Zilbermann J, 2006, FETAL PEDIATR PATHOL, V25, P249, DOI 10.1080/15513810601123367
   Mayer KM, 2011, CHEM REV, V111, P3828, DOI 10.1021/cr100313v
   Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8
   Moon S., 2011, PLOS ONE, P6
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Nair TM, 2000, NUCLEIC ACIDS RES, V28, P1935, DOI 10.1093/nar/28.9.1935                                                           
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2011, PAN ANT GUID AD AD G
   Patolsky F, 2006, NANOMEDICINE-UK, V1, P51, DOI 10.2217/17435889.1.1.51
   Perminov SV, 2007, OPT EXPRESS, V15, P8639, DOI 10.1364/OE.15.008639
   Rouet F, 2006, AIDS, V20, P2315, DOI 10.1097/QAD.0b013e328010943b
   Shafiee H., 2013, SMALL, DOI [10.1002/smll.201202195, DOI 10.1002/SM11.201202195]
   Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100
   Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4
   Sun R, 1998, J CLIN MICROBIOL, V36, P2964
   Tasoglu S., 2013, CHEM SOC REV, DOI [10.1039/C3CS60042D, DOI 10.1039/C3C560042D]
   Taylor B. N., 1994, 1297 NIST
   Taylor J. R., 1996, INTRO ERROR ANAL STU
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666                                                            
   UNAIDS, 2008, 2008 REP GLOB AIDS E
   Van Duyne RP, 2003, P SOC PHOTO-OPT INS, V5223, P197, DOI 10.1117/12.509862
   van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x
   Wang SQ, 2013, BIOTECHNOL ADV, V31, P438, DOI 10.1016/j.biotechadv.2013.01.006
   Wang SQ, 2012, INT J NANOMED, V7, P2591, DOI 10.2147/IJN.S29629
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wang W, 2008, J MATER CHEM, V18, P5770, DOI 10.1039/b810164g
   Wei QH, 2004, NANO LETT, V4, P1067, DOI 10.1021/j.nl049604h
   Weinrib H., 2012, J AT MOL OPT PHYS, V2012, P6
   White R. A., 2009, BMC GENOMICS, P10
   WORLD HEALTH ORGANIZATION (WHO), 2010, ANT THER HIV INF AD
   World Health Organization, 2012, GLOB HLTH OBS GHO HI
   World Health Organization, 2012, TECHN BRIEF HIV VIR
   World Health Organization, 2009, RAP ADV ANT THER HIV
   Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607
   Williams EH, 2013, J MATER RES, V28, P68, DOI 10.1557/jmr.2012.283
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Yu H, 2013, BIOSENS BIOELECTRON, V41, P249, DOI 10.1016/j.bios.2012.08.031
   Zhang GJ, 2010, SENSOR ACTUAT B-CHEM, V146, P138, DOI 10.1016/j.snb.2010.02.021
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
NR 68
TC 54
Z9 56
U1 3
U2 93
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2013
VL 7
IS 6
BP 4733
EP 4745
DI 10.1021/nn3036232
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 173QK
UT WOS:000321093800006
PM 23688050
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hadigal, S
   Shukla, D
AF Hadigal, Satvik
   Shukla, Deepak
TI Exploiting Herpes Simplex Virus Entry for Novel Therapeutics
SO VIRUSES-BASEL
LA English
DT Review
DE herpes; HSV-1; HSV-2; therapeutics; peptides; entry; G1 and G2;
   aptamers; dendrimers; AC-8; dermaseptins; PI3K inhibitor; K-5 compounds;
   nanoparticles; compound SP-510-50; apolipoprotein E; viral
   glycoproteins; gB; gD; gH/gL; viral surfing; hemifusion; fusion;
   endocytosis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VITRO ANTIVIRAL ACTIVITY; TO-CELL SPREAD;
   VIRAL ENTRY; GLYCOPROTEIN-B; HEPARAN-SULFATE; SPL7013 GEL; LOW-PH;
   SEROTYPE DIFFERENCES; SURFACE EXPRESSION
AB Herpes Simplex virus (HSV) is associated with a variety of diseases such as genital herpes and numerous ocular diseases. At the global level, high prevalence of individuals who are seropositive for HSV, combined with its inconspicuous infection, remains a cause for major concern. At the molecular level, HSV entry into a host cell involves multiple steps, primarily the interaction of viral glycoproteins with various cell surface receptors, many of which have alternate substitutes. The molecular complexity of the virus to enter a cell is also enhanced by the existence of different modes of viral entry. The availability of many entry receptors, along with a variety of entry mechanisms, has resulted in a virus that is capable of infecting virtually all cell types. While HSV uses a wide repertoire of viral and host factors in establishing infection, current therapeutics aimed against the virus are not as diversified. In this particular review, we will focus on the initial entry of the virus into the cell, while highlighting potential novel therapeutics that can control this process. Virus entry is a decisive step and effective therapeutics can translate to less virus replication, reduced cell death, and detrimental symptoms.
C1 [Hadigal, Satvik; Shukla, Deepak] Univ Illinois, Dept Ophthalmol & Visual Sci, Coll Med, Chicago, IL 60612 USA.
   [Shukla, Deepak] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.
   [Shukla, Deepak] Univ Illinois, Lions Illinois Eye Res Inst, Chicago, IL 60601 USA.
RP Shukla, D (reprint author), Univ Illinois, Dept Ophthalmol & Visual Sci, Coll Med, 1855 West Taylor St,M-C 648,Room 3-138, Chicago, IL 60612 USA.
EM satvikhadigal@gmail.com; dshukla@uic.edu
OI Shukla, Deepak/0000-0002-3039-6953
FU National Institutes of Health [AI081869, AI103754, EY01792]
FX This work was supported by National Institutes of Health grants
   AI081869, AI103754 (both to D. Shukla), and EY01792 (core grant).
CR Amiche M, 2008, PEPTIDES, V29, P2074, DOI 10.1016/j.peptides.2008.06.017
   Antoine TE, 2012, ANTIVIR RES, V96, P363, DOI 10.1016/j.antiviral.2012.09.020
   Atanasiu D, 2007, P NATL ACAD SCI USA, V104, P18718, DOI 10.1073/pnas.0707452104
   Atanasiu D, 2010, J VIROL, V84, P12292, DOI 10.1128/JVI.01700-10
   Atanasiu D, 2010, J VIROL, V84, P3825, DOI 10.1128/JVI.02687-09
   Avitabile E, 2009, J VIROL, V83, P10752, DOI 10.1128/JVI.01287-09
   BALL MJ, 1982, CAN J NEUROL SCI, V9, P303, DOI 10.1017/S0317167100044115                                                       
   Baram-Pinto D, 2012, CHEM COMMUN, V48, P8359, DOI 10.1039/c2cc33448h
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Belaid A, 2002, J MED VIROL, V66, P229, DOI 10.1002/jmv.2134
   Berdugo M, 2012, ANTIMICROB AGENTS CH, V56, P1390, DOI 10.1128/AAC.05145-11
   Bergaoui I, 2013, J MED VIROL, V85, P272, DOI 10.1002/jmv.23450
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Borges A. Rosa, 2005, Current Drug Targets - Infectious Disorders, V5, P247, DOI 10.2174/1568005054880127
   Bunka DHJ, 2010, CURR OPIN PHARMACOL, V10, P557, DOI 10.1016/j.coph.2010.06.009
   BZIK DJ, 1984, VIROLOGY, V137, P185, DOI 10.1016/0042-6822(84)90022-9                                                    
   Cairns TM, 2005, VIROLOGY, V332, P550, DOI 10.1016/j.virol.2004.12.006
   Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T
   Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6
   Cheshenko N, 2004, ANTIMICROB AGENTS CH, V48, P2025, DOI 10.1128/AAC.48.6.2025-2036.2004
   Cheshenko N, 2002, J GEN VIROL, V83, P2247, DOI 10.1099/0022-1317-83-9-2247                                                     
   Clement C, 2006, J CELL BIOL, V174, P1009, DOI 10.1083/jcb.200509155
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548
   DAHER KA, 1986, J VIROL, V60, P1068
   Dobson CB, 2006, J INFECT DIS, V193, P442, DOI 10.1086/499280
   Epstein SP, 2001, CORNEA, V20, P495, DOI 10.1097/00003226-200107000-00011
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Fusco D, 2005, P NATL ACAD SCI USA, V102, P9323, DOI 10.1073/pnas.0503907102
   GERBER SI, 1995, VIROLOGY, V214, P29, DOI 10.1006/viro.1995.9957
   Gianni T, 2010, P NATL ACAD SCI USA, V107, P22260, DOI 10.1073/pnas.1014923108
   Gianni T, 2010, J VIROL, V84, P4013, DOI 10.1128/JVI.02502-09
   Gianni T, 2009, J BIOL CHEM, V284, P17370, DOI 10.1074/jbc.M109.005728
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gopinath SCB, 2012, J VIROL, V86, P6732, DOI 10.1128/JVI.00377-12
   Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317
   Heegaard Peter M H, 2006, Recent Pat Antiinfect Drug Discov, V1, P331
   Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z
   Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548
   Herold BC, 1996, J VIROL, V70, P3461
   HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211                                                     
   HEROLD BC, 1991, J VIROL, V65, P1090
   HUTCHINSON L, 1992, J VIROL, V66, P2240
   Jackson JO, 2010, J VIROL, V84, P11814, DOI 10.1128/JVI.01615-10
   Jackson JO, 2010, J VIROL, V84, P2038, DOI 10.1128/JVI.02215-09
   James William, 2001, Current Opinion in Pharmacology, V1, P540, DOI 10.1016/S1471-4892(01)00093-5
   Jones LS, 2004, MOL CELL PROTEOMICS, V3, P746, DOI 10.1074/mcp.R400008-MCP200
   Karasneh GA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-481
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Krummenacher C, 2005, EMBO J, V24, P4144, DOI 10.1038/sj.emboj.7600875
   Lairson DR, 2003, ARCH OPHTHALMOL-CHIC, V121, P108
   LASS JH, 1984, ANTIVIR RES, V4, P143, DOI 10.1016/0166-3542(84)90014-7
   Lazear E, 2008, J VIROL, V82, P700, DOI 10.1128/JVI.02192-07
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Lindahl U, 2005, J MED CHEM, V48, P349, DOI 10.1021/jm049812m
   Luganini A, 2011, ANTIMICROB AGENTS CH, V55, P3231, DOI 10.1128/AAC.00149-11
   Marsh M, 1997, J CELL SCI, V110, P95
   Matanic VCA, 2004, INT J ANTIMICROB AG, V23, P382, DOI 10.1016/j.ijantimicag.2003.07.022
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Milne RSB, 2005, J VIROL, V79, P6655, DOI 10.1128/JVI.79.11.6655-6663.2005
   Moore MD, 2011, J GEN VIROL, V92, P1493, DOI 10.1099/vir.0.030601-0
   Moore MD, 2011, J BIOL CHEM, V286, P2526, DOI 10.1074/jbc.M110.178426
   MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014
   Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19
   Nicola AV, 2004, J VIROL, V78, P7508, DOI 10.1128/JVI.78.14.7508-7517.2004
   Nicola AV, 2003, J VIROL, V77, P5324, DOI 10.1128/JVI.77.9.5324-5332.2003
   Nicolas P, 2009, BBA-BIOMEMBRANES, V1788, P1537, DOI 10.1016/j.bbamem.2008.09.006
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Oh MJ, 2010, BIOCHEM BIOPH RES CO, V391, P176, DOI 10.1016/j.bbrc.2009.11.027
   PARA MF, 1985, J VIROL, V55, P483
   Peng T, 1998, J VIROL, V72, P65
   Pinna D, 2008, ANTIMICROB AGENTS CH, V52, P3078, DOI 10.1128/AAC.00359-08
   Pope LE, 1998, ANTIVIR RES, V40, P85, DOI 10.1016/S0166-3542(98)00048-5                                                   
   Radtke K, 2006, CELL MICROBIOL, V8, P387, DOI 10.1111/j.1462-5822.2005.00679.x
   Razonable RR, 2011, MAYO CLIN PROC, V86, P1009, DOI 10.4065/mcp.2011.0309
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI200113799
   Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823
   Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529
   Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003
   Subramanian RP, 2007, P NATL ACAD SCI USA, V104, P2903, DOI 10.1073/pnas.0608374104
   Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174
   Tarallo R, 2013, INT J NANOMED, V8, P521, DOI 10.2147/IJN.S37739
   Tiwari V, 2010, J GEN VIROL, V91, P3002, DOI 10.1099/vir.0.024166-0
   Tiwari V, 2010, PHYTOTHER RES, V24, P1132, DOI 10.1002/ptr.3085
   Tiwari V, 2009, ANTIVIR RES, V84, P67, DOI 10.1016/j.antiviral.2009.07.014
   Treister NS, 2010, EXPERT OPIN PHARMACO, V11, P853, DOI 10.1517/14656561003691847
   Trigilio J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048147
   Vicenzi E, 2003, AIDS, V17, P177, DOI 10.1097/01.aids.0000042949.95433.74
   Vo TS, 2011, EUR J PHARM SCI, V44, P11, DOI 10.1016/j.ejps.2011.07.005
   Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731                                                      
   Wang J, 2000, RNA, V6, P571, DOI 10.1017/S1355838200992215
   Whitley RJ, 1996, MED MICROBIOLOGY
   Willis SH, 1998, J VIROL, V72, P5937
   WITTELS M, 1991, VIRUS RES, V18, P271, DOI 10.1016/0168-1702(91)90024-P
   WUDUNN D, 1989, J VIROL, V63, P52
   Yaron S, 2003, PEPTIDES, V24, P1815, DOI 10.1016/j.peptides.2003.09.016
NR 99
TC 12
Z9 13
U1 3
U2 35
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUN
PY 2013
VL 5
IS 6
BP 1447
EP 1465
DI 10.3390/v5061447
PG 19
WC Virology
SC Virology
GA 169HE
UT WOS:000320769900005
PM 23752649
OA gold
DA 2018-01-05
ER

PT J
AU Ensign, LM
   Henning, A
   Schneider, CS
   Maisel, K
   Wang, YY
   Porosoff, MD
   Cone, R
   Hanes, J
AF Ensign, Laura M.
   Henning, Andreas
   Schneider, Craig S.
   Maisel, Katharina
   Wang, Ying-Ying
   Porosoff, Marc D.
   Cone, Richard
   Hanes, Justin
TI Ex Vivo Characterization of Particle Transport in Mucus Secretions
   Coating Freshly Excised Mucosal Tissues
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE mucus penetrating particles; particle tracking; drug delivery
ID FEMALE GENITAL-TRACT; HUMAN CERVICAL-MUCUS; GASTROINTESTINAL MUCUS;
   POLYMERIC NANOPARTICLES; BARRIER PROPERTIES; IMMUNE-RESPONSES;
   DELIVERY-SYSTEMS; HIV SURROGATES; DRUG-DELIVERY; CELL-FREE
AB Sustained drug delivery to mucosal surfaces has the potential to improve the effectiveness of prophylactic and therapeutic treatments for numerous diseases and conditions, including inflammatory bowel disease, sexually transmitted diseases, cystic fibrosis, glaucoma, dry eye, and various cancers. Sustained delivery systems such as nanoparticles can be useful for mucosal delivery, but recent work suggests they must penetrate the rapidly cleared mucus barrier that overlies all mucosal epithelia to achieve uniform distribution on epithelial surfaces and enhanced residence time. Thus, it is important to evaluate the mucus-penetrating ability of nanosized delivery systems in preclinical animal studies, and for administration to humans. We describe a simple ex vivo method to visualize and quantify nanoparticle transport in mucus on fresh mucosal tissues. Using this method in murine models, we observed variations in the mucus mesh at different anatomical locations, as well as cyclical variations that may have implications for mucosal delivery.
C1 [Ensign, Laura M.; Henning, Andreas; Schneider, Craig S.; Maisel, Katharina; Wang, Ying-Ying; Porosoff, Marc D.; Cone, Richard; Hanes, Justin] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Ctr Nanomed, Baltimore, MD 21231 USA.
   [Ensign, Laura M.; Henning, Andreas; Schneider, Craig S.; Porosoff, Marc D.; Hanes, Justin] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Maisel, Katharina; Wang, Ying-Ying; Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Wang, Ying-Ying; Cone, Richard] Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21287 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA.
   [Hanes, Justin] Johns Hopkins Univ, Inst NanoBioTechnol, Ctr Canc Nanotechnol Excellence, Baltimore, MD 21218 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21231 USA.
RP Hanes, J (reprint author), 400 N Broadway,Smith Bldg 6th Floor, Baltimore, MD 21231 USA.
EM hanes@jhmi.edu
RI Porosoff, Marc/N-2816-2015
OI Porosoff, Marc/0000-0003-3066-0029
FU Wilmer Microscopy and Imaging Core Facility [EY001765]; NIH
   [R33AI079740, R01CA140746, R21AI094519, U54CA151838]; Cystic Fibrosis
   Foundation [HANES07XX0]; National Science Foundation; Howard Hughes
   Medical Institute
FX We thank Tim Hoen for his training and assistance with animal handling
   and the Wilmer Microscopy and Imaging Core Facility (Grant EY001765).
   This work was supported by the NIH (Grants R33AI079740, R01CA140746,
   R21AI094519, U54CA151838), the Cystic Fibrosis Foundation (Grant
   HANES07XX0), and National Science Foundation (L.M.E., K.M., Y.-Y.W.) and
   Howard Hughes Medical Institute (L.M.E., C.S.S.) graduate research
   fellowships. The mucus penetrating particle technology described in this
   publication is being developed by Kala Pharmaceuticals.
CR Allen E, 1922, AM J ANAT, V30, P297, DOI 10.1002/aja.1000300303                                                          
   ASSCHER AW, 1956, J ANAT, V90, P547
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Crater JS, 2010, MACROMOL BIOSCI, V10, P1473, DOI 10.1002/mabi.201000137
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Dalal SJ, 2001, CONTEMP TOP LAB ANIM, V40, P13
   Dawson M, 2003, J BIOL CHEM, V278, P50393, DOI 10.1074/jbc.M309026200
   des Rieux A, 2006, J CONTROL RELEASE, V116, P1, DOI 10.1016/j.jconrel.2006.08.013
   ELSTEIN M, 1978, BRIT MED BULL, V34, P83, DOI 10.1093/oxfordjournals.bmb.a071464                                              
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Ensign LM, 2012, SCI TRANSL MED, V4
   Kanazawa T, 2009, J PHARM PHARMACOL, V61, P1457, DOI 10.1211/jpp/61.11.0004
   KARARLI TT, 1995, BIOPHARM DRUG DISPOS, V16, P351, DOI 10.1002/bdd.2510160502
   Kim AJ, 2013, ANGEW CHEM INT EDIT, V52, P3985, DOI 10.1002/anie.201208556
   Kirch J, 2012, P NATL ACAD SCI USA, V109, P18355, DOI 10.1073/pnas.1214066109
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2011, BIOMATERIALS, V32, P6285, DOI 10.1016/j.biomaterials.2011.05.008
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   LICHTENBERGER LM, 1995, ANNU REV PHYSIOL, V57, P565, DOI 10.1146/annurev.ph.57.030195.003025
   Lieleg O, 2010, BIOPHYS J, V98, P1782, DOI 10.1016/j.bpj.2010.01.012
   Louissaint NA, 2012, J INFECT DIS, V205, P725, DOI 10.1093/infdis/jir841
   Louissaint NA, 2012, JAIDS-J ACQ IMM DEF, V59, P10, DOI 10.1097/QAI.0b013e3182373b5e
   Macierzanka A, 2011, SOFT MATTER, V7, P8077, DOI 10.1039/c1sm05888f
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594
   ODEBLAD E, 1968, ACTA OBSTET GYN SCAN, VS 47, P57, DOI 10.3109/00016346809156845                                                       
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Parr EL, 1999, IMMUNOLOGY, V98, P639, DOI 10.1046/j.1365-2567.1999.00909.x                                                
   Sanders N, 2009, ADV DRUG DELIVER REV, V61, P115, DOI 10.1016/j.addr.2008.09.011
   Schuster BS, 2013, BIOMATERIALS, V34, P3439, DOI 10.1016/j.biomaterials.2013.01.064
   Seavey MM, 2009, VACCINE, V27, P2342, DOI 10.1016/j.vaccine.2009.02.025
   Smith BG, 1934, AM J ANAT, V54, P27, DOI 10.1002/aja.1000540103                                                          
   Suh J, 2005, ADV DRUG DELIVER REV, V57, P63, DOI 10.1016/j.addr.2004.06.001
   Suk JS, 2011, MOL THER, V19, P1981, DOI 10.1038/mt.2011.160
   Suk JS, 2009, BIOMATERIALS, V30, P2591, DOI 10.1016/j.biomaterials.2008.12.076
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Wilson SS, 2009, ANTIVIR THER, V14, P1113, DOI 10.3851/IMP1463
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Zeitlin L, 1997, CONTRACEPTION, V56, P329, DOI 10.1016/S0010-7824(97)00154-6                                                   
NR 42
TC 27
Z9 27
U1 1
U2 57
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUN
PY 2013
VL 10
IS 6
BP 2176
EP 2182
DI 10.1021/mp400087y
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 159AE
UT WOS:000320015600008
PM 23617606
OA green_accepted
DA 2018-01-05
ER

PT J
AU Viglasky, V
   Hianik, T
AF Viglasky, Viktor
   Hianik, Tibor
TI Potential uses of G-quadruplex-forming aptamers
SO GENERAL PHYSIOLOGY AND BIOPHYSICS
LA English
DT Article; Proceedings Paper
CT 5th Slovak Biophysical Symposium
CY MAR 19-21, 2012
CL Bratislava, SLOVAKIA
SP Slovak Biophys Soc
DE DNA aptamers; G-quadruplex; Circular dichroism; Biosensors
ID NUCLEIC-ACID APTAMERS; SINGLE-STRANDED-DNA; CIRCULAR-DICHROISM SPECTRA;
   ENDOTHELIAL GROWTH-FACTOR; G-RICH OLIGONUCLEOTIDES; IN-VITRO; ANTI-HIV;
   ELECTROCHEMICAL DETECTION; BIOLOGICAL-PROPERTIES; STRUCTURAL FEATURES
AB Guanine quadruplex (G-quadruplex) structures are one of a number of structures which are capable of adopting aptamers. G-rich DNA or RNA has an increased propensity to form quadruplex structures which have unusual biophysical and biological properties. G-rich aptamers which form G-quadruplexes have several advantages over unstructured sequences: G-quadruplexes are non-immunogenic, thermodynamically and chemically stable and they have both higher resistance to various serum nucleases and an enhanced cellular uptake. These advantages have led to a number of synthetic oligonucleotides being studied for their potential use as therapeutic agents for cancer therapy and in the treatment of various other diseases. In addition to their suitability in the fields of medicine and biotechnology, these, highly specified, aptameric G-quadruplexes also have great potential in the further development of nano-devices; e.g. basic components in microarrays, microfluidics, sandwich assays and electrochemical biosensors. This review summarizes the biophysical properties of G-quadruplexes and highlights the importance of the stability and recognition properties of aptamers. Examples of the application of aptamers in medical therapy and in biosensors are also discussed.
C1 [Viglasky, Viktor] Safarik Univ, Fac Sci, Dept Biochem, Inst Chem, Kosice 04001, Slovakia.
   [Hianik, Tibor] Comenius Univ, Fac Math Phys & Informat, Fac Math, Dept Nucl Phys & Biophys, Bratislava 84228, Slovakia.
RP Viglasky, V (reprint author), Safarik Univ, Fac Sci, Dept Biochem, Inst Chem, Kosice 04001, Slovakia.
EM viktor.viglasky@upjs.sk; Tibor.Hianik@fmph.uniba.sk
RI Viglasky, Viktor/B-9592-2017
OI Viglasky, Viktor/0000-0001-9811-2278
CR Adrian M., 2012, METHOD ENZYMOL, V338, P341
   Allali-Hassani A, 2007, CHEMBIOCHEM, V8, P2052, DOI 10.1002/cbic.200700257
   Ambrus A, 2005, BIOCHEMISTRY-US, V44, P2048, DOI 10.1021/bi048242p
   Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Mondragon-Sanchez JA, 2011, BIOPOLYMERS, V95, P641, DOI 10.1002/bip.21634
   AVIO A, 2012, BIOORGAN MED CHEM, V20, P4186, DOI DOI 10.1016/LBMC.2012.06.005
   Bang GS, 2005, BIOSENS BIOELECTRON, V21, P863, DOI 10.1016/j.bios.2005.02.002
   Bang I, 1910, BIOCHEM Z, V26, P293
   Bates Paula J., 2009, V542, P379, DOI 10.1007/978-1-59745-561-9_21
   Becker RC, 2010, THROMB HAEMOSTASIS, V103, P586, DOI 10.1160/TH09-10-0716
   Berliner L. J., 1992, THROMBIN STRUCTURE F
   Bini A, 2007, ANAL CHEM, V79, P3016, DOI 10.1021/ac070096g
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Boon EM, 2000, NAT BIOTECHNOL, V18, P1096, DOI 10.1038/80301
   Bugaut A, 2012, NUCLEIC ACIDS RES, V40, P4727, DOI 10.1093/nar/gks068
   Bunka DHJ, 2010, CURR OPIN PHARMACOL, V10, P557, DOI 10.1016/j.coph.2010.06.009
   Cai W, 2010, TALANTA, V81, P1810, DOI 10.1016/j.talanta.2010.03.046
   Castillo G, 2012, ELECTROANAL, V24, P1079, DOI 10.1002/elan.201200041
   Cerchia L, 2010, TRENDS BIOTECHNOL, V28, P517, DOI 10.1016/j.tibtech.2010.07.005
   Chaires JB, 2010, FEBS J, V277, P1098, DOI 10.1111/j.1742-4658.2009.07462.x
   Cheng AKH, 2009, BIOELECTROCHEMISTRY, V77, P1, DOI 10.1016/j.bioelechem.2009.04.007
   Choi MS, 2009, CHEM COMMUN, P7419, DOI 10.1039/b915994k
   Chou SH, 2005, TRENDS BIOCHEM SCI, V30, P231, DOI 10.1016/j.tibs.2005.03.004
   Coppola T, 2008, BIOORGAN MED CHEM, V16, P8244, DOI 10.1016/j.bmc.2008.07.040
   Cruz-Aguado JA, 2008, J AGR FOOD CHEM, V56, P10456, DOI 10.1021/jf801957h
   D'Atri V, 2012, CHEM COMMUN, V48, P9516, DOI 10.1039/c2cc34399a
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   Dapic V, 2002, BIOCHEMISTRY-US, V41, P3676, DOI 10.1021/bi0119520
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   DOVINOVA I, 1990, GEN PHYSIOL BIOPHYS, V9, P177
   Eggins B. R., 2004, CHEM SENSORS BIOSENS
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Ellis JS, 2004, CHEM COMMUN, P1310, DOI 10.1039/b402822h
   Evtugyn G. A., 2008, ELECTROANAL, V20, P1300, DOI DOI 10.1002/E1AN.200704186
   Evtugyn G, 2008, ELECTROANAL, V20, P2310, DOI 10.1002/elan.200804345
   Evtugyn G, 2012, ELECTROANAL, V24, P91, DOI 10.1002/elan.201100435
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550                                                   
   Ferapontova EE, 2011, CURR ORG CHEM, V15, P498
   Fialova M, 2006, BIOCHEM BIOPH RES CO, V344, P50, DOI 10.1016/j.bbrc.2006.03.144
   Foy JWD, 2007, J OCUL PHARMACOL TH, V23, P452, DOI 10.1089/jop.2006.0149
   FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950
   Gatto B, 2009, CURR MED CHEM, V16, P1248, DOI 10.2174/092986709787846640                                                      
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gray DM, 2008, CHIRALITY, V20, P431, DOI 10.1002/chir.20455
   GRAY RD, 2011, CURR PROT NUCL ACID, V45, P1741, DOI DOI 10.1002/CHIR.20455
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   GUO Q, 1992, J BIOL CHEM, V267, P15293
   Haq I, 1997, EUR BIOPHYS J BIOPHY, V26, P419, DOI 10.1007/s002490050096                                                           
   Hardin CC, 2001, BIOPOLYMERS, V56, P147
   Hasegawa H, 2008, SENSORS-BASEL, V8, P1090, DOI 10.3390/s8021090                                                                
   Hianik T, 2008, PROTEIN PEPTIDE LETT, V15, P799, DOI 10.2174/092986608785203656
   Hianik T, 2005, BIOORG MED CHEM LETT, V15, P291, DOI 10.1016/j.bmcl.2004.10.083
   Hianik T, 2009, CHEM COMMUN, P6303, DOI 10.1039/b910981a
   Hianik T, 2009, ELECTROANAL, V21, P1223, DOI 10.1002/elan.200904566
   Hirao I, 2000, J BIOL CHEM, V275, P4943, DOI 10.1074/jbc.275.7.4943
   Hong ES, 2010, J AM SOC MASS SPECTR, V21, P1245, DOI 10.1016/j.jasms.2010.03.035
   Hotoda H, 1998, J MED CHEM, V41, P3655, DOI 10.1021/jm970658w                                                               
   Hu J, 2011, CHEMBIOCHEM, V12, P424, DOI 10.1002/cbic.201000470
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   Ikebukuro K, 2005, BIOSENS BIOELECTRON, V20, P2168, DOI 10.1016/j.bios.2004.09.002
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jones LA, 2006, ANTIMICROB AGENTS CH, V50, P3019, DOI 10.1128/AAC.01603-05
   Kang Y, 2008, BIOELECTROCHEMISTRY, V73, P76, DOI 10.1016/j.bioelechem.2008.04.024
   Kankia BI, 2005, NUCLEIC ACIDS RES, V33, P4395, DOI 10.1093/nar/gki741
   Kankia BI, 2001, J AM CHEM SOC, V123, P10799, DOI 10.1021/ja010008o
   Keefe AD, 2008, CURR OPIN CHEM BIOL, V12, P448, DOI 10.1016/j.cbpa.2008.06.028
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   LAMBERTI I, 2011, LECT NOTES ELECT ENG, V91, P449
   Lee IH, 2011, J CONTROL RELEASE, V155, P435, DOI 10.1016/j.jconrel.2011.05.025
   Lee JA, 2008, SENSOR ACTUAT B-CHEM, V129, P372, DOI 10.1016/j.snb.2007.08.034
   Li RM, 2012, ANAL CHIM ACTA, V724, P80, DOI 10.1016/j.aca.2012.02.015
   Li T, 2010, ANAL CHEM, V82, P1515, DOI 10.1021/ac902638v
   Li YF, 1996, BIOCHEMISTRY-US, V35, P6911, DOI 10.1021/bi960038h
   Lim KW, 2009, J AM CHEM SOC, V131, P4301, DOI 10.1021/ja807503g
   Liu CW, 2009, ANAL CHEM, V81, P2383, DOI 10.1021/ac8022185
   Liu XQ, 2012, ACS NANO, V6, P3553, DOI 10.1021/nn300598q
   Lv L, 2012, CURR PHARM DESIGN, V18, P2076, DOI 10.2174/138161212799958459                                                      
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216-007-1346-4
   Marathias VM, 2000, NUCLEIC ACIDS RES, V28, P1969, DOI 10.1093/nar/28.9.1969
   MARKY LA, 1987, BIOPOLYMERS, V26, P1602, DOI DOI 10.1002/BIP.360260911
   Marusic M, 2012, NUCLEIC ACIDS RES, V40, P6946, DOI 10.1093/nar/gks329
   Masiero S, 2010, ORG BIOMOL CHEM, V8, P2683, DOI 10.1039/c003428b
   Mergny JL, 1998, FEBS LETT, V435, P74, DOI 10.1016/S0014-5793(98)01043-6
   Michalowski D, 2008, NUCLEIC ACIDS RES, V36, P7124, DOI 10.1093/nar/gkn891
   Mir M, 2006, ELECTROCHEM COMMUN, V8, P505, DOI 10.1016/j.elecom.2005.12.022
   MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622
   Mukundan VT, 2011, NUCLEIC ACIDS RES, V39, P8984, DOI 10.1093/nar/gkr540
   Nagatoishi S, 2007, BIOCHEM BIOPH RES CO, V352, P812, DOI 10.1016/j.bbrc.2006.11.088
   Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1
   Neundlinger I, 2011, BIOPHYS J, V101, P1781, DOI 10.1016/j.bpj.2011.07.054
   Do NQ, 2011, NUCLEIC ACIDS RES, V39, P9448, DOI 10.1093/nar/gkr539
   Ni X, 2011, CURR MED CHEM, V18, P4206, DOI 10.2174/092986711797189600                                                      
   Noma T, 2006, BIOTECHNOL LETT, V28, P1939, DOI 10.1007/s10529-006-9178-4
   Nonaka Y, 2010, MOLECULES, V15, P215, DOI 10.3390/molecules15010215
   Ogasawara D, 2009, BIOSENS BIOELECTRON, V24, P1372, DOI 10.1016/j.bios.2008.07.082
   OHSEN CM, 2009, J PHYS CHEM B, V113, P2587, DOI DOI 10.1021/JP806853N
   Okazawa A, 2000, BIOORG MED CHEM LETT, V10, P2653, DOI 10.1016/S0960-894X(00)00540-0
   Oliviero G, 2010, CHEM COMMUN, V46, P8971, DOI 10.1039/c0cc02866e
   Orava EW, 2013, ACS CHEM BIOL, V8, P170, DOI 10.1021/cb3003557
   Orava EW, 2010, BBA-BIOMEMBRANES, V1798, P2190, DOI 10.1016/j.bbamem.2010.02.004
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   Paeschke K, 2005, NAT STRUCT MOL BIOL, V12, P847, DOI 10.1038/nsmb982
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Phillips JA, 2008, ANAL CHIM ACTA, V621, P101, DOI 10.1016/j.aca.2008.05.031
   Pileur F, 2003, NUCLEIC ACIDS RES, V31, P5776, DOI 10.1093/nar/gkg748
   Ponikova S, 2011, BIOPHYS CHEM, V155, P29, DOI 10.1016/j.bpc.2011.02.004
   Ponikova S, 2008, GEN PHYSIOL BIOPHYS, V27, P271
   Potty ASR, 2009, BIOPOLYMERS, V91, P145, DOI 10.1002/bip.21097
   Radi AE, 2006, J AM CHEM SOC, V128, P117, DOI 10.1021/ja053121d
   Renciuk D, 2009, NUCLEIC ACIDS RES, V37, P6625, DOI 10.1093/nar/gkp701
   Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920
   RISTANO A, 2003, BIOCHEMISTRY-US, V42, P6507, DOI DOI 10.1021/BI026997V
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   Rodriguez MC, 2005, CHEM COMMUN, P4267, DOI 10.1039/b506571b
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Russo Krauss I, 2012, NUCLEIC ACIDS RES, V40, P8119, DOI 10.1093/nar/gks512
   Russo Krauss I, 2011, NUCLEIC ACIDS RES, V39, P7858, DOI 10.1093/nar/gkr522
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937                                                              
   SCHELLER EW, 2001, CURR OPIN BIOTECH, V12, P35, DOI DOI 10.1016/S0958-1669(00)00169-5
   Schultze P, 1999, NUCLEIC ACIDS RES, V27, P3018, DOI 10.1093/nar/27.15.3018                                                          
   Shevchenko Y, 2011, ANAL CHEM, V83, P7027, DOI 10.1021/ac201641n
   Shi Y, 2011, CHEM COMMUN, V47, P4676, DOI 10.1039/c0cc05518b
   Shieh YA, 2010, ACS NANO, V4, P1433, DOI 10.1021/nn901374b
   Shim JW, 2009, NUCLEIC ACIDS RES, V37, P972, DOI 10.1093/nar/gkn968
   Shum KT, 2011, BIOCHEMISTRY-US, V50, P3261, DOI 10.1021/bi2001455
   Shum KT, 2011, BIOCHEM J, V434, P493, DOI 10.1042/BJ20101096
   Shum KT, 2008, CHEMBIOCHEM, V9, P3037, DOI 10.1002/cbic.200800491
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Skogen M, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-65
   Smirnov I, 2000, J MOL BIOL, V296, P1, DOI 10.1006/jmbi.1999.3441
   Snejdarkova M, 2008, ANAL BIOANAL CHEM, V390, P1087, DOI 10.1007/s00216-007-1749-2
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   Strehlitz B., 2009, APTAMERS BIOANALYSIS, P31, DOI DOI 10.1002/9780470380772.CH2
   TASSET MD, 1997, J MOL BIOL, V272, P688, DOI DOI 10.1006/JMBI.1997.1275
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tong XT, 2011, NUCLEIC ACIDS RES, V39, P6753, DOI 10.1093/nar/gkr233
   Trajkovski M, 2012, J AM CHEM SOC, V134, P4132, DOI 10.1021/ja208483v
   Trajkovski M, 2009, ORG BIOMOL CHEM, V7, P4677, DOI 10.1039/b914783g
   TSIANG M, 1995, J BIOL CHEM, V270, P19370, DOI 10.1074/jbc.270.33.19370                                                        
   Tucker WO, 2012, CURR PHARM DESIGN, V18, P2014
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ueyama H, 2002, J AM CHEM SOC, V124, P14286, DOI 10.1021/ja026892f
   Viglasky V, 2011, EUR BIOPHYS J BIOPHY, V40, P29, DOI 10.1007/s00249-010-0625-8
   Viglasky V, 2010, BIOCHEMISTRY-US, V49, P2110, DOI 10.1021/bi902099u
   Virgilio A, 2012, NUCLEIC ACIDS RES, V40, P461, DOI 10.1093/nar/gkr670
   Wallimann P, 2003, J AM CHEM SOC, V125, P1203, DOI 10.1021/ja0275360
   WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003
   WANG KY, 1995, NUCLEIC ACIDS RES, V23, P844, DOI 10.1093/nar/23.5.844
   WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9
   Weiss JN, 1997, FASEB J, V11, P835
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
   Xiao Y, 2005, J AM CHEM SOC, V127, P17990, DOI 10.1021/ja056555h
   Xiao Y, 2005, ANGEW CHEM INT EDIT, V44, P5456, DOI 10.1002/anie.200500989
   Xu Y, 2006, ELECTROANAL, V18, P1449, DOI 10.1002/elan.200603566
   Yoshida W, 2009, BIOSENS BIOELECTRON, V24, P1116, DOI 10.1016/j.bios.2008.06.016
   ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0
   Zaitseva M, 2010, BIOPHYS CHEM, V146, P1, DOI 10.1016/j.bpc.2009.09.011
   Zhu QQ, 2007, J COMPUT AID MOL DES, V21, P641, DOI 10.1007/s10822-007-9147-6
NR 163
TC 6
Z9 6
U1 0
U2 57
PU GENERAL PHYSIOL AND BIOPHYSICS
PI BRATISLAVA
PA INST OF MOLEC PHYSIOL GENETICS SLOVAK ACAD OF SCI VLARSKA 5, 83334
   BRATISLAVA, SLOVAKIA
SN 0231-5882
EI 1338-4325
J9 GEN PHYSIOL BIOPHYS
JI Gen. Physiol. Biophys.
PD JUN
PY 2013
VL 32
IS 2
BP 149
EP 172
DI 10.4149/gpb_2013019
PG 24
WC Biochemistry & Molecular Biology; Biophysics; Physiology
SC Biochemistry & Molecular Biology; Biophysics; Physiology
GA 160BW
UT WOS:000320092300001
PM 23459572
OA gold
DA 2018-01-05
ER

PT J
AU Shum, K
   Guo, PX
   Rossi, JJ
AF Shum, Kato
   Guo, Peixuan
   Rossi, John J.
TI Ultra-Stable Trivalent RNA Nanoparticles for Targeting to Cancers and
   HIV-1
SO MOLECULAR THERAPY
LA English
DT Meeting Abstract
CT 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy
   (ASGCT)
CY MAY 15-18, 2013
CL Salt Lake City, UT
SP Amer Soc Gene & Cell Therapy (ASGCT)
C1 [Shum, Kato; Rossi, John J.] Beckman Res Inst City Hope, Duarte, CA USA.
   [Guo, Peixuan] Univ Kentucky, Coll Pharm, Lexington, KY USA.
RI Guo, Peixuan/I-7184-2015
NR 0
TC 0
Z9 0
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JUN
PY 2013
VL 21
SU 1
MA 515
BP S199
EP S199
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 156XY
UT WOS:000319858400514
DA 2018-01-05
ER

PT J
AU Pham, TTH
   Barratt, G
   Michel, JP
   Loiseau, PM
   Saint-Pierre-Chazalet, M
AF Pham, T. T. H.
   Barratt, G.
   Michel, J. P.
   Loiseau, P. M.
   Saint-Pierre-Chazalet, M.
TI Interactions of antileishmanial drugs with monolayers of lipids used in
   the development of amphotericin B-miltefosine-loaded nanocochleates
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Monolayer; Amphotericin B; Miltefosine; Dioleoylphosphatidylserine;
   Cholesterol; Leishmania
ID AIR-WATER-INTERFACE; POLYENE MACROLIDE ANTIBIOTICS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; LAST 10 YEARS; VISCERAL LEISHMANIASIS;
   AIR/WATER INTERFACE; MIXED MONOLAYERS; SELF-ASSOCIATION; SODIUM
   STIBOGLUCONATE; MOLECULAR-DYNAMICS
AB The emergence of strains of Leishmania resistant to existing drugs complicates the treatment of life-threatening visceral leishmaniasis. The development of new lipid formulation (nanocochleates), containing two active drugs: amphotericin B (AmB) and miltefosine (hexadecylphosphocholine, HePC), could increase effectiveness, decrease toxicity and reduce the risk of appearance of resistance. Nanocochleates are cigar-shaped structures of rolled negatively charged lipid bilayers bridged by calcium, prepared from dioleoylphosphatidylserine (DOPS) and cholesterol (Cho) and able to accommodate drugs. To determine the interaction, the orientation and the stability of the amphiphilic drugs in the lipid mixture and the optimal drugs/lipids ratio, the Langmuir film balance and RAM (Brewster angle microscopy) were used. The drugs were mixed with the lipids (DOPS or 9DOPS/1Cho) and spread at the air-water interface. A stability study showed that DOPS maintained HePC at the interface at low molar fraction of HePC; this effect became more marked in the presence of Cho. The fact that HePC can be stably associated with the monolayer at low molar fraction (below 10%) suggests that in the nanocochleates HePC is inserted between the lipid molecules rather than between the bilayers. Phase diagrams and BAM images showed that, even at low pressure, DOPS maintains AmB at low molar fraction (below 10%) in the "erect" rather than the horizontal form at the interface and that the presence of Cho reinforces this effect. These results allowed us to predict the organization and the orientation of these drugs in the nanocochleates and to determine the optimal drugs/lipids ratio. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Pham, T. T. H.; Barratt, G.; Michel, J. P.] Univ Paris 11, Fac Pharm, UMR CNRS 8612, Inst Galien Paris Sud, F-92296 Chatenay Malabry, France.
   [Pham, T. T. H.; Loiseau, P. M.; Saint-Pierre-Chazalet, M.] Univ Paris 11, Fac Pharm, UMR CNRS 8076, Grp Chimiotherapie Antiparasitaire, F-92296 Chatenay Malabry, France.
   [Saint-Pierre-Chazalet, M.] Univ Paris 06, F-75252 Paris, France.
RP Saint-Pierre-Chazalet, M (reprint author), Univ Paris 11, Fac Pharm, UMR CNRS 8076, Grp Chimiotherapie Antiparasitaire, F-92296 Chatenay Malabry, France.
EM michele.saint-pierre@upmc.fr
FU Region Ile-de-France
FX This work was supported by a Ph.D. scholarship to T.T.H. Pham from the
   Region Ile-de-France. We are grateful to Zentaris (Frankfurt, Germany)
   for providing the HePC used in this study.
CR Alvar J, 2006, ADV PARASIT, V61, P223, DOI 10.1016/S0065-308X(05)61006-8
   Andres E, 2001, REV MED INTERNE, V22, P141, DOI 10.1016/S0248-8663(00)00304-0
   Antoniadou A, 2005, J MYCOL MED, V15, P230, DOI 10.1016/j.mycmed.2005.06.005
   Baginski M, 2002, BBA-BIOMEMBRANES, V1567, P63, DOI 10.1016/S0005-2736(02)00581-3
   Balana-Fouce R, 1998, GEN PHARMACOL, V30, P435, DOI 10.1016/S0306-3623(97)00268-1
   Barratt G, 2007, INT J NANOMED, V2, P301
   Berman J., 1992, ACTIVITY AMPHOTERICI
   Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684
   Boelaert M, 2000, T ROY SOC TROP MED H, V94, P465, DOI 10.1016/S0035-9203(00)90055-5
   BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X                                                    
   BOLARD J, 1991, BIOCHEMISTRY-US, V30, P5707, DOI 10.1021/bi00237a011
   Bolard J., 1993, J LIPOSOME RES, V3, P409
   BRAJTBURG J, 1990, ANTIMICROB AGENTS CH, V34, P381, DOI 10.1128/AAC.34.3.381                                                            
   BRITTAIN HG, 1994, CHIRALITY, V6, P665, DOI 10.1002/chir.530060811
   Bryceson A, 2001, TROP MED INT HEALTH, V6, P928, DOI 10.1046/j.1365-3156.2001.00795.x
   CABIE A, 1992, PRESSE MED, V21, P1658
   Chang LC, 2008, J COLLOID INTERF SCI, V322, P263, DOI 10.1016/j.jcis.2008.02.051
   DAVIDSON RN, 1991, LANCET, V337, P1061, DOI 10.1016/0140-6736(91)91708-3
   Desjeux, 1996, CLIN DERMATOL, V14, P417
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   DOUGLAS JB, 1969, AM J MED, V46, P154, DOI 10.1016/0002-9343(69)90067-9
   Dynarowicz-Latka P, 2004, COLLOID SURFACE B, V37, P21, DOI 10.1016/j.colsurfb.2004.06.007
   Dynarowicz-Latka P, 2003, COLLOID SURFACE B, V27, P249, DOI 10.1016/S0927-7765(02)00099-1                                                   
   Ellis D, 2002, J ANTIMICROB CHEMOTH, V49, P7, DOI 10.1093/jac/49.suppl_1.7                                                        
   GHOSH D, 1971, CHEM PHYS LIPIDS, V7, P173, DOI 10.1016/0009-3084(71)90030-2
   Gomez-Serranillos IR, 2004, PHYS CHEM CHEM PHYS, V6, P1580, DOI 10.1039/b314439a
   Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X
   Gupta S, 2005, ACTA TROP, V94, P41, DOI 10.1016/j.actatropica.2004.11.009
   Hammond S M, 1977, Prog Med Chem, V14, P105, DOI 10.1016/S0079-6468(08)70148-6
   Hann IM, 2001, INT J ANTIMICROB AG, V17, P161, DOI 10.1016/S0924-8579(00)00341-1
   Hartsel S, 1996, TRENDS PHARMACOL SCI, V17, P445, DOI 10.1016/S0165-6147(96)01012-7                                                   
   Hartsel S.C., 1993, J LIPOSOME RES, V3, P377
   HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296                                                       
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Italia JL, 2009, PHARM RES-DORDR, V26, P1324, DOI 10.1007/s11095-009-9841-2
   Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403
   Johnson RH, 2007, ANN NY ACAD SCI, V1111, P434, DOI 10.1196/annals.1406.019
   JOLY V, 1992, J INFECT DIS, V165, P337, DOI 10.1093/infdis/165.2.337                                                        
   Laguna F, 1997, EUR J CLIN MICROBIOL, V16, P898, DOI 10.1007/BF01700556
   LEGRAND P, 1992, ANTIMICROB AGENTS CH, V36, P2518, DOI 10.1128/AAC.36.11.2518                                                          
   Lux H, 2000, MOL BIOCHEM PARASIT, V111, P1, DOI 10.1016/S0166-6851(00)00278-4
   MAZERSKI J, 1990, EUR BIOPHYS J, V18, P159, DOI 10.1007/BF02427375
   MAZERSKI J, 1982, BIOCHIM BIOPHYS ACTA, V719, P11, DOI 10.1016/0304-4165(82)90300-2
   Menez C, 2006, ANTIMICROB AGENTS CH, V50, P3793, DOI 10.1128/AAC.00837-06
   Minones J, 2003, COLLOID SURFACE B, V29, P205, DOI 10.1016/S0927-7765(02)00220-5
   Minones J, 2006, J COLLOID INTERF SCI, V301, P258, DOI 10.1016/j.jcis.2006.04.059
   NEWTON DW, 1978, DRUG INTEL CLIN PHAR, V12, P546, DOI 10.1177/106002807801200906                                                      
   Ngure PK, 2009, JNMU, V23, P79
   Papahadjopoulos D, 1978, Ann N Y Acad Sci, V308, P50, DOI 10.1111/j.1749-6632.1978.tb22013.x
   PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0                                                    
   Peffez-Victoria F.J., 2006, DRUG RESIST UPDATE, V9, P26
   Pintado V, 2001, MEDICINE, V80, P54, DOI 10.1097/00005792-200101000-00006
   Purkait B, 2012, ANTIMICROB AGENTS CH, V56, P1031, DOI 10.1128/AAC.00030-11
   Rakotomanga M, 2004, BBA-BIOMEMBRANES, V1661, P212, DOI 10.1016/j.bbamem.2004.01.010
   Rey-Gomez-Serranillos I, 2001, J COLLOID INTERF SCI, V234, P351, DOI 10.1006/jcis.2000.7310
   Saccani J, 2004, LANGMUIR, V20, P9190, DOI 10.1021/la0489920
   SAINTPIERRECHAZALET M, 1988, BIOCHIM BIOPHYS ACTA, V944, P477, DOI 10.1016/0005-2736(88)90519-6
   Savva M., 2009, J PHYS CHEM B, V113
   Seoane R, 1998, BBA-BIOMEMBRANES, V1375, P73, DOI 10.1016/S0005-2736(98)00137-0
   Sesana AM, 2011, MEM I OSWALDO CRUZ, V106, P251, DOI 10.1590/S0074-02762011000200022
   Sindermann H, 2006, T ROY SOC TROP MED H, V100, pS17, DOI 10.1016/j.trstmh.2006.02.010
   Souza LC, 2000, EXP TOXICOL PATHOL, V52, P169
   Sundar S, 2000, T ROY SOC TROP MED H, V94, P200, DOI 10.1016/S0035-9203(00)90277-3
   Thakur CP, 2000, T ROY SOC TROP MED H, V94, P429, DOI 10.1016/S0035-9203(00)90130-5
   Thakur CP, 2001, T ROY SOC TROP MED H, V95, P187, DOI 10.1016/S0035-9203(01)90160-9
   Tiuman TS, 2011, INT J INFECT DIS, V15, pE525, DOI 10.1016/j.ijid.2011.03.021
   van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6
   VERTUTDOI A, 1988, BIOCHEM BIOPH RES CO, V157, P692, DOI 10.1016/S0006-291X(88)80305-X
   Zarif L, 2005, METHOD ENZYMOL, V391, P314, DOI 10.1016/S0076-6879(05)91018-5                                                   
   Zarif L, 2000, ANTIMICROB AGENTS CH, V44, P1463, DOI 10.1128/AAC.44.6.1463-1469.2000
   Zarif L., 2003, HYDROGEL ISOLATED CO
NR 71
TC 8
Z9 8
U1 3
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD JUN 1
PY 2013
VL 106
BP 224
EP 233
DI 10.1016/j.colsurfb.2013.01.041
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 124CQ
UT WOS:000317441800032
PM 23434716
DA 2018-01-05
ER

PT J
AU Liu, BR
   Liou, JS
   Huang, YW
   Aronstam, RS
   Lee, HJ
AF Liu, Betty R.
   Liou, Ji-Sing
   Huang, Yue-Wern
   Aronstam, Robert S.
   Lee, Han-Jung
TI Intracellular Delivery of Nanoparticles and DNAs by IR9 Cell-penetrating
   Peptides
SO PLOS ONE
LA English
DT Article
ID NONCOVALENT PROTEIN TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS;
   ARGININE-RICH PEPTIDES; QUANTUM DOTS; LIVING CELLS; PLANT-CELLS;
   IN-VIVO; PLASMA-MEMBRANE; MOLECULAR-MECHANISM; UPTAKE KINETICS
AB Cell-penetrating peptides (CPPs) comprised of basic amino residues are able to cross cytoplasmic membranes and are able to deliver biologically active molecules inside cells. However, CPP/cargo entrapment in endosome limits biomedical utility as cargoes are destroyed in the acidic environment. In this study, we demonstrate protein transduction of a novel CPP comprised of an INF7 fusion peptide and nona-arginine (designated IR9). IR9 noncovalently interacts with quantum dots (QDs) and DNAs to form stable IR9/QD and IR9/DNA complexes which are capable of entering human A549 cells. Zeta-potentials were a better predictor of transduction efficiency than gel shift analysis, emphasizing the importance of electrostatic interactions of CPP/cargo complexes with plasma membranes. Mechanistic studies revealed that IR9, IR9/QD and IR9/DNA complexes may enter cells by endocytosis. Further, IR9, IR9/QD and IR9/DNA complexes were not cytotoxic at concentrations below 30, 5 and 20.1 mu M, respectively. Without labor intensive production of fusion proteins from prokaryotes, these results indicate that IR9 could be a safe carrier of genes and drugs in biomedical applications.
C1 [Liu, Betty R.; Liou, Ji-Sing; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien, Taiwan.
   [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien, Taiwan.
EM hjlee@mail.ndhu.edu.tw
OI Aronstam, Robert/0000-0001-7188-8412
FU National Science Council of Taiwan [NSC 101-2811-B-259-001, NSC
   101-2320-B-259-002-MY3]
FX The financial support of this study was provided by the Postdoctoral
   Fellowship NSC 101-2811-B-259-001 (to Liu BR) and the Grant Number NSC
   101-2320-B-259-002-MY3 from the National Science Council of Taiwan (to
   Lee HJ). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bharali DJ, 2005, J AM CHEM SOC, V127, P11364, DOI 10.1021/ja051455x
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   EKIMOV AI, 1981, JETP LETT+, V34, P345
   El-Sayed A, 2009, J CONTROL RELEASE, V138, P160, DOI 10.1016/j.jconrel.2009.05.018
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Floren A, 2011, METHODS MOL BIOL, V683, P117, DOI 10.1007/978-1-60761-919-2_9
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gautam A, 2012, DATABASE
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gurtovenko AA, 2007, J PHYS CHEM B, V111, P10453, DOI 10.1021/jp073113e
   Hanaor D, 2012, J EUR CERAM SOC, V32, P235, DOI 10.1016/j.jeurceramsoc.2011.08.015
   Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   Kilk K, 2009, TOXICOLOGY, V265, P87, DOI 10.1016/j.tox.2009.09.016
   Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012
   Li JF, 2010, ANTICANCER RES, V30, P2193
   Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   LIU BR, 2013, ADV STUD BIOL, V5, P11
   Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   LIU MJ, 2013, ADV STUD BIOL, V5, P71
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Madani F, 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mager I, 2012, BBA-BIOMEMBRANES, V1818, P502, DOI 10.1016/j.bbamem.2011.11.020
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Mattoussi H, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2011.09.011
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016
   Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487
   Noguchi H, 2010, CELL TRANSPLANT, V19, P649, DOI 10.3727/096368910X508744
   Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rucevic M, 2011, ELECTROPHORESIS, V32, P1549, DOI 10.1002/elps.201100212
   Schaeublin NM, 2011, NANOSCALE, V3, P410, DOI 10.1039/c0nr00478b
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Schrand AM, 2009, CRIT REV SOLID STATE, V34, P18, DOI 10.1080/10408430902831987
   Shao LJ, 2011, SENSORS-BASEL, V11, P11736, DOI 10.3390/s111211736
   Siennicka Joanna, 2003, Medycyna Doswiadczalna i Mikrobiologia, V55, P157
   Sugita T, 2007, BIOCHEM BIOPH RES CO, V363, P1027, DOI 10.1016/j.bbrc.2007.09.077
   Suhorutsenko J, 2011, BIOCONJUGATE CHEM, V22, P2255, DOI 10.1021/bc200293d
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
   Yang S, 2009, J CONTROL RELEASE, V135, P159, DOI 10.1016/j.jconrel.2008.12.015
   Ye SF, 2012, NANOMED-NANOTECHNOL, V8, P833, DOI 10.1016/j.nano.2011.10.003
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
NR 81
TC 19
Z9 20
U1 1
U2 35
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2013
VL 8
IS 5
AR e64205
DI 10.1371/journal.pone.0064205
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155FM
UT WOS:000319733000048
PM 23724035
OA gold
DA 2018-01-05
ER

PT J
AU Bailey, CM
   Sullivan, TJ
   Iyidogan, P
   Tirado-Rives, J
   Chung, R
   Ruiz-Caro, J
   Mohamed, E
   Jorgensen, W
   Hunter, R
   Anderson, KS
AF Bailey, Christopher M.
   Sullivan, Todd J.
   Iyidogan, Pinar
   Tirado-Rives, Julian
   Chung, Raymond
   Ruiz-Caro, Juliana
   Mohamed, Ebrahim
   Jorgensen, William
   Hunter, Roger
   Anderson, Karen S.
TI Bifunctional Inhibition of Human Immunodeficiency Virus Type 1 Reverse
   Transcriptase: Mechanism and Proof-of-Concept as a Novel Therapeutic
   Design Strategy
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID POTENTIAL MULTIFUNCTIONAL INHIBITORS; CONTAINING PYRIMIDINE NUCLEOSIDES;
   MITOCHONDRIAL-DNA POLYMERASE; ANTI-HIV ACTIVITY; DYNAMICS IN-VIVO;
   NONNUCLEOSIDE INHIBITORS; DRUG-RESISTANCE; CONFORMATIONAL-CHANGES;
   MOLECULAR-MECHANISM; GENETIC-VARIATION
AB Human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) is a major target for currently approved anti-HIV drugs. These drugs are divided into two classes: nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs). This study illustrates the synthesis and biochemical evaluation of a novel bifunctional RT inhibitor utilizing d4T (NRTI) and a TMC-derivative (a diarylpyrimidine NNRTI) linked via a poly(ethylene glycol) (PEG) linker. HIV-1 RT successfully incorporates the triphosphate of d4T-4PEG-TMC bifunctional inhibitor in a base-specific manner. Moreover, this inhibitor demonstrates low nanomolar potency that has 4.3-fold and 4300-fold enhancement of polymerization inhibition in vitro relative to the parent TMC-derivative and d4T, respectively. This study serves as a proof-of-concept for the development and optimization of bifunctional RT inhibitors as potent inhibitors of HIV-1 viral replication.
C1 [Bailey, Christopher M.; Sullivan, Todd J.; Iyidogan, Pinar; Chung, Raymond; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
   [Tirado-Rives, Julian; Ruiz-Caro, Juliana; Jorgensen, William] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [Mohamed, Ebrahim; Hunter, Roger] Univ Cape Town, Dept Chem, ZA-7701 Rondebosch, South Africa.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
EM karen.anderson@yale.edu
RI Tirado-Rives, Julian/A-4992-2012
OI Tirado-Rives, Julian/0000-0001-7330-189X; Hunter,
   Roger/0000-0001-8775-083X; Bailey, Chris/0000-0002-5962-9511
FU NIH [GM49551, AI44616, GM32136]; Fulbright Fellowship
FX This work was supported by NIH Grant GM49551 to K.SA, NIH Grants AI44616
   and GM32136 to W.L.J., and a Fulbright Fellowship to R.H..
CR Bailey CM, 2010, BBA-PROTEINS PROTEOM, V1804, P1213, DOI 10.1016/j.bbapap.2010.01.007
   Basavapathruni A, 2006, BIOCHEMISTRY-US, V45, P7334, DOI 10.1021/bi052362v
   Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200
   Bienstock RJ, 2004, MITOCHONDRION, V4, P203, DOI 10.1016/j.mito.2004.05.018
   Brown JA, 2011, ANTIMICROB AGENTS CH, V55, P276, DOI 10.1128/AAC.01229-10
   Burgess K, 2000, CHEM REV, V100, P2047, DOI 10.1021/cr990045m
   Fouage A. M. C. R., 1957, SEANCES ACAD SCI, V245, P174
   Ciurea A, 2001, NUCLEOS NUCLEOT NUCL, V20, P1655, DOI 10.1081/NCN-100105902
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   Delbederi Z, 2000, NUCLEOS NUCLEOT NUCL, V19, P1441, DOI 10.1080/15257770008033853                                                       
   Fuscoe J. C, 2008, MITOCHONDRION, V8, P181
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   Galmarini CM, 2008, MOL CANCER THER, V7, P3373, DOI 10.1158/1535-7163.MCT-08-0616
   Gavriliu D, 2002, NUCLEOS NUCLEOT NUCL, V21, P505, DOI 10.1081/NCN-120015066
   GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q
   HERNANDEZ E, 1992, SYNTHESIS-STUTTGART, P1164
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Hunter R, 2007, BIOORG MED CHEM LETT, V17, P2614, DOI 10.1016/j.bmcl.2007.01.107
   Iyidogan P, 2012, ANTIVIR RES, V95, P93, DOI [10.1016/j.antiviral.2012.05.012, 10.1016/j.antivira1.2012.05.012]
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862                                                               
   Koczor CA, 2010, EXPERT OPIN DRUG MET, V6, P1493, DOI 10.1517/17425255.2010.526602
   Laduree D, 1999, NUCLEOS NUCLEOT, V18, P883, DOI 10.1080/15257779908041592
   Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101
   Li DY, 2012, J MED CHEM, V55, P3595, DOI 10.1021/jm200990c
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024
   Maga G, 2010, VIRUSES-BASEL, V2, P880, DOI 10.3390/v2040880
   Mansky LM, 1998, J GEN VIROL, V79, P1337, DOI 10.1099/0022-1317-79-6-1337                                                     
   MANSURI MM, 1989, J ORG CHEM, V54, P4780, DOI 10.1021/jo00281a017
   Martinez-Cajas Jorge L., 2008, P231
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200
   Okada M, 1997, CHEM PHARM BULL, V45, P482
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Piao DY, 2013, BIOORG MED CHEM LETT, V23, P1511, DOI 10.1016/j.bmcl.2012.12.015
   Pontikis R, 2000, J MED CHEM, V43, P1927, DOI 10.1021/jm991125l                                                               
   Renoud-Grappin M, 1998, ANTIVIR CHEM CHEMOTH, V9, P205, DOI 10.1177/095632029800900302                                                      
   Rhodes T, 2003, J VIROL, V77, P11193, DOI 10.1128/JVI.77.20.11193-11200.2003
   RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046
   Rong FG, 1995, NUCLEOS NUCLEOT, V14, P1873, DOI 10.1080/15257779508010710
   RONG FG, 1994, NUCLEOS NUCLEOT, V13, P2021, DOI 10.1080/15257779408010680
   RUTH JL, 1982, J BIOL CHEM, V257, P261
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   Spychala J, 1997, SYNTHETIC COMMUN, V27, P1943, DOI 10.1080/00397919708006796
   Thoresen LH, 2003, CHEM-EUR J, V9, P4603, DOI 10.1002/chem.200304944
   Udier-Blagovic M, 2003, J AM CHEM SOC, V125, P6016, DOI 10.1021/ja034308c
   Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000                                                   
   Velazquez S, 1999, J MED CHEM, V42, P5188, DOI 10.1021/jm991092+
   VELAZQUEZ S, 1995, J MED CHEM, V38, P1641, DOI 10.1021/jm00010a008
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   WORLD HEALTH ORGANIZATION (WHO), 2010, ANT THER HIV INF AD
   [WHO] World Health Organization, ANT THER HIV INF AD
   Younis Y, 2010, BIOORGAN MED CHEM, V18, P4661, DOI 10.1016/j.bmc.2010.05.025
   Zhang YM, 2002, TETRAHEDRON LETT, V43, P8235, DOI 10.1016/S0040-4039(02)02036-1
NR 61
TC 12
Z9 12
U1 1
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 23
PY 2013
VL 56
IS 10
BP 3959
EP 3968
DI 10.1021/jm400160s
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 154CW
UT WOS:000319650100015
PM 23659183
OA green_accepted
DA 2018-01-05
ER

PT J
AU Onajole, OK
   Pieroni, M
   Tipparaju, SK
   Lun, S
   Stec, J
   Chen, G
   Gunosewoyo, H
   Guo, HD
   Ammerman, NC
   Bishai, WR
   Kozikowski, AP
AF Onajole, Oluseye K.
   Pieroni, Marco
   Tipparaju, Suresh K.
   Lun, Shichun
   Stec, Jozef
   Chen, Gang
   Gunosewoyo, Hendra
   Guo, Haidan
   Ammerman, Nicole C.
   Bishai, William R.
   Kozikowski, Alan P.
TI Preliminary Structure-Activity Relationships and Biological Evaluation
   of Novel Antitubercular Indolecarboxamide Derivatives Against
   Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IN-VITRO; DISCOVERY; DESIGN; SERIES; INHIBITORS; AGENTS
AB Tuberculosis (TB) remains one of the leading causes of mortality and morbidity worldwide, with approximately one-third of the world's population infected with latent TB. This is further aggravated by HIV coinfection and the emergence of multidrug- and extensively drug-resistant (MDR and XDR, respectively) TB; hence the quest for highly effective antitubercular drugs with novel modes of action is imperative. We report herein the discovery of an indole-2-carboxamide analogue, 3, as a highly potent antitubercular agent, and the subsequent chemical modifications aimed at establishing a preliminary body of structure activity relationships (SARs). These efforts led to the identification of three molecules (12-14) possessing an exceptional activity in the low nanomolar range against actively replicating Mycobacterium tuberculosis, with minimum inhibitory concentration (MIC) values lower than those of the most prominent antitubercular agents currently in use. These compounds were also devoid of apparent toxicity to Vero cells. Importantly, compound 12 was found to be active against the tested XDR-TB strains and orally active in the serum inhibition titration assay.
C1 [Onajole, Oluseye K.; Pieroni, Marco; Tipparaju, Suresh K.; Stec, Jozef; Chen, Gang; Gunosewoyo, Hendra; Kozikowski, Alan P.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA.
   [Lun, Shichun; Guo, Haidan; Ammerman, Nicole C.; Bishai, William R.] Johns Hopkins Sch Med, Div Infect Dis, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA.
   [Ammerman, Nicole C.; Bishai, William R.] KwaZulu Natal Res Inst TB & HIV, Nelson R Mandela Sch Med, ZA-4001 Durban, Kwazulu Natal, South Africa.
   [Bishai, William R.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Bishai, WR (reprint author), Johns Hopkins Sch Med, Div Infect Dis, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA.
EM wbishai1@jhmi.edu; kozikowa@uic.edu
RI pieroni, marco/K-4283-2017; Chen, Gang/B-6320-2014
OI Pieroni, Marco/0000-0001-9190-3712; Gunosewoyo,
   Hendra/0000-0003-3897-1948
FU K-RITH
FX We gratefully acknowledge Prof. P. Moodley, W. R. Jacobs, Jr., and M.
   Larsen for generously sharing clinical isolates of M. tuberculosis from
   KwaZulu-Natal and for providing their drug susceptibility phenotypes.
   Dr. S. C. Cho and Prof. S. G. Franzblau are acknowledged for the
   phenotypic high-throughput screening of the ASDI library. We thank
   K-RITH for their financial support of this project. We also thank Dr. J.
   A. Bergman (A.P.K. lab) for helpful discussion and suggestions.
CR Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753
   Ballell L, 2013, CHEMMEDCHEM, V8, P313, DOI 10.1002/cmdc.201200428
   Chopra S, 2012, J ANTIMICROB CHEMOTH, V67, P415, DOI 10.1093/jac/dkr449
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004
   DEAN FM, 1953, J CHEM SOC, P1250, DOI 10.1039/jr9530001250                                                            
   Ioerger TR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007778
   Jassal MS, 2010, CLIN INFECT DIS, V50, pS156, DOI 10.1086/651486
   Koul A, 2011, NATURE, V469, P483, DOI 10.1038/nature09657
   KURDUKAR RAJESHWAR, 1963, PROC INDIAN ACAD SCI SECT A, V58, P336
   Lenaerts AJ, 2005, ANTIMICROB AGENTS CH, V49, P2294, DOI 10.1285/AAC.49.6.294-2301.2005
   Li JC, 2005, BIOORG MED CHEM LETT, V15, P4961, DOI 10.1016/j.bmcl.2005.08.001
   Lienhardt C, 2010, CURR OPIN PULM MED, V16, P186, DOI 10.1097/MCP.0b013e328337580c
   Lilienkampf A, 2010, J MED CHEM, V53, P678, DOI 10.1021/jm901273n
   Lilienkampf A, 2009, J MED CHEM, V52, P2109, DOI 10.1021/jm900003c
   LUN S, MYCOBACTERIUM UNPUB
   Ma ZK, 2010, LANCET, V375, P2100, DOI 10.1016/S0140-6736(10)60359-9
   Mao J, 2007, CHEMMEDCHEM, V2, P1624, DOI 10.1002/cmdc.200700112
   Mao JL, 2007, CHEMMEDCHEM, V2, P811, DOI 10.1002/cmdc.200700048
   Ormerod LP, 1999, THORAX, V54, pS42, DOI 10.1136/thx.54.2008.S42                                                         
   PETERSON LR, 1992, CLIN MICROBIOL REV, V5, P420
   Pieroni M, 2011, CHEMMEDCHEM, V6, P334, DOI 10.1002/cmdc.201000490
   Pieroni M, 2010, CHEMMEDCHEM, V5, P1667, DOI 10.1002/cmdc.201000169
   Pieroni M, 2009, J MED CHEM, V52, P6287, DOI 10.1021/jm900513a
   Rosenthal IM, 2007, PLOS MED, V4, P1931, DOI 10.1371/journal.pmed.0040344
   Schecter GF, 2010, CLIN INFECT DIS, V50, P49, DOI 10.1086/648675
   Shandil RK, 2007, ANTIMICROB AGENTS CH, V51, P576, DOI 10.1128/AAC.00414-06
   SUZUKI T, 1983, B CHEM SOC JPN, V56, P2762, DOI 10.1246/bcsj.56.2762                                                            
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   *WORK GROUP NEW TB, 2013, DRUG PIP
   Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120
NR 30
TC 39
Z9 41
U1 1
U2 44
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 23
PY 2013
VL 56
IS 10
BP 4093
EP 4103
DI 10.1021/jm4003878
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 154CW
UT WOS:000319650100025
PM 23611124
DA 2018-01-05
ER

PT J
AU Wei, L
   Zhao, X
   Chen, B
   Li, HC
   Xiao, LH
   Yeung, ES
AF Wei, Lin
   Zhao, Xin
   Chen, Bo
   Li, Hongchang
   Xiao, Lehui
   Yeung, Edward S.
TI Frozen Translational and Rotational Motion of Human Immunodeficiency
   Virus Transacting Activator of Transcription Peptide-Modified Nanocargo
   on Neutral Lipid Bilayer
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID INTERNAL-REFLECTION FLUORESCENCE; HIV-1 TAT PEPTIDES; INTRACELLULAR
   DELIVERY; METABOLIC-INHIBITORS; BROWNIAN-MOTION; CELL BIOLOGY; LIVE
   CELLS; MEMBRANE; NANOPARTICLES; MICROSCOPY
AB With time-resolved high-precision single-particle tracking methodologies, we explored the adsorption and thermal motion of transacting activator of transcription (TAT) peptide-modified nanocargo on a model lipid bilayer in the nonelectrostatic domain. We found that the lateral and rotational motion of TAT peptide-modified nanocargo could be effectively suppressed on the surface of neutral lipid membrane, a feature that cannot be explained by existing hypotheses. A semiquantitative association activation energy analysis revealed that multiple weak bonds were required for the initial adsorption process. As a result, the localized multiple TAT peptides on the surface of the nanocargo can provide a pathway for the creation of a net of peptide lipid complexes (e.g., lipid domain). The dragging forces caused by these complexes effectively confined the thermal motion of the nanocargo on the fluid membrane that cannot be achieved by individual peptides with random spatial and conformational distributions. These interesting findings could provide insightful information for the better understanding of the intracellular internalization mechanism of TAT peptide-modified nanocargo and might shed new light on the development of highly efficient intracellular carriers for site-specific delivery of drugs and genes.
C1 [Wei, Lin; Yeung, Edward S.] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Coll Biol, Changsha 410082, Hunan, Peoples R China.
   [Wei, Lin; Zhao, Xin; Chen, Bo; Li, Hongchang; Xiao, Lehui] Hunan Normal Univ, Coll Chem & Chem Engn, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ, Changsha 410081, Hunan, Peoples R China.
   [Yeung, Edward S.] US DOE, Ames Lab, Ames, IA 50011 USA.
   [Yeung, Edward S.] Iowa State Univ, Dept Chem, Ames, IA 50011 USA.
RP Xiao, LH (reprint author), Hunan Normal Univ, Coll Chem & Chem Engn, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ, Changsha 410081, Hunan, Peoples R China.
EM lehuixiao@gmail.com; yeung@ameslab.gov
FU NSFC [21205037, 20927005, 21275049]; aid program for science and
   technology innovation research team in higher education institutions of
   Hunan Province [2010TT1001]; U.S. Department of Energy, Office of Basic
   Energy Sciences, Division of Chemical Sciences, Geosciences, and
   Biosciences through the Ames Laboratory; U.S. Department of Energy
   [DEAC02-07CH11358]; program of China Scholarships Council; National
   "863" Research Foundation [2010AA023001]
FX This work was partially supported by NSFC 21205037 and the aid program
   for science and technology innovation research team in higher education
   institutions of Hunan Province (2010TT1001). E.S.Y. was supported by the
   U.S. Department of Energy, Office of Basic Energy Sciences, Division of
   Chemical Sciences, Geosciences, and Biosciences through the Ames
   Laboratory. The Ames Laboratory is operated for the U.S. Department of
   Energy by Iowa State University under contract no. DEAC02-07CH11358.
   L.W. expresses thanks for the partial financial support from the program
   of China Scholarships Council. B.C. thanks the partial support from the
   National "863" Research Foundation (2010AA023001), the NSFC (20927005,
   21275049).
CR AXELROD D, 1984, ANNU REV BIOPHYS BIO, V13, P247, DOI 10.1146/annurev.bb.13.060184.001335
   Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x
   Bally M, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.188103
   Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Ciobanasu C, 2010, BIOPHYS J, V99, P153, DOI 10.1016/j.bpj.2010.03.065
   Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Ewers H, 2005, P NATL ACAD SCI USA, V102, P15110, DOI 10.1073/pnas.0504407102
   Ferrari R, 2001, PHYSICA D, V154, P111, DOI 10.1016/S0167-2789(01)00234-2
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Fox CB, 2009, ANAL CHEM, V81, P5130, DOI 10.1021/ac9007682
   Gupta B, 2007, ONCOL RES, V16, P351
   LEE GM, 1991, P NATL ACAD SCI USA, V88, P6274, DOI 10.1073/pnas.88.14.6274
   Mishra A, 2008, ANGEW CHEM INT EDIT, V47, P2986, DOI 10.1002/anie.200704444
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Naji A, 2007, BIOPHYS J, V93, pL49, DOI [10.1529/biophysj.107.119222, 10.1529/biophysj.l07.119222]
   Ober RJ, 2004, BIOPHYS J, V86, P1185, DOI 10.1016/S0006-3495(04)74193-4                                                   
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Pierrat S, 2009, J PHYS CHEM C, V113, P11179, DOI 10.1021/jp9030333
   SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111                                                          
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Su YC, 2010, BIOCHEMISTRY-US, V49, P6009, DOI 10.1021/bi100642n
   Sun W, 2009, ANAL CHEM, V81, P9203, DOI 10.1021/ac901623b
   Thaxton CS, 2005, ANAL CHEM, V77, P8174, DOI 10.1021/ac0514265
   Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X                                                   
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Tiriveedhi V, 2007, BIOCHEMISTRY-US, V46, P3888, DOI 10.1021/bi602527t
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Xiao LH, 2012, ANGEW CHEM INT EDIT, V51, P4181, DOI 10.1002/anie.201108647
   Xiao LH, 2011, J AM CHEM SOC, V133, P10638, DOI 10.1021/ja203289m
   Xiao LH, 2010, ANAL CHEM, V82, P5268, DOI 10.1021/ac1006848
   Xiao LH, 2009, J PHYS CHEM C, V113, P1209, DOI 10.1021/jp807776w
   Yang YH, 2009, ANAL CHEM, V81, P2564, DOI 10.1021/ac802477h
   Yuan H, 2012, J AM CHEM SOC, V134, P11358, DOI 10.1021/ja304180y
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 39
TC 10
Z9 10
U1 2
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD MAY 21
PY 2013
VL 85
IS 10
BP 5169
EP 5175
DI 10.1021/ac400503z
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 154DG
UT WOS:000319651100046
PM 23581852
DA 2018-01-05
ER

PT J
AU Takebe, Y
   Saucedo, CJ
   Lund, G
   Uenishi, R
   Hase, S
   Tsuchiura, T
   Kneteman, N
   Ramessar, K
   Tyrrell, DLJ
   Shirakura, M
   Wakita, T
   McMahon, JB
   O'Keefe, BR
AF Takebe, Yutaka
   Saucedo, Carrie J.
   Lund, Garry
   Uenishi, Rie
   Hase, Saiki
   Tsuchiura, Takayo
   Kneteman, Norman
   Ramessar, Koreen
   Tyrrell, D. Lorne J.
   Shirakura, Masayuki
   Wakita, Takaji
   McMahon, James B.
   O'Keefe, Barry R.
TI Antiviral Lectins from Red and Blue-Green Algae Show Potent In Vitro and
   In Vivo Activity against Hepatitis C Virus
SO PLOS ONE
LA English
DT Article
ID ANTI-HIV PROTEIN; CYANOBACTERIUM SCYTONEMA-VARIUM; CULTURED
   CYANOBACTERIUM; ENVELOPE PROTEIN; RECOMBINANT PRODUCTION; INACTIVATING
   PROTEIN; GLYCOSYLATION SITES; HCV INFECTION; CYANOVIRIN-N; GRIFFITHSIN
AB Hepatitis C virus (HCV) infection is a significant public health problem with over 170,000,000 chronic carriers and infection rates increasing worldwide. Chronic HCV infection is one of the leading causes of hepatocellular carcinoma which was estimated to result in,10,000 deaths in the United States in the year 2011. Current treatment options for HCV infection are limited to PEG-ylated interferon alpha (IFN-alpha), the nucleoside ribavirin and the recently approved HCV protease inhibitors telaprevir and boceprevir. Although showing significantly improved efficacy over the previous therapies, treatment with protease inhibitors has been shown to result in the rapid emergence of drug-resistant virus. Here we report the activity of two proteins, originally isolated from natural product extracts, which demonstrate low or sub-nanomolar in vitro activity against both genotype I and genotype II HCV. These proteins inhibit viral infectivity, binding to the HCV envelope glycoproteins E1 and E2 and block viral entry into human hepatocytes. In addition, we demonstrate that the most potent of these agents, the protein griffithsin, is readily bioavailable after subcutaneous injection and shows significant in vivo efficacy in reducing HCV viral titers in a mouse model system with engrafted human hepatocytes. These results indicate that HCV viral entry inhibitors can be an effective component of anti-HCV therapy and that these proteins should be studied further for their therapeutic potential.
C1 [Takebe, Yutaka; Uenishi, Rie; Hase, Saiki; Tsuchiura, Takayo] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan.
   [Saucedo, Carrie J.] SAIC Frederick, Mol Targets Lab, Frederick, MD USA.
   [Lund, Garry; Kneteman, Norman; Tyrrell, D. Lorne J.] KMT Hepatech, Edmonton, AB, Canada.
   [Ramessar, Koreen; McMahon, James B.; O'Keefe, Barry R.] NCI, Ctr Canc Res, Mol Targets Lab, Frederick, MD 21701 USA.
   [Shirakura, Masayuki; Wakita, Takaji] Natl Inst Infect Dis, Tokyo, Japan.
RP O'Keefe, BR (reprint author), NCI, Ctr Canc Res, Mol Targets Lab, Frederick, MD 21701 USA.
EM okeefeba@mail.nih.gov
FU Ministry of Health, Labor and Welfare (JAPAN); Human Sciences
   Foundation; Intramural research Program of the NIH; National Cancer
   Institute; Center for Cancer Research; National Cancer Institute,
   National Institutes of Health [N01-CO-12400, HHSN261200800001E]; NIAID
FX Y.T. is supported by grants of the hepatitis study group from the
   Ministry of Health, Labor and Welfare (JAPAN) and the Human Sciences
   Foundation. This research was supported by the Intramural research
   Program of the NIH, National Cancer Institute, Center for Cancer
   Research. This project has been funded in whole or in part with federal
   funds from the National Cancer Institute, National Institutes of Health,
   under contract N01-CO-12400 and HHSN261200800001E. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; The patents for both Griffithsin and
   Scytovirin are wholly owned by the U.S. Government. Drs. O'Keefe and
   McMahon are named inventors on patents for both proteins. Norman
   Kneteman, Garry Lund and Lorne Tyrrell are affiliated to KMT Hepatech
   which is a contract research organization funded by NIAID for hepatitis
   C studies with no competing interests. KMT Hepatech has no rights or
   interests in further developing the antiviral proteins griffithsin and
   scytovirin for commercial use. Their involvement in this manuscript does
   not alter the authors' adherence to all the PLOS ONE policies on sharing
   data and materials.
CR Barth H, 2008, J HEPATOL, V49, P134, DOI 10.1016/j.jhep.2008.03.012
   Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200
   Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Pruett TL, 2005, LIVER TRANSPLANT, V11, P941
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759
   Giomarelli B, 2006, PROTEIN EXPRES PURIF, V47, P194, DOI 10.1016/j.pep.2005.10.014
   Goffard A, 2005, J VIROL, V79, P8400, DOI 10.1128/JVI.79.13.8400-8409.2005
   Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X
   Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
   Helle F, 2007, J VIROL, V81, P8101, DOI 10.1128/JVI.00127-07
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Kato T, 2005, J CLIN MICROBIOL, V43, P5679, DOI 10.1128/JCM.43.11.5679-5684.2005
   Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635
   Krieger SE, 2010, HEPATOLOGY, V51, P1144, DOI 10.1002/hep.23445
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   McFeeters RL, 2007, J MOL BIOL, V369, P451, DOI 10.1016/j.jmb.2007.03.030
   Meuleman P, 2011, ANTIMICROB AGENTS CH, V55, P5159, DOI 10.1128/AAC.00633-11
   Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887                                                      
   Michaels AJ, CURR OPINION GASTROE, V26, P196
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838
   Moulaei T, 2007, PROTEIN SCI, V16, P2756, DOI 10.1110/ps.073157507
   Naggie S, 2010, J ANTIMICROB CHEMOTH, V65, P2063, DOI 10.1093/jac/dkq284
   O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106
   Op De Beeck A, 2004, J VIROL, V78, P2994
   Pol S, 2010, J HEPATOL, V52, pS462, DOI 10.1016/S0168-8278(10)61190-7                                                   
   Polyak SJ, 2007, GASTROENTEROLOGY, V132, P1925, DOI 10.1053/j.gastro.2007.02.038
   Sakamoto H, 2005, NAT CHEM BIOL, V1, P333, DOI 10.1038/nchembio742                                                             
   Sarrazin C, 2010, GASTROENTEROLOGY, V138, P447, DOI 10.1053/j.gastro.2009.11.055
   Schiano TD, 2006, LIVER TRANSPLANT, V12, P1381, DOI 10.1002/lt.20876
   Slater-Handshy T, 2004, VIROLOGY, V319, P36, DOI 10.1016/j.virol.2003.10.008
   Susser S, 2011, J CLIN VIROL, V52, P321, DOI 10.1016/j.jcv.2011.08.015
   Vermehren J, 2011, CLIN MICROBIOL INFEC, V17, P122, DOI 10.1111/j.1469-0691.2010.03430.x
   Vieyres G, 2010, J VIROL, V84, P10159, DOI 10.1128/JVI.01180-10
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Xiong CY, 2006, PROTEIN EXPRES PURIF, V46, P233, DOI 10.1016/j.pep.2005.09.019
   Zeisel MB, 2011, J HEPATOL, V54, P566, DOI 10.1016/j.jhep.2010.10.014
   Zhang HJ, 2009, J NAT PROD, V72, P2158, DOI 10.1021/np900549e
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
NR 43
TC 27
Z9 29
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e64449
DI 10.1371/journal.pone.0064449
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200137
PM 23700478
OA gold
DA 2018-01-05
ER

PT J
AU Dahmane, E
   Rhazi, M
   Taourirte, M
AF Dahmane, El Montassir
   Rhazi, Mohammed
   Taourirte, Moha
TI Chitosan Nanoparticles as a New Delivery System for the Anti-HIV Drug
   Zidovudine
SO BULLETIN OF THE KOREAN CHEMICAL SOCIETY
LA English
DT Article
DE Chitosan; Nanoparticles; Zidovudine; Controlled drug delivery
ID PHYSICOCHEMICAL CHARACTERISTICS; MUCOADHESIVE PROPERTIES; DEACETYLATION
   PROCESS; THERAPY; CHITIN; AIDS; SURFACE; PHARMACOKINETICS;
   BIODISTRIBUTION; POLYSACCHARIDE
AB Chitosan-based nanoparticles (CSNP) were prepared through ionic cross-linking and gelation of chitosan (CS) by tripolyphosphate (TPP). CS properties such as molecular weight, and preparation conditions were screened and the resulting nanoparticles were examined by Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and transmission electron microscopy (SEM). The obtained particles were consistently spherical with an overall diameter of approximately 107 +/- 20 nm. They were successfully used as a carrier for Zidovudine, an anti-human immunodeficiency virus (HIV) which, to our knowledge, is novel. The encapsulation ability, loading capacity, and controlled release behavior for these CSNP was evaluated. Results indicated that their intrinsic properties were strongly affected by properties inherent to CS such as molecular weight, and by the preparation condition, such as cross-linking density, which depends on the concentration of the cross-linker. In vitro release tests for the entrapped zidovudine showed that the CNNP provided a continuous release that can last upwards 20 h.
C1 [Dahmane, El Montassir; Taourirte, Moha] Fac Sci & Tech Gueliz FSTG, Lab Chim Bio Organ & Macromol LCBM, Dept Sci Chim, Marrakech 40000, Morocco.
   [Rhazi, Mohammed] Ecole Normale Super, Lab Macromol Nat LMN, Marrakech 40000, Morocco.
RP Taourirte, M (reprint author), Fac Sci & Tech Gueliz FSTG, Lab Chim Bio Organ & Macromol LCBM, Dept Sci Chim, BP 549, Marrakech 40000, Morocco.
EM el_montassirfstg@yahoo.fr; Taourirte@gmail.com
FU Korean Chemical Society
FX The publication cost of this paper was supported by the Korean Chemical
   Society.
CR Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   Bajaj A., 2006, PHARMA TIMES, V38, P12
   Banerjee T, 2002, INT J PHARM, V243, P93, DOI 10.1016/S0378-5173(02)00267-3
   BRODER S, 1990, ANN INTERN MED, V113, P604, DOI 10.7326/0003-4819-113-8-604
   Broussignac P., 1968, CHIM IND GEN CHIM, V99, P1241
   Ciofani G, 2008, BIOMED MICRODEVICES, V10, P131, DOI 10.1007/s10544-007-9118-7
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   Duarte ML, 2002, INT J BIOL MACROMOL, V31, P1, DOI 10.1016/S0141-8130(02)00039-9
   Dube A, 2010, EUR J PHARM SCI, V41, P219, DOI 10.1016/j.ejps.2010.06.010
   Dudhani AR, 2010, CARBOHYD POLYM, V81, P243, DOI 10.1016/j.carbpol.2010.02.026
   Felt O, 1998, DRUG DEV IND PHARM, V24, P979, DOI 10.3109/03639049809089942                                                       
   Gan Q, 2005, COLLOID SURFACE B, V44, P65, DOI 10.1016/j.colsurfb.2005.06.001
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   He P, 1998, INT J PHARM, V166, P75, DOI 10.1016/S0378-5173(98)00027-1
   Huang HZ, 2004, BIOMACROMOLECULES, V5, P2340, DOI 10.1021/bm0497116
   Huang X, 2009, CARBOHYD POLYM, V76, P368, DOI 10.1016/j.carbpol.2008.10.025
   Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2                                                   
   Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021
   Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004
   KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49                                                            
   Knaul JZ, 1999, J APPL POLYM SCI, V72, P1721, DOI 10.1002/(SICI)1097-4628(19990624)72:13<1721::AID-APP8>3.0.CO;2-V                
   Kumar MNVR, 2004, CHEM REV, V104, P6017, DOI 10.1021/cr030441b
   Lavertu M, 2003, J PHARMACEUT BIOMED, V32, P1149, DOI 10.1016/S0731-7085(03)00115-9
   LEHR CM, 1992, INT J PHARM, V78, P43, DOI 10.1016/0378-5173(92)90353-4                                                    
   Mitra S, 2001, J CONTROL RELEASE, V74, P317, DOI 10.1016/S0168-3659(01)00342-X                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   Palombo MS, 2009, J DRUG DELIV SCI TEC, V19, P3, DOI 10.1016/S1773-2247(09)50001-9                                                   
   Paul W, 2000, STP PHARMA SCI, V10, P5
   Porporatto C, 2005, J LEUKOCYTE BIOL, V78, P62, DOI 10.1189/jlb.0904541
   Prabaharan M, 2005, DRUG DELIV, V12, P41, DOI 10.1080/10717540590889781
   Rhazi M, 2000, POLYM INT, V49, P337, DOI 10.1002/(SICI)1097-0126(200004)49:4<337::AID-PI375>3.0.CO;2-B                   
   RINAUDO M, 1993, INT J BIOL MACROMOL, V15, P281, DOI 10.1016/0141-8130(93)90027-J
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   Shahiwala A., 2007, J HIV THER, V1, P49
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Tolaimate A, 2000, POLYMER, V41, P2463, DOI 10.1016/S0032-3861(99)00400-0                                                   
   van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wannachaiyasit S, 2008, AAPS PHARMSCITECH, V9, P840, DOI 10.1208/s12249-008-9122-0
   Wilson B, 2010, NANOMED-NANOTECHNOL, V6, P144, DOI 10.1016/j.nano.2009.04.001
   Xu YM, 2003, INT J PHARM, V250, P215, DOI 10.1016/S0378-5173(02)00548-3
   Yamamoto H, 2005, J CONTROL RELEASE, V102, P373, DOI 10.1016/j.jconrel.2004.10.010
   YARCHOAN R, 1986, LANCET, V1, P575
NR 43
TC 6
Z9 6
U1 0
U2 26
PU KOREAN CHEMICAL SOC
PI SEOUL
PA 635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 0253-2964
J9 B KOREAN CHEM SOC
JI Bull. Korean Chem. Soc.
PD MAY 20
PY 2013
VL 34
IS 5
BP 1333
EP 1338
DI 10.5012/bkcs.2013.34.5.1333
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 154XQ
UT WOS:000319710400005
OA gold
DA 2018-01-05
ER

PT J
AU Cordoba, EV
   Arnaiz, E
   Relloso, M
   Sanchez-Torres, C
   Garcia, F
   Perez-Alvarez, L
   Gomez, R
   de la Mata, FJ
   Pion, M
   Munoz-Fernandez, MA
AF Vacas Cordoba, Enrique
   Arnaiz, Eduardo
   Relloso, Miguel
   Sanchez-Torres, Carlos
   Garcia, Federico
   Perez-Alvarez, Lucia
   Gomez, Rafael
   de la Mata, Francisco J.
   Pion, Marjorie
   Angeles Munoz-Fernandez, Ma
TI Development of sulphated and naphthylsulphonated carbosilane dendrimers
   as topical microbicides to prevent HIV-1 sexual transmission
SO AIDS
LA English
DT Article
DE carbosilane dendrimer; HIV sexual transmission; microbicide
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SPL7013 GEL; SELECTIVE TRANSMISSION; PRO
   2000; INFECTION; NANOTECHNOLOGY; GATEKEEPER; MECHANISMS; INHIBITORS;
   MODEL
AB Objectives: For the last 20 years, the idea of alternative prevention strategies based on the use of topical vaginally products to inhibit HIV-1 infection in women has been established. The concept of a 'microbicide' product has been born out of the unavailability of a vaccine against HIV-1 and the problems of women in negotiating the use of preventive prophylaxis by their partners, especially in developing countries. Design: We have developed and evaluated polyanionic carbosilane dendrimers G3-S16 and G2-NF16 with sulphated and naphthylsulphonated end groups as nonspecific microbicides. Methods: Cellular in-vitro or in-vivo models were used to evaluate the safety, bio-compatibility and anti-HIV ability of two polyanionic carbosilane dendrimers. Results: Both dendrimers showed high biosafety in human epithelial cell lines derived from uterus and vagina and in primary blood human cells (PBMC). These dendrimers not only have a partial capacity to block the entry of different X4 and R5 HIV-1 isolates inside epithelial cells but protect the epithelial monolayer from cell disruption and also reduce HIV-1 infection of activated PBMC. Additionally, treatment of epithelial cells with G3-S16 or G2-NF16 dendrimers did not produce changes in proinflammatory cytokines profile, in proliferation of PBMC, on microbiota or sperm survival. Finally, no irritation or vaginal lesions were detected in female CD1(ICR) mice after dendrimers vaginal administration. Conclusion: These interesting results suggest that G3-S16 or G2-NF16 could be effective to inhibit HIV infection and transmission within genital mucosa as well as the spread of HIV transmission to human PBMC. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27: 1219-1229
C1 [Vacas Cordoba, Enrique; Relloso, Miguel; Pion, Marjorie; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
   [Vacas Cordoba, Enrique; Relloso, Miguel; Pion, Marjorie; Angeles Munoz-Fernandez, Ma] Univ Alcala De Henares, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Alcala De Henares, Spain.
   [Arnaiz, Eduardo; Gomez, Rafael; de la Mata, Francisco J.] Univ Alcala De Henares, Dept Inorgan Chem, Alcala De Henares, Spain.
   [Arnaiz, Eduardo; Gomez, Rafael; de la Mata, Francisco J.] Hosp Gen Univ Gregorio Maranon, Ctr Bioengn Biomat & Nanomed CIBER BBN, Granada, Spain.
   [Sanchez-Torres, Carlos; Garcia, Federico] Hosp Gen Univ Gregorio Maranon, Lab Reprod, Granada, Spain.
   [Sanchez-Torres, Carlos; Garcia, Federico] Hosp Univ San Cecilio, Serv Microbiol, Granada, Spain.
   [Perez-Alvarez, Lucia] Inst Salud Carlos III, Viral Pathogenesis Dept, Ctr Nacl Microbiol, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio, Maranon CIBER BBN, Lab InmunoBiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
RI Pion, Marjorie/D-8139-2012; De la Mata, F. Javier/K-1649-2014; Gomez
   Ramirez, Rafael/K-1216-2014
OI Pion, Marjorie/0000-0002-6406-747X; De la Mata, F.
   Javier/0000-0003-0418-3935; Gomez Ramirez, Rafael/0000-0001-6448-2414;
   Relloso, Miguel/0000-0002-9181-2244;
   Munoz-Fernandez/0000-0002-0813-4500; Pion, Marjorie/0000-0003-1828-4745
FU Fondos de Investigacion Sanitaria [INTRASALUD PI09/02029, P509102669];
   Red Tematica de Investigacion Cooperativa Sanitaria ISCIII [RETIC
   RD06/0006/0035]; INDIS-NET [S-2011-BMD2332]; FIPSE; Cost action
   [TD0802]; NANODENDMED [S2011/BMD-2351]; Spanish MICINN through the Ramon
   y Cajal [RYC-2009-05486]; MEyC [CTQ2011-23245]
FX This work was supported by grants from Fondos de Investigacion Sanitaria
   (INTRASALUD PI09/02029, P509102669), Red Tematica de Investigacion
   Cooperativa Sanitaria ISCIII (RETIC RD06/0006/0035), INDIS-NET
   S-2011-BMD2332, FIPSE, Cost action TD0802, CTQ2011-23245 (MEyC),
   NANODENDMED S2011/BMD-2351 and the Spanish MICINN through the Ramon y
   Cajal (RYC-2009-05486) to M.P.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Anton PA, 2012, CURR HIV RES, V10, P113, DOI 10.2174/157016212799304634
   Balzarini J, 2012, CURR HIV RES, V10, P53, DOI 10.2174/157016212799304652
   Buckheit RW, 2012, CURR HIV RES, V10, P97
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Ciepluch K, 2012, MOL PHARMACEUT, V9, P448, DOI 10.1021/mp200549c
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Fischetti L, 2004, J MED VIROL, V73, P158, DOI 10.1002/jmv.20070
   Galan M, 2012, CURR MED CHEM, V19, P4984
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grivel JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S6
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Keller MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008781
   Kim B, 2010, NEW ENGL J MED, V36, P2434
   Kish-Catalone TM, 2006, ANTIMICROB AGENTS CH, V50, P1497, DOI 10.1128/AAC.50.4.1497-1509.2006
   Klajnert B, 2001, ACTA BIOCHIM POL, V48, P199
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387                                                             
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   MNT-Statement, 2011, MTN STAT DEC DISC US
   Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852
   Ortega P, 2011, ORG BIOMOL CHEM, V9, P5238, DOI 10.1039/c1ob05321c
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Quinones-Mateu ME, 2012, CURR HIV RES, V10, P1
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Reina JJ, 2010, FUTURE MED CHEM, V2, P1141, DOI 10.4155/FMC.10.203
   Rupp R, 2007, INT J NANOMED, V2, P561
   Saba E, 2010, MUCOSAL IMMUNOL, V3, P280, DOI 10.1038/mi.2010.2
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Stephenson J., 2011, LANCET, V305, P1397
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   World Health Organization, 2009, WOMEN AND HEALTH: TODAY'S EVIDENCE TOMORROW'S AGENDA, P1
   YAHI N, 1994, J BIOL CHEM, V269, P24349
NR 45
TC 31
Z9 31
U1 1
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2013
VL 27
IS 8
BP 1219
EP 1229
DI 10.1097/QAD.0b013e32835f2b7a
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 133RG
UT WOS:000318156400004
PM 23925376
OA gold
DA 2018-01-05
ER

PT J
AU Popescu, I
   Pelin, IM
   Butnaru, M
   Fundueanu, G
   Suflet, DM
AF Popescu, Irina
   Pelin, Irina M.
   Butnaru, Maria
   Fundueanu, Gheorghe
   Suflet, Dana M.
TI Phosphorylated curdlan microgels. Preparation, characterization, and in
   vitro drug release studies
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Curdlan phosphate; Microspheres; Anionic microgels; Drug delivery
ID ANTI-HIV ACTIVITY; HYDROGELS; DELIVERY; POLYSACCHARIDES; SULFATE;
   NANOPARTICLES
AB Curdlan derivative with anionic phosphate groups was used for the first time to obtain hydrogel microspheres. The chemical cross-linking of the phosphorylated curdlan was performed with epichlorohydrin using the water-in-oil inverse emulsion technique. The optical and scanning electron microscopies were used to analyze the morphology of the microgels, whereas the FTIR spectroscopy was used to investigate their chemical structure. The main characteristics such as the swelling degree, the exchange capacity, and the thermal resistance were also studied. These new anionic microgels could be used as potential carriers for controlled release of opposite charged drugs retained through electrostatic forces. Diphenhydramine, a cationic model drug, was used to investigate the loading and the release processes in various pH media simulating physiological fluids. Several mathematical models were applied to evaluate the drug transport processes and to calculate the drug diffusion coefficients. The synthesized microspheres presented an excellent biocompatibility. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Popescu, Irina; Pelin, Irina M.; Fundueanu, Gheorghe; Suflet, Dana M.] Petru Poni Inst Macromol Chem, Iasi 700487, Romania.
   [Butnaru, Maria] Gr T Popa Univ Med & Pharm, Fac Med Bioengn, Dept Biomed Sci, Iasi, Romania.
RP Suflet, DM (reprint author), Petru Poni Inst Macromol Chem, Aleea Grigore Ghica Voda 41A, Iasi 700487, Romania.
EM dsuflet@icmpp.ro
RI Suflet, Dana/B-5681-2011; Popescu, Irina/B-4746-2012; Pelin,
   Irina/B-6030-2012; Butnaru, Maria/I-8195-2016; Fundueanu,
   Gheorghe/B-6794-2012
OI Popescu, Irina/0000-0001-6449-8408; Pelin, Irina/0000-0003-3902-7262; 
FU European Social Fund - "Cristofor I. Simionescu" Postdoctoral Fellowship
   Programme [POSDRU/89/1.5/S/55216]; Sectoral Operational Programme Human
   Resources Development [2007e2013]
FX D.M.S. acknowledges the financial support of European Social Fund -
   "Cristofor I. Simionescu" Postdoctoral Fellowship Programme (ID
   POSDRU/89/1.5/S/55216), Sectoral Operational Programme Human Resources
   Development 2007e2013. The authors also thank Prof. Yves Berthier and
   PhD. Ana-Maria Sfarghiu-Trunfio (Tribology and Interface Mechanisms,
   INSA de Lyon, France) for allowing the use of the Scanning Electron
   Microscope.
CR Alban S, 2001, BIOMACROMOLECULES, V2, P354, DOI 10.1021/bm010032u
   Bajpai AK, 2008, PROG POLYM SCI, V33, P1088, DOI 10.1016/j.progpolymsci.2008.07.005
   Borjihan G, 2003, POLYM ADVAN TECHNOL, V14, P326, DOI 10.1002/pat.315
   Chen J., 2007, MYCOLOGICAL RES, V111, P635
   Chen XY, 2009, CARBOHYD POLYM, V78, P581, DOI 10.1016/j.carbpol.2009.05.019
   Coviello T, 2007, J CONTROL RELEASE, V119, P5, DOI 10.1016/j.jconrel.2007.01.004
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Freshney R., 2005, CULTURE ANIMAL CELLS, P182
   Fritzsche J, 2006, BIOCHEM PHARMACOL, V72, P474, DOI 10.1016/j.bcp.2006.05.006
   Fundueanu G, 2005, BIOMATERIALS, V26, P4337, DOI 10.1016/j.biomaterials.2004.10.036
   Gao FP, 2008, CARBOHYD POLYM, V71, P606, DOI 10.1016/j.carbpol.2007.07.008
   Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/S0169-409X(01)00239-3                                                   
   Jeon KJ, 2000, J AM CHEM SOC, V122, P12536, DOI 10.1021/ja001577j                                                               
   KANEKO Y, 1990, BIOCHEM PHARMACOL, V39, P793
   Kim BS, 2000, BIOTECHNOL LETT, V22, P1127, DOI 10.1023/A:1005636205036                                                         
   Laroche Celine, 2007, Recent Pat Biotechnol, V1, P59, DOI 10.2174/187220807779813938
   Liu H, 2005, LANGMUIR, V21, P379, DOI 10.1021/la047934b
   Liu WQ, 2012, MAT SCI ENG C-MATER, V32, P953, DOI 10.1016/j.msec.2012.02.001
   Liu ZH, 2008, ADV DRUG DELIVER REV, V60, P1650, DOI 10.1016/j.addr.2008.09.001
   Lynch M. J., 1969, MED LAB TECHNOLOGY C
   Mocanu G, 2009, INT J BIOL MACROMOL, V44, P215, DOI 10.1016/j.ijbiomac.2008.12.005
   Mullarney MP, 2006, POLYMER, V47, P3845, DOI 10.1016/j.polymer.2006.03.096
   Nastruzzi C., 1993, PHARM PHARM LETT, V3, P51
   Oh JK, 2008, PROG POLYM SCI, V33, P448, DOI 10.1016/j.progpolymsci.2008.01.002
   Oh JK, 2009, PROG POLYM SCI, V34, P1261, DOI 10.1016/j.progpolymsci.2009.08.001
   OSAWA Z, 1993, CARBOHYD POLYM, V21, P283, DOI 10.1016/0144-8617(93)90060-H                                                    
   PEPPAS NA, 1993, ADV DRUG DELIVER REV, V11, P1, DOI 10.1016/0169-409X(93)90025-Y
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Saudagar PS, 2004, CARBOHYD POLYM, V56, P483, DOI 10.1016/j.carbpol.2004.03.015
   Serra L, 2006, BIOMATERIALS, V27, P5440, DOI 10.1016/j.biomaterials.2006.06.011
   Siepemann J., 2005, BIOMACROMOLECULES, V6, P2313
   Siepmann J, 2008, INT J PHARMACEUT, V364, P328, DOI 10.1016/j.ijpharm.2008.09.004
   Singh B, 2007, CARBOHYD POLYM, V69, P631, DOI 10.1016/j.carbpol.2007.01.020
   Suflet DM, 2011, CARBOHYD POLYM, V84, P1176, DOI 10.1016/j.carbpol.2011.01.010
   Sugikawa K, 2008, LANGMUIR, V24, P13270, DOI 10.1021/la802211q
   YOSHIDA T, 1995, CARBOHYD RES, V276, P425, DOI 10.1016/0008-6215(95)00186-W
   Zhao T, 2011, LANGMUIR, V27, P12771, DOI 10.1021/la2028912
   Zografi G., 1990, REMINGTONS PHARM SCI, P30
NR 39
TC 12
Z9 12
U1 2
U2 58
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD MAY 15
PY 2013
VL 94
IS 2
BP 889
EP 898
DI 10.1016/j.carbpol.2013.02.014
PG 10
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 130US
UT WOS:000317946200023
PM 23544647
DA 2018-01-05
ER

PT J
AU Jardine, J
   Julien, JP
   Menis, S
   Ota, T
   Kalyuzhniy, O
   McGuire, A
   Sok, D
   Huang, PS
   MacPherson, S
   Jones, M
   Nieusma, T
   Mathison, J
   Baker, D
   Ward, AB
   Burton, DR
   Stamatatos, L
   Nemazee, D
   Wilson, IA
   Schief, WR
AF Jardine, Joseph
   Julien, Jean-Philippe
   Menis, Sergey
   Ota, Takayuki
   Kalyuzhniy, Oleksandr
   McGuire, Andrew
   Sok, Devin
   Huang, Po-Ssu
   MacPherson, Skye
   Jones, Meaghan
   Nieusma, Travis
   Mathison, John
   Baker, David
   Ward, Andrew B.
   Burton, Dennis R.
   Stamatatos, Leonidas
   Nemazee, David
   Wilson, Ian A.
   Schief, William R.
TI Rational HIV Immunogen Design to Target Specific Germline B Cell
   Receptors
SO SCIENCE
LA English
DT Article
ID STRUCTURAL BASIS; ANTIBODIES; POTENT; BROAD; NEUTRALIZATION; VIRUSES;
   ENV
AB Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority. Potent VRC01-class bNAbs against the CD4 binding site of HIV gp120 have been isolated from HIV-1-infected individuals; however, such bNAbs have not been induced by vaccination. Wild-type gp120 proteins lack detectable affinity for predicted germline precursors of VRC01-class bNAbs, making them poor immunogens to prime a VRC01-class response. We employed computation-guided, in vitro screening to engineer a germline-targeting gp120 outer domain immunogen that binds to multiple VRC01-class bNAbs and germline precursors, and elucidated germline binding crystallographically. When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanoparticles have promise as a vaccine prime. In principle, germline-targeting strategies could be applied to other epitopes and pathogens.
C1 [Jardine, Joseph; Menis, Sergey; Ota, Takayuki; Kalyuzhniy, Oleksandr; Sok, Devin; MacPherson, Skye; Jones, Meaghan; Mathison, John; Burton, Dennis R.; Nemazee, David; Schief, William R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey; Kalyuzhniy, Oleksandr; Sok, Devin; MacPherson, Skye; Jones, Meaghan; Nieusma, Travis; Ward, Andrew B.; Burton, Dennis R.; Wilson, Ian A.; Schief, William R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA.
   [Jardine, Joseph; Julien, Jean-Philippe; Menis, Sergey; Kalyuzhniy, Oleksandr; Sok, Devin; MacPherson, Skye; Nieusma, Travis; Ward, Andrew B.; Burton, Dennis R.; Wilson, Ian A.; Schief, William R.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA.
   [Jardine, Joseph; Menis, Sergey; Kalyuzhniy, Oleksandr; Huang, Po-Ssu; MacPherson, Skye; Jones, Meaghan; Baker, David; Schief, William R.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Julien, Jean-Philippe; Nieusma, Travis; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [McGuire, Andrew; Stamatatos, Leonidas] Seattle Biomed Res Inst, Seattle, WA 98109 USA.
   [Burton, Dennis R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA 02129 USA.
   [Stamatatos, Leonidas] Univ Washington, Dept Global Hlth, Seattle, WA 98109 USA.
   [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Schief, WR (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
EM schief@scripps.edu
RI Ward, Andrew/F-9203-2014; Cheng, Yushao/E-6256-2011; Baker,
   David/K-8941-2012; Ota, Takayuki/Q-5528-2017
OI Ward, Andrew/0000-0001-7153-3769; Baker, David/0000-0001-7896-6217; Ota,
   Takayuki/0000-0001-6249-0664; Spencer, Skye/0000-0001-9570-9634; Julien,
   Jean-Philippe/0000-0001-7602-3995
FU IAVI Neutralizing Antibody Center, CHAVI-ID [UM1 AI100663]; NIH
   [AI84817, AI081625, AI33292]; NIH National Research Service Award
   [T32CA080416]; Canadian Institutes of Health Research; Creative and
   Novel Ideas in HIV Research grant [P30 AI027767-24]; NIH
   Interdisciplinary Training Program in Immunology [5T32AI007606-10];
   Ragon Institute; DOE Office of Biological and Environmental Research;
   NIH's National Center for Research Resources, Biomedical Technology
   Program [P41RR001209]; National Institute of General Medical Sciences
   (NIGMS); DOE, Basic Energy Sciences, Office of Science
   [DE-AC02-06CH11357]; National Cancer Institute [Y1-CO-1020]; NIGMS
   [Y1-GM-1104]
FX We thank J. Mascola and X. Wu for providing sequences of mature PGV19
   and PGV20; R. Wyatt for providing the YU2 gp140 trimer; C. Sundling and
   G. Karlsson Hedestam for the sequence of the Rhe1 VH gene; A. Bradley,
   R. L. Stanfield, and D. C. Diwanji for technical assistance and
   insightful discussions; and M. Azoitei, R. Jacak, and D. Kulp for
   comments on the manuscript. The data presented in this manuscript are
   tabulated in the main paper and the supplementary materials. Coordinates
   and structure factors for GL-VRC01 Fab, eOD-GT6, and GL-VRC01+eODGT6
   structures have been deposited with the PDB under accession codes 4JPI,
   4JPJ, and 4JPK, respectively. The International AIDS Vaccine Initiative
   (IAVI) has filed a patent relating to immunogens in this manuscript: PCT
   Application PCT/US12/60062, titled "Engineered Outer Domain (EOD) of HIV
   GP120 and Mutants Thereof," with inventors W. R. S., J. J., S. M., and
   P.-S.H. Materials and information will be provided under a material
   transfer agreement. This work was supported by IAVI Neutralizing
   Antibody Center, CHAVI-ID (UM1 AI100663); NIH grants AI84817 (I. A. W.),
   AI081625 (L. S.), and AI33292 (D. R. B.); NIH National Research Service
   Award Training Grant fellowship T32CA080416 (J. J.); Canadian Institutes
   of Health Research fellowship (J.-P.J.); Creative and Novel Ideas in HIV
   Research grant P30 AI027767-24 (T.O.); NIH Interdisciplinary Training
   Program in Immunology 5T32AI007606-10 (D. S.); and the Ragon Institute.
   Portions of this research were carried out at the Stanford Synchrotron
   Radiation Lightsource (SSRL), a directorate of the SLAC National
   Accelerator Laboratory and an Office of Science User Facility operated
   for the U.S. Department of Energy (DOE) Office of Science by Stanford
   University. The SSRL Structural Molecular Biology Program is supported
   by the DOE Office of Biological and Environmental Research; NIH's
   National Center for Research Resources, Biomedical Technology Program
   (P41RR001209); and the National Institute of General Medical Sciences
   (NIGMS). Use of the Advanced Photon Source was supported by the DOE,
   Basic Energy Sciences, Office of Science, under contract
   DE-AC02-06CH11357. GM/CA CAT has been funded in whole or in part with
   federal funds from the National Cancer Institute (grant Y1-CO-1020) and
   NIGMS (grant Y1-GM-1104). This is manuscript 23050 from The Scripps
   Research Institute.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Arnaout R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022365
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94
   Diskin R, 2011, SCIENCE, V334, P1289, DOI 10.1126/science.1213782
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197
   Hoot S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003106
   Julien JP, 2012, IMMUNOL REV, V250, P180, DOI 10.1111/imr.12005
   Knight KL, 1997, CURR OPIN IMMUNOL, V9, P228, DOI 10.1016/S0952-7915(97)80140-9
   Kong L, 2012, P NATL ACAD SCI USA, V109, P9499, DOI 10.1073/pnas.1202924109
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Leaver-Fay A., 2011, METHOD ENZYMOL, V487, P545, DOI DOI 10.1016/B978-0-12-381270-4.00019-6
   Ota T, 2012, J IMMUNOL, V189, P4816, DOI 10.4049/jimmunol.1202165
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227
   Schief WR, 2009, CURR OPIN HIV AIDS, V4, P431, DOI 10.1097/COH.0b013e32832e6184
   Sundling C, 2010, J EXP MED, V207, P2003, DOI 10.1084/jem.20100025
   West AP, 2012, P NATL ACAD SCI USA, V109, pE2083, DOI 10.1073/pnas.1208984109
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Zhang P, 2009, P NATL ACAD SCI USA, V106, P7537, DOI 10.1073/pnas.0902749106
   Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 29
TC 249
Z9 253
U1 7
U2 92
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 10
PY 2013
VL 340
IS 6133
BP 711
EP 716
DI 10.1126/science.1234150
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 139XR
UT WOS:000318619000030
PM 23539181
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Gopal, V
AF Gopal, Vijaya
TI Bioinspired peptides as versatile nucleic acid delivery platforms
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Non-viral gene delivery; Cell-penetrating peptides; TAT-PTD;
   Nanotechnology; Molecular therapy
ID CELL-PENETRATING PEPTIDES; HIV-1 TAT PROTEIN;
   HUMAN-IMMUNODEFICIENCY-VIRUS; NONVIRAL GENE DELIVERY; ARGININE-RICH
   PEPTIDES; MR CONTRAST AGENTS; INTRACELLULAR DELIVERY; IN-VIVO; PLASMID
   DNA; TRANSDUCTION DOMAIN
AB Non-viral gene therapy approaches have strongly established the utility of peptides as integral constituents of delivery platforms devised for efficient transfer of therapeutic molecules into cells. Among these, cell-penetrating peptides (CPPs), encompassing a family of short peptide sequences and their chimeric derivatives, have gained versatility through the addition of de novo peptide ligands primarily to facilitate cell-specific nucleic acid delivery in vitro and in vivo. The review illustrates the structural requirements of a noteworthy peptide TAT-PTD and other derivatives chiefly to exemplify their implication in gene therapy. An overview of the emerging concept and recent explorations will be presented through unique examples which form a facet in nanotechnology-based cancer therapy. Finally the basis for the utility of CPPs in plants will be discussed in view of its biotechnological potential. (C) 2013 Elsevier B. V. All rights reserved.
C1 CSIR, Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
RP Gopal, V (reprint author), CSIR, Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.
EM vijaya@ccmb.res.in
FU CSIR-Centre for Cellular and Molecular Biology; Department of Science
   and Technology, Govt. of India
FX I thank the anonymous reviewers for their in-depth comments that finally
   shaped this manuscript. I gratefully acknowledge constructive
   collaboration with Dr. N. Madhusudhana Rao and valuable contributions
   from present and former colleagues in this exciting area of research.
   Importantly, support from the CSIR-Centre for Cellular and Molecular
   Biology and the Department of Science and Technology, Govt. of India, is
   highly appreciated.
CR Abes S, 2007, BIOCHEM SOC T, V35, P53, DOI 10.1042/BST0350053                                                              
   Akita H, 2010, MOL THER, V18, P955, DOI 10.1038/mt.2010.33
   ANDERSON CW, 1989, VIROLOGY, V172, P506, DOI 10.1016/0042-6822(89)90193-1                                                    
   Anderson WF, 1998, NATURE, V392, P25
   Arthanari Y, 2010, J CONTROL RELEASE, V145, P272, DOI 10.1016/j.jconrel.2010.04.011
   Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723
   BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   BROWN DT, 1975, J VIROL, V16, P366
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3                                                   
   Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011
   Campbell GR, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-50
   CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X
   Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Chugh A, 2009, PLANT CELL REP, V28, P801, DOI 10.1007/s00299-009-0692-4
   Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X
   Clemens PR, 1996, GENE THER, V3, P965
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Davis SS, 1997, TRENDS BIOTECHNOL, V15, P217, DOI 10.1016/S0167-7799(97)01036-6                                                   
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dietz H., 2004, MOL CELL NEUROSCI, V27, P85
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574
   Duncan R, 2012, MOL PHARMACEUT, V9, P2380, DOI 10.1021/mp300293n
   Edelstein ML, 2007, J GENE MED, V9, P833, DOI 10.1002/jgm.1100
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006
   Endres PJ, 2008, BIOCONJUGATE CHEM, V19, P2049, DOI 10.1021/bc8002919
   Fang B., 2012, BIOCHIMIE
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Fominaya J, 1996, J BIOL CHEM, V271, P10560, DOI 10.1074/jbc.271.18.10560                                                        
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Ghandehari H, 2010, ADV DRUG DELIVER REV, V62, P1403, DOI 10.1016/j.addr.2010.07.007
   Gopal Vijaya, 2010, Syst Synth Biol, V4, P293, DOI 10.1007/s11693-011-9074-7
   Govindarajan S, 2012, BIOMATERIALS, V33, P2570, DOI 10.1016/j.biomaterials.2011.12.003
   Grabowski E, 2008, PLANT PHYSIOL, V147, P1800, DOI 10.1104/pp.108.122796
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hama S, 2006, MOL THER, V13, P786, DOI 10.1016/j.ymthe.2005.10.007
   Hansen G, 1999, TRENDS PLANT SCI, V4, P226, DOI 10.1016/S1360-1385(99)01412-0                                                   
   HAUBER J, 1989, J VIROL, V63, P1181
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313
   Ho A, 2001, CANCER RES, V61, P474
   HOSOKAWA K, 1976, J VIROL, V17, P924
   Hoyer J, 2012, ACCOUNTS CHEM RES, V45, P1048, DOI 10.1021/ar2002304
   Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610                                                        
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jenkins RG, 2000, GENE THER, V7, P393, DOI 10.1038/sj.gt.3301095
   Jeyarajan S, 2010, INT J NANOMED, V5, P725, DOI 10.2147/IJN.S13040
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Kaneda Y, 2005, POLYMERIC GENE DELIVERY: PRINCIPLES AND APPLICATIONS, P29
   Kaneda Y, 2012, ADV DRUG DELIVER REV, V64, P730, DOI 10.1016/j.addr.2011.03.007
   KARN J, 1992, TRENDS GENET, V8, P365, DOI 10.1016/0168-9525(92)90284-B                                                    
   Kay MA, 2011, NAT REV GENET, V12, P316, DOI 10.1038/nrg2971
   Keller M, 2002, BIOCHEMISTRY-US, V41, P652, DOI 10.1021/bi0156299
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   Krause K, 2005, FEBS LETT, V579, P3707, DOI 10.1016/j.febslet.2005.05.059
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977
   Lehto T, 2012, EXPERT OPIN DRUG DEL, V9, P823, DOI 10.1517/17425247.2012.689285
   Liu Y, 2010, BIOMATERIALS, V31, P5246, DOI 10.1016/j.biomaterials.2010.03.011
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001
   Maitani Y, 2009, EXPERT OPIN DRUG DEL, V6, P1065, DOI 10.1517/17425240903156366
   Major JL, 2009, ACCOUNTS CHEM RES, V42, P893, DOI 10.1021/ar800245h
   Mann A, 2008, DRUG DISCOV TODAY, V13, P152, DOI 10.1016/j.drudis.2007.11.008
   MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Matsushita M, 2004, FEBS LETT, V572, P221, DOI 10.1016/j.febslet.2004.07.033
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Medina-Kauwe LK, 2001, GENE THER, V8, P795, DOI 10.1038/sj.gt.3301448
   Medina-Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592
   Midoux P, 2009, BRIT J PHARMACOL, V157, P166, DOI 10.1111/j.1476-5381.2009.00288.x
   Misra R, 2010, DRUG DISCOV TODAY, V15, P842, DOI 10.1016/j.drudis.2010.08.006
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Murray KD, 2001, GENE THER, V8, P453, DOI 10.1038/sj.gt.3301401
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487
   Nguyen T, 2008, CURR OPIN MOL THER, V10, P158
   Nicolas J, 2013, CHEM SOC REV, V42, P1147, DOI 10.1039/c2cs35265f
   Palm-Apergi C, 2012, MOL THER, V20, P695, DOI 10.1038/mt.2012.40
   Palm-Apergi C, 2011, METHODS MOL BIOL, V683, P339, DOI 10.1007/978-1-60761-919-2_24
   Palm-Apergi C, 2009, FASEB J, V23, P214, DOI 10.1096/fj.08-110254
   Pan LM, 2012, J AM CHEM SOC, V134, P5722, DOI 10.1021/ja211035w
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04-2322fje
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pittet MJ, 2006, NAT PROTOC, V1, P73, DOI 10.1038/nprot.2006.11
   Pitzschke A, 2010, EMBO J, V29, P1021, DOI 10.1038/emboj.2010.8
   Prasad TK, 2003, FEBS LETT, V552, P199, DOI 10.1016/S0014-5793(03)00922-0
   Prasad TK, 2003, BBA-GEN SUBJECTS, V1619, P59, DOI 10.1016/S0304-4165(02)00442-7
   Raj D, 2011, EXPERT REV HEMATOL, V4, P539, DOI [10.1586/ehm.11.48, 10.1586/EHM.11.48]
   Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014
   Rao NM, 2010, CHEM PHYS LIPIDS, V163, P245, DOI 10.1016/j.chemphyslip.2010.01.001
   Regberg Jakob, 2012, Pharmaceuticals (Basel), V5, P991, DOI 10.3390/ph5090991
   Remy JS, 1998, ADV DRUG DELIVER REV, V30, P85, DOI 10.1016/S0169-409X(97)00109-9                                                   
   Renigunta A, 2006, BIOCONJUGATE CHEM, V17, P327, DOI 10.1021/bc050263o
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   RUBEN S, 1989, J VIROL, V63, P1
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   RUSSELL WC, 1968, VIROLOGY, V35, P18, DOI 10.1016/0042-6822(68)90301-2                                                    
   Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Saleh AF, 2010, J CONTROL RELEASE, V143, P233, DOI 10.1016/j.jconrel.2009.12.025
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Shi J, 2009, CURR OPIN MOL THER, V11, P547
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484                                                           
   Srinivasan D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017732
   STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x
   Tecle M, 2003, BIOCHEMISTRY-US, V42, P10343, DOI 10.1021/bi034325e
   Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2002, CELL MOL BIOL LETT, V7, P265
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Uherek C, 2000, ADV DRUG DELIVER REV, V44, P153, DOI 10.1016/S0169-409X(00)00092-2
   Unnamalai N, 2004, FEBS LETT, V566, P307, DOI 10.1016/j.febslet.2004.04.018
   VAYDA ME, 1987, J VIROL, V61, P3335
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Weaver JC, 1996, BIOELECTROCH BIOENER, V41, P135, DOI 10.1016/S0302-4598(96)05062-3
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WILLBOLD D, 1993, BIOCHEMISTRY-US, V32, P8439, DOI 10.1021/bi00084a008
   Wodrich H, 2006, J VIROL, V80, P9608, DOI 10.1128/JVI.00850-06
   Won YW, 2010, MOL THER, V18, P734, DOI 10.1038/mt.2009.297
   Xavier J, 2009, J CONTROL RELEASE, V133, P154, DOI 10.1016/j.jconrel.2008.09.090
   Xiang Y.-B., 2010, BIOMATERIALS, V31, P5886
   Yuan H, 2012, J AM CHEM SOC, V134, P11358, DOI 10.1021/ja304180y
   Zhang XK, 2012, EXPERT OPIN DRUG DEL, V9, P457, DOI 10.1517/17425247.2012.663351
   Ziemienowicz A, 2012, PLANT PHYSIOL, V158, P1503, DOI 10.1104/pp.111.192856
NR 160
TC 13
Z9 13
U1 0
U2 72
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 10
PY 2013
VL 167
IS 3
BP 323
EP 332
DI 10.1016/j.jconrel.2013.02.021
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 130EN
UT WOS:000317895600012
PM 23474032
DA 2018-01-05
ER

PT J
AU Tian, K
   He, ZJ
   Wang, Y
   Chen, SJ
   Gu, LQ
AF Tian, Kai
   He, Zhaojian
   Wang, Yong
   Chen, Shi-Jie
   Gu, Li-Qun
TI Designing a Polycationic Probe for Simultaneous Enrichment and Detection
   of MicroRNAs in a Nanopore
SO ACS NANO
LA English
DT Article
DE nanopore; single molecule; biosensor; nucleic acids; microRNA; miRNA;
   HIV-1 TAT; peptide; PNA; probe; cancer; diagnostics
ID SOLID-STATE NANOPORES; LUNG-CANCER; ALPHA-HEMOLYSIN; CIRCULATING
   MICRORNAS; TRANSMEMBRANE PORE; DNA-MOLECULES; SMALL RNAS; C-ELEGANS;
   TRANSLOCATION; QUANTIFICATION
AB The nanopore sensor can detect cancer-derived nucleic acid biomarkers such as microRNAs (miRNAs), providing a noninvasive tool potentially useful in medical diagnostics. However, the nanopore-based detection of these biomarkers remains confounded by the presence of numerous other nucleic acid species found in biofluid extracts. Their nonspecific interactions with the nanopore inevitably contaminate the target signals, reducing the detection accuracy. Here we report a novel method that utilizes a polycationic peptide-PNA probe as the carrier for selective miRNA detection in the nucleic acid mixture. The cationic probe hybridized with microRNA forms a dipole complex, which can be captured by the pore using a voltage polarity that is opposite the polarity used to capture negatively charged nucleic acids. As a result, nontarget species are driven away from the pore opening, and the target miRNA can be detected accurately without interference. In addition, we demonstrate that the PNA probe enables accurate discrimination of miRNAs with single-nucleotide difference. This highly sensitive and selective nanodielectrophoresis approach can be applied to the detection of clinically relevant nucleic acid fragments in complex samples.
C1 [Tian, Kai; Wang, Yong; Gu, Li-Qun] Univ Missouri, Dept Biol Engn, Columbia, MO 65211 USA.
   [Tian, Kai; Wang, Yong; Gu, Li-Qun] Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO 65211 USA.
   [He, Zhaojian; Chen, Shi-Jie] Univ Missouri, Dept Phys, Columbia, MO 65211 USA.
RP Gu, LQ (reprint author), Univ Missouri, Dept Biol Engn, Columbia, MO 65211 USA.
EM gul@missouri.edu
OI Chen, Shi-Jie/0000-0002-8093-7244; Tian, Kai/0000-0002-5543-571X
FU National Science Foundation [0546165]; National Institutes of Health
   [GM079613]; University of Missouri; National Centre for Research
   Resources, National Institutes of Health [C06-RR-016489-01]
FX We appreciate Dr. ZhiQiang Hu's laboratory for the help with
   zeta-potential measurement. This investigation was partially supported
   by grants from the National Science Foundation 0546165 (L.Q.G), the
   National Institutes of Health GM079613 (L.Q.G.), Coulter Translational
   Partner Program at the University of Missouri (L.Q.G.), and was
   conducted in a facility that was constructed with support from the
   Research Facilities Improvement Program Grant Number C06-RR-016489-01
   from the National Centre for Research Resources, National Institutes of
   Health.
CR Aksimentiev A, 2005, BIOPHYS J, V88, P3745, DOI 10.1529/biophysj.104.058727
   An N, 2012, P NATL ACAD SCI USA, V109, P11504, DOI 10.1073/pnas.1201669109
   Bayley H, 2004, MOL MEMBR BIOL, V21, P209, DOI 10.1080/09687680410001716853
   Bayley H, 2008, MOL BIOSYST, V4, P1191, DOI 10.1039/b808893d
   Bhattacharya S, 2011, J PHYS CHEM C, V115, P4255, DOI 10.1021/jp111441p
   Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Cao S, 2005, RNA, V11, P1884, DOI 10.1261/rna.2109105
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chen M, 2008, P NATL ACAD SCI USA, V105, P6272, DOI 10.1073/pnas.0711561105
   Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147
   Firnkes M, 2010, NANO LETT, V10, P2162, DOI 10.1021/nl100861c
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707
   Gu LQ, 2010, ANALYST, V135, P441, DOI 10.1039/b907735a
   Gu LQ, 2003, P NATL ACAD SCI USA, V100, P15498, DOI 10.1073/pnas.2531778100
   Hall AR, 2010, NAT NANOTECHNOL, V5, P874, DOI [10.1038/nnano.2010.237, 10.1038/NNANO.2010.237]
   Hornblower B, 2007, NAT METHODS, V4, P315, DOI 10.1038/NMETH1021
   Howorka S, 1998, BIOTECHNIQUES, V25, P764
   Howorka S, 2009, CHEM SOC REV, V38, P2360, DOI 10.1039/b813796j
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Hunt EA, 2009, ANAL BIOCHEM, V387, P1, DOI 10.1016/j.ab.2009.01.011
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770                                                        
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kolinski A, 2004, ACTA BIOCHIM POL, V51, P349
   Kolinski A, 2004, POLYMER, V45, P511, DOI 10.1016/j.polymer.2003.10.064
   Landi MT, 2010, CLIN CANCER RES, V16, P430, DOI 10.1158/1078-0432.CCR-09-1736
   Langecker M, 2012, SCIENCE, V338, P932, DOI 10.1126/science.1225624
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   MV lorio, 2009, J CLIN ONCOL, V27, P5848
   Luan BQ, 2010, SOFT MATTER, V6, P243, DOI 10.1039/b917973a
   Ma L, 2010, CHEMBIOCHEM, V11, P25, DOI 10.1002/cbic.200900526
   Maglia G, 2008, P NATL ACAD SCI USA, V105, P19720, DOI 10.1073/pnas.0808296105
   Majd S, 2010, CURR OPIN BIOTECH, V21, P439, DOI 10.1016/j.copbio.2010.05.002
   Manrao EA, 2012, NAT BIOTECHNOL, V30, P349, DOI 10.1038/nbt.2171
   Meller A, 2001, PHYS REV LETT, V86, P3435, DOI 10.1103/PhysRevLett.86.3435
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mohammad MM, 2012, J AM CHEM SOC, V134, P9521, DOI 10.1021/ja3043646
   Mohammad MM, 2010, J PHYS CHEM B, V114, P8750, DOI 10.1021/jp101311s
   Movileanu L, 2009, TRENDS BIOTECHNOL, V27, P333, DOI 10.1016/j.tibtech.2009.02.008
   Nakane J, 2004, BIOPHYS J, V87, P615, DOI 10.1529/biophysj.104.040212
   Natsume T, 2007, CHEM PHYS LETT, V434, P133, DOI 10.1016/j.cplett.2006.12.017
   Nielsen P E, 1999, Curr Issues Mol Biol, V1, P89
   Nielsen PE, 2011, ARTIF DNA PNA XNA, V2, P90
   Olasagasti F, 2010, NAT NANOTECHNOL, V5, P798, DOI [10.1038/nnano.2010.177, 10.1038/NNANO.2010.177]
   Ortholan C, 2009, CURR MED CHEM, V16, P1047, DOI 10.2174/092986709787581833                                                      
   Rotkiewicz P, 2008, J COMPUT CHEM, V29, P1460, DOI 10.1002/jcc.20906
   Shen J, 2011, LAB INVEST, V91, P579, DOI 10.1038/labinvest.2010.194
   Shim JW, 2007, FEBS LETT, V581, P1027, DOI 10.1016/j.febslet.2007.02.005
   Shim JW, 2009, NUCLEIC ACIDS RES, V37, P972, DOI 10.1093/nar/gkn968
   Singer A, 2010, NANO LETT, V10, P738, DOI 10.1021/nl100058y
   Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859
   Sozzi G, 2009, AM J RESP CRIT CARE, V179, P69, DOI 10.1164/rccm.200807-1068OC
   Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jcb.M208762200
   van Dorp S, 2009, NAT PHYS, V5, P347, DOI 10.1038/NPHYS1230
   Venkatesan BM, 2011, NAT NANOTECHNOL, V6, P615, DOI [10.1038/nnano.2011.129, 10.1038/NNANO.2011.129]
   Wallace EVB, 2010, CHEM COMMUN, V46, P8195, DOI 10.1039/c0cc02864a
   Wang Y, 2011, NAT NANOTECHNOL, V6, P668, DOI [10.1038/NNANO.2011.147, 10.1038/nnano.2011.147]
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P160, DOI [10.1038/nnano.2009.379, 10.1038/NNANO.2009.379]
   Wendell D, 2009, NAT NANOTECHNOL, V4, P765, DOI [10.1038/nnano.2009.259, 10.1038/NNANO.2009.259]
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Zheng DL, 2011, INT J CLIN EXP PATHO, V4, P575
NR 62
TC 34
Z9 34
U1 3
U2 129
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAY
PY 2013
VL 7
IS 5
BP 3962
EP 3969
DI 10.1021/nn305789z
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 156XD
UT WOS:000319856300032
PM 23550815
OA green_accepted
DA 2018-01-05
ER

PT J
AU Han, SH
   Lee, MK
   Lim, YB
AF Han, So-hee
   Lee, Mun-kyung
   Lim, Yong-beom
TI Bioinspired Self-Assembled Peptide Nanofibers with Thermostable
   Multivalent alpha-Helices
SO BIOMACROMOLECULES
LA English
DT Article
ID HIV-1 REV PROTEIN; CONSTRAINED PEPTIDES; STABILIZATION; NANOSTRUCTURES;
   RECOGNITION; DYNAMICS; BINDING; RRE
AB The stabilization of peptide's active conformation is a critical determinant of its target binding efficiency. Here we present a structure-based self-assembly strategy for the design of nanostructures with multiple and thermostable alpha-helices using bioinspired peptide amphiphiles. The design principle was inspired by the oligomerization of the human immunodeficiency virus type-1 (HIV-1) Rev protein. Our goal was to find a strategy to modify the Rev protein into a chemically manageable self-assembling peptide while stabilizing its alpha-helical structure. Instead of using cyclic peptides for structure stabilization, this strategy utilizes the pseudocyclization for helix stabilization. The self-assembly induced stabilization of alpha-helical conformation could be observed, and the alpha-helices were found to be stable even at high temperature (at least up to 74 degrees C). Conjugation of a hydrophobic alkyl chain to the Rev peptide was crucial for forming the self-assembled nanostructures, and no nanostructures could be obtained without this modification. Because chemical modifications to the alpha-helical peptide domain can be avoided, potentially any alpha-helical peptide fragment can be grafted into this self-assembling peptide scaffold.
C1 [Lim, Yong-beom] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
   Yonsei Univ, Dept Mat Sci & Engn, Seoul 120749, South Korea.
RP Lim, YB (reprint author), Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
EM yblim@yonsei.ac.kr
RI Lim, Yong-beom/D-3603-2011
FU National Research Foundation (NRF) of Korea (Basic Science Research
   Program) [2012R1A1A2006453]; National Research Foundation (NRF) of Korea
   (Translational Research Center for Protein Function Control)
   [2012-0000888]; Seoul RBD program [ST110029]
FX This work was supported by grants from the National Research Foundation
   (NRF) of Korea (Basic Science Research Program, 2012R1A1A2006453;
   Translational Research Center for Protein Function Control,
   2012-0000888) and from the Seoul R&BD program (ST110029).
CR Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Choi SJ, 2011, SOFT MATTER, V7, P1675, DOI 10.1039/c0sm01275k
   Daugherty MD, 2010, NAT STRUCT MOL BIOL, V17, P1337, DOI 10.1038/nsmb.1902
   DiMattia MA, 2010, P NATL ACAD SCI USA, V107, P5810, DOI 10.1073/pnas.0914946107
   DOIG AJ, 1994, BIOCHEMISTRY-US, V33, P3396, DOI 10.1021/bi00177a033
   Foms P., 2000, BIOPOLYMERS, V54, P531
   Ghosh T, 2005, J PHYS CHEM B, V109, P642, DOI 10.1021/jp0475638
   Han S, 2012, J AM CHEM SOC, V134, P16047, DOI 10.1021/ja307493t
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187                                                         
   Jain C, 2001, MOL CELL, V7, P603, DOI 10.1016/S1097-2765(01)00207-6
   Johnson LM, 2012, J AM CHEM SOC, V134, P7317, DOI 10.1021/ja302428d
   Lim YB, 2007, ANGEW CHEM INT EDIT, V46, P9011, DOI 10.1002/anie.200702732
   Lim YB, 2007, ANGEW CHEM INT EDIT, V46, P3475, DOI 10.1002/anie.200604576
   Lim YB, 2009, ANGEW CHEM INT EDIT, V48, P1601, DOI 10.1002/anie.200804665
   LYNN J, 1968, BIOPOLYMERS, V6, P159, DOI 10.1002/bip.1968.360060114
   MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898
   MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286
   McGregor CL, 2003, NAT BIOTECHNOL, V21, P171, DOI 10.1038/nbt776
   McNamara C, 2008, SCIENCE, V319, P1405, DOI 10.1126/science.1154470
   Pace CN, 1998, BIOPHYS J, V75, P422
   Patgiri A, 2012, J AM CHEM SOC, V134, P11495, DOI 10.1021/ja301953j
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   RIZO J, 1992, ANNU REV BIOCHEM, V61, P387, DOI 10.1146/annurev.bi.61.070192.002131                                             
   Roccatano D, 2002, P NATL ACAD SCI USA, V99, P12179, DOI 10.1073/pnas.182199699
   RUAN FQ, 1990, J AM CHEM SOC, V112, P9403, DOI 10.1021/ja00181a058                                                             
   Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599
   Sim S, 2012, J AM CHEM SOC, V134, P20270, DOI 10.1021/ja3098756
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191
   Wang D, 2006, J AM CHEM SOC, V128, P9248, DOI 10.1021/ja062710w
   Watts NR, 1998, J STRUCT BIOL, V121, P41, DOI 10.1006/jsbi.1998.3964
   Webber MJ, 2011, P NATL ACAD SCI USA, V108, P13438, DOI 10.1073/pnas.1016546108
   Zhang FZ, 2007, J AM CHEM SOC, V129, P14154, DOI 10.1021/ja075829t                                                               
NR 33
TC 13
Z9 13
U1 2
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD MAY
PY 2013
VL 14
IS 5
BP 1594
EP 1599
DI 10.1021/bm400233x
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 145RN
UT WOS:000319034600040
PM 23550841
DA 2018-01-05
ER

PT J
AU Banerjee, R
AF Banerjee, Rinti
TI Nanotechnology: a versatile aid in our fight against AIDS
SO NANOMEDICINE
LA English
DT Editorial Material
DE AIDS; antiretroviral therapy; drug resistance; HIV reservoir; latent
   infection; nanoparticle
ID NANOPARTICLES; EFAVIRENZ
C1 Indian Inst Technol, Dept Biosci & Bioengn, Bombay 400076, Maharashtra, India.
RP Banerjee, R (reprint author), Indian Inst Technol, Dept Biosci & Bioengn, Bombay 400076, Maharashtra, India.
EM rinti@iitb.ac.in
CR Banerjee R, 2011, NANOMEDICINE-UK, V6, P1657, DOI [10.2217/NNM.11.161, 10.2217/nnm.11.161]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Gianvincenzo P. D., 2010, BIOORG MED CHEM LETT, V20, P2718
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Lorincz O, 2012, NANOMED-NANOTECHNOL, V8, P497, DOI 10.1016/j.nano.2011.07.013
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Pedziwiatr-Werbicka E, 2011, COLLOID SURFACE B, V83, P360, DOI 10.1016/j.colsurfb.2010.12.008
   Shirakawa K, 2013, TRENDS MICROBIOL, V21, P277, DOI 10.1016/j.tim.2013.02.005
   Tian XH, 2012, MATER LETT, V68, P94, DOI 10.1016/j.matlet.2011.10.042
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   [Anonymous], 2012, UNAIDS WORLD AIDS DA
   [Anonymous], 2013, LANCET INFECT DIS, V13, P1
NR 14
TC 1
Z9 1
U1 1
U2 11
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD MAY
PY 2013
VL 8
IS 5
BP 675
EP 677
DI 10.2217/NNM.13.14
PG 3
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 143FL
UT WOS:000318852100002
PM 23656261
DA 2018-01-05
ER

PT J
AU Potticary, J
AF Potticary, James
TI Nanoparticles deliver a sting to HIV-1 infectivity
SO NANOMEDICINE
LA English
DT News Item
CR Hood JL, 2012, ANTIVIR THER, V18, P95, DOI DOI 10.3851/IMP2346
NR 1
TC 0
Z9 0
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD MAY
PY 2013
VL 8
IS 5
BP 684
EP 685
PG 2
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 143FL
UT WOS:000318852100005
PM 23802267
DA 2018-01-05
ER

PT J
AU Martinez-Skinner, AL
   Veerubhotla, RS
   Liu, H
   Xiong, HG
   Yu, F
   McMillan, JM
   Gendelman, HE
AF Martinez-Skinner, Andrea L.
   Veerubhotla, Ram S.
   Liu, Han
   Xiong, Huangui
   Yu, Fang
   McMillan, JoEllyn M.
   Gendelman, Howard E.
TI Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral
   Therapy Demonstrates Enhanced Particle Carrying Capacity
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE monocyte-derived macrophages; nanoART; pulsed stable isotope labeling of
   amino acids in cell culture; proteome; cell function
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE-DERIVED MACROPHAGES;
   BLOOD-BRAIN-BARRIER; HUMAN INTERLEUKIN-8 RECEPTOR; HIV-1 INFECTION;
   DRUG-DELIVERY; MYCOBACTERIUM-TUBERCULOSIS; TREATMENT INTERRUPTION;
   ACTIVATION; NEUROAIDS
AB Our laboratory developed long-acting nanoformulations of antiretroviral therapy (nanoART) to improve drug compliance, reduce toxicities, and facilitate access of drug to viral reservoirs. These all function to inevitably improve treatment of human immunodeficiency virus (HIV) infection. Formulations are designed to harness the carrying capacities of mononuclear phagocytes (MP; monocytes and macrophages) and to use these cells as Trojan horses for drug delivery. Such a drug distribution system limits ART metabolism and excretion while facilitating access to viral reservoirs Our prior works demonstrated a high degree of nanoART sequestration in macrophage recycling endosomes with broad and sustained drug tissue biodistribution and depots with limited untoward systemic toxicities. Despite such benefits, the effects of particle carriage on the cells' functional capacities remained poorly understood. Thus, we employed pulsed stable isotope labeling of amino acids in cell culture to elucidate the macrophage proteome and assess any alterations in cellular functions that would affect cell-drug carriage and release kinetics. NanoART-MP interactions resulted in the induction of a broad range of activation-related proteins that can enhance phagocytosis, secretory functions, and cell migration. Notably, we now demonstrate that particle-cell interactions serve to enhance drug loading while facilitating drug tissue depots and transportation.
C1 [Martinez-Skinner, Andrea L.; Veerubhotla, Ram S.; Liu, Han; Xiong, Huangui; McMillan, JoEllyn M.; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   [Yu, Fang] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 600 S 42nd St, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU Carol Swarts Neuroscience Research Laboratory Fund; Frances; Louie
   Blumkin Foundation; Community Pride in Neuroscience Research Initiative;
   Alan Baer Charitable Trust; National Institutes of Health [P01 DA028555,
   R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985]; NIH
   [R01NS077873, P30MH062261]
FX This work was supported in part by the Carol Swarts Neuroscience
   Research Laboratory Fund, the Frances and Louie Blumkin Foundation, the
   Community Pride in Neuroscience Research Initiative, the Alan Baer
   Charitable Trust, and National Institutes of Health grants P01 DA028555,
   R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, and P01 NS43985
   (to H.E.G.) and NIH grants R01NS077873, P30MH062261 (to H.X.). This
   material is available free of charge via the Internet at
   http://pubs.acs.org.
CR ALBERTS B, 2002, MOL BIOL CELL
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Azzam R, 2006, JAIDS-J ACQ IMM DEF, V42, P19
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bargagli E, 2011, INFLAMMATION, V34, P85, DOI 10.1007/s10753-010-9210-7
   Betts MR, 2006, EXPERT REV VACCINES, V5, P505, DOI 10.1586/14760584.5.4.505
   Bogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Chen RY, 2002, AIDS RES HUM RETROV, V18, P909, DOI 10.1089/088922202760265588
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012                                                       
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Delaugerre C, 2005, J MED VIROL, V77, P345, DOI 10.1002/jmv.20462
   Deretic V, 2008, FUTURE MICROBIOL, V3, P517, DOI 10.2217/17460913.3.5.517
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dussurget O, 2008, INT REV CEL MOL BIO, V270, P1, DOI 10.1016/S1937-6448(08)01401-9
   Ernst JD, 1998, INFECT IMMUN, V66, P1277
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Ghavami S, 2008, BBA-MOL CELL RES, V1783, P297, DOI 10.1016/j.bbamcr.2007.10.015
   HART PD, 1972, INFECT IMMUN, V5, P803
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701
   Hou TY, 2011, J IMMUNOL, V187, P2442, DOI 10.4049/jimmunol.1100255
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kraft-Terry SD, 2011, CELL IMMUNOL, V271, P239, DOI 10.1016/j.cellimm.2011.07.002
   Kraft-Terry SD, 2011, J PROTEOME RES, V10, P2852, DOI 10.1021/pr200124j
   LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085                                                               
   MOROHASHI H, 1995, J LEUKOCYTE BIOL, V57, P180
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716
   MURRAY HW, 1981, J EXP MED, V153, P1690, DOI 10.1084/jem.153.6.1690
   Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Orenstein JM, 2007, ULTRASTRUCT PATHOL, V31, P151, DOI 10.1080/01913120701344343
   Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3
   Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18
   Ricardo-Dukelow M, 2007, J NEUROIMMUNOL, V185, P37, DOI 10.1016/j.jneuroim.2007.01.004
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Schwanhausser B, 2009, PROTEOMICS, V9, P205, DOI 10.1002/pmic.200800275
   Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211
   Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5
   Stillie R, 2009, J LEUKOCYTE BIOL, V86, P529, DOI 10.1189/jlb.0208125
   Tardieu M, 2002, CURR TOP MICROBIOL, V265, P183
NR 58
TC 8
Z9 8
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAY
PY 2013
VL 12
IS 5
BP 2282
EP 2294
DI 10.1021/pr400185w
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 139NI
UT WOS:000318589000026
PM 23544708
OA green_accepted
DA 2018-01-05
ER

PT J
AU Shibata, A
   McMullen, E
   Pham, A
   Belshan, M
   Sanford, B
   Zhou, Y
   Goede, M
   Date, AA
   Destache, CJ
AF Shibata, Annemarie
   McMullen, Emily
   Alex Pham
   Belshan, Michael
   Sanford, Bridget
   Zhou, You
   Goede, Michael
   Date, Abjijit A.
   Destache, Christopher J.
TI Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for
   HIV Type 1 Treatment
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITOR; POLY(DL-LACTIDE-CO-GLYCOLIDE)
   NANOPARTICLES; TRIPHOSPHATE CONCENTRATIONS; ZIDOVUDINE TRIPHOSPHATE;
   PLGA NANOPARTICLES; INFECTION; THERAPY; TOXICITY; DELIVERY; SYSTEM
AB The use of combination antiretroviral nanoparticles (cART NPs) was investigated as a novel treatment approach for the inhibition of HIV-1 replication. We developed nanoparticles of biodegradable polymer, poly-(DL-lactide-co-glycolic acid; PLGA) containing efavirenz (EFV) and boosted lopinavir (lopinavir/ritonavir; LPV/r) by a high-pressure homogenization method. The method resulted in >79% drug entrapment efficiency for each of the three drugs. The average size of cART NPs was 138.3 +/- 55.4 nm as measured by dynamic light scanning, confirmed by scanning electron microscopy (SEM) with an average surface charge of -13.7 +/- 4.5. Lissamine-rhodamine-labeled fluorescent PLGA NPs exhibited efficient uptake in nonimmune (HeLa cells) and immune (H9 T cells) cells as measured by confocal microscopy. Cells treated with cART NPs resulted in minimal loss of cell viability over 28 days. Subcellular fractionation studies demonstrated that HIV-1-infected H9 monocytic cells treated with cART NPs contained significantly (p < 0.05) higher nuclear, cytoskeleton, and membrane antiretroviral drug levels compared to cells treated with drug solutions alone. Finally, cART NPs efficiently inhibited HIV-1 infection and transduction. The IC50 for each of the three drugs in the cART NPs was <31 nM. These experiments demonstrate the efficacy of a novel PLGA NPs formulation for the delivery of cART to inhibit HIV-1 replication.
C1 [Shibata, Annemarie; McMullen, Emily; Alex Pham] Univ Nebraska, Dept Biol, Lincoln, NE USA.
   [Belshan, Michael; Sanford, Bridget] Univ Nebraska, Dept Med Microbiol & Immunol, Sch Med, Lincoln, NE USA.
   [Zhou, You] Univ Nebraska, Ctr Biotechnol, Lincoln, NE USA.
   [Goede, Michael; Date, Abjijit A.; Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm, 2500 Calif Plaza, Omaha, NE 68178 USA.
EM destache@creighton.edu
OI Destache, Christopher/0000-0001-7923-3939; Date,
   Abhijit/0000-0001-6617-882X
FU C.U. Medical School; National Center for Research Resources
   [5P20RR016469, 5P30RR031151-01]; National Institute for General Medical
   Science (NIGMS) [8P20GM103427]; National Institutes of Health
   [1R15AI076039-01A1, 5RO1AI080348]; National Institute of General Medical
   Sciences [8 P30 GM103509-03]; Creighton University Graduate School
   Summer Faculty Research Fellowship
FX The authors would like to acknowledge the Creighton University
   Integrated Biomedical Imaging Facility for providing the confocal
   images. This facility, supported by the C.U. Medical School, was
   constructed with support from the National Center for Research Resources
   (5P20RR016469) and the National Institute for General Medical Science
   (NIGMS) (8P20GM103427).; This work was supported by National Institutes
   of Health grants 1R15AI076039-01A1 (to C.J.D.), 5RO1AI080348 (to M.B.),
   and grants from the National Center for Research Resources
   (5P30RR031151-01) and the National Institute of General Medical Sciences
   (8 P30 GM103509-03) and Creighton University Graduate School Summer
   Faculty Research Fellowship (to A.S.). The funders had no role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Anderson PL, 2003, AIDS, V17, P2159, DOI 10.1097/01.aids.0000076338.42412.62
   Anderson PL, 2002, CLIN PHARMACOL THER, V71, P280, DOI 10.1067/mcp.2002.121910
   Aweeka FT, 2007, HIV MED, V8, P288, DOI 10.1111/j.1468-1293.2007.00472.x
   Bangsberg DR, 2010, AIDS, V24, P2835, DOI 10.1097/QAD.0b013e328340a209
   Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766
   BECK P, 1993, J MICROENCAPSUL, V10, P101, DOI 10.3109/02652049309015316                                                       
   Calmy A, 2007, HIV MED, V8, P171, DOI 10.1111/j.1468-1293.2007.00448.x                                                
   Chaillou S, 2002, HIV Clin Trials, V3, P493
   Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324
   Clements JE, 2002, J INFECT DIS, V186, P905, DOI 10.1086/343768                                                                  
   Cohen J, 2011, SCIENCE, V334, P1614, DOI 10.1126/science.334.6063.1614
   Conway MA, 2001, VACCINE, V19, P1940, DOI 10.1016/S0264-410X(00)00433-3
   COUVREUR P, 1982, J PHARM SCI, V71, P790, DOI 10.1002/jps.2600710717
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dong Y, 2007, INT J PHARM, V342, P208, DOI 10.1016/j.ijpharm.2007.04.031
   Eisingerich AB, 2012, PLOS ONE, V7
   Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145
   Fletcher CV, 2000, AIDS, V14, P2137, DOI 10.1097/00002030-200009290-00010
   Fletcher CV, 2002, AIDS, V16, P551, DOI 10.1097/00002030-200203080-00006
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Groener JB, 2011, AIDS RES HUM RETROV, V27, P969, DOI [10.1089/AID.2010.0348, 10.1089/aid.2010.0348]
   Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864
   Kay MS, 2003, TRENDS BIOTECHNOL, V21, P420, DOI 10.1016/j.tibtech.2003.08.004
   Lamotte C, 2004, ANTIVIR THER, V9, P247
   Lee WK, J CONTROL RELEASE, V84, P115
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   Mahapatro A, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-55
   MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253
   Mehta Ashish K., 2007, Current Drug Delivery, V4, P185
   Moore JD, 2007, ANTIVIR THER, V12, P981
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Speck RR, 2002, J INFECT DIS, V186, P332, DOI 10.1086/341464
   SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504
   UNAIDS, 2009, AIDS EP UPD WHO 2009, P30
   Vidal F, 2006, ANTIMICROB AGENTS CH, V50, P3824, DOI 10.1128/AAC.00437-06
   Yeh RF, 2009, ANTIMICROB AGENTS CH, V53, P2367, DOI 10.1128/AAC.01523-08
NR 41
TC 23
Z9 23
U1 1
U2 21
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2013
VL 29
IS 5
BP 746
EP 754
DI 10.1089/aid.2012.0301
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 132NA
UT WOS:000318074200002
PM 23289671
OA green_published
DA 2018-01-05
ER

PT J
AU Muhle, M
   Hoffmann, K
   Lochelt, M
   Denner, J
AF Muehle, Michael
   Hoffmann, Kerstin
   Loechelt, Martin
   Denner, Joachim
TI Immunisation with foamy virus Bet fusion proteins as novel strategy for
   HIV-1 epitope delivery
SO IMMUNOLOGIC RESEARCH
LA English
DT Article
DE HIV-1; Vaccine; MPER; Foamy virus; Bet protein
ID PROXIMAL EXTERNAL REGION; BROADLY NEUTRALIZING ANTIBODIES; SIMIAN
   IMMUNODEFICIENCY VIRUS; HELICAL HAIRPIN PEPTIDE; ENV-MEDIATED FUSION;
   DE-NOVO DESIGN; VACCINE DESIGN; GLYCOPROTEIN GP41; RETROVIRAL VECTORS;
   TYPE-1 ANTIBODY
AB The induction of 2F5- and 4E10-like antibodies broadly neutralising HIV-1 and targeting the membrane external proximal region (MPER) of the transmembrane envelope protein gp41 would be a major advancement for the development of a preventive HIV-1 vaccine, but successful attempts remain rare. Recent studies demonstrated that broadly reactive antibodies develop relatively late during infection and after intensive affinity maturation. Therefore, a prolonged antigen delivery might be beneficial to induce them. Replicating foamy viruses which are characterised by apathogenic but persistent infection could represent suitable carrier viruses for this purpose. In order to develop such a system, we modified the accessory foamy virus Bet protein to contain the MPER of gp41, or the MPER linked to the stabilising fusion peptide proximal region of gp41 and analysed here the antigenic and immunogenic properties of such hybrid proteins. The antigens, expressed and purified to homogeneity, were recognised by the monoclonal antibodies 2F5 and 4E10 with nanomolar affinities and induced high levels of antibodies specific to gp41 after immunisation of rats. The antisera also bound to virus particles attached to infected cells, and peptide-based epitope mapping showed that they recognised the 2F5 epitope. Although no HIV-1 neutralising activity was observed, the presented data demonstrate that using the foamy virus Bet for HIV-1 epitope delivery is successfully applicable. Together with the attractive potential for sustained antigen expression after transfer to replicating virus, these results should therefore provide a first basis for the development of chimeric foamy viruses as novel HIV-1 vaccine vectors.
C1 [Muehle, Michael; Hoffmann, Kerstin; Denner, Joachim] Robert Koch Inst, Ctr HIV & Retrovirol, D-13553 Berlin, Germany.
   [Loechelt, Martin] German Canc Res Ctr, Div Genome Modificat & Carcinogenesis Res Top Inf, D-69120 Heidelberg, Germany.
RP Denner, J (reprint author), Robert Koch Inst, Ctr HIV & Retrovirol, Nordufer 20, D-13553 Berlin, Germany.
EM DennerJ@rki.de
FU Volkswagenstiftung
FX This work was supported by the Volkswagenstiftung. We thank C. M.
   Schmidt, M. Keller and D. Wirths for excellent technical support and A.
   Bleiholder for critical reading of the manuscript. All authors have
   approved the final article and declare that there is no conflict of
   interest.
CR Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Alke A, 2000, VIROLOGY, V275, P170, DOI 10.1006/viro.2000.0537
   Bastone P, 2007, GENE THER, V14, P613, DOI 10.1038/sj.gt.3302890
   Bauer TR, 2011, GENE THER, V18, P553, DOI 10.1038/gt.2010.169
   Bellamy-Mclntyre AK, 2007, J BIOL CHEM, V282, P23104, DOI 10.1074/jbc.M703485200
   Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y
   Bleiholder A, 2011, VET IMMUNOL IMMUNOP, V143, P292, DOI 10.1016/j.vetimm.2011.06.007
   Brunel FM, 2006, J VIROL, V80, P1680, DOI 10.1128/JVI.80.4.1680-1687.2006
   Bryson S, 2008, J MOL BIOL, V382, P910, DOI 10.1016/j.jmb.2008.07.057
   Burton DR, 2010, SCIENCE, V329, P770, DOI 10.1126/science.1194693
   Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102                                                         
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Cardoso RMF, 2007, J MOL BIOL, V365, P1533, DOI 10.1016/j.jmb.2006.10.088
   Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X
   de la Arada I, 2009, J PHYS CHEM B, V113, P13626, DOI 10.1021/jp905965h
   Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08
   Erlwein O, 2010, GENE THER, V17, P1423, DOI 10.1038/gt.2010.95
   FEZOUI Y, 1994, P NATL ACAD SCI USA, V91, P3675, DOI 10.1073/pnas.91.9.3675
   Fezoui Y, 1997, PROTEIN SCI, V6, P1869, DOI 10.1002/pro.5560060907                                                          
   Fiebig U, 2009, AIDS, V23, P887, DOI 10.1097/QAD.0b013e3283292153
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Frey G, 2010, NAT STRUCT MOL BIOL, V17, P1486, DOI 10.1038/nsmb.1950
   Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5
   Garrity RR, 1997, J IMMUNOL, V159, P279
   Giron ML, 1998, J VIROL, V72, P4906
   Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11
   Guenaga J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016074
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
   Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197
   Ho J, 2005, VACCINE, V23, P1559, DOI 10.1016/j.vaccine.2004.09.037
   Ho J, 2002, VACCINE, V20, P1169, DOI 10.1016/S0264-410X(01)00441-8
   Johnson RP, 1998, CURR OPIN IMMUNOL, V10, P436, DOI 10.1016/S0952-7915(98)80118-0                                                   
   Julien JP, 2008, J MOL BIOL, V384, P377, DOI 10.1016/j.jmb.2008.09.024
   Koff WC, 2006, NAT IMMUNOL, V7, P19, DOI 10.1038/ni1296
   Lecellier CH, 2002, J VIROL, V76, P3388, DOI 10.1128/JVI.76.7.3388-3394.2002
   Lindemann D, 2011, VIRUSES-BASEL, V3, P561, DOI 10.3390/v3050561
   Linial ML, 1999, J VIROL, V73, P1747
   Lorizate M, 2006, BIOCHEMISTRY-US, V45, P14337, DOI 10.1021/bi0612521
   Lorizate M, 2006, J MOL BIOL, V360, P45, DOI 10.1016/j.jmb.2006.04.056
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   McGaughey GB, 2004, CURR HIV RES, V2, P193, DOI 10.2174/1570162043484933
   McGaughey GB, 2003, BIOCHEMISTRY-US, V42, P3214, DOI 10.1021/bi026952u
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   Moody MA, 2012, J VIROL, V86, P7496, DOI 10.1128/JVI.00426-12
   Muhle M, 2012, PROTEIN EXPRES PURIF, V81, P96, DOI 10.1016/j.pep.2011.09.006
   Muhle Michael, 2011, Virology, V412, P333, DOI 10.1016/j.virol.2011.01.023
   MUSTER T, 1993, J VIROL, V67, P6642
   Noah E, 2008, BIOCHEMISTRY-US, V47, P6782, DOI 10.1021/bi7023139
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Picker LJ, 2012, ANNU REV MED, V63, P95, DOI 10.1146/annurev-med-042010-085643
   Rethwilm A, 2003, CURR TOP MICROBIOL, V277, P1
   Romen F, 2006, VIROLOGY, V345, P502, DOI 10.1016/j.virol.2005.10.022
   Salzwedel K, 1999, J VIROL, V73, P2469
   Scherer EM, 2010, P NATL ACAD SCI USA, V107, P1529, DOI 10.1073/pnas.0909680107
   Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u
   Schwantes A, 2003, J VIROL, V77, P7830, DOI 10.1128/JVI.77.14.7830-7842.2003
   Schwantes A, 2002, VIROLOGY, V301, P53, DOI 10.1006/viro.2002.1543
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Taylor JA, 2008, MOL THER, V16, P46, DOI 10.1038/sj.mt.6300335
   Trobridge GD, 2006, P NATL ACAD SCI USA, V103, P1498, DOI 10.1073/pnas.0510046103
   Trobridge GD, 2009, EXPERT OPIN BIOL TH, V9, P1427, DOI 10.1517/14712590903246388
   Wang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018233
   Zemba M, 2000, VIROLOGY, V266, P150, DOI 10.1006/viro.1999.0037
   Zhu ZY, 2011, J VIROL, V85, P11401, DOI 10.1128/JVI.05312-11
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 72
TC 4
Z9 4
U1 0
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0257-277X
J9 IMMUNOL RES
JI Immunol. Res.
PD MAY
PY 2013
VL 56
IS 1
BP 61
EP 72
DI 10.1007/s12026-013-8387-x
PG 12
WC Immunology
SC Immunology
GA 129NY
UT WOS:000317849100006
PM 23440699
DA 2018-01-05
ER

PT J
AU Tremblay, M
   Bethell, RC
   Cordingley, MG
   DeRoy, P
   Duan, JM
   Duplessis, M
   Edwards, PJ
   Faucher, AM
   Halmos, T
   James, CA
   Kuhn, C
   Lacoste, JE
   Lamorte, L
   LaPlante, SR
   Malenfant, E
   Minville, J
   Morency, L
   Morin, S
   Rajotte, D
   Salois, P
   Simoneau, B
   Tremblay, S
   Sturino, CF
AF Tremblay, Martin
   Bethell, Richard C.
   Cordingley, Michael G.
   DeRoy, Patrick
   Duan, Jianmin
   Duplessis, Martin
   Edwards, Paul J.
   Faucher, Anne-Marie
   Halmos, Ted
   James, Clint A.
   Kuhn, Cyrille
   Lacoste, Jean-Eric
   Lamorte, Louie
   LaPlante, Steven R.
   Malenfant, Eric
   Minville, Joannie
   Morency, Louis
   Morin, Sebastien
   Rajotte, Daniel
   Salois, Patrick
   Simoneau, Bruno
   Tremblay, Sonia
   Sturino, Claudio F.
TI Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of
   HIV-1 nucleotide-competing reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Reverse transcriptase; NcRTI; HIV-1; Benzofurano[3,2-d]pyrimidin-2-one
ID NONNUCLEOSIDE INHIBITORS; ANTIRETROVIRAL THERAPY; RESISTANCE;
   NUCLEOSIDE; DISCOVERY; SUBSTRATE; MUTATIONS; MECHANISM; NNRTIS; DRUGS
AB Screening of our sample collection led to the identification of a set of benzofurano[3,2-d]pyrimidine-2one hits acting as nucleotide-competing HIV-1 reverse transcriptase inhibitiors (NcRTI). Significant improvement in antiviral potency was achieved when substituents were introduced at positions N1, C4, C7 and C8 on the benzofuranopyrimidone scaffold. The series was optimized from low micromolar enzymatic activity against HIV-1 RT and no antiviral activity to low nanomolar antiviral potency. Further profiling of inhibitor 30 showed promising overall in vitro properties and also demonstrated that its potency was maintained against viruses resistant to the other major classes of HIV-1 RT inhibitors. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Tremblay, Martin; DeRoy, Patrick; Duplessis, Martin; Edwards, Paul J.; Faucher, Anne-Marie; Halmos, Ted; James, Clint A.; Kuhn, Cyrille; Lacoste, Jean-Eric; LaPlante, Steven R.; Malenfant, Eric; Minville, Joannie; Morency, Louis; Morin, Sebastien; Simoneau, Bruno; Sturino, Claudio F.] Boehringer Ingelheim Canada Ltd, Dept Chem, Laval, PQ H7S 2G5, Canada.
   [Bethell, Richard C.; Cordingley, Michael G.; Duan, Jianmin; Lamorte, Louie; Rajotte, Daniel; Salois, Patrick; Tremblay, Sonia] Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Laval, PQ H7S 2G5, Canada.
RP Tremblay, M (reprint author), Boehringer Ingelheim Canada Ltd, Dept Chem, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.
EM martin.tremblay@boehringer-ingelheim.com;
   bruno.simoneau@boehringer-ingelheim.com
CR Basavapathruni A, 2007, FASEB J, V21, P3795, DOI 10.1096/fj.07-8697rev
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Castro HC, 2006, CURR MED CHEM, V13, P313, DOI 10.2174/092986706775476089                                                      
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Edwards PJ, 2011, CURR MED CHEM, V18, P3116
   Ehteshami M, 2008, J BIOL CHEM, V283, P29904, DOI 10.1074/jbc.M804882200
   Hawkins T, 2010, ANTIVIR RES, V85, P201, DOI 10.1016/j.antiviral.2009.10.016
   Jochmans D, 2006, J VIROL, V80, P12283, DOI 10.1128/JVI.00889-06
   Lansdon EB, 2010, J MOL BIOL, V397, P967, DOI 10.1016/j.jmb.2010.02.019
   Maga G, 2007, ANGEW CHEM INT EDIT, V46, P1810, DOI 10.1002/anie.200604165
   Maga G, 2010, VIRUSES-BASEL, V2, P880, DOI 10.3390/v2040880
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007                                                             
   Palm K, 1999, J PHARMACOL EXP THER, V291, P435
   Paredes R, 2010, ANTIVIR RES, V85, P245, DOI 10.1016/j.antiviral.2009.09.015
   SHORE PA, 1957, J PHARMACOL EXP THER, V119, P361
   Swamy KCK, 2009, CHEM REV, V109, P2551, DOI 10.1021/cr800278z
   Zhang ZJ, 2006, ANTIMICROB AGENTS CH, V50, P2772, DOI 10.1128/AAC.00127-06
   Sturino C., 2010, PCT Int. Appl., Patent No. [WO 2010/115264, 2010115264]
NR 20
TC 5
Z9 5
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2013
VL 23
IS 9
BP 2775
EP 2780
DI 10.1016/j.bmcl.2013.02.042
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 122QW
UT WOS:000317333900058
PM 23511023
DA 2018-01-05
ER

PT J
AU Zhang, JJ
   Mulvenon, A
   Makarov, E
   Wagoner, J
   Knibbe, J
   Kim, JO
   Osna, N
   Bronich, TK
   Poluektova, LY
AF Zhang, Jinjin
   Mulvenon, Andrea
   Makarov, Edward
   Wagoner, Jill
   Knibbe, Jaclyn
   Kim, Jong Oh
   Osna, Natalia
   Bronich, Tatiana K.
   Poluektova, Larisa Y.
TI Antiviral peptide nanocomplexes as a potential therapeutic modality for
   HIV/HCV co-infection
SO BIOMATERIALS
LA English
DT Article
DE Amphiphatic alpha-helical peptide; Anionic poly (amino acid)-based block
   copolymer; HIV-1; HCV; Macrophages; Human hepatoma cell line Huh7.5
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYION COMPLEX
   MICELLES; DISEASE PROGRESSION; BLOCK-COPOLYMERS; IMMUNE-RESPONSES;
   DEPENDENT FUSION; HIV COINFECTION; HCV COINFECTION; LIVER-DISEASE
AB It is estimated that 4 to 5 million people are currently co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV). HIV/HCV co-infection is associated with unique health risks including increased hepatotoxicity of antiretrovirals, accelerated progression of HCV and liver diseases. The standard interferon-based therapy is effective only in about 50% of patients and often is associated with autoimmune and neuro-psychiatric complications. The treatment of co-infection (HIV/HCV) requires new strategic approaches. To this end, the formulations of an amphiphatic alpha-helical peptide, a positively charged analog of C5A peptide derived from the HCV NS5A protein, with a reported virocidal activity were prepared by electrostatic coupling with anionic poly(amino acid)-based block copolymers. The self-assembled antiviral peptide nanocomplexes (APN) were ca. 35 nm in size, stable at physiological pH and ionic strength, and retained in vitro antiviral activity against HCV and HIV. Moreover, incorporation of the peptide into APN attenuated its cytotoxicity associated with the positive charge. In vivo APN were able to decrease the viral load in mice transplanted with human lymphocytes and HIV-1-infected. Overall, these findings indicate the potential of these formulations for stabilization and delivery of antiviral peptides while maintaining their functional activity. Published by Elsevier Ltd.
C1 [Zhang, Jinjin; Mulvenon, Andrea; Kim, Jong Oh; Bronich, Tatiana K.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Zhang, Jinjin; Mulvenon, Andrea; Kim, Jong Oh; Bronich, Tatiana K.] Univ Nebraska Med Ctr, Ctr Drug Delivery & Nanomed, Omaha, NE 68198 USA.
   [Makarov, Edward; Knibbe, Jaclyn; Poluektova, Larisa Y.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Wagoner, Jill; Osna, Natalia] VA Med Ctr, Res Serv 151, Dept Internal Med, Liver Study Unit, Omaha, NE 68105 USA.
RP Poluektova, LY (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM tbronich@unmc.edu; lpoluekt@unmc.edu
OI Poluektova, Larisa/0000-0001-7339-8732
FU Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health
   [P20GM103480, CA116590]
FX This study was supported by an Institutional Development Award (IDeA)
   from the National Institute of General Medical Sciences of the National
   Institutes of Health under grant number P20GM103480 to L.Y.P. and
   T.K.B., and CA116590 to T.K.B. The authors are grateful to Dr. Irine
   Khutsishvili for her assistance with CD spectroscopy, Dr. Samuel
   Sanderson for the help with peptide purification and Dr. Santhi Gorantla
   for PCR analysis. We acknowledge the assistance of the COBRE
   Nanomaterials Core facility and UNMC Nanoimaging Core facility.
CR Alestig E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-124
   Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06
   Bobardt MD, 2008, P NATL ACAD SCI USA, V105, P5525, DOI 10.1073/pnas.0801388105
   Buskin SE, 2011, WORLD J GASTROENTERO, V17, P1807, DOI 10.3748/wjg.v17.i14.1807
   Chen TY, 2009, CLIN INFECT DIS, V49, P1605, DOI 10.1086/644771
   Cheng G, 2008, P NATL ACAD SCI USA, V105, P3088, DOI 10.1073/pnas.0712380105
   Cota M, 2000, J NEUROVIROL, V6, P75, DOI 10.3109/13550280009006384                                                       
   Daar ES, 2001, J INFECT DIS, V183, P589, DOI 10.1086/318539                                                                  
   Deming P, 2011, PHARMACOTHERAPY, V31, P357, DOI 10.1592/phco.31.4.357
   Denissen JF, 1997, DRUG METAB DISPOS, V25, P489
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   Gaydess A, 2010, CHEM-BIOL INTERACT, V187, P295, DOI 10.1016/j.cbi.2010.01.005
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gorantla S, 2005, J VIROL, V79, P2124, DOI 10.1128/JVI.79.4.2124-2132.2005
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Gorantla S, 2010, J IMMUNOL, V184, P7082, DOI 10.4049/jimmunol.1000438
   Graham CS, 2006, AIDS, V20, P345, DOI 10.1097/01.aids.0000206500.16783.2e
   Hamblin MR, 2003, BRIT J CANCER, V89, P937, DOI 10.1038/sj.bjc.6601210
   Harada A, 2001, J CONTROL RELEASE, V72, P85, DOI 10.1016/S0168-3659(01)00264-4                                                   
   Lai AR, 2006, AIDS PATIENT CARE ST, V20, P678, DOI 10.1089/apc.2006.20.678
   Lee Y, 2007, J AM CHEM SOC, V129, P5362, DOI 10.1021/ja071090b
   Lin Q, 2011, J IMMUNOL, V186, P2087, DOI 10.4049/jimmunol.1002340
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Meertens L, 2006, J VIROL, V80, P11571, DOI 10.1128/JVI.01717-06
   Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968
   Miyauchi K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000585
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Poluektova LY, 2002, J IMMUNOL, V168, P3941, DOI 10.4049/jimmunol.168.8.3941                                                     
   Puoti M., 2007, CURR OPIN HIV AIDS, V6, P460
   Ragni MV, 2009, HAEMOPHILIA, V15, P552, DOI 10.1111/j.1365-2516.2008.01935.x
   Rallon NI, 2010, AIDS, V24, pF23, DOI 10.1097/QAD.0b013e3283391d6d
   REARDON JE, 1990, J BIOL CHEM, V265, P20302
   Rosenthal E, 2003, AIDS, V17, P1803, DOI 10.1097/01.aids.0000072671.21517.44
   Seden K, 2010, J ANTIMICROB CHEMOTH, V65, P1079, DOI 10.1093/jac/dkq086
   Serpaggi J, 2006, AIDS, V20, P233, DOI 10.1097/01.aids.0000200541.40633.56
   Sharma NR, 2011, J BIOL CHEM, V286, P30361, DOI 10.1074/jbc.M111.263350
   Shivraj SO, 2006, J TROP PEDIATRICS, V52, P206, DOI 10.1093/tropej/fmi103
   Staples CT, 1999, CLIN INFECT DIS, V29, P150
   Vallet-Pichard A, 2006, J HEPATOL, V44, pS28, DOI 10.1016/j.jhep.2005.11.008
   Reiche EMV, 2008, INT J MOL MED, V21, P387
   Yuan XF, 2005, LANGMUIR, V21, P2668, DOI 10.1021/la0488811
NR 43
TC 13
Z9 13
U1 1
U2 32
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2013
VL 34
IS 15
BP 3846
EP 3857
DI 10.1016/j.biomaterials.2013.01.026
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 120KH
UT WOS:000317168700012
PM 23403120
OA green_accepted
DA 2018-01-05
ER

PT J
AU Presente, A
   Dowdy, SF
AF Presente, Asaf
   Dowdy, Steven F.
TI PTD/CPP Peptide-Mediated Delivery of siRNAs
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE PTD; CPP; siRNA; RNAi; nanoparticles; cell deliverY; macropinocytosis
ID CELL-PENETRATING PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS; SMALL
   INTERFERING RNA; IN-VIVO; MAMMALIAN-CELLS; INNATE IMMUNITY;
   TUMOR-GROWTH; TAT PROTEIN; MACROPINOCYTOSIS; INDUCTION
AB siRNA-induced RNA Interference (RNAi) responses have great potential to treat human disease; however, siRNAs are highly charged macromolecules with no ability to enter cells and require a delivery agent. Peptide Transduction Domains (PTDs), also called Cell Penetrating Peptides (CPPs), are delivery peptides with the potential to deliver macromolecular peptides, proteins and siRNAs into cells. Here we discuss the multitude of ways that PTDs/CPPs have been utilized to deliver siRNAs from direct conjugates to complex nanoparticles. PTD/CPP-mediated siRNA delivery has come a long way and has great potential to address the siRNA delivery problem.
C1 [Presente, Asaf; Dowdy, Steven F.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
RP Dowdy, SF (reprint author), Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM sdowdy@ucsd.edu
FU Howard Hughes Medical Institute
FX Howard Hughes Medical Institute.
CR Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699                                                        
   Ezzat K, 2012, J CONTROL RELEASE, V162, P1, DOI 10.1016/j.jconrel.2012.06.006
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hayashi Y, 2011, INT J PHARMACEUT, V419, P308, DOI 10.1016/j.ijpharm.2011.07.038
   Kim SS, 2010, MOL THER, V18, P993, DOI 10.1038/mt.2010.27
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Michiue H, 2009, CANCER BIOL THER, V8, P2306
   Milletti F, 2012, DRUG DISCOV TODAY
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Rettig GR, 2012, MOL THER, V20, P483, DOI 10.1038/mt.2011.263
   Robbins M, 2009, OLIGONUCLEOTIDES, V19, P89, DOI 10.1089/oli.2009.0180
   Rydstrom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025924
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Yao YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003601
NR 33
TC 12
Z9 13
U1 0
U2 32
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAY
PY 2013
VL 19
IS 16
BP 2943
EP 2947
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 116BM
UT WOS:000316857400008
PM 23140460
DA 2018-01-05
ER

PT J
AU Pilakka-Kanthikeel, S
   Atluri, VSR
   Sagar, V
   Saxena, SK
   Nair, M
AF Pilakka-Kanthikeel, Sudheesh
   Atluri, Venkata Subba Rao
   Sagar, Vidya
   Saxena, Shailendra K.
   Nair, Madhavan
TI Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the
   Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers:
   An In-Vitro Study
SO PLOS ONE
LA English
DT Article
ID ELEMENT-BINDING PROTEIN; HIV-ASSOCIATED DEMENTIA;
   CENTRAL-NERVOUS-SYSTEM; LONG-TERM-MEMORY; FACTOR PREVENTS;
   SUBSTANTIA-NIGRA; EXPOSURE ALTERS; RAT HIPPOCAMPUS; SPINE DENSITY;
   CELL-DEATH
AB Parenteral use of drugs; such as opiates exert immunomodulatory effects and serve as a cofactor in the progression of HIV-1 infection, thereby potentiating HIV related neurotoxicity ultimately leading to progression of NeuroAIDS. Morphine exposure is known to induce apoptosis, down regulate cAMP response element-binding (CREB) expression and decrease in dendritic branching and spine density in cultured cells. Use of neuroprotective agent; brain derived neurotropic factor (BDNF), which protects neurons against these effects, could be of therapeutic benefit in the treatment of opiate addiction. Previous studies have shown that BDNF was not transported through the blood brain barrier (BBB) in-vivo.; and hence it is not effective in-vivo. Therefore development of a drug delivery system that can cross BBB may have significant therapeutic advantage. In the present study, we hypothesized that magnetically guided nanocarrier may provide a viable approach for targeting BDNF across the BBB. We developed a magnetic nanoparticle (MNP) based carrier bound to BDNF and evaluated its efficacy and ability to transmigrate across the BBB using an in-vitro BBB model. The end point determinations of BDNF that crossed BBB were apoptosis, CREB expression and dendritic spine density measurement. We found that transmigrated BDNF was effective in suppressing the morphine induced apoptosis, inducing CREB expression and restoring the spine density. Our results suggest that the developed nanocarrier will provide a potential therapeutic approach to treat opiate addiction, protect neurotoxicity and synaptic density degeneration.
C1 [Pilakka-Kanthikeel, Sudheesh; Atluri, Venkata Subba Rao; Sagar, Vidya; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Miami, FL 33199 USA.
   [Saxena, Shailendra K.] CSIR Ctr Cellular & Mol Biol, Hyderabad, Andhra Pradesh, India.
RP Nair, M (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Miami, FL 33199 USA.
EM nairm@fiu.edu
RI Atluri, Venkata/G-3277-2014
OI Atluri, Venkata/0000-0002-8070-6745
FU National Institute of Drug abuse [1R01-DA027049]
FX This work was supported by grant from National Institute of Drug abuse
   (1R01-DA027049). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134
   Alexiou C, 2006, EUR BIOPHYS J BIOPHY, V35, P446, DOI 10.1007/s00249-006-0042-1
   Alonso M, 2005, LEARN MEMORY, V12, P504, DOI 10.1101/lm.27305                                                                
   ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347
   AYRE SG, 1989, MED HYPOTHESES, V29, P283, DOI 10.1016/0306-9877(89)90113-8
   Bachis A, 2003, J NEUROSCI, V23, P5715
   Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041
   BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5
   BETZ AL, 1986, ANNU REV PHYSIOL, V48, P241
   BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586                                                          
   Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3
   BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6
   Boyum A, 1968, SCAND J CLIN LAB INV, P77
   Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003
   Cammarota M, 2000, MOL BRAIN RES, V76, P36, DOI 10.1016/S0169-328X(99)00329-0
   Chapleau CA, 2008, J NEUROSCI METH, V169, P182, DOI 10.1016/j.jneumeth.2007.12.006
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   Frankfurt M, 2011, SYNAPSE, V65, P955, DOI 10.1002/syn.20918
   FREIER DO, 1993, J PHARMACOL EXP THER, V265, P81
   FUCHS BA, 1993, J PHARMACOL EXP THER, V266, P417
   Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891
   Garden GA, 2002, J NEUROSCI, V22, P4015
   Goswami R, 1998, J NEUROCHEM, V70, P1376
   Guo CJ, 2002, J INVEST MED, V50, P435, DOI 10.1136/jim-50-06-03
   Han B, 2009, ADDICTION, V104, P88, DOI 10.1111/j.1360-0443.2008.02411.x
   Han BH, 2000, NEUROBIOL DIS, V7, P38
   HURWITZ AA, 1994, ADV NEUROIMMUNOL, V4, P249, DOI 10.1016/S0960-5428(06)80263-9                                                   
   HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Itoh K, 2000, ACTA NEUROPATHOL, V99, P376, DOI 10.1007/s004010051139                                                           
   James HJ, 1999, NEUROPATH APPL NEURO, V25, P380
   Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667
   Kwon M, 2011, J NEUROSCI, V31, P9735, DOI 10.1523/JNEUROSCI.6785-10.2011
   Kwon SG, 2007, J AM CHEM SOC, V129, P12571, DOI 10.1021/ja074633q
   Li YF, 2007, NEUROSCI LETT, V418, P227, DOI 10.1016/j.neulet.2007.03.023
   Lubbe AS, 1996, CANCER RES, V56, P4694
   Mahajan SD, 2005, CLIN IMMUNOL, V115, P323, DOI 10.1016/j.clim.2005.02.004
   Mamounas LA, 1995, J NEUROSCI, V15, P7929
   Mandel RJ, 1999, EXP NEUROL, V155, P59, DOI 10.1006/exnr.1998.6961                                                          
   MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U                                                    
   Mocchetti I, 2007, ANN NY ACAD SCI, V1122, P144, DOI 10.1196/annals.1403.010
   Nair MPN, 1997, CLIN DIAGN LAB IMMUN, V4, P127
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570                                                                
   Nosheny RL, 2007, EUR J NEUROSCI, V25, P2275, DOI 10.1111/j.1460-9568.2007.05506.x
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Pardridge WM, 1998, PHARMACEUT RES, V15, P576, DOI 10.1023/A:1011981927620
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V
   Purohit V, 2011, MOL NEUROBIOL, V44, P102, DOI 10.1007/s12035-011-8195-z
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Roy S, 1996, NEUROCHEM RES, V21, P1375, DOI 10.1007/BF02532379
   Saiyed ZM, 2007, J BIOTECHNOL, V131, P240, DOI 10.1016/j.jbiotec.2007.06.017
   Saiyed ZM, 2007, ANAL BIOCHEM, V363, P288, DOI 10.1016/j.ab.2007.01.008
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Sarti F, 2007, EUR J NEUROSCI, V26, P749, DOI 10.1111/j.1460-9568.2007.05689.x
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   Singhal PC, 1998, J IMMUNOL, V160, P1886
   Singhal PG, 1999, J LEUKOCYTE BIOL, V66, P650
   Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106
   Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10                                                
   Strathdee Steffanie A, 2010, Curr HIV/AIDS Rep, V7, P99, DOI 10.1007/s11904-010-0043-7
   Suri Sarabjeet Singh, 2007, J Occup Med Toxicol, V2, P16, DOI 10.1186/1745-6673-2-16
   Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309
   Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938
   Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003
   Viola HE, 2000, J NEUROSCI, V20
   Wallace DR, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/65741
   Wang GJ, 2004, BRAIN, V127, P2452, DOI 10.1093/brain/awh269
   WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231
   Xia Y, 2010, NEUROPHARMACOLOGY, V58, P330, DOI 10.1016/j.neuropharm.2009.10.009
   Yin DL, 1999, NATURE, V397, P218, DOI 10.1038/16612                                                                   
NR 72
TC 42
Z9 44
U1 1
U2 38
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2013
VL 8
IS 4
AR e62241
DI 10.1371/journal.pone.0062241
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146GG
UT WOS:000319077300033
PM 23653680
OA gold
DA 2018-01-05
ER

PT J
AU Alodhayb, A
   Brown, N
   Rahman, SMS
   Harrigan, R
   Beaulieu, LY
AF Alodhayb, Abdullah
   Brown, Nicole
   Rahman, S. M. Saydur
   Harrigan, Richard
   Beaulieu, L. Y.
TI Towards detecting the human immunodeficiency virus using microcantilever
   sensors
SO APPLIED PHYSICS LETTERS
LA English
DT Article
ID GOLD SURFACES; DNA; NANOMECHANICS; HYBRIDIZATION; DEFLECTION; RESONANCE;
   RNA
AB Detecting the human immunodeficiency virus (HIV) is difficult because the virus is prone to mutations and is in low concentrations in the body. Inside the HIV virion are two well characterized single stranded (ss) RNA molecules (viral genome) that feature both variable regions and regions that are conserved under virus mutation. In this work, microcantilever sensors have been employed as potential HIV detectors by targeting a conserved sequence of the viral genome by attempting to detect target ssDNA and ssRNA molecules that are significantly longer than the ssDNA molecules functionalized on the cantilever. (C) 2013 AIP Publishing LLC.
C1 [Alodhayb, Abdullah; Brown, Nicole; Rahman, S. M. Saydur; Beaulieu, L. Y.] Mem Univ Newfoundland, Dept Phys & Phys Oceanog, St John, NF A1B 3X7, Canada.
   [Harrigan, Richard] BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
RP Beaulieu, LY (reprint author), Mem Univ Newfoundland, Dept Phys & Phys Oceanog, St John, NF A1B 3X7, Canada.
EM lbeaulieu@mun.ca
CR Alvarez M, 2004, LANGMUIR, V20, P9663, DOI 10.1021/la0489559
   Castelino K, 2005, LANGMUIR, V21, P1956, DOI 10.1021/la047943k
   CHEN GY, 1995, J APPL PHYS, V77, P3618, DOI 10.1063/1.359562
   Cohen MS, 2010, J INFECT DIS, V202, pS270, DOI 10.1086/655651
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316                                                    
   Hansen KM, 2001, ANAL CHEM, V73, P1567, DOI 10.1021/ac0012748
   Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586                                                               
   Huber F, 2013, NAT NANOTECHNOL, V8, P125, DOI [10.1038/NNANO.2012.263, 10.1038/nnano.2012.263]
   Lam Y, 2006, NANOMED-NANOTECHNOL, V2, P222, DOI 10.1016/j.nano.2006.10.002
   Lee J, 2010, NANO LETT, V10, P2537, DOI 10.1021/nl101107u
   Manning KY, 2013, J APPL PHYS, V113, DOI 10.1063/1.4795273
   McKendry R, 2002, P NATL ACAD SCI USA, V99, P9783, DOI 10.1073/pnas.152330199
   Raiteri R, 2001, SENSOR ACTUAT B-CHEM, V79, P115, DOI 10.1016/S0925-4005(01)00856-5
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Vikholm-Lundin I, 2007, BIOSENS BIOELECTRON, V22, P1323, DOI 10.1016/j.bios.2006.05.029
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856
   Wu GH, 2001, P NATL ACAD SCI USA, V98, P1560, DOI 10.1073/pnas.031362498
NR 18
TC 11
Z9 11
U1 0
U2 21
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD APR 29
PY 2013
VL 102
IS 17
AR 173106
DI 10.1063/1.4803771
PG 3
WC Physics, Applied
SC Physics
GA 139AG
UT WOS:000318553000054
DA 2018-01-05
ER

PT J
AU Wang, H
   Musier-Forsyth, K
   Falk, C
   Barbara, PF
AF Wang, Hui
   Musier-Forsyth, Karin
   Falk, Caroline
   Barbara, Paul F.
TI Single-Molecule Spectroscopic Study of Dynamic Nanoscale DNA Bending
   Behavior of HIV-1 Nucleocapsid Protein
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID NUCLEIC-ACID-CHAPERONE; RESONANCE ENERGY-TRANSFER; REVERSE
   TRANSCRIPTION; FLUORESCENCE SPECTROSCOPY; STRAND TRANSFER; HMGB
   PROTEINS; VIRAL-DNA; BENT DNA; MECHANISM; RNA
AB We have studied the conformational dynamics associated with the nanoscale DNA bending induced by human immunodeficiency virus type 1 (HIV-1) nucleocapsid (NC) protein using single-molecule Forster resonance energy transfer (SM-FRET). To gain molecular-level insights into how the HIV-1 NC locally distorts the structures of duplexed DNA segments, the dynamics, reversibility, and sequence specificity of the DNA bending behavior of NC have been systematically studied. We have performed SM-FRET measurements on a series of duplexed DNA segments with varying sequences, lengths, and local structures in the presence of the wide-type HIV-1 NC and NC mutants lacking either the basic N-terminal domain or the zinc fingers. On the basis of the SM-FRET results, we have proposed a possible mechanism for the NC-induced DNA bending in which both NC's zinc fingers and N-terminal domain are found to play crucial roles. The SM-FRET results reported here add new mechanistic insights into the biological behaviors and functions of HIV-1 NC as a retroviral DNA-architectural protein which may play critical roles in the compaction, nuclear import, and integration of the proviral DNA during the retroviral life cycle.
C1 [Wang, Hui] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
   [Musier-Forsyth, Karin] Ohio State Univ, Dept Chem & Biochem, Ctr RNA Biol, Columbus, OH 43210 USA.
   [Musier-Forsyth, Karin] Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA.
   [Wang, Hui; Falk, Caroline; Barbara, Paul F.] Univ Texas Austin, Ctr Nano & Mol Sci & Technol, Austin, TX 78712 USA.
RP Wang, H (reprint author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
EM wang344@mailbox.sc.edu
OI Wang, Hui/0000-0002-1874-5137
FU College of Arts and Sciences of University of South Carolina; Advanced
   Support Programs for Innovative Research Excellence (ASPIRE) provided by
   the USC Office of Research; Welch Foundation; National Institutes of
   Health [GM65056]
FX H.W. would like to acknowledge the Startup funds provided by the College
   of Arts and Sciences of University of South Carolina, the funds from
   Advanced Support Programs for Innovative Research Excellence (ASPIRE)
   provided by the USC Office of Research, and the financial support from
   Welch Foundation (awarded to P.F.B.) on the last year of his
   postdoctoral research. K.M.-F. acknowledges funding from the National
   Institutes of Health (GM65056). The authors would also like to thank
   Robert Gorelick of NCI-Frederick for providing the SSHS NC mutant used
   in this work. The single-molecule spectroscopic measurements reported in
   this paper were performed by H.W. during the last six months of his
   postdoctoral research with P.F.B. at the University of Texas at Austin.
   Data analysis and manuscript preparation were accomplished after H.W.
   joined the faculty of Chemistry and Biochemistry at University of South
   Carolina.
CR Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6
   Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003
   Cao CY, 2004, NAT STRUCT MOL BIOL, V11, P1230, DOI 10.1038/nsmb864
   Cloutier TE, 2005, P NATL ACAD SCI USA, V102, P3645, DOI 10.1073/pnas.0409059102
   Cosa G, 2006, J PHYS CHEM B, V110, P2419, DOI 10.1021/jp054189i
   Cosa G, 2004, BIOPHYS J, V87, P2759, DOI 10.1529/biophysj.104.043083
   Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457
   CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3
   Cruceanu M, 2006, J MOL BIOL, V363, P867, DOI 10.1016/j.jmb.2006.08.070
   Gansen A, 2009, P NATL ACAD SCI USA, V106, P15308, DOI 10.1073/pnas.0903005106
   Garcia HG, 2007, BIOPOLYMERS, V85, P115, DOI 10.1002/bip.20627
   Gell C., 2006, HDB SINGLE MOL FLUOR
   Godet J, 2006, J MOL BIOL, V356, P1180, DOI 10.1016/j.jmb.2005.12.038
   GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660
   GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1                                                    
   Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083
   Ha T, 2001, CURR OPIN STRUC BIOL, V11, P287, DOI 10.1016/S0959-440X(00)00204-9
   HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265
   Hohng S, 2007, SCIENCE, V318, P279, DOI 10.1126/science.1146113
   Karunatilaka KS, 2010, NATURE, V467, P935, DOI 10.1038/nature09422
   Knobler CM, 2009, ANNU REV PHYS CHEM, V60, P367, DOI 10.1146/annurev.physchem.59.032607.093728
   KOMBERG RD, 1999, CELL, V98, P285
   Krishnamoorthy G, 2003, NUCLEIC ACIDS RES, V31, P5425, DOI 10.1093/nar/gkg738
   Kuznetsov SV, 2006, P NATL ACAD SCI USA, V103, P18515, DOI 10.1073/pnas.0608394103
   LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831
   Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77                                                   
   Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6
   Liu HW, 2007, P NATL ACAD SCI USA, V104, P5261, DOI 10.1073/pnas.0700166104
   Liu HW, 2005, BIOPHYS J, V89, P3470, DOI 10.1529/biophysj.105.065326
   Liu RC, 2006, J AM CHEM SOC, V128, P10034, DOI 10.1021/ja057005m
   Liu SX, 2008, SCIENCE, V322, P1092, DOI 10.1126/science.1163108
   Mathew-Fenn RS, 2008, SCIENCE, V322, P446, DOI 10.1126/science.1158881
   Mirambeau G, 2006, J MOL BIOL, V364, P496, DOI 10.1016/j.jmb.2006.08.065
   Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049
   O'Neil LL, 2005, J AM CHEM SOC, V127, P16800, DOI 10.1021/ja056274+
   Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835                                                          
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   Roy R, 2008, NAT METHODS, V5, P507, DOI 10.1038/NMETH.1208
   SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800                                        
   Sass LE, 2010, BIOCHEMISTRY-US, V49, P3174, DOI 10.1021/bi901871u
   SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215                                             
   Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060
   Spies MA, 2002, J AM CHEM SOC, V124, P14049, DOI 10.1021/ja012272n                                                               
   Stewart-Maynard KM, 2008, J VIROL, V82, P10129, DOI 10.1128/JVI.01169-08
   Sugimura S, 2006, P NATL ACAD SCI USA, V103, P18510, DOI 10.1073/pnas.0608337103
   Tomschik M, 2005, P NATL ACAD SCI USA, V102, P3278, DOI 10.1073/pnas.0500189102
   Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8
   Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521                                                          
   VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105
   Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039
   Wang H, 2010, BIOPHYS J, V99, P3454, DOI 10.1016/j.bpj.2010.09.051
   Wang H, 2009, J AM CHEM SOC, V131, P15534, DOI 10.1021/ja9070046
   Weiss S, 2000, NAT STRUCT BIOL, V7, P724, DOI 10.1038/78941
   Wiggins PA, 2006, NAT NANOTECHNOL, V1, P137, DOI 10.1038/nnano.2006.63
   Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999
   Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198
   Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545                                                
   Xie Z, 2004, P NATL ACAD SCI USA, V101, P534, DOI 10.1073/pnas.2636333100
   Yan J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.108108
   Yuan CL, 2006, NUCLEIC ACIDS RES, V34, P4554, DOI 10.1093/nar/gkl394
   Yuan CL, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.018102
   Zeng YN, 2007, P NATL ACAD SCI USA, V104, P12651, DOI 10.1073/pnas.0700350104
   Zhang JY, 2009, NUCLEIC ACIDS RES, V37, P1107, DOI 10.1093/nar/gkn1011
   Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048
NR 64
TC 2
Z9 2
U1 1
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD APR 25
PY 2013
VL 117
IS 16
SI SI
BP 4183
EP 4196
DI 10.1021/jp3018259
PG 14
WC Chemistry, Physical
SC Chemistry
GA 134LL
UT WOS:000318211600004
PM 22591315
OA green_accepted
DA 2018-01-05
ER

PT J
AU Marko, RA
   Liu, HW
   Ablenas, CJ
   Ehteshami, M
   Gotte, M
   Cosa, G
AF Marko, Ryan A.
   Liu, Hsiao-Wei
   Ablenas, Christopher J.
   Ehteshami, Maryam
   Goette, Matthias
   Cosa, Gonzalo
TI Binding Kinetics and Affinities of Heterodimeric versus Homodimeric
   HIV-1 Reverse Transcriptase on DNA-DNA Substrates at the Single-Molecule
   Level
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODY;
   ANGSTROM RESOLUTION; P66/P51 HETERODIMER; POLYMERASE-ACTIVITY;
   TEMPLATE-PRIMER; ENERGY-TRANSFER; P51 SUBUNIT; RNASE-H
AB During viral replication, HIV-1 reverse transcriptase (RT) plays a pivotal role in converting genomic RNA into proviral DNA. While the biologically relevant form of RT is the p66-p51 heterodimer, two recombinant homodimer forms of RT, p66-p66 and p51-p51, are also catalytically active. Here we investigate the binding of the three RT isoforms to a fluorescently labeled 19/50-nucleotide primer/template DNA duplex by exploiting single-molecule protein-induced fluorescence enhancement (SM-PIFE). PIFE, which does not require labeling of the protein, allows us to directly visualize the binding/unbinding of RT to a double-stranded DNA substrate. We provide values for the association and dissociation rate constants of the RT homodimers p66-p66 and p51-p51 with a double-stranded DNA substrate and compare those to the values recorded for the RT heterodimer p66-p51. We also report values for the equilibrium dissociation constant for the three isoforms. Our data reveal great similarities in the intrinsic binding affinities of p66-p51 and p66-p66, with characteristic K-d values in the nanomolar range, much smaller (50-100-fold) than that of p51-p51. Our data also show discrepancies in the association/dissociation dynamics among the three dimeric RT isoforms. Our results further show that the apparent binding affinity of p51-p51 for its DNA substrate is to a great extent time-dependent when compared to that of p66-p66 and p66-p51, and is more likely determined by the dimer dissociation into its constituent monomers rather than the intrinsic binding affinity of dimeric RT.
C1 [Marko, Ryan A.; Liu, Hsiao-Wei; Cosa, Gonzalo] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada.
   [Marko, Ryan A.; Liu, Hsiao-Wei; Cosa, Gonzalo] McGill Univ, Ctr Self Assembled Chem Struct CSACS CRMAA, Montreal, PQ H3A 0B8, Canada.
   [Ehteshami, Maryam; Goette, Matthias] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada.
   [Ablenas, Christopher J.; Goette, Matthias] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.
   [Goette, Matthias] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada.
RP Liu, HW (reprint author), McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada.
EM hsiao-wei.liu@mail.mcgill.ca; matthias.gotte@mcgill.ca;
   gonzalo.cosa@mcgill.ca
FU Fonds de la recherche en sante du Quebec (FRSQ); McGill CIHR drug
   development training program (DDTP); GRASP; NSERC CREATE; DDTP; CIHR
FX G.C. and M.G. are thankful to the Fonds Quebecois de la Recherche sur la
   Nature et les Technologies (FQRNT) Team Grant program, the National
   Science and Engineering Research Council of Canada (NSERC) (G.C.), the
   Canadian Institutes of Health Research (CIHR) (M.G.), and Nanoquebec
   (G.C.). M.G. is the recipient of a career award from the Fonds de la
   recherche en sante du Quebec (FRSQ). H.-W.L. thanks both the McGill CIHR
   drug development training program (DDTP) and GRASP for a postdoctoral
   fellowship. R.A.M. thanks the previous two programs and the NSERC CREATE
   training program in bionanomachines for a postgraduate fellowship.
   C.J.A. is grateful for a DDTP postgraduate fellowship. M.E. is thankful
   to CIHR for a doctoral research award.
CR Abbondanzieri EA, 2008, NATURE, V453, P184, DOI 10.1038/nature06941
   BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003
   Berezhna SY, 2012, J AM CHEM SOC, V134, P11261, DOI 10.1021/ja3038273
   Biondi MJ, 2010, J BIOL CHEM, V285, P26966, DOI 10.1074/jbc.M110.105775
   Bohlayer WP, 2006, BIOCHEMISTRY-US, V45, P7628, DOI 10.1021/bi051770w
   Christian TD, 2009, P NATL ACAD SCI USA, V106, P21109, DOI 10.1073/pnas.0908640106
   Cosa G, 2004, BIOPHYS J, V87, P2759, DOI 10.1529/biophysj.104.043083
   Debyser Z, 1996, PROTEIN SCI, V5, P278
   DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   ELDIRANIDIAB R, 1992, FEBS LETT, V301, P23
   Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004
   Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j                                                               
   Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159
   HANSEN J, 1988, EMBO J, V7, P239
   HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218
   HOSTOMSKY Z, 1992, J VIROL, V66, P3179
   Hwang H, 2011, P NATL ACAD SCI USA, V108, P7414, DOI 10.1073/pnas.1017672108
   Ignatov ME, 2005, BIOCHEMISTRY-US, V44, P5346, DOI 10.1021/bi048000p
   Joo C, 2006, CELL, V126, P515, DOI 10.1016/j.cell.2006.06.042
   Karam P, 2010, P NATL ACAD SCI USA, V107, P17480, DOI 10.1073/pnas.1008068107
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KRUHOFFER M, 1993, NUCLEIC ACIDS RES, V21, P3943, DOI 10.1093/nar/21.17.3943                                                          
   LEGRICE SFJ, 1991, EMBO J, V10, P3905
   LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307
   Levitus M, 2011, Q REV BIOPHYS, V44, P123, DOI 10.1017/S0033583510000247
   Liu HW, 2007, P NATL ACAD SCI USA, V104, P5261, DOI 10.1073/pnas.0700166104
   Liu H. -W., 2011, J AM CHEM SOC, V134, P1648
   Luo G, 2007, P NATL ACAD SCI USA, V104, P12610, DOI 10.1073/pnas.0700920104
   Maier G, 1999, EUR J BIOCHEM, V261, P10, DOI 10.1046/j.1432-1327.1999.00304.x
   McKinney SA, 2006, BIOPHYS J, V91, P1941, DOI 10.1529/biophysj.106.082487
   MULLER B, 1989, J BIOL CHEM, V264, P13975
   Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049
   Ngo A. T., 2007, J AM CHEM SOC, V130, P457
   Rasnik I, 2004, J MOL BIOL, V336, P395, DOI 10.1016/j.jmb.2003.12.031
   REARDON JE, 1993, J BIOL CHEM, V268, P8743
   RESTLE T, 1990, J BIOL CHEM, V265, P8986
   Sluis-Cremer N, 2004, INT J BIOCHEM CELL B, V36, P1836, DOI 10.1016/j.biocel.2004.02.020
   STARNES MC, 1988, J BIOL CHEM, V263, P5132
   Tachedjian G, 2000, P NATL ACAD SCI USA, V97, P6334, DOI 10.1073/pnas.97.12.6334                                                         
   TISDALE M, 1988, J VIROL, V62, P3662
   Venezia CF, 2009, BIOCHEMISTRY-US, V48, P9084, DOI 10.1021/bi9010495
   Venezia CF, 2006, BIOCHEMISTRY-US, V45, P2779, DOI 10.1021/bi051915z
   VERONESE FD, 1986, SCIENCE, V231, P1289
   WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242
   WU J, 1993, J BIOL CHEM, V268, P9980
   Zheng XH, 2010, BIOCHEMISTRY-US, V49, P2821, DOI 10.1021/bi902116z
NR 48
TC 19
Z9 19
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD APR 25
PY 2013
VL 117
IS 16
SI SI
BP 4560
EP 4567
DI 10.1021/jp308674g
PG 8
WC Chemistry, Physical
SC Chemistry
GA 134LL
UT WOS:000318211600048
PM 23305243
DA 2018-01-05
ER

PT J
AU Chaowanachan, T
   Krogstad, E
   Ball, C
   Woodrow, KA
AF Chaowanachan, Thanyanan
   Krogstad, Emily
   Ball, Cameron
   Woodrow, Kim A.
TI Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV
   Prophylaxis
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR T-20; POLYMERIC
   NANOPARTICLES; INTRACELLULAR DELIVERY; TOPICAL MICROBICIDES; EXPLANT
   CULTURE; SAQUINAVIR; PREVENTION; INFECTION; THERAPY
AB Background: The use of drug combinations has revolutionized the treatment of HIV but there is no equivalent combination product that exists for prevention, particularly for topical HIV prevention. Strategies to combine chemically incompatible agents may facilitate the discovery of unique drug-drug activities, particularly unexplored combination drug synergy. We fabricated two types of nanoparticles, each loaded with a single antiretroviral (ARV) that acts on a specific step of the viral replication cycle. Here we show unique combination drug activities mediated by our polymeric delivery systems when combined with free tenofovir (TFV).
   Methodology/Principal Findings: Biodegradable poly(lactide-co-glycolide) nanoparticles loaded with efavirenz (NP-EFV) or saquinavir (NP-SQV) were individually prepared by emulsion or nanoprecipitation techniques. Nanoparticles had reproducible size (d similar to 200 nm) and zeta potential (-25 mV). The drug loading of the nanoparticles was approximately 7% (w/w). NP-EFV and NP-SQV were nontoxic to TZM-bl cells and ectocervical explants. Both NP-EFV and NP-SQV exhibited potent protection against HIV-1 BaL infection in vitro. The HIV inhibitory effect of nanoparticle formulated ARVs showed up to a 50-fold reduction in the 50% inhibitory concentration (IC50) compared to free drug. To quantify the activity arising from delivery of drug combinations, we calculated combination indices (CI) according to the median-effect principle. NP-EFV combined with free TFV demonstrated strong synergistic effects (CI50 = 0.07) at a 1:50 ratio of IC50 values and additive effects (CI50 = 1.05) at a 1:1 ratio of IC50 values. TFV combined with NP-SQV at a 1:1 ratio of IC50 values also showed strong synergy (CI50 = 0.07).
   Conclusions: ARVs with different physicochemical properties can be encapsulated individually into nanoparticles to potently inhibit HIV. Our findings demonstrate for the first time that combining TFV with either NP-EFV or NP-SQV results in pronounced combination drug effects, and emphasize the potential of nanoparticles for the realization of unique drug-drug activities.
C1 [Chaowanachan, Thanyanan; Krogstad, Emily; Ball, Cameron; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
EM woodrow@uw.edu
FU United States National Institutes of Health grant [AI094412]; University
   of Washington; Creative and Novel Ideas in HIV Research award
   [AI027767]; NSF Graduate Research Fellowships
FX The research was supported by funding to K.A.W. from United States
   National Institutes of Health grant AI094412 and partial support from
   the University of Washington and the Creative and Novel Ideas in HIV
   Research award (AI027767). C.B. and E.K. are supported by NSF Graduate
   Research Fellowships. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424                                                                  
   ASTM ASfTaM, 1985, ZET POT COLL WAT WAS, P4187
   Best BM, 2011, J ANTIMICROB CHEMOTH, V66, P354, DOI 10.1093/jac/dkq434
   Bilati U, 2005, EUR J PHARM SCI, V24, P67, DOI 10.1016/j.ejps.2004.09.011                                                      
   Bilati U, 2003, PHARM DEV TECHNOL, V8, P1, DOI 10.1081/PDT-120017517
   Borroto-Esoda K, 2007, AIDS RES HUM RETROV, V23, P988, DOI 10.1089/aid.2006.0310
   Bousquet L, 2009, ANTIMICROB AGENTS CH, V53, P896, DOI 10.1128/AAC.00733-08
   Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381                                                          
   Chen XQ, 2004, PHARM RES, V21, P1758, DOI 10.1023/B:PHAM.0000045225.76650.53
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9
   Dou, 2007, BLOOD, V109, P1816
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000
   Feng JY, 2009, RETROVIROLOGY, V6
   Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649
   Galindo-Rodriguez S, 2004, PHARM RES, V21, P1428, DOI 10.1023/B:PHAM.0000036917.75634.be
   GRECO WR, 1995, PHARMACOL REV, V47, P331
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Huisman MT, 2001, MOL PHARMACOL, V59, P806
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Jilek BL, 2012, NAT MED, V18, P446, DOI 10.1038/nm.2649
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kuo YC, 2011, COLLOID SURFACE B, V88, P627, DOI 10.1016/j.colsurfb.2011.07.053
   Lai SK, 2011, BIOMATERIALS, V32, P6285, DOI 10.1016/j.biomaterials.2011.05.008
   Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x                                                               
   LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001                                                             
   Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001
   LUSSO P, 1995, J VIROL, V69, P3712
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mayer KH, 2006, AIDS, V20, P543, DOI 10.1097/01.aids.0000210608.70762.c3
   McMichael AJ, 2012, NAT IMMUNOL, V13, P423, DOI 10.1038/ni.2264
   Mert O, 2012, J CONTROL RELEASE, V157, P455, DOI 10.1016/j.jconrel.2011.08.032
   Mudigonda K, 2006, BIOMED CHROMATOGR, V20, P1028, DOI 10.1002/bmc.631
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007                                                
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Palmer S, 2001, AIDS RES HUM RETROV, V17, P1167, DOI 10.1089/088922201316912772
   Panyam J, 2003, PHARMACEUT RES, V20, P212, DOI 10.1023/A:1022219003551                                                         
   Panyam J., 2002, FASEB J, V16
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Pirrone V, 2011, ANTIMICROB AGENTS CH, V55, P1831, DOI 10.1128/AAC.00976-10
   Platt EJ, 1998, J VIROL, V72, P2855
   Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489
   Remmel RP, 2000, CLIN CHEM, V46, P73
   Rohan LC, 2010, PLOS ONE, V5
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   UNAIDS, 2009, AIDS EP UPD DEC 2009, p[21, 27]
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
NR 64
TC 24
Z9 24
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2013
VL 8
IS 4
AR e61416
DI 10.1371/journal.pone.0061416
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130JR
UT WOS:000317911500033
PM 23630586
OA gold
DA 2018-01-05
ER

PT J
AU Tang, S
   Li, WY
   Zhu, Y
   Hu, QL
   Wang, YX
AF Tang, San
   Li, Wenyu
   Zhu, Ying
   Hu, Qiaoling
   Wang, Youxiang
TI Tat-conjugated hyaluronic acid enveloping polyplexes with facilitated
   nuclear entry and improved transfection
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article
DE Non-viral gene delivery; Hyaluronic acid; Cell-penetrating peptide;
   Nuclear entry
ID GENE DELIVERY-SYSTEMS; PROTEIN TRANSDUCTION DOMAIN; LINEAR
   POLYETHYLENIMINE; HEPARAN-SULFATE; DNA COMPLEXES; HIV-1 TAT; STRATEGIES;
   PEPTIDE; MECHANISMS; COMPONENTS
AB The biocompatible envelop of virus gives us some inspiration in designing non-viral gene delivery system. In this research, Tat-conjugated hyaluronic acid with different grafting degree was synthesized. By coating HA-Tat to PEI/DNA complexes, the enveloping ternary polyplexes was successfully constructed due to the electrostatic interaction. At N/P/COOH ratio of 8:1:8, spherical nanoparticles were formed with diameter about 150-180 nm. Gel retardation assay indicated the disassembly did not occur. The stability of enveloping polyplexes in physiological condition was improved. HA-Tat envelop improved cell uptake of polyplexes. The intracellular distribution showed the ternary polyplexes could be able to efficiently release DNA and deliver DNA into the nuclei, resulted in higher transfection efficiency than PEI/DNA polyplexes. Thereby, the HA-Tat enveloping polyplexes with facilitated nuclear entry and improved transfection might have a promising application in non-viral gene therapy. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Tang, San; Li, Wenyu; Hu, Qiaoling; Wang, Youxiang] Zhejiang Univ, MOE Key Lab Macromol Synth & Functionalizat, Hangzhou 310027, Zhejiang, Peoples R China.
   [Tang, San; Li, Wenyu; Hu, Qiaoling; Wang, Youxiang] Zhejiang Univ, Dept Polymer Sci & Engn, Hangzhou 310027, Zhejiang, Peoples R China.
   [Zhu, Ying] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Int Hlth Ctr, Hangzhou 310027, Zhejiang, Peoples R China.
RP Wang, YX (reprint author), Zhejiang Univ, MOE Key Lab Macromol Synth & Functionalizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM yx_wang@zju.edu.cn
RI Li, Wenyu/G-2172-2014
OI Li, Wenyu/0000-0002-0172-7709
FU National Natural Science Foundation of China [21074110, 51273177]
FX This work was financially supported by the National Natural Science
   Foundation of China (21074110, 51273177),
CR Alexis F, 2006, ADV MATER, V18, P2174, DOI 10.1002/adma.200502173
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Chollet P, 2002, J GENE MED, V4, P84, DOI 10.1002/jgm.237                                                                 
   Chowdhury AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001226
   Clamme JP, 2003, BIOPHYS J, V84, P1960, DOI 10.1016/S0006-3495(03)75004-8                                                   
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Gebhart CL, 2002, BIOCONJUGATE CHEM, V13, P937, DOI 10.1021/bc025504w
   Harris JD, 1996, TRENDS GENET, V12, P400, DOI 10.1016/0168-9525(96)40031-2
   Itaka K, 2004, J GENE MED, V6, P76, DOI 10.1002/jbm.470
   Itaka K, 2009, EUR J PHARM BIOPHARM, V71, P475, DOI 10.1016/j.ejpb.2008.09.019
   Ito T, 2008, J DRUG TARGET, V16, P276, DOI [10.1080/10611860801900728, 10.1080/10611860801900728 ]
   Jiang G, 2007, BIOTECHNOL BIOPROC E, V12, P684, DOI 10.1007/BF02931086                                                              
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kurosaki T, 2009, BIOMATERIALS, V30, P2846, DOI 10.1016/j.biomaterials.2009.01.055
   Li WY, 2011, ORG BIOMOL CHEM, V9, P7799, DOI 10.1039/c1ob05886j
   Liang B, 2009, BIOMATERIALS, V30, P4014, DOI 10.1016/j.biomaterials.2009.04.011
   Lin QK, 2009, COLLOID SURFACE B, V74, P298, DOI 10.1016/j.colsurfb.2009.07.036
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Luo X, 2010, J MATER SCI-MATER M, V21, P597, DOI 10.1007/s10856-009-3903-1
   Maji S, 2012, MACROMOL CHEM PHYS, V213, P1643, DOI 10.1002/macp.201200220
   MILLER N, 1995, FASEB J, V9, P190
   Nakanishi M, 2003, CURR PROTEIN PEPT SC, V4, P141, DOI 10.2174/1389203033487234
   O'Connor TP, 2006, NAT REV GENET, V7, P261, DOI 10.1038/nrg1829
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   OLMSTED J, 1977, BIOCHEMISTRY-US, V16, P3647, DOI 10.1021/bi00635a022
   Ren KF, 2006, BIOCONJUGATE CHEM, V17, P77, DOI 10.1021/bc050264g
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   SATO T, 1995, B CHEM SOC JPN, V68, P2709, DOI 10.1246/bcsj.68.2709                                                            
   Saul JM, 2008, ADV MATER, V20, P19, DOI 10.1002/adma.200700633
   Tamura M, 2004, J VIROL, V78, P3817, DOI 10.1128/JVI.78.8.3817-3826.2004
   Trubetskoy VS, 2003, GENE THER, V10, P261, DOI 10.1038/sj.gt.3301888
   Trubetskoy VS, 1999, BIOCONJUGATE CHEM, V10, P624, DOI 10.1021/bc9801530                                                               
   Wang XF, 2009, LANGMUIR, V25, P11664, DOI 10.1021/la9013575
   Wang YX, 2008, ACTA BIOMATER, V4, P1235, DOI 10.1016/j.actbio.2008.04.020
   Wang YX, 2007, COLLOID SURFACE B, V58, P188, DOI 10.1016/j.colsurfb.2007.03.008
   Wang YX, 2011, COLLOID SURFACE B, V84, P259, DOI 10.1016/j.colsurfb.2011.01.007
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Xu PS, 2009, BIOMATERIALS, V30, P5834, DOI 10.1016/j.biomaterials.2009.07.012
   Yu HJ, 2007, BIOMACROMOLECULES, V8, P1425, DOI 10.1021/bm060910u
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 41
TC 4
Z9 4
U1 0
U2 41
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
EI 1873-4359
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD APR 20
PY 2013
VL 423
BP 124
EP 130
DI 10.1016/j.colsurfa.2013.01.028
PG 7
WC Chemistry, Physical
SC Chemistry
GA 115SC
UT WOS:000316831200018
DA 2018-01-05
ER

PT J
AU Anderson, LJ
   Dormitzer, PR
   Nokes, DJ
   Rappuoli, R
   Roca, A
   Graham, BS
AF Anderson, L. J.
   Dormitzer, P. R.
   Nokes, D. J.
   Rappuoli, R.
   Roca, A.
   Graham, B. S.
TI Strategic priorities for respiratory syncytial virus (RSV) vaccine
   development
SO VACCINE
LA English
DT Review
DE Respiratory syncytial virus; Vaccines; Global health priorities
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FORMALIN-INACTIVATED RSV; HIGH-RISK
   INFANTS; YOUNG-CHILDREN; MONOCLONAL-ANTIBODY; MATERNAL ANTIBODY; BALB/C
   MICE; FIELD TRIAL; INFECTION; LIVE
AB Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naive young infant, the RSV naive child >= 6 months of age, pregnant women (to provide passive protection to newborns), and the elderly. These target populations raise different safety and efficacy concerns and may require different vaccination strategies. The highest priority target population is the RSV naive child. The occurrence of serious adverse events associated with the first vaccine candidate for young children, formalin inactivated RSV (FI-RSV), has focused vaccine development for the young RSV naive child on live virus vaccines. Enhanced disease is not a concern for persons previously primed by a live virus infection. A variety of live-attenuated viruses have been developed with none yet achieving licensure. New live-attenuated RSV vaccines are being developed and evaluated that maybe sufficiently safe and efficacious to move to licensure. A variety of subunit vaccines are being developed and evaluated primarily for adults in whom enhanced disease is not a concern. An attenuated parainfluenza virus 3 vector expressing the RSV F protein was evaluated in RSV naive children. Most of these candidate vaccines have used the RSV F protein in various vaccine platforms including virus-like particles, nanoparticles, formulated with adjuvants, and expressed by DNA or virus vectors. The other surface glycoprotein, the G protein, has also been used in candidate vaccines.
   We now have tools to make and evaluate a wide range of promising vaccines. Costly clinical trials in the target population are needed to evaluate and select candidate vaccines for advancement to efficacy trials. Better data on RSV-associated mortality in developing countries, better estimates of the risk of long term sequelae such as wheezing after infection, better measures of protection in target populations, and data on the costs and benefits of vaccines for target populations are needed to support and justify funding this process. Addressing these challenges and needs should improve the efficiency and speed of achieving a safe and effective, licensed RSV vaccine. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Anderson, L. J.] Emory Univ, Div Pediat Infect Dis, Sch Med, Atlanta, GA 30322 USA.
   [Dormitzer, P. R.] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA.
   [Nokes, D. J.] KEMRI Wellcome Trust Res Programme, Ctr Geog Med Res Coast, Kilifi 80108, Kenya.
   [Nokes, D. J.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England.
   [Rappuoli, R.] Novartis Vaccines & Diagnost Srl, I-53100 Siena, Italy.
   [Roca, A.] The Gambia, MRC Unit, Banjul, Gambia.
   [Graham, B. S.] NIAID, NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA.
RP Anderson, LJ (reprint author), Emory Univ, Div Pediat Infect Dis, Sch Med, 2015 Uppergate Dr, Atlanta, GA 30322 USA.
EM larry.anderson@emory.edu
FU MedImmune, Inc.; Novartis Vaccines and Diagnostics; Trellis, Inc.
FX Dr. Anderson has done paid consultancies on RSV vaccines and
   therapeutics for MedImmune, Inc. and Novartis Vaccines and Diagnostics;
   is a co-inventor on patents related to RSV anti-G protein antibody
   treatment and vaccines; and is doing animal studies on RSV anti-G
   protein treatment of RSV infection funded in part by Trellis, Inc.
CR Acedo L, 2010, EPIDEMIOL INFECT, V138, P853, DOI 10.1017/S0950268809991373
   Anderson R, 2010, FUTURE MICROBIOL, V5, P585, DOI 10.2217/FMB.10.22
   BELSHE RB, 1982, J INFECT DIS, V145, P311, DOI 10.1093/infdis/145.3.311                                                        
   Belshe RB, 2004, J INFECT DIS, V190, P2096, DOI 10.1086/425981                                                                  
   Bernstein DI, 2012, PEDIATR INFECT DIS J, V31, P109, DOI 10.1097/INF.0b013e31823386f1
   Chang J, 2011, BMB REP, V44, P232, DOI 10.5483/BMBRep.2011.44.4.232
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957                                              
   Collins PL, 2011, VIRUS RES, V162, P80, DOI 10.1016/j.virusres.2011.09.020
   Cox MJ, 1998, J MED VIROL, V55, P234, DOI 10.1002/(SICI)1096-9071(199807)55:3<234::AID-JMV9>3.0.CO;2-2                    
   Crowe James E Jr, 2003, Paediatr Respir Rev, V4, P112, DOI 10.1016/S1526-0542(03)00033-2
   Falsey AR, 2008, J INFECT DIS, V198, P1317, DOI 10.1086/592168
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Feltes TF, 2011, PEDIATR RES, V70, P186, DOI 10.1203/PDR.0b013e318220a553
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956                                              
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026                                            
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3                                                   
   Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x
   GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102                                                     
   Groothuis JR, 1998, J INFECT DIS, V177, P467, DOI 10.1086/517377                                                                  
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004
   Hurwitz JL, 2011, EXPERT REV VACCINES, V10, P1415, DOI [10.1586/erv.11.120, 10.1586/ERV.11.120]
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954                                              
   Karron RA, 2005, J INFECT DIS, V191, P1093, DOI 10.1086/427813                                                                  
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955                                              
   LAMPRECHT CL, 1976, J INFECT DIS, V134, P211, DOI 10.1093/infdis/134.3.211                                                        
   Luongo C, 2009, VACCINE, V27, P5667, DOI 10.1016/j.vaccine.2009.07.022
   Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019
   Null D, 1998, PEDIATRICS, V102, P531
   O'Callaghan-Gordo C, 2011, PEDIATR INFECT DIS J, V30, P39, DOI 10.1097/INF.0b013e3181f232fe
   Radu GU, 2010, J VIROL, V84, P9632, DOI 10.1128/JVI.00451-10
   Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144
   Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P398, DOI 10.1016/j.jaci.2008.10.043
   Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6
   van Bleek Grada M, 2011, Vaccine, V29, P7285, DOI 10.1016/j.vaccine.2011.07.114
   Waris ME, 1997, J VIROL, V71, P6935
   Weber MW, 1999, INT J EPIDEMIOL, V28, P157, DOI 10.1093/ije/28.1.157                                                            
   Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/ERI.11.92, 10.1586/eri.11.92]
NR 42
TC 82
Z9 83
U1 3
U2 43
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 18
PY 2013
VL 31
SU 2
BP B209
EP B215
DI 10.1016/j.vaccine.2012.11.106
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 137TV
UT WOS:000318462000025
PM 23598484
OA gold
DA 2018-01-05
ER

PT J
AU Yang, SD
   Chen, YF
   Ahmadie, R
   Ho, EA
AF Yang, Sidi
   Chen, Yufei
   Ahmadie, Roien
   Ho, Emmanuel A.
TI Advancements in the field of intravaginal siRNA delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Intravaginal drug delivery; RNA interference (RNAi); Liposomes;
   Nanoparticles; HIV/AIDS; Microbicides
ID SMALL-INTERFERING RNA; CELL-PENETRATING PEPTIDES;
   HUMAN-IMMUNODEFICIENCY-VIRUS; DOUBLE-STRANDED-RNA; HYDROPHILIC POLYMERIC
   CHAINS; PAPILLOMAVIRUS TYPE-16 DNA; VAGINAL GEL FORMULATIONS;
   HERPES-SIMPLEX VIRUS-2; POSITIVE CANCER-CELLS; HUMAN CERVICAL-MUCUS
AB The vaginal tract is a suitable site for the administration of both local and systemic acting drugs. There are numerous vaginal products on the market such as those approved for contraception, treatment of yeast infection, hormonal replacement therapy, and feminine hygiene. Despite the potential in drug delivery, the vagina is a complex and dynamic organ that requires greater understanding. The recent discovery that injections of double stranded RNA (dsRNA) in Caenorhabditis elegans (C. elegans) results in potent gene specific silencing, was a major scientific revolution. This phenomenon known as RNA interference (RNAi), is believed to protect host genome against invasion by mobile genetic elements such as transposons and viruses. Gene silencing or RNAi has opened new potential opportunities to study the function of a gene in an organism. Furthermore, its therapeutic potential is being investigated in the field of sexually transmitted infections such as human immunodeficiency virus (HIV) and other diseases such as age-related macular degeneration (AMD), diabetes, hypercholesterolemia, respiratory disease, and cancer. This review will focus on the therapeutic potential of siRNA for the treatment and/or prevention of infectious diseases such as HIV, HPV, and HSV within the vaginal tract. Specifically, formulation design parameters to improve siRNA stability and therapeutic efficacy in the vaginal tract will be discussed along with challenges, advancements, and future directions of the field. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Yang, Sidi; Chen, Yufei; Ahmadie, Roien; Ho, Emmanuel A.] Univ Manitoba, Fac Pharm, Winnipeg, MB R3E 0T5, Canada.
RP Ho, EA (reprint author), Univ Manitoba, Fac Pharm, Apotex Ctr, 750 McDermot Ave,Room 329, Winnipeg, MB R3E 0T5, Canada.
EM emmanuel_ho@umanitoba.ca
RI Chen, Yufei/R-7259-2016
OI Chen, Yufei/0000-0002-5782-3556; Ho, Emmanuel/0000-0003-4729-9970
FU Bill and Melinda Gates Foundation [OPP1007233GCE]; Canadian Institutes
   of Health Research [MOP110981]; Manitoba Medical Service Foundation
   [MMSF811.05]; Faculty of Graduate Studies International Graduate Student
   Entrance Scholarship; Manitoba Health Research Council
FX This work was supported in part by grants awarded to Dr. Emmanuel A. Ho
   from the Bill and Melinda Gates Foundation Grand Challenges Explorations
   Grant (OPP1007233GCE), the Canadian Institutes of Health Research
   (MOP110981), and the Manitoba Medical Service Foundation (MMSF811.05).
   Sidi Yang is grateful for the financial support received from the
   Faculty of Graduate Studies International Graduate Student Entrance
   Scholarship, and Yufei Chen is grateful for the financial support
   received from the Manitoba Health Research Council Graduate Studentship.
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Alshamsan A, 2011, TRANSL ONCOL, V4, P178, DOI 10.1593/tlo.11100
   Amand HL, 2012, BIOCHEM BIOPH RES CO, V418, P469, DOI 10.1016/j.bbrc.2012.01.041
   An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104
   Anderson JS, 2009, JAIDS-J ACQ IMM DEF, V52, P152, DOI 10.1097/QAI.0b013e3181b010a0
   Bagarazzi ML, 1997, J MED PRIMATOL, V26, P27, DOI 10.1111/j.1600-0684.1997.tb00316.x                                              
   Baloglu E, 2009, J PHARM PHARM SCI, V12, P312, DOI 10.18433/J3HP41                                                                 
   Banerjea A, 2003, MOL THER, V8, P62, DOI 10.1016/S01525-0016(03)00140-0
   Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499
   Berkhout B, 2009, EXPERT OPIN BIOL TH, V9, P161, DOI [10.1517/14712590802653619, 10.1517/14712590802653619 ]
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Boutros M, 2008, NAT REV GENET, V9, P554, DOI 10.1038/nrg2364
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8                                                   
   Brunot C, 2007, BIOMATERIALS, V28, P632, DOI 10.1016/j.biomaterials.2006.09.026
   Budhian A, 2005, J MICROENCAPSUL, V22, P773, DOI 10.1080/02652040500273753
   Bures P, 2001, J CONTROL RELEASE, V72, P25, DOI 10.1016/S0168-3659(01)00259-0
   Burnett JC, 2011, BIOTECHNOL J, V6, P1130, DOI 10.1002/biot.201100054
   Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897
   Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894
   Campolongo MJ, 2009, NAT MATER, V8, P447, DOI 10.1038/nmat2456
   Celum C, 2004, B WORLD HEALTH ORGAN, V82, P447
   Ceric F, 2005, J ELECTRON MICROSC, V54, P479, DOI 10.1093/jmicro/dfh106
   Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416
   Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053
   Chesnoy S, 2000, ANNU REV BIOPH BIOM, V29, P27, DOI 10.1146/annurev.biophys.29.1.27
   Choi JH, 2001, B KOR CHEM SOC, V22, P46
   Choi YS, 2011, CURR PHARM BIOTECHNO, V12, P1166
   Choung S, 2006, BIOCHEM BIOPH RES CO, V342, P919, DOI 10.1016/j.bbrc.2006.02.049
   Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002
   Cohen J, 2009, SCIENCE, V326, P652, DOI 10.1126/science.326_652
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Cun D, 2008, J BIOMED NANOTECHNOL, V4, P258, DOI 10.1166/jbn.2008.328
   Cun DM, 2011, EUR J PHARM BIOPHARM, V77, P26, DOI 10.1016/j.ejpb.2010.11.008
   Cun DM, 2010, INT J PHARMACEUT, V390, P70, DOI 10.1016/j.ijpharm.2009.10.023
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Dawson M, 2003, J BIOL CHEM, V278, P50393, DOI 10.1074/jbc.M309026200
   Pereira RRD, 2012, DRUG DEV IND PHARM, V38, P643, DOI 10.3109/03639045.2011.623355
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x                                                
   DIPAOLO JA, 1993, CRIT REV ONCOGENESIS, V4, P337
   Dmitriev RI, 2011, BIOCONJUGATE CHEM, V22, P2507, DOI 10.1021/bc200324q
   Dudek T, 2006, VIROLOGY, V344, P230, DOI 10.1016/j.virol.2005.09.020
   Duensing S, 2002, CANCER RES, V62, P7075
   DURST M, 1987, ONCOGENE, V1, P251
   El Andaloussi S, 2011, METHODS MOL BIOL, V764, P75, DOI 10.1007/978-1-61779-188-8_5
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Engelman A, 2012, NAT REV MICROBIOL, V10, P279, DOI 10.1038/nrmicro2747
   Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313
   Fattal E, 2008, INT J PHARMACEUT, V364, P237, DOI 10.1016/j.ijpharm.2008.06.011
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Florea BI, 2002, AAPS PHARMSCI, V4, DOI 10.1208/ps040312                                                                
   Fujii T, 2006, INT J ONCOL, V29, P541
   Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2
   Gomez Jose A, 2010, Pharmaceuticals (Basel), V3, P3594, DOI 10.3390/ph3123594
   Gomez-Graete C, 2007, INT J PHARM, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   Goncalves C, 2002, J GENE MED, V4, P271, DOI 10.1002/jgm.277
   Gu WY, 2007, CURR OPIN MOL THER, V9, P126
   Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003
   Hamasaki K, 2003, FEBS LETT, V543, P51, DOI 10.1016/S0014-5793(03)00400-9
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Ho EA, 2013, J PHARM SCI-US, V102, P227, DOI 10.1002/jps.23351
   Huang YB, 2000, J CONTROL RELEASE, V65, P63, DOI 10.1016/S0168-3659(99)00233-3                                                   
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Huth S, 2004, J GENE MED, V6, P923, DOI 10.1002/jgm.577
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Jiang F, 2005, ONCOGENE, V24, P3409, DOI 10.1038/sj.onc.1208459
   Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878
   Kanazawa T, 2008, INT J PHARM, V360, P164, DOI 10.1016/j.ijpharm.2008.04.038
   Kanazawa T, 2009, J PHARM PHARMACOL, V61, P1457, DOI 10.1211/jpp/61.11.0004
   Karim SSA, 2012, BEST PRACT RES CL OB, V26, P427, DOI 10.1016/j.bpobgyn.2012.01.010
   Kashuba ADM, 1998, CLIN PHARMACOKINET, V34, P203, DOI 10.2165/00003088-199834030-00003                                                
   Katagiri Y, 2006, J DERMATOL SCI, V42, P215, DOI 10.1016/j.dermsci.2005.12.016
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kieweg SL, 2006, J BIOMECH ENG-T ASME, V128, P540, DOI 10.1115/1.2206198
   Kieweg SL, 2004, J PHARM SCI-US, V93, P2941, DOI 10.1002/jps.20194
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Konishi M, 2003, HEPATOLOGY, V38, P842, DOI 10.1053/jhep.2003.50416
   Koren E, 2011, DRUG DELIV, V18, P377, DOI 10.3109/10717544.2011.567310
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lea JS, 2007, REPROD SCI, V14, P20, DOI 10.1177/1933719106298189
   Lee M, 2007, B KOR CHEM SOC, V28, P95
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953
   Lin RL, 1999, NATURE, V402, P128, DOI 10.1038/45938                                                                   
   Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513
   Liu J, 2004, WORLD J GASTROENTERO, V10, P1898
   Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710
   Liu X, 2006, RNA, V12, P1514, DOI 10.1261/rna.101606
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   Martinez MA, 2002, AIDS, V16, P2385, DOI 10.1097/00002030-200212060-00002
   Miller VM, 2004, NUCLEIC ACIDS RES, V32, P661, DOI 10.1093/nar/gkh208
   Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100
   Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Moss JA, 2012, ANTIMICROB AGENTS CH, V56, P875, DOI 10.1128/AAC.05662-11
   Muruve DA, 2004, HUM GENE THER, V15, P1157, DOI 10.1089/hum.2004.15.1157
   Naito Y, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-80
   Niu XY, 2006, INT J GYNECOL CANCER, V16, P743, DOI 10.1111/j.1525-1438.2006.00384.x                                                
   Norris DA, 1997, J APPL POLYM SCI, V63, P1481, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5               
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Oskuee RK, 2010, J GENE MED, V12, P729, DOI 10.1002/jgm.1490
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Pantaleo V, 2011, ADV EXP MED BIOL, V722, P39, DOI 10.1007/978-1-4614-0332-6_3
   Park WS, 2002, NUCLEIC ACIDS RES, V30, P4830, DOI 10.1093/nar/gkf627
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Patil Y, 2009, INT J PHARM, V367, P195, DOI 10.1016/j.ijpharm.2008.09.039
   Peer D, 2010, J CONTROL RELEASE, V148, P63, DOI 10.1016/j.jconrel.2010.06.029
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1675, DOI 10.1016/j.addr.2004.03.001
   Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2                                                   
   Pille JY, 2006, HUM GENE THER, V17, P1019, DOI 10.1089/hum.2006.17.1019
   Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029
   PIRISI L, 1987, J VIROL, V61, P1061
   Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Ren GL, 2005, BIOCHEM BIOPH RES CO, V335, P1051, DOI 10.1016/j.bbrc.2005.07.170
   Richardson L.I.J.L., 1992, ADV DRUG DELIV REV, V8, P341
   Romberg B, 2007, INT J PHARM, V331, P186, DOI 10.1016/j.ijpharm.2006.11.018
   Rullo A, 2011, BIOPOLYMERS, V95, P722, DOI 10.1002/bip.21641
   Sakuma S, 1999, INT J PHARM, V177, P161, DOI 10.1016/S0378-5173(98)00346-9
   Sakuma S, 2002, J CONTROL RELEASE, V81, P281, DOI 10.1016/S0168-3659(02)00072-X                                                   
   SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285
   Serra L, 2009, EUR J PHARM BIOPHARM, V71, P519, DOI 10.1016/j.ejpb.2008.09.022
   SHEEHAN JK, 1984, BIOCHEM J, V217, P93, DOI 10.1042/bj2170093                                                               
   SMOTKIN D, 1989, J VIROL, V63, P1441
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Sun JY, 2003, GENE THER, V10, P964, DOI 10.1038/sj.gt.3302039
   Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002
   Suzuki K, 2000, NAT GENET, V25, P427
   Svensen N, 2012, TRENDS PHARMACOL SCI, V33, P186, DOI 10.1016/j.tips.2012.02.002
   Tang M.D.B.C., 2009, P NATL ACAD SCI USA, V106, P19268
   ter Brake O, 2009, GENE THER, V16, P148, DOI 10.1038/gt.2008.124
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5
   Tomar RS, 2003, ONCOGENE, V22, P5712, DOI 10.1038/sj.onc.1206733
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   Wang Z, 2011, PHARM RES-DORDR, V28, P2983, DOI 10.1007/s11095-011-0604-5
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu JB, 2011, CANCER GENE THER, V18, P20, DOI 10.1038/cgt.2010.55
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Xie FY, 2006, DRUG DISCOV TODAY, V11, P67, DOI 10.1016/S1359-6446(05)03668-8
   Yonesaka K, 2006, INT J CANCER, V118, P812, DOI 10.1002/ijc.21350
   Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004
   Yu T., 2011, DRUG DELIV TRANSL RE, V2, P124
   Zeller Skye J., 2011, Yale Journal of Biology and Medicine, V84, P301
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhang YQ, 2008, CLIN EXP DERMATOL, V33, P56, DOI 10.1111/j.1365-2230.2007.02543.x
   Zhang YJ, 2006, MOL THER, V14, P336, DOI 10.1016/j.ymthe.2006.04.001
   Zhe R, 2008, ARCH VIROL, V153, P1401, DOI 10.1007/s00705-008-0110-1
   Zintchenko A, 2008, BIOCONJUGATE CHEM, V19, P1448, DOI 10.1021/bc800065f
   zurHausen H, 1996, BBA-REV CANCER, V1288, pF55
NR 171
TC 28
Z9 30
U1 3
U2 69
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 10
PY 2013
VL 167
IS 1
BP 29
EP 39
DI 10.1016/j.jconrel.2012.12.023
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 113OT
UT WOS:000316678100004
PM 23298612
DA 2018-01-05
ER

PT J
AU Pavot, V
   Rochereau, N
   Primard, C
   Genin, C
   Perouzel, E
   Lioux, T
   Paul, S
   Verrier, B
AF Pavot, Vincent
   Rochereau, Nicolas
   Primard, Charlotte
   Genin, Christian
   Perouzel, Eric
   Lioux, Thierry
   Paul, Stephane
   Verrier, Bernard
TI Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid)
   nanoparticles potentiates their immune properties
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Nod receptor ligands; Poly(lactic acid) nanoparticles;
   Immunostimulation; Encapsulation; Dendritic cell maturation; Vaccin
ID TOLL-LIKE RECEPTORS; INNATE IMMUNITY; PLA NANOPARTICLES; BACTERIAL
   PEPTIDOGLYCAN; ANTIBODY-RESPONSES; ADJUVANT ACTIVITY; HIV-1 P24;
   VACCINE; DISEASE; CELLS
AB Most successful vaccines are able to induce persistent antibody responses that can last a lifetime. Emerging evidences indicate that activation of immune cells through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) or Nod-like receptors (NLRs) may be critical mechanisms. Among PRRs, the use of TLR ligands as adjuvants is already largely described whereas the use of NLRs ligands remains largely unexplored. As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and Nod2 receptor ligands into Poly(Lactic Acid) (PLA) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated. Their ability to induce systemic immune responses in mice was also measured and compared to free ligands and the Alum adjuvant. Nod ligands encapsulated into PLA NPs were efficiently taken up by DCs and subsequently induced a strong up-regulation of maturation markers and the enhancement of proinflammatory cytokine secretion by DCs. Furthermore, co-injection of encapsulated Nod-ligands with PLA particles carrying Gag p24 HIV-1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum. These results suggest that encapsulation of Nod ligands into PLA-NPs could be an effective way to improve vaccine efficiency. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Pavot, Vincent; Primard, Charlotte; Verrier, Bernard] Univ Lyon, CNRS, UMR 5305, Inst Biol & Chim Prot, Lyon, France.
   [Pavot, Vincent; Rochereau, Nicolas; Genin, Christian; Paul, Stephane] Fac Med St Etienne, Grp Immun Muqueuses & Agents Pathogenes, INSERM, Vaccinol CIE3, St Etienne, France.
   [Perouzel, Eric; Lioux, Thierry] InvivoGen, CAYLA, Toulouse, France.
RP Verrier, B (reprint author), Univ Lyon, CNRS, UMR 5305, Inst Biol & Chim Prot, Lyon, France.
EM b.verrier@ibcp.fr
FU ANR (French National Research Agency) through Euronanomed grant
   (iNanoDCs); ANR (French National Research Agency) through ANabio
   research projects; Region Rhone-Alpes; Fondation Recherche Medicale
   (FRM); FP7 European grant (CutHIVac); FP7 European grant Aditec [280873]
FX This work was funded by the ANR (French National Research Agency)
   through Euronanomed grant (iNanoDCs) and ANabio research projects, and
   PhD studentships from Region Rhone-Alpes and Fondation Recherche
   Medicale (FRM) to Vincent Pavot.; This work was also partially supported
   by grants from the two FP7 European grants (CutHIVac) and Aditec (no
   280873). The funders had no role in the study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bal SM, 2012, EUR J PHARM SCI, V45, P475, DOI 10.1016/j.ejps.2011.10.003
   Brito LA, 2011, J PHARM SCI-US, V100, P34, DOI 10.1002/jps.22267
   Carneiro LAM, 2008, J PATHOL, V214, P136, DOI 10.1002/path.2271
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945                                                                   
   Charrier L, 2006, LAB INVEST, V86, P538, DOI 10.1038/labinvest.3700423
   Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Fredriksen BN, 2012, VACCINE, V30, P656, DOI 10.1016/j.vaccine.2011.10.105
   Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412
   Geddes K, 2009, NAT REV DRUG DISCOV, V8, P465, DOI 10.1038/nrd2783
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010
   Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Laroui H, 2011, AM J PHYSIOL-GASTR L, V300, pG371, DOI 10.1152/ajpgi.00466.2010
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403
   Masek J, 2011, J CONTROL RELEASE, V151, P193, DOI 10.1016/j.jconrel.2011.01.016
   Mckee AS, 2007, IMMUNITY, V27, P687, DOI 10.1016/j.immuni.2007.11.003
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Ruiz S, 2005, CELL MICROBIOL, V7, P1659, DOI 10.1111/j.1462-5822.2005.00583.x
   Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Wilkins C, 2010, CURR OPIN IMMUNOL, V22, P41, DOI 10.1016/j.coi.2009.12.003
   Wischke C, 2012, J CONTROL RELEASE, V164, P299, DOI 10.1016/j.jconrel.2012.06.034
   Zhu Q, 2012, NAT MED, V18, P1291, DOI 10.1038/nm.2866
NR 36
TC 30
Z9 30
U1 0
U2 34
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 10
PY 2013
VL 167
IS 1
BP 60
EP 67
DI 10.1016/j.jconrel.2013.01.015
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 113OT
UT WOS:000316678100007
PM 23352911
DA 2018-01-05
ER

PT J
AU Khan, Z
   Combadiere, C
   Authier, FJ
   Itier, V
   Lux, F
   Exley, C
   Mahrouf-Yorgov, M
   Decrouy, X
   Moretto, P
   Tillement, O
   Gherardi, RK
   Cadusseau, J
AF Khan, Zakir
   Combadiere, Christophe
   Authier, Francois-Jerome
   Itier, Valerie
   Lux, Francois
   Exley, Christopher
   Mahrouf-Yorgov, Meriem
   Decrouy, Xavier
   Moretto, Philippe
   Tillement, Olivier
   Gherardi, Romain K.
   Cadusseau, Josette
TI Slow CCL2-dependent translocation of biopersistent particles from muscle
   to brain
SO BMC MEDICINE
LA English
DT Article
DE Alum; Vaccine adverse effect; Vaccine adjuvant; Nanomaterial
   biodistribution; Nanomaterial neurodelivery; Macrophages; Macrophagic
   myofasciitis; CCL-2; Single nucleotide polymorphisms (SNPs)
ID DENDRITIC CELLS; MACROPHAGIC MYOFASCIITIS; ALUMINUM-HYDROXIDE;
   SKELETAL-MUSCLE; MCP-1 LEVELS; LYMPH-NODES; IN-VIVO; ANTIGEN; MICE; CNS
AB Background: Long-term biodistribution of nanomaterials used in medicine is largely unknown. This is the case for alum, the most widely used vaccine adjuvant, which is a nanocrystalline compound spontaneously forming micron/submicron-sized agglomerates. Although generally well tolerated, alum is occasionally detected within monocytelineage cells long after immunization in presumably susceptible individuals with systemic/neurologic manifestations or autoimmune (inflammatory) syndrome induced by adjuvants (ASIA).
   Methods: On the grounds of preliminary investigations in 252 patients with alum-associated ASIA showing both a selective increase of circulating CCL2, the major monocyte chemoattractant, and a variation in the CCL2 gene, we designed mouse experiments to assess biodistribution of vaccine-derived aluminum and of alum-particle fluorescent surrogates injected in muscle. Aluminum was detected in tissues by Morin stain and particle induced X-ray emission) (PIXE) Both 500 nm fluorescent latex beads and vaccine alum agglomerates-sized nanohybrids (Al-Rho) were used.
   Results: Intramuscular injection of alum-containing vaccine was associated with the appearance of aluminum deposits in distant organs, such as spleen and brain where they were still detected one year after injection. Both fluorescent materials injected into muscle translocated to draining lymph nodes (DLNs) and thereafter were detected associated with phagocytes in blood and spleen. Particles linearly accumulated in the brain up to the six-month endpoint; they were first found in perivascular CD11b(+) cells and then in microglia and other neural cells. DLN ablation dramatically reduced the biodistribution. Cerebral translocation was not observed after direct intravenous injection, but significantly increased in mice with chronically altered blood-brain-barrier. Loss/gain-of-function experiments consistently implicated CCL2 in systemic diffusion of Al-Rho particles captured by monocyte-lineage cells and in their subsequent neurodelivery. Stereotactic particle injection pointed out brain retention as a factor of progressive particle accumulation.
   Conclusion: Nanomaterials can be transported by monocyte-lineage cells to DLNs, blood and spleen, and, similarly to HIV, may use CCL2-dependent mechanisms to penetrate the brain. This occurs at a very low rate in normal conditions explaining good overall tolerance of alum despite its strong neurotoxic potential. However, continuously escalating doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe, especially in the case of overimmunization or immature/altered blood brain barrier or high constitutive CCL-2 production.
C1 [Khan, Zakir; Authier, Francois-Jerome; Itier, Valerie; Mahrouf-Yorgov, Meriem; Decrouy, Xavier; Gherardi, Romain K.; Cadusseau, Josette] Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France.
   [Khan, Zakir; Authier, Francois-Jerome; Itier, Valerie; Mahrouf-Yorgov, Meriem; Decrouy, Xavier; Gherardi, Romain K.; Cadusseau, Josette] Univ Paris Est, Fac Med, F-94010 Creteil, France.
   [Combadiere, Christophe] INSERM, UMR S 945, F-75013 Paris, France.
   [Combadiere, Christophe] Univ Paris 06, Fac Med, F-75013 Paris, France.
   [Combadiere, Christophe] Grp Hosp Pitie Salpetriere, AP HP, Serv Immunol, F-75013 Paris, France.
   [Authier, Francois-Jerome; Gherardi, Romain K.] Hop H Mondor A Chenevier, AP HP, Serv Histol, Ctr Reference Neuromusculaire GNMH, F-94000 Creteil, France.
   [Lux, Francois; Tillement, Olivier] CNRS, Lab Phys Chim Mat Luminescents, UMR 5620, F-69622 Villeurbanne, France.
   [Lux, Francois; Tillement, Olivier] Univ Lyon 1, F-69622 Villeurbanne, France.
   [Exley, Christopher] Keele Univ, Birchall Ctr, Lennard Jones Labs, Keele ST5 5BG, Staffs, England.
   [Moretto, Philippe] Ctr Etud Nucl Bordeaux Gradignan, CNRS, UMR 5797, F-33175 Gradignan, France.
   [Itier, Valerie; Mahrouf-Yorgov, Meriem; Cadusseau, Josette] UPEC, Fac Sci & Technol, Creteil, France.
   [Gherardi, Romain K.; Cadusseau, Josette] IMRB Team 10, Fac Med, F-94010 Creteil, France.
RP Gherardi, RK (reprint author), Hop Henri Mondor, INSERM, U955, 8 Rue Gen Sarrail, F-94010 Creteil, France.
EM romain.gherardi@hmn.aphp.fr; josette.cadusseau@inserm.fr
RI Combadiere, Christophe/I-5639-2013
OI Combadiere, Christophe/0000-0002-1755-4531
FU E3M (Entraide aux Malades de Myofasciite a Macrophages); AFM
   (Association Francaise contre les Myopathies); Dwoskin Foundation;
   Region Ile-de-France through a programme PICRI (Partenariat
   Institutions-Citoyens pour la Recherche et l'Innovation); European
   Community [241440]
FX This work has benefited from research funding from two patients
   associations: E3M (Entraide aux Malades de Myofasciite a Macrophages)
   "Neurodelivrance des particules injectees par voie intra musculaire et
   securite des adjuvants aluminiques", AFM (Association Francaise contre
   les Myopathies) "Etude des mecanismes de la myofasciite a macrophages"
   and Dwoskin Foundation (Nano in brain); from Region Ile-de-France
   through a programme PICRI (Partenariat Institutions-Citoyens pour la
   Recherche et l'Innovation) "Recherche de polymorphismes dans les genes
   codant pour des facteurs inflammatoires (chimiokines) dans la
   myofasciite a macrophages", and through two post-doctoral positions from
   NeRF (Neuropole de Recherche Francilien) on the topic "The macrophage as
   a Trojan horse for brain delivery" and "Brain delivery of i.m. injected
   nanoparticles: relevance to safety of aluminum-containing adjuvants of
   vaccines"; and from the European Community's Seventh Framework Programme
   in the project ENDOSTEM "Activation of vasculature associated stem cells
   and muscle stem cells for the repair and maintenance of muscle tissue"
   (Grant agreement number 241440). We would like to thank for their most
   useful contributions: Dr Sophie Hue, Dr Fabrice Chretien, Dr Madly
   Brigitte, Dr Anne Hulin, Lucie Poupel, Emilie House, Yasmine Baba-Amer,
   and Mathieu Surenaud.
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017
   Angeli V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Authier FJ, 2006, NEUROMUSCULAR DISORD, V16, P347, DOI 10.1016/j.nmd.2006.02.004
   Authier FJ, 2003, ARTHRITIS RHEUM, V48, P569, DOI 10.1002/art.10740
   Authier FJ, 2001, BRAIN, V124, P974, DOI 10.1093/brain/124.5.974
   Brigitte M, 2010, ARTHRITIS RHEUM-US, V62, P268, DOI 10.1002/art.27183
   Cain DW, 2013, VACCINE, V31, P653, DOI 10.1016/j.vaccine.2012.11.044
   Carbone FR, 2004, TRENDS IMMUNOL, V25, P655, DOI 10.1016/j.it.2004.09.013
   Cavanagh LL, 2005, NAT IMMUNOL, V6, P1029, DOI 10.1038/ni1249
   Chackerian AA, 2002, INFECT IMMUN, V70, P4501, DOI 10.1128/IAI.70.8.4501-4509.2002
   COT COM and COC, 2005, JOINT STAT NAN TOX
   Couette M, 2009, J INORG BIOCHEM, V103, P1571, DOI 10.1016/j.jinorgbio.2009.08.005
   Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f
   Drevets DA, 2004, J IMMUNOL, V172, P4418, DOI 10.4049/jimmunol.172.7.4418                                                     
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Exley C, 2010, TRENDS IMMUNOL, V31, P103, DOI 10.1016/j.it.2009.12.009
   Fizet J, 2009, J NANOSCI NANOTECHNO, V9, P5717, DOI 10.1166/jnn.2009.1237
   Flarend RE, 1997, VACCINE, V15, P1314, DOI 10.1016/S0264-410X(97)00041-8
   Galimberti D, 2006, NEUROBIOL AGING, V27, P1763, DOI 10.1016/j.neurobiolaging.2005.10.007
   Gherardi RK, 2003, IMMUNOL ALLERGY CLIN, V23, P699, DOI 10.1016/S0889-8561(03)00095-X
   Gherardi RK, 2001, BRAIN, V124, P1821, DOI 10.1093/brain/124.9.1821
   Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499
   Hall JG, 1998, IMMUNOLOGY, V53, P105
   Hamilton JA, 2000, J LEUKOCYTE BIOL, V67, P226
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Inoue K, 2009, TOXICOL APPL PHARM, V234, P68, DOI 10.1016/j.taap.2008.09.012
   Kabashima K, 2005, IMMUNITY, V22, P439, DOI 10.1016/j.immuni.2005.02.007
   Kivela R, 2007, AM J PHYSIOL-HEART C, V293, pH2573, DOI 10.1152/ajpheart.00126.2007
   Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087
   Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015
   Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050
   Moretto P, 1996, CELL MOL BIOL, V42, P1
   Nico B, 2003, GLIA, V42, P235, DOI 10.1002/glia.10216
   Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361
   Pauluhn J, 2009, TOXICOL SCI, V109, P152, DOI 10.1093/toxsci/kfp046
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Prinz M, 2011, GLIA, V59, P177, DOI 10.1002/glia.21104
   Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1                                                   
   REDHEAD K, 1992, PHARMACOL TOXICOL, V70, P278, DOI 10.1111/j.1600-0773.1992.tb00471.x                                              
   Rimaniol AC, 2004, VACCINE, V22, P3127, DOI 10.1016/j.vaccine.2004.01.061
   SAHIN G, 1994, BIOL TRACE ELEM RES, V41, P129, DOI 10.1007/BF02917223
   Shaw CA, 2009, J INORG BIOCHEM, V103, P1555, DOI 10.1016/j.jinorgbio.2009.05.019
   Shoenfeld Y, 2010, J AUTOIMMUN, V36, P4
   Si Y, 2010, J CLIN INVEST, V120, P1192, DOI 10.1172/JCI40310
   Verdier F, 2005, VACCINE, V23, P1359, DOI 10.1016/j.vaccine.2004.09.012
   Wang X-Y, 2012, IMMUNOL LETT, V149, P88, DOI DOI 10.1016/J.IMLET.2012.11.005
   Weller RO, 2009, ACTA NEUROPATHOL, V117, P1, DOI 10.1007/s00401-008-0457-0
   WEN GY, 1985, ACTA NEUROPATHOL, V68, P175, DOI 10.1007/BF00690191                                                              
NR 50
TC 41
Z9 44
U1 1
U2 27
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD APR 4
PY 2013
VL 11
AR 99
DI 10.1186/1741-7015-11-99
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 137NA
UT WOS:000318441400012
PM 23557144
OA gold
DA 2018-01-05
ER

EF